data_1bve_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1bve _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.615 0 CA-C-O 121.355 0.481 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.523 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 20.7 tt0 -86.19 118.5 25.69 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 177.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -115.15 105.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 120.806 -1.184 . . . . 0.0 110.405 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.511 ' CG2' ' CG2' ' B' ' 96' ' ' THR . 1.3 p -123.34 30.0 6.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.615 -0.678 . . . . 0.0 109.709 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.548 ' O ' ' C ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -89.56 39.33 0.94 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.13 -0.981 . . . . 0.0 109.295 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.548 ' C ' ' O ' ' A' ' 5' ' ' LEU . 46.2 m0 16.28 59.36 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 CA-C-O 121.613 0.72 . . . . 0.0 111.918 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -145.14 174.22 11.25 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.395 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -65.97 118.32 51.0 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.98 -1.075 . . . . 0.0 108.915 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 71.66 6.16 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.214 1.942 . . . . 0.0 109.545 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.564 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -92.93 157.07 16.53 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.442 -0.786 . . . . 0.0 109.523 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.524 HG23 HG13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -150.77 136.53 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.183 -0.948 . . . . 0.0 110.158 -179.599 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 55.0 m -68.32 108.9 3.39 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.573 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 1.2 pp -98.66 152.46 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 120.957 -1.09 . . . . 0.0 111.012 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.461 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 10.9 tttt -113.23 104.61 12.51 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.551 ' CG2' ' HE3' ' A' ' 36' ' ' MET . 5.1 mt -120.84 129.81 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.079 -1.013 . . . . 0.0 109.894 -179.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.58 35.57 81.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.34 73.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.461 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -121.47 -176.76 3.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.342 -1.093 . . . . 0.0 108.653 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.46 HD22 ' CA ' ' A' ' 14' ' ' LYS . 16.4 mt -151.4 124.05 8.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.938 -1.101 . . . . 0.0 110.892 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -141.97 165.99 25.94 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 178.495 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.564 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.5 mp0 -79.25 131.62 36.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.9 -1.125 . . . . 0.0 108.747 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.573 ' CB ' ' CG2' ' A' ' 13' ' ' ILE . . . -108.09 137.87 45.33 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.067 -1.021 . . . . 0.0 110.641 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 20.1 tp -104.77 98.7 8.4 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.478 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 43.2 mt -44.95 95.17 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.064 -1.022 . . . . 0.0 108.685 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 1.4 t70 -97.05 79.8 2.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.164 -0.96 . . . . 0.0 110.732 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 27.6 m -63.11 -13.71 39.8 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.991 -1.068 . . . . 0.0 108.762 178.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.8 -41.39 49.85 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.04 168.95 19.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.202 -1.176 . . . . 0.0 109.67 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.71 -17.59 16.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.185 -0.947 . . . . 0.0 111.272 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -135.7 -176.71 4.38 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.427 -179.366 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.564 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 16.7 m -98.86 87.97 3.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.359 -0.838 . . . . 0.0 110.68 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.566 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.95 168.14 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 178.787 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.566 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.23 135.22 5.14 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.975 -1.078 . . . . 0.0 110.518 -178.235 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.49 ' HG2' ' O ' ' A' ' 80' ' ' THR . 2.0 mt-10 -45.16 170.68 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.375 -0.828 . . . . 0.0 108.834 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.514 ' HA ' HG11 ' A' ' 77' ' ' VAL . 2.7 tt0 -60.59 152.68 25.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.041 -1.037 . . . . 0.0 109.888 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.551 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 8.1 ptm -177.8 -158.92 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.462 ' O ' HD23 ' A' ' 38' ' ' LEU . 6.6 t -110.67 127.21 55.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.258 -0.901 . . . . 0.0 110.351 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.614 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 3.8 mm? -131.88 170.01 12.4 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.534 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 36.3 Cg_endo -80.99 123.96 4.79 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.791 2.327 . . . . 0.0 112.514 -178.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.552 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -44.49 117.72 2.18 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.552 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 150.04 44.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.596 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 35.4 p-90 -118.81 -173.84 2.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.961 0.886 . . . . 0.0 110.709 -177.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.08 136.92 11.12 Favored Pre-proline 0 C--N 1.303 -1.451 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.05 136.89 20.88 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.846 1.698 . . . . 0.0 110.986 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.437 ' HD2' HG21 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -146.8 157.52 43.69 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.528 ' CG ' ' HG2' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -119.41 125.47 49.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.836 -1.165 . . . . 0.0 110.188 -178.889 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.563 HD13 ' CG2' ' B' ' 50' ' ' ILE . 5.7 pt -104.86 136.23 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 108.746 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.57 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.36 102.59 0.97 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.51 -127.16 3.56 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.627 -178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.552 ' CG2' HD13 ' B' ' 47' ' ' ILE . 57.0 mt -80.19 122.13 34.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.9 -0.765 . . . . 0.0 112.925 -177.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.417 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 100.0 -50.87 1.08 Allowed Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.049 177.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -177.5 -160.53 24.36 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.582 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.57 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.8 m-85 -113.47 133.37 55.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.567 -0.96 . . . . 0.0 109.926 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.528 HG12 ' CG2' ' B' ' 50' ' ' ILE . 10.6 pt -113.51 168.09 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.141 -0.974 . . . . 0.0 108.918 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.7 mtpt -113.46 132.4 55.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.201 -0.937 . . . . 0.0 109.252 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.464 HG11 ' HA3' ' A' ' 78' ' ' GLY . 8.6 m -127.79 -174.59 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.969 -1.082 . . . . 0.0 110.217 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.498 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 1.7 mtt85 -127.37 92.08 3.44 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.4 tt0 -54.58 94.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.544 -0.723 . . . . 0.0 110.484 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.614 ' CE1' ' HB3' ' A' ' 38' ' ' LEU . 26.6 m-85 -89.51 133.7 34.46 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 177.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -111.35 139.86 46.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.938 -1.101 . . . . 0.0 111.528 -177.664 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.555 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 69.48 63.48 0.27 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.727 -0.608 . . . . 0.0 110.44 178.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.544 HD12 ' CB ' ' A' ' 59' ' ' TYR . 3.6 mp -116.71 122.78 70.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.557 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -64.77 82.91 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.642 0.734 . . . . 0.0 110.48 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.547 HG12 HD13 ' A' ' 66' ' ' ILE . 2.9 tt -90.76 117.83 34.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.549 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -90.4 137.23 32.52 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.09 -1.006 . . . . 0.0 108.587 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.547 HD13 HG12 ' A' ' 64' ' ' ILE . 0.6 OUTLIER -124.37 112.61 33.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 120.902 -1.124 . . . . 0.0 108.901 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 62.37 23.08 13.65 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.713 -0.617 . . . . 0.0 109.833 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 93.93 9.22 59.85 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.547 ' N ' ' CD2' ' A' ' 69' ' ' HIS . 2.5 m170 -100.54 105.41 16.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.097 -1.237 . . . . 0.0 109.218 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.523 ' CG ' HD22 ' A' ' 63' ' ' LEU . 2.9 tttt -53.77 125.07 17.12 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.134 -0.979 . . . . 0.0 109.303 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.523 ' O ' ' N ' ' A' ' 64' ' ' ILE . . . -147.18 145.99 29.7 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.566 -0.709 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.555 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -115.43 155.31 16.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 105.93 -1.878 . . . . 0.0 105.93 177.438 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.489 ' N ' HG21 ' A' ' 72' ' ' ILE . . . -178.67 -173.38 43.97 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 118.14 -1.981 . . . . 0.0 111.367 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.485 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -93.51 107.43 19.28 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.776 -0.838 . . . . 0.0 109.555 -179.763 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.511 HG12 HD12 ' A' ' 15' ' ' ILE . 1.5 t -102.72 111.58 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.341 -0.849 . . . . 0.0 110.45 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.488 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.3 mp -81.79 122.9 28.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.439 -0.788 . . . . 0.0 109.211 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.514 HG11 ' HA ' ' A' ' 35' ' ' GLU . 71.9 t -103.96 118.84 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.093 -1.005 . . . . 0.0 109.769 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.464 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -156.03 -165.6 14.76 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.1 Cg_endo -80.31 43.26 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 122.72 2.28 . . . . 0.0 110.795 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.49 ' O ' ' HG2' ' A' ' 34' ' ' GLU . 9.2 t -89.05 139.02 28.83 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -79.6 17.96 1.18 Allowed 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.568 2.178 . . . . 0.0 111.81 -179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.481 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.74 166.98 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.543 -1.348 . . . . 0.0 110.659 -179.811 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.556 ' OD1' ' CD2' ' A' ' 33' ' ' LEU . 7.5 m-80 -96.87 93.53 6.71 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 176.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 31' ' ' THR . 26.7 mm -78.42 127.25 38.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 O-C-N 120.727 -1.233 . . . . 0.0 112.154 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.512 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -107.43 89.96 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 177.232 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.14 -165.0 28.81 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 120.276 -0.964 . . . . 0.0 111.217 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 9.5 mtm180 -64.42 -31.05 72.1 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.793 -0.828 . . . . 0.0 109.92 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.614 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 11.2 p-10 -48.61 -26.04 2.04 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.145 -0.972 . . . . 0.0 109.422 -179.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.614 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -106.75 -21.15 13.13 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.01 -1.056 . . . . 0.0 108.837 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.539 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 43.4 mt -72.61 -4.09 28.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 177.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.538 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -100.57 -18.43 16.61 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 178.294 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.47 ' HA ' ' OE1' ' A' ' 92' ' ' GLN . 50.6 mm-40 -83.06 -40.9 19.27 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.533 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 1.4 pt -89.0 5.27 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.418 -0.801 . . . . 0.0 109.397 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 58.98 47.66 89.62 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.474 ' HB1' HD13 ' A' ' 93' ' ' ILE . . . -70.69 155.1 41.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.137 -1.214 . . . . 0.0 110.76 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 24.1 p -146.74 126.09 13.12 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.58 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.0 mp -93.46 86.04 5.12 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.483 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.486 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 5.3 m120 -91.38 124.4 35.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.289 -0.882 . . . . 0.0 109.652 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.045 -0.978 . . . . 0.0 109.196 179.355 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.584 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.718 0 N-CA-C 110.572 -0.588 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.416 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 0.3 OUTLIER -99.66 117.44 34.02 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.533 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.51 HG13 ' HB3' ' B' ' 9' ' ' PRO . 9.1 t -108.04 114.69 47.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 108.605 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.537 ' C ' ' CD1' ' B' ' 5' ' ' LEU . 19.8 p -67.79 -105.19 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.274 -0.891 . . . . 0.0 109.073 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.546 ' CD2' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -171.88 -11.64 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.828 -1.17 . . . . 0.0 111.434 179.824 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.546 ' N ' ' CD2' ' B' ' 5' ' ' LEU . 72.2 m95 -66.61 -10.53 46.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.69 -1.256 . . . . 0.0 109.49 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.96 178.59 7.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 109.615 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.498 ' HG2' ' NH1' ' A' ' 87' ' ' ARG . 13.8 mtt180 -92.18 138.56 24.35 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.316 -0.865 . . . . 0.0 109.157 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.6 Cg_endo -79.49 59.93 7.6 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.246 1.964 . . . . 0.0 110.147 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.537 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.2 OUTLIER -86.43 145.72 26.73 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.945 -1.097 . . . . 0.0 109.102 -179.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.52 ' CG2' HG21 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -145.15 136.01 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.651 -179.137 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.44 HG23 HD21 ' B' ' 19' ' ' LEU . 86.5 m -68.26 90.5 0.35 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.52 HG21 ' CG2' ' B' ' 11' ' ' VAL . 47.8 pt -79.09 153.7 4.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.451 -0.781 . . . . 0.0 110.02 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.524 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 3.2 tttt -115.14 100.56 8.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.413 -0.804 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.546 ' CG1' ' HB ' ' B' ' 64' ' ' ILE . 11.1 mt -122.81 131.19 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.55 48.65 85.0 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.55 20.96 6.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.446 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -112.98 171.44 7.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.155 -1.203 . . . . 0.0 109.714 -179.805 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.524 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 55.5 mt -143.47 127.67 17.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.378 -0.826 . . . . 0.0 109.524 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -147.95 165.99 29.06 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 108.912 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.508 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 2.5 mm-40 -78.55 127.37 32.04 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.055 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.563 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.57 159.07 16.05 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.886 -1.134 . . . . 0.0 109.808 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.403 ' O ' ' C ' ' B' ' 24' ' ' LEU . 19.2 tp -122.53 93.76 4.08 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.485 -0.76 . . . . 0.0 109.109 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.525 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 21.7 mt -46.41 110.66 0.29 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.994 -1.066 . . . . 0.0 108.243 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.565 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 56.3 t0 -122.07 91.65 3.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.19 -0.944 . . . . 0.0 110.403 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.426 HG23 ' HG3' ' A' ' 9' ' ' PRO . 1.3 m -65.0 -10.3 28.49 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.9 -1.125 . . . . 0.0 108.78 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.74 -46.94 58.85 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.41 164.92 26.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.154 -1.204 . . . . 0.0 109.496 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -101.14 -15.44 17.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.027 -1.046 . . . . 0.0 110.969 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.584 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -132.08 -163.37 1.33 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.778 -1.201 . . . . 0.0 110.024 -179.3 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.659 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 67.0 m -113.39 91.34 3.61 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.052 -1.03 . . . . 0.0 110.012 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.482 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.8 OUTLIER -77.56 156.17 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.371 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.482 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -152.78 124.36 7.76 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.595 -1.316 . . . . 0.0 110.162 -178.894 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.491 ' HG2' ' N ' ' B' ' 35' ' ' GLU . 47.5 tt0 -36.56 153.3 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.491 ' N ' ' HG2' ' B' ' 34' ' ' GLU . 1.5 tt0 -53.63 152.49 5.11 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -0.981 . . . . 0.0 109.93 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.483 ' HE3' HG23 ' B' ' 15' ' ' ILE . 3.3 ptm -177.26 -174.12 0.48 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.486 -0.759 . . . . 0.0 109.406 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -91.52 105.73 17.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 109.648 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.434 HD13 ' HD2' ' B' ' 39' ' ' PRO . 32.2 tp -134.96 105.07 10.5 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.718 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.434 ' HD2' HD13 ' B' ' 38' ' ' LEU . 36.7 Cg_endo -78.24 138.7 16.19 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.451 2.101 . . . . 0.0 110.147 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.95 179.45 22.17 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.12 139.72 35.47 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.276 -1.132 . . . . 0.0 109.13 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.577 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 38.7 p-90 -150.36 153.38 35.92 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.138 -0.976 . . . . 0.0 109.958 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.77 131.16 24.25 Favored Pre-proline 0 N--CA 1.489 1.478 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.12 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.72 135.79 16.37 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.982 1.788 . . . . 0.0 110.708 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.528 ' HG3' ' CG2' ' B' ' 56' ' ' VAL . 1.1 ptmm? -158.04 -168.35 2.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.543 -0.723 . . . . 0.0 109.059 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.51 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 1.0 OUTLIER -145.36 121.1 10.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.097 -1.002 . . . . 0.0 110.015 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.552 HD13 ' CG2' ' A' ' 50' ' ' ILE . 2.4 pt -92.26 141.18 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.25 -0.906 . . . . 0.0 108.618 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.56 108.65 1.53 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.47 -119.09 2.21 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.499 -1.334 . . . . 0.0 110.244 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.563 ' CG2' HD13 ' A' ' 47' ' ' ILE . 25.8 mt -87.75 130.87 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.441 -1.035 . . . . 0.0 111.781 -178.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 54' ' ' ILE . . . 91.3 -45.0 2.79 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.549 -1.021 . . . . 0.0 110.549 178.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.417 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.36 -159.36 29.38 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.444 -1.36 . . . . 0.0 110.167 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.535 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -121.62 139.34 53.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.505 -0.997 . . . . 0.0 109.16 -179.715 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' B' ' 46' ' ' MET . 32.4 pt -114.31 -176.16 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.257 -0.902 . . . . 0.0 109.655 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.517 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -107.28 150.03 27.12 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.321 -0.862 . . . . 0.0 108.955 179.406 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.528 ' CG2' ' HG3' ' B' ' 45' ' ' LYS . 3.2 m -143.72 -174.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 120.788 -1.195 . . . . 0.0 110.655 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.479 ' HG3' ' O ' ' B' ' 77' ' ' VAL . 3.6 mtm-85 -142.41 88.47 2.08 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.525 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 2.2 tt0 -48.02 95.05 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.314 -0.866 . . . . 0.0 110.296 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.2 m-85 -92.43 92.82 8.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 4.6 m-20 -79.88 130.72 35.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.97 -1.081 . . . . 0.0 111.025 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.516 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 2.9 mt-30 84.95 59.27 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 CA-C-O 121.165 0.507 . . . . 0.0 110.968 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.494 HG13 ' HB3' ' B' ' 59' ' ' TYR . 13.2 mm -118.41 124.9 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -1.0 . . . . 0.0 108.579 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.538 ' CD2' ' HG3' ' B' ' 70' ' ' LYS . 1.9 tm? -72.16 99.99 2.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.174 -0.954 . . . . 0.0 110.998 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.572 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 1.3 tt -104.7 117.62 50.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.47 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 31.7 tt0 -90.77 108.56 19.9 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.091 -1.006 . . . . 0.0 109.118 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.489 HD12 HD11 ' B' ' 64' ' ' ILE . 1.1 mp -99.03 116.89 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.957 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.474 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 10.1 m 64.26 17.28 10.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.821 -0.55 . . . . 0.0 110.649 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 96.94 4.11 58.92 Favored Glycine 0 N--CA 1.492 2.423 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.15 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -104.68 116.33 31.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.049 -1.265 . . . . 0.0 109.418 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.538 ' HG3' ' CD2' ' B' ' 63' ' ' LEU . 14.7 tttt -52.81 137.86 30.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.45 -0.782 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.572 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -160.13 100.88 1.4 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.18 -0.95 . . . . 0.0 109.619 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.476 HD12 ' HB2' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.31 156.56 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.642 -1.286 . . . . 0.0 108.32 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.438 ' N ' HG21 ' B' ' 72' ' ' ILE . . . -177.75 176.27 47.95 Favored Glycine 0 N--CA 1.488 2.149 0 C-N-CA 118.999 -1.572 . . . . 0.0 111.167 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.525 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 10.6 m -88.51 109.85 20.39 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.63 -0.924 . . . . 0.0 110.376 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' B' ' 31' ' ' THR . 0.8 OUTLIER -99.84 110.89 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.274 -0.891 . . . . 0.0 110.534 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.584 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -79.52 104.27 10.01 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 26.3 t -88.77 125.5 41.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 120.777 -1.202 . . . . 0.0 110.017 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -153.01 -169.32 18.05 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.517 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -81.44 41.86 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.557 2.171 . . . . 0.0 110.793 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.464 HG22 HG11 ' B' ' 32' ' ' VAL . 14.6 t -84.73 140.15 37.88 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 36.6 Cg_endo -79.38 14.0 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.376 2.051 . . . . 0.0 111.175 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.516 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -160.85 176.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.825 -1.172 . . . . 0.0 110.591 -179.47 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.563 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -107.98 147.78 30.61 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 176.721 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.659 ' O ' ' HA ' ' B' ' 31' ' ' THR . 4.6 mm -135.3 100.1 2.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 O-C-N 120.902 -1.124 . . . . 0.0 110.963 -177.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.602 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 0.7 OUTLIER -79.2 88.86 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -81.23 -160.42 24.84 Favored Glycine 0 N--CA 1.494 2.555 0 O-C-N 121.363 -0.836 . . . . 0.0 112.103 -177.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . . . . . . . . . 5.8 mtm180 -58.91 -41.0 86.22 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 122.148 -0.619 . . . . 0.0 111.386 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.539 ' ND2' HD21 ' B' ' 89' ' ' LEU . 10.9 p-10 -52.23 -18.89 1.71 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.979 -1.076 . . . . 0.0 109.956 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.539 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.4 mm? -114.75 -23.92 8.96 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 120.928 -1.107 . . . . 0.0 108.933 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 25.9 mt -71.84 -6.79 44.21 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 59.9 p -101.19 -17.79 16.46 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.299 -0.876 . . . . 0.0 108.753 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -83.7 -41.49 17.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.415 -0.803 . . . . 0.0 109.502 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.508 HD11 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -84.7 -4.64 8.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.165 -0.959 . . . . 0.0 108.713 179.282 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.97 58.67 7.2 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -81.03 157.81 25.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.112 -1.228 . . . . 0.0 110.347 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.511 ' CG2' ' CG2' ' A' ' 4' ' ' THR . 9.4 p -139.6 126.07 20.34 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.58 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -95.88 89.38 5.23 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.104 -179.156 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.542 ' N ' ' ND2' ' B' ' 98' ' ' ASN . 0.6 OUTLIER -101.55 132.7 47.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -0.83 . . . . 0.0 110.568 -178.966 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.533 ' HB2' ' HB ' ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 117.946 -1.026 . . . . 0.0 108.751 178.272 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.425 ' HD2' ' C ' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.318 -0.686 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.53 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -84.26 131.92 34.69 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.403 HG13 ' HB3' ' A' ' 9' ' ' PRO . 51.2 t -131.53 118.78 40.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 120.998 -1.064 . . . . 0.0 110.209 -178.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.434 ' O ' ' C ' ' A' ' 5' ' ' LEU . 2.2 p -127.71 -90.91 0.51 Allowed 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.56 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 41.63 29.17 0.1 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.48 -0.762 . . . . 0.0 109.432 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.56 ' C ' ' O ' ' A' ' 5' ' ' LEU . 37.3 m0 18.07 51.84 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 CA-C-O 121.638 0.732 . . . . 0.0 111.326 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.546 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.9 mt-30 -142.3 -166.66 2.3 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.9 mtm180 -74.25 116.4 52.35 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.511 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.5 Cg_endo -76.53 73.84 5.0 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.269 1.979 . . . . 0.0 109.763 179.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -81.53 158.56 24.42 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.32 -0.862 . . . . 0.0 110.301 -179.113 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.495 HG12 ' HG ' ' A' ' 24' ' ' LEU . 4.0 m -149.85 130.54 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.408 -0.808 . . . . 0.0 109.588 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.0 m -68.49 106.09 2.43 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.544 ' CG2' ' HB1' ' A' ' 22' ' ' ALA . 6.8 pt -92.24 155.06 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.21 -0.931 . . . . 0.0 110.285 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.461 ' HE2' HD13 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -119.02 105.83 11.82 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.059 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.527 HG22 ' CG2' ' A' ' 62' ' ' ILE . 8.1 mt -123.99 127.08 73.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 120.987 -1.071 . . . . 0.0 109.819 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.73 35.55 91.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.63 9.88 52.71 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -104.64 -179.4 3.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.374 -1.074 . . . . 0.0 109.297 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.483 ' C ' ' HG2' ' A' ' 20' ' ' LYS . 3.6 mt -145.9 131.25 18.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 110.269 -179.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.483 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -145.51 157.02 44.06 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.272 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.519 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 19.7 mp0 -78.98 133.63 36.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.842 -1.161 . . . . 0.0 107.93 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -113.68 144.07 43.55 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.994 -1.066 . . . . 0.0 111.07 -178.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 58.8 tp -98.71 92.67 5.7 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.511 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 74.0 mt -43.94 96.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 51.4 t0 -110.74 92.8 4.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.458 -0.776 . . . . 0.0 110.461 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.52 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 6.0 m -67.31 -10.66 53.07 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 108.758 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -74.19 -43.18 33.35 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.42 149.37 50.13 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.9 -1.353 . . . . 0.0 109.202 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -84.45 -19.94 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 110.133 -179.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.494 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -136.57 -162.25 1.26 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.067 -1.02 . . . . 0.0 109.499 -179.503 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.511 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 20.4 m -115.77 100.41 8.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.473 -1.392 . . . . 0.0 111.235 -178.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -78.0 178.15 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.695 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.558 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -169.15 116.35 0.62 Allowed 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.935 -1.103 . . . . 0.0 110.213 -179.241 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.495 ' HA ' HG23 ' A' ' 80' ' ' THR . 41.2 tt0 -39.35 162.02 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.29 -0.881 . . . . 0.0 109.966 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.466 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -41.34 156.85 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.218 -0.926 . . . . 0.0 110.738 -179.562 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.516 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 11.2 ptm -179.02 -176.94 0.45 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.548 -0.72 . . . . 0.0 109.149 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.8 t -104.52 118.69 37.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.417 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.619 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 9.9 mt -132.92 170.65 10.85 Favored Pre-proline 0 N--CA 1.493 1.694 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.619 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -69.53 -163.06 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.287 0 C-N-CA 122.079 1.853 . . . . 0.0 111.671 -179.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -105.39 35.09 5.3 Favored Glycine 0 N--CA 1.494 2.502 0 C-N-CA 119.968 -1.111 . . . . 0.0 111.169 -178.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.5 mtt85 -109.56 50.44 0.79 Allowed 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.7 p-90 -133.43 176.79 8.22 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.867 0.841 . . . . 0.0 110.542 -178.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.26 151.74 34.53 Favored Pre-proline 0 C--N 1.302 -1.486 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.01 130.37 11.24 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.759 1.639 . . . . 0.0 110.655 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.527 ' O ' ' CG2' ' A' ' 56' ' ' VAL . 3.6 ptmt -161.42 129.14 4.17 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.509 ' CG ' ' HG3' ' A' ' 55' ' ' LYS . 15.4 mtp -89.58 135.01 33.85 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.941 -1.1 . . . . 0.0 109.417 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.521 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 7.0 pt -89.4 145.91 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.244 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 98.36 0.76 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.104 -1.599 . . . . 0.0 109.104 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.98 -124.1 2.99 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.46 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.516 HG22 HD13 ' B' ' 47' ' ' ILE . 9.9 mt -88.87 119.15 35.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.636 -0.92 . . . . 0.0 112.693 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.509 ' N ' HG21 ' B' ' 54' ' ' ILE . . . 106.54 -51.3 0.75 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 177.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.28 -155.52 16.13 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.6 m-85 -118.41 128.66 54.83 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.456 -1.026 . . . . 0.0 109.995 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 46' ' ' MET . 10.1 pt -101.77 169.69 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 16.1 mttt -99.62 134.57 42.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.019 -1.051 . . . . 0.0 108.958 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 34.7 m -140.51 -177.61 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.957 -1.089 . . . . 0.0 110.255 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -128.97 91.65 3.25 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.467 ' CD ' HG23 ' A' ' 74' ' ' THR . 2.4 tp-100 -55.06 105.08 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.62 -0.675 . . . . 0.0 110.71 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.646 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.4 m-85 -96.45 129.04 43.9 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.515 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 40.0 m-20 -111.17 133.41 53.55 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.738 -1.226 . . . . 0.0 109.771 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.566 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 7.8 mm100 78.29 61.91 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.648 -0.657 . . . . 0.0 109.994 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.553 ' N ' HD11 ' A' ' 62' ' ' ILE . 4.4 mp -119.45 126.55 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.349 -0.844 . . . . 0.0 108.749 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.558 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 3.1 tm? -77.87 94.47 4.55 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.149 0.976 . . . . 0.0 111.613 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.557 ' CG2' HD13 ' A' ' 89' ' ' LEU . 3.2 tt -98.02 119.79 46.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.402 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -91.11 125.3 35.85 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.827 -1.17 . . . . 0.0 108.804 -179.876 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.546 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.2 OUTLIER -121.61 135.37 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.103 -0.998 . . . . 0.0 109.748 -179.314 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 66' ' ' ILE . 59.5 m 36.93 38.23 0.08 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.088 0.47 . . . . 0.0 110.578 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.34 47.64 8.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.518 ' CB ' HG23 ' A' ' 93' ' ' ILE . 73.6 m-70 -141.18 123.28 15.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.346 -1.091 . . . . 0.0 109.353 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.544 ' CG ' HD22 ' A' ' 63' ' ' LEU . 6.9 tttt -77.76 122.09 24.92 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.223 -0.923 . . . . 0.0 108.558 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.43 ' HB2' ' CD1' ' A' ' 89' ' ' LEU . . . -144.43 124.27 13.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.033 -1.042 . . . . 0.0 110.818 -178.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.566 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -102.65 120.15 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.232 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.474 ' O ' HD11 ' A' ' 62' ' ' ILE . . . -144.15 -165.43 10.94 Favored Glycine 0 C--N 1.289 -2.06 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.872 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.478 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 38.0 m -97.43 114.72 26.6 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.503 -0.998 . . . . 0.0 110.305 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.524 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.5 t -106.43 118.89 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 C-N-CA 120.216 -0.593 . . . . 0.0 110.159 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.535 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.4 mp -89.44 126.24 35.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.103 -0.998 . . . . 0.0 109.177 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.558 ' CG2' HD13 ' A' ' 38' ' ' LEU . 1.7 t -108.5 120.58 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -157.08 -169.32 20.8 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.536 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -80.8 39.86 0.91 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.605 2.203 . . . . 0.0 110.886 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 34' ' ' GLU . 15.1 t -82.39 139.96 44.95 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.16 14.57 1.52 Allowed 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.222 1.948 . . . . 0.0 111.084 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.497 HG11 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.23 165.0 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 120.96 -1.088 . . . . 0.0 109.778 -179.408 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.616 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.75 145.92 28.47 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 175.979 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.532 HG21 ' CB ' ' A' ' 25' ' ' ASP . 3.3 mm -129.92 129.99 66.14 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 O-C-N 120.047 -1.658 . . . . 0.0 111.743 -177.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.482 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 0.8 OUTLIER -104.95 96.39 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.834 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -82.29 -169.34 43.38 Favored Glycine 0 N--CA 1.492 2.376 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.481 -178.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.43 -30.43 71.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.581 -0.953 . . . . 0.0 109.789 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.6 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 14.6 p-10 -50.51 -28.64 8.83 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.986 -1.071 . . . . 0.0 109.782 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.6 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 3.0 mm? -110.11 -27.87 8.95 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.011 -1.056 . . . . 0.0 110.652 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.52 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 33.9 mt -65.49 -13.57 59.14 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.739 -1.226 . . . . 0.0 109.322 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.4 p -96.69 -21.3 17.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.046 -1.034 . . . . 0.0 109.254 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.456 ' HG3' ' HA ' ' A' ' 89' ' ' LEU . 2.0 mt-30 -74.92 -40.26 60.96 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.176 -0.953 . . . . 0.0 108.521 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.546 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -79.59 1.11 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 178.603 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.66 59.48 8.14 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -87.86 156.43 19.39 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.301 -1.117 . . . . 0.0 109.914 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.53 HG21 ' CG2' ' B' ' 4' ' ' THR . 2.2 p -138.86 129.27 25.78 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.58 ' HB3' ' CE2' ' A' ' 99' ' ' PHE . 1.1 mp -95.52 90.38 5.73 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.5 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.5 m120 -89.52 125.77 35.33 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.213 -0.929 . . . . 0.0 109.939 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.952 -1.023 . . . . 0.0 109.022 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.5 Cg_endo . . . . . 0 N--CA 1.497 1.708 0 N-CA-C 110.14 -0.754 . . . . 0.0 110.14 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.459 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 2.9 tt0 -84.56 114.67 22.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.78 115.07 46.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.956 -1.09 . . . . 0.0 111.104 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.53 ' CG2' HG21 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.46 32.51 1.48 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.322 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.526 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.7 mt -85.55 49.05 1.68 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.598 -0.689 . . . . 0.0 109.925 -179.047 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.526 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.8 m95 17.84 52.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.229 0.537 . . . . 0.0 112.174 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.9 mt-30 -154.95 171.5 19.61 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.221 -0.924 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -63.87 144.19 98.06 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 120.99 -1.069 . . . . 0.0 109.492 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.465 ' HG3' HG23 ' A' ' 26' ' ' THR . 36.7 Cg_endo -80.15 54.9 5.42 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.645 2.23 . . . . 0.0 110.904 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 3.1 mt -80.62 135.23 36.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.988 -1.07 . . . . 0.0 108.89 179.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.47 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -134.88 141.82 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.181 -0.95 . . . . 0.0 109.604 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.405 HG21 HD21 ' B' ' 19' ' ' LEU . 10.1 m -70.17 100.53 1.68 Allowed 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 178.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.55 HG22 ' CB ' ' B' ' 22' ' ' ALA . 4.4 pt -95.12 143.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.404 -0.81 . . . . 0.0 110.055 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.0 OUTLIER -98.95 107.78 20.3 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 178.905 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.586 ' CG2' ' CE ' ' B' ' 36' ' ' MET . 10.2 mm -113.83 115.45 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 120.756 -1.215 . . . . 0.0 110.865 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.474 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.15 9.21 56.79 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.44 -10.05 42.23 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.426 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 1.5 mp0 -89.86 -173.29 3.84 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.264 -1.139 . . . . 0.0 109.063 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.448 ' C ' ' HG2' ' B' ' 20' ' ' LYS . 18.0 mt -149.13 121.86 8.66 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.889 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.465 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 4.9 mmtt -141.83 172.55 12.53 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.488 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -79.65 155.3 28.13 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.227 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.55 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -135.76 113.02 10.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.532 ' CD2' ' O ' ' A' ' 27' ' ' GLY . 3.3 tp -84.15 104.01 13.85 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.44 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 16.3 mt -52.45 103.9 0.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.548 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 19.9 t0 -101.16 77.96 1.86 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.37 -0.831 . . . . 0.0 110.174 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.486 ' CG2' HD11 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.02 -14.46 9.58 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.079 -1.013 . . . . 0.0 108.962 178.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.42 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -70.8 -35.46 66.14 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.3 170.86 14.16 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.938 -1.33 . . . . 0.0 110.234 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -100.54 -18.8 16.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.291 -0.881 . . . . 0.0 110.796 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.513 ' HB3' HD12 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -132.92 -170.54 2.47 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.599 -1.313 . . . . 0.0 110.625 -179.059 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.537 HG23 ' CD1' ' B' ' 33' ' ' LEU . 21.1 m -106.07 91.83 3.89 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.938 -1.102 . . . . 0.0 110.558 -178.769 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.481 HG23 HD12 ' B' ' 47' ' ' ILE . 0.4 OUTLIER -81.01 154.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.717 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.537 ' CD1' HG23 ' B' ' 31' ' ' THR . 1.3 mp -148.91 133.62 17.85 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.919 -1.113 . . . . 0.0 110.667 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.501 ' HA ' HG21 ' B' ' 80' ' ' THR . 3.9 mt-10 -43.5 166.69 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.468 -0.77 . . . . 0.0 109.284 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.0 OUTLIER -67.9 115.1 7.04 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.407 -0.808 . . . . 0.0 109.25 179.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.586 ' CE ' ' CG2' ' B' ' 15' ' ' ILE . 6.7 ptm -139.46 -166.8 2.13 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.4 t -95.34 115.35 27.31 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.262 -0.899 . . . . 0.0 109.93 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.489 ' O ' ' OH ' ' B' ' 59' ' ' TYR . 26.5 tp -144.42 105.0 4.67 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.472 ' HD2' HD13 ' B' ' 38' ' ' LEU . 36.5 Cg_endo -76.41 146.0 27.35 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.398 2.065 . . . . 0.0 110.848 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 136.96 145.24 4.94 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -63.95 117.94 7.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.98 -1.306 . . . . 0.0 108.501 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . . . . . . . . . 48.9 p-90 -110.95 175.89 5.24 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 110.31 -178.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.0 mmtt -126.03 137.03 29.34 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -76.56 129.14 10.75 Favored 'Trans proline' 0 C--N 1.303 -1.838 0 C-N-CA 121.799 1.666 . . . . 0.0 110.812 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.527 ' O ' ' HG3' ' B' ' 45' ' ' LYS . 0.0 OUTLIER -161.62 137.66 7.95 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.062 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.502 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 25.3 mtp -102.0 137.88 39.7 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.832 -1.168 . . . . 0.0 109.332 -179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.539 ' O ' ' HA ' ' B' ' 53' ' ' PHE . 2.1 pt -89.72 164.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -138.23 108.22 0.61 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.61 -116.89 1.4 Allowed Glycine 0 N--CA 1.484 1.881 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.357 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.512 ' CG2' HD13 ' A' ' 47' ' ' ILE . 14.3 mt -85.79 122.79 38.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.6 -0.941 . . . . 0.0 112.019 -178.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.482 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 99.02 -52.8 1.08 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.418 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.45 -153.91 18.87 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.604 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.4 m-85 -113.54 135.81 53.49 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.494 -1.003 . . . . 0.0 109.941 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.511 HG13 ' CG1' ' B' ' 47' ' ' ILE . 1.8 pt -104.31 179.49 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.564 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -108.45 130.12 55.25 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 109.164 179.574 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.492 ' CG2' ' HG3' ' B' ' 45' ' ' LYS . 3.7 m -134.0 169.61 21.38 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.947 -1.096 . . . . 0.0 110.175 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.435 ' HD3' ' HB ' ' B' ' 77' ' ' VAL . 8.9 mtp180 -120.26 87.78 2.81 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.492 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 3.0 tt0 -48.42 99.28 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.525 -0.734 . . . . 0.0 110.561 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.532 ' O ' ' HA ' ' B' ' 74' ' ' THR . 5.2 m-85 -88.78 136.96 32.73 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 177.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 7.1 m-20 -114.86 133.37 56.02 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.571 -1.331 . . . . 0.0 110.882 -178.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.584 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 3.9 mp0 71.49 63.77 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.614 0.721 . . . . 0.0 109.849 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.47 ' HB ' HG22 ' B' ' 75' ' ' VAL . 9.1 mm -111.46 111.6 36.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.536 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.1 tm? -65.39 85.71 0.07 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.445 -0.784 . . . . 0.0 110.266 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.488 ' HA ' ' O ' ' B' ' 14' ' ' LYS . 3.8 tt -89.11 125.28 42.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 33.1 tt0 -89.2 109.01 19.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.126 -0.984 . . . . 0.0 109.506 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.499 HG13 HG21 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.79 122.47 57.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.282 -0.886 . . . . 0.0 108.753 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.548 ' HB3' ' CD2' ' B' ' 69' ' ' HIS . 0.1 OUTLIER 53.83 54.56 9.63 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.489 -0.757 . . . . 0.0 110.631 179.026 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.15 20.51 28.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.548 ' CD2' ' HB3' ' B' ' 67' ' ' CYS . 87.8 m-70 -115.57 127.53 55.31 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.996 -1.296 . . . . 0.0 109.183 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.7 131.28 42.91 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.073 -1.017 . . . . 0.0 109.106 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.455 ' O ' HD23 ' B' ' 63' ' ' LEU . . . -150.69 146.6 26.57 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.632 -0.667 . . . . 0.0 109.243 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.584 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -114.25 156.71 15.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.432 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -179.3 173.37 45.38 Favored Glycine 0 N--CA 1.485 1.944 0 C-N-CA 118.632 -1.747 . . . . 0.0 111.055 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 88.2 m -89.97 112.79 24.3 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.5 -1.0 . . . . 0.0 109.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.475 HG23 HD11 ' B' ' 15' ' ' ILE . 1.4 t -100.94 112.7 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.897 179.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.513 HD12 ' HB3' ' B' ' 30' ' ' ASP . 1.9 mp -81.82 105.73 13.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.533 -0.729 . . . . 0.0 109.061 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.435 ' HB ' ' HD3' ' B' ' 57' ' ' ARG . 2.9 t -88.1 114.1 26.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 O-C-N 120.514 -1.366 . . . . 0.0 109.742 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -151.4 -170.42 18.23 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.564 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.3 Cg_endo -79.57 41.1 1.04 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 C-N-CA 122.434 2.089 . . . . 0.0 111.308 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.525 HG22 ' O ' ' B' ' 82' ' ' VAL . 0.7 OUTLIER -85.82 137.73 35.68 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 178.374 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 34.7 Cg_endo -78.5 21.52 0.69 Allowed 'Trans proline' 0 C--N 1.301 -1.921 0 C-N-CA 122.32 2.013 . . . . 0.0 112.13 -178.317 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.535 ' CG1' HG13 ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.68 151.72 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.457 -1.402 . . . . 0.0 111.097 -179.735 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.546 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -92.4 87.36 5.98 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 176.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.548 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 1.1 mt -84.71 123.62 39.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.896 0.855 . . . . 0.0 112.914 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.553 ' N ' HD11 ' B' ' 85' ' ' ILE . 3.5 mm -95.8 96.42 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.5 -161.07 18.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.108 -177.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 7' ' ' GLN . 1.4 mtm105 -64.88 -31.01 72.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.893 -0.769 . . . . 0.0 110.65 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.582 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 13.8 p-10 -54.8 -26.88 37.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.737 -1.227 . . . . 0.0 110.211 -179.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.582 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -108.83 -31.39 7.71 Favored 'General case' 0 N--CA 1.484 1.258 0 O-C-N 120.766 -1.209 . . . . 0.0 110.091 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.486 HD11 ' CG2' ' B' ' 26' ' ' THR . 81.9 mt -62.42 -31.1 71.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 57.4 p -79.09 -21.69 46.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.41 -0.806 . . . . 0.0 109.457 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -67.55 -40.15 84.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.554 HD11 ' CB ' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -87.92 -7.55 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.497 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.72 64.95 2.82 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -90.29 142.36 27.81 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.427 -1.043 . . . . 0.0 111.011 -178.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 8.3 p -130.35 130.61 44.64 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.51 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 3.9 mp -94.36 96.88 9.82 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.158 -0.964 . . . . 0.0 109.903 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.53 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -103.22 124.59 48.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.068 -1.02 . . . . 0.0 109.129 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.546 ' CB ' HD11 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.437 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.603 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.9 Cg_exo . . . . . 0 N--CA 1.494 1.549 0 N-CA-C 110.669 -0.55 . . . . 0.0 110.669 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.491 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 7.6 tt0 -84.67 108.2 17.27 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 177.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.558 HG22 ' CZ ' ' B' ' 99' ' ' PHE . 16.7 t -102.95 121.25 53.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.064 -1.022 . . . . 0.0 109.484 -178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -73.09 -4.86 35.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.351 -178.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.544 ' HB3' ' HG2' ' B' ' 87' ' ' ARG . 5.5 mt 66.24 45.15 2.34 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.192 -0.942 . . . . 0.0 110.082 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.516 ' HA ' HG22 ' B' ' 91' ' ' THR . 1.4 m95 -65.84 -20.65 66.32 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.032 -1.042 . . . . 0.0 110.511 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.575 ' O ' ' CD ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -166.35 -99.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.956 -1.09 . . . . 0.0 110.092 179.821 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -113.49 140.3 24.33 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.774 -1.204 . . . . 0.0 109.565 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.543 ' CB ' ' HB2' ' A' ' 24' ' ' LEU . 34.7 Cg_endo -80.46 53.79 4.93 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.254 1.969 . . . . 0.0 109.693 177.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.54 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 1.3 mt -79.51 134.43 36.51 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.852 -1.155 . . . . 0.0 110.2 -178.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.49 HG22 HG21 ' A' ' 66' ' ' ILE . 1.6 m -150.99 163.71 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.667 -0.646 . . . . 0.0 109.317 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.46 ' CG2' HD23 ' A' ' 19' ' ' LEU . 3.5 m -86.56 119.07 26.42 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.53 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 18.8 pt -110.49 137.49 42.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.335 -0.853 . . . . 0.0 109.709 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.522 ' CB ' HD22 ' A' ' 19' ' ' LEU . 1.1 ttpp -106.96 107.7 18.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.125 -0.984 . . . . 0.0 109.299 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.528 HG13 HG13 ' A' ' 64' ' ' ILE . 5.1 mt -113.26 131.36 65.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.962 . . . . 0.0 109.201 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.41 -88.57 0.34 Allowed Glycine 0 N--CA 1.485 1.924 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -178.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 23.9 0.32 Allowed Glycine 0 C--N 1.293 -1.829 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.462 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 29.2 mt-30 -118.25 177.99 4.6 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.64 -0.918 . . . . 0.0 109.295 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.522 HD22 ' CB ' ' A' ' 14' ' ' LYS . 13.2 mt -143.7 119.08 10.25 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.692 0.758 . . . . 0.0 110.001 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -133.62 172.53 12.62 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.54 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 21.0 mt-10 -77.58 166.35 23.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.893 -1.129 . . . . 0.0 108.143 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.591 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -147.66 132.43 17.96 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.798 -1.189 . . . . 0.0 110.405 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.423 ' O ' ' C ' ' A' ' 24' ' ' LEU . 40.7 tp -104.84 90.17 3.39 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.709 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.543 ' HB2' ' CB ' ' A' ' 9' ' ' PRO . 38.2 mt -46.86 107.23 0.1 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.852 -1.155 . . . . 0.0 108.253 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.579 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.4 t0 -112.27 89.67 3.13 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.346 -0.846 . . . . 0.0 109.852 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.593 ' CG2' HD11 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -61.8 -21.19 64.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.072 -1.017 . . . . 0.0 108.422 179.325 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.476 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -60.45 -38.21 94.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.47 160.62 18.21 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.069 -1.254 . . . . 0.0 109.566 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -100.25 -6.81 25.42 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.459 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.557 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.56 179.29 6.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.169 -0.957 . . . . 0.0 110.081 -179.489 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.681 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 5.9 m -106.11 96.01 6.18 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.224 -0.923 . . . . 0.0 109.309 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.559 HG11 ' CG2' ' A' ' 80' ' ' THR . 1.2 t -87.46 105.45 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.126 0 O-C-N 121.21 -0.931 . . . . 0.0 110.055 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.526 HD23 ' CD1' ' A' ' 15' ' ' ILE . 1.5 mp -100.17 133.4 44.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.315 -0.866 . . . . 0.0 112.14 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.627 ' HA ' HG21 ' A' ' 80' ' ' THR . 11.8 pt-20 -42.41 153.34 0.07 Allowed 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 177.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.54 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.4 mt-10 -53.17 131.32 36.75 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 120.934 -1.104 . . . . 0.0 109.614 -179.417 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.517 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -146.17 175.64 10.34 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.06 179.896 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.409 ' O ' ' SD ' ' A' ' 36' ' ' MET . 16.5 t -86.45 107.31 18.0 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.291 -0.881 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.504 HD23 ' CG2' ' A' ' 15' ' ' ILE . 20.9 mt -121.12 110.79 34.31 Favored Pre-proline 0 N--CA 1.488 1.436 0 O-C-N 121.291 -0.88 . . . . 0.0 109.213 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -78.84 116.96 3.83 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.806 2.337 . . . . 0.0 110.659 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 151.82 -168.53 31.17 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.3 mmt180 -92.65 157.09 16.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.556 -0.967 . . . . 0.0 108.891 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.585 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 59.9 p-90 -160.01 172.91 16.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.179 -0.951 . . . . 0.0 109.843 -179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.2 mttt -136.37 160.23 67.66 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.75 141.19 16.99 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.111 1.874 . . . . 0.0 110.914 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.01 171.38 15.36 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.07 132.88 15.0 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.883 -1.135 . . . . 0.0 110.074 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.472 HD13 HD12 ' A' ' 54' ' ' ILE . 6.1 pt -117.31 146.59 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.174 -0.954 . . . . 0.0 108.895 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.572 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.9 124.22 5.95 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.47 -123.73 1.78 Allowed Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.031 -1.557 . . . . 0.0 111.495 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.504 HG21 HG22 ' B' ' 54' ' ' ILE . 39.0 mt -84.55 131.49 33.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 113.663 0.986 . . . . 0.0 113.663 -176.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.82 -17.25 9.32 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 177.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.47 -158.35 28.16 Favored Glycine 0 N--CA 1.491 2.351 0 O-C-N 120.603 -1.527 . . . . 0.0 110.502 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.572 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.8 m-85 -116.45 155.6 28.28 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.599 -0.942 . . . . 0.0 109.409 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.58 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 13.0 pt -131.64 146.26 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.217 -0.927 . . . . 0.0 108.684 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.52 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 7.8 mttp -90.19 154.19 19.93 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.456 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.472 HG13 ' HA3' ' A' ' 78' ' ' GLY . 8.0 m -149.05 178.93 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.067 -1.021 . . . . 0.0 109.567 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.42 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 9.2 mmt180 -122.35 104.59 9.52 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -60.67 99.57 0.09 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.275 -0.891 . . . . 0.0 110.606 -178.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.585 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.2 m-85 -95.1 104.67 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.548 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 9.3 m-20 -88.84 129.32 35.61 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.029 -1.045 . . . . 0.0 111.173 -178.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.556 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.5 OUTLIER 82.01 60.33 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.332 0.587 . . . . 0.0 111.31 178.466 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.51 HG13 ' HB3' ' A' ' 59' ' ' TYR . 8.6 mm -115.32 120.86 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.527 ' HA ' HG12 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -71.32 95.27 1.29 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.017 -1.052 . . . . 0.0 111.273 -177.853 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.549 ' O ' HG21 ' A' ' 64' ' ' ILE . 7.2 tt -98.08 115.98 39.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 178.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.4 tt0 -89.34 105.05 17.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.85 -1.156 . . . . 0.0 108.883 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.534 HD13 ' CD1' ' A' ' 64' ' ' ILE . 1.7 mp -104.31 120.74 55.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.477 -0.764 . . . . 0.0 109.816 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.58 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.2 m 54.66 59.16 4.28 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.807 -0.558 . . . . 0.0 110.495 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 50.29 33.5 23.79 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 21.9 m-70 -131.14 102.56 6.06 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.193 -1.18 . . . . 0.0 108.813 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.477 ' HG3' HD22 ' A' ' 63' ' ' LEU . 1.8 mptt -51.46 140.09 18.49 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.539 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -160.88 99.72 1.24 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.14 -0.975 . . . . 0.0 110.052 -179.258 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.556 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -78.81 157.38 4.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.567 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -179.46 -166.66 35.58 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.221 -1.942 . . . . 0.0 112.21 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 32.5 m -98.55 108.3 20.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.573 -0.957 . . . . 0.0 110.507 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.431 HG13 ' HB2' ' A' ' 33' ' ' LEU . 1.5 t -102.53 105.61 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.646 -0.658 . . . . 0.0 110.258 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.557 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 4.8 mp -78.48 109.78 12.97 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.54 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 2.3 t -93.12 114.5 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.444 -0.785 . . . . 0.0 110.328 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -143.66 -163.95 10.11 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.52 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.45 43.3 1.5 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.559 2.173 . . . . 0.0 110.274 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.627 HG21 ' HA ' ' A' ' 34' ' ' GLU . 0.1 OUTLIER -88.6 134.06 34.87 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.438 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.5 18.54 0.94 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.559 2.173 . . . . 0.0 111.975 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.514 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.0 161.33 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.88 -1.138 . . . . 0.0 109.629 179.716 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.591 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -95.24 134.66 37.75 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.645 -2.354 . . . . 0.0 104.645 175.946 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 31' ' ' THR . 2.2 mm -124.37 121.83 62.62 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 120.538 -1.352 . . . . 0.0 110.189 -177.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -98.04 87.65 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.171 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.15 -163.57 22.45 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 120.144 -1.027 . . . . 0.0 110.588 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.551 ' NH1' ' O ' ' A' ' 26' ' ' THR . 13.8 mmt-85 -57.63 -39.31 76.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.747 -0.855 . . . . 0.0 110.892 -178.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.583 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 7.9 p-10 -44.47 -31.12 1.0 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.996 -1.065 . . . . 0.0 109.343 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.583 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.4 mm? -105.09 -27.46 11.61 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.207 -0.933 . . . . 0.0 109.884 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.593 HD11 ' CG2' ' A' ' 26' ' ' THR . 27.0 mt -70.33 -8.7 52.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.035 -1.041 . . . . 0.0 108.858 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.22 -20.25 20.62 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -86.46 -40.09 15.67 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.524 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 1.9 pt -82.62 -7.63 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.381 -0.824 . . . . 0.0 109.138 179.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.98 34.25 58.94 Favored Glycine 0 N--CA 1.5 2.903 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.187 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.589 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -70.04 130.14 41.34 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.04 -1.27 . . . . 0.0 110.335 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.509 HG23 ' CG2' ' B' ' 4' ' ' THR . 82.2 p -127.88 130.05 47.9 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.924 -1.11 . . . . 0.0 109.098 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 3.8 mp -88.22 97.52 11.06 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.162 -0.962 . . . . 0.0 109.581 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.4 m120 -107.27 123.91 49.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.292 -0.88 . . . . 0.0 109.051 179.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.575 ' CD2' HD13 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.191 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.664 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.516 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 0.2 OUTLIER -83.57 146.41 28.33 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 177.823 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.516 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 20.9 t -143.59 122.98 8.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 117.812 -1.555 . . . . 0.0 111.244 -178.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.541 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.1 OUTLIER -117.13 20.89 13.53 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 177.165 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.474 ' HG ' ' HA ' ' B' ' 9' ' ' PRO . 1.3 mm? -34.68 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.682 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.541 ' N ' ' O ' ' B' ' 4' ' ' THR . 10.5 m95 -50.94 -19.98 1.19 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.402 ' N ' ' C ' ' B' ' 5' ' ' LEU . 12.9 mm100 -108.57 -124.06 0.25 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.301 -0.874 . . . . 0.0 108.831 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 34.8 mtt180 -110.56 129.99 23.37 Favored Pre-proline 0 N--CA 1.496 1.869 0 O-C-N 120.396 -1.44 . . . . 0.0 110.407 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.53 ' HD3' ' NH1' ' A' ' 87' ' ' ARG . 37.6 Cg_endo -79.16 82.78 2.42 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.364 2.042 . . . . 0.0 109.83 178.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.461 HD22 ' C ' ' B' ' 22' ' ' ALA . 3.7 mt -90.91 140.22 30.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.016 -1.052 . . . . 0.0 109.992 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' B' ' 12' ' ' THR . 0.6 OUTLIER -143.37 168.28 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.765 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.439 ' N ' ' CG2' ' B' ' 11' ' ' VAL . 17.8 m -99.91 109.18 21.56 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.561 HG22 ' CB ' ' B' ' 22' ' ' ALA . 2.6 pt -91.35 158.03 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.138 -0.976 . . . . 0.0 110.064 -178.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.521 ' CA ' HD22 ' B' ' 19' ' ' LEU . 3.9 tttt -121.03 96.97 5.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.412 -0.805 . . . . 0.0 109.064 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.513 HD13 ' CD1' ' B' ' 13' ' ' ILE . 20.1 mt -113.3 129.44 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 O-C-N 121.337 -0.852 . . . . 0.0 109.617 -179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.75 50.13 62.41 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 54.8 24.43 33.39 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.3 OUTLIER -119.94 174.58 6.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.221 -1.164 . . . . 0.0 108.688 179.288 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.521 HD22 ' CA ' ' B' ' 14' ' ' LYS . 29.1 mt -148.52 126.05 11.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.021 -1.049 . . . . 0.0 110.843 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.451 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.1 mmmt -140.6 -177.37 5.02 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.43 ' O ' ' CG ' ' B' ' 83' ' ' ASN . 0.6 OUTLIER -80.2 176.02 10.12 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.946 -1.096 . . . . 0.0 108.671 179.415 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.561 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -162.62 111.91 1.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.854 -1.154 . . . . 0.0 111.346 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' B' ' 25' ' ' ASP . 9.0 tp -89.05 99.68 12.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.511 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.2 mt -46.79 96.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.921 -1.112 . . . . 0.0 108.093 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.551 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 65.1 t0 -105.49 84.84 2.15 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.292 -0.88 . . . . 0.0 110.861 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.545 ' CG2' ' HD2' ' B' ' 87' ' ' ARG . 49.4 m -63.14 -15.96 58.47 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 108.945 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.43 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -67.86 -45.81 71.68 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 133.62 46.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -1.111 . . . . 0.0 108.589 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.5 m-20 -71.75 -13.28 61.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.368 -0.833 . . . . 0.0 110.692 -178.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.515 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.1 OUTLIER -139.03 -174.82 3.95 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.768 -1.207 . . . . 0.0 110.583 -179.377 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.624 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.4 m -104.17 97.86 7.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.063 -1.023 . . . . 0.0 110.499 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.557 ' CG2' ' HB2' ' B' ' 76' ' ' LEU . 1.0 OUTLIER -89.59 109.67 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.324 0 O-C-N 121.198 -0.938 . . . . 0.0 109.918 -179.897 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.526 HD11 ' CG1' ' B' ' 75' ' ' VAL . 1.0 OUTLIER -99.26 130.92 45.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.117 -0.99 . . . . 0.0 111.311 -179.605 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.539 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 34.1 tt0 -40.59 163.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.439 -0.788 . . . . 0.0 109.292 178.177 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.556 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.1 mt-10 -53.01 139.27 28.42 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 110.917 -178.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.497 ' HG3' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -173.82 159.66 3.48 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.497 ' N ' ' HG3' ' B' ' 36' ' ' MET . 18.2 t -79.52 142.07 36.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.091 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.507 HD11 ' CD2' ' B' ' 59' ' ' TYR . 10.6 mt -139.16 166.0 27.87 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.449 -0.782 . . . . 0.0 108.999 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' B' ' 40' ' ' GLY . 34.5 Cg_endo -76.5 69.59 6.6 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.816 2.344 . . . . 0.0 111.996 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.68 -159.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.671 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.475 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 67.1 50.52 1.01 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.512 -0.993 . . . . 0.0 109.03 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.581 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 46.7 p-90 -135.15 -178.38 5.07 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.907 0.86 . . . . 0.0 110.411 -179.461 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.445 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 12.4 mmtm -150.56 158.76 35.48 Favored Pre-proline 0 C--N 1.302 -1.487 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.63 139.87 18.38 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.912 1.742 . . . . 0.0 110.012 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.437 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 0.4 OUTLIER -151.07 152.45 33.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.374 -0.829 . . . . 0.0 109.456 -179.433 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.432 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -127.35 111.51 13.97 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.844 -1.16 . . . . 0.0 108.828 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.502 ' CG1' HG13 ' B' ' 54' ' ' ILE . 24.4 pt -95.1 134.35 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 110.018 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.569 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.59 104.51 1.11 Allowed Glycine 0 N--CA 1.489 2.173 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -124.51 3.0 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.171 -1.49 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.53 ' CG2' HG12 ' A' ' 54' ' ' ILE . 38.7 mt -86.02 121.77 37.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.832 -0.805 . . . . 0.0 112.627 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.58 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.18 -49.13 0.97 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 177.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.97 -159.65 24.15 Favored Glycine 0 N--CA 1.488 2.153 0 O-C-N 120.913 -1.345 . . . . 0.0 110.301 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.569 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 4.9 m-85 -113.91 155.04 26.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.646 -0.914 . . . . 0.0 109.644 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.504 HG22 HG21 ' A' ' 50' ' ' ILE . 1.4 pt -138.95 176.52 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.309 -0.869 . . . . 0.0 108.849 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 8.9 mttt -116.18 151.82 34.95 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.498 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.521 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 5.6 m -146.62 -171.11 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.791 -1.193 . . . . 0.0 109.715 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' B' ' 59' ' ' TYR . 71.0 mtm-85 -133.65 85.07 2.17 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -44.36 93.69 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.692 -0.63 . . . . 0.0 110.648 -178.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.587 ' CD2' HG22 ' B' ' 77' ' ' VAL . 13.8 m-85 -88.92 125.61 35.03 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 178.174 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 14.8 m-20 -105.53 136.22 45.5 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.84 -1.163 . . . . 0.0 110.786 -178.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.606 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.8 mp0 70.81 65.44 0.18 Allowed 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.431 0.634 . . . . 0.0 111.106 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.411 HG22 HG22 ' B' ' 15' ' ' ILE . 10.0 mm -118.76 111.71 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.592 ' CD2' ' CG ' ' B' ' 70' ' ' LYS . 12.9 tp -64.85 91.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.969 -1.082 . . . . 0.0 111.097 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.501 ' CD1' HD12 ' B' ' 66' ' ' ILE . 5.4 tt -89.42 119.14 36.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.48 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.6 tt0 -88.54 120.88 30.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 109.119 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.501 HD12 ' CD1' ' B' ' 64' ' ' ILE . 1.3 mp -120.94 128.0 76.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.397 -0.814 . . . . 0.0 109.217 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 94.5 m 52.97 24.48 3.42 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.507 -0.746 . . . . 0.0 109.798 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 81.79 43.62 8.22 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -140.28 99.53 3.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -1.166 . . . . 0.0 109.418 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.592 ' CG ' ' CD2' ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.24 128.56 19.67 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.582 ' N ' ' CD1' ' B' ' 63' ' ' LEU . . . -148.23 101.98 3.31 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.301 -0.875 . . . . 0.0 110.505 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.606 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -77.31 142.83 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.773 -1.205 . . . . 0.0 108.648 178.992 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -164.94 -155.75 8.65 Favored Glycine 0 N--CA 1.494 2.566 0 C-N-CA 119.723 -1.227 . . . . 0.0 111.062 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.474 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.3 m -111.96 113.76 26.26 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.214 -1.168 . . . . 0.0 109.624 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.526 ' CG1' HD11 ' B' ' 33' ' ' LEU . 1.4 t -107.91 108.42 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.355 -0.841 . . . . 0.0 111.383 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.557 ' HB2' ' CG2' ' B' ' 32' ' ' VAL . 2.9 mp -79.92 108.79 13.77 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.127 -0.983 . . . . 0.0 108.617 178.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.587 HG22 ' CD2' ' B' ' 59' ' ' TYR . 2.1 t -92.24 117.97 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.988 -1.07 . . . . 0.0 109.659 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.556 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -146.99 -171.96 16.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.306 -1.918 . . . . 0.0 108.306 179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.8 Cg_endo -81.03 44.26 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.259 1.973 . . . . 0.0 110.514 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.539 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 5.3 t -84.69 143.75 41.38 Favored Pre-proline 0 N--CA 1.486 1.359 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.65 14.01 1.31 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.583 2.189 . . . . 0.0 111.674 -178.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.03 164.35 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.83 -1.169 . . . . 0.0 110.149 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.544 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.4 m120 -94.6 146.95 23.77 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 174.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.624 ' O ' ' HA ' ' B' ' 31' ' ' THR . 3.6 mm -133.81 123.91 46.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 120.024 -1.673 . . . . 0.0 110.713 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.488 ' HB ' ' HA ' ' B' ' 24' ' ' LEU . 5.3 mm -98.5 93.45 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.25 179.49 51.74 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 -178.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.575 ' CD ' ' O ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER -58.83 -23.11 60.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.37 -1.077 . . . . 0.0 109.627 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.535 ' ND2' HD21 ' B' ' 89' ' ' LEU . 12.9 p-10 -53.77 -37.01 63.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.694 -1.254 . . . . 0.0 108.924 178.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.535 HD21 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -96.92 -35.26 10.94 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.619 -0.676 . . . . 0.0 110.695 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.485 ' O ' HG13 ' B' ' 93' ' ' ILE . 71.7 mt -56.36 -33.87 66.11 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.038 -1.039 . . . . 0.0 109.487 -179.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.534 ' CG2' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.66 -21.84 60.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 110.899 -179.109 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -80.54 -31.47 36.98 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.229 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.575 HD13 ' CD2' ' A' ' 99' ' ' PHE . 3.1 pt -87.11 13.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.4 -0.813 . . . . 0.0 108.932 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 59.76 49.04 82.83 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.521 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -87.92 150.66 23.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.25 -1.147 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 57.2 p -146.27 123.07 11.25 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.798 . . . . 0.0 109.135 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 5.2 mp -85.36 93.54 8.74 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 7.5 m120 -92.79 119.97 32.69 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 120.703 -1.248 . . . . 0.0 110.067 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.603 ' CD2' ' HD2' ' A' ' 1' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.37 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.446 ' O ' ' HA ' ' B' ' 98' ' ' ASN . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.66 0 N-CA-C 109.889 -0.85 . . . . 0.0 109.889 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.583 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -83.17 149.66 26.72 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 177.81 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.552 HG11 ' CD2' ' A' ' 5' ' ' LEU . 37.8 t -150.49 116.43 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 C-N-CA 118.436 -1.306 . . . . 0.0 110.661 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 6' ' ' TRP . 1.7 p -122.26 -73.21 0.65 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.552 ' CD2' HG11 ' A' ' 3' ' ' VAL . 1.8 pt? 30.4 38.28 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 122.124 -0.36 . . . . 0.0 111.071 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' A' ' 5' ' ' LEU . 8.9 m95 19.3 48.96 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 121.258 0.551 . . . . 0.0 111.829 179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.552 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -149.87 -167.81 2.93 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.31 179.421 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.461 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -84.89 136.77 38.4 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.12 -0.987 . . . . 0.0 109.403 -179.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.7 Cg_endo -77.27 71.99 6.12 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.246 1.964 . . . . 0.0 109.717 178.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.432 ' O ' HG11 ' A' ' 11' ' ' VAL . 0.4 OUTLIER -79.54 151.17 30.86 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 -179.567 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.507 HG23 ' CG2' ' A' ' 66' ' ' ILE . 0.9 OUTLIER -150.64 156.47 6.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.244 -0.91 . . . . 0.0 110.027 -179.381 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 22.6 m -86.93 113.37 22.66 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.557 ' HB ' ' CG1' ' A' ' 64' ' ' ILE . 43.8 pt -99.7 147.87 6.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.167 -0.958 . . . . 0.0 111.071 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.581 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -109.27 94.9 5.28 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.937 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.525 ' CG1' ' HB ' ' A' ' 64' ' ' ILE . 8.6 mt -119.41 130.07 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.104 -0.998 . . . . 0.0 109.67 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.67 37.63 95.01 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.61 18.14 50.91 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -113.84 172.88 6.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.34 -1.094 . . . . 0.0 109.518 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.581 ' CG ' ' HD2' ' A' ' 14' ' ' LYS . 13.1 mt -139.74 122.46 16.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 111.012 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.465 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -141.96 175.32 9.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.505 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 1.3 mt-10 -78.72 178.67 7.69 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.599 -1.313 . . . . 0.0 108.23 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.533 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -156.9 103.99 2.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.14 -0.975 . . . . 0.0 109.635 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.503 ' O ' ' N ' ' A' ' 25' ' ' ASP . 30.5 tp -72.43 92.6 1.46 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.253 -0.904 . . . . 0.0 108.584 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.565 ' CD2' ' CD2' ' A' ' 90' ' ' LEU . 3.7 mt -43.78 98.43 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.548 ' CB ' HG22 ' A' ' 84' ' ' ILE . 1.9 t70 -104.89 90.3 3.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.558 -0.714 . . . . 0.0 110.777 -178.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.505 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 20.7 m -68.23 -13.53 62.31 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.528 ' CA ' HD22 ' B' ' 23' ' ' LEU . . . -70.99 -41.68 60.79 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.05 162.75 29.1 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -1.171 . . . . 0.0 109.516 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -98.92 -11.15 21.9 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.292 -0.88 . . . . 0.0 110.428 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.535 ' OD2' ' HB ' ' A' ' 74' ' ' THR . 0.1 OUTLIER -139.06 -173.2 3.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.899 -1.126 . . . . 0.0 109.781 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.531 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 66.4 m -106.32 88.52 2.8 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.576 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.559 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.19 162.97 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.244 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.559 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.4 OUTLIER -157.7 124.32 4.92 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.9 -179.003 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.53 ' HA ' HG21 ' A' ' 80' ' ' THR . 21.0 pt-20 -41.01 152.83 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.533 -0.729 . . . . 0.0 109.5 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.42 ' C ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -41.71 148.31 0.16 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.39 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -173.29 164.92 4.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.496 -0.753 . . . . 0.0 108.975 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.7 t -79.8 100.06 7.79 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.056 -1.028 . . . . 0.0 109.77 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.3 tp -126.29 100.39 29.58 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.248 -0.907 . . . . 0.0 109.34 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -78.46 165.39 25.32 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.791 2.327 . . . . 0.0 110.815 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.57 -163.12 16.09 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.33 139.03 33.9 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.223 -1.163 . . . . 0.0 108.26 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.569 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 9.7 p-90 -149.33 174.49 12.37 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.031 -1.043 . . . . 0.0 109.996 -179.423 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -138.2 163.47 47.28 Favored Pre-proline 0 C--N 1.299 -1.612 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.22 141.03 25.53 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.73 1.62 . . . . 0.0 110.189 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.36 167.46 22.12 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.434 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 10.4 ttt -151.38 118.79 6.01 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.537 ' CD1' HD13 ' A' ' 54' ' ' ILE . 1.5 pt -102.43 128.51 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 C-N-CA 118.396 -1.322 . . . . 0.0 108.897 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.594 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -117.89 98.01 0.75 Allowed Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.72 -121.06 2.9 Favored Glycine 0 C--N 1.297 -1.616 0 C-N-CA 119.416 -1.374 . . . . 0.0 110.404 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.55 ' CG2' HG12 ' B' ' 54' ' ' ILE . 74.8 mt -83.87 106.1 13.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.872 -0.781 . . . . 0.0 112.561 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 120.18 -44.62 1.35 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 178.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 168.06 -164.37 37.92 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.728 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.594 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 7.1 m-85 -110.14 118.02 35.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.602 -0.94 . . . . 0.0 110.18 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.537 HD13 ' CD1' ' A' ' 47' ' ' ILE . 32.6 pt -99.16 161.07 3.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.557 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.39 132.96 48.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.024 -1.048 . . . . 0.0 109.8 -179.406 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.45 HG13 ' HA3' ' A' ' 78' ' ' GLY . 30.6 m -134.55 178.68 5.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.477 -0.765 . . . . 0.0 109.36 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.477 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 28.1 mtt180 -111.31 171.22 7.6 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.409 ' OE1' ' OD1' ' A' ' 60' ' ' ASP . 0.3 OUTLIER -131.5 97.28 4.19 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.673 -1.267 . . . . 0.0 110.859 -179.042 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 83.7 m-85 -97.11 116.32 29.1 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.523 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -94.01 146.46 23.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.917 -1.114 . . . . 0.0 110.144 -179.05 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.548 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 4.1 mm-40 67.77 67.34 0.36 Allowed 'General case' 0 N--CA 1.489 1.516 0 CA-C-O 121.617 0.722 . . . . 0.0 109.705 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.484 ' HB ' HG21 ' A' ' 75' ' ' VAL . 1.9 mm -124.65 108.84 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.539 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 4.6 tt -59.81 102.57 0.16 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.311 -0.868 . . . . 0.0 111.175 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.557 ' CG1' ' HB ' ' A' ' 13' ' ' ILE . 3.7 tt -100.44 119.48 48.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.75 109.88 20.04 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.647 -1.283 . . . . 0.0 108.719 -178.564 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.521 ' CG1' HG21 ' A' ' 13' ' ' ILE . 2.7 mt -115.78 123.86 71.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.124 -0.985 . . . . 0.0 110.313 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.455 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 58.2 m 56.49 36.02 26.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.675 -0.641 . . . . 0.0 110.367 179.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.41 28.03 73.46 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.455 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 96.7 m-70 -126.95 110.35 12.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.118 -1.225 . . . . 0.0 109.273 179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.479 ' HG3' HD12 ' A' ' 63' ' ' LEU . 1.5 ttpm? -55.05 130.6 42.43 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.269 -0.895 . . . . 0.0 109.069 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.448 ' O ' HG23 ' A' ' 64' ' ' ILE . . . -148.51 101.46 3.23 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.372 -0.83 . . . . 0.0 109.935 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.548 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.8 OUTLIER -78.27 146.43 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 178.794 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.512 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -170.45 -177.69 40.74 Favored Glycine 0 N--CA 1.484 1.879 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.51 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.535 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 1.9 m -93.58 111.92 23.7 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.574 -0.957 . . . . 0.0 109.587 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.543 ' CG1' HD12 ' A' ' 33' ' ' LEU . 1.4 t -98.97 137.12 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.694 -0.629 . . . . 0.0 109.724 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.535 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.4 mp -107.68 136.14 47.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.209 -0.932 . . . . 0.0 108.768 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.477 ' O ' ' HG3' ' A' ' 57' ' ' ARG . 16.7 t -118.38 113.65 42.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.943 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.45 ' HA3' HG13 ' A' ' 56' ' ' VAL . . . -151.75 -164.04 11.92 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.557 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.31 39.48 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.681 2.254 . . . . 0.0 111.039 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.53 HG21 ' HA ' ' A' ' 34' ' ' GLU . 2.8 t -86.83 134.84 36.4 Favored Pre-proline 0 N--CA 1.489 1.508 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.16 18.79 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.691 2.26 . . . . 0.0 112.028 -178.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.471 HG13 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.5 158.97 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.597 -1.314 . . . . 0.0 110.341 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 67.7 m-20 -95.11 100.29 12.13 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.551 ' CG1' HG11 ' A' ' 32' ' ' VAL . 7.2 mm -88.37 128.59 40.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 O-C-N 120.858 -1.151 . . . . 0.0 112.154 -176.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.53 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.61 93.79 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.244 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -80.35 -160.99 23.63 Favored Glycine 0 N--CA 1.493 2.494 0 O-C-N 121.176 -0.952 . . . . 0.0 111.042 -177.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.491 ' NH2' ' HB2' ' A' ' 87' ' ' ARG . 7.5 mtp-105 -69.17 -29.67 67.73 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.65 -0.912 . . . . 0.0 109.925 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.589 ' ND2' HD21 ' A' ' 89' ' ' LEU . 14.7 p-10 -50.17 -24.26 2.69 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.811 -1.181 . . . . 0.0 108.951 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.589 HD21 ' ND2' ' A' ' 88' ' ' ASN . 3.1 mm? -112.76 -27.77 8.03 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.236 -0.915 . . . . 0.0 110.313 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.565 ' CD2' ' CD2' ' A' ' 24' ' ' LEU . 34.7 mt -63.09 -28.15 69.88 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.992 -1.068 . . . . 0.0 108.416 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 69.0 p -79.43 -20.64 47.03 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.136 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -80.86 -36.71 31.05 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.35 -0.844 . . . . 0.0 109.135 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.599 HD11 ' CD2' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -86.0 -0.72 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.295 -0.878 . . . . 0.0 109.243 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.68 62.22 5.23 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -97.16 135.88 38.48 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.547 -0.973 . . . . 0.0 110.481 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.416 HG21 ' CG2' ' B' ' 4' ' ' THR . 15.5 p -133.12 128.71 36.71 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.516 HD13 ' CD1' ' B' ' 97' ' ' LEU . 6.7 mp -87.1 109.38 19.39 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.277 -0.89 . . . . 0.0 108.792 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.505 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.9 m120 -105.22 120.79 42.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.81 -1.181 . . . . 0.0 109.196 179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.65 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.595 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.451 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.569 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.332 -0.68 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.528 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tm0? -84.02 145.71 28.36 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.133 -1.803 . . . . 0.0 106.133 177.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 70.1 t -146.03 122.97 3.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.218 -177.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.463 ' O ' ' C ' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -127.04 -61.94 1.14 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.673 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.1 mt 31.86 38.92 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.567 178.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.536 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.9 m95 17.31 51.46 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 CA-C-O 121.159 0.504 . . . . 0.0 111.949 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' B' ' 5' ' ' LEU . 13.1 mt-30 -168.0 -174.95 2.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.341 -0.85 . . . . 0.0 109.592 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.436 ' HG2' ' HD2' ' A' ' 87' ' ' ARG . 17.2 mtm180 -65.44 138.45 96.96 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.032 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.541 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.8 Cg_endo -81.16 62.36 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.36 2.04 . . . . 0.0 109.707 179.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.531 HD21 ' N ' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -80.84 136.4 36.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.877 -1.139 . . . . 0.0 109.56 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.519 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -130.42 137.91 55.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.286 -0.884 . . . . 0.0 109.191 -179.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 18.0 m -65.66 97.58 0.33 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.587 ' CG2' ' CB ' ' B' ' 22' ' ' ALA . 2.8 pt -88.03 154.62 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.297 -0.877 . . . . 0.0 110.702 -177.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.52 ' CA ' HD22 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -122.15 105.88 10.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.473 -0.767 . . . . 0.0 109.773 179.505 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.514 HG23 ' CE ' ' B' ' 36' ' ' MET . 97.1 mt -121.24 139.92 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 120.852 -1.155 . . . . 0.0 110.889 -179.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.81 33.38 6.48 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.76 37.27 51.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.5 OUTLIER -131.18 175.48 9.07 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 108.39 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.52 HD22 ' CA ' ' B' ' 14' ' ' LYS . 15.9 mt -152.0 124.33 8.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.995 -1.066 . . . . 0.0 110.249 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -151.38 174.57 13.18 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.521 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.0 OUTLIER -80.34 143.38 33.61 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.895 -1.128 . . . . 0.0 108.836 179.484 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.587 ' CB ' ' CG2' ' B' ' 13' ' ' ILE . . . -127.53 112.79 15.33 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 110.138 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.528 HD22 ' CA ' ' A' ' 27' ' ' GLY . 2.4 tp -81.14 102.05 10.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.691 -0.631 . . . . 0.0 109.864 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.541 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 20.1 mt -52.74 105.95 0.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.934 -1.104 . . . . 0.0 108.346 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.565 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 53.4 t0 -103.1 92.54 4.58 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.216 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -11.5 35.0 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.077 -1.015 . . . . 0.0 108.404 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.445 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -70.09 -43.62 63.77 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.82 164.96 21.28 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.117 -1.225 . . . . 0.0 109.676 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -100.4 -13.88 18.57 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.226 -0.921 . . . . 0.0 110.196 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.616 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -126.75 -165.37 1.45 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.016 -1.052 . . . . 0.0 109.664 -179.806 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.566 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 8.1 m -116.63 85.64 2.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.924 -1.11 . . . . 0.0 110.192 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.513 HG11 ' HB ' ' B' ' 84' ' ' ILE . 0.3 OUTLIER -68.65 154.75 8.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.566 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.2 OUTLIER -154.82 133.31 11.95 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.837 -1.164 . . . . 0.0 111.054 -177.609 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.473 ' HG3' ' O ' ' B' ' 80' ' ' THR . 4.1 tt0 -42.03 148.62 0.18 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.474 ' HA ' HG11 ' B' ' 77' ' ' VAL . 3.0 mt-10 -44.88 136.99 4.3 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.041 -1.037 . . . . 0.0 110.457 -179.173 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.514 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -156.75 -167.69 2.45 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.11 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.408 ' C ' HD21 ' B' ' 38' ' ' LEU . 8.6 t -112.29 115.75 29.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.756 -1.215 . . . . 0.0 111.457 -178.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.606 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 3.0 mm? -116.45 170.81 5.39 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.525 ' HD2' HD13 ' B' ' 38' ' ' LEU . 33.4 Cg_endo -76.22 115.77 4.2 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.372 2.048 . . . . 0.0 111.374 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' B' ' 41' ' ' ARG . . . -30.95 122.39 0.14 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' B' ' 40' ' ' GLY . 3.6 mtm180 148.72 43.01 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.633 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 37.3 p-90 -124.73 176.8 6.34 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.343 0.592 . . . . 0.0 109.733 -178.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -133.92 130.04 20.38 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.007 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -76.91 140.11 20.12 Favored 'Trans proline' 0 C--N 1.31 -1.45 0 C-N-CA 122.254 1.97 . . . . 0.0 110.317 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -159.41 -164.8 1.43 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.356 -0.84 . . . . 0.0 109.376 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.534 ' CG ' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -141.8 119.21 11.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.985 -179.578 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.503 HD11 HG23 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -90.44 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 178.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.459 ' HA2' ' HB3' ' B' ' 53' ' ' PHE . . . -118.41 111.75 2.22 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.81 -125.2 2.35 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.503 ' O ' ' O ' ' A' ' 50' ' ' ILE . 37.8 mt -80.95 139.12 18.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.777 -0.837 . . . . 0.0 112.664 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.465 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 73.27 5.03 65.54 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 178.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.0 -158.94 16.69 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.051 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -119.21 143.85 47.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.441 -1.035 . . . . 0.0 109.183 -179.549 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.577 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 1.0 OUTLIER -112.71 -175.29 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.977 . . . . 0.0 108.701 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.549 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 12.3 mttt -114.84 138.79 50.36 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.047 -1.033 . . . . 0.0 109.282 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.534 HG11 ' CD1' ' B' ' 54' ' ' ILE . 3.5 m -139.05 -169.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.553 -1.342 . . . . 0.0 110.73 -179.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.505 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 73.8 mtt-85 -143.78 99.88 3.49 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.565 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 6.1 tt0 -66.04 108.13 2.12 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.294 -0.879 . . . . 0.0 110.719 -178.644 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.633 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 32.3 m-85 -93.85 128.27 40.03 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 177.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.521 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -106.17 135.97 46.7 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.877 -1.139 . . . . 0.0 110.927 -177.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.567 ' HA ' HG21 ' B' ' 72' ' ' ILE . 0.2 OUTLIER 71.98 64.03 0.14 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 179.271 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.546 ' CD1' ' HB3' ' B' ' 59' ' ' TYR . 4.4 mp -118.17 119.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.563 ' CA ' HG12 ' B' ' 72' ' ' ILE . 3.3 tm? -66.29 84.95 0.1 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-O 121.661 0.743 . . . . 0.0 110.604 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.53 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 2.3 tt -91.89 130.76 40.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 178.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.513 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.8 tt0 -87.74 152.6 22.01 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.905 -1.122 . . . . 0.0 108.463 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.523 ' CD1' HD12 ' B' ' 64' ' ' ILE . 0.2 OUTLIER -150.75 135.11 9.0 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.236 -0.915 . . . . 0.0 108.962 -179.453 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 46.32 24.07 0.26 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.529 -0.732 . . . . 0.0 110.21 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.416 ' O ' ' CD2' ' B' ' 69' ' ' HIS . . . 83.72 39.6 9.47 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 179.453 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' B' ' 68' ' ' GLY . 8.9 m-70 -141.11 164.77 29.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -1.208 . . . . 0.0 109.074 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.507 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -95.73 139.19 32.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.07 -1.019 . . . . 0.0 108.472 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.53 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -154.54 104.75 2.58 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.111 -0.993 . . . . 0.0 110.051 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.567 HG21 ' HA ' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -86.94 141.64 14.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 178.701 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.485 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -168.56 -164.11 23.69 Favored Glycine 0 N--CA 1.485 1.922 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.495 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.565 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 8.6 m -95.91 105.06 17.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.682 -0.893 . . . . 0.0 109.906 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.44 HG13 HD11 ' B' ' 15' ' ' ILE . 1.3 t -100.71 106.01 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.38 -0.825 . . . . 0.0 109.983 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.616 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 0.4 OUTLIER -78.08 134.4 37.74 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.104 -0.997 . . . . 0.0 108.666 179.104 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.474 HG11 ' HA ' ' B' ' 35' ' ' GLU . 58.2 t -122.58 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.206 -0.934 . . . . 0.0 110.644 -179.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.84 -161.27 12.73 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 108.258 -1.937 . . . . 0.0 108.258 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.549 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.47 40.23 0.96 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.358 2.039 . . . . 0.0 110.244 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.483 HG22 ' O ' ' B' ' 82' ' ' VAL . 3.1 t -83.39 133.56 47.09 Favored Pre-proline 0 N--CA 1.487 1.391 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.43 18.05 0.61 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.715 2.276 . . . . 0.0 112.244 -178.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.531 ' CG1' HG13 ' B' ' 84' ' ' ILE . 1.9 t -161.27 157.9 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.692 -1.255 . . . . 0.0 110.543 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.593 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -96.57 90.36 5.32 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 177.252 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.565 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 2.9 mt -90.63 120.04 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.258 -0.901 . . . . 0.0 112.36 -176.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.55 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -95.67 93.82 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.82 -157.28 13.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.531 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -61.76 -37.22 83.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.623 -0.928 . . . . 0.0 111.887 -178.186 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.561 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 8.7 p-10 -44.67 -40.53 5.96 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.509 -1.37 . . . . 0.0 110.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.561 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 0.9 OUTLIER -96.73 -18.99 19.28 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.061 -1.024 . . . . 0.0 110.032 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.531 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 63.6 mt -73.8 -5.25 39.67 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.024 -1.048 . . . . 0.0 108.765 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.503 ' HB ' ' CH2' ' A' ' 6' ' ' TRP . 2.6 p -101.32 -21.17 14.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.081 -1.012 . . . . 0.0 109.067 179.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.8 mm-40 -74.36 -40.53 62.06 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.183 -0.948 . . . . 0.0 109.006 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.592 HD11 ' CD2' ' A' ' 99' ' ' PHE . 3.3 pt -88.15 -5.97 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.215 -0.928 . . . . 0.0 108.893 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.76 50.43 42.19 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.582 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.45 149.4 35.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.099 -1.236 . . . . 0.0 109.789 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 47.6 p -138.48 128.4 25.32 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.516 ' CD1' HD13 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -86.96 111.36 20.76 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.287 -0.883 . . . . 0.0 110.745 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.583 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 1.0 OUTLIER -115.73 121.21 41.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.3 -0.875 . . . . 0.0 109.609 179.363 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.674 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.134 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.42 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.691 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.469 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.5 tt0 -83.16 141.39 31.98 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 105.623 -1.992 . . . . 0.0 105.623 177.035 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 72.9 t -137.95 126.04 30.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 C-N-CA 117.778 -1.569 . . . . 0.0 110.647 -177.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.577 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -120.87 7.35 10.42 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.693 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.3 OUTLIER -34.42 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.953 0.882 . . . . 0.0 109.709 -179.299 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.577 ' N ' ' O ' ' A' ' 4' ' ' THR . 6.9 m95 -41.49 -20.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.434 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.536 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.2 mt-30 -107.49 -155.98 0.57 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.691 -1.255 . . . . 0.0 109.78 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.519 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 62.0 mtt180 -76.21 115.79 50.13 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 110.413 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.549 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.6 Cg_endo -81.89 83.38 2.1 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 121.994 1.796 . . . . 0.0 109.019 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.544 HD22 ' CB ' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -78.52 166.9 22.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.332 -0.855 . . . . 0.0 109.615 -179.033 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.583 HG22 ' CG2' ' A' ' 13' ' ' ILE . 15.2 m -147.88 131.18 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.108 -0.995 . . . . 0.0 110.558 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -68.68 103.05 1.63 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.527 -1.358 . . . . 0.0 107.786 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.583 ' CG2' HG22 ' A' ' 11' ' ' VAL . 2.8 pt -102.42 137.34 30.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.244 -0.91 . . . . 0.0 111.207 -178.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.0 OUTLIER -105.0 93.6 4.79 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.527 HD13 ' CD1' ' A' ' 13' ' ' ILE . 15.6 mt -104.48 124.35 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.455 -0.778 . . . . 0.0 109.488 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.75 13.0 68.36 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.88 7.72 77.43 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.536 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -105.77 171.72 7.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -1.131 . . . . 0.0 108.521 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.48 ' CD2' ' HD3' ' A' ' 14' ' ' LYS . 15.1 mt -123.6 130.58 52.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.869 -1.145 . . . . 0.0 110.959 -178.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.569 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.7 OUTLIER -150.41 143.13 24.6 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.558 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 9.1 mm-40 -78.88 127.46 32.05 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.961 -1.087 . . . . 0.0 109.101 -179.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.551 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -108.27 112.47 24.96 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.986 -1.071 . . . . 0.0 112.012 -178.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.519 ' CD1' ' HB3' ' A' ' 8' ' ' ARG . 11.9 tp -72.22 107.39 4.84 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.549 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 56.5 mt -46.79 142.97 3.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.864 -1.148 . . . . 0.0 108.294 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.574 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 11.4 t0 -156.79 99.59 1.86 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.844 -1.16 . . . . 0.0 110.272 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.447 HG21 ' O ' ' A' ' 26' ' ' THR . 10.9 m -76.12 -0.26 21.35 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.149 -0.97 . . . . 0.0 109.399 179.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.464 ' O ' HD23 ' B' ' 23' ' ' LEU . . . -89.54 -26.48 25.1 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.474 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -81.39 124.4 29.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.12 -1.224 . . . . 0.0 109.089 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.591 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 42.8 m-20 -61.83 -16.42 49.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.853 . . . . 0.0 110.171 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.625 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 5.0 m-20 -145.16 -170.48 3.44 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.022 -1.071 . . . . 0.0 109.713 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.548 HG23 ' CD1' ' A' ' 33' ' ' LEU . 8.1 m -104.84 86.56 2.49 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 120.804 -1.185 . . . . 0.0 109.818 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.576 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -70.04 163.13 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.265 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.57 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.5 OUTLIER -160.37 128.86 4.75 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.033 -1.042 . . . . 0.0 110.396 -178.01 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.598 ' N ' ' CG2' ' A' ' 80' ' ' THR . 15.8 tt0 -43.81 165.36 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.505 -0.878 . . . . 0.0 108.848 179.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.483 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -48.23 143.4 4.61 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.353 -179.426 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.466 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -155.91 -168.31 2.73 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.464 -0.773 . . . . 0.0 109.025 179.737 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.7 t -122.17 111.15 16.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.847 -1.158 . . . . 0.0 111.196 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.586 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -114.57 179.73 0.74 Allowed Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.714 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.523 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 36.1 Cg_endo -78.6 36.9 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.68 2.253 . . . . 0.0 112.502 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 55.59 33.03 58.76 Favored Glycine 0 N--CA 1.493 2.483 0 O-C-N 121.102 -0.999 . . . . 0.0 111.299 178.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.598 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 15.4 mmm180 -113.97 78.15 1.12 Allowed 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.485 -1.009 . . . . 0.0 108.337 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.561 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 59.8 p-90 -148.96 -177.41 5.79 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 120.985 -1.072 . . . . 0.0 111.37 -178.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.72 141.61 28.49 Favored Pre-proline 0 N--CA 1.487 1.377 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.47 131.23 13.54 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 C-N-CA 121.936 1.757 . . . . 0.0 111.025 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.546 ' CD ' ' HB2' ' A' ' 58' ' ' GLN . 13.1 ptmt -161.28 -169.8 2.44 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.54 -0.725 . . . . 0.0 109.233 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 38.4 mtp -151.34 137.98 18.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.36 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.534 ' CD1' HG22 ' B' ' 50' ' ' ILE . 15.4 pt -95.94 150.0 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 120.987 -1.07 . . . . 0.0 108.491 178.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.497 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.07 102.37 0.97 Allowed Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.08 -134.74 4.43 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.721 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.531 HG22 ' CD1' ' B' ' 47' ' ' ILE . 58.3 mt -83.02 122.87 38.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 CA-C-O 121.629 0.728 . . . . 0.0 112.548 -177.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 104.64 -53.77 0.66 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.484 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 178.33 -169.24 40.86 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.585 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.2 m-30 -102.37 135.28 44.26 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.282 . . . . 0.0 109.312 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.489 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.3 pt -101.52 176.1 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.131 -0.981 . . . . 0.0 109.352 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.49 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -105.35 142.02 35.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.241 -0.912 . . . . 0.0 109.323 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 31.1 m -150.93 -179.03 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 110.652 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.472 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -128.02 91.58 3.3 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.141 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.546 ' HB2' ' CD ' ' A' ' 45' ' ' LYS . 17.1 tt0 -51.29 102.98 0.05 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.443 0.639 . . . . 0.0 111.635 -178.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CD1' ' O ' ' A' ' 41' ' ' ARG . 24.8 m-85 -90.63 137.3 32.46 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -119.34 121.51 39.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.651 -1.281 . . . . 0.0 110.321 -179.091 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.576 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 5.4 mt-30 83.3 61.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.372 0.606 . . . . 0.0 109.882 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.546 ' CG2' HG22 ' A' ' 75' ' ' VAL . 2.7 mm -111.62 115.79 50.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.35 -0.844 . . . . 0.0 108.782 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.536 HD22 ' CG ' ' A' ' 70' ' ' LYS . 2.0 tm? -66.42 87.22 0.12 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.16 -0.963 . . . . 0.0 110.391 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.556 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 5.2 tt -88.8 122.94 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.0 tt0 -88.97 96.11 10.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.13 -0.981 . . . . 0.0 108.84 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.522 ' CD1' HD13 ' A' ' 89' ' ' LEU . 3.2 mt -101.51 122.8 54.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.334 -0.854 . . . . 0.0 110.043 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.579 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 60.93 44.66 10.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.636 -0.665 . . . . 0.0 109.773 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 55.7 33.32 59.45 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 90.7 m-70 -130.85 118.92 21.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.285 -1.127 . . . . 0.0 109.353 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.536 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -56.32 133.62 52.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 108.706 179.626 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.556 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -157.42 104.04 2.0 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 110.199 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.576 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -79.35 154.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 120.88 -1.138 . . . . 0.0 108.313 178.78 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.469 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -177.25 175.43 47.63 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.179 -1.486 . . . . 0.0 110.576 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 3.7 m -85.34 115.28 23.0 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.586 -0.949 . . . . 0.0 110.158 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.546 HG22 ' CG2' ' A' ' 62' ' ' ILE . 1.4 t -103.94 109.49 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.121 -0.987 . . . . 0.0 110.288 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.576 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.2 mp -82.53 115.81 21.68 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.948 -1.095 . . . . 0.0 108.345 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.509 HG22 ' CD2' ' A' ' 59' ' ' TYR . 93.9 t -96.02 121.7 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.754 -1.216 . . . . 0.0 110.213 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -160.17 -170.84 25.27 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -81.02 42.68 1.39 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.926 2.417 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.598 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.4 t -82.8 141.73 44.61 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 108.564 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.428 ' O ' ' CG2' ' A' ' 82' ' ' VAL . 36.9 Cg_endo -79.38 15.31 1.6 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.518 2.145 . . . . 0.0 110.98 -179.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.492 HG11 HG13 ' A' ' 84' ' ' ILE . 14.1 t -160.43 158.41 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.929 -1.107 . . . . 0.0 110.22 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.569 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -102.06 91.13 4.19 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 176.217 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.574 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 41.8 mt -96.63 130.6 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.891 -1.131 . . . . 0.0 113.674 -174.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.517 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -89.3 131.9 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.625 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -110.96 -143.48 9.48 Favored Glycine 0 N--CA 1.498 2.797 0 O-C-N 120.688 -1.257 . . . . 0.0 110.847 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.591 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -77.83 -41.61 36.44 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.482 -179.464 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.58 ' OD1' ' CB ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -54.63 -18.95 5.11 Favored 'General case' 0 N--CA 1.497 1.881 0 C-N-CA 117.438 -1.705 . . . . 0.0 110.246 -178.608 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.522 HD13 ' CD1' ' A' ' 66' ' ' ILE . 1.0 OUTLIER -103.03 -35.97 8.34 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.712 -1.243 . . . . 0.0 110.363 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 66.2 mt -68.86 -19.77 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.876 -1.14 . . . . 0.0 109.599 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.511 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.86 -2.9 52.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.734 -1.229 . . . . 0.0 108.809 178.962 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.46 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.0 OUTLIER -99.44 -40.84 7.67 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.261 -0.9 . . . . 0.0 108.949 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.583 HD11 ' CG ' ' B' ' 99' ' ' PHE . 1.2 pt -79.76 -16.1 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 N-CA-C 108.571 -0.899 . . . . 0.0 108.571 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 91.05 30.87 10.43 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.508 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -67.44 138.99 57.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.988 -1.301 . . . . 0.0 109.555 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.456 ' O ' ' O ' ' B' ' 96' ' ' THR . 3.0 p -132.76 128.49 36.94 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.151 -0.968 . . . . 0.0 108.558 179.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.558 HD13 ' CD1' ' B' ' 97' ' ' LEU . 4.3 mp -90.62 98.43 11.77 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.245 -0.909 . . . . 0.0 109.532 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.0 m120 -105.61 125.7 51.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.029 -1.044 . . . . 0.0 109.246 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 CA-C-O 117.959 -1.02 . . . . 0.0 109.295 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.509 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.68 0 N-CA-C 110.825 -0.49 . . . . 0.0 110.825 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.511 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.1 tt0 -85.71 134.27 33.97 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.418 ' CG1' ' H ' ' B' ' 5' ' ' LEU . 49.4 t -131.5 125.08 55.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.764 -1.21 . . . . 0.0 109.951 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.549 ' O ' ' CD1' ' B' ' 5' ' ' LEU . 46.7 p -75.89 3.58 9.81 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.48 -0.763 . . . . 0.0 109.656 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.549 ' CD1' ' O ' ' B' ' 4' ' ' THR . 0.4 OUTLIER 34.35 46.75 0.18 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.801 -0.562 . . . . 0.0 111.476 179.199 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.452 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 58.8 m95 -57.63 -20.35 32.48 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -147.11 -164.55 2.02 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.539 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 0.5 OUTLIER -59.22 122.52 64.08 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 120.897 -1.127 . . . . 0.0 109.211 179.735 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.477 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.9 Cg_endo -78.97 66.42 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.376 2.051 . . . . 0.0 109.635 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.518 HD21 ' N ' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -81.15 145.65 30.93 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.107 -0.996 . . . . 0.0 109.827 -179.31 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.464 ' O ' HG21 ' B' ' 13' ' ' ILE . 2.6 m -136.58 136.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.53 -0.731 . . . . 0.0 109.434 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -66.09 89.27 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.805 -1.184 . . . . 0.0 107.805 178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.572 HG23 HG13 ' B' ' 66' ' ' ILE . 1.1 pp -80.67 131.52 33.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 109.596 -179.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.504 ' HE2' ' CD1' ' B' ' 19' ' ' LEU . 12.0 tttm -98.84 111.59 23.93 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.354 -0.841 . . . . 0.0 108.998 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.516 ' CG2' ' HE1' ' B' ' 36' ' ' MET . 28.8 mt -116.38 134.65 59.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.221 -0.925 . . . . 0.0 108.9 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.66 -100.49 0.28 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -142.29 35.44 1.74 Allowed Glycine 0 N--CA 1.485 1.906 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.479 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 5.8 mt-30 -134.13 179.95 5.94 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.482 -1.011 . . . . 0.0 109.663 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.504 ' CD1' ' HE2' ' B' ' 14' ' ' LYS . 16.0 mt -147.39 130.26 16.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.531 -0.731 . . . . 0.0 109.139 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.426 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 39.0 mttp -146.12 171.77 14.42 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.166 -0.959 . . . . 0.0 109.199 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.495 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 2.9 mm-40 -79.03 148.48 32.48 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' B' ' 13' ' ' ILE . . . -136.16 108.28 7.22 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.056 . . . . 0.0 110.543 -178.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.539 ' CD1' ' HD2' ' B' ' 8' ' ' ARG . 18.8 tp -70.13 102.75 2.14 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.477 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.5 mt -53.7 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.055 -1.028 . . . . 0.0 108.867 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.614 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 35.2 t0 -91.92 90.06 7.28 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.391 -0.818 . . . . 0.0 110.519 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.429 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 7.3 m -71.05 -7.49 46.82 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 109.064 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.44 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -83.58 -31.3 27.61 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.42 173.15 12.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.875 -1.368 . . . . 0.0 109.337 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -101.72 -18.0 16.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.073 -1.017 . . . . 0.0 110.764 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.485 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -137.35 -172.54 3.24 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.769 -1.207 . . . . 0.0 110.142 -179.357 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.528 ' CG2' HD11 ' B' ' 85' ' ' ILE . 55.3 m -102.59 82.43 2.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.093 -1.005 . . . . 0.0 109.89 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.536 ' CG2' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -69.71 161.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.881 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.533 ' HA ' ' HA ' ' B' ' 83' ' ' ASN . 0.4 OUTLIER -153.25 129.52 10.51 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.587 -1.245 . . . . 0.0 111.618 -177.451 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HA ' HG23 ' B' ' 80' ' ' THR . 9.5 tt0 -44.22 156.28 0.07 Allowed 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' B' ' 34' ' ' GLU . 0.5 OUTLIER -40.05 138.12 0.87 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 110.601 -179.074 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.516 ' HE1' ' CG2' ' B' ' 15' ' ' ILE . 0.0 OUTLIER -165.27 148.84 8.32 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.862 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.484 ' O ' ' SD ' ' B' ' 36' ' ' MET . 23.3 t -82.8 125.5 31.37 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.046 -1.034 . . . . 0.0 110.68 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.61 HD11 ' CD1' ' B' ' 59' ' ' TYR . 2.6 mt -122.93 164.03 29.67 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.271 -0.893 . . . . 0.0 108.653 179.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.485 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.7 Cg_endo -73.88 71.78 4.06 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.655 2.237 . . . . 0.0 112.539 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.8 -159.22 0.01 OUTLIER Glycine 0 N--CA 1.497 2.727 0 O-C-N 121.528 -0.732 . . . . 0.0 111.414 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 2.8 mmt180 61.11 66.54 0.88 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.568 -0.96 . . . . 0.0 109.196 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.578 ' CZ3' ' HD2' ' B' ' 57' ' ' ARG . 65.0 p-90 -149.79 -177.96 6.19 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.575 -0.703 . . . . 0.0 109.731 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' B' ' 57' ' ' ARG . 23.6 mtmt -150.82 160.35 32.5 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 108.974 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . 0.444 ' HD2' ' HB3' ' B' ' 43' ' ' LYS . 34.7 Cg_endo -76.33 140.86 22.35 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.384 2.056 . . . . 0.0 110.241 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.51 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -157.81 120.8 3.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.342 -0.849 . . . . 0.0 109.058 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.474 ' HG3' ' CG ' ' B' ' 55' ' ' LYS . 2.5 ttt -101.18 126.72 47.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.082 -1.011 . . . . 0.0 109.94 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.531 ' CD1' HG22 ' A' ' 50' ' ' ILE . 10.0 pt -105.62 150.8 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.046 -1.034 . . . . 0.0 109.327 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -125.47 97.68 0.53 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.8 -130.9 4.09 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.291 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.534 HG22 ' CD1' ' A' ' 47' ' ' ILE . 66.3 mt -81.77 129.8 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.534 -0.98 . . . . 0.0 112.185 -178.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 100.21 -48.51 1.2 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 171.89 -164.63 37.29 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.655 -1.259 . . . . 0.0 109.994 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 3.1 m-85 -107.03 130.56 54.63 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.423 -1.045 . . . . 0.0 108.921 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.575 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 34.0 pt -112.7 155.18 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 120.977 -1.077 . . . . 0.0 109.885 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 18.6 mttt -98.95 140.62 32.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.184 -0.947 . . . . 0.0 108.68 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.537 ' CG1' ' HA3' ' B' ' 78' ' ' GLY . 9.9 m -143.7 -176.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.9 -1.125 . . . . 0.0 110.149 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.578 ' HD2' ' CZ3' ' B' ' 42' ' ' TRP . 69.0 mtm-85 -132.09 104.1 6.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.577 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -62.0 134.69 56.96 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.654 0.74 . . . . 0.0 110.967 -178.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.61 ' CD1' HD11 ' B' ' 38' ' ' LEU . 17.6 m-85 -121.61 93.93 4.16 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.517 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 9.1 m-20 -79.44 130.86 35.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.031 -1.043 . . . . 0.0 110.452 -178.659 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.517 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 6.9 mm100 83.22 62.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.329 0.585 . . . . 0.0 109.723 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.522 ' HB ' ' CG2' ' B' ' 75' ' ' VAL . 40.0 mm -119.86 115.72 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.343 -0.848 . . . . 0.0 109.063 179.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.582 ' N ' HG12 ' B' ' 72' ' ' ILE . 2.8 tm? -66.48 91.86 0.19 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 110.453 -179.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.559 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 7.3 tt -98.38 120.68 48.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.442 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.2 tt0 -90.53 111.88 23.34 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.947 -1.095 . . . . 0.0 109.491 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.572 HG13 HG23 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -100.44 126.47 54.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.741 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.425 ' C ' ' O ' ' B' ' 66' ' ' ILE . 10.2 m 39.43 61.8 1.29 Allowed 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.71 -0.619 . . . . 0.0 110.63 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.3 41.05 86.5 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 120.175 -1.012 . . . . 0.0 111.121 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.505 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 2.7 m-70 -139.44 135.46 33.61 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.9 -1.353 . . . . 0.0 109.0 178.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.484 ' HG2' HD23 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -76.64 132.93 39.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.286 -0.884 . . . . 0.0 109.739 -179.614 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -154.6 97.17 1.96 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.835 . . . . 0.0 109.822 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.582 HG12 ' N ' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -83.54 136.85 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 178.638 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.505 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -161.58 -171.96 28.32 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.96 -1.59 . . . . 0.0 110.636 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.577 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.0 m -89.97 106.36 18.42 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.825 -0.809 . . . . 0.0 110.174 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.522 ' CG2' ' HB ' ' B' ' 62' ' ' ILE . 1.4 t -99.64 116.74 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.484 -0.76 . . . . 0.0 110.03 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.536 ' HB2' ' CG2' ' B' ' 32' ' ' VAL . 1.5 mp -85.33 139.05 31.89 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.511 ' CG2' HD13 ' B' ' 38' ' ' LEU . 1.6 t -121.32 114.49 43.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.066 -1.021 . . . . 0.0 109.647 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.537 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -156.06 -162.78 11.64 Favored Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.21 40.61 0.99 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.615 2.21 . . . . 0.0 111.471 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.466 HG23 ' HA ' ' B' ' 34' ' ' GLU . 3.5 t -84.88 137.87 37.73 Favored Pre-proline 0 N--CA 1.493 1.678 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.425 ' O ' HG21 ' B' ' 82' ' ' VAL . 35.2 Cg_endo -77.31 14.43 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.565 2.177 . . . . 0.0 111.579 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.512 HG11 HG13 ' B' ' 84' ' ' ILE . 2.3 t -161.04 151.25 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.95 -1.094 . . . . 0.0 110.438 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.533 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 3.6 m-20 -90.62 102.88 15.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 176.752 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.614 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 2.2 mt -101.97 129.38 53.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 120.902 -1.124 . . . . 0.0 113.083 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.597 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 0.2 OUTLIER -98.63 111.49 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.505 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -97.47 -161.3 31.33 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.835 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.49 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -58.4 -34.9 71.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.563 -0.963 . . . . 0.0 110.451 -179.791 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.595 ' ND2' HD21 ' B' ' 89' ' ' LEU . 9.6 p-10 -48.05 -27.95 2.56 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.867 -1.145 . . . . 0.0 109.913 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.595 HD21 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -109.75 -24.79 10.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.81 -1.181 . . . . 0.0 109.63 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.49 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 90.7 mt -72.43 -4.97 33.39 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 74.4 p -100.51 -17.85 16.93 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -85.4 -41.21 15.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.354 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.561 HD11 ' CG ' ' A' ' 99' ' ' PHE . 1.5 pt -87.04 -4.03 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.29 50.56 38.02 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.136 178.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -73.05 157.77 36.69 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.071 -1.252 . . . . 0.0 110.198 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.459 HG21 HG21 ' A' ' 4' ' ' THR . 50.5 p -149.63 128.39 12.47 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.462 -0.773 . . . . 0.0 109.323 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.558 ' CD1' HD13 ' A' ' 97' ' ' LEU . 7.5 mp -89.68 104.32 16.89 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.6 m120 -107.64 127.29 53.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.05 . . . . 0.0 110.04 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.138 -0.934 . . . . 0.0 109.62 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.53 ' CD ' ' O ' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.726 0 N-CA-C 110.244 -0.714 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.476 ' HA ' ' O ' ' B' ' 97' ' ' LEU . 1.7 tm0? -84.67 144.08 28.79 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.439 ' O ' ' HG ' ' A' ' 5' ' ' LEU . 38.1 t -145.28 123.34 4.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.911 -1.118 . . . . 0.0 109.984 -179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.527 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 18.6 p -60.51 -14.76 21.5 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.546 -0.721 . . . . 0.0 110.28 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.537 ' CD2' HD11 ' B' ' 97' ' ' LEU . 39.5 mt 73.65 17.02 3.78 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.484 -0.76 . . . . 0.0 110.654 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.555 ' CE3' ' HA ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -65.45 -12.61 54.1 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.842 -1.161 . . . . 0.0 108.789 179.252 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.518 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 29.7 mm-40 -146.47 178.86 7.95 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.9 mtt180 -72.97 116.08 46.83 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.916 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.517 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 32.7 Cg_endo -75.93 77.81 3.32 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 122.091 1.86 . . . . 0.0 110.107 178.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.516 HD22 ' CB ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.88 167.83 19.44 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.111 -0.993 . . . . 0.0 109.11 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.525 HG22 ' CG2' ' A' ' 13' ' ' ILE . 27.3 m -150.22 130.0 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.763 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.403 HG23 HD23 ' A' ' 19' ' ' LEU . 91.9 m -66.95 92.18 0.23 Allowed 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.574 HG21 ' CG1' ' A' ' 66' ' ' ILE . 1.4 pt -86.71 143.05 12.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.418 -0.801 . . . . 0.0 111.216 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.3 OUTLIER -108.46 97.78 7.4 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.166 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.577 ' CD1' ' CG2' ' A' ' 75' ' ' VAL . 0.2 OUTLIER -115.69 140.38 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 110.223 -178.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.421 ' HA3' ' CD1' ' A' ' 38' ' ' LEU . . . 49.7 29.23 12.27 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 178.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.57 38.26 57.63 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -136.2 179.43 6.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.477 -1.013 . . . . 0.0 108.284 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.532 ' CD2' ' HD2' ' A' ' 14' ' ' LYS . 13.0 mt -144.55 118.98 9.63 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.957 -1.09 . . . . 0.0 109.801 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.556 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -135.44 150.18 49.79 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.605 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.516 ' CB ' HD22 ' A' ' 10' ' ' LEU . 14.9 mm-40 -78.81 112.51 16.02 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.819 -1.175 . . . . 0.0 108.133 179.602 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.58 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -91.85 140.46 29.66 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.934 0.873 . . . . 0.0 110.788 -178.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 24' ' ' LEU . 44.6 tp -93.74 97.1 10.21 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.517 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 20.2 mt -42.43 107.69 0.08 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.158 -0.964 . . . . 0.0 109.153 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 2.7 t70 -113.81 87.82 2.7 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -178.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.469 HG22 HD23 ' B' ' 5' ' ' LEU . 10.1 m -70.99 -5.68 32.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.114 -0.991 . . . . 0.0 109.081 178.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.454 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.6 -29.38 32.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 168.59 19.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.214 -1.168 . . . . 0.0 109.691 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -100.19 -19.82 16.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.394 -0.816 . . . . 0.0 109.656 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.555 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 39.4 m-20 -133.7 -167.18 1.9 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -0.971 . . . . 0.0 109.74 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.517 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 8.0 m -111.06 89.74 3.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.035 -1.04 . . . . 0.0 110.193 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.566 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -68.14 172.08 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.132 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.96 113.99 0.69 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.189 -0.944 . . . . 0.0 109.557 -179.511 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.51 ' C ' ' O ' ' A' ' 33' ' ' LEU . 9.7 pt-20 -36.24 154.84 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.438 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.0 OUTLIER -44.16 134.86 4.65 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.088 -1.008 . . . . 0.0 109.922 -178.915 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.539 ' HE2' ' CG2' ' A' ' 15' ' ' ILE . 2.3 ppp? -154.31 -163.72 1.68 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.595 -0.691 . . . . 0.0 109.644 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.499 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 3.1 t -107.81 118.27 36.29 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.921 -1.112 . . . . 0.0 111.149 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.596 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -131.32 -173.57 0.34 Allowed Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 178.512 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 33.6 Cg_endo -78.97 -163.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.919 1.746 . . . . 0.0 110.861 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -114.18 31.56 6.41 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -118.98 63.82 0.78 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.594 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 21.2 p-90 -130.38 -175.39 3.63 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.764 0.792 . . . . 0.0 110.207 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -139.85 156.51 70.71 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.65 141.56 24.96 Favored 'Trans proline' 0 C--N 1.303 -1.849 0 C-N-CA 121.868 1.712 . . . . 0.0 109.68 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.411 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 1.3 tttt -149.94 170.14 19.52 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.444 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -144.27 113.81 7.1 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.655 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.525 ' CD1' HG23 ' B' ' 50' ' ' ILE . 24.9 pt -89.47 141.62 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.079 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.607 ' CA ' ' CD1' ' A' ' 53' ' ' PHE . . . -119.32 115.46 3.05 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -136.84 -115.05 1.38 Allowed Glycine 0 N--CA 1.485 1.905 0 C-N-CA 119.212 -1.471 . . . . 0.0 111.088 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.509 ' CG2' HD13 ' B' ' 47' ' ' ILE . 17.1 mt -94.07 118.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.733 -0.863 . . . . 0.0 112.585 -177.116 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.89 -11.31 67.99 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.434 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 137.4 -177.54 19.76 Favored Glycine 0 N--CA 1.493 2.489 0 O-C-N 120.806 -1.408 . . . . 0.0 109.647 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.5 OUTLIER -102.64 143.92 31.7 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -1.133 . . . . 0.0 109.844 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.464 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 1.0 OUTLIER -109.19 -178.21 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.258 -0.901 . . . . 0.0 108.703 178.909 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 2.4 mttp -109.09 141.7 40.88 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.038 -1.039 . . . . 0.0 109.643 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -147.61 -171.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.05 -1.031 . . . . 0.0 109.521 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.409 ' HG3' ' C ' ' A' ' 56' ' ' VAL . 1.6 mtt180 -133.46 108.12 8.46 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.411 ' HB2' ' HD2' ' A' ' 45' ' ' LYS . 1.3 tt0 -65.28 97.17 0.26 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.322 -0.861 . . . . 0.0 110.428 -179.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.596 ' CZ ' ' HB3' ' A' ' 38' ' ' LEU . 10.3 m-85 -89.93 123.22 33.67 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -105.58 134.89 47.96 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.736 -1.227 . . . . 0.0 110.665 -178.589 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.503 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mp0 73.22 63.22 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 121.695 0.76 . . . . 0.0 110.195 179.239 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.512 HD11 HG22 ' A' ' 62' ' ' ILE . 22.1 mm -117.27 127.27 74.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.518 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 0.1 OUTLIER -76.37 89.08 3.18 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 112.276 -177.523 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.571 ' O ' HG21 ' A' ' 64' ' ' ILE . 7.2 tt -90.48 112.96 25.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 CA-C-O 121.888 0.852 . . . . 0.0 108.822 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.517 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -89.5 113.03 24.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.778 -1.201 . . . . 0.0 108.515 -179.69 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.574 ' CG1' HG21 ' A' ' 13' ' ' ILE . 2.9 mt -115.17 126.64 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.922 -1.111 . . . . 0.0 110.67 -178.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.2 m 66.75 24.91 9.82 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.638 -0.664 . . . . 0.0 109.895 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.435 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 80.58 7.44 88.55 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 61.0 m-70 -108.86 110.03 21.28 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.208 -1.172 . . . . 0.0 109.226 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.471 ' HG3' HD23 ' A' ' 63' ' ' LEU . 1.2 ttpt -52.58 136.29 32.79 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.474 -0.767 . . . . 0.0 109.026 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.518 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -154.94 118.38 4.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.618 -0.676 . . . . 0.0 109.36 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.507 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -95.07 158.06 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 120.807 -1.183 . . . . 0.0 108.036 178.709 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.616 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . 177.42 -170.15 42.54 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.734 -1.698 . . . . 0.0 111.47 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.457 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 1.5 m -91.18 113.25 25.46 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.918 . . . . 0.0 110.146 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.577 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 1.5 t -107.93 109.49 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.525 -0.734 . . . . 0.0 111.135 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.566 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.9 mp -80.2 125.08 29.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.276 -0.89 . . . . 0.0 109.056 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 89.9 t -113.25 131.91 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.999 -1.063 . . . . 0.0 109.853 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -164.47 -167.57 25.21 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.536 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -81.81 40.74 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.592 2.195 . . . . 0.0 110.534 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' HG21 ' A' ' 80' ' ' THR . 14.9 t -81.74 140.72 47.47 Favored Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.72 13.06 1.75 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 C-N-CA 122.227 1.952 . . . . 0.0 111.196 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.502 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.45 163.49 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.74 -1.225 . . . . 0.0 110.731 -179.755 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.58 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 60.0 m-20 -95.8 142.88 27.55 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 176.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.587 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 12.3 mm -131.95 124.63 53.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.467 -1.396 . . . . 0.0 111.337 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.499 HD13 ' HB3' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -102.96 94.72 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 88' ' ' ASN . . . -100.75 171.21 22.61 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.382 -177.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.555 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.1 OUTLIER -21.71 -41.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -179.392 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.577 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 6.8 p-10 -51.1 -42.89 60.94 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.282 -1.511 . . . . 0.0 110.774 -177.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.616 HD23 ' HA3' ' A' ' 73' ' ' GLY . 0.8 OUTLIER -97.54 -11.04 24.18 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.146 -0.971 . . . . 0.0 110.414 -179.137 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.555 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 5.7 mp -69.73 -35.14 74.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.084 -1.01 . . . . 0.0 108.788 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 p -70.5 -15.42 62.79 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.455 -0.778 . . . . 0.0 109.252 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.6 mm-40 -89.13 -41.42 12.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.019 . . . . 0.0 109.27 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.564 HD13 ' CB ' ' B' ' 99' ' ' PHE . 1.9 pt -81.99 -1.89 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 57.19 54.95 33.11 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.519 ' HB2' ' CD1' ' B' ' 5' ' ' LEU . . . -85.42 127.62 34.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.422 -1.046 . . . . 0.0 110.26 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 69.9 p -122.31 124.9 44.82 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.573 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.9 mp -89.98 100.48 13.29 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.406 -0.809 . . . . 0.0 109.384 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.475 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 1.6 m120 -105.96 129.33 54.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.234 -0.916 . . . . 0.0 110.048 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.591 ' CE2' ' HG2' ' B' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.265 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.591 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.404 -0.652 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.443 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 6.7 tt0 -84.25 129.45 34.88 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.509 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 11.4 t -121.76 96.23 4.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.762 -1.212 . . . . 0.0 109.499 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 3.0 p -55.73 135.11 51.73 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.519 ' CD1' ' HB2' ' A' ' 95' ' ' ALA . 89.5 mt -83.36 4.42 27.46 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.765 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -57.05 -20.19 23.21 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -135.4 157.67 46.31 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.0 mtt180 -53.25 125.5 42.65 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 120.886 -1.134 . . . . 0.0 109.371 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.509 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 36.4 Cg_endo -77.65 71.23 6.59 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.281 1.987 . . . . 0.0 109.819 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.527 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -90.63 144.62 25.57 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.26 -179.686 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.488 HG23 HG12 ' B' ' 66' ' ' ILE . 3.1 m -135.14 132.71 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 110.203 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.402 HG23 HD23 ' B' ' 19' ' ' LEU . 91.8 m -65.6 109.56 2.43 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.548 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.1 pt -98.58 144.23 11.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 110.841 -178.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.2 OUTLIER -112.16 101.9 10.12 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.527 HG23 ' CE ' ' B' ' 36' ' ' MET . 11.8 mt -118.58 118.87 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.162 -0.961 . . . . 0.0 109.766 -179.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.457 ' HA3' HD13 ' B' ' 38' ' ' LEU . . . 67.83 27.25 73.67 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.2 -2.78 74.84 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.416 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.4 mp0 -90.07 -179.34 5.66 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.329 -1.101 . . . . 0.0 108.973 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.534 ' CD2' ' O ' ' B' ' 13' ' ' ILE . 12.4 mt -153.17 124.02 7.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.193 -0.942 . . . . 0.0 110.269 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.449 ' NZ ' HD21 ' B' ' 33' ' ' LEU . 8.4 mtmt -143.89 158.63 43.57 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.527 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.4 OUTLIER -79.29 133.05 36.64 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.978 -1.076 . . . . 0.0 109.54 -179.114 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -107.7 156.25 19.29 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.248 -0.908 . . . . 0.0 110.022 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' B' ' 24' ' ' LEU . 62.4 tp -115.6 95.35 5.1 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.502 ' CD2' HD22 ' B' ' 90' ' ' LEU . 24.1 mt -42.15 103.44 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.393 -0.817 . . . . 0.0 109.359 -179.437 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.542 ' CB ' HG21 ' B' ' 84' ' ' ILE . 48.8 t0 -114.55 91.02 3.48 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.142 -0.974 . . . . 0.0 110.275 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.466 HG23 HD23 ' A' ' 5' ' ' LEU . 0.9 OUTLIER -68.88 -7.56 35.82 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.066 -1.021 . . . . 0.0 108.73 178.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.416 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -73.8 -41.57 41.54 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.71 166.21 23.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.149 -1.206 . . . . 0.0 109.886 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -100.93 -19.91 15.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.145 -0.972 . . . . 0.0 110.786 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.5 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -130.6 -168.17 1.94 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.874 -1.141 . . . . 0.0 109.644 -179.445 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.545 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 16.7 m -109.74 95.66 5.75 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.911 -1.118 . . . . 0.0 110.286 -179.066 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.66 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.5 OUTLIER -77.38 162.14 4.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 179.023 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.533 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -160.74 125.78 3.75 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 120.456 -1.402 . . . . 0.0 111.288 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.511 ' HA ' HG21 ' B' ' 80' ' ' THR . 3.7 tt0 -38.89 159.17 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.724 -0.61 . . . . 0.0 109.677 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.617 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.6 tt0 -51.35 150.26 3.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.95 . . . . 0.0 110.285 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.527 ' CE ' HG23 ' B' ' 15' ' ' ILE . 2.9 ppp? -168.5 -169.16 1.01 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.293 -0.879 . . . . 0.0 109.11 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.52 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.6 t -121.19 124.42 44.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.929 -1.107 . . . . 0.0 110.372 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.586 ' CB ' ' CD ' ' B' ' 39' ' ' PRO . 0.1 OUTLIER -124.64 -172.82 0.26 Allowed Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.347 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.586 ' CD ' ' CB ' ' B' ' 38' ' ' LEU . 34.8 Cg_endo -80.8 59.87 7.63 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.292 1.995 . . . . 0.0 111.005 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.95 -157.92 0.06 OUTLIER Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.405 ' O ' ' O ' ' B' ' 40' ' ' GLY . 50.7 mmt-85 51.91 96.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.544 -0.974 . . . . 0.0 109.077 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.432 ' CE3' ' HG3' ' B' ' 57' ' ' ARG . 16.7 p-90 -155.02 171.93 18.94 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.691 -0.631 . . . . 0.0 109.683 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.24 121.4 20.52 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.26 141.5 18.31 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.412 2.075 . . . . 0.0 111.423 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.28 -171.93 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' HG3' ' B' ' 55' ' ' LYS . 17.1 mtp -143.54 133.97 24.74 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.903 -1.123 . . . . 0.0 110.098 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.509 HD13 ' CG2' ' A' ' 50' ' ' ILE . 19.4 pt -104.94 139.43 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 0.0 108.8 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.9 97.35 0.7 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.294 -1.922 . . . . 0.0 108.294 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.22 -121.37 2.88 Favored Glycine 0 N--CA 1.485 1.914 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.682 -178.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.525 HG23 ' CD1' ' A' ' 47' ' ' ILE . 11.2 mt -86.58 124.79 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.854 -0.792 . . . . 0.0 111.982 -177.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 101.49 -53.46 0.83 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 176.76 -161.81 29.9 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -111.38 137.33 49.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -1.198 . . . . 0.0 109.359 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.415 HG12 HG13 ' B' ' 47' ' ' ILE . 27.6 pt -117.14 159.17 17.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.253 -0.904 . . . . 0.0 109.535 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.527 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.5 OUTLIER -94.69 126.26 39.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 108.8 179.313 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 12.5 m -134.2 153.68 36.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.519 ' N ' ' HD2' ' B' ' 57' ' ' ARG . 2.3 mpt_? -91.63 179.78 5.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -138.61 93.06 2.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.131 -0.98 . . . . 0.0 110.523 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.569 ' CE2' ' HB3' ' B' ' 38' ' ' LEU . 67.2 m-85 -89.29 92.53 9.2 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.485 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 49.0 m-20 -78.62 143.11 36.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.046 -1.034 . . . . 0.0 109.381 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.485 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 74.1 64.18 0.08 Allowed 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.529 -0.732 . . . . 0.0 109.189 -179.571 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.534 ' CD1' HD22 ' B' ' 38' ' ' LEU . 1.1 mm -121.07 117.15 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.552 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 3.4 tm? -68.62 85.27 0.3 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.476 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.59 ' CG2' HD13 ' B' ' 89' ' ' LEU . 3.4 tt -91.02 117.67 34.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.486 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.9 tt0 -89.53 111.47 22.4 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.063 -1.023 . . . . 0.0 109.563 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' B' ' 64' ' ' ILE . 0.4 OUTLIER -104.35 120.3 54.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.79 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.499 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 88.2 m 65.36 20.42 11.81 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.788 -0.57 . . . . 0.0 110.166 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.26 1.61 78.46 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.112 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -97.9 123.0 41.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.214 -1.168 . . . . 0.0 109.123 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.488 ' HG2' HD22 ' B' ' 63' ' ' LEU . 3.9 mtpt -58.71 133.85 56.3 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.488 ' O ' HG23 ' B' ' 64' ' ' ILE . . . -150.96 99.67 2.72 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.014 -1.053 . . . . 0.0 110.26 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.525 HD11 ' N ' ' B' ' 62' ' ' ILE . 0.5 OUTLIER -79.55 144.54 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.668 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.474 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -167.43 -177.8 39.2 Favored Glycine 0 N--CA 1.486 1.991 0 C-N-CA 118.915 -1.612 . . . . 0.0 110.634 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.427 ' CG2' ' OD1' ' B' ' 60' ' ' ASP . 22.0 m -95.83 102.99 14.85 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.723 -0.869 . . . . 0.0 109.432 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.486 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 0.9 OUTLIER -92.58 162.11 2.45 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.66 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.0 mp -129.95 140.35 50.94 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.617 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 9.2 t -120.8 103.19 13.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 O-C-N 121.386 -0.821 . . . . 0.0 110.507 -178.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.54 -166.12 10.87 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.527 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.5 Cg_endo -80.94 41.31 1.12 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.583 2.189 . . . . 0.0 110.956 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.511 HG21 ' HA ' ' B' ' 34' ' ' GLU . 1.8 t -84.45 138.21 38.8 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.29 14.51 1.56 Allowed 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.193 1.928 . . . . 0.0 111.497 -179.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.531 ' CG1' HD12 ' B' ' 84' ' ' ILE . 0.7 OUTLIER -161.13 171.21 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.903 -1.123 . . . . 0.0 110.11 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -105.97 116.07 31.31 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 176.591 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' B' ' 31' ' ' THR . 5.0 mm -100.45 120.59 50.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 O-C-N 120.661 -1.274 . . . . 0.0 111.562 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.472 HG23 HD21 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -95.37 89.83 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.838 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.08 -164.33 27.27 Favored Glycine 0 N--CA 1.493 2.474 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.437 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.518 ' NH2' ' HA ' ' A' ' 7' ' ' GLN . 13.5 mtm180 -60.76 -39.79 90.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.786 -0.832 . . . . 0.0 110.548 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.578 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 9.7 p-10 -45.28 -26.49 0.52 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.093 -1.005 . . . . 0.0 110.181 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.59 HD13 ' CG2' ' B' ' 64' ' ' ILE . 1.7 mm? -108.7 -29.56 8.64 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.026 -1.047 . . . . 0.0 111.041 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.502 HD22 ' CD2' ' B' ' 24' ' ' LEU . 71.9 mt -65.15 -9.62 24.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.716 -1.24 . . . . 0.0 108.748 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.2 p -101.03 -20.71 15.26 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.176 -0.952 . . . . 0.0 109.391 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 36.6 mm-40 -78.06 -40.81 37.46 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.071 -1.018 . . . . 0.0 109.141 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.435 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 4.4 pt -86.03 -4.02 9.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 77.28 29.47 56.2 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.557 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -59.97 151.0 27.26 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.042 -1.269 . . . . 0.0 109.037 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.511 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 2.6 p -136.6 173.7 11.42 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.573 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -134.31 98.82 4.2 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.735 -1.228 . . . . 0.0 110.088 -179.371 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.7 m120 -99.23 118.62 36.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.964 -1.085 . . . . 0.0 109.37 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.508 0 CA-C-O 117.94 -1.029 . . . . 0.0 108.935 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.548 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 N-CA-C 110.231 -0.719 . . . . 0.0 110.231 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.481 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.43 131.07 34.71 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 178.204 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.461 HG12 ' HB3' ' A' ' 9' ' ' PRO . 4.1 t -121.79 94.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.991 -1.068 . . . . 0.0 109.768 -178.259 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.522 ' CG2' ' HB ' ' B' ' 96' ' ' THR . 19.3 p -126.01 45.67 2.58 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.335 -0.853 . . . . 0.0 108.93 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.544 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.5 OUTLIER -89.07 36.47 0.82 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.187 -0.946 . . . . 0.0 109.589 -179.721 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 13.4 m0 17.45 51.86 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 CA-C-O 121.631 0.729 . . . . 0.0 111.512 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.544 ' N ' ' O ' ' A' ' 5' ' ' LEU . 49.4 mt-30 -156.02 -159.78 0.94 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 10.1 mtm180 -79.66 113.34 36.6 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.986 -1.071 . . . . 0.0 109.909 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.496 ' HD3' ' O ' ' A' ' 7' ' ' GLN . 36.3 Cg_endo -79.79 80.27 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 C-N-CA 122.355 2.037 . . . . 0.0 110.055 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.565 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -100.13 164.78 11.82 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.846 -179.749 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.545 HG22 ' CG2' ' A' ' 13' ' ' ILE . 2.3 m -148.86 129.47 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 110.256 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.3 m -69.22 94.05 0.66 Allowed 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 178.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.545 ' CG2' HG22 ' A' ' 11' ' ' VAL . 7.7 pt -82.95 167.42 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 110.949 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.3 tttt -128.65 102.88 6.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.559 -0.713 . . . . 0.0 109.25 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.497 HD11 HG22 ' A' ' 15' ' ' ILE . 11.6 mt -124.47 147.93 28.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 120.987 -1.07 . . . . 0.0 109.592 -179.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.03 32.53 4.83 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.9 43.62 90.97 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.6 tp-100 -138.52 170.79 15.38 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.191 -1.182 . . . . 0.0 109.022 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 19' ' ' LEU . 39.3 mt -135.57 126.41 27.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.385 -0.822 . . . . 0.0 109.445 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 mtpm? -148.22 158.65 44.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.406 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.565 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.4 mt-10 -79.17 123.81 27.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.523 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -105.08 141.98 35.67 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.333 -0.854 . . . . 0.0 110.225 -178.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.466 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 19.8 tp -97.67 103.82 15.79 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.747 -0.595 . . . . 0.0 109.918 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 23' ' ' LEU . 12.1 mt -44.62 113.62 0.58 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 178.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.487 ' CB ' HG21 ' A' ' 84' ' ' ILE . 25.4 t0 -119.64 89.13 3.07 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.948 -1.095 . . . . 0.0 111.65 -177.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.57 -2.95 35.04 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.909 -1.119 . . . . 0.0 108.562 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -90.78 -25.12 25.95 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 162.13 19.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.953 -1.322 . . . . 0.0 109.027 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -98.1 -13.06 21.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.115 -0.991 . . . . 0.0 110.287 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.539 ' HB3' HD12 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -142.78 -175.05 4.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.93 -1.106 . . . . 0.0 109.732 -179.957 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 22.6 m -104.63 91.83 4.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.703 -1.248 . . . . 0.0 111.226 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.29 173.34 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.643 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.32 122.78 1.08 Allowed 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.688 -1.257 . . . . 0.0 111.547 -179.417 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.562 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 12.6 tt0 -39.97 149.21 0.07 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.668 -0.645 . . . . 0.0 109.362 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.68 141.88 6.72 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.191 -0.943 . . . . 0.0 110.295 -179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.439 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -163.64 -172.28 2.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.344 -0.848 . . . . 0.0 109.313 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.2 t -92.7 83.95 4.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.001 -1.062 . . . . 0.0 109.626 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.554 HD22 ' CG ' ' A' ' 59' ' ' TYR . 61.6 tp -116.2 98.34 51.17 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -78.37 167.3 23.18 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.656 2.237 . . . . 0.0 110.642 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.61 171.93 13.9 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 133.41 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -1.154 . . . . 0.0 108.684 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 52.5 p-90 -136.67 -177.42 4.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.163 -0.961 . . . . 0.0 110.691 -178.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.1 tptt -146.28 162.98 32.54 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.0 140.36 17.98 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.756 1.638 . . . . 0.0 109.688 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.532 ' O ' ' CG2' ' A' ' 56' ' ' VAL . 0.0 OUTLIER -155.4 115.31 3.72 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.105 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -100.93 122.51 43.61 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.196 -0.94 . . . . 0.0 109.01 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.544 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 22.6 pt -93.24 139.26 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.016 -1.052 . . . . 0.0 109.109 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.585 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.64 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.641 -1.783 . . . . 0.0 108.641 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.74 -121.92 2.55 Favored Glycine 0 N--CA 1.483 1.812 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.698 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.56 HG22 ' CD1' ' B' ' 47' ' ' ILE . 26.3 mt -86.48 122.23 38.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.875 -0.779 . . . . 0.0 112.571 -177.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.447 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 103.49 -50.98 0.85 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.428 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 176.26 -156.94 22.29 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.585 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 5.2 m-85 -111.9 129.9 56.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -1.034 . . . . 0.0 109.837 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.544 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 1.0 OUTLIER -106.97 164.76 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.51 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 1.1 mtmt -106.82 140.28 39.91 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.865 -1.147 . . . . 0.0 110.497 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 16.1 m -146.63 178.18 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.83 110.63 16.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.329 -0.857 . . . . 0.0 108.829 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.414 ' O ' ' CG ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -64.75 107.03 1.32 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.456 -0.778 . . . . 0.0 110.271 -179.247 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.2 m-85 -100.89 100.45 11.08 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.535 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 85.2 m-20 -83.82 132.62 34.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.051 -1.031 . . . . 0.0 110.85 -178.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.558 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.2 mt-30 81.17 60.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.82 -0.55 . . . . 0.0 110.767 178.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.483 ' HB ' ' CG2' ' A' ' 75' ' ' VAL . 5.1 mm -117.93 118.46 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.545 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.608 ' CD2' ' CG ' ' A' ' 70' ' ' LYS . 1.4 tp -70.35 86.52 0.6 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.035 -1.04 . . . . 0.0 111.145 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.541 HG12 ' CD1' ' A' ' 66' ' ' ILE . 5.6 tt -86.54 119.75 35.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.79 103.98 16.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.936 -1.102 . . . . 0.0 109.165 -178.589 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.541 ' CD1' HG12 ' A' ' 64' ' ' ILE . 3.2 mt -109.61 120.93 61.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.479 -0.763 . . . . 0.0 109.717 -179.311 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.579 ' HB3' ' CD2' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 64.42 40.21 6.5 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.531 -0.731 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.24 30.49 76.11 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.579 ' CD2' ' HB3' ' A' ' 67' ' ' CYS . 87.9 m-70 -122.69 101.38 7.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -1.19 . . . . 0.0 109.592 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.608 ' CG ' ' CD2' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -53.04 108.88 0.36 Allowed 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.156 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.558 ' O ' ' CD1' ' A' ' 63' ' ' LEU . . . -126.56 148.35 49.75 Favored 'General case' 0 C--N 1.287 -2.14 0 C-N-CA 120.304 -0.558 . . . . 0.0 109.603 -179.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.558 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -118.68 147.42 22.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.504 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.535 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -172.45 -168.26 33.6 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 118.789 -1.672 . . . . 0.0 110.987 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.496 ' HB ' ' OD1' ' A' ' 30' ' ' ASP . 27.9 m -96.98 108.0 20.64 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.659 -0.906 . . . . 0.0 109.409 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.484 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -99.21 111.06 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.469 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.543 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.3 mp -81.12 118.38 22.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.057 -1.027 . . . . 0.0 108.306 178.591 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 8.5 t -104.89 109.99 29.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.124 -0.985 . . . . 0.0 109.68 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.474 ' HA3' HG13 ' A' ' 56' ' ' VAL . . . -148.16 -162.16 9.98 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.51 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -81.66 43.78 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.637 2.225 . . . . 0.0 110.599 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.562 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 9.1 t -84.75 136.33 39.31 Favored Pre-proline 0 N--CA 1.491 1.576 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -79.07 14.54 1.71 Allowed 'Trans proline' 0 C--N 1.307 -1.614 0 C-N-CA 122.389 2.059 . . . . 0.0 110.983 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.2 t -159.9 164.65 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.11 -0.994 . . . . 0.0 109.101 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -101.36 126.21 48.09 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 104.831 -2.285 . . . . 0.0 104.831 176.649 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 31' ' ' THR . 7.6 mm -113.32 128.94 69.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.333 -1.347 . . . . 0.0 111.794 -176.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.505 ' O ' HD23 ' A' ' 90' ' ' LEU . 0.8 OUTLIER -103.53 90.91 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 177.138 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.561 ' C ' ' CD2' ' A' ' 90' ' ' LEU . . . -83.97 173.6 50.66 Favored Glycine 0 N--CA 1.498 2.774 0 O-C-N 121.198 -0.939 . . . . 0.0 110.97 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.544 ' CA ' HD21 ' A' ' 90' ' ' LEU . 8.8 mmm180 -39.89 -39.97 0.92 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.806 -0.82 . . . . 0.0 111.335 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.56 ' ND2' HD21 ' A' ' 89' ' ' LEU . 12.2 p-10 -44.55 -41.18 6.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.739 -1.226 . . . . 0.0 109.986 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.56 HD21 ' ND2' ' A' ' 88' ' ' ASN . 1.7 mm? -96.67 -26.62 15.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.237 -0.914 . . . . 0.0 111.745 -179.045 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.561 ' CD2' ' C ' ' A' ' 86' ' ' GLY . 0.8 OUTLIER -60.28 -36.25 77.41 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.292 -1.505 . . . . 0.0 108.0 179.71 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 81.6 p -70.05 -21.58 63.15 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 108.846 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.422 ' HB2' ' O ' ' A' ' 89' ' ' LEU . 22.3 mm-40 -74.78 -40.66 61.04 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.582 HD11 ' CG ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -86.31 -13.08 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.384 -0.822 . . . . 0.0 108.937 179.444 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 83.92 26.78 40.05 Favored Glycine 0 N--CA 1.495 2.633 0 C-N-CA 120.32 -0.943 . . . . 0.0 111.042 178.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.543 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -59.5 143.16 50.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 109.865 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.544 HG23 ' CG2' ' B' ' 4' ' ' THR . 74.2 p -135.34 129.58 33.66 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.535 ' CD1' HD13 ' B' ' 97' ' ' LEU . 3.7 mp -92.63 99.26 12.0 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.907 -1.12 . . . . 0.0 110.688 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.573 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.4 m120 -108.0 124.48 50.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.413 -0.804 . . . . 0.0 109.046 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.589 ' CD2' HD11 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 118.037 -0.983 . . . . 0.0 109.163 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.462 ' HD2' ' O ' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.273 -0.703 . . . . 0.0 110.273 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.573 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.5 tt0 -83.39 144.11 29.85 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.477 HG21 ' O ' ' B' ' 2' ' ' GLN . 25.6 t -141.98 105.83 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.364 -1.334 . . . . 0.0 110.87 -177.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.544 ' CG2' HG23 ' A' ' 96' ' ' THR . 0.2 OUTLIER -106.61 -86.51 0.49 Allowed 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 178.137 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.55 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 43.52 20.38 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.576 -0.702 . . . . 0.0 111.308 178.498 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 40.4 m0 16.24 52.16 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.234 0.54 . . . . 0.0 112.16 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.55 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.4 mt-30 -144.03 -128.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.45 130.93 22.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.642 -1.286 . . . . 0.0 109.662 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.469 ' HB2' ' CD1' ' B' ' 24' ' ' LEU . 37.1 Cg_endo -82.52 53.63 4.56 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.456 2.104 . . . . 0.0 109.301 178.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 mt -79.05 143.73 35.33 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.237 -0.914 . . . . 0.0 109.31 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.519 HG23 ' CG2' ' B' ' 66' ' ' ILE . 0.8 OUTLIER -142.38 150.89 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -0.823 . . . . 0.0 109.452 -179.713 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 89.8 m -83.92 109.01 17.26 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.558 ' HA ' ' O ' ' B' ' 65' ' ' GLU . 1.1 pt -98.89 139.26 21.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.148 -0.97 . . . . 0.0 111.102 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.503 ' HA ' HD22 ' B' ' 19' ' ' LEU . 0.7 OUTLIER -98.5 98.31 9.52 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.535 HD13 ' CD1' ' B' ' 13' ' ' ILE . 4.9 mt -120.3 130.64 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.342 -0.849 . . . . 0.0 109.337 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.29 23.54 71.7 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.4 15.72 80.2 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.452 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -112.25 174.08 6.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.422 -1.046 . . . . 0.0 109.31 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.503 HD22 ' HA ' ' B' ' 14' ' ' LYS . 27.9 mt -134.8 113.91 12.09 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.248 -0.907 . . . . 0.0 110.018 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -134.85 177.48 7.76 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.54 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 3.5 mm-40 -79.58 177.78 8.62 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.859 -1.15 . . . . 0.0 108.883 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.537 ' HB1' HG21 ' B' ' 13' ' ' ILE . . . -159.18 101.53 1.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.322 -0.861 . . . . 0.0 109.447 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 27' ' ' GLY . 14.3 tp -77.97 98.89 5.84 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.291 -0.88 . . . . 0.0 109.438 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.469 ' CD1' ' HB2' ' B' ' 9' ' ' PRO . 89.6 mt -45.42 104.74 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.055 -1.028 . . . . 0.0 108.585 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.534 ' HB3' HG21 ' B' ' 84' ' ' ILE . 39.5 t0 -111.69 91.43 3.66 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.356 -0.84 . . . . 0.0 110.646 -178.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 55.9 m -69.79 -11.57 60.96 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.119 -0.988 . . . . 0.0 108.459 178.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.439 ' O ' HD23 ' A' ' 23' ' ' LEU . . . -69.24 -39.85 82.03 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.26 150.67 29.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.342 -1.093 . . . . 0.0 109.481 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -91.19 -10.04 43.17 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.23 -0.919 . . . . 0.0 109.805 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.482 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.81 -173.13 3.05 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.274 -0.892 . . . . 0.0 109.546 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.4 HG21 ' O ' ' B' ' 84' ' ' ILE . 29.9 m -113.44 98.51 7.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.01 -1.056 . . . . 0.0 110.229 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.624 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -83.33 166.01 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.547 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.2 OUTLIER -162.8 126.58 2.94 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.59 -1.319 . . . . 0.0 111.354 -178.438 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.506 ' N ' HG23 ' B' ' 80' ' ' THR . 8.5 tt0 -42.9 154.57 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.573 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tm-20 -38.8 148.54 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.349 -0.844 . . . . 0.0 110.366 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.534 ' CE ' HG21 ' B' ' 15' ' ' ILE . 24.5 ptm -163.57 -162.31 0.72 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.324 -0.86 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.5 t -118.68 120.2 36.73 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.083 -1.01 . . . . 0.0 110.794 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.489 HD13 ' HD3' ' B' ' 39' ' ' PRO . 0.0 OUTLIER -124.6 173.66 4.53 Favored Pre-proline 0 N--CA 1.491 1.592 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.019 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.489 ' HD3' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.72 47.72 2.61 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.676 2.25 . . . . 0.0 111.634 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.12 -166.88 0.01 OUTLIER Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.5 mmm180 63.38 70.73 0.52 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.168 -1.195 . . . . 0.0 109.361 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 10.1 p-90 -140.41 -173.43 3.67 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 121.629 -0.669 . . . . 0.0 109.519 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.94 128.58 16.76 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.216 -0.927 . . . . 0.0 108.516 179.292 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -75.34 139.54 23.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 121.879 1.719 . . . . 0.0 110.749 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.17 -162.7 1.57 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.528 -0.732 . . . . 0.0 109.232 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.534 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 0.2 OUTLIER -149.02 130.02 14.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.27 -0.894 . . . . 0.0 109.613 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.56 ' CD1' HG22 ' A' ' 50' ' ' ILE . 8.3 pt -98.67 143.56 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.899 -1.125 . . . . 0.0 108.84 179.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.629 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -118.53 113.3 2.56 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 -179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.12 -125.43 2.04 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.707 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.537 HG23 ' CD1' ' A' ' 47' ' ' ILE . 21.5 mt -88.7 119.04 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.797 -0.825 . . . . 0.0 112.852 -177.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.455 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 96.6 2.32 60.06 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.203 177.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 126.87 -158.75 20.96 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.334 -1.412 . . . . 0.0 110.221 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.66 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.9 OUTLIER -124.6 134.11 53.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.661 -0.905 . . . . 0.0 109.222 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.511 HG12 HD13 ' B' ' 47' ' ' ILE . 13.5 pt -104.26 167.65 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.979 -1.076 . . . . 0.0 109.239 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.559 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.91 134.32 48.23 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.191 -0.943 . . . . 0.0 109.159 179.734 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.465 HG11 ' C ' ' B' ' 55' ' ' LYS . 21.4 m -140.6 -171.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.991 -1.068 . . . . 0.0 110.201 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.463 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.4 mtt-85 -128.87 105.92 8.56 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 33.7 tt0 -69.62 100.34 1.44 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.444 -0.785 . . . . 0.0 110.934 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 17.1 m-85 -89.59 133.42 34.62 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.014 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 67.4 m-20 -108.49 133.14 53.05 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.713 -1.242 . . . . 0.0 109.989 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.547 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.29 63.71 0.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.917 -0.713 . . . . 0.0 109.569 179.581 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' B' ' 75' ' ' VAL . 26.9 mm -116.52 119.28 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.55 HD23 ' HG2' ' B' ' 70' ' ' LYS . 2.9 tm? -66.02 84.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 111.28 -178.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.559 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 5.7 tt -90.52 112.19 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.558 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 29.5 tt0 -89.52 115.39 26.9 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.178 -0.951 . . . . 0.0 109.033 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.519 ' CG2' HG23 ' B' ' 11' ' ' VAL . 2.3 mp -112.97 123.43 68.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.032 -1.043 . . . . 0.0 109.719 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 36.8 m 67.17 44.93 1.79 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.487 -0.758 . . . . 0.0 109.444 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 61.52 21.02 59.75 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.504 ' O ' ' HA ' ' B' ' 65' ' ' GLU . 4.4 m-70 -119.66 130.09 54.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.014 -1.286 . . . . 0.0 109.677 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.55 ' HG2' HD23 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -70.56 136.55 49.37 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -155.9 104.69 2.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.219 -0.925 . . . . 0.0 109.793 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.547 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -80.06 154.54 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.963 -1.085 . . . . 0.0 108.349 178.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.59 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 178.98 -169.74 41.24 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.16 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -95.64 105.9 17.94 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.667 -0.901 . . . . 0.0 110.618 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.54 HG22 ' HB ' ' B' ' 62' ' ' ILE . 1.0 OUTLIER -97.6 158.91 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.726 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.624 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.8 mp -126.38 125.42 42.18 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.762 -1.211 . . . . 0.0 107.901 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.573 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 94.8 t -106.43 116.39 50.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 O-C-N 120.671 -1.268 . . . . 0.0 109.663 -179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -156.37 -166.25 15.9 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.559 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -80.09 44.52 1.74 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.511 2.141 . . . . 0.0 110.604 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.506 HG23 ' N ' ' B' ' 34' ' ' GLU . 3.2 t -89.74 135.22 30.84 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.483 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -78.17 17.59 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.284 1.99 . . . . 0.0 111.137 -178.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.507 ' CG1' HG13 ' B' ' 84' ' ' ILE . 2.5 t -160.32 156.76 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 120.879 -1.138 . . . . 0.0 110.777 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.54 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 60.4 m-20 -97.41 86.28 3.84 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 176.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.534 HG21 ' HB3' ' B' ' 25' ' ' ASP . 2.6 mt -82.78 124.89 39.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 O-C-N 121.298 -0.876 . . . . 0.0 112.378 -176.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.509 ' N ' HD11 ' B' ' 85' ' ' ILE . 3.7 mm -100.19 109.18 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.572 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -108.29 164.39 12.76 Favored Glycine 0 N--CA 1.498 2.785 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.881 -178.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.5 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 20.7 mmm180 -19.26 -41.94 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -178.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.572 ' N ' ' O ' ' B' ' 86' ' ' GLY . 9.8 p-10 -49.45 -42.12 42.14 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.475 -1.391 . . . . 0.0 110.813 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.59 HD23 ' HA3' ' B' ' 73' ' ' GLY . 0.8 OUTLIER -93.75 -27.65 16.37 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.245 -0.91 . . . . 0.0 109.976 -179.653 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' B' ' 90' ' ' LEU . 4.6 mp -58.76 -33.87 70.78 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.097 -1.002 . . . . 0.0 108.831 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 4.3 p -74.12 -21.28 59.95 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.294 -0.879 . . . . 0.0 109.866 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 1.4 mm100 -80.14 -40.47 27.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.163 -0.961 . . . . 0.0 109.053 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.589 HD11 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -81.7 -5.39 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.264 -0.897 . . . . 0.0 108.916 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.31 60.74 7.79 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.52 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -87.89 160.06 18.12 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.265 -1.138 . . . . 0.0 110.706 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.522 ' HB ' ' CG2' ' A' ' 4' ' ' THR . 4.7 p -141.7 126.96 18.6 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.535 HD13 ' CD1' ' A' ' 97' ' ' LEU . 5.5 mp -92.18 97.1 10.7 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 10.4 m120 -97.41 118.92 34.96 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.378 -0.826 . . . . 0.0 110.453 -178.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.582 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.723 0 CA-C-O 117.923 -1.037 . . . . 0.0 109.334 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.588 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 4.0 Cg_exo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.763 -0.514 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.509 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 17.6 tt0 -83.77 131.75 34.89 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 20.0 t -124.12 102.06 10.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.575 -1.328 . . . . 0.0 110.484 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.53 HG22 ' CG2' ' B' ' 96' ' ' THR . 0.0 OUTLIER -139.78 48.73 1.8 Allowed 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.55 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -85.59 43.02 1.0 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.225 -0.922 . . . . 0.0 110.152 -179.238 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.583 ' CZ3' ' HB ' ' B' ' 91' ' ' THR . 13.4 m95 18.91 48.09 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 CA-C-O 121.46 0.647 . . . . 0.0 111.335 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 37.1 mt-30 -165.23 -168.0 1.3 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.455 ' HB3' HD11 ' A' ' 23' ' ' LEU . 58.8 mtt180 -75.26 122.49 87.44 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.011 -1.055 . . . . 0.0 108.632 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.5 Cg_endo -76.53 85.06 1.76 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.153 1.902 . . . . 0.0 109.991 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.528 HD21 ' HB3' ' A' ' 21' ' ' GLU . 5.5 mt -86.47 142.36 28.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.287 -0.883 . . . . 0.0 109.723 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.421 HG21 ' HB1' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -146.98 154.4 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.927 . . . . 0.0 109.243 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 85.3 m -88.95 112.87 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' HG13 ' A' ' 66' ' ' ILE . 1.9 pt -101.87 153.51 5.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.114 -0.991 . . . . 0.0 110.121 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 2.9 tttt -110.76 109.21 19.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.36 -0.838 . . . . 0.0 109.738 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.507 ' CG2' ' HE3' ' A' ' 36' ' ' MET . 4.5 mt -124.59 135.54 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.03 -1.044 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.462 ' HA3' HD11 ' A' ' 38' ' ' LEU . . . 50.04 33.8 22.49 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.68 35.2 59.11 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.466 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 9.0 mm100 -128.19 175.72 8.22 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -1.107 . . . . 0.0 109.057 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.469 ' O ' ' HG2' ' A' ' 20' ' ' LYS . 14.2 mt -145.71 123.27 11.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -0.946 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.469 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 18.3 mttp -146.61 177.32 9.16 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.528 ' HB3' HD21 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -79.19 -179.96 7.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.831 -1.168 . . . . 0.0 108.612 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.538 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -165.17 109.2 0.87 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.249 -1.532 . . . . 0.0 110.992 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 25' ' ' ASP . 2.8 tp -78.57 95.79 5.3 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.521 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 35.0 mt -48.64 93.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 23' ' ' LEU . 22.5 t0 -99.57 92.92 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 110.828 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.448 HG21 HD11 ' A' ' 90' ' ' LEU . 2.6 m -67.56 -6.84 21.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.095 -1.003 . . . . 0.0 109.467 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.494 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -78.55 -40.83 17.49 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.56 154.15 40.94 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.31 . . . . 0.0 109.256 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 1.8 m-20 -88.2 -13.59 40.73 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.25 -0.906 . . . . 0.0 110.374 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.534 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -137.51 -170.77 2.82 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.984 -1.073 . . . . 0.0 110.482 -179.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.467 HG22 HD11 ' A' ' 85' ' ' ILE . 22.8 m -109.05 89.82 3.11 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.034 -1.041 . . . . 0.0 110.677 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.569 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -71.54 167.5 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.569 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.9 130.02 2.23 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -178.212 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.582 ' CG ' ' O ' ' A' ' 80' ' ' THR . 7.2 mt-10 -39.1 157.8 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.474 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -60.12 154.0 20.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 110.103 179.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.507 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 4.1 ptm -176.0 -168.71 0.29 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.186 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.8 t -97.82 105.17 17.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.274 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.462 HD11 ' HA3' ' A' ' 16' ' ' GLY . 27.8 tp -131.64 103.4 14.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.849 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.5 154.27 27.51 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.514 2.143 . . . . 0.0 110.336 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 132.74 -173.16 21.03 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.66 141.28 29.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.33 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.598 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.0 p-90 -160.88 175.34 12.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.834 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -148.28 154.5 42.26 Favored Pre-proline 0 C--N 1.301 -1.511 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.53 136.55 13.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.233 1.956 . . . . 0.0 110.223 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HG3' HG21 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -149.94 -169.26 3.33 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.354 -0.841 . . . . 0.0 109.387 179.669 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.441 ' SD ' ' HG3' ' A' ' 55' ' ' LYS . 9.7 mmm -145.13 118.9 9.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.117 -0.99 . . . . 0.0 109.576 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.544 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 9.9 pt -89.75 135.24 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 118.886 -1.126 . . . . 0.0 108.294 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.408 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -118.7 105.47 1.19 Allowed Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.64 -123.26 2.67 Favored Glycine 0 N--CA 1.482 1.737 0 C-N-CA 119.552 -1.309 . . . . 0.0 110.632 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.52 ' O ' ' O ' ' B' ' 50' ' ' ILE . 13.5 mt -87.22 121.2 37.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.88 -0.776 . . . . 0.0 112.353 -177.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 99.92 -46.16 1.42 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.45 -163.33 33.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -120.93 137.01 54.81 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.121 -1.223 . . . . 0.0 109.628 -179.838 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.46 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 2.7 pt -111.92 159.18 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.231 -0.918 . . . . 0.0 109.222 179.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -82.19 141.16 33.27 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.225 -0.922 . . . . 0.0 110.255 -179.376 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.488 HG22 ' HB3' ' A' ' 76' ' ' LEU . 2.9 m -148.22 166.32 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -113.71 107.2 15.44 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -65.83 107.63 1.87 Allowed 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.578 -0.701 . . . . 0.0 110.282 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.3 m-85 -97.27 138.68 34.38 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.545 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 21.9 m-20 -119.37 118.02 30.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.877 -1.139 . . . . 0.0 110.267 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.545 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 66.3 mt-30 87.64 55.82 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 CA-C-O 121.362 0.601 . . . . 0.0 110.283 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.518 HG13 ' HB3' ' A' ' 59' ' ' TYR . 21.8 mm -110.04 124.55 66.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.55 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -66.56 96.4 0.38 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.221 -0.924 . . . . 0.0 110.661 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.573 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 7.7 tt -105.97 115.91 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.513 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -88.47 140.88 29.02 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 109.231 -179.079 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.549 HG13 ' CG2' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -127.7 130.34 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.3 -0.875 . . . . 0.0 108.993 -179.797 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.428 ' C ' ' O ' ' A' ' 66' ' ' ILE . 58.5 m 40.64 29.66 0.07 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.607 -0.683 . . . . 0.0 109.731 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 83.33 42.62 7.85 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.415 ' O ' ' C ' ' A' ' 70' ' ' LYS . 3.0 m-70 -134.6 100.73 4.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.313 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' A' ' 69' ' ' HIS . 16.9 ttpt -46.47 122.13 3.9 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.573 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.49 101.21 3.21 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 110.44 -179.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.53 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -81.97 158.72 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 177.932 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.42 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . 177.95 -161.46 28.48 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 118.824 -1.655 . . . . 0.0 110.579 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 98.9 m -102.0 117.26 34.43 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.122 -1.222 . . . . 0.0 109.787 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.47 ' CG1' HD12 ' A' ' 15' ' ' ILE . 1.4 t -108.21 117.7 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.341 -0.85 . . . . 0.0 110.397 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.534 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 2.3 mp -86.75 107.99 18.5 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.405 -0.81 . . . . 0.0 109.213 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.489 HG22 ' CD2' ' A' ' 59' ' ' TYR . 1.4 t -91.85 114.17 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.082 -1.011 . . . . 0.0 109.875 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.85 -168.25 15.41 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.55 42.11 1.27 Allowed 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 110.201 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.582 ' O ' ' CG ' ' A' ' 34' ' ' GLU . 5.0 t -82.05 137.91 46.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.45 21.53 0.76 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.483 2.122 . . . . 0.0 111.273 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.593 ' CG1' HG13 ' A' ' 84' ' ' ILE . 1.4 t -161.03 160.65 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 120.871 -1.143 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.637 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -102.52 94.66 5.78 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 177.217 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.593 HG13 ' CG1' ' A' ' 82' ' ' VAL . 2.8 mt -94.58 128.93 45.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 CA-C-O 122.132 0.968 . . . . 0.0 113.268 -175.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.626 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -104.08 107.87 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.353 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -87.71 -168.59 44.67 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.727 -178.142 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.419 ' O ' ' C ' ' A' ' 88' ' ' ASN . 5.9 mmt180 -60.58 -32.52 71.61 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.696 -0.885 . . . . 0.0 109.953 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.601 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 15.5 p-10 -46.88 -29.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.776 -1.203 . . . . 0.0 109.14 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.601 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -106.26 -36.72 6.78 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 95' ' ' ALA . 38.0 mt -62.55 -12.78 24.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.889 -1.132 . . . . 0.0 108.694 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.473 HG23 ' HA ' ' B' ' 6' ' ' TRP . 67.4 p -100.55 -20.36 15.74 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.207 -0.933 . . . . 0.0 108.673 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.6 mm-40 -79.23 -40.86 29.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.321 -0.862 . . . . 0.0 109.089 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.54 ' CD1' ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -79.98 -15.06 13.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.162 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 100.31 15.66 29.54 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.735 178.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.571 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -56.84 146.4 26.48 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.502 -1.587 . . . . 0.0 109.673 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.547 ' CG2' HG22 ' B' ' 4' ' ' THR . 19.2 p -137.78 129.86 28.91 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.602 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 1.1 mp -87.45 98.81 11.59 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.97 -1.081 . . . . 0.0 109.444 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.535 ' C ' ' CD1' ' A' ' 99' ' ' PHE . 1.4 m120 -111.57 136.81 50.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.394 -0.816 . . . . 0.0 110.103 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.587 ' CD1' ' CB ' ' B' ' 95' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.273 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.452 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 N-CA-C 109.984 -0.814 . . . . 0.0 109.984 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -83.56 138.87 33.19 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -128.6 111.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.769 -178.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.547 HG22 ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.66 39.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.848 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.554 ' O ' ' N ' ' B' ' 7' ' ' GLN . 4.6 tp -83.93 46.0 1.14 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.107 -0.995 . . . . 0.0 110.266 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' B' ' 5' ' ' LEU . 38.0 m95 17.94 50.06 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 121.489 0.662 . . . . 0.0 112.121 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.554 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.0 mt-30 -165.62 173.76 10.53 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.14 128.1 56.65 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 121.089 -1.007 . . . . 0.0 109.043 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.536 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 35.0 Cg_endo -79.35 64.64 8.87 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.423 2.082 . . . . 0.0 110.438 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB2' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -79.43 148.35 31.97 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.161 -0.962 . . . . 0.0 109.222 -179.929 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.521 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -143.72 137.15 24.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.232 -0.917 . . . . 0.0 109.573 -179.302 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 7.1 m -69.13 98.78 1.04 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.54 ' CG2' HG13 ' B' ' 66' ' ' ILE . 10.3 pt -89.79 151.44 3.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.351 -0.843 . . . . 0.0 110.0 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.543 ' HE3' ' CG ' ' B' ' 19' ' ' LEU . 2.1 tttt -117.37 107.1 13.96 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.337 -0.852 . . . . 0.0 108.951 179.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.514 HD13 ' CD1' ' B' ' 13' ' ' ILE . 4.1 mt -113.5 139.6 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.253 -0.905 . . . . 0.0 109.205 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.62 -90.9 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -151.79 45.72 0.61 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.436 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.6 OUTLIER -140.82 169.31 17.87 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.455 -1.026 . . . . 0.0 110.035 -179.332 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.543 ' CG ' ' HE3' ' B' ' 14' ' ' LYS . 27.8 mt -139.07 113.83 9.2 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.486 ' HE2' ' HE3' ' B' ' 36' ' ' MET . 0.5 OUTLIER -136.26 163.88 29.39 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.207 -0.933 . . . . 0.0 109.115 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB2' ' CD2' ' B' ' 10' ' ' LEU . 0.0 OUTLIER -78.13 145.01 35.96 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.277 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.519 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -134.39 116.45 15.2 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.869 -1.145 . . . . 0.0 111.297 -178.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.517 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 14.6 tp -71.47 100.13 2.16 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.536 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 18.6 mt -47.18 137.44 7.96 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 179.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.578 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 42.4 t0 -142.66 94.24 2.62 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.835 -1.166 . . . . 0.0 111.422 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 6.8 m -74.89 -14.87 60.71 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.442 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -76.05 -16.18 80.87 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.39 160.71 14.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.32 . . . . 0.0 109.053 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -88.23 -21.14 24.67 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.014 . . . . 0.0 110.479 -179.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.616 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 1.6 m-20 -143.05 -173.83 4.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.635 -1.291 . . . . 0.0 110.858 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.559 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 52.2 m -97.54 86.02 3.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.822 -1.173 . . . . 0.0 111.578 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.578 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -67.22 153.61 8.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.423 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.532 ' CD1' HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -157.08 124.42 5.26 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.083 -1.011 . . . . 0.0 110.569 -177.722 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' B' ' 80' ' ' THR . 5.7 tm-20 -43.07 153.87 0.08 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 109.078 178.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.539 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.3 tt0 -45.23 139.49 3.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 110.902 -179.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.495 ' SD ' ' N ' ' B' ' 37' ' ' SER . 2.3 ppp? -152.04 -164.4 1.96 Allowed 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.495 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -112.73 118.16 34.21 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.88 -1.138 . . . . 0.0 110.539 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.603 ' HB3' ' CZ ' ' B' ' 59' ' ' TYR . 0.2 OUTLIER -134.91 -175.08 0.45 Allowed Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.411 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.573 ' CD ' ' CB ' ' B' ' 38' ' ' LEU . 34.7 Cg_endo -79.7 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.256 1.971 . . . . 0.0 110.942 -178.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 35.93 4.63 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.35 51.75 0.75 Allowed 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.683 -0.892 . . . . 0.0 108.945 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.635 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 39.9 p-90 -137.95 179.83 6.2 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.776 0.798 . . . . 0.0 110.668 -178.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.462 ' HD3' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -140.86 146.13 42.69 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.088 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . 0.458 ' HD2' ' HG3' ' B' ' 43' ' ' LYS . 34.9 Cg_endo -78.36 138.67 15.93 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.416 2.077 . . . . 0.0 110.679 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 ptpt -160.54 -165.17 1.36 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.463 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 44.4 mtp -151.1 138.48 19.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.172 -0.955 . . . . 0.0 109.997 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.506 HG13 ' CG1' ' B' ' 54' ' ' ILE . 10.3 pt -103.71 148.3 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.114 -0.991 . . . . 0.0 108.83 178.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.596 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -119.57 116.28 3.26 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.979 -1.649 . . . . 0.0 108.979 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.45 -123.23 2.19 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.226 -1.464 . . . . 0.0 111.145 -179.046 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.52 ' O ' ' O ' ' A' ' 50' ' ' ILE . 15.8 mt -84.03 133.48 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.729 -0.866 . . . . 0.0 112.694 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.46 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 85.23 -44.17 3.34 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 178.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.457 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 171.24 -171.33 43.9 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.227 -1.463 . . . . 0.0 109.95 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.596 ' CD1' ' HA2' ' B' ' 48' ' ' GLY . 7.7 m-30 -96.29 168.82 10.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.432 -1.04 . . . . 0.0 109.748 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.506 ' CG1' HG13 ' B' ' 47' ' ' ILE . 1.8 pt -142.23 177.23 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.543 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.0 mtpt -114.18 128.65 56.47 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.922 -1.111 . . . . 0.0 109.44 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.458 HG11 ' HA3' ' B' ' 78' ' ' GLY . 4.7 m -136.61 -175.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.045 -1.034 . . . . 0.0 109.987 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 66.5 mtt180 -130.23 110.97 11.97 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.405 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 2.0 tt0 -69.98 103.49 2.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.32 -0.863 . . . . 0.0 110.442 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.635 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 10.5 m-85 -89.01 141.12 28.75 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.495 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 4.0 m-20 -120.12 130.96 54.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.681 -1.262 . . . . 0.0 110.953 -178.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.563 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 69.3 62.92 0.29 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.15 0.5 . . . . 0.0 110.756 179.003 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.553 ' CD1' ' HG ' ' B' ' 38' ' ' LEU . 0.5 OUTLIER -118.48 125.64 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.164 -0.96 . . . . 0.0 108.923 178.877 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.522 ' N ' HD12 ' B' ' 72' ' ' ILE . 3.1 tm? -70.63 101.08 1.97 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.496 -0.752 . . . . 0.0 111.658 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.509 ' CD1' HD12 ' B' ' 66' ' ' ILE . 4.0 tt -101.48 122.27 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 25.5 tt0 -89.06 100.82 13.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.938 -1.101 . . . . 0.0 109.831 -178.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.54 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.1 mp -99.53 113.05 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.163 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 63.47 25.31 14.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.61 6.75 82.85 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.328 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -103.45 109.49 21.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -1.203 . . . . 0.0 109.252 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.47 133.15 35.56 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.509 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -152.98 98.16 2.28 Favored 'General case' 0 C--N 1.294 -1.831 0 O-C-N 121.257 -0.902 . . . . 0.0 109.88 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.563 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -77.97 145.5 9.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.151 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.5 -175.07 40.96 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.005 -1.569 . . . . 0.0 110.971 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.486 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 1.5 m -85.75 112.51 21.13 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.668 -0.901 . . . . 0.0 110.461 -179.195 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.502 ' O ' ' HB2' ' B' ' 59' ' ' TYR . 1.4 t -104.8 105.53 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -0.813 . . . . 0.0 110.156 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.585 ' CD1' ' CB ' ' B' ' 30' ' ' ASP . 1.1 mp -77.14 129.78 36.45 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.539 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 45.4 t -118.52 122.95 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 110.247 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.458 ' HA3' HG11 ' B' ' 56' ' ' VAL . . . -157.56 -165.41 15.19 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.543 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.9 Cg_endo -81.98 41.87 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.547 2.165 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.53 ' CG2' ' O ' ' B' ' 82' ' ' VAL . 8.9 t -79.4 141.71 57.4 Favored Pre-proline 0 N--CA 1.49 1.56 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.444 ' O ' ' CG2' ' B' ' 82' ' ' VAL . 36.1 Cg_endo -77.68 14.39 1.46 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.135 1.89 . . . . 0.0 110.874 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.53 ' O ' ' CG2' ' B' ' 80' ' ' THR . 3.6 t -161.02 162.52 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.856 -1.152 . . . . 0.0 110.201 -179.219 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.519 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -102.97 99.77 9.68 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 176.665 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.578 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 4.7 mt -104.51 129.22 57.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 120.835 -1.166 . . . . 0.0 112.869 -175.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.519 HD12 ' N ' ' B' ' 85' ' ' ILE . 2.6 mm -88.51 132.39 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 176.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.616 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -107.16 -159.55 21.33 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 118.683 -1.723 . . . . 0.0 110.243 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.508 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -71.08 -30.28 66.36 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.737 -0.86 . . . . 0.0 108.762 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.559 ' OD1' ' N ' ' B' ' 31' ' ' THR . 5.8 p-10 -50.19 -40.07 45.88 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.822 -1.151 . . . . 0.0 108.897 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.538 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 0.4 OUTLIER -90.25 -32.86 16.38 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.42 -0.8 . . . . 0.0 110.027 -179.361 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.508 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 37.0 mt -67.04 -8.03 27.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.99 -1.069 . . . . 0.0 108.655 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.583 ' HB ' ' CZ3' ' A' ' 6' ' ' TRP . 31.5 p -99.43 -18.2 17.59 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.008 -1.058 . . . . 0.0 108.581 179.263 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.416 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 0.5 OUTLIER -85.01 -40.95 16.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.53 -0.731 . . . . 0.0 109.659 179.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.524 HD13 ' CG ' ' A' ' 99' ' ' PHE . 26.6 pt -83.17 -4.25 8.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.306 -0.871 . . . . 0.0 109.032 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.95 60.33 6.17 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.587 ' CB ' ' CD1' ' A' ' 99' ' ' PHE . . . -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.282 -1.128 . . . . 0.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.53 ' CG2' HG22 ' A' ' 4' ' ' THR . 10.7 p -137.56 129.49 28.86 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.602 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 5.4 mp -87.14 98.39 11.27 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.509 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.0 m120 -103.6 128.5 50.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.868 -1.145 . . . . 0.0 110.123 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.588 ' CD2' ' HD2' ' A' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.532 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.592 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 N-CA-C 109.899 -0.846 . . . . 0.0 109.899 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.523 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 25.0 tt0 -84.17 120.05 25.73 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 4' ' ' THR . 3.4 t -129.21 94.61 2.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.982 -1.074 . . . . 0.0 109.901 -178.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.629 ' O ' ' HB3' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -40.3 -68.85 0.15 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 109.404 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.629 ' HB3' ' O ' ' A' ' 4' ' ' THR . 0.0 OUTLIER 128.88 16.25 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.027 0.531 . . . . 0.0 110.121 179.4 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -48.26 -21.83 0.57 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.916 -1.115 . . . . 0.0 109.245 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.433 ' O ' ' HD3' ' B' ' 87' ' ' ARG . 29.8 mm100 -127.16 -128.81 0.23 Allowed 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.221 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.3 OUTLIER -111.04 133.61 21.25 Favored Pre-proline 0 C--N 1.306 -1.304 0 O-C-N 120.661 -1.274 . . . . 0.0 109.064 179.398 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.5 Cg_endo -79.96 51.76 4.03 Favored 'Trans proline' 0 C--N 1.313 -1.299 0 C-N-CA 122.203 1.935 . . . . 0.0 109.322 178.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.536 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -84.63 157.08 21.27 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.241 -0.912 . . . . 0.0 109.776 -179.315 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.526 ' CG2' ' CG2' ' A' ' 13' ' ' ILE . 1.2 m -149.15 131.72 6.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.501 -0.75 . . . . 0.0 109.368 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.476 HG23 ' CD2' ' A' ' 19' ' ' LEU . 25.3 m -65.02 94.8 0.14 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 177.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.526 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 13.6 pt -83.41 151.43 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.352 -0.843 . . . . 0.0 110.367 -178.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.497 ' HG3' ' CD1' ' A' ' 19' ' ' LEU . 14.0 ttmt -115.41 96.27 5.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 0.0 109.239 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.534 HG23 ' CE ' ' A' ' 36' ' ' MET . 11.8 mt -116.76 143.84 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.687 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.507 ' N ' HG21 ' A' ' 15' ' ' ILE . . . 46.96 50.91 14.4 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 48.44 46.78 29.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -144.48 163.22 34.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -1.207 . . . . 0.0 109.407 179.898 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.497 ' CD1' ' HG3' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -129.95 132.92 46.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.181 -0.95 . . . . 0.0 109.971 -179.403 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 4.0 mtmp? -151.13 177.7 9.94 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.536 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -93.86 118.99 32.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.579 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -97.81 143.37 28.5 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.135 -0.978 . . . . 0.0 109.42 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.465 ' CD1' ' NH2' ' B' ' 87' ' ' ARG . 10.5 tp -107.78 94.15 4.92 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.589 -0.694 . . . . 0.0 109.524 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.494 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 15.5 mt -45.14 111.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.293 -0.879 . . . . 0.0 108.648 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.567 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 19.4 t0 -126.25 80.02 1.89 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.343 -0.848 . . . . 0.0 110.12 -178.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.8 m -54.1 -18.95 4.19 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.025 -1.047 . . . . 0.0 108.867 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -56.64 -48.73 75.03 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.62 154.88 36.39 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.25 -1.147 . . . . 0.0 109.071 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.99 -7.44 33.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.162 -0.962 . . . . 0.0 110.385 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.544 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -132.59 178.87 6.51 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.981 -1.074 . . . . 0.0 109.539 179.805 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.543 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 19.0 m -104.3 89.55 3.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.772 -1.205 . . . . 0.0 110.83 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.543 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -70.07 171.48 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.946 -1.096 . . . . 0.0 108.307 178.908 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.528 ' HG ' ' HB3' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -170.19 121.38 0.64 Allowed 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.884 -1.135 . . . . 0.0 110.488 -179.011 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.491 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 6.4 tt0 -41.4 160.52 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.448 -0.782 . . . . 0.0 109.087 178.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.56 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -48.35 146.86 2.6 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.21 -0.931 . . . . 0.0 110.681 -179.756 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.534 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -159.31 -161.93 0.99 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.302 -0.874 . . . . 0.0 109.427 179.441 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 t -108.75 101.52 10.64 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.146 -0.971 . . . . 0.0 110.168 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.63 HD22 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -121.15 178.75 1.09 Allowed Pre-proline 0 N--CA 1.493 1.683 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.518 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 35.5 Cg_endo -79.54 -158.63 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.698 2.265 . . . . 0.0 110.64 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 29.63 7.75 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.9 mtt-85 -106.29 60.87 0.65 Allowed 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 59.2 p-90 -139.62 177.89 7.62 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-O 121.772 0.796 . . . . 0.0 110.696 -178.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -135.76 140.82 34.77 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.904 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -78.37 129.81 9.67 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 C-N-CA 121.813 1.675 . . . . 0.0 111.215 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.484 ' O ' ' HG3' ' A' ' 45' ' ' LYS . 2.3 ptpt -161.99 142.57 10.44 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.534 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -107.52 147.84 30.01 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.744 -1.222 . . . . 0.0 109.675 179.688 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.55 HD12 ' CD1' ' A' ' 54' ' ' ILE . 6.1 pt -103.65 150.11 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.394 -0.816 . . . . 0.0 108.982 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.24 98.0 0.71 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.084 -1.607 . . . . 0.0 109.084 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.15 -121.98 2.86 Favored Glycine 0 N--CA 1.487 2.057 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.478 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.527 HG22 ' CD1' ' B' ' 47' ' ' ILE . 18.2 mt -83.83 128.98 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.584 -0.95 . . . . 0.0 112.463 -177.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.29 -46.56 2.4 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 178.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.17 -155.51 25.29 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.099 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.513 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.5 m-85 -105.94 159.3 16.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.621 -0.929 . . . . 0.0 110.24 -179.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.55 ' CD1' HD12 ' A' ' 47' ' ' ILE . 5.8 pt -137.58 159.8 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.16 124.66 48.14 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.863 -1.148 . . . . 0.0 109.643 -179.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.429 HG21 ' O ' ' A' ' 45' ' ' LYS . 27.7 m -129.15 -178.33 2.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 109.034 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.577 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -131.95 105.4 7.4 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.278 179.834 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.547 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.8 OUTLIER -58.51 95.62 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.484 -0.76 . . . . 0.0 110.105 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.634 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 8.9 m-85 -89.98 117.87 29.11 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.56 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -99.58 141.83 31.86 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.561 -1.337 . . . . 0.0 111.035 -178.012 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.581 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 29.9 mt-30 71.16 62.33 0.17 Allowed 'General case' 0 N--CA 1.492 1.671 0 CA-C-O 121.199 0.523 . . . . 0.0 111.578 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.542 ' CD1' ' HB3' ' A' ' 59' ' ' TYR . 5.1 mp -120.76 121.31 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.23 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.559 ' HA ' HG12 ' A' ' 72' ' ' ILE . 5.6 tt -68.84 91.99 0.48 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.947 -1.096 . . . . 0.0 111.074 -178.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.532 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 2.5 tt -89.09 114.74 27.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 176.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 13.8 tt0 -86.53 101.93 13.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.873 -1.142 . . . . 0.0 108.939 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.524 HG13 HG21 ' A' ' 13' ' ' ILE . 2.1 mt -103.7 126.49 58.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.634 0.731 . . . . 0.0 110.15 -178.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.569 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.1 m 44.2 67.11 0.72 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.654 -0.654 . . . . 0.0 110.261 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 67' ' ' CYS . . . 41.57 35.86 1.46 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.569 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 74.5 m-70 -130.92 101.57 5.68 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.085 -1.244 . . . . 0.0 109.163 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.483 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -50.38 128.29 19.4 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.877 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.532 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.51 102.86 3.36 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.344 -0.848 . . . . 0.0 110.386 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.581 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -79.48 151.45 4.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.027 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -174.44 -178.13 44.1 Favored Glycine 0 N--CA 1.486 2.014 0 C-N-CA 118.444 -1.836 . . . . 0.0 111.482 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.547 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 2.5 m -88.81 103.87 16.39 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.203 -0.587 . . . . 0.0 110.418 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.525 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -97.72 108.59 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.45 -0.781 . . . . 0.0 110.582 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.544 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 3.4 mp -78.78 117.47 19.93 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.176 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.56 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.2 t -103.11 119.71 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 110.382 -178.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.418 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -153.31 -168.3 16.95 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 35.9 Cg_endo -79.52 41.94 1.2 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.64 2.227 . . . . 0.0 111.088 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.491 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 3.6 t -83.43 139.86 41.6 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.059 -1.026 . . . . 0.0 108.498 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 80' ' ' THR . 34.6 Cg_endo -78.23 13.82 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.322 2.015 . . . . 0.0 111.689 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.501 HG11 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.95 170.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.876 -1.14 . . . . 0.0 109.618 179.512 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.579 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -104.67 127.17 52.35 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 176.63 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.567 ' CG2' ' HB3' ' A' ' 25' ' ' ASP . 4.8 mm -112.86 128.33 69.63 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 O-C-N 120.406 -1.434 . . . . 0.0 111.04 -177.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.564 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -104.56 91.51 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.757 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -78.64 -167.8 32.8 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 110.637 -177.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.466 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.76 -34.25 72.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.639 -0.918 . . . . 0.0 110.338 -179.177 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.542 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 9.6 p-10 -48.94 -27.57 3.21 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.892 -1.13 . . . . 0.0 109.405 -179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.542 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.5 mm? -108.68 -29.38 8.74 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 121.121 -0.987 . . . . 0.0 110.034 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.54 HD21 ' CB ' ' A' ' 95' ' ' ALA . 96.7 mt -70.2 -6.27 33.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.08 -1.013 . . . . 0.0 108.463 179.024 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.435 HG22 ' HD3' ' A' ' 87' ' ' ARG . 4.8 p -98.11 -20.26 17.44 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.226 -0.921 . . . . 0.0 108.725 179.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 16.6 mm100 -83.66 -41.7 17.46 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 108.877 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.542 HD13 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -80.93 -3.74 6.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.71 64.11 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.522 -0.847 . . . . 0.0 110.999 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.557 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -62.42 136.25 57.82 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.805 -1.409 . . . . 0.0 109.709 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' B' ' 96' ' ' THR . 77.4 p -136.71 129.48 30.63 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.124 -0.985 . . . . 0.0 108.519 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HG ' HD13 ' B' ' 97' ' ' LEU . 5.3 mp -88.13 102.15 14.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.416 -0.802 . . . . 0.0 109.891 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.485 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.4 m120 -110.02 126.74 54.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.971 -1.081 . . . . 0.0 109.175 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.634 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.112 -0.993 . . . . 0.0 109.404 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.479 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.654 0 N-CA-C 109.958 -0.824 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.485 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 12.8 tt0 -82.52 139.34 33.93 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 177.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.57 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 7.0 t -132.69 100.01 3.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 117.937 -1.505 . . . . 0.0 110.811 -177.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.535 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -117.01 -70.48 0.79 Allowed 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 178.225 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.57 ' N ' ' CD2' ' B' ' 5' ' ' LEU . 3.7 mm? 34.86 31.7 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.889 -0.507 . . . . 0.0 110.225 178.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' THR . 13.0 m0 17.62 49.18 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.553 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.4 mt-30 -163.09 -162.5 0.77 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.038 -1.039 . . . . 0.0 110.162 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.413 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 8.1 mtm105 -86.94 117.97 69.4 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.232 -0.917 . . . . 0.0 110.394 -179.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.57 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.3 Cg_endo -81.99 90.24 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.144 1.896 . . . . 0.0 110.742 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.516 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 3.2 mp -79.49 171.06 15.67 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.821 -1.175 . . . . 0.0 108.565 179.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.474 HG11 ' O ' ' B' ' 10' ' ' LEU . 3.1 m -150.68 130.99 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.001 -1.062 . . . . 0.0 110.812 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.09 88.11 0.59 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 177.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.512 ' CG2' HG13 ' B' ' 66' ' ' ILE . 1.1 pt -90.09 157.36 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 111.118 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.48 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 3.1 tttt -122.78 109.15 13.85 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.532 ' CD1' HG12 ' B' ' 75' ' ' VAL . 3.0 mt -122.97 119.52 58.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.092 -1.005 . . . . 0.0 109.24 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.36 26.95 74.0 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -5.46 67.99 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.437 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -85.8 169.95 12.88 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.248 -1.148 . . . . 0.0 109.29 179.911 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.48 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 2.4 mt -139.8 128.22 22.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.311 -0.868 . . . . 0.0 109.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.401 ' CG ' ' C ' ' B' ' 19' ' ' LEU . 3.0 mtpp -151.23 149.94 30.01 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.434 -0.791 . . . . 0.0 109.118 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.516 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.7 OUTLIER -79.64 102.16 8.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.093 -1.005 . . . . 0.0 108.469 179.277 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.549 ' CB ' HD12 ' B' ' 85' ' ' ILE . . . -80.04 142.84 34.56 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 122.0 0.905 . . . . 0.0 110.825 -178.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -92.62 104.26 16.57 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.486 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 4.6 mt -46.29 110.48 0.28 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.878 -1.138 . . . . 0.0 108.593 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.603 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 1.0 OUTLIER -118.81 86.71 2.59 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.871 -178.553 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.429 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 0.2 OUTLIER -68.63 -7.88 37.06 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.023 -1.048 . . . . 0.0 108.704 178.488 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.552 ' HA3' ' CB ' ' A' ' 25' ' ' ASP . . . -81.24 -38.84 13.85 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.27 147.13 46.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.2 -1.176 . . . . 0.0 109.173 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.492 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 4.9 m-20 -82.83 -16.55 47.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 110.737 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.544 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 7.0 m-20 -138.04 -167.88 2.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.935 -1.103 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.589 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 43.0 m -110.57 94.24 4.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.787 -1.196 . . . . 0.0 110.782 -178.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.76 172.3 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.872 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.4 122.35 1.75 Allowed 'General case' 0 C--N 1.308 -1.225 0 O-C-N 120.775 -1.203 . . . . 0.0 110.822 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.532 ' CG ' ' O ' ' B' ' 80' ' ' THR . 0.3 OUTLIER -35.6 154.13 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.777 -0.577 . . . . 0.0 109.689 179.127 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.519 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.3 mt-10 -47.79 149.06 1.37 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.241 -0.912 . . . . 0.0 110.231 -179.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.472 ' HG3' ' CD2' ' B' ' 38' ' ' LEU . 6.1 ptm -173.45 -163.99 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.391 -0.818 . . . . 0.0 109.592 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.1 t -110.95 103.72 12.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.204 -0.935 . . . . 0.0 110.279 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.557 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -103.38 173.38 3.48 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.557 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.1 Cg_endo -73.9 -162.26 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.996 1.798 . . . . 0.0 110.516 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -100.21 -166.07 28.86 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.304 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.41 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 21.5 mmm180 58.83 70.12 0.68 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.672 -0.899 . . . . 0.0 109.152 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 21.4 p-90 -141.44 -169.89 2.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -151.02 134.1 8.77 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.175 -0.953 . . . . 0.0 108.807 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.31 137.35 16.77 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.838 1.692 . . . . 0.0 110.567 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.517 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -160.97 133.79 6.29 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.724 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 63.1 mtp -91.73 131.93 36.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.131 -0.981 . . . . 0.0 109.797 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' B' ' 53' ' ' PHE . 8.8 pt -89.36 143.96 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 101.22 0.89 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.25 -121.81 2.92 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.744 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.522 HG22 ' CD1' ' A' ' 47' ' ' ILE . 20.5 mt -84.87 117.38 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.852 -0.793 . . . . 0.0 112.695 -177.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.473 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 104.16 -53.32 0.71 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 178.314 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -178.4 -157.12 18.43 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.543 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -118.0 135.79 53.94 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.311 -1.111 . . . . 0.0 109.873 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.501 HD13 HG11 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -106.48 -177.48 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.909 . . . . 0.0 108.926 179.189 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.534 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 36.8 mtmt -111.52 135.82 51.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.019 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.517 ' CG2' ' O ' ' B' ' 45' ' ' LYS . 17.5 m -142.77 177.07 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.843 -1.161 . . . . 0.0 110.636 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.35 100.72 6.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.492 -0.755 . . . . 0.0 109.241 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -62.87 110.11 1.66 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.265 -0.897 . . . . 0.0 110.909 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.616 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 16.0 m-85 -106.92 132.35 52.96 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 177.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.508 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.7 m-20 -108.6 134.1 51.82 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.937 -1.102 . . . . 0.0 110.49 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 45.0 mt-30 78.14 61.37 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.904 -0.497 . . . . 0.0 111.178 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.553 ' CD1' ' HB3' ' B' ' 59' ' ' TYR . 3.0 mp -112.83 120.99 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 178.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.52 ' N ' HD12 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -65.07 86.44 0.06 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 110.958 -178.656 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.565 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 8.6 tt -94.49 110.7 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.3 tt0 -89.04 117.21 27.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.051 -1.031 . . . . 0.0 109.464 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.512 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.8 mp -116.33 140.95 36.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 121.746 0.784 . . . . 0.0 109.845 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.504 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 0.9 OUTLIER 47.42 39.17 8.7 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.681 -0.637 . . . . 0.0 109.778 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.2 48.28 83.9 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.504 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 80.7 m-70 -145.38 108.88 4.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.247 -1.149 . . . . 0.0 109.384 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HG2' HD23 ' B' ' 63' ' ' LEU . 0.3 OUTLIER -48.26 127.38 12.67 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.305 -0.872 . . . . 0.0 108.883 179.709 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -149.12 104.8 3.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.334 -0.854 . . . . 0.0 109.355 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -83.86 160.31 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.107 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.563 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.34 -157.24 17.87 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.419 -1.848 . . . . 0.0 111.952 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.48 HG21 ' O ' ' B' ' 59' ' ' TYR . 4.8 m -111.95 109.81 19.79 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.632 -0.922 . . . . 0.0 109.557 -179.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.532 HG12 ' CD1' ' B' ' 15' ' ' ILE . 1.6 t -105.03 127.75 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.521 -0.737 . . . . 0.0 111.22 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.483 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.8 mp -96.83 116.22 28.78 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 13.1 t -96.9 114.96 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.709 -1.244 . . . . 0.0 109.984 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -149.72 -174.12 20.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.534 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -79.78 41.83 1.19 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.493 2.129 . . . . 0.0 111.234 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.532 ' O ' ' CG ' ' B' ' 34' ' ' GLU . 9.1 t -80.68 141.01 51.45 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.76 13.44 1.68 Allowed 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.274 1.983 . . . . 0.0 111.232 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.522 ' CG1' HD13 ' B' ' 84' ' ' ILE . 0.8 OUTLIER -160.31 173.83 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.921 -1.112 . . . . 0.0 109.677 -179.754 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.542 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -109.68 138.57 45.85 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 176.625 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.603 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 4.7 mm -124.6 123.33 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.438 -1.414 . . . . 0.0 111.762 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.549 HD12 ' CB ' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -97.26 89.82 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.344 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.544 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.04 -157.59 11.58 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.891 -1.147 . . . . 0.0 111.612 -177.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.492 ' NH2' ' OD1' ' B' ' 29' ' ' ASP . 31.1 mtt180 -68.19 -35.62 78.28 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.915 -0.756 . . . . 0.0 111.407 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.589 ' OD1' ' N ' ' B' ' 31' ' ' THR . 2.6 p-10 -55.57 -24.23 31.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.461 -1.399 . . . . 0.0 110.044 -179.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.581 HD21 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -106.77 -18.41 13.95 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.999 -1.063 . . . . 0.0 110.26 -178.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' B' ' 86' ' ' GLY . 64.5 mt -71.95 -24.45 61.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 108.899 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.448 HG21 HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -81.94 -14.09 56.58 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.092 -1.005 . . . . 0.0 109.839 179.863 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.1 -40.85 23.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.99 -1.069 . . . . 0.0 109.164 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.616 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -87.26 -13.07 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.305 -0.872 . . . . 0.0 108.755 179.43 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.69 51.12 9.79 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.502 ' HA ' ' HB3' ' A' ' 99' ' ' PHE . . . -75.86 147.27 39.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 108.851 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 96' ' ' THR . 72.6 p -130.76 127.29 38.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 108.908 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.554 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.0 mp -91.58 91.06 7.87 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.516 -0.74 . . . . 0.0 109.182 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.523 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.7 m120 -96.22 125.53 40.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.148 -0.97 . . . . 0.0 109.92 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.592 ' CE2' ' HG2' ' A' ' 1' ' ' PRO . 0.4 OUTLIER . . . . . 0 C--N 1.301 -1.526 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.335 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.59 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.498 1.768 0 N-CA-C 110.064 -0.783 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.505 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.91 129.11 34.86 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.85 -1.156 . . . . 0.0 108.05 178.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 77.8 t -131.37 124.81 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.915 -1.115 . . . . 0.0 110.184 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 7.6 p -64.57 -104.01 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.516 ' CB ' ' O ' ' A' ' 4' ' ' THR . 0.6 OUTLIER 167.04 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.866 -1.146 . . . . 0.0 110.721 179.407 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 38.1 m95 -65.56 -18.66 65.49 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.809 -1.182 . . . . 0.0 108.507 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.424 ' O ' ' C ' ' A' ' 8' ' ' ARG . 23.2 mt-30 -147.3 159.64 43.43 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.459 ' HD3' ' OD2' ' B' ' 29' ' ' ASP . 16.0 mtm180 -44.04 141.15 2.52 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.003 . . . . 0.0 109.22 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.46 ' HB2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.61 60.57 7.91 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.478 2.119 . . . . 0.0 109.921 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.485 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -81.66 142.72 32.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.243 -0.91 . . . . 0.0 109.97 -179.484 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.434 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -140.99 155.62 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.46 -0.775 . . . . 0.0 109.283 -179.795 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.0 m -83.96 101.94 12.08 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 178.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.551 HG22 ' CB ' ' A' ' 22' ' ' ALA . 14.7 pt -96.31 158.66 3.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.286 -0.884 . . . . 0.0 110.341 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 3.7 tttt -120.71 103.95 9.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.433 -0.792 . . . . 0.0 109.88 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.516 HD11 ' CG1' ' A' ' 75' ' ' VAL . 10.6 mt -119.25 134.35 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.079 -1.013 . . . . 0.0 109.588 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.96 44.24 98.08 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.08 17.72 24.33 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.63 178.09 4.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.444 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.497 HD22 ' HA ' ' A' ' 14' ' ' LYS . 16.6 mt -138.61 126.34 22.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.447 -0.783 . . . . 0.0 109.826 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.473 ' HD3' ' O ' ' A' ' 19' ' ' LEU . 35.8 mmtt -144.45 -179.31 6.47 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.53 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 2.9 mt-10 -88.04 164.58 15.69 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.098 -1.001 . . . . 0.0 108.713 179.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.551 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -147.97 116.68 6.69 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.688 -1.258 . . . . 0.0 110.966 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.547 ' O ' ' N ' ' A' ' 25' ' ' ASP . 16.8 tp -82.05 94.12 7.13 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.495 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 63.7 mt -49.69 93.2 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.547 ' N ' ' O ' ' A' ' 23' ' ' LEU . 26.8 t0 -107.67 87.21 2.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 110.744 -178.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.49 ' CG2' HD11 ' A' ' 90' ' ' LEU . 1.2 m -60.74 -13.81 17.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.051 -1.031 . . . . 0.0 108.638 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.508 ' CA ' HD22 ' B' ' 23' ' ' LEU . . . -63.41 -43.69 97.9 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.4 171.52 9.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.008 -1.289 . . . . 0.0 110.069 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.486 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -98.54 -20.51 17.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.34 -0.85 . . . . 0.0 110.603 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.516 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 36.6 m-20 -140.23 -162.9 1.42 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.922 -1.111 . . . . 0.0 109.604 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.498 ' CG2' ' CD1' ' A' ' 33' ' ' LEU . 23.5 m -107.28 89.99 3.17 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.69 -1.256 . . . . 0.0 110.931 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.56 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.67 164.95 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.745 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.56 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.58 127.58 2.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.727 -1.233 . . . . 0.0 111.426 -178.742 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.594 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.2 OUTLIER -42.48 153.29 0.08 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 179.03 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.532 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.4 OUTLIER -50.54 146.34 5.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.053 -1.029 . . . . 0.0 109.868 -179.821 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.468 ' CE ' HG21 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -156.42 -162.77 1.32 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.485 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.5 t -112.73 101.0 9.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.05 -1.031 . . . . 0.0 110.362 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.621 HD22 ' CG ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -108.49 160.03 28.65 Favored Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.503 ' HD3' HD13 ' A' ' 38' ' ' LEU . 34.5 Cg_endo -75.96 69.32 6.29 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.784 2.323 . . . . 0.0 111.867 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.506 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . 37.43 -159.62 0.01 OUTLIER Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 1.3 mpt_? 64.07 68.47 0.56 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.541 -0.976 . . . . 0.0 109.912 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.575 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 64.3 p-90 -152.7 -178.24 6.75 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.653 -0.654 . . . . 0.0 110.001 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.5 mtpt -146.2 137.21 12.62 Favored Pre-proline 0 N--CA 1.49 1.537 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.14 138.35 16.09 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.224 1.95 . . . . 0.0 111.182 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.466 ' HD2' HD21 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -152.58 -163.19 1.66 Allowed 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.242 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.51 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 1.7 mtt -149.42 126.11 11.06 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.957 -1.089 . . . . 0.0 110.371 -179.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.532 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 6.8 pt -90.07 146.44 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.45 118.62 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -146.3 -127.41 1.85 Allowed Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.291 -1.433 . . . . 0.0 111.228 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.497 ' O ' ' O ' ' B' ' 50' ' ' ILE . 25.2 mt -81.68 123.85 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.957 -0.731 . . . . 0.0 112.401 -177.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.473 ' HA2' HG21 ' B' ' 54' ' ' ILE . . . 95.78 -50.11 1.78 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 178.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.423 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 175.14 -168.12 40.51 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.4 OUTLIER -107.31 132.53 53.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.085 -1.244 . . . . 0.0 109.711 -179.632 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.532 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 10.3 pt -101.74 163.4 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.238 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.55 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 35.6 mtmt -96.59 138.38 34.26 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.112 -0.993 . . . . 0.0 108.867 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.442 HG22 HD21 ' A' ' 76' ' ' LEU . 30.6 m -138.36 177.93 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 120.75 -1.219 . . . . 0.0 110.146 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.488 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -118.17 92.3 3.79 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.431 -0.793 . . . . 0.0 108.919 -179.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.545 ' CG ' ' OD1' ' A' ' 60' ' ' ASP . 16.2 tt0 -53.56 107.69 0.27 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.507 -0.745 . . . . 0.0 110.236 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.621 ' CG ' HD22 ' A' ' 38' ' ' LEU . 15.1 m-85 -105.02 95.51 5.89 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' ' CG ' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -79.01 139.62 38.14 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.867 -1.146 . . . . 0.0 111.061 -178.39 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.518 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 47.0 mt-30 68.36 63.57 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.133 0.492 . . . . 0.0 111.66 178.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.48 ' HB ' HG21 ' A' ' 75' ' ' VAL . 0.8 OUTLIER -122.67 124.78 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.543 ' C ' ' CD1' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -66.65 86.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.914 -178.342 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.519 HG12 ' CD1' ' A' ' 66' ' ' ILE . 3.6 tt -87.74 123.83 40.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 176.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.496 ' HG2' ' N ' ' A' ' 66' ' ' ILE . 8.6 tt0 -88.59 148.37 24.11 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.069 -1.019 . . . . 0.0 109.349 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.519 ' CD1' HG12 ' A' ' 64' ' ' ILE . 0.8 OUTLIER -150.19 115.35 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.501 ' SG ' ' CG ' ' A' ' 1' ' ' PRO . 0.8 OUTLIER 68.23 5.06 4.46 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.581 -0.7 . . . . 0.0 110.127 179.695 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.405 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 108.27 -3.39 33.11 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -90.2 131.31 36.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.06 -1.259 . . . . 0.0 109.318 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.538 ' CG ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.75 103.9 11.76 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 121.047 -1.033 . . . . 0.0 108.471 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.489 ' O ' HD12 ' A' ' 63' ' ' LEU . . . -112.79 151.19 30.63 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 120.361 -0.535 . . . . 0.0 109.838 -179.192 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.537 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.6 OUTLIER -122.42 146.32 27.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 177.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -173.75 -162.42 25.56 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 118.429 -1.843 . . . . 0.0 111.063 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 10.3 m -100.28 104.92 16.42 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.676 -0.896 . . . . 0.0 110.056 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.516 ' CG1' HD11 ' A' ' 15' ' ' ILE . 1.2 t -95.12 105.36 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.518 -0.739 . . . . 0.0 109.349 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.9 mp -78.57 118.07 20.34 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.532 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 2.0 t -106.9 111.09 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.145 -0.972 . . . . 0.0 110.443 -179.002 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -145.65 -157.48 7.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.55 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.14 38.8 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.509 2.139 . . . . 0.0 110.34 179.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.594 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.9 t -83.58 132.78 48.3 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -79.9 19.11 1.05 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.467 2.111 . . . . 0.0 111.558 -178.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.1 t -161.46 156.77 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.763 -1.21 . . . . 0.0 109.929 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -95.64 91.0 5.91 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.665 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.53 ' CG1' HG11 ' A' ' 32' ' ' VAL . 3.6 mm -78.54 122.74 34.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 121.418 -0.801 . . . . 0.0 112.085 -176.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.545 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -101.02 91.78 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 176.894 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.44 -157.98 13.51 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.912 -177.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.486 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -68.87 -37.66 79.19 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 122.023 -0.692 . . . . 0.0 109.828 -178.958 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.598 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 13.0 p-10 -45.71 -28.51 1.04 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.933 -1.104 . . . . 0.0 109.52 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.598 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.5 mm? -109.08 -27.03 9.85 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.259 -0.9 . . . . 0.0 110.499 -178.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.49 HD11 ' CG2' ' A' ' 26' ' ' THR . 70.0 mt -72.09 -7.88 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.82 -1.175 . . . . 0.0 109.194 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.469 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -98.15 -11.75 22.47 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.004 -1.06 . . . . 0.0 108.242 178.699 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.462 ' NE2' ' O ' ' A' ' 88' ' ' ASN . 75.4 mt-30 -90.49 -40.71 11.84 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.579 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -82.91 0.59 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.471 -0.768 . . . . 0.0 108.965 179.164 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.15 32.83 57.91 Favored Glycine 0 N--CA 1.495 2.617 0 C-N-CA 120.575 -0.822 . . . . 0.0 111.147 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.522 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -65.45 140.08 58.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.941 -1.329 . . . . 0.0 110.715 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' B' ' 96' ' ' THR . 58.9 p -137.33 126.19 24.11 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.533 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 5.1 mp -88.43 91.94 8.99 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.239 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.462 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 4.6 m120 -103.51 121.41 42.81 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.127 -0.983 . . . . 0.0 109.448 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.57 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.361 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.55 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 2.3 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 109.875 -0.856 . . . . 0.0 109.875 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.483 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 4.3 tt0 -122.26 142.41 50.49 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 177.11 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.483 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 38.4 t -142.48 102.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.192 -178.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.599 ' O ' ' C ' ' B' ' 5' ' ' LEU . 63.7 p -89.62 -30.13 18.36 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 178.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.599 ' C ' ' O ' ' B' ' 4' ' ' THR . 0.5 OUTLIER 13.14 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.832 -179.892 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.423 ' C ' ' O ' ' B' ' 5' ' ' LEU . 2.2 m95 -37.91 -22.23 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.038 -178.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.576 ' N ' ' O ' ' B' ' 5' ' ' LEU . 20.3 mp0 -107.94 -161.85 0.8 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.715 -1.241 . . . . 0.0 107.983 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.484 ' HB3' HD13 ' B' ' 23' ' ' LEU . 19.1 mtt180 -53.84 124.57 44.06 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 120.478 -1.389 . . . . 0.0 109.589 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.551 ' HA ' ' CD1' ' B' ' 5' ' ' LEU . 37.0 Cg_endo -77.7 71.01 6.7 Favored 'Trans proline' 0 C--N 1.316 -1.159 0 C-N-CA 122.331 2.021 . . . . 0.0 110.401 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 1.6 mt -78.95 143.1 36.12 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.888 -1.132 . . . . 0.0 110.356 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.481 HG22 HG21 ' B' ' 13' ' ' ILE . 1.3 m -130.76 139.92 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.509 -0.744 . . . . 0.0 109.639 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.0 m -67.49 108.01 2.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.918 -1.114 . . . . 0.0 108.279 178.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.506 HG21 HG13 ' B' ' 66' ' ' ILE . 1.2 pp -106.02 140.43 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.081 -1.012 . . . . 0.0 110.865 -178.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.533 ' CG ' ' HG ' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -109.05 106.53 16.5 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.306 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.548 HD12 ' CG1' ' B' ' 75' ' ' VAL . 15.0 mt -124.48 124.99 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 O-C-N 121.164 -0.96 . . . . 0.0 109.524 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.77 20.01 71.89 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -4.33 86.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -93.47 -178.17 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.115 -1.227 . . . . 0.0 108.908 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.533 ' HG ' ' CG ' ' B' ' 14' ' ' LYS . 4.3 mt -153.65 125.58 7.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.132 -0.98 . . . . 0.0 110.499 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.471 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -145.94 168.79 20.01 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.012 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 6.5 mt-10 -79.28 157.87 27.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.758 -1.214 . . . . 0.0 108.401 179.399 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.548 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -139.34 113.96 9.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.96 -1.087 . . . . 0.0 110.691 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.508 HD22 ' CA ' ' A' ' 27' ' ' GLY . 0.9 OUTLIER -67.75 95.36 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.031 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.472 ' HG ' HG12 ' B' ' 11' ' ' VAL . 86.2 mt -44.51 102.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.568 ' CB ' HG22 ' B' ' 84' ' ' ILE . 4.8 t70 -101.37 93.53 5.46 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.474 -0.766 . . . . 0.0 110.753 -178.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.451 HG23 HD23 ' B' ' 97' ' ' LEU . 5.6 m -76.4 3.89 10.16 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.114 -0.991 . . . . 0.0 109.004 178.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.546 ' HA3' ' CB ' ' A' ' 25' ' ' ASP . . . -99.67 -24.42 10.03 Favored Glycine 0 N--CA 1.485 1.933 0 C-N-CA 120.056 -1.069 . . . . 0.0 110.743 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.25 168.46 17.61 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.829 -1.395 . . . . 0.0 109.949 -179.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.459 ' OD2' ' HD3' ' A' ' 8' ' ' ARG . 0.9 OUTLIER -101.31 -20.3 15.28 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.366 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.561 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -131.86 -174.83 3.53 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 -179.598 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.472 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 53.2 m -105.33 83.44 1.96 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.676 -1.265 . . . . 0.0 110.315 -178.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.569 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.45 167.16 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.035 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.569 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.41 123.86 2.26 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.051 -1.031 . . . . 0.0 110.441 -178.694 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.495 ' HA ' HG23 ' B' ' 80' ' ' THR . 0.0 OUTLIER -39.49 160.0 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.551 -0.718 . . . . 0.0 109.381 179.17 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.462 ' O ' ' OE1' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -39.62 146.71 0.1 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.387 -0.821 . . . . 0.0 110.449 -179.572 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.529 ' CE ' HG23 ' B' ' 15' ' ' ILE . 3.0 ppp? -166.4 163.04 17.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.441 -0.787 . . . . 0.0 109.046 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.3 t -95.82 105.04 17.0 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.043 -1.036 . . . . 0.0 109.753 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.569 HD22 ' CG ' ' B' ' 59' ' ' TYR . 9.2 tp -122.43 106.17 35.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.372 -0.83 . . . . 0.0 108.932 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.33 140.39 19.43 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.375 2.05 . . . . 0.0 111.125 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 128.23 31.52 0.67 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.474 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 52.88 166.62 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.84 -0.8 . . . . 0.0 110.014 179.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.574 ' CD2' ' HD3' ' B' ' 57' ' ' ARG . 0.2 OUTLIER -160.98 178.49 9.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.138 -0.976 . . . . 0.0 109.769 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -125.88 104.52 26.7 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.76 138.61 41.61 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.025 1.817 . . . . 0.0 112.355 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -150.62 -155.61 0.64 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.526 ' CE ' ' HB3' ' B' ' 53' ' ' PHE . 32.2 mtp -148.13 126.55 12.35 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.026 -1.046 . . . . 0.0 110.312 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.534 HD12 ' CD1' ' B' ' 54' ' ' ILE . 7.3 pt -93.24 142.38 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.93 113.75 2.64 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.12 -123.94 2.21 Favored Glycine 0 N--CA 1.483 1.811 0 C-N-CA 119.525 -1.322 . . . . 0.0 110.493 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.507 ' CG2' HD13 ' A' ' 47' ' ' ILE . 25.6 mt -84.77 119.27 33.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.793 -0.827 . . . . 0.0 112.384 -177.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 103.83 -53.01 0.73 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 178.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.89 -161.79 27.83 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.171 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -111.84 128.86 56.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.459 -1.024 . . . . 0.0 109.241 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.534 ' CD1' HD12 ' B' ' 47' ' ' ILE . 16.3 pt -107.38 162.59 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.876 -1.14 . . . . 0.0 109.016 179.118 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.6 mptm? -94.53 147.58 23.12 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.153 -0.967 . . . . 0.0 108.88 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 27.5 m -144.94 -170.77 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 120.768 -1.207 . . . . 0.0 110.254 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.574 ' HD3' ' CD2' ' B' ' 42' ' ' TRP . 18.6 mtt85 -131.46 111.24 11.62 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -77.61 101.3 6.49 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.566 -0.709 . . . . 0.0 111.07 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.573 ' OH ' ' CD1' ' B' ' 42' ' ' TRP . 62.7 m-85 -96.18 129.74 43.41 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 14.5 m-20 -109.19 122.45 47.34 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.692 -1.255 . . . . 0.0 110.895 -178.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.546 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 3.0 mt-30 86.1 56.11 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 CA-C-O 121.31 0.576 . . . . 0.0 110.472 179.069 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.492 ' HB ' HG22 ' B' ' 75' ' ' VAL . 4.0 mm -111.27 128.07 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.533 HD23 ' CG ' ' B' ' 70' ' ' LYS . 2.3 tm? -73.84 102.26 4.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.181 -0.95 . . . . 0.0 111.293 -178.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.598 ' CG2' ' CD1' ' B' ' 89' ' ' LEU . 0.9 OUTLIER -105.59 106.11 19.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 177.579 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.4 OUTLIER -90.0 119.69 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.983 -1.073 . . . . 0.0 109.206 -178.821 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.532 HD13 ' CD1' ' B' ' 64' ' ' ILE . 1.5 mp -111.54 128.78 67.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.477 -0.765 . . . . 0.0 109.364 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.482 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 15.5 m 65.55 -89.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.752 -0.593 . . . . 0.0 109.629 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.88 39.15 0.74 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -139.36 131.91 28.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.566 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.533 ' CG ' HD23 ' B' ' 63' ' ' LEU . 15.6 ttmt -70.74 129.11 38.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.125 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.567 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -142.25 95.19 2.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.156 -0.965 . . . . 0.0 110.435 -179.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.522 HG12 ' HA ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.99 156.77 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.712 -1.243 . . . . 0.0 108.06 178.297 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.508 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 176.05 -170.59 43.52 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.674 -1.727 . . . . 0.0 111.213 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 85.9 m -88.68 112.54 23.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.848 -0.795 . . . . 0.0 110.575 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.548 ' CG1' HD12 ' B' ' 15' ' ' ILE . 0.7 OUTLIER -105.18 107.8 23.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.7 -0.625 . . . . 0.0 110.155 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.561 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 4.0 mp -82.63 121.82 27.32 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 108.853 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' B' ' 57' ' ' ARG . 69.1 t -109.3 132.04 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.058 -1.026 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -162.8 -159.89 10.76 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.43 36.1 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.651 2.234 . . . . 0.0 110.733 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.495 HG23 ' HA ' ' B' ' 34' ' ' GLU . 4.0 t -81.6 136.64 48.37 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.446 ' O ' HG21 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.5 16.36 1.43 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.322 2.015 . . . . 0.0 111.269 -178.581 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.527 HG11 HG13 ' B' ' 84' ' ' ILE . 2.2 t -161.84 148.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 120.88 -1.138 . . . . 0.0 110.108 -179.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.548 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -86.61 102.12 13.87 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 105.922 -1.881 . . . . 0.0 105.922 176.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.568 HG22 ' CB ' ' B' ' 25' ' ' ASP . 2.4 mt -101.74 126.66 55.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.856 -1.153 . . . . 0.0 112.137 -175.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.524 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 1.5 mm -97.08 121.85 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 177.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.535 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -102.58 -147.42 19.17 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.592 -1.289 . . . . 0.0 111.551 -178.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.509 ' O ' ' OG1' ' B' ' 91' ' ' THR . 11.6 mtp180 -69.08 -40.86 78.18 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 122.074 -0.662 . . . . 0.0 111.388 -178.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.596 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 15.2 p-10 -53.78 -30.47 44.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.798 -1.188 . . . . 0.0 111.254 -178.081 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.598 ' CD1' ' CG2' ' B' ' 64' ' ' ILE . 2.8 mm? -104.44 -28.58 11.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.492 -1.38 . . . . 0.0 110.914 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.52 ' N ' ' CD2' ' B' ' 90' ' ' LEU . 0.1 OUTLIER -68.2 -9.58 47.99 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.712 -1.242 . . . . 0.0 109.151 179.745 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.22 -20.44 15.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.775 -1.203 . . . . 0.0 108.831 179.154 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 46.6 mm-40 -77.89 -41.05 37.93 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.237 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 1.1 pt -81.4 -8.17 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.38 35.77 55.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.567 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -61.56 152.18 31.12 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.824 -1.398 . . . . 0.0 109.288 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 96' ' ' THR . 21.5 p -142.27 124.72 15.69 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.151 -0.968 . . . . 0.0 108.889 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.533 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 4.8 mp -86.25 91.08 8.36 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.444 -0.785 . . . . 0.0 109.505 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.522 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -93.92 121.98 35.94 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.049 -1.032 . . . . 0.0 109.227 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.606 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 118.045 -0.979 . . . . 0.0 109.477 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 3.8 Cg_exo . . . . . 0 N--CA 1.497 1.686 0 N-CA-C 110.663 -0.553 . . . . 0.0 110.663 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.502 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -84.37 136.73 33.76 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.102 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.468 ' O ' ' HG ' ' A' ' 5' ' ' LEU . 55.7 t -133.55 115.03 21.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 120.734 -1.229 . . . . 0.0 109.918 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 72.6 p -58.8 -12.59 4.53 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.698 -0.626 . . . . 0.0 110.218 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.559 ' CD2' ' CG2' ' B' ' 26' ' ' THR . 0.7 OUTLIER 80.59 -6.6 1.66 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.443 -0.785 . . . . 0.0 110.298 179.398 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.617 ' CZ3' HG23 ' B' ' 91' ' ' THR . 39.8 m95 -53.88 -20.43 5.94 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.949 -1.094 . . . . 0.0 108.848 179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.11 157.54 46.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 108.914 179.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.421 ' HA ' ' CZ ' ' B' ' 87' ' ' ARG . 4.0 mtm180 -66.92 122.99 84.94 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.155 -0.965 . . . . 0.0 109.595 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.576 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.0 Cg_endo -76.1 80.09 2.76 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 121.927 1.751 . . . . 0.0 109.429 178.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -90.0 149.34 22.59 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.589 -0.695 . . . . 0.0 109.606 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.495 HG21 ' CB ' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -150.9 159.33 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.192 -0.942 . . . . 0.0 110.377 -179.063 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.542 ' CG2' HD21 ' A' ' 19' ' ' LEU . 14.1 m -94.88 104.82 16.71 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.533 ' HB ' HG13 ' A' ' 64' ' ' ILE . 2.2 pt -89.22 141.1 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.177 -0.952 . . . . 0.0 110.389 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 29.5 ttmt -106.34 97.27 7.09 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.541 HG21 ' CG2' ' A' ' 62' ' ' ILE . 16.8 mt -113.53 120.55 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.147 -0.97 . . . . 0.0 110.06 -179.155 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.23 37.65 94.81 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.1 6.4 56.72 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.3 mm-40 -97.48 163.25 12.94 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.201 -1.176 . . . . 0.0 109.216 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.542 HD21 ' CG2' ' A' ' 12' ' ' THR . 0.1 OUTLIER -136.89 126.59 25.48 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.293 -0.879 . . . . 0.0 110.798 -179.507 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.496 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.8 mttp -150.45 179.95 7.73 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.061 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.03 -174.67 4.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.876 -1.14 . . . . 0.0 108.891 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.521 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -162.25 121.14 2.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.031 -1.043 . . . . 0.0 110.001 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.519 ' O ' ' N ' ' A' ' 25' ' ' ASP . 46.5 tp -102.61 95.42 6.21 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.449 -0.782 . . . . 0.0 109.301 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.576 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 17.1 mt -43.33 96.24 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.078 -1.013 . . . . 0.0 109.417 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -101.21 81.62 2.24 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.511 -0.743 . . . . 0.0 110.121 -179.493 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.527 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 4.3 m -61.89 -20.64 63.96 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.989 -1.07 . . . . 0.0 108.936 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.455 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -59.32 -45.49 95.35 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.96 157.56 37.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.377 -1.072 . . . . 0.0 108.729 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -92.01 -10.26 39.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.06 -1.025 . . . . 0.0 110.3 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.24 -173.46 3.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.956 -1.09 . . . . 0.0 110.053 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.555 HG23 ' CD1' ' A' ' 33' ' ' LEU . 33.4 m -103.23 89.01 3.27 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.265 -0.897 . . . . 0.0 111.281 -178.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.563 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.42 172.15 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.55 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.563 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -168.68 132.7 1.51 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.085 -1.009 . . . . 0.0 110.571 -178.966 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.456 ' O ' ' O ' ' A' ' 33' ' ' LEU . 20.6 mt-10 -41.46 161.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.7 OUTLIER -61.36 143.7 55.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.036 -1.04 . . . . 0.0 110.043 -179.46 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.476 ' HE2' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -160.1 -179.76 8.04 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.331 -0.855 . . . . 0.0 109.645 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.4 t -92.89 100.0 12.54 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 109.924 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.63 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 12.6 mt -106.45 173.28 3.26 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.7 Cg_endo -78.18 50.11 3.22 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.327 2.018 . . . . 0.0 112.735 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 34.75 -158.53 0.01 OUTLIER Glycine 0 N--CA 1.498 2.769 0 O-C-N 121.478 -0.763 . . . . 0.0 111.529 178.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.451 ' HG3' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER 53.8 80.33 0.11 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.547 -0.973 . . . . 0.0 109.442 -179.54 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 2.9 p-90 -145.93 -167.85 2.83 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-O 121.506 0.67 . . . . 0.0 109.697 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.44 116.01 11.82 Favored Pre-proline 0 C--N 1.303 -1.433 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.169 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -70.59 138.76 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 121.848 1.698 . . . . 0.0 111.731 -178.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.461 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -158.61 133.09 8.05 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.457 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.8 OUTLIER -94.03 123.56 37.48 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 -179.729 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.535 ' CD1' HG23 ' B' ' 50' ' ' ILE . 6.9 pt -92.38 148.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.814 -1.179 . . . . 0.0 108.679 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.504 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -118.39 101.86 0.92 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.764 -1.735 . . . . 0.0 108.764 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.89 -128.28 3.3 Favored Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.522 -1.323 . . . . 0.0 111.056 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.572 ' CG2' HD12 ' B' ' 54' ' ' ILE . 22.4 mt -86.29 114.35 25.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.809 -0.818 . . . . 0.0 112.494 -177.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.507 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.48 -7.14 39.4 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.207 -0.997 . . . . 0.0 110.758 177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.21 -160.98 23.83 Favored Glycine 0 N--CA 1.494 2.516 0 O-C-N 120.894 -1.357 . . . . 0.0 110.405 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.504 ' CZ ' ' HA3' ' A' ' 48' ' ' GLY . 5.1 m-85 -110.73 132.98 53.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.382 -1.07 . . . . 0.0 109.883 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.551 HG12 ' CG2' ' B' ' 50' ' ' ILE . 2.6 pp -111.04 162.47 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.065 -1.022 . . . . 0.0 108.603 178.635 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 76.0 mttt -102.36 133.69 46.87 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.034 -1.041 . . . . 0.0 109.673 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.477 HG11 ' CD1' ' A' ' 54' ' ' ILE . 3.1 m -134.77 -173.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.456 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -132.71 100.01 4.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.48 -0.762 . . . . 0.0 109.1 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.49 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 31.8 tt0 -57.92 93.79 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.328 -0.858 . . . . 0.0 109.669 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.594 ' CD2' HD11 ' A' ' 38' ' ' LEU . 15.6 m-85 -88.36 125.36 34.66 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.479 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 24.6 m-20 -105.29 137.72 42.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.861 -1.15 . . . . 0.0 110.901 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.519 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 1.7 mm-40 72.62 61.43 0.12 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.792 -0.568 . . . . 0.0 110.614 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.541 ' CG2' HG21 ' A' ' 15' ' ' ILE . 4.9 mp -119.64 123.94 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.066 . . . . 0.0 108.92 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.563 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 3.3 tm? -69.7 86.56 0.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.316 -0.865 . . . . 0.0 111.831 -178.29 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.533 HG13 ' HB ' ' A' ' 13' ' ' ILE . 3.0 tt -88.32 110.27 20.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 2.0 tt0 -88.77 118.32 28.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.962 -1.086 . . . . 0.0 109.791 -178.03 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.517 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.7 OUTLIER -108.4 120.2 59.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.326 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.72 -99.01 0.09 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -136.72 39.09 1.68 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.0 m170 -128.45 103.33 7.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.423 -1.045 . . . . 0.0 110.164 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.442 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -60.89 117.32 5.29 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.721 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.4 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -133.01 127.99 35.33 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.278 -178.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.547 HG12 ' CA ' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -105.06 139.46 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.605 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.489 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -162.73 -170.95 28.31 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 118.93 -1.605 . . . . 0.0 110.295 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.566 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 51.9 m -91.02 109.87 21.12 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.695 -0.885 . . . . 0.0 109.798 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.541 HG13 ' CD1' ' A' ' 15' ' ' ILE . 1.1 t -103.61 112.03 35.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 110.959 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.543 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 2.0 mp -79.57 122.95 27.13 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.441 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -108.39 121.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.945 -1.097 . . . . 0.0 109.907 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -155.22 -165.17 13.83 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.552 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -80.76 42.52 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.564 2.176 . . . . 0.0 110.636 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.479 ' O ' HG21 ' A' ' 80' ' ' THR . 13.1 t -85.9 141.16 35.44 Favored Pre-proline 0 C--N 1.302 -1.473 0 O-C-N 121.156 -0.965 . . . . 0.0 108.814 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.87 15.06 1.55 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.475 2.116 . . . . 0.0 111.546 -179.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.533 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 1.0 OUTLIER -160.68 167.37 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.787 -1.196 . . . . 0.0 110.371 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.54 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 69.5 m-80 -100.09 92.54 5.29 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 177.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.578 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 11.4 mm -78.91 124.33 37.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 O-C-N 121.153 -0.967 . . . . 0.0 111.846 -176.472 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.61 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -106.22 100.58 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 177.531 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -87.28 -161.61 36.74 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 120.128 -1.034 . . . . 0.0 111.481 -177.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 15.8 mmm180 -62.16 -38.73 90.13 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.843 -0.798 . . . . 0.0 109.841 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 11.5 p-10 -43.67 -29.48 0.51 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.231 -0.918 . . . . 0.0 109.387 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.587 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.7 mm? -107.78 -24.62 11.61 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.004 -1.06 . . . . 0.0 109.612 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.527 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.7 mt -70.41 -5.81 31.04 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.866 -1.146 . . . . 0.0 108.191 178.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.468 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 71.3 p -100.63 -17.87 16.83 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 19.1 mm100 -83.64 -39.19 20.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 109.434 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.54 ' CD1' ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -84.95 3.52 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.298 -0.876 . . . . 0.0 109.607 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.56 38.22 51.8 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 120.313 -0.946 . . . . 0.0 111.064 178.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.534 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -71.16 138.29 49.47 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.079 -1.248 . . . . 0.0 111.072 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' B' ' 96' ' ' THR . 48.7 p -133.18 128.76 36.69 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.536 ' CD1' HD12 ' B' ' 97' ' ' LEU . 1.6 mp -92.84 85.37 5.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.18 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.52 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.8 m120 -89.68 122.39 32.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.097 -1.002 . . . . 0.0 109.747 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.593 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 117.927 -1.035 . . . . 0.0 108.908 178.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.512 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.1 tt0 -84.2 131.5 34.75 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.325 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.402 HG22 ' CZ ' ' A' ' 99' ' ' PHE . 5.0 t -119.69 118.5 57.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 C-N-CA 118.525 -1.27 . . . . 0.0 110.483 -178.183 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.45 ' CG2' HG21 ' A' ' 96' ' ' THR . 0.1 OUTLIER -132.31 19.93 4.4 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 178.324 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.572 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -82.17 67.38 8.16 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.531 ' C ' ' O ' ' B' ' 5' ' ' LEU . 41.5 m0 -21.93 84.5 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 CA-C-O 121.578 0.704 . . . . 0.0 111.594 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.572 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.38 -163.04 0.32 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.975 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.42 121.71 71.06 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.115 -0.991 . . . . 0.0 109.27 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 33.5 Cg_endo -76.5 74.74 4.63 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.08 1.853 . . . . 0.0 109.068 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.477 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -96.98 147.15 24.28 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.463 -0.773 . . . . 0.0 110.425 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.506 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -143.63 132.47 19.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.885 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 12.0 m -67.54 99.91 0.81 Allowed 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.606 HG23 HG13 ' B' ' 66' ' ' ILE . 3.2 pt -82.73 157.17 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.738 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.532 ' CG ' HD22 ' B' ' 19' ' ' LEU . 0.5 OUTLIER -123.78 98.74 5.95 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.314 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.552 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 50.7 mt -113.98 133.37 60.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.332 -0.855 . . . . 0.0 109.605 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.474 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 49.98 54.91 16.71 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.65 34.78 21.59 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.491 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.4 mm100 -124.84 167.08 15.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -1.184 . . . . 0.0 109.185 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.532 HD22 ' CG ' ' B' ' 14' ' ' LYS . 12.0 mt -141.82 129.49 21.55 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.159 -0.963 . . . . 0.0 110.757 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.445 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 20.2 mtmt -151.7 169.43 22.2 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.481 ' O ' ' OD1' ' B' ' 83' ' ' ASN . 1.1 mp0 -78.99 126.67 31.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.943 -1.098 . . . . 0.0 109.029 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.578 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -106.88 120.77 42.94 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.088 -1.008 . . . . 0.0 110.173 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.443 ' O ' ' HG ' ' B' ' 23' ' ' LEU . 20.7 tp -91.82 94.75 9.48 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.437 -0.789 . . . . 0.0 110.093 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.491 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 58.0 mt -46.49 101.88 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.033 -1.042 . . . . 0.0 108.676 179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.548 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 12.4 t0 -113.34 98.2 6.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.92 . . . . 0.0 110.721 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.559 ' CG2' ' CD2' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -69.88 -15.32 63.06 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.111 -0.993 . . . . 0.0 108.768 178.699 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.448 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.62 -41.03 97.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.73 165.52 22.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.039 -1.271 . . . . 0.0 109.063 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -100.77 -15.42 17.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.132 -0.98 . . . . 0.0 110.573 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.509 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.66 -175.33 3.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.712 -1.242 . . . . 0.0 110.316 -179.369 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.499 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 72.8 m -103.13 87.92 3.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.017 -1.052 . . . . 0.0 110.053 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.556 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -71.43 163.12 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.52 179.611 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.588 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -160.7 138.45 9.53 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.049 -1.032 . . . . 0.0 110.469 -178.539 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.474 ' O ' ' O ' ' B' ' 33' ' ' LEU . 2.3 mt-10 -47.97 174.97 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.502 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.2 tm-20 -72.5 143.46 48.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.03 -1.044 . . . . 0.0 109.452 179.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 6.6 ptm -154.93 -167.92 2.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.393 -0.817 . . . . 0.0 109.204 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -107.22 105.98 16.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.653 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.58 HD11 ' CD2' ' B' ' 59' ' ' TYR . 90.4 mt -117.21 156.44 48.65 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.486 ' O ' ' O ' ' B' ' 40' ' ' GLY . 35.1 Cg_endo -76.63 74.24 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.885 2.39 . . . . 0.0 112.206 -178.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 34.39 -157.14 0.01 OUTLIER Glycine 0 N--CA 1.497 2.765 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.414 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.3 mtt180 70.02 47.73 0.57 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.263 -1.139 . . . . 0.0 108.459 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.602 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 57.4 p-90 -129.12 -179.03 4.89 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 121.824 0.821 . . . . 0.0 110.297 -178.815 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.462 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -145.26 156.48 54.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.667 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -75.75 139.3 22.25 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.803 1.669 . . . . 0.0 110.29 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.518 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -144.87 168.82 19.32 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.537 -0.727 . . . . 0.0 109.52 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.531 ' HE3' ' CG ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -150.1 125.08 9.92 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.565 ' CD1' HG22 ' A' ' 50' ' ' ILE . 24.1 pt -120.46 137.82 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 120.74 -1.225 . . . . 0.0 110.385 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.69 98.51 0.75 Allowed Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.68 -119.02 2.75 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.8 -178.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.551 ' CG2' HG12 ' A' ' 54' ' ' ILE . 16.4 mt -90.39 119.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.689 -0.889 . . . . 0.0 112.337 -177.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.483 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 103.34 -28.11 17.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 120.222 -0.99 . . . . 0.0 110.751 177.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 153.49 -161.9 30.01 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.285 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 8.4 m-85 -107.31 125.02 50.63 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -1.036 . . . . 0.0 110.138 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.572 HD12 ' CG2' ' A' ' 50' ' ' ILE . 11.8 pt -105.96 142.0 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.081 -1.012 . . . . 0.0 108.865 178.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.531 ' CG ' ' HE3' ' B' ' 46' ' ' MET . 5.0 mttt -89.06 138.59 31.27 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.031 -1.043 . . . . 0.0 109.294 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.518 ' CG2' ' HB3' ' B' ' 45' ' ' LYS . 29.4 m -140.44 175.52 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.079 -1.013 . . . . 0.0 110.211 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.573 ' HG2' ' CE3' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -126.29 103.95 7.93 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.403 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.542 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -58.75 112.73 1.74 Allowed 'General case' 0 C--N 1.295 -1.797 0 O-C-N 121.566 -0.709 . . . . 0.0 111.126 -178.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.602 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 15.2 m-85 -98.4 124.4 43.06 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.2 m-20 -101.97 130.1 48.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.886 -1.134 . . . . 0.0 111.03 -178.563 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.583 ' HA ' HG21 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 77.98 65.55 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 CA-C-O 121.48 0.657 . . . . 0.0 109.909 179.163 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.552 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 10.0 mm -118.54 119.6 61.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.273 -0.892 . . . . 0.0 109.721 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.541 ' HA ' HG12 ' B' ' 72' ' ' ILE . 1.4 tm? -63.9 86.93 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.603 -0.686 . . . . 0.0 111.682 -178.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.478 HG21 ' O ' ' B' ' 64' ' ' ILE . 7.9 tt -93.47 113.03 27.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 176.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 32.9 tt0 -88.32 120.42 29.67 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 -178.507 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.606 HG13 HG23 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -114.29 126.34 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.215 -0.928 . . . . 0.0 109.712 -179.253 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 5.7 m 65.18 4.75 2.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.797 -0.564 . . . . 0.0 110.763 179.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 110.81 -6.75 29.49 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.042 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -92.11 139.29 30.78 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.199 -1.177 . . . . 0.0 108.549 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.507 ' CG ' HD13 ' B' ' 63' ' ' LEU . 1.7 mttt -84.47 124.75 31.69 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.177 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -134.15 157.89 45.04 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.583 HG21 ' HA ' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -131.19 133.91 61.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.593 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.42 -166.48 17.68 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 118.617 -1.754 . . . . 0.0 110.995 -179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.542 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 51.6 m -92.39 107.1 18.96 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.924 -0.751 . . . . 0.0 109.797 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.588 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -103.77 113.29 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.544 -0.723 . . . . 0.0 109.804 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.556 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.6 mp -78.35 129.25 34.77 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.576 HG22 ' CD2' ' B' ' 59' ' ' TYR . 95.7 t -113.78 109.95 30.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.895 -1.128 . . . . 0.0 110.039 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.502 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -147.12 -163.59 10.62 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.506 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -79.87 41.37 1.1 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.325 2.016 . . . . 0.0 111.164 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.518 HG22 ' O ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -88.23 139.74 30.42 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.907 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -79.81 17.32 1.3 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 C-N-CA 122.488 2.126 . . . . 0.0 112.302 -177.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.1 t -160.69 164.63 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.527 -1.358 . . . . 0.0 110.992 -179.543 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.532 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 1.0 OUTLIER -103.61 87.04 2.74 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.135 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.548 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 1.7 mt -84.42 123.71 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 O-C-N 121.336 -0.852 . . . . 0.0 112.377 -176.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.571 ' N ' HD11 ' B' ' 85' ' ' ILE . 3.2 mm -91.78 103.25 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -84.11 -159.16 28.87 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.71 -1.244 . . . . 0.0 110.671 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 11.9 mtt-85 -66.24 -35.58 80.8 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.659 -0.907 . . . . 0.0 109.498 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.518 ' ND2' HD21 ' B' ' 89' ' ' LEU . 7.7 p-10 -48.79 -31.65 7.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.921 . . . . 0.0 109.753 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.538 ' HB3' ' CG2' ' B' ' 85' ' ' ILE . 1.2 mm? -106.16 -17.38 14.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.077 . . . . 0.0 110.251 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 87.4 mt -77.39 -1.66 31.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.143 -0.973 . . . . 0.0 108.529 179.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.617 HG23 ' CZ3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -101.68 -20.58 14.94 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.128 -0.982 . . . . 0.0 108.638 179.038 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -75.5 -40.72 56.8 Favored 'General case' 0 N--CA 1.486 1.364 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.537 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -83.39 -9.16 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.411 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.3 36.78 33.61 Favored Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.232 -0.917 . . . . 0.0 111.166 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.521 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -63.7 156.25 27.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.054 -1.263 . . . . 0.0 110.513 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 96' ' ' THR . 66.7 p -147.58 126.61 12.84 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.566 ' HB3' ' CE2' ' B' ' 99' ' ' PHE . 2.7 mp -95.49 89.28 5.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.717 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.532 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.1 m120 -96.13 118.74 33.31 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.055 -1.028 . . . . 0.0 109.318 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.566 ' CE2' ' HB3' ' B' ' 97' ' ' LEU . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.324 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.471 ' HG2' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 N-CA-C 110.501 -0.615 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.506 ' NE2' HG22 ' A' ' 4' ' ' THR . 9.1 tt0 -85.92 126.8 34.36 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 177.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.446 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 2.4 t -112.33 91.09 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 120.818 -1.176 . . . . 0.0 109.909 -178.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.506 HG22 ' NE2' ' A' ' 2' ' ' GLN . 64.7 p -117.71 33.04 5.82 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.539 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -86.79 30.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.882 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 35.8 m0 17.68 52.49 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.524 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -147.73 -163.37 1.75 Allowed 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -74.68 114.92 39.02 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.997 -1.065 . . . . 0.0 109.839 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.482 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.9 Cg_endo -78.06 71.15 6.79 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 121.976 1.784 . . . . 0.0 108.878 177.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -93.29 157.64 16.14 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.356 -179.167 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.514 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -149.96 140.55 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.82 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 m -73.2 94.15 1.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.514 HG21 ' CG2' ' A' ' 11' ' ' VAL . 4.7 pt -80.43 163.82 3.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.538 -0.726 . . . . 0.0 110.791 -178.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 21.7 tttm -129.53 103.23 6.76 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.571 -0.706 . . . . 0.0 109.8 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.539 HG23 ' CE ' ' A' ' 36' ' ' MET . 39.8 mt -119.55 117.05 52.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 120.994 -1.066 . . . . 0.0 109.38 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.27 25.55 75.28 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.96 -1.63 86.06 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.456 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 tp60 -92.11 167.41 12.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.99 -1.3 . . . . 0.0 109.396 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.449 HD22 ' HG3' ' A' ' 14' ' ' LYS . 36.4 mt -130.2 134.74 47.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.645 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 1.7 tptt -151.32 146.17 25.83 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.627 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 2.7 mm-40 -78.88 107.94 11.98 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.585 ' CB ' ' CD1' ' A' ' 85' ' ' ILE . . . -98.57 131.82 44.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.017 -1.052 . . . . 0.0 111.019 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.418 ' O ' ' C ' ' A' ' 24' ' ' LEU . 0.8 OUTLIER -87.33 105.09 17.01 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.901 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.503 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -46.99 120.36 3.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.966 -1.084 . . . . 0.0 108.4 179.702 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 56.7 t0 -124.54 83.99 2.22 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.221 -0.925 . . . . 0.0 110.488 -178.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.457 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 3.2 m -65.74 -15.26 62.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.036 -1.04 . . . . 0.0 108.565 178.807 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.504 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -67.13 -45.59 80.22 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.81 167.54 19.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -1.184 . . . . 0.0 108.597 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -99.92 -19.8 16.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.828 -1.17 . . . . 0.0 110.785 -178.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.549 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.01 179.35 6.37 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.89 -1.131 . . . . 0.0 109.781 -179.687 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.563 ' CG2' ' CD1' ' A' ' 33' ' ' LEU . 7.4 m -94.66 92.81 7.2 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 120.826 -1.171 . . . . 0.0 110.011 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.569 ' CG2' ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -84.49 118.96 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.232 -0.918 . . . . 0.0 109.102 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.563 ' CD1' ' CG2' ' A' ' 31' ' ' THR . 1.2 mp -114.1 144.41 43.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.952 -1.093 . . . . 0.0 111.128 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.522 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 0.0 OUTLIER -47.17 174.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.381 -0.825 . . . . 0.0 108.922 178.569 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.493 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.0 OUTLIER -57.59 146.13 31.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.027 . . . . 0.0 109.642 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.539 ' CE ' HG23 ' A' ' 15' ' ' ILE . 2.7 ptm -163.7 -175.49 4.16 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.392 -0.818 . . . . 0.0 109.043 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.489 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.9 t -110.74 120.44 42.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.113 -0.992 . . . . 0.0 109.788 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.562 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 82.0 mt -132.9 159.17 73.7 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 34.4 Cg_endo -76.42 133.0 14.08 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.823 2.348 . . . . 0.0 112.436 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -37.25 129.48 1.23 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.469 -1.053 . . . . 0.0 110.469 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.0 OUTLIER 148.19 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -179.519 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.617 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 50.4 p-90 -138.56 -173.29 3.51 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.741 0.782 . . . . 0.0 110.355 -177.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.463 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 0.0 OUTLIER -148.94 163.8 24.0 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 179.14 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 36.0 Cg_endo -78.37 145.66 21.41 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.966 1.777 . . . . 0.0 109.979 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.55 ' CB ' ' CG2' ' A' ' 56' ' ' VAL . 0.8 OUTLIER -146.52 142.78 28.4 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.153 -0.967 . . . . 0.0 109.67 -179.52 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.475 ' CE ' ' HE3' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -121.97 107.24 12.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 108.675 179.475 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.561 HG13 ' CG1' ' A' ' 54' ' ' ILE . 6.9 pt -101.81 132.39 47.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.588 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 53' ' ' PHE . . . -117.7 105.38 1.25 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.88 -115.89 2.45 Favored Glycine 0 N--CA 1.481 1.695 0 C-N-CA 119.715 -1.231 . . . . 0.0 110.768 -178.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.524 ' O ' ' O ' ' B' ' 50' ' ' ILE . 25.6 mt -88.6 116.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 O-C-N 121.832 -0.805 . . . . 0.0 112.834 -177.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.526 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.7 -42.35 1.94 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 166.68 -160.98 34.75 Favored Glycine 0 N--CA 1.49 2.259 0 O-C-N 120.833 -1.392 . . . . 0.0 110.172 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.491 ' HA ' ' HA2' ' A' ' 48' ' ' GLY . 6.8 m-85 -102.1 155.79 17.97 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.449 -1.03 . . . . 0.0 110.042 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.561 ' CG1' HG13 ' A' ' 47' ' ' ILE . 2.1 pt -134.42 173.54 14.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.513 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 3.3 mttt -114.15 144.62 42.86 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.315 -0.866 . . . . 0.0 108.742 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.55 ' CG2' ' CB ' ' A' ' 45' ' ' LYS . 30.6 m -143.39 -177.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.624 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.525 ' O ' ' N ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -131.52 88.82 2.62 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.51 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 3.5 tt0 -46.76 91.7 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.497 -0.752 . . . . 0.0 109.804 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 12.5 m-85 -89.96 95.68 10.33 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 12.2 m-20 -79.22 133.2 36.69 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.161 -0.962 . . . . 0.0 109.972 -179.004 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.557 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 20.4 mm-40 81.8 61.68 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.495 0.664 . . . . 0.0 110.166 179.171 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.511 ' CG2' HG22 ' A' ' 75' ' ' VAL . 15.4 mm -115.99 120.35 64.59 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.504 HD23 ' HG3' ' A' ' 70' ' ' LYS . 1.9 tm? -72.45 81.18 1.06 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.171 -0.956 . . . . 0.0 111.094 -178.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.5 HG13 HG13 ' A' ' 15' ' ' ILE . 13.5 tt -87.66 117.93 32.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.481 ' HG3' ' N ' ' A' ' 70' ' ' LYS . 1.5 tt0 -93.91 112.38 24.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.07 -1.019 . . . . 0.0 109.763 -178.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.505 HG13 HG21 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -100.34 118.81 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.3 m 56.42 54.55 7.45 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.735 -0.603 . . . . 0.0 109.807 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 57.69 16.55 23.72 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.453 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 25.7 m170 -107.93 91.18 3.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -1.223 . . . . 0.0 109.494 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.504 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -43.42 137.25 2.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 179.712 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.46 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -159.25 124.83 4.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.515 -0.74 . . . . 0.0 109.415 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.557 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -95.32 152.45 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.877 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.479 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -175.41 -171.82 39.73 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 118.832 -1.652 . . . . 0.0 111.089 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.51 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 96.5 m -98.49 108.85 21.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -1.134 . . . . 0.0 110.619 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.511 HG22 ' CG2' ' A' ' 62' ' ' ILE . 1.5 t -99.24 109.92 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.675 -0.641 . . . . 0.0 110.349 179.153 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.569 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.8 mp -79.4 100.95 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.495 HG22 HD11 ' A' ' 38' ' ' LEU . 21.6 t -87.1 121.86 38.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.98 -1.075 . . . . 0.0 110.248 -178.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -156.76 -166.15 15.97 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.513 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 35.7 Cg_endo -80.84 40.67 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.403 2.069 . . . . 0.0 111.103 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.522 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 13.4 t -81.36 140.5 48.71 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.453 ' O ' ' CG2' ' A' ' 82' ' ' VAL . 37.0 Cg_endo -78.73 15.75 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.595 2.197 . . . . 0.0 111.279 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.523 HG11 HG13 ' A' ' 84' ' ' ILE . 5.2 t -160.53 163.36 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.94 -1.1 . . . . 0.0 110.514 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.645 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -101.01 85.57 2.88 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 105.045 -2.205 . . . . 0.0 105.045 177.109 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.599 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 4.6 mt -88.88 125.31 41.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.139 -0.975 . . . . 0.0 112.69 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' CB ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -84.88 149.48 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 176.503 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -125.61 -170.23 13.01 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.672 -1.728 . . . . 0.0 110.462 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.458 ' HD3' ' HB2' ' A' ' 90' ' ' LEU . 6.4 mmt180 -62.98 -26.75 68.99 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.444 -1.033 . . . . 0.0 108.416 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.592 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 15.7 p-10 -57.65 -28.44 63.74 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.433 -0.792 . . . . 0.0 109.141 179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.592 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -102.36 -24.37 13.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.287 -0.883 . . . . 0.0 109.208 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.458 ' HB2' ' HD3' ' A' ' 87' ' ' ARG . 41.0 mt -71.51 -4.8 28.76 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.47 HG23 ' CD1' ' B' ' 6' ' ' TRP . 21.7 p -101.14 -16.08 17.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.256 -0.902 . . . . 0.0 108.717 178.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mm-40 -86.66 -40.81 14.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.31 -0.868 . . . . 0.0 109.433 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.568 HD11 ' CG ' ' B' ' 99' ' ' PHE . 1.6 pt -85.67 0.71 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.131 -0.981 . . . . 0.0 108.724 179.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.03 51.49 50.47 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.523 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.1 155.29 23.92 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.031 -1.276 . . . . 0.0 109.802 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.504 HG21 ' CG2' ' B' ' 4' ' ' THR . 10.5 p -147.98 130.88 16.16 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.581 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.6 mp -91.29 100.86 13.59 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.421 -0.799 . . . . 0.0 109.698 -179.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.53 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 1.6 m120 -102.2 123.37 45.92 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.961 -1.087 . . . . 0.0 109.111 179.352 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.617 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.09 -0.957 . . . . 0.0 109.241 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.494 1.509 0 N-CA-C 110.041 -0.792 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.52 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.7 tt0 -83.55 133.78 34.85 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 178.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 30.7 t -132.69 122.5 47.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.756 -177.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.534 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.4 OUTLIER -132.46 -79.46 0.5 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.612 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 60.1 mt 28.27 38.64 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.095 178.298 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 25.7 m0 16.51 52.75 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 CA-C-O 121.252 0.549 . . . . 0.0 111.619 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 9.9 mt-30 -142.09 -179.46 6.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 109.868 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -75.62 122.35 86.97 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HB2' ' CD1' ' B' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 75.73 4.46 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.078 1.852 . . . . 0.0 109.836 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.529 ' CD2' ' CB ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -91.78 154.91 18.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.904 . . . . 0.0 109.695 -179.543 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.477 HG23 HG12 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -147.91 134.98 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 0.0 109.908 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.542 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 6.9 m -68.15 105.1 1.97 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.766 -1.208 . . . . 0.0 108.555 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.582 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.2 pt -92.86 156.75 3.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.944 -1.098 . . . . 0.0 110.261 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.533 ' HG3' ' CD1' ' B' ' 19' ' ' LEU . 10.5 tttm -121.99 100.06 6.78 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.505 HD13 ' CD2' ' B' ' 33' ' ' LEU . 13.1 mt -116.71 124.24 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.108 -0.995 . . . . 0.0 110.122 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.83 38.86 93.04 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 68.45 21.13 74.21 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.512 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -110.13 171.0 7.71 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.201 -1.176 . . . . 0.0 109.136 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.542 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.1 OUTLIER -148.14 124.36 10.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.298 -0.876 . . . . 0.0 110.565 -179.378 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.492 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mtmp? -151.05 169.23 22.33 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.547 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -81.92 119.02 23.41 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 120.989 -1.069 . . . . 0.0 109.197 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.582 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -94.91 130.51 41.49 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.312 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' B' ' 25' ' ' ASP . 19.0 tp -92.89 92.34 7.85 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.519 ' CD1' ' HB2' ' B' ' 9' ' ' PRO . 92.4 mt -44.11 96.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.287 -0.883 . . . . 0.0 108.998 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' B' ' 23' ' ' LEU . 3.8 t0 -105.64 86.53 2.42 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.4 -0.813 . . . . 0.0 109.555 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.544 ' O ' ' NH1' ' B' ' 87' ' ' ARG . 0.6 OUTLIER -63.2 -9.44 11.22 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.267 -0.896 . . . . 0.0 109.443 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.26 -41.13 47.44 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . 0.474 ' O ' ' NH1' ' B' ' 87' ' ' ARG . . . -76.36 145.45 39.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.176 -1.191 . . . . 0.0 109.417 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.93 -16.22 60.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.322 -0.861 . . . . 0.0 111.614 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.539 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -139.03 -167.47 2.23 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.548 -1.345 . . . . 0.0 110.255 -179.532 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.545 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 23.5 m -107.88 93.71 4.68 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.247 -0.908 . . . . 0.0 110.695 -178.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.22 167.2 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.133 -0.98 . . . . 0.0 108.599 179.171 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.568 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.56 136.89 4.66 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.826 -1.171 . . . . 0.0 111.188 -178.258 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.476 ' HA ' HG21 ' B' ' 80' ' ' THR . 2.9 tt0 -45.31 157.35 0.09 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.83 . . . . 0.0 109.436 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.51 ' HA ' HG11 ' B' ' 77' ' ' VAL . 2.0 mt-10 -49.52 151.28 1.65 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.227 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.441 ' HE3' HG23 ' B' ' 15' ' ' ILE . 4.9 ptm -173.33 161.86 4.25 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.455 -0.778 . . . . 0.0 109.035 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 23.5 t -82.17 110.38 17.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.152 -0.967 . . . . 0.0 110.046 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.737 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 48.4 mt -119.36 175.98 1.95 Allowed Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.718 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.737 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.4 Cg_endo -71.79 -161.9 0.11 Allowed 'Trans proline' 0 C--N 1.319 -1.006 0 C-N-CA 121.539 1.493 . . . . 0.0 111.945 -178.248 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.73 35.86 4.74 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -178.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.4 mmt-85 -118.18 62.92 0.76 Allowed 'General case' 0 C--N 1.29 -1.991 0 O-C-N 121.598 -0.942 . . . . 0.0 109.042 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.705 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 8.3 p-90 -142.97 -172.35 3.65 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -149.26 139.77 13.65 Favored Pre-proline 0 C--N 1.303 -1.414 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.53 130.67 10.01 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.214 1.943 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.485 ' O ' ' HG3' ' B' ' 45' ' ' LYS . 3.6 ptmt -162.21 145.61 11.79 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.505 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 42.7 mtp -103.41 137.64 41.24 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.924 -1.11 . . . . 0.0 109.654 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' B' ' 53' ' ' PHE . 3.9 pt -96.45 145.78 8.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.095 -1.003 . . . . 0.0 108.392 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.87 101.27 0.86 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.53 -127.43 3.16 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.749 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.524 ' O ' ' O ' ' A' ' 50' ' ' ILE . 46.4 mt -81.79 132.31 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.835 -0.803 . . . . 0.0 112.207 -177.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.536 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 89.21 -44.71 3.11 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 178.612 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.24 -162.73 34.8 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -115.72 130.76 56.97 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.435 -1.038 . . . . 0.0 109.22 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 23.8 pt -110.51 144.24 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.828 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.505 ' CG ' ' HG2' ' B' ' 46' ' ' MET . 10.4 mtmm -72.08 144.06 48.84 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.298 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.415 HG23 ' O ' ' B' ' 45' ' ' LYS . 29.5 m -145.42 -170.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.103 -0.998 . . . . 0.0 109.873 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.582 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.4 mtt180 -142.4 102.16 4.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.329 -0.857 . . . . 0.0 109.332 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.569 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 5.5 tt0 -64.77 113.07 3.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -0.893 . . . . 0.0 109.961 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.705 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 19.1 m-85 -104.38 95.51 5.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.442 -0.786 . . . . 0.0 108.941 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.1 m-20 -78.71 137.77 37.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.966 -1.084 . . . . 0.0 109.972 -179.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.502 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 1.3 mm-40 77.66 64.12 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.456 0.646 . . . . 0.0 109.869 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.531 ' CB ' HG22 ' B' ' 75' ' ' VAL . 0.6 OUTLIER -126.48 119.27 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.569 HD23 ' CG ' ' B' ' 70' ' ' LYS . 0.2 OUTLIER -72.53 85.29 1.15 Allowed 'General case' 0 C--N 1.296 -1.724 0 O-C-N 120.933 -1.104 . . . . 0.0 111.805 -177.526 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.584 HG21 ' O ' ' B' ' 71' ' ' ALA . 4.4 tt -89.49 115.04 28.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 10.1 tt0 -89.57 117.38 28.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.539 HG13 ' CG2' ' B' ' 13' ' ' ILE . 0.7 OUTLIER -110.27 120.68 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.244 -0.91 . . . . 0.0 108.88 179.37 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 57.95 50.71 9.9 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.446 -0.784 . . . . 0.0 109.67 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 59.76 16.77 39.73 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.486 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 69.9 m-70 -106.01 121.15 43.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.101 -1.235 . . . . 0.0 109.531 179.741 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.569 ' CG ' HD23 ' B' ' 63' ' ' LEU . 21.4 ttpt -69.45 122.03 18.17 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.41 -0.806 . . . . 0.0 109.585 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.584 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -139.64 106.98 5.52 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 110.356 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.515 HD12 ' N ' ' B' ' 63' ' ' LEU . 0.4 OUTLIER -87.04 139.03 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 177.811 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.18 -159.0 9.69 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 118.545 -1.788 . . . . 0.0 111.285 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.569 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.3 m -109.17 102.57 11.51 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.64 -0.917 . . . . 0.0 109.67 -179.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.568 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.3 t -96.91 111.38 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.241 -0.912 . . . . 0.0 111.107 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.539 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 1.8 mp -78.39 134.18 37.45 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.531 ' CG2' HD13 ' B' ' 38' ' ' LEU . 46.5 t -124.43 131.29 72.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 120.869 -1.144 . . . . 0.0 110.145 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.63 -160.37 11.56 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.85 40.79 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.369 2.046 . . . . 0.0 110.401 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.476 HG21 ' HA ' ' B' ' 34' ' ' GLU . 4.6 t -84.94 138.28 37.37 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.45 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.4 Cg_endo -79.48 23.34 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 122.475 2.117 . . . . 0.0 111.668 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.564 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -161.67 170.46 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.669 -1.269 . . . . 0.0 110.113 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 0.1 OUTLIER -110.19 92.73 4.16 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.122 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' B' ' 31' ' ' THR . 20.2 mm -78.77 128.23 38.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.385 -0.822 . . . . 0.0 112.893 -175.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.512 HD13 ' HB3' ' B' ' 22' ' ' ALA . 1.4 mp -108.15 89.29 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 176.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -79.53 -162.36 24.26 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.313 -177.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.544 ' NH1' ' O ' ' B' ' 26' ' ' THR . 0.1 OUTLIER -61.89 -40.04 94.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.766 -0.844 . . . . 0.0 110.232 -179.219 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.554 ' ND2' HD21 ' B' ' 89' ' ' LEU . 11.6 p-10 -43.84 -28.89 0.48 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.141 -0.974 . . . . 0.0 109.465 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.554 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.8 mm? -107.27 -29.61 9.21 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.185 -0.947 . . . . 0.0 110.048 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.502 ' CD1' ' HA ' ' B' ' 26' ' ' THR . 13.6 mt -72.81 -3.66 26.83 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.03 -1.044 . . . . 0.0 108.506 179.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.503 ' O ' ' CZ2' ' A' ' 6' ' ' TRP . 15.5 p -101.72 -20.21 15.07 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.167 -0.958 . . . . 0.0 108.857 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.418 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 6.7 mt-30 -82.87 -38.05 23.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.321 -0.862 . . . . 0.0 109.236 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.551 HD11 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -81.06 3.71 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.877 . . . . 0.0 108.978 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 72.5 46.25 33.36 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.311 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -82.3 136.03 35.1 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.082 -1.246 . . . . 0.0 110.728 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.43 ' CG2' HG23 ' A' ' 4' ' ' THR . 36.3 p -131.78 129.43 40.53 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.581 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 2.4 mp -92.34 93.08 8.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.923 -1.11 . . . . 0.0 109.495 -179.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.523 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.3 m120 -100.39 127.27 46.76 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -0.918 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.568 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.213 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.578 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.013 -0.803 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.525 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 11.9 tt0 -84.15 138.94 32.75 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 177.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.8 t -140.04 116.27 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 117.857 -1.537 . . . . 0.0 111.921 -177.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.53 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.1 OUTLIER -121.34 -62.75 1.39 Allowed 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 176.874 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.582 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.4 OUTLIER 35.92 26.23 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.903 177.399 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.604 ' CD2' ' HB ' ' B' ' 91' ' ' THR . 27.8 m95 17.82 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.298 0.57 . . . . 0.0 112.252 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.582 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -161.91 -157.47 0.48 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.215 179.856 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HG2' ' OD1' ' B' ' 29' ' ' ASP . 40.9 mtm180 -78.8 128.82 75.64 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 120.894 -1.129 . . . . 0.0 109.893 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.539 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.64 66.02 8.86 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.36 2.04 . . . . 0.0 108.49 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.449 ' HG ' ' HA ' ' A' ' 23' ' ' LEU . 0.3 OUTLIER -90.2 145.18 25.21 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.33 -0.856 . . . . 0.0 110.756 -178.182 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.429 HG22 ' N ' ' A' ' 12' ' ' THR . 0.6 OUTLIER -150.51 164.14 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.277 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.429 ' N ' HG22 ' A' ' 11' ' ' VAL . 51.8 m -86.64 133.31 33.71 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 178.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.565 HG22 ' CB ' ' A' ' 22' ' ' ALA . 8.3 pt -121.92 156.73 26.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.996 -1.065 . . . . 0.0 110.384 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 8.0 tttt -117.94 100.55 7.63 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.504 HG23 ' CE ' ' A' ' 36' ' ' MET . 18.0 mt -112.24 145.78 17.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.368 -0.832 . . . . 0.0 110.298 -178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 39.82 41.15 1.78 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.84 44.59 94.47 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -144.13 176.56 9.22 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.121 -1.223 . . . . 0.0 108.756 179.537 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.478 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 13.0 mt -140.02 123.71 17.32 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 119.305 -0.958 . . . . 0.0 110.535 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.478 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -143.27 177.02 8.7 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 179.1 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.542 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 15.3 mp0 -79.86 -178.97 6.7 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.613 -1.304 . . . . 0.0 108.057 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.565 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -160.81 109.53 1.62 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.841 -1.162 . . . . 0.0 110.046 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.525 ' O ' ' N ' ' A' ' 25' ' ' ASP . 27.3 tp -89.26 89.36 7.88 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.669 -0.644 . . . . 0.0 109.307 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.539 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 58.2 mt -42.49 97.04 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 56.9 t0 -106.36 87.08 2.47 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.582 -0.699 . . . . 0.0 110.788 -177.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.447 HG21 ' HG2' ' A' ' 87' ' ' ARG . 2.1 m -62.15 -20.15 63.8 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.974 -1.079 . . . . 0.0 108.804 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.551 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -58.73 -48.24 86.07 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.55 160.63 31.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.311 -1.111 . . . . 0.0 108.591 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.406 ' OD1' ' HG2' ' B' ' 8' ' ' ARG . 61.9 m-20 -96.65 -11.21 25.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.986 -1.071 . . . . 0.0 110.421 -179.014 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.544 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -138.98 -165.56 1.86 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.089 . . . . 0.0 110.624 -179.211 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.526 ' CG2' ' HA ' ' A' ' 85' ' ' ILE . 0.0 OUTLIER -104.0 88.54 3.05 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.069 -1.019 . . . . 0.0 111.658 -178.001 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.639 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -72.94 122.99 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.317 -1.49 . . . . 0.0 107.333 177.784 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.475 HD21 HD11 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -131.27 131.87 44.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.539 -1.351 . . . . 0.0 111.345 -177.965 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.484 ' HA ' HG21 ' A' ' 80' ' ' THR . 10.5 pt-20 -41.91 152.98 0.07 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.546 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.1 tt0 -50.36 144.44 7.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.213 -0.93 . . . . 0.0 110.239 -179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.504 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -171.4 179.5 2.91 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.402 -0.811 . . . . 0.0 109.169 179.636 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.452 ' O ' ' SD ' ' A' ' 36' ' ' MET . 8.0 t -84.01 111.08 18.96 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.1 -1.0 . . . . 0.0 109.834 -179.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.533 ' CD1' HD11 ' A' ' 62' ' ' ILE . 18.6 tp -154.0 90.42 3.29 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 109.702 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -80.21 162.34 22.9 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.667 2.245 . . . . 0.0 110.408 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . 129.96 42.25 0.22 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.486 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER 61.1 150.68 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.658 -0.907 . . . . 0.0 109.047 -179.658 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 26.8 p-90 -154.2 158.38 40.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.101 -0.999 . . . . 0.0 109.807 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -120.67 138.38 27.47 Favored Pre-proline 0 C--N 1.299 -1.613 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.16 134.42 17.53 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 121.568 1.512 . . . . 0.0 108.736 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 46' ' ' MET . 7.1 tttt -148.15 163.49 36.79 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.548 -178.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.498 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 3.9 tpt -134.16 114.13 12.77 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.52 HD13 HG12 ' A' ' 54' ' ' ILE . 17.5 pt -89.68 143.25 11.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.619 -1.232 . . . . 0.0 109.802 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.616 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.07 98.36 0.76 Allowed Glycine 0 N--CA 1.485 1.911 0 N-CA-C 107.916 -2.074 . . . . 0.0 107.916 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.96 -136.31 4.8 Favored Glycine 0 C--N 1.298 -1.559 0 C-N-CA 119.315 -1.421 . . . . 0.0 111.387 -178.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.526 HG21 ' CG2' ' B' ' 54' ' ' ILE . 80.6 mt -78.92 132.17 32.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.768 0.794 . . . . 0.0 112.962 -177.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.466 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 85.81 -41.58 3.09 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.84 -165.11 36.16 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.493 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.616 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 1.1 m-85 -111.04 138.89 46.89 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.647 -0.914 . . . . 0.0 109.244 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.52 HG12 HD13 ' A' ' 47' ' ' ILE . 4.9 pt -119.71 134.13 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.853 -1.154 . . . . 0.0 108.854 178.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.506 ' O ' HG11 ' A' ' 56' ' ' VAL . 4.2 mttp -74.86 133.38 41.86 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.954 -1.091 . . . . 0.0 110.119 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.554 ' CG1' ' HA3' ' A' ' 78' ' ' GLY . 33.2 m -144.57 166.77 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.255 -0.903 . . . . 0.0 109.773 179.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.51 ' O ' HD22 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -111.31 172.8 6.67 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.828 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.51 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 37.1 tt0 -135.02 102.82 5.34 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.839 -1.163 . . . . 0.0 110.815 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 87.8 m-85 -91.31 123.0 34.41 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.49 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -96.37 145.82 25.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 110.463 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.49 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.8 OUTLIER 75.96 64.51 0.05 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.65 -0.656 . . . . 0.0 110.147 179.425 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.533 HD11 ' CD1' ' A' ' 38' ' ' LEU . 15.2 mm -124.13 119.91 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.331 -0.855 . . . . 0.0 109.473 179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.542 HD22 ' CG ' ' A' ' 70' ' ' LYS . 3.2 tm? -69.85 94.81 0.86 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.665 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.539 ' CD1' HD13 ' A' ' 66' ' ' ILE . 9.5 tt -96.62 119.2 44.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.1 tt0 -89.7 103.38 16.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.004 -1.06 . . . . 0.0 109.899 -178.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.539 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.7 OUTLIER -96.76 116.18 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.199 -0.938 . . . . 0.0 109.821 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 62.32 17.13 9.11 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.809 -0.557 . . . . 0.0 110.683 178.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.33 6.73 55.16 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.745 -1.217 . . . . 0.0 110.409 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -104.64 133.79 48.89 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.186 -1.184 . . . . 0.0 109.196 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -76.09 130.95 39.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.966 . . . . 0.0 109.042 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.464 ' O ' HG23 ' A' ' 64' ' ' ILE . . . -150.06 97.96 2.64 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.453 -0.78 . . . . 0.0 110.465 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.541 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -79.03 137.15 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.642 -1.286 . . . . 0.0 107.883 178.791 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.483 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -157.93 -167.88 19.49 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.536 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 31' ' ' THR . 26.0 m -97.7 102.08 13.75 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.533 -0.981 . . . . 0.0 109.516 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.509 ' HA ' ' OG1' ' A' ' 31' ' ' THR . 0.8 OUTLIER -91.47 173.91 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.265 -0.897 . . . . 0.0 109.357 179.727 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.639 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -132.54 163.3 29.16 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 179.557 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.57 HG22 ' CE2' ' A' ' 59' ' ' TYR . 2.2 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 120.948 -1.095 . . . . 0.0 110.457 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.554 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -139.82 -169.53 11.67 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.493 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 47.27 2.49 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.551 2.167 . . . . 0.0 110.791 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.494 HG22 ' O ' ' A' ' 82' ' ' VAL . 14.8 t -91.02 139.87 25.9 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.147 -0.971 . . . . 0.0 109.133 179.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.34 19.51 0.93 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.696 2.264 . . . . 0.0 112.646 -178.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.542 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 1.2 t -160.24 171.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.415 -1.428 . . . . 0.0 110.396 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.542 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 74.0 m-20 -104.9 83.74 2.04 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.54 ' CG1' HG11 ' A' ' 32' ' ' VAL . 7.7 mm -75.74 113.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.461 -0.775 . . . . 0.0 111.712 -176.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.528 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -93.92 94.09 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.84 -172.25 41.41 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.797 -1.19 . . . . 0.0 111.589 -177.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 88' ' ' ASN . 1.2 mtt-85 -56.69 -36.05 69.17 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.957 -0.731 . . . . 0.0 110.38 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.555 ' ND2' HD21 ' A' ' 89' ' ' LEU . 5.8 p-10 -43.39 -40.45 3.7 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.057 -1.027 . . . . 0.0 109.15 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.555 HD21 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -94.53 -30.04 14.6 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.318 -0.864 . . . . 0.0 111.02 -179.299 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.486 ' O ' ' CB ' ' A' ' 95' ' ' ALA . 28.2 mt -65.99 -6.83 13.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.533 -1.354 . . . . 0.0 109.795 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.568 HG22 ' CG ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -101.42 -15.0 17.33 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.978 -1.076 . . . . 0.0 109.101 179.743 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.486 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -80.0 -41.15 26.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.577 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.567 HD11 ' CG ' ' B' ' 99' ' ' PHE . 4.5 pt -82.71 5.49 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.955 . . . . 0.0 108.756 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.52 41.64 35.67 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.876 -1.289 . . . . 0.0 109.876 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -81.81 137.8 35.23 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 120.882 -1.363 . . . . 0.0 110.09 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.422 ' CG2' HG22 ' B' ' 4' ' ' THR . 11.2 p -136.6 130.38 32.23 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.594 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 1.9 mp -88.26 92.16 9.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.747 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.8 m120 -95.35 123.42 38.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.095 -1.003 . . . . 0.0 109.407 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.604 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 117.93 -1.034 . . . . 0.0 109.529 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.604 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.498 1.778 0 N-CA-C 110.326 -0.682 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.499 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -85.01 131.6 34.45 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.262 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 16.5 t -127.37 127.76 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.851 -1.156 . . . . 0.0 110.859 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.422 HG22 ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER -149.44 25.78 0.86 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -82.47 45.07 0.93 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.705 -0.622 . . . . 0.0 110.94 -178.135 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.568 ' CG ' HG22 ' A' ' 91' ' ' THR . 13.8 m95 18.84 51.7 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.177 0.513 . . . . 0.0 111.214 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.531 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.5 OUTLIER -141.53 -168.5 2.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.982 -1.074 . . . . 0.0 110.336 -179.224 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.406 ' HG2' ' OD1' ' A' ' 29' ' ' ASP . 0.2 OUTLIER -91.76 128.94 44.13 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.399 -0.813 . . . . 0.0 109.148 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.506 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.3 Cg_endo -76.52 72.83 5.41 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.305 2.003 . . . . 0.0 109.879 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' B' ' 21' ' ' GLU . 3.2 mt -95.68 134.75 38.23 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.753 -1.217 . . . . 0.0 109.936 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.466 HG21 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -140.44 154.71 22.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.09 102.78 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 178.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.571 ' CG2' ' CB ' ' B' ' 22' ' ' ALA . 1.7 pp -87.64 148.68 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.466 -0.772 . . . . 0.0 109.649 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.507 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 16.8 ttmt -117.38 107.88 14.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.399 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.537 ' CG2' HD23 ' B' ' 38' ' ' LEU . 0.9 OUTLIER -117.39 125.26 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.151 -0.968 . . . . 0.0 109.647 -179.6 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.36 14.29 68.87 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 6.71 69.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.507 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.2 mt-30 -97.83 167.55 10.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.324 -1.103 . . . . 0.0 108.839 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.437 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 16.2 mt -131.99 129.73 40.52 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.122 -0.986 . . . . 0.0 111.164 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.576 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -149.79 168.61 23.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 177.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.546 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 7.2 pt-20 -78.3 -166.09 0.78 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.571 ' CB ' ' CG2' ' B' ' 13' ' ' ILE . . . -168.8 109.84 0.5 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.844 -1.16 . . . . 0.0 109.955 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.558 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.1 tp -83.76 93.66 8.0 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.458 -0.777 . . . . 0.0 109.181 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.539 HD21 ' CG2' ' B' ' 85' ' ' ILE . 26.7 mt -44.63 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.558 ' N ' ' O ' ' B' ' 23' ' ' LEU . 7.5 t0 -99.01 81.78 2.64 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.583 -0.698 . . . . 0.0 109.897 -178.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.533 ' CG2' ' HD3' ' B' ' 87' ' ' ARG . 10.6 m -58.6 -17.27 20.53 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.491 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.26 -43.98 96.2 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . 0.476 ' HB1' ' OD2' ' B' ' 25' ' ' ASP . . . -72.31 169.33 16.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.133 -1.216 . . . . 0.0 108.852 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.47 ' OD1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -100.31 -20.37 15.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 110.217 -179.198 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.517 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 4.8 m-20 -132.9 -166.88 1.82 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.994 -1.066 . . . . 0.0 110.206 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.598 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 9.0 m -107.02 89.3 2.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.816 -1.178 . . . . 0.0 111.397 -177.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.573 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.6 OUTLIER -68.63 160.45 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.347 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.598 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.1 OUTLIER -157.83 133.92 9.39 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.759 -1.213 . . . . 0.0 111.394 -177.741 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.493 ' HA ' HG21 ' B' ' 80' ' ' THR . 15.1 tp10 -42.34 141.88 0.88 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.466 ' HA ' HG13 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -41.07 150.47 0.08 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.462 -0.774 . . . . 0.0 110.252 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.507 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -170.66 -175.87 1.94 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 11.1 t -109.48 101.76 10.68 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.826 -1.171 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.603 HD11 ' CD1' ' B' ' 59' ' ' TYR . 6.2 mt -97.08 170.25 7.55 Favored Pre-proline 0 N--CA 1.489 1.482 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.576 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.0 Cg_endo -76.06 68.31 6.61 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.407 2.071 . . . . 0.0 112.537 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 32.75 -157.27 0.01 OUTLIER Glycine 0 N--CA 1.498 2.771 0 CA-C-O 121.918 0.732 . . . . 0.0 111.594 178.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 54.31 81.91 0.1 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.312 -1.11 . . . . 0.0 109.213 -179.711 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.537 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 58.0 p-90 -155.84 -176.19 5.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.531 -0.73 . . . . 0.0 109.581 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -141.09 159.52 61.35 Favored Pre-proline 0 N--CA 1.489 1.496 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.93 139.94 12.4 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 C-N-CA 122.249 1.966 . . . . 0.0 110.998 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.536 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -148.38 118.63 7.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.401 -0.812 . . . . 0.0 108.977 179.543 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -96.24 129.57 43.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.05 -1.031 . . . . 0.0 109.557 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.528 ' CG1' HG12 ' B' ' 54' ' ' ILE . 41.0 pt -117.14 132.0 68.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.099 179.01 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.94 100.97 0.84 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 107.976 -2.049 . . . . 0.0 107.976 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -118.61 -125.87 3.51 Favored Glycine 0 N--CA 1.483 1.804 0 C-N-CA 119.184 -1.484 . . . . 0.0 111.038 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.506 ' O ' ' O ' ' A' ' 50' ' ' ILE . 52.9 mt -84.56 121.41 36.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.568 -0.96 . . . . 0.0 112.981 -177.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.486 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 100.74 -36.8 3.92 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.172 177.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 169.86 -154.83 24.2 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.553 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.614 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.5 OUTLIER -120.4 140.76 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.53 -0.983 . . . . 0.0 109.718 -179.659 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.528 HG12 ' CG1' ' B' ' 47' ' ' ILE . 12.5 pt -124.33 132.07 71.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.311 -0.868 . . . . 0.0 108.976 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.484 ' O ' ' HD3' ' B' ' 79' ' ' PRO . 15.2 mttt -77.45 140.3 39.82 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.047 -1.033 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.544 ' CG1' ' HA3' ' B' ' 78' ' ' GLY . 15.0 m -138.56 175.07 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 109.956 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.426 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 18.4 mtt-85 -124.86 102.35 7.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.501 -0.749 . . . . 0.0 109.054 179.622 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.553 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.7 OUTLIER -60.28 94.75 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.47 -0.769 . . . . 0.0 110.772 -179.653 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.603 ' CD1' HD11 ' B' ' 38' ' ' LEU . 29.9 m-85 -89.88 114.4 26.17 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.556 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -93.47 143.18 26.53 Favored 'General case' 0 C--N 1.296 -1.748 0 O-C-N 120.912 -1.117 . . . . 0.0 110.337 -178.83 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.556 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 73.18 63.08 0.1 Allowed 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.368 0.604 . . . . 0.0 110.54 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.536 ' HB ' ' CG2' ' B' ' 75' ' ' VAL . 8.1 mm -120.53 110.76 29.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 178.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.505 ' N ' HD11 ' B' ' 72' ' ' ILE . 0.0 OUTLIER -63.15 87.41 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.033 -1.042 . . . . 0.0 110.768 -178.515 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.565 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 8.0 tt -89.85 122.36 41.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.471 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 1.2 tt0 -90.0 116.96 28.44 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.995 -1.066 . . . . 0.0 109.108 -179.316 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.567 HG13 HG23 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -111.63 131.65 62.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.277 -0.889 . . . . 0.0 109.351 -179.813 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.3 m 45.27 58.95 3.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.642 -0.661 . . . . 0.0 110.856 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.471 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 53.07 31.19 40.07 Favored Glycine 0 N--CA 1.495 2.598 0 C-N-CA 120.163 -1.017 . . . . 0.0 110.865 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -132.62 142.71 49.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.337 . . . . 0.0 109.453 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.482 ' HG3' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -75.44 138.15 41.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 109.809 -179.683 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -159.03 98.71 1.48 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.955 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.505 HD11 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.01 159.96 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.798 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.55 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 177.18 -171.8 44.64 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.029 -2.034 . . . . 0.0 112.335 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.553 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 5.9 m -95.47 106.64 18.73 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.809 -0.818 . . . . 0.0 110.475 -179.353 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' B' ' 62' ' ' ILE . 1.6 t -98.11 108.81 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.627 -0.67 . . . . 0.0 110.618 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.573 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -80.95 125.32 29.99 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.041 -1.037 . . . . 0.0 108.549 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.538 ' CG2' HD13 ' B' ' 38' ' ' LEU . 1.4 t -104.18 111.3 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.224 -0.922 . . . . 0.0 110.054 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.544 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -145.27 -171.56 15.03 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 179.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' B' ' 55' ' ' LYS . 35.3 Cg_endo -79.91 43.13 1.44 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.502 2.134 . . . . 0.0 111.091 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.519 ' HB ' ' CD1' ' B' ' 54' ' ' ILE . 2.9 t -89.03 138.29 29.2 Favored Pre-proline 0 N--CA 1.488 1.433 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.453 ' O ' ' CG2' ' B' ' 82' ' ' VAL . 37.5 Cg_endo -80.42 21.78 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.508 2.139 . . . . 0.0 111.328 -178.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.8 t -161.32 161.1 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.623 -1.298 . . . . 0.0 111.029 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 1.9 m-80 -90.77 88.78 7.21 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.535 ' CG1' HG11 ' B' ' 32' ' ' VAL . 5.8 mm -78.85 118.93 27.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.041 -1.037 . . . . 0.0 111.422 -176.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.539 ' CG2' HD21 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -102.04 99.74 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 177.847 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.517 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -85.37 -163.08 36.83 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.871 -1.143 . . . . 0.0 110.704 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.533 ' HD3' ' CG2' ' B' ' 26' ' ' THR . 7.5 mmm180 -63.65 -29.03 70.32 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.653 -0.91 . . . . 0.0 110.113 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.559 ' ND2' HD21 ' B' ' 89' ' ' LEU . 10.8 p-10 -52.53 -40.06 62.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.673 -1.267 . . . . 0.0 109.237 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.559 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.3 mm? -96.04 -15.86 21.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.904 -179.056 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.522 ' O ' ' CB ' ' B' ' 95' ' ' ALA . 34.4 mt -85.18 -4.18 59.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.866 -1.146 . . . . 0.0 108.827 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.604 ' HB ' ' CD2' ' A' ' 6' ' ' TRP . 68.9 p -101.83 -13.93 17.48 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.324 -0.86 . . . . 0.0 108.748 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.525 ' NE2' ' O ' ' B' ' 88' ' ' ASN . 33.0 mt-30 -87.0 -36.44 18.24 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.41 -0.806 . . . . 0.0 109.281 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.539 HD13 ' CD2' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -85.38 4.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.803 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 78.48 31.07 47.12 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.041 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -74.15 132.79 42.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.336 . . . . 0.0 110.353 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 17.1 p -140.81 129.44 22.81 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.594 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 6.3 mp -86.04 94.46 9.24 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.329 -0.857 . . . . 0.0 109.312 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.548 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -96.26 122.63 39.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.112 -0.992 . . . . 0.0 109.207 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.578 ' CE1' ' O ' ' A' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.421 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.487 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.493 1.476 0 N-CA-C 109.884 -0.852 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.449 ' HG2' ' N ' ' A' ' 3' ' ' VAL . 1.2 tt0 -84.29 141.04 31.22 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.553 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 10.8 t -135.68 112.66 13.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.464 -1.397 . . . . 0.0 110.071 -178.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.496 ' O ' ' HG ' ' A' ' 5' ' ' LEU . 0.5 OUTLIER -128.3 -78.5 0.57 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.856 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.4 OUTLIER 34.94 37.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.802 -0.562 . . . . 0.0 110.268 179.983 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' A' ' 5' ' ' LEU . 43.7 m0 16.1 53.77 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 121.065 0.459 . . . . 0.0 112.204 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.6 mm-40 -156.35 -174.84 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.992 -1.067 . . . . 0.0 109.937 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -68.43 115.33 28.63 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.265 -0.897 . . . . 0.0 109.402 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.553 ' HB3' ' CG1' ' A' ' 3' ' ' VAL . 34.4 Cg_endo -77.15 72.68 5.79 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.12 1.88 . . . . 0.0 110.359 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.56 HD22 ' CB ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -81.76 152.77 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -0.887 . . . . 0.0 108.998 179.715 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.55 HG22 ' CG2' ' A' ' 13' ' ' ILE . 26.9 m -139.07 129.16 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.166 -0.959 . . . . 0.0 110.38 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.4 m -67.74 92.01 0.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 178.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' HG22 ' A' ' 11' ' ' VAL . 3.0 pt -88.74 147.21 5.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.462 -0.774 . . . . 0.0 110.886 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.9 tttt -109.11 100.37 9.55 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.018 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.528 ' CD1' HD23 ' A' ' 33' ' ' LEU . 3.4 mt -117.17 136.16 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.87 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' A' ' 18' ' ' GLN . . . 63.34 25.07 68.1 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.8 17.78 79.92 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 15.3 mp0 -123.75 -174.67 3.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -1.158 . . . . 0.0 108.919 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.482 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 44.0 mt -137.97 135.48 36.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.137 -0.977 . . . . 0.0 110.06 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.611 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -148.97 148.69 30.07 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.56 ' CB ' HD22 ' A' ' 10' ' ' LEU . 3.6 mm-40 -78.61 109.06 12.48 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.947 -1.095 . . . . 0.0 109.295 -179.338 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.603 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -95.05 116.95 29.35 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 122.02 0.914 . . . . 0.0 111.265 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 8.3 tp -72.46 103.09 3.37 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.553 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 20.1 mt -46.65 131.03 11.54 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.105 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.52 ' HB2' ' CG2' ' A' ' 84' ' ' ILE . 3.6 t70 -139.34 86.57 2.13 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.167 -0.958 . . . . 0.0 111.091 -177.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.564 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 1.5 m -65.64 -11.64 46.42 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.97 -1.081 . . . . 0.0 108.4 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.452 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -72.74 -44.7 37.9 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.061 -1.616 . . . . 0.0 109.061 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.49 157.79 36.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -1.162 . . . . 0.0 108.936 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -99.18 -9.5 23.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.036 . . . . 0.0 110.226 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.515 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -138.57 177.93 7.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.944 -1.098 . . . . 0.0 110.297 -179.428 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 37.6 m -101.78 102.23 12.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.036 -1.04 . . . . 0.0 109.44 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.545 ' CG1' ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -97.11 115.42 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.353 -0.842 . . . . 0.0 109.88 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.528 HD23 ' CD1' ' A' ' 15' ' ' ILE . 6.6 mp -106.52 123.13 47.62 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.309 -0.869 . . . . 0.0 109.767 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.56 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 3.0 pt-20 -43.09 165.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 108.915 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.523 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.5 tt0 -42.7 137.48 2.22 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 110.067 -179.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.0 ppp? -153.78 -162.33 1.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.565 -0.709 . . . . 0.0 109.372 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.518 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 11.7 t -106.2 100.93 10.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 110.275 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.57 HD21 ' CD2' ' A' ' 59' ' ' TYR . 1.4 tp -127.95 149.65 71.4 Favored Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.488 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.5 Cg_endo -73.97 -156.17 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.583 2.189 . . . . 0.0 110.609 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -93.01 -155.6 32.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.501 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 72.7 43.77 0.42 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.649 -0.912 . . . . 0.0 108.893 -179.557 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.624 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 29.8 p-90 -132.22 178.21 6.98 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.8 0.809 . . . . 0.0 110.328 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.446 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 1.4 mmtp -139.12 150.99 66.76 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.25 138.67 20.37 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 122.031 1.821 . . . . 0.0 110.233 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.519 ' CG ' ' N ' ' A' ' 46' ' ' MET . 0.0 OUTLIER -147.56 167.36 24.72 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.673 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.519 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 9.1 mtp -143.56 128.28 18.23 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.108 -0.995 . . . . 0.0 108.435 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.523 HG13 HG12 ' A' ' 54' ' ' ILE . 2.1 pt -106.78 141.18 22.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.881 -1.137 . . . . 0.0 109.388 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.84 96.29 0.65 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.23 -128.43 3.76 Favored Glycine 0 N--CA 1.481 1.659 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.854 -178.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.506 ' O ' ' O ' ' B' ' 50' ' ' ILE . 42.5 mt -81.2 118.22 28.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.775 -0.838 . . . . 0.0 112.511 -177.487 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.16 -42.61 1.87 Allowed Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.428 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 167.43 -157.98 30.63 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 120.875 -1.368 . . . . 0.0 110.068 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.614 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -114.62 140.6 48.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.436 -1.038 . . . . 0.0 109.784 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.554 ' CG2' HG21 ' B' ' 50' ' ' ILE . 0.9 OUTLIER -116.51 179.53 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.251 -0.906 . . . . 0.0 108.703 179.039 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 10.0 mttm -115.02 141.24 48.26 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.17 -0.957 . . . . 0.0 108.545 179.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 4.5 m -144.52 172.1 5.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.941 -1.1 . . . . 0.0 110.641 -178.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.9 mtt180 -118.96 98.37 6.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.497 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 3.3 tt0 -59.18 91.91 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.125 -0.984 . . . . 0.0 110.155 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.624 ' CD1' ' HB3' ' A' ' 42' ' ' TRP . 13.6 m-85 -88.5 92.73 9.29 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 178.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.413 ' C ' ' HG2' ' A' ' 61' ' ' GLN . 7.3 m-20 -78.79 143.37 36.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 110.811 -178.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.557 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.4 mm100 69.44 67.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-O 121.51 0.672 . . . . 0.0 109.6 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.493 HG13 ' HB3' ' A' ' 59' ' ' TYR . 1.2 mm -126.97 111.48 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.528 HD12 ' N ' ' A' ' 64' ' ' ILE . 3.3 tm? -50.97 143.27 10.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.163 -0.96 . . . . 0.0 109.469 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.551 ' CD1' HD12 ' A' ' 66' ' ' ILE . 6.9 tt -150.79 113.89 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 36.8 tt0 -89.02 102.86 15.51 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.815 -1.178 . . . . 0.0 108.753 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.551 HD12 ' CD1' ' A' ' 64' ' ' ILE . 0.8 OUTLIER -96.89 112.84 29.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-O 121.852 0.834 . . . . 0.0 108.908 -179.652 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 0.1 OUTLIER 71.13 -84.01 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.32 28.2 0.88 Allowed Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -129.68 128.49 42.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -1.112 . . . . 0.0 109.328 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.486 ' HG2' HD22 ' A' ' 63' ' ' LEU . 1.0 OUTLIER -78.79 136.28 37.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.754 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.502 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -151.94 131.81 13.31 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -0.995 . . . . 0.0 110.681 -179.045 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.557 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -95.39 148.1 5.39 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 177.848 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.421 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -166.39 -171.53 32.63 Favored Glycine 0 N--CA 1.49 2.295 0 C-N-CA 118.401 -1.857 . . . . 0.0 111.48 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.497 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 63.9 m -102.81 105.2 15.56 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.436 -1.038 . . . . 0.0 110.205 -179.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.507 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -91.36 167.49 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.586 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.495 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.1 mp -139.52 107.44 5.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.934 -1.104 . . . . 0.0 108.367 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.523 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 31.9 t -88.37 114.04 26.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 -178.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -150.41 -171.34 18.6 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.51 40.16 0.94 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.588 2.192 . . . . 0.0 111.183 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.56 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.7 t -82.9 142.3 44.79 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.411 ' O ' HG21 ' A' ' 82' ' ' VAL . 37.4 Cg_endo -79.32 16.3 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.421 2.08 . . . . 0.0 111.356 -178.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.614 HG11 ' CG1' ' A' ' 84' ' ' ILE . 2.8 t -161.44 160.43 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.828 -1.17 . . . . 0.0 110.983 -178.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.611 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 82.5 m-20 -94.35 143.55 26.3 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 103.053 -2.943 . . . . 0.0 103.053 174.408 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.614 ' CG1' HG11 ' A' ' 82' ' ' VAL . 18.4 mt -146.91 135.12 15.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 O-C-N 119.295 -2.128 . . . . 0.0 112.562 -176.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.59 ' CD1' ' CB ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.91 107.34 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.05 -167.4 43.47 Favored Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.089 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.521 ' CZ ' ' O ' ' B' ' 5' ' ' LEU . 1.9 mmm180 -60.05 -31.71 70.24 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.408 -1.054 . . . . 0.0 109.173 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.566 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 14.1 p-10 -54.58 -28.47 46.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 110.53 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.566 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.6 mm? -104.57 -29.12 10.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.83 -1.169 . . . . 0.0 110.062 -179.096 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.564 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.3 mt -71.36 -5.59 33.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.992 -1.068 . . . . 0.0 108.982 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 87' ' ' ARG . 70.0 p -101.38 -20.91 14.98 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.143 -0.973 . . . . 0.0 109.327 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 42.9 mm-40 -81.52 -40.35 23.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 109.061 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.58 HD11 ' CD2' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -80.13 -2.93 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.202 -0.936 . . . . 0.0 108.655 178.821 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 78.17 30.46 50.62 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.559 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -65.84 136.4 56.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.805 -1.409 . . . . 0.0 109.049 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 81.5 p -131.14 125.4 32.95 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.562 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 1.7 mp -84.5 93.91 8.43 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.525 0.679 . . . . 0.0 110.108 -178.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.496 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.5 m120 -108.37 130.52 55.21 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.531 ' HB2' ' HB ' ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 117.949 -1.024 . . . . 0.0 109.09 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.433 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.565 0 N-CA-C 109.989 -0.812 . . . . 0.0 109.989 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.537 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tt0 -83.96 149.38 26.35 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.059 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.537 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 6.7 t -150.25 117.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 120.665 -1.272 . . . . 0.0 109.582 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.592 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.9 OUTLIER -108.62 13.34 25.28 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.552 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.521 ' O ' ' CZ ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -26.53 84.32 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 121.641 0.734 . . . . 0.0 111.25 -179.037 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.592 ' N ' ' O ' ' B' ' 4' ' ' THR . 16.1 m95 -53.48 -16.67 1.56 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.433 ' O ' ' HG3' ' A' ' 87' ' ' ARG . 30.7 mt-30 -109.42 -106.52 0.35 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.157 -0.964 . . . . 0.0 109.602 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -111.22 120.56 42.76 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 120.945 -1.097 . . . . 0.0 110.705 -179.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.472 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 37.3 Cg_endo -80.45 62.02 8.4 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.268 1.979 . . . . 0.0 109.692 177.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 1.6 mt -81.66 148.85 28.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.076 -1.015 . . . . 0.0 110.327 -179.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.554 HG23 ' CB ' ' B' ' 22' ' ' ALA . 5.2 m -141.46 142.69 28.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.448 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 14.4 m -81.92 96.74 7.77 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.591 HG22 ' CB ' ' B' ' 22' ' ' ALA . 10.3 pt -84.3 152.41 3.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.227 -0.921 . . . . 0.0 110.41 -178.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.441 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -118.01 101.74 8.49 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.208 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.571 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 40.6 mt -105.8 127.14 61.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.07 -1.018 . . . . 0.0 109.515 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.8 -86.16 0.36 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.606 -1.798 . . . . 0.0 108.606 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.76 25.6 0.32 Allowed Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.039 -2.025 . . . . 0.0 108.039 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -121.0 171.01 8.95 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.739 -0.859 . . . . 0.0 108.749 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.452 HD21 ' O ' ' B' ' 13' ' ' ILE . 14.4 mt -134.28 130.72 37.49 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.296 -0.877 . . . . 0.0 109.924 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -139.99 166.99 23.16 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 179.628 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.574 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.6 mt-10 -78.73 -179.94 6.81 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.688 -1.257 . . . . 0.0 107.876 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.591 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -158.03 105.26 1.94 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.816 -1.178 . . . . 0.0 110.821 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.507 ' O ' ' N ' ' B' ' 25' ' ' ASP . 25.5 tp -77.35 95.52 4.42 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' B' ' 23' ' ' LEU . 0.2 OUTLIER -40.44 97.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.607 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 12.0 t0 -102.57 76.58 1.54 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.443 -0.785 . . . . 0.0 110.707 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.557 ' HA ' ' CD2' ' B' ' 90' ' ' LEU . 2.7 m -62.91 -11.19 16.81 Favored 'General case' 0 C--N 1.297 -1.679 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.118 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -79.59 -38.77 19.79 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.04 158.51 36.37 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.093 -1.239 . . . . 0.0 109.065 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -90.68 -11.5 39.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.972 -1.08 . . . . 0.0 110.437 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.514 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -138.88 -164.2 1.61 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.889 -1.132 . . . . 0.0 109.988 -179.646 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.564 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 16.8 m -115.67 92.76 4.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.927 -1.108 . . . . 0.0 109.718 -179.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.591 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -69.64 174.19 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.087 -1.008 . . . . 0.0 109.299 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.605 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.0 OUTLIER -171.31 123.25 0.57 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.792 -1.192 . . . . 0.0 110.811 -178.531 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.532 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 0.6 OUTLIER -42.85 159.75 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.232 -0.917 . . . . 0.0 108.774 178.381 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.408 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -50.61 148.15 4.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.9 -1.125 . . . . 0.0 110.475 -179.284 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.4 ptm -155.12 -164.53 1.8 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.516 ' N ' ' HG3' ' B' ' 36' ' ' MET . 3.9 t -105.08 67.27 0.78 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.865 -1.147 . . . . 0.0 110.116 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.583 HD11 ' CD1' ' B' ' 59' ' ' TYR . 11.6 mt -85.1 168.71 19.12 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.033 . . . . 0.0 108.726 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.6 Cg_endo -71.59 -162.52 0.11 Allowed 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.142 1.895 . . . . 0.0 111.374 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.96 29.93 8.85 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -178.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -107.94 46.12 0.97 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.655 ' CD1' ' CZ ' ' B' ' 59' ' ' TYR . 29.9 p-90 -117.73 -179.92 3.88 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.817 0.818 . . . . 0.0 110.356 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -134.27 134.12 22.41 Favored Pre-proline 0 C--N 1.3 -1.556 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.76 135.43 17.7 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 121.779 1.653 . . . . 0.0 110.414 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.463 ' HG2' ' CG2' ' B' ' 56' ' ' VAL . 16.2 ptmt -160.09 -165.91 1.58 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.559 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.553 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 4.3 mtp -146.56 124.7 12.14 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.451 -179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.503 HD13 ' CG2' ' A' ' 50' ' ' ILE . 2.8 pt -89.48 143.23 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.25 113.51 2.64 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.65 -123.99 2.18 Favored Glycine 0 N--CA 1.481 1.7 0 C-N-CA 119.52 -1.324 . . . . 0.0 110.213 -179.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.554 HG21 ' CG2' ' A' ' 54' ' ' ILE . 28.3 mt -91.22 134.82 28.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.694 -0.886 . . . . 0.0 111.968 -178.001 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.466 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 87.47 -29.78 5.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.427 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 156.12 -160.08 29.84 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.011 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -120.67 133.32 55.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.498 -1.001 . . . . 0.0 109.118 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.536 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 15.6 pt -110.66 141.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 120.941 -1.099 . . . . 0.0 109.774 -179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.553 ' HG3' ' CG ' ' B' ' 46' ' ' MET . 0.0 OUTLIER -65.21 154.23 38.68 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 179.792 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 19.8 m -151.13 -167.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.973 . . . . 0.0 110.005 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -145.03 96.25 2.82 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.562 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 11.3 tt0 -61.83 107.9 0.92 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 110.533 -179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.655 ' CZ ' ' CD1' ' B' ' 42' ' ' TRP . 29.2 m-85 -102.3 95.18 6.12 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.485 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -79.13 141.61 37.12 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.829 -1.17 . . . . 0.0 109.994 -179.589 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.485 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 75.01 59.25 0.06 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.695 -0.628 . . . . 0.0 110.055 179.706 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.587 ' CB ' HG22 ' B' ' 75' ' ' VAL . 5.8 mm -121.35 121.5 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.271 -0.893 . . . . 0.0 108.984 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.53 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 1.4 tm? -68.54 91.4 0.41 Allowed 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.138 -0.976 . . . . 0.0 110.503 -179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 10.8 tt -97.75 120.33 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.529 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.6 tt0 -88.32 148.56 24.23 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.044 -1.035 . . . . 0.0 108.557 -179.257 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.556 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.2 mp -147.48 132.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.086 -1.009 . . . . 0.0 109.717 -179.186 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.411 ' C ' ' O ' ' B' ' 66' ' ' ILE . 54.7 m 42.79 37.9 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.533 -0.729 . . . . 0.0 109.723 179.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.77 48.1 51.41 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -145.71 114.42 6.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.204 -1.174 . . . . 0.0 109.445 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.506 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.8 OUTLIER -56.75 130.85 47.28 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.619 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.551 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -151.8 101.19 2.74 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 110.369 -179.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' B' ' 62' ' ' ILE . 0.7 OUTLIER -80.08 157.2 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.016 -1.052 . . . . 0.0 108.583 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.552 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 175.88 -166.33 37.5 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.908 -1.615 . . . . 0.0 111.632 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.562 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 16.8 m -98.03 104.86 16.93 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.528 -0.983 . . . . 0.0 110.595 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.605 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.16 109.41 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.344 -0.848 . . . . 0.0 110.255 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.591 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -80.32 124.27 28.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.181 -0.949 . . . . 0.0 108.944 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.525 ' CG2' HD11 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -106.86 125.95 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 109.784 -179.893 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -159.42 -167.21 19.76 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.475 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.8 Cg_endo -81.71 54.87 5.28 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.795 2.33 . . . . 0.0 109.916 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.532 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 6.3 t -97.57 138.43 21.1 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.267 -0.896 . . . . 0.0 108.93 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.1 Cg_endo -80.06 16.55 1.47 Allowed 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.482 2.121 . . . . 0.0 110.71 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.478 HG12 ' O ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -161.24 172.45 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.016 -1.053 . . . . 0.0 110.206 -179.576 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.574 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 68.6 m-80 -105.03 147.76 27.49 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 104.652 -2.351 . . . . 0.0 104.652 176.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.607 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 24.7 mm -133.64 120.2 36.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 O-C-N 120.282 -1.511 . . . . 0.0 111.194 -177.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.567 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 0.9 OUTLIER -102.14 91.9 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 177.997 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -100.12 170.57 22.72 Favored Glycine 0 N--CA 1.496 2.683 0 C-N-CA 119.748 -1.215 . . . . 0.0 112.344 -177.062 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.587 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 3.7 mmt180 -21.96 -41.37 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.566 ' ND2' HD21 ' B' ' 89' ' ' LEU . 12.0 p-10 -52.43 -43.05 64.63 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.121 -1.612 . . . . 0.0 110.486 -178.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.566 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -91.29 -19.96 22.4 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.685 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.587 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 2.2 mp -67.39 -15.22 63.56 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -86.9 -18.34 31.07 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.053 -1.029 . . . . 0.0 108.801 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -87.79 -40.34 14.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 1.3 pt -87.28 -2.51 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.362 -0.836 . . . . 0.0 109.143 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.6 35.76 81.65 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 179.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.475 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -63.04 145.06 56.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.949 -1.324 . . . . 0.0 110.936 -179.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.484 HG21 ' CG2' ' A' ' 4' ' ' THR . 20.4 p -150.42 126.98 10.83 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.562 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 6.9 mp -86.62 103.25 14.93 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.259 -0.901 . . . . 0.0 109.187 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 9.9 m120 -101.4 122.41 43.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.134 -0.979 . . . . 0.0 110.036 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.58 ' CD2' HD11 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.433 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.475 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.494 1.518 0 N-CA-C 110.551 -0.596 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.479 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 8.6 tt0 -83.75 126.29 32.76 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 177.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.4 t -118.14 108.35 24.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.875 -1.14 . . . . 0.0 109.81 -177.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.511 ' CG2' HG21 ' B' ' 96' ' ' THR . 0.0 OUTLIER -131.71 41.0 3.33 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.582 -0.699 . . . . 0.0 109.481 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -88.34 43.08 1.1 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.144 -0.973 . . . . 0.0 108.965 179.644 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.527 ' C ' ' O ' ' A' ' 5' ' ' LEU . 16.3 m0 18.13 50.64 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.237 0.541 . . . . 0.0 111.545 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 5.3 mt-30 -155.45 163.82 39.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -0.895 . . . . 0.0 109.518 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.462 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -54.19 119.25 18.98 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.322 179.894 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.462 ' HB2' HD13 ' A' ' 24' ' ' LEU . 36.8 Cg_endo -78.47 75.07 5.12 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.212 1.941 . . . . 0.0 110.769 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.594 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -79.52 164.94 23.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.052 -1.03 . . . . 0.0 108.68 179.587 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.479 HG22 HG23 ' A' ' 13' ' ' ILE . 30.7 m -149.29 127.78 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.052 -1.03 . . . . 0.0 110.296 -178.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.1 m -64.65 91.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 178.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.548 HG22 ' CB ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -79.7 149.7 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.505 -178.372 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 18.3 tttt -117.1 91.2 3.51 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.516 ' CD1' HG12 ' A' ' 75' ' ' VAL . 12.5 mt -114.65 139.93 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 O-C-N 121.208 -0.933 . . . . 0.0 109.959 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.499 ' N ' HG21 ' A' ' 15' ' ' ILE . . . 48.41 49.58 25.75 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 52.24 38.37 48.99 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.535 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.7 mm-40 -131.71 168.35 17.92 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -1.154 . . . . 0.0 109.065 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.414 ' O ' ' HG2' ' A' ' 20' ' ' LYS . 20.4 mt -137.57 128.94 28.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 0.0 109.592 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.414 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 47.0 mtmt -151.1 155.86 39.82 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.395 -0.816 . . . . 0.0 109.368 179.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.594 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 27.1 mp0 -79.83 106.52 11.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.975 . . . . 0.0 108.68 179.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.554 ' HB2' ' CD1' ' A' ' 85' ' ' ILE . . . -87.55 132.88 33.89 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.513 -0.742 . . . . 0.0 110.787 -178.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' A' ' 25' ' ' ASP . 6.0 tp -85.83 98.95 11.04 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.462 HD13 ' HB2' ' A' ' 9' ' ' PRO . 10.9 mt -45.52 97.34 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.103 -0.998 . . . . 0.0 108.522 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.547 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 8.7 t0 -100.33 90.3 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.471 -0.768 . . . . 0.0 110.503 -178.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.455 HG23 ' HG3' ' B' ' 9' ' ' PRO . 5.4 m -71.1 -16.49 62.57 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.983 -1.073 . . . . 0.0 108.93 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.432 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -70.07 -33.84 69.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.31 154.4 27.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.213 -1.169 . . . . 0.0 109.342 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -93.8 -12.98 27.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.195 -0.941 . . . . 0.0 109.831 -179.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -131.64 -175.19 3.63 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.163 -0.961 . . . . 0.0 109.406 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.513 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 5.9 m -110.72 87.88 2.64 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.789 -1.194 . . . . 0.0 109.808 -179.066 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.564 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -73.01 166.33 2.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.506 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.561 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.57 132.08 3.77 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.79 -1.194 . . . . 0.0 111.343 -177.853 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.51 ' N ' HG23 ' A' ' 80' ' ' THR . 11.3 tt0 -42.21 160.38 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.535 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.4 mt-10 -61.91 137.19 58.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.857 -1.152 . . . . 0.0 109.946 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.477 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -146.95 -164.01 1.89 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.414 -0.804 . . . . 0.0 109.503 179.632 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.1 t -96.73 112.26 24.09 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.123 -0.986 . . . . 0.0 110.39 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.634 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -133.49 -177.34 0.69 Allowed Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.342 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.531 ' HD2' ' CB ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -76.4 -179.71 5.56 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.051 1.834 . . . . 0.0 110.656 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.06 29.99 10.35 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -119.76 61.7 0.83 Allowed 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 179.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.62 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 11.4 p-90 -121.83 -172.76 2.5 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.537 0.684 . . . . 0.0 109.807 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.8 mtpm? -132.85 128.21 20.65 Favored Pre-proline 0 N--CA 1.49 1.568 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -76.36 138.06 19.45 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 121.929 1.753 . . . . 0.0 110.213 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.524 ' HE3' ' N ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -157.16 -179.04 7.82 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.731 179.872 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.498 ' HA ' ' O ' ' A' ' 54' ' ' ILE . 69.4 mtp -136.54 121.23 18.48 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.382 -0.824 . . . . 0.0 108.96 179.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 6.1 pt -88.56 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.565 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.538 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.68 98.0 0.75 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 -179.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.04 -132.29 3.88 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 119.805 -1.188 . . . . 0.0 110.509 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.549 ' CG2' HD12 ' B' ' 54' ' ' ILE . 21.6 mt -84.24 110.5 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.624 -0.927 . . . . 0.0 112.531 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.85 -13.59 17.31 Favored Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.843 177.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 134.27 -154.91 21.61 Favored Glycine 0 N--CA 1.49 2.271 0 C-N-CA 119.204 -1.474 . . . . 0.0 109.951 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.538 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 9.4 m-85 -116.3 127.45 54.71 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.574 -0.956 . . . . 0.0 110.255 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.498 ' O ' ' HA ' ' A' ' 46' ' ' MET . 15.8 pt -103.32 179.1 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.556 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -116.07 145.62 42.87 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.861 -1.15 . . . . 0.0 109.302 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.483 ' CG2' ' HE2' ' A' ' 45' ' ' LYS . 0.7 OUTLIER -146.49 -170.33 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.604 -1.31 . . . . 0.0 110.297 -179.843 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.8 mtm180 -133.8 94.29 3.25 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.524 ' N ' ' HE3' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -53.44 99.56 0.03 OUTLIER 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.38 -0.825 . . . . 0.0 110.217 -179.153 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.634 ' CZ ' ' HB3' ' A' ' 38' ' ' LEU . 22.6 m-85 -98.1 84.88 3.36 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 177.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.521 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -78.16 137.98 38.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 -177.604 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.521 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 51.5 mm-40 80.77 62.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 72' ' ' ILE . 8.0 mm -124.82 122.85 64.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.615 ' CD2' ' CG ' ' A' ' 70' ' ' LYS . 17.0 tp -74.4 87.19 2.03 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.109 -1.036 . . . . 0.0 111.755 -177.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.508 HD12 HD13 ' A' ' 66' ' ' ILE . 10.9 tt -87.23 120.26 36.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.527 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -89.48 111.68 22.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.143 -0.973 . . . . 0.0 109.474 -178.634 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.508 HD13 HD12 ' A' ' 64' ' ' ILE . 1.0 OUTLIER -106.7 125.95 62.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.102 -0.999 . . . . 0.0 109.879 -179.522 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.8 m 65.22 11.56 7.33 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.762 -0.586 . . . . 0.0 110.698 178.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.433 ' HA2' ' CD ' ' A' ' 65' ' ' GLU . . . 101.3 1.28 53.98 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.201 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -106.11 119.13 38.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.12 -1.223 . . . . 0.0 108.924 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.615 ' CG ' ' CD2' ' A' ' 63' ' ' LEU . 2.2 mptp? -63.06 139.75 58.8 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.187 -0.945 . . . . 0.0 109.415 -179.156 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.538 ' O ' ' HA ' ' A' ' 63' ' ' LEU . . . -151.27 143.12 23.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.307 -179.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.53 ' CG1' HD11 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -113.19 138.94 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.864 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -163.05 -159.12 10.2 Favored Glycine 0 N--CA 1.483 1.77 0 C-N-CA 119.208 -1.472 . . . . 0.0 110.213 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.505 ' CG2' ' OD1' ' A' ' 60' ' ' ASP . 2.2 m -100.1 108.16 20.23 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.769 -0.842 . . . . 0.0 110.05 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.516 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -106.6 107.01 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.154 -0.967 . . . . 0.0 109.927 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.564 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.3 mp -78.58 128.42 33.5 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.535 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -114.49 120.53 64.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.698 -179.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.417 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -157.0 -157.72 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.556 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -83.31 36.98 0.63 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.553 2.169 . . . . 0.0 110.758 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 34' ' ' GLU . 3.9 t -80.59 134.56 54.1 Favored Pre-proline 0 N--CA 1.489 1.513 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.465 ' O ' HG21 ' A' ' 82' ' ' VAL . 34.6 Cg_endo -77.4 18.59 0.79 Allowed 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.497 2.131 . . . . 0.0 111.825 -178.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.611 ' CG1' HG13 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.02 160.3 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 109.941 -179.804 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -99.88 85.99 3.19 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 177.06 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.611 HG13 ' CG1' ' A' ' 82' ' ' VAL . 2.3 mt -83.2 122.61 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 CA-C-O 121.805 0.812 . . . . 0.0 112.902 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.554 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -95.98 102.67 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 177.225 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -90.87 -162.03 37.87 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.82 -1.181 . . . . 0.0 111.478 -178.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.533 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -57.4 -40.05 77.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.754 -0.851 . . . . 0.0 110.472 -179.237 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.588 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 6.3 p-10 -42.41 -39.28 2.15 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.293 -0.879 . . . . 0.0 110.011 -179.554 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.588 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 0.9 OUTLIER -100.59 -22.01 15.1 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 121.001 -1.062 . . . . 0.0 110.276 -179.336 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.533 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 81.2 mt -74.67 -1.63 22.65 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.061 -1.024 . . . . 0.0 108.56 179.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.0 p -99.41 -18.65 17.38 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -83.03 -41.63 18.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.391 -0.818 . . . . 0.0 108.982 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.576 HD13 ' CG ' ' B' ' 99' ' ' PHE . 3.5 pt -86.87 -10.16 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.69 45.43 44.61 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.275 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.525 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -76.03 131.45 39.52 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.932 -1.334 . . . . 0.0 109.908 179.578 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 77.8 p -129.61 137.82 50.91 Favored 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.534 ' CD1' HD12 ' B' ' 97' ' ' LEU . 5.9 mp -89.51 120.18 30.6 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.962 -1.086 . . . . 0.0 110.529 -179.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -119.48 124.77 47.29 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.256 -0.903 . . . . 0.0 108.948 178.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.59 ' CD2' ' CD1' ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.531 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.601 0 N-CA-C 109.964 -0.822 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.494 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.7 tt0 -88.88 150.0 23.08 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.494 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 3.3 t -149.83 126.16 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.498 -1.376 . . . . 0.0 110.441 -179.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.542 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -130.98 -60.04 0.97 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.733 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.655 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER 34.34 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.944 -0.472 . . . . 0.0 110.852 179.529 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.542 ' N ' ' O ' ' B' ' 4' ' ' THR . 5.5 m95 18.02 42.66 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.655 ' N ' ' O ' ' B' ' 5' ' ' LEU . 6.9 mm100 -153.01 -114.81 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.193 -0.942 . . . . 0.0 108.718 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.512 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.1 mtp180 -112.45 141.07 24.52 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 120.23 -1.543 . . . . 0.0 109.195 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.468 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 37.0 Cg_endo -82.15 50.21 3.38 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.316 2.011 . . . . 0.0 109.529 178.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.541 HD21 ' HB3' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -78.43 137.48 38.0 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.197 -0.939 . . . . 0.0 108.943 -179.597 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.486 HG21 ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -134.15 178.97 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.453 -0.779 . . . . 0.0 109.996 -178.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 47.8 m -103.86 105.28 15.43 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.547 ' CD1' ' CG1' ' B' ' 15' ' ' ILE . 1.8 pp -96.17 155.37 3.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.518 -0.738 . . . . 0.0 109.862 -178.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.53 ' CB ' HD22 ' B' ' 19' ' ' LEU . 8.9 ttmt -122.91 100.14 6.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 110.503 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.697 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 1.0 OUTLIER -115.38 142.64 27.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.812 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 47.98 47.13 26.2 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.351 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 55.23 36.42 62.16 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.162 -1.199 . . . . 0.0 110.398 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.9 OUTLIER -130.7 166.61 20.36 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -1.216 . . . . 0.0 108.425 179.077 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.53 HD22 ' CB ' ' B' ' 14' ' ' LYS . 14.8 mt -143.23 125.28 15.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.078 -1.014 . . . . 0.0 111.409 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.488 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 1.0 OUTLIER -145.11 -170.97 3.55 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.875 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.549 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -82.45 -176.48 6.25 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.863 -1.148 . . . . 0.0 109.666 -179.846 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -163.28 91.49 0.7 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.1 -1.0 . . . . 0.0 110.89 -179.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.523 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 8.8 tp -68.04 93.44 0.43 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.631 -1.293 . . . . 0.0 109.658 179.315 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' B' ' 9' ' ' PRO . 69.8 mt -50.42 94.88 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.549 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 29.5 t0 -96.0 84.75 3.89 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.351 -0.843 . . . . 0.0 110.825 -178.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.416 ' CG2' HD11 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.51 -16.0 21.69 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.956 -1.09 . . . . 0.0 108.771 178.754 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -74.19 -38.85 45.98 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.28 162.76 27.89 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.198 -1.178 . . . . 0.0 109.318 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -101.01 -10.37 20.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.502 ' HA ' ' CG ' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -139.13 -172.57 3.37 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.134 -0.979 . . . . 0.0 110.322 -179.298 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 47.7 m -108.46 89.46 3.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.984 -1.072 . . . . 0.0 111.162 -178.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.521 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.4 OUTLIER -73.34 169.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.54 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.591 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -168.81 130.89 1.28 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.777 -1.202 . . . . 0.0 110.683 -179.026 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.552 ' N ' HG21 ' B' ' 80' ' ' THR . 6.0 pt-20 -46.67 170.81 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.276 -0.89 . . . . 0.0 108.693 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.541 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tt0 -60.42 138.1 58.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.145 -0.972 . . . . 0.0 110.064 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.521 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.6 ptm -147.05 -163.5 1.78 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.405 -0.809 . . . . 0.0 109.324 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.521 ' N ' ' HG3' ' B' ' 36' ' ' MET . 8.4 t -113.74 98.01 6.77 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -0.881 . . . . 0.0 110.099 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.608 HD13 ' CD2' ' B' ' 59' ' ' TYR . 27.1 mt -106.38 160.39 26.39 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.128 -0.983 . . . . 0.0 109.476 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.47 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.6 Cg_endo -77.94 65.28 8.3 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.732 2.288 . . . . 0.0 112.029 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 35.78 -157.37 0.01 OUTLIER Glycine 0 N--CA 1.498 2.813 0 O-C-N 121.442 -0.786 . . . . 0.0 111.239 178.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.495 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 63.25 60.28 1.19 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.513 -0.992 . . . . 0.0 109.237 -179.865 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.7 p-90 -139.08 -175.62 4.22 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' B' ' 43' ' ' LYS . 13.7 mmtm -143.3 136.83 14.18 Favored Pre-proline 0 N--CA 1.488 1.467 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.77 125.67 7.59 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.899 1.733 . . . . 0.0 111.403 -179.009 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.55 ' HE3' ' CD2' ' B' ' 76' ' ' LEU . 0.0 OUTLIER -162.74 149.93 13.31 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.607 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.454 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 1.8 mtp -110.04 148.0 32.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 0.0 110.414 -178.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.549 ' CG1' HG12 ' B' ' 54' ' ' ILE . 15.5 pt -90.68 155.67 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.486 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.87 106.03 1.24 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -136.12 -128.03 2.7 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.647 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.51 ' O ' ' O ' ' A' ' 50' ' ' ILE . 21.5 mt -87.91 127.46 41.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.614 -0.933 . . . . 0.0 112.683 -177.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 96.95 -20.75 49.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.05 -164.59 26.81 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.528 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 3.3 m-85 -105.64 125.74 51.34 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.391 -1.064 . . . . 0.0 109.701 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.549 HD12 ' CG2' ' A' ' 50' ' ' ILE . 23.1 pt -96.38 139.62 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.939 -1.1 . . . . 0.0 108.964 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -78.2 143.04 37.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.806 -1.184 . . . . 0.0 108.995 -179.905 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.532 HG21 ' NZ ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -149.3 -173.49 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.87 -1.144 . . . . 0.0 110.074 -179.482 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.407 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 2.6 mtm-85 -121.28 96.08 4.94 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.462 ' HG3' HG22 ' B' ' 74' ' ' THR . 1.8 tt0 -60.38 100.18 0.09 Allowed 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.329 -0.857 . . . . 0.0 109.846 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.608 ' CD2' HD13 ' B' ' 38' ' ' LEU . 22.3 m-85 -96.31 94.59 7.55 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -78.78 140.01 38.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.894 -1.129 . . . . 0.0 110.626 -178.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.516 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.3 OUTLIER 69.17 64.89 0.28 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.714 -0.616 . . . . 0.0 110.309 179.255 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.697 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 0.7 OUTLIER -123.82 113.12 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.188 -0.945 . . . . 0.0 108.686 179.155 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.536 HD22 ' CG ' ' B' ' 70' ' ' LYS . 3.3 tm? -64.68 104.74 0.86 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.239 -0.913 . . . . 0.0 110.869 -178.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.536 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 1.2 tt -107.76 122.94 62.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.3 tt0 -88.09 114.58 24.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.04 -1.037 . . . . 0.0 109.078 -179.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.532 HG13 HG23 ' B' ' 13' ' ' ILE . 2.2 mp -111.32 116.79 53.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.321 -0.862 . . . . 0.0 110.052 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.488 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 80.0 m 63.41 8.24 3.4 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.58 -0.7 . . . . 0.0 110.668 179.124 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 104.53 22.96 8.19 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.045 179.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -125.77 130.92 52.42 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.137 -1.214 . . . . 0.0 109.231 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.536 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -69.45 131.04 44.13 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.53 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.536 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -145.77 96.87 2.88 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.887 -179.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.545 HD11 ' N ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.18 136.43 24.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 179.125 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.583 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -163.6 -173.45 32.3 Favored Glycine 0 C--N 1.294 -1.792 0 C-N-CA 118.695 -1.716 . . . . 0.0 110.658 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.462 HG22 ' HG3' ' B' ' 58' ' ' GLN . 86.5 m -92.25 106.41 18.42 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.664 -0.903 . . . . 0.0 109.331 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.591 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -95.83 105.05 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.652 -0.655 . . . . 0.0 109.982 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.55 ' CD2' ' HE3' ' B' ' 45' ' ' LYS . 5.6 mp -78.99 116.82 19.54 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.541 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 79.6 t -110.86 118.16 56.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 120.945 -1.097 . . . . 0.0 110.695 -178.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.519 ' N ' HG13 ' B' ' 56' ' ' VAL . . . -157.24 -150.4 5.69 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -83.07 41.28 1.07 Allowed 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.959 2.439 . . . . 0.0 110.258 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.552 HG21 ' N ' ' B' ' 34' ' ' GLU . 3.5 t -90.17 129.75 44.61 Favored Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 179.225 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.495 ' C ' ' CG2' ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.02 25.86 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.168 1.912 . . . . 0.0 111.558 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.495 ' CG2' ' C ' ' B' ' 81' ' ' PRO . 0.2 OUTLIER -161.4 154.01 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.719 -1.238 . . . . 0.0 110.785 -179.976 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.566 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 72.1 m-20 -96.38 83.05 3.48 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 175.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.549 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 12.4 mt -78.89 115.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.08 -1.013 . . . . 0.0 112.82 -175.248 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.51 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 1.4 mm -95.66 93.05 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.503 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -77.87 -169.84 34.43 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.12 -1.038 . . . . 0.0 111.008 -177.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.462 ' HD2' ' HA ' ' A' ' 8' ' ' ARG . 10.1 mtp85 -58.41 -37.56 75.59 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.931 -0.746 . . . . 0.0 110.766 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.57 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 14.3 p-10 -46.57 -26.9 0.98 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.554 -1.341 . . . . 0.0 109.451 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.583 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 2.4 mm? -110.56 -28.87 8.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.212 -0.93 . . . . 0.0 111.132 -178.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.416 HD11 ' CG2' ' B' ' 26' ' ' THR . 66.9 mt -65.38 -22.25 66.77 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.745 -1.222 . . . . 0.0 108.29 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.428 ' CG2' ' NH2' ' B' ' 87' ' ' ARG . 82.7 p -83.63 -18.11 39.26 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 108.97 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -79.73 -41.76 26.02 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.881 . . . . 0.0 109.569 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.59 ' CD1' ' CD2' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -82.89 -2.9 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.032 179.431 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.54 63.08 4.12 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -86.29 161.94 18.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.399 -1.059 . . . . 0.0 109.967 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.511 HG21 ' CG2' ' A' ' 4' ' ' THR . 2.6 p -141.4 129.92 22.62 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.206 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.534 HD12 ' CD1' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.9 94.4 6.28 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -179.872 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.514 ' N ' ' ND2' ' B' ' 98' ' ' ASN . 0.8 OUTLIER -105.26 130.88 53.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 110.851 -178.49 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.576 ' CG ' HD13 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.143 179.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.45 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.497 1.692 0 N-CA-C 110.76 -0.515 . . . . 0.0 110.76 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.462 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.8 tt0 -83.51 142.42 30.92 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.412 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 51.9 t -141.32 128.76 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 118.012 -1.475 . . . . 0.0 111.047 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.481 ' OG1' ' N ' ' A' ' 5' ' ' LEU . 1.3 p -132.34 -57.26 0.96 Allowed 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.205 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.0 OUTLIER 39.0 28.24 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.548 -0.72 . . . . 0.0 110.414 179.352 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.491 ' C ' ' O ' ' A' ' 5' ' ' LEU . 4.4 m95 18.02 43.91 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.411 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' A' ' 5' ' ' LEU . 15.9 mm100 -158.78 -111.5 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 108.855 179.385 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 77.1 mtt180 -111.98 134.06 21.49 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 120.621 -1.3 . . . . 0.0 109.352 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -81.18 54.4 5.19 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 122.357 2.038 . . . . 0.0 110.057 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.555 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.72 146.77 30.89 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.946 -1.096 . . . . 0.0 109.69 -179.495 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.44 HG23 HG12 ' A' ' 66' ' ' ILE . 2.4 m -138.03 136.11 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.2 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.427 HG21 HD23 ' A' ' 19' ' ' LEU . 94.9 m -60.35 113.65 2.51 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.55 ' HB ' ' CG1' ' A' ' 64' ' ' ILE . 1.0 OUTLIER -106.24 137.02 38.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 O-C-N 121.091 -1.006 . . . . 0.0 110.419 -178.684 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.53 ' CA ' HD22 ' A' ' 19' ' ' LEU . 2.7 ttpt -110.45 105.17 14.05 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.407 -0.808 . . . . 0.0 109.049 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.548 HD13 ' CD2' ' A' ' 33' ' ' LEU . 40.8 mt -118.42 122.01 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.121 -0.987 . . . . 0.0 109.887 -179.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.02 10.86 59.95 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 178.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.16 -7.02 60.05 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.6 178.36 6.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -1.109 . . . . 0.0 108.987 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.53 HD22 ' CA ' ' A' ' 14' ' ' LYS . 11.3 mt -151.06 129.66 12.24 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.236 -0.915 . . . . 0.0 110.74 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -150.61 157.0 42.46 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.555 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 61.6 mt-10 -77.94 131.36 37.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.576 -1.327 . . . . 0.0 108.428 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.607 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -107.7 148.03 29.96 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.086 -1.009 . . . . 0.0 110.235 -178.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.478 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 30.9 tp -98.9 95.85 7.45 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.163 0.506 . . . . 0.0 110.431 -178.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.523 HD21 ' N ' ' A' ' 24' ' ' LEU . 0.2 OUTLIER -47.16 115.7 1.17 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 178.916 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.566 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 12.8 t70 -131.8 108.18 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.747 -1.221 . . . . 0.0 111.15 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.481 ' OG1' ' OG1' ' B' ' 26' ' ' THR . 0.0 OUTLIER -79.97 -2.59 44.6 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.817 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.463 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -80.74 -21.66 63.32 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.84 161.83 13.55 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.131 -1.217 . . . . 0.0 109.892 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.505 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 50.4 m-20 -92.85 -20.1 21.03 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.406 -0.809 . . . . 0.0 110.919 -179.083 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -139.17 -169.08 2.58 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.621 -1.3 . . . . 0.0 110.203 -179.438 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.531 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 21.5 m -103.56 107.15 17.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.12 -0.988 . . . . 0.0 109.76 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.697 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -97.89 126.23 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.076 -1.015 . . . . 0.0 110.003 -179.469 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.548 ' CD2' HD13 ' A' ' 15' ' ' ILE . 3.8 mp -120.88 124.82 45.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.772 -1.205 . . . . 0.0 111.277 -178.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.591 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 3.2 pt-20 -43.77 163.45 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.295 -0.962 . . . . 0.0 108.525 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.47 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -44.25 137.84 3.32 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.033 -1.042 . . . . 0.0 110.212 -179.409 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.536 ' CE ' HG23 ' A' ' 15' ' ' ILE . 8.6 ptm -146.71 -163.16 1.69 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.512 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.4 t -108.22 84.3 1.92 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.975 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.62 HD11 ' CD2' ' A' ' 59' ' ' TYR . 13.4 mt -108.84 165.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 108.993 179.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.545 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.0 Cg_endo -73.45 -167.36 0.36 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.369 2.046 . . . . 0.0 111.37 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.32 33.03 6.9 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.111 -1.042 . . . . 0.0 110.503 -178.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.63 53.99 0.7 Allowed 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.624 -0.927 . . . . 0.0 108.616 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.628 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 51.2 p-90 -131.6 -168.75 2.07 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.623 0.725 . . . . 0.0 110.616 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.467 ' HG2' ' O ' ' A' ' 42' ' ' TRP . 15.3 mttt -147.17 131.07 8.41 Favored Pre-proline 0 N--CA 1.49 1.53 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -76.2 141.22 23.08 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.126 1.884 . . . . 0.0 111.042 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' NZ ' HD22 ' A' ' 76' ' ' LEU . 1.3 ptpp? -152.38 177.06 10.99 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.412 ' HE2' ' HG3' ' A' ' 55' ' ' LYS . 0.3 OUTLIER -129.65 124.75 34.42 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.079 -1.013 . . . . 0.0 108.842 179.507 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 4.9 pt -96.42 149.87 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.238 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.646 ' CA ' ' CD2' ' A' ' 53' ' ' PHE . . . -122.48 108.9 1.32 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.79 -124.03 2.41 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 119.388 -1.387 . . . . 0.0 110.453 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.545 ' CG2' HD13 ' B' ' 47' ' ' ILE . 64.7 mt -85.56 128.86 38.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.713 -0.875 . . . . 0.0 112.343 -177.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.24 -48.99 2.41 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.87 -157.78 26.22 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.646 ' CD2' ' CA ' ' A' ' 48' ' ' GLY . 3.5 m-85 -111.82 143.54 42.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -1.113 . . . . 0.0 109.573 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.553 HG12 ' CG2' ' B' ' 50' ' ' ILE . 3.8 pt -119.11 150.77 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.184 -0.947 . . . . 0.0 108.975 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 14.8 mttp -90.16 118.58 29.79 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.11 -0.994 . . . . 0.0 109.925 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.48 ' CG1' ' HA3' ' A' ' 78' ' ' GLY . 14.9 m -125.56 -167.5 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.226 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -125.76 173.82 8.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.278 -0.889 . . . . 0.0 109.493 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.501 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 3.4 tt0 -130.77 123.93 30.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.409 -0.807 . . . . 0.0 109.919 -179.804 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 41.9 m-85 -121.14 91.36 3.51 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.3 m-20 -78.98 133.26 36.86 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.098 -1.001 . . . . 0.0 109.692 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 1.6 mt-30 83.36 57.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.482 0.658 . . . . 0.0 109.379 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.481 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 3.0 mm -114.3 114.03 45.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.514 ' N ' HD11 ' A' ' 72' ' ' ILE . 0.0 OUTLIER -70.27 87.22 0.6 Allowed 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.271 -178.95 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.551 ' CG2' HD13 ' A' ' 89' ' ' LEU . 13.5 tt -88.5 123.68 41.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -89.46 106.19 18.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.985 -1.072 . . . . 0.0 109.038 -178.995 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.524 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.5 OUTLIER -106.13 123.22 60.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.009 -179.621 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 13.6 m 49.11 69.12 0.61 Allowed 'General case' 0 C--N 1.293 -1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.452 179.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 42.59 27.3 0.5 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.3 m-70 -122.97 130.74 53.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.897 -1.355 . . . . 0.0 109.065 179.268 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.497 ' CG ' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -75.01 133.21 41.71 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 108.837 179.404 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.508 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -154.47 108.32 2.94 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.876 . . . . 0.0 110.459 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.536 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.8 OUTLIER -85.48 152.45 3.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 177.971 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.507 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -175.7 -178.32 45.43 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.206 -1.949 . . . . 0.0 111.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.457 HG22 ' OD1' ' A' ' 60' ' ' ASP . 90.1 m -92.66 106.36 18.35 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.627 -0.925 . . . . 0.0 110.139 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.535 ' CG1' HD12 ' A' ' 33' ' ' LEU . 1.3 t -97.01 176.65 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.697 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.9 mp -139.4 161.48 37.35 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.966 -1.084 . . . . 0.0 108.288 178.127 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.555 ' CG2' HD11 ' A' ' 38' ' ' LEU . 19.5 t -143.47 105.46 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.91 0 O-C-N 121.379 -0.825 . . . . 0.0 109.734 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -149.7 -162.49 10.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -80.3 40.18 0.94 Allowed 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.473 2.116 . . . . 0.0 110.705 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.591 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 9.5 t -85.59 132.75 43.61 Favored Pre-proline 0 C--N 1.3 -1.572 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 179.056 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -77.92 17.5 0.99 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.407 2.071 . . . . 0.0 111.356 -179.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.493 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.1 t -162.22 162.22 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.837 -1.165 . . . . 0.0 109.983 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.607 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -96.94 154.38 17.33 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 175.21 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.566 ' CG2' ' HB3' ' A' ' 25' ' ' ASP . 1.1 mm -144.2 134.18 20.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 O-C-N 120.057 -1.652 . . . . 0.0 109.963 -178.244 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.529 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 1.1 mp -105.16 88.97 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 177.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.489 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.61 -164.45 22.81 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.905 -1.14 . . . . 0.0 110.278 -177.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HD2' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -61.82 -35.62 78.78 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.624 -0.927 . . . . 0.0 109.567 -179.134 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.582 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 8.1 p-10 -45.15 -25.07 0.31 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 108.891 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.582 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -112.91 -29.17 7.46 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 121.375 -0.828 . . . . 0.0 110.472 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.482 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 77.7 mt -68.25 -7.26 29.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.967 -1.083 . . . . 0.0 109.157 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.48 -19.69 15.42 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 108.607 179.085 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -80.65 -41.17 24.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.222 -0.924 . . . . 0.0 108.874 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.58 HD11 ' CG ' ' B' ' 99' ' ' PHE . 3.7 pt -83.77 -5.61 9.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.01 34.28 55.89 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.163 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.564 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -64.25 151.9 42.38 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.261 . . . . 0.0 110.624 -179.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 30.9 p -148.32 128.21 13.5 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.534 ' CD1' HD12 ' B' ' 97' ' ' LEU . 3.0 mp -87.81 95.05 9.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.11 -0.994 . . . . 0.0 109.443 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.591 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.0 OUTLIER -114.46 129.97 56.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 110.674 -179.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.172 178.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 N-CA-C 109.744 -0.906 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.591 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.2 tt0 -81.92 149.63 28.13 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 178.249 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.523 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 61.2 t -148.46 96.2 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 117.832 -1.547 . . . . 0.0 110.868 -178.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.449 HG22 ' OE1' ' B' ' 2' ' ' GLN . 71.3 p -100.75 -55.67 2.52 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.135 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.653 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.2 OUTLIER 43.99 18.99 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.757 -0.589 . . . . 0.0 111.524 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.537 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.3 m95 18.53 43.15 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.096 0.407 . . . . 0.0 111.895 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.653 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -170.85 -103.3 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 63.8 mtt180 -113.58 127.87 26.34 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 120.351 -1.468 . . . . 0.0 110.252 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.477 ' HB3' HG13 ' B' ' 3' ' ' VAL . 36.7 Cg_endo -78.99 71.48 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 121.94 1.76 . . . . 0.0 108.335 177.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -93.93 152.21 19.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.117 -0.989 . . . . 0.0 110.933 -178.083 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.463 HG22 HG21 ' B' ' 66' ' ' ILE . 2.0 m -151.03 150.39 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.663 -0.648 . . . . 0.0 109.414 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 99.7 m -78.16 115.45 17.89 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.552 ' HA ' ' O ' ' B' ' 65' ' ' GLU . 2.5 pp -103.89 151.4 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.024 -1.048 . . . . 0.0 110.507 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.1 OUTLIER -109.47 102.87 11.7 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.198 -0.939 . . . . 0.0 109.694 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.535 HD12 ' CG1' ' B' ' 75' ' ' VAL . 3.9 mt -121.37 134.28 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.986 -1.071 . . . . 0.0 110.159 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.478 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 58.66 27.24 61.12 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 179.317 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.13 27.3 66.55 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm-40 -124.41 -178.76 4.21 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.464 -1.021 . . . . 0.0 109.121 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.489 ' O ' ' HG2' ' B' ' 20' ' ' LYS . 19.8 mt -147.45 125.27 11.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 0.0 109.706 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.489 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mmtt -144.5 169.28 18.26 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.512 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 9.4 mt-10 -79.69 135.43 36.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 108.442 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.534 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -121.9 135.45 54.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.983 -1.073 . . . . 0.0 110.669 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 15.5 tp -92.04 94.1 9.08 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.468 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 14.2 mt -45.83 101.47 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.989 -1.069 . . . . 0.0 108.719 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.523 ' HB2' HG22 ' B' ' 84' ' ' ILE . 7.4 t70 -101.59 96.75 7.32 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.754 -0.591 . . . . 0.0 110.419 -178.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.557 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 24.6 m -79.68 13.49 2.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.504 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -109.83 -19.33 8.26 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.37 170.46 15.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.93 -1.336 . . . . 0.0 109.141 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -99.92 -18.08 17.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 110.088 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.539 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 16.1 m-20 -142.97 -155.16 0.57 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.064 -1.022 . . . . 0.0 109.658 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.588 ' OG1' ' HG ' ' B' ' 89' ' ' LEU . 78.5 m -120.19 97.82 5.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.511 -1.368 . . . . 0.0 111.262 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.585 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -76.83 174.87 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.073 -1.017 . . . . 0.0 108.445 178.969 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.585 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.04 119.46 0.61 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.765 -1.209 . . . . 0.0 110.936 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.516 ' HA ' HG21 ' B' ' 80' ' ' THR . 41.6 tt0 -36.66 158.77 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.453 0.644 . . . . 0.0 110.009 179.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.407 ' O ' ' HB3' ' B' ' 36' ' ' MET . 0.0 OUTLIER -52.42 147.31 8.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.497 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.467 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER 179.55 178.35 0.54 Allowed 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.6 t -92.49 101.62 14.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.074 -1.017 . . . . 0.0 109.563 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.585 ' O ' ' CZ ' ' B' ' 59' ' ' TYR . 58.0 tp -130.69 98.24 20.1 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.119 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -78.76 -177.77 4.15 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.618 2.212 . . . . 0.0 110.393 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 113.63 31.65 2.29 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.42 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.481 ' O ' ' O ' ' B' ' 40' ' ' GLY . 49.0 mtm180 59.78 141.44 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.901 -0.764 . . . . 0.0 109.401 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.597 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 47.9 p-90 -160.3 -172.13 3.46 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.782 -1.199 . . . . 0.0 110.832 -179.286 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.465 ' HD3' ' HD2' ' B' ' 44' ' ' PRO . 1.8 mmtp -148.27 145.16 19.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . 0.465 ' HD2' ' HD3' ' B' ' 43' ' ' LYS . 35.8 Cg_endo -78.16 136.24 14.34 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 122.018 1.812 . . . . 0.0 110.932 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.434 ' HD2' ' CD ' ' B' ' 58' ' ' GLN . 0.3 OUTLIER -160.29 -168.79 2.27 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.456 -0.778 . . . . 0.0 109.592 179.427 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.508 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 60.5 mtp -150.53 138.31 19.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.452 -0.78 . . . . 0.0 109.676 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.545 HD13 ' CG2' ' A' ' 50' ' ' ILE . 4.9 pt -95.93 150.09 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.03 -1.044 . . . . 0.0 108.535 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.82 102.53 0.94 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.81 -135.84 4.25 Favored Glycine 0 N--CA 1.483 1.821 0 C-N-CA 119.324 -1.417 . . . . 0.0 111.015 -178.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.553 ' CG2' HG12 ' A' ' 54' ' ' ILE . 46.1 mt -79.87 119.63 29.66 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.855 -0.791 . . . . 0.0 112.912 -177.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 104.97 -54.47 0.61 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.076 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.02 -159.62 20.78 Favored Glycine 0 N--CA 1.492 2.378 0 O-C-N 120.947 -1.325 . . . . 0.0 110.201 -179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.607 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-85 -118.9 125.85 50.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.475 -1.015 . . . . 0.0 109.161 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.457 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 5.2 pt -97.81 173.19 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.255 -0.903 . . . . 0.0 109.438 -179.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mtmt -109.03 125.58 52.23 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.147 -0.971 . . . . 0.0 109.626 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.525 ' CG2' ' HB3' ' B' ' 76' ' ' LEU . 15.6 m -134.86 168.76 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 110.279 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 18.4 mtt180 -110.33 111.41 22.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.588 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -69.04 121.69 17.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.409 -0.807 . . . . 0.0 110.471 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.597 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 23.9 m-85 -116.05 93.69 4.35 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 6.4 m-20 -77.6 124.97 28.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.8 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 48.6 mt-30 88.81 60.41 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 CA-C-O 121.32 0.581 . . . . 0.0 110.105 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.517 ' CG2' HG23 ' B' ' 75' ' ' VAL . 19.0 mm -115.57 109.82 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.116 179.498 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.575 HD21 HG13 ' B' ' 72' ' ' ILE . 3.0 tm? -65.27 85.56 0.06 Allowed 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.033 0.92 . . . . 0.0 110.717 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.617 HG23 ' CD1' ' B' ' 89' ' ' LEU . 0.6 OUTLIER -92.16 119.68 40.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 177.37 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.552 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.5 tt0 -87.14 128.84 35.12 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.163 -0.961 . . . . 0.0 108.957 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.492 HG13 HG23 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -114.9 129.76 70.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.014 -179.313 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 86.2 m 54.52 -91.27 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.574 -0.704 . . . . 0.0 109.804 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -147.18 40.82 0.98 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -145.72 149.58 34.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -1.046 . . . . 0.0 109.287 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.539 ' HG2' ' CD2' ' B' ' 63' ' ' LEU . 0.1 OUTLIER -79.04 139.63 38.11 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.077 -1.014 . . . . 0.0 109.467 -179.805 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.522 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -147.62 109.55 4.47 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.081 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.575 HG13 HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -94.88 145.46 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.215 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.543 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -169.22 -178.09 40.32 Favored Glycine 0 C--N 1.297 -1.636 0 C-N-CA 118.442 -1.837 . . . . 0.0 111.083 179.562 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.588 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.1 m -87.73 100.54 12.91 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 122.139 -0.624 . . . . 0.0 109.951 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.535 ' CG1' HD12 ' B' ' 15' ' ' ILE . 1.3 t -85.54 121.11 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.053 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.525 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 2.6 mp -96.73 104.25 16.23 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' B' ' 33' ' ' LEU . 21.8 t -93.45 112.03 25.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.04 -1.038 . . . . 0.0 109.993 -179.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.67 -160.85 9.45 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.556 -1.817 . . . . 0.0 108.556 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.539 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -79.98 38.31 0.73 Allowed 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.388 2.059 . . . . 0.0 110.973 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.516 HG21 ' HA ' ' B' ' 34' ' ' GLU . 1.8 t -81.98 134.96 48.79 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.464 ' O ' HG21 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -79.04 15.14 1.57 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.583 2.189 . . . . 0.0 111.311 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.2 t -160.59 161.01 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.999 -1.063 . . . . 0.0 109.804 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.534 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -98.24 129.12 44.98 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 104.157 -2.534 . . . . 0.0 104.157 175.51 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.523 HG22 ' HB2' ' B' ' 25' ' ' ASP . 5.0 mm -117.12 129.38 73.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.957 0 O-C-N 120.331 -1.481 . . . . 0.0 111.923 -176.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.418 HD11 HG21 ' B' ' 31' ' ' THR . 3.4 mm -102.19 105.19 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 176.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.539 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -98.8 -163.65 30.14 Favored Glycine 0 N--CA 1.496 2.691 0 C-N-CA 119.826 -1.178 . . . . 0.0 111.823 -177.307 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.576 ' N ' ' NH2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -53.28 -40.91 65.06 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 122.005 -0.703 . . . . 0.0 111.714 -178.193 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.487 ' CG ' HD22 ' B' ' 89' ' ' LEU . 53.0 p-10 -48.14 -26.16 1.77 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.548 -1.345 . . . . 0.0 111.007 -177.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.617 ' CD1' HG23 ' B' ' 64' ' ' ILE . 2.3 mt -115.31 -27.77 7.12 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.32 -1.487 . . . . 0.0 111.602 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mt -63.38 -11.77 25.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.212 -1.555 . . . . 0.0 108.259 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -101.67 -19.65 15.33 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.196 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 69.9 mm-40 -79.16 -41.23 28.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.726 -0.608 . . . . 0.0 110.581 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.513 ' CD1' ' HB1' ' B' ' 95' ' ' ALA . 1.0 OUTLIER -80.44 -22.12 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 179.52 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.45 ' C ' ' HB3' ' A' ' 99' ' ' PHE . . . 103.02 35.48 3.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.565 ' HB3' ' CD1' ' A' ' 99' ' ' PHE . . . -72.43 135.68 45.83 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.388 -1.066 . . . . 0.0 111.185 -178.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.4 HG23 ' CG2' ' A' ' 4' ' ' THR . 75.1 p -136.66 128.87 29.78 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.585 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.534 HD12 ' CD1' ' A' ' 97' ' ' LEU . 6.3 mp -83.49 105.32 14.33 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 108.68 -179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 5.9 m120 -103.53 122.62 45.32 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.049 -1.032 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.58 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.135 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.497 1.711 0 N-CA-C 110.178 -0.739 . . . . 0.0 110.178 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.539 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -83.16 148.94 27.17 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 106.471 -1.677 . . . . 0.0 106.471 177.815 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.516 HG12 ' CB ' ' A' ' 9' ' ' PRO . 2.3 t -140.76 105.98 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.902 -178.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.563 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -122.05 -69.03 0.85 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 176.694 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER 31.76 29.94 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.964 177.893 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.563 ' N ' ' O ' ' A' ' 4' ' ' THR . 17.3 m95 18.88 48.37 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.145 0 CA-C-O 121.331 0.586 . . . . 0.0 111.871 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.575 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -164.25 -175.5 3.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.172 -0.955 . . . . 0.0 109.401 179.8 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.474 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 1.6 mtt180 -76.38 119.27 76.61 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.267 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.516 ' CB ' HG12 ' A' ' 3' ' ' VAL . 35.3 Cg_endo -79.11 74.52 5.51 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.833 1.689 . . . . 0.0 108.92 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.427 HD22 ' C ' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -80.69 150.65 29.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.532 -0.73 . . . . 0.0 110.455 -178.609 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.482 ' HB ' ' SG ' ' A' ' 67' ' ' CYS . 2.0 m -150.05 162.04 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.413 -0.804 . . . . 0.0 109.33 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 42.5 m -96.12 114.04 25.7 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.57 HG21 ' CB ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -97.95 171.74 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.901 -178.941 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.508 ' CA ' HD22 ' A' ' 19' ' ' LEU . 6.5 tttt -131.78 102.38 5.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 109.406 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.556 HG13 HG13 ' A' ' 64' ' ' ILE . 48.6 mt -118.44 132.09 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.984 -1.072 . . . . 0.0 109.902 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.26 40.13 98.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.03 18.45 60.12 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 mm-40 -112.89 171.62 7.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.336 -1.097 . . . . 0.0 109.094 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.529 ' CD2' ' O ' ' A' ' 13' ' ' ILE . 14.4 mt -142.9 126.92 17.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.218 -0.926 . . . . 0.0 110.3 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 7.2 mttt -143.52 -167.7 2.64 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 43.5 mt-10 -79.4 -167.82 1.32 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.989 -1.07 . . . . 0.0 108.145 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.57 ' CB ' HG21 ' A' ' 13' ' ' ILE . . . -171.3 86.85 0.09 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.085 -1.009 . . . . 0.0 109.454 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.578 ' O ' ' N ' ' A' ' 25' ' ' ASP . 36.5 tp -72.47 95.35 1.77 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.346 -0.846 . . . . 0.0 109.032 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.477 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 49.6 mt -48.93 90.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' N ' ' O ' ' A' ' 23' ' ' LEU . 0.6 OUTLIER -99.52 92.98 5.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.49 -0.756 . . . . 0.0 110.825 -177.995 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.557 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 1.5 m -73.11 -2.03 19.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.574 178.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.565 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.84 -36.36 13.74 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.91 136.74 36.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.086 -1.244 . . . . 0.0 109.686 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.535 ' HA ' ' HG2' ' A' ' 87' ' ' ARG . 19.3 m-20 -64.15 -19.2 65.13 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.434 -0.791 . . . . 0.0 111.126 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.56 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 0.7 OUTLIER -141.79 -179.28 6.1 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.121 -1.432 . . . . 0.0 110.987 -179.324 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.582 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 2.3 m -96.18 89.41 5.13 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.471 -0.768 . . . . 0.0 110.612 -178.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.545 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -69.38 163.28 3.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.729 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.545 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -158.45 131.72 7.43 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.112 -0.993 . . . . 0.0 110.691 -178.558 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.476 ' HA ' HG21 ' A' ' 80' ' ' THR . 57.7 tt0 -43.44 164.77 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.7 OUTLIER -56.91 134.56 55.6 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.149 -0.97 . . . . 0.0 110.703 -179.285 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.481 ' SD ' ' HG ' ' A' ' 38' ' ' LEU . 2.2 ppp? -162.63 -167.56 1.59 Allowed 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.4 t -106.5 138.33 42.88 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.831 -1.168 . . . . 0.0 110.451 -179.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.602 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 5.4 mt -143.33 171.1 7.4 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.602 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -70.24 -153.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 121.853 1.702 . . . . 0.0 110.27 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.51 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -110.6 -167.25 19.27 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 -178.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.51 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.1 OUTLIER 73.07 54.6 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.113 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.662 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 3.9 p-90 -126.01 -176.84 3.75 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.791 0.805 . . . . 0.0 110.543 -178.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.416 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 14.0 mttp -147.54 160.87 37.66 Favored Pre-proline 0 N--CA 1.489 1.517 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.115 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 32.0 Cg_endo -75.78 147.48 31.15 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.166 1.91 . . . . 0.0 109.373 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.532 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -146.0 165.41 29.09 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.014 -1.054 . . . . 0.0 110.078 -178.932 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.451 ' HE3' ' HD3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -148.38 112.29 5.14 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.046 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.51 HG13 HG13 ' A' ' 54' ' ' ILE . 6.7 pt -106.1 129.45 59.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.48 -1.288 . . . . 0.0 109.467 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.587 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -116.82 100.71 0.91 Allowed Glycine 0 N--CA 1.482 1.753 0 N-CA-C 107.15 -2.38 . . . . 0.0 107.15 179.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.18 -128.62 3.8 Favored Glycine 0 N--CA 1.479 1.565 0 C-N-CA 119.269 -1.443 . . . . 0.0 111.084 -177.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.551 HG22 ' CD1' ' B' ' 47' ' ' ILE . 59.1 mt -85.4 119.16 33.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 O-C-N 122.074 -0.663 . . . . 0.0 112.429 -177.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 109.79 -36.42 4.31 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 162.99 -162.09 34.41 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.492 -1.337 . . . . 0.0 110.147 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.587 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.7 m-85 -115.12 141.99 47.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.467 -1.02 . . . . 0.0 109.466 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.532 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 3.0 pt -128.51 178.24 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.505 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -112.66 138.06 50.0 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.05 -1.031 . . . . 0.0 109.405 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 45' ' ' LYS . 33.5 m -144.09 161.61 15.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.294 -0.879 . . . . 0.0 109.35 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.53 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -104.49 -176.63 3.14 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.145 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.411 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 7.1 tt0 -137.6 101.45 4.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.006 . . . . 0.0 109.543 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.662 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 40.1 m-85 -103.41 95.73 6.27 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.424 -0.797 . . . . 0.0 109.517 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.504 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -78.88 140.85 38.05 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.955 -1.091 . . . . 0.0 108.982 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.504 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 76.38 64.06 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.819 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.565 ' CD1' ' HB3' ' A' ' 59' ' ' TYR . 21.4 mm -121.8 123.34 69.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.536 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -67.56 82.47 0.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.355 -0.841 . . . . 0.0 110.935 -178.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.556 HG13 HG13 ' A' ' 15' ' ' ILE . 2.5 tt -94.34 121.25 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.406 ' HG2' ' C ' ' A' ' 69' ' ' HIS . 1.7 tt0 -89.17 140.57 29.33 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.099 -1.001 . . . . 0.0 108.486 179.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.553 HD11 HG23 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -126.05 171.97 14.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 107.165 -1.421 . . . . 0.0 107.165 179.672 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.482 ' SG ' ' HB ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -47.96 -38.63 17.21 Favored 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 178.836 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.635 ' O ' ' CG ' ' A' ' 69' ' ' HIS . . . -52.79 -49.59 53.4 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 178.319 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.635 ' CG ' ' O ' ' A' ' 68' ' ' GLY . 5.2 m170 141.66 -173.39 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.076 0 CA-C-O 121.102 0.477 . . . . 0.0 109.838 178.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.523 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -36.56 139.51 0.18 Allowed 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 121.351 0.596 . . . . 0.0 109.773 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.533 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -161.8 115.33 1.87 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.304 -0.872 . . . . 0.0 110.02 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.514 ' HA ' ' O ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -85.57 150.7 3.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.595 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.24 -154.92 11.73 Favored Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.262 -1.446 . . . . 0.0 110.835 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.483 ' HB ' ' OD1' ' A' ' 88' ' ' ASN . 1.4 m -109.7 111.95 23.73 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.246 -1.149 . . . . 0.0 110.087 -179.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.535 HG21 ' HB ' ' A' ' 62' ' ' ILE . 1.4 t -106.15 108.39 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.262 -0.899 . . . . 0.0 111.243 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.532 ' CD2' ' HE2' ' A' ' 45' ' ' LYS . 2.8 mp -79.12 139.55 38.02 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 177.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.43 HG23 ' CD1' ' A' ' 38' ' ' LEU . 1.3 t -116.2 112.47 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.084 -1.01 . . . . 0.0 110.978 -178.144 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -149.54 -172.17 18.83 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.505 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.2 Cg_endo -81.45 41.62 1.18 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.58 2.187 . . . . 0.0 110.681 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.476 HG21 ' HA ' ' A' ' 34' ' ' GLU . 3.8 t -79.3 141.56 57.62 Favored Pre-proline 0 N--CA 1.49 1.553 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.21 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.514 ' O ' ' CG2' ' A' ' 82' ' ' VAL . 38.2 Cg_endo -80.07 20.02 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.583 2.188 . . . . 0.0 110.872 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.545 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 10.5 t -161.13 166.8 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.702 -1.248 . . . . 0.0 110.92 -178.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.545 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 7.8 m-80 -100.44 90.45 4.3 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 177.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.582 ' O ' ' HA ' ' A' ' 31' ' ' THR . 12.1 mm -79.14 120.04 29.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 O-C-N 121.183 -0.948 . . . . 0.0 112.379 -176.027 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.509 ' CG2' ' HB3' ' A' ' 89' ' ' LEU . 3.3 mm -99.07 106.11 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 176.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -91.47 -152.18 27.94 Favored Glycine 0 N--CA 1.489 2.197 0 O-C-N 120.679 -1.263 . . . . 0.0 111.861 -176.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.557 ' NH2' ' O ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -70.7 -41.29 72.15 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 120.111 -0.636 . . . . 0.0 109.852 -179.032 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.56 ' OD1' ' HA ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -53.33 -16.39 1.33 Allowed 'General case' 0 N--CA 1.498 1.963 0 C-N-CA 117.821 -1.552 . . . . 0.0 110.422 -178.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.679 ' CD1' ' OE1' ' A' ' 92' ' ' GLN . 0.2 OUTLIER -105.76 -20.82 13.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.658 -1.276 . . . . 0.0 109.054 179.825 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.456 HD11 ' CG2' ' A' ' 26' ' ' THR . 28.7 mt -80.95 1.1 32.55 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.654 -1.279 . . . . 0.0 108.535 178.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.551 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 0.3 OUTLIER -101.08 -10.06 20.83 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.137 -0.977 . . . . 0.0 111.159 -179.958 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.679 ' OE1' ' CD1' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -95.15 -40.81 9.41 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 120.467 -1.396 . . . . 0.0 109.562 -178.552 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.58 HD13 ' CD2' ' B' ' 99' ' ' PHE . 0.3 OUTLIER -80.48 3.3 2.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.013 -1.075 . . . . 0.0 108.349 178.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 69.87 53.05 16.71 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -77.27 144.98 37.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.121 -1.223 . . . . 0.0 109.271 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.524 ' CG2' HG21 ' B' ' 4' ' ' THR . 27.3 p -139.85 123.27 17.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.157 -0.964 . . . . 0.0 109.27 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.6 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 7.4 mp -84.72 100.61 11.61 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 178.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' B' ' 94' ' ' GLY . 18.5 m120 -99.17 120.01 38.8 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 120.447 -1.408 . . . . 0.0 108.934 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.625 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.298 -1.64 0 CA-C-O 118.101 -0.952 . . . . 0.0 109.282 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.612 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.7 Cg_exo . . . . . 0 N--CA 1.493 1.488 0 N-CA-C 109.917 -0.839 . . . . 0.0 109.917 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 130.7 35.14 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.439 HG22 ' CZ ' ' A' ' 99' ' ' PHE . 56.3 t -123.57 109.04 22.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.595 -177.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.524 HG21 ' CG2' ' A' ' 96' ' ' THR . 14.7 p -123.97 21.59 8.98 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.411 -0.806 . . . . 0.0 109.967 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.6 tp -88.82 27.31 1.34 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.023 -1.048 . . . . 0.0 108.758 178.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER 14.98 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.685 0.755 . . . . 0.0 111.918 179.698 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.512 ' O ' ' HD3' ' B' ' 9' ' ' PRO . 1.0 OUTLIER -129.31 -152.46 0.52 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.448 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 26.5 mtt180 -103.72 101.43 24.37 Favored Pre-proline 0 N--CA 1.488 1.45 0 O-C-N 120.903 -1.123 . . . . 0.0 108.133 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.541 ' HD2' ' NH2' ' A' ' 87' ' ' ARG . 33.9 Cg_endo -75.13 72.06 4.86 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.413 2.075 . . . . 0.0 110.698 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -89.78 142.88 27.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.017 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.531 HG22 ' CG2' ' B' ' 13' ' ' ILE . 21.9 m -131.15 126.05 58.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.3 m -67.34 99.88 0.76 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 177.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.578 HG22 ' HB1' ' B' ' 22' ' ' ALA . 1.1 pp -95.91 140.53 16.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.242 -0.911 . . . . 0.0 111.298 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.502 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -103.63 106.91 17.56 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.734 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.525 HD11 HG22 ' B' ' 15' ' ' ILE . 7.2 mt -119.68 115.65 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.206 -0.934 . . . . 0.0 110.154 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.48 27.78 73.13 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.606 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.77 12.3 81.63 Favored Glycine 0 N--CA 1.492 2.419 0 O-C-N 120.901 -1.353 . . . . 0.0 109.789 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.488 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.4 mt-30 -107.44 168.57 9.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.208 -1.172 . . . . 0.0 109.134 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.502 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 14.7 mt -140.48 122.95 16.06 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 0.0 109.514 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.517 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mmtt -143.87 172.95 12.15 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.503 -0.748 . . . . 0.0 109.236 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 31.1 mp0 -87.13 132.06 33.97 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.578 ' HB1' HG22 ' B' ' 13' ' ' ILE . . . -107.78 147.32 30.99 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.025 -1.047 . . . . 0.0 109.587 -179.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' B' ' 25' ' ' ASP . 18.6 tp -112.84 94.43 4.9 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.569 -0.707 . . . . 0.0 109.462 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.506 ' O ' ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -41.41 95.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.423 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.565 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 24.6 t0 -113.57 88.95 2.96 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.198 -0.939 . . . . 0.0 111.538 -178.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.69 -19.67 65.2 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 177.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.456 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -55.57 -39.51 75.13 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.46 164.73 18.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.46 -1.023 . . . . 0.0 109.306 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.459 ' OD1' ' HG3' ' A' ' 8' ' ' ARG . 12.4 m-20 -94.96 -19.57 20.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.075 -1.016 . . . . 0.0 110.921 -178.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.538 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -137.22 -175.71 4.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.747 -1.22 . . . . 0.0 110.198 -179.491 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 52.3 m -100.21 94.7 6.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.03 -1.044 . . . . 0.0 110.856 -178.224 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.632 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -75.05 158.72 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.092 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.559 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.5 OUTLIER -155.46 143.07 19.65 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.908 -1.12 . . . . 0.0 111.052 -178.092 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.528 ' N ' HG21 ' B' ' 80' ' ' THR . 20.2 tt0 -49.68 156.15 0.72 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.6 OUTLIER -61.69 132.78 54.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.076 -1.015 . . . . 0.0 109.609 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.51 ' HE3' ' CG2' ' B' ' 15' ' ' ILE . 3.8 ptm -153.33 -164.17 1.85 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -102.96 118.12 36.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.037 -1.039 . . . . 0.0 110.49 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.49 HD12 ' HD3' ' B' ' 39' ' ' PRO . 3.0 mm? -113.3 169.96 5.84 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.49 ' HD3' HD12 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.95 52.02 4.14 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.696 2.264 . . . . 0.0 111.426 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 49.03 -163.0 0.5 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.2 mmm-85 60.25 84.87 0.12 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -1.14 . . . . 0.0 109.196 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 60.3 p-90 -159.57 176.54 11.92 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.509 0.671 . . . . 0.0 110.047 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.38 159.68 64.95 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -77.95 139.53 17.44 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.21 1.94 . . . . 0.0 110.404 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.504 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 10.1 tttt -155.53 131.14 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.439 -0.788 . . . . 0.0 109.197 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.439 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -110.85 130.68 55.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.099 -1.001 . . . . 0.0 109.289 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.551 ' CD1' HG22 ' A' ' 50' ' ' ILE . 24.3 pt -113.42 149.86 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.894 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.495 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.15 111.51 2.09 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 179.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -132.36 -126.08 2.7 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.188 -1.482 . . . . 0.0 111.161 -178.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.51 ' O ' ' O ' ' A' ' 50' ' ' ILE . 19.3 mt -91.52 138.44 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 122.056 0.932 . . . . 0.0 113.179 -177.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.532 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 80.18 -20.19 6.03 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 178.585 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.14 -169.44 32.61 Favored Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.649 -1.5 . . . . 0.0 110.321 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 4.5 m-85 -105.11 153.25 21.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.372 -1.075 . . . . 0.0 109.274 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.537 HG12 ' CG2' ' A' ' 50' ' ' ILE . 7.4 pt -127.11 159.81 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.225 -0.922 . . . . 0.0 109.807 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.529 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.29 144.52 31.51 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.769 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.516 HG22 HD21 ' B' ' 76' ' ' LEU . 23.9 m -142.9 -171.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.78 -1.2 . . . . 0.0 110.598 -178.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 11.4 mtt180 -137.85 88.87 2.36 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.41 98.82 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 110.962 -179.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.593 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 18.9 m-85 -91.78 127.54 37.27 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.4 m-20 -107.69 135.22 49.48 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.785 -1.197 . . . . 0.0 110.632 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.568 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.1 mt-30 79.96 60.4 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.823 -0.548 . . . . 0.0 110.889 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.563 ' CD1' ' HB3' ' B' ' 59' ' ' TYR . 3.5 mp -113.96 119.94 62.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.086 -1.008 . . . . 0.0 109.275 179.087 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.555 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.9 tm? -68.59 83.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.506 -0.746 . . . . 0.0 110.505 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.569 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 12.5 tt -88.85 124.88 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.483 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 7.4 tt0 -90.28 100.13 13.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.085 -1.01 . . . . 0.0 109.414 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' B' ' 13' ' ' ILE . 0.5 OUTLIER -90.97 119.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 121.055 -1.028 . . . . 0.0 109.103 179.949 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.587 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 5.3 m 48.5 47.52 20.24 Favored 'General case' 0 C--N 1.291 -1.951 0 O-C-N 121.82 -0.55 . . . . 0.0 110.463 178.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.483 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 68.37 28.13 73.41 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.587 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 8.5 m170 -120.2 97.15 5.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.034 -1.274 . . . . 0.0 109.35 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -50.44 126.81 16.07 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.239 -0.913 . . . . 0.0 109.159 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.485 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -151.26 155.98 39.9 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.665 -0.647 . . . . 0.0 109.459 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.568 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -119.22 153.33 21.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.717 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.479 ' O ' HD11 ' B' ' 62' ' ' ILE . . . -175.61 -177.83 44.96 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.453 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.507 ' CG2' ' OD1' ' B' ' 60' ' ' ASP . 2.7 m -91.18 108.56 19.95 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.706 -0.879 . . . . 0.0 109.877 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.527 HG21 ' CD1' ' B' ' 62' ' ' ILE . 1.4 t -103.35 112.46 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.401 -0.812 . . . . 0.0 110.328 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.632 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.9 mp -77.73 118.71 20.36 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.012 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 72.1 t -99.02 117.44 44.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 120.916 -1.115 . . . . 0.0 109.74 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -155.55 -168.52 18.73 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.116 -1.994 . . . . 0.0 108.116 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.529 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -80.83 48.46 2.91 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 122.263 1.975 . . . . 0.0 110.816 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.528 HG21 ' N ' ' B' ' 34' ' ' GLU . 0.6 OUTLIER -91.85 137.45 25.39 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.926 -1.109 . . . . 0.0 108.573 179.481 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.6 Cg_endo -79.54 19.6 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.557 2.171 . . . . 0.0 112.209 -178.502 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.1 t -161.23 172.74 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.541 -1.349 . . . . 0.0 110.287 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.572 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 3.2 m-80 -107.55 79.53 1.3 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.452 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.562 ' O ' ' HA ' ' B' ' 31' ' ' THR . 1.2 mp -76.8 126.02 37.1 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.374 -0.829 . . . . 0.0 111.48 -176.274 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.498 ' N ' HD11 ' B' ' 85' ' ' ILE . 1.2 mp -96.14 99.94 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.535 ' C ' ' CD1' ' B' ' 90' ' ' LEU . . . -95.69 167.68 25.9 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.584 ' N ' ' CD1' ' B' ' 90' ' ' LEU . 22.5 mmm180 -25.77 -39.41 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.818 -0.813 . . . . 0.0 112.826 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.561 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 8.9 p-10 -49.79 -21.99 1.29 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.577 -1.327 . . . . 0.0 111.264 -178.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.561 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -110.58 -24.06 10.75 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.584 ' CD1' ' N ' ' B' ' 87' ' ' ARG . 3.8 mp -68.6 -8.69 44.14 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.522 ' HB ' ' CZ2' ' A' ' 6' ' ' TRP . 30.4 p -95.83 -20.22 18.99 Favored 'General case' 0 N--CA 1.485 1.307 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.496 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 68.5 mm-40 -81.73 -41.46 21.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.551 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 1.9 pt -93.29 -2.82 10.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 98' ' ' ASN . . . 75.48 22.51 75.37 Favored Glycine 0 N--CA 1.494 2.529 0 O-C-N 121.516 -0.74 . . . . 0.0 111.488 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.56 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -65.27 123.66 20.15 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.708 -1.466 . . . . 0.0 110.457 -179.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 41.4 p -131.38 132.63 44.56 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.6 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 4.8 mp -84.87 106.87 16.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.047 -1.033 . . . . 0.0 110.766 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.539 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 2.4 m120 -112.3 121.61 45.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.344 -0.847 . . . . 0.0 108.944 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.58 ' CD2' HD13 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.686 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.224 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.567 ' O ' ' CD1' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.67 0 N-CA-C 110.398 -0.655 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -88.16 139.37 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.54 155.86 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 109.943 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 p -127.66 -168.35 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.312 -0.868 . . . . 0.0 109.445 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.582 ' CD2' ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -87.16 -26.89 23.37 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.215 -0.928 . . . . 0.0 109.065 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.607 ' CZ2' HG23 ' B' ' 91' ' ' THR . 10.2 m95 -45.48 -22.72 0.16 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.629 -1.295 . . . . 0.0 109.06 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.478 ' N ' ' O ' ' A' ' 5' ' ' LEU . 34.6 mt-30 -146.25 110.32 4.98 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.705 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.462 ' C ' ' O ' ' A' ' 7' ' ' GLN . 14.6 mtm180 -40.95 148.17 0.39 Allowed Pre-proline 0 C--N 1.297 -1.713 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.5 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 36.7 Cg_endo -79.71 47.88 2.67 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.579 2.186 . . . . 0.0 109.757 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -79.33 143.43 35.17 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.098 -1.001 . . . . 0.0 109.526 -179.222 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.528 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -147.24 140.65 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.333 -178.734 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 78.4 m -74.32 96.78 2.89 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.338 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.528 HG21 ' CG2' ' A' ' 11' ' ' VAL . 4.2 pt -83.81 150.34 4.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 121.635 0.731 . . . . 0.0 111.041 -178.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.541 ' CE ' HD13 ' A' ' 19' ' ' LEU . 1.1 tttt -112.14 101.54 9.79 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.522 HG23 ' CE ' ' A' ' 36' ' ' MET . 12.2 mt -122.51 138.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.225 -0.922 . . . . 0.0 109.308 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.467 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 52.11 43.37 56.2 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.14 35.83 66.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.486 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.0 mm100 -131.32 178.59 6.6 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.151 . . . . 0.0 109.186 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.541 HD13 ' CE ' ' A' ' 14' ' ' LYS . 39.5 mt -146.94 126.45 13.23 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.129 -0.982 . . . . 0.0 110.232 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.597 ' N ' ' HE2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -146.85 163.34 36.38 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.709 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.557 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 49.3 mm-40 -79.39 137.23 37.21 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.97 -1.081 . . . . 0.0 109.113 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.572 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -119.98 156.07 31.59 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.594 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 12.3 tp -118.24 99.12 6.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.701 -0.624 . . . . 0.0 109.615 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.5 ' HB2' ' CG ' ' A' ' 9' ' ' PRO . 18.7 mt -48.34 106.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.878 -1.139 . . . . 0.0 108.932 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.535 ' CB ' HG21 ' A' ' 84' ' ' ILE . 54.2 t0 -109.24 98.39 7.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.875 . . . . 0.0 109.829 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.472 ' OG1' ' OG1' ' B' ' 26' ' ' THR . 0.2 OUTLIER -71.58 -5.01 30.18 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.303 -0.873 . . . . 0.0 108.748 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.419 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -83.58 -33.27 22.61 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.569 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.36 159.88 20.78 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.073 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.519 ' OD2' ' CZ ' ' B' ' 8' ' ' ARG . 16.8 m-20 -100.77 -13.66 18.36 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.3 -0.875 . . . . 0.0 110.629 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.487 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.1 OUTLIER -127.0 -173.54 2.92 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.982 -1.074 . . . . 0.0 109.545 -179.625 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 27.9 m -110.47 86.76 2.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.864 -1.147 . . . . 0.0 110.214 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.551 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -67.78 173.5 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 83' ' ' ASN . 0.1 OUTLIER -169.85 115.2 0.53 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.838 -1.163 . . . . 0.0 110.983 -178.14 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.552 ' HA ' HG21 ' A' ' 80' ' ' THR . 33.8 tt0 -33.85 150.05 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.879 -0.513 . . . . 0.0 109.649 178.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.513 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.1 tt0 -37.35 145.08 0.06 Allowed 'General case' 0 N--CA 1.495 1.783 0 CA-C-O 121.56 0.695 . . . . 0.0 110.674 -179.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.522 ' CE ' HG23 ' A' ' 15' ' ' ILE . 14.3 ptm -156.85 -170.8 3.42 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.0 t -127.77 90.77 3.16 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.827 -1.171 . . . . 0.0 111.364 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.617 ' CB ' ' CE1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -81.49 171.58 11.79 Favored Pre-proline 0 N--CA 1.493 1.716 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 177.901 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.576 ' CD ' HD11 ' A' ' 38' ' ' LEU . 36.2 Cg_endo -79.3 43.52 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.614 2.21 . . . . 0.0 111.499 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . 54.72 111.15 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.449 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 157.79 57.74 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.909 . . . . 0.0 108.83 179.792 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.585 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 51.5 p-90 -141.1 179.18 6.89 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-O 121.849 0.833 . . . . 0.0 110.491 -178.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.416 ' HE3' ' HA ' ' A' ' 43' ' ' LYS . 0.0 OUTLIER -130.8 158.04 76.09 Favored Pre-proline 0 C--N 1.302 -1.475 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.783 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -76.32 141.92 23.47 Favored 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.144 1.896 . . . . 0.0 110.471 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.39 169.57 19.89 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.428 -0.795 . . . . 0.0 109.352 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.459 ' SD ' ' HB3' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -144.35 111.21 5.75 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.507 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.553 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 6.0 pt -92.33 142.52 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.856 -1.152 . . . . 0.0 109.093 -179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.6 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -122.8 105.08 0.92 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.68 -120.57 2.5 Favored Glycine 0 N--CA 1.483 1.785 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.097 -179.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.569 HG22 ' CD1' ' B' ' 47' ' ' ILE . 26.3 mt -86.56 121.69 37.89 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.69 -0.888 . . . . 0.0 112.09 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.453 ' HA2' HG21 ' B' ' 54' ' ' ILE . . . 103.91 -55.71 0.61 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.76 -159.3 23.69 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.6 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.0 m-85 -107.43 131.79 53.9 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.235 -1.156 . . . . 0.0 109.887 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 7.3 pt -107.98 134.63 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.923 -1.111 . . . . 0.0 108.857 178.697 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.525 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -70.94 148.58 47.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.103 -0.998 . . . . 0.0 110.057 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.475 HG11 ' O ' ' A' ' 55' ' ' LYS . 6.4 m -150.09 -169.77 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.571 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 3.7 mmt85 -133.56 105.11 6.7 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.502 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.0 OUTLIER -62.93 102.06 0.32 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.948 . . . . 0.0 110.448 -179.133 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CB ' ' A' ' 38' ' ' LEU . 31.2 m-85 -92.62 90.68 7.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 108.858 179.113 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 3.4 m-20 -79.07 124.72 28.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.008 -1.057 . . . . 0.0 110.47 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 2.7 mm-40 88.33 61.78 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 CA-C-O 121.383 0.611 . . . . 0.0 110.163 179.319 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.545 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 14.8 mm -117.82 116.53 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.108 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.555 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 1.3 tm? -68.66 83.73 0.29 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.372 -0.83 . . . . 0.0 110.092 -179.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.506 ' CG2' HD12 ' A' ' 89' ' ' LEU . 11.8 tt -89.9 112.0 23.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 179.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 8.6 tp10 -91.63 120.44 32.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.11 -0.994 . . . . 0.0 109.228 -179.255 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.473 HD13 HG12 ' A' ' 64' ' ' ILE . 0.7 OUTLIER -107.01 121.01 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.179 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 60.04 -93.01 0.04 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.606 -0.684 . . . . 0.0 110.053 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -138.92 27.37 2.68 Favored Glycine 0 N--CA 1.486 1.978 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.42 ' C ' ' OE1' ' A' ' 65' ' ' GLU . 9.6 m-70 -125.53 103.44 7.88 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.188 -1.184 . . . . 0.0 109.385 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.505 ' N ' ' OE1' ' A' ' 65' ' ' GLU . 0.3 OUTLIER -59.52 133.43 56.09 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.544 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.494 ' O ' ' CD2' ' A' ' 63' ' ' LEU . . . -145.52 154.9 42.7 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.153 -0.967 . . . . 0.0 110.333 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.553 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -121.25 156.29 24.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 177.491 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 177.77 -177.77 48.37 Favored Glycine 0 N--CA 1.487 2.039 0 C-N-CA 117.876 -2.107 . . . . 0.0 112.084 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.502 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 91.0 m -90.62 105.12 17.6 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.921 -0.752 . . . . 0.0 109.713 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.537 HG11 HD11 ' A' ' 33' ' ' LEU . 1.4 t -98.63 107.06 19.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.688 -0.632 . . . . 0.0 110.079 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.525 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.8 mp -79.51 120.82 24.42 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.461 -0.774 . . . . 0.0 108.99 179.323 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.513 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 21.6 t -107.22 130.67 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.57 179.801 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' A' ' 56' ' ' VAL . . . -162.21 -159.4 10.23 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.039 -1.624 . . . . 0.0 109.039 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.525 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.72 38.32 0.73 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.606 2.204 . . . . 0.0 110.338 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.552 HG21 ' HA ' ' A' ' 34' ' ' GLU . 2.4 t -83.95 135.08 42.84 Favored Pre-proline 0 N--CA 1.489 1.519 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.261 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.5 16.82 1.18 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.428 2.085 . . . . 0.0 111.044 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.518 HG13 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.83 157.73 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.978 -1.076 . . . . 0.0 109.292 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.572 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -94.53 126.33 39.74 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 176.041 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.572 ' O ' ' HA ' ' A' ' 31' ' ' THR . 5.0 mm -111.57 122.57 66.19 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 O-C-N 120.486 -1.384 . . . . 0.0 112.384 -176.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.503 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -98.78 85.66 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 176.88 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.57 -157.02 9.97 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.461 -177.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.518 ' NE ' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -64.56 -33.06 75.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 122.009 -0.7 . . . . 0.0 111.265 -178.44 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.58 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 7.9 p-10 -55.9 -32.15 63.48 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.791 -1.193 . . . . 0.0 110.315 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.58 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -108.05 -19.95 13.33 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.993 -1.067 . . . . 0.0 110.516 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.461 ' O ' HG13 ' A' ' 93' ' ' ILE . 12.6 mt -69.9 -36.17 75.19 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 71.2 p -72.55 -20.83 61.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.057 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.432 ' OE1' ' HA ' ' A' ' 92' ' ' GLN . 9.4 mm100 -71.43 -40.18 70.58 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.569 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.4 OUTLIER -85.77 -2.18 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.55 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.82 60.36 6.6 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -81.41 151.72 27.77 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.365 -1.079 . . . . 0.0 110.052 -179.6 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.8 p -142.96 125.34 15.6 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.57 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 2.6 mp -91.0 94.27 9.56 Favored 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.612 -0.68 . . . . 0.0 109.17 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.531 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.3 m120 -104.79 129.0 53.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.127 -0.983 . . . . 0.0 110.285 -179.25 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.666 ' CG ' ' CD1' ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.377 178.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.476 ' HG2' ' CE1' ' A' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 N-CA-C 110.383 -0.66 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.531 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 9.9 tt0 -83.59 129.81 34.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 96.2 t -130.41 107.19 14.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.718 -1.239 . . . . 0.0 110.692 -177.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.547 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.9 p -108.71 -59.56 1.86 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' B' ' 7' ' ' GLN . 84.5 mt 35.8 27.9 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.695 -0.628 . . . . 0.0 111.068 179.153 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.547 ' N ' ' O ' ' B' ' 4' ' ' THR . 8.4 m95 17.63 46.48 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.603 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.6 mt-30 -170.65 -166.86 0.53 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.108 -0.995 . . . . 0.0 109.941 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.547 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.3 mtm180 -67.78 112.75 11.36 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.474 -0.767 . . . . 0.0 109.545 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.4 Cg_endo -80.27 86.88 1.59 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.204 1.936 . . . . 0.0 110.051 179.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.454 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.5 OUTLIER -86.12 136.25 33.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.92 . . . . 0.0 109.524 -179.771 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.436 HG21 ' HB1' ' B' ' 22' ' ' ALA . 3.4 m -125.56 154.17 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.423 -0.798 . . . . 0.0 109.711 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.517 HG23 ' CD2' ' B' ' 19' ' ' LEU . 58.5 m -86.6 111.27 20.47 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.581 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.6 pp -97.76 141.7 15.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.184 -0.948 . . . . 0.0 110.447 -178.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.407 ' HE2' HD13 ' B' ' 19' ' ' LEU . 6.8 ttmm -109.4 96.05 6.03 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.346 -0.846 . . . . 0.0 109.316 179.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.582 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 7.3 mt -113.02 116.18 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.86 50.69 63.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.96 17.15 21.27 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.224 -1.162 . . . . 0.0 110.287 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.503 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 1.7 mt-30 -108.05 134.67 50.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.055 -1.262 . . . . 0.0 109.37 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.517 ' CD2' HG23 ' B' ' 12' ' ' THR . 0.3 OUTLIER -113.51 120.06 39.68 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.098 0.951 . . . . 0.0 110.302 -179.726 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -141.04 178.55 7.3 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.552 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.1 mt-10 -85.46 178.18 7.52 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 120.802 -1.186 . . . . 0.0 108.812 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.581 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -156.58 111.65 2.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.063 -1.023 . . . . 0.0 110.302 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.547 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 27.9 tp -82.12 100.28 9.7 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.519 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 67.8 mt -43.17 105.96 0.06 Allowed 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.524 ' O ' ' HA2' ' B' ' 86' ' ' GLY . 7.7 t0 -114.38 87.47 2.64 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.517 -0.74 . . . . 0.0 110.839 -178.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.472 ' OG1' ' OG1' ' A' ' 26' ' ' THR . 20.5 m -71.22 -5.44 32.07 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.842 -1.161 . . . . 0.0 108.63 178.427 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.479 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -81.99 -32.76 28.49 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.0 162.72 28.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.952 -1.323 . . . . 0.0 109.575 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.421 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 0.7 OUTLIER -93.4 -20.86 19.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.887 -179.421 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.566 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 14.3 m-20 -139.5 -164.81 1.75 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.034 -1.041 . . . . 0.0 109.407 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 89.3 m -109.59 95.66 5.76 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.661 -1.274 . . . . 0.0 111.174 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.4 OUTLIER -72.78 178.01 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 177.879 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.13 118.34 0.68 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.781 -1.199 . . . . 0.0 110.875 -178.885 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.565 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 2.4 tt0 -35.11 150.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.557 . . . . 0.0 109.51 178.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.518 ' N ' ' HG3' ' B' ' 34' ' ' GLU . 0.0 OUTLIER -31.07 141.87 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.75 0.786 . . . . 0.0 111.497 -179.041 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.543 ' SD ' ' N ' ' B' ' 37' ' ' SER . 2.8 ppp? -169.05 175.54 5.73 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.265 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.543 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -122.53 136.28 54.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.619 -1.3 . . . . 0.0 111.235 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.614 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 0.2 OUTLIER -120.49 175.83 2.14 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.251 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.577 ' CD ' HD13 ' B' ' 38' ' ' LEU . 35.8 Cg_endo -79.47 62.47 8.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.632 2.221 . . . . 0.0 111.171 179.397 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.539 ' O ' ' CG ' ' B' ' 41' ' ' ARG . . . 40.29 87.06 0.01 OUTLIER Glycine 0 N--CA 1.495 2.621 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.539 ' CG ' ' O ' ' B' ' 40' ' ' GLY . 4.2 mtt180 -167.67 57.15 0.07 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.86 -0.788 . . . . 0.0 109.095 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.627 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 59.3 p-90 -147.96 172.33 14.38 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.07 0.938 . . . . 0.0 110.791 -179.307 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mmtm -130.98 144.29 52.94 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -74.01 133.29 17.96 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 C-N-CA 121.626 1.551 . . . . 0.0 110.486 -179.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.474 ' HG3' HG21 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.65 -178.83 7.64 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.439 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 62.9 mtp -145.13 131.52 19.66 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.141 -0.975 . . . . 0.0 109.323 179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.569 ' CD1' HG22 ' A' ' 50' ' ' ILE . 19.9 pt -96.7 145.91 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.13 -0.982 . . . . 0.0 108.791 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.486 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.6 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -122.86 2.84 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.506 ' O ' ' O ' ' A' ' 50' ' ' ILE . 33.3 mt -89.69 121.54 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.716 -0.873 . . . . 0.0 112.414 -177.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.589 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 105.43 -52.26 0.72 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 178.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.31 -164.64 33.45 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.515 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 2.9 m-85 -106.35 126.2 51.94 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.436 -1.038 . . . . 0.0 109.171 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.494 HD12 HD12 ' B' ' 47' ' ' ILE . 23.4 pt -97.28 174.99 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 120.917 -1.115 . . . . 0.0 109.149 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.514 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 35.2 mtpt -111.49 127.23 55.63 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.256 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.474 HG21 ' HG3' ' B' ' 45' ' ' LYS . 16.6 m -136.15 -174.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.583 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.598 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 0.5 OUTLIER -129.13 104.14 7.38 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.762 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.413 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 1.9 tt0 -62.38 97.4 0.09 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.523 -0.736 . . . . 0.0 110.704 -178.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.627 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 29.7 m-85 -88.56 127.49 35.55 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.523 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 5.6 m-20 -106.73 133.0 52.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.859 -1.151 . . . . 0.0 110.637 -178.548 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.539 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 52.2 mm-40 72.32 63.53 0.12 Allowed 'General case' 0 N--CA 1.49 1.539 0 CA-C-O 121.665 0.745 . . . . 0.0 109.469 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.582 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 12.6 mm -113.95 122.21 67.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.198 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.476 HD22 HG12 ' B' ' 72' ' ' ILE . 0.1 OUTLIER -69.97 84.99 0.51 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 111.568 -177.922 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.521 ' CG2' HD13 ' B' ' 89' ' ' LEU . 1.7 tt -88.62 119.47 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.8 tt0 -100.99 122.86 44.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.836 -1.165 . . . . 0.0 109.527 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.483 HG13 HG21 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -109.15 131.45 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 121.268 -0.895 . . . . 0.0 109.101 -179.956 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 57.37 -88.69 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.787 -0.57 . . . . 0.0 110.212 179.49 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -149.84 38.62 0.92 Allowed Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -136.36 123.13 21.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -1.115 . . . . 0.0 109.175 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.9 136.33 55.21 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.244 -0.91 . . . . 0.0 108.623 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.483 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -152.09 119.96 6.17 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 110.268 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.539 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 1.1 mm -89.53 163.31 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 178.016 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.504 ' N ' ' CG2' ' B' ' 72' ' ' ILE . . . 174.05 173.11 39.89 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 118.931 -1.604 . . . . 0.0 110.777 179.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 59.3 m -83.72 114.8 21.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.469 -1.018 . . . . 0.0 109.892 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.535 ' CG1' ' CD1' ' B' ' 15' ' ' ILE . 1.3 t -106.77 114.91 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.254 -0.903 . . . . 0.0 110.6 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' HB2' ' CG2' ' B' ' 32' ' ' VAL . 4.1 mp -86.38 115.03 23.64 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.698 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.518 ' O ' ' CD ' ' B' ' 57' ' ' ARG . 93.0 t -101.14 132.12 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.045 -1.034 . . . . 0.0 109.57 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.412 ' HA3' HG13 ' B' ' 56' ' ' VAL . . . -169.44 -163.26 23.16 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.514 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.1 Cg_endo -79.8 43.55 1.53 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.754 2.303 . . . . 0.0 110.892 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.565 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 12.2 t -85.32 137.61 36.82 Favored Pre-proline 0 N--CA 1.488 1.431 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -78.69 13.62 1.86 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.302 2.001 . . . . 0.0 110.879 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.44 163.34 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.132 -0.98 . . . . 0.0 109.864 -179.235 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 55.0 m-80 -94.34 136.32 34.77 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.051 -2.574 . . . . 0.0 104.051 175.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.55 ' O ' ' HA ' ' B' ' 31' ' ' THR . 5.6 mm -121.05 122.42 67.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 O-C-N 119.92 -1.737 . . . . 0.0 111.358 -177.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.527 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -98.63 92.07 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.638 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.18 -155.56 9.39 Favored Glycine 0 N--CA 1.49 2.28 0 C-N-CA 120.005 -1.093 . . . . 0.0 111.096 -178.015 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.543 ' CB ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -75.71 -29.66 59.04 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.905 -0.762 . . . . 0.0 110.159 -178.982 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.586 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 19.0 p-10 -51.08 -20.46 1.46 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.888 -1.133 . . . . 0.0 109.831 -179.365 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.586 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 4.0 mm? -116.17 -21.25 9.48 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.83 -1.169 . . . . 0.0 110.899 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' B' ' 95' ' ' ALA . 83.3 mt -66.12 -18.43 65.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.63 -1.294 . . . . 0.0 109.547 -179.711 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.607 HG23 ' CZ2' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -100.86 -5.74 25.72 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.927 -1.108 . . . . 0.0 109.212 178.683 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -94.15 -41.18 9.64 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.666 ' CD1' ' CG ' ' A' ' 99' ' ' PHE . 1.2 pt -88.94 -7.73 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.854 . . . . 0.0 108.749 179.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 89.43 28.03 20.87 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.919 178.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.544 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -71.11 125.72 27.65 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.667 -1.49 . . . . 0.0 109.52 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 66.4 p -127.05 129.91 48.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.571 ' HB3' ' CZ ' ' B' ' 99' ' ' PHE . 4.1 mp -87.35 102.46 14.54 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.249 -0.907 . . . . 0.0 110.256 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.6 m120 -102.21 125.44 48.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.352 -0.843 . . . . 0.0 109.15 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.633 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.086 -0.959 . . . . 0.0 109.296 179.465 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.497 1.724 0 CA-C-O 121.501 0.542 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.538 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.4 tt0 -83.58 144.51 29.42 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.53 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 9.5 t -143.84 112.87 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.274 -1.37 . . . . 0.0 110.314 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.566 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -117.92 -67.1 1.02 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.958 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.547 ' O ' ' C ' ' A' ' 6' ' ' TRP . 2.5 pp 27.68 36.58 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.588 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.566 ' N ' ' O ' ' A' ' 4' ' ' THR . 35.7 m95 15.9 53.57 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.245 0 CA-C-O 121.184 0.516 . . . . 0.0 112.268 179.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 2.6 mt-30 -156.88 -166.75 2.17 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 109.529 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.459 ' HA ' ' HD3' ' B' ' 87' ' ' ARG . 1.0 OUTLIER -75.04 130.89 79.79 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.363 -0.836 . . . . 0.0 109.131 179.902 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.1 Cg_endo -78.19 79.33 3.31 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.25 1.967 . . . . 0.0 109.342 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -96.91 139.52 32.82 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.761 -179.359 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.474 HG21 ' O ' ' A' ' 11' ' ' VAL . 0.9 OUTLIER -135.36 147.47 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.467 -0.771 . . . . 0.0 109.965 -179.223 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.6 m -75.8 105.69 6.98 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.548 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 7.6 pt -99.06 146.4 8.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.248 -0.907 . . . . 0.0 110.642 -178.154 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.3 OUTLIER -111.57 99.51 8.25 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.296 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.513 ' CD1' HD12 ' A' ' 33' ' ' LEU . 4.2 mt -120.4 132.46 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.21 -0.931 . . . . 0.0 109.651 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.77 32.98 83.67 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.27 21.81 70.5 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.0 OUTLIER -117.81 174.92 5.91 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.299 -1.118 . . . . 0.0 109.213 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.47 HD22 ' HA ' ' A' ' 14' ' ' LYS . 14.6 mt -140.02 120.2 13.79 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.236 -0.915 . . . . 0.0 110.379 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.7 mmmt -144.1 167.76 21.63 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -77.06 165.28 24.82 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.808 -1.183 . . . . 0.0 108.391 179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.548 ' CB ' ' CG2' ' A' ' 13' ' ' ILE . . . -142.54 119.82 11.54 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.922 -1.111 . . . . 0.0 109.817 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.476 ' O ' ' N ' ' A' ' 25' ' ' ASP . 41.6 tp -88.27 93.33 9.48 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.699 -0.626 . . . . 0.0 109.647 -179.641 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.547 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 14.7 mt -43.67 97.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.06 -1.025 . . . . 0.0 109.657 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.512 ' CB ' HG21 ' A' ' 84' ' ' ILE . 27.7 t0 -100.56 81.36 2.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.89 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.529 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 1.8 m -60.74 -14.16 19.47 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.17 -0.956 . . . . 0.0 108.88 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.27 -33.68 64.53 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.28 169.44 17.29 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.196 -1.179 . . . . 0.0 110.014 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.494 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 24.1 m-20 -98.38 -17.13 19.0 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.315 -0.866 . . . . 0.0 111.206 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.491 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -137.11 -171.13 2.87 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.694 -1.254 . . . . 0.0 110.249 -179.43 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 18.6 m -104.83 90.6 3.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.212 -0.93 . . . . 0.0 110.533 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.568 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -70.13 174.53 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.632 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.571 ' CD1' ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -168.8 121.84 0.82 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.83 -1.169 . . . . 0.0 110.859 -179.352 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 1.1 pt-20 -37.36 156.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.547 -0.721 . . . . 0.0 109.797 178.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.555 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.5 tm-20 -45.0 145.75 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.356 -0.84 . . . . 0.0 110.8 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.414 ' HG2' HG12 ' A' ' 77' ' ' VAL . 13.5 ptm -165.02 -164.97 0.83 Allowed 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -116.81 122.75 45.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.996 -1.065 . . . . 0.0 110.506 -179.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.612 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -128.08 -173.87 0.34 Allowed Pre-proline 0 N--CA 1.496 1.839 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 179.503 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -78.05 -163.3 0.21 Allowed 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 122.171 1.914 . . . . 0.0 111.371 -178.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.72 39.28 2.94 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -179.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -128.86 61.52 1.51 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.622 -0.928 . . . . 0.0 108.622 179.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.641 ' CD1' ' CE2' ' A' ' 59' ' ' TYR . 6.3 p-90 -132.9 -177.55 4.55 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.683 0.754 . . . . 0.0 110.47 -178.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -137.74 138.51 24.22 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.23 138.81 18.27 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.131 1.887 . . . . 0.0 110.85 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 46' ' ' MET . 1.6 ptpt -156.56 -169.47 3.02 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.4 ' HG2' ' O ' ' A' ' 45' ' ' LYS . 39.9 mtp -151.3 135.56 16.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 109.784 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.535 HD13 ' CG2' ' B' ' 50' ' ' ILE . 15.3 pt -100.06 139.29 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.91 106.07 1.24 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -131.78 -123.26 2.45 Favored Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.74 -1.219 . . . . 0.0 110.308 -179.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.585 HG23 ' CD1' ' B' ' 47' ' ' ILE . 66.0 mt -88.48 115.29 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.445 -1.032 . . . . 0.0 112.45 -177.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.66 -32.96 5.45 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.361 -1.095 . . . . 0.0 110.361 178.081 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.87 -160.27 28.74 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 4.6 m-85 -110.86 124.55 52.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.32 -1.106 . . . . 0.0 109.491 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.54 HG12 ' CG2' ' B' ' 50' ' ' ILE . 2.2 pt -102.26 174.03 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 108.721 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.7 OUTLIER -107.38 135.46 48.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.163 -0.961 . . . . 0.0 108.935 179.447 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.508 ' CG1' HD13 ' A' ' 54' ' ' ILE . 15.2 m -143.19 152.83 16.73 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 121.228 -0.92 . . . . 0.0 109.865 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.549 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 3.6 mtt85 -92.92 167.02 12.11 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -129.2 100.77 5.73 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.01 -1.056 . . . . 0.0 110.004 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 42' ' ' TRP . 81.8 m-85 -100.25 123.36 44.39 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.356 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -98.73 130.75 45.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.009 . . . . 0.0 109.753 -179.669 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.549 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 83.14 59.75 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.389 0.614 . . . . 0.0 109.802 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.522 ' CG2' HG22 ' A' ' 75' ' ' VAL . 5.3 mm -110.57 117.4 54.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.498 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 0.1 OUTLIER -69.86 86.82 0.52 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 111.093 -178.459 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.563 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 6.1 tt -88.87 118.21 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 6.0 tt0 -88.22 112.51 22.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.033 -1.042 . . . . 0.0 108.936 -178.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.555 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.4 OUTLIER -103.92 118.86 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.348 -0.845 . . . . 0.0 109.052 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER 61.67 40.32 13.36 Favored 'General case' 0 C--N 1.293 -1.877 0 O-C-N 121.618 -0.676 . . . . 0.0 109.873 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.07 8.44 61.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.461 ' O ' ' HG2' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -101.26 155.99 17.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.176 -1.191 . . . . 0.0 108.989 179.781 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.482 ' HG2' HD23 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -89.44 126.63 35.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.017 -1.052 . . . . 0.0 109.754 -179.814 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.563 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.89 102.44 3.27 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.313 -0.867 . . . . 0.0 109.441 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.539 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -81.07 158.89 4.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.028 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.56 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 178.45 172.81 43.23 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.48 -1.819 . . . . 0.0 111.637 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 57.2 m -84.86 111.66 19.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.665 -0.903 . . . . 0.0 109.938 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.571 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.2 t -100.39 144.53 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.637 -0.665 . . . . 0.0 109.601 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.568 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -116.07 127.38 54.83 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.555 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 97.3 t -111.03 116.13 51.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 120.956 -1.09 . . . . 0.0 110.766 -178.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -151.18 -161.93 10.37 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.544 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.16 42.78 1.4 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.443 2.095 . . . . 0.0 110.327 179.583 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.567 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.4 t -88.38 130.51 45.44 Favored Pre-proline 0 C--N 1.303 -1.435 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.27 21.05 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.417 2.078 . . . . 0.0 111.546 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.507 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.07 159.54 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.881 -1.137 . . . . 0.0 109.81 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.532 ' ND2' ' O ' ' A' ' 21' ' ' GLU . 33.5 m-80 -90.53 136.72 32.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.539 ' CG1' HG11 ' A' ' 32' ' ' VAL . 6.1 mm -125.75 122.79 62.99 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 O-C-N 119.955 -1.716 . . . . 0.0 111.498 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.547 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -105.34 95.59 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.492 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -79.75 -159.24 17.26 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.1 OUTLIER -67.77 -37.04 81.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 -179.383 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.572 ' ND2' HD21 ' A' ' 89' ' ' LEU . 14.8 p-10 -45.28 -28.97 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.89 -1.131 . . . . 0.0 109.743 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.572 HD21 ' ND2' ' A' ' 88' ' ' ASN . 2.6 mm? -106.88 -27.64 10.59 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.92 -1.113 . . . . 0.0 109.428 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.529 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 12.7 mt -70.32 -6.15 33.03 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.574 ' HB ' ' CZ3' ' B' ' 6' ' ' TRP . 71.8 p -101.87 -20.0 15.06 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.18 -0.95 . . . . 0.0 108.66 178.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -76.34 -40.22 51.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.404 -0.81 . . . . 0.0 109.112 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.624 ' CD1' ' CG ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -87.44 -1.74 8.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.375 -0.828 . . . . 0.0 109.07 179.324 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.73 29.84 50.53 Favored Glycine 0 N--CA 1.497 2.741 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -57.59 149.13 22.14 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.2 -1.177 . . . . 0.0 111.225 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.453 HG23 ' CG2' ' B' ' 4' ' ' THR . 15.8 p -150.44 126.03 10.25 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 5.2 mp -84.89 109.02 17.82 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.223 -0.923 . . . . 0.0 108.671 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 7.3 m120 -108.36 121.72 45.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.164 -179.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.641 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.606 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.474 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.515 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 109.97 -0.819 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.51 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.0 OUTLIER -83.34 144.74 29.47 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 105.985 -1.858 . . . . 0.0 105.985 177.354 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.51 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 92.8 t -148.95 114.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 117.56 -1.656 . . . . 0.0 111.413 -177.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.453 ' CG2' HG23 ' A' ' 96' ' ' THR . 2.6 p -111.64 -70.94 0.78 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.1 OUTLIER 45.44 19.41 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.668 -0.645 . . . . 0.0 111.188 178.722 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.574 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 12.1 m95 19.3 44.8 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 120.948 0.404 . . . . 0.0 111.48 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' B' ' 5' ' ' LEU . 12.9 mm100 -156.56 -156.66 0.64 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.441 -0.787 . . . . 0.0 109.405 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 117.22 61.81 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.927 -1.108 . . . . 0.0 109.543 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.19 71.55 6.98 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.142 1.895 . . . . 0.0 109.431 179.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.608 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -91.23 159.83 15.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.864 . . . . 0.0 110.304 -178.986 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.569 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.8 OUTLIER -150.24 135.85 11.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.452 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.431 HG21 HD21 ' B' ' 19' ' ' LEU . 4.9 m -65.77 107.91 1.94 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.573 ' HA ' ' O ' ' B' ' 65' ' ' GLU . 1.4 pt -103.88 150.31 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 119.15 -1.02 . . . . 0.0 111.007 -178.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.429 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 6.4 tttt -122.42 106.71 11.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.464 -0.772 . . . . 0.0 108.921 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.581 HD12 ' CG1' ' B' ' 75' ' ' VAL . 38.0 mt -115.11 143.04 25.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.052 -1.03 . . . . 0.0 109.242 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.81 -89.91 0.09 OUTLIER Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -160.32 32.79 0.41 Allowed Glycine 0 N--CA 1.485 1.935 0 N-CA-C 108.406 -1.878 . . . . 0.0 108.406 179.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 -134.97 171.66 14.1 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.671 -0.899 . . . . 0.0 109.34 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.431 HD21 HG21 ' B' ' 12' ' ' THR . 5.6 mt -120.83 137.59 54.48 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.624 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -150.59 144.18 25.11 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.375 -0.828 . . . . 0.0 108.798 -178.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.608 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.1 mt-10 -78.24 121.98 25.1 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.256 -0.903 . . . . 0.0 108.648 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.561 ' HB2' ' CD1' ' B' ' 85' ' ' ILE . . . -104.34 131.0 52.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 111.731 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.541 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 33.7 tp -88.11 96.95 10.72 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.453 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.455 ' C ' ' O ' ' B' ' 23' ' ' LEU . 18.9 mt -42.3 107.31 0.08 Allowed 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.534 ' CB ' HG21 ' B' ' 84' ' ' ILE . 41.7 t0 -116.65 92.51 3.89 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.376 -0.827 . . . . 0.0 111.642 -177.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.517 ' O ' ' NH1' ' B' ' 87' ' ' ARG . 0.2 OUTLIER -75.89 -0.78 22.55 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.903 -1.123 . . . . 0.0 108.592 177.729 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.444 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -89.37 -28.66 19.18 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -179.739 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . 0.462 ' CB ' ' OD2' ' B' ' 25' ' ' ASP . . . -78.79 170.67 16.3 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.89 -1.359 . . . . 0.0 109.443 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -100.24 -20.44 15.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.178 -0.951 . . . . 0.0 110.01 -179.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -142.39 -175.91 4.64 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.075 -1.016 . . . . 0.0 109.764 179.875 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.594 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 4.2 m -100.36 86.19 3.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 110.558 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.59 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -71.75 157.62 6.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.594 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.9 OUTLIER -153.06 128.66 10.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.918 -1.114 . . . . 0.0 110.688 -178.12 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.473 ' N ' HG23 ' B' ' 80' ' ' THR . 1.1 pt-20 -43.37 162.34 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 109.11 179.396 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.495 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.8 mt-10 -48.92 139.83 9.65 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.225 -0.922 . . . . 0.0 110.126 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.6 OUTLIER -163.0 -171.09 2.54 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.519 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -111.99 116.15 30.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.877 -1.139 . . . . 0.0 110.236 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.56 HD11 ' CD1' ' B' ' 59' ' ' TYR . 3.4 mt -113.52 167.93 8.61 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.245 -0.909 . . . . 0.0 109.05 179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.539 ' HD2' ' CD2' ' B' ' 38' ' ' LEU . 34.4 Cg_endo -77.37 70.64 6.71 Favored 'Trans proline' 0 C--N 1.312 -1.367 0 C-N-CA 122.783 2.322 . . . . 0.0 112.183 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.13 -158.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 O-C-N 121.607 -0.683 . . . . 0.0 111.631 178.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 51.71 90.65 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.633 -0.922 . . . . 0.0 109.476 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.591 ' HB3' ' CD2' ' B' ' 59' ' ' TYR . 44.6 p-90 -161.0 172.91 16.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.471 -0.768 . . . . 0.0 109.906 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.458 ' HB2' ' HB3' ' B' ' 58' ' ' GLN . 0.2 OUTLIER -135.46 128.76 18.33 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.903 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.51 141.06 19.62 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.261 1.974 . . . . 0.0 110.966 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.11 -167.56 1.97 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.452 -0.78 . . . . 0.0 109.083 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 46' ' ' MET . . . . . . . . . . . . . 81.7 mtp -143.28 133.69 24.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.329 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.585 ' CD1' HG23 ' A' ' 50' ' ' ILE . 35.0 pt -100.8 152.63 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.061 -1.024 . . . . 0.0 108.783 179.146 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.51 102.81 0.98 Allowed Glycine 0 N--CA 1.489 2.167 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.49 -131.2 3.44 Favored Glycine 0 N--CA 1.482 1.708 0 C-N-CA 119.447 -1.359 . . . . 0.0 111.123 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.54 ' CG2' HG12 ' A' ' 54' ' ' ILE . 51.6 mt -88.51 126.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 122.008 -0.701 . . . . 0.0 112.515 -177.42 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.521 ' N ' HG22 ' A' ' 54' ' ' ILE . . . 92.45 5.53 65.11 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 121.06 -166.13 14.07 Favored Glycine 0 N--CA 1.492 2.403 0 O-C-N 120.917 -1.343 . . . . 0.0 110.046 179.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.2 OUTLIER -109.42 135.43 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.377 -1.072 . . . . 0.0 109.57 -179.747 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.547 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.3 pt -104.82 -179.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 121.078 -1.014 . . . . 0.0 109.104 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.462 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 31.8 mttt -114.84 140.56 48.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.161 -0.962 . . . . 0.0 108.955 179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.525 ' CG1' HD13 ' B' ' 54' ' ' ILE . 33.8 m -149.66 176.55 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.001 -1.062 . . . . 0.0 110.262 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.554 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 1.0 OUTLIER -111.3 172.92 6.6 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.458 ' HB3' ' HB2' ' B' ' 43' ' ' LYS . 45.2 tt0 -128.82 87.92 2.65 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.152 -0.968 . . . . 0.0 110.198 -179.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.591 ' CD2' ' HB3' ' B' ' 42' ' ' TRP . 72.7 m-85 -89.77 93.98 9.65 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 179.116 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.8 m-20 -80.93 135.37 35.88 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.055 -1.028 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.53 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 7.6 mt-30 78.43 62.72 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.672 0.748 . . . . 0.0 109.866 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.561 ' HB ' ' CG2' ' B' ' 75' ' ' VAL . 35.1 mm -117.56 123.67 72.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.547 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.8 tm? -68.42 84.35 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.378 -0.827 . . . . 0.0 110.672 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.563 ' CD1' HD13 ' B' ' 66' ' ' ILE . 7.1 tt -87.55 118.39 33.31 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.573 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.3 tt0 -90.95 118.47 30.36 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.141 -0.975 . . . . 0.0 109.68 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.563 HD13 ' CD1' ' B' ' 64' ' ' ILE . 0.3 OUTLIER -120.14 128.95 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.16 -0.962 . . . . 0.0 108.908 179.753 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 85.5 m 57.05 51.41 10.51 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.495 -0.753 . . . . 0.0 109.817 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.49 19.45 13.12 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.458 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.8 m-70 -112.23 141.55 45.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.152 -1.205 . . . . 0.0 109.425 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.33 130.77 34.77 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.234 -0.917 . . . . 0.0 109.17 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.475 ' O ' HD23 ' B' ' 63' ' ' LEU . . . -149.98 141.85 23.78 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.559 -0.713 . . . . 0.0 109.134 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.53 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -115.18 158.88 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.783 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.483 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 176.62 -159.46 26.28 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.687 -1.721 . . . . 0.0 111.454 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.1 m -101.33 109.01 20.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.473 -1.016 . . . . 0.0 110.136 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.581 ' CG1' HD12 ' B' ' 15' ' ' ILE . 1.5 t -104.06 108.73 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.225 179.449 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.59 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.1 mp -82.57 137.23 34.62 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.33 -0.856 . . . . 0.0 108.842 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.557 HG22 ' CE1' ' B' ' 59' ' ' TYR . 0.2 OUTLIER -115.15 129.69 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.265 -0.897 . . . . 0.0 109.94 -179.342 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -166.07 -172.21 33.15 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.462 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -80.56 41.34 1.12 Allowed 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.53 2.153 . . . . 0.0 110.85 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.525 ' CG2' ' O ' ' B' ' 82' ' ' VAL . 5.9 t -80.93 143.67 53.92 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.451 ' O ' HG21 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -77.51 12.47 1.86 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.39 2.06 . . . . 0.0 111.296 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.525 ' O ' ' CG2' ' B' ' 80' ' ' THR . 2.3 t -161.61 161.55 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.835 -1.166 . . . . 0.0 110.486 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.624 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -98.36 92.63 5.78 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.774 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.534 HG21 ' CB ' ' B' ' 25' ' ' ASP . 2.7 mt -93.39 135.52 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.951 -1.093 . . . . 0.0 113.327 -175.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.561 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 0.2 OUTLIER -101.3 108.27 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.56 ' C ' ' CD2' ' B' ' 90' ' ' LEU . . . -95.95 173.37 30.48 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.871 -1.291 . . . . 0.0 109.871 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' B' ' 26' ' ' THR . 8.8 mtm-85 -35.91 -35.02 0.06 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.487 -1.008 . . . . 0.0 112.19 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.521 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 9.7 p-10 -49.14 -43.43 41.69 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.231 -1.543 . . . . 0.0 110.395 -178.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.521 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 0.6 OUTLIER -93.64 -30.16 15.08 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.096 -1.003 . . . . 0.0 111.168 -178.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.56 ' CD2' ' C ' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -59.5 -36.33 75.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.532 -1.355 . . . . 0.0 108.719 -179.807 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.407 ' CG2' ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -71.44 -20.7 62.07 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.879 -1.138 . . . . 0.0 109.713 -179.534 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.44 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 11.8 mm-40 -75.11 -38.87 60.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.139 -0.976 . . . . 0.0 109.018 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 2.8 pt -84.81 -8.5 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.181 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.475 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 80.51 29.56 43.68 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 178.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.567 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.83 135.38 57.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.105 -1.232 . . . . 0.0 109.824 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 73.2 p -131.86 125.64 32.28 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 1.2 mp -84.86 92.95 8.4 Favored 'General case' 0 C--N 1.293 -1.861 0 O-C-N 121.335 -0.853 . . . . 0.0 109.954 -178.611 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 2.6 m120 -105.14 138.8 40.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.577 -0.702 . . . . 0.0 109.962 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.624 ' CG ' ' CD1' ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.338 179.494 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.461 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 3.4 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.292 -0.695 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.509 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.9 tt0 -85.92 129.07 34.94 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 178.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.536 HG13 ' CB ' ' A' ' 9' ' ' PRO . 35.8 t -124.09 111.37 28.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 120.74 -1.225 . . . . 0.0 110.595 -178.333 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.406 ' O ' ' C ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -119.28 -72.67 0.68 Allowed 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.228 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.6 mm? 42.15 29.21 0.13 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.426 -0.797 . . . . 0.0 110.125 179.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 20.9 m0 18.61 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.385 0 CA-C-O 121.249 0.547 . . . . 0.0 111.742 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.5 mt-30 -165.57 -165.28 0.82 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.372 -0.83 . . . . 0.0 108.805 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.523 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 82.7 mtm180 -64.25 117.08 33.26 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.078 -1.014 . . . . 0.0 109.235 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.536 ' CB ' HG13 ' A' ' 3' ' ' VAL . 34.8 Cg_endo -76.76 75.49 4.45 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 109.974 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.534 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -79.49 160.04 26.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.883 . . . . 0.0 109.58 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 13' ' ' ILE . 2.1 m -148.73 139.1 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.282 -0.887 . . . . 0.0 110.386 -179.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 54.9 m -70.3 98.3 1.37 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.126 -0.983 . . . . 0.0 108.392 178.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.546 ' CG2' ' HB1' ' A' ' 22' ' ' ALA . 19.7 pt -92.12 150.07 3.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.453 -0.78 . . . . 0.0 109.901 -179.264 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HD3' ' CD2' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -112.07 94.98 5.21 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.478 -0.764 . . . . 0.0 109.003 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.541 ' CD1' HG12 ' A' ' 75' ' ' VAL . 6.0 mt -114.35 128.17 71.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.357 -0.84 . . . . 0.0 109.561 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.2 30.53 78.04 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.71 9.92 66.44 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.494 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -108.02 175.86 5.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -1.147 . . . . 0.0 108.935 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.529 ' CD2' ' HD3' ' A' ' 14' ' ' LYS . 20.1 mt -142.82 121.63 12.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.105 -0.997 . . . . 0.0 110.347 -179.417 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 3.2 mmtt -140.06 160.58 39.6 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.155 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.534 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.6 mp0 -78.86 123.97 27.77 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.937 -1.102 . . . . 0.0 108.461 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.546 ' HB1' ' CG2' ' A' ' 13' ' ' ILE . . . -108.16 130.51 55.12 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 110.673 -178.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 25' ' ' ASP . 42.9 tp -80.23 94.97 6.16 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.855 -0.528 . . . . 0.0 109.879 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.51 HD22 ' CG1' ' A' ' 85' ' ' ILE . 94.4 mt -46.71 95.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.324 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.63 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 34.6 t0 -99.96 89.12 3.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.317 -0.865 . . . . 0.0 110.837 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.443 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 15.7 m -65.07 -16.63 63.67 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.452 ' HA3' ' OD1' ' B' ' 25' ' ' ASP . . . -71.05 -34.59 64.78 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.66 161.37 23.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.156 -1.203 . . . . 0.0 109.071 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.411 ' HA ' ' HB2' ' A' ' 87' ' ' ARG . 34.6 m-20 -99.37 -12.54 20.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.983 -179.589 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.504 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 29.4 m-20 -137.35 173.01 12.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.024 -1.047 . . . . 0.0 110.084 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.548 ' CG2' ' O ' ' A' ' 84' ' ' ILE . 98.0 m -94.07 107.44 19.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.083 -1.011 . . . . 0.0 110.194 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.543 ' CG2' ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -100.26 117.3 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.304 -0.873 . . . . 0.0 109.022 179.441 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.531 HD11 ' CG1' ' A' ' 75' ' ' VAL . 2.2 mp -107.56 119.28 38.98 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.239 -0.913 . . . . 0.0 110.569 -179.015 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CB ' ' O ' ' A' ' 80' ' ' THR . 15.4 pt-20 -42.73 168.41 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.328 -0.857 . . . . 0.0 109.393 178.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.9 OUTLIER -43.46 145.99 0.54 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.212 -0.93 . . . . 0.0 111.03 -179.128 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.455 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.1 OUTLIER 178.68 163.05 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -81.0 103.3 10.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.871 -1.143 . . . . 0.0 110.151 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.474 HD13 ' HD2' ' A' ' 39' ' ' PRO . 5.1 tp -121.8 104.1 39.54 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.857 . . . . 0.0 109.199 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.474 ' HD2' HD13 ' A' ' 38' ' ' LEU . 36.3 Cg_endo -77.41 146.89 25.05 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.542 2.161 . . . . 0.0 110.861 -179.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 134.45 172.72 12.9 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -77.45 127.69 32.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -1.233 . . . . 0.0 108.808 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.638 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 66.6 p-90 -130.26 172.91 11.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.775 -178.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 2.1 mmtm -137.75 147.24 56.19 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.42 131.46 12.71 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.838 1.692 . . . . 0.0 110.289 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.625 ' CE ' ' CD2' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -162.05 136.85 7.02 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.696 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.475 ' HB3' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -112.64 146.32 38.84 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.661 -1.275 . . . . 0.0 109.637 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 47' ' ' ILE . 12.6 pt -101.0 140.27 20.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.487 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.66 104.61 1.11 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.49 -119.45 2.29 Favored Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.576 -1.297 . . . . 0.0 110.875 -179.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.513 ' CG2' HD12 ' B' ' 54' ' ' ILE . 49.9 mt -85.96 119.79 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.817 -0.814 . . . . 0.0 112.66 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.431 ' N ' HG22 ' B' ' 54' ' ' ILE . . . 104.21 -53.38 0.7 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.355 -0.926 . . . . 0.0 110.795 178.038 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . -177.63 -157.41 18.45 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.234 -179.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -117.3 126.73 53.2 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.484 -1.009 . . . . 0.0 109.875 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.546 ' CD1' HG11 ' A' ' 56' ' ' VAL . 1.9 pp -105.08 160.55 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.303 -0.873 . . . . 0.0 109.085 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -103.02 146.6 28.11 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.046 -1.034 . . . . 0.0 110.115 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.579 HG21 ' NZ ' ' A' ' 45' ' ' LYS . 3.1 m -149.39 -177.9 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.18 -0.95 . . . . 0.0 109.328 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.52 ' CD ' ' CE3' ' A' ' 42' ' ' TRP . 7.4 mmt85 -123.21 101.75 7.56 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.567 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 3.8 tt0 -73.18 106.17 4.91 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.4 -0.812 . . . . 0.0 111.144 -178.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CZ ' ' HB3' ' A' ' 42' ' ' TRP . 41.4 m-85 -89.47 130.75 35.76 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.543 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.0 m-20 -100.82 121.11 41.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.7 -1.25 . . . . 0.0 109.976 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.8 OUTLIER 85.15 57.07 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.206 0.527 . . . . 0.0 110.048 179.538 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.549 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 16.4 mm -105.54 119.95 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -0.923 . . . . 0.0 108.919 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.533 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.4 tm? -68.72 98.59 0.92 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.854 -178.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.572 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 7.9 tt -102.83 119.36 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.329 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.8 OUTLIER -89.58 116.84 28.03 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.809 -1.182 . . . . 0.0 109.424 -178.915 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.501 HG13 HG23 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -109.25 129.07 64.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.3 -0.875 . . . . 0.0 109.053 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.478 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.7 m 38.04 52.15 1.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.459 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 63.28 48.86 75.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.478 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 92.9 m-70 -145.15 115.19 7.43 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -1.156 . . . . 0.0 109.431 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.518 ' CG ' HD23 ' A' ' 63' ' ' LEU . 19.6 ttpt -60.97 129.25 40.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.572 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -154.28 99.65 2.23 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.392 -0.818 . . . . 0.0 109.874 -179.093 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.55 160.43 4.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 120.866 -1.146 . . . . 0.0 108.533 178.981 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . 178.99 177.15 47.37 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 118.777 -1.678 . . . . 0.0 111.59 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.567 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 17.7 m -89.03 111.77 22.57 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.815 -0.815 . . . . 0.0 110.549 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.541 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -101.05 161.33 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.465 -0.772 . . . . 0.0 109.733 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.625 ' CD2' ' CE ' ' A' ' 45' ' ' LYS . 6.0 mp -130.55 105.0 7.55 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.064 -1.022 . . . . 0.0 108.405 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 61.7 t -89.61 117.75 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.792 -1.193 . . . . 0.0 109.973 -179.477 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.558 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -156.5 -166.97 17.08 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -82.75 39.02 0.78 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.479 2.119 . . . . 0.0 111.085 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 0.8 OUTLIER -85.62 137.57 36.18 Favored Pre-proline 0 N--CA 1.49 1.525 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 178.174 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.94 23.04 0.58 Allowed 'Trans proline' 0 C--N 1.303 -1.859 0 C-N-CA 122.187 1.924 . . . . 0.0 111.689 -178.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.638 ' CG1' ' CG1' ' A' ' 84' ' ' ILE . 0.5 OUTLIER -162.94 140.93 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 120.621 -1.299 . . . . 0.0 111.899 -178.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.592 ' O ' ' CG1' ' A' ' 84' ' ' ILE . 75.1 m-20 -80.54 154.72 27.33 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.182 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.638 ' CG1' ' CG1' ' A' ' 82' ' ' VAL . 20.5 mt -155.63 134.04 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 117.065 -1.854 . . . . 0.0 112.443 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.51 ' CG1' HD22 ' A' ' 24' ' ' LEU . 9.5 mm -99.27 104.34 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 178.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.503 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.13 -161.48 35.41 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.747 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.502 ' HG2' HD11 ' B' ' 5' ' ' LEU . 1.0 OUTLIER -63.73 -35.48 80.72 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.691 -0.888 . . . . 0.0 109.663 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.576 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 18.6 p-10 -51.26 -20.88 1.8 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.987 -1.07 . . . . 0.0 110.248 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.576 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -113.03 -29.7 7.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.727 -1.233 . . . . 0.0 110.265 -179.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.443 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 21.4 mt -66.18 -11.6 50.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.994 -1.066 . . . . 0.0 108.957 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -101.38 -10.05 20.59 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.064 -1.023 . . . . 0.0 109.513 179.848 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.5 mm-40 -90.28 -41.19 11.69 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.264 -0.897 . . . . 0.0 109.85 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.523 HD11 ' CG ' ' B' ' 99' ' ' PHE . 2.2 pt -89.72 2.35 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.118 -0.989 . . . . 0.0 109.065 179.371 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 65.84 54.48 24.86 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.529 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -82.75 137.1 34.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.055 -1.262 . . . . 0.0 109.543 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.4 p -122.78 136.95 55.03 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.223 -0.923 . . . . 0.0 109.117 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.54 HD13 ' CD1' ' B' ' 97' ' ' LEU . 5.3 mp -97.36 96.67 8.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.896 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -101.02 125.17 47.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.038 -1.039 . . . . 0.0 109.251 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.296 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.678 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.475 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.3 tt0 -130.74 136.69 48.99 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 177.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 8.0 t -132.17 136.24 56.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 120.886 -1.134 . . . . 0.0 109.653 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.593 ' O ' ' HB2' ' B' ' 5' ' ' LEU . 6.0 p -69.38 -93.14 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.394 -0.816 . . . . 0.0 109.662 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.593 ' HB2' ' O ' ' B' ' 4' ' ' THR . 0.2 OUTLIER 158.81 -7.44 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.836 -0.54 . . . . 0.0 110.72 179.542 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -50.53 -19.27 0.84 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.667 -1.271 . . . . 0.0 110.535 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.41 -175.92 4.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.806 -1.184 . . . . 0.0 109.9 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.05 130.33 91.49 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -79.66 68.16 8.38 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.425 2.083 . . . . 0.0 109.471 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.549 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -87.21 156.48 19.65 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.167 -0.958 . . . . 0.0 109.977 -179.104 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.54 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -147.33 138.37 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.392 -0.817 . . . . 0.0 109.662 -179.627 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.5 m -71.53 90.68 1.02 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.89 -1.131 . . . . 0.0 108.287 178.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.54 HG21 ' CG2' ' B' ' 11' ' ' VAL . 4.4 pt -80.29 150.2 4.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.952 -179.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.529 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 10.6 tttm -121.75 104.42 9.58 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.366 -0.834 . . . . 0.0 109.403 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.555 ' CG2' HG23 ' B' ' 62' ' ' ILE . 4.8 mt -117.13 143.21 28.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.24 -90.29 0.05 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.946 -1.661 . . . . 0.0 108.946 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -158.35 38.67 0.52 Allowed Glycine 0 N--CA 1.486 1.97 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 179.286 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.419 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -137.46 166.91 22.73 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.67 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.529 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 17.5 mt -132.23 122.12 24.73 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.414 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -134.89 155.78 50.09 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.035 -1.041 . . . . 0.0 109.9 -178.961 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.549 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.5 mm-40 -78.98 110.42 14.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 178.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.546 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -98.63 154.75 17.71 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 110.341 -178.395 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.474 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.6 tp -101.85 101.18 11.58 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.668 -0.645 . . . . 0.0 109.751 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.483 HD12 ' CE2' ' A' ' 99' ' ' PHE . 19.6 mt -46.23 99.57 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.32 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.569 ' CB ' HG22 ' B' ' 84' ' ' ILE . 44.4 t0 -107.48 96.08 6.15 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.291 -0.88 . . . . 0.0 111.027 -178.225 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.525 ' HA ' ' CD2' ' B' ' 90' ' ' LEU . 0.7 OUTLIER -78.97 3.22 17.77 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.086 -1.009 . . . . 0.0 109.188 178.599 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.69 -18.62 31.97 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . 0.449 ' O ' ' HG3' ' B' ' 87' ' ' ARG . . . -85.78 170.83 12.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.019 -1.283 . . . . 0.0 109.711 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.44 ' HA ' ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER -100.67 -20.06 15.79 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.186 -0.946 . . . . 0.0 110.797 -178.88 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' HB ' ' B' ' 74' ' ' THR . 0.2 OUTLIER -137.99 -163.11 1.39 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.803 -1.186 . . . . 0.0 109.851 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.527 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 17.8 m -109.88 86.6 2.33 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.972 -1.08 . . . . 0.0 110.538 -178.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -69.04 175.39 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.825 -1.172 . . . . 0.0 108.157 179.08 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.564 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.4 116.94 0.51 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.111 -0.993 . . . . 0.0 109.804 -178.911 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.542 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 5.2 pt-20 -39.58 160.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.465 -0.772 . . . . 0.0 109.515 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.469 ' HA ' HG11 ' B' ' 77' ' ' VAL . 0.3 OUTLIER -38.31 139.81 0.35 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.728 0.775 . . . . 0.0 110.699 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -168.53 167.69 11.47 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.761 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 28.8 t -100.63 125.78 47.07 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.789 -1.194 . . . . 0.0 111.256 -178.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.575 ' HB2' ' CZ ' ' B' ' 59' ' ' TYR . 3.6 mm? -117.09 171.96 4.38 Favored Pre-proline 0 N--CA 1.493 1.696 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.505 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.3 Cg_endo -80.57 59.91 7.64 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.385 2.057 . . . . 0.0 111.38 -179.493 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 40.21 -158.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.431 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 58.49 68.22 0.85 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.443 -1.034 . . . . 0.0 109.313 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 22.8 p-90 -144.16 -167.44 2.61 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.44 -0.788 . . . . 0.0 109.879 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -146.44 132.08 9.31 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.57 132.12 11.95 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 121.93 1.753 . . . . 0.0 110.602 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.406 ' HD3' HD22 ' B' ' 76' ' ' LEU . 0.6 OUTLIER -161.33 -162.24 0.88 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.713 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.414 ' HB3' ' HA ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -152.24 146.33 25.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.992 -1.068 . . . . 0.0 109.361 178.743 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.476 HD13 HD12 ' B' ' 54' ' ' ILE . 1.1 pt -96.33 155.83 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.258 -0.901 . . . . 0.0 108.886 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.663 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.09 130.7 8.69 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -158.02 -125.42 0.83 Allowed Glycine 0 N--CA 1.482 1.76 0 C-N-CA 118.949 -1.596 . . . . 0.0 111.338 -179.196 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.506 ' O ' ' O ' ' A' ' 50' ' ' ILE . 19.0 mt -88.96 126.68 41.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.937 -0.743 . . . . 0.0 112.836 -177.271 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 90.48 -28.3 7.73 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 178.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.408 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 157.76 -159.24 29.74 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.169 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.663 ' CD2' ' CA ' ' B' ' 48' ' ' GLY . 1.5 m-85 -120.49 132.07 55.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.654 -0.909 . . . . 0.0 109.627 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.513 HD12 ' CG2' ' A' ' 50' ' ' ILE . 35.4 pt -103.9 162.84 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 108.983 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.5 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 13.0 mttt -93.3 154.73 17.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.088 -1.007 . . . . 0.0 109.771 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.564 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 6.4 m -151.23 -168.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.055 -1.028 . . . . 0.0 110.07 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.563 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 16.7 mmt180 -129.83 89.22 2.78 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -56.48 93.62 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.271 -0.893 . . . . 0.0 110.777 -178.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.607 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 27.9 m-85 -88.71 136.04 33.2 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 177.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.484 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -114.58 138.25 50.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.712 -1.242 . . . . 0.0 111.041 -178.302 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.523 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.46 60.68 0.07 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.653 -0.654 . . . . 0.0 110.602 178.884 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.555 HG23 ' CG2' ' B' ' 15' ' ' ILE . 4.2 mp -118.77 118.09 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 108.856 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.543 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.8 tm? -68.26 90.13 0.34 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.237 -0.914 . . . . 0.0 110.631 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.519 ' HB ' ' CG1' ' B' ' 15' ' ' ILE . 2.4 tt -90.07 115.21 29.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.4 tm-20 -89.13 117.53 28.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.551 -178.586 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.501 HD12 ' CD1' ' B' ' 64' ' ' ILE . 1.4 mp -115.69 125.02 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.331 -0.856 . . . . 0.0 109.351 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 62.4 m 61.57 -95.06 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.518 -0.739 . . . . 0.0 109.792 179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -145.78 39.78 1.12 Allowed Glycine 0 N--CA 1.484 1.893 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -139.62 133.06 30.15 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.381 -1.07 . . . . 0.0 109.637 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.499 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -77.04 135.55 38.65 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.022 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.483 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -145.75 97.53 2.98 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.154 -1.018 . . . . 0.0 110.665 -179.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.525 HD12 ' N ' ' B' ' 63' ' ' LEU . 0.6 OUTLIER -78.89 140.17 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 177.988 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.545 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -167.77 -168.0 29.27 Favored Glycine 0 N--CA 1.485 1.96 0 C-N-CA 118.741 -1.695 . . . . 0.0 110.939 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 28.9 m -95.95 109.18 21.59 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.781 -0.835 . . . . 0.0 110.244 -179.397 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.506 HG22 ' HB ' ' B' ' 62' ' ' ILE . 1.4 t -96.61 104.97 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.321 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.512 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.7 mp -79.86 116.74 20.19 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.202 -0.936 . . . . 0.0 108.615 178.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 4.3 t -101.39 131.44 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.051 -1.031 . . . . 0.0 109.125 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.482 ' HA3' HG13 ' B' ' 56' ' ' VAL . . . -162.38 -165.43 19.37 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.06 -1.543 . . . . 0.0 109.905 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.93 40.67 1.01 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.753 2.302 . . . . 0.0 110.054 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.542 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 8.8 t -85.55 138.5 35.89 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -78.38 14.3 1.63 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.51 2.14 . . . . 0.0 111.078 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.511 HG11 ' CD1' ' B' ' 84' ' ' ILE . 1.1 t -160.68 167.56 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.102 -0.999 . . . . 0.0 109.382 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.608 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -101.15 144.18 30.34 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 175.816 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.569 HG22 ' CB ' ' B' ' 25' ' ' ASP . 6.8 mm -129.0 123.68 59.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 O-C-N 120.069 -1.644 . . . . 0.0 112.194 -176.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.452 HG21 ' CD1' ' B' ' 90' ' ' LEU . 4.4 mm -102.54 101.48 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.491 ' O ' HD11 ' B' ' 90' ' ' LEU . . . -107.0 175.25 20.51 Favored Glycine 0 N--CA 1.496 2.695 0 C-N-CA 119.792 -1.194 . . . . 0.0 111.915 -177.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.536 ' N ' HD21 ' B' ' 90' ' ' LEU . 4.0 mtm180 -28.46 -41.44 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.376 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -178.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.536 ' ND2' HD21 ' B' ' 89' ' ' LEU . 8.8 p-10 -53.17 -41.38 65.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 120.234 -1.541 . . . . 0.0 110.661 -177.659 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.545 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 1.6 mm? -98.92 -18.33 17.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.172 -0.955 . . . . 0.0 110.342 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.536 HD21 ' N ' ' B' ' 87' ' ' ARG . 0.4 OUTLIER -69.51 -35.89 75.94 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.143 -0.973 . . . . 0.0 109.391 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 49.6 p -70.03 -15.27 62.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.189 -0.944 . . . . 0.0 108.965 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' B' ' 72' ' ' ILE . 26.7 mt-30 -91.63 -40.48 11.28 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.306 -0.871 . . . . 0.0 108.943 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.561 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -81.77 -2.98 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 177.088 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.01 43.29 99.63 Favored Glycine 0 N--CA 1.496 2.697 0 O-C-N 121.561 -0.712 . . . . 0.0 111.361 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -68.38 147.01 52.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.874 -1.368 . . . . 0.0 110.289 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 14.9 p -144.61 130.78 19.54 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.339 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.54 ' CD1' HD13 ' A' ' 97' ' ' LEU . 8.0 mp -92.68 102.85 15.27 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 110.119 -179.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 3.6 m120 -101.65 121.95 42.98 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.088 -1.007 . . . . 0.0 109.688 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 118.128 -0.939 . . . . 0.0 109.33 179.309 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.449 ' HD2' ' OXT' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.687 0 N-CA-C 110.164 -0.745 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.52 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -104.09 126.59 51.33 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.292 -0.88 . . . . 0.0 109.032 179.079 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 t -121.83 102.46 11.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 0.8 OUTLIER -52.27 -84.26 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.324 -0.86 . . . . 0.0 109.953 -178.981 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.571 HD23 ' CB ' ' B' ' 90' ' ' LEU . 31.2 tp 171.84 -25.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.259 -0.9 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 84.8 m95 -54.77 -19.36 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.07 -1.019 . . . . 0.0 108.996 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -129.51 130.53 45.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.438 -0.789 . . . . 0.0 109.513 179.594 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtt-85 -49.06 146.49 5.7 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.533 ' HD3' ' NH2' ' B' ' 87' ' ' ARG . 37.0 Cg_endo -79.8 47.75 2.63 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.838 2.359 . . . . 0.0 110.538 179.394 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 mt -80.03 144.4 33.24 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.1 -1.0 . . . . 0.0 109.276 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.402 HG22 ' CG2' ' A' ' 66' ' ' ILE . 1.9 m -148.99 160.15 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.366 -179.379 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 90.0 m -91.21 107.77 19.43 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.487 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.465 ' CG2' HD11 ' A' ' 66' ' ' ILE . 2.1 pt -99.18 157.97 3.67 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.275 -0.89 . . . . 0.0 110.084 -178.674 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.535 ' CB ' HD22 ' A' ' 19' ' ' LEU . 2.3 ttmt -118.16 100.81 7.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 108.913 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.555 ' CD1' HG12 ' A' ' 75' ' ' VAL . 1.3 mt -109.8 140.92 26.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.858 -1.151 . . . . 0.0 109.4 -179.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 62.96 -90.64 0.07 OUTLIER Glycine 0 N--CA 1.488 2.139 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -179.604 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.22 35.19 0.6 Allowed Glycine 0 C--N 1.294 -1.787 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.404 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -138.99 173.78 11.2 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -1.134 . . . . 0.0 109.591 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.535 HD22 ' CB ' ' A' ' 14' ' ' LYS . 18.5 mt -133.58 122.04 22.95 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.593 -0.692 . . . . 0.0 109.42 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.451 ' HE3' ' SD ' ' A' ' 36' ' ' MET . 0.3 OUTLIER -135.72 -179.87 5.92 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.93 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.5 mt-10 -78.32 176.36 9.39 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 108.191 179.521 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.488 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -157.71 108.74 2.25 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 120.936 -1.102 . . . . 0.0 109.619 -179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.521 ' O ' ' N ' ' A' ' 25' ' ' ASP . 20.8 tp -85.19 93.41 8.65 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.35 -0.844 . . . . 0.0 109.078 179.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 23' ' ' LEU . 97.8 mt -43.06 97.15 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.545 ' CB ' HG21 ' A' ' 84' ' ' ILE . 3.8 t0 -102.95 77.18 1.54 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.388 -0.82 . . . . 0.0 110.918 -178.245 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.464 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 2.2 m -54.92 -20.19 8.36 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.124 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.403 ' O ' HD23 ' B' ' 23' ' ' LEU . . . -65.24 -44.33 93.93 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.732 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.47 155.72 40.01 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.17 -1.194 . . . . 0.0 108.86 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.68 -17.55 31.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.05 -1.032 . . . . 0.0 110.688 -179.034 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.523 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -138.42 -159.58 0.97 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.779 -1.201 . . . . 0.0 110.108 -179.532 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 35.3 m -114.98 91.41 3.61 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.925 -1.11 . . . . 0.0 110.602 -178.547 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.533 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -74.79 160.12 5.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.675 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.533 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -160.15 123.72 3.57 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.841 -1.162 . . . . 0.0 110.473 -178.595 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.607 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.6 OUTLIER -41.99 153.46 0.06 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.14 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.459 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -43.11 146.93 0.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.021 -1.049 . . . . 0.0 110.161 -179.55 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.544 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 21.7 ptm -162.2 -163.64 0.95 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.311 -0.868 . . . . 0.0 109.597 -179.802 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.4 t -101.31 87.08 3.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.433 -0.792 . . . . 0.0 109.214 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.54 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 12.9 tp -127.71 97.34 30.5 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.145 -0.972 . . . . 0.0 110.134 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.04 178.31 7.34 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.497 2.131 . . . . 0.0 109.94 179.366 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.15 -173.86 16.31 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.486 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -78.93 134.86 36.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.326 -1.102 . . . . 0.0 109.239 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.596 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.9 p-90 -147.72 159.42 43.82 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -128.26 135.44 27.54 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 135.33 18.28 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 121.86 1.707 . . . . 0.0 109.968 -179.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.454 ' HD2' HD22 ' A' ' 76' ' ' LEU . 8.1 ptpt -155.8 -165.66 2.02 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.462 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.458 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 4.0 mtp -150.4 125.89 10.2 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.293 -0.879 . . . . 0.0 109.641 -179.624 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.513 HD13 ' CG2' ' B' ' 50' ' ' ILE . 1.1 pt -89.78 147.1 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.014 -1.054 . . . . 0.0 108.422 179.118 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.427 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -117.97 105.76 1.28 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -128.39 -132.34 3.54 Favored Glycine 0 N--CA 1.484 1.89 0 C-N-CA 119.459 -1.353 . . . . 0.0 111.043 -178.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.537 HG21 ' CG2' ' B' ' 54' ' ' ILE . 34.8 mt -83.13 121.06 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.838 -0.801 . . . . 0.0 112.537 -177.547 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.439 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 97.71 -20.48 50.46 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 178.019 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.87 -161.01 28.88 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 120.808 -1.407 . . . . 0.0 109.993 179.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -126.09 132.37 51.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.437 -1.037 . . . . 0.0 109.524 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.487 HD13 HD12 ' A' ' 47' ' ' ILE . 14.1 pt -104.38 175.33 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.079 -1.013 . . . . 0.0 109.412 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.458 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 3.6 mtmt -103.77 140.32 37.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.095 -1.003 . . . . 0.0 109.258 179.853 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.526 HG22 ' CD2' ' A' ' 76' ' ' LEU . 27.1 m -144.39 170.08 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.129 -0.982 . . . . 0.0 109.917 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.413 ' O ' ' N ' ' A' ' 59' ' ' TYR . 1.0 OUTLIER -111.21 96.76 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.057 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -55.78 93.74 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.344 -0.848 . . . . 0.0 109.704 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 5.8 m-85 -89.31 125.98 35.33 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 178.528 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.596 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 65.3 m-20 -106.38 133.8 50.5 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.792 -1.192 . . . . 0.0 110.345 -178.885 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.596 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mt-30 74.44 63.32 0.07 Allowed 'General case' 0 N--CA 1.494 1.741 0 CA-C-O 121.855 0.836 . . . . 0.0 109.904 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.528 ' CG2' HG22 ' A' ' 15' ' ' ILE . 16.0 mm -115.14 119.47 61.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 178.616 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.52 ' N ' HD11 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -70.42 90.2 0.71 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.178 -0.951 . . . . 0.0 111.277 -177.919 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.587 ' CG2' ' CD1' ' A' ' 89' ' ' LEU . 7.3 tt -88.51 113.51 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.657 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -87.99 111.79 21.88 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.244 -0.91 . . . . 0.0 109.012 -178.282 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.546 ' O ' ' N ' ' A' ' 68' ' ' GLY . 1.3 mm -97.19 168.1 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.505 ' C ' ' O ' ' A' ' 66' ' ' ILE . 61.3 m -28.68 88.87 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.488 0.661 . . . . 0.0 111.219 -179.074 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.573 ' O ' ' CD2' ' A' ' 69' ' ' HIS . . . 52.31 58.94 9.66 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.529 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 68' ' ' GLY . 6.8 m-70 -162.27 86.76 0.61 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.372 . . . . 0.0 110.42 179.496 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.519 ' CG ' HD22 ' A' ' 63' ' ' LEU . 4.4 tttm -49.04 118.54 2.69 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.537 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -141.26 108.36 5.47 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 119.416 -0.914 . . . . 0.0 110.456 -178.602 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.539 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -80.74 159.42 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.005 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.521 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 179.42 174.49 45.51 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 118.247 -1.93 . . . . 0.0 111.452 179.577 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.569 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 87.6 m -87.14 112.67 22.17 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.606 -0.938 . . . . 0.0 109.956 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.555 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -102.17 118.9 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.422 -0.799 . . . . 0.0 110.275 179.679 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.526 ' CD2' HG22 ' A' ' 56' ' ' VAL . 4.9 mp -87.81 105.75 17.62 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.77 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.459 HG11 ' HA ' ' A' ' 35' ' ' GLU . 6.5 t -88.75 113.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.233 -0.917 . . . . 0.0 110.327 -178.67 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.479 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -153.85 -168.77 17.96 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.451 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -80.35 44.5 1.75 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.634 2.223 . . . . 0.0 111.061 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.607 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.7 t -82.5 141.25 45.17 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.022 -1.049 . . . . 0.0 108.637 179.241 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -81.22 17.67 1.43 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.576 2.184 . . . . 0.0 111.163 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 2.2 t -161.26 163.28 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.86 -1.15 . . . . 0.0 110.333 -179.23 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.488 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 72.5 m-20 -99.18 89.37 4.22 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.545 HG21 ' CB ' ' A' ' 25' ' ' ASP . 8.2 mm -78.27 116.43 21.94 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 O-C-N 121.168 -0.957 . . . . 0.0 111.764 -176.436 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.602 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -101.63 85.99 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.225 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.64 -165.32 28.02 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.288 -0.958 . . . . 0.0 112.346 -176.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.485 ' HD3' ' HD3' ' B' ' 9' ' ' PRO . 27.8 mtm-85 -57.38 -39.91 77.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 122.203 -0.586 . . . . 0.0 111.481 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 16.3 p-10 -45.49 -24.31 0.31 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.537 -1.352 . . . . 0.0 109.63 -179.3 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.587 ' CD1' ' CG2' ' A' ' 64' ' ' ILE . 3.5 mm? -111.9 -32.48 6.59 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.892 -1.13 . . . . 0.0 110.712 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.464 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 90.1 mt -58.17 -36.58 73.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.824 -1.172 . . . . 0.0 108.841 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.4 p -75.69 -20.53 58.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.316 -0.865 . . . . 0.0 109.643 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -72.45 -40.31 67.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.863 -1.148 . . . . 0.0 108.472 179.428 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.552 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -81.65 -1.01 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.581 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 67.47 61.3 5.16 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.506 -1.838 . . . . 0.0 108.506 -179.527 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -89.77 149.27 22.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.442 -1.034 . . . . 0.0 110.003 -179.192 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 49.5 p -137.73 125.43 22.36 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.028 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.562 ' CD1' HD13 ' B' ' 97' ' ' LEU . 4.8 mp -86.0 104.11 15.31 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.59 -0.694 . . . . 0.0 109.279 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.2 m120 -104.4 122.32 45.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.083 -1.011 . . . . 0.0 110.03 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.612 ' CD2' ' CD1' ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.618 0 CA-C-O 117.937 -1.03 . . . . 0.0 109.25 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.478 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.626 0 N-CA-C 109.87 -0.858 . . . . 0.0 109.87 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.445 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.2 tt0 -84.64 134.0 34.39 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.459 HG11 HD11 ' B' ' 5' ' ' LEU . 22.2 t -133.73 137.07 53.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 120.762 -1.212 . . . . 0.0 109.9 -179.144 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.558 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -129.99 23.84 5.3 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 178.983 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.524 ' CD2' ' HA ' ' B' ' 9' ' ' PRO . 1.6 mp -39.54 92.24 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.767 0.794 . . . . 0.0 109.801 -179.226 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.558 ' N ' ' O ' ' B' ' 4' ' ' THR . 4.7 m95 -44.42 -21.59 0.05 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.632 -0.667 . . . . 0.0 109.912 -179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.447 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.7 mt-30 -109.4 -158.85 0.66 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.022 -1.049 . . . . 0.0 108.599 179.122 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -59.01 119.7 40.42 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.037 -1.04 . . . . 0.0 109.469 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.524 ' HA ' ' CD2' ' B' ' 5' ' ' LEU . 36.6 Cg_endo -78.22 73.14 5.92 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.254 1.969 . . . . 0.0 109.798 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.54 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -82.1 163.61 21.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.184 -0.947 . . . . 0.0 109.937 -179.425 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.483 HG21 ' O ' ' B' ' 11' ' ' VAL . 14.8 m -144.95 142.33 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.429 -0.794 . . . . 0.0 110.143 -179.697 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.7 m -73.97 99.09 3.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.01 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.531 ' CD1' HD13 ' B' ' 15' ' ' ILE . 1.3 pt -92.07 147.46 5.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.617 -178.454 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.8 tttt -114.08 94.51 4.85 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.531 HD13 ' CD1' ' B' ' 13' ' ' ILE . 22.3 mt -115.03 129.94 70.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.132 -0.98 . . . . 0.0 109.609 -179.429 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.05 52.99 49.08 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.442 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.35 23.57 9.01 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -119.26 170.67 8.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -1.151 . . . . 0.0 109.476 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.417 HD21 ' O ' ' B' ' 13' ' ' ILE . 13.8 mt -141.52 122.42 14.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.139 -0.976 . . . . 0.0 110.24 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 mttt -147.22 145.92 29.63 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.139 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.54 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 11.8 mt-10 -78.37 133.24 37.59 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.863 -1.148 . . . . 0.0 108.504 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.534 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -112.38 162.8 15.15 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.883 -179.04 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' B' ' 25' ' ' ASP . 59.4 tp -99.7 101.52 12.72 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.837 -0.539 . . . . 0.0 110.06 -178.856 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.466 HD12 HD21 ' A' ' 97' ' ' LEU . 2.9 mt -44.98 97.37 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.214 -0.929 . . . . 0.0 108.51 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.575 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 10.3 t0 -100.87 95.39 6.58 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.089 -1.007 . . . . 0.0 110.863 -178.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.0 9.67 9.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.257 -0.902 . . . . 0.0 108.861 178.301 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.0 -14.13 17.88 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.841 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.5 170.03 9.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.111 -1.229 . . . . 0.0 109.089 179.803 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.08 -14.94 17.59 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.038 -1.039 . . . . 0.0 111.825 -178.397 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.487 ' C ' ' OD1' ' B' ' 88' ' ' ASN . 14.3 m-20 -141.91 -169.33 2.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.507 -1.371 . . . . 0.0 110.639 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.749 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 38.5 m -104.48 84.75 2.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.199 -0.938 . . . . 0.0 110.475 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.523 HG13 ' CG1' ' B' ' 84' ' ' ILE . 1.0 OUTLIER -78.75 112.19 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.244 -0.91 . . . . 0.0 110.387 -179.636 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.512 ' HB2' ' CG1' ' B' ' 75' ' ' VAL . 0.5 OUTLIER -107.76 123.17 48.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.583 -0.698 . . . . 0.0 110.176 179.895 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 14.0 pt-20 -43.36 164.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.943 -1.098 . . . . 0.0 108.831 178.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.544 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -47.74 145.03 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.996 -1.065 . . . . 0.0 110.112 -179.231 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.481 ' CG ' ' HG ' ' B' ' 38' ' ' LEU . 10.5 ptm -155.66 -165.55 2.0 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.36 -0.838 . . . . 0.0 109.135 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 21.2 t -102.44 87.14 2.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.111 -0.993 . . . . 0.0 109.508 179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.486 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 31.3 mt -112.88 163.92 16.75 Favored Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 121.246 -0.909 . . . . 0.0 109.17 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.9 Cg_endo -75.8 -166.45 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.354 2.036 . . . . 0.0 110.492 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.502 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -94.28 -152.17 29.01 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 62.97 58.71 1.45 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.888 -0.772 . . . . 0.0 109.067 -179.401 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.583 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 30.0 p-90 -134.92 175.61 9.41 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.649 -0.657 . . . . 0.0 109.746 -179.537 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.03 123.65 15.97 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.229 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.38 137.44 20.9 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.217 1.944 . . . . 0.0 111.543 -178.689 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.24 -167.29 2.72 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.105 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.502 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 54.6 mtp -145.69 131.36 18.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.94 -1.1 . . . . 0.0 110.159 -179.275 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.498 HD12 HD12 ' B' ' 54' ' ' ILE . 5.2 pt -97.75 149.04 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.171 -0.955 . . . . 0.0 108.694 179.08 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.611 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.06 116.94 3.49 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.27 -125.86 2.31 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.449 -1.358 . . . . 0.0 110.536 -179.431 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.513 ' CG2' HD13 ' A' ' 47' ' ' ILE . 66.6 mt -87.23 129.27 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.948 . . . . 0.0 112.676 -177.794 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.07 -47.37 2.68 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 178.252 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.439 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 178.87 -156.26 18.31 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.055 -179.701 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.5 m-85 -120.97 136.22 55.02 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.681 -0.894 . . . . 0.0 109.414 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.537 ' CG2' HG21 ' A' ' 50' ' ' ILE . 7.1 pt -107.16 173.1 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.125 -0.984 . . . . 0.0 109.102 179.219 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.551 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 9.8 mttm -110.06 145.53 36.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.028 -1.045 . . . . 0.0 109.099 179.708 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' B' ' 76' ' ' LEU . 30.6 m -141.48 -173.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.868 -1.145 . . . . 0.0 110.39 -179.583 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' B' ' 59' ' ' TYR . 5.2 mtt85 -129.31 90.09 2.96 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.46 ' HG3' HG23 ' B' ' 74' ' ' THR . 12.0 tt0 -48.76 92.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.363 -0.836 . . . . 0.0 109.97 -179.488 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.583 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 10.3 m-85 -92.93 92.14 7.73 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -79.52 140.17 37.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.147 -0.971 . . . . 0.0 110.626 -178.519 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.515 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 76.76 60.61 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.514 0.673 . . . . 0.0 110.019 179.539 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.491 ' HB ' HG21 ' B' ' 75' ' ' VAL . 6.1 mm -120.77 115.48 47.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.519 ' CD2' ' C ' ' B' ' 63' ' ' LEU . 0.5 OUTLIER -66.7 104.0 1.21 Allowed 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.848 -1.157 . . . . 0.0 110.73 -178.664 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.559 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 9.2 tt -106.19 112.65 40.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 177.486 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.0 tt0 -88.89 106.58 18.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.955 -1.091 . . . . 0.0 109.79 -177.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.468 ' O ' ' HB2' ' B' ' 69' ' ' HIS . 1.6 mp -105.01 117.47 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.884 . . . . 0.0 109.406 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.495 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 9.7 m 58.54 57.66 3.7 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.453 -0.779 . . . . 0.0 109.916 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.56 34.48 20.29 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.636 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.495 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 61.8 m-70 -126.51 117.1 22.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.255 -1.144 . . . . 0.0 109.309 179.794 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.476 ' HG3' HD23 ' B' ' 63' ' ' LEU . 23.0 ttpt -65.38 124.82 23.27 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.452 -179.927 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -146.44 96.02 2.7 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.353 -0.842 . . . . 0.0 109.523 -179.829 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.515 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.7 OUTLIER -79.14 152.46 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.048 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.07 -157.42 14.77 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 118.428 -1.844 . . . . 0.0 111.781 179.919 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.46 HG23 ' HG3' ' B' ' 58' ' ' GLN . 3.4 m -110.66 104.97 13.71 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.679 -0.895 . . . . 0.0 110.001 -179.089 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' B' ' 33' ' ' LEU . 1.4 t -96.65 110.41 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.635 -0.666 . . . . 0.0 110.215 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.491 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 3.8 mp -79.56 106.75 11.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 179.439 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.544 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 2.8 t -88.67 111.43 22.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.95 -1.094 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -141.65 -170.5 12.42 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.551 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.09 42.55 1.36 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.474 2.116 . . . . 0.0 110.648 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.567 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.0 t -88.94 139.45 29.07 Favored Pre-proline 0 N--CA 1.49 1.536 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.6 Cg_endo -80.43 18.21 1.25 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.553 2.169 . . . . 0.0 111.19 -179.313 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.507 ' CG1' HD13 ' B' ' 84' ' ' ILE . 0.8 OUTLIER -161.59 163.01 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.917 -1.114 . . . . 0.0 110.008 -179.348 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.537 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.1 OUTLIER -94.62 160.33 14.68 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 104.482 -2.414 . . . . 0.0 104.482 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.749 ' O ' ' HA ' ' B' ' 31' ' ' THR . 12.6 mm -144.05 95.05 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 O-C-N 120.051 -1.655 . . . . 0.0 111.054 -178.354 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.577 ' CG2' ' CD1' ' B' ' 90' ' ' LEU . 0.3 OUTLIER -77.71 101.41 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 178.196 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.509 ' O ' HD11 ' B' ' 90' ' ' LEU . . . -112.99 -176.07 19.49 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.674 -177.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.54 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 7.1 mtt85 -29.65 -42.16 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -178.614 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.559 ' ND2' HD21 ' B' ' 89' ' ' LEU . 4.8 p-10 -57.56 -42.64 83.41 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.124 -1.61 . . . . 0.0 110.482 -177.688 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.559 HD21 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -95.8 -10.57 28.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.299 -0.876 . . . . 0.0 109.662 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.577 ' CD1' ' CG2' ' B' ' 85' ' ' ILE . 1.2 mp -79.06 -32.0 44.68 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.319 -0.863 . . . . 0.0 109.186 -179.623 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.56 ' N ' ' CD2' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.9 -20.22 60.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.064 -1.022 . . . . 0.0 109.413 179.611 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.523 ' OE1' ' CD1' ' B' ' 89' ' ' LEU . 28.0 mt-30 -82.13 -41.24 20.73 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.029 -1.045 . . . . 0.0 109.03 179.562 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.612 ' CD1' ' CD2' ' A' ' 99' ' ' PHE . 1.1 pt -82.48 -9.11 11.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.3 57.37 15.48 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 178.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.523 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -81.15 142.14 33.55 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.253 -1.145 . . . . 0.0 110.446 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 24.3 p -129.82 126.2 37.51 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.713 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.562 HD13 ' CD1' ' A' ' 97' ' ' LEU . 2.7 mp -90.53 90.43 8.0 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 109.537 -179.609 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.52 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 5.1 m120 -95.63 127.63 41.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.66 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.13 179.297 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.419 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.73 0 N-CA-C 110.65 -0.558 . . . . 0.0 110.65 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.1 OUTLIER -84.4 146.0 27.9 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 177.865 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.542 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 2.2 t -134.19 124.56 46.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 C-N-CA 118.486 -1.286 . . . . 0.0 110.091 -179.04 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -130.14 14.02 5.67 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.128 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -43.75 93.51 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 CA-C-O 121.9 0.857 . . . . 0.0 109.152 -179.301 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.538 ' N ' ' O ' ' A' ' 4' ' ' THR . 2.5 m95 -45.24 -15.15 0.02 OUTLIER 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.879 -0.513 . . . . 0.0 110.426 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.514 ' N ' ' O ' ' A' ' 5' ' ' LEU . 28.9 mt-30 -106.48 -115.65 0.26 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.62 -1.3 . . . . 0.0 108.951 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.504 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 46.3 mtp180 -111.03 136.48 20.8 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 120.406 -1.434 . . . . 0.0 110.235 -179.691 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.507 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 38.0 Cg_endo -81.09 63.09 8.7 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.597 2.198 . . . . 0.0 109.785 178.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.46 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 2.4 mt -84.79 140.29 31.33 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.623 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.447 HG23 ' HB1' ' A' ' 22' ' ' ALA . 1.1 m -140.32 151.64 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.321 -0.862 . . . . 0.0 109.128 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.5 m -86.08 99.92 11.82 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.206 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.56 HG22 ' CB ' ' A' ' 22' ' ' ALA . 1.9 pt -91.5 161.04 2.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.388 -0.82 . . . . 0.0 110.311 -178.178 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 1.2 tttt -117.07 97.85 6.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 109.174 179.491 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.57 ' CD1' ' CG2' ' A' ' 75' ' ' VAL . 0.2 OUTLIER -113.67 126.93 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.096 -1.003 . . . . 0.0 109.463 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.63 31.02 77.33 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.733 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.7 11.36 68.91 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.517 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 91.7 mm-40 -108.01 167.53 9.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 108.901 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.491 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 35.1 mt -126.23 123.35 37.97 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.011 -1.056 . . . . 0.0 109.368 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -140.66 173.99 10.95 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.911 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.6 mt-10 -79.25 177.23 8.99 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.56 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -154.75 112.0 3.37 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 120.849 -1.157 . . . . 0.0 109.798 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 25' ' ' ASP . 13.4 tp -89.53 95.35 10.23 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.646 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.507 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 30.4 mt -43.85 98.85 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' CB ' HG22 ' A' ' 84' ' ' ILE . 5.5 t0 -105.1 73.71 1.07 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.375 -0.828 . . . . 0.0 110.999 -177.651 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.0 m -57.15 -18.33 14.74 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.861 -1.149 . . . . 0.0 108.052 178.348 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.97 -45.34 92.66 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.71 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.66 163.48 27.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.203 -1.174 . . . . 0.0 109.328 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.43 -14.89 23.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.166 -0.958 . . . . 0.0 110.888 -179.029 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.529 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.01 -165.44 1.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.671 -1.268 . . . . 0.0 111.338 -178.972 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.727 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -102.47 88.52 3.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.487 -0.758 . . . . 0.0 110.953 -178.426 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.546 HG11 ' CG1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -79.38 113.38 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.013 -1.679 . . . . 0.0 107.933 178.566 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.51 ' HG ' ' OD1' ' A' ' 83' ' ' ASN . 1.1 mp -115.02 132.58 56.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 111.33 -177.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -43.39 165.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.202 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.565 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.4 OUTLIER -57.05 142.72 41.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.029 -1.045 . . . . 0.0 110.238 -179.561 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.534 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 4.2 ptm -161.82 -161.16 0.75 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.431 -0.793 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -104.15 114.89 29.45 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.321 -0.862 . . . . 0.0 110.358 -179.427 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.518 ' HG ' ' HD2' ' A' ' 39' ' ' PRO . 3.1 tp -138.68 145.7 47.33 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.636 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 31.6 Cg_endo -72.28 157.11 54.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.345 2.03 . . . . 0.0 110.507 -179.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.517 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -49.8 -162.09 0.01 OUTLIER Glycine 0 N--CA 1.493 2.473 0 CA-C-O 121.858 0.699 . . . . 0.0 111.881 -178.475 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.514 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 75.59 50.29 0.07 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.608 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 6.9 p-90 -122.56 177.88 5.23 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-O 122.124 0.964 . . . . 0.0 111.269 -178.297 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.426 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 1.3 mtmm -139.51 118.49 8.96 Favored Pre-proline 0 C--N 1.303 -1.417 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.698 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -74.91 138.63 23.51 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.038 1.826 . . . . 0.0 110.91 -178.706 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.74 -173.21 4.0 Favored 'General case' 0 N--CA 1.49 1.528 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.901 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.484 ' CE ' ' HG3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -138.79 120.62 15.38 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.882 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.51 HG13 ' CG1' ' A' ' 54' ' ' ILE . 3.1 pt -91.68 144.11 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.886 -1.134 . . . . 0.0 109.331 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.61 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -119.01 135.04 11.15 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 179.892 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.64 -129.5 1.06 Allowed Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.395 -179.614 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.537 ' CG2' HG12 ' B' ' 54' ' ' ILE . 77.6 mt -82.15 109.27 16.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.704 -0.88 . . . . 0.0 112.57 -177.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 111.78 -29.23 8.7 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 178.167 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.63 -161.52 29.26 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.424 179.65 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.61 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -112.02 131.97 55.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.408 -1.054 . . . . 0.0 109.931 -179.464 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.51 ' CG1' HG13 ' A' ' 47' ' ' ILE . 16.2 pt -105.12 173.0 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.978 -1.076 . . . . 0.0 108.889 178.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 6.4 mttt -110.09 128.84 55.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.253 -0.904 . . . . 0.0 109.301 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.526 ' CG1' ' HA3' ' A' ' 78' ' ' GLY . 6.9 m -137.34 -174.61 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.101 -1.0 . . . . 0.0 109.998 -179.835 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -120.37 173.57 7.06 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.98 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.52 ' OE1' ' CG2' ' A' ' 74' ' ' THR . 0.1 OUTLIER -136.66 89.53 2.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.894 -1.129 . . . . 0.0 110.8 -179.528 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.636 ' CE1' ' O ' ' A' ' 39' ' ' PRO . 96.5 m-85 -90.01 122.25 32.83 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.354 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.496 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -96.94 146.29 25.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.882 -1.136 . . . . 0.0 110.531 -178.914 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.506 ' HA ' HG21 ' A' ' 72' ' ' ILE . 0.9 OUTLIER 71.28 65.78 0.16 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.563 179.409 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.537 ' HB ' ' CG2' ' A' ' 75' ' ' VAL . 13.5 mm -120.14 106.62 19.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.327 -0.858 . . . . 0.0 109.271 179.656 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.547 ' CD2' ' HG2' ' A' ' 70' ' ' LYS . 1.6 tm? -54.43 87.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.653 -0.654 . . . . 0.0 110.413 -178.759 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.553 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 2.9 tt -89.68 122.09 40.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.872 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 7.1 tp10 -89.15 122.05 32.06 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.847 -1.158 . . . . 0.0 109.455 -178.69 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.525 HG13 HG21 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -118.18 132.18 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.275 -0.89 . . . . 0.0 108.787 -179.912 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 66' ' ' ILE . 21.5 m 38.24 49.96 1.36 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.635 . . . . 0.0 110.637 179.271 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.51 47.96 78.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.456 ' O ' ' HA ' ' A' ' 65' ' ' GLU . 77.6 m-70 -142.67 137.02 29.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.291 -1.123 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.547 ' HG2' ' CD2' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -85.28 126.19 33.51 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.27 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.553 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -147.5 98.94 3.06 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.351 -0.843 . . . . 0.0 110.094 -178.794 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.545 HG13 ' CA ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.73 142.71 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 120.887 -1.133 . . . . 0.0 107.992 179.068 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.507 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -160.85 -159.02 9.64 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.834 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.52 ' CG2' ' OE1' ' A' ' 58' ' ' GLN . 3.1 m -101.78 105.25 16.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.945 -0.738 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.57 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 1.2 t -103.24 163.59 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.063 -1.023 . . . . 0.0 109.534 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.54 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.2 mp -129.87 158.88 38.28 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 178.68 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.565 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 23.8 t -142.68 106.44 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 O-C-N 121.101 -1.0 . . . . 0.0 110.133 -179.462 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.526 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -144.86 -163.61 10.16 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.524 -1.831 . . . . 0.0 108.524 179.576 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.528 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.8 41.45 1.12 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 C-N-CA 122.374 2.049 . . . . 0.0 111.393 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' CG ' ' A' ' 34' ' ' GLU . 6.0 t -84.52 132.64 46.34 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.054 -1.029 . . . . 0.0 108.536 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.42 17.69 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.834 2.356 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.479 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -160.87 173.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.836 -1.165 . . . . 0.0 109.843 -179.776 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.55 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 57.4 m-80 -102.26 139.46 37.85 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.99 -2.596 . . . . 0.0 103.99 176.217 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.727 ' O ' ' HA ' ' A' ' 31' ' ' THR . 11.7 mm -128.66 95.59 2.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 O-C-N 120.283 -1.511 . . . . 0.0 110.533 -176.428 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.549 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -78.94 90.58 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.023 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.59 -160.44 19.97 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -178.432 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.569 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -64.15 -28.37 69.72 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.547 -0.972 . . . . 0.0 110.663 -179.154 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.546 ' ND2' HD21 ' A' ' 89' ' ' LEU . 1.5 p-10 -53.61 -42.71 67.99 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.94 -1.1 . . . . 0.0 110.725 -178.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.546 HD21 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -95.15 -24.85 16.66 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.893 -1.13 . . . . 0.0 108.874 -179.729 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.569 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 91.4 mt -69.07 -4.38 16.92 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.343 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.596 ' HB ' ' CZ3' ' B' ' 6' ' ' TRP . 36.2 p -100.82 -13.35 18.44 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.879 -1.138 . . . . 0.0 109.165 179.608 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 85.2 mm-40 -89.45 -40.99 12.33 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 0.0 109.726 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.482 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 10.5 pt -85.63 -0.09 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.144 -0.973 . . . . 0.0 108.98 179.525 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.88 43.74 40.38 Favored Glycine 0 N--CA 1.497 2.748 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.061 178.873 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.561 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -72.1 142.98 49.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.92 -1.341 . . . . 0.0 110.144 179.665 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.47 HG21 ' O ' ' A' ' 95' ' ' ALA . 16.1 p -148.35 127.69 13.05 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.541 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 7.5 mp -86.55 95.86 9.89 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.269 -0.895 . . . . 0.0 109.453 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.518 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 3.4 m120 -99.02 117.99 34.77 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.042 -1.036 . . . . 0.0 109.679 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.571 ' CG ' HD11 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.297 -1.676 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.319 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.476 ' HD3' ' NE2' ' B' ' 69' ' ' HIS . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.202 -0.73 . . . . 0.0 110.202 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.518 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 8.1 tt0 -83.64 139.44 32.81 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 178.151 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.555 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 2.5 t -131.23 111.05 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.456 -1.298 . . . . 0.0 110.911 -178.149 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.523 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -123.21 -65.55 1.08 Allowed 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.587 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.2 tp 36.47 26.96 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.572 178.152 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.596 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 24.1 m95 18.07 47.63 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.187 0.518 . . . . 0.0 112.172 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.587 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.47 -158.05 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.965 . . . . 0.0 109.443 -179.755 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -70.07 125.58 92.05 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.092 -1.005 . . . . 0.0 109.056 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.555 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.5 Cg_endo -79.09 70.69 7.39 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.434 2.09 . . . . 0.0 109.653 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.541 HD22 ' N ' ' B' ' 23' ' ' LEU . 7.0 mt -85.29 137.93 32.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.267 -0.896 . . . . 0.0 110.816 -178.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.401 HG22 ' N ' ' B' ' 12' ' ' THR . 1.7 m -141.11 168.8 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.401 ' N ' HG22 ' B' ' 11' ' ' VAL . 3.9 m -94.91 120.98 36.03 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.595 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.6 pt -115.09 147.45 18.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 121.168 -0.958 . . . . 0.0 110.061 -179.201 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.475 ' HA ' HD22 ' B' ' 19' ' ' LEU . 4.1 ttmt -106.9 101.18 10.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.403 -0.811 . . . . 0.0 109.709 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.545 HD11 ' CD2' ' B' ' 33' ' ' LEU . 39.2 mt -117.86 140.28 41.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 50.47 55.08 18.02 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.574 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 34.68 5.38 Favored Glycine 0 N--CA 1.494 2.508 0 O-C-N 121.306 -1.114 . . . . 0.0 110.428 179.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.467 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm100 -132.54 171.71 13.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.059 -1.26 . . . . 0.0 108.807 179.249 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.475 HD22 ' HA ' ' B' ' 14' ' ' LYS . 13.7 mt -135.5 119.11 17.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.121 -0.987 . . . . 0.0 109.964 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.456 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -135.62 178.12 7.29 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.682 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.527 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 3.6 mp0 -78.73 -176.06 4.73 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 179.038 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.595 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -164.82 105.07 0.81 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.786 -1.196 . . . . 0.0 110.627 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.541 ' N ' HD22 ' B' ' 10' ' ' LEU . 0.2 OUTLIER -79.9 90.04 5.31 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 108.793 179.227 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.52 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 75.7 mt -43.63 98.54 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.539 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 56.9 t0 -100.28 94.13 6.04 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.51 -0.744 . . . . 0.0 111.131 -178.348 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.471 HG22 ' CD1' ' B' ' 97' ' ' LEU . 16.8 m -67.56 -15.22 63.54 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.968 -1.083 . . . . 0.0 108.339 178.187 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.501 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -71.76 -40.8 57.67 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.83 149.91 29.36 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.963 -1.316 . . . . 0.0 109.662 -179.649 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.504 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 1.8 m-20 -92.01 -8.28 46.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.323 -0.861 . . . . 0.0 110.021 -179.471 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.506 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -129.52 178.3 6.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.105 -0.997 . . . . 0.0 109.943 -179.335 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.487 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.5 m -108.42 83.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.75 -1.219 . . . . 0.0 109.677 -179.515 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.679 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -70.31 157.34 6.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.044 179.667 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.555 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.8 OUTLIER -153.51 133.67 13.36 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.572 -178.007 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.535 ' N ' HG21 ' B' ' 80' ' ' THR . 3.1 tt0 -50.98 153.45 1.82 Allowed 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.868 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' B' ' 34' ' ' GLU . 3.3 tt0 -35.12 142.81 0.05 Allowed 'General case' 0 N--CA 1.495 1.812 0 CA-C-O 121.477 0.656 . . . . 0.0 110.78 -179.634 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.538 ' SD ' ' CD1' ' B' ' 38' ' ' LEU . 0.2 OUTLIER -155.76 -170.38 3.4 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.403 -0.81 . . . . 0.0 109.099 179.429 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.5 t -109.68 66.4 0.63 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 111.157 -178.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.584 HD22 ' CG ' ' B' ' 59' ' ' TYR . 1.2 tp -87.24 158.31 52.49 Favored Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.576 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 32.1 Cg_endo -77.24 -155.37 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.927 1.751 . . . . 0.0 110.228 -179.484 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -84.47 -148.04 8.98 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.345 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.52 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.7 mmp_? 65.41 57.06 0.92 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 122.054 -0.674 . . . . 0.0 109.234 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.653 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.8 p-90 -147.15 -176.57 5.27 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.863 0.839 . . . . 0.0 110.466 -179.67 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -148.13 139.32 13.61 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.092 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.43 136.61 15.89 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.281 1.987 . . . . 0.0 111.016 -178.889 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -160.76 -163.0 0.99 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.578 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.543 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 57.7 mtp -151.13 129.24 11.84 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.111 179.642 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.461 HG12 HG12 ' B' ' 56' ' ' VAL . 4.5 pt -91.64 144.41 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 118.356 -1.338 . . . . 0.0 107.999 178.771 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.537 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -117.44 107.43 1.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -178.923 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.23 -126.8 2.72 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.534 -1.317 . . . . 0.0 110.74 -179.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.483 ' O ' ' O ' ' A' ' 50' ' ' ILE . 56.0 mt -85.87 134.56 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.851 -0.793 . . . . 0.0 113.045 -177.402 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.03 -15.89 53.82 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.019 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.22 -160.06 27.16 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.264 179.55 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 2.9 m-85 -114.91 138.48 50.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.519 -0.989 . . . . 0.0 109.782 -179.541 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.537 HG12 ' CG2' ' A' ' 50' ' ' ILE . 23.1 pt -116.19 149.92 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 3.2 mttm -85.26 136.52 33.47 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.339 -0.851 . . . . 0.0 108.936 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.471 HG11 ' O ' ' B' ' 55' ' ' LYS . 4.4 m -142.74 -164.81 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 O-C-N 120.957 -1.09 . . . . 0.0 110.245 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' B' ' 56' ' ' VAL . 4.9 mtt180 -147.46 111.34 5.06 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.554 ' HA ' HD12 ' B' ' 76' ' ' LEU . 0.4 OUTLIER -74.69 124.81 27.42 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.059 -1.025 . . . . 0.0 110.413 -179.151 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.653 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 17.9 m-85 -112.89 109.39 18.8 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.568 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.7 m-20 -88.51 128.14 35.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.079 -1.013 . . . . 0.0 110.505 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.568 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 8.2 mm-40 89.86 61.95 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 CA-C-O 121.216 0.531 . . . . 0.0 110.598 179.266 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.552 ' CB ' HG22 ' B' ' 75' ' ' VAL . 24.0 mm -119.04 106.73 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 108.878 178.927 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.597 ' N ' ' CD1' ' B' ' 72' ' ' ILE . 1.0 OUTLIER -61.29 92.57 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.172 -0.955 . . . . 0.0 110.129 -178.884 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.55 ' CD1' HD13 ' B' ' 66' ' ' ILE . 2.6 tt -97.38 117.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 16.4 tt0 -89.16 121.11 31.16 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.84 -1.162 . . . . 0.0 109.486 -179.127 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' B' ' 13' ' ' ILE . 0.6 OUTLIER -108.87 135.7 46.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.132 -0.98 . . . . 0.0 108.789 179.769 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.63 -92.4 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.734 -0.604 . . . . 0.0 109.492 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -141.82 54.59 0.61 Allowed Glycine 0 N--CA 1.485 1.908 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.476 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 38.1 m-70 -154.24 151.82 29.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -1.131 . . . . 0.0 109.986 -179.544 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.75 139.52 30.46 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 179.086 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.512 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -151.52 97.68 2.42 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 110.817 -179.075 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.597 ' CD1' ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.48 139.65 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 178.19 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.513 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -164.1 -159.01 10.51 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 118.659 -1.734 . . . . 0.0 111.421 -179.875 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 18.7 m -106.7 108.74 20.41 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.654 -0.909 . . . . 0.0 110.852 -178.74 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.552 HG22 ' CB ' ' B' ' 62' ' ' ILE . 1.4 t -104.43 127.82 58.46 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.503 -0.748 . . . . 0.0 111.415 -179.879 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.679 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 0.6 OUTLIER -84.84 141.3 30.55 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.728 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.62 115.96 46.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 121.003 -1.061 . . . . 0.0 108.667 178.716 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -162.04 -158.12 9.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -81.71 41.57 1.16 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.746 2.297 . . . . 0.0 110.471 179.868 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.535 HG21 ' N ' ' B' ' 34' ' ' GLU . 9.3 t -89.76 133.23 34.53 Favored Pre-proline 0 C--N 1.301 -1.54 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.347 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.544 ' O ' ' CG2' ' B' ' 82' ' ' VAL . 37.8 Cg_endo -80.15 22.94 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.479 2.119 . . . . 0.0 111.432 -178.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.544 ' CG2' ' O ' ' B' ' 81' ' ' PRO . 55.2 t -160.22 153.67 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.498 -1.376 . . . . 0.0 111.888 -178.671 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.527 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 76.0 m-20 -93.98 77.57 4.13 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 176.041 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.539 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 53.6 mt -79.71 119.59 29.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.561 0.695 . . . . 0.0 112.601 -175.556 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.524 ' N ' HD11 ' B' ' 85' ' ' ILE . 4.0 mm -95.48 104.57 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.181 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -99.83 163.16 19.42 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.001 -179.38 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.582 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -25.74 -37.45 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -178.829 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.539 ' N ' ' O ' ' B' ' 86' ' ' GLY . 8.7 p-10 -46.52 -42.11 15.19 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.021 -1.674 . . . . 0.0 110.113 -178.629 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.536 HD12 ' CG2' ' B' ' 64' ' ' ILE . 0.7 OUTLIER -93.76 -17.58 23.0 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.276 -0.89 . . . . 0.0 110.116 -179.514 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.582 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 5.9 mp -69.55 -35.36 75.35 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.019 -1.073 . . . . 0.0 109.21 -179.548 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 72.3 p -70.99 -6.94 42.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.007 -1.058 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 8.3 mt-30 -100.01 -40.6 7.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.34 -0.85 . . . . 0.0 109.463 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.571 HD11 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -82.87 3.56 2.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.203 -0.936 . . . . 0.0 108.817 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.7 42.41 97.22 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.029 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.528 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.38 138.18 39.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.945 -1.327 . . . . 0.0 109.697 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 71.1 p -130.61 123.64 29.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 108.646 179.064 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -84.84 86.97 7.3 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.658 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 7.4 m120 -97.81 132.19 43.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.456 -0.777 . . . . 0.0 110.492 -178.933 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.561 ' HB3' ' CA ' ' A' ' 95' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.287 178.664 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.581 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.497 1.704 0 N-CA-C 110.316 -0.686 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.423 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 2.1 tt0 -84.05 138.41 33.09 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 178.136 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.402 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 4.4 t -132.55 134.45 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.722 -1.236 . . . . 0.0 110.441 -178.548 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.8 OUTLIER -143.3 -82.66 0.17 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.41 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.559 ' O ' ' C ' ' A' ' 6' ' ' TRP . 9.5 mt 34.41 32.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.895 -0.503 . . . . 0.0 110.719 178.896 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.559 ' C ' ' O ' ' A' ' 5' ' ' LEU . 44.2 m0 17.87 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.35 0 CA-C-O 121.393 0.616 . . . . 0.0 111.18 -179.875 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.543 ' HA ' ' NH1' ' B' ' 87' ' ' ARG . 2.3 mt-30 -144.56 -168.65 2.96 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.486 -0.759 . . . . 0.0 109.489 -179.329 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.0 mtt180 -81.22 122.37 81.3 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.337 -0.852 . . . . 0.0 108.917 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.48 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.1 Cg_endo -77.94 69.9 7.26 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.146 1.897 . . . . 0.0 109.88 179.373 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.523 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.71 145.82 29.38 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.264 -0.898 . . . . 0.0 109.482 -179.678 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.47 HG21 ' HB1' ' A' ' 22' ' ' ALA . 6.1 m -138.89 127.63 29.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.648 -179.68 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.52 HG23 ' CD2' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -62.83 103.29 0.42 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 178.354 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.54 HG21 ' CB ' ' A' ' 22' ' ' ALA . 11.5 pt -89.83 139.19 17.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.003 -1.061 . . . . 0.0 110.114 -178.458 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.2 OUTLIER -108.54 96.69 6.52 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.171 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.549 ' CD1' HG12 ' A' ' 75' ' ' VAL . 24.4 mt -113.18 119.87 61.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.361 -0.837 . . . . 0.0 109.537 -179.012 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.7 28.97 71.5 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -179.391 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.22 3.86 62.3 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 -179.197 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.513 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.59 161.92 15.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.307 -1.113 . . . . 0.0 108.891 179.675 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.52 ' CD2' HG23 ' A' ' 12' ' ' THR . 0.1 OUTLIER -133.31 125.51 29.39 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.98 -179.394 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.5 mtmt -151.51 162.88 40.19 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.525 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 1.0 OUTLIER -78.95 136.27 37.2 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 108.249 179.591 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.544 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -114.0 152.86 30.31 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.986 -1.071 . . . . 0.0 109.886 -179.313 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.495 ' O ' ' N ' ' A' ' 25' ' ' ASP . 38.6 tp -109.47 88.77 2.82 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.646 -0.659 . . . . 0.0 109.651 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.48 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 13.8 mt -43.1 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 179.526 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.553 ' HB2' HG21 ' A' ' 84' ' ' ILE . 9.9 t0 -109.9 97.58 7.07 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.427 -0.795 . . . . 0.0 110.982 -177.68 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.502 HG22 ' NH2' ' A' ' 87' ' ' ARG . 10.7 m -73.13 -6.54 46.43 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.329 -0.857 . . . . 0.0 109.114 178.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.532 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -79.96 -29.02 48.34 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.66 162.89 15.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.922 -1.34 . . . . 0.0 109.659 -179.688 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.7 OUTLIER -100.61 -8.39 23.01 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.231 -0.918 . . . . 0.0 110.729 -178.974 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.485 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -135.54 -177.69 4.78 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.075 -1.016 . . . . 0.0 109.442 -179.712 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.56 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 21.0 m -108.8 88.86 2.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.974 -1.079 . . . . 0.0 110.126 -179.196 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.12 174.02 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.558 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.05 119.46 1.29 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.823 -1.173 . . . . 0.0 111.694 -178.597 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.54 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 2.5 mt-10 -36.02 154.68 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.185 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.433 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.0 OUTLIER -47.6 137.47 9.08 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.922 -1.111 . . . . 0.0 109.739 -179.871 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.422 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -161.72 164.94 28.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.326 -0.859 . . . . 0.0 109.407 179.595 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 10.9 t -90.14 104.21 16.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.223 -0.923 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.579 HD22 ' CG ' ' A' ' 59' ' ' TYR . 48.3 tp -122.08 118.58 29.09 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.236 -0.915 . . . . 0.0 109.304 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.409 ' HD2' HD13 ' A' ' 38' ' ' LEU . 35.4 Cg_endo -77.99 120.27 4.97 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.401 2.068 . . . . 0.0 110.641 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.25 -177.75 33.95 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 179.839 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.06 144.73 28.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -1.224 . . . . 0.0 108.716 179.521 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.573 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 21.5 p-90 -138.62 156.27 47.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.176 -0.953 . . . . 0.0 110.295 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.408 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 14.2 mtpt -121.35 136.39 25.8 Favored Pre-proline 0 N--CA 1.488 1.469 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.69 129.28 9.92 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 122.263 1.975 . . . . 0.0 111.196 -178.853 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.455 ' O ' HG21 ' A' ' 56' ' ' VAL . 5.8 ptmm? -164.17 152.4 12.83 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.324 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.545 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -118.25 146.77 44.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.527 -1.358 . . . . 0.0 109.856 179.315 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.569 ' CD1' HG22 ' B' ' 50' ' ' ILE . 15.5 pt -102.6 149.56 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.37 -0.831 . . . . 0.0 109.077 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.578 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.89 111.52 2.12 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.331 -1.908 . . . . 0.0 108.331 179.832 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.89 -117.23 1.71 Allowed Glycine 0 N--CA 1.484 1.85 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.687 -178.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.507 ' O ' ' O ' ' B' ' 50' ' ' ILE . 8.2 mt -91.01 130.17 40.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.78 -0.835 . . . . 0.0 112.542 -177.564 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.439 ' HA2' ' CG2' ' B' ' 54' ' ' ILE . . . 89.76 -23.27 20.76 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.021 177.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.84 -163.19 29.63 Favored Glycine 0 N--CA 1.491 2.347 0 O-C-N 120.744 -1.445 . . . . 0.0 110.375 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.578 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.1 m-85 -109.68 132.13 54.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.514 -0.992 . . . . 0.0 109.245 -179.639 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.55 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.1 pp -107.07 177.86 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.026 -1.046 . . . . 0.0 109.472 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 11.1 mmtt -112.49 138.99 48.45 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.206 -0.934 . . . . 0.0 109.45 179.231 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.519 ' CG1' HD13 ' A' ' 54' ' ' ILE . 6.6 m -146.66 -174.9 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.908 . . . . 0.0 109.687 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.491 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 3.8 mtt85 -122.83 178.19 5.14 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.427 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 26.0 tt0 -135.97 101.57 4.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.131 -0.98 . . . . 0.0 110.827 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.579 ' CG ' HD22 ' A' ' 38' ' ' LEU . 61.7 m-85 -94.49 106.38 18.36 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.613 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.536 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 67.8 m-20 -88.28 123.27 32.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.124 -0.985 . . . . 0.0 110.576 -178.745 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.536 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 63.7 mm-40 86.06 59.98 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.635 0.731 . . . . 0.0 110.072 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.522 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 31.4 mm -115.84 121.9 68.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.777 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.585 ' CD2' ' HG2' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -73.78 88.18 1.76 Allowed 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.725 -1.19 . . . . 0.0 110.966 -178.311 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.512 HG13 HG13 ' A' ' 15' ' ' ILE . 2.5 tt -85.82 117.4 30.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 177.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 3.6 tt0 -87.08 117.96 26.16 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.054 -1.029 . . . . 0.0 109.111 -178.495 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.49 HG13 HG23 ' A' ' 13' ' ' ILE . 1.0 OUTLIER -110.43 123.9 66.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.792 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.55 36.1 4.96 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.541 -0.724 . . . . 0.0 110.039 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.52 34.24 50.43 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 70' ' ' LYS . 31.9 m-70 -122.1 91.74 3.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.03 -1.277 . . . . 0.0 109.448 179.696 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.585 ' HG2' ' CD2' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -44.74 102.82 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.616 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.515 ' N ' HD12 ' A' ' 63' ' ' LEU . . . -127.24 132.88 50.3 Favored 'General case' 0 C--N 1.287 -2.109 0 O-C-N 121.804 -0.56 . . . . 0.0 109.806 -179.151 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.519 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -108.17 152.21 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.867 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -176.41 -166.47 33.67 Favored Glycine 0 N--CA 1.487 2.045 0 C-N-CA 118.667 -1.73 . . . . 0.0 111.15 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.427 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 20.4 m -98.77 107.01 19.35 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.49 -1.006 . . . . 0.0 109.381 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.549 HG12 ' CD1' ' A' ' 15' ' ' ILE . 0.2 OUTLIER -103.52 119.49 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.335 -0.853 . . . . 0.0 110.402 -179.546 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.519 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -88.63 142.87 27.33 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.332 -0.855 . . . . 0.0 108.906 178.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 33' ' ' LEU . 3.9 t -126.8 118.65 51.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.398 -0.814 . . . . 0.0 109.875 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.466 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -150.09 -166.01 13.05 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.69 41.75 1.17 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 C-N-CA 122.416 2.077 . . . . 0.0 110.015 179.803 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.54 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.1 t -82.45 140.16 44.83 Favored Pre-proline 0 C--N 1.305 -1.347 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.062 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.435 ' C ' ' OE2' ' A' ' 34' ' ' GLU . 32.2 Cg_endo -76.22 10.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.177 1.918 . . . . 0.0 111.438 -178.873 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.506 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.19 168.02 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.882 -1.136 . . . . 0.0 109.653 179.828 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.544 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -102.72 145.78 29.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 176.707 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 31' ' ' THR . 3.5 mm -130.24 126.07 60.86 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 120.726 -1.234 . . . . 0.0 111.212 -177.536 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.57 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.6 OUTLIER -101.47 92.18 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.446 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -81.34 -163.25 30.56 Favored Glycine 0 N--CA 1.496 2.693 0 O-C-N 121.241 -0.912 . . . . 0.0 111.995 -177.242 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.509 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -60.82 -40.0 91.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.979 -0.718 . . . . 0.0 110.442 -179.283 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.585 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 11.0 p-10 -43.61 -31.1 0.69 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.274 -0.891 . . . . 0.0 109.298 -179.66 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.585 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -105.45 -26.02 12.11 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.168 -0.958 . . . . 0.0 109.998 -179.764 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.509 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 97.3 mt -71.1 -5.42 31.44 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.926 -1.109 . . . . 0.0 108.211 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -100.42 -15.21 18.02 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.691 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.2 mm-40 -86.12 -40.82 15.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.623 -0.673 . . . . 0.0 109.569 179.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.585 HD11 ' CG ' ' B' ' 99' ' ' PHE . 1.2 pt -85.06 -5.18 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.175 -0.953 . . . . 0.0 108.982 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.93 49.93 15.16 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 178.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.523 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.44 149.5 26.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.008 -1.29 . . . . 0.0 110.557 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.451 HG23 HG21 ' B' ' 4' ' ' THR . 25.6 p -140.28 126.1 19.4 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.796 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.555 HD13 ' CD1' ' B' ' 97' ' ' LEU . 3.8 mp -85.98 96.53 9.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.843 -179.225 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.535 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.6 m120 -101.13 126.8 47.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.219 -0.926 . . . . 0.0 109.441 179.694 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.039 -0.981 . . . . 0.0 109.446 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.537 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.494 1.552 0 N-CA-C 109.873 -0.857 . . . . 0.0 109.873 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.535 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 3.0 tt0 -83.64 137.64 33.71 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.432 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.522 ' CG1' ' HB2' ' B' ' 5' ' ' LEU . 8.4 t -133.68 114.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 118.565 -1.254 . . . . 0.0 110.501 -178.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.591 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -101.01 3.78 41.8 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 177.468 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.522 ' HB2' ' CG1' ' B' ' 3' ' ' VAL . 0.8 OUTLIER -21.66 83.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.654 0.74 . . . . 0.0 111.06 -179.438 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.591 ' N ' ' O ' ' B' ' 4' ' ' THR . 7.8 m95 -46.1 -21.05 0.12 Allowed 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.513 -0.742 . . . . 0.0 109.103 179.618 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.451 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -107.9 -165.51 1.05 Allowed 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.644 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.443 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.4 OUTLIER -66.68 125.49 90.72 Favored Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 120.919 -1.113 . . . . 0.0 109.65 -179.615 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.516 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.7 Cg_endo -77.49 75.72 4.57 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 122.035 1.823 . . . . 0.0 109.899 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.549 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.73 146.05 32.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.16 -0.963 . . . . 0.0 109.483 -179.69 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.473 HG22 HG12 ' B' ' 66' ' ' ILE . 5.5 m -131.02 148.71 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.82 -179.506 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.48 HG21 HD21 ' B' ' 19' ' ' LEU . 73.7 m -83.22 117.26 22.81 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 178.234 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.56 ' HB ' ' CG1' ' B' ' 64' ' ' ILE . 2.0 pp -112.62 131.35 64.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 121.117 -0.99 . . . . 0.0 110.739 -177.893 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.507 ' HA ' HD22 ' B' ' 19' ' ' LEU . 4.2 tttm -99.73 110.83 23.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.21 -0.931 . . . . 0.0 108.678 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.542 ' CD1' HD23 ' B' ' 33' ' ' LEU . 9.3 mt -116.67 141.79 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.043 . . . . 0.0 109.529 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.54 -97.69 0.07 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -148.38 39.6 0.97 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 179.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 44.5 mm-40 -140.52 -175.23 4.2 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.528 -0.984 . . . . 0.0 109.617 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' B' ' 14' ' ' LYS . 6.8 mt -150.79 129.67 12.48 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.723 0.773 . . . . 0.0 110.621 -178.916 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.479 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 2.3 mptp? -148.03 168.34 22.59 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.321 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.549 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.8 mt-10 -79.11 172.84 13.24 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.655 -1.278 . . . . 0.0 109.129 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.544 ' HB2' ' CD1' ' B' ' 85' ' ' ILE . . . -149.51 106.14 3.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.343 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.46 HD23 ' O ' ' A' ' 27' ' ' GLY . 28.0 tp -64.06 99.42 0.26 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.552 -0.717 . . . . 0.0 110.006 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.516 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 44.4 mt -52.28 111.35 0.61 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.985 -1.072 . . . . 0.0 108.658 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.597 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 49.4 t0 -124.29 90.0 3.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 110.785 -178.554 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.452 ' HA ' HD13 ' B' ' 90' ' ' LEU . 3.0 m -63.96 -14.68 55.74 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.676 -1.265 . . . . 0.0 108.676 178.595 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.472 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -64.69 -46.93 88.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.05 158.97 35.58 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.899 -1.354 . . . . 0.0 108.802 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -92.12 -13.37 30.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.086 -1.009 . . . . 0.0 110.791 -178.621 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.542 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -139.35 -173.87 3.72 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.783 -1.198 . . . . 0.0 110.041 -179.661 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.57 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 3.7 m -102.21 88.81 3.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.915 -1.115 . . . . 0.0 110.294 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.631 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -69.92 162.44 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.804 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.57 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.2 OUTLIER -158.78 126.6 5.07 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.938 -1.101 . . . . 0.0 110.719 -178.397 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' B' ' 33' ' ' LEU . 4.3 tt0 -40.68 161.25 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.826 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.422 ' N ' ' CG ' ' B' ' 34' ' ' GLU . 1.6 tt0 -50.54 146.14 5.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.195 -0.94 . . . . 0.0 110.133 -179.543 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.528 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -174.98 160.67 2.84 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.385 -0.822 . . . . 0.0 108.805 179.553 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.0 t -79.51 97.63 6.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.877 -1.139 . . . . 0.0 109.286 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.52 HD11 ' CG2' ' B' ' 77' ' ' VAL . 0.8 OUTLIER -107.21 107.59 60.67 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.69 -179.66 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 129.04 10.1 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.517 2.145 . . . . 0.0 110.521 179.796 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 147.13 -165.41 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 -95.55 124.95 39.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.278 -1.131 . . . . 0.0 108.831 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.598 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 56.8 p-90 -128.77 172.25 11.45 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.171 -0.956 . . . . 0.0 110.309 -179.197 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.1 mptt -140.07 137.75 18.54 Favored Pre-proline 0 C--N 1.3 -1.573 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.653 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -76.28 134.96 16.27 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.858 1.705 . . . . 0.0 110.299 -179.257 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.467 ' HG3' HG21 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -153.7 -177.11 6.16 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.656 -0.818 . . . . 0.0 109.823 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -138.28 115.19 10.79 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 109.192 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.466 HD13 HG22 ' A' ' 50' ' ' ILE . 31.6 pt -94.49 130.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 C-N-CA 118.772 -1.171 . . . . 0.0 108.351 178.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.02 103.73 1.13 Allowed Glycine 0 N--CA 1.486 2.001 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.337 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.04 -118.45 2.44 Favored Glycine 0 N--CA 1.483 1.816 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.569 HG22 ' CD1' ' A' ' 47' ' ' ILE . 15.6 mt -91.8 115.56 31.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.852 -0.793 . . . . 0.0 112.138 -177.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.55 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 112.34 -40.14 2.63 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.399 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 163.88 -162.77 35.39 Favored Glycine 0 N--CA 1.491 2.365 0 O-C-N 120.846 -1.385 . . . . 0.0 110.161 179.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.7 OUTLIER -112.55 127.64 56.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.456 -1.026 . . . . 0.0 109.732 -179.872 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.479 HD12 HG22 ' A' ' 50' ' ' ILE . 4.7 pt -109.81 169.18 3.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.195 -0.94 . . . . 0.0 108.657 178.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.535 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mttt -109.82 132.44 54.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.03 -1.044 . . . . 0.0 108.9 179.6 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.499 ' CG1' ' HA3' ' B' ' 78' ' ' GLY . 3.1 m -130.96 -172.45 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 110.495 -179.281 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.426 ' HG3' ' C ' ' B' ' 56' ' ' VAL . 5.6 mtp180 -134.97 85.23 2.16 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.501 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -52.73 100.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.6 -0.688 . . . . 0.0 110.901 -179.077 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.598 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 14.6 m-85 -90.28 123.07 33.75 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.498 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.0 OUTLIER -100.68 141.0 34.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.792 -1.193 . . . . 0.0 110.121 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.52 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 72.08 65.61 0.13 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.441 0.638 . . . . 0.0 109.495 179.783 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.499 ' N ' HD11 ' B' ' 72' ' ' ILE . 27.8 mm -119.26 116.15 49.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.481 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.547 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 3.1 tm? -68.94 83.22 0.31 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.454 -0.779 . . . . 0.0 110.582 -178.502 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.56 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 7.9 tt -88.16 125.1 41.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.493 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.423 ' OE2' ' HE3' ' B' ' 70' ' ' LYS . 4.0 tt0 -91.71 110.01 21.34 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.935 -1.103 . . . . 0.0 109.768 -178.409 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.534 HD13 ' CD1' ' B' ' 64' ' ' ILE . 0.3 OUTLIER -109.97 122.59 64.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.237 -0.914 . . . . 0.0 108.827 179.65 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.425 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 33.7 m 52.05 62.66 2.59 Favored 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.644 -0.66 . . . . 0.0 110.378 179.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 47.81 25.21 3.43 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.16 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.501 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 79.2 m-70 -118.29 117.43 29.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.089 -1.242 . . . . 0.0 109.101 179.39 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.423 ' HE3' ' OE2' ' B' ' 65' ' ' GLU . 0.0 OUTLIER -67.94 133.16 48.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.137 -0.977 . . . . 0.0 108.968 179.725 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.462 ' O ' HD23 ' B' ' 63' ' ' LEU . . . -149.26 139.19 21.99 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.371 -0.831 . . . . 0.0 110.168 -179.335 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.514 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -110.31 140.8 27.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 177.679 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.488 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -165.49 -168.93 28.42 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.058 -179.616 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 26.2 m -99.15 106.42 18.6 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.653 -0.91 . . . . 0.0 110.551 -179.185 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.5 ' CG1' HD12 ' B' ' 15' ' ' ILE . 1.7 t -100.68 108.89 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.47 -0.769 . . . . 0.0 110.813 179.3 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.631 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 5.2 mp -79.2 134.29 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' B' ' 38' ' ' LEU . 1.0 OUTLIER -118.39 118.44 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.109 -0.995 . . . . 0.0 109.448 -179.502 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.499 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -155.71 -167.16 16.78 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.535 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -79.54 40.13 0.91 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.689 2.259 . . . . 0.0 111.295 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.493 HG22 ' O ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.45 142.97 33.51 Favored Pre-proline 0 C--N 1.302 -1.466 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.948 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -79.86 17.56 1.28 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 C-N-CA 122.516 2.144 . . . . 0.0 112.246 -178.427 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.511 HG13 ' CD1' ' B' ' 84' ' ' ILE . 1.4 t -162.41 157.25 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.425 -1.422 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.539 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 2.1 m-20 -99.34 103.16 14.95 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.447 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.597 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 2.3 mt -104.18 131.31 53.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.723 -1.236 . . . . 0.0 112.607 -176.085 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.551 ' CG2' ' CB ' ' B' ' 89' ' ' LEU . 2.3 mm -95.35 107.72 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 177.887 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.542 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -88.99 -154.58 29.09 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 120.787 -1.196 . . . . 0.0 111.142 -178.374 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.543 ' NH1' ' HA ' ' A' ' 7' ' ' GLN . 5.5 mtm180 -64.67 -40.09 94.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.832 -0.805 . . . . 0.0 109.911 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.612 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 11.9 p-10 -45.15 -38.08 4.93 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.175 -0.953 . . . . 0.0 110.395 -179.073 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.612 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 2.0 mm? -96.75 -27.7 14.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.817 -1.177 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.457 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 53.9 mt -71.22 -5.79 34.68 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 178.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.524 HG23 ' CG ' ' A' ' 6' ' ' TRP . 17.3 p -100.97 -10.93 20.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.226 -0.921 . . . . 0.0 108.696 178.717 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.514 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 13.9 mt-30 -91.89 -41.06 10.81 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.196 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.589 HD11 ' CG ' ' A' ' 99' ' ' PHE . 2.0 pt -85.74 2.41 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.29 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.28 51.49 52.18 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.783 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -78.73 142.32 37.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.154 -1.204 . . . . 0.0 110.184 179.746 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.479 ' CG2' ' CG2' ' A' ' 4' ' ' THR . 27.6 p -137.96 130.55 29.52 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.487 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.555 ' CD1' HD13 ' A' ' 97' ' ' LEU . 6.5 mp -91.21 94.08 9.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.339 -0.851 . . . . 0.0 110.035 -179.171 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.523 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.0 m120 -97.59 120.38 37.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.057 -1.027 . . . . 0.0 109.343 179.379 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.585 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.054 179.666 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.414 ' O ' ' HA ' ' B' ' 98' ' ' ASN . 2.6 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 N-CA-C 109.622 -0.953 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.543 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 14.4 tt0 -84.3 139.71 32.13 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 178.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.79 117.46 3.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.385 -1.326 . . . . 0.0 110.583 -178.532 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.544 ' O ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -98.54 -34.25 10.67 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 177.941 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.544 ' C ' ' O ' ' A' ' 4' ' ' THR . 1.3 mm? 22.36 74.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.289 179.413 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.412 ' C ' ' O ' ' A' ' 5' ' ' LEU . 41.3 m95 -41.56 -20.62 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.751 -0.593 . . . . 0.0 110.329 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 58.9 mt-30 -108.57 -105.1 0.36 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.607 -1.308 . . . . 0.0 109.282 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 8.9 mtt-85 -110.98 132.57 21.6 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 120.654 -1.279 . . . . 0.0 110.215 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.474 ' HA ' ' HG ' ' A' ' 5' ' ' LEU . 37.3 Cg_endo -78.92 66.34 8.73 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.336 2.024 . . . . 0.0 109.867 178.25 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -80.03 152.06 29.62 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.983 -1.073 . . . . 0.0 109.975 -179.32 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.482 HG23 HG22 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -142.09 170.9 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.382 -0.824 . . . . 0.0 109.404 -179.587 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -101.04 92.29 4.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 178.238 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.539 HD11 ' CD1' ' A' ' 64' ' ' ILE . 22.1 pt -86.08 142.1 13.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.263 -0.898 . . . . 0.0 110.17 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 6.9 ttmt -114.77 99.31 7.4 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.409 -0.807 . . . . 0.0 109.499 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.589 ' CG2' ' CG2' ' A' ' 62' ' ' ILE . 0.2 OUTLIER -116.15 158.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.065 -1.022 . . . . 0.0 109.427 179.829 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 34.86 50.72 0.8 Allowed Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 50.95 52.49 30.49 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -152.1 172.49 16.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.459 -1.024 . . . . 0.0 108.493 179.574 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.526 ' O ' ' CD ' ' A' ' 20' ' ' LYS . 26.6 mt -141.96 132.03 24.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.08 -1.013 . . . . 0.0 110.549 -179.303 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 12.5 mmmt -150.68 162.52 40.54 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.714 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.4 mm-40 -79.25 141.54 37.01 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.942 -1.099 . . . . 0.0 108.19 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.55 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -124.05 131.72 53.59 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.992 -1.068 . . . . 0.0 110.21 -178.682 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' A' ' 24' ' ' LEU . 25.2 tp -91.15 97.94 11.45 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.69 -0.631 . . . . 0.0 109.783 -179.774 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.474 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.2 OUTLIER -45.97 115.16 0.91 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.397 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.549 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 14.9 t0 -125.7 84.4 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.331 -0.856 . . . . 0.0 111.021 -177.536 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.507 ' CG2' HD11 ' A' ' 90' ' ' LEU . 0.2 OUTLIER -62.68 -11.91 20.17 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.005 -1.059 . . . . 0.0 109.159 178.742 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.439 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.0 -41.52 54.52 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.28 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.23 168.8 16.51 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -1.214 . . . . 0.0 109.709 -179.4 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -100.74 -20.81 15.41 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.204 -0.935 . . . . 0.0 110.176 -179.444 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -133.32 -164.99 1.56 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.068 -1.02 . . . . 0.0 109.548 -179.61 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.592 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 30.1 m -112.64 90.86 3.46 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.738 -1.226 . . . . 0.0 110.575 -179.034 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.52 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.053 -1.029 . . . . 0.0 108.826 179.536 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.586 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.81 121.41 1.29 Allowed 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.099 -1.001 . . . . 0.0 111.019 -178.849 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.565 ' HA ' HG21 ' A' ' 80' ' ' THR . 0.6 OUTLIER -38.46 152.9 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.432 -0.792 . . . . 0.0 109.663 178.842 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.523 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.6 mt-10 -46.07 141.61 3.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 110.459 -179.279 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.521 ' HE3' ' CD1' ' A' ' 15' ' ' ILE . 6.0 ptm -158.21 -177.21 6.39 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.348 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -101.09 101.7 12.5 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.069 -1.02 . . . . 0.0 109.903 -179.498 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.561 HD11 ' CE2' ' A' ' 59' ' ' TYR . 32.5 mt -106.72 162.43 19.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.062 -1.024 . . . . 0.0 109.971 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.9 Cg_endo -78.23 65.85 8.41 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.895 2.397 . . . . 0.0 112.082 -179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 37.36 -160.67 0.01 OUTLIER Glycine 0 N--CA 1.499 2.846 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 178.74 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.49 59.94 0.61 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.354 -1.086 . . . . 0.0 109.486 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.578 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 64.1 p-90 -148.7 168.67 22.27 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.626 0.727 . . . . 0.0 110.115 -179.556 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.1 136.35 28.69 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.04 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.0 139.1 17.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.222 1.948 . . . . 0.0 110.872 -179.272 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.404 ' HE2' ' HB2' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -153.42 -165.61 2.2 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.264 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.46 ' HG3' ' HG3' ' A' ' 55' ' ' LYS . 5.4 ttt -144.71 126.57 15.34 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.951 -1.093 . . . . 0.0 110.163 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.477 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 24.8 pt -96.1 133.65 36.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.67 101.0 0.89 Allowed Glycine 0 N--CA 1.486 1.999 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.53 -117.46 2.49 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.65 -178.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.546 HG22 ' CD1' ' B' ' 47' ' ' ILE . 12.8 mt -88.94 122.85 40.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.729 -0.865 . . . . 0.0 112.506 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.454 ' HA2' HG21 ' B' ' 54' ' ' ILE . . . 100.44 -51.53 1.01 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 178.213 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.86 -159.98 24.6 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.228 -1.463 . . . . 0.0 110.748 -179.604 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.2 m-85 -113.33 129.38 56.55 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.55 -0.971 . . . . 0.0 109.95 -179.254 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.524 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.9 pt -109.94 152.98 11.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.214 -0.929 . . . . 0.0 108.701 178.895 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.6 mtpt -93.84 123.39 37.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.11 -0.994 . . . . 0.0 109.508 -179.577 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.432 ' CG1' HD13 ' A' ' 54' ' ' ILE . 25.9 m -126.59 -170.08 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.22 -0.925 . . . . 0.0 109.939 -179.529 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.528 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 22.5 mtt180 -124.31 174.42 7.73 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.249 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.419 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 37.2 tt0 -131.17 98.33 4.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.157 -0.964 . . . . 0.0 109.979 -179.342 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.578 ' CD1' ' HB3' ' A' ' 42' ' ' TRP . 64.9 m-85 -97.69 97.59 9.15 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.24 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.469 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.1 m-20 -82.44 139.48 33.96 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 0.0 110.856 -178.601 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.469 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.1 OUTLIER 75.6 60.32 0.05 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.583 -0.698 . . . . 0.0 109.693 179.607 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.589 ' CG2' ' CG2' ' A' ' 15' ' ' ILE . 3.5 mm -116.49 122.82 70.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 108.979 -179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.557 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -74.7 94.99 2.79 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 111.159 -178.751 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.539 ' CD1' HD11 ' A' ' 13' ' ' ILE . 8.2 tt -97.89 121.97 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 50.0 tt0 -89.67 101.54 14.23 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.01 -1.056 . . . . 0.0 108.86 -179.45 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.539 HD13 ' CD1' ' A' ' 64' ' ' ILE . 2.3 mp -102.68 120.5 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.993 -179.037 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 92.6 m 63.36 34.96 12.62 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.738 -0.601 . . . . 0.0 110.32 179.013 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.79 12.21 80.86 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.24 137.24 44.53 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -1.228 . . . . 0.0 109.255 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.528 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -80.96 123.93 28.72 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 109.094 179.84 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.554 ' O ' ' CD2' ' A' ' 63' ' ' LEU . . . -142.79 155.53 44.83 Favored 'General case' 0 C--N 1.293 -1.852 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.552 -179.759 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.507 ' HA ' ' O ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -125.18 149.81 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.005 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.533 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.42 176.24 47.31 Favored Glycine 0 N--CA 1.484 1.859 0 C-N-CA 118.484 -1.817 . . . . 0.0 111.158 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 6.5 m -86.76 108.74 18.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.702 -0.881 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.583 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.1 t -98.32 110.5 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.532 -0.73 . . . . 0.0 109.779 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.544 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.9 mp -78.9 139.16 38.35 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 120.997 -1.064 . . . . 0.0 108.356 179.133 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.539 HG23 ' CD1' ' A' ' 38' ' ' LEU . 15.9 t -125.04 114.72 41.55 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.481 -0.762 . . . . 0.0 110.054 -179.287 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.41 -159.67 9.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.9 Cg_endo -79.83 41.1 1.05 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.659 2.239 . . . . 0.0 111.072 -179.874 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.565 HG21 ' HA ' ' A' ' 34' ' ' GLU . 1.8 t -87.97 133.03 38.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.666 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.15 16.26 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.687 2.258 . . . . 0.0 111.77 -178.422 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.496 HG11 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.45 164.38 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.955 -1.091 . . . . 0.0 109.604 -179.812 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.597 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -100.83 132.88 46.02 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 176.53 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.592 ' O ' ' HA ' ' A' ' 31' ' ' THR . 3.9 mm -119.8 119.98 61.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 O-C-N 120.447 -1.408 . . . . 0.0 111.362 -176.867 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.48 HD11 HG21 ' A' ' 31' ' ' THR . 2.0 mm -95.01 89.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.461 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.98 -165.42 29.23 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.962 -1.114 . . . . 0.0 111.46 -177.595 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.484 ' CZ ' ' HB2' ' A' ' 87' ' ' ARG . 1.3 mtp-105 -59.34 -40.66 87.08 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.853 -0.792 . . . . 0.0 110.638 -178.904 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.577 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 12.9 p-10 -45.4 -24.99 0.35 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.971 -1.081 . . . . 0.0 109.675 -179.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.577 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.1 mm? -110.64 -26.85 9.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.011 -1.056 . . . . 0.0 109.614 -179.298 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.507 HD11 ' CG2' ' A' ' 26' ' ' THR . 65.8 mt -72.09 -6.91 45.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 108.589 179.179 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.481 ' O ' ' CZ2' ' B' ' 6' ' ' TRP . 57.4 p -100.92 -19.17 16.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.041 -1.037 . . . . 0.0 108.252 179.116 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 -84.22 -41.14 17.25 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.8 . . . . 0.0 109.159 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.596 HD11 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pp -80.36 -7.28 10.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.98 59.41 5.94 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.606 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.578 ' HB3' ' CD1' ' B' ' 99' ' ' PHE . . . -86.63 157.97 19.58 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -1.212 . . . . 0.0 110.356 -179.702 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.457 HG21 ' O ' ' A' ' 95' ' ' ALA . 21.0 p -150.24 126.66 10.78 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.464 -0.772 . . . . 0.0 109.279 179.401 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.577 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 8.6 mp -86.09 111.57 20.46 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.1 m120 -108.73 121.76 45.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.852 -1.155 . . . . 0.0 109.78 179.951 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.636 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.427 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.429 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.066 -0.782 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.462 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.9 tt0 -83.4 141.55 31.65 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 178.379 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.462 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 40.6 t -142.66 112.73 2.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 120.565 -1.334 . . . . 0.0 110.694 -178.367 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -124.11 -71.7 0.71 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.713 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.543 ' O ' ' C ' ' B' ' 6' ' ' TRP . 18.5 mt 36.62 31.01 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.737 -0.602 . . . . 0.0 109.866 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.3 m0 17.27 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.144 0 CA-C-O 121.609 0.719 . . . . 0.0 111.404 -179.427 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER -150.55 -165.84 2.38 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.691 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -84.15 115.9 62.34 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.144 -0.973 . . . . 0.0 109.389 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.424 ' HB2' HD11 ' B' ' 24' ' ' LEU . 35.9 Cg_endo -77.29 73.3 5.58 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.391 2.061 . . . . 0.0 110.507 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.548 HD22 ' CB ' ' B' ' 21' ' ' GLU . 0.6 OUTLIER -79.6 163.47 24.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.157 -0.964 . . . . 0.0 108.786 179.617 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.431 HG21 ' O ' ' B' ' 11' ' ' VAL . 4.6 m -144.53 128.01 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.994 -1.066 . . . . 0.0 110.765 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.2 m -71.07 87.88 0.77 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.529 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.554 ' CG2' HG13 ' B' ' 66' ' ' ILE . 17.3 pt -85.65 142.57 12.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-O 121.716 0.77 . . . . 0.0 111.58 -177.18 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.496 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 2.8 tttt -103.29 94.21 5.39 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.187 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.6 HG23 ' CE ' ' B' ' 36' ' ' MET . 0.3 OUTLIER -104.28 115.78 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.164 -0.96 . . . . 0.0 110.358 -178.444 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.55 26.37 71.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.28 88.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -96.96 -179.91 4.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -1.19 . . . . 0.0 108.704 179.427 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.1 mt -148.82 128.25 13.07 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.972 -1.08 . . . . 0.0 110.382 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.476 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 9.9 mttm -151.19 155.58 39.16 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.562 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.548 ' CB ' HD22 ' B' ' 10' ' ' LEU . 2.7 mm-40 -78.36 100.72 6.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.15 -0.969 . . . . 0.0 108.519 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.568 ' HB3' ' CD1' ' B' ' 85' ' ' ILE . . . -85.26 104.17 14.87 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.261 -0.899 . . . . 0.0 110.698 -178.738 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' B' ' 25' ' ' ASP . 5.4 tp -58.54 103.96 0.19 Allowed 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.445 179.26 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.44 HD21 HD22 ' B' ' 90' ' ' LEU . 13.3 mt -49.83 96.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.039 -1.038 . . . . 0.0 108.558 179.476 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 15.6 t0 -102.5 91.94 4.45 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.195 -0.94 . . . . 0.0 110.469 -179.075 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -70.39 -6.37 35.01 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.948 -1.095 . . . . 0.0 108.791 178.545 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.41 ' O ' HD23 ' A' ' 23' ' ' LEU . . . -77.45 -39.91 24.72 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.39 154.88 34.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.019 -1.283 . . . . 0.0 109.305 -179.691 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -88.47 -17.96 29.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.16 -0.962 . . . . 0.0 110.753 -178.856 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.529 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.78 -170.36 2.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.948 -1.095 . . . . 0.0 110.464 -179.178 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.518 ' O ' ' HA ' ' B' ' 75' ' ' VAL . 65.4 m -109.12 103.78 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.991 -1.068 . . . . 0.0 110.29 -178.634 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.533 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -87.82 171.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 108.678 179.417 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.578 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.06 125.57 2.29 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.928 -1.107 . . . . 0.0 110.319 -179.048 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' B' ' 33' ' ' LEU . 14.3 tt0 -37.8 160.59 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.391 0.615 . . . . 0.0 109.936 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.473 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.4 tt0 -53.6 148.45 9.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 110.46 -179.514 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.6 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -170.71 -166.55 0.51 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.611 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.46 ' N ' ' SD ' ' B' ' 36' ' ' MET . 5.4 t -115.06 76.73 1.01 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.797 -1.189 . . . . 0.0 110.923 -179.171 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.601 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 8.0 mt -80.43 173.31 7.91 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.633 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.601 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 29.3 Cg_endo -71.01 -155.63 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 121.776 1.651 . . . . 0.0 111.092 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -103.0 -157.6 25.27 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.046 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.438 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.1 mmm-85 65.72 57.91 0.82 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.511 -0.993 . . . . 0.0 108.809 -179.639 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.597 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 52.0 p-90 -135.59 -172.6 3.13 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-O 121.747 0.784 . . . . 0.0 110.282 -179.015 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mptt -148.43 140.85 14.84 Favored Pre-proline 0 N--CA 1.489 1.487 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.126 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.48 135.4 14.72 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.74 1.627 . . . . 0.0 109.856 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.484 ' O ' ' HG2' ' B' ' 46' ' ' MET . 0.0 OUTLIER -158.46 -169.68 2.83 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 109.596 -179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.484 ' HG2' ' O ' ' B' ' 45' ' ' LYS . 10.1 mtp -149.26 131.39 15.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 109.097 179.849 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.546 ' CD1' HG22 ' A' ' 50' ' ' ILE . 9.3 pt -89.04 140.34 15.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.95 -1.094 . . . . 0.0 108.312 179.271 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.18 111.43 2.17 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 -179.702 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -135.77 -114.29 1.36 Allowed Glycine 0 N--CA 1.481 1.697 0 C-N-CA 119.442 -1.361 . . . . 0.0 111.096 -178.806 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.501 ' O ' ' O ' ' A' ' 50' ' ' ILE . 11.3 mt -92.64 124.47 45.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.862 -0.787 . . . . 0.0 112.385 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.524 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 94.85 -48.86 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.87 -157.15 20.42 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.1 OUTLIER -124.21 131.79 53.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.377 -1.072 . . . . 0.0 109.391 179.87 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.47 HD13 HD13 ' B' ' 47' ' ' ILE . 4.0 pt -99.01 -177.85 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 109.101 179.839 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -108.7 137.17 47.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.955 -1.09 . . . . 0.0 109.471 179.722 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.464 HG11 ' HA3' ' B' ' 78' ' ' GLY . 4.0 m -143.78 176.71 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 0.0 109.771 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -127.19 108.64 11.06 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.461 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.6 OUTLIER -66.18 102.43 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.514 -0.741 . . . . 0.0 110.725 -179.085 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.7 m-85 -97.04 94.13 6.99 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.535 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.1 OUTLIER -79.1 134.31 36.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 0.0 110.093 -178.832 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 9.1 mm100 82.74 60.71 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.943 -0.473 . . . . 0.0 110.558 179.252 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.498 ' O ' ' HA ' ' B' ' 72' ' ' ILE . 11.6 mm -124.05 126.72 72.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.994 -1.066 . . . . 0.0 109.202 178.876 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.598 ' C ' ' CD1' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -71.91 95.91 1.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 121.72 0.771 . . . . 0.0 111.799 -178.52 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.544 ' CD1' HD13 ' B' ' 66' ' ' ILE . 3.5 tt -96.08 109.81 23.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 175.765 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.483 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.8 tm-20 -88.2 118.25 27.67 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.911 -1.118 . . . . 0.0 110.252 -177.571 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.554 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.0 OUTLIER -112.74 113.13 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.555 -0.716 . . . . 0.0 109.195 179.929 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.455 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.2 m 66.06 6.33 4.05 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.653 -0.654 . . . . 0.0 110.314 179.356 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.457 ' N ' ' OE2' ' B' ' 65' ' ' GLU . . . 110.93 -3.1 28.7 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -88.39 115.91 26.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.161 -1.199 . . . . 0.0 108.953 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.55 ' HG3' HD13 ' B' ' 63' ' ' LEU . 1.5 mptp? -69.45 107.24 3.26 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.496 ' O ' HG23 ' B' ' 64' ' ' ILE . . . -121.98 110.06 15.36 Favored 'General case' 0 C--N 1.291 -1.938 0 O-C-N 121.627 -0.671 . . . . 0.0 109.683 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.542 HG13 ' CD2' ' B' ' 63' ' ' LEU . 1.2 mt -94.63 120.64 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.894 -1.128 . . . . 0.0 108.271 178.782 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.32 -165.89 10.46 Favored Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.554 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.461 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 59.5 m -97.73 106.69 19.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.68 -0.894 . . . . 0.0 109.651 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.578 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.5 t -91.34 172.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.541 -0.724 . . . . 0.0 109.49 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.533 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.6 mp -140.36 112.67 7.83 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.495 HG23 HD13 ' B' ' 38' ' ' LEU . 1.9 t -97.52 117.49 42.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.932 -1.105 . . . . 0.0 110.305 -178.508 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -154.19 -171.42 21.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.746 -1.742 . . . . 0.0 108.746 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -80.92 41.56 1.17 Allowed 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.336 2.024 . . . . 0.0 110.926 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.533 ' CG2' ' O ' ' B' ' 82' ' ' VAL . 6.5 t -82.38 138.7 44.83 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.854 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.484 ' O ' HG21 ' B' ' 82' ' ' VAL . 36.0 Cg_endo -78.23 18.16 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.283 1.989 . . . . 0.0 110.973 -179.579 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.607 ' CG1' HG13 ' B' ' 84' ' ' ILE . 0.9 OUTLIER -159.71 163.82 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.107 -0.996 . . . . 0.0 109.638 -179.552 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.552 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -109.44 119.86 40.73 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 104.417 -2.438 . . . . 0.0 104.417 176.319 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.607 HG13 ' CG1' ' B' ' 82' ' ' VAL . 6.0 mt -120.4 132.67 69.4 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 120.117 -1.614 . . . . 0.0 113.859 -174.688 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.568 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -96.67 102.51 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.002 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -83.35 -160.26 29.32 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.076 -179.344 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.493 ' NH1' ' O ' ' A' ' 4' ' ' THR . 0.0 OUTLIER -69.79 -30.25 67.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.472 -1.016 . . . . 0.0 109.848 -179.797 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.556 ' ND2' HD21 ' B' ' 89' ' ' LEU . 11.8 p-10 -49.38 -24.29 1.87 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.942 -1.099 . . . . 0.0 109.571 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.556 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -111.06 -23.42 10.93 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.998 -1.064 . . . . 0.0 109.76 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.453 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 51.8 mt -69.32 -6.17 27.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.027 -1.045 . . . . 0.0 109.225 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.65 -20.53 15.6 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.075 -1.016 . . . . 0.0 108.969 179.401 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.43 HE22 ' N ' ' B' ' 72' ' ' ILE . 7.9 mt-30 -81.04 -40.42 24.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.418 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.609 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -82.79 -5.54 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 177.923 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.12 25.95 62.98 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.151 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.579 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.89 132.64 52.78 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.803 -1.41 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 15.7 p -131.47 128.49 39.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.156 -0.965 . . . . 0.0 108.666 179.315 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.577 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 2.4 mp -85.76 96.83 9.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.409 -0.807 . . . . 0.0 110.358 -178.773 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.563 ' C ' ' CD1' ' B' ' 99' ' ' PHE . 2.6 m120 -111.05 139.75 46.15 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.834 . . . . 0.0 109.499 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.596 ' CB ' HD11 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.056 -1.028 . . . . 0.0 109.533 179.438 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.509 ' HG2' ' CD2' ' B' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.232 -0.719 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.476 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -91.48 128.62 37.38 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.156 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.0 t -125.56 131.88 71.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.028 -178.447 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.515 ' CG2' HG21 ' B' ' 96' ' ' THR . 0.0 OUTLIER -154.41 51.57 0.65 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.352 -0.842 . . . . 0.0 109.143 -179.733 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -94.64 42.67 1.09 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.226 -0.921 . . . . 0.0 110.178 -179.401 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.529 ' C ' ' O ' ' A' ' 5' ' ' LEU . 26.9 m95 18.13 49.06 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.415 0 CA-C-O 121.131 0.491 . . . . 0.0 112.176 179.797 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -166.61 -173.89 2.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.145 -0.972 . . . . 0.0 109.359 179.66 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.489 ' HD3' ' OD1' ' B' ' 29' ' ' ASP . 5.3 mtm180 -63.88 111.09 4.61 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.324 -0.86 . . . . 0.0 110.049 -179.629 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.523 ' HD3' ' O ' ' A' ' 7' ' ' GLN . 34.1 Cg_endo -77.29 84.31 1.98 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.957 1.771 . . . . 0.0 109.117 178.668 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.545 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -89.89 149.11 22.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 110.248 -178.882 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.507 HG21 ' HB2' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -135.97 137.74 48.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.388 -0.82 . . . . 0.0 109.551 179.741 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.2 m -72.96 98.84 2.57 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 178.635 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.54 ' HA ' ' O ' ' A' ' 65' ' ' GLU . 15.3 pt -88.6 144.02 9.99 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 O-C-N 121.407 -0.808 . . . . 0.0 110.805 -178.363 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.486 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -107.01 105.23 15.16 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.725 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.468 HD13 ' CD1' ' A' ' 13' ' ' ILE . 24.8 mt -121.74 124.45 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.049 -1.032 . . . . 0.0 109.872 -179.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.88 18.4 72.46 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.372 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.55 0.61 84.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.463 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 28.7 mm-40 -99.9 -178.62 3.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.175 -1.191 . . . . 0.0 109.058 179.746 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CG ' ' HD2' ' A' ' 14' ' ' LYS . 16.7 mt -141.29 129.6 22.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.181 -0.949 . . . . 0.0 110.002 -179.579 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.452 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 3.1 mmtp -142.88 -170.49 3.25 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.492 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.513 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.2 mt-10 -103.26 146.52 28.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.161 -0.962 . . . . 0.0 109.025 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.549 ' HB3' ' CD1' ' A' ' 85' ' ' ILE . . . -130.22 136.21 48.97 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.931 -1.106 . . . . 0.0 110.221 -179.566 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.515 ' O ' ' N ' ' A' ' 25' ' ' ASP . 53.0 tp -105.17 111.55 24.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.495 -0.753 . . . . 0.0 110.041 -179.329 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.506 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -46.71 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.907 -1.121 . . . . 0.0 109.324 179.618 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.518 ' CB ' HG21 ' A' ' 84' ' ' ILE . 33.4 t0 -98.65 71.43 1.96 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.116 -0.99 . . . . 0.0 109.563 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.539 ' HA ' ' CD2' ' A' ' 90' ' ' LEU . 64.9 m -58.1 -15.88 11.12 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.103 -0.998 . . . . 0.0 108.537 179.066 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.467 ' O ' HD23 ' B' ' 23' ' ' LEU . . . -69.64 -41.14 76.17 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.742 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.94 155.97 32.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -1.213 . . . . 0.0 109.78 -179.688 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.524 ' OD2' ' CG ' ' B' ' 8' ' ' ARG . 1.3 m-20 -96.47 -9.97 28.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.769 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.541 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -131.6 -170.11 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 109.549 -179.677 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.491 HG21 ' O ' ' A' ' 84' ' ' ILE . 11.2 m -113.81 88.37 2.83 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.058 -1.027 . . . . 0.0 109.973 -179.367 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.521 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -69.93 171.19 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 178.725 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.581 ' HA ' ' HA ' ' A' ' 83' ' ' ASN . 0.1 OUTLIER -164.08 123.36 1.97 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.406 -1.434 . . . . 0.0 111.875 -179.261 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.0 OUTLIER -42.32 145.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.517 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.472 ' N ' ' HG2' ' A' ' 34' ' ' GLU . 0.8 OUTLIER -48.23 138.75 9.29 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.149 -0.969 . . . . 0.0 109.826 -179.683 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.463 ' HE2' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -147.63 -164.47 2.01 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.424 -0.798 . . . . 0.0 109.209 179.419 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.443 ' N ' ' SD ' ' A' ' 36' ' ' MET . 18.1 t -100.01 87.67 3.55 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 110.041 -179.639 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.508 ' CD1' HG22 ' A' ' 77' ' ' VAL . 16.2 mt -110.92 159.96 30.62 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.106 -0.996 . . . . 0.0 108.935 179.19 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.471 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 34.8 Cg_endo -77.35 154.23 31.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.598 2.199 . . . . 0.0 110.361 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -59.29 -154.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.538 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 4.7 mmm180 69.86 49.58 0.51 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.831 -0.805 . . . . 0.0 109.48 -179.595 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 45.8 p-90 -135.31 -171.4 2.81 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.0 mtpm? -138.9 134.36 16.97 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.963 -1.085 . . . . 0.0 108.85 179.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.69 139.26 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.073 1.849 . . . . 0.0 111.26 -179.181 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.533 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 11.4 pttt -159.03 153.6 24.35 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.307 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.494 ' HE1' ' O ' ' A' ' 53' ' ' PHE . 0.1 OUTLIER -110.85 128.94 55.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.778 -1.201 . . . . 0.0 110.4 -179.093 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.537 HD13 ' CG2' ' B' ' 50' ' ' ILE . 10.0 pt -96.81 142.07 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.95 -1.094 . . . . 0.0 108.152 178.305 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.593 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.79 100.56 0.83 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.607 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.12 -122.76 2.78 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.71 -1.234 . . . . 0.0 110.099 -179.716 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.531 ' CG2' HD12 ' B' ' 47' ' ' ILE . 10.5 mt -87.33 123.21 39.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.629 -0.924 . . . . 0.0 111.854 -178.466 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.79 -52.78 0.68 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.146 -1.181 . . . . 0.0 110.146 178.573 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.46 -155.2 21.84 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.751 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.593 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 6.8 m-85 -114.12 123.22 49.1 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.412 -1.052 . . . . 0.0 110.014 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.548 HG22 ' N ' ' B' ' 51' ' ' GLY . 32.0 pt -102.79 162.43 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.076 -1.015 . . . . 0.0 108.509 178.597 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.9 OUTLIER -95.96 144.78 25.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.215 -0.928 . . . . 0.0 109.018 -179.932 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.49 HG11 ' O ' ' A' ' 55' ' ' LYS . 17.0 m -142.91 -173.73 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.889 -1.132 . . . . 0.0 109.711 -179.83 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.564 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 36.2 mtt180 -133.04 93.21 3.14 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 179.541 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -50.03 101.65 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.585 0.707 . . . . 0.0 110.036 -179.632 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.3 m-85 -100.95 88.29 3.5 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.74 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -78.73 137.68 37.89 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.201 -0.937 . . . . 0.0 110.401 -178.517 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.497 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 74.01 61.79 0.08 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.755 -0.591 . . . . 0.0 110.531 179.329 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.562 ' CD1' ' HB3' ' A' ' 59' ' ' TYR . 1.2 mt -122.02 124.21 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.516 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.546 ' N ' HD12 ' A' ' 72' ' ' ILE . 3.1 tm? -70.06 92.24 0.73 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.442 -0.787 . . . . 0.0 111.82 -177.559 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.538 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 4.2 tt -96.91 118.53 43.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.846 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.54 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 39.1 tt0 -89.61 100.81 13.54 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.983 -1.073 . . . . 0.0 109.766 -178.778 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.489 HG13 HG21 ' A' ' 13' ' ' ILE . 1.3 mp -97.12 121.8 47.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.268 -0.895 . . . . 0.0 108.965 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.407 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 58.09 57.32 4.09 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.515 -0.741 . . . . 0.0 109.641 179.614 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.71 26.33 7.78 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.764 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.465 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 59.8 m-70 -122.24 118.9 29.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.991 -1.3 . . . . 0.0 109.267 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.541 ' CG ' HD22 ' A' ' 63' ' ' LEU . 2.9 mptt -61.38 139.58 58.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.258 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -159.88 102.33 1.48 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.173 -0.954 . . . . 0.0 110.473 -179.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.546 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.6 OUTLIER -78.58 147.25 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.525 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -173.09 -170.89 37.25 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.903 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.2 m -95.33 106.08 18.09 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.729 -0.865 . . . . 0.0 110.174 -179.488 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.513 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -99.04 106.58 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.701 -0.625 . . . . 0.0 109.708 179.358 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.533 ' CD2' ' HE2' ' A' ' 45' ' ' LYS . 2.8 mp -79.81 113.26 17.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.119 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.508 HG22 ' CD1' ' A' ' 38' ' ' LEU . 7.9 t -97.91 107.98 21.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 120.908 -1.12 . . . . 0.0 110.261 -178.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -140.24 -166.48 10.68 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.101 -2.0 . . . . 0.0 108.101 179.088 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.92 40.42 0.96 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.305 2.003 . . . . 0.0 110.522 179.208 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 11.5 t -81.75 137.25 47.45 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.33 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.91 16.3 1.35 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.483 2.122 . . . . 0.0 111.476 -179.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.421 HG13 ' CD1' ' A' ' 84' ' ' ILE . 1.4 t -161.07 149.65 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.809 -1.182 . . . . 0.0 110.251 -179.845 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.581 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -85.85 100.07 11.81 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.774 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.518 HG21 ' CB ' ' A' ' 25' ' ' ASP . 18.9 mm -84.52 120.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.234 -0.916 . . . . 0.0 112.994 -175.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.549 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -103.0 99.36 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.836 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.482 ' O ' HD12 ' A' ' 90' ' ' LEU . . . -106.54 175.99 21.31 Favored Glycine 0 N--CA 1.497 2.72 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.243 -177.069 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.643 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 13.2 mmm180 -25.81 -41.41 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -179.085 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.585 ' ND2' HD21 ' A' ' 89' ' ' LEU . 11.8 p-10 -52.54 -42.54 64.5 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.184 -1.573 . . . . 0.0 110.562 -177.683 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.585 HD21 ' ND2' ' A' ' 88' ' ' ASN . 1.8 mm? -92.98 -23.96 18.53 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.035 . . . . 0.0 108.607 179.598 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.643 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 0.4 OUTLIER -67.81 -8.03 32.59 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.309 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.82 -20.66 17.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.928 -1.108 . . . . 0.0 108.844 179.824 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 30.6 mm-40 -85.71 -40.21 16.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.216 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.537 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 1.1 pt -83.12 2.16 3.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.236 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 66.46 31.93 80.25 Favored Glycine 0 N--CA 1.499 2.887 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.186 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.528 ' CB ' HD13 ' A' ' 93' ' ' ILE . . . -61.06 143.72 54.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.247 -1.149 . . . . 0.0 111.433 -179.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.448 HG21 ' CG2' ' B' ' 4' ' ' THR . 58.0 p -152.05 141.49 21.6 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.13 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.89 HD11 HD11 ' B' ' 97' ' ' LEU . 0.0 OUTLIER -98.23 118.31 34.58 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.786 -1.196 . . . . 0.0 110.358 -179.916 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.539 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.5 m120 -118.0 123.75 46.48 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.637 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.481 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.574 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.576 0 N-CA-C 110.176 -0.74 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.516 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.8 tt0 -89.12 146.41 24.83 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.216 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 12.2 t -138.93 118.17 13.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 120.525 -1.359 . . . . 0.0 110.673 -178.615 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.448 ' CG2' HG21 ' A' ' 96' ' ' THR . 0.0 OUTLIER -123.94 -71.83 0.7 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.277 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.569 ' O ' ' N ' ' B' ' 7' ' ' GLN . 3.1 mm? 36.92 34.47 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.654 -0.654 . . . . 0.0 110.656 179.574 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.532 ' C ' ' O ' ' B' ' 5' ' ' LEU . 17.8 m95 18.61 48.17 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.285 0 CA-C-O 121.233 0.54 . . . . 0.0 112.165 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.569 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -163.16 -158.9 0.5 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.524 ' CG ' ' OD2' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -71.94 124.19 90.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.348 -0.845 . . . . 0.0 109.431 179.888 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.551 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 33.7 Cg_endo -76.99 74.15 5.12 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.146 1.897 . . . . 0.0 110.094 179.387 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.59 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.41 164.24 24.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.03 -1.044 . . . . 0.0 110.091 -179.498 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.468 HG12 ' HG ' ' B' ' 24' ' ' LEU . 2.8 m -151.27 152.76 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.475 -0.766 . . . . 0.0 109.927 -179.007 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.464 HG23 ' CD2' ' B' ' 19' ' ' LEU . 27.9 m -85.89 103.32 14.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.422 -1.423 . . . . 0.0 107.717 177.562 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.523 ' O ' ' CD2' ' B' ' 19' ' ' LEU . 1.7 pt -94.53 148.6 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.065 -1.022 . . . . 0.0 110.479 -178.566 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.487 ' CA ' HD22 ' B' ' 19' ' ' LEU . 9.6 tttt -117.12 105.47 12.3 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.538 ' CG2' HD23 ' B' ' 38' ' ' LEU . 16.3 mt -116.75 134.01 61.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 120.826 -1.171 . . . . 0.0 109.438 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.09 -99.37 0.31 Allowed Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 -179.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' B' ' 18' ' ' GLN . . . -145.31 32.05 1.66 Allowed Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.471 -1.851 . . . . 0.0 108.471 179.237 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.411 ' HG2' ' C ' ' B' ' 17' ' ' GLY . 3.0 mm100 -132.72 178.31 6.96 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.492 -1.005 . . . . 0.0 109.635 -179.539 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.523 ' CD2' ' O ' ' B' ' 13' ' ' ILE . 9.0 mt -143.62 130.8 20.74 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.434 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.3 mmmt -143.44 156.14 44.57 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.59 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.9 mp0 -79.49 122.34 26.33 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.981 -1.074 . . . . 0.0 108.811 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.589 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.38 129.93 52.28 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.434 -0.791 . . . . 0.0 110.647 -178.787 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.523 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 22.9 tp -80.17 97.72 7.02 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.5 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 15.2 mt -44.22 113.01 0.47 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.715 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 57.7 t0 -126.39 88.12 2.78 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.05 -177.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.447 ' HA ' HD13 ' B' ' 90' ' ' LEU . 1.8 m -64.06 -12.83 42.43 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.037 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.458 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -73.1 -41.92 45.8 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.171 -1.171 . . . . 0.0 110.171 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.12 152.3 46.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.061 -1.258 . . . . 0.0 109.449 -179.684 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.551 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 30.6 m-20 -85.0 -21.69 29.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 110.378 -178.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.492 ' HA ' ' OD1' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -139.98 -160.38 1.06 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.811 -1.181 . . . . 0.0 109.429 179.965 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.56 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.0 m -110.94 94.13 4.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.731 -1.23 . . . . 0.0 111.56 -178.242 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.585 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.49 174.73 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.053 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.585 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.72 117.35 0.59 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.932 -1.105 . . . . 0.0 110.311 -179.178 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.551 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 5.5 pt-20 -38.13 158.22 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.544 -0.722 . . . . 0.0 109.586 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.457 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.6 tt0 -46.34 149.71 0.72 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.212 -0.93 . . . . 0.0 110.668 -179.119 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.465 ' HE1' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -178.68 167.58 1.74 Allowed 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.513 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.456 ' O ' ' SD ' ' B' ' 36' ' ' MET . 48.0 t -87.88 109.24 19.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.967 -1.083 . . . . 0.0 109.765 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.604 HD11 ' CD2' ' B' ' 59' ' ' TYR . 8.6 mt -114.65 105.12 53.88 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.255 179.649 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -78.47 102.02 1.52 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.542 2.161 . . . . 0.0 111.233 -179.526 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 168.31 31.13 0.02 OUTLIER Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.596 179.288 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.52 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 55.63 153.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.778 -0.837 . . . . 0.0 109.721 179.647 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.614 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 51.5 p-90 -161.37 176.14 11.48 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.803 -1.185 . . . . 0.0 110.123 -179.764 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.403 ' CD ' ' HD2' ' B' ' 44' ' ' PRO . 0.1 OUTLIER -134.08 162.92 54.79 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.6 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . 0.403 ' HD2' ' CD ' ' B' ' 43' ' ' LYS . 33.4 Cg_endo -76.38 139.95 21.33 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 C-N-CA 121.827 1.685 . . . . 0.0 109.721 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.526 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 7.4 tttm -159.58 119.79 3.05 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.414 -0.804 . . . . 0.0 109.105 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.476 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 76.5 mtp -98.9 132.26 44.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.415 -0.803 . . . . 0.0 109.291 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.534 HD12 ' CD1' ' B' ' 54' ' ' ILE . 17.6 pt -94.26 149.05 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.987 -1.071 . . . . 0.0 108.826 179.386 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.529 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.36 100.51 0.81 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.829 -1.708 . . . . 0.0 108.829 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.25 -129.34 3.29 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.3 -1.429 . . . . 0.0 110.665 -179.241 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.537 ' CG2' HD13 ' A' ' 47' ' ' ILE . 47.4 mt -84.42 118.37 31.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.752 -0.852 . . . . 0.0 112.948 -177.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.548 ' N ' HG22 ' A' ' 54' ' ' ILE . . . 100.02 -1.77 56.53 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 177.805 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 127.85 -154.63 19.83 Favored Glycine 0 N--CA 1.49 2.274 0 O-C-N 120.969 -1.312 . . . . 0.0 109.999 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.4 OUTLIER -121.18 141.53 50.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.53 -0.982 . . . . 0.0 109.799 -179.628 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.534 ' CD1' HD12 ' B' ' 47' ' ' ILE . 18.8 pt -107.22 178.67 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 108.995 179.097 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.2 OUTLIER -109.5 130.13 55.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.234 -0.916 . . . . 0.0 109.568 -179.881 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' B' ' 45' ' ' LYS . 2.2 m -144.11 174.06 4.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.094 -1.004 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -116.73 115.47 25.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.813 179.847 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.499 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 5.6 tt0 -69.77 106.8 3.24 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.139 -0.976 . . . . 0.0 110.13 -179.349 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.614 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 18.0 m-85 -99.65 87.31 3.53 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 178.536 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.589 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -78.71 125.68 29.7 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.875 -1.14 . . . . 0.0 110.177 -178.783 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.589 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 1.5 mt-30 91.16 60.65 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.336 0.588 . . . . 0.0 110.402 179.329 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' B' ' 72' ' ' ILE . 33.1 mm -121.87 125.68 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.306 -0.871 . . . . 0.0 108.752 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.556 HD23 ' CG ' ' B' ' 70' ' ' LYS . 2.1 tm? -73.91 86.38 1.76 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.219 -0.926 . . . . 0.0 112.364 -178.081 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.483 HG22 ' O ' ' B' ' 64' ' ' ILE . 16.5 tt -89.8 114.61 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.426 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 0.7 OUTLIER -90.14 127.51 36.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.912 -1.118 . . . . 0.0 108.765 -179.836 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.582 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 1.0 OUTLIER -124.3 125.89 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.129 -0.982 . . . . 0.0 109.988 -179.248 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.514 ' HB2' ' CD2' ' B' ' 69' ' ' HIS . 54.9 m 55.91 12.78 0.95 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.687 -0.633 . . . . 0.0 111.111 179.169 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . 0.426 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 101.24 21.7 11.4 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.301 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.582 ' CD2' ' O ' ' B' ' 66' ' ' ILE . 23.9 m-70 -118.0 114.52 23.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.057 -1.26 . . . . 0.0 109.333 179.544 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.556 ' CG ' HD23 ' B' ' 63' ' ' LEU . 9.6 tttt -64.4 117.4 7.23 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.12 -0.987 . . . . 0.0 109.006 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.46 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -138.14 124.04 20.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.302 -0.873 . . . . 0.0 110.358 -178.981 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.548 ' HA ' ' O ' ' B' ' 62' ' ' ILE . 0.7 OUTLIER -103.43 129.89 54.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 177.749 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -149.29 -159.91 8.86 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.506 -1.331 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.499 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 7.6 m -100.93 110.71 22.78 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.442 -1.034 . . . . 0.0 109.553 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.54 ' CG2' ' HB ' ' B' ' 62' ' ' ILE . 1.4 t -100.1 107.14 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.312 -0.867 . . . . 0.0 110.516 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.544 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -79.06 121.44 24.97 Favored 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.855 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.571 HG22 ' CD2' ' B' ' 59' ' ' TYR . 3.4 t -110.7 114.27 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.106 -0.996 . . . . 0.0 110.557 -178.68 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.518 ' N ' HG13 ' B' ' 56' ' ' VAL . . . -148.63 -165.13 11.93 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.539 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.57 41.38 1.13 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.588 2.192 . . . . 0.0 110.486 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.551 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 13.6 t -81.43 140.82 48.58 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.7 Cg_endo -78.81 12.52 2.19 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.426 2.084 . . . . 0.0 110.742 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.563 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.1 t -161.22 167.12 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.191 -0.943 . . . . 0.0 109.563 -179.573 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.589 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -105.38 144.37 32.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 104.486 -2.413 . . . . 0.0 104.486 175.761 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' B' ' 31' ' ' THR . 5.7 mm -130.25 130.01 65.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 O-C-N 120.284 -1.51 . . . . 0.0 111.735 -177.059 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -101.15 100.42 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.483 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.9 -155.42 8.81 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.736 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.551 ' HD2' ' HA ' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -79.68 -30.04 41.0 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.388 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.585 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 18.4 p-10 -47.51 -22.95 0.53 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.302 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.585 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 3.4 mm? -113.42 -42.89 3.4 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.123 -0.985 . . . . 0.0 111.036 -178.58 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.466 HD23 HD21 ' B' ' 24' ' ' LEU . 93.8 mt -52.63 -35.88 55.47 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.592 -1.318 . . . . 0.0 109.425 -179.547 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.433 HG23 ' HA ' ' A' ' 6' ' ' TRP . 49.4 p -80.42 -21.79 41.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.233 -0.917 . . . . 0.0 110.978 -178.738 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.535 ' NE2' HD23 ' B' ' 89' ' ' LEU . 32.1 mt-30 -75.06 -38.19 61.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.78 -1.2 . . . . 0.0 108.737 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.525 HD13 ' CD2' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -79.84 2.09 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.392 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 71.37 60.32 4.46 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.539 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -100.01 163.42 12.44 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.308 -1.113 . . . . 0.0 110.021 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.515 HG21 ' CG2' ' A' ' 4' ' ' THR . 2.2 p -148.92 135.19 19.3 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.494 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.89 HD11 HD11 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -90.17 114.83 26.88 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.286 179.952 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.476 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.2 m120 -119.24 130.59 55.54 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.869 -0.519 . . . . 0.0 109.863 -179.069 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.537 ' HB2' ' HB ' ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.171 -0.919 . . . . 0.0 109.09 178.567 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.495 1.615 0 N-CA-C 110.179 -0.739 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.529 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -83.81 145.89 28.43 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 177.632 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.467 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 55.1 t -146.72 105.93 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 117.82 -1.552 . . . . 0.0 111.143 -178.436 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 6' ' ' TRP . 13.5 p -107.16 -57.22 2.1 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 177.811 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.588 ' O ' ' N ' ' A' ' 7' ' ' GLN . 7.8 tp 33.92 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.938 -0.476 . . . . 0.0 111.119 178.659 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.546 ' N ' ' O ' ' A' ' 4' ' ' THR . 9.0 m95 18.19 47.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.121 0.486 . . . . 0.0 111.91 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.588 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -167.41 -175.49 2.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.797 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.513 ' NH1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -56.2 125.74 65.57 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.412 -0.805 . . . . 0.0 109.558 179.755 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.9 Cg_endo -79.05 70.89 7.3 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.179 1.919 . . . . 0.0 109.177 178.843 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.578 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.99 156.12 23.6 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.42 -0.8 . . . . 0.0 110.093 -178.908 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.483 HG21 ' HB1' ' A' ' 22' ' ' ALA . 2.1 m -149.31 130.25 4.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.512 -0.743 . . . . 0.0 109.245 179.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.448 HG21 ' CD2' ' A' ' 19' ' ' LEU . 23.0 m -65.7 96.34 0.27 Allowed 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.728 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 1.9 pt -79.28 140.07 17.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.395 -0.816 . . . . 0.0 109.785 -178.737 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.519 ' CB ' ' HB3' ' A' ' 65' ' ' GLU . 29.0 tttt -105.64 95.52 5.86 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.242 -0.911 . . . . 0.0 108.981 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.515 HG13 HG13 ' A' ' 64' ' ' ILE . 15.1 mt -118.78 147.53 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.153 -0.967 . . . . 0.0 109.924 -179.295 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' N ' HG21 ' A' ' 15' ' ' ILE . . . 44.69 50.62 8.39 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.207 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.26 43.99 34.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.7 mm-40 -142.66 176.67 8.86 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.366 -1.079 . . . . 0.0 109.152 179.864 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.48 ' HG ' ' HG3' ' A' ' 14' ' ' LYS . 16.9 mt -149.64 124.2 9.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.037 -1.039 . . . . 0.0 110.115 -179.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.554 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -138.25 168.78 19.02 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.119 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.578 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.0 mm-40 -80.63 116.03 20.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.096 -1.003 . . . . 0.0 108.671 179.516 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -96.75 142.51 28.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.12 -0.988 . . . . 0.0 110.065 -179.214 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.427 ' O ' ' C ' ' A' ' 24' ' ' LEU . 26.5 tp -104.41 91.54 3.94 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.647 -0.658 . . . . 0.0 109.281 -179.753 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.513 ' CD2' ' HB ' ' A' ' 85' ' ' ILE . 15.1 mt -44.12 101.98 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -0.895 . . . . 0.0 108.714 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.5 t0 -111.57 91.4 3.64 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.351 -0.843 . . . . 0.0 110.495 -178.699 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 m -66.6 -10.61 47.46 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.144 -0.973 . . . . 0.0 108.556 178.643 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -71.44 -44.2 51.7 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.85 164.79 25.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.096 -1.237 . . . . 0.0 109.322 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -100.55 -15.21 17.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.154 -0.966 . . . . 0.0 111.282 -178.695 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' HB3' HD13 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -130.88 -169.96 2.26 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.813 -1.18 . . . . 0.0 109.571 -179.614 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.586 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 50.2 m -109.51 91.35 3.61 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.767 -1.208 . . . . 0.0 110.438 -179.099 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.57 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -72.11 171.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 120.969 -1.082 . . . . 0.0 108.167 179.099 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.596 ' CD1' ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.07 121.98 0.79 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.713 -178.857 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.54 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 0.7 OUTLIER -42.46 166.57 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.146 -0.971 . . . . 0.0 109.535 179.506 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.542 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -51.1 149.71 3.58 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.127 -0.983 . . . . 0.0 110.378 -179.447 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.508 ' CE ' HG23 ' A' ' 15' ' ' ILE . 8.2 ptm -164.95 -161.68 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.439 -0.788 . . . . 0.0 109.08 179.592 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.404 ' N ' ' CG ' ' A' ' 36' ' ' MET . 3.8 t -122.73 109.94 14.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.093 -1.005 . . . . 0.0 111.158 -178.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.584 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -111.21 167.02 9.67 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.18 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.553 ' CD ' HD11 ' A' ' 38' ' ' LEU . 35.5 Cg_endo -77.08 66.62 7.73 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 122.94 2.427 . . . . 0.0 112.352 -179.149 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.523 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 26.66 105.74 0.0 OUTLIER Glycine 0 N--CA 1.504 3.215 0 CA-C-O 121.674 0.597 . . . . 0.0 112.315 178.534 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.456 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.8 mtp180 167.11 51.19 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.316 -1.108 . . . . 0.0 109.115 178.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.608 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.5 p-90 -131.49 -179.49 5.4 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 121.829 0.823 . . . . 0.0 110.302 -179.049 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 57' ' ' ARG . 0.5 OUTLIER -138.41 166.89 22.21 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.7 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.29 140.62 22.22 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.147 1.898 . . . . 0.0 110.796 -179.773 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.495 ' O ' ' CG2' ' A' ' 56' ' ' VAL . 0.5 OUTLIER -160.17 141.36 12.34 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.464 ' HG2' ' HG2' ' A' ' 55' ' ' LYS . 59.3 mtp -125.97 141.57 51.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.837 -1.164 . . . . 0.0 109.915 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.568 ' CD1' HG22 ' B' ' 50' ' ' ILE . 6.9 pt -118.94 141.09 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.268 -0.895 . . . . 0.0 109.171 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.504 ' HA3' ' CE1' ' A' ' 53' ' ' PHE . . . -118.18 103.44 1.04 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.78 -127.47 3.22 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.445 -178.961 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.544 ' CG2' HG12 ' B' ' 54' ' ' ILE . 67.5 mt -79.67 116.33 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.703 -0.88 . . . . 0.0 112.251 -178.139 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.563 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 111.98 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.382 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.74 -161.48 34.34 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.305 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.504 ' CE1' ' HA3' ' A' ' 48' ' ' GLY . 4.3 m-30 -99.95 131.26 46.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.503 -0.998 . . . . 0.0 109.555 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.543 ' CG1' HG13 ' A' ' 47' ' ' ILE . 5.1 pt -110.41 172.45 2.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.156 -0.965 . . . . 0.0 108.841 179.103 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -110.04 147.36 33.7 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.875 . . . . 0.0 109.024 179.657 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 7.3 m -151.03 -171.53 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 120.739 -1.225 . . . . 0.0 110.424 -179.472 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.58 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 2.0 mtt180 -140.1 108.85 5.95 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.228 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.458 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 30.6 tt0 -65.85 103.38 0.9 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.308 -0.87 . . . . 0.0 111.104 -178.468 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.608 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.8 m-85 -91.58 124.67 35.92 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.547 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -109.35 124.2 50.58 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.816 -1.177 . . . . 0.0 110.59 -178.852 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.547 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 6.4 mm100 86.29 58.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 CA-C-O 121.229 0.538 . . . . 0.0 110.648 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.557 ' HB ' ' CG2' ' A' ' 75' ' ' VAL . 26.2 mm -111.88 119.9 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.577 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.546 HD21 HG12 ' A' ' 72' ' ' ILE . 1.3 tm? -67.48 84.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 111.054 -178.5 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.515 HG13 HG13 ' A' ' 15' ' ' ILE . 3.5 tt -87.86 118.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 178.248 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.519 ' HB3' ' CB ' ' A' ' 14' ' ' LYS . 28.0 tt0 -91.42 113.43 25.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.213 -0.929 . . . . 0.0 109.186 -179.189 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.503 HD13 HG12 ' A' ' 64' ' ' ILE . 1.3 mp -106.25 118.29 53.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 -179.667 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.477 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 77.8 m 65.38 21.36 11.91 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.744 -0.598 . . . . 0.0 110.935 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.472 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 90.31 1.59 75.01 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.506 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -97.34 121.18 38.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.075 -1.25 . . . . 0.0 108.827 179.548 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -61.82 127.51 31.78 Favored 'General case' 0 C--N 1.295 -1.775 0 O-C-N 121.363 -0.835 . . . . 0.0 109.416 -179.789 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.47 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -148.19 137.55 22.12 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.541 -0.724 . . . . 0.0 109.454 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.546 HG12 HD21 ' A' ' 63' ' ' LEU . 0.6 OUTLIER -110.29 160.43 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 177.819 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.532 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 175.46 177.51 44.58 Favored Glycine 0 N--CA 1.485 1.901 0 C-N-CA 118.222 -1.942 . . . . 0.0 111.527 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.499 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 75.3 m -82.27 114.74 20.96 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 122.057 -0.672 . . . . 0.0 109.902 -179.715 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.596 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -108.56 109.92 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.395 -0.816 . . . . 0.0 109.951 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.516 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.2 mp -79.21 126.06 30.26 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.114 -0.991 . . . . 0.0 108.729 179.307 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.542 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.6 t -111.43 116.48 52.64 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 109.94 -179.311 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.466 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -150.09 -166.25 13.26 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.553 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.2 Cg_endo -82.96 40.16 0.92 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.47 2.113 . . . . 0.0 110.014 179.711 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.54 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 10.2 t -81.38 137.36 48.64 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.84 15.8 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.451 2.1 . . . . 0.0 111.829 -178.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.527 ' CG1' HD13 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -161.41 165.97 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.728 -1.233 . . . . 0.0 111.025 -179.64 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.568 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 55.4 m-20 -99.39 142.61 30.65 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 177.046 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 31' ' ' THR . 2.9 mm -133.22 113.59 19.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 O-C-N 120.398 -1.439 . . . . 0.0 111.618 -176.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.545 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -92.68 92.95 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 177.326 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -84.03 -156.96 24.75 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 120.048 -1.072 . . . . 0.0 111.685 -177.852 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.484 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 1.8 mtp180 -63.38 -39.13 93.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.91 -0.759 . . . . 0.0 110.84 -178.865 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.599 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 9.2 p-10 -48.07 -26.57 1.88 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.053 -1.03 . . . . 0.0 110.282 -178.73 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.599 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.8 mm? -112.52 -12.93 13.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.762 -1.211 . . . . 0.0 109.85 -179.796 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.484 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 50.1 mt -80.67 -5.75 57.43 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.41 HG23 ' HB3' ' B' ' 6' ' ' TRP . 77.3 p -100.67 -16.91 17.24 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.922 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.7 mm-40 -83.37 -40.58 19.22 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.587 -0.696 . . . . 0.0 109.477 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.619 ' CD1' ' CG ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -87.29 -3.86 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.145 -0.972 . . . . 0.0 109.429 179.607 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 69.09 56.68 8.61 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.606 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.551 ' HB3' ' CD1' ' B' ' 99' ' ' PHE . . . -81.93 148.86 28.51 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.031 -1.276 . . . . 0.0 110.23 -179.769 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.523 HG23 ' CG2' ' B' ' 4' ' ' THR . 55.8 p -142.89 124.08 14.56 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.744 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.527 HD12 ' CD1' ' B' ' 97' ' ' LEU . 4.7 mp -85.07 108.13 17.5 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.9 m120 -107.2 122.15 45.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.742 -1.224 . . . . 0.0 109.259 -179.669 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.627 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.685 0 CA-C-O 117.922 -1.037 . . . . 0.0 109.747 -179.805 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.608 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 4.5 Cg_exo . . . . . 0 N--CA 1.495 1.613 0 N-CA-C 110.693 -0.541 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.44 131.92 35.0 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 178.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.16 115.41 44.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 120.812 -1.18 . . . . 0.0 109.853 -177.905 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.629 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -119.01 -102.34 0.42 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.919 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.671 ' CD1' ' N ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER 25.91 36.44 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.32 0 CA-C-O 120.752 0.31 . . . . 0.0 110.974 179.823 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.629 ' N ' ' O ' ' B' ' 4' ' ' THR . 19.3 m0 13.77 85.16 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 CA-C-O 121.174 0.511 . . . . 0.0 111.775 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.89 155.18 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.156 -0.965 . . . . 0.0 109.422 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 48.0 mtm180 -50.48 119.61 11.32 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.576 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 33.6 Cg_endo -75.23 71.81 5.02 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 122.158 1.905 . . . . 0.0 110.6 179.861 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.524 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -87.87 161.15 17.66 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.267 -0.896 . . . . 0.0 108.953 179.795 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.569 HG21 ' O ' ' B' ' 11' ' ' VAL . 18.7 m -150.84 138.11 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.006 -1.059 . . . . 0.0 110.198 -179.355 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.581 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 24.5 m -72.61 96.66 2.01 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.763 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.572 ' HB ' ' CG1' ' B' ' 64' ' ' ILE . 10.7 pt -90.44 142.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 O-C-N 121.293 -0.88 . . . . 0.0 110.967 -177.332 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.555 ' HE3' ' CD1' ' B' ' 19' ' ' LEU . 0.3 OUTLIER -108.04 98.6 8.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.667 -0.646 . . . . 0.0 109.608 -179.639 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.562 HG13 HG13 ' B' ' 64' ' ' ILE . 11.4 mt -120.1 135.32 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 120.981 -1.075 . . . . 0.0 109.859 -179.742 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.461 ' HA3' HD11 ' B' ' 38' ' ' LEU . . . 43.11 60.01 3.2 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 179.349 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 16' ' ' GLY . . . 43.02 41.83 4.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.698 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.501 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 38.0 mm-40 -138.45 116.24 11.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.366 -1.079 . . . . 0.0 109.464 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.2 OUTLIER -90.79 127.71 36.44 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.685 0.755 . . . . 0.0 110.069 179.699 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.585 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mttt -150.74 142.65 23.88 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.63 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.524 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -78.59 111.09 14.3 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.994 -1.066 . . . . 0.0 108.711 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.578 ' HA ' ' CB ' ' B' ' 83' ' ' ASN . . . -93.76 132.82 37.77 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.984 0.897 . . . . 0.0 111.062 -178.45 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 12.1 tp -83.8 102.46 12.34 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.535 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.525 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 13.2 mt -44.95 120.19 2.26 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.141 -0.974 . . . . 0.0 108.392 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.496 ' OD1' ' OD1' ' A' ' 25' ' ' ASP . 46.5 t0 -128.39 82.4 2.08 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.492 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 1.4 m -62.9 -15.24 54.39 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.015 -1.053 . . . . 0.0 108.738 179.125 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.93 -37.89 94.83 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.928 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 163.53 26.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.292 -1.123 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.457 ' OD1' ' NE ' ' A' ' 8' ' ' ARG . 3.9 m-20 -98.23 -10.12 24.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.525 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 19.5 m-20 -140.25 -165.9 2.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.3 -0.875 . . . . 0.0 108.844 -179.883 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.525 HG23 ' CD1' ' B' ' 33' ' ' LEU . 17.6 m -118.11 93.17 4.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.692 -1.255 . . . . 0.0 111.02 -178.668 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.575 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.89 174.03 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.152 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.575 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.46 117.16 1.32 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.82 -1.175 . . . . 0.0 110.846 -179.086 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.587 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 16.3 tt0 -36.15 155.37 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.492 -0.755 . . . . 0.0 109.94 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.513 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -33.35 146.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.766 0.793 . . . . 0.0 111.41 -179.145 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.498 ' N ' HG12 ' B' ' 77' ' ' VAL . 0.2 OUTLIER -177.64 179.61 0.9 Allowed 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.555 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -122.08 122.84 40.19 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.434 -1.416 . . . . 0.0 111.911 -178.299 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.59 HD13 ' CD ' ' B' ' 39' ' ' PRO . 0.5 OUTLIER -102.58 175.58 2.21 Favored Pre-proline 0 N--CA 1.495 1.785 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 177.899 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.59 ' CD ' HD13 ' B' ' 38' ' ' LEU . 35.4 Cg_endo -78.05 68.8 7.72 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.066 1.844 . . . . 0.0 110.953 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.8 -172.12 0.01 OUTLIER Glycine 0 N--CA 1.493 2.478 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 179.202 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 56.84 101.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.418 -1.048 . . . . 0.0 109.921 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 3.8 p-90 -160.7 171.55 18.66 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.609 -0.682 . . . . 0.0 109.625 179.682 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . 0.524 ' O ' ' CB ' ' B' ' 58' ' ' GLN . 1.4 mtmt -128.71 115.4 19.34 Favored Pre-proline 0 N--CA 1.489 1.477 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.367 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.62 136.03 18.68 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.807 1.671 . . . . 0.0 110.828 -179.334 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.586 ' CE ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.45 178.62 10.11 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.539 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.473 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 27.2 mtp -127.56 136.28 51.47 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.841 -1.162 . . . . 0.0 110.61 -178.754 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.528 HD13 ' CD1' ' B' ' 54' ' ' ILE . 5.8 pt -100.68 143.6 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.328 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.587 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.36 108.92 1.68 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.549 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.89 -125.01 2.55 Favored Glycine 0 N--CA 1.484 1.839 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.522 -179.242 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.568 HG22 ' CD1' ' A' ' 47' ' ' ILE . 50.6 mt -84.3 121.46 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.825 -0.809 . . . . 0.0 112.578 -177.939 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.456 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 98.45 -16.57 59.68 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.019 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 140.58 -155.95 25.03 Favored Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.936 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.6 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.1 m-85 -116.12 134.9 54.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.543 -0.975 . . . . 0.0 109.485 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.563 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 6.0 pt -105.53 159.58 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.004 -1.06 . . . . 0.0 109.245 179.436 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.577 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -99.61 131.43 45.61 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.372 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.586 ' CG2' ' CE ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -138.96 -173.14 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.787 -1.195 . . . . 0.0 109.756 -179.838 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -114.74 165.84 12.38 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.557 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' B' ' 43' ' ' LYS . 10.0 tp60 -128.98 91.57 3.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.57 -1.331 . . . . 0.0 110.99 -178.923 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.599 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 94.1 m-85 -93.88 92.16 7.27 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.223 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.537 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 51.5 m-20 -79.08 134.85 36.73 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.323 -0.86 . . . . 0.0 109.916 -178.841 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.557 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 42.9 mt-30 83.54 63.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.589 0.709 . . . . 0.0 109.291 179.55 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.547 HD13 ' CD1' ' B' ' 38' ' ' LEU . 24.9 mm -119.15 120.48 63.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.592 ' CD2' ' CG ' ' B' ' 70' ' ' LYS . 16.4 tp -72.86 86.83 1.28 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 118.977 -1.089 . . . . 0.0 110.695 -178.852 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.572 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 1.6 tt -85.23 122.24 38.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.647 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.8 tt0 -89.73 109.61 20.58 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.973 -1.079 . . . . 0.0 109.72 -178.411 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.56 ' CG1' HG22 ' B' ' 11' ' ' VAL . 0.4 OUTLIER -105.76 122.25 59.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.262 -0.899 . . . . 0.0 109.087 179.91 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . 0.48 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 76.2 m 66.71 12.26 8.72 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.997 -0.439 . . . . 0.0 110.294 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.37 0.42 56.89 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 6.7 m-70 -98.82 125.03 44.08 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.191 -1.182 . . . . 0.0 108.904 179.717 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.592 ' CG ' ' CD2' ' B' ' 63' ' ' LEU . 2.7 mptm? -70.28 135.11 48.64 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.281 -0.887 . . . . 0.0 108.613 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.509 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -150.27 138.72 20.53 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.383 -0.823 . . . . 0.0 109.077 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.557 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -108.13 142.69 20.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 178.212 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.478 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -163.54 -165.73 21.2 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.993 -179.694 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.501 ' CG2' ' NE2' ' B' ' 58' ' ' GLN . 7.0 m -97.81 110.33 22.92 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.745 -0.856 . . . . 0.0 110.06 -179.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.52 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -109.65 147.26 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.09 -1.006 . . . . 0.0 109.697 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.531 HD22 ' CE ' ' B' ' 45' ' ' LYS . 5.6 mp -125.27 142.91 51.22 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.058 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.519 ' HA ' ' O ' ' B' ' 33' ' ' LEU . 15.1 t -124.03 124.23 68.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.102 -0.999 . . . . 0.0 110.1 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.548 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -160.31 -158.06 9.02 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.577 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -80.57 40.56 1.0 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.806 2.338 . . . . 0.0 110.966 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.587 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.1 t -86.95 133.81 38.43 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 178.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.16 14.16 1.4 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.269 1.979 . . . . 0.0 111.086 -178.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.534 HG13 ' CD1' ' B' ' 84' ' ' ILE . 2.1 t -160.81 151.24 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 120.94 -1.1 . . . . 0.0 110.397 -179.241 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.585 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 21.0 m-20 -80.06 130.74 35.48 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.723 -2.695 . . . . 0.0 103.723 175.077 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.569 HG13 ' CG1' ' B' ' 32' ' ' VAL . 0.8 OUTLIER -125.88 116.26 45.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 119.781 -1.824 . . . . 0.0 112.93 -176.437 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.568 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -89.07 147.28 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.708 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.525 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -136.31 -161.1 9.0 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 118.771 -1.681 . . . . 0.0 110.055 -179.766 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.444 ' O ' ' OG1' ' B' ' 91' ' ' THR . 0.0 OUTLIER -57.59 -37.62 73.51 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.702 -0.881 . . . . 0.0 109.793 -179.725 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.602 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 9.8 p-10 -50.67 -29.72 11.84 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.625 -179.29 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.602 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 1.5 mm? -107.13 -24.02 12.08 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.619 -1.301 . . . . 0.0 110.815 -179.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.492 ' CD1' ' HA ' ' B' ' 26' ' ' THR . 9.2 mt -71.63 -5.68 35.33 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.883 -1.136 . . . . 0.0 108.888 -179.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.5 -14.42 18.26 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.925 . . . . 0.0 109.023 179.319 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . 0.479 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 18.6 mt-30 -85.96 -40.88 15.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -0.867 . . . . 0.0 109.363 -179.816 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.627 HD11 ' CG ' ' A' ' 99' ' ' PHE . 2.2 pt -85.99 4.78 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.144 -0.973 . . . . 0.0 108.542 178.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.7 42.97 98.49 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.345 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.503 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -69.53 145.46 52.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.901 -1.352 . . . . 0.0 108.882 179.327 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 45.4 p -136.86 128.36 28.51 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.052 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.53 ' HB3' ' CE1' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -91.13 96.66 10.71 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 -178.992 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.529 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.3 m120 -109.64 132.92 53.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.47 -0.769 . . . . 0.0 110.045 -179.426 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.619 ' CG ' ' CD1' ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.062 179.41 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.516 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.168 -0.743 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.508 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 5.8 tt0 -83.2 127.62 33.78 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 178.069 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.518 HG13 ' CD2' ' A' ' 5' ' ' LEU . 20.7 t -130.91 102.32 6.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.167 -177.663 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 5.5 p -48.68 -24.34 1.34 Allowed 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 179.213 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.575 ' HB3' ' CZ ' ' B' ' 87' ' ' ARG . 0.5 OUTLIER 71.34 35.6 1.5 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.547 -0.721 . . . . 0.0 109.817 179.679 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.43 ' C ' ' HG2' ' A' ' 7' ' ' GLN . 2.1 m95 -55.21 -20.37 10.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.876 -1.14 . . . . 0.0 108.416 179.611 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.455 ' O ' HD11 ' A' ' 5' ' ' LEU . 4.4 mm100 -138.52 -142.49 0.16 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.022 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HG2' ' OD2' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -92.18 141.8 25.5 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 120.778 -1.201 . . . . 0.0 109.339 179.494 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.513 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -80.16 59.38 7.41 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.502 2.135 . . . . 0.0 110.243 179.532 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 6.0 mt -79.47 132.41 36.34 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.969 -1.082 . . . . 0.0 109.053 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.537 HG21 ' CB ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -134.63 150.37 30.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 121.327 -0.858 . . . . 0.0 109.326 -179.323 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.52 ' CG2' HD21 ' A' ' 19' ' ' LEU . 32.8 m -86.0 95.88 9.65 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.801 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.53 HG22 ' CB ' ' A' ' 22' ' ' ALA . 1.1 pt -79.01 155.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.478 -0.764 . . . . 0.0 110.298 -178.818 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.525 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -120.06 89.96 3.23 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.516 ' CG2' HD23 ' A' ' 38' ' ' LEU . 24.9 mt -110.8 130.24 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.102 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.72 44.85 93.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 179.327 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.27 23.7 48.79 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.48 ' HB2' ' HE3' ' A' ' 36' ' ' MET . 6.7 mm100 -117.4 163.53 16.23 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.153 -1.204 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.52 HD21 ' CG2' ' A' ' 12' ' ' THR . 11.6 mt -132.97 127.68 34.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.992 -1.068 . . . . 0.0 110.853 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 1.2 mmmt -146.59 173.7 12.09 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.091 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 4.0 mm-40 -79.26 179.57 7.32 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.809 -1.182 . . . . 0.0 108.801 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.537 ' CB ' HG21 ' A' ' 11' ' ' VAL . . . -159.35 114.07 2.41 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.766 -1.209 . . . . 0.0 110.608 -179.753 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.515 ' CD2' ' O ' ' B' ' 27' ' ' GLY . 29.3 tp -87.8 96.73 10.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.684 -0.635 . . . . 0.0 109.357 179.61 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.59 HD12 ' CZ ' ' B' ' 99' ' ' PHE . 19.1 mt -43.67 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.492 ' CB ' HG21 ' A' ' 84' ' ' ILE . 8.1 t0 -106.11 86.17 2.32 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.402 -0.811 . . . . 0.0 111.165 -177.891 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.457 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 62.1 m -68.53 -14.18 62.83 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.919 -1.113 . . . . 0.0 108.596 178.437 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.41 -22.59 67.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.919 -1.273 . . . . 0.0 109.919 -179.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.71 164.77 16.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.029 -1.277 . . . . 0.0 109.807 -179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.488 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 1.3 m-20 -94.19 -21.07 19.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 110.961 -178.785 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.556 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.2 OUTLIER -141.55 -166.57 2.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.655 -1.278 . . . . 0.0 110.596 -179.524 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 60.5 m -103.25 89.48 3.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.189 -0.944 . . . . 0.0 111.02 -178.336 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.538 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -73.84 175.45 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.722 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.538 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.0 OUTLIER -171.92 121.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.75 -1.219 . . . . 0.0 110.214 -179.475 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.578 ' HA ' HG21 ' A' ' 80' ' ' THR . 0.1 OUTLIER -39.39 155.61 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.063 -1.023 . . . . 0.0 110.218 179.499 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.527 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.7 OUTLIER -46.4 151.04 0.58 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.383 -0.823 . . . . 0.0 110.265 -179.808 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.48 ' HE3' ' HB2' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -172.63 174.27 3.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.581 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.407 ' C ' ' SD ' ' A' ' 36' ' ' MET . 34.7 t -89.48 83.65 6.36 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.012 -1.055 . . . . 0.0 109.724 -179.722 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.52 ' CD2' HD13 ' A' ' 62' ' ' ILE . 6.1 tp -109.78 105.54 57.31 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.239 -0.913 . . . . 0.0 109.715 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.45 ' HD2' HD13 ' A' ' 38' ' ' LEU . 36.0 Cg_endo -78.47 146.63 21.94 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.573 2.182 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.82 -165.83 26.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.842 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 127.94 49.49 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.26 -1.141 . . . . 0.0 108.595 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.583 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 42.6 p-90 -136.0 -173.99 3.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.985 . . . . 0.0 110.293 -179.355 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.25 129.71 7.74 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.173 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -74.96 136.52 20.61 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.907 1.738 . . . . 0.0 111.369 -178.659 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HD3' HD22 ' A' ' 76' ' ' LEU . 9.5 ptmm? -153.74 -165.41 2.12 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 178.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.424 ' N ' ' HG3' ' A' ' 45' ' ' LYS . 3.3 ttt -147.6 125.92 12.31 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.66 -1.275 . . . . 0.0 110.232 -179.395 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.515 HD13 ' CG2' ' B' ' 50' ' ' ILE . 5.2 pt -98.27 135.92 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.06 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.449 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.35 112.35 2.36 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -179.653 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -129.35 -111.53 1.53 Allowed Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.041 -179.509 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.555 ' CG2' HG12 ' B' ' 54' ' ' ILE . 27.4 mt -97.84 132.53 42.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 O-C-N 121.296 -1.12 . . . . 0.0 111.477 -178.445 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 96.69 -50.48 1.56 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.074 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.49 -158.7 28.22 Favored Glycine 0 N--CA 1.491 2.3 0 O-C-N 121.022 -1.281 . . . . 0.0 110.15 -179.872 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.449 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 32.8 m-85 -107.72 151.36 25.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.611 -0.935 . . . . 0.0 109.954 -179.654 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.546 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 18.0 pt -136.2 140.61 43.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.508 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 8.8 mttt -80.7 137.12 36.28 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.389 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 27.2 m -128.66 -176.72 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.36 -0.838 . . . . 0.0 109.469 -179.73 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.551 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 2.6 mmt85 -125.74 85.35 2.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 108.981 179.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.538 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 1.2 tt0 -45.32 89.53 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 121.441 0.639 . . . . 0.0 110.261 -179.633 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.592 ' HB3' HG13 ' A' ' 62' ' ' ILE . 6.3 m-85 -90.58 82.51 5.82 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.486 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -77.57 137.39 38.56 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.235 -178.349 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.486 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 77.62 59.99 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.198 0.523 . . . . 0.0 110.399 179.701 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.592 HG13 ' HB3' ' A' ' 59' ' ' TYR . 0.6 OUTLIER -131.54 126.49 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.633 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.548 ' CD1' ' HG2' ' A' ' 70' ' ' LYS . 5.3 tt -74.68 93.33 2.54 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.187 -0.945 . . . . 0.0 112.839 -176.746 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.512 HG12 HD13 ' A' ' 66' ' ' ILE . 1.9 tt -87.33 115.76 28.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 105.966 -1.865 . . . . 0.0 105.966 176.236 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.525 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -87.97 116.97 26.51 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.11 -0.994 . . . . 0.0 109.013 -178.057 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.512 HD13 HG12 ' A' ' 64' ' ' ILE . 1.5 mp -111.92 125.64 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.243 -0.911 . . . . 0.0 109.95 -179.076 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 7.7 m 51.75 -94.84 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.697 . . . . 0.0 109.75 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -140.51 49.55 0.79 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.823 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -145.2 109.8 5.0 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.322 -1.105 . . . . 0.0 110.158 -179.767 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.548 ' HG2' ' CD1' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -63.73 120.05 11.11 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.796 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.4 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -132.7 129.01 38.2 Favored 'General case' 0 C--N 1.291 -1.953 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.755 -178.355 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.54 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -105.69 138.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 177.269 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.97 -157.23 8.79 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.641 -179.472 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.538 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 9.9 m -107.42 104.47 14.06 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.879 -0.777 . . . . 0.0 108.946 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.51 ' O ' ' HB2' ' A' ' 59' ' ' TYR . 1.4 t -91.28 99.94 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.539 -0.726 . . . . 0.0 109.721 -179.757 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.556 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 2.7 mp -78.16 106.34 9.99 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.074 -1.016 . . . . 0.0 108.857 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.527 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 50.1 t -95.75 123.9 48.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.424 -0.797 . . . . 0.0 110.358 -179.271 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -155.45 -163.92 12.62 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.36 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.538 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 34.9 Cg_endo -79.75 39.62 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.56 2.173 . . . . 0.0 111.193 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.578 HG21 ' HA ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -85.66 135.77 37.79 Favored Pre-proline 0 N--CA 1.491 1.625 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.794 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.24 18.79 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.793 2.329 . . . . 0.0 112.21 -178.529 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.513 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.87 163.02 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.575 -1.328 . . . . 0.0 110.476 -179.962 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.536 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 54.6 m-20 -91.46 140.04 30.14 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 105.175 -2.158 . . . . 0.0 105.175 176.549 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.541 ' O ' ' HA ' ' A' ' 31' ' ' THR . 18.3 mm -128.64 122.79 58.06 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 O-C-N 120.346 -1.471 . . . . 0.0 111.539 -177.211 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 1.4 mm -102.91 96.71 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.184 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.34 -156.41 10.68 Favored Glycine 0 N--CA 1.495 2.62 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.525 -177.416 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.514 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 7.9 mtt180 -72.81 -35.17 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.874 -0.78 . . . . 0.0 109.799 -179.309 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.545 ' ND2' HD21 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -54.19 -18.87 4.27 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.005 -1.06 . . . . 0.0 108.857 -178.977 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.545 HD21 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -110.37 -22.22 11.81 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.524 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.514 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 64.1 mt -74.67 -17.24 60.71 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.299 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.488 HG23 ' CD2' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -89.84 -10.28 45.97 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.029 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.522 ' NE2' ' O ' ' A' ' 88' ' ' ASN . 72.6 mt-30 -94.52 -41.74 9.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.51 HD13 ' HB3' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -84.25 -3.81 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.203 -0.936 . . . . 0.0 108.772 179.116 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 67.67 43.06 86.39 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 178.817 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -66.54 153.05 43.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.867 -1.373 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' B' ' 96' ' ' THR . 17.7 p -145.09 128.31 16.74 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.327 -0.858 . . . . 0.0 109.094 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.52 ' CD1' HD13 ' B' ' 97' ' ' LEU . 6.7 mp -93.16 96.72 10.21 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.44 -0.787 . . . . 0.0 109.441 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 3.2 m120 -101.13 121.22 41.43 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.822 -1.173 . . . . 0.0 109.674 179.654 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.576 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.479 179.541 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.576 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 N-CA-C 110.408 -0.651 . . . . 0.0 110.408 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.9 tt0 -96.37 132.08 42.26 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.456 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 52.7 t -131.82 120.85 45.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.032 -1.042 . . . . 0.0 109.624 -179.049 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.521 ' C ' ' CD1' ' B' ' 5' ' ' LEU . 0.3 OUTLIER -60.19 -97.26 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.434 -0.791 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.585 HD21 ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -168.88 -17.87 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.963 -1.086 . . . . 0.0 111.325 179.685 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.585 ' N ' HD21 ' B' ' 5' ' ' LEU . 67.0 m95 -66.19 -11.6 50.7 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.546 -1.346 . . . . 0.0 109.792 -179.799 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -117.56 147.12 43.1 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 110.235 -179.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.92 131.21 81.83 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.34 -0.85 . . . . 0.0 109.028 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.505 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 38.0 Cg_endo -81.08 45.42 1.99 Allowed 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.135 1.89 . . . . 0.0 109.825 178.732 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.492 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -81.1 147.45 30.1 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.156 -0.965 . . . . 0.0 109.279 -179.672 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.542 ' CG2' HG13 ' B' ' 66' ' ' ILE . 0.9 OUTLIER -150.31 135.48 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.023 -1.048 . . . . 0.0 110.569 -179.184 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 12' ' ' THR . . . . . 0.443 ' CG2' HD23 ' B' ' 19' ' ' LEU . 7.5 m -64.03 113.83 3.75 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.207 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.521 ' CG2' ' CB ' ' B' ' 22' ' ' ALA . 1.4 pp -100.57 135.67 35.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.323 -0.861 . . . . 0.0 110.182 -179.034 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.514 ' CG ' HD22 ' B' ' 19' ' ' LEU . 0.8 OUTLIER -108.33 108.54 19.57 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.24 -0.912 . . . . 0.0 108.967 179.5 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.539 HG23 ' CE ' ' B' ' 36' ' ' MET . 28.9 mt -110.67 123.52 66.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.163 -0.961 . . . . 0.0 108.876 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.6 -90.46 0.38 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.734 -1.746 . . . . 0.0 108.734 -179.402 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -152.34 27.05 0.88 Allowed Glycine 0 N--CA 1.483 1.813 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 179.396 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.458 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 4.6 mt-30 -125.78 176.31 7.02 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.259 -1.142 . . . . 0.0 109.579 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.514 HD22 ' CG ' ' B' ' 14' ' ' LYS . 18.9 mt -136.48 128.09 28.8 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-O 121.621 0.724 . . . . 0.0 110.312 -179.263 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.434 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 7.6 mmtt -138.64 155.93 47.88 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.494 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mm-40 -78.81 145.13 34.47 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.631 -1.293 . . . . 0.0 109.615 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -120.54 148.84 43.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.941 -1.099 . . . . 0.0 110.762 -179.303 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.422 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -118.42 95.56 4.92 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' B' ' 85' ' ' ILE . 21.2 mt -45.48 107.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.994 -1.066 . . . . 0.0 109.395 -179.659 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.474 ' HB3' HG22 ' B' ' 84' ' ' ILE . 22.5 t0 -119.77 90.4 3.32 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.791 -179.692 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.525 HG21 ' CD ' ' B' ' 87' ' ' ARG . 1.2 m -60.36 -14.27 17.75 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.067 -1.021 . . . . 0.0 108.977 179.282 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' A' ' 23' ' ' LEU . . . -61.67 -44.46 97.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.78 148.43 30.06 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -1.17 . . . . 0.0 109.654 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.47 ' OD2' ' HG2' ' A' ' 8' ' ' ARG . 37.6 m-20 -89.12 -8.79 53.1 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.281 -0.887 . . . . 0.0 110.04 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.495 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -133.39 -171.01 2.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.025 -1.047 . . . . 0.0 109.329 -179.923 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 43.5 m -111.97 93.25 4.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.778 -1.201 . . . . 0.0 110.974 -178.844 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.92 172.83 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.299 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -166.84 124.3 1.29 Allowed 'General case' 0 C--N 1.305 -1.347 0 O-C-N 120.59 -1.319 . . . . 0.0 111.92 -178.838 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.542 ' HA ' HG21 ' B' ' 80' ' ' THR . 0.2 OUTLIER -35.87 154.72 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 178.053 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -53.86 130.33 36.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.113 -0.992 . . . . 0.0 110.335 -179.428 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.539 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -141.33 -178.39 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.85 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.2 t -105.15 103.45 12.99 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.639 -1.288 . . . . 0.0 110.532 -178.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.613 HD11 ' CD1' ' B' ' 59' ' ' TYR . 51.6 mt -106.88 156.58 37.05 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 108.975 179.253 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' B' ' 40' ' ' GLY . 36.4 Cg_endo -79.35 77.99 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.695 2.263 . . . . 0.0 111.475 -179.097 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . 0.493 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 37.37 -158.41 0.01 OUTLIER Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.212 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . 0.493 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 22.5 mmm180 63.65 74.84 0.41 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.597 -0.943 . . . . 0.0 109.169 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.511 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 67.8 p-90 -159.13 175.9 12.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.746 . . . . 0.0 109.761 -179.294 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.54 138.71 31.81 Favored Pre-proline 0 N--CA 1.492 1.669 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.035 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.28 127.97 9.44 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.021 1.814 . . . . 0.0 111.286 -178.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.553 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -162.9 136.48 5.96 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.852 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.456 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 32.4 mtp -102.09 137.26 40.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.844 -1.16 . . . . 0.0 109.098 -179.91 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.5 ' CG1' ' CG1' ' B' ' 54' ' ' ILE . 19.0 pt -89.59 145.46 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.373 179.237 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . 0.458 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -118.23 100.92 0.87 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.748 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.29 -126.85 3.43 Favored Glycine 0 N--CA 1.483 1.775 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.054 -178.611 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.515 ' CG2' HD13 ' A' ' 47' ' ' ILE . 38.5 mt -83.28 118.7 31.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 O-C-N 121.863 -0.787 . . . . 0.0 112.741 -177.292 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . 0.546 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 100.62 -51.91 0.97 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 178.134 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.479 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . -174.6 -171.61 38.95 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.265 -1.445 . . . . 0.0 110.108 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.568 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-30 -106.06 128.83 54.13 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.335 -1.097 . . . . 0.0 109.349 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.555 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.0 pt -100.84 161.39 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.129 -0.982 . . . . 0.0 109.276 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 13.6 mttt -89.6 134.46 34.12 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.131 -0.981 . . . . 0.0 109.208 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.553 ' CG2' ' O ' ' B' ' 45' ' ' LYS . 17.0 m -142.05 172.99 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.966 -1.084 . . . . 0.0 109.588 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 6.9 mtm180 -124.75 101.32 7.04 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.522 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 6.7 tt0 -58.4 96.36 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 110.032 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.613 ' CD1' HD11 ' B' ' 38' ' ' LEU . 13.3 m-85 -89.57 94.34 9.83 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.006 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -78.87 141.76 37.4 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.108 -0.995 . . . . 0.0 110.307 -178.846 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.533 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 15.2 mt-30 69.38 64.02 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.334 0.588 . . . . 0.0 110.765 179.479 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.535 ' CB ' HG22 ' B' ' 75' ' ' VAL . 0.9 OUTLIER -119.84 125.01 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 108.847 178.727 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.605 ' CD2' ' CG ' ' B' ' 70' ' ' LYS . 2.8 tm? -74.4 86.45 2.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.309 -0.87 . . . . 0.0 110.903 -178.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.529 ' CD1' HD13 ' B' ' 66' ' ' ILE . 3.4 tt -90.81 116.93 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.007 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.7 tt0 -90.07 116.56 28.19 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.811 -1.181 . . . . 0.0 109.72 -179.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.542 HG13 ' CG2' ' B' ' 11' ' ' VAL . 0.5 OUTLIER -105.11 116.93 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.157 -0.964 . . . . 0.0 109.675 -179.898 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 51.85 16.55 0.52 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.782 -0.574 . . . . 0.0 111.603 178.454 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 106.99 18.65 10.3 Favored Glycine 0 N--CA 1.495 2.604 0 C-N-CA 119.277 -1.439 . . . . 0.0 110.679 179.016 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -116.08 98.85 6.86 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.084 -1.245 . . . . 0.0 108.898 179.459 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.605 ' CG ' ' CD2' ' B' ' 63' ' ' LEU . 2.6 ttpm? -54.36 120.06 6.05 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.901 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.467 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -142.65 130.86 22.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 110.693 -178.827 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.533 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -94.19 147.1 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.581 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . 0.502 ' N ' HG21 ' B' ' 72' ' ' ILE . . . -171.09 175.83 44.62 Favored Glycine 0 N--CA 1.489 2.209 0 C-N-CA 118.557 -1.782 . . . . 0.0 111.538 -179.601 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.522 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 8.6 m -87.97 102.41 14.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.927 -0.749 . . . . 0.0 110.465 -179.616 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.535 HG22 ' CB ' ' B' ' 62' ' ' ILE . 1.5 t -94.12 108.64 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.368 -0.832 . . . . 0.0 110.01 179.189 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.508 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.0 mp -79.83 111.03 15.75 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.84 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.565 HG22 ' CD1' ' B' ' 59' ' ' TYR . 11.2 t -93.68 116.51 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.117 -0.99 . . . . 0.0 110.122 -179.014 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.53 -172.83 20.76 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.477 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.6 Cg_endo -80.42 42.99 1.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.525 2.15 . . . . 0.0 110.839 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.542 HG21 ' HA ' ' B' ' 34' ' ' GLU . 0.9 OUTLIER -83.01 143.62 46.16 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.035 -1.041 . . . . 0.0 108.496 179.198 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.54 14.8 1.54 Allowed 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.275 1.983 . . . . 0.0 110.874 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.508 HG11 ' N ' ' B' ' 83' ' ' ASN . 1.2 t -160.91 165.08 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.902 -1.124 . . . . 0.0 109.816 -179.527 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.556 ' ND2' ' O ' ' B' ' 21' ' ' GLU . 1.1 m-20 -103.2 119.01 38.08 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 104.675 -2.343 . . . . 0.0 104.675 176.272 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' B' ' 31' ' ' THR . 14.6 mm -102.17 126.41 56.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 O-C-N 120.762 -1.211 . . . . 0.0 111.9 -175.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.589 ' CG2' ' CD2' ' B' ' 24' ' ' LEU . 1.0 OUTLIER -103.89 88.33 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 177.304 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.59 -158.3 11.84 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 120.145 -1.026 . . . . 0.0 111.228 -177.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.575 ' CZ ' ' HB3' ' A' ' 5' ' ' LEU . 7.3 mmm180 -69.01 -37.81 78.9 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.666 -0.902 . . . . 0.0 110.672 -178.748 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.592 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 15.7 p-10 -43.45 -25.18 0.13 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.647 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.592 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 3.3 mm? -111.5 -29.79 7.63 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.07 -1.019 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.573 ' HB2' ' CZ ' ' B' ' 87' ' ' ARG . 33.6 mt -67.33 -8.32 31.49 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.243 -0.91 . . . . 0.0 108.965 179.319 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 91' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.6 -20.28 15.74 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.162 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -81.4 -40.2 23.8 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.565 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -81.28 -2.66 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 108.839 178.89 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 81.95 24.23 55.75 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 178.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.515 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -60.58 137.62 58.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.842 -1.387 . . . . 0.0 109.994 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 96' ' ' THR . 44.5 p -132.65 122.1 24.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.645 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.52 HD13 ' CD1' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -89.51 94.37 9.85 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 121.324 0.583 . . . . 0.0 109.503 -178.683 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.508 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.8 OUTLIER -109.43 130.94 55.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.279 -0.888 . . . . 0.0 110.53 -179.312 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.59 ' CZ ' HD12 ' A' ' 24' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.096 178.464 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 1' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.495 1.604 0 N-CA-C 109.767 -0.897 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.544 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 2.4 tt0 -83.32 134.84 34.9 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 177.686 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.6 t -126.84 101.82 8.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.585 -1.246 . . . . 0.0 110.501 -178.092 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 6' ' ' TRP . 1.7 p -115.18 -81.52 0.61 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.342 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.54 ' O ' ' C ' ' A' ' 6' ' ' TRP . 92.0 mt 33.71 32.91 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.923 -0.486 . . . . 0.0 110.441 178.866 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 7.2 m0 18.33 50.74 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.499 0.666 . . . . 0.0 111.651 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.6 OUTLIER -143.6 -163.83 1.74 Allowed 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.549 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.417 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -84.86 136.64 38.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 108.869 179.703 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.4 Cg_endo -78.97 67.63 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.316 2.011 . . . . 0.0 109.776 179.099 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -86.91 143.04 27.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.19 -0.944 . . . . 0.0 109.592 -179.619 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.416 HG23 HG21 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -139.51 160.66 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.829 . . . . 0.0 109.412 -179.745 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 34.5 m -95.33 109.96 22.03 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.554 HG23 ' CG1' ' A' ' 66' ' ' ILE . 1.7 pt -97.8 159.1 3.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 110.401 -178.312 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.468 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.0 OUTLIER -119.3 99.1 6.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.485 -0.759 . . . . 0.0 109.095 179.53 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.528 HG21 ' CG2' ' A' ' 62' ' ' ILE . 17.0 mt -114.64 130.55 68.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.165 -0.959 . . . . 0.0 109.534 -179.653 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.63 50.56 62.35 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.807 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.67 26.18 16.16 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.946 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.468 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.5 mt-30 -120.37 173.66 7.0 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -1.158 . . . . 0.0 109.041 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 13.2 mt -140.46 126.94 20.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.128 -0.983 . . . . 0.0 110.352 -179.678 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.641 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -144.13 175.04 10.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.516 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 83' ' ' ASN . 1.9 mm-40 -79.44 178.15 8.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.845 -1.16 . . . . 0.0 108.721 179.67 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.529 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -158.38 117.97 3.19 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.875 -1.14 . . . . 0.0 110.035 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 25' ' ' ASP . 59.0 tp -90.56 95.47 10.18 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.431 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.643 ' CD1' ' CZ ' ' B' ' 99' ' ' PHE . 10.9 mt -46.16 97.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 -179.682 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.557 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 18.9 t0 -103.49 91.67 4.15 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.533 -0.729 . . . . 0.0 110.647 -177.851 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' B' ' 26' ' ' THR . 0.1 OUTLIER -67.77 -6.74 22.62 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.886 -1.134 . . . . 0.0 108.977 178.767 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.482 ' O ' HD22 ' B' ' 23' ' ' LEU . . . -80.11 -39.49 16.04 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.446 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.89 160.71 31.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.824 -1.398 . . . . 0.0 109.52 -179.505 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -99.85 -16.46 18.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.932 . . . . 0.0 109.062 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.574 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.4 OUTLIER -132.29 -161.19 1.11 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.44 -0.787 . . . . 0.0 109.152 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.499 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 21.5 m -121.04 89.8 3.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.559 -1.338 . . . . 0.0 110.675 -178.526 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.551 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.953 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.551 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -161.17 129.44 4.4 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.965 -1.084 . . . . 0.0 110.679 -178.707 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.466 ' C ' ' O ' ' A' ' 33' ' ' LEU . 7.0 tt0 -40.8 156.85 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.111 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.492 ' HA ' HG13 ' A' ' 77' ' ' VAL . 0.3 OUTLIER -52.89 153.09 3.52 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.06 -1.025 . . . . 0.0 110.364 -179.155 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.488 ' HG2' HG12 ' A' ' 77' ' ' VAL . 4.1 ptm -177.47 -163.76 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.407 -0.808 . . . . 0.0 109.019 179.71 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -107.52 142.17 37.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.697 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.548 HD21 ' CD ' ' A' ' 39' ' ' PRO . 9.3 mt -150.33 167.22 13.43 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.548 ' CD ' HD21 ' A' ' 38' ' ' LEU . 34.2 Cg_endo -76.78 138.43 18.86 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.299 1.999 . . . . 0.0 109.342 179.33 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.571 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -48.0 -169.33 0.01 OUTLIER Glycine 0 N--CA 1.492 2.42 0 CA-C-O 121.854 0.696 . . . . 0.0 111.438 -178.669 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.571 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.2 OUTLIER 81.91 46.92 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 -178.965 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.679 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 57.8 p-90 -137.24 -172.02 3.1 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.405 0.621 . . . . 0.0 109.798 -179.196 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.19 138.65 11.97 Favored Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 121.41 -0.806 . . . . 0.0 109.204 179.226 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.32 139.48 18.68 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.117 1.878 . . . . 0.0 110.028 179.455 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 0.2 OUTLIER -160.59 -159.46 0.69 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.432 -0.793 . . . . 0.0 108.951 -179.775 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.481 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 69.4 mtp -148.93 130.5 14.91 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.119 -0.988 . . . . 0.0 109.41 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 14.6 pt -88.95 144.68 8.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.14 97.91 0.76 Allowed Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.228 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.68 -126.43 3.26 Favored Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.325 -179.151 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.493 ' O ' ' O ' ' B' ' 50' ' ' ILE . 21.8 mt -87.43 112.17 22.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.809 -0.818 . . . . 0.0 112.639 -177.787 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.544 ' N ' HG22 ' B' ' 54' ' ' ILE . . . 116.77 -48.52 0.93 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 178.054 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.76 -154.57 21.22 Favored Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.023 -179.618 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.1 m-85 -114.14 116.4 29.04 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.562 -0.964 . . . . 0.0 110.009 -179.454 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.0 pt -89.85 175.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.149 -0.969 . . . . 0.0 109.084 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.525 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -104.13 142.5 34.38 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 108.853 179.423 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.483 HG13 ' HA3' ' A' ' 78' ' ' GLY . 15.1 m -150.93 175.25 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.943 -1.098 . . . . 0.0 110.293 -179.54 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.526 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -126.61 98.23 5.32 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.646 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.523 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 0.7 OUTLIER -58.1 102.58 0.11 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.219 -0.925 . . . . 0.0 110.971 -179.016 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.679 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 23.0 m-85 -98.89 94.35 6.53 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.114 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.499 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.02 139.41 38.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.465 -178.538 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.499 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 73.96 62.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.674 -0.641 . . . . 0.0 110.064 179.499 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.528 ' CG2' HG21 ' A' ' 15' ' ' ILE . 10.5 mm -119.69 114.46 44.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.145 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.548 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -63.61 87.02 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.362 -0.836 . . . . 0.0 110.944 -178.586 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.55 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 5.6 tt -89.59 115.23 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 178.078 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.458 ' OE2' ' N ' ' A' ' 69' ' ' HIS . 1.1 tm-20 -88.35 123.51 33.0 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.106 -0.996 . . . . 0.0 109.181 -178.773 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.554 ' CG1' HG23 ' A' ' 13' ' ' ILE . 2.3 mt -126.13 122.42 61.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 110.188 -179.049 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 56.15 46.68 21.02 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.662 -0.649 . . . . 0.0 111.174 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.77 22.62 68.42 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 120.163 -1.018 . . . . 0.0 110.928 178.406 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.458 ' N ' ' OE2' ' A' ' 65' ' ' GLU . 5.9 m-70 -123.41 130.79 53.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.993 -1.298 . . . . 0.0 109.186 179.24 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.543 ' CG ' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -72.48 129.18 37.72 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 108.908 179.713 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.55 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -146.55 109.57 4.68 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.54 -0.725 . . . . 0.0 109.677 -179.324 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.508 HD11 ' N ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -90.43 156.88 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.764 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.493 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -178.53 -171.31 41.68 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 118.435 -1.84 . . . . 0.0 111.597 179.819 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.523 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 7.7 m -96.79 104.92 16.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.737 -0.861 . . . . 0.0 109.542 -179.669 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.471 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -100.33 113.4 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.294 -0.879 . . . . 0.0 110.567 -179.573 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.3 mp -82.78 125.3 31.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.847 . . . . 0.0 108.841 178.938 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.537 ' CG2' HD13 ' A' ' 38' ' ' LEU . 3.1 t -103.92 110.45 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.0 -1.062 . . . . 0.0 109.423 -179.959 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.61 -171.47 15.21 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.949 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.525 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 42.42 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.454 2.103 . . . . 0.0 110.41 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.462 ' O ' HG21 ' A' ' 80' ' ' THR . 6.5 t -81.47 141.89 49.5 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.74 16.95 1.35 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.408 2.072 . . . . 0.0 111.339 -179.629 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.47 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 1.0 OUTLIER -161.05 165.87 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.917 -1.114 . . . . 0.0 109.894 -179.571 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.641 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -103.79 96.72 6.89 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 105.11 -2.181 . . . . 0.0 105.11 176.761 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.528 ' CG1' HG11 ' A' ' 32' ' ' VAL . 6.4 mm -83.15 115.42 25.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 O-C-N 121.082 -1.011 . . . . 0.0 113.1 -175.756 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.588 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -95.0 91.99 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 175.612 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.574 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.32 -157.38 8.6 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.884 -1.15 . . . . 0.0 110.783 -177.047 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -69.56 -37.14 76.88 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.884 -0.774 . . . . 0.0 110.37 -178.804 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.567 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 14.7 p-10 -46.58 -28.86 1.57 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.762 -1.211 . . . . 0.0 109.634 -179.757 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.567 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -110.96 -30.96 7.3 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.994 -1.067 . . . . 0.0 111.466 -178.361 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.464 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 0.6 OUTLIER -59.57 -31.46 69.46 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.769 -1.207 . . . . 0.0 108.642 -179.869 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -78.85 -20.7 48.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.898 . . . . 0.0 110.123 -179.89 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 -69.77 -40.66 75.93 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.88 -1.138 . . . . 0.0 108.262 179.319 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.523 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -83.67 -7.17 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.864 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.52 62.92 3.25 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.805 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HB3' HD13 ' A' ' 93' ' ' ILE . . . -83.21 148.88 27.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.315 -1.109 . . . . 0.0 109.674 -179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.531 ' CG2' HG23 ' B' ' 4' ' ' THR . 5.0 p -137.46 129.74 29.45 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.142 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.511 ' CD1' HD13 ' B' ' 97' ' ' LEU . 4.9 mp -96.58 88.65 4.73 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.263 -0.898 . . . . 0.0 109.422 -179.745 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.1 m120 -93.6 121.59 35.18 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.116 -0.99 . . . . 0.0 109.126 179.827 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.62 ' CG ' HD11 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.402 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 1' ' ' PRO . . . . . 0.605 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.619 0 N-CA-C 110.641 -0.561 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 2' ' ' GLN . . . . . 0.439 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -91.01 136.9 32.77 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 177.85 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.2 t -133.93 105.89 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 120.574 -1.329 . . . . 0.0 110.57 -178.558 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.531 HG23 ' CG2' ' A' ' 96' ' ' THR . 15.8 p -122.03 -70.13 0.8 Allowed 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.063 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER 31.24 37.79 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.81 -0.556 . . . . 0.0 110.743 179.146 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 5.5 m95 18.8 50.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.186 0 CA-C-O 121.504 0.669 . . . . 0.0 111.924 -179.756 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.537 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.4 OUTLIER -154.55 165.4 36.6 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.155 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.495 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 71.2 mtm180 -49.0 133.15 15.0 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.012 -179.827 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 9' ' ' PRO . . . . . 0.476 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.6 Cg_endo -80.09 64.83 8.91 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.312 2.008 . . . . 0.0 109.514 179.028 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 10' ' ' LEU . . . . . 0.555 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -79.89 148.24 31.38 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.33 -0.856 . . . . 0.0 109.521 -179.663 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 11' ' ' VAL . . . . . 0.473 HG22 HG21 ' B' ' 66' ' ' ILE . 1.4 m -140.29 132.28 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.307 -0.871 . . . . 0.0 109.592 179.872 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 11.8 m -64.09 99.77 0.28 Allowed 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.498 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 13' ' ' ILE . . . . . 0.559 ' CD1' HD13 ' B' ' 15' ' ' ILE . 1.0 OUTLIER -90.41 147.89 4.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.255 -0.903 . . . . 0.0 110.615 -178.178 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 14' ' ' LYS . . . . . 0.468 ' HG3' HD22 ' B' ' 19' ' ' LEU . 2.8 tttt -107.93 107.94 18.87 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.559 HD13 ' CD1' ' B' ' 13' ' ' ILE . 14.8 mt -122.88 119.04 56.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.205 -0.934 . . . . 0.0 109.604 -179.273 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.59 20.99 74.4 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.38 -7.74 79.66 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.545 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 18' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' B' ' 37' ' ' SER . 30.6 mt-30 -87.19 -175.25 5.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -1.107 . . . . 0.0 109.52 -179.961 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 19' ' ' LEU . . . . . 0.526 ' O ' ' CD ' ' B' ' 20' ' ' LYS . 40.9 mt -152.19 119.95 6.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.919 -179.861 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' B' ' 19' ' ' LEU . 2.5 mmmt -134.82 161.61 34.73 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.555 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -79.09 122.82 26.71 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.526 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . 0.558 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -108.63 119.4 39.43 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.921 -1.112 . . . . 0.0 111.145 -178.578 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 23' ' ' LEU . . . . . 0.495 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 24.9 tp -75.43 99.59 4.21 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.633 179.561 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 24' ' ' LEU . . . . . 0.531 ' CD2' HD23 ' B' ' 90' ' ' LEU . 4.6 mt -48.68 96.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.935 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 25' ' ' ASP . . . . . 0.61 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 8.7 t0 -96.88 95.6 7.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 110.068 -179.379 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 26' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 26' ' ' THR . 9.8 m -74.27 -4.29 35.25 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.157 -0.964 . . . . 0.0 108.467 178.455 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 27' ' ' GLY . . . . . 0.459 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -85.81 -26.25 35.54 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.85 162.32 16.22 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.869 -1.371 . . . . 0.0 109.999 -179.304 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 29' ' ' ASP . . . . . 0.501 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.2 m-20 -100.62 -13.9 18.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -0.799 . . . . 0.0 110.719 -179.132 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.509 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.82 -172.22 2.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.912 -1.117 . . . . 0.0 109.506 -179.706 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 31' ' ' THR . . . . . 0.53 HG23 ' CD1' ' B' ' 33' ' ' LEU . 20.6 m -111.04 87.28 2.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.519 -1.363 . . . . 0.0 110.702 -178.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 32' ' ' VAL . . . . . 0.559 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -73.43 170.6 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 178.179 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.559 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.51 122.12 1.99 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.533 -1.354 . . . . 0.0 110.609 -178.576 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.484 ' N ' ' CG2' ' B' ' 80' ' ' THR . 88.5 tt0 -40.26 152.92 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.371 -0.831 . . . . 0.0 109.311 179.102 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.8 tt0 -46.09 147.77 0.98 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 110.602 -179.313 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 36' ' ' MET . . . . . 0.475 ' HE3' HG23 ' B' ' 15' ' ' ILE . 3.8 ptt? -168.01 156.81 9.26 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 37' ' ' SER . . . . . 0.524 ' O ' ' NE2' ' B' ' 18' ' ' GLN . 4.6 t -79.26 85.63 5.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 109.788 -179.339 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 38' ' ' LEU . . . . . 0.515 HD22 ' CD1' ' B' ' 62' ' ' ILE . 62.7 tp -103.14 115.13 64.51 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.273 -0.892 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 39' ' ' PRO . . . . . 0.404 ' HD2' HD13 ' B' ' 38' ' ' LEU . 34.1 Cg_endo -77.05 125.28 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.44 2.094 . . . . 0.0 110.534 -179.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.96 154.49 6.18 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.98 153.02 38.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -1.182 . . . . 0.0 109.287 -179.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 42' ' ' TRP . . . . . 0.504 ' CE3' ' HB3' ' B' ' 57' ' ' ARG . 58.0 p-90 -156.58 172.45 18.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.141 -0.975 . . . . 0.0 109.394 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.66 137.39 30.26 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.028 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.35 137.74 15.2 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.112 1.874 . . . . 0.0 111.093 -179.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 45' ' ' LYS . . . . . 0.51 ' HG2' ' CG2' ' B' ' 56' ' ' VAL . 3.8 ptmt -159.98 -172.9 3.81 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.161 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 46' ' ' MET . . . . . 0.414 ' HA ' ' O ' ' B' ' 54' ' ' ILE . 28.1 mtp -141.58 137.61 32.05 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.662 -1.274 . . . . 0.0 109.842 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 47' ' ' ILE . . . . . 0.542 HD13 ' CD1' ' B' ' 54' ' ' ILE . 1.4 pt -96.06 152.74 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.475 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.48 116.33 3.37 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.778 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -149.13 -124.66 1.35 Allowed Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.25 -179.681 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 50' ' ' ILE . . . . . 0.494 HG22 ' CD1' ' A' ' 47' ' ' ILE . 20.4 mt -86.59 123.93 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.527 -0.984 . . . . 0.0 112.375 -178.181 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.78 -7.93 70.72 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 120.27 -0.967 . . . . 0.0 111.148 177.717 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 125.91 -159.22 20.32 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 53' ' ' PHE . . . . . 0.533 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -112.96 142.03 46.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.314 -1.11 . . . . 0.0 109.843 -179.585 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.544 HG22 ' N ' ' A' ' 51' ' ' GLY . 6.5 pt -107.17 -178.3 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.258 -0.901 . . . . 0.0 109.368 179.554 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 55' ' ' LYS . . . . . 0.532 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -106.34 148.21 28.3 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.421 -0.799 . . . . 0.0 108.894 179.475 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 56' ' ' VAL . . . . . 0.51 ' CG2' ' HG2' ' B' ' 45' ' ' LYS . 29.3 m -151.22 -179.1 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.687 -1.258 . . . . 0.0 110.408 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 57' ' ' ARG . . . . . 0.504 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.6 mtt-85 -130.47 86.41 2.38 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.237 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 58' ' ' GLN . . . . . 0.462 ' HB2' ' HD2' ' B' ' 45' ' ' LYS . 24.5 tt0 -47.41 105.63 0.07 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.588 -0.695 . . . . 0.0 111.301 -178.469 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 59' ' ' TYR . . . . . 0.545 ' HB3' HG13 ' B' ' 62' ' ' ILE . 5.1 m-85 -99.03 90.3 4.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 60' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 2.8 m-20 -79.0 136.32 37.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.872 -1.143 . . . . 0.0 111.502 -177.753 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 61' ' ' GLN . . . . . 0.52 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 13.9 mt-30 68.21 62.5 0.38 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-O 121.179 0.514 . . . . 0.0 110.632 178.542 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 62' ' ' ILE . . . . . 0.545 HG13 ' HB3' ' B' ' 59' ' ' TYR . 0.1 OUTLIER -122.51 122.39 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.205 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.597 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 1.3 tm? -60.51 87.4 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.759 0.79 . . . . 0.0 111.896 -177.741 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 64' ' ' ILE . . . . . 0.486 ' N ' ' O ' ' B' ' 71' ' ' ALA . 2.6 tt -95.81 111.53 26.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 176.561 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 65' ' ' GLU . . . . . 0.551 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.4 tt0 -90.25 124.64 35.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.76 -1.212 . . . . 0.0 109.152 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 66' ' ' ILE . . . . . 0.484 HG13 HG21 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -106.53 128.23 61.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.156 -0.965 . . . . 0.0 109.269 -179.728 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 58.86 -90.1 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.683 -0.636 . . . . 0.0 109.682 179.583 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.92 40.95 0.99 Allowed Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 69' ' ' HIS . . . . . 0.48 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 86.6 m-70 -137.64 114.14 10.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -1.132 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 70' ' ' LYS . . . . . 0.522 ' HG2' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -56.47 120.86 8.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.351 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 71' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' B' ' 64' ' ' ILE . . . -132.87 151.63 52.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.405 -0.809 . . . . 0.0 109.429 179.897 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 72' ' ' ILE . . . . . 0.533 ' CD1' ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -125.22 156.5 34.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 177.527 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.27 -165.15 34.86 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 117.906 -2.093 . . . . 0.0 111.492 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 74' ' ' THR . . . . . 0.487 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.5 m -99.41 103.61 15.41 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.906 -0.761 . . . . 0.0 110.017 -179.476 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 75' ' ' VAL . . . . . 0.541 ' CG1' HD11 ' B' ' 15' ' ' ILE . 1.3 t -94.73 102.19 13.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.471 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.466 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -79.12 112.74 16.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.033 -1.042 . . . . 0.0 108.981 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 77' ' ' VAL . . . . . 0.424 HG22 ' CD2' ' B' ' 59' ' ' TYR . 52.9 t -97.89 117.72 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.102 -0.999 . . . . 0.0 109.814 -179.521 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 78' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.89 -164.28 11.67 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 179.739 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 79' ' ' PRO . . . . . 0.532 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -82.76 38.04 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.202 1.935 . . . . 0.0 110.404 179.814 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 80' ' ' THR . . . . . 0.484 ' CG2' ' N ' ' B' ' 34' ' ' GLU . 3.6 t -79.85 134.32 57.08 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 178.785 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -77.5 17.04 0.97 Allowed 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.393 2.062 . . . . 0.0 111.701 -178.556 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.551 HG11 HG13 ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.23 151.4 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.755 -1.216 . . . . 0.0 109.972 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.558 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 84.8 m-20 -89.57 127.08 35.84 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.23 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 84' ' ' ILE . . . . . 0.61 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 3.9 mt -127.89 121.79 57.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 119.903 -1.748 . . . . 0.0 112.655 -176.538 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . 0.533 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -89.43 111.1 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.384 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -92.15 -159.15 35.06 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.57 -178.821 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 87' ' ' ARG . . . . . 0.432 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.0 mtp180 -68.63 -29.47 67.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.685 -0.891 . . . . 0.0 109.984 -179.524 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 88' ' ' ASN . . . . . 0.583 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 16.1 p-10 -53.62 -26.92 24.11 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.062 -1.024 . . . . 0.0 109.601 -179.588 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . 0.583 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 2.9 mm? -108.87 -30.48 8.11 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.066 -1.021 . . . . 0.0 109.847 -179.494 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . 0.531 HD23 ' CD2' ' B' ' 24' ' ' LEU . 85.0 mt -61.29 -30.31 70.4 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.247 -0.908 . . . . 0.0 108.849 179.863 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.1 p -78.47 -22.0 48.21 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.292 -0.88 . . . . 0.0 108.796 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -72.16 -40.73 67.79 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.326 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 93' ' ' ILE . . . . . 0.62 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -87.89 -8.12 10.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.349 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 94' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.09 61.41 6.11 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.255 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 95' ' ' ALA . . . . . 0.504 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -88.53 158.55 18.27 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -1.152 . . . . 0.0 110.341 -179.664 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 96' ' ' THR . . . . . 0.506 HG23 ' CG2' ' A' ' 4' ' ' THR . 43.7 p -135.29 127.6 30.23 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 97' ' ' LEU . . . . . 0.533 ' HB3' ' CE1' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -91.4 95.69 10.12 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.302 -0.874 . . . . 0.0 109.902 -178.786 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 98' ' ' ASN . . . . . 0.544 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -106.83 131.36 54.02 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.868 . . . . 0.0 109.941 -179.882 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' B' B ' 99' ' ' PHE . . . . . 0.643 ' CZ ' ' CD1' ' A' ' 24' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.284 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.615 0 CA-C-O 121.355 0.481 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.523 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 20.7 tt0 -86.19 118.5 25.69 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 177.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -115.15 105.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 120.806 -1.184 . . . . 0.0 110.405 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.511 ' CG2' ' CG2' ' B' ' 96' ' ' THR . 1.3 p -123.34 30.0 6.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.615 -0.678 . . . . 0.0 109.709 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.548 ' O ' ' C ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -89.56 39.33 0.94 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.13 -0.981 . . . . 0.0 109.295 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.548 ' C ' ' O ' ' A' ' 5' ' ' LEU . 46.2 m0 16.28 59.36 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 CA-C-O 121.613 0.72 . . . . 0.0 111.918 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -145.14 174.22 11.25 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.395 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -65.97 118.32 51.0 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.98 -1.075 . . . . 0.0 108.915 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 71.66 6.16 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.214 1.942 . . . . 0.0 109.545 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.564 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -92.93 157.07 16.53 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.442 -0.786 . . . . 0.0 109.523 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.524 HG23 HG13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -150.77 136.53 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.183 -0.948 . . . . 0.0 110.158 -179.599 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 55.0 m -68.32 108.9 3.39 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.573 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 1.2 pp -98.66 152.46 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 120.957 -1.09 . . . . 0.0 111.012 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.461 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 10.9 tttt -113.23 104.61 12.51 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.551 ' CG2' ' HE3' ' A' ' 36' ' ' MET . 5.1 mt -120.84 129.81 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.079 -1.013 . . . . 0.0 109.894 -179.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.58 35.57 81.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.34 73.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.461 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -121.47 -176.76 3.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.342 -1.093 . . . . 0.0 108.653 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.46 HD22 ' CA ' ' A' ' 14' ' ' LYS . 16.4 mt -151.4 124.05 8.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.938 -1.101 . . . . 0.0 110.892 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -141.97 165.99 25.94 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 178.495 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.564 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.5 mp0 -79.25 131.62 36.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.9 -1.125 . . . . 0.0 108.747 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.573 ' CB ' ' CG2' ' A' ' 13' ' ' ILE . . . -108.09 137.87 45.33 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.067 -1.021 . . . . 0.0 110.641 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 20.1 tp -104.77 98.7 8.4 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.478 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 43.2 mt -44.95 95.17 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.064 -1.022 . . . . 0.0 108.685 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 1.4 t70 -97.05 79.8 2.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.164 -0.96 . . . . 0.0 110.732 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 27.6 m -63.11 -13.71 39.8 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.991 -1.068 . . . . 0.0 108.762 178.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.8 -41.39 49.85 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.401 ' HB3' ' C27' ' B' ' 100' ' ' DMP . . . -77.04 168.95 19.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.202 -1.176 . . . . 0.0 109.67 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.71 -17.59 16.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.185 -0.947 . . . . 0.0 111.272 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -135.7 -176.71 4.38 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.427 -179.366 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.564 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 16.7 m -98.86 87.97 3.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.359 -0.838 . . . . 0.0 110.68 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.566 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.95 168.14 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 178.787 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.566 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.23 135.22 5.14 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.975 -1.078 . . . . 0.0 110.518 -178.235 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.49 ' HG2' ' O ' ' A' ' 80' ' ' THR . 2.0 mt-10 -45.16 170.68 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.375 -0.828 . . . . 0.0 108.834 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.514 ' HA ' HG11 ' A' ' 77' ' ' VAL . 2.7 tt0 -60.59 152.68 25.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.041 -1.037 . . . . 0.0 109.888 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.551 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 8.1 ptm -177.8 -158.92 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.462 ' O ' HD23 ' A' ' 38' ' ' LEU . 6.6 t -110.67 127.21 55.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.258 -0.901 . . . . 0.0 110.351 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.614 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 3.8 mm? -131.88 170.01 12.4 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.534 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 36.3 Cg_endo -80.99 123.96 4.79 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.791 2.327 . . . . 0.0 112.514 -178.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.552 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -44.49 117.72 2.18 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.552 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 150.04 44.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.596 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 35.4 p-90 -118.81 -173.84 2.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.961 0.886 . . . . 0.0 110.709 -177.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.08 136.92 11.12 Favored Pre-proline 0 C--N 1.303 -1.451 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.05 136.89 20.88 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.846 1.698 . . . . 0.0 110.986 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.437 ' HD2' HG21 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -146.8 157.52 43.69 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.528 ' CG ' ' HG2' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -119.41 125.47 49.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.836 -1.165 . . . . 0.0 110.188 -178.889 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.563 HD13 ' CG2' ' B' ' 50' ' ' ILE . 5.7 pt -104.86 136.23 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 108.746 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.57 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.36 102.59 0.97 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.51 -127.16 3.56 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.627 -178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.588 HD13 ' C76' ' B' ' 100' ' ' DMP . 57.0 mt -80.19 122.13 34.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.9 -0.765 . . . . 0.0 112.925 -177.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.417 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 100.0 -50.87 1.08 Allowed Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.049 177.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -177.5 -160.53 24.36 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.582 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.57 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.8 m-85 -113.47 133.37 55.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.567 -0.96 . . . . 0.0 109.926 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.528 HG12 ' CG2' ' B' ' 50' ' ' ILE . 10.6 pt -113.51 168.09 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.141 -0.974 . . . . 0.0 108.918 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.7 mtpt -113.46 132.4 55.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.201 -0.937 . . . . 0.0 109.252 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.464 HG11 ' HA3' ' A' ' 78' ' ' GLY . 8.6 m -127.79 -174.59 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.969 -1.082 . . . . 0.0 110.217 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.498 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 1.7 mtt85 -127.37 92.08 3.44 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.4 tt0 -54.58 94.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.544 -0.723 . . . . 0.0 110.484 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.614 ' CE1' ' HB3' ' A' ' 38' ' ' LEU . 26.6 m-85 -89.51 133.7 34.46 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 177.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -111.35 139.86 46.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.938 -1.101 . . . . 0.0 111.528 -177.664 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.555 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 69.48 63.48 0.27 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.727 -0.608 . . . . 0.0 110.44 178.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.544 HD12 ' CB ' ' A' ' 59' ' ' TYR . 3.6 mp -116.71 122.78 70.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.557 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -64.77 82.91 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.642 0.734 . . . . 0.0 110.48 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.547 HG12 HD13 ' A' ' 66' ' ' ILE . 2.9 tt -90.76 117.83 34.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.549 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -90.4 137.23 32.52 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.09 -1.006 . . . . 0.0 108.587 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.547 HD13 HG12 ' A' ' 64' ' ' ILE . 0.6 OUTLIER -124.37 112.61 33.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 120.902 -1.124 . . . . 0.0 108.901 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 62.37 23.08 13.65 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.713 -0.617 . . . . 0.0 109.833 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 93.93 9.22 59.85 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.547 ' N ' ' CD2' ' A' ' 69' ' ' HIS . 2.5 m170 -100.54 105.41 16.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.097 -1.237 . . . . 0.0 109.218 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.523 ' CG ' HD22 ' A' ' 63' ' ' LEU . 2.9 tttt -53.77 125.07 17.12 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.134 -0.979 . . . . 0.0 109.303 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.523 ' O ' ' N ' ' A' ' 64' ' ' ILE . . . -147.18 145.99 29.7 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.566 -0.709 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.555 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -115.43 155.31 16.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 105.93 -1.878 . . . . 0.0 105.93 177.438 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.489 ' N ' HG21 ' A' ' 72' ' ' ILE . . . -178.67 -173.38 43.97 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 118.14 -1.981 . . . . 0.0 111.367 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.485 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -93.51 107.43 19.28 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.776 -0.838 . . . . 0.0 109.555 -179.763 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.511 HG12 HD12 ' A' ' 15' ' ' ILE . 1.5 t -102.72 111.58 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.341 -0.849 . . . . 0.0 110.45 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.488 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.3 mp -81.79 122.9 28.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.439 -0.788 . . . . 0.0 109.211 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.514 HG11 ' HA ' ' A' ' 35' ' ' GLU . 71.9 t -103.96 118.84 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.093 -1.005 . . . . 0.0 109.769 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.464 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -156.03 -165.6 14.76 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.1 Cg_endo -80.31 43.26 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 122.72 2.28 . . . . 0.0 110.795 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.49 ' O ' ' HG2' ' A' ' 34' ' ' GLU . 9.2 t -89.05 139.02 28.83 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.462 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.9 Cg_endo -79.6 17.96 1.18 Allowed 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.568 2.178 . . . . 0.0 111.81 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.481 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.74 166.98 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.543 -1.348 . . . . 0.0 110.659 -179.811 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.556 ' OD1' ' CD2' ' A' ' 33' ' ' LEU . 7.5 m-80 -96.87 93.53 6.71 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 176.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 31' ' ' THR . 26.7 mm -78.42 127.25 38.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 O-C-N 120.727 -1.233 . . . . 0.0 112.154 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.512 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -107.43 89.96 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 177.232 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.14 -165.0 28.81 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 120.276 -0.964 . . . . 0.0 111.217 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 9.5 mtm180 -64.42 -31.05 72.1 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.793 -0.828 . . . . 0.0 109.92 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.614 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 11.2 p-10 -48.61 -26.04 2.04 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.145 -0.972 . . . . 0.0 109.422 -179.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.614 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -106.75 -21.15 13.13 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.01 -1.056 . . . . 0.0 108.837 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.539 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 43.4 mt -72.61 -4.09 28.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 177.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.538 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -100.57 -18.43 16.61 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 178.294 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.47 ' HA ' ' OE1' ' A' ' 92' ' ' GLN . 50.6 mm-40 -83.06 -40.9 19.27 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.533 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 1.4 pt -89.0 5.27 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.418 -0.801 . . . . 0.0 109.397 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 58.98 47.66 89.62 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.474 ' HB1' HD13 ' A' ' 93' ' ' ILE . . . -70.69 155.1 41.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.137 -1.214 . . . . 0.0 110.76 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 24.1 p -146.74 126.09 13.12 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.58 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.0 mp -93.46 86.04 5.12 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.483 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.486 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 5.3 m120 -91.38 124.4 35.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.289 -0.882 . . . . 0.0 109.652 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.59 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.045 -0.978 . . . . 0.0 109.196 179.355 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.584 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.718 0 N-CA-C 110.572 -0.588 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.416 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 0.3 OUTLIER -99.66 117.44 34.02 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.533 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.51 HG13 ' HB3' ' B' ' 9' ' ' PRO . 9.1 t -108.04 114.69 47.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 108.605 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.537 ' C ' ' CD1' ' B' ' 5' ' ' LEU . 19.8 p -67.79 -105.19 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.274 -0.891 . . . . 0.0 109.073 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.546 ' CD2' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -171.88 -11.64 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.828 -1.17 . . . . 0.0 111.434 179.824 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.546 ' N ' ' CD2' ' B' ' 5' ' ' LEU . 72.2 m95 -66.61 -10.53 46.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.69 -1.256 . . . . 0.0 109.49 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.96 178.59 7.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 109.615 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.498 ' HG2' ' NH1' ' A' ' 87' ' ' ARG . 13.8 mtt180 -92.18 138.56 24.35 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.316 -0.865 . . . . 0.0 109.157 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.6 Cg_endo -79.49 59.93 7.6 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.246 1.964 . . . . 0.0 110.147 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.537 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.2 OUTLIER -86.43 145.72 26.73 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.945 -1.097 . . . . 0.0 109.102 -179.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.52 ' CG2' HG21 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -145.15 136.01 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.651 -179.137 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.44 HG23 HD21 ' B' ' 19' ' ' LEU . 86.5 m -68.26 90.5 0.35 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.52 HG21 ' CG2' ' B' ' 11' ' ' VAL . 47.8 pt -79.09 153.7 4.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.451 -0.781 . . . . 0.0 110.02 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.524 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 3.2 tttt -115.14 100.56 8.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.413 -0.804 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.546 ' CG1' ' HB ' ' B' ' 64' ' ' ILE . 11.1 mt -122.81 131.19 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.55 48.65 85.0 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.55 20.96 6.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.446 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -112.98 171.44 7.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.155 -1.203 . . . . 0.0 109.714 -179.805 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.524 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 55.5 mt -143.47 127.67 17.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.378 -0.826 . . . . 0.0 109.524 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -147.95 165.99 29.06 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 108.912 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.508 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 2.5 mm-40 -78.55 127.37 32.04 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.055 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.563 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.57 159.07 16.05 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.886 -1.134 . . . . 0.0 109.808 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.403 ' O ' ' C ' ' B' ' 24' ' ' LEU . 19.2 tp -122.53 93.76 4.08 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.485 -0.76 . . . . 0.0 109.109 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.525 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 21.7 mt -46.41 110.66 0.29 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.994 -1.066 . . . . 0.0 108.243 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.565 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 56.3 t0 -122.07 91.65 3.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.19 -0.944 . . . . 0.0 110.403 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.426 HG23 ' HG3' ' A' ' 9' ' ' PRO . 1.3 m -65.0 -10.3 28.49 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.9 -1.125 . . . . 0.0 108.78 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.74 -46.94 58.85 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.445 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -73.41 164.92 26.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.154 -1.204 . . . . 0.0 109.496 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -101.14 -15.44 17.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.027 -1.046 . . . . 0.0 110.969 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.584 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -132.08 -163.37 1.33 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.778 -1.201 . . . . 0.0 110.024 -179.3 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.659 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 67.0 m -113.39 91.34 3.61 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.052 -1.03 . . . . 0.0 110.012 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.482 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.8 OUTLIER -77.56 156.17 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.371 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.482 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -152.78 124.36 7.76 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.595 -1.316 . . . . 0.0 110.162 -178.894 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.491 ' HG2' ' N ' ' B' ' 35' ' ' GLU . 47.5 tt0 -36.56 153.3 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.491 ' N ' ' HG2' ' B' ' 34' ' ' GLU . 1.5 tt0 -53.63 152.49 5.11 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -0.981 . . . . 0.0 109.93 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.483 ' HE3' HG23 ' B' ' 15' ' ' ILE . 3.3 ptm -177.26 -174.12 0.48 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.486 -0.759 . . . . 0.0 109.406 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -91.52 105.73 17.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 109.648 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.434 HD13 ' HD2' ' B' ' 39' ' ' PRO . 32.2 tp -134.96 105.07 10.5 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.718 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.434 ' HD2' HD13 ' B' ' 38' ' ' LEU . 36.7 Cg_endo -78.24 138.7 16.19 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.451 2.101 . . . . 0.0 110.147 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.95 179.45 22.17 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.12 139.72 35.47 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.276 -1.132 . . . . 0.0 109.13 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.577 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 38.7 p-90 -150.36 153.38 35.92 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.138 -0.976 . . . . 0.0 109.958 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.77 131.16 24.25 Favored Pre-proline 0 N--CA 1.489 1.478 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.12 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.72 135.79 16.37 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.982 1.788 . . . . 0.0 110.708 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.528 ' HG3' ' CG2' ' B' ' 56' ' ' VAL . 1.1 ptmm? -158.04 -168.35 2.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.543 -0.723 . . . . 0.0 109.059 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.51 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 1.0 OUTLIER -145.36 121.1 10.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.097 -1.002 . . . . 0.0 110.015 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.552 HD13 ' CG2' ' A' ' 50' ' ' ILE . 2.4 pt -92.26 141.18 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.25 -0.906 . . . . 0.0 108.618 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.56 108.65 1.53 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.47 -119.09 2.21 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.499 -1.334 . . . . 0.0 110.244 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.597 HG13 ' H62' ' B' ' 100' ' ' DMP . 25.8 mt -87.75 130.87 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.441 -1.035 . . . . 0.0 111.781 -178.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 54' ' ' ILE . . . 91.3 -45.0 2.79 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.549 -1.021 . . . . 0.0 110.549 178.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.417 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.36 -159.36 29.38 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.444 -1.36 . . . . 0.0 110.167 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.535 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -121.62 139.34 53.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.505 -0.997 . . . . 0.0 109.16 -179.715 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' B' ' 46' ' ' MET . 32.4 pt -114.31 -176.16 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.257 -0.902 . . . . 0.0 109.655 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.517 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -107.28 150.03 27.12 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.321 -0.862 . . . . 0.0 108.955 179.406 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.528 ' CG2' ' HG3' ' B' ' 45' ' ' LYS . 3.2 m -143.72 -174.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 120.788 -1.195 . . . . 0.0 110.655 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.479 ' HG3' ' O ' ' B' ' 77' ' ' VAL . 3.6 mtm-85 -142.41 88.47 2.08 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.525 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 2.2 tt0 -48.02 95.05 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.314 -0.866 . . . . 0.0 110.296 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.2 m-85 -92.43 92.82 8.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 4.6 m-20 -79.88 130.72 35.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.97 -1.081 . . . . 0.0 111.025 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.516 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 2.9 mt-30 84.95 59.27 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 CA-C-O 121.165 0.507 . . . . 0.0 110.968 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.494 HG13 ' HB3' ' B' ' 59' ' ' TYR . 13.2 mm -118.41 124.9 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -1.0 . . . . 0.0 108.579 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.538 ' CD2' ' HG3' ' B' ' 70' ' ' LYS . 1.9 tm? -72.16 99.99 2.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.174 -0.954 . . . . 0.0 110.998 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.572 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 1.3 tt -104.7 117.62 50.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.47 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 31.7 tt0 -90.77 108.56 19.9 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.091 -1.006 . . . . 0.0 109.118 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.489 HD12 HD11 ' B' ' 64' ' ' ILE . 1.1 mp -99.03 116.89 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.957 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.474 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 10.1 m 64.26 17.28 10.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.821 -0.55 . . . . 0.0 110.649 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 96.94 4.11 58.92 Favored Glycine 0 N--CA 1.492 2.423 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.15 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -104.68 116.33 31.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.049 -1.265 . . . . 0.0 109.418 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.538 ' HG3' ' CD2' ' B' ' 63' ' ' LEU . 14.7 tttt -52.81 137.86 30.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.45 -0.782 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.572 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -160.13 100.88 1.4 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.18 -0.95 . . . . 0.0 109.619 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.476 HD12 ' HB2' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.31 156.56 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.642 -1.286 . . . . 0.0 108.32 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.438 ' N ' HG21 ' B' ' 72' ' ' ILE . . . -177.75 176.27 47.95 Favored Glycine 0 N--CA 1.488 2.149 0 C-N-CA 118.999 -1.572 . . . . 0.0 111.167 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.525 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 10.6 m -88.51 109.85 20.39 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.63 -0.924 . . . . 0.0 110.376 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' B' ' 31' ' ' THR . 0.8 OUTLIER -99.84 110.89 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.274 -0.891 . . . . 0.0 110.534 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.584 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -79.52 104.27 10.01 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 26.3 t -88.77 125.5 41.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 120.777 -1.202 . . . . 0.0 110.017 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -153.01 -169.32 18.05 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.517 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -81.44 41.86 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.557 2.171 . . . . 0.0 110.793 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.464 HG22 HG11 ' B' ' 32' ' ' VAL . 14.6 t -84.73 140.15 37.88 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.442 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.6 Cg_endo -79.38 14.0 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.376 2.051 . . . . 0.0 111.175 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.516 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -160.85 176.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.825 -1.172 . . . . 0.0 110.591 -179.47 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.563 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -107.98 147.78 30.61 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 176.721 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.659 ' O ' ' HA ' ' B' ' 31' ' ' THR . 4.6 mm -135.3 100.1 2.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 O-C-N 120.902 -1.124 . . . . 0.0 110.963 -177.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.602 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 0.7 OUTLIER -79.2 88.86 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -81.23 -160.42 24.84 Favored Glycine 0 N--CA 1.494 2.555 0 O-C-N 121.363 -0.836 . . . . 0.0 112.103 -177.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . . . . . . . . . 5.8 mtm180 -58.91 -41.0 86.22 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 122.148 -0.619 . . . . 0.0 111.386 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.539 ' ND2' HD21 ' B' ' 89' ' ' LEU . 10.9 p-10 -52.23 -18.89 1.71 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.979 -1.076 . . . . 0.0 109.956 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.539 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.4 mm? -114.75 -23.92 8.96 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 120.928 -1.107 . . . . 0.0 108.933 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 25.9 mt -71.84 -6.79 44.21 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 59.9 p -101.19 -17.79 16.46 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.299 -0.876 . . . . 0.0 108.753 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -83.7 -41.49 17.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.415 -0.803 . . . . 0.0 109.502 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.508 HD11 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -84.7 -4.64 8.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.165 -0.959 . . . . 0.0 108.713 179.282 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.97 58.67 7.2 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -81.03 157.81 25.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.112 -1.228 . . . . 0.0 110.347 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.511 ' CG2' ' CG2' ' A' ' 4' ' ' THR . 9.4 p -139.6 126.07 20.34 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.58 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -95.88 89.38 5.23 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.104 -179.156 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.542 ' N ' ' ND2' ' B' ' 98' ' ' ASN . 0.6 OUTLIER -101.55 132.7 47.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -0.83 . . . . 0.0 110.568 -178.966 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.533 ' HB2' ' HB ' ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 117.946 -1.026 . . . . 0.0 108.751 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.597 ' H62' HG13 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.425 ' HD2' ' C ' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.318 -0.686 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.53 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -84.26 131.92 34.69 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.403 HG13 ' HB3' ' A' ' 9' ' ' PRO . 51.2 t -131.53 118.78 40.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 120.998 -1.064 . . . . 0.0 110.209 -178.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.434 ' O ' ' C ' ' A' ' 5' ' ' LEU . 2.2 p -127.71 -90.91 0.51 Allowed 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.56 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 41.63 29.17 0.1 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.48 -0.762 . . . . 0.0 109.432 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.56 ' C ' ' O ' ' A' ' 5' ' ' LEU . 37.3 m0 18.07 51.84 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 CA-C-O 121.638 0.732 . . . . 0.0 111.326 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.546 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.9 mt-30 -142.3 -166.66 2.3 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.9 mtm180 -74.25 116.4 52.35 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.511 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.5 Cg_endo -76.53 73.84 5.0 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.269 1.979 . . . . 0.0 109.763 179.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -81.53 158.56 24.42 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.32 -0.862 . . . . 0.0 110.301 -179.113 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.495 HG12 ' HG ' ' A' ' 24' ' ' LEU . 4.0 m -149.85 130.54 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.408 -0.808 . . . . 0.0 109.588 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.0 m -68.49 106.09 2.43 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.544 ' CG2' ' HB1' ' A' ' 22' ' ' ALA . 6.8 pt -92.24 155.06 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.21 -0.931 . . . . 0.0 110.285 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.461 ' HE2' HD13 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -119.02 105.83 11.82 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.059 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.527 HG22 ' CG2' ' A' ' 62' ' ' ILE . 8.1 mt -123.99 127.08 73.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 120.987 -1.071 . . . . 0.0 109.819 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.73 35.55 91.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.63 9.88 52.71 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -104.64 -179.4 3.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.374 -1.074 . . . . 0.0 109.297 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.483 ' C ' ' HG2' ' A' ' 20' ' ' LYS . 3.6 mt -145.9 131.25 18.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 110.269 -179.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.483 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -145.51 157.02 44.06 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.272 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.519 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 19.7 mp0 -78.98 133.63 36.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.842 -1.161 . . . . 0.0 107.93 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -113.68 144.07 43.55 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.994 -1.066 . . . . 0.0 111.07 -178.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 58.8 tp -98.71 92.67 5.7 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.511 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 74.0 mt -43.94 96.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 51.4 t0 -110.74 92.8 4.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.458 -0.776 . . . . 0.0 110.461 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.52 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 6.0 m -67.31 -10.66 53.07 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 108.758 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.532 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -74.19 -43.18 33.35 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.42 149.37 50.13 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.9 -1.353 . . . . 0.0 109.202 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -84.45 -19.94 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 110.133 -179.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.494 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -136.57 -162.25 1.26 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.067 -1.02 . . . . 0.0 109.499 -179.503 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.511 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 20.4 m -115.77 100.41 8.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.473 -1.392 . . . . 0.0 111.235 -178.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -78.0 178.15 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.695 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.558 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -169.15 116.35 0.62 Allowed 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.935 -1.103 . . . . 0.0 110.213 -179.241 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.495 ' HA ' HG23 ' A' ' 80' ' ' THR . 41.2 tt0 -39.35 162.02 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.29 -0.881 . . . . 0.0 109.966 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.466 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -41.34 156.85 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.218 -0.926 . . . . 0.0 110.738 -179.562 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.516 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 11.2 ptm -179.02 -176.94 0.45 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.548 -0.72 . . . . 0.0 109.149 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.8 t -104.52 118.69 37.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.417 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.619 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 9.9 mt -132.92 170.65 10.85 Favored Pre-proline 0 N--CA 1.493 1.694 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.619 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -69.53 -163.06 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.287 0 C-N-CA 122.079 1.853 . . . . 0.0 111.671 -179.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -105.39 35.09 5.3 Favored Glycine 0 N--CA 1.494 2.502 0 C-N-CA 119.968 -1.111 . . . . 0.0 111.169 -178.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.5 mtt85 -109.56 50.44 0.79 Allowed 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.7 p-90 -133.43 176.79 8.22 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.867 0.841 . . . . 0.0 110.542 -178.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.26 151.74 34.53 Favored Pre-proline 0 C--N 1.302 -1.486 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.01 130.37 11.24 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.759 1.639 . . . . 0.0 110.655 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.527 ' O ' ' CG2' ' A' ' 56' ' ' VAL . 3.6 ptmt -161.42 129.14 4.17 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.509 ' CG ' ' HG3' ' A' ' 55' ' ' LYS . 15.4 mtp -89.58 135.01 33.85 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.941 -1.1 . . . . 0.0 109.417 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.521 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 7.0 pt -89.4 145.91 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.244 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 98.36 0.76 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.104 -1.599 . . . . 0.0 109.104 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.98 -124.1 2.99 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.46 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.635 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 9.9 mt -88.87 119.15 35.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.636 -0.92 . . . . 0.0 112.693 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.509 ' N ' HG21 ' B' ' 54' ' ' ILE . . . 106.54 -51.3 0.75 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 177.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.28 -155.52 16.13 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.6 m-85 -118.41 128.66 54.83 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.456 -1.026 . . . . 0.0 109.995 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 46' ' ' MET . 10.1 pt -101.77 169.69 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 16.1 mttt -99.62 134.57 42.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.019 -1.051 . . . . 0.0 108.958 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 34.7 m -140.51 -177.61 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.957 -1.089 . . . . 0.0 110.255 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -128.97 91.65 3.25 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.467 ' CD ' HG23 ' A' ' 74' ' ' THR . 2.4 tp-100 -55.06 105.08 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.62 -0.675 . . . . 0.0 110.71 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.646 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.4 m-85 -96.45 129.04 43.9 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.515 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 40.0 m-20 -111.17 133.41 53.55 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.738 -1.226 . . . . 0.0 109.771 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.566 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 7.8 mm100 78.29 61.91 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.648 -0.657 . . . . 0.0 109.994 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.553 ' N ' HD11 ' A' ' 62' ' ' ILE . 4.4 mp -119.45 126.55 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.349 -0.844 . . . . 0.0 108.749 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.558 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 3.1 tm? -77.87 94.47 4.55 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.149 0.976 . . . . 0.0 111.613 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.557 ' CG2' HD13 ' A' ' 89' ' ' LEU . 3.2 tt -98.02 119.79 46.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.402 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -91.11 125.3 35.85 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.827 -1.17 . . . . 0.0 108.804 -179.876 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.546 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.2 OUTLIER -121.61 135.37 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.103 -0.998 . . . . 0.0 109.748 -179.314 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 66' ' ' ILE . 59.5 m 36.93 38.23 0.08 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.088 0.47 . . . . 0.0 110.578 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.34 47.64 8.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.518 ' CB ' HG23 ' A' ' 93' ' ' ILE . 73.6 m-70 -141.18 123.28 15.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.346 -1.091 . . . . 0.0 109.353 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.544 ' CG ' HD22 ' A' ' 63' ' ' LEU . 6.9 tttt -77.76 122.09 24.92 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.223 -0.923 . . . . 0.0 108.558 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.43 ' HB2' ' CD1' ' A' ' 89' ' ' LEU . . . -144.43 124.27 13.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.033 -1.042 . . . . 0.0 110.818 -178.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.566 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -102.65 120.15 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.232 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.474 ' O ' HD11 ' A' ' 62' ' ' ILE . . . -144.15 -165.43 10.94 Favored Glycine 0 C--N 1.289 -2.06 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.872 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.478 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 38.0 m -97.43 114.72 26.6 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.503 -0.998 . . . . 0.0 110.305 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.524 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.5 t -106.43 118.89 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 C-N-CA 120.216 -0.593 . . . . 0.0 110.159 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.535 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.4 mp -89.44 126.24 35.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.103 -0.998 . . . . 0.0 109.177 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.558 ' CG2' HD13 ' A' ' 38' ' ' LEU . 1.7 t -108.5 120.58 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -157.08 -169.32 20.8 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.536 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -80.8 39.86 0.91 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.605 2.203 . . . . 0.0 110.886 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 34' ' ' GLU . 15.1 t -82.39 139.96 44.95 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.16 14.57 1.52 Allowed 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.222 1.948 . . . . 0.0 111.084 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.497 HG11 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.23 165.0 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 120.96 -1.088 . . . . 0.0 109.778 -179.408 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.616 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.75 145.92 28.47 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 175.979 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.532 HG21 ' CB ' ' A' ' 25' ' ' ASP . 3.3 mm -129.92 129.99 66.14 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 O-C-N 120.047 -1.658 . . . . 0.0 111.743 -177.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.482 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 0.8 OUTLIER -104.95 96.39 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.834 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -82.29 -169.34 43.38 Favored Glycine 0 N--CA 1.492 2.376 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.481 -178.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -62.43 -30.43 71.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.581 -0.953 . . . . 0.0 109.789 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.6 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 14.6 p-10 -50.51 -28.64 8.83 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.986 -1.071 . . . . 0.0 109.782 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.6 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 3.0 mm? -110.11 -27.87 8.95 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.011 -1.056 . . . . 0.0 110.652 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.52 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 33.9 mt -65.49 -13.57 59.14 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.739 -1.226 . . . . 0.0 109.322 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.4 p -96.69 -21.3 17.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.046 -1.034 . . . . 0.0 109.254 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.456 ' HG3' ' HA ' ' A' ' 89' ' ' LEU . 2.0 mt-30 -74.92 -40.26 60.96 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.176 -0.953 . . . . 0.0 108.521 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.546 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -79.59 1.11 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 178.603 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.66 59.48 8.14 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -87.86 156.43 19.39 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.301 -1.117 . . . . 0.0 109.914 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.53 HG21 ' CG2' ' B' ' 4' ' ' THR . 2.2 p -138.86 129.27 25.78 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.58 ' HB3' ' CE2' ' A' ' 99' ' ' PHE . 1.1 mp -95.52 90.38 5.73 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.5 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.5 m120 -89.52 125.77 35.33 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.213 -0.929 . . . . 0.0 109.939 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.952 -1.023 . . . . 0.0 109.022 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.5 Cg_endo . . . . . 0 N--CA 1.497 1.708 0 N-CA-C 110.14 -0.754 . . . . 0.0 110.14 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.459 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 2.9 tt0 -84.56 114.67 22.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.78 115.07 46.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.956 -1.09 . . . . 0.0 111.104 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.53 ' CG2' HG21 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.46 32.51 1.48 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.322 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.526 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.7 mt -85.55 49.05 1.68 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.598 -0.689 . . . . 0.0 109.925 -179.047 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.526 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.8 m95 17.84 52.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.229 0.537 . . . . 0.0 112.174 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.9 mt-30 -154.95 171.5 19.61 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.221 -0.924 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -63.87 144.19 98.06 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 120.99 -1.069 . . . . 0.0 109.492 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.465 ' HG3' HG23 ' A' ' 26' ' ' THR . 36.7 Cg_endo -80.15 54.9 5.42 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.645 2.23 . . . . 0.0 110.904 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 3.1 mt -80.62 135.23 36.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.988 -1.07 . . . . 0.0 108.89 179.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.47 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -134.88 141.82 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.181 -0.95 . . . . 0.0 109.604 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.405 HG21 HD21 ' B' ' 19' ' ' LEU . 10.1 m -70.17 100.53 1.68 Allowed 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 178.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.55 HG22 ' CB ' ' B' ' 22' ' ' ALA . 4.4 pt -95.12 143.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.404 -0.81 . . . . 0.0 110.055 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.0 OUTLIER -98.95 107.78 20.3 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 178.905 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.586 ' CG2' ' CE ' ' B' ' 36' ' ' MET . 10.2 mm -113.83 115.45 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 120.756 -1.215 . . . . 0.0 110.865 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.474 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.15 9.21 56.79 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.44 -10.05 42.23 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.426 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 1.5 mp0 -89.86 -173.29 3.84 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.264 -1.139 . . . . 0.0 109.063 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.448 ' C ' ' HG2' ' B' ' 20' ' ' LYS . 18.0 mt -149.13 121.86 8.66 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.889 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.465 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 4.9 mmtt -141.83 172.55 12.53 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.488 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -79.65 155.3 28.13 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.227 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.55 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -135.76 113.02 10.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.532 ' CD2' ' O ' ' A' ' 27' ' ' GLY . 3.3 tp -84.15 104.01 13.85 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.44 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 16.3 mt -52.45 103.9 0.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.548 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 19.9 t0 -101.16 77.96 1.86 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.37 -0.831 . . . . 0.0 110.174 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.486 ' CG2' HD11 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.02 -14.46 9.58 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.079 -1.013 . . . . 0.0 108.962 178.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.42 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -70.8 -35.46 66.14 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.501 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -83.3 170.86 14.16 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.938 -1.33 . . . . 0.0 110.234 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -100.54 -18.8 16.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.291 -0.881 . . . . 0.0 110.796 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.513 ' HB3' HD12 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -132.92 -170.54 2.47 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.599 -1.313 . . . . 0.0 110.625 -179.059 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.537 HG23 ' CD1' ' B' ' 33' ' ' LEU . 21.1 m -106.07 91.83 3.89 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.938 -1.102 . . . . 0.0 110.558 -178.769 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.481 HG23 HD12 ' B' ' 47' ' ' ILE . 0.4 OUTLIER -81.01 154.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.717 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.537 ' CD1' HG23 ' B' ' 31' ' ' THR . 1.3 mp -148.91 133.62 17.85 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.919 -1.113 . . . . 0.0 110.667 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.501 ' HA ' HG21 ' B' ' 80' ' ' THR . 3.9 mt-10 -43.5 166.69 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.468 -0.77 . . . . 0.0 109.284 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.0 OUTLIER -67.9 115.1 7.04 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.407 -0.808 . . . . 0.0 109.25 179.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.586 ' CE ' ' CG2' ' B' ' 15' ' ' ILE . 6.7 ptm -139.46 -166.8 2.13 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.4 t -95.34 115.35 27.31 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.262 -0.899 . . . . 0.0 109.93 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.489 ' O ' ' OH ' ' B' ' 59' ' ' TYR . 26.5 tp -144.42 105.0 4.67 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.472 ' HD2' HD13 ' B' ' 38' ' ' LEU . 36.5 Cg_endo -76.41 146.0 27.35 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.398 2.065 . . . . 0.0 110.848 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 136.96 145.24 4.94 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -63.95 117.94 7.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.98 -1.306 . . . . 0.0 108.501 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . . . . . . . . . 48.9 p-90 -110.95 175.89 5.24 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 110.31 -178.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.0 mmtt -126.03 137.03 29.34 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -76.56 129.14 10.75 Favored 'Trans proline' 0 C--N 1.303 -1.838 0 C-N-CA 121.799 1.666 . . . . 0.0 110.812 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.527 ' O ' ' HG3' ' B' ' 45' ' ' LYS . 0.0 OUTLIER -161.62 137.66 7.95 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.062 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.502 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 25.3 mtp -102.0 137.88 39.7 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.832 -1.168 . . . . 0.0 109.332 -179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.539 ' O ' ' HA ' ' B' ' 53' ' ' PHE . 2.1 pt -89.72 164.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -138.23 108.22 0.61 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.408 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -139.61 -116.89 1.4 Allowed Glycine 0 N--CA 1.484 1.881 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.357 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.619 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 14.3 mt -85.79 122.79 38.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.6 -0.941 . . . . 0.0 112.019 -178.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.482 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 99.02 -52.8 1.08 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.418 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.45 -153.91 18.87 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.604 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.4 m-85 -113.54 135.81 53.49 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.494 -1.003 . . . . 0.0 109.941 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.511 HG13 ' CG1' ' B' ' 47' ' ' ILE . 1.8 pt -104.31 179.49 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.564 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -108.45 130.12 55.25 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 109.164 179.574 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.492 ' CG2' ' HG3' ' B' ' 45' ' ' LYS . 3.7 m -134.0 169.61 21.38 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.947 -1.096 . . . . 0.0 110.175 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.435 ' HD3' ' HB ' ' B' ' 77' ' ' VAL . 8.9 mtp180 -120.26 87.78 2.81 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.492 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 3.0 tt0 -48.42 99.28 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.525 -0.734 . . . . 0.0 110.561 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.532 ' O ' ' HA ' ' B' ' 74' ' ' THR . 5.2 m-85 -88.78 136.96 32.73 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 177.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 7.1 m-20 -114.86 133.37 56.02 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.571 -1.331 . . . . 0.0 110.882 -178.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.584 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 3.9 mp0 71.49 63.77 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.614 0.721 . . . . 0.0 109.849 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.47 ' HB ' HG22 ' B' ' 75' ' ' VAL . 9.1 mm -111.46 111.6 36.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.536 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.1 tm? -65.39 85.71 0.07 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.445 -0.784 . . . . 0.0 110.266 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.488 ' HA ' ' O ' ' B' ' 14' ' ' LYS . 3.8 tt -89.11 125.28 42.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 33.1 tt0 -89.2 109.01 19.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.126 -0.984 . . . . 0.0 109.506 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.499 HG13 HG21 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.79 122.47 57.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.282 -0.886 . . . . 0.0 108.753 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.548 ' HB3' ' CD2' ' B' ' 69' ' ' HIS . 0.1 OUTLIER 53.83 54.56 9.63 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.489 -0.757 . . . . 0.0 110.631 179.026 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.15 20.51 28.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.548 ' CD2' ' HB3' ' B' ' 67' ' ' CYS . 87.8 m-70 -115.57 127.53 55.31 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.996 -1.296 . . . . 0.0 109.183 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.7 131.28 42.91 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.073 -1.017 . . . . 0.0 109.106 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.455 ' O ' HD23 ' B' ' 63' ' ' LEU . . . -150.69 146.6 26.57 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.632 -0.667 . . . . 0.0 109.243 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.584 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -114.25 156.71 15.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.432 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -179.3 173.37 45.38 Favored Glycine 0 N--CA 1.485 1.944 0 C-N-CA 118.632 -1.747 . . . . 0.0 111.055 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 88.2 m -89.97 112.79 24.3 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.5 -1.0 . . . . 0.0 109.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.475 HG23 HD11 ' B' ' 15' ' ' ILE . 1.4 t -100.94 112.7 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.897 179.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.513 HD12 ' HB3' ' B' ' 30' ' ' ASP . 1.9 mp -81.82 105.73 13.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.533 -0.729 . . . . 0.0 109.061 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.435 ' HB ' ' HD3' ' B' ' 57' ' ' ARG . 2.9 t -88.1 114.1 26.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 O-C-N 120.514 -1.366 . . . . 0.0 109.742 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -151.4 -170.42 18.23 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.564 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.3 Cg_endo -79.57 41.1 1.04 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 C-N-CA 122.434 2.089 . . . . 0.0 111.308 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.525 HG22 ' O ' ' B' ' 82' ' ' VAL . 0.7 OUTLIER -85.82 137.73 35.68 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 178.374 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.478 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 34.7 Cg_endo -78.5 21.52 0.69 Allowed 'Trans proline' 0 C--N 1.301 -1.921 0 C-N-CA 122.32 2.013 . . . . 0.0 112.13 -178.317 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.535 ' CG1' HG13 ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.68 151.72 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.457 -1.402 . . . . 0.0 111.097 -179.735 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.546 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -92.4 87.36 5.98 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 176.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.548 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 1.1 mt -84.71 123.62 39.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.896 0.855 . . . . 0.0 112.914 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.553 ' N ' HD11 ' B' ' 85' ' ' ILE . 3.5 mm -95.8 96.42 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.5 -161.07 18.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.108 -177.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 7' ' ' GLN . 1.4 mtm105 -64.88 -31.01 72.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.893 -0.769 . . . . 0.0 110.65 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.582 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 13.8 p-10 -54.8 -26.88 37.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.737 -1.227 . . . . 0.0 110.211 -179.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.582 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -108.83 -31.39 7.71 Favored 'General case' 0 N--CA 1.484 1.258 0 O-C-N 120.766 -1.209 . . . . 0.0 110.091 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.486 HD11 ' CG2' ' B' ' 26' ' ' THR . 81.9 mt -62.42 -31.1 71.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 57.4 p -79.09 -21.69 46.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.41 -0.806 . . . . 0.0 109.457 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -67.55 -40.15 84.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.554 HD11 ' CB ' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -87.92 -7.55 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.497 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.72 64.95 2.82 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -90.29 142.36 27.81 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.427 -1.043 . . . . 0.0 111.011 -178.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 8.3 p -130.35 130.61 44.64 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.51 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 3.9 mp -94.36 96.88 9.82 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.158 -0.964 . . . . 0.0 109.903 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.53 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -103.22 124.59 48.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.068 -1.02 . . . . 0.0 109.129 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.546 ' CB ' HD11 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.437 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.635 ' H32' ' CG1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.603 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.9 Cg_exo . . . . . 0 N--CA 1.494 1.549 0 N-CA-C 110.669 -0.55 . . . . 0.0 110.669 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.491 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 7.6 tt0 -84.67 108.2 17.27 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 177.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.558 HG22 ' CZ ' ' B' ' 99' ' ' PHE . 16.7 t -102.95 121.25 53.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.064 -1.022 . . . . 0.0 109.484 -178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -73.09 -4.86 35.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.351 -178.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.544 ' HB3' ' HG2' ' B' ' 87' ' ' ARG . 5.5 mt 66.24 45.15 2.34 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.192 -0.942 . . . . 0.0 110.082 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.516 ' HA ' HG22 ' B' ' 91' ' ' THR . 1.4 m95 -65.84 -20.65 66.32 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.032 -1.042 . . . . 0.0 110.511 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.575 ' O ' ' CD ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -166.35 -99.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.956 -1.09 . . . . 0.0 110.092 179.821 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -113.49 140.3 24.33 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.774 -1.204 . . . . 0.0 109.565 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.543 ' CB ' ' HB2' ' A' ' 24' ' ' LEU . 34.7 Cg_endo -80.46 53.79 4.93 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.254 1.969 . . . . 0.0 109.693 177.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.54 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 1.3 mt -79.51 134.43 36.51 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.852 -1.155 . . . . 0.0 110.2 -178.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.49 HG22 HG21 ' A' ' 66' ' ' ILE . 1.6 m -150.99 163.71 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.667 -0.646 . . . . 0.0 109.317 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.46 ' CG2' HD23 ' A' ' 19' ' ' LEU . 3.5 m -86.56 119.07 26.42 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.53 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 18.8 pt -110.49 137.49 42.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.335 -0.853 . . . . 0.0 109.709 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.522 ' CB ' HD22 ' A' ' 19' ' ' LEU . 1.1 ttpp -106.96 107.7 18.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.125 -0.984 . . . . 0.0 109.299 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.528 HG13 HG13 ' A' ' 64' ' ' ILE . 5.1 mt -113.26 131.36 65.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.962 . . . . 0.0 109.201 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.41 -88.57 0.34 Allowed Glycine 0 N--CA 1.485 1.924 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -178.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 23.9 0.32 Allowed Glycine 0 C--N 1.293 -1.829 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.462 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 29.2 mt-30 -118.25 177.99 4.6 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.64 -0.918 . . . . 0.0 109.295 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.522 HD22 ' CB ' ' A' ' 14' ' ' LYS . 13.2 mt -143.7 119.08 10.25 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.692 0.758 . . . . 0.0 110.001 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -133.62 172.53 12.62 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.54 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 21.0 mt-10 -77.58 166.35 23.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.893 -1.129 . . . . 0.0 108.143 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.591 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -147.66 132.43 17.96 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.798 -1.189 . . . . 0.0 110.405 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.423 ' O ' ' C ' ' A' ' 24' ' ' LEU . 40.7 tp -104.84 90.17 3.39 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.709 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.543 ' HB2' ' CB ' ' A' ' 9' ' ' PRO . 38.2 mt -46.86 107.23 0.1 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.852 -1.155 . . . . 0.0 108.253 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.579 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.4 t0 -112.27 89.67 3.13 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.346 -0.846 . . . . 0.0 109.852 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.593 ' CG2' HD11 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -61.8 -21.19 64.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.072 -1.017 . . . . 0.0 108.422 179.325 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.476 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -60.45 -38.21 94.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.522 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -87.47 160.62 18.21 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.069 -1.254 . . . . 0.0 109.566 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -100.25 -6.81 25.42 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.459 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.557 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.56 179.29 6.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.169 -0.957 . . . . 0.0 110.081 -179.489 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.681 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 5.9 m -106.11 96.01 6.18 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.224 -0.923 . . . . 0.0 109.309 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.559 HG11 ' CG2' ' A' ' 80' ' ' THR . 1.2 t -87.46 105.45 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.126 0 O-C-N 121.21 -0.931 . . . . 0.0 110.055 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.526 HD23 ' CD1' ' A' ' 15' ' ' ILE . 1.5 mp -100.17 133.4 44.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.315 -0.866 . . . . 0.0 112.14 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.627 ' HA ' HG21 ' A' ' 80' ' ' THR . 11.8 pt-20 -42.41 153.34 0.07 Allowed 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 177.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.54 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.4 mt-10 -53.17 131.32 36.75 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 120.934 -1.104 . . . . 0.0 109.614 -179.417 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.517 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -146.17 175.64 10.34 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.06 179.896 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.409 ' O ' ' SD ' ' A' ' 36' ' ' MET . 16.5 t -86.45 107.31 18.0 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.291 -0.881 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.504 HD23 ' CG2' ' A' ' 15' ' ' ILE . 20.9 mt -121.12 110.79 34.31 Favored Pre-proline 0 N--CA 1.488 1.436 0 O-C-N 121.291 -0.88 . . . . 0.0 109.213 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -78.84 116.96 3.83 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.806 2.337 . . . . 0.0 110.659 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 151.82 -168.53 31.17 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.3 mmt180 -92.65 157.09 16.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.556 -0.967 . . . . 0.0 108.891 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.585 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 59.9 p-90 -160.01 172.91 16.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.179 -0.951 . . . . 0.0 109.843 -179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.2 mttt -136.37 160.23 67.66 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.75 141.19 16.99 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.111 1.874 . . . . 0.0 110.914 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.01 171.38 15.36 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.07 132.88 15.0 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.883 -1.135 . . . . 0.0 110.074 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.472 HD13 HD12 ' A' ' 54' ' ' ILE . 6.1 pt -117.31 146.59 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.174 -0.954 . . . . 0.0 108.895 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.572 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.9 124.22 5.95 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.47 -123.73 1.78 Allowed Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.031 -1.557 . . . . 0.0 111.495 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.585 HD13 ' C76' ' B' ' 100' ' ' DMP . 39.0 mt -84.55 131.49 33.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 113.663 0.986 . . . . 0.0 113.663 -176.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.82 -17.25 9.32 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 177.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.47 -158.35 28.16 Favored Glycine 0 N--CA 1.491 2.351 0 O-C-N 120.603 -1.527 . . . . 0.0 110.502 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.572 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.8 m-85 -116.45 155.6 28.28 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.599 -0.942 . . . . 0.0 109.409 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.58 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 13.0 pt -131.64 146.26 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.217 -0.927 . . . . 0.0 108.684 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.52 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 7.8 mttp -90.19 154.19 19.93 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.456 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.472 HG13 ' HA3' ' A' ' 78' ' ' GLY . 8.0 m -149.05 178.93 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.067 -1.021 . . . . 0.0 109.567 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.42 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 9.2 mmt180 -122.35 104.59 9.52 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -60.67 99.57 0.09 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.275 -0.891 . . . . 0.0 110.606 -178.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.585 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.2 m-85 -95.1 104.67 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.548 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 9.3 m-20 -88.84 129.32 35.61 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.029 -1.045 . . . . 0.0 111.173 -178.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.556 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.5 OUTLIER 82.01 60.33 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.332 0.587 . . . . 0.0 111.31 178.466 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.51 HG13 ' HB3' ' A' ' 59' ' ' TYR . 8.6 mm -115.32 120.86 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.527 ' HA ' HG12 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -71.32 95.27 1.29 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.017 -1.052 . . . . 0.0 111.273 -177.853 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.549 ' O ' HG21 ' A' ' 64' ' ' ILE . 7.2 tt -98.08 115.98 39.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 178.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.4 tt0 -89.34 105.05 17.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.85 -1.156 . . . . 0.0 108.883 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.534 HD13 ' CD1' ' A' ' 64' ' ' ILE . 1.7 mp -104.31 120.74 55.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.477 -0.764 . . . . 0.0 109.816 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.58 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.2 m 54.66 59.16 4.28 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.807 -0.558 . . . . 0.0 110.495 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 50.29 33.5 23.79 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 21.9 m-70 -131.14 102.56 6.06 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.193 -1.18 . . . . 0.0 108.813 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.477 ' HG3' HD22 ' A' ' 63' ' ' LEU . 1.8 mptt -51.46 140.09 18.49 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.539 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -160.88 99.72 1.24 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.14 -0.975 . . . . 0.0 110.052 -179.258 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.556 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -78.81 157.38 4.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.567 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -179.46 -166.66 35.58 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.221 -1.942 . . . . 0.0 112.21 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 32.5 m -98.55 108.3 20.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.573 -0.957 . . . . 0.0 110.507 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.431 HG13 ' HB2' ' A' ' 33' ' ' LEU . 1.5 t -102.53 105.61 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.646 -0.658 . . . . 0.0 110.258 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.557 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 4.8 mp -78.48 109.78 12.97 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.54 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 2.3 t -93.12 114.5 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.444 -0.785 . . . . 0.0 110.328 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -143.66 -163.95 10.11 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.52 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.45 43.3 1.5 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.559 2.173 . . . . 0.0 110.274 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.627 HG21 ' HA ' ' A' ' 34' ' ' GLU . 0.1 OUTLIER -88.6 134.06 34.87 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.438 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.5 18.54 0.94 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.559 2.173 . . . . 0.0 111.975 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.514 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.0 161.33 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.88 -1.138 . . . . 0.0 109.629 179.716 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.591 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -95.24 134.66 37.75 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.645 -2.354 . . . . 0.0 104.645 175.946 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 31' ' ' THR . 2.2 mm -124.37 121.83 62.62 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 120.538 -1.352 . . . . 0.0 110.189 -177.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -98.04 87.65 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.171 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.15 -163.57 22.45 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 120.144 -1.027 . . . . 0.0 110.588 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.551 ' NH1' ' O ' ' A' ' 26' ' ' THR . 13.8 mmt-85 -57.63 -39.31 76.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.747 -0.855 . . . . 0.0 110.892 -178.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.583 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 7.9 p-10 -44.47 -31.12 1.0 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.996 -1.065 . . . . 0.0 109.343 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.583 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.4 mm? -105.09 -27.46 11.61 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.207 -0.933 . . . . 0.0 109.884 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.593 HD11 ' CG2' ' A' ' 26' ' ' THR . 27.0 mt -70.33 -8.7 52.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.035 -1.041 . . . . 0.0 108.858 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.22 -20.25 20.62 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -86.46 -40.09 15.67 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.524 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 1.9 pt -82.62 -7.63 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.381 -0.824 . . . . 0.0 109.138 179.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.98 34.25 58.94 Favored Glycine 0 N--CA 1.5 2.903 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.187 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.589 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -70.04 130.14 41.34 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.04 -1.27 . . . . 0.0 110.335 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.509 HG23 ' CG2' ' B' ' 4' ' ' THR . 82.2 p -127.88 130.05 47.9 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.924 -1.11 . . . . 0.0 109.098 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 3.8 mp -88.22 97.52 11.06 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.162 -0.962 . . . . 0.0 109.581 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.4 m120 -107.27 123.91 49.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.292 -0.88 . . . . 0.0 109.051 179.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.575 ' CD2' HD13 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.191 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.664 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.516 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 0.2 OUTLIER -83.57 146.41 28.33 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 177.823 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.516 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 20.9 t -143.59 122.98 8.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 117.812 -1.555 . . . . 0.0 111.244 -178.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.541 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.1 OUTLIER -117.13 20.89 13.53 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 177.165 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.474 ' HG ' ' HA ' ' B' ' 9' ' ' PRO . 1.3 mm? -34.68 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.682 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.541 ' N ' ' O ' ' B' ' 4' ' ' THR . 10.5 m95 -50.94 -19.98 1.19 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.402 ' N ' ' C ' ' B' ' 5' ' ' LEU . 12.9 mm100 -108.57 -124.06 0.25 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.301 -0.874 . . . . 0.0 108.831 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 34.8 mtt180 -110.56 129.99 23.37 Favored Pre-proline 0 N--CA 1.496 1.869 0 O-C-N 120.396 -1.44 . . . . 0.0 110.407 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.53 ' HD3' ' NH1' ' A' ' 87' ' ' ARG . 37.6 Cg_endo -79.16 82.78 2.42 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.364 2.042 . . . . 0.0 109.83 178.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.461 HD22 ' C ' ' B' ' 22' ' ' ALA . 3.7 mt -90.91 140.22 30.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.016 -1.052 . . . . 0.0 109.992 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.439 ' CG2' ' N ' ' B' ' 12' ' ' THR . 0.6 OUTLIER -143.37 168.28 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.765 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.439 ' N ' ' CG2' ' B' ' 11' ' ' VAL . 17.8 m -99.91 109.18 21.56 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.561 HG22 ' CB ' ' B' ' 22' ' ' ALA . 2.6 pt -91.35 158.03 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.138 -0.976 . . . . 0.0 110.064 -178.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.521 ' CA ' HD22 ' B' ' 19' ' ' LEU . 3.9 tttt -121.03 96.97 5.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.412 -0.805 . . . . 0.0 109.064 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.513 HD13 ' CD1' ' B' ' 13' ' ' ILE . 20.1 mt -113.3 129.44 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 O-C-N 121.337 -0.852 . . . . 0.0 109.617 -179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.75 50.13 62.41 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 54.8 24.43 33.39 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.3 OUTLIER -119.94 174.58 6.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.221 -1.164 . . . . 0.0 108.688 179.288 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.521 HD22 ' CA ' ' B' ' 14' ' ' LYS . 29.1 mt -148.52 126.05 11.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.021 -1.049 . . . . 0.0 110.843 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.451 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.1 mmmt -140.6 -177.37 5.02 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.43 ' O ' ' CG ' ' B' ' 83' ' ' ASN . 0.6 OUTLIER -80.2 176.02 10.12 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.946 -1.096 . . . . 0.0 108.671 179.415 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.561 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -162.62 111.91 1.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.854 -1.154 . . . . 0.0 111.346 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' B' ' 25' ' ' ASP . 9.0 tp -89.05 99.68 12.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.511 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.2 mt -46.79 96.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.921 -1.112 . . . . 0.0 108.093 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.551 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 65.1 t0 -105.49 84.84 2.15 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.292 -0.88 . . . . 0.0 110.861 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.545 ' CG2' ' HD2' ' B' ' 87' ' ' ARG . 49.4 m -63.14 -15.96 58.47 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 108.945 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.43 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -67.86 -45.81 71.68 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.516 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -70.97 133.62 46.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -1.111 . . . . 0.0 108.589 179.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.5 m-20 -71.75 -13.28 61.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.368 -0.833 . . . . 0.0 110.692 -178.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.515 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.1 OUTLIER -139.03 -174.82 3.95 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.768 -1.207 . . . . 0.0 110.583 -179.377 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.624 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.4 m -104.17 97.86 7.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.063 -1.023 . . . . 0.0 110.499 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.557 ' CG2' ' HB2' ' B' ' 76' ' ' LEU . 1.0 OUTLIER -89.59 109.67 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.324 0 O-C-N 121.198 -0.938 . . . . 0.0 109.918 -179.897 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.526 HD11 ' CG1' ' B' ' 75' ' ' VAL . 1.0 OUTLIER -99.26 130.92 45.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.117 -0.99 . . . . 0.0 111.311 -179.605 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.539 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 34.1 tt0 -40.59 163.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.439 -0.788 . . . . 0.0 109.292 178.177 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.556 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.1 mt-10 -53.01 139.27 28.42 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 110.917 -178.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.497 ' HG3' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -173.82 159.66 3.48 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.497 ' N ' ' HG3' ' B' ' 36' ' ' MET . 18.2 t -79.52 142.07 36.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.091 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.507 HD11 ' CD2' ' B' ' 59' ' ' TYR . 10.6 mt -139.16 166.0 27.87 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.449 -0.782 . . . . 0.0 108.999 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' B' ' 40' ' ' GLY . 34.5 Cg_endo -76.5 69.59 6.6 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.816 2.344 . . . . 0.0 111.996 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.68 -159.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.671 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.475 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 67.1 50.52 1.01 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.512 -0.993 . . . . 0.0 109.03 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.581 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 46.7 p-90 -135.15 -178.38 5.07 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.907 0.86 . . . . 0.0 110.411 -179.461 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.445 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 12.4 mmtm -150.56 158.76 35.48 Favored Pre-proline 0 C--N 1.302 -1.487 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.63 139.87 18.38 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.912 1.742 . . . . 0.0 110.012 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.437 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 0.4 OUTLIER -151.07 152.45 33.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.374 -0.829 . . . . 0.0 109.456 -179.433 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.432 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -127.35 111.51 13.97 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.844 -1.16 . . . . 0.0 108.828 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.502 ' CG1' HG13 ' B' ' 54' ' ' ILE . 24.4 pt -95.1 134.35 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 110.018 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.569 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.59 104.51 1.11 Allowed Glycine 0 N--CA 1.489 2.173 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -124.51 3.0 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.171 -1.49 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.601 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 38.7 mt -86.02 121.77 37.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.832 -0.805 . . . . 0.0 112.627 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.58 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.18 -49.13 0.97 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 177.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.97 -159.65 24.15 Favored Glycine 0 N--CA 1.488 2.153 0 O-C-N 120.913 -1.345 . . . . 0.0 110.301 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.569 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 4.9 m-85 -113.91 155.04 26.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.646 -0.914 . . . . 0.0 109.644 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.504 HG22 HG21 ' A' ' 50' ' ' ILE . 1.4 pt -138.95 176.52 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.309 -0.869 . . . . 0.0 108.849 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 8.9 mttt -116.18 151.82 34.95 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.498 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.521 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 5.6 m -146.62 -171.11 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.791 -1.193 . . . . 0.0 109.715 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' B' ' 59' ' ' TYR . 71.0 mtm-85 -133.65 85.07 2.17 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -44.36 93.69 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.692 -0.63 . . . . 0.0 110.648 -178.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.587 ' CD2' HG22 ' B' ' 77' ' ' VAL . 13.8 m-85 -88.92 125.61 35.03 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 178.174 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 14.8 m-20 -105.53 136.22 45.5 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.84 -1.163 . . . . 0.0 110.786 -178.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.606 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.8 mp0 70.81 65.44 0.18 Allowed 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.431 0.634 . . . . 0.0 111.106 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.411 HG22 HG22 ' B' ' 15' ' ' ILE . 10.0 mm -118.76 111.71 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.592 ' CD2' ' CG ' ' B' ' 70' ' ' LYS . 12.9 tp -64.85 91.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.969 -1.082 . . . . 0.0 111.097 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.501 ' CD1' HD12 ' B' ' 66' ' ' ILE . 5.4 tt -89.42 119.14 36.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.48 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.6 tt0 -88.54 120.88 30.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 109.119 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.501 HD12 ' CD1' ' B' ' 64' ' ' ILE . 1.3 mp -120.94 128.0 76.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.397 -0.814 . . . . 0.0 109.217 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 94.5 m 52.97 24.48 3.42 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.507 -0.746 . . . . 0.0 109.798 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 81.79 43.62 8.22 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -140.28 99.53 3.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -1.166 . . . . 0.0 109.418 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.592 ' CG ' ' CD2' ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.24 128.56 19.67 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.582 ' N ' ' CD1' ' B' ' 63' ' ' LEU . . . -148.23 101.98 3.31 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.301 -0.875 . . . . 0.0 110.505 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.606 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -77.31 142.83 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.773 -1.205 . . . . 0.0 108.648 178.992 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.514 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -164.94 -155.75 8.65 Favored Glycine 0 N--CA 1.494 2.566 0 C-N-CA 119.723 -1.227 . . . . 0.0 111.062 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.474 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.3 m -111.96 113.76 26.26 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.214 -1.168 . . . . 0.0 109.624 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.526 ' CG1' HD11 ' B' ' 33' ' ' LEU . 1.4 t -107.91 108.42 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.355 -0.841 . . . . 0.0 111.383 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.557 ' HB2' ' CG2' ' B' ' 32' ' ' VAL . 2.9 mp -79.92 108.79 13.77 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.127 -0.983 . . . . 0.0 108.617 178.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.587 HG22 ' CD2' ' B' ' 59' ' ' TYR . 2.1 t -92.24 117.97 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.988 -1.07 . . . . 0.0 109.659 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.556 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -146.99 -171.96 16.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.306 -1.918 . . . . 0.0 108.306 179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.8 Cg_endo -81.03 44.26 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.259 1.973 . . . . 0.0 110.514 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.539 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 5.3 t -84.69 143.75 41.38 Favored Pre-proline 0 N--CA 1.486 1.359 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.65 14.01 1.31 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.583 2.189 . . . . 0.0 111.674 -178.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.03 164.35 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.83 -1.169 . . . . 0.0 110.149 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.544 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.4 m120 -94.6 146.95 23.77 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 174.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.624 ' O ' ' HA ' ' B' ' 31' ' ' THR . 3.6 mm -133.81 123.91 46.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 120.024 -1.673 . . . . 0.0 110.713 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.488 ' HB ' ' HA ' ' B' ' 24' ' ' LEU . 5.3 mm -98.5 93.45 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.25 179.49 51.74 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 -178.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.575 ' CD ' ' O ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER -58.83 -23.11 60.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.37 -1.077 . . . . 0.0 109.627 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.535 ' ND2' HD21 ' B' ' 89' ' ' LEU . 12.9 p-10 -53.77 -37.01 63.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.694 -1.254 . . . . 0.0 108.924 178.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.535 HD21 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -96.92 -35.26 10.94 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.619 -0.676 . . . . 0.0 110.695 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.485 ' O ' HG13 ' B' ' 93' ' ' ILE . 71.7 mt -56.36 -33.87 66.11 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.038 -1.039 . . . . 0.0 109.487 -179.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.534 ' CG2' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.66 -21.84 60.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 110.899 -179.109 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -80.54 -31.47 36.98 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.229 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.575 HD13 ' CD2' ' A' ' 99' ' ' PHE . 3.1 pt -87.11 13.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.4 -0.813 . . . . 0.0 108.932 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 59.76 49.04 82.83 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.521 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -87.92 150.66 23.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.25 -1.147 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 57.2 p -146.27 123.07 11.25 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.798 . . . . 0.0 109.135 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.609 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 5.2 mp -85.36 93.54 8.74 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 7.5 m120 -92.79 119.97 32.69 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 120.703 -1.248 . . . . 0.0 110.067 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.603 ' CD2' ' HD2' ' A' ' 1' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.37 178.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.601 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.446 ' O ' ' HA ' ' B' ' 98' ' ' ASN . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.66 0 N-CA-C 109.889 -0.85 . . . . 0.0 109.889 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -83.17 149.66 26.72 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 177.81 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.552 HG11 ' CD2' ' A' ' 5' ' ' LEU . 37.8 t -150.49 116.43 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 C-N-CA 118.436 -1.306 . . . . 0.0 110.661 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 6' ' ' TRP . 1.7 p -122.26 -73.21 0.65 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.552 ' CD2' HG11 ' A' ' 3' ' ' VAL . 1.8 pt? 30.4 38.28 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 122.124 -0.36 . . . . 0.0 111.071 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' A' ' 5' ' ' LEU . 8.9 m95 19.3 48.96 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 121.258 0.551 . . . . 0.0 111.829 179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.552 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -149.87 -167.81 2.93 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.31 179.421 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.461 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -84.89 136.77 38.4 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.12 -0.987 . . . . 0.0 109.403 -179.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.7 Cg_endo -77.27 71.99 6.12 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.246 1.964 . . . . 0.0 109.717 178.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.432 ' O ' HG11 ' A' ' 11' ' ' VAL . 0.4 OUTLIER -79.54 151.17 30.86 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 -179.567 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.507 HG23 ' CG2' ' A' ' 66' ' ' ILE . 0.9 OUTLIER -150.64 156.47 6.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.244 -0.91 . . . . 0.0 110.027 -179.381 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 22.6 m -86.93 113.37 22.66 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.557 ' HB ' ' CG1' ' A' ' 64' ' ' ILE . 43.8 pt -99.7 147.87 6.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.167 -0.958 . . . . 0.0 111.071 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.581 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -109.27 94.9 5.28 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.937 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.525 ' CG1' ' HB ' ' A' ' 64' ' ' ILE . 8.6 mt -119.41 130.07 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.104 -0.998 . . . . 0.0 109.67 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.67 37.63 95.01 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.61 18.14 50.91 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -113.84 172.88 6.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.34 -1.094 . . . . 0.0 109.518 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.581 ' CG ' ' HD2' ' A' ' 14' ' ' LYS . 13.1 mt -139.74 122.46 16.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 111.012 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.465 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -141.96 175.32 9.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.505 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 1.3 mt-10 -78.72 178.67 7.69 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.599 -1.313 . . . . 0.0 108.23 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.533 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -156.9 103.99 2.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.14 -0.975 . . . . 0.0 109.635 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.503 ' O ' ' N ' ' A' ' 25' ' ' ASP . 30.5 tp -72.43 92.6 1.46 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.253 -0.904 . . . . 0.0 108.584 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.565 ' CD2' ' CD2' ' A' ' 90' ' ' LEU . 3.7 mt -43.78 98.43 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.548 ' CB ' HG22 ' A' ' 84' ' ' ILE . 1.9 t70 -104.89 90.3 3.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.558 -0.714 . . . . 0.0 110.777 -178.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.505 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 20.7 m -68.23 -13.53 62.31 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.528 ' CA ' HD22 ' B' ' 23' ' ' LEU . . . -70.99 -41.68 60.79 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.5 ' HB3' ' C27' ' B' ' 100' ' ' DMP . . . -73.05 162.75 29.1 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -1.171 . . . . 0.0 109.516 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -98.92 -11.15 21.9 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.292 -0.88 . . . . 0.0 110.428 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.535 ' OD2' ' HB ' ' A' ' 74' ' ' THR . 0.1 OUTLIER -139.06 -173.2 3.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.899 -1.126 . . . . 0.0 109.781 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.531 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 66.4 m -106.32 88.52 2.8 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.576 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.559 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.19 162.97 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.244 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.559 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.4 OUTLIER -157.7 124.32 4.92 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.9 -179.003 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.53 ' HA ' HG21 ' A' ' 80' ' ' THR . 21.0 pt-20 -41.01 152.83 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.533 -0.729 . . . . 0.0 109.5 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.42 ' C ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -41.71 148.31 0.16 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.39 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -173.29 164.92 4.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.496 -0.753 . . . . 0.0 108.975 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.7 t -79.8 100.06 7.79 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.056 -1.028 . . . . 0.0 109.77 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.3 tp -126.29 100.39 29.58 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.248 -0.907 . . . . 0.0 109.34 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -78.46 165.39 25.32 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.791 2.327 . . . . 0.0 110.815 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.57 -163.12 16.09 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.33 139.03 33.9 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.223 -1.163 . . . . 0.0 108.26 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.569 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 9.7 p-90 -149.33 174.49 12.37 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.031 -1.043 . . . . 0.0 109.996 -179.423 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -138.2 163.47 47.28 Favored Pre-proline 0 C--N 1.299 -1.612 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.22 141.03 25.53 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.73 1.62 . . . . 0.0 110.189 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.36 167.46 22.12 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.434 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 10.4 ttt -151.38 118.79 6.01 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.537 ' CD1' HD13 ' A' ' 54' ' ' ILE . 1.5 pt -102.43 128.51 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 C-N-CA 118.396 -1.322 . . . . 0.0 108.897 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.594 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -117.89 98.01 0.75 Allowed Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.477 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -119.72 -121.06 2.9 Favored Glycine 0 C--N 1.297 -1.616 0 C-N-CA 119.416 -1.374 . . . . 0.0 110.404 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.585 ' CD1' ' C76' ' B' ' 100' ' ' DMP . 74.8 mt -83.87 106.1 13.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.872 -0.781 . . . . 0.0 112.561 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 120.18 -44.62 1.35 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 178.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 168.06 -164.37 37.92 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.728 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.594 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 7.1 m-85 -110.14 118.02 35.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.602 -0.94 . . . . 0.0 110.18 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.537 HD13 ' CD1' ' A' ' 47' ' ' ILE . 32.6 pt -99.16 161.07 3.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.557 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.39 132.96 48.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.024 -1.048 . . . . 0.0 109.8 -179.406 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.45 HG13 ' HA3' ' A' ' 78' ' ' GLY . 30.6 m -134.55 178.68 5.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.477 -0.765 . . . . 0.0 109.36 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.477 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 28.1 mtt180 -111.31 171.22 7.6 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.409 ' OE1' ' OD1' ' A' ' 60' ' ' ASP . 0.3 OUTLIER -131.5 97.28 4.19 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.673 -1.267 . . . . 0.0 110.859 -179.042 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 83.7 m-85 -97.11 116.32 29.1 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.523 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -94.01 146.46 23.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.917 -1.114 . . . . 0.0 110.144 -179.05 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.548 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 4.1 mm-40 67.77 67.34 0.36 Allowed 'General case' 0 N--CA 1.489 1.516 0 CA-C-O 121.617 0.722 . . . . 0.0 109.705 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.484 ' HB ' HG21 ' A' ' 75' ' ' VAL . 1.9 mm -124.65 108.84 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.539 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 4.6 tt -59.81 102.57 0.16 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.311 -0.868 . . . . 0.0 111.175 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.557 ' CG1' ' HB ' ' A' ' 13' ' ' ILE . 3.7 tt -100.44 119.48 48.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.75 109.88 20.04 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.647 -1.283 . . . . 0.0 108.719 -178.564 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.521 ' CG1' HG21 ' A' ' 13' ' ' ILE . 2.7 mt -115.78 123.86 71.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.124 -0.985 . . . . 0.0 110.313 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.455 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 58.2 m 56.49 36.02 26.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.675 -0.641 . . . . 0.0 110.367 179.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.41 28.03 73.46 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.455 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 96.7 m-70 -126.95 110.35 12.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.118 -1.225 . . . . 0.0 109.273 179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.479 ' HG3' HD12 ' A' ' 63' ' ' LEU . 1.5 ttpm? -55.05 130.6 42.43 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.269 -0.895 . . . . 0.0 109.069 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.448 ' O ' HG23 ' A' ' 64' ' ' ILE . . . -148.51 101.46 3.23 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.372 -0.83 . . . . 0.0 109.935 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.548 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.8 OUTLIER -78.27 146.43 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 178.794 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.512 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -170.45 -177.69 40.74 Favored Glycine 0 N--CA 1.484 1.879 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.51 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.535 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 1.9 m -93.58 111.92 23.7 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.574 -0.957 . . . . 0.0 109.587 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.543 ' CG1' HD12 ' A' ' 33' ' ' LEU . 1.4 t -98.97 137.12 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.694 -0.629 . . . . 0.0 109.724 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.535 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.4 mp -107.68 136.14 47.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.209 -0.932 . . . . 0.0 108.768 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.477 ' O ' ' HG3' ' A' ' 57' ' ' ARG . 16.7 t -118.38 113.65 42.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.943 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.45 ' HA3' HG13 ' A' ' 56' ' ' VAL . . . -151.75 -164.04 11.92 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.557 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.31 39.48 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.681 2.254 . . . . 0.0 111.039 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.53 HG21 ' HA ' ' A' ' 34' ' ' GLU . 2.8 t -86.83 134.84 36.4 Favored Pre-proline 0 N--CA 1.489 1.508 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.405 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -78.16 18.79 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.691 2.26 . . . . 0.0 112.028 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.471 HG13 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.5 158.97 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.597 -1.314 . . . . 0.0 110.341 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 67.7 m-20 -95.11 100.29 12.13 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.551 ' CG1' HG11 ' A' ' 32' ' ' VAL . 7.2 mm -88.37 128.59 40.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 O-C-N 120.858 -1.151 . . . . 0.0 112.154 -176.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.53 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.61 93.79 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.244 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -80.35 -160.99 23.63 Favored Glycine 0 N--CA 1.493 2.494 0 O-C-N 121.176 -0.952 . . . . 0.0 111.042 -177.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.491 ' NH2' ' HB2' ' A' ' 87' ' ' ARG . 7.5 mtp-105 -69.17 -29.67 67.73 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.65 -0.912 . . . . 0.0 109.925 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.589 ' ND2' HD21 ' A' ' 89' ' ' LEU . 14.7 p-10 -50.17 -24.26 2.69 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.811 -1.181 . . . . 0.0 108.951 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.589 HD21 ' ND2' ' A' ' 88' ' ' ASN . 3.1 mm? -112.76 -27.77 8.03 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.236 -0.915 . . . . 0.0 110.313 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.565 ' CD2' ' CD2' ' A' ' 24' ' ' LEU . 34.7 mt -63.09 -28.15 69.88 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.992 -1.068 . . . . 0.0 108.416 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 69.0 p -79.43 -20.64 47.03 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.136 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -80.86 -36.71 31.05 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.35 -0.844 . . . . 0.0 109.135 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.599 HD11 ' CD2' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -86.0 -0.72 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.295 -0.878 . . . . 0.0 109.243 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.68 62.22 5.23 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -97.16 135.88 38.48 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.547 -0.973 . . . . 0.0 110.481 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.416 HG21 ' CG2' ' B' ' 4' ' ' THR . 15.5 p -133.12 128.71 36.71 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.516 HD13 ' CD1' ' B' ' 97' ' ' LEU . 6.7 mp -87.1 109.38 19.39 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.277 -0.89 . . . . 0.0 108.792 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.505 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.9 m120 -105.22 120.79 42.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.81 -1.181 . . . . 0.0 109.196 179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.65 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.595 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.451 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.569 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.332 -0.68 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.528 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tm0? -84.02 145.71 28.36 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.133 -1.803 . . . . 0.0 106.133 177.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 70.1 t -146.03 122.97 3.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.218 -177.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.463 ' O ' ' C ' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -127.04 -61.94 1.14 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.673 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.1 mt 31.86 38.92 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.567 178.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.536 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.9 m95 17.31 51.46 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 CA-C-O 121.159 0.504 . . . . 0.0 111.949 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' B' ' 5' ' ' LEU . 13.1 mt-30 -168.0 -174.95 2.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.341 -0.85 . . . . 0.0 109.592 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.436 ' HG2' ' HD2' ' A' ' 87' ' ' ARG . 17.2 mtm180 -65.44 138.45 96.96 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.032 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.541 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.8 Cg_endo -81.16 62.36 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.36 2.04 . . . . 0.0 109.707 179.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.531 HD21 ' N ' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -80.84 136.4 36.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.877 -1.139 . . . . 0.0 109.56 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.519 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -130.42 137.91 55.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.286 -0.884 . . . . 0.0 109.191 -179.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 18.0 m -65.66 97.58 0.33 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.587 ' CG2' ' CB ' ' B' ' 22' ' ' ALA . 2.8 pt -88.03 154.62 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.297 -0.877 . . . . 0.0 110.702 -177.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.52 ' CA ' HD22 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -122.15 105.88 10.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.473 -0.767 . . . . 0.0 109.773 179.505 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.514 HG23 ' CE ' ' B' ' 36' ' ' MET . 97.1 mt -121.24 139.92 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 120.852 -1.155 . . . . 0.0 110.889 -179.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.81 33.38 6.48 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.76 37.27 51.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.5 OUTLIER -131.18 175.48 9.07 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 108.39 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.52 HD22 ' CA ' ' B' ' 14' ' ' LYS . 15.9 mt -152.0 124.33 8.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.995 -1.066 . . . . 0.0 110.249 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -151.38 174.57 13.18 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.521 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.0 OUTLIER -80.34 143.38 33.61 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.895 -1.128 . . . . 0.0 108.836 179.484 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.587 ' CB ' ' CG2' ' B' ' 13' ' ' ILE . . . -127.53 112.79 15.33 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 110.138 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.528 HD22 ' CA ' ' A' ' 27' ' ' GLY . 2.4 tp -81.14 102.05 10.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.691 -0.631 . . . . 0.0 109.864 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.541 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 20.1 mt -52.74 105.95 0.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.934 -1.104 . . . . 0.0 108.346 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.565 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 53.4 t0 -103.1 92.54 4.58 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.216 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -11.5 35.0 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.077 -1.015 . . . . 0.0 108.404 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.445 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -70.09 -43.62 63.77 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -81.82 164.96 21.28 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.117 -1.225 . . . . 0.0 109.676 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -100.4 -13.88 18.57 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.226 -0.921 . . . . 0.0 110.196 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.616 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -126.75 -165.37 1.45 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.016 -1.052 . . . . 0.0 109.664 -179.806 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.566 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 8.1 m -116.63 85.64 2.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.924 -1.11 . . . . 0.0 110.192 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.513 HG11 ' HB ' ' B' ' 84' ' ' ILE . 0.3 OUTLIER -68.65 154.75 8.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.566 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.2 OUTLIER -154.82 133.31 11.95 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.837 -1.164 . . . . 0.0 111.054 -177.609 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.473 ' HG3' ' O ' ' B' ' 80' ' ' THR . 4.1 tt0 -42.03 148.62 0.18 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.474 ' HA ' HG11 ' B' ' 77' ' ' VAL . 3.0 mt-10 -44.88 136.99 4.3 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.041 -1.037 . . . . 0.0 110.457 -179.173 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.514 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -156.75 -167.69 2.45 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.11 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.408 ' C ' HD21 ' B' ' 38' ' ' LEU . 8.6 t -112.29 115.75 29.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.756 -1.215 . . . . 0.0 111.457 -178.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.606 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 3.0 mm? -116.45 170.81 5.39 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.525 ' HD2' HD13 ' B' ' 38' ' ' LEU . 33.4 Cg_endo -76.22 115.77 4.2 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.372 2.048 . . . . 0.0 111.374 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' B' ' 41' ' ' ARG . . . -30.95 122.39 0.14 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' B' ' 40' ' ' GLY . 3.6 mtm180 148.72 43.01 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.633 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 37.3 p-90 -124.73 176.8 6.34 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.343 0.592 . . . . 0.0 109.733 -178.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -133.92 130.04 20.38 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.007 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -76.91 140.11 20.12 Favored 'Trans proline' 0 C--N 1.31 -1.45 0 C-N-CA 122.254 1.97 . . . . 0.0 110.317 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -159.41 -164.8 1.43 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.356 -0.84 . . . . 0.0 109.376 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.534 ' CG ' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -141.8 119.21 11.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.985 -179.578 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.503 HD11 HG23 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -90.44 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 178.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.459 ' HA2' ' HB3' ' B' ' 53' ' ' PHE . . . -118.41 111.75 2.22 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.81 -125.2 2.35 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.564 HD13 ' C26' ' B' ' 100' ' ' DMP . 37.8 mt -80.95 139.12 18.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.777 -0.837 . . . . 0.0 112.664 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.465 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 73.27 5.03 65.54 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 178.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.0 -158.94 16.69 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.051 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -119.21 143.85 47.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.441 -1.035 . . . . 0.0 109.183 -179.549 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.577 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 1.0 OUTLIER -112.71 -175.29 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.977 . . . . 0.0 108.701 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.549 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 12.3 mttt -114.84 138.79 50.36 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.047 -1.033 . . . . 0.0 109.282 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.534 HG11 ' CD1' ' B' ' 54' ' ' ILE . 3.5 m -139.05 -169.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.553 -1.342 . . . . 0.0 110.73 -179.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.505 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 73.8 mtt-85 -143.78 99.88 3.49 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.565 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 6.1 tt0 -66.04 108.13 2.12 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.294 -0.879 . . . . 0.0 110.719 -178.644 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.633 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 32.3 m-85 -93.85 128.27 40.03 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 177.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.521 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -106.17 135.97 46.7 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.877 -1.139 . . . . 0.0 110.927 -177.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.567 ' HA ' HG21 ' B' ' 72' ' ' ILE . 0.2 OUTLIER 71.98 64.03 0.14 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 179.271 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.546 ' CD1' ' HB3' ' B' ' 59' ' ' TYR . 4.4 mp -118.17 119.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.563 ' CA ' HG12 ' B' ' 72' ' ' ILE . 3.3 tm? -66.29 84.95 0.1 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-O 121.661 0.743 . . . . 0.0 110.604 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.53 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 2.3 tt -91.89 130.76 40.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 178.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.513 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.8 tt0 -87.74 152.6 22.01 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.905 -1.122 . . . . 0.0 108.463 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.523 ' CD1' HD12 ' B' ' 64' ' ' ILE . 0.2 OUTLIER -150.75 135.11 9.0 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.236 -0.915 . . . . 0.0 108.962 -179.453 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 46.32 24.07 0.26 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.529 -0.732 . . . . 0.0 110.21 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.416 ' O ' ' CD2' ' B' ' 69' ' ' HIS . . . 83.72 39.6 9.47 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 179.453 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' B' ' 68' ' ' GLY . 8.9 m-70 -141.11 164.77 29.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -1.208 . . . . 0.0 109.074 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.507 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -95.73 139.19 32.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.07 -1.019 . . . . 0.0 108.472 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.53 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -154.54 104.75 2.58 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.111 -0.993 . . . . 0.0 110.051 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.567 HG21 ' HA ' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -86.94 141.64 14.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 178.701 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.485 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -168.56 -164.11 23.69 Favored Glycine 0 N--CA 1.485 1.922 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.495 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.565 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 8.6 m -95.91 105.06 17.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.682 -0.893 . . . . 0.0 109.906 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.44 HG13 HD11 ' B' ' 15' ' ' ILE . 1.3 t -100.71 106.01 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.38 -0.825 . . . . 0.0 109.983 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.616 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 0.4 OUTLIER -78.08 134.4 37.74 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.104 -0.997 . . . . 0.0 108.666 179.104 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.474 HG11 ' HA ' ' B' ' 35' ' ' GLU . 58.2 t -122.58 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.206 -0.934 . . . . 0.0 110.644 -179.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.84 -161.27 12.73 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 108.258 -1.937 . . . . 0.0 108.258 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.549 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.47 40.23 0.96 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.358 2.039 . . . . 0.0 110.244 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.483 HG22 ' O ' ' B' ' 82' ' ' VAL . 3.1 t -83.39 133.56 47.09 Favored Pre-proline 0 N--CA 1.487 1.391 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.497 ' HD2' ' H33' ' B' ' 100' ' ' DMP . 34.3 Cg_endo -75.43 18.05 0.61 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.715 2.276 . . . . 0.0 112.244 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.531 ' CG1' HG13 ' B' ' 84' ' ' ILE . 1.9 t -161.27 157.9 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.692 -1.255 . . . . 0.0 110.543 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.593 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -96.57 90.36 5.32 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 177.252 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.565 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 2.9 mt -90.63 120.04 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.258 -0.901 . . . . 0.0 112.36 -176.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.55 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -95.67 93.82 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.82 -157.28 13.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.531 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -61.76 -37.22 83.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.623 -0.928 . . . . 0.0 111.887 -178.186 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.561 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 8.7 p-10 -44.67 -40.53 5.96 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.509 -1.37 . . . . 0.0 110.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.561 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 0.9 OUTLIER -96.73 -18.99 19.28 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.061 -1.024 . . . . 0.0 110.032 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.531 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 63.6 mt -73.8 -5.25 39.67 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.024 -1.048 . . . . 0.0 108.765 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.503 ' HB ' ' CH2' ' A' ' 6' ' ' TRP . 2.6 p -101.32 -21.17 14.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.081 -1.012 . . . . 0.0 109.067 179.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.8 mm-40 -74.36 -40.53 62.06 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.183 -0.948 . . . . 0.0 109.006 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.592 HD11 ' CD2' ' A' ' 99' ' ' PHE . 3.3 pt -88.15 -5.97 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.215 -0.928 . . . . 0.0 108.893 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.76 50.43 42.19 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.582 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.45 149.4 35.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.099 -1.236 . . . . 0.0 109.789 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 47.6 p -138.48 128.4 25.32 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.516 ' CD1' HD13 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -86.96 111.36 20.76 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.287 -0.883 . . . . 0.0 110.745 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.583 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 1.0 OUTLIER -115.73 121.21 41.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.3 -0.875 . . . . 0.0 109.609 179.363 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.674 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.134 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.585 ' C76' ' CD1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.42 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.691 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.469 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.5 tt0 -83.16 141.39 31.98 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 105.623 -1.992 . . . . 0.0 105.623 177.035 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 72.9 t -137.95 126.04 30.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 C-N-CA 117.778 -1.569 . . . . 0.0 110.647 -177.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.577 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -120.87 7.35 10.42 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.693 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.3 OUTLIER -34.42 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.953 0.882 . . . . 0.0 109.709 -179.299 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.577 ' N ' ' O ' ' A' ' 4' ' ' THR . 6.9 m95 -41.49 -20.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.434 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.536 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.2 mt-30 -107.49 -155.98 0.57 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.691 -1.255 . . . . 0.0 109.78 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.519 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 62.0 mtt180 -76.21 115.79 50.13 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 110.413 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.549 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.6 Cg_endo -81.89 83.38 2.1 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 121.994 1.796 . . . . 0.0 109.019 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.544 HD22 ' CB ' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -78.52 166.9 22.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.332 -0.855 . . . . 0.0 109.615 -179.033 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.583 HG22 ' CG2' ' A' ' 13' ' ' ILE . 15.2 m -147.88 131.18 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.108 -0.995 . . . . 0.0 110.558 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.1 m -68.68 103.05 1.63 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.527 -1.358 . . . . 0.0 107.786 178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.583 ' CG2' HG22 ' A' ' 11' ' ' VAL . 2.8 pt -102.42 137.34 30.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.244 -0.91 . . . . 0.0 111.207 -178.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.0 OUTLIER -105.0 93.6 4.79 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.527 HD13 ' CD1' ' A' ' 13' ' ' ILE . 15.6 mt -104.48 124.35 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.455 -0.778 . . . . 0.0 109.488 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.75 13.0 68.36 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.88 7.72 77.43 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.536 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -105.77 171.72 7.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -1.131 . . . . 0.0 108.521 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.48 ' CD2' ' HD3' ' A' ' 14' ' ' LYS . 15.1 mt -123.6 130.58 52.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.869 -1.145 . . . . 0.0 110.959 -178.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.569 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.7 OUTLIER -150.41 143.13 24.6 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.558 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 9.1 mm-40 -78.88 127.46 32.05 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.961 -1.087 . . . . 0.0 109.101 -179.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.551 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -108.27 112.47 24.96 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.986 -1.071 . . . . 0.0 112.012 -178.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.519 ' CD1' ' HB3' ' A' ' 8' ' ' ARG . 11.9 tp -72.22 107.39 4.84 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.549 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 56.5 mt -46.79 142.97 3.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.864 -1.148 . . . . 0.0 108.294 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.574 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 11.4 t0 -156.79 99.59 1.86 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.844 -1.16 . . . . 0.0 110.272 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.447 HG21 ' O ' ' A' ' 26' ' ' THR . 10.9 m -76.12 -0.26 21.35 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.149 -0.97 . . . . 0.0 109.399 179.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.464 ' O ' HD23 ' B' ' 23' ' ' LEU . . . -89.54 -26.48 25.1 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' HB2' ' C27' ' B' ' 100' ' ' DMP . . . -81.39 124.4 29.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.12 -1.224 . . . . 0.0 109.089 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.591 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 42.8 m-20 -61.83 -16.42 49.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.853 . . . . 0.0 110.171 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.625 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 5.0 m-20 -145.16 -170.48 3.44 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.022 -1.071 . . . . 0.0 109.713 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.548 HG23 ' CD1' ' A' ' 33' ' ' LEU . 8.1 m -104.84 86.56 2.49 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 120.804 -1.185 . . . . 0.0 109.818 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.576 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -70.04 163.13 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.265 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.57 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.5 OUTLIER -160.37 128.86 4.75 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.033 -1.042 . . . . 0.0 110.396 -178.01 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.598 ' N ' ' CG2' ' A' ' 80' ' ' THR . 15.8 tt0 -43.81 165.36 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.505 -0.878 . . . . 0.0 108.848 179.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.483 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -48.23 143.4 4.61 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.353 -179.426 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.466 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -155.91 -168.31 2.73 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.464 -0.773 . . . . 0.0 109.025 179.737 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.7 t -122.17 111.15 16.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.847 -1.158 . . . . 0.0 111.196 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.586 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -114.57 179.73 0.74 Allowed Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.714 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.523 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 36.1 Cg_endo -78.6 36.9 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.68 2.253 . . . . 0.0 112.502 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 55.59 33.03 58.76 Favored Glycine 0 N--CA 1.493 2.483 0 O-C-N 121.102 -0.999 . . . . 0.0 111.299 178.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.598 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 15.4 mmm180 -113.97 78.15 1.12 Allowed 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.485 -1.009 . . . . 0.0 108.337 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.561 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 59.8 p-90 -148.96 -177.41 5.79 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 120.985 -1.072 . . . . 0.0 111.37 -178.457 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.72 141.61 28.49 Favored Pre-proline 0 N--CA 1.487 1.377 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.47 131.23 13.54 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 C-N-CA 121.936 1.757 . . . . 0.0 111.025 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.546 ' CD ' ' HB2' ' A' ' 58' ' ' GLN . 13.1 ptmt -161.28 -169.8 2.44 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.54 -0.725 . . . . 0.0 109.233 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 38.4 mtp -151.34 137.98 18.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.36 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.534 ' CD1' HG22 ' B' ' 50' ' ' ILE . 15.4 pt -95.94 150.0 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 120.987 -1.07 . . . . 0.0 108.491 178.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.497 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.07 102.37 0.97 Allowed Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.486 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -123.08 -134.74 4.43 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.721 -178.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.595 HG13 ' H32' ' B' ' 100' ' ' DMP . 58.3 mt -83.02 122.87 38.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 CA-C-O 121.629 0.728 . . . . 0.0 112.548 -177.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 104.64 -53.77 0.66 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.484 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 178.33 -169.24 40.86 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.585 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.2 m-30 -102.37 135.28 44.26 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.282 . . . . 0.0 109.312 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.489 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.3 pt -101.52 176.1 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.131 -0.981 . . . . 0.0 109.352 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.49 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -105.35 142.02 35.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.241 -0.912 . . . . 0.0 109.323 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 31.1 m -150.93 -179.03 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 110.652 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.472 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -128.02 91.58 3.3 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.141 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.546 ' HB2' ' CD ' ' A' ' 45' ' ' LYS . 17.1 tt0 -51.29 102.98 0.05 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.443 0.639 . . . . 0.0 111.635 -178.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CD1' ' O ' ' A' ' 41' ' ' ARG . 24.8 m-85 -90.63 137.3 32.46 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -119.34 121.51 39.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.651 -1.281 . . . . 0.0 110.321 -179.091 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.576 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 5.4 mt-30 83.3 61.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.372 0.606 . . . . 0.0 109.882 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.546 ' CG2' HG22 ' A' ' 75' ' ' VAL . 2.7 mm -111.62 115.79 50.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.35 -0.844 . . . . 0.0 108.782 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.536 HD22 ' CG ' ' A' ' 70' ' ' LYS . 2.0 tm? -66.42 87.22 0.12 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.16 -0.963 . . . . 0.0 110.391 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.556 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 5.2 tt -88.8 122.94 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.0 tt0 -88.97 96.11 10.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.13 -0.981 . . . . 0.0 108.84 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.522 ' CD1' HD13 ' A' ' 89' ' ' LEU . 3.2 mt -101.51 122.8 54.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.334 -0.854 . . . . 0.0 110.043 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.579 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 60.93 44.66 10.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.636 -0.665 . . . . 0.0 109.773 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 55.7 33.32 59.45 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 90.7 m-70 -130.85 118.92 21.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.285 -1.127 . . . . 0.0 109.353 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.536 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -56.32 133.62 52.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 108.706 179.626 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.556 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -157.42 104.04 2.0 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 110.199 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.576 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -79.35 154.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 120.88 -1.138 . . . . 0.0 108.313 178.78 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.469 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -177.25 175.43 47.63 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.179 -1.486 . . . . 0.0 110.576 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 3.7 m -85.34 115.28 23.0 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.586 -0.949 . . . . 0.0 110.158 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.546 HG22 ' CG2' ' A' ' 62' ' ' ILE . 1.4 t -103.94 109.49 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.121 -0.987 . . . . 0.0 110.288 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.576 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.2 mp -82.53 115.81 21.68 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.948 -1.095 . . . . 0.0 108.345 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.509 HG22 ' CD2' ' A' ' 59' ' ' TYR . 93.9 t -96.02 121.7 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.754 -1.216 . . . . 0.0 110.213 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -160.17 -170.84 25.27 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -81.02 42.68 1.39 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.926 2.417 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.598 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.4 t -82.8 141.73 44.61 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 108.564 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.458 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 36.9 Cg_endo -79.38 15.31 1.6 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.518 2.145 . . . . 0.0 110.98 -179.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.492 HG11 HG13 ' A' ' 84' ' ' ILE . 14.1 t -160.43 158.41 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.929 -1.107 . . . . 0.0 110.22 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.569 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -102.06 91.13 4.19 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 176.217 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.574 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 41.8 mt -96.63 130.6 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.891 -1.131 . . . . 0.0 113.674 -174.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.517 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -89.3 131.9 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.625 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -110.96 -143.48 9.48 Favored Glycine 0 N--CA 1.498 2.797 0 O-C-N 120.688 -1.257 . . . . 0.0 110.847 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.591 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -77.83 -41.61 36.44 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.482 -179.464 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.58 ' OD1' ' CB ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -54.63 -18.95 5.11 Favored 'General case' 0 N--CA 1.497 1.881 0 C-N-CA 117.438 -1.705 . . . . 0.0 110.246 -178.608 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.522 HD13 ' CD1' ' A' ' 66' ' ' ILE . 1.0 OUTLIER -103.03 -35.97 8.34 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.712 -1.243 . . . . 0.0 110.363 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 66.2 mt -68.86 -19.77 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.876 -1.14 . . . . 0.0 109.599 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.511 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.86 -2.9 52.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.734 -1.229 . . . . 0.0 108.809 178.962 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.46 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.0 OUTLIER -99.44 -40.84 7.67 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.261 -0.9 . . . . 0.0 108.949 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.583 HD11 ' CG ' ' B' ' 99' ' ' PHE . 1.2 pt -79.76 -16.1 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 N-CA-C 108.571 -0.899 . . . . 0.0 108.571 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 91.05 30.87 10.43 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.508 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -67.44 138.99 57.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.988 -1.301 . . . . 0.0 109.555 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.456 ' O ' ' O ' ' B' ' 96' ' ' THR . 3.0 p -132.76 128.49 36.94 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.151 -0.968 . . . . 0.0 108.558 179.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.558 HD13 ' CD1' ' B' ' 97' ' ' LEU . 4.3 mp -90.62 98.43 11.77 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.245 -0.909 . . . . 0.0 109.532 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.0 m120 -105.61 125.7 51.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.029 -1.044 . . . . 0.0 109.246 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 CA-C-O 117.959 -1.02 . . . . 0.0 109.295 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.509 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.68 0 N-CA-C 110.825 -0.49 . . . . 0.0 110.825 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.511 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.1 tt0 -85.71 134.27 33.97 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.418 ' CG1' ' H ' ' B' ' 5' ' ' LEU . 49.4 t -131.5 125.08 55.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.764 -1.21 . . . . 0.0 109.951 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.549 ' O ' ' CD1' ' B' ' 5' ' ' LEU . 46.7 p -75.89 3.58 9.81 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.48 -0.763 . . . . 0.0 109.656 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' CD1' ' O ' ' B' ' 4' ' ' THR . 0.4 OUTLIER 34.35 46.75 0.18 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.801 -0.562 . . . . 0.0 111.476 179.199 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.452 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 58.8 m95 -57.63 -20.35 32.48 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -147.11 -164.55 2.02 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.539 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 0.5 OUTLIER -59.22 122.52 64.08 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 120.897 -1.127 . . . . 0.0 109.211 179.735 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.477 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.9 Cg_endo -78.97 66.42 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.376 2.051 . . . . 0.0 109.635 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.518 HD21 ' N ' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -81.15 145.65 30.93 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.107 -0.996 . . . . 0.0 109.827 -179.31 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.464 ' O ' HG21 ' B' ' 13' ' ' ILE . 2.6 m -136.58 136.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.53 -0.731 . . . . 0.0 109.434 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -66.09 89.27 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.805 -1.184 . . . . 0.0 107.805 178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.572 HG23 HG13 ' B' ' 66' ' ' ILE . 1.1 pp -80.67 131.52 33.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 109.596 -179.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.504 ' HE2' ' CD1' ' B' ' 19' ' ' LEU . 12.0 tttm -98.84 111.59 23.93 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.354 -0.841 . . . . 0.0 108.998 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.516 ' CG2' ' HE1' ' B' ' 36' ' ' MET . 28.8 mt -116.38 134.65 59.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.221 -0.925 . . . . 0.0 108.9 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.66 -100.49 0.28 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -142.29 35.44 1.74 Allowed Glycine 0 N--CA 1.485 1.906 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.479 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 5.8 mt-30 -134.13 179.95 5.94 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.482 -1.011 . . . . 0.0 109.663 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.504 ' CD1' ' HE2' ' B' ' 14' ' ' LYS . 16.0 mt -147.39 130.26 16.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.531 -0.731 . . . . 0.0 109.139 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.426 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 39.0 mttp -146.12 171.77 14.42 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.166 -0.959 . . . . 0.0 109.199 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.495 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 2.9 mm-40 -79.03 148.48 32.48 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' B' ' 13' ' ' ILE . . . -136.16 108.28 7.22 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.056 . . . . 0.0 110.543 -178.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.539 ' CD1' ' HD2' ' B' ' 8' ' ' ARG . 18.8 tp -70.13 102.75 2.14 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.477 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.5 mt -53.7 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.055 -1.028 . . . . 0.0 108.867 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.614 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 35.2 t0 -91.92 90.06 7.28 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.391 -0.818 . . . . 0.0 110.519 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.429 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 7.3 m -71.05 -7.49 46.82 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 109.064 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.44 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -83.58 -31.3 27.61 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.539 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -79.42 173.15 12.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.875 -1.368 . . . . 0.0 109.337 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -101.72 -18.0 16.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.073 -1.017 . . . . 0.0 110.764 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.485 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -137.35 -172.54 3.24 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.769 -1.207 . . . . 0.0 110.142 -179.357 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.528 ' CG2' HD11 ' B' ' 85' ' ' ILE . 55.3 m -102.59 82.43 2.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.093 -1.005 . . . . 0.0 109.89 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.536 ' CG2' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -69.71 161.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.881 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' HA ' ' HA ' ' B' ' 83' ' ' ASN . 0.4 OUTLIER -153.25 129.52 10.51 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.587 -1.245 . . . . 0.0 111.618 -177.451 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.466 ' HA ' HG23 ' B' ' 80' ' ' THR . 9.5 tt0 -44.22 156.28 0.07 Allowed 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' B' ' 34' ' ' GLU . 0.5 OUTLIER -40.05 138.12 0.87 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 110.601 -179.074 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.516 ' HE1' ' CG2' ' B' ' 15' ' ' ILE . 0.0 OUTLIER -165.27 148.84 8.32 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.862 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.484 ' O ' ' SD ' ' B' ' 36' ' ' MET . 23.3 t -82.8 125.5 31.37 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.046 -1.034 . . . . 0.0 110.68 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.61 HD11 ' CD1' ' B' ' 59' ' ' TYR . 2.6 mt -122.93 164.03 29.67 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.271 -0.893 . . . . 0.0 108.653 179.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.485 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.7 Cg_endo -73.88 71.78 4.06 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.655 2.237 . . . . 0.0 112.539 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.8 -159.22 0.01 OUTLIER Glycine 0 N--CA 1.497 2.727 0 O-C-N 121.528 -0.732 . . . . 0.0 111.414 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 2.8 mmt180 61.11 66.54 0.88 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.568 -0.96 . . . . 0.0 109.196 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.578 ' CZ3' ' HD2' ' B' ' 57' ' ' ARG . 65.0 p-90 -149.79 -177.96 6.19 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.575 -0.703 . . . . 0.0 109.731 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' B' ' 57' ' ' ARG . 23.6 mtmt -150.82 160.35 32.5 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 108.974 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . 0.444 ' HD2' ' HB3' ' B' ' 43' ' ' LYS . 34.7 Cg_endo -76.33 140.86 22.35 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.384 2.056 . . . . 0.0 110.241 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.51 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -157.81 120.8 3.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.342 -0.849 . . . . 0.0 109.058 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.474 ' HG3' ' CG ' ' B' ' 55' ' ' LYS . 2.5 ttt -101.18 126.72 47.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.082 -1.011 . . . . 0.0 109.94 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.531 ' CD1' HG22 ' A' ' 50' ' ' ILE . 10.0 pt -105.62 150.8 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.046 -1.034 . . . . 0.0 109.327 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -125.47 97.68 0.53 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.8 -130.9 4.09 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.291 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.594 HG13 ' H62' ' B' ' 100' ' ' DMP . 66.3 mt -81.77 129.8 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.534 -0.98 . . . . 0.0 112.185 -178.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 100.21 -48.51 1.2 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 171.89 -164.63 37.29 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.655 -1.259 . . . . 0.0 109.994 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 3.1 m-85 -107.03 130.56 54.63 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.423 -1.045 . . . . 0.0 108.921 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.575 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 34.0 pt -112.7 155.18 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 120.977 -1.077 . . . . 0.0 109.885 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 18.6 mttt -98.95 140.62 32.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.184 -0.947 . . . . 0.0 108.68 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.537 ' CG1' ' HA3' ' B' ' 78' ' ' GLY . 9.9 m -143.7 -176.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.9 -1.125 . . . . 0.0 110.149 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.578 ' HD2' ' CZ3' ' B' ' 42' ' ' TRP . 69.0 mtm-85 -132.09 104.1 6.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.577 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -62.0 134.69 56.96 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.654 0.74 . . . . 0.0 110.967 -178.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.61 ' CD1' HD11 ' B' ' 38' ' ' LEU . 17.6 m-85 -121.61 93.93 4.16 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.517 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 9.1 m-20 -79.44 130.86 35.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.031 -1.043 . . . . 0.0 110.452 -178.659 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.517 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 6.9 mm100 83.22 62.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.329 0.585 . . . . 0.0 109.723 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.522 ' HB ' ' CG2' ' B' ' 75' ' ' VAL . 40.0 mm -119.86 115.72 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.343 -0.848 . . . . 0.0 109.063 179.255 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.582 ' N ' HG12 ' B' ' 72' ' ' ILE . 2.8 tm? -66.48 91.86 0.19 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 110.453 -179.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.559 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 7.3 tt -98.38 120.68 48.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.442 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.2 tt0 -90.53 111.88 23.34 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.947 -1.095 . . . . 0.0 109.491 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.572 HG13 HG23 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -100.44 126.47 54.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.741 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.425 ' C ' ' O ' ' B' ' 66' ' ' ILE . 10.2 m 39.43 61.8 1.29 Allowed 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.71 -0.619 . . . . 0.0 110.63 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.3 41.05 86.5 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 120.175 -1.012 . . . . 0.0 111.121 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.505 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 2.7 m-70 -139.44 135.46 33.61 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.9 -1.353 . . . . 0.0 109.0 178.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.484 ' HG2' HD23 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -76.64 132.93 39.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.286 -0.884 . . . . 0.0 109.739 -179.614 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -154.6 97.17 1.96 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.835 . . . . 0.0 109.822 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.582 HG12 ' N ' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -83.54 136.85 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 178.638 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.505 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -161.58 -171.96 28.32 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.96 -1.59 . . . . 0.0 110.636 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.577 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.0 m -89.97 106.36 18.42 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.825 -0.809 . . . . 0.0 110.174 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.522 ' CG2' ' HB ' ' B' ' 62' ' ' ILE . 1.4 t -99.64 116.74 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.484 -0.76 . . . . 0.0 110.03 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.536 ' HB2' ' CG2' ' B' ' 32' ' ' VAL . 1.5 mp -85.33 139.05 31.89 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.511 ' CG2' HD13 ' B' ' 38' ' ' LEU . 1.6 t -121.32 114.49 43.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.066 -1.021 . . . . 0.0 109.647 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.537 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -156.06 -162.78 11.64 Favored Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.21 40.61 0.99 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.615 2.21 . . . . 0.0 111.471 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.466 HG23 ' HA ' ' B' ' 34' ' ' GLU . 3.5 t -84.88 137.87 37.73 Favored Pre-proline 0 N--CA 1.493 1.678 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.425 ' O ' HG21 ' B' ' 82' ' ' VAL . 35.2 Cg_endo -77.31 14.43 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.565 2.177 . . . . 0.0 111.579 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.512 HG11 HG13 ' B' ' 84' ' ' ILE . 2.3 t -161.04 151.25 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.95 -1.094 . . . . 0.0 110.438 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.533 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 3.6 m-20 -90.62 102.88 15.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 176.752 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.614 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 2.2 mt -101.97 129.38 53.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 120.902 -1.124 . . . . 0.0 113.083 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.597 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 0.2 OUTLIER -98.63 111.49 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.505 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -97.47 -161.3 31.33 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.835 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.49 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -58.4 -34.9 71.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.563 -0.963 . . . . 0.0 110.451 -179.791 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.595 ' ND2' HD21 ' B' ' 89' ' ' LEU . 9.6 p-10 -48.05 -27.95 2.56 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.867 -1.145 . . . . 0.0 109.913 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.595 HD21 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -109.75 -24.79 10.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.81 -1.181 . . . . 0.0 109.63 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.49 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 90.7 mt -72.43 -4.97 33.39 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 74.4 p -100.51 -17.85 16.93 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -85.4 -41.21 15.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.354 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.561 HD11 ' CG ' ' A' ' 99' ' ' PHE . 1.5 pt -87.04 -4.03 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.29 50.56 38.02 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.136 178.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -73.05 157.77 36.69 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.071 -1.252 . . . . 0.0 110.198 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.459 HG21 HG21 ' A' ' 4' ' ' THR . 50.5 p -149.63 128.39 12.47 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.462 -0.773 . . . . 0.0 109.323 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.558 ' CD1' HD13 ' A' ' 97' ' ' LEU . 7.5 mp -89.68 104.32 16.89 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.6 m120 -107.64 127.29 53.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.05 . . . . 0.0 110.04 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.138 -0.934 . . . . 0.0 109.62 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.595 ' H32' HG13 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.53 ' CD ' ' O ' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.726 0 N-CA-C 110.244 -0.714 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.476 ' HA ' ' O ' ' B' ' 97' ' ' LEU . 1.7 tm0? -84.67 144.08 28.79 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.439 ' O ' ' HG ' ' A' ' 5' ' ' LEU . 38.1 t -145.28 123.34 4.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.911 -1.118 . . . . 0.0 109.984 -179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.527 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 18.6 p -60.51 -14.76 21.5 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.546 -0.721 . . . . 0.0 110.28 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.537 ' CD2' HD11 ' B' ' 97' ' ' LEU . 39.5 mt 73.65 17.02 3.78 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.484 -0.76 . . . . 0.0 110.654 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.555 ' CE3' ' HA ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -65.45 -12.61 54.1 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.842 -1.161 . . . . 0.0 108.789 179.252 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.518 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 29.7 mm-40 -146.47 178.86 7.95 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.9 mtt180 -72.97 116.08 46.83 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.916 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.517 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 32.7 Cg_endo -75.93 77.81 3.32 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 122.091 1.86 . . . . 0.0 110.107 178.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.516 HD22 ' CB ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.88 167.83 19.44 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.111 -0.993 . . . . 0.0 109.11 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.525 HG22 ' CG2' ' A' ' 13' ' ' ILE . 27.3 m -150.22 130.0 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.763 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.403 HG23 HD23 ' A' ' 19' ' ' LEU . 91.9 m -66.95 92.18 0.23 Allowed 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.574 HG21 ' CG1' ' A' ' 66' ' ' ILE . 1.4 pt -86.71 143.05 12.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.418 -0.801 . . . . 0.0 111.216 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.3 OUTLIER -108.46 97.78 7.4 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.166 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.577 ' CD1' ' CG2' ' A' ' 75' ' ' VAL . 0.2 OUTLIER -115.69 140.38 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 110.223 -178.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.421 ' HA3' ' CD1' ' A' ' 38' ' ' LEU . . . 49.7 29.23 12.27 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 178.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.57 38.26 57.63 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -136.2 179.43 6.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.477 -1.013 . . . . 0.0 108.284 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.532 ' CD2' ' HD2' ' A' ' 14' ' ' LYS . 13.0 mt -144.55 118.98 9.63 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.957 -1.09 . . . . 0.0 109.801 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.556 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -135.44 150.18 49.79 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.605 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.516 ' CB ' HD22 ' A' ' 10' ' ' LEU . 14.9 mm-40 -78.81 112.51 16.02 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.819 -1.175 . . . . 0.0 108.133 179.602 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.58 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -91.85 140.46 29.66 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.934 0.873 . . . . 0.0 110.788 -178.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 24' ' ' LEU . 44.6 tp -93.74 97.1 10.21 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.517 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 20.2 mt -42.43 107.69 0.08 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.158 -0.964 . . . . 0.0 109.153 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 2.7 t70 -113.81 87.82 2.7 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -178.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.469 HG22 HD23 ' B' ' 5' ' ' LEU . 10.1 m -70.99 -5.68 32.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.114 -0.991 . . . . 0.0 109.081 178.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.454 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.6 -29.38 32.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.575 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -77.73 168.59 19.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.214 -1.168 . . . . 0.0 109.691 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -100.19 -19.82 16.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.394 -0.816 . . . . 0.0 109.656 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.555 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 39.4 m-20 -133.7 -167.18 1.9 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -0.971 . . . . 0.0 109.74 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.517 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 8.0 m -111.06 89.74 3.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.035 -1.04 . . . . 0.0 110.193 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.566 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -68.14 172.08 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.132 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.96 113.99 0.69 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.189 -0.944 . . . . 0.0 109.557 -179.511 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.51 ' C ' ' O ' ' A' ' 33' ' ' LEU . 9.7 pt-20 -36.24 154.84 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.438 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.0 OUTLIER -44.16 134.86 4.65 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.088 -1.008 . . . . 0.0 109.922 -178.915 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.539 ' HE2' ' CG2' ' A' ' 15' ' ' ILE . 2.3 ppp? -154.31 -163.72 1.68 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.595 -0.691 . . . . 0.0 109.644 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.499 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 3.1 t -107.81 118.27 36.29 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.921 -1.112 . . . . 0.0 111.149 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.596 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -131.32 -173.57 0.34 Allowed Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 178.512 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 33.6 Cg_endo -78.97 -163.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.919 1.746 . . . . 0.0 110.861 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -114.18 31.56 6.41 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -118.98 63.82 0.78 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.594 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 21.2 p-90 -130.38 -175.39 3.63 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.764 0.792 . . . . 0.0 110.207 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -139.85 156.51 70.71 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.65 141.56 24.96 Favored 'Trans proline' 0 C--N 1.303 -1.849 0 C-N-CA 121.868 1.712 . . . . 0.0 109.68 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.411 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 1.3 tttt -149.94 170.14 19.52 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.444 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -144.27 113.81 7.1 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.655 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.525 ' CD1' HG23 ' B' ' 50' ' ' ILE . 24.9 pt -89.47 141.62 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.079 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.607 ' CA ' ' CD1' ' A' ' 53' ' ' PHE . . . -119.32 115.46 3.05 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.417 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -136.84 -115.05 1.38 Allowed Glycine 0 N--CA 1.485 1.905 0 C-N-CA 119.212 -1.471 . . . . 0.0 111.088 -178.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.59 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 17.1 mt -94.07 118.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.733 -0.863 . . . . 0.0 112.585 -177.116 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.89 -11.31 67.99 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.434 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 137.4 -177.54 19.76 Favored Glycine 0 N--CA 1.493 2.489 0 O-C-N 120.806 -1.408 . . . . 0.0 109.647 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.5 OUTLIER -102.64 143.92 31.7 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -1.133 . . . . 0.0 109.844 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.464 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 1.0 OUTLIER -109.19 -178.21 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.258 -0.901 . . . . 0.0 108.703 178.909 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 2.4 mttp -109.09 141.7 40.88 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.038 -1.039 . . . . 0.0 109.643 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -147.61 -171.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.05 -1.031 . . . . 0.0 109.521 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.409 ' HG3' ' C ' ' A' ' 56' ' ' VAL . 1.6 mtt180 -133.46 108.12 8.46 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.411 ' HB2' ' HD2' ' A' ' 45' ' ' LYS . 1.3 tt0 -65.28 97.17 0.26 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.322 -0.861 . . . . 0.0 110.428 -179.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.596 ' CZ ' ' HB3' ' A' ' 38' ' ' LEU . 10.3 m-85 -89.93 123.22 33.67 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -105.58 134.89 47.96 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.736 -1.227 . . . . 0.0 110.665 -178.589 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.503 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mp0 73.22 63.22 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 121.695 0.76 . . . . 0.0 110.195 179.239 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.512 HD11 HG22 ' A' ' 62' ' ' ILE . 22.1 mm -117.27 127.27 74.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.518 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 0.1 OUTLIER -76.37 89.08 3.18 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 112.276 -177.523 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.571 ' O ' HG21 ' A' ' 64' ' ' ILE . 7.2 tt -90.48 112.96 25.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 CA-C-O 121.888 0.852 . . . . 0.0 108.822 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.517 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -89.5 113.03 24.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.778 -1.201 . . . . 0.0 108.515 -179.69 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.574 ' CG1' HG21 ' A' ' 13' ' ' ILE . 2.9 mt -115.17 126.64 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.922 -1.111 . . . . 0.0 110.67 -178.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.2 m 66.75 24.91 9.82 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.638 -0.664 . . . . 0.0 109.895 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.435 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 80.58 7.44 88.55 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 61.0 m-70 -108.86 110.03 21.28 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.208 -1.172 . . . . 0.0 109.226 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.471 ' HG3' HD23 ' A' ' 63' ' ' LEU . 1.2 ttpt -52.58 136.29 32.79 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.474 -0.767 . . . . 0.0 109.026 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.518 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -154.94 118.38 4.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.618 -0.676 . . . . 0.0 109.36 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.507 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -95.07 158.06 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 120.807 -1.183 . . . . 0.0 108.036 178.709 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.616 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . 177.42 -170.15 42.54 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.734 -1.698 . . . . 0.0 111.47 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.457 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 1.5 m -91.18 113.25 25.46 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.918 . . . . 0.0 110.146 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.577 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 1.5 t -107.93 109.49 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.525 -0.734 . . . . 0.0 111.135 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.566 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.9 mp -80.2 125.08 29.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.276 -0.89 . . . . 0.0 109.056 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 89.9 t -113.25 131.91 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.999 -1.063 . . . . 0.0 109.853 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -164.47 -167.57 25.21 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.536 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -81.81 40.74 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.592 2.195 . . . . 0.0 110.534 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.475 ' O ' HG21 ' A' ' 80' ' ' THR . 14.9 t -81.74 140.72 47.47 Favored Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.447 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.3 Cg_endo -77.72 13.06 1.75 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 C-N-CA 122.227 1.952 . . . . 0.0 111.196 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.502 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.45 163.49 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.74 -1.225 . . . . 0.0 110.731 -179.755 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.58 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 60.0 m-20 -95.8 142.88 27.55 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 176.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.587 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 12.3 mm -131.95 124.63 53.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.467 -1.396 . . . . 0.0 111.337 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.499 HD13 ' HB3' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -102.96 94.72 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 88' ' ' ASN . . . -100.75 171.21 22.61 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.382 -177.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.555 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.1 OUTLIER -21.71 -41.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -179.392 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.577 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 6.8 p-10 -51.1 -42.89 60.94 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.282 -1.511 . . . . 0.0 110.774 -177.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.616 HD23 ' HA3' ' A' ' 73' ' ' GLY . 0.8 OUTLIER -97.54 -11.04 24.18 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.146 -0.971 . . . . 0.0 110.414 -179.137 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.555 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 5.7 mp -69.73 -35.14 74.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.084 -1.01 . . . . 0.0 108.788 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 p -70.5 -15.42 62.79 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.455 -0.778 . . . . 0.0 109.252 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.6 mm-40 -89.13 -41.42 12.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.019 . . . . 0.0 109.27 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.564 HD13 ' CB ' ' B' ' 99' ' ' PHE . 1.9 pt -81.99 -1.89 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 57.19 54.95 33.11 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.519 ' HB2' ' CD1' ' B' ' 5' ' ' LEU . . . -85.42 127.62 34.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.422 -1.046 . . . . 0.0 110.26 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 69.9 p -122.31 124.9 44.82 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.573 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.9 mp -89.98 100.48 13.29 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.406 -0.809 . . . . 0.0 109.384 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.475 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 1.6 m120 -105.96 129.33 54.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.234 -0.916 . . . . 0.0 110.048 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.591 ' CE2' ' HG2' ' B' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.265 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.591 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.404 -0.652 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.443 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 6.7 tt0 -84.25 129.45 34.88 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.509 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 11.4 t -121.76 96.23 4.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.762 -1.212 . . . . 0.0 109.499 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 3.0 p -55.73 135.11 51.73 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.519 ' CD1' ' HB2' ' A' ' 95' ' ' ALA . 89.5 mt -83.36 4.42 27.46 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.765 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -57.05 -20.19 23.21 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -135.4 157.67 46.31 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.0 mtt180 -53.25 125.5 42.65 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 120.886 -1.134 . . . . 0.0 109.371 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.509 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 36.4 Cg_endo -77.65 71.23 6.59 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.281 1.987 . . . . 0.0 109.819 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.527 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -90.63 144.62 25.57 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.26 -179.686 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.488 HG23 HG12 ' B' ' 66' ' ' ILE . 3.1 m -135.14 132.71 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 110.203 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.402 HG23 HD23 ' B' ' 19' ' ' LEU . 91.8 m -65.6 109.56 2.43 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.548 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.1 pt -98.58 144.23 11.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 110.841 -178.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.2 OUTLIER -112.16 101.9 10.12 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.527 HG23 ' CE ' ' B' ' 36' ' ' MET . 11.8 mt -118.58 118.87 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.162 -0.961 . . . . 0.0 109.766 -179.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.457 ' HA3' HD13 ' B' ' 38' ' ' LEU . . . 67.83 27.25 73.67 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.2 -2.78 74.84 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.416 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.4 mp0 -90.07 -179.34 5.66 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.329 -1.101 . . . . 0.0 108.973 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.534 ' CD2' ' O ' ' B' ' 13' ' ' ILE . 12.4 mt -153.17 124.02 7.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.193 -0.942 . . . . 0.0 110.269 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.449 ' NZ ' HD21 ' B' ' 33' ' ' LEU . 8.4 mtmt -143.89 158.63 43.57 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.527 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.4 OUTLIER -79.29 133.05 36.64 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.978 -1.076 . . . . 0.0 109.54 -179.114 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -107.7 156.25 19.29 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.248 -0.908 . . . . 0.0 110.022 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' B' ' 24' ' ' LEU . 62.4 tp -115.6 95.35 5.1 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.502 ' CD2' HD22 ' B' ' 90' ' ' LEU . 24.1 mt -42.15 103.44 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.393 -0.817 . . . . 0.0 109.359 -179.437 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.542 ' CB ' HG21 ' B' ' 84' ' ' ILE . 48.8 t0 -114.55 91.02 3.48 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.142 -0.974 . . . . 0.0 110.275 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.466 HG23 HD23 ' A' ' 5' ' ' LEU . 0.9 OUTLIER -68.88 -7.56 35.82 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.066 -1.021 . . . . 0.0 108.73 178.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.416 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -73.8 -41.57 41.54 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.531 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -76.71 166.21 23.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.149 -1.206 . . . . 0.0 109.886 -179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -100.93 -19.91 15.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.145 -0.972 . . . . 0.0 110.786 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.5 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -130.6 -168.17 1.94 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.874 -1.141 . . . . 0.0 109.644 -179.445 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.545 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 16.7 m -109.74 95.66 5.75 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.911 -1.118 . . . . 0.0 110.286 -179.066 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.66 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.5 OUTLIER -77.38 162.14 4.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 179.023 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -160.74 125.78 3.75 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 120.456 -1.402 . . . . 0.0 111.288 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.511 ' HA ' HG21 ' B' ' 80' ' ' THR . 3.7 tt0 -38.89 159.17 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.724 -0.61 . . . . 0.0 109.677 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.617 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.6 tt0 -51.35 150.26 3.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.95 . . . . 0.0 110.285 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.527 ' CE ' HG23 ' B' ' 15' ' ' ILE . 2.9 ppp? -168.5 -169.16 1.01 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.293 -0.879 . . . . 0.0 109.11 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.52 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.6 t -121.19 124.42 44.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.929 -1.107 . . . . 0.0 110.372 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.586 ' CB ' ' CD ' ' B' ' 39' ' ' PRO . 0.1 OUTLIER -124.64 -172.82 0.26 Allowed Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.347 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.586 ' CD ' ' CB ' ' B' ' 38' ' ' LEU . 34.8 Cg_endo -80.8 59.87 7.63 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.292 1.995 . . . . 0.0 111.005 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.95 -157.92 0.06 OUTLIER Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.405 ' O ' ' O ' ' B' ' 40' ' ' GLY . 50.7 mmt-85 51.91 96.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.544 -0.974 . . . . 0.0 109.077 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.432 ' CE3' ' HG3' ' B' ' 57' ' ' ARG . 16.7 p-90 -155.02 171.93 18.94 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.691 -0.631 . . . . 0.0 109.683 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.24 121.4 20.52 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.26 141.5 18.31 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.412 2.075 . . . . 0.0 111.423 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.28 -171.93 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' HG3' ' B' ' 55' ' ' LYS . 17.1 mtp -143.54 133.97 24.74 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.903 -1.123 . . . . 0.0 110.098 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.509 HD13 ' CG2' ' A' ' 50' ' ' ILE . 19.4 pt -104.94 139.43 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 0.0 108.8 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.9 97.35 0.7 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.294 -1.922 . . . . 0.0 108.294 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.22 -121.37 2.88 Favored Glycine 0 N--CA 1.485 1.914 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.682 -178.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.611 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 11.2 mt -86.58 124.79 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.854 -0.792 . . . . 0.0 111.982 -177.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 101.49 -53.46 0.83 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 176.76 -161.81 29.9 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -111.38 137.33 49.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -1.198 . . . . 0.0 109.359 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.415 HG12 HG13 ' B' ' 47' ' ' ILE . 27.6 pt -117.14 159.17 17.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.253 -0.904 . . . . 0.0 109.535 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.527 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.5 OUTLIER -94.69 126.26 39.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 108.8 179.313 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . . . . . . . . . 12.5 m -134.2 153.68 36.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.519 ' N ' ' HD2' ' B' ' 57' ' ' ARG . 2.3 mpt_? -91.63 179.78 5.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -138.61 93.06 2.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.131 -0.98 . . . . 0.0 110.523 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.569 ' CE2' ' HB3' ' B' ' 38' ' ' LEU . 67.2 m-85 -89.29 92.53 9.2 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.485 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 49.0 m-20 -78.62 143.11 36.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.046 -1.034 . . . . 0.0 109.381 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.485 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 74.1 64.18 0.08 Allowed 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.529 -0.732 . . . . 0.0 109.189 -179.571 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.534 ' CD1' HD22 ' B' ' 38' ' ' LEU . 1.1 mm -121.07 117.15 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.552 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 3.4 tm? -68.62 85.27 0.3 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.476 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.59 ' CG2' HD13 ' B' ' 89' ' ' LEU . 3.4 tt -91.02 117.67 34.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.486 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.9 tt0 -89.53 111.47 22.4 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.063 -1.023 . . . . 0.0 109.563 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' B' ' 64' ' ' ILE . 0.4 OUTLIER -104.35 120.3 54.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.79 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.499 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 88.2 m 65.36 20.42 11.81 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.788 -0.57 . . . . 0.0 110.166 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.26 1.61 78.46 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.112 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -97.9 123.0 41.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.214 -1.168 . . . . 0.0 109.123 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.488 ' HG2' HD22 ' B' ' 63' ' ' LEU . 3.9 mtpt -58.71 133.85 56.3 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.488 ' O ' HG23 ' B' ' 64' ' ' ILE . . . -150.96 99.67 2.72 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.014 -1.053 . . . . 0.0 110.26 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.525 HD11 ' N ' ' B' ' 62' ' ' ILE . 0.5 OUTLIER -79.55 144.54 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.668 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.474 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -167.43 -177.8 39.2 Favored Glycine 0 N--CA 1.486 1.991 0 C-N-CA 118.915 -1.612 . . . . 0.0 110.634 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.427 ' CG2' ' OD1' ' B' ' 60' ' ' ASP . 22.0 m -95.83 102.99 14.85 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.723 -0.869 . . . . 0.0 109.432 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.486 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 0.9 OUTLIER -92.58 162.11 2.45 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.66 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.0 mp -129.95 140.35 50.94 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.617 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 9.2 t -120.8 103.19 13.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 O-C-N 121.386 -0.821 . . . . 0.0 110.507 -178.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.54 -166.12 10.87 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.527 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.5 Cg_endo -80.94 41.31 1.12 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.583 2.189 . . . . 0.0 110.956 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.511 HG21 ' HA ' ' B' ' 34' ' ' GLU . 1.8 t -84.45 138.21 38.8 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.29 14.51 1.56 Allowed 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.193 1.928 . . . . 0.0 111.497 -179.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.531 ' CG1' HD12 ' B' ' 84' ' ' ILE . 0.7 OUTLIER -161.13 171.21 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.903 -1.123 . . . . 0.0 110.11 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -105.97 116.07 31.31 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 176.591 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' B' ' 31' ' ' THR . 5.0 mm -100.45 120.59 50.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 O-C-N 120.661 -1.274 . . . . 0.0 111.562 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.472 HG23 HD21 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -95.37 89.83 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.838 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.08 -164.33 27.27 Favored Glycine 0 N--CA 1.493 2.474 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.437 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.518 ' NH2' ' HA ' ' A' ' 7' ' ' GLN . 13.5 mtm180 -60.76 -39.79 90.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.786 -0.832 . . . . 0.0 110.548 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.578 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 9.7 p-10 -45.28 -26.49 0.52 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.093 -1.005 . . . . 0.0 110.181 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.59 HD13 ' CG2' ' B' ' 64' ' ' ILE . 1.7 mm? -108.7 -29.56 8.64 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.026 -1.047 . . . . 0.0 111.041 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.502 HD22 ' CD2' ' B' ' 24' ' ' LEU . 71.9 mt -65.15 -9.62 24.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.716 -1.24 . . . . 0.0 108.748 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.2 p -101.03 -20.71 15.26 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.176 -0.952 . . . . 0.0 109.391 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 36.6 mm-40 -78.06 -40.81 37.46 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.071 -1.018 . . . . 0.0 109.141 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.435 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 4.4 pt -86.03 -4.02 9.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 77.28 29.47 56.2 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.557 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -59.97 151.0 27.26 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.042 -1.269 . . . . 0.0 109.037 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.511 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 2.6 p -136.6 173.7 11.42 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.573 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -134.31 98.82 4.2 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.735 -1.228 . . . . 0.0 110.088 -179.371 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.7 m120 -99.23 118.62 36.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.964 -1.085 . . . . 0.0 109.37 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.508 0 CA-C-O 117.94 -1.029 . . . . 0.0 108.935 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.611 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.548 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 N-CA-C 110.231 -0.719 . . . . 0.0 110.231 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.481 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.43 131.07 34.71 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 178.204 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.461 HG12 ' HB3' ' A' ' 9' ' ' PRO . 4.1 t -121.79 94.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.991 -1.068 . . . . 0.0 109.768 -178.259 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.522 ' CG2' ' HB ' ' B' ' 96' ' ' THR . 19.3 p -126.01 45.67 2.58 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.335 -0.853 . . . . 0.0 108.93 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.544 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.5 OUTLIER -89.07 36.47 0.82 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.187 -0.946 . . . . 0.0 109.589 -179.721 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 13.4 m0 17.45 51.86 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 CA-C-O 121.631 0.729 . . . . 0.0 111.512 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.544 ' N ' ' O ' ' A' ' 5' ' ' LEU . 49.4 mt-30 -156.02 -159.78 0.94 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 10.1 mtm180 -79.66 113.34 36.6 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.986 -1.071 . . . . 0.0 109.909 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.496 ' HD3' ' O ' ' A' ' 7' ' ' GLN . 36.3 Cg_endo -79.79 80.27 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 C-N-CA 122.355 2.037 . . . . 0.0 110.055 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -100.13 164.78 11.82 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.846 -179.749 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.545 HG22 ' CG2' ' A' ' 13' ' ' ILE . 2.3 m -148.86 129.47 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 110.256 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.3 m -69.22 94.05 0.66 Allowed 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 178.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.545 ' CG2' HG22 ' A' ' 11' ' ' VAL . 7.7 pt -82.95 167.42 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 110.949 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.3 tttt -128.65 102.88 6.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.559 -0.713 . . . . 0.0 109.25 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.497 HD11 HG22 ' A' ' 15' ' ' ILE . 11.6 mt -124.47 147.93 28.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 120.987 -1.07 . . . . 0.0 109.592 -179.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.03 32.53 4.83 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.9 43.62 90.97 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.6 tp-100 -138.52 170.79 15.38 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.191 -1.182 . . . . 0.0 109.022 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.401 HD22 ' HA ' ' A' ' 19' ' ' LEU . 39.3 mt -135.57 126.41 27.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.385 -0.822 . . . . 0.0 109.445 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 mtpm? -148.22 158.65 44.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.406 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.565 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.4 mt-10 -79.17 123.81 27.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.523 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -105.08 141.98 35.67 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.333 -0.854 . . . . 0.0 110.225 -178.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.466 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 19.8 tp -97.67 103.82 15.79 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.747 -0.595 . . . . 0.0 109.918 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 23' ' ' LEU . 12.1 mt -44.62 113.62 0.58 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 178.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.487 ' CB ' HG21 ' A' ' 84' ' ' ILE . 25.4 t0 -119.64 89.13 3.07 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.948 -1.095 . . . . 0.0 111.65 -177.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.57 -2.95 35.04 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.909 -1.119 . . . . 0.0 108.562 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.536 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -90.78 -25.12 25.95 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 162.13 19.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.953 -1.322 . . . . 0.0 109.027 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -98.1 -13.06 21.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.115 -0.991 . . . . 0.0 110.287 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.539 ' HB3' HD12 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -142.78 -175.05 4.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.93 -1.106 . . . . 0.0 109.732 -179.957 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 22.6 m -104.63 91.83 4.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.703 -1.248 . . . . 0.0 111.226 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.29 173.34 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.643 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.32 122.78 1.08 Allowed 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.688 -1.257 . . . . 0.0 111.547 -179.417 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.562 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 12.6 tt0 -39.97 149.21 0.07 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.668 -0.645 . . . . 0.0 109.362 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.68 141.88 6.72 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.191 -0.943 . . . . 0.0 110.295 -179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.439 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -163.64 -172.28 2.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.344 -0.848 . . . . 0.0 109.313 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.2 t -92.7 83.95 4.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.001 -1.062 . . . . 0.0 109.626 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.554 HD22 ' CG ' ' A' ' 59' ' ' TYR . 61.6 tp -116.2 98.34 51.17 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -78.37 167.3 23.18 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.656 2.237 . . . . 0.0 110.642 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.61 171.93 13.9 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 133.41 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -1.154 . . . . 0.0 108.684 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 52.5 p-90 -136.67 -177.42 4.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.163 -0.961 . . . . 0.0 110.691 -178.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.1 tptt -146.28 162.98 32.54 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -78.0 140.36 17.98 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.756 1.638 . . . . 0.0 109.688 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.532 ' O ' ' CG2' ' A' ' 56' ' ' VAL . 0.0 OUTLIER -155.4 115.31 3.72 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.105 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -100.93 122.51 43.61 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.196 -0.94 . . . . 0.0 109.01 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.544 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 22.6 pt -93.24 139.26 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.016 -1.052 . . . . 0.0 109.109 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.585 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.64 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.641 -1.783 . . . . 0.0 108.641 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.74 -121.92 2.55 Favored Glycine 0 N--CA 1.483 1.812 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.698 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.583 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 26.3 mt -86.48 122.23 38.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.875 -0.779 . . . . 0.0 112.571 -177.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.447 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 103.49 -50.98 0.85 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.428 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 176.26 -156.94 22.29 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.585 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 5.2 m-85 -111.9 129.9 56.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -1.034 . . . . 0.0 109.837 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.544 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 1.0 OUTLIER -106.97 164.76 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.51 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 1.1 mtmt -106.82 140.28 39.91 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.865 -1.147 . . . . 0.0 110.497 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 16.1 m -146.63 178.18 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.83 110.63 16.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.329 -0.857 . . . . 0.0 108.829 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.414 ' O ' ' CG ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -64.75 107.03 1.32 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.456 -0.778 . . . . 0.0 110.271 -179.247 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.2 m-85 -100.89 100.45 11.08 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.535 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 85.2 m-20 -83.82 132.62 34.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.051 -1.031 . . . . 0.0 110.85 -178.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.558 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.2 mt-30 81.17 60.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.82 -0.55 . . . . 0.0 110.767 178.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.483 ' HB ' ' CG2' ' A' ' 75' ' ' VAL . 5.1 mm -117.93 118.46 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.545 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.608 ' CD2' ' CG ' ' A' ' 70' ' ' LYS . 1.4 tp -70.35 86.52 0.6 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.035 -1.04 . . . . 0.0 111.145 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.541 HG12 ' CD1' ' A' ' 66' ' ' ILE . 5.6 tt -86.54 119.75 35.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.79 103.98 16.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.936 -1.102 . . . . 0.0 109.165 -178.589 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.541 ' CD1' HG12 ' A' ' 64' ' ' ILE . 3.2 mt -109.61 120.93 61.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.479 -0.763 . . . . 0.0 109.717 -179.311 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.579 ' HB3' ' CD2' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 64.42 40.21 6.5 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.531 -0.731 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.24 30.49 76.11 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.579 ' CD2' ' HB3' ' A' ' 67' ' ' CYS . 87.9 m-70 -122.69 101.38 7.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -1.19 . . . . 0.0 109.592 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.608 ' CG ' ' CD2' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -53.04 108.88 0.36 Allowed 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.156 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.558 ' O ' ' CD1' ' A' ' 63' ' ' LEU . . . -126.56 148.35 49.75 Favored 'General case' 0 C--N 1.287 -2.14 0 C-N-CA 120.304 -0.558 . . . . 0.0 109.603 -179.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.558 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -118.68 147.42 22.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.504 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.535 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -172.45 -168.26 33.6 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 118.789 -1.672 . . . . 0.0 110.987 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.496 ' HB ' ' OD1' ' A' ' 30' ' ' ASP . 27.9 m -96.98 108.0 20.64 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.659 -0.906 . . . . 0.0 109.409 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.484 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -99.21 111.06 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.469 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.543 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.3 mp -81.12 118.38 22.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.057 -1.027 . . . . 0.0 108.306 178.591 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 8.5 t -104.89 109.99 29.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.124 -0.985 . . . . 0.0 109.68 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.474 ' HA3' HG13 ' A' ' 56' ' ' VAL . . . -148.16 -162.16 9.98 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.51 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -81.66 43.78 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.637 2.225 . . . . 0.0 110.599 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.562 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 9.1 t -84.75 136.33 39.31 Favored Pre-proline 0 N--CA 1.491 1.576 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.476 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -79.07 14.54 1.71 Allowed 'Trans proline' 0 C--N 1.307 -1.614 0 C-N-CA 122.389 2.059 . . . . 0.0 110.983 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.2 t -159.9 164.65 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.11 -0.994 . . . . 0.0 109.101 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -101.36 126.21 48.09 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 104.831 -2.285 . . . . 0.0 104.831 176.649 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 31' ' ' THR . 7.6 mm -113.32 128.94 69.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.333 -1.347 . . . . 0.0 111.794 -176.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.505 ' O ' HD23 ' A' ' 90' ' ' LEU . 0.8 OUTLIER -103.53 90.91 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 177.138 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.561 ' C ' ' CD2' ' A' ' 90' ' ' LEU . . . -83.97 173.6 50.66 Favored Glycine 0 N--CA 1.498 2.774 0 O-C-N 121.198 -0.939 . . . . 0.0 110.97 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.544 ' CA ' HD21 ' A' ' 90' ' ' LEU . 8.8 mmm180 -39.89 -39.97 0.92 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.806 -0.82 . . . . 0.0 111.335 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.56 ' ND2' HD21 ' A' ' 89' ' ' LEU . 12.2 p-10 -44.55 -41.18 6.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.739 -1.226 . . . . 0.0 109.986 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.56 HD21 ' ND2' ' A' ' 88' ' ' ASN . 1.7 mm? -96.67 -26.62 15.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.237 -0.914 . . . . 0.0 111.745 -179.045 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.561 ' CD2' ' C ' ' A' ' 86' ' ' GLY . 0.8 OUTLIER -60.28 -36.25 77.41 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.292 -1.505 . . . . 0.0 108.0 179.71 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 81.6 p -70.05 -21.58 63.15 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 108.846 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.422 ' HB2' ' O ' ' A' ' 89' ' ' LEU . 22.3 mm-40 -74.78 -40.66 61.04 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.582 HD11 ' CG ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -86.31 -13.08 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.384 -0.822 . . . . 0.0 108.937 179.444 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 83.92 26.78 40.05 Favored Glycine 0 N--CA 1.495 2.633 0 C-N-CA 120.32 -0.943 . . . . 0.0 111.042 178.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.543 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -59.5 143.16 50.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 109.865 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.544 HG23 ' CG2' ' B' ' 4' ' ' THR . 74.2 p -135.34 129.58 33.66 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.535 ' CD1' HD13 ' B' ' 97' ' ' LEU . 3.7 mp -92.63 99.26 12.0 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.907 -1.12 . . . . 0.0 110.688 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.573 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.4 m120 -108.0 124.48 50.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.413 -0.804 . . . . 0.0 109.046 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.589 ' CD2' HD11 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 118.037 -0.983 . . . . 0.0 109.163 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.462 ' HD2' ' O ' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.273 -0.703 . . . . 0.0 110.273 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.573 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.5 tt0 -83.39 144.11 29.85 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.477 HG21 ' O ' ' B' ' 2' ' ' GLN . 25.6 t -141.98 105.83 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.364 -1.334 . . . . 0.0 110.87 -177.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.544 ' CG2' HG23 ' A' ' 96' ' ' THR . 0.2 OUTLIER -106.61 -86.51 0.49 Allowed 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 178.137 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.55 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 43.52 20.38 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.576 -0.702 . . . . 0.0 111.308 178.498 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 40.4 m0 16.24 52.16 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.234 0.54 . . . . 0.0 112.16 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.55 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.4 mt-30 -144.03 -128.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.45 130.93 22.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.642 -1.286 . . . . 0.0 109.662 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.469 ' HB2' ' CD1' ' B' ' 24' ' ' LEU . 37.1 Cg_endo -82.52 53.63 4.56 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.456 2.104 . . . . 0.0 109.301 178.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 mt -79.05 143.73 35.33 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.237 -0.914 . . . . 0.0 109.31 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.519 HG23 ' CG2' ' B' ' 66' ' ' ILE . 0.8 OUTLIER -142.38 150.89 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -0.823 . . . . 0.0 109.452 -179.713 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 89.8 m -83.92 109.01 17.26 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.558 ' HA ' ' O ' ' B' ' 65' ' ' GLU . 1.1 pt -98.89 139.26 21.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.148 -0.97 . . . . 0.0 111.102 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.503 ' HA ' HD22 ' B' ' 19' ' ' LEU . 0.7 OUTLIER -98.5 98.31 9.52 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.535 HD13 ' CD1' ' B' ' 13' ' ' ILE . 4.9 mt -120.3 130.64 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.342 -0.849 . . . . 0.0 109.337 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.29 23.54 71.7 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.4 15.72 80.2 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.452 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -112.25 174.08 6.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.422 -1.046 . . . . 0.0 109.31 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.503 HD22 ' HA ' ' B' ' 14' ' ' LYS . 27.9 mt -134.8 113.91 12.09 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.248 -0.907 . . . . 0.0 110.018 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -134.85 177.48 7.76 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.54 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 3.5 mm-40 -79.58 177.78 8.62 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.859 -1.15 . . . . 0.0 108.883 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.537 ' HB1' HG21 ' B' ' 13' ' ' ILE . . . -159.18 101.53 1.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.322 -0.861 . . . . 0.0 109.447 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 27' ' ' GLY . 14.3 tp -77.97 98.89 5.84 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.291 -0.88 . . . . 0.0 109.438 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.469 ' CD1' ' HB2' ' B' ' 9' ' ' PRO . 89.6 mt -45.42 104.74 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.055 -1.028 . . . . 0.0 108.585 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.534 ' HB3' HG21 ' B' ' 84' ' ' ILE . 39.5 t0 -111.69 91.43 3.66 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.356 -0.84 . . . . 0.0 110.646 -178.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 55.9 m -69.79 -11.57 60.96 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.119 -0.988 . . . . 0.0 108.459 178.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.439 ' O ' HD23 ' A' ' 23' ' ' LEU . . . -69.24 -39.85 82.03 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.542 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -80.26 150.67 29.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.342 -1.093 . . . . 0.0 109.481 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -91.19 -10.04 43.17 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.23 -0.919 . . . . 0.0 109.805 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.482 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.81 -173.13 3.05 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.274 -0.892 . . . . 0.0 109.546 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.4 HG21 ' O ' ' B' ' 84' ' ' ILE . 29.9 m -113.44 98.51 7.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.01 -1.056 . . . . 0.0 110.229 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.624 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -83.33 166.01 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.547 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.2 OUTLIER -162.8 126.58 2.94 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.59 -1.319 . . . . 0.0 111.354 -178.438 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.506 ' N ' HG23 ' B' ' 80' ' ' THR . 8.5 tt0 -42.9 154.57 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.573 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tm-20 -38.8 148.54 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.349 -0.844 . . . . 0.0 110.366 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.534 ' CE ' HG21 ' B' ' 15' ' ' ILE . 24.5 ptm -163.57 -162.31 0.72 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.324 -0.86 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.5 t -118.68 120.2 36.73 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.083 -1.01 . . . . 0.0 110.794 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.489 HD13 ' HD3' ' B' ' 39' ' ' PRO . 0.0 OUTLIER -124.6 173.66 4.53 Favored Pre-proline 0 N--CA 1.491 1.592 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.019 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.489 ' HD3' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.72 47.72 2.61 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.676 2.25 . . . . 0.0 111.634 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.12 -166.88 0.01 OUTLIER Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.5 mmm180 63.38 70.73 0.52 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.168 -1.195 . . . . 0.0 109.361 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 10.1 p-90 -140.41 -173.43 3.67 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 121.629 -0.669 . . . . 0.0 109.519 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.94 128.58 16.76 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.216 -0.927 . . . . 0.0 108.516 179.292 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -75.34 139.54 23.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 121.879 1.719 . . . . 0.0 110.749 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.17 -162.7 1.57 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.528 -0.732 . . . . 0.0 109.232 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.534 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 0.2 OUTLIER -149.02 130.02 14.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.27 -0.894 . . . . 0.0 109.613 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.56 ' CD1' HG22 ' A' ' 50' ' ' ILE . 8.3 pt -98.67 143.56 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.899 -1.125 . . . . 0.0 108.84 179.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.629 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -118.53 113.3 2.56 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 -179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.12 -125.43 2.04 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.707 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.597 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 21.5 mt -88.7 119.04 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.797 -0.825 . . . . 0.0 112.852 -177.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.455 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 96.6 2.32 60.06 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.203 177.234 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 126.87 -158.75 20.96 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.334 -1.412 . . . . 0.0 110.221 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.66 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.9 OUTLIER -124.6 134.11 53.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.661 -0.905 . . . . 0.0 109.222 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.511 HG12 HD13 ' B' ' 47' ' ' ILE . 13.5 pt -104.26 167.65 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.979 -1.076 . . . . 0.0 109.239 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.559 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.91 134.32 48.23 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.191 -0.943 . . . . 0.0 109.159 179.734 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.465 HG11 ' C ' ' B' ' 55' ' ' LYS . 21.4 m -140.6 -171.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.991 -1.068 . . . . 0.0 110.201 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.463 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.4 mtt-85 -128.87 105.92 8.56 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 33.7 tt0 -69.62 100.34 1.44 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.444 -0.785 . . . . 0.0 110.934 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 17.1 m-85 -89.59 133.42 34.62 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.014 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 67.4 m-20 -108.49 133.14 53.05 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.713 -1.242 . . . . 0.0 109.989 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.547 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.29 63.71 0.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.917 -0.713 . . . . 0.0 109.569 179.581 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' B' ' 75' ' ' VAL . 26.9 mm -116.52 119.28 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.55 HD23 ' HG2' ' B' ' 70' ' ' LYS . 2.9 tm? -66.02 84.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 111.28 -178.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.559 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 5.7 tt -90.52 112.19 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.558 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 29.5 tt0 -89.52 115.39 26.9 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.178 -0.951 . . . . 0.0 109.033 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.519 ' CG2' HG23 ' B' ' 11' ' ' VAL . 2.3 mp -112.97 123.43 68.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.032 -1.043 . . . . 0.0 109.719 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 36.8 m 67.17 44.93 1.79 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.487 -0.758 . . . . 0.0 109.444 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 61.52 21.02 59.75 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.504 ' O ' ' HA ' ' B' ' 65' ' ' GLU . 4.4 m-70 -119.66 130.09 54.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.014 -1.286 . . . . 0.0 109.677 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.55 ' HG2' HD23 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -70.56 136.55 49.37 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -155.9 104.69 2.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.219 -0.925 . . . . 0.0 109.793 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.547 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -80.06 154.54 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.963 -1.085 . . . . 0.0 108.349 178.93 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.59 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 178.98 -169.74 41.24 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.16 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -95.64 105.9 17.94 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.667 -0.901 . . . . 0.0 110.618 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.54 HG22 ' HB ' ' B' ' 62' ' ' ILE . 1.0 OUTLIER -97.6 158.91 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.726 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.624 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.8 mp -126.38 125.42 42.18 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.762 -1.211 . . . . 0.0 107.901 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.573 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 94.8 t -106.43 116.39 50.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 O-C-N 120.671 -1.268 . . . . 0.0 109.663 -179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -156.37 -166.25 15.9 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.559 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -80.09 44.52 1.74 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.511 2.141 . . . . 0.0 110.604 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.506 HG23 ' N ' ' B' ' 34' ' ' GLU . 3.2 t -89.74 135.22 30.84 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.483 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -78.17 17.59 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.284 1.99 . . . . 0.0 111.137 -178.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.507 ' CG1' HG13 ' B' ' 84' ' ' ILE . 2.5 t -160.32 156.76 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 120.879 -1.138 . . . . 0.0 110.777 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.54 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 60.4 m-20 -97.41 86.28 3.84 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 176.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.534 HG21 ' HB3' ' B' ' 25' ' ' ASP . 2.6 mt -82.78 124.89 39.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 O-C-N 121.298 -0.876 . . . . 0.0 112.378 -176.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.509 ' N ' HD11 ' B' ' 85' ' ' ILE . 3.7 mm -100.19 109.18 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.572 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -108.29 164.39 12.76 Favored Glycine 0 N--CA 1.498 2.785 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.881 -178.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.5 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 20.7 mmm180 -19.26 -41.94 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -178.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.572 ' N ' ' O ' ' B' ' 86' ' ' GLY . 9.8 p-10 -49.45 -42.12 42.14 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.475 -1.391 . . . . 0.0 110.813 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.59 HD23 ' HA3' ' B' ' 73' ' ' GLY . 0.8 OUTLIER -93.75 -27.65 16.37 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.245 -0.91 . . . . 0.0 109.976 -179.653 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' B' ' 90' ' ' LEU . 4.6 mp -58.76 -33.87 70.78 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.097 -1.002 . . . . 0.0 108.831 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 4.3 p -74.12 -21.28 59.95 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.294 -0.879 . . . . 0.0 109.866 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 1.4 mm100 -80.14 -40.47 27.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.163 -0.961 . . . . 0.0 109.053 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.589 HD11 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -81.7 -5.39 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.264 -0.897 . . . . 0.0 108.916 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.31 60.74 7.79 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.52 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -87.89 160.06 18.12 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.265 -1.138 . . . . 0.0 110.706 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.522 ' HB ' ' CG2' ' A' ' 4' ' ' THR . 4.7 p -141.7 126.96 18.6 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.535 HD13 ' CD1' ' A' ' 97' ' ' LEU . 5.5 mp -92.18 97.1 10.7 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 10.4 m120 -97.41 118.92 34.96 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.378 -0.826 . . . . 0.0 110.453 -178.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.582 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.723 0 CA-C-O 117.923 -1.037 . . . . 0.0 109.334 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.597 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.588 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 4.0 Cg_exo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.763 -0.514 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.509 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 17.6 tt0 -83.77 131.75 34.89 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 20.0 t -124.12 102.06 10.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.575 -1.328 . . . . 0.0 110.484 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.53 HG22 ' CG2' ' B' ' 96' ' ' THR . 0.0 OUTLIER -139.78 48.73 1.8 Allowed 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.55 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -85.59 43.02 1.0 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.225 -0.922 . . . . 0.0 110.152 -179.238 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.583 ' CZ3' ' HB ' ' B' ' 91' ' ' THR . 13.4 m95 18.91 48.09 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 CA-C-O 121.46 0.647 . . . . 0.0 111.335 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 37.1 mt-30 -165.23 -168.0 1.3 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.455 ' HB3' HD11 ' A' ' 23' ' ' LEU . 58.8 mtt180 -75.26 122.49 87.44 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.011 -1.055 . . . . 0.0 108.632 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.5 Cg_endo -76.53 85.06 1.76 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.153 1.902 . . . . 0.0 109.991 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.528 HD21 ' HB3' ' A' ' 21' ' ' GLU . 5.5 mt -86.47 142.36 28.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.287 -0.883 . . . . 0.0 109.723 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.421 HG21 ' HB1' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -146.98 154.4 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.927 . . . . 0.0 109.243 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 85.3 m -88.95 112.87 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.549 ' CG2' HG13 ' A' ' 66' ' ' ILE . 1.9 pt -101.87 153.51 5.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.114 -0.991 . . . . 0.0 110.121 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 2.9 tttt -110.76 109.21 19.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.36 -0.838 . . . . 0.0 109.738 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.507 ' CG2' ' HE3' ' A' ' 36' ' ' MET . 4.5 mt -124.59 135.54 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.03 -1.044 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.462 ' HA3' HD11 ' A' ' 38' ' ' LEU . . . 50.04 33.8 22.49 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.68 35.2 59.11 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.466 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 9.0 mm100 -128.19 175.72 8.22 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -1.107 . . . . 0.0 109.057 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.469 ' O ' ' HG2' ' A' ' 20' ' ' LYS . 14.2 mt -145.71 123.27 11.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -0.946 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.469 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 18.3 mttp -146.61 177.32 9.16 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.528 ' HB3' HD21 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -79.19 -179.96 7.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.831 -1.168 . . . . 0.0 108.612 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.538 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -165.17 109.2 0.87 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.249 -1.532 . . . . 0.0 110.992 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 25' ' ' ASP . 2.8 tp -78.57 95.79 5.3 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.521 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 35.0 mt -48.64 93.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 23' ' ' LEU . 22.5 t0 -99.57 92.92 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 110.828 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.448 HG21 HD11 ' A' ' 90' ' ' LEU . 2.6 m -67.56 -6.84 21.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.095 -1.003 . . . . 0.0 109.467 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.494 ' O ' ' CD2' ' B' ' 23' ' ' LEU . . . -78.55 -40.83 17.49 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.47 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -72.56 154.15 40.94 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.31 . . . . 0.0 109.256 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 1.8 m-20 -88.2 -13.59 40.73 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.25 -0.906 . . . . 0.0 110.374 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.534 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -137.51 -170.77 2.82 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.984 -1.073 . . . . 0.0 110.482 -179.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.467 HG22 HD11 ' A' ' 85' ' ' ILE . 22.8 m -109.05 89.82 3.11 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.034 -1.041 . . . . 0.0 110.677 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.569 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -71.54 167.5 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.569 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.9 130.02 2.23 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -178.212 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.582 ' CG ' ' O ' ' A' ' 80' ' ' THR . 7.2 mt-10 -39.1 157.8 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.474 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -60.12 154.0 20.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 110.103 179.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.507 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 4.1 ptm -176.0 -168.71 0.29 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.186 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.8 t -97.82 105.17 17.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.274 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.462 HD11 ' HA3' ' A' ' 16' ' ' GLY . 27.8 tp -131.64 103.4 14.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.849 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.5 154.27 27.51 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.514 2.143 . . . . 0.0 110.336 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 132.74 -173.16 21.03 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.66 141.28 29.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.33 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.598 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.0 p-90 -160.88 175.34 12.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.834 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -148.28 154.5 42.26 Favored Pre-proline 0 C--N 1.301 -1.511 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.53 136.55 13.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.233 1.956 . . . . 0.0 110.223 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HG3' HG21 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -149.94 -169.26 3.33 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.354 -0.841 . . . . 0.0 109.387 179.669 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.441 ' SD ' ' HG3' ' A' ' 55' ' ' LYS . 9.7 mmm -145.13 118.9 9.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.117 -0.99 . . . . 0.0 109.576 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.544 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 9.9 pt -89.75 135.24 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 118.886 -1.126 . . . . 0.0 108.294 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.408 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -118.7 105.47 1.19 Allowed Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.64 -123.26 2.67 Favored Glycine 0 N--CA 1.482 1.737 0 C-N-CA 119.552 -1.309 . . . . 0.0 110.632 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.6 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 13.5 mt -87.22 121.2 37.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.88 -0.776 . . . . 0.0 112.353 -177.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 99.92 -46.16 1.42 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.45 -163.33 33.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -120.93 137.01 54.81 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.121 -1.223 . . . . 0.0 109.628 -179.838 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.46 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 2.7 pt -111.92 159.18 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.231 -0.918 . . . . 0.0 109.222 179.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -82.19 141.16 33.27 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.225 -0.922 . . . . 0.0 110.255 -179.376 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.488 HG22 ' HB3' ' A' ' 76' ' ' LEU . 2.9 m -148.22 166.32 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -113.71 107.2 15.44 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -65.83 107.63 1.87 Allowed 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.578 -0.701 . . . . 0.0 110.282 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.3 m-85 -97.27 138.68 34.38 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.545 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 21.9 m-20 -119.37 118.02 30.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.877 -1.139 . . . . 0.0 110.267 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.545 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 66.3 mt-30 87.64 55.82 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 CA-C-O 121.362 0.601 . . . . 0.0 110.283 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.518 HG13 ' HB3' ' A' ' 59' ' ' TYR . 21.8 mm -110.04 124.55 66.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.55 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -66.56 96.4 0.38 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.221 -0.924 . . . . 0.0 110.661 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.573 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 7.7 tt -105.97 115.91 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.513 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -88.47 140.88 29.02 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 109.231 -179.079 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.549 HG13 ' CG2' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -127.7 130.34 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.3 -0.875 . . . . 0.0 108.993 -179.797 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.428 ' C ' ' O ' ' A' ' 66' ' ' ILE . 58.5 m 40.64 29.66 0.07 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.607 -0.683 . . . . 0.0 109.731 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 83.33 42.62 7.85 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.415 ' O ' ' C ' ' A' ' 70' ' ' LYS . 3.0 m-70 -134.6 100.73 4.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.313 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' A' ' 69' ' ' HIS . 16.9 ttpt -46.47 122.13 3.9 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.573 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.49 101.21 3.21 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 110.44 -179.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.53 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -81.97 158.72 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 177.932 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.42 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . 177.95 -161.46 28.48 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 118.824 -1.655 . . . . 0.0 110.579 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 98.9 m -102.0 117.26 34.43 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.122 -1.222 . . . . 0.0 109.787 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.47 ' CG1' HD12 ' A' ' 15' ' ' ILE . 1.4 t -108.21 117.7 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.341 -0.85 . . . . 0.0 110.397 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.534 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 2.3 mp -86.75 107.99 18.5 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.405 -0.81 . . . . 0.0 109.213 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.489 HG22 ' CD2' ' A' ' 59' ' ' TYR . 1.4 t -91.85 114.17 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.082 -1.011 . . . . 0.0 109.875 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.85 -168.25 15.41 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.55 42.11 1.27 Allowed 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 110.201 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.582 ' O ' ' CG ' ' A' ' 34' ' ' GLU . 5.0 t -82.05 137.91 46.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.45 21.53 0.76 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.483 2.122 . . . . 0.0 111.273 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.593 ' CG1' HG13 ' A' ' 84' ' ' ILE . 1.4 t -161.03 160.65 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 120.871 -1.143 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.637 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -102.52 94.66 5.78 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 177.217 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.593 HG13 ' CG1' ' A' ' 82' ' ' VAL . 2.8 mt -94.58 128.93 45.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 CA-C-O 122.132 0.968 . . . . 0.0 113.268 -175.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.626 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -104.08 107.87 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.353 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -87.71 -168.59 44.67 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.727 -178.142 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.419 ' O ' ' C ' ' A' ' 88' ' ' ASN . 5.9 mmt180 -60.58 -32.52 71.61 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.696 -0.885 . . . . 0.0 109.953 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.601 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 15.5 p-10 -46.88 -29.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.776 -1.203 . . . . 0.0 109.14 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.601 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -106.26 -36.72 6.78 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 95' ' ' ALA . 38.0 mt -62.55 -12.78 24.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.889 -1.132 . . . . 0.0 108.694 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.473 HG23 ' HA ' ' B' ' 6' ' ' TRP . 67.4 p -100.55 -20.36 15.74 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.207 -0.933 . . . . 0.0 108.673 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.6 mm-40 -79.23 -40.86 29.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.321 -0.862 . . . . 0.0 109.089 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.54 ' CD1' ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -79.98 -15.06 13.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.162 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 100.31 15.66 29.54 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.735 178.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.571 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -56.84 146.4 26.48 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.502 -1.587 . . . . 0.0 109.673 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.547 ' CG2' HG22 ' B' ' 4' ' ' THR . 19.2 p -137.78 129.86 28.91 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.602 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 1.1 mp -87.45 98.81 11.59 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.97 -1.081 . . . . 0.0 109.444 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.535 ' C ' ' CD1' ' A' ' 99' ' ' PHE . 1.4 m120 -111.57 136.81 50.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.394 -0.816 . . . . 0.0 110.103 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.587 ' CD1' ' CB ' ' B' ' 95' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.273 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.452 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 N-CA-C 109.984 -0.814 . . . . 0.0 109.984 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -83.56 138.87 33.19 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -128.6 111.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.769 -178.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.547 HG22 ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.66 39.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.848 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.554 ' O ' ' N ' ' B' ' 7' ' ' GLN . 4.6 tp -83.93 46.0 1.14 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.107 -0.995 . . . . 0.0 110.266 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' B' ' 5' ' ' LEU . 38.0 m95 17.94 50.06 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 121.489 0.662 . . . . 0.0 112.121 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.554 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.0 mt-30 -165.62 173.76 10.53 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.14 128.1 56.65 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 121.089 -1.007 . . . . 0.0 109.043 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.536 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 35.0 Cg_endo -79.35 64.64 8.87 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.423 2.082 . . . . 0.0 110.438 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB2' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -79.43 148.35 31.97 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.161 -0.962 . . . . 0.0 109.222 -179.929 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.521 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -143.72 137.15 24.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.232 -0.917 . . . . 0.0 109.573 -179.302 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 7.1 m -69.13 98.78 1.04 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.54 ' CG2' HG13 ' B' ' 66' ' ' ILE . 10.3 pt -89.79 151.44 3.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.351 -0.843 . . . . 0.0 110.0 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.543 ' HE3' ' CG ' ' B' ' 19' ' ' LEU . 2.1 tttt -117.37 107.1 13.96 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.337 -0.852 . . . . 0.0 108.951 179.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.514 HD13 ' CD1' ' B' ' 13' ' ' ILE . 4.1 mt -113.5 139.6 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.253 -0.905 . . . . 0.0 109.205 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.62 -90.9 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -151.79 45.72 0.61 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.436 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.6 OUTLIER -140.82 169.31 17.87 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.455 -1.026 . . . . 0.0 110.035 -179.332 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.543 ' CG ' ' HE3' ' B' ' 14' ' ' LYS . 27.8 mt -139.07 113.83 9.2 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.486 ' HE2' ' HE3' ' B' ' 36' ' ' MET . 0.5 OUTLIER -136.26 163.88 29.39 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.207 -0.933 . . . . 0.0 109.115 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB2' ' CD2' ' B' ' 10' ' ' LEU . 0.0 OUTLIER -78.13 145.01 35.96 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.277 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.519 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -134.39 116.45 15.2 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.869 -1.145 . . . . 0.0 111.297 -178.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.517 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 14.6 tp -71.47 100.13 2.16 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.536 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 18.6 mt -47.18 137.44 7.96 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 179.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.578 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 42.4 t0 -142.66 94.24 2.62 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.835 -1.166 . . . . 0.0 111.422 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 6.8 m -74.89 -14.87 60.71 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.442 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -76.05 -16.18 80.87 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.478 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -97.39 160.71 14.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.32 . . . . 0.0 109.053 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -88.23 -21.14 24.67 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.014 . . . . 0.0 110.479 -179.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.616 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 1.6 m-20 -143.05 -173.83 4.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.635 -1.291 . . . . 0.0 110.858 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.559 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 52.2 m -97.54 86.02 3.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.822 -1.173 . . . . 0.0 111.578 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.578 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -67.22 153.61 8.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.423 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.532 ' CD1' HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -157.08 124.42 5.26 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.083 -1.011 . . . . 0.0 110.569 -177.722 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.439 ' HG2' ' O ' ' B' ' 80' ' ' THR . 5.7 tm-20 -43.07 153.87 0.08 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 109.078 178.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.539 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.3 tt0 -45.23 139.49 3.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 110.902 -179.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.495 ' SD ' ' N ' ' B' ' 37' ' ' SER . 2.3 ppp? -152.04 -164.4 1.96 Allowed 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.495 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -112.73 118.16 34.21 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.88 -1.138 . . . . 0.0 110.539 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.603 ' HB3' ' CZ ' ' B' ' 59' ' ' TYR . 0.2 OUTLIER -134.91 -175.08 0.45 Allowed Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.411 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.573 ' CD ' ' CB ' ' B' ' 38' ' ' LEU . 34.7 Cg_endo -79.7 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.256 1.971 . . . . 0.0 110.942 -178.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 35.93 4.63 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.35 51.75 0.75 Allowed 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.683 -0.892 . . . . 0.0 108.945 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.635 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 39.9 p-90 -137.95 179.83 6.2 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.776 0.798 . . . . 0.0 110.668 -178.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.462 ' HD3' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -140.86 146.13 42.69 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.088 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . 0.458 ' HD2' ' HG3' ' B' ' 43' ' ' LYS . 34.9 Cg_endo -78.36 138.67 15.93 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.416 2.077 . . . . 0.0 110.679 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 ptpt -160.54 -165.17 1.36 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.463 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 44.4 mtp -151.1 138.48 19.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.172 -0.955 . . . . 0.0 109.997 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.506 HG13 ' CG1' ' B' ' 54' ' ' ILE . 10.3 pt -103.71 148.3 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.114 -0.991 . . . . 0.0 108.83 178.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.596 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -119.57 116.28 3.26 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.979 -1.649 . . . . 0.0 108.979 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.448 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -137.45 -123.23 2.19 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.226 -1.464 . . . . 0.0 111.145 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.601 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 15.8 mt -84.03 133.48 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.729 -0.866 . . . . 0.0 112.694 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.46 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 85.23 -44.17 3.34 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 178.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.457 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 171.24 -171.33 43.9 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.227 -1.463 . . . . 0.0 109.95 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.596 ' CD1' ' HA2' ' B' ' 48' ' ' GLY . 7.7 m-30 -96.29 168.82 10.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.432 -1.04 . . . . 0.0 109.748 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.506 ' CG1' HG13 ' B' ' 47' ' ' ILE . 1.8 pt -142.23 177.23 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.543 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.0 mtpt -114.18 128.65 56.47 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.922 -1.111 . . . . 0.0 109.44 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.458 HG11 ' HA3' ' B' ' 78' ' ' GLY . 4.7 m -136.61 -175.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.045 -1.034 . . . . 0.0 109.987 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 66.5 mtt180 -130.23 110.97 11.97 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.405 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 2.0 tt0 -69.98 103.49 2.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.32 -0.863 . . . . 0.0 110.442 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.635 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 10.5 m-85 -89.01 141.12 28.75 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.495 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 4.0 m-20 -120.12 130.96 54.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.681 -1.262 . . . . 0.0 110.953 -178.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.563 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 69.3 62.92 0.29 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.15 0.5 . . . . 0.0 110.756 179.003 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.553 ' CD1' ' HG ' ' B' ' 38' ' ' LEU . 0.5 OUTLIER -118.48 125.64 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.164 -0.96 . . . . 0.0 108.923 178.877 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.522 ' N ' HD12 ' B' ' 72' ' ' ILE . 3.1 tm? -70.63 101.08 1.97 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.496 -0.752 . . . . 0.0 111.658 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.509 ' CD1' HD12 ' B' ' 66' ' ' ILE . 4.0 tt -101.48 122.27 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 25.5 tt0 -89.06 100.82 13.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.938 -1.101 . . . . 0.0 109.831 -178.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.54 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.1 mp -99.53 113.05 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.163 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 63.47 25.31 14.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.61 6.75 82.85 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.328 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -103.45 109.49 21.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -1.203 . . . . 0.0 109.252 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.47 133.15 35.56 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.509 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -152.98 98.16 2.28 Favored 'General case' 0 C--N 1.294 -1.831 0 O-C-N 121.257 -0.902 . . . . 0.0 109.88 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.563 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -77.97 145.5 9.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.151 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.5 -175.07 40.96 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.005 -1.569 . . . . 0.0 110.971 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.486 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 1.5 m -85.75 112.51 21.13 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.668 -0.901 . . . . 0.0 110.461 -179.195 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.502 ' O ' ' HB2' ' B' ' 59' ' ' TYR . 1.4 t -104.8 105.53 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -0.813 . . . . 0.0 110.156 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.585 ' CD1' ' CB ' ' B' ' 30' ' ' ASP . 1.1 mp -77.14 129.78 36.45 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.539 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 45.4 t -118.52 122.95 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 110.247 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.458 ' HA3' HG11 ' B' ' 56' ' ' VAL . . . -157.56 -165.41 15.19 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.543 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.9 Cg_endo -81.98 41.87 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.547 2.165 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.53 ' CG2' ' O ' ' B' ' 82' ' ' VAL . 8.9 t -79.4 141.71 57.4 Favored Pre-proline 0 N--CA 1.49 1.56 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.479 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.1 Cg_endo -77.68 14.39 1.46 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.135 1.89 . . . . 0.0 110.874 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.53 ' O ' ' CG2' ' B' ' 80' ' ' THR . 3.6 t -161.02 162.52 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.856 -1.152 . . . . 0.0 110.201 -179.219 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.519 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -102.97 99.77 9.68 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 176.665 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.578 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 4.7 mt -104.51 129.22 57.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 120.835 -1.166 . . . . 0.0 112.869 -175.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.519 HD12 ' N ' ' B' ' 85' ' ' ILE . 2.6 mm -88.51 132.39 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 176.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.616 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -107.16 -159.55 21.33 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 118.683 -1.723 . . . . 0.0 110.243 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.508 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -71.08 -30.28 66.36 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.737 -0.86 . . . . 0.0 108.762 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.559 ' OD1' ' N ' ' B' ' 31' ' ' THR . 5.8 p-10 -50.19 -40.07 45.88 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.822 -1.151 . . . . 0.0 108.897 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.538 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 0.4 OUTLIER -90.25 -32.86 16.38 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.42 -0.8 . . . . 0.0 110.027 -179.361 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.508 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 37.0 mt -67.04 -8.03 27.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.99 -1.069 . . . . 0.0 108.655 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.583 ' HB ' ' CZ3' ' A' ' 6' ' ' TRP . 31.5 p -99.43 -18.2 17.59 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.008 -1.058 . . . . 0.0 108.581 179.263 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.416 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 0.5 OUTLIER -85.01 -40.95 16.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.53 -0.731 . . . . 0.0 109.659 179.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.524 HD13 ' CG ' ' A' ' 99' ' ' PHE . 26.6 pt -83.17 -4.25 8.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.306 -0.871 . . . . 0.0 109.032 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.95 60.33 6.17 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.587 ' CB ' ' CD1' ' A' ' 99' ' ' PHE . . . -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.282 -1.128 . . . . 0.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.53 ' CG2' HG22 ' A' ' 4' ' ' THR . 10.7 p -137.56 129.49 28.86 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.602 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 5.4 mp -87.14 98.39 11.27 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.509 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.0 m120 -103.6 128.5 50.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.868 -1.145 . . . . 0.0 110.123 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.588 ' CD2' ' HD2' ' A' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.532 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.601 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.592 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 N-CA-C 109.899 -0.846 . . . . 0.0 109.899 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.523 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 25.0 tt0 -84.17 120.05 25.73 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 4' ' ' THR . 3.4 t -129.21 94.61 2.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.982 -1.074 . . . . 0.0 109.901 -178.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.629 ' O ' ' HB3' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -40.3 -68.85 0.15 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 109.404 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.629 ' HB3' ' O ' ' A' ' 4' ' ' THR . 0.0 OUTLIER 128.88 16.25 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.027 0.531 . . . . 0.0 110.121 179.4 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -48.26 -21.83 0.57 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.916 -1.115 . . . . 0.0 109.245 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.433 ' O ' ' HD3' ' B' ' 87' ' ' ARG . 29.8 mm100 -127.16 -128.81 0.23 Allowed 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.221 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.3 OUTLIER -111.04 133.61 21.25 Favored Pre-proline 0 C--N 1.306 -1.304 0 O-C-N 120.661 -1.274 . . . . 0.0 109.064 179.398 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.5 Cg_endo -79.96 51.76 4.03 Favored 'Trans proline' 0 C--N 1.313 -1.299 0 C-N-CA 122.203 1.935 . . . . 0.0 109.322 178.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -84.63 157.08 21.27 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.241 -0.912 . . . . 0.0 109.776 -179.315 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.526 ' CG2' ' CG2' ' A' ' 13' ' ' ILE . 1.2 m -149.15 131.72 6.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.501 -0.75 . . . . 0.0 109.368 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.476 HG23 ' CD2' ' A' ' 19' ' ' LEU . 25.3 m -65.02 94.8 0.14 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 177.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.526 ' CG2' ' CG2' ' A' ' 11' ' ' VAL . 13.6 pt -83.41 151.43 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.352 -0.843 . . . . 0.0 110.367 -178.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.497 ' HG3' ' CD1' ' A' ' 19' ' ' LEU . 14.0 ttmt -115.41 96.27 5.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 0.0 109.239 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.534 HG23 ' CE ' ' A' ' 36' ' ' MET . 11.8 mt -116.76 143.84 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.687 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.507 ' N ' HG21 ' A' ' 15' ' ' ILE . . . 46.96 50.91 14.4 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 48.44 46.78 29.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -144.48 163.22 34.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -1.207 . . . . 0.0 109.407 179.898 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.497 ' CD1' ' HG3' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -129.95 132.92 46.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.181 -0.95 . . . . 0.0 109.971 -179.403 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 4.0 mtmp? -151.13 177.7 9.94 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.536 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 0.4 OUTLIER -93.86 118.99 32.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.579 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -97.81 143.37 28.5 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.135 -0.978 . . . . 0.0 109.42 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.465 ' CD1' ' NH2' ' B' ' 87' ' ' ARG . 10.5 tp -107.78 94.15 4.92 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.589 -0.694 . . . . 0.0 109.524 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.494 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 15.5 mt -45.14 111.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.293 -0.879 . . . . 0.0 108.648 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.567 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 19.4 t0 -126.25 80.02 1.89 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.343 -0.848 . . . . 0.0 110.12 -178.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.8 m -54.1 -18.95 4.19 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.025 -1.047 . . . . 0.0 108.867 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -56.64 -48.73 75.03 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.62 154.88 36.39 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.25 -1.147 . . . . 0.0 109.071 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.99 -7.44 33.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.162 -0.962 . . . . 0.0 110.385 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.544 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -132.59 178.87 6.51 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.981 -1.074 . . . . 0.0 109.539 179.805 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.543 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 19.0 m -104.3 89.55 3.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.772 -1.205 . . . . 0.0 110.83 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.543 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -70.07 171.48 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.946 -1.096 . . . . 0.0 108.307 178.908 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.528 ' HG ' ' HB3' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -170.19 121.38 0.64 Allowed 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.884 -1.135 . . . . 0.0 110.488 -179.011 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.491 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 6.4 tt0 -41.4 160.52 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.448 -0.782 . . . . 0.0 109.087 178.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.56 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -48.35 146.86 2.6 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.21 -0.931 . . . . 0.0 110.681 -179.756 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.534 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -159.31 -161.93 0.99 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.302 -0.874 . . . . 0.0 109.427 179.441 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 t -108.75 101.52 10.64 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.146 -0.971 . . . . 0.0 110.168 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.63 HD22 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -121.15 178.75 1.09 Allowed Pre-proline 0 N--CA 1.493 1.683 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.518 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 35.5 Cg_endo -79.54 -158.63 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.698 2.265 . . . . 0.0 110.64 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 29.63 7.75 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.9 mtt-85 -106.29 60.87 0.65 Allowed 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 59.2 p-90 -139.62 177.89 7.62 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-O 121.772 0.796 . . . . 0.0 110.696 -178.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -135.76 140.82 34.77 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.904 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -78.37 129.81 9.67 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 C-N-CA 121.813 1.675 . . . . 0.0 111.215 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.484 ' O ' ' HG3' ' A' ' 45' ' ' LYS . 2.3 ptpt -161.99 142.57 10.44 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.534 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -107.52 147.84 30.01 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.744 -1.222 . . . . 0.0 109.675 179.688 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.55 HD12 ' CD1' ' A' ' 54' ' ' ILE . 6.1 pt -103.65 150.11 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.394 -0.816 . . . . 0.0 108.982 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.24 98.0 0.71 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.084 -1.607 . . . . 0.0 109.084 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.15 -121.98 2.86 Favored Glycine 0 N--CA 1.487 2.057 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.478 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.612 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 18.2 mt -83.83 128.98 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.584 -0.95 . . . . 0.0 112.463 -177.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.29 -46.56 2.4 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 178.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.17 -155.51 25.29 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.099 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.513 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.5 m-85 -105.94 159.3 16.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.621 -0.929 . . . . 0.0 110.24 -179.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.55 ' CD1' HD12 ' A' ' 47' ' ' ILE . 5.8 pt -137.58 159.8 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.16 124.66 48.14 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.863 -1.148 . . . . 0.0 109.643 -179.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.429 HG21 ' O ' ' A' ' 45' ' ' LYS . 27.7 m -129.15 -178.33 2.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 109.034 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.577 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -131.95 105.4 7.4 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.278 179.834 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.547 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.8 OUTLIER -58.51 95.62 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.484 -0.76 . . . . 0.0 110.105 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.634 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 8.9 m-85 -89.98 117.87 29.11 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.56 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -99.58 141.83 31.86 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.561 -1.337 . . . . 0.0 111.035 -178.012 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.581 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 29.9 mt-30 71.16 62.33 0.17 Allowed 'General case' 0 N--CA 1.492 1.671 0 CA-C-O 121.199 0.523 . . . . 0.0 111.578 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.542 ' CD1' ' HB3' ' A' ' 59' ' ' TYR . 5.1 mp -120.76 121.31 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.23 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.559 ' HA ' HG12 ' A' ' 72' ' ' ILE . 5.6 tt -68.84 91.99 0.48 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.947 -1.096 . . . . 0.0 111.074 -178.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.532 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 2.5 tt -89.09 114.74 27.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 176.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 13.8 tt0 -86.53 101.93 13.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.873 -1.142 . . . . 0.0 108.939 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.524 HG13 HG21 ' A' ' 13' ' ' ILE . 2.1 mt -103.7 126.49 58.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.634 0.731 . . . . 0.0 110.15 -178.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.569 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.1 m 44.2 67.11 0.72 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.654 -0.654 . . . . 0.0 110.261 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 67' ' ' CYS . . . 41.57 35.86 1.46 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.569 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 74.5 m-70 -130.92 101.57 5.68 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.085 -1.244 . . . . 0.0 109.163 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.483 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -50.38 128.29 19.4 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.877 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.532 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.51 102.86 3.36 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.344 -0.848 . . . . 0.0 110.386 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.581 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -79.48 151.45 4.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.027 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -174.44 -178.13 44.1 Favored Glycine 0 N--CA 1.486 2.014 0 C-N-CA 118.444 -1.836 . . . . 0.0 111.482 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.547 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 2.5 m -88.81 103.87 16.39 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.203 -0.587 . . . . 0.0 110.418 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.525 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -97.72 108.59 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.45 -0.781 . . . . 0.0 110.582 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.544 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 3.4 mp -78.78 117.47 19.93 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.176 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.56 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.2 t -103.11 119.71 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 110.382 -178.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.418 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -153.31 -168.3 16.95 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 35.9 Cg_endo -79.52 41.94 1.2 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.64 2.227 . . . . 0.0 111.088 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.491 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 3.6 t -83.43 139.86 41.6 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.059 -1.026 . . . . 0.0 108.498 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.491 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -78.23 13.82 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.322 2.015 . . . . 0.0 111.689 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.501 HG11 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.95 170.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.876 -1.14 . . . . 0.0 109.618 179.512 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.579 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -104.67 127.17 52.35 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 176.63 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.567 ' CG2' ' HB3' ' A' ' 25' ' ' ASP . 4.8 mm -112.86 128.33 69.63 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 O-C-N 120.406 -1.434 . . . . 0.0 111.04 -177.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.564 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -104.56 91.51 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.757 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -78.64 -167.8 32.8 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 110.637 -177.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.466 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.76 -34.25 72.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.639 -0.918 . . . . 0.0 110.338 -179.177 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.542 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 9.6 p-10 -48.94 -27.57 3.21 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.892 -1.13 . . . . 0.0 109.405 -179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.542 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.5 mm? -108.68 -29.38 8.74 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 121.121 -0.987 . . . . 0.0 110.034 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.54 HD21 ' CB ' ' A' ' 95' ' ' ALA . 96.7 mt -70.2 -6.27 33.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.08 -1.013 . . . . 0.0 108.463 179.024 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.435 HG22 ' HD3' ' A' ' 87' ' ' ARG . 4.8 p -98.11 -20.26 17.44 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.226 -0.921 . . . . 0.0 108.725 179.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 16.6 mm100 -83.66 -41.7 17.46 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 108.877 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.542 HD13 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -80.93 -3.74 6.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.71 64.11 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.522 -0.847 . . . . 0.0 110.999 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.557 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -62.42 136.25 57.82 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.805 -1.409 . . . . 0.0 109.709 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' B' ' 96' ' ' THR . 77.4 p -136.71 129.48 30.63 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.124 -0.985 . . . . 0.0 108.519 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HG ' HD13 ' B' ' 97' ' ' LEU . 5.3 mp -88.13 102.15 14.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.416 -0.802 . . . . 0.0 109.891 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.485 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.4 m120 -110.02 126.74 54.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.971 -1.081 . . . . 0.0 109.175 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.634 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.112 -0.993 . . . . 0.0 109.404 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.479 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.654 0 N-CA-C 109.958 -0.824 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.485 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 12.8 tt0 -82.52 139.34 33.93 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 177.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.57 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 7.0 t -132.69 100.01 3.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 117.937 -1.505 . . . . 0.0 110.811 -177.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.535 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -117.01 -70.48 0.79 Allowed 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 178.225 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.57 ' N ' ' CD2' ' B' ' 5' ' ' LEU . 3.7 mm? 34.86 31.7 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.889 -0.507 . . . . 0.0 110.225 178.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' THR . 13.0 m0 17.62 49.18 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.553 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.4 mt-30 -163.09 -162.5 0.77 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.038 -1.039 . . . . 0.0 110.162 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.413 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 8.1 mtm105 -86.94 117.97 69.4 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.232 -0.917 . . . . 0.0 110.394 -179.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.57 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.3 Cg_endo -81.99 90.24 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.144 1.896 . . . . 0.0 110.742 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.516 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 3.2 mp -79.49 171.06 15.67 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.821 -1.175 . . . . 0.0 108.565 179.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.474 HG11 ' O ' ' B' ' 10' ' ' LEU . 3.1 m -150.68 130.99 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.001 -1.062 . . . . 0.0 110.812 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.09 88.11 0.59 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 177.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.512 ' CG2' HG13 ' B' ' 66' ' ' ILE . 1.1 pt -90.09 157.36 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 111.118 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.48 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 3.1 tttt -122.78 109.15 13.85 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.532 ' CD1' HG12 ' B' ' 75' ' ' VAL . 3.0 mt -122.97 119.52 58.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.092 -1.005 . . . . 0.0 109.24 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.36 26.95 74.0 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -5.46 67.99 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.437 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -85.8 169.95 12.88 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.248 -1.148 . . . . 0.0 109.29 179.911 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.48 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 2.4 mt -139.8 128.22 22.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.311 -0.868 . . . . 0.0 109.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.401 ' CG ' ' C ' ' B' ' 19' ' ' LEU . 3.0 mtpp -151.23 149.94 30.01 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.434 -0.791 . . . . 0.0 109.118 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.516 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.7 OUTLIER -79.64 102.16 8.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.093 -1.005 . . . . 0.0 108.469 179.277 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.549 ' CB ' HD12 ' B' ' 85' ' ' ILE . . . -80.04 142.84 34.56 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 122.0 0.905 . . . . 0.0 110.825 -178.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -92.62 104.26 16.57 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.486 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 4.6 mt -46.29 110.48 0.28 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.878 -1.138 . . . . 0.0 108.593 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.603 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 1.0 OUTLIER -118.81 86.71 2.59 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.871 -178.553 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.429 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 0.2 OUTLIER -68.63 -7.88 37.06 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.023 -1.048 . . . . 0.0 108.704 178.488 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.552 ' HA3' ' CB ' ' A' ' 25' ' ' ASP . . . -81.24 -38.84 13.85 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.498 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -72.27 147.13 46.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.2 -1.176 . . . . 0.0 109.173 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.492 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 4.9 m-20 -82.83 -16.55 47.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 110.737 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.544 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 7.0 m-20 -138.04 -167.88 2.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.935 -1.103 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.589 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 43.0 m -110.57 94.24 4.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.787 -1.196 . . . . 0.0 110.782 -178.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.76 172.3 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.872 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.4 122.35 1.75 Allowed 'General case' 0 C--N 1.308 -1.225 0 O-C-N 120.775 -1.203 . . . . 0.0 110.822 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.532 ' CG ' ' O ' ' B' ' 80' ' ' THR . 0.3 OUTLIER -35.6 154.13 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.777 -0.577 . . . . 0.0 109.689 179.127 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.519 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.3 mt-10 -47.79 149.06 1.37 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.241 -0.912 . . . . 0.0 110.231 -179.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.472 ' HG3' ' CD2' ' B' ' 38' ' ' LEU . 6.1 ptm -173.45 -163.99 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.391 -0.818 . . . . 0.0 109.592 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.1 t -110.95 103.72 12.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.204 -0.935 . . . . 0.0 110.279 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.557 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -103.38 173.38 3.48 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.557 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.1 Cg_endo -73.9 -162.26 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.996 1.798 . . . . 0.0 110.516 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -100.21 -166.07 28.86 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.304 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.41 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 21.5 mmm180 58.83 70.12 0.68 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.672 -0.899 . . . . 0.0 109.152 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 21.4 p-90 -141.44 -169.89 2.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -151.02 134.1 8.77 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.175 -0.953 . . . . 0.0 108.807 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.31 137.35 16.77 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.838 1.692 . . . . 0.0 110.567 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.517 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -160.97 133.79 6.29 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.724 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 63.1 mtp -91.73 131.93 36.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.131 -0.981 . . . . 0.0 109.797 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' B' ' 53' ' ' PHE . 8.8 pt -89.36 143.96 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 101.22 0.89 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.25 -121.81 2.92 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.744 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.588 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 20.5 mt -84.87 117.38 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.852 -0.793 . . . . 0.0 112.695 -177.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.473 ' HA2' HG21 ' A' ' 54' ' ' ILE . . . 104.16 -53.32 0.71 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 178.314 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -178.4 -157.12 18.43 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.543 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -118.0 135.79 53.94 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.311 -1.111 . . . . 0.0 109.873 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.501 HD13 HG11 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -106.48 -177.48 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.909 . . . . 0.0 108.926 179.189 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.534 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 36.8 mtmt -111.52 135.82 51.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.019 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.517 ' CG2' ' O ' ' B' ' 45' ' ' LYS . 17.5 m -142.77 177.07 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.843 -1.161 . . . . 0.0 110.636 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.35 100.72 6.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.492 -0.755 . . . . 0.0 109.241 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -62.87 110.11 1.66 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.265 -0.897 . . . . 0.0 110.909 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.616 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 16.0 m-85 -106.92 132.35 52.96 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 177.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.508 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.7 m-20 -108.6 134.1 51.82 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.937 -1.102 . . . . 0.0 110.49 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 45.0 mt-30 78.14 61.37 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.904 -0.497 . . . . 0.0 111.178 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.553 ' CD1' ' HB3' ' B' ' 59' ' ' TYR . 3.0 mp -112.83 120.99 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 178.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.52 ' N ' HD12 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -65.07 86.44 0.06 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 110.958 -178.656 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.565 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 8.6 tt -94.49 110.7 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.3 tt0 -89.04 117.21 27.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.051 -1.031 . . . . 0.0 109.464 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.512 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.8 mp -116.33 140.95 36.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 121.746 0.784 . . . . 0.0 109.845 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.504 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 0.9 OUTLIER 47.42 39.17 8.7 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.681 -0.637 . . . . 0.0 109.778 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.2 48.28 83.9 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.504 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 80.7 m-70 -145.38 108.88 4.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.247 -1.149 . . . . 0.0 109.384 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.456 ' HG2' HD23 ' B' ' 63' ' ' LEU . 0.3 OUTLIER -48.26 127.38 12.67 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.305 -0.872 . . . . 0.0 108.883 179.709 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -149.12 104.8 3.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.334 -0.854 . . . . 0.0 109.355 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -83.86 160.31 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.107 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.563 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.34 -157.24 17.87 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.419 -1.848 . . . . 0.0 111.952 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.48 HG21 ' O ' ' B' ' 59' ' ' TYR . 4.8 m -111.95 109.81 19.79 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.632 -0.922 . . . . 0.0 109.557 -179.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.532 HG12 ' CD1' ' B' ' 15' ' ' ILE . 1.6 t -105.03 127.75 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.521 -0.737 . . . . 0.0 111.22 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.483 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.8 mp -96.83 116.22 28.78 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 13.1 t -96.9 114.96 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.709 -1.244 . . . . 0.0 109.984 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -149.72 -174.12 20.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.534 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -79.78 41.83 1.19 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.493 2.129 . . . . 0.0 111.234 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.532 ' O ' ' CG ' ' B' ' 34' ' ' GLU . 9.1 t -80.68 141.01 51.45 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.76 13.44 1.68 Allowed 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.274 1.983 . . . . 0.0 111.232 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.522 ' CG1' HD13 ' B' ' 84' ' ' ILE . 0.8 OUTLIER -160.31 173.83 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.921 -1.112 . . . . 0.0 109.677 -179.754 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.542 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -109.68 138.57 45.85 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 176.625 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.603 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 4.7 mm -124.6 123.33 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.438 -1.414 . . . . 0.0 111.762 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.549 HD12 ' CB ' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -97.26 89.82 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.344 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.544 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.04 -157.59 11.58 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.891 -1.147 . . . . 0.0 111.612 -177.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.492 ' NH2' ' OD1' ' B' ' 29' ' ' ASP . 31.1 mtt180 -68.19 -35.62 78.28 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.915 -0.756 . . . . 0.0 111.407 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.589 ' OD1' ' N ' ' B' ' 31' ' ' THR . 2.6 p-10 -55.57 -24.23 31.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.461 -1.399 . . . . 0.0 110.044 -179.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.581 HD21 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -106.77 -18.41 13.95 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.999 -1.063 . . . . 0.0 110.26 -178.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' B' ' 86' ' ' GLY . 64.5 mt -71.95 -24.45 61.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 108.899 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.448 HG21 HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -81.94 -14.09 56.58 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.092 -1.005 . . . . 0.0 109.839 179.863 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.1 -40.85 23.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.99 -1.069 . . . . 0.0 109.164 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.616 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -87.26 -13.07 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.305 -0.872 . . . . 0.0 108.755 179.43 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.69 51.12 9.79 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.502 ' HA ' ' HB3' ' A' ' 99' ' ' PHE . . . -75.86 147.27 39.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 108.851 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 96' ' ' THR . 72.6 p -130.76 127.29 38.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 108.908 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.554 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.0 mp -91.58 91.06 7.87 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.516 -0.74 . . . . 0.0 109.182 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.523 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.7 m120 -96.22 125.53 40.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.148 -0.97 . . . . 0.0 109.92 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.592 ' CE2' ' HG2' ' A' ' 1' ' ' PRO . 0.4 OUTLIER . . . . . 0 C--N 1.301 -1.526 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.335 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.612 ' H32' ' CG1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.59 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.498 1.768 0 N-CA-C 110.064 -0.783 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.505 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.91 129.11 34.86 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.85 -1.156 . . . . 0.0 108.05 178.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 77.8 t -131.37 124.81 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.915 -1.115 . . . . 0.0 110.184 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 7.6 p -64.57 -104.01 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.516 ' CB ' ' O ' ' A' ' 4' ' ' THR . 0.6 OUTLIER 167.04 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.866 -1.146 . . . . 0.0 110.721 179.407 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 38.1 m95 -65.56 -18.66 65.49 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.809 -1.182 . . . . 0.0 108.507 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.424 ' O ' ' C ' ' A' ' 8' ' ' ARG . 23.2 mt-30 -147.3 159.64 43.43 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.459 ' HD3' ' OD2' ' B' ' 29' ' ' ASP . 16.0 mtm180 -44.04 141.15 2.52 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.003 . . . . 0.0 109.22 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.46 ' HB2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.61 60.57 7.91 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.478 2.119 . . . . 0.0 109.921 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.485 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -81.66 142.72 32.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.243 -0.91 . . . . 0.0 109.97 -179.484 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.434 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -140.99 155.62 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.46 -0.775 . . . . 0.0 109.283 -179.795 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.0 m -83.96 101.94 12.08 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 178.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.551 HG22 ' CB ' ' A' ' 22' ' ' ALA . 14.7 pt -96.31 158.66 3.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.286 -0.884 . . . . 0.0 110.341 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 3.7 tttt -120.71 103.95 9.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.433 -0.792 . . . . 0.0 109.88 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.516 HD11 ' CG1' ' A' ' 75' ' ' VAL . 10.6 mt -119.25 134.35 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.079 -1.013 . . . . 0.0 109.588 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.96 44.24 98.08 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.08 17.72 24.33 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.63 178.09 4.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.444 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.497 HD22 ' HA ' ' A' ' 14' ' ' LYS . 16.6 mt -138.61 126.34 22.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.447 -0.783 . . . . 0.0 109.826 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.473 ' HD3' ' O ' ' A' ' 19' ' ' LEU . 35.8 mmtt -144.45 -179.31 6.47 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.53 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 2.9 mt-10 -88.04 164.58 15.69 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.098 -1.001 . . . . 0.0 108.713 179.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.551 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -147.97 116.68 6.69 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.688 -1.258 . . . . 0.0 110.966 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.547 ' O ' ' N ' ' A' ' 25' ' ' ASP . 16.8 tp -82.05 94.12 7.13 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.495 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 63.7 mt -49.69 93.2 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.547 ' N ' ' O ' ' A' ' 23' ' ' LEU . 26.8 t0 -107.67 87.21 2.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 110.744 -178.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.49 ' CG2' HD11 ' A' ' 90' ' ' LEU . 1.2 m -60.74 -13.81 17.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.051 -1.031 . . . . 0.0 108.638 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.508 ' CA ' HD22 ' B' ' 23' ' ' LEU . . . -63.41 -43.69 97.9 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -70.4 171.52 9.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.008 -1.289 . . . . 0.0 110.069 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.486 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -98.54 -20.51 17.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.34 -0.85 . . . . 0.0 110.603 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.516 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 36.6 m-20 -140.23 -162.9 1.42 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.922 -1.111 . . . . 0.0 109.604 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.498 ' CG2' ' CD1' ' A' ' 33' ' ' LEU . 23.5 m -107.28 89.99 3.17 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.69 -1.256 . . . . 0.0 110.931 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.56 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.67 164.95 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.745 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.56 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.58 127.58 2.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.727 -1.233 . . . . 0.0 111.426 -178.742 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.594 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.2 OUTLIER -42.48 153.29 0.08 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 179.03 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.532 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.4 OUTLIER -50.54 146.34 5.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.053 -1.029 . . . . 0.0 109.868 -179.821 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.468 ' CE ' HG21 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -156.42 -162.77 1.32 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.485 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.5 t -112.73 101.0 9.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.05 -1.031 . . . . 0.0 110.362 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.621 HD22 ' CG ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -108.49 160.03 28.65 Favored Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.503 ' HD3' HD13 ' A' ' 38' ' ' LEU . 34.5 Cg_endo -75.96 69.32 6.29 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.784 2.323 . . . . 0.0 111.867 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.506 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . 37.43 -159.62 0.01 OUTLIER Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 1.3 mpt_? 64.07 68.47 0.56 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.541 -0.976 . . . . 0.0 109.912 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.575 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 64.3 p-90 -152.7 -178.24 6.75 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.653 -0.654 . . . . 0.0 110.001 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.5 mtpt -146.2 137.21 12.62 Favored Pre-proline 0 N--CA 1.49 1.537 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.14 138.35 16.09 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.224 1.95 . . . . 0.0 111.182 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.466 ' HD2' HD21 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -152.58 -163.19 1.66 Allowed 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.242 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.51 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 1.7 mtt -149.42 126.11 11.06 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.957 -1.089 . . . . 0.0 110.371 -179.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.532 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 6.8 pt -90.07 146.44 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.45 118.62 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.41 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -146.3 -127.41 1.85 Allowed Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.291 -1.433 . . . . 0.0 111.228 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.549 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 25.2 mt -81.68 123.85 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.957 -0.731 . . . . 0.0 112.401 -177.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.473 ' HA2' HG21 ' B' ' 54' ' ' ILE . . . 95.78 -50.11 1.78 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 178.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.423 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 175.14 -168.12 40.51 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.4 OUTLIER -107.31 132.53 53.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.085 -1.244 . . . . 0.0 109.711 -179.632 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.532 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 10.3 pt -101.74 163.4 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.238 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.55 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 35.6 mtmt -96.59 138.38 34.26 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.112 -0.993 . . . . 0.0 108.867 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.442 HG22 HD21 ' A' ' 76' ' ' LEU . 30.6 m -138.36 177.93 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 120.75 -1.219 . . . . 0.0 110.146 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.488 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -118.17 92.3 3.79 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.431 -0.793 . . . . 0.0 108.919 -179.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.545 ' CG ' ' OD1' ' A' ' 60' ' ' ASP . 16.2 tt0 -53.56 107.69 0.27 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.507 -0.745 . . . . 0.0 110.236 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.621 ' CG ' HD22 ' A' ' 38' ' ' LEU . 15.1 m-85 -105.02 95.51 5.89 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' ' CG ' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -79.01 139.62 38.14 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.867 -1.146 . . . . 0.0 111.061 -178.39 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.518 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 47.0 mt-30 68.36 63.57 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.133 0.492 . . . . 0.0 111.66 178.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.48 ' HB ' HG21 ' A' ' 75' ' ' VAL . 0.8 OUTLIER -122.67 124.78 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.543 ' C ' ' CD1' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -66.65 86.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.914 -178.342 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.519 HG12 ' CD1' ' A' ' 66' ' ' ILE . 3.6 tt -87.74 123.83 40.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 176.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.496 ' HG2' ' N ' ' A' ' 66' ' ' ILE . 8.6 tt0 -88.59 148.37 24.11 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.069 -1.019 . . . . 0.0 109.349 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.519 ' CD1' HG12 ' A' ' 64' ' ' ILE . 0.8 OUTLIER -150.19 115.35 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.501 ' SG ' ' CG ' ' A' ' 1' ' ' PRO . 0.8 OUTLIER 68.23 5.06 4.46 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.581 -0.7 . . . . 0.0 110.127 179.695 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.405 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 108.27 -3.39 33.11 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -90.2 131.31 36.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.06 -1.259 . . . . 0.0 109.318 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.538 ' CG ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.75 103.9 11.76 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 121.047 -1.033 . . . . 0.0 108.471 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.489 ' O ' HD12 ' A' ' 63' ' ' LEU . . . -112.79 151.19 30.63 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 120.361 -0.535 . . . . 0.0 109.838 -179.192 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.537 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.6 OUTLIER -122.42 146.32 27.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 177.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -173.75 -162.42 25.56 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 118.429 -1.843 . . . . 0.0 111.063 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 10.3 m -100.28 104.92 16.42 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.676 -0.896 . . . . 0.0 110.056 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.516 ' CG1' HD11 ' A' ' 15' ' ' ILE . 1.2 t -95.12 105.36 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.518 -0.739 . . . . 0.0 109.349 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.9 mp -78.57 118.07 20.34 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.532 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 2.0 t -106.9 111.09 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.145 -0.972 . . . . 0.0 110.443 -179.002 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -145.65 -157.48 7.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.55 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.14 38.8 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.509 2.139 . . . . 0.0 110.34 179.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.594 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.9 t -83.58 132.78 48.3 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.441 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 36.8 Cg_endo -79.9 19.11 1.05 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.467 2.111 . . . . 0.0 111.558 -178.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.1 t -161.46 156.77 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.763 -1.21 . . . . 0.0 109.929 -179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -95.64 91.0 5.91 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.665 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.53 ' CG1' HG11 ' A' ' 32' ' ' VAL . 3.6 mm -78.54 122.74 34.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 121.418 -0.801 . . . . 0.0 112.085 -176.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.545 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -101.02 91.78 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 176.894 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.44 -157.98 13.51 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.912 -177.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.486 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -68.87 -37.66 79.19 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 122.023 -0.692 . . . . 0.0 109.828 -178.958 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.598 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 13.0 p-10 -45.71 -28.51 1.04 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.933 -1.104 . . . . 0.0 109.52 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.598 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.5 mm? -109.08 -27.03 9.85 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.259 -0.9 . . . . 0.0 110.499 -178.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.49 HD11 ' CG2' ' A' ' 26' ' ' THR . 70.0 mt -72.09 -7.88 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.82 -1.175 . . . . 0.0 109.194 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.469 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -98.15 -11.75 22.47 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.004 -1.06 . . . . 0.0 108.242 178.699 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.462 ' NE2' ' O ' ' A' ' 88' ' ' ASN . 75.4 mt-30 -90.49 -40.71 11.84 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.579 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -82.91 0.59 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.471 -0.768 . . . . 0.0 108.965 179.164 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.15 32.83 57.91 Favored Glycine 0 N--CA 1.495 2.617 0 C-N-CA 120.575 -0.822 . . . . 0.0 111.147 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.522 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -65.45 140.08 58.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.941 -1.329 . . . . 0.0 110.715 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' B' ' 96' ' ' THR . 58.9 p -137.33 126.19 24.11 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.533 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 5.1 mp -88.43 91.94 8.99 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.239 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.462 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 4.6 m120 -103.51 121.41 42.81 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.127 -0.983 . . . . 0.0 109.448 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.57 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.361 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.55 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 2.3 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 109.875 -0.856 . . . . 0.0 109.875 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.483 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 4.3 tt0 -122.26 142.41 50.49 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 177.11 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.483 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 38.4 t -142.48 102.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.192 -178.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.599 ' O ' ' C ' ' B' ' 5' ' ' LEU . 63.7 p -89.62 -30.13 18.36 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 178.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.599 ' C ' ' O ' ' B' ' 4' ' ' THR . 0.5 OUTLIER 13.14 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.832 -179.892 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.423 ' C ' ' O ' ' B' ' 5' ' ' LEU . 2.2 m95 -37.91 -22.23 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.038 -178.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.576 ' N ' ' O ' ' B' ' 5' ' ' LEU . 20.3 mp0 -107.94 -161.85 0.8 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.715 -1.241 . . . . 0.0 107.983 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.484 ' HB3' HD13 ' B' ' 23' ' ' LEU . 19.1 mtt180 -53.84 124.57 44.06 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 120.478 -1.389 . . . . 0.0 109.589 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.551 ' HA ' ' CD1' ' B' ' 5' ' ' LEU . 37.0 Cg_endo -77.7 71.01 6.7 Favored 'Trans proline' 0 C--N 1.316 -1.159 0 C-N-CA 122.331 2.021 . . . . 0.0 110.401 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 1.6 mt -78.95 143.1 36.12 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.888 -1.132 . . . . 0.0 110.356 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.481 HG22 HG21 ' B' ' 13' ' ' ILE . 1.3 m -130.76 139.92 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.509 -0.744 . . . . 0.0 109.639 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.0 m -67.49 108.01 2.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.918 -1.114 . . . . 0.0 108.279 178.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.506 HG21 HG13 ' B' ' 66' ' ' ILE . 1.2 pp -106.02 140.43 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.081 -1.012 . . . . 0.0 110.865 -178.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.533 ' CG ' ' HG ' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -109.05 106.53 16.5 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.306 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.548 HD12 ' CG1' ' B' ' 75' ' ' VAL . 15.0 mt -124.48 124.99 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 O-C-N 121.164 -0.96 . . . . 0.0 109.524 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.77 20.01 71.89 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -4.33 86.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -93.47 -178.17 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.115 -1.227 . . . . 0.0 108.908 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.533 ' HG ' ' CG ' ' B' ' 14' ' ' LYS . 4.3 mt -153.65 125.58 7.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.132 -0.98 . . . . 0.0 110.499 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.471 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -145.94 168.79 20.01 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.012 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 6.5 mt-10 -79.28 157.87 27.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.758 -1.214 . . . . 0.0 108.401 179.399 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.548 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -139.34 113.96 9.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.96 -1.087 . . . . 0.0 110.691 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.508 HD22 ' CA ' ' A' ' 27' ' ' GLY . 0.9 OUTLIER -67.75 95.36 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.031 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.472 ' HG ' HG12 ' B' ' 11' ' ' VAL . 86.2 mt -44.51 102.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.568 ' CB ' HG22 ' B' ' 84' ' ' ILE . 4.8 t70 -101.37 93.53 5.46 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.474 -0.766 . . . . 0.0 110.753 -178.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.451 HG23 HD23 ' B' ' 97' ' ' LEU . 5.6 m -76.4 3.89 10.16 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.114 -0.991 . . . . 0.0 109.004 178.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.546 ' HA3' ' CB ' ' A' ' 25' ' ' ASP . . . -99.67 -24.42 10.03 Favored Glycine 0 N--CA 1.485 1.933 0 C-N-CA 120.056 -1.069 . . . . 0.0 110.743 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.517 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -82.25 168.46 17.61 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.829 -1.395 . . . . 0.0 109.949 -179.319 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.459 ' OD2' ' HD3' ' A' ' 8' ' ' ARG . 0.9 OUTLIER -101.31 -20.3 15.28 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.366 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.561 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -131.86 -174.83 3.53 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 -179.598 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.472 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 53.2 m -105.33 83.44 1.96 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.676 -1.265 . . . . 0.0 110.315 -178.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.569 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.45 167.16 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.035 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.569 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.41 123.86 2.26 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.051 -1.031 . . . . 0.0 110.441 -178.694 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.495 ' HA ' HG23 ' B' ' 80' ' ' THR . 0.0 OUTLIER -39.49 160.0 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.551 -0.718 . . . . 0.0 109.381 179.17 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.462 ' O ' ' OE1' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -39.62 146.71 0.1 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.387 -0.821 . . . . 0.0 110.449 -179.572 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.529 ' CE ' HG23 ' B' ' 15' ' ' ILE . 3.0 ppp? -166.4 163.04 17.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.441 -0.787 . . . . 0.0 109.046 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.3 t -95.82 105.04 17.0 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.043 -1.036 . . . . 0.0 109.753 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.569 HD22 ' CG ' ' B' ' 59' ' ' TYR . 9.2 tp -122.43 106.17 35.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.372 -0.83 . . . . 0.0 108.932 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.33 140.39 19.43 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.375 2.05 . . . . 0.0 111.125 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 128.23 31.52 0.67 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.474 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 52.88 166.62 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.84 -0.8 . . . . 0.0 110.014 179.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.574 ' CD2' ' HD3' ' B' ' 57' ' ' ARG . 0.2 OUTLIER -160.98 178.49 9.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.138 -0.976 . . . . 0.0 109.769 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -125.88 104.52 26.7 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.76 138.61 41.61 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.025 1.817 . . . . 0.0 112.355 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -150.62 -155.61 0.64 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.526 ' CE ' ' HB3' ' B' ' 53' ' ' PHE . 32.2 mtp -148.13 126.55 12.35 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.026 -1.046 . . . . 0.0 110.312 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.534 HD12 ' CD1' ' B' ' 54' ' ' ILE . 7.3 pt -93.24 142.38 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.93 113.75 2.64 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.421 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -138.12 -123.94 2.21 Favored Glycine 0 N--CA 1.483 1.811 0 C-N-CA 119.525 -1.322 . . . . 0.0 110.493 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.606 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 25.6 mt -84.77 119.27 33.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.793 -0.827 . . . . 0.0 112.384 -177.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 103.83 -53.01 0.73 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 178.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.89 -161.79 27.83 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.171 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -111.84 128.86 56.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.459 -1.024 . . . . 0.0 109.241 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.534 ' CD1' HD12 ' B' ' 47' ' ' ILE . 16.3 pt -107.38 162.59 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.876 -1.14 . . . . 0.0 109.016 179.118 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.6 mptm? -94.53 147.58 23.12 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.153 -0.967 . . . . 0.0 108.88 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 27.5 m -144.94 -170.77 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 120.768 -1.207 . . . . 0.0 110.254 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.574 ' HD3' ' CD2' ' B' ' 42' ' ' TRP . 18.6 mtt85 -131.46 111.24 11.62 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -77.61 101.3 6.49 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.566 -0.709 . . . . 0.0 111.07 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.573 ' OH ' ' CD1' ' B' ' 42' ' ' TRP . 62.7 m-85 -96.18 129.74 43.41 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 14.5 m-20 -109.19 122.45 47.34 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.692 -1.255 . . . . 0.0 110.895 -178.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.546 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 3.0 mt-30 86.1 56.11 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 CA-C-O 121.31 0.576 . . . . 0.0 110.472 179.069 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.492 ' HB ' HG22 ' B' ' 75' ' ' VAL . 4.0 mm -111.27 128.07 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.533 HD23 ' CG ' ' B' ' 70' ' ' LYS . 2.3 tm? -73.84 102.26 4.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.181 -0.95 . . . . 0.0 111.293 -178.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.598 ' CG2' ' CD1' ' B' ' 89' ' ' LEU . 0.9 OUTLIER -105.59 106.11 19.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 177.579 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.4 OUTLIER -90.0 119.69 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.983 -1.073 . . . . 0.0 109.206 -178.821 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.532 HD13 ' CD1' ' B' ' 64' ' ' ILE . 1.5 mp -111.54 128.78 67.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.477 -0.765 . . . . 0.0 109.364 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.482 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 15.5 m 65.55 -89.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.752 -0.593 . . . . 0.0 109.629 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.88 39.15 0.74 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -139.36 131.91 28.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.566 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.533 ' CG ' HD23 ' B' ' 63' ' ' LEU . 15.6 ttmt -70.74 129.11 38.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.125 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.567 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -142.25 95.19 2.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.156 -0.965 . . . . 0.0 110.435 -179.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.522 HG12 ' HA ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.99 156.77 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.712 -1.243 . . . . 0.0 108.06 178.297 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.508 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 176.05 -170.59 43.52 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.674 -1.727 . . . . 0.0 111.213 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 85.9 m -88.68 112.54 23.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.848 -0.795 . . . . 0.0 110.575 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.548 ' CG1' HD12 ' B' ' 15' ' ' ILE . 0.7 OUTLIER -105.18 107.8 23.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.7 -0.625 . . . . 0.0 110.155 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.561 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 4.0 mp -82.63 121.82 27.32 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 108.853 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' B' ' 57' ' ' ARG . 69.1 t -109.3 132.04 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.058 -1.026 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -162.8 -159.89 10.76 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.43 36.1 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.651 2.234 . . . . 0.0 110.733 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.495 HG23 ' HA ' ' B' ' 34' ' ' GLU . 4.0 t -81.6 136.64 48.37 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.446 ' O ' HG21 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.5 16.36 1.43 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.322 2.015 . . . . 0.0 111.269 -178.581 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.527 HG11 HG13 ' B' ' 84' ' ' ILE . 2.2 t -161.84 148.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 120.88 -1.138 . . . . 0.0 110.108 -179.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.548 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -86.61 102.12 13.87 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 105.922 -1.881 . . . . 0.0 105.922 176.749 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.568 HG22 ' CB ' ' B' ' 25' ' ' ASP . 2.4 mt -101.74 126.66 55.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.856 -1.153 . . . . 0.0 112.137 -175.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.524 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 1.5 mm -97.08 121.85 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 177.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.535 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -102.58 -147.42 19.17 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.592 -1.289 . . . . 0.0 111.551 -178.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.509 ' O ' ' OG1' ' B' ' 91' ' ' THR . 11.6 mtp180 -69.08 -40.86 78.18 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 122.074 -0.662 . . . . 0.0 111.388 -178.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.596 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 15.2 p-10 -53.78 -30.47 44.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.798 -1.188 . . . . 0.0 111.254 -178.081 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.598 ' CD1' ' CG2' ' B' ' 64' ' ' ILE . 2.8 mm? -104.44 -28.58 11.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.492 -1.38 . . . . 0.0 110.914 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.52 ' N ' ' CD2' ' B' ' 90' ' ' LEU . 0.1 OUTLIER -68.2 -9.58 47.99 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.712 -1.242 . . . . 0.0 109.151 179.745 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.22 -20.44 15.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.775 -1.203 . . . . 0.0 108.831 179.154 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 46.6 mm-40 -77.89 -41.05 37.93 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.237 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 1.1 pt -81.4 -8.17 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.38 35.77 55.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.567 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -61.56 152.18 31.12 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.824 -1.398 . . . . 0.0 109.288 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 96' ' ' THR . 21.5 p -142.27 124.72 15.69 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.151 -0.968 . . . . 0.0 108.889 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.533 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 4.8 mp -86.25 91.08 8.36 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.444 -0.785 . . . . 0.0 109.505 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.522 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -93.92 121.98 35.94 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.049 -1.032 . . . . 0.0 109.227 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.606 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 118.045 -0.979 . . . . 0.0 109.477 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.606 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 3.8 Cg_exo . . . . . 0 N--CA 1.497 1.686 0 N-CA-C 110.663 -0.553 . . . . 0.0 110.663 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.502 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -84.37 136.73 33.76 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.102 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.468 ' O ' ' HG ' ' A' ' 5' ' ' LEU . 55.7 t -133.55 115.03 21.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 120.734 -1.229 . . . . 0.0 109.918 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 72.6 p -58.8 -12.59 4.53 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.698 -0.626 . . . . 0.0 110.218 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.559 ' CD2' ' CG2' ' B' ' 26' ' ' THR . 0.7 OUTLIER 80.59 -6.6 1.66 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.443 -0.785 . . . . 0.0 110.298 179.398 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.617 ' CZ3' HG23 ' B' ' 91' ' ' THR . 39.8 m95 -53.88 -20.43 5.94 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.949 -1.094 . . . . 0.0 108.848 179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.11 157.54 46.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 108.914 179.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.421 ' HA ' ' CZ ' ' B' ' 87' ' ' ARG . 4.0 mtm180 -66.92 122.99 84.94 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.155 -0.965 . . . . 0.0 109.595 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.576 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.0 Cg_endo -76.1 80.09 2.76 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 121.927 1.751 . . . . 0.0 109.429 178.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -90.0 149.34 22.59 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.589 -0.695 . . . . 0.0 109.606 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.495 HG21 ' CB ' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -150.9 159.33 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.192 -0.942 . . . . 0.0 110.377 -179.063 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.542 ' CG2' HD21 ' A' ' 19' ' ' LEU . 14.1 m -94.88 104.82 16.71 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.533 ' HB ' HG13 ' A' ' 64' ' ' ILE . 2.2 pt -89.22 141.1 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.177 -0.952 . . . . 0.0 110.389 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.441 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 29.5 ttmt -106.34 97.27 7.09 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.541 HG21 ' CG2' ' A' ' 62' ' ' ILE . 16.8 mt -113.53 120.55 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.147 -0.97 . . . . 0.0 110.06 -179.155 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.23 37.65 94.81 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.1 6.4 56.72 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.3 mm-40 -97.48 163.25 12.94 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.201 -1.176 . . . . 0.0 109.216 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.542 HD21 ' CG2' ' A' ' 12' ' ' THR . 0.1 OUTLIER -136.89 126.59 25.48 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.293 -0.879 . . . . 0.0 110.798 -179.507 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.496 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.8 mttp -150.45 179.95 7.73 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.061 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.03 -174.67 4.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.876 -1.14 . . . . 0.0 108.891 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.521 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -162.25 121.14 2.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.031 -1.043 . . . . 0.0 110.001 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.519 ' O ' ' N ' ' A' ' 25' ' ' ASP . 46.5 tp -102.61 95.42 6.21 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.449 -0.782 . . . . 0.0 109.301 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.576 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 17.1 mt -43.33 96.24 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.078 -1.013 . . . . 0.0 109.417 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -101.21 81.62 2.24 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.511 -0.743 . . . . 0.0 110.121 -179.493 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.527 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 4.3 m -61.89 -20.64 63.96 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.989 -1.07 . . . . 0.0 108.936 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.455 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -59.32 -45.49 95.35 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.525 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -71.96 157.56 37.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.377 -1.072 . . . . 0.0 108.729 179.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -92.01 -10.26 39.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.06 -1.025 . . . . 0.0 110.3 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.24 -173.46 3.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.956 -1.09 . . . . 0.0 110.053 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.555 HG23 ' CD1' ' A' ' 33' ' ' LEU . 33.4 m -103.23 89.01 3.27 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.265 -0.897 . . . . 0.0 111.281 -178.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.563 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.42 172.15 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.55 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.563 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -168.68 132.7 1.51 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.085 -1.009 . . . . 0.0 110.571 -178.966 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.456 ' O ' ' O ' ' A' ' 33' ' ' LEU . 20.6 mt-10 -41.46 161.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.7 OUTLIER -61.36 143.7 55.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.036 -1.04 . . . . 0.0 110.043 -179.46 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.476 ' HE2' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -160.1 -179.76 8.04 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.331 -0.855 . . . . 0.0 109.645 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.4 t -92.89 100.0 12.54 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 109.924 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.63 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 12.6 mt -106.45 173.28 3.26 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.7 Cg_endo -78.18 50.11 3.22 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.327 2.018 . . . . 0.0 112.735 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 34.75 -158.53 0.01 OUTLIER Glycine 0 N--CA 1.498 2.769 0 O-C-N 121.478 -0.763 . . . . 0.0 111.529 178.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.451 ' HG3' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER 53.8 80.33 0.11 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.547 -0.973 . . . . 0.0 109.442 -179.54 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 2.9 p-90 -145.93 -167.85 2.83 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-O 121.506 0.67 . . . . 0.0 109.697 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.44 116.01 11.82 Favored Pre-proline 0 C--N 1.303 -1.433 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.169 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -70.59 138.76 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 121.848 1.698 . . . . 0.0 111.731 -178.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.461 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -158.61 133.09 8.05 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.457 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.8 OUTLIER -94.03 123.56 37.48 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 -179.729 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.535 ' CD1' HG23 ' B' ' 50' ' ' ILE . 6.9 pt -92.38 148.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.814 -1.179 . . . . 0.0 108.679 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.504 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -118.39 101.86 0.92 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.764 -1.735 . . . . 0.0 108.764 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.89 -128.28 3.3 Favored Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.522 -1.323 . . . . 0.0 111.056 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.584 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 22.4 mt -86.29 114.35 25.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.809 -0.818 . . . . 0.0 112.494 -177.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.507 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.48 -7.14 39.4 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.207 -0.997 . . . . 0.0 110.758 177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.21 -160.98 23.83 Favored Glycine 0 N--CA 1.494 2.516 0 O-C-N 120.894 -1.357 . . . . 0.0 110.405 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.504 ' CZ ' ' HA3' ' A' ' 48' ' ' GLY . 5.1 m-85 -110.73 132.98 53.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.382 -1.07 . . . . 0.0 109.883 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.551 HG12 ' CG2' ' B' ' 50' ' ' ILE . 2.6 pp -111.04 162.47 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.065 -1.022 . . . . 0.0 108.603 178.635 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 76.0 mttt -102.36 133.69 46.87 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.034 -1.041 . . . . 0.0 109.673 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.477 HG11 ' CD1' ' A' ' 54' ' ' ILE . 3.1 m -134.77 -173.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.456 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -132.71 100.01 4.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.48 -0.762 . . . . 0.0 109.1 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.49 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 31.8 tt0 -57.92 93.79 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.328 -0.858 . . . . 0.0 109.669 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.594 ' CD2' HD11 ' A' ' 38' ' ' LEU . 15.6 m-85 -88.36 125.36 34.66 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.479 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 24.6 m-20 -105.29 137.72 42.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.861 -1.15 . . . . 0.0 110.901 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.519 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 1.7 mm-40 72.62 61.43 0.12 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.792 -0.568 . . . . 0.0 110.614 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.541 ' CG2' HG21 ' A' ' 15' ' ' ILE . 4.9 mp -119.64 123.94 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.066 . . . . 0.0 108.92 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.563 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 3.3 tm? -69.7 86.56 0.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.316 -0.865 . . . . 0.0 111.831 -178.29 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.533 HG13 ' HB ' ' A' ' 13' ' ' ILE . 3.0 tt -88.32 110.27 20.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 2.0 tt0 -88.77 118.32 28.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.962 -1.086 . . . . 0.0 109.791 -178.03 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.517 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.7 OUTLIER -108.4 120.2 59.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.326 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.72 -99.01 0.09 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -136.72 39.09 1.68 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.0 m170 -128.45 103.33 7.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.423 -1.045 . . . . 0.0 110.164 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.442 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -60.89 117.32 5.29 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.721 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.4 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -133.01 127.99 35.33 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.278 -178.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.547 HG12 ' CA ' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -105.06 139.46 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.605 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.489 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -162.73 -170.95 28.31 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 118.93 -1.605 . . . . 0.0 110.295 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.566 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 51.9 m -91.02 109.87 21.12 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.695 -0.885 . . . . 0.0 109.798 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.541 HG13 ' CD1' ' A' ' 15' ' ' ILE . 1.1 t -103.61 112.03 35.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 110.959 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.543 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 2.0 mp -79.57 122.95 27.13 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.441 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -108.39 121.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.945 -1.097 . . . . 0.0 109.907 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -155.22 -165.17 13.83 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.552 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -80.76 42.52 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.564 2.176 . . . . 0.0 110.636 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.479 ' O ' HG21 ' A' ' 80' ' ' THR . 13.1 t -85.9 141.16 35.44 Favored Pre-proline 0 C--N 1.302 -1.473 0 O-C-N 121.156 -0.965 . . . . 0.0 108.814 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.436 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 35.5 Cg_endo -78.87 15.06 1.55 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.475 2.116 . . . . 0.0 111.546 -179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.533 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 1.0 OUTLIER -160.68 167.37 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.787 -1.196 . . . . 0.0 110.371 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.54 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 69.5 m-80 -100.09 92.54 5.29 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 177.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.578 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 11.4 mm -78.91 124.33 37.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 O-C-N 121.153 -0.967 . . . . 0.0 111.846 -176.472 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.61 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -106.22 100.58 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 177.531 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -87.28 -161.61 36.74 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 120.128 -1.034 . . . . 0.0 111.481 -177.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 15.8 mmm180 -62.16 -38.73 90.13 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.843 -0.798 . . . . 0.0 109.841 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 11.5 p-10 -43.67 -29.48 0.51 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.231 -0.918 . . . . 0.0 109.387 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.587 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.7 mm? -107.78 -24.62 11.61 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.004 -1.06 . . . . 0.0 109.612 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.527 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.7 mt -70.41 -5.81 31.04 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.866 -1.146 . . . . 0.0 108.191 178.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.468 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 71.3 p -100.63 -17.87 16.83 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 19.1 mm100 -83.64 -39.19 20.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 109.434 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.54 ' CD1' ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -84.95 3.52 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.298 -0.876 . . . . 0.0 109.607 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.56 38.22 51.8 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 120.313 -0.946 . . . . 0.0 111.064 178.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.534 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -71.16 138.29 49.47 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.079 -1.248 . . . . 0.0 111.072 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' B' ' 96' ' ' THR . 48.7 p -133.18 128.76 36.69 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.536 ' CD1' HD12 ' B' ' 97' ' ' LEU . 1.6 mp -92.84 85.37 5.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.18 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.52 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.8 m120 -89.68 122.39 32.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.097 -1.002 . . . . 0.0 109.747 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.593 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 117.927 -1.035 . . . . 0.0 108.908 178.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.512 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.1 tt0 -84.2 131.5 34.75 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.325 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.402 HG22 ' CZ ' ' A' ' 99' ' ' PHE . 5.0 t -119.69 118.5 57.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 C-N-CA 118.525 -1.27 . . . . 0.0 110.483 -178.183 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.45 ' CG2' HG21 ' A' ' 96' ' ' THR . 0.1 OUTLIER -132.31 19.93 4.4 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 178.324 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.572 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -82.17 67.38 8.16 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.531 ' C ' ' O ' ' B' ' 5' ' ' LEU . 41.5 m0 -21.93 84.5 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 CA-C-O 121.578 0.704 . . . . 0.0 111.594 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.572 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.38 -163.04 0.32 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.975 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.42 121.71 71.06 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.115 -0.991 . . . . 0.0 109.27 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 33.5 Cg_endo -76.5 74.74 4.63 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.08 1.853 . . . . 0.0 109.068 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.477 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -96.98 147.15 24.28 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.463 -0.773 . . . . 0.0 110.425 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.506 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -143.63 132.47 19.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.885 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 12.0 m -67.54 99.91 0.81 Allowed 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.606 HG23 HG13 ' B' ' 66' ' ' ILE . 3.2 pt -82.73 157.17 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.738 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.532 ' CG ' HD22 ' B' ' 19' ' ' LEU . 0.5 OUTLIER -123.78 98.74 5.95 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.314 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.552 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 50.7 mt -113.98 133.37 60.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.332 -0.855 . . . . 0.0 109.605 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.474 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 49.98 54.91 16.71 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.65 34.78 21.59 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.491 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.4 mm100 -124.84 167.08 15.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -1.184 . . . . 0.0 109.185 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.532 HD22 ' CG ' ' B' ' 14' ' ' LYS . 12.0 mt -141.82 129.49 21.55 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.159 -0.963 . . . . 0.0 110.757 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.445 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 20.2 mtmt -151.7 169.43 22.2 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.481 ' O ' ' OD1' ' B' ' 83' ' ' ASN . 1.1 mp0 -78.99 126.67 31.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.943 -1.098 . . . . 0.0 109.029 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.578 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -106.88 120.77 42.94 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.088 -1.008 . . . . 0.0 110.173 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.443 ' O ' ' HG ' ' B' ' 23' ' ' LEU . 20.7 tp -91.82 94.75 9.48 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.437 -0.789 . . . . 0.0 110.093 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.491 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 58.0 mt -46.49 101.88 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.033 -1.042 . . . . 0.0 108.676 179.583 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.548 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 12.4 t0 -113.34 98.2 6.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.92 . . . . 0.0 110.721 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.559 ' CG2' ' CD2' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -69.88 -15.32 63.06 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.111 -0.993 . . . . 0.0 108.768 178.699 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.448 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.62 -41.03 97.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.464 ' HB1' ' C75' ' B' ' 100' ' ' DMP . . . -79.73 165.52 22.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.039 -1.271 . . . . 0.0 109.063 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -100.77 -15.42 17.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.132 -0.98 . . . . 0.0 110.573 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.509 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.66 -175.33 3.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.712 -1.242 . . . . 0.0 110.316 -179.369 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.499 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 72.8 m -103.13 87.92 3.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.017 -1.052 . . . . 0.0 110.053 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.556 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -71.43 163.12 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.52 179.611 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.588 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -160.7 138.45 9.53 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.049 -1.032 . . . . 0.0 110.469 -178.539 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.474 ' O ' ' O ' ' B' ' 33' ' ' LEU . 2.3 mt-10 -47.97 174.97 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.502 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.2 tm-20 -72.5 143.46 48.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.03 -1.044 . . . . 0.0 109.452 179.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 6.6 ptm -154.93 -167.92 2.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.393 -0.817 . . . . 0.0 109.204 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -107.22 105.98 16.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.653 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.58 HD11 ' CD2' ' B' ' 59' ' ' TYR . 90.4 mt -117.21 156.44 48.65 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.486 ' O ' ' O ' ' B' ' 40' ' ' GLY . 35.1 Cg_endo -76.63 74.24 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.885 2.39 . . . . 0.0 112.206 -178.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 34.39 -157.14 0.01 OUTLIER Glycine 0 N--CA 1.497 2.765 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.414 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.3 mtt180 70.02 47.73 0.57 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.263 -1.139 . . . . 0.0 108.459 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.602 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 57.4 p-90 -129.12 -179.03 4.89 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 121.824 0.821 . . . . 0.0 110.297 -178.815 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.462 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -145.26 156.48 54.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.667 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -75.75 139.3 22.25 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.803 1.669 . . . . 0.0 110.29 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.518 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -144.87 168.82 19.32 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.537 -0.727 . . . . 0.0 109.52 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.531 ' HE3' ' CG ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -150.1 125.08 9.92 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.565 ' CD1' HG22 ' A' ' 50' ' ' ILE . 24.1 pt -120.46 137.82 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 120.74 -1.225 . . . . 0.0 110.385 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.69 98.51 0.75 Allowed Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.68 -119.02 2.75 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.8 -178.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.617 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 16.4 mt -90.39 119.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.689 -0.889 . . . . 0.0 112.337 -177.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.483 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 103.34 -28.11 17.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 120.222 -0.99 . . . . 0.0 110.751 177.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 153.49 -161.9 30.01 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.285 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 8.4 m-85 -107.31 125.02 50.63 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -1.036 . . . . 0.0 110.138 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.572 HD12 ' CG2' ' A' ' 50' ' ' ILE . 11.8 pt -105.96 142.0 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.081 -1.012 . . . . 0.0 108.865 178.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.531 ' CG ' ' HE3' ' B' ' 46' ' ' MET . 5.0 mttt -89.06 138.59 31.27 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.031 -1.043 . . . . 0.0 109.294 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.518 ' CG2' ' HB3' ' B' ' 45' ' ' LYS . 29.4 m -140.44 175.52 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.079 -1.013 . . . . 0.0 110.211 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.573 ' HG2' ' CE3' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -126.29 103.95 7.93 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.403 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.542 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -58.75 112.73 1.74 Allowed 'General case' 0 C--N 1.295 -1.797 0 O-C-N 121.566 -0.709 . . . . 0.0 111.126 -178.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.602 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 15.2 m-85 -98.4 124.4 43.06 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.2 m-20 -101.97 130.1 48.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.886 -1.134 . . . . 0.0 111.03 -178.563 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.583 ' HA ' HG21 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 77.98 65.55 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 CA-C-O 121.48 0.657 . . . . 0.0 109.909 179.163 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.552 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 10.0 mm -118.54 119.6 61.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.273 -0.892 . . . . 0.0 109.721 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.541 ' HA ' HG12 ' B' ' 72' ' ' ILE . 1.4 tm? -63.9 86.93 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.603 -0.686 . . . . 0.0 111.682 -178.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.478 HG21 ' O ' ' B' ' 64' ' ' ILE . 7.9 tt -93.47 113.03 27.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 176.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 32.9 tt0 -88.32 120.42 29.67 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 -178.507 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.606 HG13 HG23 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -114.29 126.34 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.215 -0.928 . . . . 0.0 109.712 -179.253 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 5.7 m 65.18 4.75 2.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.797 -0.564 . . . . 0.0 110.763 179.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 110.81 -6.75 29.49 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.042 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -92.11 139.29 30.78 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.199 -1.177 . . . . 0.0 108.549 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.507 ' CG ' HD13 ' B' ' 63' ' ' LEU . 1.7 mttt -84.47 124.75 31.69 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.177 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -134.15 157.89 45.04 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.583 HG21 ' HA ' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -131.19 133.91 61.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.593 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.42 -166.48 17.68 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 118.617 -1.754 . . . . 0.0 110.995 -179.594 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.542 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 51.6 m -92.39 107.1 18.96 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.924 -0.751 . . . . 0.0 109.797 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.588 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -103.77 113.29 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.544 -0.723 . . . . 0.0 109.804 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.556 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.6 mp -78.35 129.25 34.77 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.576 HG22 ' CD2' ' B' ' 59' ' ' TYR . 95.7 t -113.78 109.95 30.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.895 -1.128 . . . . 0.0 110.039 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.502 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -147.12 -163.59 10.62 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.506 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -79.87 41.37 1.1 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.325 2.016 . . . . 0.0 111.164 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.518 HG22 ' O ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -88.23 139.74 30.42 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.907 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.521 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.8 Cg_endo -79.81 17.32 1.3 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 C-N-CA 122.488 2.126 . . . . 0.0 112.302 -177.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.532 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.1 t -160.69 164.63 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.527 -1.358 . . . . 0.0 110.992 -179.543 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.532 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 1.0 OUTLIER -103.61 87.04 2.74 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.135 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.548 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 1.7 mt -84.42 123.71 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 O-C-N 121.336 -0.852 . . . . 0.0 112.377 -176.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.571 ' N ' HD11 ' B' ' 85' ' ' ILE . 3.2 mm -91.78 103.25 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -84.11 -159.16 28.87 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.71 -1.244 . . . . 0.0 110.671 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.504 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 11.9 mtt-85 -66.24 -35.58 80.8 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.659 -0.907 . . . . 0.0 109.498 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.518 ' ND2' HD21 ' B' ' 89' ' ' LEU . 7.7 p-10 -48.79 -31.65 7.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.921 . . . . 0.0 109.753 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.538 ' HB3' ' CG2' ' B' ' 85' ' ' ILE . 1.2 mm? -106.16 -17.38 14.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.077 . . . . 0.0 110.251 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 87.4 mt -77.39 -1.66 31.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.143 -0.973 . . . . 0.0 108.529 179.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.617 HG23 ' CZ3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -101.68 -20.58 14.94 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.128 -0.982 . . . . 0.0 108.638 179.038 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -75.5 -40.72 56.8 Favored 'General case' 0 N--CA 1.486 1.364 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.537 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -83.39 -9.16 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.411 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.3 36.78 33.61 Favored Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.232 -0.917 . . . . 0.0 111.166 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.521 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -63.7 156.25 27.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.054 -1.263 . . . . 0.0 110.513 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 96' ' ' THR . 66.7 p -147.58 126.61 12.84 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.566 ' HB3' ' CE2' ' B' ' 99' ' ' PHE . 2.7 mp -95.49 89.28 5.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.717 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.532 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.1 m120 -96.13 118.74 33.31 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.055 -1.028 . . . . 0.0 109.318 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.566 ' CE2' ' HB3' ' B' ' 97' ' ' LEU . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.324 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.617 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.471 ' HG2' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 N-CA-C 110.501 -0.615 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.506 ' NE2' HG22 ' A' ' 4' ' ' THR . 9.1 tt0 -85.92 126.8 34.36 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 177.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.446 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 2.4 t -112.33 91.09 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 120.818 -1.176 . . . . 0.0 109.909 -178.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.506 HG22 ' NE2' ' A' ' 2' ' ' GLN . 64.7 p -117.71 33.04 5.82 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.539 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -86.79 30.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.882 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 35.8 m0 17.68 52.49 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -147.73 -163.37 1.75 Allowed 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -74.68 114.92 39.02 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.997 -1.065 . . . . 0.0 109.839 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.482 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.9 Cg_endo -78.06 71.15 6.79 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 121.976 1.784 . . . . 0.0 108.878 177.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -93.29 157.64 16.14 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.356 -179.167 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.514 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.9 OUTLIER -149.96 140.55 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.82 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 m -73.2 94.15 1.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.514 HG21 ' CG2' ' A' ' 11' ' ' VAL . 4.7 pt -80.43 163.82 3.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.538 -0.726 . . . . 0.0 110.791 -178.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 21.7 tttm -129.53 103.23 6.76 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.571 -0.706 . . . . 0.0 109.8 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.539 HG23 ' CE ' ' A' ' 36' ' ' MET . 39.8 mt -119.55 117.05 52.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 120.994 -1.066 . . . . 0.0 109.38 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.27 25.55 75.28 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.96 -1.63 86.06 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.456 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 tp60 -92.11 167.41 12.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.99 -1.3 . . . . 0.0 109.396 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.449 HD22 ' HG3' ' A' ' 14' ' ' LYS . 36.4 mt -130.2 134.74 47.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.645 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 1.7 tptt -151.32 146.17 25.83 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.627 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 2.7 mm-40 -78.88 107.94 11.98 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.585 ' CB ' ' CD1' ' A' ' 85' ' ' ILE . . . -98.57 131.82 44.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.017 -1.052 . . . . 0.0 111.019 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.418 ' O ' ' C ' ' A' ' 24' ' ' LEU . 0.8 OUTLIER -87.33 105.09 17.01 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.901 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.503 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -46.99 120.36 3.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.966 -1.084 . . . . 0.0 108.4 179.702 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 56.7 t0 -124.54 83.99 2.22 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.221 -0.925 . . . . 0.0 110.488 -178.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.457 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 3.2 m -65.74 -15.26 62.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.036 -1.04 . . . . 0.0 108.565 178.807 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.504 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -67.13 -45.59 80.22 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.503 ' CB ' ' H25' ' B' ' 100' ' ' DMP . . . -71.81 167.54 19.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -1.184 . . . . 0.0 108.597 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -99.92 -19.8 16.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.828 -1.17 . . . . 0.0 110.785 -178.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.549 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.01 179.35 6.37 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.89 -1.131 . . . . 0.0 109.781 -179.687 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.563 ' CG2' ' CD1' ' A' ' 33' ' ' LEU . 7.4 m -94.66 92.81 7.2 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 120.826 -1.171 . . . . 0.0 110.011 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.569 ' CG2' ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -84.49 118.96 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.232 -0.918 . . . . 0.0 109.102 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.563 ' CD1' ' CG2' ' A' ' 31' ' ' THR . 1.2 mp -114.1 144.41 43.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.952 -1.093 . . . . 0.0 111.128 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.522 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 0.0 OUTLIER -47.17 174.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.381 -0.825 . . . . 0.0 108.922 178.569 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.493 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.0 OUTLIER -57.59 146.13 31.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.027 . . . . 0.0 109.642 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.539 ' CE ' HG23 ' A' ' 15' ' ' ILE . 2.7 ptm -163.7 -175.49 4.16 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.392 -0.818 . . . . 0.0 109.043 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.489 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.9 t -110.74 120.44 42.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.113 -0.992 . . . . 0.0 109.788 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.562 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 82.0 mt -132.9 159.17 73.7 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 34.4 Cg_endo -76.42 133.0 14.08 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.823 2.348 . . . . 0.0 112.436 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -37.25 129.48 1.23 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.469 -1.053 . . . . 0.0 110.469 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.0 OUTLIER 148.19 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -179.519 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.617 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 50.4 p-90 -138.56 -173.29 3.51 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.741 0.782 . . . . 0.0 110.355 -177.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.463 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 0.0 OUTLIER -148.94 163.8 24.0 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 179.14 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 36.0 Cg_endo -78.37 145.66 21.41 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.966 1.777 . . . . 0.0 109.979 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.55 ' CB ' ' CG2' ' A' ' 56' ' ' VAL . 0.8 OUTLIER -146.52 142.78 28.4 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.153 -0.967 . . . . 0.0 109.67 -179.52 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.475 ' CE ' ' HE3' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -121.97 107.24 12.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 108.675 179.475 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.561 HG13 ' CG1' ' A' ' 54' ' ' ILE . 6.9 pt -101.81 132.39 47.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.588 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.491 ' HA2' ' HA ' ' A' ' 53' ' ' PHE . . . -117.7 105.38 1.25 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.411 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -120.88 -115.89 2.45 Favored Glycine 0 N--CA 1.481 1.695 0 C-N-CA 119.715 -1.231 . . . . 0.0 110.768 -178.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.588 HD13 ' C76' ' B' ' 100' ' ' DMP . 25.6 mt -88.6 116.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 O-C-N 121.832 -0.805 . . . . 0.0 112.834 -177.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.526 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.7 -42.35 1.94 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 166.68 -160.98 34.75 Favored Glycine 0 N--CA 1.49 2.259 0 O-C-N 120.833 -1.392 . . . . 0.0 110.172 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.491 ' HA ' ' HA2' ' A' ' 48' ' ' GLY . 6.8 m-85 -102.1 155.79 17.97 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.449 -1.03 . . . . 0.0 110.042 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.561 ' CG1' HG13 ' A' ' 47' ' ' ILE . 2.1 pt -134.42 173.54 14.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.513 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 3.3 mttt -114.15 144.62 42.86 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.315 -0.866 . . . . 0.0 108.742 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.55 ' CG2' ' CB ' ' A' ' 45' ' ' LYS . 30.6 m -143.39 -177.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.624 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.525 ' O ' ' N ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -131.52 88.82 2.62 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.51 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 3.5 tt0 -46.76 91.7 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.497 -0.752 . . . . 0.0 109.804 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 12.5 m-85 -89.96 95.68 10.33 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 12.2 m-20 -79.22 133.2 36.69 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.161 -0.962 . . . . 0.0 109.972 -179.004 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.557 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 20.4 mm-40 81.8 61.68 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.495 0.664 . . . . 0.0 110.166 179.171 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.511 ' CG2' HG22 ' A' ' 75' ' ' VAL . 15.4 mm -115.99 120.35 64.59 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.504 HD23 ' HG3' ' A' ' 70' ' ' LYS . 1.9 tm? -72.45 81.18 1.06 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.171 -0.956 . . . . 0.0 111.094 -178.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.5 HG13 HG13 ' A' ' 15' ' ' ILE . 13.5 tt -87.66 117.93 32.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.481 ' HG3' ' N ' ' A' ' 70' ' ' LYS . 1.5 tt0 -93.91 112.38 24.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.07 -1.019 . . . . 0.0 109.763 -178.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.505 HG13 HG21 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -100.34 118.81 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.3 m 56.42 54.55 7.45 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.735 -0.603 . . . . 0.0 109.807 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 57.69 16.55 23.72 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.453 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 25.7 m170 -107.93 91.18 3.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -1.223 . . . . 0.0 109.494 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.504 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -43.42 137.25 2.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 179.712 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.46 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -159.25 124.83 4.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.515 -0.74 . . . . 0.0 109.415 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.557 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -95.32 152.45 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.877 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.479 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -175.41 -171.82 39.73 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 118.832 -1.652 . . . . 0.0 111.089 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.51 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 96.5 m -98.49 108.85 21.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -1.134 . . . . 0.0 110.619 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.511 HG22 ' CG2' ' A' ' 62' ' ' ILE . 1.5 t -99.24 109.92 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.675 -0.641 . . . . 0.0 110.349 179.153 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.569 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.8 mp -79.4 100.95 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.495 HG22 HD11 ' A' ' 38' ' ' LEU . 21.6 t -87.1 121.86 38.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.98 -1.075 . . . . 0.0 110.248 -178.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -156.76 -166.15 15.97 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.513 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 35.7 Cg_endo -80.84 40.67 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.403 2.069 . . . . 0.0 111.103 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.522 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 13.4 t -81.36 140.5 48.71 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.453 ' O ' ' CG2' ' A' ' 82' ' ' VAL . 37.0 Cg_endo -78.73 15.75 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.595 2.197 . . . . 0.0 111.279 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.523 HG11 HG13 ' A' ' 84' ' ' ILE . 5.2 t -160.53 163.36 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.94 -1.1 . . . . 0.0 110.514 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.645 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -101.01 85.57 2.88 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 105.045 -2.205 . . . . 0.0 105.045 177.109 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.599 ' CG2' ' CB ' ' A' ' 25' ' ' ASP . 4.6 mt -88.88 125.31 41.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.139 -0.975 . . . . 0.0 112.69 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' CB ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -84.88 149.48 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 176.503 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -125.61 -170.23 13.01 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.672 -1.728 . . . . 0.0 110.462 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.458 ' HD3' ' HB2' ' A' ' 90' ' ' LEU . 6.4 mmt180 -62.98 -26.75 68.99 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.444 -1.033 . . . . 0.0 108.416 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.592 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 15.7 p-10 -57.65 -28.44 63.74 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.433 -0.792 . . . . 0.0 109.141 179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.592 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -102.36 -24.37 13.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.287 -0.883 . . . . 0.0 109.208 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.458 ' HB2' ' HD3' ' A' ' 87' ' ' ARG . 41.0 mt -71.51 -4.8 28.76 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.47 HG23 ' CD1' ' B' ' 6' ' ' TRP . 21.7 p -101.14 -16.08 17.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.256 -0.902 . . . . 0.0 108.717 178.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mm-40 -86.66 -40.81 14.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.31 -0.868 . . . . 0.0 109.433 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.568 HD11 ' CG ' ' B' ' 99' ' ' PHE . 1.6 pt -85.67 0.71 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.131 -0.981 . . . . 0.0 108.724 179.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.455 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.03 51.49 50.47 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.523 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.1 155.29 23.92 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.031 -1.276 . . . . 0.0 109.802 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.504 HG21 ' CG2' ' B' ' 4' ' ' THR . 10.5 p -147.98 130.88 16.16 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.581 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 4.6 mp -91.29 100.86 13.59 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.421 -0.799 . . . . 0.0 109.698 -179.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.53 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 1.6 m120 -102.2 123.37 45.92 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.961 -1.087 . . . . 0.0 109.111 179.352 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.617 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.09 -0.957 . . . . 0.0 109.241 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.494 1.509 0 N-CA-C 110.041 -0.792 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.52 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.7 tt0 -83.55 133.78 34.85 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 178.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 30.7 t -132.69 122.5 47.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.756 -177.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.534 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.4 OUTLIER -132.46 -79.46 0.5 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.612 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 60.1 mt 28.27 38.64 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.095 178.298 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 25.7 m0 16.51 52.75 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 CA-C-O 121.252 0.549 . . . . 0.0 111.619 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 9.9 mt-30 -142.09 -179.46 6.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 109.868 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -75.62 122.35 86.97 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HB2' ' CD1' ' B' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 75.73 4.46 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.078 1.852 . . . . 0.0 109.836 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.529 ' CD2' ' CB ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -91.78 154.91 18.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.904 . . . . 0.0 109.695 -179.543 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.477 HG23 HG12 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -147.91 134.98 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 0.0 109.908 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.542 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 6.9 m -68.15 105.1 1.97 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.766 -1.208 . . . . 0.0 108.555 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.582 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.2 pt -92.86 156.75 3.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.944 -1.098 . . . . 0.0 110.261 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.533 ' HG3' ' CD1' ' B' ' 19' ' ' LEU . 10.5 tttm -121.99 100.06 6.78 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.505 HD13 ' CD2' ' B' ' 33' ' ' LEU . 13.1 mt -116.71 124.24 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.108 -0.995 . . . . 0.0 110.122 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.83 38.86 93.04 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 68.45 21.13 74.21 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.512 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -110.13 171.0 7.71 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.201 -1.176 . . . . 0.0 109.136 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.542 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.1 OUTLIER -148.14 124.36 10.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.298 -0.876 . . . . 0.0 110.565 -179.378 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.492 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mtmp? -151.05 169.23 22.33 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.547 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -81.92 119.02 23.41 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 120.989 -1.069 . . . . 0.0 109.197 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.582 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -94.91 130.51 41.49 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.312 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' B' ' 25' ' ' ASP . 19.0 tp -92.89 92.34 7.85 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.519 ' CD1' ' HB2' ' B' ' 9' ' ' PRO . 92.4 mt -44.11 96.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.287 -0.883 . . . . 0.0 108.998 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' B' ' 23' ' ' LEU . 3.8 t0 -105.64 86.53 2.42 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.4 -0.813 . . . . 0.0 109.555 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.544 ' O ' ' NH1' ' B' ' 87' ' ' ARG . 0.6 OUTLIER -63.2 -9.44 11.22 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.267 -0.896 . . . . 0.0 109.443 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.26 -41.13 47.44 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.526 ' HB1' ' C75' ' B' ' 100' ' ' DMP . . . -76.36 145.45 39.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.176 -1.191 . . . . 0.0 109.417 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.93 -16.22 60.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.322 -0.861 . . . . 0.0 111.614 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.539 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -139.03 -167.47 2.23 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.548 -1.345 . . . . 0.0 110.255 -179.532 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.545 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 23.5 m -107.88 93.71 4.68 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.247 -0.908 . . . . 0.0 110.695 -178.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.22 167.2 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.133 -0.98 . . . . 0.0 108.599 179.171 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.568 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.56 136.89 4.66 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.826 -1.171 . . . . 0.0 111.188 -178.258 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.476 ' HA ' HG21 ' B' ' 80' ' ' THR . 2.9 tt0 -45.31 157.35 0.09 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.83 . . . . 0.0 109.436 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.51 ' HA ' HG11 ' B' ' 77' ' ' VAL . 2.0 mt-10 -49.52 151.28 1.65 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.227 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.441 ' HE3' HG23 ' B' ' 15' ' ' ILE . 4.9 ptm -173.33 161.86 4.25 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.455 -0.778 . . . . 0.0 109.035 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 23.5 t -82.17 110.38 17.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.152 -0.967 . . . . 0.0 110.046 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.737 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 48.4 mt -119.36 175.98 1.95 Allowed Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.718 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.737 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.4 Cg_endo -71.79 -161.9 0.11 Allowed 'Trans proline' 0 C--N 1.319 -1.006 0 C-N-CA 121.539 1.493 . . . . 0.0 111.945 -178.248 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.73 35.86 4.74 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -178.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.4 mmt-85 -118.18 62.92 0.76 Allowed 'General case' 0 C--N 1.29 -1.991 0 O-C-N 121.598 -0.942 . . . . 0.0 109.042 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.705 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 8.3 p-90 -142.97 -172.35 3.65 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -149.26 139.77 13.65 Favored Pre-proline 0 C--N 1.303 -1.414 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.53 130.67 10.01 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.214 1.943 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.485 ' O ' ' HG3' ' B' ' 45' ' ' LYS . 3.6 ptmt -162.21 145.61 11.79 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.505 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 42.7 mtp -103.41 137.64 41.24 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.924 -1.11 . . . . 0.0 109.654 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' B' ' 53' ' ' PHE . 3.9 pt -96.45 145.78 8.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.095 -1.003 . . . . 0.0 108.392 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.87 101.27 0.86 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.53 -127.43 3.16 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.749 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.556 ' CD1' ' C26' ' B' ' 100' ' ' DMP . 46.4 mt -81.79 132.31 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.835 -0.803 . . . . 0.0 112.207 -177.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.536 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 89.21 -44.71 3.11 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 178.612 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.24 -162.73 34.8 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -115.72 130.76 56.97 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.435 -1.038 . . . . 0.0 109.22 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.526 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 23.8 pt -110.51 144.24 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.828 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.505 ' CG ' ' HG2' ' B' ' 46' ' ' MET . 10.4 mtmm -72.08 144.06 48.84 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.298 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.415 HG23 ' O ' ' B' ' 45' ' ' LYS . 29.5 m -145.42 -170.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.103 -0.998 . . . . 0.0 109.873 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.582 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.4 mtt180 -142.4 102.16 4.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.329 -0.857 . . . . 0.0 109.332 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.569 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 5.5 tt0 -64.77 113.07 3.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -0.893 . . . . 0.0 109.961 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.705 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 19.1 m-85 -104.38 95.51 5.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.442 -0.786 . . . . 0.0 108.941 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.1 m-20 -78.71 137.77 37.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.966 -1.084 . . . . 0.0 109.972 -179.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.502 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 1.3 mm-40 77.66 64.12 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.456 0.646 . . . . 0.0 109.869 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.531 ' CB ' HG22 ' B' ' 75' ' ' VAL . 0.6 OUTLIER -126.48 119.27 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.569 HD23 ' CG ' ' B' ' 70' ' ' LYS . 0.2 OUTLIER -72.53 85.29 1.15 Allowed 'General case' 0 C--N 1.296 -1.724 0 O-C-N 120.933 -1.104 . . . . 0.0 111.805 -177.526 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.584 HG21 ' O ' ' B' ' 71' ' ' ALA . 4.4 tt -89.49 115.04 28.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 10.1 tt0 -89.57 117.38 28.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.539 HG13 ' CG2' ' B' ' 13' ' ' ILE . 0.7 OUTLIER -110.27 120.68 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.244 -0.91 . . . . 0.0 108.88 179.37 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 57.95 50.71 9.9 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.446 -0.784 . . . . 0.0 109.67 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 59.76 16.77 39.73 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.486 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 69.9 m-70 -106.01 121.15 43.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.101 -1.235 . . . . 0.0 109.531 179.741 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.569 ' CG ' HD23 ' B' ' 63' ' ' LEU . 21.4 ttpt -69.45 122.03 18.17 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.41 -0.806 . . . . 0.0 109.585 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.584 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -139.64 106.98 5.52 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 110.356 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.515 HD12 ' N ' ' B' ' 63' ' ' LEU . 0.4 OUTLIER -87.04 139.03 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 177.811 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.18 -159.0 9.69 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 118.545 -1.788 . . . . 0.0 111.285 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.569 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.3 m -109.17 102.57 11.51 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.64 -0.917 . . . . 0.0 109.67 -179.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.568 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.3 t -96.91 111.38 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.241 -0.912 . . . . 0.0 111.107 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.539 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 1.8 mp -78.39 134.18 37.45 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.531 ' CG2' HD13 ' B' ' 38' ' ' LEU . 46.5 t -124.43 131.29 72.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 120.869 -1.144 . . . . 0.0 110.145 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.63 -160.37 11.56 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.85 40.79 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.369 2.046 . . . . 0.0 110.401 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.476 HG21 ' HA ' ' B' ' 34' ' ' GLU . 4.6 t -84.94 138.28 37.37 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.492 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.4 Cg_endo -79.48 23.34 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 122.475 2.117 . . . . 0.0 111.668 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.564 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -161.67 170.46 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.669 -1.269 . . . . 0.0 110.113 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 0.1 OUTLIER -110.19 92.73 4.16 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.122 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' B' ' 31' ' ' THR . 20.2 mm -78.77 128.23 38.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.385 -0.822 . . . . 0.0 112.893 -175.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.512 HD13 ' HB3' ' B' ' 22' ' ' ALA . 1.4 mp -108.15 89.29 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 176.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -79.53 -162.36 24.26 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.313 -177.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.544 ' NH1' ' O ' ' B' ' 26' ' ' THR . 0.1 OUTLIER -61.89 -40.04 94.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.766 -0.844 . . . . 0.0 110.232 -179.219 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.554 ' ND2' HD21 ' B' ' 89' ' ' LEU . 11.6 p-10 -43.84 -28.89 0.48 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.141 -0.974 . . . . 0.0 109.465 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.554 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.8 mm? -107.27 -29.61 9.21 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.185 -0.947 . . . . 0.0 110.048 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.502 ' CD1' ' HA ' ' B' ' 26' ' ' THR . 13.6 mt -72.81 -3.66 26.83 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.03 -1.044 . . . . 0.0 108.506 179.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.503 ' O ' ' CZ2' ' A' ' 6' ' ' TRP . 15.5 p -101.72 -20.21 15.07 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.167 -0.958 . . . . 0.0 108.857 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.418 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 6.7 mt-30 -82.87 -38.05 23.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.321 -0.862 . . . . 0.0 109.236 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.551 HD11 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -81.06 3.71 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.877 . . . . 0.0 108.978 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 72.5 46.25 33.36 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.311 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -82.3 136.03 35.1 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.082 -1.246 . . . . 0.0 110.728 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.43 ' CG2' HG23 ' A' ' 4' ' ' THR . 36.3 p -131.78 129.43 40.53 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.581 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 2.4 mp -92.34 93.08 8.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.923 -1.11 . . . . 0.0 109.495 -179.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.523 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.3 m120 -100.39 127.27 46.76 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -0.918 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.568 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.213 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.588 ' C76' HD13 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.578 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.013 -0.803 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.525 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 11.9 tt0 -84.15 138.94 32.75 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 177.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.8 t -140.04 116.27 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 117.857 -1.537 . . . . 0.0 111.921 -177.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.53 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.1 OUTLIER -121.34 -62.75 1.39 Allowed 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 176.874 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.582 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.4 OUTLIER 35.92 26.23 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.903 177.399 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.604 ' CD2' ' HB ' ' B' ' 91' ' ' THR . 27.8 m95 17.82 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.298 0.57 . . . . 0.0 112.252 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.582 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -161.91 -157.47 0.48 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.215 179.856 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HG2' ' OD1' ' B' ' 29' ' ' ASP . 40.9 mtm180 -78.8 128.82 75.64 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 120.894 -1.129 . . . . 0.0 109.893 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.539 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.64 66.02 8.86 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.36 2.04 . . . . 0.0 108.49 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.449 ' HG ' ' HA ' ' A' ' 23' ' ' LEU . 0.3 OUTLIER -90.2 145.18 25.21 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.33 -0.856 . . . . 0.0 110.756 -178.182 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.429 HG22 ' N ' ' A' ' 12' ' ' THR . 0.6 OUTLIER -150.51 164.14 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.277 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.429 ' N ' HG22 ' A' ' 11' ' ' VAL . 51.8 m -86.64 133.31 33.71 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 178.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.565 HG22 ' CB ' ' A' ' 22' ' ' ALA . 8.3 pt -121.92 156.73 26.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.996 -1.065 . . . . 0.0 110.384 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 8.0 tttt -117.94 100.55 7.63 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.504 HG23 ' CE ' ' A' ' 36' ' ' MET . 18.0 mt -112.24 145.78 17.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.368 -0.832 . . . . 0.0 110.298 -178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 39.82 41.15 1.78 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.84 44.59 94.47 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -144.13 176.56 9.22 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.121 -1.223 . . . . 0.0 108.756 179.537 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.478 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 13.0 mt -140.02 123.71 17.32 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 119.305 -0.958 . . . . 0.0 110.535 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.478 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -143.27 177.02 8.7 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 179.1 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.542 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 15.3 mp0 -79.86 -178.97 6.7 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.613 -1.304 . . . . 0.0 108.057 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.565 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -160.81 109.53 1.62 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.841 -1.162 . . . . 0.0 110.046 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.525 ' O ' ' N ' ' A' ' 25' ' ' ASP . 27.3 tp -89.26 89.36 7.88 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.669 -0.644 . . . . 0.0 109.307 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.539 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 58.2 mt -42.49 97.04 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 56.9 t0 -106.36 87.08 2.47 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.582 -0.699 . . . . 0.0 110.788 -177.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.447 HG21 ' HG2' ' A' ' 87' ' ' ARG . 2.1 m -62.15 -20.15 63.8 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.974 -1.079 . . . . 0.0 108.804 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.551 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -58.73 -48.24 86.07 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.489 ' HB3' ' C27' ' B' ' 100' ' ' DMP . . . -73.55 160.63 31.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.311 -1.111 . . . . 0.0 108.591 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.406 ' OD1' ' HG2' ' B' ' 8' ' ' ARG . 61.9 m-20 -96.65 -11.21 25.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.986 -1.071 . . . . 0.0 110.421 -179.014 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.544 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -138.98 -165.56 1.86 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.089 . . . . 0.0 110.624 -179.211 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.526 ' CG2' ' HA ' ' A' ' 85' ' ' ILE . 0.0 OUTLIER -104.0 88.54 3.05 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.069 -1.019 . . . . 0.0 111.658 -178.001 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.639 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -72.94 122.99 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.317 -1.49 . . . . 0.0 107.333 177.784 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.475 HD21 HD11 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -131.27 131.87 44.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.539 -1.351 . . . . 0.0 111.345 -177.965 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.484 ' HA ' HG21 ' A' ' 80' ' ' THR . 10.5 pt-20 -41.91 152.98 0.07 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.546 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.1 tt0 -50.36 144.44 7.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.213 -0.93 . . . . 0.0 110.239 -179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.504 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -171.4 179.5 2.91 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.402 -0.811 . . . . 0.0 109.169 179.636 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.452 ' O ' ' SD ' ' A' ' 36' ' ' MET . 8.0 t -84.01 111.08 18.96 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.1 -1.0 . . . . 0.0 109.834 -179.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.533 ' CD1' HD11 ' A' ' 62' ' ' ILE . 18.6 tp -154.0 90.42 3.29 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 109.702 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -80.21 162.34 22.9 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.667 2.245 . . . . 0.0 110.408 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . 129.96 42.25 0.22 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.486 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER 61.1 150.68 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.658 -0.907 . . . . 0.0 109.047 -179.658 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 26.8 p-90 -154.2 158.38 40.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.101 -0.999 . . . . 0.0 109.807 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -120.67 138.38 27.47 Favored Pre-proline 0 C--N 1.299 -1.613 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.16 134.42 17.53 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 121.568 1.512 . . . . 0.0 108.736 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 46' ' ' MET . 7.1 tttt -148.15 163.49 36.79 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.548 -178.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.498 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 3.9 tpt -134.16 114.13 12.77 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.52 HD13 HG12 ' A' ' 54' ' ' ILE . 17.5 pt -89.68 143.25 11.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.619 -1.232 . . . . 0.0 109.802 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.616 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.07 98.36 0.76 Allowed Glycine 0 N--CA 1.485 1.911 0 N-CA-C 107.916 -2.074 . . . . 0.0 107.916 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.527 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -122.96 -136.31 4.8 Favored Glycine 0 C--N 1.298 -1.559 0 C-N-CA 119.315 -1.421 . . . . 0.0 111.387 -178.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.61 HD13 ' C76' ' B' ' 100' ' ' DMP . 80.6 mt -78.92 132.17 32.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.768 0.794 . . . . 0.0 112.962 -177.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 85.81 -41.58 3.09 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.84 -165.11 36.16 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.493 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.616 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 1.1 m-85 -111.04 138.89 46.89 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.647 -0.914 . . . . 0.0 109.244 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.52 HG12 HD13 ' A' ' 47' ' ' ILE . 4.9 pt -119.71 134.13 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.853 -1.154 . . . . 0.0 108.854 178.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.506 ' O ' HG11 ' A' ' 56' ' ' VAL . 4.2 mttp -74.86 133.38 41.86 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.954 -1.091 . . . . 0.0 110.119 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.554 ' CG1' ' HA3' ' A' ' 78' ' ' GLY . 33.2 m -144.57 166.77 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.255 -0.903 . . . . 0.0 109.773 179.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.51 ' O ' HD22 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -111.31 172.8 6.67 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.828 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.51 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 37.1 tt0 -135.02 102.82 5.34 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.839 -1.163 . . . . 0.0 110.815 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 87.8 m-85 -91.31 123.0 34.41 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.49 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -96.37 145.82 25.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 110.463 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.49 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.8 OUTLIER 75.96 64.51 0.05 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.65 -0.656 . . . . 0.0 110.147 179.425 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.533 HD11 ' CD1' ' A' ' 38' ' ' LEU . 15.2 mm -124.13 119.91 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.331 -0.855 . . . . 0.0 109.473 179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.542 HD22 ' CG ' ' A' ' 70' ' ' LYS . 3.2 tm? -69.85 94.81 0.86 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.665 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.539 ' CD1' HD13 ' A' ' 66' ' ' ILE . 9.5 tt -96.62 119.2 44.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.1 tt0 -89.7 103.38 16.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.004 -1.06 . . . . 0.0 109.899 -178.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.539 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.7 OUTLIER -96.76 116.18 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.199 -0.938 . . . . 0.0 109.821 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 62.32 17.13 9.11 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.809 -0.557 . . . . 0.0 110.683 178.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.33 6.73 55.16 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.745 -1.217 . . . . 0.0 110.409 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -104.64 133.79 48.89 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.186 -1.184 . . . . 0.0 109.196 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -76.09 130.95 39.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.966 . . . . 0.0 109.042 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.464 ' O ' HG23 ' A' ' 64' ' ' ILE . . . -150.06 97.96 2.64 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.453 -0.78 . . . . 0.0 110.465 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.541 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -79.03 137.15 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.642 -1.286 . . . . 0.0 107.883 178.791 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.483 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -157.93 -167.88 19.49 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.536 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 31' ' ' THR . 26.0 m -97.7 102.08 13.75 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.533 -0.981 . . . . 0.0 109.516 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.509 ' HA ' ' OG1' ' A' ' 31' ' ' THR . 0.8 OUTLIER -91.47 173.91 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.265 -0.897 . . . . 0.0 109.357 179.727 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.639 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -132.54 163.3 29.16 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 179.557 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.57 HG22 ' CE2' ' A' ' 59' ' ' TYR . 2.2 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 120.948 -1.095 . . . . 0.0 110.457 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.554 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -139.82 -169.53 11.67 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.493 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 47.27 2.49 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.551 2.167 . . . . 0.0 110.791 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.494 HG22 ' O ' ' A' ' 82' ' ' VAL . 14.8 t -91.02 139.87 25.9 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.147 -0.971 . . . . 0.0 109.133 179.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.34 19.51 0.93 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.696 2.264 . . . . 0.0 112.646 -178.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.542 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 1.2 t -160.24 171.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.415 -1.428 . . . . 0.0 110.396 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.542 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 74.0 m-20 -104.9 83.74 2.04 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.54 ' CG1' HG11 ' A' ' 32' ' ' VAL . 7.7 mm -75.74 113.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.461 -0.775 . . . . 0.0 111.712 -176.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.528 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -93.92 94.09 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.84 -172.25 41.41 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.797 -1.19 . . . . 0.0 111.589 -177.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 88' ' ' ASN . 1.2 mtt-85 -56.69 -36.05 69.17 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.957 -0.731 . . . . 0.0 110.38 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.555 ' ND2' HD21 ' A' ' 89' ' ' LEU . 5.8 p-10 -43.39 -40.45 3.7 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.057 -1.027 . . . . 0.0 109.15 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.555 HD21 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -94.53 -30.04 14.6 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.318 -0.864 . . . . 0.0 111.02 -179.299 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.486 ' O ' ' CB ' ' A' ' 95' ' ' ALA . 28.2 mt -65.99 -6.83 13.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.533 -1.354 . . . . 0.0 109.795 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.568 HG22 ' CG ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -101.42 -15.0 17.33 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.978 -1.076 . . . . 0.0 109.101 179.743 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.486 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -80.0 -41.15 26.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.577 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.567 HD11 ' CG ' ' B' ' 99' ' ' PHE . 4.5 pt -82.71 5.49 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.955 . . . . 0.0 108.756 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.52 41.64 35.67 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.876 -1.289 . . . . 0.0 109.876 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -81.81 137.8 35.23 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 120.882 -1.363 . . . . 0.0 110.09 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.422 ' CG2' HG22 ' B' ' 4' ' ' THR . 11.2 p -136.6 130.38 32.23 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.594 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 1.9 mp -88.26 92.16 9.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.747 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.541 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.8 m120 -95.35 123.42 38.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.095 -1.003 . . . . 0.0 109.407 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.604 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 117.93 -1.034 . . . . 0.0 109.529 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.604 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.498 1.778 0 N-CA-C 110.326 -0.682 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.499 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -85.01 131.6 34.45 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.262 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 16.5 t -127.37 127.76 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.851 -1.156 . . . . 0.0 110.859 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.422 HG22 ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER -149.44 25.78 0.86 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -82.47 45.07 0.93 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.705 -0.622 . . . . 0.0 110.94 -178.135 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.568 ' CG ' HG22 ' A' ' 91' ' ' THR . 13.8 m95 18.84 51.7 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.177 0.513 . . . . 0.0 111.214 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.531 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.5 OUTLIER -141.53 -168.5 2.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.982 -1.074 . . . . 0.0 110.336 -179.224 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.406 ' HG2' ' OD1' ' A' ' 29' ' ' ASP . 0.2 OUTLIER -91.76 128.94 44.13 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.399 -0.813 . . . . 0.0 109.148 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.506 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.3 Cg_endo -76.52 72.83 5.41 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.305 2.003 . . . . 0.0 109.879 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.496 HD21 ' HB2' ' B' ' 21' ' ' GLU . 3.2 mt -95.68 134.75 38.23 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.753 -1.217 . . . . 0.0 109.936 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.466 HG21 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -140.44 154.71 22.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.09 102.78 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 178.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.571 ' CG2' ' CB ' ' B' ' 22' ' ' ALA . 1.7 pp -87.64 148.68 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.466 -0.772 . . . . 0.0 109.649 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.507 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 16.8 ttmt -117.38 107.88 14.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.399 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.537 ' CG2' HD23 ' B' ' 38' ' ' LEU . 0.9 OUTLIER -117.39 125.26 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.151 -0.968 . . . . 0.0 109.647 -179.6 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.36 14.29 68.87 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 6.71 69.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.507 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.2 mt-30 -97.83 167.55 10.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.324 -1.103 . . . . 0.0 108.839 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.437 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 16.2 mt -131.99 129.73 40.52 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.122 -0.986 . . . . 0.0 111.164 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.576 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -149.79 168.61 23.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 177.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.546 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 7.2 pt-20 -78.3 -166.09 0.78 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.571 ' CB ' ' CG2' ' B' ' 13' ' ' ILE . . . -168.8 109.84 0.5 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.844 -1.16 . . . . 0.0 109.955 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.558 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.1 tp -83.76 93.66 8.0 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.458 -0.777 . . . . 0.0 109.181 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.539 HD21 ' CG2' ' B' ' 85' ' ' ILE . 26.7 mt -44.63 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.558 ' N ' ' O ' ' B' ' 23' ' ' LEU . 7.5 t0 -99.01 81.78 2.64 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.583 -0.698 . . . . 0.0 109.897 -178.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.533 ' CG2' ' HD3' ' B' ' 87' ' ' ARG . 10.6 m -58.6 -17.27 20.53 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.491 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.26 -43.98 96.2 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.54 ' HB1' ' C75' ' B' ' 100' ' ' DMP . . . -72.31 169.33 16.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.133 -1.216 . . . . 0.0 108.852 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.47 ' OD1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -100.31 -20.37 15.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 110.217 -179.198 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.517 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 4.8 m-20 -132.9 -166.88 1.82 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.994 -1.066 . . . . 0.0 110.206 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.598 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 9.0 m -107.02 89.3 2.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.816 -1.178 . . . . 0.0 111.397 -177.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.573 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.6 OUTLIER -68.63 160.45 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.347 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.598 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.1 OUTLIER -157.83 133.92 9.39 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.759 -1.213 . . . . 0.0 111.394 -177.741 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.493 ' HA ' HG21 ' B' ' 80' ' ' THR . 15.1 tp10 -42.34 141.88 0.88 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.466 ' HA ' HG13 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -41.07 150.47 0.08 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.462 -0.774 . . . . 0.0 110.252 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.507 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -170.66 -175.87 1.94 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 11.1 t -109.48 101.76 10.68 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.826 -1.171 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.603 HD11 ' CD1' ' B' ' 59' ' ' TYR . 6.2 mt -97.08 170.25 7.55 Favored Pre-proline 0 N--CA 1.489 1.482 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.576 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.0 Cg_endo -76.06 68.31 6.61 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.407 2.071 . . . . 0.0 112.537 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 32.75 -157.27 0.01 OUTLIER Glycine 0 N--CA 1.498 2.771 0 CA-C-O 121.918 0.732 . . . . 0.0 111.594 178.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 54.31 81.91 0.1 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.312 -1.11 . . . . 0.0 109.213 -179.711 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.537 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 58.0 p-90 -155.84 -176.19 5.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.531 -0.73 . . . . 0.0 109.581 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -141.09 159.52 61.35 Favored Pre-proline 0 N--CA 1.489 1.496 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.93 139.94 12.4 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 C-N-CA 122.249 1.966 . . . . 0.0 110.998 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.536 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -148.38 118.63 7.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.401 -0.812 . . . . 0.0 108.977 179.543 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -96.24 129.57 43.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.05 -1.031 . . . . 0.0 109.557 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.528 ' CG1' HG12 ' B' ' 54' ' ' ILE . 41.0 pt -117.14 132.0 68.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.099 179.01 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.94 100.97 0.84 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 107.976 -2.049 . . . . 0.0 107.976 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -118.61 -125.87 3.51 Favored Glycine 0 N--CA 1.483 1.804 0 C-N-CA 119.184 -1.484 . . . . 0.0 111.038 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.581 HG13 ' H62' ' B' ' 100' ' ' DMP . 52.9 mt -84.56 121.41 36.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.568 -0.96 . . . . 0.0 112.981 -177.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.486 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 100.74 -36.8 3.92 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.172 177.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 169.86 -154.83 24.2 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.553 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.614 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.5 OUTLIER -120.4 140.76 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.53 -0.983 . . . . 0.0 109.718 -179.659 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.528 HG12 ' CG1' ' B' ' 47' ' ' ILE . 12.5 pt -124.33 132.07 71.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.311 -0.868 . . . . 0.0 108.976 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.484 ' O ' ' HD3' ' B' ' 79' ' ' PRO . 15.2 mttt -77.45 140.3 39.82 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.047 -1.033 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.544 ' CG1' ' HA3' ' B' ' 78' ' ' GLY . 15.0 m -138.56 175.07 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 109.956 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.426 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 18.4 mtt-85 -124.86 102.35 7.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.501 -0.749 . . . . 0.0 109.054 179.622 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.553 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.7 OUTLIER -60.28 94.75 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.47 -0.769 . . . . 0.0 110.772 -179.653 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.603 ' CD1' HD11 ' B' ' 38' ' ' LEU . 29.9 m-85 -89.88 114.4 26.17 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.556 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -93.47 143.18 26.53 Favored 'General case' 0 C--N 1.296 -1.748 0 O-C-N 120.912 -1.117 . . . . 0.0 110.337 -178.83 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.556 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 73.18 63.08 0.1 Allowed 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.368 0.604 . . . . 0.0 110.54 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.536 ' HB ' ' CG2' ' B' ' 75' ' ' VAL . 8.1 mm -120.53 110.76 29.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 178.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.505 ' N ' HD11 ' B' ' 72' ' ' ILE . 0.0 OUTLIER -63.15 87.41 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.033 -1.042 . . . . 0.0 110.768 -178.515 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.565 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 8.0 tt -89.85 122.36 41.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.471 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 1.2 tt0 -90.0 116.96 28.44 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.995 -1.066 . . . . 0.0 109.108 -179.316 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.567 HG13 HG23 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -111.63 131.65 62.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.277 -0.889 . . . . 0.0 109.351 -179.813 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.3 m 45.27 58.95 3.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.642 -0.661 . . . . 0.0 110.856 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.471 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 53.07 31.19 40.07 Favored Glycine 0 N--CA 1.495 2.598 0 C-N-CA 120.163 -1.017 . . . . 0.0 110.865 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -132.62 142.71 49.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.337 . . . . 0.0 109.453 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.482 ' HG3' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -75.44 138.15 41.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 109.809 -179.683 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -159.03 98.71 1.48 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.955 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.505 HD11 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.01 159.96 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.798 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.55 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 177.18 -171.8 44.64 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.029 -2.034 . . . . 0.0 112.335 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.553 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 5.9 m -95.47 106.64 18.73 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.809 -0.818 . . . . 0.0 110.475 -179.353 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' B' ' 62' ' ' ILE . 1.6 t -98.11 108.81 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.627 -0.67 . . . . 0.0 110.618 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.573 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -80.95 125.32 29.99 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.041 -1.037 . . . . 0.0 108.549 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.538 ' CG2' HD13 ' B' ' 38' ' ' LEU . 1.4 t -104.18 111.3 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.224 -0.922 . . . . 0.0 110.054 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.544 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -145.27 -171.56 15.03 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 179.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' B' ' 55' ' ' LYS . 35.3 Cg_endo -79.91 43.13 1.44 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.502 2.134 . . . . 0.0 111.091 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.519 ' HB ' ' CD1' ' B' ' 54' ' ' ILE . 2.9 t -89.03 138.29 29.2 Favored Pre-proline 0 N--CA 1.488 1.433 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.453 ' O ' ' CG2' ' B' ' 82' ' ' VAL . 37.5 Cg_endo -80.42 21.78 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.508 2.139 . . . . 0.0 111.328 -178.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.8 t -161.32 161.1 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.623 -1.298 . . . . 0.0 111.029 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 1.9 m-80 -90.77 88.78 7.21 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.535 ' CG1' HG11 ' B' ' 32' ' ' VAL . 5.8 mm -78.85 118.93 27.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.041 -1.037 . . . . 0.0 111.422 -176.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.539 ' CG2' HD21 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -102.04 99.74 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 177.847 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.517 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -85.37 -163.08 36.83 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.871 -1.143 . . . . 0.0 110.704 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.533 ' HD3' ' CG2' ' B' ' 26' ' ' THR . 7.5 mmm180 -63.65 -29.03 70.32 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.653 -0.91 . . . . 0.0 110.113 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.559 ' ND2' HD21 ' B' ' 89' ' ' LEU . 10.8 p-10 -52.53 -40.06 62.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.673 -1.267 . . . . 0.0 109.237 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.559 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.3 mm? -96.04 -15.86 21.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.904 -179.056 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.522 ' O ' ' CB ' ' B' ' 95' ' ' ALA . 34.4 mt -85.18 -4.18 59.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.866 -1.146 . . . . 0.0 108.827 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.604 ' HB ' ' CD2' ' A' ' 6' ' ' TRP . 68.9 p -101.83 -13.93 17.48 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.324 -0.86 . . . . 0.0 108.748 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.525 ' NE2' ' O ' ' B' ' 88' ' ' ASN . 33.0 mt-30 -87.0 -36.44 18.24 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.41 -0.806 . . . . 0.0 109.281 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.539 HD13 ' CD2' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -85.38 4.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.803 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 78.48 31.07 47.12 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.041 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -74.15 132.79 42.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.336 . . . . 0.0 110.353 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 17.1 p -140.81 129.44 22.81 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.594 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 6.3 mp -86.04 94.46 9.24 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.329 -0.857 . . . . 0.0 109.312 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.548 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -96.26 122.63 39.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.112 -0.992 . . . . 0.0 109.207 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.578 ' CE1' ' O ' ' A' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.421 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.61 ' C76' HD13 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.487 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.493 1.476 0 N-CA-C 109.884 -0.852 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.449 ' HG2' ' N ' ' A' ' 3' ' ' VAL . 1.2 tt0 -84.29 141.04 31.22 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.553 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 10.8 t -135.68 112.66 13.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.464 -1.397 . . . . 0.0 110.071 -178.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.496 ' O ' ' HG ' ' A' ' 5' ' ' LEU . 0.5 OUTLIER -128.3 -78.5 0.57 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.856 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.4 OUTLIER 34.94 37.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.802 -0.562 . . . . 0.0 110.268 179.983 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' A' ' 5' ' ' LEU . 43.7 m0 16.1 53.77 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 121.065 0.459 . . . . 0.0 112.204 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.502 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.6 mm-40 -156.35 -174.84 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.992 -1.067 . . . . 0.0 109.937 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -68.43 115.33 28.63 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.265 -0.897 . . . . 0.0 109.402 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.553 ' HB3' ' CG1' ' A' ' 3' ' ' VAL . 34.4 Cg_endo -77.15 72.68 5.79 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.12 1.88 . . . . 0.0 110.359 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.56 HD22 ' CB ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -81.76 152.77 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -0.887 . . . . 0.0 108.998 179.715 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.55 HG22 ' CG2' ' A' ' 13' ' ' ILE . 26.9 m -139.07 129.16 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.166 -0.959 . . . . 0.0 110.38 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.4 m -67.74 92.01 0.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 178.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.55 ' CG2' HG22 ' A' ' 11' ' ' VAL . 3.0 pt -88.74 147.21 5.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.462 -0.774 . . . . 0.0 110.886 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.9 tttt -109.11 100.37 9.55 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.018 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.528 ' CD1' HD23 ' A' ' 33' ' ' LEU . 3.4 mt -117.17 136.16 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.87 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' A' ' 18' ' ' GLN . . . 63.34 25.07 68.1 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.8 17.78 79.92 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 15.3 mp0 -123.75 -174.67 3.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -1.158 . . . . 0.0 108.919 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.482 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 44.0 mt -137.97 135.48 36.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.137 -0.977 . . . . 0.0 110.06 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.611 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -148.97 148.69 30.07 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.56 ' CB ' HD22 ' A' ' 10' ' ' LEU . 3.6 mm-40 -78.61 109.06 12.48 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.947 -1.095 . . . . 0.0 109.295 -179.338 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.603 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -95.05 116.95 29.35 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 122.02 0.914 . . . . 0.0 111.265 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 8.3 tp -72.46 103.09 3.37 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.553 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 20.1 mt -46.65 131.03 11.54 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.105 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.52 ' HB2' ' CG2' ' A' ' 84' ' ' ILE . 3.6 t70 -139.34 86.57 2.13 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.167 -0.958 . . . . 0.0 111.091 -177.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.564 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 1.5 m -65.64 -11.64 46.42 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.97 -1.081 . . . . 0.0 108.4 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.452 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -72.74 -44.7 37.9 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.061 -1.616 . . . . 0.0 109.061 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.49 157.79 36.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -1.162 . . . . 0.0 108.936 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -99.18 -9.5 23.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.036 . . . . 0.0 110.226 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.515 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -138.57 177.93 7.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.944 -1.098 . . . . 0.0 110.297 -179.428 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 37.6 m -101.78 102.23 12.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.036 -1.04 . . . . 0.0 109.44 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.545 ' CG1' ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -97.11 115.42 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.353 -0.842 . . . . 0.0 109.88 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.528 HD23 ' CD1' ' A' ' 15' ' ' ILE . 6.6 mp -106.52 123.13 47.62 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.309 -0.869 . . . . 0.0 109.767 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.56 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 3.0 pt-20 -43.09 165.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 108.915 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.523 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.5 tt0 -42.7 137.48 2.22 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 110.067 -179.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.0 ppp? -153.78 -162.33 1.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.565 -0.709 . . . . 0.0 109.372 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.518 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 11.7 t -106.2 100.93 10.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 110.275 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.57 HD21 ' CD2' ' A' ' 59' ' ' TYR . 1.4 tp -127.95 149.65 71.4 Favored Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.488 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.5 Cg_endo -73.97 -156.17 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.583 2.189 . . . . 0.0 110.609 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -93.01 -155.6 32.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.501 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 72.7 43.77 0.42 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.649 -0.912 . . . . 0.0 108.893 -179.557 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.624 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 29.8 p-90 -132.22 178.21 6.98 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.8 0.809 . . . . 0.0 110.328 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.446 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 1.4 mmtp -139.12 150.99 66.76 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.25 138.67 20.37 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 122.031 1.821 . . . . 0.0 110.233 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.519 ' CG ' ' N ' ' A' ' 46' ' ' MET . 0.0 OUTLIER -147.56 167.36 24.72 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.673 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.519 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 9.1 mtp -143.56 128.28 18.23 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.108 -0.995 . . . . 0.0 108.435 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.523 HG13 HG12 ' A' ' 54' ' ' ILE . 2.1 pt -106.78 141.18 22.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.881 -1.137 . . . . 0.0 109.388 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.84 96.29 0.65 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.23 -128.43 3.76 Favored Glycine 0 N--CA 1.481 1.659 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.854 -178.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.58 ' CD1' ' C76' ' B' ' 100' ' ' DMP . 42.5 mt -81.2 118.22 28.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.775 -0.838 . . . . 0.0 112.511 -177.487 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.16 -42.61 1.87 Allowed Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.428 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 167.43 -157.98 30.63 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 120.875 -1.368 . . . . 0.0 110.068 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.614 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -114.62 140.6 48.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.436 -1.038 . . . . 0.0 109.784 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.554 ' CG2' HG21 ' B' ' 50' ' ' ILE . 0.9 OUTLIER -116.51 179.53 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.251 -0.906 . . . . 0.0 108.703 179.039 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 10.0 mttm -115.02 141.24 48.26 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.17 -0.957 . . . . 0.0 108.545 179.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 4.5 m -144.52 172.1 5.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.941 -1.1 . . . . 0.0 110.641 -178.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.9 mtt180 -118.96 98.37 6.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.497 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 3.3 tt0 -59.18 91.91 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.125 -0.984 . . . . 0.0 110.155 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.624 ' CD1' ' HB3' ' A' ' 42' ' ' TRP . 13.6 m-85 -88.5 92.73 9.29 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 178.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.413 ' C ' ' HG2' ' A' ' 61' ' ' GLN . 7.3 m-20 -78.79 143.37 36.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 110.811 -178.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.557 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.4 mm100 69.44 67.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-O 121.51 0.672 . . . . 0.0 109.6 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.493 HG13 ' HB3' ' A' ' 59' ' ' TYR . 1.2 mm -126.97 111.48 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.528 HD12 ' N ' ' A' ' 64' ' ' ILE . 3.3 tm? -50.97 143.27 10.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.163 -0.96 . . . . 0.0 109.469 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.551 ' CD1' HD12 ' A' ' 66' ' ' ILE . 6.9 tt -150.79 113.89 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.484 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 36.8 tt0 -89.02 102.86 15.51 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.815 -1.178 . . . . 0.0 108.753 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.551 HD12 ' CD1' ' A' ' 64' ' ' ILE . 0.8 OUTLIER -96.89 112.84 29.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-O 121.852 0.834 . . . . 0.0 108.908 -179.652 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 0.1 OUTLIER 71.13 -84.01 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.32 28.2 0.88 Allowed Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -129.68 128.49 42.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -1.112 . . . . 0.0 109.328 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.486 ' HG2' HD22 ' A' ' 63' ' ' LEU . 1.0 OUTLIER -78.79 136.28 37.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.754 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.502 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -151.94 131.81 13.31 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -0.995 . . . . 0.0 110.681 -179.045 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.557 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -95.39 148.1 5.39 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 177.848 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.421 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -166.39 -171.53 32.63 Favored Glycine 0 N--CA 1.49 2.295 0 C-N-CA 118.401 -1.857 . . . . 0.0 111.48 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.497 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 63.9 m -102.81 105.2 15.56 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.436 -1.038 . . . . 0.0 110.205 -179.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.507 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -91.36 167.49 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.586 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.495 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.1 mp -139.52 107.44 5.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.934 -1.104 . . . . 0.0 108.367 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.523 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 31.9 t -88.37 114.04 26.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 -178.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -150.41 -171.34 18.6 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.51 40.16 0.94 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.588 2.192 . . . . 0.0 111.183 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.56 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.7 t -82.9 142.3 44.79 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.411 ' O ' HG21 ' A' ' 82' ' ' VAL . 37.4 Cg_endo -79.32 16.3 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.421 2.08 . . . . 0.0 111.356 -178.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.614 HG11 ' CG1' ' A' ' 84' ' ' ILE . 2.8 t -161.44 160.43 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.828 -1.17 . . . . 0.0 110.983 -178.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.611 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 82.5 m-20 -94.35 143.55 26.3 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 103.053 -2.943 . . . . 0.0 103.053 174.408 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.614 ' CG1' HG11 ' A' ' 82' ' ' VAL . 18.4 mt -146.91 135.12 15.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 O-C-N 119.295 -2.128 . . . . 0.0 112.562 -176.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.59 ' CD1' ' CB ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.91 107.34 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.05 -167.4 43.47 Favored Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.089 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.521 ' CZ ' ' O ' ' B' ' 5' ' ' LEU . 1.9 mmm180 -60.05 -31.71 70.24 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.408 -1.054 . . . . 0.0 109.173 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.566 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 14.1 p-10 -54.58 -28.47 46.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 110.53 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.566 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.6 mm? -104.57 -29.12 10.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.83 -1.169 . . . . 0.0 110.062 -179.096 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.564 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.3 mt -71.36 -5.59 33.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.992 -1.068 . . . . 0.0 108.982 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 87' ' ' ARG . 70.0 p -101.38 -20.91 14.98 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.143 -0.973 . . . . 0.0 109.327 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 42.9 mm-40 -81.52 -40.35 23.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 109.061 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.58 HD11 ' CD2' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -80.13 -2.93 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.202 -0.936 . . . . 0.0 108.655 178.821 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 78.17 30.46 50.62 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.559 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -65.84 136.4 56.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.805 -1.409 . . . . 0.0 109.049 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 81.5 p -131.14 125.4 32.95 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.562 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 1.7 mp -84.5 93.91 8.43 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.525 0.679 . . . . 0.0 110.108 -178.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.496 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.5 m120 -108.37 130.52 55.21 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.531 ' HB2' ' HB ' ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 117.949 -1.024 . . . . 0.0 109.09 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.433 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.565 0 N-CA-C 109.989 -0.812 . . . . 0.0 109.989 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.537 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tt0 -83.96 149.38 26.35 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.059 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.537 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 6.7 t -150.25 117.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 120.665 -1.272 . . . . 0.0 109.582 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.592 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.9 OUTLIER -108.62 13.34 25.28 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.552 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.521 ' O ' ' CZ ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -26.53 84.32 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 121.641 0.734 . . . . 0.0 111.25 -179.037 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.592 ' N ' ' O ' ' B' ' 4' ' ' THR . 16.1 m95 -53.48 -16.67 1.56 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.433 ' O ' ' HG3' ' A' ' 87' ' ' ARG . 30.7 mt-30 -109.42 -106.52 0.35 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.157 -0.964 . . . . 0.0 109.602 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 -111.22 120.56 42.76 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 120.945 -1.097 . . . . 0.0 110.705 -179.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.472 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 37.3 Cg_endo -80.45 62.02 8.4 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.268 1.979 . . . . 0.0 109.692 177.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 1.6 mt -81.66 148.85 28.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.076 -1.015 . . . . 0.0 110.327 -179.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.554 HG23 ' CB ' ' B' ' 22' ' ' ALA . 5.2 m -141.46 142.69 28.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.448 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 14.4 m -81.92 96.74 7.77 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.591 HG22 ' CB ' ' B' ' 22' ' ' ALA . 10.3 pt -84.3 152.41 3.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.227 -0.921 . . . . 0.0 110.41 -178.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.441 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -118.01 101.74 8.49 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.208 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.571 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 40.6 mt -105.8 127.14 61.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.07 -1.018 . . . . 0.0 109.515 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.8 -86.16 0.36 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.606 -1.798 . . . . 0.0 108.606 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.76 25.6 0.32 Allowed Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.039 -2.025 . . . . 0.0 108.039 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -121.0 171.01 8.95 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.739 -0.859 . . . . 0.0 108.749 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.452 HD21 ' O ' ' B' ' 13' ' ' ILE . 14.4 mt -134.28 130.72 37.49 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.296 -0.877 . . . . 0.0 109.924 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -139.99 166.99 23.16 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 179.628 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.574 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.6 mt-10 -78.73 -179.94 6.81 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.688 -1.257 . . . . 0.0 107.876 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.591 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -158.03 105.26 1.94 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.816 -1.178 . . . . 0.0 110.821 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.507 ' O ' ' N ' ' B' ' 25' ' ' ASP . 25.5 tp -77.35 95.52 4.42 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' B' ' 23' ' ' LEU . 0.2 OUTLIER -40.44 97.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.607 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 12.0 t0 -102.57 76.58 1.54 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.443 -0.785 . . . . 0.0 110.707 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.557 ' HA ' ' CD2' ' B' ' 90' ' ' LEU . 2.7 m -62.91 -11.19 16.81 Favored 'General case' 0 C--N 1.297 -1.679 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.118 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -79.59 -38.77 19.79 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.431 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -71.04 158.51 36.37 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.093 -1.239 . . . . 0.0 109.065 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -90.68 -11.5 39.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.972 -1.08 . . . . 0.0 110.437 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.514 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -138.88 -164.2 1.61 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.889 -1.132 . . . . 0.0 109.988 -179.646 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.564 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 16.8 m -115.67 92.76 4.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.927 -1.108 . . . . 0.0 109.718 -179.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.591 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -69.64 174.19 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.087 -1.008 . . . . 0.0 109.299 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.605 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.0 OUTLIER -171.31 123.25 0.57 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.792 -1.192 . . . . 0.0 110.811 -178.531 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.532 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 0.6 OUTLIER -42.85 159.75 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.232 -0.917 . . . . 0.0 108.774 178.381 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.408 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -50.61 148.15 4.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.9 -1.125 . . . . 0.0 110.475 -179.284 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.4 ptm -155.12 -164.53 1.8 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.516 ' N ' ' HG3' ' B' ' 36' ' ' MET . 3.9 t -105.08 67.27 0.78 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.865 -1.147 . . . . 0.0 110.116 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.583 HD11 ' CD1' ' B' ' 59' ' ' TYR . 11.6 mt -85.1 168.71 19.12 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.033 . . . . 0.0 108.726 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.6 Cg_endo -71.59 -162.52 0.11 Allowed 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.142 1.895 . . . . 0.0 111.374 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.96 29.93 8.85 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -178.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -107.94 46.12 0.97 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.655 ' CD1' ' CZ ' ' B' ' 59' ' ' TYR . 29.9 p-90 -117.73 -179.92 3.88 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.817 0.818 . . . . 0.0 110.356 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -134.27 134.12 22.41 Favored Pre-proline 0 C--N 1.3 -1.556 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.76 135.43 17.7 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 121.779 1.653 . . . . 0.0 110.414 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.463 ' HG2' ' CG2' ' B' ' 56' ' ' VAL . 16.2 ptmt -160.09 -165.91 1.58 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.559 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.553 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 4.3 mtp -146.56 124.7 12.14 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.451 -179.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.503 HD13 ' CG2' ' A' ' 50' ' ' ILE . 2.8 pt -89.48 143.23 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.25 113.51 2.64 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.463 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -138.65 -123.99 2.18 Favored Glycine 0 N--CA 1.481 1.7 0 C-N-CA 119.52 -1.324 . . . . 0.0 110.213 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.585 ' CD1' ' C26' ' B' ' 100' ' ' DMP . 28.3 mt -91.22 134.82 28.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.694 -0.886 . . . . 0.0 111.968 -178.001 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.466 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 87.47 -29.78 5.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.427 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 156.12 -160.08 29.84 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.011 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.47 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -120.67 133.32 55.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.498 -1.001 . . . . 0.0 109.118 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.536 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 15.6 pt -110.66 141.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 120.941 -1.099 . . . . 0.0 109.774 -179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.553 ' HG3' ' CG ' ' B' ' 46' ' ' MET . 0.0 OUTLIER -65.21 154.23 38.68 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 179.792 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 19.8 m -151.13 -167.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.973 . . . . 0.0 110.005 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -145.03 96.25 2.82 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.562 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 11.3 tt0 -61.83 107.9 0.92 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 110.533 -179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.655 ' CZ ' ' CD1' ' B' ' 42' ' ' TRP . 29.2 m-85 -102.3 95.18 6.12 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.485 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -79.13 141.61 37.12 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.829 -1.17 . . . . 0.0 109.994 -179.589 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.485 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 75.01 59.25 0.06 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.695 -0.628 . . . . 0.0 110.055 179.706 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.587 ' CB ' HG22 ' B' ' 75' ' ' VAL . 5.8 mm -121.35 121.5 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.271 -0.893 . . . . 0.0 108.984 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.53 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 1.4 tm? -68.54 91.4 0.41 Allowed 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.138 -0.976 . . . . 0.0 110.503 -179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 10.8 tt -97.75 120.33 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.529 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.6 tt0 -88.32 148.56 24.23 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.044 -1.035 . . . . 0.0 108.557 -179.257 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.556 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.2 mp -147.48 132.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.086 -1.009 . . . . 0.0 109.717 -179.186 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.411 ' C ' ' O ' ' B' ' 66' ' ' ILE . 54.7 m 42.79 37.9 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.533 -0.729 . . . . 0.0 109.723 179.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.77 48.1 51.41 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -145.71 114.42 6.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.204 -1.174 . . . . 0.0 109.445 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.506 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.8 OUTLIER -56.75 130.85 47.28 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.619 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.551 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -151.8 101.19 2.74 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 110.369 -179.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' B' ' 62' ' ' ILE . 0.7 OUTLIER -80.08 157.2 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.016 -1.052 . . . . 0.0 108.583 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.552 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 175.88 -166.33 37.5 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.908 -1.615 . . . . 0.0 111.632 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.562 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 16.8 m -98.03 104.86 16.93 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.528 -0.983 . . . . 0.0 110.595 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.605 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.16 109.41 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.344 -0.848 . . . . 0.0 110.255 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.591 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -80.32 124.27 28.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.181 -0.949 . . . . 0.0 108.944 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.525 ' CG2' HD11 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -106.86 125.95 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 109.784 -179.893 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -159.42 -167.21 19.76 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.475 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.8 Cg_endo -81.71 54.87 5.28 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.795 2.33 . . . . 0.0 109.916 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.532 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 6.3 t -97.57 138.43 21.1 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.267 -0.896 . . . . 0.0 108.93 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.441 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -80.06 16.55 1.47 Allowed 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.482 2.121 . . . . 0.0 110.71 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.478 HG12 ' O ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -161.24 172.45 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.016 -1.053 . . . . 0.0 110.206 -179.576 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.574 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 68.6 m-80 -105.03 147.76 27.49 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 104.652 -2.351 . . . . 0.0 104.652 176.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.607 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 24.7 mm -133.64 120.2 36.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 O-C-N 120.282 -1.511 . . . . 0.0 111.194 -177.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.567 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 0.9 OUTLIER -102.14 91.9 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 177.997 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -100.12 170.57 22.72 Favored Glycine 0 N--CA 1.496 2.683 0 C-N-CA 119.748 -1.215 . . . . 0.0 112.344 -177.062 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.587 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 3.7 mmt180 -21.96 -41.37 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.566 ' ND2' HD21 ' B' ' 89' ' ' LEU . 12.0 p-10 -52.43 -43.05 64.63 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.121 -1.612 . . . . 0.0 110.486 -178.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.566 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -91.29 -19.96 22.4 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.685 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.587 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 2.2 mp -67.39 -15.22 63.56 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 17.2 p -86.9 -18.34 31.07 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.053 -1.029 . . . . 0.0 108.801 179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -87.79 -40.34 14.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 1.3 pt -87.28 -2.51 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.362 -0.836 . . . . 0.0 109.143 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.6 35.76 81.65 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 179.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.475 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -63.04 145.06 56.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.949 -1.324 . . . . 0.0 110.936 -179.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.484 HG21 ' CG2' ' A' ' 4' ' ' THR . 20.4 p -150.42 126.98 10.83 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.562 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 6.9 mp -86.62 103.25 14.93 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.259 -0.901 . . . . 0.0 109.187 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 9.9 m120 -101.4 122.41 43.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.134 -0.979 . . . . 0.0 110.036 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.58 ' CD2' HD11 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.433 179.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.585 ' C26' ' CD1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.475 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.494 1.518 0 N-CA-C 110.551 -0.596 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.479 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 8.6 tt0 -83.75 126.29 32.76 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 177.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.4 t -118.14 108.35 24.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.875 -1.14 . . . . 0.0 109.81 -177.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.511 ' CG2' HG21 ' B' ' 96' ' ' THR . 0.0 OUTLIER -131.71 41.0 3.33 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.582 -0.699 . . . . 0.0 109.481 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -88.34 43.08 1.1 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.144 -0.973 . . . . 0.0 108.965 179.644 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.527 ' C ' ' O ' ' A' ' 5' ' ' LEU . 16.3 m0 18.13 50.64 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.237 0.541 . . . . 0.0 111.545 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 5.3 mt-30 -155.45 163.82 39.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -0.895 . . . . 0.0 109.518 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.462 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -54.19 119.25 18.98 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.322 179.894 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.462 ' HB2' HD13 ' A' ' 24' ' ' LEU . 36.8 Cg_endo -78.47 75.07 5.12 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.212 1.941 . . . . 0.0 110.769 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.594 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -79.52 164.94 23.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.052 -1.03 . . . . 0.0 108.68 179.587 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.479 HG22 HG23 ' A' ' 13' ' ' ILE . 30.7 m -149.29 127.78 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.052 -1.03 . . . . 0.0 110.296 -178.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.1 m -64.65 91.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 178.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.548 HG22 ' CB ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -79.7 149.7 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.505 -178.372 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 18.3 tttt -117.1 91.2 3.51 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.516 ' CD1' HG12 ' A' ' 75' ' ' VAL . 12.5 mt -114.65 139.93 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 O-C-N 121.208 -0.933 . . . . 0.0 109.959 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.499 ' N ' HG21 ' A' ' 15' ' ' ILE . . . 48.41 49.58 25.75 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 52.24 38.37 48.99 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.535 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.7 mm-40 -131.71 168.35 17.92 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -1.154 . . . . 0.0 109.065 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.414 ' O ' ' HG2' ' A' ' 20' ' ' LYS . 20.4 mt -137.57 128.94 28.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 0.0 109.592 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.414 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 47.0 mtmt -151.1 155.86 39.82 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.395 -0.816 . . . . 0.0 109.368 179.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.594 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 27.1 mp0 -79.83 106.52 11.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.975 . . . . 0.0 108.68 179.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.554 ' HB2' ' CD1' ' A' ' 85' ' ' ILE . . . -87.55 132.88 33.89 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.513 -0.742 . . . . 0.0 110.787 -178.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' A' ' 25' ' ' ASP . 6.0 tp -85.83 98.95 11.04 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.462 HD13 ' HB2' ' A' ' 9' ' ' PRO . 10.9 mt -45.52 97.34 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.103 -0.998 . . . . 0.0 108.522 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.547 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 8.7 t0 -100.33 90.3 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.471 -0.768 . . . . 0.0 110.503 -178.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.455 HG23 ' HG3' ' B' ' 9' ' ' PRO . 5.4 m -71.1 -16.49 62.57 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.983 -1.073 . . . . 0.0 108.93 178.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.432 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -70.07 -33.84 69.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.445 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -80.31 154.4 27.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.213 -1.169 . . . . 0.0 109.342 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -93.8 -12.98 27.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.195 -0.941 . . . . 0.0 109.831 -179.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -131.64 -175.19 3.63 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.163 -0.961 . . . . 0.0 109.406 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.513 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 5.9 m -110.72 87.88 2.64 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.789 -1.194 . . . . 0.0 109.808 -179.066 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.564 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -73.01 166.33 2.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.506 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.561 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.57 132.08 3.77 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.79 -1.194 . . . . 0.0 111.343 -177.853 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.51 ' N ' HG23 ' A' ' 80' ' ' THR . 11.3 tt0 -42.21 160.38 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.535 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.4 mt-10 -61.91 137.19 58.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.857 -1.152 . . . . 0.0 109.946 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.477 ' CE ' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -146.95 -164.01 1.89 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.414 -0.804 . . . . 0.0 109.503 179.632 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.1 t -96.73 112.26 24.09 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.123 -0.986 . . . . 0.0 110.39 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.634 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -133.49 -177.34 0.69 Allowed Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.342 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.531 ' HD2' ' CB ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -76.4 -179.71 5.56 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.051 1.834 . . . . 0.0 110.656 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.06 29.99 10.35 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -119.76 61.7 0.83 Allowed 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 179.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.62 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 11.4 p-90 -121.83 -172.76 2.5 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.537 0.684 . . . . 0.0 109.807 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.8 mtpm? -132.85 128.21 20.65 Favored Pre-proline 0 N--CA 1.49 1.568 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -76.36 138.06 19.45 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 121.929 1.753 . . . . 0.0 110.213 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.524 ' HE3' ' N ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -157.16 -179.04 7.82 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.731 179.872 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.498 ' HA ' ' O ' ' A' ' 54' ' ' ILE . 69.4 mtp -136.54 121.23 18.48 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.382 -0.824 . . . . 0.0 108.96 179.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 6.1 pt -88.56 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.565 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.538 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.68 98.0 0.75 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 -179.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -124.04 -132.29 3.88 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 119.805 -1.188 . . . . 0.0 110.509 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.588 ' CD1' ' C76' ' B' ' 100' ' ' DMP . 21.6 mt -84.24 110.5 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.624 -0.927 . . . . 0.0 112.531 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.85 -13.59 17.31 Favored Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.843 177.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 134.27 -154.91 21.61 Favored Glycine 0 N--CA 1.49 2.271 0 C-N-CA 119.204 -1.474 . . . . 0.0 109.951 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.538 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 9.4 m-85 -116.3 127.45 54.71 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.574 -0.956 . . . . 0.0 110.255 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.498 ' O ' ' HA ' ' A' ' 46' ' ' MET . 15.8 pt -103.32 179.1 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.556 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -116.07 145.62 42.87 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.861 -1.15 . . . . 0.0 109.302 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.483 ' CG2' ' HE2' ' A' ' 45' ' ' LYS . 0.7 OUTLIER -146.49 -170.33 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.604 -1.31 . . . . 0.0 110.297 -179.843 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.8 mtm180 -133.8 94.29 3.25 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.524 ' N ' ' HE3' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -53.44 99.56 0.03 OUTLIER 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.38 -0.825 . . . . 0.0 110.217 -179.153 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.634 ' CZ ' ' HB3' ' A' ' 38' ' ' LEU . 22.6 m-85 -98.1 84.88 3.36 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 177.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.521 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -78.16 137.98 38.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 -177.604 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.521 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 51.5 mm-40 80.77 62.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 72' ' ' ILE . 8.0 mm -124.82 122.85 64.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.615 ' CD2' ' CG ' ' A' ' 70' ' ' LYS . 17.0 tp -74.4 87.19 2.03 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.109 -1.036 . . . . 0.0 111.755 -177.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.508 HD12 HD13 ' A' ' 66' ' ' ILE . 10.9 tt -87.23 120.26 36.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.527 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -89.48 111.68 22.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.143 -0.973 . . . . 0.0 109.474 -178.634 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.508 HD13 HD12 ' A' ' 64' ' ' ILE . 1.0 OUTLIER -106.7 125.95 62.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.102 -0.999 . . . . 0.0 109.879 -179.522 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.8 m 65.22 11.56 7.33 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.762 -0.586 . . . . 0.0 110.698 178.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.433 ' HA2' ' CD ' ' A' ' 65' ' ' GLU . . . 101.3 1.28 53.98 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.201 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -106.11 119.13 38.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.12 -1.223 . . . . 0.0 108.924 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.615 ' CG ' ' CD2' ' A' ' 63' ' ' LEU . 2.2 mptp? -63.06 139.75 58.8 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.187 -0.945 . . . . 0.0 109.415 -179.156 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.538 ' O ' ' HA ' ' A' ' 63' ' ' LEU . . . -151.27 143.12 23.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.307 -179.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.53 ' CG1' HD11 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -113.19 138.94 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.864 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -163.05 -159.12 10.2 Favored Glycine 0 N--CA 1.483 1.77 0 C-N-CA 119.208 -1.472 . . . . 0.0 110.213 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.505 ' CG2' ' OD1' ' A' ' 60' ' ' ASP . 2.2 m -100.1 108.16 20.23 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.769 -0.842 . . . . 0.0 110.05 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.516 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -106.6 107.01 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.154 -0.967 . . . . 0.0 109.927 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.564 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.3 mp -78.58 128.42 33.5 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.535 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -114.49 120.53 64.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.698 -179.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.417 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -157.0 -157.72 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.556 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -83.31 36.98 0.63 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.553 2.169 . . . . 0.0 110.758 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 34' ' ' GLU . 3.9 t -80.59 134.56 54.1 Favored Pre-proline 0 N--CA 1.489 1.513 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.465 ' O ' HG21 ' A' ' 82' ' ' VAL . 34.6 Cg_endo -77.4 18.59 0.79 Allowed 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.497 2.131 . . . . 0.0 111.825 -178.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.611 ' CG1' HG13 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.02 160.3 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 109.941 -179.804 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -99.88 85.99 3.19 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 177.06 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.611 HG13 ' CG1' ' A' ' 82' ' ' VAL . 2.3 mt -83.2 122.61 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 CA-C-O 121.805 0.812 . . . . 0.0 112.902 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.554 ' CD1' ' HB2' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -95.98 102.67 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 177.225 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -90.87 -162.03 37.87 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.82 -1.181 . . . . 0.0 111.478 -178.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.533 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -57.4 -40.05 77.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.754 -0.851 . . . . 0.0 110.472 -179.237 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.588 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 6.3 p-10 -42.41 -39.28 2.15 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.293 -0.879 . . . . 0.0 110.011 -179.554 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.588 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 0.9 OUTLIER -100.59 -22.01 15.1 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 121.001 -1.062 . . . . 0.0 110.276 -179.336 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.533 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 81.2 mt -74.67 -1.63 22.65 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.061 -1.024 . . . . 0.0 108.56 179.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.0 p -99.41 -18.65 17.38 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -83.03 -41.63 18.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.391 -0.818 . . . . 0.0 108.982 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.576 HD13 ' CG ' ' B' ' 99' ' ' PHE . 3.5 pt -86.87 -10.16 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.69 45.43 44.61 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.275 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.525 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -76.03 131.45 39.52 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.932 -1.334 . . . . 0.0 109.908 179.578 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 77.8 p -129.61 137.82 50.91 Favored 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.534 ' CD1' HD12 ' B' ' 97' ' ' LEU . 5.9 mp -89.51 120.18 30.6 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.962 -1.086 . . . . 0.0 110.529 -179.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -119.48 124.77 47.29 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.256 -0.903 . . . . 0.0 108.948 178.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.59 ' CD2' ' CD1' ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.531 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.601 0 N-CA-C 109.964 -0.822 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.494 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.7 tt0 -88.88 150.0 23.08 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.494 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 3.3 t -149.83 126.16 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.498 -1.376 . . . . 0.0 110.441 -179.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.542 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -130.98 -60.04 0.97 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.733 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.655 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER 34.34 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.944 -0.472 . . . . 0.0 110.852 179.529 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.542 ' N ' ' O ' ' B' ' 4' ' ' THR . 5.5 m95 18.02 42.66 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.655 ' N ' ' O ' ' B' ' 5' ' ' LEU . 6.9 mm100 -153.01 -114.81 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.193 -0.942 . . . . 0.0 108.718 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.512 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.1 mtp180 -112.45 141.07 24.52 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 120.23 -1.543 . . . . 0.0 109.195 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.468 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 37.0 Cg_endo -82.15 50.21 3.38 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.316 2.011 . . . . 0.0 109.529 178.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.541 HD21 ' HB3' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -78.43 137.48 38.0 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.197 -0.939 . . . . 0.0 108.943 -179.597 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.486 HG21 ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -134.15 178.97 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.453 -0.779 . . . . 0.0 109.996 -178.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 47.8 m -103.86 105.28 15.43 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.547 ' CD1' ' CG1' ' B' ' 15' ' ' ILE . 1.8 pp -96.17 155.37 3.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.518 -0.738 . . . . 0.0 109.862 -178.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.53 ' CB ' HD22 ' B' ' 19' ' ' LEU . 8.9 ttmt -122.91 100.14 6.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 110.503 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.697 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 1.0 OUTLIER -115.38 142.64 27.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.812 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 47.98 47.13 26.2 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.351 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 55.23 36.42 62.16 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.162 -1.199 . . . . 0.0 110.398 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.9 OUTLIER -130.7 166.61 20.36 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -1.216 . . . . 0.0 108.425 179.077 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.53 HD22 ' CB ' ' B' ' 14' ' ' LYS . 14.8 mt -143.23 125.28 15.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.078 -1.014 . . . . 0.0 111.409 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.488 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 1.0 OUTLIER -145.11 -170.97 3.55 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.875 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.549 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -82.45 -176.48 6.25 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.863 -1.148 . . . . 0.0 109.666 -179.846 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -163.28 91.49 0.7 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.1 -1.0 . . . . 0.0 110.89 -179.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.523 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 8.8 tp -68.04 93.44 0.43 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.631 -1.293 . . . . 0.0 109.658 179.315 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' B' ' 9' ' ' PRO . 69.8 mt -50.42 94.88 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.549 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 29.5 t0 -96.0 84.75 3.89 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.351 -0.843 . . . . 0.0 110.825 -178.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.416 ' CG2' HD11 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.51 -16.0 21.69 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.956 -1.09 . . . . 0.0 108.771 178.754 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -74.19 -38.85 45.98 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.452 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -70.28 162.76 27.89 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.198 -1.178 . . . . 0.0 109.318 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -101.01 -10.37 20.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.502 ' HA ' ' CG ' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -139.13 -172.57 3.37 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.134 -0.979 . . . . 0.0 110.322 -179.298 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 47.7 m -108.46 89.46 3.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.984 -1.072 . . . . 0.0 111.162 -178.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.521 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.4 OUTLIER -73.34 169.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.54 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.591 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -168.81 130.89 1.28 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.777 -1.202 . . . . 0.0 110.683 -179.026 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.552 ' N ' HG21 ' B' ' 80' ' ' THR . 6.0 pt-20 -46.67 170.81 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.276 -0.89 . . . . 0.0 108.693 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.541 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tt0 -60.42 138.1 58.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.145 -0.972 . . . . 0.0 110.064 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.521 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.6 ptm -147.05 -163.5 1.78 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.405 -0.809 . . . . 0.0 109.324 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.521 ' N ' ' HG3' ' B' ' 36' ' ' MET . 8.4 t -113.74 98.01 6.77 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -0.881 . . . . 0.0 110.099 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.608 HD13 ' CD2' ' B' ' 59' ' ' TYR . 27.1 mt -106.38 160.39 26.39 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.128 -0.983 . . . . 0.0 109.476 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.47 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.6 Cg_endo -77.94 65.28 8.3 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.732 2.288 . . . . 0.0 112.029 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 35.78 -157.37 0.01 OUTLIER Glycine 0 N--CA 1.498 2.813 0 O-C-N 121.442 -0.786 . . . . 0.0 111.239 178.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.495 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 63.25 60.28 1.19 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.513 -0.992 . . . . 0.0 109.237 -179.865 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.7 p-90 -139.08 -175.62 4.22 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' B' ' 43' ' ' LYS . 13.7 mmtm -143.3 136.83 14.18 Favored Pre-proline 0 N--CA 1.488 1.467 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.77 125.67 7.59 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.899 1.733 . . . . 0.0 111.403 -179.009 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.55 ' HE3' ' CD2' ' B' ' 76' ' ' LEU . 0.0 OUTLIER -162.74 149.93 13.31 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.607 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.454 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 1.8 mtp -110.04 148.0 32.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 0.0 110.414 -178.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.549 ' CG1' HG12 ' B' ' 54' ' ' ILE . 15.5 pt -90.68 155.67 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.486 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.87 106.03 1.24 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.472 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -136.12 -128.03 2.7 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.647 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.609 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 21.5 mt -87.91 127.46 41.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.614 -0.933 . . . . 0.0 112.683 -177.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 96.95 -20.75 49.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.05 -164.59 26.81 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.528 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 3.3 m-85 -105.64 125.74 51.34 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.391 -1.064 . . . . 0.0 109.701 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.549 HD12 ' CG2' ' A' ' 50' ' ' ILE . 23.1 pt -96.38 139.62 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.939 -1.1 . . . . 0.0 108.964 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -78.2 143.04 37.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.806 -1.184 . . . . 0.0 108.995 -179.905 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.532 HG21 ' NZ ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -149.3 -173.49 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.87 -1.144 . . . . 0.0 110.074 -179.482 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.407 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 2.6 mtm-85 -121.28 96.08 4.94 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.462 ' HG3' HG22 ' B' ' 74' ' ' THR . 1.8 tt0 -60.38 100.18 0.09 Allowed 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.329 -0.857 . . . . 0.0 109.846 -179.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.608 ' CD2' HD13 ' B' ' 38' ' ' LEU . 22.3 m-85 -96.31 94.59 7.55 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -78.78 140.01 38.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.894 -1.129 . . . . 0.0 110.626 -178.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.516 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.3 OUTLIER 69.17 64.89 0.28 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.714 -0.616 . . . . 0.0 110.309 179.255 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.697 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 0.7 OUTLIER -123.82 113.12 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.188 -0.945 . . . . 0.0 108.686 179.155 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.536 HD22 ' CG ' ' B' ' 70' ' ' LYS . 3.3 tm? -64.68 104.74 0.86 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.239 -0.913 . . . . 0.0 110.869 -178.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.536 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 1.2 tt -107.76 122.94 62.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.3 tt0 -88.09 114.58 24.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.04 -1.037 . . . . 0.0 109.078 -179.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.532 HG13 HG23 ' B' ' 13' ' ' ILE . 2.2 mp -111.32 116.79 53.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.321 -0.862 . . . . 0.0 110.052 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.488 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 80.0 m 63.41 8.24 3.4 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.58 -0.7 . . . . 0.0 110.668 179.124 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 104.53 22.96 8.19 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.045 179.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -125.77 130.92 52.42 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.137 -1.214 . . . . 0.0 109.231 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.536 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -69.45 131.04 44.13 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.53 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.536 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -145.77 96.87 2.88 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.887 -179.569 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.545 HD11 ' N ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.18 136.43 24.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 179.125 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.583 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -163.6 -173.45 32.3 Favored Glycine 0 C--N 1.294 -1.792 0 C-N-CA 118.695 -1.716 . . . . 0.0 110.658 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.462 HG22 ' HG3' ' B' ' 58' ' ' GLN . 86.5 m -92.25 106.41 18.42 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.664 -0.903 . . . . 0.0 109.331 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.591 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -95.83 105.05 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.652 -0.655 . . . . 0.0 109.982 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.55 ' CD2' ' HE3' ' B' ' 45' ' ' LYS . 5.6 mp -78.99 116.82 19.54 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.541 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 79.6 t -110.86 118.16 56.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 120.945 -1.097 . . . . 0.0 110.695 -178.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.519 ' N ' HG13 ' B' ' 56' ' ' VAL . . . -157.24 -150.4 5.69 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -83.07 41.28 1.07 Allowed 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.959 2.439 . . . . 0.0 110.258 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.552 HG21 ' N ' ' B' ' 34' ' ' GLU . 3.5 t -90.17 129.75 44.61 Favored Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 179.225 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.495 ' C ' ' CG2' ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.02 25.86 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.168 1.912 . . . . 0.0 111.558 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.573 HG22 ' C33' ' B' ' 100' ' ' DMP . 0.2 OUTLIER -161.4 154.01 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.719 -1.238 . . . . 0.0 110.785 -179.976 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.566 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 72.1 m-20 -96.38 83.05 3.48 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 175.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.549 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 12.4 mt -78.89 115.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.08 -1.013 . . . . 0.0 112.82 -175.248 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.51 ' CD1' ' N ' ' B' ' 85' ' ' ILE . 1.4 mm -95.66 93.05 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.503 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -77.87 -169.84 34.43 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.12 -1.038 . . . . 0.0 111.008 -177.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.462 ' HD2' ' HA ' ' A' ' 8' ' ' ARG . 10.1 mtp85 -58.41 -37.56 75.59 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.931 -0.746 . . . . 0.0 110.766 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.57 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 14.3 p-10 -46.57 -26.9 0.98 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.554 -1.341 . . . . 0.0 109.451 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.583 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 2.4 mm? -110.56 -28.87 8.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.212 -0.93 . . . . 0.0 111.132 -178.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.416 HD11 ' CG2' ' B' ' 26' ' ' THR . 66.9 mt -65.38 -22.25 66.77 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.745 -1.222 . . . . 0.0 108.29 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.428 ' CG2' ' NH2' ' B' ' 87' ' ' ARG . 82.7 p -83.63 -18.11 39.26 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 108.97 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -79.73 -41.76 26.02 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.881 . . . . 0.0 109.569 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.59 ' CD1' ' CD2' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -82.89 -2.9 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.032 179.431 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.54 63.08 4.12 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -86.29 161.94 18.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.399 -1.059 . . . . 0.0 109.967 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.511 HG21 ' CG2' ' A' ' 4' ' ' THR . 2.6 p -141.4 129.92 22.62 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.206 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.534 HD12 ' CD1' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.9 94.4 6.28 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -179.872 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.514 ' N ' ' ND2' ' B' ' 98' ' ' ASN . 0.8 OUTLIER -105.26 130.88 53.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 110.851 -178.49 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.576 ' CG ' HD13 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.143 179.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.609 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.45 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.497 1.692 0 N-CA-C 110.76 -0.515 . . . . 0.0 110.76 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.462 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.8 tt0 -83.51 142.42 30.92 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.412 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 51.9 t -141.32 128.76 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 118.012 -1.475 . . . . 0.0 111.047 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.481 ' OG1' ' N ' ' A' ' 5' ' ' LEU . 1.3 p -132.34 -57.26 0.96 Allowed 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.205 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.0 OUTLIER 39.0 28.24 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.548 -0.72 . . . . 0.0 110.414 179.352 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.491 ' C ' ' O ' ' A' ' 5' ' ' LEU . 4.4 m95 18.02 43.91 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.411 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' A' ' 5' ' ' LEU . 15.9 mm100 -158.78 -111.5 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 108.855 179.385 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 77.1 mtt180 -111.98 134.06 21.49 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 120.621 -1.3 . . . . 0.0 109.352 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -81.18 54.4 5.19 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 122.357 2.038 . . . . 0.0 110.057 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.555 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.72 146.77 30.89 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.946 -1.096 . . . . 0.0 109.69 -179.495 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.44 HG23 HG12 ' A' ' 66' ' ' ILE . 2.4 m -138.03 136.11 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.2 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.427 HG21 HD23 ' A' ' 19' ' ' LEU . 94.9 m -60.35 113.65 2.51 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.55 ' HB ' ' CG1' ' A' ' 64' ' ' ILE . 1.0 OUTLIER -106.24 137.02 38.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 O-C-N 121.091 -1.006 . . . . 0.0 110.419 -178.684 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.53 ' CA ' HD22 ' A' ' 19' ' ' LEU . 2.7 ttpt -110.45 105.17 14.05 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.407 -0.808 . . . . 0.0 109.049 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.548 HD13 ' CD2' ' A' ' 33' ' ' LEU . 40.8 mt -118.42 122.01 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.121 -0.987 . . . . 0.0 109.887 -179.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.02 10.86 59.95 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 178.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.16 -7.02 60.05 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.6 178.36 6.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -1.109 . . . . 0.0 108.987 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.53 HD22 ' CA ' ' A' ' 14' ' ' LYS . 11.3 mt -151.06 129.66 12.24 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.236 -0.915 . . . . 0.0 110.74 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -150.61 157.0 42.46 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.555 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 61.6 mt-10 -77.94 131.36 37.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.576 -1.327 . . . . 0.0 108.428 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.607 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -107.7 148.03 29.96 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.086 -1.009 . . . . 0.0 110.235 -178.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.478 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 30.9 tp -98.9 95.85 7.45 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.163 0.506 . . . . 0.0 110.431 -178.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.523 HD21 ' N ' ' A' ' 24' ' ' LEU . 0.2 OUTLIER -47.16 115.7 1.17 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 178.916 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.566 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 12.8 t70 -131.8 108.18 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.747 -1.221 . . . . 0.0 111.15 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.481 ' OG1' ' OG1' ' B' ' 26' ' ' THR . 0.0 OUTLIER -79.97 -2.59 44.6 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.817 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.463 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -80.74 -21.66 63.32 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.84 161.83 13.55 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.131 -1.217 . . . . 0.0 109.892 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.505 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 50.4 m-20 -92.85 -20.1 21.03 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.406 -0.809 . . . . 0.0 110.919 -179.083 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -139.17 -169.08 2.58 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.621 -1.3 . . . . 0.0 110.203 -179.438 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.531 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 21.5 m -103.56 107.15 17.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.12 -0.988 . . . . 0.0 109.76 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.697 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -97.89 126.23 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.076 -1.015 . . . . 0.0 110.003 -179.469 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.548 ' CD2' HD13 ' A' ' 15' ' ' ILE . 3.8 mp -120.88 124.82 45.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.772 -1.205 . . . . 0.0 111.277 -178.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.591 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 3.2 pt-20 -43.77 163.45 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.295 -0.962 . . . . 0.0 108.525 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.47 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -44.25 137.84 3.32 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.033 -1.042 . . . . 0.0 110.212 -179.409 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.536 ' CE ' HG23 ' A' ' 15' ' ' ILE . 8.6 ptm -146.71 -163.16 1.69 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.512 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.4 t -108.22 84.3 1.92 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.975 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.62 HD11 ' CD2' ' A' ' 59' ' ' TYR . 13.4 mt -108.84 165.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 108.993 179.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.545 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.0 Cg_endo -73.45 -167.36 0.36 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.369 2.046 . . . . 0.0 111.37 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.32 33.03 6.9 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.111 -1.042 . . . . 0.0 110.503 -178.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.63 53.99 0.7 Allowed 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.624 -0.927 . . . . 0.0 108.616 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.628 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 51.2 p-90 -131.6 -168.75 2.07 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.623 0.725 . . . . 0.0 110.616 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.467 ' HG2' ' O ' ' A' ' 42' ' ' TRP . 15.3 mttt -147.17 131.07 8.41 Favored Pre-proline 0 N--CA 1.49 1.53 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -76.2 141.22 23.08 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.126 1.884 . . . . 0.0 111.042 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' NZ ' HD22 ' A' ' 76' ' ' LEU . 1.3 ptpp? -152.38 177.06 10.99 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.412 ' HE2' ' HG3' ' A' ' 55' ' ' LYS . 0.3 OUTLIER -129.65 124.75 34.42 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.079 -1.013 . . . . 0.0 108.842 179.507 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 4.9 pt -96.42 149.87 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.238 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.646 ' CA ' ' CD2' ' A' ' 53' ' ' PHE . . . -122.48 108.9 1.32 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.79 -124.03 2.41 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 119.388 -1.387 . . . . 0.0 110.453 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.611 HG13 ' H32' ' B' ' 100' ' ' DMP . 64.7 mt -85.56 128.86 38.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.713 -0.875 . . . . 0.0 112.343 -177.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.24 -48.99 2.41 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.87 -157.78 26.22 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.646 ' CD2' ' CA ' ' A' ' 48' ' ' GLY . 3.5 m-85 -111.82 143.54 42.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -1.113 . . . . 0.0 109.573 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.553 HG12 ' CG2' ' B' ' 50' ' ' ILE . 3.8 pt -119.11 150.77 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.184 -0.947 . . . . 0.0 108.975 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 14.8 mttp -90.16 118.58 29.79 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.11 -0.994 . . . . 0.0 109.925 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.48 ' CG1' ' HA3' ' A' ' 78' ' ' GLY . 14.9 m -125.56 -167.5 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.226 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 mtt85 -125.76 173.82 8.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.278 -0.889 . . . . 0.0 109.493 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.501 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 3.4 tt0 -130.77 123.93 30.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.409 -0.807 . . . . 0.0 109.919 -179.804 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 41.9 m-85 -121.14 91.36 3.51 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.3 m-20 -78.98 133.26 36.86 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.098 -1.001 . . . . 0.0 109.692 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 1.6 mt-30 83.36 57.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.482 0.658 . . . . 0.0 109.379 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.481 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 3.0 mm -114.3 114.03 45.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.514 ' N ' HD11 ' A' ' 72' ' ' ILE . 0.0 OUTLIER -70.27 87.22 0.6 Allowed 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.271 -178.95 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.551 ' CG2' HD13 ' A' ' 89' ' ' LEU . 13.5 tt -88.5 123.68 41.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -89.46 106.19 18.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.985 -1.072 . . . . 0.0 109.038 -178.995 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.524 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.5 OUTLIER -106.13 123.22 60.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.009 -179.621 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 13.6 m 49.11 69.12 0.61 Allowed 'General case' 0 C--N 1.293 -1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.452 179.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 42.59 27.3 0.5 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.3 m-70 -122.97 130.74 53.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.897 -1.355 . . . . 0.0 109.065 179.268 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.497 ' CG ' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -75.01 133.21 41.71 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 108.837 179.404 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.508 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -154.47 108.32 2.94 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.876 . . . . 0.0 110.459 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.536 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.8 OUTLIER -85.48 152.45 3.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 177.971 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.507 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -175.7 -178.32 45.43 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.206 -1.949 . . . . 0.0 111.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.457 HG22 ' OD1' ' A' ' 60' ' ' ASP . 90.1 m -92.66 106.36 18.35 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.627 -0.925 . . . . 0.0 110.139 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.535 ' CG1' HD12 ' A' ' 33' ' ' LEU . 1.3 t -97.01 176.65 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.697 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.9 mp -139.4 161.48 37.35 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.966 -1.084 . . . . 0.0 108.288 178.127 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.555 ' CG2' HD11 ' A' ' 38' ' ' LEU . 19.5 t -143.47 105.46 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.91 0 O-C-N 121.379 -0.825 . . . . 0.0 109.734 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -149.7 -162.49 10.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -80.3 40.18 0.94 Allowed 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.473 2.116 . . . . 0.0 110.705 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.591 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 9.5 t -85.59 132.75 43.61 Favored Pre-proline 0 C--N 1.3 -1.572 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 179.056 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.468 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 33.0 Cg_endo -77.92 17.5 0.99 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.407 2.071 . . . . 0.0 111.356 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.493 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.1 t -162.22 162.22 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.837 -1.165 . . . . 0.0 109.983 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.607 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -96.94 154.38 17.33 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 175.21 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.566 ' CG2' ' HB3' ' A' ' 25' ' ' ASP . 1.1 mm -144.2 134.18 20.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 O-C-N 120.057 -1.652 . . . . 0.0 109.963 -178.244 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.529 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 1.1 mp -105.16 88.97 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 177.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.489 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.61 -164.45 22.81 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.905 -1.14 . . . . 0.0 110.278 -177.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.539 ' HD2' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -61.82 -35.62 78.78 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.624 -0.927 . . . . 0.0 109.567 -179.134 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.582 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 8.1 p-10 -45.15 -25.07 0.31 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 108.891 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.582 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -112.91 -29.17 7.46 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 121.375 -0.828 . . . . 0.0 110.472 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.482 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 77.7 mt -68.25 -7.26 29.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.967 -1.083 . . . . 0.0 109.157 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.48 -19.69 15.42 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 108.607 179.085 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -80.65 -41.17 24.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.222 -0.924 . . . . 0.0 108.874 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.58 HD11 ' CG ' ' B' ' 99' ' ' PHE . 3.7 pt -83.77 -5.61 9.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.01 34.28 55.89 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.163 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.564 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -64.25 151.9 42.38 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.261 . . . . 0.0 110.624 -179.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 30.9 p -148.32 128.21 13.5 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.534 ' CD1' HD12 ' B' ' 97' ' ' LEU . 3.0 mp -87.81 95.05 9.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.11 -0.994 . . . . 0.0 109.443 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.591 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.0 OUTLIER -114.46 129.97 56.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 110.674 -179.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.172 178.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 N-CA-C 109.744 -0.906 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.591 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.2 tt0 -81.92 149.63 28.13 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 178.249 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.523 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 61.2 t -148.46 96.2 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 117.832 -1.547 . . . . 0.0 110.868 -178.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.449 HG22 ' OE1' ' B' ' 2' ' ' GLN . 71.3 p -100.75 -55.67 2.52 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.135 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.653 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.2 OUTLIER 43.99 18.99 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.757 -0.589 . . . . 0.0 111.524 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.537 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.3 m95 18.53 43.15 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.096 0.407 . . . . 0.0 111.895 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.653 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -170.85 -103.3 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 63.8 mtt180 -113.58 127.87 26.34 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 120.351 -1.468 . . . . 0.0 110.252 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.477 ' HB3' HG13 ' B' ' 3' ' ' VAL . 36.7 Cg_endo -78.99 71.48 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 121.94 1.76 . . . . 0.0 108.335 177.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -93.93 152.21 19.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.117 -0.989 . . . . 0.0 110.933 -178.083 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.463 HG22 HG21 ' B' ' 66' ' ' ILE . 2.0 m -151.03 150.39 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.663 -0.648 . . . . 0.0 109.414 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 99.7 m -78.16 115.45 17.89 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.552 ' HA ' ' O ' ' B' ' 65' ' ' GLU . 2.5 pp -103.89 151.4 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.024 -1.048 . . . . 0.0 110.507 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.1 OUTLIER -109.47 102.87 11.7 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.198 -0.939 . . . . 0.0 109.694 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.535 HD12 ' CG1' ' B' ' 75' ' ' VAL . 3.9 mt -121.37 134.28 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.986 -1.071 . . . . 0.0 110.159 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.478 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 58.66 27.24 61.12 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 179.317 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.13 27.3 66.55 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm-40 -124.41 -178.76 4.21 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.464 -1.021 . . . . 0.0 109.121 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.489 ' O ' ' HG2' ' B' ' 20' ' ' LYS . 19.8 mt -147.45 125.27 11.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 0.0 109.706 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.489 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mmtt -144.5 169.28 18.26 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.512 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 9.4 mt-10 -79.69 135.43 36.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 108.442 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.534 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -121.9 135.45 54.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.983 -1.073 . . . . 0.0 110.669 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 15.5 tp -92.04 94.1 9.08 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.468 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 14.2 mt -45.83 101.47 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.989 -1.069 . . . . 0.0 108.719 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.523 ' HB2' HG22 ' B' ' 84' ' ' ILE . 7.4 t70 -101.59 96.75 7.32 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.754 -0.591 . . . . 0.0 110.419 -178.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.557 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 24.6 m -79.68 13.49 2.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.504 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -109.83 -19.33 8.26 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.37 170.46 15.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.93 -1.336 . . . . 0.0 109.141 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -99.92 -18.08 17.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 110.088 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.539 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 16.1 m-20 -142.97 -155.16 0.57 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.064 -1.022 . . . . 0.0 109.658 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.588 ' OG1' ' HG ' ' B' ' 89' ' ' LEU . 78.5 m -120.19 97.82 5.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.511 -1.368 . . . . 0.0 111.262 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.585 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -76.83 174.87 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.073 -1.017 . . . . 0.0 108.445 178.969 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.585 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.04 119.46 0.61 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.765 -1.209 . . . . 0.0 110.936 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.516 ' HA ' HG21 ' B' ' 80' ' ' THR . 41.6 tt0 -36.66 158.77 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.453 0.644 . . . . 0.0 110.009 179.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.407 ' O ' ' HB3' ' B' ' 36' ' ' MET . 0.0 OUTLIER -52.42 147.31 8.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.497 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.467 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER 179.55 178.35 0.54 Allowed 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.6 t -92.49 101.62 14.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.074 -1.017 . . . . 0.0 109.563 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.585 ' O ' ' CZ ' ' B' ' 59' ' ' TYR . 58.0 tp -130.69 98.24 20.1 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.119 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -78.76 -177.77 4.15 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.618 2.212 . . . . 0.0 110.393 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 113.63 31.65 2.29 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.42 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.481 ' O ' ' O ' ' B' ' 40' ' ' GLY . 49.0 mtm180 59.78 141.44 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.901 -0.764 . . . . 0.0 109.401 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.597 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 47.9 p-90 -160.3 -172.13 3.46 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.782 -1.199 . . . . 0.0 110.832 -179.286 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.465 ' HD3' ' HD2' ' B' ' 44' ' ' PRO . 1.8 mmtp -148.27 145.16 19.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . 0.465 ' HD2' ' HD3' ' B' ' 43' ' ' LYS . 35.8 Cg_endo -78.16 136.24 14.34 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 122.018 1.812 . . . . 0.0 110.932 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.434 ' HD2' ' CD ' ' B' ' 58' ' ' GLN . 0.3 OUTLIER -160.29 -168.79 2.27 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.456 -0.778 . . . . 0.0 109.592 179.427 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.508 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 60.5 mtp -150.53 138.31 19.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.452 -0.78 . . . . 0.0 109.676 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.545 HD13 ' CG2' ' A' ' 50' ' ' ILE . 4.9 pt -95.93 150.09 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.03 -1.044 . . . . 0.0 108.535 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.82 102.53 0.94 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.81 -135.84 4.25 Favored Glycine 0 N--CA 1.483 1.821 0 C-N-CA 119.324 -1.417 . . . . 0.0 111.015 -178.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.579 ' CD1' ' C26' ' B' ' 100' ' ' DMP . 46.1 mt -79.87 119.63 29.66 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.855 -0.791 . . . . 0.0 112.912 -177.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 104.97 -54.47 0.61 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.076 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.02 -159.62 20.78 Favored Glycine 0 N--CA 1.492 2.378 0 O-C-N 120.947 -1.325 . . . . 0.0 110.201 -179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.607 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-85 -118.9 125.85 50.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.475 -1.015 . . . . 0.0 109.161 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.457 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 5.2 pt -97.81 173.19 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.255 -0.903 . . . . 0.0 109.438 -179.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mtmt -109.03 125.58 52.23 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.147 -0.971 . . . . 0.0 109.626 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.525 ' CG2' ' HB3' ' B' ' 76' ' ' LEU . 15.6 m -134.86 168.76 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 110.279 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 18.4 mtt180 -110.33 111.41 22.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.588 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -69.04 121.69 17.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.409 -0.807 . . . . 0.0 110.471 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.597 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 23.9 m-85 -116.05 93.69 4.35 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 6.4 m-20 -77.6 124.97 28.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.8 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 48.6 mt-30 88.81 60.41 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 CA-C-O 121.32 0.581 . . . . 0.0 110.105 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.517 ' CG2' HG23 ' B' ' 75' ' ' VAL . 19.0 mm -115.57 109.82 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.116 179.498 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.575 HD21 HG13 ' B' ' 72' ' ' ILE . 3.0 tm? -65.27 85.56 0.06 Allowed 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.033 0.92 . . . . 0.0 110.717 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.617 HG23 ' CD1' ' B' ' 89' ' ' LEU . 0.6 OUTLIER -92.16 119.68 40.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 177.37 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.552 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.5 tt0 -87.14 128.84 35.12 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.163 -0.961 . . . . 0.0 108.957 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.492 HG13 HG23 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -114.9 129.76 70.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.014 -179.313 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 86.2 m 54.52 -91.27 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.574 -0.704 . . . . 0.0 109.804 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -147.18 40.82 0.98 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -145.72 149.58 34.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -1.046 . . . . 0.0 109.287 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.539 ' HG2' ' CD2' ' B' ' 63' ' ' LEU . 0.1 OUTLIER -79.04 139.63 38.11 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.077 -1.014 . . . . 0.0 109.467 -179.805 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.522 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -147.62 109.55 4.47 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.081 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.575 HG13 HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -94.88 145.46 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.215 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.543 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -169.22 -178.09 40.32 Favored Glycine 0 C--N 1.297 -1.636 0 C-N-CA 118.442 -1.837 . . . . 0.0 111.083 179.562 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.588 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.1 m -87.73 100.54 12.91 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 122.139 -0.624 . . . . 0.0 109.951 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.535 ' CG1' HD12 ' B' ' 15' ' ' ILE . 1.3 t -85.54 121.11 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.053 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.525 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 2.6 mp -96.73 104.25 16.23 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' B' ' 33' ' ' LEU . 21.8 t -93.45 112.03 25.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.04 -1.038 . . . . 0.0 109.993 -179.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.67 -160.85 9.45 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.556 -1.817 . . . . 0.0 108.556 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.539 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -79.98 38.31 0.73 Allowed 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.388 2.059 . . . . 0.0 110.973 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.516 HG21 ' HA ' ' B' ' 34' ' ' GLU . 1.8 t -81.98 134.96 48.79 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.464 ' O ' HG21 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -79.04 15.14 1.57 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.583 2.189 . . . . 0.0 111.311 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.2 t -160.59 161.01 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.999 -1.063 . . . . 0.0 109.804 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.534 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -98.24 129.12 44.98 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 104.157 -2.534 . . . . 0.0 104.157 175.51 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.523 HG22 ' HB2' ' B' ' 25' ' ' ASP . 5.0 mm -117.12 129.38 73.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.957 0 O-C-N 120.331 -1.481 . . . . 0.0 111.923 -176.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.418 HD11 HG21 ' B' ' 31' ' ' THR . 3.4 mm -102.19 105.19 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 176.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.539 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -98.8 -163.65 30.14 Favored Glycine 0 N--CA 1.496 2.691 0 C-N-CA 119.826 -1.178 . . . . 0.0 111.823 -177.307 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.576 ' N ' ' NH2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -53.28 -40.91 65.06 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 122.005 -0.703 . . . . 0.0 111.714 -178.193 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.487 ' CG ' HD22 ' B' ' 89' ' ' LEU . 53.0 p-10 -48.14 -26.16 1.77 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.548 -1.345 . . . . 0.0 111.007 -177.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.617 ' CD1' HG23 ' B' ' 64' ' ' ILE . 2.3 mt -115.31 -27.77 7.12 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.32 -1.487 . . . . 0.0 111.602 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mt -63.38 -11.77 25.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.212 -1.555 . . . . 0.0 108.259 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -101.67 -19.65 15.33 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.196 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 69.9 mm-40 -79.16 -41.23 28.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.726 -0.608 . . . . 0.0 110.581 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.513 ' CD1' ' HB1' ' B' ' 95' ' ' ALA . 1.0 OUTLIER -80.44 -22.12 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 179.52 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.45 ' C ' ' HB3' ' A' ' 99' ' ' PHE . . . 103.02 35.48 3.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.565 ' HB3' ' CD1' ' A' ' 99' ' ' PHE . . . -72.43 135.68 45.83 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.388 -1.066 . . . . 0.0 111.185 -178.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.4 HG23 ' CG2' ' A' ' 4' ' ' THR . 75.1 p -136.66 128.87 29.78 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.585 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.534 HD12 ' CD1' ' A' ' 97' ' ' LEU . 6.3 mp -83.49 105.32 14.33 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 108.68 -179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 5.9 m120 -103.53 122.62 45.32 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.049 -1.032 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.58 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.135 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.611 ' H32' HG13 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.497 1.711 0 N-CA-C 110.178 -0.739 . . . . 0.0 110.178 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.539 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -83.16 148.94 27.17 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 106.471 -1.677 . . . . 0.0 106.471 177.815 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.516 HG12 ' CB ' ' A' ' 9' ' ' PRO . 2.3 t -140.76 105.98 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.902 -178.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.563 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -122.05 -69.03 0.85 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 176.694 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER 31.76 29.94 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.964 177.893 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.563 ' N ' ' O ' ' A' ' 4' ' ' THR . 17.3 m95 18.88 48.37 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.145 0 CA-C-O 121.331 0.586 . . . . 0.0 111.871 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.575 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -164.25 -175.5 3.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.172 -0.955 . . . . 0.0 109.401 179.8 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.474 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 1.6 mtt180 -76.38 119.27 76.61 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.267 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.516 ' CB ' HG12 ' A' ' 3' ' ' VAL . 35.3 Cg_endo -79.11 74.52 5.51 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.833 1.689 . . . . 0.0 108.92 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.427 HD22 ' C ' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -80.69 150.65 29.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.532 -0.73 . . . . 0.0 110.455 -178.609 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.482 ' HB ' ' SG ' ' A' ' 67' ' ' CYS . 2.0 m -150.05 162.04 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.413 -0.804 . . . . 0.0 109.33 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 42.5 m -96.12 114.04 25.7 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.57 HG21 ' CB ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -97.95 171.74 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.901 -178.941 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.508 ' CA ' HD22 ' A' ' 19' ' ' LEU . 6.5 tttt -131.78 102.38 5.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 109.406 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.556 HG13 HG13 ' A' ' 64' ' ' ILE . 48.6 mt -118.44 132.09 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.984 -1.072 . . . . 0.0 109.902 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.26 40.13 98.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.03 18.45 60.12 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 mm-40 -112.89 171.62 7.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.336 -1.097 . . . . 0.0 109.094 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.529 ' CD2' ' O ' ' A' ' 13' ' ' ILE . 14.4 mt -142.9 126.92 17.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.218 -0.926 . . . . 0.0 110.3 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 7.2 mttt -143.52 -167.7 2.64 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 43.5 mt-10 -79.4 -167.82 1.32 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.989 -1.07 . . . . 0.0 108.145 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.57 ' CB ' HG21 ' A' ' 13' ' ' ILE . . . -171.3 86.85 0.09 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.085 -1.009 . . . . 0.0 109.454 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.578 ' O ' ' N ' ' A' ' 25' ' ' ASP . 36.5 tp -72.47 95.35 1.77 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.346 -0.846 . . . . 0.0 109.032 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.477 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 49.6 mt -48.93 90.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' N ' ' O ' ' A' ' 23' ' ' LEU . 0.6 OUTLIER -99.52 92.98 5.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.49 -0.756 . . . . 0.0 110.825 -177.995 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.557 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 1.5 m -73.11 -2.03 19.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.574 178.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.565 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.84 -36.36 13.74 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.412 ' HB3' ' C27' ' B' ' 100' ' ' DMP . . . -79.91 136.74 36.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.086 -1.244 . . . . 0.0 109.686 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.535 ' HA ' ' HG2' ' A' ' 87' ' ' ARG . 19.3 m-20 -64.15 -19.2 65.13 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.434 -0.791 . . . . 0.0 111.126 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.56 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 0.7 OUTLIER -141.79 -179.28 6.1 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.121 -1.432 . . . . 0.0 110.987 -179.324 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.582 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 2.3 m -96.18 89.41 5.13 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.471 -0.768 . . . . 0.0 110.612 -178.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.545 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -69.38 163.28 3.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.729 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.545 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -158.45 131.72 7.43 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.112 -0.993 . . . . 0.0 110.691 -178.558 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.476 ' HA ' HG21 ' A' ' 80' ' ' THR . 57.7 tt0 -43.44 164.77 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.7 OUTLIER -56.91 134.56 55.6 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.149 -0.97 . . . . 0.0 110.703 -179.285 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.481 ' SD ' ' HG ' ' A' ' 38' ' ' LEU . 2.2 ppp? -162.63 -167.56 1.59 Allowed 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.4 t -106.5 138.33 42.88 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.831 -1.168 . . . . 0.0 110.451 -179.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.602 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 5.4 mt -143.33 171.1 7.4 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.602 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -70.24 -153.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 121.853 1.702 . . . . 0.0 110.27 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.51 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -110.6 -167.25 19.27 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 -178.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.51 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.1 OUTLIER 73.07 54.6 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.113 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.662 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 3.9 p-90 -126.01 -176.84 3.75 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.791 0.805 . . . . 0.0 110.543 -178.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.416 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 14.0 mttp -147.54 160.87 37.66 Favored Pre-proline 0 N--CA 1.489 1.517 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.115 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 32.0 Cg_endo -75.78 147.48 31.15 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.166 1.91 . . . . 0.0 109.373 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.532 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -146.0 165.41 29.09 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.014 -1.054 . . . . 0.0 110.078 -178.932 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.451 ' HE3' ' HD3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -148.38 112.29 5.14 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.046 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.51 HG13 HG13 ' A' ' 54' ' ' ILE . 6.7 pt -106.1 129.45 59.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.48 -1.288 . . . . 0.0 109.467 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.587 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -116.82 100.71 0.91 Allowed Glycine 0 N--CA 1.482 1.753 0 N-CA-C 107.15 -2.38 . . . . 0.0 107.15 179.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.421 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -119.18 -128.62 3.8 Favored Glycine 0 N--CA 1.479 1.565 0 C-N-CA 119.269 -1.443 . . . . 0.0 111.084 -177.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.598 ' CD1' ' C76' ' B' ' 100' ' ' DMP . 59.1 mt -85.4 119.16 33.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 O-C-N 122.074 -0.663 . . . . 0.0 112.429 -177.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 109.79 -36.42 4.31 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 162.99 -162.09 34.41 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.492 -1.337 . . . . 0.0 110.147 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.587 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.7 m-85 -115.12 141.99 47.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.467 -1.02 . . . . 0.0 109.466 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.532 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 3.0 pt -128.51 178.24 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.505 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -112.66 138.06 50.0 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.05 -1.031 . . . . 0.0 109.405 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 45' ' ' LYS . 33.5 m -144.09 161.61 15.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.294 -0.879 . . . . 0.0 109.35 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.53 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -104.49 -176.63 3.14 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.145 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.411 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 7.1 tt0 -137.6 101.45 4.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.006 . . . . 0.0 109.543 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.662 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 40.1 m-85 -103.41 95.73 6.27 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.424 -0.797 . . . . 0.0 109.517 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.504 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -78.88 140.85 38.05 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.955 -1.091 . . . . 0.0 108.982 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.504 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 76.38 64.06 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.819 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.565 ' CD1' ' HB3' ' A' ' 59' ' ' TYR . 21.4 mm -121.8 123.34 69.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.536 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -67.56 82.47 0.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.355 -0.841 . . . . 0.0 110.935 -178.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.556 HG13 HG13 ' A' ' 15' ' ' ILE . 2.5 tt -94.34 121.25 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.406 ' HG2' ' C ' ' A' ' 69' ' ' HIS . 1.7 tt0 -89.17 140.57 29.33 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.099 -1.001 . . . . 0.0 108.486 179.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.553 HD11 HG23 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -126.05 171.97 14.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 107.165 -1.421 . . . . 0.0 107.165 179.672 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.482 ' SG ' ' HB ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -47.96 -38.63 17.21 Favored 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 178.836 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.635 ' O ' ' CG ' ' A' ' 69' ' ' HIS . . . -52.79 -49.59 53.4 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 178.319 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.635 ' CG ' ' O ' ' A' ' 68' ' ' GLY . 5.2 m170 141.66 -173.39 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.076 0 CA-C-O 121.102 0.477 . . . . 0.0 109.838 178.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.523 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -36.56 139.51 0.18 Allowed 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 121.351 0.596 . . . . 0.0 109.773 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.533 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -161.8 115.33 1.87 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.304 -0.872 . . . . 0.0 110.02 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.514 ' HA ' ' O ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -85.57 150.7 3.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.595 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.24 -154.92 11.73 Favored Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.262 -1.446 . . . . 0.0 110.835 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.483 ' HB ' ' OD1' ' A' ' 88' ' ' ASN . 1.4 m -109.7 111.95 23.73 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.246 -1.149 . . . . 0.0 110.087 -179.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.535 HG21 ' HB ' ' A' ' 62' ' ' ILE . 1.4 t -106.15 108.39 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.262 -0.899 . . . . 0.0 111.243 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.532 ' CD2' ' HE2' ' A' ' 45' ' ' LYS . 2.8 mp -79.12 139.55 38.02 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 177.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.43 HG23 ' CD1' ' A' ' 38' ' ' LEU . 1.3 t -116.2 112.47 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.084 -1.01 . . . . 0.0 110.978 -178.144 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -149.54 -172.17 18.83 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.505 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.2 Cg_endo -81.45 41.62 1.18 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.58 2.187 . . . . 0.0 110.681 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.476 HG21 ' HA ' ' A' ' 34' ' ' GLU . 3.8 t -79.3 141.56 57.62 Favored Pre-proline 0 N--CA 1.49 1.553 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.21 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.514 ' O ' ' CG2' ' A' ' 82' ' ' VAL . 38.2 Cg_endo -80.07 20.02 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.583 2.188 . . . . 0.0 110.872 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.545 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 10.5 t -161.13 166.8 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.702 -1.248 . . . . 0.0 110.92 -178.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.545 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 7.8 m-80 -100.44 90.45 4.3 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 177.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.582 ' O ' ' HA ' ' A' ' 31' ' ' THR . 12.1 mm -79.14 120.04 29.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 O-C-N 121.183 -0.948 . . . . 0.0 112.379 -176.027 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.509 ' CG2' ' HB3' ' A' ' 89' ' ' LEU . 3.3 mm -99.07 106.11 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 176.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -91.47 -152.18 27.94 Favored Glycine 0 N--CA 1.489 2.197 0 O-C-N 120.679 -1.263 . . . . 0.0 111.861 -176.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.557 ' NH2' ' O ' ' A' ' 26' ' ' THR . 0.1 OUTLIER -70.7 -41.29 72.15 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 120.111 -0.636 . . . . 0.0 109.852 -179.032 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.56 ' OD1' ' HA ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -53.33 -16.39 1.33 Allowed 'General case' 0 N--CA 1.498 1.963 0 C-N-CA 117.821 -1.552 . . . . 0.0 110.422 -178.965 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.679 ' CD1' ' OE1' ' A' ' 92' ' ' GLN . 0.2 OUTLIER -105.76 -20.82 13.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.658 -1.276 . . . . 0.0 109.054 179.825 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.456 HD11 ' CG2' ' A' ' 26' ' ' THR . 28.7 mt -80.95 1.1 32.55 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.654 -1.279 . . . . 0.0 108.535 178.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.551 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 0.3 OUTLIER -101.08 -10.06 20.83 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.137 -0.977 . . . . 0.0 111.159 -179.958 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.679 ' OE1' ' CD1' ' A' ' 89' ' ' LEU . 0.0 OUTLIER -95.15 -40.81 9.41 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 120.467 -1.396 . . . . 0.0 109.562 -178.552 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.58 HD13 ' CD2' ' B' ' 99' ' ' PHE . 0.3 OUTLIER -80.48 3.3 2.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.013 -1.075 . . . . 0.0 108.349 178.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 69.87 53.05 16.71 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -77.27 144.98 37.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.121 -1.223 . . . . 0.0 109.271 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.524 ' CG2' HG21 ' B' ' 4' ' ' THR . 27.3 p -139.85 123.27 17.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.157 -0.964 . . . . 0.0 109.27 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.6 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 7.4 mp -84.72 100.61 11.61 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 178.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' B' ' 94' ' ' GLY . 18.5 m120 -99.17 120.01 38.8 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 120.447 -1.408 . . . . 0.0 108.934 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.625 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.298 -1.64 0 CA-C-O 118.101 -0.952 . . . . 0.0 109.282 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.612 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.7 Cg_exo . . . . . 0 N--CA 1.493 1.488 0 N-CA-C 109.917 -0.839 . . . . 0.0 109.917 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 130.7 35.14 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.439 HG22 ' CZ ' ' A' ' 99' ' ' PHE . 56.3 t -123.57 109.04 22.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.595 -177.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.524 HG21 ' CG2' ' A' ' 96' ' ' THR . 14.7 p -123.97 21.59 8.98 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.411 -0.806 . . . . 0.0 109.967 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.6 tp -88.82 27.31 1.34 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.023 -1.048 . . . . 0.0 108.758 178.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER 14.98 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.685 0.755 . . . . 0.0 111.918 179.698 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.512 ' O ' ' HD3' ' B' ' 9' ' ' PRO . 1.0 OUTLIER -129.31 -152.46 0.52 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.448 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 26.5 mtt180 -103.72 101.43 24.37 Favored Pre-proline 0 N--CA 1.488 1.45 0 O-C-N 120.903 -1.123 . . . . 0.0 108.133 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.541 ' HD2' ' NH2' ' A' ' 87' ' ' ARG . 33.9 Cg_endo -75.13 72.06 4.86 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.413 2.075 . . . . 0.0 110.698 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -89.78 142.88 27.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.017 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.531 HG22 ' CG2' ' B' ' 13' ' ' ILE . 21.9 m -131.15 126.05 58.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.3 m -67.34 99.88 0.76 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 177.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.578 HG22 ' HB1' ' B' ' 22' ' ' ALA . 1.1 pp -95.91 140.53 16.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.242 -0.911 . . . . 0.0 111.298 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.502 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -103.63 106.91 17.56 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.734 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.525 HD11 HG22 ' B' ' 15' ' ' ILE . 7.2 mt -119.68 115.65 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.206 -0.934 . . . . 0.0 110.154 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.48 27.78 73.13 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.606 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.77 12.3 81.63 Favored Glycine 0 N--CA 1.492 2.419 0 O-C-N 120.901 -1.353 . . . . 0.0 109.789 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.488 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.4 mt-30 -107.44 168.57 9.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.208 -1.172 . . . . 0.0 109.134 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.502 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 14.7 mt -140.48 122.95 16.06 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 0.0 109.514 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.517 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mmtt -143.87 172.95 12.15 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.503 -0.748 . . . . 0.0 109.236 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 31.1 mp0 -87.13 132.06 33.97 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.578 ' HB1' HG22 ' B' ' 13' ' ' ILE . . . -107.78 147.32 30.99 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.025 -1.047 . . . . 0.0 109.587 -179.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' B' ' 25' ' ' ASP . 18.6 tp -112.84 94.43 4.9 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.569 -0.707 . . . . 0.0 109.462 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.506 ' O ' ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -41.41 95.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.423 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.565 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 24.6 t0 -113.57 88.95 2.96 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.198 -0.939 . . . . 0.0 111.538 -178.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.69 -19.67 65.2 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 177.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.456 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -55.57 -39.51 75.13 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.522 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -84.46 164.73 18.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.46 -1.023 . . . . 0.0 109.306 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.459 ' OD1' ' HG3' ' A' ' 8' ' ' ARG . 12.4 m-20 -94.96 -19.57 20.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.075 -1.016 . . . . 0.0 110.921 -178.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.538 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -137.22 -175.71 4.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.747 -1.22 . . . . 0.0 110.198 -179.491 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 52.3 m -100.21 94.7 6.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.03 -1.044 . . . . 0.0 110.856 -178.224 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.632 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -75.05 158.72 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.092 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.559 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.5 OUTLIER -155.46 143.07 19.65 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.908 -1.12 . . . . 0.0 111.052 -178.092 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.528 ' N ' HG21 ' B' ' 80' ' ' THR . 20.2 tt0 -49.68 156.15 0.72 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.6 OUTLIER -61.69 132.78 54.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.076 -1.015 . . . . 0.0 109.609 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.51 ' HE3' ' CG2' ' B' ' 15' ' ' ILE . 3.8 ptm -153.33 -164.17 1.85 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -102.96 118.12 36.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.037 -1.039 . . . . 0.0 110.49 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.49 HD12 ' HD3' ' B' ' 39' ' ' PRO . 3.0 mm? -113.3 169.96 5.84 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.49 ' HD3' HD12 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.95 52.02 4.14 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.696 2.264 . . . . 0.0 111.426 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 49.03 -163.0 0.5 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.2 mmm-85 60.25 84.87 0.12 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -1.14 . . . . 0.0 109.196 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 60.3 p-90 -159.57 176.54 11.92 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.509 0.671 . . . . 0.0 110.047 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.38 159.68 64.95 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -77.95 139.53 17.44 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.21 1.94 . . . . 0.0 110.404 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.504 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 10.1 tttt -155.53 131.14 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.439 -0.788 . . . . 0.0 109.197 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.439 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -110.85 130.68 55.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.099 -1.001 . . . . 0.0 109.289 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.551 ' CD1' HG22 ' A' ' 50' ' ' ILE . 24.3 pt -113.42 149.86 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.894 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.495 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.15 111.51 2.09 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 179.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.481 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -132.36 -126.08 2.7 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.188 -1.482 . . . . 0.0 111.161 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.585 HG13 ' H62' ' B' ' 100' ' ' DMP . 19.3 mt -91.52 138.44 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 122.056 0.932 . . . . 0.0 113.179 -177.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.532 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 80.18 -20.19 6.03 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 178.585 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.14 -169.44 32.61 Favored Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.649 -1.5 . . . . 0.0 110.321 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 4.5 m-85 -105.11 153.25 21.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.372 -1.075 . . . . 0.0 109.274 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.537 HG12 ' CG2' ' A' ' 50' ' ' ILE . 7.4 pt -127.11 159.81 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.225 -0.922 . . . . 0.0 109.807 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.529 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.29 144.52 31.51 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.769 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.516 HG22 HD21 ' B' ' 76' ' ' LEU . 23.9 m -142.9 -171.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.78 -1.2 . . . . 0.0 110.598 -178.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 11.4 mtt180 -137.85 88.87 2.36 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.41 98.82 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 110.962 -179.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.593 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 18.9 m-85 -91.78 127.54 37.27 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.4 m-20 -107.69 135.22 49.48 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.785 -1.197 . . . . 0.0 110.632 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.568 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.1 mt-30 79.96 60.4 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.823 -0.548 . . . . 0.0 110.889 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.563 ' CD1' ' HB3' ' B' ' 59' ' ' TYR . 3.5 mp -113.96 119.94 62.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.086 -1.008 . . . . 0.0 109.275 179.087 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.555 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.9 tm? -68.59 83.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.506 -0.746 . . . . 0.0 110.505 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.569 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 12.5 tt -88.85 124.88 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.483 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 7.4 tt0 -90.28 100.13 13.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.085 -1.01 . . . . 0.0 109.414 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' B' ' 13' ' ' ILE . 0.5 OUTLIER -90.97 119.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 121.055 -1.028 . . . . 0.0 109.103 179.949 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.587 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 5.3 m 48.5 47.52 20.24 Favored 'General case' 0 C--N 1.291 -1.951 0 O-C-N 121.82 -0.55 . . . . 0.0 110.463 178.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.483 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 68.37 28.13 73.41 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.587 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 8.5 m170 -120.2 97.15 5.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.034 -1.274 . . . . 0.0 109.35 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -50.44 126.81 16.07 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.239 -0.913 . . . . 0.0 109.159 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.485 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -151.26 155.98 39.9 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.665 -0.647 . . . . 0.0 109.459 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.568 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.9 OUTLIER -119.22 153.33 21.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.717 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.479 ' O ' HD11 ' B' ' 62' ' ' ILE . . . -175.61 -177.83 44.96 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.453 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.507 ' CG2' ' OD1' ' B' ' 60' ' ' ASP . 2.7 m -91.18 108.56 19.95 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.706 -0.879 . . . . 0.0 109.877 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.527 HG21 ' CD1' ' B' ' 62' ' ' ILE . 1.4 t -103.35 112.46 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.401 -0.812 . . . . 0.0 110.328 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.632 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.9 mp -77.73 118.71 20.36 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.012 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 72.1 t -99.02 117.44 44.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 120.916 -1.115 . . . . 0.0 109.74 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -155.55 -168.52 18.73 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.116 -1.994 . . . . 0.0 108.116 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.529 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -80.83 48.46 2.91 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 122.263 1.975 . . . . 0.0 110.816 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.528 HG21 ' N ' ' B' ' 34' ' ' GLU . 0.6 OUTLIER -91.85 137.45 25.39 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.926 -1.109 . . . . 0.0 108.573 179.481 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.451 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.6 Cg_endo -79.54 19.6 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.557 2.171 . . . . 0.0 112.209 -178.502 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.572 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.1 t -161.23 172.74 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.541 -1.349 . . . . 0.0 110.287 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.572 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 3.2 m-80 -107.55 79.53 1.3 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.452 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.592 ' CD1' ' C32' ' B' ' 100' ' ' DMP . 1.2 mp -76.8 126.02 37.1 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.374 -0.829 . . . . 0.0 111.48 -176.274 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.498 ' N ' HD11 ' B' ' 85' ' ' ILE . 1.2 mp -96.14 99.94 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.535 ' C ' ' CD1' ' B' ' 90' ' ' LEU . . . -95.69 167.68 25.9 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.584 ' N ' ' CD1' ' B' ' 90' ' ' LEU . 22.5 mmm180 -25.77 -39.41 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.818 -0.813 . . . . 0.0 112.826 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.561 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 8.9 p-10 -49.79 -21.99 1.29 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.577 -1.327 . . . . 0.0 111.264 -178.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.561 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -110.58 -24.06 10.75 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.584 ' CD1' ' N ' ' B' ' 87' ' ' ARG . 3.8 mp -68.6 -8.69 44.14 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.522 ' HB ' ' CZ2' ' A' ' 6' ' ' TRP . 30.4 p -95.83 -20.22 18.99 Favored 'General case' 0 N--CA 1.485 1.307 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.496 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 68.5 mm-40 -81.73 -41.46 21.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.551 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 1.9 pt -93.29 -2.82 10.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 98' ' ' ASN . . . 75.48 22.51 75.37 Favored Glycine 0 N--CA 1.494 2.529 0 O-C-N 121.516 -0.74 . . . . 0.0 111.488 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.56 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -65.27 123.66 20.15 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.708 -1.466 . . . . 0.0 110.457 -179.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 41.4 p -131.38 132.63 44.56 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.6 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 4.8 mp -84.87 106.87 16.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.047 -1.033 . . . . 0.0 110.766 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.539 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 2.4 m120 -112.3 121.61 45.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.344 -0.847 . . . . 0.0 108.944 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.58 ' CD2' HD13 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.686 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.224 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.598 ' C76' ' CD1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.567 ' O ' ' CD1' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.67 0 N-CA-C 110.398 -0.655 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -88.16 139.37 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.54 155.86 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 109.943 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 1.1 p -127.66 -168.35 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.312 -0.868 . . . . 0.0 109.445 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.582 ' CD2' ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -87.16 -26.89 23.37 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.215 -0.928 . . . . 0.0 109.065 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.607 ' CZ2' HG23 ' B' ' 91' ' ' THR . 10.2 m95 -45.48 -22.72 0.16 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.629 -1.295 . . . . 0.0 109.06 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.478 ' N ' ' O ' ' A' ' 5' ' ' LEU . 34.6 mt-30 -146.25 110.32 4.98 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.705 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.462 ' C ' ' O ' ' A' ' 7' ' ' GLN . 14.6 mtm180 -40.95 148.17 0.39 Allowed Pre-proline 0 C--N 1.297 -1.713 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.5 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 36.7 Cg_endo -79.71 47.88 2.67 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.579 2.186 . . . . 0.0 109.757 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -79.33 143.43 35.17 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.098 -1.001 . . . . 0.0 109.526 -179.222 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.528 ' CG2' HG21 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -147.24 140.65 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.333 -178.734 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 78.4 m -74.32 96.78 2.89 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.338 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.528 HG21 ' CG2' ' A' ' 11' ' ' VAL . 4.2 pt -83.81 150.34 4.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 121.635 0.731 . . . . 0.0 111.041 -178.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.541 ' CE ' HD13 ' A' ' 19' ' ' LEU . 1.1 tttt -112.14 101.54 9.79 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.522 HG23 ' CE ' ' A' ' 36' ' ' MET . 12.2 mt -122.51 138.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.225 -0.922 . . . . 0.0 109.308 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.467 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 52.11 43.37 56.2 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.14 35.83 66.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.486 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.0 mm100 -131.32 178.59 6.6 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.151 . . . . 0.0 109.186 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.541 HD13 ' CE ' ' A' ' 14' ' ' LYS . 39.5 mt -146.94 126.45 13.23 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.129 -0.982 . . . . 0.0 110.232 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.597 ' N ' ' HE2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -146.85 163.34 36.38 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.709 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.557 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 49.3 mm-40 -79.39 137.23 37.21 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.97 -1.081 . . . . 0.0 109.113 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.572 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -119.98 156.07 31.59 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.594 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 12.3 tp -118.24 99.12 6.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.701 -0.624 . . . . 0.0 109.615 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.5 ' HB2' ' CG ' ' A' ' 9' ' ' PRO . 18.7 mt -48.34 106.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.878 -1.139 . . . . 0.0 108.932 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.535 ' CB ' HG21 ' A' ' 84' ' ' ILE . 54.2 t0 -109.24 98.39 7.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.875 . . . . 0.0 109.829 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.472 ' OG1' ' OG1' ' B' ' 26' ' ' THR . 0.2 OUTLIER -71.58 -5.01 30.18 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.303 -0.873 . . . . 0.0 108.748 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.419 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -83.58 -33.27 22.61 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.569 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.486 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -84.36 159.88 20.78 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.519 ' OD2' ' CZ ' ' B' ' 8' ' ' ARG . 16.8 m-20 -100.77 -13.66 18.36 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.3 -0.875 . . . . 0.0 110.629 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.487 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.1 OUTLIER -127.0 -173.54 2.92 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.982 -1.074 . . . . 0.0 109.545 -179.625 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 27.9 m -110.47 86.76 2.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.864 -1.147 . . . . 0.0 110.214 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.551 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.4 OUTLIER -67.78 173.5 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 83' ' ' ASN . 0.1 OUTLIER -169.85 115.2 0.53 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.838 -1.163 . . . . 0.0 110.983 -178.14 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.552 ' HA ' HG21 ' A' ' 80' ' ' THR . 33.8 tt0 -33.85 150.05 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.879 -0.513 . . . . 0.0 109.649 178.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.513 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.1 tt0 -37.35 145.08 0.06 Allowed 'General case' 0 N--CA 1.495 1.783 0 CA-C-O 121.56 0.695 . . . . 0.0 110.674 -179.206 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.522 ' CE ' HG23 ' A' ' 15' ' ' ILE . 14.3 ptm -156.85 -170.8 3.42 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.0 t -127.77 90.77 3.16 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.827 -1.171 . . . . 0.0 111.364 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.617 ' CB ' ' CE1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -81.49 171.58 11.79 Favored Pre-proline 0 N--CA 1.493 1.716 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 177.901 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.576 ' CD ' HD11 ' A' ' 38' ' ' LEU . 36.2 Cg_endo -79.3 43.52 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.614 2.21 . . . . 0.0 111.499 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . 54.72 111.15 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.449 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 157.79 57.74 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.909 . . . . 0.0 108.83 179.792 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.585 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 51.5 p-90 -141.1 179.18 6.89 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-O 121.849 0.833 . . . . 0.0 110.491 -178.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.416 ' HE3' ' HA ' ' A' ' 43' ' ' LYS . 0.0 OUTLIER -130.8 158.04 76.09 Favored Pre-proline 0 C--N 1.302 -1.475 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.783 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -76.32 141.92 23.47 Favored 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.144 1.896 . . . . 0.0 110.471 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.39 169.57 19.89 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.428 -0.795 . . . . 0.0 109.352 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.459 ' SD ' ' HB3' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -144.35 111.21 5.75 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.507 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.553 ' O ' ' HA ' ' A' ' 53' ' ' PHE . 6.0 pt -92.33 142.52 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.856 -1.152 . . . . 0.0 109.093 -179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.6 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -122.8 105.08 0.92 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.488 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -124.68 -120.57 2.5 Favored Glycine 0 N--CA 1.483 1.785 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.097 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.574 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 26.3 mt -86.56 121.69 37.89 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.69 -0.888 . . . . 0.0 112.09 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.453 ' HA2' HG21 ' B' ' 54' ' ' ILE . . . 103.91 -55.71 0.61 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.76 -159.3 23.69 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.6 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.0 m-85 -107.43 131.79 53.9 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.235 -1.156 . . . . 0.0 109.887 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 7.3 pt -107.98 134.63 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.923 -1.111 . . . . 0.0 108.857 178.697 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.525 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -70.94 148.58 47.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.103 -0.998 . . . . 0.0 110.057 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.475 HG11 ' O ' ' A' ' 55' ' ' LYS . 6.4 m -150.09 -169.77 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.571 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 3.7 mmt85 -133.56 105.11 6.7 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.502 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.0 OUTLIER -62.93 102.06 0.32 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.948 . . . . 0.0 110.448 -179.133 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CB ' ' A' ' 38' ' ' LEU . 31.2 m-85 -92.62 90.68 7.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 108.858 179.113 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 3.4 m-20 -79.07 124.72 28.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.008 -1.057 . . . . 0.0 110.47 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 2.7 mm-40 88.33 61.78 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 CA-C-O 121.383 0.611 . . . . 0.0 110.163 179.319 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.545 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 14.8 mm -117.82 116.53 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.108 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.555 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 1.3 tm? -68.66 83.73 0.29 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.372 -0.83 . . . . 0.0 110.092 -179.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.506 ' CG2' HD12 ' A' ' 89' ' ' LEU . 11.8 tt -89.9 112.0 23.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 179.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.509 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 8.6 tp10 -91.63 120.44 32.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.11 -0.994 . . . . 0.0 109.228 -179.255 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.473 HD13 HG12 ' A' ' 64' ' ' ILE . 0.7 OUTLIER -107.01 121.01 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.179 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 60.04 -93.01 0.04 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.606 -0.684 . . . . 0.0 110.053 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -138.92 27.37 2.68 Favored Glycine 0 N--CA 1.486 1.978 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.42 ' C ' ' OE1' ' A' ' 65' ' ' GLU . 9.6 m-70 -125.53 103.44 7.88 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.188 -1.184 . . . . 0.0 109.385 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.505 ' N ' ' OE1' ' A' ' 65' ' ' GLU . 0.3 OUTLIER -59.52 133.43 56.09 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.544 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.494 ' O ' ' CD2' ' A' ' 63' ' ' LEU . . . -145.52 154.9 42.7 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.153 -0.967 . . . . 0.0 110.333 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.553 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -121.25 156.29 24.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 177.491 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 177.77 -177.77 48.37 Favored Glycine 0 N--CA 1.487 2.039 0 C-N-CA 117.876 -2.107 . . . . 0.0 112.084 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.502 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 91.0 m -90.62 105.12 17.6 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.921 -0.752 . . . . 0.0 109.713 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.537 HG11 HD11 ' A' ' 33' ' ' LEU . 1.4 t -98.63 107.06 19.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.688 -0.632 . . . . 0.0 110.079 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.525 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.8 mp -79.51 120.82 24.42 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.461 -0.774 . . . . 0.0 108.99 179.323 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.513 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 21.6 t -107.22 130.67 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.57 179.801 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' A' ' 56' ' ' VAL . . . -162.21 -159.4 10.23 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.039 -1.624 . . . . 0.0 109.039 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.525 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.72 38.32 0.73 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.606 2.204 . . . . 0.0 110.338 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.552 HG21 ' HA ' ' A' ' 34' ' ' GLU . 2.4 t -83.95 135.08 42.84 Favored Pre-proline 0 N--CA 1.489 1.519 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.261 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.5 16.82 1.18 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.428 2.085 . . . . 0.0 111.044 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.518 HG13 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.83 157.73 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.978 -1.076 . . . . 0.0 109.292 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.572 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -94.53 126.33 39.74 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 176.041 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.572 ' O ' ' HA ' ' A' ' 31' ' ' THR . 5.0 mm -111.57 122.57 66.19 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 O-C-N 120.486 -1.384 . . . . 0.0 112.384 -176.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.503 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -98.78 85.66 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 176.88 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.57 -157.02 9.97 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.461 -177.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.518 ' NE ' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -64.56 -33.06 75.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 122.009 -0.7 . . . . 0.0 111.265 -178.44 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.58 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 7.9 p-10 -55.9 -32.15 63.48 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.791 -1.193 . . . . 0.0 110.315 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.58 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -108.05 -19.95 13.33 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.993 -1.067 . . . . 0.0 110.516 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.461 ' O ' HG13 ' A' ' 93' ' ' ILE . 12.6 mt -69.9 -36.17 75.19 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 71.2 p -72.55 -20.83 61.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.057 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.432 ' OE1' ' HA ' ' A' ' 92' ' ' GLN . 9.4 mm100 -71.43 -40.18 70.58 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.569 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.4 OUTLIER -85.77 -2.18 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.55 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.82 60.36 6.6 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -81.41 151.72 27.77 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.365 -1.079 . . . . 0.0 110.052 -179.6 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.8 p -142.96 125.34 15.6 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.57 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 2.6 mp -91.0 94.27 9.56 Favored 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.612 -0.68 . . . . 0.0 109.17 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.531 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.3 m120 -104.79 129.0 53.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.127 -0.983 . . . . 0.0 110.285 -179.25 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.666 ' CG ' ' CD1' ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.377 178.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.476 ' HG2' ' CE1' ' A' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 N-CA-C 110.383 -0.66 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.531 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 9.9 tt0 -83.59 129.81 34.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 96.2 t -130.41 107.19 14.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.718 -1.239 . . . . 0.0 110.692 -177.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.547 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.9 p -108.71 -59.56 1.86 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' B' ' 7' ' ' GLN . 84.5 mt 35.8 27.9 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.695 -0.628 . . . . 0.0 111.068 179.153 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.547 ' N ' ' O ' ' B' ' 4' ' ' THR . 8.4 m95 17.63 46.48 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.603 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.6 mt-30 -170.65 -166.86 0.53 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.108 -0.995 . . . . 0.0 109.941 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.547 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.3 mtm180 -67.78 112.75 11.36 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.474 -0.767 . . . . 0.0 109.545 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.4 Cg_endo -80.27 86.88 1.59 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.204 1.936 . . . . 0.0 110.051 179.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.454 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.5 OUTLIER -86.12 136.25 33.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.92 . . . . 0.0 109.524 -179.771 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.436 HG21 ' HB1' ' B' ' 22' ' ' ALA . 3.4 m -125.56 154.17 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.423 -0.798 . . . . 0.0 109.711 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.517 HG23 ' CD2' ' B' ' 19' ' ' LEU . 58.5 m -86.6 111.27 20.47 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.581 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.6 pp -97.76 141.7 15.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.184 -0.948 . . . . 0.0 110.447 -178.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.407 ' HE2' HD13 ' B' ' 19' ' ' LEU . 6.8 ttmm -109.4 96.05 6.03 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.346 -0.846 . . . . 0.0 109.316 179.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.582 ' CG2' ' CG2' ' B' ' 62' ' ' ILE . 7.3 mt -113.02 116.18 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.86 50.69 63.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.96 17.15 21.27 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.224 -1.162 . . . . 0.0 110.287 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.503 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 1.7 mt-30 -108.05 134.67 50.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.055 -1.262 . . . . 0.0 109.37 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.517 ' CD2' HG23 ' B' ' 12' ' ' THR . 0.3 OUTLIER -113.51 120.06 39.68 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.098 0.951 . . . . 0.0 110.302 -179.726 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -141.04 178.55 7.3 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.552 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.1 mt-10 -85.46 178.18 7.52 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 120.802 -1.186 . . . . 0.0 108.812 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.581 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -156.58 111.65 2.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.063 -1.023 . . . . 0.0 110.302 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.547 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 27.9 tp -82.12 100.28 9.7 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.519 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 67.8 mt -43.17 105.96 0.06 Allowed 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.524 ' O ' ' HA2' ' B' ' 86' ' ' GLY . 7.7 t0 -114.38 87.47 2.64 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.517 -0.74 . . . . 0.0 110.839 -178.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.472 ' OG1' ' OG1' ' A' ' 26' ' ' THR . 20.5 m -71.22 -5.44 32.07 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.842 -1.161 . . . . 0.0 108.63 178.427 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.479 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -81.99 -32.76 28.49 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.513 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -75.0 162.72 28.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.952 -1.323 . . . . 0.0 109.575 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.421 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 0.7 OUTLIER -93.4 -20.86 19.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.887 -179.421 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.566 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 14.3 m-20 -139.5 -164.81 1.75 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.034 -1.041 . . . . 0.0 109.407 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 89.3 m -109.59 95.66 5.76 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.661 -1.274 . . . . 0.0 111.174 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.4 OUTLIER -72.78 178.01 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 177.879 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.13 118.34 0.68 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.781 -1.199 . . . . 0.0 110.875 -178.885 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.565 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 2.4 tt0 -35.11 150.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.557 . . . . 0.0 109.51 178.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.518 ' N ' ' HG3' ' B' ' 34' ' ' GLU . 0.0 OUTLIER -31.07 141.87 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.75 0.786 . . . . 0.0 111.497 -179.041 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.543 ' SD ' ' N ' ' B' ' 37' ' ' SER . 2.8 ppp? -169.05 175.54 5.73 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.265 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.543 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -122.53 136.28 54.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.619 -1.3 . . . . 0.0 111.235 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.614 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 0.2 OUTLIER -120.49 175.83 2.14 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.251 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.577 ' CD ' HD13 ' B' ' 38' ' ' LEU . 35.8 Cg_endo -79.47 62.47 8.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.632 2.221 . . . . 0.0 111.171 179.397 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.539 ' O ' ' CG ' ' B' ' 41' ' ' ARG . . . 40.29 87.06 0.01 OUTLIER Glycine 0 N--CA 1.495 2.621 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.539 ' CG ' ' O ' ' B' ' 40' ' ' GLY . 4.2 mtt180 -167.67 57.15 0.07 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.86 -0.788 . . . . 0.0 109.095 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.627 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 59.3 p-90 -147.96 172.33 14.38 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.07 0.938 . . . . 0.0 110.791 -179.307 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mmtm -130.98 144.29 52.94 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -74.01 133.29 17.96 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 C-N-CA 121.626 1.551 . . . . 0.0 110.486 -179.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.474 ' HG3' HG21 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.65 -178.83 7.64 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.439 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 62.9 mtp -145.13 131.52 19.66 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.141 -0.975 . . . . 0.0 109.323 179.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.569 ' CD1' HG22 ' A' ' 50' ' ' ILE . 19.9 pt -96.7 145.91 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.13 -0.982 . . . . 0.0 108.791 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.486 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.6 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -122.86 2.84 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.592 HG13 ' H62' ' B' ' 100' ' ' DMP . 33.3 mt -89.69 121.54 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.716 -0.873 . . . . 0.0 112.414 -177.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.589 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 105.43 -52.26 0.72 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 178.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.31 -164.64 33.45 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.515 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 2.9 m-85 -106.35 126.2 51.94 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.436 -1.038 . . . . 0.0 109.171 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.494 HD12 HD12 ' B' ' 47' ' ' ILE . 23.4 pt -97.28 174.99 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 120.917 -1.115 . . . . 0.0 109.149 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.514 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 35.2 mtpt -111.49 127.23 55.63 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.256 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.474 HG21 ' HG3' ' B' ' 45' ' ' LYS . 16.6 m -136.15 -174.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.583 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.598 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 0.5 OUTLIER -129.13 104.14 7.38 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.762 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.413 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 1.9 tt0 -62.38 97.4 0.09 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.523 -0.736 . . . . 0.0 110.704 -178.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.627 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 29.7 m-85 -88.56 127.49 35.55 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.523 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 5.6 m-20 -106.73 133.0 52.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.859 -1.151 . . . . 0.0 110.637 -178.548 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.539 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 52.2 mm-40 72.32 63.53 0.12 Allowed 'General case' 0 N--CA 1.49 1.539 0 CA-C-O 121.665 0.745 . . . . 0.0 109.469 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.582 ' CG2' ' CG2' ' B' ' 15' ' ' ILE . 12.6 mm -113.95 122.21 67.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.198 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.476 HD22 HG12 ' B' ' 72' ' ' ILE . 0.1 OUTLIER -69.97 84.99 0.51 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 111.568 -177.922 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.521 ' CG2' HD13 ' B' ' 89' ' ' LEU . 1.7 tt -88.62 119.47 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.8 tt0 -100.99 122.86 44.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.836 -1.165 . . . . 0.0 109.527 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.483 HG13 HG21 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -109.15 131.45 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 121.268 -0.895 . . . . 0.0 109.101 -179.956 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 57.37 -88.69 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.787 -0.57 . . . . 0.0 110.212 179.49 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -149.84 38.62 0.92 Allowed Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -136.36 123.13 21.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -1.115 . . . . 0.0 109.175 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.9 136.33 55.21 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.244 -0.91 . . . . 0.0 108.623 179.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.483 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -152.09 119.96 6.17 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 110.268 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.539 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 1.1 mm -89.53 163.31 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 178.016 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.504 ' N ' ' CG2' ' B' ' 72' ' ' ILE . . . 174.05 173.11 39.89 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 118.931 -1.604 . . . . 0.0 110.777 179.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 59.3 m -83.72 114.8 21.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.469 -1.018 . . . . 0.0 109.892 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.535 ' CG1' ' CD1' ' B' ' 15' ' ' ILE . 1.3 t -106.77 114.91 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.254 -0.903 . . . . 0.0 110.6 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' HB2' ' CG2' ' B' ' 32' ' ' VAL . 4.1 mp -86.38 115.03 23.64 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.698 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.518 ' O ' ' CD ' ' B' ' 57' ' ' ARG . 93.0 t -101.14 132.12 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.045 -1.034 . . . . 0.0 109.57 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.412 ' HA3' HG13 ' B' ' 56' ' ' VAL . . . -169.44 -163.26 23.16 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.514 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.1 Cg_endo -79.8 43.55 1.53 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.754 2.303 . . . . 0.0 110.892 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.565 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 12.2 t -85.32 137.61 36.82 Favored Pre-proline 0 N--CA 1.488 1.431 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.416 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 34.7 Cg_endo -78.69 13.62 1.86 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.302 2.001 . . . . 0.0 110.879 -179.315 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.44 163.34 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.132 -0.98 . . . . 0.0 109.864 -179.235 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.552 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 55.0 m-80 -94.34 136.32 34.77 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.051 -2.574 . . . . 0.0 104.051 175.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.55 ' O ' ' HA ' ' B' ' 31' ' ' THR . 5.6 mm -121.05 122.42 67.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 O-C-N 119.92 -1.737 . . . . 0.0 111.358 -177.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.527 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -98.63 92.07 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.638 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.18 -155.56 9.39 Favored Glycine 0 N--CA 1.49 2.28 0 C-N-CA 120.005 -1.093 . . . . 0.0 111.096 -178.015 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.543 ' CB ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -75.71 -29.66 59.04 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.905 -0.762 . . . . 0.0 110.159 -178.982 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.586 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 19.0 p-10 -51.08 -20.46 1.46 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.888 -1.133 . . . . 0.0 109.831 -179.365 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.586 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 4.0 mm? -116.17 -21.25 9.48 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.83 -1.169 . . . . 0.0 110.899 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' B' ' 95' ' ' ALA . 83.3 mt -66.12 -18.43 65.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.63 -1.294 . . . . 0.0 109.547 -179.711 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.607 HG23 ' CZ2' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -100.86 -5.74 25.72 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.927 -1.108 . . . . 0.0 109.212 178.683 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -94.15 -41.18 9.64 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.666 ' CD1' ' CG ' ' A' ' 99' ' ' PHE . 1.2 pt -88.94 -7.73 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.854 . . . . 0.0 108.749 179.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 89.43 28.03 20.87 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.919 178.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.544 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -71.11 125.72 27.65 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.667 -1.49 . . . . 0.0 109.52 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 66.4 p -127.05 129.91 48.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.571 ' HB3' ' CZ ' ' B' ' 99' ' ' PHE . 4.1 mp -87.35 102.46 14.54 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.249 -0.907 . . . . 0.0 110.256 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.6 m120 -102.21 125.44 48.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.352 -0.843 . . . . 0.0 109.15 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.633 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.086 -0.959 . . . . 0.0 109.296 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.592 ' H62' HG13 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.497 1.724 0 CA-C-O 121.501 0.542 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.538 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.4 tt0 -83.58 144.51 29.42 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.53 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 9.5 t -143.84 112.87 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.274 -1.37 . . . . 0.0 110.314 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.566 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -117.92 -67.1 1.02 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.958 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.547 ' O ' ' C ' ' A' ' 6' ' ' TRP . 2.5 pp 27.68 36.58 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.588 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.566 ' N ' ' O ' ' A' ' 4' ' ' THR . 35.7 m95 15.9 53.57 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.245 0 CA-C-O 121.184 0.516 . . . . 0.0 112.268 179.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 2.6 mt-30 -156.88 -166.75 2.17 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 109.529 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.459 ' HA ' ' HD3' ' B' ' 87' ' ' ARG . 1.0 OUTLIER -75.04 130.89 79.79 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.363 -0.836 . . . . 0.0 109.131 179.902 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.1 Cg_endo -78.19 79.33 3.31 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.25 1.967 . . . . 0.0 109.342 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -96.91 139.52 32.82 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.761 -179.359 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.474 HG21 ' O ' ' A' ' 11' ' ' VAL . 0.9 OUTLIER -135.36 147.47 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.467 -0.771 . . . . 0.0 109.965 -179.223 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.6 m -75.8 105.69 6.98 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.548 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 7.6 pt -99.06 146.4 8.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.248 -0.907 . . . . 0.0 110.642 -178.154 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.3 OUTLIER -111.57 99.51 8.25 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.296 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.513 ' CD1' HD12 ' A' ' 33' ' ' LEU . 4.2 mt -120.4 132.46 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.21 -0.931 . . . . 0.0 109.651 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.77 32.98 83.67 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.27 21.81 70.5 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.0 OUTLIER -117.81 174.92 5.91 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.299 -1.118 . . . . 0.0 109.213 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.47 HD22 ' HA ' ' A' ' 14' ' ' LYS . 14.6 mt -140.02 120.2 13.79 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.236 -0.915 . . . . 0.0 110.379 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.7 mmmt -144.1 167.76 21.63 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -77.06 165.28 24.82 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.808 -1.183 . . . . 0.0 108.391 179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.548 ' CB ' ' CG2' ' A' ' 13' ' ' ILE . . . -142.54 119.82 11.54 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.922 -1.111 . . . . 0.0 109.817 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.476 ' O ' ' N ' ' A' ' 25' ' ' ASP . 41.6 tp -88.27 93.33 9.48 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.699 -0.626 . . . . 0.0 109.647 -179.641 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.547 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 14.7 mt -43.67 97.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.06 -1.025 . . . . 0.0 109.657 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.512 ' CB ' HG21 ' A' ' 84' ' ' ILE . 27.7 t0 -100.56 81.36 2.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.89 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.529 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 1.8 m -60.74 -14.16 19.47 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.17 -0.956 . . . . 0.0 108.88 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.27 -33.68 64.53 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.533 ' HB3' ' C27' ' B' ' 100' ' ' DMP . . . -81.28 169.44 17.29 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.196 -1.179 . . . . 0.0 110.014 -179.607 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.494 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 24.1 m-20 -98.38 -17.13 19.0 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.315 -0.866 . . . . 0.0 111.206 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.491 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -137.11 -171.13 2.87 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.694 -1.254 . . . . 0.0 110.249 -179.43 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 18.6 m -104.83 90.6 3.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.212 -0.93 . . . . 0.0 110.533 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.568 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -70.13 174.53 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.632 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.571 ' CD1' ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -168.8 121.84 0.82 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.83 -1.169 . . . . 0.0 110.859 -179.352 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 1.1 pt-20 -37.36 156.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.547 -0.721 . . . . 0.0 109.797 178.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.555 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.5 tm-20 -45.0 145.75 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.356 -0.84 . . . . 0.0 110.8 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.414 ' HG2' HG12 ' A' ' 77' ' ' VAL . 13.5 ptm -165.02 -164.97 0.83 Allowed 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -116.81 122.75 45.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.996 -1.065 . . . . 0.0 110.506 -179.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.612 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -128.08 -173.87 0.34 Allowed Pre-proline 0 N--CA 1.496 1.839 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 179.503 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.571 ' CD ' ' CB ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -78.05 -163.3 0.21 Allowed 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 122.171 1.914 . . . . 0.0 111.371 -178.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.72 39.28 2.94 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -179.072 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -128.86 61.52 1.51 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.622 -0.928 . . . . 0.0 108.622 179.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.641 ' CD1' ' CE2' ' A' ' 59' ' ' TYR . 6.3 p-90 -132.9 -177.55 4.55 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.683 0.754 . . . . 0.0 110.47 -178.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -137.74 138.51 24.22 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.23 138.81 18.27 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.131 1.887 . . . . 0.0 110.85 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 46' ' ' MET . 1.6 ptpt -156.56 -169.47 3.02 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.4 ' HG2' ' O ' ' A' ' 45' ' ' LYS . 39.9 mtp -151.3 135.56 16.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 109.784 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.535 HD13 ' CG2' ' B' ' 50' ' ' ILE . 15.3 pt -100.06 139.29 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.91 106.07 1.24 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -131.78 -123.26 2.45 Favored Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.74 -1.219 . . . . 0.0 110.308 -179.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.62 HG13 ' H32' ' B' ' 100' ' ' DMP . 66.0 mt -88.48 115.29 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.445 -1.032 . . . . 0.0 112.45 -177.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.66 -32.96 5.45 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.361 -1.095 . . . . 0.0 110.361 178.081 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.87 -160.27 28.74 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 4.6 m-85 -110.86 124.55 52.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.32 -1.106 . . . . 0.0 109.491 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.54 HG12 ' CG2' ' B' ' 50' ' ' ILE . 2.2 pt -102.26 174.03 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 108.721 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.7 OUTLIER -107.38 135.46 48.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.163 -0.961 . . . . 0.0 108.935 179.447 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.508 ' CG1' HD13 ' A' ' 54' ' ' ILE . 15.2 m -143.19 152.83 16.73 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 121.228 -0.92 . . . . 0.0 109.865 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.549 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 3.6 mtt85 -92.92 167.02 12.11 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -129.2 100.77 5.73 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.01 -1.056 . . . . 0.0 110.004 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.641 ' CE2' ' CD1' ' A' ' 42' ' ' TRP . 81.8 m-85 -100.25 123.36 44.39 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.356 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -98.73 130.75 45.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.009 . . . . 0.0 109.753 -179.669 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.549 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 83.14 59.75 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.389 0.614 . . . . 0.0 109.802 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.522 ' CG2' HG22 ' A' ' 75' ' ' VAL . 5.3 mm -110.57 117.4 54.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.498 ' C ' ' CD2' ' A' ' 63' ' ' LEU . 0.1 OUTLIER -69.86 86.82 0.52 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 111.093 -178.459 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.563 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 6.1 tt -88.87 118.21 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 6.0 tt0 -88.22 112.51 22.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.033 -1.042 . . . . 0.0 108.936 -178.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.555 HD13 ' CD1' ' A' ' 64' ' ' ILE . 0.4 OUTLIER -103.92 118.86 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.348 -0.845 . . . . 0.0 109.052 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER 61.67 40.32 13.36 Favored 'General case' 0 C--N 1.293 -1.877 0 O-C-N 121.618 -0.676 . . . . 0.0 109.873 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.07 8.44 61.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.461 ' O ' ' HG2' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -101.26 155.99 17.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.176 -1.191 . . . . 0.0 108.989 179.781 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.482 ' HG2' HD23 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -89.44 126.63 35.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.017 -1.052 . . . . 0.0 109.754 -179.814 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.563 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.89 102.44 3.27 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.313 -0.867 . . . . 0.0 109.441 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.539 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -81.07 158.89 4.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.028 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.56 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 178.45 172.81 43.23 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.48 -1.819 . . . . 0.0 111.637 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.471 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 57.2 m -84.86 111.66 19.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.665 -0.903 . . . . 0.0 109.938 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.571 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.2 t -100.39 144.53 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.637 -0.665 . . . . 0.0 109.601 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.568 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -116.07 127.38 54.83 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.555 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 97.3 t -111.03 116.13 51.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 120.956 -1.09 . . . . 0.0 110.766 -178.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -151.18 -161.93 10.37 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.544 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.16 42.78 1.4 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.443 2.095 . . . . 0.0 110.327 179.583 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.567 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.4 t -88.38 130.51 45.44 Favored Pre-proline 0 C--N 1.303 -1.435 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.27 21.05 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.417 2.078 . . . . 0.0 111.546 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.507 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.07 159.54 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.881 -1.137 . . . . 0.0 109.81 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.532 ' ND2' ' O ' ' A' ' 21' ' ' GLU . 33.5 m-80 -90.53 136.72 32.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.539 ' CG1' HG11 ' A' ' 32' ' ' VAL . 6.1 mm -125.75 122.79 62.99 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 O-C-N 119.955 -1.716 . . . . 0.0 111.498 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.547 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -105.34 95.59 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.492 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -79.75 -159.24 17.26 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.1 OUTLIER -67.77 -37.04 81.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 -179.383 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.572 ' ND2' HD21 ' A' ' 89' ' ' LEU . 14.8 p-10 -45.28 -28.97 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.89 -1.131 . . . . 0.0 109.743 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.572 HD21 ' ND2' ' A' ' 88' ' ' ASN . 2.6 mm? -106.88 -27.64 10.59 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.92 -1.113 . . . . 0.0 109.428 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.529 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 12.7 mt -70.32 -6.15 33.03 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.574 ' HB ' ' CZ3' ' B' ' 6' ' ' TRP . 71.8 p -101.87 -20.0 15.06 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.18 -0.95 . . . . 0.0 108.66 178.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -76.34 -40.22 51.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.404 -0.81 . . . . 0.0 109.112 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.624 ' CD1' ' CG ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -87.44 -1.74 8.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.375 -0.828 . . . . 0.0 109.07 179.324 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.73 29.84 50.53 Favored Glycine 0 N--CA 1.497 2.741 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -57.59 149.13 22.14 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.2 -1.177 . . . . 0.0 111.225 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.453 HG23 ' CG2' ' B' ' 4' ' ' THR . 15.8 p -150.44 126.03 10.25 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 5.2 mp -84.89 109.02 17.82 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.223 -0.923 . . . . 0.0 108.671 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 7.3 m120 -108.36 121.72 45.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.164 -179.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.641 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.606 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.474 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.515 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 109.97 -0.819 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.51 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.0 OUTLIER -83.34 144.74 29.47 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 105.985 -1.858 . . . . 0.0 105.985 177.354 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.51 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 92.8 t -148.95 114.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 117.56 -1.656 . . . . 0.0 111.413 -177.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.453 ' CG2' HG23 ' A' ' 96' ' ' THR . 2.6 p -111.64 -70.94 0.78 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.1 OUTLIER 45.44 19.41 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.668 -0.645 . . . . 0.0 111.188 178.722 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.574 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 12.1 m95 19.3 44.8 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 120.948 0.404 . . . . 0.0 111.48 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' B' ' 5' ' ' LEU . 12.9 mm100 -156.56 -156.66 0.64 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.441 -0.787 . . . . 0.0 109.405 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 117.22 61.81 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.927 -1.108 . . . . 0.0 109.543 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.19 71.55 6.98 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.142 1.895 . . . . 0.0 109.431 179.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.608 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -91.23 159.83 15.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.864 . . . . 0.0 110.304 -178.986 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.569 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.8 OUTLIER -150.24 135.85 11.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.452 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.431 HG21 HD21 ' B' ' 19' ' ' LEU . 4.9 m -65.77 107.91 1.94 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.573 ' HA ' ' O ' ' B' ' 65' ' ' GLU . 1.4 pt -103.88 150.31 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 119.15 -1.02 . . . . 0.0 111.007 -178.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.429 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 6.4 tttt -122.42 106.71 11.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.464 -0.772 . . . . 0.0 108.921 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.581 HD12 ' CG1' ' B' ' 75' ' ' VAL . 38.0 mt -115.11 143.04 25.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.052 -1.03 . . . . 0.0 109.242 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.81 -89.91 0.09 OUTLIER Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -160.32 32.79 0.41 Allowed Glycine 0 N--CA 1.485 1.935 0 N-CA-C 108.406 -1.878 . . . . 0.0 108.406 179.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 -134.97 171.66 14.1 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.671 -0.899 . . . . 0.0 109.34 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.431 HD21 HG21 ' B' ' 12' ' ' THR . 5.6 mt -120.83 137.59 54.48 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.624 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -150.59 144.18 25.11 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.375 -0.828 . . . . 0.0 108.798 -178.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.608 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.1 mt-10 -78.24 121.98 25.1 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.256 -0.903 . . . . 0.0 108.648 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.561 ' HB2' ' CD1' ' B' ' 85' ' ' ILE . . . -104.34 131.0 52.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 111.731 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.541 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 33.7 tp -88.11 96.95 10.72 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.453 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.455 ' C ' ' O ' ' B' ' 23' ' ' LEU . 18.9 mt -42.3 107.31 0.08 Allowed 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.534 ' CB ' HG21 ' B' ' 84' ' ' ILE . 41.7 t0 -116.65 92.51 3.89 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.376 -0.827 . . . . 0.0 111.642 -177.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.517 ' O ' ' NH1' ' B' ' 87' ' ' ARG . 0.2 OUTLIER -75.89 -0.78 22.55 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.903 -1.123 . . . . 0.0 108.592 177.729 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.444 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -89.37 -28.66 19.18 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -179.739 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.462 ' CB ' ' OD2' ' B' ' 25' ' ' ASP . . . -78.79 170.67 16.3 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.89 -1.359 . . . . 0.0 109.443 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -100.24 -20.44 15.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.178 -0.951 . . . . 0.0 110.01 -179.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -142.39 -175.91 4.64 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.075 -1.016 . . . . 0.0 109.764 179.875 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.594 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 4.2 m -100.36 86.19 3.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 110.558 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.59 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -71.75 157.62 6.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.594 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.9 OUTLIER -153.06 128.66 10.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.918 -1.114 . . . . 0.0 110.688 -178.12 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.473 ' N ' HG23 ' B' ' 80' ' ' THR . 1.1 pt-20 -43.37 162.34 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 109.11 179.396 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.495 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.8 mt-10 -48.92 139.83 9.65 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.225 -0.922 . . . . 0.0 110.126 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.6 OUTLIER -163.0 -171.09 2.54 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.519 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -111.99 116.15 30.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.877 -1.139 . . . . 0.0 110.236 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.56 HD11 ' CD1' ' B' ' 59' ' ' TYR . 3.4 mt -113.52 167.93 8.61 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.245 -0.909 . . . . 0.0 109.05 179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.539 ' HD2' ' CD2' ' B' ' 38' ' ' LEU . 34.4 Cg_endo -77.37 70.64 6.71 Favored 'Trans proline' 0 C--N 1.312 -1.367 0 C-N-CA 122.783 2.322 . . . . 0.0 112.183 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.13 -158.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 O-C-N 121.607 -0.683 . . . . 0.0 111.631 178.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 51.71 90.65 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.633 -0.922 . . . . 0.0 109.476 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.591 ' HB3' ' CD2' ' B' ' 59' ' ' TYR . 44.6 p-90 -161.0 172.91 16.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.471 -0.768 . . . . 0.0 109.906 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.458 ' HB2' ' HB3' ' B' ' 58' ' ' GLN . 0.2 OUTLIER -135.46 128.76 18.33 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.903 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.51 141.06 19.62 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.261 1.974 . . . . 0.0 110.966 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.11 -167.56 1.97 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.452 -0.78 . . . . 0.0 109.083 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 46' ' ' MET . . . . . . . . . . . . . 81.7 mtp -143.28 133.69 24.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.329 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.585 ' CD1' HG23 ' A' ' 50' ' ' ILE . 35.0 pt -100.8 152.63 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.061 -1.024 . . . . 0.0 108.783 179.146 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.51 102.81 0.98 Allowed Glycine 0 N--CA 1.489 2.167 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.431 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -127.49 -131.2 3.44 Favored Glycine 0 N--CA 1.482 1.708 0 C-N-CA 119.447 -1.359 . . . . 0.0 111.123 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.578 HD13 ' C26' ' B' ' 100' ' ' DMP . 51.6 mt -88.51 126.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 122.008 -0.701 . . . . 0.0 112.515 -177.42 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.521 ' N ' HG22 ' A' ' 54' ' ' ILE . . . 92.45 5.53 65.11 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 121.06 -166.13 14.07 Favored Glycine 0 N--CA 1.492 2.403 0 O-C-N 120.917 -1.343 . . . . 0.0 110.046 179.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.2 OUTLIER -109.42 135.43 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.377 -1.072 . . . . 0.0 109.57 -179.747 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.547 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.3 pt -104.82 -179.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 121.078 -1.014 . . . . 0.0 109.104 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.462 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 31.8 mttt -114.84 140.56 48.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.161 -0.962 . . . . 0.0 108.955 179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.525 ' CG1' HD13 ' B' ' 54' ' ' ILE . 33.8 m -149.66 176.55 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.001 -1.062 . . . . 0.0 110.262 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.554 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 1.0 OUTLIER -111.3 172.92 6.6 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.981 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.458 ' HB3' ' HB2' ' B' ' 43' ' ' LYS . 45.2 tt0 -128.82 87.92 2.65 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.152 -0.968 . . . . 0.0 110.198 -179.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.591 ' CD2' ' HB3' ' B' ' 42' ' ' TRP . 72.7 m-85 -89.77 93.98 9.65 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 179.116 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.8 m-20 -80.93 135.37 35.88 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.055 -1.028 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.53 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 7.6 mt-30 78.43 62.72 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.672 0.748 . . . . 0.0 109.866 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.561 ' HB ' ' CG2' ' B' ' 75' ' ' VAL . 35.1 mm -117.56 123.67 72.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.547 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.8 tm? -68.42 84.35 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.378 -0.827 . . . . 0.0 110.672 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.563 ' CD1' HD13 ' B' ' 66' ' ' ILE . 7.1 tt -87.55 118.39 33.31 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.573 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.3 tt0 -90.95 118.47 30.36 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.141 -0.975 . . . . 0.0 109.68 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.563 HD13 ' CD1' ' B' ' 64' ' ' ILE . 0.3 OUTLIER -120.14 128.95 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.16 -0.962 . . . . 0.0 108.908 179.753 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 85.5 m 57.05 51.41 10.51 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.495 -0.753 . . . . 0.0 109.817 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.49 19.45 13.12 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.458 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.8 m-70 -112.23 141.55 45.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.152 -1.205 . . . . 0.0 109.425 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.33 130.77 34.77 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.234 -0.917 . . . . 0.0 109.17 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.475 ' O ' HD23 ' B' ' 63' ' ' LEU . . . -149.98 141.85 23.78 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.559 -0.713 . . . . 0.0 109.134 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.53 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -115.18 158.88 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.783 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.483 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . 176.62 -159.46 26.28 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.687 -1.721 . . . . 0.0 111.454 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.1 m -101.33 109.01 20.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.473 -1.016 . . . . 0.0 110.136 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.581 ' CG1' HD12 ' B' ' 15' ' ' ILE . 1.5 t -104.06 108.73 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.225 179.449 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.59 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.1 mp -82.57 137.23 34.62 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.33 -0.856 . . . . 0.0 108.842 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.557 HG22 ' CE1' ' B' ' 59' ' ' TYR . 0.2 OUTLIER -115.15 129.69 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.265 -0.897 . . . . 0.0 109.94 -179.342 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -166.07 -172.21 33.15 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.462 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -80.56 41.34 1.12 Allowed 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.53 2.153 . . . . 0.0 110.85 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.525 ' CG2' ' O ' ' B' ' 82' ' ' VAL . 5.9 t -80.93 143.67 53.92 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.506 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 34.7 Cg_endo -77.51 12.47 1.86 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.39 2.06 . . . . 0.0 111.296 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.525 ' O ' ' CG2' ' B' ' 80' ' ' THR . 2.3 t -161.61 161.55 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.835 -1.166 . . . . 0.0 110.486 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.624 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -98.36 92.63 5.78 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.774 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.536 ' CD1' ' C32' ' B' ' 100' ' ' DMP . 2.7 mt -93.39 135.52 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.951 -1.093 . . . . 0.0 113.327 -175.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.561 ' CD1' ' HB2' ' B' ' 22' ' ' ALA . 0.2 OUTLIER -101.3 108.27 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.984 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.56 ' C ' ' CD2' ' B' ' 90' ' ' LEU . . . -95.95 173.37 30.48 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.871 -1.291 . . . . 0.0 109.871 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' B' ' 26' ' ' THR . 8.8 mtm-85 -35.91 -35.02 0.06 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.487 -1.008 . . . . 0.0 112.19 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.521 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 9.7 p-10 -49.14 -43.43 41.69 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.231 -1.543 . . . . 0.0 110.395 -178.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.521 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 0.6 OUTLIER -93.64 -30.16 15.08 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.096 -1.003 . . . . 0.0 111.168 -178.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.56 ' CD2' ' C ' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -59.5 -36.33 75.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.532 -1.355 . . . . 0.0 108.719 -179.807 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.407 ' CG2' ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -71.44 -20.7 62.07 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.879 -1.138 . . . . 0.0 109.713 -179.534 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.44 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 11.8 mm-40 -75.11 -38.87 60.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.139 -0.976 . . . . 0.0 109.018 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 2.8 pt -84.81 -8.5 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.181 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.475 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 80.51 29.56 43.68 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 178.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.567 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.83 135.38 57.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.105 -1.232 . . . . 0.0 109.824 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 73.2 p -131.86 125.64 32.28 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.595 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 1.2 mp -84.86 92.95 8.4 Favored 'General case' 0 C--N 1.293 -1.861 0 O-C-N 121.335 -0.853 . . . . 0.0 109.954 -178.611 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 2.6 m120 -105.14 138.8 40.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.577 -0.702 . . . . 0.0 109.962 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.624 ' CG ' ' CD1' ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.338 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.62 ' H32' HG13 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.461 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 3.4 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.292 -0.695 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.509 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.9 tt0 -85.92 129.07 34.94 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 178.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.536 HG13 ' CB ' ' A' ' 9' ' ' PRO . 35.8 t -124.09 111.37 28.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 120.74 -1.225 . . . . 0.0 110.595 -178.333 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.406 ' O ' ' C ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -119.28 -72.67 0.68 Allowed 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.228 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.6 mm? 42.15 29.21 0.13 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.426 -0.797 . . . . 0.0 110.125 179.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 20.9 m0 18.61 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.385 0 CA-C-O 121.249 0.547 . . . . 0.0 111.742 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.5 mt-30 -165.57 -165.28 0.82 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.372 -0.83 . . . . 0.0 108.805 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.523 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 82.7 mtm180 -64.25 117.08 33.26 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.078 -1.014 . . . . 0.0 109.235 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.536 ' CB ' HG13 ' A' ' 3' ' ' VAL . 34.8 Cg_endo -76.76 75.49 4.45 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 109.974 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.534 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -79.49 160.04 26.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.883 . . . . 0.0 109.58 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 13' ' ' ILE . 2.1 m -148.73 139.1 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.282 -0.887 . . . . 0.0 110.386 -179.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 54.9 m -70.3 98.3 1.37 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.126 -0.983 . . . . 0.0 108.392 178.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.546 ' CG2' ' HB1' ' A' ' 22' ' ' ALA . 19.7 pt -92.12 150.07 3.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.453 -0.78 . . . . 0.0 109.901 -179.264 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HD3' ' CD2' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -112.07 94.98 5.21 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.478 -0.764 . . . . 0.0 109.003 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.541 ' CD1' HG12 ' A' ' 75' ' ' VAL . 6.0 mt -114.35 128.17 71.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.357 -0.84 . . . . 0.0 109.561 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.2 30.53 78.04 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.71 9.92 66.44 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.494 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -108.02 175.86 5.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -1.147 . . . . 0.0 108.935 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.529 ' CD2' ' HD3' ' A' ' 14' ' ' LYS . 20.1 mt -142.82 121.63 12.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.105 -0.997 . . . . 0.0 110.347 -179.417 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 3.2 mmtt -140.06 160.58 39.6 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.155 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.534 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.6 mp0 -78.86 123.97 27.77 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.937 -1.102 . . . . 0.0 108.461 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.546 ' HB1' ' CG2' ' A' ' 13' ' ' ILE . . . -108.16 130.51 55.12 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 110.673 -178.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 25' ' ' ASP . 42.9 tp -80.23 94.97 6.16 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.855 -0.528 . . . . 0.0 109.879 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.51 HD22 ' CG1' ' A' ' 85' ' ' ILE . 94.4 mt -46.71 95.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.324 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.63 ' CB ' ' CG2' ' A' ' 84' ' ' ILE . 34.6 t0 -99.96 89.12 3.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.317 -0.865 . . . . 0.0 110.837 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.443 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 15.7 m -65.07 -16.63 63.67 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.452 ' HA3' ' OD1' ' B' ' 25' ' ' ASP . . . -71.05 -34.59 64.78 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.474 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -81.66 161.37 23.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.156 -1.203 . . . . 0.0 109.071 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.411 ' HA ' ' HB2' ' A' ' 87' ' ' ARG . 34.6 m-20 -99.37 -12.54 20.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.983 -179.589 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.504 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 29.4 m-20 -137.35 173.01 12.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.024 -1.047 . . . . 0.0 110.084 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.548 ' CG2' ' O ' ' A' ' 84' ' ' ILE . 98.0 m -94.07 107.44 19.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.083 -1.011 . . . . 0.0 110.194 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.543 ' CG2' ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -100.26 117.3 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.304 -0.873 . . . . 0.0 109.022 179.441 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.531 HD11 ' CG1' ' A' ' 75' ' ' VAL . 2.2 mp -107.56 119.28 38.98 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.239 -0.913 . . . . 0.0 110.569 -179.015 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CB ' ' O ' ' A' ' 80' ' ' THR . 15.4 pt-20 -42.73 168.41 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.328 -0.857 . . . . 0.0 109.393 178.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.9 OUTLIER -43.46 145.99 0.54 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.212 -0.93 . . . . 0.0 111.03 -179.128 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.455 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.1 OUTLIER 178.68 163.05 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -81.0 103.3 10.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.871 -1.143 . . . . 0.0 110.151 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.474 HD13 ' HD2' ' A' ' 39' ' ' PRO . 5.1 tp -121.8 104.1 39.54 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.857 . . . . 0.0 109.199 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.474 ' HD2' HD13 ' A' ' 38' ' ' LEU . 36.3 Cg_endo -77.41 146.89 25.05 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.542 2.161 . . . . 0.0 110.861 -179.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 134.45 172.72 12.9 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -77.45 127.69 32.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -1.233 . . . . 0.0 108.808 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.638 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 66.6 p-90 -130.26 172.91 11.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.775 -178.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.403 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 2.1 mmtm -137.75 147.24 56.19 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.42 131.46 12.71 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.838 1.692 . . . . 0.0 110.289 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.625 ' CE ' ' CD2' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -162.05 136.85 7.02 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.696 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.475 ' HB3' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -112.64 146.32 38.84 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.661 -1.275 . . . . 0.0 109.637 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 47' ' ' ILE . 12.6 pt -101.0 140.27 20.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.487 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.66 104.61 1.11 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.49 -119.45 2.29 Favored Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.576 -1.297 . . . . 0.0 110.875 -179.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.566 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 49.9 mt -85.96 119.79 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.817 -0.814 . . . . 0.0 112.66 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.431 ' N ' HG22 ' B' ' 54' ' ' ILE . . . 104.21 -53.38 0.7 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.355 -0.926 . . . . 0.0 110.795 178.038 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . -177.63 -157.41 18.45 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.234 -179.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -117.3 126.73 53.2 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.484 -1.009 . . . . 0.0 109.875 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.546 ' CD1' HG11 ' A' ' 56' ' ' VAL . 1.9 pp -105.08 160.55 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.303 -0.873 . . . . 0.0 109.085 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -103.02 146.6 28.11 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.046 -1.034 . . . . 0.0 110.115 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.579 HG21 ' NZ ' ' A' ' 45' ' ' LYS . 3.1 m -149.39 -177.9 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.18 -0.95 . . . . 0.0 109.328 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.52 ' CD ' ' CE3' ' A' ' 42' ' ' TRP . 7.4 mmt85 -123.21 101.75 7.56 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.567 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 3.8 tt0 -73.18 106.17 4.91 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.4 -0.812 . . . . 0.0 111.144 -178.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CZ ' ' HB3' ' A' ' 42' ' ' TRP . 41.4 m-85 -89.47 130.75 35.76 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.543 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.0 m-20 -100.82 121.11 41.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.7 -1.25 . . . . 0.0 109.976 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.8 OUTLIER 85.15 57.07 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.206 0.527 . . . . 0.0 110.048 179.538 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.549 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 16.4 mm -105.54 119.95 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -0.923 . . . . 0.0 108.919 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.533 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.4 tm? -68.72 98.59 0.92 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.854 -178.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.572 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 7.9 tt -102.83 119.36 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.329 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.8 OUTLIER -89.58 116.84 28.03 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.809 -1.182 . . . . 0.0 109.424 -178.915 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.501 HG13 HG23 ' A' ' 13' ' ' ILE . 0.4 OUTLIER -109.25 129.07 64.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.3 -0.875 . . . . 0.0 109.053 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.478 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.7 m 38.04 52.15 1.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.459 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 63.28 48.86 75.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.478 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 92.9 m-70 -145.15 115.19 7.43 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -1.156 . . . . 0.0 109.431 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.518 ' CG ' HD23 ' A' ' 63' ' ' LEU . 19.6 ttpt -60.97 129.25 40.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.572 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -154.28 99.65 2.23 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.392 -0.818 . . . . 0.0 109.874 -179.093 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.55 160.43 4.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 120.866 -1.146 . . . . 0.0 108.533 178.981 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . 178.99 177.15 47.37 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 118.777 -1.678 . . . . 0.0 111.59 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.567 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 17.7 m -89.03 111.77 22.57 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.815 -0.815 . . . . 0.0 110.549 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.541 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -101.05 161.33 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.465 -0.772 . . . . 0.0 109.733 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.625 ' CD2' ' CE ' ' A' ' 45' ' ' LYS . 6.0 mp -130.55 105.0 7.55 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.064 -1.022 . . . . 0.0 108.405 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 61.7 t -89.61 117.75 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.792 -1.193 . . . . 0.0 109.973 -179.477 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.558 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -156.5 -166.97 17.08 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -82.75 39.02 0.78 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.479 2.119 . . . . 0.0 111.085 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 0.8 OUTLIER -85.62 137.57 36.18 Favored Pre-proline 0 N--CA 1.49 1.525 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 178.174 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.94 23.04 0.58 Allowed 'Trans proline' 0 C--N 1.303 -1.859 0 C-N-CA 122.187 1.924 . . . . 0.0 111.689 -178.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.638 ' CG1' ' CG1' ' A' ' 84' ' ' ILE . 0.5 OUTLIER -162.94 140.93 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 120.621 -1.299 . . . . 0.0 111.899 -178.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.592 ' O ' ' CG1' ' A' ' 84' ' ' ILE . 75.1 m-20 -80.54 154.72 27.33 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.182 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.638 ' CG1' ' CG1' ' A' ' 82' ' ' VAL . 20.5 mt -155.63 134.04 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 117.065 -1.854 . . . . 0.0 112.443 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.51 ' CG1' HD22 ' A' ' 24' ' ' LEU . 9.5 mm -99.27 104.34 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 178.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.503 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.13 -161.48 35.41 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.747 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.502 ' HG2' HD11 ' B' ' 5' ' ' LEU . 1.0 OUTLIER -63.73 -35.48 80.72 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.691 -0.888 . . . . 0.0 109.663 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.576 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 18.6 p-10 -51.26 -20.88 1.8 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.987 -1.07 . . . . 0.0 110.248 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.576 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -113.03 -29.7 7.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.727 -1.233 . . . . 0.0 110.265 -179.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.443 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 21.4 mt -66.18 -11.6 50.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.994 -1.066 . . . . 0.0 108.957 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -101.38 -10.05 20.59 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.064 -1.023 . . . . 0.0 109.513 179.848 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.5 mm-40 -90.28 -41.19 11.69 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.264 -0.897 . . . . 0.0 109.85 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.523 HD11 ' CG ' ' B' ' 99' ' ' PHE . 2.2 pt -89.72 2.35 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.118 -0.989 . . . . 0.0 109.065 179.371 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 65.84 54.48 24.86 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.529 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -82.75 137.1 34.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.055 -1.262 . . . . 0.0 109.543 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.4 p -122.78 136.95 55.03 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.223 -0.923 . . . . 0.0 109.117 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.54 HD13 ' CD1' ' B' ' 97' ' ' LEU . 5.3 mp -97.36 96.67 8.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.896 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -101.02 125.17 47.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.038 -1.039 . . . . 0.0 109.251 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.296 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.678 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.475 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.3 tt0 -130.74 136.69 48.99 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 177.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 8.0 t -132.17 136.24 56.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 120.886 -1.134 . . . . 0.0 109.653 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.593 ' O ' ' HB2' ' B' ' 5' ' ' LEU . 6.0 p -69.38 -93.14 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.394 -0.816 . . . . 0.0 109.662 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.593 ' HB2' ' O ' ' B' ' 4' ' ' THR . 0.2 OUTLIER 158.81 -7.44 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.836 -0.54 . . . . 0.0 110.72 179.542 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -50.53 -19.27 0.84 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.667 -1.271 . . . . 0.0 110.535 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.41 -175.92 4.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.806 -1.184 . . . . 0.0 109.9 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.05 130.33 91.49 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -79.66 68.16 8.38 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.425 2.083 . . . . 0.0 109.471 179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.549 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -87.21 156.48 19.65 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.167 -0.958 . . . . 0.0 109.977 -179.104 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.54 ' CG2' HG21 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -147.33 138.37 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.392 -0.817 . . . . 0.0 109.662 -179.627 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.5 m -71.53 90.68 1.02 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.89 -1.131 . . . . 0.0 108.287 178.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.54 HG21 ' CG2' ' B' ' 11' ' ' VAL . 4.4 pt -80.29 150.2 4.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.952 -179.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.529 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 10.6 tttm -121.75 104.42 9.58 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.366 -0.834 . . . . 0.0 109.403 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.555 ' CG2' HG23 ' B' ' 62' ' ' ILE . 4.8 mt -117.13 143.21 28.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.24 -90.29 0.05 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.946 -1.661 . . . . 0.0 108.946 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -158.35 38.67 0.52 Allowed Glycine 0 N--CA 1.486 1.97 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 179.286 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.419 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -137.46 166.91 22.73 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.67 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.529 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 17.5 mt -132.23 122.12 24.73 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.414 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -134.89 155.78 50.09 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.035 -1.041 . . . . 0.0 109.9 -178.961 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.549 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.5 mm-40 -78.98 110.42 14.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 178.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.546 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -98.63 154.75 17.71 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 110.341 -178.395 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.474 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.6 tp -101.85 101.18 11.58 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.668 -0.645 . . . . 0.0 109.751 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.483 HD12 ' CE2' ' A' ' 99' ' ' PHE . 19.6 mt -46.23 99.57 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.32 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.569 ' CB ' HG22 ' B' ' 84' ' ' ILE . 44.4 t0 -107.48 96.08 6.15 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.291 -0.88 . . . . 0.0 111.027 -178.225 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.525 ' HA ' ' CD2' ' B' ' 90' ' ' LEU . 0.7 OUTLIER -78.97 3.22 17.77 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.086 -1.009 . . . . 0.0 109.188 178.599 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -95.69 -18.62 31.97 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.449 ' O ' ' HG3' ' B' ' 87' ' ' ARG . . . -85.78 170.83 12.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.019 -1.283 . . . . 0.0 109.711 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.44 ' HA ' ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER -100.67 -20.06 15.79 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.186 -0.946 . . . . 0.0 110.797 -178.88 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' HB ' ' B' ' 74' ' ' THR . 0.2 OUTLIER -137.99 -163.11 1.39 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.803 -1.186 . . . . 0.0 109.851 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.527 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 17.8 m -109.88 86.6 2.33 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.972 -1.08 . . . . 0.0 110.538 -178.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -69.04 175.39 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.825 -1.172 . . . . 0.0 108.157 179.08 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.564 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.4 116.94 0.51 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.111 -0.993 . . . . 0.0 109.804 -178.911 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.542 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 5.2 pt-20 -39.58 160.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.465 -0.772 . . . . 0.0 109.515 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.469 ' HA ' HG11 ' B' ' 77' ' ' VAL . 0.3 OUTLIER -38.31 139.81 0.35 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.728 0.775 . . . . 0.0 110.699 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -168.53 167.69 11.47 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.761 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 28.8 t -100.63 125.78 47.07 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.789 -1.194 . . . . 0.0 111.256 -178.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.575 ' HB2' ' CZ ' ' B' ' 59' ' ' TYR . 3.6 mm? -117.09 171.96 4.38 Favored Pre-proline 0 N--CA 1.493 1.696 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.505 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.3 Cg_endo -80.57 59.91 7.64 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.385 2.057 . . . . 0.0 111.38 -179.493 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 40.21 -158.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.431 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 58.49 68.22 0.85 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.443 -1.034 . . . . 0.0 109.313 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 22.8 p-90 -144.16 -167.44 2.61 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.44 -0.788 . . . . 0.0 109.879 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -146.44 132.08 9.31 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.57 132.12 11.95 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 121.93 1.753 . . . . 0.0 110.602 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.406 ' HD3' HD22 ' B' ' 76' ' ' LEU . 0.6 OUTLIER -161.33 -162.24 0.88 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.713 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.414 ' HB3' ' HA ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -152.24 146.33 25.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.992 -1.068 . . . . 0.0 109.361 178.743 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.476 HD13 HD12 ' B' ' 54' ' ' ILE . 1.1 pt -96.33 155.83 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.258 -0.901 . . . . 0.0 108.886 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.663 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.09 130.7 8.69 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.487 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -158.02 -125.42 0.83 Allowed Glycine 0 N--CA 1.482 1.76 0 C-N-CA 118.949 -1.596 . . . . 0.0 111.338 -179.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.588 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 19.0 mt -88.96 126.68 41.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.937 -0.743 . . . . 0.0 112.836 -177.271 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.42 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 90.48 -28.3 7.73 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 178.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.408 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 157.76 -159.24 29.74 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.169 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.663 ' CD2' ' CA ' ' B' ' 48' ' ' GLY . 1.5 m-85 -120.49 132.07 55.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.654 -0.909 . . . . 0.0 109.627 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.513 HD12 ' CG2' ' A' ' 50' ' ' ILE . 35.4 pt -103.9 162.84 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 108.983 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.5 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 13.0 mttt -93.3 154.73 17.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.088 -1.007 . . . . 0.0 109.771 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.564 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 6.4 m -151.23 -168.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.055 -1.028 . . . . 0.0 110.07 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.563 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 16.7 mmt180 -129.83 89.22 2.78 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -56.48 93.62 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.271 -0.893 . . . . 0.0 110.777 -178.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.607 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 27.9 m-85 -88.71 136.04 33.2 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 177.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.484 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -114.58 138.25 50.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.712 -1.242 . . . . 0.0 111.041 -178.302 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.523 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.46 60.68 0.07 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.653 -0.654 . . . . 0.0 110.602 178.884 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.555 HG23 ' CG2' ' B' ' 15' ' ' ILE . 4.2 mp -118.77 118.09 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 108.856 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.543 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 2.8 tm? -68.26 90.13 0.34 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.237 -0.914 . . . . 0.0 110.631 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.519 ' HB ' ' CG1' ' B' ' 15' ' ' ILE . 2.4 tt -90.07 115.21 29.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.4 tm-20 -89.13 117.53 28.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.551 -178.586 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.501 HD12 ' CD1' ' B' ' 64' ' ' ILE . 1.4 mp -115.69 125.02 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.331 -0.856 . . . . 0.0 109.351 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 62.4 m 61.57 -95.06 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.518 -0.739 . . . . 0.0 109.792 179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -145.78 39.78 1.12 Allowed Glycine 0 N--CA 1.484 1.893 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -139.62 133.06 30.15 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.381 -1.07 . . . . 0.0 109.637 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.499 ' CG ' HD22 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -77.04 135.55 38.65 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.022 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.483 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -145.75 97.53 2.98 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.154 -1.018 . . . . 0.0 110.665 -179.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.525 HD12 ' N ' ' B' ' 63' ' ' LEU . 0.6 OUTLIER -78.89 140.17 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 177.988 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.545 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -167.77 -168.0 29.27 Favored Glycine 0 N--CA 1.485 1.96 0 C-N-CA 118.741 -1.695 . . . . 0.0 110.939 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 28.9 m -95.95 109.18 21.59 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.781 -0.835 . . . . 0.0 110.244 -179.397 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.506 HG22 ' HB ' ' B' ' 62' ' ' ILE . 1.4 t -96.61 104.97 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.321 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.7 mp -79.86 116.74 20.19 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.202 -0.936 . . . . 0.0 108.615 178.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 4.3 t -101.39 131.44 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.051 -1.031 . . . . 0.0 109.125 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.482 ' HA3' HG13 ' B' ' 56' ' ' VAL . . . -162.38 -165.43 19.37 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.06 -1.543 . . . . 0.0 109.905 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.93 40.67 1.01 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.753 2.302 . . . . 0.0 110.054 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.542 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 8.8 t -85.55 138.5 35.89 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.497 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 33.9 Cg_endo -78.38 14.3 1.63 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.51 2.14 . . . . 0.0 111.078 -179.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.511 HG11 ' CD1' ' B' ' 84' ' ' ILE . 1.1 t -160.68 167.56 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.102 -0.999 . . . . 0.0 109.382 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.608 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -101.15 144.18 30.34 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 175.816 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.569 HG22 ' CB ' ' B' ' 25' ' ' ASP . 6.8 mm -129.0 123.68 59.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 O-C-N 120.069 -1.644 . . . . 0.0 112.194 -176.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.452 HG21 ' CD1' ' B' ' 90' ' ' LEU . 4.4 mm -102.54 101.48 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.491 ' O ' HD11 ' B' ' 90' ' ' LEU . . . -107.0 175.25 20.51 Favored Glycine 0 N--CA 1.496 2.695 0 C-N-CA 119.792 -1.194 . . . . 0.0 111.915 -177.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.536 ' N ' HD21 ' B' ' 90' ' ' LEU . 4.0 mtm180 -28.46 -41.44 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.376 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -178.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.536 ' ND2' HD21 ' B' ' 89' ' ' LEU . 8.8 p-10 -53.17 -41.38 65.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 120.234 -1.541 . . . . 0.0 110.661 -177.659 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.545 ' CD2' ' HA3' ' B' ' 73' ' ' GLY . 1.6 mm? -98.92 -18.33 17.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.172 -0.955 . . . . 0.0 110.342 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.536 HD21 ' N ' ' B' ' 87' ' ' ARG . 0.4 OUTLIER -69.51 -35.89 75.94 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.143 -0.973 . . . . 0.0 109.391 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 49.6 p -70.03 -15.27 62.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.189 -0.944 . . . . 0.0 108.965 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' B' ' 72' ' ' ILE . 26.7 mt-30 -91.63 -40.48 11.28 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.306 -0.871 . . . . 0.0 108.943 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.561 ' HB ' ' HB2' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -81.77 -2.98 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 177.088 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.01 43.29 99.63 Favored Glycine 0 N--CA 1.496 2.697 0 O-C-N 121.561 -0.712 . . . . 0.0 111.361 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -68.38 147.01 52.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.874 -1.368 . . . . 0.0 110.289 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 14.9 p -144.61 130.78 19.54 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.339 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.54 ' CD1' HD13 ' A' ' 97' ' ' LEU . 8.0 mp -92.68 102.85 15.27 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 110.119 -179.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 3.6 m120 -101.65 121.95 42.98 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.088 -1.007 . . . . 0.0 109.688 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 118.128 -0.939 . . . . 0.0 109.33 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.588 ' H62' ' CG1' ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.449 ' HD2' ' OXT' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.687 0 N-CA-C 110.164 -0.745 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.52 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -104.09 126.59 51.33 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.292 -0.88 . . . . 0.0 109.032 179.079 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 t -121.83 102.46 11.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 0.8 OUTLIER -52.27 -84.26 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.324 -0.86 . . . . 0.0 109.953 -178.981 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.571 HD23 ' CB ' ' B' ' 90' ' ' LEU . 31.2 tp 171.84 -25.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.259 -0.9 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 84.8 m95 -54.77 -19.36 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.07 -1.019 . . . . 0.0 108.996 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -129.51 130.53 45.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.438 -0.789 . . . . 0.0 109.513 179.594 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtt-85 -49.06 146.49 5.7 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.533 ' HD3' ' NH2' ' B' ' 87' ' ' ARG . 37.0 Cg_endo -79.8 47.75 2.63 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.838 2.359 . . . . 0.0 110.538 179.394 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 mt -80.03 144.4 33.24 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.1 -1.0 . . . . 0.0 109.276 -179.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.402 HG22 ' CG2' ' A' ' 66' ' ' ILE . 1.9 m -148.99 160.15 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.366 -179.379 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 90.0 m -91.21 107.77 19.43 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.487 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.465 ' CG2' HD11 ' A' ' 66' ' ' ILE . 2.1 pt -99.18 157.97 3.67 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.275 -0.89 . . . . 0.0 110.084 -178.674 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.535 ' CB ' HD22 ' A' ' 19' ' ' LEU . 2.3 ttmt -118.16 100.81 7.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 108.913 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.555 ' CD1' HG12 ' A' ' 75' ' ' VAL . 1.3 mt -109.8 140.92 26.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.858 -1.151 . . . . 0.0 109.4 -179.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 62.96 -90.64 0.07 OUTLIER Glycine 0 N--CA 1.488 2.139 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -179.604 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.22 35.19 0.6 Allowed Glycine 0 C--N 1.294 -1.787 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.404 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -138.99 173.78 11.2 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -1.134 . . . . 0.0 109.591 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.535 HD22 ' CB ' ' A' ' 14' ' ' LYS . 18.5 mt -133.58 122.04 22.95 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.593 -0.692 . . . . 0.0 109.42 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.451 ' HE3' ' SD ' ' A' ' 36' ' ' MET . 0.3 OUTLIER -135.72 -179.87 5.92 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.93 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.5 mt-10 -78.32 176.36 9.39 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 108.191 179.521 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.488 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -157.71 108.74 2.25 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 120.936 -1.102 . . . . 0.0 109.619 -179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.521 ' O ' ' N ' ' A' ' 25' ' ' ASP . 20.8 tp -85.19 93.41 8.65 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.35 -0.844 . . . . 0.0 109.078 179.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.436 ' C ' ' O ' ' A' ' 23' ' ' LEU . 97.8 mt -43.06 97.15 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.545 ' CB ' HG21 ' A' ' 84' ' ' ILE . 3.8 t0 -102.95 77.18 1.54 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.388 -0.82 . . . . 0.0 110.918 -178.245 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.464 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 2.2 m -54.92 -20.19 8.36 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.124 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.403 ' O ' HD23 ' B' ' 23' ' ' LEU . . . -65.24 -44.33 93.93 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.732 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.465 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -69.47 155.72 40.01 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.17 -1.194 . . . . 0.0 108.86 179.766 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.68 -17.55 31.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.05 -1.032 . . . . 0.0 110.688 -179.034 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.523 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -138.42 -159.58 0.97 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.779 -1.201 . . . . 0.0 110.108 -179.532 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 35.3 m -114.98 91.41 3.61 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.925 -1.11 . . . . 0.0 110.602 -178.547 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.533 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -74.79 160.12 5.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.675 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.533 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -160.15 123.72 3.57 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.841 -1.162 . . . . 0.0 110.473 -178.595 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.607 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.6 OUTLIER -41.99 153.46 0.06 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.14 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.459 ' HA ' HG11 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -43.11 146.93 0.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.021 -1.049 . . . . 0.0 110.161 -179.55 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.544 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 21.7 ptm -162.2 -163.64 0.95 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.311 -0.868 . . . . 0.0 109.597 -179.802 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.4 t -101.31 87.08 3.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.433 -0.792 . . . . 0.0 109.214 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.54 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 12.9 tp -127.71 97.34 30.5 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.145 -0.972 . . . . 0.0 110.134 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.04 178.31 7.34 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.497 2.131 . . . . 0.0 109.94 179.366 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.15 -173.86 16.31 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.486 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -78.93 134.86 36.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.326 -1.102 . . . . 0.0 109.239 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.596 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.9 p-90 -147.72 159.42 43.82 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -128.26 135.44 27.54 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 135.33 18.28 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 121.86 1.707 . . . . 0.0 109.968 -179.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.454 ' HD2' HD22 ' A' ' 76' ' ' LEU . 8.1 ptpt -155.8 -165.66 2.02 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.462 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.458 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 4.0 mtp -150.4 125.89 10.2 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.293 -0.879 . . . . 0.0 109.641 -179.624 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.513 HD13 ' CG2' ' B' ' 50' ' ' ILE . 1.1 pt -89.78 147.1 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.014 -1.054 . . . . 0.0 108.422 179.118 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.427 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -117.97 105.76 1.28 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.466 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -128.39 -132.34 3.54 Favored Glycine 0 N--CA 1.484 1.89 0 C-N-CA 119.459 -1.353 . . . . 0.0 111.043 -178.815 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.589 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 34.8 mt -83.13 121.06 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.838 -0.801 . . . . 0.0 112.537 -177.547 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.439 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 97.71 -20.48 50.46 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 178.019 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.87 -161.01 28.88 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 120.808 -1.407 . . . . 0.0 109.993 179.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -126.09 132.37 51.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.437 -1.037 . . . . 0.0 109.524 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.487 HD13 HD12 ' A' ' 47' ' ' ILE . 14.1 pt -104.38 175.33 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.079 -1.013 . . . . 0.0 109.412 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.458 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 3.6 mtmt -103.77 140.32 37.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.095 -1.003 . . . . 0.0 109.258 179.853 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.526 HG22 ' CD2' ' A' ' 76' ' ' LEU . 27.1 m -144.39 170.08 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.129 -0.982 . . . . 0.0 109.917 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.413 ' O ' ' N ' ' A' ' 59' ' ' TYR . 1.0 OUTLIER -111.21 96.76 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.057 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -55.78 93.74 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.344 -0.848 . . . . 0.0 109.704 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 5.8 m-85 -89.31 125.98 35.33 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 178.528 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.596 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 65.3 m-20 -106.38 133.8 50.5 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.792 -1.192 . . . . 0.0 110.345 -178.885 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.596 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mt-30 74.44 63.32 0.07 Allowed 'General case' 0 N--CA 1.494 1.741 0 CA-C-O 121.855 0.836 . . . . 0.0 109.904 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.528 ' CG2' HG22 ' A' ' 15' ' ' ILE . 16.0 mm -115.14 119.47 61.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 178.616 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.52 ' N ' HD11 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -70.42 90.2 0.71 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.178 -0.951 . . . . 0.0 111.277 -177.919 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.587 ' CG2' ' CD1' ' A' ' 89' ' ' LEU . 7.3 tt -88.51 113.51 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.657 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -87.99 111.79 21.88 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.244 -0.91 . . . . 0.0 109.012 -178.282 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.546 ' O ' ' N ' ' A' ' 68' ' ' GLY . 1.3 mm -97.19 168.1 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.505 ' C ' ' O ' ' A' ' 66' ' ' ILE . 61.3 m -28.68 88.87 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.488 0.661 . . . . 0.0 111.219 -179.074 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.573 ' O ' ' CD2' ' A' ' 69' ' ' HIS . . . 52.31 58.94 9.66 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.529 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 68' ' ' GLY . 6.8 m-70 -162.27 86.76 0.61 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.372 . . . . 0.0 110.42 179.496 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.519 ' CG ' HD22 ' A' ' 63' ' ' LEU . 4.4 tttm -49.04 118.54 2.69 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.537 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -141.26 108.36 5.47 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 119.416 -0.914 . . . . 0.0 110.456 -178.602 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.539 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -80.74 159.42 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.005 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.521 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 179.42 174.49 45.51 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 118.247 -1.93 . . . . 0.0 111.452 179.577 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.569 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 87.6 m -87.14 112.67 22.17 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.606 -0.938 . . . . 0.0 109.956 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.555 HG12 ' CD1' ' A' ' 15' ' ' ILE . 1.4 t -102.17 118.9 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.422 -0.799 . . . . 0.0 110.275 179.679 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.526 ' CD2' HG22 ' A' ' 56' ' ' VAL . 4.9 mp -87.81 105.75 17.62 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.77 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.459 HG11 ' HA ' ' A' ' 35' ' ' GLU . 6.5 t -88.75 113.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.233 -0.917 . . . . 0.0 110.327 -178.67 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.479 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -153.85 -168.77 17.96 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.451 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -80.35 44.5 1.75 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.634 2.223 . . . . 0.0 111.061 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.607 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.7 t -82.5 141.25 45.17 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.022 -1.049 . . . . 0.0 108.637 179.241 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -81.22 17.67 1.43 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.576 2.184 . . . . 0.0 111.163 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.485 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 2.2 t -161.26 163.28 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.86 -1.15 . . . . 0.0 110.333 -179.23 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.488 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 72.5 m-20 -99.18 89.37 4.22 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.545 HG21 ' CB ' ' A' ' 25' ' ' ASP . 8.2 mm -78.27 116.43 21.94 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 O-C-N 121.168 -0.957 . . . . 0.0 111.764 -176.436 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.602 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -101.63 85.99 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.225 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.64 -165.32 28.02 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.288 -0.958 . . . . 0.0 112.346 -176.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.485 ' HD3' ' HD3' ' B' ' 9' ' ' PRO . 27.8 mtm-85 -57.38 -39.91 77.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 122.203 -0.586 . . . . 0.0 111.481 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 16.3 p-10 -45.49 -24.31 0.31 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.537 -1.352 . . . . 0.0 109.63 -179.3 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.587 ' CD1' ' CG2' ' A' ' 64' ' ' ILE . 3.5 mm? -111.9 -32.48 6.59 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.892 -1.13 . . . . 0.0 110.712 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.464 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 90.1 mt -58.17 -36.58 73.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.824 -1.172 . . . . 0.0 108.841 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.4 p -75.69 -20.53 58.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.316 -0.865 . . . . 0.0 109.643 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -72.45 -40.31 67.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.863 -1.148 . . . . 0.0 108.472 179.428 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.552 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -81.65 -1.01 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.581 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 67.47 61.3 5.16 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.506 -1.838 . . . . 0.0 108.506 -179.527 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -89.77 149.27 22.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.442 -1.034 . . . . 0.0 110.003 -179.192 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 49.5 p -137.73 125.43 22.36 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.028 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.562 ' CD1' HD13 ' B' ' 97' ' ' LEU . 4.8 mp -86.0 104.11 15.31 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.59 -0.694 . . . . 0.0 109.279 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.2 m120 -104.4 122.32 45.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.083 -1.011 . . . . 0.0 110.03 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.612 ' CD2' ' CD1' ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.618 0 CA-C-O 117.937 -1.03 . . . . 0.0 109.25 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.478 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.626 0 N-CA-C 109.87 -0.858 . . . . 0.0 109.87 . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.445 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.2 tt0 -84.64 134.0 34.39 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.459 HG11 HD11 ' B' ' 5' ' ' LEU . 22.2 t -133.73 137.07 53.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 120.762 -1.212 . . . . 0.0 109.9 -179.144 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.558 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -129.99 23.84 5.3 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 178.983 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.524 ' CD2' ' HA ' ' B' ' 9' ' ' PRO . 1.6 mp -39.54 92.24 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.767 0.794 . . . . 0.0 109.801 -179.226 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.558 ' N ' ' O ' ' B' ' 4' ' ' THR . 4.7 m95 -44.42 -21.59 0.05 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.632 -0.667 . . . . 0.0 109.912 -179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.447 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.7 mt-30 -109.4 -158.85 0.66 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.022 -1.049 . . . . 0.0 108.599 179.122 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -59.01 119.7 40.42 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.037 -1.04 . . . . 0.0 109.469 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.524 ' HA ' ' CD2' ' B' ' 5' ' ' LEU . 36.6 Cg_endo -78.22 73.14 5.92 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.254 1.969 . . . . 0.0 109.798 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.54 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -82.1 163.61 21.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.184 -0.947 . . . . 0.0 109.937 -179.425 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.483 HG21 ' O ' ' B' ' 11' ' ' VAL . 14.8 m -144.95 142.33 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.429 -0.794 . . . . 0.0 110.143 -179.697 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.7 m -73.97 99.09 3.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.01 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.531 ' CD1' HD13 ' B' ' 15' ' ' ILE . 1.3 pt -92.07 147.46 5.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.617 -178.454 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.8 tttt -114.08 94.51 4.85 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.531 HD13 ' CD1' ' B' ' 13' ' ' ILE . 22.3 mt -115.03 129.94 70.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.132 -0.98 . . . . 0.0 109.609 -179.429 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.05 52.99 49.08 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.442 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.35 23.57 9.01 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.472 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -119.26 170.67 8.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -1.151 . . . . 0.0 109.476 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.417 HD21 ' O ' ' B' ' 13' ' ' ILE . 13.8 mt -141.52 122.42 14.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.139 -0.976 . . . . 0.0 110.24 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 mttt -147.22 145.92 29.63 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.139 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.54 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 11.8 mt-10 -78.37 133.24 37.59 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.863 -1.148 . . . . 0.0 108.504 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.534 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -112.38 162.8 15.15 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.883 -179.04 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' B' ' 25' ' ' ASP . 59.4 tp -99.7 101.52 12.72 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.837 -0.539 . . . . 0.0 110.06 -178.856 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.466 HD12 HD21 ' A' ' 97' ' ' LEU . 2.9 mt -44.98 97.37 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.214 -0.929 . . . . 0.0 108.51 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.575 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 10.3 t0 -100.87 95.39 6.58 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.089 -1.007 . . . . 0.0 110.863 -178.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -83.0 9.67 9.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.257 -0.902 . . . . 0.0 108.861 178.301 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.0 -14.13 17.88 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.841 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.5 170.03 9.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.111 -1.229 . . . . 0.0 109.089 179.803 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.08 -14.94 17.59 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.038 -1.039 . . . . 0.0 111.825 -178.397 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.487 ' C ' ' OD1' ' B' ' 88' ' ' ASN . 14.3 m-20 -141.91 -169.33 2.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.507 -1.371 . . . . 0.0 110.639 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.749 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 38.5 m -104.48 84.75 2.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.199 -0.938 . . . . 0.0 110.475 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.523 HG13 ' CG1' ' B' ' 84' ' ' ILE . 1.0 OUTLIER -78.75 112.19 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.244 -0.91 . . . . 0.0 110.387 -179.636 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.512 ' HB2' ' CG1' ' B' ' 75' ' ' VAL . 0.5 OUTLIER -107.76 123.17 48.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.583 -0.698 . . . . 0.0 110.176 179.895 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 14.0 pt-20 -43.36 164.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.943 -1.098 . . . . 0.0 108.831 178.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.544 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -47.74 145.03 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.996 -1.065 . . . . 0.0 110.112 -179.231 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.481 ' CG ' ' HG ' ' B' ' 38' ' ' LEU . 10.5 ptm -155.66 -165.55 2.0 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.36 -0.838 . . . . 0.0 109.135 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 21.2 t -102.44 87.14 2.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.111 -0.993 . . . . 0.0 109.508 179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.486 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 31.3 mt -112.88 163.92 16.75 Favored Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 121.246 -0.909 . . . . 0.0 109.17 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.9 Cg_endo -75.8 -166.45 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.354 2.036 . . . . 0.0 110.492 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.502 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -94.28 -152.17 29.01 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 62.97 58.71 1.45 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.888 -0.772 . . . . 0.0 109.067 -179.401 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.583 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 30.0 p-90 -134.92 175.61 9.41 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.649 -0.657 . . . . 0.0 109.746 -179.537 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.03 123.65 15.97 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.229 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.38 137.44 20.9 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.217 1.944 . . . . 0.0 111.543 -178.689 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.24 -167.29 2.72 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.105 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.502 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 54.6 mtp -145.69 131.36 18.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.94 -1.1 . . . . 0.0 110.159 -179.275 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.498 HD12 HD12 ' B' ' 54' ' ' ILE . 5.2 pt -97.75 149.04 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.171 -0.955 . . . . 0.0 108.694 179.08 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.611 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.06 116.94 3.49 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.27 -125.86 2.31 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.449 -1.358 . . . . 0.0 110.536 -179.431 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.597 HG13 ' H62' ' B' ' 100' ' ' DMP . 66.6 mt -87.23 129.27 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.948 . . . . 0.0 112.676 -177.794 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.07 -47.37 2.68 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 178.252 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.439 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 178.87 -156.26 18.31 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.055 -179.701 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.5 m-85 -120.97 136.22 55.02 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.681 -0.894 . . . . 0.0 109.414 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.537 ' CG2' HG21 ' A' ' 50' ' ' ILE . 7.1 pt -107.16 173.1 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.125 -0.984 . . . . 0.0 109.102 179.219 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.551 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 9.8 mttm -110.06 145.53 36.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.028 -1.045 . . . . 0.0 109.099 179.708 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' B' ' 76' ' ' LEU . 30.6 m -141.48 -173.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.868 -1.145 . . . . 0.0 110.39 -179.583 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' B' ' 59' ' ' TYR . 5.2 mtt85 -129.31 90.09 2.96 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.46 ' HG3' HG23 ' B' ' 74' ' ' THR . 12.0 tt0 -48.76 92.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.363 -0.836 . . . . 0.0 109.97 -179.488 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.583 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 10.3 m-85 -92.93 92.14 7.73 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -79.52 140.17 37.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.147 -0.971 . . . . 0.0 110.626 -178.519 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.515 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 76.76 60.61 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.514 0.673 . . . . 0.0 110.019 179.539 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.491 ' HB ' HG21 ' B' ' 75' ' ' VAL . 6.1 mm -120.77 115.48 47.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.519 ' CD2' ' C ' ' B' ' 63' ' ' LEU . 0.5 OUTLIER -66.7 104.0 1.21 Allowed 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.848 -1.157 . . . . 0.0 110.73 -178.664 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.559 ' CG2' ' O ' ' B' ' 71' ' ' ALA . 9.2 tt -106.19 112.65 40.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 177.486 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.473 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.0 tt0 -88.89 106.58 18.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.955 -1.091 . . . . 0.0 109.79 -177.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.468 ' O ' ' HB2' ' B' ' 69' ' ' HIS . 1.6 mp -105.01 117.47 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.884 . . . . 0.0 109.406 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.495 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 9.7 m 58.54 57.66 3.7 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.453 -0.779 . . . . 0.0 109.916 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.56 34.48 20.29 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.636 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.495 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 61.8 m-70 -126.51 117.1 22.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.255 -1.144 . . . . 0.0 109.309 179.794 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.476 ' HG3' HD23 ' B' ' 63' ' ' LEU . 23.0 ttpt -65.38 124.82 23.27 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.452 -179.927 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -146.44 96.02 2.7 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.353 -0.842 . . . . 0.0 109.523 -179.829 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.515 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.7 OUTLIER -79.14 152.46 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.048 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.07 -157.42 14.77 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 118.428 -1.844 . . . . 0.0 111.781 179.919 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.46 HG23 ' HG3' ' B' ' 58' ' ' GLN . 3.4 m -110.66 104.97 13.71 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.679 -0.895 . . . . 0.0 110.001 -179.089 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' B' ' 33' ' ' LEU . 1.4 t -96.65 110.41 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.635 -0.666 . . . . 0.0 110.215 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.491 ' HB3' ' CG2' ' B' ' 56' ' ' VAL . 3.8 mp -79.56 106.75 11.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 179.439 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.544 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 2.8 t -88.67 111.43 22.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.95 -1.094 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -141.65 -170.5 12.42 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.551 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.09 42.55 1.36 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.474 2.116 . . . . 0.0 110.648 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.567 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.0 t -88.94 139.45 29.07 Favored Pre-proline 0 N--CA 1.49 1.536 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.444 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.6 Cg_endo -80.43 18.21 1.25 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.553 2.169 . . . . 0.0 111.19 -179.313 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.507 ' CG1' HD13 ' B' ' 84' ' ' ILE . 0.8 OUTLIER -161.59 163.01 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.917 -1.114 . . . . 0.0 110.008 -179.348 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.537 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.1 OUTLIER -94.62 160.33 14.68 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 104.482 -2.414 . . . . 0.0 104.482 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.749 ' O ' ' HA ' ' B' ' 31' ' ' THR . 12.6 mm -144.05 95.05 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 O-C-N 120.051 -1.655 . . . . 0.0 111.054 -178.354 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.577 ' CG2' ' CD1' ' B' ' 90' ' ' LEU . 0.3 OUTLIER -77.71 101.41 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 178.196 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.509 ' O ' HD11 ' B' ' 90' ' ' LEU . . . -112.99 -176.07 19.49 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.674 -177.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.54 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 7.1 mtt85 -29.65 -42.16 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -178.614 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.559 ' ND2' HD21 ' B' ' 89' ' ' LEU . 4.8 p-10 -57.56 -42.64 83.41 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.124 -1.61 . . . . 0.0 110.482 -177.688 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.559 HD21 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -95.8 -10.57 28.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.299 -0.876 . . . . 0.0 109.662 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.577 ' CD1' ' CG2' ' B' ' 85' ' ' ILE . 1.2 mp -79.06 -32.0 44.68 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.319 -0.863 . . . . 0.0 109.186 -179.623 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.56 ' N ' ' CD2' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.9 -20.22 60.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.064 -1.022 . . . . 0.0 109.413 179.611 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.523 ' OE1' ' CD1' ' B' ' 89' ' ' LEU . 28.0 mt-30 -82.13 -41.24 20.73 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.029 -1.045 . . . . 0.0 109.03 179.562 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.612 ' CD1' ' CD2' ' A' ' 99' ' ' PHE . 1.1 pt -82.48 -9.11 11.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.3 57.37 15.48 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 178.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.523 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -81.15 142.14 33.55 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.253 -1.145 . . . . 0.0 110.446 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 24.3 p -129.82 126.2 37.51 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.713 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.562 HD13 ' CD1' ' A' ' 97' ' ' LEU . 2.7 mp -90.53 90.43 8.0 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 109.537 -179.609 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.52 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 5.1 m120 -95.63 127.63 41.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.66 ' CD1' ' N ' ' B' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.13 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.597 ' H62' HG13 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.419 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.73 0 N-CA-C 110.65 -0.558 . . . . 0.0 110.65 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.1 OUTLIER -84.4 146.0 27.9 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 177.865 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.542 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 2.2 t -134.19 124.56 46.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 C-N-CA 118.486 -1.286 . . . . 0.0 110.091 -179.04 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.538 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -130.14 14.02 5.67 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.128 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -43.75 93.51 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 CA-C-O 121.9 0.857 . . . . 0.0 109.152 -179.301 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.538 ' N ' ' O ' ' A' ' 4' ' ' THR . 2.5 m95 -45.24 -15.15 0.02 OUTLIER 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.879 -0.513 . . . . 0.0 110.426 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.514 ' N ' ' O ' ' A' ' 5' ' ' LEU . 28.9 mt-30 -106.48 -115.65 0.26 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.62 -1.3 . . . . 0.0 108.951 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.504 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 46.3 mtp180 -111.03 136.48 20.8 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 120.406 -1.434 . . . . 0.0 110.235 -179.691 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.507 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 38.0 Cg_endo -81.09 63.09 8.7 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.597 2.198 . . . . 0.0 109.785 178.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.46 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 2.4 mt -84.79 140.29 31.33 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.623 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.447 HG23 ' HB1' ' A' ' 22' ' ' ALA . 1.1 m -140.32 151.64 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.321 -0.862 . . . . 0.0 109.128 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.5 m -86.08 99.92 11.82 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.206 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.56 HG22 ' CB ' ' A' ' 22' ' ' ALA . 1.9 pt -91.5 161.04 2.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.388 -0.82 . . . . 0.0 110.311 -178.178 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 1.2 tttt -117.07 97.85 6.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 109.174 179.491 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.57 ' CD1' ' CG2' ' A' ' 75' ' ' VAL . 0.2 OUTLIER -113.67 126.93 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.096 -1.003 . . . . 0.0 109.463 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.63 31.02 77.33 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.733 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.7 11.36 68.91 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.517 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 91.7 mm-40 -108.01 167.53 9.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 108.901 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.491 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 35.1 mt -126.23 123.35 37.97 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.011 -1.056 . . . . 0.0 109.368 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -140.66 173.99 10.95 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.911 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.6 mt-10 -79.25 177.23 8.99 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.56 ' CB ' HG22 ' A' ' 13' ' ' ILE . . . -154.75 112.0 3.37 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 120.849 -1.157 . . . . 0.0 109.798 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 25' ' ' ASP . 13.4 tp -89.53 95.35 10.23 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.646 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.507 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 30.4 mt -43.85 98.85 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' CB ' HG22 ' A' ' 84' ' ' ILE . 5.5 t0 -105.1 73.71 1.07 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.375 -0.828 . . . . 0.0 110.999 -177.651 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.0 m -57.15 -18.33 14.74 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.861 -1.149 . . . . 0.0 108.052 178.348 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.97 -45.34 92.66 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.71 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.523 ' HB1' ' C25' ' B' ' 100' ' ' DMP . . . -75.66 163.48 27.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.203 -1.174 . . . . 0.0 109.328 -179.923 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.43 -14.89 23.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.166 -0.958 . . . . 0.0 110.888 -179.029 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.529 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.01 -165.44 1.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.671 -1.268 . . . . 0.0 111.338 -178.972 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.727 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -102.47 88.52 3.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.487 -0.758 . . . . 0.0 110.953 -178.426 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.546 HG11 ' CG1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -79.38 113.38 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.013 -1.679 . . . . 0.0 107.933 178.566 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.51 ' HG ' ' OD1' ' A' ' 83' ' ' ASN . 1.1 mp -115.02 132.58 56.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 111.33 -177.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -43.39 165.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.202 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.565 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.4 OUTLIER -57.05 142.72 41.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.029 -1.045 . . . . 0.0 110.238 -179.561 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.534 ' HE3' ' CG2' ' A' ' 15' ' ' ILE . 4.2 ptm -161.82 -161.16 0.75 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.431 -0.793 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -104.15 114.89 29.45 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.321 -0.862 . . . . 0.0 110.358 -179.427 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.518 ' HG ' ' HD2' ' A' ' 39' ' ' PRO . 3.1 tp -138.68 145.7 47.33 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.636 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 31.6 Cg_endo -72.28 157.11 54.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.345 2.03 . . . . 0.0 110.507 -179.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.517 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -49.8 -162.09 0.01 OUTLIER Glycine 0 N--CA 1.493 2.473 0 CA-C-O 121.858 0.699 . . . . 0.0 111.881 -178.475 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.514 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 75.59 50.29 0.07 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.608 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 6.9 p-90 -122.56 177.88 5.23 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-O 122.124 0.964 . . . . 0.0 111.269 -178.297 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.426 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 1.3 mtmm -139.51 118.49 8.96 Favored Pre-proline 0 C--N 1.303 -1.417 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.698 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -74.91 138.63 23.51 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.038 1.826 . . . . 0.0 110.91 -178.706 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.74 -173.21 4.0 Favored 'General case' 0 N--CA 1.49 1.528 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.901 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.484 ' CE ' ' HG3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -138.79 120.62 15.38 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.882 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.51 HG13 ' CG1' ' A' ' 54' ' ' ILE . 3.1 pt -91.68 144.11 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.886 -1.134 . . . . 0.0 109.331 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.61 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -119.01 135.04 11.15 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 179.892 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -159.64 -129.5 1.06 Allowed Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.395 -179.614 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.597 ' CD1' ' C76' ' B' ' 100' ' ' DMP . 77.6 mt -82.15 109.27 16.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.704 -0.88 . . . . 0.0 112.57 -177.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 111.78 -29.23 8.7 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 178.167 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.63 -161.52 29.26 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.424 179.65 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.61 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -112.02 131.97 55.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.408 -1.054 . . . . 0.0 109.931 -179.464 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.51 ' CG1' HG13 ' A' ' 47' ' ' ILE . 16.2 pt -105.12 173.0 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.978 -1.076 . . . . 0.0 108.889 178.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 6.4 mttt -110.09 128.84 55.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.253 -0.904 . . . . 0.0 109.301 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.526 ' CG1' ' HA3' ' A' ' 78' ' ' GLY . 6.9 m -137.34 -174.61 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.101 -1.0 . . . . 0.0 109.998 -179.835 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -120.37 173.57 7.06 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.98 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.52 ' OE1' ' CG2' ' A' ' 74' ' ' THR . 0.1 OUTLIER -136.66 89.53 2.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.894 -1.129 . . . . 0.0 110.8 -179.528 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.636 ' CE1' ' O ' ' A' ' 39' ' ' PRO . 96.5 m-85 -90.01 122.25 32.83 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.354 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.496 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -96.94 146.29 25.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.882 -1.136 . . . . 0.0 110.531 -178.914 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.506 ' HA ' HG21 ' A' ' 72' ' ' ILE . 0.9 OUTLIER 71.28 65.78 0.16 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.563 179.409 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.537 ' HB ' ' CG2' ' A' ' 75' ' ' VAL . 13.5 mm -120.14 106.62 19.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.327 -0.858 . . . . 0.0 109.271 179.656 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.547 ' CD2' ' HG2' ' A' ' 70' ' ' LYS . 1.6 tm? -54.43 87.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.653 -0.654 . . . . 0.0 110.413 -178.759 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.553 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 2.9 tt -89.68 122.09 40.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.872 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 7.1 tp10 -89.15 122.05 32.06 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.847 -1.158 . . . . 0.0 109.455 -178.69 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.525 HG13 HG21 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -118.18 132.18 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.275 -0.89 . . . . 0.0 108.787 -179.912 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 66' ' ' ILE . 21.5 m 38.24 49.96 1.36 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.635 . . . . 0.0 110.637 179.271 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.51 47.96 78.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.456 ' O ' ' HA ' ' A' ' 65' ' ' GLU . 77.6 m-70 -142.67 137.02 29.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.291 -1.123 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.547 ' HG2' ' CD2' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -85.28 126.19 33.51 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.27 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.553 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -147.5 98.94 3.06 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.351 -0.843 . . . . 0.0 110.094 -178.794 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.545 HG13 ' CA ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.73 142.71 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 120.887 -1.133 . . . . 0.0 107.992 179.068 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.507 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -160.85 -159.02 9.64 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.834 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.52 ' CG2' ' OE1' ' A' ' 58' ' ' GLN . 3.1 m -101.78 105.25 16.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.945 -0.738 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.57 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 1.2 t -103.24 163.59 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.063 -1.023 . . . . 0.0 109.534 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.54 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.2 mp -129.87 158.88 38.28 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 178.68 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.565 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 23.8 t -142.68 106.44 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 O-C-N 121.101 -1.0 . . . . 0.0 110.133 -179.462 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.526 ' HA3' ' CG1' ' A' ' 56' ' ' VAL . . . -144.86 -163.61 10.16 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.524 -1.831 . . . . 0.0 108.524 179.576 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.528 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.8 41.45 1.12 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 C-N-CA 122.374 2.049 . . . . 0.0 111.393 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' CG ' ' A' ' 34' ' ' GLU . 6.0 t -84.52 132.64 46.34 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.054 -1.029 . . . . 0.0 108.536 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.42 17.69 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.834 2.356 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.479 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -160.87 173.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.836 -1.165 . . . . 0.0 109.843 -179.776 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.55 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 57.4 m-80 -102.26 139.46 37.85 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.99 -2.596 . . . . 0.0 103.99 176.217 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.727 ' O ' ' HA ' ' A' ' 31' ' ' THR . 11.7 mm -128.66 95.59 2.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 O-C-N 120.283 -1.511 . . . . 0.0 110.533 -176.428 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.549 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -78.94 90.58 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.023 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.59 -160.44 19.97 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -178.432 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.569 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -64.15 -28.37 69.72 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.547 -0.972 . . . . 0.0 110.663 -179.154 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.546 ' ND2' HD21 ' A' ' 89' ' ' LEU . 1.5 p-10 -53.61 -42.71 67.99 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.94 -1.1 . . . . 0.0 110.725 -178.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.546 HD21 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -95.15 -24.85 16.66 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.893 -1.13 . . . . 0.0 108.874 -179.729 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.569 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 91.4 mt -69.07 -4.38 16.92 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.343 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.596 ' HB ' ' CZ3' ' B' ' 6' ' ' TRP . 36.2 p -100.82 -13.35 18.44 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.879 -1.138 . . . . 0.0 109.165 179.608 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 85.2 mm-40 -89.45 -40.99 12.33 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 0.0 109.726 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.482 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 10.5 pt -85.63 -0.09 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.144 -0.973 . . . . 0.0 108.98 179.525 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.88 43.74 40.38 Favored Glycine 0 N--CA 1.497 2.748 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.061 178.873 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.561 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -72.1 142.98 49.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.92 -1.341 . . . . 0.0 110.144 179.665 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.47 HG21 ' O ' ' A' ' 95' ' ' ALA . 16.1 p -148.35 127.69 13.05 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.541 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 7.5 mp -86.55 95.86 9.89 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.269 -0.895 . . . . 0.0 109.453 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.518 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 3.4 m120 -99.02 117.99 34.77 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.042 -1.036 . . . . 0.0 109.679 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.571 ' CG ' HD11 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.297 -1.676 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.319 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.476 ' HD3' ' NE2' ' B' ' 69' ' ' HIS . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.202 -0.73 . . . . 0.0 110.202 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.518 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 8.1 tt0 -83.64 139.44 32.81 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 178.151 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.555 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 2.5 t -131.23 111.05 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.456 -1.298 . . . . 0.0 110.911 -178.149 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.523 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -123.21 -65.55 1.08 Allowed 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.587 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.2 tp 36.47 26.96 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.572 178.152 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.596 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 24.1 m95 18.07 47.63 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.187 0.518 . . . . 0.0 112.172 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.587 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.47 -158.05 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.965 . . . . 0.0 109.443 -179.755 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -70.07 125.58 92.05 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.092 -1.005 . . . . 0.0 109.056 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.555 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.5 Cg_endo -79.09 70.69 7.39 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.434 2.09 . . . . 0.0 109.653 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.541 HD22 ' N ' ' B' ' 23' ' ' LEU . 7.0 mt -85.29 137.93 32.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.267 -0.896 . . . . 0.0 110.816 -178.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.401 HG22 ' N ' ' B' ' 12' ' ' THR . 1.7 m -141.11 168.8 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.401 ' N ' HG22 ' B' ' 11' ' ' VAL . 3.9 m -94.91 120.98 36.03 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.595 HG22 ' CB ' ' B' ' 22' ' ' ALA . 1.6 pt -115.09 147.45 18.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 121.168 -0.958 . . . . 0.0 110.061 -179.201 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.475 ' HA ' HD22 ' B' ' 19' ' ' LEU . 4.1 ttmt -106.9 101.18 10.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.403 -0.811 . . . . 0.0 109.709 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.545 HD11 ' CD2' ' B' ' 33' ' ' LEU . 39.2 mt -117.86 140.28 41.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 50.47 55.08 18.02 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.574 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 34.68 5.38 Favored Glycine 0 N--CA 1.494 2.508 0 O-C-N 121.306 -1.114 . . . . 0.0 110.428 179.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.467 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm100 -132.54 171.71 13.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.059 -1.26 . . . . 0.0 108.807 179.249 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.475 HD22 ' HA ' ' B' ' 14' ' ' LYS . 13.7 mt -135.5 119.11 17.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.121 -0.987 . . . . 0.0 109.964 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.456 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -135.62 178.12 7.29 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.682 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.527 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 3.6 mp0 -78.73 -176.06 4.73 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 179.038 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.595 ' CB ' HG22 ' B' ' 13' ' ' ILE . . . -164.82 105.07 0.81 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.786 -1.196 . . . . 0.0 110.627 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.541 ' N ' HD22 ' B' ' 10' ' ' LEU . 0.2 OUTLIER -79.9 90.04 5.31 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 108.793 179.227 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.52 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 75.7 mt -43.63 98.54 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.539 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 56.9 t0 -100.28 94.13 6.04 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.51 -0.744 . . . . 0.0 111.131 -178.348 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.471 HG22 ' CD1' ' B' ' 97' ' ' LEU . 16.8 m -67.56 -15.22 63.54 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.968 -1.083 . . . . 0.0 108.339 178.187 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.501 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -71.76 -40.8 57.67 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.83 149.91 29.36 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.963 -1.316 . . . . 0.0 109.662 -179.649 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.504 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 1.8 m-20 -92.01 -8.28 46.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.323 -0.861 . . . . 0.0 110.021 -179.471 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.506 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -129.52 178.3 6.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.105 -0.997 . . . . 0.0 109.943 -179.335 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.487 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.5 m -108.42 83.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.75 -1.219 . . . . 0.0 109.677 -179.515 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.679 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -70.31 157.34 6.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.044 179.667 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.555 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.8 OUTLIER -153.51 133.67 13.36 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.572 -178.007 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.535 ' N ' HG21 ' B' ' 80' ' ' THR . 3.1 tt0 -50.98 153.45 1.82 Allowed 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.868 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' B' ' 34' ' ' GLU . 3.3 tt0 -35.12 142.81 0.05 Allowed 'General case' 0 N--CA 1.495 1.812 0 CA-C-O 121.477 0.656 . . . . 0.0 110.78 -179.634 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.538 ' SD ' ' CD1' ' B' ' 38' ' ' LEU . 0.2 OUTLIER -155.76 -170.38 3.4 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.403 -0.81 . . . . 0.0 109.099 179.429 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.5 t -109.68 66.4 0.63 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 111.157 -178.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.584 HD22 ' CG ' ' B' ' 59' ' ' TYR . 1.2 tp -87.24 158.31 52.49 Favored Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.576 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 32.1 Cg_endo -77.24 -155.37 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.927 1.751 . . . . 0.0 110.228 -179.484 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -84.47 -148.04 8.98 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.345 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.52 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.7 mmp_? 65.41 57.06 0.92 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 122.054 -0.674 . . . . 0.0 109.234 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.653 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.8 p-90 -147.15 -176.57 5.27 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.863 0.839 . . . . 0.0 110.466 -179.67 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -148.13 139.32 13.61 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.092 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.43 136.61 15.89 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.281 1.987 . . . . 0.0 111.016 -178.889 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -160.76 -163.0 0.99 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.578 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.543 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 57.7 mtp -151.13 129.24 11.84 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.111 179.642 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.461 HG12 HG12 ' B' ' 56' ' ' VAL . 4.5 pt -91.64 144.41 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 118.356 -1.338 . . . . 0.0 107.999 178.771 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.537 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -117.44 107.43 1.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -178.923 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.479 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -133.23 -126.8 2.72 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.534 -1.317 . . . . 0.0 110.74 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.573 HG13 ' H62' ' B' ' 100' ' ' DMP . 56.0 mt -85.87 134.56 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.851 -0.793 . . . . 0.0 113.045 -177.402 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.03 -15.89 53.82 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.019 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.22 -160.06 27.16 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.264 179.55 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 2.9 m-85 -114.91 138.48 50.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.519 -0.989 . . . . 0.0 109.782 -179.541 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.537 HG12 ' CG2' ' A' ' 50' ' ' ILE . 23.1 pt -116.19 149.92 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 3.2 mttm -85.26 136.52 33.47 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.339 -0.851 . . . . 0.0 108.936 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.471 HG11 ' O ' ' B' ' 55' ' ' LYS . 4.4 m -142.74 -164.81 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 O-C-N 120.957 -1.09 . . . . 0.0 110.245 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' B' ' 56' ' ' VAL . 4.9 mtt180 -147.46 111.34 5.06 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.554 ' HA ' HD12 ' B' ' 76' ' ' LEU . 0.4 OUTLIER -74.69 124.81 27.42 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.059 -1.025 . . . . 0.0 110.413 -179.151 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.653 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 17.9 m-85 -112.89 109.39 18.8 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.568 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.7 m-20 -88.51 128.14 35.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.079 -1.013 . . . . 0.0 110.505 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.568 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 8.2 mm-40 89.86 61.95 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 CA-C-O 121.216 0.531 . . . . 0.0 110.598 179.266 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.552 ' CB ' HG22 ' B' ' 75' ' ' VAL . 24.0 mm -119.04 106.73 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 108.878 178.927 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.597 ' N ' ' CD1' ' B' ' 72' ' ' ILE . 1.0 OUTLIER -61.29 92.57 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.172 -0.955 . . . . 0.0 110.129 -178.884 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.55 ' CD1' HD13 ' B' ' 66' ' ' ILE . 2.6 tt -97.38 117.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 16.4 tt0 -89.16 121.11 31.16 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.84 -1.162 . . . . 0.0 109.486 -179.127 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' B' ' 13' ' ' ILE . 0.6 OUTLIER -108.87 135.7 46.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.132 -0.98 . . . . 0.0 108.789 179.769 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.63 -92.4 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.734 -0.604 . . . . 0.0 109.492 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -141.82 54.59 0.61 Allowed Glycine 0 N--CA 1.485 1.908 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.476 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 38.1 m-70 -154.24 151.82 29.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -1.131 . . . . 0.0 109.986 -179.544 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.75 139.52 30.46 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 179.086 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.512 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -151.52 97.68 2.42 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 110.817 -179.075 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.597 ' CD1' ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.48 139.65 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 178.19 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.513 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -164.1 -159.01 10.51 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 118.659 -1.734 . . . . 0.0 111.421 -179.875 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 18.7 m -106.7 108.74 20.41 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.654 -0.909 . . . . 0.0 110.852 -178.74 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.552 HG22 ' CB ' ' B' ' 62' ' ' ILE . 1.4 t -104.43 127.82 58.46 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.503 -0.748 . . . . 0.0 111.415 -179.879 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.679 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 0.6 OUTLIER -84.84 141.3 30.55 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.728 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.62 115.96 46.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 121.003 -1.061 . . . . 0.0 108.667 178.716 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -162.04 -158.12 9.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -81.71 41.57 1.16 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.746 2.297 . . . . 0.0 110.471 179.868 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.535 HG21 ' N ' ' B' ' 34' ' ' GLU . 9.3 t -89.76 133.23 34.53 Favored Pre-proline 0 C--N 1.301 -1.54 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.347 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.544 ' O ' ' CG2' ' B' ' 82' ' ' VAL . 37.8 Cg_endo -80.15 22.94 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.479 2.119 . . . . 0.0 111.432 -178.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.544 ' CG2' ' O ' ' B' ' 81' ' ' PRO . 55.2 t -160.22 153.67 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.498 -1.376 . . . . 0.0 111.888 -178.671 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.527 ' CB ' ' O ' ' B' ' 21' ' ' GLU . 76.0 m-20 -93.98 77.57 4.13 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 176.041 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.563 HD12 ' C30' ' B' ' 100' ' ' DMP . 53.6 mt -79.71 119.59 29.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.561 0.695 . . . . 0.0 112.601 -175.556 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.524 ' N ' HD11 ' B' ' 85' ' ' ILE . 4.0 mm -95.48 104.57 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.181 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -99.83 163.16 19.42 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.001 -179.38 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.582 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -25.74 -37.45 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -178.829 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.539 ' N ' ' O ' ' B' ' 86' ' ' GLY . 8.7 p-10 -46.52 -42.11 15.19 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.021 -1.674 . . . . 0.0 110.113 -178.629 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.536 HD12 ' CG2' ' B' ' 64' ' ' ILE . 0.7 OUTLIER -93.76 -17.58 23.0 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.276 -0.89 . . . . 0.0 110.116 -179.514 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.582 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 5.9 mp -69.55 -35.36 75.35 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.019 -1.073 . . . . 0.0 109.21 -179.548 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 72.3 p -70.99 -6.94 42.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.007 -1.058 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 8.3 mt-30 -100.01 -40.6 7.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.34 -0.85 . . . . 0.0 109.463 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.571 HD11 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -82.87 3.56 2.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.203 -0.936 . . . . 0.0 108.817 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.7 42.41 97.22 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.029 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.528 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.38 138.18 39.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.945 -1.327 . . . . 0.0 109.697 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 71.1 p -130.61 123.64 29.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 108.646 179.064 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.584 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 0.7 OUTLIER -84.84 86.97 7.3 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.658 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 7.4 m120 -97.81 132.19 43.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.456 -0.777 . . . . 0.0 110.492 -178.933 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.561 ' HB3' ' CA ' ' A' ' 95' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.287 178.664 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.597 ' C76' ' CD1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.581 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.497 1.704 0 N-CA-C 110.316 -0.686 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.423 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 2.1 tt0 -84.05 138.41 33.09 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 178.136 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.402 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 4.4 t -132.55 134.45 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.722 -1.236 . . . . 0.0 110.441 -178.548 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.525 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.8 OUTLIER -143.3 -82.66 0.17 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.41 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.559 ' O ' ' C ' ' A' ' 6' ' ' TRP . 9.5 mt 34.41 32.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.895 -0.503 . . . . 0.0 110.719 178.896 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.559 ' C ' ' O ' ' A' ' 5' ' ' LEU . 44.2 m0 17.87 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.35 0 CA-C-O 121.393 0.616 . . . . 0.0 111.18 -179.875 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.543 ' HA ' ' NH1' ' B' ' 87' ' ' ARG . 2.3 mt-30 -144.56 -168.65 2.96 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.486 -0.759 . . . . 0.0 109.489 -179.329 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.0 mtt180 -81.22 122.37 81.3 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.337 -0.852 . . . . 0.0 108.917 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.48 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.1 Cg_endo -77.94 69.9 7.26 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.146 1.897 . . . . 0.0 109.88 179.373 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.523 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.71 145.82 29.38 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.264 -0.898 . . . . 0.0 109.482 -179.678 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.47 HG21 ' HB1' ' A' ' 22' ' ' ALA . 6.1 m -138.89 127.63 29.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.648 -179.68 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.52 HG23 ' CD2' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -62.83 103.29 0.42 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 178.354 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.54 HG21 ' CB ' ' A' ' 22' ' ' ALA . 11.5 pt -89.83 139.19 17.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.003 -1.061 . . . . 0.0 110.114 -178.458 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.513 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.2 OUTLIER -108.54 96.69 6.52 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.171 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.549 ' CD1' HG12 ' A' ' 75' ' ' VAL . 24.4 mt -113.18 119.87 61.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.361 -0.837 . . . . 0.0 109.537 -179.012 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.7 28.97 71.5 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -179.391 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.22 3.86 62.3 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 -179.197 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.513 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.59 161.92 15.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.307 -1.113 . . . . 0.0 108.891 179.675 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.52 ' CD2' HG23 ' A' ' 12' ' ' THR . 0.1 OUTLIER -133.31 125.51 29.39 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.98 -179.394 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.5 mtmt -151.51 162.88 40.19 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.525 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 1.0 OUTLIER -78.95 136.27 37.2 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 108.249 179.591 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.544 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -114.0 152.86 30.31 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.986 -1.071 . . . . 0.0 109.886 -179.313 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.495 ' O ' ' N ' ' A' ' 25' ' ' ASP . 38.6 tp -109.47 88.77 2.82 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.646 -0.659 . . . . 0.0 109.651 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.48 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 13.8 mt -43.1 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 179.526 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.553 ' HB2' HG21 ' A' ' 84' ' ' ILE . 9.9 t0 -109.9 97.58 7.07 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.427 -0.795 . . . . 0.0 110.982 -177.68 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.502 HG22 ' NH2' ' A' ' 87' ' ' ARG . 10.7 m -73.13 -6.54 46.43 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.329 -0.857 . . . . 0.0 109.114 178.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.532 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -79.96 -29.02 48.34 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' HB3' ' C27' ' B' ' 100' ' ' DMP . . . -89.66 162.89 15.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.922 -1.34 . . . . 0.0 109.659 -179.688 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.7 OUTLIER -100.61 -8.39 23.01 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.231 -0.918 . . . . 0.0 110.729 -178.974 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.485 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -135.54 -177.69 4.78 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.075 -1.016 . . . . 0.0 109.442 -179.712 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.56 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 21.0 m -108.8 88.86 2.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.974 -1.079 . . . . 0.0 110.126 -179.196 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.12 174.02 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.558 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.05 119.46 1.29 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.823 -1.173 . . . . 0.0 111.694 -178.597 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.54 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 2.5 mt-10 -36.02 154.68 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.185 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.433 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.0 OUTLIER -47.6 137.47 9.08 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.922 -1.111 . . . . 0.0 109.739 -179.871 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.422 ' HE2' HG23 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -161.72 164.94 28.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.326 -0.859 . . . . 0.0 109.407 179.595 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 10.9 t -90.14 104.21 16.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.223 -0.923 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.579 HD22 ' CG ' ' A' ' 59' ' ' TYR . 48.3 tp -122.08 118.58 29.09 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.236 -0.915 . . . . 0.0 109.304 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.409 ' HD2' HD13 ' A' ' 38' ' ' LEU . 35.4 Cg_endo -77.99 120.27 4.97 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.401 2.068 . . . . 0.0 110.641 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.25 -177.75 33.95 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 179.839 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.06 144.73 28.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -1.224 . . . . 0.0 108.716 179.521 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.573 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 21.5 p-90 -138.62 156.27 47.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.176 -0.953 . . . . 0.0 110.295 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.408 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 14.2 mtpt -121.35 136.39 25.8 Favored Pre-proline 0 N--CA 1.488 1.469 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.69 129.28 9.92 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 122.263 1.975 . . . . 0.0 111.196 -178.853 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.455 ' O ' HG21 ' A' ' 56' ' ' VAL . 5.8 ptmm? -164.17 152.4 12.83 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.324 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.545 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -118.25 146.77 44.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.527 -1.358 . . . . 0.0 109.856 179.315 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.569 ' CD1' HG22 ' B' ' 50' ' ' ILE . 15.5 pt -102.6 149.56 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.37 -0.831 . . . . 0.0 109.077 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.578 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.89 111.52 2.12 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.331 -1.908 . . . . 0.0 108.331 179.832 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.89 -117.23 1.71 Allowed Glycine 0 N--CA 1.484 1.85 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.687 -178.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.645 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 8.2 mt -91.01 130.17 40.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.78 -0.835 . . . . 0.0 112.542 -177.564 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.439 ' HA2' ' CG2' ' B' ' 54' ' ' ILE . . . 89.76 -23.27 20.76 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.021 177.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.84 -163.19 29.63 Favored Glycine 0 N--CA 1.491 2.347 0 O-C-N 120.744 -1.445 . . . . 0.0 110.375 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.578 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.1 m-85 -109.68 132.13 54.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.514 -0.992 . . . . 0.0 109.245 -179.639 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.55 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.1 pp -107.07 177.86 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.026 -1.046 . . . . 0.0 109.472 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 11.1 mmtt -112.49 138.99 48.45 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.206 -0.934 . . . . 0.0 109.45 179.231 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.519 ' CG1' HD13 ' A' ' 54' ' ' ILE . 6.6 m -146.66 -174.9 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.908 . . . . 0.0 109.687 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.491 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 3.8 mtt85 -122.83 178.19 5.14 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.427 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 26.0 tt0 -135.97 101.57 4.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.131 -0.98 . . . . 0.0 110.827 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.579 ' CG ' HD22 ' A' ' 38' ' ' LEU . 61.7 m-85 -94.49 106.38 18.36 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.613 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.536 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 67.8 m-20 -88.28 123.27 32.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.124 -0.985 . . . . 0.0 110.576 -178.745 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.536 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 63.7 mm-40 86.06 59.98 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.635 0.731 . . . . 0.0 110.072 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.522 ' CG1' ' HB3' ' A' ' 59' ' ' TYR . 31.4 mm -115.84 121.9 68.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.777 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.585 ' CD2' ' HG2' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -73.78 88.18 1.76 Allowed 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.725 -1.19 . . . . 0.0 110.966 -178.311 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.512 HG13 HG13 ' A' ' 15' ' ' ILE . 2.5 tt -85.82 117.4 30.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 177.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 3.6 tt0 -87.08 117.96 26.16 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.054 -1.029 . . . . 0.0 109.111 -178.495 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.49 HG13 HG23 ' A' ' 13' ' ' ILE . 1.0 OUTLIER -110.43 123.9 66.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.792 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.55 36.1 4.96 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.541 -0.724 . . . . 0.0 110.039 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.52 34.24 50.43 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 70' ' ' LYS . 31.9 m-70 -122.1 91.74 3.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.03 -1.277 . . . . 0.0 109.448 179.696 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.585 ' HG2' ' CD2' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -44.74 102.82 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.616 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.515 ' N ' HD12 ' A' ' 63' ' ' LEU . . . -127.24 132.88 50.3 Favored 'General case' 0 C--N 1.287 -2.109 0 O-C-N 121.804 -0.56 . . . . 0.0 109.806 -179.151 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.519 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -108.17 152.21 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.867 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -176.41 -166.47 33.67 Favored Glycine 0 N--CA 1.487 2.045 0 C-N-CA 118.667 -1.73 . . . . 0.0 111.15 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.427 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 20.4 m -98.77 107.01 19.35 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.49 -1.006 . . . . 0.0 109.381 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.549 HG12 ' CD1' ' A' ' 15' ' ' ILE . 0.2 OUTLIER -103.52 119.49 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.335 -0.853 . . . . 0.0 110.402 -179.546 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.519 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -88.63 142.87 27.33 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.332 -0.855 . . . . 0.0 108.906 178.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 33' ' ' LEU . 3.9 t -126.8 118.65 51.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.398 -0.814 . . . . 0.0 109.875 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.466 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -150.09 -166.01 13.05 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.69 41.75 1.17 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 C-N-CA 122.416 2.077 . . . . 0.0 110.015 179.803 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.54 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.1 t -82.45 140.16 44.83 Favored Pre-proline 0 C--N 1.305 -1.347 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.062 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.473 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 32.2 Cg_endo -76.22 10.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.177 1.918 . . . . 0.0 111.438 -178.873 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.506 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.19 168.02 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.882 -1.136 . . . . 0.0 109.653 179.828 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.544 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -102.72 145.78 29.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 176.707 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 31' ' ' THR . 3.5 mm -130.24 126.07 60.86 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 120.726 -1.234 . . . . 0.0 111.212 -177.536 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.57 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.6 OUTLIER -101.47 92.18 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.446 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -81.34 -163.25 30.56 Favored Glycine 0 N--CA 1.496 2.693 0 O-C-N 121.241 -0.912 . . . . 0.0 111.995 -177.242 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.509 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -60.82 -40.0 91.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.979 -0.718 . . . . 0.0 110.442 -179.283 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.585 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 11.0 p-10 -43.61 -31.1 0.69 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.274 -0.891 . . . . 0.0 109.298 -179.66 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.585 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -105.45 -26.02 12.11 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.168 -0.958 . . . . 0.0 109.998 -179.764 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.509 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 97.3 mt -71.1 -5.42 31.44 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.926 -1.109 . . . . 0.0 108.211 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -100.42 -15.21 18.02 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.691 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.2 mm-40 -86.12 -40.82 15.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.623 -0.673 . . . . 0.0 109.569 179.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.585 HD11 ' CG ' ' B' ' 99' ' ' PHE . 1.2 pt -85.06 -5.18 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.175 -0.953 . . . . 0.0 108.982 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.93 49.93 15.16 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 178.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.523 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.44 149.5 26.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.008 -1.29 . . . . 0.0 110.557 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.451 HG23 HG21 ' B' ' 4' ' ' THR . 25.6 p -140.28 126.1 19.4 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.796 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.555 HD13 ' CD1' ' B' ' 97' ' ' LEU . 3.8 mp -85.98 96.53 9.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.843 -179.225 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.535 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.6 m120 -101.13 126.8 47.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.219 -0.926 . . . . 0.0 109.441 179.694 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.039 -0.981 . . . . 0.0 109.446 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.537 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.494 1.552 0 N-CA-C 109.873 -0.857 . . . . 0.0 109.873 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.535 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 3.0 tt0 -83.64 137.64 33.71 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.432 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.522 ' CG1' ' HB2' ' B' ' 5' ' ' LEU . 8.4 t -133.68 114.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 118.565 -1.254 . . . . 0.0 110.501 -178.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.591 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -101.01 3.78 41.8 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 177.468 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.522 ' HB2' ' CG1' ' B' ' 3' ' ' VAL . 0.8 OUTLIER -21.66 83.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.654 0.74 . . . . 0.0 111.06 -179.438 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.591 ' N ' ' O ' ' B' ' 4' ' ' THR . 7.8 m95 -46.1 -21.05 0.12 Allowed 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.513 -0.742 . . . . 0.0 109.103 179.618 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.451 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -107.9 -165.51 1.05 Allowed 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.644 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.443 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.4 OUTLIER -66.68 125.49 90.72 Favored Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 120.919 -1.113 . . . . 0.0 109.65 -179.615 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.516 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.7 Cg_endo -77.49 75.72 4.57 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 122.035 1.823 . . . . 0.0 109.899 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.549 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.73 146.05 32.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.16 -0.963 . . . . 0.0 109.483 -179.69 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.473 HG22 HG12 ' B' ' 66' ' ' ILE . 5.5 m -131.02 148.71 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.82 -179.506 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.48 HG21 HD21 ' B' ' 19' ' ' LEU . 73.7 m -83.22 117.26 22.81 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 178.234 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.56 ' HB ' ' CG1' ' B' ' 64' ' ' ILE . 2.0 pp -112.62 131.35 64.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 121.117 -0.99 . . . . 0.0 110.739 -177.893 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.507 ' HA ' HD22 ' B' ' 19' ' ' LEU . 4.2 tttm -99.73 110.83 23.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.21 -0.931 . . . . 0.0 108.678 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.542 ' CD1' HD23 ' B' ' 33' ' ' LEU . 9.3 mt -116.67 141.79 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.043 . . . . 0.0 109.529 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.54 -97.69 0.07 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -148.38 39.6 0.97 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 179.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 44.5 mm-40 -140.52 -175.23 4.2 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.528 -0.984 . . . . 0.0 109.617 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' B' ' 14' ' ' LYS . 6.8 mt -150.79 129.67 12.48 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.723 0.773 . . . . 0.0 110.621 -178.916 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.479 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 2.3 mptp? -148.03 168.34 22.59 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.321 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.549 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.8 mt-10 -79.11 172.84 13.24 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.655 -1.278 . . . . 0.0 109.129 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.544 ' HB2' ' CD1' ' B' ' 85' ' ' ILE . . . -149.51 106.14 3.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.343 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.46 HD23 ' O ' ' A' ' 27' ' ' GLY . 28.0 tp -64.06 99.42 0.26 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.552 -0.717 . . . . 0.0 110.006 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.516 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 44.4 mt -52.28 111.35 0.61 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.985 -1.072 . . . . 0.0 108.658 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.597 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 49.4 t0 -124.29 90.0 3.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 110.785 -178.554 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.452 ' HA ' HD13 ' B' ' 90' ' ' LEU . 3.0 m -63.96 -14.68 55.74 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.676 -1.265 . . . . 0.0 108.676 178.595 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.472 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -64.69 -46.93 88.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.05 158.97 35.58 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.899 -1.354 . . . . 0.0 108.802 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -92.12 -13.37 30.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.086 -1.009 . . . . 0.0 110.791 -178.621 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.542 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -139.35 -173.87 3.72 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.783 -1.198 . . . . 0.0 110.041 -179.661 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.57 ' CG2' ' CD1' ' B' ' 33' ' ' LEU . 3.7 m -102.21 88.81 3.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.915 -1.115 . . . . 0.0 110.294 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.631 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -69.92 162.44 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.804 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.57 ' CD1' ' CG2' ' B' ' 31' ' ' THR . 0.2 OUTLIER -158.78 126.6 5.07 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.938 -1.101 . . . . 0.0 110.719 -178.397 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' B' ' 33' ' ' LEU . 4.3 tt0 -40.68 161.25 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.826 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.422 ' N ' ' CG ' ' B' ' 34' ' ' GLU . 1.6 tt0 -50.54 146.14 5.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.195 -0.94 . . . . 0.0 110.133 -179.543 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.528 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -174.98 160.67 2.84 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.385 -0.822 . . . . 0.0 108.805 179.553 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.0 t -79.51 97.63 6.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.877 -1.139 . . . . 0.0 109.286 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.52 HD11 ' CG2' ' B' ' 77' ' ' VAL . 0.8 OUTLIER -107.21 107.59 60.67 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.69 -179.66 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 129.04 10.1 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.517 2.145 . . . . 0.0 110.521 179.796 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 147.13 -165.41 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 -95.55 124.95 39.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.278 -1.131 . . . . 0.0 108.831 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.598 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 56.8 p-90 -128.77 172.25 11.45 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.171 -0.956 . . . . 0.0 110.309 -179.197 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.1 mptt -140.07 137.75 18.54 Favored Pre-proline 0 C--N 1.3 -1.573 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.653 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -76.28 134.96 16.27 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.858 1.705 . . . . 0.0 110.299 -179.257 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.467 ' HG3' HG21 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -153.7 -177.11 6.16 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.656 -0.818 . . . . 0.0 109.823 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -138.28 115.19 10.79 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 109.192 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.466 HD13 HG22 ' A' ' 50' ' ' ILE . 31.6 pt -94.49 130.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 C-N-CA 118.772 -1.171 . . . . 0.0 108.351 178.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.02 103.73 1.13 Allowed Glycine 0 N--CA 1.486 2.001 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.337 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.04 -118.45 2.44 Favored Glycine 0 N--CA 1.483 1.816 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.623 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 15.6 mt -91.8 115.56 31.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.852 -0.793 . . . . 0.0 112.138 -177.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.55 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 112.34 -40.14 2.63 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.399 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 163.88 -162.77 35.39 Favored Glycine 0 N--CA 1.491 2.365 0 O-C-N 120.846 -1.385 . . . . 0.0 110.161 179.896 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.7 OUTLIER -112.55 127.64 56.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.456 -1.026 . . . . 0.0 109.732 -179.872 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.479 HD12 HG22 ' A' ' 50' ' ' ILE . 4.7 pt -109.81 169.18 3.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.195 -0.94 . . . . 0.0 108.657 178.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.535 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mttt -109.82 132.44 54.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.03 -1.044 . . . . 0.0 108.9 179.6 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.499 ' CG1' ' HA3' ' B' ' 78' ' ' GLY . 3.1 m -130.96 -172.45 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 110.495 -179.281 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.426 ' HG3' ' C ' ' B' ' 56' ' ' VAL . 5.6 mtp180 -134.97 85.23 2.16 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.501 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -52.73 100.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.6 -0.688 . . . . 0.0 110.901 -179.077 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.598 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 14.6 m-85 -90.28 123.07 33.75 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.498 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.0 OUTLIER -100.68 141.0 34.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.792 -1.193 . . . . 0.0 110.121 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.52 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 72.08 65.61 0.13 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.441 0.638 . . . . 0.0 109.495 179.783 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.499 ' N ' HD11 ' B' ' 72' ' ' ILE . 27.8 mm -119.26 116.15 49.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.481 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.547 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 3.1 tm? -68.94 83.22 0.31 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.454 -0.779 . . . . 0.0 110.582 -178.502 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.56 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 7.9 tt -88.16 125.1 41.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.493 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.423 ' OE2' ' HE3' ' B' ' 70' ' ' LYS . 4.0 tt0 -91.71 110.01 21.34 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.935 -1.103 . . . . 0.0 109.768 -178.409 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.534 HD13 ' CD1' ' B' ' 64' ' ' ILE . 0.3 OUTLIER -109.97 122.59 64.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.237 -0.914 . . . . 0.0 108.827 179.65 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.425 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 33.7 m 52.05 62.66 2.59 Favored 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.644 -0.66 . . . . 0.0 110.378 179.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 47.81 25.21 3.43 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.16 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.501 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 79.2 m-70 -118.29 117.43 29.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.089 -1.242 . . . . 0.0 109.101 179.39 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.423 ' HE3' ' OE2' ' B' ' 65' ' ' GLU . 0.0 OUTLIER -67.94 133.16 48.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.137 -0.977 . . . . 0.0 108.968 179.725 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.462 ' O ' HD23 ' B' ' 63' ' ' LEU . . . -149.26 139.19 21.99 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.371 -0.831 . . . . 0.0 110.168 -179.335 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.514 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -110.31 140.8 27.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 177.679 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.488 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -165.49 -168.93 28.42 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.058 -179.616 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 26.2 m -99.15 106.42 18.6 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.653 -0.91 . . . . 0.0 110.551 -179.185 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.5 ' CG1' HD12 ' B' ' 15' ' ' ILE . 1.7 t -100.68 108.89 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.47 -0.769 . . . . 0.0 110.813 179.3 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.631 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 5.2 mp -79.2 134.29 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' B' ' 38' ' ' LEU . 1.0 OUTLIER -118.39 118.44 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.109 -0.995 . . . . 0.0 109.448 -179.502 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.499 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -155.71 -167.16 16.78 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.535 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -79.54 40.13 0.91 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.689 2.259 . . . . 0.0 111.295 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.493 HG22 ' O ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.45 142.97 33.51 Favored Pre-proline 0 C--N 1.302 -1.466 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.948 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.406 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.9 Cg_endo -79.86 17.56 1.28 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 C-N-CA 122.516 2.144 . . . . 0.0 112.246 -178.427 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.511 HG13 ' CD1' ' B' ' 84' ' ' ILE . 1.4 t -162.41 157.25 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.425 -1.422 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.539 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 2.1 m-20 -99.34 103.16 14.95 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.447 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.597 ' CG2' ' HB3' ' B' ' 25' ' ' ASP . 2.3 mt -104.18 131.31 53.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.723 -1.236 . . . . 0.0 112.607 -176.085 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.551 ' CG2' ' CB ' ' B' ' 89' ' ' LEU . 2.3 mm -95.35 107.72 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 177.887 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.542 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -88.99 -154.58 29.09 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 120.787 -1.196 . . . . 0.0 111.142 -178.374 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.543 ' NH1' ' HA ' ' A' ' 7' ' ' GLN . 5.5 mtm180 -64.67 -40.09 94.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.832 -0.805 . . . . 0.0 109.911 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.612 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 11.9 p-10 -45.15 -38.08 4.93 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.175 -0.953 . . . . 0.0 110.395 -179.073 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.612 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 2.0 mm? -96.75 -27.7 14.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.817 -1.177 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.457 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 53.9 mt -71.22 -5.79 34.68 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 178.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.524 HG23 ' CG ' ' A' ' 6' ' ' TRP . 17.3 p -100.97 -10.93 20.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.226 -0.921 . . . . 0.0 108.696 178.717 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.514 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 13.9 mt-30 -91.89 -41.06 10.81 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.196 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.589 HD11 ' CG ' ' A' ' 99' ' ' PHE . 2.0 pt -85.74 2.41 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.29 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.28 51.49 52.18 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.783 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -78.73 142.32 37.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.154 -1.204 . . . . 0.0 110.184 179.746 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.479 ' CG2' ' CG2' ' A' ' 4' ' ' THR . 27.6 p -137.96 130.55 29.52 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.487 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.555 ' CD1' HD13 ' A' ' 97' ' ' LEU . 6.5 mp -91.21 94.08 9.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.339 -0.851 . . . . 0.0 110.035 -179.171 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.523 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.0 m120 -97.59 120.38 37.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.057 -1.027 . . . . 0.0 109.343 179.379 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.585 ' CG ' HD11 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.054 179.666 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.645 ' H32' ' CG1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.414 ' O ' ' HA ' ' B' ' 98' ' ' ASN . 2.6 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 N-CA-C 109.622 -0.953 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.543 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 14.4 tt0 -84.3 139.71 32.13 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 178.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.7 t -143.79 117.46 3.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.385 -1.326 . . . . 0.0 110.583 -178.532 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.544 ' O ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -98.54 -34.25 10.67 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 177.941 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.544 ' C ' ' O ' ' A' ' 4' ' ' THR . 1.3 mm? 22.36 74.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.289 179.413 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.412 ' C ' ' O ' ' A' ' 5' ' ' LEU . 41.3 m95 -41.56 -20.62 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.751 -0.593 . . . . 0.0 110.329 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 58.9 mt-30 -108.57 -105.1 0.36 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.607 -1.308 . . . . 0.0 109.282 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 8.9 mtt-85 -110.98 132.57 21.6 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 120.654 -1.279 . . . . 0.0 110.215 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.474 ' HA ' ' HG ' ' A' ' 5' ' ' LEU . 37.3 Cg_endo -78.92 66.34 8.73 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.336 2.024 . . . . 0.0 109.867 178.25 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -80.03 152.06 29.62 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.983 -1.073 . . . . 0.0 109.975 -179.32 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.482 HG23 HG22 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -142.09 170.9 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.382 -0.824 . . . . 0.0 109.404 -179.587 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -101.04 92.29 4.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 178.238 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.539 HD11 ' CD1' ' A' ' 64' ' ' ILE . 22.1 pt -86.08 142.1 13.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.263 -0.898 . . . . 0.0 110.17 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 6.9 ttmt -114.77 99.31 7.4 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.409 -0.807 . . . . 0.0 109.499 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.589 ' CG2' ' CG2' ' A' ' 62' ' ' ILE . 0.2 OUTLIER -116.15 158.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.065 -1.022 . . . . 0.0 109.427 179.829 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.477 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 34.86 50.72 0.8 Allowed Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 50.95 52.49 30.49 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.797 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -152.1 172.49 16.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.459 -1.024 . . . . 0.0 108.493 179.574 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.526 ' O ' ' CD ' ' A' ' 20' ' ' LYS . 26.6 mt -141.96 132.03 24.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.08 -1.013 . . . . 0.0 110.549 -179.303 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 12.5 mmmt -150.68 162.52 40.54 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.714 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.4 mm-40 -79.25 141.54 37.01 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.942 -1.099 . . . . 0.0 108.19 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.55 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -124.05 131.72 53.59 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.992 -1.068 . . . . 0.0 110.21 -178.682 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' A' ' 24' ' ' LEU . 25.2 tp -91.15 97.94 11.45 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.69 -0.631 . . . . 0.0 109.783 -179.774 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.474 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.2 OUTLIER -45.97 115.16 0.91 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.397 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.549 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 14.9 t0 -125.7 84.4 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.331 -0.856 . . . . 0.0 111.021 -177.536 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.507 ' CG2' HD11 ' A' ' 90' ' ' LEU . 0.2 OUTLIER -62.68 -11.91 20.17 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.005 -1.059 . . . . 0.0 109.159 178.742 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.439 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.0 -41.52 54.52 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.28 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.516 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -71.23 168.8 16.51 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -1.214 . . . . 0.0 109.709 -179.4 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -100.74 -20.81 15.41 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.204 -0.935 . . . . 0.0 110.176 -179.444 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -133.32 -164.99 1.56 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.068 -1.02 . . . . 0.0 109.548 -179.61 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.592 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 30.1 m -112.64 90.86 3.46 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.738 -1.226 . . . . 0.0 110.575 -179.034 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.586 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.52 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.053 -1.029 . . . . 0.0 108.826 179.536 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.586 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.81 121.41 1.29 Allowed 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.099 -1.001 . . . . 0.0 111.019 -178.849 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.565 ' HA ' HG21 ' A' ' 80' ' ' THR . 0.6 OUTLIER -38.46 152.9 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.432 -0.792 . . . . 0.0 109.663 178.842 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.523 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.6 mt-10 -46.07 141.61 3.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 110.459 -179.279 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.521 ' HE3' ' CD1' ' A' ' 15' ' ' ILE . 6.0 ptm -158.21 -177.21 6.39 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.348 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -101.09 101.7 12.5 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.069 -1.02 . . . . 0.0 109.903 -179.498 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.561 HD11 ' CE2' ' A' ' 59' ' ' TYR . 32.5 mt -106.72 162.43 19.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.062 -1.024 . . . . 0.0 109.971 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.9 Cg_endo -78.23 65.85 8.41 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.895 2.397 . . . . 0.0 112.082 -179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 37.36 -160.67 0.01 OUTLIER Glycine 0 N--CA 1.499 2.846 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 178.74 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.49 59.94 0.61 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.354 -1.086 . . . . 0.0 109.486 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.578 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 64.1 p-90 -148.7 168.67 22.27 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.626 0.727 . . . . 0.0 110.115 -179.556 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.1 136.35 28.69 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.04 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.0 139.1 17.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.222 1.948 . . . . 0.0 110.872 -179.272 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.404 ' HE2' ' HB2' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -153.42 -165.61 2.2 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.264 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.46 ' HG3' ' HG3' ' A' ' 55' ' ' LYS . 5.4 ttt -144.71 126.57 15.34 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.951 -1.093 . . . . 0.0 110.163 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.477 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 24.8 pt -96.1 133.65 36.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.59 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.67 101.0 0.89 Allowed Glycine 0 N--CA 1.486 1.999 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.53 -117.46 2.49 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.65 -178.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.639 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 12.8 mt -88.94 122.85 40.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.729 -0.865 . . . . 0.0 112.506 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.454 ' HA2' HG21 ' B' ' 54' ' ' ILE . . . 100.44 -51.53 1.01 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 178.213 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.86 -159.98 24.6 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.228 -1.463 . . . . 0.0 110.748 -179.604 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.59 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.2 m-85 -113.33 129.38 56.55 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.55 -0.971 . . . . 0.0 109.95 -179.254 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.524 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.9 pt -109.94 152.98 11.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.214 -0.929 . . . . 0.0 108.701 178.895 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.6 mtpt -93.84 123.39 37.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.11 -0.994 . . . . 0.0 109.508 -179.577 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.432 ' CG1' HD13 ' A' ' 54' ' ' ILE . 25.9 m -126.59 -170.08 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.22 -0.925 . . . . 0.0 109.939 -179.529 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.528 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 22.5 mtt180 -124.31 174.42 7.73 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.249 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.419 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 37.2 tt0 -131.17 98.33 4.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.157 -0.964 . . . . 0.0 109.979 -179.342 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.578 ' CD1' ' HB3' ' A' ' 42' ' ' TRP . 64.9 m-85 -97.69 97.59 9.15 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.24 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.469 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.1 m-20 -82.44 139.48 33.96 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 0.0 110.856 -178.601 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.469 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.1 OUTLIER 75.6 60.32 0.05 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.583 -0.698 . . . . 0.0 109.693 179.607 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.589 ' CG2' ' CG2' ' A' ' 15' ' ' ILE . 3.5 mm -116.49 122.82 70.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 108.979 -179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.557 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -74.7 94.99 2.79 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 111.159 -178.751 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.539 ' CD1' HD11 ' A' ' 13' ' ' ILE . 8.2 tt -97.89 121.97 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 50.0 tt0 -89.67 101.54 14.23 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.01 -1.056 . . . . 0.0 108.86 -179.45 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.539 HD13 ' CD1' ' A' ' 64' ' ' ILE . 2.3 mp -102.68 120.5 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.993 -179.037 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 92.6 m 63.36 34.96 12.62 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.738 -0.601 . . . . 0.0 110.32 179.013 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.79 12.21 80.86 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.24 137.24 44.53 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -1.228 . . . . 0.0 109.255 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.528 ' CG ' HD22 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -80.96 123.93 28.72 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 109.094 179.84 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.554 ' O ' ' CD2' ' A' ' 63' ' ' LEU . . . -142.79 155.53 44.83 Favored 'General case' 0 C--N 1.293 -1.852 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.552 -179.759 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.507 ' HA ' ' O ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -125.18 149.81 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.005 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.533 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.42 176.24 47.31 Favored Glycine 0 N--CA 1.484 1.859 0 C-N-CA 118.484 -1.817 . . . . 0.0 111.158 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 6.5 m -86.76 108.74 18.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.702 -0.881 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.583 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.1 t -98.32 110.5 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.532 -0.73 . . . . 0.0 109.779 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.544 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.9 mp -78.9 139.16 38.35 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 120.997 -1.064 . . . . 0.0 108.356 179.133 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.539 HG23 ' CD1' ' A' ' 38' ' ' LEU . 15.9 t -125.04 114.72 41.55 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.481 -0.762 . . . . 0.0 110.054 -179.287 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.41 -159.67 9.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.664 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.9 Cg_endo -79.83 41.1 1.05 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.659 2.239 . . . . 0.0 111.072 -179.874 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.565 HG21 ' HA ' ' A' ' 34' ' ' GLU . 1.8 t -87.97 133.03 38.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.666 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.15 16.26 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.687 2.258 . . . . 0.0 111.77 -178.422 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.496 HG11 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.45 164.38 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.955 -1.091 . . . . 0.0 109.604 -179.812 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.597 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -100.83 132.88 46.02 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 176.53 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.592 ' O ' ' HA ' ' A' ' 31' ' ' THR . 3.9 mm -119.8 119.98 61.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 O-C-N 120.447 -1.408 . . . . 0.0 111.362 -176.867 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.48 HD11 HG21 ' A' ' 31' ' ' THR . 2.0 mm -95.01 89.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.461 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.98 -165.42 29.23 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.962 -1.114 . . . . 0.0 111.46 -177.595 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.484 ' CZ ' ' HB2' ' A' ' 87' ' ' ARG . 1.3 mtp-105 -59.34 -40.66 87.08 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.853 -0.792 . . . . 0.0 110.638 -178.904 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.577 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 12.9 p-10 -45.4 -24.99 0.35 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.971 -1.081 . . . . 0.0 109.675 -179.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.577 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.1 mm? -110.64 -26.85 9.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.011 -1.056 . . . . 0.0 109.614 -179.298 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.507 HD11 ' CG2' ' A' ' 26' ' ' THR . 65.8 mt -72.09 -6.91 45.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 108.589 179.179 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.481 ' O ' ' CZ2' ' B' ' 6' ' ' TRP . 57.4 p -100.92 -19.17 16.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.041 -1.037 . . . . 0.0 108.252 179.116 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 -84.22 -41.14 17.25 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.8 . . . . 0.0 109.159 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.596 HD11 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pp -80.36 -7.28 10.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.98 59.41 5.94 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.606 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.578 ' HB3' ' CD1' ' B' ' 99' ' ' PHE . . . -86.63 157.97 19.58 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -1.212 . . . . 0.0 110.356 -179.702 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.457 HG21 ' O ' ' A' ' 95' ' ' ALA . 21.0 p -150.24 126.66 10.78 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.464 -0.772 . . . . 0.0 109.279 179.401 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.577 ' CD1' ' CD1' ' B' ' 97' ' ' LEU . 8.6 mp -86.09 111.57 20.46 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.1 m120 -108.73 121.76 45.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.852 -1.155 . . . . 0.0 109.78 179.951 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.636 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.427 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.429 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.066 -0.782 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.462 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.9 tt0 -83.4 141.55 31.65 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 178.379 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.462 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 40.6 t -142.66 112.73 2.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 120.565 -1.334 . . . . 0.0 110.694 -178.367 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -124.11 -71.7 0.71 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.713 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.543 ' O ' ' C ' ' B' ' 6' ' ' TRP . 18.5 mt 36.62 31.01 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.737 -0.602 . . . . 0.0 109.866 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.3 m0 17.27 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.144 0 CA-C-O 121.609 0.719 . . . . 0.0 111.404 -179.427 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER -150.55 -165.84 2.38 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.691 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -84.15 115.9 62.34 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.144 -0.973 . . . . 0.0 109.389 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.424 ' HB2' HD11 ' B' ' 24' ' ' LEU . 35.9 Cg_endo -77.29 73.3 5.58 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.391 2.061 . . . . 0.0 110.507 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.548 HD22 ' CB ' ' B' ' 21' ' ' GLU . 0.6 OUTLIER -79.6 163.47 24.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.157 -0.964 . . . . 0.0 108.786 179.617 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.431 HG21 ' O ' ' B' ' 11' ' ' VAL . 4.6 m -144.53 128.01 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.994 -1.066 . . . . 0.0 110.765 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.2 m -71.07 87.88 0.77 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.529 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.554 ' CG2' HG13 ' B' ' 66' ' ' ILE . 17.3 pt -85.65 142.57 12.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-O 121.716 0.77 . . . . 0.0 111.58 -177.18 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.496 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 2.8 tttt -103.29 94.21 5.39 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.187 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.6 HG23 ' CE ' ' B' ' 36' ' ' MET . 0.3 OUTLIER -104.28 115.78 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.164 -0.96 . . . . 0.0 110.358 -178.444 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.55 26.37 71.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.28 88.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -96.96 -179.91 4.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -1.19 . . . . 0.0 108.704 179.427 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . . . . . . . . . 5.1 mt -148.82 128.25 13.07 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.972 -1.08 . . . . 0.0 110.382 -179.625 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.476 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 9.9 mttm -151.19 155.58 39.16 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.562 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.548 ' CB ' HD22 ' B' ' 10' ' ' LEU . 2.7 mm-40 -78.36 100.72 6.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.15 -0.969 . . . . 0.0 108.519 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.568 ' HB3' ' CD1' ' B' ' 85' ' ' ILE . . . -85.26 104.17 14.87 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.261 -0.899 . . . . 0.0 110.698 -178.738 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' B' ' 25' ' ' ASP . 5.4 tp -58.54 103.96 0.19 Allowed 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.445 179.26 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.44 HD21 HD22 ' B' ' 90' ' ' LEU . 13.3 mt -49.83 96.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.039 -1.038 . . . . 0.0 108.558 179.476 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 15.6 t0 -102.5 91.94 4.45 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.195 -0.94 . . . . 0.0 110.469 -179.075 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -70.39 -6.37 35.01 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.948 -1.095 . . . . 0.0 108.791 178.545 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.41 ' O ' HD23 ' A' ' 23' ' ' LEU . . . -77.45 -39.91 24.72 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.474 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -76.39 154.88 34.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.019 -1.283 . . . . 0.0 109.305 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -88.47 -17.96 29.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.16 -0.962 . . . . 0.0 110.753 -178.856 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.529 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.78 -170.36 2.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.948 -1.095 . . . . 0.0 110.464 -179.178 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.518 ' O ' ' HA ' ' B' ' 75' ' ' VAL . 65.4 m -109.12 103.78 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.991 -1.068 . . . . 0.0 110.29 -178.634 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.533 ' HA ' ' HB2' ' B' ' 76' ' ' LEU . 0.3 OUTLIER -87.82 171.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 108.678 179.417 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.578 ' CD1' ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.06 125.57 2.29 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.928 -1.107 . . . . 0.0 110.319 -179.048 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' B' ' 33' ' ' LEU . 14.3 tt0 -37.8 160.59 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.391 0.615 . . . . 0.0 109.936 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.473 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.4 tt0 -53.6 148.45 9.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 110.46 -179.514 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.6 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -170.71 -166.55 0.51 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.611 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.46 ' N ' ' SD ' ' B' ' 36' ' ' MET . 5.4 t -115.06 76.73 1.01 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.797 -1.189 . . . . 0.0 110.923 -179.171 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.601 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 8.0 mt -80.43 173.31 7.91 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.633 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.601 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 29.3 Cg_endo -71.01 -155.63 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 121.776 1.651 . . . . 0.0 111.092 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -103.0 -157.6 25.27 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.046 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.438 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.1 mmm-85 65.72 57.91 0.82 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.511 -0.993 . . . . 0.0 108.809 -179.639 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.597 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 52.0 p-90 -135.59 -172.6 3.13 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-O 121.747 0.784 . . . . 0.0 110.282 -179.015 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mptt -148.43 140.85 14.84 Favored Pre-proline 0 N--CA 1.489 1.487 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.126 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.48 135.4 14.72 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.74 1.627 . . . . 0.0 109.856 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.484 ' O ' ' HG2' ' B' ' 46' ' ' MET . 0.0 OUTLIER -158.46 -169.68 2.83 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 109.596 -179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.484 ' HG2' ' O ' ' B' ' 45' ' ' LYS . 10.1 mtp -149.26 131.39 15.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 109.097 179.849 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.546 ' CD1' HG22 ' A' ' 50' ' ' ILE . 9.3 pt -89.04 140.34 15.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.95 -1.094 . . . . 0.0 108.312 179.271 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.18 111.43 2.17 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 -179.702 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.447 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -135.77 -114.29 1.36 Allowed Glycine 0 N--CA 1.481 1.697 0 C-N-CA 119.442 -1.361 . . . . 0.0 111.096 -178.806 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.619 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 11.3 mt -92.64 124.47 45.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.862 -0.787 . . . . 0.0 112.385 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.524 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 94.85 -48.86 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.87 -157.15 20.42 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.1 OUTLIER -124.21 131.79 53.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.377 -1.072 . . . . 0.0 109.391 179.87 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.47 HD13 HD13 ' B' ' 47' ' ' ILE . 4.0 pt -99.01 -177.85 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 109.101 179.839 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -108.7 137.17 47.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.955 -1.09 . . . . 0.0 109.471 179.722 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.464 HG11 ' HA3' ' B' ' 78' ' ' GLY . 4.0 m -143.78 176.71 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 0.0 109.771 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -127.19 108.64 11.06 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.461 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.6 OUTLIER -66.18 102.43 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.514 -0.741 . . . . 0.0 110.725 -179.085 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.7 m-85 -97.04 94.13 6.99 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.535 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.1 OUTLIER -79.1 134.31 36.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 0.0 110.093 -178.832 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 9.1 mm100 82.74 60.71 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.943 -0.473 . . . . 0.0 110.558 179.252 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.498 ' O ' ' HA ' ' B' ' 72' ' ' ILE . 11.6 mm -124.05 126.72 72.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.994 -1.066 . . . . 0.0 109.202 178.876 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.598 ' C ' ' CD1' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -71.91 95.91 1.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 121.72 0.771 . . . . 0.0 111.799 -178.52 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.544 ' CD1' HD13 ' B' ' 66' ' ' ILE . 3.5 tt -96.08 109.81 23.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 175.765 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.483 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.8 tm-20 -88.2 118.25 27.67 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.911 -1.118 . . . . 0.0 110.252 -177.571 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.554 HG13 ' CG2' ' B' ' 13' ' ' ILE . 1.0 OUTLIER -112.74 113.13 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.555 -0.716 . . . . 0.0 109.195 179.929 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.455 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.2 m 66.06 6.33 4.05 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.653 -0.654 . . . . 0.0 110.314 179.356 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.457 ' N ' ' OE2' ' B' ' 65' ' ' GLU . . . 110.93 -3.1 28.7 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -88.39 115.91 26.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.161 -1.199 . . . . 0.0 108.953 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.55 ' HG3' HD13 ' B' ' 63' ' ' LEU . 1.5 mptp? -69.45 107.24 3.26 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.496 ' O ' HG23 ' B' ' 64' ' ' ILE . . . -121.98 110.06 15.36 Favored 'General case' 0 C--N 1.291 -1.938 0 O-C-N 121.627 -0.671 . . . . 0.0 109.683 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.542 HG13 ' CD2' ' B' ' 63' ' ' LEU . 1.2 mt -94.63 120.64 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.894 -1.128 . . . . 0.0 108.271 178.782 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -140.32 -165.89 10.46 Favored Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.554 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.461 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 59.5 m -97.73 106.69 19.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.68 -0.894 . . . . 0.0 109.651 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.578 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.5 t -91.34 172.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.541 -0.724 . . . . 0.0 109.49 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.533 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.6 mp -140.36 112.67 7.83 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.495 HG23 HD13 ' B' ' 38' ' ' LEU . 1.9 t -97.52 117.49 42.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.932 -1.105 . . . . 0.0 110.305 -178.508 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -154.19 -171.42 21.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.746 -1.742 . . . . 0.0 108.746 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -80.92 41.56 1.17 Allowed 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.336 2.024 . . . . 0.0 110.926 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.533 ' CG2' ' O ' ' B' ' 82' ' ' VAL . 6.5 t -82.38 138.7 44.83 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.854 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.484 ' O ' HG21 ' B' ' 82' ' ' VAL . 36.0 Cg_endo -78.23 18.16 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.283 1.989 . . . . 0.0 110.973 -179.579 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.607 ' CG1' HG13 ' B' ' 84' ' ' ILE . 0.9 OUTLIER -159.71 163.82 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.107 -0.996 . . . . 0.0 109.638 -179.552 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.552 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -109.44 119.86 40.73 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 104.417 -2.438 . . . . 0.0 104.417 176.319 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.607 HG13 ' CG1' ' B' ' 82' ' ' VAL . 6.0 mt -120.4 132.67 69.4 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 120.117 -1.614 . . . . 0.0 113.859 -174.688 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.568 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -96.67 102.51 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.002 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -83.35 -160.26 29.32 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.076 -179.344 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.493 ' NH1' ' O ' ' A' ' 4' ' ' THR . 0.0 OUTLIER -69.79 -30.25 67.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.472 -1.016 . . . . 0.0 109.848 -179.797 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.556 ' ND2' HD21 ' B' ' 89' ' ' LEU . 11.8 p-10 -49.38 -24.29 1.87 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.942 -1.099 . . . . 0.0 109.571 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.556 HD21 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -111.06 -23.42 10.93 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.998 -1.064 . . . . 0.0 109.76 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.453 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 51.8 mt -69.32 -6.17 27.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.027 -1.045 . . . . 0.0 109.225 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.65 -20.53 15.6 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.075 -1.016 . . . . 0.0 108.969 179.401 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.43 HE22 ' N ' ' B' ' 72' ' ' ILE . 7.9 mt-30 -81.04 -40.42 24.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.418 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.609 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -82.79 -5.54 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 177.923 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.12 25.95 62.98 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.151 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.579 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.89 132.64 52.78 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.803 -1.41 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 15.7 p -131.47 128.49 39.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.156 -0.965 . . . . 0.0 108.666 179.315 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.577 ' CD1' ' CD1' ' A' ' 97' ' ' LEU . 2.4 mp -85.76 96.83 9.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.409 -0.807 . . . . 0.0 110.358 -178.773 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.563 ' C ' ' CD1' ' B' ' 99' ' ' PHE . 2.6 m120 -111.05 139.75 46.15 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.834 . . . . 0.0 109.499 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.596 ' CB ' HD11 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.056 -1.028 . . . . 0.0 109.533 179.438 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.639 ' H32' ' CG1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.509 ' HG2' ' CD2' ' B' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.232 -0.719 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.476 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -91.48 128.62 37.38 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.156 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 53.0 t -125.56 131.88 71.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.028 -178.447 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.515 ' CG2' HG21 ' B' ' 96' ' ' THR . 0.0 OUTLIER -154.41 51.57 0.65 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.352 -0.842 . . . . 0.0 109.143 -179.733 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -94.64 42.67 1.09 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.226 -0.921 . . . . 0.0 110.178 -179.401 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.529 ' C ' ' O ' ' A' ' 5' ' ' LEU . 26.9 m95 18.13 49.06 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.415 0 CA-C-O 121.131 0.491 . . . . 0.0 112.176 179.797 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -166.61 -173.89 2.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.145 -0.972 . . . . 0.0 109.359 179.66 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.489 ' HD3' ' OD1' ' B' ' 29' ' ' ASP . 5.3 mtm180 -63.88 111.09 4.61 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.324 -0.86 . . . . 0.0 110.049 -179.629 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.523 ' HD3' ' O ' ' A' ' 7' ' ' GLN . 34.1 Cg_endo -77.29 84.31 1.98 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.957 1.771 . . . . 0.0 109.117 178.668 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.545 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -89.89 149.11 22.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 110.248 -178.882 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.507 HG21 ' HB2' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -135.97 137.74 48.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.388 -0.82 . . . . 0.0 109.551 179.741 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.2 m -72.96 98.84 2.57 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 178.635 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.54 ' HA ' ' O ' ' A' ' 65' ' ' GLU . 15.3 pt -88.6 144.02 9.99 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 O-C-N 121.407 -0.808 . . . . 0.0 110.805 -178.363 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.486 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -107.01 105.23 15.16 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.725 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.468 HD13 ' CD1' ' A' ' 13' ' ' ILE . 24.8 mt -121.74 124.45 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.049 -1.032 . . . . 0.0 109.872 -179.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.88 18.4 72.46 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.372 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.55 0.61 84.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.463 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 28.7 mm-40 -99.9 -178.62 3.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.175 -1.191 . . . . 0.0 109.058 179.746 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.486 ' CG ' ' HD2' ' A' ' 14' ' ' LYS . 16.7 mt -141.29 129.6 22.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.181 -0.949 . . . . 0.0 110.002 -179.579 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.452 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 3.1 mmtp -142.88 -170.49 3.25 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.492 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.513 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.2 mt-10 -103.26 146.52 28.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.161 -0.962 . . . . 0.0 109.025 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.549 ' HB3' ' CD1' ' A' ' 85' ' ' ILE . . . -130.22 136.21 48.97 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.931 -1.106 . . . . 0.0 110.221 -179.566 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.515 ' O ' ' N ' ' A' ' 25' ' ' ASP . 53.0 tp -105.17 111.55 24.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.495 -0.753 . . . . 0.0 110.041 -179.329 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.506 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -46.71 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.907 -1.121 . . . . 0.0 109.324 179.618 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.518 ' CB ' HG21 ' A' ' 84' ' ' ILE . 33.4 t0 -98.65 71.43 1.96 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.116 -0.99 . . . . 0.0 109.563 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.539 ' HA ' ' CD2' ' A' ' 90' ' ' LEU . 64.9 m -58.1 -15.88 11.12 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.103 -0.998 . . . . 0.0 108.537 179.066 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.467 ' O ' HD23 ' B' ' 23' ' ' LEU . . . -69.64 -41.14 76.17 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.742 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.517 ' HB3' ' C25' ' B' ' 100' ' ' DMP . . . -76.94 155.97 32.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -1.213 . . . . 0.0 109.78 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.524 ' OD2' ' CG ' ' B' ' 8' ' ' ARG . 1.3 m-20 -96.47 -9.97 28.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.769 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.541 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -131.6 -170.11 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 109.549 -179.677 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.491 HG21 ' O ' ' A' ' 84' ' ' ILE . 11.2 m -113.81 88.37 2.83 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.058 -1.027 . . . . 0.0 109.973 -179.367 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.521 ' HA ' ' HB2' ' A' ' 76' ' ' LEU . 0.5 OUTLIER -69.93 171.19 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 178.725 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.581 ' HA ' ' HA ' ' A' ' 83' ' ' ASN . 0.1 OUTLIER -164.08 123.36 1.97 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.406 -1.434 . . . . 0.0 111.875 -179.261 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.585 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.0 OUTLIER -42.32 145.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.517 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.472 ' N ' ' HG2' ' A' ' 34' ' ' GLU . 0.8 OUTLIER -48.23 138.75 9.29 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.149 -0.969 . . . . 0.0 109.826 -179.683 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.463 ' HE2' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -147.63 -164.47 2.01 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.424 -0.798 . . . . 0.0 109.209 179.419 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.443 ' N ' ' SD ' ' A' ' 36' ' ' MET . 18.1 t -100.01 87.67 3.55 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 110.041 -179.639 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.508 ' CD1' HG22 ' A' ' 77' ' ' VAL . 16.2 mt -110.92 159.96 30.62 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.106 -0.996 . . . . 0.0 108.935 179.19 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.471 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 34.8 Cg_endo -77.35 154.23 31.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.598 2.199 . . . . 0.0 110.361 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -59.29 -154.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.538 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 4.7 mmm180 69.86 49.58 0.51 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.831 -0.805 . . . . 0.0 109.48 -179.595 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 45.8 p-90 -135.31 -171.4 2.81 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.0 mtpm? -138.9 134.36 16.97 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.963 -1.085 . . . . 0.0 108.85 179.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.69 139.26 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.073 1.849 . . . . 0.0 111.26 -179.181 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.533 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 11.4 pttt -159.03 153.6 24.35 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.307 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.494 ' HE1' ' O ' ' A' ' 53' ' ' PHE . 0.1 OUTLIER -110.85 128.94 55.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.778 -1.201 . . . . 0.0 110.4 -179.093 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.537 HD13 ' CG2' ' B' ' 50' ' ' ILE . 10.0 pt -96.81 142.07 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.95 -1.094 . . . . 0.0 108.152 178.305 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.593 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.79 100.56 0.83 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.607 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.12 -122.76 2.78 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.71 -1.234 . . . . 0.0 110.099 -179.716 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.628 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 10.5 mt -87.33 123.21 39.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.629 -0.924 . . . . 0.0 111.854 -178.466 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.79 -52.78 0.68 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.146 -1.181 . . . . 0.0 110.146 178.573 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.46 -155.2 21.84 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.751 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.593 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 6.8 m-85 -114.12 123.22 49.1 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.412 -1.052 . . . . 0.0 110.014 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.548 HG22 ' N ' ' B' ' 51' ' ' GLY . 32.0 pt -102.79 162.43 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.076 -1.015 . . . . 0.0 108.509 178.597 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.9 OUTLIER -95.96 144.78 25.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.215 -0.928 . . . . 0.0 109.018 -179.932 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.49 HG11 ' O ' ' A' ' 55' ' ' LYS . 17.0 m -142.91 -173.73 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.889 -1.132 . . . . 0.0 109.711 -179.83 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.564 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 36.2 mtt180 -133.04 93.21 3.14 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 179.541 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -50.03 101.65 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.585 0.707 . . . . 0.0 110.036 -179.632 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.3 m-85 -100.95 88.29 3.5 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.74 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -78.73 137.68 37.89 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.201 -0.937 . . . . 0.0 110.401 -178.517 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.497 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 74.01 61.79 0.08 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.755 -0.591 . . . . 0.0 110.531 179.329 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.562 ' CD1' ' HB3' ' A' ' 59' ' ' TYR . 1.2 mt -122.02 124.21 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.516 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.546 ' N ' HD12 ' A' ' 72' ' ' ILE . 3.1 tm? -70.06 92.24 0.73 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.442 -0.787 . . . . 0.0 111.82 -177.559 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.538 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 4.2 tt -96.91 118.53 43.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.846 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.54 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 39.1 tt0 -89.61 100.81 13.54 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.983 -1.073 . . . . 0.0 109.766 -178.778 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.489 HG13 HG21 ' A' ' 13' ' ' ILE . 1.3 mp -97.12 121.8 47.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.268 -0.895 . . . . 0.0 108.965 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.407 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 58.09 57.32 4.09 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.515 -0.741 . . . . 0.0 109.641 179.614 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.71 26.33 7.78 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.764 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.465 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 59.8 m-70 -122.24 118.9 29.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.991 -1.3 . . . . 0.0 109.267 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.541 ' CG ' HD22 ' A' ' 63' ' ' LEU . 2.9 mptt -61.38 139.58 58.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.258 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.538 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -159.88 102.33 1.48 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.173 -0.954 . . . . 0.0 110.473 -179.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.546 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.6 OUTLIER -78.58 147.25 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.525 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -173.09 -170.89 37.25 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.903 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.2 m -95.33 106.08 18.09 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.729 -0.865 . . . . 0.0 110.174 -179.488 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.513 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -99.04 106.58 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.701 -0.625 . . . . 0.0 109.708 179.358 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.533 ' CD2' ' HE2' ' A' ' 45' ' ' LYS . 2.8 mp -79.81 113.26 17.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.119 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.508 HG22 ' CD1' ' A' ' 38' ' ' LEU . 7.9 t -97.91 107.98 21.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 120.908 -1.12 . . . . 0.0 110.261 -178.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -140.24 -166.48 10.68 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.101 -2.0 . . . . 0.0 108.101 179.088 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.92 40.42 0.96 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.305 2.003 . . . . 0.0 110.522 179.208 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.585 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 11.5 t -81.75 137.25 47.45 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.33 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.519 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 36.1 Cg_endo -78.91 16.3 1.35 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.483 2.122 . . . . 0.0 111.476 -179.089 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.421 HG13 ' CD1' ' A' ' 84' ' ' ILE . 1.4 t -161.07 149.65 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.809 -1.182 . . . . 0.0 110.251 -179.845 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.581 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -85.85 100.07 11.81 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.774 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.518 HG21 ' CB ' ' A' ' 25' ' ' ASP . 18.9 mm -84.52 120.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.234 -0.916 . . . . 0.0 112.994 -175.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.549 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -103.0 99.36 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.836 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.482 ' O ' HD12 ' A' ' 90' ' ' LEU . . . -106.54 175.99 21.31 Favored Glycine 0 N--CA 1.497 2.72 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.243 -177.069 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.643 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 13.2 mmm180 -25.81 -41.41 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -179.085 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.585 ' ND2' HD21 ' A' ' 89' ' ' LEU . 11.8 p-10 -52.54 -42.54 64.5 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.184 -1.573 . . . . 0.0 110.562 -177.683 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.585 HD21 ' ND2' ' A' ' 88' ' ' ASN . 1.8 mm? -92.98 -23.96 18.53 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.035 . . . . 0.0 108.607 179.598 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.643 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 0.4 OUTLIER -67.81 -8.03 32.59 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.309 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.82 -20.66 17.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.928 -1.108 . . . . 0.0 108.844 179.824 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 30.6 mm-40 -85.71 -40.21 16.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.216 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.537 ' HB ' ' HB2' ' B' ' 99' ' ' PHE . 1.1 pt -83.12 2.16 3.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.236 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 66.46 31.93 80.25 Favored Glycine 0 N--CA 1.499 2.887 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.186 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.528 ' CB ' HD13 ' A' ' 93' ' ' ILE . . . -61.06 143.72 54.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.247 -1.149 . . . . 0.0 111.433 -179.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.448 HG21 ' CG2' ' B' ' 4' ' ' THR . 58.0 p -152.05 141.49 21.6 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.13 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.89 HD11 HD11 ' B' ' 97' ' ' LEU . 0.0 OUTLIER -98.23 118.31 34.58 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.786 -1.196 . . . . 0.0 110.358 -179.916 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.539 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.5 m120 -118.0 123.75 46.48 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.637 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.574 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.481 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.574 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.576 0 N-CA-C 110.176 -0.74 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.516 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.8 tt0 -89.12 146.41 24.83 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.216 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 12.2 t -138.93 118.17 13.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 120.525 -1.359 . . . . 0.0 110.673 -178.615 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.448 ' CG2' HG21 ' A' ' 96' ' ' THR . 0.0 OUTLIER -123.94 -71.83 0.7 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.277 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.569 ' O ' ' N ' ' B' ' 7' ' ' GLN . 3.1 mm? 36.92 34.47 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.654 -0.654 . . . . 0.0 110.656 179.574 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.532 ' C ' ' O ' ' B' ' 5' ' ' LEU . 17.8 m95 18.61 48.17 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.285 0 CA-C-O 121.233 0.54 . . . . 0.0 112.165 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.569 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -163.16 -158.9 0.5 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.524 ' CG ' ' OD2' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -71.94 124.19 90.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.348 -0.845 . . . . 0.0 109.431 179.888 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.551 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 33.7 Cg_endo -76.99 74.15 5.12 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.146 1.897 . . . . 0.0 110.094 179.387 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.59 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.41 164.24 24.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.03 -1.044 . . . . 0.0 110.091 -179.498 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.468 HG12 ' HG ' ' B' ' 24' ' ' LEU . 2.8 m -151.27 152.76 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.475 -0.766 . . . . 0.0 109.927 -179.007 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.464 HG23 ' CD2' ' B' ' 19' ' ' LEU . 27.9 m -85.89 103.32 14.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.422 -1.423 . . . . 0.0 107.717 177.562 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.523 ' O ' ' CD2' ' B' ' 19' ' ' LEU . 1.7 pt -94.53 148.6 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.065 -1.022 . . . . 0.0 110.479 -178.566 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.487 ' CA ' HD22 ' B' ' 19' ' ' LEU . 9.6 tttt -117.12 105.47 12.3 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.538 ' CG2' HD23 ' B' ' 38' ' ' LEU . 16.3 mt -116.75 134.01 61.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 120.826 -1.171 . . . . 0.0 109.438 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.09 -99.37 0.31 Allowed Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 -179.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' B' ' 18' ' ' GLN . . . -145.31 32.05 1.66 Allowed Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.471 -1.851 . . . . 0.0 108.471 179.237 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.411 ' HG2' ' C ' ' B' ' 17' ' ' GLY . 3.0 mm100 -132.72 178.31 6.96 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.492 -1.005 . . . . 0.0 109.635 -179.539 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.523 ' CD2' ' O ' ' B' ' 13' ' ' ILE . 9.0 mt -143.62 130.8 20.74 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.434 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.3 mmmt -143.44 156.14 44.57 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.59 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.9 mp0 -79.49 122.34 26.33 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.981 -1.074 . . . . 0.0 108.811 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.589 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.38 129.93 52.28 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.434 -0.791 . . . . 0.0 110.647 -178.787 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.523 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 22.9 tp -80.17 97.72 7.02 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.5 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 15.2 mt -44.22 113.01 0.47 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.715 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 57.7 t0 -126.39 88.12 2.78 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.05 -177.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.447 ' HA ' HD13 ' B' ' 90' ' ' LEU . 1.8 m -64.06 -12.83 42.43 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.037 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.458 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -73.1 -41.92 45.8 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.171 -1.171 . . . . 0.0 110.171 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.534 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -67.12 152.3 46.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.061 -1.258 . . . . 0.0 109.449 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.551 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 30.6 m-20 -85.0 -21.69 29.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 110.378 -178.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.492 ' HA ' ' OD1' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -139.98 -160.38 1.06 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.811 -1.181 . . . . 0.0 109.429 179.965 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.56 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.0 m -110.94 94.13 4.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.731 -1.23 . . . . 0.0 111.56 -178.242 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.585 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.49 174.73 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.053 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.585 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.72 117.35 0.59 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.932 -1.105 . . . . 0.0 110.311 -179.178 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.551 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 5.5 pt-20 -38.13 158.22 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.544 -0.722 . . . . 0.0 109.586 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.457 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.6 tt0 -46.34 149.71 0.72 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.212 -0.93 . . . . 0.0 110.668 -179.119 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.465 ' HE1' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -178.68 167.58 1.74 Allowed 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.513 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.456 ' O ' ' SD ' ' B' ' 36' ' ' MET . 48.0 t -87.88 109.24 19.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.967 -1.083 . . . . 0.0 109.765 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.604 HD11 ' CD2' ' B' ' 59' ' ' TYR . 8.6 mt -114.65 105.12 53.88 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.255 179.649 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -78.47 102.02 1.52 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.542 2.161 . . . . 0.0 111.233 -179.526 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 168.31 31.13 0.02 OUTLIER Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.596 179.288 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.52 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 55.63 153.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.778 -0.837 . . . . 0.0 109.721 179.647 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.614 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 51.5 p-90 -161.37 176.14 11.48 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.803 -1.185 . . . . 0.0 110.123 -179.764 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.403 ' CD ' ' HD2' ' B' ' 44' ' ' PRO . 0.1 OUTLIER -134.08 162.92 54.79 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.6 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . 0.403 ' HD2' ' CD ' ' B' ' 43' ' ' LYS . 33.4 Cg_endo -76.38 139.95 21.33 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 C-N-CA 121.827 1.685 . . . . 0.0 109.721 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.526 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 7.4 tttm -159.58 119.79 3.05 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.414 -0.804 . . . . 0.0 109.105 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.476 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 76.5 mtp -98.9 132.26 44.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.415 -0.803 . . . . 0.0 109.291 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.534 HD12 ' CD1' ' B' ' 54' ' ' ILE . 17.6 pt -94.26 149.05 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.987 -1.071 . . . . 0.0 108.826 179.386 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.529 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.36 100.51 0.81 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.829 -1.708 . . . . 0.0 108.829 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . 0.401 ' HA3' H702 ' B' ' 100' ' ' DMP . . . -126.25 -129.34 3.29 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.3 -1.429 . . . . 0.0 110.665 -179.241 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.573 HD13 ' C26' ' B' ' 100' ' ' DMP . 47.4 mt -84.42 118.37 31.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.752 -0.852 . . . . 0.0 112.948 -177.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.548 ' N ' HG22 ' A' ' 54' ' ' ILE . . . 100.02 -1.77 56.53 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 177.805 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 127.85 -154.63 19.83 Favored Glycine 0 N--CA 1.49 2.274 0 O-C-N 120.969 -1.312 . . . . 0.0 109.999 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.4 OUTLIER -121.18 141.53 50.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.53 -0.982 . . . . 0.0 109.799 -179.628 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.534 ' CD1' HD12 ' B' ' 47' ' ' ILE . 18.8 pt -107.22 178.67 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 108.995 179.097 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.2 OUTLIER -109.5 130.13 55.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.234 -0.916 . . . . 0.0 109.568 -179.881 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' B' ' 45' ' ' LYS . 2.2 m -144.11 174.06 4.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.094 -1.004 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -116.73 115.47 25.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.813 179.847 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.499 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 5.6 tt0 -69.77 106.8 3.24 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.139 -0.976 . . . . 0.0 110.13 -179.349 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.614 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 18.0 m-85 -99.65 87.31 3.53 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 178.536 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.589 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -78.71 125.68 29.7 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.875 -1.14 . . . . 0.0 110.177 -178.783 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.589 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 1.5 mt-30 91.16 60.65 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.336 0.588 . . . . 0.0 110.402 179.329 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' B' ' 72' ' ' ILE . 33.1 mm -121.87 125.68 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.306 -0.871 . . . . 0.0 108.752 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.556 HD23 ' CG ' ' B' ' 70' ' ' LYS . 2.1 tm? -73.91 86.38 1.76 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.219 -0.926 . . . . 0.0 112.364 -178.081 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.483 HG22 ' O ' ' B' ' 64' ' ' ILE . 16.5 tt -89.8 114.61 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.426 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 0.7 OUTLIER -90.14 127.51 36.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.912 -1.118 . . . . 0.0 108.765 -179.836 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.582 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 1.0 OUTLIER -124.3 125.89 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.129 -0.982 . . . . 0.0 109.988 -179.248 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.514 ' HB2' ' CD2' ' B' ' 69' ' ' HIS . 54.9 m 55.91 12.78 0.95 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.687 -0.633 . . . . 0.0 111.111 179.169 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . 0.426 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 101.24 21.7 11.4 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.301 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.582 ' CD2' ' O ' ' B' ' 66' ' ' ILE . 23.9 m-70 -118.0 114.52 23.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.057 -1.26 . . . . 0.0 109.333 179.544 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.556 ' CG ' HD23 ' B' ' 63' ' ' LEU . 9.6 tttt -64.4 117.4 7.23 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.12 -0.987 . . . . 0.0 109.006 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.46 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -138.14 124.04 20.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.302 -0.873 . . . . 0.0 110.358 -178.981 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.548 ' HA ' ' O ' ' B' ' 62' ' ' ILE . 0.7 OUTLIER -103.43 129.89 54.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 177.749 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -149.29 -159.91 8.86 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.506 -1.331 . . . . 0.0 110.364 -179.439 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.499 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 7.6 m -100.93 110.71 22.78 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.442 -1.034 . . . . 0.0 109.553 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.54 ' CG2' ' HB ' ' B' ' 62' ' ' ILE . 1.4 t -100.1 107.14 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.312 -0.867 . . . . 0.0 110.516 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.544 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -79.06 121.44 24.97 Favored 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.855 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.571 HG22 ' CD2' ' B' ' 59' ' ' TYR . 3.4 t -110.7 114.27 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.106 -0.996 . . . . 0.0 110.557 -178.68 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.518 ' N ' HG13 ' B' ' 56' ' ' VAL . . . -148.63 -165.13 11.93 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.539 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.57 41.38 1.13 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.588 2.192 . . . . 0.0 110.486 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.551 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 13.6 t -81.43 140.82 48.58 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.7 Cg_endo -78.81 12.52 2.19 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.426 2.084 . . . . 0.0 110.742 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.563 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 2.1 t -161.22 167.12 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.191 -0.943 . . . . 0.0 109.563 -179.573 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.589 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -105.38 144.37 32.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 104.486 -2.413 . . . . 0.0 104.486 175.761 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' B' ' 31' ' ' THR . 5.7 mm -130.25 130.01 65.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 O-C-N 120.284 -1.51 . . . . 0.0 111.735 -177.059 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -101.15 100.42 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.483 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.9 -155.42 8.81 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.736 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.551 ' HD2' ' HA ' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -79.68 -30.04 41.0 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.388 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.585 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 18.4 p-10 -47.51 -22.95 0.53 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.302 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.585 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 3.4 mm? -113.42 -42.89 3.4 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.123 -0.985 . . . . 0.0 111.036 -178.58 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.466 HD23 HD21 ' B' ' 24' ' ' LEU . 93.8 mt -52.63 -35.88 55.47 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.592 -1.318 . . . . 0.0 109.425 -179.547 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.433 HG23 ' HA ' ' A' ' 6' ' ' TRP . 49.4 p -80.42 -21.79 41.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.233 -0.917 . . . . 0.0 110.978 -178.738 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.535 ' NE2' HD23 ' B' ' 89' ' ' LEU . 32.1 mt-30 -75.06 -38.19 61.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.78 -1.2 . . . . 0.0 108.737 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.525 HD13 ' CD2' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -79.84 2.09 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.392 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 71.37 60.32 4.46 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.539 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -100.01 163.42 12.44 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.308 -1.113 . . . . 0.0 110.021 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.515 HG21 ' CG2' ' A' ' 4' ' ' THR . 2.2 p -148.92 135.19 19.3 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.494 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.89 HD11 HD11 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -90.17 114.83 26.88 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.286 179.952 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.476 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.2 m120 -119.24 130.59 55.54 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.869 -0.519 . . . . 0.0 109.863 -179.069 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.537 ' HB2' ' HB ' ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.171 -0.919 . . . . 0.0 109.09 178.567 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.628 ' H32' ' CG1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.495 1.615 0 N-CA-C 110.179 -0.739 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.529 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -83.81 145.89 28.43 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 177.632 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.467 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 55.1 t -146.72 105.93 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 117.82 -1.552 . . . . 0.0 111.143 -178.436 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 6' ' ' TRP . 13.5 p -107.16 -57.22 2.1 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 177.811 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.588 ' O ' ' N ' ' A' ' 7' ' ' GLN . 7.8 tp 33.92 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.938 -0.476 . . . . 0.0 111.119 178.659 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.546 ' N ' ' O ' ' A' ' 4' ' ' THR . 9.0 m95 18.19 47.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.121 0.486 . . . . 0.0 111.91 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.588 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -167.41 -175.49 2.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.797 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.513 ' NH1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -56.2 125.74 65.57 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.412 -0.805 . . . . 0.0 109.558 179.755 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.9 Cg_endo -79.05 70.89 7.3 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.179 1.919 . . . . 0.0 109.177 178.843 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.578 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.99 156.12 23.6 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.42 -0.8 . . . . 0.0 110.093 -178.908 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.483 HG21 ' HB1' ' A' ' 22' ' ' ALA . 2.1 m -149.31 130.25 4.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.512 -0.743 . . . . 0.0 109.245 179.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.448 HG21 ' CD2' ' A' ' 19' ' ' LEU . 23.0 m -65.7 96.34 0.27 Allowed 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.728 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.552 ' CG2' ' CB ' ' A' ' 22' ' ' ALA . 1.9 pt -79.28 140.07 17.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.395 -0.816 . . . . 0.0 109.785 -178.737 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.519 ' CB ' ' HB3' ' A' ' 65' ' ' GLU . 29.0 tttt -105.64 95.52 5.86 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.242 -0.911 . . . . 0.0 108.981 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.515 HG13 HG13 ' A' ' 64' ' ' ILE . 15.1 mt -118.78 147.53 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.153 -0.967 . . . . 0.0 109.924 -179.295 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.509 ' N ' HG21 ' A' ' 15' ' ' ILE . . . 44.69 50.62 8.39 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.207 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.26 43.99 34.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.7 mm-40 -142.66 176.67 8.86 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.366 -1.079 . . . . 0.0 109.152 179.864 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.48 ' HG ' ' HG3' ' A' ' 14' ' ' LYS . 16.9 mt -149.64 124.2 9.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.037 -1.039 . . . . 0.0 110.115 -179.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.554 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -138.25 168.78 19.02 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.119 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.578 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.0 mm-40 -80.63 116.03 20.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.096 -1.003 . . . . 0.0 108.671 179.516 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -96.75 142.51 28.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.12 -0.988 . . . . 0.0 110.065 -179.214 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.427 ' O ' ' C ' ' A' ' 24' ' ' LEU . 26.5 tp -104.41 91.54 3.94 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.647 -0.658 . . . . 0.0 109.281 -179.753 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.513 ' CD2' ' HB ' ' A' ' 85' ' ' ILE . 15.1 mt -44.12 101.98 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -0.895 . . . . 0.0 108.714 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.5 t0 -111.57 91.4 3.64 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.351 -0.843 . . . . 0.0 110.495 -178.699 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 m -66.6 -10.61 47.46 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.144 -0.973 . . . . 0.0 108.556 178.643 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -71.44 -44.2 51.7 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.438 ' HB2' ' C27' ' B' ' 100' ' ' DMP . . . -75.85 164.79 25.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.096 -1.237 . . . . 0.0 109.322 -179.844 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -100.55 -15.21 17.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.154 -0.966 . . . . 0.0 111.282 -178.695 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' HB3' HD13 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -130.88 -169.96 2.26 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.813 -1.18 . . . . 0.0 109.571 -179.614 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.586 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 50.2 m -109.51 91.35 3.61 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.767 -1.208 . . . . 0.0 110.438 -179.099 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.57 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -72.11 171.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 120.969 -1.082 . . . . 0.0 108.167 179.099 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.596 ' CD1' ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.07 121.98 0.79 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.713 -178.857 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.54 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 0.7 OUTLIER -42.46 166.57 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.146 -0.971 . . . . 0.0 109.535 179.506 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.542 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -51.1 149.71 3.58 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.127 -0.983 . . . . 0.0 110.378 -179.447 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.508 ' CE ' HG23 ' A' ' 15' ' ' ILE . 8.2 ptm -164.95 -161.68 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.439 -0.788 . . . . 0.0 109.08 179.592 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.404 ' N ' ' CG ' ' A' ' 36' ' ' MET . 3.8 t -122.73 109.94 14.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.093 -1.005 . . . . 0.0 111.158 -178.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.584 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -111.21 167.02 9.67 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.18 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.553 ' CD ' HD11 ' A' ' 38' ' ' LEU . 35.5 Cg_endo -77.08 66.62 7.73 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 122.94 2.427 . . . . 0.0 112.352 -179.149 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.523 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 26.66 105.74 0.0 OUTLIER Glycine 0 N--CA 1.504 3.215 0 CA-C-O 121.674 0.597 . . . . 0.0 112.315 178.534 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.456 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.8 mtp180 167.11 51.19 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.316 -1.108 . . . . 0.0 109.115 178.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.608 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.5 p-90 -131.49 -179.49 5.4 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 121.829 0.823 . . . . 0.0 110.302 -179.049 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 57' ' ' ARG . 0.5 OUTLIER -138.41 166.89 22.21 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.7 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.29 140.62 22.22 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.147 1.898 . . . . 0.0 110.796 -179.773 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.495 ' O ' ' CG2' ' A' ' 56' ' ' VAL . 0.5 OUTLIER -160.17 141.36 12.34 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.464 ' HG2' ' HG2' ' A' ' 55' ' ' LYS . 59.3 mtp -125.97 141.57 51.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.837 -1.164 . . . . 0.0 109.915 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.568 ' CD1' HG22 ' B' ' 50' ' ' ILE . 6.9 pt -118.94 141.09 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.268 -0.895 . . . . 0.0 109.171 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.504 ' HA3' ' CE1' ' A' ' 53' ' ' PHE . . . -118.18 103.44 1.04 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.78 -127.47 3.22 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.445 -178.961 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.571 ' CD1' ' C76' ' B' ' 100' ' ' DMP . 67.5 mt -79.67 116.33 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.703 -0.88 . . . . 0.0 112.251 -178.139 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.563 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 111.98 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.382 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.74 -161.48 34.34 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.305 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.504 ' CE1' ' HA3' ' A' ' 48' ' ' GLY . 4.3 m-30 -99.95 131.26 46.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.503 -0.998 . . . . 0.0 109.555 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.543 ' CG1' HG13 ' A' ' 47' ' ' ILE . 5.1 pt -110.41 172.45 2.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.156 -0.965 . . . . 0.0 108.841 179.103 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -110.04 147.36 33.7 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.875 . . . . 0.0 109.024 179.657 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 7.3 m -151.03 -171.53 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 120.739 -1.225 . . . . 0.0 110.424 -179.472 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.58 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 2.0 mtt180 -140.1 108.85 5.95 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.228 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.458 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 30.6 tt0 -65.85 103.38 0.9 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.308 -0.87 . . . . 0.0 111.104 -178.468 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.608 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.8 m-85 -91.58 124.67 35.92 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.547 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -109.35 124.2 50.58 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.816 -1.177 . . . . 0.0 110.59 -178.852 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.547 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 6.4 mm100 86.29 58.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 CA-C-O 121.229 0.538 . . . . 0.0 110.648 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.557 ' HB ' ' CG2' ' A' ' 75' ' ' VAL . 26.2 mm -111.88 119.9 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.577 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.546 HD21 HG12 ' A' ' 72' ' ' ILE . 1.3 tm? -67.48 84.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 111.054 -178.5 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.515 HG13 HG13 ' A' ' 15' ' ' ILE . 3.5 tt -87.86 118.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 178.248 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.519 ' HB3' ' CB ' ' A' ' 14' ' ' LYS . 28.0 tt0 -91.42 113.43 25.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.213 -0.929 . . . . 0.0 109.186 -179.189 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.503 HD13 HG12 ' A' ' 64' ' ' ILE . 1.3 mp -106.25 118.29 53.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 -179.667 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.477 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 77.8 m 65.38 21.36 11.91 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.744 -0.598 . . . . 0.0 110.935 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.472 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 90.31 1.59 75.01 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.506 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -97.34 121.18 38.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.075 -1.25 . . . . 0.0 108.827 179.548 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -61.82 127.51 31.78 Favored 'General case' 0 C--N 1.295 -1.775 0 O-C-N 121.363 -0.835 . . . . 0.0 109.416 -179.789 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.47 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -148.19 137.55 22.12 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.541 -0.724 . . . . 0.0 109.454 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.546 HG12 HD21 ' A' ' 63' ' ' LEU . 0.6 OUTLIER -110.29 160.43 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 177.819 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.532 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 175.46 177.51 44.58 Favored Glycine 0 N--CA 1.485 1.901 0 C-N-CA 118.222 -1.942 . . . . 0.0 111.527 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.499 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 75.3 m -82.27 114.74 20.96 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 122.057 -0.672 . . . . 0.0 109.902 -179.715 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.596 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -108.56 109.92 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.395 -0.816 . . . . 0.0 109.951 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.516 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.2 mp -79.21 126.06 30.26 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.114 -0.991 . . . . 0.0 108.729 179.307 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.542 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.6 t -111.43 116.48 52.64 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 109.94 -179.311 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.466 ' HA3' HG11 ' A' ' 56' ' ' VAL . . . -150.09 -166.25 13.26 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.553 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.2 Cg_endo -82.96 40.16 0.92 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.47 2.113 . . . . 0.0 110.014 179.711 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.54 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 10.2 t -81.38 137.36 48.64 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.472 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.9 Cg_endo -77.84 15.8 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.451 2.1 . . . . 0.0 111.829 -178.664 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.527 ' CG1' HD13 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -161.41 165.97 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.728 -1.233 . . . . 0.0 111.025 -179.64 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.568 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 55.4 m-20 -99.39 142.61 30.65 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 177.046 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 31' ' ' THR . 2.9 mm -133.22 113.59 19.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 O-C-N 120.398 -1.439 . . . . 0.0 111.618 -176.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.545 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -92.68 92.95 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 177.326 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -84.03 -156.96 24.75 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 120.048 -1.072 . . . . 0.0 111.685 -177.852 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.484 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 1.8 mtp180 -63.38 -39.13 93.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.91 -0.759 . . . . 0.0 110.84 -178.865 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.599 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 9.2 p-10 -48.07 -26.57 1.88 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.053 -1.03 . . . . 0.0 110.282 -178.73 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.599 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.8 mm? -112.52 -12.93 13.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.762 -1.211 . . . . 0.0 109.85 -179.796 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.484 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 50.1 mt -80.67 -5.75 57.43 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.41 HG23 ' HB3' ' B' ' 6' ' ' TRP . 77.3 p -100.67 -16.91 17.24 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.922 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.7 mm-40 -83.37 -40.58 19.22 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.587 -0.696 . . . . 0.0 109.477 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.619 ' CD1' ' CG ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -87.29 -3.86 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.145 -0.972 . . . . 0.0 109.429 179.607 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 69.09 56.68 8.61 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.606 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.551 ' HB3' ' CD1' ' B' ' 99' ' ' PHE . . . -81.93 148.86 28.51 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.031 -1.276 . . . . 0.0 110.23 -179.769 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.523 HG23 ' CG2' ' B' ' 4' ' ' THR . 55.8 p -142.89 124.08 14.56 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.744 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.527 HD12 ' CD1' ' B' ' 97' ' ' LEU . 4.7 mp -85.07 108.13 17.5 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.9 m120 -107.2 122.15 45.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.742 -1.224 . . . . 0.0 109.259 -179.669 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.627 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.685 0 CA-C-O 117.922 -1.037 . . . . 0.0 109.747 -179.805 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.608 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 4.5 Cg_exo . . . . . 0 N--CA 1.495 1.613 0 N-CA-C 110.693 -0.541 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.44 131.92 35.0 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 178.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.16 115.41 44.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 120.812 -1.18 . . . . 0.0 109.853 -177.905 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.629 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -119.01 -102.34 0.42 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.919 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.671 ' CD1' ' N ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER 25.91 36.44 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.32 0 CA-C-O 120.752 0.31 . . . . 0.0 110.974 179.823 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.629 ' N ' ' O ' ' B' ' 4' ' ' THR . 19.3 m0 13.77 85.16 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 CA-C-O 121.174 0.511 . . . . 0.0 111.775 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.89 155.18 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.156 -0.965 . . . . 0.0 109.422 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 48.0 mtm180 -50.48 119.61 11.32 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.576 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 33.6 Cg_endo -75.23 71.81 5.02 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 122.158 1.905 . . . . 0.0 110.6 179.861 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.524 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -87.87 161.15 17.66 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.267 -0.896 . . . . 0.0 108.953 179.795 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.569 HG21 ' O ' ' B' ' 11' ' ' VAL . 18.7 m -150.84 138.11 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.006 -1.059 . . . . 0.0 110.198 -179.355 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.581 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 24.5 m -72.61 96.66 2.01 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.763 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.572 ' HB ' ' CG1' ' B' ' 64' ' ' ILE . 10.7 pt -90.44 142.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 O-C-N 121.293 -0.88 . . . . 0.0 110.967 -177.332 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.555 ' HE3' ' CD1' ' B' ' 19' ' ' LEU . 0.3 OUTLIER -108.04 98.6 8.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.667 -0.646 . . . . 0.0 109.608 -179.639 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.562 HG13 HG13 ' B' ' 64' ' ' ILE . 11.4 mt -120.1 135.32 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 120.981 -1.075 . . . . 0.0 109.859 -179.742 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.461 ' HA3' HD11 ' B' ' 38' ' ' LEU . . . 43.11 60.01 3.2 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 179.349 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 16' ' ' GLY . . . 43.02 41.83 4.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.698 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.501 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 38.0 mm-40 -138.45 116.24 11.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.366 -1.079 . . . . 0.0 109.464 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.2 OUTLIER -90.79 127.71 36.44 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.685 0.755 . . . . 0.0 110.069 179.699 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.585 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mttt -150.74 142.65 23.88 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.63 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.524 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -78.59 111.09 14.3 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.994 -1.066 . . . . 0.0 108.711 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.578 ' HA ' ' CB ' ' B' ' 83' ' ' ASN . . . -93.76 132.82 37.77 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.984 0.897 . . . . 0.0 111.062 -178.45 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 12.1 tp -83.8 102.46 12.34 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.535 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.525 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 13.2 mt -44.95 120.19 2.26 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.141 -0.974 . . . . 0.0 108.392 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.496 ' OD1' ' OD1' ' A' ' 25' ' ' ASP . 46.5 t0 -128.39 82.4 2.08 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.492 ' HA ' ' CD1' ' B' ' 90' ' ' LEU . 1.4 m -62.9 -15.24 54.39 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.015 -1.053 . . . . 0.0 108.738 179.125 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.93 -37.89 94.83 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.928 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.518 ' HB3' ' C75' ' B' ' 100' ' ' DMP . . . -77.73 163.53 26.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.292 -1.123 . . . . 0.0 109.463 -179.905 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.457 ' OD1' ' NE ' ' A' ' 8' ' ' ARG . 3.9 m-20 -98.23 -10.12 24.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.525 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 19.5 m-20 -140.25 -165.9 2.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.3 -0.875 . . . . 0.0 108.844 -179.883 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.525 HG23 ' CD1' ' B' ' 33' ' ' LEU . 17.6 m -118.11 93.17 4.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.692 -1.255 . . . . 0.0 111.02 -178.668 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.575 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.89 174.03 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.152 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.575 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.46 117.16 1.32 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.82 -1.175 . . . . 0.0 110.846 -179.086 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.587 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 16.3 tt0 -36.15 155.37 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.492 -0.755 . . . . 0.0 109.94 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.513 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -33.35 146.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.766 0.793 . . . . 0.0 111.41 -179.145 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.498 ' N ' HG12 ' B' ' 77' ' ' VAL . 0.2 OUTLIER -177.64 179.61 0.9 Allowed 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.555 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -122.08 122.84 40.19 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.434 -1.416 . . . . 0.0 111.911 -178.299 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.59 HD13 ' CD ' ' B' ' 39' ' ' PRO . 0.5 OUTLIER -102.58 175.58 2.21 Favored Pre-proline 0 N--CA 1.495 1.785 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 177.899 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.59 ' CD ' HD13 ' B' ' 38' ' ' LEU . 35.4 Cg_endo -78.05 68.8 7.72 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.066 1.844 . . . . 0.0 110.953 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.8 -172.12 0.01 OUTLIER Glycine 0 N--CA 1.493 2.478 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 179.202 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 56.84 101.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.418 -1.048 . . . . 0.0 109.921 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 3.8 p-90 -160.7 171.55 18.66 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.609 -0.682 . . . . 0.0 109.625 179.682 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . 0.524 ' O ' ' CB ' ' B' ' 58' ' ' GLN . 1.4 mtmt -128.71 115.4 19.34 Favored Pre-proline 0 N--CA 1.489 1.477 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.367 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.62 136.03 18.68 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.807 1.671 . . . . 0.0 110.828 -179.334 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.586 ' CE ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.45 178.62 10.11 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.539 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.473 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 27.2 mtp -127.56 136.28 51.47 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.841 -1.162 . . . . 0.0 110.61 -178.754 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.528 HD13 ' CD1' ' B' ' 54' ' ' ILE . 5.8 pt -100.68 143.6 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.328 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.587 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.36 108.92 1.68 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.549 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.89 -125.01 2.55 Favored Glycine 0 N--CA 1.484 1.839 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.522 -179.242 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.568 HG22 ' CD1' ' A' ' 47' ' ' ILE . 50.6 mt -84.3 121.46 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.825 -0.809 . . . . 0.0 112.578 -177.939 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.456 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 98.45 -16.57 59.68 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.019 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 140.58 -155.95 25.03 Favored Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.936 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.6 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.1 m-85 -116.12 134.9 54.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.543 -0.975 . . . . 0.0 109.485 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.563 ' CG2' ' N ' ' A' ' 51' ' ' GLY . 6.0 pt -105.53 159.58 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.004 -1.06 . . . . 0.0 109.245 179.436 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.577 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -99.61 131.43 45.61 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.372 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.586 ' CG2' ' CE ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -138.96 -173.14 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.787 -1.195 . . . . 0.0 109.756 -179.838 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -114.74 165.84 12.38 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.557 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' B' ' 43' ' ' LYS . 10.0 tp60 -128.98 91.57 3.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.57 -1.331 . . . . 0.0 110.99 -178.923 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.599 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 94.1 m-85 -93.88 92.16 7.27 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.223 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.537 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 51.5 m-20 -79.08 134.85 36.73 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.323 -0.86 . . . . 0.0 109.916 -178.841 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.557 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 42.9 mt-30 83.54 63.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.589 0.709 . . . . 0.0 109.291 179.55 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.547 HD13 ' CD1' ' B' ' 38' ' ' LEU . 24.9 mm -119.15 120.48 63.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.592 ' CD2' ' CG ' ' B' ' 70' ' ' LYS . 16.4 tp -72.86 86.83 1.28 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 118.977 -1.089 . . . . 0.0 110.695 -178.852 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.572 ' CG1' ' HB ' ' B' ' 13' ' ' ILE . 1.6 tt -85.23 122.24 38.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.647 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.8 tt0 -89.73 109.61 20.58 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.973 -1.079 . . . . 0.0 109.72 -178.411 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.56 ' CG1' HG22 ' B' ' 11' ' ' VAL . 0.4 OUTLIER -105.76 122.25 59.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.262 -0.899 . . . . 0.0 109.087 179.91 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . 0.48 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 76.2 m 66.71 12.26 8.72 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.997 -0.439 . . . . 0.0 110.294 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.37 0.42 56.89 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 6.7 m-70 -98.82 125.03 44.08 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.191 -1.182 . . . . 0.0 108.904 179.717 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.592 ' CG ' ' CD2' ' B' ' 63' ' ' LEU . 2.7 mptm? -70.28 135.11 48.64 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.281 -0.887 . . . . 0.0 108.613 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.509 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -150.27 138.72 20.53 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.383 -0.823 . . . . 0.0 109.077 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.557 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -108.13 142.69 20.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 178.212 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.478 ' HA3' HD23 ' B' ' 89' ' ' LEU . . . -163.54 -165.73 21.2 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.993 -179.694 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.501 ' CG2' ' NE2' ' B' ' 58' ' ' GLN . 7.0 m -97.81 110.33 22.92 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.745 -0.856 . . . . 0.0 110.06 -179.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.52 ' CG1' ' CD1' ' B' ' 33' ' ' LEU . 1.4 t -109.65 147.26 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.09 -1.006 . . . . 0.0 109.697 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.531 HD22 ' CE ' ' B' ' 45' ' ' LYS . 5.6 mp -125.27 142.91 51.22 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.058 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.519 ' HA ' ' O ' ' B' ' 33' ' ' LEU . 15.1 t -124.03 124.23 68.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.102 -0.999 . . . . 0.0 110.1 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.548 ' HA3' ' CG1' ' B' ' 56' ' ' VAL . . . -160.31 -158.06 9.02 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.577 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -80.57 40.56 1.0 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.806 2.338 . . . . 0.0 110.966 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.587 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.1 t -86.95 133.81 38.43 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 178.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.42 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.5 Cg_endo -77.16 14.16 1.4 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.269 1.979 . . . . 0.0 111.086 -178.939 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.534 HG13 ' CD1' ' B' ' 84' ' ' ILE . 2.1 t -160.81 151.24 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 120.94 -1.1 . . . . 0.0 110.397 -179.241 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.585 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 21.0 m-20 -80.06 130.74 35.48 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.723 -2.695 . . . . 0.0 103.723 175.077 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.569 HG13 ' CG1' ' B' ' 32' ' ' VAL . 0.8 OUTLIER -125.88 116.26 45.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 119.781 -1.824 . . . . 0.0 112.93 -176.437 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.568 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -89.07 147.28 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.708 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.525 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -136.31 -161.1 9.0 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 118.771 -1.681 . . . . 0.0 110.055 -179.766 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.444 ' O ' ' OG1' ' B' ' 91' ' ' THR . 0.0 OUTLIER -57.59 -37.62 73.51 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.702 -0.881 . . . . 0.0 109.793 -179.725 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.602 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 9.8 p-10 -50.67 -29.72 11.84 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.625 -179.29 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.602 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 1.5 mm? -107.13 -24.02 12.08 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.619 -1.301 . . . . 0.0 110.815 -179.082 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.492 ' CD1' ' HA ' ' B' ' 26' ' ' THR . 9.2 mt -71.63 -5.68 35.33 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.883 -1.136 . . . . 0.0 108.888 -179.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.5 -14.42 18.26 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.925 . . . . 0.0 109.023 179.319 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . 0.479 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 18.6 mt-30 -85.96 -40.88 15.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -0.867 . . . . 0.0 109.363 -179.816 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.627 HD11 ' CG ' ' A' ' 99' ' ' PHE . 2.2 pt -85.99 4.78 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.144 -0.973 . . . . 0.0 108.542 178.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.7 42.97 98.49 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.345 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.503 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -69.53 145.46 52.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.901 -1.352 . . . . 0.0 108.882 179.327 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 45.4 p -136.86 128.36 28.51 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.052 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.53 ' HB3' ' CE1' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -91.13 96.66 10.71 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 -178.992 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.529 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.3 m120 -109.64 132.92 53.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.47 -0.769 . . . . 0.0 110.045 -179.426 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.619 ' CG ' ' CD1' ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.062 179.41 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.571 ' C76' ' CD1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.516 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.168 -0.743 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.508 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 5.8 tt0 -83.2 127.62 33.78 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 178.069 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.518 HG13 ' CD2' ' A' ' 5' ' ' LEU . 20.7 t -130.91 102.32 6.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.167 -177.663 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 5.5 p -48.68 -24.34 1.34 Allowed 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 179.213 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.575 ' HB3' ' CZ ' ' B' ' 87' ' ' ARG . 0.5 OUTLIER 71.34 35.6 1.5 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.547 -0.721 . . . . 0.0 109.817 179.679 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.43 ' C ' ' HG2' ' A' ' 7' ' ' GLN . 2.1 m95 -55.21 -20.37 10.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.876 -1.14 . . . . 0.0 108.416 179.611 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.455 ' O ' HD11 ' A' ' 5' ' ' LEU . 4.4 mm100 -138.52 -142.49 0.16 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.022 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.47 ' HG2' ' OD2' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -92.18 141.8 25.5 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 120.778 -1.201 . . . . 0.0 109.339 179.494 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.513 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -80.16 59.38 7.41 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.502 2.135 . . . . 0.0 110.243 179.532 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 6.0 mt -79.47 132.41 36.34 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.969 -1.082 . . . . 0.0 109.053 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.537 HG21 ' CB ' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -134.63 150.37 30.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 121.327 -0.858 . . . . 0.0 109.326 -179.323 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.52 ' CG2' HD21 ' A' ' 19' ' ' LEU . 32.8 m -86.0 95.88 9.65 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.801 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.53 HG22 ' CB ' ' A' ' 22' ' ' ALA . 1.1 pt -79.01 155.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.478 -0.764 . . . . 0.0 110.298 -178.818 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.525 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -120.06 89.96 3.23 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.516 ' CG2' HD23 ' A' ' 38' ' ' LEU . 24.9 mt -110.8 130.24 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.102 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.72 44.85 93.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 179.327 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.27 23.7 48.79 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.48 ' HB2' ' HE3' ' A' ' 36' ' ' MET . 6.7 mm100 -117.4 163.53 16.23 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.153 -1.204 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.52 HD21 ' CG2' ' A' ' 12' ' ' THR . 11.6 mt -132.97 127.68 34.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.992 -1.068 . . . . 0.0 110.853 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 1.2 mmmt -146.59 173.7 12.09 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.091 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 4.0 mm-40 -79.26 179.57 7.32 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.809 -1.182 . . . . 0.0 108.801 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.537 ' CB ' HG21 ' A' ' 11' ' ' VAL . . . -159.35 114.07 2.41 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.766 -1.209 . . . . 0.0 110.608 -179.753 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.515 ' CD2' ' O ' ' B' ' 27' ' ' GLY . 29.3 tp -87.8 96.73 10.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.684 -0.635 . . . . 0.0 109.357 179.61 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.59 HD12 ' CZ ' ' B' ' 99' ' ' PHE . 19.1 mt -43.67 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.492 ' CB ' HG21 ' A' ' 84' ' ' ILE . 8.1 t0 -106.11 86.17 2.32 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.402 -0.811 . . . . 0.0 111.165 -177.891 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.457 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 62.1 m -68.53 -14.18 62.83 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.919 -1.113 . . . . 0.0 108.596 178.437 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.41 -22.59 67.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.919 -1.273 . . . . 0.0 109.919 -179.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.51 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -86.71 164.77 16.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.029 -1.277 . . . . 0.0 109.807 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.488 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 1.3 m-20 -94.19 -21.07 19.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 110.961 -178.785 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.556 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.2 OUTLIER -141.55 -166.57 2.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.655 -1.278 . . . . 0.0 110.596 -179.524 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 60.5 m -103.25 89.48 3.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.189 -0.944 . . . . 0.0 111.02 -178.336 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.538 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -73.84 175.45 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.722 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.538 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.0 OUTLIER -171.92 121.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.75 -1.219 . . . . 0.0 110.214 -179.475 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.578 ' HA ' HG21 ' A' ' 80' ' ' THR . 0.1 OUTLIER -39.39 155.61 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.063 -1.023 . . . . 0.0 110.218 179.499 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.527 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.7 OUTLIER -46.4 151.04 0.58 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.383 -0.823 . . . . 0.0 110.265 -179.808 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.48 ' HE3' ' HB2' ' A' ' 18' ' ' GLN . 0.1 OUTLIER -172.63 174.27 3.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.581 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.407 ' C ' ' SD ' ' A' ' 36' ' ' MET . 34.7 t -89.48 83.65 6.36 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.012 -1.055 . . . . 0.0 109.724 -179.722 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.52 ' CD2' HD13 ' A' ' 62' ' ' ILE . 6.1 tp -109.78 105.54 57.31 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.239 -0.913 . . . . 0.0 109.715 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.45 ' HD2' HD13 ' A' ' 38' ' ' LEU . 36.0 Cg_endo -78.47 146.63 21.94 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.573 2.182 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.82 -165.83 26.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.842 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 127.94 49.49 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.26 -1.141 . . . . 0.0 108.595 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.583 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 42.6 p-90 -136.0 -173.99 3.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.985 . . . . 0.0 110.293 -179.355 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.25 129.71 7.74 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.173 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -74.96 136.52 20.61 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.907 1.738 . . . . 0.0 111.369 -178.659 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HD3' HD22 ' A' ' 76' ' ' LEU . 9.5 ptmm? -153.74 -165.41 2.12 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 178.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.424 ' N ' ' HG3' ' A' ' 45' ' ' LYS . 3.3 ttt -147.6 125.92 12.31 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.66 -1.275 . . . . 0.0 110.232 -179.395 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.515 HD13 ' CG2' ' B' ' 50' ' ' ILE . 5.2 pt -98.27 135.92 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.06 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.449 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.35 112.35 2.36 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -179.653 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -129.35 -111.53 1.53 Allowed Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.041 -179.509 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.597 HG13 ' H32' ' B' ' 100' ' ' DMP . 27.4 mt -97.84 132.53 42.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 O-C-N 121.296 -1.12 . . . . 0.0 111.477 -178.445 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 96.69 -50.48 1.56 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.074 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.49 -158.7 28.22 Favored Glycine 0 N--CA 1.491 2.3 0 O-C-N 121.022 -1.281 . . . . 0.0 110.15 -179.872 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.449 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 32.8 m-85 -107.72 151.36 25.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.611 -0.935 . . . . 0.0 109.954 -179.654 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.546 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 18.0 pt -136.2 140.61 43.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.508 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 8.8 mttt -80.7 137.12 36.28 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.389 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 27.2 m -128.66 -176.72 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.36 -0.838 . . . . 0.0 109.469 -179.73 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.551 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 2.6 mmt85 -125.74 85.35 2.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 108.981 179.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.538 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 1.2 tt0 -45.32 89.53 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 121.441 0.639 . . . . 0.0 110.261 -179.633 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.592 ' HB3' HG13 ' A' ' 62' ' ' ILE . 6.3 m-85 -90.58 82.51 5.82 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.486 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -77.57 137.39 38.56 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.235 -178.349 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.486 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 77.62 59.99 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.198 0.523 . . . . 0.0 110.399 179.701 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.592 HG13 ' HB3' ' A' ' 59' ' ' TYR . 0.6 OUTLIER -131.54 126.49 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.633 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.548 ' CD1' ' HG2' ' A' ' 70' ' ' LYS . 5.3 tt -74.68 93.33 2.54 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.187 -0.945 . . . . 0.0 112.839 -176.746 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.512 HG12 HD13 ' A' ' 66' ' ' ILE . 1.9 tt -87.33 115.76 28.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 105.966 -1.865 . . . . 0.0 105.966 176.236 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.525 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -87.97 116.97 26.51 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.11 -0.994 . . . . 0.0 109.013 -178.057 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.512 HD13 HG12 ' A' ' 64' ' ' ILE . 1.5 mp -111.92 125.64 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.243 -0.911 . . . . 0.0 109.95 -179.076 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 7.7 m 51.75 -94.84 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.697 . . . . 0.0 109.75 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -140.51 49.55 0.79 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.823 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -145.2 109.8 5.0 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.322 -1.105 . . . . 0.0 110.158 -179.767 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.548 ' HG2' ' CD1' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -63.73 120.05 11.11 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.796 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.4 ' O ' HG21 ' A' ' 64' ' ' ILE . . . -132.7 129.01 38.2 Favored 'General case' 0 C--N 1.291 -1.953 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.755 -178.355 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.54 HD12 ' N ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -105.69 138.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 177.269 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.97 -157.23 8.79 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.641 -179.472 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.538 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 9.9 m -107.42 104.47 14.06 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.879 -0.777 . . . . 0.0 108.946 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.51 ' O ' ' HB2' ' A' ' 59' ' ' TYR . 1.4 t -91.28 99.94 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.539 -0.726 . . . . 0.0 109.721 -179.757 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.556 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 2.7 mp -78.16 106.34 9.99 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.074 -1.016 . . . . 0.0 108.857 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.527 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 50.1 t -95.75 123.9 48.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.424 -0.797 . . . . 0.0 110.358 -179.271 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -155.45 -163.92 12.62 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.36 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.538 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 34.9 Cg_endo -79.75 39.62 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.56 2.173 . . . . 0.0 111.193 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.578 HG21 ' HA ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -85.66 135.77 37.79 Favored Pre-proline 0 N--CA 1.491 1.625 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.794 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.444 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -78.24 18.79 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.793 2.329 . . . . 0.0 112.21 -178.529 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.513 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.87 163.02 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.575 -1.328 . . . . 0.0 110.476 -179.962 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.536 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 54.6 m-20 -91.46 140.04 30.14 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 105.175 -2.158 . . . . 0.0 105.175 176.549 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.541 ' O ' ' HA ' ' A' ' 31' ' ' THR . 18.3 mm -128.64 122.79 58.06 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 O-C-N 120.346 -1.471 . . . . 0.0 111.539 -177.211 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.523 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 1.4 mm -102.91 96.71 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.184 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.34 -156.41 10.68 Favored Glycine 0 N--CA 1.495 2.62 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.525 -177.416 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.514 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 7.9 mtt180 -72.81 -35.17 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.874 -0.78 . . . . 0.0 109.799 -179.309 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.545 ' ND2' HD21 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -54.19 -18.87 4.27 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.005 -1.06 . . . . 0.0 108.857 -178.977 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.545 HD21 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -110.37 -22.22 11.81 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.524 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.514 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 64.1 mt -74.67 -17.24 60.71 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.299 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.488 HG23 ' CD2' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -89.84 -10.28 45.97 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.029 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.522 ' NE2' ' O ' ' A' ' 88' ' ' ASN . 72.6 mt-30 -94.52 -41.74 9.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.51 HD13 ' HB3' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -84.25 -3.81 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.203 -0.936 . . . . 0.0 108.772 179.116 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 67.67 43.06 86.39 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 178.817 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -66.54 153.05 43.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.867 -1.373 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' B' ' 96' ' ' THR . 17.7 p -145.09 128.31 16.74 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.327 -0.858 . . . . 0.0 109.094 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.52 ' CD1' HD13 ' B' ' 97' ' ' LEU . 6.7 mp -93.16 96.72 10.21 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.44 -0.787 . . . . 0.0 109.441 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 3.2 m120 -101.13 121.22 41.43 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.822 -1.173 . . . . 0.0 109.674 179.654 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.576 ' CE1' ' O ' ' B' ' 1' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.479 179.541 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.576 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 N-CA-C 110.408 -0.651 . . . . 0.0 110.408 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.9 tt0 -96.37 132.08 42.26 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.456 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 52.7 t -131.82 120.85 45.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.032 -1.042 . . . . 0.0 109.624 -179.049 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.521 ' C ' ' CD1' ' B' ' 5' ' ' LEU . 0.3 OUTLIER -60.19 -97.26 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.434 -0.791 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.585 HD21 ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -168.88 -17.87 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.963 -1.086 . . . . 0.0 111.325 179.685 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.585 ' N ' HD21 ' B' ' 5' ' ' LEU . 67.0 m95 -66.19 -11.6 50.7 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.546 -1.346 . . . . 0.0 109.792 -179.799 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -117.56 147.12 43.1 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 110.235 -179.601 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.92 131.21 81.83 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.34 -0.85 . . . . 0.0 109.028 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.505 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 38.0 Cg_endo -81.08 45.42 1.99 Allowed 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.135 1.89 . . . . 0.0 109.825 178.732 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.492 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -81.1 147.45 30.1 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.156 -0.965 . . . . 0.0 109.279 -179.672 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.542 ' CG2' HG13 ' B' ' 66' ' ' ILE . 0.9 OUTLIER -150.31 135.48 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.023 -1.048 . . . . 0.0 110.569 -179.184 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 12' ' ' THR . . . . . 0.443 ' CG2' HD23 ' B' ' 19' ' ' LEU . 7.5 m -64.03 113.83 3.75 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.207 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.521 ' CG2' ' CB ' ' B' ' 22' ' ' ALA . 1.4 pp -100.57 135.67 35.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.323 -0.861 . . . . 0.0 110.182 -179.034 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.514 ' CG ' HD22 ' B' ' 19' ' ' LEU . 0.8 OUTLIER -108.33 108.54 19.57 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.24 -0.912 . . . . 0.0 108.967 179.5 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.539 HG23 ' CE ' ' B' ' 36' ' ' MET . 28.9 mt -110.67 123.52 66.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.163 -0.961 . . . . 0.0 108.876 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.6 -90.46 0.38 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.734 -1.746 . . . . 0.0 108.734 -179.402 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -152.34 27.05 0.88 Allowed Glycine 0 N--CA 1.483 1.813 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 179.396 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.458 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 4.6 mt-30 -125.78 176.31 7.02 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.259 -1.142 . . . . 0.0 109.579 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.514 HD22 ' CG ' ' B' ' 14' ' ' LYS . 18.9 mt -136.48 128.09 28.8 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-O 121.621 0.724 . . . . 0.0 110.312 -179.263 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.434 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 7.6 mmtt -138.64 155.93 47.88 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.494 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mm-40 -78.81 145.13 34.47 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.631 -1.293 . . . . 0.0 109.615 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -120.54 148.84 43.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.941 -1.099 . . . . 0.0 110.762 -179.303 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.422 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -118.42 95.56 4.92 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' B' ' 85' ' ' ILE . 21.2 mt -45.48 107.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.994 -1.066 . . . . 0.0 109.395 -179.659 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.474 ' HB3' HG22 ' B' ' 84' ' ' ILE . 22.5 t0 -119.77 90.4 3.32 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.791 -179.692 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.525 HG21 ' CD ' ' B' ' 87' ' ' ARG . 1.2 m -60.36 -14.27 17.75 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.067 -1.021 . . . . 0.0 108.977 179.282 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.515 ' O ' ' CD2' ' A' ' 23' ' ' LEU . . . -61.67 -44.46 97.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.433 ' HB3' ' C77' ' B' ' 100' ' ' DMP . . . -80.78 148.43 30.06 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -1.17 . . . . 0.0 109.654 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.47 ' OD2' ' HG2' ' A' ' 8' ' ' ARG . 37.6 m-20 -89.12 -8.79 53.1 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.281 -0.887 . . . . 0.0 110.04 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.495 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -133.39 -171.01 2.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.025 -1.047 . . . . 0.0 109.329 -179.923 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 43.5 m -111.97 93.25 4.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.778 -1.201 . . . . 0.0 110.974 -178.844 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.92 172.83 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.299 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -166.84 124.3 1.29 Allowed 'General case' 0 C--N 1.305 -1.347 0 O-C-N 120.59 -1.319 . . . . 0.0 111.92 -178.838 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.542 ' HA ' HG21 ' B' ' 80' ' ' THR . 0.2 OUTLIER -35.87 154.72 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 178.053 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -53.86 130.33 36.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.113 -0.992 . . . . 0.0 110.335 -179.428 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.539 ' CE ' HG23 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -141.33 -178.39 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.85 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.2 t -105.15 103.45 12.99 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.639 -1.288 . . . . 0.0 110.532 -178.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.613 HD11 ' CD1' ' B' ' 59' ' ' TYR . 51.6 mt -106.88 156.58 37.05 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 108.975 179.253 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' B' ' 40' ' ' GLY . 36.4 Cg_endo -79.35 77.99 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.695 2.263 . . . . 0.0 111.475 -179.097 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . 0.493 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 37.37 -158.41 0.01 OUTLIER Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.212 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . 0.493 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 22.5 mmm180 63.65 74.84 0.41 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.597 -0.943 . . . . 0.0 109.169 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.511 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 67.8 p-90 -159.13 175.9 12.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.746 . . . . 0.0 109.761 -179.294 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.54 138.71 31.81 Favored Pre-proline 0 N--CA 1.492 1.669 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.035 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.28 127.97 9.44 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.021 1.814 . . . . 0.0 111.286 -178.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.553 ' O ' ' CG2' ' B' ' 56' ' ' VAL . 0.0 OUTLIER -162.9 136.48 5.96 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.852 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.456 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 32.4 mtp -102.09 137.26 40.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.844 -1.16 . . . . 0.0 109.098 -179.91 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.5 ' CG1' ' CG1' ' B' ' 54' ' ' ILE . 19.0 pt -89.59 145.46 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.373 179.237 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . 0.458 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -118.23 100.92 0.87 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.748 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.29 -126.85 3.43 Favored Glycine 0 N--CA 1.483 1.775 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.054 -178.611 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.586 HD13 ' C26' ' B' ' 100' ' ' DMP . 38.5 mt -83.28 118.7 31.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 O-C-N 121.863 -0.787 . . . . 0.0 112.741 -177.292 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . 0.546 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 100.62 -51.91 0.97 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 178.134 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.479 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . -174.6 -171.61 38.95 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.265 -1.445 . . . . 0.0 110.108 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.568 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-30 -106.06 128.83 54.13 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.335 -1.097 . . . . 0.0 109.349 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.555 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.0 pt -100.84 161.39 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.129 -0.982 . . . . 0.0 109.276 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 13.6 mttt -89.6 134.46 34.12 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.131 -0.981 . . . . 0.0 109.208 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.553 ' CG2' ' O ' ' B' ' 45' ' ' LYS . 17.0 m -142.05 172.99 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.966 -1.084 . . . . 0.0 109.588 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 6.9 mtm180 -124.75 101.32 7.04 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.522 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 6.7 tt0 -58.4 96.36 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 110.032 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.613 ' CD1' HD11 ' B' ' 38' ' ' LEU . 13.3 m-85 -89.57 94.34 9.83 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.006 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -78.87 141.76 37.4 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.108 -0.995 . . . . 0.0 110.307 -178.846 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.533 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 15.2 mt-30 69.38 64.02 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.334 0.588 . . . . 0.0 110.765 179.479 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.535 ' CB ' HG22 ' B' ' 75' ' ' VAL . 0.9 OUTLIER -119.84 125.01 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 108.847 178.727 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.605 ' CD2' ' CG ' ' B' ' 70' ' ' LYS . 2.8 tm? -74.4 86.45 2.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.309 -0.87 . . . . 0.0 110.903 -178.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.529 ' CD1' HD13 ' B' ' 66' ' ' ILE . 3.4 tt -90.81 116.93 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.007 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.7 tt0 -90.07 116.56 28.19 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.811 -1.181 . . . . 0.0 109.72 -179.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.542 HG13 ' CG2' ' B' ' 11' ' ' VAL . 0.5 OUTLIER -105.11 116.93 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.157 -0.964 . . . . 0.0 109.675 -179.898 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 51.85 16.55 0.52 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.782 -0.574 . . . . 0.0 111.603 178.454 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 106.99 18.65 10.3 Favored Glycine 0 N--CA 1.495 2.604 0 C-N-CA 119.277 -1.439 . . . . 0.0 110.679 179.016 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -116.08 98.85 6.86 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.084 -1.245 . . . . 0.0 108.898 179.459 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.605 ' CG ' ' CD2' ' B' ' 63' ' ' LEU . 2.6 ttpm? -54.36 120.06 6.05 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.901 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.467 ' O ' HG21 ' B' ' 64' ' ' ILE . . . -142.65 130.86 22.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 110.693 -178.827 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.533 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -94.19 147.1 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.581 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . 0.502 ' N ' HG21 ' B' ' 72' ' ' ILE . . . -171.09 175.83 44.62 Favored Glycine 0 N--CA 1.489 2.209 0 C-N-CA 118.557 -1.782 . . . . 0.0 111.538 -179.601 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.522 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 8.6 m -87.97 102.41 14.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.927 -0.749 . . . . 0.0 110.465 -179.616 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.535 HG22 ' CB ' ' B' ' 62' ' ' ILE . 1.5 t -94.12 108.64 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.368 -0.832 . . . . 0.0 110.01 179.189 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.508 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.0 mp -79.83 111.03 15.75 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.84 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.565 HG22 ' CD1' ' B' ' 59' ' ' TYR . 11.2 t -93.68 116.51 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.117 -0.99 . . . . 0.0 110.122 -179.014 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.53 -172.83 20.76 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.477 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.6 Cg_endo -80.42 42.99 1.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.525 2.15 . . . . 0.0 110.839 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.542 HG21 ' HA ' ' B' ' 34' ' ' GLU . 0.9 OUTLIER -83.01 143.62 46.16 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.035 -1.041 . . . . 0.0 108.496 179.198 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.54 14.8 1.54 Allowed 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.275 1.983 . . . . 0.0 110.874 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.508 HG11 ' N ' ' B' ' 83' ' ' ASN . 1.2 t -160.91 165.08 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.902 -1.124 . . . . 0.0 109.816 -179.527 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.556 ' ND2' ' O ' ' B' ' 21' ' ' GLU . 1.1 m-20 -103.2 119.01 38.08 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 104.675 -2.343 . . . . 0.0 104.675 176.272 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' B' ' 31' ' ' THR . 14.6 mm -102.17 126.41 56.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 O-C-N 120.762 -1.211 . . . . 0.0 111.9 -175.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.589 ' CG2' ' CD2' ' B' ' 24' ' ' LEU . 1.0 OUTLIER -103.89 88.33 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 177.304 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.59 -158.3 11.84 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 120.145 -1.026 . . . . 0.0 111.228 -177.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.575 ' CZ ' ' HB3' ' A' ' 5' ' ' LEU . 7.3 mmm180 -69.01 -37.81 78.9 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.666 -0.902 . . . . 0.0 110.672 -178.748 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.592 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 15.7 p-10 -43.45 -25.18 0.13 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.647 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.592 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 3.3 mm? -111.5 -29.79 7.63 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.07 -1.019 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.573 ' HB2' ' CZ ' ' B' ' 87' ' ' ARG . 33.6 mt -67.33 -8.32 31.49 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.243 -0.91 . . . . 0.0 108.965 179.319 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 91' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.6 -20.28 15.74 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.162 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -81.4 -40.2 23.8 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.565 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -81.28 -2.66 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 108.839 178.89 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 81.95 24.23 55.75 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 178.996 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.515 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -60.58 137.62 58.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.842 -1.387 . . . . 0.0 109.994 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 96' ' ' THR . 44.5 p -132.65 122.1 24.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.645 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.52 HD13 ' CD1' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -89.51 94.37 9.85 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 121.324 0.583 . . . . 0.0 109.503 -178.683 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.508 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.8 OUTLIER -109.43 130.94 55.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.279 -0.888 . . . . 0.0 110.53 -179.312 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.59 ' CZ ' HD12 ' A' ' 24' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.096 178.464 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.597 ' H32' HG13 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.495 1.604 0 N-CA-C 109.767 -0.897 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.544 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 2.4 tt0 -83.32 134.84 34.9 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 177.686 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.6 t -126.84 101.82 8.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.585 -1.246 . . . . 0.0 110.501 -178.092 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 6' ' ' TRP . 1.7 p -115.18 -81.52 0.61 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.342 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.54 ' O ' ' C ' ' A' ' 6' ' ' TRP . 92.0 mt 33.71 32.91 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.923 -0.486 . . . . 0.0 110.441 178.866 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 7.2 m0 18.33 50.74 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.499 0.666 . . . . 0.0 111.651 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.6 OUTLIER -143.6 -163.83 1.74 Allowed 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.549 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.417 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -84.86 136.64 38.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 108.869 179.703 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.4 Cg_endo -78.97 67.63 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.316 2.011 . . . . 0.0 109.776 179.099 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -86.91 143.04 27.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.19 -0.944 . . . . 0.0 109.592 -179.619 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.416 HG23 HG21 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -139.51 160.66 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.829 . . . . 0.0 109.412 -179.745 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 34.5 m -95.33 109.96 22.03 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.554 HG23 ' CG1' ' A' ' 66' ' ' ILE . 1.7 pt -97.8 159.1 3.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 110.401 -178.312 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.468 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 0.0 OUTLIER -119.3 99.1 6.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.485 -0.759 . . . . 0.0 109.095 179.53 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.528 HG21 ' CG2' ' A' ' 62' ' ' ILE . 17.0 mt -114.64 130.55 68.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.165 -0.959 . . . . 0.0 109.534 -179.653 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.63 50.56 62.35 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.807 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.67 26.18 16.16 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.946 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.468 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.5 mt-30 -120.37 173.66 7.0 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -1.158 . . . . 0.0 109.041 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 13.2 mt -140.46 126.94 20.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.128 -0.983 . . . . 0.0 110.352 -179.678 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.641 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -144.13 175.04 10.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.516 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 83' ' ' ASN . 1.9 mm-40 -79.44 178.15 8.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.845 -1.16 . . . . 0.0 108.721 179.67 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.529 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -158.38 117.97 3.19 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.875 -1.14 . . . . 0.0 110.035 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 25' ' ' ASP . 59.0 tp -90.56 95.47 10.18 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.431 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.643 ' CD1' ' CZ ' ' B' ' 99' ' ' PHE . 10.9 mt -46.16 97.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 -179.682 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.557 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 18.9 t0 -103.49 91.67 4.15 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.533 -0.729 . . . . 0.0 110.647 -177.851 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' B' ' 26' ' ' THR . 0.1 OUTLIER -67.77 -6.74 22.62 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.886 -1.134 . . . . 0.0 108.977 178.767 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.482 ' O ' HD22 ' B' ' 23' ' ' LEU . . . -80.11 -39.49 16.04 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.446 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.89 160.71 31.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.824 -1.398 . . . . 0.0 109.52 -179.505 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -99.85 -16.46 18.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.932 . . . . 0.0 109.062 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.574 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.4 OUTLIER -132.29 -161.19 1.11 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.44 -0.787 . . . . 0.0 109.152 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.499 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 21.5 m -121.04 89.8 3.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.559 -1.338 . . . . 0.0 110.675 -178.526 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.551 ' O ' ' CD1' ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.953 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.551 ' CD1' ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -161.17 129.44 4.4 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.965 -1.084 . . . . 0.0 110.679 -178.707 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.466 ' C ' ' O ' ' A' ' 33' ' ' LEU . 7.0 tt0 -40.8 156.85 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.111 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.492 ' HA ' HG13 ' A' ' 77' ' ' VAL . 0.3 OUTLIER -52.89 153.09 3.52 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.06 -1.025 . . . . 0.0 110.364 -179.155 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.488 ' HG2' HG12 ' A' ' 77' ' ' VAL . 4.1 ptm -177.47 -163.76 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.407 -0.808 . . . . 0.0 109.019 179.71 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -107.52 142.17 37.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.697 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.548 HD21 ' CD ' ' A' ' 39' ' ' PRO . 9.3 mt -150.33 167.22 13.43 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.548 ' CD ' HD21 ' A' ' 38' ' ' LEU . 34.2 Cg_endo -76.78 138.43 18.86 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.299 1.999 . . . . 0.0 109.342 179.33 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.571 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -48.0 -169.33 0.01 OUTLIER Glycine 0 N--CA 1.492 2.42 0 CA-C-O 121.854 0.696 . . . . 0.0 111.438 -178.669 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.571 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.2 OUTLIER 81.91 46.92 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 -178.965 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.679 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 57.8 p-90 -137.24 -172.02 3.1 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.405 0.621 . . . . 0.0 109.798 -179.196 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.19 138.65 11.97 Favored Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 121.41 -0.806 . . . . 0.0 109.204 179.226 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.32 139.48 18.68 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.117 1.878 . . . . 0.0 110.028 179.455 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 0.2 OUTLIER -160.59 -159.46 0.69 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.432 -0.793 . . . . 0.0 108.951 -179.775 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.481 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 69.4 mtp -148.93 130.5 14.91 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.119 -0.988 . . . . 0.0 109.41 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 54' ' ' ILE . 14.6 pt -88.95 144.68 8.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.14 97.91 0.76 Allowed Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.228 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.419 ' HA3' H202 ' B' ' 100' ' ' DMP . . . -121.68 -126.43 3.26 Favored Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.325 -179.151 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.588 ' CG1' ' H32' ' B' ' 100' ' ' DMP . 21.8 mt -87.43 112.17 22.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.809 -0.818 . . . . 0.0 112.639 -177.787 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.544 ' N ' HG22 ' B' ' 54' ' ' ILE . . . 116.77 -48.52 0.93 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 178.054 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.76 -154.57 21.22 Favored Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.023 -179.618 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.1 m-85 -114.14 116.4 29.04 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.562 -0.964 . . . . 0.0 110.009 -179.454 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.0 pt -89.85 175.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.149 -0.969 . . . . 0.0 109.084 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.525 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -104.13 142.5 34.38 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 108.853 179.423 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.483 HG13 ' HA3' ' A' ' 78' ' ' GLY . 15.1 m -150.93 175.25 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.943 -1.098 . . . . 0.0 110.293 -179.54 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.526 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -126.61 98.23 5.32 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.646 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.523 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 0.7 OUTLIER -58.1 102.58 0.11 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.219 -0.925 . . . . 0.0 110.971 -179.016 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.679 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 23.0 m-85 -98.89 94.35 6.53 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.114 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.499 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.02 139.41 38.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.465 -178.538 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.499 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 73.96 62.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.674 -0.641 . . . . 0.0 110.064 179.499 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.528 ' CG2' HG21 ' A' ' 15' ' ' ILE . 10.5 mm -119.69 114.46 44.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.145 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.548 ' CD1' ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -63.61 87.02 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.362 -0.836 . . . . 0.0 110.944 -178.586 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.55 ' CG2' ' O ' ' A' ' 71' ' ' ALA . 5.6 tt -89.59 115.23 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 178.078 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.458 ' OE2' ' N ' ' A' ' 69' ' ' HIS . 1.1 tm-20 -88.35 123.51 33.0 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.106 -0.996 . . . . 0.0 109.181 -178.773 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.554 ' CG1' HG23 ' A' ' 13' ' ' ILE . 2.3 mt -126.13 122.42 61.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 110.188 -179.049 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 56.15 46.68 21.02 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.662 -0.649 . . . . 0.0 111.174 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.77 22.62 68.42 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 120.163 -1.018 . . . . 0.0 110.928 178.406 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.458 ' N ' ' OE2' ' A' ' 65' ' ' GLU . 5.9 m-70 -123.41 130.79 53.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.993 -1.298 . . . . 0.0 109.186 179.24 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.543 ' CG ' HD23 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -72.48 129.18 37.72 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 108.908 179.713 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.55 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -146.55 109.57 4.68 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.54 -0.725 . . . . 0.0 109.677 -179.324 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.508 HD11 ' N ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -90.43 156.88 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.764 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.493 ' HA3' HD23 ' A' ' 89' ' ' LEU . . . -178.53 -171.31 41.68 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 118.435 -1.84 . . . . 0.0 111.597 179.819 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.523 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 7.7 m -96.79 104.92 16.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.737 -0.861 . . . . 0.0 109.542 -179.669 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.471 ' CG1' ' CD1' ' A' ' 33' ' ' LEU . 1.4 t -100.33 113.4 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.294 -0.879 . . . . 0.0 110.567 -179.573 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.3 mp -82.78 125.3 31.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.847 . . . . 0.0 108.841 178.938 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.537 ' CG2' HD13 ' A' ' 38' ' ' LEU . 3.1 t -103.92 110.45 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.0 -1.062 . . . . 0.0 109.423 -179.959 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.61 -171.47 15.21 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.949 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.525 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 42.42 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.454 2.103 . . . . 0.0 110.41 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.462 ' O ' HG21 ' A' ' 80' ' ' THR . 6.5 t -81.47 141.89 49.5 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.416 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 36.3 Cg_endo -79.74 16.95 1.35 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.408 2.072 . . . . 0.0 111.339 -179.629 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.47 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 1.0 OUTLIER -161.05 165.87 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.917 -1.114 . . . . 0.0 109.894 -179.571 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.641 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -103.79 96.72 6.89 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 105.11 -2.181 . . . . 0.0 105.11 176.761 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.528 ' CG1' HG11 ' A' ' 32' ' ' VAL . 6.4 mm -83.15 115.42 25.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 O-C-N 121.082 -1.011 . . . . 0.0 113.1 -175.756 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.588 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -95.0 91.99 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 175.612 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.574 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.32 -157.38 8.6 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.884 -1.15 . . . . 0.0 110.783 -177.047 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -69.56 -37.14 76.88 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.884 -0.774 . . . . 0.0 110.37 -178.804 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.567 ' ND2' ' CD2' ' A' ' 89' ' ' LEU . 14.7 p-10 -46.58 -28.86 1.57 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.762 -1.211 . . . . 0.0 109.634 -179.757 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.567 ' CD2' ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -110.96 -30.96 7.3 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.994 -1.067 . . . . 0.0 111.466 -178.361 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.464 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 0.6 OUTLIER -59.57 -31.46 69.46 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.769 -1.207 . . . . 0.0 108.642 -179.869 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -78.85 -20.7 48.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.898 . . . . 0.0 110.123 -179.89 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 -69.77 -40.66 75.93 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.88 -1.138 . . . . 0.0 108.262 179.319 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.523 HD11 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -83.67 -7.17 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.864 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.52 62.92 3.25 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.805 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HB3' HD13 ' A' ' 93' ' ' ILE . . . -83.21 148.88 27.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.315 -1.109 . . . . 0.0 109.674 -179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.531 ' CG2' HG23 ' B' ' 4' ' ' THR . 5.0 p -137.46 129.74 29.45 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.142 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.511 ' CD1' HD13 ' B' ' 97' ' ' LEU . 4.9 mp -96.58 88.65 4.73 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.263 -0.898 . . . . 0.0 109.422 -179.745 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.1 m120 -93.6 121.59 35.18 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.116 -0.99 . . . . 0.0 109.126 179.827 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.62 ' CG ' HD11 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.402 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 1' ' ' PRO . . . . . 0.605 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.619 0 N-CA-C 110.641 -0.561 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 2' ' ' GLN . . . . . 0.439 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -91.01 136.9 32.77 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 177.85 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.2 t -133.93 105.89 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 120.574 -1.329 . . . . 0.0 110.57 -178.558 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.531 HG23 ' CG2' ' A' ' 96' ' ' THR . 15.8 p -122.03 -70.13 0.8 Allowed 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.063 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER 31.24 37.79 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.81 -0.556 . . . . 0.0 110.743 179.146 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 5.5 m95 18.8 50.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.186 0 CA-C-O 121.504 0.669 . . . . 0.0 111.924 -179.756 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.537 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.4 OUTLIER -154.55 165.4 36.6 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.155 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.495 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 71.2 mtm180 -49.0 133.15 15.0 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.012 -179.827 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 9' ' ' PRO . . . . . 0.476 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.6 Cg_endo -80.09 64.83 8.91 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.312 2.008 . . . . 0.0 109.514 179.028 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 10' ' ' LEU . . . . . 0.555 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -79.89 148.24 31.38 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.33 -0.856 . . . . 0.0 109.521 -179.663 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.473 HG22 HG21 ' B' ' 66' ' ' ILE . 1.4 m -140.29 132.28 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.307 -0.871 . . . . 0.0 109.592 179.872 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 11.8 m -64.09 99.77 0.28 Allowed 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.498 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.559 ' CD1' HD13 ' B' ' 15' ' ' ILE . 1.0 OUTLIER -90.41 147.89 4.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.255 -0.903 . . . . 0.0 110.615 -178.178 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 14' ' ' LYS . . . . . 0.468 ' HG3' HD22 ' B' ' 19' ' ' LEU . 2.8 tttt -107.93 107.94 18.87 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.559 HD13 ' CD1' ' B' ' 13' ' ' ILE . 14.8 mt -122.88 119.04 56.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.205 -0.934 . . . . 0.0 109.604 -179.273 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.59 20.99 74.4 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.38 -7.74 79.66 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.545 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 18' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' B' ' 37' ' ' SER . 30.6 mt-30 -87.19 -175.25 5.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -1.107 . . . . 0.0 109.52 -179.961 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 19' ' ' LEU . . . . . 0.526 ' O ' ' CD ' ' B' ' 20' ' ' LYS . 40.9 mt -152.19 119.95 6.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.919 -179.861 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' B' ' 19' ' ' LEU . 2.5 mmmt -134.82 161.61 34.73 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.555 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -79.09 122.82 26.71 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.526 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . 0.558 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -108.63 119.4 39.43 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.921 -1.112 . . . . 0.0 111.145 -178.578 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 23' ' ' LEU . . . . . 0.495 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 24.9 tp -75.43 99.59 4.21 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.633 179.561 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 24' ' ' LEU . . . . . 0.531 ' CD2' HD23 ' B' ' 90' ' ' LEU . 4.6 mt -48.68 96.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.935 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 25' ' ' ASP . . . . . 0.61 ' CB ' ' CG2' ' B' ' 84' ' ' ILE . 8.7 t0 -96.88 95.6 7.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 110.068 -179.379 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 26' ' ' THR . . . . . 0.413 ' OG1' ' OG1' ' A' ' 26' ' ' THR . 9.8 m -74.27 -4.29 35.25 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.157 -0.964 . . . . 0.0 108.467 178.455 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 27' ' ' GLY . . . . . 0.459 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -85.81 -26.25 35.54 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 28' ' ' ALA . . . . . 0.406 ' HB3' ' C77' ' B' ' 100' ' ' DMP . . . -88.85 162.32 16.22 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.869 -1.371 . . . . 0.0 109.999 -179.304 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 29' ' ' ASP . . . . . 0.501 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.2 m-20 -100.62 -13.9 18.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -0.799 . . . . 0.0 110.719 -179.132 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.509 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.82 -172.22 2.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.912 -1.117 . . . . 0.0 109.506 -179.706 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 31' ' ' THR . . . . . 0.53 HG23 ' CD1' ' B' ' 33' ' ' LEU . 20.6 m -111.04 87.28 2.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.519 -1.363 . . . . 0.0 110.702 -178.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 32' ' ' VAL . . . . . 0.559 ' O ' ' CD1' ' B' ' 33' ' ' LEU . 0.5 OUTLIER -73.43 170.6 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 178.179 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.559 ' CD1' ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.51 122.12 1.99 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.533 -1.354 . . . . 0.0 110.609 -178.576 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.484 ' N ' ' CG2' ' B' ' 80' ' ' THR . 88.5 tt0 -40.26 152.92 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.371 -0.831 . . . . 0.0 109.311 179.102 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.8 tt0 -46.09 147.77 0.98 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 110.602 -179.313 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 36' ' ' MET . . . . . 0.475 ' HE3' HG23 ' B' ' 15' ' ' ILE . 3.8 ptt? -168.01 156.81 9.26 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.477 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 37' ' ' SER . . . . . 0.524 ' O ' ' NE2' ' B' ' 18' ' ' GLN . 4.6 t -79.26 85.63 5.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 109.788 -179.339 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.515 HD22 ' CD1' ' B' ' 62' ' ' ILE . 62.7 tp -103.14 115.13 64.51 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.273 -0.892 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 39' ' ' PRO . . . . . 0.404 ' HD2' HD13 ' B' ' 38' ' ' LEU . 34.1 Cg_endo -77.05 125.28 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.44 2.094 . . . . 0.0 110.534 -179.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.96 154.49 6.18 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.98 153.02 38.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -1.182 . . . . 0.0 109.287 -179.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 42' ' ' TRP . . . . . 0.504 ' CE3' ' HB3' ' B' ' 57' ' ' ARG . 58.0 p-90 -156.58 172.45 18.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.141 -0.975 . . . . 0.0 109.394 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.66 137.39 30.26 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.028 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.35 137.74 15.2 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.112 1.874 . . . . 0.0 111.093 -179.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 45' ' ' LYS . . . . . 0.51 ' HG2' ' CG2' ' B' ' 56' ' ' VAL . 3.8 ptmt -159.98 -172.9 3.81 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.161 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 46' ' ' MET . . . . . 0.414 ' HA ' ' O ' ' B' ' 54' ' ' ILE . 28.1 mtp -141.58 137.61 32.05 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.662 -1.274 . . . . 0.0 109.842 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 47' ' ' ILE . . . . . 0.542 HD13 ' CD1' ' B' ' 54' ' ' ILE . 1.4 pt -96.06 152.74 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.475 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.48 116.33 3.37 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.778 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -149.13 -124.66 1.35 Allowed Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.25 -179.681 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 50' ' ' ILE . . . . . 0.585 ' CG1' ' H62' ' B' ' 100' ' ' DMP . 20.4 mt -86.59 123.93 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.527 -0.984 . . . . 0.0 112.375 -178.181 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.78 -7.93 70.72 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 120.27 -0.967 . . . . 0.0 111.148 177.717 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 125.91 -159.22 20.32 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 53' ' ' PHE . . . . . 0.533 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -112.96 142.03 46.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.314 -1.11 . . . . 0.0 109.843 -179.585 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.544 HG22 ' N ' ' A' ' 51' ' ' GLY . 6.5 pt -107.17 -178.3 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.258 -0.901 . . . . 0.0 109.368 179.554 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 55' ' ' LYS . . . . . 0.532 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -106.34 148.21 28.3 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.421 -0.799 . . . . 0.0 108.894 179.475 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 56' ' ' VAL . . . . . 0.51 ' CG2' ' HG2' ' B' ' 45' ' ' LYS . 29.3 m -151.22 -179.1 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.687 -1.258 . . . . 0.0 110.408 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 57' ' ' ARG . . . . . 0.504 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.6 mtt-85 -130.47 86.41 2.38 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.237 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 58' ' ' GLN . . . . . 0.462 ' HB2' ' HD2' ' B' ' 45' ' ' LYS . 24.5 tt0 -47.41 105.63 0.07 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.588 -0.695 . . . . 0.0 111.301 -178.469 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 59' ' ' TYR . . . . . 0.545 ' HB3' HG13 ' B' ' 62' ' ' ILE . 5.1 m-85 -99.03 90.3 4.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 60' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 2.8 m-20 -79.0 136.32 37.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.872 -1.143 . . . . 0.0 111.502 -177.753 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 61' ' ' GLN . . . . . 0.52 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 13.9 mt-30 68.21 62.5 0.38 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-O 121.179 0.514 . . . . 0.0 110.632 178.542 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 62' ' ' ILE . . . . . 0.545 HG13 ' HB3' ' B' ' 59' ' ' TYR . 0.1 OUTLIER -122.51 122.39 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.205 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.597 ' O ' ' CD1' ' B' ' 63' ' ' LEU . 1.3 tm? -60.51 87.4 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.759 0.79 . . . . 0.0 111.896 -177.741 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 64' ' ' ILE . . . . . 0.486 ' N ' ' O ' ' B' ' 71' ' ' ALA . 2.6 tt -95.81 111.53 26.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 176.561 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 65' ' ' GLU . . . . . 0.551 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.4 tt0 -90.25 124.64 35.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.76 -1.212 . . . . 0.0 109.152 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 66' ' ' ILE . . . . . 0.484 HG13 HG21 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -106.53 128.23 61.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.156 -0.965 . . . . 0.0 109.269 -179.728 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 58.86 -90.1 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.683 -0.636 . . . . 0.0 109.682 179.583 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.92 40.95 0.99 Allowed Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 69' ' ' HIS . . . . . 0.48 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 86.6 m-70 -137.64 114.14 10.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -1.132 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 70' ' ' LYS . . . . . 0.522 ' HG2' HD22 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -56.47 120.86 8.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.351 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 71' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' B' ' 64' ' ' ILE . . . -132.87 151.63 52.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.405 -0.809 . . . . 0.0 109.429 179.897 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 72' ' ' ILE . . . . . 0.533 ' CD1' ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -125.22 156.5 34.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 177.527 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.27 -165.15 34.86 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 117.906 -2.093 . . . . 0.0 111.492 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 74' ' ' THR . . . . . 0.487 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.5 m -99.41 103.61 15.41 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.906 -0.761 . . . . 0.0 110.017 -179.476 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 75' ' ' VAL . . . . . 0.541 ' CG1' HD11 ' B' ' 15' ' ' ILE . 1.3 t -94.73 102.19 13.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.471 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.466 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -79.12 112.74 16.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.033 -1.042 . . . . 0.0 108.981 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 77' ' ' VAL . . . . . 0.424 HG22 ' CD2' ' B' ' 59' ' ' TYR . 52.9 t -97.89 117.72 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.102 -0.999 . . . . 0.0 109.814 -179.521 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.89 -164.28 11.67 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 179.739 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 79' ' ' PRO . . . . . 0.532 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -82.76 38.04 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.202 1.935 . . . . 0.0 110.404 179.814 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 80' ' ' THR . . . . . 0.484 ' CG2' ' N ' ' B' ' 34' ' ' GLU . 3.6 t -79.85 134.32 57.08 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 178.785 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 81' ' ' PRO . . . . . 0.491 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 32.1 Cg_endo -77.5 17.04 0.97 Allowed 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.393 2.062 . . . . 0.0 111.701 -178.556 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.551 HG11 HG13 ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.23 151.4 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.755 -1.216 . . . . 0.0 109.972 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.558 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 84.8 m-20 -89.57 127.08 35.84 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.23 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 84' ' ' ILE . . . . . 0.61 ' CG2' ' CB ' ' B' ' 25' ' ' ASP . 3.9 mt -127.89 121.79 57.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 119.903 -1.748 . . . . 0.0 112.655 -176.538 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . 0.533 ' CD1' ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -89.43 111.1 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.384 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -92.15 -159.15 35.06 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.57 -178.821 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 87' ' ' ARG . . . . . 0.432 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.0 mtp180 -68.63 -29.47 67.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.685 -0.891 . . . . 0.0 109.984 -179.524 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 88' ' ' ASN . . . . . 0.583 ' ND2' ' CD2' ' B' ' 89' ' ' LEU . 16.1 p-10 -53.62 -26.92 24.11 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.062 -1.024 . . . . 0.0 109.601 -179.588 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . 0.583 ' CD2' ' ND2' ' B' ' 88' ' ' ASN . 2.9 mm? -108.87 -30.48 8.11 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.066 -1.021 . . . . 0.0 109.847 -179.494 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . 0.531 HD23 ' CD2' ' B' ' 24' ' ' LEU . 85.0 mt -61.29 -30.31 70.4 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.247 -0.908 . . . . 0.0 108.849 179.863 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.1 p -78.47 -22.0 48.21 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.292 -0.88 . . . . 0.0 108.796 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -72.16 -40.73 67.79 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.326 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 93' ' ' ILE . . . . . 0.62 HD11 ' CG ' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -87.89 -8.12 10.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.349 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.09 61.41 6.11 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.255 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 95' ' ' ALA . . . . . 0.504 ' HB1' HD13 ' B' ' 93' ' ' ILE . . . -88.53 158.55 18.27 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -1.152 . . . . 0.0 110.341 -179.664 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 96' ' ' THR . . . . . 0.506 HG23 ' CG2' ' A' ' 4' ' ' THR . 43.7 p -135.29 127.6 30.23 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 97' ' ' LEU . . . . . 0.533 ' HB3' ' CE1' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -91.4 95.69 10.12 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.302 -0.874 . . . . 0.0 109.902 -178.786 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 98' ' ' ASN . . . . . 0.544 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -106.83 131.36 54.02 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.868 . . . . 0.0 109.941 -179.882 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' B' B ' 99' ' ' PHE . . . . . 0.643 ' CZ ' ' CD1' ' A' ' 24' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.284 179.476 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 100' ' ' DMP . . . . . 0.588 ' H32' ' CG1' ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.615 0 CA-C-O 121.355 0.481 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.433 ' HG3' ' CG ' ' B' ' 98' ' ' ASN . 20.7 tt0 -86.19 118.5 25.69 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 177.279 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -115.15 105.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 120.806 -1.184 . . . . 0.0 110.405 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.818 HG22 HG22 ' B' ' 96' ' ' THR . 1.3 p -123.34 30.0 6.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.615 -0.678 . . . . 0.0 109.709 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.548 ' O ' ' C ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -89.56 39.33 0.94 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.13 -0.981 . . . . 0.0 109.295 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.548 ' C ' ' O ' ' A' ' 5' ' ' LEU . 46.2 m0 16.28 59.36 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 CA-C-O 121.613 0.72 . . . . 0.0 111.918 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -145.14 174.22 11.25 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.395 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -65.97 118.32 51.0 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.98 -1.075 . . . . 0.0 108.915 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.974 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 71.66 6.16 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.214 1.942 . . . . 0.0 109.545 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -92.93 157.07 16.53 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.442 -0.786 . . . . 0.0 109.523 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.535 HG21 HG13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -150.77 136.53 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.183 -0.948 . . . . 0.0 110.158 -179.599 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.84 HG22 HD22 ' A' ' 19' ' ' LEU . 55.0 m -68.32 108.9 3.39 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.919 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.2 pp -98.66 152.46 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 120.957 -1.09 . . . . 0.0 111.012 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.51 ' HE3' HD11 ' A' ' 19' ' ' LEU . 10.9 tttt -113.23 104.61 12.51 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' A' ' 75' ' ' VAL . 5.1 mt -120.84 129.81 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.079 -1.013 . . . . 0.0 109.894 -179.319 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.58 35.57 81.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.34 73.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -121.47 -176.76 3.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.342 -1.093 . . . . 0.0 108.653 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.919 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.4 mt -151.4 124.05 8.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.938 -1.101 . . . . 0.0 110.892 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.543 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -141.97 165.99 25.94 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 178.495 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.5 mp0 -79.25 131.62 36.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.9 -1.125 . . . . 0.0 108.747 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.655 ' HB2' ' CG2' ' A' ' 13' ' ' ILE . . . -108.09 137.87 45.33 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.067 -1.021 . . . . 0.0 110.641 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.615 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.1 tp -104.77 98.7 8.4 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.974 HD12 ' HB2' ' A' ' 9' ' ' PRO . 43.2 mt -44.95 95.17 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.064 -1.022 . . . . 0.0 108.685 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 1.4 t70 -97.05 79.8 2.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.164 -0.96 . . . . 0.0 110.732 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.407 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 27.6 m -63.11 -13.71 39.8 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.991 -1.068 . . . . 0.0 108.762 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.445 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.8 -41.39 49.85 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.04 168.95 19.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.202 -1.176 . . . . 0.0 109.67 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.71 -17.59 16.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.185 -0.947 . . . . 0.0 111.272 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.831 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -135.7 -176.71 4.38 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.427 -179.366 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 16.7 m -98.86 87.97 3.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.359 -0.838 . . . . 0.0 110.68 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.95 168.14 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 178.787 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.23 135.22 5.14 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.975 -1.078 . . . . 0.0 110.518 -178.235 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 80' ' ' THR . 2.0 mt-10 -45.16 170.68 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.375 -0.828 . . . . 0.0 108.834 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -60.59 152.68 25.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.041 -1.037 . . . . 0.0 109.888 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.633 ' HE2' HG22 ' A' ' 15' ' ' ILE . 8.1 ptm -177.8 -158.92 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.909 ' O ' HD22 ' A' ' 38' ' ' LEU . 6.6 t -110.67 127.21 55.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.258 -0.901 . . . . 0.0 110.351 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.909 HD22 ' O ' ' A' ' 37' ' ' SER . 3.8 mm? -131.88 170.01 12.4 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 36.3 Cg_endo -80.99 123.96 4.79 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.791 2.327 . . . . 0.0 112.514 -178.288 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.552 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -44.49 117.72 2.18 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.029 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.552 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 150.04 44.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 35.4 p-90 -118.81 -173.84 2.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.961 0.886 . . . . 0.0 110.709 -177.308 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.08 136.92 11.12 Favored Pre-proline 0 C--N 1.303 -1.451 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.05 136.89 20.88 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.846 1.698 . . . . 0.0 110.986 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.709 ' HD2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -146.8 157.52 43.69 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.547 ' CG ' ' HG2' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -119.41 125.47 49.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.836 -1.165 . . . . 0.0 110.188 -178.889 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 54' ' ' ILE . 5.7 pt -104.86 136.23 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 108.746 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.595 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.36 102.59 0.97 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.51 -127.16 3.56 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.627 -178.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.648 HG21 HD12 ' B' ' 47' ' ' ILE . 57.0 mt -80.19 122.13 34.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.9 -0.765 . . . . 0.0 112.925 -177.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.431 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 100.0 -50.87 1.08 Allowed Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.049 177.614 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -177.5 -160.53 24.36 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.582 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.595 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.8 m-85 -113.47 133.37 55.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.567 -0.96 . . . . 0.0 109.926 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 47' ' ' ILE . 10.6 pt -113.51 168.09 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.141 -0.974 . . . . 0.0 108.918 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.7 mtpt -113.46 132.4 55.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.201 -0.937 . . . . 0.0 109.252 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.642 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.6 m -127.79 -174.59 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.969 -1.082 . . . . 0.0 110.217 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.522 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 1.7 mtt85 -127.37 92.08 3.44 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.4 tt0 -54.58 94.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.544 -0.723 . . . . 0.0 110.484 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.881 ' HB3' HD11 ' A' ' 62' ' ' ILE . 26.6 m-85 -89.51 133.7 34.46 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 177.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.5 OUTLIER -111.35 139.86 46.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.938 -1.101 . . . . 0.0 111.528 -177.664 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 69.48 63.48 0.27 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.727 -0.608 . . . . 0.0 110.44 178.868 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.881 HD11 ' HB3' ' A' ' 59' ' ' TYR . 3.6 mp -116.71 122.78 70.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -64.77 82.91 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.642 0.734 . . . . 0.0 110.48 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.928 HD12 HD11 ' A' ' 15' ' ' ILE . 2.9 tt -90.76 117.83 34.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.55 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -90.4 137.23 32.52 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.09 -1.006 . . . . 0.0 108.587 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.579 HD12 HG12 ' A' ' 64' ' ' ILE . 0.6 OUTLIER -124.37 112.61 33.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 120.902 -1.124 . . . . 0.0 108.901 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.534 ' HB3' ' CE1' ' A' ' 69' ' ' HIS . 0.1 OUTLIER 62.37 23.08 13.65 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.713 -0.617 . . . . 0.0 109.833 179.712 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 93.93 9.22 59.85 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.534 ' CE1' ' HB3' ' A' ' 67' ' ' CYS . 1.4 m-70 -100.54 105.41 16.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.097 -1.237 . . . . 0.0 109.218 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.567 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 tttt -53.77 125.07 17.12 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.134 -0.979 . . . . 0.0 109.303 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.601 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -147.18 145.99 29.7 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.566 -0.709 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.785 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.7 OUTLIER -115.43 155.31 16.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 105.93 -1.878 . . . . 0.0 105.93 177.438 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.596 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.67 -173.38 43.97 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 118.14 -1.981 . . . . 0.0 111.367 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.545 HG23 ' OD1' ' A' ' 60' ' ' ASP . 0.2 OUTLIER -93.51 107.43 19.28 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.776 -0.838 . . . . 0.0 109.555 -179.763 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' A' ' 15' ' ' ILE . 1.5 t -102.72 111.58 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.341 -0.849 . . . . 0.0 110.45 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.831 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.3 mp -81.79 122.9 28.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.439 -0.788 . . . . 0.0 109.211 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.564 HG21 HD23 ' A' ' 38' ' ' LEU . 71.9 t -103.96 118.84 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.093 -1.005 . . . . 0.0 109.769 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.642 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.03 -165.6 14.76 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.1 Cg_endo -80.31 43.26 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 122.72 2.28 . . . . 0.0 110.795 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.645 HG21 HG13 ' A' ' 32' ' ' VAL . 9.2 t -89.05 139.02 28.83 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -79.6 17.96 1.18 Allowed 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.568 2.178 . . . . 0.0 111.81 -179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG12 ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.74 166.98 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.543 -1.348 . . . . 0.0 110.659 -179.811 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.556 ' OD1' ' CD2' ' A' ' 33' ' ' LEU . 7.5 m-80 -96.87 93.53 6.71 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 176.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.816 ' CG1' HG12 ' A' ' 32' ' ' VAL . 26.7 mm -78.42 127.25 38.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 O-C-N 120.727 -1.233 . . . . 0.0 112.154 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.627 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -107.43 89.96 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 177.232 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.14 -165.0 28.81 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 120.276 -0.964 . . . . 0.0 111.217 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 9.5 mtm180 -64.42 -31.05 72.1 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.793 -0.828 . . . . 0.0 109.92 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.2 p-10 -48.61 -26.04 2.04 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.145 -0.972 . . . . 0.0 109.422 -179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -106.75 -21.15 13.13 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.01 -1.056 . . . . 0.0 108.837 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.556 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 43.4 mt -72.61 -4.09 28.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 177.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.637 ' CG2' HD23 ' B' ' 5' ' ' LEU . 0.0 OUTLIER -100.57 -18.43 16.61 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 178.294 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.475 ' HA ' ' OE1' ' A' ' 92' ' ' GLN . 50.6 mm-40 -83.06 -40.9 19.27 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.874 HD12 ' CG ' ' B' ' 99' ' ' PHE . 1.4 pt -89.0 5.27 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.418 -0.801 . . . . 0.0 109.397 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 58.98 47.66 89.62 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.476 ' O ' HD12 ' B' ' 5' ' ' LEU . . . -70.69 155.1 41.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.137 -1.214 . . . . 0.0 110.76 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 24.1 p -146.74 126.09 13.12 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' B' ' 97' ' ' LEU . 4.0 mp -93.46 86.04 5.12 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.483 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 18.6 m-20 -91.38 124.4 35.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.289 -0.882 . . . . 0.0 109.652 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.045 -0.978 . . . . 0.0 109.196 179.355 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.584 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.718 0 N-CA-C 110.572 -0.588 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.66 117.44 34.02 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.533 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' B' ' 9' ' ' PRO . 9.1 t -108.04 114.69 47.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 108.605 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.935 ' C ' HD13 ' B' ' 5' ' ' LEU . 19.8 p -67.79 -105.19 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.274 -0.891 . . . . 0.0 109.073 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.935 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -171.88 -11.64 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.828 -1.17 . . . . 0.0 111.434 179.824 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.661 ' N ' HD22 ' B' ' 5' ' ' LEU . 72.2 m95 -66.61 -10.53 46.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.69 -1.256 . . . . 0.0 109.49 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.96 178.59 7.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 109.615 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.509 ' HG2' ' NH1' ' A' ' 87' ' ' ARG . 13.8 mtt180 -92.18 138.56 24.35 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.316 -0.865 . . . . 0.0 109.157 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.758 ' HB3' HG11 ' B' ' 3' ' ' VAL . 36.6 Cg_endo -79.49 59.93 7.6 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.246 1.964 . . . . 0.0 110.147 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.684 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -86.43 145.72 26.73 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.945 -1.097 . . . . 0.0 109.102 -179.923 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.599 HG21 HG23 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -145.15 136.01 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.651 -179.137 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.743 HG22 HD22 ' B' ' 19' ' ' LEU . 86.5 m -68.26 90.5 0.35 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.701 HG22 HG13 ' B' ' 66' ' ' ILE . 47.8 pt -79.09 153.7 4.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.451 -0.781 . . . . 0.0 110.02 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.81 ' HG3' HD21 ' B' ' 19' ' ' LEU . 3.2 tttt -115.14 100.56 8.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.413 -0.804 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.724 HG23 HG21 ' B' ' 62' ' ' ILE . 11.1 mt -122.81 131.19 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.55 48.65 85.0 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.55 20.96 6.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.1 mp0 -112.98 171.44 7.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.155 -1.203 . . . . 0.0 109.714 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.81 HD21 ' HG3' ' B' ' 14' ' ' LYS . 55.5 mt -143.47 127.67 17.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.378 -0.826 . . . . 0.0 109.524 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -147.95 165.99 29.06 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 108.912 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.684 ' HB3' HD22 ' B' ' 10' ' ' LEU . 2.5 mm-40 -78.55 127.37 32.04 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.055 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.664 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.57 159.07 16.05 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.886 -1.134 . . . . 0.0 109.808 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.461 HD11 HH22 ' A' ' 87' ' ' ARG . 19.2 tp -122.53 93.76 4.08 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.485 -0.76 . . . . 0.0 109.109 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.565 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.7 mt -46.41 110.66 0.29 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.994 -1.066 . . . . 0.0 108.243 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.611 ' HB3' HG22 ' B' ' 84' ' ' ILE . 56.3 t0 -122.07 91.65 3.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.19 -0.944 . . . . 0.0 110.403 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.69 HG23 HD13 ' B' ' 90' ' ' LEU . 1.3 m -65.0 -10.3 28.49 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.9 -1.125 . . . . 0.0 108.78 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.615 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -68.74 -46.94 58.85 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.41 164.92 26.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.154 -1.204 . . . . 0.0 109.496 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -101.14 -15.44 17.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.027 -1.046 . . . . 0.0 110.969 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.613 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -132.08 -163.37 1.33 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.778 -1.201 . . . . 0.0 110.024 -179.3 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.673 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 67.0 m -113.39 91.34 3.61 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.052 -1.03 . . . . 0.0 110.012 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -77.56 156.17 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.371 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.004 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -152.78 124.36 7.76 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.595 -1.316 . . . . 0.0 110.162 -178.894 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.527 ' HA ' HG22 ' B' ' 80' ' ' THR . 47.5 tt0 -36.56 153.3 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.548 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.5 tt0 -53.63 152.49 5.11 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -0.981 . . . . 0.0 109.93 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.3 ptm -177.26 -174.12 0.48 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.486 -0.759 . . . . 0.0 109.406 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -91.52 105.73 17.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 109.648 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' B' ' 39' ' ' PRO . 32.2 tp -134.96 105.07 10.5 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.718 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.7 Cg_endo -78.24 138.7 16.19 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.451 2.101 . . . . 0.0 110.147 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.95 179.45 22.17 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.12 139.72 35.47 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.276 -1.132 . . . . 0.0 109.13 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.578 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 38.7 p-90 -150.36 153.38 35.92 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.138 -0.976 . . . . 0.0 109.958 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.77 131.16 24.25 Favored Pre-proline 0 N--CA 1.489 1.478 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.12 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.72 135.79 16.37 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.982 1.788 . . . . 0.0 110.708 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.573 ' HG3' HG22 ' B' ' 56' ' ' VAL . 1.1 ptmm? -158.04 -168.35 2.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.543 -0.723 . . . . 0.0 109.059 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.513 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 1.0 OUTLIER -145.36 121.1 10.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.097 -1.002 . . . . 0.0 110.015 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.648 HD12 HG21 ' A' ' 50' ' ' ILE . 2.4 pt -92.26 141.18 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.25 -0.906 . . . . 0.0 108.618 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.56 108.65 1.53 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.47 -119.09 2.21 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.499 -1.334 . . . . 0.0 110.244 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.686 HG21 HD12 ' A' ' 47' ' ' ILE . 25.8 mt -87.75 130.87 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.441 -1.035 . . . . 0.0 111.781 -178.29 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.485 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 91.3 -45.0 2.79 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.549 -1.021 . . . . 0.0 110.549 178.579 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.431 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.36 -159.36 29.38 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.444 -1.36 . . . . 0.0 110.167 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -121.62 139.34 53.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.505 -0.997 . . . . 0.0 109.16 -179.715 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' B' ' 46' ' ' MET . 32.4 pt -114.31 -176.16 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.257 -0.902 . . . . 0.0 109.655 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.526 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -107.28 150.03 27.12 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.321 -0.862 . . . . 0.0 108.955 179.406 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.599 HG21 HD23 ' B' ' 76' ' ' LEU . 3.2 m -143.72 -174.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 120.788 -1.195 . . . . 0.0 110.655 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' B' ' 77' ' ' VAL . 3.6 mtm-85 -142.41 88.47 2.08 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.522 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 2.2 tt0 -48.02 95.05 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.314 -0.866 . . . . 0.0 110.296 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.578 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.2 m-85 -92.43 92.82 8.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 4.6 m-20 -79.88 130.72 35.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.97 -1.081 . . . . 0.0 111.025 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.516 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 2.9 mt-30 84.95 59.27 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 CA-C-O 121.165 0.507 . . . . 0.0 110.968 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.724 HG21 HG23 ' B' ' 15' ' ' ILE . 13.2 mm -118.41 124.9 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -1.0 . . . . 0.0 108.579 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.675 HD21 ' HG3' ' B' ' 70' ' ' LYS . 1.9 tm? -72.16 99.99 2.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.174 -0.954 . . . . 0.0 110.998 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.97 HD13 HD11 ' B' ' 66' ' ' ILE . 1.3 tt -104.7 117.62 50.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.48 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 31.7 tt0 -90.77 108.56 19.9 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.091 -1.006 . . . . 0.0 109.118 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.97 HD11 HD13 ' B' ' 64' ' ' ILE . 1.1 mp -99.03 116.89 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.957 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 10.1 m 64.26 17.28 10.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.821 -0.55 . . . . 0.0 110.649 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 96.94 4.11 58.92 Favored Glycine 0 N--CA 1.492 2.423 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.15 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -104.68 116.33 31.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.049 -1.265 . . . . 0.0 109.418 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.675 ' HG3' HD21 ' B' ' 63' ' ' LEU . 14.7 tttt -52.81 137.86 30.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.45 -0.782 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.677 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -160.13 100.88 1.4 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.18 -0.95 . . . . 0.0 109.619 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.606 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.31 156.56 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.642 -1.286 . . . . 0.0 108.32 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.746 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -177.75 176.27 47.95 Favored Glycine 0 N--CA 1.488 2.149 0 C-N-CA 118.999 -1.572 . . . . 0.0 111.167 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.522 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 10.6 m -88.51 109.85 20.39 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.63 -0.924 . . . . 0.0 110.376 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.867 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -99.84 110.89 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.274 -0.891 . . . . 0.0 110.534 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.613 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -79.52 104.27 10.01 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' B' ' 35' ' ' GLU . 26.3 t -88.77 125.5 41.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 120.777 -1.202 . . . . 0.0 110.017 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -153.01 -169.32 18.05 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.526 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -81.44 41.86 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.557 2.171 . . . . 0.0 110.793 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.616 HG21 HG13 ' B' ' 32' ' ' VAL . 14.6 t -84.73 140.15 37.88 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 36.6 Cg_endo -79.38 14.0 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.376 2.051 . . . . 0.0 111.175 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.673 HG12 HD11 ' B' ' 84' ' ' ILE . 0.5 OUTLIER -160.85 176.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.825 -1.172 . . . . 0.0 110.591 -179.47 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.665 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -107.98 147.78 30.61 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 176.721 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.673 HD11 HG12 ' B' ' 82' ' ' VAL . 4.6 mm -135.3 100.1 2.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 O-C-N 120.902 -1.124 . . . . 0.0 110.963 -177.224 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.664 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -79.2 88.86 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.336 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -81.23 -160.42 24.84 Favored Glycine 0 N--CA 1.494 2.555 0 O-C-N 121.363 -0.836 . . . . 0.0 112.103 -177.147 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.414 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.8 mtm180 -58.91 -41.0 86.22 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 122.148 -0.619 . . . . 0.0 111.386 -178.853 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.862 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.9 p-10 -52.23 -18.89 1.71 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.979 -1.076 . . . . 0.0 109.956 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.862 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.4 mm? -114.75 -23.92 8.96 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 120.928 -1.107 . . . . 0.0 108.933 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.69 HD13 HG23 ' B' ' 26' ' ' THR . 25.9 mt -71.84 -6.79 44.21 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.05 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 59.9 p -101.19 -17.79 16.46 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.299 -0.876 . . . . 0.0 108.753 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 57.4 mm-40 -83.7 -41.49 17.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.415 -0.803 . . . . 0.0 109.502 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -84.7 -4.64 8.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.165 -0.959 . . . . 0.0 108.713 179.282 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.97 58.67 7.2 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.03 157.81 25.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.112 -1.228 . . . . 0.0 110.347 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.818 HG22 HG22 ' A' ' 4' ' ' THR . 9.4 p -139.6 126.07 20.34 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -95.88 89.38 5.23 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.104 -179.156 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.472 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.0 OUTLIER -101.55 132.7 47.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -0.83 . . . . 0.0 110.568 -178.966 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.874 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 117.946 -1.026 . . . . 0.0 108.751 178.272 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.439 ' HD2' ' C ' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.318 -0.686 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.41 ' HG3' ' OD1' ' B' ' 98' ' ' ASN . 1.6 tt0 -84.26 131.92 34.69 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -131.53 118.78 40.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 120.998 -1.064 . . . . 0.0 110.209 -178.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.609 ' CG2' HG22 ' B' ' 96' ' ' THR . 2.2 p -127.71 -90.91 0.51 Allowed 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.56 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 41.63 29.17 0.1 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.48 -0.762 . . . . 0.0 109.432 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.56 ' C ' ' O ' ' A' ' 5' ' ' LEU . 37.3 m0 18.07 51.84 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 CA-C-O 121.638 0.732 . . . . 0.0 111.326 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.546 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.9 mt-30 -142.3 -166.66 2.3 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.9 mtm180 -74.25 116.4 52.35 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HB2' HD12 ' A' ' 24' ' ' LEU . 33.5 Cg_endo -76.53 73.84 5.0 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.269 1.979 . . . . 0.0 109.763 179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -81.53 158.56 24.42 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.32 -0.862 . . . . 0.0 110.301 -179.113 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 24' ' ' LEU . 4.0 m -149.85 130.54 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.408 -0.808 . . . . 0.0 109.588 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.785 HG22 HD22 ' A' ' 19' ' ' LEU . 2.0 m -68.49 106.09 2.43 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.728 HD11 HD21 ' A' ' 33' ' ' LEU . 6.8 pt -92.24 155.06 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.21 -0.931 . . . . 0.0 110.285 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.8 OUTLIER -119.02 105.83 11.82 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.059 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.586 ' CD1' HG11 ' A' ' 75' ' ' VAL . 8.1 mt -123.99 127.08 73.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 120.987 -1.071 . . . . 0.0 109.819 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.73 35.55 91.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.63 9.88 52.71 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -104.64 -179.4 3.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.374 -1.074 . . . . 0.0 109.297 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.785 HD22 HG22 ' A' ' 12' ' ' THR . 3.6 mt -145.9 131.25 18.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 110.269 -179.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.479 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -145.51 157.02 44.06 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.272 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.519 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 19.7 mp0 -78.98 133.63 36.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.842 -1.161 . . . . 0.0 107.93 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -113.68 144.07 43.55 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.994 -1.066 . . . . 0.0 111.07 -178.266 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 58.8 tp -98.71 92.67 5.7 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.348 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.766 HD12 ' HB2' ' A' ' 9' ' ' PRO . 74.0 mt -43.94 96.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 51.4 t0 -110.74 92.8 4.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.458 -0.776 . . . . 0.0 110.461 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 6.0 m -67.31 -10.66 53.07 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 108.758 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 1.055 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -74.19 -43.18 33.35 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.42 149.37 50.13 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.9 -1.353 . . . . 0.0 109.202 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -84.45 -19.94 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 110.133 -179.331 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' HB3' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -136.57 -162.25 1.26 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.067 -1.02 . . . . 0.0 109.499 -179.503 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 HD12 ' A' ' 85' ' ' ILE . 20.4 m -115.77 100.41 8.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.473 -1.392 . . . . 0.0 111.235 -178.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -78.0 178.15 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.695 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.037 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.15 116.35 0.62 Allowed 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.935 -1.103 . . . . 0.0 110.213 -179.241 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.756 ' HA ' HG22 ' A' ' 80' ' ' THR . 41.2 tt0 -39.35 162.02 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.29 -0.881 . . . . 0.0 109.966 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -41.34 156.85 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.218 -0.926 . . . . 0.0 110.738 -179.562 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.626 ' HG2' HG11 ' A' ' 77' ' ' VAL . 11.2 ptm -179.02 -176.94 0.45 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.548 -0.72 . . . . 0.0 109.149 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.8 t -104.52 118.69 37.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.417 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.631 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 9.9 mt -132.92 170.65 10.85 Favored Pre-proline 0 N--CA 1.493 1.694 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.631 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -69.53 -163.06 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.287 0 C-N-CA 122.079 1.853 . . . . 0.0 111.671 -179.214 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -105.39 35.09 5.3 Favored Glycine 0 N--CA 1.494 2.502 0 C-N-CA 119.968 -1.111 . . . . 0.0 111.169 -178.129 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.5 mtt85 -109.56 50.44 0.79 Allowed 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.7 p-90 -133.43 176.79 8.22 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.867 0.841 . . . . 0.0 110.542 -178.597 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.26 151.74 34.53 Favored Pre-proline 0 C--N 1.302 -1.486 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.01 130.37 11.24 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.759 1.639 . . . . 0.0 110.655 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.761 ' O ' HG22 ' A' ' 56' ' ' VAL . 3.6 ptmt -161.42 129.14 4.17 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.533 ' CG ' ' HG3' ' A' ' 55' ' ' LYS . 15.4 mtp -89.58 135.01 33.85 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.941 -1.1 . . . . 0.0 109.417 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 7.0 pt -89.4 145.91 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.244 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 98.36 0.76 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.104 -1.599 . . . . 0.0 109.104 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.98 -124.1 2.99 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.46 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.977 HG21 HD12 ' B' ' 47' ' ' ILE . 9.9 mt -88.87 119.15 35.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.636 -0.92 . . . . 0.0 112.693 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 106.54 -51.3 0.75 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 177.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.28 -155.52 16.13 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.6 m-85 -118.41 128.66 54.83 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.456 -1.026 . . . . 0.0 109.995 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' MET . 10.1 pt -101.77 169.69 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 16.1 mttt -99.62 134.57 42.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.019 -1.051 . . . . 0.0 108.958 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 45' ' ' LYS . 34.7 m -140.51 -177.61 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.957 -1.089 . . . . 0.0 110.255 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -128.97 91.65 3.25 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.451 ' OE1' ' CG2' ' A' ' 74' ' ' THR . 2.4 tp-100 -55.06 105.08 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.62 -0.675 . . . . 0.0 110.71 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.669 ' C ' HD11 ' A' ' 62' ' ' ILE . 11.4 m-85 -96.45 129.04 43.9 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.508 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 40.0 m-20 -111.17 133.41 53.55 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.738 -1.226 . . . . 0.0 109.771 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.575 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 7.8 mm100 78.29 61.91 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.648 -0.657 . . . . 0.0 109.994 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.704 HD12 ' N ' ' A' ' 62' ' ' ILE . 4.4 mp -119.45 126.55 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.349 -0.844 . . . . 0.0 108.749 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.865 HD13 ' O ' ' A' ' 63' ' ' LEU . 3.1 tm? -77.87 94.47 4.55 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.149 0.976 . . . . 0.0 111.613 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.878 HG12 HD12 ' A' ' 66' ' ' ILE . 3.2 tt -98.02 119.79 46.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.407 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -91.11 125.3 35.85 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.827 -1.17 . . . . 0.0 108.804 -179.876 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.878 HD12 HG12 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -121.61 135.37 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.103 -0.998 . . . . 0.0 109.748 -179.314 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 66' ' ' ILE . 59.5 m 36.93 38.23 0.08 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.088 0.47 . . . . 0.0 110.578 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.34 47.64 8.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.707 ' CB ' HG22 ' A' ' 93' ' ' ILE . 73.6 m-70 -141.18 123.28 15.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.346 -1.091 . . . . 0.0 109.353 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.44 ' CG ' HD21 ' A' ' 63' ' ' LEU . 6.9 tttt -77.76 122.09 24.92 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.223 -0.923 . . . . 0.0 108.558 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.43 124.27 13.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.033 -1.042 . . . . 0.0 110.818 -178.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.575 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -102.65 120.15 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.232 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.522 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -144.15 -165.43 10.94 Favored Glycine 0 C--N 1.289 -2.06 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.872 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.487 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 38.0 m -97.43 114.72 26.6 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.503 -0.998 . . . . 0.0 110.305 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.037 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -106.43 118.89 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 C-N-CA 120.216 -0.593 . . . . 0.0 110.159 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.557 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.4 mp -89.44 126.24 35.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.103 -0.998 . . . . 0.0 109.177 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.626 HG11 ' HG2' ' A' ' 36' ' ' MET . 1.7 t -108.5 120.58 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.6 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.08 -169.32 20.8 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.536 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -80.8 39.86 0.91 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.605 2.203 . . . . 0.0 110.886 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.756 HG22 ' HA ' ' A' ' 34' ' ' GLU . 15.1 t -82.39 139.96 44.95 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 82' ' ' VAL . 34.5 Cg_endo -78.16 14.57 1.52 Allowed 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.222 1.948 . . . . 0.0 111.084 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.533 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.23 165.0 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 120.96 -1.088 . . . . 0.0 109.778 -179.408 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.616 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.75 145.92 28.47 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 175.979 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.681 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.3 mm -129.92 129.99 66.14 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 O-C-N 120.047 -1.658 . . . . 0.0 111.743 -177.101 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.608 HD12 HG23 ' A' ' 31' ' ' THR . 0.8 OUTLIER -104.95 96.39 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.834 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -82.29 -169.34 43.38 Favored Glycine 0 N--CA 1.492 2.376 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.481 -178.653 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HE ' HG23 ' A' ' 26' ' ' THR . 0.1 OUTLIER -62.43 -30.43 71.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.581 -0.953 . . . . 0.0 109.789 -179.81 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.6 p-10 -50.51 -28.64 8.83 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.986 -1.071 . . . . 0.0 109.782 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.0 mm? -110.11 -27.87 8.95 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.011 -1.056 . . . . 0.0 110.652 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.537 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 33.9 mt -65.49 -13.57 59.14 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.739 -1.226 . . . . 0.0 109.322 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.4 p -96.69 -21.3 17.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.046 -1.034 . . . . 0.0 109.254 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.48 ' HG3' ' HA ' ' A' ' 89' ' ' LEU . 6.6 mt-30 -74.92 -40.26 60.96 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.176 -0.953 . . . . 0.0 108.521 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.889 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -79.59 1.11 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 178.603 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.66 59.48 8.14 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -87.86 156.43 19.39 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.301 -1.117 . . . . 0.0 109.914 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.767 HG22 ' CG2' ' B' ' 4' ' ' THR . 2.2 p -138.86 129.27 25.78 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.236 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -95.52 90.38 5.73 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 12.1 m-20 -89.52 125.77 35.33 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.213 -0.929 . . . . 0.0 109.939 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.711 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.952 -1.023 . . . . 0.0 109.022 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.5 Cg_endo . . . . . 0 N--CA 1.497 1.708 0 N-CA-C 110.14 -0.754 . . . . 0.0 110.14 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -84.56 114.67 22.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.78 115.07 46.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.956 -1.09 . . . . 0.0 111.104 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.767 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.46 32.51 1.48 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.322 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.526 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.7 mt -85.55 49.05 1.68 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.598 -0.689 . . . . 0.0 109.925 -179.047 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.526 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.8 m95 17.84 52.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.229 0.537 . . . . 0.0 112.174 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' B' ' 5' ' ' LEU . 8.5 mt-30 -154.95 171.5 19.61 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.221 -0.924 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.405 ' HA ' ' HD3' ' B' ' 9' ' ' PRO . 4.7 mtt180 -63.87 144.19 98.06 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 120.99 -1.069 . . . . 0.0 109.492 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.447 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -80.15 54.9 5.42 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.645 2.23 . . . . 0.0 110.904 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.954 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.1 mt -80.62 135.23 36.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.988 -1.07 . . . . 0.0 108.89 179.489 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.464 HG22 HG23 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -134.88 141.82 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.181 -0.95 . . . . 0.0 109.604 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.826 HG22 HD22 ' B' ' 19' ' ' LEU . 10.1 m -70.17 100.53 1.68 Allowed 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 178.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.789 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -95.12 143.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.404 -0.81 . . . . 0.0 110.055 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.6 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.0 OUTLIER -98.95 107.78 20.3 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 178.905 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.68 HG12 HD12 ' B' ' 13' ' ' ILE . 10.2 mm -113.83 115.45 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 120.756 -1.215 . . . . 0.0 110.865 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.491 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.15 9.21 56.79 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.44 -10.05 42.23 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.429 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 1.5 mp0 -89.86 -173.29 3.84 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.264 -1.139 . . . . 0.0 109.063 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.826 HD22 HG22 ' B' ' 12' ' ' THR . 18.0 mt -149.13 121.86 8.66 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.889 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.488 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 4.9 mmtt -141.83 172.55 12.53 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.954 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.9 OUTLIER -79.65 155.3 28.13 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.227 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.58 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -135.76 113.02 10.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 1.055 HD21 ' O ' ' A' ' 27' ' ' GLY . 3.3 tp -84.15 104.01 13.85 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.447 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 16.3 mt -52.45 103.9 0.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.91 ' HB3' HG23 ' B' ' 84' ' ' ILE . 19.9 t0 -101.16 77.96 1.86 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.37 -0.831 . . . . 0.0 110.174 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.782 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.02 -14.46 9.58 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.079 -1.013 . . . . 0.0 108.962 178.95 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -70.8 -35.46 66.14 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.3 170.86 14.16 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.938 -1.33 . . . . 0.0 110.234 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -100.54 -18.8 16.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.291 -0.881 . . . . 0.0 110.796 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.609 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -132.92 -170.54 2.47 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.599 -1.313 . . . . 0.0 110.625 -179.059 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.679 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.1 m -106.07 91.83 3.89 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.938 -1.102 . . . . 0.0 110.558 -178.769 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.953 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -81.01 154.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.717 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.953 HD12 ' O ' ' B' ' 32' ' ' VAL . 1.3 mp -148.91 133.62 17.85 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.919 -1.113 . . . . 0.0 110.667 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.559 ' N ' HG22 ' B' ' 80' ' ' THR . 3.9 mt-10 -43.5 166.69 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.468 -0.77 . . . . 0.0 109.284 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.0 OUTLIER -67.9 115.1 7.04 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.407 -0.808 . . . . 0.0 109.25 179.797 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.586 ' CE ' ' CG2' ' B' ' 15' ' ' ILE . 6.7 ptm -139.46 -166.8 2.13 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.4 t -95.34 115.35 27.31 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.262 -0.899 . . . . 0.0 109.93 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.565 HD12 ' HD2' ' B' ' 39' ' ' PRO . 26.5 tp -144.42 105.0 4.67 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.565 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.5 Cg_endo -76.41 146.0 27.35 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.398 2.065 . . . . 0.0 110.848 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 136.96 145.24 4.94 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -63.95 117.94 7.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.98 -1.306 . . . . 0.0 108.501 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' TRP . . . . . . . . . . . . . 48.9 p-90 -110.95 175.89 5.24 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 110.31 -178.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.0 mmtt -126.03 137.03 29.34 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -76.56 129.14 10.75 Favored 'Trans proline' 0 C--N 1.303 -1.838 0 C-N-CA 121.799 1.666 . . . . 0.0 110.812 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.859 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -161.62 137.66 7.95 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.062 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.495 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 25.3 mtp -102.0 137.88 39.7 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.832 -1.168 . . . . 0.0 109.332 -179.225 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.977 HD12 HG21 ' A' ' 50' ' ' ILE . 2.1 pt -89.72 164.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.628 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -138.23 108.22 0.61 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.61 -116.89 1.4 Allowed Glycine 0 N--CA 1.484 1.881 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.357 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.843 HG21 ' CD1' ' A' ' 47' ' ' ILE . 14.3 mt -85.79 122.79 38.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.6 -0.941 . . . . 0.0 112.019 -178.08 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 99.02 -52.8 1.08 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.437 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.45 -153.91 18.87 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.628 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.4 m-85 -113.54 135.81 53.49 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.494 -1.003 . . . . 0.0 109.941 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.645 HD11 HD11 ' B' ' 47' ' ' ILE . 1.8 pt -104.31 179.49 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.564 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -108.45 130.12 55.25 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 109.164 179.574 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.859 HG22 ' O ' ' B' ' 45' ' ' LYS . 3.7 m -134.0 169.61 21.38 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.947 -1.096 . . . . 0.0 110.175 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.459 ' HD3' ' HB ' ' B' ' 77' ' ' VAL . 8.9 mtp180 -120.26 87.78 2.81 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.517 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 13.0 tt0 -48.42 99.28 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.525 -0.734 . . . . 0.0 110.561 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.8 ' O ' HG23 ' B' ' 74' ' ' THR . 5.2 m-85 -88.78 136.96 32.73 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 177.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 7.1 m-20 -114.86 133.37 56.02 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.571 -1.331 . . . . 0.0 110.882 -178.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.597 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 3.9 mp0 71.49 63.77 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.614 0.721 . . . . 0.0 109.849 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.455 HD12 HD21 ' B' ' 38' ' ' LEU . 9.1 mm -111.46 111.6 36.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.896 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.1 tm? -65.39 85.71 0.07 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.445 -0.784 . . . . 0.0 110.266 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.734 HD13 HD11 ' B' ' 66' ' ' ILE . 3.8 tt -89.11 125.28 42.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 33.1 tt0 -89.2 109.01 19.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.126 -0.984 . . . . 0.0 109.506 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.79 122.47 57.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.282 -0.886 . . . . 0.0 108.753 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.83 54.56 9.63 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.489 -0.757 . . . . 0.0 110.631 179.026 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.15 20.51 28.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -115.57 127.53 55.31 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.996 -1.296 . . . . 0.0 109.183 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.454 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -71.7 131.28 42.91 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.073 -1.017 . . . . 0.0 109.106 179.813 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.688 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -150.69 146.6 26.57 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.632 -0.667 . . . . 0.0 109.243 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.597 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -114.25 156.71 15.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.432 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.968 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -179.3 173.37 45.38 Favored Glycine 0 N--CA 1.485 1.944 0 C-N-CA 118.632 -1.747 . . . . 0.0 111.055 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.8 HG23 ' O ' ' B' ' 59' ' ' TYR . 88.2 m -89.97 112.79 24.3 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.5 -1.0 . . . . 0.0 109.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.94 112.7 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.897 179.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.616 ' HB2' HG23 ' B' ' 32' ' ' VAL . 1.9 mp -81.82 105.73 13.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.533 -0.729 . . . . 0.0 109.061 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.459 ' HB ' ' HD3' ' B' ' 57' ' ' ARG . 2.9 t -88.1 114.1 26.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 O-C-N 120.514 -1.366 . . . . 0.0 109.742 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -151.4 -170.42 18.23 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.564 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.3 Cg_endo -79.57 41.1 1.04 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 C-N-CA 122.434 2.089 . . . . 0.0 111.308 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.7 OUTLIER -85.82 137.73 35.68 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 178.374 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.601 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.5 21.52 0.69 Allowed 'Trans proline' 0 C--N 1.301 -1.921 0 C-N-CA 122.32 2.013 . . . . 0.0 112.13 -178.317 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -162.68 151.72 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.457 -1.402 . . . . 0.0 111.097 -179.735 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.58 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -92.4 87.36 5.98 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 176.982 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.91 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.1 mt -84.71 123.62 39.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.896 0.855 . . . . 0.0 112.914 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.545 ' CG1' ' HB1' ' B' ' 22' ' ' ALA . 3.5 mm -95.8 96.42 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.512 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.5 -161.07 18.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.108 -177.434 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 7' ' ' GLN . 1.4 mtm105 -64.88 -31.01 72.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.893 -0.769 . . . . 0.0 110.65 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.014 ' ND2' HD23 ' B' ' 89' ' ' LEU . 13.8 p-10 -54.8 -26.88 37.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.737 -1.227 . . . . 0.0 110.211 -179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.014 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -108.83 -31.39 7.71 Favored 'General case' 0 N--CA 1.484 1.258 0 O-C-N 120.766 -1.209 . . . . 0.0 110.091 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.782 HD13 HG23 ' B' ' 26' ' ' THR . 81.9 mt -62.42 -31.1 71.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 57.4 p -79.09 -21.69 46.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.41 -0.806 . . . . 0.0 109.457 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -67.55 -40.15 84.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -87.92 -7.55 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.72 64.95 2.82 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.711 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -90.29 142.36 27.81 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.427 -1.043 . . . . 0.0 111.011 -178.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.609 HG22 ' CG2' ' A' ' 4' ' ' THR . 8.3 p -130.35 130.61 44.64 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' A' ' 97' ' ' LEU . 3.9 mp -94.36 96.88 9.82 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.158 -0.964 . . . . 0.0 109.903 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.7 m-20 -103.22 124.59 48.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.068 -1.02 . . . . 0.0 109.129 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.889 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.437 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.605 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.9 Cg_exo . . . . . 0 N--CA 1.494 1.549 0 N-CA-C 110.669 -0.55 . . . . 0.0 110.669 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -84.67 108.2 17.27 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 177.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 5' ' ' LEU . 16.7 t -102.95 121.25 53.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.064 -1.022 . . . . 0.0 109.484 -178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.52 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.7 OUTLIER -73.09 -4.86 35.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.351 -178.841 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.716 ' O ' HG23 ' B' ' 91' ' ' THR . 5.5 mt 66.24 45.15 2.34 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.192 -0.942 . . . . 0.0 110.082 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.529 ' HA ' HG21 ' B' ' 91' ' ' THR . 1.4 m95 -65.84 -20.65 66.32 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.032 -1.042 . . . . 0.0 110.511 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.575 ' O ' ' CD ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -166.35 -99.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.956 -1.09 . . . . 0.0 110.092 179.821 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -113.49 140.3 24.33 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.774 -1.204 . . . . 0.0 109.565 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.576 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.7 Cg_endo -80.46 53.79 4.93 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.254 1.969 . . . . 0.0 109.693 177.626 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.556 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 1.3 mt -79.51 134.43 36.51 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.852 -1.155 . . . . 0.0 110.2 -178.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.456 HG21 HG23 ' A' ' 66' ' ' ILE . 1.6 m -150.99 163.71 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.667 -0.646 . . . . 0.0 109.317 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.812 ' CG2' HD22 ' A' ' 19' ' ' LEU . 3.5 m -86.56 119.07 26.42 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.617 HG22 HG13 ' A' ' 66' ' ' ILE . 18.8 pt -110.49 137.49 42.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.335 -0.853 . . . . 0.0 109.709 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 1.1 ttpp -106.96 107.7 18.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.125 -0.984 . . . . 0.0 109.299 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.939 HG23 ' CG2' ' A' ' 62' ' ' ILE . 5.1 mt -113.26 131.36 65.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.962 . . . . 0.0 109.201 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.41 -88.57 0.34 Allowed Glycine 0 N--CA 1.485 1.924 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -178.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 23.9 0.32 Allowed Glycine 0 C--N 1.293 -1.829 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 29.2 mt-30 -118.25 177.99 4.6 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.64 -0.918 . . . . 0.0 109.295 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.812 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.2 mt -143.7 119.08 10.25 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.692 0.758 . . . . 0.0 110.001 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -133.62 172.53 12.62 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.556 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 21.0 mt-10 -77.58 166.35 23.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.893 -1.129 . . . . 0.0 108.143 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.623 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -147.66 132.43 17.96 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.798 -1.189 . . . . 0.0 110.405 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.603 HD21 ' O ' ' B' ' 27' ' ' GLY . 40.7 tp -104.84 90.17 3.39 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.709 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.67 HD23 ' HB ' ' A' ' 85' ' ' ILE . 38.2 mt -46.86 107.23 0.1 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.852 -1.155 . . . . 0.0 108.253 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.608 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.4 t0 -112.27 89.67 3.13 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.346 -0.846 . . . . 0.0 109.852 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.986 HG23 HD13 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -61.8 -21.19 64.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.072 -1.017 . . . . 0.0 108.422 179.325 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.475 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -60.45 -38.21 94.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.47 160.62 18.21 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.069 -1.254 . . . . 0.0 109.566 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -100.25 -6.81 25.42 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.459 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.567 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.56 179.29 6.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.169 -0.957 . . . . 0.0 110.081 -179.489 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.718 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 5.9 m -106.11 96.01 6.18 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.224 -0.923 . . . . 0.0 109.309 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.985 HG13 HG21 ' A' ' 80' ' ' THR . 1.2 t -87.46 105.45 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.126 0 O-C-N 121.21 -0.931 . . . . 0.0 110.055 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.784 HD13 HG13 ' A' ' 75' ' ' VAL . 1.5 mp -100.17 133.4 44.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.315 -0.866 . . . . 0.0 112.14 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.706 ' HA ' HG23 ' A' ' 80' ' ' THR . 11.8 pt-20 -42.41 153.34 0.07 Allowed 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 177.477 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.913 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.4 mt-10 -53.17 131.32 36.75 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 120.934 -1.104 . . . . 0.0 109.614 -179.417 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.44 ' SD ' ' HG ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -146.17 175.64 10.34 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.06 179.896 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.409 ' O ' ' SD ' ' A' ' 36' ' ' MET . 16.5 t -86.45 107.31 18.0 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.291 -0.881 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.936 HD12 HG21 ' A' ' 77' ' ' VAL . 20.9 mt -121.12 110.79 34.31 Favored Pre-proline 0 N--CA 1.488 1.436 0 O-C-N 121.291 -0.88 . . . . 0.0 109.213 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -78.84 116.96 3.83 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.806 2.337 . . . . 0.0 110.659 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 151.82 -168.53 31.17 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.3 mmt180 -92.65 157.09 16.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.556 -0.967 . . . . 0.0 108.891 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 59.9 p-90 -160.01 172.91 16.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.179 -0.951 . . . . 0.0 109.843 -179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.2 mttt -136.37 160.23 67.66 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.75 141.19 16.99 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.111 1.874 . . . . 0.0 110.914 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.01 171.38 15.36 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.07 132.88 15.0 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.883 -1.135 . . . . 0.0 110.074 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.725 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -117.31 146.59 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.174 -0.954 . . . . 0.0 108.895 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.601 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.9 124.22 5.95 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.47 -123.73 1.78 Allowed Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.031 -1.557 . . . . 0.0 111.495 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.499 ' O ' ' O ' ' B' ' 50' ' ' ILE . 39.0 mt -84.55 131.49 33.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 113.663 0.986 . . . . 0.0 113.663 -176.752 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.82 -17.25 9.32 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 177.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.47 -158.35 28.16 Favored Glycine 0 N--CA 1.491 2.351 0 O-C-N 120.603 -1.527 . . . . 0.0 110.502 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.601 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.8 m-85 -116.45 155.6 28.28 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.599 -0.942 . . . . 0.0 109.409 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.776 HD13 HG23 ' B' ' 50' ' ' ILE . 13.0 pt -131.64 146.26 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.217 -0.927 . . . . 0.0 108.684 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 7.8 mttp -90.19 154.19 19.93 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.456 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.0 m -149.05 178.93 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.067 -1.021 . . . . 0.0 109.567 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.427 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 9.2 mmt180 -122.35 104.59 9.52 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.408 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 1.7 tt0 -60.67 99.57 0.09 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.275 -0.891 . . . . 0.0 110.606 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.593 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.2 m-85 -95.1 104.67 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 9.3 m-20 -88.84 129.32 35.61 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.029 -1.045 . . . . 0.0 111.173 -178.45 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.566 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.5 OUTLIER 82.01 60.33 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.332 0.587 . . . . 0.0 111.31 178.466 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.939 ' CG2' HG23 ' A' ' 15' ' ' ILE . 8.6 mm -115.32 120.86 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.622 HD22 ' C ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -71.32 95.27 1.29 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.017 -1.052 . . . . 0.0 111.273 -177.853 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -98.08 115.98 39.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 178.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.4 tt0 -89.34 105.05 17.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.85 -1.156 . . . . 0.0 108.883 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.75 HD11 HD13 ' A' ' 64' ' ' ILE . 1.7 mp -104.31 120.74 55.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.477 -0.764 . . . . 0.0 109.816 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.58 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.2 m 54.66 59.16 4.28 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.807 -0.558 . . . . 0.0 110.495 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 50.29 33.5 23.79 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 21.9 m-70 -131.14 102.56 6.06 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.193 -1.18 . . . . 0.0 108.813 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.599 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.8 mptt -51.46 140.09 18.49 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -160.88 99.72 1.24 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.14 -0.975 . . . . 0.0 110.052 -179.258 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.566 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -78.81 157.38 4.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 72' ' ' ILE . . . -179.46 -166.66 35.58 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.221 -1.942 . . . . 0.0 112.21 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.455 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 32.5 m -98.55 108.3 20.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.573 -0.957 . . . . 0.0 110.507 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.784 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -102.53 105.61 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.646 -0.658 . . . . 0.0 110.258 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.567 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 4.8 mp -78.48 109.78 12.97 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.936 HG21 HD12 ' A' ' 38' ' ' LEU . 2.3 t -93.12 114.5 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.444 -0.785 . . . . 0.0 110.328 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -143.66 -163.95 10.11 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.45 43.3 1.5 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.559 2.173 . . . . 0.0 110.274 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.985 HG21 HG13 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -88.6 134.06 34.87 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.438 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.5 18.54 0.94 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.559 2.173 . . . . 0.0 111.975 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.514 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.0 161.33 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.88 -1.138 . . . . 0.0 109.629 179.716 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.623 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -95.24 134.66 37.75 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.645 -2.354 . . . . 0.0 104.645 175.946 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.739 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.2 mm -124.37 121.83 62.62 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 120.538 -1.352 . . . . 0.0 110.189 -177.318 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.868 ' N ' HD13 ' A' ' 85' ' ' ILE . 1.0 OUTLIER -98.04 87.65 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.171 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.15 -163.57 22.45 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 120.144 -1.027 . . . . 0.0 110.588 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.571 ' NH1' ' HD3' ' B' ' 9' ' ' PRO . 13.8 mmt-85 -57.63 -39.31 76.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.747 -0.855 . . . . 0.0 110.892 -178.781 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.045 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -44.47 -31.12 1.0 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.996 -1.065 . . . . 0.0 109.343 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.045 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.4 mm? -105.09 -27.46 11.61 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.207 -0.933 . . . . 0.0 109.884 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.986 HD13 HG23 ' A' ' 26' ' ' THR . 27.0 mt -70.33 -8.7 52.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.035 -1.041 . . . . 0.0 108.858 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.22 -20.25 20.62 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -86.46 -40.09 15.67 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.826 HD11 HD23 ' A' ' 90' ' ' LEU . 1.9 pt -82.62 -7.63 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.381 -0.824 . . . . 0.0 109.138 179.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.98 34.25 58.94 Favored Glycine 0 N--CA 1.5 2.903 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.187 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.607 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -70.04 130.14 41.34 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.04 -1.27 . . . . 0.0 110.335 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.533 HG22 ' CG2' ' B' ' 4' ' ' THR . 82.2 p -127.88 130.05 47.9 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.924 -1.11 . . . . 0.0 109.098 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -88.22 97.52 11.06 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.162 -0.962 . . . . 0.0 109.581 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.515 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 6.3 m-20 -107.27 123.91 49.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.292 -0.88 . . . . 0.0 109.051 179.334 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.771 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.191 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.664 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.51 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 0.2 OUTLIER -83.57 146.41 28.33 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 177.823 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.82 HG13 HD23 ' B' ' 5' ' ' LEU . 20.9 t -143.59 122.98 8.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 117.812 -1.555 . . . . 0.0 111.244 -178.032 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.541 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.1 OUTLIER -117.13 20.89 13.53 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 177.165 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.82 HD23 HG13 ' B' ' 3' ' ' VAL . 1.3 mm? -34.68 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.682 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.541 ' N ' ' O ' ' B' ' 4' ' ' THR . 10.5 m95 -50.94 -19.98 1.19 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.402 ' N ' ' C ' ' B' ' 5' ' ' LEU . 12.9 mm100 -108.57 -124.06 0.25 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.301 -0.874 . . . . 0.0 108.831 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 34.8 mtt180 -110.56 129.99 23.37 Favored Pre-proline 0 N--CA 1.496 1.869 0 O-C-N 120.396 -1.44 . . . . 0.0 110.407 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.571 ' HD3' ' NH1' ' A' ' 87' ' ' ARG . 37.6 Cg_endo -79.16 82.78 2.42 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.364 2.042 . . . . 0.0 109.83 178.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.642 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.7 mt -90.91 140.22 30.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.016 -1.052 . . . . 0.0 109.992 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.537 HG23 ' N ' ' B' ' 12' ' ' THR . 0.6 OUTLIER -143.37 168.28 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.765 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.537 ' N ' HG23 ' B' ' 11' ' ' VAL . 17.8 m -99.91 109.18 21.56 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.924 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.6 pt -91.35 158.03 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.138 -0.976 . . . . 0.0 110.064 -178.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.9 tttt -121.03 96.97 5.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.412 -0.805 . . . . 0.0 109.064 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.804 HG23 ' CG2' ' B' ' 62' ' ' ILE . 20.1 mt -113.3 129.44 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 O-C-N 121.337 -0.852 . . . . 0.0 109.617 -179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.75 50.13 62.41 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 54.8 24.43 33.39 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.3 OUTLIER -119.94 174.58 6.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.221 -1.164 . . . . 0.0 108.688 179.288 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.924 HD23 ' O ' ' B' ' 13' ' ' ILE . 29.1 mt -148.52 126.05 11.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.021 -1.049 . . . . 0.0 110.843 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.449 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.1 mmmt -140.6 -177.37 5.02 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.693 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.642 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.6 OUTLIER -80.2 176.02 10.12 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.946 -1.096 . . . . 0.0 108.671 179.415 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -162.62 111.91 1.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.854 -1.154 . . . . 0.0 111.346 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' B' ' 25' ' ' ASP . 9.0 tp -89.05 99.68 12.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.539 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.2 mt -46.79 96.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.921 -1.112 . . . . 0.0 108.093 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.582 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 65.1 t0 -105.49 84.84 2.15 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.292 -0.88 . . . . 0.0 110.861 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.562 ' CG2' ' HD2' ' B' ' 87' ' ' ARG . 49.4 m -63.14 -15.96 58.47 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 108.945 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.603 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -67.86 -45.81 71.68 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 133.62 46.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -1.111 . . . . 0.0 108.589 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.5 m-20 -71.75 -13.28 61.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.368 -0.833 . . . . 0.0 110.692 -178.629 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.777 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -139.03 -174.82 3.95 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.768 -1.207 . . . . 0.0 110.583 -179.377 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.654 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.4 m -104.17 97.86 7.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.063 -1.023 . . . . 0.0 110.499 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.609 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -89.59 109.67 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.324 0 O-C-N 121.198 -0.938 . . . . 0.0 109.918 -179.897 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.902 HD21 HD11 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -99.26 130.92 45.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.117 -0.99 . . . . 0.0 111.311 -179.605 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.55 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 34.1 tt0 -40.59 163.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.439 -0.788 . . . . 0.0 109.292 178.177 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.646 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.1 mt-10 -53.01 139.27 28.42 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 110.917 -178.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.51 ' HG3' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -173.82 159.66 3.48 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.51 ' N ' ' HG3' ' B' ' 36' ' ' MET . 18.2 t -79.52 142.07 36.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.091 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 1.013 HD12 HG21 ' B' ' 77' ' ' VAL . 10.6 mt -139.16 166.0 27.87 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.449 -0.782 . . . . 0.0 108.999 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.5 ' HD3' HD23 ' B' ' 38' ' ' LEU . 34.5 Cg_endo -76.5 69.59 6.6 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.816 2.344 . . . . 0.0 111.996 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.68 -159.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.671 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.472 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 67.1 50.52 1.01 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.512 -0.993 . . . . 0.0 109.03 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.587 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 46.7 p-90 -135.15 -178.38 5.07 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.907 0.86 . . . . 0.0 110.411 -179.461 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.44 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 12.4 mmtm -150.56 158.76 35.48 Favored Pre-proline 0 C--N 1.302 -1.487 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.63 139.87 18.38 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.912 1.742 . . . . 0.0 110.012 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.756 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.4 OUTLIER -151.07 152.45 33.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.374 -0.829 . . . . 0.0 109.456 -179.433 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -127.35 111.51 13.97 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.844 -1.16 . . . . 0.0 108.828 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 54' ' ' ILE . 24.4 pt -95.1 134.35 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 110.018 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.594 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.59 104.51 1.11 Allowed Glycine 0 N--CA 1.489 2.173 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -124.51 3.0 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.171 -1.49 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.776 HG23 HD13 ' A' ' 54' ' ' ILE . 38.7 mt -86.02 121.77 37.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.832 -0.805 . . . . 0.0 112.627 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.58 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.18 -49.13 0.97 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 177.808 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.97 -159.65 24.15 Favored Glycine 0 N--CA 1.488 2.153 0 O-C-N 120.913 -1.345 . . . . 0.0 110.301 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.594 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 4.9 m-85 -113.91 155.04 26.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.646 -0.914 . . . . 0.0 109.644 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 47' ' ' ILE . 1.4 pt -138.95 176.52 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.309 -0.869 . . . . 0.0 108.849 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 8.9 mttt -116.18 151.82 34.95 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.498 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB3' ' B' ' 45' ' ' LYS . 5.6 m -146.62 -171.11 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.791 -1.193 . . . . 0.0 109.715 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' B' ' 59' ' ' TYR . 71.0 mtm-85 -133.65 85.07 2.17 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -44.36 93.69 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.692 -0.63 . . . . 0.0 110.648 -178.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.587 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 13.8 m-85 -88.92 125.61 35.03 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 178.174 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.511 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 14.8 m-20 -105.53 136.22 45.5 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.84 -1.163 . . . . 0.0 110.786 -178.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.623 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.8 mp0 70.81 65.44 0.18 Allowed 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.431 0.634 . . . . 0.0 111.106 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.804 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.76 111.71 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 1.059 HD21 ' CG ' ' B' ' 70' ' ' LYS . 12.9 tp -64.85 91.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.969 -1.082 . . . . 0.0 111.097 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.8 ' CG2' HD11 ' B' ' 89' ' ' LEU . 5.4 tt -89.42 119.14 36.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.486 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.6 tt0 -88.54 120.88 30.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 109.119 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.655 HG13 HG22 ' B' ' 13' ' ' ILE . 1.3 mp -120.94 128.0 76.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.397 -0.814 . . . . 0.0 109.217 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 94.5 m 52.97 24.48 3.42 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.507 -0.746 . . . . 0.0 109.798 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 81.79 43.62 8.22 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -140.28 99.53 3.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -1.166 . . . . 0.0 109.418 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 1.059 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.24 128.56 19.67 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.656 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -148.23 101.98 3.31 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.301 -0.875 . . . . 0.0 110.505 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.623 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -77.31 142.83 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.773 -1.205 . . . . 0.0 108.648 178.992 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.523 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -164.94 -155.75 8.65 Favored Glycine 0 N--CA 1.494 2.566 0 C-N-CA 119.723 -1.227 . . . . 0.0 111.062 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.484 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.3 m -111.96 113.76 26.26 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.214 -1.168 . . . . 0.0 109.624 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.676 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -107.91 108.42 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.355 -0.841 . . . . 0.0 111.383 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.788 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.9 mp -79.92 108.79 13.77 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.127 -0.983 . . . . 0.0 108.617 178.28 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 1.013 HG21 HD12 ' B' ' 38' ' ' LEU . 2.1 t -92.24 117.97 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.988 -1.07 . . . . 0.0 109.659 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.721 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -146.99 -171.96 16.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.306 -1.918 . . . . 0.0 108.306 179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.8 Cg_endo -81.03 44.26 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.259 1.973 . . . . 0.0 110.514 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.609 HG21 HG13 ' B' ' 32' ' ' VAL . 5.3 t -84.69 143.75 41.38 Favored Pre-proline 0 N--CA 1.486 1.359 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.9 Cg_endo -76.65 14.01 1.31 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.583 2.189 . . . . 0.0 111.674 -178.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.03 164.35 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.83 -1.169 . . . . 0.0 110.149 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.566 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.4 m120 -94.6 146.95 23.77 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 174.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.654 ' O ' ' HA ' ' B' ' 31' ' ' THR . 3.6 mm -133.81 123.91 46.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 120.024 -1.673 . . . . 0.0 110.713 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.504 ' HB ' ' HA ' ' B' ' 24' ' ' LEU . 5.3 mm -98.5 93.45 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.25 179.49 51.74 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 -178.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.588 ' HG2' ' HB3' ' A' ' 5' ' ' LEU . 0.8 OUTLIER -58.83 -23.11 60.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.37 -1.077 . . . . 0.0 109.627 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.739 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.9 p-10 -53.77 -37.01 63.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.694 -1.254 . . . . 0.0 108.924 178.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.8 HD11 ' CG2' ' B' ' 64' ' ' ILE . 0.4 OUTLIER -96.92 -35.26 10.94 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.619 -0.676 . . . . 0.0 110.695 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.51 ' O ' HG13 ' B' ' 93' ' ' ILE . 71.7 mt -56.36 -33.87 66.11 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.038 -1.039 . . . . 0.0 109.487 -179.327 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.66 -21.84 60.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 110.899 -179.109 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -80.54 -31.47 36.98 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.229 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.771 HD12 ' CB ' ' A' ' 99' ' ' PHE . 3.1 pt -87.11 13.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.4 -0.813 . . . . 0.0 108.932 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 59.76 49.04 82.83 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.527 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -87.92 150.66 23.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.25 -1.147 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.52 HG22 ' HA ' ' A' ' 4' ' ' THR . 57.2 p -146.27 123.07 11.25 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.798 . . . . 0.0 109.135 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' A' ' 97' ' ' LEU . 5.2 mp -85.36 93.54 8.74 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 34.0 m-20 -92.79 119.97 32.69 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 120.703 -1.248 . . . . 0.0 110.067 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.675 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.37 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.462 ' HD3' ' CE1' ' A' ' 69' ' ' HIS . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.66 0 N-CA-C 109.889 -0.85 . . . . 0.0 109.889 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.433 ' CG ' ' OD1' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -83.17 149.66 26.72 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 177.81 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.543 HG13 ' CD2' ' A' ' 5' ' ' LEU . 37.8 t -150.49 116.43 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 C-N-CA 118.436 -1.306 . . . . 0.0 110.661 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.782 ' C ' HD23 ' A' ' 5' ' ' LEU . 1.7 p -122.26 -73.21 0.65 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.782 HD23 ' C ' ' A' ' 4' ' ' THR . 1.8 pt? 30.4 38.28 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 122.124 -0.36 . . . . 0.0 111.071 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' A' ' 5' ' ' LEU . 8.9 m95 19.3 48.96 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 121.258 0.551 . . . . 0.0 111.829 179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.552 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -149.87 -167.81 2.93 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.31 179.421 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.622 ' HB3' HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -84.89 136.77 38.4 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.12 -0.987 . . . . 0.0 109.403 -179.889 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.7 Cg_endo -77.27 71.99 6.12 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.246 1.964 . . . . 0.0 109.717 178.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' CG1' ' A' ' 11' ' ' VAL . 0.4 OUTLIER -79.54 151.17 30.86 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 -179.567 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 1.053 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -150.64 156.47 6.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.244 -0.91 . . . . 0.0 110.027 -179.381 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.694 ' CG2' HD22 ' A' ' 19' ' ' LEU . 22.6 m -86.93 113.37 22.66 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.769 HD11 HD21 ' A' ' 33' ' ' LEU . 43.8 pt -99.7 147.87 6.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.167 -0.958 . . . . 0.0 111.071 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.647 ' CD ' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -109.27 94.9 5.28 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.937 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.836 HD13 HG11 ' A' ' 75' ' ' VAL . 8.6 mt -119.41 130.07 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.104 -0.998 . . . . 0.0 109.67 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.67 37.63 95.01 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.61 18.14 50.91 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -113.84 172.88 6.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.34 -1.094 . . . . 0.0 109.518 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.694 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.1 mt -139.74 122.46 16.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 111.012 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.463 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -141.96 175.32 9.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.963 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 1.3 mt-10 -78.72 178.67 7.69 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.599 -1.313 . . . . 0.0 108.23 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.824 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -156.9 103.99 2.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.14 -0.975 . . . . 0.0 109.635 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.622 HD11 ' HB3' ' A' ' 8' ' ' ARG . 30.5 tp -72.43 92.6 1.46 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.253 -0.904 . . . . 0.0 108.584 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.767 ' CD2' HD21 ' A' ' 90' ' ' LEU . 3.7 mt -43.78 98.43 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' A' ' 84' ' ' ILE . 1.9 t70 -104.89 90.3 3.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.558 -0.714 . . . . 0.0 110.777 -178.026 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.526 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 20.7 m -68.23 -13.53 62.31 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.725 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.99 -41.68 60.79 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.05 162.75 29.1 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -1.171 . . . . 0.0 109.516 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -98.92 -11.15 21.9 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.292 -0.88 . . . . 0.0 110.428 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.551 ' OD2' ' HB ' ' A' ' 74' ' ' THR . 0.1 OUTLIER -139.06 -173.2 3.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.899 -1.126 . . . . 0.0 109.781 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' A' ' 33' ' ' LEU . 66.4 m -106.32 88.52 2.8 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.576 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.19 162.97 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.244 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.01 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.4 OUTLIER -157.7 124.32 4.92 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.9 -179.003 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 35' ' ' GLU . 21.0 pt-20 -41.01 152.83 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.533 -0.729 . . . . 0.0 109.5 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -41.71 148.31 0.16 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.39 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.431 ' HE1' HG22 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -173.29 164.92 4.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.496 -0.753 . . . . 0.0 108.975 179.457 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.7 t -79.8 100.06 7.79 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.056 -1.028 . . . . 0.0 109.77 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 39' ' ' PRO . 13.3 tp -126.29 100.39 29.58 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.248 -0.907 . . . . 0.0 109.34 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.531 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.4 Cg_endo -78.46 165.39 25.32 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.791 2.327 . . . . 0.0 110.815 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.57 -163.12 16.09 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.408 ' NE ' ' H ' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -97.33 139.03 33.9 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.223 -1.163 . . . . 0.0 108.26 179.502 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.569 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 9.7 p-90 -149.33 174.49 12.37 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.031 -1.043 . . . . 0.0 109.996 -179.423 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -138.2 163.47 47.28 Favored Pre-proline 0 C--N 1.299 -1.612 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.104 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.22 141.03 25.53 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.73 1.62 . . . . 0.0 110.189 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.36 167.46 22.12 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.451 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 10.4 ttt -151.38 118.79 6.01 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 54' ' ' ILE . 1.5 pt -102.43 128.51 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 C-N-CA 118.396 -1.322 . . . . 0.0 108.897 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.618 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -117.89 98.01 0.75 Allowed Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.72 -121.06 2.9 Favored Glycine 0 C--N 1.297 -1.616 0 C-N-CA 119.416 -1.374 . . . . 0.0 110.404 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.883 HG21 HD12 ' B' ' 47' ' ' ILE . 74.8 mt -83.87 106.1 13.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.872 -0.781 . . . . 0.0 112.561 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 120.18 -44.62 1.35 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 178.13 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 168.06 -164.37 37.92 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.728 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 7.1 m-85 -110.14 118.02 35.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.602 -0.94 . . . . 0.0 110.18 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 47' ' ' ILE . 32.6 pt -99.16 161.07 3.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.319 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.557 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.39 132.96 48.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.024 -1.048 . . . . 0.0 109.8 -179.406 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' A' ' 78' ' ' GLY . 30.6 m -134.55 178.68 5.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.477 -0.765 . . . . 0.0 109.36 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 28.1 mtt180 -111.31 171.22 7.6 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.409 ' OE1' ' OD1' ' A' ' 60' ' ' ASP . 0.3 OUTLIER -131.5 97.28 4.19 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.673 -1.267 . . . . 0.0 110.859 -179.042 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 83.7 m-85 -97.11 116.32 29.1 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.406 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.522 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -94.01 146.46 23.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.917 -1.114 . . . . 0.0 110.144 -179.05 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.559 ' HA ' HG23 ' A' ' 72' ' ' ILE . 4.1 mm-40 67.77 67.34 0.36 Allowed 'General case' 0 N--CA 1.489 1.516 0 CA-C-O 121.617 0.722 . . . . 0.0 109.705 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.616 ' HB ' HG23 ' A' ' 75' ' ' VAL . 1.9 mm -124.65 108.84 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.769 HD11 ' CG ' ' A' ' 70' ' ' LYS . 4.6 tt -59.81 102.57 0.16 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.311 -0.868 . . . . 0.0 111.175 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 1.009 HD13 HD11 ' A' ' 66' ' ' ILE . 3.7 tt -100.44 119.48 48.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.75 109.88 20.04 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.647 -1.283 . . . . 0.0 108.719 -178.564 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.053 HG23 HG21 ' A' ' 11' ' ' VAL . 2.7 mt -115.78 123.86 71.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.124 -0.985 . . . . 0.0 110.313 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.2 m 56.49 36.02 26.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.675 -0.641 . . . . 0.0 110.367 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.41 28.03 73.46 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.462 ' CE1' ' HD3' ' A' ' 1' ' ' PRO . 46.4 m80 -126.95 110.35 12.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.118 -1.225 . . . . 0.0 109.273 179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.769 ' CG ' HD11 ' A' ' 63' ' ' LEU . 1.5 ttpm? -55.05 130.6 42.43 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.269 -0.895 . . . . 0.0 109.069 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 101.46 3.23 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.372 -0.83 . . . . 0.0 109.935 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.646 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -78.27 146.43 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 178.794 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.659 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -170.45 -177.69 40.74 Favored Glycine 0 N--CA 1.484 1.879 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.51 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.551 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 1.9 m -93.58 111.92 23.7 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.574 -0.957 . . . . 0.0 109.587 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.001 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.97 137.12 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.694 -0.629 . . . . 0.0 109.724 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.4 mp -107.68 136.14 47.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.209 -0.932 . . . . 0.0 108.768 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.492 ' O ' ' HG3' ' A' ' 57' ' ' ARG . 16.7 t -118.38 113.65 42.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.943 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -151.75 -164.04 11.92 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.557 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.31 39.48 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.681 2.254 . . . . 0.0 111.039 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.832 HG21 HG13 ' A' ' 32' ' ' VAL . 2.8 t -86.83 134.84 36.4 Favored Pre-proline 0 N--CA 1.489 1.508 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.1 Cg_endo -78.16 18.79 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.691 2.26 . . . . 0.0 112.028 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 81' ' ' PRO . 0.9 OUTLIER -161.5 158.97 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.597 -1.314 . . . . 0.0 110.341 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 67.7 m-20 -95.11 100.29 12.13 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' A' ' 25' ' ' ASP . 7.2 mm -88.37 128.59 40.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 O-C-N 120.858 -1.151 . . . . 0.0 112.154 -176.531 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.824 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.61 93.79 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.244 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -80.35 -160.99 23.63 Favored Glycine 0 N--CA 1.493 2.494 0 O-C-N 121.176 -0.952 . . . . 0.0 111.042 -177.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.513 ' HB2' ' NH2' ' A' ' 87' ' ' ARG . 7.5 mtp-105 -69.17 -29.67 67.73 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.65 -0.912 . . . . 0.0 109.925 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.943 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -50.17 -24.26 2.69 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.811 -1.181 . . . . 0.0 108.951 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.943 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.1 mm? -112.76 -27.77 8.03 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.236 -0.915 . . . . 0.0 110.313 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.767 HD21 ' CD2' ' A' ' 24' ' ' LEU . 34.7 mt -63.09 -28.15 69.88 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.992 -1.068 . . . . 0.0 108.416 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 69.0 p -79.43 -20.64 47.03 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.136 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -80.86 -36.71 31.05 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.35 -0.844 . . . . 0.0 109.135 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.829 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -86.0 -0.72 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.295 -0.878 . . . . 0.0 109.243 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.68 62.22 5.23 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -97.16 135.88 38.48 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.547 -0.973 . . . . 0.0 110.481 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.719 HG22 ' CG2' ' B' ' 4' ' ' THR . 15.5 p -133.12 128.71 36.71 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.613 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -87.1 109.38 19.39 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.277 -0.89 . . . . 0.0 108.792 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.513 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 62.9 m-20 -105.22 120.79 42.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.81 -1.181 . . . . 0.0 109.196 179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.86 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.595 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.451 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.56 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.332 -0.68 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.523 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tm0? -84.02 145.71 28.36 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.133 -1.803 . . . . 0.0 106.133 177.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.523 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 70.1 t -146.03 122.97 3.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.218 -177.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.719 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.8 OUTLIER -127.04 -61.94 1.14 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.673 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.1 mt 31.86 38.92 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.567 178.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.536 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.9 m95 17.31 51.46 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 CA-C-O 121.159 0.504 . . . . 0.0 111.949 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' B' ' 5' ' ' LEU . 13.1 mt-30 -168.0 -174.95 2.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.341 -0.85 . . . . 0.0 109.592 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.472 ' HG2' ' HD2' ' A' ' 87' ' ' ARG . 17.2 mtm180 -65.44 138.45 96.96 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.032 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.554 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.8 Cg_endo -81.16 62.36 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.36 2.04 . . . . 0.0 109.707 179.104 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 1.052 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -80.84 136.4 36.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.877 -1.139 . . . . 0.0 109.56 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.533 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -130.42 137.91 55.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.286 -0.884 . . . . 0.0 109.191 -179.933 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.714 HG22 HD22 ' B' ' 19' ' ' LEU . 18.0 m -65.66 97.58 0.33 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.941 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.8 pt -88.03 154.62 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.297 -0.877 . . . . 0.0 110.702 -177.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.2 OUTLIER -122.15 105.88 10.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.473 -0.767 . . . . 0.0 109.773 179.505 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.76 HD13 HG11 ' B' ' 75' ' ' VAL . 97.1 mt -121.24 139.92 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 120.852 -1.155 . . . . 0.0 110.889 -179.24 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.81 33.38 6.48 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.76 37.27 51.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.8 mp0 -131.18 175.48 9.07 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 108.39 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.941 HD23 ' O ' ' B' ' 13' ' ' ILE . 15.9 mt -152.0 124.33 8.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.995 -1.066 . . . . 0.0 110.249 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -151.38 174.57 13.18 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 1.052 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -80.34 143.38 33.61 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.895 -1.128 . . . . 0.0 108.836 179.484 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.679 ' N ' HD23 ' B' ' 10' ' ' LEU . . . -127.53 112.79 15.33 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 110.138 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.725 HD21 ' O ' ' A' ' 27' ' ' GLY . 2.4 tp -81.14 102.05 10.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.691 -0.631 . . . . 0.0 109.864 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 20.1 mt -52.74 105.95 0.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.934 -1.104 . . . . 0.0 108.346 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.886 ' CB ' HG23 ' B' ' 84' ' ' ILE . 53.4 t0 -103.1 92.54 4.58 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.216 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.696 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -64.54 -11.5 35.0 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.077 -1.015 . . . . 0.0 108.404 178.437 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -70.09 -43.62 63.77 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.82 164.96 21.28 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.117 -1.225 . . . . 0.0 109.676 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -100.4 -13.88 18.57 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.226 -0.921 . . . . 0.0 110.196 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.644 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -126.75 -165.37 1.45 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.016 -1.052 . . . . 0.0 109.664 -179.806 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.78 HG23 HD12 ' B' ' 85' ' ' ILE . 8.1 m -116.63 85.64 2.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.924 -1.11 . . . . 0.0 110.192 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.934 HG12 ' HB ' ' B' ' 84' ' ' ILE . 0.3 OUTLIER -68.65 154.75 8.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.806 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -154.82 133.31 11.95 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.837 -1.164 . . . . 0.0 111.054 -177.609 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.489 ' HG3' ' O ' ' B' ' 80' ' ' THR . 4.1 tt0 -42.03 148.62 0.18 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.465 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 3.0 mt-10 -44.88 136.99 4.3 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.041 -1.037 . . . . 0.0 110.457 -179.173 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.584 ' SD ' HD22 ' B' ' 38' ' ' LEU . 0.0 OUTLIER -156.75 -167.69 2.45 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.11 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.6 t -112.29 115.75 29.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.756 -1.215 . . . . 0.0 111.457 -178.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.685 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -116.45 170.81 5.39 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.153 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.685 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.4 Cg_endo -76.22 115.77 4.2 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.372 2.048 . . . . 0.0 111.374 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' B' ' 41' ' ' ARG . . . -30.95 122.39 0.14 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' B' ' 40' ' ' GLY . 3.6 mtm180 148.72 43.01 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.633 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 37.3 p-90 -124.73 176.8 6.34 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.343 0.592 . . . . 0.0 109.733 -178.139 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -133.92 130.04 20.38 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.007 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -76.91 140.11 20.12 Favored 'Trans proline' 0 C--N 1.31 -1.45 0 C-N-CA 122.254 1.97 . . . . 0.0 110.317 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -159.41 -164.8 1.43 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.356 -0.84 . . . . 0.0 109.376 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.548 ' HE2' ' HG3' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -141.8 119.21 11.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.985 -179.578 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.883 HD12 HG21 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -90.44 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 178.473 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.467 ' HA2' ' HB3' ' B' ' 53' ' ' PHE . . . -118.41 111.75 2.22 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.81 -125.2 2.35 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.702 HG23 HD13 ' A' ' 54' ' ' ILE . 37.8 mt -80.95 139.12 18.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.777 -0.837 . . . . 0.0 112.664 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.27 5.03 65.54 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.0 -158.94 16.69 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.051 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.601 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -119.21 143.85 47.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.441 -1.035 . . . . 0.0 109.183 -179.549 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.754 HG12 HG23 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -112.71 -175.29 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.977 . . . . 0.0 108.701 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.549 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 12.3 mttt -114.84 138.79 50.36 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.047 -1.033 . . . . 0.0 109.282 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.653 HG13 HD11 ' B' ' 54' ' ' ILE . 3.5 m -139.05 -169.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.553 -1.342 . . . . 0.0 110.73 -179.498 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.496 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 73.8 mtt-85 -143.78 99.88 3.49 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.565 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 6.1 tt0 -66.04 108.13 2.12 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.294 -0.879 . . . . 0.0 110.719 -178.644 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 32.3 m-85 -93.85 128.27 40.03 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 177.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.534 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -106.17 135.97 46.7 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.877 -1.139 . . . . 0.0 110.927 -177.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.594 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.2 OUTLIER 71.98 64.03 0.14 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 179.271 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 4.4 mp -118.17 119.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.717 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.3 tm? -66.29 84.95 0.1 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-O 121.661 0.743 . . . . 0.0 110.604 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.647 HG22 ' O ' ' B' ' 71' ' ' ALA . 2.3 tt -91.89 130.76 40.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 178.272 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.514 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.8 tt0 -87.74 152.6 22.01 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.905 -1.122 . . . . 0.0 108.463 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.593 HG13 HG22 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -150.75 135.11 9.0 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.236 -0.915 . . . . 0.0 108.962 -179.453 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 46.32 24.07 0.26 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.529 -0.732 . . . . 0.0 110.21 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 83.72 39.6 9.47 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 17.0 m80 -141.11 164.77 29.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -1.208 . . . . 0.0 109.074 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.527 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -95.73 139.19 32.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.07 -1.019 . . . . 0.0 108.472 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.647 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.54 104.75 2.58 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.111 -0.993 . . . . 0.0 110.051 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.597 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.4 OUTLIER -86.94 141.64 14.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 178.701 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.56 -164.11 23.69 Favored Glycine 0 N--CA 1.485 1.922 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.495 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.565 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 8.6 m -95.91 105.06 17.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.682 -0.893 . . . . 0.0 109.906 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.806 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -100.71 106.01 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.38 -0.825 . . . . 0.0 109.983 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.644 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 0.4 OUTLIER -78.08 134.4 37.74 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.104 -0.997 . . . . 0.0 108.666 179.104 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 58.2 t -122.58 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.206 -0.934 . . . . 0.0 110.644 -179.153 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.441 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -163.84 -161.27 12.73 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 108.258 -1.937 . . . . 0.0 108.258 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' B' ' 54' ' ' ILE . 36.5 Cg_endo -81.47 40.23 0.96 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.358 2.039 . . . . 0.0 110.244 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' B' ' 32' ' ' VAL . 3.1 t -83.39 133.56 47.09 Favored Pre-proline 0 N--CA 1.487 1.391 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.665 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.3 Cg_endo -75.43 18.05 0.61 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.715 2.276 . . . . 0.0 112.244 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.665 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.9 t -161.27 157.9 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.692 -1.255 . . . . 0.0 110.543 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.593 ' OD1' ' N ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -96.57 90.36 5.32 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 177.252 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.934 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.9 mt -90.63 120.04 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.258 -0.901 . . . . 0.0 112.36 -176.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.78 HD12 HG23 ' B' ' 31' ' ' THR . 0.5 OUTLIER -95.67 93.82 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.82 -157.28 13.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -61.76 -37.22 83.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.623 -0.928 . . . . 0.0 111.887 -178.186 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.956 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -44.67 -40.53 5.96 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.509 -1.37 . . . . 0.0 110.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.956 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.9 OUTLIER -96.73 -18.99 19.28 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.061 -1.024 . . . . 0.0 110.032 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.557 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 63.6 mt -73.8 -5.25 39.67 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.024 -1.048 . . . . 0.0 108.765 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.512 ' HB ' ' CH2' ' A' ' 6' ' ' TRP . 2.6 p -101.32 -21.17 14.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.081 -1.012 . . . . 0.0 109.067 179.589 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.8 mm-40 -74.36 -40.53 62.06 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.183 -0.948 . . . . 0.0 109.006 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.86 HD12 ' CG ' ' A' ' 99' ' ' PHE . 3.3 pt -88.15 -5.97 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.215 -0.928 . . . . 0.0 108.893 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.76 50.43 42.19 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.594 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.45 149.4 35.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.099 -1.236 . . . . 0.0 109.789 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.727 HG22 ' CG2' ' A' ' 4' ' ' THR . 47.6 p -138.48 128.4 25.32 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.696 HD13 HG21 ' B' ' 26' ' ' THR . 0.0 OUTLIER -86.96 111.36 20.76 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.287 -0.883 . . . . 0.0 110.745 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.8 m-20 -115.73 121.21 41.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.3 -0.875 . . . . 0.0 109.609 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.829 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.134 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.417 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.691 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.474 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.5 tt0 -83.16 141.39 31.98 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 105.623 -1.992 . . . . 0.0 105.623 177.035 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 72.9 t -137.95 126.04 30.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 C-N-CA 117.778 -1.569 . . . . 0.0 110.647 -177.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.577 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -120.87 7.35 10.42 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.693 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.3 OUTLIER -34.42 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.953 0.882 . . . . 0.0 109.709 -179.299 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.577 ' N ' ' O ' ' A' ' 4' ' ' THR . 6.9 m95 -41.49 -20.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.434 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.536 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.2 mt-30 -107.49 -155.98 0.57 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.691 -1.255 . . . . 0.0 109.78 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.694 ' HB3' HD13 ' A' ' 23' ' ' LEU . 62.0 mtt180 -76.21 115.79 50.13 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 110.413 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.596 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.6 Cg_endo -81.89 83.38 2.1 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 121.994 1.796 . . . . 0.0 109.019 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 1.01 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -78.52 166.9 22.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.332 -0.855 . . . . 0.0 109.615 -179.033 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.879 HG23 HG23 ' A' ' 13' ' ' ILE . 15.2 m -147.88 131.18 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.108 -0.995 . . . . 0.0 110.558 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.648 HG22 HD22 ' A' ' 19' ' ' LEU . 3.1 m -68.68 103.05 1.63 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.527 -1.358 . . . . 0.0 107.786 178.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.879 HG23 HG23 ' A' ' 11' ' ' VAL . 2.8 pt -102.42 137.34 30.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.244 -0.91 . . . . 0.0 111.207 -178.077 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.946 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -105.0 93.6 4.79 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.625 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.766 HD11 HD12 ' A' ' 64' ' ' ILE . 15.6 mt -104.48 124.35 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.455 -0.778 . . . . 0.0 109.488 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.75 13.0 68.36 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.88 7.72 77.43 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.555 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -105.77 171.72 7.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -1.131 . . . . 0.0 108.521 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.946 HD21 ' HD3' ' A' ' 14' ' ' LYS . 15.1 mt -123.6 130.58 52.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.869 -1.145 . . . . 0.0 110.959 -178.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HE3' ' HB3' ' A' ' 36' ' ' MET . 0.7 OUTLIER -150.41 143.13 24.6 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 1.01 ' HB3' HD23 ' A' ' 10' ' ' LEU . 9.1 mm-40 -78.88 127.46 32.05 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.961 -1.087 . . . . 0.0 109.101 -179.055 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.87 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -108.27 112.47 24.96 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.986 -1.071 . . . . 0.0 112.012 -178.153 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.694 HD13 ' HB3' ' A' ' 8' ' ' ARG . 11.9 tp -72.22 107.39 4.84 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.596 HD12 ' HB2' ' A' ' 9' ' ' PRO . 56.5 mt -46.79 142.97 3.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.864 -1.148 . . . . 0.0 108.294 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.622 ' HB3' HG22 ' A' ' 84' ' ' ILE . 11.4 t0 -156.79 99.59 1.86 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.844 -1.16 . . . . 0.0 110.272 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.405 ' HA ' HH12 ' A' ' 87' ' ' ARG . 10.9 m -76.12 -0.26 21.35 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.149 -0.97 . . . . 0.0 109.399 179.357 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.842 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -89.54 -26.48 25.1 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.616 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -81.39 124.4 29.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.12 -1.224 . . . . 0.0 109.089 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.633 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 42.8 m-20 -61.83 -16.42 49.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.853 . . . . 0.0 110.171 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.639 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 5.0 m-20 -145.16 -170.48 3.44 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.022 -1.071 . . . . 0.0 109.713 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.832 HG22 ' CD1' ' A' ' 33' ' ' LEU . 8.1 m -104.84 86.56 2.49 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 120.804 -1.185 . . . . 0.0 109.818 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.981 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.3 OUTLIER -70.04 163.13 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.265 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.981 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.5 OUTLIER -160.37 128.86 4.75 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.033 -1.042 . . . . 0.0 110.396 -178.01 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.8 tt0 -43.81 165.36 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.505 -0.878 . . . . 0.0 108.848 179.16 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.479 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -48.23 143.4 4.61 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.353 -179.426 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.794 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.5 OUTLIER -155.91 -168.31 2.73 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.464 -0.773 . . . . 0.0 109.025 179.737 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.7 t -122.17 111.15 16.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.847 -1.158 . . . . 0.0 111.196 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.81 HD23 ' CG ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -114.57 179.73 0.74 Allowed Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.714 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.571 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 36.1 Cg_endo -78.6 36.9 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.68 2.253 . . . . 0.0 112.502 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 55.59 33.03 58.76 Favored Glycine 0 N--CA 1.493 2.483 0 O-C-N 121.102 -0.999 . . . . 0.0 111.299 178.524 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.598 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 15.4 mmm180 -113.97 78.15 1.12 Allowed 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.485 -1.009 . . . . 0.0 108.337 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.567 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 59.8 p-90 -148.96 -177.41 5.79 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 120.985 -1.072 . . . . 0.0 111.37 -178.457 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.72 141.61 28.49 Favored Pre-proline 0 N--CA 1.487 1.377 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.47 131.23 13.54 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 C-N-CA 121.936 1.757 . . . . 0.0 111.025 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.559 ' CD ' ' HB2' ' A' ' 58' ' ' GLN . 13.1 ptmt -161.28 -169.8 2.44 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.54 -0.725 . . . . 0.0 109.233 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.486 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 38.4 mtp -151.34 137.98 18.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.36 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.768 HD11 HG21 ' B' ' 50' ' ' ILE . 15.4 pt -95.94 150.0 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 120.987 -1.07 . . . . 0.0 108.491 178.79 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.07 102.37 0.97 Allowed Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.08 -134.74 4.43 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.721 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.732 HG23 HD13 ' B' ' 54' ' ' ILE . 58.3 mt -83.02 122.87 38.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 CA-C-O 121.629 0.728 . . . . 0.0 112.548 -177.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 104.64 -53.77 0.66 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.504 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 178.33 -169.24 40.86 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.585 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.2 m-30 -102.37 135.28 44.26 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.282 . . . . 0.0 109.312 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.489 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.3 pt -101.52 176.1 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.131 -0.981 . . . . 0.0 109.352 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.527 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -105.35 142.02 35.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.241 -0.912 . . . . 0.0 109.323 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.538 HG12 ' HA3' ' A' ' 78' ' ' GLY . 31.1 m -150.93 -179.03 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 110.652 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.491 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -128.02 91.58 3.3 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.141 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.559 ' HB2' ' CD ' ' A' ' 45' ' ' LYS . 17.1 tt0 -51.29 102.98 0.05 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.443 0.639 . . . . 0.0 111.635 -178.44 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.81 ' CG ' HD23 ' A' ' 38' ' ' LEU . 24.8 m-85 -90.63 137.3 32.46 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -119.34 121.51 39.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.651 -1.281 . . . . 0.0 110.321 -179.091 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.583 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 5.4 mt-30 83.3 61.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.372 0.606 . . . . 0.0 109.882 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.732 HG21 HG21 ' A' ' 75' ' ' VAL . 2.7 mm -111.62 115.79 50.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.35 -0.844 . . . . 0.0 108.782 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.875 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.0 tm? -66.42 87.22 0.12 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.16 -0.963 . . . . 0.0 110.391 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 1.038 HD13 HD11 ' A' ' 66' ' ' ILE . 5.2 tt -88.8 122.94 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.49 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.0 tt0 -88.97 96.11 10.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.13 -0.981 . . . . 0.0 108.84 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.038 HD11 HD13 ' A' ' 64' ' ' ILE . 3.2 mt -101.51 122.8 54.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.334 -0.854 . . . . 0.0 110.043 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.3 m 60.93 44.66 10.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.636 -0.665 . . . . 0.0 109.773 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 55.7 33.32 59.45 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -130.85 118.92 21.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.285 -1.127 . . . . 0.0 109.353 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.496 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -56.32 133.62 52.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 108.706 179.626 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -157.42 104.04 2.0 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 110.199 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.583 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -79.35 154.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 120.88 -1.138 . . . . 0.0 108.313 178.78 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.496 ' HA3' HD22 ' A' ' 89' ' ' LEU . . . -177.25 175.43 47.63 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.179 -1.486 . . . . 0.0 110.576 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 59' ' ' TYR . 3.7 m -85.34 115.28 23.0 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.586 -0.949 . . . . 0.0 110.158 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -103.94 109.49 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.121 -0.987 . . . . 0.0 110.288 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.611 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.2 mp -82.53 115.81 21.68 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.948 -1.095 . . . . 0.0 108.345 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 93.9 t -96.02 121.7 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.754 -1.216 . . . . 0.0 110.213 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.538 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -160.17 -170.84 25.27 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -81.02 42.68 1.39 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.926 2.417 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.664 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.4 t -82.8 141.73 44.61 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 108.564 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.9 Cg_endo -79.38 15.31 1.6 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.518 2.145 . . . . 0.0 110.98 -179.229 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 81' ' ' PRO . 14.1 t -160.43 158.41 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.929 -1.107 . . . . 0.0 110.22 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.695 HD21 ' N ' ' A' ' 83' ' ' ASN . 0.1 OUTLIER -102.06 91.13 4.19 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 176.217 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.622 HG22 ' HB3' ' A' ' 25' ' ' ASP . 41.8 mt -96.63 130.6 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.891 -1.131 . . . . 0.0 113.674 -174.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.87 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -89.3 131.9 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.839 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.639 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -110.96 -143.48 9.48 Favored Glycine 0 N--CA 1.498 2.797 0 O-C-N 120.688 -1.257 . . . . 0.0 110.847 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.633 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -77.83 -41.61 36.44 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.482 -179.464 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -54.63 -18.95 5.11 Favored 'General case' 0 N--CA 1.497 1.881 0 C-N-CA 117.438 -1.705 . . . . 0.0 110.246 -178.608 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.713 ' CB ' HG23 ' A' ' 85' ' ' ILE . 1.0 OUTLIER -103.03 -35.97 8.34 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.712 -1.243 . . . . 0.0 110.363 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.49 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 66.2 mt -68.86 -19.77 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.876 -1.14 . . . . 0.0 109.599 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.528 HG21 ' HA ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -93.86 -2.9 52.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.734 -1.229 . . . . 0.0 108.809 178.962 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.46 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.0 OUTLIER -99.44 -40.84 7.67 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.261 -0.9 . . . . 0.0 108.949 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.059 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -79.76 -16.1 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 N-CA-C 108.571 -0.899 . . . . 0.0 108.571 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 91.05 30.87 10.43 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.85 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -67.44 138.99 57.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.988 -1.301 . . . . 0.0 109.555 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.456 ' O ' ' O ' ' B' ' 96' ' ' THR . 3.0 p -132.76 128.49 36.94 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.151 -0.968 . . . . 0.0 108.558 179.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.665 HD13 HD23 ' B' ' 5' ' ' LEU . 4.3 mp -90.62 98.43 11.77 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.245 -0.909 . . . . 0.0 109.532 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 16.0 m-20 -105.61 125.7 51.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.029 -1.044 . . . . 0.0 109.246 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.741 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 CA-C-O 117.959 -1.02 . . . . 0.0 109.295 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.509 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.68 0 N-CA-C 110.825 -0.49 . . . . 0.0 110.825 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -85.71 134.27 33.97 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.834 HG12 ' H ' ' B' ' 5' ' ' LEU . 49.4 t -131.5 125.08 55.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.764 -1.21 . . . . 0.0 109.951 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.909 ' O ' HD12 ' B' ' 5' ' ' LEU . 46.7 p -75.89 3.58 9.81 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.48 -0.763 . . . . 0.0 109.656 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.909 HD12 ' O ' ' B' ' 4' ' ' THR . 0.4 OUTLIER 34.35 46.75 0.18 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.801 -0.562 . . . . 0.0 111.476 179.199 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.528 ' HA ' HG21 ' A' ' 91' ' ' THR . 58.8 m95 -57.63 -20.35 32.48 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -147.11 -164.55 2.02 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 1.075 ' HD2' HD13 ' B' ' 23' ' ' LEU . 0.5 OUTLIER -59.22 122.52 64.08 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 120.897 -1.127 . . . . 0.0 109.211 179.735 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.607 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -78.97 66.42 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.376 2.051 . . . . 0.0 109.635 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.536 HD22 ' CB ' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -81.15 145.65 30.93 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.107 -0.996 . . . . 0.0 109.827 -179.31 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.674 HG21 HG13 ' B' ' 66' ' ' ILE . 2.6 m -136.58 136.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.53 -0.731 . . . . 0.0 109.434 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -66.09 89.27 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.805 -1.184 . . . . 0.0 107.805 178.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.756 HG12 ' HB2' ' B' ' 22' ' ' ALA . 1.1 pp -80.67 131.52 33.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 109.596 -179.04 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.728 ' HE2' HD11 ' B' ' 19' ' ' LEU . 12.0 tttm -98.84 111.59 23.93 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.354 -0.841 . . . . 0.0 108.998 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.796 ' CG2' HD21 ' B' ' 38' ' ' LEU . 28.8 mt -116.38 134.65 59.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.221 -0.925 . . . . 0.0 108.9 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.66 -100.49 0.28 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -142.29 35.44 1.74 Allowed Glycine 0 N--CA 1.485 1.906 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 5.8 mt-30 -134.13 179.95 5.94 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.482 -1.011 . . . . 0.0 109.663 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.728 HD11 ' HE2' ' B' ' 14' ' ' LYS . 16.0 mt -147.39 130.26 16.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.531 -0.731 . . . . 0.0 109.139 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.451 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 39.0 mttp -146.12 171.77 14.42 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.166 -0.959 . . . . 0.0 109.199 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.536 ' CB ' HD22 ' B' ' 10' ' ' LEU . 2.9 mm-40 -79.03 148.48 32.48 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.756 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -136.16 108.28 7.22 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.056 . . . . 0.0 110.543 -178.846 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 1.075 HD13 ' HD2' ' B' ' 8' ' ' ARG . 18.8 tp -70.13 102.75 2.14 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' B' ' 9' ' ' PRO . 82.5 mt -53.7 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.055 -1.028 . . . . 0.0 108.867 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 1.003 ' CB ' HG23 ' B' ' 84' ' ' ILE . 35.2 t0 -91.92 90.06 7.28 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.391 -0.818 . . . . 0.0 110.519 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.643 HG22 ' NH2' ' B' ' 87' ' ' ARG . 7.3 m -71.05 -7.49 46.82 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 109.064 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.434 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -83.58 -31.3 27.61 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.42 173.15 12.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.875 -1.368 . . . . 0.0 109.337 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -101.72 -18.0 16.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.073 -1.017 . . . . 0.0 110.764 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.477 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -137.35 -172.54 3.24 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.769 -1.207 . . . . 0.0 110.142 -179.357 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 31' ' ' THR . . . . . 1.012 HG23 HD12 ' B' ' 85' ' ' ILE . 55.3 m -102.59 82.43 2.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.093 -1.005 . . . . 0.0 109.89 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.012 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.71 161.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.881 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.012 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -153.25 129.52 10.51 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.587 -1.245 . . . . 0.0 111.618 -177.451 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.719 ' HA ' HG22 ' B' ' 80' ' ' THR . 9.5 tt0 -44.22 156.28 0.07 Allowed 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' B' ' 34' ' ' GLU . 0.5 OUTLIER -40.05 138.12 0.87 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 110.601 -179.074 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.555 ' O ' HG11 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -165.27 148.84 8.32 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.862 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.484 ' O ' ' SD ' ' B' ' 36' ' ' MET . 23.3 t -82.8 125.5 31.37 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.046 -1.034 . . . . 0.0 110.68 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.91 HD12 HG21 ' B' ' 77' ' ' VAL . 2.6 mt -122.93 164.03 29.67 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.271 -0.893 . . . . 0.0 108.653 179.03 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.485 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.7 Cg_endo -73.88 71.78 4.06 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.655 2.237 . . . . 0.0 112.539 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.8 -159.22 0.01 OUTLIER Glycine 0 N--CA 1.497 2.727 0 O-C-N 121.528 -0.732 . . . . 0.0 111.414 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.434 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 2.8 mmt180 61.11 66.54 0.88 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.568 -0.96 . . . . 0.0 109.196 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.591 ' CZ3' ' HD2' ' B' ' 57' ' ' ARG . 65.0 p-90 -149.79 -177.96 6.19 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.575 -0.703 . . . . 0.0 109.731 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' B' ' 57' ' ' ARG . 23.6 mtmt -150.82 160.35 32.5 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 108.974 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 44' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' B' ' 43' ' ' LYS . 34.7 Cg_endo -76.33 140.86 22.35 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.384 2.056 . . . . 0.0 110.241 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.621 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -157.81 120.8 3.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.342 -0.849 . . . . 0.0 109.058 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.476 ' HG3' ' CG ' ' B' ' 55' ' ' LYS . 2.5 ttt -101.18 126.72 47.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.082 -1.011 . . . . 0.0 109.94 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.696 HD11 HD11 ' B' ' 54' ' ' ILE . 10.0 pt -105.62 150.8 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.046 -1.034 . . . . 0.0 109.327 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.608 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -125.47 97.68 0.53 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.8 -130.9 4.09 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.291 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.768 HG21 HD11 ' A' ' 47' ' ' ILE . 66.3 mt -81.77 129.8 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.534 -0.98 . . . . 0.0 112.185 -178.11 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 100.21 -48.51 1.2 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 171.89 -164.63 37.29 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.655 -1.259 . . . . 0.0 109.994 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.608 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 3.1 m-85 -107.03 130.56 54.63 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.423 -1.045 . . . . 0.0 108.921 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.732 HD13 HG23 ' A' ' 50' ' ' ILE . 34.0 pt -112.7 155.18 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 120.977 -1.077 . . . . 0.0 109.885 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 18.6 mttt -98.95 140.62 32.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.184 -0.947 . . . . 0.0 108.68 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.956 HG12 ' HA3' ' B' ' 78' ' ' GLY . 9.9 m -143.7 -176.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.9 -1.125 . . . . 0.0 110.149 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.591 ' HD2' ' CZ3' ' B' ' 42' ' ' TRP . 69.0 mtm-85 -132.09 104.1 6.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.637 ' HG3' HG22 ' B' ' 74' ' ' THR . 8.5 tt0 -62.0 134.69 56.96 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.654 0.74 . . . . 0.0 110.967 -178.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.54 ' HB3' ' CG1' ' B' ' 62' ' ' ILE . 17.6 m-85 -121.61 93.93 4.16 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.515 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 9.1 m-20 -79.44 130.86 35.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.031 -1.043 . . . . 0.0 110.452 -178.659 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.515 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 6.9 mm100 83.22 62.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.329 0.585 . . . . 0.0 109.723 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.57 ' HB ' HG23 ' B' ' 75' ' ' VAL . 40.0 mm -119.86 115.72 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.343 -0.848 . . . . 0.0 109.063 179.255 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.848 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.8 tm? -66.48 91.86 0.19 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 110.453 -179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.726 HG12 HD12 ' B' ' 66' ' ' ILE . 7.3 tt -98.38 120.68 48.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.452 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.2 tt0 -90.53 111.88 23.34 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.947 -1.095 . . . . 0.0 109.491 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.726 HD12 HG12 ' B' ' 64' ' ' ILE . 1.0 OUTLIER -100.44 126.47 54.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.741 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.425 ' C ' ' O ' ' B' ' 66' ' ' ILE . 10.2 m 39.43 61.8 1.29 Allowed 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.71 -0.619 . . . . 0.0 110.63 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.3 41.05 86.5 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 120.175 -1.012 . . . . 0.0 111.121 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 2.7 m-70 -139.44 135.46 33.61 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.9 -1.353 . . . . 0.0 109.0 178.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.549 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -76.64 132.93 39.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.286 -0.884 . . . . 0.0 109.739 -179.614 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.709 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.6 97.17 1.96 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.835 . . . . 0.0 109.822 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.605 HG12 ' N ' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -83.54 136.85 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 178.638 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.642 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -161.58 -171.96 28.32 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.96 -1.59 . . . . 0.0 110.636 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.637 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.0 m -89.97 106.36 18.42 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.825 -0.809 . . . . 0.0 110.174 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -99.64 116.74 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.484 -0.76 . . . . 0.0 110.03 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.572 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.5 mp -85.33 139.05 31.89 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.618 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.91 HG21 HD12 ' B' ' 38' ' ' LEU . 1.6 t -121.32 114.49 43.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.066 -1.021 . . . . 0.0 109.647 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.956 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.06 -162.78 11.64 Favored Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.21 40.61 0.99 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.615 2.21 . . . . 0.0 111.471 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.719 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.5 t -84.88 137.87 37.73 Favored Pre-proline 0 N--CA 1.493 1.678 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.71 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.2 Cg_endo -77.31 14.43 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.565 2.177 . . . . 0.0 111.579 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.71 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.04 151.25 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.95 -1.094 . . . . 0.0 110.438 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.567 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 3.6 m-20 -90.62 102.88 15.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 176.752 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 1.003 HG23 ' CB ' ' B' ' 25' ' ' ASP . 2.2 mt -101.97 129.38 53.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 120.902 -1.124 . . . . 0.0 113.083 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 1.012 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -98.63 111.49 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.505 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -97.47 -161.3 31.33 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.835 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.643 ' NH2' HG22 ' B' ' 26' ' ' THR . 0.4 OUTLIER -58.4 -34.9 71.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.563 -0.963 . . . . 0.0 110.451 -179.791 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.007 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.6 p-10 -48.05 -27.95 2.56 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.867 -1.145 . . . . 0.0 109.913 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.007 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -109.75 -24.79 10.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.81 -1.181 . . . . 0.0 109.63 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.51 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 90.7 mt -72.43 -4.97 33.39 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.509 HG23 ' O ' ' B' ' 87' ' ' ARG . 74.4 p -100.51 -17.85 16.93 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -85.4 -41.21 15.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.354 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.741 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.5 pt -87.04 -4.03 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.29 50.56 38.02 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.136 178.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.677 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -73.05 157.77 36.69 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.071 -1.252 . . . . 0.0 110.198 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.54 HG22 ' CG2' ' A' ' 4' ' ' THR . 50.5 p -149.63 128.39 12.47 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.462 -0.773 . . . . 0.0 109.323 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.54 HD11 HD11 ' A' ' 97' ' ' LEU . 7.5 mp -89.68 104.32 16.89 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m-20 -107.64 127.29 53.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.05 . . . . 0.0 110.04 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 1.059 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.138 -0.934 . . . . 0.0 109.62 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.53 ' CD ' ' O ' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.726 0 N-CA-C 110.244 -0.714 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' B' ' 97' ' ' LEU . 1.7 tm0? -84.67 144.08 28.79 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.431 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.765 HG12 ' H ' ' A' ' 5' ' ' LEU . 38.1 t -145.28 123.34 4.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.911 -1.118 . . . . 0.0 109.984 -179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 18.6 p -60.51 -14.76 21.5 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.546 -0.721 . . . . 0.0 110.28 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.765 ' H ' HG12 ' A' ' 3' ' ' VAL . 39.5 mt 73.65 17.02 3.78 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.484 -0.76 . . . . 0.0 110.654 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.698 ' CE3' HG21 ' B' ' 91' ' ' THR . 0.3 OUTLIER -65.45 -12.61 54.1 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.842 -1.161 . . . . 0.0 108.789 179.252 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.521 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 29.7 mm-40 -146.47 178.86 7.95 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.9 mtt180 -72.97 116.08 46.83 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.916 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.745 ' HB2' HD12 ' A' ' 24' ' ' LEU . 32.7 Cg_endo -75.93 77.81 3.32 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 122.091 1.86 . . . . 0.0 110.107 178.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.568 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.88 167.83 19.44 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.111 -0.993 . . . . 0.0 109.11 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.806 HG23 HG23 ' A' ' 13' ' ' ILE . 27.3 m -150.22 130.0 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.763 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 1.08 HG22 HD22 ' A' ' 19' ' ' LEU . 91.9 m -66.95 92.18 0.23 Allowed 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.871 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.4 pt -86.71 143.05 12.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.418 -0.801 . . . . 0.0 111.216 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.79 ' HD2' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -108.46 97.78 7.4 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.166 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.971 HD12 HG11 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -115.69 140.38 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 110.223 -178.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 38' ' ' LEU . . . 49.7 29.23 12.27 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 178.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.57 38.26 57.63 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.568 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -136.2 179.43 6.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.477 -1.013 . . . . 0.0 108.284 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 1.08 HD22 HG22 ' A' ' 12' ' ' THR . 13.0 mt -144.55 118.98 9.63 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.957 -1.09 . . . . 0.0 109.801 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.571 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -135.44 150.18 49.79 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.605 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 14.9 mm-40 -78.81 112.51 16.02 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.819 -1.175 . . . . 0.0 108.133 179.602 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.884 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -91.85 140.46 29.66 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.934 0.873 . . . . 0.0 110.788 -178.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 24' ' ' LEU . 44.6 tp -93.74 97.1 10.21 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.745 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.2 mt -42.43 107.69 0.08 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.158 -0.964 . . . . 0.0 109.153 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.778 ' CB ' HG23 ' A' ' 84' ' ' ILE . 2.7 t70 -113.81 87.82 2.7 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -178.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.842 ' HA ' HD21 ' A' ' 90' ' ' LEU . 10.1 m -70.99 -5.68 32.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.114 -0.991 . . . . 0.0 109.081 178.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.639 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.6 -29.38 32.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 168.59 19.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.214 -1.168 . . . . 0.0 109.691 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -100.19 -19.82 16.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.394 -0.816 . . . . 0.0 109.656 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 39.4 m-20 -133.7 -167.18 1.9 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -0.971 . . . . 0.0 109.74 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.547 HG22 ' O ' ' A' ' 31' ' ' THR . 8.0 m -111.06 89.74 3.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.035 -1.04 . . . . 0.0 110.193 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.018 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -68.14 172.08 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.132 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.072 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -167.96 113.99 0.69 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.189 -0.944 . . . . 0.0 109.557 -179.511 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.735 ' HA ' HG22 ' A' ' 80' ' ' THR . 9.7 pt-20 -36.24 154.84 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.445 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -44.16 134.86 4.65 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.088 -1.008 . . . . 0.0 109.922 -178.915 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.697 ' HE1' HG22 ' A' ' 15' ' ' ILE . 2.3 ppp? -154.31 -163.72 1.68 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.595 -0.691 . . . . 0.0 109.644 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.513 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 3.1 t -107.81 118.27 36.29 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.921 -1.112 . . . . 0.0 111.149 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.746 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -131.32 -173.57 0.34 Allowed Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 178.512 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.657 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.6 Cg_endo -78.97 -163.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.919 1.746 . . . . 0.0 110.861 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -114.18 31.56 6.41 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -118.98 63.82 0.78 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 21.2 p-90 -130.38 -175.39 3.63 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.764 0.792 . . . . 0.0 110.207 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -139.85 156.51 70.71 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.65 141.56 24.96 Favored 'Trans proline' 0 C--N 1.303 -1.849 0 C-N-CA 121.868 1.712 . . . . 0.0 109.68 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 1.3 tttt -149.94 170.14 19.52 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.445 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -144.27 113.81 7.1 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.655 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.606 ' CD1' HG21 ' B' ' 50' ' ' ILE . 24.9 pt -89.47 141.62 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.079 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.615 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -119.32 115.46 3.05 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -136.84 -115.05 1.38 Allowed Glycine 0 N--CA 1.485 1.905 0 C-N-CA 119.212 -1.471 . . . . 0.0 111.088 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.692 HG21 HD12 ' B' ' 47' ' ' ILE . 17.1 mt -94.07 118.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.733 -0.863 . . . . 0.0 112.585 -177.116 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.89 -11.31 67.99 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.452 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 137.4 -177.54 19.76 Favored Glycine 0 N--CA 1.493 2.489 0 O-C-N 120.806 -1.408 . . . . 0.0 109.647 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.5 OUTLIER -102.64 143.92 31.7 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -1.133 . . . . 0.0 109.844 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.59 HD11 HG13 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -109.19 -178.21 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.258 -0.901 . . . . 0.0 108.703 178.909 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.58 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 2.4 mttp -109.09 141.7 40.88 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.038 -1.039 . . . . 0.0 109.643 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -147.61 -171.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.05 -1.031 . . . . 0.0 109.521 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.406 ' HG3' ' C ' ' A' ' 56' ' ' VAL . 1.6 mtt180 -133.46 108.12 8.46 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.441 ' HB2' ' HD2' ' A' ' 45' ' ' LYS . 1.3 tt0 -65.28 97.17 0.26 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.322 -0.861 . . . . 0.0 110.428 -179.166 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.746 ' CD2' HD23 ' A' ' 38' ' ' LEU . 10.3 m-85 -89.93 123.22 33.67 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -105.58 134.89 47.96 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.736 -1.227 . . . . 0.0 110.665 -178.589 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mp0 73.22 63.22 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 121.695 0.76 . . . . 0.0 110.195 179.239 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.526 HG13 ' HB3' ' A' ' 59' ' ' TYR . 22.1 mm -117.27 127.27 74.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.586 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -76.37 89.08 3.18 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 112.276 -177.523 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.747 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -90.48 112.96 25.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 CA-C-O 121.888 0.852 . . . . 0.0 108.822 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.537 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -89.5 113.03 24.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.778 -1.201 . . . . 0.0 108.515 -179.69 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.747 HD11 HD13 ' A' ' 64' ' ' ILE . 2.9 mt -115.17 126.64 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.922 -1.111 . . . . 0.0 110.67 -178.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.2 m 66.75 24.91 9.82 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.638 -0.664 . . . . 0.0 109.895 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.431 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 80.58 7.44 88.55 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -108.86 110.03 21.28 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.208 -1.172 . . . . 0.0 109.226 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.542 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.2 ttpt -52.58 136.29 32.79 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.474 -0.767 . . . . 0.0 109.026 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.94 118.38 4.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.618 -0.676 . . . . 0.0 109.36 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.586 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -95.07 158.06 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 120.807 -1.183 . . . . 0.0 108.036 178.709 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.479 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 177.42 -170.15 42.54 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.734 -1.698 . . . . 0.0 111.47 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 1.5 m -91.18 113.25 25.46 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.918 . . . . 0.0 110.146 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.072 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -107.93 109.49 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.525 -0.734 . . . . 0.0 111.135 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.594 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.9 mp -80.2 125.08 29.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.276 -0.89 . . . . 0.0 109.056 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 89.9 t -113.25 131.91 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.999 -1.063 . . . . 0.0 109.853 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -164.47 -167.57 25.21 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.58 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -81.81 40.74 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.592 2.195 . . . . 0.0 110.534 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.735 HG22 ' HA ' ' A' ' 34' ' ' GLU . 14.9 t -81.74 140.72 47.47 Favored Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.72 13.06 1.75 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 C-N-CA 122.227 1.952 . . . . 0.0 111.196 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.647 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.45 163.49 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.74 -1.225 . . . . 0.0 110.731 -179.755 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.642 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 60.0 m-20 -95.8 142.88 27.55 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 176.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 25' ' ' ASP . 12.3 mm -131.95 124.63 53.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.467 -1.396 . . . . 0.0 111.337 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.884 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -102.96 94.72 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.656 ' C ' HD13 ' A' ' 90' ' ' LEU . . . -100.75 171.21 22.61 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.382 -177.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.622 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.1 OUTLIER -21.71 -41.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -179.392 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.978 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.8 p-10 -51.1 -42.89 60.94 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.282 -1.511 . . . . 0.0 110.774 -177.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.978 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -97.54 -11.04 24.18 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.146 -0.971 . . . . 0.0 110.414 -179.137 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.842 HD21 ' HA ' ' A' ' 26' ' ' THR . 5.7 mp -69.73 -35.14 74.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.084 -1.01 . . . . 0.0 108.788 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 p -70.5 -15.42 62.79 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.455 -0.778 . . . . 0.0 109.252 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.6 mm-40 -89.13 -41.42 12.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.019 . . . . 0.0 109.27 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.674 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.9 pt -81.99 -1.89 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 57.19 54.95 33.11 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.876 ' HB3' HD12 ' B' ' 5' ' ' LEU . . . -85.42 127.62 34.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.422 -1.046 . . . . 0.0 110.26 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 69.9 p -122.31 124.9 44.82 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -89.98 100.48 13.29 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.406 -0.809 . . . . 0.0 109.384 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.1 m-20 -105.96 129.33 54.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.234 -0.916 . . . . 0.0 110.048 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.736 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.265 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.404 -0.652 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -84.25 129.45 34.88 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 11.4 t -121.76 96.23 4.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.762 -1.212 . . . . 0.0 109.499 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.418 HG23 ' H ' ' B' ' 4' ' ' THR . 3.0 p -55.73 135.11 51.73 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.876 HD12 ' HB3' ' A' ' 95' ' ' ALA . 89.5 mt -83.36 4.42 27.46 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.765 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -57.05 -20.19 23.21 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -135.4 157.67 46.31 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.0 mtt180 -53.25 125.5 42.65 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 120.886 -1.134 . . . . 0.0 109.371 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.799 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.4 Cg_endo -77.65 71.23 6.59 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.281 1.987 . . . . 0.0 109.819 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -90.63 144.62 25.57 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.26 -179.686 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.659 HG21 HG12 ' B' ' 66' ' ' ILE . 3.1 m -135.14 132.71 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 110.203 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.809 HG22 HD22 ' B' ' 19' ' ' LEU . 91.8 m -65.6 109.56 2.43 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 1.034 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.1 pt -98.58 144.23 11.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 110.841 -178.416 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.483 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -112.16 101.9 10.12 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' B' ' 13' ' ' ILE . 11.8 mt -118.58 118.87 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.162 -0.961 . . . . 0.0 109.766 -179.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.421 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.83 27.25 73.67 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.2 -2.78 74.84 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.423 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.4 mp0 -90.07 -179.34 5.66 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.329 -1.101 . . . . 0.0 108.973 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 1.034 HD23 ' O ' ' B' ' 13' ' ' ILE . 12.4 mt -153.17 124.02 7.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.193 -0.942 . . . . 0.0 110.269 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.443 ' NZ ' HD23 ' B' ' 33' ' ' LEU . 8.4 mtmt -143.89 158.63 43.57 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.4 OUTLIER -79.29 133.05 36.64 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.978 -1.076 . . . . 0.0 109.54 -179.114 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.824 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.7 156.25 19.29 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.248 -0.908 . . . . 0.0 110.022 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.639 HD21 ' O ' ' A' ' 27' ' ' GLY . 62.4 tp -115.6 95.35 5.1 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.871 HD22 HD21 ' B' ' 90' ' ' LEU . 24.1 mt -42.15 103.44 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.393 -0.817 . . . . 0.0 109.359 -179.437 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.509 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 48.8 t0 -114.55 91.02 3.48 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.142 -0.974 . . . . 0.0 110.275 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.563 HG21 HD22 ' A' ' 5' ' ' LEU . 0.9 OUTLIER -68.88 -7.56 35.82 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.066 -1.021 . . . . 0.0 108.73 178.581 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.429 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -73.8 -41.57 41.54 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.71 166.21 23.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.149 -1.206 . . . . 0.0 109.886 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -100.93 -19.91 15.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.145 -0.972 . . . . 0.0 110.786 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.499 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -130.6 -168.17 1.94 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.874 -1.141 . . . . 0.0 109.644 -179.445 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.596 HG22 ' CD1' ' B' ' 33' ' ' LEU . 16.7 m -109.74 95.66 5.75 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.911 -1.118 . . . . 0.0 110.286 -179.066 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.993 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -77.38 162.14 4.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 179.023 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.032 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -160.74 125.78 3.75 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 120.456 -1.402 . . . . 0.0 111.288 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 33' ' ' LEU . 3.7 tt0 -38.89 159.17 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.724 -0.61 . . . . 0.0 109.677 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.78 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -51.35 150.26 3.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.95 . . . . 0.0 110.285 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.534 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.9 ppp? -168.5 -169.16 1.01 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.293 -0.879 . . . . 0.0 109.11 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.52 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.6 t -121.19 124.42 44.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.929 -1.107 . . . . 0.0 110.372 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.868 HD21 HD12 ' B' ' 62' ' ' ILE . 0.1 OUTLIER -124.64 -172.82 0.26 Allowed Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.347 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.648 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.8 Cg_endo -80.8 59.87 7.63 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.292 1.995 . . . . 0.0 111.005 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.95 -157.92 0.06 OUTLIER Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.414 ' HD3' ' HA ' ' B' ' 41' ' ' ARG . 50.7 mmt-85 51.91 96.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.544 -0.974 . . . . 0.0 109.077 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.453 ' CE3' ' HG3' ' B' ' 57' ' ' ARG . 16.7 p-90 -155.02 171.93 18.94 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.691 -0.631 . . . . 0.0 109.683 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.24 121.4 20.52 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.26 141.5 18.31 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.412 2.075 . . . . 0.0 111.423 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.28 -171.93 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.221 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.516 ' HG2' ' HG3' ' B' ' 55' ' ' LYS . 17.1 mtp -143.54 133.97 24.74 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.903 -1.123 . . . . 0.0 110.098 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.692 HD12 HG21 ' A' ' 50' ' ' ILE . 19.4 pt -104.94 139.43 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 0.0 108.8 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.9 97.35 0.7 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.294 -1.922 . . . . 0.0 108.294 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.22 -121.37 2.88 Favored Glycine 0 N--CA 1.485 1.914 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.682 -178.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.606 HG21 ' CD1' ' A' ' 47' ' ' ILE . 11.2 mt -86.58 124.79 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.854 -0.792 . . . . 0.0 111.982 -177.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 101.49 -53.46 0.83 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.711 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 176.76 -161.81 29.9 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -111.38 137.33 49.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -1.198 . . . . 0.0 109.359 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.591 HD11 HD11 ' B' ' 47' ' ' ILE . 27.6 pt -117.14 159.17 17.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.253 -0.904 . . . . 0.0 109.535 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.527 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.5 OUTLIER -94.69 126.26 39.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 108.8 179.313 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.585 HG12 ' HA3' ' B' ' 78' ' ' GLY . 12.5 m -134.2 153.68 36.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.542 ' N ' ' HD2' ' B' ' 57' ' ' ARG . 2.3 mpt_? -91.63 179.78 5.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -138.61 93.06 2.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.131 -0.98 . . . . 0.0 110.523 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.599 ' CG ' HD23 ' B' ' 38' ' ' LEU . 67.2 m-85 -89.29 92.53 9.2 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 49.0 m-20 -78.62 143.11 36.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.046 -1.034 . . . . 0.0 109.381 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.586 ' HA ' HG23 ' B' ' 72' ' ' ILE . 1.4 mp0 74.1 64.18 0.08 Allowed 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.529 -0.732 . . . . 0.0 109.189 -179.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.868 HD12 HD21 ' B' ' 38' ' ' LEU . 1.1 mm -121.07 117.15 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.741 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.4 tm? -68.62 85.27 0.3 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.476 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.613 HG22 ' O ' ' B' ' 71' ' ' ALA . 3.4 tt -91.02 117.67 34.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.9 tt0 -89.53 111.47 22.4 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.063 -1.023 . . . . 0.0 109.563 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.35 120.3 54.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.79 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 88.2 m 65.36 20.42 11.81 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.788 -0.57 . . . . 0.0 110.166 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.26 1.61 78.46 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.112 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -97.9 123.0 41.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.214 -1.168 . . . . 0.0 109.123 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.493 ' HG2' HD21 ' B' ' 63' ' ' LEU . 3.9 mtpt -58.71 133.85 56.3 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.613 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -150.96 99.67 2.72 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.014 -1.053 . . . . 0.0 110.26 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.711 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.5 OUTLIER -79.55 144.54 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.668 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.74 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.43 -177.8 39.2 Favored Glycine 0 N--CA 1.486 1.991 0 C-N-CA 118.915 -1.612 . . . . 0.0 110.634 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.449 HG23 ' OD1' ' B' ' 60' ' ' ASP . 22.0 m -95.83 102.99 14.85 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.723 -0.869 . . . . 0.0 109.432 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.032 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.9 OUTLIER -92.58 162.11 2.45 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.704 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.0 mp -129.95 140.35 50.94 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' B' ' 35' ' ' GLU . 9.2 t -120.8 103.19 13.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 O-C-N 121.386 -0.821 . . . . 0.0 110.507 -178.566 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.585 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -142.54 -166.12 10.87 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.527 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.5 Cg_endo -80.94 41.31 1.12 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.583 2.189 . . . . 0.0 110.956 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -84.45 138.21 38.8 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.29 14.51 1.56 Allowed 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.193 1.928 . . . . 0.0 111.497 -179.035 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.541 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.7 OUTLIER -161.13 171.21 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.903 -1.123 . . . . 0.0 110.11 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -105.97 116.07 31.31 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 176.591 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.733 HG12 HG12 ' B' ' 32' ' ' VAL . 5.0 mm -100.45 120.59 50.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 O-C-N 120.661 -1.274 . . . . 0.0 111.562 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.824 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -95.37 89.83 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.838 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.08 -164.33 27.27 Favored Glycine 0 N--CA 1.493 2.474 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.437 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.521 ' NH2' ' HA ' ' A' ' 7' ' ' GLN . 13.5 mtm180 -60.76 -39.79 90.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.786 -0.832 . . . . 0.0 110.548 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -45.28 -26.49 0.52 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.093 -1.005 . . . . 0.0 110.181 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -108.7 -29.56 8.64 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.026 -1.047 . . . . 0.0 111.041 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.871 HD21 HD22 ' B' ' 24' ' ' LEU . 71.9 mt -65.15 -9.62 24.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.716 -1.24 . . . . 0.0 108.748 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.698 HG21 ' CE3' ' A' ' 6' ' ' TRP . 1.2 p -101.03 -20.71 15.26 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.176 -0.952 . . . . 0.0 109.391 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 36.6 mm-40 -78.06 -40.81 37.46 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.071 -1.018 . . . . 0.0 109.141 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.736 HD12 ' CG ' ' A' ' 99' ' ' PHE . 4.4 pt -86.03 -4.02 9.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.137 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 77.28 29.47 56.2 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.558 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -59.97 151.0 27.26 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.042 -1.269 . . . . 0.0 109.037 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.524 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 2.6 p -136.6 173.7 11.42 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' A' ' 97' ' ' LEU . 0.5 OUTLIER -134.31 98.82 4.2 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.735 -1.228 . . . . 0.0 110.088 -179.371 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 20.9 m-20 -99.23 118.62 36.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.964 -1.085 . . . . 0.0 109.37 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.674 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.508 0 CA-C-O 117.94 -1.029 . . . . 0.0 108.935 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.542 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 N-CA-C 110.231 -0.719 . . . . 0.0 110.231 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.497 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.43 131.07 34.71 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 178.204 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.559 HG21 ' HZ ' ' B' ' 99' ' ' PHE . 4.1 t -121.79 94.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.991 -1.068 . . . . 0.0 109.768 -178.259 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.528 ' CG2' ' HB ' ' B' ' 96' ' ' THR . 19.3 p -126.01 45.67 2.58 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.335 -0.853 . . . . 0.0 108.93 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 1.03 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.5 OUTLIER -89.07 36.47 0.82 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.187 -0.946 . . . . 0.0 109.589 -179.721 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 13.4 m0 17.45 51.86 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 CA-C-O 121.631 0.729 . . . . 0.0 111.512 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 1.03 ' HB2' HD12 ' A' ' 5' ' ' LEU . 49.4 mt-30 -156.02 -159.78 0.94 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 10.1 mtm180 -79.66 113.34 36.6 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.986 -1.071 . . . . 0.0 109.909 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.77 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.3 Cg_endo -79.79 80.27 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 C-N-CA 122.355 2.037 . . . . 0.0 110.055 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -100.13 164.78 11.82 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.846 -179.749 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.987 HG21 HG23 ' A' ' 66' ' ' ILE . 2.3 m -148.86 129.47 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 110.256 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.3 m -69.22 94.05 0.66 Allowed 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 178.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.805 HG23 HG23 ' A' ' 11' ' ' VAL . 7.7 pt -82.95 167.42 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 110.949 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.3 tttt -128.65 102.88 6.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.559 -0.713 . . . . 0.0 109.25 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.952 HD11 HD12 ' A' ' 64' ' ' ILE . 11.6 mt -124.47 147.93 28.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 120.987 -1.07 . . . . 0.0 109.592 -179.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.03 32.53 4.83 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.9 43.62 90.97 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.6 tp-100 -138.52 170.79 15.38 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.191 -1.182 . . . . 0.0 109.022 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.484 HD23 ' O ' ' A' ' 13' ' ' ILE . 39.3 mt -135.57 126.41 27.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.385 -0.822 . . . . 0.0 109.445 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.41 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 2.3 mtpm? -148.22 158.65 44.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.406 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.4 mt-10 -79.17 123.81 27.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.319 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.585 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -105.08 141.98 35.67 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.333 -0.854 . . . . 0.0 110.225 -178.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.871 HD21 ' O ' ' B' ' 27' ' ' GLY . 19.8 tp -97.67 103.82 15.79 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.747 -0.595 . . . . 0.0 109.918 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.77 HD12 ' HB2' ' A' ' 9' ' ' PRO . 12.1 mt -44.62 113.62 0.58 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 178.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.486 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 25.4 t0 -119.64 89.13 3.07 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.948 -1.095 . . . . 0.0 111.65 -177.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.57 -2.95 35.04 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.909 -1.119 . . . . 0.0 108.562 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 1.023 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -90.78 -25.12 25.95 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 162.13 19.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.953 -1.322 . . . . 0.0 109.027 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -98.1 -13.06 21.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.115 -0.991 . . . . 0.0 110.287 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.513 ' OD1' ' HB ' ' A' ' 74' ' ' THR . 0.2 OUTLIER -142.78 -175.05 4.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.93 -1.106 . . . . 0.0 109.732 -179.957 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.57 HG23 HD12 ' A' ' 85' ' ' ILE . 22.6 m -104.63 91.83 4.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.703 -1.248 . . . . 0.0 111.226 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.027 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.29 173.34 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.643 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.027 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.32 122.78 1.08 Allowed 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.688 -1.257 . . . . 0.0 111.547 -179.417 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.57 ' HA ' HG22 ' A' ' 80' ' ' THR . 12.6 tt0 -39.97 149.21 0.07 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.668 -0.645 . . . . 0.0 109.362 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.426 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -48.68 141.88 6.72 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.191 -0.943 . . . . 0.0 110.295 -179.599 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.514 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -163.64 -172.28 2.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.344 -0.848 . . . . 0.0 109.313 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.2 t -92.7 83.95 4.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.001 -1.062 . . . . 0.0 109.626 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.879 HD11 HD12 ' A' ' 62' ' ' ILE . 61.6 tp -116.2 98.34 51.17 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -78.37 167.3 23.18 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.656 2.237 . . . . 0.0 110.642 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.61 171.93 13.9 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 133.41 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -1.154 . . . . 0.0 108.684 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.615 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 52.5 p-90 -136.67 -177.42 4.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.163 -0.961 . . . . 0.0 110.691 -178.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.401 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 1.1 tptt -146.28 162.98 32.54 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.401 ' HD2' ' CG ' ' A' ' 43' ' ' LYS . 33.8 Cg_endo -78.0 140.36 17.98 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.756 1.638 . . . . 0.0 109.688 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.591 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -155.4 115.31 3.72 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.105 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.496 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -100.93 122.51 43.61 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.196 -0.94 . . . . 0.0 109.01 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.578 HD12 HG21 ' B' ' 50' ' ' ILE . 22.6 pt -93.24 139.26 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.016 -1.052 . . . . 0.0 109.109 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.606 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.64 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.641 -1.783 . . . . 0.0 108.641 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.74 -121.92 2.55 Favored Glycine 0 N--CA 1.483 1.812 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.698 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.793 HG21 HD12 ' B' ' 47' ' ' ILE . 26.3 mt -86.48 122.23 38.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.875 -0.779 . . . . 0.0 112.571 -177.686 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.447 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 103.49 -50.98 0.85 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 176.26 -156.94 22.29 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.606 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 5.2 m-85 -111.9 129.9 56.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -1.034 . . . . 0.0 109.837 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.561 HG13 ' CG1' ' A' ' 47' ' ' ILE . 1.0 OUTLIER -106.97 164.76 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.1 mtmt -106.82 140.28 39.91 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.865 -1.147 . . . . 0.0 110.497 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.861 HG12 ' HA3' ' A' ' 78' ' ' GLY . 16.1 m -146.63 178.18 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.83 110.63 16.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.329 -0.857 . . . . 0.0 108.829 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.414 ' O ' ' CG ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -64.75 107.03 1.32 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.456 -0.778 . . . . 0.0 110.271 -179.247 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.615 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.2 m-85 -100.89 100.45 11.08 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.535 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 85.2 m-20 -83.82 132.62 34.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.051 -1.031 . . . . 0.0 110.85 -178.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.2 mt-30 81.17 60.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.82 -0.55 . . . . 0.0 110.767 178.583 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.879 HD12 HD11 ' A' ' 38' ' ' LEU . 5.1 mm -117.93 118.46 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.545 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.156 HD21 ' CG ' ' A' ' 70' ' ' LYS . 1.4 tp -70.35 86.52 0.6 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.035 -1.04 . . . . 0.0 111.145 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.952 HD12 HD11 ' A' ' 15' ' ' ILE . 5.6 tt -86.54 119.75 35.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.79 103.98 16.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.936 -1.102 . . . . 0.0 109.165 -178.589 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.987 HG23 HG21 ' A' ' 11' ' ' VAL . 3.2 mt -109.61 120.93 61.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.479 -0.763 . . . . 0.0 109.717 -179.311 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.411 ' HB3' ' CE1' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 64.42 40.21 6.5 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.531 -0.731 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.24 30.49 76.11 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.411 ' CE1' ' HB3' ' A' ' 67' ' ' CYS . 36.9 m80 -122.69 101.38 7.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -1.19 . . . . 0.0 109.592 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 1.156 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -53.04 108.88 0.36 Allowed 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.156 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.74 ' O ' HD12 ' A' ' 63' ' ' LEU . . . -126.56 148.35 49.75 Favored 'General case' 0 C--N 1.287 -2.14 0 C-N-CA 120.304 -0.558 . . . . 0.0 109.603 -179.08 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 63' ' ' LEU . 1.0 OUTLIER -118.68 147.42 22.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.504 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.817 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -172.45 -168.26 33.6 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 118.789 -1.672 . . . . 0.0 110.987 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.513 ' HB ' ' OD1' ' A' ' 30' ' ' ASP . 27.9 m -96.98 108.0 20.64 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.659 -0.906 . . . . 0.0 109.409 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.801 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.21 111.06 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.469 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.3 mp -81.12 118.38 22.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.057 -1.027 . . . . 0.0 108.306 178.591 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.426 HG12 ' HA ' ' A' ' 35' ' ' GLU . 8.5 t -104.89 109.99 29.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.124 -0.985 . . . . 0.0 109.68 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.861 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -148.16 -162.16 9.98 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.538 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -81.66 43.78 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.637 2.225 . . . . 0.0 110.599 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.57 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.1 t -84.75 136.33 39.31 Favored Pre-proline 0 N--CA 1.491 1.576 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -79.07 14.54 1.71 Allowed 'Trans proline' 0 C--N 1.307 -1.614 0 C-N-CA 122.389 2.059 . . . . 0.0 110.983 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.2 t -159.9 164.65 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.11 -0.994 . . . . 0.0 109.101 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.531 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -101.36 126.21 48.09 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 104.831 -2.285 . . . . 0.0 104.831 176.649 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 31' ' ' THR . 7.6 mm -113.32 128.94 69.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.333 -1.347 . . . . 0.0 111.794 -176.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.53 90.91 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 177.138 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.75 ' O ' HD22 ' A' ' 90' ' ' LEU . . . -83.97 173.6 50.66 Favored Glycine 0 N--CA 1.498 2.774 0 O-C-N 121.198 -0.939 . . . . 0.0 110.97 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.678 ' HA ' HD23 ' A' ' 90' ' ' LEU . 8.8 mmm180 -39.89 -39.97 0.92 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.806 -0.82 . . . . 0.0 111.335 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.992 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.2 p-10 -44.55 -41.18 6.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.739 -1.226 . . . . 0.0 109.986 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.992 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.7 mm? -96.67 -26.62 15.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.237 -0.914 . . . . 0.0 111.745 -179.045 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.75 HD22 ' O ' ' A' ' 86' ' ' GLY . 0.8 OUTLIER -60.28 -36.25 77.41 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.292 -1.505 . . . . 0.0 108.0 179.71 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 81.6 p -70.05 -21.58 63.15 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 108.846 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.42 ' HB2' ' O ' ' A' ' 89' ' ' LEU . 22.3 mm-40 -74.78 -40.66 61.04 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.723 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -86.31 -13.08 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.384 -0.822 . . . . 0.0 108.937 179.444 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 83.92 26.78 40.05 Favored Glycine 0 N--CA 1.495 2.633 0 C-N-CA 120.32 -0.943 . . . . 0.0 111.042 178.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.556 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -59.5 143.16 50.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 109.865 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.458 HG22 ' CG2' ' B' ' 4' ' ' THR . 74.2 p -135.34 129.58 33.66 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.401 HD11 HD11 ' B' ' 97' ' ' LEU . 3.7 mp -92.63 99.26 12.0 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.907 -1.12 . . . . 0.0 110.688 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.533 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.3 m-20 -108.0 124.48 50.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.413 -0.804 . . . . 0.0 109.046 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.73 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 118.037 -0.983 . . . . 0.0 109.163 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.273 -0.703 . . . . 0.0 110.273 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.419 ' CG ' ' OD1' ' A' ' 98' ' ' ASN . 2.5 tt0 -83.39 144.11 29.85 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.6 t -141.98 105.83 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.364 -1.334 . . . . 0.0 110.87 -177.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.458 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.2 OUTLIER -106.61 -86.51 0.49 Allowed 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 178.137 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.55 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 43.52 20.38 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.576 -0.702 . . . . 0.0 111.308 178.498 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 40.4 m0 16.24 52.16 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.234 0.54 . . . . 0.0 112.16 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.55 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.4 mt-30 -144.03 -128.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.45 130.93 22.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.642 -1.286 . . . . 0.0 109.662 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.873 ' HB2' HD12 ' B' ' 24' ' ' LEU . 37.1 Cg_endo -82.52 53.63 4.56 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.456 2.104 . . . . 0.0 109.301 178.64 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.68 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.7 mt -79.05 143.73 35.33 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.237 -0.914 . . . . 0.0 109.31 -179.175 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 1.062 HG21 HG23 ' B' ' 66' ' ' ILE . 0.8 OUTLIER -142.38 150.89 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -0.823 . . . . 0.0 109.452 -179.713 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 89.8 m -83.92 109.01 17.26 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.751 HD11 HD21 ' B' ' 33' ' ' LEU . 1.1 pt -98.89 139.26 21.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.148 -0.97 . . . . 0.0 111.102 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.463 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.7 OUTLIER -98.5 98.31 9.52 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.867 HD11 HD12 ' B' ' 64' ' ' ILE . 4.9 mt -120.3 130.64 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.342 -0.849 . . . . 0.0 109.337 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.29 23.54 71.7 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.4 15.72 80.2 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.463 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -112.25 174.08 6.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.422 -1.046 . . . . 0.0 109.31 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.484 HD23 ' HA ' ' B' ' 19' ' ' LEU . 27.9 mt -134.8 113.91 12.09 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.248 -0.907 . . . . 0.0 110.018 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -134.85 177.48 7.76 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.5 mm-40 -79.58 177.78 8.62 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.859 -1.15 . . . . 0.0 108.883 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.651 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -159.18 101.53 1.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.322 -0.861 . . . . 0.0 109.447 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 1.023 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.3 tp -77.97 98.89 5.84 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.291 -0.88 . . . . 0.0 109.438 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.873 HD12 ' HB2' ' B' ' 9' ' ' PRO . 89.6 mt -45.42 104.74 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.055 -1.028 . . . . 0.0 108.585 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.988 ' HB3' HG23 ' B' ' 84' ' ' ILE . 39.5 t0 -111.69 91.43 3.66 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.356 -0.84 . . . . 0.0 110.646 -178.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.444 HG23 HH11 ' B' ' 87' ' ' ARG . 55.9 m -69.79 -11.57 60.96 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.119 -0.988 . . . . 0.0 108.459 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.871 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -69.24 -39.85 82.03 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.26 150.67 29.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.342 -1.093 . . . . 0.0 109.481 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -91.19 -10.04 43.17 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.23 -0.919 . . . . 0.0 109.805 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.479 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -131.81 -173.13 3.05 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.274 -0.892 . . . . 0.0 109.546 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.664 HG22 ' CD1' ' B' ' 33' ' ' LEU . 29.9 m -113.44 98.51 7.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.01 -1.056 . . . . 0.0 110.229 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.914 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -83.33 166.01 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.017 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -162.8 126.58 2.94 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.59 -1.319 . . . . 0.0 111.354 -178.438 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.582 ' N ' HG22 ' B' ' 80' ' ' THR . 8.5 tt0 -42.9 154.57 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.602 ' HA ' HG13 ' B' ' 77' ' ' VAL . 1.6 tm-20 -38.8 148.54 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.349 -0.844 . . . . 0.0 110.366 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.577 ' CE ' HG22 ' B' ' 15' ' ' ILE . 24.5 ptm -163.57 -162.31 0.72 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.324 -0.86 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.5 t -118.68 120.2 36.73 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.083 -1.01 . . . . 0.0 110.794 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.761 HD23 ' CD2' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -124.6 173.66 4.53 Favored Pre-proline 0 N--CA 1.491 1.592 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.019 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.59 ' HD3' HD12 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.72 47.72 2.61 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.676 2.25 . . . . 0.0 111.634 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.12 -166.88 0.01 OUTLIER Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.408 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.5 mmm180 63.38 70.73 0.52 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.168 -1.195 . . . . 0.0 109.361 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.618 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 10.1 p-90 -140.41 -173.43 3.67 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 121.629 -0.669 . . . . 0.0 109.519 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.94 128.58 16.76 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.216 -0.927 . . . . 0.0 108.516 179.292 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -75.34 139.54 23.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 121.879 1.719 . . . . 0.0 110.749 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.17 -162.7 1.57 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.528 -0.732 . . . . 0.0 109.232 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.555 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 0.2 OUTLIER -149.02 130.02 14.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.27 -0.894 . . . . 0.0 109.613 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.793 HD12 HG21 ' A' ' 50' ' ' ILE . 8.3 pt -98.67 143.56 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.899 -1.125 . . . . 0.0 108.84 179.111 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.629 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -118.53 113.3 2.56 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 -179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.12 -125.43 2.04 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.707 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.578 HG21 HD12 ' A' ' 47' ' ' ILE . 21.5 mt -88.7 119.04 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.797 -0.825 . . . . 0.0 112.852 -177.537 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.446 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 96.6 2.32 60.06 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.203 177.234 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 126.87 -158.75 20.96 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.334 -1.412 . . . . 0.0 110.221 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.66 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.9 OUTLIER -124.6 134.11 53.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.661 -0.905 . . . . 0.0 109.222 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.733 HD11 HD11 ' B' ' 47' ' ' ILE . 13.5 pt -104.26 167.65 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.979 -1.076 . . . . 0.0 109.239 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.559 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.91 134.32 48.23 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.191 -0.943 . . . . 0.0 109.159 179.734 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.826 HG12 ' HA3' ' B' ' 78' ' ' GLY . 21.4 m -140.6 -171.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.991 -1.068 . . . . 0.0 110.201 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.457 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.4 mtt-85 -128.87 105.92 8.56 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 33.7 tt0 -69.62 100.34 1.44 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.444 -0.785 . . . . 0.0 110.934 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.761 ' CD2' HD23 ' B' ' 38' ' ' LEU . 17.1 m-85 -89.59 133.42 34.62 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.014 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.55 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 67.4 m-20 -108.49 133.14 53.05 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.713 -1.242 . . . . 0.0 109.989 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.558 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.29 63.71 0.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.917 -0.713 . . . . 0.0 109.569 179.581 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.698 ' C ' HD13 ' B' ' 72' ' ' ILE . 26.9 mm -116.52 119.28 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.844 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.9 tm? -66.02 84.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 111.28 -178.521 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.867 HD12 HD11 ' B' ' 15' ' ' ILE . 5.7 tt -90.52 112.19 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.564 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 29.5 tt0 -89.52 115.39 26.9 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.178 -0.951 . . . . 0.0 109.033 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 1.062 HG23 HG21 ' B' ' 11' ' ' VAL . 2.3 mp -112.97 123.43 68.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.032 -1.043 . . . . 0.0 109.719 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.636 ' SG ' HG22 ' B' ' 66' ' ' ILE . 36.8 m 67.17 44.93 1.79 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.487 -0.758 . . . . 0.0 109.444 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 61.52 21.02 59.75 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.52 ' O ' ' HA ' ' B' ' 65' ' ' GLU . 4.4 m-70 -119.66 130.09 54.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.014 -1.286 . . . . 0.0 109.677 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.581 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -70.56 136.55 49.37 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -155.9 104.69 2.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.219 -0.925 . . . . 0.0 109.793 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.716 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -80.06 154.54 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.963 -1.085 . . . . 0.0 108.349 178.93 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.564 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 178.98 -169.74 41.24 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.16 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -95.64 105.9 17.94 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.667 -0.901 . . . . 0.0 110.618 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.017 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.6 158.91 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.726 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.8 mp -126.38 125.42 42.18 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.762 -1.211 . . . . 0.0 107.901 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.602 HG13 ' HA ' ' B' ' 35' ' ' GLU . 94.8 t -106.43 116.39 50.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 O-C-N 120.671 -1.268 . . . . 0.0 109.663 -179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.826 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.37 -166.25 15.9 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.559 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -80.09 44.52 1.74 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.511 2.141 . . . . 0.0 110.604 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.66 HG21 HG13 ' B' ' 32' ' ' VAL . 3.2 t -89.74 135.22 30.84 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.645 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -78.17 17.59 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.284 1.99 . . . . 0.0 111.137 -178.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.645 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.5 t -160.32 156.76 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 120.879 -1.138 . . . . 0.0 110.777 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.613 ' OD1' HD23 ' B' ' 33' ' ' LEU . 60.4 m-20 -97.41 86.28 3.84 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 176.699 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.988 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.6 mt -82.78 124.89 39.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 O-C-N 121.298 -0.876 . . . . 0.0 112.378 -176.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.52 ' N ' HD13 ' B' ' 85' ' ' ILE . 3.7 mm -100.19 109.18 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.572 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -108.29 164.39 12.76 Favored Glycine 0 N--CA 1.498 2.785 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.881 -178.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.564 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 20.7 mmm180 -19.26 -41.94 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -178.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.9 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -49.45 -42.12 42.14 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.475 -1.391 . . . . 0.0 110.813 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.9 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -93.75 -27.65 16.37 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.245 -0.91 . . . . 0.0 109.976 -179.653 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' B' ' 90' ' ' LEU . 4.6 mp -58.76 -33.87 70.78 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.097 -1.002 . . . . 0.0 108.831 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 4.3 p -74.12 -21.28 59.95 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.294 -0.879 . . . . 0.0 109.866 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -80.14 -40.47 27.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.163 -0.961 . . . . 0.0 109.053 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.73 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -81.7 -5.39 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.264 -0.897 . . . . 0.0 108.916 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.31 60.74 7.79 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.553 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -87.89 160.06 18.12 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.265 -1.138 . . . . 0.0 110.706 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.528 ' HB ' ' CG2' ' A' ' 4' ' ' THR . 4.7 p -141.7 126.96 18.6 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.502 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.5 mp -92.18 97.1 10.7 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.556 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 10.4 m120 -97.41 118.92 34.96 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.378 -0.826 . . . . 0.0 110.453 -178.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.723 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.723 0 CA-C-O 117.923 -1.037 . . . . 0.0 109.334 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.589 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 4.0 Cg_exo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.763 -0.514 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -83.77 131.75 34.89 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.494 HG11 ' HB3' ' A' ' 9' ' ' PRO . 20.0 t -124.12 102.06 10.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.575 -1.328 . . . . 0.0 110.484 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.987 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -139.78 48.73 1.8 Allowed 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.55 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -85.59 43.02 1.0 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.225 -0.922 . . . . 0.0 110.152 -179.238 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.597 ' CZ3' ' HB ' ' B' ' 91' ' ' THR . 13.4 m95 18.91 48.09 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 CA-C-O 121.46 0.647 . . . . 0.0 111.335 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 37.1 mt-30 -165.23 -168.0 1.3 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.419 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 58.8 mtt180 -75.26 122.49 87.44 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.011 -1.055 . . . . 0.0 108.632 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.818 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.5 Cg_endo -76.53 85.06 1.76 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.153 1.902 . . . . 0.0 109.991 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.803 HD22 ' HB3' ' A' ' 21' ' ' GLU . 5.5 mt -86.47 142.36 28.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.287 -0.883 . . . . 0.0 109.723 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.635 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -146.98 154.4 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.927 . . . . 0.0 109.243 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.779 HG22 HD22 ' A' ' 19' ' ' LEU . 85.3 m -88.95 112.87 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.877 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -101.87 153.51 5.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.114 -0.991 . . . . 0.0 110.121 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 2.9 tttt -110.76 109.21 19.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.36 -0.838 . . . . 0.0 109.738 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.937 HD13 HG11 ' A' ' 75' ' ' VAL . 4.5 mt -124.59 135.54 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.03 -1.044 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 50.04 33.8 22.49 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.085 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.68 35.2 59.11 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 9.0 mm100 -128.19 175.72 8.22 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -1.107 . . . . 0.0 109.057 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.779 HD22 HG22 ' A' ' 12' ' ' THR . 14.2 mt -145.71 123.27 11.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -0.946 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 18.3 mttp -146.61 177.32 9.16 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.803 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -79.19 -179.96 7.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.831 -1.168 . . . . 0.0 108.612 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.699 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -165.17 109.2 0.87 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.249 -1.532 . . . . 0.0 110.992 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.636 HD21 ' O ' ' B' ' 27' ' ' GLY . 2.8 tp -78.57 95.79 5.3 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.818 HD12 ' HB2' ' A' ' 9' ' ' PRO . 35.0 mt -48.64 93.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.608 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.735 ' HB3' HG23 ' A' ' 84' ' ' ILE . 22.5 t0 -99.57 92.92 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 110.828 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.51 ' OG1' HD21 ' B' ' 97' ' ' LEU . 2.6 m -67.56 -6.84 21.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.095 -1.003 . . . . 0.0 109.467 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.984 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -78.55 -40.83 17.49 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.56 154.15 40.94 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.31 . . . . 0.0 109.256 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 1.8 m-20 -88.2 -13.59 40.73 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.25 -0.906 . . . . 0.0 110.374 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.843 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -137.51 -170.77 2.82 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.984 -1.073 . . . . 0.0 110.482 -179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.712 HG23 HD12 ' A' ' 85' ' ' ILE . 22.8 m -109.05 89.82 3.11 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.034 -1.041 . . . . 0.0 110.677 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -71.54 167.5 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.009 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.9 130.02 2.23 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -178.212 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.582 ' CG ' ' O ' ' A' ' 80' ' ' THR . 7.2 mt-10 -39.1 157.8 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.618 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -60.12 154.0 20.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 110.103 179.764 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.596 ' CE ' HG22 ' A' ' 15' ' ' ILE . 4.1 ptm -176.0 -168.71 0.29 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.186 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.8 t -97.82 105.17 17.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.274 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 39' ' ' PRO . 27.8 tp -131.64 103.4 14.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.849 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.6 Cg_endo -78.5 154.27 27.51 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.514 2.143 . . . . 0.0 110.336 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 132.74 -173.16 21.03 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.66 141.28 29.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.33 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.0 p-90 -160.88 175.34 12.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.834 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -148.28 154.5 42.26 Favored Pre-proline 0 C--N 1.301 -1.511 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.216 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.53 136.55 13.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.233 1.956 . . . . 0.0 110.223 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.569 ' HG3' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -149.94 -169.26 3.33 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.354 -0.841 . . . . 0.0 109.387 179.669 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.439 ' SD ' ' HG3' ' A' ' 55' ' ' LYS . 9.7 mmm -145.13 118.9 9.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.117 -0.99 . . . . 0.0 109.576 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 9.9 pt -89.75 135.24 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 118.886 -1.126 . . . . 0.0 108.294 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.414 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -118.7 105.47 1.19 Allowed Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.64 -123.26 2.67 Favored Glycine 0 N--CA 1.482 1.737 0 C-N-CA 119.552 -1.309 . . . . 0.0 110.632 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.71 HG21 ' CD1' ' B' ' 47' ' ' ILE . 13.5 mt -87.22 121.2 37.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.88 -0.776 . . . . 0.0 112.353 -177.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 99.92 -46.16 1.42 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.45 -163.33 33.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -120.93 137.01 54.81 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.121 -1.223 . . . . 0.0 109.628 -179.838 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 79' ' ' PRO . 2.7 pt -111.92 159.18 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.231 -0.918 . . . . 0.0 109.222 179.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -82.19 141.16 33.27 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.225 -0.922 . . . . 0.0 110.255 -179.376 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.569 HG22 ' HG3' ' A' ' 45' ' ' LYS . 2.9 m -148.22 166.32 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -113.71 107.2 15.44 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 42.6 tt0 -65.83 107.63 1.87 Allowed 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.578 -0.701 . . . . 0.0 110.282 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 74' ' ' THR . 8.3 m-85 -97.27 138.68 34.38 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.541 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 21.9 m-20 -119.37 118.02 30.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.877 -1.139 . . . . 0.0 110.267 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.541 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 66.3 mt-30 87.64 55.82 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 CA-C-O 121.362 0.601 . . . . 0.0 110.283 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.571 HG13 ' HB3' ' A' ' 59' ' ' TYR . 21.8 mm -110.04 124.55 66.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -66.56 96.4 0.38 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.221 -0.924 . . . . 0.0 110.661 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.846 HD12 HD11 ' A' ' 15' ' ' ILE . 7.7 tt -105.97 115.91 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.526 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -88.47 140.88 29.02 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 109.231 -179.079 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 1.0 OUTLIER -127.7 130.34 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.3 -0.875 . . . . 0.0 108.993 -179.797 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.428 ' C ' ' O ' ' A' ' 66' ' ' ILE . 58.5 m 40.64 29.66 0.07 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.607 -0.683 . . . . 0.0 109.731 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 83.33 42.62 7.85 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.415 ' O ' ' C ' ' A' ' 70' ' ' LYS . 2.2 m80 -134.6 100.73 4.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.313 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' A' ' 69' ' ' HIS . 16.9 ttpt -46.47 122.13 3.9 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.573 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.49 101.21 3.21 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 110.44 -179.013 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.517 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -81.97 158.72 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 177.932 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.508 ' N ' HG22 ' A' ' 72' ' ' ILE . . . 177.95 -161.46 28.48 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 118.824 -1.655 . . . . 0.0 110.579 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 59' ' ' TYR . 98.9 m -102.0 117.26 34.43 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.122 -1.222 . . . . 0.0 109.787 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.937 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -108.21 117.7 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.341 -0.85 . . . . 0.0 110.397 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.843 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.3 mp -86.75 107.99 18.5 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.405 -0.81 . . . . 0.0 109.213 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 35' ' ' GLU . 1.4 t -91.85 114.17 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.082 -1.011 . . . . 0.0 109.875 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.85 -168.25 15.41 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 54' ' ' ILE . 37.0 Cg_endo -81.55 42.11 1.27 Allowed 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 110.201 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.629 HG21 HG13 ' A' ' 32' ' ' VAL . 5.0 t -82.05 137.91 46.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.439 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.577 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.2 Cg_endo -79.45 21.53 0.76 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.483 2.122 . . . . 0.0 111.273 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.591 ' CG1' HG13 ' A' ' 84' ' ' ILE . 1.4 t -161.03 160.65 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 120.871 -1.143 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.637 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -102.52 94.66 5.78 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 177.217 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.761 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.8 mt -94.58 128.93 45.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 CA-C-O 122.132 0.968 . . . . 0.0 113.268 -175.079 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.871 ' N ' HD13 ' A' ' 85' ' ' ILE . 0.5 OUTLIER -104.08 107.87 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.353 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -87.71 -168.59 44.67 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.727 -178.142 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.436 ' HD2' ' CG2' ' A' ' 91' ' ' THR . 5.9 mmt180 -60.58 -32.52 71.61 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.696 -0.885 . . . . 0.0 109.953 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.5 p-10 -46.88 -29.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.776 -1.203 . . . . 0.0 109.14 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -106.26 -36.72 6.78 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.505 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 38.0 mt -62.55 -12.78 24.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.889 -1.132 . . . . 0.0 108.694 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.463 ' O ' ' CH2' ' B' ' 6' ' ' TRP . 67.4 p -100.55 -20.36 15.74 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.207 -0.933 . . . . 0.0 108.673 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.436 ' NE2' ' O ' ' A' ' 72' ' ' ILE . 7.4 mm100 -79.23 -40.86 29.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.321 -0.862 . . . . 0.0 109.089 179.549 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.029 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -79.98 -15.06 13.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.162 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 100.31 15.66 29.54 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.735 178.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.572 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -56.84 146.4 26.48 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.502 -1.587 . . . . 0.0 109.673 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.664 HG22 ' CG2' ' B' ' 4' ' ' THR . 19.2 p -137.78 129.86 28.91 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -87.45 98.81 11.59 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.97 -1.081 . . . . 0.0 109.444 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.535 ' C ' ' CD1' ' A' ' 99' ' ' PHE . 3.0 m-20 -111.57 136.81 50.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.394 -0.816 . . . . 0.0 110.103 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.758 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.273 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 N-CA-C 109.984 -0.814 . . . . 0.0 109.984 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -83.56 138.87 33.19 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.618 HG11 ' HB3' ' B' ' 9' ' ' PRO . 4.4 t -128.6 111.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.769 -178.325 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.664 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.66 39.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.848 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.554 ' O ' ' N ' ' B' ' 7' ' ' GLN . 4.6 tp -83.93 46.0 1.14 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.107 -0.995 . . . . 0.0 110.266 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' B' ' 5' ' ' LEU . 38.0 m95 17.94 50.06 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 121.489 0.662 . . . . 0.0 112.121 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.554 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.0 mt-30 -165.62 173.76 10.53 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.14 128.1 56.65 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 121.089 -1.007 . . . . 0.0 109.043 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.618 ' HB3' HG11 ' B' ' 3' ' ' VAL . 35.0 Cg_endo -79.35 64.64 8.87 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.423 2.082 . . . . 0.0 110.438 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.908 HD22 ' HB2' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -79.43 148.35 31.97 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.161 -0.962 . . . . 0.0 109.222 -179.929 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.78 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -143.72 137.15 24.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.232 -0.917 . . . . 0.0 109.573 -179.302 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 7.1 m -69.13 98.78 1.04 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 1.005 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -89.79 151.44 3.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.351 -0.843 . . . . 0.0 110.0 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.553 ' HE3' ' CG ' ' B' ' 19' ' ' LEU . 2.1 tttt -117.37 107.1 13.96 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.337 -0.852 . . . . 0.0 108.951 179.203 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.891 HD13 HG11 ' B' ' 75' ' ' VAL . 4.1 mt -113.5 139.6 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.253 -0.905 . . . . 0.0 109.205 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.62 -90.9 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -151.79 45.72 0.61 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.6 OUTLIER -140.82 169.31 17.87 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.455 -1.026 . . . . 0.0 110.035 -179.332 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.553 ' CG ' ' HE3' ' B' ' 14' ' ' LYS . 27.8 mt -139.07 113.83 9.2 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.483 ' HG3' ' C ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -136.26 163.88 29.39 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.207 -0.933 . . . . 0.0 109.115 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.908 ' HB2' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -78.13 145.01 35.96 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.277 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.795 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -134.39 116.45 15.2 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.869 -1.145 . . . . 0.0 111.297 -178.116 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.984 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -71.47 100.13 2.16 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.645 HD22 HD21 ' B' ' 90' ' ' LEU . 18.6 mt -47.18 137.44 7.96 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 179.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.824 ' HB2' HG23 ' B' ' 84' ' ' ILE . 42.4 t0 -142.66 94.24 2.62 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.835 -1.166 . . . . 0.0 111.422 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.526 HG23 ' HD3' ' B' ' 87' ' ' ARG . 6.8 m -74.89 -14.87 60.71 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.088 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.636 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -76.05 -16.18 80.87 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.39 160.71 14.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.32 . . . . 0.0 109.053 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -88.23 -21.14 24.67 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.014 . . . . 0.0 110.479 -179.201 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.637 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 1.6 m-20 -143.05 -173.83 4.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.635 -1.291 . . . . 0.0 110.858 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.804 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.2 m -97.54 86.02 3.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.822 -1.173 . . . . 0.0 111.578 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.923 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -67.22 153.61 8.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.423 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.923 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.2 OUTLIER -157.08 124.42 5.26 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.083 -1.011 . . . . 0.0 110.569 -177.722 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.564 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.7 tm-20 -43.07 153.87 0.08 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 109.078 178.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.566 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.3 tt0 -45.23 139.49 3.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 110.902 -179.336 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.655 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.3 ppp? -152.04 -164.4 1.96 Allowed 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.495 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -112.73 118.16 34.21 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.88 -1.138 . . . . 0.0 110.539 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.641 ' HG ' ' HD2' ' B' ' 39' ' ' PRO . 0.2 OUTLIER -134.91 -175.08 0.45 Allowed Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.411 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.641 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.7 Cg_endo -79.7 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.256 1.971 . . . . 0.0 110.942 -178.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 35.93 4.63 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.35 51.75 0.75 Allowed 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.683 -0.892 . . . . 0.0 108.945 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.65 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 39.9 p-90 -137.95 179.83 6.2 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.776 0.798 . . . . 0.0 110.668 -178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.494 ' HG3' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -140.86 146.13 42.69 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.088 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 44' ' ' PRO . . . . . 0.494 ' HD2' ' HG3' ' B' ' 43' ' ' LYS . 34.9 Cg_endo -78.36 138.67 15.93 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.416 2.077 . . . . 0.0 110.679 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' B' ' 58' ' ' GLN . 1.1 ptpt -160.54 -165.17 1.36 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.45 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 44.4 mtp -151.1 138.48 19.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.172 -0.955 . . . . 0.0 109.997 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.71 ' CD1' HG21 ' A' ' 50' ' ' ILE . 10.3 pt -103.71 148.3 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.114 -0.991 . . . . 0.0 108.83 178.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.626 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -119.57 116.28 3.26 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.979 -1.649 . . . . 0.0 108.979 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.45 -123.23 2.19 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.226 -1.464 . . . . 0.0 111.145 -179.046 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.777 HG21 ' CD1' ' A' ' 47' ' ' ILE . 15.8 mt -84.03 133.48 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.729 -0.866 . . . . 0.0 112.694 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.461 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 85.23 -44.17 3.34 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 178.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 171.24 -171.33 43.9 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.227 -1.463 . . . . 0.0 109.95 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' HA2' ' B' ' 48' ' ' GLY . 7.7 m-30 -96.29 168.82 10.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.432 -1.04 . . . . 0.0 109.748 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.64 HD12 HG13 ' B' ' 56' ' ' VAL . 1.8 pt -142.23 177.23 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.543 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.0 mtpt -114.18 128.65 56.47 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.922 -1.111 . . . . 0.0 109.44 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.654 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.7 m -136.61 -175.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.045 -1.034 . . . . 0.0 109.987 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 66.5 mtt180 -130.23 110.97 11.97 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.415 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 2.0 tt0 -69.98 103.49 2.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.32 -0.863 . . . . 0.0 110.442 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.65 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 10.5 m-85 -89.01 141.12 28.75 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 4.0 m-20 -120.12 130.96 54.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.681 -1.262 . . . . 0.0 110.953 -178.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.576 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 69.3 62.92 0.29 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.15 0.5 . . . . 0.0 110.756 179.003 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.784 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -118.48 125.64 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.164 -0.96 . . . . 0.0 108.923 178.877 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.787 ' N ' HD13 ' B' ' 72' ' ' ILE . 3.1 tm? -70.63 101.08 1.97 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.496 -0.752 . . . . 0.0 111.658 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.885 HD13 HD11 ' B' ' 66' ' ' ILE . 4.0 tt -101.48 122.27 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 25.5 tt0 -89.06 100.82 13.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.938 -1.101 . . . . 0.0 109.831 -178.555 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 1.005 HG13 HG22 ' B' ' 13' ' ' ILE . 1.1 mp -99.53 113.05 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.163 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 63.47 25.31 14.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.61 6.75 82.85 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.328 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -103.45 109.49 21.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -1.203 . . . . 0.0 109.252 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.47 133.15 35.56 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.724 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -152.98 98.16 2.28 Favored 'General case' 0 C--N 1.294 -1.831 0 O-C-N 121.257 -0.902 . . . . 0.0 109.88 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.787 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -77.97 145.5 9.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.151 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.5 -175.07 40.96 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.005 -1.569 . . . . 0.0 110.971 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.563 HG23 ' O ' ' B' ' 59' ' ' TYR . 1.5 m -85.75 112.51 21.13 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.668 -0.901 . . . . 0.0 110.461 -179.195 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.891 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -104.8 105.53 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -0.813 . . . . 0.0 110.156 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.6 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.1 mp -77.14 129.78 36.45 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.566 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 45.4 t -118.52 122.95 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 110.247 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.654 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -157.56 -165.41 15.19 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.543 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.9 Cg_endo -81.98 41.87 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.547 2.165 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.602 HG23 ' O ' ' B' ' 82' ' ' VAL . 8.9 t -79.4 141.71 57.4 Favored Pre-proline 0 N--CA 1.49 1.56 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.702 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.1 Cg_endo -77.68 14.39 1.46 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.135 1.89 . . . . 0.0 110.874 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.702 HG23 ' O ' ' B' ' 81' ' ' PRO . 3.6 t -161.02 162.52 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.856 -1.152 . . . . 0.0 110.201 -179.219 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -102.97 99.77 9.68 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 176.665 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.893 ' HB ' HG12 ' B' ' 32' ' ' VAL . 4.7 mt -104.51 129.22 57.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 120.835 -1.166 . . . . 0.0 112.869 -175.798 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.795 HD11 ' HB1' ' B' ' 22' ' ' ALA . 2.6 mm -88.51 132.39 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 176.7 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.637 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -107.16 -159.55 21.33 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 118.683 -1.723 . . . . 0.0 110.243 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.526 ' HD3' HG23 ' B' ' 26' ' ' THR . 0.4 OUTLIER -71.08 -30.28 66.36 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.737 -0.86 . . . . 0.0 108.762 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.799 ' ND2' HD23 ' B' ' 89' ' ' LEU . 5.8 p-10 -50.19 -40.07 45.88 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.822 -1.151 . . . . 0.0 108.897 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.799 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -90.25 -32.86 16.38 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.42 -0.8 . . . . 0.0 110.027 -179.361 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.645 HD21 HD22 ' B' ' 24' ' ' LEU . 37.0 mt -67.04 -8.03 27.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.99 -1.069 . . . . 0.0 108.655 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.597 ' HB ' ' CZ3' ' A' ' 6' ' ' TRP . 31.5 p -99.43 -18.2 17.59 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.008 -1.058 . . . . 0.0 108.581 179.263 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 29.4 mm-40 -85.01 -40.95 16.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.53 -0.731 . . . . 0.0 109.659 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.758 HD12 ' CD2' ' A' ' 99' ' ' PHE . 26.6 pt -83.17 -4.25 8.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.306 -0.871 . . . . 0.0 109.032 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.95 60.33 6.17 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.587 ' CB ' ' CD1' ' A' ' 99' ' ' PHE . . . -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.282 -1.128 . . . . 0.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.987 HG22 ' CG2' ' A' ' 4' ' ' THR . 10.7 p -137.56 129.49 28.86 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' A' ' 97' ' ' LEU . 5.4 mp -87.14 98.39 11.27 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 11.0 m-20 -103.6 128.5 50.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.868 -1.145 . . . . 0.0 110.123 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 1.029 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.532 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 N-CA-C 109.899 -0.846 . . . . 0.0 109.899 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.401 ' HG3' ' OD1' ' B' ' 98' ' ' ASN . 25.0 tt0 -84.17 120.05 25.73 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 4' ' ' THR . 3.4 t -129.21 94.61 2.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.982 -1.074 . . . . 0.0 109.901 -178.207 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.766 ' C ' HD12 ' A' ' 5' ' ' LEU . 0.7 OUTLIER -40.3 -68.85 0.15 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 109.404 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.967 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER 128.88 16.25 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.027 0.531 . . . . 0.0 110.121 179.4 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -48.26 -21.83 0.57 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.916 -1.115 . . . . 0.0 109.245 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.455 ' O ' ' HD3' ' B' ' 87' ' ' ARG . 29.8 mm100 -127.16 -128.81 0.23 Allowed 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.221 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.466 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.3 OUTLIER -111.04 133.61 21.25 Favored Pre-proline 0 C--N 1.306 -1.304 0 O-C-N 120.661 -1.274 . . . . 0.0 109.064 179.398 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.5 Cg_endo -79.96 51.76 4.03 Favored 'Trans proline' 0 C--N 1.313 -1.299 0 C-N-CA 122.203 1.935 . . . . 0.0 109.322 178.069 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.596 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -84.63 157.08 21.27 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.241 -0.912 . . . . 0.0 109.776 -179.315 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.728 HG21 HG23 ' A' ' 66' ' ' ILE . 1.2 m -149.15 131.72 6.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.501 -0.75 . . . . 0.0 109.368 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.651 HG21 HD23 ' A' ' 19' ' ' LEU . 25.3 m -65.02 94.8 0.14 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 177.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.771 HG22 HG13 ' A' ' 66' ' ' ILE . 13.6 pt -83.41 151.43 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.352 -0.843 . . . . 0.0 110.367 -178.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.547 ' HG3' HD12 ' A' ' 19' ' ' LEU . 14.0 ttmt -115.41 96.27 5.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 0.0 109.239 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 62' ' ' ILE . 11.8 mt -116.76 143.84 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.687 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.96 50.91 14.4 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 48.44 46.78 29.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -144.48 163.22 34.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -1.207 . . . . 0.0 109.407 179.898 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.651 HD23 HG21 ' A' ' 12' ' ' THR . 0.4 OUTLIER -129.95 132.92 46.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.181 -0.95 . . . . 0.0 109.971 -179.403 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' NZ ' HD23 ' A' ' 33' ' ' LEU . 4.0 mtmp? -151.13 177.7 9.94 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.596 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -93.86 118.99 32.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.618 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -97.81 143.37 28.5 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.135 -0.978 . . . . 0.0 109.42 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.999 HD11 ' NH2' ' B' ' 87' ' ' ARG . 10.5 tp -107.78 94.15 4.92 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.589 -0.694 . . . . 0.0 109.524 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.572 HD22 HD21 ' A' ' 90' ' ' LEU . 15.5 mt -45.14 111.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.293 -0.879 . . . . 0.0 108.648 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.59 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 19.4 t0 -126.25 80.02 1.89 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.343 -0.848 . . . . 0.0 110.12 -178.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.509 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.8 m -54.1 -18.95 4.19 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.025 -1.047 . . . . 0.0 108.867 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -56.64 -48.73 75.03 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.62 154.88 36.39 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.25 -1.147 . . . . 0.0 109.071 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.99 -7.44 33.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.162 -0.962 . . . . 0.0 110.385 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.667 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -132.59 178.87 6.51 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.981 -1.074 . . . . 0.0 109.539 179.805 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 19.0 m -104.3 89.55 3.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.772 -1.205 . . . . 0.0 110.83 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.975 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 171.48 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.946 -1.096 . . . . 0.0 108.307 178.908 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.031 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -170.19 121.38 0.64 Allowed 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.884 -1.135 . . . . 0.0 110.488 -179.011 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.511 ' HA ' HG22 ' A' ' 80' ' ' THR . 6.4 tt0 -41.4 160.52 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.448 -0.782 . . . . 0.0 109.087 178.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.583 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -48.35 146.86 2.6 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.21 -0.931 . . . . 0.0 110.681 -179.756 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.639 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.1 OUTLIER -159.31 -161.93 0.99 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.302 -0.874 . . . . 0.0 109.427 179.441 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 t -108.75 101.52 10.64 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.146 -0.971 . . . . 0.0 110.168 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.667 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -121.15 178.75 1.09 Allowed Pre-proline 0 N--CA 1.493 1.683 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.595 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 35.5 Cg_endo -79.54 -158.63 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.698 2.265 . . . . 0.0 110.64 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 29.63 7.75 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.9 mtt-85 -106.29 60.87 0.65 Allowed 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 59.2 p-90 -139.62 177.89 7.62 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-O 121.772 0.796 . . . . 0.0 110.696 -178.679 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.487 ' HD3' ' O ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -135.76 140.82 34.77 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.904 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -78.37 129.81 9.67 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 C-N-CA 121.813 1.675 . . . . 0.0 111.215 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' O ' ' HG3' ' A' ' 45' ' ' LYS . 2.3 ptpt -161.99 142.57 10.44 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.534 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -107.52 147.84 30.01 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.744 -1.222 . . . . 0.0 109.675 179.688 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -103.65 150.11 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.394 -0.816 . . . . 0.0 108.982 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.24 98.0 0.71 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.084 -1.607 . . . . 0.0 109.084 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.15 -121.98 2.86 Favored Glycine 0 N--CA 1.487 2.057 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.478 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.708 HG21 HD11 ' B' ' 47' ' ' ILE . 18.2 mt -83.83 128.98 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.584 -0.95 . . . . 0.0 112.463 -177.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.534 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 93.29 -46.56 2.4 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.17 -155.51 25.29 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.099 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.513 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.5 m-85 -105.94 159.3 16.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.621 -0.929 . . . . 0.0 110.24 -179.374 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 47' ' ' ILE . 5.8 pt -137.58 159.8 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.16 124.66 48.14 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.863 -1.148 . . . . 0.0 109.643 -179.814 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.756 HG12 ' HA3' ' A' ' 78' ' ' GLY . 27.7 m -129.15 -178.33 2.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 109.034 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -131.95 105.4 7.4 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.278 179.834 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.56 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.8 OUTLIER -58.51 95.62 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.484 -0.76 . . . . 0.0 110.105 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.672 ' HB3' HD11 ' A' ' 62' ' ' ILE . 8.9 m-85 -89.98 117.87 29.11 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -99.58 141.83 31.86 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.561 -1.337 . . . . 0.0 111.035 -178.012 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.593 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 29.9 mt-30 71.16 62.33 0.17 Allowed 'General case' 0 N--CA 1.492 1.671 0 CA-C-O 121.199 0.523 . . . . 0.0 111.578 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.888 HG21 HG23 ' A' ' 15' ' ' ILE . 5.1 mp -120.76 121.31 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.23 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.894 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.6 tt -68.84 91.99 0.48 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.947 -1.096 . . . . 0.0 111.074 -178.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 1.003 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -89.09 114.74 27.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 176.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 13.8 tt0 -86.53 101.93 13.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.873 -1.142 . . . . 0.0 108.939 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.003 HD11 HD13 ' A' ' 64' ' ' ILE . 2.1 mt -103.7 126.49 58.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.634 0.731 . . . . 0.0 110.15 -178.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.569 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.1 m 44.2 67.11 0.72 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.654 -0.654 . . . . 0.0 110.261 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 67' ' ' CYS . . . 41.57 35.86 1.46 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.382 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.569 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 74.5 m-70 -130.92 101.57 5.68 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.085 -1.244 . . . . 0.0 109.163 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.894 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -50.38 128.29 19.4 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.877 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.661 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 102.86 3.36 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.344 -0.848 . . . . 0.0 110.386 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.596 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -79.48 151.45 4.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.027 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.721 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -174.44 -178.13 44.1 Favored Glycine 0 N--CA 1.486 2.014 0 C-N-CA 118.444 -1.836 . . . . 0.0 111.482 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.56 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 2.5 m -88.81 103.87 16.39 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.203 -0.587 . . . . 0.0 110.418 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.031 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -97.72 108.59 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.45 -0.781 . . . . 0.0 110.582 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.667 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.4 mp -78.78 117.47 19.93 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.176 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.583 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.2 t -103.11 119.71 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 110.382 -178.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.756 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.31 -168.3 16.95 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 35.9 Cg_endo -79.52 41.94 1.2 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.64 2.227 . . . . 0.0 111.088 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.557 HG21 HG13 ' A' ' 32' ' ' VAL . 3.6 t -83.43 139.86 41.6 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.059 -1.026 . . . . 0.0 108.498 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 80' ' ' THR . 34.6 Cg_endo -78.23 13.82 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.322 2.015 . . . . 0.0 111.689 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.9 OUTLIER -160.95 170.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.876 -1.14 . . . . 0.0 109.618 179.512 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.618 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -104.67 127.17 52.35 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 176.63 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.658 HG12 HG12 ' A' ' 32' ' ' VAL . 4.8 mm -112.86 128.33 69.63 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 O-C-N 120.406 -1.434 . . . . 0.0 111.04 -177.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.564 ' N ' ' CD1' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -104.56 91.51 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.757 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -78.64 -167.8 32.8 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 110.637 -177.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.76 -34.25 72.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.639 -0.918 . . . . 0.0 110.338 -179.177 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.6 p-10 -48.94 -27.57 3.21 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.892 -1.13 . . . . 0.0 109.405 -179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.5 mm? -108.68 -29.38 8.74 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 121.121 -0.987 . . . . 0.0 110.034 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.603 HD23 HD11 ' A' ' 93' ' ' ILE . 96.7 mt -70.2 -6.27 33.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.08 -1.013 . . . . 0.0 108.463 179.024 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 87' ' ' ARG . 4.8 p -98.11 -20.26 17.44 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.226 -0.921 . . . . 0.0 108.725 179.2 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 16.6 mm100 -83.66 -41.7 17.46 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 108.877 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.7 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -80.93 -3.74 6.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 73.15 29.71 64.11 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.522 -0.847 . . . . 0.0 110.999 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -62.42 136.25 57.82 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.805 -1.409 . . . . 0.0 109.709 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' B' ' 96' ' ' THR . 77.4 p -136.71 129.48 30.63 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.124 -0.985 . . . . 0.0 108.519 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.452 ' O ' ' HB ' ' B' ' 3' ' ' VAL . 5.3 mp -88.13 102.15 14.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.416 -0.802 . . . . 0.0 109.891 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' B' ' 1' ' ' PRO . 6.8 m-20 -110.02 126.74 54.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.971 -1.081 . . . . 0.0 109.175 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.922 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.112 -0.993 . . . . 0.0 109.404 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.484 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.654 0 N-CA-C 109.958 -0.824 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.463 ' OE1' ' CG2' ' B' ' 4' ' ' THR . 12.8 tt0 -82.52 139.34 33.93 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 177.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.761 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 7.0 t -132.69 100.01 3.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 117.937 -1.505 . . . . 0.0 110.811 -177.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.535 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -117.01 -70.48 0.79 Allowed 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 178.225 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.745 ' H ' HD22 ' B' ' 5' ' ' LEU . 3.7 mm? 34.86 31.7 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.889 -0.507 . . . . 0.0 110.225 178.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' THR . 13.0 m0 17.62 49.18 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.553 ' N ' ' O ' ' B' ' 5' ' ' LEU . 7.1 mt-30 -163.09 -162.5 0.77 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.038 -1.039 . . . . 0.0 110.162 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.42 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 8.1 mtm105 -86.94 117.97 69.4 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.232 -0.917 . . . . 0.0 110.394 -179.222 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.592 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.3 Cg_endo -81.99 90.24 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.144 1.896 . . . . 0.0 110.742 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 1.004 HD23 ' HB3' ' B' ' 21' ' ' GLU . 3.2 mp -79.49 171.06 15.67 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.821 -1.175 . . . . 0.0 108.565 179.189 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.595 HG23 HG23 ' B' ' 13' ' ' ILE . 3.1 m -150.68 130.99 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.001 -1.062 . . . . 0.0 110.812 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.685 HG22 HD22 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -70.09 88.11 0.59 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 177.592 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.828 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pt -90.09 157.36 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 111.118 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 3.1 tttt -122.78 109.15 13.85 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.745 HG23 HG21 ' B' ' 62' ' ' ILE . 3.0 mt -122.97 119.52 58.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.092 -1.005 . . . . 0.0 109.24 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.36 26.95 74.0 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -5.46 67.99 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -85.8 169.95 12.88 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.248 -1.148 . . . . 0.0 109.29 179.911 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.685 HD22 HG22 ' B' ' 12' ' ' THR . 2.4 mt -139.8 128.22 22.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.311 -0.868 . . . . 0.0 109.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.423 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 3.0 mtpp -151.23 149.94 30.01 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.434 -0.791 . . . . 0.0 109.118 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 1.004 ' HB3' HD23 ' B' ' 10' ' ' LEU . 0.7 OUTLIER -79.64 102.16 8.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.093 -1.005 . . . . 0.0 108.469 179.277 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.876 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -80.04 142.84 34.56 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 122.0 0.905 . . . . 0.0 110.825 -178.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -92.62 104.26 16.57 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.66 HD22 HD21 ' B' ' 90' ' ' LEU . 4.6 mt -46.29 110.48 0.28 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.878 -1.138 . . . . 0.0 108.593 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.613 ' HB2' HG23 ' B' ' 84' ' ' ILE . 1.0 OUTLIER -118.81 86.71 2.59 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.871 -178.553 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.877 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -68.63 -7.88 37.06 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.023 -1.048 . . . . 0.0 108.704 178.488 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.86 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -81.24 -38.84 13.85 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.27 147.13 46.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.2 -1.176 . . . . 0.0 109.173 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.492 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 4.9 m-20 -82.83 -16.55 47.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 110.737 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.548 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 7.0 m-20 -138.04 -167.88 2.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.935 -1.103 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.589 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 43.0 m -110.57 94.24 4.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.787 -1.196 . . . . 0.0 110.782 -178.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.008 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.76 172.3 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.872 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.008 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.4 122.35 1.75 Allowed 'General case' 0 C--N 1.308 -1.225 0 O-C-N 120.775 -1.203 . . . . 0.0 110.822 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.532 ' CG ' ' O ' ' B' ' 80' ' ' THR . 0.3 OUTLIER -35.6 154.13 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.777 -0.577 . . . . 0.0 109.689 179.127 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.519 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.3 mt-10 -47.79 149.06 1.37 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.241 -0.912 . . . . 0.0 110.231 -179.202 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.49 ' CG ' HD23 ' B' ' 38' ' ' LEU . 6.1 ptm -173.45 -163.99 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.391 -0.818 . . . . 0.0 109.592 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.1 t -110.95 103.72 12.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.204 -0.935 . . . . 0.0 110.279 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.575 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -103.38 173.38 3.48 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.575 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.1 Cg_endo -73.9 -162.26 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.996 1.798 . . . . 0.0 110.516 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -100.21 -166.07 28.86 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.304 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 58.83 70.12 0.68 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.672 -0.899 . . . . 0.0 109.152 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.619 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 21.4 p-90 -141.44 -169.89 2.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -151.02 134.1 8.77 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.175 -0.953 . . . . 0.0 108.807 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.31 137.35 16.77 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.838 1.692 . . . . 0.0 110.567 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.629 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -160.97 133.79 6.29 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.724 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.517 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 63.1 mtp -91.73 131.93 36.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.131 -0.981 . . . . 0.0 109.797 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 50' ' ' ILE . 8.8 pt -89.36 143.96 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 101.22 0.89 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.25 -121.81 2.92 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.744 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.573 HG21 ' CD1' ' A' ' 47' ' ' ILE . 20.5 mt -84.87 117.38 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.852 -0.793 . . . . 0.0 112.695 -177.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.459 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 104.16 -53.32 0.71 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 178.314 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -178.4 -157.12 18.43 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.543 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -118.0 135.79 53.94 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.311 -1.111 . . . . 0.0 109.873 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.675 HD12 HG13 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -106.48 -177.48 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.909 . . . . 0.0 108.926 179.189 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.534 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 36.8 mtmt -111.52 135.82 51.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.019 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' B' ' 78' ' ' GLY . 17.5 m -142.77 177.07 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.843 -1.161 . . . . 0.0 110.636 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.35 100.72 6.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.492 -0.755 . . . . 0.0 109.241 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -62.87 110.11 1.66 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.265 -0.897 . . . . 0.0 110.909 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.988 ' HB3' HD11 ' B' ' 62' ' ' ILE . 16.0 m-85 -106.92 132.35 52.96 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 177.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.7 m-20 -108.6 134.1 51.82 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.937 -1.102 . . . . 0.0 110.49 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.589 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 45.0 mt-30 78.14 61.37 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.904 -0.497 . . . . 0.0 111.178 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.988 HD11 ' HB3' ' B' ' 59' ' ' TYR . 3.0 mp -112.83 120.99 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 178.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.84 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -65.07 86.44 0.06 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 110.958 -178.656 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.934 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.6 tt -94.49 110.7 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.3 tt0 -89.04 117.21 27.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.051 -1.031 . . . . 0.0 109.464 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.828 HG13 HG22 ' B' ' 13' ' ' ILE . 1.8 mp -116.33 140.95 36.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 121.746 0.784 . . . . 0.0 109.845 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.504 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 0.9 OUTLIER 47.42 39.17 8.7 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.681 -0.637 . . . . 0.0 109.778 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.2 48.28 83.9 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.504 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 80.7 m-70 -145.38 108.88 4.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.247 -1.149 . . . . 0.0 109.384 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.619 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.3 OUTLIER -48.26 127.38 12.67 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.305 -0.872 . . . . 0.0 108.883 179.709 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -149.12 104.8 3.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.334 -0.854 . . . . 0.0 109.355 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.84 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -83.86 160.31 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.107 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.574 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.34 -157.24 17.87 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.419 -1.848 . . . . 0.0 111.952 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 4.8 m -111.95 109.81 19.79 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.632 -0.922 . . . . 0.0 109.557 -179.398 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.929 HG23 HD13 ' B' ' 62' ' ' ILE . 1.6 t -105.03 127.75 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.521 -0.737 . . . . 0.0 111.22 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.8 mp -96.83 116.22 28.78 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' B' ' 35' ' ' GLU . 13.1 t -96.9 114.96 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.709 -1.244 . . . . 0.0 109.984 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.72 -174.12 20.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.534 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -79.78 41.83 1.19 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.493 2.129 . . . . 0.0 111.234 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.532 ' O ' ' CG ' ' B' ' 34' ' ' GLU . 9.1 t -80.68 141.01 51.45 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.8 Cg_endo -77.76 13.44 1.68 Allowed 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.274 1.983 . . . . 0.0 111.232 -179.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.61 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -160.31 173.83 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.921 -1.112 . . . . 0.0 109.677 -179.754 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.61 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.0 OUTLIER -109.68 138.57 45.85 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 176.625 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.613 HG23 ' HB2' ' B' ' 25' ' ' ASP . 4.7 mm -124.6 123.33 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.438 -1.414 . . . . 0.0 111.762 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.876 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -97.26 89.82 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.344 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.548 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.04 -157.59 11.58 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.891 -1.147 . . . . 0.0 111.612 -177.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.999 ' NH2' HD11 ' A' ' 23' ' ' LEU . 31.1 mtt180 -68.19 -35.62 78.28 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.915 -0.756 . . . . 0.0 111.407 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.004 ' ND2' HD23 ' B' ' 89' ' ' LEU . 2.6 p-10 -55.57 -24.23 31.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.461 -1.399 . . . . 0.0 110.044 -179.113 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.004 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -106.77 -18.41 13.95 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.999 -1.063 . . . . 0.0 110.26 -178.982 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.877 HD13 HG23 ' B' ' 26' ' ' THR . 64.5 mt -71.95 -24.45 61.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 108.899 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.94 -14.09 56.58 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.092 -1.005 . . . . 0.0 109.839 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.483 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 9.0 mm-40 -81.1 -40.85 23.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.99 -1.069 . . . . 0.0 109.164 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.922 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -87.26 -13.07 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.305 -0.872 . . . . 0.0 108.755 179.43 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.69 51.12 9.79 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.67 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -75.86 147.27 39.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 108.851 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 96' ' ' THR . 72.6 p -130.76 127.29 38.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 108.908 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.554 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.0 mp -91.58 91.06 7.87 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.516 -0.74 . . . . 0.0 109.182 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.7 m-20 -96.22 125.53 40.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.148 -0.97 . . . . 0.0 109.92 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.7 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.301 -1.526 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.335 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.59 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.498 1.768 0 N-CA-C 110.064 -0.783 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -84.91 129.11 34.86 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.85 -1.156 . . . . 0.0 108.05 178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 77.8 t -131.37 124.81 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.915 -1.115 . . . . 0.0 110.184 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 7.6 p -64.57 -104.01 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.857 HD11 HG23 ' B' ' 26' ' ' THR . 0.6 OUTLIER 167.04 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.866 -1.146 . . . . 0.0 110.721 179.407 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 38.1 m95 -65.56 -18.66 65.49 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.809 -1.182 . . . . 0.0 108.507 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.424 ' O ' ' C ' ' A' ' 8' ' ' ARG . 23.2 mt-30 -147.3 159.64 43.43 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.477 ' HD2' HD13 ' A' ' 23' ' ' LEU . 16.0 mtm180 -44.04 141.15 2.52 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.003 . . . . 0.0 109.22 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG3' HG22 ' B' ' 26' ' ' THR . 36.2 Cg_endo -80.61 60.57 7.91 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.478 2.119 . . . . 0.0 109.921 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.676 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -81.66 142.72 32.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.243 -0.91 . . . . 0.0 109.97 -179.484 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -140.99 155.62 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.46 -0.775 . . . . 0.0 109.283 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.418 HG22 HD22 ' A' ' 19' ' ' LEU . 11.0 m -83.96 101.94 12.08 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 178.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.795 HG22 HG13 ' A' ' 66' ' ' ILE . 14.7 pt -96.31 158.66 3.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.286 -0.884 . . . . 0.0 110.341 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 3.7 tttt -120.71 103.95 9.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.433 -0.792 . . . . 0.0 109.88 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.013 HD13 HG11 ' A' ' 75' ' ' VAL . 10.6 mt -119.25 134.35 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.079 -1.013 . . . . 0.0 109.588 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.96 44.24 98.08 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.08 17.72 24.33 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.63 178.09 4.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.444 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.536 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.6 mt -138.61 126.34 22.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.447 -0.783 . . . . 0.0 109.826 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.459 ' HD3' ' O ' ' A' ' 19' ' ' LEU . 35.8 mmtt -144.45 -179.31 6.47 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.676 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.9 mt-10 -88.04 164.58 15.69 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.098 -1.001 . . . . 0.0 108.713 179.452 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.614 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -147.97 116.68 6.69 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.688 -1.258 . . . . 0.0 110.966 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.002 HD21 ' O ' ' B' ' 27' ' ' GLY . 16.8 tp -82.05 94.12 7.13 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.602 HD13 ' CE2' ' B' ' 99' ' ' PHE . 63.7 mt -49.69 93.2 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.568 ' CB ' ' HA3' ' B' ' 27' ' ' GLY . 26.8 t0 -107.67 87.21 2.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 110.744 -178.347 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.675 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.2 m -60.74 -13.81 17.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.051 -1.031 . . . . 0.0 108.638 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -63.41 -43.69 97.9 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.4 171.52 9.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.008 -1.289 . . . . 0.0 110.069 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.513 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -98.54 -20.51 17.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.34 -0.85 . . . . 0.0 110.603 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.515 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 36.6 m-20 -140.23 -162.9 1.42 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.922 -1.111 . . . . 0.0 109.604 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.759 HG22 ' CD1' ' A' ' 33' ' ' LEU . 23.5 m -107.28 89.99 3.17 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.69 -1.256 . . . . 0.0 110.931 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.966 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.67 164.95 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.745 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.966 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.58 127.58 2.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.727 -1.233 . . . . 0.0 111.426 -178.742 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.594 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.2 OUTLIER -42.48 153.29 0.08 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 179.03 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.966 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -50.54 146.34 5.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.053 -1.029 . . . . 0.0 109.868 -179.821 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.522 ' CE ' HG22 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -156.42 -162.77 1.32 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.485 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.5 t -112.73 101.0 9.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.05 -1.031 . . . . 0.0 110.362 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.625 HD21 HD12 ' A' ' 62' ' ' ILE . 0.1 OUTLIER -108.49 160.03 28.65 Favored Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.573 ' HD3' HD12 ' A' ' 38' ' ' LEU . 34.5 Cg_endo -75.96 69.32 6.29 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.784 2.323 . . . . 0.0 111.867 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . 37.43 -159.62 0.01 OUTLIER Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.51 ' HD3' ' N ' ' A' ' 41' ' ' ARG . 1.3 mpt_? 64.07 68.47 0.56 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.541 -0.976 . . . . 0.0 109.912 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.582 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 64.3 p-90 -152.7 -178.24 6.75 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.653 -0.654 . . . . 0.0 110.001 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.5 mtpt -146.2 137.21 12.62 Favored Pre-proline 0 N--CA 1.49 1.537 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.14 138.35 16.09 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.224 1.95 . . . . 0.0 111.182 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.557 ' HD2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -152.58 -163.19 1.66 Allowed 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.242 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.565 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 1.7 mtt -149.42 126.11 11.06 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.957 -1.089 . . . . 0.0 110.371 -179.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 54' ' ' ILE . 6.8 pt -90.07 146.44 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.509 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.45 118.62 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -146.3 -127.41 1.85 Allowed Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.291 -1.433 . . . . 0.0 111.228 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.613 HG21 HD12 ' B' ' 47' ' ' ILE . 25.2 mt -81.68 123.85 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.957 -0.731 . . . . 0.0 112.401 -177.548 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.78 -50.11 1.78 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 178.683 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.441 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 175.14 -168.12 40.51 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.4 OUTLIER -107.31 132.53 53.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.085 -1.244 . . . . 0.0 109.711 -179.632 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 47' ' ' ILE . 10.3 pt -101.74 163.4 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.238 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.565 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 35.6 mtmt -96.59 138.38 34.26 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.112 -0.993 . . . . 0.0 108.867 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.461 HG21 HD23 ' A' ' 76' ' ' LEU . 30.6 m -138.36 177.93 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 120.75 -1.219 . . . . 0.0 110.146 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.512 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -118.17 92.3 3.79 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.431 -0.793 . . . . 0.0 108.919 -179.954 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.545 ' CG ' ' OD1' ' A' ' 60' ' ' ASP . 16.2 tt0 -53.56 107.69 0.27 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.507 -0.745 . . . . 0.0 110.236 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 38' ' ' LEU . 15.1 m-85 -105.02 95.51 5.89 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' ' CG ' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -79.01 139.62 38.14 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.867 -1.146 . . . . 0.0 111.061 -178.39 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.564 ' HA ' HG23 ' A' ' 72' ' ' ILE . 47.0 mt-30 68.36 63.57 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.133 0.492 . . . . 0.0 111.66 178.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.813 ' C ' HD13 ' A' ' 72' ' ' ILE . 0.8 OUTLIER -122.67 124.78 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.955 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.795 HD22 HG12 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -66.65 86.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.914 -178.342 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.868 HD12 HD11 ' A' ' 15' ' ' ILE . 3.6 tt -87.74 123.83 40.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 176.846 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 66' ' ' ILE . 8.6 tt0 -88.59 148.37 24.11 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.069 -1.019 . . . . 0.0 109.349 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.795 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -150.19 115.35 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.501 ' SG ' ' CG ' ' A' ' 1' ' ' PRO . 0.8 OUTLIER 68.23 5.06 4.46 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.581 -0.7 . . . . 0.0 110.127 179.695 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.405 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 108.27 -3.39 33.11 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -90.2 131.31 36.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.06 -1.259 . . . . 0.0 109.318 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.505 ' CG ' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.75 103.9 11.76 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 121.047 -1.033 . . . . 0.0 108.471 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 63' ' ' LEU . . . -112.79 151.19 30.63 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 120.361 -0.535 . . . . 0.0 109.838 -179.192 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.813 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -122.42 146.32 27.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 177.716 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.474 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.75 -162.42 25.56 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 118.429 -1.843 . . . . 0.0 111.063 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 10.3 m -100.28 104.92 16.42 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.676 -0.896 . . . . 0.0 110.056 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.013 HG11 HD13 ' A' ' 15' ' ' ILE . 1.2 t -95.12 105.36 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.518 -0.739 . . . . 0.0 109.349 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.561 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.9 mp -78.57 118.07 20.34 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.966 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.0 t -106.9 111.09 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.145 -0.972 . . . . 0.0 110.443 -179.002 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.65 -157.48 7.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.55 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.14 38.8 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.509 2.139 . . . . 0.0 110.34 179.369 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.594 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.9 t -83.58 132.78 48.3 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.683 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.8 Cg_endo -79.9 19.11 1.05 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.467 2.111 . . . . 0.0 111.558 -178.589 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.1 t -161.46 156.77 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.763 -1.21 . . . . 0.0 109.929 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.575 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -95.64 91.0 5.91 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.665 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.68 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.6 mm -78.54 122.74 34.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 121.418 -0.801 . . . . 0.0 112.085 -176.464 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.628 HD12 HG23 ' A' ' 31' ' ' THR . 0.9 OUTLIER -101.02 91.78 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 176.894 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.44 -157.98 13.51 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.912 -177.052 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.513 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -68.87 -37.66 79.19 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 122.023 -0.692 . . . . 0.0 109.828 -178.958 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 13.0 p-10 -45.71 -28.51 1.04 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.933 -1.104 . . . . 0.0 109.52 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.5 mm? -109.08 -27.03 9.85 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.259 -0.9 . . . . 0.0 110.499 -178.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.679 HD23 HD11 ' A' ' 93' ' ' ILE . 70.0 mt -72.09 -7.88 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.82 -1.175 . . . . 0.0 109.194 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -98.15 -11.75 22.47 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.004 -1.06 . . . . 0.0 108.242 178.699 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.605 ' OE1' HD13 ' A' ' 89' ' ' LEU . 75.4 mt-30 -90.49 -40.71 11.84 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.75 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -82.91 0.59 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.471 -0.768 . . . . 0.0 108.965 179.164 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.15 32.83 57.91 Favored Glycine 0 N--CA 1.495 2.617 0 C-N-CA 120.575 -0.822 . . . . 0.0 111.147 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.679 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -65.45 140.08 58.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.941 -1.329 . . . . 0.0 110.715 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' B' ' 96' ' ' THR . 58.9 p -137.33 126.19 24.11 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' B' ' 97' ' ' LEU . 5.1 mp -88.43 91.94 8.99 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.239 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.433 ' HA ' ' O ' ' B' ' 1' ' ' PRO . 18.2 m-20 -103.51 121.41 42.81 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.127 -0.983 . . . . 0.0 109.448 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.904 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.361 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.55 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 2.3 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 109.875 -0.856 . . . . 0.0 109.875 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.479 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 4.3 tt0 -122.26 142.41 50.49 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 177.11 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.487 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 38.4 t -142.48 102.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.192 -178.234 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.599 ' O ' ' C ' ' B' ' 5' ' ' LEU . 63.7 p -89.62 -30.13 18.36 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 178.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.803 HD13 ' HA ' ' B' ' 9' ' ' PRO . 0.5 OUTLIER 13.14 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.832 -179.892 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.423 ' C ' ' O ' ' B' ' 5' ' ' LEU . 2.2 m95 -37.91 -22.23 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.038 -178.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.576 ' N ' ' O ' ' B' ' 5' ' ' LEU . 20.3 mp0 -107.94 -161.85 0.8 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.715 -1.241 . . . . 0.0 107.983 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.511 ' HB3' HD12 ' B' ' 23' ' ' LEU . 19.1 mtt180 -53.84 124.57 44.06 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 120.478 -1.389 . . . . 0.0 109.589 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.803 ' HA ' HD13 ' B' ' 5' ' ' LEU . 37.0 Cg_endo -77.7 71.01 6.7 Favored 'Trans proline' 0 C--N 1.316 -1.159 0 C-N-CA 122.331 2.021 . . . . 0.0 110.401 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.918 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.6 mt -78.95 143.1 36.12 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.888 -1.132 . . . . 0.0 110.356 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.816 HG21 HG23 ' B' ' 66' ' ' ILE . 1.3 m -130.76 139.92 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.509 -0.744 . . . . 0.0 109.639 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.933 HG22 HD22 ' B' ' 19' ' ' LEU . 2.0 m -67.49 108.01 2.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.918 -1.114 . . . . 0.0 108.279 178.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.904 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.2 pp -106.02 140.43 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.081 -1.012 . . . . 0.0 110.865 -178.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.541 ' CG ' ' HG ' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -109.05 106.53 16.5 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.306 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' B' ' 75' ' ' VAL . 15.0 mt -124.48 124.99 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 O-C-N 121.164 -0.96 . . . . 0.0 109.524 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.77 20.01 71.89 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -4.33 86.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -93.47 -178.17 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.115 -1.227 . . . . 0.0 108.908 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.933 HD22 HG22 ' B' ' 12' ' ' THR . 4.3 mt -153.65 125.58 7.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.132 -0.98 . . . . 0.0 110.499 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -145.94 168.79 20.01 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.012 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.918 ' HB3' HD22 ' B' ' 10' ' ' LEU . 6.5 mt-10 -79.28 157.87 27.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.758 -1.214 . . . . 0.0 108.401 179.399 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.626 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -139.34 113.96 9.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.96 -1.087 . . . . 0.0 110.691 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.511 HD12 ' HB3' ' B' ' 8' ' ' ARG . 0.9 OUTLIER -67.75 95.36 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.031 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.731 HD12 ' HB2' ' B' ' 9' ' ' PRO . 86.2 mt -44.51 102.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.806 ' HB2' HG23 ' B' ' 84' ' ' ILE . 4.8 t70 -101.37 93.53 5.46 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.474 -0.766 . . . . 0.0 110.753 -178.462 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 5' ' ' LEU . 5.6 m -76.4 3.89 10.16 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.114 -0.991 . . . . 0.0 109.004 178.455 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 1.002 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -99.67 -24.42 10.03 Favored Glycine 0 N--CA 1.485 1.933 0 C-N-CA 120.056 -1.069 . . . . 0.0 110.743 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.25 168.46 17.61 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.829 -1.395 . . . . 0.0 109.949 -179.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.458 ' OD2' ' HD3' ' A' ' 8' ' ' ARG . 0.9 OUTLIER -101.31 -20.3 15.28 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.366 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.576 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -131.86 -174.83 3.53 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 -179.598 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.687 HG23 HD12 ' B' ' 85' ' ' ILE . 53.2 m -105.33 83.44 1.96 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.676 -1.265 . . . . 0.0 110.315 -178.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.056 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.45 167.16 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.035 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.056 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.41 123.86 2.26 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.051 -1.031 . . . . 0.0 110.441 -178.694 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.823 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.0 OUTLIER -39.49 160.0 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.551 -0.718 . . . . 0.0 109.381 179.17 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.462 ' O ' ' OE1' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -39.62 146.71 0.1 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.387 -0.821 . . . . 0.0 110.449 -179.572 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.444 ' HE2' ' HE2' ' B' ' 20' ' ' LYS . 3.0 ppp? -166.4 163.04 17.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.441 -0.787 . . . . 0.0 109.046 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.3 t -95.82 105.04 17.0 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.043 -1.036 . . . . 0.0 109.753 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.739 HD21 HD12 ' B' ' 62' ' ' ILE . 9.2 tp -122.43 106.17 35.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.372 -0.83 . . . . 0.0 108.932 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.33 140.39 19.43 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.375 2.05 . . . . 0.0 111.125 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 128.23 31.52 0.67 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.474 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 52.88 166.62 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.84 -0.8 . . . . 0.0 110.014 179.749 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.579 ' CD2' ' HD3' ' B' ' 57' ' ' ARG . 0.2 OUTLIER -160.98 178.49 9.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.138 -0.976 . . . . 0.0 109.769 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -125.88 104.52 26.7 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.76 138.61 41.61 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.025 1.817 . . . . 0.0 112.355 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -150.62 -155.61 0.64 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.55 ' CE ' ' HB3' ' B' ' 53' ' ' PHE . 32.2 mtp -148.13 126.55 12.35 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.026 -1.046 . . . . 0.0 110.312 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 54' ' ' ILE . 7.3 pt -93.24 142.38 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.611 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.93 113.75 2.64 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.12 -123.94 2.21 Favored Glycine 0 N--CA 1.483 1.811 0 C-N-CA 119.525 -1.322 . . . . 0.0 110.493 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.711 HG21 HD12 ' A' ' 47' ' ' ILE . 25.6 mt -84.77 119.27 33.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.793 -0.827 . . . . 0.0 112.384 -177.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 103.83 -53.01 0.73 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.89 -161.79 27.83 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.171 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.611 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -111.84 128.86 56.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.459 -1.024 . . . . 0.0 109.241 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 47' ' ' ILE . 16.3 pt -107.38 162.59 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.876 -1.14 . . . . 0.0 109.016 179.118 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.6 mptm? -94.53 147.58 23.12 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.153 -0.967 . . . . 0.0 108.88 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 27.5 m -144.94 -170.77 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 120.768 -1.207 . . . . 0.0 110.254 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.579 ' HD3' ' CD2' ' B' ' 42' ' ' TRP . 18.6 mtt85 -131.46 111.24 11.62 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -77.61 101.3 6.49 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.566 -0.709 . . . . 0.0 111.07 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.642 ' CG ' HD23 ' B' ' 38' ' ' LEU . 62.7 m-85 -96.18 129.74 43.41 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.068 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 14.5 m-20 -109.19 122.45 47.34 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.692 -1.255 . . . . 0.0 110.895 -178.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.546 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 3.0 mt-30 86.1 56.11 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 CA-C-O 121.31 0.576 . . . . 0.0 110.472 179.069 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.855 HG21 HG23 ' B' ' 15' ' ' ILE . 4.0 mm -111.27 128.07 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.449 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.879 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.3 tm? -73.84 102.26 4.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.181 -0.95 . . . . 0.0 111.293 -178.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.829 ' CG2' HD11 ' B' ' 89' ' ' LEU . 0.9 OUTLIER -105.59 106.11 19.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 177.579 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.4 OUTLIER -90.0 119.69 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.983 -1.073 . . . . 0.0 109.206 -178.821 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.816 HG23 HG21 ' B' ' 11' ' ' VAL . 1.5 mp -111.54 128.78 67.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.477 -0.765 . . . . 0.0 109.364 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.487 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 15.5 m 65.55 -89.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.752 -0.593 . . . . 0.0 109.629 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.88 39.15 0.74 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -139.36 131.91 28.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.566 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.68 ' CG ' HD21 ' B' ' 63' ' ' LEU . 15.6 ttmt -70.74 129.11 38.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.125 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.625 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -142.25 95.19 2.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.156 -0.965 . . . . 0.0 110.435 -179.257 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.631 HG12 HD23 ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.99 156.77 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.712 -1.243 . . . . 0.0 108.06 178.297 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.506 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.05 -170.59 43.52 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.674 -1.727 . . . . 0.0 111.213 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 85.9 m -88.68 112.54 23.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.848 -0.795 . . . . 0.0 110.575 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' B' ' 15' ' ' ILE . 0.7 OUTLIER -105.18 107.8 23.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.7 -0.625 . . . . 0.0 110.155 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.576 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 4.0 mp -82.63 121.82 27.32 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 108.853 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.52 ' O ' ' HG3' ' B' ' 57' ' ' ARG . 69.1 t -109.3 132.04 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.058 -1.026 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -162.8 -159.89 10.76 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.43 36.1 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.651 2.234 . . . . 0.0 110.733 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.823 HG22 ' HA ' ' B' ' 34' ' ' GLU . 4.0 t -81.6 136.64 48.37 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.682 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.5 16.36 1.43 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.322 2.015 . . . . 0.0 111.269 -178.581 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.682 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -161.84 148.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 120.88 -1.138 . . . . 0.0 110.108 -179.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.7 OUTLIER -86.61 102.12 13.87 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 105.922 -1.881 . . . . 0.0 105.922 176.749 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.833 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.4 mt -101.74 126.66 55.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.856 -1.153 . . . . 0.0 112.137 -175.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.745 ' N ' HD13 ' B' ' 85' ' ' ILE . 1.5 mm -97.08 121.85 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 177.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.537 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -102.58 -147.42 19.17 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.592 -1.289 . . . . 0.0 111.551 -178.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.509 ' O ' ' OG1' ' B' ' 91' ' ' THR . 11.6 mtp180 -69.08 -40.86 78.18 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 122.074 -0.662 . . . . 0.0 111.388 -178.41 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.98 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.2 p-10 -53.78 -30.47 44.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.798 -1.188 . . . . 0.0 111.254 -178.081 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.98 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.8 mm? -104.44 -28.58 11.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.492 -1.38 . . . . 0.0 110.914 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.662 ' N ' HD23 ' B' ' 90' ' ' LEU . 0.1 OUTLIER -68.2 -9.58 47.99 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.712 -1.242 . . . . 0.0 109.151 179.745 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.22 -20.44 15.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.775 -1.203 . . . . 0.0 108.831 179.154 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 46.6 mm-40 -77.89 -41.05 37.93 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.237 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.904 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -81.4 -8.17 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.38 35.77 55.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.568 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -61.56 152.18 31.12 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.824 -1.398 . . . . 0.0 109.288 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 4' ' ' THR . 21.5 p -142.27 124.72 15.69 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.151 -0.968 . . . . 0.0 108.889 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' A' ' 97' ' ' LEU . 4.8 mp -86.25 91.08 8.36 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.444 -0.785 . . . . 0.0 109.505 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.545 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 13.5 m-20 -93.92 121.98 35.94 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.049 -1.032 . . . . 0.0 109.227 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.75 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 118.045 -0.979 . . . . 0.0 109.477 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 3.8 Cg_exo . . . . . 0 N--CA 1.497 1.686 0 N-CA-C 110.663 -0.553 . . . . 0.0 110.663 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.472 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -84.37 136.73 33.76 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.102 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.622 HG12 ' H ' ' A' ' 5' ' ' LEU . 55.7 t -133.55 115.03 21.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 120.734 -1.229 . . . . 0.0 109.918 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 72.6 p -58.8 -12.59 4.53 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.698 -0.626 . . . . 0.0 110.218 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.767 HD21 HD13 ' B' ' 97' ' ' LEU . 0.7 OUTLIER 80.59 -6.6 1.66 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.443 -0.785 . . . . 0.0 110.298 179.398 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.598 ' CZ3' HG21 ' B' ' 91' ' ' THR . 39.8 m95 -53.88 -20.43 5.94 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.949 -1.094 . . . . 0.0 108.848 179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.11 157.54 46.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 108.914 179.378 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.433 ' HA ' ' CZ ' ' B' ' 87' ' ' ARG . 4.0 mtm180 -66.92 122.99 84.94 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.155 -0.965 . . . . 0.0 109.595 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.612 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.0 Cg_endo -76.1 80.09 2.76 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 121.927 1.751 . . . . 0.0 109.429 178.75 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -90.0 149.34 22.59 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.589 -0.695 . . . . 0.0 109.606 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.926 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -150.9 159.33 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.192 -0.942 . . . . 0.0 110.377 -179.063 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.679 HG21 HD23 ' A' ' 19' ' ' LEU . 14.1 m -94.88 104.82 16.71 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.771 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 1.154 HD11 HD21 ' A' ' 33' ' ' LEU . 2.2 pt -89.22 141.1 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.177 -0.952 . . . . 0.0 110.389 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.589 ' HG3' HD12 ' A' ' 19' ' ' LEU . 29.5 ttmt -106.34 97.27 7.09 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.469 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.868 HG23 ' CG2' ' A' ' 62' ' ' ILE . 16.8 mt -113.53 120.55 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.147 -0.97 . . . . 0.0 110.06 -179.155 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.23 37.65 94.81 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.1 6.4 56.72 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.453 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.3 mm-40 -97.48 163.25 12.94 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.201 -1.176 . . . . 0.0 109.216 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.679 HD23 HG21 ' A' ' 12' ' ' THR . 0.1 OUTLIER -136.89 126.59 25.48 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.293 -0.879 . . . . 0.0 110.798 -179.507 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.8 mttp -150.45 179.95 7.73 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.061 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.03 -174.67 4.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.876 -1.14 . . . . 0.0 108.891 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -162.25 121.14 2.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.031 -1.043 . . . . 0.0 110.001 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.519 ' O ' ' N ' ' A' ' 25' ' ' ASP . 46.5 tp -102.61 95.42 6.21 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.449 -0.782 . . . . 0.0 109.301 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 17.1 mt -43.33 96.24 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.078 -1.013 . . . . 0.0 109.417 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.759 ' CB ' HG23 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -101.21 81.62 2.24 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.511 -0.743 . . . . 0.0 110.121 -179.493 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.712 HG23 HD13 ' A' ' 90' ' ' LEU . 4.3 m -61.89 -20.64 63.96 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.989 -1.07 . . . . 0.0 108.936 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.805 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -59.32 -45.49 95.35 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.96 157.56 37.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.377 -1.072 . . . . 0.0 108.729 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -92.01 -10.26 39.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.06 -1.025 . . . . 0.0 110.3 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 1.019 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.24 -173.46 3.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.956 -1.09 . . . . 0.0 110.053 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.574 HG22 ' CD1' ' A' ' 33' ' ' LEU . 33.4 m -103.23 89.01 3.27 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.265 -0.897 . . . . 0.0 111.281 -178.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.015 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.42 172.15 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.55 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.154 HD21 HD11 ' A' ' 13' ' ' ILE . 0.1 OUTLIER -168.68 132.7 1.51 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.085 -1.009 . . . . 0.0 110.571 -178.966 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.541 ' HA ' HG22 ' A' ' 80' ' ' THR . 20.6 mt-10 -41.46 161.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.499 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -61.36 143.7 55.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.036 -1.04 . . . . 0.0 110.043 -179.46 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.544 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -160.1 -179.76 8.04 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.331 -0.855 . . . . 0.0 109.645 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.4 t -92.89 100.0 12.54 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 109.924 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.9 HD12 HG21 ' A' ' 77' ' ' VAL . 12.6 mt -106.45 173.28 3.26 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.658 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.7 Cg_endo -78.18 50.11 3.22 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.327 2.018 . . . . 0.0 112.735 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 34.75 -158.53 0.01 OUTLIER Glycine 0 N--CA 1.498 2.769 0 O-C-N 121.478 -0.763 . . . . 0.0 111.529 178.456 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.448 ' HG3' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER 53.8 80.33 0.11 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.547 -0.973 . . . . 0.0 109.442 -179.54 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 2.9 p-90 -145.93 -167.85 2.83 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-O 121.506 0.67 . . . . 0.0 109.697 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.44 116.01 11.82 Favored Pre-proline 0 C--N 1.303 -1.433 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.169 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -70.59 138.76 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 121.848 1.698 . . . . 0.0 111.731 -178.225 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.468 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -158.61 133.09 8.05 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.8 OUTLIER -94.03 123.56 37.48 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 -179.729 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.808 HD11 HG21 ' B' ' 50' ' ' ILE . 6.9 pt -92.38 148.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.814 -1.179 . . . . 0.0 108.679 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.525 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -118.39 101.86 0.92 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.764 -1.735 . . . . 0.0 108.764 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.89 -128.28 3.3 Favored Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.522 -1.323 . . . . 0.0 111.056 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.791 HG21 ' CD1' ' B' ' 47' ' ' ILE . 22.4 mt -86.29 114.35 25.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.809 -0.818 . . . . 0.0 112.494 -177.684 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.507 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.48 -7.14 39.4 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.207 -0.997 . . . . 0.0 110.758 177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.21 -160.98 23.83 Favored Glycine 0 N--CA 1.494 2.516 0 O-C-N 120.894 -1.357 . . . . 0.0 110.405 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.525 ' CZ ' ' HA3' ' A' ' 48' ' ' GLY . 5.1 m-85 -110.73 132.98 53.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.382 -1.07 . . . . 0.0 109.883 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.799 ' C ' HD12 ' A' ' 54' ' ' ILE . 2.6 pp -111.04 162.47 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.065 -1.022 . . . . 0.0 108.603 178.635 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 76.0 mttt -102.36 133.69 46.87 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.034 -1.041 . . . . 0.0 109.673 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.776 HG13 ' CD1' ' A' ' 54' ' ' ILE . 3.1 m -134.77 -173.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.477 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -132.71 100.01 4.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.48 -0.762 . . . . 0.0 109.1 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.514 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 31.8 tt0 -57.92 93.79 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.328 -0.858 . . . . 0.0 109.669 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.724 ' C ' HD11 ' A' ' 62' ' ' ILE . 15.6 m-85 -88.36 125.36 34.66 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.466 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 24.6 m-20 -105.29 137.72 42.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.861 -1.15 . . . . 0.0 110.901 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.528 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 1.7 mm-40 72.62 61.43 0.12 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.792 -0.568 . . . . 0.0 110.614 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.868 ' CG2' HG23 ' A' ' 15' ' ' ILE . 4.9 mp -119.64 123.94 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.066 . . . . 0.0 108.92 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.803 HD13 ' O ' ' A' ' 63' ' ' LEU . 3.3 tm? -69.7 86.56 0.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.316 -0.865 . . . . 0.0 111.831 -178.29 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.576 HG13 ' HB ' ' A' ' 13' ' ' ILE . 3.0 tt -88.32 110.27 20.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.141 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 2.0 tt0 -88.77 118.32 28.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.962 -1.086 . . . . 0.0 109.791 -178.03 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.898 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -108.4 120.2 59.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.326 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.72 -99.01 0.09 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -136.72 39.09 1.68 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 8.5 m-70 -128.45 103.33 7.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.423 -1.045 . . . . 0.0 110.164 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.509 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -60.89 117.32 5.29 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.721 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.01 127.99 35.33 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.278 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.577 HG12 ' CA ' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -105.06 139.46 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.605 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.589 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -162.73 -170.95 28.31 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 118.93 -1.605 . . . . 0.0 110.295 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.581 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 51.9 m -91.02 109.87 21.12 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.695 -0.885 . . . . 0.0 109.798 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.073 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -103.61 112.03 35.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 110.959 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 1.019 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.0 mp -79.57 122.95 27.13 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.9 HG21 HD12 ' A' ' 38' ' ' LEU . 54.3 t -108.39 121.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.945 -1.097 . . . . 0.0 109.907 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -155.22 -165.17 13.83 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.552 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -80.76 42.52 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.564 2.176 . . . . 0.0 110.636 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.571 HG21 HG13 ' A' ' 32' ' ' VAL . 13.1 t -85.9 141.16 35.44 Favored Pre-proline 0 C--N 1.302 -1.473 0 O-C-N 121.156 -0.965 . . . . 0.0 108.814 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.5 Cg_endo -78.87 15.06 1.55 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.475 2.116 . . . . 0.0 111.546 -179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -160.68 167.37 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.787 -1.196 . . . . 0.0 110.371 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.558 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 69.5 m-80 -100.09 92.54 5.29 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 177.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.759 HG23 ' CB ' ' A' ' 25' ' ' ASP . 11.4 mm -78.91 124.33 37.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 O-C-N 121.153 -0.967 . . . . 0.0 111.846 -176.472 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.61 ' N ' ' CD1' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -106.22 100.58 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 177.531 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -87.28 -161.61 36.74 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 120.128 -1.034 . . . . 0.0 111.481 -177.541 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 15.8 mmm180 -62.16 -38.73 90.13 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.843 -0.798 . . . . 0.0 109.841 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.029 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.5 p-10 -43.67 -29.48 0.51 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.231 -0.918 . . . . 0.0 109.387 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.029 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.7 mm? -107.78 -24.62 11.61 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.004 -1.06 . . . . 0.0 109.612 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.712 HD13 HG23 ' A' ' 26' ' ' THR . 14.7 mt -70.41 -5.81 31.04 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.866 -1.146 . . . . 0.0 108.191 178.14 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.476 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 71.3 p -100.63 -17.87 16.83 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 19.1 mm100 -83.64 -39.19 20.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 109.434 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.092 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -84.95 3.52 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.298 -0.876 . . . . 0.0 109.607 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.56 38.22 51.8 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 120.313 -0.946 . . . . 0.0 111.064 178.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -71.16 138.29 49.47 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.079 -1.248 . . . . 0.0 111.072 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.762 HG22 ' CG2' ' B' ' 4' ' ' THR . 48.7 p -133.18 128.76 36.69 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' B' ' 97' ' ' LEU . 1.6 mp -92.84 85.37 5.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.18 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 14.1 m-20 -89.68 122.39 32.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.097 -1.002 . . . . 0.0 109.747 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.802 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 117.927 -1.035 . . . . 0.0 108.908 178.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.1 tt0 -84.2 131.5 34.75 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.325 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -119.69 118.5 57.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 C-N-CA 118.525 -1.27 . . . . 0.0 110.483 -178.183 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.762 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.1 OUTLIER -132.31 19.93 4.4 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 178.324 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.572 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -82.17 67.38 8.16 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.531 ' C ' ' O ' ' B' ' 5' ' ' LEU . 41.5 m0 -21.93 84.5 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 CA-C-O 121.578 0.704 . . . . 0.0 111.594 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.572 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.38 -163.04 0.32 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.975 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.42 121.71 71.06 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.115 -0.991 . . . . 0.0 109.27 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.753 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.5 Cg_endo -76.5 74.74 4.63 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.08 1.853 . . . . 0.0 109.068 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.499 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -96.98 147.15 24.28 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.463 -0.773 . . . . 0.0 110.425 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.453 HG21 HG23 ' B' ' 66' ' ' ILE . 0.9 OUTLIER -143.63 132.47 19.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.885 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.951 HG22 HD22 ' B' ' 19' ' ' LEU . 12.0 m -67.54 99.91 0.81 Allowed 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 178.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 3.2 pt -82.73 157.17 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.738 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HB2' ' HB3' ' B' ' 65' ' ' GLU . 0.5 OUTLIER -123.78 98.74 5.95 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.314 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.943 HG23 ' CG2' ' B' ' 62' ' ' ILE . 50.7 mt -113.98 133.37 60.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.332 -0.855 . . . . 0.0 109.605 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.502 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 49.98 54.91 16.71 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.65 34.78 21.59 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.51 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.6 mm-40 -124.84 167.08 15.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -1.184 . . . . 0.0 109.185 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.951 HD22 HG22 ' B' ' 12' ' ' THR . 12.0 mt -141.82 129.49 21.55 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.159 -0.963 . . . . 0.0 110.757 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 20.2 mtmt -151.7 169.43 22.2 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.63 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mp0 -78.99 126.67 31.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.943 -1.098 . . . . 0.0 109.029 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.855 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -106.88 120.77 42.94 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.088 -1.008 . . . . 0.0 110.173 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.805 HD21 ' O ' ' A' ' 27' ' ' GLY . 20.7 tp -91.82 94.75 9.48 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.437 -0.789 . . . . 0.0 110.093 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.753 HD12 ' HB2' ' B' ' 9' ' ' PRO . 58.0 mt -46.49 101.88 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.033 -1.042 . . . . 0.0 108.676 179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.903 ' HB3' HG23 ' B' ' 84' ' ' ILE . 12.4 t0 -113.34 98.2 6.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.92 . . . . 0.0 110.721 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.738 ' CG2' HD22 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -69.88 -15.32 63.06 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.111 -0.993 . . . . 0.0 108.768 178.699 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.455 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.62 -41.03 97.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.73 165.52 22.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.039 -1.271 . . . . 0.0 109.063 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -100.77 -15.42 17.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.132 -0.98 . . . . 0.0 110.573 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.861 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -132.66 -175.33 3.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.712 -1.242 . . . . 0.0 110.316 -179.369 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.62 HG22 ' CD1' ' B' ' 33' ' ' LEU . 72.8 m -103.13 87.92 3.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.017 -1.052 . . . . 0.0 110.053 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.43 163.12 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.52 179.611 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.14 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -160.7 138.45 9.53 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.049 -1.032 . . . . 0.0 110.469 -178.539 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.617 ' N ' HG22 ' B' ' 80' ' ' THR . 2.3 mt-10 -47.97 174.97 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.512 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.2 tm-20 -72.5 143.46 48.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.03 -1.044 . . . . 0.0 109.452 179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.413 ' HG3' ' HG ' ' B' ' 38' ' ' LEU . 6.6 ptm -154.93 -167.92 2.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.393 -0.817 . . . . 0.0 109.204 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -107.22 105.98 16.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.653 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.888 HD12 HG21 ' B' ' 77' ' ' VAL . 90.4 mt -117.21 156.44 48.65 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.486 ' O ' ' O ' ' B' ' 40' ' ' GLY . 35.1 Cg_endo -76.63 74.24 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.885 2.39 . . . . 0.0 112.206 -178.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 34.39 -157.14 0.01 OUTLIER Glycine 0 N--CA 1.497 2.765 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.418 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.3 mtt180 70.02 47.73 0.57 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.263 -1.139 . . . . 0.0 108.459 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 57.4 p-90 -129.12 -179.03 4.89 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 121.824 0.821 . . . . 0.0 110.297 -178.815 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -145.26 156.48 54.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.667 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -75.75 139.3 22.25 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.803 1.669 . . . . 0.0 110.29 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -144.87 168.82 19.32 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.537 -0.727 . . . . 0.0 109.52 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -150.1 125.08 9.92 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.791 ' CD1' HG21 ' A' ' 50' ' ' ILE . 24.1 pt -120.46 137.82 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 120.74 -1.225 . . . . 0.0 110.385 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.613 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.69 98.51 0.75 Allowed Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.68 -119.02 2.75 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.8 -178.534 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.808 HG21 HD11 ' A' ' 47' ' ' ILE . 16.4 mt -90.39 119.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.689 -0.889 . . . . 0.0 112.337 -177.748 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.482 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 103.34 -28.11 17.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 120.222 -0.99 . . . . 0.0 110.751 177.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 153.49 -161.9 30.01 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.285 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.613 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 8.4 m-85 -107.31 125.02 50.63 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -1.036 . . . . 0.0 110.138 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.709 HD13 HG23 ' A' ' 50' ' ' ILE . 11.8 pt -105.96 142.0 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.081 -1.012 . . . . 0.0 108.865 178.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.506 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 5.0 mttt -89.06 138.59 31.27 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.031 -1.043 . . . . 0.0 109.294 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.965 HG12 ' HA3' ' B' ' 78' ' ' GLY . 29.4 m -140.44 175.52 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.079 -1.013 . . . . 0.0 110.211 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.592 ' HG2' ' CE3' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -126.29 103.95 7.93 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.403 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.554 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -58.75 112.73 1.74 Allowed 'General case' 0 C--N 1.295 -1.797 0 O-C-N 121.566 -0.709 . . . . 0.0 111.126 -178.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 15.2 m-85 -98.4 124.4 43.06 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.2 m-20 -101.97 130.1 48.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.886 -1.134 . . . . 0.0 111.03 -178.563 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.611 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 77.98 65.55 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 CA-C-O 121.48 0.657 . . . . 0.0 109.909 179.163 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.943 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.54 119.6 61.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.273 -0.892 . . . . 0.0 109.721 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.669 HD13 ' C ' ' B' ' 63' ' ' LEU . 1.4 tm? -63.9 86.93 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.603 -0.686 . . . . 0.0 111.682 -178.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.599 HG23 ' O ' ' B' ' 64' ' ' ILE . 7.9 tt -93.47 113.03 27.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 176.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' B' ' 14' ' ' LYS . 32.9 tt0 -88.32 120.42 29.67 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 -178.507 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -114.29 126.34 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.215 -0.928 . . . . 0.0 109.712 -179.253 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 5.7 m 65.18 4.75 2.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.797 -0.564 . . . . 0.0 110.763 179.054 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 110.81 -6.75 29.49 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.042 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -92.11 139.29 30.78 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.199 -1.177 . . . . 0.0 108.549 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.539 ' CG ' HD11 ' B' ' 63' ' ' LEU . 1.7 mttt -84.47 124.75 31.69 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.177 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.533 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -134.15 157.89 45.04 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.611 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -131.19 133.91 61.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.593 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.593 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -158.42 -166.48 17.68 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 118.617 -1.754 . . . . 0.0 110.995 -179.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.554 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 51.6 m -92.39 107.1 18.96 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.924 -0.751 . . . . 0.0 109.797 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.14 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -103.77 113.29 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.544 -0.723 . . . . 0.0 109.804 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.861 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -78.35 129.25 34.77 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.888 HG21 HD12 ' B' ' 38' ' ' LEU . 95.7 t -113.78 109.95 30.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.895 -1.128 . . . . 0.0 110.039 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.965 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -147.12 -163.59 10.62 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.506 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -79.87 41.37 1.1 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.325 2.016 . . . . 0.0 111.164 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -88.23 139.74 30.42 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.907 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.652 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.8 Cg_endo -79.81 17.32 1.3 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 C-N-CA 122.488 2.126 . . . . 0.0 112.302 -177.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 2.1 t -160.69 164.63 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.527 -1.358 . . . . 0.0 110.992 -179.543 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.63 ' ND2' ' O ' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -103.61 87.04 2.74 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.135 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.903 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.7 mt -84.42 123.71 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 O-C-N 121.336 -0.852 . . . . 0.0 112.377 -176.064 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.597 HD11 ' HB1' ' B' ' 22' ' ' ALA . 3.2 mm -91.78 103.25 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -84.11 -159.16 28.87 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.71 -1.244 . . . . 0.0 110.671 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.551 ' NH1' HG22 ' B' ' 26' ' ' THR . 11.9 mtt-85 -66.24 -35.58 80.8 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.659 -0.907 . . . . 0.0 109.498 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.994 ' ND2' HD23 ' B' ' 89' ' ' LEU . 7.7 p-10 -48.79 -31.65 7.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.921 . . . . 0.0 109.753 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.994 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -106.16 -17.38 14.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.077 . . . . 0.0 110.251 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.523 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 87.4 mt -77.39 -1.66 31.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.143 -0.973 . . . . 0.0 108.529 179.234 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.598 HG21 ' CZ3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -101.68 -20.58 14.94 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.128 -0.982 . . . . 0.0 108.638 179.038 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 30.4 mt-30 -75.5 -40.72 56.8 Favored 'General case' 0 N--CA 1.486 1.364 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.802 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -83.39 -9.16 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.411 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.3 36.78 33.61 Favored Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.232 -0.917 . . . . 0.0 111.166 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.643 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -63.7 156.25 27.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.054 -1.263 . . . . 0.0 110.513 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 96' ' ' THR . 66.7 p -147.58 126.61 12.84 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -95.49 89.28 5.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.717 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.56 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 5.9 m-20 -96.13 118.74 33.31 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.055 -1.028 . . . . 0.0 109.318 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 1.092 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.324 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.458 ' HG2' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 N-CA-C 110.501 -0.615 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.557 ' NE2' HG21 ' A' ' 4' ' ' THR . 9.1 tt0 -85.92 126.8 34.36 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 177.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.705 HG12 ' O ' ' A' ' 3' ' ' VAL . 2.4 t -112.33 91.09 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 120.818 -1.176 . . . . 0.0 109.909 -178.453 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.73 HG22 HG22 ' B' ' 96' ' ' THR . 64.7 p -117.71 33.04 5.82 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.539 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -86.79 30.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.882 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 35.8 m0 17.68 52.49 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.524 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -147.73 -163.37 1.75 Allowed 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -74.68 114.92 39.02 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.997 -1.065 . . . . 0.0 109.839 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.609 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.9 Cg_endo -78.06 71.15 6.79 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 121.976 1.784 . . . . 0.0 108.878 177.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -93.29 157.64 16.14 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.356 -179.167 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.407 ' CG1' ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -149.96 140.55 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.82 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' A' ' 19' ' ' LEU . 9.6 m -73.2 94.15 1.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.416 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.869 HD11 HD21 ' A' ' 33' ' ' LEU . 4.7 pt -80.43 163.82 3.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.538 -0.726 . . . . 0.0 110.791 -178.243 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 21.7 tttm -129.53 103.23 6.76 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.571 -0.706 . . . . 0.0 109.8 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.918 HG23 ' CG2' ' A' ' 62' ' ' ILE . 39.8 mt -119.55 117.05 52.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 120.994 -1.066 . . . . 0.0 109.38 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.27 25.55 75.28 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.96 -1.63 86.06 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.464 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 tp60 -92.11 167.41 12.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.99 -1.3 . . . . 0.0 109.396 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' A' ' 12' ' ' THR . 36.4 mt -130.2 134.74 47.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' HB3' ' OD1' ' A' ' 83' ' ' ASN . 1.7 tptt -151.32 146.17 25.83 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.627 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.445 ' N ' ' CD ' ' A' ' 21' ' ' GLU . 2.7 mm-40 -78.88 107.94 11.98 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.982 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -98.57 131.82 44.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.017 -1.052 . . . . 0.0 111.019 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.604 HD21 ' O ' ' B' ' 27' ' ' GLY . 0.8 OUTLIER -87.33 105.09 17.01 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.901 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.522 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -46.99 120.36 3.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.966 -1.084 . . . . 0.0 108.4 179.702 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.851 ' HB2' HG23 ' A' ' 84' ' ' ILE . 56.7 t0 -124.54 83.99 2.22 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.221 -0.925 . . . . 0.0 110.488 -178.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.676 HG23 HD13 ' A' ' 90' ' ' LEU . 3.2 m -65.74 -15.26 62.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.036 -1.04 . . . . 0.0 108.565 178.807 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.524 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -67.13 -45.59 80.22 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.81 167.54 19.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -1.184 . . . . 0.0 108.597 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -99.92 -19.8 16.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.828 -1.17 . . . . 0.0 110.785 -178.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 1.031 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.01 179.35 6.37 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.89 -1.131 . . . . 0.0 109.781 -179.687 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.594 HG22 ' CD1' ' A' ' 33' ' ' LEU . 7.4 m -94.66 92.81 7.2 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 120.826 -1.171 . . . . 0.0 110.011 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.872 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -84.49 118.96 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.232 -0.918 . . . . 0.0 109.102 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.869 HD21 HD11 ' A' ' 13' ' ' ILE . 1.2 mp -114.1 144.41 43.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.952 -1.093 . . . . 0.0 111.128 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.86 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -47.17 174.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.381 -0.825 . . . . 0.0 108.922 178.569 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -57.59 146.13 31.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.027 . . . . 0.0 109.642 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.502 ' HG3' ' N ' ' A' ' 37' ' ' SER . 2.7 ptm -163.7 -175.49 4.16 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.392 -0.818 . . . . 0.0 109.043 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.502 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.9 t -110.74 120.44 42.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.113 -0.992 . . . . 0.0 109.788 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.783 HD12 HG21 ' A' ' 77' ' ' VAL . 82.0 mt -132.9 159.17 73.7 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.478 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 34.4 Cg_endo -76.42 133.0 14.08 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.823 2.348 . . . . 0.0 112.436 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -37.25 129.48 1.23 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.469 -1.053 . . . . 0.0 110.469 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.0 OUTLIER 148.19 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -179.519 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.617 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 50.4 p-90 -138.56 -173.29 3.51 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.741 0.782 . . . . 0.0 110.355 -177.234 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.454 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 0.0 OUTLIER -148.94 163.8 24.0 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 179.14 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 36.0 Cg_endo -78.37 145.66 21.41 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.966 1.777 . . . . 0.0 109.979 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.756 ' HB2' HG23 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -146.52 142.78 28.4 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.153 -0.967 . . . . 0.0 109.67 -179.52 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.497 ' CE ' ' HE3' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -121.97 107.24 12.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 108.675 179.475 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.672 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.9 pt -101.81 132.39 47.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.588 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 53' ' ' PHE . . . -117.7 105.38 1.25 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.88 -115.89 2.45 Favored Glycine 0 N--CA 1.481 1.695 0 C-N-CA 119.715 -1.231 . . . . 0.0 110.768 -178.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.732 HG21 HD12 ' B' ' 47' ' ' ILE . 25.6 mt -88.6 116.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 O-C-N 121.832 -0.805 . . . . 0.0 112.834 -177.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.544 ' HA2' HG22 ' B' ' 54' ' ' ILE . . . 106.7 -42.35 1.94 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 166.68 -160.98 34.75 Favored Glycine 0 N--CA 1.49 2.259 0 O-C-N 120.833 -1.392 . . . . 0.0 110.172 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.514 ' HA ' ' HA2' ' A' ' 48' ' ' GLY . 6.8 m-85 -102.1 155.79 17.97 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.449 -1.03 . . . . 0.0 110.042 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.647 HD11 HD11 ' A' ' 47' ' ' ILE . 2.1 pt -134.42 173.54 14.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 3.3 mttt -114.15 144.62 42.86 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.315 -0.866 . . . . 0.0 108.742 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB2' ' A' ' 45' ' ' LYS . 30.6 m -143.39 -177.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.624 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.525 ' O ' ' N ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -131.52 88.82 2.62 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.547 ' HG3' HG23 ' A' ' 74' ' ' THR . 3.5 tt0 -46.76 91.7 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.497 -0.752 . . . . 0.0 109.804 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 12.5 m-85 -89.96 95.68 10.33 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.525 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 12.2 m-20 -79.22 133.2 36.69 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.161 -0.962 . . . . 0.0 109.972 -179.004 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 20.4 mm-40 81.8 61.68 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.495 0.664 . . . . 0.0 110.166 179.171 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.918 ' CG2' HG23 ' A' ' 15' ' ' ILE . 15.4 mm -115.99 120.35 64.59 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.632 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.858 HD13 ' O ' ' A' ' 63' ' ' LEU . 1.9 tm? -72.45 81.18 1.06 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.171 -0.956 . . . . 0.0 111.094 -178.039 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.812 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -87.66 117.93 32.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.345 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.487 ' HG3' ' N ' ' A' ' 70' ' ' LYS . 1.5 tt0 -93.91 112.38 24.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.07 -1.019 . . . . 0.0 109.763 -178.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.801 HG13 HG22 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -100.34 118.81 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.3 m 56.42 54.55 7.45 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.735 -0.603 . . . . 0.0 109.807 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 57.69 16.55 23.72 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' C ' ' HG3' ' A' ' 65' ' ' GLU . 25.7 m170 -107.93 91.18 3.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -1.223 . . . . 0.0 109.494 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -43.42 137.25 2.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 179.712 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -159.25 124.83 4.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.515 -0.74 . . . . 0.0 109.415 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.68 HD13 ' C ' ' A' ' 62' ' ' ILE . 1.0 OUTLIER -95.32 152.45 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.877 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.443 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.41 -171.82 39.73 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 118.832 -1.652 . . . . 0.0 111.089 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.547 HG23 ' HG3' ' A' ' 58' ' ' GLN . 96.5 m -98.49 108.85 21.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -1.134 . . . . 0.0 110.619 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.83 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -99.24 109.92 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.675 -0.641 . . . . 0.0 110.349 179.153 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 1.031 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.4 100.95 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.783 HG21 HD12 ' A' ' 38' ' ' LEU . 21.6 t -87.1 121.86 38.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.98 -1.075 . . . . 0.0 110.248 -178.705 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.534 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -156.76 -166.15 15.97 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.552 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 35.7 Cg_endo -80.84 40.67 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.403 2.069 . . . . 0.0 111.103 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.86 HG22 ' HA ' ' A' ' 34' ' ' GLU . 13.4 t -81.36 140.5 48.71 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.713 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.0 Cg_endo -78.73 15.75 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.595 2.197 . . . . 0.0 111.279 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 81' ' ' PRO . 5.2 t -160.53 163.36 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.94 -1.1 . . . . 0.0 110.514 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.01 85.57 2.88 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 105.045 -2.205 . . . . 0.0 105.045 177.109 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.851 HG23 ' HB2' ' A' ' 25' ' ' ASP . 4.6 mt -88.88 125.31 41.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.139 -0.975 . . . . 0.0 112.69 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.982 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -84.88 149.48 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 176.503 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.496 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -125.61 -170.23 13.01 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.672 -1.728 . . . . 0.0 110.462 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HD3' ' HB2' ' A' ' 90' ' ' LEU . 6.4 mmt180 -62.98 -26.75 68.99 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.444 -1.033 . . . . 0.0 108.416 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.023 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.7 p-10 -57.65 -28.44 63.74 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.433 -0.792 . . . . 0.0 109.141 179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.023 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -102.36 -24.37 13.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.287 -0.883 . . . . 0.0 109.208 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.676 HD13 HG23 ' A' ' 26' ' ' THR . 41.0 mt -71.51 -4.8 28.76 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.473 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.466 ' HB ' ' CE2' ' B' ' 6' ' ' TRP . 21.7 p -101.14 -16.08 17.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.256 -0.902 . . . . 0.0 108.717 178.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mm-40 -86.66 -40.81 14.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.31 -0.868 . . . . 0.0 109.433 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.774 HD12 ' CD2' ' B' ' 99' ' ' PHE . 1.6 pt -85.67 0.71 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.131 -0.981 . . . . 0.0 108.724 179.395 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.03 51.49 50.47 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.525 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.1 155.29 23.92 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.031 -1.276 . . . . 0.0 109.802 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.74 HG22 ' CG2' ' B' ' 4' ' ' THR . 10.5 p -147.98 130.88 16.16 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' B' ' 97' ' ' LEU . 4.6 mp -91.29 100.86 13.59 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.421 -0.799 . . . . 0.0 109.698 -179.453 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.544 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.8 m-20 -102.2 123.37 45.92 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.961 -1.087 . . . . 0.0 109.111 179.352 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.836 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.09 -0.957 . . . . 0.0 109.241 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.494 1.509 0 N-CA-C 110.041 -0.792 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -83.55 133.78 34.85 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 30.7 t -132.69 122.5 47.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.756 -177.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.74 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.4 OUTLIER -132.46 -79.46 0.5 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.612 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 60.1 mt 28.27 38.64 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.095 178.298 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 25.7 m0 16.51 52.75 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 CA-C-O 121.252 0.549 . . . . 0.0 111.619 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 9.9 mt-30 -142.09 -179.46 6.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 109.868 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -75.62 122.35 86.97 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 1.064 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 75.73 4.46 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.078 1.852 . . . . 0.0 109.836 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.529 ' CD2' ' CB ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -91.78 154.91 18.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.904 . . . . 0.0 109.695 -179.543 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.623 HG21 HG12 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -147.91 134.98 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 0.0 109.908 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.653 ' CG2' HD23 ' B' ' 19' ' ' LEU . 6.9 m -68.15 105.1 1.97 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.766 -1.208 . . . . 0.0 108.555 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 1.052 HG22 HG13 ' B' ' 66' ' ' ILE . 1.2 pt -92.86 156.75 3.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.944 -1.098 . . . . 0.0 110.261 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.793 ' HG3' HD12 ' B' ' 19' ' ' LEU . 10.5 tttm -121.99 100.06 6.78 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.762 ' CD1' HG11 ' B' ' 75' ' ' VAL . 13.1 mt -116.71 124.24 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.108 -0.995 . . . . 0.0 110.122 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.83 38.86 93.04 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 68.45 21.13 74.21 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.526 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -110.13 171.0 7.71 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.201 -1.176 . . . . 0.0 109.136 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.793 HD12 ' HG3' ' B' ' 14' ' ' LYS . 0.1 OUTLIER -148.14 124.36 10.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.298 -0.876 . . . . 0.0 110.565 -179.378 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mtmp? -151.05 169.23 22.33 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.547 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -81.92 119.02 23.41 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 120.989 -1.069 . . . . 0.0 109.197 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.968 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -94.91 130.51 41.49 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.312 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.524 HD21 ' O ' ' A' ' 27' ' ' GLY . 19.0 tp -92.89 92.34 7.85 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 1.064 HD12 ' HB2' ' B' ' 9' ' ' PRO . 92.4 mt -44.11 96.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.287 -0.883 . . . . 0.0 108.998 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.784 ' HB3' HG23 ' B' ' 84' ' ' ILE . 3.8 t0 -105.64 86.53 2.42 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.4 -0.813 . . . . 0.0 109.555 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.665 HG23 HD13 ' B' ' 90' ' ' LEU . 0.6 OUTLIER -63.2 -9.44 11.22 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.267 -0.896 . . . . 0.0 109.443 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.604 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.26 -41.13 47.44 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 28' ' ' ALA . . . . . 0.474 ' O ' ' NH1' ' B' ' 87' ' ' ARG . . . -76.36 145.45 39.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.176 -1.191 . . . . 0.0 109.417 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.93 -16.22 60.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.322 -0.861 . . . . 0.0 111.614 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.786 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -139.03 -167.47 2.23 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.548 -1.345 . . . . 0.0 110.255 -179.532 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.697 HG23 ' O ' ' B' ' 84' ' ' ILE . 23.5 m -107.88 93.71 4.68 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.247 -0.908 . . . . 0.0 110.695 -178.266 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.0 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.22 167.2 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.133 -0.98 . . . . 0.0 108.599 179.171 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.124 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.56 136.89 4.66 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.826 -1.171 . . . . 0.0 111.188 -178.258 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.592 ' O ' HG13 ' B' ' 77' ' ' VAL . 2.9 tt0 -45.31 157.35 0.09 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.83 . . . . 0.0 109.436 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.668 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.0 mt-10 -49.52 151.28 1.65 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.227 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 4.9 ptm -173.33 161.86 4.25 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.455 -0.778 . . . . 0.0 109.035 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 23.5 t -82.17 110.38 17.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.152 -0.967 . . . . 0.0 110.046 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.771 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 48.4 mt -119.36 175.98 1.95 Allowed Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.718 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.771 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.4 Cg_endo -71.79 -161.9 0.11 Allowed 'Trans proline' 0 C--N 1.319 -1.006 0 C-N-CA 121.539 1.493 . . . . 0.0 111.945 -178.248 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.73 35.86 4.74 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -178.335 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.4 mmt-85 -118.18 62.92 0.76 Allowed 'General case' 0 C--N 1.29 -1.991 0 O-C-N 121.598 -0.942 . . . . 0.0 109.042 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.705 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 8.3 p-90 -142.97 -172.35 3.65 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -149.26 139.77 13.65 Favored Pre-proline 0 C--N 1.303 -1.414 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.53 130.67 10.01 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.214 1.943 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.557 ' O ' HG22 ' B' ' 56' ' ' VAL . 3.6 ptmt -162.21 145.61 11.79 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.505 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 42.7 mtp -103.41 137.64 41.24 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.924 -1.11 . . . . 0.0 109.654 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' A' ' 50' ' ' ILE . 3.9 pt -96.45 145.78 8.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.095 -1.003 . . . . 0.0 108.392 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.87 101.27 0.86 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.53 -127.43 3.16 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.749 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.672 HG21 ' CD1' ' A' ' 47' ' ' ILE . 46.4 mt -81.79 132.31 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.835 -0.803 . . . . 0.0 112.207 -177.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.545 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 89.21 -44.71 3.11 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 178.612 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.24 -162.73 34.8 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -115.72 130.76 56.97 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.435 -1.038 . . . . 0.0 109.22 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.544 HG22 ' HA2' ' A' ' 51' ' ' GLY . 23.8 pt -110.51 144.24 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.828 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 10.4 mtmm -72.08 144.06 48.84 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.298 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.557 HG22 ' O ' ' B' ' 45' ' ' LYS . 29.5 m -145.42 -170.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.103 -0.998 . . . . 0.0 109.873 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.583 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.4 mtt180 -142.4 102.16 4.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.329 -0.857 . . . . 0.0 109.332 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.679 ' HG3' HG22 ' B' ' 74' ' ' THR . 5.5 tt0 -64.77 113.07 3.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -0.893 . . . . 0.0 109.961 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.705 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 19.1 m-85 -104.38 95.51 5.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.442 -0.786 . . . . 0.0 108.941 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.1 m-20 -78.71 137.77 37.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.966 -1.084 . . . . 0.0 109.972 -179.303 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.535 ' HA ' HG23 ' B' ' 72' ' ' ILE . 1.3 mm-40 77.66 64.12 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.456 0.646 . . . . 0.0 109.869 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.797 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.6 OUTLIER -126.48 119.27 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.953 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.621 HD11 ' HG3' ' B' ' 70' ' ' LYS . 0.2 OUTLIER -72.53 85.29 1.15 Allowed 'General case' 0 C--N 1.296 -1.724 0 O-C-N 120.933 -1.104 . . . . 0.0 111.805 -177.526 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.645 ' CG2' HD11 ' B' ' 89' ' ' LEU . 4.4 tt -89.49 115.04 28.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 10.1 tt0 -89.57 117.38 28.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 1.052 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -110.27 120.68 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.244 -0.91 . . . . 0.0 108.88 179.37 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 57.95 50.71 9.9 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.446 -0.784 . . . . 0.0 109.67 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 59.76 16.77 39.73 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.48 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 69.9 m-70 -106.01 121.15 43.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.101 -1.235 . . . . 0.0 109.531 179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.621 ' HG3' HD11 ' B' ' 63' ' ' LEU . 21.4 ttpt -69.45 122.03 18.17 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.41 -0.806 . . . . 0.0 109.585 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.751 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -139.64 106.98 5.52 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 110.356 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.797 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.4 OUTLIER -87.04 139.03 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 177.811 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.18 -159.0 9.69 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 118.545 -1.788 . . . . 0.0 111.285 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.679 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.3 m -109.17 102.57 11.51 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.64 -0.917 . . . . 0.0 109.67 -179.543 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.124 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -96.91 111.38 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.241 -0.912 . . . . 0.0 111.107 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.786 HD11 ' HB3' ' B' ' 30' ' ' ASP . 1.8 mp -78.39 134.18 37.45 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.369 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.754 HG21 ' CD1' ' B' ' 38' ' ' LEU . 46.5 t -124.43 131.29 72.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 120.869 -1.144 . . . . 0.0 110.145 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.63 -160.37 11.56 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.85 40.79 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.369 2.046 . . . . 0.0 110.401 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' B' ' 32' ' ' VAL . 4.6 t -84.94 138.28 37.37 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.507 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.4 Cg_endo -79.48 23.34 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 122.475 2.117 . . . . 0.0 111.668 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.564 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -161.67 170.46 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.669 -1.269 . . . . 0.0 110.113 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 0.1 OUTLIER -110.19 92.73 4.16 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.122 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.784 HG23 ' HB3' ' B' ' 25' ' ' ASP . 20.2 mm -78.77 128.23 38.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.385 -0.822 . . . . 0.0 112.893 -175.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.968 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.4 mp -108.15 89.29 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 176.705 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -79.53 -162.36 24.26 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.313 -177.767 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.544 ' NH1' ' O ' ' B' ' 26' ' ' THR . 0.1 OUTLIER -61.89 -40.04 94.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.766 -0.844 . . . . 0.0 110.232 -179.219 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.039 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.6 p-10 -43.84 -28.89 0.48 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.141 -0.974 . . . . 0.0 109.465 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.039 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.8 mm? -107.27 -29.61 9.21 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.185 -0.947 . . . . 0.0 110.048 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.717 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 13.6 mt -72.81 -3.66 26.83 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.03 -1.044 . . . . 0.0 108.506 179.145 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.503 ' O ' ' CZ2' ' A' ' 6' ' ' TRP . 15.5 p -101.72 -20.21 15.07 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.167 -0.958 . . . . 0.0 108.857 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.751 HE21 ' HB1' ' B' ' 71' ' ' ALA . 6.7 mt-30 -82.87 -38.05 23.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.321 -0.862 . . . . 0.0 109.236 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.836 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -81.06 3.71 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.877 . . . . 0.0 108.978 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.509 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 72.5 46.25 33.36 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.311 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.717 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -82.3 136.03 35.1 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.082 -1.246 . . . . 0.0 110.728 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 4' ' ' THR . 36.3 p -131.78 129.43 40.53 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -92.34 93.08 8.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.923 -1.11 . . . . 0.0 109.495 -179.552 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 6.1 m-20 -100.39 127.27 46.76 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -0.918 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.774 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.213 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.578 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.013 -0.803 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -84.15 138.94 32.75 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 177.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.8 t -140.04 116.27 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 117.857 -1.537 . . . . 0.0 111.921 -177.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.53 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.1 OUTLIER -121.34 -62.75 1.39 Allowed 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 176.874 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.594 HD23 ' O ' ' A' ' 5' ' ' LEU . 0.4 OUTLIER 35.92 26.23 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.903 177.399 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.616 ' HA ' HG21 ' B' ' 91' ' ' THR . 27.8 m95 17.82 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.298 0.57 . . . . 0.0 112.252 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.582 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -161.91 -157.47 0.48 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.215 179.856 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.478 ' HG2' ' OD1' ' B' ' 29' ' ' ASP . 40.9 mtm180 -78.8 128.82 75.64 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 120.894 -1.129 . . . . 0.0 109.893 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.64 66.02 8.86 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.36 2.04 . . . . 0.0 108.49 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.614 HD23 ' H ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -90.2 145.18 25.21 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.33 -0.856 . . . . 0.0 110.756 -178.182 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.469 HG23 ' N ' ' A' ' 12' ' ' THR . 0.6 OUTLIER -150.51 164.14 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.277 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.592 HG22 HD22 ' A' ' 19' ' ' LEU . 51.8 m -86.64 133.31 33.71 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 178.012 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.862 ' O ' HD23 ' A' ' 19' ' ' LEU . 8.3 pt -121.92 156.73 26.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.996 -1.065 . . . . 0.0 110.384 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 8.0 tttt -117.94 100.55 7.63 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.762 HD11 HD12 ' A' ' 64' ' ' ILE . 18.0 mt -112.24 145.78 17.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.368 -0.832 . . . . 0.0 110.298 -178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 39.82 41.15 1.78 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.84 44.59 94.47 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.552 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -144.13 176.56 9.22 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.121 -1.223 . . . . 0.0 108.756 179.537 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.862 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.0 mt -140.02 123.71 17.32 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 119.305 -0.958 . . . . 0.0 110.535 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -143.27 177.02 8.7 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 179.1 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.542 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 15.3 mp0 -79.86 -178.97 6.7 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.613 -1.304 . . . . 0.0 108.057 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.614 ' H ' HD23 ' A' ' 10' ' ' LEU . . . -160.81 109.53 1.62 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.841 -1.162 . . . . 0.0 110.046 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.611 HD21 ' O ' ' B' ' 27' ' ' GLY . 27.3 tp -89.26 89.36 7.88 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.669 -0.644 . . . . 0.0 109.307 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.555 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 58.2 mt -42.49 97.04 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 56.9 t0 -106.36 87.08 2.47 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.582 -0.699 . . . . 0.0 110.788 -177.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -62.15 -20.15 63.8 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.974 -1.079 . . . . 0.0 108.804 178.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.56 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -58.73 -48.24 86.07 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.55 160.63 31.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.311 -1.111 . . . . 0.0 108.591 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.414 ' OD1' ' HG2' ' B' ' 8' ' ' ARG . 61.9 m-20 -96.65 -11.21 25.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.986 -1.071 . . . . 0.0 110.421 -179.014 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.562 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -138.98 -165.56 1.86 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.089 . . . . 0.0 110.624 -179.211 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.539 ' HG1' ' HA ' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -104.0 88.54 3.05 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.069 -1.019 . . . . 0.0 111.658 -178.001 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.775 HG21 HD13 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -72.94 122.99 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.317 -1.49 . . . . 0.0 107.333 177.784 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.787 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.4 OUTLIER -131.27 131.87 44.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.539 -1.351 . . . . 0.0 111.345 -177.965 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 33' ' ' LEU . 10.5 pt-20 -41.91 152.98 0.07 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.87 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -50.36 144.44 7.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.213 -0.93 . . . . 0.0 110.239 -179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.452 ' SD ' ' O ' ' A' ' 37' ' ' SER . 0.0 OUTLIER -171.4 179.5 2.91 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.402 -0.811 . . . . 0.0 109.169 179.636 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.452 ' O ' ' SD ' ' A' ' 36' ' ' MET . 8.0 t -84.01 111.08 18.96 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.1 -1.0 . . . . 0.0 109.834 -179.658 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.845 HD11 HD12 ' A' ' 62' ' ' ILE . 18.6 tp -154.0 90.42 3.29 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 109.702 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -80.21 162.34 22.9 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.667 2.245 . . . . 0.0 110.408 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . 129.96 42.25 0.22 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.486 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER 61.1 150.68 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.658 -0.907 . . . . 0.0 109.047 -179.658 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.609 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 26.8 p-90 -154.2 158.38 40.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.101 -0.999 . . . . 0.0 109.807 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -120.67 138.38 27.47 Favored Pre-proline 0 C--N 1.299 -1.613 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.16 134.42 17.53 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 121.568 1.512 . . . . 0.0 108.736 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 46' ' ' MET . 7.1 tttt -148.15 163.49 36.79 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.548 -178.716 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.498 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 3.9 tpt -134.16 114.13 12.77 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.074 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.775 HD13 HG21 ' A' ' 32' ' ' VAL . 17.5 pt -89.68 143.25 11.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.619 -1.232 . . . . 0.0 109.802 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.653 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.07 98.36 0.76 Allowed Glycine 0 N--CA 1.485 1.911 0 N-CA-C 107.916 -2.074 . . . . 0.0 107.916 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.96 -136.31 4.8 Favored Glycine 0 C--N 1.298 -1.559 0 C-N-CA 119.315 -1.421 . . . . 0.0 111.387 -178.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.89 HG23 HD13 ' B' ' 54' ' ' ILE . 80.6 mt -78.92 132.17 32.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.768 0.794 . . . . 0.0 112.962 -177.339 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.466 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 85.81 -41.58 3.09 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.84 -165.11 36.16 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.493 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.653 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 1.1 m-85 -111.04 138.89 46.89 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.647 -0.914 . . . . 0.0 109.244 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.55 HG12 HD11 ' A' ' 47' ' ' ILE . 4.9 pt -119.71 134.13 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.853 -1.154 . . . . 0.0 108.854 178.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.496 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 4.2 mttp -74.86 133.38 41.86 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.954 -1.091 . . . . 0.0 110.119 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 1.025 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.2 m -144.57 166.77 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.255 -0.903 . . . . 0.0 109.773 179.765 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.516 ' HG2' ' CE3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -111.31 172.8 6.67 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.828 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.51 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 37.1 tt0 -135.02 102.82 5.34 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.839 -1.163 . . . . 0.0 110.815 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.609 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 87.8 m-85 -91.31 123.0 34.41 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.504 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -96.37 145.82 25.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 110.463 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.504 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.8 OUTLIER 75.96 64.51 0.05 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.65 -0.656 . . . . 0.0 110.147 179.425 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.845 HD12 HD11 ' A' ' 38' ' ' LEU . 15.2 mm -124.13 119.91 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.331 -0.855 . . . . 0.0 109.473 179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.776 HD21 ' HG3' ' A' ' 70' ' ' LYS . 3.2 tm? -69.85 94.81 0.86 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.665 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.762 HD12 HD11 ' A' ' 15' ' ' ILE . 9.5 tt -96.62 119.2 44.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.1 tt0 -89.7 103.38 16.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.004 -1.06 . . . . 0.0 109.899 -178.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.838 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -96.76 116.18 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.199 -0.938 . . . . 0.0 109.821 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 62.32 17.13 9.11 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.809 -0.557 . . . . 0.0 110.683 178.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.33 6.73 55.16 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.745 -1.217 . . . . 0.0 110.409 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -104.64 133.79 48.89 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.186 -1.184 . . . . 0.0 109.196 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.776 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -76.09 130.95 39.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.966 . . . . 0.0 109.042 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -150.06 97.96 2.64 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.453 -0.78 . . . . 0.0 110.465 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.568 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -79.03 137.15 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.642 -1.286 . . . . 0.0 107.883 178.791 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.418 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -157.93 -167.88 19.49 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.536 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 31' ' ' THR . 26.0 m -97.7 102.08 13.75 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.533 -0.981 . . . . 0.0 109.516 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.787 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.8 OUTLIER -91.47 173.91 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.265 -0.897 . . . . 0.0 109.357 179.727 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -132.54 163.3 29.16 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 179.557 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.87 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.2 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 120.948 -1.095 . . . . 0.0 110.457 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 1.025 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -139.82 -169.53 11.67 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 47.27 2.49 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.551 2.167 . . . . 0.0 110.791 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.684 HG21 HG13 ' A' ' 32' ' ' VAL . 14.8 t -91.02 139.87 25.9 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.147 -0.971 . . . . 0.0 109.133 179.649 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.34 19.51 0.93 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.696 2.264 . . . . 0.0 112.646 -178.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 1.2 t -160.24 171.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.415 -1.428 . . . . 0.0 110.396 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.574 ' N ' HG13 ' A' ' 82' ' ' VAL . 28.7 m120 -104.9 83.74 2.04 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.273 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.673 ' CG1' HG12 ' A' ' 32' ' ' VAL . 7.7 mm -75.74 113.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.461 -0.775 . . . . 0.0 111.712 -176.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.537 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -93.92 94.09 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.774 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.84 -172.25 41.41 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.797 -1.19 . . . . 0.0 111.589 -177.739 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 88' ' ' ASN . 1.2 mtt-85 -56.69 -36.05 69.17 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.957 -0.731 . . . . 0.0 110.38 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.778 ' ND2' HD23 ' A' ' 89' ' ' LEU . 5.8 p-10 -43.39 -40.45 3.7 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.057 -1.027 . . . . 0.0 109.15 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.778 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -94.53 -30.04 14.6 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.318 -0.864 . . . . 0.0 111.02 -179.299 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.801 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 28.2 mt -65.99 -6.83 13.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.533 -1.354 . . . . 0.0 109.795 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.793 HG21 ' CG ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -101.42 -15.0 17.33 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.978 -1.076 . . . . 0.0 109.101 179.743 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.486 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -80.0 -41.15 26.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.577 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.819 HD12 ' CG ' ' B' ' 99' ' ' PHE . 4.5 pt -82.71 5.49 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.955 . . . . 0.0 108.756 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.52 41.64 35.67 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.876 -1.289 . . . . 0.0 109.876 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' A' ' 90' ' ' LEU . . . -81.81 137.8 35.23 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 120.882 -1.363 . . . . 0.0 110.09 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.821 HG22 ' CG2' ' B' ' 4' ' ' THR . 11.2 p -136.6 130.38 32.23 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' B' ' 97' ' ' LEU . 1.9 mp -88.26 92.16 9.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.747 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.559 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.0 m-20 -95.35 123.42 38.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.095 -1.003 . . . . 0.0 109.407 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.872 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 117.93 -1.034 . . . . 0.0 109.529 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.604 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.498 1.778 0 N-CA-C 110.326 -0.682 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -85.01 131.6 34.45 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.262 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 16.5 t -127.37 127.76 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.851 -1.156 . . . . 0.0 110.859 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.821 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -149.44 25.78 0.86 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -82.47 45.07 0.93 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.705 -0.622 . . . . 0.0 110.94 -178.135 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.793 ' CG ' HG21 ' A' ' 91' ' ' THR . 13.8 m95 18.84 51.7 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.177 0.513 . . . . 0.0 111.214 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.531 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.5 OUTLIER -141.53 -168.5 2.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.982 -1.074 . . . . 0.0 110.336 -179.224 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.414 ' HG2' ' OD1' ' A' ' 29' ' ' ASP . 0.2 OUTLIER -91.76 128.94 44.13 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.399 -0.813 . . . . 0.0 109.148 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.3 Cg_endo -76.52 72.83 5.41 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.305 2.003 . . . . 0.0 109.879 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.506 HD22 ' HB2' ' B' ' 21' ' ' GLU . 3.2 mt -95.68 134.75 38.23 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.753 -1.217 . . . . 0.0 109.936 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.454 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -140.44 154.71 22.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.7 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.09 102.78 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 178.535 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.981 ' CD1' HD12 ' B' ' 15' ' ' ILE . 1.7 pp -87.64 148.68 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.466 -0.772 . . . . 0.0 109.649 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.518 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 16.8 ttmt -117.38 107.88 14.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.399 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.981 HD12 ' CD1' ' B' ' 13' ' ' ILE . 0.9 OUTLIER -117.39 125.26 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.151 -0.968 . . . . 0.0 109.647 -179.6 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.36 14.29 68.87 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 6.71 69.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.518 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.2 mt-30 -97.83 167.55 10.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.324 -1.103 . . . . 0.0 108.839 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.464 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 16.2 mt -131.99 129.73 40.52 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.122 -0.986 . . . . 0.0 111.164 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.606 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -149.79 168.61 23.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 177.91 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.546 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 7.2 pt-20 -78.3 -166.09 0.78 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.684 ' HB2' HG23 ' B' ' 13' ' ' ILE . . . -168.8 109.84 0.5 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.844 -1.16 . . . . 0.0 109.955 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.558 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.1 tp -83.76 93.66 8.0 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.458 -0.777 . . . . 0.0 109.181 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.705 HD22 HG21 ' B' ' 85' ' ' ILE . 26.7 mt -44.63 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 7.5 t0 -99.01 81.78 2.64 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.583 -0.698 . . . . 0.0 109.897 -178.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.557 ' CG2' ' HD3' ' B' ' 87' ' ' ARG . 10.6 m -58.6 -17.27 20.53 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.611 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.26 -43.98 96.2 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 28' ' ' ALA . . . . . 0.43 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -72.31 169.33 16.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.133 -1.216 . . . . 0.0 108.852 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.478 ' OD1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -100.31 -20.37 15.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 110.217 -179.198 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 4.8 m-20 -132.9 -166.88 1.82 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.994 -1.066 . . . . 0.0 110.206 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' B' ' 33' ' ' LEU . 9.0 m -107.02 89.3 2.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.816 -1.178 . . . . 0.0 111.397 -177.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.96 HG13 HG21 ' B' ' 80' ' ' THR . 0.6 OUTLIER -68.63 160.45 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.347 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.889 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -157.83 133.92 9.39 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.759 -1.213 . . . . 0.0 111.394 -177.741 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.469 ' OE1' ' O ' ' B' ' 80' ' ' THR . 15.1 tp10 -42.34 141.88 0.88 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.479 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.732 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -41.07 150.47 0.08 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.462 -0.774 . . . . 0.0 110.252 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.49 ' HE1' ' O ' ' B' ' 15' ' ' ILE . 0.1 OUTLIER -170.66 -175.87 1.94 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 11.1 t -109.48 101.76 10.68 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.826 -1.171 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.905 HD12 HG21 ' B' ' 77' ' ' VAL . 6.2 mt -97.08 170.25 7.55 Favored Pre-proline 0 N--CA 1.489 1.482 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.207 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.579 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.0 Cg_endo -76.06 68.31 6.61 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.407 2.071 . . . . 0.0 112.537 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 32.75 -157.27 0.01 OUTLIER Glycine 0 N--CA 1.498 2.771 0 CA-C-O 121.918 0.732 . . . . 0.0 111.594 178.358 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 54.31 81.91 0.1 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.312 -1.11 . . . . 0.0 109.213 -179.711 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.544 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 58.0 p-90 -155.84 -176.19 5.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.531 -0.73 . . . . 0.0 109.581 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -141.09 159.52 61.35 Favored Pre-proline 0 N--CA 1.489 1.496 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.264 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.93 139.94 12.4 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 C-N-CA 122.249 1.966 . . . . 0.0 110.998 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.644 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -148.38 118.63 7.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.401 -0.812 . . . . 0.0 108.977 179.543 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.521 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -96.24 129.57 43.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.05 -1.031 . . . . 0.0 109.557 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.602 HD11 HD11 ' B' ' 54' ' ' ILE . 41.0 pt -117.14 132.0 68.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.099 179.01 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.94 100.97 0.84 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 107.976 -2.049 . . . . 0.0 107.976 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -118.61 -125.87 3.51 Favored Glycine 0 N--CA 1.483 1.804 0 C-N-CA 119.184 -1.484 . . . . 0.0 111.038 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.506 ' O ' ' O ' ' A' ' 50' ' ' ILE . 52.9 mt -84.56 121.41 36.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.568 -0.96 . . . . 0.0 112.981 -177.089 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.506 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 100.74 -36.8 3.92 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.172 177.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 169.86 -154.83 24.2 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.553 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.614 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.5 OUTLIER -120.4 140.76 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.53 -0.983 . . . . 0.0 109.718 -179.659 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.89 HD13 HG23 ' A' ' 50' ' ' ILE . 12.5 pt -124.33 132.07 71.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.311 -0.868 . . . . 0.0 108.976 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.524 ' O ' ' HD3' ' B' ' 79' ' ' PRO . 15.2 mttt -77.45 140.3 39.82 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.047 -1.033 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.897 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.0 m -138.56 175.07 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 109.956 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.421 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 18.4 mtt-85 -124.86 102.35 7.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.501 -0.749 . . . . 0.0 109.054 179.622 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.559 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.7 OUTLIER -60.28 94.75 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.47 -0.769 . . . . 0.0 110.772 -179.653 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 29.9 m-85 -89.88 114.4 26.17 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.566 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -93.47 143.18 26.53 Favored 'General case' 0 C--N 1.296 -1.748 0 O-C-N 120.912 -1.117 . . . . 0.0 110.337 -178.83 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.566 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 73.18 63.08 0.1 Allowed 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.368 0.604 . . . . 0.0 110.54 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 8.1 mm -120.53 110.76 29.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 178.649 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.623 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.0 OUTLIER -63.15 87.41 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.033 -1.042 . . . . 0.0 110.768 -178.515 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.893 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.0 tt -89.85 122.36 41.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.467 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 1.2 tt0 -90.0 116.96 28.44 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.995 -1.066 . . . . 0.0 109.108 -179.316 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.665 HD12 HG12 ' B' ' 64' ' ' ILE . 0.4 OUTLIER -111.63 131.65 62.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.277 -0.889 . . . . 0.0 109.351 -179.813 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.3 m 45.27 58.95 3.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.642 -0.661 . . . . 0.0 110.856 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 68' ' ' GLY . . . . . 0.467 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 53.07 31.19 40.07 Favored Glycine 0 N--CA 1.495 2.598 0 C-N-CA 120.163 -1.017 . . . . 0.0 110.865 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -132.62 142.71 49.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.337 . . . . 0.0 109.453 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.505 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -75.44 138.15 41.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 109.809 -179.683 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.665 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -159.03 98.71 1.48 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.955 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.623 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.01 159.96 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.798 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.491 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.18 -171.8 44.64 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.029 -2.034 . . . . 0.0 112.335 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.559 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 5.9 m -95.47 106.64 18.73 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.809 -0.818 . . . . 0.0 110.475 -179.353 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.854 HG13 HD13 ' B' ' 33' ' ' LEU . 1.6 t -98.11 108.81 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.627 -0.67 . . . . 0.0 110.618 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.59 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -80.95 125.32 29.99 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.041 -1.037 . . . . 0.0 108.549 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.905 HG21 HD12 ' B' ' 38' ' ' LEU . 1.4 t -104.18 111.3 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.224 -0.922 . . . . 0.0 110.054 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.897 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -145.27 -171.56 15.03 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 179.523 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.524 ' HD3' ' O ' ' B' ' 55' ' ' LYS . 35.3 Cg_endo -79.91 43.13 1.44 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.502 2.134 . . . . 0.0 111.091 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.96 HG21 HG13 ' B' ' 32' ' ' VAL . 2.9 t -89.03 138.29 29.2 Favored Pre-proline 0 N--CA 1.488 1.433 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.725 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.5 Cg_endo -80.42 21.78 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.508 2.139 . . . . 0.0 111.328 -178.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.725 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.8 t -161.32 161.1 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.623 -1.298 . . . . 0.0 111.029 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.606 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 1.9 m-80 -90.77 88.78 7.21 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.024 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.724 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.8 mm -78.85 118.93 27.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.041 -1.037 . . . . 0.0 111.422 -176.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.705 HG21 HD22 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -102.04 99.74 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 177.847 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -85.37 -163.08 36.83 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.871 -1.143 . . . . 0.0 110.704 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HD3' ' CG2' ' B' ' 26' ' ' THR . 7.5 mmm180 -63.65 -29.03 70.32 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.653 -0.91 . . . . 0.0 110.113 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.02 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.8 p-10 -52.53 -40.06 62.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.673 -1.267 . . . . 0.0 109.237 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.02 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.3 mm? -96.04 -15.86 21.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.904 -179.056 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.845 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 34.4 mt -85.18 -4.18 59.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.866 -1.146 . . . . 0.0 108.827 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.616 HG21 ' HA ' ' A' ' 6' ' ' TRP . 68.9 p -101.83 -13.93 17.48 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.324 -0.86 . . . . 0.0 108.748 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.818 ' OE1' HD13 ' B' ' 89' ' ' LEU . 33.0 mt-30 -87.0 -36.44 18.24 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.41 -0.806 . . . . 0.0 109.281 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.872 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -85.38 4.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.803 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 78.48 31.07 47.12 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.041 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.845 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -74.15 132.79 42.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.336 . . . . 0.0 110.353 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 17.1 p -140.81 129.44 22.81 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.418 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -86.04 94.46 9.24 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.329 -0.857 . . . . 0.0 109.312 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 13.0 m-20 -96.26 122.63 39.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.112 -0.992 . . . . 0.0 109.207 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.819 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.421 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.478 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.493 1.476 0 N-CA-C 109.884 -0.852 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.438 ' HG2' ' N ' ' A' ' 3' ' ' VAL . 1.2 tt0 -84.29 141.04 31.22 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.586 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 10.8 t -135.68 112.66 13.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.464 -1.397 . . . . 0.0 110.071 -178.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.807 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.5 OUTLIER -128.3 -78.5 0.57 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.856 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.708 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.4 OUTLIER 34.94 37.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.802 -0.562 . . . . 0.0 110.268 179.983 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' A' ' 5' ' ' LEU . 43.7 m0 16.1 53.77 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 121.065 0.459 . . . . 0.0 112.204 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.708 ' HB2' HD12 ' A' ' 5' ' ' LEU . 1.6 mm-40 -156.35 -174.84 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.992 -1.067 . . . . 0.0 109.937 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -68.43 115.33 28.63 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.265 -0.897 . . . . 0.0 109.402 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.4 Cg_endo -77.15 72.68 5.79 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.12 1.88 . . . . 0.0 110.359 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.797 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -81.76 152.77 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -0.887 . . . . 0.0 108.998 179.715 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.771 HG23 HG23 ' A' ' 13' ' ' ILE . 26.9 m -139.07 129.16 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.166 -0.959 . . . . 0.0 110.38 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.503 HG22 HD22 ' A' ' 19' ' ' LEU . 4.4 m -67.74 92.01 0.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 178.186 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.907 HD11 HD21 ' A' ' 33' ' ' LEU . 3.0 pt -88.74 147.21 5.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.462 -0.774 . . . . 0.0 110.886 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.9 tttt -109.11 100.37 9.55 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.018 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.709 HD12 ' CD2' ' A' ' 33' ' ' LEU . 3.4 mt -117.17 136.16 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.87 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' A' ' 18' ' ' GLN . . . 63.34 25.07 68.1 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.134 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.8 17.78 79.92 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.669 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 15.3 mp0 -123.75 -174.67 3.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -1.158 . . . . 0.0 108.919 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 44.0 mt -137.97 135.48 36.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.137 -0.977 . . . . 0.0 110.06 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.508 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -148.97 148.69 30.07 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.797 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.6 mm-40 -78.61 109.06 12.48 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.947 -1.095 . . . . 0.0 109.295 -179.338 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.046 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -95.05 116.95 29.35 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 122.02 0.914 . . . . 0.0 111.265 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.469 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 8.3 tp -72.46 103.09 3.37 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.1 mt -46.65 131.03 11.54 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.105 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.763 ' HB2' HG23 ' A' ' 84' ' ' ILE . 3.6 t70 -139.34 86.57 2.13 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.167 -0.958 . . . . 0.0 111.091 -177.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.967 HG21 HD22 ' A' ' 97' ' ' LEU . 1.5 m -65.64 -11.64 46.42 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.97 -1.081 . . . . 0.0 108.4 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.701 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -72.74 -44.7 37.9 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.061 -1.616 . . . . 0.0 109.061 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.49 157.79 36.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -1.162 . . . . 0.0 108.936 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -99.18 -9.5 23.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.036 . . . . 0.0 110.226 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -138.57 177.93 7.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.944 -1.098 . . . . 0.0 110.297 -179.428 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.689 HG22 ' CD1' ' A' ' 33' ' ' LEU . 37.6 m -101.78 102.23 12.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.036 -1.04 . . . . 0.0 109.44 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.778 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -97.11 115.42 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.353 -0.842 . . . . 0.0 109.88 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.054 HD13 ' CG1' ' A' ' 75' ' ' VAL . 6.6 mp -106.52 123.13 47.62 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.309 -0.869 . . . . 0.0 109.767 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.704 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.0 pt-20 -43.09 165.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 108.915 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.539 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.5 tt0 -42.7 137.48 2.22 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 110.067 -179.206 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.489 ' SD ' HD13 ' A' ' 38' ' ' LEU . 2.0 ppp? -153.78 -162.33 1.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.565 -0.709 . . . . 0.0 109.372 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.529 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 11.7 t -106.2 100.93 10.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 110.275 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.763 HD23 ' CD2' ' A' ' 59' ' ' TYR . 1.4 tp -127.95 149.65 71.4 Favored Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.5 Cg_endo -73.97 -156.17 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.583 2.189 . . . . 0.0 110.609 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.506 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -93.01 -155.6 32.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 72.7 43.77 0.42 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.649 -0.912 . . . . 0.0 108.893 -179.557 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.643 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 29.8 p-90 -132.22 178.21 6.98 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.8 0.809 . . . . 0.0 110.328 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.448 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 1.4 mmtp -139.12 150.99 66.76 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.25 138.67 20.37 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 122.031 1.821 . . . . 0.0 110.233 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.519 ' CG ' ' N ' ' A' ' 46' ' ' MET . 0.0 OUTLIER -147.56 167.36 24.72 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.673 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.519 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 9.1 mtp -143.56 128.28 18.23 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.108 -0.995 . . . . 0.0 108.435 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.835 HD12 HG21 ' B' ' 50' ' ' ILE . 2.1 pt -106.78 141.18 22.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.881 -1.137 . . . . 0.0 109.388 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.64 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.84 96.29 0.65 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.294 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.23 -128.43 3.76 Favored Glycine 0 N--CA 1.481 1.659 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.854 -178.394 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.965 HG21 HD12 ' B' ' 47' ' ' ILE . 42.5 mt -81.2 118.22 28.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.775 -0.838 . . . . 0.0 112.511 -177.487 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.16 -42.61 1.87 Allowed Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.302 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 167.43 -157.98 30.63 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 120.875 -1.368 . . . . 0.0 110.068 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.64 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.1 m-85 -114.62 140.6 48.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.436 -1.038 . . . . 0.0 109.784 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.607 HG22 ' HA2' ' B' ' 51' ' ' GLY . 0.9 OUTLIER -116.51 179.53 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.251 -0.906 . . . . 0.0 108.703 179.039 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 10.0 mttm -115.02 141.24 48.26 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.17 -0.957 . . . . 0.0 108.545 179.124 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 4.5 m -144.52 172.1 5.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.941 -1.1 . . . . 0.0 110.641 -178.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.456 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.9 mtt180 -118.96 98.37 6.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.516 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 3.3 tt0 -59.18 91.91 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.125 -0.984 . . . . 0.0 110.155 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.763 ' CD2' HD23 ' A' ' 38' ' ' LEU . 13.6 m-85 -88.5 92.73 9.29 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 178.636 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.402 ' HB3' ' OE1' ' A' ' 61' ' ' GLN . 7.3 m-20 -78.79 143.37 36.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 110.811 -178.161 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.4 mm100 69.44 67.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-O 121.51 0.672 . . . . 0.0 109.6 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.521 HG13 ' HB3' ' A' ' 59' ' ' TYR . 1.2 mm -126.97 111.48 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.976 HD13 ' N ' ' A' ' 64' ' ' ILE . 3.3 tm? -50.97 143.27 10.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.163 -0.96 . . . . 0.0 109.469 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.976 ' N ' HD13 ' A' ' 63' ' ' LEU . 6.9 tt -150.79 113.89 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 36.8 tt0 -89.02 102.86 15.51 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.815 -1.178 . . . . 0.0 108.753 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.88 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -96.89 112.84 29.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-O 121.852 0.834 . . . . 0.0 108.908 -179.652 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 0.1 OUTLIER 71.13 -84.01 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.32 28.2 0.88 Allowed Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -129.68 128.49 42.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -1.112 . . . . 0.0 109.328 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.809 ' HG2' HD21 ' A' ' 63' ' ' LEU . 1.0 OUTLIER -78.79 136.28 37.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.754 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.839 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -151.94 131.81 13.31 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -0.995 . . . . 0.0 110.681 -179.045 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.711 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -95.39 148.1 5.39 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 177.848 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -166.39 -171.53 32.63 Favored Glycine 0 N--CA 1.49 2.295 0 C-N-CA 118.401 -1.857 . . . . 0.0 111.48 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.516 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 63.9 m -102.81 105.2 15.56 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.436 -1.038 . . . . 0.0 110.205 -179.452 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.054 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.36 167.49 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.586 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.778 ' HB2' HG23 ' A' ' 32' ' ' VAL . 2.1 mp -139.52 107.44 5.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.934 -1.104 . . . . 0.0 108.367 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.539 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 31.9 t -88.37 114.04 26.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 -178.41 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -150.41 -171.34 18.6 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.51 40.16 0.94 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.588 2.192 . . . . 0.0 111.183 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.704 HG22 ' HA ' ' A' ' 34' ' ' GLU . 5.7 t -82.9 142.3 44.79 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.65 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.4 Cg_endo -79.32 16.3 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.421 2.08 . . . . 0.0 111.356 -178.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.704 HG12 ' CG1' ' A' ' 84' ' ' ILE . 2.8 t -161.44 160.43 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.828 -1.17 . . . . 0.0 110.983 -178.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.665 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 17.7 m120 -94.35 143.55 26.3 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 103.053 -2.943 . . . . 0.0 103.053 174.408 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.763 HG23 ' HB2' ' A' ' 25' ' ' ASP . 18.4 mt -146.91 135.12 15.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 O-C-N 119.295 -2.128 . . . . 0.0 112.562 -176.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 1.046 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.91 107.34 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.05 -167.4 43.47 Favored Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.089 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.581 ' O ' HG23 ' A' ' 91' ' ' THR . 1.9 mmm180 -60.05 -31.71 70.24 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.408 -1.054 . . . . 0.0 109.173 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.051 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.1 p-10 -54.58 -28.47 46.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 110.53 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.051 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.6 mm? -104.57 -29.12 10.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.83 -1.169 . . . . 0.0 110.062 -179.096 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.584 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.3 mt -71.36 -5.59 33.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.992 -1.068 . . . . 0.0 108.982 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 87' ' ' ARG . 70.0 p -101.38 -20.91 14.98 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.143 -0.973 . . . . 0.0 109.327 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 42.9 mm-40 -81.52 -40.35 23.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 109.061 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.965 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -80.13 -2.93 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.202 -0.936 . . . . 0.0 108.655 178.821 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 78.17 30.46 50.62 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.566 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -65.84 136.4 56.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.805 -1.409 . . . . 0.0 109.049 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.493 HG22 HG22 ' B' ' 4' ' ' THR . 81.5 p -131.14 125.4 32.95 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.153 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.967 HD22 HG21 ' A' ' 26' ' ' THR . 1.7 mp -84.5 93.91 8.43 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.525 0.679 . . . . 0.0 110.108 -178.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 7.1 m-20 -108.37 130.52 55.21 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.737 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 117.949 -1.024 . . . . 0.0 109.09 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.445 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.565 0 N-CA-C 109.989 -0.812 . . . . 0.0 109.989 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.536 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tt0 -83.96 149.38 26.35 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.059 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.536 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 6.7 t -150.25 117.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 120.665 -1.272 . . . . 0.0 109.582 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.592 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.9 OUTLIER -108.62 13.34 25.28 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.552 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.521 ' O ' ' CZ ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -26.53 84.32 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 121.641 0.734 . . . . 0.0 111.25 -179.037 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.592 ' N ' ' O ' ' B' ' 4' ' ' THR . 16.1 m95 -53.48 -16.67 1.56 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.441 ' O ' ' HG3' ' A' ' 87' ' ' ARG . 30.7 mt-30 -109.42 -106.52 0.35 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.157 -0.964 . . . . 0.0 109.602 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.423 ' HE ' ' CD1' ' B' ' 10' ' ' LEU . 6.1 mtp180 -111.22 120.56 42.76 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 120.945 -1.097 . . . . 0.0 110.705 -179.207 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.46 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 37.3 Cg_endo -80.45 62.02 8.4 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.268 1.979 . . . . 0.0 109.692 177.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 1.6 mt -81.66 148.85 28.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.076 -1.015 . . . . 0.0 110.327 -179.09 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 1.059 HG22 ' HB3' ' B' ' 22' ' ' ALA . 5.2 m -141.46 142.69 28.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.448 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' B' ' 19' ' ' LEU . 14.4 m -81.92 96.74 7.77 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 1.032 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -84.3 152.41 3.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.227 -0.921 . . . . 0.0 110.41 -178.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.458 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -118.01 101.74 8.49 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.208 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.842 HG23 ' CG2' ' B' ' 62' ' ' ILE . 40.6 mt -105.8 127.14 61.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.07 -1.018 . . . . 0.0 109.515 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.8 -86.16 0.36 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.606 -1.798 . . . . 0.0 108.606 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.76 25.6 0.32 Allowed Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.039 -2.025 . . . . 0.0 108.039 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -121.0 171.01 8.95 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.739 -0.859 . . . . 0.0 108.749 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' B' ' 12' ' ' THR . 14.4 mt -134.28 130.72 37.49 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.296 -0.877 . . . . 0.0 109.924 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -139.99 166.99 23.16 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 179.628 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.574 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.6 mt-10 -78.73 -179.94 6.81 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.688 -1.257 . . . . 0.0 107.876 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 1.059 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -158.03 105.26 1.94 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.816 -1.178 . . . . 0.0 110.821 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.701 HD21 ' O ' ' A' ' 27' ' ' GLY . 25.5 tp -77.35 95.52 4.42 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.48 HD22 ' HA ' ' B' ' 24' ' ' LEU . 0.2 OUTLIER -40.44 97.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.881 ' HB2' HG23 ' B' ' 84' ' ' ILE . 12.0 t0 -102.57 76.58 1.54 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.443 -0.785 . . . . 0.0 110.707 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.946 HG23 HD23 ' B' ' 90' ' ' LEU . 2.7 m -62.91 -11.19 16.81 Favored 'General case' 0 C--N 1.297 -1.679 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.118 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.475 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -79.59 -38.77 19.79 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.04 158.51 36.37 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.093 -1.239 . . . . 0.0 109.065 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -90.68 -11.5 39.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.972 -1.08 . . . . 0.0 110.437 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.538 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -138.88 -164.2 1.61 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.889 -1.132 . . . . 0.0 109.988 -179.646 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.661 HG23 ' O ' ' B' ' 84' ' ' ILE . 16.8 m -115.67 92.76 4.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.927 -1.108 . . . . 0.0 109.718 -179.072 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.64 174.19 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.087 -1.008 . . . . 0.0 109.299 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.149 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.0 OUTLIER -171.31 123.25 0.57 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.792 -1.192 . . . . 0.0 110.811 -178.531 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.625 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.6 OUTLIER -42.85 159.75 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.232 -0.917 . . . . 0.0 108.774 178.381 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.886 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -50.61 148.15 4.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.9 -1.125 . . . . 0.0 110.475 -179.284 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.526 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.4 ptm -155.12 -164.53 1.8 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.211 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.526 ' N ' ' HG3' ' B' ' 36' ' ' MET . 3.9 t -105.08 67.27 0.78 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.865 -1.147 . . . . 0.0 110.116 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.657 HD13 ' CG ' ' B' ' 59' ' ' TYR . 11.6 mt -85.1 168.71 19.12 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.033 . . . . 0.0 108.726 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.589 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.6 Cg_endo -71.59 -162.52 0.11 Allowed 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.142 1.895 . . . . 0.0 111.374 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.96 29.93 8.85 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -178.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -107.94 46.12 0.97 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.655 ' CD1' ' CZ ' ' B' ' 59' ' ' TYR . 29.9 p-90 -117.73 -179.92 3.88 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.817 0.818 . . . . 0.0 110.356 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -134.27 134.12 22.41 Favored Pre-proline 0 C--N 1.3 -1.556 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.76 135.43 17.7 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 121.779 1.653 . . . . 0.0 110.414 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.652 ' HD3' HD23 ' B' ' 76' ' ' LEU . 16.2 ptmt -160.09 -165.91 1.58 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.559 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.562 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 4.3 mtp -146.56 124.7 12.14 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.451 -179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.965 HD12 HG21 ' A' ' 50' ' ' ILE . 2.8 pt -89.48 143.23 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.25 113.51 2.64 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.65 -123.99 2.18 Favored Glycine 0 N--CA 1.481 1.7 0 C-N-CA 119.52 -1.324 . . . . 0.0 110.213 -179.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.835 HG21 HD12 ' A' ' 47' ' ' ILE . 28.3 mt -91.22 134.82 28.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.694 -0.886 . . . . 0.0 111.968 -178.001 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.607 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 87.47 -29.78 5.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.444 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 156.12 -160.08 29.84 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.011 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -120.67 133.32 55.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.498 -1.001 . . . . 0.0 109.118 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.682 HD13 HG23 ' A' ' 50' ' ' ILE . 15.6 pt -110.66 141.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 120.941 -1.099 . . . . 0.0 109.774 -179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.562 ' HG3' ' CG ' ' B' ' 46' ' ' MET . 0.0 OUTLIER -65.21 154.23 38.68 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 179.792 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.516 HG23 ' HG2' ' B' ' 45' ' ' LYS . 19.8 m -151.13 -167.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.973 . . . . 0.0 110.005 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -145.03 96.25 2.82 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.562 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 11.3 tt0 -61.83 107.9 0.92 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 110.533 -179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.657 ' CG ' HD13 ' B' ' 38' ' ' LEU . 29.2 m-85 -102.3 95.18 6.12 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.593 ' OD1' HG23 ' B' ' 74' ' ' THR . 0.5 OUTLIER -79.13 141.61 37.12 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.829 -1.17 . . . . 0.0 109.994 -179.589 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.496 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 75.01 59.25 0.06 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.695 -0.628 . . . . 0.0 110.055 179.706 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.842 ' CG2' HG23 ' B' ' 15' ' ' ILE . 5.8 mm -121.35 121.5 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.271 -0.893 . . . . 0.0 108.984 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.92 HD13 ' O ' ' B' ' 63' ' ' LEU . 1.4 tm? -68.54 91.4 0.41 Allowed 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.138 -0.976 . . . . 0.0 110.503 -179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.632 HG22 ' O ' ' B' ' 71' ' ' ALA . 10.8 tt -97.75 120.33 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.6 tt0 -88.32 148.56 24.23 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.044 -1.035 . . . . 0.0 108.557 -179.257 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 1.032 HG13 HG22 ' B' ' 13' ' ' ILE . 1.2 mp -147.48 132.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.086 -1.009 . . . . 0.0 109.717 -179.186 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.411 ' C ' ' O ' ' B' ' 66' ' ' ILE . 54.7 m 42.79 37.9 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.533 -0.729 . . . . 0.0 109.723 179.648 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.77 48.1 51.41 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -145.71 114.42 6.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.204 -1.174 . . . . 0.0 109.445 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.75 130.85 47.28 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.632 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.8 101.19 2.74 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 110.369 -179.118 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.584 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.08 157.2 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.016 -1.052 . . . . 0.0 108.583 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.611 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 175.88 -166.33 37.5 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.908 -1.615 . . . . 0.0 111.632 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.593 HG23 ' OD1' ' B' ' 60' ' ' ASP . 16.8 m -98.03 104.86 16.93 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.528 -0.983 . . . . 0.0 110.595 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.149 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.16 109.41 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.344 -0.848 . . . . 0.0 110.255 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.652 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.4 mp -80.32 124.27 28.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.181 -0.949 . . . . 0.0 108.944 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.886 HG12 ' HA ' ' B' ' 35' ' ' GLU . 0.2 OUTLIER -106.86 125.95 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 109.784 -179.893 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -159.42 -167.21 19.76 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.468 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.8 Cg_endo -81.71 54.87 5.28 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.795 2.33 . . . . 0.0 109.916 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.625 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.3 t -97.57 138.43 21.1 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.267 -0.896 . . . . 0.0 108.93 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.1 Cg_endo -80.06 16.55 1.47 Allowed 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.482 2.121 . . . . 0.0 110.71 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.575 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -161.24 172.45 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.016 -1.053 . . . . 0.0 110.206 -179.576 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.619 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 68.6 m-80 -105.03 147.76 27.49 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 104.652 -2.351 . . . . 0.0 104.652 176.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' B' ' 25' ' ' ASP . 24.7 mm -133.64 120.2 36.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 O-C-N 120.282 -1.511 . . . . 0.0 111.194 -177.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.806 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -102.14 91.9 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 177.997 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.546 ' O ' HD13 ' B' ' 90' ' ' LEU . . . -100.12 170.57 22.72 Favored Glycine 0 N--CA 1.496 2.683 0 C-N-CA 119.748 -1.215 . . . . 0.0 112.344 -177.062 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.789 ' O ' HG23 ' B' ' 91' ' ' THR . 3.7 mmt180 -21.96 -41.37 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.987 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.0 p-10 -52.43 -43.05 64.63 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.121 -1.612 . . . . 0.0 110.486 -178.398 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.987 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -91.29 -19.96 22.4 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.685 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.946 HD23 HG23 ' B' ' 26' ' ' THR . 2.2 mp -67.39 -15.22 63.56 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.789 HG23 ' O ' ' B' ' 87' ' ' ARG . 17.2 p -86.9 -18.34 31.07 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.053 -1.029 . . . . 0.0 108.801 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -87.79 -40.34 14.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.737 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.3 pt -87.28 -2.51 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.362 -0.836 . . . . 0.0 109.143 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.6 35.76 81.65 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 179.189 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.497 ' HB3' ' HB3' ' B' ' 90' ' ' LEU . . . -63.04 145.06 56.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.949 -1.324 . . . . 0.0 110.936 -179.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.807 HG22 ' CG2' ' A' ' 4' ' ' THR . 20.4 p -150.42 126.98 10.83 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.681 HD11 HD11 ' A' ' 97' ' ' LEU . 6.9 mp -86.62 103.25 14.93 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.259 -0.901 . . . . 0.0 109.187 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 31.8 m-20 -101.4 122.41 43.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.134 -0.979 . . . . 0.0 110.036 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.965 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.433 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.494 1.518 0 N-CA-C 110.551 -0.596 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -83.75 126.29 32.76 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 177.382 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.4 t -118.14 108.35 24.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.875 -1.14 . . . . 0.0 109.81 -177.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -131.71 41.0 3.33 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.582 -0.699 . . . . 0.0 109.481 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -88.34 43.08 1.1 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.144 -0.973 . . . . 0.0 108.965 179.644 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.527 ' C ' ' O ' ' A' ' 5' ' ' LEU . 16.3 m0 18.13 50.64 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.237 0.541 . . . . 0.0 111.545 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 5.3 mt-30 -155.45 163.82 39.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -0.895 . . . . 0.0 109.518 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.493 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -54.19 119.25 18.98 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.322 179.894 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.667 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.8 Cg_endo -78.47 75.07 5.12 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.212 1.941 . . . . 0.0 110.769 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.815 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -79.52 164.94 23.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.052 -1.03 . . . . 0.0 108.68 179.587 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.7 m -149.29 127.78 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.052 -1.03 . . . . 0.0 110.296 -178.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.844 HG22 HD22 ' A' ' 19' ' ' LEU . 8.1 m -64.65 91.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 178.348 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.67 HD12 HG13 ' A' ' 15' ' ' ILE . 1.0 OUTLIER -79.7 149.7 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.505 -178.372 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 18.3 tttt -117.1 91.2 3.51 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.098 HD11 HD12 ' A' ' 64' ' ' ILE . 12.5 mt -114.65 139.93 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 O-C-N 121.208 -0.933 . . . . 0.0 109.959 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 48.41 49.58 25.75 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 52.24 38.37 48.99 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.545 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.7 mm-40 -131.71 168.35 17.92 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -1.154 . . . . 0.0 109.065 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.844 HD22 HG22 ' A' ' 12' ' ' THR . 20.4 mt -137.57 128.94 28.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 0.0 109.592 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.433 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 47.0 mtmt -151.1 155.86 39.82 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.395 -0.816 . . . . 0.0 109.368 179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.815 ' HB3' HD23 ' A' ' 10' ' ' LEU . 27.1 mp0 -79.83 106.52 11.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.975 . . . . 0.0 108.68 179.459 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.661 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -87.55 132.88 33.89 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.513 -0.742 . . . . 0.0 110.787 -178.809 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.755 HD21 ' O ' ' B' ' 27' ' ' GLY . 6.0 tp -85.83 98.95 11.04 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.699 HD22 HD21 ' A' ' 90' ' ' LEU . 10.9 mt -45.52 97.34 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.103 -0.998 . . . . 0.0 108.522 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 1.025 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.7 t0 -100.33 90.3 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.471 -0.768 . . . . 0.0 110.503 -178.579 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -71.1 -16.49 62.57 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.983 -1.073 . . . . 0.0 108.93 178.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.49 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.07 -33.84 69.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.31 154.4 27.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.213 -1.169 . . . . 0.0 109.342 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -93.8 -12.98 27.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.195 -0.941 . . . . 0.0 109.831 -179.585 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.559 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -131.64 -175.19 3.63 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.163 -0.961 . . . . 0.0 109.406 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.689 HG23 HD12 ' A' ' 85' ' ' ILE . 5.9 m -110.72 87.88 2.64 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.789 -1.194 . . . . 0.0 109.808 -179.066 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -73.01 166.33 2.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.506 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.022 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.57 132.08 3.77 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.79 -1.194 . . . . 0.0 111.343 -177.853 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 80' ' ' THR . 11.3 tt0 -42.21 160.38 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.576 ' HA ' HG13 ' A' ' 77' ' ' VAL . 1.4 mt-10 -61.91 137.19 58.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.857 -1.152 . . . . 0.0 109.946 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.95 -164.01 1.89 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.414 -0.804 . . . . 0.0 109.503 179.632 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.1 t -96.73 112.26 24.09 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.123 -0.986 . . . . 0.0 110.39 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.739 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -133.49 -177.34 0.69 Allowed Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.342 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.601 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -76.4 -179.71 5.56 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.051 1.834 . . . . 0.0 110.656 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.06 29.99 10.35 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -119.76 61.7 0.83 Allowed 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.625 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 11.4 p-90 -121.83 -172.76 2.5 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.537 0.684 . . . . 0.0 109.807 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.8 mtpm? -132.85 128.21 20.65 Favored Pre-proline 0 N--CA 1.49 1.568 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -76.36 138.06 19.45 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 121.929 1.753 . . . . 0.0 110.213 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.73 ' HE2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -157.16 -179.04 7.82 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.731 179.872 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 54' ' ' ILE . 69.4 mtp -136.54 121.23 18.48 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.382 -0.824 . . . . 0.0 108.96 179.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.1 pt -88.56 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.565 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.562 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.68 98.0 0.75 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 -179.309 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.04 -132.29 3.88 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 119.805 -1.188 . . . . 0.0 110.509 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.834 HD11 ' CD1' ' B' ' 84' ' ' ILE . 21.6 mt -84.24 110.5 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.624 -0.927 . . . . 0.0 112.531 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.85 -13.59 17.31 Favored Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.843 177.734 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 134.27 -154.91 21.61 Favored Glycine 0 N--CA 1.49 2.271 0 C-N-CA 119.204 -1.474 . . . . 0.0 109.951 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.562 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 9.4 m-85 -116.3 127.45 54.71 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.574 -0.956 . . . . 0.0 110.255 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 46' ' ' MET . 15.8 pt -103.32 179.1 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.439 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.572 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -116.07 145.62 42.87 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.861 -1.15 . . . . 0.0 109.302 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 ' HE2' ' A' ' 45' ' ' LYS . 0.7 OUTLIER -146.49 -170.33 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.604 -1.31 . . . . 0.0 110.297 -179.843 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.425 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.8 mtm180 -133.8 94.29 3.25 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.539 ' N ' ' HE3' ' A' ' 45' ' ' LYS . 1.1 tt0 -53.44 99.56 0.03 OUTLIER 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.38 -0.825 . . . . 0.0 110.217 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.739 ' CD2' HD23 ' A' ' 38' ' ' LEU . 22.6 m-85 -98.1 84.88 3.36 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 177.58 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.837 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.4 OUTLIER -78.16 137.98 38.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 -177.604 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.515 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 51.5 mm-40 80.77 62.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.785 HG21 HG23 ' A' ' 15' ' ' ILE . 8.0 mm -124.82 122.85 64.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.893 HD21 ' CG ' ' A' ' 70' ' ' LYS . 17.0 tp -74.4 87.19 2.03 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.109 -1.036 . . . . 0.0 111.755 -177.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 1.098 HD12 HD11 ' A' ' 15' ' ' ILE . 10.9 tt -87.23 120.26 36.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.539 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -89.48 111.68 22.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.143 -0.973 . . . . 0.0 109.474 -178.634 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' CYS . 1.0 OUTLIER -106.7 125.95 62.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.102 -0.999 . . . . 0.0 109.879 -179.522 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.8 m 65.22 11.56 7.33 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.762 -0.586 . . . . 0.0 110.698 178.784 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.424 ' HA2' ' CD ' ' A' ' 65' ' ' GLU . . . 101.3 1.28 53.98 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.201 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -106.11 119.13 38.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.12 -1.223 . . . . 0.0 108.924 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.893 ' CG ' HD21 ' A' ' 63' ' ' LEU . 2.2 mptp? -63.06 139.75 58.8 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.187 -0.945 . . . . 0.0 109.415 -179.156 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.704 ' C ' HD12 ' A' ' 63' ' ' LEU . . . -151.27 143.12 23.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.307 -179.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.71 HG13 HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -113.19 138.94 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.864 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.412 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -163.05 -159.12 10.2 Favored Glycine 0 N--CA 1.483 1.77 0 C-N-CA 119.208 -1.472 . . . . 0.0 110.213 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.837 HG23 ' OD1' ' A' ' 60' ' ' ASP . 2.2 m -100.1 108.16 20.23 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.769 -0.842 . . . . 0.0 110.05 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.881 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -106.6 107.01 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.154 -0.967 . . . . 0.0 109.927 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.73 HD23 ' HE2' ' A' ' 45' ' ' LYS . 3.3 mp -78.58 128.42 33.5 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.576 HG13 ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -114.49 120.53 64.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.698 -179.573 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.561 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.0 -157.72 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.572 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -83.31 36.98 0.63 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.553 2.169 . . . . 0.0 110.758 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.725 HG21 HG13 ' A' ' 32' ' ' VAL . 3.9 t -80.59 134.56 54.1 Favored Pre-proline 0 N--CA 1.489 1.513 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.038 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.453 ' O ' HG23 ' A' ' 82' ' ' VAL . 34.6 Cg_endo -77.4 18.59 0.79 Allowed 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.497 2.131 . . . . 0.0 111.825 -178.53 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.605 ' CG1' HG13 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.02 160.3 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 109.941 -179.804 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.67 ' ND2' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -99.88 85.99 3.19 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 177.06 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 1.025 HG23 ' CB ' ' A' ' 25' ' ' ASP . 2.3 mt -83.2 122.61 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 CA-C-O 121.805 0.812 . . . . 0.0 112.902 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.689 HD12 HG23 ' A' ' 31' ' ' THR . 0.4 OUTLIER -95.98 102.67 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 177.225 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.531 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -90.87 -162.03 37.87 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.82 -1.181 . . . . 0.0 111.478 -178.204 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -57.4 -40.05 77.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.754 -0.851 . . . . 0.0 110.472 -179.237 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.021 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.3 p-10 -42.41 -39.28 2.15 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.293 -0.879 . . . . 0.0 110.011 -179.554 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.021 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.9 OUTLIER -100.59 -22.01 15.1 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 121.001 -1.062 . . . . 0.0 110.276 -179.336 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.699 HD21 HD22 ' A' ' 24' ' ' LEU . 81.2 mt -74.67 -1.63 22.65 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.061 -1.024 . . . . 0.0 108.56 179.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.0 p -99.41 -18.65 17.38 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.447 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -83.03 -41.63 18.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.391 -0.818 . . . . 0.0 108.982 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.838 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.5 pt -86.87 -10.16 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.69 45.43 44.61 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.275 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.529 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -76.03 131.45 39.52 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.932 -1.334 . . . . 0.0 109.908 179.578 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 77.8 p -129.61 137.82 50.91 Favored 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' B' ' 97' ' ' LEU . 5.9 mp -89.51 120.18 30.6 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.962 -1.086 . . . . 0.0 110.529 -179.134 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.535 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.6 m-20 -119.48 124.77 47.29 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.256 -0.903 . . . . 0.0 108.948 178.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.939 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.531 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.601 0 N-CA-C 109.964 -0.822 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.488 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.7 tt0 -88.88 150.0 23.08 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.488 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 3.3 t -149.83 126.16 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.498 -1.376 . . . . 0.0 110.441 -179.127 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.542 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -130.98 -60.04 0.97 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.733 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.655 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER 34.34 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.944 -0.472 . . . . 0.0 110.852 179.529 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.542 ' N ' ' O ' ' B' ' 4' ' ' THR . 5.5 m95 18.02 42.66 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.655 ' N ' ' O ' ' B' ' 5' ' ' LEU . 6.9 mm100 -153.01 -114.81 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.193 -0.942 . . . . 0.0 108.718 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.525 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.1 mtp180 -112.45 141.07 24.52 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 120.23 -1.543 . . . . 0.0 109.195 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 37.0 Cg_endo -82.15 50.21 3.38 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.316 2.011 . . . . 0.0 109.529 178.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.557 HD23 ' H ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -78.43 137.48 38.0 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.197 -0.939 . . . . 0.0 108.943 -179.597 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -134.15 178.97 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.453 -0.779 . . . . 0.0 109.996 -178.999 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.768 HG22 HD22 ' B' ' 19' ' ' LEU . 47.8 m -103.86 105.28 15.43 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.814 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.826 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.8 pp -96.17 155.37 3.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.518 -0.738 . . . . 0.0 109.862 -178.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.529 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 8.9 ttmt -122.91 100.14 6.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 110.503 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.728 HG13 HD12 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -115.38 142.64 27.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.812 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 47.98 47.13 26.2 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.351 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 55.23 36.42 62.16 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.162 -1.199 . . . . 0.0 110.398 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.9 OUTLIER -130.7 166.61 20.36 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -1.216 . . . . 0.0 108.425 179.077 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.826 HD23 ' O ' ' B' ' 13' ' ' ILE . 14.8 mt -143.23 125.28 15.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.078 -1.014 . . . . 0.0 111.409 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.503 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 1.0 OUTLIER -145.11 -170.97 3.55 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.875 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.549 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -82.45 -176.48 6.25 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.863 -1.148 . . . . 0.0 109.666 -179.846 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.854 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -163.28 91.49 0.7 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.1 -1.0 . . . . 0.0 110.89 -179.296 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.543 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 8.8 tp -68.04 93.44 0.43 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.631 -1.293 . . . . 0.0 109.658 179.315 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.824 HD23 ' HB ' ' B' ' 85' ' ' ILE . 69.8 mt -50.42 94.88 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.856 ' CB ' HG23 ' B' ' 84' ' ' ILE . 29.5 t0 -96.0 84.75 3.89 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.351 -0.843 . . . . 0.0 110.825 -178.736 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.579 ' HA ' HD12 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.51 -16.0 21.69 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.956 -1.09 . . . . 0.0 108.771 178.754 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.755 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -74.19 -38.85 45.98 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.28 162.76 27.89 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.198 -1.178 . . . . 0.0 109.318 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -101.01 -10.37 20.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.53 ' HA ' ' CG ' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -139.13 -172.57 3.37 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.134 -0.979 . . . . 0.0 110.322 -179.298 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.609 HG22 ' CD1' ' B' ' 33' ' ' LEU . 47.7 m -108.46 89.46 3.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.984 -1.072 . . . . 0.0 111.162 -178.514 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.897 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -73.34 169.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.54 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.125 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -168.81 130.89 1.28 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.777 -1.202 . . . . 0.0 110.683 -179.026 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.566 ' N ' HG23 ' B' ' 80' ' ' THR . 6.0 pt-20 -46.67 170.81 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.276 -0.89 . . . . 0.0 108.693 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.559 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tt0 -60.42 138.1 58.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.145 -0.972 . . . . 0.0 110.064 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.629 ' HE2' HD21 ' B' ' 38' ' ' LEU . 7.6 ptm -147.05 -163.5 1.78 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.405 -0.809 . . . . 0.0 109.324 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.529 ' N ' ' HG3' ' B' ' 36' ' ' MET . 8.4 t -113.74 98.01 6.77 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -0.881 . . . . 0.0 110.099 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.81 HD12 ' CD2' ' B' ' 59' ' ' TYR . 27.1 mt -106.38 160.39 26.39 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.128 -0.983 . . . . 0.0 109.476 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.475 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.6 Cg_endo -77.94 65.28 8.3 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.732 2.288 . . . . 0.0 112.029 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 35.78 -157.37 0.01 OUTLIER Glycine 0 N--CA 1.498 2.813 0 O-C-N 121.442 -0.786 . . . . 0.0 111.239 178.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.494 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 63.25 60.28 1.19 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.513 -0.992 . . . . 0.0 109.237 -179.865 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.7 p-90 -139.08 -175.62 4.22 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' B' ' 43' ' ' LYS . 13.7 mmtm -143.3 136.83 14.18 Favored Pre-proline 0 N--CA 1.488 1.467 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.082 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.77 125.67 7.59 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.899 1.733 . . . . 0.0 111.403 -179.009 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.82 ' CE ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -162.74 149.93 13.31 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.607 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.463 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 1.8 mtp -110.04 148.0 32.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 0.0 110.414 -178.663 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.803 ' CD1' HG21 ' A' ' 50' ' ' ILE . 15.5 pt -90.68 155.67 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.513 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.87 106.03 1.24 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.793 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -136.12 -128.03 2.7 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.647 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.777 HG21 ' CD1' ' A' ' 47' ' ' ILE . 21.5 mt -87.91 127.46 41.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.614 -0.933 . . . . 0.0 112.683 -177.57 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 96.95 -20.75 49.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.234 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.05 -164.59 26.81 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.528 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 3.3 m-85 -105.64 125.74 51.34 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.391 -1.064 . . . . 0.0 109.701 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.7 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -96.38 139.62 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.939 -1.1 . . . . 0.0 108.964 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.579 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -78.2 143.04 37.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.806 -1.184 . . . . 0.0 108.995 -179.905 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.658 HG12 ' N ' ' B' ' 78' ' ' GLY . 0.2 OUTLIER -149.3 -173.49 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.87 -1.144 . . . . 0.0 110.074 -179.482 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.435 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 2.6 mtm-85 -121.28 96.08 4.94 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -60.38 100.18 0.09 Allowed 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.329 -0.857 . . . . 0.0 109.846 -179.092 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.81 ' CD2' HD12 ' B' ' 38' ' ' LEU . 22.3 m-85 -96.31 94.59 7.55 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.408 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 37.0 m-20 -78.78 140.01 38.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.894 -1.129 . . . . 0.0 110.626 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.681 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.3 OUTLIER 69.17 64.89 0.28 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.714 -0.616 . . . . 0.0 110.309 179.255 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.742 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.7 OUTLIER -123.82 113.12 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.188 -0.945 . . . . 0.0 108.686 179.155 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.672 HD13 ' C ' ' B' ' 63' ' ' LEU . 3.3 tm? -64.68 104.74 0.86 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.239 -0.913 . . . . 0.0 110.869 -178.428 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.633 HG22 ' O ' ' B' ' 71' ' ' ALA . 1.2 tt -107.76 122.94 62.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.3 tt0 -88.09 114.58 24.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.04 -1.037 . . . . 0.0 109.078 -179.186 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.63 HD11 HD13 ' B' ' 64' ' ' ILE . 2.2 mp -111.32 116.79 53.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.321 -0.862 . . . . 0.0 110.052 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.548 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 80.0 m 63.41 8.24 3.4 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.58 -0.7 . . . . 0.0 110.668 179.124 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 104.53 22.96 8.19 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.045 179.515 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -125.77 130.92 52.42 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.137 -1.214 . . . . 0.0 109.231 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.534 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -69.45 131.04 44.13 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.53 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.633 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.77 96.87 2.88 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.887 -179.569 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.742 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.18 136.43 24.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 179.125 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -163.6 -173.45 32.3 Favored Glycine 0 C--N 1.294 -1.792 0 C-N-CA 118.695 -1.716 . . . . 0.0 110.658 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 86.5 m -92.25 106.41 18.42 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.664 -0.903 . . . . 0.0 109.331 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.125 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -95.83 105.05 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.652 -0.655 . . . . 0.0 109.982 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.82 HD23 ' CE ' ' B' ' 45' ' ' LYS . 5.6 mp -78.99 116.82 19.54 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.559 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 79.6 t -110.86 118.16 56.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 120.945 -1.097 . . . . 0.0 110.695 -178.405 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.658 ' N ' HG12 ' B' ' 56' ' ' VAL . . . -157.24 -150.4 5.69 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.579 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -83.07 41.28 1.07 Allowed 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.959 2.439 . . . . 0.0 110.258 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.566 HG23 ' N ' ' B' ' 34' ' ' GLU . 3.5 t -90.17 129.75 44.61 Favored Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 179.225 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.552 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.02 25.86 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.168 1.912 . . . . 0.0 111.558 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.552 HG22 ' O ' ' B' ' 81' ' ' PRO . 0.2 OUTLIER -161.4 154.01 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.719 -1.238 . . . . 0.0 110.785 -179.976 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.63 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 72.1 m-20 -96.38 83.05 3.48 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 175.781 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.856 HG23 ' CB ' ' B' ' 25' ' ' ASP . 12.4 mt -78.89 115.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.08 -1.013 . . . . 0.0 112.82 -175.248 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.824 ' HB ' HD23 ' B' ' 24' ' ' LEU . 1.4 mm -95.66 93.05 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -77.87 -169.84 34.43 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.12 -1.038 . . . . 0.0 111.008 -177.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.493 ' HD2' ' HA ' ' A' ' 8' ' ' ARG . 10.1 mtp85 -58.41 -37.56 75.59 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.931 -0.746 . . . . 0.0 110.766 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.01 ' ND2' HD23 ' B' ' 89' ' ' LEU . 14.3 p-10 -46.57 -26.9 0.98 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.554 -1.341 . . . . 0.0 109.451 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.01 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -110.56 -28.87 8.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.212 -0.93 . . . . 0.0 111.132 -178.716 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.654 HD21 HD22 ' B' ' 24' ' ' LEU . 66.9 mt -65.38 -22.25 66.77 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.745 -1.222 . . . . 0.0 108.29 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.428 ' CG2' ' NH2' ' B' ' 87' ' ' ARG . 82.7 p -83.63 -18.11 39.26 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 108.97 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -79.73 -41.76 26.02 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.881 . . . . 0.0 109.569 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.939 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -82.89 -2.9 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.032 179.431 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.54 63.08 4.12 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.623 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -86.29 161.94 18.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.399 -1.059 . . . . 0.0 109.967 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.6 p -141.4 129.92 22.62 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.206 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.9 94.4 6.28 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -179.872 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.3 m-20 -105.26 130.88 53.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 110.851 -178.49 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.838 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.143 179.095 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.437 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.497 1.692 0 N-CA-C 110.76 -0.515 . . . . 0.0 110.76 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.427 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.8 tt0 -83.51 142.42 30.92 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.405 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 51.9 t -141.32 128.76 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 118.012 -1.475 . . . . 0.0 111.047 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.481 ' OG1' ' N ' ' A' ' 5' ' ' LEU . 1.3 p -132.34 -57.26 0.96 Allowed 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.205 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.0 OUTLIER 39.0 28.24 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.548 -0.72 . . . . 0.0 110.414 179.352 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.491 ' C ' ' O ' ' A' ' 5' ' ' LEU . 4.4 m95 18.02 43.91 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.411 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' A' ' 5' ' ' LEU . 15.9 mm100 -158.78 -111.5 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 108.855 179.385 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 77.1 mtt180 -111.98 134.06 21.49 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 120.621 -1.3 . . . . 0.0 109.352 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -81.18 54.4 5.19 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 122.357 2.038 . . . . 0.0 110.057 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.743 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.72 146.77 30.89 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.946 -1.096 . . . . 0.0 109.69 -179.495 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.643 HG21 HG12 ' A' ' 66' ' ' ILE . 2.4 m -138.03 136.11 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.2 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.663 HG22 HD22 ' A' ' 19' ' ' LEU . 94.9 m -60.35 113.65 2.51 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -106.24 137.02 38.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 O-C-N 121.091 -1.006 . . . . 0.0 110.419 -178.684 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 2.7 ttpt -110.45 105.17 14.05 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.407 -0.808 . . . . 0.0 109.049 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 64' ' ' ILE . 40.8 mt -118.42 122.01 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.121 -0.987 . . . . 0.0 109.887 -179.225 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.02 10.86 59.95 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 178.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.16 -7.02 60.05 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.6 178.36 6.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -1.109 . . . . 0.0 108.987 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 11.3 mt -151.06 129.66 12.24 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.236 -0.915 . . . . 0.0 110.74 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -150.61 157.0 42.46 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.743 ' HB3' HD22 ' A' ' 10' ' ' LEU . 61.6 mt-10 -77.94 131.36 37.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.576 -1.327 . . . . 0.0 108.428 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.886 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -107.7 148.03 29.96 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.086 -1.009 . . . . 0.0 110.235 -178.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' O ' ' B' ' 27' ' ' GLY . 30.9 tp -98.9 95.85 7.45 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.163 0.506 . . . . 0.0 110.431 -178.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.536 HD22 ' HB ' ' A' ' 85' ' ' ILE . 0.2 OUTLIER -47.16 115.7 1.17 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 178.916 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 12.8 t70 -131.8 108.18 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.747 -1.221 . . . . 0.0 111.15 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . 1.013 HG23 HD13 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -79.97 -2.59 44.6 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.817 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.48 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -80.74 -21.66 63.32 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.84 161.83 13.55 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.131 -1.217 . . . . 0.0 109.892 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.54 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 50.4 m-20 -92.85 -20.1 21.03 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.406 -0.809 . . . . 0.0 110.919 -179.083 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -139.17 -169.08 2.58 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.621 -1.3 . . . . 0.0 110.203 -179.438 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' THR . . . . . 1.006 ' O ' HD12 ' A' ' 76' ' ' LEU . 21.5 m -103.56 107.15 17.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.12 -0.988 . . . . 0.0 109.76 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.821 HG12 HG13 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -97.89 126.23 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.076 -1.015 . . . . 0.0 110.003 -179.469 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.046 HD13 ' CG1' ' A' ' 75' ' ' VAL . 3.8 mp -120.88 124.82 45.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.772 -1.205 . . . . 0.0 111.277 -178.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.2 pt-20 -43.77 163.45 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.295 -0.962 . . . . 0.0 108.525 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -44.25 137.84 3.32 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.033 -1.042 . . . . 0.0 110.212 -179.409 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.6 ptm -146.71 -163.16 1.69 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.511 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.516 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.4 t -108.22 84.3 1.92 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.975 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.825 HD12 HG21 ' A' ' 77' ' ' VAL . 13.4 mt -108.84 165.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 108.993 179.533 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.0 Cg_endo -73.45 -167.36 0.36 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.369 2.046 . . . . 0.0 111.37 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.32 33.03 6.9 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.111 -1.042 . . . . 0.0 110.503 -178.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.63 53.99 0.7 Allowed 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.624 -0.927 . . . . 0.0 108.616 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.628 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 51.2 p-90 -131.6 -168.75 2.07 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.623 0.725 . . . . 0.0 110.616 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 42' ' ' TRP . 15.3 mttt -147.17 131.07 8.41 Favored Pre-proline 0 N--CA 1.49 1.53 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -76.2 141.22 23.08 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.126 1.884 . . . . 0.0 111.042 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.428 ' NZ ' HD23 ' A' ' 76' ' ' LEU . 1.3 ptpp? -152.38 177.06 10.99 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.403 ' N ' ' HG3' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -129.65 124.75 34.42 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.079 -1.013 . . . . 0.0 108.842 179.507 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.798 HD12 HG21 ' B' ' 50' ' ' ILE . 4.9 pt -96.42 149.87 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.238 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.646 ' CA ' ' CD2' ' A' ' 53' ' ' PHE . . . -122.48 108.9 1.32 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.79 -124.03 2.41 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 119.388 -1.387 . . . . 0.0 110.453 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.669 HG21 ' CD1' ' B' ' 47' ' ' ILE . 64.7 mt -85.56 128.86 38.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.713 -0.875 . . . . 0.0 112.343 -177.897 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.24 -48.99 2.41 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.87 -157.78 26.22 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.646 ' CD2' ' CA ' ' A' ' 48' ' ' GLY . 3.5 m-85 -111.82 143.54 42.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -1.113 . . . . 0.0 109.573 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.609 HD11 HD11 ' A' ' 47' ' ' ILE . 3.8 pt -119.11 150.77 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.184 -0.947 . . . . 0.0 108.975 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 14.8 mttp -90.16 118.58 29.79 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.11 -0.994 . . . . 0.0 109.925 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.868 HG12 ' HA3' ' A' ' 78' ' ' GLY . 14.9 m -125.56 -167.5 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.226 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.415 ' O ' HD23 ' A' ' 76' ' ' LEU . 75.1 mtt85 -125.76 173.82 8.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.278 -0.889 . . . . 0.0 109.493 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 3.4 tt0 -130.77 123.93 30.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.409 -0.807 . . . . 0.0 109.919 -179.804 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 41.9 m-85 -121.14 91.36 3.51 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 20.3 m-20 -78.98 133.26 36.86 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.098 -1.001 . . . . 0.0 109.692 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 1.6 mt-30 83.36 57.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.482 0.658 . . . . 0.0 109.379 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.715 ' CG2' HG23 ' A' ' 15' ' ' ILE . 3.0 mm -114.3 114.03 45.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.681 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.0 OUTLIER -70.27 87.22 0.6 Allowed 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.271 -178.95 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.806 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -88.5 123.68 41.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.495 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -89.46 106.19 18.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.985 -1.072 . . . . 0.0 109.038 -178.995 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.71 HG13 HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER -106.13 123.22 60.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.009 -179.621 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 13.6 m 49.11 69.12 0.61 Allowed 'General case' 0 C--N 1.293 -1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.452 179.17 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 42.59 27.3 0.5 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.092 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.3 m-70 -122.97 130.74 53.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.897 -1.355 . . . . 0.0 109.065 179.268 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -75.01 133.21 41.71 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 108.837 179.404 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.47 108.32 2.94 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.876 . . . . 0.0 110.459 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.681 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -85.48 152.45 3.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 177.971 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.42 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.7 -178.32 45.43 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.206 -1.949 . . . . 0.0 111.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.1 m -92.66 106.36 18.35 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.627 -0.925 . . . . 0.0 110.139 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.046 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.3 t -97.01 176.65 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 1.006 HD12 ' O ' ' A' ' 31' ' ' THR . 1.9 mp -139.4 161.48 37.35 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.966 -1.084 . . . . 0.0 108.288 178.127 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.825 HG21 HD12 ' A' ' 38' ' ' LEU . 19.5 t -143.47 105.46 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.91 0 O-C-N 121.379 -0.825 . . . . 0.0 109.734 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.868 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.7 -162.49 10.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -80.3 40.18 0.94 Allowed 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.473 2.116 . . . . 0.0 110.705 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.5 t -85.59 132.75 43.61 Favored Pre-proline 0 C--N 1.3 -1.572 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 179.056 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -77.92 17.5 0.99 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.407 2.071 . . . . 0.0 111.356 -179.081 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 83' ' ' ASN . 1.1 t -162.22 162.22 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.837 -1.165 . . . . 0.0 109.983 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.646 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -96.94 154.38 17.33 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 175.21 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.821 HG13 HG12 ' A' ' 32' ' ' VAL . 1.1 mm -144.2 134.18 20.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 O-C-N 120.057 -1.652 . . . . 0.0 109.963 -178.244 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.886 HD13 ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.16 88.97 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 177.525 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.61 -164.45 22.81 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.905 -1.14 . . . . 0.0 110.278 -177.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HD2' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -61.82 -35.62 78.78 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.624 -0.927 . . . . 0.0 109.567 -179.134 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.018 ' ND2' HD23 ' A' ' 89' ' ' LEU . 8.1 p-10 -45.15 -25.07 0.31 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 108.891 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.018 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -112.91 -29.17 7.46 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 121.375 -0.828 . . . . 0.0 110.472 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 1.013 HD13 HG23 ' A' ' 26' ' ' THR . 77.7 mt -68.25 -7.26 29.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.967 -1.083 . . . . 0.0 109.157 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.48 -19.69 15.42 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 108.607 179.085 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -80.65 -41.17 24.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.222 -0.924 . . . . 0.0 108.874 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.624 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.7 pt -83.77 -5.61 9.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.01 34.28 55.89 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.163 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.577 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -64.25 151.9 42.38 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.261 . . . . 0.0 110.624 -179.707 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 30.9 p -148.32 128.21 13.5 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' B' ' 97' ' ' LEU . 3.0 mp -87.81 95.05 9.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.11 -0.994 . . . . 0.0 109.443 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.461 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 1.7 m-20 -114.46 129.97 56.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 110.674 -179.149 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.601 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.172 178.17 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 N-CA-C 109.744 -0.906 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.517 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 2.2 tt0 -81.92 149.63 28.13 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 178.249 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.517 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 61.2 t -148.46 96.2 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 117.832 -1.547 . . . . 0.0 110.868 -178.301 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.447 ' O ' ' N ' ' B' ' 6' ' ' TRP . 71.3 p -100.75 -55.67 2.52 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.135 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.653 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.2 OUTLIER 43.99 18.99 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.757 -0.589 . . . . 0.0 111.524 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.537 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.3 m95 18.53 43.15 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.096 0.407 . . . . 0.0 111.895 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.653 ' N ' ' O ' ' B' ' 5' ' ' LEU . 4.6 mt-30 -170.85 -103.3 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 63.8 mtt180 -113.58 127.87 26.34 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 120.351 -1.468 . . . . 0.0 110.252 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.474 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -78.99 71.48 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 121.94 1.76 . . . . 0.0 108.335 177.638 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.545 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -93.93 152.21 19.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.117 -0.989 . . . . 0.0 110.933 -178.083 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.57 HG21 HG23 ' B' ' 66' ' ' ILE . 2.0 m -151.03 150.39 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.663 -0.648 . . . . 0.0 109.414 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.878 HG22 HD22 ' B' ' 19' ' ' LEU . 99.7 m -78.16 115.45 17.89 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.733 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.5 pp -103.89 151.4 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.024 -1.048 . . . . 0.0 110.507 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.1 OUTLIER -109.47 102.87 11.7 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.198 -0.939 . . . . 0.0 109.694 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.854 HD13 HG11 ' B' ' 75' ' ' VAL . 3.9 mt -121.37 134.28 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.986 -1.071 . . . . 0.0 110.159 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.494 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 58.66 27.24 61.12 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 179.317 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.13 27.3 66.55 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm-40 -124.41 -178.76 4.21 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.464 -1.021 . . . . 0.0 109.121 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 HG22 ' B' ' 12' ' ' THR . 19.8 mt -147.45 125.27 11.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 0.0 109.706 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.487 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mmtt -144.5 169.28 18.26 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.545 ' HB3' HD22 ' B' ' 10' ' ' LEU . 9.4 mt-10 -79.69 135.43 36.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 108.442 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.603 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -121.9 135.45 54.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.983 -1.073 . . . . 0.0 110.669 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 15.5 tp -92.04 94.1 9.08 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.48 HD23 ' CG1' ' B' ' 85' ' ' ILE . 14.2 mt -45.83 101.47 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.989 -1.069 . . . . 0.0 108.719 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.4 t70 -101.59 96.75 7.32 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.754 -0.591 . . . . 0.0 110.419 -178.582 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.788 ' OG1' HD21 ' A' ' 97' ' ' LEU . 24.6 m -79.68 13.49 2.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.906 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -109.83 -19.33 8.26 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.37 170.46 15.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.93 -1.336 . . . . 0.0 109.141 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -99.92 -18.08 17.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 110.088 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.54 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 16.1 m-20 -142.97 -155.16 0.57 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.064 -1.022 . . . . 0.0 109.658 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.57 ' OG1' ' HG ' ' B' ' 89' ' ' LEU . 78.5 m -120.19 97.82 5.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.511 -1.368 . . . . 0.0 111.262 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.044 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -76.83 174.87 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.073 -1.017 . . . . 0.0 108.445 178.969 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.044 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.04 119.46 0.61 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.765 -1.209 . . . . 0.0 110.936 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' B' ' 80' ' ' THR . 41.6 tt0 -36.66 158.77 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.453 0.644 . . . . 0.0 110.009 179.149 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.506 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -52.42 147.31 8.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.497 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.449 ' SD ' ' HB2' ' B' ' 38' ' ' LEU . 0.0 OUTLIER 179.55 178.35 0.54 Allowed 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.6 t -92.49 101.62 14.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.074 -1.017 . . . . 0.0 109.563 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.658 HD13 HG22 ' B' ' 15' ' ' ILE . 58.0 tp -130.69 98.24 20.1 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.119 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -78.76 -177.77 4.15 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.618 2.212 . . . . 0.0 110.393 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 113.63 31.65 2.29 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.42 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.481 ' O ' ' O ' ' B' ' 40' ' ' GLY . 49.0 mtm180 59.78 141.44 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.901 -0.764 . . . . 0.0 109.401 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 47.9 p-90 -160.3 -172.13 3.46 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.782 -1.199 . . . . 0.0 110.832 -179.286 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.495 ' HD3' ' HD2' ' B' ' 44' ' ' PRO . 1.8 mmtp -148.27 145.16 19.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 44' ' ' PRO . . . . . 0.495 ' HD2' ' HD3' ' B' ' 43' ' ' LYS . 35.8 Cg_endo -78.16 136.24 14.34 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 122.018 1.812 . . . . 0.0 110.932 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.581 ' HD3' HD23 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -160.29 -168.79 2.27 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.456 -0.778 . . . . 0.0 109.592 179.427 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.524 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 60.5 mtp -150.53 138.31 19.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.452 -0.78 . . . . 0.0 109.676 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.669 ' CD1' HG21 ' A' ' 50' ' ' ILE . 4.9 pt -95.93 150.09 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.03 -1.044 . . . . 0.0 108.535 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.82 102.53 0.94 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.81 -135.84 4.25 Favored Glycine 0 N--CA 1.483 1.821 0 C-N-CA 119.324 -1.417 . . . . 0.0 111.015 -178.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.798 HG21 HD12 ' A' ' 47' ' ' ILE . 46.1 mt -79.87 119.63 29.66 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.855 -0.791 . . . . 0.0 112.912 -177.419 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 104.97 -54.47 0.61 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.076 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.02 -159.62 20.78 Favored Glycine 0 N--CA 1.492 2.378 0 O-C-N 120.947 -1.325 . . . . 0.0 110.201 -179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.607 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 1.2 m-85 -118.9 125.85 50.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.475 -1.015 . . . . 0.0 109.161 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.457 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 5.2 pt -97.81 173.19 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.255 -0.903 . . . . 0.0 109.438 -179.785 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mtmt -109.03 125.58 52.23 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.147 -0.971 . . . . 0.0 109.626 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.652 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.6 m -134.86 168.76 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 110.279 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 18.4 mtt180 -110.33 111.41 22.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.588 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -69.04 121.69 17.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.409 -0.807 . . . . 0.0 110.471 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.6 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 23.9 m-85 -116.05 93.69 4.35 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.677 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 6.4 m-20 -77.6 124.97 28.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.8 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 48.6 mt-30 88.81 60.41 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 CA-C-O 121.32 0.581 . . . . 0.0 110.105 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.909 HG21 HG21 ' B' ' 75' ' ' VAL . 19.0 mm -115.57 109.82 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.116 179.498 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.93 HD21 ' HG2' ' B' ' 70' ' ' LYS . 3.0 tm? -65.27 85.56 0.06 Allowed 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.033 0.92 . . . . 0.0 110.717 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.652 HG21 ' CD1' ' B' ' 89' ' ' LEU . 0.6 OUTLIER -92.16 119.68 40.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 177.37 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.5 tt0 -87.14 128.84 35.12 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.163 -0.961 . . . . 0.0 108.957 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.57 HG23 HG21 ' B' ' 11' ' ' VAL . 0.9 OUTLIER -114.9 129.76 70.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.014 -179.313 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 86.2 m 54.52 -91.27 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.574 -0.704 . . . . 0.0 109.804 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -147.18 40.82 0.98 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.497 ' CB ' HG22 ' B' ' 93' ' ' ILE . 31.3 m80 -145.72 149.58 34.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -1.046 . . . . 0.0 109.287 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.93 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -79.04 139.63 38.11 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.077 -1.014 . . . . 0.0 109.467 -179.805 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.522 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -147.62 109.55 4.47 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.081 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.577 HG12 ' HA ' ' B' ' 63' ' ' LEU . 0.0 OUTLIER -94.88 145.46 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.215 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.786 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -169.22 -178.09 40.32 Favored Glycine 0 C--N 1.297 -1.636 0 C-N-CA 118.442 -1.837 . . . . 0.0 111.083 179.562 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.588 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.1 m -87.73 100.54 12.91 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 122.139 -0.624 . . . . 0.0 109.951 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.909 HG21 HG21 ' B' ' 62' ' ' ILE . 1.3 t -85.54 121.11 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.053 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.581 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.6 mp -96.73 104.25 16.23 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' B' ' 35' ' ' GLU . 21.8 t -93.45 112.03 25.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.04 -1.038 . . . . 0.0 109.993 -179.065 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.652 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.67 -160.85 9.45 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.556 -1.817 . . . . 0.0 108.556 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.539 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -79.98 38.31 0.73 Allowed 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.388 2.059 . . . . 0.0 110.973 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.678 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -81.98 134.96 48.79 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.584 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -79.04 15.14 1.57 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.583 2.189 . . . . 0.0 111.311 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.584 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -160.59 161.01 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.999 -1.063 . . . . 0.0 109.804 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.9 OUTLIER -98.24 129.12 44.98 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 104.157 -2.534 . . . . 0.0 104.157 175.51 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' B' ' 25' ' ' ASP . 5.0 mm -117.12 129.38 73.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.957 0 O-C-N 120.331 -1.481 . . . . 0.0 111.923 -176.171 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.62 HG23 HD12 ' B' ' 89' ' ' LEU . 3.4 mm -102.19 105.19 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 176.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -98.8 -163.65 30.14 Favored Glycine 0 N--CA 1.496 2.691 0 C-N-CA 119.826 -1.178 . . . . 0.0 111.823 -177.307 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.587 ' NH1' ' HG2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -53.28 -40.91 65.06 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 122.005 -0.703 . . . . 0.0 111.714 -178.193 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.747 ' C ' HD23 ' B' ' 89' ' ' LEU . 53.0 p-10 -48.14 -26.16 1.77 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.548 -1.345 . . . . 0.0 111.007 -177.621 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.786 HD21 ' HA3' ' B' ' 73' ' ' GLY . 2.3 mt -115.31 -27.77 7.12 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.32 -1.487 . . . . 0.0 111.602 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.772 ' HA ' HD11 ' B' ' 93' ' ' ILE . 3.5 mt -63.38 -11.77 25.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.212 -1.555 . . . . 0.0 108.259 -179.565 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -101.67 -19.65 15.33 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.196 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 69.9 mm-40 -79.16 -41.23 28.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.726 -0.608 . . . . 0.0 110.581 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.772 HD11 ' HA ' ' B' ' 90' ' ' LEU . 1.0 OUTLIER -80.44 -22.12 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 179.52 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' N ' HD12 ' B' ' 93' ' ' ILE . . . 103.02 35.48 3.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.507 ' HA ' ' HD1' ' A' ' 99' ' ' PHE . . . -72.43 135.68 45.83 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.388 -1.066 . . . . 0.0 111.185 -178.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 75.1 p -136.66 128.87 29.78 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -83.49 105.32 14.33 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 108.68 -179.466 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 23.8 m-20 -103.53 122.62 45.32 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.049 -1.032 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.624 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.135 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.497 1.711 0 N-CA-C 110.178 -0.739 . . . . 0.0 110.178 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 9.8 tt0 -83.16 148.94 27.17 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 106.471 -1.677 . . . . 0.0 106.471 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 2.3 t -140.76 105.98 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.902 -178.042 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.563 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -122.05 -69.03 0.85 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 176.694 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER 31.76 29.94 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.964 177.893 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.563 ' N ' ' O ' ' A' ' 4' ' ' THR . 17.3 m95 18.88 48.37 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.145 0 CA-C-O 121.331 0.586 . . . . 0.0 111.871 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.575 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -164.25 -175.5 3.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.172 -0.955 . . . . 0.0 109.401 179.8 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.486 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 1.6 mtt180 -76.38 119.27 76.61 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.267 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.532 ' HB3' ' CG1' ' A' ' 3' ' ' VAL . 35.3 Cg_endo -79.11 74.52 5.51 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.833 1.689 . . . . 0.0 108.92 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.425 ' HG ' ' HA ' ' A' ' 23' ' ' LEU . 0.4 OUTLIER -80.69 150.65 29.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.532 -0.73 . . . . 0.0 110.455 -178.609 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.605 ' O ' ' HB3' ' A' ' 22' ' ' ALA . 2.0 m -150.05 162.04 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.413 -0.804 . . . . 0.0 109.33 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.424 HG22 HD22 ' A' ' 19' ' ' LEU . 42.5 m -96.12 114.04 25.7 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -97.95 171.74 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.901 -178.941 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.516 ' HE3' HD11 ' A' ' 19' ' ' LEU . 6.5 tttt -131.78 102.38 5.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 109.406 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.756 HD13 HG11 ' A' ' 75' ' ' VAL . 48.6 mt -118.44 132.09 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.984 -1.072 . . . . 0.0 109.902 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.26 40.13 98.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.03 18.45 60.12 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 mm-40 -112.89 171.62 7.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.336 -1.097 . . . . 0.0 109.094 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 14.4 mt -142.9 126.92 17.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.218 -0.926 . . . . 0.0 110.3 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 7.2 mttt -143.52 -167.7 2.64 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 43.5 mt-10 -79.4 -167.82 1.32 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.989 -1.07 . . . . 0.0 108.145 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.706 ' CB ' HG23 ' A' ' 13' ' ' ILE . . . -171.3 86.85 0.09 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.085 -1.009 . . . . 0.0 109.454 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.578 ' O ' ' N ' ' A' ' 25' ' ' ASP . 36.5 tp -72.47 95.35 1.77 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.346 -0.846 . . . . 0.0 109.032 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.493 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 49.6 mt -48.93 90.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' N ' ' O ' ' A' ' 23' ' ' LEU . 0.6 OUTLIER -99.52 92.98 5.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.49 -0.756 . . . . 0.0 110.825 -177.995 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . 1.022 ' OG1' HD21 ' B' ' 97' ' ' LEU . 1.5 m -73.11 -2.03 19.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.574 178.152 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.556 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.84 -36.36 13.74 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.91 136.74 36.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.086 -1.244 . . . . 0.0 109.686 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 87' ' ' ARG . 19.3 m-20 -64.15 -19.2 65.13 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.434 -0.791 . . . . 0.0 111.126 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.744 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.7 OUTLIER -141.79 -179.28 6.1 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.121 -1.432 . . . . 0.0 110.987 -179.324 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.662 HG22 ' CD1' ' A' ' 33' ' ' LEU . 2.3 m -96.18 89.41 5.13 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.471 -0.768 . . . . 0.0 110.612 -178.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.7 OUTLIER -69.38 163.28 3.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.729 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -158.45 131.72 7.43 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.112 -0.993 . . . . 0.0 110.691 -178.558 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.461 ' N ' ' CG2' ' A' ' 80' ' ' THR . 57.7 tt0 -43.44 164.77 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.82 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.538 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -56.91 134.56 55.6 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.149 -0.97 . . . . 0.0 110.703 -179.285 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' VAL . 2.2 ppp? -162.63 -167.56 1.59 Allowed 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.4 t -106.5 138.33 42.88 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.831 -1.168 . . . . 0.0 110.451 -179.313 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.837 HD22 HD12 ' A' ' 62' ' ' ILE . 5.4 mt -143.33 171.1 7.4 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.606 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -70.24 -153.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 121.853 1.702 . . . . 0.0 110.27 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.52 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -110.6 -167.25 19.27 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 -178.736 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.52 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.1 OUTLIER 73.07 54.6 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.113 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.662 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 3.9 p-90 -126.01 -176.84 3.75 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.791 0.805 . . . . 0.0 110.543 -178.692 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.41 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 14.0 mttp -147.54 160.87 37.66 Favored Pre-proline 0 N--CA 1.489 1.517 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.115 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 32.0 Cg_endo -75.78 147.48 31.15 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.166 1.91 . . . . 0.0 109.373 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.577 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -146.0 165.41 29.09 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.014 -1.054 . . . . 0.0 110.078 -178.932 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.406 ' SD ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -148.38 112.29 5.14 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.046 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 54' ' ' ILE . 6.7 pt -106.1 129.45 59.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.48 -1.288 . . . . 0.0 109.467 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -116.82 100.71 0.91 Allowed Glycine 0 N--CA 1.482 1.753 0 N-CA-C 107.15 -2.38 . . . . 0.0 107.15 179.415 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.18 -128.62 3.8 Favored Glycine 0 N--CA 1.479 1.565 0 C-N-CA 119.269 -1.443 . . . . 0.0 111.084 -177.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.806 HG21 HD11 ' B' ' 47' ' ' ILE . 59.1 mt -85.4 119.16 33.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 O-C-N 122.074 -0.663 . . . . 0.0 112.429 -177.374 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 109.79 -36.42 4.31 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 162.99 -162.09 34.41 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.492 -1.337 . . . . 0.0 110.147 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.7 m-85 -115.12 141.99 47.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.467 -1.02 . . . . 0.0 109.466 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 47' ' ' ILE . 3.0 pt -128.51 178.24 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.711 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.509 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -112.66 138.06 50.0 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.05 -1.031 . . . . 0.0 109.405 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.7 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.5 m -144.09 161.61 15.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.294 -0.879 . . . . 0.0 109.35 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.564 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -104.49 -176.63 3.14 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.145 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 44.5 tt0 -137.6 101.45 4.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.006 . . . . 0.0 109.543 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.815 ' HB3' HD11 ' A' ' 62' ' ' ILE . 40.1 m-85 -103.41 95.73 6.27 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.424 -0.797 . . . . 0.0 109.517 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -78.88 140.85 38.05 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.955 -1.091 . . . . 0.0 108.982 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 76.38 64.06 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.819 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.837 HD12 HD22 ' A' ' 38' ' ' LEU . 21.4 mm -121.8 123.34 69.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.859 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -67.56 82.47 0.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.355 -0.841 . . . . 0.0 110.935 -178.608 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 1.028 ' CG2' HD11 ' A' ' 89' ' ' LEU . 2.5 tt -94.34 121.25 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.43 ' HG2' ' C ' ' A' ' 69' ' ' HIS . 1.7 tt0 -89.17 140.57 29.33 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.099 -1.001 . . . . 0.0 108.486 179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.821 HD11 ' CD1' ' A' ' 89' ' ' LEU . 0.4 OUTLIER -126.05 171.97 14.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 107.165 -1.421 . . . . 0.0 107.165 179.672 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.458 ' SG ' ' HB ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -47.96 -38.63 17.21 Favored 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 178.836 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.635 ' O ' ' CG ' ' A' ' 69' ' ' HIS . . . -52.79 -49.59 53.4 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 178.319 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.635 ' CG ' ' O ' ' A' ' 68' ' ' GLY . 0.2 OUTLIER 141.66 -173.39 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.076 0 CA-C-O 121.102 0.477 . . . . 0.0 109.838 178.583 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.533 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -36.56 139.51 0.18 Allowed 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 121.351 0.596 . . . . 0.0 109.773 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -161.8 115.33 1.87 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.304 -0.872 . . . . 0.0 110.02 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.772 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -85.57 150.7 3.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.706 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.608 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.24 -154.92 11.73 Favored Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.262 -1.446 . . . . 0.0 110.835 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.494 ' HB ' ' OD1' ' A' ' 88' ' ' ASN . 1.4 m -109.7 111.95 23.73 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.246 -1.149 . . . . 0.0 110.087 -179.15 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.03 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -106.15 108.39 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.262 -0.899 . . . . 0.0 111.243 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.744 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.12 139.55 38.02 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 177.674 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.56 ' CG2' HD12 ' A' ' 38' ' ' LEU . 1.3 t -116.2 112.47 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.084 -1.01 . . . . 0.0 110.978 -178.144 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.7 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.54 -172.17 18.83 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.2 Cg_endo -81.45 41.62 1.18 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.58 2.187 . . . . 0.0 110.681 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.632 HG21 HG13 ' A' ' 32' ' ' VAL . 3.8 t -79.3 141.56 57.62 Favored Pre-proline 0 N--CA 1.49 1.553 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.21 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.733 ' O ' HG23 ' A' ' 82' ' ' VAL . 38.2 Cg_endo -80.07 20.02 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.583 2.188 . . . . 0.0 110.872 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 81' ' ' PRO . 10.5 t -161.13 166.8 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.702 -1.248 . . . . 0.0 110.92 -178.694 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.545 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 7.8 m-80 -100.44 90.45 4.3 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 177.551 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.598 ' O ' ' HA ' ' A' ' 31' ' ' THR . 12.1 mm -79.14 120.04 29.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 O-C-N 121.183 -0.948 . . . . 0.0 112.379 -176.027 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.576 ' N ' HD13 ' A' ' 85' ' ' ILE . 3.3 mm -99.07 106.11 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 176.587 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.507 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -91.47 -152.18 27.94 Favored Glycine 0 N--CA 1.489 2.197 0 O-C-N 120.679 -1.263 . . . . 0.0 111.861 -176.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.774 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -70.7 -41.29 72.15 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 120.111 -0.636 . . . . 0.0 109.852 -179.032 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.57 ' OD1' ' HA ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -53.33 -16.39 1.33 Allowed 'General case' 0 N--CA 1.498 1.963 0 C-N-CA 117.821 -1.552 . . . . 0.0 110.422 -178.965 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.157 HD13 ' OE1' ' A' ' 92' ' ' GLN . 0.2 OUTLIER -105.76 -20.82 13.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.658 -1.276 . . . . 0.0 109.054 179.825 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.933 HD13 HG23 ' A' ' 26' ' ' THR . 28.7 mt -80.95 1.1 32.55 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.654 -1.279 . . . . 0.0 108.535 178.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.774 HG23 ' O ' ' A' ' 87' ' ' ARG . 0.3 OUTLIER -101.08 -10.06 20.83 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.137 -0.977 . . . . 0.0 111.159 -179.958 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 1.157 ' OE1' HD13 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -95.15 -40.81 9.41 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 120.467 -1.396 . . . . 0.0 109.562 -178.552 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.052 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.3 OUTLIER -80.48 3.3 2.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.013 -1.075 . . . . 0.0 108.349 178.576 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 69.87 53.05 16.71 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.575 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -77.27 144.98 37.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.121 -1.223 . . . . 0.0 109.271 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.95 HG22 HG22 ' B' ' 4' ' ' THR . 27.3 p -139.85 123.27 17.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.157 -0.964 . . . . 0.0 109.27 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.738 HD11 HD11 ' B' ' 97' ' ' LEU . 7.4 mp -84.72 100.61 11.61 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 178.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' B' ' 94' ' ' GLY . 65.1 m-20 -99.17 120.01 38.8 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 120.447 -1.408 . . . . 0.0 108.934 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.64 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.298 -1.64 0 CA-C-O 118.101 -0.952 . . . . 0.0 109.282 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.7 Cg_exo . . . . . 0 N--CA 1.493 1.488 0 N-CA-C 109.917 -0.839 . . . . 0.0 109.917 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 130.7 35.14 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 56.3 t -123.57 109.04 22.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.595 -177.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 96' ' ' THR . 14.7 p -123.97 21.59 8.98 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.411 -0.806 . . . . 0.0 109.967 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.6 tp -88.82 27.31 1.34 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.023 -1.048 . . . . 0.0 108.758 178.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.763 ' HB3' HG22 ' A' ' 91' ' ' THR . 0.7 OUTLIER 14.98 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.685 0.755 . . . . 0.0 111.918 179.698 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.54 ' O ' ' HD3' ' B' ' 9' ' ' PRO . 1.0 OUTLIER -129.31 -152.46 0.52 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.448 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 26.5 mtt180 -103.72 101.43 24.37 Favored Pre-proline 0 N--CA 1.488 1.45 0 O-C-N 120.903 -1.123 . . . . 0.0 108.133 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.561 ' HD2' ' CZ ' ' A' ' 87' ' ' ARG . 33.9 Cg_endo -75.13 72.06 4.86 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.413 2.075 . . . . 0.0 110.698 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -89.78 142.88 27.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.017 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.781 HG23 HG23 ' B' ' 13' ' ' ILE . 21.9 m -131.15 126.05 58.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.3 m -67.34 99.88 0.76 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 177.366 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.857 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pp -95.91 140.53 16.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.242 -0.911 . . . . 0.0 111.298 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.1 OUTLIER -103.63 106.91 17.56 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.734 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.862 HD13 HG11 ' B' ' 75' ' ' VAL . 7.2 mt -119.68 115.65 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.206 -0.934 . . . . 0.0 110.154 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.48 27.78 73.13 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.606 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.77 12.3 81.63 Favored Glycine 0 N--CA 1.492 2.419 0 O-C-N 120.901 -1.353 . . . . 0.0 109.789 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.4 mt-30 -107.44 168.57 9.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.208 -1.172 . . . . 0.0 109.134 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.519 HD11 ' HE3' ' B' ' 14' ' ' LYS . 14.7 mt -140.48 122.95 16.06 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 0.0 109.514 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.517 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mmtt -143.87 172.95 12.15 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.503 -0.748 . . . . 0.0 109.236 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 31.1 mp0 -87.13 132.06 33.97 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.919 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.78 147.32 30.99 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.025 -1.047 . . . . 0.0 109.587 -179.489 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' B' ' 25' ' ' ASP . 18.6 tp -112.84 94.43 4.9 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.569 -0.707 . . . . 0.0 109.462 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.517 ' O ' ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -41.41 95.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.423 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.951 ' HB3' HG23 ' B' ' 84' ' ' ILE . 24.6 t0 -113.57 88.95 2.96 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.198 -0.939 . . . . 0.0 111.538 -178.23 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.81 HG23 HD22 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -67.69 -19.67 65.2 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 177.265 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.457 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -55.57 -39.51 75.13 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.46 164.73 18.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.46 -1.023 . . . . 0.0 109.306 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.477 ' OD1' ' HG3' ' A' ' 8' ' ' ARG . 12.4 m-20 -94.96 -19.57 20.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.075 -1.016 . . . . 0.0 110.921 -178.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.947 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.9 OUTLIER -137.22 -175.71 4.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.747 -1.22 . . . . 0.0 110.198 -179.491 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.741 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.3 m -100.21 94.7 6.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.03 -1.044 . . . . 0.0 110.856 -178.224 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.037 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -75.05 158.72 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.092 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.037 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.5 OUTLIER -155.46 143.07 19.65 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.908 -1.12 . . . . 0.0 111.052 -178.092 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.729 ' N ' HG22 ' B' ' 80' ' ' THR . 20.2 tt0 -49.68 156.15 0.72 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.6 OUTLIER -61.69 132.78 54.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.076 -1.015 . . . . 0.0 109.609 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.568 ' HE2' HG22 ' B' ' 15' ' ' ILE . 3.8 ptm -153.33 -164.17 1.85 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.402 ' O ' HD22 ' B' ' 38' ' ' LEU . 28.5 t -102.96 118.12 36.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.037 -1.039 . . . . 0.0 110.49 -179.321 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.552 HD13 ' HD3' ' B' ' 39' ' ' PRO . 3.0 mm? -113.3 169.96 5.84 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.552 ' HD3' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.95 52.02 4.14 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.696 2.264 . . . . 0.0 111.426 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 49.03 -163.0 0.5 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.2 mmm-85 60.25 84.87 0.12 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -1.14 . . . . 0.0 109.196 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.606 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 60.3 p-90 -159.57 176.54 11.92 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.509 0.671 . . . . 0.0 110.047 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.412 ' CG ' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -139.38 159.68 64.95 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.374 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 44' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' B' ' 43' ' ' LYS . 35.9 Cg_endo -77.95 139.53 17.44 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.21 1.94 . . . . 0.0 110.404 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.793 ' O ' HG22 ' B' ' 56' ' ' VAL . 10.1 tttt -155.53 131.14 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.439 -0.788 . . . . 0.0 109.197 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -110.85 130.68 55.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.099 -1.001 . . . . 0.0 109.289 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.806 HD11 HG21 ' A' ' 50' ' ' ILE . 24.3 pt -113.42 149.86 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.894 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.495 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.15 111.51 2.09 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 179.458 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -132.36 -126.08 2.7 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.188 -1.482 . . . . 0.0 111.161 -178.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.51 ' O ' ' O ' ' A' ' 50' ' ' ILE . 19.3 mt -91.52 138.44 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 122.056 0.932 . . . . 0.0 113.179 -177.098 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.542 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 80.18 -20.19 6.03 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 178.585 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.14 -169.44 32.61 Favored Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.649 -1.5 . . . . 0.0 110.321 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 4.5 m-85 -105.11 153.25 21.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.372 -1.075 . . . . 0.0 109.274 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.693 HD13 HG23 ' A' ' 50' ' ' ILE . 7.4 pt -127.11 159.81 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.225 -0.922 . . . . 0.0 109.807 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.529 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.29 144.52 31.51 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.769 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.793 HG22 ' O ' ' B' ' 45' ' ' LYS . 23.9 m -142.9 -171.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.78 -1.2 . . . . 0.0 110.598 -178.75 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 11.4 mtt180 -137.85 88.87 2.36 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.41 98.82 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 110.962 -179.082 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.975 ' HB3' HD11 ' B' ' 62' ' ' ILE . 18.9 m-85 -91.78 127.54 37.27 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.814 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.935 ' OD1' HG23 ' B' ' 74' ' ' THR . 2.4 m-20 -107.69 135.22 49.48 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.785 -1.197 . . . . 0.0 110.632 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.585 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.1 mt-30 79.96 60.4 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.823 -0.548 . . . . 0.0 110.889 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 1.058 HD13 HG23 ' B' ' 75' ' ' VAL . 3.5 mp -113.96 119.94 62.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.086 -1.008 . . . . 0.0 109.275 179.087 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.848 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.9 tm? -68.59 83.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.506 -0.746 . . . . 0.0 110.505 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.761 HD12 HD11 ' B' ' 15' ' ' ILE . 12.5 tt -88.85 124.88 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.489 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 7.4 tt0 -90.28 100.13 13.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.085 -1.01 . . . . 0.0 109.414 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.857 HG13 HG22 ' B' ' 13' ' ' ILE . 0.5 OUTLIER -90.97 119.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 121.055 -1.028 . . . . 0.0 109.103 179.949 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.643 ' SG ' HG12 ' B' ' 11' ' ' VAL . 5.3 m 48.5 47.52 20.24 Favored 'General case' 0 C--N 1.291 -1.951 0 O-C-N 121.82 -0.55 . . . . 0.0 110.463 178.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 68' ' ' GLY . . . . . 0.484 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 68.37 28.13 73.41 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.623 ' CE1' ' O ' ' B' ' 67' ' ' CYS . 3.2 m-70 -120.2 97.15 5.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.034 -1.274 . . . . 0.0 109.35 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.57 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.44 126.81 16.07 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.239 -0.913 . . . . 0.0 109.159 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.764 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -151.26 155.98 39.9 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.665 -0.647 . . . . 0.0 109.459 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.751 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.9 OUTLIER -119.22 153.33 21.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.717 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.419 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -175.61 -177.83 44.96 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.453 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.935 HG23 ' OD1' ' B' ' 60' ' ' ASP . 2.7 m -91.18 108.56 19.95 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.706 -0.879 . . . . 0.0 109.877 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.058 HG23 HD13 ' B' ' 62' ' ' ILE . 1.4 t -103.35 112.46 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.401 -0.812 . . . . 0.0 110.328 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.947 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.9 mp -77.73 118.71 20.36 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.012 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 72.1 t -99.02 117.44 44.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 120.916 -1.115 . . . . 0.0 109.74 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.75 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.55 -168.52 18.73 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.116 -1.994 . . . . 0.0 108.116 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.529 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -80.83 48.46 2.91 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 122.263 1.975 . . . . 0.0 110.816 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.842 HG21 HG13 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -91.85 137.45 25.39 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.926 -1.109 . . . . 0.0 108.573 179.481 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.6 Cg_endo -79.54 19.6 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.557 2.171 . . . . 0.0 112.209 -178.502 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.76 ' H ' HG23 ' B' ' 80' ' ' THR . 1.1 t -161.23 172.74 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.541 -1.349 . . . . 0.0 110.287 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.585 ' N ' HG13 ' B' ' 82' ' ' VAL . 3.2 m-80 -107.55 79.53 1.3 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.452 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.951 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.2 mp -76.8 126.02 37.1 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.374 -0.829 . . . . 0.0 111.48 -176.274 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.919 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.2 mp -96.14 99.94 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.272 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.549 ' C ' HD12 ' B' ' 90' ' ' LEU . . . -95.69 167.68 25.9 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.189 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.764 ' O ' HG23 ' B' ' 91' ' ' THR . 22.5 mmm180 -25.77 -39.41 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.818 -0.813 . . . . 0.0 112.826 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.009 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.9 p-10 -49.79 -21.99 1.29 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.577 -1.327 . . . . 0.0 111.264 -178.522 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.009 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -110.58 -24.06 10.75 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.81 HD22 HG23 ' B' ' 26' ' ' THR . 3.8 mp -68.6 -8.69 44.14 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.764 HG23 ' O ' ' B' ' 87' ' ' ARG . 30.4 p -95.83 -20.22 18.99 Favored 'General case' 0 N--CA 1.485 1.307 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.775 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.504 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 68.5 mm-40 -81.73 -41.46 21.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.137 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.64 HD12 ' CG ' ' A' ' 99' ' ' PHE . 1.9 pt -93.29 -2.82 10.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 98' ' ' ASN . . . 75.48 22.51 75.37 Favored Glycine 0 N--CA 1.494 2.529 0 O-C-N 121.516 -0.74 . . . . 0.0 111.488 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.573 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -65.27 123.66 20.15 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.708 -1.466 . . . . 0.0 110.457 -179.583 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 41.4 p -131.38 132.63 44.56 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 1.022 HD21 ' OG1' ' A' ' 26' ' ' THR . 4.8 mp -84.87 106.87 16.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.047 -1.033 . . . . 0.0 110.766 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 6.7 m-20 -112.3 121.61 45.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.344 -0.847 . . . . 0.0 108.944 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 1.052 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.686 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.224 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.567 ' O ' ' CD1' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.67 0 N-CA-C 110.398 -0.655 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -88.16 139.37 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.54 155.86 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 109.943 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.539 HG22 HG22 ' B' ' 96' ' ' THR . 1.1 p -127.66 -168.35 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.312 -0.868 . . . . 0.0 109.445 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 1.023 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -87.16 -26.89 23.37 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.215 -0.928 . . . . 0.0 109.065 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.589 ' N ' HD13 ' A' ' 5' ' ' LEU . 10.2 m95 -45.48 -22.72 0.16 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.629 -1.295 . . . . 0.0 109.06 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.478 ' N ' ' O ' ' A' ' 5' ' ' LEU . 34.6 mt-30 -146.25 110.32 4.98 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.705 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.462 ' C ' ' O ' ' A' ' 7' ' ' GLN . 14.6 mtm180 -40.95 148.17 0.39 Allowed Pre-proline 0 C--N 1.297 -1.713 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 36.7 Cg_endo -79.71 47.88 2.67 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.579 2.186 . . . . 0.0 109.757 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.587 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -79.33 143.43 35.17 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.098 -1.001 . . . . 0.0 109.526 -179.222 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 HG23 ' A' ' 66' ' ' ILE . 0.7 OUTLIER -147.24 140.65 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.333 -178.734 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.752 HG22 HD22 ' A' ' 19' ' ' LEU . 78.4 m -74.32 96.78 2.89 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.876 HG22 HG13 ' A' ' 66' ' ' ILE . 4.2 pt -83.81 150.34 4.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 121.635 0.731 . . . . 0.0 111.041 -178.252 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.666 ' HE3' HD11 ' A' ' 19' ' ' LEU . 1.1 tttt -112.14 101.54 9.79 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.43 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.028 HD11 HD12 ' A' ' 64' ' ' ILE . 12.2 mt -122.51 138.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.225 -0.922 . . . . 0.0 109.308 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 52.11 43.37 56.2 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.14 35.83 66.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 68.8 mm-40 -131.32 178.59 6.6 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.151 . . . . 0.0 109.186 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.752 HD22 HG22 ' A' ' 12' ' ' THR . 39.5 mt -146.94 126.45 13.23 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.129 -0.982 . . . . 0.0 110.232 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.601 ' N ' ' HE2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -146.85 163.34 36.38 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.709 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.557 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 49.3 mm-40 -79.39 137.23 37.21 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.97 -1.081 . . . . 0.0 109.113 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -119.98 156.07 31.59 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.594 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.431 HD21 ' O ' ' B' ' 27' ' ' GLY . 12.3 tp -118.24 99.12 6.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.701 -0.624 . . . . 0.0 109.615 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.527 HD23 ' HB ' ' A' ' 85' ' ' ILE . 18.7 mt -48.34 106.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.878 -1.139 . . . . 0.0 108.932 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' CB ' HG23 ' A' ' 84' ' ' ILE . 54.2 t0 -109.24 98.39 7.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.875 . . . . 0.0 109.829 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.724 HG22 HH12 ' A' ' 87' ' ' ARG . 0.2 OUTLIER -71.58 -5.01 30.18 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.303 -0.873 . . . . 0.0 108.748 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.827 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.58 -33.27 22.61 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.569 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.36 159.88 20.78 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.073 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.519 ' OD2' ' CZ ' ' B' ' 8' ' ' ARG . 16.8 m-20 -100.77 -13.66 18.36 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.3 -0.875 . . . . 0.0 110.629 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.496 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -127.0 -173.54 2.92 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.982 -1.074 . . . . 0.0 109.545 -179.625 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.582 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 27.9 m -110.47 86.76 2.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.864 -1.147 . . . . 0.0 110.214 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -67.78 173.5 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -169.85 115.2 0.53 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.838 -1.163 . . . . 0.0 110.983 -178.14 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.508 ' C ' ' O ' ' A' ' 33' ' ' LEU . 33.8 tt0 -33.85 150.05 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.879 -0.513 . . . . 0.0 109.649 178.724 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.649 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -37.35 145.08 0.06 Allowed 'General case' 0 N--CA 1.495 1.783 0 CA-C-O 121.56 0.695 . . . . 0.0 110.674 -179.206 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.404 ' SD ' ' CD2' ' A' ' 38' ' ' LEU . 14.3 ptm -156.85 -170.8 3.42 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.0 t -127.77 90.77 3.16 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.827 -1.171 . . . . 0.0 111.364 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.637 ' HB2' ' CE1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -81.49 171.58 11.79 Favored Pre-proline 0 N--CA 1.493 1.716 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 177.901 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.537 ' CD ' HD12 ' A' ' 38' ' ' LEU . 36.2 Cg_endo -79.3 43.52 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.614 2.21 . . . . 0.0 111.499 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . 54.72 111.15 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.449 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 157.79 57.74 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.909 . . . . 0.0 108.83 179.792 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 51.5 p-90 -141.1 179.18 6.89 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-O 121.849 0.833 . . . . 0.0 110.491 -178.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.452 ' HA ' ' HE3' ' A' ' 43' ' ' LYS . 0.0 OUTLIER -130.8 158.04 76.09 Favored Pre-proline 0 C--N 1.302 -1.475 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.783 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -76.32 141.92 23.47 Favored 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.144 1.896 . . . . 0.0 110.471 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.497 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -148.39 169.57 19.89 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.428 -0.795 . . . . 0.0 109.352 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.485 ' SD ' ' HB3' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -144.35 111.21 5.75 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.507 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.563 HD11 HD11 ' A' ' 54' ' ' ILE . 6.0 pt -92.33 142.52 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.856 -1.152 . . . . 0.0 109.093 -179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.621 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -122.8 105.08 0.92 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.68 -120.57 2.5 Favored Glycine 0 N--CA 1.483 1.785 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.097 -179.654 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.865 HG21 HD11 ' B' ' 47' ' ' ILE . 26.3 mt -86.56 121.69 37.89 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.69 -0.888 . . . . 0.0 112.09 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 103.91 -55.71 0.61 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.76 -159.3 23.69 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.621 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.0 m-85 -107.43 131.79 53.9 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.235 -1.156 . . . . 0.0 109.887 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 7.3 pt -107.98 134.63 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.923 -1.111 . . . . 0.0 108.857 178.697 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -70.94 148.58 47.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.103 -0.998 . . . . 0.0 110.057 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.4 m -150.09 -169.77 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.595 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 3.7 mmt85 -133.56 105.11 6.7 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.503 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.0 OUTLIER -62.93 102.06 0.32 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.948 . . . . 0.0 110.448 -179.133 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.637 ' CE1' ' HB2' ' A' ' 38' ' ' LEU . 31.2 m-85 -92.62 90.68 7.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 108.858 179.113 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 3.4 m-20 -79.07 124.72 28.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.008 -1.057 . . . . 0.0 110.47 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 2.7 mm-40 88.33 61.78 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 CA-C-O 121.383 0.611 . . . . 0.0 110.163 179.319 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.975 ' CG2' HG23 ' A' ' 15' ' ' ILE . 14.8 mm -117.82 116.53 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.108 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.953 HD13 ' O ' ' A' ' 63' ' ' LEU . 1.3 tm? -68.66 83.73 0.29 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.372 -0.83 . . . . 0.0 110.092 -179.137 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 1.028 HD12 HD11 ' A' ' 15' ' ' ILE . 11.8 tt -89.9 112.0 23.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 179.029 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.517 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 8.6 tp10 -91.63 120.44 32.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.11 -0.994 . . . . 0.0 109.228 -179.255 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -107.01 121.01 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.179 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 60.04 -93.01 0.04 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.606 -0.684 . . . . 0.0 110.053 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -138.92 27.37 2.68 Favored Glycine 0 N--CA 1.486 1.978 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.42 ' C ' ' OE1' ' A' ' 65' ' ' GLU . 9.6 m-70 -125.53 103.44 7.88 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.188 -1.184 . . . . 0.0 109.385 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.603 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -59.52 133.43 56.09 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.544 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.712 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -145.52 154.9 42.7 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.153 -0.967 . . . . 0.0 110.333 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.556 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -121.25 156.29 24.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 177.491 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.909 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 177.77 -177.77 48.37 Favored Glycine 0 N--CA 1.487 2.039 0 C-N-CA 117.876 -2.107 . . . . 0.0 112.084 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.503 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 91.0 m -90.62 105.12 17.6 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.921 -0.752 . . . . 0.0 109.713 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.63 107.06 19.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.688 -0.632 . . . . 0.0 110.079 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.543 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.8 mp -79.51 120.82 24.42 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.461 -0.774 . . . . 0.0 108.99 179.323 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.649 HG12 ' HA ' ' A' ' 35' ' ' GLU . 21.6 t -107.22 130.67 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.57 179.801 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -162.21 -159.4 10.23 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.039 -1.624 . . . . 0.0 109.039 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.72 38.32 0.73 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.606 2.204 . . . . 0.0 110.338 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' A' ' 32' ' ' VAL . 2.4 t -83.95 135.08 42.84 Favored Pre-proline 0 N--CA 1.489 1.519 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.261 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.5 16.82 1.18 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.428 2.085 . . . . 0.0 111.044 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.461 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.83 157.73 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.978 -1.076 . . . . 0.0 109.292 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -94.53 126.33 39.74 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 176.041 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.709 ' CG1' HG12 ' A' ' 32' ' ' VAL . 5.0 mm -111.57 122.57 66.19 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 O-C-N 120.486 -1.384 . . . . 0.0 112.384 -176.186 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.561 HG22 ' O ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -98.78 85.66 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 176.88 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.57 -157.02 9.97 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.461 -177.236 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.724 HH12 HG22 ' A' ' 26' ' ' THR . 0.0 OUTLIER -64.56 -33.06 75.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 122.009 -0.7 . . . . 0.0 111.265 -178.44 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -55.9 -32.15 63.48 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.791 -1.193 . . . . 0.0 110.315 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -108.05 -19.95 13.33 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.993 -1.067 . . . . 0.0 110.516 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.501 HD23 HD11 ' A' ' 93' ' ' ILE . 12.6 mt -69.9 -36.17 75.19 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 71.2 p -72.55 -20.83 61.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.057 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.449 ' OE1' ' HA ' ' A' ' 92' ' ' GLN . 9.4 mm100 -71.43 -40.18 70.58 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.697 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.4 OUTLIER -85.77 -2.18 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.55 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.82 60.36 6.6 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.669 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -81.41 151.72 27.77 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.365 -1.079 . . . . 0.0 110.052 -179.6 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.8 p -142.96 125.34 15.6 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.035 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' B' ' 97' ' ' LEU . 2.6 mp -91.0 94.27 9.56 Favored 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.612 -0.68 . . . . 0.0 109.17 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.457 ' CG ' ' HG3' ' B' ' 2' ' ' GLN . 6.4 m-20 -104.79 129.0 53.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.127 -0.983 . . . . 0.0 110.285 -179.25 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 1.017 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.377 178.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.492 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 N-CA-C 110.383 -0.66 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.457 ' HG3' ' CG ' ' A' ' 98' ' ' ASN . 7.1 tt0 -83.59 129.81 34.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 96.2 t -130.41 107.19 14.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.718 -1.239 . . . . 0.0 110.692 -177.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.547 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.9 p -108.71 -59.56 1.86 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' B' ' 7' ' ' GLN . 84.5 mt 35.8 27.9 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.695 -0.628 . . . . 0.0 111.068 179.153 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.547 ' N ' ' O ' ' B' ' 4' ' ' THR . 8.4 m95 17.63 46.48 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.603 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.6 mt-30 -170.65 -166.86 0.53 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.108 -0.995 . . . . 0.0 109.941 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.554 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.3 mtm180 -67.78 112.75 11.36 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.474 -0.767 . . . . 0.0 109.545 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.795 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.4 Cg_endo -80.27 86.88 1.59 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.204 1.936 . . . . 0.0 110.051 179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.473 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.5 OUTLIER -86.12 136.25 33.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.92 . . . . 0.0 109.524 -179.771 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' B' ' 22' ' ' ALA . 3.4 m -125.56 154.17 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.423 -0.798 . . . . 0.0 109.711 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.453 HG21 ' CD2' ' B' ' 19' ' ' LEU . 58.5 m -86.6 111.27 20.47 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.912 HD11 HD21 ' B' ' 33' ' ' LEU . 1.6 pp -97.76 141.7 15.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.184 -0.948 . . . . 0.0 110.447 -178.674 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.439 ' HG3' HD12 ' B' ' 19' ' ' LEU . 6.8 ttmm -109.4 96.05 6.03 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.346 -0.846 . . . . 0.0 109.316 179.658 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 1.095 HG23 ' CG2' ' B' ' 62' ' ' ILE . 7.3 mt -113.02 116.18 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.86 50.69 63.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.96 17.15 21.27 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.224 -1.162 . . . . 0.0 110.287 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.506 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 1.7 mt-30 -108.05 134.67 50.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.055 -1.262 . . . . 0.0 109.37 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.453 ' CD2' HG21 ' B' ' 12' ' ' THR . 0.3 OUTLIER -113.51 120.06 39.68 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.098 0.951 . . . . 0.0 110.302 -179.726 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.413 ' HB3' HD21 ' B' ' 83' ' ' ASN . 0.7 OUTLIER -141.04 178.55 7.3 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.094 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.552 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.1 mt-10 -85.46 178.18 7.52 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 120.802 -1.186 . . . . 0.0 108.812 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.914 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -156.58 111.65 2.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.063 -1.023 . . . . 0.0 110.302 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.827 HD21 ' O ' ' A' ' 27' ' ' GLY . 27.9 tp -82.12 100.28 9.7 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.795 HD12 ' HB2' ' B' ' 9' ' ' PRO . 67.8 mt -43.17 105.96 0.06 Allowed 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.7 t0 -114.38 87.47 2.64 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.517 -0.74 . . . . 0.0 110.839 -178.259 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -71.22 -5.44 32.07 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.842 -1.161 . . . . 0.0 108.63 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.474 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -81.99 -32.76 28.49 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.0 162.72 28.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.952 -1.323 . . . . 0.0 109.575 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.421 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 0.7 OUTLIER -93.4 -20.86 19.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.887 -179.421 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.577 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 14.3 m-20 -139.5 -164.81 1.75 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.034 -1.041 . . . . 0.0 109.407 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.643 HG23 ' O ' ' B' ' 84' ' ' ILE . 89.3 m -109.59 95.66 5.76 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.661 -1.274 . . . . 0.0 111.174 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -72.78 178.01 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 177.879 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.026 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -169.13 118.34 0.68 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.781 -1.199 . . . . 0.0 110.875 -178.885 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.643 ' HA ' HG22 ' B' ' 80' ' ' THR . 2.4 tt0 -35.11 150.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.557 . . . . 0.0 109.51 178.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.538 ' N ' ' HG3' ' B' ' 34' ' ' GLU . 0.0 OUTLIER -31.07 141.87 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.75 0.786 . . . . 0.0 111.497 -179.041 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.912 ' SD ' HD22 ' B' ' 38' ' ' LEU . 2.8 ppp? -169.05 175.54 5.73 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.265 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.543 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -122.53 136.28 54.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.619 -1.3 . . . . 0.0 111.235 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.912 HD22 ' SD ' ' B' ' 36' ' ' MET . 0.2 OUTLIER -120.49 175.83 2.14 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.251 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.85 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.8 Cg_endo -79.47 62.47 8.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.632 2.221 . . . . 0.0 111.171 179.397 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.539 ' O ' ' CG ' ' B' ' 41' ' ' ARG . . . 40.29 87.06 0.01 OUTLIER Glycine 0 N--CA 1.495 2.621 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.539 ' CG ' ' O ' ' B' ' 40' ' ' GLY . 4.2 mtt180 -167.67 57.15 0.07 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.86 -0.788 . . . . 0.0 109.095 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.629 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 59.3 p-90 -147.96 172.33 14.38 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.07 0.938 . . . . 0.0 110.791 -179.307 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mmtm -130.98 144.29 52.94 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.225 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -74.01 133.29 17.96 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 C-N-CA 121.626 1.551 . . . . 0.0 110.486 -179.266 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.449 ' HG3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.65 -178.83 7.64 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.462 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 62.9 mtp -145.13 131.52 19.66 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.141 -0.975 . . . . 0.0 109.323 179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.865 HD11 HG21 ' A' ' 50' ' ' ILE . 19.9 pt -96.7 145.91 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.13 -0.982 . . . . 0.0 108.791 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.515 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.6 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -122.86 2.84 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.558 HG21 HD12 ' A' ' 47' ' ' ILE . 33.3 mt -89.69 121.54 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.716 -0.873 . . . . 0.0 112.414 -177.867 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.589 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 105.43 -52.26 0.72 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 178.38 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.31 -164.64 33.45 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.515 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -106.35 126.2 51.94 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.436 -1.038 . . . . 0.0 109.171 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.512 HD13 HG23 ' A' ' 50' ' ' ILE . 23.4 pt -97.28 174.99 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 120.917 -1.115 . . . . 0.0 109.149 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.514 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 35.2 mtpt -111.49 127.23 55.63 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.256 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.565 HG12 ' HA3' ' B' ' 78' ' ' GLY . 16.6 m -136.15 -174.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.583 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.586 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 0.5 OUTLIER -129.13 104.14 7.38 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.762 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.421 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 1.9 tt0 -62.38 97.4 0.09 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.523 -0.736 . . . . 0.0 110.704 -178.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.639 ' CE2' ' HB2' ' B' ' 38' ' ' LEU . 29.7 m-85 -88.56 127.49 35.55 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 5.6 m-20 -106.73 133.0 52.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.859 -1.151 . . . . 0.0 110.637 -178.548 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.544 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 52.2 mm-40 72.32 63.53 0.12 Allowed 'General case' 0 N--CA 1.49 1.539 0 CA-C-O 121.665 0.745 . . . . 0.0 109.469 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 1.095 ' CG2' HG23 ' B' ' 15' ' ' ILE . 12.6 mm -113.95 122.21 67.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.198 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.788 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.1 OUTLIER -69.97 84.99 0.51 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 111.568 -177.922 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.527 HD11 HD11 ' B' ' 66' ' ' ILE . 1.7 tt -88.62 119.47 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.8 tt0 -100.99 122.86 44.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.836 -1.165 . . . . 0.0 109.527 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.555 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -109.15 131.45 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 121.268 -0.895 . . . . 0.0 109.101 -179.956 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 57.37 -88.69 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.787 -0.57 . . . . 0.0 110.212 179.49 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -149.84 38.62 0.92 Allowed Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -136.36 123.13 21.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -1.115 . . . . 0.0 109.175 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.461 ' CG ' HD11 ' B' ' 63' ' ' LEU . 0.4 OUTLIER -66.9 136.33 55.21 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.244 -0.91 . . . . 0.0 108.623 179.551 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.566 ' HB2' HG22 ' B' ' 93' ' ' ILE . . . -152.09 119.96 6.17 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 110.268 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.788 HD13 ' N ' ' B' ' 63' ' ' LEU . 1.1 mm -89.53 163.31 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 178.016 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.792 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 174.05 173.11 39.89 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 118.931 -1.604 . . . . 0.0 110.777 179.568 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 59.3 m -83.72 114.8 21.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.469 -1.018 . . . . 0.0 109.892 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.026 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -106.77 114.91 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.254 -0.903 . . . . 0.0 110.6 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.757 ' HB2' HG23 ' B' ' 32' ' ' VAL . 4.1 mp -86.38 115.03 23.64 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.698 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.518 ' O ' ' CD ' ' B' ' 57' ' ' ARG . 93.0 t -101.14 132.12 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.045 -1.034 . . . . 0.0 109.57 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.565 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -169.44 -163.26 23.16 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.514 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.1 Cg_endo -79.8 43.55 1.53 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.754 2.303 . . . . 0.0 110.892 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.643 HG22 ' HA ' ' B' ' 34' ' ' GLU . 12.2 t -85.32 137.61 36.82 Favored Pre-proline 0 N--CA 1.488 1.431 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.571 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.69 13.62 1.86 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.302 2.001 . . . . 0.0 110.879 -179.315 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.571 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.4 t -161.44 163.34 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.132 -0.98 . . . . 0.0 109.864 -179.235 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 55.0 m-80 -94.34 136.32 34.77 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.051 -2.574 . . . . 0.0 104.051 175.599 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.782 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.6 mm -121.05 122.42 67.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 O-C-N 119.92 -1.737 . . . . 0.0 111.358 -177.545 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.914 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -98.63 92.07 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.638 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.18 -155.56 9.39 Favored Glycine 0 N--CA 1.49 2.28 0 C-N-CA 120.005 -1.093 . . . . 0.0 111.096 -178.015 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.938 ' HD2' HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -75.71 -29.66 59.04 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.905 -0.762 . . . . 0.0 110.159 -178.982 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.885 ' ND2' HD23 ' B' ' 89' ' ' LEU . 19.0 p-10 -51.08 -20.46 1.46 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.888 -1.133 . . . . 0.0 109.831 -179.365 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.885 HD23 ' ND2' ' B' ' 88' ' ' ASN . 4.0 mm? -116.17 -21.25 9.48 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.83 -1.169 . . . . 0.0 110.899 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.455 ' CD2' ' CB ' ' B' ' 95' ' ' ALA . 83.3 mt -66.12 -18.43 65.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.63 -1.294 . . . . 0.0 109.547 -179.711 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.86 -5.74 25.72 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.927 -1.108 . . . . 0.0 109.212 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 10.2 mm100 -94.15 -41.18 9.64 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 1.017 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.2 pt -88.94 -7.73 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.854 . . . . 0.0 108.749 179.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 89.43 28.03 20.87 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.919 178.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -71.11 125.72 27.65 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.667 -1.49 . . . . 0.0 109.52 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.539 HG22 HG22 ' A' ' 4' ' ' THR . 66.4 p -127.05 129.91 48.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' A' ' 97' ' ' LEU . 4.1 mp -87.35 102.46 14.54 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.249 -0.907 . . . . 0.0 110.256 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.528 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.1 m-20 -102.21 125.44 48.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.352 -0.843 . . . . 0.0 109.15 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.697 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.086 -0.959 . . . . 0.0 109.296 179.465 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.497 1.724 0 CA-C-O 121.501 0.542 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.4 tt0 -83.58 144.51 29.42 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.114 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.527 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 9.5 t -143.84 112.87 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.274 -1.37 . . . . 0.0 110.314 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.719 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -117.92 -67.1 1.02 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.958 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.547 ' O ' ' C ' ' A' ' 6' ' ' TRP . 2.5 pp 27.68 36.58 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.588 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.566 ' N ' ' O ' ' A' ' 4' ' ' THR . 35.7 m95 15.9 53.57 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.245 0 CA-C-O 121.184 0.516 . . . . 0.0 112.268 179.427 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 2.6 mt-30 -156.88 -166.75 2.17 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 109.529 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.479 ' HA ' ' HD3' ' B' ' 87' ' ' ARG . 1.0 OUTLIER -75.04 130.89 79.79 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.363 -0.836 . . . . 0.0 109.131 179.902 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.496 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.1 Cg_endo -78.19 79.33 3.31 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.25 1.967 . . . . 0.0 109.342 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.813 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -96.91 139.52 32.82 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.761 -179.359 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.568 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -135.36 147.47 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.467 -0.771 . . . . 0.0 109.965 -179.223 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.675 HG22 HD22 ' A' ' 19' ' ' LEU . 23.6 m -75.8 105.69 6.98 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.188 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.847 HD11 HD21 ' A' ' 33' ' ' LEU . 7.6 pt -99.06 146.4 8.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.248 -0.907 . . . . 0.0 110.642 -178.154 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.3 OUTLIER -111.57 99.51 8.25 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.296 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.875 HD13 HG11 ' A' ' 75' ' ' VAL . 4.2 mt -120.4 132.46 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.21 -0.931 . . . . 0.0 109.651 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.77 32.98 83.67 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.27 21.81 70.5 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.462 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.0 OUTLIER -117.81 174.92 5.91 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.299 -1.118 . . . . 0.0 109.213 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.675 HD22 HG22 ' A' ' 12' ' ' THR . 14.6 mt -140.02 120.2 13.79 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.236 -0.915 . . . . 0.0 110.379 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.7 mmmt -144.1 167.76 21.63 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.813 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -77.06 165.28 24.82 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.808 -1.183 . . . . 0.0 108.391 179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.694 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -142.54 119.82 11.54 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.922 -1.111 . . . . 0.0 109.817 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.608 HD21 ' O ' ' B' ' 27' ' ' GLY . 41.6 tp -88.27 93.33 9.48 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.699 -0.626 . . . . 0.0 109.647 -179.641 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 14.7 mt -43.67 97.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.06 -1.025 . . . . 0.0 109.657 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.647 ' CB ' HG23 ' A' ' 84' ' ' ILE . 27.7 t0 -100.56 81.36 2.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.89 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.641 HG23 HD13 ' A' ' 90' ' ' LEU . 1.8 m -60.74 -14.16 19.47 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.17 -0.956 . . . . 0.0 108.88 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.673 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.27 -33.68 64.53 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.28 169.44 17.29 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.196 -1.179 . . . . 0.0 110.014 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.527 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 24.1 m-20 -98.38 -17.13 19.0 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.315 -0.866 . . . . 0.0 111.206 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.565 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -137.11 -171.13 2.87 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.694 -1.254 . . . . 0.0 110.249 -179.43 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.582 HG23 HD12 ' A' ' 85' ' ' ILE . 18.6 m -104.83 90.6 3.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.212 -0.93 . . . . 0.0 110.533 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.13 174.53 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.632 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.088 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -168.8 121.84 0.82 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.83 -1.169 . . . . 0.0 110.859 -179.352 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.578 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 1.1 pt-20 -37.36 156.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.547 -0.721 . . . . 0.0 109.797 178.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.578 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.5 tm-20 -45.0 145.75 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.356 -0.84 . . . . 0.0 110.8 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 13.5 ptm -165.02 -164.97 0.83 Allowed 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -116.81 122.75 45.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.996 -1.065 . . . . 0.0 110.506 -179.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 1.047 HD23 ' CD1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -128.08 -173.87 0.34 Allowed Pre-proline 0 N--CA 1.496 1.839 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 179.503 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.624 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -78.05 -163.3 0.21 Allowed 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 122.171 1.914 . . . . 0.0 111.371 -178.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.72 39.28 2.94 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -179.072 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -128.86 61.52 1.51 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.622 -0.928 . . . . 0.0 108.622 179.438 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.641 ' CD1' ' CE2' ' A' ' 59' ' ' TYR . 6.3 p-90 -132.9 -177.55 4.55 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.683 0.754 . . . . 0.0 110.47 -178.719 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -137.74 138.51 24.22 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.23 138.81 18.27 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.131 1.887 . . . . 0.0 110.85 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.419 ' O ' ' HG2' ' A' ' 46' ' ' MET . 1.6 ptpt -156.56 -169.47 3.02 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.419 ' HG2' ' O ' ' A' ' 45' ' ' LYS . 39.9 mtp -151.3 135.56 16.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 109.784 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 54' ' ' ILE . 15.3 pt -100.06 139.29 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.4 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.91 106.07 1.24 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -131.78 -123.26 2.45 Favored Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.74 -1.219 . . . . 0.0 110.308 -179.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.892 HG21 HD11 ' B' ' 47' ' ' ILE . 66.0 mt -88.48 115.29 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.445 -1.032 . . . . 0.0 112.45 -177.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.66 -32.96 5.45 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.361 -1.095 . . . . 0.0 110.361 178.081 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.87 -160.27 28.74 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 4.6 m-85 -110.86 124.55 52.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.32 -1.106 . . . . 0.0 109.491 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 47' ' ' ILE . 2.2 pt -102.26 174.03 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 108.721 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.7 OUTLIER -107.38 135.46 48.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.163 -0.961 . . . . 0.0 108.935 179.447 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.451 HG12 ' HA3' ' A' ' 78' ' ' GLY . 15.2 m -143.19 152.83 16.73 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 121.228 -0.92 . . . . 0.0 109.865 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 3.6 mtt85 -92.92 167.02 12.11 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -129.2 100.77 5.73 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.01 -1.056 . . . . 0.0 110.004 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 1.047 ' CD1' HD23 ' A' ' 38' ' ' LEU . 81.8 m-85 -100.25 123.36 44.39 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.356 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -98.73 130.75 45.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.009 . . . . 0.0 109.753 -179.669 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.549 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 83.14 59.75 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.389 0.614 . . . . 0.0 109.802 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.755 HG21 HG21 ' A' ' 75' ' ' VAL . 5.3 mm -110.57 117.4 54.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.729 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -69.86 86.82 0.52 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 111.093 -178.459 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.703 HG12 HD12 ' A' ' 66' ' ' ILE . 6.1 tt -88.87 118.21 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 69' ' ' HIS . 6.0 tt0 -88.22 112.51 22.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.033 -1.042 . . . . 0.0 108.936 -178.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.703 HD12 HG12 ' A' ' 64' ' ' ILE . 0.4 OUTLIER -103.92 118.86 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.348 -0.845 . . . . 0.0 109.052 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER 61.67 40.32 13.36 Favored 'General case' 0 C--N 1.293 -1.877 0 O-C-N 121.618 -0.676 . . . . 0.0 109.873 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.07 8.44 61.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.484 ' O ' ' HG2' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -101.26 155.99 17.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.176 -1.191 . . . . 0.0 108.989 179.781 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.643 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -89.44 126.63 35.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.017 -1.052 . . . . 0.0 109.754 -179.814 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.89 102.44 3.27 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.313 -0.867 . . . . 0.0 109.441 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.729 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -81.07 158.89 4.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.028 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.969 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.45 172.81 43.23 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.48 -1.819 . . . . 0.0 111.637 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 57.2 m -84.86 111.66 19.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.665 -0.903 . . . . 0.0 109.938 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.088 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -100.39 144.53 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.637 -0.665 . . . . 0.0 109.601 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -116.07 127.38 54.83 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.578 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 97.3 t -111.03 116.13 51.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 120.956 -1.09 . . . . 0.0 110.766 -178.469 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -151.18 -161.93 10.37 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.544 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.16 42.78 1.4 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.443 2.095 . . . . 0.0 110.327 179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.578 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.4 t -88.38 130.51 45.44 Favored Pre-proline 0 C--N 1.303 -1.435 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.469 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.27 21.05 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.417 2.078 . . . . 0.0 111.546 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.516 ' CG1' HD11 ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.07 159.54 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.881 -1.137 . . . . 0.0 109.81 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 33.5 m-80 -90.53 136.72 32.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.715 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.1 mm -125.75 122.79 62.99 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 O-C-N 119.955 -1.716 . . . . 0.0 111.498 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.694 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.34 95.59 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.501 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -79.75 -159.24 17.26 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.59 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -67.77 -37.04 81.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 -179.383 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.957 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.8 p-10 -45.28 -28.97 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.89 -1.131 . . . . 0.0 109.743 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.969 HD21 ' HA3' ' A' ' 73' ' ' GLY . 2.6 mm? -106.88 -27.64 10.59 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.92 -1.113 . . . . 0.0 109.428 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.641 HD13 HG23 ' A' ' 26' ' ' THR . 12.7 mt -70.32 -6.15 33.03 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.59 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.8 p -101.87 -20.0 15.06 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.18 -0.95 . . . . 0.0 108.66 178.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -76.34 -40.22 51.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.404 -0.81 . . . . 0.0 109.112 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.974 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -87.44 -1.74 8.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.375 -0.828 . . . . 0.0 109.07 179.324 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.73 29.84 50.53 Favored Glycine 0 N--CA 1.497 2.741 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -57.59 149.13 22.14 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.2 -1.177 . . . . 0.0 111.225 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.8 p -150.44 126.03 10.25 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' B' ' 97' ' ' LEU . 5.2 mp -84.89 109.02 17.82 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.223 -0.923 . . . . 0.0 108.671 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 40.9 m-20 -108.36 121.72 45.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.164 -179.333 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.606 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.474 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.504 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 109.97 -0.819 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.0 OUTLIER -83.34 144.74 29.47 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 105.985 -1.858 . . . . 0.0 105.985 177.354 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.502 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 92.8 t -148.95 114.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 117.56 -1.656 . . . . 0.0 111.413 -177.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.414 ' O ' ' N ' ' B' ' 6' ' ' TRP . 2.6 p -111.64 -70.94 0.78 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.303 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.1 OUTLIER 45.44 19.41 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.668 -0.645 . . . . 0.0 111.188 178.722 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.585 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 12.1 m95 19.3 44.8 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 120.948 0.404 . . . . 0.0 111.48 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' B' ' 5' ' ' LEU . 12.9 mm100 -156.56 -156.66 0.64 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.441 -0.787 . . . . 0.0 109.405 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 117.22 61.81 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.927 -1.108 . . . . 0.0 109.543 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -79.19 71.55 6.98 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.142 1.895 . . . . 0.0 109.431 179.076 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.623 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -91.23 159.83 15.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.864 . . . . 0.0 110.304 -178.986 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.559 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.8 OUTLIER -150.24 135.85 11.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.452 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.871 HG22 HD22 ' B' ' 19' ' ' LEU . 4.9 m -65.77 107.91 1.94 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.907 HG22 HG13 ' B' ' 66' ' ' ILE . 1.4 pt -103.88 150.31 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 119.15 -1.02 . . . . 0.0 111.007 -178.337 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.446 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 6.4 tttt -122.42 106.71 11.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.464 -0.772 . . . . 0.0 108.921 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 1.0 HD13 HG11 ' B' ' 75' ' ' VAL . 38.0 mt -115.11 143.04 25.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.052 -1.03 . . . . 0.0 109.242 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.81 -89.91 0.09 OUTLIER Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -160.32 32.79 0.41 Allowed Glycine 0 N--CA 1.485 1.935 0 N-CA-C 108.406 -1.878 . . . . 0.0 108.406 179.188 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 -134.97 171.66 14.1 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.671 -0.899 . . . . 0.0 109.34 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.871 HD22 HG22 ' B' ' 12' ' ' THR . 5.6 mt -120.83 137.59 54.48 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.481 ' HB3' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -150.59 144.18 25.11 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.375 -0.828 . . . . 0.0 108.798 -178.951 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.623 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.1 mt-10 -78.24 121.98 25.1 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.256 -0.903 . . . . 0.0 108.648 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.602 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.34 131.0 52.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 111.731 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.673 HD21 ' O ' ' A' ' 27' ' ' GLY . 33.7 tp -88.11 96.95 10.72 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.453 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' B' ' 9' ' ' PRO . 18.9 mt -42.3 107.31 0.08 Allowed 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.683 ' OD2' ' HB2' ' B' ' 28' ' ' ALA . 41.7 t0 -116.65 92.51 3.89 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.376 -0.827 . . . . 0.0 111.642 -177.645 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.528 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -75.89 -0.78 22.55 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.903 -1.123 . . . . 0.0 108.592 177.729 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.608 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -89.37 -28.66 19.18 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -179.739 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 28' ' ' ALA . . . . . 0.683 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -78.79 170.67 16.3 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.89 -1.359 . . . . 0.0 109.443 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -100.24 -20.44 15.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.178 -0.951 . . . . 0.0 110.01 -179.494 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.608 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -142.39 -175.91 4.64 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.075 -1.016 . . . . 0.0 109.764 179.875 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.79 HG23 HD12 ' B' ' 85' ' ' ILE . 4.2 m -100.36 86.19 3.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 110.558 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.042 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.75 157.62 6.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.042 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.9 OUTLIER -153.06 128.66 10.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.918 -1.114 . . . . 0.0 110.688 -178.12 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.641 ' HA ' HG22 ' B' ' 80' ' ' THR . 1.1 pt-20 -43.37 162.34 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 109.11 179.396 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.495 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.8 mt-10 -48.92 139.83 9.65 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.225 -0.922 . . . . 0.0 110.126 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.6 OUTLIER -163.0 -171.09 2.54 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.519 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -111.99 116.15 30.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.877 -1.139 . . . . 0.0 110.236 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.706 HD12 HG21 ' B' ' 77' ' ' VAL . 3.4 mt -113.52 167.93 8.61 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.245 -0.909 . . . . 0.0 109.05 179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.574 ' HD2' ' CD2' ' B' ' 38' ' ' LEU . 34.4 Cg_endo -77.37 70.64 6.71 Favored 'Trans proline' 0 C--N 1.312 -1.367 0 C-N-CA 122.783 2.322 . . . . 0.0 112.183 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.13 -158.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 O-C-N 121.607 -0.683 . . . . 0.0 111.631 178.501 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 51.71 90.65 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.633 -0.922 . . . . 0.0 109.476 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CD2' ' B' ' 59' ' ' TYR . 44.6 p-90 -161.0 172.91 16.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.471 -0.768 . . . . 0.0 109.906 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.466 ' HB2' ' HB3' ' B' ' 58' ' ' GLN . 0.2 OUTLIER -135.46 128.76 18.33 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.903 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.51 141.06 19.62 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.261 1.974 . . . . 0.0 110.966 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.11 -167.56 1.97 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.452 -0.78 . . . . 0.0 109.083 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 46' ' ' MET . . . . . . . . . . . . . 81.7 mtp -143.28 133.69 24.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.329 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.892 HD11 HG21 ' A' ' 50' ' ' ILE . 35.0 pt -100.8 152.63 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.061 -1.024 . . . . 0.0 108.783 179.146 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.51 102.81 0.98 Allowed Glycine 0 N--CA 1.489 2.167 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.49 -131.2 3.44 Favored Glycine 0 N--CA 1.482 1.708 0 C-N-CA 119.447 -1.359 . . . . 0.0 111.123 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.588 HG21 HD12 ' A' ' 47' ' ' ILE . 51.6 mt -88.51 126.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 122.008 -0.701 . . . . 0.0 112.515 -177.42 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 92.45 5.53 65.11 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 121.06 -166.13 14.07 Favored Glycine 0 N--CA 1.492 2.403 0 O-C-N 120.917 -1.343 . . . . 0.0 110.046 179.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.2 OUTLIER -109.42 135.43 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.377 -1.072 . . . . 0.0 109.57 -179.747 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.539 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.3 pt -104.82 -179.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 121.078 -1.014 . . . . 0.0 109.104 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.493 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 31.8 mttt -114.84 140.56 48.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.161 -0.962 . . . . 0.0 108.955 179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 33.8 m -149.66 176.55 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.001 -1.062 . . . . 0.0 110.262 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.558 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 1.0 OUTLIER -111.3 172.92 6.6 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.981 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.466 ' HB3' ' HB2' ' B' ' 43' ' ' LYS . 45.2 tt0 -128.82 87.92 2.65 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.152 -0.968 . . . . 0.0 110.198 -179.573 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.653 ' HB3' HD11 ' B' ' 62' ' ' ILE . 72.7 m-85 -89.77 93.98 9.65 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 179.116 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.498 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 3.8 m-20 -80.93 135.37 35.88 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.055 -1.028 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 7.6 mt-30 78.43 62.72 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.672 0.748 . . . . 0.0 109.866 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.653 HD11 ' HB3' ' B' ' 59' ' ' TYR . 35.1 mm -117.56 123.67 72.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.854 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.8 tm? -68.42 84.35 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.378 -0.827 . . . . 0.0 110.672 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.829 HG12 HD12 ' B' ' 66' ' ' ILE . 7.1 tt -87.55 118.39 33.31 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.586 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.3 tt0 -90.95 118.47 30.36 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.141 -0.975 . . . . 0.0 109.68 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.907 HG13 HG22 ' B' ' 13' ' ' ILE . 0.3 OUTLIER -120.14 128.95 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.16 -0.962 . . . . 0.0 108.908 179.753 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 85.5 m 57.05 51.41 10.51 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.495 -0.753 . . . . 0.0 109.817 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.49 19.45 13.12 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.467 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.8 m-70 -112.23 141.55 45.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.152 -1.205 . . . . 0.0 109.425 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.33 130.77 34.77 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.234 -0.917 . . . . 0.0 109.17 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.503 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -149.98 141.85 23.78 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.559 -0.713 . . . . 0.0 109.134 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.534 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -115.18 158.88 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.783 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.472 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.62 -159.46 26.28 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.687 -1.721 . . . . 0.0 111.454 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.1 m -101.33 109.01 20.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.473 -1.016 . . . . 0.0 110.136 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.0 HG11 HD13 ' B' ' 15' ' ' ILE . 1.5 t -104.06 108.73 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.225 179.449 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.618 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.1 mp -82.57 137.23 34.62 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.33 -0.856 . . . . 0.0 108.842 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.706 HG21 HD12 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -115.15 129.69 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.265 -0.897 . . . . 0.0 109.94 -179.342 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -166.07 -172.21 33.15 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.493 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -80.56 41.34 1.12 Allowed 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.53 2.153 . . . . 0.0 110.85 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.641 HG22 ' HA ' ' B' ' 34' ' ' GLU . 5.9 t -80.93 143.67 53.92 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.711 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -77.51 12.47 1.86 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.39 2.06 . . . . 0.0 111.296 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.711 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.61 161.55 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.835 -1.166 . . . . 0.0 110.486 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.596 ' ND2' ' N ' ' B' ' 83' ' ' ASN . 0.2 OUTLIER -98.36 92.63 5.78 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.774 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.669 HG23 ' CB ' ' B' ' 25' ' ' ASP . 2.7 mt -93.39 135.52 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.951 -1.093 . . . . 0.0 113.327 -175.266 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.79 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -101.3 108.27 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.984 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.704 ' O ' HD22 ' B' ' 90' ' ' LEU . . . -95.95 173.37 30.48 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.871 -1.291 . . . . 0.0 109.871 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' B' ' 26' ' ' THR . 8.8 mtm-85 -35.91 -35.02 0.06 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.487 -1.008 . . . . 0.0 112.19 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.904 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -49.14 -43.43 41.69 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.231 -1.543 . . . . 0.0 110.395 -178.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.904 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.6 OUTLIER -93.64 -30.16 15.08 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.096 -1.003 . . . . 0.0 111.168 -178.931 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.704 HD22 ' O ' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -59.5 -36.33 75.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.532 -1.355 . . . . 0.0 108.719 -179.807 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.407 ' CG2' ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -71.44 -20.7 62.07 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.879 -1.138 . . . . 0.0 109.713 -179.534 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.44 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 11.8 mm-40 -75.11 -38.87 60.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.139 -0.976 . . . . 0.0 109.018 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.62 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -84.81 -8.5 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.181 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 80.51 29.56 43.68 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 178.842 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.583 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.83 135.38 57.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.105 -1.232 . . . . 0.0 109.824 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.719 HG22 HG23 ' A' ' 4' ' ' THR . 73.2 p -131.86 125.64 32.28 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' A' ' 97' ' ' LEU . 1.2 mp -84.86 92.95 8.4 Favored 'General case' 0 C--N 1.293 -1.861 0 O-C-N 121.335 -0.853 . . . . 0.0 109.954 -178.611 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.549 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 7.4 m-20 -105.14 138.8 40.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.577 -0.702 . . . . 0.0 109.962 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.974 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.338 179.494 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.512 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 3.4 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.292 -0.695 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.92 129.07 34.94 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 178.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.626 HG12 ' HB3' ' A' ' 9' ' ' PRO . 35.8 t -124.09 111.37 28.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 120.74 -1.225 . . . . 0.0 110.595 -178.333 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.506 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -119.28 -72.67 0.68 Allowed 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.228 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.6 mm? 42.15 29.21 0.13 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.426 -0.797 . . . . 0.0 110.125 179.165 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 20.9 m0 18.61 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.385 0 CA-C-O 121.249 0.547 . . . . 0.0 111.742 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.5 mt-30 -165.57 -165.28 0.82 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.372 -0.83 . . . . 0.0 108.805 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 82.7 mtm180 -64.25 117.08 33.26 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.078 -1.014 . . . . 0.0 109.235 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.626 ' HB3' HG12 ' A' ' 3' ' ' VAL . 34.8 Cg_endo -76.76 75.49 4.45 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 109.974 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.575 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -79.49 160.04 26.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.883 . . . . 0.0 109.58 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 24' ' ' LEU . 2.1 m -148.73 139.1 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.282 -0.887 . . . . 0.0 110.386 -179.076 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.891 HG22 HD22 ' A' ' 19' ' ' LEU . 54.9 m -70.3 98.3 1.37 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.126 -0.983 . . . . 0.0 108.392 178.58 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.834 ' O ' HD23 ' A' ' 19' ' ' LEU . 19.7 pt -92.12 150.07 3.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.453 -0.78 . . . . 0.0 109.901 -179.264 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 1.014 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -112.07 94.98 5.21 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.478 -0.764 . . . . 0.0 109.003 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.861 HD12 HD22 ' A' ' 33' ' ' LEU . 6.0 mt -114.35 128.17 71.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.357 -0.84 . . . . 0.0 109.561 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.2 30.53 78.04 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.71 9.92 66.44 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.5 mm100 -108.02 175.86 5.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -1.147 . . . . 0.0 108.935 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 1.014 HD21 ' HD3' ' A' ' 14' ' ' LYS . 20.1 mt -142.82 121.63 12.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.105 -0.997 . . . . 0.0 110.347 -179.417 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 3.2 mmtt -140.06 160.58 39.6 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.155 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.6 mp0 -78.86 123.97 27.77 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.937 -1.102 . . . . 0.0 108.461 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.689 ' HB2' HD13 ' A' ' 13' ' ' ILE . . . -108.16 130.51 55.12 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 110.673 -178.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.763 HD21 ' O ' ' B' ' 27' ' ' GLY . 42.9 tp -80.23 94.97 6.16 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.855 -0.528 . . . . 0.0 109.879 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.62 HD12 ' HB2' ' A' ' 9' ' ' PRO . 94.4 mt -46.71 95.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.324 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.878 ' HB2' HG23 ' A' ' 84' ' ' ILE . 34.6 t0 -99.96 89.12 3.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.317 -0.865 . . . . 0.0 110.837 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.461 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 15.7 m -65.07 -16.63 63.67 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.572 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.05 -34.59 64.78 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.66 161.37 23.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.156 -1.203 . . . . 0.0 109.071 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.429 ' HA ' ' HB2' ' A' ' 87' ' ' ARG . 34.6 m-20 -99.37 -12.54 20.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.983 -179.589 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 29.4 m-20 -137.35 173.01 12.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.024 -1.047 . . . . 0.0 110.084 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.856 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -94.07 107.44 19.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.083 -1.011 . . . . 0.0 110.194 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.842 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -100.26 117.3 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.304 -0.873 . . . . 0.0 109.022 179.441 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.861 HD22 HD12 ' A' ' 15' ' ' ILE . 2.2 mp -107.56 119.28 38.98 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.239 -0.913 . . . . 0.0 110.569 -179.015 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.711 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.4 pt-20 -42.73 168.41 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.328 -0.857 . . . . 0.0 109.393 178.556 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.9 OUTLIER -43.46 145.99 0.54 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.212 -0.93 . . . . 0.0 111.03 -179.128 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.435 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER 178.68 163.05 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -81.0 103.3 10.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.871 -1.143 . . . . 0.0 110.151 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.732 HD12 ' HD2' ' A' ' 39' ' ' PRO . 5.1 tp -121.8 104.1 39.54 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.857 . . . . 0.0 109.199 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.732 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.3 Cg_endo -77.41 146.89 25.05 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.542 2.161 . . . . 0.0 110.861 -179.695 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 134.45 172.72 12.9 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -77.45 127.69 32.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -1.233 . . . . 0.0 108.808 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 66.6 p-90 -130.26 172.91 11.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.775 -178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.408 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 2.1 mmtm -137.75 147.24 56.19 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.42 131.46 12.71 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.838 1.692 . . . . 0.0 110.289 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.627 ' NZ ' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -162.05 136.85 7.02 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.696 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -112.64 146.32 38.84 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.661 -1.275 . . . . 0.0 109.637 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.755 HD13 HG21 ' A' ' 32' ' ' VAL . 12.6 pt -101.0 140.27 20.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.517 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.66 104.61 1.11 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.49 -119.45 2.29 Favored Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.576 -1.297 . . . . 0.0 110.875 -179.05 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.838 HG23 HD13 ' B' ' 54' ' ' ILE . 49.9 mt -85.96 119.79 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.817 -0.814 . . . . 0.0 112.66 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.437 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 104.21 -53.38 0.7 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.355 -0.926 . . . . 0.0 110.795 178.038 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.435 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . -177.63 -157.41 18.45 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.234 -179.456 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -117.3 126.73 53.2 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.484 -1.009 . . . . 0.0 109.875 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.734 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.9 pp -105.08 160.55 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.303 -0.873 . . . . 0.0 109.085 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.561 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -103.02 146.6 28.11 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.046 -1.034 . . . . 0.0 110.115 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.768 HG12 ' HA3' ' A' ' 78' ' ' GLY . 3.1 m -149.39 -177.9 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.18 -0.95 . . . . 0.0 109.328 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.521 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 7.4 mmt85 -123.21 101.75 7.56 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.573 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 10.4 tt0 -73.18 106.17 4.91 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.4 -0.812 . . . . 0.0 111.144 -178.017 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 42' ' ' TRP . 41.4 m-85 -89.47 130.75 35.76 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.543 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.0 m-20 -100.82 121.11 41.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.7 -1.25 . . . . 0.0 109.976 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.8 OUTLIER 85.15 57.07 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.206 0.527 . . . . 0.0 110.048 179.538 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.634 HG21 HG23 ' A' ' 15' ' ' ILE . 16.4 mm -105.54 119.95 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -0.923 . . . . 0.0 108.919 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.881 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.4 tm? -68.72 98.59 0.92 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.854 -178.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.739 HG22 ' O ' ' A' ' 71' ' ' ALA . 7.9 tt -102.83 119.36 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.329 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.58 116.84 28.03 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.809 -1.182 . . . . 0.0 109.424 -178.915 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.526 HG21 HD13 ' A' ' 93' ' ' ILE . 0.4 OUTLIER -109.25 129.07 64.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.3 -0.875 . . . . 0.0 109.053 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.512 ' HB3' ' HG3' ' A' ' 1' ' ' PRO . 1.7 m 38.04 52.15 1.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.459 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 63.28 48.86 75.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.464 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.478 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 92.9 m-70 -145.15 115.19 7.43 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -1.156 . . . . 0.0 109.431 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.596 ' CG ' HD21 ' A' ' 63' ' ' LEU . 19.6 ttpt -60.97 129.25 40.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.739 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.28 99.65 2.23 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.392 -0.818 . . . . 0.0 109.874 -179.093 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.55 160.43 4.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 120.866 -1.146 . . . . 0.0 108.533 178.981 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.641 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.99 177.15 47.37 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 118.777 -1.678 . . . . 0.0 111.59 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.573 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 17.7 m -89.03 111.77 22.57 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.815 -0.815 . . . . 0.0 110.549 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.976 ' C ' HD12 ' A' ' 76' ' ' LEU . 1.4 t -101.05 161.33 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.465 -0.772 . . . . 0.0 109.733 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.976 HD12 ' C ' ' A' ' 75' ' ' VAL . 6.0 mp -130.55 105.0 7.55 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.064 -1.022 . . . . 0.0 108.405 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 61.7 t -89.61 117.75 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.792 -1.193 . . . . 0.0 109.973 -179.477 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.768 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.5 -166.97 17.08 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.561 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -82.75 39.02 0.78 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.479 2.119 . . . . 0.0 111.085 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.713 HG23 ' H ' ' A' ' 82' ' ' VAL . 0.8 OUTLIER -85.62 137.57 36.18 Favored Pre-proline 0 N--CA 1.49 1.525 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 178.174 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.94 23.04 0.58 Allowed 'Trans proline' 0 C--N 1.303 -1.859 0 C-N-CA 122.187 1.924 . . . . 0.0 111.689 -178.363 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.713 ' H ' HG23 ' A' ' 80' ' ' THR . 0.5 OUTLIER -162.94 140.93 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 120.621 -1.299 . . . . 0.0 111.899 -178.983 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.592 ' O ' ' CG1' ' A' ' 84' ' ' ILE . 75.1 m-20 -80.54 154.72 27.33 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.182 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.878 HG23 ' HB2' ' A' ' 25' ' ' ASP . 20.5 mt -155.63 134.04 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 117.065 -1.854 . . . . 0.0 112.443 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.565 ' HB ' HD23 ' A' ' 24' ' ' LEU . 9.5 mm -99.27 104.34 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 178.132 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.13 -161.48 35.41 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.747 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.474 ' O ' ' OG1' ' A' ' 91' ' ' THR . 1.0 OUTLIER -63.73 -35.48 80.72 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.691 -0.888 . . . . 0.0 109.663 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.921 ' ND2' HD23 ' A' ' 89' ' ' LEU . 18.6 p-10 -51.26 -20.88 1.8 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.987 -1.07 . . . . 0.0 110.248 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.921 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -113.03 -29.7 7.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.727 -1.233 . . . . 0.0 110.265 -179.448 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.461 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 21.4 mt -66.18 -11.6 50.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.994 -1.066 . . . . 0.0 108.957 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -101.38 -10.05 20.59 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.064 -1.023 . . . . 0.0 109.513 179.848 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.409 ' NE2' ' O ' ' A' ' 72' ' ' ILE . 4.9 mm100 -90.28 -41.19 11.69 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.264 -0.897 . . . . 0.0 109.85 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.708 HD12 ' CD2' ' B' ' 99' ' ' PHE . 2.2 pt -89.72 2.35 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.118 -0.989 . . . . 0.0 109.065 179.371 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 65.84 54.48 24.86 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -82.75 137.1 34.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.055 -1.262 . . . . 0.0 109.543 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.405 HG22 ' HA ' ' B' ' 4' ' ' THR . 16.4 p -122.78 136.95 55.03 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.223 -0.923 . . . . 0.0 109.117 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' B' ' 97' ' ' LEU . 5.3 mp -97.36 96.67 8.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.896 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 11.4 m-20 -101.02 125.17 47.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.038 -1.039 . . . . 0.0 109.251 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.691 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.296 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.678 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -130.74 136.69 48.99 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 8.0 t -132.17 136.24 56.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 120.886 -1.134 . . . . 0.0 109.653 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.673 ' O ' HD23 ' B' ' 5' ' ' LEU . 6.0 p -69.38 -93.14 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.394 -0.816 . . . . 0.0 109.662 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.673 HD23 ' O ' ' B' ' 4' ' ' THR . 0.2 OUTLIER 158.81 -7.44 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.836 -0.54 . . . . 0.0 110.72 179.542 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -50.53 -19.27 0.84 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.667 -1.271 . . . . 0.0 110.535 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.41 -175.92 4.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.806 -1.184 . . . . 0.0 109.9 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.05 130.33 91.49 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.474 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -79.66 68.16 8.38 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.425 2.083 . . . . 0.0 109.471 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.79 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -87.21 156.48 19.65 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.167 -0.958 . . . . 0.0 109.977 -179.104 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.897 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -147.33 138.37 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.392 -0.817 . . . . 0.0 109.662 -179.627 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.404 HG22 ' HB3' ' B' ' 19' ' ' LEU . 1.5 m -71.53 90.68 1.02 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.89 -1.131 . . . . 0.0 108.287 178.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.929 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -80.29 150.2 4.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.952 -179.251 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 10.6 tttm -121.75 104.42 9.58 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.366 -0.834 . . . . 0.0 109.403 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.962 HD13 HG11 ' B' ' 75' ' ' VAL . 4.8 mt -117.13 143.21 28.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.24 -90.29 0.05 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.946 -1.661 . . . . 0.0 108.946 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 17' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -158.35 38.67 0.52 Allowed Glycine 0 N--CA 1.486 1.97 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 179.286 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -137.46 166.91 22.73 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.67 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.514 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 17.5 mt -132.23 122.12 24.73 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.431 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -134.89 155.78 50.09 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.035 -1.041 . . . . 0.0 109.9 -178.961 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.79 ' HB3' HD22 ' B' ' 10' ' ' LEU . 5.5 mm-40 -78.98 110.42 14.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 178.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -98.63 154.75 17.71 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 110.341 -178.395 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.572 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -101.85 101.18 11.58 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.668 -0.645 . . . . 0.0 109.751 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.681 HD13 ' HE2' ' A' ' 99' ' ' PHE . 19.6 mt -46.23 99.57 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.32 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.671 ' CB ' HG23 ' B' ' 84' ' ' ILE . 44.4 t0 -107.48 96.08 6.15 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.291 -0.88 . . . . 0.0 111.027 -178.225 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.624 ' HA ' HD21 ' B' ' 90' ' ' LEU . 0.7 OUTLIER -78.97 3.22 17.77 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.086 -1.009 . . . . 0.0 109.188 178.599 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.763 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -95.69 -18.62 31.97 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 28' ' ' ALA . . . . . 0.517 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -85.78 170.83 12.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.019 -1.283 . . . . 0.0 109.711 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.453 ' HA ' ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER -100.67 -20.06 15.79 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.186 -0.946 . . . . 0.0 110.797 -178.88 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.51 ' OD1' ' HB ' ' B' ' 74' ' ' THR . 0.2 OUTLIER -137.99 -163.11 1.39 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.803 -1.186 . . . . 0.0 109.851 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.534 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 17.8 m -109.88 86.6 2.33 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.972 -1.08 . . . . 0.0 110.538 -178.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.02 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -69.04 175.39 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.825 -1.172 . . . . 0.0 108.157 179.08 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.02 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.4 116.94 0.51 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.111 -0.993 . . . . 0.0 109.804 -178.911 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.2 pt-20 -39.58 160.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.465 -0.772 . . . . 0.0 109.515 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.3 OUTLIER -38.31 139.81 0.35 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.728 0.775 . . . . 0.0 110.699 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -168.53 167.69 11.47 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.761 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 28.8 t -100.63 125.78 47.07 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.789 -1.194 . . . . 0.0 111.256 -178.762 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.603 ' HB2' ' CZ ' ' B' ' 59' ' ' TYR . 3.6 mm? -117.09 171.96 4.38 Favored Pre-proline 0 N--CA 1.493 1.696 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.544 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.3 Cg_endo -80.57 59.91 7.64 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.385 2.057 . . . . 0.0 111.38 -179.493 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 40.21 -158.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 3.0 mmp_? 58.49 68.22 0.85 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.443 -1.034 . . . . 0.0 109.313 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.62 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 22.8 p-90 -144.16 -167.44 2.61 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.44 -0.788 . . . . 0.0 109.879 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -146.44 132.08 9.31 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.57 132.12 11.95 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 121.93 1.753 . . . . 0.0 110.602 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -161.33 -162.24 0.88 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.421 ' HB3' ' HA ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -152.24 146.33 25.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.992 -1.068 . . . . 0.0 109.361 178.743 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.73 HD11 HD11 ' B' ' 54' ' ' ILE . 1.1 pt -96.33 155.83 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.258 -0.901 . . . . 0.0 108.886 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.663 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.09 130.7 8.69 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -158.02 -125.42 0.83 Allowed Glycine 0 N--CA 1.482 1.76 0 C-N-CA 118.949 -1.596 . . . . 0.0 111.338 -179.196 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.51 HG23 HG12 ' A' ' 54' ' ' ILE . 19.0 mt -88.96 126.68 41.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.937 -0.743 . . . . 0.0 112.836 -177.271 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.435 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 90.48 -28.3 7.73 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 178.011 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.427 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 157.76 -159.24 29.74 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.169 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.663 ' CD2' ' CA ' ' B' ' 48' ' ' GLY . 1.5 m-85 -120.49 132.07 55.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.654 -0.909 . . . . 0.0 109.627 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.838 HD13 HG23 ' A' ' 50' ' ' ILE . 35.4 pt -103.9 162.84 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 108.983 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 13.0 mttt -93.3 154.73 17.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.088 -1.007 . . . . 0.0 109.771 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.597 HG12 ' HA3' ' B' ' 78' ' ' GLY . 6.4 m -151.23 -168.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.055 -1.028 . . . . 0.0 110.07 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.577 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 16.7 mmt180 -129.83 89.22 2.78 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -56.48 93.62 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.271 -0.893 . . . . 0.0 110.777 -178.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.873 ' HB3' HD11 ' B' ' 62' ' ' ILE . 27.9 m-85 -88.71 136.04 33.2 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 177.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -114.58 138.25 50.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.712 -1.242 . . . . 0.0 111.041 -178.302 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.543 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.46 60.68 0.07 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.653 -0.654 . . . . 0.0 110.602 178.884 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.933 HG21 HG23 ' B' ' 15' ' ' ILE . 4.2 mp -118.77 118.09 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 108.856 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.841 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.8 tm? -68.26 90.13 0.34 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.237 -0.914 . . . . 0.0 110.631 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.701 ' CD1' HD11 ' B' ' 66' ' ' ILE . 2.4 tt -90.07 115.21 29.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.4 tm-20 -89.13 117.53 28.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.551 -178.586 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.929 HG13 HG22 ' B' ' 13' ' ' ILE . 1.4 mp -115.69 125.02 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.331 -0.856 . . . . 0.0 109.351 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 62.4 m 61.57 -95.06 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.518 -0.739 . . . . 0.0 109.792 179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -145.78 39.78 1.12 Allowed Glycine 0 N--CA 1.484 1.893 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 3.2 m80 -139.62 133.06 30.15 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.381 -1.07 . . . . 0.0 109.637 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.462 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -77.04 135.55 38.65 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.022 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.648 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.75 97.53 2.98 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.154 -1.018 . . . . 0.0 110.665 -179.326 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.775 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.89 140.17 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 177.988 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.838 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.77 -168.0 29.27 Favored Glycine 0 N--CA 1.485 1.96 0 C-N-CA 118.741 -1.695 . . . . 0.0 110.939 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 28.9 m -95.95 109.18 21.59 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.781 -0.835 . . . . 0.0 110.244 -179.397 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.962 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -96.61 104.97 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.321 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.7 mp -79.86 116.74 20.19 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.202 -0.936 . . . . 0.0 108.615 178.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.577 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.3 t -101.39 131.44 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.051 -1.031 . . . . 0.0 109.125 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.597 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -162.38 -165.43 19.37 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.06 -1.543 . . . . 0.0 109.905 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.539 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.93 40.67 1.01 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.753 2.302 . . . . 0.0 110.054 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' B' ' 34' ' ' GLU . 8.8 t -85.55 138.5 35.89 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 33.9 Cg_endo -78.38 14.3 1.63 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.51 2.14 . . . . 0.0 111.078 -179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.526 HG12 ' CD1' ' B' ' 84' ' ' ILE . 1.1 t -160.68 167.56 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.102 -0.999 . . . . 0.0 109.382 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.608 ' OD1' ' N ' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -101.15 144.18 30.34 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 175.816 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.697 ' CG1' HG12 ' B' ' 32' ' ' VAL . 6.8 mm -129.0 123.68 59.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 O-C-N 120.069 -1.644 . . . . 0.0 112.194 -176.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.735 HG22 ' CD1' ' B' ' 90' ' ' LEU . 4.4 mm -102.54 101.48 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.615 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -107.0 175.25 20.51 Favored Glycine 0 N--CA 1.496 2.695 0 C-N-CA 119.792 -1.194 . . . . 0.0 111.915 -177.578 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.786 ' N ' HD22 ' B' ' 90' ' ' LEU . 4.0 mtm180 -28.46 -41.44 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.376 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -178.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.991 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.8 p-10 -53.17 -41.38 65.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 120.234 -1.541 . . . . 0.0 110.661 -177.659 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.991 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.6 mm? -98.92 -18.33 17.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.172 -0.955 . . . . 0.0 110.342 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.786 HD22 ' N ' ' B' ' 87' ' ' ARG . 0.4 OUTLIER -69.51 -35.89 75.94 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.143 -0.973 . . . . 0.0 109.391 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 49.6 p -70.03 -15.27 62.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.189 -0.944 . . . . 0.0 108.965 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' B' ' 72' ' ' ILE . 26.7 mt-30 -91.63 -40.48 11.28 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.306 -0.871 . . . . 0.0 108.943 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.645 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -81.77 -2.98 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 177.088 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.01 43.29 99.63 Favored Glycine 0 N--CA 1.496 2.697 0 O-C-N 121.561 -0.712 . . . . 0.0 111.361 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.691 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -68.38 147.01 52.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.874 -1.368 . . . . 0.0 110.289 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.506 HG22 ' CG2' ' A' ' 4' ' ' THR . 14.9 p -144.61 130.78 19.54 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.339 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' A' ' 97' ' ' LEU . 8.0 mp -92.68 102.85 15.27 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 110.119 -179.195 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 8.5 m-20 -101.65 121.95 42.98 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.088 -1.007 . . . . 0.0 109.688 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.708 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 118.128 -0.939 . . . . 0.0 109.33 179.309 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.468 ' HD2' ' OXT' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.687 0 N-CA-C 110.164 -0.745 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.403 ' OE1' HG23 ' A' ' 4' ' ' THR . 0.3 OUTLIER -104.09 126.59 51.33 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.292 -0.88 . . . . 0.0 109.032 179.079 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.436 HG11 ' HB3' ' A' ' 9' ' ' PRO . 13.8 t -121.83 102.46 11.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.878 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.554 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -52.27 -84.26 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.324 -0.86 . . . . 0.0 109.953 -178.981 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.846 HD23 HG23 ' B' ' 91' ' ' THR . 31.2 tp 171.84 -25.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.259 -0.9 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 84.8 m95 -54.77 -19.36 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.07 -1.019 . . . . 0.0 108.996 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -129.51 130.53 45.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.438 -0.789 . . . . 0.0 109.513 179.594 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtt-85 -49.06 146.49 5.7 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.833 ' HB2' HD12 ' A' ' 24' ' ' LEU . 37.0 Cg_endo -79.8 47.75 2.63 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.838 2.359 . . . . 0.0 110.538 179.394 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.553 HD22 ' HB3' ' A' ' 21' ' ' GLU . 1.8 mt -80.03 144.4 33.24 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.1 -1.0 . . . . 0.0 109.276 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG22 ' A' ' 66' ' ' ILE . 1.9 m -148.99 160.15 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.366 -179.379 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.664 HG22 HD22 ' A' ' 19' ' ' LEU . 90.0 m -91.21 107.77 19.43 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.487 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.811 HG12 ' HB2' ' A' ' 22' ' ' ALA . 2.1 pt -99.18 157.97 3.67 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.275 -0.89 . . . . 0.0 110.084 -178.674 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.484 ' HE3' HD11 ' A' ' 19' ' ' LEU . 2.3 ttmt -118.16 100.81 7.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 108.913 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.796 HD13 HG21 ' A' ' 75' ' ' VAL . 1.3 mt -109.8 140.92 26.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.858 -1.151 . . . . 0.0 109.4 -179.587 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 62.96 -90.64 0.07 OUTLIER Glycine 0 N--CA 1.488 2.139 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -179.604 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.22 35.19 0.6 Allowed Glycine 0 C--N 1.294 -1.787 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.404 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.409 ' OE1' ' HB2' ' A' ' 37' ' ' SER . 8.2 mt-30 -138.99 173.78 11.2 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -1.134 . . . . 0.0 109.591 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.766 HD23 ' O ' ' A' ' 13' ' ' ILE . 18.5 mt -133.58 122.04 22.95 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.593 -0.692 . . . . 0.0 109.42 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HE3' ' SD ' ' A' ' 36' ' ' MET . 0.3 OUTLIER -135.72 -179.87 5.92 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.93 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.553 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.5 mt-10 -78.32 176.36 9.39 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 108.191 179.521 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.811 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -157.71 108.74 2.25 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 120.936 -1.102 . . . . 0.0 109.619 -179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.699 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.8 tp -85.19 93.41 8.65 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.35 -0.844 . . . . 0.0 109.078 179.786 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.833 HD12 ' HB2' ' A' ' 9' ' ' PRO . 97.8 mt -43.06 97.15 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.686 ' CB ' HG23 ' A' ' 84' ' ' ILE . 3.8 t0 -102.95 77.18 1.54 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.388 -0.82 . . . . 0.0 110.918 -178.245 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.48 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 2.2 m -54.92 -20.19 8.36 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.124 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.731 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -65.24 -44.33 93.93 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.732 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.47 155.72 40.01 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.17 -1.194 . . . . 0.0 108.86 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.68 -17.55 31.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.05 -1.032 . . . . 0.0 110.688 -179.034 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.523 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -138.42 -159.58 0.97 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.779 -1.201 . . . . 0.0 110.108 -179.532 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.83 HG22 ' CD1' ' A' ' 33' ' ' LEU . 35.3 m -114.98 91.41 3.61 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.925 -1.11 . . . . 0.0 110.602 -178.547 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.95 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -74.79 160.12 5.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.675 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -160.15 123.72 3.57 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.841 -1.162 . . . . 0.0 110.473 -178.595 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.607 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.6 OUTLIER -41.99 153.46 0.06 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.14 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.542 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -43.11 146.93 0.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.021 -1.049 . . . . 0.0 110.161 -179.55 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.458 ' HE1' ' HB ' ' A' ' 15' ' ' ILE . 21.7 ptm -162.2 -163.64 0.95 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.311 -0.868 . . . . 0.0 109.597 -179.802 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.409 ' HB2' ' OE1' ' A' ' 18' ' ' GLN . 7.4 t -101.31 87.08 3.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.433 -0.792 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.643 HD13 HG22 ' A' ' 15' ' ' ILE . 12.9 tp -127.71 97.34 30.5 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.145 -0.972 . . . . 0.0 110.134 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.04 178.31 7.34 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.497 2.131 . . . . 0.0 109.94 179.366 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.15 -173.86 16.31 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.486 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -78.93 134.86 36.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.326 -1.102 . . . . 0.0 109.239 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.605 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.9 p-90 -147.72 159.42 43.82 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -128.26 135.44 27.54 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 135.33 18.28 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 121.86 1.707 . . . . 0.0 109.968 -179.637 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.1 ptpt -155.8 -165.66 2.02 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.462 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.481 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 4.0 mtp -150.4 125.89 10.2 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.293 -0.879 . . . . 0.0 109.641 -179.624 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' B' ' 50' ' ' ILE . 1.1 pt -89.78 147.1 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.014 -1.054 . . . . 0.0 108.422 179.118 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.433 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -117.97 105.76 1.28 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -128.39 -132.34 3.54 Favored Glycine 0 N--CA 1.484 1.89 0 C-N-CA 119.459 -1.353 . . . . 0.0 111.043 -178.815 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.579 HG21 ' CD1' ' B' ' 47' ' ' ILE . 34.8 mt -83.13 121.06 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.838 -0.801 . . . . 0.0 112.537 -177.547 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.457 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 97.71 -20.48 50.46 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 178.019 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.87 -161.01 28.88 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 120.808 -1.407 . . . . 0.0 109.993 179.925 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -126.09 132.37 51.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.437 -1.037 . . . . 0.0 109.524 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.585 HD11 HD11 ' A' ' 47' ' ' ILE . 14.1 pt -104.38 175.33 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.079 -1.013 . . . . 0.0 109.412 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.481 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 3.6 mtmt -103.77 140.32 37.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.095 -1.003 . . . . 0.0 109.258 179.853 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.592 HG21 HD23 ' A' ' 76' ' ' LEU . 27.1 m -144.39 170.08 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.129 -0.982 . . . . 0.0 109.917 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.413 ' O ' ' N ' ' A' ' 59' ' ' TYR . 1.0 OUTLIER -111.21 96.76 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.057 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -55.78 93.74 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.344 -0.848 . . . . 0.0 109.704 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 5.8 m-85 -89.31 125.98 35.33 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 178.528 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.606 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 65.3 m-20 -106.38 133.8 50.5 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.792 -1.192 . . . . 0.0 110.345 -178.885 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.606 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mt-30 74.44 63.32 0.07 Allowed 'General case' 0 N--CA 1.494 1.741 0 CA-C-O 121.855 0.836 . . . . 0.0 109.904 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.584 ' HB ' HG23 ' A' ' 75' ' ' VAL . 16.0 mm -115.14 119.47 61.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 178.616 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.599 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -70.42 90.2 0.71 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.178 -0.951 . . . . 0.0 111.277 -177.919 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.708 ' CG2' HD11 ' A' ' 89' ' ' LEU . 7.3 tt -88.51 113.51 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.657 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -87.99 111.79 21.88 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.244 -0.91 . . . . 0.0 109.012 -178.282 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.549 HD13 HG22 ' A' ' 13' ' ' ILE . 1.3 mm -97.19 168.1 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.505 ' C ' ' O ' ' A' ' 66' ' ' ILE . 61.3 m -28.68 88.87 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.488 0.661 . . . . 0.0 111.219 -179.074 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.546 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 52.31 58.94 9.66 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.529 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.552 ' CD2' HG22 ' A' ' 93' ' ' ILE . 5.5 m80 -162.27 86.76 0.61 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.372 . . . . 0.0 110.42 179.496 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.566 ' HG3' HD21 ' A' ' 63' ' ' LEU . 4.4 tttm -49.04 118.54 2.69 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.621 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -141.26 108.36 5.47 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 119.416 -0.914 . . . . 0.0 110.456 -178.602 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.599 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -80.74 159.42 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.005 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.894 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 179.42 174.49 45.51 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 118.247 -1.93 . . . . 0.0 111.452 179.577 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 87.6 m -87.14 112.67 22.17 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.606 -0.938 . . . . 0.0 109.956 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.888 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -102.17 118.9 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.422 -0.799 . . . . 0.0 110.275 179.679 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.592 HD23 HG21 ' A' ' 56' ' ' VAL . 4.9 mp -87.81 105.75 17.62 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.77 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 35' ' ' GLU . 6.5 t -88.75 113.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.233 -0.917 . . . . 0.0 110.327 -178.67 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.85 -168.77 17.96 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.451 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -80.35 44.5 1.75 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.634 2.223 . . . . 0.0 111.061 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.695 HG21 HG13 ' A' ' 32' ' ' VAL . 9.7 t -82.5 141.25 45.17 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.022 -1.049 . . . . 0.0 108.637 179.241 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.674 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.7 Cg_endo -81.22 17.67 1.43 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.576 2.184 . . . . 0.0 111.163 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.674 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.2 t -161.26 163.28 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.86 -1.15 . . . . 0.0 110.333 -179.23 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 72.5 m-20 -99.18 89.37 4.22 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.686 HG23 ' CB ' ' A' ' 25' ' ' ASP . 8.2 mm -78.27 116.43 21.94 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 O-C-N 121.168 -0.957 . . . . 0.0 111.764 -176.436 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.651 HG12 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -101.63 85.99 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.225 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.64 -165.32 28.02 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.288 -0.958 . . . . 0.0 112.346 -176.397 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.552 ' HD3' ' HD3' ' B' ' 9' ' ' PRO . 27.8 mtm-85 -57.38 -39.91 77.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 122.203 -0.586 . . . . 0.0 111.481 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.929 ' ND2' HD23 ' A' ' 89' ' ' LEU . 16.3 p-10 -45.49 -24.31 0.31 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.537 -1.352 . . . . 0.0 109.63 -179.3 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.929 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -111.9 -32.48 6.59 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.892 -1.13 . . . . 0.0 110.712 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.48 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 90.1 mt -58.17 -36.58 73.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.824 -1.172 . . . . 0.0 108.841 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.4 p -75.69 -20.53 58.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.316 -0.865 . . . . 0.0 109.643 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -72.45 -40.31 67.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.863 -1.148 . . . . 0.0 108.472 179.428 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -81.65 -1.01 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.581 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 67.47 61.3 5.16 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.506 -1.838 . . . . 0.0 108.506 -179.527 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -89.77 149.27 22.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.442 -1.034 . . . . 0.0 110.003 -179.192 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.731 HG22 HG23 ' B' ' 4' ' ' THR . 49.5 p -137.73 125.43 22.36 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.028 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' B' ' 97' ' ' LEU . 4.8 mp -86.0 104.11 15.31 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.59 -0.694 . . . . 0.0 109.279 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.564 ' OD1' ' ND2' ' B' ' 98' ' ' ASN . 4.2 m120 -104.4 122.32 45.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.083 -1.011 . . . . 0.0 110.03 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.783 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.618 0 CA-C-O 117.937 -1.03 . . . . 0.0 109.25 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.478 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.626 0 N-CA-C 109.87 -0.858 . . . . 0.0 109.87 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 1.2 tt0 -84.64 134.0 34.39 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.633 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.62 HG13 HD13 ' B' ' 5' ' ' LEU . 22.2 t -133.73 137.07 53.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 120.762 -1.212 . . . . 0.0 109.9 -179.144 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.731 HG23 HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -129.99 23.84 5.3 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 178.983 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.71 HD23 ' HA ' ' B' ' 9' ' ' PRO . 1.6 mp -39.54 92.24 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.767 0.794 . . . . 0.0 109.801 -179.226 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.558 ' N ' ' O ' ' B' ' 4' ' ' THR . 4.7 m95 -44.42 -21.59 0.05 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.632 -0.667 . . . . 0.0 109.912 -179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.447 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.7 mt-30 -109.4 -158.85 0.66 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.022 -1.049 . . . . 0.0 108.599 179.122 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -59.01 119.7 40.42 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.037 -1.04 . . . . 0.0 109.469 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.71 ' HA ' HD23 ' B' ' 5' ' ' LEU . 36.6 Cg_endo -78.22 73.14 5.92 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.254 1.969 . . . . 0.0 109.798 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -82.1 163.61 21.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.184 -0.947 . . . . 0.0 109.937 -179.425 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.518 HG23 ' CG2' ' B' ' 13' ' ' ILE . 14.8 m -144.95 142.33 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.429 -0.794 . . . . 0.0 110.143 -179.697 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.744 HG22 HD22 ' B' ' 19' ' ' LEU . 2.7 m -73.97 99.09 3.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.01 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 1.3 pt -92.07 147.46 5.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.617 -178.454 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.8 tttt -114.08 94.51 4.85 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.826 HD11 HD12 ' B' ' 64' ' ' ILE . 22.3 mt -115.03 129.94 70.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.132 -0.98 . . . . 0.0 109.609 -179.429 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.05 52.99 49.08 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.442 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.35 23.57 9.01 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -119.26 170.67 8.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -1.151 . . . . 0.0 109.476 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.744 HD22 HG22 ' B' ' 12' ' ' THR . 13.8 mt -141.52 122.42 14.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.139 -0.976 . . . . 0.0 110.24 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 mttt -147.22 145.92 29.63 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.139 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 11.8 mt-10 -78.37 133.24 37.59 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.863 -1.148 . . . . 0.0 108.504 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -112.38 162.8 15.15 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.883 -179.04 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.731 HD21 ' O ' ' A' ' 27' ' ' GLY . 59.4 tp -99.7 101.52 12.72 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.837 -0.539 . . . . 0.0 110.06 -178.856 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' B' ' 9' ' ' PRO . 2.9 mt -44.98 97.37 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.214 -0.929 . . . . 0.0 108.51 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.733 ' CB ' HG23 ' B' ' 84' ' ' ILE . 10.3 t0 -100.87 95.39 6.58 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.089 -1.007 . . . . 0.0 110.863 -178.786 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.53 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -83.0 9.67 9.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.257 -0.902 . . . . 0.0 108.861 178.301 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.699 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -108.0 -14.13 17.88 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.5 170.03 9.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.111 -1.229 . . . . 0.0 109.089 179.803 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.08 -14.94 17.59 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.038 -1.039 . . . . 0.0 111.825 -178.397 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.535 ' HB3' HD11 ' B' ' 76' ' ' LEU . 14.3 m-20 -141.91 -169.33 2.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.507 -1.371 . . . . 0.0 110.639 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.779 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 38.5 m -104.48 84.75 2.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.199 -0.938 . . . . 0.0 110.475 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.659 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -78.75 112.19 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.244 -0.91 . . . . 0.0 110.387 -179.636 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.886 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.5 OUTLIER -107.76 123.17 48.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.583 -0.698 . . . . 0.0 110.176 179.895 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.736 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.0 pt-20 -43.36 164.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.943 -1.098 . . . . 0.0 108.831 178.606 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.819 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -47.74 145.03 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.996 -1.065 . . . . 0.0 110.112 -179.231 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.488 ' CG ' ' HG ' ' B' ' 38' ' ' LEU . 10.5 ptm -155.66 -165.55 2.0 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.36 -0.838 . . . . 0.0 109.135 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' B' ' 36' ' ' MET . 21.2 t -102.44 87.14 2.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.111 -0.993 . . . . 0.0 109.508 179.809 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 1.06 HD12 HG21 ' B' ' 77' ' ' VAL . 31.3 mt -112.88 163.92 16.75 Favored Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 121.246 -0.909 . . . . 0.0 109.17 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.9 Cg_endo -75.8 -166.45 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.354 2.036 . . . . 0.0 110.492 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -94.28 -152.17 29.01 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 62.97 58.71 1.45 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.888 -0.772 . . . . 0.0 109.067 -179.401 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.584 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 30.0 p-90 -134.92 175.61 9.41 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.649 -0.657 . . . . 0.0 109.746 -179.537 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.03 123.65 15.97 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.229 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.38 137.44 20.9 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.217 1.944 . . . . 0.0 111.543 -178.689 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.24 -167.29 2.72 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.105 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.51 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 54.6 mtp -145.69 131.36 18.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.94 -1.1 . . . . 0.0 110.159 -179.275 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.579 ' CD1' HG21 ' A' ' 50' ' ' ILE . 5.2 pt -97.75 149.04 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.171 -0.955 . . . . 0.0 108.694 179.08 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.06 116.94 3.49 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.27 -125.86 2.31 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.449 -1.358 . . . . 0.0 110.536 -179.431 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.732 HG21 HD12 ' A' ' 47' ' ' ILE . 66.6 mt -87.23 129.27 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.948 . . . . 0.0 112.676 -177.794 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.07 -47.37 2.68 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 178.252 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.457 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 178.87 -156.26 18.31 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.055 -179.701 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 1.5 m-85 -120.97 136.22 55.02 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.681 -0.894 . . . . 0.0 109.414 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.45 HG12 ' CG2' ' A' ' 50' ' ' ILE . 7.1 pt -107.16 173.1 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.125 -0.984 . . . . 0.0 109.102 179.219 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.551 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 9.8 mttm -110.06 145.53 36.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.028 -1.045 . . . . 0.0 109.099 179.708 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.589 HG12 ' HA3' ' B' ' 78' ' ' GLY . 30.6 m -141.48 -173.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.868 -1.145 . . . . 0.0 110.39 -179.583 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' B' ' 59' ' ' TYR . 5.2 mtt85 -129.31 90.09 2.96 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -48.76 92.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.363 -0.836 . . . . 0.0 109.97 -179.488 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.584 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 10.3 m-85 -92.93 92.14 7.73 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -79.52 140.17 37.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.147 -0.971 . . . . 0.0 110.626 -178.519 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.522 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 76.76 60.61 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.514 0.673 . . . . 0.0 110.019 179.539 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.786 ' CG2' HG23 ' B' ' 15' ' ' ILE . 6.1 mm -120.77 115.48 47.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.786 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -66.7 104.0 1.21 Allowed 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.848 -1.157 . . . . 0.0 110.73 -178.664 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.826 HD12 HD11 ' B' ' 15' ' ' ILE . 9.2 tt -106.19 112.65 40.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 177.486 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.492 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.0 tt0 -88.89 106.58 18.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.955 -1.091 . . . . 0.0 109.79 -177.951 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.75 HG13 HG22 ' B' ' 13' ' ' ILE . 1.6 mp -105.01 117.47 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.884 . . . . 0.0 109.406 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.495 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 9.7 m 58.54 57.66 3.7 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.453 -0.779 . . . . 0.0 109.916 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.56 34.48 20.29 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.636 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.495 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 61.8 m-70 -126.51 117.1 22.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.255 -1.144 . . . . 0.0 109.309 179.794 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.678 ' HG3' HD21 ' B' ' 63' ' ' LEU . 23.0 ttpt -65.38 124.82 23.27 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.452 -179.927 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.703 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -146.44 96.02 2.7 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.353 -0.842 . . . . 0.0 109.523 -179.829 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.786 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -79.14 152.46 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.048 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.56 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.07 -157.42 14.77 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 118.428 -1.844 . . . . 0.0 111.781 179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.447 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 3.4 m -110.66 104.97 13.71 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.679 -0.895 . . . . 0.0 110.001 -179.089 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.886 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -96.65 110.41 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.635 -0.666 . . . . 0.0 110.215 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.602 HD12 ' H ' ' B' ' 76' ' ' LEU . 3.8 mp -79.56 106.75 11.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 179.439 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 1.06 HG21 HD12 ' B' ' 38' ' ' LEU . 2.8 t -88.67 111.43 22.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.95 -1.094 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.589 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -141.65 -170.5 12.42 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.551 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.09 42.55 1.36 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.474 2.116 . . . . 0.0 110.648 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.736 HG22 ' HA ' ' B' ' 34' ' ' GLU . 10.0 t -88.94 139.45 29.07 Favored Pre-proline 0 N--CA 1.49 1.536 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.6 Cg_endo -80.43 18.21 1.25 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.553 2.169 . . . . 0.0 111.19 -179.313 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.669 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -161.59 163.01 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.917 -1.114 . . . . 0.0 110.008 -179.348 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.669 ' O ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -94.62 160.33 14.68 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 104.482 -2.414 . . . . 0.0 104.482 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.779 ' O ' ' HA ' ' B' ' 31' ' ' THR . 12.6 mm -144.05 95.05 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 O-C-N 120.051 -1.655 . . . . 0.0 111.054 -178.354 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 1.051 HG22 HD11 ' B' ' 90' ' ' LEU . 0.3 OUTLIER -77.71 101.41 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 178.196 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.691 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -112.99 -176.07 19.49 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.674 -177.786 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.73 ' N ' HD22 ' B' ' 90' ' ' LEU . 7.1 mtt85 -29.65 -42.16 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -178.614 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.011 ' ND2' HD23 ' B' ' 89' ' ' LEU . 4.8 p-10 -57.56 -42.64 83.41 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.124 -1.61 . . . . 0.0 110.482 -177.688 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.011 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -95.8 -10.57 28.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.299 -0.876 . . . . 0.0 109.662 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 1.051 HD11 HG22 ' B' ' 85' ' ' ILE . 1.2 mp -79.06 -32.0 44.68 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.319 -0.863 . . . . 0.0 109.186 -179.623 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.846 HG23 HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.9 -20.22 60.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.064 -1.022 . . . . 0.0 109.413 179.611 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.819 ' OE1' HD13 ' B' ' 89' ' ' LEU . 28.0 mt-30 -82.13 -41.24 20.73 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.029 -1.045 . . . . 0.0 109.03 179.562 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.783 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -82.48 -9.11 11.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.702 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.3 57.37 15.48 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 178.967 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.15 142.14 33.55 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.253 -1.145 . . . . 0.0 110.446 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.554 HG22 ' HA ' ' A' ' 4' ' ' THR . 24.3 p -129.82 126.2 37.51 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.713 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -90.53 90.43 8.0 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 109.537 -179.609 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.564 ' ND2' ' OD1' ' A' ' 98' ' ' ASN . 14.0 m-20 -95.63 127.63 41.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.684 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.13 179.297 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.73 0 N-CA-C 110.65 -0.558 . . . . 0.0 110.65 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.532 ' HG2' ' N ' ' A' ' 3' ' ' VAL . 0.1 OUTLIER -84.4 146.0 27.9 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 177.865 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.54 HG11 ' HB3' ' A' ' 9' ' ' PRO . 2.2 t -134.19 124.56 46.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 C-N-CA 118.486 -1.286 . . . . 0.0 110.091 -179.04 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -130.14 14.02 5.67 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.128 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -43.75 93.51 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 CA-C-O 121.9 0.857 . . . . 0.0 109.152 -179.301 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.538 ' N ' ' O ' ' A' ' 4' ' ' THR . 2.5 m95 -45.24 -15.15 0.02 OUTLIER 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.879 -0.513 . . . . 0.0 110.426 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.514 ' N ' ' O ' ' A' ' 5' ' ' LEU . 28.9 mt-30 -106.48 -115.65 0.26 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.62 -1.3 . . . . 0.0 108.951 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.504 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 46.3 mtp180 -111.03 136.48 20.8 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 120.406 -1.434 . . . . 0.0 110.235 -179.691 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HB3' HG11 ' A' ' 3' ' ' VAL . 38.0 Cg_endo -81.09 63.09 8.7 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.597 2.198 . . . . 0.0 109.785 178.955 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.484 HD22 ' HB3' ' A' ' 21' ' ' GLU . 2.4 mt -84.79 140.29 31.33 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.623 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.499 HG22 ' HB3' ' A' ' 22' ' ' ALA . 1.1 m -140.32 151.64 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.321 -0.862 . . . . 0.0 109.128 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.5 m -86.08 99.92 11.82 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.206 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 66' ' ' ILE . 1.9 pt -91.5 161.04 2.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.388 -0.82 . . . . 0.0 110.311 -178.178 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 1.2 tttt -117.07 97.85 6.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 109.174 179.491 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.912 ' CD1' HG21 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -113.67 126.93 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.096 -1.003 . . . . 0.0 109.463 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.63 31.02 77.33 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.733 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.7 11.36 68.91 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 91.7 mm-40 -108.01 167.53 9.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 108.901 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 35.1 mt -126.23 123.35 37.97 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.011 -1.056 . . . . 0.0 109.368 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.508 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -140.66 173.99 10.95 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.911 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.6 mt-10 -79.25 177.23 8.99 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -154.75 112.0 3.37 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 120.849 -1.157 . . . . 0.0 109.798 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 25' ' ' ASP . 13.4 tp -89.53 95.35 10.23 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.646 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.536 HD13 HD23 ' B' ' 97' ' ' LEU . 30.4 mt -43.85 98.85 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.691 ' CB ' HG23 ' A' ' 84' ' ' ILE . 5.5 t0 -105.1 73.71 1.07 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.375 -0.828 . . . . 0.0 110.999 -177.651 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.0 m -57.15 -18.33 14.74 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.861 -1.149 . . . . 0.0 108.052 178.348 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.658 ' O ' HD11 ' B' ' 23' ' ' LEU . . . -64.97 -45.34 92.66 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.71 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.66 163.48 27.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.203 -1.174 . . . . 0.0 109.328 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.43 -14.89 23.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.166 -0.958 . . . . 0.0 110.888 -179.029 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.547 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.01 -165.44 1.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.671 -1.268 . . . . 0.0 111.338 -178.972 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.747 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -102.47 88.52 3.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.487 -0.758 . . . . 0.0 110.953 -178.426 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.886 HG21 HD13 ' A' ' 47' ' ' ILE . 0.6 OUTLIER -79.38 113.38 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.013 -1.679 . . . . 0.0 107.933 178.566 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.93 HD13 ' CG1' ' A' ' 75' ' ' VAL . 1.1 mp -115.02 132.58 56.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 111.33 -177.824 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -43.39 165.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.202 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -57.05 142.72 41.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.029 -1.045 . . . . 0.0 110.238 -179.561 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.646 ' HE2' HG22 ' A' ' 15' ' ' ILE . 4.2 ptm -161.82 -161.16 0.75 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.431 -0.793 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -104.15 114.89 29.45 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.321 -0.862 . . . . 0.0 110.358 -179.427 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.878 HD23 ' CD2' ' A' ' 59' ' ' TYR . 3.1 tp -138.68 145.7 47.33 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.636 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 31.6 Cg_endo -72.28 157.11 54.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.345 2.03 . . . . 0.0 110.507 -179.461 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.525 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -49.8 -162.09 0.01 OUTLIER Glycine 0 N--CA 1.493 2.473 0 CA-C-O 121.858 0.699 . . . . 0.0 111.881 -178.475 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.525 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 75.59 50.29 0.07 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.614 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 6.9 p-90 -122.56 177.88 5.23 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-O 122.124 0.964 . . . . 0.0 111.269 -178.297 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.46 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 1.3 mtmm -139.51 118.49 8.96 Favored Pre-proline 0 C--N 1.303 -1.417 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.698 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -74.91 138.63 23.51 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.038 1.826 . . . . 0.0 110.91 -178.706 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.74 -173.21 4.0 Favored 'General case' 0 N--CA 1.49 1.528 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.901 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.5 ' CE ' ' HG3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -138.79 120.62 15.38 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.882 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 54' ' ' ILE . 3.1 pt -91.68 144.11 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.886 -1.134 . . . . 0.0 109.331 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.631 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -119.01 135.04 11.15 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 179.892 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.64 -129.5 1.06 Allowed Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.395 -179.614 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.711 HG23 HD13 ' B' ' 54' ' ' ILE . 77.6 mt -82.15 109.27 16.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.704 -0.88 . . . . 0.0 112.57 -177.951 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 111.78 -29.23 8.7 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 178.167 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.63 -161.52 29.26 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.424 179.65 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.631 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -112.02 131.97 55.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.408 -1.054 . . . . 0.0 109.931 -179.464 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 47' ' ' ILE . 16.2 pt -105.12 173.0 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.978 -1.076 . . . . 0.0 108.889 178.729 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 6.4 mttt -110.09 128.84 55.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.253 -0.904 . . . . 0.0 109.301 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.894 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.9 m -137.34 -174.61 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.101 -1.0 . . . . 0.0 109.998 -179.835 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -120.37 173.57 7.06 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.98 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.96 ' NE2' HG22 ' A' ' 74' ' ' THR . 0.0 OUTLIER -136.66 89.53 2.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.894 -1.129 . . . . 0.0 110.8 -179.528 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.878 ' CD2' HD23 ' A' ' 38' ' ' LEU . 96.5 m-85 -90.01 122.25 32.83 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.354 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -96.94 146.29 25.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.882 -1.136 . . . . 0.0 110.531 -178.914 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.601 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.9 OUTLIER 71.28 65.78 0.16 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.563 179.409 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.556 ' C ' HG12 ' A' ' 72' ' ' ILE . 13.5 mm -120.14 106.62 19.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.327 -0.858 . . . . 0.0 109.271 179.656 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.87 HD21 ' HG2' ' A' ' 70' ' ' LYS . 1.6 tm? -54.43 87.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.653 -0.654 . . . . 0.0 110.413 -178.759 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.815 HG22 ' O ' ' A' ' 71' ' ' ALA . 2.9 tt -89.68 122.09 40.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.872 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 7.1 tp10 -89.15 122.05 32.06 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.847 -1.158 . . . . 0.0 109.455 -178.69 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.854 HG13 HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -118.18 132.18 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.275 -0.89 . . . . 0.0 108.787 -179.912 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 66' ' ' ILE . 21.5 m 38.24 49.96 1.36 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.635 . . . . 0.0 110.637 179.271 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.51 47.96 78.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.511 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.46 ' O ' ' HA ' ' A' ' 65' ' ' GLU . 77.6 m-70 -142.67 137.02 29.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.291 -1.123 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.87 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -85.28 126.19 33.51 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.27 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.815 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -147.5 98.94 3.06 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.351 -0.843 . . . . 0.0 110.094 -178.794 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.601 HG23 ' HA ' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -81.73 142.71 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 120.887 -1.133 . . . . 0.0 107.992 179.068 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -160.85 -159.02 9.64 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.834 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.96 HG22 ' NE2' ' A' ' 58' ' ' GLN . 3.1 m -101.78 105.25 16.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.945 -0.738 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.93 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -103.24 163.59 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.063 -1.023 . . . . 0.0 109.534 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.553 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.2 mp -129.87 158.88 38.28 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 178.68 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.601 HG12 ' HA ' ' A' ' 35' ' ' GLU . 23.8 t -142.68 106.44 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 O-C-N 121.101 -1.0 . . . . 0.0 110.133 -179.462 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.894 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -144.86 -163.61 10.16 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.524 -1.831 . . . . 0.0 108.524 179.576 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.528 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.8 41.45 1.12 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 C-N-CA 122.374 2.049 . . . . 0.0 111.393 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.572 HG21 HG13 ' A' ' 32' ' ' VAL . 6.0 t -84.52 132.64 46.34 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.054 -1.029 . . . . 0.0 108.536 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.42 17.69 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.834 2.356 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.612 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -160.87 173.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.836 -1.165 . . . . 0.0 109.843 -179.776 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.612 ' N ' HG13 ' A' ' 82' ' ' VAL . 57.4 m-80 -102.26 139.46 37.85 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.99 -2.596 . . . . 0.0 103.99 176.217 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.747 ' O ' ' HA ' ' A' ' 31' ' ' THR . 11.7 mm -128.66 95.59 2.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 O-C-N 120.283 -1.511 . . . . 0.0 110.533 -176.428 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.64 ' HA ' HG23 ' A' ' 31' ' ' THR . 1.0 OUTLIER -78.94 90.58 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.023 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.59 -160.44 19.97 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -178.432 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.612 ' O ' HG23 ' A' ' 91' ' ' THR . 0.0 OUTLIER -64.15 -28.37 69.72 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.547 -0.972 . . . . 0.0 110.663 -179.154 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.819 ' ND2' HD23 ' A' ' 89' ' ' LEU . 1.5 p-10 -53.61 -42.71 67.99 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.94 -1.1 . . . . 0.0 110.725 -178.93 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.819 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -95.15 -24.85 16.66 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.893 -1.13 . . . . 0.0 108.874 -179.729 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 91.4 mt -69.07 -4.38 16.92 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.343 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.612 HG23 ' O ' ' A' ' 87' ' ' ARG . 36.2 p -100.82 -13.35 18.44 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.879 -1.138 . . . . 0.0 109.165 179.608 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 85.2 mm-40 -89.45 -40.99 12.33 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 0.0 109.726 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.686 HD12 ' CG ' ' B' ' 99' ' ' PHE . 10.5 pt -85.63 -0.09 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.144 -0.973 . . . . 0.0 108.98 179.525 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.88 43.74 40.38 Favored Glycine 0 N--CA 1.497 2.748 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.061 178.873 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.565 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -72.1 142.98 49.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.92 -1.341 . . . . 0.0 110.144 179.665 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.1 p -148.35 127.69 13.05 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.541 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' B' ' 97' ' ' LEU . 7.5 mp -86.55 95.86 9.89 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.269 -0.895 . . . . 0.0 109.453 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.521 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 16.9 m-20 -99.02 117.99 34.77 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.042 -1.036 . . . . 0.0 109.679 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.748 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.297 -1.676 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.319 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.503 ' HD3' ' NE2' ' B' ' 69' ' ' HIS . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.202 -0.73 . . . . 0.0 110.202 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.405 ' HG3' ' OD1' ' A' ' 98' ' ' ASN . 6.0 tt0 -83.64 139.44 32.81 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 178.151 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.589 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 2.5 t -131.23 111.05 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.456 -1.298 . . . . 0.0 110.911 -178.149 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.523 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -123.21 -65.55 1.08 Allowed 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.587 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.2 tp 36.47 26.96 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.572 178.152 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.609 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 24.1 m95 18.07 47.63 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.187 0.518 . . . . 0.0 112.172 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.587 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.47 -158.05 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.965 . . . . 0.0 109.443 -179.755 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.643 ' HB3' HD12 ' B' ' 23' ' ' LEU . 11.5 mtm180 -70.07 125.58 92.05 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.092 -1.005 . . . . 0.0 109.056 179.467 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.589 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.5 Cg_endo -79.09 70.69 7.39 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.434 2.09 . . . . 0.0 109.653 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.806 HD23 ' C ' ' B' ' 22' ' ' ALA . 7.0 mt -85.29 137.93 32.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.267 -0.896 . . . . 0.0 110.816 -178.712 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.521 HG23 ' N ' ' B' ' 12' ' ' THR . 1.7 m -141.11 168.8 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.521 ' N ' HG23 ' B' ' 11' ' ' VAL . 3.9 m -94.91 120.98 36.03 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.894 HG22 HG13 ' B' ' 66' ' ' ILE . 1.6 pt -115.09 147.45 18.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 121.168 -0.958 . . . . 0.0 110.061 -179.201 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 4.1 ttmt -106.9 101.18 10.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.403 -0.811 . . . . 0.0 109.709 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.87 HG23 ' CG2' ' B' ' 62' ' ' ILE . 39.2 mt -117.86 140.28 41.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.464 ' HA3' HD12 ' B' ' 38' ' ' LEU . . . 50.47 55.08 18.02 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 34.68 5.38 Favored Glycine 0 N--CA 1.494 2.508 0 O-C-N 121.306 -1.114 . . . . 0.0 110.428 179.552 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm100 -132.54 171.71 13.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.059 -1.26 . . . . 0.0 108.807 179.249 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.475 HD23 ' HA ' ' B' ' 19' ' ' LEU . 13.7 mt -135.5 119.11 17.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.121 -0.987 . . . . 0.0 109.964 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.478 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -135.62 178.12 7.29 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.682 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.572 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.6 mp0 -78.73 -176.06 4.73 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 179.038 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.823 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -164.82 105.07 0.81 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.786 -1.196 . . . . 0.0 110.627 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.658 HD11 ' O ' ' A' ' 27' ' ' GLY . 0.2 OUTLIER -79.9 90.04 5.31 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 108.793 179.227 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 75.7 mt -43.63 98.54 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.821 ' HB2' HG23 ' B' ' 84' ' ' ILE . 56.9 t0 -100.28 94.13 6.04 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.51 -0.744 . . . . 0.0 111.131 -178.348 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.676 ' OG1' HD21 ' A' ' 97' ' ' LEU . 16.8 m -67.56 -15.22 63.54 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.968 -1.083 . . . . 0.0 108.339 178.187 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.494 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -71.76 -40.8 57.67 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.83 149.91 29.36 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.963 -1.316 . . . . 0.0 109.662 -179.649 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.504 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 1.8 m-20 -92.01 -8.28 46.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.323 -0.861 . . . . 0.0 110.021 -179.471 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -129.52 178.3 6.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.105 -0.997 . . . . 0.0 109.943 -179.335 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.785 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.5 m -108.42 83.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.75 -1.219 . . . . 0.0 109.677 -179.515 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.023 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -70.31 157.34 6.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.044 179.667 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.082 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.8 OUTLIER -153.51 133.67 13.36 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.572 -178.007 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.537 ' N ' HG23 ' B' ' 80' ' ' THR . 3.1 tt0 -50.98 153.45 1.82 Allowed 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.868 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' B' ' 34' ' ' GLU . 3.3 tt0 -35.12 142.81 0.05 Allowed 'General case' 0 N--CA 1.495 1.812 0 CA-C-O 121.477 0.656 . . . . 0.0 110.78 -179.634 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.652 ' SD ' HD13 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -155.76 -170.38 3.4 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.403 -0.81 . . . . 0.0 109.099 179.429 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.5 t -109.68 66.4 0.63 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 111.157 -178.974 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.742 HD23 ' CG ' ' B' ' 59' ' ' TYR . 1.2 tp -87.24 158.31 52.49 Favored Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.636 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 32.1 Cg_endo -77.24 -155.37 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.927 1.751 . . . . 0.0 110.228 -179.484 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.514 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -84.47 -148.04 8.98 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.345 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.514 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.7 mmp_? 65.41 57.06 0.92 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 122.054 -0.674 . . . . 0.0 109.234 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.668 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.8 p-90 -147.15 -176.57 5.27 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.863 0.839 . . . . 0.0 110.466 -179.67 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -148.13 139.32 13.61 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.092 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.43 136.61 15.89 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.281 1.987 . . . . 0.0 111.016 -178.889 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -160.76 -163.0 0.99 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.578 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.549 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 57.7 mtp -151.13 129.24 11.84 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.111 179.642 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.698 HD11 HD11 ' B' ' 54' ' ' ILE . 4.5 pt -91.64 144.41 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 118.356 -1.338 . . . . 0.0 107.999 178.771 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.565 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -117.44 107.43 1.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -178.923 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.23 -126.8 2.72 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.534 -1.317 . . . . 0.0 110.74 -179.138 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.564 HG21 HD12 ' A' ' 47' ' ' ILE . 56.0 mt -85.87 134.56 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.851 -0.793 . . . . 0.0 113.045 -177.402 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.415 ' N ' HG23 ' A' ' 54' ' ' ILE . . . 88.03 -15.89 53.82 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.019 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.22 -160.06 27.16 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.264 179.55 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 2.9 m-85 -114.91 138.48 50.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.519 -0.989 . . . . 0.0 109.782 -179.541 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.711 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -116.19 149.92 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.549 ' HG3' ' CE ' ' B' ' 46' ' ' MET . 3.2 mttm -85.26 136.52 33.47 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.339 -0.851 . . . . 0.0 108.936 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.483 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.4 m -142.74 -164.81 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 O-C-N 120.957 -1.09 . . . . 0.0 110.245 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 56' ' ' VAL . 4.9 mtt180 -147.46 111.34 5.06 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.736 ' NE2' HG21 ' B' ' 74' ' ' THR . 0.4 OUTLIER -74.69 124.81 27.42 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.059 -1.025 . . . . 0.0 110.413 -179.151 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.742 ' CG ' HD23 ' B' ' 38' ' ' LEU . 17.9 m-85 -112.89 109.39 18.8 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.568 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.7 m-20 -88.51 128.14 35.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.079 -1.013 . . . . 0.0 110.505 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.581 ' HA ' HG23 ' B' ' 72' ' ' ILE . 8.2 mm-40 89.86 61.95 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 CA-C-O 121.216 0.531 . . . . 0.0 110.598 179.266 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.87 ' CG2' HG23 ' B' ' 15' ' ' ILE . 24.0 mm -119.04 106.73 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 108.878 178.927 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.805 ' N ' HD13 ' B' ' 72' ' ' ILE . 1.0 OUTLIER -61.29 92.57 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.172 -0.955 . . . . 0.0 110.129 -178.884 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.832 ' CG2' HD11 ' B' ' 89' ' ' LEU . 2.6 tt -97.38 117.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.53 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 16.4 tt0 -89.16 121.11 31.16 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.84 -1.162 . . . . 0.0 109.486 -179.127 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.894 HG13 HG22 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -108.87 135.7 46.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.132 -0.98 . . . . 0.0 108.789 179.769 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.63 -92.4 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.734 -0.604 . . . . 0.0 109.492 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 68' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -141.82 54.59 0.61 Allowed Glycine 0 N--CA 1.485 1.908 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.765 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.503 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 38.1 m-70 -154.24 151.82 29.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -1.131 . . . . 0.0 109.986 -179.544 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.75 139.52 30.46 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 179.086 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.685 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.52 97.68 2.42 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 110.817 -179.075 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.805 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.48 139.65 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 178.19 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.611 ' HA3' HE22 ' B' ' 92' ' ' GLN . . . -164.1 -159.01 10.51 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 118.659 -1.734 . . . . 0.0 111.421 -179.875 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.736 HG21 ' NE2' ' B' ' 58' ' ' GLN . 18.7 m -106.7 108.74 20.41 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.654 -0.909 . . . . 0.0 110.852 -178.74 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.082 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -104.43 127.82 58.46 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.503 -0.748 . . . . 0.0 111.415 -179.879 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.742 ' HB2' HG23 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -84.84 141.3 30.55 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.728 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.62 115.96 46.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 121.003 -1.061 . . . . 0.0 108.667 178.716 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -162.04 -158.12 9.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -81.71 41.57 1.16 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.746 2.297 . . . . 0.0 110.471 179.868 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.537 HG23 ' N ' ' B' ' 34' ' ' GLU . 9.3 t -89.76 133.23 34.53 Favored Pre-proline 0 C--N 1.301 -1.54 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.347 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.618 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.8 Cg_endo -80.15 22.94 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.479 2.119 . . . . 0.0 111.432 -178.504 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.618 HG23 ' O ' ' B' ' 81' ' ' PRO . 55.2 t -160.22 153.67 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.498 -1.376 . . . . 0.0 111.888 -178.671 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 76.0 m-20 -93.98 77.57 4.13 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 176.041 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.821 HG23 ' HB2' ' B' ' 25' ' ' ASP . 53.6 mt -79.71 119.59 29.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.561 0.695 . . . . 0.0 112.601 -175.556 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.521 ' N ' HD13 ' B' ' 85' ' ' ILE . 4.0 mm -95.48 104.57 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.181 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.748 ' C ' HD13 ' B' ' 90' ' ' LEU . . . -99.83 163.16 19.42 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.001 -179.38 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.645 ' N ' HD13 ' B' ' 90' ' ' LEU . 0.0 OUTLIER -25.74 -37.45 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -178.829 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.931 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -46.52 -42.11 15.19 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.021 -1.674 . . . . 0.0 110.113 -178.629 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.931 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -93.76 -17.58 23.0 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.276 -0.89 . . . . 0.0 110.116 -179.514 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.748 HD13 ' C ' ' B' ' 86' ' ' GLY . 5.9 mp -69.55 -35.36 75.35 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.019 -1.073 . . . . 0.0 109.21 -179.548 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 72.3 p -70.99 -6.94 42.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.007 -1.058 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.9 HE22 HD22 ' B' ' 89' ' ' LEU . 30.5 mt-30 -100.01 -40.6 7.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.34 -0.85 . . . . 0.0 109.463 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.748 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -82.87 3.56 2.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.203 -0.936 . . . . 0.0 108.817 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.7 42.41 97.22 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.029 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.534 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.38 138.18 39.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.945 -1.327 . . . . 0.0 109.697 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 71.1 p -130.61 123.64 29.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 108.646 179.064 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -84.84 86.97 7.3 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.658 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.525 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 32.0 m-20 -97.81 132.19 43.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.456 -0.777 . . . . 0.0 110.492 -178.933 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.686 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.287 178.664 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.581 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.497 1.704 0 N-CA-C 110.316 -0.686 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -84.05 138.41 33.09 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 178.136 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' A' ' 9' ' ' PRO . 4.4 t -132.55 134.45 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.722 -1.236 . . . . 0.0 110.441 -178.548 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.832 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -143.3 -82.66 0.17 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.41 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.559 ' O ' ' C ' ' A' ' 6' ' ' TRP . 9.5 mt 34.41 32.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.895 -0.503 . . . . 0.0 110.719 178.896 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.559 ' C ' ' O ' ' A' ' 5' ' ' LEU . 44.2 m0 17.87 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.35 0 CA-C-O 121.393 0.616 . . . . 0.0 111.18 -179.875 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.553 ' HA ' ' NH1' ' B' ' 87' ' ' ARG . 2.3 mt-30 -144.56 -168.65 2.96 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.486 -0.759 . . . . 0.0 109.489 -179.329 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.0 mtt180 -81.22 122.37 81.3 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.337 -0.852 . . . . 0.0 108.917 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.1 Cg_endo -77.94 69.9 7.26 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.146 1.897 . . . . 0.0 109.88 179.373 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.71 145.82 29.38 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.264 -0.898 . . . . 0.0 109.482 -179.678 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' HG23 ' A' ' 11' ' ' VAL . 6.1 m -138.89 127.63 29.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.648 -179.68 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.876 HG22 HD23 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -62.83 103.29 0.42 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 178.354 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.765 HD11 HD21 ' A' ' 33' ' ' LEU . 11.5 pt -89.83 139.19 17.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.003 -1.061 . . . . 0.0 110.114 -178.458 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.773 ' HE2' HD11 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -108.54 96.69 6.52 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.171 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.894 ' CD1' HG11 ' A' ' 75' ' ' VAL . 24.4 mt -113.18 119.87 61.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.361 -0.837 . . . . 0.0 109.537 -179.012 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD12 ' A' ' 38' ' ' LEU . . . 69.7 28.97 71.5 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -179.391 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.22 3.86 62.3 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 -179.197 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.524 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.59 161.92 15.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.307 -1.113 . . . . 0.0 108.891 179.675 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.876 HD23 HG22 ' A' ' 12' ' ' THR . 0.1 OUTLIER -133.31 125.51 29.39 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.98 -179.394 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.5 mtmt -151.51 162.88 40.19 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -78.95 136.27 37.2 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 108.249 179.591 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.707 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -114.0 152.86 30.31 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.986 -1.071 . . . . 0.0 109.886 -179.313 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.495 ' O ' ' N ' ' A' ' 25' ' ' ASP . 38.6 tp -109.47 88.77 2.82 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.646 -0.659 . . . . 0.0 109.651 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.644 HD12 ' HB2' ' A' ' 9' ' ' PRO . 13.8 mt -43.1 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 179.526 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.645 ' HB3' HG22 ' A' ' 84' ' ' ILE . 9.9 t0 -109.9 97.58 7.07 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.427 -0.795 . . . . 0.0 110.982 -177.68 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.563 HG23 ' NH2' ' A' ' 87' ' ' ARG . 10.7 m -73.13 -6.54 46.43 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.329 -0.857 . . . . 0.0 109.114 178.954 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.567 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -79.96 -29.02 48.34 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.66 162.89 15.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.922 -1.34 . . . . 0.0 109.659 -179.688 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.7 OUTLIER -100.61 -8.39 23.01 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.231 -0.918 . . . . 0.0 110.729 -178.974 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.525 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.54 -177.69 4.78 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.075 -1.016 . . . . 0.0 109.442 -179.712 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.585 HG23 HD12 ' A' ' 85' ' ' ILE . 21.0 m -108.8 88.86 2.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.974 -1.079 . . . . 0.0 110.126 -179.196 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.12 174.02 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.098 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.05 119.46 1.29 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.823 -1.173 . . . . 0.0 111.694 -178.597 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.562 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 2.5 mt-10 -36.02 154.68 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.185 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -47.6 137.47 9.08 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.922 -1.111 . . . . 0.0 109.739 -179.871 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.72 164.94 28.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.326 -0.859 . . . . 0.0 109.407 179.595 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 10.9 t -90.14 104.21 16.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.223 -0.923 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.846 HD13 HG22 ' A' ' 15' ' ' ILE . 48.3 tp -122.08 118.58 29.09 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.236 -0.915 . . . . 0.0 109.304 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.4 Cg_endo -77.99 120.27 4.97 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.401 2.068 . . . . 0.0 110.641 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.25 -177.75 33.95 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 179.839 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.06 144.73 28.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -1.224 . . . . 0.0 108.716 179.521 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.577 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 21.5 p-90 -138.62 156.27 47.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.176 -0.953 . . . . 0.0 110.295 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 14.2 mtpt -121.35 136.39 25.8 Favored Pre-proline 0 N--CA 1.488 1.469 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.69 129.28 9.92 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 122.263 1.975 . . . . 0.0 111.196 -178.853 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.8 ptmm? -164.17 152.4 12.83 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.324 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.545 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -118.25 146.77 44.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.527 -1.358 . . . . 0.0 109.856 179.315 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.752 ' CD1' HG21 ' B' ' 50' ' ' ILE . 15.5 pt -102.6 149.56 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.37 -0.831 . . . . 0.0 109.077 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.89 111.52 2.12 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.331 -1.908 . . . . 0.0 108.331 179.832 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.89 -117.23 1.71 Allowed Glycine 0 N--CA 1.484 1.85 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.687 -178.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.507 ' O ' ' O ' ' B' ' 50' ' ' ILE . 8.2 mt -91.01 130.17 40.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.78 -0.835 . . . . 0.0 112.542 -177.564 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.632 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 89.76 -23.27 20.76 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.021 177.914 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.84 -163.19 29.63 Favored Glycine 0 N--CA 1.491 2.347 0 O-C-N 120.744 -1.445 . . . . 0.0 110.375 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.604 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.1 m-85 -109.68 132.13 54.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.514 -0.992 . . . . 0.0 109.245 -179.639 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.784 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.1 pp -107.07 177.86 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.026 -1.046 . . . . 0.0 109.472 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 11.1 mmtt -112.49 138.99 48.45 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.206 -0.934 . . . . 0.0 109.45 179.231 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.815 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.6 m -146.66 -174.9 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.908 . . . . 0.0 109.687 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.519 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 3.8 mtt85 -122.83 178.19 5.14 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.577 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.445 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 26.0 tt0 -135.97 101.57 4.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.131 -0.98 . . . . 0.0 110.827 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.703 ' CG ' HD23 ' A' ' 38' ' ' LEU . 61.7 m-85 -94.49 106.38 18.36 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.613 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 67.8 m-20 -88.28 123.27 32.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.124 -0.985 . . . . 0.0 110.576 -178.745 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.532 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 63.7 mm-40 86.06 59.98 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.635 0.731 . . . . 0.0 110.072 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.81 HG21 HG23 ' A' ' 15' ' ' ILE . 31.4 mm -115.84 121.9 68.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.777 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 ' HG2' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -73.78 88.18 1.76 Allowed 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.725 -1.19 . . . . 0.0 110.966 -178.311 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.694 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -85.82 117.4 30.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 177.949 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 3.6 tt0 -87.08 117.96 26.16 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.054 -1.029 . . . . 0.0 109.111 -178.495 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.694 HD11 HD13 ' A' ' 64' ' ' ILE . 1.0 OUTLIER -110.43 123.9 66.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.792 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.55 36.1 4.96 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.541 -0.724 . . . . 0.0 110.039 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.52 34.24 50.43 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 70' ' ' LYS . 31.9 m-70 -122.1 91.74 3.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.03 -1.277 . . . . 0.0 109.448 179.696 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 1.009 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -44.74 102.82 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.616 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.492 ' N ' HD11 ' A' ' 63' ' ' LEU . . . -127.24 132.88 50.3 Favored 'General case' 0 C--N 1.287 -2.109 0 O-C-N 121.804 -0.56 . . . . 0.0 109.806 -179.151 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.537 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -108.17 152.21 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.867 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.542 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -176.41 -166.47 33.67 Favored Glycine 0 N--CA 1.487 2.045 0 C-N-CA 118.667 -1.73 . . . . 0.0 111.15 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.505 HG23 ' OD1' ' A' ' 60' ' ' ASP . 20.4 m -98.77 107.01 19.35 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.49 -1.006 . . . . 0.0 109.381 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.098 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.2 OUTLIER -103.52 119.49 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.335 -0.853 . . . . 0.0 110.402 -179.546 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.0 mp -88.63 142.87 27.33 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.332 -0.855 . . . . 0.0 108.906 178.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.556 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.9 t -126.8 118.65 51.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.398 -0.814 . . . . 0.0 109.875 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.815 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.01 13.05 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.69 41.75 1.17 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 C-N-CA 122.416 2.077 . . . . 0.0 110.015 179.803 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.562 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.1 t -82.45 140.16 44.83 Favored Pre-proline 0 C--N 1.305 -1.347 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.062 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.435 ' C ' ' OE2' ' A' ' 34' ' ' GLU . 32.2 Cg_endo -76.22 10.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.177 1.918 . . . . 0.0 111.438 -178.873 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.72 HG12 HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.19 168.02 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.882 -1.136 . . . . 0.0 109.653 179.828 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -102.72 145.78 29.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 176.707 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.722 ' C ' HD13 ' A' ' 85' ' ' ILE . 3.5 mm -130.24 126.07 60.86 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 120.726 -1.234 . . . . 0.0 111.212 -177.536 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.85 ' N ' HD13 ' A' ' 85' ' ' ILE . 0.6 OUTLIER -101.47 92.18 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.446 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -81.34 -163.25 30.56 Favored Glycine 0 N--CA 1.496 2.693 0 O-C-N 121.241 -0.912 . . . . 0.0 111.995 -177.242 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.563 ' NH2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -60.82 -40.0 91.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.979 -0.718 . . . . 0.0 110.442 -179.283 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.052 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.0 p-10 -43.61 -31.1 0.69 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.274 -0.891 . . . . 0.0 109.298 -179.66 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.052 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -105.45 -26.02 12.11 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.168 -0.958 . . . . 0.0 109.998 -179.764 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 97.3 mt -71.1 -5.42 31.44 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.926 -1.109 . . . . 0.0 108.211 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -100.42 -15.21 18.02 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.691 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.2 mm-40 -86.12 -40.82 15.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.623 -0.673 . . . . 0.0 109.569 179.769 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.955 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -85.06 -5.18 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.175 -0.953 . . . . 0.0 108.982 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.93 49.93 15.16 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 178.917 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.571 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -83.44 149.5 26.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.008 -1.29 . . . . 0.0 110.557 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 25.6 p -140.28 126.1 19.4 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.796 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -85.98 96.53 9.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.843 -179.225 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.513 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.6 m-20 -101.13 126.8 47.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.219 -0.926 . . . . 0.0 109.441 179.694 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.803 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.039 -0.981 . . . . 0.0 109.446 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.537 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.494 1.552 0 N-CA-C 109.873 -0.857 . . . . 0.0 109.873 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.41 ' HG3' ' OD1' ' A' ' 98' ' ' ASN . 3.0 tt0 -83.64 137.64 33.71 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.432 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' B' ' 5' ' ' LEU . 8.4 t -133.68 114.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 118.565 -1.254 . . . . 0.0 110.501 -178.456 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.591 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -101.01 3.78 41.8 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 177.468 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.52 ' HB2' ' CG1' ' B' ' 3' ' ' VAL . 0.8 OUTLIER -21.66 83.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.654 0.74 . . . . 0.0 111.06 -179.438 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.591 ' N ' ' O ' ' B' ' 4' ' ' THR . 7.8 m95 -46.1 -21.05 0.12 Allowed 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.513 -0.742 . . . . 0.0 109.103 179.618 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.451 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -107.9 -165.51 1.05 Allowed 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.644 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.451 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.4 OUTLIER -66.68 125.49 90.72 Favored Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 120.919 -1.113 . . . . 0.0 109.65 -179.615 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.742 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.7 Cg_endo -77.49 75.72 4.57 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 122.035 1.823 . . . . 0.0 109.899 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.73 146.05 32.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.16 -0.963 . . . . 0.0 109.483 -179.69 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.551 ' CG1' HD11 ' B' ' 24' ' ' LEU . 5.5 m -131.02 148.71 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.82 -179.506 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.711 HG22 HD22 ' B' ' 19' ' ' LEU . 73.7 m -83.22 117.26 22.81 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 178.234 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 2.0 pp -112.62 131.35 64.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 121.117 -0.99 . . . . 0.0 110.739 -177.893 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.488 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -99.73 110.83 23.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.21 -0.931 . . . . 0.0 108.678 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.779 HD13 HG11 ' B' ' 75' ' ' VAL . 9.3 mt -116.67 141.79 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.043 . . . . 0.0 109.529 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.54 -97.69 0.07 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -148.38 39.6 0.97 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 179.247 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.414 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 44.5 mm-40 -140.52 -175.23 4.2 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.528 -0.984 . . . . 0.0 109.617 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.711 HD22 HG22 ' B' ' 12' ' ' THR . 6.8 mt -150.79 129.67 12.48 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.723 0.773 . . . . 0.0 110.621 -178.916 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.513 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 2.3 mptp? -148.03 168.34 22.59 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.321 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.8 mt-10 -79.11 172.84 13.24 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.655 -1.278 . . . . 0.0 109.129 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.568 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -149.51 106.14 3.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.343 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.567 HD21 ' O ' ' A' ' 27' ' ' GLY . 28.0 tp -64.06 99.42 0.26 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.552 -0.717 . . . . 0.0 110.006 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.742 HD12 ' HB2' ' B' ' 9' ' ' PRO . 44.4 mt -52.28 111.35 0.61 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.985 -1.072 . . . . 0.0 108.658 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.836 ' HB3' HG23 ' B' ' 84' ' ' ILE . 49.4 t0 -124.29 90.0 3.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 110.785 -178.554 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.58 ' HA ' HD12 ' B' ' 90' ' ' LEU . 3.0 m -63.96 -14.68 55.74 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.676 -1.265 . . . . 0.0 108.676 178.595 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -64.69 -46.93 88.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.05 158.97 35.58 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.899 -1.354 . . . . 0.0 108.802 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -92.12 -13.37 30.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.086 -1.009 . . . . 0.0 110.791 -178.621 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.564 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.7 OUTLIER -139.35 -173.87 3.72 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.783 -1.198 . . . . 0.0 110.041 -179.661 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.732 HG22 ' CD1' ' B' ' 33' ' ' LEU . 3.7 m -102.21 88.81 3.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.915 -1.115 . . . . 0.0 110.294 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.92 162.44 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.804 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.0 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -158.78 126.6 5.07 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.938 -1.101 . . . . 0.0 110.719 -178.397 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' B' ' 33' ' ' LEU . 4.3 tt0 -40.68 161.25 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.826 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.543 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.6 tt0 -50.54 146.14 5.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.195 -0.94 . . . . 0.0 110.133 -179.543 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.526 ' HE1' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -174.98 160.67 2.84 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.385 -0.822 . . . . 0.0 108.805 179.553 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.0 t -79.51 97.63 6.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.877 -1.139 . . . . 0.0 109.286 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.576 HD21 ' CG2' ' B' ' 15' ' ' ILE . 0.8 OUTLIER -107.21 107.59 60.67 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.69 -179.66 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 129.04 10.1 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.517 2.145 . . . . 0.0 110.521 179.796 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 147.13 -165.41 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 -95.55 124.95 39.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.278 -1.131 . . . . 0.0 108.831 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.601 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 56.8 p-90 -128.77 172.25 11.45 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.171 -0.956 . . . . 0.0 110.309 -179.197 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.1 mptt -140.07 137.75 18.54 Favored Pre-proline 0 C--N 1.3 -1.573 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.653 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -76.28 134.96 16.27 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.858 1.705 . . . . 0.0 110.299 -179.257 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.464 ' CG ' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -153.7 -177.11 6.16 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.656 -0.818 . . . . 0.0 109.823 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -138.28 115.19 10.79 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 109.192 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 54' ' ' ILE . 31.6 pt -94.49 130.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 C-N-CA 118.772 -1.171 . . . . 0.0 108.351 178.997 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.421 ' HA2' ' HA ' ' B' ' 53' ' ' PHE . . . -117.02 103.73 1.13 Allowed Glycine 0 N--CA 1.486 2.001 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.337 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.04 -118.45 2.44 Favored Glycine 0 N--CA 1.483 1.816 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.752 HG21 ' CD1' ' A' ' 47' ' ' ILE . 15.6 mt -91.8 115.56 31.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.852 -0.793 . . . . 0.0 112.138 -177.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.605 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 112.34 -40.14 2.63 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.399 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 163.88 -162.77 35.39 Favored Glycine 0 N--CA 1.491 2.365 0 O-C-N 120.846 -1.385 . . . . 0.0 110.161 179.896 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.539 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.7 OUTLIER -112.55 127.64 56.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.456 -1.026 . . . . 0.0 109.732 -179.872 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 47' ' ' ILE . 4.7 pt -109.81 169.18 3.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.195 -0.94 . . . . 0.0 108.657 178.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.535 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mttt -109.82 132.44 54.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.03 -1.044 . . . . 0.0 108.9 179.6 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.782 HG12 ' HA3' ' B' ' 78' ' ' GLY . 3.1 m -130.96 -172.45 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 110.495 -179.281 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.427 ' HG3' ' C ' ' B' ' 56' ' ' VAL . 5.6 mtp180 -134.97 85.23 2.16 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.523 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -52.73 100.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.6 -0.688 . . . . 0.0 110.901 -179.077 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.601 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 14.6 m-85 -90.28 123.07 33.75 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.498 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.0 OUTLIER -100.68 141.0 34.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.792 -1.193 . . . . 0.0 110.121 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.763 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 72.08 65.61 0.13 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.441 0.638 . . . . 0.0 109.495 179.783 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.665 ' C ' HD13 ' B' ' 72' ' ' ILE . 27.8 mm -119.26 116.15 49.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.481 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.835 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.1 tm? -68.94 83.22 0.31 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.454 -0.779 . . . . 0.0 110.582 -178.502 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.879 HG12 HD12 ' B' ' 66' ' ' ILE . 7.9 tt -88.16 125.1 41.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.493 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.446 ' OE2' ' HE3' ' B' ' 70' ' ' LYS . 4.0 tt0 -91.71 110.01 21.34 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.935 -1.103 . . . . 0.0 109.768 -178.409 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.879 HD12 HG12 ' B' ' 64' ' ' ILE . 0.3 OUTLIER -109.97 122.59 64.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.237 -0.914 . . . . 0.0 108.827 179.65 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.7 m 52.05 62.66 2.59 Favored 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.644 -0.66 . . . . 0.0 110.378 179.505 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 47.81 25.21 3.43 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.16 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 36.5 m80 -118.29 117.43 29.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.089 -1.242 . . . . 0.0 109.101 179.39 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.446 ' HE3' ' OE2' ' B' ' 65' ' ' GLU . 0.0 OUTLIER -67.94 133.16 48.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.137 -0.977 . . . . 0.0 108.968 179.725 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.693 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -149.26 139.19 21.99 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.371 -0.831 . . . . 0.0 110.168 -179.335 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.763 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -110.31 140.8 27.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 177.679 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.49 -168.93 28.42 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.058 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 26.2 m -99.15 106.42 18.6 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.653 -0.91 . . . . 0.0 110.551 -179.185 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.0 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.7 t -100.68 108.89 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.47 -0.769 . . . . 0.0 110.813 179.3 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.662 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 5.2 mp -79.2 134.29 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.562 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.0 OUTLIER -118.39 118.44 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.109 -0.995 . . . . 0.0 109.448 -179.502 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.782 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.71 -167.16 16.78 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.535 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -79.54 40.13 0.91 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.689 2.259 . . . . 0.0 111.295 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.837 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.45 142.97 33.51 Favored Pre-proline 0 C--N 1.302 -1.466 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.948 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.637 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.9 Cg_endo -79.86 17.56 1.28 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 C-N-CA 122.516 2.144 . . . . 0.0 112.246 -178.427 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.837 ' H ' HG23 ' B' ' 80' ' ' THR . 1.4 t -162.41 157.25 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.425 -1.422 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.581 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 2.1 m-20 -99.34 103.16 14.95 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.447 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.836 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.3 mt -104.18 131.31 53.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.723 -1.236 . . . . 0.0 112.607 -176.085 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.577 ' N ' HD13 ' B' ' 85' ' ' ILE . 2.3 mm -95.35 107.72 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 177.887 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -88.99 -154.58 29.09 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 120.787 -1.196 . . . . 0.0 111.142 -178.374 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 7' ' ' GLN . 5.5 mtm180 -64.67 -40.09 94.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.832 -0.805 . . . . 0.0 109.911 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.984 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.9 p-10 -45.15 -38.08 4.93 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.175 -0.953 . . . . 0.0 110.395 -179.073 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.984 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.0 mm? -96.75 -27.7 14.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.817 -1.177 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.58 HD12 ' HA ' ' B' ' 26' ' ' THR . 53.9 mt -71.22 -5.79 34.68 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 178.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 17.3 p -100.97 -10.93 20.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.226 -0.921 . . . . 0.0 108.696 178.717 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.722 ' OE1' HD22 ' B' ' 89' ' ' LEU . 13.9 mt-30 -91.89 -41.06 10.81 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.196 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.803 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -85.74 2.41 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.29 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.28 51.49 52.18 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.783 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.7 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -78.73 142.32 37.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.154 -1.204 . . . . 0.0 110.184 179.746 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.832 HG22 ' CG2' ' A' ' 4' ' ' THR . 27.6 p -137.96 130.55 29.52 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.487 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' A' ' 97' ' ' LEU . 6.5 mp -91.21 94.08 9.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.339 -0.851 . . . . 0.0 110.035 -179.171 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.537 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 5.5 m-20 -97.59 120.38 37.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.057 -1.027 . . . . 0.0 109.343 179.379 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.955 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.054 179.666 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.428 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 2.6 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 N-CA-C 109.622 -0.953 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 14.4 tt0 -84.3 139.71 32.13 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 178.408 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 1.114 HG13 HD23 ' A' ' 5' ' ' LEU . 87.7 t -143.79 117.46 3.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.385 -1.326 . . . . 0.0 110.583 -178.532 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.634 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -98.54 -34.25 10.67 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 177.941 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 1.114 HD23 HG13 ' A' ' 3' ' ' VAL . 1.3 mm? 22.36 74.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.289 179.413 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.634 ' CE3' HG21 ' B' ' 91' ' ' THR . 41.3 m95 -41.56 -20.62 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.751 -0.593 . . . . 0.0 110.329 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 58.9 mt-30 -108.57 -105.1 0.36 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.607 -1.308 . . . . 0.0 109.282 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 8.9 mtt-85 -110.98 132.57 21.6 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 120.654 -1.279 . . . . 0.0 110.215 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.3 Cg_endo -78.92 66.34 8.73 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.336 2.024 . . . . 0.0 109.867 178.25 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -80.03 152.06 29.62 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.983 -1.073 . . . . 0.0 109.975 -179.32 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.638 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -142.09 170.9 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.382 -0.824 . . . . 0.0 109.404 -179.587 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.665 HG22 HD22 ' A' ' 19' ' ' LEU . 4.3 m -101.04 92.29 4.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 178.238 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.553 ' HA ' ' O ' ' A' ' 65' ' ' GLU . 22.1 pt -86.08 142.1 13.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.263 -0.898 . . . . 0.0 110.17 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 6.9 ttmt -114.77 99.31 7.4 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.409 -0.807 . . . . 0.0 109.499 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.759 HG22 ' CG2' ' A' ' 62' ' ' ILE . 0.2 OUTLIER -116.15 158.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.065 -1.022 . . . . 0.0 109.427 179.829 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 34.86 50.72 0.8 Allowed Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 50.95 52.49 30.49 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.797 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.543 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -152.1 172.49 16.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.459 -1.024 . . . . 0.0 108.493 179.574 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.665 HD22 HG22 ' A' ' 12' ' ' THR . 26.6 mt -141.96 132.03 24.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.08 -1.013 . . . . 0.0 110.549 -179.303 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 12.5 mmmt -150.68 162.52 40.54 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.714 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.4 mm-40 -79.25 141.54 37.01 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.942 -1.099 . . . . 0.0 108.19 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.664 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -124.05 131.72 53.59 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.992 -1.068 . . . . 0.0 110.21 -178.682 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.516 HD21 ' O ' ' B' ' 27' ' ' GLY . 25.2 tp -91.15 97.94 11.45 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.69 -0.631 . . . . 0.0 109.783 -179.774 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.547 HD13 HD21 ' A' ' 90' ' ' LEU . 0.2 OUTLIER -45.97 115.16 0.91 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.397 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' HB3' HG22 ' A' ' 84' ' ' ILE . 14.9 t0 -125.7 84.4 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.331 -0.856 . . . . 0.0 111.021 -177.536 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' CD1' ' A' ' 90' ' ' LEU . 0.2 OUTLIER -62.68 -11.91 20.17 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.005 -1.059 . . . . 0.0 109.159 178.742 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.0 -41.52 54.52 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.28 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.508 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -71.23 168.8 16.51 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -1.214 . . . . 0.0 109.709 -179.4 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -100.74 -20.81 15.41 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.204 -0.935 . . . . 0.0 110.176 -179.444 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.576 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.32 -164.99 1.56 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.068 -1.02 . . . . 0.0 109.548 -179.61 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 30.1 m -112.64 90.86 3.46 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.738 -1.226 . . . . 0.0 110.575 -179.034 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.071 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.52 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.053 -1.029 . . . . 0.0 108.826 179.536 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.126 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.81 121.41 1.29 Allowed 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.099 -1.001 . . . . 0.0 111.019 -178.849 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.496 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.6 OUTLIER -38.46 152.9 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.432 -0.792 . . . . 0.0 109.663 178.842 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 77' ' ' VAL . 2.6 mt-10 -46.07 141.61 3.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 110.459 -179.279 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.498 ' CE ' HD13 ' A' ' 15' ' ' ILE . 6.0 ptm -158.21 -177.21 6.39 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.348 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -101.09 101.7 12.5 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.069 -1.02 . . . . 0.0 109.903 -179.498 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 1.001 HD12 HG21 ' A' ' 77' ' ' VAL . 32.5 mt -106.72 162.43 19.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.062 -1.024 . . . . 0.0 109.971 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.9 Cg_endo -78.23 65.85 8.41 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.895 2.397 . . . . 0.0 112.082 -179.219 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 37.36 -160.67 0.01 OUTLIER Glycine 0 N--CA 1.499 2.846 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 178.74 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.49 59.94 0.61 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.354 -1.086 . . . . 0.0 109.486 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.588 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 64.1 p-90 -148.7 168.67 22.27 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.626 0.727 . . . . 0.0 110.115 -179.556 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.1 136.35 28.69 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.04 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.0 139.1 17.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.222 1.948 . . . . 0.0 110.872 -179.272 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HE2' ' HB2' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -153.42 -165.61 2.2 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.264 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.491 ' HG3' ' HG3' ' A' ' 55' ' ' LYS . 5.4 ttt -144.71 126.57 15.34 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.951 -1.093 . . . . 0.0 110.163 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.684 HD12 HG21 ' B' ' 50' ' ' ILE . 24.8 pt -96.1 133.65 36.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.932 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.67 101.0 0.89 Allowed Glycine 0 N--CA 1.486 1.999 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.53 -117.46 2.49 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.65 -178.969 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.699 HG21 HD12 ' B' ' 47' ' ' ILE . 12.8 mt -88.94 122.85 40.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.729 -0.865 . . . . 0.0 112.506 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.44 -51.53 1.01 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 178.213 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.86 -159.98 24.6 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.228 -1.463 . . . . 0.0 110.748 -179.604 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.2 m-85 -113.33 129.38 56.55 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.55 -0.971 . . . . 0.0 109.95 -179.254 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.525 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.9 pt -109.94 152.98 11.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.214 -0.929 . . . . 0.0 108.701 178.895 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.6 mtpt -93.84 123.39 37.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.11 -0.994 . . . . 0.0 109.508 -179.577 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.529 HG12 ' HA3' ' A' ' 78' ' ' GLY . 25.9 m -126.59 -170.08 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.22 -0.925 . . . . 0.0 109.939 -179.529 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.55 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 22.5 mtt180 -124.31 174.42 7.73 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.249 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.452 ' HB2' ' HE2' ' A' ' 45' ' ' LYS . 37.2 tt0 -131.17 98.33 4.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.157 -0.964 . . . . 0.0 109.979 -179.342 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CG ' HD13 ' A' ' 38' ' ' LEU . 64.9 m-85 -97.69 97.59 9.15 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.24 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.624 ' OD1' HG23 ' A' ' 74' ' ' THR . 1.1 m-20 -82.44 139.48 33.96 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 0.0 110.856 -178.601 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.473 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.1 OUTLIER 75.6 60.32 0.05 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.583 -0.698 . . . . 0.0 109.693 179.607 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.839 HG21 HG21 ' A' ' 75' ' ' VAL . 3.5 mm -116.49 122.82 70.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 108.979 -179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.93 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -74.7 94.99 2.79 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 111.159 -178.751 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 66' ' ' ILE . 8.2 tt -97.89 121.97 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.289 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.553 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 50.0 tt0 -89.67 101.54 14.23 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.01 -1.056 . . . . 0.0 108.86 -179.45 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 2.3 mp -102.68 120.5 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.993 -179.037 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 92.6 m 63.36 34.96 12.62 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.738 -0.601 . . . . 0.0 110.32 179.013 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.79 12.21 80.86 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.24 137.24 44.53 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -1.228 . . . . 0.0 109.255 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.449 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -80.96 123.93 28.72 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 109.094 179.84 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -142.79 155.53 44.83 Favored 'General case' 0 C--N 1.293 -1.852 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.552 -179.759 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.721 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -125.18 149.81 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.005 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.898 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.42 176.24 47.31 Favored Glycine 0 N--CA 1.484 1.859 0 C-N-CA 118.484 -1.817 . . . . 0.0 111.158 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.624 HG23 ' OD1' ' A' ' 60' ' ' ASP . 6.5 m -86.76 108.74 18.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.702 -0.881 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.126 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -98.32 110.5 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.532 -0.73 . . . . 0.0 109.779 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.576 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.9 mp -78.9 139.16 38.35 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 120.997 -1.064 . . . . 0.0 108.356 179.133 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 1.001 HG21 HD12 ' A' ' 38' ' ' LEU . 15.9 t -125.04 114.72 41.55 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.481 -0.762 . . . . 0.0 110.054 -179.287 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.529 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -154.41 -159.67 9.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.664 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.9 Cg_endo -79.83 41.1 1.05 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.659 2.239 . . . . 0.0 111.072 -179.874 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.68 HG21 HG13 ' A' ' 32' ' ' VAL . 1.8 t -87.97 133.03 38.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.666 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -77.15 16.26 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.687 2.258 . . . . 0.0 111.77 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.55 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.45 164.38 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.955 -1.091 . . . . 0.0 109.604 -179.812 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.597 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -100.83 132.88 46.02 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 176.53 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.604 HG22 ' HB3' ' A' ' 25' ' ' ASP . 3.9 mm -119.8 119.98 61.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 O-C-N 120.447 -1.408 . . . . 0.0 111.362 -176.867 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.701 ' N ' HD13 ' A' ' 85' ' ' ILE . 2.0 mm -95.01 89.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.461 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.98 -165.42 29.23 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.962 -1.114 . . . . 0.0 111.46 -177.595 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 87' ' ' ARG . 1.3 mtp-105 -59.34 -40.66 87.08 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.853 -0.792 . . . . 0.0 110.638 -178.904 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.986 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.9 p-10 -45.4 -24.99 0.35 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.971 -1.081 . . . . 0.0 109.675 -179.327 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.986 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.1 mm? -110.64 -26.85 9.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.011 -1.056 . . . . 0.0 109.614 -179.298 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.679 ' CD1' HG23 ' A' ' 26' ' ' THR . 65.8 mt -72.09 -6.91 45.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 108.589 179.179 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.481 ' O ' ' CZ2' ' B' ' 6' ' ' TRP . 57.4 p -100.92 -19.17 16.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.041 -1.037 . . . . 0.0 108.252 179.116 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 -84.22 -41.14 17.25 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.8 . . . . 0.0 109.159 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.867 HD12 ' HB3' ' B' ' 99' ' ' PHE . 1.1 pp -80.36 -7.28 10.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.98 59.41 5.94 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.606 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.841 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -86.63 157.97 19.58 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -1.212 . . . . 0.0 110.356 -179.702 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -150.24 126.66 10.78 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.464 -0.772 . . . . 0.0 109.279 179.401 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' B' ' 97' ' ' LEU . 8.6 mp -86.09 111.57 20.46 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 12.6 m-20 -108.73 121.76 45.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.852 -1.155 . . . . 0.0 109.78 179.951 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.692 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.427 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.418 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.066 -0.782 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.9 tt0 -83.4 141.55 31.65 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 178.379 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.466 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 40.6 t -142.66 112.73 2.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 120.565 -1.334 . . . . 0.0 110.694 -178.367 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -124.11 -71.7 0.71 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.713 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.543 ' O ' ' C ' ' B' ' 6' ' ' TRP . 18.5 mt 36.62 31.01 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.737 -0.602 . . . . 0.0 109.866 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.3 m0 17.27 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.144 0 CA-C-O 121.609 0.719 . . . . 0.0 111.404 -179.427 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER -150.55 -165.84 2.38 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.691 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -84.15 115.9 62.34 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.144 -0.973 . . . . 0.0 109.389 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.744 ' HB2' HD12 ' B' ' 24' ' ' LEU . 35.9 Cg_endo -77.29 73.3 5.58 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.391 2.061 . . . . 0.0 110.507 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 1.024 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.6 OUTLIER -79.6 163.47 24.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.157 -0.964 . . . . 0.0 108.786 179.617 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.663 HG23 HG23 ' B' ' 13' ' ' ILE . 4.6 m -144.53 128.01 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.994 -1.066 . . . . 0.0 110.765 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 12' ' ' THR . . . . . 1.045 HG22 HD22 ' B' ' 19' ' ' LEU . 1.2 m -71.07 87.88 0.77 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.529 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 1.07 HG22 HG13 ' B' ' 66' ' ' ILE . 17.3 pt -85.65 142.57 12.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-O 121.716 0.77 . . . . 0.0 111.58 -177.18 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.511 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 2.8 tttt -103.29 94.21 5.39 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.187 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.616 HG22 ' CE ' ' B' ' 36' ' ' MET . 0.3 OUTLIER -104.28 115.78 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.164 -0.96 . . . . 0.0 110.358 -178.444 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.55 26.37 71.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.28 88.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -96.96 -179.91 4.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -1.19 . . . . 0.0 108.704 179.427 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 1.045 HD22 HG22 ' B' ' 12' ' ' THR . 5.1 mt -148.82 128.25 13.07 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.972 -1.08 . . . . 0.0 110.382 -179.625 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.403 ' HG3' ' C ' ' B' ' 19' ' ' LEU . 9.9 mttm -151.19 155.58 39.16 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.562 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 1.024 ' HB3' HD23 ' B' ' 10' ' ' LEU . 2.7 mm-40 -78.36 100.72 6.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.15 -0.969 . . . . 0.0 108.519 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 1.085 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -85.26 104.17 14.87 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.261 -0.899 . . . . 0.0 110.698 -178.738 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' B' ' 25' ' ' ASP . 5.4 tp -58.54 103.96 0.19 Allowed 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.445 179.26 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.744 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.3 mt -49.83 96.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.039 -1.038 . . . . 0.0 108.558 179.476 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.92 ' CB ' HG23 ' B' ' 84' ' ' ILE . 15.6 t0 -102.5 91.94 4.45 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.195 -0.94 . . . . 0.0 110.469 -179.075 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.503 HG23 HD13 ' B' ' 90' ' ' LEU . 6.9 m -70.39 -6.37 35.01 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.948 -1.095 . . . . 0.0 108.791 178.545 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.516 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -77.45 -39.91 24.72 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.39 154.88 34.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.019 -1.283 . . . . 0.0 109.305 -179.691 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -88.47 -17.96 29.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.16 -0.962 . . . . 0.0 110.753 -178.856 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.536 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.78 -170.36 2.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.948 -1.095 . . . . 0.0 110.464 -179.178 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.809 HG23 HD12 ' B' ' 85' ' ' ILE . 65.4 m -109.12 103.78 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.991 -1.068 . . . . 0.0 110.29 -178.634 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 0.943 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -87.82 171.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 108.678 179.417 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.02 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.06 125.57 2.29 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.928 -1.107 . . . . 0.0 110.319 -179.048 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.663 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.3 tt0 -37.8 160.59 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.391 0.615 . . . . 0.0 109.936 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.473 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.4 tt0 -53.6 148.45 9.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 110.46 -179.514 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.616 ' CE ' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -170.71 -166.55 0.51 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.611 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.46 ' N ' ' SD ' ' B' ' 36' ' ' MET . 5.4 t -115.06 76.73 1.01 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.797 -1.189 . . . . 0.0 110.923 -179.171 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.795 HD12 ' CG2' ' B' ' 77' ' ' VAL . 8.0 mt -80.43 173.31 7.91 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.633 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.618 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 29.3 Cg_endo -71.01 -155.63 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 121.776 1.651 . . . . 0.0 111.092 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -103.0 -157.6 25.27 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.046 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.44 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.1 mmm-85 65.72 57.91 0.82 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.511 -0.993 . . . . 0.0 108.809 -179.639 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 52.0 p-90 -135.59 -172.6 3.13 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-O 121.747 0.784 . . . . 0.0 110.282 -179.015 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mptt -148.43 140.85 14.84 Favored Pre-proline 0 N--CA 1.489 1.487 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.126 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.48 135.4 14.72 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.74 1.627 . . . . 0.0 109.856 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.5 ' O ' ' HG2' ' B' ' 46' ' ' MET . 0.0 OUTLIER -158.46 -169.68 2.83 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 109.596 -179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' O ' ' B' ' 45' ' ' LYS . 10.1 mtp -149.26 131.39 15.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 109.097 179.849 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 54' ' ' ILE . 9.3 pt -89.04 140.34 15.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.95 -1.094 . . . . 0.0 108.312 179.271 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.18 111.43 2.17 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 -179.702 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -135.77 -114.29 1.36 Allowed Glycine 0 N--CA 1.481 1.697 0 C-N-CA 119.442 -1.361 . . . . 0.0 111.096 -178.806 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.684 HG21 HD12 ' A' ' 47' ' ' ILE . 11.3 mt -92.64 124.47 45.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.862 -0.787 . . . . 0.0 112.385 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.525 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 94.85 -48.86 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.452 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.87 -157.15 20.42 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.66 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.1 OUTLIER -124.21 131.79 53.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.377 -1.072 . . . . 0.0 109.391 179.87 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 47' ' ' ILE . 4.0 pt -99.01 -177.85 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 109.101 179.839 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -108.7 137.17 47.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.955 -1.09 . . . . 0.0 109.471 179.722 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.463 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.0 m -143.78 176.71 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 0.0 109.771 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -127.19 108.64 11.06 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.468 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.6 OUTLIER -66.18 102.43 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.514 -0.741 . . . . 0.0 110.725 -179.085 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.607 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.7 m-85 -97.04 94.13 6.99 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.535 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.1 OUTLIER -79.1 134.31 36.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 0.0 110.093 -178.832 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 37.2 mm-40 82.74 60.71 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.943 -0.473 . . . . 0.0 110.558 179.252 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.509 HG13 ' HB3' ' B' ' 59' ' ' TYR . 11.6 mm -124.05 126.72 72.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.994 -1.066 . . . . 0.0 109.202 178.876 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.81 HD22 HG13 ' B' ' 72' ' ' ILE . 0.2 OUTLIER -71.91 95.91 1.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 121.72 0.771 . . . . 0.0 111.799 -178.52 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.551 ' HB ' HD11 ' B' ' 15' ' ' ILE . 3.5 tt -96.08 109.81 23.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 175.765 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.493 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.8 tm-20 -88.2 118.25 27.67 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.911 -1.118 . . . . 0.0 110.252 -177.571 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 1.07 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -112.74 113.13 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.555 -0.716 . . . . 0.0 109.195 179.929 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.2 m 66.06 6.33 4.05 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.653 -0.654 . . . . 0.0 110.314 179.356 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 68' ' ' GLY . . . . . 0.457 ' N ' ' OE2' ' B' ' 65' ' ' GLU . . . 110.93 -3.1 28.7 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -88.39 115.91 26.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.161 -1.199 . . . . 0.0 108.953 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.556 ' HG3' HD11 ' B' ' 63' ' ' LEU . 1.5 mptp? -69.45 107.24 3.26 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.549 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -121.98 110.06 15.36 Favored 'General case' 0 C--N 1.291 -1.938 0 O-C-N 121.627 -0.671 . . . . 0.0 109.683 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.81 HG13 HD22 ' B' ' 63' ' ' LEU . 1.2 mt -94.63 120.64 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.894 -1.128 . . . . 0.0 108.271 178.782 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.677 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -140.32 -165.89 10.46 Favored Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.554 -179.645 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.468 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 59.5 m -97.73 106.69 19.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.68 -0.894 . . . . 0.0 109.651 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.02 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.5 t -91.34 172.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.541 -0.724 . . . . 0.0 109.49 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' HG23 ' B' ' 32' ' ' VAL . 3.6 mp -140.36 112.67 7.83 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.924 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.795 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.9 t -97.52 117.49 42.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.932 -1.105 . . . . 0.0 110.305 -178.508 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -154.19 -171.42 21.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.746 -1.742 . . . . 0.0 108.746 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -80.92 41.56 1.17 Allowed 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.336 2.024 . . . . 0.0 110.926 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.663 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.5 t -82.38 138.7 44.83 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.854 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.411 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.0 Cg_endo -78.23 18.16 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.283 1.989 . . . . 0.0 110.973 -179.579 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.657 ' O ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -159.71 163.82 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.107 -0.996 . . . . 0.0 109.638 -179.552 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.68 ' ND2' ' N ' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -109.44 119.86 40.73 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 104.417 -2.438 . . . . 0.0 104.417 176.319 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.92 HG23 ' CB ' ' B' ' 25' ' ' ASP . 6.0 mt -120.4 132.67 69.4 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 120.117 -1.614 . . . . 0.0 113.859 -174.688 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 1.085 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -96.67 102.51 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.002 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.536 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -83.35 -160.26 29.32 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.076 -179.344 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.494 ' HD2' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -69.79 -30.25 67.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.472 -1.016 . . . . 0.0 109.848 -179.797 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.938 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.8 p-10 -49.38 -24.29 1.87 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.942 -1.099 . . . . 0.0 109.571 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.938 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -111.06 -23.42 10.93 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.998 -1.064 . . . . 0.0 109.76 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.625 HD21 HD22 ' B' ' 24' ' ' LEU . 51.8 mt -69.32 -6.17 27.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.027 -1.045 . . . . 0.0 109.225 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.634 HG21 ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -100.65 -20.53 15.6 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.075 -1.016 . . . . 0.0 108.969 179.401 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.446 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 28.1 mt-30 -81.04 -40.42 24.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.418 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.692 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -82.79 -5.54 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 177.923 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.12 25.95 62.98 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.151 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.596 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.89 132.64 52.78 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.803 -1.41 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.634 HG22 HG23 ' A' ' 4' ' ' THR . 15.7 p -131.47 128.49 39.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.156 -0.965 . . . . 0.0 108.666 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -85.76 96.83 9.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.409 -0.807 . . . . 0.0 110.358 -178.773 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.563 ' C ' ' CD1' ' B' ' 99' ' ' PHE . 7.9 m-20 -111.05 139.75 46.15 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.834 . . . . 0.0 109.499 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.867 ' HB3' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.056 -1.028 . . . . 0.0 109.533 179.438 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.504 ' HG2' ' CD2' ' B' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.232 -0.719 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -91.48 128.62 37.38 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.156 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.413 HG11 ' HB3' ' A' ' 9' ' ' PRO . 53.0 t -125.56 131.88 71.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.028 -178.447 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.621 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -154.41 51.57 0.65 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.352 -0.842 . . . . 0.0 109.143 -179.733 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -94.64 42.67 1.09 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.226 -0.921 . . . . 0.0 110.178 -179.401 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.529 ' C ' ' O ' ' A' ' 5' ' ' LEU . 26.9 m95 18.13 49.06 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.415 0 CA-C-O 121.131 0.491 . . . . 0.0 112.176 179.797 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -166.61 -173.89 2.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.145 -0.972 . . . . 0.0 109.359 179.66 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HD3' ' OD1' ' B' ' 29' ' ' ASP . 5.3 mtm180 -63.88 111.09 4.61 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.324 -0.86 . . . . 0.0 110.049 -179.629 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.1 Cg_endo -77.29 84.31 1.98 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.957 1.771 . . . . 0.0 109.117 178.668 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.732 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -89.89 149.11 22.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 110.248 -178.882 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.855 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -135.97 137.74 48.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.388 -0.82 . . . . 0.0 109.551 179.741 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.821 HG22 HD22 ' A' ' 19' ' ' LEU . 29.2 m -72.96 98.84 2.57 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 178.635 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.687 HG22 HG13 ' A' ' 66' ' ' ILE . 15.3 pt -88.6 144.02 9.99 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 O-C-N 121.407 -0.808 . . . . 0.0 110.805 -178.363 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.814 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -107.01 105.23 15.16 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.725 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.688 HD13 HG11 ' A' ' 75' ' ' VAL . 24.8 mt -121.74 124.45 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.049 -1.032 . . . . 0.0 109.872 -179.291 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.88 18.4 72.46 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.372 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.55 0.61 84.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.471 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 28.7 mm-40 -99.9 -178.62 3.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.175 -1.191 . . . . 0.0 109.058 179.746 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.821 HD22 HG22 ' A' ' 12' ' ' THR . 16.7 mt -141.29 129.6 22.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.181 -0.949 . . . . 0.0 110.002 -179.579 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 3.1 mmtp -142.88 -170.49 3.25 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.492 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.732 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.2 mt-10 -103.26 146.52 28.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.161 -0.962 . . . . 0.0 109.025 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.712 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -130.22 136.21 48.97 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.931 -1.106 . . . . 0.0 110.221 -179.566 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.841 HD21 ' O ' ' B' ' 27' ' ' GLY . 53.0 tp -105.17 111.55 24.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.495 -0.753 . . . . 0.0 110.041 -179.329 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -46.71 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.907 -1.121 . . . . 0.0 109.324 179.618 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.701 ' CB ' HG23 ' A' ' 84' ' ' ILE . 33.4 t0 -98.65 71.43 1.96 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.116 -0.99 . . . . 0.0 109.563 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.564 ' CG2' ' HG3' ' B' ' 9' ' ' PRO . 64.9 m -58.1 -15.88 11.12 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.103 -0.998 . . . . 0.0 108.537 179.066 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.686 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -69.64 -41.14 76.17 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.742 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.94 155.97 32.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -1.213 . . . . 0.0 109.78 -179.688 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.524 ' OD2' ' CG ' ' B' ' 8' ' ' ARG . 1.3 m-20 -96.47 -9.97 28.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.769 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -131.6 -170.11 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 109.549 -179.677 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.563 HG23 HD12 ' A' ' 85' ' ' ILE . 11.2 m -113.81 88.37 2.83 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.058 -1.027 . . . . 0.0 109.973 -179.367 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.93 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.19 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 178.725 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.039 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -164.08 123.36 1.97 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.406 -1.434 . . . . 0.0 111.875 -179.261 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -42.32 145.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.517 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.8 OUTLIER -48.23 138.75 9.29 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.149 -0.969 . . . . 0.0 109.826 -179.683 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.506 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -147.63 -164.47 2.01 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.424 -0.798 . . . . 0.0 109.209 179.419 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.443 ' N ' ' SD ' ' A' ' 36' ' ' MET . 18.1 t -100.01 87.67 3.55 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 110.041 -179.639 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 1.054 HD12 HG21 ' A' ' 77' ' ' VAL . 16.2 mt -110.92 159.96 30.62 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.106 -0.996 . . . . 0.0 108.935 179.19 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.471 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 34.8 Cg_endo -77.35 154.23 31.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.598 2.199 . . . . 0.0 110.361 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.542 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -59.29 -154.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.542 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 4.7 mmm180 69.86 49.58 0.51 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.831 -0.805 . . . . 0.0 109.48 -179.595 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 45.8 p-90 -135.31 -171.4 2.81 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.819 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.0 mtpm? -138.9 134.36 16.97 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.963 -1.085 . . . . 0.0 108.85 179.598 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.69 139.26 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.073 1.849 . . . . 0.0 111.26 -179.181 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.523 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 11.4 pttt -159.03 153.6 24.35 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.307 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.458 ' HG3' ' O ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -110.85 128.94 55.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.778 -1.201 . . . . 0.0 110.4 -179.093 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 10.0 pt -96.81 142.07 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.95 -1.094 . . . . 0.0 108.152 178.305 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.619 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.79 100.56 0.83 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.607 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.12 -122.76 2.78 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.71 -1.234 . . . . 0.0 110.099 -179.716 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.798 HG21 ' CD1' ' B' ' 47' ' ' ILE . 10.5 mt -87.33 123.21 39.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.629 -0.924 . . . . 0.0 111.854 -178.466 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.79 -52.78 0.68 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.146 -1.181 . . . . 0.0 110.146 178.573 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.46 -155.2 21.84 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.751 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.619 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 6.8 m-85 -114.12 123.22 49.1 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.412 -1.052 . . . . 0.0 110.014 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.71 ' CD1' HG23 ' B' ' 50' ' ' ILE . 32.0 pt -102.79 162.43 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.076 -1.015 . . . . 0.0 108.509 178.597 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.9 OUTLIER -95.96 144.78 25.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.215 -0.928 . . . . 0.0 109.018 -179.932 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.65 HG12 ' HA3' ' A' ' 78' ' ' GLY . 17.0 m -142.91 -173.73 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.889 -1.132 . . . . 0.0 109.711 -179.83 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.571 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 36.2 mtt180 -133.04 93.21 3.14 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 179.541 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -50.03 101.65 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.585 0.707 . . . . 0.0 110.036 -179.632 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.616 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.3 m-85 -100.95 88.29 3.5 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.74 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.498 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -78.73 137.68 37.89 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.201 -0.937 . . . . 0.0 110.401 -178.517 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.628 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.0 OUTLIER 74.01 61.79 0.08 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.755 -0.591 . . . . 0.0 110.531 179.329 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.851 ' C ' HD13 ' A' ' 72' ' ' ILE . 1.2 mt -122.02 124.21 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.516 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.815 HD13 ' O ' ' A' ' 63' ' ' LEU . 3.1 tm? -70.06 92.24 0.73 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.442 -0.787 . . . . 0.0 111.82 -177.559 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.77 HD13 HD11 ' A' ' 66' ' ' ILE . 4.2 tt -96.91 118.53 43.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.846 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.556 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 39.1 tt0 -89.61 100.81 13.54 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.983 -1.073 . . . . 0.0 109.766 -178.778 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.855 HG23 HG21 ' A' ' 11' ' ' VAL . 1.3 mp -97.12 121.8 47.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.268 -0.895 . . . . 0.0 108.965 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.3 m 58.09 57.32 4.09 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.515 -0.741 . . . . 0.0 109.641 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.71 26.33 7.78 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.764 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.461 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 34.5 m170 -122.24 118.9 29.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.991 -1.3 . . . . 0.0 109.267 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.638 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 mptt -61.38 139.58 58.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.258 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.67 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -159.88 102.33 1.48 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.173 -0.954 . . . . 0.0 110.473 -179.686 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.851 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -78.58 147.25 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.525 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.847 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.09 -170.89 37.25 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.903 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.2 m -95.33 106.08 18.09 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.729 -0.865 . . . . 0.0 110.174 -179.488 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.039 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.04 106.58 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.701 -0.625 . . . . 0.0 109.708 179.358 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.548 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.8 mp -79.81 113.26 17.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.119 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 1.054 HG21 HD12 ' A' ' 38' ' ' LEU . 7.9 t -97.91 107.98 21.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 120.908 -1.12 . . . . 0.0 110.261 -178.97 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.65 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -140.24 -166.48 10.68 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.101 -2.0 . . . . 0.0 108.101 179.088 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.92 40.42 0.96 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.305 2.003 . . . . 0.0 110.522 179.208 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' A' ' 34' ' ' GLU . 11.5 t -81.75 137.25 47.45 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.33 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.566 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.1 Cg_endo -78.91 16.3 1.35 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.483 2.122 . . . . 0.0 111.476 -179.089 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.4 t -161.07 149.65 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.809 -1.182 . . . . 0.0 110.251 -179.845 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -85.85 100.07 11.81 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.774 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.701 HG23 ' CB ' ' A' ' 25' ' ' ASP . 18.9 mm -84.52 120.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.234 -0.916 . . . . 0.0 112.994 -175.804 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.912 HG22 HD11 ' A' ' 90' ' ' LEU . 0.6 OUTLIER -103.0 99.36 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.836 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.493 ' O ' HD13 ' A' ' 90' ' ' LEU . . . -106.54 175.99 21.31 Favored Glycine 0 N--CA 1.497 2.72 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.243 -177.069 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.753 ' N ' HD22 ' A' ' 90' ' ' LEU . 13.2 mmm180 -25.81 -41.41 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -179.085 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.8 p-10 -52.54 -42.54 64.5 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.184 -1.573 . . . . 0.0 110.562 -177.683 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.8 mm? -92.98 -23.96 18.53 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.035 . . . . 0.0 108.607 179.598 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.912 HD11 HG22 ' A' ' 85' ' ' ILE . 0.4 OUTLIER -67.81 -8.03 32.59 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.309 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.82 -20.66 17.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.928 -1.108 . . . . 0.0 108.844 179.824 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 30.6 mm-40 -85.71 -40.21 16.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.216 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.71 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -83.12 2.16 3.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.236 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 66.46 31.93 80.25 Favored Glycine 0 N--CA 1.499 2.887 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.186 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.685 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -61.06 143.72 54.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.247 -1.149 . . . . 0.0 111.433 -179.542 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.707 HG22 ' CG2' ' B' ' 4' ' ' THR . 58.0 p -152.05 141.49 21.6 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.13 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' B' ' 97' ' ' LEU . 0.0 OUTLIER -98.23 118.31 34.58 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.786 -1.196 . . . . 0.0 110.358 -179.916 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.5 m120 -118.0 123.75 46.48 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.637 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.481 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.574 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.576 0 N-CA-C 110.176 -0.74 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.511 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.8 tt0 -89.12 146.41 24.83 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.216 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 3' ' ' VAL . . . . . 0.58 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 12.2 t -138.93 118.17 13.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 120.525 -1.359 . . . . 0.0 110.673 -178.615 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.707 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -123.94 -71.83 0.7 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.277 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.743 ' N ' HD22 ' B' ' 5' ' ' LEU . 3.1 mm? 36.92 34.47 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.654 -0.654 . . . . 0.0 110.656 179.574 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.532 ' C ' ' O ' ' B' ' 5' ' ' LEU . 17.8 m95 18.61 48.17 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.285 0 CA-C-O 121.233 0.54 . . . . 0.0 112.165 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.569 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -163.16 -158.9 0.5 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.53 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.0 OUTLIER -71.94 124.19 90.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.348 -0.845 . . . . 0.0 109.431 179.888 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.639 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.7 Cg_endo -76.99 74.15 5.12 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.146 1.897 . . . . 0.0 110.094 179.387 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.818 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.41 164.24 24.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.03 -1.044 . . . . 0.0 110.091 -179.498 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.467 HG23 HG23 ' B' ' 13' ' ' ILE . 2.8 m -151.27 152.76 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.475 -0.766 . . . . 0.0 109.927 -179.007 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.947 HG22 HD22 ' B' ' 19' ' ' LEU . 27.9 m -85.89 103.32 14.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.422 -1.423 . . . . 0.0 107.717 177.562 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 1.06 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.7 pt -94.53 148.6 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.065 -1.022 . . . . 0.0 110.479 -178.566 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 14' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -117.12 105.47 12.3 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.739 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.945 HG22 HD21 ' B' ' 38' ' ' LEU . 16.3 mt -116.75 134.01 61.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 120.826 -1.171 . . . . 0.0 109.438 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.09 -99.37 0.31 Allowed Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 -179.672 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 17' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' B' ' 18' ' ' GLN . . . -145.31 32.05 1.66 Allowed Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.471 -1.851 . . . . 0.0 108.471 179.237 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' B' ' 17' ' ' GLY . 3.0 mm100 -132.72 178.31 6.96 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.492 -1.005 . . . . 0.0 109.635 -179.539 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 1.06 HD23 ' O ' ' B' ' 13' ' ' ILE . 9.0 mt -143.62 130.8 20.74 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.416 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.3 mmmt -143.44 156.14 44.57 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.818 ' HB3' HD23 ' B' ' 10' ' ' LEU . 1.9 mp0 -79.49 122.34 26.33 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.981 -1.074 . . . . 0.0 108.811 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.609 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.38 129.93 52.28 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.434 -0.791 . . . . 0.0 110.647 -178.787 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.686 HD21 ' O ' ' A' ' 27' ' ' GLY . 22.9 tp -80.17 97.72 7.02 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.841 HD22 HD21 ' B' ' 90' ' ' LEU . 15.2 mt -44.22 113.01 0.47 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.715 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.609 ' HB3' HG22 ' B' ' 84' ' ' ILE . 57.7 t0 -126.39 88.12 2.78 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.05 -177.789 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.576 HG21 ' CD2' ' B' ' 97' ' ' LEU . 1.8 m -64.06 -12.83 42.43 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.037 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.841 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.1 -41.92 45.8 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.171 -1.171 . . . . 0.0 110.171 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.12 152.3 46.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.061 -1.258 . . . . 0.0 109.449 -179.684 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.574 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 30.6 m-20 -85.0 -21.69 29.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 110.378 -178.946 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.51 ' HA ' ' OD1' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -139.98 -160.38 1.06 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.811 -1.181 . . . . 0.0 109.429 179.965 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.567 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.0 m -110.94 94.13 4.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.731 -1.23 . . . . 0.0 111.56 -178.242 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.051 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.49 174.73 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.053 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.051 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.72 117.35 0.59 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.932 -1.105 . . . . 0.0 110.311 -179.178 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.772 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.5 pt-20 -38.13 158.22 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.544 -0.722 . . . . 0.0 109.586 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.689 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -46.34 149.71 0.72 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.212 -0.93 . . . . 0.0 110.668 -179.119 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.456 ' SD ' ' O ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -178.68 167.58 1.74 Allowed 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.513 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.456 ' O ' ' SD ' ' B' ' 36' ' ' MET . 48.0 t -87.88 109.24 19.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.967 -1.083 . . . . 0.0 109.765 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.945 HD21 HG22 ' B' ' 15' ' ' ILE . 8.6 mt -114.65 105.12 53.88 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.255 179.649 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -78.47 102.02 1.52 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.542 2.161 . . . . 0.0 111.233 -179.526 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 168.31 31.13 0.02 OUTLIER Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.596 179.288 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.52 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 55.63 153.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.778 -0.837 . . . . 0.0 109.721 179.647 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.621 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 51.5 p-90 -161.37 176.14 11.48 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.803 -1.185 . . . . 0.0 110.123 -179.764 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.421 ' CD ' ' HD2' ' B' ' 44' ' ' PRO . 0.1 OUTLIER -134.08 162.92 54.79 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.6 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 44' ' ' PRO . . . . . 0.421 ' HD2' ' CD ' ' B' ' 43' ' ' LYS . 33.4 Cg_endo -76.38 139.95 21.33 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 C-N-CA 121.827 1.685 . . . . 0.0 109.721 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.715 ' O ' HG23 ' B' ' 56' ' ' VAL . 7.4 tttm -159.58 119.79 3.05 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.414 -0.804 . . . . 0.0 109.105 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 76.5 mtp -98.9 132.26 44.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.415 -0.803 . . . . 0.0 109.291 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.798 ' CD1' HG21 ' A' ' 50' ' ' ILE . 17.6 pt -94.26 149.05 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.987 -1.071 . . . . 0.0 108.826 179.386 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.534 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.36 100.51 0.81 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.829 -1.708 . . . . 0.0 108.829 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.25 -129.34 3.29 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.3 -1.429 . . . . 0.0 110.665 -179.241 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.843 HG21 ' CD1' ' A' ' 47' ' ' ILE . 47.4 mt -84.42 118.37 31.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.752 -0.852 . . . . 0.0 112.948 -177.488 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.654 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 100.02 -1.77 56.53 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 177.805 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 127.85 -154.63 19.83 Favored Glycine 0 N--CA 1.49 2.274 0 O-C-N 120.969 -1.312 . . . . 0.0 109.999 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.63 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.4 OUTLIER -121.18 141.53 50.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.53 -0.982 . . . . 0.0 109.799 -179.628 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.607 HD11 HD11 ' B' ' 47' ' ' ILE . 18.8 pt -107.22 178.67 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 108.995 179.097 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.583 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.2 OUTLIER -109.5 130.13 55.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.234 -0.916 . . . . 0.0 109.568 -179.881 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.715 HG23 ' O ' ' B' ' 45' ' ' LYS . 2.2 m -144.11 174.06 4.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.094 -1.004 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -116.73 115.47 25.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.813 179.847 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.521 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 5.6 tt0 -69.77 106.8 3.24 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.139 -0.976 . . . . 0.0 110.13 -179.349 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.621 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 18.0 m-85 -99.65 87.31 3.53 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 178.536 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.589 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -78.71 125.68 29.7 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.875 -1.14 . . . . 0.0 110.177 -178.783 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.589 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 1.5 mt-30 91.16 60.65 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.336 0.588 . . . . 0.0 110.402 179.329 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.695 ' CG2' HG23 ' B' ' 15' ' ' ILE . 33.1 mm -121.87 125.68 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.306 -0.871 . . . . 0.0 108.752 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.915 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.1 tm? -73.91 86.38 1.76 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.219 -0.926 . . . . 0.0 112.364 -178.081 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.93 HD12 HD11 ' B' ' 15' ' ' ILE . 16.5 tt -89.8 114.61 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.426 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.7 OUTLIER -90.14 127.51 36.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.912 -1.118 . . . . 0.0 108.765 -179.836 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.666 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -124.3 125.89 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.129 -0.982 . . . . 0.0 109.988 -179.248 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.532 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 54.9 m 55.91 12.78 0.95 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.687 -0.633 . . . . 0.0 111.111 179.169 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 68' ' ' GLY . . . . . 0.425 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 101.24 21.7 11.4 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.301 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.919 ' HB2' HG22 ' B' ' 93' ' ' ILE . 23.9 m-70 -118.0 114.52 23.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.057 -1.26 . . . . 0.0 109.333 179.544 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.691 ' CG ' HD21 ' B' ' 63' ' ' LEU . 9.6 tttt -64.4 117.4 7.23 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.12 -0.987 . . . . 0.0 109.006 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -138.14 124.04 20.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.302 -0.873 . . . . 0.0 110.358 -178.981 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.578 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -103.43 129.89 54.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 177.749 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.428 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -149.29 -159.91 8.86 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.506 -1.331 . . . . 0.0 110.364 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.521 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 7.6 m -100.93 110.71 22.78 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.442 -1.034 . . . . 0.0 109.553 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 0.975 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.1 107.14 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.312 -0.867 . . . . 0.0 110.516 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -79.06 121.44 24.97 Favored 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.855 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.758 HG21 HD12 ' B' ' 38' ' ' LEU . 3.4 t -110.7 114.27 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.106 -0.996 . . . . 0.0 110.557 -178.68 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.692 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -148.63 -165.13 11.93 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.583 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.57 41.38 1.13 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.588 2.192 . . . . 0.0 110.486 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.772 HG22 ' HA ' ' B' ' 34' ' ' GLU . 13.6 t -81.43 140.82 48.58 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.596 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.7 Cg_endo -78.81 12.52 2.19 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.426 2.084 . . . . 0.0 110.742 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.596 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -161.22 167.12 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.191 -0.943 . . . . 0.0 109.563 -179.573 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.609 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -105.38 144.37 32.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 104.486 -2.413 . . . . 0.0 104.486 175.761 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.609 HG22 ' HB3' ' B' ' 25' ' ' ASP . 5.7 mm -130.25 130.01 65.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 O-C-N 120.284 -1.51 . . . . 0.0 111.735 -177.059 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.497 ' CD1' HG23 ' B' ' 31' ' ' THR . 0.8 OUTLIER -101.15 100.42 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.483 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.9 -155.42 8.81 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.736 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.574 ' HD2' ' HA ' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -79.68 -30.04 41.0 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.388 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.982 ' ND2' HD23 ' B' ' 89' ' ' LEU . 18.4 p-10 -47.51 -22.95 0.53 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.302 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.982 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.4 mm? -113.42 -42.89 3.4 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.123 -0.985 . . . . 0.0 111.036 -178.58 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.841 HD21 HD22 ' B' ' 24' ' ' LEU . 93.8 mt -52.63 -35.88 55.47 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.592 -1.318 . . . . 0.0 109.425 -179.547 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.504 HG21 ' HA ' ' A' ' 6' ' ' TRP . 49.4 p -80.42 -21.79 41.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.233 -0.917 . . . . 0.0 110.978 -178.738 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.568 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 66.7 mt-30 -75.06 -38.19 61.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.78 -1.2 . . . . 0.0 108.737 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -79.84 2.09 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.392 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 71.37 60.32 4.46 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -100.01 163.42 12.44 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.308 -1.113 . . . . 0.0 110.021 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.621 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.2 p -148.92 135.19 19.3 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.494 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -90.17 114.83 26.88 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.286 179.952 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.4 m-20 -119.24 130.59 55.54 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.869 -0.519 . . . . 0.0 109.863 -179.069 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.71 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.171 -0.919 . . . . 0.0 109.09 178.567 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.495 1.615 0 N-CA-C 110.179 -0.739 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.468 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -83.81 145.89 28.43 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 177.632 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.462 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 55.1 t -146.72 105.93 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 117.82 -1.552 . . . . 0.0 111.143 -178.436 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 6' ' ' TRP . 13.5 p -107.16 -57.22 2.1 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 177.811 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.588 ' O ' ' N ' ' A' ' 7' ' ' GLN . 7.8 tp 33.92 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.938 -0.476 . . . . 0.0 111.119 178.659 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.546 ' N ' ' O ' ' A' ' 4' ' ' THR . 9.0 m95 18.19 47.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.121 0.486 . . . . 0.0 111.91 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.588 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -167.41 -175.49 2.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.797 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.546 HH21 HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -56.2 125.74 65.57 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.412 -0.805 . . . . 0.0 109.558 179.755 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.528 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.9 Cg_endo -79.05 70.89 7.3 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.179 1.919 . . . . 0.0 109.177 178.843 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.606 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.99 156.12 23.6 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.42 -0.8 . . . . 0.0 110.093 -178.908 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.545 HG21 HG23 ' A' ' 66' ' ' ILE . 2.1 m -149.31 130.25 4.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.512 -0.743 . . . . 0.0 109.245 179.776 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' THR . . . . . 1.01 HG22 HD22 ' A' ' 19' ' ' LEU . 23.0 m -65.7 96.34 0.27 Allowed 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.728 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.831 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -79.28 140.07 17.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.395 -0.816 . . . . 0.0 109.785 -178.737 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.651 ' HE3' HD11 ' A' ' 19' ' ' LEU . 29.0 tttt -105.64 95.52 5.86 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.242 -0.911 . . . . 0.0 108.981 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.791 HG23 ' CG2' ' A' ' 62' ' ' ILE . 15.1 mt -118.78 147.53 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.153 -0.967 . . . . 0.0 109.924 -179.295 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 44.69 50.62 8.39 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.207 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.26 43.99 34.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.7 mm-40 -142.66 176.67 8.86 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.366 -1.079 . . . . 0.0 109.152 179.864 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 12' ' ' THR . 16.9 mt -149.64 124.2 9.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.037 -1.039 . . . . 0.0 110.115 -179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.578 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -138.25 168.78 19.02 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.119 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.606 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.0 mm-40 -80.63 116.03 20.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.096 -1.003 . . . . 0.0 108.671 179.516 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.675 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -96.75 142.51 28.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.12 -0.988 . . . . 0.0 110.065 -179.214 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.605 HD21 ' O ' ' B' ' 27' ' ' GLY . 26.5 tp -104.41 91.54 3.94 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.647 -0.658 . . . . 0.0 109.281 -179.753 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.827 HD23 ' HB ' ' A' ' 85' ' ' ILE . 15.1 mt -44.12 101.98 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -0.895 . . . . 0.0 108.714 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.563 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.5 t0 -111.57 91.4 3.64 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.351 -0.843 . . . . 0.0 110.495 -178.699 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HD13 ' A' ' 90' ' ' LEU . 1.1 m -66.6 -10.61 47.46 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.144 -0.973 . . . . 0.0 108.556 178.643 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.472 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.44 -44.2 51.7 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.85 164.79 25.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.096 -1.237 . . . . 0.0 109.322 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -100.55 -15.21 17.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.154 -0.966 . . . . 0.0 111.282 -178.695 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -130.88 -169.96 2.26 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.813 -1.18 . . . . 0.0 109.571 -179.614 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.597 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 50.2 m -109.51 91.35 3.61 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.767 -1.208 . . . . 0.0 110.438 -179.099 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.034 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -72.11 171.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 120.969 -1.082 . . . . 0.0 108.167 179.099 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.123 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.07 121.98 0.79 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.713 -178.857 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.712 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -42.46 166.57 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.146 -0.971 . . . . 0.0 109.535 179.506 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.561 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -51.1 149.71 3.58 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.127 -0.983 . . . . 0.0 110.378 -179.447 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.409 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.2 ptm -164.95 -161.68 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.439 -0.788 . . . . 0.0 109.08 179.592 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.409 ' N ' ' HG3' ' A' ' 36' ' ' MET . 3.8 t -122.73 109.94 14.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.093 -1.005 . . . . 0.0 111.158 -178.949 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.605 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -111.21 167.02 9.67 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.18 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.578 ' HD3' HD12 ' A' ' 38' ' ' LEU . 35.5 Cg_endo -77.08 66.62 7.73 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 122.94 2.427 . . . . 0.0 112.352 -179.149 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.523 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 26.66 105.74 0.0 OUTLIER Glycine 0 N--CA 1.504 3.215 0 CA-C-O 121.674 0.597 . . . . 0.0 112.315 178.534 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.456 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.8 mtp180 167.11 51.19 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.316 -1.108 . . . . 0.0 109.115 178.776 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.608 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.5 p-90 -131.49 -179.49 5.4 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 121.829 0.823 . . . . 0.0 110.302 -179.049 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 57' ' ' ARG . 0.5 OUTLIER -138.41 166.89 22.21 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.7 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.29 140.62 22.22 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.147 1.898 . . . . 0.0 110.796 -179.773 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.91 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -160.17 141.36 12.34 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.48 ' HG2' ' HG2' ' A' ' 55' ' ' LYS . 59.3 mtp -125.97 141.57 51.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.837 -1.164 . . . . 0.0 109.915 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 54' ' ' ILE . 6.9 pt -118.94 141.09 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.268 -0.895 . . . . 0.0 109.171 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.527 ' HA3' ' CE1' ' A' ' 53' ' ' PHE . . . -118.18 103.44 1.04 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.78 -127.47 3.22 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.445 -178.961 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.542 ' CG2' HG12 ' B' ' 54' ' ' ILE . 67.5 mt -79.67 116.33 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.703 -0.88 . . . . 0.0 112.251 -178.139 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.563 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 111.98 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.382 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.74 -161.48 34.34 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.305 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CE1' ' HA3' ' A' ' 48' ' ' GLY . 4.3 m-30 -99.95 131.26 46.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.503 -0.998 . . . . 0.0 109.555 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 47' ' ' ILE . 5.1 pt -110.41 172.45 2.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.156 -0.965 . . . . 0.0 108.841 179.103 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -110.04 147.36 33.7 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.875 . . . . 0.0 109.024 179.657 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.91 HG22 ' O ' ' A' ' 45' ' ' LYS . 7.3 m -151.03 -171.53 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 120.739 -1.225 . . . . 0.0 110.424 -179.472 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.587 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 2.0 mtt180 -140.1 108.85 5.95 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.228 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.475 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 12.5 tt0 -65.85 103.38 0.9 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.308 -0.87 . . . . 0.0 111.104 -178.468 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.608 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.8 m-85 -91.58 124.67 35.92 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -109.35 124.2 50.58 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.816 -1.177 . . . . 0.0 110.59 -178.852 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 6.4 mm100 86.29 58.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 CA-C-O 121.229 0.538 . . . . 0.0 110.648 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.791 ' CG2' HG23 ' A' ' 15' ' ' ILE . 26.2 mm -111.88 119.9 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.577 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.896 HD13 ' O ' ' A' ' 63' ' ' LEU . 1.3 tm? -67.48 84.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 111.054 -178.5 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.593 HD13 HD11 ' A' ' 66' ' ' ILE . 3.5 tt -87.86 118.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 178.248 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' CB ' ' A' ' 14' ' ' LYS . 28.0 tt0 -91.42 113.43 25.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.213 -0.929 . . . . 0.0 109.186 -179.189 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.593 HD11 HD13 ' A' ' 64' ' ' ILE . 1.3 mp -106.25 118.29 53.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 -179.667 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 77.8 m 65.38 21.36 11.91 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.744 -0.598 . . . . 0.0 110.935 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.475 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 90.31 1.59 75.01 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.506 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -97.34 121.18 38.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.075 -1.25 . . . . 0.0 108.827 179.548 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -61.82 127.51 31.78 Favored 'General case' 0 C--N 1.295 -1.775 0 O-C-N 121.363 -0.835 . . . . 0.0 109.416 -179.789 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.482 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -148.19 137.55 22.12 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.541 -0.724 . . . . 0.0 109.454 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.536 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -110.29 160.43 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 177.819 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.875 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 175.46 177.51 44.58 Favored Glycine 0 N--CA 1.485 1.901 0 C-N-CA 118.222 -1.942 . . . . 0.0 111.527 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.508 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 75.3 m -82.27 114.74 20.96 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 122.057 -0.672 . . . . 0.0 109.902 -179.715 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.123 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -108.56 109.92 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.395 -0.816 . . . . 0.0 109.951 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.543 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.2 mp -79.21 126.06 30.26 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.114 -0.991 . . . . 0.0 108.729 179.307 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.561 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.6 t -111.43 116.48 52.64 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 109.94 -179.311 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.474 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.25 13.26 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.553 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.2 Cg_endo -82.96 40.16 0.92 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.47 2.113 . . . . 0.0 110.014 179.711 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.712 HG22 ' HA ' ' A' ' 34' ' ' GLU . 10.2 t -81.38 137.36 48.64 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.84 15.8 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.451 2.1 . . . . 0.0 111.829 -178.664 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -161.41 165.97 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.728 -1.233 . . . . 0.0 111.025 -179.64 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.631 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 55.4 m-20 -99.39 142.61 30.65 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 177.046 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.73 ' CG1' HG12 ' A' ' 32' ' ' VAL . 2.9 mm -133.22 113.59 19.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 O-C-N 120.398 -1.439 . . . . 0.0 111.618 -176.953 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.827 ' HB ' HD23 ' A' ' 24' ' ' LEU . 0.9 OUTLIER -92.68 92.95 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 177.326 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -84.03 -156.96 24.75 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 120.048 -1.072 . . . . 0.0 111.685 -177.852 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.512 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 1.8 mtp180 -63.38 -39.13 93.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.91 -0.759 . . . . 0.0 110.84 -178.865 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.002 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.2 p-10 -48.07 -26.57 1.88 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.053 -1.03 . . . . 0.0 110.282 -178.73 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.002 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.8 mm? -112.52 -12.93 13.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.762 -1.211 . . . . 0.0 109.85 -179.796 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.593 HD13 HG23 ' A' ' 26' ' ' THR . 50.1 mt -80.67 -5.75 57.43 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 77.3 p -100.67 -16.91 17.24 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.922 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.8 mm100 -83.37 -40.58 19.22 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.587 -0.696 . . . . 0.0 109.477 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.987 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -87.29 -3.86 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.145 -0.972 . . . . 0.0 109.429 179.607 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 69.09 56.68 8.61 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.606 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HA ' ' HD1' ' B' ' 99' ' ' PHE . . . -81.93 148.86 28.51 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.031 -1.276 . . . . 0.0 110.23 -179.769 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.869 HG22 HG22 ' B' ' 4' ' ' THR . 55.8 p -142.89 124.08 14.56 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.744 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' B' ' 97' ' ' LEU . 4.7 mp -85.07 108.13 17.5 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 15.9 m-20 -107.2 122.15 45.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.742 -1.224 . . . . 0.0 109.259 -179.669 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.632 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.685 0 CA-C-O 117.922 -1.037 . . . . 0.0 109.747 -179.805 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 4.5 Cg_exo . . . . . 0 N--CA 1.495 1.613 0 N-CA-C 110.693 -0.541 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.44 131.92 35.0 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 178.082 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.16 115.41 44.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 120.812 -1.18 . . . . 0.0 109.853 -177.905 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.998 ' O ' HD22 ' B' ' 5' ' ' LEU . 1.0 OUTLIER -119.01 -102.34 0.42 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.919 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.998 HD22 ' O ' ' B' ' 4' ' ' THR . 0.0 OUTLIER 25.91 36.44 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.32 0 CA-C-O 120.752 0.31 . . . . 0.0 110.974 179.823 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.629 ' N ' ' O ' ' B' ' 4' ' ' THR . 19.3 m0 13.77 85.16 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 CA-C-O 121.174 0.511 . . . . 0.0 111.775 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.89 155.18 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.156 -0.965 . . . . 0.0 109.422 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 48.0 mtm180 -50.48 119.61 11.32 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.576 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.822 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.6 Cg_endo -75.23 71.81 5.02 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 122.158 1.905 . . . . 0.0 110.6 179.861 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.518 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -87.87 161.15 17.66 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.267 -0.896 . . . . 0.0 108.953 179.795 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.954 HG23 HG23 ' B' ' 13' ' ' ILE . 18.7 m -150.84 138.11 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.006 -1.059 . . . . 0.0 110.198 -179.355 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.581 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 24.5 m -72.61 96.66 2.01 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.763 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 10.7 pt -90.44 142.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 O-C-N 121.293 -0.88 . . . . 0.0 110.967 -177.332 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.557 ' HE3' ' CD1' ' B' ' 19' ' ' LEU . 0.3 OUTLIER -108.04 98.6 8.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.667 -0.646 . . . . 0.0 109.608 -179.639 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 1.016 HG23 HG21 ' B' ' 62' ' ' ILE . 11.4 mt -120.1 135.32 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 120.981 -1.075 . . . . 0.0 109.859 -179.742 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD13 ' B' ' 38' ' ' LEU . . . 43.11 60.01 3.2 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 179.349 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 17' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 16' ' ' GLY . . . 43.02 41.83 4.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.698 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.519 ' HB2' ' CE ' ' B' ' 36' ' ' MET . 38.0 mm-40 -138.45 116.24 11.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.366 -1.079 . . . . 0.0 109.464 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.2 OUTLIER -90.79 127.71 36.44 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.685 0.755 . . . . 0.0 110.069 179.699 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.597 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mttt -150.74 142.65 23.88 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.63 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.518 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -78.59 111.09 14.3 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.994 -1.066 . . . . 0.0 108.711 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 1.012 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -93.76 132.82 37.77 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.984 0.897 . . . . 0.0 111.062 -178.45 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.488 HD12 HD12 ' B' ' 10' ' ' LEU . 12.1 tp -83.8 102.46 12.34 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.535 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.822 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.2 mt -44.95 120.19 2.26 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.141 -0.974 . . . . 0.0 108.392 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.523 ' HB3' HG22 ' B' ' 84' ' ' ILE . 46.5 t0 -128.39 82.4 2.08 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.906 HG23 HD13 ' B' ' 90' ' ' LEU . 1.4 m -62.9 -15.24 54.39 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.015 -1.053 . . . . 0.0 108.738 179.125 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.605 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.93 -37.89 94.83 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 163.53 26.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.292 -1.123 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.457 ' OD1' ' NE ' ' A' ' 8' ' ' ARG . 3.9 m-20 -98.23 -10.12 24.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.528 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 19.5 m-20 -140.25 -165.9 2.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.3 -0.875 . . . . 0.0 108.844 -179.883 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.727 HG23 HD12 ' B' ' 85' ' ' ILE . 17.6 m -118.11 93.17 4.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.692 -1.255 . . . . 0.0 111.02 -178.668 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.053 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.89 174.03 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.152 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.46 117.16 1.32 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.82 -1.175 . . . . 0.0 110.846 -179.086 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.601 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 16.3 tt0 -36.15 155.37 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.492 -0.755 . . . . 0.0 109.94 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.711 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -33.35 146.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.766 0.793 . . . . 0.0 111.41 -179.145 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.538 ' N ' HG11 ' B' ' 77' ' ' VAL . 0.2 OUTLIER -177.64 179.61 0.9 Allowed 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.555 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -122.08 122.84 40.19 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.434 -1.416 . . . . 0.0 111.911 -178.299 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.604 HD12 ' CD ' ' B' ' 39' ' ' PRO . 0.5 OUTLIER -102.58 175.58 2.21 Favored Pre-proline 0 N--CA 1.495 1.785 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 177.899 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.604 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.4 Cg_endo -78.05 68.8 7.72 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.066 1.844 . . . . 0.0 110.953 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.8 -172.12 0.01 OUTLIER Glycine 0 N--CA 1.493 2.478 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 179.202 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 56.84 101.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.418 -1.048 . . . . 0.0 109.921 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 3.8 p-90 -160.7 171.55 18.66 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.609 -0.682 . . . . 0.0 109.625 179.682 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 43' ' ' LYS . . . . . 0.524 ' O ' ' CB ' ' B' ' 58' ' ' GLN . 1.4 mtmt -128.71 115.4 19.34 Favored Pre-proline 0 N--CA 1.489 1.477 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.367 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.62 136.03 18.68 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.807 1.671 . . . . 0.0 110.828 -179.334 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 1.024 ' NZ ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -156.45 178.62 10.11 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.539 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 27.2 mtp -127.56 136.28 51.47 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.841 -1.162 . . . . 0.0 110.61 -178.754 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 54' ' ' ILE . 5.8 pt -100.68 143.6 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.328 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.36 108.92 1.68 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.549 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.89 -125.01 2.55 Favored Glycine 0 N--CA 1.484 1.839 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.522 -179.242 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.582 HG21 HD12 ' A' ' 47' ' ' ILE . 50.6 mt -84.3 121.46 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.825 -0.809 . . . . 0.0 112.578 -177.939 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.456 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 98.45 -16.57 59.68 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.019 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 140.58 -155.95 25.03 Favored Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.936 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 1.1 m-85 -116.12 134.9 54.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.543 -0.975 . . . . 0.0 109.485 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 47' ' ' ILE . 6.0 pt -105.53 159.58 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.004 -1.06 . . . . 0.0 109.245 179.436 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.577 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -99.61 131.43 45.61 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.372 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.946 HG23 ' CE ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -138.96 -173.14 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.787 -1.195 . . . . 0.0 109.756 -179.838 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -114.74 165.84 12.38 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.557 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.569 ' NE2' HG22 ' B' ' 74' ' ' THR . 10.0 tp60 -128.98 91.57 3.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.57 -1.331 . . . . 0.0 110.99 -178.923 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 94.1 m-85 -93.88 92.16 7.27 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.223 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.537 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 51.5 m-20 -79.08 134.85 36.73 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.323 -0.86 . . . . 0.0 109.916 -178.841 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.56 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 42.9 mt-30 83.54 63.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.589 0.709 . . . . 0.0 109.291 179.55 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 1.016 HG21 HG23 ' B' ' 15' ' ' ILE . 24.9 mm -119.15 120.48 63.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.951 HD21 ' CG ' ' B' ' 70' ' ' LYS . 16.4 tp -72.86 86.83 1.28 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 118.977 -1.089 . . . . 0.0 110.695 -178.852 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.731 ' CD1' HD11 ' B' ' 66' ' ' ILE . 1.6 tt -85.23 122.24 38.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.647 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.5 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.8 tt0 -89.73 109.61 20.58 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.973 -1.079 . . . . 0.0 109.72 -178.411 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -105.76 122.25 59.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.262 -0.899 . . . . 0.0 109.087 179.91 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 67' ' ' CYS . . . . . 0.475 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 76.2 m 66.71 12.26 8.72 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.997 -0.439 . . . . 0.0 110.294 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.37 0.42 56.89 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 6.7 m-70 -98.82 125.03 44.08 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.191 -1.182 . . . . 0.0 108.904 179.717 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 0.951 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.7 mptm? -70.28 135.11 48.64 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.281 -0.887 . . . . 0.0 108.613 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.612 ' C ' HD12 ' B' ' 63' ' ' LEU . . . -150.27 138.72 20.53 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.383 -0.823 . . . . 0.0 109.077 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.56 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -108.13 142.69 20.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 178.212 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.726 ' HA3' HE22 ' B' ' 92' ' ' GLN . . . -163.54 -165.73 21.2 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.993 -179.694 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.569 HG22 ' NE2' ' B' ' 58' ' ' GLN . 7.0 m -97.81 110.33 22.92 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.745 -0.856 . . . . 0.0 110.06 -179.344 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.065 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -109.65 147.26 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.09 -1.006 . . . . 0.0 109.697 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 1.024 HD23 ' NZ ' ' B' ' 45' ' ' LYS . 5.6 mp -125.27 142.91 51.22 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.058 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' B' ' 35' ' ' GLU . 15.1 t -124.03 124.23 68.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.102 -0.999 . . . . 0.0 110.1 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.723 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -160.31 -158.06 9.02 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.577 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -80.57 40.56 1.0 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.806 2.338 . . . . 0.0 110.966 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.601 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.1 t -86.95 133.81 38.43 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 178.963 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.606 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.5 Cg_endo -77.16 14.16 1.4 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.269 1.979 . . . . 0.0 111.086 -178.939 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.606 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -160.81 151.24 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 120.94 -1.1 . . . . 0.0 110.397 -179.241 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.597 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 21.0 m-20 -80.06 130.74 35.48 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.723 -2.695 . . . . 0.0 103.723 175.077 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.663 HG13 HG12 ' B' ' 32' ' ' VAL . 0.8 OUTLIER -125.88 116.26 45.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 119.781 -1.824 . . . . 0.0 112.93 -176.437 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 1.012 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -89.07 147.28 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.708 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.528 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -136.31 -161.1 9.0 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 118.771 -1.681 . . . . 0.0 110.055 -179.766 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.444 ' O ' ' OG1' ' B' ' 91' ' ' THR . 0.0 OUTLIER -57.59 -37.62 73.51 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.702 -0.881 . . . . 0.0 109.793 -179.725 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 1.049 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -50.67 -29.72 11.84 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.625 -179.29 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 1.049 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.5 mm? -107.13 -24.02 12.08 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.619 -1.301 . . . . 0.0 110.815 -179.082 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.906 HD13 HG23 ' B' ' 26' ' ' THR . 9.2 mt -71.63 -5.68 35.33 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.883 -1.136 . . . . 0.0 108.888 -179.921 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.5 -14.42 18.26 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.925 . . . . 0.0 109.023 179.319 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 92' ' ' GLN . . . . . 0.886 ' NE2' HD22 ' B' ' 89' ' ' LEU . 55.0 mt-30 -85.96 -40.88 15.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -0.867 . . . . 0.0 109.363 -179.816 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.632 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.2 pt -85.99 4.78 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.144 -0.973 . . . . 0.0 108.542 178.75 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.7 42.97 98.49 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.345 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.509 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -69.53 145.46 52.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.901 -1.352 . . . . 0.0 108.882 179.327 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 45.4 p -136.86 128.36 28.51 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.052 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -91.13 96.66 10.71 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 -178.992 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 3.1 m-20 -109.64 132.92 53.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.47 -0.769 . . . . 0.0 110.045 -179.426 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.987 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.062 179.41 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.513 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.168 -0.743 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.479 ' HG3' ' CG ' ' B' ' 98' ' ' ASN . 5.8 tt0 -83.2 127.62 33.78 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 178.069 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.48 HG12 HD22 ' A' ' 5' ' ' LEU . 20.7 t -130.91 102.32 6.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.167 -177.663 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 5.5 p -48.68 -24.34 1.34 Allowed 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 179.213 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.869 HD12 ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER 71.34 35.6 1.5 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.547 -0.721 . . . . 0.0 109.817 179.679 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.433 ' C ' ' HG2' ' A' ' 7' ' ' GLN . 2.1 m95 -55.21 -20.37 10.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.876 -1.14 . . . . 0.0 108.416 179.611 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HG2' ' C ' ' A' ' 6' ' ' TRP . 4.4 mm100 -138.52 -142.49 0.16 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.022 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HG2' ' OD2' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -92.18 141.8 25.5 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 120.778 -1.201 . . . . 0.0 109.339 179.494 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.656 ' HD3' HD11 ' A' ' 5' ' ' LEU . 37.6 Cg_endo -80.16 59.38 7.41 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.502 2.135 . . . . 0.0 110.243 179.532 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 21' ' ' GLU . 6.0 mt -79.47 132.41 36.34 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.969 -1.082 . . . . 0.0 109.053 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 1.01 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -134.63 150.37 30.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 121.327 -0.858 . . . . 0.0 109.326 -179.323 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 12' ' ' THR . . . . . 1.099 HG22 HD22 ' A' ' 19' ' ' LEU . 32.8 m -86.0 95.88 9.65 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.801 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.75 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.1 pt -79.01 155.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.478 -0.764 . . . . 0.0 110.298 -178.818 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -120.06 89.96 3.23 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.8 HD13 HG11 ' A' ' 75' ' ' VAL . 24.9 mt -110.8 130.24 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.102 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.72 44.85 93.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 179.327 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.27 23.7 48.79 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 21.6 mm-40 -117.4 163.53 16.23 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.153 -1.204 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 1.099 HD22 HG22 ' A' ' 12' ' ' THR . 11.6 mt -132.97 127.68 34.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.992 -1.068 . . . . 0.0 110.853 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 1.2 mmmt -146.59 173.7 12.09 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.091 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.792 ' HB3' HD22 ' A' ' 10' ' ' LEU . 4.0 mm-40 -79.26 179.57 7.32 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.809 -1.182 . . . . 0.0 108.801 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -159.35 114.07 2.41 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.766 -1.209 . . . . 0.0 110.608 -179.753 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.041 HD21 ' O ' ' B' ' 27' ' ' GLY . 29.3 tp -87.8 96.73 10.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.684 -0.635 . . . . 0.0 109.357 179.61 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.568 HD23 ' HB ' ' A' ' 85' ' ' ILE . 19.1 mt -43.67 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.698 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.1 t0 -106.11 86.17 2.32 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.402 -0.811 . . . . 0.0 111.165 -177.891 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.473 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 62.1 m -68.53 -14.18 62.83 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.919 -1.113 . . . . 0.0 108.596 178.437 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.41 -22.59 67.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.919 -1.273 . . . . 0.0 109.919 -179.826 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.71 164.77 16.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.029 -1.277 . . . . 0.0 109.807 -179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.481 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 1.3 m-20 -94.19 -21.07 19.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 110.961 -178.785 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.824 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -141.55 -166.57 2.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.655 -1.278 . . . . 0.0 110.596 -179.524 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 60.5 m -103.25 89.48 3.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.189 -0.944 . . . . 0.0 111.02 -178.336 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -73.84 175.45 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.722 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.0 OUTLIER -171.92 121.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.75 -1.219 . . . . 0.0 110.214 -179.475 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.497 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.1 OUTLIER -39.39 155.61 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.063 -1.023 . . . . 0.0 110.218 179.499 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.548 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.7 OUTLIER -46.4 151.04 0.58 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.383 -0.823 . . . . 0.0 110.265 -179.808 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.407 ' SD ' ' C ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -172.63 174.27 3.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.581 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.407 ' C ' ' SD ' ' A' ' 36' ' ' MET . 34.7 t -89.48 83.65 6.36 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.012 -1.055 . . . . 0.0 109.724 -179.722 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.9 HD21 HD12 ' A' ' 62' ' ' ILE . 6.1 tp -109.78 105.54 57.31 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.239 -0.913 . . . . 0.0 109.715 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.0 Cg_endo -78.47 146.63 21.94 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.573 2.182 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.82 -165.83 26.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.842 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 127.94 49.49 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.26 -1.141 . . . . 0.0 108.595 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 42.6 p-90 -136.0 -173.99 3.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.985 . . . . 0.0 110.293 -179.355 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.25 129.71 7.74 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.173 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -74.96 136.52 20.61 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.907 1.738 . . . . 0.0 111.369 -178.659 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.586 ' HG2' HG23 ' A' ' 56' ' ' VAL . 9.5 ptmm? -153.74 -165.41 2.12 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 178.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.435 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 3.3 ttt -147.6 125.92 12.31 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.66 -1.275 . . . . 0.0 110.232 -179.395 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 54' ' ' ILE . 5.2 pt -98.27 135.92 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.06 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.473 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.35 112.35 2.36 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -179.653 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -129.35 -111.53 1.53 Allowed Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.041 -179.509 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.784 HG21 ' CD1' ' B' ' 47' ' ' ILE . 27.4 mt -97.84 132.53 42.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 O-C-N 121.296 -1.12 . . . . 0.0 111.477 -178.445 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 96.69 -50.48 1.56 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.074 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.49 -158.7 28.22 Favored Glycine 0 N--CA 1.491 2.3 0 O-C-N 121.022 -1.281 . . . . 0.0 110.15 -179.872 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.473 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 32.8 m-85 -107.72 151.36 25.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.611 -0.935 . . . . 0.0 109.954 -179.654 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 47' ' ' ILE . 18.0 pt -136.2 140.61 43.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.508 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 8.8 mttt -80.7 137.12 36.28 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.389 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.586 HG23 ' HG2' ' A' ' 45' ' ' LYS . 27.2 m -128.66 -176.72 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.36 -0.838 . . . . 0.0 109.469 -179.73 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 2.6 mmt85 -125.74 85.35 2.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 108.981 179.72 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.552 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 1.2 tt0 -45.32 89.53 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 121.441 0.639 . . . . 0.0 110.261 -179.633 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.618 ' HB3' HG13 ' A' ' 62' ' ' ILE . 6.3 m-85 -90.58 82.51 5.82 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.981 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -77.57 137.39 38.56 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.235 -178.349 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 77.62 59.99 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.198 0.523 . . . . 0.0 110.399 179.701 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.9 HD12 HD21 ' A' ' 38' ' ' LEU . 0.6 OUTLIER -131.54 126.49 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.633 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.056 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.3 tt -74.68 93.33 2.54 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.187 -0.945 . . . . 0.0 112.839 -176.746 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.687 ' CG2' HD11 ' A' ' 89' ' ' LEU . 1.9 tt -87.33 115.76 28.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 105.966 -1.865 . . . . 0.0 105.966 176.236 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -87.97 116.97 26.51 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.11 -0.994 . . . . 0.0 109.013 -178.057 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 1.5 mp -111.92 125.64 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.243 -0.911 . . . . 0.0 109.95 -179.076 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 7.7 m 51.75 -94.84 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.697 . . . . 0.0 109.75 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -140.51 49.55 0.79 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.823 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -145.2 109.8 5.0 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.322 -1.105 . . . . 0.0 110.158 -179.767 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 1.056 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -63.73 120.05 11.11 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.796 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.643 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -132.7 129.01 38.2 Favored 'General case' 0 C--N 1.291 -1.953 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.755 -178.355 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.815 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.5 OUTLIER -105.69 138.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 177.269 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.458 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -161.97 -157.23 8.79 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.641 -179.472 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.552 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 9.9 m -107.42 104.47 14.06 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.879 -0.777 . . . . 0.0 108.946 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.935 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.28 99.94 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.539 -0.726 . . . . 0.0 109.721 -179.757 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.824 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.7 mp -78.16 106.34 9.99 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.074 -1.016 . . . . 0.0 108.857 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.548 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 50.1 t -95.75 123.9 48.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.424 -0.797 . . . . 0.0 110.358 -179.271 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -155.45 -163.92 12.62 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.36 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.538 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 34.9 Cg_endo -79.75 39.62 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.56 2.173 . . . . 0.0 111.193 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -85.66 135.77 37.79 Favored Pre-proline 0 N--CA 1.491 1.625 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.794 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.24 18.79 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.793 2.329 . . . . 0.0 112.21 -178.529 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.589 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.87 163.02 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.575 -1.328 . . . . 0.0 110.476 -179.962 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.587 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 54.6 m-20 -91.46 140.04 30.14 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 105.175 -2.158 . . . . 0.0 105.175 176.549 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.796 ' C ' HD13 ' A' ' 85' ' ' ILE . 18.3 mm -128.64 122.79 58.06 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 O-C-N 120.346 -1.471 . . . . 0.0 111.539 -177.211 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.796 HD13 ' C ' ' A' ' 84' ' ' ILE . 1.4 mm -102.91 96.71 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.184 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.34 -156.41 10.68 Favored Glycine 0 N--CA 1.495 2.62 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.525 -177.416 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.522 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 7.9 mtt180 -72.81 -35.17 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.874 -0.78 . . . . 0.0 109.799 -179.309 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.893 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -54.19 -18.87 4.27 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.005 -1.06 . . . . 0.0 108.857 -178.977 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.893 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -110.37 -22.22 11.81 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.524 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.634 HD23 HD11 ' A' ' 93' ' ' ILE . 64.1 mt -74.67 -17.24 60.71 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.299 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.59 HG22 ' CD2' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -89.84 -10.28 45.97 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.029 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.643 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 72.6 mt-30 -94.52 -41.74 9.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.854 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -84.25 -3.81 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.203 -0.936 . . . . 0.0 108.772 179.116 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 67.67 43.06 86.39 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 178.817 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.527 ' CB ' HD22 ' A' ' 90' ' ' LEU . . . -66.54 153.05 43.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.867 -1.373 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.499 HG22 ' HA ' ' B' ' 4' ' ' THR . 17.7 p -145.09 128.31 16.74 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.327 -0.858 . . . . 0.0 109.094 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -93.16 96.72 10.21 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.44 -0.787 . . . . 0.0 109.441 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.523 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.2 m-20 -101.13 121.22 41.43 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.822 -1.173 . . . . 0.0 109.674 179.654 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.77 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.479 179.541 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.576 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 N-CA-C 110.408 -0.651 . . . . 0.0 110.408 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 2' ' ' GLN . . . . . 0.428 ' CG ' ' OD1' ' A' ' 98' ' ' ASN . 1.9 tt0 -96.37 132.08 42.26 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.456 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 52.7 t -131.82 120.85 45.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.032 -1.042 . . . . 0.0 109.624 -179.049 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.941 ' C ' HD13 ' B' ' 5' ' ' LEU . 0.3 OUTLIER -60.19 -97.26 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.434 -0.791 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.941 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -168.88 -17.87 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.963 -1.086 . . . . 0.0 111.325 179.685 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.591 ' H ' HD22 ' B' ' 5' ' ' LEU . 67.0 m95 -66.19 -11.6 50.7 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.546 -1.346 . . . . 0.0 109.792 -179.799 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -117.56 147.12 43.1 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 110.235 -179.601 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.92 131.21 81.83 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.34 -0.85 . . . . 0.0 109.028 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.802 ' HB2' HD12 ' B' ' 24' ' ' LEU . 38.0 Cg_endo -81.08 45.42 1.99 Allowed 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.135 1.89 . . . . 0.0 109.825 178.732 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -81.1 147.45 30.1 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.156 -0.965 . . . . 0.0 109.279 -179.672 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' B' ' 66' ' ' ILE . 0.9 OUTLIER -150.31 135.48 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.023 -1.048 . . . . 0.0 110.569 -179.184 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.878 ' CG2' HD22 ' B' ' 19' ' ' LEU . 7.5 m -64.03 113.83 3.75 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.207 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.725 HG21 ' HB2' ' B' ' 22' ' ' ALA . 1.4 pp -100.57 135.67 35.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.323 -0.861 . . . . 0.0 110.182 -179.034 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.604 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.8 OUTLIER -108.33 108.54 19.57 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.24 -0.912 . . . . 0.0 108.967 179.5 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.74 HD13 HG11 ' B' ' 75' ' ' VAL . 28.9 mt -110.67 123.52 66.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.163 -0.961 . . . . 0.0 108.876 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.6 -90.46 0.38 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.734 -1.746 . . . . 0.0 108.734 -179.402 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -152.34 27.05 0.88 Allowed Glycine 0 N--CA 1.483 1.813 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 179.396 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.478 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 4.6 mt-30 -125.78 176.31 7.02 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.259 -1.142 . . . . 0.0 109.579 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 ' CG2' ' B' ' 12' ' ' THR . 18.9 mt -136.48 128.09 28.8 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-O 121.621 0.724 . . . . 0.0 110.312 -179.263 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.45 ' HB3' HD21 ' B' ' 83' ' ' ASN . 7.6 mmtt -138.64 155.93 47.88 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.494 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mm-40 -78.81 145.13 34.47 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.631 -1.293 . . . . 0.0 109.615 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.76 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -120.54 148.84 43.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.941 -1.099 . . . . 0.0 110.762 -179.303 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.422 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -118.42 95.56 4.92 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.802 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.2 mt -45.48 107.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.994 -1.066 . . . . 0.0 109.395 -179.659 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 0.639 ' HB3' HG23 ' B' ' 84' ' ' ILE . 22.5 t0 -119.77 90.4 3.32 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.791 -179.692 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.475 HG23 ' CD ' ' B' ' 87' ' ' ARG . 1.2 m -60.36 -14.27 17.75 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.067 -1.021 . . . . 0.0 108.977 179.282 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 1.041 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -61.67 -44.46 97.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.78 148.43 30.06 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -1.17 . . . . 0.0 109.654 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.49 ' OD2' ' HG2' ' A' ' 8' ' ' ARG . 37.6 m-20 -89.12 -8.79 53.1 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.281 -0.887 . . . . 0.0 110.04 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.741 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -133.39 -171.01 2.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.025 -1.047 . . . . 0.0 109.329 -179.923 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.592 HG23 ' O ' ' B' ' 84' ' ' ILE . 43.5 m -111.97 93.25 4.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.778 -1.201 . . . . 0.0 110.974 -178.844 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.017 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.92 172.83 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.299 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 HG13 ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.84 124.3 1.29 Allowed 'General case' 0 C--N 1.305 -1.347 0 O-C-N 120.59 -1.319 . . . . 0.0 111.92 -178.838 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' B' ' 33' ' ' LEU . 0.2 OUTLIER -35.87 154.72 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 178.053 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -53.86 130.33 36.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.113 -0.992 . . . . 0.0 110.335 -179.428 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -141.33 -178.39 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.85 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.2 t -105.15 103.45 12.99 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.639 -1.288 . . . . 0.0 110.532 -178.921 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 0.709 HD12 HG21 ' B' ' 77' ' ' VAL . 51.6 mt -106.88 156.58 37.05 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 108.975 179.253 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' B' ' 40' ' ' GLY . 36.4 Cg_endo -79.35 77.99 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.695 2.263 . . . . 0.0 111.475 -179.097 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 40' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 37.37 -158.41 0.01 OUTLIER Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.212 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 41' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 22.5 mmm180 63.65 74.84 0.41 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.597 -0.943 . . . . 0.0 109.169 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.519 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 67.8 p-90 -159.13 175.9 12.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.746 . . . . 0.0 109.761 -179.294 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.54 138.71 31.81 Favored Pre-proline 0 N--CA 1.492 1.669 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.035 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.28 127.97 9.44 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.021 1.814 . . . . 0.0 111.286 -178.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.798 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -162.9 136.48 5.96 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.852 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.475 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 32.4 mtp -102.09 137.26 40.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.844 -1.16 . . . . 0.0 109.098 -179.91 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.784 ' CD1' HG21 ' A' ' 50' ' ' ILE . 19.0 pt -89.59 145.46 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.373 179.237 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 48' ' ' GLY . . . . . 0.491 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -118.23 100.92 0.87 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.748 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.29 -126.85 3.43 Favored Glycine 0 N--CA 1.483 1.775 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.054 -178.611 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.663 HG21 HD12 ' A' ' 47' ' ' ILE . 38.5 mt -83.28 118.7 31.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 O-C-N 121.863 -0.787 . . . . 0.0 112.741 -177.292 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 51' ' ' GLY . . . . . 0.55 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 100.62 -51.91 0.97 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 178.134 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.497 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . -174.6 -171.61 38.95 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.265 -1.445 . . . . 0.0 110.108 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.568 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 1.2 m-30 -106.06 128.83 54.13 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.335 -1.097 . . . . 0.0 109.349 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.554 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.0 pt -100.84 161.39 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.129 -0.982 . . . . 0.0 109.276 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 13.6 mttt -89.6 134.46 34.12 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.131 -0.981 . . . . 0.0 109.208 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.798 HG22 ' O ' ' B' ' 45' ' ' LYS . 17.0 m -142.05 172.99 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.966 -1.084 . . . . 0.0 109.588 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 6.9 mtm180 -124.75 101.32 7.04 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.547 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 34.3 tt0 -58.4 96.36 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 110.032 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.564 ' HB3' HG13 ' B' ' 62' ' ' ILE . 13.3 m-85 -89.57 94.34 9.83 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.006 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -78.87 141.76 37.4 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.108 -0.995 . . . . 0.0 110.307 -178.846 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.65 ' HA ' HG23 ' B' ' 72' ' ' ILE . 15.2 mt-30 69.38 64.02 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.334 0.588 . . . . 0.0 110.765 179.479 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 0.812 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.9 OUTLIER -119.84 125.01 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 108.847 178.727 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 1.148 HD21 ' CG ' ' B' ' 70' ' ' LYS . 2.8 tm? -74.4 86.45 2.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.309 -0.87 . . . . 0.0 110.903 -178.942 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.616 HG23 ' O ' ' B' ' 64' ' ' ILE . 3.4 tt -90.81 116.93 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.007 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.7 tt0 -90.07 116.56 28.19 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.811 -1.181 . . . . 0.0 109.72 -179.404 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.628 ' CG1' HG21 ' B' ' 11' ' ' VAL . 0.5 OUTLIER -105.11 116.93 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.157 -0.964 . . . . 0.0 109.675 -179.898 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 51.85 16.55 0.52 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.782 -0.574 . . . . 0.0 111.603 178.454 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 106.99 18.65 10.3 Favored Glycine 0 N--CA 1.495 2.604 0 C-N-CA 119.277 -1.439 . . . . 0.0 110.679 179.016 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -116.08 98.85 6.86 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.084 -1.245 . . . . 0.0 108.898 179.459 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 70' ' ' LYS . . . . . 1.148 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.6 ttpm? -54.36 120.06 6.05 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.901 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.65 130.86 22.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 110.693 -178.827 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.812 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.8 OUTLIER -94.19 147.1 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.581 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.813 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -171.09 175.83 44.62 Favored Glycine 0 N--CA 1.489 2.209 0 C-N-CA 118.557 -1.782 . . . . 0.0 111.538 -179.601 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.547 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 8.6 m -87.97 102.41 14.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.927 -0.749 . . . . 0.0 110.465 -179.616 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.065 HG13 HD13 ' B' ' 33' ' ' LEU . 1.5 t -94.12 108.64 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.368 -0.832 . . . . 0.0 110.01 179.189 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.741 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.0 mp -79.83 111.03 15.75 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.84 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 77' ' ' VAL . . . . . 0.709 HG21 HD12 ' B' ' 38' ' ' LEU . 11.2 t -93.68 116.51 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.117 -0.99 . . . . 0.0 110.122 -179.014 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -151.53 -172.83 20.76 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.477 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.6 Cg_endo -80.42 42.99 1.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.525 2.15 . . . . 0.0 110.839 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.722 HG21 HG13 ' B' ' 32' ' ' VAL . 0.9 OUTLIER -83.01 143.62 46.16 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.035 -1.041 . . . . 0.0 108.496 179.198 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.54 14.8 1.54 Allowed 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.275 1.983 . . . . 0.0 110.874 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.459 HG13 ' N ' ' B' ' 83' ' ' ASN . 1.2 t -160.91 165.08 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.902 -1.124 . . . . 0.0 109.816 -179.527 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.61 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 1.1 m-20 -103.2 119.01 38.08 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 104.675 -2.343 . . . . 0.0 104.675 176.272 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 0.639 HG23 ' HB3' ' B' ' 25' ' ' ASP . 14.6 mm -102.17 126.41 56.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 O-C-N 120.762 -1.211 . . . . 0.0 111.9 -175.981 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.76 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -103.89 88.33 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 177.304 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.59 -158.3 11.84 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 120.145 -1.026 . . . . 0.0 111.228 -177.568 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.869 ' HG3' HD12 ' A' ' 5' ' ' LEU . 7.3 mmm180 -69.01 -37.81 78.9 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.666 -0.902 . . . . 0.0 110.672 -178.748 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.977 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.7 p-10 -43.45 -25.18 0.13 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.647 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.977 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.3 mm? -111.5 -29.79 7.63 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.07 -1.019 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.711 HD21 HD22 ' B' ' 24' ' ' LEU . 33.6 mt -67.33 -8.32 31.49 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.243 -0.91 . . . . 0.0 108.965 179.319 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 91' ' ' THR . . . . . 0.599 HG23 HH21 ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.6 -20.28 15.74 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.162 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -81.4 -40.2 23.8 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.77 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -81.28 -2.66 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 108.839 178.89 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 81.95 24.23 55.75 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 178.996 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.706 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -60.58 137.62 58.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.842 -1.387 . . . . 0.0 109.994 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 96' ' ' THR . 44.5 p -132.65 122.1 24.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.645 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -89.51 94.37 9.85 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 121.324 0.583 . . . . 0.0 109.503 -178.683 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.4 m-20 -109.43 130.94 55.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.279 -0.888 . . . . 0.0 110.53 -179.312 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.854 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.096 178.464 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 1' ' ' PRO . . . . . 0.514 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.495 1.604 0 N-CA-C 109.767 -0.897 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -83.32 134.84 34.9 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 177.686 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.566 HG11 ' HB3' ' A' ' 9' ' ' PRO . 6.6 t -126.84 101.82 8.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.585 -1.246 . . . . 0.0 110.501 -178.092 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.695 HG22 HG22 ' B' ' 96' ' ' THR . 1.7 p -115.18 -81.52 0.61 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.342 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.54 ' O ' ' C ' ' A' ' 6' ' ' TRP . 92.0 mt 33.71 32.91 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.923 -0.486 . . . . 0.0 110.441 178.866 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 7.2 m0 18.33 50.74 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.499 0.666 . . . . 0.0 111.651 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.6 OUTLIER -143.6 -163.83 1.74 Allowed 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.549 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.436 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -84.86 136.64 38.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 108.869 179.703 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.566 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.4 Cg_endo -78.97 67.63 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.316 2.011 . . . . 0.0 109.776 179.099 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.434 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -86.91 143.04 27.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.19 -0.944 . . . . 0.0 109.592 -179.619 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.606 HG21 HG23 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -139.51 160.66 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.829 . . . . 0.0 109.412 -179.745 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.841 HG22 HD22 ' A' ' 19' ' ' LEU . 34.5 m -95.33 109.96 22.03 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.237 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.882 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.7 pt -97.8 159.1 3.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 110.401 -178.312 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.52 ' HE3' HD11 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -119.3 99.1 6.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.485 -0.759 . . . . 0.0 109.095 179.53 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.935 HD13 HG11 ' A' ' 75' ' ' VAL . 17.0 mt -114.64 130.55 68.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.165 -0.959 . . . . 0.0 109.534 -179.653 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.63 50.56 62.35 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.807 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.67 26.18 16.16 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.946 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.5 mt-30 -120.37 173.66 7.0 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -1.158 . . . . 0.0 109.041 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.2 mt -140.46 126.94 20.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.128 -0.983 . . . . 0.0 110.352 -179.678 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.656 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -144.13 175.04 10.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.516 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 83' ' ' ASN . 1.9 mm-40 -79.44 178.15 8.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.845 -1.16 . . . . 0.0 108.721 179.67 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.691 ' HB1' HG12 ' A' ' 85' ' ' ILE . . . -158.38 117.97 3.19 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.875 -1.14 . . . . 0.0 110.035 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 25' ' ' ASP . 59.0 tp -90.56 95.47 10.18 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.431 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.643 ' CD1' ' CZ ' ' B' ' 99' ' ' PHE . 10.9 mt -46.16 97.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 -179.682 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.566 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 18.9 t0 -103.49 91.67 4.15 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.533 -0.729 . . . . 0.0 110.647 -177.851 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.877 HG23 HD12 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -67.77 -6.74 22.62 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.886 -1.134 . . . . 0.0 108.977 178.767 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.49 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -80.11 -39.49 16.04 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.446 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.89 160.71 31.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.824 -1.398 . . . . 0.0 109.52 -179.505 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -99.85 -16.46 18.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.932 . . . . 0.0 109.062 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.4 OUTLIER -132.29 -161.19 1.11 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.44 -0.787 . . . . 0.0 109.152 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.748 HG22 ' CD1' ' A' ' 33' ' ' LEU . 21.5 m -121.04 89.8 3.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.559 -1.338 . . . . 0.0 110.675 -178.526 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.03 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.953 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 1.03 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -161.17 129.44 4.4 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.965 -1.084 . . . . 0.0 110.679 -178.707 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.466 ' C ' ' O ' ' A' ' 33' ' ' LEU . 7.0 tt0 -40.8 156.85 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.111 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.794 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.3 OUTLIER -52.89 153.09 3.52 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.06 -1.025 . . . . 0.0 110.364 -179.155 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 4.1 ptm -177.47 -163.76 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.407 -0.808 . . . . 0.0 109.019 179.71 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -107.52 142.17 37.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.697 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.779 HD21 HG22 ' A' ' 15' ' ' ILE . 9.3 mt -150.33 167.22 13.43 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.531 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.2 Cg_endo -76.78 138.43 18.86 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.299 1.999 . . . . 0.0 109.342 179.33 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.59 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -48.0 -169.33 0.01 OUTLIER Glycine 0 N--CA 1.492 2.42 0 CA-C-O 121.854 0.696 . . . . 0.0 111.438 -178.669 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.59 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.2 OUTLIER 81.91 46.92 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 -178.965 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.679 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 57.8 p-90 -137.24 -172.02 3.1 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.405 0.621 . . . . 0.0 109.798 -179.196 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.19 138.65 11.97 Favored Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 121.41 -0.806 . . . . 0.0 109.204 179.226 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.32 139.48 18.68 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.117 1.878 . . . . 0.0 110.028 179.455 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 0.2 OUTLIER -160.59 -159.46 0.69 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.432 -0.793 . . . . 0.0 108.951 -179.775 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.509 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 69.4 mtp -148.93 130.5 14.91 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.119 -0.988 . . . . 0.0 109.41 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.828 HD11 HG21 ' B' ' 50' ' ' ILE . 14.6 pt -88.95 144.68 8.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.14 97.91 0.76 Allowed Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.228 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.68 -126.43 3.26 Favored Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.325 -179.151 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.902 HG21 HD12 ' B' ' 47' ' ' ILE . 21.8 mt -87.43 112.17 22.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.809 -0.818 . . . . 0.0 112.639 -177.787 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.544 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 116.77 -48.52 0.93 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 178.054 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.76 -154.57 21.22 Favored Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.023 -179.618 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.1 m-85 -114.14 116.4 29.04 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.562 -0.964 . . . . 0.0 110.009 -179.454 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.0 pt -89.85 175.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.149 -0.969 . . . . 0.0 109.084 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.542 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -104.13 142.5 34.38 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 108.853 179.423 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.76 HG21 HD23 ' A' ' 76' ' ' LEU . 15.1 m -150.93 175.25 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.943 -1.098 . . . . 0.0 110.293 -179.54 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.53 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -126.61 98.23 5.32 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.646 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.541 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 0.7 OUTLIER -58.1 102.58 0.11 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.219 -0.925 . . . . 0.0 110.971 -179.016 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.679 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 23.0 m-85 -98.89 94.35 6.53 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.114 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.6 OUTLIER -79.02 139.41 38.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.465 -178.538 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 73.96 62.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.674 -0.641 . . . . 0.0 110.064 179.499 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.603 HG21 HG23 ' A' ' 15' ' ' ILE . 10.5 mm -119.69 114.46 44.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.145 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.905 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -63.61 87.02 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.362 -0.836 . . . . 0.0 110.944 -178.586 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 66' ' ' ILE . 5.6 tt -89.59 115.23 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 178.078 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.458 ' OE2' ' N ' ' A' ' 69' ' ' HIS . 1.1 tm-20 -88.35 123.51 33.0 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.106 -0.996 . . . . 0.0 109.181 -178.773 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.67 HD11 ' CD1' ' A' ' 64' ' ' ILE . 2.3 mt -126.13 122.42 61.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 110.188 -179.049 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 56.15 46.68 21.02 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.662 -0.649 . . . . 0.0 111.174 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.77 22.62 68.42 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 120.163 -1.018 . . . . 0.0 110.928 178.406 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.458 ' N ' ' OE2' ' A' ' 65' ' ' GLU . 5.9 m-70 -123.41 130.79 53.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.993 -1.298 . . . . 0.0 109.186 179.24 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.618 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -72.48 129.18 37.72 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 108.908 179.713 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.56 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -146.55 109.57 4.68 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.54 -0.725 . . . . 0.0 109.677 -179.324 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.588 HG12 HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -90.43 156.88 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.764 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.788 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.53 -171.31 41.68 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 118.435 -1.84 . . . . 0.0 111.597 179.819 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 7.7 m -96.79 104.92 16.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.737 -0.861 . . . . 0.0 109.542 -179.669 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 1.023 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -100.33 113.4 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.294 -0.879 . . . . 0.0 110.567 -179.573 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.76 HD23 HG21 ' A' ' 56' ' ' VAL . 5.3 mp -82.78 125.3 31.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.847 . . . . 0.0 108.841 178.938 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.794 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.1 t -103.92 110.45 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.0 -1.062 . . . . 0.0 109.423 -179.959 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.524 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.61 -171.47 15.21 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.949 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.542 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 42.42 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.454 2.103 . . . . 0.0 110.41 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.601 HG21 HG13 ' A' ' 32' ' ' VAL . 6.5 t -81.47 141.89 49.5 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.542 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -79.74 16.95 1.35 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.408 2.072 . . . . 0.0 111.339 -179.629 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.542 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -161.05 165.87 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.917 -1.114 . . . . 0.0 109.894 -179.571 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.656 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -103.79 96.72 6.89 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 105.11 -2.181 . . . . 0.0 105.11 176.761 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.613 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.4 mm -83.15 115.42 25.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 O-C-N 121.082 -1.011 . . . . 0.0 113.1 -175.756 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.837 ' N ' HD13 ' A' ' 85' ' ' ILE . 0.5 OUTLIER -95.0 91.99 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 175.612 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.32 -157.38 8.6 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.884 -1.15 . . . . 0.0 110.783 -177.047 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -69.56 -37.14 76.88 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.884 -0.774 . . . . 0.0 110.37 -178.804 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -46.58 -28.86 1.57 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.762 -1.211 . . . . 0.0 109.634 -179.757 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -110.96 -30.96 7.3 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.994 -1.067 . . . . 0.0 111.466 -178.361 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.877 HD12 HG23 ' A' ' 26' ' ' THR . 0.6 OUTLIER -59.57 -31.46 69.46 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.769 -1.207 . . . . 0.0 108.642 -179.869 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -78.85 -20.7 48.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.898 . . . . 0.0 110.123 -179.89 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 -69.77 -40.66 75.93 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.88 -1.138 . . . . 0.0 108.262 179.319 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.943 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -83.67 -7.17 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.864 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.52 62.92 3.25 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.805 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -83.21 148.88 27.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.315 -1.109 . . . . 0.0 109.674 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.579 HG22 ' CG2' ' B' ' 4' ' ' THR . 5.0 p -137.46 129.74 29.45 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.142 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.679 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -96.58 88.65 4.73 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.263 -0.898 . . . . 0.0 109.422 -179.745 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 10.6 m-20 -93.6 121.59 35.18 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.116 -0.99 . . . . 0.0 109.126 179.827 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.636 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.402 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 1' ' ' PRO . . . . . 0.605 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.619 0 N-CA-C 110.641 -0.561 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.01 136.9 32.77 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 177.85 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.2 t -133.93 105.89 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 120.574 -1.329 . . . . 0.0 110.57 -178.558 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.579 ' CG2' HG22 ' A' ' 96' ' ' THR . 15.8 p -122.03 -70.13 0.8 Allowed 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.063 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER 31.24 37.79 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.81 -0.556 . . . . 0.0 110.743 179.146 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 5.5 m95 18.8 50.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.186 0 CA-C-O 121.504 0.669 . . . . 0.0 111.924 -179.756 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.537 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.4 OUTLIER -154.55 165.4 36.6 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.155 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.5 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 71.2 mtm180 -49.0 133.15 15.0 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.012 -179.827 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 9' ' ' PRO . . . . . 0.494 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.6 Cg_endo -80.09 64.83 8.91 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.312 2.008 . . . . 0.0 109.514 179.028 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 10' ' ' LEU . . . . . 0.699 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -79.89 148.24 31.38 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.33 -0.856 . . . . 0.0 109.521 -179.663 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 11' ' ' VAL . . . . . 0.756 HG21 HG23 ' B' ' 66' ' ' ILE . 1.4 m -140.29 132.28 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.307 -0.871 . . . . 0.0 109.592 179.872 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 12' ' ' THR . . . . . 0.66 HG22 HD22 ' B' ' 19' ' ' LEU . 11.8 m -64.09 99.77 0.28 Allowed 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.498 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 13' ' ' ILE . . . . . 0.635 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.0 OUTLIER -90.41 147.89 4.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.255 -0.903 . . . . 0.0 110.615 -178.178 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 14' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 2.8 tttt -107.93 107.94 18.87 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 1.046 HD13 HG11 ' B' ' 75' ' ' VAL . 14.8 mt -122.88 119.04 56.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.205 -0.934 . . . . 0.0 109.604 -179.273 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 16' ' ' GLY . . . . . 0.402 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.59 20.99 74.4 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.38 -7.74 79.66 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.545 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 18' ' ' GLN . . . . . 0.479 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 29.8 mt-30 -87.19 -175.25 5.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -1.107 . . . . 0.0 109.52 -179.961 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 19' ' ' LEU . . . . . 0.66 HD22 HG22 ' B' ' 12' ' ' THR . 40.9 mt -152.19 119.95 6.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.919 -179.861 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' B' ' 19' ' ' LEU . 2.5 mmmt -134.82 161.61 34.73 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.699 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.1 OUTLIER -79.09 122.82 26.71 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.526 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 22' ' ' ALA . . . . . 0.759 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -108.63 119.4 39.43 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.921 -1.112 . . . . 0.0 111.145 -178.578 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 23' ' ' LEU . . . . . 0.5 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 24.9 tp -75.43 99.59 4.21 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.633 179.561 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 24' ' ' LEU . . . . . 0.698 ' CD2' HD21 ' B' ' 90' ' ' LEU . 4.6 mt -48.68 96.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 25' ' ' ASP . . . . . 1.05 ' CB ' HG23 ' B' ' 84' ' ' ILE . 8.7 t0 -96.88 95.6 7.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 110.068 -179.379 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 26' ' ' THR . . . . . 0.684 HG21 HD13 ' B' ' 97' ' ' LEU . 9.8 m -74.27 -4.29 35.25 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.157 -0.964 . . . . 0.0 108.467 178.455 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 27' ' ' GLY . . . . . 0.478 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -85.81 -26.25 35.54 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.85 162.32 16.22 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.869 -1.371 . . . . 0.0 109.999 -179.304 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 29' ' ' ASP . . . . . 0.501 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.2 m-20 -100.62 -13.9 18.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -0.799 . . . . 0.0 110.719 -179.132 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.511 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.82 -172.22 2.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.912 -1.117 . . . . 0.0 109.506 -179.706 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 31' ' ' THR . . . . . 0.55 HG22 ' CD1' ' B' ' 33' ' ' LEU . 20.6 m -111.04 87.28 2.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.519 -1.363 . . . . 0.0 110.702 -178.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 32' ' ' VAL . . . . . 1.041 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -73.43 170.6 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 178.179 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 1.041 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.51 122.12 1.99 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.533 -1.354 . . . . 0.0 110.609 -178.576 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.696 ' HA ' HG22 ' B' ' 80' ' ' THR . 88.5 tt0 -40.26 152.92 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.371 -0.831 . . . . 0.0 109.311 179.102 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.8 tt0 -46.09 147.77 0.98 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 110.602 -179.313 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.8 ptt? -168.01 156.81 9.26 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.6 t -79.26 85.63 5.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 109.788 -179.339 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 38' ' ' LEU . . . . . 1.075 HD21 HD12 ' B' ' 62' ' ' ILE . 62.7 tp -103.14 115.13 64.51 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.273 -0.892 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 39' ' ' PRO . . . . . 0.737 ' HD2' HD12 ' B' ' 38' ' ' LEU . 34.1 Cg_endo -77.05 125.28 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.44 2.094 . . . . 0.0 110.534 -179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.96 154.49 6.18 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.98 153.02 38.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -1.182 . . . . 0.0 109.287 -179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 42' ' ' TRP . . . . . 0.492 ' CE3' ' HB3' ' B' ' 57' ' ' ARG . 58.0 p-90 -156.58 172.45 18.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.141 -0.975 . . . . 0.0 109.394 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.66 137.39 30.26 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.028 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.35 137.74 15.2 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.112 1.874 . . . . 0.0 111.093 -179.613 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 45' ' ' LYS . . . . . 0.563 ' HG2' HG23 ' B' ' 56' ' ' VAL . 3.8 ptmt -159.98 -172.9 3.81 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.161 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 46' ' ' MET . . . . . 0.415 ' HA ' ' O ' ' B' ' 54' ' ' ILE . 28.1 mtp -141.58 137.61 32.05 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.662 -1.274 . . . . 0.0 109.842 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 47' ' ' ILE . . . . . 0.902 HD12 HG21 ' A' ' 50' ' ' ILE . 1.4 pt -96.06 152.74 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.475 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.48 116.33 3.37 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.778 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -149.13 -124.66 1.35 Allowed Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.25 -179.681 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 50' ' ' ILE . . . . . 0.828 HG21 HD11 ' A' ' 47' ' ' ILE . 20.4 mt -86.59 123.93 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.527 -0.984 . . . . 0.0 112.375 -178.181 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.78 -7.93 70.72 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 120.27 -0.967 . . . . 0.0 111.148 177.717 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 125.91 -159.22 20.32 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 53' ' ' PHE . . . . . 0.538 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -112.96 142.03 46.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.314 -1.11 . . . . 0.0 109.843 -179.585 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.831 HD11 HD11 ' B' ' 47' ' ' ILE . 6.5 pt -107.17 -178.3 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.258 -0.901 . . . . 0.0 109.368 179.554 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 55' ' ' LYS . . . . . 0.576 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -106.34 148.21 28.3 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.421 -0.799 . . . . 0.0 108.894 179.475 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 56' ' ' VAL . . . . . 0.563 HG23 ' HG2' ' B' ' 45' ' ' LYS . 29.3 m -151.22 -179.1 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.687 -1.258 . . . . 0.0 110.408 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 57' ' ' ARG . . . . . 0.492 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.6 mtt-85 -130.47 86.41 2.38 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.237 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 58' ' ' GLN . . . . . 0.5 ' HB2' ' HD2' ' B' ' 45' ' ' LYS . 24.5 tt0 -47.41 105.63 0.07 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.588 -0.695 . . . . 0.0 111.301 -178.469 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 59' ' ' TYR . . . . . 0.715 ' CD2' HD23 ' B' ' 38' ' ' LEU . 5.1 m-85 -99.03 90.3 4.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 60' ' ' ASP . . . . . 0.438 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 2.8 m-20 -79.0 136.32 37.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.872 -1.143 . . . . 0.0 111.502 -177.753 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 13.9 mt-30 68.21 62.5 0.38 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-O 121.179 0.514 . . . . 0.0 110.632 178.542 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 62' ' ' ILE . . . . . 1.075 HD12 HD21 ' B' ' 38' ' ' LEU . 0.1 OUTLIER -122.51 122.39 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.205 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 1.01 HD13 ' O ' ' B' ' 63' ' ' LEU . 1.3 tm? -60.51 87.4 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.759 0.79 . . . . 0.0 111.896 -177.741 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 64' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' B' ' 71' ' ' ALA . 2.6 tt -95.81 111.53 26.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 176.561 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.4 tt0 -90.25 124.64 35.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.76 -1.212 . . . . 0.0 109.152 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 66' ' ' ILE . . . . . 0.756 HG23 HG21 ' B' ' 11' ' ' VAL . 1.0 OUTLIER -106.53 128.23 61.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.156 -0.965 . . . . 0.0 109.269 -179.728 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 58.86 -90.1 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.683 -0.636 . . . . 0.0 109.682 179.583 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.92 40.95 0.99 Allowed Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 69' ' ' HIS . . . . . 0.509 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 86.6 m-70 -137.64 114.14 10.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -1.132 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.47 120.86 8.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.351 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 71' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' B' ' 64' ' ' ILE . . . -132.87 151.63 52.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.405 -0.809 . . . . 0.0 109.429 179.897 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 72' ' ' ILE . . . . . 0.857 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -125.22 156.5 34.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 177.527 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 73' ' ' GLY . . . . . 0.601 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.27 -165.15 34.86 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 117.906 -2.093 . . . . 0.0 111.492 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 74' ' ' THR . . . . . 0.501 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.5 m -99.41 103.61 15.41 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.906 -0.761 . . . . 0.0 110.017 -179.476 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 75' ' ' VAL . . . . . 1.046 HG11 HD13 ' B' ' 15' ' ' ILE . 1.3 t -94.73 102.19 13.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.471 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.49 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.8 mp -79.12 112.74 16.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.033 -1.042 . . . . 0.0 108.981 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 52.9 t -97.89 117.72 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.102 -0.999 . . . . 0.0 109.814 -179.521 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.89 -164.28 11.67 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 179.739 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 79' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -82.76 38.04 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.202 1.935 . . . . 0.0 110.404 179.814 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 80' ' ' THR . . . . . 0.696 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.6 t -79.85 134.32 57.08 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 178.785 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 81' ' ' PRO . . . . . 0.547 ' O ' HG23 ' B' ' 82' ' ' VAL . 32.1 Cg_endo -77.5 17.04 0.97 Allowed 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.393 2.062 . . . . 0.0 111.701 -178.556 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.651 HG12 ' CD1' ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.23 151.4 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.755 -1.216 . . . . 0.0 109.972 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.611 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 84.8 m-20 -89.57 127.08 35.84 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.23 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 84' ' ' ILE . . . . . 1.05 HG23 ' CB ' ' B' ' 25' ' ' ASP . 3.9 mt -127.89 121.79 57.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 119.903 -1.748 . . . . 0.0 112.655 -176.538 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.759 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -89.43 111.1 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.384 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -92.15 -159.15 35.06 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.57 -178.821 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 87' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.0 mtp180 -68.63 -29.47 67.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.685 -0.891 . . . . 0.0 109.984 -179.524 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 88' ' ' ASN . . . . . 0.989 ' ND2' HD23 ' B' ' 89' ' ' LEU . 16.1 p-10 -53.62 -26.92 24.11 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.062 -1.024 . . . . 0.0 109.601 -179.588 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.989 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.9 mm? -108.87 -30.48 8.11 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.066 -1.021 . . . . 0.0 109.847 -179.494 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.698 HD21 ' CD2' ' B' ' 24' ' ' LEU . 85.0 mt -61.29 -30.31 70.4 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.247 -0.908 . . . . 0.0 108.849 179.863 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.1 p -78.47 -22.0 48.21 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.292 -0.88 . . . . 0.0 108.796 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -72.16 -40.73 67.79 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.326 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 93' ' ' ILE . . . . . 0.636 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -87.89 -8.12 10.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.349 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 94' ' ' GLY . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.09 61.41 6.11 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.255 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 95' ' ' ALA . . . . . 0.549 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -88.53 158.55 18.27 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -1.152 . . . . 0.0 110.341 -179.664 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 96' ' ' THR . . . . . 0.695 HG22 HG22 ' A' ' 4' ' ' THR . 43.7 p -135.29 127.6 30.23 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.596 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 97' ' ' LEU . . . . . 0.684 HD13 HG21 ' B' ' 26' ' ' THR . 0.2 OUTLIER -91.4 95.69 10.12 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.302 -0.874 . . . . 0.0 109.902 -178.786 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' B' B ' 98' ' ' ASN . . . . . 0.465 ' HA ' ' O ' ' A' ' 1' ' ' PRO . 1.6 m-20 -106.83 131.36 54.02 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.868 . . . . 0.0 109.941 -179.882 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 99' ' ' PHE . . . . . 0.943 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.284 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.615 0 CA-C-O 121.355 0.481 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.433 ' HG3' ' CG ' ' B' ' 98' ' ' ASN . 20.7 tt0 -86.19 118.5 25.69 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 177.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -115.15 105.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 120.806 -1.184 . . . . 0.0 110.405 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.818 HG22 HG22 ' B' ' 96' ' ' THR . 1.3 p -123.34 30.0 6.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.615 -0.678 . . . . 0.0 109.709 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.548 ' O ' ' C ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -89.56 39.33 0.94 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.13 -0.981 . . . . 0.0 109.295 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.548 ' C ' ' O ' ' A' ' 5' ' ' LEU . 46.2 m0 16.28 59.36 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 CA-C-O 121.613 0.72 . . . . 0.0 111.918 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -145.14 174.22 11.25 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.395 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -65.97 118.32 51.0 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.98 -1.075 . . . . 0.0 108.915 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.974 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 71.66 6.16 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.214 1.942 . . . . 0.0 109.545 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -92.93 157.07 16.53 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.442 -0.786 . . . . 0.0 109.523 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.535 HG21 HG13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -150.77 136.53 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.183 -0.948 . . . . 0.0 110.158 -179.599 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.84 HG22 HD22 ' A' ' 19' ' ' LEU . 55.0 m -68.32 108.9 3.39 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.919 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.2 pp -98.66 152.46 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 120.957 -1.09 . . . . 0.0 111.012 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.51 ' HE3' HD11 ' A' ' 19' ' ' LEU . 10.9 tttt -113.23 104.61 12.51 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' A' ' 75' ' ' VAL . 5.1 mt -120.84 129.81 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.079 -1.013 . . . . 0.0 109.894 -179.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.58 35.57 81.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.34 73.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -121.47 -176.76 3.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.342 -1.093 . . . . 0.0 108.653 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.919 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.4 mt -151.4 124.05 8.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.938 -1.101 . . . . 0.0 110.892 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.543 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -141.97 165.99 25.94 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 178.495 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.5 mp0 -79.25 131.62 36.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.9 -1.125 . . . . 0.0 108.747 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.655 ' HB2' ' CG2' ' A' ' 13' ' ' ILE . . . -108.09 137.87 45.33 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.067 -1.021 . . . . 0.0 110.641 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.615 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.1 tp -104.77 98.7 8.4 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.974 HD12 ' HB2' ' A' ' 9' ' ' PRO . 43.2 mt -44.95 95.17 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.064 -1.022 . . . . 0.0 108.685 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 1.4 t70 -97.05 79.8 2.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.164 -0.96 . . . . 0.0 110.732 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.407 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 27.6 m -63.11 -13.71 39.8 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.991 -1.068 . . . . 0.0 108.762 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.445 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.8 -41.39 49.85 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.04 168.95 19.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.202 -1.176 . . . . 0.0 109.67 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.71 -17.59 16.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.185 -0.947 . . . . 0.0 111.272 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.831 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -135.7 -176.71 4.38 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.427 -179.366 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 16.7 m -98.86 87.97 3.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.359 -0.838 . . . . 0.0 110.68 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.95 168.14 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 178.787 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.23 135.22 5.14 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.975 -1.078 . . . . 0.0 110.518 -178.235 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 80' ' ' THR . 2.0 mt-10 -45.16 170.68 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.375 -0.828 . . . . 0.0 108.834 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -60.59 152.68 25.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.041 -1.037 . . . . 0.0 109.888 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.633 ' HE2' HG22 ' A' ' 15' ' ' ILE . 8.1 ptm -177.8 -158.92 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.909 ' O ' HD22 ' A' ' 38' ' ' LEU . 6.6 t -110.67 127.21 55.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.258 -0.901 . . . . 0.0 110.351 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.909 HD22 ' O ' ' A' ' 37' ' ' SER . 3.8 mm? -131.88 170.01 12.4 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 36.3 Cg_endo -80.99 123.96 4.79 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.791 2.327 . . . . 0.0 112.514 -178.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.552 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -44.49 117.72 2.18 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.552 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 150.04 44.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 35.4 p-90 -118.81 -173.84 2.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.961 0.886 . . . . 0.0 110.709 -177.308 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.08 136.92 11.12 Favored Pre-proline 0 C--N 1.303 -1.451 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.05 136.89 20.88 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.846 1.698 . . . . 0.0 110.986 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.709 ' HD2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -146.8 157.52 43.69 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.547 ' CG ' ' HG2' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -119.41 125.47 49.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.836 -1.165 . . . . 0.0 110.188 -178.889 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 54' ' ' ILE . 5.7 pt -104.86 136.23 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 108.746 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.595 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.36 102.59 0.97 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -119.51 -127.16 3.56 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.627 -178.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.883 HD12 H702 ' B' ' 100' ' ' DMP . 57.0 mt -80.19 122.13 34.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.9 -0.765 . . . . 0.0 112.925 -177.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.431 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 100.0 -50.87 1.08 Allowed Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.049 177.614 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -177.5 -160.53 24.36 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.582 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.595 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.8 m-85 -113.47 133.37 55.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.567 -0.96 . . . . 0.0 109.926 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 47' ' ' ILE . 10.6 pt -113.51 168.09 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.141 -0.974 . . . . 0.0 108.918 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.7 mtpt -113.46 132.4 55.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.201 -0.937 . . . . 0.0 109.252 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.642 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.6 m -127.79 -174.59 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.969 -1.082 . . . . 0.0 110.217 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.522 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 1.7 mtt85 -127.37 92.08 3.44 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.4 tt0 -54.58 94.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.544 -0.723 . . . . 0.0 110.484 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.881 ' HB3' HD11 ' A' ' 62' ' ' ILE . 26.6 m-85 -89.51 133.7 34.46 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 177.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.5 OUTLIER -111.35 139.86 46.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.938 -1.101 . . . . 0.0 111.528 -177.664 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 69.48 63.48 0.27 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.727 -0.608 . . . . 0.0 110.44 178.868 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.881 HD11 ' HB3' ' A' ' 59' ' ' TYR . 3.6 mp -116.71 122.78 70.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -64.77 82.91 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.642 0.734 . . . . 0.0 110.48 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.928 HD12 HD11 ' A' ' 15' ' ' ILE . 2.9 tt -90.76 117.83 34.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.55 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -90.4 137.23 32.52 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.09 -1.006 . . . . 0.0 108.587 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.579 HD12 HG12 ' A' ' 64' ' ' ILE . 0.6 OUTLIER -124.37 112.61 33.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 120.902 -1.124 . . . . 0.0 108.901 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.534 ' HB3' ' CE1' ' A' ' 69' ' ' HIS . 0.1 OUTLIER 62.37 23.08 13.65 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.713 -0.617 . . . . 0.0 109.833 179.712 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 93.93 9.22 59.85 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.534 ' CE1' ' HB3' ' A' ' 67' ' ' CYS . 1.4 m-70 -100.54 105.41 16.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.097 -1.237 . . . . 0.0 109.218 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.567 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 tttt -53.77 125.07 17.12 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.134 -0.979 . . . . 0.0 109.303 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.601 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -147.18 145.99 29.7 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.566 -0.709 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.785 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.7 OUTLIER -115.43 155.31 16.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 105.93 -1.878 . . . . 0.0 105.93 177.438 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.596 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.67 -173.38 43.97 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 118.14 -1.981 . . . . 0.0 111.367 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.545 HG23 ' OD1' ' A' ' 60' ' ' ASP . 0.2 OUTLIER -93.51 107.43 19.28 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.776 -0.838 . . . . 0.0 109.555 -179.763 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' A' ' 15' ' ' ILE . 1.5 t -102.72 111.58 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.341 -0.849 . . . . 0.0 110.45 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.831 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.3 mp -81.79 122.9 28.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.439 -0.788 . . . . 0.0 109.211 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.564 HG21 HD23 ' A' ' 38' ' ' LEU . 71.9 t -103.96 118.84 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.093 -1.005 . . . . 0.0 109.769 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.642 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.03 -165.6 14.76 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.1 Cg_endo -80.31 43.26 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 122.72 2.28 . . . . 0.0 110.795 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.645 HG21 HG13 ' A' ' 32' ' ' VAL . 9.2 t -89.05 139.02 28.83 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.472 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.9 Cg_endo -79.6 17.96 1.18 Allowed 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.568 2.178 . . . . 0.0 111.81 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG12 ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.74 166.98 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.543 -1.348 . . . . 0.0 110.659 -179.811 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.556 ' OD1' ' CD2' ' A' ' 33' ' ' LEU . 7.5 m-80 -96.87 93.53 6.71 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 176.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.816 ' CG1' HG12 ' A' ' 32' ' ' VAL . 26.7 mm -78.42 127.25 38.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 O-C-N 120.727 -1.233 . . . . 0.0 112.154 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.627 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -107.43 89.96 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 177.232 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.14 -165.0 28.81 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 120.276 -0.964 . . . . 0.0 111.217 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 9.5 mtm180 -64.42 -31.05 72.1 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.793 -0.828 . . . . 0.0 109.92 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.2 p-10 -48.61 -26.04 2.04 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.145 -0.972 . . . . 0.0 109.422 -179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -106.75 -21.15 13.13 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.01 -1.056 . . . . 0.0 108.837 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.556 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 43.4 mt -72.61 -4.09 28.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 177.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.637 ' CG2' HD23 ' B' ' 5' ' ' LEU . 0.0 OUTLIER -100.57 -18.43 16.61 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 178.294 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.475 ' HA ' ' OE1' ' A' ' 92' ' ' GLN . 50.6 mm-40 -83.06 -40.9 19.27 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.874 HD12 ' CG ' ' B' ' 99' ' ' PHE . 1.4 pt -89.0 5.27 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.418 -0.801 . . . . 0.0 109.397 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 58.98 47.66 89.62 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.476 ' O ' HD12 ' B' ' 5' ' ' LEU . . . -70.69 155.1 41.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.137 -1.214 . . . . 0.0 110.76 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 24.1 p -146.74 126.09 13.12 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' B' ' 97' ' ' LEU . 4.0 mp -93.46 86.04 5.12 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.483 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 18.6 m-20 -91.38 124.4 35.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.289 -0.882 . . . . 0.0 109.652 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.045 -0.978 . . . . 0.0 109.196 179.355 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.584 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.718 0 N-CA-C 110.572 -0.588 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.66 117.44 34.02 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' B' ' 9' ' ' PRO . 9.1 t -108.04 114.69 47.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 108.605 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.935 ' C ' HD13 ' B' ' 5' ' ' LEU . 19.8 p -67.79 -105.19 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.274 -0.891 . . . . 0.0 109.073 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.935 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -171.88 -11.64 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.828 -1.17 . . . . 0.0 111.434 179.824 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.661 ' N ' HD22 ' B' ' 5' ' ' LEU . 72.2 m95 -66.61 -10.53 46.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.69 -1.256 . . . . 0.0 109.49 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.96 178.59 7.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 109.615 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.509 ' HG2' ' NH1' ' A' ' 87' ' ' ARG . 13.8 mtt180 -92.18 138.56 24.35 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.316 -0.865 . . . . 0.0 109.157 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.758 ' HB3' HG11 ' B' ' 3' ' ' VAL . 36.6 Cg_endo -79.49 59.93 7.6 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.246 1.964 . . . . 0.0 110.147 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.684 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -86.43 145.72 26.73 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.945 -1.097 . . . . 0.0 109.102 -179.923 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.599 HG21 HG23 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -145.15 136.01 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.651 -179.137 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.743 HG22 HD22 ' B' ' 19' ' ' LEU . 86.5 m -68.26 90.5 0.35 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.701 HG22 HG13 ' B' ' 66' ' ' ILE . 47.8 pt -79.09 153.7 4.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.451 -0.781 . . . . 0.0 110.02 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.81 ' HG3' HD21 ' B' ' 19' ' ' LEU . 3.2 tttt -115.14 100.56 8.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.413 -0.804 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.724 HG23 HG21 ' B' ' 62' ' ' ILE . 11.1 mt -122.81 131.19 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.55 48.65 85.0 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.55 20.96 6.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.1 mp0 -112.98 171.44 7.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.155 -1.203 . . . . 0.0 109.714 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.81 HD21 ' HG3' ' B' ' 14' ' ' LYS . 55.5 mt -143.47 127.67 17.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.378 -0.826 . . . . 0.0 109.524 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -147.95 165.99 29.06 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 108.912 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.684 ' HB3' HD22 ' B' ' 10' ' ' LEU . 2.5 mm-40 -78.55 127.37 32.04 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.055 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.664 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.57 159.07 16.05 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.886 -1.134 . . . . 0.0 109.808 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.461 HD11 HH22 ' A' ' 87' ' ' ARG . 19.2 tp -122.53 93.76 4.08 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.485 -0.76 . . . . 0.0 109.109 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.565 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.7 mt -46.41 110.66 0.29 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.994 -1.066 . . . . 0.0 108.243 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.611 ' HB3' HG22 ' B' ' 84' ' ' ILE . 56.3 t0 -122.07 91.65 3.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.19 -0.944 . . . . 0.0 110.403 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.69 HG23 HD13 ' B' ' 90' ' ' LEU . 1.3 m -65.0 -10.3 28.49 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.9 -1.125 . . . . 0.0 108.78 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.615 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -68.74 -46.94 58.85 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.488 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -73.41 164.92 26.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.154 -1.204 . . . . 0.0 109.496 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -101.14 -15.44 17.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.027 -1.046 . . . . 0.0 110.969 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.613 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -132.08 -163.37 1.33 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.778 -1.201 . . . . 0.0 110.024 -179.3 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.673 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 67.0 m -113.39 91.34 3.61 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.052 -1.03 . . . . 0.0 110.012 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -77.56 156.17 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.371 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.004 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -152.78 124.36 7.76 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.595 -1.316 . . . . 0.0 110.162 -178.894 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.527 ' HA ' HG22 ' B' ' 80' ' ' THR . 47.5 tt0 -36.56 153.3 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.548 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.5 tt0 -53.63 152.49 5.11 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -0.981 . . . . 0.0 109.93 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.3 ptm -177.26 -174.12 0.48 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.486 -0.759 . . . . 0.0 109.406 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -91.52 105.73 17.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 109.648 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' B' ' 39' ' ' PRO . 32.2 tp -134.96 105.07 10.5 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.718 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.7 Cg_endo -78.24 138.7 16.19 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.451 2.101 . . . . 0.0 110.147 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.95 179.45 22.17 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.12 139.72 35.47 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.276 -1.132 . . . . 0.0 109.13 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.578 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 38.7 p-90 -150.36 153.38 35.92 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.138 -0.976 . . . . 0.0 109.958 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.77 131.16 24.25 Favored Pre-proline 0 N--CA 1.489 1.478 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.12 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.72 135.79 16.37 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.982 1.788 . . . . 0.0 110.708 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.573 ' HG3' HG22 ' B' ' 56' ' ' VAL . 1.1 ptmm? -158.04 -168.35 2.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.543 -0.723 . . . . 0.0 109.059 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.513 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 1.0 OUTLIER -145.36 121.1 10.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.097 -1.002 . . . . 0.0 110.015 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.648 HD12 HG21 ' A' ' 50' ' ' ILE . 2.4 pt -92.26 141.18 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.25 -0.906 . . . . 0.0 108.618 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.56 108.65 1.53 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.47 -119.09 2.21 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.499 -1.334 . . . . 0.0 110.244 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.686 HG21 HD12 ' A' ' 47' ' ' ILE . 25.8 mt -87.75 130.87 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.441 -1.035 . . . . 0.0 111.781 -178.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.485 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 91.3 -45.0 2.79 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.549 -1.021 . . . . 0.0 110.549 178.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.431 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.36 -159.36 29.38 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.444 -1.36 . . . . 0.0 110.167 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -121.62 139.34 53.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.505 -0.997 . . . . 0.0 109.16 -179.715 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' B' ' 46' ' ' MET . 32.4 pt -114.31 -176.16 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.257 -0.902 . . . . 0.0 109.655 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.526 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -107.28 150.03 27.12 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.321 -0.862 . . . . 0.0 108.955 179.406 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.599 HG21 HD23 ' B' ' 76' ' ' LEU . 3.2 m -143.72 -174.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 120.788 -1.195 . . . . 0.0 110.655 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' B' ' 77' ' ' VAL . 3.6 mtm-85 -142.41 88.47 2.08 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.522 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 2.2 tt0 -48.02 95.05 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.314 -0.866 . . . . 0.0 110.296 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.578 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.2 m-85 -92.43 92.82 8.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 4.6 m-20 -79.88 130.72 35.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.97 -1.081 . . . . 0.0 111.025 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.516 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 2.9 mt-30 84.95 59.27 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 CA-C-O 121.165 0.507 . . . . 0.0 110.968 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.724 HG21 HG23 ' B' ' 15' ' ' ILE . 13.2 mm -118.41 124.9 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -1.0 . . . . 0.0 108.579 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.675 HD21 ' HG3' ' B' ' 70' ' ' LYS . 1.9 tm? -72.16 99.99 2.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.174 -0.954 . . . . 0.0 110.998 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.97 HD13 HD11 ' B' ' 66' ' ' ILE . 1.3 tt -104.7 117.62 50.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.48 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 31.7 tt0 -90.77 108.56 19.9 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.091 -1.006 . . . . 0.0 109.118 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.97 HD11 HD13 ' B' ' 64' ' ' ILE . 1.1 mp -99.03 116.89 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.957 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 10.1 m 64.26 17.28 10.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.821 -0.55 . . . . 0.0 110.649 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 96.94 4.11 58.92 Favored Glycine 0 N--CA 1.492 2.423 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.15 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m80 -104.68 116.33 31.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.049 -1.265 . . . . 0.0 109.418 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.675 ' HG3' HD21 ' B' ' 63' ' ' LEU . 14.7 tttt -52.81 137.86 30.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.45 -0.782 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.677 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -160.13 100.88 1.4 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.18 -0.95 . . . . 0.0 109.619 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.606 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.31 156.56 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.642 -1.286 . . . . 0.0 108.32 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.746 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -177.75 176.27 47.95 Favored Glycine 0 N--CA 1.488 2.149 0 C-N-CA 118.999 -1.572 . . . . 0.0 111.167 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.522 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 10.6 m -88.51 109.85 20.39 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.63 -0.924 . . . . 0.0 110.376 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.867 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -99.84 110.89 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.274 -0.891 . . . . 0.0 110.534 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.613 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -79.52 104.27 10.01 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' B' ' 35' ' ' GLU . 26.3 t -88.77 125.5 41.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 120.777 -1.202 . . . . 0.0 110.017 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -153.01 -169.32 18.05 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.526 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -81.44 41.86 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.557 2.171 . . . . 0.0 110.793 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.616 HG21 HG13 ' B' ' 32' ' ' VAL . 14.6 t -84.73 140.15 37.88 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.452 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.6 Cg_endo -79.38 14.0 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.376 2.051 . . . . 0.0 111.175 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.673 HG12 HD11 ' B' ' 84' ' ' ILE . 0.5 OUTLIER -160.85 176.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.825 -1.172 . . . . 0.0 110.591 -179.47 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.665 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -107.98 147.78 30.61 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 176.721 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.673 HD11 HG12 ' B' ' 82' ' ' VAL . 4.6 mm -135.3 100.1 2.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 O-C-N 120.902 -1.124 . . . . 0.0 110.963 -177.224 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.664 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -79.2 88.86 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.336 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -81.23 -160.42 24.84 Favored Glycine 0 N--CA 1.494 2.555 0 O-C-N 121.363 -0.836 . . . . 0.0 112.103 -177.147 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.414 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.8 mtm180 -58.91 -41.0 86.22 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 122.148 -0.619 . . . . 0.0 111.386 -178.853 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.862 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.9 p-10 -52.23 -18.89 1.71 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.979 -1.076 . . . . 0.0 109.956 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.862 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.4 mm? -114.75 -23.92 8.96 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 120.928 -1.107 . . . . 0.0 108.933 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.69 HD13 HG23 ' B' ' 26' ' ' THR . 25.9 mt -71.84 -6.79 44.21 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 59.9 p -101.19 -17.79 16.46 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.299 -0.876 . . . . 0.0 108.753 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 57.4 mm-40 -83.7 -41.49 17.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.415 -0.803 . . . . 0.0 109.502 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -84.7 -4.64 8.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.165 -0.959 . . . . 0.0 108.713 179.282 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.97 58.67 7.2 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.03 157.81 25.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.112 -1.228 . . . . 0.0 110.347 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.818 HG22 HG22 ' A' ' 4' ' ' THR . 9.4 p -139.6 126.07 20.34 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -95.88 89.38 5.23 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.104 -179.156 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.472 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.0 OUTLIER -101.55 132.7 47.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -0.83 . . . . 0.0 110.568 -178.966 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.874 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 117.946 -1.026 . . . . 0.0 108.751 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.883 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.439 ' HD2' ' C ' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.318 -0.686 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.41 ' HG3' ' OD1' ' B' ' 98' ' ' ASN . 1.6 tt0 -84.26 131.92 34.69 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -131.53 118.78 40.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 120.998 -1.064 . . . . 0.0 110.209 -178.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.609 ' CG2' HG22 ' B' ' 96' ' ' THR . 2.2 p -127.71 -90.91 0.51 Allowed 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.56 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 41.63 29.17 0.1 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.48 -0.762 . . . . 0.0 109.432 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.56 ' C ' ' O ' ' A' ' 5' ' ' LEU . 37.3 m0 18.07 51.84 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 CA-C-O 121.638 0.732 . . . . 0.0 111.326 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.546 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.9 mt-30 -142.3 -166.66 2.3 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.9 mtm180 -74.25 116.4 52.35 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HB2' HD12 ' A' ' 24' ' ' LEU . 33.5 Cg_endo -76.53 73.84 5.0 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.269 1.979 . . . . 0.0 109.763 179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -81.53 158.56 24.42 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.32 -0.862 . . . . 0.0 110.301 -179.113 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 24' ' ' LEU . 4.0 m -149.85 130.54 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.408 -0.808 . . . . 0.0 109.588 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.785 HG22 HD22 ' A' ' 19' ' ' LEU . 2.0 m -68.49 106.09 2.43 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.728 HD11 HD21 ' A' ' 33' ' ' LEU . 6.8 pt -92.24 155.06 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.21 -0.931 . . . . 0.0 110.285 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.8 OUTLIER -119.02 105.83 11.82 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.059 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.586 ' CD1' HG11 ' A' ' 75' ' ' VAL . 8.1 mt -123.99 127.08 73.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 120.987 -1.071 . . . . 0.0 109.819 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.73 35.55 91.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.63 9.88 52.71 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -104.64 -179.4 3.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.374 -1.074 . . . . 0.0 109.297 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.785 HD22 HG22 ' A' ' 12' ' ' THR . 3.6 mt -145.9 131.25 18.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 110.269 -179.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.479 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -145.51 157.02 44.06 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.272 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.519 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 19.7 mp0 -78.98 133.63 36.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.842 -1.161 . . . . 0.0 107.93 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -113.68 144.07 43.55 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.994 -1.066 . . . . 0.0 111.07 -178.266 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 58.8 tp -98.71 92.67 5.7 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.348 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.766 HD12 ' HB2' ' A' ' 9' ' ' PRO . 74.0 mt -43.94 96.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 51.4 t0 -110.74 92.8 4.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.458 -0.776 . . . . 0.0 110.461 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 6.0 m -67.31 -10.66 53.07 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 108.758 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 1.055 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -74.19 -43.18 33.35 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.42 149.37 50.13 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.9 -1.353 . . . . 0.0 109.202 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -84.45 -19.94 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 110.133 -179.331 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' HB3' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -136.57 -162.25 1.26 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.067 -1.02 . . . . 0.0 109.499 -179.503 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 HD12 ' A' ' 85' ' ' ILE . 20.4 m -115.77 100.41 8.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.473 -1.392 . . . . 0.0 111.235 -178.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -78.0 178.15 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.695 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.037 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.15 116.35 0.62 Allowed 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.935 -1.103 . . . . 0.0 110.213 -179.241 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.756 ' HA ' HG22 ' A' ' 80' ' ' THR . 41.2 tt0 -39.35 162.02 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.29 -0.881 . . . . 0.0 109.966 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -41.34 156.85 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.218 -0.926 . . . . 0.0 110.738 -179.562 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.626 ' HG2' HG11 ' A' ' 77' ' ' VAL . 11.2 ptm -179.02 -176.94 0.45 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.548 -0.72 . . . . 0.0 109.149 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.8 t -104.52 118.69 37.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.417 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.631 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 9.9 mt -132.92 170.65 10.85 Favored Pre-proline 0 N--CA 1.493 1.694 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.631 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -69.53 -163.06 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.287 0 C-N-CA 122.079 1.853 . . . . 0.0 111.671 -179.214 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -105.39 35.09 5.3 Favored Glycine 0 N--CA 1.494 2.502 0 C-N-CA 119.968 -1.111 . . . . 0.0 111.169 -178.129 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.5 mtt85 -109.56 50.44 0.79 Allowed 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.7 p-90 -133.43 176.79 8.22 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.867 0.841 . . . . 0.0 110.542 -178.597 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.26 151.74 34.53 Favored Pre-proline 0 C--N 1.302 -1.486 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.01 130.37 11.24 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.759 1.639 . . . . 0.0 110.655 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.761 ' O ' HG22 ' A' ' 56' ' ' VAL . 3.6 ptmt -161.42 129.14 4.17 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.533 ' CG ' ' HG3' ' A' ' 55' ' ' LYS . 15.4 mtp -89.58 135.01 33.85 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.941 -1.1 . . . . 0.0 109.417 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 7.0 pt -89.4 145.91 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.244 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 98.36 0.76 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.104 -1.599 . . . . 0.0 109.104 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.98 -124.1 2.99 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.46 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.977 HG21 HD12 ' B' ' 47' ' ' ILE . 9.9 mt -88.87 119.15 35.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.636 -0.92 . . . . 0.0 112.693 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 106.54 -51.3 0.75 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 177.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.28 -155.52 16.13 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.6 m-85 -118.41 128.66 54.83 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.456 -1.026 . . . . 0.0 109.995 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' MET . 10.1 pt -101.77 169.69 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 16.1 mttt -99.62 134.57 42.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.019 -1.051 . . . . 0.0 108.958 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 45' ' ' LYS . 34.7 m -140.51 -177.61 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.957 -1.089 . . . . 0.0 110.255 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -128.97 91.65 3.25 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.451 ' OE1' ' CG2' ' A' ' 74' ' ' THR . 2.4 tp-100 -55.06 105.08 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.62 -0.675 . . . . 0.0 110.71 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.669 ' C ' HD11 ' A' ' 62' ' ' ILE . 11.4 m-85 -96.45 129.04 43.9 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.508 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 40.0 m-20 -111.17 133.41 53.55 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.738 -1.226 . . . . 0.0 109.771 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.575 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 7.8 mm100 78.29 61.91 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.648 -0.657 . . . . 0.0 109.994 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.704 HD12 ' N ' ' A' ' 62' ' ' ILE . 4.4 mp -119.45 126.55 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.349 -0.844 . . . . 0.0 108.749 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.865 HD13 ' O ' ' A' ' 63' ' ' LEU . 3.1 tm? -77.87 94.47 4.55 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.149 0.976 . . . . 0.0 111.613 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.878 HG12 HD12 ' A' ' 66' ' ' ILE . 3.2 tt -98.02 119.79 46.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.407 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -91.11 125.3 35.85 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.827 -1.17 . . . . 0.0 108.804 -179.876 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.878 HD12 HG12 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -121.61 135.37 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.103 -0.998 . . . . 0.0 109.748 -179.314 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 66' ' ' ILE . 59.5 m 36.93 38.23 0.08 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.088 0.47 . . . . 0.0 110.578 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.34 47.64 8.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.707 ' CB ' HG22 ' A' ' 93' ' ' ILE . 73.6 m-70 -141.18 123.28 15.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.346 -1.091 . . . . 0.0 109.353 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.44 ' CG ' HD21 ' A' ' 63' ' ' LEU . 6.9 tttt -77.76 122.09 24.92 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.223 -0.923 . . . . 0.0 108.558 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.43 124.27 13.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.033 -1.042 . . . . 0.0 110.818 -178.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.575 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -102.65 120.15 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.232 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.522 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -144.15 -165.43 10.94 Favored Glycine 0 C--N 1.289 -2.06 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.872 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.487 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 38.0 m -97.43 114.72 26.6 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.503 -0.998 . . . . 0.0 110.305 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.037 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -106.43 118.89 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 C-N-CA 120.216 -0.593 . . . . 0.0 110.159 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.557 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.4 mp -89.44 126.24 35.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.103 -0.998 . . . . 0.0 109.177 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.626 HG11 ' HG2' ' A' ' 36' ' ' MET . 1.7 t -108.5 120.58 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.6 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.08 -169.32 20.8 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.536 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -80.8 39.86 0.91 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.605 2.203 . . . . 0.0 110.886 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.756 HG22 ' HA ' ' A' ' 34' ' ' GLU . 15.1 t -82.39 139.96 44.95 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 82' ' ' VAL . 34.5 Cg_endo -78.16 14.57 1.52 Allowed 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.222 1.948 . . . . 0.0 111.084 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.533 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.23 165.0 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 120.96 -1.088 . . . . 0.0 109.778 -179.408 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.616 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.75 145.92 28.47 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 175.979 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.681 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.3 mm -129.92 129.99 66.14 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 O-C-N 120.047 -1.658 . . . . 0.0 111.743 -177.101 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.608 HD12 HG23 ' A' ' 31' ' ' THR . 0.8 OUTLIER -104.95 96.39 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.834 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -82.29 -169.34 43.38 Favored Glycine 0 N--CA 1.492 2.376 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.481 -178.653 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HE ' HG23 ' A' ' 26' ' ' THR . 0.1 OUTLIER -62.43 -30.43 71.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.581 -0.953 . . . . 0.0 109.789 -179.81 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.6 p-10 -50.51 -28.64 8.83 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.986 -1.071 . . . . 0.0 109.782 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.0 mm? -110.11 -27.87 8.95 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.011 -1.056 . . . . 0.0 110.652 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.537 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 33.9 mt -65.49 -13.57 59.14 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.739 -1.226 . . . . 0.0 109.322 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.4 p -96.69 -21.3 17.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.046 -1.034 . . . . 0.0 109.254 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.48 ' HG3' ' HA ' ' A' ' 89' ' ' LEU . 6.6 mt-30 -74.92 -40.26 60.96 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.176 -0.953 . . . . 0.0 108.521 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.889 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -79.59 1.11 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 178.603 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.66 59.48 8.14 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -87.86 156.43 19.39 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.301 -1.117 . . . . 0.0 109.914 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.767 HG22 ' CG2' ' B' ' 4' ' ' THR . 2.2 p -138.86 129.27 25.78 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.236 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -95.52 90.38 5.73 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 12.1 m-20 -89.52 125.77 35.33 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.213 -0.929 . . . . 0.0 109.939 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.711 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.952 -1.023 . . . . 0.0 109.022 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.5 Cg_endo . . . . . 0 N--CA 1.497 1.708 0 N-CA-C 110.14 -0.754 . . . . 0.0 110.14 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -84.56 114.67 22.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.78 115.07 46.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.956 -1.09 . . . . 0.0 111.104 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.767 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.46 32.51 1.48 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.322 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.526 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.7 mt -85.55 49.05 1.68 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.598 -0.689 . . . . 0.0 109.925 -179.047 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.526 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.8 m95 17.84 52.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.229 0.537 . . . . 0.0 112.174 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' B' ' 5' ' ' LEU . 8.5 mt-30 -154.95 171.5 19.61 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.221 -0.924 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.405 ' HA ' ' HD3' ' B' ' 9' ' ' PRO . 4.7 mtt180 -63.87 144.19 98.06 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 120.99 -1.069 . . . . 0.0 109.492 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.447 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -80.15 54.9 5.42 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.645 2.23 . . . . 0.0 110.904 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.954 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.1 mt -80.62 135.23 36.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.988 -1.07 . . . . 0.0 108.89 179.489 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.464 HG22 HG23 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -134.88 141.82 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.181 -0.95 . . . . 0.0 109.604 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.826 HG22 HD22 ' B' ' 19' ' ' LEU . 10.1 m -70.17 100.53 1.68 Allowed 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 178.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.789 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -95.12 143.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.404 -0.81 . . . . 0.0 110.055 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.6 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.0 OUTLIER -98.95 107.78 20.3 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 178.905 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.68 HG12 HD12 ' B' ' 13' ' ' ILE . 10.2 mm -113.83 115.45 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 120.756 -1.215 . . . . 0.0 110.865 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.491 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.15 9.21 56.79 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.44 -10.05 42.23 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.429 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 1.5 mp0 -89.86 -173.29 3.84 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.264 -1.139 . . . . 0.0 109.063 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.826 HD22 HG22 ' B' ' 12' ' ' THR . 18.0 mt -149.13 121.86 8.66 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.889 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.488 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 4.9 mmtt -141.83 172.55 12.53 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.954 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.9 OUTLIER -79.65 155.3 28.13 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.227 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.58 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -135.76 113.02 10.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 1.055 HD21 ' O ' ' A' ' 27' ' ' GLY . 3.3 tp -84.15 104.01 13.85 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.447 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 16.3 mt -52.45 103.9 0.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.91 ' HB3' HG23 ' B' ' 84' ' ' ILE . 19.9 t0 -101.16 77.96 1.86 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.37 -0.831 . . . . 0.0 110.174 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.782 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.02 -14.46 9.58 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.079 -1.013 . . . . 0.0 108.962 178.95 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -70.8 -35.46 66.14 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.477 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -83.3 170.86 14.16 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.938 -1.33 . . . . 0.0 110.234 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -100.54 -18.8 16.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.291 -0.881 . . . . 0.0 110.796 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.609 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -132.92 -170.54 2.47 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.599 -1.313 . . . . 0.0 110.625 -179.059 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.679 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.1 m -106.07 91.83 3.89 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.938 -1.102 . . . . 0.0 110.558 -178.769 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.953 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -81.01 154.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.717 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.953 HD12 ' O ' ' B' ' 32' ' ' VAL . 1.3 mp -148.91 133.62 17.85 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.919 -1.113 . . . . 0.0 110.667 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.559 ' N ' HG22 ' B' ' 80' ' ' THR . 3.9 mt-10 -43.5 166.69 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.468 -0.77 . . . . 0.0 109.284 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.0 OUTLIER -67.9 115.1 7.04 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.407 -0.808 . . . . 0.0 109.25 179.797 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.586 ' CE ' ' CG2' ' B' ' 15' ' ' ILE . 6.7 ptm -139.46 -166.8 2.13 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.4 t -95.34 115.35 27.31 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.262 -0.899 . . . . 0.0 109.93 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.565 HD12 ' HD2' ' B' ' 39' ' ' PRO . 26.5 tp -144.42 105.0 4.67 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.565 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.5 Cg_endo -76.41 146.0 27.35 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.398 2.065 . . . . 0.0 110.848 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 136.96 145.24 4.94 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -63.95 117.94 7.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.98 -1.306 . . . . 0.0 108.501 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' TRP . . . . . . . . . . . . . 48.9 p-90 -110.95 175.89 5.24 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 110.31 -178.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.0 mmtt -126.03 137.03 29.34 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -76.56 129.14 10.75 Favored 'Trans proline' 0 C--N 1.303 -1.838 0 C-N-CA 121.799 1.666 . . . . 0.0 110.812 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.859 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -161.62 137.66 7.95 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.062 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.495 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 25.3 mtp -102.0 137.88 39.7 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.832 -1.168 . . . . 0.0 109.332 -179.225 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.977 HD12 HG21 ' A' ' 50' ' ' ILE . 2.1 pt -89.72 164.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.628 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -138.23 108.22 0.61 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.445 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -139.61 -116.89 1.4 Allowed Glycine 0 N--CA 1.484 1.881 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.357 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.866 HD12 ' C21' ' B' ' 100' ' ' DMP . 14.3 mt -85.79 122.79 38.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.6 -0.941 . . . . 0.0 112.019 -178.08 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 99.02 -52.8 1.08 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.437 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.45 -153.91 18.87 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.628 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.4 m-85 -113.54 135.81 53.49 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.494 -1.003 . . . . 0.0 109.941 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.645 HD11 HD11 ' B' ' 47' ' ' ILE . 1.8 pt -104.31 179.49 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.564 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -108.45 130.12 55.25 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 109.164 179.574 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.859 HG22 ' O ' ' B' ' 45' ' ' LYS . 3.7 m -134.0 169.61 21.38 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.947 -1.096 . . . . 0.0 110.175 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.459 ' HD3' ' HB ' ' B' ' 77' ' ' VAL . 8.9 mtp180 -120.26 87.78 2.81 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.517 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 13.0 tt0 -48.42 99.28 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.525 -0.734 . . . . 0.0 110.561 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.8 ' O ' HG23 ' B' ' 74' ' ' THR . 5.2 m-85 -88.78 136.96 32.73 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 177.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 7.1 m-20 -114.86 133.37 56.02 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.571 -1.331 . . . . 0.0 110.882 -178.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.597 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 3.9 mp0 71.49 63.77 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.614 0.721 . . . . 0.0 109.849 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.455 HD12 HD21 ' B' ' 38' ' ' LEU . 9.1 mm -111.46 111.6 36.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.896 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.1 tm? -65.39 85.71 0.07 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.445 -0.784 . . . . 0.0 110.266 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.734 HD13 HD11 ' B' ' 66' ' ' ILE . 3.8 tt -89.11 125.28 42.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 33.1 tt0 -89.2 109.01 19.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.126 -0.984 . . . . 0.0 109.506 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.79 122.47 57.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.282 -0.886 . . . . 0.0 108.753 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 53.83 54.56 9.63 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.489 -0.757 . . . . 0.0 110.631 179.026 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.15 20.51 28.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -115.57 127.53 55.31 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.996 -1.296 . . . . 0.0 109.183 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.454 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -71.7 131.28 42.91 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.073 -1.017 . . . . 0.0 109.106 179.813 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.688 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -150.69 146.6 26.57 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.632 -0.667 . . . . 0.0 109.243 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.597 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -114.25 156.71 15.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.432 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.968 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -179.3 173.37 45.38 Favored Glycine 0 N--CA 1.485 1.944 0 C-N-CA 118.632 -1.747 . . . . 0.0 111.055 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.8 HG23 ' O ' ' B' ' 59' ' ' TYR . 88.2 m -89.97 112.79 24.3 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.5 -1.0 . . . . 0.0 109.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.94 112.7 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.897 179.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.616 ' HB2' HG23 ' B' ' 32' ' ' VAL . 1.9 mp -81.82 105.73 13.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.533 -0.729 . . . . 0.0 109.061 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.459 ' HB ' ' HD3' ' B' ' 57' ' ' ARG . 2.9 t -88.1 114.1 26.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 O-C-N 120.514 -1.366 . . . . 0.0 109.742 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -151.4 -170.42 18.23 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.564 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.3 Cg_endo -79.57 41.1 1.04 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 C-N-CA 122.434 2.089 . . . . 0.0 111.308 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.7 OUTLIER -85.82 137.73 35.68 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 178.374 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.601 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.5 21.52 0.69 Allowed 'Trans proline' 0 C--N 1.301 -1.921 0 C-N-CA 122.32 2.013 . . . . 0.0 112.13 -178.317 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -162.68 151.72 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.457 -1.402 . . . . 0.0 111.097 -179.735 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.58 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -92.4 87.36 5.98 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 176.982 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.91 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.1 mt -84.71 123.62 39.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.896 0.855 . . . . 0.0 112.914 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.545 ' CG1' ' HB1' ' B' ' 22' ' ' ALA . 3.5 mm -95.8 96.42 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.512 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.5 -161.07 18.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.108 -177.434 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 7' ' ' GLN . 1.4 mtm105 -64.88 -31.01 72.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.893 -0.769 . . . . 0.0 110.65 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.014 ' ND2' HD23 ' B' ' 89' ' ' LEU . 13.8 p-10 -54.8 -26.88 37.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.737 -1.227 . . . . 0.0 110.211 -179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.014 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -108.83 -31.39 7.71 Favored 'General case' 0 N--CA 1.484 1.258 0 O-C-N 120.766 -1.209 . . . . 0.0 110.091 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.782 HD13 HG23 ' B' ' 26' ' ' THR . 81.9 mt -62.42 -31.1 71.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 57.4 p -79.09 -21.69 46.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.41 -0.806 . . . . 0.0 109.457 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -67.55 -40.15 84.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -87.92 -7.55 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.72 64.95 2.82 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.711 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -90.29 142.36 27.81 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.427 -1.043 . . . . 0.0 111.011 -178.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.609 HG22 ' CG2' ' A' ' 4' ' ' THR . 8.3 p -130.35 130.61 44.64 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' A' ' 97' ' ' LEU . 3.9 mp -94.36 96.88 9.82 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.158 -0.964 . . . . 0.0 109.903 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.7 m-20 -103.22 124.59 48.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.068 -1.02 . . . . 0.0 109.129 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.889 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.437 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.866 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.605 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.9 Cg_exo . . . . . 0 N--CA 1.494 1.549 0 N-CA-C 110.669 -0.55 . . . . 0.0 110.669 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -84.67 108.2 17.27 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 177.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 5' ' ' LEU . 16.7 t -102.95 121.25 53.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.064 -1.022 . . . . 0.0 109.484 -178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.52 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.7 OUTLIER -73.09 -4.86 35.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.351 -178.841 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.716 ' O ' HG23 ' B' ' 91' ' ' THR . 5.5 mt 66.24 45.15 2.34 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.192 -0.942 . . . . 0.0 110.082 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.529 ' HA ' HG21 ' B' ' 91' ' ' THR . 1.4 m95 -65.84 -20.65 66.32 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.032 -1.042 . . . . 0.0 110.511 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.575 ' O ' ' CD ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -166.35 -99.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.956 -1.09 . . . . 0.0 110.092 179.821 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -113.49 140.3 24.33 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.774 -1.204 . . . . 0.0 109.565 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.576 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.7 Cg_endo -80.46 53.79 4.93 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.254 1.969 . . . . 0.0 109.693 177.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.556 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 1.3 mt -79.51 134.43 36.51 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.852 -1.155 . . . . 0.0 110.2 -178.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.456 HG21 HG23 ' A' ' 66' ' ' ILE . 1.6 m -150.99 163.71 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.667 -0.646 . . . . 0.0 109.317 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.812 ' CG2' HD22 ' A' ' 19' ' ' LEU . 3.5 m -86.56 119.07 26.42 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.617 HG22 HG13 ' A' ' 66' ' ' ILE . 18.8 pt -110.49 137.49 42.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.335 -0.853 . . . . 0.0 109.709 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 1.1 ttpp -106.96 107.7 18.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.125 -0.984 . . . . 0.0 109.299 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.939 HG23 ' CG2' ' A' ' 62' ' ' ILE . 5.1 mt -113.26 131.36 65.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.962 . . . . 0.0 109.201 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.41 -88.57 0.34 Allowed Glycine 0 N--CA 1.485 1.924 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -178.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 23.9 0.32 Allowed Glycine 0 C--N 1.293 -1.829 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 29.2 mt-30 -118.25 177.99 4.6 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.64 -0.918 . . . . 0.0 109.295 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.812 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.2 mt -143.7 119.08 10.25 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.692 0.758 . . . . 0.0 110.001 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -133.62 172.53 12.62 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.556 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 21.0 mt-10 -77.58 166.35 23.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.893 -1.129 . . . . 0.0 108.143 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.623 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -147.66 132.43 17.96 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.798 -1.189 . . . . 0.0 110.405 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.603 HD21 ' O ' ' B' ' 27' ' ' GLY . 40.7 tp -104.84 90.17 3.39 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.709 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.67 HD23 ' HB ' ' A' ' 85' ' ' ILE . 38.2 mt -46.86 107.23 0.1 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.852 -1.155 . . . . 0.0 108.253 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.608 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.4 t0 -112.27 89.67 3.13 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.346 -0.846 . . . . 0.0 109.852 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.986 HG23 HD13 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -61.8 -21.19 64.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.072 -1.017 . . . . 0.0 108.422 179.325 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.475 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -60.45 -38.21 94.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.452 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -87.47 160.62 18.21 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.069 -1.254 . . . . 0.0 109.566 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -100.25 -6.81 25.42 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.459 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.567 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.56 179.29 6.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.169 -0.957 . . . . 0.0 110.081 -179.489 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.718 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 5.9 m -106.11 96.01 6.18 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.224 -0.923 . . . . 0.0 109.309 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.985 HG13 HG21 ' A' ' 80' ' ' THR . 1.2 t -87.46 105.45 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.126 0 O-C-N 121.21 -0.931 . . . . 0.0 110.055 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.784 HD13 HG13 ' A' ' 75' ' ' VAL . 1.5 mp -100.17 133.4 44.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.315 -0.866 . . . . 0.0 112.14 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.706 ' HA ' HG23 ' A' ' 80' ' ' THR . 11.8 pt-20 -42.41 153.34 0.07 Allowed 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 177.477 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.913 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.4 mt-10 -53.17 131.32 36.75 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 120.934 -1.104 . . . . 0.0 109.614 -179.417 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.44 ' SD ' ' HG ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -146.17 175.64 10.34 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.06 179.896 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.409 ' O ' ' SD ' ' A' ' 36' ' ' MET . 16.5 t -86.45 107.31 18.0 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.291 -0.881 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.936 HD12 HG21 ' A' ' 77' ' ' VAL . 20.9 mt -121.12 110.79 34.31 Favored Pre-proline 0 N--CA 1.488 1.436 0 O-C-N 121.291 -0.88 . . . . 0.0 109.213 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -78.84 116.96 3.83 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.806 2.337 . . . . 0.0 110.659 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 151.82 -168.53 31.17 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.3 mmt180 -92.65 157.09 16.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.556 -0.967 . . . . 0.0 108.891 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 59.9 p-90 -160.01 172.91 16.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.179 -0.951 . . . . 0.0 109.843 -179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.2 mttt -136.37 160.23 67.66 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.75 141.19 16.99 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.111 1.874 . . . . 0.0 110.914 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.01 171.38 15.36 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.07 132.88 15.0 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.883 -1.135 . . . . 0.0 110.074 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.725 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -117.31 146.59 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.174 -0.954 . . . . 0.0 108.895 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.601 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.9 124.22 5.95 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.47 -123.73 1.78 Allowed Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.031 -1.557 . . . . 0.0 111.495 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.996 HD12 H702 ' B' ' 100' ' ' DMP . 39.0 mt -84.55 131.49 33.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 113.663 0.986 . . . . 0.0 113.663 -176.752 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.82 -17.25 9.32 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 177.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.47 -158.35 28.16 Favored Glycine 0 N--CA 1.491 2.351 0 O-C-N 120.603 -1.527 . . . . 0.0 110.502 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.601 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.8 m-85 -116.45 155.6 28.28 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.599 -0.942 . . . . 0.0 109.409 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.776 HD13 HG23 ' B' ' 50' ' ' ILE . 13.0 pt -131.64 146.26 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.217 -0.927 . . . . 0.0 108.684 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 7.8 mttp -90.19 154.19 19.93 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.456 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.0 m -149.05 178.93 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.067 -1.021 . . . . 0.0 109.567 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.427 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 9.2 mmt180 -122.35 104.59 9.52 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.408 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 1.7 tt0 -60.67 99.57 0.09 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.275 -0.891 . . . . 0.0 110.606 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.593 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.2 m-85 -95.1 104.67 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 9.3 m-20 -88.84 129.32 35.61 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.029 -1.045 . . . . 0.0 111.173 -178.45 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.566 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.5 OUTLIER 82.01 60.33 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.332 0.587 . . . . 0.0 111.31 178.466 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.939 ' CG2' HG23 ' A' ' 15' ' ' ILE . 8.6 mm -115.32 120.86 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.622 HD22 ' C ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -71.32 95.27 1.29 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.017 -1.052 . . . . 0.0 111.273 -177.853 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -98.08 115.98 39.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 178.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.4 tt0 -89.34 105.05 17.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.85 -1.156 . . . . 0.0 108.883 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.75 HD11 HD13 ' A' ' 64' ' ' ILE . 1.7 mp -104.31 120.74 55.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.477 -0.764 . . . . 0.0 109.816 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.58 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.2 m 54.66 59.16 4.28 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.807 -0.558 . . . . 0.0 110.495 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 50.29 33.5 23.79 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 21.9 m-70 -131.14 102.56 6.06 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.193 -1.18 . . . . 0.0 108.813 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.599 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.8 mptt -51.46 140.09 18.49 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -160.88 99.72 1.24 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.14 -0.975 . . . . 0.0 110.052 -179.258 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.566 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -78.81 157.38 4.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 72' ' ' ILE . . . -179.46 -166.66 35.58 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.221 -1.942 . . . . 0.0 112.21 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.455 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 32.5 m -98.55 108.3 20.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.573 -0.957 . . . . 0.0 110.507 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.784 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -102.53 105.61 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.646 -0.658 . . . . 0.0 110.258 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.567 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 4.8 mp -78.48 109.78 12.97 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.936 HG21 HD12 ' A' ' 38' ' ' LEU . 2.3 t -93.12 114.5 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.444 -0.785 . . . . 0.0 110.328 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -143.66 -163.95 10.11 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.45 43.3 1.5 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.559 2.173 . . . . 0.0 110.274 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.985 HG21 HG13 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -88.6 134.06 34.87 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.438 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.5 18.54 0.94 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.559 2.173 . . . . 0.0 111.975 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.514 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.0 161.33 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.88 -1.138 . . . . 0.0 109.629 179.716 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.623 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -95.24 134.66 37.75 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.645 -2.354 . . . . 0.0 104.645 175.946 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.739 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.2 mm -124.37 121.83 62.62 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 120.538 -1.352 . . . . 0.0 110.189 -177.318 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.868 ' N ' HD13 ' A' ' 85' ' ' ILE . 1.0 OUTLIER -98.04 87.65 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.171 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.15 -163.57 22.45 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 120.144 -1.027 . . . . 0.0 110.588 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.571 ' NH1' ' HD3' ' B' ' 9' ' ' PRO . 13.8 mmt-85 -57.63 -39.31 76.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.747 -0.855 . . . . 0.0 110.892 -178.781 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.045 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -44.47 -31.12 1.0 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.996 -1.065 . . . . 0.0 109.343 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.045 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.4 mm? -105.09 -27.46 11.61 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.207 -0.933 . . . . 0.0 109.884 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.986 HD13 HG23 ' A' ' 26' ' ' THR . 27.0 mt -70.33 -8.7 52.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.035 -1.041 . . . . 0.0 108.858 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.22 -20.25 20.62 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -86.46 -40.09 15.67 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.826 HD11 HD23 ' A' ' 90' ' ' LEU . 1.9 pt -82.62 -7.63 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.381 -0.824 . . . . 0.0 109.138 179.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.98 34.25 58.94 Favored Glycine 0 N--CA 1.5 2.903 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.187 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.607 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -70.04 130.14 41.34 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.04 -1.27 . . . . 0.0 110.335 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.533 HG22 ' CG2' ' B' ' 4' ' ' THR . 82.2 p -127.88 130.05 47.9 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.924 -1.11 . . . . 0.0 109.098 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -88.22 97.52 11.06 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.162 -0.962 . . . . 0.0 109.581 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.515 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 6.3 m-20 -107.27 123.91 49.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.292 -0.88 . . . . 0.0 109.051 179.334 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.771 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.191 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.664 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.51 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 0.2 OUTLIER -83.57 146.41 28.33 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 177.823 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.82 HG13 HD23 ' B' ' 5' ' ' LEU . 20.9 t -143.59 122.98 8.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 117.812 -1.555 . . . . 0.0 111.244 -178.032 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.541 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.1 OUTLIER -117.13 20.89 13.53 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 177.165 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.82 HD23 HG13 ' B' ' 3' ' ' VAL . 1.3 mm? -34.68 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.682 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.541 ' N ' ' O ' ' B' ' 4' ' ' THR . 10.5 m95 -50.94 -19.98 1.19 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.402 ' N ' ' C ' ' B' ' 5' ' ' LEU . 12.9 mm100 -108.57 -124.06 0.25 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.301 -0.874 . . . . 0.0 108.831 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 34.8 mtt180 -110.56 129.99 23.37 Favored Pre-proline 0 N--CA 1.496 1.869 0 O-C-N 120.396 -1.44 . . . . 0.0 110.407 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.571 ' HD3' ' NH1' ' A' ' 87' ' ' ARG . 37.6 Cg_endo -79.16 82.78 2.42 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.364 2.042 . . . . 0.0 109.83 178.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.642 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.7 mt -90.91 140.22 30.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.016 -1.052 . . . . 0.0 109.992 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.537 HG23 ' N ' ' B' ' 12' ' ' THR . 0.6 OUTLIER -143.37 168.28 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.765 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.537 ' N ' HG23 ' B' ' 11' ' ' VAL . 17.8 m -99.91 109.18 21.56 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.924 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.6 pt -91.35 158.03 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.138 -0.976 . . . . 0.0 110.064 -178.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.9 tttt -121.03 96.97 5.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.412 -0.805 . . . . 0.0 109.064 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.804 HG23 ' CG2' ' B' ' 62' ' ' ILE . 20.1 mt -113.3 129.44 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 O-C-N 121.337 -0.852 . . . . 0.0 109.617 -179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.75 50.13 62.41 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 54.8 24.43 33.39 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.3 OUTLIER -119.94 174.58 6.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.221 -1.164 . . . . 0.0 108.688 179.288 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.924 HD23 ' O ' ' B' ' 13' ' ' ILE . 29.1 mt -148.52 126.05 11.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.021 -1.049 . . . . 0.0 110.843 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.449 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.1 mmmt -140.6 -177.37 5.02 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.693 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.642 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.6 OUTLIER -80.2 176.02 10.12 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.946 -1.096 . . . . 0.0 108.671 179.415 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -162.62 111.91 1.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.854 -1.154 . . . . 0.0 111.346 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' B' ' 25' ' ' ASP . 9.0 tp -89.05 99.68 12.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.539 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.2 mt -46.79 96.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.921 -1.112 . . . . 0.0 108.093 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.582 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 65.1 t0 -105.49 84.84 2.15 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.292 -0.88 . . . . 0.0 110.861 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.562 ' CG2' ' HD2' ' B' ' 87' ' ' ARG . 49.4 m -63.14 -15.96 58.47 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 108.945 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.603 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -67.86 -45.81 71.68 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 133.62 46.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -1.111 . . . . 0.0 108.589 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.5 m-20 -71.75 -13.28 61.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.368 -0.833 . . . . 0.0 110.692 -178.629 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.777 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -139.03 -174.82 3.95 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.768 -1.207 . . . . 0.0 110.583 -179.377 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.654 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.4 m -104.17 97.86 7.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.063 -1.023 . . . . 0.0 110.499 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.609 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -89.59 109.67 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.324 0 O-C-N 121.198 -0.938 . . . . 0.0 109.918 -179.897 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.902 HD21 HD11 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -99.26 130.92 45.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.117 -0.99 . . . . 0.0 111.311 -179.605 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.55 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 34.1 tt0 -40.59 163.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.439 -0.788 . . . . 0.0 109.292 178.177 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.646 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.1 mt-10 -53.01 139.27 28.42 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 110.917 -178.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.51 ' HG3' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -173.82 159.66 3.48 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.51 ' N ' ' HG3' ' B' ' 36' ' ' MET . 18.2 t -79.52 142.07 36.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.091 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 1.013 HD12 HG21 ' B' ' 77' ' ' VAL . 10.6 mt -139.16 166.0 27.87 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.449 -0.782 . . . . 0.0 108.999 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.5 ' HD3' HD23 ' B' ' 38' ' ' LEU . 34.5 Cg_endo -76.5 69.59 6.6 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.816 2.344 . . . . 0.0 111.996 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.68 -159.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.671 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.472 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 67.1 50.52 1.01 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.512 -0.993 . . . . 0.0 109.03 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.587 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 46.7 p-90 -135.15 -178.38 5.07 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.907 0.86 . . . . 0.0 110.411 -179.461 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.44 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 12.4 mmtm -150.56 158.76 35.48 Favored Pre-proline 0 C--N 1.302 -1.487 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.63 139.87 18.38 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.912 1.742 . . . . 0.0 110.012 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.756 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.4 OUTLIER -151.07 152.45 33.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.374 -0.829 . . . . 0.0 109.456 -179.433 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -127.35 111.51 13.97 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.844 -1.16 . . . . 0.0 108.828 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 54' ' ' ILE . 24.4 pt -95.1 134.35 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 110.018 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.594 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.59 104.51 1.11 Allowed Glycine 0 N--CA 1.489 2.173 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.401 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -122.34 -124.51 3.0 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.171 -1.49 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.817 HD12 ' C21' ' B' ' 100' ' ' DMP . 38.7 mt -86.02 121.77 37.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.832 -0.805 . . . . 0.0 112.627 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.58 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.18 -49.13 0.97 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 177.808 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.97 -159.65 24.15 Favored Glycine 0 N--CA 1.488 2.153 0 O-C-N 120.913 -1.345 . . . . 0.0 110.301 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.594 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 4.9 m-85 -113.91 155.04 26.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.646 -0.914 . . . . 0.0 109.644 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 47' ' ' ILE . 1.4 pt -138.95 176.52 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.309 -0.869 . . . . 0.0 108.849 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 8.9 mttt -116.18 151.82 34.95 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.498 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB3' ' B' ' 45' ' ' LYS . 5.6 m -146.62 -171.11 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.791 -1.193 . . . . 0.0 109.715 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' B' ' 59' ' ' TYR . 71.0 mtm-85 -133.65 85.07 2.17 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -44.36 93.69 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.692 -0.63 . . . . 0.0 110.648 -178.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.587 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 13.8 m-85 -88.92 125.61 35.03 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 178.174 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.511 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 14.8 m-20 -105.53 136.22 45.5 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.84 -1.163 . . . . 0.0 110.786 -178.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.623 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.8 mp0 70.81 65.44 0.18 Allowed 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.431 0.634 . . . . 0.0 111.106 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.804 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.76 111.71 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 1.059 HD21 ' CG ' ' B' ' 70' ' ' LYS . 12.9 tp -64.85 91.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.969 -1.082 . . . . 0.0 111.097 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.8 ' CG2' HD11 ' B' ' 89' ' ' LEU . 5.4 tt -89.42 119.14 36.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.486 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.6 tt0 -88.54 120.88 30.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 109.119 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.655 HG13 HG22 ' B' ' 13' ' ' ILE . 1.3 mp -120.94 128.0 76.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.397 -0.814 . . . . 0.0 109.217 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 94.5 m 52.97 24.48 3.42 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.507 -0.746 . . . . 0.0 109.798 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 81.79 43.62 8.22 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -140.28 99.53 3.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -1.166 . . . . 0.0 109.418 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 1.059 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.24 128.56 19.67 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.656 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -148.23 101.98 3.31 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.301 -0.875 . . . . 0.0 110.505 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.623 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -77.31 142.83 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.773 -1.205 . . . . 0.0 108.648 178.992 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.523 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -164.94 -155.75 8.65 Favored Glycine 0 N--CA 1.494 2.566 0 C-N-CA 119.723 -1.227 . . . . 0.0 111.062 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.484 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.3 m -111.96 113.76 26.26 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.214 -1.168 . . . . 0.0 109.624 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.676 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -107.91 108.42 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.355 -0.841 . . . . 0.0 111.383 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.788 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.9 mp -79.92 108.79 13.77 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.127 -0.983 . . . . 0.0 108.617 178.28 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 1.013 HG21 HD12 ' B' ' 38' ' ' LEU . 2.1 t -92.24 117.97 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.988 -1.07 . . . . 0.0 109.659 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.721 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -146.99 -171.96 16.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.306 -1.918 . . . . 0.0 108.306 179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.8 Cg_endo -81.03 44.26 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.259 1.973 . . . . 0.0 110.514 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.609 HG21 HG13 ' B' ' 32' ' ' VAL . 5.3 t -84.69 143.75 41.38 Favored Pre-proline 0 N--CA 1.486 1.359 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.9 Cg_endo -76.65 14.01 1.31 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.583 2.189 . . . . 0.0 111.674 -178.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.03 164.35 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.83 -1.169 . . . . 0.0 110.149 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.566 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.4 m120 -94.6 146.95 23.77 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 174.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.654 ' O ' ' HA ' ' B' ' 31' ' ' THR . 3.6 mm -133.81 123.91 46.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 120.024 -1.673 . . . . 0.0 110.713 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.504 ' HB ' ' HA ' ' B' ' 24' ' ' LEU . 5.3 mm -98.5 93.45 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.25 179.49 51.74 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 -178.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.588 ' HG2' ' HB3' ' A' ' 5' ' ' LEU . 0.8 OUTLIER -58.83 -23.11 60.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.37 -1.077 . . . . 0.0 109.627 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.739 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.9 p-10 -53.77 -37.01 63.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.694 -1.254 . . . . 0.0 108.924 178.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.8 HD11 ' CG2' ' B' ' 64' ' ' ILE . 0.4 OUTLIER -96.92 -35.26 10.94 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.619 -0.676 . . . . 0.0 110.695 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.51 ' O ' HG13 ' B' ' 93' ' ' ILE . 71.7 mt -56.36 -33.87 66.11 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.038 -1.039 . . . . 0.0 109.487 -179.327 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.66 -21.84 60.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 110.899 -179.109 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -80.54 -31.47 36.98 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.229 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.771 HD12 ' CB ' ' A' ' 99' ' ' PHE . 3.1 pt -87.11 13.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.4 -0.813 . . . . 0.0 108.932 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 59.76 49.04 82.83 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.527 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -87.92 150.66 23.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.25 -1.147 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.52 HG22 ' HA ' ' A' ' 4' ' ' THR . 57.2 p -146.27 123.07 11.25 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.798 . . . . 0.0 109.135 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' A' ' 97' ' ' LEU . 5.2 mp -85.36 93.54 8.74 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 34.0 m-20 -92.79 119.97 32.69 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 120.703 -1.248 . . . . 0.0 110.067 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.675 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.37 178.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.996 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.462 ' HD3' ' CE1' ' A' ' 69' ' ' HIS . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.66 0 N-CA-C 109.889 -0.85 . . . . 0.0 109.889 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.433 ' CG ' ' OD1' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -83.17 149.66 26.72 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 177.81 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.543 HG13 ' CD2' ' A' ' 5' ' ' LEU . 37.8 t -150.49 116.43 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 C-N-CA 118.436 -1.306 . . . . 0.0 110.661 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.782 ' C ' HD23 ' A' ' 5' ' ' LEU . 1.7 p -122.26 -73.21 0.65 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.782 HD23 ' C ' ' A' ' 4' ' ' THR . 1.8 pt? 30.4 38.28 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 122.124 -0.36 . . . . 0.0 111.071 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' A' ' 5' ' ' LEU . 8.9 m95 19.3 48.96 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 121.258 0.551 . . . . 0.0 111.829 179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.552 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -149.87 -167.81 2.93 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.31 179.421 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.622 ' HB3' HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -84.89 136.77 38.4 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.12 -0.987 . . . . 0.0 109.403 -179.889 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.7 Cg_endo -77.27 71.99 6.12 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.246 1.964 . . . . 0.0 109.717 178.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' CG1' ' A' ' 11' ' ' VAL . 0.4 OUTLIER -79.54 151.17 30.86 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 -179.567 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 1.053 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -150.64 156.47 6.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.244 -0.91 . . . . 0.0 110.027 -179.381 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.694 ' CG2' HD22 ' A' ' 19' ' ' LEU . 22.6 m -86.93 113.37 22.66 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.769 HD11 HD21 ' A' ' 33' ' ' LEU . 43.8 pt -99.7 147.87 6.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.167 -0.958 . . . . 0.0 111.071 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.647 ' CD ' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -109.27 94.9 5.28 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.937 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.836 HD13 HG11 ' A' ' 75' ' ' VAL . 8.6 mt -119.41 130.07 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.104 -0.998 . . . . 0.0 109.67 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.67 37.63 95.01 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.61 18.14 50.91 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -113.84 172.88 6.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.34 -1.094 . . . . 0.0 109.518 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.694 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.1 mt -139.74 122.46 16.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 111.012 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.463 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -141.96 175.32 9.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.963 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 1.3 mt-10 -78.72 178.67 7.69 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.599 -1.313 . . . . 0.0 108.23 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.824 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -156.9 103.99 2.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.14 -0.975 . . . . 0.0 109.635 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.622 HD11 ' HB3' ' A' ' 8' ' ' ARG . 30.5 tp -72.43 92.6 1.46 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.253 -0.904 . . . . 0.0 108.584 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.767 ' CD2' HD21 ' A' ' 90' ' ' LEU . 3.7 mt -43.78 98.43 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' A' ' 84' ' ' ILE . 1.9 t70 -104.89 90.3 3.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.558 -0.714 . . . . 0.0 110.777 -178.026 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.526 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 20.7 m -68.23 -13.53 62.31 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.725 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.99 -41.68 60.79 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.518 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -73.05 162.75 29.1 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -1.171 . . . . 0.0 109.516 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -98.92 -11.15 21.9 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.292 -0.88 . . . . 0.0 110.428 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.551 ' OD2' ' HB ' ' A' ' 74' ' ' THR . 0.1 OUTLIER -139.06 -173.2 3.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.899 -1.126 . . . . 0.0 109.781 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' A' ' 33' ' ' LEU . 66.4 m -106.32 88.52 2.8 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.576 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.19 162.97 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.244 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.01 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.4 OUTLIER -157.7 124.32 4.92 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.9 -179.003 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 35' ' ' GLU . 21.0 pt-20 -41.01 152.83 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.533 -0.729 . . . . 0.0 109.5 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -41.71 148.31 0.16 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.39 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.431 ' HE1' HG22 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -173.29 164.92 4.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.496 -0.753 . . . . 0.0 108.975 179.457 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.7 t -79.8 100.06 7.79 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.056 -1.028 . . . . 0.0 109.77 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 39' ' ' PRO . 13.3 tp -126.29 100.39 29.58 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.248 -0.907 . . . . 0.0 109.34 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.531 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.4 Cg_endo -78.46 165.39 25.32 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.791 2.327 . . . . 0.0 110.815 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.57 -163.12 16.09 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.408 ' NE ' ' H ' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -97.33 139.03 33.9 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.223 -1.163 . . . . 0.0 108.26 179.502 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.569 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 9.7 p-90 -149.33 174.49 12.37 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.031 -1.043 . . . . 0.0 109.996 -179.423 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -138.2 163.47 47.28 Favored Pre-proline 0 C--N 1.299 -1.612 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.104 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.22 141.03 25.53 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.73 1.62 . . . . 0.0 110.189 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.36 167.46 22.12 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.451 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 10.4 ttt -151.38 118.79 6.01 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 54' ' ' ILE . 1.5 pt -102.43 128.51 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 C-N-CA 118.396 -1.322 . . . . 0.0 108.897 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.618 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -117.89 98.01 0.75 Allowed Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.519 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -119.72 -121.06 2.9 Favored Glycine 0 C--N 1.297 -1.616 0 C-N-CA 119.416 -1.374 . . . . 0.0 110.404 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.883 HG21 HD12 ' B' ' 47' ' ' ILE . 74.8 mt -83.87 106.1 13.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.872 -0.781 . . . . 0.0 112.561 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 120.18 -44.62 1.35 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 178.13 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 168.06 -164.37 37.92 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.728 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 7.1 m-85 -110.14 118.02 35.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.602 -0.94 . . . . 0.0 110.18 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 47' ' ' ILE . 32.6 pt -99.16 161.07 3.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.319 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.557 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.39 132.96 48.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.024 -1.048 . . . . 0.0 109.8 -179.406 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' A' ' 78' ' ' GLY . 30.6 m -134.55 178.68 5.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.477 -0.765 . . . . 0.0 109.36 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 28.1 mtt180 -111.31 171.22 7.6 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.409 ' OE1' ' OD1' ' A' ' 60' ' ' ASP . 0.3 OUTLIER -131.5 97.28 4.19 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.673 -1.267 . . . . 0.0 110.859 -179.042 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 83.7 m-85 -97.11 116.32 29.1 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.406 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.522 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -94.01 146.46 23.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.917 -1.114 . . . . 0.0 110.144 -179.05 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.559 ' HA ' HG23 ' A' ' 72' ' ' ILE . 4.1 mm-40 67.77 67.34 0.36 Allowed 'General case' 0 N--CA 1.489 1.516 0 CA-C-O 121.617 0.722 . . . . 0.0 109.705 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.616 ' HB ' HG23 ' A' ' 75' ' ' VAL . 1.9 mm -124.65 108.84 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.769 HD11 ' CG ' ' A' ' 70' ' ' LYS . 4.6 tt -59.81 102.57 0.16 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.311 -0.868 . . . . 0.0 111.175 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 1.009 HD13 HD11 ' A' ' 66' ' ' ILE . 3.7 tt -100.44 119.48 48.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.75 109.88 20.04 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.647 -1.283 . . . . 0.0 108.719 -178.564 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.053 HG23 HG21 ' A' ' 11' ' ' VAL . 2.7 mt -115.78 123.86 71.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.124 -0.985 . . . . 0.0 110.313 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.2 m 56.49 36.02 26.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.675 -0.641 . . . . 0.0 110.367 179.04 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.41 28.03 73.46 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.462 ' CE1' ' HD3' ' A' ' 1' ' ' PRO . 46.4 m80 -126.95 110.35 12.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.118 -1.225 . . . . 0.0 109.273 179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.769 ' CG ' HD11 ' A' ' 63' ' ' LEU . 1.5 ttpm? -55.05 130.6 42.43 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.269 -0.895 . . . . 0.0 109.069 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 101.46 3.23 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.372 -0.83 . . . . 0.0 109.935 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.646 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -78.27 146.43 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 178.794 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.659 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -170.45 -177.69 40.74 Favored Glycine 0 N--CA 1.484 1.879 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.51 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.551 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 1.9 m -93.58 111.92 23.7 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.574 -0.957 . . . . 0.0 109.587 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.001 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.97 137.12 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.694 -0.629 . . . . 0.0 109.724 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.4 mp -107.68 136.14 47.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.209 -0.932 . . . . 0.0 108.768 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.492 ' O ' ' HG3' ' A' ' 57' ' ' ARG . 16.7 t -118.38 113.65 42.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.943 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -151.75 -164.04 11.92 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.557 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.31 39.48 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.681 2.254 . . . . 0.0 111.039 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.832 HG21 HG13 ' A' ' 32' ' ' VAL . 2.8 t -86.83 134.84 36.4 Favored Pre-proline 0 N--CA 1.489 1.508 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.1 Cg_endo -78.16 18.79 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.691 2.26 . . . . 0.0 112.028 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 81' ' ' PRO . 0.9 OUTLIER -161.5 158.97 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.597 -1.314 . . . . 0.0 110.341 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 67.7 m-20 -95.11 100.29 12.13 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' A' ' 25' ' ' ASP . 7.2 mm -88.37 128.59 40.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 O-C-N 120.858 -1.151 . . . . 0.0 112.154 -176.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.824 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.61 93.79 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.244 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -80.35 -160.99 23.63 Favored Glycine 0 N--CA 1.493 2.494 0 O-C-N 121.176 -0.952 . . . . 0.0 111.042 -177.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.513 ' HB2' ' NH2' ' A' ' 87' ' ' ARG . 7.5 mtp-105 -69.17 -29.67 67.73 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.65 -0.912 . . . . 0.0 109.925 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.943 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -50.17 -24.26 2.69 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.811 -1.181 . . . . 0.0 108.951 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.943 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.1 mm? -112.76 -27.77 8.03 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.236 -0.915 . . . . 0.0 110.313 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.767 HD21 ' CD2' ' A' ' 24' ' ' LEU . 34.7 mt -63.09 -28.15 69.88 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.992 -1.068 . . . . 0.0 108.416 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 69.0 p -79.43 -20.64 47.03 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.136 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -80.86 -36.71 31.05 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.35 -0.844 . . . . 0.0 109.135 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.829 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -86.0 -0.72 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.295 -0.878 . . . . 0.0 109.243 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.68 62.22 5.23 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -97.16 135.88 38.48 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.547 -0.973 . . . . 0.0 110.481 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.719 HG22 ' CG2' ' B' ' 4' ' ' THR . 15.5 p -133.12 128.71 36.71 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.613 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -87.1 109.38 19.39 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.277 -0.89 . . . . 0.0 108.792 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.513 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 62.9 m-20 -105.22 120.79 42.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.81 -1.181 . . . . 0.0 109.196 179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.86 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.595 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.451 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.56 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.332 -0.68 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.523 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tm0? -84.02 145.71 28.36 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.133 -1.803 . . . . 0.0 106.133 177.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.523 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 70.1 t -146.03 122.97 3.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.218 -177.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.719 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.8 OUTLIER -127.04 -61.94 1.14 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.673 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.1 mt 31.86 38.92 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.567 178.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.536 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.9 m95 17.31 51.46 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 CA-C-O 121.159 0.504 . . . . 0.0 111.949 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' B' ' 5' ' ' LEU . 13.1 mt-30 -168.0 -174.95 2.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.341 -0.85 . . . . 0.0 109.592 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.472 ' HG2' ' HD2' ' A' ' 87' ' ' ARG . 17.2 mtm180 -65.44 138.45 96.96 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.032 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.554 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.8 Cg_endo -81.16 62.36 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.36 2.04 . . . . 0.0 109.707 179.104 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 1.052 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -80.84 136.4 36.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.877 -1.139 . . . . 0.0 109.56 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.533 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -130.42 137.91 55.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.286 -0.884 . . . . 0.0 109.191 -179.933 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.714 HG22 HD22 ' B' ' 19' ' ' LEU . 18.0 m -65.66 97.58 0.33 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.941 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.8 pt -88.03 154.62 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.297 -0.877 . . . . 0.0 110.702 -177.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.2 OUTLIER -122.15 105.88 10.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.473 -0.767 . . . . 0.0 109.773 179.505 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.76 HD13 HG11 ' B' ' 75' ' ' VAL . 97.1 mt -121.24 139.92 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 120.852 -1.155 . . . . 0.0 110.889 -179.24 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.81 33.38 6.48 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.76 37.27 51.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.8 mp0 -131.18 175.48 9.07 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 108.39 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.941 HD23 ' O ' ' B' ' 13' ' ' ILE . 15.9 mt -152.0 124.33 8.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.995 -1.066 . . . . 0.0 110.249 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -151.38 174.57 13.18 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 1.052 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -80.34 143.38 33.61 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.895 -1.128 . . . . 0.0 108.836 179.484 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.679 ' N ' HD23 ' B' ' 10' ' ' LEU . . . -127.53 112.79 15.33 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 110.138 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.725 HD21 ' O ' ' A' ' 27' ' ' GLY . 2.4 tp -81.14 102.05 10.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.691 -0.631 . . . . 0.0 109.864 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 20.1 mt -52.74 105.95 0.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.934 -1.104 . . . . 0.0 108.346 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.886 ' CB ' HG23 ' B' ' 84' ' ' ILE . 53.4 t0 -103.1 92.54 4.58 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.216 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.696 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -64.54 -11.5 35.0 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.077 -1.015 . . . . 0.0 108.404 178.437 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -70.09 -43.62 63.77 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.611 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -81.82 164.96 21.28 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.117 -1.225 . . . . 0.0 109.676 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -100.4 -13.88 18.57 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.226 -0.921 . . . . 0.0 110.196 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.644 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -126.75 -165.37 1.45 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.016 -1.052 . . . . 0.0 109.664 -179.806 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.78 HG23 HD12 ' B' ' 85' ' ' ILE . 8.1 m -116.63 85.64 2.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.924 -1.11 . . . . 0.0 110.192 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.934 HG12 ' HB ' ' B' ' 84' ' ' ILE . 0.3 OUTLIER -68.65 154.75 8.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.806 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -154.82 133.31 11.95 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.837 -1.164 . . . . 0.0 111.054 -177.609 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.489 ' HG3' ' O ' ' B' ' 80' ' ' THR . 4.1 tt0 -42.03 148.62 0.18 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.465 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 3.0 mt-10 -44.88 136.99 4.3 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.041 -1.037 . . . . 0.0 110.457 -179.173 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.584 ' SD ' HD22 ' B' ' 38' ' ' LEU . 0.0 OUTLIER -156.75 -167.69 2.45 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.11 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.6 t -112.29 115.75 29.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.756 -1.215 . . . . 0.0 111.457 -178.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.685 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -116.45 170.81 5.39 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.153 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.685 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.4 Cg_endo -76.22 115.77 4.2 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.372 2.048 . . . . 0.0 111.374 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' B' ' 41' ' ' ARG . . . -30.95 122.39 0.14 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' B' ' 40' ' ' GLY . 3.6 mtm180 148.72 43.01 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.633 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 37.3 p-90 -124.73 176.8 6.34 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.343 0.592 . . . . 0.0 109.733 -178.139 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -133.92 130.04 20.38 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.007 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -76.91 140.11 20.12 Favored 'Trans proline' 0 C--N 1.31 -1.45 0 C-N-CA 122.254 1.97 . . . . 0.0 110.317 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -159.41 -164.8 1.43 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.356 -0.84 . . . . 0.0 109.376 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.548 ' HE2' ' HG3' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -141.8 119.21 11.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.985 -179.578 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.883 HD12 HG21 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -90.44 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 178.473 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.467 ' HA2' ' HB3' ' B' ' 53' ' ' PHE . . . -118.41 111.75 2.22 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.81 -125.2 2.35 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.915 HD12 H202 ' B' ' 100' ' ' DMP . 37.8 mt -80.95 139.12 18.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.777 -0.837 . . . . 0.0 112.664 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.27 5.03 65.54 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.0 -158.94 16.69 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.051 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.601 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -119.21 143.85 47.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.441 -1.035 . . . . 0.0 109.183 -179.549 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.754 HG12 HG23 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -112.71 -175.29 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.977 . . . . 0.0 108.701 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.549 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 12.3 mttt -114.84 138.79 50.36 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.047 -1.033 . . . . 0.0 109.282 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.653 HG13 HD11 ' B' ' 54' ' ' ILE . 3.5 m -139.05 -169.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.553 -1.342 . . . . 0.0 110.73 -179.498 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.496 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 73.8 mtt-85 -143.78 99.88 3.49 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.565 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 6.1 tt0 -66.04 108.13 2.12 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.294 -0.879 . . . . 0.0 110.719 -178.644 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 32.3 m-85 -93.85 128.27 40.03 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 177.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.534 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -106.17 135.97 46.7 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.877 -1.139 . . . . 0.0 110.927 -177.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.594 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.2 OUTLIER 71.98 64.03 0.14 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 179.271 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 4.4 mp -118.17 119.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.717 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.3 tm? -66.29 84.95 0.1 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-O 121.661 0.743 . . . . 0.0 110.604 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.647 HG22 ' O ' ' B' ' 71' ' ' ALA . 2.3 tt -91.89 130.76 40.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 178.272 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.514 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.8 tt0 -87.74 152.6 22.01 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.905 -1.122 . . . . 0.0 108.463 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.593 HG13 HG22 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -150.75 135.11 9.0 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.236 -0.915 . . . . 0.0 108.962 -179.453 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 46.32 24.07 0.26 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.529 -0.732 . . . . 0.0 110.21 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 83.72 39.6 9.47 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 17.0 m80 -141.11 164.77 29.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -1.208 . . . . 0.0 109.074 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.527 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -95.73 139.19 32.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.07 -1.019 . . . . 0.0 108.472 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.647 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.54 104.75 2.58 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.111 -0.993 . . . . 0.0 110.051 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.597 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.4 OUTLIER -86.94 141.64 14.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 178.701 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.56 -164.11 23.69 Favored Glycine 0 N--CA 1.485 1.922 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.495 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.565 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 8.6 m -95.91 105.06 17.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.682 -0.893 . . . . 0.0 109.906 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.806 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -100.71 106.01 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.38 -0.825 . . . . 0.0 109.983 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.644 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 0.4 OUTLIER -78.08 134.4 37.74 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.104 -0.997 . . . . 0.0 108.666 179.104 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 58.2 t -122.58 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.206 -0.934 . . . . 0.0 110.644 -179.153 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.441 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -163.84 -161.27 12.73 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 108.258 -1.937 . . . . 0.0 108.258 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' B' ' 54' ' ' ILE . 36.5 Cg_endo -81.47 40.23 0.96 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.358 2.039 . . . . 0.0 110.244 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' B' ' 32' ' ' VAL . 3.1 t -83.39 133.56 47.09 Favored Pre-proline 0 N--CA 1.487 1.391 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.665 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.3 Cg_endo -75.43 18.05 0.61 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.715 2.276 . . . . 0.0 112.244 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.665 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.9 t -161.27 157.9 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.692 -1.255 . . . . 0.0 110.543 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.593 ' OD1' ' N ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -96.57 90.36 5.32 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 177.252 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.934 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.9 mt -90.63 120.04 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.258 -0.901 . . . . 0.0 112.36 -176.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.78 HD12 HG23 ' B' ' 31' ' ' THR . 0.5 OUTLIER -95.67 93.82 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.82 -157.28 13.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -61.76 -37.22 83.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.623 -0.928 . . . . 0.0 111.887 -178.186 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.956 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -44.67 -40.53 5.96 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.509 -1.37 . . . . 0.0 110.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.956 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.9 OUTLIER -96.73 -18.99 19.28 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.061 -1.024 . . . . 0.0 110.032 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.557 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 63.6 mt -73.8 -5.25 39.67 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.024 -1.048 . . . . 0.0 108.765 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.512 ' HB ' ' CH2' ' A' ' 6' ' ' TRP . 2.6 p -101.32 -21.17 14.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.081 -1.012 . . . . 0.0 109.067 179.589 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.8 mm-40 -74.36 -40.53 62.06 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.183 -0.948 . . . . 0.0 109.006 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.86 HD12 ' CG ' ' A' ' 99' ' ' PHE . 3.3 pt -88.15 -5.97 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.215 -0.928 . . . . 0.0 108.893 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.76 50.43 42.19 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.594 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.45 149.4 35.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.099 -1.236 . . . . 0.0 109.789 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.727 HG22 ' CG2' ' A' ' 4' ' ' THR . 47.6 p -138.48 128.4 25.32 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.696 HD13 HG21 ' B' ' 26' ' ' THR . 0.0 OUTLIER -86.96 111.36 20.76 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.287 -0.883 . . . . 0.0 110.745 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.8 m-20 -115.73 121.21 41.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.3 -0.875 . . . . 0.0 109.609 179.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.829 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.134 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.915 H202 HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.417 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.691 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.474 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.5 tt0 -83.16 141.39 31.98 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 105.623 -1.992 . . . . 0.0 105.623 177.035 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 72.9 t -137.95 126.04 30.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 C-N-CA 117.778 -1.569 . . . . 0.0 110.647 -177.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.577 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -120.87 7.35 10.42 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.693 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.3 OUTLIER -34.42 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.953 0.882 . . . . 0.0 109.709 -179.299 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.577 ' N ' ' O ' ' A' ' 4' ' ' THR . 6.9 m95 -41.49 -20.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.434 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.536 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.2 mt-30 -107.49 -155.98 0.57 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.691 -1.255 . . . . 0.0 109.78 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.694 ' HB3' HD13 ' A' ' 23' ' ' LEU . 62.0 mtt180 -76.21 115.79 50.13 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 110.413 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.596 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.6 Cg_endo -81.89 83.38 2.1 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 121.994 1.796 . . . . 0.0 109.019 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 1.01 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -78.52 166.9 22.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.332 -0.855 . . . . 0.0 109.615 -179.033 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.879 HG23 HG23 ' A' ' 13' ' ' ILE . 15.2 m -147.88 131.18 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.108 -0.995 . . . . 0.0 110.558 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.648 HG22 HD22 ' A' ' 19' ' ' LEU . 3.1 m -68.68 103.05 1.63 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.527 -1.358 . . . . 0.0 107.786 178.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.879 HG23 HG23 ' A' ' 11' ' ' VAL . 2.8 pt -102.42 137.34 30.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.244 -0.91 . . . . 0.0 111.207 -178.077 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.946 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -105.0 93.6 4.79 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.625 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.766 HD11 HD12 ' A' ' 64' ' ' ILE . 15.6 mt -104.48 124.35 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.455 -0.778 . . . . 0.0 109.488 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.75 13.0 68.36 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.88 7.72 77.43 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.555 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -105.77 171.72 7.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -1.131 . . . . 0.0 108.521 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.946 HD21 ' HD3' ' A' ' 14' ' ' LYS . 15.1 mt -123.6 130.58 52.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.869 -1.145 . . . . 0.0 110.959 -178.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' HE3' ' HB3' ' A' ' 36' ' ' MET . 0.7 OUTLIER -150.41 143.13 24.6 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 1.01 ' HB3' HD23 ' A' ' 10' ' ' LEU . 9.1 mm-40 -78.88 127.46 32.05 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.961 -1.087 . . . . 0.0 109.101 -179.055 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.87 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -108.27 112.47 24.96 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.986 -1.071 . . . . 0.0 112.012 -178.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.694 HD13 ' HB3' ' A' ' 8' ' ' ARG . 11.9 tp -72.22 107.39 4.84 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.596 HD12 ' HB2' ' A' ' 9' ' ' PRO . 56.5 mt -46.79 142.97 3.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.864 -1.148 . . . . 0.0 108.294 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.622 ' HB3' HG22 ' A' ' 84' ' ' ILE . 11.4 t0 -156.79 99.59 1.86 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.844 -1.16 . . . . 0.0 110.272 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.405 ' HA ' HH12 ' A' ' 87' ' ' ARG . 10.9 m -76.12 -0.26 21.35 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.149 -0.97 . . . . 0.0 109.399 179.357 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.842 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -89.54 -26.48 25.1 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.623 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -81.39 124.4 29.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.12 -1.224 . . . . 0.0 109.089 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.633 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 42.8 m-20 -61.83 -16.42 49.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.853 . . . . 0.0 110.171 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.639 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 5.0 m-20 -145.16 -170.48 3.44 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.022 -1.071 . . . . 0.0 109.713 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.832 HG22 ' CD1' ' A' ' 33' ' ' LEU . 8.1 m -104.84 86.56 2.49 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 120.804 -1.185 . . . . 0.0 109.818 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.981 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.3 OUTLIER -70.04 163.13 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.265 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.981 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.5 OUTLIER -160.37 128.86 4.75 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.033 -1.042 . . . . 0.0 110.396 -178.01 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.8 tt0 -43.81 165.36 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.505 -0.878 . . . . 0.0 108.848 179.16 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.479 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -48.23 143.4 4.61 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.353 -179.426 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.794 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.5 OUTLIER -155.91 -168.31 2.73 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.464 -0.773 . . . . 0.0 109.025 179.737 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.7 t -122.17 111.15 16.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.847 -1.158 . . . . 0.0 111.196 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.81 HD23 ' CG ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -114.57 179.73 0.74 Allowed Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.714 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.571 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 36.1 Cg_endo -78.6 36.9 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.68 2.253 . . . . 0.0 112.502 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 55.59 33.03 58.76 Favored Glycine 0 N--CA 1.493 2.483 0 O-C-N 121.102 -0.999 . . . . 0.0 111.299 178.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.598 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 15.4 mmm180 -113.97 78.15 1.12 Allowed 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.485 -1.009 . . . . 0.0 108.337 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.567 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 59.8 p-90 -148.96 -177.41 5.79 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 120.985 -1.072 . . . . 0.0 111.37 -178.457 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.72 141.61 28.49 Favored Pre-proline 0 N--CA 1.487 1.377 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.47 131.23 13.54 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 C-N-CA 121.936 1.757 . . . . 0.0 111.025 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.559 ' CD ' ' HB2' ' A' ' 58' ' ' GLN . 13.1 ptmt -161.28 -169.8 2.44 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.54 -0.725 . . . . 0.0 109.233 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.486 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 38.4 mtp -151.34 137.98 18.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.36 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.768 HD11 HG21 ' B' ' 50' ' ' ILE . 15.4 pt -95.94 150.0 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 120.987 -1.07 . . . . 0.0 108.491 178.79 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.07 102.37 0.97 Allowed Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.534 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -123.08 -134.74 4.43 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.721 -178.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.732 HG23 HD13 ' B' ' 54' ' ' ILE . 58.3 mt -83.02 122.87 38.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 CA-C-O 121.629 0.728 . . . . 0.0 112.548 -177.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 104.64 -53.77 0.66 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.504 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 178.33 -169.24 40.86 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.585 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.2 m-30 -102.37 135.28 44.26 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.282 . . . . 0.0 109.312 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.489 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.3 pt -101.52 176.1 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.131 -0.981 . . . . 0.0 109.352 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.527 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -105.35 142.02 35.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.241 -0.912 . . . . 0.0 109.323 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.538 HG12 ' HA3' ' A' ' 78' ' ' GLY . 31.1 m -150.93 -179.03 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 110.652 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.491 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -128.02 91.58 3.3 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.141 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.559 ' HB2' ' CD ' ' A' ' 45' ' ' LYS . 17.1 tt0 -51.29 102.98 0.05 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.443 0.639 . . . . 0.0 111.635 -178.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.81 ' CG ' HD23 ' A' ' 38' ' ' LEU . 24.8 m-85 -90.63 137.3 32.46 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -119.34 121.51 39.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.651 -1.281 . . . . 0.0 110.321 -179.091 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.583 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 5.4 mt-30 83.3 61.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.372 0.606 . . . . 0.0 109.882 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.732 HG21 HG21 ' A' ' 75' ' ' VAL . 2.7 mm -111.62 115.79 50.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.35 -0.844 . . . . 0.0 108.782 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.875 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.0 tm? -66.42 87.22 0.12 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.16 -0.963 . . . . 0.0 110.391 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 1.038 HD13 HD11 ' A' ' 66' ' ' ILE . 5.2 tt -88.8 122.94 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.49 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.0 tt0 -88.97 96.11 10.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.13 -0.981 . . . . 0.0 108.84 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.038 HD11 HD13 ' A' ' 64' ' ' ILE . 3.2 mt -101.51 122.8 54.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.334 -0.854 . . . . 0.0 110.043 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.3 m 60.93 44.66 10.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.636 -0.665 . . . . 0.0 109.773 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 55.7 33.32 59.45 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -130.85 118.92 21.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.285 -1.127 . . . . 0.0 109.353 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.496 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -56.32 133.62 52.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 108.706 179.626 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -157.42 104.04 2.0 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 110.199 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.583 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -79.35 154.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 120.88 -1.138 . . . . 0.0 108.313 178.78 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.496 ' HA3' HD22 ' A' ' 89' ' ' LEU . . . -177.25 175.43 47.63 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.179 -1.486 . . . . 0.0 110.576 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 59' ' ' TYR . 3.7 m -85.34 115.28 23.0 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.586 -0.949 . . . . 0.0 110.158 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -103.94 109.49 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.121 -0.987 . . . . 0.0 110.288 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.611 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.2 mp -82.53 115.81 21.68 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.948 -1.095 . . . . 0.0 108.345 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 93.9 t -96.02 121.7 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.754 -1.216 . . . . 0.0 110.213 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.538 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -160.17 -170.84 25.27 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -81.02 42.68 1.39 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.926 2.417 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.664 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.4 t -82.8 141.73 44.61 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 108.564 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.9 Cg_endo -79.38 15.31 1.6 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.518 2.145 . . . . 0.0 110.98 -179.229 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 81' ' ' PRO . 14.1 t -160.43 158.41 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.929 -1.107 . . . . 0.0 110.22 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.695 HD21 ' N ' ' A' ' 83' ' ' ASN . 0.1 OUTLIER -102.06 91.13 4.19 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 176.217 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.622 HG22 ' HB3' ' A' ' 25' ' ' ASP . 41.8 mt -96.63 130.6 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.891 -1.131 . . . . 0.0 113.674 -174.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.87 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -89.3 131.9 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.839 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.639 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -110.96 -143.48 9.48 Favored Glycine 0 N--CA 1.498 2.797 0 O-C-N 120.688 -1.257 . . . . 0.0 110.847 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.633 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -77.83 -41.61 36.44 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.482 -179.464 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -54.63 -18.95 5.11 Favored 'General case' 0 N--CA 1.497 1.881 0 C-N-CA 117.438 -1.705 . . . . 0.0 110.246 -178.608 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.713 ' CB ' HG23 ' A' ' 85' ' ' ILE . 1.0 OUTLIER -103.03 -35.97 8.34 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.712 -1.243 . . . . 0.0 110.363 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.49 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 66.2 mt -68.86 -19.77 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.876 -1.14 . . . . 0.0 109.599 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.528 HG21 ' HA ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -93.86 -2.9 52.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.734 -1.229 . . . . 0.0 108.809 178.962 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.46 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.0 OUTLIER -99.44 -40.84 7.67 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.261 -0.9 . . . . 0.0 108.949 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.059 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -79.76 -16.1 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 N-CA-C 108.571 -0.899 . . . . 0.0 108.571 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 91.05 30.87 10.43 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.85 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -67.44 138.99 57.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.988 -1.301 . . . . 0.0 109.555 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.456 ' O ' ' O ' ' B' ' 96' ' ' THR . 3.0 p -132.76 128.49 36.94 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.151 -0.968 . . . . 0.0 108.558 179.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.665 HD13 HD23 ' B' ' 5' ' ' LEU . 4.3 mp -90.62 98.43 11.77 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.245 -0.909 . . . . 0.0 109.532 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 16.0 m-20 -105.61 125.7 51.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.029 -1.044 . . . . 0.0 109.246 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.741 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 CA-C-O 117.959 -1.02 . . . . 0.0 109.295 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.509 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.68 0 N-CA-C 110.825 -0.49 . . . . 0.0 110.825 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -85.71 134.27 33.97 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.834 HG12 ' H ' ' B' ' 5' ' ' LEU . 49.4 t -131.5 125.08 55.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.764 -1.21 . . . . 0.0 109.951 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.909 ' O ' HD12 ' B' ' 5' ' ' LEU . 46.7 p -75.89 3.58 9.81 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.48 -0.763 . . . . 0.0 109.656 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.909 HD12 ' O ' ' B' ' 4' ' ' THR . 0.4 OUTLIER 34.35 46.75 0.18 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.801 -0.562 . . . . 0.0 111.476 179.199 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.528 ' HA ' HG21 ' A' ' 91' ' ' THR . 58.8 m95 -57.63 -20.35 32.48 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -147.11 -164.55 2.02 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 1.075 ' HD2' HD13 ' B' ' 23' ' ' LEU . 0.5 OUTLIER -59.22 122.52 64.08 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 120.897 -1.127 . . . . 0.0 109.211 179.735 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.607 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -78.97 66.42 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.376 2.051 . . . . 0.0 109.635 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.536 HD22 ' CB ' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -81.15 145.65 30.93 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.107 -0.996 . . . . 0.0 109.827 -179.31 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.674 HG21 HG13 ' B' ' 66' ' ' ILE . 2.6 m -136.58 136.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.53 -0.731 . . . . 0.0 109.434 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -66.09 89.27 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.805 -1.184 . . . . 0.0 107.805 178.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.756 HG12 ' HB2' ' B' ' 22' ' ' ALA . 1.1 pp -80.67 131.52 33.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 109.596 -179.04 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.728 ' HE2' HD11 ' B' ' 19' ' ' LEU . 12.0 tttm -98.84 111.59 23.93 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.354 -0.841 . . . . 0.0 108.998 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.796 ' CG2' HD21 ' B' ' 38' ' ' LEU . 28.8 mt -116.38 134.65 59.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.221 -0.925 . . . . 0.0 108.9 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.66 -100.49 0.28 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -142.29 35.44 1.74 Allowed Glycine 0 N--CA 1.485 1.906 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 5.8 mt-30 -134.13 179.95 5.94 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.482 -1.011 . . . . 0.0 109.663 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.728 HD11 ' HE2' ' B' ' 14' ' ' LYS . 16.0 mt -147.39 130.26 16.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.531 -0.731 . . . . 0.0 109.139 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.451 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 39.0 mttp -146.12 171.77 14.42 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.166 -0.959 . . . . 0.0 109.199 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.536 ' CB ' HD22 ' B' ' 10' ' ' LEU . 2.9 mm-40 -79.03 148.48 32.48 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.756 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -136.16 108.28 7.22 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.056 . . . . 0.0 110.543 -178.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 1.075 HD13 ' HD2' ' B' ' 8' ' ' ARG . 18.8 tp -70.13 102.75 2.14 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' B' ' 9' ' ' PRO . 82.5 mt -53.7 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.055 -1.028 . . . . 0.0 108.867 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 1.003 ' CB ' HG23 ' B' ' 84' ' ' ILE . 35.2 t0 -91.92 90.06 7.28 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.391 -0.818 . . . . 0.0 110.519 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.643 HG22 ' NH2' ' B' ' 87' ' ' ARG . 7.3 m -71.05 -7.49 46.82 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 109.064 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.434 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -83.58 -31.3 27.61 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.42 173.15 12.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.875 -1.368 . . . . 0.0 109.337 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -101.72 -18.0 16.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.073 -1.017 . . . . 0.0 110.764 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.477 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -137.35 -172.54 3.24 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.769 -1.207 . . . . 0.0 110.142 -179.357 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 31' ' ' THR . . . . . 1.012 HG23 HD12 ' B' ' 85' ' ' ILE . 55.3 m -102.59 82.43 2.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.093 -1.005 . . . . 0.0 109.89 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.012 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.71 161.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.881 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.012 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -153.25 129.52 10.51 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.587 -1.245 . . . . 0.0 111.618 -177.451 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.719 ' HA ' HG22 ' B' ' 80' ' ' THR . 9.5 tt0 -44.22 156.28 0.07 Allowed 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' B' ' 34' ' ' GLU . 0.5 OUTLIER -40.05 138.12 0.87 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 110.601 -179.074 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.555 ' O ' HG11 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -165.27 148.84 8.32 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.862 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.484 ' O ' ' SD ' ' B' ' 36' ' ' MET . 23.3 t -82.8 125.5 31.37 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.046 -1.034 . . . . 0.0 110.68 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.91 HD12 HG21 ' B' ' 77' ' ' VAL . 2.6 mt -122.93 164.03 29.67 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.271 -0.893 . . . . 0.0 108.653 179.03 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.485 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.7 Cg_endo -73.88 71.78 4.06 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.655 2.237 . . . . 0.0 112.539 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.8 -159.22 0.01 OUTLIER Glycine 0 N--CA 1.497 2.727 0 O-C-N 121.528 -0.732 . . . . 0.0 111.414 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.434 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 2.8 mmt180 61.11 66.54 0.88 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.568 -0.96 . . . . 0.0 109.196 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.591 ' CZ3' ' HD2' ' B' ' 57' ' ' ARG . 65.0 p-90 -149.79 -177.96 6.19 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.575 -0.703 . . . . 0.0 109.731 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' B' ' 57' ' ' ARG . 23.6 mtmt -150.82 160.35 32.5 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 108.974 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 44' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' B' ' 43' ' ' LYS . 34.7 Cg_endo -76.33 140.86 22.35 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.384 2.056 . . . . 0.0 110.241 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.621 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -157.81 120.8 3.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.342 -0.849 . . . . 0.0 109.058 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.476 ' HG3' ' CG ' ' B' ' 55' ' ' LYS . 2.5 ttt -101.18 126.72 47.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.082 -1.011 . . . . 0.0 109.94 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.696 HD11 HD11 ' B' ' 54' ' ' ILE . 10.0 pt -105.62 150.8 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.046 -1.034 . . . . 0.0 109.327 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.608 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -125.47 97.68 0.53 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.8 -130.9 4.09 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.291 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.768 HG21 HD11 ' A' ' 47' ' ' ILE . 66.3 mt -81.77 129.8 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.534 -0.98 . . . . 0.0 112.185 -178.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 100.21 -48.51 1.2 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 171.89 -164.63 37.29 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.655 -1.259 . . . . 0.0 109.994 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.608 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 3.1 m-85 -107.03 130.56 54.63 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.423 -1.045 . . . . 0.0 108.921 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.732 HD13 HG23 ' A' ' 50' ' ' ILE . 34.0 pt -112.7 155.18 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 120.977 -1.077 . . . . 0.0 109.885 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 18.6 mttt -98.95 140.62 32.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.184 -0.947 . . . . 0.0 108.68 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.956 HG12 ' HA3' ' B' ' 78' ' ' GLY . 9.9 m -143.7 -176.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.9 -1.125 . . . . 0.0 110.149 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.591 ' HD2' ' CZ3' ' B' ' 42' ' ' TRP . 69.0 mtm-85 -132.09 104.1 6.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.637 ' HG3' HG22 ' B' ' 74' ' ' THR . 8.5 tt0 -62.0 134.69 56.96 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.654 0.74 . . . . 0.0 110.967 -178.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.54 ' HB3' ' CG1' ' B' ' 62' ' ' ILE . 17.6 m-85 -121.61 93.93 4.16 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.515 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 9.1 m-20 -79.44 130.86 35.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.031 -1.043 . . . . 0.0 110.452 -178.659 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.515 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 6.9 mm100 83.22 62.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.329 0.585 . . . . 0.0 109.723 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.57 ' HB ' HG23 ' B' ' 75' ' ' VAL . 40.0 mm -119.86 115.72 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.343 -0.848 . . . . 0.0 109.063 179.255 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.848 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.8 tm? -66.48 91.86 0.19 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 110.453 -179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.726 HG12 HD12 ' B' ' 66' ' ' ILE . 7.3 tt -98.38 120.68 48.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.452 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.2 tt0 -90.53 111.88 23.34 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.947 -1.095 . . . . 0.0 109.491 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.726 HD12 HG12 ' B' ' 64' ' ' ILE . 1.0 OUTLIER -100.44 126.47 54.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.741 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.425 ' C ' ' O ' ' B' ' 66' ' ' ILE . 10.2 m 39.43 61.8 1.29 Allowed 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.71 -0.619 . . . . 0.0 110.63 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.3 41.05 86.5 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 120.175 -1.012 . . . . 0.0 111.121 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 2.7 m-70 -139.44 135.46 33.61 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.9 -1.353 . . . . 0.0 109.0 178.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.549 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -76.64 132.93 39.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.286 -0.884 . . . . 0.0 109.739 -179.614 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.709 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.6 97.17 1.96 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.835 . . . . 0.0 109.822 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.605 HG12 ' N ' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -83.54 136.85 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 178.638 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.642 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -161.58 -171.96 28.32 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.96 -1.59 . . . . 0.0 110.636 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.637 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.0 m -89.97 106.36 18.42 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.825 -0.809 . . . . 0.0 110.174 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -99.64 116.74 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.484 -0.76 . . . . 0.0 110.03 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.572 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.5 mp -85.33 139.05 31.89 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.618 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.91 HG21 HD12 ' B' ' 38' ' ' LEU . 1.6 t -121.32 114.49 43.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.066 -1.021 . . . . 0.0 109.647 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.956 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.06 -162.78 11.64 Favored Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.21 40.61 0.99 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.615 2.21 . . . . 0.0 111.471 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.719 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.5 t -84.88 137.87 37.73 Favored Pre-proline 0 N--CA 1.493 1.678 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.71 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.2 Cg_endo -77.31 14.43 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.565 2.177 . . . . 0.0 111.579 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.71 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.04 151.25 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.95 -1.094 . . . . 0.0 110.438 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.567 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 3.6 m-20 -90.62 102.88 15.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 176.752 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 1.003 HG23 ' CB ' ' B' ' 25' ' ' ASP . 2.2 mt -101.97 129.38 53.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 120.902 -1.124 . . . . 0.0 113.083 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 1.012 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -98.63 111.49 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.505 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -97.47 -161.3 31.33 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.835 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.643 ' NH2' HG22 ' B' ' 26' ' ' THR . 0.4 OUTLIER -58.4 -34.9 71.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.563 -0.963 . . . . 0.0 110.451 -179.791 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.007 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.6 p-10 -48.05 -27.95 2.56 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.867 -1.145 . . . . 0.0 109.913 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.007 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -109.75 -24.79 10.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.81 -1.181 . . . . 0.0 109.63 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.51 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 90.7 mt -72.43 -4.97 33.39 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.509 HG23 ' O ' ' B' ' 87' ' ' ARG . 74.4 p -100.51 -17.85 16.93 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -85.4 -41.21 15.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.354 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.741 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.5 pt -87.04 -4.03 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.29 50.56 38.02 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.136 178.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.677 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -73.05 157.77 36.69 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.071 -1.252 . . . . 0.0 110.198 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.54 HG22 ' CG2' ' A' ' 4' ' ' THR . 50.5 p -149.63 128.39 12.47 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.462 -0.773 . . . . 0.0 109.323 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.54 HD11 HD11 ' A' ' 97' ' ' LEU . 7.5 mp -89.68 104.32 16.89 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m-20 -107.64 127.29 53.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.05 . . . . 0.0 110.04 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 1.059 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.138 -0.934 . . . . 0.0 109.62 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.623 ' C27' ' HB1' ' A' ' 28' ' ' ALA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.53 ' CD ' ' O ' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.726 0 N-CA-C 110.244 -0.714 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' B' ' 97' ' ' LEU . 1.7 tm0? -84.67 144.08 28.79 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.431 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.765 HG12 ' H ' ' A' ' 5' ' ' LEU . 38.1 t -145.28 123.34 4.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.911 -1.118 . . . . 0.0 109.984 -179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 18.6 p -60.51 -14.76 21.5 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.546 -0.721 . . . . 0.0 110.28 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.765 ' H ' HG12 ' A' ' 3' ' ' VAL . 39.5 mt 73.65 17.02 3.78 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.484 -0.76 . . . . 0.0 110.654 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.698 ' CE3' HG21 ' B' ' 91' ' ' THR . 0.3 OUTLIER -65.45 -12.61 54.1 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.842 -1.161 . . . . 0.0 108.789 179.252 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.521 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 29.7 mm-40 -146.47 178.86 7.95 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.9 mtt180 -72.97 116.08 46.83 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.916 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.745 ' HB2' HD12 ' A' ' 24' ' ' LEU . 32.7 Cg_endo -75.93 77.81 3.32 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 122.091 1.86 . . . . 0.0 110.107 178.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.568 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.88 167.83 19.44 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.111 -0.993 . . . . 0.0 109.11 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.806 HG23 HG23 ' A' ' 13' ' ' ILE . 27.3 m -150.22 130.0 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.763 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 1.08 HG22 HD22 ' A' ' 19' ' ' LEU . 91.9 m -66.95 92.18 0.23 Allowed 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.871 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.4 pt -86.71 143.05 12.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.418 -0.801 . . . . 0.0 111.216 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.79 ' HD2' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -108.46 97.78 7.4 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.166 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.971 HD12 HG11 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -115.69 140.38 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 110.223 -178.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 38' ' ' LEU . . . 49.7 29.23 12.27 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 178.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.57 38.26 57.63 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.568 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -136.2 179.43 6.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.477 -1.013 . . . . 0.0 108.284 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 1.08 HD22 HG22 ' A' ' 12' ' ' THR . 13.0 mt -144.55 118.98 9.63 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.957 -1.09 . . . . 0.0 109.801 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.571 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -135.44 150.18 49.79 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.605 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 14.9 mm-40 -78.81 112.51 16.02 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.819 -1.175 . . . . 0.0 108.133 179.602 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.884 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -91.85 140.46 29.66 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.934 0.873 . . . . 0.0 110.788 -178.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 24' ' ' LEU . 44.6 tp -93.74 97.1 10.21 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.745 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.2 mt -42.43 107.69 0.08 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.158 -0.964 . . . . 0.0 109.153 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.778 ' CB ' HG23 ' A' ' 84' ' ' ILE . 2.7 t70 -113.81 87.82 2.7 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -178.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.842 ' HA ' HD21 ' A' ' 90' ' ' LEU . 10.1 m -70.99 -5.68 32.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.114 -0.991 . . . . 0.0 109.081 178.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.639 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.6 -29.38 32.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 168.59 19.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.214 -1.168 . . . . 0.0 109.691 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -100.19 -19.82 16.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.394 -0.816 . . . . 0.0 109.656 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 39.4 m-20 -133.7 -167.18 1.9 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -0.971 . . . . 0.0 109.74 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.547 HG22 ' O ' ' A' ' 31' ' ' THR . 8.0 m -111.06 89.74 3.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.035 -1.04 . . . . 0.0 110.193 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.018 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -68.14 172.08 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.132 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.072 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -167.96 113.99 0.69 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.189 -0.944 . . . . 0.0 109.557 -179.511 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.735 ' HA ' HG22 ' A' ' 80' ' ' THR . 9.7 pt-20 -36.24 154.84 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.445 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -44.16 134.86 4.65 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.088 -1.008 . . . . 0.0 109.922 -178.915 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.697 ' HE1' HG22 ' A' ' 15' ' ' ILE . 2.3 ppp? -154.31 -163.72 1.68 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.595 -0.691 . . . . 0.0 109.644 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.513 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 3.1 t -107.81 118.27 36.29 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.921 -1.112 . . . . 0.0 111.149 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.746 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -131.32 -173.57 0.34 Allowed Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 178.512 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.657 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.6 Cg_endo -78.97 -163.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.919 1.746 . . . . 0.0 110.861 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -114.18 31.56 6.41 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -118.98 63.82 0.78 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 21.2 p-90 -130.38 -175.39 3.63 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.764 0.792 . . . . 0.0 110.207 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -139.85 156.51 70.71 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.65 141.56 24.96 Favored 'Trans proline' 0 C--N 1.303 -1.849 0 C-N-CA 121.868 1.712 . . . . 0.0 109.68 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 1.3 tttt -149.94 170.14 19.52 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.445 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -144.27 113.81 7.1 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.655 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.606 ' CD1' HG21 ' B' ' 50' ' ' ILE . 24.9 pt -89.47 141.62 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.079 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.615 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -119.32 115.46 3.05 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.456 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -136.84 -115.05 1.38 Allowed Glycine 0 N--CA 1.485 1.905 0 C-N-CA 119.212 -1.471 . . . . 0.0 111.088 -178.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.835 HD12 H702 ' B' ' 100' ' ' DMP . 17.1 mt -94.07 118.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.733 -0.863 . . . . 0.0 112.585 -177.116 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.89 -11.31 67.99 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.452 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 137.4 -177.54 19.76 Favored Glycine 0 N--CA 1.493 2.489 0 O-C-N 120.806 -1.408 . . . . 0.0 109.647 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.5 OUTLIER -102.64 143.92 31.7 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -1.133 . . . . 0.0 109.844 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.59 HD11 HG13 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -109.19 -178.21 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.258 -0.901 . . . . 0.0 108.703 178.909 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.58 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 2.4 mttp -109.09 141.7 40.88 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.038 -1.039 . . . . 0.0 109.643 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -147.61 -171.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.05 -1.031 . . . . 0.0 109.521 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.406 ' HG3' ' C ' ' A' ' 56' ' ' VAL . 1.6 mtt180 -133.46 108.12 8.46 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.441 ' HB2' ' HD2' ' A' ' 45' ' ' LYS . 1.3 tt0 -65.28 97.17 0.26 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.322 -0.861 . . . . 0.0 110.428 -179.166 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.746 ' CD2' HD23 ' A' ' 38' ' ' LEU . 10.3 m-85 -89.93 123.22 33.67 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -105.58 134.89 47.96 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.736 -1.227 . . . . 0.0 110.665 -178.589 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mp0 73.22 63.22 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 121.695 0.76 . . . . 0.0 110.195 179.239 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.526 HG13 ' HB3' ' A' ' 59' ' ' TYR . 22.1 mm -117.27 127.27 74.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.586 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -76.37 89.08 3.18 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 112.276 -177.523 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.747 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -90.48 112.96 25.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 CA-C-O 121.888 0.852 . . . . 0.0 108.822 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.537 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -89.5 113.03 24.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.778 -1.201 . . . . 0.0 108.515 -179.69 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.747 HD11 HD13 ' A' ' 64' ' ' ILE . 2.9 mt -115.17 126.64 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.922 -1.111 . . . . 0.0 110.67 -178.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.2 m 66.75 24.91 9.82 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.638 -0.664 . . . . 0.0 109.895 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.431 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 80.58 7.44 88.55 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -108.86 110.03 21.28 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.208 -1.172 . . . . 0.0 109.226 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.2 ttpt -52.58 136.29 32.79 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.474 -0.767 . . . . 0.0 109.026 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.94 118.38 4.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.618 -0.676 . . . . 0.0 109.36 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.586 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -95.07 158.06 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 120.807 -1.183 . . . . 0.0 108.036 178.709 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.479 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 177.42 -170.15 42.54 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.734 -1.698 . . . . 0.0 111.47 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 1.5 m -91.18 113.25 25.46 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.918 . . . . 0.0 110.146 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.072 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -107.93 109.49 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.525 -0.734 . . . . 0.0 111.135 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.594 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.9 mp -80.2 125.08 29.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.276 -0.89 . . . . 0.0 109.056 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 89.9 t -113.25 131.91 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.999 -1.063 . . . . 0.0 109.853 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -164.47 -167.57 25.21 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.58 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -81.81 40.74 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.592 2.195 . . . . 0.0 110.534 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.735 HG22 ' HA ' ' A' ' 34' ' ' GLU . 14.9 t -81.74 140.72 47.47 Favored Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.463 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.3 Cg_endo -77.72 13.06 1.75 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 C-N-CA 122.227 1.952 . . . . 0.0 111.196 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.647 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.45 163.49 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.74 -1.225 . . . . 0.0 110.731 -179.755 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.642 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 60.0 m-20 -95.8 142.88 27.55 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 176.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 25' ' ' ASP . 12.3 mm -131.95 124.63 53.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.467 -1.396 . . . . 0.0 111.337 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.884 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -102.96 94.72 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.656 ' C ' HD13 ' A' ' 90' ' ' LEU . . . -100.75 171.21 22.61 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.382 -177.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.622 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.1 OUTLIER -21.71 -41.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -179.392 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.978 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.8 p-10 -51.1 -42.89 60.94 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.282 -1.511 . . . . 0.0 110.774 -177.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.978 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -97.54 -11.04 24.18 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.146 -0.971 . . . . 0.0 110.414 -179.137 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.842 HD21 ' HA ' ' A' ' 26' ' ' THR . 5.7 mp -69.73 -35.14 74.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.084 -1.01 . . . . 0.0 108.788 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 p -70.5 -15.42 62.79 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.455 -0.778 . . . . 0.0 109.252 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.6 mm-40 -89.13 -41.42 12.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.019 . . . . 0.0 109.27 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.674 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.9 pt -81.99 -1.89 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 57.19 54.95 33.11 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.876 ' HB3' HD12 ' B' ' 5' ' ' LEU . . . -85.42 127.62 34.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.422 -1.046 . . . . 0.0 110.26 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 69.9 p -122.31 124.9 44.82 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -89.98 100.48 13.29 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.406 -0.809 . . . . 0.0 109.384 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.1 m-20 -105.96 129.33 54.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.234 -0.916 . . . . 0.0 110.048 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.736 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.265 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.404 -0.652 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -84.25 129.45 34.88 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 11.4 t -121.76 96.23 4.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.762 -1.212 . . . . 0.0 109.499 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.418 HG23 ' H ' ' B' ' 4' ' ' THR . 3.0 p -55.73 135.11 51.73 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.876 HD12 ' HB3' ' A' ' 95' ' ' ALA . 89.5 mt -83.36 4.42 27.46 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.765 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -57.05 -20.19 23.21 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -135.4 157.67 46.31 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.0 mtt180 -53.25 125.5 42.65 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 120.886 -1.134 . . . . 0.0 109.371 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.799 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.4 Cg_endo -77.65 71.23 6.59 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.281 1.987 . . . . 0.0 109.819 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -90.63 144.62 25.57 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.26 -179.686 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.659 HG21 HG12 ' B' ' 66' ' ' ILE . 3.1 m -135.14 132.71 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 110.203 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.809 HG22 HD22 ' B' ' 19' ' ' LEU . 91.8 m -65.6 109.56 2.43 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.034 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.1 pt -98.58 144.23 11.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 110.841 -178.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.483 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -112.16 101.9 10.12 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' B' ' 13' ' ' ILE . 11.8 mt -118.58 118.87 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.162 -0.961 . . . . 0.0 109.766 -179.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.421 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.83 27.25 73.67 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.2 -2.78 74.84 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.423 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.4 mp0 -90.07 -179.34 5.66 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.329 -1.101 . . . . 0.0 108.973 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 1.034 HD23 ' O ' ' B' ' 13' ' ' ILE . 12.4 mt -153.17 124.02 7.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.193 -0.942 . . . . 0.0 110.269 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.443 ' NZ ' HD23 ' B' ' 33' ' ' LEU . 8.4 mtmt -143.89 158.63 43.57 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.4 OUTLIER -79.29 133.05 36.64 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.978 -1.076 . . . . 0.0 109.54 -179.114 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.824 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.7 156.25 19.29 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.248 -0.908 . . . . 0.0 110.022 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.639 HD21 ' O ' ' A' ' 27' ' ' GLY . 62.4 tp -115.6 95.35 5.1 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.871 HD22 HD21 ' B' ' 90' ' ' LEU . 24.1 mt -42.15 103.44 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.393 -0.817 . . . . 0.0 109.359 -179.437 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.509 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 48.8 t0 -114.55 91.02 3.48 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.142 -0.974 . . . . 0.0 110.275 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.563 HG21 HD22 ' A' ' 5' ' ' LEU . 0.9 OUTLIER -68.88 -7.56 35.82 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.066 -1.021 . . . . 0.0 108.73 178.581 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.429 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -73.8 -41.57 41.54 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.71 166.21 23.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.149 -1.206 . . . . 0.0 109.886 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -100.93 -19.91 15.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.145 -0.972 . . . . 0.0 110.786 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.499 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -130.6 -168.17 1.94 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.874 -1.141 . . . . 0.0 109.644 -179.445 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.596 HG22 ' CD1' ' B' ' 33' ' ' LEU . 16.7 m -109.74 95.66 5.75 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.911 -1.118 . . . . 0.0 110.286 -179.066 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.993 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -77.38 162.14 4.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 179.023 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.032 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -160.74 125.78 3.75 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 120.456 -1.402 . . . . 0.0 111.288 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 33' ' ' LEU . 3.7 tt0 -38.89 159.17 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.724 -0.61 . . . . 0.0 109.677 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.78 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -51.35 150.26 3.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.95 . . . . 0.0 110.285 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.534 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.9 ppp? -168.5 -169.16 1.01 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.293 -0.879 . . . . 0.0 109.11 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.52 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.6 t -121.19 124.42 44.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.929 -1.107 . . . . 0.0 110.372 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.868 HD21 HD12 ' B' ' 62' ' ' ILE . 0.1 OUTLIER -124.64 -172.82 0.26 Allowed Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.347 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.648 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.8 Cg_endo -80.8 59.87 7.63 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.292 1.995 . . . . 0.0 111.005 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.95 -157.92 0.06 OUTLIER Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.414 ' HD3' ' HA ' ' B' ' 41' ' ' ARG . 50.7 mmt-85 51.91 96.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.544 -0.974 . . . . 0.0 109.077 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.453 ' CE3' ' HG3' ' B' ' 57' ' ' ARG . 16.7 p-90 -155.02 171.93 18.94 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.691 -0.631 . . . . 0.0 109.683 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.24 121.4 20.52 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.26 141.5 18.31 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.412 2.075 . . . . 0.0 111.423 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.28 -171.93 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.221 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.516 ' HG2' ' HG3' ' B' ' 55' ' ' LYS . 17.1 mtp -143.54 133.97 24.74 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.903 -1.123 . . . . 0.0 110.098 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.692 HD12 HG21 ' A' ' 50' ' ' ILE . 19.4 pt -104.94 139.43 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 0.0 108.8 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.9 97.35 0.7 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.294 -1.922 . . . . 0.0 108.294 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.22 -121.37 2.88 Favored Glycine 0 N--CA 1.485 1.914 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.682 -178.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.832 HD12 ' C21' ' B' ' 100' ' ' DMP . 11.2 mt -86.58 124.79 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.854 -0.792 . . . . 0.0 111.982 -177.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 101.49 -53.46 0.83 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.711 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 176.76 -161.81 29.9 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -111.38 137.33 49.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -1.198 . . . . 0.0 109.359 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.591 HD11 HD11 ' B' ' 47' ' ' ILE . 27.6 pt -117.14 159.17 17.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.253 -0.904 . . . . 0.0 109.535 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.527 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.5 OUTLIER -94.69 126.26 39.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 108.8 179.313 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.585 HG12 ' HA3' ' B' ' 78' ' ' GLY . 12.5 m -134.2 153.68 36.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.542 ' N ' ' HD2' ' B' ' 57' ' ' ARG . 2.3 mpt_? -91.63 179.78 5.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -138.61 93.06 2.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.131 -0.98 . . . . 0.0 110.523 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.599 ' CG ' HD23 ' B' ' 38' ' ' LEU . 67.2 m-85 -89.29 92.53 9.2 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 49.0 m-20 -78.62 143.11 36.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.046 -1.034 . . . . 0.0 109.381 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.586 ' HA ' HG23 ' B' ' 72' ' ' ILE . 1.4 mp0 74.1 64.18 0.08 Allowed 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.529 -0.732 . . . . 0.0 109.189 -179.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.868 HD12 HD21 ' B' ' 38' ' ' LEU . 1.1 mm -121.07 117.15 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.741 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.4 tm? -68.62 85.27 0.3 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.476 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.613 HG22 ' O ' ' B' ' 71' ' ' ALA . 3.4 tt -91.02 117.67 34.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.9 tt0 -89.53 111.47 22.4 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.063 -1.023 . . . . 0.0 109.563 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.35 120.3 54.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.79 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 88.2 m 65.36 20.42 11.81 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.788 -0.57 . . . . 0.0 110.166 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.26 1.61 78.46 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.112 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -97.9 123.0 41.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.214 -1.168 . . . . 0.0 109.123 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.493 ' HG2' HD21 ' B' ' 63' ' ' LEU . 3.9 mtpt -58.71 133.85 56.3 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.613 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -150.96 99.67 2.72 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.014 -1.053 . . . . 0.0 110.26 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.711 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.5 OUTLIER -79.55 144.54 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.668 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.74 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.43 -177.8 39.2 Favored Glycine 0 N--CA 1.486 1.991 0 C-N-CA 118.915 -1.612 . . . . 0.0 110.634 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.449 HG23 ' OD1' ' B' ' 60' ' ' ASP . 22.0 m -95.83 102.99 14.85 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.723 -0.869 . . . . 0.0 109.432 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.032 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.9 OUTLIER -92.58 162.11 2.45 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.704 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.0 mp -129.95 140.35 50.94 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' B' ' 35' ' ' GLU . 9.2 t -120.8 103.19 13.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 O-C-N 121.386 -0.821 . . . . 0.0 110.507 -178.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.585 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -142.54 -166.12 10.87 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.527 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.5 Cg_endo -80.94 41.31 1.12 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.583 2.189 . . . . 0.0 110.956 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -84.45 138.21 38.8 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.29 14.51 1.56 Allowed 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.193 1.928 . . . . 0.0 111.497 -179.035 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.541 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.7 OUTLIER -161.13 171.21 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.903 -1.123 . . . . 0.0 110.11 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -105.97 116.07 31.31 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 176.591 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.733 HG12 HG12 ' B' ' 32' ' ' VAL . 5.0 mm -100.45 120.59 50.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 O-C-N 120.661 -1.274 . . . . 0.0 111.562 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.824 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -95.37 89.83 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.838 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.08 -164.33 27.27 Favored Glycine 0 N--CA 1.493 2.474 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.437 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.521 ' NH2' ' HA ' ' A' ' 7' ' ' GLN . 13.5 mtm180 -60.76 -39.79 90.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.786 -0.832 . . . . 0.0 110.548 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -45.28 -26.49 0.52 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.093 -1.005 . . . . 0.0 110.181 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -108.7 -29.56 8.64 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.026 -1.047 . . . . 0.0 111.041 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.871 HD21 HD22 ' B' ' 24' ' ' LEU . 71.9 mt -65.15 -9.62 24.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.716 -1.24 . . . . 0.0 108.748 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.698 HG21 ' CE3' ' A' ' 6' ' ' TRP . 1.2 p -101.03 -20.71 15.26 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.176 -0.952 . . . . 0.0 109.391 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 36.6 mm-40 -78.06 -40.81 37.46 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.071 -1.018 . . . . 0.0 109.141 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.736 HD12 ' CG ' ' A' ' 99' ' ' PHE . 4.4 pt -86.03 -4.02 9.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.137 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 77.28 29.47 56.2 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.558 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -59.97 151.0 27.26 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.042 -1.269 . . . . 0.0 109.037 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.524 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 2.6 p -136.6 173.7 11.42 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' A' ' 97' ' ' LEU . 0.5 OUTLIER -134.31 98.82 4.2 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.735 -1.228 . . . . 0.0 110.088 -179.371 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 20.9 m-20 -99.23 118.62 36.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.964 -1.085 . . . . 0.0 109.37 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.674 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.508 0 CA-C-O 117.94 -1.029 . . . . 0.0 108.935 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.835 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.542 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 N-CA-C 110.231 -0.719 . . . . 0.0 110.231 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.497 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.43 131.07 34.71 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 178.204 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.559 HG21 ' HZ ' ' B' ' 99' ' ' PHE . 4.1 t -121.79 94.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.991 -1.068 . . . . 0.0 109.768 -178.259 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.528 ' CG2' ' HB ' ' B' ' 96' ' ' THR . 19.3 p -126.01 45.67 2.58 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.335 -0.853 . . . . 0.0 108.93 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.03 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.5 OUTLIER -89.07 36.47 0.82 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.187 -0.946 . . . . 0.0 109.589 -179.721 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 13.4 m0 17.45 51.86 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 CA-C-O 121.631 0.729 . . . . 0.0 111.512 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 1.03 ' HB2' HD12 ' A' ' 5' ' ' LEU . 49.4 mt-30 -156.02 -159.78 0.94 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 10.1 mtm180 -79.66 113.34 36.6 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.986 -1.071 . . . . 0.0 109.909 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.77 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.3 Cg_endo -79.79 80.27 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 C-N-CA 122.355 2.037 . . . . 0.0 110.055 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -100.13 164.78 11.82 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.846 -179.749 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.987 HG21 HG23 ' A' ' 66' ' ' ILE . 2.3 m -148.86 129.47 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 110.256 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.3 m -69.22 94.05 0.66 Allowed 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 178.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.805 HG23 HG23 ' A' ' 11' ' ' VAL . 7.7 pt -82.95 167.42 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 110.949 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.3 tttt -128.65 102.88 6.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.559 -0.713 . . . . 0.0 109.25 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.952 HD11 HD12 ' A' ' 64' ' ' ILE . 11.6 mt -124.47 147.93 28.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 120.987 -1.07 . . . . 0.0 109.592 -179.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.03 32.53 4.83 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.9 43.62 90.97 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.6 tp-100 -138.52 170.79 15.38 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.191 -1.182 . . . . 0.0 109.022 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.484 HD23 ' O ' ' A' ' 13' ' ' ILE . 39.3 mt -135.57 126.41 27.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.385 -0.822 . . . . 0.0 109.445 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.41 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 2.3 mtpm? -148.22 158.65 44.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.406 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.4 mt-10 -79.17 123.81 27.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.585 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -105.08 141.98 35.67 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.333 -0.854 . . . . 0.0 110.225 -178.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.871 HD21 ' O ' ' B' ' 27' ' ' GLY . 19.8 tp -97.67 103.82 15.79 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.747 -0.595 . . . . 0.0 109.918 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.77 HD12 ' HB2' ' A' ' 9' ' ' PRO . 12.1 mt -44.62 113.62 0.58 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 178.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.486 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 25.4 t0 -119.64 89.13 3.07 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.948 -1.095 . . . . 0.0 111.65 -177.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.57 -2.95 35.04 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.909 -1.119 . . . . 0.0 108.562 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 1.023 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -90.78 -25.12 25.95 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 162.13 19.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.953 -1.322 . . . . 0.0 109.027 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -98.1 -13.06 21.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.115 -0.991 . . . . 0.0 110.287 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.513 ' OD1' ' HB ' ' A' ' 74' ' ' THR . 0.2 OUTLIER -142.78 -175.05 4.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.93 -1.106 . . . . 0.0 109.732 -179.957 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.57 HG23 HD12 ' A' ' 85' ' ' ILE . 22.6 m -104.63 91.83 4.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.703 -1.248 . . . . 0.0 111.226 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.027 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.29 173.34 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.643 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.027 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.32 122.78 1.08 Allowed 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.688 -1.257 . . . . 0.0 111.547 -179.417 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.57 ' HA ' HG22 ' A' ' 80' ' ' THR . 12.6 tt0 -39.97 149.21 0.07 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.668 -0.645 . . . . 0.0 109.362 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.426 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -48.68 141.88 6.72 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.191 -0.943 . . . . 0.0 110.295 -179.599 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.514 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -163.64 -172.28 2.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.344 -0.848 . . . . 0.0 109.313 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.2 t -92.7 83.95 4.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.001 -1.062 . . . . 0.0 109.626 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.879 HD11 HD12 ' A' ' 62' ' ' ILE . 61.6 tp -116.2 98.34 51.17 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -78.37 167.3 23.18 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.656 2.237 . . . . 0.0 110.642 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.61 171.93 13.9 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 133.41 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -1.154 . . . . 0.0 108.684 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.615 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 52.5 p-90 -136.67 -177.42 4.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.163 -0.961 . . . . 0.0 110.691 -178.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.401 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 1.1 tptt -146.28 162.98 32.54 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.401 ' HD2' ' CG ' ' A' ' 43' ' ' LYS . 33.8 Cg_endo -78.0 140.36 17.98 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.756 1.638 . . . . 0.0 109.688 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.591 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -155.4 115.31 3.72 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.105 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.496 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -100.93 122.51 43.61 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.196 -0.94 . . . . 0.0 109.01 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.578 HD12 HG21 ' B' ' 50' ' ' ILE . 22.6 pt -93.24 139.26 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.016 -1.052 . . . . 0.0 109.109 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.606 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.64 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.641 -1.783 . . . . 0.0 108.641 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.411 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -125.74 -121.92 2.55 Favored Glycine 0 N--CA 1.483 1.812 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.698 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.82 HD12 ' C71' ' B' ' 100' ' ' DMP . 26.3 mt -86.48 122.23 38.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.875 -0.779 . . . . 0.0 112.571 -177.686 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.447 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 103.49 -50.98 0.85 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 176.26 -156.94 22.29 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.606 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 5.2 m-85 -111.9 129.9 56.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -1.034 . . . . 0.0 109.837 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.561 HG13 ' CG1' ' A' ' 47' ' ' ILE . 1.0 OUTLIER -106.97 164.76 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.1 mtmt -106.82 140.28 39.91 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.865 -1.147 . . . . 0.0 110.497 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.861 HG12 ' HA3' ' A' ' 78' ' ' GLY . 16.1 m -146.63 178.18 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.83 110.63 16.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.329 -0.857 . . . . 0.0 108.829 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.414 ' O ' ' CG ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -64.75 107.03 1.32 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.456 -0.778 . . . . 0.0 110.271 -179.247 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.615 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.2 m-85 -100.89 100.45 11.08 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.535 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 85.2 m-20 -83.82 132.62 34.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.051 -1.031 . . . . 0.0 110.85 -178.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.2 mt-30 81.17 60.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.82 -0.55 . . . . 0.0 110.767 178.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.879 HD12 HD11 ' A' ' 38' ' ' LEU . 5.1 mm -117.93 118.46 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.545 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.156 HD21 ' CG ' ' A' ' 70' ' ' LYS . 1.4 tp -70.35 86.52 0.6 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.035 -1.04 . . . . 0.0 111.145 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.952 HD12 HD11 ' A' ' 15' ' ' ILE . 5.6 tt -86.54 119.75 35.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.79 103.98 16.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.936 -1.102 . . . . 0.0 109.165 -178.589 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.987 HG23 HG21 ' A' ' 11' ' ' VAL . 3.2 mt -109.61 120.93 61.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.479 -0.763 . . . . 0.0 109.717 -179.311 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.411 ' HB3' ' CE1' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 64.42 40.21 6.5 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.531 -0.731 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.24 30.49 76.11 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.411 ' CE1' ' HB3' ' A' ' 67' ' ' CYS . 36.9 m80 -122.69 101.38 7.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -1.19 . . . . 0.0 109.592 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 1.156 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -53.04 108.88 0.36 Allowed 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.156 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.74 ' O ' HD12 ' A' ' 63' ' ' LEU . . . -126.56 148.35 49.75 Favored 'General case' 0 C--N 1.287 -2.14 0 C-N-CA 120.304 -0.558 . . . . 0.0 109.603 -179.08 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 63' ' ' LEU . 1.0 OUTLIER -118.68 147.42 22.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.504 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.817 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -172.45 -168.26 33.6 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 118.789 -1.672 . . . . 0.0 110.987 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.513 ' HB ' ' OD1' ' A' ' 30' ' ' ASP . 27.9 m -96.98 108.0 20.64 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.659 -0.906 . . . . 0.0 109.409 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.801 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.21 111.06 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.469 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.3 mp -81.12 118.38 22.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.057 -1.027 . . . . 0.0 108.306 178.591 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.426 HG12 ' HA ' ' A' ' 35' ' ' GLU . 8.5 t -104.89 109.99 29.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.124 -0.985 . . . . 0.0 109.68 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.861 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -148.16 -162.16 9.98 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.538 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -81.66 43.78 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.637 2.225 . . . . 0.0 110.599 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.57 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.1 t -84.75 136.33 39.31 Favored Pre-proline 0 N--CA 1.491 1.576 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.491 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -79.07 14.54 1.71 Allowed 'Trans proline' 0 C--N 1.307 -1.614 0 C-N-CA 122.389 2.059 . . . . 0.0 110.983 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.2 t -159.9 164.65 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.11 -0.994 . . . . 0.0 109.101 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.531 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -101.36 126.21 48.09 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 104.831 -2.285 . . . . 0.0 104.831 176.649 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 31' ' ' THR . 7.6 mm -113.32 128.94 69.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.333 -1.347 . . . . 0.0 111.794 -176.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.53 90.91 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 177.138 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.75 ' O ' HD22 ' A' ' 90' ' ' LEU . . . -83.97 173.6 50.66 Favored Glycine 0 N--CA 1.498 2.774 0 O-C-N 121.198 -0.939 . . . . 0.0 110.97 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.678 ' HA ' HD23 ' A' ' 90' ' ' LEU . 8.8 mmm180 -39.89 -39.97 0.92 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.806 -0.82 . . . . 0.0 111.335 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.992 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.2 p-10 -44.55 -41.18 6.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.739 -1.226 . . . . 0.0 109.986 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.992 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.7 mm? -96.67 -26.62 15.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.237 -0.914 . . . . 0.0 111.745 -179.045 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.75 HD22 ' O ' ' A' ' 86' ' ' GLY . 0.8 OUTLIER -60.28 -36.25 77.41 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.292 -1.505 . . . . 0.0 108.0 179.71 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 81.6 p -70.05 -21.58 63.15 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 108.846 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.42 ' HB2' ' O ' ' A' ' 89' ' ' LEU . 22.3 mm-40 -74.78 -40.66 61.04 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.723 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -86.31 -13.08 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.384 -0.822 . . . . 0.0 108.937 179.444 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 83.92 26.78 40.05 Favored Glycine 0 N--CA 1.495 2.633 0 C-N-CA 120.32 -0.943 . . . . 0.0 111.042 178.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.556 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -59.5 143.16 50.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 109.865 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.458 HG22 ' CG2' ' B' ' 4' ' ' THR . 74.2 p -135.34 129.58 33.66 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.401 HD11 HD11 ' B' ' 97' ' ' LEU . 3.7 mp -92.63 99.26 12.0 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.907 -1.12 . . . . 0.0 110.688 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.533 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.3 m-20 -108.0 124.48 50.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.413 -0.804 . . . . 0.0 109.046 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.73 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 118.037 -0.983 . . . . 0.0 109.163 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.273 -0.703 . . . . 0.0 110.273 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.419 ' CG ' ' OD1' ' A' ' 98' ' ' ASN . 2.5 tt0 -83.39 144.11 29.85 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.6 t -141.98 105.83 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.364 -1.334 . . . . 0.0 110.87 -177.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.458 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.2 OUTLIER -106.61 -86.51 0.49 Allowed 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 178.137 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.55 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 43.52 20.38 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.576 -0.702 . . . . 0.0 111.308 178.498 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 40.4 m0 16.24 52.16 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.234 0.54 . . . . 0.0 112.16 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.55 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.4 mt-30 -144.03 -128.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.45 130.93 22.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.642 -1.286 . . . . 0.0 109.662 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.873 ' HB2' HD12 ' B' ' 24' ' ' LEU . 37.1 Cg_endo -82.52 53.63 4.56 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.456 2.104 . . . . 0.0 109.301 178.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.68 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.7 mt -79.05 143.73 35.33 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.237 -0.914 . . . . 0.0 109.31 -179.175 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 1.062 HG21 HG23 ' B' ' 66' ' ' ILE . 0.8 OUTLIER -142.38 150.89 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -0.823 . . . . 0.0 109.452 -179.713 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 89.8 m -83.92 109.01 17.26 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.751 HD11 HD21 ' B' ' 33' ' ' LEU . 1.1 pt -98.89 139.26 21.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.148 -0.97 . . . . 0.0 111.102 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.463 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.7 OUTLIER -98.5 98.31 9.52 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.867 HD11 HD12 ' B' ' 64' ' ' ILE . 4.9 mt -120.3 130.64 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.342 -0.849 . . . . 0.0 109.337 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.29 23.54 71.7 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.4 15.72 80.2 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.463 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -112.25 174.08 6.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.422 -1.046 . . . . 0.0 109.31 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.484 HD23 ' HA ' ' B' ' 19' ' ' LEU . 27.9 mt -134.8 113.91 12.09 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.248 -0.907 . . . . 0.0 110.018 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -134.85 177.48 7.76 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.5 mm-40 -79.58 177.78 8.62 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.859 -1.15 . . . . 0.0 108.883 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.651 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -159.18 101.53 1.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.322 -0.861 . . . . 0.0 109.447 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 1.023 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.3 tp -77.97 98.89 5.84 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.291 -0.88 . . . . 0.0 109.438 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.873 HD12 ' HB2' ' B' ' 9' ' ' PRO . 89.6 mt -45.42 104.74 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.055 -1.028 . . . . 0.0 108.585 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.988 ' HB3' HG23 ' B' ' 84' ' ' ILE . 39.5 t0 -111.69 91.43 3.66 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.356 -0.84 . . . . 0.0 110.646 -178.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.444 HG23 HH11 ' B' ' 87' ' ' ARG . 55.9 m -69.79 -11.57 60.96 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.119 -0.988 . . . . 0.0 108.459 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.871 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -69.24 -39.85 82.03 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.26 150.67 29.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.342 -1.093 . . . . 0.0 109.481 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -91.19 -10.04 43.17 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.23 -0.919 . . . . 0.0 109.805 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.479 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -131.81 -173.13 3.05 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.274 -0.892 . . . . 0.0 109.546 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.664 HG22 ' CD1' ' B' ' 33' ' ' LEU . 29.9 m -113.44 98.51 7.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.01 -1.056 . . . . 0.0 110.229 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.914 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -83.33 166.01 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.017 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -162.8 126.58 2.94 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.59 -1.319 . . . . 0.0 111.354 -178.438 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.582 ' N ' HG22 ' B' ' 80' ' ' THR . 8.5 tt0 -42.9 154.57 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.602 ' HA ' HG13 ' B' ' 77' ' ' VAL . 1.6 tm-20 -38.8 148.54 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.349 -0.844 . . . . 0.0 110.366 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.577 ' CE ' HG22 ' B' ' 15' ' ' ILE . 24.5 ptm -163.57 -162.31 0.72 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.324 -0.86 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.5 t -118.68 120.2 36.73 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.083 -1.01 . . . . 0.0 110.794 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.761 HD23 ' CD2' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -124.6 173.66 4.53 Favored Pre-proline 0 N--CA 1.491 1.592 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.019 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.59 ' HD3' HD12 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.72 47.72 2.61 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.676 2.25 . . . . 0.0 111.634 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.12 -166.88 0.01 OUTLIER Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.408 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.5 mmm180 63.38 70.73 0.52 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.168 -1.195 . . . . 0.0 109.361 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.618 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 10.1 p-90 -140.41 -173.43 3.67 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 121.629 -0.669 . . . . 0.0 109.519 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.94 128.58 16.76 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.216 -0.927 . . . . 0.0 108.516 179.292 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -75.34 139.54 23.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 121.879 1.719 . . . . 0.0 110.749 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.17 -162.7 1.57 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.528 -0.732 . . . . 0.0 109.232 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.555 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 0.2 OUTLIER -149.02 130.02 14.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.27 -0.894 . . . . 0.0 109.613 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.793 HD12 HG21 ' A' ' 50' ' ' ILE . 8.3 pt -98.67 143.56 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.899 -1.125 . . . . 0.0 108.84 179.111 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.629 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -118.53 113.3 2.56 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 -179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.12 -125.43 2.04 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.707 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.775 HD12 ' C21' ' B' ' 100' ' ' DMP . 21.5 mt -88.7 119.04 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.797 -0.825 . . . . 0.0 112.852 -177.537 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.446 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 96.6 2.32 60.06 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.203 177.234 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 126.87 -158.75 20.96 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.334 -1.412 . . . . 0.0 110.221 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.66 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.9 OUTLIER -124.6 134.11 53.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.661 -0.905 . . . . 0.0 109.222 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.733 HD11 HD11 ' B' ' 47' ' ' ILE . 13.5 pt -104.26 167.65 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.979 -1.076 . . . . 0.0 109.239 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.559 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.91 134.32 48.23 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.191 -0.943 . . . . 0.0 109.159 179.734 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.826 HG12 ' HA3' ' B' ' 78' ' ' GLY . 21.4 m -140.6 -171.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.991 -1.068 . . . . 0.0 110.201 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.457 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.4 mtt-85 -128.87 105.92 8.56 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 33.7 tt0 -69.62 100.34 1.44 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.444 -0.785 . . . . 0.0 110.934 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.761 ' CD2' HD23 ' B' ' 38' ' ' LEU . 17.1 m-85 -89.59 133.42 34.62 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.014 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.55 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 67.4 m-20 -108.49 133.14 53.05 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.713 -1.242 . . . . 0.0 109.989 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.558 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.29 63.71 0.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.917 -0.713 . . . . 0.0 109.569 179.581 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.698 ' C ' HD13 ' B' ' 72' ' ' ILE . 26.9 mm -116.52 119.28 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.844 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.9 tm? -66.02 84.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 111.28 -178.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.867 HD12 HD11 ' B' ' 15' ' ' ILE . 5.7 tt -90.52 112.19 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.564 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 29.5 tt0 -89.52 115.39 26.9 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.178 -0.951 . . . . 0.0 109.033 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 1.062 HG23 HG21 ' B' ' 11' ' ' VAL . 2.3 mp -112.97 123.43 68.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.032 -1.043 . . . . 0.0 109.719 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.636 ' SG ' HG22 ' B' ' 66' ' ' ILE . 36.8 m 67.17 44.93 1.79 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.487 -0.758 . . . . 0.0 109.444 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 61.52 21.02 59.75 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.52 ' O ' ' HA ' ' B' ' 65' ' ' GLU . 4.4 m-70 -119.66 130.09 54.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.014 -1.286 . . . . 0.0 109.677 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.581 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -70.56 136.55 49.37 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -155.9 104.69 2.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.219 -0.925 . . . . 0.0 109.793 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.716 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -80.06 154.54 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.963 -1.085 . . . . 0.0 108.349 178.93 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.564 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 178.98 -169.74 41.24 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.16 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -95.64 105.9 17.94 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.667 -0.901 . . . . 0.0 110.618 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.017 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.6 158.91 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.726 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.8 mp -126.38 125.42 42.18 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.762 -1.211 . . . . 0.0 107.901 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.602 HG13 ' HA ' ' B' ' 35' ' ' GLU . 94.8 t -106.43 116.39 50.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 O-C-N 120.671 -1.268 . . . . 0.0 109.663 -179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.826 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.37 -166.25 15.9 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.559 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -80.09 44.52 1.74 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.511 2.141 . . . . 0.0 110.604 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.66 HG21 HG13 ' B' ' 32' ' ' VAL . 3.2 t -89.74 135.22 30.84 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.645 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -78.17 17.59 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.284 1.99 . . . . 0.0 111.137 -178.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.645 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.5 t -160.32 156.76 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 120.879 -1.138 . . . . 0.0 110.777 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.613 ' OD1' HD23 ' B' ' 33' ' ' LEU . 60.4 m-20 -97.41 86.28 3.84 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 176.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.988 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.6 mt -82.78 124.89 39.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 O-C-N 121.298 -0.876 . . . . 0.0 112.378 -176.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.52 ' N ' HD13 ' B' ' 85' ' ' ILE . 3.7 mm -100.19 109.18 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.572 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -108.29 164.39 12.76 Favored Glycine 0 N--CA 1.498 2.785 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.881 -178.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.564 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 20.7 mmm180 -19.26 -41.94 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -178.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.9 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -49.45 -42.12 42.14 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.475 -1.391 . . . . 0.0 110.813 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.9 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -93.75 -27.65 16.37 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.245 -0.91 . . . . 0.0 109.976 -179.653 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' B' ' 90' ' ' LEU . 4.6 mp -58.76 -33.87 70.78 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.097 -1.002 . . . . 0.0 108.831 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 4.3 p -74.12 -21.28 59.95 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.294 -0.879 . . . . 0.0 109.866 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 34.9 mm-40 -80.14 -40.47 27.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.163 -0.961 . . . . 0.0 109.053 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.73 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -81.7 -5.39 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.264 -0.897 . . . . 0.0 108.916 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.31 60.74 7.79 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.553 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -87.89 160.06 18.12 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.265 -1.138 . . . . 0.0 110.706 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.528 ' HB ' ' CG2' ' A' ' 4' ' ' THR . 4.7 p -141.7 126.96 18.6 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.502 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.5 mp -92.18 97.1 10.7 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.556 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 10.4 m120 -97.41 118.92 34.96 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.378 -0.826 . . . . 0.0 110.453 -178.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.723 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.723 0 CA-C-O 117.923 -1.037 . . . . 0.0 109.334 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.82 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.589 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 4.0 Cg_exo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.763 -0.514 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -83.77 131.75 34.89 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.494 HG11 ' HB3' ' A' ' 9' ' ' PRO . 20.0 t -124.12 102.06 10.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.575 -1.328 . . . . 0.0 110.484 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.987 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -139.78 48.73 1.8 Allowed 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.55 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -85.59 43.02 1.0 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.225 -0.922 . . . . 0.0 110.152 -179.238 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.597 ' CZ3' ' HB ' ' B' ' 91' ' ' THR . 13.4 m95 18.91 48.09 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 CA-C-O 121.46 0.647 . . . . 0.0 111.335 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 37.1 mt-30 -165.23 -168.0 1.3 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.419 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 58.8 mtt180 -75.26 122.49 87.44 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.011 -1.055 . . . . 0.0 108.632 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.818 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.5 Cg_endo -76.53 85.06 1.76 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.153 1.902 . . . . 0.0 109.991 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.803 HD22 ' HB3' ' A' ' 21' ' ' GLU . 5.5 mt -86.47 142.36 28.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.287 -0.883 . . . . 0.0 109.723 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.635 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -146.98 154.4 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.927 . . . . 0.0 109.243 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.779 HG22 HD22 ' A' ' 19' ' ' LEU . 85.3 m -88.95 112.87 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.877 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -101.87 153.51 5.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.114 -0.991 . . . . 0.0 110.121 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 2.9 tttt -110.76 109.21 19.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.36 -0.838 . . . . 0.0 109.738 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.937 HD13 HG11 ' A' ' 75' ' ' VAL . 4.5 mt -124.59 135.54 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.03 -1.044 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 50.04 33.8 22.49 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.085 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.68 35.2 59.11 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 9.0 mm100 -128.19 175.72 8.22 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -1.107 . . . . 0.0 109.057 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.779 HD22 HG22 ' A' ' 12' ' ' THR . 14.2 mt -145.71 123.27 11.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -0.946 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 18.3 mttp -146.61 177.32 9.16 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.803 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -79.19 -179.96 7.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.831 -1.168 . . . . 0.0 108.612 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.699 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -165.17 109.2 0.87 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.249 -1.532 . . . . 0.0 110.992 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.636 HD21 ' O ' ' B' ' 27' ' ' GLY . 2.8 tp -78.57 95.79 5.3 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.818 HD12 ' HB2' ' A' ' 9' ' ' PRO . 35.0 mt -48.64 93.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.608 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.735 ' HB3' HG23 ' A' ' 84' ' ' ILE . 22.5 t0 -99.57 92.92 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 110.828 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.51 ' OG1' HD21 ' B' ' 97' ' ' LEU . 2.6 m -67.56 -6.84 21.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.095 -1.003 . . . . 0.0 109.467 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.984 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -78.55 -40.83 17.49 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.462 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -72.56 154.15 40.94 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.31 . . . . 0.0 109.256 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 1.8 m-20 -88.2 -13.59 40.73 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.25 -0.906 . . . . 0.0 110.374 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.843 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -137.51 -170.77 2.82 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.984 -1.073 . . . . 0.0 110.482 -179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.712 HG23 HD12 ' A' ' 85' ' ' ILE . 22.8 m -109.05 89.82 3.11 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.034 -1.041 . . . . 0.0 110.677 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -71.54 167.5 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.009 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.9 130.02 2.23 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -178.212 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.582 ' CG ' ' O ' ' A' ' 80' ' ' THR . 7.2 mt-10 -39.1 157.8 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.618 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -60.12 154.0 20.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 110.103 179.764 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.596 ' CE ' HG22 ' A' ' 15' ' ' ILE . 4.1 ptm -176.0 -168.71 0.29 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.186 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.8 t -97.82 105.17 17.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.274 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 39' ' ' PRO . 27.8 tp -131.64 103.4 14.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.849 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.6 Cg_endo -78.5 154.27 27.51 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.514 2.143 . . . . 0.0 110.336 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 132.74 -173.16 21.03 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.66 141.28 29.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.33 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.0 p-90 -160.88 175.34 12.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.834 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -148.28 154.5 42.26 Favored Pre-proline 0 C--N 1.301 -1.511 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.216 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.53 136.55 13.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.233 1.956 . . . . 0.0 110.223 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.569 ' HG3' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -149.94 -169.26 3.33 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.354 -0.841 . . . . 0.0 109.387 179.669 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.439 ' SD ' ' HG3' ' A' ' 55' ' ' LYS . 9.7 mmm -145.13 118.9 9.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.117 -0.99 . . . . 0.0 109.576 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 9.9 pt -89.75 135.24 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 118.886 -1.126 . . . . 0.0 108.294 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.414 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -118.7 105.47 1.19 Allowed Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.417 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -125.64 -123.26 2.67 Favored Glycine 0 N--CA 1.482 1.737 0 C-N-CA 119.552 -1.309 . . . . 0.0 110.632 -179.03 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.835 HD12 ' C71' ' B' ' 100' ' ' DMP . 13.5 mt -87.22 121.2 37.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.88 -0.776 . . . . 0.0 112.353 -177.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 99.92 -46.16 1.42 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.45 -163.33 33.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -120.93 137.01 54.81 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.121 -1.223 . . . . 0.0 109.628 -179.838 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 79' ' ' PRO . 2.7 pt -111.92 159.18 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.231 -0.918 . . . . 0.0 109.222 179.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -82.19 141.16 33.27 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.225 -0.922 . . . . 0.0 110.255 -179.376 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.569 HG22 ' HG3' ' A' ' 45' ' ' LYS . 2.9 m -148.22 166.32 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -113.71 107.2 15.44 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 42.6 tt0 -65.83 107.63 1.87 Allowed 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.578 -0.701 . . . . 0.0 110.282 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 74' ' ' THR . 8.3 m-85 -97.27 138.68 34.38 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.541 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 21.9 m-20 -119.37 118.02 30.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.877 -1.139 . . . . 0.0 110.267 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.541 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 66.3 mt-30 87.64 55.82 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 CA-C-O 121.362 0.601 . . . . 0.0 110.283 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.571 HG13 ' HB3' ' A' ' 59' ' ' TYR . 21.8 mm -110.04 124.55 66.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -66.56 96.4 0.38 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.221 -0.924 . . . . 0.0 110.661 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.846 HD12 HD11 ' A' ' 15' ' ' ILE . 7.7 tt -105.97 115.91 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.526 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -88.47 140.88 29.02 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 109.231 -179.079 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 1.0 OUTLIER -127.7 130.34 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.3 -0.875 . . . . 0.0 108.993 -179.797 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.428 ' C ' ' O ' ' A' ' 66' ' ' ILE . 58.5 m 40.64 29.66 0.07 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.607 -0.683 . . . . 0.0 109.731 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 83.33 42.62 7.85 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.415 ' O ' ' C ' ' A' ' 70' ' ' LYS . 2.2 m80 -134.6 100.73 4.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.313 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' A' ' 69' ' ' HIS . 16.9 ttpt -46.47 122.13 3.9 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.573 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.49 101.21 3.21 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 110.44 -179.013 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.517 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -81.97 158.72 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 177.932 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.508 ' N ' HG22 ' A' ' 72' ' ' ILE . . . 177.95 -161.46 28.48 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 118.824 -1.655 . . . . 0.0 110.579 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 59' ' ' TYR . 98.9 m -102.0 117.26 34.43 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.122 -1.222 . . . . 0.0 109.787 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.937 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -108.21 117.7 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.341 -0.85 . . . . 0.0 110.397 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.843 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.3 mp -86.75 107.99 18.5 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.405 -0.81 . . . . 0.0 109.213 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 35' ' ' GLU . 1.4 t -91.85 114.17 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.082 -1.011 . . . . 0.0 109.875 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.85 -168.25 15.41 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 54' ' ' ILE . 37.0 Cg_endo -81.55 42.11 1.27 Allowed 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 110.201 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.629 HG21 HG13 ' A' ' 32' ' ' VAL . 5.0 t -82.05 137.91 46.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.439 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.577 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.2 Cg_endo -79.45 21.53 0.76 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.483 2.122 . . . . 0.0 111.273 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.591 ' CG1' HG13 ' A' ' 84' ' ' ILE . 1.4 t -161.03 160.65 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 120.871 -1.143 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.637 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -102.52 94.66 5.78 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 177.217 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.761 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.8 mt -94.58 128.93 45.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 CA-C-O 122.132 0.968 . . . . 0.0 113.268 -175.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.871 ' N ' HD13 ' A' ' 85' ' ' ILE . 0.5 OUTLIER -104.08 107.87 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.353 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -87.71 -168.59 44.67 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.727 -178.142 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.436 ' HD2' ' CG2' ' A' ' 91' ' ' THR . 5.9 mmt180 -60.58 -32.52 71.61 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.696 -0.885 . . . . 0.0 109.953 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.5 p-10 -46.88 -29.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.776 -1.203 . . . . 0.0 109.14 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -106.26 -36.72 6.78 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.505 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 38.0 mt -62.55 -12.78 24.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.889 -1.132 . . . . 0.0 108.694 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.463 ' O ' ' CH2' ' B' ' 6' ' ' TRP . 67.4 p -100.55 -20.36 15.74 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.207 -0.933 . . . . 0.0 108.673 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.436 ' NE2' ' O ' ' A' ' 72' ' ' ILE . 7.4 mm100 -79.23 -40.86 29.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.321 -0.862 . . . . 0.0 109.089 179.549 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.029 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -79.98 -15.06 13.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.162 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 100.31 15.66 29.54 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.735 178.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.572 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -56.84 146.4 26.48 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.502 -1.587 . . . . 0.0 109.673 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.664 HG22 ' CG2' ' B' ' 4' ' ' THR . 19.2 p -137.78 129.86 28.91 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -87.45 98.81 11.59 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.97 -1.081 . . . . 0.0 109.444 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.535 ' C ' ' CD1' ' A' ' 99' ' ' PHE . 3.0 m-20 -111.57 136.81 50.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.394 -0.816 . . . . 0.0 110.103 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.758 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.273 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 N-CA-C 109.984 -0.814 . . . . 0.0 109.984 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -83.56 138.87 33.19 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.618 HG11 ' HB3' ' B' ' 9' ' ' PRO . 4.4 t -128.6 111.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.769 -178.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.664 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.66 39.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.848 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.554 ' O ' ' N ' ' B' ' 7' ' ' GLN . 4.6 tp -83.93 46.0 1.14 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.107 -0.995 . . . . 0.0 110.266 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' B' ' 5' ' ' LEU . 38.0 m95 17.94 50.06 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 121.489 0.662 . . . . 0.0 112.121 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.554 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.0 mt-30 -165.62 173.76 10.53 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.14 128.1 56.65 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 121.089 -1.007 . . . . 0.0 109.043 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.618 ' HB3' HG11 ' B' ' 3' ' ' VAL . 35.0 Cg_endo -79.35 64.64 8.87 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.423 2.082 . . . . 0.0 110.438 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.908 HD22 ' HB2' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -79.43 148.35 31.97 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.161 -0.962 . . . . 0.0 109.222 -179.929 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.78 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -143.72 137.15 24.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.232 -0.917 . . . . 0.0 109.573 -179.302 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 7.1 m -69.13 98.78 1.04 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.005 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -89.79 151.44 3.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.351 -0.843 . . . . 0.0 110.0 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.553 ' HE3' ' CG ' ' B' ' 19' ' ' LEU . 2.1 tttt -117.37 107.1 13.96 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.337 -0.852 . . . . 0.0 108.951 179.203 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.891 HD13 HG11 ' B' ' 75' ' ' VAL . 4.1 mt -113.5 139.6 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.253 -0.905 . . . . 0.0 109.205 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.62 -90.9 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -151.79 45.72 0.61 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.6 OUTLIER -140.82 169.31 17.87 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.455 -1.026 . . . . 0.0 110.035 -179.332 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.553 ' CG ' ' HE3' ' B' ' 14' ' ' LYS . 27.8 mt -139.07 113.83 9.2 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.483 ' HG3' ' C ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -136.26 163.88 29.39 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.207 -0.933 . . . . 0.0 109.115 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.908 ' HB2' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -78.13 145.01 35.96 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.277 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.795 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -134.39 116.45 15.2 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.869 -1.145 . . . . 0.0 111.297 -178.116 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.984 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -71.47 100.13 2.16 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.645 HD22 HD21 ' B' ' 90' ' ' LEU . 18.6 mt -47.18 137.44 7.96 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 179.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.824 ' HB2' HG23 ' B' ' 84' ' ' ILE . 42.4 t0 -142.66 94.24 2.62 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.835 -1.166 . . . . 0.0 111.422 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.526 HG23 ' HD3' ' B' ' 87' ' ' ARG . 6.8 m -74.89 -14.87 60.71 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.088 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.636 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -76.05 -16.18 80.87 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.474 ' HB1' ' C75' ' B' ' 100' ' ' DMP . . . -97.39 160.71 14.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.32 . . . . 0.0 109.053 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -88.23 -21.14 24.67 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.014 . . . . 0.0 110.479 -179.201 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.637 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 1.6 m-20 -143.05 -173.83 4.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.635 -1.291 . . . . 0.0 110.858 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.804 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.2 m -97.54 86.02 3.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.822 -1.173 . . . . 0.0 111.578 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.923 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -67.22 153.61 8.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.423 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.923 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.2 OUTLIER -157.08 124.42 5.26 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.083 -1.011 . . . . 0.0 110.569 -177.722 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.564 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.7 tm-20 -43.07 153.87 0.08 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 109.078 178.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.566 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.3 tt0 -45.23 139.49 3.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 110.902 -179.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.655 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.3 ppp? -152.04 -164.4 1.96 Allowed 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.495 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -112.73 118.16 34.21 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.88 -1.138 . . . . 0.0 110.539 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.641 ' HG ' ' HD2' ' B' ' 39' ' ' PRO . 0.2 OUTLIER -134.91 -175.08 0.45 Allowed Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.411 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.641 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.7 Cg_endo -79.7 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.256 1.971 . . . . 0.0 110.942 -178.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 35.93 4.63 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.35 51.75 0.75 Allowed 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.683 -0.892 . . . . 0.0 108.945 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.65 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 39.9 p-90 -137.95 179.83 6.2 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.776 0.798 . . . . 0.0 110.668 -178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.494 ' HG3' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -140.86 146.13 42.69 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.088 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 44' ' ' PRO . . . . . 0.494 ' HD2' ' HG3' ' B' ' 43' ' ' LYS . 34.9 Cg_endo -78.36 138.67 15.93 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.416 2.077 . . . . 0.0 110.679 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' B' ' 58' ' ' GLN . 1.1 ptpt -160.54 -165.17 1.36 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.45 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 44.4 mtp -151.1 138.48 19.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.172 -0.955 . . . . 0.0 109.997 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.71 ' CD1' HG21 ' A' ' 50' ' ' ILE . 10.3 pt -103.71 148.3 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.114 -0.991 . . . . 0.0 108.83 178.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.626 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -119.57 116.28 3.26 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.979 -1.649 . . . . 0.0 108.979 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.486 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -137.45 -123.23 2.19 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.226 -1.464 . . . . 0.0 111.145 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.889 HD12 ' C21' ' B' ' 100' ' ' DMP . 15.8 mt -84.03 133.48 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.729 -0.866 . . . . 0.0 112.694 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.461 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 85.23 -44.17 3.34 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 178.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 171.24 -171.33 43.9 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.227 -1.463 . . . . 0.0 109.95 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' HA2' ' B' ' 48' ' ' GLY . 7.7 m-30 -96.29 168.82 10.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.432 -1.04 . . . . 0.0 109.748 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.64 HD12 HG13 ' B' ' 56' ' ' VAL . 1.8 pt -142.23 177.23 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.543 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.0 mtpt -114.18 128.65 56.47 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.922 -1.111 . . . . 0.0 109.44 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.654 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.7 m -136.61 -175.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.045 -1.034 . . . . 0.0 109.987 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 66.5 mtt180 -130.23 110.97 11.97 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.415 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 2.0 tt0 -69.98 103.49 2.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.32 -0.863 . . . . 0.0 110.442 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.65 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 10.5 m-85 -89.01 141.12 28.75 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 4.0 m-20 -120.12 130.96 54.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.681 -1.262 . . . . 0.0 110.953 -178.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.576 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 69.3 62.92 0.29 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.15 0.5 . . . . 0.0 110.756 179.003 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.784 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -118.48 125.64 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.164 -0.96 . . . . 0.0 108.923 178.877 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.787 ' N ' HD13 ' B' ' 72' ' ' ILE . 3.1 tm? -70.63 101.08 1.97 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.496 -0.752 . . . . 0.0 111.658 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.885 HD13 HD11 ' B' ' 66' ' ' ILE . 4.0 tt -101.48 122.27 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 25.5 tt0 -89.06 100.82 13.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.938 -1.101 . . . . 0.0 109.831 -178.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 1.005 HG13 HG22 ' B' ' 13' ' ' ILE . 1.1 mp -99.53 113.05 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.163 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 63.47 25.31 14.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.61 6.75 82.85 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.328 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -103.45 109.49 21.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -1.203 . . . . 0.0 109.252 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.47 133.15 35.56 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.724 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -152.98 98.16 2.28 Favored 'General case' 0 C--N 1.294 -1.831 0 O-C-N 121.257 -0.902 . . . . 0.0 109.88 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.787 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -77.97 145.5 9.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.151 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.5 -175.07 40.96 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.005 -1.569 . . . . 0.0 110.971 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.563 HG23 ' O ' ' B' ' 59' ' ' TYR . 1.5 m -85.75 112.51 21.13 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.668 -0.901 . . . . 0.0 110.461 -179.195 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.891 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -104.8 105.53 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -0.813 . . . . 0.0 110.156 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.6 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.1 mp -77.14 129.78 36.45 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.566 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 45.4 t -118.52 122.95 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 110.247 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.654 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -157.56 -165.41 15.19 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.543 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.9 Cg_endo -81.98 41.87 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.547 2.165 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.602 HG23 ' O ' ' B' ' 82' ' ' VAL . 8.9 t -79.4 141.71 57.4 Favored Pre-proline 0 N--CA 1.49 1.56 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.702 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.1 Cg_endo -77.68 14.39 1.46 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.135 1.89 . . . . 0.0 110.874 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.702 HG23 ' O ' ' B' ' 81' ' ' PRO . 3.6 t -161.02 162.52 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.856 -1.152 . . . . 0.0 110.201 -179.219 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -102.97 99.77 9.68 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 176.665 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.893 ' HB ' HG12 ' B' ' 32' ' ' VAL . 4.7 mt -104.51 129.22 57.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 120.835 -1.166 . . . . 0.0 112.869 -175.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.795 HD11 ' HB1' ' B' ' 22' ' ' ALA . 2.6 mm -88.51 132.39 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 176.7 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.637 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -107.16 -159.55 21.33 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 118.683 -1.723 . . . . 0.0 110.243 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.526 ' HD3' HG23 ' B' ' 26' ' ' THR . 0.4 OUTLIER -71.08 -30.28 66.36 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.737 -0.86 . . . . 0.0 108.762 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.799 ' ND2' HD23 ' B' ' 89' ' ' LEU . 5.8 p-10 -50.19 -40.07 45.88 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.822 -1.151 . . . . 0.0 108.897 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.799 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -90.25 -32.86 16.38 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.42 -0.8 . . . . 0.0 110.027 -179.361 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.645 HD21 HD22 ' B' ' 24' ' ' LEU . 37.0 mt -67.04 -8.03 27.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.99 -1.069 . . . . 0.0 108.655 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.597 ' HB ' ' CZ3' ' A' ' 6' ' ' TRP . 31.5 p -99.43 -18.2 17.59 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.008 -1.058 . . . . 0.0 108.581 179.263 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 29.4 mm-40 -85.01 -40.95 16.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.53 -0.731 . . . . 0.0 109.659 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.758 HD12 ' CD2' ' A' ' 99' ' ' PHE . 26.6 pt -83.17 -4.25 8.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.306 -0.871 . . . . 0.0 109.032 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.95 60.33 6.17 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.587 ' CB ' ' CD1' ' A' ' 99' ' ' PHE . . . -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.282 -1.128 . . . . 0.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.987 HG22 ' CG2' ' A' ' 4' ' ' THR . 10.7 p -137.56 129.49 28.86 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' A' ' 97' ' ' LEU . 5.4 mp -87.14 98.39 11.27 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 11.0 m-20 -103.6 128.5 50.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.868 -1.145 . . . . 0.0 110.123 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 1.029 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.532 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.889 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 N-CA-C 109.899 -0.846 . . . . 0.0 109.899 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.401 ' HG3' ' OD1' ' B' ' 98' ' ' ASN . 25.0 tt0 -84.17 120.05 25.73 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 4' ' ' THR . 3.4 t -129.21 94.61 2.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.982 -1.074 . . . . 0.0 109.901 -178.207 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.766 ' C ' HD12 ' A' ' 5' ' ' LEU . 0.7 OUTLIER -40.3 -68.85 0.15 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 109.404 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.967 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER 128.88 16.25 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.027 0.531 . . . . 0.0 110.121 179.4 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -48.26 -21.83 0.57 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.916 -1.115 . . . . 0.0 109.245 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.455 ' O ' ' HD3' ' B' ' 87' ' ' ARG . 29.8 mm100 -127.16 -128.81 0.23 Allowed 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.221 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.466 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.3 OUTLIER -111.04 133.61 21.25 Favored Pre-proline 0 C--N 1.306 -1.304 0 O-C-N 120.661 -1.274 . . . . 0.0 109.064 179.398 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.5 Cg_endo -79.96 51.76 4.03 Favored 'Trans proline' 0 C--N 1.313 -1.299 0 C-N-CA 122.203 1.935 . . . . 0.0 109.322 178.069 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.596 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -84.63 157.08 21.27 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.241 -0.912 . . . . 0.0 109.776 -179.315 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.728 HG21 HG23 ' A' ' 66' ' ' ILE . 1.2 m -149.15 131.72 6.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.501 -0.75 . . . . 0.0 109.368 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.651 HG21 HD23 ' A' ' 19' ' ' LEU . 25.3 m -65.02 94.8 0.14 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 177.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.771 HG22 HG13 ' A' ' 66' ' ' ILE . 13.6 pt -83.41 151.43 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.352 -0.843 . . . . 0.0 110.367 -178.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.547 ' HG3' HD12 ' A' ' 19' ' ' LEU . 14.0 ttmt -115.41 96.27 5.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 0.0 109.239 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 62' ' ' ILE . 11.8 mt -116.76 143.84 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.687 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.96 50.91 14.4 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 48.44 46.78 29.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -144.48 163.22 34.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -1.207 . . . . 0.0 109.407 179.898 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.651 HD23 HG21 ' A' ' 12' ' ' THR . 0.4 OUTLIER -129.95 132.92 46.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.181 -0.95 . . . . 0.0 109.971 -179.403 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' NZ ' HD23 ' A' ' 33' ' ' LEU . 4.0 mtmp? -151.13 177.7 9.94 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.596 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -93.86 118.99 32.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.618 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -97.81 143.37 28.5 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.135 -0.978 . . . . 0.0 109.42 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.999 HD11 ' NH2' ' B' ' 87' ' ' ARG . 10.5 tp -107.78 94.15 4.92 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.589 -0.694 . . . . 0.0 109.524 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.572 HD22 HD21 ' A' ' 90' ' ' LEU . 15.5 mt -45.14 111.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.293 -0.879 . . . . 0.0 108.648 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.59 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 19.4 t0 -126.25 80.02 1.89 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.343 -0.848 . . . . 0.0 110.12 -178.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.509 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.8 m -54.1 -18.95 4.19 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.025 -1.047 . . . . 0.0 108.867 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -56.64 -48.73 75.03 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.62 154.88 36.39 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.25 -1.147 . . . . 0.0 109.071 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.99 -7.44 33.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.162 -0.962 . . . . 0.0 110.385 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.667 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -132.59 178.87 6.51 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.981 -1.074 . . . . 0.0 109.539 179.805 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 19.0 m -104.3 89.55 3.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.772 -1.205 . . . . 0.0 110.83 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.975 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 171.48 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.946 -1.096 . . . . 0.0 108.307 178.908 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.031 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -170.19 121.38 0.64 Allowed 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.884 -1.135 . . . . 0.0 110.488 -179.011 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.511 ' HA ' HG22 ' A' ' 80' ' ' THR . 6.4 tt0 -41.4 160.52 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.448 -0.782 . . . . 0.0 109.087 178.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.583 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -48.35 146.86 2.6 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.21 -0.931 . . . . 0.0 110.681 -179.756 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.639 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.1 OUTLIER -159.31 -161.93 0.99 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.302 -0.874 . . . . 0.0 109.427 179.441 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 t -108.75 101.52 10.64 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.146 -0.971 . . . . 0.0 110.168 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.667 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -121.15 178.75 1.09 Allowed Pre-proline 0 N--CA 1.493 1.683 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.595 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 35.5 Cg_endo -79.54 -158.63 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.698 2.265 . . . . 0.0 110.64 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 29.63 7.75 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.9 mtt-85 -106.29 60.87 0.65 Allowed 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 59.2 p-90 -139.62 177.89 7.62 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-O 121.772 0.796 . . . . 0.0 110.696 -178.679 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.487 ' HD3' ' O ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -135.76 140.82 34.77 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.904 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -78.37 129.81 9.67 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 C-N-CA 121.813 1.675 . . . . 0.0 111.215 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' O ' ' HG3' ' A' ' 45' ' ' LYS . 2.3 ptpt -161.99 142.57 10.44 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.534 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -107.52 147.84 30.01 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.744 -1.222 . . . . 0.0 109.675 179.688 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -103.65 150.11 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.394 -0.816 . . . . 0.0 108.982 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.24 98.0 0.71 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.084 -1.607 . . . . 0.0 109.084 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.15 -121.98 2.86 Favored Glycine 0 N--CA 1.487 2.057 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.478 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.88 HD12 H702 ' B' ' 100' ' ' DMP . 18.2 mt -83.83 128.98 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.584 -0.95 . . . . 0.0 112.463 -177.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.534 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 93.29 -46.56 2.4 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.17 -155.51 25.29 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.099 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.513 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.5 m-85 -105.94 159.3 16.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.621 -0.929 . . . . 0.0 110.24 -179.374 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 47' ' ' ILE . 5.8 pt -137.58 159.8 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.16 124.66 48.14 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.863 -1.148 . . . . 0.0 109.643 -179.814 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.756 HG12 ' HA3' ' A' ' 78' ' ' GLY . 27.7 m -129.15 -178.33 2.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 109.034 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -131.95 105.4 7.4 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.278 179.834 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.56 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.8 OUTLIER -58.51 95.62 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.484 -0.76 . . . . 0.0 110.105 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.672 ' HB3' HD11 ' A' ' 62' ' ' ILE . 8.9 m-85 -89.98 117.87 29.11 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -99.58 141.83 31.86 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.561 -1.337 . . . . 0.0 111.035 -178.012 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.593 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 29.9 mt-30 71.16 62.33 0.17 Allowed 'General case' 0 N--CA 1.492 1.671 0 CA-C-O 121.199 0.523 . . . . 0.0 111.578 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.888 HG21 HG23 ' A' ' 15' ' ' ILE . 5.1 mp -120.76 121.31 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.23 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.894 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.6 tt -68.84 91.99 0.48 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.947 -1.096 . . . . 0.0 111.074 -178.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 1.003 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -89.09 114.74 27.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 176.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 13.8 tt0 -86.53 101.93 13.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.873 -1.142 . . . . 0.0 108.939 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.003 HD11 HD13 ' A' ' 64' ' ' ILE . 2.1 mt -103.7 126.49 58.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.634 0.731 . . . . 0.0 110.15 -178.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.569 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.1 m 44.2 67.11 0.72 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.654 -0.654 . . . . 0.0 110.261 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 67' ' ' CYS . . . 41.57 35.86 1.46 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.382 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.569 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 74.5 m-70 -130.92 101.57 5.68 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.085 -1.244 . . . . 0.0 109.163 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.894 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -50.38 128.29 19.4 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.877 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.661 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 102.86 3.36 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.344 -0.848 . . . . 0.0 110.386 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.596 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -79.48 151.45 4.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.027 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.721 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -174.44 -178.13 44.1 Favored Glycine 0 N--CA 1.486 2.014 0 C-N-CA 118.444 -1.836 . . . . 0.0 111.482 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.56 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 2.5 m -88.81 103.87 16.39 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.203 -0.587 . . . . 0.0 110.418 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.031 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -97.72 108.59 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.45 -0.781 . . . . 0.0 110.582 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.667 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.4 mp -78.78 117.47 19.93 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.176 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.583 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.2 t -103.11 119.71 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 110.382 -178.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.756 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.31 -168.3 16.95 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 35.9 Cg_endo -79.52 41.94 1.2 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.64 2.227 . . . . 0.0 111.088 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.557 HG21 HG13 ' A' ' 32' ' ' VAL . 3.6 t -83.43 139.86 41.6 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.059 -1.026 . . . . 0.0 108.498 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.505 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -78.23 13.82 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.322 2.015 . . . . 0.0 111.689 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.9 OUTLIER -160.95 170.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.876 -1.14 . . . . 0.0 109.618 179.512 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.618 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -104.67 127.17 52.35 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 176.63 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.658 HG12 HG12 ' A' ' 32' ' ' VAL . 4.8 mm -112.86 128.33 69.63 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 O-C-N 120.406 -1.434 . . . . 0.0 111.04 -177.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.564 ' N ' ' CD1' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -104.56 91.51 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.757 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -78.64 -167.8 32.8 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 110.637 -177.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.76 -34.25 72.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.639 -0.918 . . . . 0.0 110.338 -179.177 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.6 p-10 -48.94 -27.57 3.21 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.892 -1.13 . . . . 0.0 109.405 -179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.5 mm? -108.68 -29.38 8.74 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 121.121 -0.987 . . . . 0.0 110.034 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.603 HD23 HD11 ' A' ' 93' ' ' ILE . 96.7 mt -70.2 -6.27 33.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.08 -1.013 . . . . 0.0 108.463 179.024 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 87' ' ' ARG . 4.8 p -98.11 -20.26 17.44 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.226 -0.921 . . . . 0.0 108.725 179.2 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 16.6 mm100 -83.66 -41.7 17.46 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 108.877 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.7 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -80.93 -3.74 6.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 73.15 29.71 64.11 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.522 -0.847 . . . . 0.0 110.999 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -62.42 136.25 57.82 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.805 -1.409 . . . . 0.0 109.709 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' B' ' 96' ' ' THR . 77.4 p -136.71 129.48 30.63 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.124 -0.985 . . . . 0.0 108.519 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.452 ' O ' ' HB ' ' B' ' 3' ' ' VAL . 5.3 mp -88.13 102.15 14.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.416 -0.802 . . . . 0.0 109.891 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' B' ' 1' ' ' PRO . 6.8 m-20 -110.02 126.74 54.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.971 -1.081 . . . . 0.0 109.175 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.922 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.112 -0.993 . . . . 0.0 109.404 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.484 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.654 0 N-CA-C 109.958 -0.824 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.463 ' OE1' ' CG2' ' B' ' 4' ' ' THR . 12.8 tt0 -82.52 139.34 33.93 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 177.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.761 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 7.0 t -132.69 100.01 3.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 117.937 -1.505 . . . . 0.0 110.811 -177.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.535 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -117.01 -70.48 0.79 Allowed 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 178.225 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.745 ' H ' HD22 ' B' ' 5' ' ' LEU . 3.7 mm? 34.86 31.7 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.889 -0.507 . . . . 0.0 110.225 178.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' THR . 13.0 m0 17.62 49.18 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.553 ' N ' ' O ' ' B' ' 5' ' ' LEU . 7.1 mt-30 -163.09 -162.5 0.77 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.038 -1.039 . . . . 0.0 110.162 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.42 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 8.1 mtm105 -86.94 117.97 69.4 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.232 -0.917 . . . . 0.0 110.394 -179.222 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.592 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.3 Cg_endo -81.99 90.24 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.144 1.896 . . . . 0.0 110.742 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 1.004 HD23 ' HB3' ' B' ' 21' ' ' GLU . 3.2 mp -79.49 171.06 15.67 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.821 -1.175 . . . . 0.0 108.565 179.189 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.595 HG23 HG23 ' B' ' 13' ' ' ILE . 3.1 m -150.68 130.99 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.001 -1.062 . . . . 0.0 110.812 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.685 HG22 HD22 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -70.09 88.11 0.59 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 177.592 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.828 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pt -90.09 157.36 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 111.118 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 3.1 tttt -122.78 109.15 13.85 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.745 HG23 HG21 ' B' ' 62' ' ' ILE . 3.0 mt -122.97 119.52 58.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.092 -1.005 . . . . 0.0 109.24 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.36 26.95 74.0 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -5.46 67.99 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -85.8 169.95 12.88 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.248 -1.148 . . . . 0.0 109.29 179.911 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.685 HD22 HG22 ' B' ' 12' ' ' THR . 2.4 mt -139.8 128.22 22.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.311 -0.868 . . . . 0.0 109.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.423 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 3.0 mtpp -151.23 149.94 30.01 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.434 -0.791 . . . . 0.0 109.118 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 1.004 ' HB3' HD23 ' B' ' 10' ' ' LEU . 0.7 OUTLIER -79.64 102.16 8.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.093 -1.005 . . . . 0.0 108.469 179.277 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.876 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -80.04 142.84 34.56 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 122.0 0.905 . . . . 0.0 110.825 -178.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -92.62 104.26 16.57 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.66 HD22 HD21 ' B' ' 90' ' ' LEU . 4.6 mt -46.29 110.48 0.28 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.878 -1.138 . . . . 0.0 108.593 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.613 ' HB2' HG23 ' B' ' 84' ' ' ILE . 1.0 OUTLIER -118.81 86.71 2.59 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.871 -178.553 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.877 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -68.63 -7.88 37.06 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.023 -1.048 . . . . 0.0 108.704 178.488 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.86 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -81.24 -38.84 13.85 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.27 147.13 46.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.2 -1.176 . . . . 0.0 109.173 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.492 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 4.9 m-20 -82.83 -16.55 47.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 110.737 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.548 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 7.0 m-20 -138.04 -167.88 2.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.935 -1.103 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.589 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 43.0 m -110.57 94.24 4.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.787 -1.196 . . . . 0.0 110.782 -178.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.008 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.76 172.3 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.872 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.008 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.4 122.35 1.75 Allowed 'General case' 0 C--N 1.308 -1.225 0 O-C-N 120.775 -1.203 . . . . 0.0 110.822 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.532 ' CG ' ' O ' ' B' ' 80' ' ' THR . 0.3 OUTLIER -35.6 154.13 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.777 -0.577 . . . . 0.0 109.689 179.127 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.519 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.3 mt-10 -47.79 149.06 1.37 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.241 -0.912 . . . . 0.0 110.231 -179.202 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.49 ' CG ' HD23 ' B' ' 38' ' ' LEU . 6.1 ptm -173.45 -163.99 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.391 -0.818 . . . . 0.0 109.592 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.1 t -110.95 103.72 12.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.204 -0.935 . . . . 0.0 110.279 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.575 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -103.38 173.38 3.48 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.575 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.1 Cg_endo -73.9 -162.26 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.996 1.798 . . . . 0.0 110.516 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -100.21 -166.07 28.86 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.304 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 58.83 70.12 0.68 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.672 -0.899 . . . . 0.0 109.152 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.619 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 21.4 p-90 -141.44 -169.89 2.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -151.02 134.1 8.77 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.175 -0.953 . . . . 0.0 108.807 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.31 137.35 16.77 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.838 1.692 . . . . 0.0 110.567 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.629 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -160.97 133.79 6.29 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.724 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.517 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 63.1 mtp -91.73 131.93 36.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.131 -0.981 . . . . 0.0 109.797 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 50' ' ' ILE . 8.8 pt -89.36 143.96 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 101.22 0.89 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.25 -121.81 2.92 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.744 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.827 HD12 ' C20' ' B' ' 100' ' ' DMP . 20.5 mt -84.87 117.38 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.852 -0.793 . . . . 0.0 112.695 -177.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.459 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 104.16 -53.32 0.71 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 178.314 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -178.4 -157.12 18.43 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.543 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -118.0 135.79 53.94 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.311 -1.111 . . . . 0.0 109.873 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.675 HD12 HG13 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -106.48 -177.48 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.909 . . . . 0.0 108.926 179.189 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.534 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 36.8 mtmt -111.52 135.82 51.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.019 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' B' ' 78' ' ' GLY . 17.5 m -142.77 177.07 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.843 -1.161 . . . . 0.0 110.636 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.35 100.72 6.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.492 -0.755 . . . . 0.0 109.241 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -62.87 110.11 1.66 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.265 -0.897 . . . . 0.0 110.909 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.988 ' HB3' HD11 ' B' ' 62' ' ' ILE . 16.0 m-85 -106.92 132.35 52.96 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 177.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.7 m-20 -108.6 134.1 51.82 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.937 -1.102 . . . . 0.0 110.49 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.589 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 45.0 mt-30 78.14 61.37 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.904 -0.497 . . . . 0.0 111.178 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.988 HD11 ' HB3' ' B' ' 59' ' ' TYR . 3.0 mp -112.83 120.99 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 178.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.84 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -65.07 86.44 0.06 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 110.958 -178.656 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.934 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.6 tt -94.49 110.7 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.3 tt0 -89.04 117.21 27.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.051 -1.031 . . . . 0.0 109.464 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.828 HG13 HG22 ' B' ' 13' ' ' ILE . 1.8 mp -116.33 140.95 36.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 121.746 0.784 . . . . 0.0 109.845 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.504 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 0.9 OUTLIER 47.42 39.17 8.7 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.681 -0.637 . . . . 0.0 109.778 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.2 48.28 83.9 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.504 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 80.7 m-70 -145.38 108.88 4.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.247 -1.149 . . . . 0.0 109.384 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.619 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.3 OUTLIER -48.26 127.38 12.67 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.305 -0.872 . . . . 0.0 108.883 179.709 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -149.12 104.8 3.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.334 -0.854 . . . . 0.0 109.355 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.84 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -83.86 160.31 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.107 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.574 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.34 -157.24 17.87 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.419 -1.848 . . . . 0.0 111.952 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 4.8 m -111.95 109.81 19.79 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.632 -0.922 . . . . 0.0 109.557 -179.398 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.929 HG23 HD13 ' B' ' 62' ' ' ILE . 1.6 t -105.03 127.75 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.521 -0.737 . . . . 0.0 111.22 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.8 mp -96.83 116.22 28.78 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' B' ' 35' ' ' GLU . 13.1 t -96.9 114.96 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.709 -1.244 . . . . 0.0 109.984 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.72 -174.12 20.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.534 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -79.78 41.83 1.19 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.493 2.129 . . . . 0.0 111.234 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.532 ' O ' ' CG ' ' B' ' 34' ' ' GLU . 9.1 t -80.68 141.01 51.45 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.8 Cg_endo -77.76 13.44 1.68 Allowed 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.274 1.983 . . . . 0.0 111.232 -179.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.61 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -160.31 173.83 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.921 -1.112 . . . . 0.0 109.677 -179.754 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.61 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.0 OUTLIER -109.68 138.57 45.85 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 176.625 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.613 HG23 ' HB2' ' B' ' 25' ' ' ASP . 4.7 mm -124.6 123.33 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.438 -1.414 . . . . 0.0 111.762 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.876 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -97.26 89.82 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.344 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.548 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.04 -157.59 11.58 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.891 -1.147 . . . . 0.0 111.612 -177.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.999 ' NH2' HD11 ' A' ' 23' ' ' LEU . 31.1 mtt180 -68.19 -35.62 78.28 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.915 -0.756 . . . . 0.0 111.407 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.004 ' ND2' HD23 ' B' ' 89' ' ' LEU . 2.6 p-10 -55.57 -24.23 31.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.461 -1.399 . . . . 0.0 110.044 -179.113 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.004 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -106.77 -18.41 13.95 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.999 -1.063 . . . . 0.0 110.26 -178.982 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.877 HD13 HG23 ' B' ' 26' ' ' THR . 64.5 mt -71.95 -24.45 61.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 108.899 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.94 -14.09 56.58 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.092 -1.005 . . . . 0.0 109.839 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.483 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 9.0 mm-40 -81.1 -40.85 23.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.99 -1.069 . . . . 0.0 109.164 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.922 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -87.26 -13.07 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.305 -0.872 . . . . 0.0 108.755 179.43 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.69 51.12 9.79 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.67 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -75.86 147.27 39.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 108.851 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 96' ' ' THR . 72.6 p -130.76 127.29 38.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 108.908 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.554 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.0 mp -91.58 91.06 7.87 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.516 -0.74 . . . . 0.0 109.182 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.7 m-20 -96.22 125.53 40.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.148 -0.97 . . . . 0.0 109.92 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.7 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.301 -1.526 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.335 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.88 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.59 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.498 1.768 0 N-CA-C 110.064 -0.783 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -84.91 129.11 34.86 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.85 -1.156 . . . . 0.0 108.05 178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 77.8 t -131.37 124.81 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.915 -1.115 . . . . 0.0 110.184 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 7.6 p -64.57 -104.01 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.857 HD11 HG23 ' B' ' 26' ' ' THR . 0.6 OUTLIER 167.04 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.866 -1.146 . . . . 0.0 110.721 179.407 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 38.1 m95 -65.56 -18.66 65.49 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.809 -1.182 . . . . 0.0 108.507 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.424 ' O ' ' C ' ' A' ' 8' ' ' ARG . 23.2 mt-30 -147.3 159.64 43.43 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.477 ' HD2' HD13 ' A' ' 23' ' ' LEU . 16.0 mtm180 -44.04 141.15 2.52 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.003 . . . . 0.0 109.22 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG3' HG22 ' B' ' 26' ' ' THR . 36.2 Cg_endo -80.61 60.57 7.91 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.478 2.119 . . . . 0.0 109.921 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.676 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -81.66 142.72 32.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.243 -0.91 . . . . 0.0 109.97 -179.484 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -140.99 155.62 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.46 -0.775 . . . . 0.0 109.283 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.418 HG22 HD22 ' A' ' 19' ' ' LEU . 11.0 m -83.96 101.94 12.08 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 178.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.795 HG22 HG13 ' A' ' 66' ' ' ILE . 14.7 pt -96.31 158.66 3.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.286 -0.884 . . . . 0.0 110.341 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 3.7 tttt -120.71 103.95 9.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.433 -0.792 . . . . 0.0 109.88 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.013 HD13 HG11 ' A' ' 75' ' ' VAL . 10.6 mt -119.25 134.35 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.079 -1.013 . . . . 0.0 109.588 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.96 44.24 98.08 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.08 17.72 24.33 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.63 178.09 4.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.444 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.536 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.6 mt -138.61 126.34 22.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.447 -0.783 . . . . 0.0 109.826 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.459 ' HD3' ' O ' ' A' ' 19' ' ' LEU . 35.8 mmtt -144.45 -179.31 6.47 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.676 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.9 mt-10 -88.04 164.58 15.69 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.098 -1.001 . . . . 0.0 108.713 179.452 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.614 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -147.97 116.68 6.69 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.688 -1.258 . . . . 0.0 110.966 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.002 HD21 ' O ' ' B' ' 27' ' ' GLY . 16.8 tp -82.05 94.12 7.13 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.602 HD13 ' CE2' ' B' ' 99' ' ' PHE . 63.7 mt -49.69 93.2 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.568 ' CB ' ' HA3' ' B' ' 27' ' ' GLY . 26.8 t0 -107.67 87.21 2.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 110.744 -178.347 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.675 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.2 m -60.74 -13.81 17.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.051 -1.031 . . . . 0.0 108.638 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -63.41 -43.69 97.9 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -70.4 171.52 9.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.008 -1.289 . . . . 0.0 110.069 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.513 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -98.54 -20.51 17.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.34 -0.85 . . . . 0.0 110.603 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.515 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 36.6 m-20 -140.23 -162.9 1.42 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.922 -1.111 . . . . 0.0 109.604 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.759 HG22 ' CD1' ' A' ' 33' ' ' LEU . 23.5 m -107.28 89.99 3.17 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.69 -1.256 . . . . 0.0 110.931 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.966 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.67 164.95 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.745 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.966 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.58 127.58 2.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.727 -1.233 . . . . 0.0 111.426 -178.742 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.594 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.2 OUTLIER -42.48 153.29 0.08 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 179.03 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.966 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -50.54 146.34 5.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.053 -1.029 . . . . 0.0 109.868 -179.821 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.522 ' CE ' HG22 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -156.42 -162.77 1.32 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.485 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.5 t -112.73 101.0 9.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.05 -1.031 . . . . 0.0 110.362 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.625 HD21 HD12 ' A' ' 62' ' ' ILE . 0.1 OUTLIER -108.49 160.03 28.65 Favored Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.573 ' HD3' HD12 ' A' ' 38' ' ' LEU . 34.5 Cg_endo -75.96 69.32 6.29 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.784 2.323 . . . . 0.0 111.867 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . 37.43 -159.62 0.01 OUTLIER Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.51 ' HD3' ' N ' ' A' ' 41' ' ' ARG . 1.3 mpt_? 64.07 68.47 0.56 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.541 -0.976 . . . . 0.0 109.912 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.582 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 64.3 p-90 -152.7 -178.24 6.75 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.653 -0.654 . . . . 0.0 110.001 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.5 mtpt -146.2 137.21 12.62 Favored Pre-proline 0 N--CA 1.49 1.537 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.14 138.35 16.09 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.224 1.95 . . . . 0.0 111.182 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.557 ' HD2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -152.58 -163.19 1.66 Allowed 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.242 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.565 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 1.7 mtt -149.42 126.11 11.06 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.957 -1.089 . . . . 0.0 110.371 -179.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 54' ' ' ILE . 6.8 pt -90.07 146.44 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.509 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.45 118.62 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.448 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -146.3 -127.41 1.85 Allowed Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.291 -1.433 . . . . 0.0 111.228 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.821 HD12 ' C70' ' B' ' 100' ' ' DMP . 25.2 mt -81.68 123.85 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.957 -0.731 . . . . 0.0 112.401 -177.548 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.78 -50.11 1.78 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 178.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.441 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 175.14 -168.12 40.51 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.4 OUTLIER -107.31 132.53 53.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.085 -1.244 . . . . 0.0 109.711 -179.632 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 47' ' ' ILE . 10.3 pt -101.74 163.4 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.238 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.565 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 35.6 mtmt -96.59 138.38 34.26 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.112 -0.993 . . . . 0.0 108.867 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.461 HG21 HD23 ' A' ' 76' ' ' LEU . 30.6 m -138.36 177.93 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 120.75 -1.219 . . . . 0.0 110.146 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.512 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -118.17 92.3 3.79 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.431 -0.793 . . . . 0.0 108.919 -179.954 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.545 ' CG ' ' OD1' ' A' ' 60' ' ' ASP . 16.2 tt0 -53.56 107.69 0.27 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.507 -0.745 . . . . 0.0 110.236 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 38' ' ' LEU . 15.1 m-85 -105.02 95.51 5.89 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' ' CG ' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -79.01 139.62 38.14 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.867 -1.146 . . . . 0.0 111.061 -178.39 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.564 ' HA ' HG23 ' A' ' 72' ' ' ILE . 47.0 mt-30 68.36 63.57 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.133 0.492 . . . . 0.0 111.66 178.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.813 ' C ' HD13 ' A' ' 72' ' ' ILE . 0.8 OUTLIER -122.67 124.78 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.795 HD22 HG12 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -66.65 86.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.914 -178.342 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.868 HD12 HD11 ' A' ' 15' ' ' ILE . 3.6 tt -87.74 123.83 40.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 176.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 66' ' ' ILE . 8.6 tt0 -88.59 148.37 24.11 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.069 -1.019 . . . . 0.0 109.349 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.795 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -150.19 115.35 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.501 ' SG ' ' CG ' ' A' ' 1' ' ' PRO . 0.8 OUTLIER 68.23 5.06 4.46 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.581 -0.7 . . . . 0.0 110.127 179.695 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.405 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 108.27 -3.39 33.11 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -90.2 131.31 36.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.06 -1.259 . . . . 0.0 109.318 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.505 ' CG ' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.75 103.9 11.76 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 121.047 -1.033 . . . . 0.0 108.471 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 63' ' ' LEU . . . -112.79 151.19 30.63 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 120.361 -0.535 . . . . 0.0 109.838 -179.192 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.813 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -122.42 146.32 27.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 177.716 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.474 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.75 -162.42 25.56 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 118.429 -1.843 . . . . 0.0 111.063 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 10.3 m -100.28 104.92 16.42 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.676 -0.896 . . . . 0.0 110.056 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.013 HG11 HD13 ' A' ' 15' ' ' ILE . 1.2 t -95.12 105.36 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.518 -0.739 . . . . 0.0 109.349 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.561 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.9 mp -78.57 118.07 20.34 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.966 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.0 t -106.9 111.09 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.145 -0.972 . . . . 0.0 110.443 -179.002 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.65 -157.48 7.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.55 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.14 38.8 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.509 2.139 . . . . 0.0 110.34 179.369 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.594 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.9 t -83.58 132.78 48.3 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.683 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.8 Cg_endo -79.9 19.11 1.05 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.467 2.111 . . . . 0.0 111.558 -178.589 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.1 t -161.46 156.77 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.763 -1.21 . . . . 0.0 109.929 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.575 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -95.64 91.0 5.91 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.665 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.68 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.6 mm -78.54 122.74 34.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 121.418 -0.801 . . . . 0.0 112.085 -176.464 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.628 HD12 HG23 ' A' ' 31' ' ' THR . 0.9 OUTLIER -101.02 91.78 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 176.894 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.44 -157.98 13.51 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.912 -177.052 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.513 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -68.87 -37.66 79.19 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 122.023 -0.692 . . . . 0.0 109.828 -178.958 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 13.0 p-10 -45.71 -28.51 1.04 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.933 -1.104 . . . . 0.0 109.52 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.5 mm? -109.08 -27.03 9.85 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.259 -0.9 . . . . 0.0 110.499 -178.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.679 HD23 HD11 ' A' ' 93' ' ' ILE . 70.0 mt -72.09 -7.88 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.82 -1.175 . . . . 0.0 109.194 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -98.15 -11.75 22.47 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.004 -1.06 . . . . 0.0 108.242 178.699 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.605 ' OE1' HD13 ' A' ' 89' ' ' LEU . 75.4 mt-30 -90.49 -40.71 11.84 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.75 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -82.91 0.59 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.471 -0.768 . . . . 0.0 108.965 179.164 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.15 32.83 57.91 Favored Glycine 0 N--CA 1.495 2.617 0 C-N-CA 120.575 -0.822 . . . . 0.0 111.147 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.679 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -65.45 140.08 58.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.941 -1.329 . . . . 0.0 110.715 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' B' ' 96' ' ' THR . 58.9 p -137.33 126.19 24.11 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' B' ' 97' ' ' LEU . 5.1 mp -88.43 91.94 8.99 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.239 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.433 ' HA ' ' O ' ' B' ' 1' ' ' PRO . 18.2 m-20 -103.51 121.41 42.81 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.127 -0.983 . . . . 0.0 109.448 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.904 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.361 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.55 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 2.3 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 109.875 -0.856 . . . . 0.0 109.875 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.479 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 4.3 tt0 -122.26 142.41 50.49 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 177.11 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.487 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 38.4 t -142.48 102.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.192 -178.234 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.599 ' O ' ' C ' ' B' ' 5' ' ' LEU . 63.7 p -89.62 -30.13 18.36 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 178.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.803 HD13 ' HA ' ' B' ' 9' ' ' PRO . 0.5 OUTLIER 13.14 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.832 -179.892 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.423 ' C ' ' O ' ' B' ' 5' ' ' LEU . 2.2 m95 -37.91 -22.23 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.038 -178.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.576 ' N ' ' O ' ' B' ' 5' ' ' LEU . 20.3 mp0 -107.94 -161.85 0.8 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.715 -1.241 . . . . 0.0 107.983 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.511 ' HB3' HD12 ' B' ' 23' ' ' LEU . 19.1 mtt180 -53.84 124.57 44.06 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 120.478 -1.389 . . . . 0.0 109.589 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.803 ' HA ' HD13 ' B' ' 5' ' ' LEU . 37.0 Cg_endo -77.7 71.01 6.7 Favored 'Trans proline' 0 C--N 1.316 -1.159 0 C-N-CA 122.331 2.021 . . . . 0.0 110.401 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.918 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.6 mt -78.95 143.1 36.12 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.888 -1.132 . . . . 0.0 110.356 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.816 HG21 HG23 ' B' ' 66' ' ' ILE . 1.3 m -130.76 139.92 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.509 -0.744 . . . . 0.0 109.639 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.933 HG22 HD22 ' B' ' 19' ' ' LEU . 2.0 m -67.49 108.01 2.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.918 -1.114 . . . . 0.0 108.279 178.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.904 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.2 pp -106.02 140.43 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.081 -1.012 . . . . 0.0 110.865 -178.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.541 ' CG ' ' HG ' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -109.05 106.53 16.5 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.306 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' B' ' 75' ' ' VAL . 15.0 mt -124.48 124.99 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 O-C-N 121.164 -0.96 . . . . 0.0 109.524 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.77 20.01 71.89 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -4.33 86.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -93.47 -178.17 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.115 -1.227 . . . . 0.0 108.908 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.933 HD22 HG22 ' B' ' 12' ' ' THR . 4.3 mt -153.65 125.58 7.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.132 -0.98 . . . . 0.0 110.499 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -145.94 168.79 20.01 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.012 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.918 ' HB3' HD22 ' B' ' 10' ' ' LEU . 6.5 mt-10 -79.28 157.87 27.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.758 -1.214 . . . . 0.0 108.401 179.399 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.626 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -139.34 113.96 9.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.96 -1.087 . . . . 0.0 110.691 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.511 HD12 ' HB3' ' B' ' 8' ' ' ARG . 0.9 OUTLIER -67.75 95.36 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.031 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.731 HD12 ' HB2' ' B' ' 9' ' ' PRO . 86.2 mt -44.51 102.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.806 ' HB2' HG23 ' B' ' 84' ' ' ILE . 4.8 t70 -101.37 93.53 5.46 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.474 -0.766 . . . . 0.0 110.753 -178.462 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 5' ' ' LEU . 5.6 m -76.4 3.89 10.16 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.114 -0.991 . . . . 0.0 109.004 178.455 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 1.002 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -99.67 -24.42 10.03 Favored Glycine 0 N--CA 1.485 1.933 0 C-N-CA 120.056 -1.069 . . . . 0.0 110.743 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.25 168.46 17.61 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.829 -1.395 . . . . 0.0 109.949 -179.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.458 ' OD2' ' HD3' ' A' ' 8' ' ' ARG . 0.9 OUTLIER -101.31 -20.3 15.28 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.366 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.576 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -131.86 -174.83 3.53 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 -179.598 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.687 HG23 HD12 ' B' ' 85' ' ' ILE . 53.2 m -105.33 83.44 1.96 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.676 -1.265 . . . . 0.0 110.315 -178.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.056 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.45 167.16 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.035 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.056 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.41 123.86 2.26 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.051 -1.031 . . . . 0.0 110.441 -178.694 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.823 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.0 OUTLIER -39.49 160.0 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.551 -0.718 . . . . 0.0 109.381 179.17 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.462 ' O ' ' OE1' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -39.62 146.71 0.1 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.387 -0.821 . . . . 0.0 110.449 -179.572 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.444 ' HE2' ' HE2' ' B' ' 20' ' ' LYS . 3.0 ppp? -166.4 163.04 17.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.441 -0.787 . . . . 0.0 109.046 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.3 t -95.82 105.04 17.0 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.043 -1.036 . . . . 0.0 109.753 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.739 HD21 HD12 ' B' ' 62' ' ' ILE . 9.2 tp -122.43 106.17 35.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.372 -0.83 . . . . 0.0 108.932 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.33 140.39 19.43 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.375 2.05 . . . . 0.0 111.125 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 128.23 31.52 0.67 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.474 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 52.88 166.62 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.84 -0.8 . . . . 0.0 110.014 179.749 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.579 ' CD2' ' HD3' ' B' ' 57' ' ' ARG . 0.2 OUTLIER -160.98 178.49 9.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.138 -0.976 . . . . 0.0 109.769 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -125.88 104.52 26.7 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.76 138.61 41.61 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.025 1.817 . . . . 0.0 112.355 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -150.62 -155.61 0.64 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.55 ' CE ' ' HB3' ' B' ' 53' ' ' PHE . 32.2 mtp -148.13 126.55 12.35 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.026 -1.046 . . . . 0.0 110.312 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 54' ' ' ILE . 7.3 pt -93.24 142.38 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.611 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.93 113.75 2.64 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.459 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -138.12 -123.94 2.21 Favored Glycine 0 N--CA 1.483 1.811 0 C-N-CA 119.525 -1.322 . . . . 0.0 110.493 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.86 HD12 ' C21' ' B' ' 100' ' ' DMP . 25.6 mt -84.77 119.27 33.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.793 -0.827 . . . . 0.0 112.384 -177.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 103.83 -53.01 0.73 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.89 -161.79 27.83 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.171 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.611 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -111.84 128.86 56.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.459 -1.024 . . . . 0.0 109.241 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 47' ' ' ILE . 16.3 pt -107.38 162.59 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.876 -1.14 . . . . 0.0 109.016 179.118 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.6 mptm? -94.53 147.58 23.12 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.153 -0.967 . . . . 0.0 108.88 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 27.5 m -144.94 -170.77 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 120.768 -1.207 . . . . 0.0 110.254 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.579 ' HD3' ' CD2' ' B' ' 42' ' ' TRP . 18.6 mtt85 -131.46 111.24 11.62 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -77.61 101.3 6.49 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.566 -0.709 . . . . 0.0 111.07 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.642 ' CG ' HD23 ' B' ' 38' ' ' LEU . 62.7 m-85 -96.18 129.74 43.41 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.068 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 14.5 m-20 -109.19 122.45 47.34 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.692 -1.255 . . . . 0.0 110.895 -178.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.546 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 3.0 mt-30 86.1 56.11 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 CA-C-O 121.31 0.576 . . . . 0.0 110.472 179.069 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.855 HG21 HG23 ' B' ' 15' ' ' ILE . 4.0 mm -111.27 128.07 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.449 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.879 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.3 tm? -73.84 102.26 4.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.181 -0.95 . . . . 0.0 111.293 -178.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.829 ' CG2' HD11 ' B' ' 89' ' ' LEU . 0.9 OUTLIER -105.59 106.11 19.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 177.579 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.4 OUTLIER -90.0 119.69 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.983 -1.073 . . . . 0.0 109.206 -178.821 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.816 HG23 HG21 ' B' ' 11' ' ' VAL . 1.5 mp -111.54 128.78 67.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.477 -0.765 . . . . 0.0 109.364 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.487 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 15.5 m 65.55 -89.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.752 -0.593 . . . . 0.0 109.629 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.88 39.15 0.74 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -139.36 131.91 28.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.566 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.68 ' CG ' HD21 ' B' ' 63' ' ' LEU . 15.6 ttmt -70.74 129.11 38.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.125 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.625 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -142.25 95.19 2.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.156 -0.965 . . . . 0.0 110.435 -179.257 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.631 HG12 HD23 ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.99 156.77 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.712 -1.243 . . . . 0.0 108.06 178.297 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.506 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.05 -170.59 43.52 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.674 -1.727 . . . . 0.0 111.213 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 85.9 m -88.68 112.54 23.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.848 -0.795 . . . . 0.0 110.575 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' B' ' 15' ' ' ILE . 0.7 OUTLIER -105.18 107.8 23.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.7 -0.625 . . . . 0.0 110.155 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.576 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 4.0 mp -82.63 121.82 27.32 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 108.853 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.52 ' O ' ' HG3' ' B' ' 57' ' ' ARG . 69.1 t -109.3 132.04 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.058 -1.026 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -162.8 -159.89 10.76 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.43 36.1 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.651 2.234 . . . . 0.0 110.733 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.823 HG22 ' HA ' ' B' ' 34' ' ' GLU . 4.0 t -81.6 136.64 48.37 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.682 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.5 16.36 1.43 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.322 2.015 . . . . 0.0 111.269 -178.581 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.682 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -161.84 148.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 120.88 -1.138 . . . . 0.0 110.108 -179.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.7 OUTLIER -86.61 102.12 13.87 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 105.922 -1.881 . . . . 0.0 105.922 176.749 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.833 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.4 mt -101.74 126.66 55.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.856 -1.153 . . . . 0.0 112.137 -175.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.745 ' N ' HD13 ' B' ' 85' ' ' ILE . 1.5 mm -97.08 121.85 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 177.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.537 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -102.58 -147.42 19.17 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.592 -1.289 . . . . 0.0 111.551 -178.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.509 ' O ' ' OG1' ' B' ' 91' ' ' THR . 11.6 mtp180 -69.08 -40.86 78.18 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 122.074 -0.662 . . . . 0.0 111.388 -178.41 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.98 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.2 p-10 -53.78 -30.47 44.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.798 -1.188 . . . . 0.0 111.254 -178.081 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.98 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.8 mm? -104.44 -28.58 11.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.492 -1.38 . . . . 0.0 110.914 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.662 ' N ' HD23 ' B' ' 90' ' ' LEU . 0.1 OUTLIER -68.2 -9.58 47.99 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.712 -1.242 . . . . 0.0 109.151 179.745 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.22 -20.44 15.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.775 -1.203 . . . . 0.0 108.831 179.154 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 46.6 mm-40 -77.89 -41.05 37.93 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.237 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.904 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -81.4 -8.17 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.38 35.77 55.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.568 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -61.56 152.18 31.12 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.824 -1.398 . . . . 0.0 109.288 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 4' ' ' THR . 21.5 p -142.27 124.72 15.69 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.151 -0.968 . . . . 0.0 108.889 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' A' ' 97' ' ' LEU . 4.8 mp -86.25 91.08 8.36 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.444 -0.785 . . . . 0.0 109.505 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.545 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 13.5 m-20 -93.92 121.98 35.94 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.049 -1.032 . . . . 0.0 109.227 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.75 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 118.045 -0.979 . . . . 0.0 109.477 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.86 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 3.8 Cg_exo . . . . . 0 N--CA 1.497 1.686 0 N-CA-C 110.663 -0.553 . . . . 0.0 110.663 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.472 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -84.37 136.73 33.76 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.102 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.622 HG12 ' H ' ' A' ' 5' ' ' LEU . 55.7 t -133.55 115.03 21.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 120.734 -1.229 . . . . 0.0 109.918 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 72.6 p -58.8 -12.59 4.53 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.698 -0.626 . . . . 0.0 110.218 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.767 HD21 HD13 ' B' ' 97' ' ' LEU . 0.7 OUTLIER 80.59 -6.6 1.66 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.443 -0.785 . . . . 0.0 110.298 179.398 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.598 ' CZ3' HG21 ' B' ' 91' ' ' THR . 39.8 m95 -53.88 -20.43 5.94 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.949 -1.094 . . . . 0.0 108.848 179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.11 157.54 46.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 108.914 179.378 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.433 ' HA ' ' CZ ' ' B' ' 87' ' ' ARG . 4.0 mtm180 -66.92 122.99 84.94 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.155 -0.965 . . . . 0.0 109.595 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.612 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.0 Cg_endo -76.1 80.09 2.76 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 121.927 1.751 . . . . 0.0 109.429 178.75 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -90.0 149.34 22.59 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.589 -0.695 . . . . 0.0 109.606 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.926 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -150.9 159.33 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.192 -0.942 . . . . 0.0 110.377 -179.063 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.679 HG21 HD23 ' A' ' 19' ' ' LEU . 14.1 m -94.88 104.82 16.71 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 1.154 HD11 HD21 ' A' ' 33' ' ' LEU . 2.2 pt -89.22 141.1 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.177 -0.952 . . . . 0.0 110.389 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.589 ' HG3' HD12 ' A' ' 19' ' ' LEU . 29.5 ttmt -106.34 97.27 7.09 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.469 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.868 HG23 ' CG2' ' A' ' 62' ' ' ILE . 16.8 mt -113.53 120.55 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.147 -0.97 . . . . 0.0 110.06 -179.155 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.23 37.65 94.81 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.1 6.4 56.72 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.453 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.3 mm-40 -97.48 163.25 12.94 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.201 -1.176 . . . . 0.0 109.216 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.679 HD23 HG21 ' A' ' 12' ' ' THR . 0.1 OUTLIER -136.89 126.59 25.48 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.293 -0.879 . . . . 0.0 110.798 -179.507 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.8 mttp -150.45 179.95 7.73 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.061 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.03 -174.67 4.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.876 -1.14 . . . . 0.0 108.891 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -162.25 121.14 2.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.031 -1.043 . . . . 0.0 110.001 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.519 ' O ' ' N ' ' A' ' 25' ' ' ASP . 46.5 tp -102.61 95.42 6.21 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.449 -0.782 . . . . 0.0 109.301 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 17.1 mt -43.33 96.24 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.078 -1.013 . . . . 0.0 109.417 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.759 ' CB ' HG23 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -101.21 81.62 2.24 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.511 -0.743 . . . . 0.0 110.121 -179.493 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.712 HG23 HD13 ' A' ' 90' ' ' LEU . 4.3 m -61.89 -20.64 63.96 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.989 -1.07 . . . . 0.0 108.936 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.805 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -59.32 -45.49 95.35 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -71.96 157.56 37.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.377 -1.072 . . . . 0.0 108.729 179.346 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -92.01 -10.26 39.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.06 -1.025 . . . . 0.0 110.3 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 1.019 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.24 -173.46 3.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.956 -1.09 . . . . 0.0 110.053 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.574 HG22 ' CD1' ' A' ' 33' ' ' LEU . 33.4 m -103.23 89.01 3.27 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.265 -0.897 . . . . 0.0 111.281 -178.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.015 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.42 172.15 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.55 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.154 HD21 HD11 ' A' ' 13' ' ' ILE . 0.1 OUTLIER -168.68 132.7 1.51 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.085 -1.009 . . . . 0.0 110.571 -178.966 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.541 ' HA ' HG22 ' A' ' 80' ' ' THR . 20.6 mt-10 -41.46 161.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.499 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -61.36 143.7 55.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.036 -1.04 . . . . 0.0 110.043 -179.46 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.544 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -160.1 -179.76 8.04 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.331 -0.855 . . . . 0.0 109.645 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.4 t -92.89 100.0 12.54 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 109.924 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.9 HD12 HG21 ' A' ' 77' ' ' VAL . 12.6 mt -106.45 173.28 3.26 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.658 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.7 Cg_endo -78.18 50.11 3.22 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.327 2.018 . . . . 0.0 112.735 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 34.75 -158.53 0.01 OUTLIER Glycine 0 N--CA 1.498 2.769 0 O-C-N 121.478 -0.763 . . . . 0.0 111.529 178.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.448 ' HG3' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER 53.8 80.33 0.11 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.547 -0.973 . . . . 0.0 109.442 -179.54 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 2.9 p-90 -145.93 -167.85 2.83 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-O 121.506 0.67 . . . . 0.0 109.697 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.44 116.01 11.82 Favored Pre-proline 0 C--N 1.303 -1.433 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.169 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -70.59 138.76 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 121.848 1.698 . . . . 0.0 111.731 -178.225 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.468 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -158.61 133.09 8.05 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.8 OUTLIER -94.03 123.56 37.48 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 -179.729 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.808 HD11 HG21 ' B' ' 50' ' ' ILE . 6.9 pt -92.38 148.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.814 -1.179 . . . . 0.0 108.679 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.525 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -118.39 101.86 0.92 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.764 -1.735 . . . . 0.0 108.764 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.89 -128.28 3.3 Favored Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.522 -1.323 . . . . 0.0 111.056 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.86 HD12 ' C70' ' B' ' 100' ' ' DMP . 22.4 mt -86.29 114.35 25.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.809 -0.818 . . . . 0.0 112.494 -177.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.507 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.48 -7.14 39.4 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.207 -0.997 . . . . 0.0 110.758 177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.21 -160.98 23.83 Favored Glycine 0 N--CA 1.494 2.516 0 O-C-N 120.894 -1.357 . . . . 0.0 110.405 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.525 ' CZ ' ' HA3' ' A' ' 48' ' ' GLY . 5.1 m-85 -110.73 132.98 53.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.382 -1.07 . . . . 0.0 109.883 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.799 ' C ' HD12 ' A' ' 54' ' ' ILE . 2.6 pp -111.04 162.47 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.065 -1.022 . . . . 0.0 108.603 178.635 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 76.0 mttt -102.36 133.69 46.87 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.034 -1.041 . . . . 0.0 109.673 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.776 HG13 ' CD1' ' A' ' 54' ' ' ILE . 3.1 m -134.77 -173.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.477 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -132.71 100.01 4.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.48 -0.762 . . . . 0.0 109.1 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.514 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 31.8 tt0 -57.92 93.79 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.328 -0.858 . . . . 0.0 109.669 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.724 ' C ' HD11 ' A' ' 62' ' ' ILE . 15.6 m-85 -88.36 125.36 34.66 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.466 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 24.6 m-20 -105.29 137.72 42.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.861 -1.15 . . . . 0.0 110.901 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.528 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 1.7 mm-40 72.62 61.43 0.12 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.792 -0.568 . . . . 0.0 110.614 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.868 ' CG2' HG23 ' A' ' 15' ' ' ILE . 4.9 mp -119.64 123.94 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.066 . . . . 0.0 108.92 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.803 HD13 ' O ' ' A' ' 63' ' ' LEU . 3.3 tm? -69.7 86.56 0.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.316 -0.865 . . . . 0.0 111.831 -178.29 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.576 HG13 ' HB ' ' A' ' 13' ' ' ILE . 3.0 tt -88.32 110.27 20.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 2.0 tt0 -88.77 118.32 28.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.962 -1.086 . . . . 0.0 109.791 -178.03 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.898 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -108.4 120.2 59.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.326 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.72 -99.01 0.09 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -136.72 39.09 1.68 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 8.5 m-70 -128.45 103.33 7.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.423 -1.045 . . . . 0.0 110.164 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.509 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -60.89 117.32 5.29 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.721 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.01 127.99 35.33 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.278 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.577 HG12 ' CA ' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -105.06 139.46 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.605 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.589 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -162.73 -170.95 28.31 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 118.93 -1.605 . . . . 0.0 110.295 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.581 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 51.9 m -91.02 109.87 21.12 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.695 -0.885 . . . . 0.0 109.798 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.073 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -103.61 112.03 35.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 110.959 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 1.019 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.0 mp -79.57 122.95 27.13 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.9 HG21 HD12 ' A' ' 38' ' ' LEU . 54.3 t -108.39 121.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.945 -1.097 . . . . 0.0 109.907 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -155.22 -165.17 13.83 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.552 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -80.76 42.52 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.564 2.176 . . . . 0.0 110.636 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.571 HG21 HG13 ' A' ' 32' ' ' VAL . 13.1 t -85.9 141.16 35.44 Favored Pre-proline 0 C--N 1.302 -1.473 0 O-C-N 121.156 -0.965 . . . . 0.0 108.814 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.5 Cg_endo -78.87 15.06 1.55 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.475 2.116 . . . . 0.0 111.546 -179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -160.68 167.37 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.787 -1.196 . . . . 0.0 110.371 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.558 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 69.5 m-80 -100.09 92.54 5.29 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 177.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.759 HG23 ' CB ' ' A' ' 25' ' ' ASP . 11.4 mm -78.91 124.33 37.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 O-C-N 121.153 -0.967 . . . . 0.0 111.846 -176.472 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.61 ' N ' ' CD1' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -106.22 100.58 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 177.531 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -87.28 -161.61 36.74 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 120.128 -1.034 . . . . 0.0 111.481 -177.541 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 15.8 mmm180 -62.16 -38.73 90.13 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.843 -0.798 . . . . 0.0 109.841 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.029 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.5 p-10 -43.67 -29.48 0.51 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.231 -0.918 . . . . 0.0 109.387 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.029 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.7 mm? -107.78 -24.62 11.61 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.004 -1.06 . . . . 0.0 109.612 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.712 HD13 HG23 ' A' ' 26' ' ' THR . 14.7 mt -70.41 -5.81 31.04 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.866 -1.146 . . . . 0.0 108.191 178.14 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.476 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 71.3 p -100.63 -17.87 16.83 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 19.1 mm100 -83.64 -39.19 20.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 109.434 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.092 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -84.95 3.52 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.298 -0.876 . . . . 0.0 109.607 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.56 38.22 51.8 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 120.313 -0.946 . . . . 0.0 111.064 178.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -71.16 138.29 49.47 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.079 -1.248 . . . . 0.0 111.072 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.762 HG22 ' CG2' ' B' ' 4' ' ' THR . 48.7 p -133.18 128.76 36.69 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' B' ' 97' ' ' LEU . 1.6 mp -92.84 85.37 5.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.18 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 14.1 m-20 -89.68 122.39 32.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.097 -1.002 . . . . 0.0 109.747 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.802 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 117.927 -1.035 . . . . 0.0 108.908 178.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.1 tt0 -84.2 131.5 34.75 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.325 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -119.69 118.5 57.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 C-N-CA 118.525 -1.27 . . . . 0.0 110.483 -178.183 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.762 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.1 OUTLIER -132.31 19.93 4.4 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 178.324 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.572 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -82.17 67.38 8.16 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.531 ' C ' ' O ' ' B' ' 5' ' ' LEU . 41.5 m0 -21.93 84.5 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 CA-C-O 121.578 0.704 . . . . 0.0 111.594 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.572 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.38 -163.04 0.32 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.975 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.42 121.71 71.06 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.115 -0.991 . . . . 0.0 109.27 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.753 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.5 Cg_endo -76.5 74.74 4.63 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.08 1.853 . . . . 0.0 109.068 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.499 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -96.98 147.15 24.28 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.463 -0.773 . . . . 0.0 110.425 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.453 HG21 HG23 ' B' ' 66' ' ' ILE . 0.9 OUTLIER -143.63 132.47 19.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.885 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.951 HG22 HD22 ' B' ' 19' ' ' LEU . 12.0 m -67.54 99.91 0.81 Allowed 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 178.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 3.2 pt -82.73 157.17 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.738 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HB2' ' HB3' ' B' ' 65' ' ' GLU . 0.5 OUTLIER -123.78 98.74 5.95 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.314 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.943 HG23 ' CG2' ' B' ' 62' ' ' ILE . 50.7 mt -113.98 133.37 60.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.332 -0.855 . . . . 0.0 109.605 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.502 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 49.98 54.91 16.71 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.65 34.78 21.59 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.51 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.6 mm-40 -124.84 167.08 15.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -1.184 . . . . 0.0 109.185 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.951 HD22 HG22 ' B' ' 12' ' ' THR . 12.0 mt -141.82 129.49 21.55 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.159 -0.963 . . . . 0.0 110.757 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 20.2 mtmt -151.7 169.43 22.2 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.63 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mp0 -78.99 126.67 31.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.943 -1.098 . . . . 0.0 109.029 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.855 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -106.88 120.77 42.94 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.088 -1.008 . . . . 0.0 110.173 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.805 HD21 ' O ' ' A' ' 27' ' ' GLY . 20.7 tp -91.82 94.75 9.48 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.437 -0.789 . . . . 0.0 110.093 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.753 HD12 ' HB2' ' B' ' 9' ' ' PRO . 58.0 mt -46.49 101.88 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.033 -1.042 . . . . 0.0 108.676 179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.903 ' HB3' HG23 ' B' ' 84' ' ' ILE . 12.4 t0 -113.34 98.2 6.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.92 . . . . 0.0 110.721 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.738 ' CG2' HD22 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -69.88 -15.32 63.06 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.111 -0.993 . . . . 0.0 108.768 178.699 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.455 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.62 -41.03 97.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.478 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -79.73 165.52 22.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.039 -1.271 . . . . 0.0 109.063 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -100.77 -15.42 17.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.132 -0.98 . . . . 0.0 110.573 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.861 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -132.66 -175.33 3.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.712 -1.242 . . . . 0.0 110.316 -179.369 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.62 HG22 ' CD1' ' B' ' 33' ' ' LEU . 72.8 m -103.13 87.92 3.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.017 -1.052 . . . . 0.0 110.053 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.43 163.12 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.52 179.611 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.14 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -160.7 138.45 9.53 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.049 -1.032 . . . . 0.0 110.469 -178.539 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.617 ' N ' HG22 ' B' ' 80' ' ' THR . 2.3 mt-10 -47.97 174.97 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.512 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.2 tm-20 -72.5 143.46 48.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.03 -1.044 . . . . 0.0 109.452 179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.413 ' HG3' ' HG ' ' B' ' 38' ' ' LEU . 6.6 ptm -154.93 -167.92 2.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.393 -0.817 . . . . 0.0 109.204 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -107.22 105.98 16.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.653 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.888 HD12 HG21 ' B' ' 77' ' ' VAL . 90.4 mt -117.21 156.44 48.65 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.486 ' O ' ' O ' ' B' ' 40' ' ' GLY . 35.1 Cg_endo -76.63 74.24 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.885 2.39 . . . . 0.0 112.206 -178.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 34.39 -157.14 0.01 OUTLIER Glycine 0 N--CA 1.497 2.765 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.418 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.3 mtt180 70.02 47.73 0.57 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.263 -1.139 . . . . 0.0 108.459 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 57.4 p-90 -129.12 -179.03 4.89 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 121.824 0.821 . . . . 0.0 110.297 -178.815 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -145.26 156.48 54.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.667 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -75.75 139.3 22.25 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.803 1.669 . . . . 0.0 110.29 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -144.87 168.82 19.32 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.537 -0.727 . . . . 0.0 109.52 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -150.1 125.08 9.92 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.791 ' CD1' HG21 ' A' ' 50' ' ' ILE . 24.1 pt -120.46 137.82 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 120.74 -1.225 . . . . 0.0 110.385 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.613 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.69 98.51 0.75 Allowed Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.68 -119.02 2.75 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.8 -178.534 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.86 HD12 ' C20' ' B' ' 100' ' ' DMP . 16.4 mt -90.39 119.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.689 -0.889 . . . . 0.0 112.337 -177.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.482 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 103.34 -28.11 17.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 120.222 -0.99 . . . . 0.0 110.751 177.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 153.49 -161.9 30.01 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.285 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.613 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 8.4 m-85 -107.31 125.02 50.63 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -1.036 . . . . 0.0 110.138 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.709 HD13 HG23 ' A' ' 50' ' ' ILE . 11.8 pt -105.96 142.0 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.081 -1.012 . . . . 0.0 108.865 178.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.506 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 5.0 mttt -89.06 138.59 31.27 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.031 -1.043 . . . . 0.0 109.294 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.965 HG12 ' HA3' ' B' ' 78' ' ' GLY . 29.4 m -140.44 175.52 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.079 -1.013 . . . . 0.0 110.211 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.592 ' HG2' ' CE3' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -126.29 103.95 7.93 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.403 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.554 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -58.75 112.73 1.74 Allowed 'General case' 0 C--N 1.295 -1.797 0 O-C-N 121.566 -0.709 . . . . 0.0 111.126 -178.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 15.2 m-85 -98.4 124.4 43.06 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.2 m-20 -101.97 130.1 48.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.886 -1.134 . . . . 0.0 111.03 -178.563 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.611 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 77.98 65.55 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 CA-C-O 121.48 0.657 . . . . 0.0 109.909 179.163 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.943 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.54 119.6 61.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.273 -0.892 . . . . 0.0 109.721 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.669 HD13 ' C ' ' B' ' 63' ' ' LEU . 1.4 tm? -63.9 86.93 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.603 -0.686 . . . . 0.0 111.682 -178.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.599 HG23 ' O ' ' B' ' 64' ' ' ILE . 7.9 tt -93.47 113.03 27.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 176.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' B' ' 14' ' ' LYS . 32.9 tt0 -88.32 120.42 29.67 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 -178.507 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -114.29 126.34 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.215 -0.928 . . . . 0.0 109.712 -179.253 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 5.7 m 65.18 4.75 2.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.797 -0.564 . . . . 0.0 110.763 179.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 110.81 -6.75 29.49 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.042 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -92.11 139.29 30.78 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.199 -1.177 . . . . 0.0 108.549 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.539 ' CG ' HD11 ' B' ' 63' ' ' LEU . 1.7 mttt -84.47 124.75 31.69 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.177 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.533 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -134.15 157.89 45.04 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.611 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -131.19 133.91 61.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.593 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.593 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -158.42 -166.48 17.68 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 118.617 -1.754 . . . . 0.0 110.995 -179.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.554 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 51.6 m -92.39 107.1 18.96 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.924 -0.751 . . . . 0.0 109.797 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.14 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -103.77 113.29 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.544 -0.723 . . . . 0.0 109.804 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.861 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -78.35 129.25 34.77 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.888 HG21 HD12 ' B' ' 38' ' ' LEU . 95.7 t -113.78 109.95 30.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.895 -1.128 . . . . 0.0 110.039 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.965 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -147.12 -163.59 10.62 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.506 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -79.87 41.37 1.1 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.325 2.016 . . . . 0.0 111.164 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -88.23 139.74 30.42 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.907 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.652 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.8 Cg_endo -79.81 17.32 1.3 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 C-N-CA 122.488 2.126 . . . . 0.0 112.302 -177.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 2.1 t -160.69 164.63 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.527 -1.358 . . . . 0.0 110.992 -179.543 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.63 ' ND2' ' O ' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -103.61 87.04 2.74 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.135 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.903 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.7 mt -84.42 123.71 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 O-C-N 121.336 -0.852 . . . . 0.0 112.377 -176.064 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.597 HD11 ' HB1' ' B' ' 22' ' ' ALA . 3.2 mm -91.78 103.25 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -84.11 -159.16 28.87 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.71 -1.244 . . . . 0.0 110.671 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.551 ' NH1' HG22 ' B' ' 26' ' ' THR . 11.9 mtt-85 -66.24 -35.58 80.8 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.659 -0.907 . . . . 0.0 109.498 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.994 ' ND2' HD23 ' B' ' 89' ' ' LEU . 7.7 p-10 -48.79 -31.65 7.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.921 . . . . 0.0 109.753 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.994 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -106.16 -17.38 14.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.077 . . . . 0.0 110.251 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.523 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 87.4 mt -77.39 -1.66 31.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.143 -0.973 . . . . 0.0 108.529 179.234 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.598 HG21 ' CZ3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -101.68 -20.58 14.94 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.128 -0.982 . . . . 0.0 108.638 179.038 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.518 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 30.4 mt-30 -75.5 -40.72 56.8 Favored 'General case' 0 N--CA 1.486 1.364 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.802 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -83.39 -9.16 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.411 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.3 36.78 33.61 Favored Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.232 -0.917 . . . . 0.0 111.166 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.643 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -63.7 156.25 27.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.054 -1.263 . . . . 0.0 110.513 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 96' ' ' THR . 66.7 p -147.58 126.61 12.84 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -95.49 89.28 5.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.717 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.56 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 5.9 m-20 -96.13 118.74 33.31 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.055 -1.028 . . . . 0.0 109.318 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 1.092 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.324 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.86 ' C70' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.458 ' HG2' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 N-CA-C 110.501 -0.615 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.557 ' NE2' HG21 ' A' ' 4' ' ' THR . 9.1 tt0 -85.92 126.8 34.36 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 177.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.705 HG12 ' O ' ' A' ' 3' ' ' VAL . 2.4 t -112.33 91.09 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 120.818 -1.176 . . . . 0.0 109.909 -178.453 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.73 HG22 HG22 ' B' ' 96' ' ' THR . 64.7 p -117.71 33.04 5.82 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.539 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -86.79 30.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.882 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 35.8 m0 17.68 52.49 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -147.73 -163.37 1.75 Allowed 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -74.68 114.92 39.02 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.997 -1.065 . . . . 0.0 109.839 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.609 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.9 Cg_endo -78.06 71.15 6.79 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 121.976 1.784 . . . . 0.0 108.878 177.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -93.29 157.64 16.14 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.356 -179.167 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.407 ' CG1' ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -149.96 140.55 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.82 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' A' ' 19' ' ' LEU . 9.6 m -73.2 94.15 1.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.416 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.869 HD11 HD21 ' A' ' 33' ' ' LEU . 4.7 pt -80.43 163.82 3.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.538 -0.726 . . . . 0.0 110.791 -178.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 21.7 tttm -129.53 103.23 6.76 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.571 -0.706 . . . . 0.0 109.8 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.918 HG23 ' CG2' ' A' ' 62' ' ' ILE . 39.8 mt -119.55 117.05 52.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 120.994 -1.066 . . . . 0.0 109.38 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.27 25.55 75.28 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.96 -1.63 86.06 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.464 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 tp60 -92.11 167.41 12.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.99 -1.3 . . . . 0.0 109.396 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' A' ' 12' ' ' THR . 36.4 mt -130.2 134.74 47.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' HB3' ' OD1' ' A' ' 83' ' ' ASN . 1.7 tptt -151.32 146.17 25.83 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.627 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.445 ' N ' ' CD ' ' A' ' 21' ' ' GLU . 2.7 mm-40 -78.88 107.94 11.98 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.982 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -98.57 131.82 44.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.017 -1.052 . . . . 0.0 111.019 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.604 HD21 ' O ' ' B' ' 27' ' ' GLY . 0.8 OUTLIER -87.33 105.09 17.01 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.901 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.522 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -46.99 120.36 3.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.966 -1.084 . . . . 0.0 108.4 179.702 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.851 ' HB2' HG23 ' A' ' 84' ' ' ILE . 56.7 t0 -124.54 83.99 2.22 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.221 -0.925 . . . . 0.0 110.488 -178.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.676 HG23 HD13 ' A' ' 90' ' ' LEU . 3.2 m -65.74 -15.26 62.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.036 -1.04 . . . . 0.0 108.565 178.807 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.524 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -67.13 -45.59 80.22 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.509 ' CB ' ' H25' ' B' ' 100' ' ' DMP . . . -71.81 167.54 19.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -1.184 . . . . 0.0 108.597 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -99.92 -19.8 16.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.828 -1.17 . . . . 0.0 110.785 -178.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 1.031 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.01 179.35 6.37 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.89 -1.131 . . . . 0.0 109.781 -179.687 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.594 HG22 ' CD1' ' A' ' 33' ' ' LEU . 7.4 m -94.66 92.81 7.2 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 120.826 -1.171 . . . . 0.0 110.011 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.872 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -84.49 118.96 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.232 -0.918 . . . . 0.0 109.102 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.869 HD21 HD11 ' A' ' 13' ' ' ILE . 1.2 mp -114.1 144.41 43.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.952 -1.093 . . . . 0.0 111.128 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.86 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -47.17 174.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.381 -0.825 . . . . 0.0 108.922 178.569 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -57.59 146.13 31.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.027 . . . . 0.0 109.642 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.502 ' HG3' ' N ' ' A' ' 37' ' ' SER . 2.7 ptm -163.7 -175.49 4.16 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.392 -0.818 . . . . 0.0 109.043 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.502 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.9 t -110.74 120.44 42.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.113 -0.992 . . . . 0.0 109.788 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.783 HD12 HG21 ' A' ' 77' ' ' VAL . 82.0 mt -132.9 159.17 73.7 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.478 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 34.4 Cg_endo -76.42 133.0 14.08 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.823 2.348 . . . . 0.0 112.436 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -37.25 129.48 1.23 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.469 -1.053 . . . . 0.0 110.469 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.0 OUTLIER 148.19 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -179.519 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.617 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 50.4 p-90 -138.56 -173.29 3.51 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.741 0.782 . . . . 0.0 110.355 -177.234 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.454 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 0.0 OUTLIER -148.94 163.8 24.0 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 179.14 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 36.0 Cg_endo -78.37 145.66 21.41 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.966 1.777 . . . . 0.0 109.979 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.756 ' HB2' HG23 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -146.52 142.78 28.4 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.153 -0.967 . . . . 0.0 109.67 -179.52 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.497 ' CE ' ' HE3' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -121.97 107.24 12.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 108.675 179.475 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.672 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.9 pt -101.81 132.39 47.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.588 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 53' ' ' PHE . . . -117.7 105.38 1.25 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.451 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -120.88 -115.89 2.45 Favored Glycine 0 N--CA 1.481 1.695 0 C-N-CA 119.715 -1.231 . . . . 0.0 110.768 -178.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.864 HD12 ' C70' ' B' ' 100' ' ' DMP . 25.6 mt -88.6 116.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 O-C-N 121.832 -0.805 . . . . 0.0 112.834 -177.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.544 ' HA2' HG22 ' B' ' 54' ' ' ILE . . . 106.7 -42.35 1.94 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 166.68 -160.98 34.75 Favored Glycine 0 N--CA 1.49 2.259 0 O-C-N 120.833 -1.392 . . . . 0.0 110.172 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.514 ' HA ' ' HA2' ' A' ' 48' ' ' GLY . 6.8 m-85 -102.1 155.79 17.97 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.449 -1.03 . . . . 0.0 110.042 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.647 HD11 HD11 ' A' ' 47' ' ' ILE . 2.1 pt -134.42 173.54 14.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 3.3 mttt -114.15 144.62 42.86 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.315 -0.866 . . . . 0.0 108.742 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB2' ' A' ' 45' ' ' LYS . 30.6 m -143.39 -177.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.624 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.525 ' O ' ' N ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -131.52 88.82 2.62 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.547 ' HG3' HG23 ' A' ' 74' ' ' THR . 3.5 tt0 -46.76 91.7 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.497 -0.752 . . . . 0.0 109.804 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 12.5 m-85 -89.96 95.68 10.33 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.525 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 12.2 m-20 -79.22 133.2 36.69 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.161 -0.962 . . . . 0.0 109.972 -179.004 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 20.4 mm-40 81.8 61.68 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.495 0.664 . . . . 0.0 110.166 179.171 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.918 ' CG2' HG23 ' A' ' 15' ' ' ILE . 15.4 mm -115.99 120.35 64.59 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.632 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.858 HD13 ' O ' ' A' ' 63' ' ' LEU . 1.9 tm? -72.45 81.18 1.06 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.171 -0.956 . . . . 0.0 111.094 -178.039 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.812 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -87.66 117.93 32.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.345 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.487 ' HG3' ' N ' ' A' ' 70' ' ' LYS . 1.5 tt0 -93.91 112.38 24.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.07 -1.019 . . . . 0.0 109.763 -178.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.801 HG13 HG22 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -100.34 118.81 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.3 m 56.42 54.55 7.45 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.735 -0.603 . . . . 0.0 109.807 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 57.69 16.55 23.72 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' C ' ' HG3' ' A' ' 65' ' ' GLU . 25.7 m170 -107.93 91.18 3.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -1.223 . . . . 0.0 109.494 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -43.42 137.25 2.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 179.712 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -159.25 124.83 4.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.515 -0.74 . . . . 0.0 109.415 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.68 HD13 ' C ' ' A' ' 62' ' ' ILE . 1.0 OUTLIER -95.32 152.45 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.877 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.443 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.41 -171.82 39.73 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 118.832 -1.652 . . . . 0.0 111.089 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.547 HG23 ' HG3' ' A' ' 58' ' ' GLN . 96.5 m -98.49 108.85 21.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -1.134 . . . . 0.0 110.619 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.83 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -99.24 109.92 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.675 -0.641 . . . . 0.0 110.349 179.153 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 1.031 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.4 100.95 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.783 HG21 HD12 ' A' ' 38' ' ' LEU . 21.6 t -87.1 121.86 38.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.98 -1.075 . . . . 0.0 110.248 -178.705 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.534 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -156.76 -166.15 15.97 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.552 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 35.7 Cg_endo -80.84 40.67 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.403 2.069 . . . . 0.0 111.103 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.86 HG22 ' HA ' ' A' ' 34' ' ' GLU . 13.4 t -81.36 140.5 48.71 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.713 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.0 Cg_endo -78.73 15.75 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.595 2.197 . . . . 0.0 111.279 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 81' ' ' PRO . 5.2 t -160.53 163.36 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.94 -1.1 . . . . 0.0 110.514 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.656 ' ND2' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.01 85.57 2.88 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 105.045 -2.205 . . . . 0.0 105.045 177.109 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.925 HD11 ' C62' ' B' ' 100' ' ' DMP . 4.6 mt -88.88 125.31 41.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.139 -0.975 . . . . 0.0 112.69 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.982 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -84.88 149.48 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 176.503 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.496 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -125.61 -170.23 13.01 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.672 -1.728 . . . . 0.0 110.462 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HD3' ' HB2' ' A' ' 90' ' ' LEU . 6.4 mmt180 -62.98 -26.75 68.99 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.444 -1.033 . . . . 0.0 108.416 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.023 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.7 p-10 -57.65 -28.44 63.74 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.433 -0.792 . . . . 0.0 109.141 179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.023 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -102.36 -24.37 13.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.287 -0.883 . . . . 0.0 109.208 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.676 HD13 HG23 ' A' ' 26' ' ' THR . 41.0 mt -71.51 -4.8 28.76 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.473 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.466 ' HB ' ' CE2' ' B' ' 6' ' ' TRP . 21.7 p -101.14 -16.08 17.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.256 -0.902 . . . . 0.0 108.717 178.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mm-40 -86.66 -40.81 14.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.31 -0.868 . . . . 0.0 109.433 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.774 HD12 ' CD2' ' B' ' 99' ' ' PHE . 1.6 pt -85.67 0.71 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.131 -0.981 . . . . 0.0 108.724 179.395 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.03 51.49 50.47 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.525 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.1 155.29 23.92 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.031 -1.276 . . . . 0.0 109.802 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.74 HG22 ' CG2' ' B' ' 4' ' ' THR . 10.5 p -147.98 130.88 16.16 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' B' ' 97' ' ' LEU . 4.6 mp -91.29 100.86 13.59 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.421 -0.799 . . . . 0.0 109.698 -179.453 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.544 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.8 m-20 -102.2 123.37 45.92 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.961 -1.087 . . . . 0.0 109.111 179.352 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.836 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.09 -0.957 . . . . 0.0 109.241 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.494 1.509 0 N-CA-C 110.041 -0.792 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -83.55 133.78 34.85 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 30.7 t -132.69 122.5 47.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.756 -177.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.74 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.4 OUTLIER -132.46 -79.46 0.5 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.612 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 60.1 mt 28.27 38.64 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.095 178.298 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 25.7 m0 16.51 52.75 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 CA-C-O 121.252 0.549 . . . . 0.0 111.619 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 9.9 mt-30 -142.09 -179.46 6.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 109.868 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -75.62 122.35 86.97 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 1.064 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 75.73 4.46 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.078 1.852 . . . . 0.0 109.836 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.529 ' CD2' ' CB ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -91.78 154.91 18.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.904 . . . . 0.0 109.695 -179.543 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.623 HG21 HG12 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -147.91 134.98 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 0.0 109.908 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.653 ' CG2' HD23 ' B' ' 19' ' ' LEU . 6.9 m -68.15 105.1 1.97 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.766 -1.208 . . . . 0.0 108.555 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.052 HG22 HG13 ' B' ' 66' ' ' ILE . 1.2 pt -92.86 156.75 3.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.944 -1.098 . . . . 0.0 110.261 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.793 ' HG3' HD12 ' B' ' 19' ' ' LEU . 10.5 tttm -121.99 100.06 6.78 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.762 ' CD1' HG11 ' B' ' 75' ' ' VAL . 13.1 mt -116.71 124.24 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.108 -0.995 . . . . 0.0 110.122 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.83 38.86 93.04 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 68.45 21.13 74.21 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.526 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -110.13 171.0 7.71 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.201 -1.176 . . . . 0.0 109.136 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.793 HD12 ' HG3' ' B' ' 14' ' ' LYS . 0.1 OUTLIER -148.14 124.36 10.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.298 -0.876 . . . . 0.0 110.565 -179.378 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mtmp? -151.05 169.23 22.33 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.547 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -81.92 119.02 23.41 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 120.989 -1.069 . . . . 0.0 109.197 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.968 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -94.91 130.51 41.49 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.312 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.524 HD21 ' O ' ' A' ' 27' ' ' GLY . 19.0 tp -92.89 92.34 7.85 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 1.064 HD12 ' HB2' ' B' ' 9' ' ' PRO . 92.4 mt -44.11 96.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.287 -0.883 . . . . 0.0 108.998 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.784 ' HB3' HG23 ' B' ' 84' ' ' ILE . 3.8 t0 -105.64 86.53 2.42 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.4 -0.813 . . . . 0.0 109.555 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.665 HG23 HD13 ' B' ' 90' ' ' LEU . 0.6 OUTLIER -63.2 -9.44 11.22 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.267 -0.896 . . . . 0.0 109.443 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.604 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.26 -41.13 47.44 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.543 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -76.36 145.45 39.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.176 -1.191 . . . . 0.0 109.417 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.93 -16.22 60.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.322 -0.861 . . . . 0.0 111.614 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.786 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -139.03 -167.47 2.23 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.548 -1.345 . . . . 0.0 110.255 -179.532 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.697 HG23 ' O ' ' B' ' 84' ' ' ILE . 23.5 m -107.88 93.71 4.68 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.247 -0.908 . . . . 0.0 110.695 -178.266 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.0 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.22 167.2 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.133 -0.98 . . . . 0.0 108.599 179.171 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.124 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.56 136.89 4.66 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.826 -1.171 . . . . 0.0 111.188 -178.258 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.592 ' O ' HG13 ' B' ' 77' ' ' VAL . 2.9 tt0 -45.31 157.35 0.09 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.83 . . . . 0.0 109.436 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.668 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.0 mt-10 -49.52 151.28 1.65 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.227 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 4.9 ptm -173.33 161.86 4.25 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.455 -0.778 . . . . 0.0 109.035 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 23.5 t -82.17 110.38 17.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.152 -0.967 . . . . 0.0 110.046 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.771 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 48.4 mt -119.36 175.98 1.95 Allowed Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.718 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.771 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.4 Cg_endo -71.79 -161.9 0.11 Allowed 'Trans proline' 0 C--N 1.319 -1.006 0 C-N-CA 121.539 1.493 . . . . 0.0 111.945 -178.248 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.73 35.86 4.74 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -178.335 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.4 mmt-85 -118.18 62.92 0.76 Allowed 'General case' 0 C--N 1.29 -1.991 0 O-C-N 121.598 -0.942 . . . . 0.0 109.042 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.705 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 8.3 p-90 -142.97 -172.35 3.65 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -149.26 139.77 13.65 Favored Pre-proline 0 C--N 1.303 -1.414 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.53 130.67 10.01 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.214 1.943 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.557 ' O ' HG22 ' B' ' 56' ' ' VAL . 3.6 ptmt -162.21 145.61 11.79 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.505 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 42.7 mtp -103.41 137.64 41.24 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.924 -1.11 . . . . 0.0 109.654 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' A' ' 50' ' ' ILE . 3.9 pt -96.45 145.78 8.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.095 -1.003 . . . . 0.0 108.392 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.87 101.27 0.86 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.53 -127.43 3.16 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.749 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.81 HD12 ' C20' ' B' ' 100' ' ' DMP . 46.4 mt -81.79 132.31 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.835 -0.803 . . . . 0.0 112.207 -177.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.545 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 89.21 -44.71 3.11 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 178.612 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.24 -162.73 34.8 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -115.72 130.76 56.97 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.435 -1.038 . . . . 0.0 109.22 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.544 HG22 ' HA2' ' A' ' 51' ' ' GLY . 23.8 pt -110.51 144.24 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.828 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 10.4 mtmm -72.08 144.06 48.84 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.298 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.557 HG22 ' O ' ' B' ' 45' ' ' LYS . 29.5 m -145.42 -170.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.103 -0.998 . . . . 0.0 109.873 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.583 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.4 mtt180 -142.4 102.16 4.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.329 -0.857 . . . . 0.0 109.332 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.679 ' HG3' HG22 ' B' ' 74' ' ' THR . 5.5 tt0 -64.77 113.07 3.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -0.893 . . . . 0.0 109.961 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.705 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 19.1 m-85 -104.38 95.51 5.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.442 -0.786 . . . . 0.0 108.941 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.1 m-20 -78.71 137.77 37.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.966 -1.084 . . . . 0.0 109.972 -179.303 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.535 ' HA ' HG23 ' B' ' 72' ' ' ILE . 1.3 mm-40 77.66 64.12 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.456 0.646 . . . . 0.0 109.869 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.797 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.6 OUTLIER -126.48 119.27 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.953 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.621 HD11 ' HG3' ' B' ' 70' ' ' LYS . 0.2 OUTLIER -72.53 85.29 1.15 Allowed 'General case' 0 C--N 1.296 -1.724 0 O-C-N 120.933 -1.104 . . . . 0.0 111.805 -177.526 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.645 ' CG2' HD11 ' B' ' 89' ' ' LEU . 4.4 tt -89.49 115.04 28.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 10.1 tt0 -89.57 117.38 28.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 1.052 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -110.27 120.68 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.244 -0.91 . . . . 0.0 108.88 179.37 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 57.95 50.71 9.9 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.446 -0.784 . . . . 0.0 109.67 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 59.76 16.77 39.73 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.48 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 69.9 m-70 -106.01 121.15 43.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.101 -1.235 . . . . 0.0 109.531 179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.621 ' HG3' HD11 ' B' ' 63' ' ' LEU . 21.4 ttpt -69.45 122.03 18.17 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.41 -0.806 . . . . 0.0 109.585 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.751 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -139.64 106.98 5.52 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 110.356 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.797 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.4 OUTLIER -87.04 139.03 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 177.811 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.18 -159.0 9.69 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 118.545 -1.788 . . . . 0.0 111.285 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.679 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.3 m -109.17 102.57 11.51 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.64 -0.917 . . . . 0.0 109.67 -179.543 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.124 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -96.91 111.38 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.241 -0.912 . . . . 0.0 111.107 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.786 HD11 ' HB3' ' B' ' 30' ' ' ASP . 1.8 mp -78.39 134.18 37.45 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.369 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.754 HG21 ' CD1' ' B' ' 38' ' ' LEU . 46.5 t -124.43 131.29 72.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 120.869 -1.144 . . . . 0.0 110.145 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.63 -160.37 11.56 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.85 40.79 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.369 2.046 . . . . 0.0 110.401 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' B' ' 32' ' ' VAL . 4.6 t -84.94 138.28 37.37 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.507 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.4 Cg_endo -79.48 23.34 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 122.475 2.117 . . . . 0.0 111.668 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.564 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -161.67 170.46 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.669 -1.269 . . . . 0.0 110.113 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 0.1 OUTLIER -110.19 92.73 4.16 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.122 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.784 HG23 ' HB3' ' B' ' 25' ' ' ASP . 20.2 mm -78.77 128.23 38.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.385 -0.822 . . . . 0.0 112.893 -175.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.968 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.4 mp -108.15 89.29 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 176.705 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -79.53 -162.36 24.26 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.313 -177.767 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.544 ' NH1' ' O ' ' B' ' 26' ' ' THR . 0.1 OUTLIER -61.89 -40.04 94.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.766 -0.844 . . . . 0.0 110.232 -179.219 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.039 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.6 p-10 -43.84 -28.89 0.48 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.141 -0.974 . . . . 0.0 109.465 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.039 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.8 mm? -107.27 -29.61 9.21 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.185 -0.947 . . . . 0.0 110.048 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.717 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 13.6 mt -72.81 -3.66 26.83 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.03 -1.044 . . . . 0.0 108.506 179.145 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.503 ' O ' ' CZ2' ' A' ' 6' ' ' TRP . 15.5 p -101.72 -20.21 15.07 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.167 -0.958 . . . . 0.0 108.857 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.751 HE21 ' HB1' ' B' ' 71' ' ' ALA . 6.7 mt-30 -82.87 -38.05 23.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.321 -0.862 . . . . 0.0 109.236 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.836 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -81.06 3.71 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.877 . . . . 0.0 108.978 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.509 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 72.5 46.25 33.36 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.311 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.717 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -82.3 136.03 35.1 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.082 -1.246 . . . . 0.0 110.728 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 4' ' ' THR . 36.3 p -131.78 129.43 40.53 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -92.34 93.08 8.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.923 -1.11 . . . . 0.0 109.495 -179.552 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 6.1 m-20 -100.39 127.27 46.76 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -0.918 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.774 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.213 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.925 ' C62' HD11 ' A' ' 84' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.578 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.013 -0.803 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 11.9 tt0 -84.15 138.94 32.75 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 177.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.8 t -140.04 116.27 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 117.857 -1.537 . . . . 0.0 111.921 -177.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.53 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.1 OUTLIER -121.34 -62.75 1.39 Allowed 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 176.874 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.594 HD23 ' O ' ' A' ' 5' ' ' LEU . 0.4 OUTLIER 35.92 26.23 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.903 177.399 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.616 ' HA ' HG21 ' B' ' 91' ' ' THR . 27.8 m95 17.82 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.298 0.57 . . . . 0.0 112.252 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.582 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -161.91 -157.47 0.48 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.215 179.856 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.478 ' HG2' ' OD1' ' B' ' 29' ' ' ASP . 40.9 mtm180 -78.8 128.82 75.64 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 120.894 -1.129 . . . . 0.0 109.893 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.64 66.02 8.86 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.36 2.04 . . . . 0.0 108.49 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.614 HD23 ' H ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -90.2 145.18 25.21 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.33 -0.856 . . . . 0.0 110.756 -178.182 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.469 HG23 ' N ' ' A' ' 12' ' ' THR . 0.6 OUTLIER -150.51 164.14 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.277 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.592 HG22 HD22 ' A' ' 19' ' ' LEU . 51.8 m -86.64 133.31 33.71 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 178.012 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.862 ' O ' HD23 ' A' ' 19' ' ' LEU . 8.3 pt -121.92 156.73 26.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.996 -1.065 . . . . 0.0 110.384 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 8.0 tttt -117.94 100.55 7.63 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.762 HD11 HD12 ' A' ' 64' ' ' ILE . 18.0 mt -112.24 145.78 17.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.368 -0.832 . . . . 0.0 110.298 -178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 39.82 41.15 1.78 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.84 44.59 94.47 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.552 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -144.13 176.56 9.22 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.121 -1.223 . . . . 0.0 108.756 179.537 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.862 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.0 mt -140.02 123.71 17.32 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 119.305 -0.958 . . . . 0.0 110.535 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -143.27 177.02 8.7 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 179.1 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.542 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 15.3 mp0 -79.86 -178.97 6.7 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.613 -1.304 . . . . 0.0 108.057 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.614 ' H ' HD23 ' A' ' 10' ' ' LEU . . . -160.81 109.53 1.62 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.841 -1.162 . . . . 0.0 110.046 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.611 HD21 ' O ' ' B' ' 27' ' ' GLY . 27.3 tp -89.26 89.36 7.88 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.669 -0.644 . . . . 0.0 109.307 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.555 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 58.2 mt -42.49 97.04 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 56.9 t0 -106.36 87.08 2.47 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.582 -0.699 . . . . 0.0 110.788 -177.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -62.15 -20.15 63.8 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.974 -1.079 . . . . 0.0 108.804 178.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.56 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -58.73 -48.24 86.07 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.55 160.63 31.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.311 -1.111 . . . . 0.0 108.591 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.414 ' OD1' ' HG2' ' B' ' 8' ' ' ARG . 61.9 m-20 -96.65 -11.21 25.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.986 -1.071 . . . . 0.0 110.421 -179.014 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.562 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -138.98 -165.56 1.86 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.089 . . . . 0.0 110.624 -179.211 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.539 ' HG1' ' HA ' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -104.0 88.54 3.05 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.069 -1.019 . . . . 0.0 111.658 -178.001 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.775 HG21 HD13 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -72.94 122.99 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.317 -1.49 . . . . 0.0 107.333 177.784 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.787 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.4 OUTLIER -131.27 131.87 44.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.539 -1.351 . . . . 0.0 111.345 -177.965 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 33' ' ' LEU . 10.5 pt-20 -41.91 152.98 0.07 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.87 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -50.36 144.44 7.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.213 -0.93 . . . . 0.0 110.239 -179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.452 ' SD ' ' O ' ' A' ' 37' ' ' SER . 0.0 OUTLIER -171.4 179.5 2.91 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.402 -0.811 . . . . 0.0 109.169 179.636 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.452 ' O ' ' SD ' ' A' ' 36' ' ' MET . 8.0 t -84.01 111.08 18.96 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.1 -1.0 . . . . 0.0 109.834 -179.658 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.845 HD11 HD12 ' A' ' 62' ' ' ILE . 18.6 tp -154.0 90.42 3.29 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 109.702 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -80.21 162.34 22.9 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.667 2.245 . . . . 0.0 110.408 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . 129.96 42.25 0.22 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.486 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER 61.1 150.68 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.658 -0.907 . . . . 0.0 109.047 -179.658 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.609 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 26.8 p-90 -154.2 158.38 40.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.101 -0.999 . . . . 0.0 109.807 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -120.67 138.38 27.47 Favored Pre-proline 0 C--N 1.299 -1.613 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.16 134.42 17.53 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 121.568 1.512 . . . . 0.0 108.736 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 46' ' ' MET . 7.1 tttt -148.15 163.49 36.79 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.548 -178.716 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.498 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 3.9 tpt -134.16 114.13 12.77 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.074 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.775 HD13 HG21 ' A' ' 32' ' ' VAL . 17.5 pt -89.68 143.25 11.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.619 -1.232 . . . . 0.0 109.802 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.653 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.07 98.36 0.76 Allowed Glycine 0 N--CA 1.485 1.911 0 N-CA-C 107.916 -2.074 . . . . 0.0 107.916 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.587 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -122.96 -136.31 4.8 Favored Glycine 0 C--N 1.298 -1.559 0 C-N-CA 119.315 -1.421 . . . . 0.0 111.387 -178.168 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.922 HD12 ' C70' ' B' ' 100' ' ' DMP . 80.6 mt -78.92 132.17 32.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.768 0.794 . . . . 0.0 112.962 -177.339 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 85.81 -41.58 3.09 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.84 -165.11 36.16 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.493 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.653 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 1.1 m-85 -111.04 138.89 46.89 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.647 -0.914 . . . . 0.0 109.244 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.55 HG12 HD11 ' A' ' 47' ' ' ILE . 4.9 pt -119.71 134.13 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.853 -1.154 . . . . 0.0 108.854 178.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.496 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 4.2 mttp -74.86 133.38 41.86 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.954 -1.091 . . . . 0.0 110.119 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 1.025 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.2 m -144.57 166.77 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.255 -0.903 . . . . 0.0 109.773 179.765 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.516 ' HG2' ' CE3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -111.31 172.8 6.67 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.828 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.51 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 37.1 tt0 -135.02 102.82 5.34 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.839 -1.163 . . . . 0.0 110.815 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.609 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 87.8 m-85 -91.31 123.0 34.41 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.504 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -96.37 145.82 25.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 110.463 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.504 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.8 OUTLIER 75.96 64.51 0.05 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.65 -0.656 . . . . 0.0 110.147 179.425 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.845 HD12 HD11 ' A' ' 38' ' ' LEU . 15.2 mm -124.13 119.91 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.331 -0.855 . . . . 0.0 109.473 179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.776 HD21 ' HG3' ' A' ' 70' ' ' LYS . 3.2 tm? -69.85 94.81 0.86 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.665 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.762 HD12 HD11 ' A' ' 15' ' ' ILE . 9.5 tt -96.62 119.2 44.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.1 tt0 -89.7 103.38 16.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.004 -1.06 . . . . 0.0 109.899 -178.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.838 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -96.76 116.18 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.199 -0.938 . . . . 0.0 109.821 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 62.32 17.13 9.11 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.809 -0.557 . . . . 0.0 110.683 178.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.33 6.73 55.16 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.745 -1.217 . . . . 0.0 110.409 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -104.64 133.79 48.89 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.186 -1.184 . . . . 0.0 109.196 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.776 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -76.09 130.95 39.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.966 . . . . 0.0 109.042 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -150.06 97.96 2.64 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.453 -0.78 . . . . 0.0 110.465 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.568 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -79.03 137.15 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.642 -1.286 . . . . 0.0 107.883 178.791 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.418 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -157.93 -167.88 19.49 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.536 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 31' ' ' THR . 26.0 m -97.7 102.08 13.75 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.533 -0.981 . . . . 0.0 109.516 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.787 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.8 OUTLIER -91.47 173.91 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.265 -0.897 . . . . 0.0 109.357 179.727 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -132.54 163.3 29.16 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 179.557 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.87 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.2 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 120.948 -1.095 . . . . 0.0 110.457 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 1.025 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -139.82 -169.53 11.67 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 47.27 2.49 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.551 2.167 . . . . 0.0 110.791 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.684 HG21 HG13 ' A' ' 32' ' ' VAL . 14.8 t -91.02 139.87 25.9 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.147 -0.971 . . . . 0.0 109.133 179.649 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.34 19.51 0.93 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.696 2.264 . . . . 0.0 112.646 -178.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 1.2 t -160.24 171.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.415 -1.428 . . . . 0.0 110.396 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.574 ' N ' HG13 ' A' ' 82' ' ' VAL . 28.7 m120 -104.9 83.74 2.04 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.273 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.673 ' CG1' HG12 ' A' ' 32' ' ' VAL . 7.7 mm -75.74 113.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.461 -0.775 . . . . 0.0 111.712 -176.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.537 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -93.92 94.09 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.774 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.84 -172.25 41.41 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.797 -1.19 . . . . 0.0 111.589 -177.739 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 88' ' ' ASN . 1.2 mtt-85 -56.69 -36.05 69.17 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.957 -0.731 . . . . 0.0 110.38 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.778 ' ND2' HD23 ' A' ' 89' ' ' LEU . 5.8 p-10 -43.39 -40.45 3.7 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.057 -1.027 . . . . 0.0 109.15 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.778 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -94.53 -30.04 14.6 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.318 -0.864 . . . . 0.0 111.02 -179.299 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.801 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 28.2 mt -65.99 -6.83 13.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.533 -1.354 . . . . 0.0 109.795 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.793 HG21 ' CG ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -101.42 -15.0 17.33 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.978 -1.076 . . . . 0.0 109.101 179.743 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.486 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -80.0 -41.15 26.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.577 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.819 HD12 ' CG ' ' B' ' 99' ' ' PHE . 4.5 pt -82.71 5.49 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.955 . . . . 0.0 108.756 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.52 41.64 35.67 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.876 -1.289 . . . . 0.0 109.876 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' A' ' 90' ' ' LEU . . . -81.81 137.8 35.23 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 120.882 -1.363 . . . . 0.0 110.09 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.821 HG22 ' CG2' ' B' ' 4' ' ' THR . 11.2 p -136.6 130.38 32.23 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' B' ' 97' ' ' LEU . 1.9 mp -88.26 92.16 9.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.747 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.559 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.0 m-20 -95.35 123.42 38.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.095 -1.003 . . . . 0.0 109.407 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.872 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 117.93 -1.034 . . . . 0.0 109.529 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.604 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.498 1.778 0 N-CA-C 110.326 -0.682 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -85.01 131.6 34.45 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.262 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 16.5 t -127.37 127.76 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.851 -1.156 . . . . 0.0 110.859 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.821 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -149.44 25.78 0.86 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -82.47 45.07 0.93 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.705 -0.622 . . . . 0.0 110.94 -178.135 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.793 ' CG ' HG21 ' A' ' 91' ' ' THR . 13.8 m95 18.84 51.7 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.177 0.513 . . . . 0.0 111.214 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.531 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.5 OUTLIER -141.53 -168.5 2.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.982 -1.074 . . . . 0.0 110.336 -179.224 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.414 ' HG2' ' OD1' ' A' ' 29' ' ' ASP . 0.2 OUTLIER -91.76 128.94 44.13 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.399 -0.813 . . . . 0.0 109.148 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.3 Cg_endo -76.52 72.83 5.41 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.305 2.003 . . . . 0.0 109.879 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.506 HD22 ' HB2' ' B' ' 21' ' ' GLU . 3.2 mt -95.68 134.75 38.23 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.753 -1.217 . . . . 0.0 109.936 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.454 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -140.44 154.71 22.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.7 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.09 102.78 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 178.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.981 ' CD1' HD12 ' B' ' 15' ' ' ILE . 1.7 pp -87.64 148.68 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.466 -0.772 . . . . 0.0 109.649 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.518 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 16.8 ttmt -117.38 107.88 14.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.399 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.981 HD12 ' CD1' ' B' ' 13' ' ' ILE . 0.9 OUTLIER -117.39 125.26 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.151 -0.968 . . . . 0.0 109.647 -179.6 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.36 14.29 68.87 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 6.71 69.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.518 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.2 mt-30 -97.83 167.55 10.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.324 -1.103 . . . . 0.0 108.839 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.464 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 16.2 mt -131.99 129.73 40.52 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.122 -0.986 . . . . 0.0 111.164 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.606 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -149.79 168.61 23.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 177.91 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.546 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 7.2 pt-20 -78.3 -166.09 0.78 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.684 ' HB2' HG23 ' B' ' 13' ' ' ILE . . . -168.8 109.84 0.5 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.844 -1.16 . . . . 0.0 109.955 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.558 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.1 tp -83.76 93.66 8.0 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.458 -0.777 . . . . 0.0 109.181 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.705 HD22 HG21 ' B' ' 85' ' ' ILE . 26.7 mt -44.63 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 7.5 t0 -99.01 81.78 2.64 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.583 -0.698 . . . . 0.0 109.897 -178.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.557 ' CG2' ' HD3' ' B' ' 87' ' ' ARG . 10.6 m -58.6 -17.27 20.53 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.611 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.26 -43.98 96.2 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.594 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -72.31 169.33 16.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.133 -1.216 . . . . 0.0 108.852 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.478 ' OD1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -100.31 -20.37 15.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 110.217 -179.198 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 4.8 m-20 -132.9 -166.88 1.82 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.994 -1.066 . . . . 0.0 110.206 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' B' ' 33' ' ' LEU . 9.0 m -107.02 89.3 2.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.816 -1.178 . . . . 0.0 111.397 -177.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.96 HG13 HG21 ' B' ' 80' ' ' THR . 0.6 OUTLIER -68.63 160.45 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.347 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.889 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -157.83 133.92 9.39 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.759 -1.213 . . . . 0.0 111.394 -177.741 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.469 ' OE1' ' O ' ' B' ' 80' ' ' THR . 15.1 tp10 -42.34 141.88 0.88 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.479 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.732 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -41.07 150.47 0.08 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.462 -0.774 . . . . 0.0 110.252 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.49 ' HE1' ' O ' ' B' ' 15' ' ' ILE . 0.1 OUTLIER -170.66 -175.87 1.94 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 11.1 t -109.48 101.76 10.68 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.826 -1.171 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.905 HD12 HG21 ' B' ' 77' ' ' VAL . 6.2 mt -97.08 170.25 7.55 Favored Pre-proline 0 N--CA 1.489 1.482 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.207 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.579 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.0 Cg_endo -76.06 68.31 6.61 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.407 2.071 . . . . 0.0 112.537 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 32.75 -157.27 0.01 OUTLIER Glycine 0 N--CA 1.498 2.771 0 CA-C-O 121.918 0.732 . . . . 0.0 111.594 178.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 54.31 81.91 0.1 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.312 -1.11 . . . . 0.0 109.213 -179.711 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.544 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 58.0 p-90 -155.84 -176.19 5.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.531 -0.73 . . . . 0.0 109.581 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -141.09 159.52 61.35 Favored Pre-proline 0 N--CA 1.489 1.496 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.264 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.93 139.94 12.4 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 C-N-CA 122.249 1.966 . . . . 0.0 110.998 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.644 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -148.38 118.63 7.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.401 -0.812 . . . . 0.0 108.977 179.543 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.521 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -96.24 129.57 43.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.05 -1.031 . . . . 0.0 109.557 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.602 HD11 HD11 ' B' ' 54' ' ' ILE . 41.0 pt -117.14 132.0 68.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.099 179.01 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.94 100.97 0.84 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 107.976 -2.049 . . . . 0.0 107.976 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.425 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -118.61 -125.87 3.51 Favored Glycine 0 N--CA 1.483 1.804 0 C-N-CA 119.184 -1.484 . . . . 0.0 111.038 -178.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.605 HG13 ' H62' ' B' ' 100' ' ' DMP . 52.9 mt -84.56 121.41 36.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.568 -0.96 . . . . 0.0 112.981 -177.089 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.506 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 100.74 -36.8 3.92 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.172 177.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 169.86 -154.83 24.2 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.553 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.614 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.5 OUTLIER -120.4 140.76 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.53 -0.983 . . . . 0.0 109.718 -179.659 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.89 HD13 HG23 ' A' ' 50' ' ' ILE . 12.5 pt -124.33 132.07 71.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.311 -0.868 . . . . 0.0 108.976 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.524 ' O ' ' HD3' ' B' ' 79' ' ' PRO . 15.2 mttt -77.45 140.3 39.82 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.047 -1.033 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.897 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.0 m -138.56 175.07 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 109.956 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.421 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 18.4 mtt-85 -124.86 102.35 7.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.501 -0.749 . . . . 0.0 109.054 179.622 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.559 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.7 OUTLIER -60.28 94.75 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.47 -0.769 . . . . 0.0 110.772 -179.653 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 29.9 m-85 -89.88 114.4 26.17 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.566 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -93.47 143.18 26.53 Favored 'General case' 0 C--N 1.296 -1.748 0 O-C-N 120.912 -1.117 . . . . 0.0 110.337 -178.83 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.566 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 73.18 63.08 0.1 Allowed 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.368 0.604 . . . . 0.0 110.54 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 8.1 mm -120.53 110.76 29.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 178.649 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.623 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.0 OUTLIER -63.15 87.41 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.033 -1.042 . . . . 0.0 110.768 -178.515 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.893 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.0 tt -89.85 122.36 41.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.467 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 1.2 tt0 -90.0 116.96 28.44 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.995 -1.066 . . . . 0.0 109.108 -179.316 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.665 HD12 HG12 ' B' ' 64' ' ' ILE . 0.4 OUTLIER -111.63 131.65 62.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.277 -0.889 . . . . 0.0 109.351 -179.813 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.3 m 45.27 58.95 3.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.642 -0.661 . . . . 0.0 110.856 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 68' ' ' GLY . . . . . 0.467 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 53.07 31.19 40.07 Favored Glycine 0 N--CA 1.495 2.598 0 C-N-CA 120.163 -1.017 . . . . 0.0 110.865 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -132.62 142.71 49.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.337 . . . . 0.0 109.453 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.505 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -75.44 138.15 41.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 109.809 -179.683 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.665 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -159.03 98.71 1.48 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.955 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.623 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.01 159.96 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.798 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.491 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.18 -171.8 44.64 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.029 -2.034 . . . . 0.0 112.335 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.559 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 5.9 m -95.47 106.64 18.73 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.809 -0.818 . . . . 0.0 110.475 -179.353 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.854 HG13 HD13 ' B' ' 33' ' ' LEU . 1.6 t -98.11 108.81 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.627 -0.67 . . . . 0.0 110.618 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.59 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -80.95 125.32 29.99 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.041 -1.037 . . . . 0.0 108.549 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.905 HG21 HD12 ' B' ' 38' ' ' LEU . 1.4 t -104.18 111.3 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.224 -0.922 . . . . 0.0 110.054 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.897 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -145.27 -171.56 15.03 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 179.523 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.524 ' HD3' ' O ' ' B' ' 55' ' ' LYS . 35.3 Cg_endo -79.91 43.13 1.44 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.502 2.134 . . . . 0.0 111.091 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.96 HG21 HG13 ' B' ' 32' ' ' VAL . 2.9 t -89.03 138.29 29.2 Favored Pre-proline 0 N--CA 1.488 1.433 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.725 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.5 Cg_endo -80.42 21.78 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.508 2.139 . . . . 0.0 111.328 -178.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.725 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.8 t -161.32 161.1 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.623 -1.298 . . . . 0.0 111.029 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.606 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 1.9 m-80 -90.77 88.78 7.21 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.024 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.724 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.8 mm -78.85 118.93 27.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.041 -1.037 . . . . 0.0 111.422 -176.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.705 HG21 HD22 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -102.04 99.74 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 177.847 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -85.37 -163.08 36.83 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.871 -1.143 . . . . 0.0 110.704 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HD3' ' CG2' ' B' ' 26' ' ' THR . 7.5 mmm180 -63.65 -29.03 70.32 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.653 -0.91 . . . . 0.0 110.113 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.02 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.8 p-10 -52.53 -40.06 62.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.673 -1.267 . . . . 0.0 109.237 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.02 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.3 mm? -96.04 -15.86 21.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.904 -179.056 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.845 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 34.4 mt -85.18 -4.18 59.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.866 -1.146 . . . . 0.0 108.827 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.616 HG21 ' HA ' ' A' ' 6' ' ' TRP . 68.9 p -101.83 -13.93 17.48 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.324 -0.86 . . . . 0.0 108.748 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.818 ' OE1' HD13 ' B' ' 89' ' ' LEU . 33.0 mt-30 -87.0 -36.44 18.24 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.41 -0.806 . . . . 0.0 109.281 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.872 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -85.38 4.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.803 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 78.48 31.07 47.12 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.041 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.845 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -74.15 132.79 42.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.336 . . . . 0.0 110.353 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 17.1 p -140.81 129.44 22.81 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.418 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -86.04 94.46 9.24 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.329 -0.857 . . . . 0.0 109.312 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 13.0 m-20 -96.26 122.63 39.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.112 -0.992 . . . . 0.0 109.207 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.819 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.421 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.922 ' C70' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.478 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.493 1.476 0 N-CA-C 109.884 -0.852 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.438 ' HG2' ' N ' ' A' ' 3' ' ' VAL . 1.2 tt0 -84.29 141.04 31.22 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.586 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 10.8 t -135.68 112.66 13.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.464 -1.397 . . . . 0.0 110.071 -178.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.807 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.5 OUTLIER -128.3 -78.5 0.57 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.856 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.708 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.4 OUTLIER 34.94 37.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.802 -0.562 . . . . 0.0 110.268 179.983 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' A' ' 5' ' ' LEU . 43.7 m0 16.1 53.77 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 121.065 0.459 . . . . 0.0 112.204 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.708 ' HB2' HD12 ' A' ' 5' ' ' LEU . 1.6 mm-40 -156.35 -174.84 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.992 -1.067 . . . . 0.0 109.937 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -68.43 115.33 28.63 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.265 -0.897 . . . . 0.0 109.402 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.4 Cg_endo -77.15 72.68 5.79 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.12 1.88 . . . . 0.0 110.359 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.797 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -81.76 152.77 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -0.887 . . . . 0.0 108.998 179.715 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.771 HG23 HG23 ' A' ' 13' ' ' ILE . 26.9 m -139.07 129.16 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.166 -0.959 . . . . 0.0 110.38 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.503 HG22 HD22 ' A' ' 19' ' ' LEU . 4.4 m -67.74 92.01 0.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 178.186 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.907 HD11 HD21 ' A' ' 33' ' ' LEU . 3.0 pt -88.74 147.21 5.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.462 -0.774 . . . . 0.0 110.886 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.9 tttt -109.11 100.37 9.55 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.018 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.709 HD12 ' CD2' ' A' ' 33' ' ' LEU . 3.4 mt -117.17 136.16 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.87 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' A' ' 18' ' ' GLN . . . 63.34 25.07 68.1 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.134 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.8 17.78 79.92 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.669 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 15.3 mp0 -123.75 -174.67 3.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -1.158 . . . . 0.0 108.919 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 44.0 mt -137.97 135.48 36.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.137 -0.977 . . . . 0.0 110.06 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.508 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -148.97 148.69 30.07 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.797 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.6 mm-40 -78.61 109.06 12.48 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.947 -1.095 . . . . 0.0 109.295 -179.338 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.046 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -95.05 116.95 29.35 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 122.02 0.914 . . . . 0.0 111.265 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.469 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 8.3 tp -72.46 103.09 3.37 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.1 mt -46.65 131.03 11.54 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.105 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.763 ' HB2' HG23 ' A' ' 84' ' ' ILE . 3.6 t70 -139.34 86.57 2.13 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.167 -0.958 . . . . 0.0 111.091 -177.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.967 HG21 HD22 ' A' ' 97' ' ' LEU . 1.5 m -65.64 -11.64 46.42 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.97 -1.081 . . . . 0.0 108.4 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.701 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -72.74 -44.7 37.9 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.061 -1.616 . . . . 0.0 109.061 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.49 157.79 36.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -1.162 . . . . 0.0 108.936 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -99.18 -9.5 23.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.036 . . . . 0.0 110.226 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -138.57 177.93 7.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.944 -1.098 . . . . 0.0 110.297 -179.428 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.689 HG22 ' CD1' ' A' ' 33' ' ' LEU . 37.6 m -101.78 102.23 12.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.036 -1.04 . . . . 0.0 109.44 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.778 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -97.11 115.42 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.353 -0.842 . . . . 0.0 109.88 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.054 HD13 ' CG1' ' A' ' 75' ' ' VAL . 6.6 mp -106.52 123.13 47.62 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.309 -0.869 . . . . 0.0 109.767 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.704 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.0 pt-20 -43.09 165.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 108.915 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.539 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.5 tt0 -42.7 137.48 2.22 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 110.067 -179.206 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.489 ' SD ' HD13 ' A' ' 38' ' ' LEU . 2.0 ppp? -153.78 -162.33 1.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.565 -0.709 . . . . 0.0 109.372 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.529 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 11.7 t -106.2 100.93 10.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 110.275 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.763 HD23 ' CD2' ' A' ' 59' ' ' TYR . 1.4 tp -127.95 149.65 71.4 Favored Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.5 Cg_endo -73.97 -156.17 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.583 2.189 . . . . 0.0 110.609 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.506 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -93.01 -155.6 32.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 72.7 43.77 0.42 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.649 -0.912 . . . . 0.0 108.893 -179.557 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.643 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 29.8 p-90 -132.22 178.21 6.98 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.8 0.809 . . . . 0.0 110.328 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.448 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 1.4 mmtp -139.12 150.99 66.76 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.25 138.67 20.37 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 122.031 1.821 . . . . 0.0 110.233 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.519 ' CG ' ' N ' ' A' ' 46' ' ' MET . 0.0 OUTLIER -147.56 167.36 24.72 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.673 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.519 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 9.1 mtp -143.56 128.28 18.23 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.108 -0.995 . . . . 0.0 108.435 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.835 HD12 HG21 ' B' ' 50' ' ' ILE . 2.1 pt -106.78 141.18 22.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.881 -1.137 . . . . 0.0 109.388 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.64 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.84 96.29 0.65 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.294 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.23 -128.43 3.76 Favored Glycine 0 N--CA 1.481 1.659 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.854 -178.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.965 HG21 HD12 ' B' ' 47' ' ' ILE . 42.5 mt -81.2 118.22 28.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.775 -0.838 . . . . 0.0 112.511 -177.487 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.16 -42.61 1.87 Allowed Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.302 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 167.43 -157.98 30.63 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 120.875 -1.368 . . . . 0.0 110.068 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.64 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.1 m-85 -114.62 140.6 48.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.436 -1.038 . . . . 0.0 109.784 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.607 HG22 ' HA2' ' B' ' 51' ' ' GLY . 0.9 OUTLIER -116.51 179.53 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.251 -0.906 . . . . 0.0 108.703 179.039 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 10.0 mttm -115.02 141.24 48.26 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.17 -0.957 . . . . 0.0 108.545 179.124 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 4.5 m -144.52 172.1 5.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.941 -1.1 . . . . 0.0 110.641 -178.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.456 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.9 mtt180 -118.96 98.37 6.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.516 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 3.3 tt0 -59.18 91.91 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.125 -0.984 . . . . 0.0 110.155 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.763 ' CD2' HD23 ' A' ' 38' ' ' LEU . 13.6 m-85 -88.5 92.73 9.29 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 178.636 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.402 ' HB3' ' OE1' ' A' ' 61' ' ' GLN . 7.3 m-20 -78.79 143.37 36.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 110.811 -178.161 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.4 mm100 69.44 67.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-O 121.51 0.672 . . . . 0.0 109.6 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.521 HG13 ' HB3' ' A' ' 59' ' ' TYR . 1.2 mm -126.97 111.48 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.976 HD13 ' N ' ' A' ' 64' ' ' ILE . 3.3 tm? -50.97 143.27 10.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.163 -0.96 . . . . 0.0 109.469 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.976 ' N ' HD13 ' A' ' 63' ' ' LEU . 6.9 tt -150.79 113.89 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 36.8 tt0 -89.02 102.86 15.51 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.815 -1.178 . . . . 0.0 108.753 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.88 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -96.89 112.84 29.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-O 121.852 0.834 . . . . 0.0 108.908 -179.652 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 0.1 OUTLIER 71.13 -84.01 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.32 28.2 0.88 Allowed Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -129.68 128.49 42.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -1.112 . . . . 0.0 109.328 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.809 ' HG2' HD21 ' A' ' 63' ' ' LEU . 1.0 OUTLIER -78.79 136.28 37.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.754 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.839 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -151.94 131.81 13.31 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -0.995 . . . . 0.0 110.681 -179.045 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.711 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -95.39 148.1 5.39 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 177.848 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -166.39 -171.53 32.63 Favored Glycine 0 N--CA 1.49 2.295 0 C-N-CA 118.401 -1.857 . . . . 0.0 111.48 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.516 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 63.9 m -102.81 105.2 15.56 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.436 -1.038 . . . . 0.0 110.205 -179.452 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.054 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.36 167.49 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.586 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.778 ' HB2' HG23 ' A' ' 32' ' ' VAL . 2.1 mp -139.52 107.44 5.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.934 -1.104 . . . . 0.0 108.367 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.539 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 31.9 t -88.37 114.04 26.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 -178.41 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -150.41 -171.34 18.6 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.51 40.16 0.94 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.588 2.192 . . . . 0.0 111.183 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.704 HG22 ' HA ' ' A' ' 34' ' ' GLU . 5.7 t -82.9 142.3 44.79 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.65 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.4 Cg_endo -79.32 16.3 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.421 2.08 . . . . 0.0 111.356 -178.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.704 HG12 ' CG1' ' A' ' 84' ' ' ILE . 2.8 t -161.44 160.43 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.828 -1.17 . . . . 0.0 110.983 -178.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.665 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 17.7 m120 -94.35 143.55 26.3 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 103.053 -2.943 . . . . 0.0 103.053 174.408 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.763 HG23 ' HB2' ' A' ' 25' ' ' ASP . 18.4 mt -146.91 135.12 15.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 O-C-N 119.295 -2.128 . . . . 0.0 112.562 -176.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 1.046 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.91 107.34 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.05 -167.4 43.47 Favored Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.089 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.581 ' O ' HG23 ' A' ' 91' ' ' THR . 1.9 mmm180 -60.05 -31.71 70.24 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.408 -1.054 . . . . 0.0 109.173 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.051 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.1 p-10 -54.58 -28.47 46.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 110.53 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.051 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.6 mm? -104.57 -29.12 10.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.83 -1.169 . . . . 0.0 110.062 -179.096 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.584 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.3 mt -71.36 -5.59 33.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.992 -1.068 . . . . 0.0 108.982 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 87' ' ' ARG . 70.0 p -101.38 -20.91 14.98 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.143 -0.973 . . . . 0.0 109.327 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 42.9 mm-40 -81.52 -40.35 23.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 109.061 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.965 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -80.13 -2.93 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.202 -0.936 . . . . 0.0 108.655 178.821 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 78.17 30.46 50.62 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.566 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -65.84 136.4 56.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.805 -1.409 . . . . 0.0 109.049 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.493 HG22 HG22 ' B' ' 4' ' ' THR . 81.5 p -131.14 125.4 32.95 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.153 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.967 HD22 HG21 ' A' ' 26' ' ' THR . 1.7 mp -84.5 93.91 8.43 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.525 0.679 . . . . 0.0 110.108 -178.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 7.1 m-20 -108.37 130.52 55.21 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.737 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 117.949 -1.024 . . . . 0.0 109.09 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.445 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.565 0 N-CA-C 109.989 -0.812 . . . . 0.0 109.989 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.536 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tt0 -83.96 149.38 26.35 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.059 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.536 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 6.7 t -150.25 117.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 120.665 -1.272 . . . . 0.0 109.582 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.592 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.9 OUTLIER -108.62 13.34 25.28 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.552 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.521 ' O ' ' CZ ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -26.53 84.32 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 121.641 0.734 . . . . 0.0 111.25 -179.037 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.592 ' N ' ' O ' ' B' ' 4' ' ' THR . 16.1 m95 -53.48 -16.67 1.56 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.441 ' O ' ' HG3' ' A' ' 87' ' ' ARG . 30.7 mt-30 -109.42 -106.52 0.35 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.157 -0.964 . . . . 0.0 109.602 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.423 ' HE ' ' CD1' ' B' ' 10' ' ' LEU . 6.1 mtp180 -111.22 120.56 42.76 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 120.945 -1.097 . . . . 0.0 110.705 -179.207 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.46 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 37.3 Cg_endo -80.45 62.02 8.4 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.268 1.979 . . . . 0.0 109.692 177.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 1.6 mt -81.66 148.85 28.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.076 -1.015 . . . . 0.0 110.327 -179.09 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 1.059 HG22 ' HB3' ' B' ' 22' ' ' ALA . 5.2 m -141.46 142.69 28.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.448 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' B' ' 19' ' ' LEU . 14.4 m -81.92 96.74 7.77 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.032 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -84.3 152.41 3.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.227 -0.921 . . . . 0.0 110.41 -178.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.458 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -118.01 101.74 8.49 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.208 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.842 HG23 ' CG2' ' B' ' 62' ' ' ILE . 40.6 mt -105.8 127.14 61.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.07 -1.018 . . . . 0.0 109.515 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.8 -86.16 0.36 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.606 -1.798 . . . . 0.0 108.606 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.76 25.6 0.32 Allowed Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.039 -2.025 . . . . 0.0 108.039 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -121.0 171.01 8.95 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.739 -0.859 . . . . 0.0 108.749 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' B' ' 12' ' ' THR . 14.4 mt -134.28 130.72 37.49 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.296 -0.877 . . . . 0.0 109.924 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -139.99 166.99 23.16 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 179.628 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.574 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.6 mt-10 -78.73 -179.94 6.81 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.688 -1.257 . . . . 0.0 107.876 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 1.059 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -158.03 105.26 1.94 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.816 -1.178 . . . . 0.0 110.821 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.701 HD21 ' O ' ' A' ' 27' ' ' GLY . 25.5 tp -77.35 95.52 4.42 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.48 HD22 ' HA ' ' B' ' 24' ' ' LEU . 0.2 OUTLIER -40.44 97.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.881 ' HB2' HG23 ' B' ' 84' ' ' ILE . 12.0 t0 -102.57 76.58 1.54 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.443 -0.785 . . . . 0.0 110.707 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.946 HG23 HD23 ' B' ' 90' ' ' LEU . 2.7 m -62.91 -11.19 16.81 Favored 'General case' 0 C--N 1.297 -1.679 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.118 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.475 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -79.59 -38.77 19.79 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.04 158.51 36.37 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.093 -1.239 . . . . 0.0 109.065 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -90.68 -11.5 39.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.972 -1.08 . . . . 0.0 110.437 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.538 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -138.88 -164.2 1.61 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.889 -1.132 . . . . 0.0 109.988 -179.646 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.661 HG23 ' O ' ' B' ' 84' ' ' ILE . 16.8 m -115.67 92.76 4.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.927 -1.108 . . . . 0.0 109.718 -179.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.64 174.19 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.087 -1.008 . . . . 0.0 109.299 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.149 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.0 OUTLIER -171.31 123.25 0.57 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.792 -1.192 . . . . 0.0 110.811 -178.531 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.625 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.6 OUTLIER -42.85 159.75 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.232 -0.917 . . . . 0.0 108.774 178.381 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.886 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -50.61 148.15 4.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.9 -1.125 . . . . 0.0 110.475 -179.284 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.526 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.4 ptm -155.12 -164.53 1.8 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.211 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.526 ' N ' ' HG3' ' B' ' 36' ' ' MET . 3.9 t -105.08 67.27 0.78 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.865 -1.147 . . . . 0.0 110.116 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.657 HD13 ' CG ' ' B' ' 59' ' ' TYR . 11.6 mt -85.1 168.71 19.12 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.033 . . . . 0.0 108.726 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.589 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.6 Cg_endo -71.59 -162.52 0.11 Allowed 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.142 1.895 . . . . 0.0 111.374 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.96 29.93 8.85 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -178.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -107.94 46.12 0.97 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.655 ' CD1' ' CZ ' ' B' ' 59' ' ' TYR . 29.9 p-90 -117.73 -179.92 3.88 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.817 0.818 . . . . 0.0 110.356 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -134.27 134.12 22.41 Favored Pre-proline 0 C--N 1.3 -1.556 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.76 135.43 17.7 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 121.779 1.653 . . . . 0.0 110.414 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.652 ' HD3' HD23 ' B' ' 76' ' ' LEU . 16.2 ptmt -160.09 -165.91 1.58 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.559 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.562 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 4.3 mtp -146.56 124.7 12.14 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.451 -179.766 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.965 HD12 HG21 ' A' ' 50' ' ' ILE . 2.8 pt -89.48 143.23 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.25 113.51 2.64 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.505 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -138.65 -123.99 2.18 Favored Glycine 0 N--CA 1.481 1.7 0 C-N-CA 119.52 -1.324 . . . . 0.0 110.213 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.835 HG21 HD12 ' A' ' 47' ' ' ILE . 28.3 mt -91.22 134.82 28.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.694 -0.886 . . . . 0.0 111.968 -178.001 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.607 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 87.47 -29.78 5.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.444 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 156.12 -160.08 29.84 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.011 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -120.67 133.32 55.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.498 -1.001 . . . . 0.0 109.118 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.682 HD13 HG23 ' A' ' 50' ' ' ILE . 15.6 pt -110.66 141.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 120.941 -1.099 . . . . 0.0 109.774 -179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.562 ' HG3' ' CG ' ' B' ' 46' ' ' MET . 0.0 OUTLIER -65.21 154.23 38.68 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 179.792 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.516 HG23 ' HG2' ' B' ' 45' ' ' LYS . 19.8 m -151.13 -167.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.973 . . . . 0.0 110.005 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -145.03 96.25 2.82 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.562 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 11.3 tt0 -61.83 107.9 0.92 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 110.533 -179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.657 ' CG ' HD13 ' B' ' 38' ' ' LEU . 29.2 m-85 -102.3 95.18 6.12 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.593 ' OD1' HG23 ' B' ' 74' ' ' THR . 0.5 OUTLIER -79.13 141.61 37.12 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.829 -1.17 . . . . 0.0 109.994 -179.589 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.496 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 75.01 59.25 0.06 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.695 -0.628 . . . . 0.0 110.055 179.706 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.842 ' CG2' HG23 ' B' ' 15' ' ' ILE . 5.8 mm -121.35 121.5 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.271 -0.893 . . . . 0.0 108.984 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.92 HD13 ' O ' ' B' ' 63' ' ' LEU . 1.4 tm? -68.54 91.4 0.41 Allowed 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.138 -0.976 . . . . 0.0 110.503 -179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.632 HG22 ' O ' ' B' ' 71' ' ' ALA . 10.8 tt -97.75 120.33 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.6 tt0 -88.32 148.56 24.23 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.044 -1.035 . . . . 0.0 108.557 -179.257 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 1.032 HG13 HG22 ' B' ' 13' ' ' ILE . 1.2 mp -147.48 132.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.086 -1.009 . . . . 0.0 109.717 -179.186 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.411 ' C ' ' O ' ' B' ' 66' ' ' ILE . 54.7 m 42.79 37.9 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.533 -0.729 . . . . 0.0 109.723 179.648 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.77 48.1 51.41 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -145.71 114.42 6.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.204 -1.174 . . . . 0.0 109.445 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.75 130.85 47.28 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.632 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.8 101.19 2.74 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 110.369 -179.118 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.584 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.08 157.2 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.016 -1.052 . . . . 0.0 108.583 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.611 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 175.88 -166.33 37.5 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.908 -1.615 . . . . 0.0 111.632 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.593 HG23 ' OD1' ' B' ' 60' ' ' ASP . 16.8 m -98.03 104.86 16.93 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.528 -0.983 . . . . 0.0 110.595 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.149 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.16 109.41 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.344 -0.848 . . . . 0.0 110.255 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.652 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.4 mp -80.32 124.27 28.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.181 -0.949 . . . . 0.0 108.944 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.886 HG12 ' HA ' ' B' ' 35' ' ' GLU . 0.2 OUTLIER -106.86 125.95 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 109.784 -179.893 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -159.42 -167.21 19.76 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.468 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.8 Cg_endo -81.71 54.87 5.28 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.795 2.33 . . . . 0.0 109.916 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.625 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.3 t -97.57 138.43 21.1 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.267 -0.896 . . . . 0.0 108.93 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.445 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -80.06 16.55 1.47 Allowed 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.482 2.121 . . . . 0.0 110.71 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.575 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -161.24 172.45 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.016 -1.053 . . . . 0.0 110.206 -179.576 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.619 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 68.6 m-80 -105.03 147.76 27.49 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 104.652 -2.351 . . . . 0.0 104.652 176.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' B' ' 25' ' ' ASP . 24.7 mm -133.64 120.2 36.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 O-C-N 120.282 -1.511 . . . . 0.0 111.194 -177.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.806 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -102.14 91.9 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 177.997 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.546 ' O ' HD13 ' B' ' 90' ' ' LEU . . . -100.12 170.57 22.72 Favored Glycine 0 N--CA 1.496 2.683 0 C-N-CA 119.748 -1.215 . . . . 0.0 112.344 -177.062 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.789 ' O ' HG23 ' B' ' 91' ' ' THR . 3.7 mmt180 -21.96 -41.37 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.987 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.0 p-10 -52.43 -43.05 64.63 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.121 -1.612 . . . . 0.0 110.486 -178.398 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.987 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -91.29 -19.96 22.4 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.685 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.946 HD23 HG23 ' B' ' 26' ' ' THR . 2.2 mp -67.39 -15.22 63.56 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.789 HG23 ' O ' ' B' ' 87' ' ' ARG . 17.2 p -86.9 -18.34 31.07 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.053 -1.029 . . . . 0.0 108.801 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -87.79 -40.34 14.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.737 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.3 pt -87.28 -2.51 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.362 -0.836 . . . . 0.0 109.143 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.6 35.76 81.65 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 179.189 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.497 ' HB3' ' HB3' ' B' ' 90' ' ' LEU . . . -63.04 145.06 56.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.949 -1.324 . . . . 0.0 110.936 -179.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.807 HG22 ' CG2' ' A' ' 4' ' ' THR . 20.4 p -150.42 126.98 10.83 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.681 HD11 HD11 ' A' ' 97' ' ' LEU . 6.9 mp -86.62 103.25 14.93 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.259 -0.901 . . . . 0.0 109.187 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 31.8 m-20 -101.4 122.41 43.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.134 -0.979 . . . . 0.0 110.036 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.965 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.433 179.644 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.829 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.494 1.518 0 N-CA-C 110.551 -0.596 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -83.75 126.29 32.76 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 177.382 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.4 t -118.14 108.35 24.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.875 -1.14 . . . . 0.0 109.81 -177.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -131.71 41.0 3.33 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.582 -0.699 . . . . 0.0 109.481 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -88.34 43.08 1.1 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.144 -0.973 . . . . 0.0 108.965 179.644 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.527 ' C ' ' O ' ' A' ' 5' ' ' LEU . 16.3 m0 18.13 50.64 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.237 0.541 . . . . 0.0 111.545 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 5.3 mt-30 -155.45 163.82 39.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -0.895 . . . . 0.0 109.518 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.493 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -54.19 119.25 18.98 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.322 179.894 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.667 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.8 Cg_endo -78.47 75.07 5.12 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.212 1.941 . . . . 0.0 110.769 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.815 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -79.52 164.94 23.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.052 -1.03 . . . . 0.0 108.68 179.587 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.7 m -149.29 127.78 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.052 -1.03 . . . . 0.0 110.296 -178.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.844 HG22 HD22 ' A' ' 19' ' ' LEU . 8.1 m -64.65 91.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 178.348 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.67 HD12 HG13 ' A' ' 15' ' ' ILE . 1.0 OUTLIER -79.7 149.7 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.505 -178.372 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 18.3 tttt -117.1 91.2 3.51 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.098 HD11 HD12 ' A' ' 64' ' ' ILE . 12.5 mt -114.65 139.93 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 O-C-N 121.208 -0.933 . . . . 0.0 109.959 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 48.41 49.58 25.75 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 52.24 38.37 48.99 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.545 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.7 mm-40 -131.71 168.35 17.92 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -1.154 . . . . 0.0 109.065 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.844 HD22 HG22 ' A' ' 12' ' ' THR . 20.4 mt -137.57 128.94 28.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 0.0 109.592 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.433 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 47.0 mtmt -151.1 155.86 39.82 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.395 -0.816 . . . . 0.0 109.368 179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.815 ' HB3' HD23 ' A' ' 10' ' ' LEU . 27.1 mp0 -79.83 106.52 11.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.975 . . . . 0.0 108.68 179.459 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.661 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -87.55 132.88 33.89 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.513 -0.742 . . . . 0.0 110.787 -178.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.755 HD21 ' O ' ' B' ' 27' ' ' GLY . 6.0 tp -85.83 98.95 11.04 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.699 HD22 HD21 ' A' ' 90' ' ' LEU . 10.9 mt -45.52 97.34 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.103 -0.998 . . . . 0.0 108.522 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 1.025 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.7 t0 -100.33 90.3 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.471 -0.768 . . . . 0.0 110.503 -178.579 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -71.1 -16.49 62.57 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.983 -1.073 . . . . 0.0 108.93 178.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.49 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.07 -33.84 69.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.445 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -80.31 154.4 27.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.213 -1.169 . . . . 0.0 109.342 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -93.8 -12.98 27.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.195 -0.941 . . . . 0.0 109.831 -179.585 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.559 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -131.64 -175.19 3.63 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.163 -0.961 . . . . 0.0 109.406 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.689 HG23 HD12 ' A' ' 85' ' ' ILE . 5.9 m -110.72 87.88 2.64 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.789 -1.194 . . . . 0.0 109.808 -179.066 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -73.01 166.33 2.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.506 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.022 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.57 132.08 3.77 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.79 -1.194 . . . . 0.0 111.343 -177.853 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 80' ' ' THR . 11.3 tt0 -42.21 160.38 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.576 ' HA ' HG13 ' A' ' 77' ' ' VAL . 1.4 mt-10 -61.91 137.19 58.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.857 -1.152 . . . . 0.0 109.946 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.95 -164.01 1.89 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.414 -0.804 . . . . 0.0 109.503 179.632 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.1 t -96.73 112.26 24.09 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.123 -0.986 . . . . 0.0 110.39 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.739 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -133.49 -177.34 0.69 Allowed Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.342 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.601 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -76.4 -179.71 5.56 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.051 1.834 . . . . 0.0 110.656 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.06 29.99 10.35 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -119.76 61.7 0.83 Allowed 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.625 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 11.4 p-90 -121.83 -172.76 2.5 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.537 0.684 . . . . 0.0 109.807 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.8 mtpm? -132.85 128.21 20.65 Favored Pre-proline 0 N--CA 1.49 1.568 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -76.36 138.06 19.45 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 121.929 1.753 . . . . 0.0 110.213 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.73 ' HE2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -157.16 -179.04 7.82 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.731 179.872 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 54' ' ' ILE . 69.4 mtp -136.54 121.23 18.48 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.382 -0.824 . . . . 0.0 108.96 179.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.1 pt -88.56 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.565 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.562 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.68 98.0 0.75 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 -179.309 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.507 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -124.04 -132.29 3.88 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 119.805 -1.188 . . . . 0.0 110.509 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.834 HD11 ' CD1' ' B' ' 84' ' ' ILE . 21.6 mt -84.24 110.5 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.624 -0.927 . . . . 0.0 112.531 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.85 -13.59 17.31 Favored Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.843 177.734 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 134.27 -154.91 21.61 Favored Glycine 0 N--CA 1.49 2.271 0 C-N-CA 119.204 -1.474 . . . . 0.0 109.951 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.562 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 9.4 m-85 -116.3 127.45 54.71 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.574 -0.956 . . . . 0.0 110.255 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 46' ' ' MET . 15.8 pt -103.32 179.1 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.439 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.572 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -116.07 145.62 42.87 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.861 -1.15 . . . . 0.0 109.302 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 ' HE2' ' A' ' 45' ' ' LYS . 0.7 OUTLIER -146.49 -170.33 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.604 -1.31 . . . . 0.0 110.297 -179.843 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.425 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.8 mtm180 -133.8 94.29 3.25 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.539 ' N ' ' HE3' ' A' ' 45' ' ' LYS . 1.1 tt0 -53.44 99.56 0.03 OUTLIER 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.38 -0.825 . . . . 0.0 110.217 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.739 ' CD2' HD23 ' A' ' 38' ' ' LEU . 22.6 m-85 -98.1 84.88 3.36 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 177.58 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.837 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.4 OUTLIER -78.16 137.98 38.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 -177.604 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.515 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 51.5 mm-40 80.77 62.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.785 HG21 HG23 ' A' ' 15' ' ' ILE . 8.0 mm -124.82 122.85 64.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.893 HD21 ' CG ' ' A' ' 70' ' ' LYS . 17.0 tp -74.4 87.19 2.03 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.109 -1.036 . . . . 0.0 111.755 -177.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 1.098 HD12 HD11 ' A' ' 15' ' ' ILE . 10.9 tt -87.23 120.26 36.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.539 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -89.48 111.68 22.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.143 -0.973 . . . . 0.0 109.474 -178.634 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' CYS . 1.0 OUTLIER -106.7 125.95 62.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.102 -0.999 . . . . 0.0 109.879 -179.522 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.8 m 65.22 11.56 7.33 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.762 -0.586 . . . . 0.0 110.698 178.784 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.424 ' HA2' ' CD ' ' A' ' 65' ' ' GLU . . . 101.3 1.28 53.98 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.201 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -106.11 119.13 38.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.12 -1.223 . . . . 0.0 108.924 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.893 ' CG ' HD21 ' A' ' 63' ' ' LEU . 2.2 mptp? -63.06 139.75 58.8 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.187 -0.945 . . . . 0.0 109.415 -179.156 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.704 ' C ' HD12 ' A' ' 63' ' ' LEU . . . -151.27 143.12 23.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.307 -179.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.71 HG13 HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -113.19 138.94 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.864 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.412 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -163.05 -159.12 10.2 Favored Glycine 0 N--CA 1.483 1.77 0 C-N-CA 119.208 -1.472 . . . . 0.0 110.213 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.837 HG23 ' OD1' ' A' ' 60' ' ' ASP . 2.2 m -100.1 108.16 20.23 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.769 -0.842 . . . . 0.0 110.05 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.881 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -106.6 107.01 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.154 -0.967 . . . . 0.0 109.927 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.73 HD23 ' HE2' ' A' ' 45' ' ' LYS . 3.3 mp -78.58 128.42 33.5 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.576 HG13 ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -114.49 120.53 64.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.698 -179.573 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.561 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.0 -157.72 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.572 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -83.31 36.98 0.63 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.553 2.169 . . . . 0.0 110.758 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.725 HG21 HG13 ' A' ' 32' ' ' VAL . 3.9 t -80.59 134.56 54.1 Favored Pre-proline 0 N--CA 1.489 1.513 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.038 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.476 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -77.4 18.59 0.79 Allowed 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.497 2.131 . . . . 0.0 111.825 -178.53 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.605 ' CG1' HG13 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.02 160.3 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 109.941 -179.804 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.67 ' ND2' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -99.88 85.99 3.19 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 177.06 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 1.025 HG23 ' CB ' ' A' ' 25' ' ' ASP . 2.3 mt -83.2 122.61 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 CA-C-O 121.805 0.812 . . . . 0.0 112.902 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.689 HD12 HG23 ' A' ' 31' ' ' THR . 0.4 OUTLIER -95.98 102.67 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 177.225 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.531 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -90.87 -162.03 37.87 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.82 -1.181 . . . . 0.0 111.478 -178.204 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -57.4 -40.05 77.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.754 -0.851 . . . . 0.0 110.472 -179.237 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.021 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.3 p-10 -42.41 -39.28 2.15 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.293 -0.879 . . . . 0.0 110.011 -179.554 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.021 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.9 OUTLIER -100.59 -22.01 15.1 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 121.001 -1.062 . . . . 0.0 110.276 -179.336 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.699 HD21 HD22 ' A' ' 24' ' ' LEU . 81.2 mt -74.67 -1.63 22.65 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.061 -1.024 . . . . 0.0 108.56 179.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.0 p -99.41 -18.65 17.38 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -83.03 -41.63 18.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.391 -0.818 . . . . 0.0 108.982 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.838 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.5 pt -86.87 -10.16 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.69 45.43 44.61 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.275 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.529 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -76.03 131.45 39.52 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.932 -1.334 . . . . 0.0 109.908 179.578 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 77.8 p -129.61 137.82 50.91 Favored 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' B' ' 97' ' ' LEU . 5.9 mp -89.51 120.18 30.6 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.962 -1.086 . . . . 0.0 110.529 -179.134 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.535 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.6 m-20 -119.48 124.77 47.29 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.256 -0.903 . . . . 0.0 108.948 178.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.939 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.531 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.601 0 N-CA-C 109.964 -0.822 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.488 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.7 tt0 -88.88 150.0 23.08 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.488 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 3.3 t -149.83 126.16 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.498 -1.376 . . . . 0.0 110.441 -179.127 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.542 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -130.98 -60.04 0.97 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.733 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.655 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER 34.34 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.944 -0.472 . . . . 0.0 110.852 179.529 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.542 ' N ' ' O ' ' B' ' 4' ' ' THR . 5.5 m95 18.02 42.66 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.655 ' N ' ' O ' ' B' ' 5' ' ' LEU . 6.9 mm100 -153.01 -114.81 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.193 -0.942 . . . . 0.0 108.718 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.525 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.1 mtp180 -112.45 141.07 24.52 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 120.23 -1.543 . . . . 0.0 109.195 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 37.0 Cg_endo -82.15 50.21 3.38 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.316 2.011 . . . . 0.0 109.529 178.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.557 HD23 ' H ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -78.43 137.48 38.0 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.197 -0.939 . . . . 0.0 108.943 -179.597 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -134.15 178.97 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.453 -0.779 . . . . 0.0 109.996 -178.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.768 HG22 HD22 ' B' ' 19' ' ' LEU . 47.8 m -103.86 105.28 15.43 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.814 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.826 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.8 pp -96.17 155.37 3.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.518 -0.738 . . . . 0.0 109.862 -178.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.529 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 8.9 ttmt -122.91 100.14 6.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 110.503 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.728 HG13 HD12 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -115.38 142.64 27.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.812 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 47.98 47.13 26.2 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.351 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 55.23 36.42 62.16 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.162 -1.199 . . . . 0.0 110.398 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.9 OUTLIER -130.7 166.61 20.36 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -1.216 . . . . 0.0 108.425 179.077 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.826 HD23 ' O ' ' B' ' 13' ' ' ILE . 14.8 mt -143.23 125.28 15.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.078 -1.014 . . . . 0.0 111.409 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.503 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 1.0 OUTLIER -145.11 -170.97 3.55 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.875 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.549 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -82.45 -176.48 6.25 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.863 -1.148 . . . . 0.0 109.666 -179.846 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.854 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -163.28 91.49 0.7 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.1 -1.0 . . . . 0.0 110.89 -179.296 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.543 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 8.8 tp -68.04 93.44 0.43 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.631 -1.293 . . . . 0.0 109.658 179.315 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.824 HD23 ' HB ' ' B' ' 85' ' ' ILE . 69.8 mt -50.42 94.88 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.856 ' CB ' HG23 ' B' ' 84' ' ' ILE . 29.5 t0 -96.0 84.75 3.89 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.351 -0.843 . . . . 0.0 110.825 -178.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.579 ' HA ' HD12 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.51 -16.0 21.69 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.956 -1.09 . . . . 0.0 108.771 178.754 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.755 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -74.19 -38.85 45.98 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.452 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -70.28 162.76 27.89 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.198 -1.178 . . . . 0.0 109.318 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -101.01 -10.37 20.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.53 ' HA ' ' CG ' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -139.13 -172.57 3.37 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.134 -0.979 . . . . 0.0 110.322 -179.298 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.609 HG22 ' CD1' ' B' ' 33' ' ' LEU . 47.7 m -108.46 89.46 3.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.984 -1.072 . . . . 0.0 111.162 -178.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.897 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -73.34 169.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.54 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.125 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -168.81 130.89 1.28 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.777 -1.202 . . . . 0.0 110.683 -179.026 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.566 ' N ' HG23 ' B' ' 80' ' ' THR . 6.0 pt-20 -46.67 170.81 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.276 -0.89 . . . . 0.0 108.693 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.559 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tt0 -60.42 138.1 58.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.145 -0.972 . . . . 0.0 110.064 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.629 ' HE2' HD21 ' B' ' 38' ' ' LEU . 7.6 ptm -147.05 -163.5 1.78 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.405 -0.809 . . . . 0.0 109.324 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.529 ' N ' ' HG3' ' B' ' 36' ' ' MET . 8.4 t -113.74 98.01 6.77 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -0.881 . . . . 0.0 110.099 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.81 HD12 ' CD2' ' B' ' 59' ' ' TYR . 27.1 mt -106.38 160.39 26.39 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.128 -0.983 . . . . 0.0 109.476 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.475 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.6 Cg_endo -77.94 65.28 8.3 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.732 2.288 . . . . 0.0 112.029 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 35.78 -157.37 0.01 OUTLIER Glycine 0 N--CA 1.498 2.813 0 O-C-N 121.442 -0.786 . . . . 0.0 111.239 178.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.494 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 63.25 60.28 1.19 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.513 -0.992 . . . . 0.0 109.237 -179.865 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.7 p-90 -139.08 -175.62 4.22 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' B' ' 43' ' ' LYS . 13.7 mmtm -143.3 136.83 14.18 Favored Pre-proline 0 N--CA 1.488 1.467 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.082 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.77 125.67 7.59 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.899 1.733 . . . . 0.0 111.403 -179.009 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.82 ' CE ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -162.74 149.93 13.31 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.607 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.463 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 1.8 mtp -110.04 148.0 32.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 0.0 110.414 -178.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.803 ' CD1' HG21 ' A' ' 50' ' ' ILE . 15.5 pt -90.68 155.67 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.513 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.87 106.03 1.24 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.793 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.512 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -136.12 -128.03 2.7 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.647 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.873 HD12 ' C21' ' B' ' 100' ' ' DMP . 21.5 mt -87.91 127.46 41.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.614 -0.933 . . . . 0.0 112.683 -177.57 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 96.95 -20.75 49.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.234 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.05 -164.59 26.81 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.528 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 3.3 m-85 -105.64 125.74 51.34 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.391 -1.064 . . . . 0.0 109.701 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.7 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -96.38 139.62 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.939 -1.1 . . . . 0.0 108.964 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.579 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -78.2 143.04 37.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.806 -1.184 . . . . 0.0 108.995 -179.905 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.658 HG12 ' N ' ' B' ' 78' ' ' GLY . 0.2 OUTLIER -149.3 -173.49 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.87 -1.144 . . . . 0.0 110.074 -179.482 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.435 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 2.6 mtm-85 -121.28 96.08 4.94 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -60.38 100.18 0.09 Allowed 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.329 -0.857 . . . . 0.0 109.846 -179.092 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.81 ' CD2' HD12 ' B' ' 38' ' ' LEU . 22.3 m-85 -96.31 94.59 7.55 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.408 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 37.0 m-20 -78.78 140.01 38.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.894 -1.129 . . . . 0.0 110.626 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.681 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.3 OUTLIER 69.17 64.89 0.28 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.714 -0.616 . . . . 0.0 110.309 179.255 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.742 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.7 OUTLIER -123.82 113.12 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.188 -0.945 . . . . 0.0 108.686 179.155 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.672 HD13 ' C ' ' B' ' 63' ' ' LEU . 3.3 tm? -64.68 104.74 0.86 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.239 -0.913 . . . . 0.0 110.869 -178.428 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.633 HG22 ' O ' ' B' ' 71' ' ' ALA . 1.2 tt -107.76 122.94 62.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.3 tt0 -88.09 114.58 24.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.04 -1.037 . . . . 0.0 109.078 -179.186 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.63 HD11 HD13 ' B' ' 64' ' ' ILE . 2.2 mp -111.32 116.79 53.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.321 -0.862 . . . . 0.0 110.052 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.548 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 80.0 m 63.41 8.24 3.4 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.58 -0.7 . . . . 0.0 110.668 179.124 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 104.53 22.96 8.19 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.045 179.515 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -125.77 130.92 52.42 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.137 -1.214 . . . . 0.0 109.231 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.534 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -69.45 131.04 44.13 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.53 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.633 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.77 96.87 2.88 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.887 -179.569 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.742 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.18 136.43 24.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 179.125 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -163.6 -173.45 32.3 Favored Glycine 0 C--N 1.294 -1.792 0 C-N-CA 118.695 -1.716 . . . . 0.0 110.658 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 86.5 m -92.25 106.41 18.42 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.664 -0.903 . . . . 0.0 109.331 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.125 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -95.83 105.05 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.652 -0.655 . . . . 0.0 109.982 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.82 HD23 ' CE ' ' B' ' 45' ' ' LYS . 5.6 mp -78.99 116.82 19.54 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.559 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 79.6 t -110.86 118.16 56.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 120.945 -1.097 . . . . 0.0 110.695 -178.405 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.658 ' N ' HG12 ' B' ' 56' ' ' VAL . . . -157.24 -150.4 5.69 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.579 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -83.07 41.28 1.07 Allowed 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.959 2.439 . . . . 0.0 110.258 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.566 HG23 ' N ' ' B' ' 34' ' ' GLU . 3.5 t -90.17 129.75 44.61 Favored Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 179.225 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.552 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.02 25.86 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.168 1.912 . . . . 0.0 111.558 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.552 HG22 ' O ' ' B' ' 81' ' ' PRO . 0.2 OUTLIER -161.4 154.01 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.719 -1.238 . . . . 0.0 110.785 -179.976 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.63 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 72.1 m-20 -96.38 83.05 3.48 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 175.781 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.856 HG23 ' CB ' ' B' ' 25' ' ' ASP . 12.4 mt -78.89 115.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.08 -1.013 . . . . 0.0 112.82 -175.248 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.824 ' HB ' HD23 ' B' ' 24' ' ' LEU . 1.4 mm -95.66 93.05 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -77.87 -169.84 34.43 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.12 -1.038 . . . . 0.0 111.008 -177.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.493 ' HD2' ' HA ' ' A' ' 8' ' ' ARG . 10.1 mtp85 -58.41 -37.56 75.59 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.931 -0.746 . . . . 0.0 110.766 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.01 ' ND2' HD23 ' B' ' 89' ' ' LEU . 14.3 p-10 -46.57 -26.9 0.98 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.554 -1.341 . . . . 0.0 109.451 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.01 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -110.56 -28.87 8.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.212 -0.93 . . . . 0.0 111.132 -178.716 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.654 HD21 HD22 ' B' ' 24' ' ' LEU . 66.9 mt -65.38 -22.25 66.77 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.745 -1.222 . . . . 0.0 108.29 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.428 ' CG2' ' NH2' ' B' ' 87' ' ' ARG . 82.7 p -83.63 -18.11 39.26 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 108.97 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -79.73 -41.76 26.02 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.881 . . . . 0.0 109.569 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.939 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -82.89 -2.9 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.032 179.431 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.54 63.08 4.12 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.623 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -86.29 161.94 18.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.399 -1.059 . . . . 0.0 109.967 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.6 p -141.4 129.92 22.62 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.206 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.9 94.4 6.28 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -179.872 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.3 m-20 -105.26 130.88 53.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 110.851 -178.49 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.838 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.143 179.095 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.873 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.437 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.497 1.692 0 N-CA-C 110.76 -0.515 . . . . 0.0 110.76 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.427 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.8 tt0 -83.51 142.42 30.92 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.405 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 51.9 t -141.32 128.76 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 118.012 -1.475 . . . . 0.0 111.047 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.481 ' OG1' ' N ' ' A' ' 5' ' ' LEU . 1.3 p -132.34 -57.26 0.96 Allowed 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.205 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.0 OUTLIER 39.0 28.24 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.548 -0.72 . . . . 0.0 110.414 179.352 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.491 ' C ' ' O ' ' A' ' 5' ' ' LEU . 4.4 m95 18.02 43.91 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.411 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' A' ' 5' ' ' LEU . 15.9 mm100 -158.78 -111.5 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 108.855 179.385 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 77.1 mtt180 -111.98 134.06 21.49 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 120.621 -1.3 . . . . 0.0 109.352 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -81.18 54.4 5.19 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 122.357 2.038 . . . . 0.0 110.057 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.743 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.72 146.77 30.89 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.946 -1.096 . . . . 0.0 109.69 -179.495 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.643 HG21 HG12 ' A' ' 66' ' ' ILE . 2.4 m -138.03 136.11 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.2 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.663 HG22 HD22 ' A' ' 19' ' ' LEU . 94.9 m -60.35 113.65 2.51 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -106.24 137.02 38.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 O-C-N 121.091 -1.006 . . . . 0.0 110.419 -178.684 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 2.7 ttpt -110.45 105.17 14.05 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.407 -0.808 . . . . 0.0 109.049 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 64' ' ' ILE . 40.8 mt -118.42 122.01 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.121 -0.987 . . . . 0.0 109.887 -179.225 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.02 10.86 59.95 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 178.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.16 -7.02 60.05 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.6 178.36 6.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -1.109 . . . . 0.0 108.987 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 11.3 mt -151.06 129.66 12.24 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.236 -0.915 . . . . 0.0 110.74 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -150.61 157.0 42.46 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.743 ' HB3' HD22 ' A' ' 10' ' ' LEU . 61.6 mt-10 -77.94 131.36 37.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.576 -1.327 . . . . 0.0 108.428 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.886 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -107.7 148.03 29.96 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.086 -1.009 . . . . 0.0 110.235 -178.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' O ' ' B' ' 27' ' ' GLY . 30.9 tp -98.9 95.85 7.45 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.163 0.506 . . . . 0.0 110.431 -178.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.536 HD22 ' HB ' ' A' ' 85' ' ' ILE . 0.2 OUTLIER -47.16 115.7 1.17 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 178.916 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 12.8 t70 -131.8 108.18 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.747 -1.221 . . . . 0.0 111.15 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . 1.013 HG23 HD13 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -79.97 -2.59 44.6 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.817 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.48 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -80.74 -21.66 63.32 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.84 161.83 13.55 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.131 -1.217 . . . . 0.0 109.892 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.54 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 50.4 m-20 -92.85 -20.1 21.03 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.406 -0.809 . . . . 0.0 110.919 -179.083 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -139.17 -169.08 2.58 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.621 -1.3 . . . . 0.0 110.203 -179.438 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' THR . . . . . 1.006 ' O ' HD12 ' A' ' 76' ' ' LEU . 21.5 m -103.56 107.15 17.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.12 -0.988 . . . . 0.0 109.76 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.821 HG12 HG13 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -97.89 126.23 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.076 -1.015 . . . . 0.0 110.003 -179.469 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.046 HD13 ' CG1' ' A' ' 75' ' ' VAL . 3.8 mp -120.88 124.82 45.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.772 -1.205 . . . . 0.0 111.277 -178.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.2 pt-20 -43.77 163.45 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.295 -0.962 . . . . 0.0 108.525 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -44.25 137.84 3.32 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.033 -1.042 . . . . 0.0 110.212 -179.409 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.6 ptm -146.71 -163.16 1.69 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.511 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.516 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.4 t -108.22 84.3 1.92 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.975 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.825 HD12 HG21 ' A' ' 77' ' ' VAL . 13.4 mt -108.84 165.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 108.993 179.533 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.0 Cg_endo -73.45 -167.36 0.36 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.369 2.046 . . . . 0.0 111.37 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.32 33.03 6.9 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.111 -1.042 . . . . 0.0 110.503 -178.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.63 53.99 0.7 Allowed 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.624 -0.927 . . . . 0.0 108.616 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.628 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 51.2 p-90 -131.6 -168.75 2.07 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.623 0.725 . . . . 0.0 110.616 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 42' ' ' TRP . 15.3 mttt -147.17 131.07 8.41 Favored Pre-proline 0 N--CA 1.49 1.53 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -76.2 141.22 23.08 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.126 1.884 . . . . 0.0 111.042 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.428 ' NZ ' HD23 ' A' ' 76' ' ' LEU . 1.3 ptpp? -152.38 177.06 10.99 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.403 ' N ' ' HG3' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -129.65 124.75 34.42 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.079 -1.013 . . . . 0.0 108.842 179.507 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.798 HD12 HG21 ' B' ' 50' ' ' ILE . 4.9 pt -96.42 149.87 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.238 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.646 ' CA ' ' CD2' ' A' ' 53' ' ' PHE . . . -122.48 108.9 1.32 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.79 -124.03 2.41 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 119.388 -1.387 . . . . 0.0 110.453 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.673 HD12 H702 ' B' ' 100' ' ' DMP . 64.7 mt -85.56 128.86 38.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.713 -0.875 . . . . 0.0 112.343 -177.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.24 -48.99 2.41 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.87 -157.78 26.22 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.646 ' CD2' ' CA ' ' A' ' 48' ' ' GLY . 3.5 m-85 -111.82 143.54 42.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -1.113 . . . . 0.0 109.573 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.609 HD11 HD11 ' A' ' 47' ' ' ILE . 3.8 pt -119.11 150.77 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.184 -0.947 . . . . 0.0 108.975 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 14.8 mttp -90.16 118.58 29.79 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.11 -0.994 . . . . 0.0 109.925 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.868 HG12 ' HA3' ' A' ' 78' ' ' GLY . 14.9 m -125.56 -167.5 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.226 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.415 ' O ' HD23 ' A' ' 76' ' ' LEU . 75.1 mtt85 -125.76 173.82 8.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.278 -0.889 . . . . 0.0 109.493 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 3.4 tt0 -130.77 123.93 30.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.409 -0.807 . . . . 0.0 109.919 -179.804 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 41.9 m-85 -121.14 91.36 3.51 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 20.3 m-20 -78.98 133.26 36.86 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.098 -1.001 . . . . 0.0 109.692 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 1.6 mt-30 83.36 57.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.482 0.658 . . . . 0.0 109.379 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.715 ' CG2' HG23 ' A' ' 15' ' ' ILE . 3.0 mm -114.3 114.03 45.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.681 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.0 OUTLIER -70.27 87.22 0.6 Allowed 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.271 -178.95 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.806 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -88.5 123.68 41.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.495 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -89.46 106.19 18.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.985 -1.072 . . . . 0.0 109.038 -178.995 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.71 HG13 HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER -106.13 123.22 60.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.009 -179.621 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 13.6 m 49.11 69.12 0.61 Allowed 'General case' 0 C--N 1.293 -1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.452 179.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 42.59 27.3 0.5 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.092 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.3 m-70 -122.97 130.74 53.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.897 -1.355 . . . . 0.0 109.065 179.268 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -75.01 133.21 41.71 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 108.837 179.404 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.47 108.32 2.94 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.876 . . . . 0.0 110.459 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.681 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -85.48 152.45 3.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 177.971 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.42 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.7 -178.32 45.43 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.206 -1.949 . . . . 0.0 111.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.1 m -92.66 106.36 18.35 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.627 -0.925 . . . . 0.0 110.139 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.046 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.3 t -97.01 176.65 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 1.006 HD12 ' O ' ' A' ' 31' ' ' THR . 1.9 mp -139.4 161.48 37.35 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.966 -1.084 . . . . 0.0 108.288 178.127 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.825 HG21 HD12 ' A' ' 38' ' ' LEU . 19.5 t -143.47 105.46 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.91 0 O-C-N 121.379 -0.825 . . . . 0.0 109.734 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.868 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.7 -162.49 10.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -80.3 40.18 0.94 Allowed 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.473 2.116 . . . . 0.0 110.705 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.5 t -85.59 132.75 43.61 Favored Pre-proline 0 C--N 1.3 -1.572 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 179.056 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.474 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 33.0 Cg_endo -77.92 17.5 0.99 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.407 2.071 . . . . 0.0 111.356 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 83' ' ' ASN . 1.1 t -162.22 162.22 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.837 -1.165 . . . . 0.0 109.983 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.646 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -96.94 154.38 17.33 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 175.21 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.821 HG13 HG12 ' A' ' 32' ' ' VAL . 1.1 mm -144.2 134.18 20.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 O-C-N 120.057 -1.652 . . . . 0.0 109.963 -178.244 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.886 HD13 ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.16 88.97 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 177.525 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.61 -164.45 22.81 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.905 -1.14 . . . . 0.0 110.278 -177.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HD2' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -61.82 -35.62 78.78 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.624 -0.927 . . . . 0.0 109.567 -179.134 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.018 ' ND2' HD23 ' A' ' 89' ' ' LEU . 8.1 p-10 -45.15 -25.07 0.31 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 108.891 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.018 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -112.91 -29.17 7.46 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 121.375 -0.828 . . . . 0.0 110.472 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 1.013 HD13 HG23 ' A' ' 26' ' ' THR . 77.7 mt -68.25 -7.26 29.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.967 -1.083 . . . . 0.0 109.157 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.48 -19.69 15.42 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 108.607 179.085 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -80.65 -41.17 24.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.222 -0.924 . . . . 0.0 108.874 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.624 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.7 pt -83.77 -5.61 9.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.01 34.28 55.89 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.163 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.577 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -64.25 151.9 42.38 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.261 . . . . 0.0 110.624 -179.707 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 30.9 p -148.32 128.21 13.5 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' B' ' 97' ' ' LEU . 3.0 mp -87.81 95.05 9.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.11 -0.994 . . . . 0.0 109.443 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.461 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 1.7 m-20 -114.46 129.97 56.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 110.674 -179.149 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.601 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.172 178.17 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 N-CA-C 109.744 -0.906 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.517 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 2.2 tt0 -81.92 149.63 28.13 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 178.249 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.517 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 61.2 t -148.46 96.2 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 117.832 -1.547 . . . . 0.0 110.868 -178.301 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.447 ' O ' ' N ' ' B' ' 6' ' ' TRP . 71.3 p -100.75 -55.67 2.52 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.135 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.653 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.2 OUTLIER 43.99 18.99 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.757 -0.589 . . . . 0.0 111.524 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.537 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.3 m95 18.53 43.15 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.096 0.407 . . . . 0.0 111.895 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.653 ' N ' ' O ' ' B' ' 5' ' ' LEU . 4.6 mt-30 -170.85 -103.3 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 63.8 mtt180 -113.58 127.87 26.34 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 120.351 -1.468 . . . . 0.0 110.252 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.474 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -78.99 71.48 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 121.94 1.76 . . . . 0.0 108.335 177.638 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.545 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -93.93 152.21 19.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.117 -0.989 . . . . 0.0 110.933 -178.083 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.57 HG21 HG23 ' B' ' 66' ' ' ILE . 2.0 m -151.03 150.39 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.663 -0.648 . . . . 0.0 109.414 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.878 HG22 HD22 ' B' ' 19' ' ' LEU . 99.7 m -78.16 115.45 17.89 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.733 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.5 pp -103.89 151.4 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.024 -1.048 . . . . 0.0 110.507 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.1 OUTLIER -109.47 102.87 11.7 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.198 -0.939 . . . . 0.0 109.694 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.854 HD13 HG11 ' B' ' 75' ' ' VAL . 3.9 mt -121.37 134.28 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.986 -1.071 . . . . 0.0 110.159 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.494 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 58.66 27.24 61.12 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 179.317 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.13 27.3 66.55 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm-40 -124.41 -178.76 4.21 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.464 -1.021 . . . . 0.0 109.121 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 HG22 ' B' ' 12' ' ' THR . 19.8 mt -147.45 125.27 11.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 0.0 109.706 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.487 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mmtt -144.5 169.28 18.26 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.545 ' HB3' HD22 ' B' ' 10' ' ' LEU . 9.4 mt-10 -79.69 135.43 36.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 108.442 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.603 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -121.9 135.45 54.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.983 -1.073 . . . . 0.0 110.669 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 15.5 tp -92.04 94.1 9.08 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.48 HD23 ' CG1' ' B' ' 85' ' ' ILE . 14.2 mt -45.83 101.47 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.989 -1.069 . . . . 0.0 108.719 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.4 t70 -101.59 96.75 7.32 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.754 -0.591 . . . . 0.0 110.419 -178.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.788 ' OG1' HD21 ' A' ' 97' ' ' LEU . 24.6 m -79.68 13.49 2.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.906 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -109.83 -19.33 8.26 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.37 170.46 15.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.93 -1.336 . . . . 0.0 109.141 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -99.92 -18.08 17.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 110.088 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.54 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 16.1 m-20 -142.97 -155.16 0.57 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.064 -1.022 . . . . 0.0 109.658 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.57 ' OG1' ' HG ' ' B' ' 89' ' ' LEU . 78.5 m -120.19 97.82 5.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.511 -1.368 . . . . 0.0 111.262 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.044 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -76.83 174.87 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.073 -1.017 . . . . 0.0 108.445 178.969 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.044 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.04 119.46 0.61 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.765 -1.209 . . . . 0.0 110.936 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' B' ' 80' ' ' THR . 41.6 tt0 -36.66 158.77 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.453 0.644 . . . . 0.0 110.009 179.149 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.506 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -52.42 147.31 8.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.497 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.449 ' SD ' ' HB2' ' B' ' 38' ' ' LEU . 0.0 OUTLIER 179.55 178.35 0.54 Allowed 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.6 t -92.49 101.62 14.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.074 -1.017 . . . . 0.0 109.563 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.658 HD13 HG22 ' B' ' 15' ' ' ILE . 58.0 tp -130.69 98.24 20.1 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.119 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -78.76 -177.77 4.15 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.618 2.212 . . . . 0.0 110.393 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 113.63 31.65 2.29 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.42 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.481 ' O ' ' O ' ' B' ' 40' ' ' GLY . 49.0 mtm180 59.78 141.44 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.901 -0.764 . . . . 0.0 109.401 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 47.9 p-90 -160.3 -172.13 3.46 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.782 -1.199 . . . . 0.0 110.832 -179.286 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.495 ' HD3' ' HD2' ' B' ' 44' ' ' PRO . 1.8 mmtp -148.27 145.16 19.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 44' ' ' PRO . . . . . 0.495 ' HD2' ' HD3' ' B' ' 43' ' ' LYS . 35.8 Cg_endo -78.16 136.24 14.34 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 122.018 1.812 . . . . 0.0 110.932 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.581 ' HD3' HD23 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -160.29 -168.79 2.27 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.456 -0.778 . . . . 0.0 109.592 179.427 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.524 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 60.5 mtp -150.53 138.31 19.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.452 -0.78 . . . . 0.0 109.676 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.669 ' CD1' HG21 ' A' ' 50' ' ' ILE . 4.9 pt -95.93 150.09 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.03 -1.044 . . . . 0.0 108.535 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.82 102.53 0.94 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.41 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -126.81 -135.84 4.25 Favored Glycine 0 N--CA 1.483 1.821 0 C-N-CA 119.324 -1.417 . . . . 0.0 111.015 -178.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.798 HG21 HD12 ' A' ' 47' ' ' ILE . 46.1 mt -79.87 119.63 29.66 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.855 -0.791 . . . . 0.0 112.912 -177.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 104.97 -54.47 0.61 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.076 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.02 -159.62 20.78 Favored Glycine 0 N--CA 1.492 2.378 0 O-C-N 120.947 -1.325 . . . . 0.0 110.201 -179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.607 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 1.2 m-85 -118.9 125.85 50.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.475 -1.015 . . . . 0.0 109.161 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.457 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 5.2 pt -97.81 173.19 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.255 -0.903 . . . . 0.0 109.438 -179.785 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mtmt -109.03 125.58 52.23 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.147 -0.971 . . . . 0.0 109.626 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.652 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.6 m -134.86 168.76 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 110.279 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 18.4 mtt180 -110.33 111.41 22.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.588 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -69.04 121.69 17.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.409 -0.807 . . . . 0.0 110.471 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.6 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 23.9 m-85 -116.05 93.69 4.35 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.677 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 6.4 m-20 -77.6 124.97 28.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.8 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 48.6 mt-30 88.81 60.41 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 CA-C-O 121.32 0.581 . . . . 0.0 110.105 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.909 HG21 HG21 ' B' ' 75' ' ' VAL . 19.0 mm -115.57 109.82 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.116 179.498 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.93 HD21 ' HG2' ' B' ' 70' ' ' LYS . 3.0 tm? -65.27 85.56 0.06 Allowed 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.033 0.92 . . . . 0.0 110.717 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.652 HG21 ' CD1' ' B' ' 89' ' ' LEU . 0.6 OUTLIER -92.16 119.68 40.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 177.37 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.5 tt0 -87.14 128.84 35.12 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.163 -0.961 . . . . 0.0 108.957 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.57 HG23 HG21 ' B' ' 11' ' ' VAL . 0.9 OUTLIER -114.9 129.76 70.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.014 -179.313 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 86.2 m 54.52 -91.27 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.574 -0.704 . . . . 0.0 109.804 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -147.18 40.82 0.98 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.497 ' CB ' HG22 ' B' ' 93' ' ' ILE . 31.3 m80 -145.72 149.58 34.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -1.046 . . . . 0.0 109.287 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.93 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -79.04 139.63 38.11 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.077 -1.014 . . . . 0.0 109.467 -179.805 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.522 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -147.62 109.55 4.47 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.081 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.577 HG12 ' HA ' ' B' ' 63' ' ' LEU . 0.0 OUTLIER -94.88 145.46 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.215 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.786 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -169.22 -178.09 40.32 Favored Glycine 0 C--N 1.297 -1.636 0 C-N-CA 118.442 -1.837 . . . . 0.0 111.083 179.562 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.588 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.1 m -87.73 100.54 12.91 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 122.139 -0.624 . . . . 0.0 109.951 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.909 HG21 HG21 ' B' ' 62' ' ' ILE . 1.3 t -85.54 121.11 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.053 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.581 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.6 mp -96.73 104.25 16.23 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' B' ' 35' ' ' GLU . 21.8 t -93.45 112.03 25.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.04 -1.038 . . . . 0.0 109.993 -179.065 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.652 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.67 -160.85 9.45 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.556 -1.817 . . . . 0.0 108.556 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.539 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -79.98 38.31 0.73 Allowed 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.388 2.059 . . . . 0.0 110.973 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.678 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -81.98 134.96 48.79 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.584 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -79.04 15.14 1.57 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.583 2.189 . . . . 0.0 111.311 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.584 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -160.59 161.01 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.999 -1.063 . . . . 0.0 109.804 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.9 OUTLIER -98.24 129.12 44.98 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 104.157 -2.534 . . . . 0.0 104.157 175.51 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' B' ' 25' ' ' ASP . 5.0 mm -117.12 129.38 73.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.957 0 O-C-N 120.331 -1.481 . . . . 0.0 111.923 -176.171 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.62 HG23 HD12 ' B' ' 89' ' ' LEU . 3.4 mm -102.19 105.19 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 176.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -98.8 -163.65 30.14 Favored Glycine 0 N--CA 1.496 2.691 0 C-N-CA 119.826 -1.178 . . . . 0.0 111.823 -177.307 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.587 ' NH1' ' HG2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -53.28 -40.91 65.06 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 122.005 -0.703 . . . . 0.0 111.714 -178.193 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.747 ' C ' HD23 ' B' ' 89' ' ' LEU . 53.0 p-10 -48.14 -26.16 1.77 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.548 -1.345 . . . . 0.0 111.007 -177.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.786 HD21 ' HA3' ' B' ' 73' ' ' GLY . 2.3 mt -115.31 -27.77 7.12 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.32 -1.487 . . . . 0.0 111.602 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.772 ' HA ' HD11 ' B' ' 93' ' ' ILE . 3.5 mt -63.38 -11.77 25.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.212 -1.555 . . . . 0.0 108.259 -179.565 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -101.67 -19.65 15.33 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.196 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 69.9 mm-40 -79.16 -41.23 28.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.726 -0.608 . . . . 0.0 110.581 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.772 HD11 ' HA ' ' B' ' 90' ' ' LEU . 1.0 OUTLIER -80.44 -22.12 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 179.52 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' N ' HD12 ' B' ' 93' ' ' ILE . . . 103.02 35.48 3.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.507 ' HA ' ' HD1' ' A' ' 99' ' ' PHE . . . -72.43 135.68 45.83 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.388 -1.066 . . . . 0.0 111.185 -178.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 75.1 p -136.66 128.87 29.78 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -83.49 105.32 14.33 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 108.68 -179.466 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 23.8 m-20 -103.53 122.62 45.32 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.049 -1.032 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.624 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.135 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.787 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.497 1.711 0 N-CA-C 110.178 -0.739 . . . . 0.0 110.178 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 9.8 tt0 -83.16 148.94 27.17 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 106.471 -1.677 . . . . 0.0 106.471 177.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 2.3 t -140.76 105.98 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.902 -178.042 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.563 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -122.05 -69.03 0.85 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 176.694 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER 31.76 29.94 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.964 177.893 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.563 ' N ' ' O ' ' A' ' 4' ' ' THR . 17.3 m95 18.88 48.37 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.145 0 CA-C-O 121.331 0.586 . . . . 0.0 111.871 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.575 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -164.25 -175.5 3.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.172 -0.955 . . . . 0.0 109.401 179.8 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.486 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 1.6 mtt180 -76.38 119.27 76.61 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.267 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.532 ' HB3' ' CG1' ' A' ' 3' ' ' VAL . 35.3 Cg_endo -79.11 74.52 5.51 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.833 1.689 . . . . 0.0 108.92 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.425 ' HG ' ' HA ' ' A' ' 23' ' ' LEU . 0.4 OUTLIER -80.69 150.65 29.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.532 -0.73 . . . . 0.0 110.455 -178.609 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.605 ' O ' ' HB3' ' A' ' 22' ' ' ALA . 2.0 m -150.05 162.04 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.413 -0.804 . . . . 0.0 109.33 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.424 HG22 HD22 ' A' ' 19' ' ' LEU . 42.5 m -96.12 114.04 25.7 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -97.95 171.74 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.901 -178.941 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.516 ' HE3' HD11 ' A' ' 19' ' ' LEU . 6.5 tttt -131.78 102.38 5.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 109.406 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.756 HD13 HG11 ' A' ' 75' ' ' VAL . 48.6 mt -118.44 132.09 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.984 -1.072 . . . . 0.0 109.902 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.26 40.13 98.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.03 18.45 60.12 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 mm-40 -112.89 171.62 7.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.336 -1.097 . . . . 0.0 109.094 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 14.4 mt -142.9 126.92 17.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.218 -0.926 . . . . 0.0 110.3 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 7.2 mttt -143.52 -167.7 2.64 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 43.5 mt-10 -79.4 -167.82 1.32 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.989 -1.07 . . . . 0.0 108.145 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.706 ' CB ' HG23 ' A' ' 13' ' ' ILE . . . -171.3 86.85 0.09 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.085 -1.009 . . . . 0.0 109.454 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.578 ' O ' ' N ' ' A' ' 25' ' ' ASP . 36.5 tp -72.47 95.35 1.77 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.346 -0.846 . . . . 0.0 109.032 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.493 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 49.6 mt -48.93 90.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' N ' ' O ' ' A' ' 23' ' ' LEU . 0.6 OUTLIER -99.52 92.98 5.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.49 -0.756 . . . . 0.0 110.825 -177.995 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . 1.022 ' OG1' HD21 ' B' ' 97' ' ' LEU . 1.5 m -73.11 -2.03 19.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.574 178.152 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.556 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.84 -36.36 13.74 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.91 136.74 36.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.086 -1.244 . . . . 0.0 109.686 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 87' ' ' ARG . 19.3 m-20 -64.15 -19.2 65.13 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.434 -0.791 . . . . 0.0 111.126 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.744 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.7 OUTLIER -141.79 -179.28 6.1 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.121 -1.432 . . . . 0.0 110.987 -179.324 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.662 HG22 ' CD1' ' A' ' 33' ' ' LEU . 2.3 m -96.18 89.41 5.13 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.471 -0.768 . . . . 0.0 110.612 -178.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.7 OUTLIER -69.38 163.28 3.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.729 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -158.45 131.72 7.43 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.112 -0.993 . . . . 0.0 110.691 -178.558 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.461 ' N ' ' CG2' ' A' ' 80' ' ' THR . 57.7 tt0 -43.44 164.77 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.82 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.538 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -56.91 134.56 55.6 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.149 -0.97 . . . . 0.0 110.703 -179.285 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' VAL . 2.2 ppp? -162.63 -167.56 1.59 Allowed 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.4 t -106.5 138.33 42.88 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.831 -1.168 . . . . 0.0 110.451 -179.313 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.837 HD22 HD12 ' A' ' 62' ' ' ILE . 5.4 mt -143.33 171.1 7.4 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.606 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -70.24 -153.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 121.853 1.702 . . . . 0.0 110.27 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.52 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -110.6 -167.25 19.27 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 -178.736 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.52 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.1 OUTLIER 73.07 54.6 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.113 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.662 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 3.9 p-90 -126.01 -176.84 3.75 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.791 0.805 . . . . 0.0 110.543 -178.692 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.41 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 14.0 mttp -147.54 160.87 37.66 Favored Pre-proline 0 N--CA 1.489 1.517 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.115 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 32.0 Cg_endo -75.78 147.48 31.15 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.166 1.91 . . . . 0.0 109.373 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.577 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -146.0 165.41 29.09 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.014 -1.054 . . . . 0.0 110.078 -178.932 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.406 ' SD ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -148.38 112.29 5.14 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.046 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 54' ' ' ILE . 6.7 pt -106.1 129.45 59.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.48 -1.288 . . . . 0.0 109.467 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -116.82 100.71 0.91 Allowed Glycine 0 N--CA 1.482 1.753 0 N-CA-C 107.15 -2.38 . . . . 0.0 107.15 179.415 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.464 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -119.18 -128.62 3.8 Favored Glycine 0 N--CA 1.479 1.565 0 C-N-CA 119.269 -1.443 . . . . 0.0 111.084 -177.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.806 HG21 HD11 ' B' ' 47' ' ' ILE . 59.1 mt -85.4 119.16 33.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 O-C-N 122.074 -0.663 . . . . 0.0 112.429 -177.374 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 109.79 -36.42 4.31 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 162.99 -162.09 34.41 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.492 -1.337 . . . . 0.0 110.147 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.7 m-85 -115.12 141.99 47.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.467 -1.02 . . . . 0.0 109.466 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 47' ' ' ILE . 3.0 pt -128.51 178.24 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.509 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -112.66 138.06 50.0 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.05 -1.031 . . . . 0.0 109.405 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.7 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.5 m -144.09 161.61 15.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.294 -0.879 . . . . 0.0 109.35 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.564 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -104.49 -176.63 3.14 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.145 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 44.5 tt0 -137.6 101.45 4.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.006 . . . . 0.0 109.543 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.815 ' HB3' HD11 ' A' ' 62' ' ' ILE . 40.1 m-85 -103.41 95.73 6.27 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.424 -0.797 . . . . 0.0 109.517 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -78.88 140.85 38.05 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.955 -1.091 . . . . 0.0 108.982 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 76.38 64.06 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.819 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.837 HD12 HD22 ' A' ' 38' ' ' LEU . 21.4 mm -121.8 123.34 69.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.859 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -67.56 82.47 0.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.355 -0.841 . . . . 0.0 110.935 -178.608 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 1.028 ' CG2' HD11 ' A' ' 89' ' ' LEU . 2.5 tt -94.34 121.25 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.43 ' HG2' ' C ' ' A' ' 69' ' ' HIS . 1.7 tt0 -89.17 140.57 29.33 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.099 -1.001 . . . . 0.0 108.486 179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.821 HD11 ' CD1' ' A' ' 89' ' ' LEU . 0.4 OUTLIER -126.05 171.97 14.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 107.165 -1.421 . . . . 0.0 107.165 179.672 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.458 ' SG ' ' HB ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -47.96 -38.63 17.21 Favored 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 178.836 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.635 ' O ' ' CG ' ' A' ' 69' ' ' HIS . . . -52.79 -49.59 53.4 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 178.319 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.635 ' CG ' ' O ' ' A' ' 68' ' ' GLY . 0.2 OUTLIER 141.66 -173.39 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.076 0 CA-C-O 121.102 0.477 . . . . 0.0 109.838 178.583 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.533 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -36.56 139.51 0.18 Allowed 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 121.351 0.596 . . . . 0.0 109.773 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -161.8 115.33 1.87 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.304 -0.872 . . . . 0.0 110.02 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.772 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -85.57 150.7 3.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.706 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.608 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.24 -154.92 11.73 Favored Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.262 -1.446 . . . . 0.0 110.835 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.494 ' HB ' ' OD1' ' A' ' 88' ' ' ASN . 1.4 m -109.7 111.95 23.73 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.246 -1.149 . . . . 0.0 110.087 -179.15 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.03 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -106.15 108.39 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.262 -0.899 . . . . 0.0 111.243 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.744 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.12 139.55 38.02 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 177.674 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.56 ' CG2' HD12 ' A' ' 38' ' ' LEU . 1.3 t -116.2 112.47 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.084 -1.01 . . . . 0.0 110.978 -178.144 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.7 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.54 -172.17 18.83 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.2 Cg_endo -81.45 41.62 1.18 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.58 2.187 . . . . 0.0 110.681 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.632 HG21 HG13 ' A' ' 32' ' ' VAL . 3.8 t -79.3 141.56 57.62 Favored Pre-proline 0 N--CA 1.49 1.553 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.21 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.733 ' O ' HG23 ' A' ' 82' ' ' VAL . 38.2 Cg_endo -80.07 20.02 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.583 2.188 . . . . 0.0 110.872 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 81' ' ' PRO . 10.5 t -161.13 166.8 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.702 -1.248 . . . . 0.0 110.92 -178.694 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.545 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 7.8 m-80 -100.44 90.45 4.3 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 177.551 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.598 ' O ' ' HA ' ' A' ' 31' ' ' THR . 12.1 mm -79.14 120.04 29.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 O-C-N 121.183 -0.948 . . . . 0.0 112.379 -176.027 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.576 ' N ' HD13 ' A' ' 85' ' ' ILE . 3.3 mm -99.07 106.11 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 176.587 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.507 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -91.47 -152.18 27.94 Favored Glycine 0 N--CA 1.489 2.197 0 O-C-N 120.679 -1.263 . . . . 0.0 111.861 -176.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.774 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -70.7 -41.29 72.15 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 120.111 -0.636 . . . . 0.0 109.852 -179.032 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.57 ' OD1' ' HA ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -53.33 -16.39 1.33 Allowed 'General case' 0 N--CA 1.498 1.963 0 C-N-CA 117.821 -1.552 . . . . 0.0 110.422 -178.965 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.157 HD13 ' OE1' ' A' ' 92' ' ' GLN . 0.2 OUTLIER -105.76 -20.82 13.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.658 -1.276 . . . . 0.0 109.054 179.825 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.933 HD13 HG23 ' A' ' 26' ' ' THR . 28.7 mt -80.95 1.1 32.55 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.654 -1.279 . . . . 0.0 108.535 178.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.774 HG23 ' O ' ' A' ' 87' ' ' ARG . 0.3 OUTLIER -101.08 -10.06 20.83 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.137 -0.977 . . . . 0.0 111.159 -179.958 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 1.157 ' OE1' HD13 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -95.15 -40.81 9.41 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 120.467 -1.396 . . . . 0.0 109.562 -178.552 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.052 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.3 OUTLIER -80.48 3.3 2.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.013 -1.075 . . . . 0.0 108.349 178.576 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 69.87 53.05 16.71 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.575 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -77.27 144.98 37.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.121 -1.223 . . . . 0.0 109.271 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.95 HG22 HG22 ' B' ' 4' ' ' THR . 27.3 p -139.85 123.27 17.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.157 -0.964 . . . . 0.0 109.27 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.738 HD11 HD11 ' B' ' 97' ' ' LEU . 7.4 mp -84.72 100.61 11.61 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 178.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' B' ' 94' ' ' GLY . 65.1 m-20 -99.17 120.01 38.8 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 120.447 -1.408 . . . . 0.0 108.934 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.64 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.298 -1.64 0 CA-C-O 118.101 -0.952 . . . . 0.0 109.282 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.7 Cg_exo . . . . . 0 N--CA 1.493 1.488 0 N-CA-C 109.917 -0.839 . . . . 0.0 109.917 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 130.7 35.14 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 56.3 t -123.57 109.04 22.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.595 -177.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 96' ' ' THR . 14.7 p -123.97 21.59 8.98 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.411 -0.806 . . . . 0.0 109.967 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.6 tp -88.82 27.31 1.34 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.023 -1.048 . . . . 0.0 108.758 178.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.763 ' HB3' HG22 ' A' ' 91' ' ' THR . 0.7 OUTLIER 14.98 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.685 0.755 . . . . 0.0 111.918 179.698 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.54 ' O ' ' HD3' ' B' ' 9' ' ' PRO . 1.0 OUTLIER -129.31 -152.46 0.52 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.448 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 26.5 mtt180 -103.72 101.43 24.37 Favored Pre-proline 0 N--CA 1.488 1.45 0 O-C-N 120.903 -1.123 . . . . 0.0 108.133 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.561 ' HD2' ' CZ ' ' A' ' 87' ' ' ARG . 33.9 Cg_endo -75.13 72.06 4.86 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.413 2.075 . . . . 0.0 110.698 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -89.78 142.88 27.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.017 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.781 HG23 HG23 ' B' ' 13' ' ' ILE . 21.9 m -131.15 126.05 58.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.3 m -67.34 99.88 0.76 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 177.366 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.857 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pp -95.91 140.53 16.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.242 -0.911 . . . . 0.0 111.298 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.1 OUTLIER -103.63 106.91 17.56 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.734 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.862 HD13 HG11 ' B' ' 75' ' ' VAL . 7.2 mt -119.68 115.65 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.206 -0.934 . . . . 0.0 110.154 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.48 27.78 73.13 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.606 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.77 12.3 81.63 Favored Glycine 0 N--CA 1.492 2.419 0 O-C-N 120.901 -1.353 . . . . 0.0 109.789 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.4 mt-30 -107.44 168.57 9.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.208 -1.172 . . . . 0.0 109.134 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.519 HD11 ' HE3' ' B' ' 14' ' ' LYS . 14.7 mt -140.48 122.95 16.06 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 0.0 109.514 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.517 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mmtt -143.87 172.95 12.15 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.503 -0.748 . . . . 0.0 109.236 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 31.1 mp0 -87.13 132.06 33.97 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.919 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.78 147.32 30.99 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.025 -1.047 . . . . 0.0 109.587 -179.489 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' B' ' 25' ' ' ASP . 18.6 tp -112.84 94.43 4.9 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.569 -0.707 . . . . 0.0 109.462 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.517 ' O ' ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -41.41 95.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.423 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.951 ' HB3' HG23 ' B' ' 84' ' ' ILE . 24.6 t0 -113.57 88.95 2.96 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.198 -0.939 . . . . 0.0 111.538 -178.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.81 HG23 HD22 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -67.69 -19.67 65.2 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 177.265 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.457 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -55.57 -39.51 75.13 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.404 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -84.46 164.73 18.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.46 -1.023 . . . . 0.0 109.306 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.477 ' OD1' ' HG3' ' A' ' 8' ' ' ARG . 12.4 m-20 -94.96 -19.57 20.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.075 -1.016 . . . . 0.0 110.921 -178.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.947 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.9 OUTLIER -137.22 -175.71 4.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.747 -1.22 . . . . 0.0 110.198 -179.491 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.741 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.3 m -100.21 94.7 6.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.03 -1.044 . . . . 0.0 110.856 -178.224 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.037 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -75.05 158.72 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.092 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.037 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.5 OUTLIER -155.46 143.07 19.65 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.908 -1.12 . . . . 0.0 111.052 -178.092 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.729 ' N ' HG22 ' B' ' 80' ' ' THR . 20.2 tt0 -49.68 156.15 0.72 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.6 OUTLIER -61.69 132.78 54.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.076 -1.015 . . . . 0.0 109.609 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.568 ' HE2' HG22 ' B' ' 15' ' ' ILE . 3.8 ptm -153.33 -164.17 1.85 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.402 ' O ' HD22 ' B' ' 38' ' ' LEU . 28.5 t -102.96 118.12 36.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.037 -1.039 . . . . 0.0 110.49 -179.321 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.552 HD13 ' HD3' ' B' ' 39' ' ' PRO . 3.0 mm? -113.3 169.96 5.84 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.552 ' HD3' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.95 52.02 4.14 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.696 2.264 . . . . 0.0 111.426 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 49.03 -163.0 0.5 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.2 mmm-85 60.25 84.87 0.12 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -1.14 . . . . 0.0 109.196 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.606 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 60.3 p-90 -159.57 176.54 11.92 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.509 0.671 . . . . 0.0 110.047 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.412 ' CG ' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -139.38 159.68 64.95 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.374 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 44' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' B' ' 43' ' ' LYS . 35.9 Cg_endo -77.95 139.53 17.44 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.21 1.94 . . . . 0.0 110.404 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.793 ' O ' HG22 ' B' ' 56' ' ' VAL . 10.1 tttt -155.53 131.14 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.439 -0.788 . . . . 0.0 109.197 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -110.85 130.68 55.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.099 -1.001 . . . . 0.0 109.289 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.806 HD11 HG21 ' A' ' 50' ' ' ILE . 24.3 pt -113.42 149.86 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.894 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.495 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.15 111.51 2.09 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 179.458 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.526 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -132.36 -126.08 2.7 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.188 -1.482 . . . . 0.0 111.161 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.598 HG13 ' H62' ' B' ' 100' ' ' DMP . 19.3 mt -91.52 138.44 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 122.056 0.932 . . . . 0.0 113.179 -177.098 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.542 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 80.18 -20.19 6.03 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 178.585 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.14 -169.44 32.61 Favored Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.649 -1.5 . . . . 0.0 110.321 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 4.5 m-85 -105.11 153.25 21.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.372 -1.075 . . . . 0.0 109.274 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.693 HD13 HG23 ' A' ' 50' ' ' ILE . 7.4 pt -127.11 159.81 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.225 -0.922 . . . . 0.0 109.807 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.529 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.29 144.52 31.51 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.769 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.793 HG22 ' O ' ' B' ' 45' ' ' LYS . 23.9 m -142.9 -171.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.78 -1.2 . . . . 0.0 110.598 -178.75 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 11.4 mtt180 -137.85 88.87 2.36 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.41 98.82 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 110.962 -179.082 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.975 ' HB3' HD11 ' B' ' 62' ' ' ILE . 18.9 m-85 -91.78 127.54 37.27 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.935 ' OD1' HG23 ' B' ' 74' ' ' THR . 2.4 m-20 -107.69 135.22 49.48 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.785 -1.197 . . . . 0.0 110.632 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.585 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.1 mt-30 79.96 60.4 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.823 -0.548 . . . . 0.0 110.889 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 1.058 HD13 HG23 ' B' ' 75' ' ' VAL . 3.5 mp -113.96 119.94 62.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.086 -1.008 . . . . 0.0 109.275 179.087 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.848 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.9 tm? -68.59 83.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.506 -0.746 . . . . 0.0 110.505 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.761 HD12 HD11 ' B' ' 15' ' ' ILE . 12.5 tt -88.85 124.88 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.489 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 7.4 tt0 -90.28 100.13 13.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.085 -1.01 . . . . 0.0 109.414 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.857 HG13 HG22 ' B' ' 13' ' ' ILE . 0.5 OUTLIER -90.97 119.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 121.055 -1.028 . . . . 0.0 109.103 179.949 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.643 ' SG ' HG12 ' B' ' 11' ' ' VAL . 5.3 m 48.5 47.52 20.24 Favored 'General case' 0 C--N 1.291 -1.951 0 O-C-N 121.82 -0.55 . . . . 0.0 110.463 178.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 68' ' ' GLY . . . . . 0.484 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 68.37 28.13 73.41 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.623 ' CE1' ' O ' ' B' ' 67' ' ' CYS . 3.2 m-70 -120.2 97.15 5.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.034 -1.274 . . . . 0.0 109.35 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.57 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.44 126.81 16.07 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.239 -0.913 . . . . 0.0 109.159 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.764 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -151.26 155.98 39.9 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.665 -0.647 . . . . 0.0 109.459 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.751 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.9 OUTLIER -119.22 153.33 21.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.717 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.419 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -175.61 -177.83 44.96 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.453 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.935 HG23 ' OD1' ' B' ' 60' ' ' ASP . 2.7 m -91.18 108.56 19.95 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.706 -0.879 . . . . 0.0 109.877 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.058 HG23 HD13 ' B' ' 62' ' ' ILE . 1.4 t -103.35 112.46 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.401 -0.812 . . . . 0.0 110.328 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.947 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.9 mp -77.73 118.71 20.36 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.012 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 72.1 t -99.02 117.44 44.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 120.916 -1.115 . . . . 0.0 109.74 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.75 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.55 -168.52 18.73 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.116 -1.994 . . . . 0.0 108.116 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.529 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -80.83 48.46 2.91 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 122.263 1.975 . . . . 0.0 110.816 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.842 HG21 HG13 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -91.85 137.45 25.39 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.926 -1.109 . . . . 0.0 108.573 179.481 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.451 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.6 Cg_endo -79.54 19.6 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.557 2.171 . . . . 0.0 112.209 -178.502 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.76 ' H ' HG23 ' B' ' 80' ' ' THR . 1.1 t -161.23 172.74 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.541 -1.349 . . . . 0.0 110.287 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.585 ' N ' HG13 ' B' ' 82' ' ' VAL . 3.2 m-80 -107.55 79.53 1.3 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.452 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 1.003 HD11 ' C32' ' B' ' 100' ' ' DMP . 1.2 mp -76.8 126.02 37.1 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.374 -0.829 . . . . 0.0 111.48 -176.274 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.919 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.2 mp -96.14 99.94 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.272 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.549 ' C ' HD12 ' B' ' 90' ' ' LEU . . . -95.69 167.68 25.9 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.189 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.764 ' O ' HG23 ' B' ' 91' ' ' THR . 22.5 mmm180 -25.77 -39.41 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.818 -0.813 . . . . 0.0 112.826 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.009 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.9 p-10 -49.79 -21.99 1.29 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.577 -1.327 . . . . 0.0 111.264 -178.522 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.009 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -110.58 -24.06 10.75 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.81 HD22 HG23 ' B' ' 26' ' ' THR . 3.8 mp -68.6 -8.69 44.14 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.764 HG23 ' O ' ' B' ' 87' ' ' ARG . 30.4 p -95.83 -20.22 18.99 Favored 'General case' 0 N--CA 1.485 1.307 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.775 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.504 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 68.5 mm-40 -81.73 -41.46 21.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.137 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.64 HD12 ' CG ' ' A' ' 99' ' ' PHE . 1.9 pt -93.29 -2.82 10.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 98' ' ' ASN . . . 75.48 22.51 75.37 Favored Glycine 0 N--CA 1.494 2.529 0 O-C-N 121.516 -0.74 . . . . 0.0 111.488 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.573 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -65.27 123.66 20.15 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.708 -1.466 . . . . 0.0 110.457 -179.583 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 41.4 p -131.38 132.63 44.56 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 1.022 HD21 ' OG1' ' A' ' 26' ' ' THR . 4.8 mp -84.87 106.87 16.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.047 -1.033 . . . . 0.0 110.766 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.524 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 6.7 m-20 -112.3 121.61 45.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.344 -0.847 . . . . 0.0 108.944 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 1.052 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.686 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.224 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 1.003 ' C32' HD11 ' B' ' 84' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.567 ' O ' ' CD1' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.67 0 N-CA-C 110.398 -0.655 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -88.16 139.37 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.54 155.86 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 109.943 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.539 HG22 HG22 ' B' ' 96' ' ' THR . 1.1 p -127.66 -168.35 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.312 -0.868 . . . . 0.0 109.445 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.023 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -87.16 -26.89 23.37 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.215 -0.928 . . . . 0.0 109.065 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.589 ' N ' HD13 ' A' ' 5' ' ' LEU . 10.2 m95 -45.48 -22.72 0.16 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.629 -1.295 . . . . 0.0 109.06 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.478 ' N ' ' O ' ' A' ' 5' ' ' LEU . 34.6 mt-30 -146.25 110.32 4.98 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.705 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.462 ' C ' ' O ' ' A' ' 7' ' ' GLN . 14.6 mtm180 -40.95 148.17 0.39 Allowed Pre-proline 0 C--N 1.297 -1.713 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 36.7 Cg_endo -79.71 47.88 2.67 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.579 2.186 . . . . 0.0 109.757 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.587 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -79.33 143.43 35.17 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.098 -1.001 . . . . 0.0 109.526 -179.222 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 HG23 ' A' ' 66' ' ' ILE . 0.7 OUTLIER -147.24 140.65 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.333 -178.734 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.752 HG22 HD22 ' A' ' 19' ' ' LEU . 78.4 m -74.32 96.78 2.89 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.876 HG22 HG13 ' A' ' 66' ' ' ILE . 4.2 pt -83.81 150.34 4.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 121.635 0.731 . . . . 0.0 111.041 -178.252 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.666 ' HE3' HD11 ' A' ' 19' ' ' LEU . 1.1 tttt -112.14 101.54 9.79 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.43 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.028 HD11 HD12 ' A' ' 64' ' ' ILE . 12.2 mt -122.51 138.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.225 -0.922 . . . . 0.0 109.308 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 52.11 43.37 56.2 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.14 35.83 66.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 68.8 mm-40 -131.32 178.59 6.6 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.151 . . . . 0.0 109.186 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.752 HD22 HG22 ' A' ' 12' ' ' THR . 39.5 mt -146.94 126.45 13.23 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.129 -0.982 . . . . 0.0 110.232 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.601 ' N ' ' HE2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -146.85 163.34 36.38 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.709 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.557 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 49.3 mm-40 -79.39 137.23 37.21 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.97 -1.081 . . . . 0.0 109.113 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -119.98 156.07 31.59 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.594 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.431 HD21 ' O ' ' B' ' 27' ' ' GLY . 12.3 tp -118.24 99.12 6.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.701 -0.624 . . . . 0.0 109.615 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.527 HD23 ' HB ' ' A' ' 85' ' ' ILE . 18.7 mt -48.34 106.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.878 -1.139 . . . . 0.0 108.932 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' CB ' HG23 ' A' ' 84' ' ' ILE . 54.2 t0 -109.24 98.39 7.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.875 . . . . 0.0 109.829 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.724 HG22 HH12 ' A' ' 87' ' ' ARG . 0.2 OUTLIER -71.58 -5.01 30.18 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.303 -0.873 . . . . 0.0 108.748 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.827 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.58 -33.27 22.61 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.569 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.36 159.88 20.78 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.073 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.519 ' OD2' ' CZ ' ' B' ' 8' ' ' ARG . 16.8 m-20 -100.77 -13.66 18.36 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.3 -0.875 . . . . 0.0 110.629 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.496 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -127.0 -173.54 2.92 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.982 -1.074 . . . . 0.0 109.545 -179.625 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.582 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 27.9 m -110.47 86.76 2.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.864 -1.147 . . . . 0.0 110.214 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -67.78 173.5 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -169.85 115.2 0.53 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.838 -1.163 . . . . 0.0 110.983 -178.14 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.508 ' C ' ' O ' ' A' ' 33' ' ' LEU . 33.8 tt0 -33.85 150.05 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.879 -0.513 . . . . 0.0 109.649 178.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.649 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -37.35 145.08 0.06 Allowed 'General case' 0 N--CA 1.495 1.783 0 CA-C-O 121.56 0.695 . . . . 0.0 110.674 -179.206 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.404 ' SD ' ' CD2' ' A' ' 38' ' ' LEU . 14.3 ptm -156.85 -170.8 3.42 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.0 t -127.77 90.77 3.16 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.827 -1.171 . . . . 0.0 111.364 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.637 ' HB2' ' CE1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -81.49 171.58 11.79 Favored Pre-proline 0 N--CA 1.493 1.716 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 177.901 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.537 ' CD ' HD12 ' A' ' 38' ' ' LEU . 36.2 Cg_endo -79.3 43.52 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.614 2.21 . . . . 0.0 111.499 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . 54.72 111.15 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.449 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 157.79 57.74 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.909 . . . . 0.0 108.83 179.792 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 51.5 p-90 -141.1 179.18 6.89 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-O 121.849 0.833 . . . . 0.0 110.491 -178.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.452 ' HA ' ' HE3' ' A' ' 43' ' ' LYS . 0.0 OUTLIER -130.8 158.04 76.09 Favored Pre-proline 0 C--N 1.302 -1.475 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.783 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -76.32 141.92 23.47 Favored 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.144 1.896 . . . . 0.0 110.471 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.497 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -148.39 169.57 19.89 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.428 -0.795 . . . . 0.0 109.352 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.485 ' SD ' ' HB3' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -144.35 111.21 5.75 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.507 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.563 HD11 HD11 ' A' ' 54' ' ' ILE . 6.0 pt -92.33 142.52 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.856 -1.152 . . . . 0.0 109.093 -179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.621 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -122.8 105.08 0.92 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.529 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -124.68 -120.57 2.5 Favored Glycine 0 N--CA 1.483 1.785 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.097 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.865 HG21 HD11 ' B' ' 47' ' ' ILE . 26.3 mt -86.56 121.69 37.89 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.69 -0.888 . . . . 0.0 112.09 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 103.91 -55.71 0.61 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.76 -159.3 23.69 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.621 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.0 m-85 -107.43 131.79 53.9 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.235 -1.156 . . . . 0.0 109.887 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 7.3 pt -107.98 134.63 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.923 -1.111 . . . . 0.0 108.857 178.697 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -70.94 148.58 47.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.103 -0.998 . . . . 0.0 110.057 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.4 m -150.09 -169.77 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.595 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 3.7 mmt85 -133.56 105.11 6.7 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.503 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.0 OUTLIER -62.93 102.06 0.32 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.948 . . . . 0.0 110.448 -179.133 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.637 ' CE1' ' HB2' ' A' ' 38' ' ' LEU . 31.2 m-85 -92.62 90.68 7.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 108.858 179.113 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 3.4 m-20 -79.07 124.72 28.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.008 -1.057 . . . . 0.0 110.47 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 2.7 mm-40 88.33 61.78 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 CA-C-O 121.383 0.611 . . . . 0.0 110.163 179.319 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.975 ' CG2' HG23 ' A' ' 15' ' ' ILE . 14.8 mm -117.82 116.53 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.108 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.953 HD13 ' O ' ' A' ' 63' ' ' LEU . 1.3 tm? -68.66 83.73 0.29 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.372 -0.83 . . . . 0.0 110.092 -179.137 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 1.028 HD12 HD11 ' A' ' 15' ' ' ILE . 11.8 tt -89.9 112.0 23.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 179.029 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.517 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 8.6 tp10 -91.63 120.44 32.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.11 -0.994 . . . . 0.0 109.228 -179.255 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -107.01 121.01 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.179 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 60.04 -93.01 0.04 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.606 -0.684 . . . . 0.0 110.053 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -138.92 27.37 2.68 Favored Glycine 0 N--CA 1.486 1.978 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.42 ' C ' ' OE1' ' A' ' 65' ' ' GLU . 9.6 m-70 -125.53 103.44 7.88 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.188 -1.184 . . . . 0.0 109.385 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.603 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -59.52 133.43 56.09 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.544 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.712 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -145.52 154.9 42.7 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.153 -0.967 . . . . 0.0 110.333 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.556 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -121.25 156.29 24.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 177.491 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.909 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 177.77 -177.77 48.37 Favored Glycine 0 N--CA 1.487 2.039 0 C-N-CA 117.876 -2.107 . . . . 0.0 112.084 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.503 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 91.0 m -90.62 105.12 17.6 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.921 -0.752 . . . . 0.0 109.713 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.63 107.06 19.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.688 -0.632 . . . . 0.0 110.079 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.543 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.8 mp -79.51 120.82 24.42 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.461 -0.774 . . . . 0.0 108.99 179.323 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.649 HG12 ' HA ' ' A' ' 35' ' ' GLU . 21.6 t -107.22 130.67 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.57 179.801 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -162.21 -159.4 10.23 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.039 -1.624 . . . . 0.0 109.039 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.72 38.32 0.73 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.606 2.204 . . . . 0.0 110.338 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' A' ' 32' ' ' VAL . 2.4 t -83.95 135.08 42.84 Favored Pre-proline 0 N--CA 1.489 1.519 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.261 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.5 16.82 1.18 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.428 2.085 . . . . 0.0 111.044 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.461 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.83 157.73 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.978 -1.076 . . . . 0.0 109.292 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -94.53 126.33 39.74 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 176.041 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.709 ' CG1' HG12 ' A' ' 32' ' ' VAL . 5.0 mm -111.57 122.57 66.19 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 O-C-N 120.486 -1.384 . . . . 0.0 112.384 -176.186 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.561 HG22 ' O ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -98.78 85.66 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 176.88 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.57 -157.02 9.97 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.461 -177.236 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.724 HH12 HG22 ' A' ' 26' ' ' THR . 0.0 OUTLIER -64.56 -33.06 75.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 122.009 -0.7 . . . . 0.0 111.265 -178.44 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -55.9 -32.15 63.48 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.791 -1.193 . . . . 0.0 110.315 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -108.05 -19.95 13.33 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.993 -1.067 . . . . 0.0 110.516 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.501 HD23 HD11 ' A' ' 93' ' ' ILE . 12.6 mt -69.9 -36.17 75.19 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 71.2 p -72.55 -20.83 61.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.057 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.449 ' OE1' ' HA ' ' A' ' 92' ' ' GLN . 9.4 mm100 -71.43 -40.18 70.58 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.697 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.4 OUTLIER -85.77 -2.18 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.55 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.82 60.36 6.6 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.669 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -81.41 151.72 27.77 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.365 -1.079 . . . . 0.0 110.052 -179.6 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.8 p -142.96 125.34 15.6 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.035 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' B' ' 97' ' ' LEU . 2.6 mp -91.0 94.27 9.56 Favored 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.612 -0.68 . . . . 0.0 109.17 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.457 ' CG ' ' HG3' ' B' ' 2' ' ' GLN . 6.4 m-20 -104.79 129.0 53.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.127 -0.983 . . . . 0.0 110.285 -179.25 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 1.017 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.377 178.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.492 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 N-CA-C 110.383 -0.66 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.457 ' HG3' ' CG ' ' A' ' 98' ' ' ASN . 7.1 tt0 -83.59 129.81 34.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 96.2 t -130.41 107.19 14.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.718 -1.239 . . . . 0.0 110.692 -177.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.547 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.9 p -108.71 -59.56 1.86 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' B' ' 7' ' ' GLN . 84.5 mt 35.8 27.9 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.695 -0.628 . . . . 0.0 111.068 179.153 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.547 ' N ' ' O ' ' B' ' 4' ' ' THR . 8.4 m95 17.63 46.48 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.603 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.6 mt-30 -170.65 -166.86 0.53 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.108 -0.995 . . . . 0.0 109.941 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.554 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.3 mtm180 -67.78 112.75 11.36 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.474 -0.767 . . . . 0.0 109.545 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.795 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.4 Cg_endo -80.27 86.88 1.59 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.204 1.936 . . . . 0.0 110.051 179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.473 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.5 OUTLIER -86.12 136.25 33.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.92 . . . . 0.0 109.524 -179.771 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' B' ' 22' ' ' ALA . 3.4 m -125.56 154.17 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.423 -0.798 . . . . 0.0 109.711 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.453 HG21 ' CD2' ' B' ' 19' ' ' LEU . 58.5 m -86.6 111.27 20.47 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.912 HD11 HD21 ' B' ' 33' ' ' LEU . 1.6 pp -97.76 141.7 15.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.184 -0.948 . . . . 0.0 110.447 -178.674 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.439 ' HG3' HD12 ' B' ' 19' ' ' LEU . 6.8 ttmm -109.4 96.05 6.03 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.346 -0.846 . . . . 0.0 109.316 179.658 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 1.095 HG23 ' CG2' ' B' ' 62' ' ' ILE . 7.3 mt -113.02 116.18 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.86 50.69 63.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.96 17.15 21.27 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.224 -1.162 . . . . 0.0 110.287 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.506 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 1.7 mt-30 -108.05 134.67 50.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.055 -1.262 . . . . 0.0 109.37 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.453 ' CD2' HG21 ' B' ' 12' ' ' THR . 0.3 OUTLIER -113.51 120.06 39.68 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.098 0.951 . . . . 0.0 110.302 -179.726 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.413 ' HB3' HD21 ' B' ' 83' ' ' ASN . 0.7 OUTLIER -141.04 178.55 7.3 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.094 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.552 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.1 mt-10 -85.46 178.18 7.52 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 120.802 -1.186 . . . . 0.0 108.812 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.914 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -156.58 111.65 2.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.063 -1.023 . . . . 0.0 110.302 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.827 HD21 ' O ' ' A' ' 27' ' ' GLY . 27.9 tp -82.12 100.28 9.7 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.795 HD12 ' HB2' ' B' ' 9' ' ' PRO . 67.8 mt -43.17 105.96 0.06 Allowed 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.7 t0 -114.38 87.47 2.64 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.517 -0.74 . . . . 0.0 110.839 -178.259 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -71.22 -5.44 32.07 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.842 -1.161 . . . . 0.0 108.63 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.474 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -81.99 -32.76 28.49 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.423 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -75.0 162.72 28.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.952 -1.323 . . . . 0.0 109.575 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.421 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 0.7 OUTLIER -93.4 -20.86 19.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.887 -179.421 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.577 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 14.3 m-20 -139.5 -164.81 1.75 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.034 -1.041 . . . . 0.0 109.407 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.643 HG23 ' O ' ' B' ' 84' ' ' ILE . 89.3 m -109.59 95.66 5.76 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.661 -1.274 . . . . 0.0 111.174 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -72.78 178.01 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 177.879 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.026 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -169.13 118.34 0.68 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.781 -1.199 . . . . 0.0 110.875 -178.885 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.643 ' HA ' HG22 ' B' ' 80' ' ' THR . 2.4 tt0 -35.11 150.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.557 . . . . 0.0 109.51 178.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.538 ' N ' ' HG3' ' B' ' 34' ' ' GLU . 0.0 OUTLIER -31.07 141.87 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.75 0.786 . . . . 0.0 111.497 -179.041 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.912 ' SD ' HD22 ' B' ' 38' ' ' LEU . 2.8 ppp? -169.05 175.54 5.73 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.265 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.543 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -122.53 136.28 54.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.619 -1.3 . . . . 0.0 111.235 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.912 HD22 ' SD ' ' B' ' 36' ' ' MET . 0.2 OUTLIER -120.49 175.83 2.14 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.251 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.85 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.8 Cg_endo -79.47 62.47 8.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.632 2.221 . . . . 0.0 111.171 179.397 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.539 ' O ' ' CG ' ' B' ' 41' ' ' ARG . . . 40.29 87.06 0.01 OUTLIER Glycine 0 N--CA 1.495 2.621 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.539 ' CG ' ' O ' ' B' ' 40' ' ' GLY . 4.2 mtt180 -167.67 57.15 0.07 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.86 -0.788 . . . . 0.0 109.095 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.629 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 59.3 p-90 -147.96 172.33 14.38 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.07 0.938 . . . . 0.0 110.791 -179.307 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mmtm -130.98 144.29 52.94 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.225 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -74.01 133.29 17.96 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 C-N-CA 121.626 1.551 . . . . 0.0 110.486 -179.266 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.449 ' HG3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.65 -178.83 7.64 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.462 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 62.9 mtp -145.13 131.52 19.66 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.141 -0.975 . . . . 0.0 109.323 179.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.865 HD11 HG21 ' A' ' 50' ' ' ILE . 19.9 pt -96.7 145.91 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.13 -0.982 . . . . 0.0 108.791 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.515 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.6 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.411 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -122.34 -122.86 2.84 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.272 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.608 HG13 ' H62' ' B' ' 100' ' ' DMP . 33.3 mt -89.69 121.54 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.716 -0.873 . . . . 0.0 112.414 -177.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.589 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 105.43 -52.26 0.72 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 178.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.31 -164.64 33.45 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.515 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -106.35 126.2 51.94 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.436 -1.038 . . . . 0.0 109.171 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.512 HD13 HG23 ' A' ' 50' ' ' ILE . 23.4 pt -97.28 174.99 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 120.917 -1.115 . . . . 0.0 109.149 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.514 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 35.2 mtpt -111.49 127.23 55.63 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.256 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.565 HG12 ' HA3' ' B' ' 78' ' ' GLY . 16.6 m -136.15 -174.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.583 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.586 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 0.5 OUTLIER -129.13 104.14 7.38 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.762 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.421 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 1.9 tt0 -62.38 97.4 0.09 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.523 -0.736 . . . . 0.0 110.704 -178.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.639 ' CE2' ' HB2' ' B' ' 38' ' ' LEU . 29.7 m-85 -88.56 127.49 35.55 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 5.6 m-20 -106.73 133.0 52.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.859 -1.151 . . . . 0.0 110.637 -178.548 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.544 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 52.2 mm-40 72.32 63.53 0.12 Allowed 'General case' 0 N--CA 1.49 1.539 0 CA-C-O 121.665 0.745 . . . . 0.0 109.469 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 1.095 ' CG2' HG23 ' B' ' 15' ' ' ILE . 12.6 mm -113.95 122.21 67.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.198 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.788 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.1 OUTLIER -69.97 84.99 0.51 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 111.568 -177.922 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.527 HD11 HD11 ' B' ' 66' ' ' ILE . 1.7 tt -88.62 119.47 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.8 tt0 -100.99 122.86 44.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.836 -1.165 . . . . 0.0 109.527 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.555 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -109.15 131.45 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 121.268 -0.895 . . . . 0.0 109.101 -179.956 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 57.37 -88.69 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.787 -0.57 . . . . 0.0 110.212 179.49 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -149.84 38.62 0.92 Allowed Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -136.36 123.13 21.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -1.115 . . . . 0.0 109.175 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.461 ' CG ' HD11 ' B' ' 63' ' ' LEU . 0.4 OUTLIER -66.9 136.33 55.21 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.244 -0.91 . . . . 0.0 108.623 179.551 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.566 ' HB2' HG22 ' B' ' 93' ' ' ILE . . . -152.09 119.96 6.17 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 110.268 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.788 HD13 ' N ' ' B' ' 63' ' ' LEU . 1.1 mm -89.53 163.31 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 178.016 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.792 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 174.05 173.11 39.89 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 118.931 -1.604 . . . . 0.0 110.777 179.568 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 59.3 m -83.72 114.8 21.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.469 -1.018 . . . . 0.0 109.892 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.026 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -106.77 114.91 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.254 -0.903 . . . . 0.0 110.6 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.757 ' HB2' HG23 ' B' ' 32' ' ' VAL . 4.1 mp -86.38 115.03 23.64 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.698 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.518 ' O ' ' CD ' ' B' ' 57' ' ' ARG . 93.0 t -101.14 132.12 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.045 -1.034 . . . . 0.0 109.57 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.565 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -169.44 -163.26 23.16 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.514 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.1 Cg_endo -79.8 43.55 1.53 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.754 2.303 . . . . 0.0 110.892 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.643 HG22 ' HA ' ' B' ' 34' ' ' GLU . 12.2 t -85.32 137.61 36.82 Favored Pre-proline 0 N--CA 1.488 1.431 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.571 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.69 13.62 1.86 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.302 2.001 . . . . 0.0 110.879 -179.315 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.571 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.4 t -161.44 163.34 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.132 -0.98 . . . . 0.0 109.864 -179.235 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 55.0 m-80 -94.34 136.32 34.77 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.051 -2.574 . . . . 0.0 104.051 175.599 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.782 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.6 mm -121.05 122.42 67.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 O-C-N 119.92 -1.737 . . . . 0.0 111.358 -177.545 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.914 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -98.63 92.07 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.638 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.18 -155.56 9.39 Favored Glycine 0 N--CA 1.49 2.28 0 C-N-CA 120.005 -1.093 . . . . 0.0 111.096 -178.015 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.938 ' HD2' HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -75.71 -29.66 59.04 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.905 -0.762 . . . . 0.0 110.159 -178.982 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.885 ' ND2' HD23 ' B' ' 89' ' ' LEU . 19.0 p-10 -51.08 -20.46 1.46 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.888 -1.133 . . . . 0.0 109.831 -179.365 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.885 HD23 ' ND2' ' B' ' 88' ' ' ASN . 4.0 mm? -116.17 -21.25 9.48 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.83 -1.169 . . . . 0.0 110.899 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.455 ' CD2' ' CB ' ' B' ' 95' ' ' ALA . 83.3 mt -66.12 -18.43 65.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.63 -1.294 . . . . 0.0 109.547 -179.711 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.86 -5.74 25.72 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.927 -1.108 . . . . 0.0 109.212 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 10.2 mm100 -94.15 -41.18 9.64 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 1.017 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.2 pt -88.94 -7.73 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.854 . . . . 0.0 108.749 179.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 89.43 28.03 20.87 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.919 178.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -71.11 125.72 27.65 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.667 -1.49 . . . . 0.0 109.52 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.539 HG22 HG22 ' A' ' 4' ' ' THR . 66.4 p -127.05 129.91 48.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' A' ' 97' ' ' LEU . 4.1 mp -87.35 102.46 14.54 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.249 -0.907 . . . . 0.0 110.256 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.528 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.1 m-20 -102.21 125.44 48.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.352 -0.843 . . . . 0.0 109.15 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.697 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.086 -0.959 . . . . 0.0 109.296 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.846 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.497 1.724 0 CA-C-O 121.501 0.542 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.4 tt0 -83.58 144.51 29.42 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.114 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.527 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 9.5 t -143.84 112.87 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.274 -1.37 . . . . 0.0 110.314 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.719 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -117.92 -67.1 1.02 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.958 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.547 ' O ' ' C ' ' A' ' 6' ' ' TRP . 2.5 pp 27.68 36.58 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.588 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.566 ' N ' ' O ' ' A' ' 4' ' ' THR . 35.7 m95 15.9 53.57 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.245 0 CA-C-O 121.184 0.516 . . . . 0.0 112.268 179.427 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 2.6 mt-30 -156.88 -166.75 2.17 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 109.529 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.479 ' HA ' ' HD3' ' B' ' 87' ' ' ARG . 1.0 OUTLIER -75.04 130.89 79.79 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.363 -0.836 . . . . 0.0 109.131 179.902 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.496 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.1 Cg_endo -78.19 79.33 3.31 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.25 1.967 . . . . 0.0 109.342 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.813 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -96.91 139.52 32.82 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.761 -179.359 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.568 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -135.36 147.47 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.467 -0.771 . . . . 0.0 109.965 -179.223 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.675 HG22 HD22 ' A' ' 19' ' ' LEU . 23.6 m -75.8 105.69 6.98 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.188 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.847 HD11 HD21 ' A' ' 33' ' ' LEU . 7.6 pt -99.06 146.4 8.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.248 -0.907 . . . . 0.0 110.642 -178.154 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.3 OUTLIER -111.57 99.51 8.25 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.296 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.875 HD13 HG11 ' A' ' 75' ' ' VAL . 4.2 mt -120.4 132.46 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.21 -0.931 . . . . 0.0 109.651 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.77 32.98 83.67 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.27 21.81 70.5 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.462 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.0 OUTLIER -117.81 174.92 5.91 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.299 -1.118 . . . . 0.0 109.213 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.675 HD22 HG22 ' A' ' 12' ' ' THR . 14.6 mt -140.02 120.2 13.79 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.236 -0.915 . . . . 0.0 110.379 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.7 mmmt -144.1 167.76 21.63 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.813 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -77.06 165.28 24.82 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.808 -1.183 . . . . 0.0 108.391 179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.694 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -142.54 119.82 11.54 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.922 -1.111 . . . . 0.0 109.817 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.608 HD21 ' O ' ' B' ' 27' ' ' GLY . 41.6 tp -88.27 93.33 9.48 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.699 -0.626 . . . . 0.0 109.647 -179.641 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 14.7 mt -43.67 97.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.06 -1.025 . . . . 0.0 109.657 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.647 ' CB ' HG23 ' A' ' 84' ' ' ILE . 27.7 t0 -100.56 81.36 2.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.89 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.641 HG23 HD13 ' A' ' 90' ' ' LEU . 1.8 m -60.74 -14.16 19.47 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.17 -0.956 . . . . 0.0 108.88 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.673 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.27 -33.68 64.53 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.526 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -81.28 169.44 17.29 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.196 -1.179 . . . . 0.0 110.014 -179.607 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.527 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 24.1 m-20 -98.38 -17.13 19.0 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.315 -0.866 . . . . 0.0 111.206 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.565 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -137.11 -171.13 2.87 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.694 -1.254 . . . . 0.0 110.249 -179.43 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.582 HG23 HD12 ' A' ' 85' ' ' ILE . 18.6 m -104.83 90.6 3.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.212 -0.93 . . . . 0.0 110.533 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.13 174.53 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.632 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.088 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -168.8 121.84 0.82 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.83 -1.169 . . . . 0.0 110.859 -179.352 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.578 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 1.1 pt-20 -37.36 156.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.547 -0.721 . . . . 0.0 109.797 178.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.578 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.5 tm-20 -45.0 145.75 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.356 -0.84 . . . . 0.0 110.8 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 13.5 ptm -165.02 -164.97 0.83 Allowed 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -116.81 122.75 45.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.996 -1.065 . . . . 0.0 110.506 -179.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 1.047 HD23 ' CD1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -128.08 -173.87 0.34 Allowed Pre-proline 0 N--CA 1.496 1.839 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 179.503 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.624 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -78.05 -163.3 0.21 Allowed 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 122.171 1.914 . . . . 0.0 111.371 -178.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.72 39.28 2.94 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -179.072 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -128.86 61.52 1.51 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.622 -0.928 . . . . 0.0 108.622 179.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.641 ' CD1' ' CE2' ' A' ' 59' ' ' TYR . 6.3 p-90 -132.9 -177.55 4.55 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.683 0.754 . . . . 0.0 110.47 -178.719 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -137.74 138.51 24.22 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.23 138.81 18.27 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.131 1.887 . . . . 0.0 110.85 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.419 ' O ' ' HG2' ' A' ' 46' ' ' MET . 1.6 ptpt -156.56 -169.47 3.02 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.419 ' HG2' ' O ' ' A' ' 45' ' ' LYS . 39.9 mtp -151.3 135.56 16.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 109.784 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 54' ' ' ILE . 15.3 pt -100.06 139.29 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.4 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.91 106.07 1.24 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -131.78 -123.26 2.45 Favored Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.74 -1.219 . . . . 0.0 110.308 -179.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.892 HG21 HD11 ' B' ' 47' ' ' ILE . 66.0 mt -88.48 115.29 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.445 -1.032 . . . . 0.0 112.45 -177.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.66 -32.96 5.45 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.361 -1.095 . . . . 0.0 110.361 178.081 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.87 -160.27 28.74 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 4.6 m-85 -110.86 124.55 52.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.32 -1.106 . . . . 0.0 109.491 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 47' ' ' ILE . 2.2 pt -102.26 174.03 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 108.721 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.7 OUTLIER -107.38 135.46 48.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.163 -0.961 . . . . 0.0 108.935 179.447 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.451 HG12 ' HA3' ' A' ' 78' ' ' GLY . 15.2 m -143.19 152.83 16.73 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 121.228 -0.92 . . . . 0.0 109.865 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 3.6 mtt85 -92.92 167.02 12.11 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -129.2 100.77 5.73 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.01 -1.056 . . . . 0.0 110.004 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 1.047 ' CD1' HD23 ' A' ' 38' ' ' LEU . 81.8 m-85 -100.25 123.36 44.39 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.356 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -98.73 130.75 45.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.009 . . . . 0.0 109.753 -179.669 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.549 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 83.14 59.75 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.389 0.614 . . . . 0.0 109.802 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.755 HG21 HG21 ' A' ' 75' ' ' VAL . 5.3 mm -110.57 117.4 54.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.729 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -69.86 86.82 0.52 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 111.093 -178.459 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.703 HG12 HD12 ' A' ' 66' ' ' ILE . 6.1 tt -88.87 118.21 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 69' ' ' HIS . 6.0 tt0 -88.22 112.51 22.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.033 -1.042 . . . . 0.0 108.936 -178.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.703 HD12 HG12 ' A' ' 64' ' ' ILE . 0.4 OUTLIER -103.92 118.86 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.348 -0.845 . . . . 0.0 109.052 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER 61.67 40.32 13.36 Favored 'General case' 0 C--N 1.293 -1.877 0 O-C-N 121.618 -0.676 . . . . 0.0 109.873 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.07 8.44 61.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.484 ' O ' ' HG2' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -101.26 155.99 17.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.176 -1.191 . . . . 0.0 108.989 179.781 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.643 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -89.44 126.63 35.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.017 -1.052 . . . . 0.0 109.754 -179.814 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.89 102.44 3.27 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.313 -0.867 . . . . 0.0 109.441 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.729 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -81.07 158.89 4.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.028 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.969 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.45 172.81 43.23 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.48 -1.819 . . . . 0.0 111.637 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 57.2 m -84.86 111.66 19.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.665 -0.903 . . . . 0.0 109.938 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.088 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -100.39 144.53 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.637 -0.665 . . . . 0.0 109.601 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -116.07 127.38 54.83 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.578 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 97.3 t -111.03 116.13 51.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 120.956 -1.09 . . . . 0.0 110.766 -178.469 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -151.18 -161.93 10.37 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.544 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.16 42.78 1.4 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.443 2.095 . . . . 0.0 110.327 179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.578 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.4 t -88.38 130.51 45.44 Favored Pre-proline 0 C--N 1.303 -1.435 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.469 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.27 21.05 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.417 2.078 . . . . 0.0 111.546 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.516 ' CG1' HD11 ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.07 159.54 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.881 -1.137 . . . . 0.0 109.81 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 33.5 m-80 -90.53 136.72 32.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.715 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.1 mm -125.75 122.79 62.99 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 O-C-N 119.955 -1.716 . . . . 0.0 111.498 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.694 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.34 95.59 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.501 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -79.75 -159.24 17.26 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.59 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -67.77 -37.04 81.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 -179.383 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.957 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.8 p-10 -45.28 -28.97 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.89 -1.131 . . . . 0.0 109.743 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.969 HD21 ' HA3' ' A' ' 73' ' ' GLY . 2.6 mm? -106.88 -27.64 10.59 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.92 -1.113 . . . . 0.0 109.428 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.641 HD13 HG23 ' A' ' 26' ' ' THR . 12.7 mt -70.32 -6.15 33.03 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.59 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.8 p -101.87 -20.0 15.06 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.18 -0.95 . . . . 0.0 108.66 178.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -76.34 -40.22 51.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.404 -0.81 . . . . 0.0 109.112 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.974 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -87.44 -1.74 8.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.375 -0.828 . . . . 0.0 109.07 179.324 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.73 29.84 50.53 Favored Glycine 0 N--CA 1.497 2.741 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -57.59 149.13 22.14 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.2 -1.177 . . . . 0.0 111.225 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.8 p -150.44 126.03 10.25 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' B' ' 97' ' ' LEU . 5.2 mp -84.89 109.02 17.82 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.223 -0.923 . . . . 0.0 108.671 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 40.9 m-20 -108.36 121.72 45.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.164 -179.333 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.606 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.474 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.504 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 109.97 -0.819 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.0 OUTLIER -83.34 144.74 29.47 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 105.985 -1.858 . . . . 0.0 105.985 177.354 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.502 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 92.8 t -148.95 114.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 117.56 -1.656 . . . . 0.0 111.413 -177.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.414 ' O ' ' N ' ' B' ' 6' ' ' TRP . 2.6 p -111.64 -70.94 0.78 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.303 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.1 OUTLIER 45.44 19.41 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.668 -0.645 . . . . 0.0 111.188 178.722 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.585 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 12.1 m95 19.3 44.8 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 120.948 0.404 . . . . 0.0 111.48 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' B' ' 5' ' ' LEU . 12.9 mm100 -156.56 -156.66 0.64 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.441 -0.787 . . . . 0.0 109.405 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 117.22 61.81 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.927 -1.108 . . . . 0.0 109.543 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -79.19 71.55 6.98 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.142 1.895 . . . . 0.0 109.431 179.076 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.623 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -91.23 159.83 15.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.864 . . . . 0.0 110.304 -178.986 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.559 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.8 OUTLIER -150.24 135.85 11.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.452 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.871 HG22 HD22 ' B' ' 19' ' ' LEU . 4.9 m -65.77 107.91 1.94 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.907 HG22 HG13 ' B' ' 66' ' ' ILE . 1.4 pt -103.88 150.31 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 119.15 -1.02 . . . . 0.0 111.007 -178.337 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.446 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 6.4 tttt -122.42 106.71 11.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.464 -0.772 . . . . 0.0 108.921 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 1.0 HD13 HG11 ' B' ' 75' ' ' VAL . 38.0 mt -115.11 143.04 25.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.052 -1.03 . . . . 0.0 109.242 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.81 -89.91 0.09 OUTLIER Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -160.32 32.79 0.41 Allowed Glycine 0 N--CA 1.485 1.935 0 N-CA-C 108.406 -1.878 . . . . 0.0 108.406 179.188 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 -134.97 171.66 14.1 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.671 -0.899 . . . . 0.0 109.34 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.871 HD22 HG22 ' B' ' 12' ' ' THR . 5.6 mt -120.83 137.59 54.48 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.481 ' HB3' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -150.59 144.18 25.11 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.375 -0.828 . . . . 0.0 108.798 -178.951 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.623 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.1 mt-10 -78.24 121.98 25.1 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.256 -0.903 . . . . 0.0 108.648 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.602 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.34 131.0 52.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 111.731 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.673 HD21 ' O ' ' A' ' 27' ' ' GLY . 33.7 tp -88.11 96.95 10.72 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.453 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' B' ' 9' ' ' PRO . 18.9 mt -42.3 107.31 0.08 Allowed 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.683 ' OD2' ' HB2' ' B' ' 28' ' ' ALA . 41.7 t0 -116.65 92.51 3.89 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.376 -0.827 . . . . 0.0 111.642 -177.645 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.528 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -75.89 -0.78 22.55 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.903 -1.123 . . . . 0.0 108.592 177.729 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.608 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -89.37 -28.66 19.18 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -179.739 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.683 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -78.79 170.67 16.3 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.89 -1.359 . . . . 0.0 109.443 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -100.24 -20.44 15.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.178 -0.951 . . . . 0.0 110.01 -179.494 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.608 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -142.39 -175.91 4.64 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.075 -1.016 . . . . 0.0 109.764 179.875 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.79 HG23 HD12 ' B' ' 85' ' ' ILE . 4.2 m -100.36 86.19 3.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 110.558 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.042 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.75 157.62 6.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.042 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.9 OUTLIER -153.06 128.66 10.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.918 -1.114 . . . . 0.0 110.688 -178.12 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.641 ' HA ' HG22 ' B' ' 80' ' ' THR . 1.1 pt-20 -43.37 162.34 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 109.11 179.396 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.495 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.8 mt-10 -48.92 139.83 9.65 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.225 -0.922 . . . . 0.0 110.126 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.6 OUTLIER -163.0 -171.09 2.54 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.519 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -111.99 116.15 30.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.877 -1.139 . . . . 0.0 110.236 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.706 HD12 HG21 ' B' ' 77' ' ' VAL . 3.4 mt -113.52 167.93 8.61 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.245 -0.909 . . . . 0.0 109.05 179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.574 ' HD2' ' CD2' ' B' ' 38' ' ' LEU . 34.4 Cg_endo -77.37 70.64 6.71 Favored 'Trans proline' 0 C--N 1.312 -1.367 0 C-N-CA 122.783 2.322 . . . . 0.0 112.183 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.13 -158.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 O-C-N 121.607 -0.683 . . . . 0.0 111.631 178.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 51.71 90.65 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.633 -0.922 . . . . 0.0 109.476 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CD2' ' B' ' 59' ' ' TYR . 44.6 p-90 -161.0 172.91 16.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.471 -0.768 . . . . 0.0 109.906 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.466 ' HB2' ' HB3' ' B' ' 58' ' ' GLN . 0.2 OUTLIER -135.46 128.76 18.33 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.903 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.51 141.06 19.62 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.261 1.974 . . . . 0.0 110.966 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.11 -167.56 1.97 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.452 -0.78 . . . . 0.0 109.083 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 46' ' ' MET . . . . . . . . . . . . . 81.7 mtp -143.28 133.69 24.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.329 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.892 HD11 HG21 ' A' ' 50' ' ' ILE . 35.0 pt -100.8 152.63 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.061 -1.024 . . . . 0.0 108.783 179.146 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.51 102.81 0.98 Allowed Glycine 0 N--CA 1.489 2.167 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.475 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -127.49 -131.2 3.44 Favored Glycine 0 N--CA 1.482 1.708 0 C-N-CA 119.447 -1.359 . . . . 0.0 111.123 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.939 HD12 ' C20' ' B' ' 100' ' ' DMP . 51.6 mt -88.51 126.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 122.008 -0.701 . . . . 0.0 112.515 -177.42 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 92.45 5.53 65.11 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 121.06 -166.13 14.07 Favored Glycine 0 N--CA 1.492 2.403 0 O-C-N 120.917 -1.343 . . . . 0.0 110.046 179.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.2 OUTLIER -109.42 135.43 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.377 -1.072 . . . . 0.0 109.57 -179.747 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.539 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.3 pt -104.82 -179.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 121.078 -1.014 . . . . 0.0 109.104 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.493 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 31.8 mttt -114.84 140.56 48.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.161 -0.962 . . . . 0.0 108.955 179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 33.8 m -149.66 176.55 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.001 -1.062 . . . . 0.0 110.262 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.558 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 1.0 OUTLIER -111.3 172.92 6.6 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.981 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.466 ' HB3' ' HB2' ' B' ' 43' ' ' LYS . 45.2 tt0 -128.82 87.92 2.65 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.152 -0.968 . . . . 0.0 110.198 -179.573 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.653 ' HB3' HD11 ' B' ' 62' ' ' ILE . 72.7 m-85 -89.77 93.98 9.65 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 179.116 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.498 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 3.8 m-20 -80.93 135.37 35.88 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.055 -1.028 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 7.6 mt-30 78.43 62.72 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.672 0.748 . . . . 0.0 109.866 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.653 HD11 ' HB3' ' B' ' 59' ' ' TYR . 35.1 mm -117.56 123.67 72.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.854 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.8 tm? -68.42 84.35 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.378 -0.827 . . . . 0.0 110.672 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.829 HG12 HD12 ' B' ' 66' ' ' ILE . 7.1 tt -87.55 118.39 33.31 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.586 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.3 tt0 -90.95 118.47 30.36 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.141 -0.975 . . . . 0.0 109.68 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.907 HG13 HG22 ' B' ' 13' ' ' ILE . 0.3 OUTLIER -120.14 128.95 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.16 -0.962 . . . . 0.0 108.908 179.753 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 85.5 m 57.05 51.41 10.51 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.495 -0.753 . . . . 0.0 109.817 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.49 19.45 13.12 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.467 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.8 m-70 -112.23 141.55 45.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.152 -1.205 . . . . 0.0 109.425 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.33 130.77 34.77 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.234 -0.917 . . . . 0.0 109.17 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.503 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -149.98 141.85 23.78 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.559 -0.713 . . . . 0.0 109.134 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.534 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -115.18 158.88 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.783 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.472 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.62 -159.46 26.28 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.687 -1.721 . . . . 0.0 111.454 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.1 m -101.33 109.01 20.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.473 -1.016 . . . . 0.0 110.136 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.0 HG11 HD13 ' B' ' 15' ' ' ILE . 1.5 t -104.06 108.73 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.225 179.449 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.618 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.1 mp -82.57 137.23 34.62 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.33 -0.856 . . . . 0.0 108.842 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.706 HG21 HD12 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -115.15 129.69 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.265 -0.897 . . . . 0.0 109.94 -179.342 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -166.07 -172.21 33.15 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.493 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -80.56 41.34 1.12 Allowed 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.53 2.153 . . . . 0.0 110.85 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.641 HG22 ' HA ' ' B' ' 34' ' ' GLU . 5.9 t -80.93 143.67 53.92 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.711 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -77.51 12.47 1.86 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.39 2.06 . . . . 0.0 111.296 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.711 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.61 161.55 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.835 -1.166 . . . . 0.0 110.486 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.596 ' ND2' ' N ' ' B' ' 83' ' ' ASN . 0.2 OUTLIER -98.36 92.63 5.78 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.774 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.816 HD11 ' C32' ' B' ' 100' ' ' DMP . 2.7 mt -93.39 135.52 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.951 -1.093 . . . . 0.0 113.327 -175.266 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.79 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -101.3 108.27 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.984 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.704 ' O ' HD22 ' B' ' 90' ' ' LEU . . . -95.95 173.37 30.48 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.871 -1.291 . . . . 0.0 109.871 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' B' ' 26' ' ' THR . 8.8 mtm-85 -35.91 -35.02 0.06 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.487 -1.008 . . . . 0.0 112.19 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.904 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -49.14 -43.43 41.69 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.231 -1.543 . . . . 0.0 110.395 -178.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.904 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.6 OUTLIER -93.64 -30.16 15.08 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.096 -1.003 . . . . 0.0 111.168 -178.931 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.704 HD22 ' O ' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -59.5 -36.33 75.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.532 -1.355 . . . . 0.0 108.719 -179.807 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.407 ' CG2' ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -71.44 -20.7 62.07 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.879 -1.138 . . . . 0.0 109.713 -179.534 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.44 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 11.8 mm-40 -75.11 -38.87 60.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.139 -0.976 . . . . 0.0 109.018 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.62 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -84.81 -8.5 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.181 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 80.51 29.56 43.68 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 178.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.583 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.83 135.38 57.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.105 -1.232 . . . . 0.0 109.824 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.719 HG22 HG23 ' A' ' 4' ' ' THR . 73.2 p -131.86 125.64 32.28 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' A' ' 97' ' ' LEU . 1.2 mp -84.86 92.95 8.4 Favored 'General case' 0 C--N 1.293 -1.861 0 O-C-N 121.335 -0.853 . . . . 0.0 109.954 -178.611 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.549 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 7.4 m-20 -105.14 138.8 40.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.577 -0.702 . . . . 0.0 109.962 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.974 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.338 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.939 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.512 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 3.4 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.292 -0.695 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.92 129.07 34.94 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 178.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.626 HG12 ' HB3' ' A' ' 9' ' ' PRO . 35.8 t -124.09 111.37 28.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 120.74 -1.225 . . . . 0.0 110.595 -178.333 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.506 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -119.28 -72.67 0.68 Allowed 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.228 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.6 mm? 42.15 29.21 0.13 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.426 -0.797 . . . . 0.0 110.125 179.165 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 20.9 m0 18.61 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.385 0 CA-C-O 121.249 0.547 . . . . 0.0 111.742 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.5 mt-30 -165.57 -165.28 0.82 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.372 -0.83 . . . . 0.0 108.805 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 82.7 mtm180 -64.25 117.08 33.26 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.078 -1.014 . . . . 0.0 109.235 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.626 ' HB3' HG12 ' A' ' 3' ' ' VAL . 34.8 Cg_endo -76.76 75.49 4.45 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 109.974 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.575 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -79.49 160.04 26.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.883 . . . . 0.0 109.58 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 24' ' ' LEU . 2.1 m -148.73 139.1 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.282 -0.887 . . . . 0.0 110.386 -179.076 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.891 HG22 HD22 ' A' ' 19' ' ' LEU . 54.9 m -70.3 98.3 1.37 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.126 -0.983 . . . . 0.0 108.392 178.58 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.834 ' O ' HD23 ' A' ' 19' ' ' LEU . 19.7 pt -92.12 150.07 3.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.453 -0.78 . . . . 0.0 109.901 -179.264 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 1.014 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -112.07 94.98 5.21 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.478 -0.764 . . . . 0.0 109.003 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.861 HD12 HD22 ' A' ' 33' ' ' LEU . 6.0 mt -114.35 128.17 71.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.357 -0.84 . . . . 0.0 109.561 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.2 30.53 78.04 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.71 9.92 66.44 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.5 mm100 -108.02 175.86 5.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -1.147 . . . . 0.0 108.935 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 1.014 HD21 ' HD3' ' A' ' 14' ' ' LYS . 20.1 mt -142.82 121.63 12.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.105 -0.997 . . . . 0.0 110.347 -179.417 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 3.2 mmtt -140.06 160.58 39.6 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.155 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.6 mp0 -78.86 123.97 27.77 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.937 -1.102 . . . . 0.0 108.461 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.689 ' HB2' HD13 ' A' ' 13' ' ' ILE . . . -108.16 130.51 55.12 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 110.673 -178.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.763 HD21 ' O ' ' B' ' 27' ' ' GLY . 42.9 tp -80.23 94.97 6.16 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.855 -0.528 . . . . 0.0 109.879 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.62 HD12 ' HB2' ' A' ' 9' ' ' PRO . 94.4 mt -46.71 95.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.324 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.878 ' HB2' HG23 ' A' ' 84' ' ' ILE . 34.6 t0 -99.96 89.12 3.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.317 -0.865 . . . . 0.0 110.837 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.461 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 15.7 m -65.07 -16.63 63.67 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.572 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.05 -34.59 64.78 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.66 161.37 23.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.156 -1.203 . . . . 0.0 109.071 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.429 ' HA ' ' HB2' ' A' ' 87' ' ' ARG . 34.6 m-20 -99.37 -12.54 20.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.983 -179.589 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 29.4 m-20 -137.35 173.01 12.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.024 -1.047 . . . . 0.0 110.084 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.856 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -94.07 107.44 19.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.083 -1.011 . . . . 0.0 110.194 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.842 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -100.26 117.3 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.304 -0.873 . . . . 0.0 109.022 179.441 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.861 HD22 HD12 ' A' ' 15' ' ' ILE . 2.2 mp -107.56 119.28 38.98 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.239 -0.913 . . . . 0.0 110.569 -179.015 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.711 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.4 pt-20 -42.73 168.41 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.328 -0.857 . . . . 0.0 109.393 178.556 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.9 OUTLIER -43.46 145.99 0.54 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.212 -0.93 . . . . 0.0 111.03 -179.128 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.435 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER 178.68 163.05 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -81.0 103.3 10.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.871 -1.143 . . . . 0.0 110.151 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.732 HD12 ' HD2' ' A' ' 39' ' ' PRO . 5.1 tp -121.8 104.1 39.54 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.857 . . . . 0.0 109.199 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.732 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.3 Cg_endo -77.41 146.89 25.05 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.542 2.161 . . . . 0.0 110.861 -179.695 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 134.45 172.72 12.9 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -77.45 127.69 32.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -1.233 . . . . 0.0 108.808 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 66.6 p-90 -130.26 172.91 11.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.775 -178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.408 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 2.1 mmtm -137.75 147.24 56.19 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.42 131.46 12.71 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.838 1.692 . . . . 0.0 110.289 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.627 ' NZ ' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -162.05 136.85 7.02 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.696 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -112.64 146.32 38.84 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.661 -1.275 . . . . 0.0 109.637 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.755 HD13 HG21 ' A' ' 32' ' ' VAL . 12.6 pt -101.0 140.27 20.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.517 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.66 104.61 1.11 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.49 -119.45 2.29 Favored Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.576 -1.297 . . . . 0.0 110.875 -179.05 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.838 HG23 HD13 ' B' ' 54' ' ' ILE . 49.9 mt -85.96 119.79 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.817 -0.814 . . . . 0.0 112.66 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.437 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 104.21 -53.38 0.7 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.355 -0.926 . . . . 0.0 110.795 178.038 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.435 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . -177.63 -157.41 18.45 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.234 -179.456 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -117.3 126.73 53.2 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.484 -1.009 . . . . 0.0 109.875 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.734 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.9 pp -105.08 160.55 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.303 -0.873 . . . . 0.0 109.085 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.561 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -103.02 146.6 28.11 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.046 -1.034 . . . . 0.0 110.115 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.768 HG12 ' HA3' ' A' ' 78' ' ' GLY . 3.1 m -149.39 -177.9 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.18 -0.95 . . . . 0.0 109.328 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.521 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 7.4 mmt85 -123.21 101.75 7.56 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.573 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 10.4 tt0 -73.18 106.17 4.91 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.4 -0.812 . . . . 0.0 111.144 -178.017 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 42' ' ' TRP . 41.4 m-85 -89.47 130.75 35.76 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.543 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.0 m-20 -100.82 121.11 41.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.7 -1.25 . . . . 0.0 109.976 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.8 OUTLIER 85.15 57.07 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.206 0.527 . . . . 0.0 110.048 179.538 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.634 HG21 HG23 ' A' ' 15' ' ' ILE . 16.4 mm -105.54 119.95 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -0.923 . . . . 0.0 108.919 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.881 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.4 tm? -68.72 98.59 0.92 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.854 -178.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.739 HG22 ' O ' ' A' ' 71' ' ' ALA . 7.9 tt -102.83 119.36 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.329 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.58 116.84 28.03 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.809 -1.182 . . . . 0.0 109.424 -178.915 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.526 HG21 HD13 ' A' ' 93' ' ' ILE . 0.4 OUTLIER -109.25 129.07 64.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.3 -0.875 . . . . 0.0 109.053 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.512 ' HB3' ' HG3' ' A' ' 1' ' ' PRO . 1.7 m 38.04 52.15 1.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.459 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 63.28 48.86 75.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.464 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.478 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 92.9 m-70 -145.15 115.19 7.43 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -1.156 . . . . 0.0 109.431 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.596 ' CG ' HD21 ' A' ' 63' ' ' LEU . 19.6 ttpt -60.97 129.25 40.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.739 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.28 99.65 2.23 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.392 -0.818 . . . . 0.0 109.874 -179.093 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.55 160.43 4.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 120.866 -1.146 . . . . 0.0 108.533 178.981 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.641 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.99 177.15 47.37 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 118.777 -1.678 . . . . 0.0 111.59 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.573 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 17.7 m -89.03 111.77 22.57 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.815 -0.815 . . . . 0.0 110.549 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.976 ' C ' HD12 ' A' ' 76' ' ' LEU . 1.4 t -101.05 161.33 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.465 -0.772 . . . . 0.0 109.733 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.976 HD12 ' C ' ' A' ' 75' ' ' VAL . 6.0 mp -130.55 105.0 7.55 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.064 -1.022 . . . . 0.0 108.405 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 61.7 t -89.61 117.75 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.792 -1.193 . . . . 0.0 109.973 -179.477 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.768 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.5 -166.97 17.08 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.561 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -82.75 39.02 0.78 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.479 2.119 . . . . 0.0 111.085 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.713 HG23 ' H ' ' A' ' 82' ' ' VAL . 0.8 OUTLIER -85.62 137.57 36.18 Favored Pre-proline 0 N--CA 1.49 1.525 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 178.174 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.94 23.04 0.58 Allowed 'Trans proline' 0 C--N 1.303 -1.859 0 C-N-CA 122.187 1.924 . . . . 0.0 111.689 -178.363 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.713 ' H ' HG23 ' A' ' 80' ' ' THR . 0.5 OUTLIER -162.94 140.93 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 120.621 -1.299 . . . . 0.0 111.899 -178.983 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.592 ' O ' ' CG1' ' A' ' 84' ' ' ILE . 75.1 m-20 -80.54 154.72 27.33 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.182 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.878 HG23 ' HB2' ' A' ' 25' ' ' ASP . 20.5 mt -155.63 134.04 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 117.065 -1.854 . . . . 0.0 112.443 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.565 ' HB ' HD23 ' A' ' 24' ' ' LEU . 9.5 mm -99.27 104.34 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 178.132 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.13 -161.48 35.41 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.747 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.474 ' O ' ' OG1' ' A' ' 91' ' ' THR . 1.0 OUTLIER -63.73 -35.48 80.72 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.691 -0.888 . . . . 0.0 109.663 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.921 ' ND2' HD23 ' A' ' 89' ' ' LEU . 18.6 p-10 -51.26 -20.88 1.8 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.987 -1.07 . . . . 0.0 110.248 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.921 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -113.03 -29.7 7.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.727 -1.233 . . . . 0.0 110.265 -179.448 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.461 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 21.4 mt -66.18 -11.6 50.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.994 -1.066 . . . . 0.0 108.957 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -101.38 -10.05 20.59 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.064 -1.023 . . . . 0.0 109.513 179.848 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.409 ' NE2' ' O ' ' A' ' 72' ' ' ILE . 4.9 mm100 -90.28 -41.19 11.69 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.264 -0.897 . . . . 0.0 109.85 -179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.708 HD12 ' CD2' ' B' ' 99' ' ' PHE . 2.2 pt -89.72 2.35 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.118 -0.989 . . . . 0.0 109.065 179.371 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 65.84 54.48 24.86 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -82.75 137.1 34.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.055 -1.262 . . . . 0.0 109.543 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.405 HG22 ' HA ' ' B' ' 4' ' ' THR . 16.4 p -122.78 136.95 55.03 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.223 -0.923 . . . . 0.0 109.117 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' B' ' 97' ' ' LEU . 5.3 mp -97.36 96.67 8.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.896 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 11.4 m-20 -101.02 125.17 47.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.038 -1.039 . . . . 0.0 109.251 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.691 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.296 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.678 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -130.74 136.69 48.99 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 8.0 t -132.17 136.24 56.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 120.886 -1.134 . . . . 0.0 109.653 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.673 ' O ' HD23 ' B' ' 5' ' ' LEU . 6.0 p -69.38 -93.14 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.394 -0.816 . . . . 0.0 109.662 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.673 HD23 ' O ' ' B' ' 4' ' ' THR . 0.2 OUTLIER 158.81 -7.44 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.836 -0.54 . . . . 0.0 110.72 179.542 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -50.53 -19.27 0.84 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.667 -1.271 . . . . 0.0 110.535 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.41 -175.92 4.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.806 -1.184 . . . . 0.0 109.9 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.05 130.33 91.49 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.474 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -79.66 68.16 8.38 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.425 2.083 . . . . 0.0 109.471 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.79 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -87.21 156.48 19.65 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.167 -0.958 . . . . 0.0 109.977 -179.104 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.897 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -147.33 138.37 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.392 -0.817 . . . . 0.0 109.662 -179.627 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.404 HG22 ' HB3' ' B' ' 19' ' ' LEU . 1.5 m -71.53 90.68 1.02 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.89 -1.131 . . . . 0.0 108.287 178.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.929 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -80.29 150.2 4.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.952 -179.251 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 10.6 tttm -121.75 104.42 9.58 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.366 -0.834 . . . . 0.0 109.403 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.962 HD13 HG11 ' B' ' 75' ' ' VAL . 4.8 mt -117.13 143.21 28.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.24 -90.29 0.05 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.946 -1.661 . . . . 0.0 108.946 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -158.35 38.67 0.52 Allowed Glycine 0 N--CA 1.486 1.97 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 179.286 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -137.46 166.91 22.73 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.67 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.514 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 17.5 mt -132.23 122.12 24.73 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.431 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -134.89 155.78 50.09 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.035 -1.041 . . . . 0.0 109.9 -178.961 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.79 ' HB3' HD22 ' B' ' 10' ' ' LEU . 5.5 mm-40 -78.98 110.42 14.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 178.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -98.63 154.75 17.71 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 110.341 -178.395 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.572 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -101.85 101.18 11.58 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.668 -0.645 . . . . 0.0 109.751 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.681 HD13 ' HE2' ' A' ' 99' ' ' PHE . 19.6 mt -46.23 99.57 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.32 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.671 ' CB ' HG23 ' B' ' 84' ' ' ILE . 44.4 t0 -107.48 96.08 6.15 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.291 -0.88 . . . . 0.0 111.027 -178.225 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.624 ' HA ' HD21 ' B' ' 90' ' ' LEU . 0.7 OUTLIER -78.97 3.22 17.77 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.086 -1.009 . . . . 0.0 109.188 178.599 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.763 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -95.69 -18.62 31.97 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.517 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -85.78 170.83 12.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.019 -1.283 . . . . 0.0 109.711 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.453 ' HA ' ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER -100.67 -20.06 15.79 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.186 -0.946 . . . . 0.0 110.797 -178.88 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.51 ' OD1' ' HB ' ' B' ' 74' ' ' THR . 0.2 OUTLIER -137.99 -163.11 1.39 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.803 -1.186 . . . . 0.0 109.851 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.534 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 17.8 m -109.88 86.6 2.33 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.972 -1.08 . . . . 0.0 110.538 -178.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.02 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -69.04 175.39 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.825 -1.172 . . . . 0.0 108.157 179.08 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.02 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.4 116.94 0.51 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.111 -0.993 . . . . 0.0 109.804 -178.911 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.2 pt-20 -39.58 160.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.465 -0.772 . . . . 0.0 109.515 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.3 OUTLIER -38.31 139.81 0.35 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.728 0.775 . . . . 0.0 110.699 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -168.53 167.69 11.47 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.761 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 28.8 t -100.63 125.78 47.07 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.789 -1.194 . . . . 0.0 111.256 -178.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.603 ' HB2' ' CZ ' ' B' ' 59' ' ' TYR . 3.6 mm? -117.09 171.96 4.38 Favored Pre-proline 0 N--CA 1.493 1.696 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.544 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.3 Cg_endo -80.57 59.91 7.64 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.385 2.057 . . . . 0.0 111.38 -179.493 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 40.21 -158.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 3.0 mmp_? 58.49 68.22 0.85 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.443 -1.034 . . . . 0.0 109.313 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.62 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 22.8 p-90 -144.16 -167.44 2.61 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.44 -0.788 . . . . 0.0 109.879 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -146.44 132.08 9.31 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.57 132.12 11.95 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 121.93 1.753 . . . . 0.0 110.602 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -161.33 -162.24 0.88 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.421 ' HB3' ' HA ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -152.24 146.33 25.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.992 -1.068 . . . . 0.0 109.361 178.743 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.73 HD11 HD11 ' B' ' 54' ' ' ILE . 1.1 pt -96.33 155.83 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.258 -0.901 . . . . 0.0 108.886 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.663 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.09 130.7 8.69 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.531 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -158.02 -125.42 0.83 Allowed Glycine 0 N--CA 1.482 1.76 0 C-N-CA 118.949 -1.596 . . . . 0.0 111.338 -179.196 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.798 HD12 ' C21' ' B' ' 100' ' ' DMP . 19.0 mt -88.96 126.68 41.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.937 -0.743 . . . . 0.0 112.836 -177.271 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.435 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 90.48 -28.3 7.73 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 178.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.427 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 157.76 -159.24 29.74 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.169 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.663 ' CD2' ' CA ' ' B' ' 48' ' ' GLY . 1.5 m-85 -120.49 132.07 55.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.654 -0.909 . . . . 0.0 109.627 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.838 HD13 HG23 ' A' ' 50' ' ' ILE . 35.4 pt -103.9 162.84 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 108.983 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 13.0 mttt -93.3 154.73 17.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.088 -1.007 . . . . 0.0 109.771 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.597 HG12 ' HA3' ' B' ' 78' ' ' GLY . 6.4 m -151.23 -168.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.055 -1.028 . . . . 0.0 110.07 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.577 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 16.7 mmt180 -129.83 89.22 2.78 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -56.48 93.62 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.271 -0.893 . . . . 0.0 110.777 -178.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.873 ' HB3' HD11 ' B' ' 62' ' ' ILE . 27.9 m-85 -88.71 136.04 33.2 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 177.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -114.58 138.25 50.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.712 -1.242 . . . . 0.0 111.041 -178.302 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.543 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.46 60.68 0.07 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.653 -0.654 . . . . 0.0 110.602 178.884 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.933 HG21 HG23 ' B' ' 15' ' ' ILE . 4.2 mp -118.77 118.09 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 108.856 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.841 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.8 tm? -68.26 90.13 0.34 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.237 -0.914 . . . . 0.0 110.631 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.701 ' CD1' HD11 ' B' ' 66' ' ' ILE . 2.4 tt -90.07 115.21 29.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.4 tm-20 -89.13 117.53 28.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.551 -178.586 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.929 HG13 HG22 ' B' ' 13' ' ' ILE . 1.4 mp -115.69 125.02 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.331 -0.856 . . . . 0.0 109.351 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 62.4 m 61.57 -95.06 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.518 -0.739 . . . . 0.0 109.792 179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -145.78 39.78 1.12 Allowed Glycine 0 N--CA 1.484 1.893 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 3.2 m80 -139.62 133.06 30.15 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.381 -1.07 . . . . 0.0 109.637 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.462 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -77.04 135.55 38.65 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.022 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.648 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.75 97.53 2.98 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.154 -1.018 . . . . 0.0 110.665 -179.326 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.775 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.89 140.17 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 177.988 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.838 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.77 -168.0 29.27 Favored Glycine 0 N--CA 1.485 1.96 0 C-N-CA 118.741 -1.695 . . . . 0.0 110.939 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 28.9 m -95.95 109.18 21.59 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.781 -0.835 . . . . 0.0 110.244 -179.397 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.962 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -96.61 104.97 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.321 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.7 mp -79.86 116.74 20.19 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.202 -0.936 . . . . 0.0 108.615 178.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.577 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.3 t -101.39 131.44 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.051 -1.031 . . . . 0.0 109.125 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.597 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -162.38 -165.43 19.37 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.06 -1.543 . . . . 0.0 109.905 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.539 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.93 40.67 1.01 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.753 2.302 . . . . 0.0 110.054 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' B' ' 34' ' ' GLU . 8.8 t -85.55 138.5 35.89 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.516 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 33.9 Cg_endo -78.38 14.3 1.63 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.51 2.14 . . . . 0.0 111.078 -179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.526 HG12 ' CD1' ' B' ' 84' ' ' ILE . 1.1 t -160.68 167.56 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.102 -0.999 . . . . 0.0 109.382 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.608 ' OD1' ' N ' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -101.15 144.18 30.34 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 175.816 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.697 ' CG1' HG12 ' B' ' 32' ' ' VAL . 6.8 mm -129.0 123.68 59.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 O-C-N 120.069 -1.644 . . . . 0.0 112.194 -176.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.735 HG22 ' CD1' ' B' ' 90' ' ' LEU . 4.4 mm -102.54 101.48 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.615 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -107.0 175.25 20.51 Favored Glycine 0 N--CA 1.496 2.695 0 C-N-CA 119.792 -1.194 . . . . 0.0 111.915 -177.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.786 ' N ' HD22 ' B' ' 90' ' ' LEU . 4.0 mtm180 -28.46 -41.44 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.376 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -178.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.991 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.8 p-10 -53.17 -41.38 65.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 120.234 -1.541 . . . . 0.0 110.661 -177.659 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.991 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.6 mm? -98.92 -18.33 17.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.172 -0.955 . . . . 0.0 110.342 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.786 HD22 ' N ' ' B' ' 87' ' ' ARG . 0.4 OUTLIER -69.51 -35.89 75.94 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.143 -0.973 . . . . 0.0 109.391 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 49.6 p -70.03 -15.27 62.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.189 -0.944 . . . . 0.0 108.965 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' B' ' 72' ' ' ILE . 26.7 mt-30 -91.63 -40.48 11.28 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.306 -0.871 . . . . 0.0 108.943 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.645 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -81.77 -2.98 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 177.088 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.01 43.29 99.63 Favored Glycine 0 N--CA 1.496 2.697 0 O-C-N 121.561 -0.712 . . . . 0.0 111.361 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.691 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -68.38 147.01 52.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.874 -1.368 . . . . 0.0 110.289 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.506 HG22 ' CG2' ' A' ' 4' ' ' THR . 14.9 p -144.61 130.78 19.54 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.339 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' A' ' 97' ' ' LEU . 8.0 mp -92.68 102.85 15.27 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 110.119 -179.195 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 8.5 m-20 -101.65 121.95 42.98 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.088 -1.007 . . . . 0.0 109.688 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.708 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 118.128 -0.939 . . . . 0.0 109.33 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.798 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.468 ' HD2' ' OXT' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.687 0 N-CA-C 110.164 -0.745 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.403 ' OE1' HG23 ' A' ' 4' ' ' THR . 0.3 OUTLIER -104.09 126.59 51.33 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.292 -0.88 . . . . 0.0 109.032 179.079 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.436 HG11 ' HB3' ' A' ' 9' ' ' PRO . 13.8 t -121.83 102.46 11.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.878 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.554 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -52.27 -84.26 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.324 -0.86 . . . . 0.0 109.953 -178.981 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.846 HD23 HG23 ' B' ' 91' ' ' THR . 31.2 tp 171.84 -25.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.259 -0.9 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 84.8 m95 -54.77 -19.36 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.07 -1.019 . . . . 0.0 108.996 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -129.51 130.53 45.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.438 -0.789 . . . . 0.0 109.513 179.594 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtt-85 -49.06 146.49 5.7 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.833 ' HB2' HD12 ' A' ' 24' ' ' LEU . 37.0 Cg_endo -79.8 47.75 2.63 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.838 2.359 . . . . 0.0 110.538 179.394 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.553 HD22 ' HB3' ' A' ' 21' ' ' GLU . 1.8 mt -80.03 144.4 33.24 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.1 -1.0 . . . . 0.0 109.276 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG22 ' A' ' 66' ' ' ILE . 1.9 m -148.99 160.15 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.366 -179.379 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.664 HG22 HD22 ' A' ' 19' ' ' LEU . 90.0 m -91.21 107.77 19.43 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.487 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.811 HG12 ' HB2' ' A' ' 22' ' ' ALA . 2.1 pt -99.18 157.97 3.67 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.275 -0.89 . . . . 0.0 110.084 -178.674 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.484 ' HE3' HD11 ' A' ' 19' ' ' LEU . 2.3 ttmt -118.16 100.81 7.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 108.913 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.796 HD13 HG21 ' A' ' 75' ' ' VAL . 1.3 mt -109.8 140.92 26.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.858 -1.151 . . . . 0.0 109.4 -179.587 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 62.96 -90.64 0.07 OUTLIER Glycine 0 N--CA 1.488 2.139 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -179.604 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.22 35.19 0.6 Allowed Glycine 0 C--N 1.294 -1.787 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.404 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.409 ' OE1' ' HB2' ' A' ' 37' ' ' SER . 8.2 mt-30 -138.99 173.78 11.2 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -1.134 . . . . 0.0 109.591 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.766 HD23 ' O ' ' A' ' 13' ' ' ILE . 18.5 mt -133.58 122.04 22.95 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.593 -0.692 . . . . 0.0 109.42 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HE3' ' SD ' ' A' ' 36' ' ' MET . 0.3 OUTLIER -135.72 -179.87 5.92 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.93 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.553 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.5 mt-10 -78.32 176.36 9.39 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 108.191 179.521 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.811 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -157.71 108.74 2.25 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 120.936 -1.102 . . . . 0.0 109.619 -179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.699 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.8 tp -85.19 93.41 8.65 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.35 -0.844 . . . . 0.0 109.078 179.786 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.833 HD12 ' HB2' ' A' ' 9' ' ' PRO . 97.8 mt -43.06 97.15 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.686 ' CB ' HG23 ' A' ' 84' ' ' ILE . 3.8 t0 -102.95 77.18 1.54 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.388 -0.82 . . . . 0.0 110.918 -178.245 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.48 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 2.2 m -54.92 -20.19 8.36 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.124 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.731 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -65.24 -44.33 93.93 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.732 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.47 155.72 40.01 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.17 -1.194 . . . . 0.0 108.86 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.68 -17.55 31.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.05 -1.032 . . . . 0.0 110.688 -179.034 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.523 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -138.42 -159.58 0.97 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.779 -1.201 . . . . 0.0 110.108 -179.532 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.83 HG22 ' CD1' ' A' ' 33' ' ' LEU . 35.3 m -114.98 91.41 3.61 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.925 -1.11 . . . . 0.0 110.602 -178.547 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.95 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -74.79 160.12 5.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.675 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -160.15 123.72 3.57 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.841 -1.162 . . . . 0.0 110.473 -178.595 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.607 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.6 OUTLIER -41.99 153.46 0.06 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.14 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.542 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -43.11 146.93 0.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.021 -1.049 . . . . 0.0 110.161 -179.55 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.458 ' HE1' ' HB ' ' A' ' 15' ' ' ILE . 21.7 ptm -162.2 -163.64 0.95 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.311 -0.868 . . . . 0.0 109.597 -179.802 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.409 ' HB2' ' OE1' ' A' ' 18' ' ' GLN . 7.4 t -101.31 87.08 3.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.433 -0.792 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.643 HD13 HG22 ' A' ' 15' ' ' ILE . 12.9 tp -127.71 97.34 30.5 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.145 -0.972 . . . . 0.0 110.134 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.04 178.31 7.34 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.497 2.131 . . . . 0.0 109.94 179.366 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.15 -173.86 16.31 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.486 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -78.93 134.86 36.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.326 -1.102 . . . . 0.0 109.239 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.605 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.9 p-90 -147.72 159.42 43.82 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -128.26 135.44 27.54 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 135.33 18.28 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 121.86 1.707 . . . . 0.0 109.968 -179.637 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.1 ptpt -155.8 -165.66 2.02 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.462 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.481 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 4.0 mtp -150.4 125.89 10.2 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.293 -0.879 . . . . 0.0 109.641 -179.624 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' B' ' 50' ' ' ILE . 1.1 pt -89.78 147.1 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.014 -1.054 . . . . 0.0 108.422 179.118 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.433 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -117.97 105.76 1.28 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.503 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -128.39 -132.34 3.54 Favored Glycine 0 N--CA 1.484 1.89 0 C-N-CA 119.459 -1.353 . . . . 0.0 111.043 -178.815 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.812 HD12 ' C71' ' B' ' 100' ' ' DMP . 34.8 mt -83.13 121.06 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.838 -0.801 . . . . 0.0 112.537 -177.547 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.457 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 97.71 -20.48 50.46 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 178.019 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.87 -161.01 28.88 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 120.808 -1.407 . . . . 0.0 109.993 179.925 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -126.09 132.37 51.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.437 -1.037 . . . . 0.0 109.524 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.585 HD11 HD11 ' A' ' 47' ' ' ILE . 14.1 pt -104.38 175.33 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.079 -1.013 . . . . 0.0 109.412 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.481 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 3.6 mtmt -103.77 140.32 37.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.095 -1.003 . . . . 0.0 109.258 179.853 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.592 HG21 HD23 ' A' ' 76' ' ' LEU . 27.1 m -144.39 170.08 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.129 -0.982 . . . . 0.0 109.917 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.413 ' O ' ' N ' ' A' ' 59' ' ' TYR . 1.0 OUTLIER -111.21 96.76 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.057 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -55.78 93.74 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.344 -0.848 . . . . 0.0 109.704 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 5.8 m-85 -89.31 125.98 35.33 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 178.528 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.606 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 65.3 m-20 -106.38 133.8 50.5 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.792 -1.192 . . . . 0.0 110.345 -178.885 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.606 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mt-30 74.44 63.32 0.07 Allowed 'General case' 0 N--CA 1.494 1.741 0 CA-C-O 121.855 0.836 . . . . 0.0 109.904 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.584 ' HB ' HG23 ' A' ' 75' ' ' VAL . 16.0 mm -115.14 119.47 61.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 178.616 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.599 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -70.42 90.2 0.71 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.178 -0.951 . . . . 0.0 111.277 -177.919 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.708 ' CG2' HD11 ' A' ' 89' ' ' LEU . 7.3 tt -88.51 113.51 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.657 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -87.99 111.79 21.88 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.244 -0.91 . . . . 0.0 109.012 -178.282 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.549 HD13 HG22 ' A' ' 13' ' ' ILE . 1.3 mm -97.19 168.1 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.505 ' C ' ' O ' ' A' ' 66' ' ' ILE . 61.3 m -28.68 88.87 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.488 0.661 . . . . 0.0 111.219 -179.074 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.546 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 52.31 58.94 9.66 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.529 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.552 ' CD2' HG22 ' A' ' 93' ' ' ILE . 5.5 m80 -162.27 86.76 0.61 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.372 . . . . 0.0 110.42 179.496 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.566 ' HG3' HD21 ' A' ' 63' ' ' LEU . 4.4 tttm -49.04 118.54 2.69 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.621 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -141.26 108.36 5.47 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 119.416 -0.914 . . . . 0.0 110.456 -178.602 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.599 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -80.74 159.42 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.005 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.894 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 179.42 174.49 45.51 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 118.247 -1.93 . . . . 0.0 111.452 179.577 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 87.6 m -87.14 112.67 22.17 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.606 -0.938 . . . . 0.0 109.956 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.888 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -102.17 118.9 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.422 -0.799 . . . . 0.0 110.275 179.679 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.592 HD23 HG21 ' A' ' 56' ' ' VAL . 4.9 mp -87.81 105.75 17.62 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.77 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 35' ' ' GLU . 6.5 t -88.75 113.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.233 -0.917 . . . . 0.0 110.327 -178.67 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.85 -168.77 17.96 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.451 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -80.35 44.5 1.75 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.634 2.223 . . . . 0.0 111.061 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.695 HG21 HG13 ' A' ' 32' ' ' VAL . 9.7 t -82.5 141.25 45.17 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.022 -1.049 . . . . 0.0 108.637 179.241 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.674 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.7 Cg_endo -81.22 17.67 1.43 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.576 2.184 . . . . 0.0 111.163 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.674 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.2 t -161.26 163.28 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.86 -1.15 . . . . 0.0 110.333 -179.23 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 72.5 m-20 -99.18 89.37 4.22 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.686 HG23 ' CB ' ' A' ' 25' ' ' ASP . 8.2 mm -78.27 116.43 21.94 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 O-C-N 121.168 -0.957 . . . . 0.0 111.764 -176.436 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.651 HG12 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -101.63 85.99 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.225 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.64 -165.32 28.02 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.288 -0.958 . . . . 0.0 112.346 -176.397 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.552 ' HD3' ' HD3' ' B' ' 9' ' ' PRO . 27.8 mtm-85 -57.38 -39.91 77.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 122.203 -0.586 . . . . 0.0 111.481 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.929 ' ND2' HD23 ' A' ' 89' ' ' LEU . 16.3 p-10 -45.49 -24.31 0.31 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.537 -1.352 . . . . 0.0 109.63 -179.3 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.929 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -111.9 -32.48 6.59 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.892 -1.13 . . . . 0.0 110.712 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.48 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 90.1 mt -58.17 -36.58 73.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.824 -1.172 . . . . 0.0 108.841 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.4 p -75.69 -20.53 58.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.316 -0.865 . . . . 0.0 109.643 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -72.45 -40.31 67.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.863 -1.148 . . . . 0.0 108.472 179.428 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -81.65 -1.01 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.581 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 67.47 61.3 5.16 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.506 -1.838 . . . . 0.0 108.506 -179.527 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -89.77 149.27 22.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.442 -1.034 . . . . 0.0 110.003 -179.192 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.731 HG22 HG23 ' B' ' 4' ' ' THR . 49.5 p -137.73 125.43 22.36 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.028 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' B' ' 97' ' ' LEU . 4.8 mp -86.0 104.11 15.31 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.59 -0.694 . . . . 0.0 109.279 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.564 ' OD1' ' ND2' ' B' ' 98' ' ' ASN . 4.2 m120 -104.4 122.32 45.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.083 -1.011 . . . . 0.0 110.03 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.783 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.618 0 CA-C-O 117.937 -1.03 . . . . 0.0 109.25 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.478 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.626 0 N-CA-C 109.87 -0.858 . . . . 0.0 109.87 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 1.2 tt0 -84.64 134.0 34.39 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.633 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.62 HG13 HD13 ' B' ' 5' ' ' LEU . 22.2 t -133.73 137.07 53.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 120.762 -1.212 . . . . 0.0 109.9 -179.144 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.731 HG23 HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -129.99 23.84 5.3 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 178.983 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.71 HD23 ' HA ' ' B' ' 9' ' ' PRO . 1.6 mp -39.54 92.24 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.767 0.794 . . . . 0.0 109.801 -179.226 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.558 ' N ' ' O ' ' B' ' 4' ' ' THR . 4.7 m95 -44.42 -21.59 0.05 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.632 -0.667 . . . . 0.0 109.912 -179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.447 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.7 mt-30 -109.4 -158.85 0.66 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.022 -1.049 . . . . 0.0 108.599 179.122 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -59.01 119.7 40.42 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.037 -1.04 . . . . 0.0 109.469 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.71 ' HA ' HD23 ' B' ' 5' ' ' LEU . 36.6 Cg_endo -78.22 73.14 5.92 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.254 1.969 . . . . 0.0 109.798 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -82.1 163.61 21.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.184 -0.947 . . . . 0.0 109.937 -179.425 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.518 HG23 ' CG2' ' B' ' 13' ' ' ILE . 14.8 m -144.95 142.33 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.429 -0.794 . . . . 0.0 110.143 -179.697 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.744 HG22 HD22 ' B' ' 19' ' ' LEU . 2.7 m -73.97 99.09 3.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.01 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 1.3 pt -92.07 147.46 5.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.617 -178.454 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.8 tttt -114.08 94.51 4.85 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.826 HD11 HD12 ' B' ' 64' ' ' ILE . 22.3 mt -115.03 129.94 70.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.132 -0.98 . . . . 0.0 109.609 -179.429 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.05 52.99 49.08 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.442 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.35 23.57 9.01 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -119.26 170.67 8.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -1.151 . . . . 0.0 109.476 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.744 HD22 HG22 ' B' ' 12' ' ' THR . 13.8 mt -141.52 122.42 14.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.139 -0.976 . . . . 0.0 110.24 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 mttt -147.22 145.92 29.63 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.139 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 11.8 mt-10 -78.37 133.24 37.59 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.863 -1.148 . . . . 0.0 108.504 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -112.38 162.8 15.15 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.883 -179.04 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.731 HD21 ' O ' ' A' ' 27' ' ' GLY . 59.4 tp -99.7 101.52 12.72 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.837 -0.539 . . . . 0.0 110.06 -178.856 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' B' ' 9' ' ' PRO . 2.9 mt -44.98 97.37 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.214 -0.929 . . . . 0.0 108.51 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.733 ' CB ' HG23 ' B' ' 84' ' ' ILE . 10.3 t0 -100.87 95.39 6.58 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.089 -1.007 . . . . 0.0 110.863 -178.786 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.53 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -83.0 9.67 9.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.257 -0.902 . . . . 0.0 108.861 178.301 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.699 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -108.0 -14.13 17.88 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.5 170.03 9.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.111 -1.229 . . . . 0.0 109.089 179.803 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.08 -14.94 17.59 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.038 -1.039 . . . . 0.0 111.825 -178.397 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.535 ' HB3' HD11 ' B' ' 76' ' ' LEU . 14.3 m-20 -141.91 -169.33 2.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.507 -1.371 . . . . 0.0 110.639 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.779 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 38.5 m -104.48 84.75 2.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.199 -0.938 . . . . 0.0 110.475 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.659 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -78.75 112.19 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.244 -0.91 . . . . 0.0 110.387 -179.636 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.886 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.5 OUTLIER -107.76 123.17 48.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.583 -0.698 . . . . 0.0 110.176 179.895 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.736 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.0 pt-20 -43.36 164.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.943 -1.098 . . . . 0.0 108.831 178.606 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.819 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -47.74 145.03 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.996 -1.065 . . . . 0.0 110.112 -179.231 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.488 ' CG ' ' HG ' ' B' ' 38' ' ' LEU . 10.5 ptm -155.66 -165.55 2.0 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.36 -0.838 . . . . 0.0 109.135 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' B' ' 36' ' ' MET . 21.2 t -102.44 87.14 2.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.111 -0.993 . . . . 0.0 109.508 179.809 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 1.06 HD12 HG21 ' B' ' 77' ' ' VAL . 31.3 mt -112.88 163.92 16.75 Favored Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 121.246 -0.909 . . . . 0.0 109.17 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.9 Cg_endo -75.8 -166.45 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.354 2.036 . . . . 0.0 110.492 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -94.28 -152.17 29.01 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 62.97 58.71 1.45 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.888 -0.772 . . . . 0.0 109.067 -179.401 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.584 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 30.0 p-90 -134.92 175.61 9.41 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.649 -0.657 . . . . 0.0 109.746 -179.537 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.03 123.65 15.97 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.229 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.38 137.44 20.9 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.217 1.944 . . . . 0.0 111.543 -178.689 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.24 -167.29 2.72 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.105 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.51 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 54.6 mtp -145.69 131.36 18.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.94 -1.1 . . . . 0.0 110.159 -179.275 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.579 ' CD1' HG21 ' A' ' 50' ' ' ILE . 5.2 pt -97.75 149.04 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.171 -0.955 . . . . 0.0 108.694 179.08 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.06 116.94 3.49 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.42 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -139.27 -125.86 2.31 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.449 -1.358 . . . . 0.0 110.536 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.732 HG21 HD12 ' A' ' 47' ' ' ILE . 66.6 mt -87.23 129.27 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.948 . . . . 0.0 112.676 -177.794 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.07 -47.37 2.68 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 178.252 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.457 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 178.87 -156.26 18.31 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.055 -179.701 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 1.5 m-85 -120.97 136.22 55.02 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.681 -0.894 . . . . 0.0 109.414 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.45 HG12 ' CG2' ' A' ' 50' ' ' ILE . 7.1 pt -107.16 173.1 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.125 -0.984 . . . . 0.0 109.102 179.219 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.551 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 9.8 mttm -110.06 145.53 36.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.028 -1.045 . . . . 0.0 109.099 179.708 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.589 HG12 ' HA3' ' B' ' 78' ' ' GLY . 30.6 m -141.48 -173.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.868 -1.145 . . . . 0.0 110.39 -179.583 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' B' ' 59' ' ' TYR . 5.2 mtt85 -129.31 90.09 2.96 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -48.76 92.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.363 -0.836 . . . . 0.0 109.97 -179.488 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.584 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 10.3 m-85 -92.93 92.14 7.73 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -79.52 140.17 37.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.147 -0.971 . . . . 0.0 110.626 -178.519 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.522 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 76.76 60.61 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.514 0.673 . . . . 0.0 110.019 179.539 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.786 ' CG2' HG23 ' B' ' 15' ' ' ILE . 6.1 mm -120.77 115.48 47.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.786 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -66.7 104.0 1.21 Allowed 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.848 -1.157 . . . . 0.0 110.73 -178.664 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.826 HD12 HD11 ' B' ' 15' ' ' ILE . 9.2 tt -106.19 112.65 40.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 177.486 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.492 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.0 tt0 -88.89 106.58 18.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.955 -1.091 . . . . 0.0 109.79 -177.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.75 HG13 HG22 ' B' ' 13' ' ' ILE . 1.6 mp -105.01 117.47 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.884 . . . . 0.0 109.406 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.495 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 9.7 m 58.54 57.66 3.7 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.453 -0.779 . . . . 0.0 109.916 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.56 34.48 20.29 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.636 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.495 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 61.8 m-70 -126.51 117.1 22.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.255 -1.144 . . . . 0.0 109.309 179.794 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.678 ' HG3' HD21 ' B' ' 63' ' ' LEU . 23.0 ttpt -65.38 124.82 23.27 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.452 -179.927 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.703 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -146.44 96.02 2.7 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.353 -0.842 . . . . 0.0 109.523 -179.829 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.786 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -79.14 152.46 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.048 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.56 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.07 -157.42 14.77 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 118.428 -1.844 . . . . 0.0 111.781 179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.447 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 3.4 m -110.66 104.97 13.71 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.679 -0.895 . . . . 0.0 110.001 -179.089 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.886 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -96.65 110.41 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.635 -0.666 . . . . 0.0 110.215 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.602 HD12 ' H ' ' B' ' 76' ' ' LEU . 3.8 mp -79.56 106.75 11.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 179.439 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 1.06 HG21 HD12 ' B' ' 38' ' ' LEU . 2.8 t -88.67 111.43 22.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.95 -1.094 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.589 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -141.65 -170.5 12.42 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.551 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.09 42.55 1.36 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.474 2.116 . . . . 0.0 110.648 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.736 HG22 ' HA ' ' B' ' 34' ' ' GLU . 10.0 t -88.94 139.45 29.07 Favored Pre-proline 0 N--CA 1.49 1.536 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.458 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.6 Cg_endo -80.43 18.21 1.25 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.553 2.169 . . . . 0.0 111.19 -179.313 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.669 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -161.59 163.01 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.917 -1.114 . . . . 0.0 110.008 -179.348 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.669 ' O ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -94.62 160.33 14.68 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 104.482 -2.414 . . . . 0.0 104.482 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.779 ' O ' ' HA ' ' B' ' 31' ' ' THR . 12.6 mm -144.05 95.05 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 O-C-N 120.051 -1.655 . . . . 0.0 111.054 -178.354 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 1.051 HG22 HD11 ' B' ' 90' ' ' LEU . 0.3 OUTLIER -77.71 101.41 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 178.196 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.691 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -112.99 -176.07 19.49 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.674 -177.786 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.73 ' N ' HD22 ' B' ' 90' ' ' LEU . 7.1 mtt85 -29.65 -42.16 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -178.614 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.011 ' ND2' HD23 ' B' ' 89' ' ' LEU . 4.8 p-10 -57.56 -42.64 83.41 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.124 -1.61 . . . . 0.0 110.482 -177.688 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.011 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -95.8 -10.57 28.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.299 -0.876 . . . . 0.0 109.662 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 1.051 HD11 HG22 ' B' ' 85' ' ' ILE . 1.2 mp -79.06 -32.0 44.68 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.319 -0.863 . . . . 0.0 109.186 -179.623 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.846 HG23 HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.9 -20.22 60.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.064 -1.022 . . . . 0.0 109.413 179.611 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.819 ' OE1' HD13 ' B' ' 89' ' ' LEU . 28.0 mt-30 -82.13 -41.24 20.73 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.029 -1.045 . . . . 0.0 109.03 179.562 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.783 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -82.48 -9.11 11.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.702 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.3 57.37 15.48 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 178.967 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.15 142.14 33.55 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.253 -1.145 . . . . 0.0 110.446 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.554 HG22 ' HA ' ' A' ' 4' ' ' THR . 24.3 p -129.82 126.2 37.51 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.713 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -90.53 90.43 8.0 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 109.537 -179.609 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.564 ' ND2' ' OD1' ' A' ' 98' ' ' ASN . 14.0 m-20 -95.63 127.63 41.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.684 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.13 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.812 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.73 0 N-CA-C 110.65 -0.558 . . . . 0.0 110.65 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.532 ' HG2' ' N ' ' A' ' 3' ' ' VAL . 0.1 OUTLIER -84.4 146.0 27.9 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 177.865 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.54 HG11 ' HB3' ' A' ' 9' ' ' PRO . 2.2 t -134.19 124.56 46.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 C-N-CA 118.486 -1.286 . . . . 0.0 110.091 -179.04 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -130.14 14.02 5.67 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.128 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -43.75 93.51 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 CA-C-O 121.9 0.857 . . . . 0.0 109.152 -179.301 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.538 ' N ' ' O ' ' A' ' 4' ' ' THR . 2.5 m95 -45.24 -15.15 0.02 OUTLIER 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.879 -0.513 . . . . 0.0 110.426 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.514 ' N ' ' O ' ' A' ' 5' ' ' LEU . 28.9 mt-30 -106.48 -115.65 0.26 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.62 -1.3 . . . . 0.0 108.951 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.504 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 46.3 mtp180 -111.03 136.48 20.8 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 120.406 -1.434 . . . . 0.0 110.235 -179.691 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HB3' HG11 ' A' ' 3' ' ' VAL . 38.0 Cg_endo -81.09 63.09 8.7 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.597 2.198 . . . . 0.0 109.785 178.955 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.484 HD22 ' HB3' ' A' ' 21' ' ' GLU . 2.4 mt -84.79 140.29 31.33 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.623 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.499 HG22 ' HB3' ' A' ' 22' ' ' ALA . 1.1 m -140.32 151.64 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.321 -0.862 . . . . 0.0 109.128 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.5 m -86.08 99.92 11.82 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.206 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 66' ' ' ILE . 1.9 pt -91.5 161.04 2.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.388 -0.82 . . . . 0.0 110.311 -178.178 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 1.2 tttt -117.07 97.85 6.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 109.174 179.491 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.912 ' CD1' HG21 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -113.67 126.93 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.096 -1.003 . . . . 0.0 109.463 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.63 31.02 77.33 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.733 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.7 11.36 68.91 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 91.7 mm-40 -108.01 167.53 9.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 108.901 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 35.1 mt -126.23 123.35 37.97 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.011 -1.056 . . . . 0.0 109.368 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.508 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -140.66 173.99 10.95 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.911 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.6 mt-10 -79.25 177.23 8.99 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -154.75 112.0 3.37 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 120.849 -1.157 . . . . 0.0 109.798 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 25' ' ' ASP . 13.4 tp -89.53 95.35 10.23 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.646 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.536 HD13 HD23 ' B' ' 97' ' ' LEU . 30.4 mt -43.85 98.85 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.691 ' CB ' HG23 ' A' ' 84' ' ' ILE . 5.5 t0 -105.1 73.71 1.07 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.375 -0.828 . . . . 0.0 110.999 -177.651 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.0 m -57.15 -18.33 14.74 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.861 -1.149 . . . . 0.0 108.052 178.348 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.658 ' O ' HD11 ' B' ' 23' ' ' LEU . . . -64.97 -45.34 92.66 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.71 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.546 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -75.66 163.48 27.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.203 -1.174 . . . . 0.0 109.328 -179.923 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.43 -14.89 23.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.166 -0.958 . . . . 0.0 110.888 -179.029 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.547 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.01 -165.44 1.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.671 -1.268 . . . . 0.0 111.338 -178.972 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.747 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -102.47 88.52 3.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.487 -0.758 . . . . 0.0 110.953 -178.426 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.886 HG21 HD13 ' A' ' 47' ' ' ILE . 0.6 OUTLIER -79.38 113.38 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.013 -1.679 . . . . 0.0 107.933 178.566 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.93 HD13 ' CG1' ' A' ' 75' ' ' VAL . 1.1 mp -115.02 132.58 56.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 111.33 -177.824 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -43.39 165.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.202 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -57.05 142.72 41.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.029 -1.045 . . . . 0.0 110.238 -179.561 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.646 ' HE2' HG22 ' A' ' 15' ' ' ILE . 4.2 ptm -161.82 -161.16 0.75 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.431 -0.793 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -104.15 114.89 29.45 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.321 -0.862 . . . . 0.0 110.358 -179.427 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.878 HD23 ' CD2' ' A' ' 59' ' ' TYR . 3.1 tp -138.68 145.7 47.33 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.636 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 31.6 Cg_endo -72.28 157.11 54.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.345 2.03 . . . . 0.0 110.507 -179.461 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.525 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -49.8 -162.09 0.01 OUTLIER Glycine 0 N--CA 1.493 2.473 0 CA-C-O 121.858 0.699 . . . . 0.0 111.881 -178.475 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.525 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 75.59 50.29 0.07 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.614 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 6.9 p-90 -122.56 177.88 5.23 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-O 122.124 0.964 . . . . 0.0 111.269 -178.297 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.46 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 1.3 mtmm -139.51 118.49 8.96 Favored Pre-proline 0 C--N 1.303 -1.417 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.698 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -74.91 138.63 23.51 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.038 1.826 . . . . 0.0 110.91 -178.706 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.74 -173.21 4.0 Favored 'General case' 0 N--CA 1.49 1.528 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.901 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.5 ' CE ' ' HG3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -138.79 120.62 15.38 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.882 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 54' ' ' ILE . 3.1 pt -91.68 144.11 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.886 -1.134 . . . . 0.0 109.331 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.631 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -119.01 135.04 11.15 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 179.892 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.475 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -159.64 -129.5 1.06 Allowed Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.395 -179.614 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.711 HG23 HD13 ' B' ' 54' ' ' ILE . 77.6 mt -82.15 109.27 16.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.704 -0.88 . . . . 0.0 112.57 -177.951 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 111.78 -29.23 8.7 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 178.167 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.63 -161.52 29.26 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.424 179.65 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.631 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -112.02 131.97 55.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.408 -1.054 . . . . 0.0 109.931 -179.464 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 47' ' ' ILE . 16.2 pt -105.12 173.0 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.978 -1.076 . . . . 0.0 108.889 178.729 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 6.4 mttt -110.09 128.84 55.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.253 -0.904 . . . . 0.0 109.301 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.894 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.9 m -137.34 -174.61 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.101 -1.0 . . . . 0.0 109.998 -179.835 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -120.37 173.57 7.06 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.98 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.96 ' NE2' HG22 ' A' ' 74' ' ' THR . 0.0 OUTLIER -136.66 89.53 2.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.894 -1.129 . . . . 0.0 110.8 -179.528 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.878 ' CD2' HD23 ' A' ' 38' ' ' LEU . 96.5 m-85 -90.01 122.25 32.83 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.354 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -96.94 146.29 25.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.882 -1.136 . . . . 0.0 110.531 -178.914 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.601 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.9 OUTLIER 71.28 65.78 0.16 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.563 179.409 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.556 ' C ' HG12 ' A' ' 72' ' ' ILE . 13.5 mm -120.14 106.62 19.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.327 -0.858 . . . . 0.0 109.271 179.656 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.87 HD21 ' HG2' ' A' ' 70' ' ' LYS . 1.6 tm? -54.43 87.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.653 -0.654 . . . . 0.0 110.413 -178.759 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.815 HG22 ' O ' ' A' ' 71' ' ' ALA . 2.9 tt -89.68 122.09 40.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.872 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 7.1 tp10 -89.15 122.05 32.06 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.847 -1.158 . . . . 0.0 109.455 -178.69 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.854 HG13 HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -118.18 132.18 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.275 -0.89 . . . . 0.0 108.787 -179.912 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 66' ' ' ILE . 21.5 m 38.24 49.96 1.36 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.635 . . . . 0.0 110.637 179.271 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.51 47.96 78.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.511 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.46 ' O ' ' HA ' ' A' ' 65' ' ' GLU . 77.6 m-70 -142.67 137.02 29.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.291 -1.123 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.87 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -85.28 126.19 33.51 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.27 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.815 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -147.5 98.94 3.06 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.351 -0.843 . . . . 0.0 110.094 -178.794 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.601 HG23 ' HA ' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -81.73 142.71 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 120.887 -1.133 . . . . 0.0 107.992 179.068 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -160.85 -159.02 9.64 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.834 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.96 HG22 ' NE2' ' A' ' 58' ' ' GLN . 3.1 m -101.78 105.25 16.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.945 -0.738 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.93 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -103.24 163.59 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.063 -1.023 . . . . 0.0 109.534 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.553 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.2 mp -129.87 158.88 38.28 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 178.68 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.601 HG12 ' HA ' ' A' ' 35' ' ' GLU . 23.8 t -142.68 106.44 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 O-C-N 121.101 -1.0 . . . . 0.0 110.133 -179.462 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.894 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -144.86 -163.61 10.16 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.524 -1.831 . . . . 0.0 108.524 179.576 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.528 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.8 41.45 1.12 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 C-N-CA 122.374 2.049 . . . . 0.0 111.393 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.572 HG21 HG13 ' A' ' 32' ' ' VAL . 6.0 t -84.52 132.64 46.34 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.054 -1.029 . . . . 0.0 108.536 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.42 17.69 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.834 2.356 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.612 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -160.87 173.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.836 -1.165 . . . . 0.0 109.843 -179.776 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.612 ' N ' HG13 ' A' ' 82' ' ' VAL . 57.4 m-80 -102.26 139.46 37.85 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.99 -2.596 . . . . 0.0 103.99 176.217 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.747 ' O ' ' HA ' ' A' ' 31' ' ' THR . 11.7 mm -128.66 95.59 2.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 O-C-N 120.283 -1.511 . . . . 0.0 110.533 -176.428 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.64 ' HA ' HG23 ' A' ' 31' ' ' THR . 1.0 OUTLIER -78.94 90.58 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.023 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.59 -160.44 19.97 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -178.432 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.612 ' O ' HG23 ' A' ' 91' ' ' THR . 0.0 OUTLIER -64.15 -28.37 69.72 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.547 -0.972 . . . . 0.0 110.663 -179.154 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.819 ' ND2' HD23 ' A' ' 89' ' ' LEU . 1.5 p-10 -53.61 -42.71 67.99 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.94 -1.1 . . . . 0.0 110.725 -178.93 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.819 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -95.15 -24.85 16.66 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.893 -1.13 . . . . 0.0 108.874 -179.729 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 91.4 mt -69.07 -4.38 16.92 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.343 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.612 HG23 ' O ' ' A' ' 87' ' ' ARG . 36.2 p -100.82 -13.35 18.44 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.879 -1.138 . . . . 0.0 109.165 179.608 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 85.2 mm-40 -89.45 -40.99 12.33 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 0.0 109.726 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.686 HD12 ' CG ' ' B' ' 99' ' ' PHE . 10.5 pt -85.63 -0.09 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.144 -0.973 . . . . 0.0 108.98 179.525 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.88 43.74 40.38 Favored Glycine 0 N--CA 1.497 2.748 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.061 178.873 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.565 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -72.1 142.98 49.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.92 -1.341 . . . . 0.0 110.144 179.665 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.1 p -148.35 127.69 13.05 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.541 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' B' ' 97' ' ' LEU . 7.5 mp -86.55 95.86 9.89 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.269 -0.895 . . . . 0.0 109.453 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.521 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 16.9 m-20 -99.02 117.99 34.77 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.042 -1.036 . . . . 0.0 109.679 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.748 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.297 -1.676 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.319 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.503 ' HD3' ' NE2' ' B' ' 69' ' ' HIS . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.202 -0.73 . . . . 0.0 110.202 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.405 ' HG3' ' OD1' ' A' ' 98' ' ' ASN . 6.0 tt0 -83.64 139.44 32.81 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 178.151 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.589 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 2.5 t -131.23 111.05 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.456 -1.298 . . . . 0.0 110.911 -178.149 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.523 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -123.21 -65.55 1.08 Allowed 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.587 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.2 tp 36.47 26.96 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.572 178.152 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.609 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 24.1 m95 18.07 47.63 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.187 0.518 . . . . 0.0 112.172 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.587 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.47 -158.05 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.965 . . . . 0.0 109.443 -179.755 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.643 ' HB3' HD12 ' B' ' 23' ' ' LEU . 11.5 mtm180 -70.07 125.58 92.05 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.092 -1.005 . . . . 0.0 109.056 179.467 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.589 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.5 Cg_endo -79.09 70.69 7.39 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.434 2.09 . . . . 0.0 109.653 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.806 HD23 ' C ' ' B' ' 22' ' ' ALA . 7.0 mt -85.29 137.93 32.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.267 -0.896 . . . . 0.0 110.816 -178.712 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.521 HG23 ' N ' ' B' ' 12' ' ' THR . 1.7 m -141.11 168.8 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.521 ' N ' HG23 ' B' ' 11' ' ' VAL . 3.9 m -94.91 120.98 36.03 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.894 HG22 HG13 ' B' ' 66' ' ' ILE . 1.6 pt -115.09 147.45 18.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 121.168 -0.958 . . . . 0.0 110.061 -179.201 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 4.1 ttmt -106.9 101.18 10.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.403 -0.811 . . . . 0.0 109.709 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.87 HG23 ' CG2' ' B' ' 62' ' ' ILE . 39.2 mt -117.86 140.28 41.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.464 ' HA3' HD12 ' B' ' 38' ' ' LEU . . . 50.47 55.08 18.02 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 34.68 5.38 Favored Glycine 0 N--CA 1.494 2.508 0 O-C-N 121.306 -1.114 . . . . 0.0 110.428 179.552 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm100 -132.54 171.71 13.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.059 -1.26 . . . . 0.0 108.807 179.249 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.475 HD23 ' HA ' ' B' ' 19' ' ' LEU . 13.7 mt -135.5 119.11 17.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.121 -0.987 . . . . 0.0 109.964 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.478 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -135.62 178.12 7.29 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.682 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.572 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.6 mp0 -78.73 -176.06 4.73 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 179.038 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.823 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -164.82 105.07 0.81 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.786 -1.196 . . . . 0.0 110.627 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.658 HD11 ' O ' ' A' ' 27' ' ' GLY . 0.2 OUTLIER -79.9 90.04 5.31 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 108.793 179.227 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 75.7 mt -43.63 98.54 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.821 ' HB2' HG23 ' B' ' 84' ' ' ILE . 56.9 t0 -100.28 94.13 6.04 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.51 -0.744 . . . . 0.0 111.131 -178.348 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.676 ' OG1' HD21 ' A' ' 97' ' ' LEU . 16.8 m -67.56 -15.22 63.54 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.968 -1.083 . . . . 0.0 108.339 178.187 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.494 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -71.76 -40.8 57.67 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.83 149.91 29.36 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.963 -1.316 . . . . 0.0 109.662 -179.649 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.504 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 1.8 m-20 -92.01 -8.28 46.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.323 -0.861 . . . . 0.0 110.021 -179.471 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -129.52 178.3 6.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.105 -0.997 . . . . 0.0 109.943 -179.335 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.785 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.5 m -108.42 83.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.75 -1.219 . . . . 0.0 109.677 -179.515 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.023 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -70.31 157.34 6.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.044 179.667 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.082 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.8 OUTLIER -153.51 133.67 13.36 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.572 -178.007 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.537 ' N ' HG23 ' B' ' 80' ' ' THR . 3.1 tt0 -50.98 153.45 1.82 Allowed 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.868 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' B' ' 34' ' ' GLU . 3.3 tt0 -35.12 142.81 0.05 Allowed 'General case' 0 N--CA 1.495 1.812 0 CA-C-O 121.477 0.656 . . . . 0.0 110.78 -179.634 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.652 ' SD ' HD13 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -155.76 -170.38 3.4 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.403 -0.81 . . . . 0.0 109.099 179.429 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.5 t -109.68 66.4 0.63 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 111.157 -178.974 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.742 HD23 ' CG ' ' B' ' 59' ' ' TYR . 1.2 tp -87.24 158.31 52.49 Favored Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.636 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 32.1 Cg_endo -77.24 -155.37 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.927 1.751 . . . . 0.0 110.228 -179.484 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.514 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -84.47 -148.04 8.98 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.345 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.514 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.7 mmp_? 65.41 57.06 0.92 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 122.054 -0.674 . . . . 0.0 109.234 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.668 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.8 p-90 -147.15 -176.57 5.27 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.863 0.839 . . . . 0.0 110.466 -179.67 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -148.13 139.32 13.61 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.092 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.43 136.61 15.89 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.281 1.987 . . . . 0.0 111.016 -178.889 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -160.76 -163.0 0.99 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.578 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.549 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 57.7 mtp -151.13 129.24 11.84 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.111 179.642 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.698 HD11 HD11 ' B' ' 54' ' ' ILE . 4.5 pt -91.64 144.41 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 118.356 -1.338 . . . . 0.0 107.999 178.771 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.565 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -117.44 107.43 1.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -178.923 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.52 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -133.23 -126.8 2.72 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.534 -1.317 . . . . 0.0 110.74 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.829 HD12 ' C21' ' B' ' 100' ' ' DMP . 56.0 mt -85.87 134.56 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.851 -0.793 . . . . 0.0 113.045 -177.402 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.415 ' N ' HG23 ' A' ' 54' ' ' ILE . . . 88.03 -15.89 53.82 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.019 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.22 -160.06 27.16 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.264 179.55 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 2.9 m-85 -114.91 138.48 50.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.519 -0.989 . . . . 0.0 109.782 -179.541 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.711 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -116.19 149.92 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.549 ' HG3' ' CE ' ' B' ' 46' ' ' MET . 3.2 mttm -85.26 136.52 33.47 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.339 -0.851 . . . . 0.0 108.936 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.483 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.4 m -142.74 -164.81 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 O-C-N 120.957 -1.09 . . . . 0.0 110.245 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 56' ' ' VAL . 4.9 mtt180 -147.46 111.34 5.06 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.736 ' NE2' HG21 ' B' ' 74' ' ' THR . 0.4 OUTLIER -74.69 124.81 27.42 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.059 -1.025 . . . . 0.0 110.413 -179.151 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.742 ' CG ' HD23 ' B' ' 38' ' ' LEU . 17.9 m-85 -112.89 109.39 18.8 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.568 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.7 m-20 -88.51 128.14 35.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.079 -1.013 . . . . 0.0 110.505 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.581 ' HA ' HG23 ' B' ' 72' ' ' ILE . 8.2 mm-40 89.86 61.95 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 CA-C-O 121.216 0.531 . . . . 0.0 110.598 179.266 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.87 ' CG2' HG23 ' B' ' 15' ' ' ILE . 24.0 mm -119.04 106.73 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 108.878 178.927 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.805 ' N ' HD13 ' B' ' 72' ' ' ILE . 1.0 OUTLIER -61.29 92.57 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.172 -0.955 . . . . 0.0 110.129 -178.884 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.832 ' CG2' HD11 ' B' ' 89' ' ' LEU . 2.6 tt -97.38 117.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.53 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 16.4 tt0 -89.16 121.11 31.16 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.84 -1.162 . . . . 0.0 109.486 -179.127 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.894 HG13 HG22 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -108.87 135.7 46.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.132 -0.98 . . . . 0.0 108.789 179.769 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.63 -92.4 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.734 -0.604 . . . . 0.0 109.492 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 68' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -141.82 54.59 0.61 Allowed Glycine 0 N--CA 1.485 1.908 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.765 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.503 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 38.1 m-70 -154.24 151.82 29.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -1.131 . . . . 0.0 109.986 -179.544 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.75 139.52 30.46 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 179.086 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.685 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.52 97.68 2.42 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 110.817 -179.075 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.805 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.48 139.65 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 178.19 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.611 ' HA3' HE22 ' B' ' 92' ' ' GLN . . . -164.1 -159.01 10.51 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 118.659 -1.734 . . . . 0.0 111.421 -179.875 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.736 HG21 ' NE2' ' B' ' 58' ' ' GLN . 18.7 m -106.7 108.74 20.41 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.654 -0.909 . . . . 0.0 110.852 -178.74 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.082 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -104.43 127.82 58.46 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.503 -0.748 . . . . 0.0 111.415 -179.879 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.742 ' HB2' HG23 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -84.84 141.3 30.55 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.728 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.62 115.96 46.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 121.003 -1.061 . . . . 0.0 108.667 178.716 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -162.04 -158.12 9.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -81.71 41.57 1.16 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.746 2.297 . . . . 0.0 110.471 179.868 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.537 HG23 ' N ' ' B' ' 34' ' ' GLU . 9.3 t -89.76 133.23 34.53 Favored Pre-proline 0 C--N 1.301 -1.54 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.347 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.618 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.8 Cg_endo -80.15 22.94 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.479 2.119 . . . . 0.0 111.432 -178.504 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.618 HG23 ' O ' ' B' ' 81' ' ' PRO . 55.2 t -160.22 153.67 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.498 -1.376 . . . . 0.0 111.888 -178.671 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 76.0 m-20 -93.98 77.57 4.13 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 176.041 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.821 HG23 ' HB2' ' B' ' 25' ' ' ASP . 53.6 mt -79.71 119.59 29.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.561 0.695 . . . . 0.0 112.601 -175.556 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.521 ' N ' HD13 ' B' ' 85' ' ' ILE . 4.0 mm -95.48 104.57 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.181 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.748 ' C ' HD13 ' B' ' 90' ' ' LEU . . . -99.83 163.16 19.42 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.001 -179.38 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.645 ' N ' HD13 ' B' ' 90' ' ' LEU . 0.0 OUTLIER -25.74 -37.45 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -178.829 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.931 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -46.52 -42.11 15.19 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.021 -1.674 . . . . 0.0 110.113 -178.629 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.931 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -93.76 -17.58 23.0 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.276 -0.89 . . . . 0.0 110.116 -179.514 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.748 HD13 ' C ' ' B' ' 86' ' ' GLY . 5.9 mp -69.55 -35.36 75.35 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.019 -1.073 . . . . 0.0 109.21 -179.548 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 72.3 p -70.99 -6.94 42.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.007 -1.058 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.9 HE22 HD22 ' B' ' 89' ' ' LEU . 30.5 mt-30 -100.01 -40.6 7.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.34 -0.85 . . . . 0.0 109.463 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.748 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -82.87 3.56 2.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.203 -0.936 . . . . 0.0 108.817 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.7 42.41 97.22 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.029 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.534 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.38 138.18 39.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.945 -1.327 . . . . 0.0 109.697 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 71.1 p -130.61 123.64 29.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 108.646 179.064 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -84.84 86.97 7.3 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.658 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.525 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 32.0 m-20 -97.81 132.19 43.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.456 -0.777 . . . . 0.0 110.492 -178.933 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.686 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.287 178.664 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.829 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.581 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.497 1.704 0 N-CA-C 110.316 -0.686 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -84.05 138.41 33.09 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 178.136 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' A' ' 9' ' ' PRO . 4.4 t -132.55 134.45 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.722 -1.236 . . . . 0.0 110.441 -178.548 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.832 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -143.3 -82.66 0.17 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.41 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.559 ' O ' ' C ' ' A' ' 6' ' ' TRP . 9.5 mt 34.41 32.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.895 -0.503 . . . . 0.0 110.719 178.896 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.559 ' C ' ' O ' ' A' ' 5' ' ' LEU . 44.2 m0 17.87 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.35 0 CA-C-O 121.393 0.616 . . . . 0.0 111.18 -179.875 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.553 ' HA ' ' NH1' ' B' ' 87' ' ' ARG . 2.3 mt-30 -144.56 -168.65 2.96 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.486 -0.759 . . . . 0.0 109.489 -179.329 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.0 mtt180 -81.22 122.37 81.3 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.337 -0.852 . . . . 0.0 108.917 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.1 Cg_endo -77.94 69.9 7.26 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.146 1.897 . . . . 0.0 109.88 179.373 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.71 145.82 29.38 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.264 -0.898 . . . . 0.0 109.482 -179.678 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' HG23 ' A' ' 11' ' ' VAL . 6.1 m -138.89 127.63 29.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.648 -179.68 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.876 HG22 HD23 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -62.83 103.29 0.42 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 178.354 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.765 HD11 HD21 ' A' ' 33' ' ' LEU . 11.5 pt -89.83 139.19 17.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.003 -1.061 . . . . 0.0 110.114 -178.458 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.773 ' HE2' HD11 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -108.54 96.69 6.52 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.171 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.894 ' CD1' HG11 ' A' ' 75' ' ' VAL . 24.4 mt -113.18 119.87 61.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.361 -0.837 . . . . 0.0 109.537 -179.012 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD12 ' A' ' 38' ' ' LEU . . . 69.7 28.97 71.5 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -179.391 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.22 3.86 62.3 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 -179.197 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.524 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.59 161.92 15.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.307 -1.113 . . . . 0.0 108.891 179.675 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.876 HD23 HG22 ' A' ' 12' ' ' THR . 0.1 OUTLIER -133.31 125.51 29.39 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.98 -179.394 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.5 mtmt -151.51 162.88 40.19 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -78.95 136.27 37.2 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 108.249 179.591 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.707 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -114.0 152.86 30.31 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.986 -1.071 . . . . 0.0 109.886 -179.313 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.495 ' O ' ' N ' ' A' ' 25' ' ' ASP . 38.6 tp -109.47 88.77 2.82 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.646 -0.659 . . . . 0.0 109.651 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.644 HD12 ' HB2' ' A' ' 9' ' ' PRO . 13.8 mt -43.1 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 179.526 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.645 ' HB3' HG22 ' A' ' 84' ' ' ILE . 9.9 t0 -109.9 97.58 7.07 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.427 -0.795 . . . . 0.0 110.982 -177.68 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.563 HG23 ' NH2' ' A' ' 87' ' ' ARG . 10.7 m -73.13 -6.54 46.43 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.329 -0.857 . . . . 0.0 109.114 178.954 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.567 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -79.96 -29.02 48.34 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.493 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -89.66 162.89 15.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.922 -1.34 . . . . 0.0 109.659 -179.688 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.7 OUTLIER -100.61 -8.39 23.01 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.231 -0.918 . . . . 0.0 110.729 -178.974 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.525 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.54 -177.69 4.78 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.075 -1.016 . . . . 0.0 109.442 -179.712 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.585 HG23 HD12 ' A' ' 85' ' ' ILE . 21.0 m -108.8 88.86 2.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.974 -1.079 . . . . 0.0 110.126 -179.196 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.12 174.02 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.098 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.05 119.46 1.29 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.823 -1.173 . . . . 0.0 111.694 -178.597 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.562 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 2.5 mt-10 -36.02 154.68 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.185 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -47.6 137.47 9.08 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.922 -1.111 . . . . 0.0 109.739 -179.871 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.72 164.94 28.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.326 -0.859 . . . . 0.0 109.407 179.595 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 10.9 t -90.14 104.21 16.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.223 -0.923 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.846 HD13 HG22 ' A' ' 15' ' ' ILE . 48.3 tp -122.08 118.58 29.09 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.236 -0.915 . . . . 0.0 109.304 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.4 Cg_endo -77.99 120.27 4.97 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.401 2.068 . . . . 0.0 110.641 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.25 -177.75 33.95 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 179.839 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.06 144.73 28.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -1.224 . . . . 0.0 108.716 179.521 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.577 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 21.5 p-90 -138.62 156.27 47.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.176 -0.953 . . . . 0.0 110.295 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 14.2 mtpt -121.35 136.39 25.8 Favored Pre-proline 0 N--CA 1.488 1.469 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.69 129.28 9.92 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 122.263 1.975 . . . . 0.0 111.196 -178.853 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.8 ptmm? -164.17 152.4 12.83 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.324 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.545 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -118.25 146.77 44.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.527 -1.358 . . . . 0.0 109.856 179.315 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.752 ' CD1' HG21 ' B' ' 50' ' ' ILE . 15.5 pt -102.6 149.56 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.37 -0.831 . . . . 0.0 109.077 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.89 111.52 2.12 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.331 -1.908 . . . . 0.0 108.331 179.832 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.89 -117.23 1.71 Allowed Glycine 0 N--CA 1.484 1.85 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.687 -178.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.824 HD12 ' C71' ' B' ' 100' ' ' DMP . 8.2 mt -91.01 130.17 40.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.78 -0.835 . . . . 0.0 112.542 -177.564 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.632 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 89.76 -23.27 20.76 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.021 177.914 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.84 -163.19 29.63 Favored Glycine 0 N--CA 1.491 2.347 0 O-C-N 120.744 -1.445 . . . . 0.0 110.375 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.604 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.1 m-85 -109.68 132.13 54.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.514 -0.992 . . . . 0.0 109.245 -179.639 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.784 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.1 pp -107.07 177.86 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.026 -1.046 . . . . 0.0 109.472 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 11.1 mmtt -112.49 138.99 48.45 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.206 -0.934 . . . . 0.0 109.45 179.231 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.815 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.6 m -146.66 -174.9 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.908 . . . . 0.0 109.687 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.519 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 3.8 mtt85 -122.83 178.19 5.14 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.577 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.445 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 26.0 tt0 -135.97 101.57 4.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.131 -0.98 . . . . 0.0 110.827 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.703 ' CG ' HD23 ' A' ' 38' ' ' LEU . 61.7 m-85 -94.49 106.38 18.36 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.613 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 67.8 m-20 -88.28 123.27 32.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.124 -0.985 . . . . 0.0 110.576 -178.745 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.532 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 63.7 mm-40 86.06 59.98 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.635 0.731 . . . . 0.0 110.072 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.81 HG21 HG23 ' A' ' 15' ' ' ILE . 31.4 mm -115.84 121.9 68.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.777 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 ' HG2' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -73.78 88.18 1.76 Allowed 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.725 -1.19 . . . . 0.0 110.966 -178.311 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.694 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -85.82 117.4 30.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 177.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 3.6 tt0 -87.08 117.96 26.16 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.054 -1.029 . . . . 0.0 109.111 -178.495 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.694 HD11 HD13 ' A' ' 64' ' ' ILE . 1.0 OUTLIER -110.43 123.9 66.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.792 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.55 36.1 4.96 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.541 -0.724 . . . . 0.0 110.039 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.52 34.24 50.43 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 70' ' ' LYS . 31.9 m-70 -122.1 91.74 3.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.03 -1.277 . . . . 0.0 109.448 179.696 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 1.009 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -44.74 102.82 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.616 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.492 ' N ' HD11 ' A' ' 63' ' ' LEU . . . -127.24 132.88 50.3 Favored 'General case' 0 C--N 1.287 -2.109 0 O-C-N 121.804 -0.56 . . . . 0.0 109.806 -179.151 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.537 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -108.17 152.21 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.867 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.542 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -176.41 -166.47 33.67 Favored Glycine 0 N--CA 1.487 2.045 0 C-N-CA 118.667 -1.73 . . . . 0.0 111.15 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.505 HG23 ' OD1' ' A' ' 60' ' ' ASP . 20.4 m -98.77 107.01 19.35 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.49 -1.006 . . . . 0.0 109.381 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.098 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.2 OUTLIER -103.52 119.49 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.335 -0.853 . . . . 0.0 110.402 -179.546 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.0 mp -88.63 142.87 27.33 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.332 -0.855 . . . . 0.0 108.906 178.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.556 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.9 t -126.8 118.65 51.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.398 -0.814 . . . . 0.0 109.875 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.815 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.01 13.05 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.69 41.75 1.17 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 C-N-CA 122.416 2.077 . . . . 0.0 110.015 179.803 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.562 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.1 t -82.45 140.16 44.83 Favored Pre-proline 0 C--N 1.305 -1.347 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.062 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.477 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 32.2 Cg_endo -76.22 10.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.177 1.918 . . . . 0.0 111.438 -178.873 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.72 HG12 HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.19 168.02 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.882 -1.136 . . . . 0.0 109.653 179.828 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -102.72 145.78 29.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 176.707 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.722 ' C ' HD13 ' A' ' 85' ' ' ILE . 3.5 mm -130.24 126.07 60.86 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 120.726 -1.234 . . . . 0.0 111.212 -177.536 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.85 ' N ' HD13 ' A' ' 85' ' ' ILE . 0.6 OUTLIER -101.47 92.18 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.446 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -81.34 -163.25 30.56 Favored Glycine 0 N--CA 1.496 2.693 0 O-C-N 121.241 -0.912 . . . . 0.0 111.995 -177.242 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.563 ' NH2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -60.82 -40.0 91.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.979 -0.718 . . . . 0.0 110.442 -179.283 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.052 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.0 p-10 -43.61 -31.1 0.69 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.274 -0.891 . . . . 0.0 109.298 -179.66 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.052 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -105.45 -26.02 12.11 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.168 -0.958 . . . . 0.0 109.998 -179.764 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 97.3 mt -71.1 -5.42 31.44 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.926 -1.109 . . . . 0.0 108.211 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -100.42 -15.21 18.02 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.691 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.2 mm-40 -86.12 -40.82 15.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.623 -0.673 . . . . 0.0 109.569 179.769 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.955 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -85.06 -5.18 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.175 -0.953 . . . . 0.0 108.982 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.93 49.93 15.16 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 178.917 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.571 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -83.44 149.5 26.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.008 -1.29 . . . . 0.0 110.557 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 25.6 p -140.28 126.1 19.4 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.796 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -85.98 96.53 9.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.843 -179.225 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.513 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.6 m-20 -101.13 126.8 47.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.219 -0.926 . . . . 0.0 109.441 179.694 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.803 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.039 -0.981 . . . . 0.0 109.446 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.537 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.494 1.552 0 N-CA-C 109.873 -0.857 . . . . 0.0 109.873 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.41 ' HG3' ' OD1' ' A' ' 98' ' ' ASN . 3.0 tt0 -83.64 137.64 33.71 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.432 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' B' ' 5' ' ' LEU . 8.4 t -133.68 114.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 118.565 -1.254 . . . . 0.0 110.501 -178.456 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.591 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -101.01 3.78 41.8 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 177.468 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.52 ' HB2' ' CG1' ' B' ' 3' ' ' VAL . 0.8 OUTLIER -21.66 83.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.654 0.74 . . . . 0.0 111.06 -179.438 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.591 ' N ' ' O ' ' B' ' 4' ' ' THR . 7.8 m95 -46.1 -21.05 0.12 Allowed 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.513 -0.742 . . . . 0.0 109.103 179.618 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.451 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -107.9 -165.51 1.05 Allowed 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.644 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.451 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.4 OUTLIER -66.68 125.49 90.72 Favored Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 120.919 -1.113 . . . . 0.0 109.65 -179.615 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.742 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.7 Cg_endo -77.49 75.72 4.57 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 122.035 1.823 . . . . 0.0 109.899 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.73 146.05 32.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.16 -0.963 . . . . 0.0 109.483 -179.69 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.551 ' CG1' HD11 ' B' ' 24' ' ' LEU . 5.5 m -131.02 148.71 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.82 -179.506 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.711 HG22 HD22 ' B' ' 19' ' ' LEU . 73.7 m -83.22 117.26 22.81 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 178.234 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 2.0 pp -112.62 131.35 64.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 121.117 -0.99 . . . . 0.0 110.739 -177.893 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.488 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -99.73 110.83 23.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.21 -0.931 . . . . 0.0 108.678 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.779 HD13 HG11 ' B' ' 75' ' ' VAL . 9.3 mt -116.67 141.79 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.043 . . . . 0.0 109.529 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.54 -97.69 0.07 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -148.38 39.6 0.97 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 179.247 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.414 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 44.5 mm-40 -140.52 -175.23 4.2 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.528 -0.984 . . . . 0.0 109.617 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.711 HD22 HG22 ' B' ' 12' ' ' THR . 6.8 mt -150.79 129.67 12.48 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.723 0.773 . . . . 0.0 110.621 -178.916 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.513 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 2.3 mptp? -148.03 168.34 22.59 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.321 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.8 mt-10 -79.11 172.84 13.24 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.655 -1.278 . . . . 0.0 109.129 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.568 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -149.51 106.14 3.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.343 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.567 HD21 ' O ' ' A' ' 27' ' ' GLY . 28.0 tp -64.06 99.42 0.26 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.552 -0.717 . . . . 0.0 110.006 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.742 HD12 ' HB2' ' B' ' 9' ' ' PRO . 44.4 mt -52.28 111.35 0.61 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.985 -1.072 . . . . 0.0 108.658 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.836 ' HB3' HG23 ' B' ' 84' ' ' ILE . 49.4 t0 -124.29 90.0 3.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 110.785 -178.554 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.58 ' HA ' HD12 ' B' ' 90' ' ' LEU . 3.0 m -63.96 -14.68 55.74 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.676 -1.265 . . . . 0.0 108.676 178.595 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -64.69 -46.93 88.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.05 158.97 35.58 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.899 -1.354 . . . . 0.0 108.802 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -92.12 -13.37 30.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.086 -1.009 . . . . 0.0 110.791 -178.621 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.564 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.7 OUTLIER -139.35 -173.87 3.72 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.783 -1.198 . . . . 0.0 110.041 -179.661 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.732 HG22 ' CD1' ' B' ' 33' ' ' LEU . 3.7 m -102.21 88.81 3.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.915 -1.115 . . . . 0.0 110.294 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.92 162.44 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.804 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.0 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -158.78 126.6 5.07 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.938 -1.101 . . . . 0.0 110.719 -178.397 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' B' ' 33' ' ' LEU . 4.3 tt0 -40.68 161.25 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.826 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.543 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.6 tt0 -50.54 146.14 5.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.195 -0.94 . . . . 0.0 110.133 -179.543 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.526 ' HE1' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -174.98 160.67 2.84 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.385 -0.822 . . . . 0.0 108.805 179.553 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.0 t -79.51 97.63 6.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.877 -1.139 . . . . 0.0 109.286 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.576 HD21 ' CG2' ' B' ' 15' ' ' ILE . 0.8 OUTLIER -107.21 107.59 60.67 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.69 -179.66 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 129.04 10.1 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.517 2.145 . . . . 0.0 110.521 179.796 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 147.13 -165.41 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 -95.55 124.95 39.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.278 -1.131 . . . . 0.0 108.831 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.601 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 56.8 p-90 -128.77 172.25 11.45 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.171 -0.956 . . . . 0.0 110.309 -179.197 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.1 mptt -140.07 137.75 18.54 Favored Pre-proline 0 C--N 1.3 -1.573 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.653 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -76.28 134.96 16.27 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.858 1.705 . . . . 0.0 110.299 -179.257 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.464 ' CG ' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -153.7 -177.11 6.16 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.656 -0.818 . . . . 0.0 109.823 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -138.28 115.19 10.79 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 109.192 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 54' ' ' ILE . 31.6 pt -94.49 130.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 C-N-CA 118.772 -1.171 . . . . 0.0 108.351 178.997 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.421 ' HA2' ' HA ' ' B' ' 53' ' ' PHE . . . -117.02 103.73 1.13 Allowed Glycine 0 N--CA 1.486 2.001 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.337 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.419 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -123.04 -118.45 2.44 Favored Glycine 0 N--CA 1.483 1.816 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.367 -178.968 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.804 HD12 ' C21' ' B' ' 100' ' ' DMP . 15.6 mt -91.8 115.56 31.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.852 -0.793 . . . . 0.0 112.138 -177.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.605 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 112.34 -40.14 2.63 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.399 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 163.88 -162.77 35.39 Favored Glycine 0 N--CA 1.491 2.365 0 O-C-N 120.846 -1.385 . . . . 0.0 110.161 179.896 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.539 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.7 OUTLIER -112.55 127.64 56.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.456 -1.026 . . . . 0.0 109.732 -179.872 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 47' ' ' ILE . 4.7 pt -109.81 169.18 3.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.195 -0.94 . . . . 0.0 108.657 178.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.535 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mttt -109.82 132.44 54.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.03 -1.044 . . . . 0.0 108.9 179.6 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.782 HG12 ' HA3' ' B' ' 78' ' ' GLY . 3.1 m -130.96 -172.45 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 110.495 -179.281 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.427 ' HG3' ' C ' ' B' ' 56' ' ' VAL . 5.6 mtp180 -134.97 85.23 2.16 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.523 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -52.73 100.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.6 -0.688 . . . . 0.0 110.901 -179.077 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.601 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 14.6 m-85 -90.28 123.07 33.75 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.498 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.0 OUTLIER -100.68 141.0 34.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.792 -1.193 . . . . 0.0 110.121 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.763 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 72.08 65.61 0.13 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.441 0.638 . . . . 0.0 109.495 179.783 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.665 ' C ' HD13 ' B' ' 72' ' ' ILE . 27.8 mm -119.26 116.15 49.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.481 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.835 HD13 ' O ' ' B' ' 63' ' ' LEU . 3.1 tm? -68.94 83.22 0.31 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.454 -0.779 . . . . 0.0 110.582 -178.502 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.879 HG12 HD12 ' B' ' 66' ' ' ILE . 7.9 tt -88.16 125.1 41.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.493 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.446 ' OE2' ' HE3' ' B' ' 70' ' ' LYS . 4.0 tt0 -91.71 110.01 21.34 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.935 -1.103 . . . . 0.0 109.768 -178.409 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.879 HD12 HG12 ' B' ' 64' ' ' ILE . 0.3 OUTLIER -109.97 122.59 64.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.237 -0.914 . . . . 0.0 108.827 179.65 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.7 m 52.05 62.66 2.59 Favored 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.644 -0.66 . . . . 0.0 110.378 179.505 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 47.81 25.21 3.43 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.16 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 36.5 m80 -118.29 117.43 29.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.089 -1.242 . . . . 0.0 109.101 179.39 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.446 ' HE3' ' OE2' ' B' ' 65' ' ' GLU . 0.0 OUTLIER -67.94 133.16 48.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.137 -0.977 . . . . 0.0 108.968 179.725 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.693 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -149.26 139.19 21.99 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.371 -0.831 . . . . 0.0 110.168 -179.335 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.763 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -110.31 140.8 27.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 177.679 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.49 -168.93 28.42 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.058 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 26.2 m -99.15 106.42 18.6 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.653 -0.91 . . . . 0.0 110.551 -179.185 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.0 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.7 t -100.68 108.89 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.47 -0.769 . . . . 0.0 110.813 179.3 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.662 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 5.2 mp -79.2 134.29 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.562 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.0 OUTLIER -118.39 118.44 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.109 -0.995 . . . . 0.0 109.448 -179.502 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.782 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.71 -167.16 16.78 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.535 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -79.54 40.13 0.91 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.689 2.259 . . . . 0.0 111.295 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.837 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.45 142.97 33.51 Favored Pre-proline 0 C--N 1.302 -1.466 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.948 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.637 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.9 Cg_endo -79.86 17.56 1.28 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 C-N-CA 122.516 2.144 . . . . 0.0 112.246 -178.427 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.837 ' H ' HG23 ' B' ' 80' ' ' THR . 1.4 t -162.41 157.25 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.425 -1.422 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.581 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 2.1 m-20 -99.34 103.16 14.95 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.447 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.836 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.3 mt -104.18 131.31 53.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.723 -1.236 . . . . 0.0 112.607 -176.085 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.577 ' N ' HD13 ' B' ' 85' ' ' ILE . 2.3 mm -95.35 107.72 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 177.887 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -88.99 -154.58 29.09 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 120.787 -1.196 . . . . 0.0 111.142 -178.374 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 7' ' ' GLN . 5.5 mtm180 -64.67 -40.09 94.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.832 -0.805 . . . . 0.0 109.911 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.984 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.9 p-10 -45.15 -38.08 4.93 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.175 -0.953 . . . . 0.0 110.395 -179.073 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.984 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.0 mm? -96.75 -27.7 14.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.817 -1.177 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.58 HD12 ' HA ' ' B' ' 26' ' ' THR . 53.9 mt -71.22 -5.79 34.68 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 178.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 17.3 p -100.97 -10.93 20.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.226 -0.921 . . . . 0.0 108.696 178.717 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.722 ' OE1' HD22 ' B' ' 89' ' ' LEU . 13.9 mt-30 -91.89 -41.06 10.81 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.196 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.803 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -85.74 2.41 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.29 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.28 51.49 52.18 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.783 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.7 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -78.73 142.32 37.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.154 -1.204 . . . . 0.0 110.184 179.746 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.832 HG22 ' CG2' ' A' ' 4' ' ' THR . 27.6 p -137.96 130.55 29.52 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.487 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' A' ' 97' ' ' LEU . 6.5 mp -91.21 94.08 9.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.339 -0.851 . . . . 0.0 110.035 -179.171 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.537 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 5.5 m-20 -97.59 120.38 37.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.057 -1.027 . . . . 0.0 109.343 179.379 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.955 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.054 179.666 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.824 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.428 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 2.6 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 N-CA-C 109.622 -0.953 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 14.4 tt0 -84.3 139.71 32.13 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 178.408 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 1.114 HG13 HD23 ' A' ' 5' ' ' LEU . 87.7 t -143.79 117.46 3.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.385 -1.326 . . . . 0.0 110.583 -178.532 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.634 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -98.54 -34.25 10.67 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 177.941 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.114 HD23 HG13 ' A' ' 3' ' ' VAL . 1.3 mm? 22.36 74.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.289 179.413 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.634 ' CE3' HG21 ' B' ' 91' ' ' THR . 41.3 m95 -41.56 -20.62 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.751 -0.593 . . . . 0.0 110.329 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 58.9 mt-30 -108.57 -105.1 0.36 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.607 -1.308 . . . . 0.0 109.282 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 8.9 mtt-85 -110.98 132.57 21.6 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 120.654 -1.279 . . . . 0.0 110.215 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.3 Cg_endo -78.92 66.34 8.73 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.336 2.024 . . . . 0.0 109.867 178.25 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -80.03 152.06 29.62 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.983 -1.073 . . . . 0.0 109.975 -179.32 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.638 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -142.09 170.9 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.382 -0.824 . . . . 0.0 109.404 -179.587 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.665 HG22 HD22 ' A' ' 19' ' ' LEU . 4.3 m -101.04 92.29 4.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 178.238 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.553 ' HA ' ' O ' ' A' ' 65' ' ' GLU . 22.1 pt -86.08 142.1 13.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.263 -0.898 . . . . 0.0 110.17 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 6.9 ttmt -114.77 99.31 7.4 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.409 -0.807 . . . . 0.0 109.499 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.759 HG22 ' CG2' ' A' ' 62' ' ' ILE . 0.2 OUTLIER -116.15 158.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.065 -1.022 . . . . 0.0 109.427 179.829 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.477 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 34.86 50.72 0.8 Allowed Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 50.95 52.49 30.49 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.797 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.543 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -152.1 172.49 16.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.459 -1.024 . . . . 0.0 108.493 179.574 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.665 HD22 HG22 ' A' ' 12' ' ' THR . 26.6 mt -141.96 132.03 24.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.08 -1.013 . . . . 0.0 110.549 -179.303 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 12.5 mmmt -150.68 162.52 40.54 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.714 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.4 mm-40 -79.25 141.54 37.01 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.942 -1.099 . . . . 0.0 108.19 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.664 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -124.05 131.72 53.59 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.992 -1.068 . . . . 0.0 110.21 -178.682 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.516 HD21 ' O ' ' B' ' 27' ' ' GLY . 25.2 tp -91.15 97.94 11.45 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.69 -0.631 . . . . 0.0 109.783 -179.774 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.547 HD13 HD21 ' A' ' 90' ' ' LEU . 0.2 OUTLIER -45.97 115.16 0.91 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.397 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' HB3' HG22 ' A' ' 84' ' ' ILE . 14.9 t0 -125.7 84.4 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.331 -0.856 . . . . 0.0 111.021 -177.536 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' CD1' ' A' ' 90' ' ' LEU . 0.2 OUTLIER -62.68 -11.91 20.17 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.005 -1.059 . . . . 0.0 109.159 178.742 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.0 -41.52 54.52 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.28 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.508 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -71.23 168.8 16.51 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -1.214 . . . . 0.0 109.709 -179.4 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -100.74 -20.81 15.41 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.204 -0.935 . . . . 0.0 110.176 -179.444 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.576 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.32 -164.99 1.56 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.068 -1.02 . . . . 0.0 109.548 -179.61 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 30.1 m -112.64 90.86 3.46 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.738 -1.226 . . . . 0.0 110.575 -179.034 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.071 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.52 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.053 -1.029 . . . . 0.0 108.826 179.536 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.126 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.81 121.41 1.29 Allowed 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.099 -1.001 . . . . 0.0 111.019 -178.849 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.496 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.6 OUTLIER -38.46 152.9 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.432 -0.792 . . . . 0.0 109.663 178.842 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 77' ' ' VAL . 2.6 mt-10 -46.07 141.61 3.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 110.459 -179.279 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.498 ' CE ' HD13 ' A' ' 15' ' ' ILE . 6.0 ptm -158.21 -177.21 6.39 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.348 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -101.09 101.7 12.5 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.069 -1.02 . . . . 0.0 109.903 -179.498 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 1.001 HD12 HG21 ' A' ' 77' ' ' VAL . 32.5 mt -106.72 162.43 19.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.062 -1.024 . . . . 0.0 109.971 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.9 Cg_endo -78.23 65.85 8.41 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.895 2.397 . . . . 0.0 112.082 -179.219 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 37.36 -160.67 0.01 OUTLIER Glycine 0 N--CA 1.499 2.846 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 178.74 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.49 59.94 0.61 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.354 -1.086 . . . . 0.0 109.486 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.588 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 64.1 p-90 -148.7 168.67 22.27 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.626 0.727 . . . . 0.0 110.115 -179.556 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.1 136.35 28.69 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.04 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.0 139.1 17.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.222 1.948 . . . . 0.0 110.872 -179.272 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HE2' ' HB2' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -153.42 -165.61 2.2 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.264 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.491 ' HG3' ' HG3' ' A' ' 55' ' ' LYS . 5.4 ttt -144.71 126.57 15.34 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.951 -1.093 . . . . 0.0 110.163 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.684 HD12 HG21 ' B' ' 50' ' ' ILE . 24.8 pt -96.1 133.65 36.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.932 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.67 101.0 0.89 Allowed Glycine 0 N--CA 1.486 1.999 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.413 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -121.53 -117.46 2.49 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.65 -178.969 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.845 HD12 ' C71' ' B' ' 100' ' ' DMP . 12.8 mt -88.94 122.85 40.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.729 -0.865 . . . . 0.0 112.506 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.44 -51.53 1.01 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 178.213 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.86 -159.98 24.6 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.228 -1.463 . . . . 0.0 110.748 -179.604 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.2 m-85 -113.33 129.38 56.55 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.55 -0.971 . . . . 0.0 109.95 -179.254 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.525 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.9 pt -109.94 152.98 11.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.214 -0.929 . . . . 0.0 108.701 178.895 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.6 mtpt -93.84 123.39 37.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.11 -0.994 . . . . 0.0 109.508 -179.577 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.529 HG12 ' HA3' ' A' ' 78' ' ' GLY . 25.9 m -126.59 -170.08 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.22 -0.925 . . . . 0.0 109.939 -179.529 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.55 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 22.5 mtt180 -124.31 174.42 7.73 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.249 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.452 ' HB2' ' HE2' ' A' ' 45' ' ' LYS . 37.2 tt0 -131.17 98.33 4.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.157 -0.964 . . . . 0.0 109.979 -179.342 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CG ' HD13 ' A' ' 38' ' ' LEU . 64.9 m-85 -97.69 97.59 9.15 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.24 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.624 ' OD1' HG23 ' A' ' 74' ' ' THR . 1.1 m-20 -82.44 139.48 33.96 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 0.0 110.856 -178.601 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.473 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.1 OUTLIER 75.6 60.32 0.05 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.583 -0.698 . . . . 0.0 109.693 179.607 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.839 HG21 HG21 ' A' ' 75' ' ' VAL . 3.5 mm -116.49 122.82 70.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 108.979 -179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.93 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.1 tm? -74.7 94.99 2.79 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 111.159 -178.751 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 66' ' ' ILE . 8.2 tt -97.89 121.97 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.289 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.553 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 50.0 tt0 -89.67 101.54 14.23 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.01 -1.056 . . . . 0.0 108.86 -179.45 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 2.3 mp -102.68 120.5 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.993 -179.037 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 92.6 m 63.36 34.96 12.62 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.738 -0.601 . . . . 0.0 110.32 179.013 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.79 12.21 80.86 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.24 137.24 44.53 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -1.228 . . . . 0.0 109.255 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.449 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -80.96 123.93 28.72 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 109.094 179.84 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -142.79 155.53 44.83 Favored 'General case' 0 C--N 1.293 -1.852 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.552 -179.759 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.721 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -125.18 149.81 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.005 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.898 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.42 176.24 47.31 Favored Glycine 0 N--CA 1.484 1.859 0 C-N-CA 118.484 -1.817 . . . . 0.0 111.158 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.624 HG23 ' OD1' ' A' ' 60' ' ' ASP . 6.5 m -86.76 108.74 18.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.702 -0.881 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.126 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -98.32 110.5 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.532 -0.73 . . . . 0.0 109.779 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.576 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 3.9 mp -78.9 139.16 38.35 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 120.997 -1.064 . . . . 0.0 108.356 179.133 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 1.001 HG21 HD12 ' A' ' 38' ' ' LEU . 15.9 t -125.04 114.72 41.55 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.481 -0.762 . . . . 0.0 110.054 -179.287 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.529 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -154.41 -159.67 9.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.664 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.9 Cg_endo -79.83 41.1 1.05 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.659 2.239 . . . . 0.0 111.072 -179.874 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.68 HG21 HG13 ' A' ' 32' ' ' VAL . 1.8 t -87.97 133.03 38.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.666 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -77.15 16.26 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.687 2.258 . . . . 0.0 111.77 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.55 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.45 164.38 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.955 -1.091 . . . . 0.0 109.604 -179.812 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.597 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -100.83 132.88 46.02 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 176.53 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.604 HG22 ' HB3' ' A' ' 25' ' ' ASP . 3.9 mm -119.8 119.98 61.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 O-C-N 120.447 -1.408 . . . . 0.0 111.362 -176.867 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.701 ' N ' HD13 ' A' ' 85' ' ' ILE . 2.0 mm -95.01 89.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.461 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.98 -165.42 29.23 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.962 -1.114 . . . . 0.0 111.46 -177.595 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 87' ' ' ARG . 1.3 mtp-105 -59.34 -40.66 87.08 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.853 -0.792 . . . . 0.0 110.638 -178.904 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.986 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.9 p-10 -45.4 -24.99 0.35 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.971 -1.081 . . . . 0.0 109.675 -179.327 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.986 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.1 mm? -110.64 -26.85 9.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.011 -1.056 . . . . 0.0 109.614 -179.298 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.679 ' CD1' HG23 ' A' ' 26' ' ' THR . 65.8 mt -72.09 -6.91 45.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 108.589 179.179 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.481 ' O ' ' CZ2' ' B' ' 6' ' ' TRP . 57.4 p -100.92 -19.17 16.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.041 -1.037 . . . . 0.0 108.252 179.116 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 -84.22 -41.14 17.25 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.8 . . . . 0.0 109.159 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.867 HD12 ' HB3' ' B' ' 99' ' ' PHE . 1.1 pp -80.36 -7.28 10.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.98 59.41 5.94 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.606 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.841 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -86.63 157.97 19.58 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -1.212 . . . . 0.0 110.356 -179.702 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -150.24 126.66 10.78 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.464 -0.772 . . . . 0.0 109.279 179.401 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' B' ' 97' ' ' LEU . 8.6 mp -86.09 111.57 20.46 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 12.6 m-20 -108.73 121.76 45.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.852 -1.155 . . . . 0.0 109.78 179.951 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.692 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.427 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.418 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.066 -0.782 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.9 tt0 -83.4 141.55 31.65 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 178.379 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.466 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 40.6 t -142.66 112.73 2.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 120.565 -1.334 . . . . 0.0 110.694 -178.367 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -124.11 -71.7 0.71 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.713 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.543 ' O ' ' C ' ' B' ' 6' ' ' TRP . 18.5 mt 36.62 31.01 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.737 -0.602 . . . . 0.0 109.866 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.3 m0 17.27 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.144 0 CA-C-O 121.609 0.719 . . . . 0.0 111.404 -179.427 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER -150.55 -165.84 2.38 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.691 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -84.15 115.9 62.34 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.144 -0.973 . . . . 0.0 109.389 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.744 ' HB2' HD12 ' B' ' 24' ' ' LEU . 35.9 Cg_endo -77.29 73.3 5.58 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.391 2.061 . . . . 0.0 110.507 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 1.024 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.6 OUTLIER -79.6 163.47 24.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.157 -0.964 . . . . 0.0 108.786 179.617 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.663 HG23 HG23 ' B' ' 13' ' ' ILE . 4.6 m -144.53 128.01 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.994 -1.066 . . . . 0.0 110.765 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 12' ' ' THR . . . . . 1.045 HG22 HD22 ' B' ' 19' ' ' LEU . 1.2 m -71.07 87.88 0.77 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.529 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.07 HG22 HG13 ' B' ' 66' ' ' ILE . 17.3 pt -85.65 142.57 12.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-O 121.716 0.77 . . . . 0.0 111.58 -177.18 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.511 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 2.8 tttt -103.29 94.21 5.39 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.187 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.616 HG22 ' CE ' ' B' ' 36' ' ' MET . 0.3 OUTLIER -104.28 115.78 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.164 -0.96 . . . . 0.0 110.358 -178.444 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.55 26.37 71.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.28 88.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -96.96 -179.91 4.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -1.19 . . . . 0.0 108.704 179.427 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 1.045 HD22 HG22 ' B' ' 12' ' ' THR . 5.1 mt -148.82 128.25 13.07 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.972 -1.08 . . . . 0.0 110.382 -179.625 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.403 ' HG3' ' C ' ' B' ' 19' ' ' LEU . 9.9 mttm -151.19 155.58 39.16 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.562 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 1.024 ' HB3' HD23 ' B' ' 10' ' ' LEU . 2.7 mm-40 -78.36 100.72 6.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.15 -0.969 . . . . 0.0 108.519 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 1.085 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -85.26 104.17 14.87 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.261 -0.899 . . . . 0.0 110.698 -178.738 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' B' ' 25' ' ' ASP . 5.4 tp -58.54 103.96 0.19 Allowed 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.445 179.26 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.744 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.3 mt -49.83 96.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.039 -1.038 . . . . 0.0 108.558 179.476 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.92 ' CB ' HG23 ' B' ' 84' ' ' ILE . 15.6 t0 -102.5 91.94 4.45 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.195 -0.94 . . . . 0.0 110.469 -179.075 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.503 HG23 HD13 ' B' ' 90' ' ' LEU . 6.9 m -70.39 -6.37 35.01 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.948 -1.095 . . . . 0.0 108.791 178.545 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.516 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -77.45 -39.91 24.72 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.39 154.88 34.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.019 -1.283 . . . . 0.0 109.305 -179.691 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -88.47 -17.96 29.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.16 -0.962 . . . . 0.0 110.753 -178.856 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.536 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.78 -170.36 2.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.948 -1.095 . . . . 0.0 110.464 -179.178 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.809 HG23 HD12 ' B' ' 85' ' ' ILE . 65.4 m -109.12 103.78 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.991 -1.068 . . . . 0.0 110.29 -178.634 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 0.943 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -87.82 171.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 108.678 179.417 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.02 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.06 125.57 2.29 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.928 -1.107 . . . . 0.0 110.319 -179.048 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.663 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.3 tt0 -37.8 160.59 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.391 0.615 . . . . 0.0 109.936 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.473 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.4 tt0 -53.6 148.45 9.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 110.46 -179.514 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.616 ' CE ' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -170.71 -166.55 0.51 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.611 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.46 ' N ' ' SD ' ' B' ' 36' ' ' MET . 5.4 t -115.06 76.73 1.01 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.797 -1.189 . . . . 0.0 110.923 -179.171 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.795 HD12 ' CG2' ' B' ' 77' ' ' VAL . 8.0 mt -80.43 173.31 7.91 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.633 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.618 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 29.3 Cg_endo -71.01 -155.63 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 121.776 1.651 . . . . 0.0 111.092 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -103.0 -157.6 25.27 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.046 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.44 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.1 mmm-85 65.72 57.91 0.82 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.511 -0.993 . . . . 0.0 108.809 -179.639 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 52.0 p-90 -135.59 -172.6 3.13 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-O 121.747 0.784 . . . . 0.0 110.282 -179.015 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mptt -148.43 140.85 14.84 Favored Pre-proline 0 N--CA 1.489 1.487 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.126 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.48 135.4 14.72 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.74 1.627 . . . . 0.0 109.856 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.5 ' O ' ' HG2' ' B' ' 46' ' ' MET . 0.0 OUTLIER -158.46 -169.68 2.83 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 109.596 -179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' O ' ' B' ' 45' ' ' LYS . 10.1 mtp -149.26 131.39 15.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 109.097 179.849 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 54' ' ' ILE . 9.3 pt -89.04 140.34 15.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.95 -1.094 . . . . 0.0 108.312 179.271 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.18 111.43 2.17 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 -179.702 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.488 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -135.77 -114.29 1.36 Allowed Glycine 0 N--CA 1.481 1.697 0 C-N-CA 119.442 -1.361 . . . . 0.0 111.096 -178.806 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.848 HD12 ' C21' ' B' ' 100' ' ' DMP . 11.3 mt -92.64 124.47 45.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.862 -0.787 . . . . 0.0 112.385 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.525 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 94.85 -48.86 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.452 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.87 -157.15 20.42 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.66 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.1 OUTLIER -124.21 131.79 53.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.377 -1.072 . . . . 0.0 109.391 179.87 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 47' ' ' ILE . 4.0 pt -99.01 -177.85 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 109.101 179.839 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -108.7 137.17 47.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.955 -1.09 . . . . 0.0 109.471 179.722 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.463 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.0 m -143.78 176.71 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 0.0 109.771 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -127.19 108.64 11.06 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.468 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.6 OUTLIER -66.18 102.43 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.514 -0.741 . . . . 0.0 110.725 -179.085 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.607 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.7 m-85 -97.04 94.13 6.99 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.535 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.1 OUTLIER -79.1 134.31 36.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 0.0 110.093 -178.832 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 37.2 mm-40 82.74 60.71 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.943 -0.473 . . . . 0.0 110.558 179.252 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.509 HG13 ' HB3' ' B' ' 59' ' ' TYR . 11.6 mm -124.05 126.72 72.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.994 -1.066 . . . . 0.0 109.202 178.876 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.81 HD22 HG13 ' B' ' 72' ' ' ILE . 0.2 OUTLIER -71.91 95.91 1.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 121.72 0.771 . . . . 0.0 111.799 -178.52 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.551 ' HB ' HD11 ' B' ' 15' ' ' ILE . 3.5 tt -96.08 109.81 23.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 175.765 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.493 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.8 tm-20 -88.2 118.25 27.67 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.911 -1.118 . . . . 0.0 110.252 -177.571 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 1.07 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -112.74 113.13 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.555 -0.716 . . . . 0.0 109.195 179.929 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.2 m 66.06 6.33 4.05 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.653 -0.654 . . . . 0.0 110.314 179.356 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 68' ' ' GLY . . . . . 0.457 ' N ' ' OE2' ' B' ' 65' ' ' GLU . . . 110.93 -3.1 28.7 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -88.39 115.91 26.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.161 -1.199 . . . . 0.0 108.953 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.556 ' HG3' HD11 ' B' ' 63' ' ' LEU . 1.5 mptp? -69.45 107.24 3.26 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.549 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -121.98 110.06 15.36 Favored 'General case' 0 C--N 1.291 -1.938 0 O-C-N 121.627 -0.671 . . . . 0.0 109.683 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.81 HG13 HD22 ' B' ' 63' ' ' LEU . 1.2 mt -94.63 120.64 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.894 -1.128 . . . . 0.0 108.271 178.782 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.677 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -140.32 -165.89 10.46 Favored Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.554 -179.645 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.468 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 59.5 m -97.73 106.69 19.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.68 -0.894 . . . . 0.0 109.651 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.02 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.5 t -91.34 172.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.541 -0.724 . . . . 0.0 109.49 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' HG23 ' B' ' 32' ' ' VAL . 3.6 mp -140.36 112.67 7.83 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.924 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.795 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.9 t -97.52 117.49 42.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.932 -1.105 . . . . 0.0 110.305 -178.508 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -154.19 -171.42 21.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.746 -1.742 . . . . 0.0 108.746 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -80.92 41.56 1.17 Allowed 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.336 2.024 . . . . 0.0 110.926 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.663 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.5 t -82.38 138.7 44.83 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.854 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.411 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.0 Cg_endo -78.23 18.16 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.283 1.989 . . . . 0.0 110.973 -179.579 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.657 ' O ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -159.71 163.82 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.107 -0.996 . . . . 0.0 109.638 -179.552 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.68 ' ND2' ' N ' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -109.44 119.86 40.73 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 104.417 -2.438 . . . . 0.0 104.417 176.319 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.92 HG23 ' CB ' ' B' ' 25' ' ' ASP . 6.0 mt -120.4 132.67 69.4 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 120.117 -1.614 . . . . 0.0 113.859 -174.688 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 1.085 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -96.67 102.51 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.002 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.536 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -83.35 -160.26 29.32 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.076 -179.344 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.494 ' HD2' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -69.79 -30.25 67.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.472 -1.016 . . . . 0.0 109.848 -179.797 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.938 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.8 p-10 -49.38 -24.29 1.87 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.942 -1.099 . . . . 0.0 109.571 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.938 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -111.06 -23.42 10.93 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.998 -1.064 . . . . 0.0 109.76 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.625 HD21 HD22 ' B' ' 24' ' ' LEU . 51.8 mt -69.32 -6.17 27.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.027 -1.045 . . . . 0.0 109.225 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.634 HG21 ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -100.65 -20.53 15.6 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.075 -1.016 . . . . 0.0 108.969 179.401 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.446 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 28.1 mt-30 -81.04 -40.42 24.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.418 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.692 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -82.79 -5.54 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 177.923 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.12 25.95 62.98 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.151 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.596 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.89 132.64 52.78 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.803 -1.41 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.634 HG22 HG23 ' A' ' 4' ' ' THR . 15.7 p -131.47 128.49 39.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.156 -0.965 . . . . 0.0 108.666 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -85.76 96.83 9.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.409 -0.807 . . . . 0.0 110.358 -178.773 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.563 ' C ' ' CD1' ' B' ' 99' ' ' PHE . 7.9 m-20 -111.05 139.75 46.15 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.834 . . . . 0.0 109.499 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.867 ' HB3' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.056 -1.028 . . . . 0.0 109.533 179.438 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.848 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.504 ' HG2' ' CD2' ' B' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.232 -0.719 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -91.48 128.62 37.38 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.156 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.413 HG11 ' HB3' ' A' ' 9' ' ' PRO . 53.0 t -125.56 131.88 71.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.028 -178.447 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.621 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -154.41 51.57 0.65 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.352 -0.842 . . . . 0.0 109.143 -179.733 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -94.64 42.67 1.09 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.226 -0.921 . . . . 0.0 110.178 -179.401 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.529 ' C ' ' O ' ' A' ' 5' ' ' LEU . 26.9 m95 18.13 49.06 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.415 0 CA-C-O 121.131 0.491 . . . . 0.0 112.176 179.797 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -166.61 -173.89 2.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.145 -0.972 . . . . 0.0 109.359 179.66 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HD3' ' OD1' ' B' ' 29' ' ' ASP . 5.3 mtm180 -63.88 111.09 4.61 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.324 -0.86 . . . . 0.0 110.049 -179.629 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.1 Cg_endo -77.29 84.31 1.98 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.957 1.771 . . . . 0.0 109.117 178.668 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.732 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -89.89 149.11 22.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 110.248 -178.882 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.855 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -135.97 137.74 48.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.388 -0.82 . . . . 0.0 109.551 179.741 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.821 HG22 HD22 ' A' ' 19' ' ' LEU . 29.2 m -72.96 98.84 2.57 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 178.635 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.687 HG22 HG13 ' A' ' 66' ' ' ILE . 15.3 pt -88.6 144.02 9.99 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 O-C-N 121.407 -0.808 . . . . 0.0 110.805 -178.363 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.814 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -107.01 105.23 15.16 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.725 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.688 HD13 HG11 ' A' ' 75' ' ' VAL . 24.8 mt -121.74 124.45 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.049 -1.032 . . . . 0.0 109.872 -179.291 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.88 18.4 72.46 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.372 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.55 0.61 84.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.471 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 28.7 mm-40 -99.9 -178.62 3.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.175 -1.191 . . . . 0.0 109.058 179.746 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.821 HD22 HG22 ' A' ' 12' ' ' THR . 16.7 mt -141.29 129.6 22.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.181 -0.949 . . . . 0.0 110.002 -179.579 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 3.1 mmtp -142.88 -170.49 3.25 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.492 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.732 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.2 mt-10 -103.26 146.52 28.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.161 -0.962 . . . . 0.0 109.025 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.712 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -130.22 136.21 48.97 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.931 -1.106 . . . . 0.0 110.221 -179.566 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.841 HD21 ' O ' ' B' ' 27' ' ' GLY . 53.0 tp -105.17 111.55 24.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.495 -0.753 . . . . 0.0 110.041 -179.329 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -46.71 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.907 -1.121 . . . . 0.0 109.324 179.618 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.701 ' CB ' HG23 ' A' ' 84' ' ' ILE . 33.4 t0 -98.65 71.43 1.96 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.116 -0.99 . . . . 0.0 109.563 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.564 ' CG2' ' HG3' ' B' ' 9' ' ' PRO . 64.9 m -58.1 -15.88 11.12 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.103 -0.998 . . . . 0.0 108.537 179.066 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.686 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -69.64 -41.14 76.17 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.742 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.502 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -76.94 155.97 32.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -1.213 . . . . 0.0 109.78 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.524 ' OD2' ' CG ' ' B' ' 8' ' ' ARG . 1.3 m-20 -96.47 -9.97 28.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.769 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -131.6 -170.11 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 109.549 -179.677 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.563 HG23 HD12 ' A' ' 85' ' ' ILE . 11.2 m -113.81 88.37 2.83 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.058 -1.027 . . . . 0.0 109.973 -179.367 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.93 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.19 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 178.725 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.039 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -164.08 123.36 1.97 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.406 -1.434 . . . . 0.0 111.875 -179.261 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -42.32 145.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.517 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.8 OUTLIER -48.23 138.75 9.29 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.149 -0.969 . . . . 0.0 109.826 -179.683 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.506 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -147.63 -164.47 2.01 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.424 -0.798 . . . . 0.0 109.209 179.419 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.443 ' N ' ' SD ' ' A' ' 36' ' ' MET . 18.1 t -100.01 87.67 3.55 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 110.041 -179.639 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 1.054 HD12 HG21 ' A' ' 77' ' ' VAL . 16.2 mt -110.92 159.96 30.62 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.106 -0.996 . . . . 0.0 108.935 179.19 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.471 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 34.8 Cg_endo -77.35 154.23 31.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.598 2.199 . . . . 0.0 110.361 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.542 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -59.29 -154.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.542 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 4.7 mmm180 69.86 49.58 0.51 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.831 -0.805 . . . . 0.0 109.48 -179.595 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 45.8 p-90 -135.31 -171.4 2.81 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.819 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.0 mtpm? -138.9 134.36 16.97 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.963 -1.085 . . . . 0.0 108.85 179.598 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.69 139.26 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.073 1.849 . . . . 0.0 111.26 -179.181 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.523 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 11.4 pttt -159.03 153.6 24.35 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.307 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.458 ' HG3' ' O ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -110.85 128.94 55.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.778 -1.201 . . . . 0.0 110.4 -179.093 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 10.0 pt -96.81 142.07 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.95 -1.094 . . . . 0.0 108.152 178.305 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.619 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.79 100.56 0.83 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.607 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.12 -122.76 2.78 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.71 -1.234 . . . . 0.0 110.099 -179.716 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.819 HD12 ' C71' ' B' ' 100' ' ' DMP . 10.5 mt -87.33 123.21 39.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.629 -0.924 . . . . 0.0 111.854 -178.466 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.79 -52.78 0.68 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.146 -1.181 . . . . 0.0 110.146 178.573 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.46 -155.2 21.84 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.751 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.619 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 6.8 m-85 -114.12 123.22 49.1 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.412 -1.052 . . . . 0.0 110.014 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.71 ' CD1' HG23 ' B' ' 50' ' ' ILE . 32.0 pt -102.79 162.43 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.076 -1.015 . . . . 0.0 108.509 178.597 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.9 OUTLIER -95.96 144.78 25.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.215 -0.928 . . . . 0.0 109.018 -179.932 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.65 HG12 ' HA3' ' A' ' 78' ' ' GLY . 17.0 m -142.91 -173.73 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.889 -1.132 . . . . 0.0 109.711 -179.83 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.571 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 36.2 mtt180 -133.04 93.21 3.14 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 179.541 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -50.03 101.65 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.585 0.707 . . . . 0.0 110.036 -179.632 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.616 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.3 m-85 -100.95 88.29 3.5 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.74 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.498 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -78.73 137.68 37.89 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.201 -0.937 . . . . 0.0 110.401 -178.517 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.628 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.0 OUTLIER 74.01 61.79 0.08 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.755 -0.591 . . . . 0.0 110.531 179.329 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.851 ' C ' HD13 ' A' ' 72' ' ' ILE . 1.2 mt -122.02 124.21 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.516 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.815 HD13 ' O ' ' A' ' 63' ' ' LEU . 3.1 tm? -70.06 92.24 0.73 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.442 -0.787 . . . . 0.0 111.82 -177.559 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.77 HD13 HD11 ' A' ' 66' ' ' ILE . 4.2 tt -96.91 118.53 43.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.846 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.556 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 39.1 tt0 -89.61 100.81 13.54 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.983 -1.073 . . . . 0.0 109.766 -178.778 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.855 HG23 HG21 ' A' ' 11' ' ' VAL . 1.3 mp -97.12 121.8 47.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.268 -0.895 . . . . 0.0 108.965 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.3 m 58.09 57.32 4.09 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.515 -0.741 . . . . 0.0 109.641 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.71 26.33 7.78 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.764 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.461 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 34.5 m170 -122.24 118.9 29.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.991 -1.3 . . . . 0.0 109.267 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.638 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 mptt -61.38 139.58 58.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.258 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.67 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -159.88 102.33 1.48 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.173 -0.954 . . . . 0.0 110.473 -179.686 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.851 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -78.58 147.25 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.525 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.847 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.09 -170.89 37.25 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.903 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.2 m -95.33 106.08 18.09 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.729 -0.865 . . . . 0.0 110.174 -179.488 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.039 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.04 106.58 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.701 -0.625 . . . . 0.0 109.708 179.358 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.548 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.8 mp -79.81 113.26 17.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.119 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 1.054 HG21 HD12 ' A' ' 38' ' ' LEU . 7.9 t -97.91 107.98 21.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 120.908 -1.12 . . . . 0.0 110.261 -178.97 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.65 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -140.24 -166.48 10.68 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.101 -2.0 . . . . 0.0 108.101 179.088 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.92 40.42 0.96 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.305 2.003 . . . . 0.0 110.522 179.208 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' A' ' 34' ' ' GLU . 11.5 t -81.75 137.25 47.45 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.33 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.566 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.1 Cg_endo -78.91 16.3 1.35 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.483 2.122 . . . . 0.0 111.476 -179.089 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.4 t -161.07 149.65 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.809 -1.182 . . . . 0.0 110.251 -179.845 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -85.85 100.07 11.81 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.774 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.701 HG23 ' CB ' ' A' ' 25' ' ' ASP . 18.9 mm -84.52 120.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.234 -0.916 . . . . 0.0 112.994 -175.804 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.912 HG22 HD11 ' A' ' 90' ' ' LEU . 0.6 OUTLIER -103.0 99.36 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.836 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.493 ' O ' HD13 ' A' ' 90' ' ' LEU . . . -106.54 175.99 21.31 Favored Glycine 0 N--CA 1.497 2.72 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.243 -177.069 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.753 ' N ' HD22 ' A' ' 90' ' ' LEU . 13.2 mmm180 -25.81 -41.41 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -179.085 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.8 p-10 -52.54 -42.54 64.5 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.184 -1.573 . . . . 0.0 110.562 -177.683 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.8 mm? -92.98 -23.96 18.53 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.035 . . . . 0.0 108.607 179.598 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.912 HD11 HG22 ' A' ' 85' ' ' ILE . 0.4 OUTLIER -67.81 -8.03 32.59 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.309 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.82 -20.66 17.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.928 -1.108 . . . . 0.0 108.844 179.824 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 30.6 mm-40 -85.71 -40.21 16.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.216 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.71 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -83.12 2.16 3.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.236 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 66.46 31.93 80.25 Favored Glycine 0 N--CA 1.499 2.887 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.186 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.685 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -61.06 143.72 54.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.247 -1.149 . . . . 0.0 111.433 -179.542 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.707 HG22 ' CG2' ' B' ' 4' ' ' THR . 58.0 p -152.05 141.49 21.6 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.13 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' B' ' 97' ' ' LEU . 0.0 OUTLIER -98.23 118.31 34.58 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.786 -1.196 . . . . 0.0 110.358 -179.916 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.5 m120 -118.0 123.75 46.48 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.637 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.481 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.574 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.576 0 N-CA-C 110.176 -0.74 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.511 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.8 tt0 -89.12 146.41 24.83 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.216 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 3' ' ' VAL . . . . . 0.58 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 12.2 t -138.93 118.17 13.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 120.525 -1.359 . . . . 0.0 110.673 -178.615 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.707 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -123.94 -71.83 0.7 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.277 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.743 ' N ' HD22 ' B' ' 5' ' ' LEU . 3.1 mm? 36.92 34.47 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.654 -0.654 . . . . 0.0 110.656 179.574 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.532 ' C ' ' O ' ' B' ' 5' ' ' LEU . 17.8 m95 18.61 48.17 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.285 0 CA-C-O 121.233 0.54 . . . . 0.0 112.165 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.569 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -163.16 -158.9 0.5 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.53 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.0 OUTLIER -71.94 124.19 90.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.348 -0.845 . . . . 0.0 109.431 179.888 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.639 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.7 Cg_endo -76.99 74.15 5.12 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.146 1.897 . . . . 0.0 110.094 179.387 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.818 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.41 164.24 24.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.03 -1.044 . . . . 0.0 110.091 -179.498 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.467 HG23 HG23 ' B' ' 13' ' ' ILE . 2.8 m -151.27 152.76 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.475 -0.766 . . . . 0.0 109.927 -179.007 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.947 HG22 HD22 ' B' ' 19' ' ' LEU . 27.9 m -85.89 103.32 14.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.422 -1.423 . . . . 0.0 107.717 177.562 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 1.06 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.7 pt -94.53 148.6 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.065 -1.022 . . . . 0.0 110.479 -178.566 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 14' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -117.12 105.47 12.3 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.739 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.945 HG22 HD21 ' B' ' 38' ' ' LEU . 16.3 mt -116.75 134.01 61.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 120.826 -1.171 . . . . 0.0 109.438 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.09 -99.37 0.31 Allowed Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 -179.672 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 17' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' B' ' 18' ' ' GLN . . . -145.31 32.05 1.66 Allowed Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.471 -1.851 . . . . 0.0 108.471 179.237 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' B' ' 17' ' ' GLY . 3.0 mm100 -132.72 178.31 6.96 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.492 -1.005 . . . . 0.0 109.635 -179.539 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 1.06 HD23 ' O ' ' B' ' 13' ' ' ILE . 9.0 mt -143.62 130.8 20.74 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.416 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.3 mmmt -143.44 156.14 44.57 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.818 ' HB3' HD23 ' B' ' 10' ' ' LEU . 1.9 mp0 -79.49 122.34 26.33 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.981 -1.074 . . . . 0.0 108.811 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.609 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.38 129.93 52.28 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.434 -0.791 . . . . 0.0 110.647 -178.787 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.686 HD21 ' O ' ' A' ' 27' ' ' GLY . 22.9 tp -80.17 97.72 7.02 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.841 HD22 HD21 ' B' ' 90' ' ' LEU . 15.2 mt -44.22 113.01 0.47 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.715 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.609 ' HB3' HG22 ' B' ' 84' ' ' ILE . 57.7 t0 -126.39 88.12 2.78 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.05 -177.789 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.576 HG21 ' CD2' ' B' ' 97' ' ' LEU . 1.8 m -64.06 -12.83 42.43 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.037 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.841 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.1 -41.92 45.8 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.171 -1.171 . . . . 0.0 110.171 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.12 152.3 46.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.061 -1.258 . . . . 0.0 109.449 -179.684 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.574 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 30.6 m-20 -85.0 -21.69 29.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 110.378 -178.946 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.51 ' HA ' ' OD1' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -139.98 -160.38 1.06 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.811 -1.181 . . . . 0.0 109.429 179.965 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.567 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.0 m -110.94 94.13 4.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.731 -1.23 . . . . 0.0 111.56 -178.242 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.051 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.49 174.73 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.053 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.051 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.72 117.35 0.59 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.932 -1.105 . . . . 0.0 110.311 -179.178 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.772 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.5 pt-20 -38.13 158.22 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.544 -0.722 . . . . 0.0 109.586 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.689 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -46.34 149.71 0.72 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.212 -0.93 . . . . 0.0 110.668 -179.119 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.456 ' SD ' ' O ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -178.68 167.58 1.74 Allowed 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.513 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.456 ' O ' ' SD ' ' B' ' 36' ' ' MET . 48.0 t -87.88 109.24 19.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.967 -1.083 . . . . 0.0 109.765 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.945 HD21 HG22 ' B' ' 15' ' ' ILE . 8.6 mt -114.65 105.12 53.88 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.255 179.649 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -78.47 102.02 1.52 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.542 2.161 . . . . 0.0 111.233 -179.526 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 168.31 31.13 0.02 OUTLIER Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.596 179.288 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.52 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 55.63 153.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.778 -0.837 . . . . 0.0 109.721 179.647 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.621 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 51.5 p-90 -161.37 176.14 11.48 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.803 -1.185 . . . . 0.0 110.123 -179.764 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.421 ' CD ' ' HD2' ' B' ' 44' ' ' PRO . 0.1 OUTLIER -134.08 162.92 54.79 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.6 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 44' ' ' PRO . . . . . 0.421 ' HD2' ' CD ' ' B' ' 43' ' ' LYS . 33.4 Cg_endo -76.38 139.95 21.33 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 C-N-CA 121.827 1.685 . . . . 0.0 109.721 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.715 ' O ' HG23 ' B' ' 56' ' ' VAL . 7.4 tttm -159.58 119.79 3.05 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.414 -0.804 . . . . 0.0 109.105 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 76.5 mtp -98.9 132.26 44.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.415 -0.803 . . . . 0.0 109.291 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.798 ' CD1' HG21 ' A' ' 50' ' ' ILE . 17.6 pt -94.26 149.05 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.987 -1.071 . . . . 0.0 108.826 179.386 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.534 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.36 100.51 0.81 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.829 -1.708 . . . . 0.0 108.829 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.445 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -126.25 -129.34 3.29 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.3 -1.429 . . . . 0.0 110.665 -179.241 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.904 HD12 ' C20' ' B' ' 100' ' ' DMP . 47.4 mt -84.42 118.37 31.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.752 -0.852 . . . . 0.0 112.948 -177.488 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.654 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 100.02 -1.77 56.53 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 177.805 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 127.85 -154.63 19.83 Favored Glycine 0 N--CA 1.49 2.274 0 O-C-N 120.969 -1.312 . . . . 0.0 109.999 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.63 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 0.4 OUTLIER -121.18 141.53 50.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.53 -0.982 . . . . 0.0 109.799 -179.628 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.607 HD11 HD11 ' B' ' 47' ' ' ILE . 18.8 pt -107.22 178.67 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 108.995 179.097 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.583 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.2 OUTLIER -109.5 130.13 55.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.234 -0.916 . . . . 0.0 109.568 -179.881 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.715 HG23 ' O ' ' B' ' 45' ' ' LYS . 2.2 m -144.11 174.06 4.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.094 -1.004 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -116.73 115.47 25.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.813 179.847 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.521 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 5.6 tt0 -69.77 106.8 3.24 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.139 -0.976 . . . . 0.0 110.13 -179.349 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.621 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 18.0 m-85 -99.65 87.31 3.53 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 178.536 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.589 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -78.71 125.68 29.7 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.875 -1.14 . . . . 0.0 110.177 -178.783 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.589 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 1.5 mt-30 91.16 60.65 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.336 0.588 . . . . 0.0 110.402 179.329 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.695 ' CG2' HG23 ' B' ' 15' ' ' ILE . 33.1 mm -121.87 125.68 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.306 -0.871 . . . . 0.0 108.752 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.915 HD13 ' O ' ' B' ' 63' ' ' LEU . 2.1 tm? -73.91 86.38 1.76 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.219 -0.926 . . . . 0.0 112.364 -178.081 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.93 HD12 HD11 ' B' ' 15' ' ' ILE . 16.5 tt -89.8 114.61 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.426 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.7 OUTLIER -90.14 127.51 36.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.912 -1.118 . . . . 0.0 108.765 -179.836 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.666 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -124.3 125.89 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.129 -0.982 . . . . 0.0 109.988 -179.248 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.532 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 54.9 m 55.91 12.78 0.95 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.687 -0.633 . . . . 0.0 111.111 179.169 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 68' ' ' GLY . . . . . 0.425 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 101.24 21.7 11.4 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.301 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.919 ' HB2' HG22 ' B' ' 93' ' ' ILE . 23.9 m-70 -118.0 114.52 23.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.057 -1.26 . . . . 0.0 109.333 179.544 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.691 ' CG ' HD21 ' B' ' 63' ' ' LEU . 9.6 tttt -64.4 117.4 7.23 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.12 -0.987 . . . . 0.0 109.006 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -138.14 124.04 20.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.302 -0.873 . . . . 0.0 110.358 -178.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.578 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -103.43 129.89 54.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 177.749 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.428 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -149.29 -159.91 8.86 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.506 -1.331 . . . . 0.0 110.364 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.521 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 7.6 m -100.93 110.71 22.78 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.442 -1.034 . . . . 0.0 109.553 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 0.975 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.1 107.14 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.312 -0.867 . . . . 0.0 110.516 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -79.06 121.44 24.97 Favored 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.855 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.758 HG21 HD12 ' B' ' 38' ' ' LEU . 3.4 t -110.7 114.27 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.106 -0.996 . . . . 0.0 110.557 -178.68 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.692 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -148.63 -165.13 11.93 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.583 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.57 41.38 1.13 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.588 2.192 . . . . 0.0 110.486 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.772 HG22 ' HA ' ' B' ' 34' ' ' GLU . 13.6 t -81.43 140.82 48.58 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.596 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.7 Cg_endo -78.81 12.52 2.19 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.426 2.084 . . . . 0.0 110.742 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.596 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -161.22 167.12 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.191 -0.943 . . . . 0.0 109.563 -179.573 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.609 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -105.38 144.37 32.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 104.486 -2.413 . . . . 0.0 104.486 175.761 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.609 HG22 ' HB3' ' B' ' 25' ' ' ASP . 5.7 mm -130.25 130.01 65.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 O-C-N 120.284 -1.51 . . . . 0.0 111.735 -177.059 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.497 ' CD1' HG23 ' B' ' 31' ' ' THR . 0.8 OUTLIER -101.15 100.42 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.483 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.9 -155.42 8.81 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.736 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.574 ' HD2' ' HA ' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -79.68 -30.04 41.0 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.388 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.982 ' ND2' HD23 ' B' ' 89' ' ' LEU . 18.4 p-10 -47.51 -22.95 0.53 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.302 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.982 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.4 mm? -113.42 -42.89 3.4 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.123 -0.985 . . . . 0.0 111.036 -178.58 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.841 HD21 HD22 ' B' ' 24' ' ' LEU . 93.8 mt -52.63 -35.88 55.47 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.592 -1.318 . . . . 0.0 109.425 -179.547 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.504 HG21 ' HA ' ' A' ' 6' ' ' TRP . 49.4 p -80.42 -21.79 41.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.233 -0.917 . . . . 0.0 110.978 -178.738 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.568 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 66.7 mt-30 -75.06 -38.19 61.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.78 -1.2 . . . . 0.0 108.737 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -79.84 2.09 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.392 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 71.37 60.32 4.46 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -100.01 163.42 12.44 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.308 -1.113 . . . . 0.0 110.021 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.621 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.2 p -148.92 135.19 19.3 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.494 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -90.17 114.83 26.88 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.286 179.952 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.4 m-20 -119.24 130.59 55.54 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.869 -0.519 . . . . 0.0 109.863 -179.069 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.71 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.171 -0.919 . . . . 0.0 109.09 178.567 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.904 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.495 1.615 0 N-CA-C 110.179 -0.739 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.468 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -83.81 145.89 28.43 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 177.632 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.462 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 55.1 t -146.72 105.93 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 117.82 -1.552 . . . . 0.0 111.143 -178.436 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 6' ' ' TRP . 13.5 p -107.16 -57.22 2.1 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 177.811 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.588 ' O ' ' N ' ' A' ' 7' ' ' GLN . 7.8 tp 33.92 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.938 -0.476 . . . . 0.0 111.119 178.659 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.546 ' N ' ' O ' ' A' ' 4' ' ' THR . 9.0 m95 18.19 47.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.121 0.486 . . . . 0.0 111.91 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.588 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -167.41 -175.49 2.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.797 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.546 HH21 HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -56.2 125.74 65.57 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.412 -0.805 . . . . 0.0 109.558 179.755 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.528 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.9 Cg_endo -79.05 70.89 7.3 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.179 1.919 . . . . 0.0 109.177 178.843 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.606 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.99 156.12 23.6 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.42 -0.8 . . . . 0.0 110.093 -178.908 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.545 HG21 HG23 ' A' ' 66' ' ' ILE . 2.1 m -149.31 130.25 4.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.512 -0.743 . . . . 0.0 109.245 179.776 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' THR . . . . . 1.01 HG22 HD22 ' A' ' 19' ' ' LEU . 23.0 m -65.7 96.34 0.27 Allowed 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.728 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.831 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -79.28 140.07 17.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.395 -0.816 . . . . 0.0 109.785 -178.737 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.651 ' HE3' HD11 ' A' ' 19' ' ' LEU . 29.0 tttt -105.64 95.52 5.86 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.242 -0.911 . . . . 0.0 108.981 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.791 HG23 ' CG2' ' A' ' 62' ' ' ILE . 15.1 mt -118.78 147.53 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.153 -0.967 . . . . 0.0 109.924 -179.295 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 44.69 50.62 8.39 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.207 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.26 43.99 34.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.7 mm-40 -142.66 176.67 8.86 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.366 -1.079 . . . . 0.0 109.152 179.864 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 12' ' ' THR . 16.9 mt -149.64 124.2 9.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.037 -1.039 . . . . 0.0 110.115 -179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.578 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -138.25 168.78 19.02 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.119 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.606 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.0 mm-40 -80.63 116.03 20.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.096 -1.003 . . . . 0.0 108.671 179.516 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.675 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -96.75 142.51 28.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.12 -0.988 . . . . 0.0 110.065 -179.214 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.605 HD21 ' O ' ' B' ' 27' ' ' GLY . 26.5 tp -104.41 91.54 3.94 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.647 -0.658 . . . . 0.0 109.281 -179.753 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.827 HD23 ' HB ' ' A' ' 85' ' ' ILE . 15.1 mt -44.12 101.98 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -0.895 . . . . 0.0 108.714 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.563 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.5 t0 -111.57 91.4 3.64 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.351 -0.843 . . . . 0.0 110.495 -178.699 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HD13 ' A' ' 90' ' ' LEU . 1.1 m -66.6 -10.61 47.46 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.144 -0.973 . . . . 0.0 108.556 178.643 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.472 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.44 -44.2 51.7 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.468 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -75.85 164.79 25.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.096 -1.237 . . . . 0.0 109.322 -179.844 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -100.55 -15.21 17.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.154 -0.966 . . . . 0.0 111.282 -178.695 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -130.88 -169.96 2.26 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.813 -1.18 . . . . 0.0 109.571 -179.614 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.597 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 50.2 m -109.51 91.35 3.61 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.767 -1.208 . . . . 0.0 110.438 -179.099 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.034 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -72.11 171.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 120.969 -1.082 . . . . 0.0 108.167 179.099 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.123 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.07 121.98 0.79 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.713 -178.857 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.712 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -42.46 166.57 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.146 -0.971 . . . . 0.0 109.535 179.506 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.561 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -51.1 149.71 3.58 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.127 -0.983 . . . . 0.0 110.378 -179.447 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.409 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.2 ptm -164.95 -161.68 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.439 -0.788 . . . . 0.0 109.08 179.592 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.409 ' N ' ' HG3' ' A' ' 36' ' ' MET . 3.8 t -122.73 109.94 14.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.093 -1.005 . . . . 0.0 111.158 -178.949 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.605 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -111.21 167.02 9.67 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.18 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.578 ' HD3' HD12 ' A' ' 38' ' ' LEU . 35.5 Cg_endo -77.08 66.62 7.73 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 122.94 2.427 . . . . 0.0 112.352 -179.149 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.523 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 26.66 105.74 0.0 OUTLIER Glycine 0 N--CA 1.504 3.215 0 CA-C-O 121.674 0.597 . . . . 0.0 112.315 178.534 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.456 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.8 mtp180 167.11 51.19 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.316 -1.108 . . . . 0.0 109.115 178.776 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.608 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.5 p-90 -131.49 -179.49 5.4 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 121.829 0.823 . . . . 0.0 110.302 -179.049 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 57' ' ' ARG . 0.5 OUTLIER -138.41 166.89 22.21 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.7 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.29 140.62 22.22 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.147 1.898 . . . . 0.0 110.796 -179.773 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.91 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -160.17 141.36 12.34 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.48 ' HG2' ' HG2' ' A' ' 55' ' ' LYS . 59.3 mtp -125.97 141.57 51.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.837 -1.164 . . . . 0.0 109.915 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 54' ' ' ILE . 6.9 pt -118.94 141.09 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.268 -0.895 . . . . 0.0 109.171 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.527 ' HA3' ' CE1' ' A' ' 53' ' ' PHE . . . -118.18 103.44 1.04 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.78 -127.47 3.22 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.445 -178.961 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.755 HD12 ' C70' ' B' ' 100' ' ' DMP . 67.5 mt -79.67 116.33 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.703 -0.88 . . . . 0.0 112.251 -178.139 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.563 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 111.98 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.382 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.74 -161.48 34.34 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.305 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CE1' ' HA3' ' A' ' 48' ' ' GLY . 4.3 m-30 -99.95 131.26 46.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.503 -0.998 . . . . 0.0 109.555 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 47' ' ' ILE . 5.1 pt -110.41 172.45 2.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.156 -0.965 . . . . 0.0 108.841 179.103 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -110.04 147.36 33.7 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.875 . . . . 0.0 109.024 179.657 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.91 HG22 ' O ' ' A' ' 45' ' ' LYS . 7.3 m -151.03 -171.53 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 120.739 -1.225 . . . . 0.0 110.424 -179.472 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.587 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 2.0 mtt180 -140.1 108.85 5.95 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.228 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.475 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 12.5 tt0 -65.85 103.38 0.9 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.308 -0.87 . . . . 0.0 111.104 -178.468 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.608 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.8 m-85 -91.58 124.67 35.92 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -109.35 124.2 50.58 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.816 -1.177 . . . . 0.0 110.59 -178.852 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 6.4 mm100 86.29 58.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 CA-C-O 121.229 0.538 . . . . 0.0 110.648 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.791 ' CG2' HG23 ' A' ' 15' ' ' ILE . 26.2 mm -111.88 119.9 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.577 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.896 HD13 ' O ' ' A' ' 63' ' ' LEU . 1.3 tm? -67.48 84.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 111.054 -178.5 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.593 HD13 HD11 ' A' ' 66' ' ' ILE . 3.5 tt -87.86 118.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 178.248 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' CB ' ' A' ' 14' ' ' LYS . 28.0 tt0 -91.42 113.43 25.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.213 -0.929 . . . . 0.0 109.186 -179.189 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.593 HD11 HD13 ' A' ' 64' ' ' ILE . 1.3 mp -106.25 118.29 53.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 -179.667 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 77.8 m 65.38 21.36 11.91 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.744 -0.598 . . . . 0.0 110.935 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.475 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 90.31 1.59 75.01 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.506 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -97.34 121.18 38.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.075 -1.25 . . . . 0.0 108.827 179.548 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -61.82 127.51 31.78 Favored 'General case' 0 C--N 1.295 -1.775 0 O-C-N 121.363 -0.835 . . . . 0.0 109.416 -179.789 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.482 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -148.19 137.55 22.12 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.541 -0.724 . . . . 0.0 109.454 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.536 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -110.29 160.43 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 177.819 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.875 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 175.46 177.51 44.58 Favored Glycine 0 N--CA 1.485 1.901 0 C-N-CA 118.222 -1.942 . . . . 0.0 111.527 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.508 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 75.3 m -82.27 114.74 20.96 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 122.057 -0.672 . . . . 0.0 109.902 -179.715 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.123 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -108.56 109.92 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.395 -0.816 . . . . 0.0 109.951 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.543 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.2 mp -79.21 126.06 30.26 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.114 -0.991 . . . . 0.0 108.729 179.307 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.561 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.6 t -111.43 116.48 52.64 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 109.94 -179.311 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.474 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.25 13.26 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.553 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.2 Cg_endo -82.96 40.16 0.92 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.47 2.113 . . . . 0.0 110.014 179.711 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.712 HG22 ' HA ' ' A' ' 34' ' ' GLU . 10.2 t -81.38 137.36 48.64 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.48 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.9 Cg_endo -77.84 15.8 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.451 2.1 . . . . 0.0 111.829 -178.664 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -161.41 165.97 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.728 -1.233 . . . . 0.0 111.025 -179.64 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.631 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 55.4 m-20 -99.39 142.61 30.65 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 177.046 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.73 ' CG1' HG12 ' A' ' 32' ' ' VAL . 2.9 mm -133.22 113.59 19.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 O-C-N 120.398 -1.439 . . . . 0.0 111.618 -176.953 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.827 ' HB ' HD23 ' A' ' 24' ' ' LEU . 0.9 OUTLIER -92.68 92.95 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 177.326 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -84.03 -156.96 24.75 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 120.048 -1.072 . . . . 0.0 111.685 -177.852 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.512 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 1.8 mtp180 -63.38 -39.13 93.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.91 -0.759 . . . . 0.0 110.84 -178.865 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.002 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.2 p-10 -48.07 -26.57 1.88 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.053 -1.03 . . . . 0.0 110.282 -178.73 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.002 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.8 mm? -112.52 -12.93 13.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.762 -1.211 . . . . 0.0 109.85 -179.796 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.593 HD13 HG23 ' A' ' 26' ' ' THR . 50.1 mt -80.67 -5.75 57.43 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 77.3 p -100.67 -16.91 17.24 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.922 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.8 mm100 -83.37 -40.58 19.22 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.587 -0.696 . . . . 0.0 109.477 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.987 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -87.29 -3.86 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.145 -0.972 . . . . 0.0 109.429 179.607 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 69.09 56.68 8.61 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.606 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HA ' ' HD1' ' B' ' 99' ' ' PHE . . . -81.93 148.86 28.51 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.031 -1.276 . . . . 0.0 110.23 -179.769 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.869 HG22 HG22 ' B' ' 4' ' ' THR . 55.8 p -142.89 124.08 14.56 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.744 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' B' ' 97' ' ' LEU . 4.7 mp -85.07 108.13 17.5 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 15.9 m-20 -107.2 122.15 45.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.742 -1.224 . . . . 0.0 109.259 -179.669 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.632 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.685 0 CA-C-O 117.922 -1.037 . . . . 0.0 109.747 -179.805 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 4.5 Cg_exo . . . . . 0 N--CA 1.495 1.613 0 N-CA-C 110.693 -0.541 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.44 131.92 35.0 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 178.082 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.16 115.41 44.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 120.812 -1.18 . . . . 0.0 109.853 -177.905 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.998 ' O ' HD22 ' B' ' 5' ' ' LEU . 1.0 OUTLIER -119.01 -102.34 0.42 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.919 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.998 HD22 ' O ' ' B' ' 4' ' ' THR . 0.0 OUTLIER 25.91 36.44 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.32 0 CA-C-O 120.752 0.31 . . . . 0.0 110.974 179.823 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.629 ' N ' ' O ' ' B' ' 4' ' ' THR . 19.3 m0 13.77 85.16 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 CA-C-O 121.174 0.511 . . . . 0.0 111.775 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.89 155.18 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.156 -0.965 . . . . 0.0 109.422 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 48.0 mtm180 -50.48 119.61 11.32 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.576 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.822 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.6 Cg_endo -75.23 71.81 5.02 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 122.158 1.905 . . . . 0.0 110.6 179.861 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.518 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -87.87 161.15 17.66 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.267 -0.896 . . . . 0.0 108.953 179.795 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.954 HG23 HG23 ' B' ' 13' ' ' ILE . 18.7 m -150.84 138.11 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.006 -1.059 . . . . 0.0 110.198 -179.355 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.581 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 24.5 m -72.61 96.66 2.01 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.763 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 10.7 pt -90.44 142.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 O-C-N 121.293 -0.88 . . . . 0.0 110.967 -177.332 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.557 ' HE3' ' CD1' ' B' ' 19' ' ' LEU . 0.3 OUTLIER -108.04 98.6 8.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.667 -0.646 . . . . 0.0 109.608 -179.639 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 1.016 HG23 HG21 ' B' ' 62' ' ' ILE . 11.4 mt -120.1 135.32 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 120.981 -1.075 . . . . 0.0 109.859 -179.742 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD13 ' B' ' 38' ' ' LEU . . . 43.11 60.01 3.2 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 179.349 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 17' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 16' ' ' GLY . . . 43.02 41.83 4.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.698 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.519 ' HB2' ' CE ' ' B' ' 36' ' ' MET . 38.0 mm-40 -138.45 116.24 11.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.366 -1.079 . . . . 0.0 109.464 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.2 OUTLIER -90.79 127.71 36.44 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.685 0.755 . . . . 0.0 110.069 179.699 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.597 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mttt -150.74 142.65 23.88 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.63 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.518 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -78.59 111.09 14.3 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.994 -1.066 . . . . 0.0 108.711 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 1.012 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -93.76 132.82 37.77 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.984 0.897 . . . . 0.0 111.062 -178.45 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.488 HD12 HD12 ' B' ' 10' ' ' LEU . 12.1 tp -83.8 102.46 12.34 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.535 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.822 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.2 mt -44.95 120.19 2.26 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.141 -0.974 . . . . 0.0 108.392 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.523 ' HB3' HG22 ' B' ' 84' ' ' ILE . 46.5 t0 -128.39 82.4 2.08 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.906 HG23 HD13 ' B' ' 90' ' ' LEU . 1.4 m -62.9 -15.24 54.39 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.015 -1.053 . . . . 0.0 108.738 179.125 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.605 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.93 -37.89 94.83 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.411 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -77.73 163.53 26.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.292 -1.123 . . . . 0.0 109.463 -179.905 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.457 ' OD1' ' NE ' ' A' ' 8' ' ' ARG . 3.9 m-20 -98.23 -10.12 24.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.528 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 19.5 m-20 -140.25 -165.9 2.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.3 -0.875 . . . . 0.0 108.844 -179.883 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.727 HG23 HD12 ' B' ' 85' ' ' ILE . 17.6 m -118.11 93.17 4.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.692 -1.255 . . . . 0.0 111.02 -178.668 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.053 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.89 174.03 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.152 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.46 117.16 1.32 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.82 -1.175 . . . . 0.0 110.846 -179.086 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.601 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 16.3 tt0 -36.15 155.37 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.492 -0.755 . . . . 0.0 109.94 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.711 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -33.35 146.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.766 0.793 . . . . 0.0 111.41 -179.145 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.538 ' N ' HG11 ' B' ' 77' ' ' VAL . 0.2 OUTLIER -177.64 179.61 0.9 Allowed 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.555 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -122.08 122.84 40.19 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.434 -1.416 . . . . 0.0 111.911 -178.299 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.604 HD12 ' CD ' ' B' ' 39' ' ' PRO . 0.5 OUTLIER -102.58 175.58 2.21 Favored Pre-proline 0 N--CA 1.495 1.785 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 177.899 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.604 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.4 Cg_endo -78.05 68.8 7.72 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.066 1.844 . . . . 0.0 110.953 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.8 -172.12 0.01 OUTLIER Glycine 0 N--CA 1.493 2.478 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 179.202 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 56.84 101.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.418 -1.048 . . . . 0.0 109.921 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 3.8 p-90 -160.7 171.55 18.66 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.609 -0.682 . . . . 0.0 109.625 179.682 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 43' ' ' LYS . . . . . 0.524 ' O ' ' CB ' ' B' ' 58' ' ' GLN . 1.4 mtmt -128.71 115.4 19.34 Favored Pre-proline 0 N--CA 1.489 1.477 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.367 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.62 136.03 18.68 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.807 1.671 . . . . 0.0 110.828 -179.334 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 1.024 ' NZ ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -156.45 178.62 10.11 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.539 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 27.2 mtp -127.56 136.28 51.47 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.841 -1.162 . . . . 0.0 110.61 -178.754 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 54' ' ' ILE . 5.8 pt -100.68 143.6 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.328 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.36 108.92 1.68 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.549 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.89 -125.01 2.55 Favored Glycine 0 N--CA 1.484 1.839 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.522 -179.242 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.865 HD12 H202 ' B' ' 100' ' ' DMP . 50.6 mt -84.3 121.46 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.825 -0.809 . . . . 0.0 112.578 -177.939 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.456 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 98.45 -16.57 59.68 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.019 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 140.58 -155.95 25.03 Favored Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.936 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 1.1 m-85 -116.12 134.9 54.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.543 -0.975 . . . . 0.0 109.485 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 47' ' ' ILE . 6.0 pt -105.53 159.58 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.004 -1.06 . . . . 0.0 109.245 179.436 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.577 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -99.61 131.43 45.61 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.372 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.946 HG23 ' CE ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -138.96 -173.14 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.787 -1.195 . . . . 0.0 109.756 -179.838 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -114.74 165.84 12.38 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.557 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.569 ' NE2' HG22 ' B' ' 74' ' ' THR . 10.0 tp60 -128.98 91.57 3.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.57 -1.331 . . . . 0.0 110.99 -178.923 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 94.1 m-85 -93.88 92.16 7.27 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.223 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.537 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 51.5 m-20 -79.08 134.85 36.73 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.323 -0.86 . . . . 0.0 109.916 -178.841 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.56 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 42.9 mt-30 83.54 63.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.589 0.709 . . . . 0.0 109.291 179.55 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 1.016 HG21 HG23 ' B' ' 15' ' ' ILE . 24.9 mm -119.15 120.48 63.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.951 HD21 ' CG ' ' B' ' 70' ' ' LYS . 16.4 tp -72.86 86.83 1.28 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 118.977 -1.089 . . . . 0.0 110.695 -178.852 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.731 ' CD1' HD11 ' B' ' 66' ' ' ILE . 1.6 tt -85.23 122.24 38.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.647 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.5 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.8 tt0 -89.73 109.61 20.58 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.973 -1.079 . . . . 0.0 109.72 -178.411 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -105.76 122.25 59.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.262 -0.899 . . . . 0.0 109.087 179.91 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 67' ' ' CYS . . . . . 0.475 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 76.2 m 66.71 12.26 8.72 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.997 -0.439 . . . . 0.0 110.294 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.37 0.42 56.89 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 6.7 m-70 -98.82 125.03 44.08 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.191 -1.182 . . . . 0.0 108.904 179.717 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 0.951 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.7 mptm? -70.28 135.11 48.64 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.281 -0.887 . . . . 0.0 108.613 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.612 ' C ' HD12 ' B' ' 63' ' ' LEU . . . -150.27 138.72 20.53 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.383 -0.823 . . . . 0.0 109.077 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.56 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -108.13 142.69 20.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 178.212 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.726 ' HA3' HE22 ' B' ' 92' ' ' GLN . . . -163.54 -165.73 21.2 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.993 -179.694 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.569 HG22 ' NE2' ' B' ' 58' ' ' GLN . 7.0 m -97.81 110.33 22.92 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.745 -0.856 . . . . 0.0 110.06 -179.344 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.065 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -109.65 147.26 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.09 -1.006 . . . . 0.0 109.697 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 1.024 HD23 ' NZ ' ' B' ' 45' ' ' LYS . 5.6 mp -125.27 142.91 51.22 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.058 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' B' ' 35' ' ' GLU . 15.1 t -124.03 124.23 68.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.102 -0.999 . . . . 0.0 110.1 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.723 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -160.31 -158.06 9.02 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.577 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -80.57 40.56 1.0 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.806 2.338 . . . . 0.0 110.966 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.601 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.1 t -86.95 133.81 38.43 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 178.963 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.606 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.5 Cg_endo -77.16 14.16 1.4 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.269 1.979 . . . . 0.0 111.086 -178.939 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.606 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -160.81 151.24 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 120.94 -1.1 . . . . 0.0 110.397 -179.241 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.597 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 21.0 m-20 -80.06 130.74 35.48 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.723 -2.695 . . . . 0.0 103.723 175.077 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.663 HG13 HG12 ' B' ' 32' ' ' VAL . 0.8 OUTLIER -125.88 116.26 45.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 119.781 -1.824 . . . . 0.0 112.93 -176.437 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 1.012 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -89.07 147.28 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.708 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.528 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -136.31 -161.1 9.0 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 118.771 -1.681 . . . . 0.0 110.055 -179.766 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.444 ' O ' ' OG1' ' B' ' 91' ' ' THR . 0.0 OUTLIER -57.59 -37.62 73.51 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.702 -0.881 . . . . 0.0 109.793 -179.725 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 1.049 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -50.67 -29.72 11.84 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.625 -179.29 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 1.049 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.5 mm? -107.13 -24.02 12.08 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.619 -1.301 . . . . 0.0 110.815 -179.082 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.906 HD13 HG23 ' B' ' 26' ' ' THR . 9.2 mt -71.63 -5.68 35.33 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.883 -1.136 . . . . 0.0 108.888 -179.921 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.5 -14.42 18.26 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.925 . . . . 0.0 109.023 179.319 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 92' ' ' GLN . . . . . 0.886 ' NE2' HD22 ' B' ' 89' ' ' LEU . 55.0 mt-30 -85.96 -40.88 15.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -0.867 . . . . 0.0 109.363 -179.816 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.632 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.2 pt -85.99 4.78 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.144 -0.973 . . . . 0.0 108.542 178.75 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.7 42.97 98.49 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.345 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.509 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -69.53 145.46 52.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.901 -1.352 . . . . 0.0 108.882 179.327 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 45.4 p -136.86 128.36 28.51 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.052 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -91.13 96.66 10.71 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 -178.992 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.468 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 3.1 m-20 -109.64 132.92 53.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.47 -0.769 . . . . 0.0 110.045 -179.426 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.987 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.062 179.41 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.865 H202 HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.513 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.168 -0.743 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.479 ' HG3' ' CG ' ' B' ' 98' ' ' ASN . 5.8 tt0 -83.2 127.62 33.78 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 178.069 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.48 HG12 HD22 ' A' ' 5' ' ' LEU . 20.7 t -130.91 102.32 6.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.167 -177.663 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 5.5 p -48.68 -24.34 1.34 Allowed 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 179.213 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.869 HD12 ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER 71.34 35.6 1.5 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.547 -0.721 . . . . 0.0 109.817 179.679 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.433 ' C ' ' HG2' ' A' ' 7' ' ' GLN . 2.1 m95 -55.21 -20.37 10.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.876 -1.14 . . . . 0.0 108.416 179.611 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HG2' ' C ' ' A' ' 6' ' ' TRP . 4.4 mm100 -138.52 -142.49 0.16 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.022 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HG2' ' OD2' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -92.18 141.8 25.5 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 120.778 -1.201 . . . . 0.0 109.339 179.494 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.656 ' HD3' HD11 ' A' ' 5' ' ' LEU . 37.6 Cg_endo -80.16 59.38 7.41 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.502 2.135 . . . . 0.0 110.243 179.532 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 21' ' ' GLU . 6.0 mt -79.47 132.41 36.34 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.969 -1.082 . . . . 0.0 109.053 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 1.01 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -134.63 150.37 30.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 121.327 -0.858 . . . . 0.0 109.326 -179.323 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 12' ' ' THR . . . . . 1.099 HG22 HD22 ' A' ' 19' ' ' LEU . 32.8 m -86.0 95.88 9.65 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.801 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.75 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.1 pt -79.01 155.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.478 -0.764 . . . . 0.0 110.298 -178.818 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -120.06 89.96 3.23 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.8 HD13 HG11 ' A' ' 75' ' ' VAL . 24.9 mt -110.8 130.24 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.102 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.72 44.85 93.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 179.327 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.27 23.7 48.79 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 21.6 mm-40 -117.4 163.53 16.23 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.153 -1.204 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 1.099 HD22 HG22 ' A' ' 12' ' ' THR . 11.6 mt -132.97 127.68 34.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.992 -1.068 . . . . 0.0 110.853 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 1.2 mmmt -146.59 173.7 12.09 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.091 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.792 ' HB3' HD22 ' A' ' 10' ' ' LEU . 4.0 mm-40 -79.26 179.57 7.32 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.809 -1.182 . . . . 0.0 108.801 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -159.35 114.07 2.41 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.766 -1.209 . . . . 0.0 110.608 -179.753 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.041 HD21 ' O ' ' B' ' 27' ' ' GLY . 29.3 tp -87.8 96.73 10.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.684 -0.635 . . . . 0.0 109.357 179.61 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.568 HD23 ' HB ' ' A' ' 85' ' ' ILE . 19.1 mt -43.67 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.698 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.1 t0 -106.11 86.17 2.32 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.402 -0.811 . . . . 0.0 111.165 -177.891 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.473 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 62.1 m -68.53 -14.18 62.83 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.919 -1.113 . . . . 0.0 108.596 178.437 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.41 -22.59 67.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.919 -1.273 . . . . 0.0 109.919 -179.826 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.51 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -86.71 164.77 16.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.029 -1.277 . . . . 0.0 109.807 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.481 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 1.3 m-20 -94.19 -21.07 19.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 110.961 -178.785 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.824 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -141.55 -166.57 2.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.655 -1.278 . . . . 0.0 110.596 -179.524 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 60.5 m -103.25 89.48 3.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.189 -0.944 . . . . 0.0 111.02 -178.336 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -73.84 175.45 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.722 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.0 OUTLIER -171.92 121.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.75 -1.219 . . . . 0.0 110.214 -179.475 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.497 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.1 OUTLIER -39.39 155.61 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.063 -1.023 . . . . 0.0 110.218 179.499 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.548 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.7 OUTLIER -46.4 151.04 0.58 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.383 -0.823 . . . . 0.0 110.265 -179.808 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.407 ' SD ' ' C ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -172.63 174.27 3.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.581 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.407 ' C ' ' SD ' ' A' ' 36' ' ' MET . 34.7 t -89.48 83.65 6.36 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.012 -1.055 . . . . 0.0 109.724 -179.722 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.9 HD21 HD12 ' A' ' 62' ' ' ILE . 6.1 tp -109.78 105.54 57.31 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.239 -0.913 . . . . 0.0 109.715 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.0 Cg_endo -78.47 146.63 21.94 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.573 2.182 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.82 -165.83 26.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.842 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 127.94 49.49 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.26 -1.141 . . . . 0.0 108.595 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 42.6 p-90 -136.0 -173.99 3.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.985 . . . . 0.0 110.293 -179.355 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.25 129.71 7.74 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.173 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -74.96 136.52 20.61 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.907 1.738 . . . . 0.0 111.369 -178.659 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.586 ' HG2' HG23 ' A' ' 56' ' ' VAL . 9.5 ptmm? -153.74 -165.41 2.12 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 178.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.435 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 3.3 ttt -147.6 125.92 12.31 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.66 -1.275 . . . . 0.0 110.232 -179.395 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 54' ' ' ILE . 5.2 pt -98.27 135.92 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.06 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.473 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.35 112.35 2.36 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -179.653 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -129.35 -111.53 1.53 Allowed Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.041 -179.509 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.784 HG21 ' CD1' ' B' ' 47' ' ' ILE . 27.4 mt -97.84 132.53 42.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 O-C-N 121.296 -1.12 . . . . 0.0 111.477 -178.445 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 96.69 -50.48 1.56 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.074 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.49 -158.7 28.22 Favored Glycine 0 N--CA 1.491 2.3 0 O-C-N 121.022 -1.281 . . . . 0.0 110.15 -179.872 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.473 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 32.8 m-85 -107.72 151.36 25.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.611 -0.935 . . . . 0.0 109.954 -179.654 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 47' ' ' ILE . 18.0 pt -136.2 140.61 43.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.508 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 8.8 mttt -80.7 137.12 36.28 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.389 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.586 HG23 ' HG2' ' A' ' 45' ' ' LYS . 27.2 m -128.66 -176.72 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.36 -0.838 . . . . 0.0 109.469 -179.73 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 2.6 mmt85 -125.74 85.35 2.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 108.981 179.72 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.552 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 1.2 tt0 -45.32 89.53 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 121.441 0.639 . . . . 0.0 110.261 -179.633 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.618 ' HB3' HG13 ' A' ' 62' ' ' ILE . 6.3 m-85 -90.58 82.51 5.82 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.981 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -77.57 137.39 38.56 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.235 -178.349 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 77.62 59.99 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.198 0.523 . . . . 0.0 110.399 179.701 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.9 HD12 HD21 ' A' ' 38' ' ' LEU . 0.6 OUTLIER -131.54 126.49 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.633 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.056 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.3 tt -74.68 93.33 2.54 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.187 -0.945 . . . . 0.0 112.839 -176.746 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.687 ' CG2' HD11 ' A' ' 89' ' ' LEU . 1.9 tt -87.33 115.76 28.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 105.966 -1.865 . . . . 0.0 105.966 176.236 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -87.97 116.97 26.51 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.11 -0.994 . . . . 0.0 109.013 -178.057 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 1.5 mp -111.92 125.64 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.243 -0.911 . . . . 0.0 109.95 -179.076 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 7.7 m 51.75 -94.84 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.697 . . . . 0.0 109.75 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -140.51 49.55 0.79 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.823 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -145.2 109.8 5.0 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.322 -1.105 . . . . 0.0 110.158 -179.767 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 1.056 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -63.73 120.05 11.11 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.796 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.643 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -132.7 129.01 38.2 Favored 'General case' 0 C--N 1.291 -1.953 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.755 -178.355 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.815 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.5 OUTLIER -105.69 138.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 177.269 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.458 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -161.97 -157.23 8.79 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.641 -179.472 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.552 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 9.9 m -107.42 104.47 14.06 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.879 -0.777 . . . . 0.0 108.946 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.935 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.28 99.94 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.539 -0.726 . . . . 0.0 109.721 -179.757 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.824 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.7 mp -78.16 106.34 9.99 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.074 -1.016 . . . . 0.0 108.857 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.548 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 50.1 t -95.75 123.9 48.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.424 -0.797 . . . . 0.0 110.358 -179.271 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -155.45 -163.92 12.62 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.36 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.538 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 34.9 Cg_endo -79.75 39.62 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.56 2.173 . . . . 0.0 111.193 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -85.66 135.77 37.79 Favored Pre-proline 0 N--CA 1.491 1.625 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.794 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -78.24 18.79 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.793 2.329 . . . . 0.0 112.21 -178.529 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.589 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.87 163.02 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.575 -1.328 . . . . 0.0 110.476 -179.962 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.587 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 54.6 m-20 -91.46 140.04 30.14 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 105.175 -2.158 . . . . 0.0 105.175 176.549 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.796 ' C ' HD13 ' A' ' 85' ' ' ILE . 18.3 mm -128.64 122.79 58.06 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 O-C-N 120.346 -1.471 . . . . 0.0 111.539 -177.211 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.796 HD13 ' C ' ' A' ' 84' ' ' ILE . 1.4 mm -102.91 96.71 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.184 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.34 -156.41 10.68 Favored Glycine 0 N--CA 1.495 2.62 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.525 -177.416 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.522 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 7.9 mtt180 -72.81 -35.17 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.874 -0.78 . . . . 0.0 109.799 -179.309 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.893 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -54.19 -18.87 4.27 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.005 -1.06 . . . . 0.0 108.857 -178.977 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.893 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -110.37 -22.22 11.81 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.524 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.634 HD23 HD11 ' A' ' 93' ' ' ILE . 64.1 mt -74.67 -17.24 60.71 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.299 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.59 HG22 ' CD2' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -89.84 -10.28 45.97 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.029 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.643 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 72.6 mt-30 -94.52 -41.74 9.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.854 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -84.25 -3.81 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.203 -0.936 . . . . 0.0 108.772 179.116 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 67.67 43.06 86.39 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 178.817 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.527 ' CB ' HD22 ' A' ' 90' ' ' LEU . . . -66.54 153.05 43.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.867 -1.373 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.499 HG22 ' HA ' ' B' ' 4' ' ' THR . 17.7 p -145.09 128.31 16.74 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.327 -0.858 . . . . 0.0 109.094 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -93.16 96.72 10.21 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.44 -0.787 . . . . 0.0 109.441 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.523 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.2 m-20 -101.13 121.22 41.43 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.822 -1.173 . . . . 0.0 109.674 179.654 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.77 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.479 179.541 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.576 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 N-CA-C 110.408 -0.651 . . . . 0.0 110.408 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 2' ' ' GLN . . . . . 0.428 ' CG ' ' OD1' ' A' ' 98' ' ' ASN . 1.9 tt0 -96.37 132.08 42.26 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.456 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 52.7 t -131.82 120.85 45.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.032 -1.042 . . . . 0.0 109.624 -179.049 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.941 ' C ' HD13 ' B' ' 5' ' ' LEU . 0.3 OUTLIER -60.19 -97.26 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.434 -0.791 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.941 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -168.88 -17.87 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.963 -1.086 . . . . 0.0 111.325 179.685 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.591 ' H ' HD22 ' B' ' 5' ' ' LEU . 67.0 m95 -66.19 -11.6 50.7 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.546 -1.346 . . . . 0.0 109.792 -179.799 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -117.56 147.12 43.1 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 110.235 -179.601 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.92 131.21 81.83 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.34 -0.85 . . . . 0.0 109.028 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.802 ' HB2' HD12 ' B' ' 24' ' ' LEU . 38.0 Cg_endo -81.08 45.42 1.99 Allowed 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.135 1.89 . . . . 0.0 109.825 178.732 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -81.1 147.45 30.1 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.156 -0.965 . . . . 0.0 109.279 -179.672 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' B' ' 66' ' ' ILE . 0.9 OUTLIER -150.31 135.48 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.023 -1.048 . . . . 0.0 110.569 -179.184 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.878 ' CG2' HD22 ' B' ' 19' ' ' LEU . 7.5 m -64.03 113.83 3.75 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.207 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.725 HG21 ' HB2' ' B' ' 22' ' ' ALA . 1.4 pp -100.57 135.67 35.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.323 -0.861 . . . . 0.0 110.182 -179.034 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.604 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.8 OUTLIER -108.33 108.54 19.57 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.24 -0.912 . . . . 0.0 108.967 179.5 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.74 HD13 HG11 ' B' ' 75' ' ' VAL . 28.9 mt -110.67 123.52 66.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.163 -0.961 . . . . 0.0 108.876 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.6 -90.46 0.38 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.734 -1.746 . . . . 0.0 108.734 -179.402 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -152.34 27.05 0.88 Allowed Glycine 0 N--CA 1.483 1.813 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 179.396 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.478 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 4.6 mt-30 -125.78 176.31 7.02 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.259 -1.142 . . . . 0.0 109.579 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 ' CG2' ' B' ' 12' ' ' THR . 18.9 mt -136.48 128.09 28.8 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-O 121.621 0.724 . . . . 0.0 110.312 -179.263 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.45 ' HB3' HD21 ' B' ' 83' ' ' ASN . 7.6 mmtt -138.64 155.93 47.88 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.494 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mm-40 -78.81 145.13 34.47 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.631 -1.293 . . . . 0.0 109.615 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.76 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -120.54 148.84 43.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.941 -1.099 . . . . 0.0 110.762 -179.303 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.422 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -118.42 95.56 4.92 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.802 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.2 mt -45.48 107.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.994 -1.066 . . . . 0.0 109.395 -179.659 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 0.639 ' HB3' HG23 ' B' ' 84' ' ' ILE . 22.5 t0 -119.77 90.4 3.32 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.791 -179.692 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.475 HG23 ' CD ' ' B' ' 87' ' ' ARG . 1.2 m -60.36 -14.27 17.75 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.067 -1.021 . . . . 0.0 108.977 179.282 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 1.041 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -61.67 -44.46 97.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 28' ' ' ALA . . . . . 0.515 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -80.78 148.43 30.06 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -1.17 . . . . 0.0 109.654 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.49 ' OD2' ' HG2' ' A' ' 8' ' ' ARG . 37.6 m-20 -89.12 -8.79 53.1 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.281 -0.887 . . . . 0.0 110.04 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.741 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -133.39 -171.01 2.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.025 -1.047 . . . . 0.0 109.329 -179.923 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.592 HG23 ' O ' ' B' ' 84' ' ' ILE . 43.5 m -111.97 93.25 4.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.778 -1.201 . . . . 0.0 110.974 -178.844 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.017 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.92 172.83 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.299 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 HG13 ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.84 124.3 1.29 Allowed 'General case' 0 C--N 1.305 -1.347 0 O-C-N 120.59 -1.319 . . . . 0.0 111.92 -178.838 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' B' ' 33' ' ' LEU . 0.2 OUTLIER -35.87 154.72 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 178.053 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -53.86 130.33 36.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.113 -0.992 . . . . 0.0 110.335 -179.428 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -141.33 -178.39 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.85 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.2 t -105.15 103.45 12.99 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.639 -1.288 . . . . 0.0 110.532 -178.921 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.709 HD12 HG21 ' B' ' 77' ' ' VAL . 51.6 mt -106.88 156.58 37.05 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 108.975 179.253 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' B' ' 40' ' ' GLY . 36.4 Cg_endo -79.35 77.99 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.695 2.263 . . . . 0.0 111.475 -179.097 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 40' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 37.37 -158.41 0.01 OUTLIER Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.212 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 41' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 22.5 mmm180 63.65 74.84 0.41 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.597 -0.943 . . . . 0.0 109.169 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.519 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 67.8 p-90 -159.13 175.9 12.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.746 . . . . 0.0 109.761 -179.294 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.54 138.71 31.81 Favored Pre-proline 0 N--CA 1.492 1.669 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.035 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.28 127.97 9.44 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.021 1.814 . . . . 0.0 111.286 -178.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.798 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -162.9 136.48 5.96 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.852 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.475 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 32.4 mtp -102.09 137.26 40.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.844 -1.16 . . . . 0.0 109.098 -179.91 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.784 ' CD1' HG21 ' A' ' 50' ' ' ILE . 19.0 pt -89.59 145.46 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.373 179.237 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 48' ' ' GLY . . . . . 0.491 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -118.23 100.92 0.87 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.748 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 49' ' ' GLY . . . . . 0.426 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -120.29 -126.85 3.43 Favored Glycine 0 N--CA 1.483 1.775 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.054 -178.611 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.931 HD12 ' C20' ' B' ' 100' ' ' DMP . 38.5 mt -83.28 118.7 31.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 O-C-N 121.863 -0.787 . . . . 0.0 112.741 -177.292 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 51' ' ' GLY . . . . . 0.55 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 100.62 -51.91 0.97 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 178.134 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.497 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . -174.6 -171.61 38.95 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.265 -1.445 . . . . 0.0 110.108 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.568 ' N ' ' CD1' ' B' ' 53' ' ' PHE . 1.2 m-30 -106.06 128.83 54.13 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.335 -1.097 . . . . 0.0 109.349 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.554 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.0 pt -100.84 161.39 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.129 -0.982 . . . . 0.0 109.276 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 13.6 mttt -89.6 134.46 34.12 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.131 -0.981 . . . . 0.0 109.208 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.798 HG22 ' O ' ' B' ' 45' ' ' LYS . 17.0 m -142.05 172.99 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.966 -1.084 . . . . 0.0 109.588 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 6.9 mtm180 -124.75 101.32 7.04 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.547 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 34.3 tt0 -58.4 96.36 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 110.032 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.564 ' HB3' HG13 ' B' ' 62' ' ' ILE . 13.3 m-85 -89.57 94.34 9.83 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.006 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -78.87 141.76 37.4 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.108 -0.995 . . . . 0.0 110.307 -178.846 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.65 ' HA ' HG23 ' B' ' 72' ' ' ILE . 15.2 mt-30 69.38 64.02 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.334 0.588 . . . . 0.0 110.765 179.479 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 0.812 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.9 OUTLIER -119.84 125.01 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 108.847 178.727 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 1.148 HD21 ' CG ' ' B' ' 70' ' ' LYS . 2.8 tm? -74.4 86.45 2.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.309 -0.87 . . . . 0.0 110.903 -178.942 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.616 HG23 ' O ' ' B' ' 64' ' ' ILE . 3.4 tt -90.81 116.93 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.007 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.7 tt0 -90.07 116.56 28.19 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.811 -1.181 . . . . 0.0 109.72 -179.404 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.628 ' CG1' HG21 ' B' ' 11' ' ' VAL . 0.5 OUTLIER -105.11 116.93 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.157 -0.964 . . . . 0.0 109.675 -179.898 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 51.85 16.55 0.52 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.782 -0.574 . . . . 0.0 111.603 178.454 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 106.99 18.65 10.3 Favored Glycine 0 N--CA 1.495 2.604 0 C-N-CA 119.277 -1.439 . . . . 0.0 110.679 179.016 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -116.08 98.85 6.86 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.084 -1.245 . . . . 0.0 108.898 179.459 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 70' ' ' LYS . . . . . 1.148 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.6 ttpm? -54.36 120.06 6.05 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.901 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.65 130.86 22.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 110.693 -178.827 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.812 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.8 OUTLIER -94.19 147.1 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.581 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.813 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -171.09 175.83 44.62 Favored Glycine 0 N--CA 1.489 2.209 0 C-N-CA 118.557 -1.782 . . . . 0.0 111.538 -179.601 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.547 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 8.6 m -87.97 102.41 14.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.927 -0.749 . . . . 0.0 110.465 -179.616 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.065 HG13 HD13 ' B' ' 33' ' ' LEU . 1.5 t -94.12 108.64 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.368 -0.832 . . . . 0.0 110.01 179.189 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.741 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.0 mp -79.83 111.03 15.75 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.84 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 77' ' ' VAL . . . . . 0.709 HG21 HD12 ' B' ' 38' ' ' LEU . 11.2 t -93.68 116.51 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.117 -0.99 . . . . 0.0 110.122 -179.014 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -151.53 -172.83 20.76 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.477 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.6 Cg_endo -80.42 42.99 1.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.525 2.15 . . . . 0.0 110.839 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.722 HG21 HG13 ' B' ' 32' ' ' VAL . 0.9 OUTLIER -83.01 143.62 46.16 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.035 -1.041 . . . . 0.0 108.496 179.198 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.54 14.8 1.54 Allowed 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.275 1.983 . . . . 0.0 110.874 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.459 HG13 ' N ' ' B' ' 83' ' ' ASN . 1.2 t -160.91 165.08 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.902 -1.124 . . . . 0.0 109.816 -179.527 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.61 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 1.1 m-20 -103.2 119.01 38.08 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 104.675 -2.343 . . . . 0.0 104.675 176.272 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 0.639 HG23 ' HB3' ' B' ' 25' ' ' ASP . 14.6 mm -102.17 126.41 56.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 O-C-N 120.762 -1.211 . . . . 0.0 111.9 -175.981 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.76 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -103.89 88.33 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 177.304 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.59 -158.3 11.84 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 120.145 -1.026 . . . . 0.0 111.228 -177.568 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.869 ' HG3' HD12 ' A' ' 5' ' ' LEU . 7.3 mmm180 -69.01 -37.81 78.9 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.666 -0.902 . . . . 0.0 110.672 -178.748 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.977 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.7 p-10 -43.45 -25.18 0.13 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.647 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.977 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.3 mm? -111.5 -29.79 7.63 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.07 -1.019 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.711 HD21 HD22 ' B' ' 24' ' ' LEU . 33.6 mt -67.33 -8.32 31.49 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.243 -0.91 . . . . 0.0 108.965 179.319 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 91' ' ' THR . . . . . 0.599 HG23 HH21 ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.6 -20.28 15.74 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.162 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -81.4 -40.2 23.8 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.77 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -81.28 -2.66 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 108.839 178.89 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 81.95 24.23 55.75 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 178.996 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.706 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -60.58 137.62 58.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.842 -1.387 . . . . 0.0 109.994 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 96' ' ' THR . 44.5 p -132.65 122.1 24.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.645 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -89.51 94.37 9.85 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 121.324 0.583 . . . . 0.0 109.503 -178.683 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.495 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.4 m-20 -109.43 130.94 55.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.279 -0.888 . . . . 0.0 110.53 -179.312 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.854 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.096 178.464 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.931 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.514 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.495 1.604 0 N-CA-C 109.767 -0.897 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -83.32 134.84 34.9 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 177.686 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.566 HG11 ' HB3' ' A' ' 9' ' ' PRO . 6.6 t -126.84 101.82 8.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.585 -1.246 . . . . 0.0 110.501 -178.092 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.695 HG22 HG22 ' B' ' 96' ' ' THR . 1.7 p -115.18 -81.52 0.61 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.342 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.54 ' O ' ' C ' ' A' ' 6' ' ' TRP . 92.0 mt 33.71 32.91 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.923 -0.486 . . . . 0.0 110.441 178.866 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 7.2 m0 18.33 50.74 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.499 0.666 . . . . 0.0 111.651 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.6 OUTLIER -143.6 -163.83 1.74 Allowed 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.549 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.436 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -84.86 136.64 38.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 108.869 179.703 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.566 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.4 Cg_endo -78.97 67.63 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.316 2.011 . . . . 0.0 109.776 179.099 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.434 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -86.91 143.04 27.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.19 -0.944 . . . . 0.0 109.592 -179.619 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.606 HG21 HG23 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -139.51 160.66 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.829 . . . . 0.0 109.412 -179.745 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.841 HG22 HD22 ' A' ' 19' ' ' LEU . 34.5 m -95.33 109.96 22.03 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.237 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.882 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.7 pt -97.8 159.1 3.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 110.401 -178.312 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.52 ' HE3' HD11 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -119.3 99.1 6.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.485 -0.759 . . . . 0.0 109.095 179.53 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.935 HD13 HG11 ' A' ' 75' ' ' VAL . 17.0 mt -114.64 130.55 68.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.165 -0.959 . . . . 0.0 109.534 -179.653 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.63 50.56 62.35 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.807 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.67 26.18 16.16 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.946 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.5 mt-30 -120.37 173.66 7.0 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -1.158 . . . . 0.0 109.041 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.2 mt -140.46 126.94 20.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.128 -0.983 . . . . 0.0 110.352 -179.678 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.656 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -144.13 175.04 10.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.516 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 83' ' ' ASN . 1.9 mm-40 -79.44 178.15 8.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.845 -1.16 . . . . 0.0 108.721 179.67 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.691 ' HB1' HG12 ' A' ' 85' ' ' ILE . . . -158.38 117.97 3.19 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.875 -1.14 . . . . 0.0 110.035 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 25' ' ' ASP . 59.0 tp -90.56 95.47 10.18 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.431 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.643 ' CD1' ' CZ ' ' B' ' 99' ' ' PHE . 10.9 mt -46.16 97.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 -179.682 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.566 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 18.9 t0 -103.49 91.67 4.15 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.533 -0.729 . . . . 0.0 110.647 -177.851 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.877 HG23 HD12 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -67.77 -6.74 22.62 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.886 -1.134 . . . . 0.0 108.977 178.767 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.49 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -80.11 -39.49 16.04 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.446 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.89 160.71 31.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.824 -1.398 . . . . 0.0 109.52 -179.505 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -99.85 -16.46 18.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.932 . . . . 0.0 109.062 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.4 OUTLIER -132.29 -161.19 1.11 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.44 -0.787 . . . . 0.0 109.152 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.748 HG22 ' CD1' ' A' ' 33' ' ' LEU . 21.5 m -121.04 89.8 3.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.559 -1.338 . . . . 0.0 110.675 -178.526 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.03 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.953 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 1.03 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -161.17 129.44 4.4 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.965 -1.084 . . . . 0.0 110.679 -178.707 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.466 ' C ' ' O ' ' A' ' 33' ' ' LEU . 7.0 tt0 -40.8 156.85 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.111 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.794 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.3 OUTLIER -52.89 153.09 3.52 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.06 -1.025 . . . . 0.0 110.364 -179.155 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 4.1 ptm -177.47 -163.76 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.407 -0.808 . . . . 0.0 109.019 179.71 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -107.52 142.17 37.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.697 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.779 HD21 HG22 ' A' ' 15' ' ' ILE . 9.3 mt -150.33 167.22 13.43 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.531 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.2 Cg_endo -76.78 138.43 18.86 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.299 1.999 . . . . 0.0 109.342 179.33 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.59 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -48.0 -169.33 0.01 OUTLIER Glycine 0 N--CA 1.492 2.42 0 CA-C-O 121.854 0.696 . . . . 0.0 111.438 -178.669 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.59 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.2 OUTLIER 81.91 46.92 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 -178.965 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.679 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 57.8 p-90 -137.24 -172.02 3.1 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.405 0.621 . . . . 0.0 109.798 -179.196 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.19 138.65 11.97 Favored Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 121.41 -0.806 . . . . 0.0 109.204 179.226 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.32 139.48 18.68 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.117 1.878 . . . . 0.0 110.028 179.455 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 0.2 OUTLIER -160.59 -159.46 0.69 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.432 -0.793 . . . . 0.0 108.951 -179.775 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.509 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 69.4 mtp -148.93 130.5 14.91 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.119 -0.988 . . . . 0.0 109.41 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.828 HD11 HG21 ' B' ' 50' ' ' ILE . 14.6 pt -88.95 144.68 8.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.14 97.91 0.76 Allowed Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.228 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.458 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -121.68 -126.43 3.26 Favored Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.325 -179.151 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.902 HG21 HD12 ' B' ' 47' ' ' ILE . 21.8 mt -87.43 112.17 22.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.809 -0.818 . . . . 0.0 112.639 -177.787 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.544 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 116.77 -48.52 0.93 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 178.054 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.76 -154.57 21.22 Favored Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.023 -179.618 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.1 m-85 -114.14 116.4 29.04 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.562 -0.964 . . . . 0.0 110.009 -179.454 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.0 pt -89.85 175.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.149 -0.969 . . . . 0.0 109.084 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.542 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -104.13 142.5 34.38 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 108.853 179.423 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.76 HG21 HD23 ' A' ' 76' ' ' LEU . 15.1 m -150.93 175.25 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.943 -1.098 . . . . 0.0 110.293 -179.54 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.53 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -126.61 98.23 5.32 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.646 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.541 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 0.7 OUTLIER -58.1 102.58 0.11 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.219 -0.925 . . . . 0.0 110.971 -179.016 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.679 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 23.0 m-85 -98.89 94.35 6.53 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.114 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.6 OUTLIER -79.02 139.41 38.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.465 -178.538 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 73.96 62.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.674 -0.641 . . . . 0.0 110.064 179.499 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.603 HG21 HG23 ' A' ' 15' ' ' ILE . 10.5 mm -119.69 114.46 44.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.145 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.905 HD13 ' O ' ' A' ' 63' ' ' LEU . 2.3 tm? -63.61 87.02 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.362 -0.836 . . . . 0.0 110.944 -178.586 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 66' ' ' ILE . 5.6 tt -89.59 115.23 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 178.078 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.458 ' OE2' ' N ' ' A' ' 69' ' ' HIS . 1.1 tm-20 -88.35 123.51 33.0 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.106 -0.996 . . . . 0.0 109.181 -178.773 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.67 HD11 ' CD1' ' A' ' 64' ' ' ILE . 2.3 mt -126.13 122.42 61.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 110.188 -179.049 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 56.15 46.68 21.02 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.662 -0.649 . . . . 0.0 111.174 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.77 22.62 68.42 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 120.163 -1.018 . . . . 0.0 110.928 178.406 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.458 ' N ' ' OE2' ' A' ' 65' ' ' GLU . 5.9 m-70 -123.41 130.79 53.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.993 -1.298 . . . . 0.0 109.186 179.24 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.618 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -72.48 129.18 37.72 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 108.908 179.713 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.56 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -146.55 109.57 4.68 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.54 -0.725 . . . . 0.0 109.677 -179.324 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.588 HG12 HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -90.43 156.88 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.764 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.788 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.53 -171.31 41.68 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 118.435 -1.84 . . . . 0.0 111.597 179.819 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 7.7 m -96.79 104.92 16.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.737 -0.861 . . . . 0.0 109.542 -179.669 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 1.023 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -100.33 113.4 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.294 -0.879 . . . . 0.0 110.567 -179.573 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.76 HD23 HG21 ' A' ' 56' ' ' VAL . 5.3 mp -82.78 125.3 31.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.847 . . . . 0.0 108.841 178.938 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.794 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.1 t -103.92 110.45 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.0 -1.062 . . . . 0.0 109.423 -179.959 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.524 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.61 -171.47 15.21 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.949 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.542 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 42.42 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.454 2.103 . . . . 0.0 110.41 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.601 HG21 HG13 ' A' ' 32' ' ' VAL . 6.5 t -81.47 141.89 49.5 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.542 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -79.74 16.95 1.35 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.408 2.072 . . . . 0.0 111.339 -179.629 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.542 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -161.05 165.87 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.917 -1.114 . . . . 0.0 109.894 -179.571 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.656 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -103.79 96.72 6.89 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 105.11 -2.181 . . . . 0.0 105.11 176.761 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.613 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.4 mm -83.15 115.42 25.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 O-C-N 121.082 -1.011 . . . . 0.0 113.1 -175.756 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.837 ' N ' HD13 ' A' ' 85' ' ' ILE . 0.5 OUTLIER -95.0 91.99 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 175.612 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.32 -157.38 8.6 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.884 -1.15 . . . . 0.0 110.783 -177.047 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -69.56 -37.14 76.88 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.884 -0.774 . . . . 0.0 110.37 -178.804 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -46.58 -28.86 1.57 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.762 -1.211 . . . . 0.0 109.634 -179.757 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -110.96 -30.96 7.3 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.994 -1.067 . . . . 0.0 111.466 -178.361 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.877 HD12 HG23 ' A' ' 26' ' ' THR . 0.6 OUTLIER -59.57 -31.46 69.46 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.769 -1.207 . . . . 0.0 108.642 -179.869 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -78.85 -20.7 48.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.898 . . . . 0.0 110.123 -179.89 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 -69.77 -40.66 75.93 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.88 -1.138 . . . . 0.0 108.262 179.319 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.943 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -83.67 -7.17 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.864 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.52 62.92 3.25 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.805 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -83.21 148.88 27.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.315 -1.109 . . . . 0.0 109.674 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.579 HG22 ' CG2' ' B' ' 4' ' ' THR . 5.0 p -137.46 129.74 29.45 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.142 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.679 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -96.58 88.65 4.73 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.263 -0.898 . . . . 0.0 109.422 -179.745 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 10.6 m-20 -93.6 121.59 35.18 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.116 -0.99 . . . . 0.0 109.126 179.827 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.636 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.402 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 1' ' ' PRO . . . . . 0.605 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.619 0 N-CA-C 110.641 -0.561 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.01 136.9 32.77 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 177.85 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.2 t -133.93 105.89 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 120.574 -1.329 . . . . 0.0 110.57 -178.558 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.579 ' CG2' HG22 ' A' ' 96' ' ' THR . 15.8 p -122.03 -70.13 0.8 Allowed 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.063 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER 31.24 37.79 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.81 -0.556 . . . . 0.0 110.743 179.146 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 5.5 m95 18.8 50.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.186 0 CA-C-O 121.504 0.669 . . . . 0.0 111.924 -179.756 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.537 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.4 OUTLIER -154.55 165.4 36.6 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.155 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.5 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 71.2 mtm180 -49.0 133.15 15.0 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.012 -179.827 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 9' ' ' PRO . . . . . 0.494 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.6 Cg_endo -80.09 64.83 8.91 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.312 2.008 . . . . 0.0 109.514 179.028 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 10' ' ' LEU . . . . . 0.699 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -79.89 148.24 31.38 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.33 -0.856 . . . . 0.0 109.521 -179.663 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.756 HG21 HG23 ' B' ' 66' ' ' ILE . 1.4 m -140.29 132.28 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.307 -0.871 . . . . 0.0 109.592 179.872 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 12' ' ' THR . . . . . 0.66 HG22 HD22 ' B' ' 19' ' ' LEU . 11.8 m -64.09 99.77 0.28 Allowed 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.498 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.635 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.0 OUTLIER -90.41 147.89 4.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.255 -0.903 . . . . 0.0 110.615 -178.178 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 14' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 2.8 tttt -107.93 107.94 18.87 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 1.046 HD13 HG11 ' B' ' 75' ' ' VAL . 14.8 mt -122.88 119.04 56.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.205 -0.934 . . . . 0.0 109.604 -179.273 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 16' ' ' GLY . . . . . 0.402 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.59 20.99 74.4 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.38 -7.74 79.66 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.545 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 18' ' ' GLN . . . . . 0.479 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 29.8 mt-30 -87.19 -175.25 5.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -1.107 . . . . 0.0 109.52 -179.961 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 19' ' ' LEU . . . . . 0.66 HD22 HG22 ' B' ' 12' ' ' THR . 40.9 mt -152.19 119.95 6.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.919 -179.861 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' B' ' 19' ' ' LEU . 2.5 mmmt -134.82 161.61 34.73 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.699 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.1 OUTLIER -79.09 122.82 26.71 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.526 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 22' ' ' ALA . . . . . 0.759 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -108.63 119.4 39.43 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.921 -1.112 . . . . 0.0 111.145 -178.578 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 23' ' ' LEU . . . . . 0.5 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 24.9 tp -75.43 99.59 4.21 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.633 179.561 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 24' ' ' LEU . . . . . 0.698 ' CD2' HD21 ' B' ' 90' ' ' LEU . 4.6 mt -48.68 96.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 25' ' ' ASP . . . . . 1.05 ' CB ' HG23 ' B' ' 84' ' ' ILE . 8.7 t0 -96.88 95.6 7.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 110.068 -179.379 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 26' ' ' THR . . . . . 0.684 HG21 HD13 ' B' ' 97' ' ' LEU . 9.8 m -74.27 -4.29 35.25 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.157 -0.964 . . . . 0.0 108.467 178.455 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 27' ' ' GLY . . . . . 0.478 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -85.81 -26.25 35.54 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.85 162.32 16.22 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.869 -1.371 . . . . 0.0 109.999 -179.304 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 29' ' ' ASP . . . . . 0.501 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.2 m-20 -100.62 -13.9 18.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -0.799 . . . . 0.0 110.719 -179.132 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.511 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.82 -172.22 2.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.912 -1.117 . . . . 0.0 109.506 -179.706 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 31' ' ' THR . . . . . 0.55 HG22 ' CD1' ' B' ' 33' ' ' LEU . 20.6 m -111.04 87.28 2.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.519 -1.363 . . . . 0.0 110.702 -178.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 32' ' ' VAL . . . . . 1.041 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -73.43 170.6 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 178.179 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 1.041 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.51 122.12 1.99 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.533 -1.354 . . . . 0.0 110.609 -178.576 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.696 ' HA ' HG22 ' B' ' 80' ' ' THR . 88.5 tt0 -40.26 152.92 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.371 -0.831 . . . . 0.0 109.311 179.102 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.8 tt0 -46.09 147.77 0.98 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 110.602 -179.313 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.8 ptt? -168.01 156.81 9.26 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.6 t -79.26 85.63 5.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 109.788 -179.339 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 1.075 HD21 HD12 ' B' ' 62' ' ' ILE . 62.7 tp -103.14 115.13 64.51 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.273 -0.892 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 39' ' ' PRO . . . . . 0.737 ' HD2' HD12 ' B' ' 38' ' ' LEU . 34.1 Cg_endo -77.05 125.28 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.44 2.094 . . . . 0.0 110.534 -179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.96 154.49 6.18 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.98 153.02 38.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -1.182 . . . . 0.0 109.287 -179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 42' ' ' TRP . . . . . 0.492 ' CE3' ' HB3' ' B' ' 57' ' ' ARG . 58.0 p-90 -156.58 172.45 18.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.141 -0.975 . . . . 0.0 109.394 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.66 137.39 30.26 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.028 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.35 137.74 15.2 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.112 1.874 . . . . 0.0 111.093 -179.613 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 45' ' ' LYS . . . . . 0.563 ' HG2' HG23 ' B' ' 56' ' ' VAL . 3.8 ptmt -159.98 -172.9 3.81 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.161 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 46' ' ' MET . . . . . 0.415 ' HA ' ' O ' ' B' ' 54' ' ' ILE . 28.1 mtp -141.58 137.61 32.05 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.662 -1.274 . . . . 0.0 109.842 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 47' ' ' ILE . . . . . 0.902 HD12 HG21 ' A' ' 50' ' ' ILE . 1.4 pt -96.06 152.74 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.475 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.48 116.33 3.37 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.778 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -149.13 -124.66 1.35 Allowed Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.25 -179.681 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 50' ' ' ILE . . . . . 0.882 HD12 ' C20' ' B' ' 100' ' ' DMP . 20.4 mt -86.59 123.93 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.527 -0.984 . . . . 0.0 112.375 -178.181 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.78 -7.93 70.72 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 120.27 -0.967 . . . . 0.0 111.148 177.717 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 125.91 -159.22 20.32 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 53' ' ' PHE . . . . . 0.538 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -112.96 142.03 46.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.314 -1.11 . . . . 0.0 109.843 -179.585 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.831 HD11 HD11 ' B' ' 47' ' ' ILE . 6.5 pt -107.17 -178.3 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.258 -0.901 . . . . 0.0 109.368 179.554 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 55' ' ' LYS . . . . . 0.576 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -106.34 148.21 28.3 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.421 -0.799 . . . . 0.0 108.894 179.475 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 56' ' ' VAL . . . . . 0.563 HG23 ' HG2' ' B' ' 45' ' ' LYS . 29.3 m -151.22 -179.1 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.687 -1.258 . . . . 0.0 110.408 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 57' ' ' ARG . . . . . 0.492 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.6 mtt-85 -130.47 86.41 2.38 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.237 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 58' ' ' GLN . . . . . 0.5 ' HB2' ' HD2' ' B' ' 45' ' ' LYS . 24.5 tt0 -47.41 105.63 0.07 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.588 -0.695 . . . . 0.0 111.301 -178.469 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 59' ' ' TYR . . . . . 0.715 ' CD2' HD23 ' B' ' 38' ' ' LEU . 5.1 m-85 -99.03 90.3 4.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 60' ' ' ASP . . . . . 0.438 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 2.8 m-20 -79.0 136.32 37.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.872 -1.143 . . . . 0.0 111.502 -177.753 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 13.9 mt-30 68.21 62.5 0.38 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-O 121.179 0.514 . . . . 0.0 110.632 178.542 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 62' ' ' ILE . . . . . 1.075 HD12 HD21 ' B' ' 38' ' ' LEU . 0.1 OUTLIER -122.51 122.39 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.205 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 1.01 HD13 ' O ' ' B' ' 63' ' ' LEU . 1.3 tm? -60.51 87.4 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.759 0.79 . . . . 0.0 111.896 -177.741 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 64' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' B' ' 71' ' ' ALA . 2.6 tt -95.81 111.53 26.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 176.561 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.4 tt0 -90.25 124.64 35.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.76 -1.212 . . . . 0.0 109.152 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 66' ' ' ILE . . . . . 0.756 HG23 HG21 ' B' ' 11' ' ' VAL . 1.0 OUTLIER -106.53 128.23 61.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.156 -0.965 . . . . 0.0 109.269 -179.728 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 58.86 -90.1 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.683 -0.636 . . . . 0.0 109.682 179.583 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.92 40.95 0.99 Allowed Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 69' ' ' HIS . . . . . 0.509 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 86.6 m-70 -137.64 114.14 10.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -1.132 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.47 120.86 8.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.351 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 71' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' B' ' 64' ' ' ILE . . . -132.87 151.63 52.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.405 -0.809 . . . . 0.0 109.429 179.897 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 72' ' ' ILE . . . . . 0.857 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -125.22 156.5 34.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 177.527 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 73' ' ' GLY . . . . . 0.601 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.27 -165.15 34.86 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 117.906 -2.093 . . . . 0.0 111.492 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.501 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.5 m -99.41 103.61 15.41 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.906 -0.761 . . . . 0.0 110.017 -179.476 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 75' ' ' VAL . . . . . 1.046 HG11 HD13 ' B' ' 15' ' ' ILE . 1.3 t -94.73 102.19 13.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.471 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.49 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.8 mp -79.12 112.74 16.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.033 -1.042 . . . . 0.0 108.981 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 52.9 t -97.89 117.72 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.102 -0.999 . . . . 0.0 109.814 -179.521 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.89 -164.28 11.67 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 179.739 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 79' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -82.76 38.04 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.202 1.935 . . . . 0.0 110.404 179.814 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 80' ' ' THR . . . . . 0.696 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.6 t -79.85 134.32 57.08 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 178.785 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 81' ' ' PRO . . . . . 0.547 ' O ' HG23 ' B' ' 82' ' ' VAL . 32.1 Cg_endo -77.5 17.04 0.97 Allowed 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.393 2.062 . . . . 0.0 111.701 -178.556 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.651 HG12 ' CD1' ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.23 151.4 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.755 -1.216 . . . . 0.0 109.972 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.611 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 84.8 m-20 -89.57 127.08 35.84 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.23 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 84' ' ' ILE . . . . . 1.05 HG23 ' CB ' ' B' ' 25' ' ' ASP . 3.9 mt -127.89 121.79 57.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 119.903 -1.748 . . . . 0.0 112.655 -176.538 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.759 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -89.43 111.1 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.384 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -92.15 -159.15 35.06 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.57 -178.821 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 87' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.0 mtp180 -68.63 -29.47 67.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.685 -0.891 . . . . 0.0 109.984 -179.524 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 88' ' ' ASN . . . . . 0.989 ' ND2' HD23 ' B' ' 89' ' ' LEU . 16.1 p-10 -53.62 -26.92 24.11 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.062 -1.024 . . . . 0.0 109.601 -179.588 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.989 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.9 mm? -108.87 -30.48 8.11 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.066 -1.021 . . . . 0.0 109.847 -179.494 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.698 HD21 ' CD2' ' B' ' 24' ' ' LEU . 85.0 mt -61.29 -30.31 70.4 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.247 -0.908 . . . . 0.0 108.849 179.863 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.1 p -78.47 -22.0 48.21 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.292 -0.88 . . . . 0.0 108.796 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -72.16 -40.73 67.79 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.326 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 93' ' ' ILE . . . . . 0.636 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -87.89 -8.12 10.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.349 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.09 61.41 6.11 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.255 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 95' ' ' ALA . . . . . 0.549 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -88.53 158.55 18.27 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -1.152 . . . . 0.0 110.341 -179.664 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 96' ' ' THR . . . . . 0.695 HG22 HG22 ' A' ' 4' ' ' THR . 43.7 p -135.29 127.6 30.23 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.596 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 97' ' ' LEU . . . . . 0.684 HD13 HG21 ' B' ' 26' ' ' THR . 0.2 OUTLIER -91.4 95.69 10.12 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.302 -0.874 . . . . 0.0 109.902 -178.786 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' B' B ' 98' ' ' ASN . . . . . 0.465 ' HA ' ' O ' ' A' ' 1' ' ' PRO . 1.6 m-20 -106.83 131.36 54.02 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.868 . . . . 0.0 109.941 -179.882 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 99' ' ' PHE . . . . . 0.943 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.284 179.476 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 100' ' ' DMP . . . . . 0.882 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.615 0 CA-C-O 121.355 0.481 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.55 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 20.7 tt0 -86.19 118.5 25.69 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 177.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -115.15 105.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 120.806 -1.184 . . . . 0.0 110.405 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.818 HG22 HG22 ' B' ' 96' ' ' THR . 1.3 p -123.34 30.0 6.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.615 -0.678 . . . . 0.0 109.709 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.548 ' O ' ' C ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -89.56 39.33 0.94 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.13 -0.981 . . . . 0.0 109.295 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.548 ' C ' ' O ' ' A' ' 5' ' ' LEU . 46.2 m0 16.28 59.36 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 CA-C-O 121.613 0.72 . . . . 0.0 111.918 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -145.14 174.22 11.25 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.395 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -65.97 118.32 51.0 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.98 -1.075 . . . . 0.0 108.915 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.974 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 71.66 6.16 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.214 1.942 . . . . 0.0 109.545 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -92.93 157.07 16.53 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.442 -0.786 . . . . 0.0 109.523 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.535 HG21 HG13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -150.77 136.53 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.183 -0.948 . . . . 0.0 110.158 -179.599 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.84 HG22 HD22 ' A' ' 19' ' ' LEU . 55.0 m -68.32 108.9 3.39 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.919 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.2 pp -98.66 152.46 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 120.957 -1.09 . . . . 0.0 111.012 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.51 ' HE3' HD11 ' A' ' 19' ' ' LEU . 10.9 tttt -113.23 104.61 12.51 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' A' ' 75' ' ' VAL . 5.1 mt -120.84 129.81 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.079 -1.013 . . . . 0.0 109.894 -179.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.58 35.57 81.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.34 73.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -121.47 -176.76 3.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.342 -1.093 . . . . 0.0 108.653 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.919 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.4 mt -151.4 124.05 8.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.938 -1.101 . . . . 0.0 110.892 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.543 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -141.97 165.99 25.94 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 178.495 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.5 mp0 -79.25 131.62 36.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.9 -1.125 . . . . 0.0 108.747 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.655 ' HB2' ' CG2' ' A' ' 13' ' ' ILE . . . -108.09 137.87 45.33 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.067 -1.021 . . . . 0.0 110.641 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.615 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.1 tp -104.77 98.7 8.4 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.974 HD12 ' HB2' ' A' ' 9' ' ' PRO . 43.2 mt -44.95 95.17 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.064 -1.022 . . . . 0.0 108.685 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 1.4 t70 -97.05 79.8 2.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.164 -0.96 . . . . 0.0 110.732 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.407 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 27.6 m -63.11 -13.71 39.8 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.991 -1.068 . . . . 0.0 108.762 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.445 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.8 -41.39 49.85 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.04 168.95 19.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.202 -1.176 . . . . 0.0 109.67 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.71 -17.59 16.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.185 -0.947 . . . . 0.0 111.272 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.831 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -135.7 -176.71 4.38 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.427 -179.366 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 16.7 m -98.86 87.97 3.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.359 -0.838 . . . . 0.0 110.68 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.95 168.14 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 178.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.23 135.22 5.14 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.975 -1.078 . . . . 0.0 110.518 -178.235 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 80' ' ' THR . 2.0 mt-10 -45.16 170.68 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.375 -0.828 . . . . 0.0 108.834 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -60.59 152.68 25.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.041 -1.037 . . . . 0.0 109.888 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.633 ' HE2' HG22 ' A' ' 15' ' ' ILE . 8.1 ptm -177.8 -158.92 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.909 ' O ' HD22 ' A' ' 38' ' ' LEU . 6.6 t -110.67 127.21 55.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.258 -0.901 . . . . 0.0 110.351 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.909 HD22 ' O ' ' A' ' 37' ' ' SER . 3.8 mm? -131.88 170.01 12.4 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 36.3 Cg_endo -80.99 123.96 4.79 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.791 2.327 . . . . 0.0 112.514 -178.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.552 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -44.49 117.72 2.18 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.552 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 150.04 44.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 35.4 p-90 -118.81 -173.84 2.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.961 0.886 . . . . 0.0 110.709 -177.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.08 136.92 11.12 Favored Pre-proline 0 C--N 1.303 -1.451 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.05 136.89 20.88 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.846 1.698 . . . . 0.0 110.986 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.709 ' HD2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -146.8 157.52 43.69 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.547 ' CG ' ' HG2' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -119.41 125.47 49.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.836 -1.165 . . . . 0.0 110.188 -178.889 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 54' ' ' ILE . 5.7 pt -104.86 136.23 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 108.746 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.595 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.36 102.59 0.97 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.51 -127.16 3.56 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.627 -178.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.648 HG21 HD12 ' B' ' 47' ' ' ILE . 57.0 mt -80.19 122.13 34.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.9 -0.765 . . . . 0.0 112.925 -177.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.431 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 100.0 -50.87 1.08 Allowed Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.049 177.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -177.5 -160.53 24.36 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.582 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.595 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.8 m-85 -113.47 133.37 55.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.567 -0.96 . . . . 0.0 109.926 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 47' ' ' ILE . 10.6 pt -113.51 168.09 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.141 -0.974 . . . . 0.0 108.918 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.7 mtpt -113.46 132.4 55.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.201 -0.937 . . . . 0.0 109.252 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.642 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.6 m -127.79 -174.59 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.969 -1.082 . . . . 0.0 110.217 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.522 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 1.7 mtt85 -127.37 92.08 3.44 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.4 tt0 -54.58 94.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.544 -0.723 . . . . 0.0 110.484 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.881 ' HB3' HD11 ' A' ' 62' ' ' ILE . 26.6 m-85 -89.51 133.7 34.46 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 177.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.5 OUTLIER -111.35 139.86 46.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.938 -1.101 . . . . 0.0 111.528 -177.664 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 69.48 63.48 0.27 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.727 -0.608 . . . . 0.0 110.44 178.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.881 HD11 ' HB3' ' A' ' 59' ' ' TYR . 3.6 mp -116.71 122.78 70.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.1 tm? -64.77 82.91 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.642 0.734 . . . . 0.0 110.48 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.928 HD12 HD11 ' A' ' 15' ' ' ILE . 2.9 tt -90.76 117.83 34.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.55 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -90.4 137.23 32.52 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.09 -1.006 . . . . 0.0 108.587 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.579 HG13 HG22 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -124.37 112.61 33.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 120.902 -1.124 . . . . 0.0 108.901 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 62.37 23.08 13.65 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.713 -0.617 . . . . 0.0 109.833 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 93.93 9.22 59.85 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.547 ' N ' ' CD2' ' A' ' 69' ' ' HIS . 2.5 m170 -100.54 105.41 16.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.097 -1.237 . . . . 0.0 109.218 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.567 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 tttt -53.77 125.07 17.12 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.134 -0.979 . . . . 0.0 109.303 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.601 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -147.18 145.99 29.7 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.566 -0.709 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.785 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.7 OUTLIER -115.43 155.31 16.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 105.93 -1.878 . . . . 0.0 105.93 177.438 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.596 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.67 -173.38 43.97 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 118.14 -1.981 . . . . 0.0 111.367 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.545 HG23 ' OD1' ' A' ' 60' ' ' ASP . 0.2 OUTLIER -93.51 107.43 19.28 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.776 -0.838 . . . . 0.0 109.555 -179.763 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' A' ' 15' ' ' ILE . 1.5 t -102.72 111.58 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.341 -0.849 . . . . 0.0 110.45 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.831 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.3 mp -81.79 122.9 28.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.439 -0.788 . . . . 0.0 109.211 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.564 HG21 HD23 ' A' ' 38' ' ' LEU . 71.9 t -103.96 118.84 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.093 -1.005 . . . . 0.0 109.769 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.642 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.03 -165.6 14.76 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.1 Cg_endo -80.31 43.26 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 122.72 2.28 . . . . 0.0 110.795 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.645 HG21 HG13 ' A' ' 32' ' ' VAL . 9.2 t -89.05 139.02 28.83 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -79.6 17.96 1.18 Allowed 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.568 2.178 . . . . 0.0 111.81 -179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG12 ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.74 166.98 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.543 -1.348 . . . . 0.0 110.659 -179.811 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.556 ' OD1' ' CD2' ' A' ' 33' ' ' LEU . 7.5 m-80 -96.87 93.53 6.71 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 176.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.816 ' CG1' HG12 ' A' ' 32' ' ' VAL . 26.7 mm -78.42 127.25 38.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 O-C-N 120.727 -1.233 . . . . 0.0 112.154 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.627 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -107.43 89.96 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 177.232 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.14 -165.0 28.81 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 120.276 -0.964 . . . . 0.0 111.217 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 9.5 mtm180 -64.42 -31.05 72.1 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.793 -0.828 . . . . 0.0 109.92 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.2 p-10 -48.61 -26.04 2.04 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.145 -0.972 . . . . 0.0 109.422 -179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -106.75 -21.15 13.13 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.01 -1.056 . . . . 0.0 108.837 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.556 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 43.4 mt -72.61 -4.09 28.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 177.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.637 ' CG2' HD23 ' B' ' 5' ' ' LEU . 0.0 OUTLIER -100.57 -18.43 16.61 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 178.294 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.475 ' HA ' ' OE1' ' A' ' 92' ' ' GLN . 50.6 mm-40 -83.06 -40.9 19.27 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.874 HD12 ' CG ' ' B' ' 99' ' ' PHE . 1.4 pt -89.0 5.27 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.418 -0.801 . . . . 0.0 109.397 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 58.98 47.66 89.62 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.476 ' O ' HD12 ' B' ' 5' ' ' LEU . . . -70.69 155.1 41.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.137 -1.214 . . . . 0.0 110.76 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 24.1 p -146.74 126.09 13.12 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' B' ' 97' ' ' LEU . 4.0 mp -93.46 86.04 5.12 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.483 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 5.3 m120 -91.38 124.4 35.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.289 -0.882 . . . . 0.0 109.652 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.045 -0.978 . . . . 0.0 109.196 179.355 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.584 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.718 0 N-CA-C 110.572 -0.588 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.439 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 0.3 OUTLIER -99.66 117.44 34.02 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.533 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' B' ' 9' ' ' PRO . 9.1 t -108.04 114.69 47.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 108.605 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.935 ' C ' HD13 ' B' ' 5' ' ' LEU . 19.8 p -67.79 -105.19 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.274 -0.891 . . . . 0.0 109.073 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.935 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -171.88 -11.64 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.828 -1.17 . . . . 0.0 111.434 179.824 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.661 ' N ' HD22 ' B' ' 5' ' ' LEU . 72.2 m95 -66.61 -10.53 46.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.69 -1.256 . . . . 0.0 109.49 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.96 178.59 7.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 109.615 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.509 ' HG2' ' NH1' ' A' ' 87' ' ' ARG . 13.8 mtt180 -92.18 138.56 24.35 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.316 -0.865 . . . . 0.0 109.157 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.758 ' HB3' HG11 ' B' ' 3' ' ' VAL . 36.6 Cg_endo -79.49 59.93 7.6 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.246 1.964 . . . . 0.0 110.147 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.684 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -86.43 145.72 26.73 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.945 -1.097 . . . . 0.0 109.102 -179.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.599 HG21 HG23 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -145.15 136.01 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.651 -179.137 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.743 HG22 HD22 ' B' ' 19' ' ' LEU . 86.5 m -68.26 90.5 0.35 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.701 HG22 HG13 ' B' ' 66' ' ' ILE . 47.8 pt -79.09 153.7 4.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.451 -0.781 . . . . 0.0 110.02 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.81 ' HG3' HD21 ' B' ' 19' ' ' LEU . 3.2 tttt -115.14 100.56 8.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.413 -0.804 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.724 HG23 HG21 ' B' ' 62' ' ' ILE . 11.1 mt -122.81 131.19 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.55 48.65 85.0 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.55 20.96 6.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -112.98 171.44 7.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.155 -1.203 . . . . 0.0 109.714 -179.805 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.81 HD21 ' HG3' ' B' ' 14' ' ' LYS . 55.5 mt -143.47 127.67 17.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.378 -0.826 . . . . 0.0 109.524 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -147.95 165.99 29.06 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 108.912 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.684 ' HB3' HD22 ' B' ' 10' ' ' LEU . 2.5 mm-40 -78.55 127.37 32.04 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.055 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.664 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.57 159.07 16.05 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.886 -1.134 . . . . 0.0 109.808 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.461 HD11 HH22 ' A' ' 87' ' ' ARG . 19.2 tp -122.53 93.76 4.08 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.485 -0.76 . . . . 0.0 109.109 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.565 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.7 mt -46.41 110.66 0.29 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.994 -1.066 . . . . 0.0 108.243 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.611 ' HB3' HG22 ' B' ' 84' ' ' ILE . 56.3 t0 -122.07 91.65 3.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.19 -0.944 . . . . 0.0 110.403 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.69 HG23 HD13 ' B' ' 90' ' ' LEU . 1.3 m -65.0 -10.3 28.49 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.9 -1.125 . . . . 0.0 108.78 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.615 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -68.74 -46.94 58.85 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.41 164.92 26.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.154 -1.204 . . . . 0.0 109.496 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -101.14 -15.44 17.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.027 -1.046 . . . . 0.0 110.969 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.613 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -132.08 -163.37 1.33 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.778 -1.201 . . . . 0.0 110.024 -179.3 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.673 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 67.0 m -113.39 91.34 3.61 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.052 -1.03 . . . . 0.0 110.012 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -77.56 156.17 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.371 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.004 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -152.78 124.36 7.76 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.595 -1.316 . . . . 0.0 110.162 -178.894 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.527 ' HA ' HG22 ' B' ' 80' ' ' THR . 47.5 tt0 -36.56 153.3 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.548 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.5 tt0 -53.63 152.49 5.11 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -0.981 . . . . 0.0 109.93 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.3 ptm -177.26 -174.12 0.48 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.486 -0.759 . . . . 0.0 109.406 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -91.52 105.73 17.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 109.648 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' B' ' 39' ' ' PRO . 32.2 tp -134.96 105.07 10.5 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.718 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.7 Cg_endo -78.24 138.7 16.19 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.451 2.101 . . . . 0.0 110.147 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.95 179.45 22.17 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.12 139.72 35.47 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.276 -1.132 . . . . 0.0 109.13 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.578 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 38.7 p-90 -150.36 153.38 35.92 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.138 -0.976 . . . . 0.0 109.958 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.77 131.16 24.25 Favored Pre-proline 0 N--CA 1.489 1.478 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.12 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.72 135.79 16.37 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.982 1.788 . . . . 0.0 110.708 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.573 ' HG3' HG22 ' B' ' 56' ' ' VAL . 1.1 ptmm? -158.04 -168.35 2.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.543 -0.723 . . . . 0.0 109.059 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.513 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 1.0 OUTLIER -145.36 121.1 10.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.097 -1.002 . . . . 0.0 110.015 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.648 HD12 HG21 ' A' ' 50' ' ' ILE . 2.4 pt -92.26 141.18 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.25 -0.906 . . . . 0.0 108.618 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.56 108.65 1.53 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.47 -119.09 2.21 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.499 -1.334 . . . . 0.0 110.244 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.686 HG21 HD12 ' A' ' 47' ' ' ILE . 25.8 mt -87.75 130.87 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.441 -1.035 . . . . 0.0 111.781 -178.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.485 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 91.3 -45.0 2.79 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.549 -1.021 . . . . 0.0 110.549 178.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.431 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.36 -159.36 29.38 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.444 -1.36 . . . . 0.0 110.167 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.535 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -121.62 139.34 53.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.505 -0.997 . . . . 0.0 109.16 -179.715 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' B' ' 46' ' ' MET . 32.4 pt -114.31 -176.16 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.257 -0.902 . . . . 0.0 109.655 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.526 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -107.28 150.03 27.12 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.321 -0.862 . . . . 0.0 108.955 179.406 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.599 HG21 HD23 ' B' ' 76' ' ' LEU . 3.2 m -143.72 -174.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 120.788 -1.195 . . . . 0.0 110.655 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' B' ' 77' ' ' VAL . 3.6 mtm-85 -142.41 88.47 2.08 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.522 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 2.2 tt0 -48.02 95.05 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.314 -0.866 . . . . 0.0 110.296 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.578 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.2 m-85 -92.43 92.82 8.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 4.6 m-20 -79.88 130.72 35.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.97 -1.081 . . . . 0.0 111.025 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.516 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 2.9 mt-30 84.95 59.27 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 CA-C-O 121.165 0.507 . . . . 0.0 110.968 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.724 HG21 HG23 ' B' ' 15' ' ' ILE . 13.2 mm -118.41 124.9 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -1.0 . . . . 0.0 108.579 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.675 HD21 ' HG3' ' B' ' 70' ' ' LYS . 1.9 tm? -72.16 99.99 2.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.174 -0.954 . . . . 0.0 110.998 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.97 HD13 HD11 ' B' ' 66' ' ' ILE . 1.3 tt -104.7 117.62 50.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.48 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 31.7 tt0 -90.77 108.56 19.9 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.091 -1.006 . . . . 0.0 109.118 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.97 HD11 HD13 ' B' ' 64' ' ' ILE . 1.1 mp -99.03 116.89 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.957 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 10.1 m 64.26 17.28 10.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.821 -0.55 . . . . 0.0 110.649 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 96.94 4.11 58.92 Favored Glycine 0 N--CA 1.492 2.423 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.15 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -104.68 116.33 31.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.049 -1.265 . . . . 0.0 109.418 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.675 ' HG3' HD21 ' B' ' 63' ' ' LEU . 14.7 tttt -52.81 137.86 30.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.45 -0.782 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.677 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -160.13 100.88 1.4 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.18 -0.95 . . . . 0.0 109.619 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.606 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.31 156.56 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.642 -1.286 . . . . 0.0 108.32 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.746 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -177.75 176.27 47.95 Favored Glycine 0 N--CA 1.488 2.149 0 C-N-CA 118.999 -1.572 . . . . 0.0 111.167 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.522 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 10.6 m -88.51 109.85 20.39 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.63 -0.924 . . . . 0.0 110.376 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.867 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -99.84 110.89 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.274 -0.891 . . . . 0.0 110.534 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.613 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -79.52 104.27 10.01 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' B' ' 35' ' ' GLU . 26.3 t -88.77 125.5 41.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 120.777 -1.202 . . . . 0.0 110.017 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -153.01 -169.32 18.05 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.526 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -81.44 41.86 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.557 2.171 . . . . 0.0 110.793 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.616 HG21 HG13 ' B' ' 32' ' ' VAL . 14.6 t -84.73 140.15 37.88 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 36.6 Cg_endo -79.38 14.0 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.376 2.051 . . . . 0.0 111.175 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.673 HG12 HD11 ' B' ' 84' ' ' ILE . 0.5 OUTLIER -160.85 176.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.825 -1.172 . . . . 0.0 110.591 -179.47 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.665 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -107.98 147.78 30.61 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 176.721 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.673 ' O ' ' HA ' ' B' ' 31' ' ' THR . 4.6 mm -135.3 100.1 2.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 O-C-N 120.902 -1.124 . . . . 0.0 110.963 -177.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.664 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -79.2 88.86 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -81.23 -160.42 24.84 Favored Glycine 0 N--CA 1.494 2.555 0 O-C-N 121.363 -0.836 . . . . 0.0 112.103 -177.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.414 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.8 mtm180 -58.91 -41.0 86.22 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 122.148 -0.619 . . . . 0.0 111.386 -178.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.862 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.9 p-10 -52.23 -18.89 1.71 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.979 -1.076 . . . . 0.0 109.956 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.862 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.4 mm? -114.75 -23.92 8.96 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 120.928 -1.107 . . . . 0.0 108.933 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.69 HD13 HG23 ' B' ' 26' ' ' THR . 25.9 mt -71.84 -6.79 44.21 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 59.9 p -101.19 -17.79 16.46 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.299 -0.876 . . . . 0.0 108.753 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -83.7 -41.49 17.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.415 -0.803 . . . . 0.0 109.502 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -84.7 -4.64 8.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.165 -0.959 . . . . 0.0 108.713 179.282 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.97 58.67 7.2 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.03 157.81 25.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.112 -1.228 . . . . 0.0 110.347 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.818 HG22 HG22 ' A' ' 4' ' ' THR . 9.4 p -139.6 126.07 20.34 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -95.88 89.38 5.23 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.104 -179.156 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.55 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 0.6 OUTLIER -101.55 132.7 47.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -0.83 . . . . 0.0 110.568 -178.966 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.874 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 117.946 -1.026 . . . . 0.0 108.751 178.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.439 ' HD2' ' C ' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.318 -0.686 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.554 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -84.26 131.92 34.69 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -131.53 118.78 40.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 120.998 -1.064 . . . . 0.0 110.209 -178.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.609 ' CG2' HG22 ' B' ' 96' ' ' THR . 2.2 p -127.71 -90.91 0.51 Allowed 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.56 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 41.63 29.17 0.1 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.48 -0.762 . . . . 0.0 109.432 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.56 ' C ' ' O ' ' A' ' 5' ' ' LEU . 37.3 m0 18.07 51.84 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 CA-C-O 121.638 0.732 . . . . 0.0 111.326 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.546 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.9 mt-30 -142.3 -166.66 2.3 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.9 mtm180 -74.25 116.4 52.35 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HB2' HD12 ' A' ' 24' ' ' LEU . 33.5 Cg_endo -76.53 73.84 5.0 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.269 1.979 . . . . 0.0 109.763 179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -81.53 158.56 24.42 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.32 -0.862 . . . . 0.0 110.301 -179.113 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 24' ' ' LEU . 4.0 m -149.85 130.54 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.408 -0.808 . . . . 0.0 109.588 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.785 HG22 HD22 ' A' ' 19' ' ' LEU . 2.0 m -68.49 106.09 2.43 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.728 HD11 HD21 ' A' ' 33' ' ' LEU . 6.8 pt -92.24 155.06 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.21 -0.931 . . . . 0.0 110.285 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.8 OUTLIER -119.02 105.83 11.82 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.059 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.586 ' CD1' HG11 ' A' ' 75' ' ' VAL . 8.1 mt -123.99 127.08 73.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 120.987 -1.071 . . . . 0.0 109.819 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.73 35.55 91.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.63 9.88 52.71 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -104.64 -179.4 3.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.374 -1.074 . . . . 0.0 109.297 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.785 HD22 HG22 ' A' ' 12' ' ' THR . 3.6 mt -145.9 131.25 18.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 110.269 -179.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.479 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -145.51 157.02 44.06 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.272 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.519 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 19.7 mp0 -78.98 133.63 36.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.842 -1.161 . . . . 0.0 107.93 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -113.68 144.07 43.55 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.994 -1.066 . . . . 0.0 111.07 -178.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 58.8 tp -98.71 92.67 5.7 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.766 HD12 ' HB2' ' A' ' 9' ' ' PRO . 74.0 mt -43.94 96.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 51.4 t0 -110.74 92.8 4.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.458 -0.776 . . . . 0.0 110.461 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 6.0 m -67.31 -10.66 53.07 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 108.758 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 1.055 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -74.19 -43.18 33.35 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.42 149.37 50.13 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.9 -1.353 . . . . 0.0 109.202 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -84.45 -19.94 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 110.133 -179.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' HB3' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -136.57 -162.25 1.26 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.067 -1.02 . . . . 0.0 109.499 -179.503 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 HD12 ' A' ' 85' ' ' ILE . 20.4 m -115.77 100.41 8.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.473 -1.392 . . . . 0.0 111.235 -178.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -78.0 178.15 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.695 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.037 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.15 116.35 0.62 Allowed 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.935 -1.103 . . . . 0.0 110.213 -179.241 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.756 ' HA ' HG22 ' A' ' 80' ' ' THR . 41.2 tt0 -39.35 162.02 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.29 -0.881 . . . . 0.0 109.966 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -41.34 156.85 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.218 -0.926 . . . . 0.0 110.738 -179.562 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.626 ' HG2' HG11 ' A' ' 77' ' ' VAL . 11.2 ptm -179.02 -176.94 0.45 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.548 -0.72 . . . . 0.0 109.149 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.8 t -104.52 118.69 37.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.417 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.631 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 9.9 mt -132.92 170.65 10.85 Favored Pre-proline 0 N--CA 1.493 1.694 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.631 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -69.53 -163.06 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.287 0 C-N-CA 122.079 1.853 . . . . 0.0 111.671 -179.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -105.39 35.09 5.3 Favored Glycine 0 N--CA 1.494 2.502 0 C-N-CA 119.968 -1.111 . . . . 0.0 111.169 -178.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.5 mtt85 -109.56 50.44 0.79 Allowed 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.7 p-90 -133.43 176.79 8.22 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.867 0.841 . . . . 0.0 110.542 -178.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.26 151.74 34.53 Favored Pre-proline 0 C--N 1.302 -1.486 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.01 130.37 11.24 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.759 1.639 . . . . 0.0 110.655 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.761 ' O ' HG22 ' A' ' 56' ' ' VAL . 3.6 ptmt -161.42 129.14 4.17 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.533 ' CG ' ' HG3' ' A' ' 55' ' ' LYS . 15.4 mtp -89.58 135.01 33.85 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.941 -1.1 . . . . 0.0 109.417 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 7.0 pt -89.4 145.91 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.244 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 98.36 0.76 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.104 -1.599 . . . . 0.0 109.104 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.98 -124.1 2.99 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.46 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.977 HG21 HD12 ' B' ' 47' ' ' ILE . 9.9 mt -88.87 119.15 35.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.636 -0.92 . . . . 0.0 112.693 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 106.54 -51.3 0.75 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 177.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.28 -155.52 16.13 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.6 m-85 -118.41 128.66 54.83 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.456 -1.026 . . . . 0.0 109.995 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' MET . 10.1 pt -101.77 169.69 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 16.1 mttt -99.62 134.57 42.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.019 -1.051 . . . . 0.0 108.958 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 45' ' ' LYS . 34.7 m -140.51 -177.61 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.957 -1.089 . . . . 0.0 110.255 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -128.97 91.65 3.25 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.451 ' OE1' ' CG2' ' A' ' 74' ' ' THR . 2.4 tp-100 -55.06 105.08 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.62 -0.675 . . . . 0.0 110.71 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.669 ' C ' HD11 ' A' ' 62' ' ' ILE . 11.4 m-85 -96.45 129.04 43.9 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.508 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 40.0 m-20 -111.17 133.41 53.55 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.738 -1.226 . . . . 0.0 109.771 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.575 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 7.8 mm100 78.29 61.91 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.648 -0.657 . . . . 0.0 109.994 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.704 HD12 ' N ' ' A' ' 62' ' ' ILE . 4.4 mp -119.45 126.55 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.349 -0.844 . . . . 0.0 108.749 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.865 ' O ' HD13 ' A' ' 63' ' ' LEU . 3.1 tm? -77.87 94.47 4.55 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.149 0.976 . . . . 0.0 111.613 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.878 HG12 HD12 ' A' ' 66' ' ' ILE . 3.2 tt -98.02 119.79 46.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.407 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -91.11 125.3 35.85 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.827 -1.17 . . . . 0.0 108.804 -179.876 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.878 HD12 HG12 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -121.61 135.37 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.103 -0.998 . . . . 0.0 109.748 -179.314 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 66' ' ' ILE . 59.5 m 36.93 38.23 0.08 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.088 0.47 . . . . 0.0 110.578 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.34 47.64 8.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.707 ' CB ' HG22 ' A' ' 93' ' ' ILE . 73.6 m-70 -141.18 123.28 15.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.346 -1.091 . . . . 0.0 109.353 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.44 ' CG ' HD21 ' A' ' 63' ' ' LEU . 6.9 tttt -77.76 122.09 24.92 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.223 -0.923 . . . . 0.0 108.558 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.68 ' HB1' HE21 ' A' ' 92' ' ' GLN . . . -144.43 124.27 13.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.033 -1.042 . . . . 0.0 110.818 -178.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.575 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -102.65 120.15 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.232 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.522 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -144.15 -165.43 10.94 Favored Glycine 0 C--N 1.289 -2.06 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.872 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.487 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 38.0 m -97.43 114.72 26.6 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.503 -0.998 . . . . 0.0 110.305 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.037 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -106.43 118.89 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 C-N-CA 120.216 -0.593 . . . . 0.0 110.159 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.557 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.4 mp -89.44 126.24 35.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.103 -0.998 . . . . 0.0 109.177 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.626 HG11 ' HG2' ' A' ' 36' ' ' MET . 1.7 t -108.5 120.58 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.6 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.08 -169.32 20.8 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.536 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -80.8 39.86 0.91 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.605 2.203 . . . . 0.0 110.886 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.756 HG22 ' HA ' ' A' ' 34' ' ' GLU . 15.1 t -82.39 139.96 44.95 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 82' ' ' VAL . 34.5 Cg_endo -78.16 14.57 1.52 Allowed 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.222 1.948 . . . . 0.0 111.084 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.533 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.23 165.0 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 120.96 -1.088 . . . . 0.0 109.778 -179.408 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.616 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.75 145.92 28.47 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 175.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.681 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.3 mm -129.92 129.99 66.14 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 O-C-N 120.047 -1.658 . . . . 0.0 111.743 -177.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.608 HD12 HG23 ' A' ' 31' ' ' THR . 0.8 OUTLIER -104.95 96.39 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.834 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -82.29 -169.34 43.38 Favored Glycine 0 N--CA 1.492 2.376 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.481 -178.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HE ' HG23 ' A' ' 26' ' ' THR . 0.1 OUTLIER -62.43 -30.43 71.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.581 -0.953 . . . . 0.0 109.789 -179.81 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.6 p-10 -50.51 -28.64 8.83 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.986 -1.071 . . . . 0.0 109.782 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.0 mm? -110.11 -27.87 8.95 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.011 -1.056 . . . . 0.0 110.652 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.537 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 33.9 mt -65.49 -13.57 59.14 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.739 -1.226 . . . . 0.0 109.322 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.4 p -96.69 -21.3 17.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.046 -1.034 . . . . 0.0 109.254 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.68 HE21 ' HB1' ' A' ' 71' ' ' ALA . 2.0 mt-30 -74.92 -40.26 60.96 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.176 -0.953 . . . . 0.0 108.521 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.889 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -79.59 1.11 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 178.603 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.66 59.48 8.14 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -87.86 156.43 19.39 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.301 -1.117 . . . . 0.0 109.914 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.767 HG22 ' CG2' ' B' ' 4' ' ' THR . 2.2 p -138.86 129.27 25.78 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -95.52 90.38 5.73 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.5 m120 -89.52 125.77 35.33 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.213 -0.929 . . . . 0.0 109.939 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.711 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.952 -1.023 . . . . 0.0 109.022 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.5 Cg_endo . . . . . 0 N--CA 1.497 1.708 0 N-CA-C 110.14 -0.754 . . . . 0.0 110.14 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.483 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 2.9 tt0 -84.56 114.67 22.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.78 115.07 46.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.956 -1.09 . . . . 0.0 111.104 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.767 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.46 32.51 1.48 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.322 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.526 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.7 mt -85.55 49.05 1.68 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.598 -0.689 . . . . 0.0 109.925 -179.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.526 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.8 m95 17.84 52.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.229 0.537 . . . . 0.0 112.174 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.9 mt-30 -154.95 171.5 19.61 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.221 -0.924 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.405 ' HA ' ' HD3' ' B' ' 9' ' ' PRO . 4.7 mtt180 -63.87 144.19 98.06 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 120.99 -1.069 . . . . 0.0 109.492 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.447 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -80.15 54.9 5.42 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.645 2.23 . . . . 0.0 110.904 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.954 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.1 mt -80.62 135.23 36.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.988 -1.07 . . . . 0.0 108.89 179.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.464 HG22 HG23 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -134.88 141.82 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.181 -0.95 . . . . 0.0 109.604 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.826 HG22 HD22 ' B' ' 19' ' ' LEU . 10.1 m -70.17 100.53 1.68 Allowed 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 178.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.789 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -95.12 143.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.404 -0.81 . . . . 0.0 110.055 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.6 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.0 OUTLIER -98.95 107.78 20.3 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 178.905 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.68 HG12 HD12 ' B' ' 13' ' ' ILE . 10.2 mm -113.83 115.45 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 120.756 -1.215 . . . . 0.0 110.865 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.491 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.15 9.21 56.79 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.44 -10.05 42.23 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.429 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 1.5 mp0 -89.86 -173.29 3.84 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.264 -1.139 . . . . 0.0 109.063 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.826 HD22 HG22 ' B' ' 12' ' ' THR . 18.0 mt -149.13 121.86 8.66 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.889 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.488 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 4.9 mmtt -141.83 172.55 12.53 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.954 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.9 OUTLIER -79.65 155.3 28.13 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.227 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.58 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -135.76 113.02 10.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 1.055 HD21 ' O ' ' A' ' 27' ' ' GLY . 3.3 tp -84.15 104.01 13.85 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.447 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 16.3 mt -52.45 103.9 0.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.91 ' HB3' HG23 ' B' ' 84' ' ' ILE . 19.9 t0 -101.16 77.96 1.86 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.37 -0.831 . . . . 0.0 110.174 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.782 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.02 -14.46 9.58 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.079 -1.013 . . . . 0.0 108.962 178.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -70.8 -35.46 66.14 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -83.3 170.86 14.16 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.938 -1.33 . . . . 0.0 110.234 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -100.54 -18.8 16.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.291 -0.881 . . . . 0.0 110.796 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.609 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -132.92 -170.54 2.47 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.599 -1.313 . . . . 0.0 110.625 -179.059 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.679 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.1 m -106.07 91.83 3.89 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.938 -1.102 . . . . 0.0 110.558 -178.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.953 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -81.01 154.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.717 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.953 HD12 ' O ' ' B' ' 32' ' ' VAL . 1.3 mp -148.91 133.62 17.85 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.919 -1.113 . . . . 0.0 110.667 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.559 ' N ' HG22 ' B' ' 80' ' ' THR . 3.9 mt-10 -43.5 166.69 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.468 -0.77 . . . . 0.0 109.284 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.0 OUTLIER -67.9 115.1 7.04 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.407 -0.808 . . . . 0.0 109.25 179.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.586 ' CE ' ' CG2' ' B' ' 15' ' ' ILE . 6.7 ptm -139.46 -166.8 2.13 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.4 t -95.34 115.35 27.31 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.262 -0.899 . . . . 0.0 109.93 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.565 HD12 ' HD2' ' B' ' 39' ' ' PRO . 26.5 tp -144.42 105.0 4.67 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.565 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.5 Cg_endo -76.41 146.0 27.35 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.398 2.065 . . . . 0.0 110.848 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 136.96 145.24 4.94 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -63.95 117.94 7.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.98 -1.306 . . . . 0.0 108.501 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . . . . . . . . . 48.9 p-90 -110.95 175.89 5.24 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 110.31 -178.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.0 mmtt -126.03 137.03 29.34 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -76.56 129.14 10.75 Favored 'Trans proline' 0 C--N 1.303 -1.838 0 C-N-CA 121.799 1.666 . . . . 0.0 110.812 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.859 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -161.62 137.66 7.95 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.062 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.495 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 25.3 mtp -102.0 137.88 39.7 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.832 -1.168 . . . . 0.0 109.332 -179.225 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.977 HD12 HG21 ' A' ' 50' ' ' ILE . 2.1 pt -89.72 164.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.628 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -138.23 108.22 0.61 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.61 -116.89 1.4 Allowed Glycine 0 N--CA 1.484 1.881 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.357 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.843 HG21 ' CD1' ' A' ' 47' ' ' ILE . 14.3 mt -85.79 122.79 38.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.6 -0.941 . . . . 0.0 112.019 -178.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 99.02 -52.8 1.08 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.437 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.45 -153.91 18.87 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.628 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.4 m-85 -113.54 135.81 53.49 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.494 -1.003 . . . . 0.0 109.941 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.645 HD11 HD11 ' B' ' 47' ' ' ILE . 1.8 pt -104.31 179.49 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.564 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -108.45 130.12 55.25 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 109.164 179.574 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.859 HG22 ' O ' ' B' ' 45' ' ' LYS . 3.7 m -134.0 169.61 21.38 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.947 -1.096 . . . . 0.0 110.175 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.459 ' HD3' ' HB ' ' B' ' 77' ' ' VAL . 8.9 mtp180 -120.26 87.78 2.81 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.517 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 3.0 tt0 -48.42 99.28 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.525 -0.734 . . . . 0.0 110.561 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.8 ' O ' HG23 ' B' ' 74' ' ' THR . 5.2 m-85 -88.78 136.96 32.73 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 177.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 7.1 m-20 -114.86 133.37 56.02 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.571 -1.331 . . . . 0.0 110.882 -178.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.597 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 3.9 mp0 71.49 63.77 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.614 0.721 . . . . 0.0 109.849 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.455 HD12 HD21 ' B' ' 38' ' ' LEU . 9.1 mm -111.46 111.6 36.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.896 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.1 tm? -65.39 85.71 0.07 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.445 -0.784 . . . . 0.0 110.266 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.734 HD13 HD11 ' B' ' 66' ' ' ILE . 3.8 tt -89.11 125.28 42.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 33.1 tt0 -89.2 109.01 19.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.126 -0.984 . . . . 0.0 109.506 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.79 122.47 57.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.282 -0.886 . . . . 0.0 108.753 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.568 ' HB3' ' CD2' ' B' ' 69' ' ' HIS . 0.1 OUTLIER 53.83 54.56 9.63 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.489 -0.757 . . . . 0.0 110.631 179.026 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.15 20.51 28.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.568 ' CD2' ' HB3' ' B' ' 67' ' ' CYS . 87.8 m-70 -115.57 127.53 55.31 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.996 -1.296 . . . . 0.0 109.183 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.454 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -71.7 131.28 42.91 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.073 -1.017 . . . . 0.0 109.106 179.813 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.688 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -150.69 146.6 26.57 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.632 -0.667 . . . . 0.0 109.243 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.597 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -114.25 156.71 15.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.432 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.968 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -179.3 173.37 45.38 Favored Glycine 0 N--CA 1.485 1.944 0 C-N-CA 118.632 -1.747 . . . . 0.0 111.055 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.8 HG23 ' O ' ' B' ' 59' ' ' TYR . 88.2 m -89.97 112.79 24.3 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.5 -1.0 . . . . 0.0 109.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.94 112.7 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.897 179.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.616 ' HB2' HG23 ' B' ' 32' ' ' VAL . 1.9 mp -81.82 105.73 13.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.533 -0.729 . . . . 0.0 109.061 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.459 ' HB ' ' HD3' ' B' ' 57' ' ' ARG . 2.9 t -88.1 114.1 26.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 O-C-N 120.514 -1.366 . . . . 0.0 109.742 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -151.4 -170.42 18.23 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.564 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.3 Cg_endo -79.57 41.1 1.04 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 C-N-CA 122.434 2.089 . . . . 0.0 111.308 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.7 OUTLIER -85.82 137.73 35.68 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 178.374 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.601 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.5 21.52 0.69 Allowed 'Trans proline' 0 C--N 1.301 -1.921 0 C-N-CA 122.32 2.013 . . . . 0.0 112.13 -178.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -162.68 151.72 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.457 -1.402 . . . . 0.0 111.097 -179.735 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.58 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -92.4 87.36 5.98 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 176.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.91 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.1 mt -84.71 123.62 39.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.896 0.855 . . . . 0.0 112.914 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.545 ' CG1' ' HB1' ' B' ' 22' ' ' ALA . 3.5 mm -95.8 96.42 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.512 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.5 -161.07 18.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.108 -177.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 7' ' ' GLN . 1.4 mtm105 -64.88 -31.01 72.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.893 -0.769 . . . . 0.0 110.65 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.014 ' ND2' HD23 ' B' ' 89' ' ' LEU . 13.8 p-10 -54.8 -26.88 37.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.737 -1.227 . . . . 0.0 110.211 -179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.014 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -108.83 -31.39 7.71 Favored 'General case' 0 N--CA 1.484 1.258 0 O-C-N 120.766 -1.209 . . . . 0.0 110.091 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.782 HD13 HG23 ' B' ' 26' ' ' THR . 81.9 mt -62.42 -31.1 71.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 57.4 p -79.09 -21.69 46.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.41 -0.806 . . . . 0.0 109.457 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -67.55 -40.15 84.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -87.92 -7.55 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.72 64.95 2.82 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.711 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -90.29 142.36 27.81 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.427 -1.043 . . . . 0.0 111.011 -178.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.609 HG22 ' CG2' ' A' ' 4' ' ' THR . 8.3 p -130.35 130.61 44.64 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' A' ' 97' ' ' LEU . 3.9 mp -94.36 96.88 9.82 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.158 -0.964 . . . . 0.0 109.903 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.554 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -103.22 124.59 48.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.068 -1.02 . . . . 0.0 109.129 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.889 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.437 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.605 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.9 Cg_exo . . . . . 0 N--CA 1.494 1.549 0 N-CA-C 110.669 -0.55 . . . . 0.0 110.669 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.491 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 7.6 tt0 -84.67 108.2 17.27 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 177.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 5' ' ' LEU . 16.7 t -102.95 121.25 53.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.064 -1.022 . . . . 0.0 109.484 -178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.52 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.7 OUTLIER -73.09 -4.86 35.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.351 -178.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.716 ' O ' HG23 ' B' ' 91' ' ' THR . 5.5 mt 66.24 45.15 2.34 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.192 -0.942 . . . . 0.0 110.082 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.529 ' HA ' HG21 ' B' ' 91' ' ' THR . 1.4 m95 -65.84 -20.65 66.32 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.032 -1.042 . . . . 0.0 110.511 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.575 ' O ' ' CD ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -166.35 -99.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.956 -1.09 . . . . 0.0 110.092 179.821 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -113.49 140.3 24.33 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.774 -1.204 . . . . 0.0 109.565 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.576 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.7 Cg_endo -80.46 53.79 4.93 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.254 1.969 . . . . 0.0 109.693 177.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.556 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 1.3 mt -79.51 134.43 36.51 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.852 -1.155 . . . . 0.0 110.2 -178.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.456 HG21 HG23 ' A' ' 66' ' ' ILE . 1.6 m -150.99 163.71 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.667 -0.646 . . . . 0.0 109.317 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.812 ' CG2' HD22 ' A' ' 19' ' ' LEU . 3.5 m -86.56 119.07 26.42 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.617 HG22 HG13 ' A' ' 66' ' ' ILE . 18.8 pt -110.49 137.49 42.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.335 -0.853 . . . . 0.0 109.709 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 1.1 ttpp -106.96 107.7 18.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.125 -0.984 . . . . 0.0 109.299 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.939 HG23 ' CG2' ' A' ' 62' ' ' ILE . 5.1 mt -113.26 131.36 65.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.962 . . . . 0.0 109.201 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.41 -88.57 0.34 Allowed Glycine 0 N--CA 1.485 1.924 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -178.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 23.9 0.32 Allowed Glycine 0 C--N 1.293 -1.829 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 29.2 mt-30 -118.25 177.99 4.6 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.64 -0.918 . . . . 0.0 109.295 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.812 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.2 mt -143.7 119.08 10.25 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.692 0.758 . . . . 0.0 110.001 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -133.62 172.53 12.62 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.556 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 21.0 mt-10 -77.58 166.35 23.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.893 -1.129 . . . . 0.0 108.143 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.623 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -147.66 132.43 17.96 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.798 -1.189 . . . . 0.0 110.405 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.603 HD21 ' O ' ' B' ' 27' ' ' GLY . 40.7 tp -104.84 90.17 3.39 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.709 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.67 HD23 ' HB ' ' A' ' 85' ' ' ILE . 38.2 mt -46.86 107.23 0.1 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.852 -1.155 . . . . 0.0 108.253 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.608 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.4 t0 -112.27 89.67 3.13 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.346 -0.846 . . . . 0.0 109.852 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.986 HG23 HD13 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -61.8 -21.19 64.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.072 -1.017 . . . . 0.0 108.422 179.325 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.475 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -60.45 -38.21 94.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -87.47 160.62 18.21 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.069 -1.254 . . . . 0.0 109.566 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -100.25 -6.81 25.42 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.459 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.567 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.56 179.29 6.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.169 -0.957 . . . . 0.0 110.081 -179.489 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.718 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 5.9 m -106.11 96.01 6.18 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.224 -0.923 . . . . 0.0 109.309 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.985 HG13 HG21 ' A' ' 80' ' ' THR . 1.2 t -87.46 105.45 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.126 0 O-C-N 121.21 -0.931 . . . . 0.0 110.055 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.784 HD13 HG13 ' A' ' 75' ' ' VAL . 1.5 mp -100.17 133.4 44.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.315 -0.866 . . . . 0.0 112.14 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.706 ' HA ' HG23 ' A' ' 80' ' ' THR . 11.8 pt-20 -42.41 153.34 0.07 Allowed 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 177.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.913 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.4 mt-10 -53.17 131.32 36.75 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 120.934 -1.104 . . . . 0.0 109.614 -179.417 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.44 ' SD ' ' HG ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -146.17 175.64 10.34 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.06 179.896 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.409 ' O ' ' SD ' ' A' ' 36' ' ' MET . 16.5 t -86.45 107.31 18.0 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.291 -0.881 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.936 HD12 HG21 ' A' ' 77' ' ' VAL . 20.9 mt -121.12 110.79 34.31 Favored Pre-proline 0 N--CA 1.488 1.436 0 O-C-N 121.291 -0.88 . . . . 0.0 109.213 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -78.84 116.96 3.83 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.806 2.337 . . . . 0.0 110.659 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 151.82 -168.53 31.17 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.3 mmt180 -92.65 157.09 16.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.556 -0.967 . . . . 0.0 108.891 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 59.9 p-90 -160.01 172.91 16.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.179 -0.951 . . . . 0.0 109.843 -179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.2 mttt -136.37 160.23 67.66 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.75 141.19 16.99 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.111 1.874 . . . . 0.0 110.914 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.01 171.38 15.36 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.07 132.88 15.0 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.883 -1.135 . . . . 0.0 110.074 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.725 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -117.31 146.59 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.174 -0.954 . . . . 0.0 108.895 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.601 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.9 124.22 5.95 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.47 -123.73 1.78 Allowed Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.031 -1.557 . . . . 0.0 111.495 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.499 ' O ' ' O ' ' B' ' 50' ' ' ILE . 39.0 mt -84.55 131.49 33.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 113.663 0.986 . . . . 0.0 113.663 -176.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.82 -17.25 9.32 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 177.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.47 -158.35 28.16 Favored Glycine 0 N--CA 1.491 2.351 0 O-C-N 120.603 -1.527 . . . . 0.0 110.502 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.601 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.8 m-85 -116.45 155.6 28.28 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.599 -0.942 . . . . 0.0 109.409 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.776 HD13 HG23 ' B' ' 50' ' ' ILE . 13.0 pt -131.64 146.26 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.217 -0.927 . . . . 0.0 108.684 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 7.8 mttp -90.19 154.19 19.93 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.456 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.0 m -149.05 178.93 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.067 -1.021 . . . . 0.0 109.567 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.427 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 9.2 mmt180 -122.35 104.59 9.52 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.408 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 1.4 tt0 -60.67 99.57 0.09 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.275 -0.891 . . . . 0.0 110.606 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.593 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.2 m-85 -95.1 104.67 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 9.3 m-20 -88.84 129.32 35.61 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.029 -1.045 . . . . 0.0 111.173 -178.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.566 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.5 OUTLIER 82.01 60.33 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.332 0.587 . . . . 0.0 111.31 178.466 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.939 ' CG2' HG23 ' A' ' 15' ' ' ILE . 8.6 mm -115.32 120.86 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.622 HD22 ' C ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -71.32 95.27 1.29 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.017 -1.052 . . . . 0.0 111.273 -177.853 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -98.08 115.98 39.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 178.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.4 tt0 -89.34 105.05 17.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.85 -1.156 . . . . 0.0 108.883 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.75 HD11 HD13 ' A' ' 64' ' ' ILE . 1.7 mp -104.31 120.74 55.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.477 -0.764 . . . . 0.0 109.816 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.58 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.2 m 54.66 59.16 4.28 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.807 -0.558 . . . . 0.0 110.495 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 50.29 33.5 23.79 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 21.9 m-70 -131.14 102.56 6.06 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.193 -1.18 . . . . 0.0 108.813 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.599 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.8 mptt -51.46 140.09 18.49 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -160.88 99.72 1.24 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.14 -0.975 . . . . 0.0 110.052 -179.258 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.566 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -78.81 157.38 4.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 72' ' ' ILE . . . -179.46 -166.66 35.58 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.221 -1.942 . . . . 0.0 112.21 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.455 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 32.5 m -98.55 108.3 20.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.573 -0.957 . . . . 0.0 110.507 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.784 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -102.53 105.61 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.646 -0.658 . . . . 0.0 110.258 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.567 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 4.8 mp -78.48 109.78 12.97 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.936 HG21 HD12 ' A' ' 38' ' ' LEU . 2.3 t -93.12 114.5 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.444 -0.785 . . . . 0.0 110.328 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -143.66 -163.95 10.11 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.45 43.3 1.5 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.559 2.173 . . . . 0.0 110.274 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.985 HG21 HG13 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -88.6 134.06 34.87 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.438 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.5 18.54 0.94 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.559 2.173 . . . . 0.0 111.975 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.514 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.0 161.33 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.88 -1.138 . . . . 0.0 109.629 179.716 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.623 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -95.24 134.66 37.75 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.645 -2.354 . . . . 0.0 104.645 175.946 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.739 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.2 mm -124.37 121.83 62.62 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 120.538 -1.352 . . . . 0.0 110.189 -177.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.868 HD13 ' N ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -98.04 87.65 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.171 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.15 -163.57 22.45 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 120.144 -1.027 . . . . 0.0 110.588 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.571 ' NH1' ' HD3' ' B' ' 9' ' ' PRO . 13.8 mmt-85 -57.63 -39.31 76.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.747 -0.855 . . . . 0.0 110.892 -178.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.045 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -44.47 -31.12 1.0 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.996 -1.065 . . . . 0.0 109.343 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.045 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.4 mm? -105.09 -27.46 11.61 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.207 -0.933 . . . . 0.0 109.884 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.986 HD13 HG23 ' A' ' 26' ' ' THR . 27.0 mt -70.33 -8.7 52.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.035 -1.041 . . . . 0.0 108.858 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.22 -20.25 20.62 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -86.46 -40.09 15.67 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.826 HD11 HD23 ' A' ' 90' ' ' LEU . 1.9 pt -82.62 -7.63 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.381 -0.824 . . . . 0.0 109.138 179.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.98 34.25 58.94 Favored Glycine 0 N--CA 1.5 2.903 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.187 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.607 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -70.04 130.14 41.34 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.04 -1.27 . . . . 0.0 110.335 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.533 HG22 ' CG2' ' B' ' 4' ' ' THR . 82.2 p -127.88 130.05 47.9 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.924 -1.11 . . . . 0.0 109.098 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -88.22 97.52 11.06 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.162 -0.962 . . . . 0.0 109.581 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.519 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 2.4 m120 -107.27 123.91 49.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.292 -0.88 . . . . 0.0 109.051 179.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.771 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.191 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.664 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.519 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 0.2 OUTLIER -83.57 146.41 28.33 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 177.823 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.82 HG13 HD23 ' B' ' 5' ' ' LEU . 20.9 t -143.59 122.98 8.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 117.812 -1.555 . . . . 0.0 111.244 -178.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.541 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.1 OUTLIER -117.13 20.89 13.53 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 177.165 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.82 HD23 HG13 ' B' ' 3' ' ' VAL . 1.3 mm? -34.68 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.682 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.541 ' N ' ' O ' ' B' ' 4' ' ' THR . 10.5 m95 -50.94 -19.98 1.19 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.402 ' N ' ' C ' ' B' ' 5' ' ' LEU . 12.9 mm100 -108.57 -124.06 0.25 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.301 -0.874 . . . . 0.0 108.831 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 34.8 mtt180 -110.56 129.99 23.37 Favored Pre-proline 0 N--CA 1.496 1.869 0 O-C-N 120.396 -1.44 . . . . 0.0 110.407 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.571 ' HD3' ' NH1' ' A' ' 87' ' ' ARG . 37.6 Cg_endo -79.16 82.78 2.42 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.364 2.042 . . . . 0.0 109.83 178.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.642 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.7 mt -90.91 140.22 30.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.016 -1.052 . . . . 0.0 109.992 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.537 HG23 ' N ' ' B' ' 12' ' ' THR . 0.6 OUTLIER -143.37 168.28 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.765 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.537 ' N ' HG23 ' B' ' 11' ' ' VAL . 17.8 m -99.91 109.18 21.56 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.924 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.6 pt -91.35 158.03 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.138 -0.976 . . . . 0.0 110.064 -178.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.9 tttt -121.03 96.97 5.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.412 -0.805 . . . . 0.0 109.064 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.804 HG23 ' CG2' ' B' ' 62' ' ' ILE . 20.1 mt -113.3 129.44 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 O-C-N 121.337 -0.852 . . . . 0.0 109.617 -179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.75 50.13 62.41 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 54.8 24.43 33.39 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.3 OUTLIER -119.94 174.58 6.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.221 -1.164 . . . . 0.0 108.688 179.288 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.924 HD23 ' O ' ' B' ' 13' ' ' ILE . 29.1 mt -148.52 126.05 11.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.021 -1.049 . . . . 0.0 110.843 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.449 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.1 mmmt -140.6 -177.37 5.02 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.642 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.6 OUTLIER -80.2 176.02 10.12 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.946 -1.096 . . . . 0.0 108.671 179.415 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -162.62 111.91 1.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.854 -1.154 . . . . 0.0 111.346 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' B' ' 25' ' ' ASP . 9.0 tp -89.05 99.68 12.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.539 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.2 mt -46.79 96.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.921 -1.112 . . . . 0.0 108.093 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.582 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 65.1 t0 -105.49 84.84 2.15 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.292 -0.88 . . . . 0.0 110.861 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.562 ' CG2' ' HD2' ' B' ' 87' ' ' ARG . 49.4 m -63.14 -15.96 58.47 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 108.945 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.603 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -67.86 -45.81 71.68 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 133.62 46.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -1.111 . . . . 0.0 108.589 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.5 m-20 -71.75 -13.28 61.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.368 -0.833 . . . . 0.0 110.692 -178.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.777 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -139.03 -174.82 3.95 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.768 -1.207 . . . . 0.0 110.583 -179.377 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.654 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.4 m -104.17 97.86 7.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.063 -1.023 . . . . 0.0 110.499 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.609 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -89.59 109.67 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.324 0 O-C-N 121.198 -0.938 . . . . 0.0 109.918 -179.897 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.902 HD21 HD11 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -99.26 130.92 45.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.117 -0.99 . . . . 0.0 111.311 -179.605 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.55 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 34.1 tt0 -40.59 163.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.439 -0.788 . . . . 0.0 109.292 178.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.646 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.1 mt-10 -53.01 139.27 28.42 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 110.917 -178.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.51 ' HG3' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -173.82 159.66 3.48 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.51 ' N ' ' HG3' ' B' ' 36' ' ' MET . 18.2 t -79.52 142.07 36.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.091 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 1.013 HD12 HG21 ' B' ' 77' ' ' VAL . 10.6 mt -139.16 166.0 27.87 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.449 -0.782 . . . . 0.0 108.999 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.5 ' HD3' HD23 ' B' ' 38' ' ' LEU . 34.5 Cg_endo -76.5 69.59 6.6 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.816 2.344 . . . . 0.0 111.996 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.68 -159.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.671 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.472 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 67.1 50.52 1.01 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.512 -0.993 . . . . 0.0 109.03 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.587 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 46.7 p-90 -135.15 -178.38 5.07 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.907 0.86 . . . . 0.0 110.411 -179.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.44 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 12.4 mmtm -150.56 158.76 35.48 Favored Pre-proline 0 C--N 1.302 -1.487 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.63 139.87 18.38 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.912 1.742 . . . . 0.0 110.012 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.756 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.4 OUTLIER -151.07 152.45 33.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.374 -0.829 . . . . 0.0 109.456 -179.433 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -127.35 111.51 13.97 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.844 -1.16 . . . . 0.0 108.828 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 54' ' ' ILE . 24.4 pt -95.1 134.35 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 110.018 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.594 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.59 104.51 1.11 Allowed Glycine 0 N--CA 1.489 2.173 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -124.51 3.0 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.171 -1.49 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.776 HG23 HD13 ' A' ' 54' ' ' ILE . 38.7 mt -86.02 121.77 37.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.832 -0.805 . . . . 0.0 112.627 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.58 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.18 -49.13 0.97 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 177.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.97 -159.65 24.15 Favored Glycine 0 N--CA 1.488 2.153 0 O-C-N 120.913 -1.345 . . . . 0.0 110.301 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.594 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 4.9 m-85 -113.91 155.04 26.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.646 -0.914 . . . . 0.0 109.644 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 47' ' ' ILE . 1.4 pt -138.95 176.52 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.309 -0.869 . . . . 0.0 108.849 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 8.9 mttt -116.18 151.82 34.95 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.498 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB3' ' B' ' 45' ' ' LYS . 5.6 m -146.62 -171.11 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.791 -1.193 . . . . 0.0 109.715 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' B' ' 59' ' ' TYR . 71.0 mtm-85 -133.65 85.07 2.17 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -44.36 93.69 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.692 -0.63 . . . . 0.0 110.648 -178.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.587 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 13.8 m-85 -88.92 125.61 35.03 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 178.174 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.511 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 14.8 m-20 -105.53 136.22 45.5 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.84 -1.163 . . . . 0.0 110.786 -178.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.623 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.8 mp0 70.81 65.44 0.18 Allowed 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.431 0.634 . . . . 0.0 111.106 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.804 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.76 111.71 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 1.059 HD21 ' CG ' ' B' ' 70' ' ' LYS . 12.9 tp -64.85 91.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.969 -1.082 . . . . 0.0 111.097 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.8 ' CG2' HD11 ' B' ' 89' ' ' LEU . 5.4 tt -89.42 119.14 36.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.486 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.6 tt0 -88.54 120.88 30.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 109.119 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.655 HG13 HG22 ' B' ' 13' ' ' ILE . 1.3 mp -120.94 128.0 76.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.397 -0.814 . . . . 0.0 109.217 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 94.5 m 52.97 24.48 3.42 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.507 -0.746 . . . . 0.0 109.798 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 81.79 43.62 8.22 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -140.28 99.53 3.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -1.166 . . . . 0.0 109.418 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 1.059 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.24 128.56 19.67 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.656 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -148.23 101.98 3.31 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.301 -0.875 . . . . 0.0 110.505 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.623 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -77.31 142.83 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.773 -1.205 . . . . 0.0 108.648 178.992 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.523 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -164.94 -155.75 8.65 Favored Glycine 0 N--CA 1.494 2.566 0 C-N-CA 119.723 -1.227 . . . . 0.0 111.062 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.484 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.3 m -111.96 113.76 26.26 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.214 -1.168 . . . . 0.0 109.624 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.676 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -107.91 108.42 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.355 -0.841 . . . . 0.0 111.383 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.788 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.9 mp -79.92 108.79 13.77 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.127 -0.983 . . . . 0.0 108.617 178.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 1.013 HG21 HD12 ' B' ' 38' ' ' LEU . 2.1 t -92.24 117.97 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.988 -1.07 . . . . 0.0 109.659 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.721 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -146.99 -171.96 16.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.306 -1.918 . . . . 0.0 108.306 179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.8 Cg_endo -81.03 44.26 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.259 1.973 . . . . 0.0 110.514 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.609 HG21 HG13 ' B' ' 32' ' ' VAL . 5.3 t -84.69 143.75 41.38 Favored Pre-proline 0 N--CA 1.486 1.359 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.9 Cg_endo -76.65 14.01 1.31 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.583 2.189 . . . . 0.0 111.674 -178.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.03 164.35 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.83 -1.169 . . . . 0.0 110.149 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.566 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.4 m120 -94.6 146.95 23.77 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 174.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.654 ' O ' ' HA ' ' B' ' 31' ' ' THR . 3.6 mm -133.81 123.91 46.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 120.024 -1.673 . . . . 0.0 110.713 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.504 ' HB ' ' HA ' ' B' ' 24' ' ' LEU . 5.3 mm -98.5 93.45 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.25 179.49 51.74 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 -178.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.588 ' HG2' ' HB3' ' A' ' 5' ' ' LEU . 0.8 OUTLIER -58.83 -23.11 60.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.37 -1.077 . . . . 0.0 109.627 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.739 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.9 p-10 -53.77 -37.01 63.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.694 -1.254 . . . . 0.0 108.924 178.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.8 HD11 ' CG2' ' B' ' 64' ' ' ILE . 0.4 OUTLIER -96.92 -35.26 10.94 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.619 -0.676 . . . . 0.0 110.695 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.51 ' O ' HG13 ' B' ' 93' ' ' ILE . 71.7 mt -56.36 -33.87 66.11 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.038 -1.039 . . . . 0.0 109.487 -179.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.66 -21.84 60.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 110.899 -179.109 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -80.54 -31.47 36.98 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.229 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.771 HD12 ' CB ' ' A' ' 99' ' ' PHE . 3.1 pt -87.11 13.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.4 -0.813 . . . . 0.0 108.932 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 59.76 49.04 82.83 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.527 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -87.92 150.66 23.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.25 -1.147 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.52 HG22 ' HA ' ' A' ' 4' ' ' THR . 57.2 p -146.27 123.07 11.25 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.798 . . . . 0.0 109.135 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' A' ' 97' ' ' LEU . 5.2 mp -85.36 93.54 8.74 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 7.5 m120 -92.79 119.97 32.69 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 120.703 -1.248 . . . . 0.0 110.067 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.675 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.37 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.446 ' O ' ' HA ' ' B' ' 98' ' ' ASN . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.66 0 N-CA-C 109.889 -0.85 . . . . 0.0 109.889 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.583 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -83.17 149.66 26.72 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 177.81 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.543 HG13 ' CD2' ' A' ' 5' ' ' LEU . 37.8 t -150.49 116.43 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 C-N-CA 118.436 -1.306 . . . . 0.0 110.661 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.782 ' C ' HD23 ' A' ' 5' ' ' LEU . 1.7 p -122.26 -73.21 0.65 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.782 HD23 ' C ' ' A' ' 4' ' ' THR . 1.8 pt? 30.4 38.28 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 122.124 -0.36 . . . . 0.0 111.071 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' A' ' 5' ' ' LEU . 8.9 m95 19.3 48.96 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 121.258 0.551 . . . . 0.0 111.829 179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.552 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -149.87 -167.81 2.93 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.31 179.421 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.622 ' HB3' HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -84.89 136.77 38.4 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.12 -0.987 . . . . 0.0 109.403 -179.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.7 Cg_endo -77.27 71.99 6.12 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.246 1.964 . . . . 0.0 109.717 178.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' CG1' ' A' ' 11' ' ' VAL . 0.4 OUTLIER -79.54 151.17 30.86 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 -179.567 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 1.053 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -150.64 156.47 6.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.244 -0.91 . . . . 0.0 110.027 -179.381 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.694 ' CG2' HD22 ' A' ' 19' ' ' LEU . 22.6 m -86.93 113.37 22.66 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.769 HD11 HD21 ' A' ' 33' ' ' LEU . 43.8 pt -99.7 147.87 6.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.167 -0.958 . . . . 0.0 111.071 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.647 ' CD ' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -109.27 94.9 5.28 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.937 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.836 HD13 HG11 ' A' ' 75' ' ' VAL . 8.6 mt -119.41 130.07 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.104 -0.998 . . . . 0.0 109.67 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.67 37.63 95.01 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.61 18.14 50.91 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -113.84 172.88 6.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.34 -1.094 . . . . 0.0 109.518 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.694 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.1 mt -139.74 122.46 16.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 111.012 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.463 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -141.96 175.32 9.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 1.3 mt-10 -78.72 178.67 7.69 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.599 -1.313 . . . . 0.0 108.23 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.824 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -156.9 103.99 2.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.14 -0.975 . . . . 0.0 109.635 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.622 HD11 ' HB3' ' A' ' 8' ' ' ARG . 30.5 tp -72.43 92.6 1.46 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.253 -0.904 . . . . 0.0 108.584 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.767 ' CD2' HD21 ' A' ' 90' ' ' LEU . 3.7 mt -43.78 98.43 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' A' ' 84' ' ' ILE . 1.9 t70 -104.89 90.3 3.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.558 -0.714 . . . . 0.0 110.777 -178.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.526 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 20.7 m -68.23 -13.53 62.31 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.725 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.99 -41.68 60.79 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.05 162.75 29.1 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -1.171 . . . . 0.0 109.516 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -98.92 -11.15 21.9 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.292 -0.88 . . . . 0.0 110.428 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.551 ' OD2' ' HB ' ' A' ' 74' ' ' THR . 0.1 OUTLIER -139.06 -173.2 3.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.899 -1.126 . . . . 0.0 109.781 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' A' ' 33' ' ' LEU . 66.4 m -106.32 88.52 2.8 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.576 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.19 162.97 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.244 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.01 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.4 OUTLIER -157.7 124.32 4.92 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.9 -179.003 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 35' ' ' GLU . 21.0 pt-20 -41.01 152.83 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.533 -0.729 . . . . 0.0 109.5 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -41.71 148.31 0.16 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.39 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.431 ' HE1' HG22 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -173.29 164.92 4.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.496 -0.753 . . . . 0.0 108.975 179.457 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.7 t -79.8 100.06 7.79 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.056 -1.028 . . . . 0.0 109.77 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 39' ' ' PRO . 13.3 tp -126.29 100.39 29.58 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.248 -0.907 . . . . 0.0 109.34 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.531 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.4 Cg_endo -78.46 165.39 25.32 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.791 2.327 . . . . 0.0 110.815 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.57 -163.12 16.09 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.408 ' H ' ' NE ' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -97.33 139.03 33.9 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.223 -1.163 . . . . 0.0 108.26 179.502 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.569 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 9.7 p-90 -149.33 174.49 12.37 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.031 -1.043 . . . . 0.0 109.996 -179.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -138.2 163.47 47.28 Favored Pre-proline 0 C--N 1.299 -1.612 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.22 141.03 25.53 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.73 1.62 . . . . 0.0 110.189 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.36 167.46 22.12 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.451 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 10.4 ttt -151.38 118.79 6.01 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 54' ' ' ILE . 1.5 pt -102.43 128.51 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 C-N-CA 118.396 -1.322 . . . . 0.0 108.897 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.618 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -117.89 98.01 0.75 Allowed Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.72 -121.06 2.9 Favored Glycine 0 C--N 1.297 -1.616 0 C-N-CA 119.416 -1.374 . . . . 0.0 110.404 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.883 HG21 HD12 ' B' ' 47' ' ' ILE . 74.8 mt -83.87 106.1 13.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.872 -0.781 . . . . 0.0 112.561 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 120.18 -44.62 1.35 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 178.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 168.06 -164.37 37.92 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.728 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 7.1 m-85 -110.14 118.02 35.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.602 -0.94 . . . . 0.0 110.18 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 47' ' ' ILE . 32.6 pt -99.16 161.07 3.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.557 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.39 132.96 48.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.024 -1.048 . . . . 0.0 109.8 -179.406 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' A' ' 78' ' ' GLY . 30.6 m -134.55 178.68 5.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.477 -0.765 . . . . 0.0 109.36 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 28.1 mtt180 -111.31 171.22 7.6 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.409 ' OE1' ' OD1' ' A' ' 60' ' ' ASP . 0.3 OUTLIER -131.5 97.28 4.19 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.673 -1.267 . . . . 0.0 110.859 -179.042 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 83.7 m-85 -97.11 116.32 29.1 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.522 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -94.01 146.46 23.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.917 -1.114 . . . . 0.0 110.144 -179.05 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.559 ' HA ' HG23 ' A' ' 72' ' ' ILE . 4.1 mm-40 67.77 67.34 0.36 Allowed 'General case' 0 N--CA 1.489 1.516 0 CA-C-O 121.617 0.722 . . . . 0.0 109.705 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.616 ' HB ' HG23 ' A' ' 75' ' ' VAL . 1.9 mm -124.65 108.84 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.769 HD11 ' CG ' ' A' ' 70' ' ' LYS . 4.6 tt -59.81 102.57 0.16 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.311 -0.868 . . . . 0.0 111.175 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 1.009 HD13 HD11 ' A' ' 66' ' ' ILE . 3.7 tt -100.44 119.48 48.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.75 109.88 20.04 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.647 -1.283 . . . . 0.0 108.719 -178.564 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.053 HG23 HG21 ' A' ' 11' ' ' VAL . 2.7 mt -115.78 123.86 71.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.124 -0.985 . . . . 0.0 110.313 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.455 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 58.2 m 56.49 36.02 26.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.675 -0.641 . . . . 0.0 110.367 179.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.41 28.03 73.46 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.455 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 96.7 m-70 -126.95 110.35 12.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.118 -1.225 . . . . 0.0 109.273 179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.769 ' CG ' HD11 ' A' ' 63' ' ' LEU . 1.5 ttpm? -55.05 130.6 42.43 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.269 -0.895 . . . . 0.0 109.069 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 101.46 3.23 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.372 -0.83 . . . . 0.0 109.935 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.646 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -78.27 146.43 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 178.794 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.659 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -170.45 -177.69 40.74 Favored Glycine 0 N--CA 1.484 1.879 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.51 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.551 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 1.9 m -93.58 111.92 23.7 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.574 -0.957 . . . . 0.0 109.587 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.001 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.97 137.12 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.694 -0.629 . . . . 0.0 109.724 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.4 mp -107.68 136.14 47.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.209 -0.932 . . . . 0.0 108.768 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.492 ' O ' ' HG3' ' A' ' 57' ' ' ARG . 16.7 t -118.38 113.65 42.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.943 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -151.75 -164.04 11.92 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.557 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.31 39.48 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.681 2.254 . . . . 0.0 111.039 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.832 HG21 HG13 ' A' ' 32' ' ' VAL . 2.8 t -86.83 134.84 36.4 Favored Pre-proline 0 N--CA 1.489 1.508 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.1 Cg_endo -78.16 18.79 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.691 2.26 . . . . 0.0 112.028 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 81' ' ' PRO . 0.9 OUTLIER -161.5 158.97 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.597 -1.314 . . . . 0.0 110.341 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 67.7 m-20 -95.11 100.29 12.13 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' A' ' 25' ' ' ASP . 7.2 mm -88.37 128.59 40.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 O-C-N 120.858 -1.151 . . . . 0.0 112.154 -176.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.824 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.61 93.79 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.244 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -80.35 -160.99 23.63 Favored Glycine 0 N--CA 1.493 2.494 0 O-C-N 121.176 -0.952 . . . . 0.0 111.042 -177.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.513 ' NH2' ' HB2' ' A' ' 87' ' ' ARG . 7.5 mtp-105 -69.17 -29.67 67.73 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.65 -0.912 . . . . 0.0 109.925 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.943 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -50.17 -24.26 2.69 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.811 -1.181 . . . . 0.0 108.951 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.943 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.1 mm? -112.76 -27.77 8.03 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.236 -0.915 . . . . 0.0 110.313 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.767 HD21 ' CD2' ' A' ' 24' ' ' LEU . 34.7 mt -63.09 -28.15 69.88 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.992 -1.068 . . . . 0.0 108.416 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 69.0 p -79.43 -20.64 47.03 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.136 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -80.86 -36.71 31.05 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.35 -0.844 . . . . 0.0 109.135 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.829 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -86.0 -0.72 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.295 -0.878 . . . . 0.0 109.243 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.68 62.22 5.23 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -97.16 135.88 38.48 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.547 -0.973 . . . . 0.0 110.481 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.719 HG22 ' CG2' ' B' ' 4' ' ' THR . 15.5 p -133.12 128.71 36.71 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.613 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -87.1 109.38 19.39 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.277 -0.89 . . . . 0.0 108.792 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.513 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.9 m120 -105.22 120.79 42.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.81 -1.181 . . . . 0.0 109.196 179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.86 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.595 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.451 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.56 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.332 -0.68 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.523 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tm0? -84.02 145.71 28.36 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.133 -1.803 . . . . 0.0 106.133 177.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.523 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 70.1 t -146.03 122.97 3.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.218 -177.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.719 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.8 OUTLIER -127.04 -61.94 1.14 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.673 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.1 mt 31.86 38.92 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.567 178.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.536 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.9 m95 17.31 51.46 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 CA-C-O 121.159 0.504 . . . . 0.0 111.949 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' B' ' 5' ' ' LEU . 13.1 mt-30 -168.0 -174.95 2.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.341 -0.85 . . . . 0.0 109.592 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.472 ' HG2' ' HD2' ' A' ' 87' ' ' ARG . 17.2 mtm180 -65.44 138.45 96.96 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.032 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.554 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.8 Cg_endo -81.16 62.36 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.36 2.04 . . . . 0.0 109.707 179.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 1.052 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -80.84 136.4 36.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.877 -1.139 . . . . 0.0 109.56 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.533 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -130.42 137.91 55.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.286 -0.884 . . . . 0.0 109.191 -179.933 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.714 HG22 HD22 ' B' ' 19' ' ' LEU . 18.0 m -65.66 97.58 0.33 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.941 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.8 pt -88.03 154.62 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.297 -0.877 . . . . 0.0 110.702 -177.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.2 OUTLIER -122.15 105.88 10.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.473 -0.767 . . . . 0.0 109.773 179.505 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.76 HD13 HG11 ' B' ' 75' ' ' VAL . 97.1 mt -121.24 139.92 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 120.852 -1.155 . . . . 0.0 110.889 -179.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.81 33.38 6.48 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.76 37.27 51.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.5 OUTLIER -131.18 175.48 9.07 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 108.39 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.941 HD23 ' O ' ' B' ' 13' ' ' ILE . 15.9 mt -152.0 124.33 8.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.995 -1.066 . . . . 0.0 110.249 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -151.38 174.57 13.18 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 1.052 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -80.34 143.38 33.61 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.895 -1.128 . . . . 0.0 108.836 179.484 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.679 ' N ' HD23 ' B' ' 10' ' ' LEU . . . -127.53 112.79 15.33 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 110.138 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.725 HD21 ' O ' ' A' ' 27' ' ' GLY . 2.4 tp -81.14 102.05 10.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.691 -0.631 . . . . 0.0 109.864 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 20.1 mt -52.74 105.95 0.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.934 -1.104 . . . . 0.0 108.346 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.886 ' CB ' HG23 ' B' ' 84' ' ' ILE . 53.4 t0 -103.1 92.54 4.58 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.216 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.696 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -64.54 -11.5 35.0 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.077 -1.015 . . . . 0.0 108.404 178.437 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -70.09 -43.62 63.77 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.82 164.96 21.28 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.117 -1.225 . . . . 0.0 109.676 -179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -100.4 -13.88 18.57 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.226 -0.921 . . . . 0.0 110.196 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.644 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -126.75 -165.37 1.45 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.016 -1.052 . . . . 0.0 109.664 -179.806 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.78 HG23 HD12 ' B' ' 85' ' ' ILE . 8.1 m -116.63 85.64 2.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.924 -1.11 . . . . 0.0 110.192 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.934 HG12 ' HB ' ' B' ' 84' ' ' ILE . 0.3 OUTLIER -68.65 154.75 8.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.806 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -154.82 133.31 11.95 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.837 -1.164 . . . . 0.0 111.054 -177.609 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.489 ' HG3' ' O ' ' B' ' 80' ' ' THR . 4.1 tt0 -42.03 148.62 0.18 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.465 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 3.0 mt-10 -44.88 136.99 4.3 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.041 -1.037 . . . . 0.0 110.457 -179.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.584 ' SD ' HD22 ' B' ' 38' ' ' LEU . 0.0 OUTLIER -156.75 -167.69 2.45 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.11 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.6 t -112.29 115.75 29.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.756 -1.215 . . . . 0.0 111.457 -178.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.685 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -116.45 170.81 5.39 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.685 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.4 Cg_endo -76.22 115.77 4.2 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.372 2.048 . . . . 0.0 111.374 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' B' ' 41' ' ' ARG . . . -30.95 122.39 0.14 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' B' ' 40' ' ' GLY . 3.6 mtm180 148.72 43.01 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.633 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 37.3 p-90 -124.73 176.8 6.34 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.343 0.592 . . . . 0.0 109.733 -178.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -133.92 130.04 20.38 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.007 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -76.91 140.11 20.12 Favored 'Trans proline' 0 C--N 1.31 -1.45 0 C-N-CA 122.254 1.97 . . . . 0.0 110.317 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -159.41 -164.8 1.43 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.356 -0.84 . . . . 0.0 109.376 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.548 ' CG ' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -141.8 119.21 11.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.985 -179.578 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.883 HD12 HG21 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -90.44 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 178.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.467 ' HA2' ' HB3' ' B' ' 53' ' ' PHE . . . -118.41 111.75 2.22 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.81 -125.2 2.35 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.702 HG23 HD13 ' A' ' 54' ' ' ILE . 37.8 mt -80.95 139.12 18.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.777 -0.837 . . . . 0.0 112.664 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.27 5.03 65.54 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.0 -158.94 16.69 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.051 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -119.21 143.85 47.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.441 -1.035 . . . . 0.0 109.183 -179.549 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.754 HG12 HG23 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -112.71 -175.29 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.977 . . . . 0.0 108.701 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.549 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 12.3 mttt -114.84 138.79 50.36 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.047 -1.033 . . . . 0.0 109.282 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.653 HG13 HD11 ' B' ' 54' ' ' ILE . 3.5 m -139.05 -169.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.553 -1.342 . . . . 0.0 110.73 -179.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.496 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 73.8 mtt-85 -143.78 99.88 3.49 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.565 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 6.1 tt0 -66.04 108.13 2.12 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.294 -0.879 . . . . 0.0 110.719 -178.644 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 32.3 m-85 -93.85 128.27 40.03 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 177.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.534 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -106.17 135.97 46.7 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.877 -1.139 . . . . 0.0 110.927 -177.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.594 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.2 OUTLIER 71.98 64.03 0.14 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 179.271 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 4.4 mp -118.17 119.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.717 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.3 tm? -66.29 84.95 0.1 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-O 121.661 0.743 . . . . 0.0 110.604 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.647 HG22 ' O ' ' B' ' 71' ' ' ALA . 2.3 tt -91.89 130.76 40.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 178.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.514 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.8 tt0 -87.74 152.6 22.01 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.905 -1.122 . . . . 0.0 108.463 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.593 HG13 HG22 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -150.75 135.11 9.0 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.236 -0.915 . . . . 0.0 108.962 -179.453 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 46.32 24.07 0.26 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.529 -0.732 . . . . 0.0 110.21 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.416 ' O ' ' CD2' ' B' ' 69' ' ' HIS . . . 83.72 39.6 9.47 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 179.453 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' B' ' 68' ' ' GLY . 8.9 m-70 -141.11 164.77 29.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -1.208 . . . . 0.0 109.074 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.527 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -95.73 139.19 32.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.07 -1.019 . . . . 0.0 108.472 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.647 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.54 104.75 2.58 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.111 -0.993 . . . . 0.0 110.051 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.597 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.4 OUTLIER -86.94 141.64 14.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 178.701 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.56 -164.11 23.69 Favored Glycine 0 N--CA 1.485 1.922 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.495 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.565 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 8.6 m -95.91 105.06 17.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.682 -0.893 . . . . 0.0 109.906 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.806 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -100.71 106.01 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.38 -0.825 . . . . 0.0 109.983 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.644 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 0.4 OUTLIER -78.08 134.4 37.74 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.104 -0.997 . . . . 0.0 108.666 179.104 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 58.2 t -122.58 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.206 -0.934 . . . . 0.0 110.644 -179.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.441 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -163.84 -161.27 12.73 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 108.258 -1.937 . . . . 0.0 108.258 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' B' ' 54' ' ' ILE . 36.5 Cg_endo -81.47 40.23 0.96 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.358 2.039 . . . . 0.0 110.244 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' B' ' 32' ' ' VAL . 3.1 t -83.39 133.56 47.09 Favored Pre-proline 0 N--CA 1.487 1.391 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.665 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.3 Cg_endo -75.43 18.05 0.61 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.715 2.276 . . . . 0.0 112.244 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.665 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.9 t -161.27 157.9 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.692 -1.255 . . . . 0.0 110.543 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.593 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -96.57 90.36 5.32 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 177.252 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.934 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.9 mt -90.63 120.04 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.258 -0.901 . . . . 0.0 112.36 -176.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.78 HD12 HG23 ' B' ' 31' ' ' THR . 0.5 OUTLIER -95.67 93.82 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.82 -157.28 13.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -61.76 -37.22 83.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.623 -0.928 . . . . 0.0 111.887 -178.186 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.956 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -44.67 -40.53 5.96 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.509 -1.37 . . . . 0.0 110.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.956 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.9 OUTLIER -96.73 -18.99 19.28 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.061 -1.024 . . . . 0.0 110.032 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.557 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 63.6 mt -73.8 -5.25 39.67 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.024 -1.048 . . . . 0.0 108.765 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.512 ' HB ' ' CH2' ' A' ' 6' ' ' TRP . 2.6 p -101.32 -21.17 14.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.081 -1.012 . . . . 0.0 109.067 179.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.8 mm-40 -74.36 -40.53 62.06 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.183 -0.948 . . . . 0.0 109.006 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.86 HD12 ' CG ' ' A' ' 99' ' ' PHE . 3.3 pt -88.15 -5.97 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.215 -0.928 . . . . 0.0 108.893 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.76 50.43 42.19 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.594 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.45 149.4 35.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.099 -1.236 . . . . 0.0 109.789 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.727 HG22 ' CG2' ' A' ' 4' ' ' THR . 47.6 p -138.48 128.4 25.32 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.696 HD13 HG21 ' B' ' 26' ' ' THR . 0.0 OUTLIER -86.96 111.36 20.76 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.287 -0.883 . . . . 0.0 110.745 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.583 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 1.0 OUTLIER -115.73 121.21 41.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.3 -0.875 . . . . 0.0 109.609 179.363 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.829 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.134 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.417 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.691 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.474 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.5 tt0 -83.16 141.39 31.98 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 105.623 -1.992 . . . . 0.0 105.623 177.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 72.9 t -137.95 126.04 30.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 C-N-CA 117.778 -1.569 . . . . 0.0 110.647 -177.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.577 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -120.87 7.35 10.42 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.693 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.3 OUTLIER -34.42 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.953 0.882 . . . . 0.0 109.709 -179.299 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.577 ' N ' ' O ' ' A' ' 4' ' ' THR . 6.9 m95 -41.49 -20.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.434 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.536 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.2 mt-30 -107.49 -155.98 0.57 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.691 -1.255 . . . . 0.0 109.78 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.694 ' HB3' HD13 ' A' ' 23' ' ' LEU . 62.0 mtt180 -76.21 115.79 50.13 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 110.413 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.596 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.6 Cg_endo -81.89 83.38 2.1 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 121.994 1.796 . . . . 0.0 109.019 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 1.01 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -78.52 166.9 22.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.332 -0.855 . . . . 0.0 109.615 -179.033 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.879 HG23 HG23 ' A' ' 13' ' ' ILE . 15.2 m -147.88 131.18 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.108 -0.995 . . . . 0.0 110.558 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.648 HG22 HD22 ' A' ' 19' ' ' LEU . 3.1 m -68.68 103.05 1.63 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.527 -1.358 . . . . 0.0 107.786 178.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.879 HG23 HG23 ' A' ' 11' ' ' VAL . 2.8 pt -102.42 137.34 30.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.244 -0.91 . . . . 0.0 111.207 -178.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.946 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -105.0 93.6 4.79 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.766 HD11 HD12 ' A' ' 64' ' ' ILE . 15.6 mt -104.48 124.35 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.455 -0.778 . . . . 0.0 109.488 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.75 13.0 68.36 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.88 7.72 77.43 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.555 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -105.77 171.72 7.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -1.131 . . . . 0.0 108.521 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.946 HD21 ' HD3' ' A' ' 14' ' ' LYS . 15.1 mt -123.6 130.58 52.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.869 -1.145 . . . . 0.0 110.959 -178.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.57 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.7 OUTLIER -150.41 143.13 24.6 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 1.01 ' HB3' HD23 ' A' ' 10' ' ' LEU . 9.1 mm-40 -78.88 127.46 32.05 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.961 -1.087 . . . . 0.0 109.101 -179.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.87 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -108.27 112.47 24.96 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.986 -1.071 . . . . 0.0 112.012 -178.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.694 HD13 ' HB3' ' A' ' 8' ' ' ARG . 11.9 tp -72.22 107.39 4.84 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.596 HD12 ' HB2' ' A' ' 9' ' ' PRO . 56.5 mt -46.79 142.97 3.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.864 -1.148 . . . . 0.0 108.294 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.622 ' HB3' HG22 ' A' ' 84' ' ' ILE . 11.4 t0 -156.79 99.59 1.86 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.844 -1.16 . . . . 0.0 110.272 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.405 ' HA ' HH12 ' A' ' 87' ' ' ARG . 10.9 m -76.12 -0.26 21.35 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.149 -0.97 . . . . 0.0 109.399 179.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.842 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -89.54 -26.48 25.1 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.616 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -81.39 124.4 29.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.12 -1.224 . . . . 0.0 109.089 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.633 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 42.8 m-20 -61.83 -16.42 49.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.853 . . . . 0.0 110.171 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.639 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 5.0 m-20 -145.16 -170.48 3.44 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.022 -1.071 . . . . 0.0 109.713 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.832 HG22 ' CD1' ' A' ' 33' ' ' LEU . 8.1 m -104.84 86.56 2.49 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 120.804 -1.185 . . . . 0.0 109.818 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.981 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.3 OUTLIER -70.04 163.13 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.265 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.981 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.5 OUTLIER -160.37 128.86 4.75 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.033 -1.042 . . . . 0.0 110.396 -178.01 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.8 tt0 -43.81 165.36 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.505 -0.878 . . . . 0.0 108.848 179.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.479 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -48.23 143.4 4.61 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.353 -179.426 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.794 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.5 OUTLIER -155.91 -168.31 2.73 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.464 -0.773 . . . . 0.0 109.025 179.737 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.7 t -122.17 111.15 16.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.847 -1.158 . . . . 0.0 111.196 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.81 HD23 ' CG ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -114.57 179.73 0.74 Allowed Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.714 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.571 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 36.1 Cg_endo -78.6 36.9 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.68 2.253 . . . . 0.0 112.502 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 55.59 33.03 58.76 Favored Glycine 0 N--CA 1.493 2.483 0 O-C-N 121.102 -0.999 . . . . 0.0 111.299 178.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.598 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 15.4 mmm180 -113.97 78.15 1.12 Allowed 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.485 -1.009 . . . . 0.0 108.337 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.567 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 59.8 p-90 -148.96 -177.41 5.79 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 120.985 -1.072 . . . . 0.0 111.37 -178.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.72 141.61 28.49 Favored Pre-proline 0 N--CA 1.487 1.377 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.47 131.23 13.54 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 C-N-CA 121.936 1.757 . . . . 0.0 111.025 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.559 ' CD ' ' HB2' ' A' ' 58' ' ' GLN . 13.1 ptmt -161.28 -169.8 2.44 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.54 -0.725 . . . . 0.0 109.233 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.486 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 38.4 mtp -151.34 137.98 18.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.36 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.768 HD11 HG21 ' B' ' 50' ' ' ILE . 15.4 pt -95.94 150.0 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 120.987 -1.07 . . . . 0.0 108.491 178.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.07 102.37 0.97 Allowed Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.08 -134.74 4.43 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.721 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.732 HG23 HD13 ' B' ' 54' ' ' ILE . 58.3 mt -83.02 122.87 38.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 CA-C-O 121.629 0.728 . . . . 0.0 112.548 -177.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 104.64 -53.77 0.66 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.504 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 178.33 -169.24 40.86 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.585 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.2 m-30 -102.37 135.28 44.26 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.282 . . . . 0.0 109.312 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.489 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.3 pt -101.52 176.1 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.131 -0.981 . . . . 0.0 109.352 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.527 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -105.35 142.02 35.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.241 -0.912 . . . . 0.0 109.323 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.538 HG12 ' HA3' ' A' ' 78' ' ' GLY . 31.1 m -150.93 -179.03 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 110.652 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.491 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -128.02 91.58 3.3 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.141 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.559 ' HB2' ' CD ' ' A' ' 45' ' ' LYS . 17.1 tt0 -51.29 102.98 0.05 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.443 0.639 . . . . 0.0 111.635 -178.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.81 ' CG ' HD23 ' A' ' 38' ' ' LEU . 24.8 m-85 -90.63 137.3 32.46 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -119.34 121.51 39.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.651 -1.281 . . . . 0.0 110.321 -179.091 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.583 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 5.4 mt-30 83.3 61.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.372 0.606 . . . . 0.0 109.882 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.732 HG21 HG21 ' A' ' 75' ' ' VAL . 2.7 mm -111.62 115.79 50.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.35 -0.844 . . . . 0.0 108.782 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.875 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.0 tm? -66.42 87.22 0.12 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.16 -0.963 . . . . 0.0 110.391 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 1.038 HD13 HD11 ' A' ' 66' ' ' ILE . 5.2 tt -88.8 122.94 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.49 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.0 tt0 -88.97 96.11 10.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.13 -0.981 . . . . 0.0 108.84 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.038 HD11 HD13 ' A' ' 64' ' ' ILE . 3.2 mt -101.51 122.8 54.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.334 -0.854 . . . . 0.0 110.043 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.579 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 60.93 44.66 10.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.636 -0.665 . . . . 0.0 109.773 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 55.7 33.32 59.45 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 90.7 m-70 -130.85 118.92 21.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.285 -1.127 . . . . 0.0 109.353 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.496 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -56.32 133.62 52.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 108.706 179.626 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -157.42 104.04 2.0 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 110.199 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.583 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -79.35 154.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 120.88 -1.138 . . . . 0.0 108.313 178.78 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.496 ' HA3' HD22 ' A' ' 89' ' ' LEU . . . -177.25 175.43 47.63 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.179 -1.486 . . . . 0.0 110.576 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 59' ' ' TYR . 3.7 m -85.34 115.28 23.0 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.586 -0.949 . . . . 0.0 110.158 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -103.94 109.49 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.121 -0.987 . . . . 0.0 110.288 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.611 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.2 mp -82.53 115.81 21.68 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.948 -1.095 . . . . 0.0 108.345 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 93.9 t -96.02 121.7 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.754 -1.216 . . . . 0.0 110.213 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.538 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -160.17 -170.84 25.27 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -81.02 42.68 1.39 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.926 2.417 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.664 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.4 t -82.8 141.73 44.61 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 108.564 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.9 Cg_endo -79.38 15.31 1.6 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.518 2.145 . . . . 0.0 110.98 -179.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 81' ' ' PRO . 14.1 t -160.43 158.41 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.929 -1.107 . . . . 0.0 110.22 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.57 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -102.06 91.13 4.19 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 176.217 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.622 HG22 ' HB3' ' A' ' 25' ' ' ASP . 41.8 mt -96.63 130.6 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.891 -1.131 . . . . 0.0 113.674 -174.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.87 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -89.3 131.9 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.639 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -110.96 -143.48 9.48 Favored Glycine 0 N--CA 1.498 2.797 0 O-C-N 120.688 -1.257 . . . . 0.0 110.847 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.633 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -77.83 -41.61 36.44 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.482 -179.464 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -54.63 -18.95 5.11 Favored 'General case' 0 N--CA 1.497 1.881 0 C-N-CA 117.438 -1.705 . . . . 0.0 110.246 -178.608 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.713 ' CB ' HG23 ' A' ' 85' ' ' ILE . 1.0 OUTLIER -103.03 -35.97 8.34 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.712 -1.243 . . . . 0.0 110.363 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.49 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 66.2 mt -68.86 -19.77 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.876 -1.14 . . . . 0.0 109.599 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.528 HG21 ' HA ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -93.86 -2.9 52.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.734 -1.229 . . . . 0.0 108.809 178.962 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.46 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.0 OUTLIER -99.44 -40.84 7.67 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.261 -0.9 . . . . 0.0 108.949 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.059 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -79.76 -16.1 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 N-CA-C 108.571 -0.899 . . . . 0.0 108.571 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 91.05 30.87 10.43 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.85 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -67.44 138.99 57.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.988 -1.301 . . . . 0.0 109.555 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.456 ' O ' ' O ' ' B' ' 96' ' ' THR . 3.0 p -132.76 128.49 36.94 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.151 -0.968 . . . . 0.0 108.558 179.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.665 HD13 HD23 ' B' ' 5' ' ' LEU . 4.3 mp -90.62 98.43 11.77 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.245 -0.909 . . . . 0.0 109.532 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.0 m120 -105.61 125.7 51.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.029 -1.044 . . . . 0.0 109.246 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.741 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 CA-C-O 117.959 -1.02 . . . . 0.0 109.295 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.509 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.68 0 N-CA-C 110.825 -0.49 . . . . 0.0 110.825 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.538 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.1 tt0 -85.71 134.27 33.97 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.834 HG12 ' H ' ' B' ' 5' ' ' LEU . 49.4 t -131.5 125.08 55.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.764 -1.21 . . . . 0.0 109.951 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.909 ' O ' HD12 ' B' ' 5' ' ' LEU . 46.7 p -75.89 3.58 9.81 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.48 -0.763 . . . . 0.0 109.656 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.909 HD12 ' O ' ' B' ' 4' ' ' THR . 0.4 OUTLIER 34.35 46.75 0.18 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.801 -0.562 . . . . 0.0 111.476 179.199 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.528 ' HA ' HG21 ' A' ' 91' ' ' THR . 58.8 m95 -57.63 -20.35 32.48 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -147.11 -164.55 2.02 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 1.075 ' HD2' HD13 ' B' ' 23' ' ' LEU . 0.5 OUTLIER -59.22 122.52 64.08 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 120.897 -1.127 . . . . 0.0 109.211 179.735 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.607 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -78.97 66.42 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.376 2.051 . . . . 0.0 109.635 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.536 HD22 ' CB ' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -81.15 145.65 30.93 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.107 -0.996 . . . . 0.0 109.827 -179.31 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.674 HG21 HG13 ' B' ' 66' ' ' ILE . 2.6 m -136.58 136.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.53 -0.731 . . . . 0.0 109.434 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -66.09 89.27 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.805 -1.184 . . . . 0.0 107.805 178.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.756 HG12 ' HB2' ' B' ' 22' ' ' ALA . 1.1 pp -80.67 131.52 33.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 109.596 -179.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.728 ' HE2' HD11 ' B' ' 19' ' ' LEU . 12.0 tttm -98.84 111.59 23.93 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.354 -0.841 . . . . 0.0 108.998 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.796 ' CG2' HD21 ' B' ' 38' ' ' LEU . 28.8 mt -116.38 134.65 59.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.221 -0.925 . . . . 0.0 108.9 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.66 -100.49 0.28 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -142.29 35.44 1.74 Allowed Glycine 0 N--CA 1.485 1.906 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 5.8 mt-30 -134.13 179.95 5.94 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.482 -1.011 . . . . 0.0 109.663 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.728 HD11 ' HE2' ' B' ' 14' ' ' LYS . 16.0 mt -147.39 130.26 16.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.531 -0.731 . . . . 0.0 109.139 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.451 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 39.0 mttp -146.12 171.77 14.42 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.166 -0.959 . . . . 0.0 109.199 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.536 ' CB ' HD22 ' B' ' 10' ' ' LEU . 2.9 mm-40 -79.03 148.48 32.48 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.756 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -136.16 108.28 7.22 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.056 . . . . 0.0 110.543 -178.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 1.075 HD13 ' HD2' ' B' ' 8' ' ' ARG . 18.8 tp -70.13 102.75 2.14 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' B' ' 9' ' ' PRO . 82.5 mt -53.7 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.055 -1.028 . . . . 0.0 108.867 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 1.003 ' CB ' HG23 ' B' ' 84' ' ' ILE . 35.2 t0 -91.92 90.06 7.28 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.391 -0.818 . . . . 0.0 110.519 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.643 HG22 ' NH2' ' B' ' 87' ' ' ARG . 7.3 m -71.05 -7.49 46.82 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 109.064 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.434 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -83.58 -31.3 27.61 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.42 173.15 12.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.875 -1.368 . . . . 0.0 109.337 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -101.72 -18.0 16.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.073 -1.017 . . . . 0.0 110.764 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.477 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.8 OUTLIER -137.35 -172.54 3.24 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.769 -1.207 . . . . 0.0 110.142 -179.357 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 1.012 HG23 HD12 ' B' ' 85' ' ' ILE . 55.3 m -102.59 82.43 2.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.093 -1.005 . . . . 0.0 109.89 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.012 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.71 161.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.881 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.012 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -153.25 129.52 10.51 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.587 -1.245 . . . . 0.0 111.618 -177.451 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.719 ' HA ' HG22 ' B' ' 80' ' ' THR . 9.5 tt0 -44.22 156.28 0.07 Allowed 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' B' ' 34' ' ' GLU . 0.5 OUTLIER -40.05 138.12 0.87 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 110.601 -179.074 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.555 ' O ' HG11 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -165.27 148.84 8.32 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.862 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.484 ' O ' ' SD ' ' B' ' 36' ' ' MET . 23.3 t -82.8 125.5 31.37 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.046 -1.034 . . . . 0.0 110.68 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.91 HD12 HG21 ' B' ' 77' ' ' VAL . 2.6 mt -122.93 164.03 29.67 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.271 -0.893 . . . . 0.0 108.653 179.03 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.485 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.7 Cg_endo -73.88 71.78 4.06 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.655 2.237 . . . . 0.0 112.539 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.8 -159.22 0.01 OUTLIER Glycine 0 N--CA 1.497 2.727 0 O-C-N 121.528 -0.732 . . . . 0.0 111.414 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.434 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 2.8 mmt180 61.11 66.54 0.88 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.568 -0.96 . . . . 0.0 109.196 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.591 ' CZ3' ' HD2' ' B' ' 57' ' ' ARG . 65.0 p-90 -149.79 -177.96 6.19 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.575 -0.703 . . . . 0.0 109.731 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' B' ' 57' ' ' ARG . 23.6 mtmt -150.82 160.35 32.5 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 108.974 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' B' ' 43' ' ' LYS . 34.7 Cg_endo -76.33 140.86 22.35 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.384 2.056 . . . . 0.0 110.241 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.621 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -157.81 120.8 3.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.342 -0.849 . . . . 0.0 109.058 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.476 ' HG3' ' CG ' ' B' ' 55' ' ' LYS . 2.5 ttt -101.18 126.72 47.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.082 -1.011 . . . . 0.0 109.94 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.696 HD11 HD11 ' B' ' 54' ' ' ILE . 10.0 pt -105.62 150.8 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.046 -1.034 . . . . 0.0 109.327 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.608 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -125.47 97.68 0.53 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.8 -130.9 4.09 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.291 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.768 HG21 HD11 ' A' ' 47' ' ' ILE . 66.3 mt -81.77 129.8 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.534 -0.98 . . . . 0.0 112.185 -178.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 100.21 -48.51 1.2 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 171.89 -164.63 37.29 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.655 -1.259 . . . . 0.0 109.994 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.608 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 3.1 m-85 -107.03 130.56 54.63 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.423 -1.045 . . . . 0.0 108.921 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.732 HD13 HG23 ' A' ' 50' ' ' ILE . 34.0 pt -112.7 155.18 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 120.977 -1.077 . . . . 0.0 109.885 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 18.6 mttt -98.95 140.62 32.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.184 -0.947 . . . . 0.0 108.68 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.956 HG12 ' HA3' ' B' ' 78' ' ' GLY . 9.9 m -143.7 -176.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.9 -1.125 . . . . 0.0 110.149 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.591 ' HD2' ' CZ3' ' B' ' 42' ' ' TRP . 69.0 mtm-85 -132.09 104.1 6.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.637 ' HG3' HG22 ' B' ' 74' ' ' THR . 8.5 tt0 -62.0 134.69 56.96 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.654 0.74 . . . . 0.0 110.967 -178.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.54 ' HB3' ' CG1' ' B' ' 62' ' ' ILE . 17.6 m-85 -121.61 93.93 4.16 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.515 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 9.1 m-20 -79.44 130.86 35.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.031 -1.043 . . . . 0.0 110.452 -178.659 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.515 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 6.9 mm100 83.22 62.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.329 0.585 . . . . 0.0 109.723 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.57 ' HB ' HG23 ' B' ' 75' ' ' VAL . 40.0 mm -119.86 115.72 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.343 -0.848 . . . . 0.0 109.063 179.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.848 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.8 tm? -66.48 91.86 0.19 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 110.453 -179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.726 HG12 HD12 ' B' ' 66' ' ' ILE . 7.3 tt -98.38 120.68 48.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.452 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.2 tt0 -90.53 111.88 23.34 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.947 -1.095 . . . . 0.0 109.491 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.726 HD12 HG12 ' B' ' 64' ' ' ILE . 1.0 OUTLIER -100.44 126.47 54.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.741 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.425 ' C ' ' O ' ' B' ' 66' ' ' ILE . 10.2 m 39.43 61.8 1.29 Allowed 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.71 -0.619 . . . . 0.0 110.63 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.3 41.05 86.5 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 120.175 -1.012 . . . . 0.0 111.121 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 2.7 m-70 -139.44 135.46 33.61 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.9 -1.353 . . . . 0.0 109.0 178.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.549 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -76.64 132.93 39.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.286 -0.884 . . . . 0.0 109.739 -179.614 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.709 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.6 97.17 1.96 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.835 . . . . 0.0 109.822 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.605 HG12 ' N ' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -83.54 136.85 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 178.638 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.642 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -161.58 -171.96 28.32 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.96 -1.59 . . . . 0.0 110.636 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.637 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.0 m -89.97 106.36 18.42 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.825 -0.809 . . . . 0.0 110.174 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -99.64 116.74 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.484 -0.76 . . . . 0.0 110.03 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.572 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.5 mp -85.33 139.05 31.89 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.91 HG21 HD12 ' B' ' 38' ' ' LEU . 1.6 t -121.32 114.49 43.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.066 -1.021 . . . . 0.0 109.647 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.956 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.06 -162.78 11.64 Favored Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.21 40.61 0.99 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.615 2.21 . . . . 0.0 111.471 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.719 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.5 t -84.88 137.87 37.73 Favored Pre-proline 0 N--CA 1.493 1.678 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.71 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.2 Cg_endo -77.31 14.43 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.565 2.177 . . . . 0.0 111.579 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.71 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.04 151.25 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.95 -1.094 . . . . 0.0 110.438 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.567 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 3.6 m-20 -90.62 102.88 15.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 176.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 1.003 HG23 ' CB ' ' B' ' 25' ' ' ASP . 2.2 mt -101.97 129.38 53.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 120.902 -1.124 . . . . 0.0 113.083 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 1.012 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -98.63 111.49 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.505 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -97.47 -161.3 31.33 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.835 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.643 ' NH2' HG22 ' B' ' 26' ' ' THR . 0.4 OUTLIER -58.4 -34.9 71.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.563 -0.963 . . . . 0.0 110.451 -179.791 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.007 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.6 p-10 -48.05 -27.95 2.56 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.867 -1.145 . . . . 0.0 109.913 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.007 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -109.75 -24.79 10.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.81 -1.181 . . . . 0.0 109.63 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.51 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 90.7 mt -72.43 -4.97 33.39 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.509 HG23 ' O ' ' B' ' 87' ' ' ARG . 74.4 p -100.51 -17.85 16.93 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -85.4 -41.21 15.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.354 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.741 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.5 pt -87.04 -4.03 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.29 50.56 38.02 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.136 178.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.677 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -73.05 157.77 36.69 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.071 -1.252 . . . . 0.0 110.198 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.54 HG22 ' CG2' ' A' ' 4' ' ' THR . 50.5 p -149.63 128.39 12.47 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.462 -0.773 . . . . 0.0 109.323 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.54 HD11 HD11 ' A' ' 97' ' ' LEU . 7.5 mp -89.68 104.32 16.89 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.6 m120 -107.64 127.29 53.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.05 . . . . 0.0 110.04 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 1.059 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.138 -0.934 . . . . 0.0 109.62 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.53 ' CD ' ' O ' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.726 0 N-CA-C 110.244 -0.714 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' B' ' 97' ' ' LEU . 1.7 tm0? -84.67 144.08 28.79 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.765 HG12 ' H ' ' A' ' 5' ' ' LEU . 38.1 t -145.28 123.34 4.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.911 -1.118 . . . . 0.0 109.984 -179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 18.6 p -60.51 -14.76 21.5 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.546 -0.721 . . . . 0.0 110.28 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.765 ' H ' HG12 ' A' ' 3' ' ' VAL . 39.5 mt 73.65 17.02 3.78 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.484 -0.76 . . . . 0.0 110.654 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.698 ' CE3' HG21 ' B' ' 91' ' ' THR . 0.3 OUTLIER -65.45 -12.61 54.1 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.842 -1.161 . . . . 0.0 108.789 179.252 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.521 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 29.7 mm-40 -146.47 178.86 7.95 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.9 mtt180 -72.97 116.08 46.83 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.916 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.745 ' HB2' HD12 ' A' ' 24' ' ' LEU . 32.7 Cg_endo -75.93 77.81 3.32 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 122.091 1.86 . . . . 0.0 110.107 178.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.568 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.88 167.83 19.44 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.111 -0.993 . . . . 0.0 109.11 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.806 HG23 HG23 ' A' ' 13' ' ' ILE . 27.3 m -150.22 130.0 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.763 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 1.08 HG22 HD22 ' A' ' 19' ' ' LEU . 91.9 m -66.95 92.18 0.23 Allowed 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.871 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.4 pt -86.71 143.05 12.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.418 -0.801 . . . . 0.0 111.216 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.79 ' HD2' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -108.46 97.78 7.4 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.166 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.971 HD12 HG11 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -115.69 140.38 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 110.223 -178.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 38' ' ' LEU . . . 49.7 29.23 12.27 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 178.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.57 38.26 57.63 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.568 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -136.2 179.43 6.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.477 -1.013 . . . . 0.0 108.284 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 1.08 HD22 HG22 ' A' ' 12' ' ' THR . 13.0 mt -144.55 118.98 9.63 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.957 -1.09 . . . . 0.0 109.801 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.571 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -135.44 150.18 49.79 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.605 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 14.9 mm-40 -78.81 112.51 16.02 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.819 -1.175 . . . . 0.0 108.133 179.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.884 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -91.85 140.46 29.66 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.934 0.873 . . . . 0.0 110.788 -178.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 24' ' ' LEU . 44.6 tp -93.74 97.1 10.21 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.745 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.2 mt -42.43 107.69 0.08 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.158 -0.964 . . . . 0.0 109.153 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.778 ' CB ' HG23 ' A' ' 84' ' ' ILE . 2.7 t70 -113.81 87.82 2.7 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -178.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.842 ' HA ' HD21 ' A' ' 90' ' ' LEU . 10.1 m -70.99 -5.68 32.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.114 -0.991 . . . . 0.0 109.081 178.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.639 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.6 -29.38 32.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 168.59 19.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.214 -1.168 . . . . 0.0 109.691 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -100.19 -19.82 16.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.394 -0.816 . . . . 0.0 109.656 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 39.4 m-20 -133.7 -167.18 1.9 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -0.971 . . . . 0.0 109.74 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.547 HG22 ' O ' ' A' ' 31' ' ' THR . 8.0 m -111.06 89.74 3.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.035 -1.04 . . . . 0.0 110.193 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.018 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -68.14 172.08 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.132 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.072 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -167.96 113.99 0.69 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.189 -0.944 . . . . 0.0 109.557 -179.511 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.735 ' HA ' HG22 ' A' ' 80' ' ' THR . 9.7 pt-20 -36.24 154.84 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.445 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -44.16 134.86 4.65 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.088 -1.008 . . . . 0.0 109.922 -178.915 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.697 ' HE1' HG22 ' A' ' 15' ' ' ILE . 2.3 ppp? -154.31 -163.72 1.68 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.595 -0.691 . . . . 0.0 109.644 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.513 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 3.1 t -107.81 118.27 36.29 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.921 -1.112 . . . . 0.0 111.149 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.746 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -131.32 -173.57 0.34 Allowed Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 178.512 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.657 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.6 Cg_endo -78.97 -163.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.919 1.746 . . . . 0.0 110.861 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -114.18 31.56 6.41 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -118.98 63.82 0.78 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 21.2 p-90 -130.38 -175.39 3.63 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.764 0.792 . . . . 0.0 110.207 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -139.85 156.51 70.71 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.65 141.56 24.96 Favored 'Trans proline' 0 C--N 1.303 -1.849 0 C-N-CA 121.868 1.712 . . . . 0.0 109.68 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 1.3 tttt -149.94 170.14 19.52 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.445 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -144.27 113.81 7.1 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.655 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.606 ' CD1' HG21 ' B' ' 50' ' ' ILE . 24.9 pt -89.47 141.62 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.079 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.615 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -119.32 115.46 3.05 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -136.84 -115.05 1.38 Allowed Glycine 0 N--CA 1.485 1.905 0 C-N-CA 119.212 -1.471 . . . . 0.0 111.088 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.692 HG21 HD12 ' B' ' 47' ' ' ILE . 17.1 mt -94.07 118.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.733 -0.863 . . . . 0.0 112.585 -177.116 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.89 -11.31 67.99 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.452 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 137.4 -177.54 19.76 Favored Glycine 0 N--CA 1.493 2.489 0 O-C-N 120.806 -1.408 . . . . 0.0 109.647 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.5 OUTLIER -102.64 143.92 31.7 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -1.133 . . . . 0.0 109.844 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.59 HD11 HG13 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -109.19 -178.21 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.258 -0.901 . . . . 0.0 108.703 178.909 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.58 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 2.4 mttp -109.09 141.7 40.88 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.038 -1.039 . . . . 0.0 109.643 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -147.61 -171.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.05 -1.031 . . . . 0.0 109.521 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.406 ' HG3' ' C ' ' A' ' 56' ' ' VAL . 1.6 mtt180 -133.46 108.12 8.46 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.441 ' HB2' ' HD2' ' A' ' 45' ' ' LYS . 1.3 tt0 -65.28 97.17 0.26 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.322 -0.861 . . . . 0.0 110.428 -179.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.746 ' CD2' HD23 ' A' ' 38' ' ' LEU . 10.3 m-85 -89.93 123.22 33.67 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -105.58 134.89 47.96 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.736 -1.227 . . . . 0.0 110.665 -178.589 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mp0 73.22 63.22 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 121.695 0.76 . . . . 0.0 110.195 179.239 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.526 HG13 ' HB3' ' A' ' 59' ' ' TYR . 22.1 mm -117.27 127.27 74.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.586 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -76.37 89.08 3.18 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 112.276 -177.523 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.747 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -90.48 112.96 25.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 CA-C-O 121.888 0.852 . . . . 0.0 108.822 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.537 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -89.5 113.03 24.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.778 -1.201 . . . . 0.0 108.515 -179.69 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.747 HD11 HD13 ' A' ' 64' ' ' ILE . 2.9 mt -115.17 126.64 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.922 -1.111 . . . . 0.0 110.67 -178.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.2 m 66.75 24.91 9.82 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.638 -0.664 . . . . 0.0 109.895 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.431 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 80.58 7.44 88.55 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 61.0 m-70 -108.86 110.03 21.28 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.208 -1.172 . . . . 0.0 109.226 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.542 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.2 ttpt -52.58 136.29 32.79 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.474 -0.767 . . . . 0.0 109.026 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.94 118.38 4.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.618 -0.676 . . . . 0.0 109.36 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.586 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -95.07 158.06 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 120.807 -1.183 . . . . 0.0 108.036 178.709 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.479 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 177.42 -170.15 42.54 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.734 -1.698 . . . . 0.0 111.47 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 1.5 m -91.18 113.25 25.46 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.918 . . . . 0.0 110.146 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.072 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -107.93 109.49 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.525 -0.734 . . . . 0.0 111.135 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.594 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.9 mp -80.2 125.08 29.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.276 -0.89 . . . . 0.0 109.056 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 89.9 t -113.25 131.91 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.999 -1.063 . . . . 0.0 109.853 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -164.47 -167.57 25.21 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.58 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -81.81 40.74 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.592 2.195 . . . . 0.0 110.534 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.735 HG22 ' HA ' ' A' ' 34' ' ' GLU . 14.9 t -81.74 140.72 47.47 Favored Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.72 13.06 1.75 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 C-N-CA 122.227 1.952 . . . . 0.0 111.196 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.647 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.45 163.49 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.74 -1.225 . . . . 0.0 110.731 -179.755 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.642 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 60.0 m-20 -95.8 142.88 27.55 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 176.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 25' ' ' ASP . 12.3 mm -131.95 124.63 53.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.467 -1.396 . . . . 0.0 111.337 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.884 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -102.96 94.72 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.656 ' C ' HD13 ' A' ' 90' ' ' LEU . . . -100.75 171.21 22.61 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.382 -177.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.622 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.1 OUTLIER -21.71 -41.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -179.392 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.978 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.8 p-10 -51.1 -42.89 60.94 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.282 -1.511 . . . . 0.0 110.774 -177.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.978 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -97.54 -11.04 24.18 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.146 -0.971 . . . . 0.0 110.414 -179.137 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.842 HD21 ' HA ' ' A' ' 26' ' ' THR . 5.7 mp -69.73 -35.14 74.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.084 -1.01 . . . . 0.0 108.788 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 p -70.5 -15.42 62.79 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.455 -0.778 . . . . 0.0 109.252 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.6 mm-40 -89.13 -41.42 12.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.019 . . . . 0.0 109.27 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.674 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.9 pt -81.99 -1.89 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 57.19 54.95 33.11 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.876 ' HB3' HD12 ' B' ' 5' ' ' LEU . . . -85.42 127.62 34.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.422 -1.046 . . . . 0.0 110.26 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 69.9 p -122.31 124.9 44.82 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -89.98 100.48 13.29 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.406 -0.809 . . . . 0.0 109.384 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 1.6 m120 -105.96 129.33 54.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.234 -0.916 . . . . 0.0 110.048 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.736 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.265 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.404 -0.652 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.443 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 6.7 tt0 -84.25 129.45 34.88 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 11.4 t -121.76 96.23 4.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.762 -1.212 . . . . 0.0 109.499 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.418 HG23 ' H ' ' B' ' 4' ' ' THR . 3.0 p -55.73 135.11 51.73 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.876 HD12 ' HB3' ' A' ' 95' ' ' ALA . 89.5 mt -83.36 4.42 27.46 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.765 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -57.05 -20.19 23.21 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -135.4 157.67 46.31 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.0 mtt180 -53.25 125.5 42.65 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 120.886 -1.134 . . . . 0.0 109.371 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.799 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.4 Cg_endo -77.65 71.23 6.59 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.281 1.987 . . . . 0.0 109.819 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -90.63 144.62 25.57 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.26 -179.686 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.659 HG21 HG12 ' B' ' 66' ' ' ILE . 3.1 m -135.14 132.71 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 110.203 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.809 HG22 HD22 ' B' ' 19' ' ' LEU . 91.8 m -65.6 109.56 2.43 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 1.034 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.1 pt -98.58 144.23 11.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 110.841 -178.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.483 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -112.16 101.9 10.12 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' B' ' 13' ' ' ILE . 11.8 mt -118.58 118.87 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.162 -0.961 . . . . 0.0 109.766 -179.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.421 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.83 27.25 73.67 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.2 -2.78 74.84 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.423 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.4 mp0 -90.07 -179.34 5.66 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.329 -1.101 . . . . 0.0 108.973 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 1.034 HD23 ' O ' ' B' ' 13' ' ' ILE . 12.4 mt -153.17 124.02 7.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.193 -0.942 . . . . 0.0 110.269 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.443 ' NZ ' HD23 ' B' ' 33' ' ' LEU . 8.4 mtmt -143.89 158.63 43.57 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.4 OUTLIER -79.29 133.05 36.64 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.978 -1.076 . . . . 0.0 109.54 -179.114 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.824 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.7 156.25 19.29 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.248 -0.908 . . . . 0.0 110.022 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.639 HD21 ' O ' ' A' ' 27' ' ' GLY . 62.4 tp -115.6 95.35 5.1 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.871 HD22 HD21 ' B' ' 90' ' ' LEU . 24.1 mt -42.15 103.44 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.393 -0.817 . . . . 0.0 109.359 -179.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.509 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 48.8 t0 -114.55 91.02 3.48 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.142 -0.974 . . . . 0.0 110.275 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.563 HG21 HD22 ' A' ' 5' ' ' LEU . 0.9 OUTLIER -68.88 -7.56 35.82 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.066 -1.021 . . . . 0.0 108.73 178.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.429 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -73.8 -41.57 41.54 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.71 166.21 23.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.149 -1.206 . . . . 0.0 109.886 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -100.93 -19.91 15.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.145 -0.972 . . . . 0.0 110.786 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.499 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -130.6 -168.17 1.94 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.874 -1.141 . . . . 0.0 109.644 -179.445 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.596 HG22 ' CD1' ' B' ' 33' ' ' LEU . 16.7 m -109.74 95.66 5.75 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.911 -1.118 . . . . 0.0 110.286 -179.066 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.993 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -77.38 162.14 4.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 179.023 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.032 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -160.74 125.78 3.75 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 120.456 -1.402 . . . . 0.0 111.288 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 33' ' ' LEU . 3.7 tt0 -38.89 159.17 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.724 -0.61 . . . . 0.0 109.677 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.78 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -51.35 150.26 3.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.95 . . . . 0.0 110.285 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.534 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.9 ppp? -168.5 -169.16 1.01 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.293 -0.879 . . . . 0.0 109.11 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.52 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.6 t -121.19 124.42 44.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.929 -1.107 . . . . 0.0 110.372 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.868 HD21 HD12 ' B' ' 62' ' ' ILE . 0.1 OUTLIER -124.64 -172.82 0.26 Allowed Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.347 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.648 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.8 Cg_endo -80.8 59.87 7.63 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.292 1.995 . . . . 0.0 111.005 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.95 -157.92 0.06 OUTLIER Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.414 ' HD3' ' HA ' ' B' ' 41' ' ' ARG . 50.7 mmt-85 51.91 96.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.544 -0.974 . . . . 0.0 109.077 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.453 ' CE3' ' HG3' ' B' ' 57' ' ' ARG . 16.7 p-90 -155.02 171.93 18.94 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.691 -0.631 . . . . 0.0 109.683 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.24 121.4 20.52 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.26 141.5 18.31 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.412 2.075 . . . . 0.0 111.423 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.28 -171.93 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.516 ' HG2' ' HG3' ' B' ' 55' ' ' LYS . 17.1 mtp -143.54 133.97 24.74 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.903 -1.123 . . . . 0.0 110.098 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.692 HD12 HG21 ' A' ' 50' ' ' ILE . 19.4 pt -104.94 139.43 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 0.0 108.8 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.9 97.35 0.7 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.294 -1.922 . . . . 0.0 108.294 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.22 -121.37 2.88 Favored Glycine 0 N--CA 1.485 1.914 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.682 -178.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.606 HG21 ' CD1' ' A' ' 47' ' ' ILE . 11.2 mt -86.58 124.79 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.854 -0.792 . . . . 0.0 111.982 -177.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 101.49 -53.46 0.83 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 176.76 -161.81 29.9 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -111.38 137.33 49.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -1.198 . . . . 0.0 109.359 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.591 HD11 HD11 ' B' ' 47' ' ' ILE . 27.6 pt -117.14 159.17 17.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.253 -0.904 . . . . 0.0 109.535 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.527 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.5 OUTLIER -94.69 126.26 39.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 108.8 179.313 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.585 HG12 ' HA3' ' B' ' 78' ' ' GLY . 12.5 m -134.2 153.68 36.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.542 ' N ' ' HD2' ' B' ' 57' ' ' ARG . 2.3 mpt_? -91.63 179.78 5.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -138.61 93.06 2.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.131 -0.98 . . . . 0.0 110.523 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.599 ' CG ' HD23 ' B' ' 38' ' ' LEU . 67.2 m-85 -89.29 92.53 9.2 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 49.0 m-20 -78.62 143.11 36.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.046 -1.034 . . . . 0.0 109.381 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.586 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.1 OUTLIER 74.1 64.18 0.08 Allowed 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.529 -0.732 . . . . 0.0 109.189 -179.571 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.868 HD12 HD21 ' B' ' 38' ' ' LEU . 1.1 mm -121.07 117.15 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.741 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.4 tm? -68.62 85.27 0.3 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.476 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.613 HG22 ' O ' ' B' ' 71' ' ' ALA . 3.4 tt -91.02 117.67 34.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.9 tt0 -89.53 111.47 22.4 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.063 -1.023 . . . . 0.0 109.563 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.35 120.3 54.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.79 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 88.2 m 65.36 20.42 11.81 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.788 -0.57 . . . . 0.0 110.166 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.26 1.61 78.46 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.112 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -97.9 123.0 41.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.214 -1.168 . . . . 0.0 109.123 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.493 ' HG2' HD21 ' B' ' 63' ' ' LEU . 3.9 mtpt -58.71 133.85 56.3 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.613 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -150.96 99.67 2.72 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.014 -1.053 . . . . 0.0 110.26 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.711 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.5 OUTLIER -79.55 144.54 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.668 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.74 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.43 -177.8 39.2 Favored Glycine 0 N--CA 1.486 1.991 0 C-N-CA 118.915 -1.612 . . . . 0.0 110.634 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.449 HG23 ' OD1' ' B' ' 60' ' ' ASP . 22.0 m -95.83 102.99 14.85 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.723 -0.869 . . . . 0.0 109.432 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.032 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.9 OUTLIER -92.58 162.11 2.45 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.704 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.0 mp -129.95 140.35 50.94 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' B' ' 35' ' ' GLU . 9.2 t -120.8 103.19 13.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 O-C-N 121.386 -0.821 . . . . 0.0 110.507 -178.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.585 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -142.54 -166.12 10.87 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.527 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.5 Cg_endo -80.94 41.31 1.12 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.583 2.189 . . . . 0.0 110.956 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -84.45 138.21 38.8 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.29 14.51 1.56 Allowed 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.193 1.928 . . . . 0.0 111.497 -179.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.541 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.7 OUTLIER -161.13 171.21 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.903 -1.123 . . . . 0.0 110.11 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -105.97 116.07 31.31 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 176.591 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.733 HG12 HG12 ' B' ' 32' ' ' VAL . 5.0 mm -100.45 120.59 50.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 O-C-N 120.661 -1.274 . . . . 0.0 111.562 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.824 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -95.37 89.83 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.838 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.08 -164.33 27.27 Favored Glycine 0 N--CA 1.493 2.474 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.437 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.521 ' NH2' ' HA ' ' A' ' 7' ' ' GLN . 13.5 mtm180 -60.76 -39.79 90.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.786 -0.832 . . . . 0.0 110.548 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -45.28 -26.49 0.52 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.093 -1.005 . . . . 0.0 110.181 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -108.7 -29.56 8.64 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.026 -1.047 . . . . 0.0 111.041 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.871 HD21 HD22 ' B' ' 24' ' ' LEU . 71.9 mt -65.15 -9.62 24.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.716 -1.24 . . . . 0.0 108.748 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.698 HG21 ' CE3' ' A' ' 6' ' ' TRP . 1.2 p -101.03 -20.71 15.26 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.176 -0.952 . . . . 0.0 109.391 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 36.6 mm-40 -78.06 -40.81 37.46 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.071 -1.018 . . . . 0.0 109.141 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.736 HD12 ' CG ' ' A' ' 99' ' ' PHE . 4.4 pt -86.03 -4.02 9.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 77.28 29.47 56.2 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.558 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -59.97 151.0 27.26 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.042 -1.269 . . . . 0.0 109.037 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.524 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 2.6 p -136.6 173.7 11.42 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' A' ' 97' ' ' LEU . 0.5 OUTLIER -134.31 98.82 4.2 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.735 -1.228 . . . . 0.0 110.088 -179.371 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.7 m120 -99.23 118.62 36.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.964 -1.085 . . . . 0.0 109.37 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.674 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.508 0 CA-C-O 117.94 -1.029 . . . . 0.0 108.935 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.542 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 N-CA-C 110.231 -0.719 . . . . 0.0 110.231 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.497 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.43 131.07 34.71 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 178.204 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.559 HG21 ' HZ ' ' B' ' 99' ' ' PHE . 4.1 t -121.79 94.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.991 -1.068 . . . . 0.0 109.768 -178.259 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.528 ' CG2' ' HB ' ' B' ' 96' ' ' THR . 19.3 p -126.01 45.67 2.58 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.335 -0.853 . . . . 0.0 108.93 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 1.03 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.5 OUTLIER -89.07 36.47 0.82 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.187 -0.946 . . . . 0.0 109.589 -179.721 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 13.4 m0 17.45 51.86 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 CA-C-O 121.631 0.729 . . . . 0.0 111.512 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 1.03 ' HB2' HD12 ' A' ' 5' ' ' LEU . 49.4 mt-30 -156.02 -159.78 0.94 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 10.1 mtm180 -79.66 113.34 36.6 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.986 -1.071 . . . . 0.0 109.909 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.77 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.3 Cg_endo -79.79 80.27 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 C-N-CA 122.355 2.037 . . . . 0.0 110.055 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -100.13 164.78 11.82 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.846 -179.749 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.987 HG21 HG23 ' A' ' 66' ' ' ILE . 2.3 m -148.86 129.47 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 110.256 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.3 m -69.22 94.05 0.66 Allowed 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 178.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.805 HG23 HG23 ' A' ' 11' ' ' VAL . 7.7 pt -82.95 167.42 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 110.949 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.3 tttt -128.65 102.88 6.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.559 -0.713 . . . . 0.0 109.25 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.952 HD11 HD12 ' A' ' 64' ' ' ILE . 11.6 mt -124.47 147.93 28.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 120.987 -1.07 . . . . 0.0 109.592 -179.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.03 32.53 4.83 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.9 43.62 90.97 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.6 tp-100 -138.52 170.79 15.38 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.191 -1.182 . . . . 0.0 109.022 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.484 HD23 ' O ' ' A' ' 13' ' ' ILE . 39.3 mt -135.57 126.41 27.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.385 -0.822 . . . . 0.0 109.445 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.41 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 2.3 mtpm? -148.22 158.65 44.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.406 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.4 mt-10 -79.17 123.81 27.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.585 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -105.08 141.98 35.67 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.333 -0.854 . . . . 0.0 110.225 -178.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.871 HD21 ' O ' ' B' ' 27' ' ' GLY . 19.8 tp -97.67 103.82 15.79 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.747 -0.595 . . . . 0.0 109.918 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.77 HD12 ' HB2' ' A' ' 9' ' ' PRO . 12.1 mt -44.62 113.62 0.58 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 178.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.486 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 25.4 t0 -119.64 89.13 3.07 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.948 -1.095 . . . . 0.0 111.65 -177.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.57 -2.95 35.04 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.909 -1.119 . . . . 0.0 108.562 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 1.023 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -90.78 -25.12 25.95 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 162.13 19.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.953 -1.322 . . . . 0.0 109.027 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -98.1 -13.06 21.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.115 -0.991 . . . . 0.0 110.287 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.513 ' OD1' ' HB ' ' A' ' 74' ' ' THR . 0.2 OUTLIER -142.78 -175.05 4.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.93 -1.106 . . . . 0.0 109.732 -179.957 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.57 HG23 HD12 ' A' ' 85' ' ' ILE . 22.6 m -104.63 91.83 4.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.703 -1.248 . . . . 0.0 111.226 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.027 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.29 173.34 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.643 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.027 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.32 122.78 1.08 Allowed 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.688 -1.257 . . . . 0.0 111.547 -179.417 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.57 ' HA ' HG22 ' A' ' 80' ' ' THR . 12.6 tt0 -39.97 149.21 0.07 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.668 -0.645 . . . . 0.0 109.362 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.426 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -48.68 141.88 6.72 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.191 -0.943 . . . . 0.0 110.295 -179.599 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.514 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -163.64 -172.28 2.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.344 -0.848 . . . . 0.0 109.313 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.2 t -92.7 83.95 4.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.001 -1.062 . . . . 0.0 109.626 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.879 HD11 HD12 ' A' ' 62' ' ' ILE . 61.6 tp -116.2 98.34 51.17 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -78.37 167.3 23.18 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.656 2.237 . . . . 0.0 110.642 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.61 171.93 13.9 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 133.41 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -1.154 . . . . 0.0 108.684 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.615 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 52.5 p-90 -136.67 -177.42 4.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.163 -0.961 . . . . 0.0 110.691 -178.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.401 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 1.1 tptt -146.28 162.98 32.54 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.401 ' HD2' ' CG ' ' A' ' 43' ' ' LYS . 33.8 Cg_endo -78.0 140.36 17.98 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.756 1.638 . . . . 0.0 109.688 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.591 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -155.4 115.31 3.72 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.105 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.496 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -100.93 122.51 43.61 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.196 -0.94 . . . . 0.0 109.01 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.578 HD12 HG21 ' B' ' 50' ' ' ILE . 22.6 pt -93.24 139.26 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.016 -1.052 . . . . 0.0 109.109 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.606 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.64 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.641 -1.783 . . . . 0.0 108.641 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.74 -121.92 2.55 Favored Glycine 0 N--CA 1.483 1.812 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.698 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.793 HG21 HD12 ' B' ' 47' ' ' ILE . 26.3 mt -86.48 122.23 38.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.875 -0.779 . . . . 0.0 112.571 -177.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.447 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 103.49 -50.98 0.85 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 176.26 -156.94 22.29 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.606 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 5.2 m-85 -111.9 129.9 56.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -1.034 . . . . 0.0 109.837 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.561 HG13 ' CG1' ' A' ' 47' ' ' ILE . 1.0 OUTLIER -106.97 164.76 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.1 mtmt -106.82 140.28 39.91 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.865 -1.147 . . . . 0.0 110.497 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.861 HG12 ' HA3' ' A' ' 78' ' ' GLY . 16.1 m -146.63 178.18 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.83 110.63 16.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.329 -0.857 . . . . 0.0 108.829 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.414 ' O ' ' CG ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -64.75 107.03 1.32 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.456 -0.778 . . . . 0.0 110.271 -179.247 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.615 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.2 m-85 -100.89 100.45 11.08 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.535 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 85.2 m-20 -83.82 132.62 34.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.051 -1.031 . . . . 0.0 110.85 -178.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.2 mt-30 81.17 60.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.82 -0.55 . . . . 0.0 110.767 178.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.879 HD12 HD11 ' A' ' 38' ' ' LEU . 5.1 mm -117.93 118.46 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.156 HD21 ' CG ' ' A' ' 70' ' ' LYS . 1.4 tp -70.35 86.52 0.6 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.035 -1.04 . . . . 0.0 111.145 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.952 HD12 HD11 ' A' ' 15' ' ' ILE . 5.6 tt -86.54 119.75 35.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.79 103.98 16.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.936 -1.102 . . . . 0.0 109.165 -178.589 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.987 HG23 HG21 ' A' ' 11' ' ' VAL . 3.2 mt -109.61 120.93 61.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.479 -0.763 . . . . 0.0 109.717 -179.311 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.601 ' HB3' ' CD2' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 64.42 40.21 6.5 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.531 -0.731 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.24 30.49 76.11 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.601 ' CD2' ' HB3' ' A' ' 67' ' ' CYS . 87.9 m-70 -122.69 101.38 7.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -1.19 . . . . 0.0 109.592 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 1.156 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -53.04 108.88 0.36 Allowed 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.156 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.74 ' O ' HD12 ' A' ' 63' ' ' LEU . . . -126.56 148.35 49.75 Favored 'General case' 0 C--N 1.287 -2.14 0 C-N-CA 120.304 -0.558 . . . . 0.0 109.603 -179.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 63' ' ' LEU . 1.0 OUTLIER -118.68 147.42 22.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.504 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.817 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -172.45 -168.26 33.6 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 118.789 -1.672 . . . . 0.0 110.987 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.513 ' HB ' ' OD1' ' A' ' 30' ' ' ASP . 27.9 m -96.98 108.0 20.64 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.659 -0.906 . . . . 0.0 109.409 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.801 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.21 111.06 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.469 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.3 mp -81.12 118.38 22.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.057 -1.027 . . . . 0.0 108.306 178.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.426 HG12 ' HA ' ' A' ' 35' ' ' GLU . 8.5 t -104.89 109.99 29.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.124 -0.985 . . . . 0.0 109.68 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.861 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -148.16 -162.16 9.98 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.538 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -81.66 43.78 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.637 2.225 . . . . 0.0 110.599 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.57 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.1 t -84.75 136.33 39.31 Favored Pre-proline 0 N--CA 1.491 1.576 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -79.07 14.54 1.71 Allowed 'Trans proline' 0 C--N 1.307 -1.614 0 C-N-CA 122.389 2.059 . . . . 0.0 110.983 -179.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.2 t -159.9 164.65 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.11 -0.994 . . . . 0.0 109.101 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.531 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -101.36 126.21 48.09 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 104.831 -2.285 . . . . 0.0 104.831 176.649 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 31' ' ' THR . 7.6 mm -113.32 128.94 69.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.333 -1.347 . . . . 0.0 111.794 -176.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.53 90.91 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 177.138 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.75 ' O ' HD22 ' A' ' 90' ' ' LEU . . . -83.97 173.6 50.66 Favored Glycine 0 N--CA 1.498 2.774 0 O-C-N 121.198 -0.939 . . . . 0.0 110.97 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.678 ' HA ' HD23 ' A' ' 90' ' ' LEU . 8.8 mmm180 -39.89 -39.97 0.92 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.806 -0.82 . . . . 0.0 111.335 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.992 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.2 p-10 -44.55 -41.18 6.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.739 -1.226 . . . . 0.0 109.986 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.992 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.7 mm? -96.67 -26.62 15.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.237 -0.914 . . . . 0.0 111.745 -179.045 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.75 HD22 ' O ' ' A' ' 86' ' ' GLY . 0.8 OUTLIER -60.28 -36.25 77.41 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.292 -1.505 . . . . 0.0 108.0 179.71 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 81.6 p -70.05 -21.58 63.15 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 108.846 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.42 ' HB2' ' O ' ' A' ' 89' ' ' LEU . 22.3 mm-40 -74.78 -40.66 61.04 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.723 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -86.31 -13.08 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.384 -0.822 . . . . 0.0 108.937 179.444 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 83.92 26.78 40.05 Favored Glycine 0 N--CA 1.495 2.633 0 C-N-CA 120.32 -0.943 . . . . 0.0 111.042 178.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.556 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -59.5 143.16 50.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 109.865 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.458 HG22 ' CG2' ' B' ' 4' ' ' THR . 74.2 p -135.34 129.58 33.66 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.401 HD11 HD11 ' B' ' 97' ' ' LEU . 3.7 mp -92.63 99.26 12.0 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.907 -1.12 . . . . 0.0 110.688 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.573 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.4 m120 -108.0 124.48 50.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.413 -0.804 . . . . 0.0 109.046 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.73 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 118.037 -0.983 . . . . 0.0 109.163 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.273 -0.703 . . . . 0.0 110.273 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.573 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.5 tt0 -83.39 144.11 29.85 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.6 t -141.98 105.83 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.364 -1.334 . . . . 0.0 110.87 -177.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.458 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.2 OUTLIER -106.61 -86.51 0.49 Allowed 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 178.137 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.55 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 43.52 20.38 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.576 -0.702 . . . . 0.0 111.308 178.498 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 40.4 m0 16.24 52.16 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.234 0.54 . . . . 0.0 112.16 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.55 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.4 mt-30 -144.03 -128.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.45 130.93 22.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.642 -1.286 . . . . 0.0 109.662 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.873 ' HB2' HD12 ' B' ' 24' ' ' LEU . 37.1 Cg_endo -82.52 53.63 4.56 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.456 2.104 . . . . 0.0 109.301 178.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.68 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.7 mt -79.05 143.73 35.33 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.237 -0.914 . . . . 0.0 109.31 -179.175 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 1.062 HG21 HG23 ' B' ' 66' ' ' ILE . 0.8 OUTLIER -142.38 150.89 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -0.823 . . . . 0.0 109.452 -179.713 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 89.8 m -83.92 109.01 17.26 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.751 HD11 HD21 ' B' ' 33' ' ' LEU . 1.1 pt -98.89 139.26 21.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.148 -0.97 . . . . 0.0 111.102 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.463 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.7 OUTLIER -98.5 98.31 9.52 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.867 HD11 HD12 ' B' ' 64' ' ' ILE . 4.9 mt -120.3 130.64 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.342 -0.849 . . . . 0.0 109.337 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.29 23.54 71.7 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.4 15.72 80.2 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.463 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -112.25 174.08 6.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.422 -1.046 . . . . 0.0 109.31 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.484 ' HA ' HD23 ' B' ' 19' ' ' LEU . 27.9 mt -134.8 113.91 12.09 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.248 -0.907 . . . . 0.0 110.018 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -134.85 177.48 7.76 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.5 mm-40 -79.58 177.78 8.62 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.859 -1.15 . . . . 0.0 108.883 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.651 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -159.18 101.53 1.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.322 -0.861 . . . . 0.0 109.447 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 1.023 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.3 tp -77.97 98.89 5.84 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.291 -0.88 . . . . 0.0 109.438 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.873 HD12 ' HB2' ' B' ' 9' ' ' PRO . 89.6 mt -45.42 104.74 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.055 -1.028 . . . . 0.0 108.585 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.988 ' HB3' HG23 ' B' ' 84' ' ' ILE . 39.5 t0 -111.69 91.43 3.66 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.356 -0.84 . . . . 0.0 110.646 -178.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.444 HG23 HH11 ' B' ' 87' ' ' ARG . 55.9 m -69.79 -11.57 60.96 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.119 -0.988 . . . . 0.0 108.459 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.871 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -69.24 -39.85 82.03 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.26 150.67 29.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.342 -1.093 . . . . 0.0 109.481 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -91.19 -10.04 43.17 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.23 -0.919 . . . . 0.0 109.805 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.479 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -131.81 -173.13 3.05 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.274 -0.892 . . . . 0.0 109.546 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.664 HG22 ' CD1' ' B' ' 33' ' ' LEU . 29.9 m -113.44 98.51 7.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.01 -1.056 . . . . 0.0 110.229 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.914 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -83.33 166.01 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.017 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -162.8 126.58 2.94 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.59 -1.319 . . . . 0.0 111.354 -178.438 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.582 ' N ' HG22 ' B' ' 80' ' ' THR . 8.5 tt0 -42.9 154.57 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.602 ' HA ' HG13 ' B' ' 77' ' ' VAL . 1.6 tm-20 -38.8 148.54 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.349 -0.844 . . . . 0.0 110.366 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.577 ' CE ' HG22 ' B' ' 15' ' ' ILE . 24.5 ptm -163.57 -162.31 0.72 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.324 -0.86 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.5 t -118.68 120.2 36.73 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.083 -1.01 . . . . 0.0 110.794 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.761 HD23 ' CD2' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -124.6 173.66 4.53 Favored Pre-proline 0 N--CA 1.491 1.592 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.019 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.59 ' HD3' HD12 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.72 47.72 2.61 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.676 2.25 . . . . 0.0 111.634 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.12 -166.88 0.01 OUTLIER Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.408 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.5 mmm180 63.38 70.73 0.52 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.168 -1.195 . . . . 0.0 109.361 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.618 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 10.1 p-90 -140.41 -173.43 3.67 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 121.629 -0.669 . . . . 0.0 109.519 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.94 128.58 16.76 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.216 -0.927 . . . . 0.0 108.516 179.292 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -75.34 139.54 23.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 121.879 1.719 . . . . 0.0 110.749 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.17 -162.7 1.57 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.528 -0.732 . . . . 0.0 109.232 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.555 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 0.2 OUTLIER -149.02 130.02 14.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.27 -0.894 . . . . 0.0 109.613 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.793 HD12 HG21 ' A' ' 50' ' ' ILE . 8.3 pt -98.67 143.56 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.899 -1.125 . . . . 0.0 108.84 179.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.629 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -118.53 113.3 2.56 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 -179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.12 -125.43 2.04 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.707 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.578 HG21 HD12 ' A' ' 47' ' ' ILE . 21.5 mt -88.7 119.04 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.797 -0.825 . . . . 0.0 112.852 -177.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.446 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 96.6 2.32 60.06 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.203 177.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 126.87 -158.75 20.96 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.334 -1.412 . . . . 0.0 110.221 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.66 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.9 OUTLIER -124.6 134.11 53.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.661 -0.905 . . . . 0.0 109.222 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.733 HD11 HD11 ' B' ' 47' ' ' ILE . 13.5 pt -104.26 167.65 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.979 -1.076 . . . . 0.0 109.239 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.559 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.91 134.32 48.23 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.191 -0.943 . . . . 0.0 109.159 179.734 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.826 HG12 ' HA3' ' B' ' 78' ' ' GLY . 21.4 m -140.6 -171.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.991 -1.068 . . . . 0.0 110.201 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.457 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.4 mtt-85 -128.87 105.92 8.56 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 33.7 tt0 -69.62 100.34 1.44 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.444 -0.785 . . . . 0.0 110.934 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.761 ' CD2' HD23 ' B' ' 38' ' ' LEU . 17.1 m-85 -89.59 133.42 34.62 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.55 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 67.4 m-20 -108.49 133.14 53.05 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.713 -1.242 . . . . 0.0 109.989 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.558 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.29 63.71 0.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.917 -0.713 . . . . 0.0 109.569 179.581 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.698 ' C ' HD13 ' B' ' 72' ' ' ILE . 26.9 mm -116.52 119.28 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.844 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.9 tm? -66.02 84.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 111.28 -178.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.867 HD12 HD11 ' B' ' 15' ' ' ILE . 5.7 tt -90.52 112.19 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.564 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 29.5 tt0 -89.52 115.39 26.9 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.178 -0.951 . . . . 0.0 109.033 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 1.062 HG23 HG21 ' B' ' 11' ' ' VAL . 2.3 mp -112.97 123.43 68.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.032 -1.043 . . . . 0.0 109.719 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.636 ' SG ' HG22 ' B' ' 66' ' ' ILE . 36.8 m 67.17 44.93 1.79 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.487 -0.758 . . . . 0.0 109.444 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 61.52 21.02 59.75 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.52 ' O ' ' HA ' ' B' ' 65' ' ' GLU . 4.4 m-70 -119.66 130.09 54.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.014 -1.286 . . . . 0.0 109.677 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.581 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -70.56 136.55 49.37 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -155.9 104.69 2.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.219 -0.925 . . . . 0.0 109.793 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.716 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -80.06 154.54 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.963 -1.085 . . . . 0.0 108.349 178.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.564 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 178.98 -169.74 41.24 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.16 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -95.64 105.9 17.94 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.667 -0.901 . . . . 0.0 110.618 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.017 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.6 158.91 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.726 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.8 mp -126.38 125.42 42.18 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.762 -1.211 . . . . 0.0 107.901 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.602 HG13 ' HA ' ' B' ' 35' ' ' GLU . 94.8 t -106.43 116.39 50.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 O-C-N 120.671 -1.268 . . . . 0.0 109.663 -179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.826 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.37 -166.25 15.9 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.559 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -80.09 44.52 1.74 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.511 2.141 . . . . 0.0 110.604 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.66 HG21 HG13 ' B' ' 32' ' ' VAL . 3.2 t -89.74 135.22 30.84 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.645 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -78.17 17.59 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.284 1.99 . . . . 0.0 111.137 -178.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.645 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.5 t -160.32 156.76 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 120.879 -1.138 . . . . 0.0 110.777 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.613 ' OD1' HD23 ' B' ' 33' ' ' LEU . 60.4 m-20 -97.41 86.28 3.84 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 176.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.988 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.6 mt -82.78 124.89 39.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 O-C-N 121.298 -0.876 . . . . 0.0 112.378 -176.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.52 HD13 ' N ' ' B' ' 85' ' ' ILE . 3.7 mm -100.19 109.18 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.572 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -108.29 164.39 12.76 Favored Glycine 0 N--CA 1.498 2.785 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.881 -178.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.564 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 20.7 mmm180 -19.26 -41.94 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -178.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.9 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -49.45 -42.12 42.14 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.475 -1.391 . . . . 0.0 110.813 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.9 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -93.75 -27.65 16.37 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.245 -0.91 . . . . 0.0 109.976 -179.653 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' B' ' 90' ' ' LEU . 4.6 mp -58.76 -33.87 70.78 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.097 -1.002 . . . . 0.0 108.831 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 4.3 p -74.12 -21.28 59.95 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.294 -0.879 . . . . 0.0 109.866 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 1.4 mm100 -80.14 -40.47 27.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.163 -0.961 . . . . 0.0 109.053 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.73 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -81.7 -5.39 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.264 -0.897 . . . . 0.0 108.916 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.31 60.74 7.79 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.553 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -87.89 160.06 18.12 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.265 -1.138 . . . . 0.0 110.706 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.528 ' HB ' ' CG2' ' A' ' 4' ' ' THR . 4.7 p -141.7 126.96 18.6 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.502 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.5 mp -92.18 97.1 10.7 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.556 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 10.4 m120 -97.41 118.92 34.96 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.378 -0.826 . . . . 0.0 110.453 -178.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.723 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.723 0 CA-C-O 117.923 -1.037 . . . . 0.0 109.334 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.589 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 4.0 Cg_exo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.763 -0.514 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.534 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 17.6 tt0 -83.77 131.75 34.89 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.494 HG11 ' HB3' ' A' ' 9' ' ' PRO . 20.0 t -124.12 102.06 10.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.575 -1.328 . . . . 0.0 110.484 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.987 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -139.78 48.73 1.8 Allowed 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.55 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -85.59 43.02 1.0 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.225 -0.922 . . . . 0.0 110.152 -179.238 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.597 ' CZ3' ' HB ' ' B' ' 91' ' ' THR . 13.4 m95 18.91 48.09 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 CA-C-O 121.46 0.647 . . . . 0.0 111.335 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 37.1 mt-30 -165.23 -168.0 1.3 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.419 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 58.8 mtt180 -75.26 122.49 87.44 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.011 -1.055 . . . . 0.0 108.632 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.818 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.5 Cg_endo -76.53 85.06 1.76 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.153 1.902 . . . . 0.0 109.991 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.803 HD22 ' HB3' ' A' ' 21' ' ' GLU . 5.5 mt -86.47 142.36 28.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.287 -0.883 . . . . 0.0 109.723 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.635 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -146.98 154.4 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.927 . . . . 0.0 109.243 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.779 HG22 HD22 ' A' ' 19' ' ' LEU . 85.3 m -88.95 112.87 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.877 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -101.87 153.51 5.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.114 -0.991 . . . . 0.0 110.121 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 2.9 tttt -110.76 109.21 19.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.36 -0.838 . . . . 0.0 109.738 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.937 HD13 HG11 ' A' ' 75' ' ' VAL . 4.5 mt -124.59 135.54 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.03 -1.044 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 50.04 33.8 22.49 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.68 35.2 59.11 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 9.0 mm100 -128.19 175.72 8.22 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -1.107 . . . . 0.0 109.057 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.779 HD22 HG22 ' A' ' 12' ' ' THR . 14.2 mt -145.71 123.27 11.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -0.946 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 18.3 mttp -146.61 177.32 9.16 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.803 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -79.19 -179.96 7.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.831 -1.168 . . . . 0.0 108.612 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.699 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -165.17 109.2 0.87 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.249 -1.532 . . . . 0.0 110.992 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.636 HD21 ' O ' ' B' ' 27' ' ' GLY . 2.8 tp -78.57 95.79 5.3 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.818 HD12 ' HB2' ' A' ' 9' ' ' PRO . 35.0 mt -48.64 93.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.735 ' HB3' HG23 ' A' ' 84' ' ' ILE . 22.5 t0 -99.57 92.92 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 110.828 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.51 ' OG1' HD21 ' B' ' 97' ' ' LEU . 2.6 m -67.56 -6.84 21.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.095 -1.003 . . . . 0.0 109.467 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.984 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -78.55 -40.83 17.49 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.56 154.15 40.94 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.31 . . . . 0.0 109.256 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 1.8 m-20 -88.2 -13.59 40.73 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.25 -0.906 . . . . 0.0 110.374 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.843 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -137.51 -170.77 2.82 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.984 -1.073 . . . . 0.0 110.482 -179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.712 HG23 HD12 ' A' ' 85' ' ' ILE . 22.8 m -109.05 89.82 3.11 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.034 -1.041 . . . . 0.0 110.677 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -71.54 167.5 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.009 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.9 130.02 2.23 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -178.212 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.582 ' CG ' ' O ' ' A' ' 80' ' ' THR . 7.2 mt-10 -39.1 157.8 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.618 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -60.12 154.0 20.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 110.103 179.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.596 ' CE ' HG22 ' A' ' 15' ' ' ILE . 4.1 ptm -176.0 -168.71 0.29 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.186 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.8 t -97.82 105.17 17.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.274 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 39' ' ' PRO . 27.8 tp -131.64 103.4 14.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.849 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.6 Cg_endo -78.5 154.27 27.51 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.514 2.143 . . . . 0.0 110.336 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 132.74 -173.16 21.03 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.66 141.28 29.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.33 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.0 p-90 -160.88 175.34 12.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.834 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -148.28 154.5 42.26 Favored Pre-proline 0 C--N 1.301 -1.511 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.53 136.55 13.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.233 1.956 . . . . 0.0 110.223 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.569 ' HG3' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -149.94 -169.26 3.33 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.354 -0.841 . . . . 0.0 109.387 179.669 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.439 ' SD ' ' HG3' ' A' ' 55' ' ' LYS . 9.7 mmm -145.13 118.9 9.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.117 -0.99 . . . . 0.0 109.576 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 9.9 pt -89.75 135.24 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 118.886 -1.126 . . . . 0.0 108.294 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.414 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -118.7 105.47 1.19 Allowed Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -125.64 -123.26 2.67 Favored Glycine 0 N--CA 1.482 1.737 0 C-N-CA 119.552 -1.309 . . . . 0.0 110.632 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.71 HG21 ' CD1' ' B' ' 47' ' ' ILE . 13.5 mt -87.22 121.2 37.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.88 -0.776 . . . . 0.0 112.353 -177.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 99.92 -46.16 1.42 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.45 -163.33 33.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -120.93 137.01 54.81 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.121 -1.223 . . . . 0.0 109.628 -179.838 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 79' ' ' PRO . 2.7 pt -111.92 159.18 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.231 -0.918 . . . . 0.0 109.222 179.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -82.19 141.16 33.27 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.225 -0.922 . . . . 0.0 110.255 -179.376 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.569 HG22 ' HG3' ' A' ' 45' ' ' LYS . 2.9 m -148.22 166.32 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -113.71 107.2 15.44 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -65.83 107.63 1.87 Allowed 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.578 -0.701 . . . . 0.0 110.282 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 74' ' ' THR . 8.3 m-85 -97.27 138.68 34.38 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.541 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 21.9 m-20 -119.37 118.02 30.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.877 -1.139 . . . . 0.0 110.267 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.541 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 66.3 mt-30 87.64 55.82 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 CA-C-O 121.362 0.601 . . . . 0.0 110.283 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.571 HG13 ' HB3' ' A' ' 59' ' ' TYR . 21.8 mm -110.04 124.55 66.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.3 tm? -66.56 96.4 0.38 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.221 -0.924 . . . . 0.0 110.661 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.846 HD12 HD11 ' A' ' 15' ' ' ILE . 7.7 tt -105.97 115.91 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.526 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -88.47 140.88 29.02 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 109.231 -179.079 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 1.0 OUTLIER -127.7 130.34 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.3 -0.875 . . . . 0.0 108.993 -179.797 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.428 ' C ' ' O ' ' A' ' 66' ' ' ILE . 58.5 m 40.64 29.66 0.07 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.607 -0.683 . . . . 0.0 109.731 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 83.33 42.62 7.85 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.415 ' O ' ' C ' ' A' ' 70' ' ' LYS . 3.0 m-70 -134.6 100.73 4.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.313 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' A' ' 69' ' ' HIS . 16.9 ttpt -46.47 122.13 3.9 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.573 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.49 101.21 3.21 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 110.44 -179.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.517 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -81.97 158.72 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 177.932 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.508 ' N ' HG22 ' A' ' 72' ' ' ILE . . . 177.95 -161.46 28.48 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 118.824 -1.655 . . . . 0.0 110.579 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 59' ' ' TYR . 98.9 m -102.0 117.26 34.43 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.122 -1.222 . . . . 0.0 109.787 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.937 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -108.21 117.7 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.341 -0.85 . . . . 0.0 110.397 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.843 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.3 mp -86.75 107.99 18.5 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.405 -0.81 . . . . 0.0 109.213 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 35' ' ' GLU . 1.4 t -91.85 114.17 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.082 -1.011 . . . . 0.0 109.875 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.85 -168.25 15.41 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 54' ' ' ILE . 37.0 Cg_endo -81.55 42.11 1.27 Allowed 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 110.201 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.629 HG21 HG13 ' A' ' 32' ' ' VAL . 5.0 t -82.05 137.91 46.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.577 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.2 Cg_endo -79.45 21.53 0.76 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.483 2.122 . . . . 0.0 111.273 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.591 ' CG1' HG13 ' A' ' 84' ' ' ILE . 1.4 t -161.03 160.65 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 120.871 -1.143 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.637 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -102.52 94.66 5.78 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 177.217 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.761 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.8 mt -94.58 128.93 45.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 CA-C-O 122.132 0.968 . . . . 0.0 113.268 -175.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.871 HD13 ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -104.08 107.87 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.353 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -87.71 -168.59 44.67 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.727 -178.142 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.436 ' HD2' ' CG2' ' A' ' 91' ' ' THR . 5.9 mmt180 -60.58 -32.52 71.61 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.696 -0.885 . . . . 0.0 109.953 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.5 p-10 -46.88 -29.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.776 -1.203 . . . . 0.0 109.14 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -106.26 -36.72 6.78 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.505 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 38.0 mt -62.55 -12.78 24.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.889 -1.132 . . . . 0.0 108.694 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.463 ' O ' ' CH2' ' B' ' 6' ' ' TRP . 67.4 p -100.55 -20.36 15.74 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.207 -0.933 . . . . 0.0 108.673 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.6 mm-40 -79.23 -40.86 29.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.321 -0.862 . . . . 0.0 109.089 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.029 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -79.98 -15.06 13.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.162 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 100.31 15.66 29.54 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.735 178.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.572 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -56.84 146.4 26.48 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.502 -1.587 . . . . 0.0 109.673 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.664 HG22 ' CG2' ' B' ' 4' ' ' THR . 19.2 p -137.78 129.86 28.91 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -87.45 98.81 11.59 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.97 -1.081 . . . . 0.0 109.444 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.535 ' C ' ' CD1' ' A' ' 99' ' ' PHE . 1.4 m120 -111.57 136.81 50.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.394 -0.816 . . . . 0.0 110.103 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.758 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.273 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 N-CA-C 109.984 -0.814 . . . . 0.0 109.984 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -83.56 138.87 33.19 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.618 HG11 ' HB3' ' B' ' 9' ' ' PRO . 4.4 t -128.6 111.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.769 -178.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.664 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.66 39.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.848 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.554 ' O ' ' N ' ' B' ' 7' ' ' GLN . 4.6 tp -83.93 46.0 1.14 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.107 -0.995 . . . . 0.0 110.266 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' B' ' 5' ' ' LEU . 38.0 m95 17.94 50.06 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 121.489 0.662 . . . . 0.0 112.121 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.554 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.0 mt-30 -165.62 173.76 10.53 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.14 128.1 56.65 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 121.089 -1.007 . . . . 0.0 109.043 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.618 ' HB3' HG11 ' B' ' 3' ' ' VAL . 35.0 Cg_endo -79.35 64.64 8.87 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.423 2.082 . . . . 0.0 110.438 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.908 HD22 ' HB2' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -79.43 148.35 31.97 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.161 -0.962 . . . . 0.0 109.222 -179.929 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.78 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -143.72 137.15 24.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.232 -0.917 . . . . 0.0 109.573 -179.302 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 7.1 m -69.13 98.78 1.04 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 1.005 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -89.79 151.44 3.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.351 -0.843 . . . . 0.0 110.0 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.553 ' HE3' ' CG ' ' B' ' 19' ' ' LEU . 2.1 tttt -117.37 107.1 13.96 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.337 -0.852 . . . . 0.0 108.951 179.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.891 HD13 HG11 ' B' ' 75' ' ' VAL . 4.1 mt -113.5 139.6 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.253 -0.905 . . . . 0.0 109.205 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.62 -90.9 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -151.79 45.72 0.61 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.6 OUTLIER -140.82 169.31 17.87 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.455 -1.026 . . . . 0.0 110.035 -179.332 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.553 ' CG ' ' HE3' ' B' ' 14' ' ' LYS . 27.8 mt -139.07 113.83 9.2 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.483 ' HG3' ' C ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -136.26 163.88 29.39 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.207 -0.933 . . . . 0.0 109.115 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.908 ' HB2' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -78.13 145.01 35.96 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.277 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.795 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -134.39 116.45 15.2 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.869 -1.145 . . . . 0.0 111.297 -178.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.984 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -71.47 100.13 2.16 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.645 HD22 HD21 ' B' ' 90' ' ' LEU . 18.6 mt -47.18 137.44 7.96 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 179.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.824 ' HB2' HG23 ' B' ' 84' ' ' ILE . 42.4 t0 -142.66 94.24 2.62 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.835 -1.166 . . . . 0.0 111.422 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.526 HG23 ' HD3' ' B' ' 87' ' ' ARG . 6.8 m -74.89 -14.87 60.71 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.636 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -76.05 -16.18 80.87 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.39 160.71 14.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.32 . . . . 0.0 109.053 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -88.23 -21.14 24.67 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.014 . . . . 0.0 110.479 -179.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.637 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 1.6 m-20 -143.05 -173.83 4.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.635 -1.291 . . . . 0.0 110.858 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.804 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.2 m -97.54 86.02 3.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.822 -1.173 . . . . 0.0 111.578 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.923 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -67.22 153.61 8.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.423 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.923 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.2 OUTLIER -157.08 124.42 5.26 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.083 -1.011 . . . . 0.0 110.569 -177.722 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.564 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.7 tm-20 -43.07 153.87 0.08 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 109.078 178.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.566 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.3 tt0 -45.23 139.49 3.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 110.902 -179.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.655 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.3 ppp? -152.04 -164.4 1.96 Allowed 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.495 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -112.73 118.16 34.21 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.88 -1.138 . . . . 0.0 110.539 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.641 ' HG ' ' HD2' ' B' ' 39' ' ' PRO . 0.2 OUTLIER -134.91 -175.08 0.45 Allowed Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.411 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.641 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.7 Cg_endo -79.7 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.256 1.971 . . . . 0.0 110.942 -178.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 35.93 4.63 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.35 51.75 0.75 Allowed 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.683 -0.892 . . . . 0.0 108.945 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.65 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 39.9 p-90 -137.95 179.83 6.2 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.776 0.798 . . . . 0.0 110.668 -178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.494 ' HG3' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -140.86 146.13 42.69 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.088 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . 0.494 ' HD2' ' HG3' ' B' ' 43' ' ' LYS . 34.9 Cg_endo -78.36 138.67 15.93 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.416 2.077 . . . . 0.0 110.679 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' B' ' 58' ' ' GLN . 1.1 ptpt -160.54 -165.17 1.36 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.45 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 44.4 mtp -151.1 138.48 19.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.172 -0.955 . . . . 0.0 109.997 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.71 ' CD1' HG21 ' A' ' 50' ' ' ILE . 10.3 pt -103.71 148.3 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.114 -0.991 . . . . 0.0 108.83 178.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.626 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -119.57 116.28 3.26 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.979 -1.649 . . . . 0.0 108.979 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.45 -123.23 2.19 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.226 -1.464 . . . . 0.0 111.145 -179.046 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.777 HG21 ' CD1' ' A' ' 47' ' ' ILE . 15.8 mt -84.03 133.48 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.729 -0.866 . . . . 0.0 112.694 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.461 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 85.23 -44.17 3.34 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 178.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 171.24 -171.33 43.9 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.227 -1.463 . . . . 0.0 109.95 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' HA2' ' B' ' 48' ' ' GLY . 7.7 m-30 -96.29 168.82 10.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.432 -1.04 . . . . 0.0 109.748 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.64 HD12 HG13 ' B' ' 56' ' ' VAL . 1.8 pt -142.23 177.23 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.543 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.0 mtpt -114.18 128.65 56.47 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.922 -1.111 . . . . 0.0 109.44 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.654 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.7 m -136.61 -175.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.045 -1.034 . . . . 0.0 109.987 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 66.5 mtt180 -130.23 110.97 11.97 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.415 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 2.0 tt0 -69.98 103.49 2.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.32 -0.863 . . . . 0.0 110.442 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.65 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 10.5 m-85 -89.01 141.12 28.75 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 4.0 m-20 -120.12 130.96 54.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.681 -1.262 . . . . 0.0 110.953 -178.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.576 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 69.3 62.92 0.29 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.15 0.5 . . . . 0.0 110.756 179.003 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.784 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -118.48 125.64 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.164 -0.96 . . . . 0.0 108.923 178.877 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.787 ' N ' HD13 ' B' ' 72' ' ' ILE . 3.1 tm? -70.63 101.08 1.97 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.496 -0.752 . . . . 0.0 111.658 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.885 HD13 HD11 ' B' ' 66' ' ' ILE . 4.0 tt -101.48 122.27 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 25.5 tt0 -89.06 100.82 13.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.938 -1.101 . . . . 0.0 109.831 -178.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 1.005 HG13 HG22 ' B' ' 13' ' ' ILE . 1.1 mp -99.53 113.05 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.163 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 63.47 25.31 14.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.61 6.75 82.85 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.328 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -103.45 109.49 21.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -1.203 . . . . 0.0 109.252 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.47 133.15 35.56 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.724 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -152.98 98.16 2.28 Favored 'General case' 0 C--N 1.294 -1.831 0 O-C-N 121.257 -0.902 . . . . 0.0 109.88 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.787 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -77.97 145.5 9.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.151 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.5 -175.07 40.96 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.005 -1.569 . . . . 0.0 110.971 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.563 HG23 ' O ' ' B' ' 59' ' ' TYR . 1.5 m -85.75 112.51 21.13 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.668 -0.901 . . . . 0.0 110.461 -179.195 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.891 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -104.8 105.53 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -0.813 . . . . 0.0 110.156 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.6 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.1 mp -77.14 129.78 36.45 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.566 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 45.4 t -118.52 122.95 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 110.247 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.654 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -157.56 -165.41 15.19 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.543 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.9 Cg_endo -81.98 41.87 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.547 2.165 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.602 HG23 ' O ' ' B' ' 82' ' ' VAL . 8.9 t -79.4 141.71 57.4 Favored Pre-proline 0 N--CA 1.49 1.56 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.702 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.1 Cg_endo -77.68 14.39 1.46 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.135 1.89 . . . . 0.0 110.874 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.702 HG23 ' O ' ' B' ' 81' ' ' PRO . 3.6 t -161.02 162.52 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.856 -1.152 . . . . 0.0 110.201 -179.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -102.97 99.77 9.68 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 176.665 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.893 ' HB ' HG12 ' B' ' 32' ' ' VAL . 4.7 mt -104.51 129.22 57.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 120.835 -1.166 . . . . 0.0 112.869 -175.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.795 HD11 ' HB1' ' B' ' 22' ' ' ALA . 2.6 mm -88.51 132.39 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 176.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.637 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -107.16 -159.55 21.33 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 118.683 -1.723 . . . . 0.0 110.243 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.526 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -71.08 -30.28 66.36 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.737 -0.86 . . . . 0.0 108.762 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.799 ' ND2' HD23 ' B' ' 89' ' ' LEU . 5.8 p-10 -50.19 -40.07 45.88 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.822 -1.151 . . . . 0.0 108.897 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.799 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -90.25 -32.86 16.38 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.42 -0.8 . . . . 0.0 110.027 -179.361 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.645 HD21 HD22 ' B' ' 24' ' ' LEU . 37.0 mt -67.04 -8.03 27.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.99 -1.069 . . . . 0.0 108.655 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.597 ' HB ' ' CZ3' ' A' ' 6' ' ' TRP . 31.5 p -99.43 -18.2 17.59 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.008 -1.058 . . . . 0.0 108.581 179.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 0.5 OUTLIER -85.01 -40.95 16.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.53 -0.731 . . . . 0.0 109.659 179.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.758 HD12 ' CD2' ' A' ' 99' ' ' PHE . 26.6 pt -83.17 -4.25 8.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.306 -0.871 . . . . 0.0 109.032 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.95 60.33 6.17 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.587 ' CB ' ' CD1' ' A' ' 99' ' ' PHE . . . -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.282 -1.128 . . . . 0.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.987 HG22 ' CG2' ' A' ' 4' ' ' THR . 10.7 p -137.56 129.49 28.86 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' A' ' 97' ' ' LEU . 5.4 mp -87.14 98.39 11.27 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.534 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.0 m120 -103.6 128.5 50.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.868 -1.145 . . . . 0.0 110.123 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 1.029 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.532 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 N-CA-C 109.899 -0.846 . . . . 0.0 109.899 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 25.0 tt0 -84.17 120.05 25.73 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 4' ' ' THR . 3.4 t -129.21 94.61 2.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.982 -1.074 . . . . 0.0 109.901 -178.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.766 ' C ' HD12 ' A' ' 5' ' ' LEU . 0.7 OUTLIER -40.3 -68.85 0.15 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 109.404 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.967 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER 128.88 16.25 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.027 0.531 . . . . 0.0 110.121 179.4 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -48.26 -21.83 0.57 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.916 -1.115 . . . . 0.0 109.245 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.455 ' O ' ' HD3' ' B' ' 87' ' ' ARG . 29.8 mm100 -127.16 -128.81 0.23 Allowed 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.221 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.466 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.3 OUTLIER -111.04 133.61 21.25 Favored Pre-proline 0 C--N 1.306 -1.304 0 O-C-N 120.661 -1.274 . . . . 0.0 109.064 179.398 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.5 Cg_endo -79.96 51.76 4.03 Favored 'Trans proline' 0 C--N 1.313 -1.299 0 C-N-CA 122.203 1.935 . . . . 0.0 109.322 178.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.596 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -84.63 157.08 21.27 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.241 -0.912 . . . . 0.0 109.776 -179.315 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.728 HG21 HG23 ' A' ' 66' ' ' ILE . 1.2 m -149.15 131.72 6.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.501 -0.75 . . . . 0.0 109.368 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.651 HG21 HD23 ' A' ' 19' ' ' LEU . 25.3 m -65.02 94.8 0.14 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 177.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.771 HG22 HG13 ' A' ' 66' ' ' ILE . 13.6 pt -83.41 151.43 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.352 -0.843 . . . . 0.0 110.367 -178.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.547 ' HG3' HD12 ' A' ' 19' ' ' LEU . 14.0 ttmt -115.41 96.27 5.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 0.0 109.239 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 62' ' ' ILE . 11.8 mt -116.76 143.84 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.687 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.96 50.91 14.4 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 48.44 46.78 29.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -144.48 163.22 34.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -1.207 . . . . 0.0 109.407 179.898 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.651 HD23 HG21 ' A' ' 12' ' ' THR . 0.4 OUTLIER -129.95 132.92 46.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.181 -0.95 . . . . 0.0 109.971 -179.403 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.455 ' NZ ' HD23 ' A' ' 33' ' ' LEU . 4.0 mtmp? -151.13 177.7 9.94 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.596 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -93.86 118.99 32.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.618 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -97.81 143.37 28.5 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.135 -0.978 . . . . 0.0 109.42 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.999 HD11 ' NH2' ' B' ' 87' ' ' ARG . 10.5 tp -107.78 94.15 4.92 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.589 -0.694 . . . . 0.0 109.524 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.572 HD22 HD21 ' A' ' 90' ' ' LEU . 15.5 mt -45.14 111.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.293 -0.879 . . . . 0.0 108.648 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.59 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 19.4 t0 -126.25 80.02 1.89 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.343 -0.848 . . . . 0.0 110.12 -178.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.509 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.8 m -54.1 -18.95 4.19 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.025 -1.047 . . . . 0.0 108.867 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -56.64 -48.73 75.03 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.62 154.88 36.39 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.25 -1.147 . . . . 0.0 109.071 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.99 -7.44 33.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.162 -0.962 . . . . 0.0 110.385 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.667 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -132.59 178.87 6.51 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.981 -1.074 . . . . 0.0 109.539 179.805 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 19.0 m -104.3 89.55 3.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.772 -1.205 . . . . 0.0 110.83 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.975 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 171.48 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.946 -1.096 . . . . 0.0 108.307 178.908 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.031 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -170.19 121.38 0.64 Allowed 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.884 -1.135 . . . . 0.0 110.488 -179.011 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.511 ' HA ' HG22 ' A' ' 80' ' ' THR . 6.4 tt0 -41.4 160.52 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.448 -0.782 . . . . 0.0 109.087 178.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.583 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -48.35 146.86 2.6 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.21 -0.931 . . . . 0.0 110.681 -179.756 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.639 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.1 OUTLIER -159.31 -161.93 0.99 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.302 -0.874 . . . . 0.0 109.427 179.441 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 t -108.75 101.52 10.64 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.146 -0.971 . . . . 0.0 110.168 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.667 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -121.15 178.75 1.09 Allowed Pre-proline 0 N--CA 1.493 1.683 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.595 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 35.5 Cg_endo -79.54 -158.63 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.698 2.265 . . . . 0.0 110.64 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 29.63 7.75 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.9 mtt-85 -106.29 60.87 0.65 Allowed 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 59.2 p-90 -139.62 177.89 7.62 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-O 121.772 0.796 . . . . 0.0 110.696 -178.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.487 ' HD3' ' O ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -135.76 140.82 34.77 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.904 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -78.37 129.81 9.67 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 C-N-CA 121.813 1.675 . . . . 0.0 111.215 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HG3' ' O ' ' A' ' 45' ' ' LYS . 2.3 ptpt -161.99 142.57 10.44 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.534 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -107.52 147.84 30.01 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.744 -1.222 . . . . 0.0 109.675 179.688 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -103.65 150.11 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.394 -0.816 . . . . 0.0 108.982 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.24 98.0 0.71 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.084 -1.607 . . . . 0.0 109.084 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.15 -121.98 2.86 Favored Glycine 0 N--CA 1.487 2.057 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.478 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.708 HG21 HD11 ' B' ' 47' ' ' ILE . 18.2 mt -83.83 128.98 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.584 -0.95 . . . . 0.0 112.463 -177.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.534 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 93.29 -46.56 2.4 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.17 -155.51 25.29 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.099 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.513 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.5 m-85 -105.94 159.3 16.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.621 -0.929 . . . . 0.0 110.24 -179.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 47' ' ' ILE . 5.8 pt -137.58 159.8 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.16 124.66 48.14 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.863 -1.148 . . . . 0.0 109.643 -179.814 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.756 HG12 ' HA3' ' A' ' 78' ' ' GLY . 27.7 m -129.15 -178.33 2.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 109.034 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -131.95 105.4 7.4 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.278 179.834 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.56 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.8 OUTLIER -58.51 95.62 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.484 -0.76 . . . . 0.0 110.105 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.672 ' HB3' HD11 ' A' ' 62' ' ' ILE . 8.9 m-85 -89.98 117.87 29.11 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -99.58 141.83 31.86 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.561 -1.337 . . . . 0.0 111.035 -178.012 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.593 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 29.9 mt-30 71.16 62.33 0.17 Allowed 'General case' 0 N--CA 1.492 1.671 0 CA-C-O 121.199 0.523 . . . . 0.0 111.578 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.888 HG21 HG23 ' A' ' 15' ' ' ILE . 5.1 mp -120.76 121.31 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.894 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.6 tt -68.84 91.99 0.48 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.947 -1.096 . . . . 0.0 111.074 -178.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 1.003 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -89.09 114.74 27.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 176.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 13.8 tt0 -86.53 101.93 13.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.873 -1.142 . . . . 0.0 108.939 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.003 HD11 HD13 ' A' ' 64' ' ' ILE . 2.1 mt -103.7 126.49 58.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.634 0.731 . . . . 0.0 110.15 -178.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.569 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.1 m 44.2 67.11 0.72 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.654 -0.654 . . . . 0.0 110.261 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 67' ' ' CYS . . . 41.57 35.86 1.46 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.569 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 74.5 m-70 -130.92 101.57 5.68 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.085 -1.244 . . . . 0.0 109.163 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.894 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -50.38 128.29 19.4 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.877 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.661 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 102.86 3.36 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.344 -0.848 . . . . 0.0 110.386 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.596 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -79.48 151.45 4.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.027 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.721 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -174.44 -178.13 44.1 Favored Glycine 0 N--CA 1.486 2.014 0 C-N-CA 118.444 -1.836 . . . . 0.0 111.482 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.56 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 2.5 m -88.81 103.87 16.39 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.203 -0.587 . . . . 0.0 110.418 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.031 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -97.72 108.59 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.45 -0.781 . . . . 0.0 110.582 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.667 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.4 mp -78.78 117.47 19.93 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.583 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.2 t -103.11 119.71 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 110.382 -178.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.756 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.31 -168.3 16.95 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 35.9 Cg_endo -79.52 41.94 1.2 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.64 2.227 . . . . 0.0 111.088 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.557 HG21 HG13 ' A' ' 32' ' ' VAL . 3.6 t -83.43 139.86 41.6 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.059 -1.026 . . . . 0.0 108.498 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 80' ' ' THR . 34.6 Cg_endo -78.23 13.82 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.322 2.015 . . . . 0.0 111.689 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.9 OUTLIER -160.95 170.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.876 -1.14 . . . . 0.0 109.618 179.512 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.618 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -104.67 127.17 52.35 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 176.63 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.658 HG12 HG12 ' A' ' 32' ' ' VAL . 4.8 mm -112.86 128.33 69.63 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 O-C-N 120.406 -1.434 . . . . 0.0 111.04 -177.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.564 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -104.56 91.51 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -78.64 -167.8 32.8 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 110.637 -177.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.76 -34.25 72.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.639 -0.918 . . . . 0.0 110.338 -179.177 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.6 p-10 -48.94 -27.57 3.21 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.892 -1.13 . . . . 0.0 109.405 -179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.5 mm? -108.68 -29.38 8.74 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 121.121 -0.987 . . . . 0.0 110.034 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.603 HD23 HD11 ' A' ' 93' ' ' ILE . 96.7 mt -70.2 -6.27 33.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.08 -1.013 . . . . 0.0 108.463 179.024 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 87' ' ' ARG . 4.8 p -98.11 -20.26 17.44 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.226 -0.921 . . . . 0.0 108.725 179.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 16.6 mm100 -83.66 -41.7 17.46 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 108.877 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.7 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -80.93 -3.74 6.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 73.15 29.71 64.11 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.522 -0.847 . . . . 0.0 110.999 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -62.42 136.25 57.82 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.805 -1.409 . . . . 0.0 109.709 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' B' ' 96' ' ' THR . 77.4 p -136.71 129.48 30.63 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.124 -0.985 . . . . 0.0 108.519 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.452 ' O ' ' HB ' ' B' ' 3' ' ' VAL . 5.3 mp -88.13 102.15 14.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.416 -0.802 . . . . 0.0 109.891 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.485 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.4 m120 -110.02 126.74 54.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.971 -1.081 . . . . 0.0 109.175 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.922 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.112 -0.993 . . . . 0.0 109.404 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.484 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.654 0 N-CA-C 109.958 -0.824 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.485 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 12.8 tt0 -82.52 139.34 33.93 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 177.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.761 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 7.0 t -132.69 100.01 3.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 117.937 -1.505 . . . . 0.0 110.811 -177.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.535 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -117.01 -70.48 0.79 Allowed 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 178.225 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.745 ' H ' HD22 ' B' ' 5' ' ' LEU . 3.7 mm? 34.86 31.7 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.889 -0.507 . . . . 0.0 110.225 178.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' THR . 13.0 m0 17.62 49.18 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.553 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.4 mt-30 -163.09 -162.5 0.77 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.038 -1.039 . . . . 0.0 110.162 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.42 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 8.1 mtm105 -86.94 117.97 69.4 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.232 -0.917 . . . . 0.0 110.394 -179.222 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.592 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.3 Cg_endo -81.99 90.24 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.144 1.896 . . . . 0.0 110.742 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 1.004 HD23 ' HB3' ' B' ' 21' ' ' GLU . 3.2 mp -79.49 171.06 15.67 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.821 -1.175 . . . . 0.0 108.565 179.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.595 HG23 HG23 ' B' ' 13' ' ' ILE . 3.1 m -150.68 130.99 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.001 -1.062 . . . . 0.0 110.812 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.685 HG22 HD22 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -70.09 88.11 0.59 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 177.592 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.828 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pt -90.09 157.36 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 111.118 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 3.1 tttt -122.78 109.15 13.85 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.745 HG23 HG21 ' B' ' 62' ' ' ILE . 3.0 mt -122.97 119.52 58.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.092 -1.005 . . . . 0.0 109.24 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.36 26.95 74.0 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -5.46 67.99 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -85.8 169.95 12.88 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.248 -1.148 . . . . 0.0 109.29 179.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.685 HD22 HG22 ' B' ' 12' ' ' THR . 2.4 mt -139.8 128.22 22.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.311 -0.868 . . . . 0.0 109.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.423 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 3.0 mtpp -151.23 149.94 30.01 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.434 -0.791 . . . . 0.0 109.118 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 1.004 ' HB3' HD23 ' B' ' 10' ' ' LEU . 0.7 OUTLIER -79.64 102.16 8.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.093 -1.005 . . . . 0.0 108.469 179.277 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.876 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -80.04 142.84 34.56 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 122.0 0.905 . . . . 0.0 110.825 -178.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -92.62 104.26 16.57 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.66 HD22 HD21 ' B' ' 90' ' ' LEU . 4.6 mt -46.29 110.48 0.28 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.878 -1.138 . . . . 0.0 108.593 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.613 ' HB2' HG23 ' B' ' 84' ' ' ILE . 1.0 OUTLIER -118.81 86.71 2.59 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.871 -178.553 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.877 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -68.63 -7.88 37.06 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.023 -1.048 . . . . 0.0 108.704 178.488 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.86 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -81.24 -38.84 13.85 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.27 147.13 46.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.2 -1.176 . . . . 0.0 109.173 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.492 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 4.9 m-20 -82.83 -16.55 47.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 110.737 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.548 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 7.0 m-20 -138.04 -167.88 2.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.935 -1.103 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.589 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 43.0 m -110.57 94.24 4.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.787 -1.196 . . . . 0.0 110.782 -178.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.008 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.76 172.3 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.872 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.008 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.4 122.35 1.75 Allowed 'General case' 0 C--N 1.308 -1.225 0 O-C-N 120.775 -1.203 . . . . 0.0 110.822 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.532 ' CG ' ' O ' ' B' ' 80' ' ' THR . 0.3 OUTLIER -35.6 154.13 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.777 -0.577 . . . . 0.0 109.689 179.127 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.519 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.3 mt-10 -47.79 149.06 1.37 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.241 -0.912 . . . . 0.0 110.231 -179.202 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.49 ' CG ' HD23 ' B' ' 38' ' ' LEU . 6.1 ptm -173.45 -163.99 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.391 -0.818 . . . . 0.0 109.592 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.1 t -110.95 103.72 12.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.204 -0.935 . . . . 0.0 110.279 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.575 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -103.38 173.38 3.48 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.575 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.1 Cg_endo -73.9 -162.26 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.996 1.798 . . . . 0.0 110.516 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -100.21 -166.07 28.86 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.304 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 58.83 70.12 0.68 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.672 -0.899 . . . . 0.0 109.152 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.619 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 21.4 p-90 -141.44 -169.89 2.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -151.02 134.1 8.77 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.175 -0.953 . . . . 0.0 108.807 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.31 137.35 16.77 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.838 1.692 . . . . 0.0 110.567 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.629 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -160.97 133.79 6.29 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.724 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.517 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 63.1 mtp -91.73 131.93 36.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.131 -0.981 . . . . 0.0 109.797 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 50' ' ' ILE . 8.8 pt -89.36 143.96 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 101.22 0.89 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.25 -121.81 2.92 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.744 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.573 HG21 ' CD1' ' A' ' 47' ' ' ILE . 20.5 mt -84.87 117.38 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.852 -0.793 . . . . 0.0 112.695 -177.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.459 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 104.16 -53.32 0.71 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 178.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -178.4 -157.12 18.43 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.543 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -118.0 135.79 53.94 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.311 -1.111 . . . . 0.0 109.873 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.675 HD12 HG13 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -106.48 -177.48 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.909 . . . . 0.0 108.926 179.189 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.534 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 36.8 mtmt -111.52 135.82 51.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.019 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' B' ' 78' ' ' GLY . 17.5 m -142.77 177.07 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.843 -1.161 . . . . 0.0 110.636 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.35 100.72 6.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.492 -0.755 . . . . 0.0 109.241 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -62.87 110.11 1.66 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.265 -0.897 . . . . 0.0 110.909 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.988 ' HB3' HD11 ' B' ' 62' ' ' ILE . 16.0 m-85 -106.92 132.35 52.96 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 177.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.7 m-20 -108.6 134.1 51.82 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.937 -1.102 . . . . 0.0 110.49 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.589 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 45.0 mt-30 78.14 61.37 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.904 -0.497 . . . . 0.0 111.178 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.988 HD11 ' HB3' ' B' ' 59' ' ' TYR . 3.0 mp -112.83 120.99 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 178.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.84 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -65.07 86.44 0.06 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 110.958 -178.656 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.934 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.6 tt -94.49 110.7 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.3 tt0 -89.04 117.21 27.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.051 -1.031 . . . . 0.0 109.464 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.828 HG13 HG22 ' B' ' 13' ' ' ILE . 1.8 mp -116.33 140.95 36.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 121.746 0.784 . . . . 0.0 109.845 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.504 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 0.9 OUTLIER 47.42 39.17 8.7 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.681 -0.637 . . . . 0.0 109.778 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.2 48.28 83.9 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.504 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 80.7 m-70 -145.38 108.88 4.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.247 -1.149 . . . . 0.0 109.384 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.619 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.3 OUTLIER -48.26 127.38 12.67 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.305 -0.872 . . . . 0.0 108.883 179.709 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -149.12 104.8 3.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.334 -0.854 . . . . 0.0 109.355 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.84 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -83.86 160.31 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.107 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.574 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.34 -157.24 17.87 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.419 -1.848 . . . . 0.0 111.952 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 4.8 m -111.95 109.81 19.79 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.632 -0.922 . . . . 0.0 109.557 -179.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.929 HG23 HD13 ' B' ' 62' ' ' ILE . 1.6 t -105.03 127.75 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.521 -0.737 . . . . 0.0 111.22 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.8 mp -96.83 116.22 28.78 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' B' ' 35' ' ' GLU . 13.1 t -96.9 114.96 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.709 -1.244 . . . . 0.0 109.984 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.72 -174.12 20.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.534 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -79.78 41.83 1.19 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.493 2.129 . . . . 0.0 111.234 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.532 ' O ' ' CG ' ' B' ' 34' ' ' GLU . 9.1 t -80.68 141.01 51.45 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.8 Cg_endo -77.76 13.44 1.68 Allowed 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.274 1.983 . . . . 0.0 111.232 -179.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.61 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -160.31 173.83 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.921 -1.112 . . . . 0.0 109.677 -179.754 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.61 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.0 OUTLIER -109.68 138.57 45.85 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 176.625 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.613 HG23 ' HB2' ' B' ' 25' ' ' ASP . 4.7 mm -124.6 123.33 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.438 -1.414 . . . . 0.0 111.762 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.876 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -97.26 89.82 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.344 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.548 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.04 -157.59 11.58 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.891 -1.147 . . . . 0.0 111.612 -177.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.999 ' NH2' HD11 ' A' ' 23' ' ' LEU . 31.1 mtt180 -68.19 -35.62 78.28 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.915 -0.756 . . . . 0.0 111.407 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.004 ' ND2' HD23 ' B' ' 89' ' ' LEU . 2.6 p-10 -55.57 -24.23 31.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.461 -1.399 . . . . 0.0 110.044 -179.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.004 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -106.77 -18.41 13.95 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.999 -1.063 . . . . 0.0 110.26 -178.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.877 HD13 HG23 ' B' ' 26' ' ' THR . 64.5 mt -71.95 -24.45 61.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 108.899 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.94 -14.09 56.58 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.092 -1.005 . . . . 0.0 109.839 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.1 -40.85 23.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.99 -1.069 . . . . 0.0 109.164 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.922 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -87.26 -13.07 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.305 -0.872 . . . . 0.0 108.755 179.43 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.69 51.12 9.79 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.67 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -75.86 147.27 39.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 108.851 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 96' ' ' THR . 72.6 p -130.76 127.29 38.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 108.908 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.554 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.0 mp -91.58 91.06 7.87 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.516 -0.74 . . . . 0.0 109.182 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.549 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.7 m120 -96.22 125.53 40.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.148 -0.97 . . . . 0.0 109.92 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.7 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.301 -1.526 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.335 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.59 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.498 1.768 0 N-CA-C 110.064 -0.783 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.53 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.91 129.11 34.86 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.85 -1.156 . . . . 0.0 108.05 178.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 77.8 t -131.37 124.81 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.915 -1.115 . . . . 0.0 110.184 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 7.6 p -64.57 -104.01 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.857 HD11 HG23 ' B' ' 26' ' ' THR . 0.6 OUTLIER 167.04 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.866 -1.146 . . . . 0.0 110.721 179.407 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 38.1 m95 -65.56 -18.66 65.49 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.809 -1.182 . . . . 0.0 108.507 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.424 ' O ' ' C ' ' A' ' 8' ' ' ARG . 23.2 mt-30 -147.3 159.64 43.43 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.477 ' HD2' HD13 ' A' ' 23' ' ' LEU . 16.0 mtm180 -44.04 141.15 2.52 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.003 . . . . 0.0 109.22 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG3' HG22 ' B' ' 26' ' ' THR . 36.2 Cg_endo -80.61 60.57 7.91 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.478 2.119 . . . . 0.0 109.921 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.676 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -81.66 142.72 32.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.243 -0.91 . . . . 0.0 109.97 -179.484 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -140.99 155.62 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.46 -0.775 . . . . 0.0 109.283 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.418 HG22 HD22 ' A' ' 19' ' ' LEU . 11.0 m -83.96 101.94 12.08 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 178.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.795 HG22 HG13 ' A' ' 66' ' ' ILE . 14.7 pt -96.31 158.66 3.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.286 -0.884 . . . . 0.0 110.341 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 3.7 tttt -120.71 103.95 9.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.433 -0.792 . . . . 0.0 109.88 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.013 HD13 HG11 ' A' ' 75' ' ' VAL . 10.6 mt -119.25 134.35 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.079 -1.013 . . . . 0.0 109.588 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.96 44.24 98.08 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.08 17.72 24.33 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.63 178.09 4.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.444 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.536 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.6 mt -138.61 126.34 22.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.447 -0.783 . . . . 0.0 109.826 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.459 ' HD3' ' O ' ' A' ' 19' ' ' LEU . 35.8 mmtt -144.45 -179.31 6.47 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.676 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.9 mt-10 -88.04 164.58 15.69 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.098 -1.001 . . . . 0.0 108.713 179.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.614 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -147.97 116.68 6.69 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.688 -1.258 . . . . 0.0 110.966 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.002 HD21 ' O ' ' B' ' 27' ' ' GLY . 16.8 tp -82.05 94.12 7.13 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.602 HD13 ' CE2' ' B' ' 99' ' ' PHE . 63.7 mt -49.69 93.2 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.568 ' CB ' ' HA3' ' B' ' 27' ' ' GLY . 26.8 t0 -107.67 87.21 2.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 110.744 -178.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.675 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.2 m -60.74 -13.81 17.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.051 -1.031 . . . . 0.0 108.638 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -63.41 -43.69 97.9 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.4 171.52 9.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.008 -1.289 . . . . 0.0 110.069 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.513 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -98.54 -20.51 17.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.34 -0.85 . . . . 0.0 110.603 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.515 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 36.6 m-20 -140.23 -162.9 1.42 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.922 -1.111 . . . . 0.0 109.604 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.759 HG22 ' CD1' ' A' ' 33' ' ' LEU . 23.5 m -107.28 89.99 3.17 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.69 -1.256 . . . . 0.0 110.931 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.966 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.67 164.95 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.745 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.966 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.58 127.58 2.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.727 -1.233 . . . . 0.0 111.426 -178.742 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.594 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.2 OUTLIER -42.48 153.29 0.08 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 179.03 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.966 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -50.54 146.34 5.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.053 -1.029 . . . . 0.0 109.868 -179.821 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.522 ' CE ' HG22 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -156.42 -162.77 1.32 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.485 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.5 t -112.73 101.0 9.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.05 -1.031 . . . . 0.0 110.362 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.625 HD21 HD12 ' A' ' 62' ' ' ILE . 0.1 OUTLIER -108.49 160.03 28.65 Favored Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.573 ' HD3' HD12 ' A' ' 38' ' ' LEU . 34.5 Cg_endo -75.96 69.32 6.29 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.784 2.323 . . . . 0.0 111.867 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . 37.43 -159.62 0.01 OUTLIER Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.51 ' N ' ' HD3' ' A' ' 41' ' ' ARG . 1.3 mpt_? 64.07 68.47 0.56 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.541 -0.976 . . . . 0.0 109.912 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.582 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 64.3 p-90 -152.7 -178.24 6.75 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.653 -0.654 . . . . 0.0 110.001 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.5 mtpt -146.2 137.21 12.62 Favored Pre-proline 0 N--CA 1.49 1.537 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.14 138.35 16.09 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.224 1.95 . . . . 0.0 111.182 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.557 ' HD2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -152.58 -163.19 1.66 Allowed 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.242 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.565 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 1.7 mtt -149.42 126.11 11.06 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.957 -1.089 . . . . 0.0 110.371 -179.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 54' ' ' ILE . 6.8 pt -90.07 146.44 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.512 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.45 118.62 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -146.3 -127.41 1.85 Allowed Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.291 -1.433 . . . . 0.0 111.228 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.613 HG21 HD12 ' B' ' 47' ' ' ILE . 25.2 mt -81.68 123.85 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.957 -0.731 . . . . 0.0 112.401 -177.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.78 -50.11 1.78 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 178.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.441 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 175.14 -168.12 40.51 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.4 OUTLIER -107.31 132.53 53.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.085 -1.244 . . . . 0.0 109.711 -179.632 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 47' ' ' ILE . 10.3 pt -101.74 163.4 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.238 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.565 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 35.6 mtmt -96.59 138.38 34.26 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.112 -0.993 . . . . 0.0 108.867 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.461 HG21 HD23 ' A' ' 76' ' ' LEU . 30.6 m -138.36 177.93 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 120.75 -1.219 . . . . 0.0 110.146 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.512 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -118.17 92.3 3.79 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.431 -0.793 . . . . 0.0 108.919 -179.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.545 ' CG ' ' OD1' ' A' ' 60' ' ' ASP . 16.2 tt0 -53.56 107.69 0.27 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.507 -0.745 . . . . 0.0 110.236 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 38' ' ' LEU . 15.1 m-85 -105.02 95.51 5.89 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' ' CG ' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -79.01 139.62 38.14 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.867 -1.146 . . . . 0.0 111.061 -178.39 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.564 ' HA ' HG23 ' A' ' 72' ' ' ILE . 47.0 mt-30 68.36 63.57 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.133 0.492 . . . . 0.0 111.66 178.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.813 ' C ' HD13 ' A' ' 72' ' ' ILE . 0.8 OUTLIER -122.67 124.78 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.795 HD22 HG12 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -66.65 86.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.914 -178.342 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.868 HD12 HD11 ' A' ' 15' ' ' ILE . 3.6 tt -87.74 123.83 40.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 176.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 66' ' ' ILE . 8.6 tt0 -88.59 148.37 24.11 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.069 -1.019 . . . . 0.0 109.349 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.795 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -150.19 115.35 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.501 ' SG ' ' CG ' ' A' ' 1' ' ' PRO . 0.8 OUTLIER 68.23 5.06 4.46 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.581 -0.7 . . . . 0.0 110.127 179.695 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.405 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 108.27 -3.39 33.11 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -90.2 131.31 36.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.06 -1.259 . . . . 0.0 109.318 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.505 ' CG ' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.75 103.9 11.76 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 121.047 -1.033 . . . . 0.0 108.471 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 63' ' ' LEU . . . -112.79 151.19 30.63 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 120.361 -0.535 . . . . 0.0 109.838 -179.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.813 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -122.42 146.32 27.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 177.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.474 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.75 -162.42 25.56 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 118.429 -1.843 . . . . 0.0 111.063 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 10.3 m -100.28 104.92 16.42 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.676 -0.896 . . . . 0.0 110.056 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.013 HG11 HD13 ' A' ' 15' ' ' ILE . 1.2 t -95.12 105.36 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.518 -0.739 . . . . 0.0 109.349 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.561 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.9 mp -78.57 118.07 20.34 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.966 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.0 t -106.9 111.09 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.145 -0.972 . . . . 0.0 110.443 -179.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.65 -157.48 7.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.55 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.14 38.8 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.509 2.139 . . . . 0.0 110.34 179.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.594 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.9 t -83.58 132.78 48.3 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.683 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.8 Cg_endo -79.9 19.11 1.05 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.467 2.111 . . . . 0.0 111.558 -178.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.1 t -161.46 156.77 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.763 -1.21 . . . . 0.0 109.929 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.575 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -95.64 91.0 5.91 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.665 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.68 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.6 mm -78.54 122.74 34.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 121.418 -0.801 . . . . 0.0 112.085 -176.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.628 HD12 HG23 ' A' ' 31' ' ' THR . 0.9 OUTLIER -101.02 91.78 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 176.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.44 -157.98 13.51 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.912 -177.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.513 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -68.87 -37.66 79.19 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 122.023 -0.692 . . . . 0.0 109.828 -178.958 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 13.0 p-10 -45.71 -28.51 1.04 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.933 -1.104 . . . . 0.0 109.52 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.5 mm? -109.08 -27.03 9.85 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.259 -0.9 . . . . 0.0 110.499 -178.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.679 HD23 HD11 ' A' ' 93' ' ' ILE . 70.0 mt -72.09 -7.88 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.82 -1.175 . . . . 0.0 109.194 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -98.15 -11.75 22.47 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.004 -1.06 . . . . 0.0 108.242 178.699 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.605 ' OE1' HD13 ' A' ' 89' ' ' LEU . 75.4 mt-30 -90.49 -40.71 11.84 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.75 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -82.91 0.59 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.471 -0.768 . . . . 0.0 108.965 179.164 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.15 32.83 57.91 Favored Glycine 0 N--CA 1.495 2.617 0 C-N-CA 120.575 -0.822 . . . . 0.0 111.147 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.679 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -65.45 140.08 58.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.941 -1.329 . . . . 0.0 110.715 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' B' ' 96' ' ' THR . 58.9 p -137.33 126.19 24.11 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' B' ' 97' ' ' LEU . 5.1 mp -88.43 91.94 8.99 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.239 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.462 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 4.6 m120 -103.51 121.41 42.81 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.127 -0.983 . . . . 0.0 109.448 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.904 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.361 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.55 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 2.3 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 109.875 -0.856 . . . . 0.0 109.875 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.479 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 4.3 tt0 -122.26 142.41 50.49 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 177.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.487 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 38.4 t -142.48 102.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.192 -178.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.599 ' O ' ' C ' ' B' ' 5' ' ' LEU . 63.7 p -89.62 -30.13 18.36 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 178.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.803 HD13 ' HA ' ' B' ' 9' ' ' PRO . 0.5 OUTLIER 13.14 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.832 -179.892 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.423 ' C ' ' O ' ' B' ' 5' ' ' LEU . 2.2 m95 -37.91 -22.23 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.038 -178.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.576 ' N ' ' O ' ' B' ' 5' ' ' LEU . 20.3 mp0 -107.94 -161.85 0.8 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.715 -1.241 . . . . 0.0 107.983 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.511 ' HB3' HD12 ' B' ' 23' ' ' LEU . 19.1 mtt180 -53.84 124.57 44.06 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 120.478 -1.389 . . . . 0.0 109.589 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.803 ' HA ' HD13 ' B' ' 5' ' ' LEU . 37.0 Cg_endo -77.7 71.01 6.7 Favored 'Trans proline' 0 C--N 1.316 -1.159 0 C-N-CA 122.331 2.021 . . . . 0.0 110.401 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.918 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.6 mt -78.95 143.1 36.12 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.888 -1.132 . . . . 0.0 110.356 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.816 HG21 HG23 ' B' ' 66' ' ' ILE . 1.3 m -130.76 139.92 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.509 -0.744 . . . . 0.0 109.639 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.933 HG22 HD22 ' B' ' 19' ' ' LEU . 2.0 m -67.49 108.01 2.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.918 -1.114 . . . . 0.0 108.279 178.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.904 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.2 pp -106.02 140.43 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.081 -1.012 . . . . 0.0 110.865 -178.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.541 ' CG ' ' HG ' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -109.05 106.53 16.5 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.306 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' B' ' 75' ' ' VAL . 15.0 mt -124.48 124.99 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 O-C-N 121.164 -0.96 . . . . 0.0 109.524 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.77 20.01 71.89 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -4.33 86.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -93.47 -178.17 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.115 -1.227 . . . . 0.0 108.908 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.933 HD22 HG22 ' B' ' 12' ' ' THR . 4.3 mt -153.65 125.58 7.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.132 -0.98 . . . . 0.0 110.499 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -145.94 168.79 20.01 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.012 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.918 ' HB3' HD22 ' B' ' 10' ' ' LEU . 6.5 mt-10 -79.28 157.87 27.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.758 -1.214 . . . . 0.0 108.401 179.399 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.626 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -139.34 113.96 9.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.96 -1.087 . . . . 0.0 110.691 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.511 HD12 ' HB3' ' B' ' 8' ' ' ARG . 0.9 OUTLIER -67.75 95.36 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.031 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.731 HD12 ' HB2' ' B' ' 9' ' ' PRO . 86.2 mt -44.51 102.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.806 ' HB2' HG23 ' B' ' 84' ' ' ILE . 4.8 t70 -101.37 93.53 5.46 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.474 -0.766 . . . . 0.0 110.753 -178.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 5' ' ' LEU . 5.6 m -76.4 3.89 10.16 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.114 -0.991 . . . . 0.0 109.004 178.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 1.002 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -99.67 -24.42 10.03 Favored Glycine 0 N--CA 1.485 1.933 0 C-N-CA 120.056 -1.069 . . . . 0.0 110.743 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.25 168.46 17.61 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.829 -1.395 . . . . 0.0 109.949 -179.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.458 ' OD2' ' HD3' ' A' ' 8' ' ' ARG . 0.9 OUTLIER -101.31 -20.3 15.28 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.366 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.576 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -131.86 -174.83 3.53 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 -179.598 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.687 HG23 HD12 ' B' ' 85' ' ' ILE . 53.2 m -105.33 83.44 1.96 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.676 -1.265 . . . . 0.0 110.315 -178.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.056 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.45 167.16 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.035 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.056 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.41 123.86 2.26 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.051 -1.031 . . . . 0.0 110.441 -178.694 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.823 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.0 OUTLIER -39.49 160.0 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.551 -0.718 . . . . 0.0 109.381 179.17 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.462 ' O ' ' OE1' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -39.62 146.71 0.1 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.387 -0.821 . . . . 0.0 110.449 -179.572 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.444 ' HE2' ' HE2' ' B' ' 20' ' ' LYS . 3.0 ppp? -166.4 163.04 17.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.441 -0.787 . . . . 0.0 109.046 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.3 t -95.82 105.04 17.0 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.043 -1.036 . . . . 0.0 109.753 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.739 HD21 HD12 ' B' ' 62' ' ' ILE . 9.2 tp -122.43 106.17 35.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.372 -0.83 . . . . 0.0 108.932 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.33 140.39 19.43 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.375 2.05 . . . . 0.0 111.125 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 128.23 31.52 0.67 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.474 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 52.88 166.62 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.84 -0.8 . . . . 0.0 110.014 179.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.579 ' CD2' ' HD3' ' B' ' 57' ' ' ARG . 0.2 OUTLIER -160.98 178.49 9.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.138 -0.976 . . . . 0.0 109.769 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -125.88 104.52 26.7 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.76 138.61 41.61 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.025 1.817 . . . . 0.0 112.355 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -150.62 -155.61 0.64 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.55 ' CE ' ' HB3' ' B' ' 53' ' ' PHE . 32.2 mtp -148.13 126.55 12.35 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.026 -1.046 . . . . 0.0 110.312 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 54' ' ' ILE . 7.3 pt -93.24 142.38 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.611 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.93 113.75 2.64 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.12 -123.94 2.21 Favored Glycine 0 N--CA 1.483 1.811 0 C-N-CA 119.525 -1.322 . . . . 0.0 110.493 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.711 HG21 HD12 ' A' ' 47' ' ' ILE . 25.6 mt -84.77 119.27 33.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.793 -0.827 . . . . 0.0 112.384 -177.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 103.83 -53.01 0.73 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.89 -161.79 27.83 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.171 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.611 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -111.84 128.86 56.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.459 -1.024 . . . . 0.0 109.241 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 47' ' ' ILE . 16.3 pt -107.38 162.59 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.876 -1.14 . . . . 0.0 109.016 179.118 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.6 mptm? -94.53 147.58 23.12 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.153 -0.967 . . . . 0.0 108.88 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 27.5 m -144.94 -170.77 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 120.768 -1.207 . . . . 0.0 110.254 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.579 ' HD3' ' CD2' ' B' ' 42' ' ' TRP . 18.6 mtt85 -131.46 111.24 11.62 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -77.61 101.3 6.49 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.566 -0.709 . . . . 0.0 111.07 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.642 ' CG ' HD23 ' B' ' 38' ' ' LEU . 62.7 m-85 -96.18 129.74 43.41 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 14.5 m-20 -109.19 122.45 47.34 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.692 -1.255 . . . . 0.0 110.895 -178.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.546 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 3.0 mt-30 86.1 56.11 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 CA-C-O 121.31 0.576 . . . . 0.0 110.472 179.069 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.855 HG21 HG23 ' B' ' 15' ' ' ILE . 4.0 mm -111.27 128.07 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.879 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.3 tm? -73.84 102.26 4.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.181 -0.95 . . . . 0.0 111.293 -178.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.829 ' CG2' HD11 ' B' ' 89' ' ' LEU . 0.9 OUTLIER -105.59 106.11 19.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 177.579 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.4 OUTLIER -90.0 119.69 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.983 -1.073 . . . . 0.0 109.206 -178.821 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.816 HG23 HG21 ' B' ' 11' ' ' VAL . 1.5 mp -111.54 128.78 67.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.477 -0.765 . . . . 0.0 109.364 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.487 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 15.5 m 65.55 -89.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.752 -0.593 . . . . 0.0 109.629 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.88 39.15 0.74 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -139.36 131.91 28.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.566 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.68 ' CG ' HD21 ' B' ' 63' ' ' LEU . 15.6 ttmt -70.74 129.11 38.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.125 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.625 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -142.25 95.19 2.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.156 -0.965 . . . . 0.0 110.435 -179.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.631 HG12 HD23 ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.99 156.77 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.712 -1.243 . . . . 0.0 108.06 178.297 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.506 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.05 -170.59 43.52 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.674 -1.727 . . . . 0.0 111.213 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 85.9 m -88.68 112.54 23.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.848 -0.795 . . . . 0.0 110.575 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' B' ' 15' ' ' ILE . 0.7 OUTLIER -105.18 107.8 23.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.7 -0.625 . . . . 0.0 110.155 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.576 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 4.0 mp -82.63 121.82 27.32 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 108.853 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.52 ' O ' ' HG3' ' B' ' 57' ' ' ARG . 69.1 t -109.3 132.04 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.058 -1.026 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -162.8 -159.89 10.76 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.43 36.1 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.651 2.234 . . . . 0.0 110.733 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.823 HG22 ' HA ' ' B' ' 34' ' ' GLU . 4.0 t -81.6 136.64 48.37 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.682 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.5 16.36 1.43 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.322 2.015 . . . . 0.0 111.269 -178.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.682 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -161.84 148.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 120.88 -1.138 . . . . 0.0 110.108 -179.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.7 OUTLIER -86.61 102.12 13.87 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 105.922 -1.881 . . . . 0.0 105.922 176.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.833 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.4 mt -101.74 126.66 55.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.856 -1.153 . . . . 0.0 112.137 -175.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.745 HD13 ' N ' ' B' ' 85' ' ' ILE . 1.5 mm -97.08 121.85 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 177.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.537 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -102.58 -147.42 19.17 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.592 -1.289 . . . . 0.0 111.551 -178.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.509 ' O ' ' OG1' ' B' ' 91' ' ' THR . 11.6 mtp180 -69.08 -40.86 78.18 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 122.074 -0.662 . . . . 0.0 111.388 -178.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.98 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.2 p-10 -53.78 -30.47 44.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.798 -1.188 . . . . 0.0 111.254 -178.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.98 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.8 mm? -104.44 -28.58 11.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.492 -1.38 . . . . 0.0 110.914 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.662 HD23 ' N ' ' B' ' 90' ' ' LEU . 0.1 OUTLIER -68.2 -9.58 47.99 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.712 -1.242 . . . . 0.0 109.151 179.745 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.22 -20.44 15.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.775 -1.203 . . . . 0.0 108.831 179.154 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 46.6 mm-40 -77.89 -41.05 37.93 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.237 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.904 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -81.4 -8.17 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.38 35.77 55.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.568 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -61.56 152.18 31.12 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.824 -1.398 . . . . 0.0 109.288 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 4' ' ' THR . 21.5 p -142.27 124.72 15.69 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.151 -0.968 . . . . 0.0 108.889 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' A' ' 97' ' ' LEU . 4.8 mp -86.25 91.08 8.36 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.444 -0.785 . . . . 0.0 109.505 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.545 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -93.92 121.98 35.94 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.049 -1.032 . . . . 0.0 109.227 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.75 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 118.045 -0.979 . . . . 0.0 109.477 179.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 3.8 Cg_exo . . . . . 0 N--CA 1.497 1.686 0 N-CA-C 110.663 -0.553 . . . . 0.0 110.663 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.526 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -84.37 136.73 33.76 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.102 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.622 HG12 ' H ' ' A' ' 5' ' ' LEU . 55.7 t -133.55 115.03 21.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 120.734 -1.229 . . . . 0.0 109.918 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 72.6 p -58.8 -12.59 4.53 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.698 -0.626 . . . . 0.0 110.218 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.767 HD21 HD13 ' B' ' 97' ' ' LEU . 0.7 OUTLIER 80.59 -6.6 1.66 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.443 -0.785 . . . . 0.0 110.298 179.398 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.598 ' CZ3' HG21 ' B' ' 91' ' ' THR . 39.8 m95 -53.88 -20.43 5.94 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.949 -1.094 . . . . 0.0 108.848 179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.11 157.54 46.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 108.914 179.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.433 ' HA ' ' CZ ' ' B' ' 87' ' ' ARG . 4.0 mtm180 -66.92 122.99 84.94 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.155 -0.965 . . . . 0.0 109.595 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.612 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.0 Cg_endo -76.1 80.09 2.76 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 121.927 1.751 . . . . 0.0 109.429 178.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -90.0 149.34 22.59 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.589 -0.695 . . . . 0.0 109.606 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.926 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -150.9 159.33 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.192 -0.942 . . . . 0.0 110.377 -179.063 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.679 HG21 HD23 ' A' ' 19' ' ' LEU . 14.1 m -94.88 104.82 16.71 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 1.154 HD11 HD21 ' A' ' 33' ' ' LEU . 2.2 pt -89.22 141.1 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.177 -0.952 . . . . 0.0 110.389 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.589 ' HG3' HD12 ' A' ' 19' ' ' LEU . 29.5 ttmt -106.34 97.27 7.09 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.868 HG23 ' CG2' ' A' ' 62' ' ' ILE . 16.8 mt -113.53 120.55 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.147 -0.97 . . . . 0.0 110.06 -179.155 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.23 37.65 94.81 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.1 6.4 56.72 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.453 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.3 mm-40 -97.48 163.25 12.94 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.201 -1.176 . . . . 0.0 109.216 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.679 HD23 HG21 ' A' ' 12' ' ' THR . 0.1 OUTLIER -136.89 126.59 25.48 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.293 -0.879 . . . . 0.0 110.798 -179.507 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.8 mttp -150.45 179.95 7.73 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.03 -174.67 4.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.876 -1.14 . . . . 0.0 108.891 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -162.25 121.14 2.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.031 -1.043 . . . . 0.0 110.001 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.519 ' O ' ' N ' ' A' ' 25' ' ' ASP . 46.5 tp -102.61 95.42 6.21 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.449 -0.782 . . . . 0.0 109.301 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 17.1 mt -43.33 96.24 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.078 -1.013 . . . . 0.0 109.417 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.759 ' CB ' HG23 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -101.21 81.62 2.24 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.511 -0.743 . . . . 0.0 110.121 -179.493 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.712 HG23 HD13 ' A' ' 90' ' ' LEU . 4.3 m -61.89 -20.64 63.96 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.989 -1.07 . . . . 0.0 108.936 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.805 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -59.32 -45.49 95.35 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.96 157.56 37.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.377 -1.072 . . . . 0.0 108.729 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -92.01 -10.26 39.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.06 -1.025 . . . . 0.0 110.3 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 1.019 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.24 -173.46 3.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.956 -1.09 . . . . 0.0 110.053 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.574 HG22 ' CD1' ' A' ' 33' ' ' LEU . 33.4 m -103.23 89.01 3.27 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.265 -0.897 . . . . 0.0 111.281 -178.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.015 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.42 172.15 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.55 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.154 HD21 HD11 ' A' ' 13' ' ' ILE . 0.1 OUTLIER -168.68 132.7 1.51 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.085 -1.009 . . . . 0.0 110.571 -178.966 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.541 ' HA ' HG22 ' A' ' 80' ' ' THR . 20.6 mt-10 -41.46 161.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.499 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -61.36 143.7 55.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.036 -1.04 . . . . 0.0 110.043 -179.46 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.544 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -160.1 -179.76 8.04 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.331 -0.855 . . . . 0.0 109.645 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.4 t -92.89 100.0 12.54 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 109.924 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.9 HD12 HG21 ' A' ' 77' ' ' VAL . 12.6 mt -106.45 173.28 3.26 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.658 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.7 Cg_endo -78.18 50.11 3.22 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.327 2.018 . . . . 0.0 112.735 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 34.75 -158.53 0.01 OUTLIER Glycine 0 N--CA 1.498 2.769 0 O-C-N 121.478 -0.763 . . . . 0.0 111.529 178.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.448 ' HG3' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER 53.8 80.33 0.11 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.547 -0.973 . . . . 0.0 109.442 -179.54 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 2.9 p-90 -145.93 -167.85 2.83 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-O 121.506 0.67 . . . . 0.0 109.697 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.44 116.01 11.82 Favored Pre-proline 0 C--N 1.303 -1.433 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.169 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -70.59 138.76 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 121.848 1.698 . . . . 0.0 111.731 -178.225 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.468 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -158.61 133.09 8.05 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.8 OUTLIER -94.03 123.56 37.48 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 -179.729 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.808 HD11 HG21 ' B' ' 50' ' ' ILE . 6.9 pt -92.38 148.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.814 -1.179 . . . . 0.0 108.679 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.525 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -118.39 101.86 0.92 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.764 -1.735 . . . . 0.0 108.764 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.89 -128.28 3.3 Favored Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.522 -1.323 . . . . 0.0 111.056 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.791 HG21 ' CD1' ' B' ' 47' ' ' ILE . 22.4 mt -86.29 114.35 25.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.809 -0.818 . . . . 0.0 112.494 -177.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.507 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.48 -7.14 39.4 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.207 -0.997 . . . . 0.0 110.758 177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.21 -160.98 23.83 Favored Glycine 0 N--CA 1.494 2.516 0 O-C-N 120.894 -1.357 . . . . 0.0 110.405 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.525 ' CZ ' ' HA3' ' A' ' 48' ' ' GLY . 5.1 m-85 -110.73 132.98 53.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.382 -1.07 . . . . 0.0 109.883 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.799 HD12 ' C ' ' A' ' 54' ' ' ILE . 2.6 pp -111.04 162.47 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.065 -1.022 . . . . 0.0 108.603 178.635 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 76.0 mttt -102.36 133.69 46.87 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.034 -1.041 . . . . 0.0 109.673 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.776 HG13 ' CD1' ' A' ' 54' ' ' ILE . 3.1 m -134.77 -173.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.477 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -132.71 100.01 4.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.48 -0.762 . . . . 0.0 109.1 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.514 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 31.8 tt0 -57.92 93.79 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.328 -0.858 . . . . 0.0 109.669 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.724 ' C ' HD11 ' A' ' 62' ' ' ILE . 15.6 m-85 -88.36 125.36 34.66 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.466 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 24.6 m-20 -105.29 137.72 42.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.861 -1.15 . . . . 0.0 110.901 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.528 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 1.7 mm-40 72.62 61.43 0.12 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.792 -0.568 . . . . 0.0 110.614 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.868 ' CG2' HG23 ' A' ' 15' ' ' ILE . 4.9 mp -119.64 123.94 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.066 . . . . 0.0 108.92 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.803 ' O ' HD13 ' A' ' 63' ' ' LEU . 3.3 tm? -69.7 86.56 0.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.316 -0.865 . . . . 0.0 111.831 -178.29 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.576 HG13 ' HB ' ' A' ' 13' ' ' ILE . 3.0 tt -88.32 110.27 20.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 2.0 tt0 -88.77 118.32 28.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.962 -1.086 . . . . 0.0 109.791 -178.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.898 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -108.4 120.2 59.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.326 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.72 -99.01 0.09 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -136.72 39.09 1.68 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.0 m170 -128.45 103.33 7.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.423 -1.045 . . . . 0.0 110.164 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.509 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -60.89 117.32 5.29 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.721 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.01 127.99 35.33 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.278 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.577 HG12 ' CA ' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -105.06 139.46 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.605 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.589 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -162.73 -170.95 28.31 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 118.93 -1.605 . . . . 0.0 110.295 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.581 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 51.9 m -91.02 109.87 21.12 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.695 -0.885 . . . . 0.0 109.798 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.073 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -103.61 112.03 35.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 110.959 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 1.019 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.0 mp -79.57 122.95 27.13 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.9 HG21 HD12 ' A' ' 38' ' ' LEU . 54.3 t -108.39 121.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.945 -1.097 . . . . 0.0 109.907 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -155.22 -165.17 13.83 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.552 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -80.76 42.52 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.564 2.176 . . . . 0.0 110.636 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.571 HG21 HG13 ' A' ' 32' ' ' VAL . 13.1 t -85.9 141.16 35.44 Favored Pre-proline 0 C--N 1.302 -1.473 0 O-C-N 121.156 -0.965 . . . . 0.0 108.814 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.5 Cg_endo -78.87 15.06 1.55 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.475 2.116 . . . . 0.0 111.546 -179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -160.68 167.37 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.787 -1.196 . . . . 0.0 110.371 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.558 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 69.5 m-80 -100.09 92.54 5.29 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 177.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.759 HG23 ' CB ' ' A' ' 25' ' ' ASP . 11.4 mm -78.91 124.33 37.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 O-C-N 121.153 -0.967 . . . . 0.0 111.846 -176.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.61 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -106.22 100.58 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 177.531 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -87.28 -161.61 36.74 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 120.128 -1.034 . . . . 0.0 111.481 -177.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 15.8 mmm180 -62.16 -38.73 90.13 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.843 -0.798 . . . . 0.0 109.841 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.029 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.5 p-10 -43.67 -29.48 0.51 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.231 -0.918 . . . . 0.0 109.387 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.029 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.7 mm? -107.78 -24.62 11.61 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.004 -1.06 . . . . 0.0 109.612 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.712 HD13 HG23 ' A' ' 26' ' ' THR . 14.7 mt -70.41 -5.81 31.04 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.866 -1.146 . . . . 0.0 108.191 178.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.476 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 71.3 p -100.63 -17.87 16.83 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 19.1 mm100 -83.64 -39.19 20.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 109.434 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.092 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -84.95 3.52 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.298 -0.876 . . . . 0.0 109.607 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.56 38.22 51.8 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 120.313 -0.946 . . . . 0.0 111.064 178.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -71.16 138.29 49.47 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.079 -1.248 . . . . 0.0 111.072 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.762 HG22 ' CG2' ' B' ' 4' ' ' THR . 48.7 p -133.18 128.76 36.69 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' B' ' 97' ' ' LEU . 1.6 mp -92.84 85.37 5.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.18 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.8 m120 -89.68 122.39 32.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.097 -1.002 . . . . 0.0 109.747 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.802 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 117.927 -1.035 . . . . 0.0 108.908 178.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.1 tt0 -84.2 131.5 34.75 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.325 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -119.69 118.5 57.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 C-N-CA 118.525 -1.27 . . . . 0.0 110.483 -178.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.762 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.1 OUTLIER -132.31 19.93 4.4 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 178.324 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.572 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -82.17 67.38 8.16 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.531 ' C ' ' O ' ' B' ' 5' ' ' LEU . 41.5 m0 -21.93 84.5 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 CA-C-O 121.578 0.704 . . . . 0.0 111.594 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.572 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.38 -163.04 0.32 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.975 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.42 121.71 71.06 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.115 -0.991 . . . . 0.0 109.27 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.753 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.5 Cg_endo -76.5 74.74 4.63 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.08 1.853 . . . . 0.0 109.068 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.499 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -96.98 147.15 24.28 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.463 -0.773 . . . . 0.0 110.425 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.453 HG21 HG23 ' B' ' 66' ' ' ILE . 0.9 OUTLIER -143.63 132.47 19.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.885 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.951 HG22 HD22 ' B' ' 19' ' ' LEU . 12.0 m -67.54 99.91 0.81 Allowed 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 178.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 3.2 pt -82.73 157.17 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.738 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HB2' ' HB3' ' B' ' 65' ' ' GLU . 0.5 OUTLIER -123.78 98.74 5.95 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.314 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.943 HG23 ' CG2' ' B' ' 62' ' ' ILE . 50.7 mt -113.98 133.37 60.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.332 -0.855 . . . . 0.0 109.605 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.502 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 49.98 54.91 16.71 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.65 34.78 21.59 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.51 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.4 mm100 -124.84 167.08 15.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -1.184 . . . . 0.0 109.185 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.951 HD22 HG22 ' B' ' 12' ' ' THR . 12.0 mt -141.82 129.49 21.55 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.159 -0.963 . . . . 0.0 110.757 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.467 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 20.2 mtmt -151.7 169.43 22.2 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.499 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.1 mp0 -78.99 126.67 31.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.943 -1.098 . . . . 0.0 109.029 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.855 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -106.88 120.77 42.94 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.088 -1.008 . . . . 0.0 110.173 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.805 HD21 ' O ' ' A' ' 27' ' ' GLY . 20.7 tp -91.82 94.75 9.48 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.437 -0.789 . . . . 0.0 110.093 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.753 HD12 ' HB2' ' B' ' 9' ' ' PRO . 58.0 mt -46.49 101.88 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.033 -1.042 . . . . 0.0 108.676 179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.903 ' HB3' HG23 ' B' ' 84' ' ' ILE . 12.4 t0 -113.34 98.2 6.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.92 . . . . 0.0 110.721 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.738 ' CG2' HD22 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -69.88 -15.32 63.06 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.111 -0.993 . . . . 0.0 108.768 178.699 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.455 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.62 -41.03 97.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.73 165.52 22.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.039 -1.271 . . . . 0.0 109.063 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -100.77 -15.42 17.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.132 -0.98 . . . . 0.0 110.573 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.861 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -132.66 -175.33 3.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.712 -1.242 . . . . 0.0 110.316 -179.369 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.62 HG22 ' CD1' ' B' ' 33' ' ' LEU . 72.8 m -103.13 87.92 3.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.017 -1.052 . . . . 0.0 110.053 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.43 163.12 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.52 179.611 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.14 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -160.7 138.45 9.53 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.049 -1.032 . . . . 0.0 110.469 -178.539 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.617 ' N ' HG22 ' B' ' 80' ' ' THR . 2.3 mt-10 -47.97 174.97 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.512 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.2 tm-20 -72.5 143.46 48.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.03 -1.044 . . . . 0.0 109.452 179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.413 ' HG3' ' HG ' ' B' ' 38' ' ' LEU . 6.6 ptm -154.93 -167.92 2.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.393 -0.817 . . . . 0.0 109.204 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -107.22 105.98 16.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.653 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.888 HD12 HG21 ' B' ' 77' ' ' VAL . 90.4 mt -117.21 156.44 48.65 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.486 ' O ' ' O ' ' B' ' 40' ' ' GLY . 35.1 Cg_endo -76.63 74.24 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.885 2.39 . . . . 0.0 112.206 -178.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 34.39 -157.14 0.01 OUTLIER Glycine 0 N--CA 1.497 2.765 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.418 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.3 mtt180 70.02 47.73 0.57 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.263 -1.139 . . . . 0.0 108.459 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 57.4 p-90 -129.12 -179.03 4.89 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 121.824 0.821 . . . . 0.0 110.297 -178.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -145.26 156.48 54.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.667 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -75.75 139.3 22.25 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.803 1.669 . . . . 0.0 110.29 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -144.87 168.82 19.32 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.537 -0.727 . . . . 0.0 109.52 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -150.1 125.08 9.92 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.791 ' CD1' HG21 ' A' ' 50' ' ' ILE . 24.1 pt -120.46 137.82 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 120.74 -1.225 . . . . 0.0 110.385 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.613 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.69 98.51 0.75 Allowed Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.68 -119.02 2.75 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.8 -178.534 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.808 HG21 HD11 ' A' ' 47' ' ' ILE . 16.4 mt -90.39 119.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.689 -0.889 . . . . 0.0 112.337 -177.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.482 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 103.34 -28.11 17.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 120.222 -0.99 . . . . 0.0 110.751 177.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 153.49 -161.9 30.01 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.285 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.613 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 8.4 m-85 -107.31 125.02 50.63 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -1.036 . . . . 0.0 110.138 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.709 HD13 HG23 ' A' ' 50' ' ' ILE . 11.8 pt -105.96 142.0 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.081 -1.012 . . . . 0.0 108.865 178.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.506 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 5.0 mttt -89.06 138.59 31.27 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.031 -1.043 . . . . 0.0 109.294 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.965 HG12 ' HA3' ' B' ' 78' ' ' GLY . 29.4 m -140.44 175.52 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.079 -1.013 . . . . 0.0 110.211 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.592 ' HG2' ' CE3' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -126.29 103.95 7.93 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.403 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.554 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -58.75 112.73 1.74 Allowed 'General case' 0 C--N 1.295 -1.797 0 O-C-N 121.566 -0.709 . . . . 0.0 111.126 -178.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 15.2 m-85 -98.4 124.4 43.06 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.2 m-20 -101.97 130.1 48.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.886 -1.134 . . . . 0.0 111.03 -178.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.611 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 77.98 65.55 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 CA-C-O 121.48 0.657 . . . . 0.0 109.909 179.163 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.943 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.54 119.6 61.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.273 -0.892 . . . . 0.0 109.721 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.669 ' C ' HD13 ' B' ' 63' ' ' LEU . 1.4 tm? -63.9 86.93 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.603 -0.686 . . . . 0.0 111.682 -178.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.599 HG23 ' O ' ' B' ' 64' ' ' ILE . 7.9 tt -93.47 113.03 27.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 176.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' B' ' 14' ' ' LYS . 32.9 tt0 -88.32 120.42 29.67 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 -178.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -114.29 126.34 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.215 -0.928 . . . . 0.0 109.712 -179.253 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 5.7 m 65.18 4.75 2.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.797 -0.564 . . . . 0.0 110.763 179.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 110.81 -6.75 29.49 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.042 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -92.11 139.29 30.78 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.199 -1.177 . . . . 0.0 108.549 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.539 ' CG ' HD11 ' B' ' 63' ' ' LEU . 1.7 mttt -84.47 124.75 31.69 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.177 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.533 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -134.15 157.89 45.04 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.611 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -131.19 133.91 61.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.593 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.593 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -158.42 -166.48 17.68 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 118.617 -1.754 . . . . 0.0 110.995 -179.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.554 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 51.6 m -92.39 107.1 18.96 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.924 -0.751 . . . . 0.0 109.797 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.14 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -103.77 113.29 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.544 -0.723 . . . . 0.0 109.804 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.861 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -78.35 129.25 34.77 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.888 HG21 HD12 ' B' ' 38' ' ' LEU . 95.7 t -113.78 109.95 30.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.895 -1.128 . . . . 0.0 110.039 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.965 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -147.12 -163.59 10.62 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.506 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -79.87 41.37 1.1 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.325 2.016 . . . . 0.0 111.164 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -88.23 139.74 30.42 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.907 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.652 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.8 Cg_endo -79.81 17.32 1.3 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 C-N-CA 122.488 2.126 . . . . 0.0 112.302 -177.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 2.1 t -160.69 164.63 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.527 -1.358 . . . . 0.0 110.992 -179.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.567 ' HA ' ' HG ' ' B' ' 33' ' ' LEU . 1.0 OUTLIER -103.61 87.04 2.74 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.135 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.903 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.7 mt -84.42 123.71 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 O-C-N 121.336 -0.852 . . . . 0.0 112.377 -176.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.597 HD11 ' HB1' ' B' ' 22' ' ' ALA . 3.2 mm -91.78 103.25 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -84.11 -159.16 28.87 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.71 -1.244 . . . . 0.0 110.671 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.551 ' NH1' HG22 ' B' ' 26' ' ' THR . 11.9 mtt-85 -66.24 -35.58 80.8 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.659 -0.907 . . . . 0.0 109.498 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.994 ' ND2' HD23 ' B' ' 89' ' ' LEU . 7.7 p-10 -48.79 -31.65 7.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.921 . . . . 0.0 109.753 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.994 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -106.16 -17.38 14.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.077 . . . . 0.0 110.251 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.523 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 87.4 mt -77.39 -1.66 31.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.143 -0.973 . . . . 0.0 108.529 179.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.598 HG21 ' CZ3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -101.68 -20.58 14.94 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.128 -0.982 . . . . 0.0 108.638 179.038 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.565 HE21 HD13 ' B' ' 89' ' ' LEU . 14.5 mt-30 -75.5 -40.72 56.8 Favored 'General case' 0 N--CA 1.486 1.364 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.802 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -83.39 -9.16 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.411 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.3 36.78 33.61 Favored Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.232 -0.917 . . . . 0.0 111.166 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.643 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -63.7 156.25 27.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.054 -1.263 . . . . 0.0 110.513 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 96' ' ' THR . 66.7 p -147.58 126.61 12.84 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -95.49 89.28 5.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.717 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.56 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.1 m120 -96.13 118.74 33.31 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.055 -1.028 . . . . 0.0 109.318 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 1.092 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.324 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.458 ' HG2' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 N-CA-C 110.501 -0.615 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.557 ' NE2' HG21 ' A' ' 4' ' ' THR . 9.1 tt0 -85.92 126.8 34.36 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 177.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.705 ' O ' HG12 ' A' ' 3' ' ' VAL . 2.4 t -112.33 91.09 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 120.818 -1.176 . . . . 0.0 109.909 -178.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.73 HG22 HG22 ' B' ' 96' ' ' THR . 64.7 p -117.71 33.04 5.82 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.539 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -86.79 30.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.882 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 35.8 m0 17.68 52.49 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.524 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -147.73 -163.37 1.75 Allowed 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -74.68 114.92 39.02 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.997 -1.065 . . . . 0.0 109.839 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.609 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.9 Cg_endo -78.06 71.15 6.79 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 121.976 1.784 . . . . 0.0 108.878 177.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -93.29 157.64 16.14 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.356 -179.167 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.407 ' CG1' ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -149.96 140.55 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.82 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' A' ' 19' ' ' LEU . 9.6 m -73.2 94.15 1.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.416 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.869 HD11 HD21 ' A' ' 33' ' ' LEU . 4.7 pt -80.43 163.82 3.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.538 -0.726 . . . . 0.0 110.791 -178.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 21.7 tttm -129.53 103.23 6.76 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.571 -0.706 . . . . 0.0 109.8 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.918 HG23 ' CG2' ' A' ' 62' ' ' ILE . 39.8 mt -119.55 117.05 52.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 120.994 -1.066 . . . . 0.0 109.38 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.27 25.55 75.28 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.96 -1.63 86.06 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.464 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 tp60 -92.11 167.41 12.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.99 -1.3 . . . . 0.0 109.396 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' A' ' 12' ' ' THR . 36.4 mt -130.2 134.74 47.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.648 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 1.7 tptt -151.32 146.17 25.83 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.627 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 2.7 mm-40 -78.88 107.94 11.98 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.982 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -98.57 131.82 44.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.017 -1.052 . . . . 0.0 111.019 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.604 HD21 ' O ' ' B' ' 27' ' ' GLY . 0.8 OUTLIER -87.33 105.09 17.01 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.901 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.522 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -46.99 120.36 3.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.966 -1.084 . . . . 0.0 108.4 179.702 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.851 ' HB2' HG23 ' A' ' 84' ' ' ILE . 56.7 t0 -124.54 83.99 2.22 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.221 -0.925 . . . . 0.0 110.488 -178.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.676 HG23 HD13 ' A' ' 90' ' ' LEU . 3.2 m -65.74 -15.26 62.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.036 -1.04 . . . . 0.0 108.565 178.807 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.524 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -67.13 -45.59 80.22 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.81 167.54 19.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -1.184 . . . . 0.0 108.597 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -99.92 -19.8 16.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.828 -1.17 . . . . 0.0 110.785 -178.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 1.031 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.01 179.35 6.37 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.89 -1.131 . . . . 0.0 109.781 -179.687 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.594 HG22 ' CD1' ' A' ' 33' ' ' LEU . 7.4 m -94.66 92.81 7.2 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 120.826 -1.171 . . . . 0.0 110.011 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.872 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -84.49 118.96 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.232 -0.918 . . . . 0.0 109.102 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.869 HD21 HD11 ' A' ' 13' ' ' ILE . 1.2 mp -114.1 144.41 43.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.952 -1.093 . . . . 0.0 111.128 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.86 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -47.17 174.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.381 -0.825 . . . . 0.0 108.922 178.569 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -57.59 146.13 31.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.027 . . . . 0.0 109.642 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.502 ' HG3' ' N ' ' A' ' 37' ' ' SER . 2.7 ptm -163.7 -175.49 4.16 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.392 -0.818 . . . . 0.0 109.043 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.502 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.9 t -110.74 120.44 42.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.113 -0.992 . . . . 0.0 109.788 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.783 HD12 HG21 ' A' ' 77' ' ' VAL . 82.0 mt -132.9 159.17 73.7 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.478 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 34.4 Cg_endo -76.42 133.0 14.08 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.823 2.348 . . . . 0.0 112.436 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -37.25 129.48 1.23 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.469 -1.053 . . . . 0.0 110.469 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.0 OUTLIER 148.19 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -179.519 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.617 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 50.4 p-90 -138.56 -173.29 3.51 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.741 0.782 . . . . 0.0 110.355 -177.234 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.454 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 0.0 OUTLIER -148.94 163.8 24.0 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 179.14 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 36.0 Cg_endo -78.37 145.66 21.41 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.966 1.777 . . . . 0.0 109.979 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.756 ' HB2' HG23 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -146.52 142.78 28.4 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.153 -0.967 . . . . 0.0 109.67 -179.52 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.497 ' CE ' ' HE3' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -121.97 107.24 12.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 108.675 179.475 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.672 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.9 pt -101.81 132.39 47.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.588 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 53' ' ' PHE . . . -117.7 105.38 1.25 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.88 -115.89 2.45 Favored Glycine 0 N--CA 1.481 1.695 0 C-N-CA 119.715 -1.231 . . . . 0.0 110.768 -178.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.732 HG21 HD12 ' B' ' 47' ' ' ILE . 25.6 mt -88.6 116.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 O-C-N 121.832 -0.805 . . . . 0.0 112.834 -177.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.544 ' HA2' HG22 ' B' ' 54' ' ' ILE . . . 106.7 -42.35 1.94 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 166.68 -160.98 34.75 Favored Glycine 0 N--CA 1.49 2.259 0 O-C-N 120.833 -1.392 . . . . 0.0 110.172 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.514 ' HA ' ' HA2' ' A' ' 48' ' ' GLY . 6.8 m-85 -102.1 155.79 17.97 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.449 -1.03 . . . . 0.0 110.042 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.647 HD11 HD11 ' A' ' 47' ' ' ILE . 2.1 pt -134.42 173.54 14.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 3.3 mttt -114.15 144.62 42.86 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.315 -0.866 . . . . 0.0 108.742 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB2' ' A' ' 45' ' ' LYS . 30.6 m -143.39 -177.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.624 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.525 ' O ' ' N ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -131.52 88.82 2.62 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.547 ' HG3' HG23 ' A' ' 74' ' ' THR . 3.5 tt0 -46.76 91.7 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.497 -0.752 . . . . 0.0 109.804 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 12.5 m-85 -89.96 95.68 10.33 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.525 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 12.2 m-20 -79.22 133.2 36.69 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.161 -0.962 . . . . 0.0 109.972 -179.004 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 20.4 mm-40 81.8 61.68 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.495 0.664 . . . . 0.0 110.166 179.171 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.918 ' CG2' HG23 ' A' ' 15' ' ' ILE . 15.4 mm -115.99 120.35 64.59 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.858 ' O ' HD13 ' A' ' 63' ' ' LEU . 1.9 tm? -72.45 81.18 1.06 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.171 -0.956 . . . . 0.0 111.094 -178.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.812 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -87.66 117.93 32.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.487 ' HG3' ' N ' ' A' ' 70' ' ' LYS . 1.5 tt0 -93.91 112.38 24.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.07 -1.019 . . . . 0.0 109.763 -178.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.801 HG13 HG22 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -100.34 118.81 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.3 m 56.42 54.55 7.45 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.735 -0.603 . . . . 0.0 109.807 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 57.69 16.55 23.72 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.446 ' C ' ' HG3' ' A' ' 65' ' ' GLU . 25.7 m170 -107.93 91.18 3.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -1.223 . . . . 0.0 109.494 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -43.42 137.25 2.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 179.712 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -159.25 124.83 4.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.515 -0.74 . . . . 0.0 109.415 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.68 HD13 ' C ' ' A' ' 62' ' ' ILE . 1.0 OUTLIER -95.32 152.45 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.877 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.443 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.41 -171.82 39.73 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 118.832 -1.652 . . . . 0.0 111.089 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.547 HG23 ' HG3' ' A' ' 58' ' ' GLN . 96.5 m -98.49 108.85 21.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -1.134 . . . . 0.0 110.619 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.83 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -99.24 109.92 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.675 -0.641 . . . . 0.0 110.349 179.153 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 1.031 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.4 100.95 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.783 HG21 HD12 ' A' ' 38' ' ' LEU . 21.6 t -87.1 121.86 38.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.98 -1.075 . . . . 0.0 110.248 -178.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.534 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -156.76 -166.15 15.97 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.552 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 35.7 Cg_endo -80.84 40.67 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.403 2.069 . . . . 0.0 111.103 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.86 HG22 ' HA ' ' A' ' 34' ' ' GLU . 13.4 t -81.36 140.5 48.71 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.713 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.0 Cg_endo -78.73 15.75 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.595 2.197 . . . . 0.0 111.279 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 81' ' ' PRO . 5.2 t -160.53 163.36 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.94 -1.1 . . . . 0.0 110.514 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.648 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -101.01 85.57 2.88 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 105.045 -2.205 . . . . 0.0 105.045 177.109 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.851 HG23 ' HB2' ' A' ' 25' ' ' ASP . 4.6 mt -88.88 125.31 41.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.139 -0.975 . . . . 0.0 112.69 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.982 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -84.88 149.48 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 176.503 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.496 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -125.61 -170.23 13.01 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.672 -1.728 . . . . 0.0 110.462 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HD3' ' HB2' ' A' ' 90' ' ' LEU . 6.4 mmt180 -62.98 -26.75 68.99 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.444 -1.033 . . . . 0.0 108.416 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.023 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.7 p-10 -57.65 -28.44 63.74 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.433 -0.792 . . . . 0.0 109.141 179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.023 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -102.36 -24.37 13.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.287 -0.883 . . . . 0.0 109.208 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.676 HD13 HG23 ' A' ' 26' ' ' THR . 41.0 mt -71.51 -4.8 28.76 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.466 ' HB ' ' CE2' ' B' ' 6' ' ' TRP . 21.7 p -101.14 -16.08 17.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.256 -0.902 . . . . 0.0 108.717 178.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mm-40 -86.66 -40.81 14.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.31 -0.868 . . . . 0.0 109.433 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.774 HD12 ' CD2' ' B' ' 99' ' ' PHE . 1.6 pt -85.67 0.71 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.131 -0.981 . . . . 0.0 108.724 179.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.03 51.49 50.47 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.525 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.1 155.29 23.92 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.031 -1.276 . . . . 0.0 109.802 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.74 HG22 ' CG2' ' B' ' 4' ' ' THR . 10.5 p -147.98 130.88 16.16 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' B' ' 97' ' ' LEU . 4.6 mp -91.29 100.86 13.59 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.421 -0.799 . . . . 0.0 109.698 -179.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.546 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 1.6 m120 -102.2 123.37 45.92 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.961 -1.087 . . . . 0.0 109.111 179.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.836 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.09 -0.957 . . . . 0.0 109.241 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.494 1.509 0 N-CA-C 110.041 -0.792 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.546 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.7 tt0 -83.55 133.78 34.85 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 178.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 30.7 t -132.69 122.5 47.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.756 -177.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.74 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.4 OUTLIER -132.46 -79.46 0.5 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.612 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 60.1 mt 28.27 38.64 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.095 178.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 25.7 m0 16.51 52.75 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 CA-C-O 121.252 0.549 . . . . 0.0 111.619 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 9.9 mt-30 -142.09 -179.46 6.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 109.868 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -75.62 122.35 86.97 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 1.064 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 75.73 4.46 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.078 1.852 . . . . 0.0 109.836 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.529 ' CD2' ' CB ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -91.78 154.91 18.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.904 . . . . 0.0 109.695 -179.543 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.623 HG21 HG12 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -147.91 134.98 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 0.0 109.908 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.653 ' CG2' HD23 ' B' ' 19' ' ' LEU . 6.9 m -68.15 105.1 1.97 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.766 -1.208 . . . . 0.0 108.555 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 1.052 HG22 HG13 ' B' ' 66' ' ' ILE . 1.2 pt -92.86 156.75 3.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.944 -1.098 . . . . 0.0 110.261 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.793 ' HG3' HD12 ' B' ' 19' ' ' LEU . 10.5 tttm -121.99 100.06 6.78 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.762 ' CD1' HG11 ' B' ' 75' ' ' VAL . 13.1 mt -116.71 124.24 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.108 -0.995 . . . . 0.0 110.122 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.83 38.86 93.04 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 68.45 21.13 74.21 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.526 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -110.13 171.0 7.71 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.201 -1.176 . . . . 0.0 109.136 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.793 HD12 ' HG3' ' B' ' 14' ' ' LYS . 0.1 OUTLIER -148.14 124.36 10.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.298 -0.876 . . . . 0.0 110.565 -179.378 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mtmp? -151.05 169.23 22.33 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.547 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -81.92 119.02 23.41 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 120.989 -1.069 . . . . 0.0 109.197 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.968 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -94.91 130.51 41.49 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.312 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.524 HD21 ' O ' ' A' ' 27' ' ' GLY . 19.0 tp -92.89 92.34 7.85 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 1.064 HD12 ' HB2' ' B' ' 9' ' ' PRO . 92.4 mt -44.11 96.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.287 -0.883 . . . . 0.0 108.998 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.784 ' HB3' HG23 ' B' ' 84' ' ' ILE . 3.8 t0 -105.64 86.53 2.42 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.4 -0.813 . . . . 0.0 109.555 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.665 HG23 HD13 ' B' ' 90' ' ' LEU . 0.6 OUTLIER -63.2 -9.44 11.22 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.267 -0.896 . . . . 0.0 109.443 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.604 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.26 -41.13 47.44 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . 0.474 ' O ' ' NH1' ' B' ' 87' ' ' ARG . . . -76.36 145.45 39.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.176 -1.191 . . . . 0.0 109.417 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.93 -16.22 60.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.322 -0.861 . . . . 0.0 111.614 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.786 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -139.03 -167.47 2.23 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.548 -1.345 . . . . 0.0 110.255 -179.532 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.697 HG23 ' O ' ' B' ' 84' ' ' ILE . 23.5 m -107.88 93.71 4.68 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.247 -0.908 . . . . 0.0 110.695 -178.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.0 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.22 167.2 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.133 -0.98 . . . . 0.0 108.599 179.171 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.124 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.56 136.89 4.66 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.826 -1.171 . . . . 0.0 111.188 -178.258 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.592 ' O ' HG13 ' B' ' 77' ' ' VAL . 2.9 tt0 -45.31 157.35 0.09 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.83 . . . . 0.0 109.436 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.668 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.0 mt-10 -49.52 151.28 1.65 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.227 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 4.9 ptm -173.33 161.86 4.25 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.455 -0.778 . . . . 0.0 109.035 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 23.5 t -82.17 110.38 17.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.152 -0.967 . . . . 0.0 110.046 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.771 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 48.4 mt -119.36 175.98 1.95 Allowed Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.771 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.4 Cg_endo -71.79 -161.9 0.11 Allowed 'Trans proline' 0 C--N 1.319 -1.006 0 C-N-CA 121.539 1.493 . . . . 0.0 111.945 -178.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.73 35.86 4.74 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -178.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.4 mmt-85 -118.18 62.92 0.76 Allowed 'General case' 0 C--N 1.29 -1.991 0 O-C-N 121.598 -0.942 . . . . 0.0 109.042 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.705 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 8.3 p-90 -142.97 -172.35 3.65 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -149.26 139.77 13.65 Favored Pre-proline 0 C--N 1.303 -1.414 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.53 130.67 10.01 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.214 1.943 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.557 ' O ' HG22 ' B' ' 56' ' ' VAL . 3.6 ptmt -162.21 145.61 11.79 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.505 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 42.7 mtp -103.41 137.64 41.24 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.924 -1.11 . . . . 0.0 109.654 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' A' ' 50' ' ' ILE . 3.9 pt -96.45 145.78 8.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.095 -1.003 . . . . 0.0 108.392 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.87 101.27 0.86 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.53 -127.43 3.16 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.749 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.672 HG21 ' CD1' ' A' ' 47' ' ' ILE . 46.4 mt -81.79 132.31 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.835 -0.803 . . . . 0.0 112.207 -177.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.545 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 89.21 -44.71 3.11 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 178.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.24 -162.73 34.8 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -115.72 130.76 56.97 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.435 -1.038 . . . . 0.0 109.22 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.544 HG22 ' HA2' ' A' ' 51' ' ' GLY . 23.8 pt -110.51 144.24 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.828 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 10.4 mtmm -72.08 144.06 48.84 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.298 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.557 HG22 ' O ' ' B' ' 45' ' ' LYS . 29.5 m -145.42 -170.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.103 -0.998 . . . . 0.0 109.873 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.583 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.4 mtt180 -142.4 102.16 4.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.329 -0.857 . . . . 0.0 109.332 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.679 ' HG3' HG22 ' B' ' 74' ' ' THR . 5.5 tt0 -64.77 113.07 3.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -0.893 . . . . 0.0 109.961 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.705 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 19.1 m-85 -104.38 95.51 5.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.442 -0.786 . . . . 0.0 108.941 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.1 m-20 -78.71 137.77 37.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.966 -1.084 . . . . 0.0 109.972 -179.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.535 ' HA ' HG23 ' B' ' 72' ' ' ILE . 1.3 mm-40 77.66 64.12 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.456 0.646 . . . . 0.0 109.869 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.797 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.6 OUTLIER -126.48 119.27 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.621 HD11 ' HG3' ' B' ' 70' ' ' LYS . 0.2 OUTLIER -72.53 85.29 1.15 Allowed 'General case' 0 C--N 1.296 -1.724 0 O-C-N 120.933 -1.104 . . . . 0.0 111.805 -177.526 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.645 ' CG2' HD11 ' B' ' 89' ' ' LEU . 4.4 tt -89.49 115.04 28.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 10.1 tt0 -89.57 117.38 28.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 1.052 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -110.27 120.68 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.244 -0.91 . . . . 0.0 108.88 179.37 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 57.95 50.71 9.9 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.446 -0.784 . . . . 0.0 109.67 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 59.76 16.77 39.73 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.48 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 69.9 m-70 -106.01 121.15 43.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.101 -1.235 . . . . 0.0 109.531 179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.621 ' HG3' HD11 ' B' ' 63' ' ' LEU . 21.4 ttpt -69.45 122.03 18.17 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.41 -0.806 . . . . 0.0 109.585 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.751 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -139.64 106.98 5.52 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 110.356 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.797 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.4 OUTLIER -87.04 139.03 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 177.811 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.18 -159.0 9.69 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 118.545 -1.788 . . . . 0.0 111.285 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.679 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.3 m -109.17 102.57 11.51 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.64 -0.917 . . . . 0.0 109.67 -179.543 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.124 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -96.91 111.38 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.241 -0.912 . . . . 0.0 111.107 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.786 HD11 ' HB3' ' B' ' 30' ' ' ASP . 1.8 mp -78.39 134.18 37.45 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.754 HG21 ' CD1' ' B' ' 38' ' ' LEU . 46.5 t -124.43 131.29 72.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 120.869 -1.144 . . . . 0.0 110.145 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.63 -160.37 11.56 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.85 40.79 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.369 2.046 . . . . 0.0 110.401 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' B' ' 32' ' ' VAL . 4.6 t -84.94 138.28 37.37 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.507 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.4 Cg_endo -79.48 23.34 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 122.475 2.117 . . . . 0.0 111.668 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.564 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -161.67 170.46 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.669 -1.269 . . . . 0.0 110.113 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 0.1 OUTLIER -110.19 92.73 4.16 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.122 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.784 HG23 ' HB3' ' B' ' 25' ' ' ASP . 20.2 mm -78.77 128.23 38.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.385 -0.822 . . . . 0.0 112.893 -175.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.968 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.4 mp -108.15 89.29 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 176.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -79.53 -162.36 24.26 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.313 -177.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.544 ' NH1' ' O ' ' B' ' 26' ' ' THR . 0.1 OUTLIER -61.89 -40.04 94.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.766 -0.844 . . . . 0.0 110.232 -179.219 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.039 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.6 p-10 -43.84 -28.89 0.48 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.141 -0.974 . . . . 0.0 109.465 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.039 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.8 mm? -107.27 -29.61 9.21 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.185 -0.947 . . . . 0.0 110.048 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.717 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 13.6 mt -72.81 -3.66 26.83 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.03 -1.044 . . . . 0.0 108.506 179.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.503 ' O ' ' CZ2' ' A' ' 6' ' ' TRP . 15.5 p -101.72 -20.21 15.07 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.167 -0.958 . . . . 0.0 108.857 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.751 HE21 ' HB1' ' B' ' 71' ' ' ALA . 6.7 mt-30 -82.87 -38.05 23.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.321 -0.862 . . . . 0.0 109.236 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.836 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -81.06 3.71 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.877 . . . . 0.0 108.978 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.509 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 72.5 46.25 33.36 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.311 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.717 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -82.3 136.03 35.1 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.082 -1.246 . . . . 0.0 110.728 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 4' ' ' THR . 36.3 p -131.78 129.43 40.53 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -92.34 93.08 8.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.923 -1.11 . . . . 0.0 109.495 -179.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.3 m120 -100.39 127.27 46.76 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -0.918 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.774 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.213 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.578 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.013 -0.803 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 11.9 tt0 -84.15 138.94 32.75 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 177.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.8 t -140.04 116.27 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 117.857 -1.537 . . . . 0.0 111.921 -177.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.53 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.1 OUTLIER -121.34 -62.75 1.39 Allowed 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 176.874 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.594 ' O ' HD23 ' A' ' 5' ' ' LEU . 0.4 OUTLIER 35.92 26.23 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.903 177.399 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.616 ' HA ' HG21 ' B' ' 91' ' ' THR . 27.8 m95 17.82 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.298 0.57 . . . . 0.0 112.252 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.582 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -161.91 -157.47 0.48 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.215 179.856 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.478 ' HG2' ' OD1' ' B' ' 29' ' ' ASP . 40.9 mtm180 -78.8 128.82 75.64 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 120.894 -1.129 . . . . 0.0 109.893 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.64 66.02 8.86 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.36 2.04 . . . . 0.0 108.49 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.614 HD23 ' H ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -90.2 145.18 25.21 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.33 -0.856 . . . . 0.0 110.756 -178.182 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.469 HG23 ' N ' ' A' ' 12' ' ' THR . 0.6 OUTLIER -150.51 164.14 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.277 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.592 HG22 HD22 ' A' ' 19' ' ' LEU . 51.8 m -86.64 133.31 33.71 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 178.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.862 ' O ' HD23 ' A' ' 19' ' ' LEU . 8.3 pt -121.92 156.73 26.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.996 -1.065 . . . . 0.0 110.384 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 8.0 tttt -117.94 100.55 7.63 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.762 HD11 HD12 ' A' ' 64' ' ' ILE . 18.0 mt -112.24 145.78 17.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.368 -0.832 . . . . 0.0 110.298 -178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 39.82 41.15 1.78 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.84 44.59 94.47 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.552 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -144.13 176.56 9.22 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.121 -1.223 . . . . 0.0 108.756 179.537 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.862 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.0 mt -140.02 123.71 17.32 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 119.305 -0.958 . . . . 0.0 110.535 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -143.27 177.02 8.7 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 179.1 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.542 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 15.3 mp0 -79.86 -178.97 6.7 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.613 -1.304 . . . . 0.0 108.057 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.614 ' H ' HD23 ' A' ' 10' ' ' LEU . . . -160.81 109.53 1.62 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.841 -1.162 . . . . 0.0 110.046 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.611 HD21 ' O ' ' B' ' 27' ' ' GLY . 27.3 tp -89.26 89.36 7.88 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.669 -0.644 . . . . 0.0 109.307 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.555 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 58.2 mt -42.49 97.04 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 56.9 t0 -106.36 87.08 2.47 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.582 -0.699 . . . . 0.0 110.788 -177.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -62.15 -20.15 63.8 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.974 -1.079 . . . . 0.0 108.804 178.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.56 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -58.73 -48.24 86.07 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.55 160.63 31.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.311 -1.111 . . . . 0.0 108.591 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.414 ' OD1' ' HG2' ' B' ' 8' ' ' ARG . 61.9 m-20 -96.65 -11.21 25.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.986 -1.071 . . . . 0.0 110.421 -179.014 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.562 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -138.98 -165.56 1.86 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.089 . . . . 0.0 110.624 -179.211 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.539 ' HG1' ' HA ' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -104.0 88.54 3.05 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.069 -1.019 . . . . 0.0 111.658 -178.001 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.775 HG21 HD13 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -72.94 122.99 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.317 -1.49 . . . . 0.0 107.333 177.784 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.787 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.4 OUTLIER -131.27 131.87 44.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.539 -1.351 . . . . 0.0 111.345 -177.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 33' ' ' LEU . 10.5 pt-20 -41.91 152.98 0.07 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.87 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -50.36 144.44 7.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.213 -0.93 . . . . 0.0 110.239 -179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.452 ' SD ' ' O ' ' A' ' 37' ' ' SER . 0.0 OUTLIER -171.4 179.5 2.91 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.402 -0.811 . . . . 0.0 109.169 179.636 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.452 ' O ' ' SD ' ' A' ' 36' ' ' MET . 8.0 t -84.01 111.08 18.96 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.1 -1.0 . . . . 0.0 109.834 -179.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.845 HD11 HD12 ' A' ' 62' ' ' ILE . 18.6 tp -154.0 90.42 3.29 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 109.702 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -80.21 162.34 22.9 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.667 2.245 . . . . 0.0 110.408 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . 129.96 42.25 0.22 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.486 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER 61.1 150.68 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.658 -0.907 . . . . 0.0 109.047 -179.658 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.609 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 26.8 p-90 -154.2 158.38 40.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.101 -0.999 . . . . 0.0 109.807 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -120.67 138.38 27.47 Favored Pre-proline 0 C--N 1.299 -1.613 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.16 134.42 17.53 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 121.568 1.512 . . . . 0.0 108.736 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 46' ' ' MET . 7.1 tttt -148.15 163.49 36.79 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.548 -178.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.498 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 3.9 tpt -134.16 114.13 12.77 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.775 HD13 HG21 ' A' ' 32' ' ' VAL . 17.5 pt -89.68 143.25 11.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.619 -1.232 . . . . 0.0 109.802 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.653 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.07 98.36 0.76 Allowed Glycine 0 N--CA 1.485 1.911 0 N-CA-C 107.916 -2.074 . . . . 0.0 107.916 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.96 -136.31 4.8 Favored Glycine 0 C--N 1.298 -1.559 0 C-N-CA 119.315 -1.421 . . . . 0.0 111.387 -178.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.89 HG23 HD13 ' B' ' 54' ' ' ILE . 80.6 mt -78.92 132.17 32.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.768 0.794 . . . . 0.0 112.962 -177.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.466 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 85.81 -41.58 3.09 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.84 -165.11 36.16 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.493 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.653 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 1.1 m-85 -111.04 138.89 46.89 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.647 -0.914 . . . . 0.0 109.244 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.55 HG12 HD11 ' A' ' 47' ' ' ILE . 4.9 pt -119.71 134.13 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.853 -1.154 . . . . 0.0 108.854 178.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.496 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 4.2 mttp -74.86 133.38 41.86 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.954 -1.091 . . . . 0.0 110.119 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 1.025 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.2 m -144.57 166.77 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.255 -0.903 . . . . 0.0 109.773 179.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.516 ' HG2' ' CE3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -111.31 172.8 6.67 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.828 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.51 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 37.1 tt0 -135.02 102.82 5.34 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.839 -1.163 . . . . 0.0 110.815 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.609 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 87.8 m-85 -91.31 123.0 34.41 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.504 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -96.37 145.82 25.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 110.463 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.504 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.8 OUTLIER 75.96 64.51 0.05 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.65 -0.656 . . . . 0.0 110.147 179.425 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.845 HD12 HD11 ' A' ' 38' ' ' LEU . 15.2 mm -124.13 119.91 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.331 -0.855 . . . . 0.0 109.473 179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.776 HD21 ' HG3' ' A' ' 70' ' ' LYS . 3.2 tm? -69.85 94.81 0.86 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.665 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.762 HD12 HD11 ' A' ' 15' ' ' ILE . 9.5 tt -96.62 119.2 44.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.1 tt0 -89.7 103.38 16.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.004 -1.06 . . . . 0.0 109.899 -178.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.838 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -96.76 116.18 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.199 -0.938 . . . . 0.0 109.821 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 62.32 17.13 9.11 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.809 -0.557 . . . . 0.0 110.683 178.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.33 6.73 55.16 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.745 -1.217 . . . . 0.0 110.409 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -104.64 133.79 48.89 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.186 -1.184 . . . . 0.0 109.196 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.776 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -76.09 130.95 39.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.966 . . . . 0.0 109.042 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -150.06 97.96 2.64 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.453 -0.78 . . . . 0.0 110.465 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.568 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -79.03 137.15 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.642 -1.286 . . . . 0.0 107.883 178.791 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.418 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -157.93 -167.88 19.49 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.536 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 31' ' ' THR . 26.0 m -97.7 102.08 13.75 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.533 -0.981 . . . . 0.0 109.516 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.787 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.8 OUTLIER -91.47 173.91 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.265 -0.897 . . . . 0.0 109.357 179.727 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -132.54 163.3 29.16 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 179.557 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.87 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.2 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 120.948 -1.095 . . . . 0.0 110.457 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 1.025 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -139.82 -169.53 11.67 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 47.27 2.49 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.551 2.167 . . . . 0.0 110.791 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.684 HG21 HG13 ' A' ' 32' ' ' VAL . 14.8 t -91.02 139.87 25.9 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.147 -0.971 . . . . 0.0 109.133 179.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.34 19.51 0.93 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.696 2.264 . . . . 0.0 112.646 -178.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 1.2 t -160.24 171.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.415 -1.428 . . . . 0.0 110.396 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.574 ' N ' HG13 ' A' ' 82' ' ' VAL . 74.0 m-20 -104.9 83.74 2.04 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.673 ' CG1' HG12 ' A' ' 32' ' ' VAL . 7.7 mm -75.74 113.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.461 -0.775 . . . . 0.0 111.712 -176.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.537 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -93.92 94.09 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.84 -172.25 41.41 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.797 -1.19 . . . . 0.0 111.589 -177.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 88' ' ' ASN . 1.2 mtt-85 -56.69 -36.05 69.17 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.957 -0.731 . . . . 0.0 110.38 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.778 ' ND2' HD23 ' A' ' 89' ' ' LEU . 5.8 p-10 -43.39 -40.45 3.7 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.057 -1.027 . . . . 0.0 109.15 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.778 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -94.53 -30.04 14.6 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.318 -0.864 . . . . 0.0 111.02 -179.299 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.801 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 28.2 mt -65.99 -6.83 13.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.533 -1.354 . . . . 0.0 109.795 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.793 HG21 ' CG ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -101.42 -15.0 17.33 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.978 -1.076 . . . . 0.0 109.101 179.743 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.486 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -80.0 -41.15 26.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.577 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.819 HD12 ' CG ' ' B' ' 99' ' ' PHE . 4.5 pt -82.71 5.49 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.955 . . . . 0.0 108.756 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.52 41.64 35.67 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.876 -1.289 . . . . 0.0 109.876 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' A' ' 90' ' ' LEU . . . -81.81 137.8 35.23 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 120.882 -1.363 . . . . 0.0 110.09 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.821 HG22 ' CG2' ' B' ' 4' ' ' THR . 11.2 p -136.6 130.38 32.23 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' B' ' 97' ' ' LEU . 1.9 mp -88.26 92.16 9.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.747 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.559 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.8 m120 -95.35 123.42 38.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.095 -1.003 . . . . 0.0 109.407 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.872 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 117.93 -1.034 . . . . 0.0 109.529 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.604 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.498 1.778 0 N-CA-C 110.326 -0.682 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.499 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -85.01 131.6 34.45 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.262 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 16.5 t -127.37 127.76 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.851 -1.156 . . . . 0.0 110.859 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.821 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -149.44 25.78 0.86 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -82.47 45.07 0.93 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.705 -0.622 . . . . 0.0 110.94 -178.135 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.793 ' CG ' HG21 ' A' ' 91' ' ' THR . 13.8 m95 18.84 51.7 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.177 0.513 . . . . 0.0 111.214 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.531 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.5 OUTLIER -141.53 -168.5 2.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.982 -1.074 . . . . 0.0 110.336 -179.224 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.414 ' HG2' ' OD1' ' A' ' 29' ' ' ASP . 0.2 OUTLIER -91.76 128.94 44.13 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.399 -0.813 . . . . 0.0 109.148 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.3 Cg_endo -76.52 72.83 5.41 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.305 2.003 . . . . 0.0 109.879 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.506 HD22 ' HB2' ' B' ' 21' ' ' GLU . 3.2 mt -95.68 134.75 38.23 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.753 -1.217 . . . . 0.0 109.936 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.454 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -140.44 154.71 22.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.09 102.78 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 178.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.981 ' CD1' HD12 ' B' ' 15' ' ' ILE . 1.7 pp -87.64 148.68 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.466 -0.772 . . . . 0.0 109.649 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.518 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 16.8 ttmt -117.38 107.88 14.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.399 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.981 HD12 ' CD1' ' B' ' 13' ' ' ILE . 0.9 OUTLIER -117.39 125.26 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.151 -0.968 . . . . 0.0 109.647 -179.6 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.36 14.29 68.87 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 6.71 69.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.518 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.2 mt-30 -97.83 167.55 10.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.324 -1.103 . . . . 0.0 108.839 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.464 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 16.2 mt -131.99 129.73 40.52 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.122 -0.986 . . . . 0.0 111.164 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.606 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -149.79 168.61 23.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 177.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.546 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 7.2 pt-20 -78.3 -166.09 0.78 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.684 ' HB2' HG23 ' B' ' 13' ' ' ILE . . . -168.8 109.84 0.5 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.844 -1.16 . . . . 0.0 109.955 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.558 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.1 tp -83.76 93.66 8.0 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.458 -0.777 . . . . 0.0 109.181 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.705 HD22 HG21 ' B' ' 85' ' ' ILE . 26.7 mt -44.63 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 7.5 t0 -99.01 81.78 2.64 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.583 -0.698 . . . . 0.0 109.897 -178.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.557 ' CG2' ' HD3' ' B' ' 87' ' ' ARG . 10.6 m -58.6 -17.27 20.53 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.611 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.26 -43.98 96.2 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . 0.43 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -72.31 169.33 16.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.133 -1.216 . . . . 0.0 108.852 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.478 ' OD1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -100.31 -20.37 15.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 110.217 -179.198 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 4.8 m-20 -132.9 -166.88 1.82 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.994 -1.066 . . . . 0.0 110.206 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' B' ' 33' ' ' LEU . 9.0 m -107.02 89.3 2.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.816 -1.178 . . . . 0.0 111.397 -177.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.96 HG13 HG21 ' B' ' 80' ' ' THR . 0.6 OUTLIER -68.63 160.45 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.347 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.889 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -157.83 133.92 9.39 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.759 -1.213 . . . . 0.0 111.394 -177.741 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.469 ' OE1' ' O ' ' B' ' 80' ' ' THR . 15.1 tp10 -42.34 141.88 0.88 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.732 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -41.07 150.47 0.08 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.462 -0.774 . . . . 0.0 110.252 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.49 ' HE1' ' O ' ' B' ' 15' ' ' ILE . 0.1 OUTLIER -170.66 -175.87 1.94 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 11.1 t -109.48 101.76 10.68 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.826 -1.171 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.905 HD12 HG21 ' B' ' 77' ' ' VAL . 6.2 mt -97.08 170.25 7.55 Favored Pre-proline 0 N--CA 1.489 1.482 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.579 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.0 Cg_endo -76.06 68.31 6.61 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.407 2.071 . . . . 0.0 112.537 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 32.75 -157.27 0.01 OUTLIER Glycine 0 N--CA 1.498 2.771 0 CA-C-O 121.918 0.732 . . . . 0.0 111.594 178.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 54.31 81.91 0.1 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.312 -1.11 . . . . 0.0 109.213 -179.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.544 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 58.0 p-90 -155.84 -176.19 5.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.531 -0.73 . . . . 0.0 109.581 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -141.09 159.52 61.35 Favored Pre-proline 0 N--CA 1.489 1.496 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.93 139.94 12.4 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 C-N-CA 122.249 1.966 . . . . 0.0 110.998 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.644 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -148.38 118.63 7.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.401 -0.812 . . . . 0.0 108.977 179.543 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.521 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -96.24 129.57 43.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.05 -1.031 . . . . 0.0 109.557 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.602 HD11 HD11 ' B' ' 54' ' ' ILE . 41.0 pt -117.14 132.0 68.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.099 179.01 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.94 100.97 0.84 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 107.976 -2.049 . . . . 0.0 107.976 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -118.61 -125.87 3.51 Favored Glycine 0 N--CA 1.483 1.804 0 C-N-CA 119.184 -1.484 . . . . 0.0 111.038 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.506 ' O ' ' O ' ' A' ' 50' ' ' ILE . 52.9 mt -84.56 121.41 36.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.568 -0.96 . . . . 0.0 112.981 -177.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.506 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 100.74 -36.8 3.92 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.172 177.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 169.86 -154.83 24.2 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.553 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.614 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.5 OUTLIER -120.4 140.76 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.53 -0.983 . . . . 0.0 109.718 -179.659 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.89 HD13 HG23 ' A' ' 50' ' ' ILE . 12.5 pt -124.33 132.07 71.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.311 -0.868 . . . . 0.0 108.976 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.524 ' O ' ' HD3' ' B' ' 79' ' ' PRO . 15.2 mttt -77.45 140.3 39.82 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.047 -1.033 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.897 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.0 m -138.56 175.07 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 109.956 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.421 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 18.4 mtt-85 -124.86 102.35 7.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.501 -0.749 . . . . 0.0 109.054 179.622 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.559 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.7 OUTLIER -60.28 94.75 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.47 -0.769 . . . . 0.0 110.772 -179.653 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 29.9 m-85 -89.88 114.4 26.17 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.566 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -93.47 143.18 26.53 Favored 'General case' 0 C--N 1.296 -1.748 0 O-C-N 120.912 -1.117 . . . . 0.0 110.337 -178.83 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.566 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 73.18 63.08 0.1 Allowed 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.368 0.604 . . . . 0.0 110.54 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 8.1 mm -120.53 110.76 29.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 178.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.623 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.0 OUTLIER -63.15 87.41 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.033 -1.042 . . . . 0.0 110.768 -178.515 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.893 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.0 tt -89.85 122.36 41.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.467 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 1.2 tt0 -90.0 116.96 28.44 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.995 -1.066 . . . . 0.0 109.108 -179.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.665 HD12 HG12 ' B' ' 64' ' ' ILE . 0.4 OUTLIER -111.63 131.65 62.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.277 -0.889 . . . . 0.0 109.351 -179.813 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.3 m 45.27 58.95 3.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.642 -0.661 . . . . 0.0 110.856 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.467 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 53.07 31.19 40.07 Favored Glycine 0 N--CA 1.495 2.598 0 C-N-CA 120.163 -1.017 . . . . 0.0 110.865 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -132.62 142.71 49.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.337 . . . . 0.0 109.453 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.505 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -75.44 138.15 41.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 109.809 -179.683 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.665 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -159.03 98.71 1.48 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.955 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.623 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.01 159.96 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.798 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.491 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.18 -171.8 44.64 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.029 -2.034 . . . . 0.0 112.335 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.559 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 5.9 m -95.47 106.64 18.73 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.809 -0.818 . . . . 0.0 110.475 -179.353 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.854 HG13 HD13 ' B' ' 33' ' ' LEU . 1.6 t -98.11 108.81 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.627 -0.67 . . . . 0.0 110.618 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.59 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -80.95 125.32 29.99 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.041 -1.037 . . . . 0.0 108.549 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.905 HG21 HD12 ' B' ' 38' ' ' LEU . 1.4 t -104.18 111.3 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.224 -0.922 . . . . 0.0 110.054 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.897 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -145.27 -171.56 15.03 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 179.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.524 ' HD3' ' O ' ' B' ' 55' ' ' LYS . 35.3 Cg_endo -79.91 43.13 1.44 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.502 2.134 . . . . 0.0 111.091 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.96 HG21 HG13 ' B' ' 32' ' ' VAL . 2.9 t -89.03 138.29 29.2 Favored Pre-proline 0 N--CA 1.488 1.433 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.725 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.5 Cg_endo -80.42 21.78 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.508 2.139 . . . . 0.0 111.328 -178.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.725 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.8 t -161.32 161.1 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.623 -1.298 . . . . 0.0 111.029 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.606 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 1.9 m-80 -90.77 88.78 7.21 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.724 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.8 mm -78.85 118.93 27.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.041 -1.037 . . . . 0.0 111.422 -176.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.705 HG21 HD22 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -102.04 99.74 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 177.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -85.37 -163.08 36.83 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.871 -1.143 . . . . 0.0 110.704 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HD3' ' CG2' ' B' ' 26' ' ' THR . 7.5 mmm180 -63.65 -29.03 70.32 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.653 -0.91 . . . . 0.0 110.113 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.02 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.8 p-10 -52.53 -40.06 62.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.673 -1.267 . . . . 0.0 109.237 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.02 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.3 mm? -96.04 -15.86 21.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.904 -179.056 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.845 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 34.4 mt -85.18 -4.18 59.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.866 -1.146 . . . . 0.0 108.827 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.616 HG21 ' HA ' ' A' ' 6' ' ' TRP . 68.9 p -101.83 -13.93 17.48 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.324 -0.86 . . . . 0.0 108.748 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.818 ' OE1' HD13 ' B' ' 89' ' ' LEU . 33.0 mt-30 -87.0 -36.44 18.24 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.41 -0.806 . . . . 0.0 109.281 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.872 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -85.38 4.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.803 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 78.48 31.07 47.12 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.041 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.845 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -74.15 132.79 42.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.336 . . . . 0.0 110.353 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 17.1 p -140.81 129.44 22.81 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -86.04 94.46 9.24 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.329 -0.857 . . . . 0.0 109.312 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -96.26 122.63 39.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.112 -0.992 . . . . 0.0 109.207 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.819 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.421 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.478 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.493 1.476 0 N-CA-C 109.884 -0.852 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.466 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.2 tt0 -84.29 141.04 31.22 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.586 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 10.8 t -135.68 112.66 13.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.464 -1.397 . . . . 0.0 110.071 -178.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.807 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.5 OUTLIER -128.3 -78.5 0.57 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.856 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.708 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.4 OUTLIER 34.94 37.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.802 -0.562 . . . . 0.0 110.268 179.983 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' A' ' 5' ' ' LEU . 43.7 m0 16.1 53.77 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 121.065 0.459 . . . . 0.0 112.204 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.708 ' HB2' HD12 ' A' ' 5' ' ' LEU . 1.6 mm-40 -156.35 -174.84 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.992 -1.067 . . . . 0.0 109.937 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -68.43 115.33 28.63 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.265 -0.897 . . . . 0.0 109.402 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.4 Cg_endo -77.15 72.68 5.79 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.12 1.88 . . . . 0.0 110.359 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.797 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -81.76 152.77 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -0.887 . . . . 0.0 108.998 179.715 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.771 HG23 HG23 ' A' ' 13' ' ' ILE . 26.9 m -139.07 129.16 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.166 -0.959 . . . . 0.0 110.38 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.503 HG22 HD22 ' A' ' 19' ' ' LEU . 4.4 m -67.74 92.01 0.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 178.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.907 HD11 HD21 ' A' ' 33' ' ' LEU . 3.0 pt -88.74 147.21 5.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.462 -0.774 . . . . 0.0 110.886 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.9 tttt -109.11 100.37 9.55 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.018 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.709 HD12 ' CD2' ' A' ' 33' ' ' LEU . 3.4 mt -117.17 136.16 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.87 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' A' ' 18' ' ' GLN . . . 63.34 25.07 68.1 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.8 17.78 79.92 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 15.3 mp0 -123.75 -174.67 3.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -1.158 . . . . 0.0 108.919 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 44.0 mt -137.97 135.48 36.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.137 -0.977 . . . . 0.0 110.06 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.614 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -148.97 148.69 30.07 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.797 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.6 mm-40 -78.61 109.06 12.48 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.947 -1.095 . . . . 0.0 109.295 -179.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.046 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -95.05 116.95 29.35 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 122.02 0.914 . . . . 0.0 111.265 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.469 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 8.3 tp -72.46 103.09 3.37 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.1 mt -46.65 131.03 11.54 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.105 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.763 ' HB2' HG23 ' A' ' 84' ' ' ILE . 3.6 t70 -139.34 86.57 2.13 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.167 -0.958 . . . . 0.0 111.091 -177.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.967 HG21 HD22 ' A' ' 97' ' ' LEU . 1.5 m -65.64 -11.64 46.42 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.97 -1.081 . . . . 0.0 108.4 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.701 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -72.74 -44.7 37.9 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.061 -1.616 . . . . 0.0 109.061 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.49 157.79 36.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -1.162 . . . . 0.0 108.936 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -99.18 -9.5 23.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.036 . . . . 0.0 110.226 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -138.57 177.93 7.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.944 -1.098 . . . . 0.0 110.297 -179.428 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.689 HG22 ' CD1' ' A' ' 33' ' ' LEU . 37.6 m -101.78 102.23 12.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.036 -1.04 . . . . 0.0 109.44 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.778 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -97.11 115.42 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.353 -0.842 . . . . 0.0 109.88 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.054 HD13 ' CG1' ' A' ' 75' ' ' VAL . 6.6 mp -106.52 123.13 47.62 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.309 -0.869 . . . . 0.0 109.767 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.704 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.0 pt-20 -43.09 165.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 108.915 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.539 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.5 tt0 -42.7 137.48 2.22 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 110.067 -179.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.489 ' SD ' HD13 ' A' ' 38' ' ' LEU . 2.0 ppp? -153.78 -162.33 1.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.565 -0.709 . . . . 0.0 109.372 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.529 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 11.7 t -106.2 100.93 10.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 110.275 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.763 HD23 ' CD2' ' A' ' 59' ' ' TYR . 1.4 tp -127.95 149.65 71.4 Favored Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.5 Cg_endo -73.97 -156.17 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.583 2.189 . . . . 0.0 110.609 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.506 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -93.01 -155.6 32.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 72.7 43.77 0.42 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.649 -0.912 . . . . 0.0 108.893 -179.557 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.643 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 29.8 p-90 -132.22 178.21 6.98 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.8 0.809 . . . . 0.0 110.328 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.448 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 1.4 mmtp -139.12 150.99 66.76 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.25 138.67 20.37 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 122.031 1.821 . . . . 0.0 110.233 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.519 ' CG ' ' N ' ' A' ' 46' ' ' MET . 0.0 OUTLIER -147.56 167.36 24.72 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.673 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.519 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 9.1 mtp -143.56 128.28 18.23 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.108 -0.995 . . . . 0.0 108.435 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.835 HD12 HG21 ' B' ' 50' ' ' ILE . 2.1 pt -106.78 141.18 22.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.881 -1.137 . . . . 0.0 109.388 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.64 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.84 96.29 0.65 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.23 -128.43 3.76 Favored Glycine 0 N--CA 1.481 1.659 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.854 -178.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.965 HG21 HD12 ' B' ' 47' ' ' ILE . 42.5 mt -81.2 118.22 28.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.775 -0.838 . . . . 0.0 112.511 -177.487 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.16 -42.61 1.87 Allowed Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 167.43 -157.98 30.63 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 120.875 -1.368 . . . . 0.0 110.068 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.64 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.1 m-85 -114.62 140.6 48.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.436 -1.038 . . . . 0.0 109.784 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.607 HG22 ' HA2' ' B' ' 51' ' ' GLY . 0.9 OUTLIER -116.51 179.53 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.251 -0.906 . . . . 0.0 108.703 179.039 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 10.0 mttm -115.02 141.24 48.26 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.17 -0.957 . . . . 0.0 108.545 179.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 4.5 m -144.52 172.1 5.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.941 -1.1 . . . . 0.0 110.641 -178.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.456 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.9 mtt180 -118.96 98.37 6.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.516 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 3.3 tt0 -59.18 91.91 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.125 -0.984 . . . . 0.0 110.155 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.763 ' CD2' HD23 ' A' ' 38' ' ' LEU . 13.6 m-85 -88.5 92.73 9.29 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 178.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.402 ' HB3' ' OE1' ' A' ' 61' ' ' GLN . 7.3 m-20 -78.79 143.37 36.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 110.811 -178.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.4 mm100 69.44 67.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-O 121.51 0.672 . . . . 0.0 109.6 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.521 HG13 ' HB3' ' A' ' 59' ' ' TYR . 1.2 mm -126.97 111.48 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.976 HD13 ' N ' ' A' ' 64' ' ' ILE . 3.3 tm? -50.97 143.27 10.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.163 -0.96 . . . . 0.0 109.469 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.976 ' N ' HD13 ' A' ' 63' ' ' LEU . 6.9 tt -150.79 113.89 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 36.8 tt0 -89.02 102.86 15.51 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.815 -1.178 . . . . 0.0 108.753 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.88 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -96.89 112.84 29.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-O 121.852 0.834 . . . . 0.0 108.908 -179.652 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 0.1 OUTLIER 71.13 -84.01 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.32 28.2 0.88 Allowed Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -129.68 128.49 42.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -1.112 . . . . 0.0 109.328 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.809 ' HG2' HD21 ' A' ' 63' ' ' LEU . 1.0 OUTLIER -78.79 136.28 37.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.754 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.839 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -151.94 131.81 13.31 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -0.995 . . . . 0.0 110.681 -179.045 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.711 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -95.39 148.1 5.39 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 177.848 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -166.39 -171.53 32.63 Favored Glycine 0 N--CA 1.49 2.295 0 C-N-CA 118.401 -1.857 . . . . 0.0 111.48 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.516 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 63.9 m -102.81 105.2 15.56 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.436 -1.038 . . . . 0.0 110.205 -179.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.054 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.36 167.49 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.778 ' HB2' HG23 ' A' ' 32' ' ' VAL . 2.1 mp -139.52 107.44 5.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.934 -1.104 . . . . 0.0 108.367 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.539 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 31.9 t -88.37 114.04 26.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 -178.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -150.41 -171.34 18.6 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.51 40.16 0.94 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.588 2.192 . . . . 0.0 111.183 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.704 HG22 ' HA ' ' A' ' 34' ' ' GLU . 5.7 t -82.9 142.3 44.79 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.65 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.4 Cg_endo -79.32 16.3 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.421 2.08 . . . . 0.0 111.356 -178.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.704 HG12 ' CG1' ' A' ' 84' ' ' ILE . 2.8 t -161.44 160.43 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.828 -1.17 . . . . 0.0 110.983 -178.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.665 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 82.5 m-20 -94.35 143.55 26.3 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 103.053 -2.943 . . . . 0.0 103.053 174.408 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.763 HG23 ' HB2' ' A' ' 25' ' ' ASP . 18.4 mt -146.91 135.12 15.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 O-C-N 119.295 -2.128 . . . . 0.0 112.562 -176.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 1.046 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.91 107.34 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.05 -167.4 43.47 Favored Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.089 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.581 ' O ' HG23 ' A' ' 91' ' ' THR . 1.9 mmm180 -60.05 -31.71 70.24 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.408 -1.054 . . . . 0.0 109.173 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.051 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.1 p-10 -54.58 -28.47 46.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 110.53 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.051 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.6 mm? -104.57 -29.12 10.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.83 -1.169 . . . . 0.0 110.062 -179.096 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.584 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.3 mt -71.36 -5.59 33.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.992 -1.068 . . . . 0.0 108.982 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 87' ' ' ARG . 70.0 p -101.38 -20.91 14.98 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.143 -0.973 . . . . 0.0 109.327 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 42.9 mm-40 -81.52 -40.35 23.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 109.061 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.965 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -80.13 -2.93 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.202 -0.936 . . . . 0.0 108.655 178.821 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 78.17 30.46 50.62 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.566 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -65.84 136.4 56.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.805 -1.409 . . . . 0.0 109.049 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.493 HG22 HG22 ' B' ' 4' ' ' THR . 81.5 p -131.14 125.4 32.95 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.153 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.967 HD22 HG21 ' A' ' 26' ' ' THR . 1.7 mp -84.5 93.91 8.43 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.525 0.679 . . . . 0.0 110.108 -178.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.496 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.5 m120 -108.37 130.52 55.21 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.737 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 117.949 -1.024 . . . . 0.0 109.09 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.445 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.565 0 N-CA-C 109.989 -0.812 . . . . 0.0 109.989 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.536 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tt0 -83.96 149.38 26.35 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.059 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.536 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 6.7 t -150.25 117.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 120.665 -1.272 . . . . 0.0 109.582 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.592 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.9 OUTLIER -108.62 13.34 25.28 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.552 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.521 ' O ' ' CZ ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -26.53 84.32 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 121.641 0.734 . . . . 0.0 111.25 -179.037 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.592 ' N ' ' O ' ' B' ' 4' ' ' THR . 16.1 m95 -53.48 -16.67 1.56 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.441 ' O ' ' HG3' ' A' ' 87' ' ' ARG . 30.7 mt-30 -109.42 -106.52 0.35 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.157 -0.964 . . . . 0.0 109.602 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.423 ' HE ' ' CD1' ' B' ' 10' ' ' LEU . 6.1 mtp180 -111.22 120.56 42.76 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 120.945 -1.097 . . . . 0.0 110.705 -179.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.46 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 37.3 Cg_endo -80.45 62.02 8.4 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.268 1.979 . . . . 0.0 109.692 177.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 1.6 mt -81.66 148.85 28.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.076 -1.015 . . . . 0.0 110.327 -179.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 1.059 HG22 ' HB3' ' B' ' 22' ' ' ALA . 5.2 m -141.46 142.69 28.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.448 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' B' ' 19' ' ' LEU . 14.4 m -81.92 96.74 7.77 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 1.032 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -84.3 152.41 3.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.227 -0.921 . . . . 0.0 110.41 -178.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.458 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -118.01 101.74 8.49 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.208 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.842 HG23 ' CG2' ' B' ' 62' ' ' ILE . 40.6 mt -105.8 127.14 61.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.07 -1.018 . . . . 0.0 109.515 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.8 -86.16 0.36 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.606 -1.798 . . . . 0.0 108.606 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.76 25.6 0.32 Allowed Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.039 -2.025 . . . . 0.0 108.039 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -121.0 171.01 8.95 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.739 -0.859 . . . . 0.0 108.749 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' B' ' 12' ' ' THR . 14.4 mt -134.28 130.72 37.49 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.296 -0.877 . . . . 0.0 109.924 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -139.99 166.99 23.16 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 179.628 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.574 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.6 mt-10 -78.73 -179.94 6.81 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.688 -1.257 . . . . 0.0 107.876 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 1.059 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -158.03 105.26 1.94 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.816 -1.178 . . . . 0.0 110.821 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.701 HD21 ' O ' ' A' ' 27' ' ' GLY . 25.5 tp -77.35 95.52 4.42 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.48 ' HA ' HD22 ' B' ' 24' ' ' LEU . 0.2 OUTLIER -40.44 97.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.881 ' HB2' HG23 ' B' ' 84' ' ' ILE . 12.0 t0 -102.57 76.58 1.54 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.443 -0.785 . . . . 0.0 110.707 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.946 HG23 HD23 ' B' ' 90' ' ' LEU . 2.7 m -62.91 -11.19 16.81 Favored 'General case' 0 C--N 1.297 -1.679 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.118 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.475 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -79.59 -38.77 19.79 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.04 158.51 36.37 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.093 -1.239 . . . . 0.0 109.065 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -90.68 -11.5 39.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.972 -1.08 . . . . 0.0 110.437 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.538 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -138.88 -164.2 1.61 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.889 -1.132 . . . . 0.0 109.988 -179.646 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.661 HG23 ' O ' ' B' ' 84' ' ' ILE . 16.8 m -115.67 92.76 4.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.927 -1.108 . . . . 0.0 109.718 -179.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.64 174.19 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.087 -1.008 . . . . 0.0 109.299 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.149 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.0 OUTLIER -171.31 123.25 0.57 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.792 -1.192 . . . . 0.0 110.811 -178.531 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.625 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.6 OUTLIER -42.85 159.75 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.232 -0.917 . . . . 0.0 108.774 178.381 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.886 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -50.61 148.15 4.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.9 -1.125 . . . . 0.0 110.475 -179.284 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.526 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.4 ptm -155.12 -164.53 1.8 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.526 ' N ' ' HG3' ' B' ' 36' ' ' MET . 3.9 t -105.08 67.27 0.78 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.865 -1.147 . . . . 0.0 110.116 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.657 HD13 ' CG ' ' B' ' 59' ' ' TYR . 11.6 mt -85.1 168.71 19.12 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.033 . . . . 0.0 108.726 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.589 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.6 Cg_endo -71.59 -162.52 0.11 Allowed 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.142 1.895 . . . . 0.0 111.374 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.96 29.93 8.85 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -178.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -107.94 46.12 0.97 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.655 ' CD1' ' CZ ' ' B' ' 59' ' ' TYR . 29.9 p-90 -117.73 -179.92 3.88 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.817 0.818 . . . . 0.0 110.356 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -134.27 134.12 22.41 Favored Pre-proline 0 C--N 1.3 -1.556 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.76 135.43 17.7 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 121.779 1.653 . . . . 0.0 110.414 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.652 ' HD3' HD23 ' B' ' 76' ' ' LEU . 16.2 ptmt -160.09 -165.91 1.58 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.559 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.562 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 4.3 mtp -146.56 124.7 12.14 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.451 -179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.965 HD12 HG21 ' A' ' 50' ' ' ILE . 2.8 pt -89.48 143.23 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.25 113.51 2.64 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -138.65 -123.99 2.18 Favored Glycine 0 N--CA 1.481 1.7 0 C-N-CA 119.52 -1.324 . . . . 0.0 110.213 -179.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.835 HG21 HD12 ' A' ' 47' ' ' ILE . 28.3 mt -91.22 134.82 28.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.694 -0.886 . . . . 0.0 111.968 -178.001 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.607 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 87.47 -29.78 5.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.444 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 156.12 -160.08 29.84 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.011 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -120.67 133.32 55.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.498 -1.001 . . . . 0.0 109.118 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.682 HD13 HG23 ' A' ' 50' ' ' ILE . 15.6 pt -110.66 141.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 120.941 -1.099 . . . . 0.0 109.774 -179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.562 ' HG3' ' CG ' ' B' ' 46' ' ' MET . 0.0 OUTLIER -65.21 154.23 38.68 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 179.792 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.516 HG23 ' HG2' ' B' ' 45' ' ' LYS . 19.8 m -151.13 -167.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.973 . . . . 0.0 110.005 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -145.03 96.25 2.82 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.562 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 11.3 tt0 -61.83 107.9 0.92 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 110.533 -179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.657 ' CG ' HD13 ' B' ' 38' ' ' LEU . 29.2 m-85 -102.3 95.18 6.12 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.593 ' OD1' HG23 ' B' ' 74' ' ' THR . 0.5 OUTLIER -79.13 141.61 37.12 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.829 -1.17 . . . . 0.0 109.994 -179.589 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.496 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 75.01 59.25 0.06 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.695 -0.628 . . . . 0.0 110.055 179.706 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.842 ' CG2' HG23 ' B' ' 15' ' ' ILE . 5.8 mm -121.35 121.5 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.271 -0.893 . . . . 0.0 108.984 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.92 ' O ' HD13 ' B' ' 63' ' ' LEU . 1.4 tm? -68.54 91.4 0.41 Allowed 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.138 -0.976 . . . . 0.0 110.503 -179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.632 HG22 ' O ' ' B' ' 71' ' ' ALA . 10.8 tt -97.75 120.33 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.6 tt0 -88.32 148.56 24.23 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.044 -1.035 . . . . 0.0 108.557 -179.257 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 1.032 HG13 HG22 ' B' ' 13' ' ' ILE . 1.2 mp -147.48 132.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.086 -1.009 . . . . 0.0 109.717 -179.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.411 ' C ' ' O ' ' B' ' 66' ' ' ILE . 54.7 m 42.79 37.9 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.533 -0.729 . . . . 0.0 109.723 179.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.77 48.1 51.41 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -145.71 114.42 6.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.204 -1.174 . . . . 0.0 109.445 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.75 130.85 47.28 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.632 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.8 101.19 2.74 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 110.369 -179.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.584 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.08 157.2 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.016 -1.052 . . . . 0.0 108.583 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.611 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 175.88 -166.33 37.5 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.908 -1.615 . . . . 0.0 111.632 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.593 HG23 ' OD1' ' B' ' 60' ' ' ASP . 16.8 m -98.03 104.86 16.93 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.528 -0.983 . . . . 0.0 110.595 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.149 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.16 109.41 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.344 -0.848 . . . . 0.0 110.255 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.652 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.4 mp -80.32 124.27 28.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.181 -0.949 . . . . 0.0 108.944 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.886 HG12 ' HA ' ' B' ' 35' ' ' GLU . 0.2 OUTLIER -106.86 125.95 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 109.784 -179.893 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -159.42 -167.21 19.76 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.8 Cg_endo -81.71 54.87 5.28 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.795 2.33 . . . . 0.0 109.916 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.625 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.3 t -97.57 138.43 21.1 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.267 -0.896 . . . . 0.0 108.93 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.1 Cg_endo -80.06 16.55 1.47 Allowed 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.482 2.121 . . . . 0.0 110.71 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.575 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -161.24 172.45 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.016 -1.053 . . . . 0.0 110.206 -179.576 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.619 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 68.6 m-80 -105.03 147.76 27.49 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 104.652 -2.351 . . . . 0.0 104.652 176.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' B' ' 25' ' ' ASP . 24.7 mm -133.64 120.2 36.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 O-C-N 120.282 -1.511 . . . . 0.0 111.194 -177.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.806 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -102.14 91.9 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 177.997 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.546 ' O ' HD13 ' B' ' 90' ' ' LEU . . . -100.12 170.57 22.72 Favored Glycine 0 N--CA 1.496 2.683 0 C-N-CA 119.748 -1.215 . . . . 0.0 112.344 -177.062 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.789 ' O ' HG23 ' B' ' 91' ' ' THR . 3.7 mmt180 -21.96 -41.37 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.987 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.0 p-10 -52.43 -43.05 64.63 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.121 -1.612 . . . . 0.0 110.486 -178.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.987 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -91.29 -19.96 22.4 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.685 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.946 HD23 HG23 ' B' ' 26' ' ' THR . 2.2 mp -67.39 -15.22 63.56 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.789 HG23 ' O ' ' B' ' 87' ' ' ARG . 17.2 p -86.9 -18.34 31.07 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.053 -1.029 . . . . 0.0 108.801 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -87.79 -40.34 14.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.737 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.3 pt -87.28 -2.51 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.362 -0.836 . . . . 0.0 109.143 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.6 35.76 81.65 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 179.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.497 ' HB3' ' HB3' ' B' ' 90' ' ' LEU . . . -63.04 145.06 56.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.949 -1.324 . . . . 0.0 110.936 -179.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.807 HG22 ' CG2' ' A' ' 4' ' ' THR . 20.4 p -150.42 126.98 10.83 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.681 HD11 HD11 ' A' ' 97' ' ' LEU . 6.9 mp -86.62 103.25 14.93 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.259 -0.901 . . . . 0.0 109.187 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 9.9 m120 -101.4 122.41 43.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.134 -0.979 . . . . 0.0 110.036 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.965 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.433 179.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.494 1.518 0 N-CA-C 110.551 -0.596 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.503 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 8.6 tt0 -83.75 126.29 32.76 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 177.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.4 t -118.14 108.35 24.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.875 -1.14 . . . . 0.0 109.81 -177.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -131.71 41.0 3.33 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.582 -0.699 . . . . 0.0 109.481 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -88.34 43.08 1.1 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.144 -0.973 . . . . 0.0 108.965 179.644 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.527 ' C ' ' O ' ' A' ' 5' ' ' LEU . 16.3 m0 18.13 50.64 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.237 0.541 . . . . 0.0 111.545 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 5.3 mt-30 -155.45 163.82 39.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -0.895 . . . . 0.0 109.518 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.493 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -54.19 119.25 18.98 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.322 179.894 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.667 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.8 Cg_endo -78.47 75.07 5.12 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.212 1.941 . . . . 0.0 110.769 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.815 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -79.52 164.94 23.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.052 -1.03 . . . . 0.0 108.68 179.587 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.7 m -149.29 127.78 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.052 -1.03 . . . . 0.0 110.296 -178.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.844 HG22 HD22 ' A' ' 19' ' ' LEU . 8.1 m -64.65 91.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 178.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.67 HD12 HG13 ' A' ' 15' ' ' ILE . 1.0 OUTLIER -79.7 149.7 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.505 -178.372 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 18.3 tttt -117.1 91.2 3.51 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.098 HD11 HD12 ' A' ' 64' ' ' ILE . 12.5 mt -114.65 139.93 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 O-C-N 121.208 -0.933 . . . . 0.0 109.959 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 48.41 49.58 25.75 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 52.24 38.37 48.99 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.545 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.7 mm-40 -131.71 168.35 17.92 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -1.154 . . . . 0.0 109.065 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.844 HD22 HG22 ' A' ' 12' ' ' THR . 20.4 mt -137.57 128.94 28.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 0.0 109.592 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.433 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 47.0 mtmt -151.1 155.86 39.82 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.395 -0.816 . . . . 0.0 109.368 179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.815 ' HB3' HD23 ' A' ' 10' ' ' LEU . 27.1 mp0 -79.83 106.52 11.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.975 . . . . 0.0 108.68 179.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.661 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -87.55 132.88 33.89 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.513 -0.742 . . . . 0.0 110.787 -178.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.755 HD21 ' O ' ' B' ' 27' ' ' GLY . 6.0 tp -85.83 98.95 11.04 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.699 HD22 HD21 ' A' ' 90' ' ' LEU . 10.9 mt -45.52 97.34 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.103 -0.998 . . . . 0.0 108.522 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 1.025 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.7 t0 -100.33 90.3 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.471 -0.768 . . . . 0.0 110.503 -178.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -71.1 -16.49 62.57 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.983 -1.073 . . . . 0.0 108.93 178.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.49 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.07 -33.84 69.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.31 154.4 27.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.213 -1.169 . . . . 0.0 109.342 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -93.8 -12.98 27.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.195 -0.941 . . . . 0.0 109.831 -179.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.559 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -131.64 -175.19 3.63 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.163 -0.961 . . . . 0.0 109.406 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.689 HG23 HD12 ' A' ' 85' ' ' ILE . 5.9 m -110.72 87.88 2.64 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.789 -1.194 . . . . 0.0 109.808 -179.066 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -73.01 166.33 2.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.506 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.022 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.57 132.08 3.77 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.79 -1.194 . . . . 0.0 111.343 -177.853 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 80' ' ' THR . 11.3 tt0 -42.21 160.38 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.576 ' HA ' HG13 ' A' ' 77' ' ' VAL . 1.4 mt-10 -61.91 137.19 58.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.857 -1.152 . . . . 0.0 109.946 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.95 -164.01 1.89 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.414 -0.804 . . . . 0.0 109.503 179.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.1 t -96.73 112.26 24.09 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.123 -0.986 . . . . 0.0 110.39 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.739 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -133.49 -177.34 0.69 Allowed Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.342 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.601 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -76.4 -179.71 5.56 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.051 1.834 . . . . 0.0 110.656 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.06 29.99 10.35 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -119.76 61.7 0.83 Allowed 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.625 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 11.4 p-90 -121.83 -172.76 2.5 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.537 0.684 . . . . 0.0 109.807 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.8 mtpm? -132.85 128.21 20.65 Favored Pre-proline 0 N--CA 1.49 1.568 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -76.36 138.06 19.45 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 121.929 1.753 . . . . 0.0 110.213 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.73 ' HE2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -157.16 -179.04 7.82 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.731 179.872 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 54' ' ' ILE . 69.4 mtp -136.54 121.23 18.48 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.382 -0.824 . . . . 0.0 108.96 179.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.1 pt -88.56 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.565 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.562 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.68 98.0 0.75 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 -179.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.04 -132.29 3.88 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 119.805 -1.188 . . . . 0.0 110.509 -179.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.834 HD11 ' CD1' ' B' ' 84' ' ' ILE . 21.6 mt -84.24 110.5 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.624 -0.927 . . . . 0.0 112.531 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.85 -13.59 17.31 Favored Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.843 177.734 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 134.27 -154.91 21.61 Favored Glycine 0 N--CA 1.49 2.271 0 C-N-CA 119.204 -1.474 . . . . 0.0 109.951 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.562 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 9.4 m-85 -116.3 127.45 54.71 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.574 -0.956 . . . . 0.0 110.255 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 46' ' ' MET . 15.8 pt -103.32 179.1 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.572 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -116.07 145.62 42.87 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.861 -1.15 . . . . 0.0 109.302 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 ' HE2' ' A' ' 45' ' ' LYS . 0.7 OUTLIER -146.49 -170.33 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.604 -1.31 . . . . 0.0 110.297 -179.843 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.425 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.8 mtm180 -133.8 94.29 3.25 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.539 ' N ' ' HE3' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -53.44 99.56 0.03 OUTLIER 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.38 -0.825 . . . . 0.0 110.217 -179.153 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.739 ' CD2' HD23 ' A' ' 38' ' ' LEU . 22.6 m-85 -98.1 84.88 3.36 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 177.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.837 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.4 OUTLIER -78.16 137.98 38.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 -177.604 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.515 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 51.5 mm-40 80.77 62.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.785 HG21 HG23 ' A' ' 15' ' ' ILE . 8.0 mm -124.82 122.85 64.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.893 HD21 ' CG ' ' A' ' 70' ' ' LYS . 17.0 tp -74.4 87.19 2.03 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.109 -1.036 . . . . 0.0 111.755 -177.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 1.098 HD12 HD11 ' A' ' 15' ' ' ILE . 10.9 tt -87.23 120.26 36.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.539 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -89.48 111.68 22.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.143 -0.973 . . . . 0.0 109.474 -178.634 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' CYS . 1.0 OUTLIER -106.7 125.95 62.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.102 -0.999 . . . . 0.0 109.879 -179.522 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.8 m 65.22 11.56 7.33 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.762 -0.586 . . . . 0.0 110.698 178.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.424 ' HA2' ' CD ' ' A' ' 65' ' ' GLU . . . 101.3 1.28 53.98 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.201 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -106.11 119.13 38.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.12 -1.223 . . . . 0.0 108.924 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.893 ' CG ' HD21 ' A' ' 63' ' ' LEU . 2.2 mptp? -63.06 139.75 58.8 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.187 -0.945 . . . . 0.0 109.415 -179.156 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.704 ' C ' HD12 ' A' ' 63' ' ' LEU . . . -151.27 143.12 23.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.307 -179.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.71 HG13 HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -113.19 138.94 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.864 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.412 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -163.05 -159.12 10.2 Favored Glycine 0 N--CA 1.483 1.77 0 C-N-CA 119.208 -1.472 . . . . 0.0 110.213 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.837 HG23 ' OD1' ' A' ' 60' ' ' ASP . 2.2 m -100.1 108.16 20.23 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.769 -0.842 . . . . 0.0 110.05 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.881 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -106.6 107.01 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.154 -0.967 . . . . 0.0 109.927 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.73 HD23 ' HE2' ' A' ' 45' ' ' LYS . 3.3 mp -78.58 128.42 33.5 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.576 HG13 ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -114.49 120.53 64.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.698 -179.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.561 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.0 -157.72 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.572 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -83.31 36.98 0.63 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.553 2.169 . . . . 0.0 110.758 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.725 HG21 HG13 ' A' ' 32' ' ' VAL . 3.9 t -80.59 134.56 54.1 Favored Pre-proline 0 N--CA 1.489 1.513 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.453 ' O ' HG23 ' A' ' 82' ' ' VAL . 34.6 Cg_endo -77.4 18.59 0.79 Allowed 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.497 2.131 . . . . 0.0 111.825 -178.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.605 ' CG1' HG13 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.02 160.3 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 109.941 -179.804 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -99.88 85.99 3.19 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 177.06 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 1.025 HG23 ' CB ' ' A' ' 25' ' ' ASP . 2.3 mt -83.2 122.61 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 CA-C-O 121.805 0.812 . . . . 0.0 112.902 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.689 HD12 HG23 ' A' ' 31' ' ' THR . 0.4 OUTLIER -95.98 102.67 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 177.225 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.531 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -90.87 -162.03 37.87 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.82 -1.181 . . . . 0.0 111.478 -178.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -57.4 -40.05 77.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.754 -0.851 . . . . 0.0 110.472 -179.237 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.021 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.3 p-10 -42.41 -39.28 2.15 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.293 -0.879 . . . . 0.0 110.011 -179.554 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.021 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.9 OUTLIER -100.59 -22.01 15.1 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 121.001 -1.062 . . . . 0.0 110.276 -179.336 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.699 HD21 HD22 ' A' ' 24' ' ' LEU . 81.2 mt -74.67 -1.63 22.65 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.061 -1.024 . . . . 0.0 108.56 179.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.0 p -99.41 -18.65 17.38 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -83.03 -41.63 18.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.391 -0.818 . . . . 0.0 108.982 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.838 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.5 pt -86.87 -10.16 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.69 45.43 44.61 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.275 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.529 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -76.03 131.45 39.52 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.932 -1.334 . . . . 0.0 109.908 179.578 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 77.8 p -129.61 137.82 50.91 Favored 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' B' ' 97' ' ' LEU . 5.9 mp -89.51 120.18 30.6 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.962 -1.086 . . . . 0.0 110.529 -179.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.535 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -119.48 124.77 47.29 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.256 -0.903 . . . . 0.0 108.948 178.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.939 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.531 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.601 0 N-CA-C 109.964 -0.822 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.489 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.7 tt0 -88.88 150.0 23.08 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.488 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 3.3 t -149.83 126.16 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.498 -1.376 . . . . 0.0 110.441 -179.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.542 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -130.98 -60.04 0.97 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.733 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.655 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER 34.34 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.944 -0.472 . . . . 0.0 110.852 179.529 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.542 ' N ' ' O ' ' B' ' 4' ' ' THR . 5.5 m95 18.02 42.66 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.655 ' N ' ' O ' ' B' ' 5' ' ' LEU . 6.9 mm100 -153.01 -114.81 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.193 -0.942 . . . . 0.0 108.718 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.525 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.1 mtp180 -112.45 141.07 24.52 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 120.23 -1.543 . . . . 0.0 109.195 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 37.0 Cg_endo -82.15 50.21 3.38 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.316 2.011 . . . . 0.0 109.529 178.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.557 HD23 ' H ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -78.43 137.48 38.0 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.197 -0.939 . . . . 0.0 108.943 -179.597 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -134.15 178.97 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.453 -0.779 . . . . 0.0 109.996 -178.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.768 HG22 HD22 ' B' ' 19' ' ' LEU . 47.8 m -103.86 105.28 15.43 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.814 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.826 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.8 pp -96.17 155.37 3.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.518 -0.738 . . . . 0.0 109.862 -178.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.529 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 8.9 ttmt -122.91 100.14 6.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 110.503 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.728 HG13 HD12 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -115.38 142.64 27.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.812 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 47.98 47.13 26.2 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.351 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 55.23 36.42 62.16 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.162 -1.199 . . . . 0.0 110.398 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.9 OUTLIER -130.7 166.61 20.36 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -1.216 . . . . 0.0 108.425 179.077 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.826 HD23 ' O ' ' B' ' 13' ' ' ILE . 14.8 mt -143.23 125.28 15.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.078 -1.014 . . . . 0.0 111.409 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.503 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 1.0 OUTLIER -145.11 -170.97 3.55 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.875 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.549 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -82.45 -176.48 6.25 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.863 -1.148 . . . . 0.0 109.666 -179.846 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.854 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -163.28 91.49 0.7 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.1 -1.0 . . . . 0.0 110.89 -179.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.543 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 8.8 tp -68.04 93.44 0.43 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.631 -1.293 . . . . 0.0 109.658 179.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.824 HD23 ' HB ' ' B' ' 85' ' ' ILE . 69.8 mt -50.42 94.88 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.856 ' CB ' HG23 ' B' ' 84' ' ' ILE . 29.5 t0 -96.0 84.75 3.89 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.351 -0.843 . . . . 0.0 110.825 -178.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.579 ' HA ' HD12 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.51 -16.0 21.69 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.956 -1.09 . . . . 0.0 108.771 178.754 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.755 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -74.19 -38.85 45.98 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.28 162.76 27.89 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.198 -1.178 . . . . 0.0 109.318 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -101.01 -10.37 20.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.53 ' HA ' ' CG ' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -139.13 -172.57 3.37 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.134 -0.979 . . . . 0.0 110.322 -179.298 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.609 HG22 ' CD1' ' B' ' 33' ' ' LEU . 47.7 m -108.46 89.46 3.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.984 -1.072 . . . . 0.0 111.162 -178.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.897 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -73.34 169.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.54 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.125 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -168.81 130.89 1.28 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.777 -1.202 . . . . 0.0 110.683 -179.026 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.566 ' N ' HG23 ' B' ' 80' ' ' THR . 6.0 pt-20 -46.67 170.81 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.276 -0.89 . . . . 0.0 108.693 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.559 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tt0 -60.42 138.1 58.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.145 -0.972 . . . . 0.0 110.064 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.629 ' HE2' HD21 ' B' ' 38' ' ' LEU . 7.6 ptm -147.05 -163.5 1.78 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.405 -0.809 . . . . 0.0 109.324 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.529 ' N ' ' HG3' ' B' ' 36' ' ' MET . 8.4 t -113.74 98.01 6.77 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -0.881 . . . . 0.0 110.099 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.81 HD12 ' CD2' ' B' ' 59' ' ' TYR . 27.1 mt -106.38 160.39 26.39 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.128 -0.983 . . . . 0.0 109.476 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.475 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.6 Cg_endo -77.94 65.28 8.3 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.732 2.288 . . . . 0.0 112.029 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 35.78 -157.37 0.01 OUTLIER Glycine 0 N--CA 1.498 2.813 0 O-C-N 121.442 -0.786 . . . . 0.0 111.239 178.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.494 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 63.25 60.28 1.19 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.513 -0.992 . . . . 0.0 109.237 -179.865 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.7 p-90 -139.08 -175.62 4.22 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' B' ' 43' ' ' LYS . 13.7 mmtm -143.3 136.83 14.18 Favored Pre-proline 0 N--CA 1.488 1.467 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.77 125.67 7.59 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.899 1.733 . . . . 0.0 111.403 -179.009 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.82 ' CE ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -162.74 149.93 13.31 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.607 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.463 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 1.8 mtp -110.04 148.0 32.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 0.0 110.414 -178.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.803 ' CD1' HG21 ' A' ' 50' ' ' ILE . 15.5 pt -90.68 155.67 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.513 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.87 106.03 1.24 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -136.12 -128.03 2.7 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.647 -179.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.777 HG21 ' CD1' ' A' ' 47' ' ' ILE . 21.5 mt -87.91 127.46 41.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.614 -0.933 . . . . 0.0 112.683 -177.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 96.95 -20.75 49.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.05 -164.59 26.81 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.528 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 3.3 m-85 -105.64 125.74 51.34 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.391 -1.064 . . . . 0.0 109.701 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.7 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -96.38 139.62 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.939 -1.1 . . . . 0.0 108.964 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.579 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -78.2 143.04 37.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.806 -1.184 . . . . 0.0 108.995 -179.905 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.658 HG12 ' N ' ' B' ' 78' ' ' GLY . 0.2 OUTLIER -149.3 -173.49 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.87 -1.144 . . . . 0.0 110.074 -179.482 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.435 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 2.6 mtm-85 -121.28 96.08 4.94 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -60.38 100.18 0.09 Allowed 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.329 -0.857 . . . . 0.0 109.846 -179.092 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.81 ' CD2' HD12 ' B' ' 38' ' ' LEU . 22.3 m-85 -96.31 94.59 7.55 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.408 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 37.0 m-20 -78.78 140.01 38.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.894 -1.129 . . . . 0.0 110.626 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.681 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.3 OUTLIER 69.17 64.89 0.28 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.714 -0.616 . . . . 0.0 110.309 179.255 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.742 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.7 OUTLIER -123.82 113.12 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.188 -0.945 . . . . 0.0 108.686 179.155 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.672 ' C ' HD13 ' B' ' 63' ' ' LEU . 3.3 tm? -64.68 104.74 0.86 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.239 -0.913 . . . . 0.0 110.869 -178.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.633 HG22 ' O ' ' B' ' 71' ' ' ALA . 1.2 tt -107.76 122.94 62.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.3 tt0 -88.09 114.58 24.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.04 -1.037 . . . . 0.0 109.078 -179.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.63 HD11 HD13 ' B' ' 64' ' ' ILE . 2.2 mp -111.32 116.79 53.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.321 -0.862 . . . . 0.0 110.052 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.548 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 80.0 m 63.41 8.24 3.4 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.58 -0.7 . . . . 0.0 110.668 179.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 104.53 22.96 8.19 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.045 179.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -125.77 130.92 52.42 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.137 -1.214 . . . . 0.0 109.231 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.534 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -69.45 131.04 44.13 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.53 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.633 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.77 96.87 2.88 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.887 -179.569 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.742 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.18 136.43 24.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 179.125 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -163.6 -173.45 32.3 Favored Glycine 0 C--N 1.294 -1.792 0 C-N-CA 118.695 -1.716 . . . . 0.0 110.658 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 86.5 m -92.25 106.41 18.42 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.664 -0.903 . . . . 0.0 109.331 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.125 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -95.83 105.05 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.652 -0.655 . . . . 0.0 109.982 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.82 HD23 ' CE ' ' B' ' 45' ' ' LYS . 5.6 mp -78.99 116.82 19.54 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.559 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 79.6 t -110.86 118.16 56.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 120.945 -1.097 . . . . 0.0 110.695 -178.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.658 ' N ' HG12 ' B' ' 56' ' ' VAL . . . -157.24 -150.4 5.69 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.579 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -83.07 41.28 1.07 Allowed 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.959 2.439 . . . . 0.0 110.258 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.566 HG23 ' N ' ' B' ' 34' ' ' GLU . 3.5 t -90.17 129.75 44.61 Favored Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 179.225 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.552 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.02 25.86 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.168 1.912 . . . . 0.0 111.558 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.552 HG22 ' O ' ' B' ' 81' ' ' PRO . 0.2 OUTLIER -161.4 154.01 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.719 -1.238 . . . . 0.0 110.785 -179.976 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.63 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 72.1 m-20 -96.38 83.05 3.48 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 175.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.856 HG23 ' CB ' ' B' ' 25' ' ' ASP . 12.4 mt -78.89 115.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.08 -1.013 . . . . 0.0 112.82 -175.248 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.824 ' HB ' HD23 ' B' ' 24' ' ' LEU . 1.4 mm -95.66 93.05 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -77.87 -169.84 34.43 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.12 -1.038 . . . . 0.0 111.008 -177.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.493 ' HD2' ' HA ' ' A' ' 8' ' ' ARG . 10.1 mtp85 -58.41 -37.56 75.59 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.931 -0.746 . . . . 0.0 110.766 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.01 ' ND2' HD23 ' B' ' 89' ' ' LEU . 14.3 p-10 -46.57 -26.9 0.98 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.554 -1.341 . . . . 0.0 109.451 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.01 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -110.56 -28.87 8.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.212 -0.93 . . . . 0.0 111.132 -178.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.654 HD21 HD22 ' B' ' 24' ' ' LEU . 66.9 mt -65.38 -22.25 66.77 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.745 -1.222 . . . . 0.0 108.29 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.428 ' CG2' ' NH2' ' B' ' 87' ' ' ARG . 82.7 p -83.63 -18.11 39.26 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 108.97 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -79.73 -41.76 26.02 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.881 . . . . 0.0 109.569 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.939 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -82.89 -2.9 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.032 179.431 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.54 63.08 4.12 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.623 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -86.29 161.94 18.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.399 -1.059 . . . . 0.0 109.967 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.6 p -141.4 129.92 22.62 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.206 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.9 94.4 6.28 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -179.872 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.514 ' N ' ' ND2' ' B' ' 98' ' ' ASN . 0.8 OUTLIER -105.26 130.88 53.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 110.851 -178.49 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.838 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.143 179.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.437 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.497 1.692 0 N-CA-C 110.76 -0.515 . . . . 0.0 110.76 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.8 tt0 -83.51 142.42 30.92 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.405 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 51.9 t -141.32 128.76 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 118.012 -1.475 . . . . 0.0 111.047 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.481 ' OG1' ' N ' ' A' ' 5' ' ' LEU . 1.3 p -132.34 -57.26 0.96 Allowed 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.205 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.0 OUTLIER 39.0 28.24 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.548 -0.72 . . . . 0.0 110.414 179.352 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.491 ' C ' ' O ' ' A' ' 5' ' ' LEU . 4.4 m95 18.02 43.91 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.411 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' A' ' 5' ' ' LEU . 15.9 mm100 -158.78 -111.5 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 108.855 179.385 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 77.1 mtt180 -111.98 134.06 21.49 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 120.621 -1.3 . . . . 0.0 109.352 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -81.18 54.4 5.19 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 122.357 2.038 . . . . 0.0 110.057 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.743 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.72 146.77 30.89 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.946 -1.096 . . . . 0.0 109.69 -179.495 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.643 HG21 HG12 ' A' ' 66' ' ' ILE . 2.4 m -138.03 136.11 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.2 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.663 HG22 HD22 ' A' ' 19' ' ' LEU . 94.9 m -60.35 113.65 2.51 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -106.24 137.02 38.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 O-C-N 121.091 -1.006 . . . . 0.0 110.419 -178.684 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 2.7 ttpt -110.45 105.17 14.05 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.407 -0.808 . . . . 0.0 109.049 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 64' ' ' ILE . 40.8 mt -118.42 122.01 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.121 -0.987 . . . . 0.0 109.887 -179.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.02 10.86 59.95 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 178.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.16 -7.02 60.05 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.6 178.36 6.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -1.109 . . . . 0.0 108.987 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 11.3 mt -151.06 129.66 12.24 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.236 -0.915 . . . . 0.0 110.74 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -150.61 157.0 42.46 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.743 ' HB3' HD22 ' A' ' 10' ' ' LEU . 61.6 mt-10 -77.94 131.36 37.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.576 -1.327 . . . . 0.0 108.428 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.886 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -107.7 148.03 29.96 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.086 -1.009 . . . . 0.0 110.235 -178.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' O ' ' B' ' 27' ' ' GLY . 30.9 tp -98.9 95.85 7.45 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.163 0.506 . . . . 0.0 110.431 -178.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.536 HD22 ' HB ' ' A' ' 85' ' ' ILE . 0.2 OUTLIER -47.16 115.7 1.17 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 178.916 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 12.8 t70 -131.8 108.18 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.747 -1.221 . . . . 0.0 111.15 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 1.013 HG23 HD13 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -79.97 -2.59 44.6 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.817 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.48 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -80.74 -21.66 63.32 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.84 161.83 13.55 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.131 -1.217 . . . . 0.0 109.892 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.54 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 50.4 m-20 -92.85 -20.1 21.03 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.406 -0.809 . . . . 0.0 110.919 -179.083 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -139.17 -169.08 2.58 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.621 -1.3 . . . . 0.0 110.203 -179.438 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 1.006 ' O ' HD12 ' A' ' 76' ' ' LEU . 21.5 m -103.56 107.15 17.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.12 -0.988 . . . . 0.0 109.76 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.821 HG12 HG13 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -97.89 126.23 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.076 -1.015 . . . . 0.0 110.003 -179.469 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.046 HD13 ' CG1' ' A' ' 75' ' ' VAL . 3.8 mp -120.88 124.82 45.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.772 -1.205 . . . . 0.0 111.277 -178.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.2 pt-20 -43.77 163.45 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.295 -0.962 . . . . 0.0 108.525 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -44.25 137.84 3.32 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.033 -1.042 . . . . 0.0 110.212 -179.409 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.6 ptm -146.71 -163.16 1.69 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.516 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.4 t -108.22 84.3 1.92 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.975 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.825 HD12 HG21 ' A' ' 77' ' ' VAL . 13.4 mt -108.84 165.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 108.993 179.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.0 Cg_endo -73.45 -167.36 0.36 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.369 2.046 . . . . 0.0 111.37 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.32 33.03 6.9 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.111 -1.042 . . . . 0.0 110.503 -178.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.63 53.99 0.7 Allowed 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.624 -0.927 . . . . 0.0 108.616 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.628 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 51.2 p-90 -131.6 -168.75 2.07 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.623 0.725 . . . . 0.0 110.616 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 42' ' ' TRP . 15.3 mttt -147.17 131.07 8.41 Favored Pre-proline 0 N--CA 1.49 1.53 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -76.2 141.22 23.08 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.126 1.884 . . . . 0.0 111.042 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.428 ' NZ ' HD23 ' A' ' 76' ' ' LEU . 1.3 ptpp? -152.38 177.06 10.99 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.403 ' N ' ' HG3' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -129.65 124.75 34.42 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.079 -1.013 . . . . 0.0 108.842 179.507 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.798 HD12 HG21 ' B' ' 50' ' ' ILE . 4.9 pt -96.42 149.87 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.238 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.646 ' CA ' ' CD2' ' A' ' 53' ' ' PHE . . . -122.48 108.9 1.32 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.79 -124.03 2.41 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 119.388 -1.387 . . . . 0.0 110.453 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.669 HG21 ' CD1' ' B' ' 47' ' ' ILE . 64.7 mt -85.56 128.86 38.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.713 -0.875 . . . . 0.0 112.343 -177.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.24 -48.99 2.41 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.87 -157.78 26.22 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.646 ' CD2' ' CA ' ' A' ' 48' ' ' GLY . 3.5 m-85 -111.82 143.54 42.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -1.113 . . . . 0.0 109.573 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.609 HD11 HD11 ' A' ' 47' ' ' ILE . 3.8 pt -119.11 150.77 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.184 -0.947 . . . . 0.0 108.975 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 14.8 mttp -90.16 118.58 29.79 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.11 -0.994 . . . . 0.0 109.925 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.868 HG12 ' HA3' ' A' ' 78' ' ' GLY . 14.9 m -125.56 -167.5 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.226 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.415 ' O ' HD23 ' A' ' 76' ' ' LEU . 75.1 mtt85 -125.76 173.82 8.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.278 -0.889 . . . . 0.0 109.493 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 3.4 tt0 -130.77 123.93 30.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.409 -0.807 . . . . 0.0 109.919 -179.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 41.9 m-85 -121.14 91.36 3.51 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 20.3 m-20 -78.98 133.26 36.86 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.098 -1.001 . . . . 0.0 109.692 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 1.6 mt-30 83.36 57.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.482 0.658 . . . . 0.0 109.379 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.715 ' CG2' HG23 ' A' ' 15' ' ' ILE . 3.0 mm -114.3 114.03 45.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.681 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.0 OUTLIER -70.27 87.22 0.6 Allowed 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.271 -178.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.806 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -88.5 123.68 41.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.495 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -89.46 106.19 18.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.985 -1.072 . . . . 0.0 109.038 -178.995 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.71 HG13 HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER -106.13 123.22 60.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.009 -179.621 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 13.6 m 49.11 69.12 0.61 Allowed 'General case' 0 C--N 1.293 -1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.452 179.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 42.59 27.3 0.5 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.3 m-70 -122.97 130.74 53.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.897 -1.355 . . . . 0.0 109.065 179.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -75.01 133.21 41.71 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 108.837 179.404 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.47 108.32 2.94 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.876 . . . . 0.0 110.459 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.681 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -85.48 152.45 3.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 177.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.42 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.7 -178.32 45.43 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.206 -1.949 . . . . 0.0 111.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.1 m -92.66 106.36 18.35 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.627 -0.925 . . . . 0.0 110.139 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.046 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.3 t -97.01 176.65 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 1.006 HD12 ' O ' ' A' ' 31' ' ' THR . 1.9 mp -139.4 161.48 37.35 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.966 -1.084 . . . . 0.0 108.288 178.127 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.825 HG21 HD12 ' A' ' 38' ' ' LEU . 19.5 t -143.47 105.46 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.91 0 O-C-N 121.379 -0.825 . . . . 0.0 109.734 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.868 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.7 -162.49 10.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -80.3 40.18 0.94 Allowed 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.473 2.116 . . . . 0.0 110.705 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.5 t -85.59 132.75 43.61 Favored Pre-proline 0 C--N 1.3 -1.572 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 179.056 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -77.92 17.5 0.99 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.407 2.071 . . . . 0.0 111.356 -179.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 83' ' ' ASN . 1.1 t -162.22 162.22 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.837 -1.165 . . . . 0.0 109.983 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.646 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -96.94 154.38 17.33 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 175.21 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.821 HG13 HG12 ' A' ' 32' ' ' VAL . 1.1 mm -144.2 134.18 20.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 O-C-N 120.057 -1.652 . . . . 0.0 109.963 -178.244 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.886 HD13 ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.16 88.97 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 177.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.61 -164.45 22.81 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.905 -1.14 . . . . 0.0 110.278 -177.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HD2' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -61.82 -35.62 78.78 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.624 -0.927 . . . . 0.0 109.567 -179.134 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.018 ' ND2' HD23 ' A' ' 89' ' ' LEU . 8.1 p-10 -45.15 -25.07 0.31 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 108.891 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.018 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -112.91 -29.17 7.46 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 121.375 -0.828 . . . . 0.0 110.472 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 1.013 HD13 HG23 ' A' ' 26' ' ' THR . 77.7 mt -68.25 -7.26 29.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.967 -1.083 . . . . 0.0 109.157 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.48 -19.69 15.42 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 108.607 179.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -80.65 -41.17 24.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.222 -0.924 . . . . 0.0 108.874 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.624 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.7 pt -83.77 -5.61 9.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.01 34.28 55.89 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.577 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -64.25 151.9 42.38 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.261 . . . . 0.0 110.624 -179.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 30.9 p -148.32 128.21 13.5 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' B' ' 97' ' ' LEU . 3.0 mp -87.81 95.05 9.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.11 -0.994 . . . . 0.0 109.443 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.591 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.0 OUTLIER -114.46 129.97 56.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 110.674 -179.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.172 178.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 N-CA-C 109.744 -0.906 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.591 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.2 tt0 -81.92 149.63 28.13 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 178.249 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.517 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 61.2 t -148.46 96.2 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 117.832 -1.547 . . . . 0.0 110.868 -178.301 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.447 ' O ' ' N ' ' B' ' 6' ' ' TRP . 71.3 p -100.75 -55.67 2.52 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.653 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.2 OUTLIER 43.99 18.99 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.757 -0.589 . . . . 0.0 111.524 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.537 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.3 m95 18.53 43.15 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.096 0.407 . . . . 0.0 111.895 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.653 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -170.85 -103.3 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 63.8 mtt180 -113.58 127.87 26.34 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 120.351 -1.468 . . . . 0.0 110.252 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.474 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -78.99 71.48 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 121.94 1.76 . . . . 0.0 108.335 177.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.545 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -93.93 152.21 19.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.117 -0.989 . . . . 0.0 110.933 -178.083 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.57 HG21 HG23 ' B' ' 66' ' ' ILE . 2.0 m -151.03 150.39 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.663 -0.648 . . . . 0.0 109.414 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.878 HG22 HD22 ' B' ' 19' ' ' LEU . 99.7 m -78.16 115.45 17.89 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.733 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.5 pp -103.89 151.4 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.024 -1.048 . . . . 0.0 110.507 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.1 OUTLIER -109.47 102.87 11.7 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.198 -0.939 . . . . 0.0 109.694 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.854 HD13 HG11 ' B' ' 75' ' ' VAL . 3.9 mt -121.37 134.28 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.986 -1.071 . . . . 0.0 110.159 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.494 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 58.66 27.24 61.12 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 179.317 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.13 27.3 66.55 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm-40 -124.41 -178.76 4.21 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.464 -1.021 . . . . 0.0 109.121 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 HG22 ' B' ' 12' ' ' THR . 19.8 mt -147.45 125.27 11.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 0.0 109.706 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.487 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mmtt -144.5 169.28 18.26 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.545 ' HB3' HD22 ' B' ' 10' ' ' LEU . 9.4 mt-10 -79.69 135.43 36.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 108.442 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.603 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -121.9 135.45 54.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.983 -1.073 . . . . 0.0 110.669 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 15.5 tp -92.04 94.1 9.08 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.48 HD23 ' CG1' ' B' ' 85' ' ' ILE . 14.2 mt -45.83 101.47 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.989 -1.069 . . . . 0.0 108.719 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.4 t70 -101.59 96.75 7.32 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.754 -0.591 . . . . 0.0 110.419 -178.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.788 ' OG1' HD21 ' A' ' 97' ' ' LEU . 24.6 m -79.68 13.49 2.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.906 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -109.83 -19.33 8.26 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.37 170.46 15.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.93 -1.336 . . . . 0.0 109.141 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -99.92 -18.08 17.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 110.088 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.54 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 16.1 m-20 -142.97 -155.16 0.57 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.064 -1.022 . . . . 0.0 109.658 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.57 ' OG1' ' HG ' ' B' ' 89' ' ' LEU . 78.5 m -120.19 97.82 5.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.511 -1.368 . . . . 0.0 111.262 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.044 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -76.83 174.87 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.073 -1.017 . . . . 0.0 108.445 178.969 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.044 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.04 119.46 0.61 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.765 -1.209 . . . . 0.0 110.936 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' B' ' 80' ' ' THR . 41.6 tt0 -36.66 158.77 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.453 0.644 . . . . 0.0 110.009 179.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.506 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -52.42 147.31 8.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.497 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.449 ' SD ' ' HB2' ' B' ' 38' ' ' LEU . 0.0 OUTLIER 179.55 178.35 0.54 Allowed 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.6 t -92.49 101.62 14.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.074 -1.017 . . . . 0.0 109.563 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.658 HD13 HG22 ' B' ' 15' ' ' ILE . 58.0 tp -130.69 98.24 20.1 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.119 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -78.76 -177.77 4.15 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.618 2.212 . . . . 0.0 110.393 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 113.63 31.65 2.29 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.42 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.481 ' O ' ' O ' ' B' ' 40' ' ' GLY . 49.0 mtm180 59.78 141.44 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.901 -0.764 . . . . 0.0 109.401 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 47.9 p-90 -160.3 -172.13 3.46 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.782 -1.199 . . . . 0.0 110.832 -179.286 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.495 ' HD3' ' HD2' ' B' ' 44' ' ' PRO . 1.8 mmtp -148.27 145.16 19.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . 0.495 ' HD2' ' HD3' ' B' ' 43' ' ' LYS . 35.8 Cg_endo -78.16 136.24 14.34 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 122.018 1.812 . . . . 0.0 110.932 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.581 ' HD3' HD23 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -160.29 -168.79 2.27 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.456 -0.778 . . . . 0.0 109.592 179.427 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.524 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 60.5 mtp -150.53 138.31 19.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.452 -0.78 . . . . 0.0 109.676 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.669 ' CD1' HG21 ' A' ' 50' ' ' ILE . 4.9 pt -95.93 150.09 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.03 -1.044 . . . . 0.0 108.535 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.82 102.53 0.94 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.81 -135.84 4.25 Favored Glycine 0 N--CA 1.483 1.821 0 C-N-CA 119.324 -1.417 . . . . 0.0 111.015 -178.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.798 HG21 HD12 ' A' ' 47' ' ' ILE . 46.1 mt -79.87 119.63 29.66 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.855 -0.791 . . . . 0.0 112.912 -177.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 104.97 -54.47 0.61 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.076 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.02 -159.62 20.78 Favored Glycine 0 N--CA 1.492 2.378 0 O-C-N 120.947 -1.325 . . . . 0.0 110.201 -179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.607 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-85 -118.9 125.85 50.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.475 -1.015 . . . . 0.0 109.161 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.457 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 5.2 pt -97.81 173.19 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.255 -0.903 . . . . 0.0 109.438 -179.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mtmt -109.03 125.58 52.23 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.147 -0.971 . . . . 0.0 109.626 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.652 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.6 m -134.86 168.76 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 110.279 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 18.4 mtt180 -110.33 111.41 22.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.588 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -69.04 121.69 17.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.409 -0.807 . . . . 0.0 110.471 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.6 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 23.9 m-85 -116.05 93.69 4.35 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 6.4 m-20 -77.6 124.97 28.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.8 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 48.6 mt-30 88.81 60.41 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 CA-C-O 121.32 0.581 . . . . 0.0 110.105 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.909 HG21 HG21 ' B' ' 75' ' ' VAL . 19.0 mm -115.57 109.82 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.116 179.498 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.93 HD21 ' HG2' ' B' ' 70' ' ' LYS . 3.0 tm? -65.27 85.56 0.06 Allowed 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.033 0.92 . . . . 0.0 110.717 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.652 HG21 ' CD1' ' B' ' 89' ' ' LEU . 0.6 OUTLIER -92.16 119.68 40.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 177.37 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.5 tt0 -87.14 128.84 35.12 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.163 -0.961 . . . . 0.0 108.957 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.57 HG23 HG21 ' B' ' 11' ' ' VAL . 0.9 OUTLIER -114.9 129.76 70.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.014 -179.313 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 86.2 m 54.52 -91.27 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.574 -0.704 . . . . 0.0 109.804 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -147.18 40.82 0.98 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.497 ' CB ' HG22 ' B' ' 93' ' ' ILE . 17.6 m-70 -145.72 149.58 34.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -1.046 . . . . 0.0 109.287 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.93 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -79.04 139.63 38.11 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.077 -1.014 . . . . 0.0 109.467 -179.805 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.522 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -147.62 109.55 4.47 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.081 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.577 HG12 ' HA ' ' B' ' 63' ' ' LEU . 0.0 OUTLIER -94.88 145.46 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.215 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.786 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -169.22 -178.09 40.32 Favored Glycine 0 C--N 1.297 -1.636 0 C-N-CA 118.442 -1.837 . . . . 0.0 111.083 179.562 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.588 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.1 m -87.73 100.54 12.91 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 122.139 -0.624 . . . . 0.0 109.951 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.909 HG21 HG21 ' B' ' 62' ' ' ILE . 1.3 t -85.54 121.11 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.053 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.581 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.6 mp -96.73 104.25 16.23 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' B' ' 35' ' ' GLU . 21.8 t -93.45 112.03 25.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.04 -1.038 . . . . 0.0 109.993 -179.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.652 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.67 -160.85 9.45 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.556 -1.817 . . . . 0.0 108.556 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.539 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -79.98 38.31 0.73 Allowed 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.388 2.059 . . . . 0.0 110.973 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.678 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -81.98 134.96 48.79 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.584 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -79.04 15.14 1.57 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.583 2.189 . . . . 0.0 111.311 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.584 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -160.59 161.01 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.999 -1.063 . . . . 0.0 109.804 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.9 OUTLIER -98.24 129.12 44.98 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 104.157 -2.534 . . . . 0.0 104.157 175.51 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' B' ' 25' ' ' ASP . 5.0 mm -117.12 129.38 73.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.957 0 O-C-N 120.331 -1.481 . . . . 0.0 111.923 -176.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.62 HG23 HD12 ' B' ' 89' ' ' LEU . 3.4 mm -102.19 105.19 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 176.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -98.8 -163.65 30.14 Favored Glycine 0 N--CA 1.496 2.691 0 C-N-CA 119.826 -1.178 . . . . 0.0 111.823 -177.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.587 ' NH1' ' HG2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -53.28 -40.91 65.06 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 122.005 -0.703 . . . . 0.0 111.714 -178.193 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.747 ' C ' HD23 ' B' ' 89' ' ' LEU . 53.0 p-10 -48.14 -26.16 1.77 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.548 -1.345 . . . . 0.0 111.007 -177.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.786 HD21 ' HA3' ' B' ' 73' ' ' GLY . 2.3 mt -115.31 -27.77 7.12 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.32 -1.487 . . . . 0.0 111.602 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.772 ' HA ' HD11 ' B' ' 93' ' ' ILE . 3.5 mt -63.38 -11.77 25.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.212 -1.555 . . . . 0.0 108.259 -179.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -101.67 -19.65 15.33 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.196 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 69.9 mm-40 -79.16 -41.23 28.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.726 -0.608 . . . . 0.0 110.581 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.772 HD11 ' HA ' ' B' ' 90' ' ' LEU . 1.0 OUTLIER -80.44 -22.12 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 179.52 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' N ' HD12 ' B' ' 93' ' ' ILE . . . 103.02 35.48 3.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.507 ' HA ' ' HD1' ' A' ' 99' ' ' PHE . . . -72.43 135.68 45.83 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.388 -1.066 . . . . 0.0 111.185 -178.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 75.1 p -136.66 128.87 29.78 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -83.49 105.32 14.33 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 108.68 -179.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.487 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 5.9 m120 -103.53 122.62 45.32 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.049 -1.032 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.624 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.135 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.497 1.711 0 N-CA-C 110.178 -0.739 . . . . 0.0 110.178 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.544 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -83.16 148.94 27.17 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 106.471 -1.677 . . . . 0.0 106.471 177.815 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 2.3 t -140.76 105.98 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.902 -178.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.563 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -122.05 -69.03 0.85 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 176.694 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER 31.76 29.94 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.964 177.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.563 ' N ' ' O ' ' A' ' 4' ' ' THR . 17.3 m95 18.88 48.37 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.145 0 CA-C-O 121.331 0.586 . . . . 0.0 111.871 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.575 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -164.25 -175.5 3.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.172 -0.955 . . . . 0.0 109.401 179.8 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.486 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 1.6 mtt180 -76.38 119.27 76.61 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.267 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.532 ' HB3' ' CG1' ' A' ' 3' ' ' VAL . 35.3 Cg_endo -79.11 74.52 5.51 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.833 1.689 . . . . 0.0 108.92 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.425 ' HG ' ' HA ' ' A' ' 23' ' ' LEU . 0.4 OUTLIER -80.69 150.65 29.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.532 -0.73 . . . . 0.0 110.455 -178.609 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.605 ' O ' ' HB3' ' A' ' 22' ' ' ALA . 2.0 m -150.05 162.04 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.413 -0.804 . . . . 0.0 109.33 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.424 HG22 HD22 ' A' ' 19' ' ' LEU . 42.5 m -96.12 114.04 25.7 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -97.95 171.74 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.901 -178.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.516 ' HE3' HD11 ' A' ' 19' ' ' LEU . 6.5 tttt -131.78 102.38 5.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 109.406 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.756 HD13 HG11 ' A' ' 75' ' ' VAL . 48.6 mt -118.44 132.09 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.984 -1.072 . . . . 0.0 109.902 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.26 40.13 98.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.03 18.45 60.12 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 mm-40 -112.89 171.62 7.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.336 -1.097 . . . . 0.0 109.094 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 14.4 mt -142.9 126.92 17.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.218 -0.926 . . . . 0.0 110.3 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 7.2 mttt -143.52 -167.7 2.64 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 43.5 mt-10 -79.4 -167.82 1.32 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.989 -1.07 . . . . 0.0 108.145 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.706 ' CB ' HG23 ' A' ' 13' ' ' ILE . . . -171.3 86.85 0.09 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.085 -1.009 . . . . 0.0 109.454 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.578 ' O ' ' N ' ' A' ' 25' ' ' ASP . 36.5 tp -72.47 95.35 1.77 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.346 -0.846 . . . . 0.0 109.032 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.493 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 49.6 mt -48.93 90.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' N ' ' O ' ' A' ' 23' ' ' LEU . 0.6 OUTLIER -99.52 92.98 5.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.49 -0.756 . . . . 0.0 110.825 -177.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 1.022 ' OG1' HD21 ' B' ' 97' ' ' LEU . 1.5 m -73.11 -2.03 19.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.574 178.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.556 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.84 -36.36 13.74 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.91 136.74 36.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.086 -1.244 . . . . 0.0 109.686 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 87' ' ' ARG . 19.3 m-20 -64.15 -19.2 65.13 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.434 -0.791 . . . . 0.0 111.126 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.744 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.7 OUTLIER -141.79 -179.28 6.1 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.121 -1.432 . . . . 0.0 110.987 -179.324 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.662 HG22 ' CD1' ' A' ' 33' ' ' LEU . 2.3 m -96.18 89.41 5.13 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.471 -0.768 . . . . 0.0 110.612 -178.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.7 OUTLIER -69.38 163.28 3.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.729 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -158.45 131.72 7.43 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.112 -0.993 . . . . 0.0 110.691 -178.558 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.461 ' N ' ' CG2' ' A' ' 80' ' ' THR . 57.7 tt0 -43.44 164.77 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.538 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -56.91 134.56 55.6 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.149 -0.97 . . . . 0.0 110.703 -179.285 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' VAL . 2.2 ppp? -162.63 -167.56 1.59 Allowed 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.4 t -106.5 138.33 42.88 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.831 -1.168 . . . . 0.0 110.451 -179.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.837 HD22 HD12 ' A' ' 62' ' ' ILE . 5.4 mt -143.33 171.1 7.4 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.606 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -70.24 -153.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 121.853 1.702 . . . . 0.0 110.27 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.52 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -110.6 -167.25 19.27 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 -178.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.52 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.1 OUTLIER 73.07 54.6 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.113 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.662 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 3.9 p-90 -126.01 -176.84 3.75 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.791 0.805 . . . . 0.0 110.543 -178.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.41 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 14.0 mttp -147.54 160.87 37.66 Favored Pre-proline 0 N--CA 1.489 1.517 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.115 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 32.0 Cg_endo -75.78 147.48 31.15 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.166 1.91 . . . . 0.0 109.373 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.577 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -146.0 165.41 29.09 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.014 -1.054 . . . . 0.0 110.078 -178.932 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.406 ' SD ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -148.38 112.29 5.14 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.046 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 54' ' ' ILE . 6.7 pt -106.1 129.45 59.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.48 -1.288 . . . . 0.0 109.467 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -116.82 100.71 0.91 Allowed Glycine 0 N--CA 1.482 1.753 0 N-CA-C 107.15 -2.38 . . . . 0.0 107.15 179.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.18 -128.62 3.8 Favored Glycine 0 N--CA 1.479 1.565 0 C-N-CA 119.269 -1.443 . . . . 0.0 111.084 -177.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.806 HG21 HD11 ' B' ' 47' ' ' ILE . 59.1 mt -85.4 119.16 33.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 O-C-N 122.074 -0.663 . . . . 0.0 112.429 -177.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 109.79 -36.42 4.31 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 162.99 -162.09 34.41 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.492 -1.337 . . . . 0.0 110.147 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.7 m-85 -115.12 141.99 47.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.467 -1.02 . . . . 0.0 109.466 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 47' ' ' ILE . 3.0 pt -128.51 178.24 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.509 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -112.66 138.06 50.0 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.05 -1.031 . . . . 0.0 109.405 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.7 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.5 m -144.09 161.61 15.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.294 -0.879 . . . . 0.0 109.35 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.564 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -104.49 -176.63 3.14 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.145 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 7.1 tt0 -137.6 101.45 4.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.006 . . . . 0.0 109.543 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.815 ' HB3' HD11 ' A' ' 62' ' ' ILE . 40.1 m-85 -103.41 95.73 6.27 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.424 -0.797 . . . . 0.0 109.517 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -78.88 140.85 38.05 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.955 -1.091 . . . . 0.0 108.982 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 76.38 64.06 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.819 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.837 HD12 HD22 ' A' ' 38' ' ' LEU . 21.4 mm -121.8 123.34 69.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.859 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.3 tm? -67.56 82.47 0.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.355 -0.841 . . . . 0.0 110.935 -178.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 1.028 ' CG2' HD11 ' A' ' 89' ' ' LEU . 2.5 tt -94.34 121.25 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.43 ' HG2' ' C ' ' A' ' 69' ' ' HIS . 1.7 tt0 -89.17 140.57 29.33 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.099 -1.001 . . . . 0.0 108.486 179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.821 HD11 ' CD1' ' A' ' 89' ' ' LEU . 0.4 OUTLIER -126.05 171.97 14.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 107.165 -1.421 . . . . 0.0 107.165 179.672 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.458 ' SG ' ' HB ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -47.96 -38.63 17.21 Favored 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 178.836 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.635 ' O ' ' CG ' ' A' ' 69' ' ' HIS . . . -52.79 -49.59 53.4 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 178.319 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.635 ' CG ' ' O ' ' A' ' 68' ' ' GLY . 5.2 m170 141.66 -173.39 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.076 0 CA-C-O 121.102 0.477 . . . . 0.0 109.838 178.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.533 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -36.56 139.51 0.18 Allowed 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 121.351 0.596 . . . . 0.0 109.773 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -161.8 115.33 1.87 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.304 -0.872 . . . . 0.0 110.02 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.772 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -85.57 150.7 3.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.608 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.24 -154.92 11.73 Favored Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.262 -1.446 . . . . 0.0 110.835 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.494 ' HB ' ' OD1' ' A' ' 88' ' ' ASN . 1.4 m -109.7 111.95 23.73 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.246 -1.149 . . . . 0.0 110.087 -179.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.03 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -106.15 108.39 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.262 -0.899 . . . . 0.0 111.243 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.744 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.12 139.55 38.02 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 177.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.56 ' CG2' HD12 ' A' ' 38' ' ' LEU . 1.3 t -116.2 112.47 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.084 -1.01 . . . . 0.0 110.978 -178.144 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.7 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.54 -172.17 18.83 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.2 Cg_endo -81.45 41.62 1.18 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.58 2.187 . . . . 0.0 110.681 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.632 HG21 HG13 ' A' ' 32' ' ' VAL . 3.8 t -79.3 141.56 57.62 Favored Pre-proline 0 N--CA 1.49 1.553 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.21 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.733 ' O ' HG23 ' A' ' 82' ' ' VAL . 38.2 Cg_endo -80.07 20.02 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.583 2.188 . . . . 0.0 110.872 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 81' ' ' PRO . 10.5 t -161.13 166.8 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.702 -1.248 . . . . 0.0 110.92 -178.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.545 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 7.8 m-80 -100.44 90.45 4.3 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 177.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.598 ' O ' ' HA ' ' A' ' 31' ' ' THR . 12.1 mm -79.14 120.04 29.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 O-C-N 121.183 -0.948 . . . . 0.0 112.379 -176.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.576 HD13 ' N ' ' A' ' 85' ' ' ILE . 3.3 mm -99.07 106.11 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 176.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.507 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -91.47 -152.18 27.94 Favored Glycine 0 N--CA 1.489 2.197 0 O-C-N 120.679 -1.263 . . . . 0.0 111.861 -176.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.774 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -70.7 -41.29 72.15 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 120.111 -0.636 . . . . 0.0 109.852 -179.032 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.57 ' OD1' ' HA ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -53.33 -16.39 1.33 Allowed 'General case' 0 N--CA 1.498 1.963 0 C-N-CA 117.821 -1.552 . . . . 0.0 110.422 -178.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.157 HD13 ' OE1' ' A' ' 92' ' ' GLN . 0.2 OUTLIER -105.76 -20.82 13.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.658 -1.276 . . . . 0.0 109.054 179.825 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.933 HD13 HG23 ' A' ' 26' ' ' THR . 28.7 mt -80.95 1.1 32.55 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.654 -1.279 . . . . 0.0 108.535 178.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.774 HG23 ' O ' ' A' ' 87' ' ' ARG . 0.3 OUTLIER -101.08 -10.06 20.83 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.137 -0.977 . . . . 0.0 111.159 -179.958 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 1.157 ' OE1' HD13 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -95.15 -40.81 9.41 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 120.467 -1.396 . . . . 0.0 109.562 -178.552 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.052 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.3 OUTLIER -80.48 3.3 2.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.013 -1.075 . . . . 0.0 108.349 178.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 69.87 53.05 16.71 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.575 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -77.27 144.98 37.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.121 -1.223 . . . . 0.0 109.271 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.95 HG22 HG22 ' B' ' 4' ' ' THR . 27.3 p -139.85 123.27 17.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.157 -0.964 . . . . 0.0 109.27 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.738 HD11 HD11 ' B' ' 97' ' ' LEU . 7.4 mp -84.72 100.61 11.61 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 178.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' B' ' 94' ' ' GLY . 18.5 m120 -99.17 120.01 38.8 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 120.447 -1.408 . . . . 0.0 108.934 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.64 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.298 -1.64 0 CA-C-O 118.101 -0.952 . . . . 0.0 109.282 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.7 Cg_exo . . . . . 0 N--CA 1.493 1.488 0 N-CA-C 109.917 -0.839 . . . . 0.0 109.917 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 130.7 35.14 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 56.3 t -123.57 109.04 22.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.595 -177.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 96' ' ' THR . 14.7 p -123.97 21.59 8.98 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.411 -0.806 . . . . 0.0 109.967 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.6 tp -88.82 27.31 1.34 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.023 -1.048 . . . . 0.0 108.758 178.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.763 ' HB3' HG22 ' A' ' 91' ' ' THR . 0.7 OUTLIER 14.98 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.685 0.755 . . . . 0.0 111.918 179.698 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.54 ' O ' ' HD3' ' B' ' 9' ' ' PRO . 1.0 OUTLIER -129.31 -152.46 0.52 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.448 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 26.5 mtt180 -103.72 101.43 24.37 Favored Pre-proline 0 N--CA 1.488 1.45 0 O-C-N 120.903 -1.123 . . . . 0.0 108.133 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.561 ' HD2' ' CZ ' ' A' ' 87' ' ' ARG . 33.9 Cg_endo -75.13 72.06 4.86 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.413 2.075 . . . . 0.0 110.698 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -89.78 142.88 27.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.017 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.781 HG23 HG23 ' B' ' 13' ' ' ILE . 21.9 m -131.15 126.05 58.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.3 m -67.34 99.88 0.76 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 177.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.857 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pp -95.91 140.53 16.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.242 -0.911 . . . . 0.0 111.298 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.1 OUTLIER -103.63 106.91 17.56 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.734 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.862 HD13 HG11 ' B' ' 75' ' ' VAL . 7.2 mt -119.68 115.65 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.206 -0.934 . . . . 0.0 110.154 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.48 27.78 73.13 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.606 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.77 12.3 81.63 Favored Glycine 0 N--CA 1.492 2.419 0 O-C-N 120.901 -1.353 . . . . 0.0 109.789 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.4 mt-30 -107.44 168.57 9.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.208 -1.172 . . . . 0.0 109.134 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.519 HD11 ' HE3' ' B' ' 14' ' ' LYS . 14.7 mt -140.48 122.95 16.06 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 0.0 109.514 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.517 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mmtt -143.87 172.95 12.15 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.503 -0.748 . . . . 0.0 109.236 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 31.1 mp0 -87.13 132.06 33.97 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.919 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.78 147.32 30.99 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.025 -1.047 . . . . 0.0 109.587 -179.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' B' ' 25' ' ' ASP . 18.6 tp -112.84 94.43 4.9 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.569 -0.707 . . . . 0.0 109.462 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.517 ' O ' ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -41.41 95.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.423 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.951 ' HB3' HG23 ' B' ' 84' ' ' ILE . 24.6 t0 -113.57 88.95 2.96 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.198 -0.939 . . . . 0.0 111.538 -178.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.81 HG23 HD22 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -67.69 -19.67 65.2 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 177.265 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.457 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -55.57 -39.51 75.13 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.46 164.73 18.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.46 -1.023 . . . . 0.0 109.306 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.477 ' OD1' ' HG3' ' A' ' 8' ' ' ARG . 12.4 m-20 -94.96 -19.57 20.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.075 -1.016 . . . . 0.0 110.921 -178.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.947 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.9 OUTLIER -137.22 -175.71 4.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.747 -1.22 . . . . 0.0 110.198 -179.491 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.741 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.3 m -100.21 94.7 6.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.03 -1.044 . . . . 0.0 110.856 -178.224 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.037 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -75.05 158.72 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.092 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.037 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.5 OUTLIER -155.46 143.07 19.65 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.908 -1.12 . . . . 0.0 111.052 -178.092 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.729 ' N ' HG22 ' B' ' 80' ' ' THR . 20.2 tt0 -49.68 156.15 0.72 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.6 OUTLIER -61.69 132.78 54.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.076 -1.015 . . . . 0.0 109.609 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.568 ' HE2' HG22 ' B' ' 15' ' ' ILE . 3.8 ptm -153.33 -164.17 1.85 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.402 ' O ' HD22 ' B' ' 38' ' ' LEU . 28.5 t -102.96 118.12 36.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.037 -1.039 . . . . 0.0 110.49 -179.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.552 HD13 ' HD3' ' B' ' 39' ' ' PRO . 3.0 mm? -113.3 169.96 5.84 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.552 ' HD3' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.95 52.02 4.14 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.696 2.264 . . . . 0.0 111.426 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 49.03 -163.0 0.5 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.2 mmm-85 60.25 84.87 0.12 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -1.14 . . . . 0.0 109.196 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.606 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 60.3 p-90 -159.57 176.54 11.92 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.509 0.671 . . . . 0.0 110.047 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.412 ' CG ' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -139.38 159.68 64.95 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.374 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' B' ' 43' ' ' LYS . 35.9 Cg_endo -77.95 139.53 17.44 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.21 1.94 . . . . 0.0 110.404 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.793 ' O ' HG22 ' B' ' 56' ' ' VAL . 10.1 tttt -155.53 131.14 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.439 -0.788 . . . . 0.0 109.197 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -110.85 130.68 55.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.099 -1.001 . . . . 0.0 109.289 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.806 HD11 HG21 ' A' ' 50' ' ' ILE . 24.3 pt -113.42 149.86 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.894 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.495 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.15 111.51 2.09 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 179.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -132.36 -126.08 2.7 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.188 -1.482 . . . . 0.0 111.161 -178.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.51 ' O ' ' O ' ' A' ' 50' ' ' ILE . 19.3 mt -91.52 138.44 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 122.056 0.932 . . . . 0.0 113.179 -177.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.542 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 80.18 -20.19 6.03 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 178.585 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.14 -169.44 32.61 Favored Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.649 -1.5 . . . . 0.0 110.321 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 4.5 m-85 -105.11 153.25 21.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.372 -1.075 . . . . 0.0 109.274 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.693 HD13 HG23 ' A' ' 50' ' ' ILE . 7.4 pt -127.11 159.81 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.225 -0.922 . . . . 0.0 109.807 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.529 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.29 144.52 31.51 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.769 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.793 HG22 ' O ' ' B' ' 45' ' ' LYS . 23.9 m -142.9 -171.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.78 -1.2 . . . . 0.0 110.598 -178.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 11.4 mtt180 -137.85 88.87 2.36 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.41 98.82 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 110.962 -179.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.975 ' HB3' HD11 ' B' ' 62' ' ' ILE . 18.9 m-85 -91.78 127.54 37.27 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.935 ' OD1' HG23 ' B' ' 74' ' ' THR . 2.4 m-20 -107.69 135.22 49.48 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.785 -1.197 . . . . 0.0 110.632 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.585 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.1 mt-30 79.96 60.4 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.823 -0.548 . . . . 0.0 110.889 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 1.058 HD13 HG23 ' B' ' 75' ' ' VAL . 3.5 mp -113.96 119.94 62.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.086 -1.008 . . . . 0.0 109.275 179.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.848 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.9 tm? -68.59 83.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.506 -0.746 . . . . 0.0 110.505 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.761 HD12 HD11 ' B' ' 15' ' ' ILE . 12.5 tt -88.85 124.88 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.489 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 7.4 tt0 -90.28 100.13 13.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.085 -1.01 . . . . 0.0 109.414 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.857 HG13 HG22 ' B' ' 13' ' ' ILE . 0.5 OUTLIER -90.97 119.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 121.055 -1.028 . . . . 0.0 109.103 179.949 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.643 ' SG ' HG12 ' B' ' 11' ' ' VAL . 5.3 m 48.5 47.52 20.24 Favored 'General case' 0 C--N 1.291 -1.951 0 O-C-N 121.82 -0.55 . . . . 0.0 110.463 178.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.484 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 68.37 28.13 73.41 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.587 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 8.5 m170 -120.2 97.15 5.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.034 -1.274 . . . . 0.0 109.35 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.57 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.44 126.81 16.07 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.239 -0.913 . . . . 0.0 109.159 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.764 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -151.26 155.98 39.9 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.665 -0.647 . . . . 0.0 109.459 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.751 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.9 OUTLIER -119.22 153.33 21.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.717 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.419 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -175.61 -177.83 44.96 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.453 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.935 HG23 ' OD1' ' B' ' 60' ' ' ASP . 2.7 m -91.18 108.56 19.95 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.706 -0.879 . . . . 0.0 109.877 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.058 HG23 HD13 ' B' ' 62' ' ' ILE . 1.4 t -103.35 112.46 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.401 -0.812 . . . . 0.0 110.328 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.947 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.9 mp -77.73 118.71 20.36 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.012 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 72.1 t -99.02 117.44 44.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 120.916 -1.115 . . . . 0.0 109.74 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.75 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.55 -168.52 18.73 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.116 -1.994 . . . . 0.0 108.116 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.529 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -80.83 48.46 2.91 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 122.263 1.975 . . . . 0.0 110.816 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.842 HG21 HG13 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -91.85 137.45 25.39 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.926 -1.109 . . . . 0.0 108.573 179.481 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.6 Cg_endo -79.54 19.6 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.557 2.171 . . . . 0.0 112.209 -178.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.76 ' H ' HG23 ' B' ' 80' ' ' THR . 1.1 t -161.23 172.74 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.541 -1.349 . . . . 0.0 110.287 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.585 ' N ' HG13 ' B' ' 82' ' ' VAL . 3.2 m-80 -107.55 79.53 1.3 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.452 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.951 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.2 mp -76.8 126.02 37.1 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.374 -0.829 . . . . 0.0 111.48 -176.274 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.919 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.2 mp -96.14 99.94 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.549 ' C ' HD12 ' B' ' 90' ' ' LEU . . . -95.69 167.68 25.9 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.764 ' O ' HG23 ' B' ' 91' ' ' THR . 22.5 mmm180 -25.77 -39.41 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.818 -0.813 . . . . 0.0 112.826 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.009 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.9 p-10 -49.79 -21.99 1.29 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.577 -1.327 . . . . 0.0 111.264 -178.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.009 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -110.58 -24.06 10.75 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.81 HD22 HG23 ' B' ' 26' ' ' THR . 3.8 mp -68.6 -8.69 44.14 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.764 HG23 ' O ' ' B' ' 87' ' ' ARG . 30.4 p -95.83 -20.22 18.99 Favored 'General case' 0 N--CA 1.485 1.307 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.775 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.504 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 68.5 mm-40 -81.73 -41.46 21.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.137 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.64 HD12 ' CG ' ' A' ' 99' ' ' PHE . 1.9 pt -93.29 -2.82 10.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 98' ' ' ASN . . . 75.48 22.51 75.37 Favored Glycine 0 N--CA 1.494 2.529 0 O-C-N 121.516 -0.74 . . . . 0.0 111.488 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.573 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -65.27 123.66 20.15 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.708 -1.466 . . . . 0.0 110.457 -179.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 41.4 p -131.38 132.63 44.56 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 1.022 HD21 ' OG1' ' A' ' 26' ' ' THR . 4.8 mp -84.87 106.87 16.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.047 -1.033 . . . . 0.0 110.766 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.544 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 2.4 m120 -112.3 121.61 45.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.344 -0.847 . . . . 0.0 108.944 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 1.052 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.686 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.224 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.567 ' O ' ' CD1' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.67 0 N-CA-C 110.398 -0.655 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.413 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.2 tt0 -88.16 139.37 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.54 155.86 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 109.943 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.539 HG22 HG22 ' B' ' 96' ' ' THR . 1.1 p -127.66 -168.35 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.312 -0.868 . . . . 0.0 109.445 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 1.023 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -87.16 -26.89 23.37 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.215 -0.928 . . . . 0.0 109.065 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.589 ' N ' HD13 ' A' ' 5' ' ' LEU . 10.2 m95 -45.48 -22.72 0.16 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.629 -1.295 . . . . 0.0 109.06 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.478 ' N ' ' O ' ' A' ' 5' ' ' LEU . 34.6 mt-30 -146.25 110.32 4.98 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.705 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.462 ' C ' ' O ' ' A' ' 7' ' ' GLN . 14.6 mtm180 -40.95 148.17 0.39 Allowed Pre-proline 0 C--N 1.297 -1.713 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 36.7 Cg_endo -79.71 47.88 2.67 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.579 2.186 . . . . 0.0 109.757 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.587 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -79.33 143.43 35.17 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.098 -1.001 . . . . 0.0 109.526 -179.222 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 HG23 ' A' ' 66' ' ' ILE . 0.7 OUTLIER -147.24 140.65 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.333 -178.734 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.752 HG22 HD22 ' A' ' 19' ' ' LEU . 78.4 m -74.32 96.78 2.89 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.876 HG22 HG13 ' A' ' 66' ' ' ILE . 4.2 pt -83.81 150.34 4.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 121.635 0.731 . . . . 0.0 111.041 -178.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.666 ' HE3' HD11 ' A' ' 19' ' ' LEU . 1.1 tttt -112.14 101.54 9.79 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.028 HD11 HD12 ' A' ' 64' ' ' ILE . 12.2 mt -122.51 138.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.225 -0.922 . . . . 0.0 109.308 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 52.11 43.37 56.2 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.14 35.83 66.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.0 mm100 -131.32 178.59 6.6 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.151 . . . . 0.0 109.186 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.752 HD22 HG22 ' A' ' 12' ' ' THR . 39.5 mt -146.94 126.45 13.23 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.129 -0.982 . . . . 0.0 110.232 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.601 ' N ' ' HE2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -146.85 163.34 36.38 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.709 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.557 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 49.3 mm-40 -79.39 137.23 37.21 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.97 -1.081 . . . . 0.0 109.113 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -119.98 156.07 31.59 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.594 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.431 HD21 ' O ' ' B' ' 27' ' ' GLY . 12.3 tp -118.24 99.12 6.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.701 -0.624 . . . . 0.0 109.615 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.527 HD23 ' HB ' ' A' ' 85' ' ' ILE . 18.7 mt -48.34 106.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.878 -1.139 . . . . 0.0 108.932 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' CB ' HG23 ' A' ' 84' ' ' ILE . 54.2 t0 -109.24 98.39 7.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.875 . . . . 0.0 109.829 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.724 HG22 HH12 ' A' ' 87' ' ' ARG . 0.2 OUTLIER -71.58 -5.01 30.18 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.303 -0.873 . . . . 0.0 108.748 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.827 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.58 -33.27 22.61 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.569 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.36 159.88 20.78 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.073 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.519 ' OD2' ' CZ ' ' B' ' 8' ' ' ARG . 16.8 m-20 -100.77 -13.66 18.36 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.3 -0.875 . . . . 0.0 110.629 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.496 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -127.0 -173.54 2.92 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.982 -1.074 . . . . 0.0 109.545 -179.625 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.582 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 27.9 m -110.47 86.76 2.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.864 -1.147 . . . . 0.0 110.214 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -67.78 173.5 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -169.85 115.2 0.53 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.838 -1.163 . . . . 0.0 110.983 -178.14 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.508 ' C ' ' O ' ' A' ' 33' ' ' LEU . 33.8 tt0 -33.85 150.05 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.879 -0.513 . . . . 0.0 109.649 178.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.649 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -37.35 145.08 0.06 Allowed 'General case' 0 N--CA 1.495 1.783 0 CA-C-O 121.56 0.695 . . . . 0.0 110.674 -179.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.404 ' SD ' ' CD2' ' A' ' 38' ' ' LEU . 14.3 ptm -156.85 -170.8 3.42 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.0 t -127.77 90.77 3.16 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.827 -1.171 . . . . 0.0 111.364 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.637 ' HB2' ' CE1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -81.49 171.58 11.79 Favored Pre-proline 0 N--CA 1.493 1.716 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 177.901 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.537 ' CD ' HD12 ' A' ' 38' ' ' LEU . 36.2 Cg_endo -79.3 43.52 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.614 2.21 . . . . 0.0 111.499 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . 54.72 111.15 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.449 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 157.79 57.74 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.909 . . . . 0.0 108.83 179.792 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 51.5 p-90 -141.1 179.18 6.89 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-O 121.849 0.833 . . . . 0.0 110.491 -178.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.452 ' HE3' ' HA ' ' A' ' 43' ' ' LYS . 0.0 OUTLIER -130.8 158.04 76.09 Favored Pre-proline 0 C--N 1.302 -1.475 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.783 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -76.32 141.92 23.47 Favored 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.144 1.896 . . . . 0.0 110.471 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.497 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -148.39 169.57 19.89 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.428 -0.795 . . . . 0.0 109.352 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.485 ' SD ' ' HB3' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -144.35 111.21 5.75 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.507 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.563 HD11 HD11 ' A' ' 54' ' ' ILE . 6.0 pt -92.33 142.52 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.856 -1.152 . . . . 0.0 109.093 -179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.621 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -122.8 105.08 0.92 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.68 -120.57 2.5 Favored Glycine 0 N--CA 1.483 1.785 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.097 -179.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.865 HG21 HD11 ' B' ' 47' ' ' ILE . 26.3 mt -86.56 121.69 37.89 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.69 -0.888 . . . . 0.0 112.09 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 103.91 -55.71 0.61 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.76 -159.3 23.69 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.621 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.0 m-85 -107.43 131.79 53.9 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.235 -1.156 . . . . 0.0 109.887 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 7.3 pt -107.98 134.63 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.923 -1.111 . . . . 0.0 108.857 178.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -70.94 148.58 47.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.103 -0.998 . . . . 0.0 110.057 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.4 m -150.09 -169.77 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.595 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 3.7 mmt85 -133.56 105.11 6.7 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.503 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.0 OUTLIER -62.93 102.06 0.32 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.948 . . . . 0.0 110.448 -179.133 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.637 ' CE1' ' HB2' ' A' ' 38' ' ' LEU . 31.2 m-85 -92.62 90.68 7.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 108.858 179.113 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 3.4 m-20 -79.07 124.72 28.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.008 -1.057 . . . . 0.0 110.47 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 2.7 mm-40 88.33 61.78 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 CA-C-O 121.383 0.611 . . . . 0.0 110.163 179.319 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.975 ' CG2' HG23 ' A' ' 15' ' ' ILE . 14.8 mm -117.82 116.53 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.108 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.953 ' O ' HD13 ' A' ' 63' ' ' LEU . 1.3 tm? -68.66 83.73 0.29 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.372 -0.83 . . . . 0.0 110.092 -179.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 1.028 HD12 HD11 ' A' ' 15' ' ' ILE . 11.8 tt -89.9 112.0 23.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 179.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.517 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 8.6 tp10 -91.63 120.44 32.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.11 -0.994 . . . . 0.0 109.228 -179.255 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -107.01 121.01 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.179 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 60.04 -93.01 0.04 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.606 -0.684 . . . . 0.0 110.053 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -138.92 27.37 2.68 Favored Glycine 0 N--CA 1.486 1.978 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.42 ' C ' ' OE1' ' A' ' 65' ' ' GLU . 9.6 m-70 -125.53 103.44 7.88 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.188 -1.184 . . . . 0.0 109.385 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.603 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -59.52 133.43 56.09 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.544 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.712 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -145.52 154.9 42.7 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.153 -0.967 . . . . 0.0 110.333 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.556 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -121.25 156.29 24.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 177.491 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.909 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 177.77 -177.77 48.37 Favored Glycine 0 N--CA 1.487 2.039 0 C-N-CA 117.876 -2.107 . . . . 0.0 112.084 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.503 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 91.0 m -90.62 105.12 17.6 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.921 -0.752 . . . . 0.0 109.713 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.63 107.06 19.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.688 -0.632 . . . . 0.0 110.079 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.543 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.8 mp -79.51 120.82 24.42 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.461 -0.774 . . . . 0.0 108.99 179.323 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.649 HG12 ' HA ' ' A' ' 35' ' ' GLU . 21.6 t -107.22 130.67 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.57 179.801 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -162.21 -159.4 10.23 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.039 -1.624 . . . . 0.0 109.039 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.72 38.32 0.73 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.606 2.204 . . . . 0.0 110.338 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' A' ' 32' ' ' VAL . 2.4 t -83.95 135.08 42.84 Favored Pre-proline 0 N--CA 1.489 1.519 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.5 16.82 1.18 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.428 2.085 . . . . 0.0 111.044 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.461 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.83 157.73 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.978 -1.076 . . . . 0.0 109.292 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -94.53 126.33 39.74 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 176.041 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.709 ' CG1' HG12 ' A' ' 32' ' ' VAL . 5.0 mm -111.57 122.57 66.19 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 O-C-N 120.486 -1.384 . . . . 0.0 112.384 -176.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.561 HG22 ' O ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -98.78 85.66 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 176.88 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.57 -157.02 9.97 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.461 -177.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.724 HH12 HG22 ' A' ' 26' ' ' THR . 0.0 OUTLIER -64.56 -33.06 75.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 122.009 -0.7 . . . . 0.0 111.265 -178.44 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -55.9 -32.15 63.48 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.791 -1.193 . . . . 0.0 110.315 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -108.05 -19.95 13.33 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.993 -1.067 . . . . 0.0 110.516 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.501 HD23 HD11 ' A' ' 93' ' ' ILE . 12.6 mt -69.9 -36.17 75.19 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 71.2 p -72.55 -20.83 61.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.057 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.449 ' OE1' ' HA ' ' A' ' 92' ' ' GLN . 9.4 mm100 -71.43 -40.18 70.58 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.697 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.4 OUTLIER -85.77 -2.18 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.55 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.82 60.36 6.6 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.669 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -81.41 151.72 27.77 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.365 -1.079 . . . . 0.0 110.052 -179.6 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.8 p -142.96 125.34 15.6 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' B' ' 97' ' ' LEU . 2.6 mp -91.0 94.27 9.56 Favored 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.612 -0.68 . . . . 0.0 109.17 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.531 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.3 m120 -104.79 129.0 53.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.127 -0.983 . . . . 0.0 110.285 -179.25 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 1.017 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.377 178.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.492 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 N-CA-C 110.383 -0.66 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.531 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 9.9 tt0 -83.59 129.81 34.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 96.2 t -130.41 107.19 14.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.718 -1.239 . . . . 0.0 110.692 -177.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.547 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.9 p -108.71 -59.56 1.86 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' B' ' 7' ' ' GLN . 84.5 mt 35.8 27.9 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.695 -0.628 . . . . 0.0 111.068 179.153 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.547 ' N ' ' O ' ' B' ' 4' ' ' THR . 8.4 m95 17.63 46.48 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.603 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.6 mt-30 -170.65 -166.86 0.53 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.108 -0.995 . . . . 0.0 109.941 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.554 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.3 mtm180 -67.78 112.75 11.36 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.474 -0.767 . . . . 0.0 109.545 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.795 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.4 Cg_endo -80.27 86.88 1.59 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.204 1.936 . . . . 0.0 110.051 179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.473 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.5 OUTLIER -86.12 136.25 33.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.92 . . . . 0.0 109.524 -179.771 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' B' ' 22' ' ' ALA . 3.4 m -125.56 154.17 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.423 -0.798 . . . . 0.0 109.711 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.453 HG21 ' CD2' ' B' ' 19' ' ' LEU . 58.5 m -86.6 111.27 20.47 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.912 HD11 HD21 ' B' ' 33' ' ' LEU . 1.6 pp -97.76 141.7 15.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.184 -0.948 . . . . 0.0 110.447 -178.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.439 ' HG3' HD12 ' B' ' 19' ' ' LEU . 6.8 ttmm -109.4 96.05 6.03 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.346 -0.846 . . . . 0.0 109.316 179.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 1.095 HG23 ' CG2' ' B' ' 62' ' ' ILE . 7.3 mt -113.02 116.18 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.86 50.69 63.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.96 17.15 21.27 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.224 -1.162 . . . . 0.0 110.287 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.506 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 1.7 mt-30 -108.05 134.67 50.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.055 -1.262 . . . . 0.0 109.37 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.453 ' CD2' HG21 ' B' ' 12' ' ' THR . 0.3 OUTLIER -113.51 120.06 39.68 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.098 0.951 . . . . 0.0 110.302 -179.726 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.413 ' HB3' HD21 ' B' ' 83' ' ' ASN . 0.7 OUTLIER -141.04 178.55 7.3 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.094 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.552 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.1 mt-10 -85.46 178.18 7.52 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 120.802 -1.186 . . . . 0.0 108.812 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.914 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -156.58 111.65 2.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.063 -1.023 . . . . 0.0 110.302 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.827 HD21 ' O ' ' A' ' 27' ' ' GLY . 27.9 tp -82.12 100.28 9.7 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.795 HD12 ' HB2' ' B' ' 9' ' ' PRO . 67.8 mt -43.17 105.96 0.06 Allowed 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.7 t0 -114.38 87.47 2.64 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.517 -0.74 . . . . 0.0 110.839 -178.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -71.22 -5.44 32.07 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.842 -1.161 . . . . 0.0 108.63 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.474 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -81.99 -32.76 28.49 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.0 162.72 28.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.952 -1.323 . . . . 0.0 109.575 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.421 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 0.7 OUTLIER -93.4 -20.86 19.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.887 -179.421 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.577 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 14.3 m-20 -139.5 -164.81 1.75 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.034 -1.041 . . . . 0.0 109.407 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.643 HG23 ' O ' ' B' ' 84' ' ' ILE . 89.3 m -109.59 95.66 5.76 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.661 -1.274 . . . . 0.0 111.174 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -72.78 178.01 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 177.879 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.026 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -169.13 118.34 0.68 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.781 -1.199 . . . . 0.0 110.875 -178.885 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.643 ' HA ' HG22 ' B' ' 80' ' ' THR . 2.4 tt0 -35.11 150.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.557 . . . . 0.0 109.51 178.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.538 ' N ' ' HG3' ' B' ' 34' ' ' GLU . 0.0 OUTLIER -31.07 141.87 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.75 0.786 . . . . 0.0 111.497 -179.041 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.912 ' SD ' HD22 ' B' ' 38' ' ' LEU . 2.8 ppp? -169.05 175.54 5.73 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.543 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -122.53 136.28 54.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.619 -1.3 . . . . 0.0 111.235 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.912 HD22 ' SD ' ' B' ' 36' ' ' MET . 0.2 OUTLIER -120.49 175.83 2.14 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.251 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.85 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.8 Cg_endo -79.47 62.47 8.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.632 2.221 . . . . 0.0 111.171 179.397 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.539 ' O ' ' CG ' ' B' ' 41' ' ' ARG . . . 40.29 87.06 0.01 OUTLIER Glycine 0 N--CA 1.495 2.621 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.539 ' CG ' ' O ' ' B' ' 40' ' ' GLY . 4.2 mtt180 -167.67 57.15 0.07 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.86 -0.788 . . . . 0.0 109.095 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.629 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 59.3 p-90 -147.96 172.33 14.38 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.07 0.938 . . . . 0.0 110.791 -179.307 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mmtm -130.98 144.29 52.94 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.225 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -74.01 133.29 17.96 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 C-N-CA 121.626 1.551 . . . . 0.0 110.486 -179.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.449 ' HG3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.65 -178.83 7.64 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.462 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 62.9 mtp -145.13 131.52 19.66 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.141 -0.975 . . . . 0.0 109.323 179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.865 HD11 HG21 ' A' ' 50' ' ' ILE . 19.9 pt -96.7 145.91 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.13 -0.982 . . . . 0.0 108.791 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.515 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.6 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -122.34 -122.86 2.84 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.558 HG21 HD12 ' A' ' 47' ' ' ILE . 33.3 mt -89.69 121.54 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.716 -0.873 . . . . 0.0 112.414 -177.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.589 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 105.43 -52.26 0.72 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 178.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.31 -164.64 33.45 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.515 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -106.35 126.2 51.94 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.436 -1.038 . . . . 0.0 109.171 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.512 HD13 HG23 ' A' ' 50' ' ' ILE . 23.4 pt -97.28 174.99 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 120.917 -1.115 . . . . 0.0 109.149 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.514 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 35.2 mtpt -111.49 127.23 55.63 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.256 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.565 HG12 ' HA3' ' B' ' 78' ' ' GLY . 16.6 m -136.15 -174.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.583 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.586 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 0.5 OUTLIER -129.13 104.14 7.38 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.762 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.421 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 1.9 tt0 -62.38 97.4 0.09 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.523 -0.736 . . . . 0.0 110.704 -178.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.639 ' CE2' ' HB2' ' B' ' 38' ' ' LEU . 29.7 m-85 -88.56 127.49 35.55 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 5.6 m-20 -106.73 133.0 52.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.859 -1.151 . . . . 0.0 110.637 -178.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.544 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 52.2 mm-40 72.32 63.53 0.12 Allowed 'General case' 0 N--CA 1.49 1.539 0 CA-C-O 121.665 0.745 . . . . 0.0 109.469 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 1.095 ' CG2' HG23 ' B' ' 15' ' ' ILE . 12.6 mm -113.95 122.21 67.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.198 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.788 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.1 OUTLIER -69.97 84.99 0.51 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 111.568 -177.922 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.527 HD11 HD11 ' B' ' 66' ' ' ILE . 1.7 tt -88.62 119.47 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.8 tt0 -100.99 122.86 44.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.836 -1.165 . . . . 0.0 109.527 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.555 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -109.15 131.45 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 121.268 -0.895 . . . . 0.0 109.101 -179.956 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 57.37 -88.69 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.787 -0.57 . . . . 0.0 110.212 179.49 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -149.84 38.62 0.92 Allowed Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -136.36 123.13 21.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -1.115 . . . . 0.0 109.175 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.461 ' CG ' HD11 ' B' ' 63' ' ' LEU . 0.4 OUTLIER -66.9 136.33 55.21 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.244 -0.91 . . . . 0.0 108.623 179.551 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.566 ' HB2' HG22 ' B' ' 93' ' ' ILE . . . -152.09 119.96 6.17 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 110.268 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.788 HD13 ' N ' ' B' ' 63' ' ' LEU . 1.1 mm -89.53 163.31 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 178.016 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.792 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 174.05 173.11 39.89 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 118.931 -1.604 . . . . 0.0 110.777 179.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 59.3 m -83.72 114.8 21.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.469 -1.018 . . . . 0.0 109.892 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.026 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -106.77 114.91 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.254 -0.903 . . . . 0.0 110.6 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.757 ' HB2' HG23 ' B' ' 32' ' ' VAL . 4.1 mp -86.38 115.03 23.64 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.698 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.518 ' O ' ' CD ' ' B' ' 57' ' ' ARG . 93.0 t -101.14 132.12 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.045 -1.034 . . . . 0.0 109.57 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.565 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -169.44 -163.26 23.16 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.514 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.1 Cg_endo -79.8 43.55 1.53 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.754 2.303 . . . . 0.0 110.892 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.643 HG22 ' HA ' ' B' ' 34' ' ' GLU . 12.2 t -85.32 137.61 36.82 Favored Pre-proline 0 N--CA 1.488 1.431 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.571 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.69 13.62 1.86 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.302 2.001 . . . . 0.0 110.879 -179.315 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.571 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.4 t -161.44 163.34 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.132 -0.98 . . . . 0.0 109.864 -179.235 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 55.0 m-80 -94.34 136.32 34.77 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.051 -2.574 . . . . 0.0 104.051 175.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.782 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.6 mm -121.05 122.42 67.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 O-C-N 119.92 -1.737 . . . . 0.0 111.358 -177.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.914 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -98.63 92.07 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.638 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.18 -155.56 9.39 Favored Glycine 0 N--CA 1.49 2.28 0 C-N-CA 120.005 -1.093 . . . . 0.0 111.096 -178.015 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.938 ' HD2' HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -75.71 -29.66 59.04 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.905 -0.762 . . . . 0.0 110.159 -178.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.885 ' ND2' HD23 ' B' ' 89' ' ' LEU . 19.0 p-10 -51.08 -20.46 1.46 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.888 -1.133 . . . . 0.0 109.831 -179.365 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.885 HD23 ' ND2' ' B' ' 88' ' ' ASN . 4.0 mm? -116.17 -21.25 9.48 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.83 -1.169 . . . . 0.0 110.899 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.455 ' CD2' ' CB ' ' B' ' 95' ' ' ALA . 83.3 mt -66.12 -18.43 65.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.63 -1.294 . . . . 0.0 109.547 -179.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.86 -5.74 25.72 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.927 -1.108 . . . . 0.0 109.212 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -94.15 -41.18 9.64 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 1.017 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.2 pt -88.94 -7.73 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.854 . . . . 0.0 108.749 179.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 89.43 28.03 20.87 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.919 178.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -71.11 125.72 27.65 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.667 -1.49 . . . . 0.0 109.52 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.539 HG22 HG22 ' A' ' 4' ' ' THR . 66.4 p -127.05 129.91 48.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' A' ' 97' ' ' LEU . 4.1 mp -87.35 102.46 14.54 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.249 -0.907 . . . . 0.0 110.256 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.528 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.6 m120 -102.21 125.44 48.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.352 -0.843 . . . . 0.0 109.15 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.697 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.086 -0.959 . . . . 0.0 109.296 179.465 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.497 1.724 0 CA-C-O 121.501 0.542 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.4 tt0 -83.58 144.51 29.42 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.114 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.527 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 9.5 t -143.84 112.87 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.274 -1.37 . . . . 0.0 110.314 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.719 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -117.92 -67.1 1.02 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.547 ' O ' ' C ' ' A' ' 6' ' ' TRP . 2.5 pp 27.68 36.58 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.588 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.566 ' N ' ' O ' ' A' ' 4' ' ' THR . 35.7 m95 15.9 53.57 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.245 0 CA-C-O 121.184 0.516 . . . . 0.0 112.268 179.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 2.6 mt-30 -156.88 -166.75 2.17 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 109.529 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.479 ' HA ' ' HD3' ' B' ' 87' ' ' ARG . 1.0 OUTLIER -75.04 130.89 79.79 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.363 -0.836 . . . . 0.0 109.131 179.902 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.496 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.1 Cg_endo -78.19 79.33 3.31 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.25 1.967 . . . . 0.0 109.342 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.813 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -96.91 139.52 32.82 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.761 -179.359 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.568 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -135.36 147.47 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.467 -0.771 . . . . 0.0 109.965 -179.223 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.675 HG22 HD22 ' A' ' 19' ' ' LEU . 23.6 m -75.8 105.69 6.98 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.847 HD11 HD21 ' A' ' 33' ' ' LEU . 7.6 pt -99.06 146.4 8.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.248 -0.907 . . . . 0.0 110.642 -178.154 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.3 OUTLIER -111.57 99.51 8.25 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.296 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.875 HD13 HG11 ' A' ' 75' ' ' VAL . 4.2 mt -120.4 132.46 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.21 -0.931 . . . . 0.0 109.651 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.77 32.98 83.67 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.27 21.81 70.5 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.462 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.0 OUTLIER -117.81 174.92 5.91 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.299 -1.118 . . . . 0.0 109.213 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.675 HD22 HG22 ' A' ' 12' ' ' THR . 14.6 mt -140.02 120.2 13.79 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.236 -0.915 . . . . 0.0 110.379 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.7 mmmt -144.1 167.76 21.63 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.813 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -77.06 165.28 24.82 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.808 -1.183 . . . . 0.0 108.391 179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.694 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -142.54 119.82 11.54 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.922 -1.111 . . . . 0.0 109.817 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.608 HD21 ' O ' ' B' ' 27' ' ' GLY . 41.6 tp -88.27 93.33 9.48 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.699 -0.626 . . . . 0.0 109.647 -179.641 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 14.7 mt -43.67 97.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.06 -1.025 . . . . 0.0 109.657 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.647 ' CB ' HG23 ' A' ' 84' ' ' ILE . 27.7 t0 -100.56 81.36 2.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.89 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.641 HG23 HD13 ' A' ' 90' ' ' LEU . 1.8 m -60.74 -14.16 19.47 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.17 -0.956 . . . . 0.0 108.88 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.673 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.27 -33.68 64.53 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.28 169.44 17.29 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.196 -1.179 . . . . 0.0 110.014 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.527 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 24.1 m-20 -98.38 -17.13 19.0 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.315 -0.866 . . . . 0.0 111.206 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.565 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -137.11 -171.13 2.87 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.694 -1.254 . . . . 0.0 110.249 -179.43 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.582 HG23 HD12 ' A' ' 85' ' ' ILE . 18.6 m -104.83 90.6 3.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.212 -0.93 . . . . 0.0 110.533 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.13 174.53 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.632 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.088 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -168.8 121.84 0.82 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.83 -1.169 . . . . 0.0 110.859 -179.352 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.578 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 1.1 pt-20 -37.36 156.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.547 -0.721 . . . . 0.0 109.797 178.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.578 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.5 tm-20 -45.0 145.75 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.356 -0.84 . . . . 0.0 110.8 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 13.5 ptm -165.02 -164.97 0.83 Allowed 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -116.81 122.75 45.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.996 -1.065 . . . . 0.0 110.506 -179.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 1.047 HD23 ' CD1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -128.08 -173.87 0.34 Allowed Pre-proline 0 N--CA 1.496 1.839 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 179.503 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.624 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -78.05 -163.3 0.21 Allowed 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 122.171 1.914 . . . . 0.0 111.371 -178.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.72 39.28 2.94 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -179.072 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -128.86 61.52 1.51 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.622 -0.928 . . . . 0.0 108.622 179.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.641 ' CD1' ' CE2' ' A' ' 59' ' ' TYR . 6.3 p-90 -132.9 -177.55 4.55 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.683 0.754 . . . . 0.0 110.47 -178.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -137.74 138.51 24.22 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.23 138.81 18.27 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.131 1.887 . . . . 0.0 110.85 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.419 ' O ' ' HG2' ' A' ' 46' ' ' MET . 1.6 ptpt -156.56 -169.47 3.02 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.419 ' HG2' ' O ' ' A' ' 45' ' ' LYS . 39.9 mtp -151.3 135.56 16.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 109.784 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 54' ' ' ILE . 15.3 pt -100.06 139.29 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.4 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.91 106.07 1.24 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -131.78 -123.26 2.45 Favored Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.74 -1.219 . . . . 0.0 110.308 -179.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.892 HG21 HD11 ' B' ' 47' ' ' ILE . 66.0 mt -88.48 115.29 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.445 -1.032 . . . . 0.0 112.45 -177.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.66 -32.96 5.45 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.361 -1.095 . . . . 0.0 110.361 178.081 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.87 -160.27 28.74 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 4.6 m-85 -110.86 124.55 52.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.32 -1.106 . . . . 0.0 109.491 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 47' ' ' ILE . 2.2 pt -102.26 174.03 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 108.721 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.544 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.7 OUTLIER -107.38 135.46 48.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.163 -0.961 . . . . 0.0 108.935 179.447 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.451 HG12 ' HA3' ' A' ' 78' ' ' GLY . 15.2 m -143.19 152.83 16.73 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 121.228 -0.92 . . . . 0.0 109.865 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 3.6 mtt85 -92.92 167.02 12.11 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -129.2 100.77 5.73 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.01 -1.056 . . . . 0.0 110.004 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 1.047 ' CD1' HD23 ' A' ' 38' ' ' LEU . 81.8 m-85 -100.25 123.36 44.39 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.356 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -98.73 130.75 45.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.009 . . . . 0.0 109.753 -179.669 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.549 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 83.14 59.75 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.389 0.614 . . . . 0.0 109.802 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.755 HG21 HG21 ' A' ' 75' ' ' VAL . 5.3 mm -110.57 117.4 54.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.729 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -69.86 86.82 0.52 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 111.093 -178.459 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.703 HG12 HD12 ' A' ' 66' ' ' ILE . 6.1 tt -88.87 118.21 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 69' ' ' HIS . 6.0 tt0 -88.22 112.51 22.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.033 -1.042 . . . . 0.0 108.936 -178.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.703 HD12 HG12 ' A' ' 64' ' ' ILE . 0.4 OUTLIER -103.92 118.86 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.348 -0.845 . . . . 0.0 109.052 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER 61.67 40.32 13.36 Favored 'General case' 0 C--N 1.293 -1.877 0 O-C-N 121.618 -0.676 . . . . 0.0 109.873 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.07 8.44 61.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.484 ' O ' ' HG2' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -101.26 155.99 17.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.176 -1.191 . . . . 0.0 108.989 179.781 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.643 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -89.44 126.63 35.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.017 -1.052 . . . . 0.0 109.754 -179.814 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.89 102.44 3.27 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.313 -0.867 . . . . 0.0 109.441 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.729 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -81.07 158.89 4.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.028 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.969 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.45 172.81 43.23 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.48 -1.819 . . . . 0.0 111.637 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 57.2 m -84.86 111.66 19.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.665 -0.903 . . . . 0.0 109.938 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.088 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -100.39 144.53 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.637 -0.665 . . . . 0.0 109.601 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -116.07 127.38 54.83 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.578 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 97.3 t -111.03 116.13 51.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 120.956 -1.09 . . . . 0.0 110.766 -178.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -151.18 -161.93 10.37 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.544 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.16 42.78 1.4 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.443 2.095 . . . . 0.0 110.327 179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.578 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.4 t -88.38 130.51 45.44 Favored Pre-proline 0 C--N 1.303 -1.435 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.27 21.05 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.417 2.078 . . . . 0.0 111.546 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.516 ' CG1' HD11 ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.07 159.54 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.881 -1.137 . . . . 0.0 109.81 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 33.5 m-80 -90.53 136.72 32.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.715 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.1 mm -125.75 122.79 62.99 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 O-C-N 119.955 -1.716 . . . . 0.0 111.498 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.694 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.34 95.59 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.501 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -79.75 -159.24 17.26 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.59 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -67.77 -37.04 81.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 -179.383 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.957 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.8 p-10 -45.28 -28.97 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.89 -1.131 . . . . 0.0 109.743 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.969 HD21 ' HA3' ' A' ' 73' ' ' GLY . 2.6 mm? -106.88 -27.64 10.59 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.92 -1.113 . . . . 0.0 109.428 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.641 HD13 HG23 ' A' ' 26' ' ' THR . 12.7 mt -70.32 -6.15 33.03 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.59 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.8 p -101.87 -20.0 15.06 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.18 -0.95 . . . . 0.0 108.66 178.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -76.34 -40.22 51.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.404 -0.81 . . . . 0.0 109.112 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.974 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -87.44 -1.74 8.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.375 -0.828 . . . . 0.0 109.07 179.324 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.73 29.84 50.53 Favored Glycine 0 N--CA 1.497 2.741 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -57.59 149.13 22.14 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.2 -1.177 . . . . 0.0 111.225 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.8 p -150.44 126.03 10.25 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' B' ' 97' ' ' LEU . 5.2 mp -84.89 109.02 17.82 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.223 -0.923 . . . . 0.0 108.671 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 7.3 m120 -108.36 121.72 45.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.164 -179.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.641 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.606 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.474 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.504 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 109.97 -0.819 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.0 OUTLIER -83.34 144.74 29.47 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 105.985 -1.858 . . . . 0.0 105.985 177.354 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.502 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 92.8 t -148.95 114.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 117.56 -1.656 . . . . 0.0 111.413 -177.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.414 ' O ' ' N ' ' B' ' 6' ' ' TRP . 2.6 p -111.64 -70.94 0.78 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.1 OUTLIER 45.44 19.41 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.668 -0.645 . . . . 0.0 111.188 178.722 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.585 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 12.1 m95 19.3 44.8 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 120.948 0.404 . . . . 0.0 111.48 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' B' ' 5' ' ' LEU . 12.9 mm100 -156.56 -156.66 0.64 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.441 -0.787 . . . . 0.0 109.405 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 117.22 61.81 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.927 -1.108 . . . . 0.0 109.543 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -79.19 71.55 6.98 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.142 1.895 . . . . 0.0 109.431 179.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.623 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -91.23 159.83 15.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.864 . . . . 0.0 110.304 -178.986 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.559 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.8 OUTLIER -150.24 135.85 11.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.452 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.871 HG22 HD22 ' B' ' 19' ' ' LEU . 4.9 m -65.77 107.91 1.94 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.907 HG22 HG13 ' B' ' 66' ' ' ILE . 1.4 pt -103.88 150.31 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 119.15 -1.02 . . . . 0.0 111.007 -178.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.446 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 6.4 tttt -122.42 106.71 11.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.464 -0.772 . . . . 0.0 108.921 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 1.0 HD13 HG11 ' B' ' 75' ' ' VAL . 38.0 mt -115.11 143.04 25.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.052 -1.03 . . . . 0.0 109.242 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.81 -89.91 0.09 OUTLIER Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -160.32 32.79 0.41 Allowed Glycine 0 N--CA 1.485 1.935 0 N-CA-C 108.406 -1.878 . . . . 0.0 108.406 179.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 -134.97 171.66 14.1 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.671 -0.899 . . . . 0.0 109.34 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.871 HD22 HG22 ' B' ' 12' ' ' THR . 5.6 mt -120.83 137.59 54.48 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.631 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -150.59 144.18 25.11 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.375 -0.828 . . . . 0.0 108.798 -178.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.623 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.1 mt-10 -78.24 121.98 25.1 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.256 -0.903 . . . . 0.0 108.648 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.602 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.34 131.0 52.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 111.731 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.673 HD21 ' O ' ' A' ' 27' ' ' GLY . 33.7 tp -88.11 96.95 10.72 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' B' ' 9' ' ' PRO . 18.9 mt -42.3 107.31 0.08 Allowed 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.683 ' OD2' ' HB2' ' B' ' 28' ' ' ALA . 41.7 t0 -116.65 92.51 3.89 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.376 -0.827 . . . . 0.0 111.642 -177.645 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.528 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -75.89 -0.78 22.55 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.903 -1.123 . . . . 0.0 108.592 177.729 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.608 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -89.37 -28.66 19.18 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -179.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . 0.683 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -78.79 170.67 16.3 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.89 -1.359 . . . . 0.0 109.443 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -100.24 -20.44 15.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.178 -0.951 . . . . 0.0 110.01 -179.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.608 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -142.39 -175.91 4.64 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.075 -1.016 . . . . 0.0 109.764 179.875 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.79 HG23 HD12 ' B' ' 85' ' ' ILE . 4.2 m -100.36 86.19 3.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 110.558 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.042 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.75 157.62 6.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.042 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.9 OUTLIER -153.06 128.66 10.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.918 -1.114 . . . . 0.0 110.688 -178.12 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.641 ' HA ' HG22 ' B' ' 80' ' ' THR . 1.1 pt-20 -43.37 162.34 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 109.11 179.396 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.495 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.8 mt-10 -48.92 139.83 9.65 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.225 -0.922 . . . . 0.0 110.126 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.6 OUTLIER -163.0 -171.09 2.54 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.519 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -111.99 116.15 30.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.877 -1.139 . . . . 0.0 110.236 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.706 HD12 HG21 ' B' ' 77' ' ' VAL . 3.4 mt -113.52 167.93 8.61 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.245 -0.909 . . . . 0.0 109.05 179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.574 ' HD2' ' CD2' ' B' ' 38' ' ' LEU . 34.4 Cg_endo -77.37 70.64 6.71 Favored 'Trans proline' 0 C--N 1.312 -1.367 0 C-N-CA 122.783 2.322 . . . . 0.0 112.183 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.13 -158.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 O-C-N 121.607 -0.683 . . . . 0.0 111.631 178.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 51.71 90.65 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.633 -0.922 . . . . 0.0 109.476 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CD2' ' B' ' 59' ' ' TYR . 44.6 p-90 -161.0 172.91 16.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.471 -0.768 . . . . 0.0 109.906 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.466 ' HB2' ' HB3' ' B' ' 58' ' ' GLN . 0.2 OUTLIER -135.46 128.76 18.33 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.903 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.51 141.06 19.62 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.261 1.974 . . . . 0.0 110.966 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.11 -167.56 1.97 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.452 -0.78 . . . . 0.0 109.083 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . . . . . . . . . 81.7 mtp -143.28 133.69 24.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.329 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.892 HD11 HG21 ' A' ' 50' ' ' ILE . 35.0 pt -100.8 152.63 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.061 -1.024 . . . . 0.0 108.783 179.146 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.51 102.81 0.98 Allowed Glycine 0 N--CA 1.489 2.167 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.49 -131.2 3.44 Favored Glycine 0 N--CA 1.482 1.708 0 C-N-CA 119.447 -1.359 . . . . 0.0 111.123 -178.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.588 HG21 HD12 ' A' ' 47' ' ' ILE . 51.6 mt -88.51 126.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 122.008 -0.701 . . . . 0.0 112.515 -177.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.464 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 92.45 5.53 65.11 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 121.06 -166.13 14.07 Favored Glycine 0 N--CA 1.492 2.403 0 O-C-N 120.917 -1.343 . . . . 0.0 110.046 179.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.2 OUTLIER -109.42 135.43 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.377 -1.072 . . . . 0.0 109.57 -179.747 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.539 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.3 pt -104.82 -179.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 121.078 -1.014 . . . . 0.0 109.104 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.493 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 31.8 mttt -114.84 140.56 48.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.161 -0.962 . . . . 0.0 108.955 179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 33.8 m -149.66 176.55 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.001 -1.062 . . . . 0.0 110.262 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.558 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 1.0 OUTLIER -111.3 172.92 6.6 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.466 ' HB3' ' HB2' ' B' ' 43' ' ' LYS . 45.2 tt0 -128.82 87.92 2.65 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.152 -0.968 . . . . 0.0 110.198 -179.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.653 ' HB3' HD11 ' B' ' 62' ' ' ILE . 72.7 m-85 -89.77 93.98 9.65 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 179.116 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.498 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 3.8 m-20 -80.93 135.37 35.88 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.055 -1.028 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 7.6 mt-30 78.43 62.72 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.672 0.748 . . . . 0.0 109.866 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.653 HD11 ' HB3' ' B' ' 59' ' ' TYR . 35.1 mm -117.56 123.67 72.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.854 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.8 tm? -68.42 84.35 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.378 -0.827 . . . . 0.0 110.672 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.829 HG12 HD12 ' B' ' 66' ' ' ILE . 7.1 tt -87.55 118.39 33.31 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.586 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.3 tt0 -90.95 118.47 30.36 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.141 -0.975 . . . . 0.0 109.68 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.907 HG13 HG22 ' B' ' 13' ' ' ILE . 0.3 OUTLIER -120.14 128.95 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.16 -0.962 . . . . 0.0 108.908 179.753 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 85.5 m 57.05 51.41 10.51 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.495 -0.753 . . . . 0.0 109.817 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.49 19.45 13.12 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.467 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.8 m-70 -112.23 141.55 45.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.152 -1.205 . . . . 0.0 109.425 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.33 130.77 34.77 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.234 -0.917 . . . . 0.0 109.17 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.503 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -149.98 141.85 23.78 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.559 -0.713 . . . . 0.0 109.134 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.534 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -115.18 158.88 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.783 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.472 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.62 -159.46 26.28 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.687 -1.721 . . . . 0.0 111.454 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.1 m -101.33 109.01 20.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.473 -1.016 . . . . 0.0 110.136 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.0 HG11 HD13 ' B' ' 15' ' ' ILE . 1.5 t -104.06 108.73 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.225 179.449 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.618 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.1 mp -82.57 137.23 34.62 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.33 -0.856 . . . . 0.0 108.842 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.706 HG21 HD12 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -115.15 129.69 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.265 -0.897 . . . . 0.0 109.94 -179.342 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -166.07 -172.21 33.15 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.493 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -80.56 41.34 1.12 Allowed 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.53 2.153 . . . . 0.0 110.85 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.641 HG22 ' HA ' ' B' ' 34' ' ' GLU . 5.9 t -80.93 143.67 53.92 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.711 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -77.51 12.47 1.86 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.39 2.06 . . . . 0.0 111.296 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.711 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.61 161.55 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.835 -1.166 . . . . 0.0 110.486 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.631 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -98.36 92.63 5.78 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.774 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.669 HG23 ' CB ' ' B' ' 25' ' ' ASP . 2.7 mt -93.39 135.52 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.951 -1.093 . . . . 0.0 113.327 -175.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.79 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -101.3 108.27 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.704 ' O ' HD22 ' B' ' 90' ' ' LEU . . . -95.95 173.37 30.48 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.871 -1.291 . . . . 0.0 109.871 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' B' ' 26' ' ' THR . 8.8 mtm-85 -35.91 -35.02 0.06 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.487 -1.008 . . . . 0.0 112.19 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.904 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -49.14 -43.43 41.69 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.231 -1.543 . . . . 0.0 110.395 -178.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.904 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.6 OUTLIER -93.64 -30.16 15.08 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.096 -1.003 . . . . 0.0 111.168 -178.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.704 HD22 ' O ' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -59.5 -36.33 75.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.532 -1.355 . . . . 0.0 108.719 -179.807 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.407 ' CG2' ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -71.44 -20.7 62.07 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.879 -1.138 . . . . 0.0 109.713 -179.534 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.44 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 11.8 mm-40 -75.11 -38.87 60.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.139 -0.976 . . . . 0.0 109.018 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.62 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -84.81 -8.5 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.181 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 80.51 29.56 43.68 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 178.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.583 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.83 135.38 57.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.105 -1.232 . . . . 0.0 109.824 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.719 HG22 HG23 ' A' ' 4' ' ' THR . 73.2 p -131.86 125.64 32.28 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' A' ' 97' ' ' LEU . 1.2 mp -84.86 92.95 8.4 Favored 'General case' 0 C--N 1.293 -1.861 0 O-C-N 121.335 -0.853 . . . . 0.0 109.954 -178.611 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.549 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 2.6 m120 -105.14 138.8 40.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.577 -0.702 . . . . 0.0 109.962 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.974 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.338 179.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.512 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 3.4 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.292 -0.695 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.534 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.9 tt0 -85.92 129.07 34.94 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 178.233 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.626 HG12 ' HB3' ' A' ' 9' ' ' PRO . 35.8 t -124.09 111.37 28.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 120.74 -1.225 . . . . 0.0 110.595 -178.333 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.506 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -119.28 -72.67 0.68 Allowed 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.228 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.6 mm? 42.15 29.21 0.13 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.426 -0.797 . . . . 0.0 110.125 179.165 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 20.9 m0 18.61 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.385 0 CA-C-O 121.249 0.547 . . . . 0.0 111.742 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.5 mt-30 -165.57 -165.28 0.82 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.372 -0.83 . . . . 0.0 108.805 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 82.7 mtm180 -64.25 117.08 33.26 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.078 -1.014 . . . . 0.0 109.235 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.626 ' HB3' HG12 ' A' ' 3' ' ' VAL . 34.8 Cg_endo -76.76 75.49 4.45 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 109.974 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.575 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -79.49 160.04 26.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.883 . . . . 0.0 109.58 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 24' ' ' LEU . 2.1 m -148.73 139.1 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.282 -0.887 . . . . 0.0 110.386 -179.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.891 HG22 HD22 ' A' ' 19' ' ' LEU . 54.9 m -70.3 98.3 1.37 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.126 -0.983 . . . . 0.0 108.392 178.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.834 ' O ' HD23 ' A' ' 19' ' ' LEU . 19.7 pt -92.12 150.07 3.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.453 -0.78 . . . . 0.0 109.901 -179.264 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 1.014 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -112.07 94.98 5.21 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.478 -0.764 . . . . 0.0 109.003 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.861 HD12 HD22 ' A' ' 33' ' ' LEU . 6.0 mt -114.35 128.17 71.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.357 -0.84 . . . . 0.0 109.561 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.2 30.53 78.04 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.71 9.92 66.44 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -108.02 175.86 5.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -1.147 . . . . 0.0 108.935 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 1.014 HD21 ' HD3' ' A' ' 14' ' ' LYS . 20.1 mt -142.82 121.63 12.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.105 -0.997 . . . . 0.0 110.347 -179.417 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 3.2 mmtt -140.06 160.58 39.6 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.155 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.6 mp0 -78.86 123.97 27.77 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.937 -1.102 . . . . 0.0 108.461 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.689 ' HB2' HD13 ' A' ' 13' ' ' ILE . . . -108.16 130.51 55.12 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 110.673 -178.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.763 HD21 ' O ' ' B' ' 27' ' ' GLY . 42.9 tp -80.23 94.97 6.16 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.855 -0.528 . . . . 0.0 109.879 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.62 HD12 ' HB2' ' A' ' 9' ' ' PRO . 94.4 mt -46.71 95.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.878 ' HB2' HG23 ' A' ' 84' ' ' ILE . 34.6 t0 -99.96 89.12 3.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.317 -0.865 . . . . 0.0 110.837 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.461 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 15.7 m -65.07 -16.63 63.67 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.572 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.05 -34.59 64.78 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.66 161.37 23.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.156 -1.203 . . . . 0.0 109.071 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.429 ' HA ' ' HB2' ' A' ' 87' ' ' ARG . 34.6 m-20 -99.37 -12.54 20.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.983 -179.589 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 29.4 m-20 -137.35 173.01 12.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.024 -1.047 . . . . 0.0 110.084 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.856 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -94.07 107.44 19.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.083 -1.011 . . . . 0.0 110.194 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.842 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -100.26 117.3 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.304 -0.873 . . . . 0.0 109.022 179.441 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.861 HD22 HD12 ' A' ' 15' ' ' ILE . 2.2 mp -107.56 119.28 38.98 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.239 -0.913 . . . . 0.0 110.569 -179.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.711 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.4 pt-20 -42.73 168.41 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.328 -0.857 . . . . 0.0 109.393 178.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.9 OUTLIER -43.46 145.99 0.54 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.212 -0.93 . . . . 0.0 111.03 -179.128 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.435 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER 178.68 163.05 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -81.0 103.3 10.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.871 -1.143 . . . . 0.0 110.151 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.732 HD12 ' HD2' ' A' ' 39' ' ' PRO . 5.1 tp -121.8 104.1 39.54 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.857 . . . . 0.0 109.199 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.732 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.3 Cg_endo -77.41 146.89 25.05 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.542 2.161 . . . . 0.0 110.861 -179.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 134.45 172.72 12.9 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -77.45 127.69 32.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -1.233 . . . . 0.0 108.808 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 66.6 p-90 -130.26 172.91 11.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.775 -178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.408 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 2.1 mmtm -137.75 147.24 56.19 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.42 131.46 12.71 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.838 1.692 . . . . 0.0 110.289 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.627 ' NZ ' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -162.05 136.85 7.02 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.696 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -112.64 146.32 38.84 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.661 -1.275 . . . . 0.0 109.637 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.755 HD13 HG21 ' A' ' 32' ' ' VAL . 12.6 pt -101.0 140.27 20.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.517 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.66 104.61 1.11 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.49 -119.45 2.29 Favored Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.576 -1.297 . . . . 0.0 110.875 -179.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.838 HG23 HD13 ' B' ' 54' ' ' ILE . 49.9 mt -85.96 119.79 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.817 -0.814 . . . . 0.0 112.66 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.437 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 104.21 -53.38 0.7 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.355 -0.926 . . . . 0.0 110.795 178.038 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.435 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . -177.63 -157.41 18.45 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.234 -179.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -117.3 126.73 53.2 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.484 -1.009 . . . . 0.0 109.875 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.734 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.9 pp -105.08 160.55 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.303 -0.873 . . . . 0.0 109.085 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.561 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -103.02 146.6 28.11 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.046 -1.034 . . . . 0.0 110.115 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.768 HG12 ' HA3' ' A' ' 78' ' ' GLY . 3.1 m -149.39 -177.9 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.18 -0.95 . . . . 0.0 109.328 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.521 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 7.4 mmt85 -123.21 101.75 7.56 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.573 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 3.8 tt0 -73.18 106.17 4.91 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.4 -0.812 . . . . 0.0 111.144 -178.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 42' ' ' TRP . 41.4 m-85 -89.47 130.75 35.76 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.543 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.0 m-20 -100.82 121.11 41.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.7 -1.25 . . . . 0.0 109.976 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.8 OUTLIER 85.15 57.07 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.206 0.527 . . . . 0.0 110.048 179.538 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.634 HG21 HG23 ' A' ' 15' ' ' ILE . 16.4 mm -105.54 119.95 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -0.923 . . . . 0.0 108.919 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.881 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.4 tm? -68.72 98.59 0.92 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.854 -178.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.739 HG22 ' O ' ' A' ' 71' ' ' ALA . 7.9 tt -102.83 119.36 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.58 116.84 28.03 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.809 -1.182 . . . . 0.0 109.424 -178.915 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.526 HG21 HD13 ' A' ' 93' ' ' ILE . 0.4 OUTLIER -109.25 129.07 64.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.3 -0.875 . . . . 0.0 109.053 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.512 ' HB3' ' HG3' ' A' ' 1' ' ' PRO . 1.7 m 38.04 52.15 1.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.459 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 63.28 48.86 75.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.464 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.478 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 92.9 m-70 -145.15 115.19 7.43 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -1.156 . . . . 0.0 109.431 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.596 ' CG ' HD21 ' A' ' 63' ' ' LEU . 19.6 ttpt -60.97 129.25 40.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.739 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.28 99.65 2.23 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.392 -0.818 . . . . 0.0 109.874 -179.093 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.55 160.43 4.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 120.866 -1.146 . . . . 0.0 108.533 178.981 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.641 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.99 177.15 47.37 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 118.777 -1.678 . . . . 0.0 111.59 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.573 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 17.7 m -89.03 111.77 22.57 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.815 -0.815 . . . . 0.0 110.549 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.976 ' C ' HD12 ' A' ' 76' ' ' LEU . 1.4 t -101.05 161.33 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.465 -0.772 . . . . 0.0 109.733 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.976 HD12 ' C ' ' A' ' 75' ' ' VAL . 6.0 mp -130.55 105.0 7.55 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.064 -1.022 . . . . 0.0 108.405 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 61.7 t -89.61 117.75 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.792 -1.193 . . . . 0.0 109.973 -179.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.768 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.5 -166.97 17.08 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.561 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -82.75 39.02 0.78 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.479 2.119 . . . . 0.0 111.085 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.713 HG23 ' H ' ' A' ' 82' ' ' VAL . 0.8 OUTLIER -85.62 137.57 36.18 Favored Pre-proline 0 N--CA 1.49 1.525 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 178.174 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.94 23.04 0.58 Allowed 'Trans proline' 0 C--N 1.303 -1.859 0 C-N-CA 122.187 1.924 . . . . 0.0 111.689 -178.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.713 ' H ' HG23 ' A' ' 80' ' ' THR . 0.5 OUTLIER -162.94 140.93 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 120.621 -1.299 . . . . 0.0 111.899 -178.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.592 ' O ' ' CG1' ' A' ' 84' ' ' ILE . 75.1 m-20 -80.54 154.72 27.33 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.182 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.878 HG23 ' HB2' ' A' ' 25' ' ' ASP . 20.5 mt -155.63 134.04 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 117.065 -1.854 . . . . 0.0 112.443 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.565 ' HB ' HD23 ' A' ' 24' ' ' LEU . 9.5 mm -99.27 104.34 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 178.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.13 -161.48 35.41 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.747 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.474 ' O ' ' OG1' ' A' ' 91' ' ' THR . 1.0 OUTLIER -63.73 -35.48 80.72 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.691 -0.888 . . . . 0.0 109.663 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.921 ' ND2' HD23 ' A' ' 89' ' ' LEU . 18.6 p-10 -51.26 -20.88 1.8 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.987 -1.07 . . . . 0.0 110.248 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.921 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -113.03 -29.7 7.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.727 -1.233 . . . . 0.0 110.265 -179.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.461 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 21.4 mt -66.18 -11.6 50.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.994 -1.066 . . . . 0.0 108.957 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -101.38 -10.05 20.59 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.064 -1.023 . . . . 0.0 109.513 179.848 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.5 mm-40 -90.28 -41.19 11.69 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.264 -0.897 . . . . 0.0 109.85 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.708 HD12 ' CD2' ' B' ' 99' ' ' PHE . 2.2 pt -89.72 2.35 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.118 -0.989 . . . . 0.0 109.065 179.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 65.84 54.48 24.86 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -82.75 137.1 34.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.055 -1.262 . . . . 0.0 109.543 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.405 HG22 ' HA ' ' B' ' 4' ' ' THR . 16.4 p -122.78 136.95 55.03 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.223 -0.923 . . . . 0.0 109.117 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' B' ' 97' ' ' LEU . 5.3 mp -97.36 96.67 8.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.896 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -101.02 125.17 47.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.038 -1.039 . . . . 0.0 109.251 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.691 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.296 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.678 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.475 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.3 tt0 -130.74 136.69 48.99 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 177.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 8.0 t -132.17 136.24 56.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 120.886 -1.134 . . . . 0.0 109.653 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.673 ' O ' HD23 ' B' ' 5' ' ' LEU . 6.0 p -69.38 -93.14 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.394 -0.816 . . . . 0.0 109.662 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.673 HD23 ' O ' ' B' ' 4' ' ' THR . 0.2 OUTLIER 158.81 -7.44 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.836 -0.54 . . . . 0.0 110.72 179.542 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -50.53 -19.27 0.84 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.667 -1.271 . . . . 0.0 110.535 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.41 -175.92 4.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.806 -1.184 . . . . 0.0 109.9 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.05 130.33 91.49 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.474 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -79.66 68.16 8.38 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.425 2.083 . . . . 0.0 109.471 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.79 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -87.21 156.48 19.65 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.167 -0.958 . . . . 0.0 109.977 -179.104 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.897 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -147.33 138.37 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.392 -0.817 . . . . 0.0 109.662 -179.627 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.404 HG22 ' HB3' ' B' ' 19' ' ' LEU . 1.5 m -71.53 90.68 1.02 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.89 -1.131 . . . . 0.0 108.287 178.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.929 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -80.29 150.2 4.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.952 -179.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 10.6 tttm -121.75 104.42 9.58 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.366 -0.834 . . . . 0.0 109.403 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.962 HD13 HG11 ' B' ' 75' ' ' VAL . 4.8 mt -117.13 143.21 28.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.24 -90.29 0.05 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.946 -1.661 . . . . 0.0 108.946 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -158.35 38.67 0.52 Allowed Glycine 0 N--CA 1.486 1.97 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 179.286 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -137.46 166.91 22.73 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.67 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.514 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 17.5 mt -132.23 122.12 24.73 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.431 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -134.89 155.78 50.09 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.035 -1.041 . . . . 0.0 109.9 -178.961 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.79 ' HB3' HD22 ' B' ' 10' ' ' LEU . 5.5 mm-40 -78.98 110.42 14.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 178.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -98.63 154.75 17.71 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 110.341 -178.395 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.572 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -101.85 101.18 11.58 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.668 -0.645 . . . . 0.0 109.751 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.681 HD13 ' HE2' ' A' ' 99' ' ' PHE . 19.6 mt -46.23 99.57 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.32 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.671 ' CB ' HG23 ' B' ' 84' ' ' ILE . 44.4 t0 -107.48 96.08 6.15 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.291 -0.88 . . . . 0.0 111.027 -178.225 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.624 ' HA ' HD21 ' B' ' 90' ' ' LEU . 0.7 OUTLIER -78.97 3.22 17.77 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.086 -1.009 . . . . 0.0 109.188 178.599 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.763 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -95.69 -18.62 31.97 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . 0.517 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -85.78 170.83 12.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.019 -1.283 . . . . 0.0 109.711 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.453 ' HA ' ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER -100.67 -20.06 15.79 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.186 -0.946 . . . . 0.0 110.797 -178.88 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.51 ' OD1' ' HB ' ' B' ' 74' ' ' THR . 0.2 OUTLIER -137.99 -163.11 1.39 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.803 -1.186 . . . . 0.0 109.851 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.534 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 17.8 m -109.88 86.6 2.33 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.972 -1.08 . . . . 0.0 110.538 -178.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.02 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -69.04 175.39 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.825 -1.172 . . . . 0.0 108.157 179.08 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.02 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.4 116.94 0.51 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.111 -0.993 . . . . 0.0 109.804 -178.911 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.2 pt-20 -39.58 160.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.465 -0.772 . . . . 0.0 109.515 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.3 OUTLIER -38.31 139.81 0.35 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.728 0.775 . . . . 0.0 110.699 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -168.53 167.69 11.47 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.761 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 28.8 t -100.63 125.78 47.07 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.789 -1.194 . . . . 0.0 111.256 -178.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.603 ' HB2' ' CZ ' ' B' ' 59' ' ' TYR . 3.6 mm? -117.09 171.96 4.38 Favored Pre-proline 0 N--CA 1.493 1.696 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.544 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.3 Cg_endo -80.57 59.91 7.64 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.385 2.057 . . . . 0.0 111.38 -179.493 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 40.21 -158.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 3.0 mmp_? 58.49 68.22 0.85 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.443 -1.034 . . . . 0.0 109.313 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.62 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 22.8 p-90 -144.16 -167.44 2.61 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.44 -0.788 . . . . 0.0 109.879 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -146.44 132.08 9.31 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.57 132.12 11.95 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 121.93 1.753 . . . . 0.0 110.602 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -161.33 -162.24 0.88 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.421 ' HB3' ' HA ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -152.24 146.33 25.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.992 -1.068 . . . . 0.0 109.361 178.743 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.73 HD11 HD11 ' B' ' 54' ' ' ILE . 1.1 pt -96.33 155.83 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.258 -0.901 . . . . 0.0 108.886 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.663 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.09 130.7 8.69 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -158.02 -125.42 0.83 Allowed Glycine 0 N--CA 1.482 1.76 0 C-N-CA 118.949 -1.596 . . . . 0.0 111.338 -179.196 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.51 HG23 HG12 ' A' ' 54' ' ' ILE . 19.0 mt -88.96 126.68 41.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.937 -0.743 . . . . 0.0 112.836 -177.271 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.435 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 90.48 -28.3 7.73 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 178.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.427 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 157.76 -159.24 29.74 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.169 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.663 ' CD2' ' CA ' ' B' ' 48' ' ' GLY . 1.5 m-85 -120.49 132.07 55.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.654 -0.909 . . . . 0.0 109.627 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.838 HD13 HG23 ' A' ' 50' ' ' ILE . 35.4 pt -103.9 162.84 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 108.983 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 13.0 mttt -93.3 154.73 17.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.088 -1.007 . . . . 0.0 109.771 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.597 HG12 ' HA3' ' B' ' 78' ' ' GLY . 6.4 m -151.23 -168.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.055 -1.028 . . . . 0.0 110.07 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.577 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 16.7 mmt180 -129.83 89.22 2.78 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -56.48 93.62 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.271 -0.893 . . . . 0.0 110.777 -178.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.873 ' HB3' HD11 ' B' ' 62' ' ' ILE . 27.9 m-85 -88.71 136.04 33.2 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 177.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -114.58 138.25 50.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.712 -1.242 . . . . 0.0 111.041 -178.302 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.543 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.46 60.68 0.07 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.653 -0.654 . . . . 0.0 110.602 178.884 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.933 HG21 HG23 ' B' ' 15' ' ' ILE . 4.2 mp -118.77 118.09 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 108.856 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.841 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.8 tm? -68.26 90.13 0.34 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.237 -0.914 . . . . 0.0 110.631 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.701 ' CD1' HD11 ' B' ' 66' ' ' ILE . 2.4 tt -90.07 115.21 29.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.4 tm-20 -89.13 117.53 28.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.551 -178.586 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.929 HG13 HG22 ' B' ' 13' ' ' ILE . 1.4 mp -115.69 125.02 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.331 -0.856 . . . . 0.0 109.351 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 62.4 m 61.57 -95.06 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.518 -0.739 . . . . 0.0 109.792 179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -145.78 39.78 1.12 Allowed Glycine 0 N--CA 1.484 1.893 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -139.62 133.06 30.15 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.381 -1.07 . . . . 0.0 109.637 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.462 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -77.04 135.55 38.65 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.022 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.648 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.75 97.53 2.98 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.154 -1.018 . . . . 0.0 110.665 -179.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.775 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.89 140.17 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 177.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.838 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.77 -168.0 29.27 Favored Glycine 0 N--CA 1.485 1.96 0 C-N-CA 118.741 -1.695 . . . . 0.0 110.939 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 28.9 m -95.95 109.18 21.59 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.781 -0.835 . . . . 0.0 110.244 -179.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.962 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -96.61 104.97 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.321 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.7 mp -79.86 116.74 20.19 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.202 -0.936 . . . . 0.0 108.615 178.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.577 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.3 t -101.39 131.44 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.051 -1.031 . . . . 0.0 109.125 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.597 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -162.38 -165.43 19.37 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.06 -1.543 . . . . 0.0 109.905 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.539 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.93 40.67 1.01 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.753 2.302 . . . . 0.0 110.054 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' B' ' 34' ' ' GLU . 8.8 t -85.55 138.5 35.89 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 33.9 Cg_endo -78.38 14.3 1.63 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.51 2.14 . . . . 0.0 111.078 -179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.526 HG12 ' CD1' ' B' ' 84' ' ' ILE . 1.1 t -160.68 167.56 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.102 -0.999 . . . . 0.0 109.382 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.608 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -101.15 144.18 30.34 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 175.816 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.697 ' CG1' HG12 ' B' ' 32' ' ' VAL . 6.8 mm -129.0 123.68 59.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 O-C-N 120.069 -1.644 . . . . 0.0 112.194 -176.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.735 HG22 ' CD1' ' B' ' 90' ' ' LEU . 4.4 mm -102.54 101.48 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.615 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -107.0 175.25 20.51 Favored Glycine 0 N--CA 1.496 2.695 0 C-N-CA 119.792 -1.194 . . . . 0.0 111.915 -177.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.786 ' N ' HD22 ' B' ' 90' ' ' LEU . 4.0 mtm180 -28.46 -41.44 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.376 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -178.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.991 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.8 p-10 -53.17 -41.38 65.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 120.234 -1.541 . . . . 0.0 110.661 -177.659 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.991 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.6 mm? -98.92 -18.33 17.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.172 -0.955 . . . . 0.0 110.342 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.786 HD22 ' N ' ' B' ' 87' ' ' ARG . 0.4 OUTLIER -69.51 -35.89 75.94 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.143 -0.973 . . . . 0.0 109.391 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 49.6 p -70.03 -15.27 62.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.189 -0.944 . . . . 0.0 108.965 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' B' ' 72' ' ' ILE . 26.7 mt-30 -91.63 -40.48 11.28 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.306 -0.871 . . . . 0.0 108.943 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.645 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -81.77 -2.98 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 177.088 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.01 43.29 99.63 Favored Glycine 0 N--CA 1.496 2.697 0 O-C-N 121.561 -0.712 . . . . 0.0 111.361 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.691 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -68.38 147.01 52.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.874 -1.368 . . . . 0.0 110.289 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.506 HG22 ' CG2' ' A' ' 4' ' ' THR . 14.9 p -144.61 130.78 19.54 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.339 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' A' ' 97' ' ' LEU . 8.0 mp -92.68 102.85 15.27 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 110.119 -179.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 3.6 m120 -101.65 121.95 42.98 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.088 -1.007 . . . . 0.0 109.688 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.708 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 118.128 -0.939 . . . . 0.0 109.33 179.309 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.468 ' HD2' ' OXT' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.687 0 N-CA-C 110.164 -0.745 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.543 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -104.09 126.59 51.33 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.292 -0.88 . . . . 0.0 109.032 179.079 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.436 HG11 ' HB3' ' A' ' 9' ' ' PRO . 13.8 t -121.83 102.46 11.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.878 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.554 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -52.27 -84.26 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.324 -0.86 . . . . 0.0 109.953 -178.981 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.846 HD23 HG23 ' B' ' 91' ' ' THR . 31.2 tp 171.84 -25.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.259 -0.9 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 84.8 m95 -54.77 -19.36 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.07 -1.019 . . . . 0.0 108.996 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -129.51 130.53 45.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.438 -0.789 . . . . 0.0 109.513 179.594 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtt-85 -49.06 146.49 5.7 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.833 ' HB2' HD12 ' A' ' 24' ' ' LEU . 37.0 Cg_endo -79.8 47.75 2.63 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.838 2.359 . . . . 0.0 110.538 179.394 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.553 HD22 ' HB3' ' A' ' 21' ' ' GLU . 1.8 mt -80.03 144.4 33.24 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.1 -1.0 . . . . 0.0 109.276 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG22 ' A' ' 66' ' ' ILE . 1.9 m -148.99 160.15 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.366 -179.379 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.664 HG22 HD22 ' A' ' 19' ' ' LEU . 90.0 m -91.21 107.77 19.43 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.487 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.811 HG12 ' HB2' ' A' ' 22' ' ' ALA . 2.1 pt -99.18 157.97 3.67 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.275 -0.89 . . . . 0.0 110.084 -178.674 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.484 ' HE3' HD11 ' A' ' 19' ' ' LEU . 2.3 ttmt -118.16 100.81 7.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 108.913 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.796 HD13 HG21 ' A' ' 75' ' ' VAL . 1.3 mt -109.8 140.92 26.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.858 -1.151 . . . . 0.0 109.4 -179.587 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 62.96 -90.64 0.07 OUTLIER Glycine 0 N--CA 1.488 2.139 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -179.604 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.22 35.19 0.6 Allowed Glycine 0 C--N 1.294 -1.787 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.404 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.409 ' OE1' ' HB2' ' A' ' 37' ' ' SER . 8.2 mt-30 -138.99 173.78 11.2 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -1.134 . . . . 0.0 109.591 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.766 HD23 ' O ' ' A' ' 13' ' ' ILE . 18.5 mt -133.58 122.04 22.95 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.593 -0.692 . . . . 0.0 109.42 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HE3' ' SD ' ' A' ' 36' ' ' MET . 0.3 OUTLIER -135.72 -179.87 5.92 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.93 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.553 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.5 mt-10 -78.32 176.36 9.39 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 108.191 179.521 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.811 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -157.71 108.74 2.25 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 120.936 -1.102 . . . . 0.0 109.619 -179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.699 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.8 tp -85.19 93.41 8.65 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.35 -0.844 . . . . 0.0 109.078 179.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.833 HD12 ' HB2' ' A' ' 9' ' ' PRO . 97.8 mt -43.06 97.15 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.686 ' CB ' HG23 ' A' ' 84' ' ' ILE . 3.8 t0 -102.95 77.18 1.54 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.388 -0.82 . . . . 0.0 110.918 -178.245 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.48 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 2.2 m -54.92 -20.19 8.36 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.124 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.731 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -65.24 -44.33 93.93 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.732 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.47 155.72 40.01 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.17 -1.194 . . . . 0.0 108.86 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.68 -17.55 31.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.05 -1.032 . . . . 0.0 110.688 -179.034 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.523 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -138.42 -159.58 0.97 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.779 -1.201 . . . . 0.0 110.108 -179.532 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.83 HG22 ' CD1' ' A' ' 33' ' ' LEU . 35.3 m -114.98 91.41 3.61 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.925 -1.11 . . . . 0.0 110.602 -178.547 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.95 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -74.79 160.12 5.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.675 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -160.15 123.72 3.57 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.841 -1.162 . . . . 0.0 110.473 -178.595 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.607 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.6 OUTLIER -41.99 153.46 0.06 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.14 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.542 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -43.11 146.93 0.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.021 -1.049 . . . . 0.0 110.161 -179.55 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.458 ' HE1' ' HB ' ' A' ' 15' ' ' ILE . 21.7 ptm -162.2 -163.64 0.95 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.311 -0.868 . . . . 0.0 109.597 -179.802 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.409 ' HB2' ' OE1' ' A' ' 18' ' ' GLN . 7.4 t -101.31 87.08 3.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.433 -0.792 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.643 HD13 HG22 ' A' ' 15' ' ' ILE . 12.9 tp -127.71 97.34 30.5 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.145 -0.972 . . . . 0.0 110.134 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.04 178.31 7.34 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.497 2.131 . . . . 0.0 109.94 179.366 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.15 -173.86 16.31 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.486 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -78.93 134.86 36.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.326 -1.102 . . . . 0.0 109.239 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.605 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.9 p-90 -147.72 159.42 43.82 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -128.26 135.44 27.54 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 135.33 18.28 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 121.86 1.707 . . . . 0.0 109.968 -179.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.1 ptpt -155.8 -165.66 2.02 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.462 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.481 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 4.0 mtp -150.4 125.89 10.2 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.293 -0.879 . . . . 0.0 109.641 -179.624 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' B' ' 50' ' ' ILE . 1.1 pt -89.78 147.1 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.014 -1.054 . . . . 0.0 108.422 179.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.433 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -117.97 105.76 1.28 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -128.39 -132.34 3.54 Favored Glycine 0 N--CA 1.484 1.89 0 C-N-CA 119.459 -1.353 . . . . 0.0 111.043 -178.815 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.579 HG21 ' CD1' ' B' ' 47' ' ' ILE . 34.8 mt -83.13 121.06 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.838 -0.801 . . . . 0.0 112.537 -177.547 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.457 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 97.71 -20.48 50.46 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 178.019 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.87 -161.01 28.88 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 120.808 -1.407 . . . . 0.0 109.993 179.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -126.09 132.37 51.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.437 -1.037 . . . . 0.0 109.524 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.585 HD11 HD11 ' A' ' 47' ' ' ILE . 14.1 pt -104.38 175.33 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.079 -1.013 . . . . 0.0 109.412 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.481 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 3.6 mtmt -103.77 140.32 37.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.095 -1.003 . . . . 0.0 109.258 179.853 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.592 HG21 HD23 ' A' ' 76' ' ' LEU . 27.1 m -144.39 170.08 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.129 -0.982 . . . . 0.0 109.917 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.413 ' O ' ' N ' ' A' ' 59' ' ' TYR . 1.0 OUTLIER -111.21 96.76 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.057 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -55.78 93.74 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.344 -0.848 . . . . 0.0 109.704 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 5.8 m-85 -89.31 125.98 35.33 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 178.528 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.606 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 65.3 m-20 -106.38 133.8 50.5 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.792 -1.192 . . . . 0.0 110.345 -178.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.606 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mt-30 74.44 63.32 0.07 Allowed 'General case' 0 N--CA 1.494 1.741 0 CA-C-O 121.855 0.836 . . . . 0.0 109.904 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.584 ' HB ' HG23 ' A' ' 75' ' ' VAL . 16.0 mm -115.14 119.47 61.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 178.616 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.599 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -70.42 90.2 0.71 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.178 -0.951 . . . . 0.0 111.277 -177.919 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.708 ' CG2' HD11 ' A' ' 89' ' ' LEU . 7.3 tt -88.51 113.51 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -87.99 111.79 21.88 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.244 -0.91 . . . . 0.0 109.012 -178.282 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.549 HD13 HG22 ' A' ' 13' ' ' ILE . 1.3 mm -97.19 168.1 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.505 ' C ' ' O ' ' A' ' 66' ' ' ILE . 61.3 m -28.68 88.87 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.488 0.661 . . . . 0.0 111.219 -179.074 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.573 ' O ' ' CD2' ' A' ' 69' ' ' HIS . . . 52.31 58.94 9.66 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.529 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 68' ' ' GLY . 6.8 m-70 -162.27 86.76 0.61 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.372 . . . . 0.0 110.42 179.496 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.566 ' HG3' HD21 ' A' ' 63' ' ' LEU . 4.4 tttm -49.04 118.54 2.69 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.621 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -141.26 108.36 5.47 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 119.416 -0.914 . . . . 0.0 110.456 -178.602 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.599 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -80.74 159.42 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.005 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.894 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 179.42 174.49 45.51 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 118.247 -1.93 . . . . 0.0 111.452 179.577 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 87.6 m -87.14 112.67 22.17 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.606 -0.938 . . . . 0.0 109.956 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.888 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -102.17 118.9 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.422 -0.799 . . . . 0.0 110.275 179.679 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.592 HD23 HG21 ' A' ' 56' ' ' VAL . 4.9 mp -87.81 105.75 17.62 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.77 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 35' ' ' GLU . 6.5 t -88.75 113.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.233 -0.917 . . . . 0.0 110.327 -178.67 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.85 -168.77 17.96 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.451 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -80.35 44.5 1.75 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.634 2.223 . . . . 0.0 111.061 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.695 HG21 HG13 ' A' ' 32' ' ' VAL . 9.7 t -82.5 141.25 45.17 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.022 -1.049 . . . . 0.0 108.637 179.241 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.674 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.7 Cg_endo -81.22 17.67 1.43 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.576 2.184 . . . . 0.0 111.163 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.674 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.2 t -161.26 163.28 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.86 -1.15 . . . . 0.0 110.333 -179.23 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 72.5 m-20 -99.18 89.37 4.22 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.686 HG23 ' CB ' ' A' ' 25' ' ' ASP . 8.2 mm -78.27 116.43 21.94 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 O-C-N 121.168 -0.957 . . . . 0.0 111.764 -176.436 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.651 HG12 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -101.63 85.99 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.225 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.64 -165.32 28.02 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.288 -0.958 . . . . 0.0 112.346 -176.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.552 ' HD3' ' HD3' ' B' ' 9' ' ' PRO . 27.8 mtm-85 -57.38 -39.91 77.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 122.203 -0.586 . . . . 0.0 111.481 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.929 ' ND2' HD23 ' A' ' 89' ' ' LEU . 16.3 p-10 -45.49 -24.31 0.31 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.537 -1.352 . . . . 0.0 109.63 -179.3 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.929 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -111.9 -32.48 6.59 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.892 -1.13 . . . . 0.0 110.712 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.48 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 90.1 mt -58.17 -36.58 73.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.824 -1.172 . . . . 0.0 108.841 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.4 p -75.69 -20.53 58.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.316 -0.865 . . . . 0.0 109.643 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -72.45 -40.31 67.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.863 -1.148 . . . . 0.0 108.472 179.428 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -81.65 -1.01 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.581 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 67.47 61.3 5.16 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.506 -1.838 . . . . 0.0 108.506 -179.527 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -89.77 149.27 22.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.442 -1.034 . . . . 0.0 110.003 -179.192 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.731 HG22 HG23 ' B' ' 4' ' ' THR . 49.5 p -137.73 125.43 22.36 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.028 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' B' ' 97' ' ' LEU . 4.8 mp -86.0 104.11 15.31 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.59 -0.694 . . . . 0.0 109.279 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.533 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.2 m120 -104.4 122.32 45.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.083 -1.011 . . . . 0.0 110.03 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.783 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.618 0 CA-C-O 117.937 -1.03 . . . . 0.0 109.25 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.478 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.626 0 N-CA-C 109.87 -0.858 . . . . 0.0 109.87 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 1.2 tt0 -84.64 134.0 34.39 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.62 HG13 HD13 ' B' ' 5' ' ' LEU . 22.2 t -133.73 137.07 53.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 120.762 -1.212 . . . . 0.0 109.9 -179.144 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.731 HG23 HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -129.99 23.84 5.3 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 178.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.71 HD23 ' HA ' ' B' ' 9' ' ' PRO . 1.6 mp -39.54 92.24 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.767 0.794 . . . . 0.0 109.801 -179.226 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.558 ' N ' ' O ' ' B' ' 4' ' ' THR . 4.7 m95 -44.42 -21.59 0.05 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.632 -0.667 . . . . 0.0 109.912 -179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.447 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.7 mt-30 -109.4 -158.85 0.66 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.022 -1.049 . . . . 0.0 108.599 179.122 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -59.01 119.7 40.42 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.037 -1.04 . . . . 0.0 109.469 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.71 ' HA ' HD23 ' B' ' 5' ' ' LEU . 36.6 Cg_endo -78.22 73.14 5.92 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.254 1.969 . . . . 0.0 109.798 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -82.1 163.61 21.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.184 -0.947 . . . . 0.0 109.937 -179.425 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.518 HG23 ' CG2' ' B' ' 13' ' ' ILE . 14.8 m -144.95 142.33 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.429 -0.794 . . . . 0.0 110.143 -179.697 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.744 HG22 HD22 ' B' ' 19' ' ' LEU . 2.7 m -73.97 99.09 3.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.01 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 1.3 pt -92.07 147.46 5.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.617 -178.454 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.8 tttt -114.08 94.51 4.85 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.826 HD11 HD12 ' B' ' 64' ' ' ILE . 22.3 mt -115.03 129.94 70.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.132 -0.98 . . . . 0.0 109.609 -179.429 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.05 52.99 49.08 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.442 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.35 23.57 9.01 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -119.26 170.67 8.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -1.151 . . . . 0.0 109.476 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.744 HD22 HG22 ' B' ' 12' ' ' THR . 13.8 mt -141.52 122.42 14.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.139 -0.976 . . . . 0.0 110.24 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 mttt -147.22 145.92 29.63 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.139 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 11.8 mt-10 -78.37 133.24 37.59 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.863 -1.148 . . . . 0.0 108.504 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -112.38 162.8 15.15 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.883 -179.04 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.731 HD21 ' O ' ' A' ' 27' ' ' GLY . 59.4 tp -99.7 101.52 12.72 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.837 -0.539 . . . . 0.0 110.06 -178.856 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' B' ' 9' ' ' PRO . 2.9 mt -44.98 97.37 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.214 -0.929 . . . . 0.0 108.51 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.733 ' CB ' HG23 ' B' ' 84' ' ' ILE . 10.3 t0 -100.87 95.39 6.58 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.089 -1.007 . . . . 0.0 110.863 -178.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.53 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -83.0 9.67 9.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.257 -0.902 . . . . 0.0 108.861 178.301 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.699 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -108.0 -14.13 17.88 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.5 170.03 9.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.111 -1.229 . . . . 0.0 109.089 179.803 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.08 -14.94 17.59 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.038 -1.039 . . . . 0.0 111.825 -178.397 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.535 ' HB3' HD11 ' B' ' 76' ' ' LEU . 14.3 m-20 -141.91 -169.33 2.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.507 -1.371 . . . . 0.0 110.639 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.779 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 38.5 m -104.48 84.75 2.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.199 -0.938 . . . . 0.0 110.475 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.659 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -78.75 112.19 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.244 -0.91 . . . . 0.0 110.387 -179.636 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.886 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.5 OUTLIER -107.76 123.17 48.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.583 -0.698 . . . . 0.0 110.176 179.895 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.736 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.0 pt-20 -43.36 164.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.943 -1.098 . . . . 0.0 108.831 178.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.819 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -47.74 145.03 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.996 -1.065 . . . . 0.0 110.112 -179.231 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.488 ' CG ' ' HG ' ' B' ' 38' ' ' LEU . 10.5 ptm -155.66 -165.55 2.0 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.36 -0.838 . . . . 0.0 109.135 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' B' ' 36' ' ' MET . 21.2 t -102.44 87.14 2.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.111 -0.993 . . . . 0.0 109.508 179.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 1.06 HD12 HG21 ' B' ' 77' ' ' VAL . 31.3 mt -112.88 163.92 16.75 Favored Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 121.246 -0.909 . . . . 0.0 109.17 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.9 Cg_endo -75.8 -166.45 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.354 2.036 . . . . 0.0 110.492 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -94.28 -152.17 29.01 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 62.97 58.71 1.45 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.888 -0.772 . . . . 0.0 109.067 -179.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.584 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 30.0 p-90 -134.92 175.61 9.41 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.649 -0.657 . . . . 0.0 109.746 -179.537 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.03 123.65 15.97 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.229 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.38 137.44 20.9 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.217 1.944 . . . . 0.0 111.543 -178.689 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.24 -167.29 2.72 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.105 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.51 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 54.6 mtp -145.69 131.36 18.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.94 -1.1 . . . . 0.0 110.159 -179.275 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.579 ' CD1' HG21 ' A' ' 50' ' ' ILE . 5.2 pt -97.75 149.04 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.171 -0.955 . . . . 0.0 108.694 179.08 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.06 116.94 3.49 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -139.27 -125.86 2.31 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.449 -1.358 . . . . 0.0 110.536 -179.431 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.732 HG21 HD12 ' A' ' 47' ' ' ILE . 66.6 mt -87.23 129.27 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.948 . . . . 0.0 112.676 -177.794 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.07 -47.37 2.68 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 178.252 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.457 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 178.87 -156.26 18.31 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.055 -179.701 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.5 m-85 -120.97 136.22 55.02 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.681 -0.894 . . . . 0.0 109.414 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.45 HG12 ' CG2' ' A' ' 50' ' ' ILE . 7.1 pt -107.16 173.1 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.125 -0.984 . . . . 0.0 109.102 179.219 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.551 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 9.8 mttm -110.06 145.53 36.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.028 -1.045 . . . . 0.0 109.099 179.708 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.589 HG12 ' HA3' ' B' ' 78' ' ' GLY . 30.6 m -141.48 -173.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.868 -1.145 . . . . 0.0 110.39 -179.583 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' B' ' 59' ' ' TYR . 5.2 mtt85 -129.31 90.09 2.96 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 12.0 tt0 -48.76 92.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.363 -0.836 . . . . 0.0 109.97 -179.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.584 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 10.3 m-85 -92.93 92.14 7.73 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -79.52 140.17 37.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.147 -0.971 . . . . 0.0 110.626 -178.519 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.522 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 76.76 60.61 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.514 0.673 . . . . 0.0 110.019 179.539 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.786 ' CG2' HG23 ' B' ' 15' ' ' ILE . 6.1 mm -120.77 115.48 47.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.786 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -66.7 104.0 1.21 Allowed 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.848 -1.157 . . . . 0.0 110.73 -178.664 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.826 HD12 HD11 ' B' ' 15' ' ' ILE . 9.2 tt -106.19 112.65 40.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 177.486 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.492 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.0 tt0 -88.89 106.58 18.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.955 -1.091 . . . . 0.0 109.79 -177.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.75 HG13 HG22 ' B' ' 13' ' ' ILE . 1.6 mp -105.01 117.47 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.884 . . . . 0.0 109.406 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.495 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 9.7 m 58.54 57.66 3.7 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.453 -0.779 . . . . 0.0 109.916 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.56 34.48 20.29 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.636 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.495 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 61.8 m-70 -126.51 117.1 22.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.255 -1.144 . . . . 0.0 109.309 179.794 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.678 ' HG3' HD21 ' B' ' 63' ' ' LEU . 23.0 ttpt -65.38 124.82 23.27 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.452 -179.927 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.703 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -146.44 96.02 2.7 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.353 -0.842 . . . . 0.0 109.523 -179.829 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.786 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -79.14 152.46 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.048 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.56 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.07 -157.42 14.77 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 118.428 -1.844 . . . . 0.0 111.781 179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.447 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 3.4 m -110.66 104.97 13.71 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.679 -0.895 . . . . 0.0 110.001 -179.089 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.886 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -96.65 110.41 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.635 -0.666 . . . . 0.0 110.215 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.602 HD12 ' H ' ' B' ' 76' ' ' LEU . 3.8 mp -79.56 106.75 11.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 179.439 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 1.06 HG21 HD12 ' B' ' 38' ' ' LEU . 2.8 t -88.67 111.43 22.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.95 -1.094 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.589 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -141.65 -170.5 12.42 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.551 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.09 42.55 1.36 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.474 2.116 . . . . 0.0 110.648 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.736 HG22 ' HA ' ' B' ' 34' ' ' GLU . 10.0 t -88.94 139.45 29.07 Favored Pre-proline 0 N--CA 1.49 1.536 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.6 Cg_endo -80.43 18.21 1.25 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.553 2.169 . . . . 0.0 111.19 -179.313 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.669 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -161.59 163.01 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.917 -1.114 . . . . 0.0 110.008 -179.348 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.669 ' O ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -94.62 160.33 14.68 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 104.482 -2.414 . . . . 0.0 104.482 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.779 ' O ' ' HA ' ' B' ' 31' ' ' THR . 12.6 mm -144.05 95.05 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 O-C-N 120.051 -1.655 . . . . 0.0 111.054 -178.354 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 1.051 HG22 HD11 ' B' ' 90' ' ' LEU . 0.3 OUTLIER -77.71 101.41 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 178.196 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.691 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -112.99 -176.07 19.49 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.674 -177.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.73 ' N ' HD22 ' B' ' 90' ' ' LEU . 7.1 mtt85 -29.65 -42.16 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -178.614 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.011 ' ND2' HD23 ' B' ' 89' ' ' LEU . 4.8 p-10 -57.56 -42.64 83.41 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.124 -1.61 . . . . 0.0 110.482 -177.688 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.011 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -95.8 -10.57 28.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.299 -0.876 . . . . 0.0 109.662 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 1.051 HD11 HG22 ' B' ' 85' ' ' ILE . 1.2 mp -79.06 -32.0 44.68 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.319 -0.863 . . . . 0.0 109.186 -179.623 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.846 HG23 HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.9 -20.22 60.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.064 -1.022 . . . . 0.0 109.413 179.611 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.819 ' OE1' HD13 ' B' ' 89' ' ' LEU . 28.0 mt-30 -82.13 -41.24 20.73 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.029 -1.045 . . . . 0.0 109.03 179.562 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.783 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -82.48 -9.11 11.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.3 57.37 15.48 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 178.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.15 142.14 33.55 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.253 -1.145 . . . . 0.0 110.446 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.554 HG22 ' HA ' ' A' ' 4' ' ' THR . 24.3 p -129.82 126.2 37.51 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.713 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -90.53 90.43 8.0 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 109.537 -179.609 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.543 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 5.1 m120 -95.63 127.63 41.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.684 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.13 179.297 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.73 0 N-CA-C 110.65 -0.558 . . . . 0.0 110.65 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.1 OUTLIER -84.4 146.0 27.9 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 177.865 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.54 HG11 ' HB3' ' A' ' 9' ' ' PRO . 2.2 t -134.19 124.56 46.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 C-N-CA 118.486 -1.286 . . . . 0.0 110.091 -179.04 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -130.14 14.02 5.67 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.128 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -43.75 93.51 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 CA-C-O 121.9 0.857 . . . . 0.0 109.152 -179.301 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.538 ' N ' ' O ' ' A' ' 4' ' ' THR . 2.5 m95 -45.24 -15.15 0.02 OUTLIER 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.879 -0.513 . . . . 0.0 110.426 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.514 ' N ' ' O ' ' A' ' 5' ' ' LEU . 28.9 mt-30 -106.48 -115.65 0.26 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.62 -1.3 . . . . 0.0 108.951 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.504 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 46.3 mtp180 -111.03 136.48 20.8 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 120.406 -1.434 . . . . 0.0 110.235 -179.691 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HB3' HG11 ' A' ' 3' ' ' VAL . 38.0 Cg_endo -81.09 63.09 8.7 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.597 2.198 . . . . 0.0 109.785 178.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.484 HD22 ' HB3' ' A' ' 21' ' ' GLU . 2.4 mt -84.79 140.29 31.33 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.623 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.499 HG22 ' HB3' ' A' ' 22' ' ' ALA . 1.1 m -140.32 151.64 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.321 -0.862 . . . . 0.0 109.128 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.5 m -86.08 99.92 11.82 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.206 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 66' ' ' ILE . 1.9 pt -91.5 161.04 2.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.388 -0.82 . . . . 0.0 110.311 -178.178 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 1.2 tttt -117.07 97.85 6.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 109.174 179.491 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.912 ' CD1' HG21 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -113.67 126.93 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.096 -1.003 . . . . 0.0 109.463 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.63 31.02 77.33 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.733 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.7 11.36 68.91 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 91.7 mm-40 -108.01 167.53 9.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 108.901 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 35.1 mt -126.23 123.35 37.97 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.011 -1.056 . . . . 0.0 109.368 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.508 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -140.66 173.99 10.95 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.911 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.6 mt-10 -79.25 177.23 8.99 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -154.75 112.0 3.37 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 120.849 -1.157 . . . . 0.0 109.798 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 25' ' ' ASP . 13.4 tp -89.53 95.35 10.23 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.646 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.536 HD13 HD23 ' B' ' 97' ' ' LEU . 30.4 mt -43.85 98.85 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.691 ' CB ' HG23 ' A' ' 84' ' ' ILE . 5.5 t0 -105.1 73.71 1.07 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.375 -0.828 . . . . 0.0 110.999 -177.651 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.0 m -57.15 -18.33 14.74 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.861 -1.149 . . . . 0.0 108.052 178.348 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.658 ' O ' HD11 ' B' ' 23' ' ' LEU . . . -64.97 -45.34 92.66 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.71 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.66 163.48 27.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.203 -1.174 . . . . 0.0 109.328 -179.923 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.43 -14.89 23.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.166 -0.958 . . . . 0.0 110.888 -179.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.547 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.01 -165.44 1.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.671 -1.268 . . . . 0.0 111.338 -178.972 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.747 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -102.47 88.52 3.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.487 -0.758 . . . . 0.0 110.953 -178.426 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.886 HG21 HD13 ' A' ' 47' ' ' ILE . 0.6 OUTLIER -79.38 113.38 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.013 -1.679 . . . . 0.0 107.933 178.566 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.93 HD13 ' CG1' ' A' ' 75' ' ' VAL . 1.1 mp -115.02 132.58 56.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 111.33 -177.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -43.39 165.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.202 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -57.05 142.72 41.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.029 -1.045 . . . . 0.0 110.238 -179.561 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.646 ' HE2' HG22 ' A' ' 15' ' ' ILE . 4.2 ptm -161.82 -161.16 0.75 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.431 -0.793 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -104.15 114.89 29.45 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.321 -0.862 . . . . 0.0 110.358 -179.427 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.878 HD23 ' CD2' ' A' ' 59' ' ' TYR . 3.1 tp -138.68 145.7 47.33 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.636 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 31.6 Cg_endo -72.28 157.11 54.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.345 2.03 . . . . 0.0 110.507 -179.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.525 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -49.8 -162.09 0.01 OUTLIER Glycine 0 N--CA 1.493 2.473 0 CA-C-O 121.858 0.699 . . . . 0.0 111.881 -178.475 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.525 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 75.59 50.29 0.07 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.614 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 6.9 p-90 -122.56 177.88 5.23 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-O 122.124 0.964 . . . . 0.0 111.269 -178.297 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.46 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 1.3 mtmm -139.51 118.49 8.96 Favored Pre-proline 0 C--N 1.303 -1.417 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.698 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -74.91 138.63 23.51 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.038 1.826 . . . . 0.0 110.91 -178.706 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.74 -173.21 4.0 Favored 'General case' 0 N--CA 1.49 1.528 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.901 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.5 ' CE ' ' HG3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -138.79 120.62 15.38 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.882 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 54' ' ' ILE . 3.1 pt -91.68 144.11 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.886 -1.134 . . . . 0.0 109.331 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.631 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -119.01 135.04 11.15 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 179.892 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.64 -129.5 1.06 Allowed Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.395 -179.614 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.711 HG23 HD13 ' B' ' 54' ' ' ILE . 77.6 mt -82.15 109.27 16.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.704 -0.88 . . . . 0.0 112.57 -177.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 111.78 -29.23 8.7 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 178.167 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.63 -161.52 29.26 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.424 179.65 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.631 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -112.02 131.97 55.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.408 -1.054 . . . . 0.0 109.931 -179.464 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 47' ' ' ILE . 16.2 pt -105.12 173.0 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.978 -1.076 . . . . 0.0 108.889 178.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.528 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 6.4 mttt -110.09 128.84 55.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.253 -0.904 . . . . 0.0 109.301 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.894 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.9 m -137.34 -174.61 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.101 -1.0 . . . . 0.0 109.998 -179.835 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -120.37 173.57 7.06 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.98 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.81 ' OE1' HG22 ' A' ' 74' ' ' THR . 0.1 OUTLIER -136.66 89.53 2.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.894 -1.129 . . . . 0.0 110.8 -179.528 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.878 ' CD2' HD23 ' A' ' 38' ' ' LEU . 96.5 m-85 -90.01 122.25 32.83 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.354 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -96.94 146.29 25.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.882 -1.136 . . . . 0.0 110.531 -178.914 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.601 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.9 OUTLIER 71.28 65.78 0.16 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.563 179.409 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.556 ' C ' HG12 ' A' ' 72' ' ' ILE . 13.5 mm -120.14 106.62 19.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.327 -0.858 . . . . 0.0 109.271 179.656 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.87 HD21 ' HG2' ' A' ' 70' ' ' LYS . 1.6 tm? -54.43 87.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.653 -0.654 . . . . 0.0 110.413 -178.759 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.815 HG22 ' O ' ' A' ' 71' ' ' ALA . 2.9 tt -89.68 122.09 40.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.872 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 7.1 tp10 -89.15 122.05 32.06 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.847 -1.158 . . . . 0.0 109.455 -178.69 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.854 HG13 HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -118.18 132.18 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.275 -0.89 . . . . 0.0 108.787 -179.912 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 66' ' ' ILE . 21.5 m 38.24 49.96 1.36 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.635 . . . . 0.0 110.637 179.271 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.51 47.96 78.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.46 ' O ' ' HA ' ' A' ' 65' ' ' GLU . 77.6 m-70 -142.67 137.02 29.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.291 -1.123 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.87 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -85.28 126.19 33.51 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.27 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.815 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -147.5 98.94 3.06 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.351 -0.843 . . . . 0.0 110.094 -178.794 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.601 HG23 ' HA ' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -81.73 142.71 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 120.887 -1.133 . . . . 0.0 107.992 179.068 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -160.85 -159.02 9.64 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.834 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.81 HG22 ' OE1' ' A' ' 58' ' ' GLN . 3.1 m -101.78 105.25 16.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.945 -0.738 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.93 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -103.24 163.59 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.063 -1.023 . . . . 0.0 109.534 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.553 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.2 mp -129.87 158.88 38.28 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 178.68 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.601 HG12 ' HA ' ' A' ' 35' ' ' GLU . 23.8 t -142.68 106.44 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 O-C-N 121.101 -1.0 . . . . 0.0 110.133 -179.462 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.894 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -144.86 -163.61 10.16 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.524 -1.831 . . . . 0.0 108.524 179.576 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.528 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.8 41.45 1.12 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 C-N-CA 122.374 2.049 . . . . 0.0 111.393 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.572 HG21 HG13 ' A' ' 32' ' ' VAL . 6.0 t -84.52 132.64 46.34 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.054 -1.029 . . . . 0.0 108.536 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.42 17.69 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.834 2.356 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.612 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -160.87 173.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.836 -1.165 . . . . 0.0 109.843 -179.776 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.612 ' N ' HG13 ' A' ' 82' ' ' VAL . 57.4 m-80 -102.26 139.46 37.85 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.99 -2.596 . . . . 0.0 103.99 176.217 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.747 ' O ' ' HA ' ' A' ' 31' ' ' THR . 11.7 mm -128.66 95.59 2.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 O-C-N 120.283 -1.511 . . . . 0.0 110.533 -176.428 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.64 ' HA ' HG23 ' A' ' 31' ' ' THR . 1.0 OUTLIER -78.94 90.58 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.023 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.59 -160.44 19.97 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -178.432 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.612 ' O ' HG23 ' A' ' 91' ' ' THR . 0.0 OUTLIER -64.15 -28.37 69.72 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.547 -0.972 . . . . 0.0 110.663 -179.154 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.819 ' ND2' HD23 ' A' ' 89' ' ' LEU . 1.5 p-10 -53.61 -42.71 67.99 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.94 -1.1 . . . . 0.0 110.725 -178.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.819 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -95.15 -24.85 16.66 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.893 -1.13 . . . . 0.0 108.874 -179.729 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 91.4 mt -69.07 -4.38 16.92 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.343 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.612 HG23 ' O ' ' A' ' 87' ' ' ARG . 36.2 p -100.82 -13.35 18.44 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.879 -1.138 . . . . 0.0 109.165 179.608 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 85.2 mm-40 -89.45 -40.99 12.33 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 0.0 109.726 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.686 HD12 ' CG ' ' B' ' 99' ' ' PHE . 10.5 pt -85.63 -0.09 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.144 -0.973 . . . . 0.0 108.98 179.525 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.88 43.74 40.38 Favored Glycine 0 N--CA 1.497 2.748 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.061 178.873 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.565 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -72.1 142.98 49.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.92 -1.341 . . . . 0.0 110.144 179.665 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.1 p -148.35 127.69 13.05 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.541 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' B' ' 97' ' ' LEU . 7.5 mp -86.55 95.86 9.89 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.269 -0.895 . . . . 0.0 109.453 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.546 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 3.4 m120 -99.02 117.99 34.77 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.042 -1.036 . . . . 0.0 109.679 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.748 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.297 -1.676 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.319 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.503 ' HD3' ' NE2' ' B' ' 69' ' ' HIS . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.202 -0.73 . . . . 0.0 110.202 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.546 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 8.1 tt0 -83.64 139.44 32.81 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 178.151 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.589 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 2.5 t -131.23 111.05 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.456 -1.298 . . . . 0.0 110.911 -178.149 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.523 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -123.21 -65.55 1.08 Allowed 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.587 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.2 tp 36.47 26.96 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.572 178.152 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.609 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 24.1 m95 18.07 47.63 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.187 0.518 . . . . 0.0 112.172 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.587 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.47 -158.05 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.965 . . . . 0.0 109.443 -179.755 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.643 ' HB3' HD12 ' B' ' 23' ' ' LEU . 11.5 mtm180 -70.07 125.58 92.05 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.092 -1.005 . . . . 0.0 109.056 179.467 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.589 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.5 Cg_endo -79.09 70.69 7.39 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.434 2.09 . . . . 0.0 109.653 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.806 HD23 ' C ' ' B' ' 22' ' ' ALA . 7.0 mt -85.29 137.93 32.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.267 -0.896 . . . . 0.0 110.816 -178.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.521 HG23 ' N ' ' B' ' 12' ' ' THR . 1.7 m -141.11 168.8 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.521 ' N ' HG23 ' B' ' 11' ' ' VAL . 3.9 m -94.91 120.98 36.03 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.894 HG22 HG13 ' B' ' 66' ' ' ILE . 1.6 pt -115.09 147.45 18.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 121.168 -0.958 . . . . 0.0 110.061 -179.201 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 4.1 ttmt -106.9 101.18 10.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.403 -0.811 . . . . 0.0 109.709 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.87 HG23 ' CG2' ' B' ' 62' ' ' ILE . 39.2 mt -117.86 140.28 41.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.464 ' HA3' HD12 ' B' ' 38' ' ' LEU . . . 50.47 55.08 18.02 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 34.68 5.38 Favored Glycine 0 N--CA 1.494 2.508 0 O-C-N 121.306 -1.114 . . . . 0.0 110.428 179.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm100 -132.54 171.71 13.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.059 -1.26 . . . . 0.0 108.807 179.249 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.475 ' HA ' HD23 ' B' ' 19' ' ' LEU . 13.7 mt -135.5 119.11 17.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.121 -0.987 . . . . 0.0 109.964 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.478 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -135.62 178.12 7.29 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.682 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.572 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.6 mp0 -78.73 -176.06 4.73 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 179.038 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.823 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -164.82 105.07 0.81 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.786 -1.196 . . . . 0.0 110.627 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.658 HD11 ' O ' ' A' ' 27' ' ' GLY . 0.2 OUTLIER -79.9 90.04 5.31 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 108.793 179.227 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 75.7 mt -43.63 98.54 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.821 ' HB2' HG23 ' B' ' 84' ' ' ILE . 56.9 t0 -100.28 94.13 6.04 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.51 -0.744 . . . . 0.0 111.131 -178.348 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.676 ' OG1' HD21 ' A' ' 97' ' ' LEU . 16.8 m -67.56 -15.22 63.54 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.968 -1.083 . . . . 0.0 108.339 178.187 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.494 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -71.76 -40.8 57.67 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.83 149.91 29.36 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.963 -1.316 . . . . 0.0 109.662 -179.649 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.504 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 1.8 m-20 -92.01 -8.28 46.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.323 -0.861 . . . . 0.0 110.021 -179.471 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -129.52 178.3 6.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.105 -0.997 . . . . 0.0 109.943 -179.335 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.785 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.5 m -108.42 83.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.75 -1.219 . . . . 0.0 109.677 -179.515 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.023 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -70.31 157.34 6.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.044 179.667 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.082 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.8 OUTLIER -153.51 133.67 13.36 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.572 -178.007 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.537 ' N ' HG23 ' B' ' 80' ' ' THR . 3.1 tt0 -50.98 153.45 1.82 Allowed 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.868 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' B' ' 34' ' ' GLU . 3.3 tt0 -35.12 142.81 0.05 Allowed 'General case' 0 N--CA 1.495 1.812 0 CA-C-O 121.477 0.656 . . . . 0.0 110.78 -179.634 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.652 ' SD ' HD13 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -155.76 -170.38 3.4 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.403 -0.81 . . . . 0.0 109.099 179.429 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.5 t -109.68 66.4 0.63 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 111.157 -178.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.742 HD23 ' CG ' ' B' ' 59' ' ' TYR . 1.2 tp -87.24 158.31 52.49 Favored Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.636 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 32.1 Cg_endo -77.24 -155.37 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.927 1.751 . . . . 0.0 110.228 -179.484 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.514 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -84.47 -148.04 8.98 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.345 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.514 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.7 mmp_? 65.41 57.06 0.92 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 122.054 -0.674 . . . . 0.0 109.234 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.668 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.8 p-90 -147.15 -176.57 5.27 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.863 0.839 . . . . 0.0 110.466 -179.67 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -148.13 139.32 13.61 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.092 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.43 136.61 15.89 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.281 1.987 . . . . 0.0 111.016 -178.889 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -160.76 -163.0 0.99 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.578 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.549 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 57.7 mtp -151.13 129.24 11.84 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.111 179.642 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.698 HD11 HD11 ' B' ' 54' ' ' ILE . 4.5 pt -91.64 144.41 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 118.356 -1.338 . . . . 0.0 107.999 178.771 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.565 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -117.44 107.43 1.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -178.923 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.23 -126.8 2.72 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.534 -1.317 . . . . 0.0 110.74 -179.138 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.564 HG21 HD12 ' A' ' 47' ' ' ILE . 56.0 mt -85.87 134.56 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.851 -0.793 . . . . 0.0 113.045 -177.402 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.415 ' N ' HG23 ' A' ' 54' ' ' ILE . . . 88.03 -15.89 53.82 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.019 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.22 -160.06 27.16 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.264 179.55 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 2.9 m-85 -114.91 138.48 50.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.519 -0.989 . . . . 0.0 109.782 -179.541 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.711 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -116.19 149.92 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.549 ' HG3' ' CE ' ' B' ' 46' ' ' MET . 3.2 mttm -85.26 136.52 33.47 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.339 -0.851 . . . . 0.0 108.936 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.483 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.4 m -142.74 -164.81 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 O-C-N 120.957 -1.09 . . . . 0.0 110.245 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 56' ' ' VAL . 4.9 mtt180 -147.46 111.34 5.06 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.736 ' NE2' HG21 ' B' ' 74' ' ' THR . 0.4 OUTLIER -74.69 124.81 27.42 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.059 -1.025 . . . . 0.0 110.413 -179.151 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.742 ' CG ' HD23 ' B' ' 38' ' ' LEU . 17.9 m-85 -112.89 109.39 18.8 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.568 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.7 m-20 -88.51 128.14 35.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.079 -1.013 . . . . 0.0 110.505 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.581 ' HA ' HG23 ' B' ' 72' ' ' ILE . 8.2 mm-40 89.86 61.95 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 CA-C-O 121.216 0.531 . . . . 0.0 110.598 179.266 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.87 ' CG2' HG23 ' B' ' 15' ' ' ILE . 24.0 mm -119.04 106.73 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 108.878 178.927 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.805 ' N ' HD13 ' B' ' 72' ' ' ILE . 1.0 OUTLIER -61.29 92.57 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.172 -0.955 . . . . 0.0 110.129 -178.884 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.832 ' CG2' HD11 ' B' ' 89' ' ' LEU . 2.6 tt -97.38 117.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.53 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 16.4 tt0 -89.16 121.11 31.16 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.84 -1.162 . . . . 0.0 109.486 -179.127 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.894 HG13 HG22 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -108.87 135.7 46.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.132 -0.98 . . . . 0.0 108.789 179.769 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.63 -92.4 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.734 -0.604 . . . . 0.0 109.492 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -141.82 54.59 0.61 Allowed Glycine 0 N--CA 1.485 1.908 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.503 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 38.1 m-70 -154.24 151.82 29.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -1.131 . . . . 0.0 109.986 -179.544 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.75 139.52 30.46 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 179.086 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.685 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.52 97.68 2.42 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 110.817 -179.075 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.805 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.48 139.65 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 178.19 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -164.1 -159.01 10.51 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 118.659 -1.734 . . . . 0.0 111.421 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.736 HG21 ' NE2' ' B' ' 58' ' ' GLN . 18.7 m -106.7 108.74 20.41 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.654 -0.909 . . . . 0.0 110.852 -178.74 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.082 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -104.43 127.82 58.46 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.503 -0.748 . . . . 0.0 111.415 -179.879 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.742 ' HB2' HG23 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -84.84 141.3 30.55 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.728 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.62 115.96 46.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 121.003 -1.061 . . . . 0.0 108.667 178.716 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -162.04 -158.12 9.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -81.71 41.57 1.16 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.746 2.297 . . . . 0.0 110.471 179.868 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.537 HG23 ' N ' ' B' ' 34' ' ' GLU . 9.3 t -89.76 133.23 34.53 Favored Pre-proline 0 C--N 1.301 -1.54 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.347 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.618 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.8 Cg_endo -80.15 22.94 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.479 2.119 . . . . 0.0 111.432 -178.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.618 HG23 ' O ' ' B' ' 81' ' ' PRO . 55.2 t -160.22 153.67 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.498 -1.376 . . . . 0.0 111.888 -178.671 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 76.0 m-20 -93.98 77.57 4.13 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 176.041 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.821 HG23 ' HB2' ' B' ' 25' ' ' ASP . 53.6 mt -79.71 119.59 29.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.561 0.695 . . . . 0.0 112.601 -175.556 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.521 HD13 ' N ' ' B' ' 85' ' ' ILE . 4.0 mm -95.48 104.57 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.181 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.748 ' C ' HD13 ' B' ' 90' ' ' LEU . . . -99.83 163.16 19.42 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.001 -179.38 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.645 ' N ' HD13 ' B' ' 90' ' ' LEU . 0.0 OUTLIER -25.74 -37.45 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -178.829 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.931 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -46.52 -42.11 15.19 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.021 -1.674 . . . . 0.0 110.113 -178.629 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.931 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -93.76 -17.58 23.0 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.276 -0.89 . . . . 0.0 110.116 -179.514 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.748 HD13 ' C ' ' B' ' 86' ' ' GLY . 5.9 mp -69.55 -35.36 75.35 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.019 -1.073 . . . . 0.0 109.21 -179.548 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 72.3 p -70.99 -6.94 42.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.007 -1.058 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.703 ' OE1' HD22 ' B' ' 89' ' ' LEU . 8.3 mt-30 -100.01 -40.6 7.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.34 -0.85 . . . . 0.0 109.463 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.748 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -82.87 3.56 2.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.203 -0.936 . . . . 0.0 108.817 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.7 42.41 97.22 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.534 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.38 138.18 39.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.945 -1.327 . . . . 0.0 109.697 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 71.1 p -130.61 123.64 29.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 108.646 179.064 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -84.84 86.97 7.3 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.658 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 7.4 m120 -97.81 132.19 43.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.456 -0.777 . . . . 0.0 110.492 -178.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.686 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.287 178.664 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.581 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.497 1.704 0 N-CA-C 110.316 -0.686 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.442 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 2.1 tt0 -84.05 138.41 33.09 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 178.136 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' A' ' 9' ' ' PRO . 4.4 t -132.55 134.45 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.722 -1.236 . . . . 0.0 110.441 -178.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.832 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -143.3 -82.66 0.17 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.41 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.559 ' O ' ' C ' ' A' ' 6' ' ' TRP . 9.5 mt 34.41 32.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.895 -0.503 . . . . 0.0 110.719 178.896 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.559 ' C ' ' O ' ' A' ' 5' ' ' LEU . 44.2 m0 17.87 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.35 0 CA-C-O 121.393 0.616 . . . . 0.0 111.18 -179.875 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.553 ' HA ' ' NH1' ' B' ' 87' ' ' ARG . 2.3 mt-30 -144.56 -168.65 2.96 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.486 -0.759 . . . . 0.0 109.489 -179.329 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.0 mtt180 -81.22 122.37 81.3 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.337 -0.852 . . . . 0.0 108.917 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.1 Cg_endo -77.94 69.9 7.26 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.146 1.897 . . . . 0.0 109.88 179.373 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.71 145.82 29.38 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.264 -0.898 . . . . 0.0 109.482 -179.678 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' HG23 ' A' ' 11' ' ' VAL . 6.1 m -138.89 127.63 29.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.648 -179.68 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.876 HG22 HD23 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -62.83 103.29 0.42 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 178.354 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.765 HD11 HD21 ' A' ' 33' ' ' LEU . 11.5 pt -89.83 139.19 17.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.003 -1.061 . . . . 0.0 110.114 -178.458 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.773 ' HE2' HD11 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -108.54 96.69 6.52 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.171 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.894 ' CD1' HG11 ' A' ' 75' ' ' VAL . 24.4 mt -113.18 119.87 61.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.361 -0.837 . . . . 0.0 109.537 -179.012 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD12 ' A' ' 38' ' ' LEU . . . 69.7 28.97 71.5 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -179.391 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.22 3.86 62.3 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 -179.197 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.524 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.59 161.92 15.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.307 -1.113 . . . . 0.0 108.891 179.675 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.876 HD23 HG22 ' A' ' 12' ' ' THR . 0.1 OUTLIER -133.31 125.51 29.39 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.98 -179.394 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.5 mtmt -151.51 162.88 40.19 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -78.95 136.27 37.2 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 108.249 179.591 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.707 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -114.0 152.86 30.31 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.986 -1.071 . . . . 0.0 109.886 -179.313 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.495 ' O ' ' N ' ' A' ' 25' ' ' ASP . 38.6 tp -109.47 88.77 2.82 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.646 -0.659 . . . . 0.0 109.651 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.644 HD12 ' HB2' ' A' ' 9' ' ' PRO . 13.8 mt -43.1 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 179.526 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.645 ' HB3' HG22 ' A' ' 84' ' ' ILE . 9.9 t0 -109.9 97.58 7.07 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.427 -0.795 . . . . 0.0 110.982 -177.68 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.563 HG23 ' NH2' ' A' ' 87' ' ' ARG . 10.7 m -73.13 -6.54 46.43 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.329 -0.857 . . . . 0.0 109.114 178.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.567 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -79.96 -29.02 48.34 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -89.66 162.89 15.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.922 -1.34 . . . . 0.0 109.659 -179.688 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.7 OUTLIER -100.61 -8.39 23.01 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.231 -0.918 . . . . 0.0 110.729 -178.974 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.525 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.54 -177.69 4.78 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.075 -1.016 . . . . 0.0 109.442 -179.712 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.585 HG23 HD12 ' A' ' 85' ' ' ILE . 21.0 m -108.8 88.86 2.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.974 -1.079 . . . . 0.0 110.126 -179.196 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.12 174.02 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.098 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.05 119.46 1.29 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.823 -1.173 . . . . 0.0 111.694 -178.597 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.562 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 2.5 mt-10 -36.02 154.68 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.185 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -47.6 137.47 9.08 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.922 -1.111 . . . . 0.0 109.739 -179.871 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.72 164.94 28.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.326 -0.859 . . . . 0.0 109.407 179.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 10.9 t -90.14 104.21 16.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.223 -0.923 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.846 HD13 HG22 ' A' ' 15' ' ' ILE . 48.3 tp -122.08 118.58 29.09 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.236 -0.915 . . . . 0.0 109.304 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.4 Cg_endo -77.99 120.27 4.97 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.401 2.068 . . . . 0.0 110.641 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.25 -177.75 33.95 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 179.839 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.06 144.73 28.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -1.224 . . . . 0.0 108.716 179.521 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.577 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 21.5 p-90 -138.62 156.27 47.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.176 -0.953 . . . . 0.0 110.295 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 14.2 mtpt -121.35 136.39 25.8 Favored Pre-proline 0 N--CA 1.488 1.469 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.69 129.28 9.92 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 122.263 1.975 . . . . 0.0 111.196 -178.853 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.8 ptmm? -164.17 152.4 12.83 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.324 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.545 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -118.25 146.77 44.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.527 -1.358 . . . . 0.0 109.856 179.315 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.752 ' CD1' HG21 ' B' ' 50' ' ' ILE . 15.5 pt -102.6 149.56 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.37 -0.831 . . . . 0.0 109.077 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.89 111.52 2.12 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.331 -1.908 . . . . 0.0 108.331 179.832 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.89 -117.23 1.71 Allowed Glycine 0 N--CA 1.484 1.85 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.687 -178.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.507 ' O ' ' O ' ' B' ' 50' ' ' ILE . 8.2 mt -91.01 130.17 40.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.78 -0.835 . . . . 0.0 112.542 -177.564 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.632 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 89.76 -23.27 20.76 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.021 177.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.84 -163.19 29.63 Favored Glycine 0 N--CA 1.491 2.347 0 O-C-N 120.744 -1.445 . . . . 0.0 110.375 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.604 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.1 m-85 -109.68 132.13 54.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.514 -0.992 . . . . 0.0 109.245 -179.639 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.784 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.1 pp -107.07 177.86 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.026 -1.046 . . . . 0.0 109.472 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 11.1 mmtt -112.49 138.99 48.45 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.206 -0.934 . . . . 0.0 109.45 179.231 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.815 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.6 m -146.66 -174.9 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.908 . . . . 0.0 109.687 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.519 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 3.8 mtt85 -122.83 178.19 5.14 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.445 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 26.0 tt0 -135.97 101.57 4.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.131 -0.98 . . . . 0.0 110.827 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.703 ' CG ' HD23 ' A' ' 38' ' ' LEU . 61.7 m-85 -94.49 106.38 18.36 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.613 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 67.8 m-20 -88.28 123.27 32.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.124 -0.985 . . . . 0.0 110.576 -178.745 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.532 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 63.7 mm-40 86.06 59.98 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.635 0.731 . . . . 0.0 110.072 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.81 HG21 HG23 ' A' ' 15' ' ' ILE . 31.4 mm -115.84 121.9 68.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.777 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 ' HG2' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -73.78 88.18 1.76 Allowed 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.725 -1.19 . . . . 0.0 110.966 -178.311 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.694 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -85.82 117.4 30.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 177.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 3.6 tt0 -87.08 117.96 26.16 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.054 -1.029 . . . . 0.0 109.111 -178.495 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.694 HD11 HD13 ' A' ' 64' ' ' ILE . 1.0 OUTLIER -110.43 123.9 66.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.792 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.55 36.1 4.96 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.541 -0.724 . . . . 0.0 110.039 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.52 34.24 50.43 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 70' ' ' LYS . 31.9 m-70 -122.1 91.74 3.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.03 -1.277 . . . . 0.0 109.448 179.696 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 1.009 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -44.74 102.82 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.616 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.492 ' N ' HD11 ' A' ' 63' ' ' LEU . . . -127.24 132.88 50.3 Favored 'General case' 0 C--N 1.287 -2.109 0 O-C-N 121.804 -0.56 . . . . 0.0 109.806 -179.151 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.537 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -108.17 152.21 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.867 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.542 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -176.41 -166.47 33.67 Favored Glycine 0 N--CA 1.487 2.045 0 C-N-CA 118.667 -1.73 . . . . 0.0 111.15 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.505 HG23 ' OD1' ' A' ' 60' ' ' ASP . 20.4 m -98.77 107.01 19.35 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.49 -1.006 . . . . 0.0 109.381 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.098 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.2 OUTLIER -103.52 119.49 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.335 -0.853 . . . . 0.0 110.402 -179.546 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.0 mp -88.63 142.87 27.33 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.332 -0.855 . . . . 0.0 108.906 178.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.556 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.9 t -126.8 118.65 51.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.398 -0.814 . . . . 0.0 109.875 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.815 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.01 13.05 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.69 41.75 1.17 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 C-N-CA 122.416 2.077 . . . . 0.0 110.015 179.803 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.562 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.1 t -82.45 140.16 44.83 Favored Pre-proline 0 C--N 1.305 -1.347 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.062 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.435 ' C ' ' OE2' ' A' ' 34' ' ' GLU . 32.2 Cg_endo -76.22 10.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.177 1.918 . . . . 0.0 111.438 -178.873 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.72 HG12 HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.19 168.02 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.882 -1.136 . . . . 0.0 109.653 179.828 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -102.72 145.78 29.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 176.707 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.722 ' C ' HD13 ' A' ' 85' ' ' ILE . 3.5 mm -130.24 126.07 60.86 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 120.726 -1.234 . . . . 0.0 111.212 -177.536 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.85 HD13 ' N ' ' A' ' 85' ' ' ILE . 0.6 OUTLIER -101.47 92.18 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.446 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -81.34 -163.25 30.56 Favored Glycine 0 N--CA 1.496 2.693 0 O-C-N 121.241 -0.912 . . . . 0.0 111.995 -177.242 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.563 ' NH2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -60.82 -40.0 91.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.979 -0.718 . . . . 0.0 110.442 -179.283 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.052 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.0 p-10 -43.61 -31.1 0.69 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.274 -0.891 . . . . 0.0 109.298 -179.66 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.052 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -105.45 -26.02 12.11 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.168 -0.958 . . . . 0.0 109.998 -179.764 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 97.3 mt -71.1 -5.42 31.44 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.926 -1.109 . . . . 0.0 108.211 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -100.42 -15.21 18.02 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.691 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.2 mm-40 -86.12 -40.82 15.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.623 -0.673 . . . . 0.0 109.569 179.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.955 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -85.06 -5.18 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.175 -0.953 . . . . 0.0 108.982 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.93 49.93 15.16 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 178.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.571 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -83.44 149.5 26.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.008 -1.29 . . . . 0.0 110.557 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 25.6 p -140.28 126.1 19.4 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -85.98 96.53 9.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.843 -179.225 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.553 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 2.6 m120 -101.13 126.8 47.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.219 -0.926 . . . . 0.0 109.441 179.694 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.803 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.039 -0.981 . . . . 0.0 109.446 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.537 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.494 1.552 0 N-CA-C 109.873 -0.857 . . . . 0.0 109.873 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.553 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.0 tt0 -83.64 137.64 33.71 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.432 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' B' ' 5' ' ' LEU . 8.4 t -133.68 114.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 118.565 -1.254 . . . . 0.0 110.501 -178.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.591 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -101.01 3.78 41.8 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 177.468 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.52 ' HB2' ' CG1' ' B' ' 3' ' ' VAL . 0.8 OUTLIER -21.66 83.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.654 0.74 . . . . 0.0 111.06 -179.438 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.591 ' N ' ' O ' ' B' ' 4' ' ' THR . 7.8 m95 -46.1 -21.05 0.12 Allowed 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.513 -0.742 . . . . 0.0 109.103 179.618 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.451 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -107.9 -165.51 1.05 Allowed 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.644 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.451 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.4 OUTLIER -66.68 125.49 90.72 Favored Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 120.919 -1.113 . . . . 0.0 109.65 -179.615 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.742 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.7 Cg_endo -77.49 75.72 4.57 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 122.035 1.823 . . . . 0.0 109.899 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.73 146.05 32.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.16 -0.963 . . . . 0.0 109.483 -179.69 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.551 ' CG1' HD11 ' B' ' 24' ' ' LEU . 5.5 m -131.02 148.71 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.82 -179.506 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.711 HG22 HD22 ' B' ' 19' ' ' LEU . 73.7 m -83.22 117.26 22.81 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 178.234 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 2.0 pp -112.62 131.35 64.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 121.117 -0.99 . . . . 0.0 110.739 -177.893 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.488 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -99.73 110.83 23.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.21 -0.931 . . . . 0.0 108.678 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.779 HD13 HG11 ' B' ' 75' ' ' VAL . 9.3 mt -116.67 141.79 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.043 . . . . 0.0 109.529 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.54 -97.69 0.07 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -148.38 39.6 0.97 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 179.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.414 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 44.5 mm-40 -140.52 -175.23 4.2 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.528 -0.984 . . . . 0.0 109.617 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.711 HD22 HG22 ' B' ' 12' ' ' THR . 6.8 mt -150.79 129.67 12.48 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.723 0.773 . . . . 0.0 110.621 -178.916 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.513 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 2.3 mptp? -148.03 168.34 22.59 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.321 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.8 mt-10 -79.11 172.84 13.24 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.655 -1.278 . . . . 0.0 109.129 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.568 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -149.51 106.14 3.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.343 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.567 HD21 ' O ' ' A' ' 27' ' ' GLY . 28.0 tp -64.06 99.42 0.26 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.552 -0.717 . . . . 0.0 110.006 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.742 HD12 ' HB2' ' B' ' 9' ' ' PRO . 44.4 mt -52.28 111.35 0.61 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.985 -1.072 . . . . 0.0 108.658 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.836 ' HB3' HG23 ' B' ' 84' ' ' ILE . 49.4 t0 -124.29 90.0 3.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 110.785 -178.554 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.58 ' HA ' HD12 ' B' ' 90' ' ' LEU . 3.0 m -63.96 -14.68 55.74 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.676 -1.265 . . . . 0.0 108.676 178.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -64.69 -46.93 88.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.05 158.97 35.58 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.899 -1.354 . . . . 0.0 108.802 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -92.12 -13.37 30.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.086 -1.009 . . . . 0.0 110.791 -178.621 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.564 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.7 OUTLIER -139.35 -173.87 3.72 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.783 -1.198 . . . . 0.0 110.041 -179.661 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.732 HG22 ' CD1' ' B' ' 33' ' ' LEU . 3.7 m -102.21 88.81 3.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.915 -1.115 . . . . 0.0 110.294 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.92 162.44 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.804 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.0 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -158.78 126.6 5.07 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.938 -1.101 . . . . 0.0 110.719 -178.397 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' B' ' 33' ' ' LEU . 4.3 tt0 -40.68 161.25 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.826 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.543 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.6 tt0 -50.54 146.14 5.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.195 -0.94 . . . . 0.0 110.133 -179.543 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.526 ' HE1' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -174.98 160.67 2.84 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.385 -0.822 . . . . 0.0 108.805 179.553 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.0 t -79.51 97.63 6.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.877 -1.139 . . . . 0.0 109.286 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.576 HD21 ' CG2' ' B' ' 15' ' ' ILE . 0.8 OUTLIER -107.21 107.59 60.67 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.69 -179.66 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 129.04 10.1 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.517 2.145 . . . . 0.0 110.521 179.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 147.13 -165.41 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 -95.55 124.95 39.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.278 -1.131 . . . . 0.0 108.831 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.601 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 56.8 p-90 -128.77 172.25 11.45 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.171 -0.956 . . . . 0.0 110.309 -179.197 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.1 mptt -140.07 137.75 18.54 Favored Pre-proline 0 C--N 1.3 -1.573 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.653 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -76.28 134.96 16.27 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.858 1.705 . . . . 0.0 110.299 -179.257 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.464 ' CG ' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -153.7 -177.11 6.16 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.656 -0.818 . . . . 0.0 109.823 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -138.28 115.19 10.79 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 109.192 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 54' ' ' ILE . 31.6 pt -94.49 130.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 C-N-CA 118.772 -1.171 . . . . 0.0 108.351 178.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.421 ' HA2' ' HA ' ' B' ' 53' ' ' PHE . . . -117.02 103.73 1.13 Allowed Glycine 0 N--CA 1.486 2.001 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.337 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.04 -118.45 2.44 Favored Glycine 0 N--CA 1.483 1.816 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.367 -178.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.752 HG21 ' CD1' ' A' ' 47' ' ' ILE . 15.6 mt -91.8 115.56 31.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.852 -0.793 . . . . 0.0 112.138 -177.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.605 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 112.34 -40.14 2.63 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.399 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 163.88 -162.77 35.39 Favored Glycine 0 N--CA 1.491 2.365 0 O-C-N 120.846 -1.385 . . . . 0.0 110.161 179.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.7 OUTLIER -112.55 127.64 56.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.456 -1.026 . . . . 0.0 109.732 -179.872 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 47' ' ' ILE . 4.7 pt -109.81 169.18 3.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.195 -0.94 . . . . 0.0 108.657 178.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.535 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mttt -109.82 132.44 54.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.03 -1.044 . . . . 0.0 108.9 179.6 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.782 HG12 ' HA3' ' B' ' 78' ' ' GLY . 3.1 m -130.96 -172.45 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 110.495 -179.281 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.427 ' HG3' ' C ' ' B' ' 56' ' ' VAL . 5.6 mtp180 -134.97 85.23 2.16 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.523 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -52.73 100.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.6 -0.688 . . . . 0.0 110.901 -179.077 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.601 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 14.6 m-85 -90.28 123.07 33.75 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.498 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.0 OUTLIER -100.68 141.0 34.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.792 -1.193 . . . . 0.0 110.121 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.763 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 72.08 65.61 0.13 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.441 0.638 . . . . 0.0 109.495 179.783 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.665 ' C ' HD13 ' B' ' 72' ' ' ILE . 27.8 mm -119.26 116.15 49.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.481 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.835 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.1 tm? -68.94 83.22 0.31 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.454 -0.779 . . . . 0.0 110.582 -178.502 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.879 HG12 HD12 ' B' ' 66' ' ' ILE . 7.9 tt -88.16 125.1 41.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.493 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.446 ' OE2' ' HE3' ' B' ' 70' ' ' LYS . 4.0 tt0 -91.71 110.01 21.34 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.935 -1.103 . . . . 0.0 109.768 -178.409 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.879 HD12 HG12 ' B' ' 64' ' ' ILE . 0.3 OUTLIER -109.97 122.59 64.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.237 -0.914 . . . . 0.0 108.827 179.65 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.425 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 33.7 m 52.05 62.66 2.59 Favored 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.644 -0.66 . . . . 0.0 110.378 179.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 47.81 25.21 3.43 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.16 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 79.2 m-70 -118.29 117.43 29.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.089 -1.242 . . . . 0.0 109.101 179.39 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.446 ' HE3' ' OE2' ' B' ' 65' ' ' GLU . 0.0 OUTLIER -67.94 133.16 48.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.137 -0.977 . . . . 0.0 108.968 179.725 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.693 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -149.26 139.19 21.99 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.371 -0.831 . . . . 0.0 110.168 -179.335 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.763 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -110.31 140.8 27.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 177.679 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.49 -168.93 28.42 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.058 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 26.2 m -99.15 106.42 18.6 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.653 -0.91 . . . . 0.0 110.551 -179.185 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.0 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.7 t -100.68 108.89 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.47 -0.769 . . . . 0.0 110.813 179.3 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.662 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 5.2 mp -79.2 134.29 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.562 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.0 OUTLIER -118.39 118.44 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.109 -0.995 . . . . 0.0 109.448 -179.502 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.782 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.71 -167.16 16.78 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.535 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -79.54 40.13 0.91 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.689 2.259 . . . . 0.0 111.295 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.837 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.45 142.97 33.51 Favored Pre-proline 0 C--N 1.302 -1.466 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.948 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.637 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.9 Cg_endo -79.86 17.56 1.28 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 C-N-CA 122.516 2.144 . . . . 0.0 112.246 -178.427 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.837 ' H ' HG23 ' B' ' 80' ' ' THR . 1.4 t -162.41 157.25 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.425 -1.422 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.581 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 2.1 m-20 -99.34 103.16 14.95 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.447 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.836 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.3 mt -104.18 131.31 53.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.723 -1.236 . . . . 0.0 112.607 -176.085 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.577 HD13 ' N ' ' B' ' 85' ' ' ILE . 2.3 mm -95.35 107.72 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 177.887 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -88.99 -154.58 29.09 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 120.787 -1.196 . . . . 0.0 111.142 -178.374 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 7' ' ' GLN . 5.5 mtm180 -64.67 -40.09 94.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.832 -0.805 . . . . 0.0 109.911 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.984 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.9 p-10 -45.15 -38.08 4.93 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.175 -0.953 . . . . 0.0 110.395 -179.073 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.984 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.0 mm? -96.75 -27.7 14.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.817 -1.177 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.58 HD12 ' HA ' ' B' ' 26' ' ' THR . 53.9 mt -71.22 -5.79 34.68 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 178.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 17.3 p -100.97 -10.93 20.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.226 -0.921 . . . . 0.0 108.696 178.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.722 ' OE1' HD22 ' B' ' 89' ' ' LEU . 13.9 mt-30 -91.89 -41.06 10.81 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.196 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.803 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -85.74 2.41 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.29 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.28 51.49 52.18 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.783 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.7 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -78.73 142.32 37.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.154 -1.204 . . . . 0.0 110.184 179.746 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.832 HG22 ' CG2' ' A' ' 4' ' ' THR . 27.6 p -137.96 130.55 29.52 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.487 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' A' ' 97' ' ' LEU . 6.5 mp -91.21 94.08 9.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.339 -0.851 . . . . 0.0 110.035 -179.171 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.537 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.0 m120 -97.59 120.38 37.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.057 -1.027 . . . . 0.0 109.343 179.379 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.955 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.054 179.666 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.428 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 2.6 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 N-CA-C 109.622 -0.953 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.543 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 14.4 tt0 -84.3 139.71 32.13 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 178.408 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 1.114 HG13 HD23 ' A' ' 5' ' ' LEU . 87.7 t -143.79 117.46 3.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.385 -1.326 . . . . 0.0 110.583 -178.532 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.634 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -98.54 -34.25 10.67 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 177.941 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 1.114 HD23 HG13 ' A' ' 3' ' ' VAL . 1.3 mm? 22.36 74.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.289 179.413 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.634 ' CE3' HG21 ' B' ' 91' ' ' THR . 41.3 m95 -41.56 -20.62 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.751 -0.593 . . . . 0.0 110.329 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 58.9 mt-30 -108.57 -105.1 0.36 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.607 -1.308 . . . . 0.0 109.282 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 8.9 mtt-85 -110.98 132.57 21.6 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 120.654 -1.279 . . . . 0.0 110.215 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.3 Cg_endo -78.92 66.34 8.73 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.336 2.024 . . . . 0.0 109.867 178.25 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -80.03 152.06 29.62 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.983 -1.073 . . . . 0.0 109.975 -179.32 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.638 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -142.09 170.9 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.382 -0.824 . . . . 0.0 109.404 -179.587 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.665 HG22 HD22 ' A' ' 19' ' ' LEU . 4.3 m -101.04 92.29 4.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 178.238 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.553 ' HA ' ' O ' ' A' ' 65' ' ' GLU . 22.1 pt -86.08 142.1 13.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.263 -0.898 . . . . 0.0 110.17 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 6.9 ttmt -114.77 99.31 7.4 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.409 -0.807 . . . . 0.0 109.499 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.759 HG22 ' CG2' ' A' ' 62' ' ' ILE . 0.2 OUTLIER -116.15 158.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.065 -1.022 . . . . 0.0 109.427 179.829 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 34.86 50.72 0.8 Allowed Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 50.95 52.49 30.49 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.797 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.543 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -152.1 172.49 16.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.459 -1.024 . . . . 0.0 108.493 179.574 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.665 HD22 HG22 ' A' ' 12' ' ' THR . 26.6 mt -141.96 132.03 24.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.08 -1.013 . . . . 0.0 110.549 -179.303 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 12.5 mmmt -150.68 162.52 40.54 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.714 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.4 mm-40 -79.25 141.54 37.01 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.942 -1.099 . . . . 0.0 108.19 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.664 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -124.05 131.72 53.59 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.992 -1.068 . . . . 0.0 110.21 -178.682 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.516 HD21 ' O ' ' B' ' 27' ' ' GLY . 25.2 tp -91.15 97.94 11.45 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.69 -0.631 . . . . 0.0 109.783 -179.774 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.547 HD13 HD21 ' A' ' 90' ' ' LEU . 0.2 OUTLIER -45.97 115.16 0.91 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.397 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' HB3' HG22 ' A' ' 84' ' ' ILE . 14.9 t0 -125.7 84.4 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.331 -0.856 . . . . 0.0 111.021 -177.536 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' CD1' ' A' ' 90' ' ' LEU . 0.2 OUTLIER -62.68 -11.91 20.17 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.005 -1.059 . . . . 0.0 109.159 178.742 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.0 -41.52 54.52 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.28 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.508 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -71.23 168.8 16.51 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -1.214 . . . . 0.0 109.709 -179.4 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -100.74 -20.81 15.41 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.204 -0.935 . . . . 0.0 110.176 -179.444 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.576 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.32 -164.99 1.56 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.068 -1.02 . . . . 0.0 109.548 -179.61 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 30.1 m -112.64 90.86 3.46 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.738 -1.226 . . . . 0.0 110.575 -179.034 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.071 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.52 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.053 -1.029 . . . . 0.0 108.826 179.536 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.126 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.81 121.41 1.29 Allowed 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.099 -1.001 . . . . 0.0 111.019 -178.849 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.496 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.6 OUTLIER -38.46 152.9 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.432 -0.792 . . . . 0.0 109.663 178.842 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 77' ' ' VAL . 2.6 mt-10 -46.07 141.61 3.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 110.459 -179.279 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.498 ' CE ' HD13 ' A' ' 15' ' ' ILE . 6.0 ptm -158.21 -177.21 6.39 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.348 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -101.09 101.7 12.5 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.069 -1.02 . . . . 0.0 109.903 -179.498 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 1.001 HD12 HG21 ' A' ' 77' ' ' VAL . 32.5 mt -106.72 162.43 19.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.062 -1.024 . . . . 0.0 109.971 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.9 Cg_endo -78.23 65.85 8.41 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.895 2.397 . . . . 0.0 112.082 -179.219 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 37.36 -160.67 0.01 OUTLIER Glycine 0 N--CA 1.499 2.846 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 178.74 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.49 59.94 0.61 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.354 -1.086 . . . . 0.0 109.486 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.588 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 64.1 p-90 -148.7 168.67 22.27 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.626 0.727 . . . . 0.0 110.115 -179.556 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.1 136.35 28.69 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.04 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.0 139.1 17.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.222 1.948 . . . . 0.0 110.872 -179.272 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HE2' ' HB2' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -153.42 -165.61 2.2 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.264 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.491 ' HG3' ' HG3' ' A' ' 55' ' ' LYS . 5.4 ttt -144.71 126.57 15.34 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.951 -1.093 . . . . 0.0 110.163 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.684 HD12 HG21 ' B' ' 50' ' ' ILE . 24.8 pt -96.1 133.65 36.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.67 101.0 0.89 Allowed Glycine 0 N--CA 1.486 1.999 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.53 -117.46 2.49 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.65 -178.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.699 HG21 HD12 ' B' ' 47' ' ' ILE . 12.8 mt -88.94 122.85 40.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.729 -0.865 . . . . 0.0 112.506 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.44 -51.53 1.01 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 178.213 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.86 -159.98 24.6 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.228 -1.463 . . . . 0.0 110.748 -179.604 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.612 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.2 m-85 -113.33 129.38 56.55 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.55 -0.971 . . . . 0.0 109.95 -179.254 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.525 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.9 pt -109.94 152.98 11.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.214 -0.929 . . . . 0.0 108.701 178.895 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.6 mtpt -93.84 123.39 37.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.11 -0.994 . . . . 0.0 109.508 -179.577 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.529 HG12 ' HA3' ' A' ' 78' ' ' GLY . 25.9 m -126.59 -170.08 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.22 -0.925 . . . . 0.0 109.939 -179.529 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.55 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 22.5 mtt180 -124.31 174.42 7.73 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.249 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.452 ' HB2' ' HE2' ' A' ' 45' ' ' LYS . 37.2 tt0 -131.17 98.33 4.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.157 -0.964 . . . . 0.0 109.979 -179.342 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CG ' HD13 ' A' ' 38' ' ' LEU . 64.9 m-85 -97.69 97.59 9.15 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.24 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.624 ' OD1' HG23 ' A' ' 74' ' ' THR . 1.1 m-20 -82.44 139.48 33.96 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 0.0 110.856 -178.601 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.473 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.1 OUTLIER 75.6 60.32 0.05 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.583 -0.698 . . . . 0.0 109.693 179.607 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.839 HG21 HG21 ' A' ' 75' ' ' VAL . 3.5 mm -116.49 122.82 70.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 108.979 -179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.93 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.1 tm? -74.7 94.99 2.79 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 111.159 -178.751 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 66' ' ' ILE . 8.2 tt -97.89 121.97 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.553 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 50.0 tt0 -89.67 101.54 14.23 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.01 -1.056 . . . . 0.0 108.86 -179.45 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 2.3 mp -102.68 120.5 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.993 -179.037 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 92.6 m 63.36 34.96 12.62 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.738 -0.601 . . . . 0.0 110.32 179.013 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.79 12.21 80.86 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.24 137.24 44.53 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -1.228 . . . . 0.0 109.255 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.449 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -80.96 123.93 28.72 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 109.094 179.84 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -142.79 155.53 44.83 Favored 'General case' 0 C--N 1.293 -1.852 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.552 -179.759 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.721 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -125.18 149.81 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.005 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.898 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.42 176.24 47.31 Favored Glycine 0 N--CA 1.484 1.859 0 C-N-CA 118.484 -1.817 . . . . 0.0 111.158 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.624 HG23 ' OD1' ' A' ' 60' ' ' ASP . 6.5 m -86.76 108.74 18.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.702 -0.881 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.126 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -98.32 110.5 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.532 -0.73 . . . . 0.0 109.779 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.576 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.9 mp -78.9 139.16 38.35 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 120.997 -1.064 . . . . 0.0 108.356 179.133 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 1.001 HG21 HD12 ' A' ' 38' ' ' LEU . 15.9 t -125.04 114.72 41.55 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.481 -0.762 . . . . 0.0 110.054 -179.287 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.529 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -154.41 -159.67 9.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.664 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.9 Cg_endo -79.83 41.1 1.05 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.659 2.239 . . . . 0.0 111.072 -179.874 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.68 HG21 HG13 ' A' ' 32' ' ' VAL . 1.8 t -87.97 133.03 38.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.666 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -77.15 16.26 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.687 2.258 . . . . 0.0 111.77 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.55 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.45 164.38 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.955 -1.091 . . . . 0.0 109.604 -179.812 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.597 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -100.83 132.88 46.02 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 176.53 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.604 HG22 ' HB3' ' A' ' 25' ' ' ASP . 3.9 mm -119.8 119.98 61.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 O-C-N 120.447 -1.408 . . . . 0.0 111.362 -176.867 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.701 HD13 ' N ' ' A' ' 85' ' ' ILE . 2.0 mm -95.01 89.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.461 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.98 -165.42 29.23 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.962 -1.114 . . . . 0.0 111.46 -177.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 87' ' ' ARG . 1.3 mtp-105 -59.34 -40.66 87.08 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.853 -0.792 . . . . 0.0 110.638 -178.904 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.986 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.9 p-10 -45.4 -24.99 0.35 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.971 -1.081 . . . . 0.0 109.675 -179.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.986 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.1 mm? -110.64 -26.85 9.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.011 -1.056 . . . . 0.0 109.614 -179.298 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.679 ' CD1' HG23 ' A' ' 26' ' ' THR . 65.8 mt -72.09 -6.91 45.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 108.589 179.179 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.481 ' O ' ' CZ2' ' B' ' 6' ' ' TRP . 57.4 p -100.92 -19.17 16.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.041 -1.037 . . . . 0.0 108.252 179.116 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 -84.22 -41.14 17.25 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.8 . . . . 0.0 109.159 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.867 HD12 ' HB3' ' B' ' 99' ' ' PHE . 1.1 pp -80.36 -7.28 10.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.98 59.41 5.94 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.606 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.841 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -86.63 157.97 19.58 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -1.212 . . . . 0.0 110.356 -179.702 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -150.24 126.66 10.78 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.464 -0.772 . . . . 0.0 109.279 179.401 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' B' ' 97' ' ' LEU . 8.6 mp -86.09 111.57 20.46 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.1 m120 -108.73 121.76 45.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.852 -1.155 . . . . 0.0 109.78 179.951 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.692 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.427 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.418 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.066 -0.782 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.9 tt0 -83.4 141.55 31.65 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 178.379 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.466 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 40.6 t -142.66 112.73 2.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 120.565 -1.334 . . . . 0.0 110.694 -178.367 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -124.11 -71.7 0.71 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.713 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.543 ' O ' ' C ' ' B' ' 6' ' ' TRP . 18.5 mt 36.62 31.01 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.737 -0.602 . . . . 0.0 109.866 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.3 m0 17.27 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.144 0 CA-C-O 121.609 0.719 . . . . 0.0 111.404 -179.427 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER -150.55 -165.84 2.38 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.691 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -84.15 115.9 62.34 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.144 -0.973 . . . . 0.0 109.389 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.744 ' HB2' HD12 ' B' ' 24' ' ' LEU . 35.9 Cg_endo -77.29 73.3 5.58 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.391 2.061 . . . . 0.0 110.507 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 1.024 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.6 OUTLIER -79.6 163.47 24.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.157 -0.964 . . . . 0.0 108.786 179.617 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.663 HG23 HG23 ' B' ' 13' ' ' ILE . 4.6 m -144.53 128.01 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.994 -1.066 . . . . 0.0 110.765 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 1.045 HG22 HD22 ' B' ' 19' ' ' LEU . 1.2 m -71.07 87.88 0.77 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.529 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 1.07 HG22 HG13 ' B' ' 66' ' ' ILE . 17.3 pt -85.65 142.57 12.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-O 121.716 0.77 . . . . 0.0 111.58 -177.18 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.511 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 2.8 tttt -103.29 94.21 5.39 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.187 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.616 HG22 ' CE ' ' B' ' 36' ' ' MET . 0.3 OUTLIER -104.28 115.78 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.164 -0.96 . . . . 0.0 110.358 -178.444 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.55 26.37 71.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.28 88.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -96.96 -179.91 4.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -1.19 . . . . 0.0 108.704 179.427 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 1.045 HD22 HG22 ' B' ' 12' ' ' THR . 5.1 mt -148.82 128.25 13.07 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.972 -1.08 . . . . 0.0 110.382 -179.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.498 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 9.9 mttm -151.19 155.58 39.16 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.562 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 1.024 ' HB3' HD23 ' B' ' 10' ' ' LEU . 2.7 mm-40 -78.36 100.72 6.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.15 -0.969 . . . . 0.0 108.519 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 1.085 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -85.26 104.17 14.87 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.261 -0.899 . . . . 0.0 110.698 -178.738 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' B' ' 25' ' ' ASP . 5.4 tp -58.54 103.96 0.19 Allowed 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.445 179.26 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.744 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.3 mt -49.83 96.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.039 -1.038 . . . . 0.0 108.558 179.476 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.92 ' CB ' HG23 ' B' ' 84' ' ' ILE . 15.6 t0 -102.5 91.94 4.45 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.195 -0.94 . . . . 0.0 110.469 -179.075 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.503 HG23 HD13 ' B' ' 90' ' ' LEU . 6.9 m -70.39 -6.37 35.01 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.948 -1.095 . . . . 0.0 108.791 178.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.516 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -77.45 -39.91 24.72 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.39 154.88 34.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.019 -1.283 . . . . 0.0 109.305 -179.691 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -88.47 -17.96 29.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.16 -0.962 . . . . 0.0 110.753 -178.856 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.536 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.78 -170.36 2.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.948 -1.095 . . . . 0.0 110.464 -179.178 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.809 HG23 HD12 ' B' ' 85' ' ' ILE . 65.4 m -109.12 103.78 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.991 -1.068 . . . . 0.0 110.29 -178.634 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 0.943 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -87.82 171.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 108.678 179.417 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.02 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.06 125.57 2.29 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.928 -1.107 . . . . 0.0 110.319 -179.048 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.663 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.3 tt0 -37.8 160.59 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.391 0.615 . . . . 0.0 109.936 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.473 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.4 tt0 -53.6 148.45 9.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 110.46 -179.514 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.616 ' CE ' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -170.71 -166.55 0.51 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.611 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.46 ' N ' ' SD ' ' B' ' 36' ' ' MET . 5.4 t -115.06 76.73 1.01 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.797 -1.189 . . . . 0.0 110.923 -179.171 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.795 HD12 ' CG2' ' B' ' 77' ' ' VAL . 8.0 mt -80.43 173.31 7.91 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.633 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.618 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 29.3 Cg_endo -71.01 -155.63 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 121.776 1.651 . . . . 0.0 111.092 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -103.0 -157.6 25.27 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.046 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.44 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.1 mmm-85 65.72 57.91 0.82 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.511 -0.993 . . . . 0.0 108.809 -179.639 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 52.0 p-90 -135.59 -172.6 3.13 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-O 121.747 0.784 . . . . 0.0 110.282 -179.015 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mptt -148.43 140.85 14.84 Favored Pre-proline 0 N--CA 1.489 1.487 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.126 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.48 135.4 14.72 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.74 1.627 . . . . 0.0 109.856 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.5 ' O ' ' HG2' ' B' ' 46' ' ' MET . 0.0 OUTLIER -158.46 -169.68 2.83 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 109.596 -179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' O ' ' B' ' 45' ' ' LYS . 10.1 mtp -149.26 131.39 15.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 109.097 179.849 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 54' ' ' ILE . 9.3 pt -89.04 140.34 15.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.95 -1.094 . . . . 0.0 108.312 179.271 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.18 111.43 2.17 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 -179.702 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -135.77 -114.29 1.36 Allowed Glycine 0 N--CA 1.481 1.697 0 C-N-CA 119.442 -1.361 . . . . 0.0 111.096 -178.806 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.684 HG21 HD12 ' A' ' 47' ' ' ILE . 11.3 mt -92.64 124.47 45.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.862 -0.787 . . . . 0.0 112.385 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.525 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 94.85 -48.86 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.87 -157.15 20.42 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.66 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.1 OUTLIER -124.21 131.79 53.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.377 -1.072 . . . . 0.0 109.391 179.87 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 47' ' ' ILE . 4.0 pt -99.01 -177.85 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 109.101 179.839 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -108.7 137.17 47.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.955 -1.09 . . . . 0.0 109.471 179.722 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.463 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.0 m -143.78 176.71 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 0.0 109.771 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -127.19 108.64 11.06 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.468 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.6 OUTLIER -66.18 102.43 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.514 -0.741 . . . . 0.0 110.725 -179.085 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.607 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.7 m-85 -97.04 94.13 6.99 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.535 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.1 OUTLIER -79.1 134.31 36.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 0.0 110.093 -178.832 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 9.1 mm100 82.74 60.71 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.943 -0.473 . . . . 0.0 110.558 179.252 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.509 HG13 ' HB3' ' B' ' 59' ' ' TYR . 11.6 mm -124.05 126.72 72.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.994 -1.066 . . . . 0.0 109.202 178.876 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.81 HD22 HG13 ' B' ' 72' ' ' ILE . 0.2 OUTLIER -71.91 95.91 1.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 121.72 0.771 . . . . 0.0 111.799 -178.52 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.551 ' HB ' HD11 ' B' ' 15' ' ' ILE . 3.5 tt -96.08 109.81 23.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 175.765 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.493 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.8 tm-20 -88.2 118.25 27.67 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.911 -1.118 . . . . 0.0 110.252 -177.571 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 1.07 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -112.74 113.13 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.555 -0.716 . . . . 0.0 109.195 179.929 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.2 m 66.06 6.33 4.05 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.653 -0.654 . . . . 0.0 110.314 179.356 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.457 ' N ' ' OE2' ' B' ' 65' ' ' GLU . . . 110.93 -3.1 28.7 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -88.39 115.91 26.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.161 -1.199 . . . . 0.0 108.953 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.556 ' HG3' HD11 ' B' ' 63' ' ' LEU . 1.5 mptp? -69.45 107.24 3.26 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.574 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -121.98 110.06 15.36 Favored 'General case' 0 C--N 1.291 -1.938 0 O-C-N 121.627 -0.671 . . . . 0.0 109.683 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.81 HG13 HD22 ' B' ' 63' ' ' LEU . 1.2 mt -94.63 120.64 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.894 -1.128 . . . . 0.0 108.271 178.782 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.677 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -140.32 -165.89 10.46 Favored Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.554 -179.645 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.468 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 59.5 m -97.73 106.69 19.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.68 -0.894 . . . . 0.0 109.651 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.02 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.5 t -91.34 172.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.541 -0.724 . . . . 0.0 109.49 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' HG23 ' B' ' 32' ' ' VAL . 3.6 mp -140.36 112.67 7.83 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.795 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.9 t -97.52 117.49 42.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.932 -1.105 . . . . 0.0 110.305 -178.508 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -154.19 -171.42 21.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.746 -1.742 . . . . 0.0 108.746 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -80.92 41.56 1.17 Allowed 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.336 2.024 . . . . 0.0 110.926 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.663 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.5 t -82.38 138.7 44.83 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.854 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.411 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.0 Cg_endo -78.23 18.16 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.283 1.989 . . . . 0.0 110.973 -179.579 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.657 ' O ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -159.71 163.82 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.107 -0.996 . . . . 0.0 109.638 -179.552 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.555 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -109.44 119.86 40.73 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 104.417 -2.438 . . . . 0.0 104.417 176.319 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.92 HG23 ' CB ' ' B' ' 25' ' ' ASP . 6.0 mt -120.4 132.67 69.4 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 120.117 -1.614 . . . . 0.0 113.859 -174.688 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 1.085 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -96.67 102.51 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.002 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.536 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -83.35 -160.26 29.32 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.076 -179.344 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.494 ' HD2' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -69.79 -30.25 67.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.472 -1.016 . . . . 0.0 109.848 -179.797 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.938 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.8 p-10 -49.38 -24.29 1.87 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.942 -1.099 . . . . 0.0 109.571 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.938 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -111.06 -23.42 10.93 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.998 -1.064 . . . . 0.0 109.76 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.625 HD21 HD22 ' B' ' 24' ' ' LEU . 51.8 mt -69.32 -6.17 27.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.027 -1.045 . . . . 0.0 109.225 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.634 HG21 ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -100.65 -20.53 15.6 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.075 -1.016 . . . . 0.0 108.969 179.401 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.574 HE21 ' HB1' ' B' ' 71' ' ' ALA . 7.9 mt-30 -81.04 -40.42 24.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.418 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.692 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -82.79 -5.54 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 177.923 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.12 25.95 62.98 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.151 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.596 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.89 132.64 52.78 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.803 -1.41 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.634 HG22 HG23 ' A' ' 4' ' ' THR . 15.7 p -131.47 128.49 39.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.156 -0.965 . . . . 0.0 108.666 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -85.76 96.83 9.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.409 -0.807 . . . . 0.0 110.358 -178.773 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.563 ' C ' ' CD1' ' B' ' 99' ' ' PHE . 2.6 m120 -111.05 139.75 46.15 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.834 . . . . 0.0 109.499 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.867 ' HB3' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.056 -1.028 . . . . 0.0 109.533 179.438 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.504 ' HG2' ' CD2' ' B' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.232 -0.719 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.503 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -91.48 128.62 37.38 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.156 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.413 HG11 ' HB3' ' A' ' 9' ' ' PRO . 53.0 t -125.56 131.88 71.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.028 -178.447 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.621 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -154.41 51.57 0.65 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.352 -0.842 . . . . 0.0 109.143 -179.733 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -94.64 42.67 1.09 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.226 -0.921 . . . . 0.0 110.178 -179.401 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.529 ' C ' ' O ' ' A' ' 5' ' ' LEU . 26.9 m95 18.13 49.06 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.415 0 CA-C-O 121.131 0.491 . . . . 0.0 112.176 179.797 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -166.61 -173.89 2.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.145 -0.972 . . . . 0.0 109.359 179.66 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HD3' ' OD1' ' B' ' 29' ' ' ASP . 5.3 mtm180 -63.88 111.09 4.61 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.324 -0.86 . . . . 0.0 110.049 -179.629 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.1 Cg_endo -77.29 84.31 1.98 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.957 1.771 . . . . 0.0 109.117 178.668 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.732 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -89.89 149.11 22.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 110.248 -178.882 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.855 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -135.97 137.74 48.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.388 -0.82 . . . . 0.0 109.551 179.741 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.821 HG22 HD22 ' A' ' 19' ' ' LEU . 29.2 m -72.96 98.84 2.57 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 178.635 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.687 HG22 HG13 ' A' ' 66' ' ' ILE . 15.3 pt -88.6 144.02 9.99 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 O-C-N 121.407 -0.808 . . . . 0.0 110.805 -178.363 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.814 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -107.01 105.23 15.16 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.725 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.688 HD13 HG11 ' A' ' 75' ' ' VAL . 24.8 mt -121.74 124.45 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.049 -1.032 . . . . 0.0 109.872 -179.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.88 18.4 72.46 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.372 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.55 0.61 84.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.471 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 28.7 mm-40 -99.9 -178.62 3.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.175 -1.191 . . . . 0.0 109.058 179.746 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.821 HD22 HG22 ' A' ' 12' ' ' THR . 16.7 mt -141.29 129.6 22.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.181 -0.949 . . . . 0.0 110.002 -179.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 3.1 mmtp -142.88 -170.49 3.25 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.492 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.732 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.2 mt-10 -103.26 146.52 28.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.161 -0.962 . . . . 0.0 109.025 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.712 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -130.22 136.21 48.97 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.931 -1.106 . . . . 0.0 110.221 -179.566 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.841 HD21 ' O ' ' B' ' 27' ' ' GLY . 53.0 tp -105.17 111.55 24.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.495 -0.753 . . . . 0.0 110.041 -179.329 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -46.71 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.907 -1.121 . . . . 0.0 109.324 179.618 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.701 ' CB ' HG23 ' A' ' 84' ' ' ILE . 33.4 t0 -98.65 71.43 1.96 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.116 -0.99 . . . . 0.0 109.563 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.564 ' CG2' ' HG3' ' B' ' 9' ' ' PRO . 64.9 m -58.1 -15.88 11.12 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.103 -0.998 . . . . 0.0 108.537 179.066 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.686 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -69.64 -41.14 76.17 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.742 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.94 155.97 32.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -1.213 . . . . 0.0 109.78 -179.688 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.524 ' OD2' ' CG ' ' B' ' 8' ' ' ARG . 1.3 m-20 -96.47 -9.97 28.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.769 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -131.6 -170.11 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 109.549 -179.677 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.563 HG23 HD12 ' A' ' 85' ' ' ILE . 11.2 m -113.81 88.37 2.83 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.058 -1.027 . . . . 0.0 109.973 -179.367 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.93 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.19 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 178.725 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.039 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -164.08 123.36 1.97 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.406 -1.434 . . . . 0.0 111.875 -179.261 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -42.32 145.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.517 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.8 OUTLIER -48.23 138.75 9.29 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.149 -0.969 . . . . 0.0 109.826 -179.683 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.506 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -147.63 -164.47 2.01 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.424 -0.798 . . . . 0.0 109.209 179.419 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.443 ' N ' ' SD ' ' A' ' 36' ' ' MET . 18.1 t -100.01 87.67 3.55 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 110.041 -179.639 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 1.054 HD12 HG21 ' A' ' 77' ' ' VAL . 16.2 mt -110.92 159.96 30.62 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.106 -0.996 . . . . 0.0 108.935 179.19 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.471 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 34.8 Cg_endo -77.35 154.23 31.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.598 2.199 . . . . 0.0 110.361 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.542 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -59.29 -154.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.542 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 4.7 mmm180 69.86 49.58 0.51 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.831 -0.805 . . . . 0.0 109.48 -179.595 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 45.8 p-90 -135.31 -171.4 2.81 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.0 mtpm? -138.9 134.36 16.97 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.963 -1.085 . . . . 0.0 108.85 179.598 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.69 139.26 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.073 1.849 . . . . 0.0 111.26 -179.181 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.523 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 11.4 pttt -159.03 153.6 24.35 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.307 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.458 ' HG3' ' O ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -110.85 128.94 55.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.778 -1.201 . . . . 0.0 110.4 -179.093 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 10.0 pt -96.81 142.07 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.95 -1.094 . . . . 0.0 108.152 178.305 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.619 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.79 100.56 0.83 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.607 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.12 -122.76 2.78 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.71 -1.234 . . . . 0.0 110.099 -179.716 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.798 HG21 ' CD1' ' B' ' 47' ' ' ILE . 10.5 mt -87.33 123.21 39.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.629 -0.924 . . . . 0.0 111.854 -178.466 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.79 -52.78 0.68 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.146 -1.181 . . . . 0.0 110.146 178.573 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.46 -155.2 21.84 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.751 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.619 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 6.8 m-85 -114.12 123.22 49.1 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.412 -1.052 . . . . 0.0 110.014 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.71 ' CD1' HG23 ' B' ' 50' ' ' ILE . 32.0 pt -102.79 162.43 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.076 -1.015 . . . . 0.0 108.509 178.597 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.9 OUTLIER -95.96 144.78 25.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.215 -0.928 . . . . 0.0 109.018 -179.932 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.65 HG12 ' HA3' ' A' ' 78' ' ' GLY . 17.0 m -142.91 -173.73 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.889 -1.132 . . . . 0.0 109.711 -179.83 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.571 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 36.2 mtt180 -133.04 93.21 3.14 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 179.541 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -50.03 101.65 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.585 0.707 . . . . 0.0 110.036 -179.632 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.616 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.3 m-85 -100.95 88.29 3.5 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.74 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.498 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -78.73 137.68 37.89 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.201 -0.937 . . . . 0.0 110.401 -178.517 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.628 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.0 OUTLIER 74.01 61.79 0.08 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.755 -0.591 . . . . 0.0 110.531 179.329 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.851 ' C ' HD13 ' A' ' 72' ' ' ILE . 1.2 mt -122.02 124.21 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.516 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.815 ' O ' HD13 ' A' ' 63' ' ' LEU . 3.1 tm? -70.06 92.24 0.73 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.442 -0.787 . . . . 0.0 111.82 -177.559 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.77 HD13 HD11 ' A' ' 66' ' ' ILE . 4.2 tt -96.91 118.53 43.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.846 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.556 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 39.1 tt0 -89.61 100.81 13.54 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.983 -1.073 . . . . 0.0 109.766 -178.778 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.855 HG23 HG21 ' A' ' 11' ' ' VAL . 1.3 mp -97.12 121.8 47.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.268 -0.895 . . . . 0.0 108.965 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.407 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 58.09 57.32 4.09 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.515 -0.741 . . . . 0.0 109.641 179.614 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.71 26.33 7.78 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.764 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.461 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 59.8 m-70 -122.24 118.9 29.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.991 -1.3 . . . . 0.0 109.267 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.638 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 mptt -61.38 139.58 58.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.258 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.67 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -159.88 102.33 1.48 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.173 -0.954 . . . . 0.0 110.473 -179.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.851 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -78.58 147.25 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.525 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.847 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.09 -170.89 37.25 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.903 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.2 m -95.33 106.08 18.09 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.729 -0.865 . . . . 0.0 110.174 -179.488 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.039 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.04 106.58 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.701 -0.625 . . . . 0.0 109.708 179.358 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.548 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.8 mp -79.81 113.26 17.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.119 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 1.054 HG21 HD12 ' A' ' 38' ' ' LEU . 7.9 t -97.91 107.98 21.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 120.908 -1.12 . . . . 0.0 110.261 -178.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.65 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -140.24 -166.48 10.68 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.101 -2.0 . . . . 0.0 108.101 179.088 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.92 40.42 0.96 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.305 2.003 . . . . 0.0 110.522 179.208 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' A' ' 34' ' ' GLU . 11.5 t -81.75 137.25 47.45 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.33 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.566 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.1 Cg_endo -78.91 16.3 1.35 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.483 2.122 . . . . 0.0 111.476 -179.089 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.4 t -161.07 149.65 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.809 -1.182 . . . . 0.0 110.251 -179.845 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -85.85 100.07 11.81 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.774 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.701 HG23 ' CB ' ' A' ' 25' ' ' ASP . 18.9 mm -84.52 120.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.234 -0.916 . . . . 0.0 112.994 -175.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.912 HG22 HD11 ' A' ' 90' ' ' LEU . 0.6 OUTLIER -103.0 99.36 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.836 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.493 ' O ' HD13 ' A' ' 90' ' ' LEU . . . -106.54 175.99 21.31 Favored Glycine 0 N--CA 1.497 2.72 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.243 -177.069 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.753 ' N ' HD22 ' A' ' 90' ' ' LEU . 13.2 mmm180 -25.81 -41.41 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -179.085 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.8 p-10 -52.54 -42.54 64.5 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.184 -1.573 . . . . 0.0 110.562 -177.683 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.8 mm? -92.98 -23.96 18.53 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.035 . . . . 0.0 108.607 179.598 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.912 HD11 HG22 ' A' ' 85' ' ' ILE . 0.4 OUTLIER -67.81 -8.03 32.59 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.309 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.82 -20.66 17.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.928 -1.108 . . . . 0.0 108.844 179.824 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 30.6 mm-40 -85.71 -40.21 16.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.216 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.71 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -83.12 2.16 3.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.236 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 66.46 31.93 80.25 Favored Glycine 0 N--CA 1.499 2.887 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.186 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.685 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -61.06 143.72 54.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.247 -1.149 . . . . 0.0 111.433 -179.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.707 HG22 ' CG2' ' B' ' 4' ' ' THR . 58.0 p -152.05 141.49 21.6 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.13 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' B' ' 97' ' ' LEU . 0.0 OUTLIER -98.23 118.31 34.58 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.786 -1.196 . . . . 0.0 110.358 -179.916 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.5 m120 -118.0 123.75 46.48 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.637 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.481 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.574 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.576 0 N-CA-C 110.176 -0.74 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.511 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.8 tt0 -89.12 146.41 24.83 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.216 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . 0.58 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 12.2 t -138.93 118.17 13.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 120.525 -1.359 . . . . 0.0 110.673 -178.615 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.707 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -123.94 -71.83 0.7 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.277 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.743 ' N ' HD22 ' B' ' 5' ' ' LEU . 3.1 mm? 36.92 34.47 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.654 -0.654 . . . . 0.0 110.656 179.574 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.532 ' C ' ' O ' ' B' ' 5' ' ' LEU . 17.8 m95 18.61 48.17 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.285 0 CA-C-O 121.233 0.54 . . . . 0.0 112.165 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.569 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -163.16 -158.9 0.5 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.53 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.0 OUTLIER -71.94 124.19 90.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.348 -0.845 . . . . 0.0 109.431 179.888 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.639 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.7 Cg_endo -76.99 74.15 5.12 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.146 1.897 . . . . 0.0 110.094 179.387 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.818 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.41 164.24 24.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.03 -1.044 . . . . 0.0 110.091 -179.498 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.467 HG23 HG23 ' B' ' 13' ' ' ILE . 2.8 m -151.27 152.76 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.475 -0.766 . . . . 0.0 109.927 -179.007 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.947 HG22 HD22 ' B' ' 19' ' ' LEU . 27.9 m -85.89 103.32 14.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.422 -1.423 . . . . 0.0 107.717 177.562 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 1.06 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.7 pt -94.53 148.6 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.065 -1.022 . . . . 0.0 110.479 -178.566 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -117.12 105.47 12.3 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.739 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.945 HG22 HD21 ' B' ' 38' ' ' LEU . 16.3 mt -116.75 134.01 61.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 120.826 -1.171 . . . . 0.0 109.438 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.09 -99.37 0.31 Allowed Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 -179.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' B' ' 18' ' ' GLN . . . -145.31 32.05 1.66 Allowed Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.471 -1.851 . . . . 0.0 108.471 179.237 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' B' ' 17' ' ' GLY . 3.0 mm100 -132.72 178.31 6.96 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.492 -1.005 . . . . 0.0 109.635 -179.539 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 1.06 HD23 ' O ' ' B' ' 13' ' ' ILE . 9.0 mt -143.62 130.8 20.74 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.416 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.3 mmmt -143.44 156.14 44.57 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.818 ' HB3' HD23 ' B' ' 10' ' ' LEU . 1.9 mp0 -79.49 122.34 26.33 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.981 -1.074 . . . . 0.0 108.811 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.609 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.38 129.93 52.28 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.434 -0.791 . . . . 0.0 110.647 -178.787 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.686 HD21 ' O ' ' A' ' 27' ' ' GLY . 22.9 tp -80.17 97.72 7.02 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.841 HD22 HD21 ' B' ' 90' ' ' LEU . 15.2 mt -44.22 113.01 0.47 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.715 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.609 ' HB3' HG22 ' B' ' 84' ' ' ILE . 57.7 t0 -126.39 88.12 2.78 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.05 -177.789 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.576 HG21 ' CD2' ' B' ' 97' ' ' LEU . 1.8 m -64.06 -12.83 42.43 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.037 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.841 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.1 -41.92 45.8 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.171 -1.171 . . . . 0.0 110.171 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.12 152.3 46.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.061 -1.258 . . . . 0.0 109.449 -179.684 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.574 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 30.6 m-20 -85.0 -21.69 29.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 110.378 -178.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.51 ' HA ' ' OD1' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -139.98 -160.38 1.06 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.811 -1.181 . . . . 0.0 109.429 179.965 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.567 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.0 m -110.94 94.13 4.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.731 -1.23 . . . . 0.0 111.56 -178.242 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.051 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.49 174.73 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.053 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.051 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.72 117.35 0.59 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.932 -1.105 . . . . 0.0 110.311 -179.178 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.772 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.5 pt-20 -38.13 158.22 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.544 -0.722 . . . . 0.0 109.586 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.689 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -46.34 149.71 0.72 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.212 -0.93 . . . . 0.0 110.668 -179.119 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.456 ' SD ' ' O ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -178.68 167.58 1.74 Allowed 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.513 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.456 ' O ' ' SD ' ' B' ' 36' ' ' MET . 48.0 t -87.88 109.24 19.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.967 -1.083 . . . . 0.0 109.765 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.945 HD21 HG22 ' B' ' 15' ' ' ILE . 8.6 mt -114.65 105.12 53.88 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.255 179.649 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -78.47 102.02 1.52 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.542 2.161 . . . . 0.0 111.233 -179.526 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 168.31 31.13 0.02 OUTLIER Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.596 179.288 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.52 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 55.63 153.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.778 -0.837 . . . . 0.0 109.721 179.647 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.621 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 51.5 p-90 -161.37 176.14 11.48 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.803 -1.185 . . . . 0.0 110.123 -179.764 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.421 ' CD ' ' HD2' ' B' ' 44' ' ' PRO . 0.1 OUTLIER -134.08 162.92 54.79 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.6 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . 0.421 ' HD2' ' CD ' ' B' ' 43' ' ' LYS . 33.4 Cg_endo -76.38 139.95 21.33 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 C-N-CA 121.827 1.685 . . . . 0.0 109.721 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.715 ' O ' HG23 ' B' ' 56' ' ' VAL . 7.4 tttm -159.58 119.79 3.05 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.414 -0.804 . . . . 0.0 109.105 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 76.5 mtp -98.9 132.26 44.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.415 -0.803 . . . . 0.0 109.291 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.798 ' CD1' HG21 ' A' ' 50' ' ' ILE . 17.6 pt -94.26 149.05 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.987 -1.071 . . . . 0.0 108.826 179.386 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.534 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.36 100.51 0.81 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.829 -1.708 . . . . 0.0 108.829 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.25 -129.34 3.29 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.3 -1.429 . . . . 0.0 110.665 -179.241 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.843 HG21 ' CD1' ' A' ' 47' ' ' ILE . 47.4 mt -84.42 118.37 31.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.752 -0.852 . . . . 0.0 112.948 -177.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.654 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 100.02 -1.77 56.53 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 177.805 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 127.85 -154.63 19.83 Favored Glycine 0 N--CA 1.49 2.274 0 O-C-N 120.969 -1.312 . . . . 0.0 109.999 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.4 OUTLIER -121.18 141.53 50.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.53 -0.982 . . . . 0.0 109.799 -179.628 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.607 HD11 HD11 ' B' ' 47' ' ' ILE . 18.8 pt -107.22 178.67 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 108.995 179.097 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.583 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.2 OUTLIER -109.5 130.13 55.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.234 -0.916 . . . . 0.0 109.568 -179.881 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.715 HG23 ' O ' ' B' ' 45' ' ' LYS . 2.2 m -144.11 174.06 4.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.094 -1.004 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -116.73 115.47 25.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.813 179.847 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.521 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 5.6 tt0 -69.77 106.8 3.24 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.139 -0.976 . . . . 0.0 110.13 -179.349 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.621 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 18.0 m-85 -99.65 87.31 3.53 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 178.536 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.589 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -78.71 125.68 29.7 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.875 -1.14 . . . . 0.0 110.177 -178.783 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.589 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 1.5 mt-30 91.16 60.65 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.336 0.588 . . . . 0.0 110.402 179.329 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.695 ' CG2' HG23 ' B' ' 15' ' ' ILE . 33.1 mm -121.87 125.68 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.306 -0.871 . . . . 0.0 108.752 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.915 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.1 tm? -73.91 86.38 1.76 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.219 -0.926 . . . . 0.0 112.364 -178.081 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.93 HD12 HD11 ' B' ' 15' ' ' ILE . 16.5 tt -89.8 114.61 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.426 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.7 OUTLIER -90.14 127.51 36.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.912 -1.118 . . . . 0.0 108.765 -179.836 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.666 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -124.3 125.89 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.129 -0.982 . . . . 0.0 109.988 -179.248 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.532 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 54.9 m 55.91 12.78 0.95 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.687 -0.633 . . . . 0.0 111.111 179.169 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . 0.425 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 101.24 21.7 11.4 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.301 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.919 ' HB2' HG22 ' B' ' 93' ' ' ILE . 23.9 m-70 -118.0 114.52 23.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.057 -1.26 . . . . 0.0 109.333 179.544 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.691 ' CG ' HD21 ' B' ' 63' ' ' LEU . 9.6 tttt -64.4 117.4 7.23 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.12 -0.987 . . . . 0.0 109.006 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -138.14 124.04 20.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.302 -0.873 . . . . 0.0 110.358 -178.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.578 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -103.43 129.89 54.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 177.749 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.428 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -149.29 -159.91 8.86 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.506 -1.331 . . . . 0.0 110.364 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.521 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 7.6 m -100.93 110.71 22.78 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.442 -1.034 . . . . 0.0 109.553 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 0.975 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.1 107.14 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.312 -0.867 . . . . 0.0 110.516 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -79.06 121.44 24.97 Favored 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.855 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.758 HG21 HD12 ' B' ' 38' ' ' LEU . 3.4 t -110.7 114.27 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.106 -0.996 . . . . 0.0 110.557 -178.68 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.692 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -148.63 -165.13 11.93 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.583 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.57 41.38 1.13 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.588 2.192 . . . . 0.0 110.486 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.772 HG22 ' HA ' ' B' ' 34' ' ' GLU . 13.6 t -81.43 140.82 48.58 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.596 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.7 Cg_endo -78.81 12.52 2.19 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.426 2.084 . . . . 0.0 110.742 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.596 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -161.22 167.12 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.191 -0.943 . . . . 0.0 109.563 -179.573 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.609 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -105.38 144.37 32.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 104.486 -2.413 . . . . 0.0 104.486 175.761 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.609 HG22 ' HB3' ' B' ' 25' ' ' ASP . 5.7 mm -130.25 130.01 65.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 O-C-N 120.284 -1.51 . . . . 0.0 111.735 -177.059 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.497 ' CD1' HG23 ' B' ' 31' ' ' THR . 0.8 OUTLIER -101.15 100.42 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.483 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.9 -155.42 8.81 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.736 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.574 ' HD2' ' HA ' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -79.68 -30.04 41.0 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.388 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.982 ' ND2' HD23 ' B' ' 89' ' ' LEU . 18.4 p-10 -47.51 -22.95 0.53 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.302 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.982 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.4 mm? -113.42 -42.89 3.4 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.123 -0.985 . . . . 0.0 111.036 -178.58 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.841 HD21 HD22 ' B' ' 24' ' ' LEU . 93.8 mt -52.63 -35.88 55.47 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.592 -1.318 . . . . 0.0 109.425 -179.547 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.504 HG21 ' HA ' ' A' ' 6' ' ' TRP . 49.4 p -80.42 -21.79 41.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.233 -0.917 . . . . 0.0 110.978 -178.738 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.718 HE21 HD13 ' B' ' 89' ' ' LEU . 32.1 mt-30 -75.06 -38.19 61.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.78 -1.2 . . . . 0.0 108.737 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -79.84 2.09 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.392 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 71.37 60.32 4.46 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -100.01 163.42 12.44 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.308 -1.113 . . . . 0.0 110.021 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.621 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.2 p -148.92 135.19 19.3 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.494 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -90.17 114.83 26.88 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.286 179.952 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.503 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.2 m120 -119.24 130.59 55.54 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.869 -0.519 . . . . 0.0 109.863 -179.069 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.71 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.171 -0.919 . . . . 0.0 109.09 178.567 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.495 1.615 0 N-CA-C 110.179 -0.739 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.551 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -83.81 145.89 28.43 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 177.632 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.462 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 55.1 t -146.72 105.93 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 117.82 -1.552 . . . . 0.0 111.143 -178.436 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 6' ' ' TRP . 13.5 p -107.16 -57.22 2.1 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 177.811 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.588 ' O ' ' N ' ' A' ' 7' ' ' GLN . 7.8 tp 33.92 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.938 -0.476 . . . . 0.0 111.119 178.659 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.546 ' N ' ' O ' ' A' ' 4' ' ' THR . 9.0 m95 18.19 47.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.121 0.486 . . . . 0.0 111.91 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.588 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -167.41 -175.49 2.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.797 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.546 HH21 HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -56.2 125.74 65.57 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.412 -0.805 . . . . 0.0 109.558 179.755 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.528 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.9 Cg_endo -79.05 70.89 7.3 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.179 1.919 . . . . 0.0 109.177 178.843 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.606 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.99 156.12 23.6 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.42 -0.8 . . . . 0.0 110.093 -178.908 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.545 HG21 HG23 ' A' ' 66' ' ' ILE . 2.1 m -149.31 130.25 4.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.512 -0.743 . . . . 0.0 109.245 179.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 1.01 HG22 HD22 ' A' ' 19' ' ' LEU . 23.0 m -65.7 96.34 0.27 Allowed 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.728 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.831 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -79.28 140.07 17.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.395 -0.816 . . . . 0.0 109.785 -178.737 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.651 ' HE3' HD11 ' A' ' 19' ' ' LEU . 29.0 tttt -105.64 95.52 5.86 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.242 -0.911 . . . . 0.0 108.981 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.791 HG23 ' CG2' ' A' ' 62' ' ' ILE . 15.1 mt -118.78 147.53 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.153 -0.967 . . . . 0.0 109.924 -179.295 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 44.69 50.62 8.39 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.207 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.26 43.99 34.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.7 mm-40 -142.66 176.67 8.86 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.366 -1.079 . . . . 0.0 109.152 179.864 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 12' ' ' THR . 16.9 mt -149.64 124.2 9.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.037 -1.039 . . . . 0.0 110.115 -179.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.578 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -138.25 168.78 19.02 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.119 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.606 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.0 mm-40 -80.63 116.03 20.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.096 -1.003 . . . . 0.0 108.671 179.516 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.675 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -96.75 142.51 28.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.12 -0.988 . . . . 0.0 110.065 -179.214 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.605 HD21 ' O ' ' B' ' 27' ' ' GLY . 26.5 tp -104.41 91.54 3.94 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.647 -0.658 . . . . 0.0 109.281 -179.753 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.827 HD23 ' HB ' ' A' ' 85' ' ' ILE . 15.1 mt -44.12 101.98 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -0.895 . . . . 0.0 108.714 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.563 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.5 t0 -111.57 91.4 3.64 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.351 -0.843 . . . . 0.0 110.495 -178.699 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HD13 ' A' ' 90' ' ' LEU . 1.1 m -66.6 -10.61 47.46 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.144 -0.973 . . . . 0.0 108.556 178.643 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.472 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.44 -44.2 51.7 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.85 164.79 25.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.096 -1.237 . . . . 0.0 109.322 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -100.55 -15.21 17.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.154 -0.966 . . . . 0.0 111.282 -178.695 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -130.88 -169.96 2.26 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.813 -1.18 . . . . 0.0 109.571 -179.614 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.597 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 50.2 m -109.51 91.35 3.61 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.767 -1.208 . . . . 0.0 110.438 -179.099 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.034 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -72.11 171.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 120.969 -1.082 . . . . 0.0 108.167 179.099 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.123 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.07 121.98 0.79 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.713 -178.857 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.712 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -42.46 166.57 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.146 -0.971 . . . . 0.0 109.535 179.506 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.561 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -51.1 149.71 3.58 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.127 -0.983 . . . . 0.0 110.378 -179.447 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.409 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.2 ptm -164.95 -161.68 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.439 -0.788 . . . . 0.0 109.08 179.592 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.409 ' N ' ' HG3' ' A' ' 36' ' ' MET . 3.8 t -122.73 109.94 14.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.093 -1.005 . . . . 0.0 111.158 -178.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.605 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -111.21 167.02 9.67 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.18 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.578 ' HD3' HD12 ' A' ' 38' ' ' LEU . 35.5 Cg_endo -77.08 66.62 7.73 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 122.94 2.427 . . . . 0.0 112.352 -179.149 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.523 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 26.66 105.74 0.0 OUTLIER Glycine 0 N--CA 1.504 3.215 0 CA-C-O 121.674 0.597 . . . . 0.0 112.315 178.534 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.456 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.8 mtp180 167.11 51.19 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.316 -1.108 . . . . 0.0 109.115 178.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.608 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.5 p-90 -131.49 -179.49 5.4 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 121.829 0.823 . . . . 0.0 110.302 -179.049 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 57' ' ' ARG . 0.5 OUTLIER -138.41 166.89 22.21 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.7 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.29 140.62 22.22 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.147 1.898 . . . . 0.0 110.796 -179.773 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.91 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -160.17 141.36 12.34 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.48 ' HG2' ' HG2' ' A' ' 55' ' ' LYS . 59.3 mtp -125.97 141.57 51.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.837 -1.164 . . . . 0.0 109.915 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 54' ' ' ILE . 6.9 pt -118.94 141.09 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.268 -0.895 . . . . 0.0 109.171 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.527 ' HA3' ' CE1' ' A' ' 53' ' ' PHE . . . -118.18 103.44 1.04 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.78 -127.47 3.22 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.445 -178.961 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.542 ' CG2' HG12 ' B' ' 54' ' ' ILE . 67.5 mt -79.67 116.33 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.703 -0.88 . . . . 0.0 112.251 -178.139 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.563 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 111.98 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.382 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.74 -161.48 34.34 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.305 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CE1' ' HA3' ' A' ' 48' ' ' GLY . 4.3 m-30 -99.95 131.26 46.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.503 -0.998 . . . . 0.0 109.555 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 47' ' ' ILE . 5.1 pt -110.41 172.45 2.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.156 -0.965 . . . . 0.0 108.841 179.103 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -110.04 147.36 33.7 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.875 . . . . 0.0 109.024 179.657 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.91 HG22 ' O ' ' A' ' 45' ' ' LYS . 7.3 m -151.03 -171.53 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 120.739 -1.225 . . . . 0.0 110.424 -179.472 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.587 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 2.0 mtt180 -140.1 108.85 5.95 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.228 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.475 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 30.6 tt0 -65.85 103.38 0.9 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.308 -0.87 . . . . 0.0 111.104 -178.468 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.608 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.8 m-85 -91.58 124.67 35.92 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -109.35 124.2 50.58 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.816 -1.177 . . . . 0.0 110.59 -178.852 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 6.4 mm100 86.29 58.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 CA-C-O 121.229 0.538 . . . . 0.0 110.648 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.791 ' CG2' HG23 ' A' ' 15' ' ' ILE . 26.2 mm -111.88 119.9 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.577 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.896 ' O ' HD13 ' A' ' 63' ' ' LEU . 1.3 tm? -67.48 84.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 111.054 -178.5 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.593 HD13 HD11 ' A' ' 66' ' ' ILE . 3.5 tt -87.86 118.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 178.248 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' CB ' ' A' ' 14' ' ' LYS . 28.0 tt0 -91.42 113.43 25.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.213 -0.929 . . . . 0.0 109.186 -179.189 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.593 HD11 HD13 ' A' ' 64' ' ' ILE . 1.3 mp -106.25 118.29 53.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 -179.667 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 77.8 m 65.38 21.36 11.91 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.744 -0.598 . . . . 0.0 110.935 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.475 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 90.31 1.59 75.01 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.506 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -97.34 121.18 38.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.075 -1.25 . . . . 0.0 108.827 179.548 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -61.82 127.51 31.78 Favored 'General case' 0 C--N 1.295 -1.775 0 O-C-N 121.363 -0.835 . . . . 0.0 109.416 -179.789 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.482 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -148.19 137.55 22.12 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.541 -0.724 . . . . 0.0 109.454 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.536 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -110.29 160.43 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 177.819 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.875 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 175.46 177.51 44.58 Favored Glycine 0 N--CA 1.485 1.901 0 C-N-CA 118.222 -1.942 . . . . 0.0 111.527 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.508 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 75.3 m -82.27 114.74 20.96 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 122.057 -0.672 . . . . 0.0 109.902 -179.715 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.123 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -108.56 109.92 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.395 -0.816 . . . . 0.0 109.951 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.543 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.2 mp -79.21 126.06 30.26 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.114 -0.991 . . . . 0.0 108.729 179.307 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.561 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.6 t -111.43 116.48 52.64 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 109.94 -179.311 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.474 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.25 13.26 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.553 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.2 Cg_endo -82.96 40.16 0.92 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.47 2.113 . . . . 0.0 110.014 179.711 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.712 HG22 ' HA ' ' A' ' 34' ' ' GLU . 10.2 t -81.38 137.36 48.64 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.84 15.8 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.451 2.1 . . . . 0.0 111.829 -178.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -161.41 165.97 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.728 -1.233 . . . . 0.0 111.025 -179.64 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.631 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 55.4 m-20 -99.39 142.61 30.65 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 177.046 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.73 ' CG1' HG12 ' A' ' 32' ' ' VAL . 2.9 mm -133.22 113.59 19.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 O-C-N 120.398 -1.439 . . . . 0.0 111.618 -176.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.827 ' HB ' HD23 ' A' ' 24' ' ' LEU . 0.9 OUTLIER -92.68 92.95 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 177.326 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -84.03 -156.96 24.75 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 120.048 -1.072 . . . . 0.0 111.685 -177.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.512 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 1.8 mtp180 -63.38 -39.13 93.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.91 -0.759 . . . . 0.0 110.84 -178.865 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.002 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.2 p-10 -48.07 -26.57 1.88 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.053 -1.03 . . . . 0.0 110.282 -178.73 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.002 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.8 mm? -112.52 -12.93 13.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.762 -1.211 . . . . 0.0 109.85 -179.796 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.593 HD13 HG23 ' A' ' 26' ' ' THR . 50.1 mt -80.67 -5.75 57.43 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 77.3 p -100.67 -16.91 17.24 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.7 mm-40 -83.37 -40.58 19.22 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.587 -0.696 . . . . 0.0 109.477 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.987 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -87.29 -3.86 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.145 -0.972 . . . . 0.0 109.429 179.607 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 69.09 56.68 8.61 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HA ' ' HD1' ' B' ' 99' ' ' PHE . . . -81.93 148.86 28.51 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.031 -1.276 . . . . 0.0 110.23 -179.769 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.869 HG22 HG22 ' B' ' 4' ' ' THR . 55.8 p -142.89 124.08 14.56 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.744 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' B' ' 97' ' ' LEU . 4.7 mp -85.07 108.13 17.5 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.9 m120 -107.2 122.15 45.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.742 -1.224 . . . . 0.0 109.259 -179.669 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.632 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.685 0 CA-C-O 117.922 -1.037 . . . . 0.0 109.747 -179.805 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 4.5 Cg_exo . . . . . 0 N--CA 1.495 1.613 0 N-CA-C 110.693 -0.541 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.44 131.92 35.0 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 178.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.16 115.41 44.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 120.812 -1.18 . . . . 0.0 109.853 -177.905 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.998 ' O ' HD22 ' B' ' 5' ' ' LEU . 1.0 OUTLIER -119.01 -102.34 0.42 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.919 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.998 HD22 ' O ' ' B' ' 4' ' ' THR . 0.0 OUTLIER 25.91 36.44 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.32 0 CA-C-O 120.752 0.31 . . . . 0.0 110.974 179.823 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.629 ' N ' ' O ' ' B' ' 4' ' ' THR . 19.3 m0 13.77 85.16 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 CA-C-O 121.174 0.511 . . . . 0.0 111.775 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.89 155.18 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.156 -0.965 . . . . 0.0 109.422 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 48.0 mtm180 -50.48 119.61 11.32 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.576 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.822 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.6 Cg_endo -75.23 71.81 5.02 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 122.158 1.905 . . . . 0.0 110.6 179.861 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.518 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -87.87 161.15 17.66 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.267 -0.896 . . . . 0.0 108.953 179.795 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.954 HG23 HG23 ' B' ' 13' ' ' ILE . 18.7 m -150.84 138.11 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.006 -1.059 . . . . 0.0 110.198 -179.355 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.581 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 24.5 m -72.61 96.66 2.01 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.763 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 10.7 pt -90.44 142.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 O-C-N 121.293 -0.88 . . . . 0.0 110.967 -177.332 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.557 ' HE3' ' CD1' ' B' ' 19' ' ' LEU . 0.3 OUTLIER -108.04 98.6 8.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.667 -0.646 . . . . 0.0 109.608 -179.639 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 1.016 HG23 HG21 ' B' ' 62' ' ' ILE . 11.4 mt -120.1 135.32 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 120.981 -1.075 . . . . 0.0 109.859 -179.742 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD13 ' B' ' 38' ' ' LEU . . . 43.11 60.01 3.2 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 179.349 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 16' ' ' GLY . . . 43.02 41.83 4.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.698 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.519 ' HB2' ' CE ' ' B' ' 36' ' ' MET . 38.0 mm-40 -138.45 116.24 11.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.366 -1.079 . . . . 0.0 109.464 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.2 OUTLIER -90.79 127.71 36.44 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.685 0.755 . . . . 0.0 110.069 179.699 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.597 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mttt -150.74 142.65 23.88 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.63 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.518 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -78.59 111.09 14.3 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.994 -1.066 . . . . 0.0 108.711 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 1.012 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -93.76 132.82 37.77 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.984 0.897 . . . . 0.0 111.062 -178.45 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.488 HD12 HD12 ' B' ' 10' ' ' LEU . 12.1 tp -83.8 102.46 12.34 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.535 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.822 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.2 mt -44.95 120.19 2.26 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.141 -0.974 . . . . 0.0 108.392 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.523 ' HB3' HG22 ' B' ' 84' ' ' ILE . 46.5 t0 -128.39 82.4 2.08 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.906 HG23 HD13 ' B' ' 90' ' ' LEU . 1.4 m -62.9 -15.24 54.39 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.015 -1.053 . . . . 0.0 108.738 179.125 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.605 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.93 -37.89 94.83 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 163.53 26.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.292 -1.123 . . . . 0.0 109.463 -179.905 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.457 ' OD1' ' NE ' ' A' ' 8' ' ' ARG . 3.9 m-20 -98.23 -10.12 24.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.528 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 19.5 m-20 -140.25 -165.9 2.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.3 -0.875 . . . . 0.0 108.844 -179.883 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.727 HG23 HD12 ' B' ' 85' ' ' ILE . 17.6 m -118.11 93.17 4.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.692 -1.255 . . . . 0.0 111.02 -178.668 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.053 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.89 174.03 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.152 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.46 117.16 1.32 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.82 -1.175 . . . . 0.0 110.846 -179.086 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.601 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 16.3 tt0 -36.15 155.37 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.492 -0.755 . . . . 0.0 109.94 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.711 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -33.35 146.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.766 0.793 . . . . 0.0 111.41 -179.145 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.538 ' N ' HG11 ' B' ' 77' ' ' VAL . 0.2 OUTLIER -177.64 179.61 0.9 Allowed 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.555 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -122.08 122.84 40.19 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.434 -1.416 . . . . 0.0 111.911 -178.299 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.604 HD12 ' CD ' ' B' ' 39' ' ' PRO . 0.5 OUTLIER -102.58 175.58 2.21 Favored Pre-proline 0 N--CA 1.495 1.785 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 177.899 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.604 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.4 Cg_endo -78.05 68.8 7.72 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.066 1.844 . . . . 0.0 110.953 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.8 -172.12 0.01 OUTLIER Glycine 0 N--CA 1.493 2.478 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 179.202 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 56.84 101.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.418 -1.048 . . . . 0.0 109.921 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 3.8 p-90 -160.7 171.55 18.66 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.609 -0.682 . . . . 0.0 109.625 179.682 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . 0.524 ' O ' ' CB ' ' B' ' 58' ' ' GLN . 1.4 mtmt -128.71 115.4 19.34 Favored Pre-proline 0 N--CA 1.489 1.477 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.367 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.62 136.03 18.68 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.807 1.671 . . . . 0.0 110.828 -179.334 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 1.024 ' NZ ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -156.45 178.62 10.11 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.539 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 27.2 mtp -127.56 136.28 51.47 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.841 -1.162 . . . . 0.0 110.61 -178.754 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 54' ' ' ILE . 5.8 pt -100.68 143.6 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.328 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.36 108.92 1.68 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.549 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.89 -125.01 2.55 Favored Glycine 0 N--CA 1.484 1.839 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.522 -179.242 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.582 HG21 HD12 ' A' ' 47' ' ' ILE . 50.6 mt -84.3 121.46 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.825 -0.809 . . . . 0.0 112.578 -177.939 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.456 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 98.45 -16.57 59.68 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.019 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 140.58 -155.95 25.03 Favored Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.936 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 1.1 m-85 -116.12 134.9 54.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.543 -0.975 . . . . 0.0 109.485 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 47' ' ' ILE . 6.0 pt -105.53 159.58 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.004 -1.06 . . . . 0.0 109.245 179.436 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.577 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -99.61 131.43 45.61 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.372 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.946 HG23 ' CE ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -138.96 -173.14 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.787 -1.195 . . . . 0.0 109.756 -179.838 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -114.74 165.84 12.38 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.557 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.569 ' NE2' HG22 ' B' ' 74' ' ' THR . 10.0 tp60 -128.98 91.57 3.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.57 -1.331 . . . . 0.0 110.99 -178.923 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 94.1 m-85 -93.88 92.16 7.27 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.223 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.537 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 51.5 m-20 -79.08 134.85 36.73 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.323 -0.86 . . . . 0.0 109.916 -178.841 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.56 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 42.9 mt-30 83.54 63.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.589 0.709 . . . . 0.0 109.291 179.55 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 1.016 HG21 HG23 ' B' ' 15' ' ' ILE . 24.9 mm -119.15 120.48 63.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.951 HD21 ' CG ' ' B' ' 70' ' ' LYS . 16.4 tp -72.86 86.83 1.28 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 118.977 -1.089 . . . . 0.0 110.695 -178.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.731 ' CD1' HD11 ' B' ' 66' ' ' ILE . 1.6 tt -85.23 122.24 38.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.647 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.5 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.8 tt0 -89.73 109.61 20.58 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.973 -1.079 . . . . 0.0 109.72 -178.411 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -105.76 122.25 59.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.262 -0.899 . . . . 0.0 109.087 179.91 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . 0.475 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 76.2 m 66.71 12.26 8.72 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.997 -0.439 . . . . 0.0 110.294 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.37 0.42 56.89 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 6.7 m-70 -98.82 125.03 44.08 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.191 -1.182 . . . . 0.0 108.904 179.717 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 0.951 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.7 mptm? -70.28 135.11 48.64 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.281 -0.887 . . . . 0.0 108.613 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.824 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -150.27 138.72 20.53 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.383 -0.823 . . . . 0.0 109.077 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.56 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -108.13 142.69 20.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 178.212 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -163.54 -165.73 21.2 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.993 -179.694 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.569 HG22 ' NE2' ' B' ' 58' ' ' GLN . 7.0 m -97.81 110.33 22.92 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.745 -0.856 . . . . 0.0 110.06 -179.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.065 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -109.65 147.26 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.09 -1.006 . . . . 0.0 109.697 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 1.024 HD23 ' NZ ' ' B' ' 45' ' ' LYS . 5.6 mp -125.27 142.91 51.22 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.058 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' B' ' 35' ' ' GLU . 15.1 t -124.03 124.23 68.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.102 -0.999 . . . . 0.0 110.1 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.723 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -160.31 -158.06 9.02 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.577 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -80.57 40.56 1.0 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.806 2.338 . . . . 0.0 110.966 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.601 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.1 t -86.95 133.81 38.43 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 178.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.606 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.5 Cg_endo -77.16 14.16 1.4 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.269 1.979 . . . . 0.0 111.086 -178.939 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.606 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -160.81 151.24 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 120.94 -1.1 . . . . 0.0 110.397 -179.241 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.597 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 21.0 m-20 -80.06 130.74 35.48 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.723 -2.695 . . . . 0.0 103.723 175.077 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.663 HG13 HG12 ' B' ' 32' ' ' VAL . 0.8 OUTLIER -125.88 116.26 45.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 119.781 -1.824 . . . . 0.0 112.93 -176.437 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 1.012 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -89.07 147.28 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.708 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.528 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -136.31 -161.1 9.0 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 118.771 -1.681 . . . . 0.0 110.055 -179.766 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.444 ' O ' ' OG1' ' B' ' 91' ' ' THR . 0.0 OUTLIER -57.59 -37.62 73.51 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.702 -0.881 . . . . 0.0 109.793 -179.725 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 1.049 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -50.67 -29.72 11.84 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.625 -179.29 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 1.049 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.5 mm? -107.13 -24.02 12.08 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.619 -1.301 . . . . 0.0 110.815 -179.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.906 HD13 HG23 ' B' ' 26' ' ' THR . 9.2 mt -71.63 -5.68 35.33 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.883 -1.136 . . . . 0.0 108.888 -179.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.5 -14.42 18.26 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.925 . . . . 0.0 109.023 179.319 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . 0.824 HE21 ' HB1' ' B' ' 71' ' ' ALA . 18.6 mt-30 -85.96 -40.88 15.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -0.867 . . . . 0.0 109.363 -179.816 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.632 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.2 pt -85.99 4.78 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.144 -0.973 . . . . 0.0 108.542 178.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.7 42.97 98.49 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.345 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.509 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -69.53 145.46 52.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.901 -1.352 . . . . 0.0 108.882 179.327 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 45.4 p -136.86 128.36 28.51 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.052 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -91.13 96.66 10.71 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 -178.992 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.551 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.3 m120 -109.64 132.92 53.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.47 -0.769 . . . . 0.0 110.045 -179.426 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.987 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.062 179.41 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.513 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.168 -0.743 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.508 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 5.8 tt0 -83.2 127.62 33.78 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 178.069 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.48 HG12 HD22 ' A' ' 5' ' ' LEU . 20.7 t -130.91 102.32 6.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.167 -177.663 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 5.5 p -48.68 -24.34 1.34 Allowed 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 179.213 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.869 HD12 ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER 71.34 35.6 1.5 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.547 -0.721 . . . . 0.0 109.817 179.679 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.433 ' C ' ' HG2' ' A' ' 7' ' ' GLN . 2.1 m95 -55.21 -20.37 10.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.876 -1.14 . . . . 0.0 108.416 179.611 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HG2' ' C ' ' A' ' 6' ' ' TRP . 4.4 mm100 -138.52 -142.49 0.16 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.022 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HG2' ' OD2' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -92.18 141.8 25.5 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 120.778 -1.201 . . . . 0.0 109.339 179.494 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.656 ' HD3' HD11 ' A' ' 5' ' ' LEU . 37.6 Cg_endo -80.16 59.38 7.41 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.502 2.135 . . . . 0.0 110.243 179.532 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 21' ' ' GLU . 6.0 mt -79.47 132.41 36.34 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.969 -1.082 . . . . 0.0 109.053 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 1.01 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -134.63 150.37 30.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 121.327 -0.858 . . . . 0.0 109.326 -179.323 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 1.099 HG22 HD22 ' A' ' 19' ' ' LEU . 32.8 m -86.0 95.88 9.65 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.801 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.75 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.1 pt -79.01 155.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.478 -0.764 . . . . 0.0 110.298 -178.818 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -120.06 89.96 3.23 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.8 HD13 HG11 ' A' ' 75' ' ' VAL . 24.9 mt -110.8 130.24 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.102 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.72 44.85 93.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 179.327 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.27 23.7 48.79 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 6.7 mm100 -117.4 163.53 16.23 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.153 -1.204 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 1.099 HD22 HG22 ' A' ' 12' ' ' THR . 11.6 mt -132.97 127.68 34.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.992 -1.068 . . . . 0.0 110.853 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 1.2 mmmt -146.59 173.7 12.09 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.091 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.792 ' HB3' HD22 ' A' ' 10' ' ' LEU . 4.0 mm-40 -79.26 179.57 7.32 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.809 -1.182 . . . . 0.0 108.801 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -159.35 114.07 2.41 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.766 -1.209 . . . . 0.0 110.608 -179.753 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.041 HD21 ' O ' ' B' ' 27' ' ' GLY . 29.3 tp -87.8 96.73 10.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.684 -0.635 . . . . 0.0 109.357 179.61 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.568 HD23 ' HB ' ' A' ' 85' ' ' ILE . 19.1 mt -43.67 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.698 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.1 t0 -106.11 86.17 2.32 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.402 -0.811 . . . . 0.0 111.165 -177.891 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.473 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 62.1 m -68.53 -14.18 62.83 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.919 -1.113 . . . . 0.0 108.596 178.437 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.41 -22.59 67.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.919 -1.273 . . . . 0.0 109.919 -179.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -86.71 164.77 16.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.029 -1.277 . . . . 0.0 109.807 -179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.481 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 1.3 m-20 -94.19 -21.07 19.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 110.961 -178.785 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.824 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -141.55 -166.57 2.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.655 -1.278 . . . . 0.0 110.596 -179.524 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 60.5 m -103.25 89.48 3.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.189 -0.944 . . . . 0.0 111.02 -178.336 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -73.84 175.45 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.722 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.0 OUTLIER -171.92 121.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.75 -1.219 . . . . 0.0 110.214 -179.475 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.497 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.1 OUTLIER -39.39 155.61 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.063 -1.023 . . . . 0.0 110.218 179.499 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.548 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.7 OUTLIER -46.4 151.04 0.58 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.383 -0.823 . . . . 0.0 110.265 -179.808 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.407 ' SD ' ' C ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -172.63 174.27 3.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.581 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.407 ' C ' ' SD ' ' A' ' 36' ' ' MET . 34.7 t -89.48 83.65 6.36 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.012 -1.055 . . . . 0.0 109.724 -179.722 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.9 HD21 HD12 ' A' ' 62' ' ' ILE . 6.1 tp -109.78 105.54 57.31 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.239 -0.913 . . . . 0.0 109.715 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.0 Cg_endo -78.47 146.63 21.94 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.573 2.182 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.82 -165.83 26.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.842 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 127.94 49.49 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.26 -1.141 . . . . 0.0 108.595 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 42.6 p-90 -136.0 -173.99 3.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.985 . . . . 0.0 110.293 -179.355 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.25 129.71 7.74 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.173 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -74.96 136.52 20.61 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.907 1.738 . . . . 0.0 111.369 -178.659 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.586 ' HG2' HG23 ' A' ' 56' ' ' VAL . 9.5 ptmm? -153.74 -165.41 2.12 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 178.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.435 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 3.3 ttt -147.6 125.92 12.31 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.66 -1.275 . . . . 0.0 110.232 -179.395 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 54' ' ' ILE . 5.2 pt -98.27 135.92 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.06 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.473 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.35 112.35 2.36 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -179.653 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -129.35 -111.53 1.53 Allowed Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.041 -179.509 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.784 HG21 ' CD1' ' B' ' 47' ' ' ILE . 27.4 mt -97.84 132.53 42.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 O-C-N 121.296 -1.12 . . . . 0.0 111.477 -178.445 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 96.69 -50.48 1.56 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.074 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.49 -158.7 28.22 Favored Glycine 0 N--CA 1.491 2.3 0 O-C-N 121.022 -1.281 . . . . 0.0 110.15 -179.872 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.473 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 32.8 m-85 -107.72 151.36 25.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.611 -0.935 . . . . 0.0 109.954 -179.654 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 47' ' ' ILE . 18.0 pt -136.2 140.61 43.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.508 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 8.8 mttt -80.7 137.12 36.28 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.389 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.586 HG23 ' HG2' ' A' ' 45' ' ' LYS . 27.2 m -128.66 -176.72 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.36 -0.838 . . . . 0.0 109.469 -179.73 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 2.6 mmt85 -125.74 85.35 2.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 108.981 179.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.552 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 1.2 tt0 -45.32 89.53 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 121.441 0.639 . . . . 0.0 110.261 -179.633 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.618 ' HB3' HG13 ' A' ' 62' ' ' ILE . 6.3 m-85 -90.58 82.51 5.82 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -77.57 137.39 38.56 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.235 -178.349 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 77.62 59.99 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.198 0.523 . . . . 0.0 110.399 179.701 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.9 HD12 HD21 ' A' ' 38' ' ' LEU . 0.6 OUTLIER -131.54 126.49 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.633 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.056 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.3 tt -74.68 93.33 2.54 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.187 -0.945 . . . . 0.0 112.839 -176.746 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.687 ' CG2' HD11 ' A' ' 89' ' ' LEU . 1.9 tt -87.33 115.76 28.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 105.966 -1.865 . . . . 0.0 105.966 176.236 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -87.97 116.97 26.51 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.11 -0.994 . . . . 0.0 109.013 -178.057 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 1.5 mp -111.92 125.64 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.243 -0.911 . . . . 0.0 109.95 -179.076 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 7.7 m 51.75 -94.84 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.697 . . . . 0.0 109.75 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -140.51 49.55 0.79 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.823 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -145.2 109.8 5.0 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.322 -1.105 . . . . 0.0 110.158 -179.767 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 1.056 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -63.73 120.05 11.11 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.796 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.643 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -132.7 129.01 38.2 Favored 'General case' 0 C--N 1.291 -1.953 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.755 -178.355 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.815 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.5 OUTLIER -105.69 138.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 177.269 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.458 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -161.97 -157.23 8.79 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.641 -179.472 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.552 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 9.9 m -107.42 104.47 14.06 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.879 -0.777 . . . . 0.0 108.946 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.935 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.28 99.94 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.539 -0.726 . . . . 0.0 109.721 -179.757 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.824 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.7 mp -78.16 106.34 9.99 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.074 -1.016 . . . . 0.0 108.857 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.548 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 50.1 t -95.75 123.9 48.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.424 -0.797 . . . . 0.0 110.358 -179.271 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -155.45 -163.92 12.62 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.36 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.538 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 34.9 Cg_endo -79.75 39.62 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.56 2.173 . . . . 0.0 111.193 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -85.66 135.77 37.79 Favored Pre-proline 0 N--CA 1.491 1.625 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.794 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.24 18.79 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.793 2.329 . . . . 0.0 112.21 -178.529 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.589 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.87 163.02 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.575 -1.328 . . . . 0.0 110.476 -179.962 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.587 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 54.6 m-20 -91.46 140.04 30.14 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 105.175 -2.158 . . . . 0.0 105.175 176.549 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.796 ' C ' HD13 ' A' ' 85' ' ' ILE . 18.3 mm -128.64 122.79 58.06 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 O-C-N 120.346 -1.471 . . . . 0.0 111.539 -177.211 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.796 HD13 ' C ' ' A' ' 84' ' ' ILE . 1.4 mm -102.91 96.71 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.184 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.34 -156.41 10.68 Favored Glycine 0 N--CA 1.495 2.62 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.525 -177.416 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.522 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 7.9 mtt180 -72.81 -35.17 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.874 -0.78 . . . . 0.0 109.799 -179.309 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.893 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -54.19 -18.87 4.27 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.005 -1.06 . . . . 0.0 108.857 -178.977 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.893 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -110.37 -22.22 11.81 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.524 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.634 HD23 HD11 ' A' ' 93' ' ' ILE . 64.1 mt -74.67 -17.24 60.71 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.299 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.59 HG22 ' CD2' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -89.84 -10.28 45.97 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.029 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.643 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 72.6 mt-30 -94.52 -41.74 9.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.854 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -84.25 -3.81 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.203 -0.936 . . . . 0.0 108.772 179.116 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 67.67 43.06 86.39 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 178.817 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.527 ' CB ' HD22 ' A' ' 90' ' ' LEU . . . -66.54 153.05 43.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.867 -1.373 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.499 HG22 ' HA ' ' B' ' 4' ' ' THR . 17.7 p -145.09 128.31 16.74 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.327 -0.858 . . . . 0.0 109.094 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -93.16 96.72 10.21 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.44 -0.787 . . . . 0.0 109.441 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 3.2 m120 -101.13 121.22 41.43 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.822 -1.173 . . . . 0.0 109.674 179.654 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.77 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.479 179.541 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.576 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 N-CA-C 110.408 -0.651 . . . . 0.0 110.408 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.9 tt0 -96.37 132.08 42.26 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.456 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 52.7 t -131.82 120.85 45.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.032 -1.042 . . . . 0.0 109.624 -179.049 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.941 ' C ' HD13 ' B' ' 5' ' ' LEU . 0.3 OUTLIER -60.19 -97.26 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.434 -0.791 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.941 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -168.88 -17.87 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.963 -1.086 . . . . 0.0 111.325 179.685 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.591 ' H ' HD22 ' B' ' 5' ' ' LEU . 67.0 m95 -66.19 -11.6 50.7 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.546 -1.346 . . . . 0.0 109.792 -179.799 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -117.56 147.12 43.1 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 110.235 -179.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.92 131.21 81.83 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.34 -0.85 . . . . 0.0 109.028 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.802 ' HB2' HD12 ' B' ' 24' ' ' LEU . 38.0 Cg_endo -81.08 45.42 1.99 Allowed 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.135 1.89 . . . . 0.0 109.825 178.732 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -81.1 147.45 30.1 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.156 -0.965 . . . . 0.0 109.279 -179.672 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' B' ' 66' ' ' ILE . 0.9 OUTLIER -150.31 135.48 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.023 -1.048 . . . . 0.0 110.569 -179.184 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.878 ' CG2' HD22 ' B' ' 19' ' ' LEU . 7.5 m -64.03 113.83 3.75 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.207 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.725 HG21 ' HB2' ' B' ' 22' ' ' ALA . 1.4 pp -100.57 135.67 35.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.323 -0.861 . . . . 0.0 110.182 -179.034 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.604 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.8 OUTLIER -108.33 108.54 19.57 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.24 -0.912 . . . . 0.0 108.967 179.5 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.74 HD13 HG11 ' B' ' 75' ' ' VAL . 28.9 mt -110.67 123.52 66.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.163 -0.961 . . . . 0.0 108.876 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.6 -90.46 0.38 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.734 -1.746 . . . . 0.0 108.734 -179.402 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -152.34 27.05 0.88 Allowed Glycine 0 N--CA 1.483 1.813 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 179.396 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.478 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 4.6 mt-30 -125.78 176.31 7.02 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.259 -1.142 . . . . 0.0 109.579 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 ' CG2' ' B' ' 12' ' ' THR . 18.9 mt -136.48 128.09 28.8 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-O 121.621 0.724 . . . . 0.0 110.312 -179.263 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.45 ' HB3' HD21 ' B' ' 83' ' ' ASN . 7.6 mmtt -138.64 155.93 47.88 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.494 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mm-40 -78.81 145.13 34.47 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.631 -1.293 . . . . 0.0 109.615 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.76 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -120.54 148.84 43.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.941 -1.099 . . . . 0.0 110.762 -179.303 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.422 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -118.42 95.56 4.92 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.802 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.2 mt -45.48 107.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.994 -1.066 . . . . 0.0 109.395 -179.659 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 0.639 ' HB3' HG23 ' B' ' 84' ' ' ILE . 22.5 t0 -119.77 90.4 3.32 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.791 -179.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.475 HG23 ' CD ' ' B' ' 87' ' ' ARG . 1.2 m -60.36 -14.27 17.75 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.067 -1.021 . . . . 0.0 108.977 179.282 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 1.041 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -61.67 -44.46 97.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.78 148.43 30.06 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -1.17 . . . . 0.0 109.654 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.49 ' OD2' ' HG2' ' A' ' 8' ' ' ARG . 37.6 m-20 -89.12 -8.79 53.1 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.281 -0.887 . . . . 0.0 110.04 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.741 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -133.39 -171.01 2.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.025 -1.047 . . . . 0.0 109.329 -179.923 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.592 HG23 ' O ' ' B' ' 84' ' ' ILE . 43.5 m -111.97 93.25 4.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.778 -1.201 . . . . 0.0 110.974 -178.844 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.017 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.92 172.83 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.299 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 HG13 ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.84 124.3 1.29 Allowed 'General case' 0 C--N 1.305 -1.347 0 O-C-N 120.59 -1.319 . . . . 0.0 111.92 -178.838 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' B' ' 33' ' ' LEU . 0.2 OUTLIER -35.87 154.72 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 178.053 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -53.86 130.33 36.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.113 -0.992 . . . . 0.0 110.335 -179.428 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -141.33 -178.39 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.85 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.2 t -105.15 103.45 12.99 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.639 -1.288 . . . . 0.0 110.532 -178.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 0.709 HD12 HG21 ' B' ' 77' ' ' VAL . 51.6 mt -106.88 156.58 37.05 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 108.975 179.253 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' B' ' 40' ' ' GLY . 36.4 Cg_endo -79.35 77.99 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.695 2.263 . . . . 0.0 111.475 -179.097 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 37.37 -158.41 0.01 OUTLIER Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.212 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 22.5 mmm180 63.65 74.84 0.41 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.597 -0.943 . . . . 0.0 109.169 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.519 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 67.8 p-90 -159.13 175.9 12.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.746 . . . . 0.0 109.761 -179.294 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.54 138.71 31.81 Favored Pre-proline 0 N--CA 1.492 1.669 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.035 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.28 127.97 9.44 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.021 1.814 . . . . 0.0 111.286 -178.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.798 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -162.9 136.48 5.96 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.852 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.475 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 32.4 mtp -102.09 137.26 40.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.844 -1.16 . . . . 0.0 109.098 -179.91 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.784 ' CD1' HG21 ' A' ' 50' ' ' ILE . 19.0 pt -89.59 145.46 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.373 179.237 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . 0.491 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -118.23 100.92 0.87 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.748 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.29 -126.85 3.43 Favored Glycine 0 N--CA 1.483 1.775 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.054 -178.611 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.663 HG21 HD12 ' A' ' 47' ' ' ILE . 38.5 mt -83.28 118.7 31.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 O-C-N 121.863 -0.787 . . . . 0.0 112.741 -177.292 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . 0.55 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 100.62 -51.91 0.97 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 178.134 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.497 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . -174.6 -171.61 38.95 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.265 -1.445 . . . . 0.0 110.108 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.568 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-30 -106.06 128.83 54.13 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.335 -1.097 . . . . 0.0 109.349 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.554 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.0 pt -100.84 161.39 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.129 -0.982 . . . . 0.0 109.276 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 13.6 mttt -89.6 134.46 34.12 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.131 -0.981 . . . . 0.0 109.208 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.798 HG22 ' O ' ' B' ' 45' ' ' LYS . 17.0 m -142.05 172.99 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.966 -1.084 . . . . 0.0 109.588 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 6.9 mtm180 -124.75 101.32 7.04 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.547 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 6.7 tt0 -58.4 96.36 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 110.032 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.564 ' HB3' HG13 ' B' ' 62' ' ' ILE . 13.3 m-85 -89.57 94.34 9.83 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.006 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -78.87 141.76 37.4 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.108 -0.995 . . . . 0.0 110.307 -178.846 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.65 ' HA ' HG23 ' B' ' 72' ' ' ILE . 15.2 mt-30 69.38 64.02 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.334 0.588 . . . . 0.0 110.765 179.479 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 0.812 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.9 OUTLIER -119.84 125.01 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 108.847 178.727 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 1.148 HD21 ' CG ' ' B' ' 70' ' ' LYS . 2.8 tm? -74.4 86.45 2.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.309 -0.87 . . . . 0.0 110.903 -178.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.616 HG23 ' O ' ' B' ' 64' ' ' ILE . 3.4 tt -90.81 116.93 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.007 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.7 tt0 -90.07 116.56 28.19 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.811 -1.181 . . . . 0.0 109.72 -179.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.628 ' CG1' HG21 ' B' ' 11' ' ' VAL . 0.5 OUTLIER -105.11 116.93 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.157 -0.964 . . . . 0.0 109.675 -179.898 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 51.85 16.55 0.52 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.782 -0.574 . . . . 0.0 111.603 178.454 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 106.99 18.65 10.3 Favored Glycine 0 N--CA 1.495 2.604 0 C-N-CA 119.277 -1.439 . . . . 0.0 110.679 179.016 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -116.08 98.85 6.86 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.084 -1.245 . . . . 0.0 108.898 179.459 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . 1.148 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.6 ttpm? -54.36 120.06 6.05 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.901 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.65 130.86 22.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 110.693 -178.827 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.812 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.8 OUTLIER -94.19 147.1 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.581 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.813 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -171.09 175.83 44.62 Favored Glycine 0 N--CA 1.489 2.209 0 C-N-CA 118.557 -1.782 . . . . 0.0 111.538 -179.601 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.547 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 8.6 m -87.97 102.41 14.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.927 -0.749 . . . . 0.0 110.465 -179.616 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.065 HG13 HD13 ' B' ' 33' ' ' LEU . 1.5 t -94.12 108.64 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.368 -0.832 . . . . 0.0 110.01 179.189 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.741 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.0 mp -79.83 111.03 15.75 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.84 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . 0.709 HG21 HD12 ' B' ' 38' ' ' LEU . 11.2 t -93.68 116.51 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.117 -0.99 . . . . 0.0 110.122 -179.014 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -151.53 -172.83 20.76 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.477 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.6 Cg_endo -80.42 42.99 1.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.525 2.15 . . . . 0.0 110.839 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.722 HG21 HG13 ' B' ' 32' ' ' VAL . 0.9 OUTLIER -83.01 143.62 46.16 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.035 -1.041 . . . . 0.0 108.496 179.198 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.54 14.8 1.54 Allowed 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.275 1.983 . . . . 0.0 110.874 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.459 HG13 ' N ' ' B' ' 83' ' ' ASN . 1.2 t -160.91 165.08 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.902 -1.124 . . . . 0.0 109.816 -179.527 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.61 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 1.1 m-20 -103.2 119.01 38.08 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 104.675 -2.343 . . . . 0.0 104.675 176.272 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 0.639 HG23 ' HB3' ' B' ' 25' ' ' ASP . 14.6 mm -102.17 126.41 56.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 O-C-N 120.762 -1.211 . . . . 0.0 111.9 -175.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.76 HG21 ' CD2' ' B' ' 24' ' ' LEU . 1.0 OUTLIER -103.89 88.33 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 177.304 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.59 -158.3 11.84 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 120.145 -1.026 . . . . 0.0 111.228 -177.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.869 ' HG3' HD12 ' A' ' 5' ' ' LEU . 7.3 mmm180 -69.01 -37.81 78.9 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.666 -0.902 . . . . 0.0 110.672 -178.748 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.977 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.7 p-10 -43.45 -25.18 0.13 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.647 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.977 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.3 mm? -111.5 -29.79 7.63 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.07 -1.019 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.711 HD21 HD22 ' B' ' 24' ' ' LEU . 33.6 mt -67.33 -8.32 31.49 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.243 -0.91 . . . . 0.0 108.965 179.319 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . 0.599 HG23 HH21 ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.6 -20.28 15.74 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.162 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -81.4 -40.2 23.8 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.77 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -81.28 -2.66 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 108.839 178.89 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 81.95 24.23 55.75 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 178.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.706 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -60.58 137.62 58.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.842 -1.387 . . . . 0.0 109.994 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 96' ' ' THR . 44.5 p -132.65 122.1 24.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.645 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -89.51 94.37 9.85 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 121.324 0.583 . . . . 0.0 109.503 -178.683 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.508 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.8 OUTLIER -109.43 130.94 55.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.279 -0.888 . . . . 0.0 110.53 -179.312 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.854 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.096 178.464 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 1' ' ' PRO . . . . . 0.514 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.495 1.604 0 N-CA-C 109.767 -0.897 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.544 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 2.4 tt0 -83.32 134.84 34.9 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 177.686 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.566 HG11 ' HB3' ' A' ' 9' ' ' PRO . 6.6 t -126.84 101.82 8.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.585 -1.246 . . . . 0.0 110.501 -178.092 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.695 HG22 HG22 ' B' ' 96' ' ' THR . 1.7 p -115.18 -81.52 0.61 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.342 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.54 ' O ' ' C ' ' A' ' 6' ' ' TRP . 92.0 mt 33.71 32.91 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.923 -0.486 . . . . 0.0 110.441 178.866 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 7.2 m0 18.33 50.74 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.499 0.666 . . . . 0.0 111.651 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.6 OUTLIER -143.6 -163.83 1.74 Allowed 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.549 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.436 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -84.86 136.64 38.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 108.869 179.703 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.566 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.4 Cg_endo -78.97 67.63 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.316 2.011 . . . . 0.0 109.776 179.099 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.434 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -86.91 143.04 27.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.19 -0.944 . . . . 0.0 109.592 -179.619 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.606 HG21 HG23 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -139.51 160.66 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.829 . . . . 0.0 109.412 -179.745 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.841 HG22 HD22 ' A' ' 19' ' ' LEU . 34.5 m -95.33 109.96 22.03 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.882 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.7 pt -97.8 159.1 3.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 110.401 -178.312 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.52 ' HE3' HD11 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -119.3 99.1 6.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.485 -0.759 . . . . 0.0 109.095 179.53 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.935 HD13 HG11 ' A' ' 75' ' ' VAL . 17.0 mt -114.64 130.55 68.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.165 -0.959 . . . . 0.0 109.534 -179.653 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.63 50.56 62.35 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.807 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.67 26.18 16.16 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.946 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.5 mt-30 -120.37 173.66 7.0 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -1.158 . . . . 0.0 109.041 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.2 mt -140.46 126.94 20.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.128 -0.983 . . . . 0.0 110.352 -179.678 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.656 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -144.13 175.04 10.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.516 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 83' ' ' ASN . 1.9 mm-40 -79.44 178.15 8.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.845 -1.16 . . . . 0.0 108.721 179.67 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.691 ' HB1' HG12 ' A' ' 85' ' ' ILE . . . -158.38 117.97 3.19 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.875 -1.14 . . . . 0.0 110.035 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 25' ' ' ASP . 59.0 tp -90.56 95.47 10.18 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.431 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.643 ' CD1' ' CZ ' ' B' ' 99' ' ' PHE . 10.9 mt -46.16 97.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 -179.682 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.566 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 18.9 t0 -103.49 91.67 4.15 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.533 -0.729 . . . . 0.0 110.647 -177.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.877 HG23 HD12 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -67.77 -6.74 22.62 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.886 -1.134 . . . . 0.0 108.977 178.767 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.49 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -80.11 -39.49 16.04 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.446 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.89 160.71 31.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.824 -1.398 . . . . 0.0 109.52 -179.505 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -99.85 -16.46 18.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.932 . . . . 0.0 109.062 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.4 OUTLIER -132.29 -161.19 1.11 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.44 -0.787 . . . . 0.0 109.152 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.748 HG22 ' CD1' ' A' ' 33' ' ' LEU . 21.5 m -121.04 89.8 3.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.559 -1.338 . . . . 0.0 110.675 -178.526 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.03 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.953 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 1.03 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -161.17 129.44 4.4 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.965 -1.084 . . . . 0.0 110.679 -178.707 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.466 ' C ' ' O ' ' A' ' 33' ' ' LEU . 7.0 tt0 -40.8 156.85 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.111 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.794 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.3 OUTLIER -52.89 153.09 3.52 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.06 -1.025 . . . . 0.0 110.364 -179.155 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 4.1 ptm -177.47 -163.76 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.407 -0.808 . . . . 0.0 109.019 179.71 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -107.52 142.17 37.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.697 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.779 HD21 HG22 ' A' ' 15' ' ' ILE . 9.3 mt -150.33 167.22 13.43 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.531 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.2 Cg_endo -76.78 138.43 18.86 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.299 1.999 . . . . 0.0 109.342 179.33 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.59 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -48.0 -169.33 0.01 OUTLIER Glycine 0 N--CA 1.492 2.42 0 CA-C-O 121.854 0.696 . . . . 0.0 111.438 -178.669 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.59 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.2 OUTLIER 81.91 46.92 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 -178.965 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.679 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 57.8 p-90 -137.24 -172.02 3.1 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.405 0.621 . . . . 0.0 109.798 -179.196 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.19 138.65 11.97 Favored Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 121.41 -0.806 . . . . 0.0 109.204 179.226 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.32 139.48 18.68 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.117 1.878 . . . . 0.0 110.028 179.455 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 0.2 OUTLIER -160.59 -159.46 0.69 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.432 -0.793 . . . . 0.0 108.951 -179.775 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.509 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 69.4 mtp -148.93 130.5 14.91 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.119 -0.988 . . . . 0.0 109.41 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.828 HD11 HG21 ' B' ' 50' ' ' ILE . 14.6 pt -88.95 144.68 8.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.14 97.91 0.76 Allowed Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.228 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.68 -126.43 3.26 Favored Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.325 -179.151 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.902 HG21 HD12 ' B' ' 47' ' ' ILE . 21.8 mt -87.43 112.17 22.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.809 -0.818 . . . . 0.0 112.639 -177.787 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.544 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 116.77 -48.52 0.93 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 178.054 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.76 -154.57 21.22 Favored Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.023 -179.618 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.1 m-85 -114.14 116.4 29.04 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.562 -0.964 . . . . 0.0 110.009 -179.454 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.0 pt -89.85 175.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.149 -0.969 . . . . 0.0 109.084 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.542 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -104.13 142.5 34.38 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 108.853 179.423 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.76 HG21 HD23 ' A' ' 76' ' ' LEU . 15.1 m -150.93 175.25 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.943 -1.098 . . . . 0.0 110.293 -179.54 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.53 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -126.61 98.23 5.32 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.646 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.541 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 0.7 OUTLIER -58.1 102.58 0.11 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.219 -0.925 . . . . 0.0 110.971 -179.016 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.679 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 23.0 m-85 -98.89 94.35 6.53 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.114 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.6 OUTLIER -79.02 139.41 38.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.465 -178.538 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 73.96 62.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.674 -0.641 . . . . 0.0 110.064 179.499 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.603 HG21 HG23 ' A' ' 15' ' ' ILE . 10.5 mm -119.69 114.46 44.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.145 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.905 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.3 tm? -63.61 87.02 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.362 -0.836 . . . . 0.0 110.944 -178.586 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 66' ' ' ILE . 5.6 tt -89.59 115.23 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 178.078 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.458 ' OE2' ' N ' ' A' ' 69' ' ' HIS . 1.1 tm-20 -88.35 123.51 33.0 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.106 -0.996 . . . . 0.0 109.181 -178.773 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.67 HD11 ' CD1' ' A' ' 64' ' ' ILE . 2.3 mt -126.13 122.42 61.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 110.188 -179.049 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 56.15 46.68 21.02 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.662 -0.649 . . . . 0.0 111.174 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.77 22.62 68.42 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 120.163 -1.018 . . . . 0.0 110.928 178.406 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.458 ' N ' ' OE2' ' A' ' 65' ' ' GLU . 5.9 m-70 -123.41 130.79 53.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.993 -1.298 . . . . 0.0 109.186 179.24 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.618 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -72.48 129.18 37.72 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 108.908 179.713 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.56 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -146.55 109.57 4.68 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.54 -0.725 . . . . 0.0 109.677 -179.324 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.588 HG12 HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -90.43 156.88 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.764 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.788 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.53 -171.31 41.68 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 118.435 -1.84 . . . . 0.0 111.597 179.819 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 7.7 m -96.79 104.92 16.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.737 -0.861 . . . . 0.0 109.542 -179.669 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 1.023 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -100.33 113.4 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.294 -0.879 . . . . 0.0 110.567 -179.573 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.76 HD23 HG21 ' A' ' 56' ' ' VAL . 5.3 mp -82.78 125.3 31.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.847 . . . . 0.0 108.841 178.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.794 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.1 t -103.92 110.45 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.0 -1.062 . . . . 0.0 109.423 -179.959 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.524 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.61 -171.47 15.21 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.949 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.542 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 42.42 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.454 2.103 . . . . 0.0 110.41 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.601 HG21 HG13 ' A' ' 32' ' ' VAL . 6.5 t -81.47 141.89 49.5 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.542 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -79.74 16.95 1.35 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.408 2.072 . . . . 0.0 111.339 -179.629 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.542 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -161.05 165.87 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.917 -1.114 . . . . 0.0 109.894 -179.571 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.656 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -103.79 96.72 6.89 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 105.11 -2.181 . . . . 0.0 105.11 176.761 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.613 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.4 mm -83.15 115.42 25.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 O-C-N 121.082 -1.011 . . . . 0.0 113.1 -175.756 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.837 HD13 ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -95.0 91.99 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 175.612 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.32 -157.38 8.6 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.884 -1.15 . . . . 0.0 110.783 -177.047 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -69.56 -37.14 76.88 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.884 -0.774 . . . . 0.0 110.37 -178.804 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -46.58 -28.86 1.57 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.762 -1.211 . . . . 0.0 109.634 -179.757 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -110.96 -30.96 7.3 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.994 -1.067 . . . . 0.0 111.466 -178.361 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.877 HD12 HG23 ' A' ' 26' ' ' THR . 0.6 OUTLIER -59.57 -31.46 69.46 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.769 -1.207 . . . . 0.0 108.642 -179.869 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -78.85 -20.7 48.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.898 . . . . 0.0 110.123 -179.89 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 -69.77 -40.66 75.93 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.88 -1.138 . . . . 0.0 108.262 179.319 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.943 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -83.67 -7.17 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.864 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.52 62.92 3.25 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.805 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -83.21 148.88 27.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.315 -1.109 . . . . 0.0 109.674 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.579 HG22 ' CG2' ' B' ' 4' ' ' THR . 5.0 p -137.46 129.74 29.45 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.142 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.679 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -96.58 88.65 4.73 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.263 -0.898 . . . . 0.0 109.422 -179.745 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.1 m120 -93.6 121.59 35.18 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.116 -0.99 . . . . 0.0 109.126 179.827 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.636 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.402 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 1' ' ' PRO . . . . . 0.605 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.619 0 N-CA-C 110.641 -0.561 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 2' ' ' GLN . . . . . 0.439 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -91.01 136.9 32.77 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 177.85 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.2 t -133.93 105.89 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 120.574 -1.329 . . . . 0.0 110.57 -178.558 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.579 ' CG2' HG22 ' A' ' 96' ' ' THR . 15.8 p -122.03 -70.13 0.8 Allowed 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.063 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER 31.24 37.79 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.81 -0.556 . . . . 0.0 110.743 179.146 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 5.5 m95 18.8 50.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.186 0 CA-C-O 121.504 0.669 . . . . 0.0 111.924 -179.756 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.537 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.4 OUTLIER -154.55 165.4 36.6 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.155 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.5 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 71.2 mtm180 -49.0 133.15 15.0 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.012 -179.827 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 9' ' ' PRO . . . . . 0.494 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.6 Cg_endo -80.09 64.83 8.91 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.312 2.008 . . . . 0.0 109.514 179.028 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 10' ' ' LEU . . . . . 0.699 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -79.89 148.24 31.38 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.33 -0.856 . . . . 0.0 109.521 -179.663 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 11' ' ' VAL . . . . . 0.756 HG21 HG23 ' B' ' 66' ' ' ILE . 1.4 m -140.29 132.28 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.307 -0.871 . . . . 0.0 109.592 179.872 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 12' ' ' THR . . . . . 0.66 HG22 HD22 ' B' ' 19' ' ' LEU . 11.8 m -64.09 99.77 0.28 Allowed 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.498 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 13' ' ' ILE . . . . . 0.635 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.0 OUTLIER -90.41 147.89 4.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.255 -0.903 . . . . 0.0 110.615 -178.178 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 14' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 2.8 tttt -107.93 107.94 18.87 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 1.046 HD13 HG11 ' B' ' 75' ' ' VAL . 14.8 mt -122.88 119.04 56.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.205 -0.934 . . . . 0.0 109.604 -179.273 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . 0.402 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.59 20.99 74.4 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.38 -7.74 79.66 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.545 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 18' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' B' ' 37' ' ' SER . 30.6 mt-30 -87.19 -175.25 5.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -1.107 . . . . 0.0 109.52 -179.961 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 19' ' ' LEU . . . . . 0.66 HD22 HG22 ' B' ' 12' ' ' THR . 40.9 mt -152.19 119.95 6.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.919 -179.861 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' B' ' 19' ' ' LEU . 2.5 mmmt -134.82 161.61 34.73 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.699 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.1 OUTLIER -79.09 122.82 26.71 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.526 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . 0.759 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -108.63 119.4 39.43 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.921 -1.112 . . . . 0.0 111.145 -178.578 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 23' ' ' LEU . . . . . 0.5 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 24.9 tp -75.43 99.59 4.21 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.633 179.561 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 24' ' ' LEU . . . . . 0.698 ' CD2' HD21 ' B' ' 90' ' ' LEU . 4.6 mt -48.68 96.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 25' ' ' ASP . . . . . 1.05 ' CB ' HG23 ' B' ' 84' ' ' ILE . 8.7 t0 -96.88 95.6 7.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 110.068 -179.379 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 26' ' ' THR . . . . . 0.684 HG21 HD13 ' B' ' 97' ' ' LEU . 9.8 m -74.27 -4.29 35.25 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.157 -0.964 . . . . 0.0 108.467 178.455 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 27' ' ' GLY . . . . . 0.478 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -85.81 -26.25 35.54 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.85 162.32 16.22 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.869 -1.371 . . . . 0.0 109.999 -179.304 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 29' ' ' ASP . . . . . 0.501 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.2 m-20 -100.62 -13.9 18.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -0.799 . . . . 0.0 110.719 -179.132 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.511 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.82 -172.22 2.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.912 -1.117 . . . . 0.0 109.506 -179.706 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 31' ' ' THR . . . . . 0.55 HG22 ' CD1' ' B' ' 33' ' ' LEU . 20.6 m -111.04 87.28 2.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.519 -1.363 . . . . 0.0 110.702 -178.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 32' ' ' VAL . . . . . 1.041 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -73.43 170.6 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 178.179 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 1.041 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.51 122.12 1.99 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.533 -1.354 . . . . 0.0 110.609 -178.576 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.696 ' HA ' HG22 ' B' ' 80' ' ' THR . 88.5 tt0 -40.26 152.92 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.371 -0.831 . . . . 0.0 109.311 179.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.8 tt0 -46.09 147.77 0.98 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 110.602 -179.313 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.8 ptt? -168.01 156.81 9.26 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 37' ' ' SER . . . . . 0.524 ' O ' ' NE2' ' B' ' 18' ' ' GLN . 4.6 t -79.26 85.63 5.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 109.788 -179.339 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 38' ' ' LEU . . . . . 1.075 HD21 HD12 ' B' ' 62' ' ' ILE . 62.7 tp -103.14 115.13 64.51 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.273 -0.892 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 39' ' ' PRO . . . . . 0.737 ' HD2' HD12 ' B' ' 38' ' ' LEU . 34.1 Cg_endo -77.05 125.28 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.44 2.094 . . . . 0.0 110.534 -179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.96 154.49 6.18 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.98 153.02 38.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -1.182 . . . . 0.0 109.287 -179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 42' ' ' TRP . . . . . 0.492 ' CE3' ' HB3' ' B' ' 57' ' ' ARG . 58.0 p-90 -156.58 172.45 18.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.141 -0.975 . . . . 0.0 109.394 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.66 137.39 30.26 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.028 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.35 137.74 15.2 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.112 1.874 . . . . 0.0 111.093 -179.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 45' ' ' LYS . . . . . 0.563 ' HG2' HG23 ' B' ' 56' ' ' VAL . 3.8 ptmt -159.98 -172.9 3.81 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.161 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 46' ' ' MET . . . . . 0.415 ' HA ' ' O ' ' B' ' 54' ' ' ILE . 28.1 mtp -141.58 137.61 32.05 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.662 -1.274 . . . . 0.0 109.842 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 47' ' ' ILE . . . . . 0.902 HD12 HG21 ' A' ' 50' ' ' ILE . 1.4 pt -96.06 152.74 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.475 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.48 116.33 3.37 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.778 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -149.13 -124.66 1.35 Allowed Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.25 -179.681 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 50' ' ' ILE . . . . . 0.828 HG21 HD11 ' A' ' 47' ' ' ILE . 20.4 mt -86.59 123.93 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.527 -0.984 . . . . 0.0 112.375 -178.181 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.78 -7.93 70.72 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 120.27 -0.967 . . . . 0.0 111.148 177.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 125.91 -159.22 20.32 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 53' ' ' PHE . . . . . 0.538 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -112.96 142.03 46.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.314 -1.11 . . . . 0.0 109.843 -179.585 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.831 HD11 HD11 ' B' ' 47' ' ' ILE . 6.5 pt -107.17 -178.3 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.258 -0.901 . . . . 0.0 109.368 179.554 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 55' ' ' LYS . . . . . 0.576 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -106.34 148.21 28.3 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.421 -0.799 . . . . 0.0 108.894 179.475 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 56' ' ' VAL . . . . . 0.563 HG23 ' HG2' ' B' ' 45' ' ' LYS . 29.3 m -151.22 -179.1 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.687 -1.258 . . . . 0.0 110.408 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 57' ' ' ARG . . . . . 0.492 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.6 mtt-85 -130.47 86.41 2.38 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 58' ' ' GLN . . . . . 0.5 ' HB2' ' HD2' ' B' ' 45' ' ' LYS . 24.5 tt0 -47.41 105.63 0.07 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.588 -0.695 . . . . 0.0 111.301 -178.469 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 59' ' ' TYR . . . . . 0.715 ' CD2' HD23 ' B' ' 38' ' ' LEU . 5.1 m-85 -99.03 90.3 4.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 60' ' ' ASP . . . . . 0.438 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 2.8 m-20 -79.0 136.32 37.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.872 -1.143 . . . . 0.0 111.502 -177.753 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 13.9 mt-30 68.21 62.5 0.38 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-O 121.179 0.514 . . . . 0.0 110.632 178.542 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 62' ' ' ILE . . . . . 1.075 HD12 HD21 ' B' ' 38' ' ' LEU . 0.1 OUTLIER -122.51 122.39 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.205 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 1.01 ' O ' HD13 ' B' ' 63' ' ' LEU . 1.3 tm? -60.51 87.4 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.759 0.79 . . . . 0.0 111.896 -177.741 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 64' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' B' ' 71' ' ' ALA . 2.6 tt -95.81 111.53 26.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 176.561 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.4 tt0 -90.25 124.64 35.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.76 -1.212 . . . . 0.0 109.152 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 66' ' ' ILE . . . . . 0.756 HG23 HG21 ' B' ' 11' ' ' VAL . 1.0 OUTLIER -106.53 128.23 61.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.156 -0.965 . . . . 0.0 109.269 -179.728 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 58.86 -90.1 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.683 -0.636 . . . . 0.0 109.682 179.583 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.92 40.95 0.99 Allowed Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 69' ' ' HIS . . . . . 0.509 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 86.6 m-70 -137.64 114.14 10.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -1.132 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.47 120.86 8.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.351 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 71' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' B' ' 64' ' ' ILE . . . -132.87 151.63 52.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.405 -0.809 . . . . 0.0 109.429 179.897 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 72' ' ' ILE . . . . . 0.857 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -125.22 156.5 34.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 177.527 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 73' ' ' GLY . . . . . 0.601 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.27 -165.15 34.86 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 117.906 -2.093 . . . . 0.0 111.492 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 74' ' ' THR . . . . . 0.501 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.5 m -99.41 103.61 15.41 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.906 -0.761 . . . . 0.0 110.017 -179.476 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 75' ' ' VAL . . . . . 1.046 HG11 HD13 ' B' ' 15' ' ' ILE . 1.3 t -94.73 102.19 13.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.471 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.49 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.8 mp -79.12 112.74 16.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.033 -1.042 . . . . 0.0 108.981 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 52.9 t -97.89 117.72 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.102 -0.999 . . . . 0.0 109.814 -179.521 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.89 -164.28 11.67 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 179.739 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 79' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -82.76 38.04 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.202 1.935 . . . . 0.0 110.404 179.814 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 80' ' ' THR . . . . . 0.696 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.6 t -79.85 134.32 57.08 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 178.785 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 81' ' ' PRO . . . . . 0.547 ' O ' HG23 ' B' ' 82' ' ' VAL . 32.1 Cg_endo -77.5 17.04 0.97 Allowed 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.393 2.062 . . . . 0.0 111.701 -178.556 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.651 HG12 ' CD1' ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.23 151.4 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.755 -1.216 . . . . 0.0 109.972 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.611 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 84.8 m-20 -89.57 127.08 35.84 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.23 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 84' ' ' ILE . . . . . 1.05 HG23 ' CB ' ' B' ' 25' ' ' ASP . 3.9 mt -127.89 121.79 57.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 119.903 -1.748 . . . . 0.0 112.655 -176.538 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.759 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -89.43 111.1 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.384 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -92.15 -159.15 35.06 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.57 -178.821 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 87' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.0 mtp180 -68.63 -29.47 67.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.685 -0.891 . . . . 0.0 109.984 -179.524 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 88' ' ' ASN . . . . . 0.989 ' ND2' HD23 ' B' ' 89' ' ' LEU . 16.1 p-10 -53.62 -26.92 24.11 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.062 -1.024 . . . . 0.0 109.601 -179.588 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.989 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.9 mm? -108.87 -30.48 8.11 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.066 -1.021 . . . . 0.0 109.847 -179.494 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.698 HD21 ' CD2' ' B' ' 24' ' ' LEU . 85.0 mt -61.29 -30.31 70.4 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.247 -0.908 . . . . 0.0 108.849 179.863 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.1 p -78.47 -22.0 48.21 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.292 -0.88 . . . . 0.0 108.796 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -72.16 -40.73 67.79 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.326 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 93' ' ' ILE . . . . . 0.636 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -87.89 -8.12 10.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.349 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 94' ' ' GLY . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.09 61.41 6.11 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.255 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 95' ' ' ALA . . . . . 0.549 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -88.53 158.55 18.27 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -1.152 . . . . 0.0 110.341 -179.664 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 96' ' ' THR . . . . . 0.695 HG22 HG22 ' A' ' 4' ' ' THR . 43.7 p -135.29 127.6 30.23 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 97' ' ' LEU . . . . . 0.684 HD13 HG21 ' B' ' 26' ' ' THR . 0.2 OUTLIER -91.4 95.69 10.12 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.302 -0.874 . . . . 0.0 109.902 -178.786 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 98' ' ' ASN . . . . . 0.544 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -106.83 131.36 54.02 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.868 . . . . 0.0 109.941 -179.882 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' B' B ' 99' ' ' PHE . . . . . 0.943 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.284 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.615 0 CA-C-O 121.355 0.481 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.55 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 20.7 tt0 -86.19 118.5 25.69 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 177.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 65.9 t -115.15 105.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 120.806 -1.184 . . . . 0.0 110.405 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.818 HG22 HG22 ' B' ' 96' ' ' THR . 1.3 p -123.34 30.0 6.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.615 -0.678 . . . . 0.0 109.709 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.548 ' O ' ' C ' ' A' ' 6' ' ' TRP . 1.0 OUTLIER -89.56 39.33 0.94 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.13 -0.981 . . . . 0.0 109.295 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.548 ' C ' ' O ' ' A' ' 5' ' ' LEU . 46.2 m0 16.28 59.36 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 CA-C-O 121.613 0.72 . . . . 0.0 111.918 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.424 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -145.14 174.22 11.25 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.395 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 20.8 mtt180 -65.97 118.32 51.0 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.98 -1.075 . . . . 0.0 108.915 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.974 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 71.66 6.16 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 C-N-CA 122.214 1.942 . . . . 0.0 109.545 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -92.93 157.07 16.53 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.442 -0.786 . . . . 0.0 109.523 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.535 HG21 HG13 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -150.77 136.53 11.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.183 -0.948 . . . . 0.0 110.158 -179.599 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.84 HG22 HD22 ' A' ' 19' ' ' LEU . 55.0 m -68.32 108.9 3.39 Favored 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.919 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.2 pp -98.66 152.46 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 120.957 -1.09 . . . . 0.0 111.012 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.51 ' HE3' HD11 ' A' ' 19' ' ' LEU . 10.9 tttt -113.23 104.61 12.51 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' A' ' 75' ' ' VAL . 5.1 mt -120.84 129.81 75.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.079 -1.013 . . . . 0.0 109.894 -179.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.58 35.57 81.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.34 73.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -121.47 -176.76 3.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.342 -1.093 . . . . 0.0 108.653 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.919 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.4 mt -151.4 124.05 8.48 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.938 -1.101 . . . . 0.0 110.892 -179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.543 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -141.97 165.99 25.94 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 178.495 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.5 mp0 -79.25 131.62 36.23 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.9 -1.125 . . . . 0.0 108.747 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.655 ' HB2' ' CG2' ' A' ' 13' ' ' ILE . . . -108.09 137.87 45.33 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.067 -1.021 . . . . 0.0 110.641 -178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.615 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.1 tp -104.77 98.7 8.4 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.974 HD12 ' HB2' ' A' ' 9' ' ' PRO . 43.2 mt -44.95 95.17 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.064 -1.022 . . . . 0.0 108.685 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 23' ' ' LEU . 1.4 t70 -97.05 79.8 2.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.164 -0.96 . . . . 0.0 110.732 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.407 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 27.6 m -63.11 -13.71 39.8 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.991 -1.068 . . . . 0.0 108.762 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.445 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.8 -41.39 49.85 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.04 168.95 19.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.202 -1.176 . . . . 0.0 109.67 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.71 -17.59 16.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.185 -0.947 . . . . 0.0 111.272 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.831 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -135.7 -176.71 4.38 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.553 -1.342 . . . . 0.0 110.427 -179.366 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 16.7 m -98.86 87.97 3.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.359 -0.838 . . . . 0.0 110.68 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.95 168.14 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 178.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.23 135.22 5.14 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 120.975 -1.078 . . . . 0.0 110.518 -178.235 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 80' ' ' THR . 2.0 mt-10 -45.16 170.68 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.375 -0.828 . . . . 0.0 108.834 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -60.59 152.68 25.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.041 -1.037 . . . . 0.0 109.888 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.633 ' HE2' HG22 ' A' ' 15' ' ' ILE . 8.1 ptm -177.8 -158.92 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.33 -0.856 . . . . 0.0 109.566 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.909 ' O ' HD22 ' A' ' 38' ' ' LEU . 6.6 t -110.67 127.21 55.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.258 -0.901 . . . . 0.0 110.351 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.909 HD22 ' O ' ' A' ' 37' ' ' SER . 3.8 mm? -131.88 170.01 12.4 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 36.3 Cg_endo -80.99 123.96 4.79 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.791 2.327 . . . . 0.0 112.514 -178.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.552 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -44.49 117.72 2.18 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.552 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 150.04 44.33 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.263 -1.754 . . . . 0.0 106.263 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 35.4 p-90 -118.81 -173.84 2.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.961 0.886 . . . . 0.0 110.709 -177.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.08 136.92 11.12 Favored Pre-proline 0 C--N 1.303 -1.451 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.05 136.89 20.88 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.846 1.698 . . . . 0.0 110.986 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.709 ' HD2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -146.8 157.52 43.69 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.547 ' CG ' ' HG2' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -119.41 125.47 49.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.836 -1.165 . . . . 0.0 110.188 -178.889 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 54' ' ' ILE . 5.7 pt -104.86 136.23 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.036 -1.04 . . . . 0.0 108.746 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.595 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.36 102.59 0.97 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -119.51 -127.16 3.56 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.627 -178.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.883 HD12 H702 ' B' ' 100' ' ' DMP . 57.0 mt -80.19 122.13 34.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.9 -0.765 . . . . 0.0 112.925 -177.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.431 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 100.0 -50.87 1.08 Allowed Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.049 177.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -177.5 -160.53 24.36 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.255 -1.45 . . . . 0.0 110.582 -179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.595 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 3.8 m-85 -113.47 133.37 55.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.567 -0.96 . . . . 0.0 109.926 -179.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.994 HD11 HD11 ' A' ' 47' ' ' ILE . 10.6 pt -113.51 168.09 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.141 -0.974 . . . . 0.0 108.918 178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.7 mtpt -113.46 132.4 55.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.201 -0.937 . . . . 0.0 109.252 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.642 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.6 m -127.79 -174.59 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.969 -1.082 . . . . 0.0 110.217 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.522 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 1.7 mtt85 -127.37 92.08 3.44 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.4 tt0 -54.58 94.54 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.544 -0.723 . . . . 0.0 110.484 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.881 ' HB3' HD11 ' A' ' 62' ' ' ILE . 26.6 m-85 -89.51 133.7 34.46 Favored 'General case' 0 C--N 1.303 -1.451 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 177.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.5 OUTLIER -111.35 139.86 46.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.938 -1.101 . . . . 0.0 111.528 -177.664 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.0 OUTLIER 69.48 63.48 0.27 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.727 -0.608 . . . . 0.0 110.44 178.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.881 HD11 ' HB3' ' A' ' 59' ' ' TYR . 3.6 mp -116.71 122.78 70.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.1 tm? -64.77 82.91 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 CA-C-O 121.642 0.734 . . . . 0.0 110.48 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.928 HD12 HD11 ' A' ' 15' ' ' ILE . 2.9 tt -90.76 117.83 34.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.55 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -90.4 137.23 32.52 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.09 -1.006 . . . . 0.0 108.587 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.579 HG13 HG22 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -124.37 112.61 33.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 120.902 -1.124 . . . . 0.0 108.901 179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 62.37 23.08 13.65 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.713 -0.617 . . . . 0.0 109.833 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 93.93 9.22 59.85 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.547 ' N ' ' CD2' ' A' ' 69' ' ' HIS . 2.5 m170 -100.54 105.41 16.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.097 -1.237 . . . . 0.0 109.218 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.567 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 tttt -53.77 125.07 17.12 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.134 -0.979 . . . . 0.0 109.303 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.601 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -147.18 145.99 29.7 Favored 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.566 -0.709 . . . . 0.0 109.397 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.785 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.7 OUTLIER -115.43 155.31 16.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 105.93 -1.878 . . . . 0.0 105.93 177.438 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.596 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.67 -173.38 43.97 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 118.14 -1.981 . . . . 0.0 111.367 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.545 HG23 ' OD1' ' A' ' 60' ' ' ASP . 0.2 OUTLIER -93.51 107.43 19.28 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.776 -0.838 . . . . 0.0 109.555 -179.763 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' A' ' 15' ' ' ILE . 1.5 t -102.72 111.58 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.341 -0.849 . . . . 0.0 110.45 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.831 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.3 mp -81.79 122.9 28.28 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.439 -0.788 . . . . 0.0 109.211 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.564 HG21 HD23 ' A' ' 38' ' ' LEU . 71.9 t -103.96 118.84 51.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.093 -1.005 . . . . 0.0 109.769 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.642 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.03 -165.6 14.76 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.1 Cg_endo -80.31 43.26 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.329 0 C-N-CA 122.72 2.28 . . . . 0.0 110.795 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.645 HG21 HG13 ' A' ' 32' ' ' VAL . 9.2 t -89.05 139.02 28.83 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 108.377 -0.972 . . . . 0.0 108.377 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.472 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.9 Cg_endo -79.6 17.96 1.18 Allowed 'Trans proline' 0 C--N 1.306 -1.696 0 C-N-CA 122.568 2.178 . . . . 0.0 111.81 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG12 ' CD1' ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.74 166.98 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 120.543 -1.348 . . . . 0.0 110.659 -179.811 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.556 ' OD1' ' CD2' ' A' ' 33' ' ' LEU . 7.5 m-80 -96.87 93.53 6.71 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 176.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.816 ' CG1' HG12 ' A' ' 32' ' ' VAL . 26.7 mm -78.42 127.25 38.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 O-C-N 120.727 -1.233 . . . . 0.0 112.154 -176.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.627 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -107.43 89.96 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 177.232 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.14 -165.0 28.81 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 120.276 -0.964 . . . . 0.0 111.217 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 9.5 mtm180 -64.42 -31.05 72.1 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.793 -0.828 . . . . 0.0 109.92 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.2 p-10 -48.61 -26.04 2.04 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.145 -0.972 . . . . 0.0 109.422 -179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -106.75 -21.15 13.13 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 121.01 -1.056 . . . . 0.0 108.837 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.556 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 43.4 mt -72.61 -4.09 28.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 177.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.637 ' CG2' HD23 ' B' ' 5' ' ' LEU . 0.0 OUTLIER -100.57 -18.43 16.61 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 178.294 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.475 ' HA ' ' OE1' ' A' ' 92' ' ' GLN . 50.6 mm-40 -83.06 -40.9 19.27 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.874 HD12 ' CG ' ' B' ' 99' ' ' PHE . 1.4 pt -89.0 5.27 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 O-C-N 121.418 -0.801 . . . . 0.0 109.397 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 58.98 47.66 89.62 Favored Glycine 0 N--CA 1.496 2.686 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.476 ' O ' HD12 ' B' ' 5' ' ' LEU . . . -70.69 155.1 41.18 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.137 -1.214 . . . . 0.0 110.76 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 24.1 p -146.74 126.09 13.12 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' B' ' 97' ' ' LEU . 4.0 mp -93.46 86.04 5.12 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.483 -179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 5.3 m120 -91.38 124.4 35.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.289 -0.882 . . . . 0.0 109.652 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.045 -0.978 . . . . 0.0 109.196 179.355 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.584 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.718 0 N-CA-C 110.572 -0.588 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.439 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 0.3 OUTLIER -99.66 117.44 34.02 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.533 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' B' ' 9' ' ' PRO . 9.1 t -108.04 114.69 47.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 108.605 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.935 ' C ' HD13 ' B' ' 5' ' ' LEU . 19.8 p -67.79 -105.19 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.274 -0.891 . . . . 0.0 109.073 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.935 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -171.88 -11.64 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.828 -1.17 . . . . 0.0 111.434 179.824 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.661 ' N ' HD22 ' B' ' 5' ' ' LEU . 72.2 m95 -66.61 -10.53 46.65 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.69 -1.256 . . . . 0.0 109.49 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.96 178.59 7.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 109.615 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.509 ' HG2' ' NH1' ' A' ' 87' ' ' ARG . 13.8 mtt180 -92.18 138.56 24.35 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.316 -0.865 . . . . 0.0 109.157 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.758 ' HB3' HG11 ' B' ' 3' ' ' VAL . 36.6 Cg_endo -79.49 59.93 7.6 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.246 1.964 . . . . 0.0 110.147 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.684 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -86.43 145.72 26.73 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.945 -1.097 . . . . 0.0 109.102 -179.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.599 HG21 HG23 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -145.15 136.01 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.651 -179.137 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.743 HG22 HD22 ' B' ' 19' ' ' LEU . 86.5 m -68.26 90.5 0.35 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.701 HG22 HG13 ' B' ' 66' ' ' ILE . 47.8 pt -79.09 153.7 4.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.451 -0.781 . . . . 0.0 110.02 -178.59 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.81 ' HG3' HD21 ' B' ' 19' ' ' LEU . 3.2 tttt -115.14 100.56 8.25 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.413 -0.804 . . . . 0.0 109.82 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.724 HG23 HG21 ' B' ' 62' ' ' ILE . 11.1 mt -122.81 131.19 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.55 48.65 85.0 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.55 20.96 6.01 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -112.98 171.44 7.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.155 -1.203 . . . . 0.0 109.714 -179.805 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.81 HD21 ' HG3' ' B' ' 14' ' ' LYS . 55.5 mt -143.47 127.67 17.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.378 -0.826 . . . . 0.0 109.524 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -147.95 165.99 29.06 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 108.912 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.684 ' HB3' HD22 ' B' ' 10' ' ' LEU . 2.5 mm-40 -78.55 127.37 32.04 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.055 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.664 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.57 159.07 16.05 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.886 -1.134 . . . . 0.0 109.808 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.461 HD11 HH22 ' A' ' 87' ' ' ARG . 19.2 tp -122.53 93.76 4.08 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.485 -0.76 . . . . 0.0 109.109 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.565 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.7 mt -46.41 110.66 0.29 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.994 -1.066 . . . . 0.0 108.243 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.611 ' HB3' HG22 ' B' ' 84' ' ' ILE . 56.3 t0 -122.07 91.65 3.56 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.19 -0.944 . . . . 0.0 110.403 -178.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.69 HG23 HD13 ' B' ' 90' ' ' LEU . 1.3 m -65.0 -10.3 28.49 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.9 -1.125 . . . . 0.0 108.78 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.615 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -68.74 -46.94 58.85 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.488 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -73.41 164.92 26.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.154 -1.204 . . . . 0.0 109.496 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 -101.14 -15.44 17.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.027 -1.046 . . . . 0.0 110.969 -178.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.613 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -132.08 -163.37 1.33 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.778 -1.201 . . . . 0.0 110.024 -179.3 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.673 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 67.0 m -113.39 91.34 3.61 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.052 -1.03 . . . . 0.0 110.012 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -77.56 156.17 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 179.371 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.004 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -152.78 124.36 7.76 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.595 -1.316 . . . . 0.0 110.162 -178.894 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.527 ' HA ' HG22 ' B' ' 80' ' ' THR . 47.5 tt0 -36.56 153.3 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.548 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.5 tt0 -53.63 152.49 5.11 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -0.981 . . . . 0.0 109.93 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.3 ptm -177.26 -174.12 0.48 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.486 -0.759 . . . . 0.0 109.406 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -91.52 105.73 17.97 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 109.648 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.652 HD12 ' HD2' ' B' ' 39' ' ' PRO . 32.2 tp -134.96 105.07 10.5 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.718 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.652 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.7 Cg_endo -78.24 138.7 16.19 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.451 2.101 . . . . 0.0 110.147 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.95 179.45 22.17 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -81.12 139.72 35.47 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.276 -1.132 . . . . 0.0 109.13 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.578 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 38.7 p-90 -150.36 153.38 35.92 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.138 -0.976 . . . . 0.0 109.958 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.77 131.16 24.25 Favored Pre-proline 0 N--CA 1.489 1.478 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.12 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -76.72 135.79 16.37 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.982 1.788 . . . . 0.0 110.708 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.573 ' HG3' HG22 ' B' ' 56' ' ' VAL . 1.1 ptmm? -158.04 -168.35 2.48 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.543 -0.723 . . . . 0.0 109.059 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.513 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 1.0 OUTLIER -145.36 121.1 10.53 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.097 -1.002 . . . . 0.0 110.015 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.648 HD12 HG21 ' A' ' 50' ' ' ILE . 2.4 pt -92.26 141.18 14.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.25 -0.906 . . . . 0.0 108.618 179.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.56 108.65 1.53 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.47 -119.09 2.21 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.499 -1.334 . . . . 0.0 110.244 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.686 HG21 HD12 ' A' ' 47' ' ' ILE . 25.8 mt -87.75 130.87 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.441 -1.035 . . . . 0.0 111.781 -178.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.485 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 91.3 -45.0 2.79 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.549 -1.021 . . . . 0.0 110.549 178.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.431 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.36 -159.36 29.38 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.444 -1.36 . . . . 0.0 110.167 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.535 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -121.62 139.34 53.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.505 -0.997 . . . . 0.0 109.16 -179.715 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' B' ' 46' ' ' MET . 32.4 pt -114.31 -176.16 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.257 -0.902 . . . . 0.0 109.655 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.526 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -107.28 150.03 27.12 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.321 -0.862 . . . . 0.0 108.955 179.406 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.599 HG21 HD23 ' B' ' 76' ' ' LEU . 3.2 m -143.72 -174.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 120.788 -1.195 . . . . 0.0 110.655 -179.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.5 ' HG3' ' O ' ' B' ' 77' ' ' VAL . 3.6 mtm-85 -142.41 88.47 2.08 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.522 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 2.2 tt0 -48.02 95.05 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.314 -0.866 . . . . 0.0 110.296 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.578 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.2 m-85 -92.43 92.82 8.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 4.6 m-20 -79.88 130.72 35.53 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.97 -1.081 . . . . 0.0 111.025 -178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.516 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 2.9 mt-30 84.95 59.27 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 CA-C-O 121.165 0.507 . . . . 0.0 110.968 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.724 HG21 HG23 ' B' ' 15' ' ' ILE . 13.2 mm -118.41 124.9 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -1.0 . . . . 0.0 108.579 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.675 HD21 ' HG3' ' B' ' 70' ' ' LYS . 1.9 tm? -72.16 99.99 2.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.174 -0.954 . . . . 0.0 110.998 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.97 HD13 HD11 ' B' ' 66' ' ' ILE . 1.3 tt -104.7 117.62 50.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.48 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 31.7 tt0 -90.77 108.56 19.9 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.091 -1.006 . . . . 0.0 109.118 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.97 HD11 HD13 ' B' ' 64' ' ' ILE . 1.1 mp -99.03 116.89 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.234 -0.916 . . . . 0.0 109.957 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.476 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 10.1 m 64.26 17.28 10.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.821 -0.55 . . . . 0.0 110.649 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 96.94 4.11 58.92 Favored Glycine 0 N--CA 1.492 2.423 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.15 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -104.68 116.33 31.87 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.049 -1.265 . . . . 0.0 109.418 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.675 ' HG3' HD21 ' B' ' 63' ' ' LEU . 14.7 tttt -52.81 137.86 30.81 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.45 -0.782 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.677 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -160.13 100.88 1.4 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.18 -0.95 . . . . 0.0 109.619 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.606 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.31 156.56 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.642 -1.286 . . . . 0.0 108.32 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.746 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -177.75 176.27 47.95 Favored Glycine 0 N--CA 1.488 2.149 0 C-N-CA 118.999 -1.572 . . . . 0.0 111.167 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.522 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 10.6 m -88.51 109.85 20.39 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.63 -0.924 . . . . 0.0 110.376 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.867 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.8 OUTLIER -99.84 110.89 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.274 -0.891 . . . . 0.0 110.534 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.613 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -79.52 104.27 10.01 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.548 HG12 ' HA ' ' B' ' 35' ' ' GLU . 26.3 t -88.77 125.5 41.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 120.777 -1.202 . . . . 0.0 110.017 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -153.01 -169.32 18.05 Favored Glycine 0 N--CA 1.487 2.076 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.526 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -81.44 41.86 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 C-N-CA 122.557 2.171 . . . . 0.0 110.793 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.616 HG21 HG13 ' B' ' 32' ' ' VAL . 14.6 t -84.73 140.15 37.88 Favored Pre-proline 0 N--CA 1.489 1.504 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.452 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 36.6 Cg_endo -79.38 14.0 1.91 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.376 2.051 . . . . 0.0 111.175 -178.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.673 HG12 HD11 ' B' ' 84' ' ' ILE . 0.5 OUTLIER -160.85 176.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.825 -1.172 . . . . 0.0 110.591 -179.47 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.665 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -107.98 147.78 30.61 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 176.721 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.673 ' O ' ' HA ' ' B' ' 31' ' ' THR . 4.6 mm -135.3 100.1 2.6 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 O-C-N 120.902 -1.124 . . . . 0.0 110.963 -177.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.664 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -79.2 88.86 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 178.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -81.23 -160.42 24.84 Favored Glycine 0 N--CA 1.494 2.555 0 O-C-N 121.363 -0.836 . . . . 0.0 112.103 -177.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.414 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.8 mtm180 -58.91 -41.0 86.22 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 122.148 -0.619 . . . . 0.0 111.386 -178.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.862 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.9 p-10 -52.23 -18.89 1.71 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.979 -1.076 . . . . 0.0 109.956 -178.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.862 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.4 mm? -114.75 -23.92 8.96 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 120.928 -1.107 . . . . 0.0 108.933 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.69 HD13 HG23 ' B' ' 26' ' ' THR . 25.9 mt -71.84 -6.79 44.21 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 59.9 p -101.19 -17.79 16.46 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.299 -0.876 . . . . 0.0 108.753 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -83.7 -41.49 17.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.415 -0.803 . . . . 0.0 109.502 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -84.7 -4.64 8.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.165 -0.959 . . . . 0.0 108.713 179.282 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.97 58.67 7.2 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.03 157.81 25.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.112 -1.228 . . . . 0.0 110.347 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.818 HG22 HG22 ' A' ' 4' ' ' THR . 9.4 p -139.6 126.07 20.34 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 1.003 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -95.88 89.38 5.23 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.104 -179.156 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.55 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 0.6 OUTLIER -101.55 132.7 47.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -0.83 . . . . 0.0 110.568 -178.966 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.874 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 117.946 -1.026 . . . . 0.0 108.751 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.883 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.439 ' HD2' ' C ' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.318 -0.686 . . . . 0.0 110.318 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.554 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -84.26 131.92 34.69 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.2 t -131.53 118.78 40.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 120.998 -1.064 . . . . 0.0 110.209 -178.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.609 ' CG2' HG22 ' B' ' 96' ' ' THR . 2.2 p -127.71 -90.91 0.51 Allowed 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.56 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.9 OUTLIER 41.63 29.17 0.1 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.48 -0.762 . . . . 0.0 109.432 179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.56 ' C ' ' O ' ' A' ' 5' ' ' LEU . 37.3 m0 18.07 51.84 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 CA-C-O 121.638 0.732 . . . . 0.0 111.326 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.546 ' N ' ' O ' ' A' ' 5' ' ' LEU . 1.9 mt-30 -142.3 -166.66 2.3 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.9 mtm180 -74.25 116.4 52.35 Favored Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.766 ' HB2' HD12 ' A' ' 24' ' ' LEU . 33.5 Cg_endo -76.53 73.84 5.0 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.269 1.979 . . . . 0.0 109.763 179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -81.53 158.56 24.42 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.32 -0.862 . . . . 0.0 110.301 -179.113 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 24' ' ' LEU . 4.0 m -149.85 130.54 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.408 -0.808 . . . . 0.0 109.588 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.785 HG22 HD22 ' A' ' 19' ' ' LEU . 2.0 m -68.49 106.09 2.43 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.728 HD11 HD21 ' A' ' 33' ' ' LEU . 6.8 pt -92.24 155.06 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.21 -0.931 . . . . 0.0 110.285 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.8 OUTLIER -119.02 105.83 11.82 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.059 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.586 ' CD1' HG11 ' A' ' 75' ' ' VAL . 8.1 mt -123.99 127.08 73.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 120.987 -1.071 . . . . 0.0 109.819 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.73 35.55 91.14 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.63 9.88 52.71 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -104.64 -179.4 3.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.374 -1.074 . . . . 0.0 109.297 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.785 HD22 HG22 ' A' ' 12' ' ' THR . 3.6 mt -145.9 131.25 18.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.255 -0.903 . . . . 0.0 110.269 -179.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.479 ' HG2' ' C ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -145.51 157.02 44.06 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.272 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.519 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 19.7 mp0 -78.98 133.63 36.85 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.842 -1.161 . . . . 0.0 107.93 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -113.68 144.07 43.55 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.994 -1.066 . . . . 0.0 111.07 -178.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 25' ' ' ASP . 58.8 tp -98.71 92.67 5.7 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 179.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.766 HD12 ' HB2' ' A' ' 9' ' ' PRO . 74.0 mt -43.94 96.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 51.4 t0 -110.74 92.8 4.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.458 -0.776 . . . . 0.0 110.461 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 6.0 m -67.31 -10.66 53.07 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 108.758 178.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 1.055 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -74.19 -43.18 33.35 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.42 149.37 50.13 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.9 -1.353 . . . . 0.0 109.202 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -84.45 -19.94 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.119 -0.988 . . . . 0.0 110.133 -179.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' HB3' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -136.57 -162.25 1.26 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.067 -1.02 . . . . 0.0 109.499 -179.503 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 HD12 ' A' ' 85' ' ' ILE . 20.4 m -115.77 100.41 8.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.473 -1.392 . . . . 0.0 111.235 -178.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -78.0 178.15 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.695 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.037 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.15 116.35 0.62 Allowed 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.935 -1.103 . . . . 0.0 110.213 -179.241 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.756 ' HA ' HG22 ' A' ' 80' ' ' THR . 41.2 tt0 -39.35 162.02 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.29 -0.881 . . . . 0.0 109.966 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -41.34 156.85 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.218 -0.926 . . . . 0.0 110.738 -179.562 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.626 ' HG2' HG11 ' A' ' 77' ' ' VAL . 11.2 ptm -179.02 -176.94 0.45 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.548 -0.72 . . . . 0.0 109.149 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.8 t -104.52 118.69 37.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.23 -0.919 . . . . 0.0 109.417 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.631 ' HB3' ' HD2' ' A' ' 39' ' ' PRO . 9.9 mt -132.92 170.65 10.85 Favored Pre-proline 0 N--CA 1.493 1.694 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.631 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -69.53 -163.06 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.287 0 C-N-CA 122.079 1.853 . . . . 0.0 111.671 -179.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -105.39 35.09 5.3 Favored Glycine 0 N--CA 1.494 2.502 0 C-N-CA 119.968 -1.111 . . . . 0.0 111.169 -178.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.5 mtt85 -109.56 50.44 0.79 Allowed 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.7 p-90 -133.43 176.79 8.22 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.867 0.841 . . . . 0.0 110.542 -178.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -149.26 151.74 34.53 Favored Pre-proline 0 C--N 1.302 -1.486 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.01 130.37 11.24 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 C-N-CA 121.759 1.639 . . . . 0.0 110.655 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.761 ' O ' HG22 ' A' ' 56' ' ' VAL . 3.6 ptmt -161.42 129.14 4.17 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.533 ' CG ' ' HG3' ' A' ' 55' ' ' LYS . 15.4 mtp -89.58 135.01 33.85 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 120.941 -1.1 . . . . 0.0 109.417 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 7.0 pt -89.4 145.91 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.244 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 98.36 0.76 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.104 -1.599 . . . . 0.0 109.104 -179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.98 -124.1 2.99 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.61 -1.281 . . . . 0.0 110.46 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.977 HG21 HD12 ' B' ' 47' ' ' ILE . 9.9 mt -88.87 119.15 35.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.636 -0.92 . . . . 0.0 112.693 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 106.54 -51.3 0.75 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 177.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.28 -155.52 16.13 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.6 m-85 -118.41 128.66 54.83 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.456 -1.026 . . . . 0.0 109.995 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' MET . 10.1 pt -101.77 169.69 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.536 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 16.1 mttt -99.62 134.57 42.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.019 -1.051 . . . . 0.0 108.958 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 45' ' ' LYS . 34.7 m -140.51 -177.61 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.957 -1.089 . . . . 0.0 110.255 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.9 mtt180 -128.97 91.65 3.25 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.451 ' OE1' ' CG2' ' A' ' 74' ' ' THR . 2.4 tp-100 -55.06 105.08 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.62 -0.675 . . . . 0.0 110.71 -179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.669 ' C ' HD11 ' A' ' 62' ' ' ILE . 11.4 m-85 -96.45 129.04 43.9 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.508 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 40.0 m-20 -111.17 133.41 53.55 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.738 -1.226 . . . . 0.0 109.771 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.575 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 7.8 mm100 78.29 61.91 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.648 -0.657 . . . . 0.0 109.994 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.704 HD12 ' N ' ' A' ' 62' ' ' ILE . 4.4 mp -119.45 126.55 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.349 -0.844 . . . . 0.0 108.749 179.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.865 ' O ' HD13 ' A' ' 63' ' ' LEU . 3.1 tm? -77.87 94.47 4.55 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.149 0.976 . . . . 0.0 111.613 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.878 HG12 HD12 ' A' ' 66' ' ' ILE . 3.2 tt -98.02 119.79 46.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.407 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -91.11 125.3 35.85 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.827 -1.17 . . . . 0.0 108.804 -179.876 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.878 HD12 HG12 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -121.61 135.37 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.103 -0.998 . . . . 0.0 109.748 -179.314 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.44 ' C ' ' O ' ' A' ' 66' ' ' ILE . 59.5 m 36.93 38.23 0.08 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 121.088 0.47 . . . . 0.0 110.578 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.34 47.64 8.86 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.707 ' CB ' HG22 ' A' ' 93' ' ' ILE . 73.6 m-70 -141.18 123.28 15.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.346 -1.091 . . . . 0.0 109.353 179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.44 ' CG ' HD21 ' A' ' 63' ' ' LEU . 6.9 tttt -77.76 122.09 24.92 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.223 -0.923 . . . . 0.0 108.558 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.68 ' HB1' HE21 ' A' ' 92' ' ' GLN . . . -144.43 124.27 13.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.033 -1.042 . . . . 0.0 110.818 -178.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.575 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.4 OUTLIER -102.65 120.15 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.232 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.522 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -144.15 -165.43 10.94 Favored Glycine 0 C--N 1.289 -2.06 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.872 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.487 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 38.0 m -97.43 114.72 26.6 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.503 -0.998 . . . . 0.0 110.305 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.037 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -106.43 118.89 54.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 C-N-CA 120.216 -0.593 . . . . 0.0 110.159 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.557 ' HB2' ' CG2' ' A' ' 32' ' ' VAL . 2.4 mp -89.44 126.24 35.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.103 -0.998 . . . . 0.0 109.177 179.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.626 HG11 ' HG2' ' A' ' 36' ' ' MET . 1.7 t -108.5 120.58 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.943 -1.098 . . . . 0.0 109.427 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.6 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.08 -169.32 20.8 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.536 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -80.8 39.86 0.91 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.605 2.203 . . . . 0.0 110.886 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.756 HG22 ' HA ' ' A' ' 34' ' ' GLU . 15.1 t -82.39 139.96 44.95 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 82' ' ' VAL . 34.5 Cg_endo -78.16 14.57 1.52 Allowed 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.222 1.948 . . . . 0.0 111.084 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.533 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.23 165.0 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 120.96 -1.088 . . . . 0.0 109.778 -179.408 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.616 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -101.75 145.92 28.47 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 104.176 -2.527 . . . . 0.0 104.176 175.979 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.681 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.3 mm -129.92 129.99 66.14 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 O-C-N 120.047 -1.658 . . . . 0.0 111.743 -177.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.608 HD12 HG23 ' A' ' 31' ' ' THR . 0.8 OUTLIER -104.95 96.39 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.834 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -82.29 -169.34 43.38 Favored Glycine 0 N--CA 1.492 2.376 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.481 -178.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HE ' HG23 ' A' ' 26' ' ' THR . 0.1 OUTLIER -62.43 -30.43 71.22 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.581 -0.953 . . . . 0.0 109.789 -179.81 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.6 p-10 -50.51 -28.64 8.83 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.986 -1.071 . . . . 0.0 109.782 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.0 mm? -110.11 -27.87 8.95 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.011 -1.056 . . . . 0.0 110.652 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.537 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 33.9 mt -65.49 -13.57 59.14 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.739 -1.226 . . . . 0.0 109.322 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.4 p -96.69 -21.3 17.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.046 -1.034 . . . . 0.0 109.254 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.68 HE21 ' HB1' ' A' ' 71' ' ' ALA . 2.0 mt-30 -74.92 -40.26 60.96 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.176 -0.953 . . . . 0.0 108.521 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.889 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -79.59 1.11 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 178.603 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.66 59.48 8.14 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -87.86 156.43 19.39 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.301 -1.117 . . . . 0.0 109.914 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.767 HG22 ' CG2' ' B' ' 4' ' ' THR . 2.2 p -138.86 129.27 25.78 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -95.52 90.38 5.73 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.519 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.5 m120 -89.52 125.77 35.33 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.213 -0.929 . . . . 0.0 109.939 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.711 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.952 -1.023 . . . . 0.0 109.022 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.5 Cg_endo . . . . . 0 N--CA 1.497 1.708 0 N-CA-C 110.14 -0.754 . . . . 0.0 110.14 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.483 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 2.9 tt0 -84.56 114.67 22.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 42.3 t -105.78 115.07 46.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.956 -1.09 . . . . 0.0 111.104 -177.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.767 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.46 32.51 1.48 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.322 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.526 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.7 mt -85.55 49.05 1.68 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.598 -0.689 . . . . 0.0 109.925 -179.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.526 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.8 m95 17.84 52.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.229 0.537 . . . . 0.0 112.174 179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.9 mt-30 -154.95 171.5 19.61 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.221 -0.924 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.405 ' HA ' ' HD3' ' B' ' 9' ' ' PRO . 4.7 mtt180 -63.87 144.19 98.06 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 120.99 -1.069 . . . . 0.0 109.492 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.447 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -80.15 54.9 5.42 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.645 2.23 . . . . 0.0 110.904 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.954 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.1 mt -80.62 135.23 36.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.988 -1.07 . . . . 0.0 108.89 179.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.464 HG22 HG23 ' B' ' 13' ' ' ILE . 0.9 OUTLIER -134.88 141.82 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.181 -0.95 . . . . 0.0 109.604 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.826 HG22 HD22 ' B' ' 19' ' ' LEU . 10.1 m -70.17 100.53 1.68 Allowed 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 178.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.789 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -95.12 143.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.404 -0.81 . . . . 0.0 110.055 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.6 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.0 OUTLIER -98.95 107.78 20.3 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 178.905 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.68 HG12 HD12 ' B' ' 13' ' ' ILE . 10.2 mm -113.83 115.45 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 O-C-N 120.756 -1.215 . . . . 0.0 110.865 -178.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.491 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.15 9.21 56.79 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.44 -10.05 42.23 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.429 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 1.5 mp0 -89.86 -173.29 3.84 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.264 -1.139 . . . . 0.0 109.063 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.826 HD22 HG22 ' B' ' 12' ' ' THR . 18.0 mt -149.13 121.86 8.66 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.277 -0.889 . . . . 0.0 109.889 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.488 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 4.9 mmtt -141.83 172.55 12.53 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 108.38 -0.971 . . . . 0.0 108.38 179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.954 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.9 OUTLIER -79.65 155.3 28.13 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 179.227 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.58 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -135.76 113.02 10.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 1.055 HD21 ' O ' ' A' ' 27' ' ' GLY . 3.3 tp -84.15 104.01 13.85 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.447 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 16.3 mt -52.45 103.9 0.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.91 ' HB3' HG23 ' B' ' 84' ' ' ILE . 19.9 t0 -101.16 77.96 1.86 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.37 -0.831 . . . . 0.0 110.174 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.782 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.02 -14.46 9.58 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.079 -1.013 . . . . 0.0 108.962 178.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.431 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -70.8 -35.46 66.14 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.477 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -83.3 170.86 14.16 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.938 -1.33 . . . . 0.0 110.234 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -100.54 -18.8 16.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.291 -0.881 . . . . 0.0 110.796 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.609 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -132.92 -170.54 2.47 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.599 -1.313 . . . . 0.0 110.625 -179.059 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.679 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.1 m -106.07 91.83 3.89 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.938 -1.102 . . . . 0.0 110.558 -178.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.953 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -81.01 154.31 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.717 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.953 HD12 ' O ' ' B' ' 32' ' ' VAL . 1.3 mp -148.91 133.62 17.85 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.919 -1.113 . . . . 0.0 110.667 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.559 ' N ' HG22 ' B' ' 80' ' ' THR . 3.9 mt-10 -43.5 166.69 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.468 -0.77 . . . . 0.0 109.284 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.0 OUTLIER -67.9 115.1 7.04 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.407 -0.808 . . . . 0.0 109.25 179.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.586 ' CE ' ' CG2' ' B' ' 15' ' ' ILE . 6.7 ptm -139.46 -166.8 2.13 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.4 t -95.34 115.35 27.31 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.262 -0.899 . . . . 0.0 109.93 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.565 HD12 ' HD2' ' B' ' 39' ' ' PRO . 26.5 tp -144.42 105.0 4.67 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.565 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.5 Cg_endo -76.41 146.0 27.35 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.398 2.065 . . . . 0.0 110.848 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 136.96 145.24 4.94 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -63.95 117.94 7.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.98 -1.306 . . . . 0.0 108.501 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . . . . . . . . . 48.9 p-90 -110.95 175.89 5.24 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 110.31 -178.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.0 mmtt -126.03 137.03 29.34 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -76.56 129.14 10.75 Favored 'Trans proline' 0 C--N 1.303 -1.838 0 C-N-CA 121.799 1.666 . . . . 0.0 110.812 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.859 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -161.62 137.66 7.95 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.062 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.495 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 25.3 mtp -102.0 137.88 39.7 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 120.832 -1.168 . . . . 0.0 109.332 -179.225 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.977 HD12 HG21 ' A' ' 50' ' ' ILE . 2.1 pt -89.72 164.01 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.628 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -138.23 108.22 0.61 Allowed Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.445 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -139.61 -116.89 1.4 Allowed Glycine 0 N--CA 1.484 1.881 0 C-N-CA 119.46 -1.352 . . . . 0.0 110.357 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.866 HD12 ' C21' ' B' ' 100' ' ' DMP . 14.3 mt -85.79 122.79 38.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.6 -0.941 . . . . 0.0 112.019 -178.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 99.02 -52.8 1.08 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.437 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 173.45 -153.91 18.87 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 -179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.628 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.4 m-85 -113.54 135.81 53.49 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.494 -1.003 . . . . 0.0 109.941 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.645 HD11 HD11 ' B' ' 47' ' ' ILE . 1.8 pt -104.31 179.49 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.564 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -108.45 130.12 55.25 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.936 -1.103 . . . . 0.0 109.164 179.574 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.859 HG22 ' O ' ' B' ' 45' ' ' LYS . 3.7 m -134.0 169.61 21.38 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.947 -1.096 . . . . 0.0 110.175 -179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.459 ' HD3' ' HB ' ' B' ' 77' ' ' VAL . 8.9 mtp180 -120.26 87.78 2.81 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.517 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 3.0 tt0 -48.42 99.28 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.525 -0.734 . . . . 0.0 110.561 -178.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.8 ' O ' HG23 ' B' ' 74' ' ' THR . 5.2 m-85 -88.78 136.96 32.73 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 177.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 7.1 m-20 -114.86 133.37 56.02 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.571 -1.331 . . . . 0.0 110.882 -178.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.597 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 3.9 mp0 71.49 63.77 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.614 0.721 . . . . 0.0 109.849 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.455 HD12 HD21 ' B' ' 38' ' ' LEU . 9.1 mm -111.46 111.6 36.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.896 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.1 tm? -65.39 85.71 0.07 Allowed 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.445 -0.784 . . . . 0.0 110.266 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.734 HD13 HD11 ' B' ' 66' ' ' ILE . 3.8 tt -89.11 125.28 42.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.158 -1.052 . . . . 0.0 108.158 178.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 33.1 tt0 -89.2 109.01 19.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.126 -0.984 . . . . 0.0 109.506 -179.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.79 122.47 57.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.282 -0.886 . . . . 0.0 108.753 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.568 ' HB3' ' CD2' ' B' ' 69' ' ' HIS . 0.1 OUTLIER 53.83 54.56 9.63 Favored 'General case' 0 C--N 1.292 -1.926 0 O-C-N 121.489 -0.757 . . . . 0.0 110.631 179.026 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.15 20.51 28.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.568 ' CD2' ' HB3' ' B' ' 67' ' ' CYS . 87.8 m-70 -115.57 127.53 55.31 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.996 -1.296 . . . . 0.0 109.183 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.454 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -71.7 131.28 42.91 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.073 -1.017 . . . . 0.0 109.106 179.813 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.688 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -150.69 146.6 26.57 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.632 -0.667 . . . . 0.0 109.243 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.597 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.8 OUTLIER -114.25 156.71 15.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.432 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.968 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -179.3 173.37 45.38 Favored Glycine 0 N--CA 1.485 1.944 0 C-N-CA 118.632 -1.747 . . . . 0.0 111.055 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.8 HG23 ' O ' ' B' ' 59' ' ' TYR . 88.2 m -89.97 112.79 24.3 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.5 -1.0 . . . . 0.0 109.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.94 112.7 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.897 179.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.616 ' HB2' HG23 ' B' ' 32' ' ' VAL . 1.9 mp -81.82 105.73 13.19 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.533 -0.729 . . . . 0.0 109.061 179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.459 ' HB ' ' HD3' ' B' ' 57' ' ' ARG . 2.9 t -88.1 114.1 26.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 O-C-N 120.514 -1.366 . . . . 0.0 109.742 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -151.4 -170.42 18.23 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.564 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.3 Cg_endo -79.57 41.1 1.04 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 C-N-CA 122.434 2.089 . . . . 0.0 111.308 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.7 OUTLIER -85.82 137.73 35.68 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 178.374 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.601 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.5 21.52 0.69 Allowed 'Trans proline' 0 C--N 1.301 -1.921 0 C-N-CA 122.32 2.013 . . . . 0.0 112.13 -178.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -162.68 151.72 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 120.457 -1.402 . . . . 0.0 111.097 -179.735 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.58 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.5 OUTLIER -92.4 87.36 5.98 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 105.986 -1.857 . . . . 0.0 105.986 176.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.91 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.1 mt -84.71 123.62 39.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-O 121.896 0.855 . . . . 0.0 112.914 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.545 ' CG1' ' HB1' ' B' ' 22' ' ' ALA . 3.5 mm -95.8 96.42 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 176.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.512 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.5 -161.07 18.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.108 -177.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 7' ' ' GLN . 1.4 mtm105 -64.88 -31.01 72.04 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.893 -0.769 . . . . 0.0 110.65 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.014 ' ND2' HD23 ' B' ' 89' ' ' LEU . 13.8 p-10 -54.8 -26.88 37.65 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.737 -1.227 . . . . 0.0 110.211 -179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.014 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -108.83 -31.39 7.71 Favored 'General case' 0 N--CA 1.484 1.258 0 O-C-N 120.766 -1.209 . . . . 0.0 110.091 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.782 HD13 HG23 ' B' ' 26' ' ' THR . 81.9 mt -62.42 -31.1 71.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 57.4 p -79.09 -21.69 46.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.41 -0.806 . . . . 0.0 109.457 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -67.55 -40.15 84.98 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.4 OUTLIER -87.92 -7.55 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.72 64.95 2.82 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.711 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -90.29 142.36 27.81 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.427 -1.043 . . . . 0.0 111.011 -178.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.609 HG22 ' CG2' ' A' ' 4' ' ' THR . 8.3 p -130.35 130.61 44.64 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.816 HD11 HD11 ' A' ' 97' ' ' LEU . 3.9 mp -94.36 96.88 9.82 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.158 -0.964 . . . . 0.0 109.903 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.554 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -103.22 124.59 48.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.068 -1.02 . . . . 0.0 109.129 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.889 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.437 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.866 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.605 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.9 Cg_exo . . . . . 0 N--CA 1.494 1.549 0 N-CA-C 110.669 -0.55 . . . . 0.0 110.669 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.491 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 7.6 tt0 -84.67 108.2 17.27 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 177.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.552 HG12 ' H ' ' A' ' 5' ' ' LEU . 16.7 t -102.95 121.25 53.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.064 -1.022 . . . . 0.0 109.484 -178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.52 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.7 OUTLIER -73.09 -4.86 35.21 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.351 -178.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.716 ' O ' HG23 ' B' ' 91' ' ' THR . 5.5 mt 66.24 45.15 2.34 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.192 -0.942 . . . . 0.0 110.082 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.529 ' HA ' HG21 ' B' ' 91' ' ' THR . 1.4 m95 -65.84 -20.65 66.32 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.032 -1.042 . . . . 0.0 110.511 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.575 ' O ' ' CD ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -166.35 -99.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.956 -1.09 . . . . 0.0 110.092 179.821 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -113.49 140.3 24.33 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 120.774 -1.204 . . . . 0.0 109.565 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.576 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.7 Cg_endo -80.46 53.79 4.93 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.254 1.969 . . . . 0.0 109.693 177.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.556 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 1.3 mt -79.51 134.43 36.51 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.852 -1.155 . . . . 0.0 110.2 -178.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.456 HG21 HG23 ' A' ' 66' ' ' ILE . 1.6 m -150.99 163.71 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.667 -0.646 . . . . 0.0 109.317 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.812 ' CG2' HD22 ' A' ' 19' ' ' LEU . 3.5 m -86.56 119.07 26.42 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 178.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.617 HG22 HG13 ' A' ' 66' ' ' ILE . 18.8 pt -110.49 137.49 42.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.335 -0.853 . . . . 0.0 109.709 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 1.1 ttpp -106.96 107.7 18.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.125 -0.984 . . . . 0.0 109.299 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.939 HG23 ' CG2' ' A' ' 62' ' ' ILE . 5.1 mt -113.26 131.36 65.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.962 . . . . 0.0 109.201 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.41 -88.57 0.34 Allowed Glycine 0 N--CA 1.485 1.924 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -178.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -158.99 23.9 0.32 Allowed Glycine 0 C--N 1.293 -1.829 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 29.2 mt-30 -118.25 177.99 4.6 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.64 -0.918 . . . . 0.0 109.295 -179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.812 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.2 mt -143.7 119.08 10.25 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.692 0.758 . . . . 0.0 110.001 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -133.62 172.53 12.62 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.556 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 21.0 mt-10 -77.58 166.35 23.15 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.893 -1.129 . . . . 0.0 108.143 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.623 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -147.66 132.43 17.96 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.798 -1.189 . . . . 0.0 110.405 -179.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.603 HD21 ' O ' ' B' ' 27' ' ' GLY . 40.7 tp -104.84 90.17 3.39 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.709 -178.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.67 HD23 ' HB ' ' A' ' 85' ' ' ILE . 38.2 mt -46.86 107.23 0.1 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.852 -1.155 . . . . 0.0 108.253 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.608 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.4 t0 -112.27 89.67 3.13 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.346 -0.846 . . . . 0.0 109.852 -178.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.986 HG23 HD13 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -61.8 -21.19 64.39 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.072 -1.017 . . . . 0.0 108.422 179.325 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.475 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -60.45 -38.21 94.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.321 -1.111 . . . . 0.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.452 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -87.47 160.62 18.21 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.069 -1.254 . . . . 0.0 109.566 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -100.25 -6.81 25.42 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.459 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.567 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.56 179.29 6.31 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.169 -0.957 . . . . 0.0 110.081 -179.489 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.718 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 5.9 m -106.11 96.01 6.18 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.224 -0.923 . . . . 0.0 109.309 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.985 HG13 HG21 ' A' ' 80' ' ' THR . 1.2 t -87.46 105.45 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.126 0 O-C-N 121.21 -0.931 . . . . 0.0 110.055 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.784 HD13 HG13 ' A' ' 75' ' ' VAL . 1.5 mp -100.17 133.4 44.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.315 -0.866 . . . . 0.0 112.14 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.706 ' HA ' HG23 ' A' ' 80' ' ' THR . 11.8 pt-20 -42.41 153.34 0.07 Allowed 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 177.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.913 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.4 mt-10 -53.17 131.32 36.75 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 120.934 -1.104 . . . . 0.0 109.614 -179.417 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.44 ' SD ' ' HG ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -146.17 175.64 10.34 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.06 179.896 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.409 ' O ' ' SD ' ' A' ' 36' ' ' MET . 16.5 t -86.45 107.31 18.0 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.291 -0.881 . . . . 0.0 109.776 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.936 HD12 HG21 ' A' ' 77' ' ' VAL . 20.9 mt -121.12 110.79 34.31 Favored Pre-proline 0 N--CA 1.488 1.436 0 O-C-N 121.291 -0.88 . . . . 0.0 109.213 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -78.84 116.96 3.83 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.806 2.337 . . . . 0.0 110.659 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 151.82 -168.53 31.17 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.3 mmt180 -92.65 157.09 16.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.556 -0.967 . . . . 0.0 108.891 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 59.9 p-90 -160.01 172.91 16.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.179 -0.951 . . . . 0.0 109.843 -179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.2 mttt -136.37 160.23 67.66 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.75 141.19 16.99 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.111 1.874 . . . . 0.0 110.914 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.01 171.38 15.36 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.07 132.88 15.0 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.883 -1.135 . . . . 0.0 110.074 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.725 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -117.31 146.59 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.174 -0.954 . . . . 0.0 108.895 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.601 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.9 124.22 5.95 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.47 -123.73 1.78 Allowed Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.031 -1.557 . . . . 0.0 111.495 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.996 HD12 H702 ' B' ' 100' ' ' DMP . 39.0 mt -84.55 131.49 33.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 113.663 0.986 . . . . 0.0 113.663 -176.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.82 -17.25 9.32 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 177.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.47 -158.35 28.16 Favored Glycine 0 N--CA 1.491 2.351 0 O-C-N 120.603 -1.527 . . . . 0.0 110.502 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.601 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.8 m-85 -116.45 155.6 28.28 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.599 -0.942 . . . . 0.0 109.409 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.776 HD13 HG23 ' B' ' 50' ' ' ILE . 13.0 pt -131.64 146.26 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.217 -0.927 . . . . 0.0 108.684 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.533 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 7.8 mttp -90.19 154.19 19.93 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.069 -1.019 . . . . 0.0 109.456 179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 8.0 m -149.05 178.93 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.067 -1.021 . . . . 0.0 109.567 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.427 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 9.2 mmt180 -122.35 104.59 9.52 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.408 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 1.4 tt0 -60.67 99.57 0.09 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.275 -0.891 . . . . 0.0 110.606 -178.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.593 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.2 m-85 -95.1 104.67 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 9.3 m-20 -88.84 129.32 35.61 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.029 -1.045 . . . . 0.0 111.173 -178.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.566 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.5 OUTLIER 82.01 60.33 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 CA-C-O 121.332 0.587 . . . . 0.0 111.31 178.466 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.939 ' CG2' HG23 ' A' ' 15' ' ' ILE . 8.6 mm -115.32 120.86 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.622 HD22 ' C ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -71.32 95.27 1.29 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.017 -1.052 . . . . 0.0 111.273 -177.853 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -98.08 115.98 39.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 178.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.491 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.4 tt0 -89.34 105.05 17.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.85 -1.156 . . . . 0.0 108.883 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.75 HD11 HD13 ' A' ' 64' ' ' ILE . 1.7 mp -104.31 120.74 55.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.477 -0.764 . . . . 0.0 109.816 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.58 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.2 m 54.66 59.16 4.28 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.807 -0.558 . . . . 0.0 110.495 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 50.29 33.5 23.79 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.58 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 21.9 m-70 -131.14 102.56 6.06 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.193 -1.18 . . . . 0.0 108.813 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.599 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.8 mptt -51.46 140.09 18.49 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -160.88 99.72 1.24 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.14 -0.975 . . . . 0.0 110.052 -179.258 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.566 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -78.81 157.38 4.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 72' ' ' ILE . . . -179.46 -166.66 35.58 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.221 -1.942 . . . . 0.0 112.21 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.455 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 32.5 m -98.55 108.3 20.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.573 -0.957 . . . . 0.0 110.507 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.784 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -102.53 105.61 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.646 -0.658 . . . . 0.0 110.258 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.567 ' CD1' ' HB3' ' A' ' 30' ' ' ASP . 4.8 mp -78.48 109.78 12.97 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.936 HG21 HD12 ' A' ' 38' ' ' LEU . 2.3 t -93.12 114.5 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.444 -0.785 . . . . 0.0 110.328 -178.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -143.66 -163.95 10.11 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.533 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.45 43.3 1.5 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.559 2.173 . . . . 0.0 110.274 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.985 HG21 HG13 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -88.6 134.06 34.87 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.438 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.5 18.54 0.94 Allowed 'Trans proline' 0 C--N 1.313 -1.338 0 C-N-CA 122.559 2.173 . . . . 0.0 111.975 -178.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.514 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.0 161.33 1.39 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.88 -1.138 . . . . 0.0 109.629 179.716 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.623 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -95.24 134.66 37.75 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.645 -2.354 . . . . 0.0 104.645 175.946 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.739 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.2 mm -124.37 121.83 62.62 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 120.538 -1.352 . . . . 0.0 110.189 -177.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.868 HD13 ' N ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -98.04 87.65 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.171 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.15 -163.57 22.45 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 120.144 -1.027 . . . . 0.0 110.588 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.571 ' NH1' ' HD3' ' B' ' 9' ' ' PRO . 13.8 mmt-85 -57.63 -39.31 76.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.747 -0.855 . . . . 0.0 110.892 -178.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.045 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -44.47 -31.12 1.0 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.996 -1.065 . . . . 0.0 109.343 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.045 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.4 mm? -105.09 -27.46 11.61 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.207 -0.933 . . . . 0.0 109.884 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.986 HD13 HG23 ' A' ' 26' ' ' THR . 27.0 mt -70.33 -8.7 52.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.035 -1.041 . . . . 0.0 108.858 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -93.22 -20.25 20.62 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -86.46 -40.09 15.67 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.826 HD11 HD23 ' A' ' 90' ' ' LEU . 1.9 pt -82.62 -7.63 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.381 -0.824 . . . . 0.0 109.138 179.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.98 34.25 58.94 Favored Glycine 0 N--CA 1.5 2.903 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.187 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.607 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -70.04 130.14 41.34 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.04 -1.27 . . . . 0.0 110.335 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.533 HG22 ' CG2' ' B' ' 4' ' ' THR . 82.2 p -127.88 130.05 47.9 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.924 -1.11 . . . . 0.0 109.098 179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -88.22 97.52 11.06 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.162 -0.962 . . . . 0.0 109.581 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.519 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 2.4 m120 -107.27 123.91 49.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.292 -0.88 . . . . 0.0 109.051 179.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.771 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.191 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.664 0 N-CA-C 110.167 -0.743 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.519 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 0.2 OUTLIER -83.57 146.41 28.33 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 177.823 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.82 HG13 HD23 ' B' ' 5' ' ' LEU . 20.9 t -143.59 122.98 8.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 117.812 -1.555 . . . . 0.0 111.244 -178.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.541 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.1 OUTLIER -117.13 20.89 13.53 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 177.165 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.82 HD23 HG13 ' B' ' 3' ' ' VAL . 1.3 mm? -34.68 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.682 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.541 ' N ' ' O ' ' B' ' 4' ' ' THR . 10.5 m95 -50.94 -19.98 1.19 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.402 ' N ' ' C ' ' B' ' 5' ' ' LEU . 12.9 mm100 -108.57 -124.06 0.25 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.301 -0.874 . . . . 0.0 108.831 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 34.8 mtt180 -110.56 129.99 23.37 Favored Pre-proline 0 N--CA 1.496 1.869 0 O-C-N 120.396 -1.44 . . . . 0.0 110.407 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.571 ' HD3' ' NH1' ' A' ' 87' ' ' ARG . 37.6 Cg_endo -79.16 82.78 2.42 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.364 2.042 . . . . 0.0 109.83 178.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.642 HD22 ' HB3' ' B' ' 21' ' ' GLU . 3.7 mt -90.91 140.22 30.02 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.016 -1.052 . . . . 0.0 109.992 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.537 HG23 ' N ' ' B' ' 12' ' ' THR . 0.6 OUTLIER -143.37 168.28 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.765 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.537 ' N ' HG23 ' B' ' 11' ' ' VAL . 17.8 m -99.91 109.18 21.56 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.924 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.6 pt -91.35 158.03 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.138 -0.976 . . . . 0.0 110.064 -178.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.9 tttt -121.03 96.97 5.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.412 -0.805 . . . . 0.0 109.064 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.804 HG23 ' CG2' ' B' ' 62' ' ' ILE . 20.1 mt -113.3 129.44 69.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 O-C-N 121.337 -0.852 . . . . 0.0 109.617 -179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.75 50.13 62.41 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 54.8 24.43 33.39 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.3 OUTLIER -119.94 174.58 6.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.221 -1.164 . . . . 0.0 108.688 179.288 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.924 HD23 ' O ' ' B' ' 13' ' ' ILE . 29.1 mt -148.52 126.05 11.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.021 -1.049 . . . . 0.0 110.843 -179.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.449 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.1 mmmt -140.6 -177.37 5.02 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.642 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.6 OUTLIER -80.2 176.02 10.12 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.946 -1.096 . . . . 0.0 108.671 179.415 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -162.62 111.91 1.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.854 -1.154 . . . . 0.0 111.346 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' B' ' 25' ' ' ASP . 9.0 tp -89.05 99.68 12.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.539 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 82.2 mt -46.79 96.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.921 -1.112 . . . . 0.0 108.093 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.582 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 65.1 t0 -105.49 84.84 2.15 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.292 -0.88 . . . . 0.0 110.861 -177.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.562 ' CG2' ' HD2' ' B' ' 87' ' ' ARG . 49.4 m -63.14 -15.96 58.47 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 108.945 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.603 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -67.86 -45.81 71.68 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.179 -1.569 . . . . 0.0 109.179 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -70.97 133.62 46.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -1.111 . . . . 0.0 108.589 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.5 m-20 -71.75 -13.28 61.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.368 -0.833 . . . . 0.0 110.692 -178.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.777 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -139.03 -174.82 3.95 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.768 -1.207 . . . . 0.0 110.583 -179.377 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.654 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.4 m -104.17 97.86 7.76 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.063 -1.023 . . . . 0.0 110.499 -178.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.609 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -89.59 109.67 20.74 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.324 0 O-C-N 121.198 -0.938 . . . . 0.0 109.918 -179.897 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.902 HD21 HD11 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -99.26 130.92 45.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.117 -0.99 . . . . 0.0 111.311 -179.605 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.55 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 34.1 tt0 -40.59 163.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.439 -0.788 . . . . 0.0 109.292 178.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.646 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.1 mt-10 -53.01 139.27 28.42 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 110.917 -178.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.51 ' HG3' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -173.82 159.66 3.48 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.51 ' N ' ' HG3' ' B' ' 36' ' ' MET . 18.2 t -79.52 142.07 36.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.091 -179.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 1.013 HD12 HG21 ' B' ' 77' ' ' VAL . 10.6 mt -139.16 166.0 27.87 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.449 -0.782 . . . . 0.0 108.999 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.5 ' HD3' HD23 ' B' ' 38' ' ' LEU . 34.5 Cg_endo -76.5 69.59 6.6 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 122.816 2.344 . . . . 0.0 111.996 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.68 -159.59 0.01 OUTLIER Glycine 0 N--CA 1.496 2.671 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.472 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 67.1 50.52 1.01 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.512 -0.993 . . . . 0.0 109.03 -179.428 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.587 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 46.7 p-90 -135.15 -178.38 5.07 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.907 0.86 . . . . 0.0 110.411 -179.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.44 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 12.4 mmtm -150.56 158.76 35.48 Favored Pre-proline 0 C--N 1.302 -1.487 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.63 139.87 18.38 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 C-N-CA 121.912 1.742 . . . . 0.0 110.012 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.756 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.4 OUTLIER -151.07 152.45 33.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.374 -0.829 . . . . 0.0 109.456 -179.433 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -127.35 111.51 13.97 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.844 -1.16 . . . . 0.0 108.828 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 54' ' ' ILE . 24.4 pt -95.1 134.35 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 110.018 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.594 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.59 104.51 1.11 Allowed Glycine 0 N--CA 1.489 2.173 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.401 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -122.34 -124.51 3.0 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.171 -1.49 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.817 HD12 ' C21' ' B' ' 100' ' ' DMP . 38.7 mt -86.02 121.77 37.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.832 -0.805 . . . . 0.0 112.627 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.58 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 103.18 -49.13 0.97 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 177.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.97 -159.65 24.15 Favored Glycine 0 N--CA 1.488 2.153 0 O-C-N 120.913 -1.345 . . . . 0.0 110.301 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.594 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 4.9 m-85 -113.91 155.04 26.51 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.646 -0.914 . . . . 0.0 109.644 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.773 HD11 HD11 ' B' ' 47' ' ' ILE . 1.4 pt -138.95 176.52 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 121.309 -0.869 . . . . 0.0 108.849 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 8.9 mttt -116.18 151.82 34.95 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.498 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB3' ' B' ' 45' ' ' LYS . 5.6 m -146.62 -171.11 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 120.791 -1.193 . . . . 0.0 109.715 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.475 ' O ' ' N ' ' B' ' 59' ' ' TYR . 71.0 mtm-85 -133.65 85.07 2.17 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -44.36 93.69 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.692 -0.63 . . . . 0.0 110.648 -178.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.587 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 13.8 m-85 -88.92 125.61 35.03 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 178.174 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.511 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 14.8 m-20 -105.53 136.22 45.5 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 120.84 -1.163 . . . . 0.0 110.786 -178.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.623 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.8 mp0 70.81 65.44 0.18 Allowed 'General case' 0 C--N 1.303 -1.436 0 CA-C-O 121.431 0.634 . . . . 0.0 111.106 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.804 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.76 111.71 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 1.059 HD21 ' CG ' ' B' ' 70' ' ' LYS . 12.9 tp -64.85 91.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.969 -1.082 . . . . 0.0 111.097 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.8 ' CG2' HD11 ' B' ' 89' ' ' LEU . 5.4 tt -89.42 119.14 36.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.486 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.6 tt0 -88.54 120.88 30.34 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 109.119 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.655 HG13 HG22 ' B' ' 13' ' ' ILE . 1.3 mp -120.94 128.0 76.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.397 -0.814 . . . . 0.0 109.217 -179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 94.5 m 52.97 24.48 3.42 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.507 -0.746 . . . . 0.0 109.798 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 81.79 43.62 8.22 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -140.28 99.53 3.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -1.166 . . . . 0.0 109.418 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 1.059 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.24 128.56 19.67 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.656 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -148.23 101.98 3.31 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.301 -0.875 . . . . 0.0 110.505 -179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.623 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -77.31 142.83 13.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.773 -1.205 . . . . 0.0 108.648 178.992 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.523 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -164.94 -155.75 8.65 Favored Glycine 0 N--CA 1.494 2.566 0 C-N-CA 119.723 -1.227 . . . . 0.0 111.062 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.484 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.3 m -111.96 113.76 26.26 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.214 -1.168 . . . . 0.0 109.624 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.676 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -107.91 108.42 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.355 -0.841 . . . . 0.0 111.383 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.788 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.9 mp -79.92 108.79 13.77 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.127 -0.983 . . . . 0.0 108.617 178.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 1.013 HG21 HD12 ' B' ' 38' ' ' LEU . 2.1 t -92.24 117.97 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.988 -1.07 . . . . 0.0 109.659 -179.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.721 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -146.99 -171.96 16.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.306 -1.918 . . . . 0.0 108.306 179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.8 Cg_endo -81.03 44.26 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.259 1.973 . . . . 0.0 110.514 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.609 HG21 HG13 ' B' ' 32' ' ' VAL . 5.3 t -84.69 143.75 41.38 Favored Pre-proline 0 N--CA 1.486 1.359 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.9 Cg_endo -76.65 14.01 1.31 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.583 2.189 . . . . 0.0 111.674 -178.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.528 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 1.4 t -161.03 164.35 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 120.83 -1.169 . . . . 0.0 110.149 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.566 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.4 m120 -94.6 146.95 23.77 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 103.184 -2.895 . . . . 0.0 103.184 174.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.654 ' O ' ' HA ' ' B' ' 31' ' ' THR . 3.6 mm -133.81 123.91 46.13 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.157 0 O-C-N 120.024 -1.673 . . . . 0.0 110.713 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.504 ' HB ' ' HA ' ' B' ' 24' ' ' LEU . 5.3 mm -98.5 93.45 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.25 179.49 51.74 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 -178.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.588 ' HG2' ' HB3' ' A' ' 5' ' ' LEU . 0.8 OUTLIER -58.83 -23.11 60.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.37 -1.077 . . . . 0.0 109.627 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.739 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.9 p-10 -53.77 -37.01 63.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.694 -1.254 . . . . 0.0 108.924 178.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.8 HD11 ' CG2' ' B' ' 64' ' ' ILE . 0.4 OUTLIER -96.92 -35.26 10.94 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.619 -0.676 . . . . 0.0 110.695 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.51 ' O ' HG13 ' B' ' 93' ' ' ILE . 71.7 mt -56.36 -33.87 66.11 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.038 -1.039 . . . . 0.0 109.487 -179.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.66 -21.84 60.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 110.899 -179.109 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 21.9 mm-40 -80.54 -31.47 36.98 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.229 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.771 HD12 ' CB ' ' A' ' 99' ' ' PHE . 3.1 pt -87.11 13.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.4 -0.813 . . . . 0.0 108.932 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 59.76 49.04 82.83 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.527 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -87.92 150.66 23.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.25 -1.147 . . . . 0.0 109.604 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.52 HG22 ' HA ' ' A' ' 4' ' ' THR . 57.2 p -146.27 123.07 11.25 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.424 -0.798 . . . . 0.0 109.135 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.91 HD11 HD11 ' A' ' 97' ' ' LEU . 5.2 mp -85.36 93.54 8.74 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.529 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 7.5 m120 -92.79 119.97 32.69 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 120.703 -1.248 . . . . 0.0 110.067 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.675 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.37 178.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.996 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.446 ' O ' ' HA ' ' B' ' 98' ' ' ASN . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.66 0 N-CA-C 109.889 -0.85 . . . . 0.0 109.889 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -83.17 149.66 26.72 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 177.81 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.543 HG13 ' CD2' ' A' ' 5' ' ' LEU . 37.8 t -150.49 116.43 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 C-N-CA 118.436 -1.306 . . . . 0.0 110.661 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.782 ' C ' HD23 ' A' ' 5' ' ' LEU . 1.7 p -122.26 -73.21 0.65 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.782 HD23 ' C ' ' A' ' 4' ' ' THR . 1.8 pt? 30.4 38.28 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 122.124 -0.36 . . . . 0.0 111.071 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.549 ' C ' ' O ' ' A' ' 5' ' ' LEU . 8.9 m95 19.3 48.96 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-O 121.258 0.551 . . . . 0.0 111.829 179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.552 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -149.87 -167.81 2.93 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.276 -0.89 . . . . 0.0 109.31 179.421 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.622 ' HB3' HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -84.89 136.77 38.4 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 121.12 -0.987 . . . . 0.0 109.403 -179.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 33.7 Cg_endo -77.27 71.99 6.12 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.246 1.964 . . . . 0.0 109.717 178.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' C ' ' CG1' ' A' ' 11' ' ' VAL . 0.4 OUTLIER -79.54 151.17 30.86 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.26 -0.9 . . . . 0.0 109.231 -179.567 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 1.053 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -150.64 156.47 6.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.244 -0.91 . . . . 0.0 110.027 -179.381 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.694 ' CG2' HD22 ' A' ' 19' ' ' LEU . 22.6 m -86.93 113.37 22.66 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.769 HD11 HD21 ' A' ' 33' ' ' LEU . 43.8 pt -99.7 147.87 6.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.167 -0.958 . . . . 0.0 111.071 -178.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.647 ' CD ' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -109.27 94.9 5.28 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.937 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.836 HD13 HG11 ' A' ' 75' ' ' VAL . 8.6 mt -119.41 130.07 74.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.104 -0.998 . . . . 0.0 109.67 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.67 37.63 95.01 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.61 18.14 50.91 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 26.7 mm-40 -113.84 172.88 6.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.34 -1.094 . . . . 0.0 109.518 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.694 HD22 ' CG2' ' A' ' 12' ' ' THR . 13.1 mt -139.74 122.46 16.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.329 -0.857 . . . . 0.0 111.012 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.463 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -141.96 175.32 9.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 1.3 mt-10 -78.72 178.67 7.69 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.599 -1.313 . . . . 0.0 108.23 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.824 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -156.9 103.99 2.09 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.14 -0.975 . . . . 0.0 109.635 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.622 HD11 ' HB3' ' A' ' 8' ' ' ARG . 30.5 tp -72.43 92.6 1.46 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.253 -0.904 . . . . 0.0 108.584 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.767 ' CD2' HD21 ' A' ' 90' ' ' LEU . 3.7 mt -43.78 98.43 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' A' ' 84' ' ' ILE . 1.9 t70 -104.89 90.3 3.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.558 -0.714 . . . . 0.0 110.777 -178.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.526 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 20.7 m -68.23 -13.53 62.31 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.725 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.99 -41.68 60.79 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.518 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -73.05 162.75 29.1 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -1.171 . . . . 0.0 109.516 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -98.92 -11.15 21.9 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.292 -0.88 . . . . 0.0 110.428 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.551 ' OD2' ' HB ' ' A' ' 74' ' ' THR . 0.1 OUTLIER -139.06 -173.2 3.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.899 -1.126 . . . . 0.0 109.781 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' A' ' 33' ' ' LEU . 66.4 m -106.32 88.52 2.8 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.576 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.19 162.97 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.244 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.01 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.4 OUTLIER -157.7 124.32 4.92 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.9 -179.003 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 35' ' ' GLU . 21.0 pt-20 -41.01 152.83 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.533 -0.729 . . . . 0.0 109.5 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -41.71 148.31 0.16 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.406 -0.809 . . . . 0.0 110.39 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.431 ' HE1' HG22 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -173.29 164.92 4.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.496 -0.753 . . . . 0.0 108.975 179.457 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.7 t -79.8 100.06 7.79 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.056 -1.028 . . . . 0.0 109.77 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 39' ' ' PRO . 13.3 tp -126.29 100.39 29.58 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.248 -0.907 . . . . 0.0 109.34 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.531 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.4 Cg_endo -78.46 165.39 25.32 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.791 2.327 . . . . 0.0 110.815 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.57 -163.12 16.09 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.408 ' H ' ' NE ' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -97.33 139.03 33.9 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.223 -1.163 . . . . 0.0 108.26 179.502 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.569 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 9.7 p-90 -149.33 174.49 12.37 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.031 -1.043 . . . . 0.0 109.996 -179.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -138.2 163.47 47.28 Favored Pre-proline 0 C--N 1.299 -1.612 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.22 141.03 25.53 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.73 1.62 . . . . 0.0 110.189 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.36 167.46 22.12 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.451 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 10.4 ttt -151.38 118.79 6.01 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 54' ' ' ILE . 1.5 pt -102.43 128.51 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 C-N-CA 118.396 -1.322 . . . . 0.0 108.897 179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.618 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -117.89 98.01 0.75 Allowed Glycine 0 N--CA 1.485 1.953 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.519 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -119.72 -121.06 2.9 Favored Glycine 0 C--N 1.297 -1.616 0 C-N-CA 119.416 -1.374 . . . . 0.0 110.404 -179.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.883 HG21 HD12 ' B' ' 47' ' ' ILE . 74.8 mt -83.87 106.1 13.98 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.872 -0.781 . . . . 0.0 112.561 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.577 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 120.18 -44.62 1.35 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 178.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 168.06 -164.37 37.92 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.728 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 7.1 m-85 -110.14 118.02 35.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.602 -0.94 . . . . 0.0 110.18 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.812 HD11 HD11 ' A' ' 47' ' ' ILE . 32.6 pt -99.16 161.07 3.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 178.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.557 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.39 132.96 48.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.024 -1.048 . . . . 0.0 109.8 -179.406 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' A' ' 78' ' ' GLY . 30.6 m -134.55 178.68 5.13 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 O-C-N 121.477 -0.765 . . . . 0.0 109.36 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 28.1 mtt180 -111.31 171.22 7.6 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.409 ' OE1' ' OD1' ' A' ' 60' ' ' ASP . 0.3 OUTLIER -131.5 97.28 4.19 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.673 -1.267 . . . . 0.0 110.859 -179.042 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 83.7 m-85 -97.11 116.32 29.1 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.522 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -94.01 146.46 23.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.917 -1.114 . . . . 0.0 110.144 -179.05 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.559 ' HA ' HG23 ' A' ' 72' ' ' ILE . 4.1 mm-40 67.77 67.34 0.36 Allowed 'General case' 0 N--CA 1.489 1.516 0 CA-C-O 121.617 0.722 . . . . 0.0 109.705 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.616 ' HB ' HG23 ' A' ' 75' ' ' VAL . 1.9 mm -124.65 108.84 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.769 HD11 ' CG ' ' A' ' 70' ' ' LYS . 4.6 tt -59.81 102.57 0.16 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.311 -0.868 . . . . 0.0 111.175 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 1.009 HD13 HD11 ' A' ' 66' ' ' ILE . 3.7 tt -100.44 119.48 48.6 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 176.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.75 109.88 20.04 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.647 -1.283 . . . . 0.0 108.719 -178.564 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.053 HG23 HG21 ' A' ' 11' ' ' VAL . 2.7 mt -115.78 123.86 71.58 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.124 -0.985 . . . . 0.0 110.313 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.455 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 58.2 m 56.49 36.02 26.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.675 -0.641 . . . . 0.0 110.367 179.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.41 28.03 73.46 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.455 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 96.7 m-70 -126.95 110.35 12.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.118 -1.225 . . . . 0.0 109.273 179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.769 ' CG ' HD11 ' A' ' 63' ' ' LEU . 1.5 ttpm? -55.05 130.6 42.43 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.269 -0.895 . . . . 0.0 109.069 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.657 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 101.46 3.23 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.372 -0.83 . . . . 0.0 109.935 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.646 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -78.27 146.43 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 178.794 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.659 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -170.45 -177.69 40.74 Favored Glycine 0 N--CA 1.484 1.879 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.51 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.551 ' HB ' ' OD2' ' A' ' 30' ' ' ASP . 1.9 m -93.58 111.92 23.7 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.574 -0.957 . . . . 0.0 109.587 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.001 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.97 137.12 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.694 -0.629 . . . . 0.0 109.724 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.4 mp -107.68 136.14 47.93 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.209 -0.932 . . . . 0.0 108.768 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.492 ' O ' ' HG3' ' A' ' 57' ' ' ARG . 16.7 t -118.38 113.65 42.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.943 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -151.75 -164.04 11.92 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.557 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.31 39.48 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.681 2.254 . . . . 0.0 111.039 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.832 HG21 HG13 ' A' ' 32' ' ' VAL . 2.8 t -86.83 134.84 36.4 Favored Pre-proline 0 N--CA 1.489 1.508 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.1 Cg_endo -78.16 18.79 0.87 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.691 2.26 . . . . 0.0 112.028 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.536 HG23 ' O ' ' A' ' 81' ' ' PRO . 0.9 OUTLIER -161.5 158.97 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.597 -1.314 . . . . 0.0 110.341 -179.849 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.556 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 67.7 m-20 -95.11 100.29 12.13 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' A' ' 25' ' ' ASP . 7.2 mm -88.37 128.59 40.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 O-C-N 120.858 -1.151 . . . . 0.0 112.154 -176.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.824 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -105.61 93.79 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.244 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -80.35 -160.99 23.63 Favored Glycine 0 N--CA 1.493 2.494 0 O-C-N 121.176 -0.952 . . . . 0.0 111.042 -177.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.513 ' NH2' ' HB2' ' A' ' 87' ' ' ARG . 7.5 mtp-105 -69.17 -29.67 67.73 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.65 -0.912 . . . . 0.0 109.925 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.943 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -50.17 -24.26 2.69 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 120.811 -1.181 . . . . 0.0 108.951 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.943 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.1 mm? -112.76 -27.77 8.03 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.236 -0.915 . . . . 0.0 110.313 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.767 HD21 ' CD2' ' A' ' 24' ' ' LEU . 34.7 mt -63.09 -28.15 69.88 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.992 -1.068 . . . . 0.0 108.416 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 69.0 p -79.43 -20.64 47.03 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.136 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -80.86 -36.71 31.05 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.35 -0.844 . . . . 0.0 109.135 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.829 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -86.0 -0.72 6.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.295 -0.878 . . . . 0.0 109.243 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 64.68 62.22 5.23 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -97.16 135.88 38.48 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.547 -0.973 . . . . 0.0 110.481 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.719 HG22 ' CG2' ' B' ' 4' ' ' THR . 15.5 p -133.12 128.71 36.71 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.613 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -87.1 109.38 19.39 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.277 -0.89 . . . . 0.0 108.792 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.513 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 8.9 m120 -105.22 120.79 42.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.81 -1.181 . . . . 0.0 109.196 179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.86 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.595 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.451 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.56 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.332 -0.68 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.523 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tm0? -84.02 145.71 28.36 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.133 -1.803 . . . . 0.0 106.133 177.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.523 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 70.1 t -146.03 122.97 3.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.218 -177.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.719 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.8 OUTLIER -127.04 -61.94 1.14 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.673 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.1 mt 31.86 38.92 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.567 178.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.536 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.9 m95 17.31 51.46 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 CA-C-O 121.159 0.504 . . . . 0.0 111.949 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.545 ' N ' ' O ' ' B' ' 5' ' ' LEU . 13.1 mt-30 -168.0 -174.95 2.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.341 -0.85 . . . . 0.0 109.592 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.472 ' HG2' ' HD2' ' A' ' 87' ' ' ARG . 17.2 mtm180 -65.44 138.45 96.96 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.032 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.554 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.8 Cg_endo -81.16 62.36 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.36 2.04 . . . . 0.0 109.707 179.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 1.052 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -80.84 136.4 36.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.877 -1.139 . . . . 0.0 109.56 -179.475 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.533 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -130.42 137.91 55.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.286 -0.884 . . . . 0.0 109.191 -179.933 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.714 HG22 HD22 ' B' ' 19' ' ' LEU . 18.0 m -65.66 97.58 0.33 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.941 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.8 pt -88.03 154.62 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.297 -0.877 . . . . 0.0 110.702 -177.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.523 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.2 OUTLIER -122.15 105.88 10.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.473 -0.767 . . . . 0.0 109.773 179.505 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.76 HD13 HG11 ' B' ' 75' ' ' VAL . 97.1 mt -121.24 139.92 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 120.852 -1.155 . . . . 0.0 110.889 -179.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.81 33.38 6.48 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.76 37.27 51.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.5 OUTLIER -131.18 175.48 9.07 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.262 -1.14 . . . . 0.0 108.39 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.941 HD23 ' O ' ' B' ' 13' ' ' ILE . 15.9 mt -152.0 124.33 8.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.995 -1.066 . . . . 0.0 110.249 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -151.38 174.57 13.18 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 1.052 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -80.34 143.38 33.61 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.895 -1.128 . . . . 0.0 108.836 179.484 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.679 ' N ' HD23 ' B' ' 10' ' ' LEU . . . -127.53 112.79 15.33 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.009 -1.057 . . . . 0.0 110.138 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.725 HD21 ' O ' ' A' ' 27' ' ' GLY . 2.4 tp -81.14 102.05 10.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.691 -0.631 . . . . 0.0 109.864 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' B' ' 9' ' ' PRO . 20.1 mt -52.74 105.95 0.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.934 -1.104 . . . . 0.0 108.346 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.886 ' CB ' HG23 ' B' ' 84' ' ' ILE . 53.4 t0 -103.1 92.54 4.58 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.216 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.696 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -64.54 -11.5 35.0 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.077 -1.015 . . . . 0.0 108.404 178.437 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.462 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -70.09 -43.62 63.77 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.611 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -81.82 164.96 21.28 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.117 -1.225 . . . . 0.0 109.676 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -100.4 -13.88 18.57 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.226 -0.921 . . . . 0.0 110.196 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.644 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.4 OUTLIER -126.75 -165.37 1.45 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.016 -1.052 . . . . 0.0 109.664 -179.806 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.78 HG23 HD12 ' B' ' 85' ' ' ILE . 8.1 m -116.63 85.64 2.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.924 -1.11 . . . . 0.0 110.192 -179.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.934 HG12 ' HB ' ' B' ' 84' ' ' ILE . 0.3 OUTLIER -68.65 154.75 8.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.806 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -154.82 133.31 11.95 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.837 -1.164 . . . . 0.0 111.054 -177.609 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.489 ' HG3' ' O ' ' B' ' 80' ' ' THR . 4.1 tt0 -42.03 148.62 0.18 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.465 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 3.0 mt-10 -44.88 136.99 4.3 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.041 -1.037 . . . . 0.0 110.457 -179.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.584 ' SD ' HD22 ' B' ' 38' ' ' LEU . 0.0 OUTLIER -156.75 -167.69 2.45 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.11 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.6 t -112.29 115.75 29.28 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.756 -1.215 . . . . 0.0 111.457 -178.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.685 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -116.45 170.81 5.39 Favored Pre-proline 0 N--CA 1.496 1.843 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.685 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.4 Cg_endo -76.22 115.77 4.2 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.372 2.048 . . . . 0.0 111.374 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' B' ' 41' ' ' ARG . . . -30.95 122.39 0.14 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' B' ' 40' ' ' GLY . 3.6 mtm180 148.72 43.01 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.633 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 37.3 p-90 -124.73 176.8 6.34 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.343 0.592 . . . . 0.0 109.733 -178.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 3.2 mttp -133.92 130.04 20.38 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.007 179.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -76.91 140.11 20.12 Favored 'Trans proline' 0 C--N 1.31 -1.45 0 C-N-CA 122.254 1.97 . . . . 0.0 110.317 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 2.9 ptpp? -159.41 -164.8 1.43 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.356 -0.84 . . . . 0.0 109.376 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.548 ' CG ' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -141.8 119.21 11.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.985 -179.578 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.883 HD12 HG21 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -90.44 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 178.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.467 ' HA2' ' HB3' ' B' ' 53' ' ' PHE . . . -118.41 111.75 2.22 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -137.81 -125.2 2.35 Favored Glycine 0 N--CA 1.484 1.838 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.915 HD12 H202 ' B' ' 100' ' ' DMP . 37.8 mt -80.95 139.12 18.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.777 -0.837 . . . . 0.0 112.664 -178.045 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.27 5.03 65.54 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.0 -158.94 16.69 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.278 -1.439 . . . . 0.0 110.051 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -119.21 143.85 47.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.441 -1.035 . . . . 0.0 109.183 -179.549 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.754 HG12 HG23 ' A' ' 50' ' ' ILE . 1.0 OUTLIER -112.71 -175.29 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.977 . . . . 0.0 108.701 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.549 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 12.3 mttt -114.84 138.79 50.36 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.047 -1.033 . . . . 0.0 109.282 179.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.653 HG13 HD11 ' B' ' 54' ' ' ILE . 3.5 m -139.05 -169.33 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 120.553 -1.342 . . . . 0.0 110.73 -179.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.496 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 73.8 mtt-85 -143.78 99.88 3.49 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.565 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 6.1 tt0 -66.04 108.13 2.12 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.294 -0.879 . . . . 0.0 110.719 -178.644 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 32.3 m-85 -93.85 128.27 40.03 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 177.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.534 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -106.17 135.97 46.7 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.877 -1.139 . . . . 0.0 110.927 -177.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.594 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.2 OUTLIER 71.98 64.03 0.14 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 179.271 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 4.4 mp -118.17 119.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.717 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.3 tm? -66.29 84.95 0.1 Allowed 'General case' 0 N--CA 1.49 1.564 0 CA-C-O 121.661 0.743 . . . . 0.0 110.604 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.647 HG22 ' O ' ' B' ' 71' ' ' ALA . 2.3 tt -91.89 130.76 40.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 178.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.514 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.8 tt0 -87.74 152.6 22.01 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.905 -1.122 . . . . 0.0 108.463 -179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.593 HG13 HG22 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -150.75 135.11 9.0 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.236 -0.915 . . . . 0.0 108.962 -179.453 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 46.32 24.07 0.26 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.529 -0.732 . . . . 0.0 110.21 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.416 ' O ' ' CD2' ' B' ' 69' ' ' HIS . . . 83.72 39.6 9.47 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.048 -1.221 . . . . 0.0 110.048 179.453 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' B' ' 68' ' ' GLY . 8.9 m-70 -141.11 164.77 29.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -1.208 . . . . 0.0 109.074 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.527 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -95.73 139.19 32.32 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.07 -1.019 . . . . 0.0 108.472 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.647 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.54 104.75 2.58 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.111 -0.993 . . . . 0.0 110.051 -179.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.597 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.4 OUTLIER -86.94 141.64 14.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 178.701 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.56 -164.11 23.69 Favored Glycine 0 N--CA 1.485 1.922 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.495 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.565 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 8.6 m -95.91 105.06 17.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.682 -0.893 . . . . 0.0 109.906 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.806 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -100.71 106.01 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.38 -0.825 . . . . 0.0 109.983 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.644 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 0.4 OUTLIER -78.08 134.4 37.74 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.104 -0.997 . . . . 0.0 108.666 179.104 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 58.2 t -122.58 130.86 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.206 -0.934 . . . . 0.0 110.644 -179.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.441 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -163.84 -161.27 12.73 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 108.258 -1.937 . . . . 0.0 108.258 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' B' ' 54' ' ' ILE . 36.5 Cg_endo -81.47 40.23 0.96 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.358 2.039 . . . . 0.0 110.244 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' B' ' 32' ' ' VAL . 3.1 t -83.39 133.56 47.09 Favored Pre-proline 0 N--CA 1.487 1.391 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.665 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.3 Cg_endo -75.43 18.05 0.61 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.715 2.276 . . . . 0.0 112.244 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.665 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.9 t -161.27 157.9 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.692 -1.255 . . . . 0.0 110.543 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.593 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -96.57 90.36 5.32 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 177.252 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.934 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.9 mt -90.63 120.04 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.258 -0.901 . . . . 0.0 112.36 -176.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.78 HD12 HG23 ' B' ' 31' ' ' THR . 0.5 OUTLIER -95.67 93.82 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.82 -157.28 13.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.0 OUTLIER -61.76 -37.22 83.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.623 -0.928 . . . . 0.0 111.887 -178.186 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.956 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -44.67 -40.53 5.96 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.509 -1.37 . . . . 0.0 110.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.956 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.9 OUTLIER -96.73 -18.99 19.28 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.061 -1.024 . . . . 0.0 110.032 -179.44 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.557 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 63.6 mt -73.8 -5.25 39.67 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.024 -1.048 . . . . 0.0 108.765 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.512 ' HB ' ' CH2' ' A' ' 6' ' ' TRP . 2.6 p -101.32 -21.17 14.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.081 -1.012 . . . . 0.0 109.067 179.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 19.8 mm-40 -74.36 -40.53 62.06 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.183 -0.948 . . . . 0.0 109.006 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.86 HD12 ' CG ' ' A' ' 99' ' ' PHE . 3.3 pt -88.15 -5.97 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.215 -0.928 . . . . 0.0 108.893 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 67.76 50.43 42.19 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.594 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.45 149.4 35.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.099 -1.236 . . . . 0.0 109.789 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.727 HG22 ' CG2' ' A' ' 4' ' ' THR . 47.6 p -138.48 128.4 25.32 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.696 HD13 HG21 ' B' ' 26' ' ' THR . 0.0 OUTLIER -86.96 111.36 20.76 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.287 -0.883 . . . . 0.0 110.745 -178.685 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.583 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 1.0 OUTLIER -115.73 121.21 41.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.3 -0.875 . . . . 0.0 109.609 179.363 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.829 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.134 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.915 H202 HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.417 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.691 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.474 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.5 tt0 -83.16 141.39 31.98 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 105.623 -1.992 . . . . 0.0 105.623 177.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 72.9 t -137.95 126.04 30.98 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 C-N-CA 117.778 -1.569 . . . . 0.0 110.647 -177.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.577 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -120.87 7.35 10.42 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.693 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.3 OUTLIER -34.42 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.953 0.882 . . . . 0.0 109.709 -179.299 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.577 ' N ' ' O ' ' A' ' 4' ' ' THR . 6.9 m95 -41.49 -20.21 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.711 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.434 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.536 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.2 mt-30 -107.49 -155.98 0.57 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.691 -1.255 . . . . 0.0 109.78 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.694 ' HB3' HD13 ' A' ' 23' ' ' LEU . 62.0 mtt180 -76.21 115.79 50.13 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.231 -0.918 . . . . 0.0 110.413 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.596 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.6 Cg_endo -81.89 83.38 2.1 Favored 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 121.994 1.796 . . . . 0.0 109.019 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 1.01 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -78.52 166.9 22.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.332 -0.855 . . . . 0.0 109.615 -179.033 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.879 HG23 HG23 ' A' ' 13' ' ' ILE . 15.2 m -147.88 131.18 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.108 -0.995 . . . . 0.0 110.558 -178.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.648 HG22 HD22 ' A' ' 19' ' ' LEU . 3.1 m -68.68 103.05 1.63 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.527 -1.358 . . . . 0.0 107.786 178.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.879 HG23 HG23 ' A' ' 11' ' ' VAL . 2.8 pt -102.42 137.34 30.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.244 -0.91 . . . . 0.0 111.207 -178.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.946 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -105.0 93.6 4.79 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.766 HD11 HD12 ' A' ' 64' ' ' ILE . 15.6 mt -104.48 124.35 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.455 -0.778 . . . . 0.0 109.488 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.75 13.0 68.36 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.88 7.72 77.43 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.555 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -105.77 171.72 7.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -1.131 . . . . 0.0 108.521 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.946 HD21 ' HD3' ' A' ' 14' ' ' LYS . 15.1 mt -123.6 130.58 52.88 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.869 -1.145 . . . . 0.0 110.959 -178.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.57 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.7 OUTLIER -150.41 143.13 24.6 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 1.01 ' HB3' HD23 ' A' ' 10' ' ' LEU . 9.1 mm-40 -78.88 127.46 32.05 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 120.961 -1.087 . . . . 0.0 109.101 -179.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.87 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -108.27 112.47 24.96 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.986 -1.071 . . . . 0.0 112.012 -178.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.694 HD13 ' HB3' ' A' ' 8' ' ' ARG . 11.9 tp -72.22 107.39 4.84 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.596 HD12 ' HB2' ' A' ' 9' ' ' PRO . 56.5 mt -46.79 142.97 3.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.864 -1.148 . . . . 0.0 108.294 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.622 ' HB3' HG22 ' A' ' 84' ' ' ILE . 11.4 t0 -156.79 99.59 1.86 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.844 -1.16 . . . . 0.0 110.272 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.405 ' HA ' HH12 ' A' ' 87' ' ' ARG . 10.9 m -76.12 -0.26 21.35 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.149 -0.97 . . . . 0.0 109.399 179.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.842 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -89.54 -26.48 25.1 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.623 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -81.39 124.4 29.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.12 -1.224 . . . . 0.0 109.089 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.633 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 42.8 m-20 -61.83 -16.42 49.96 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.853 . . . . 0.0 110.171 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.639 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 5.0 m-20 -145.16 -170.48 3.44 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 119.022 -1.071 . . . . 0.0 109.713 -179.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.832 HG22 ' CD1' ' A' ' 33' ' ' LEU . 8.1 m -104.84 86.56 2.49 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 120.804 -1.185 . . . . 0.0 109.818 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.981 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.3 OUTLIER -70.04 163.13 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 179.265 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.981 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.5 OUTLIER -160.37 128.86 4.75 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.033 -1.042 . . . . 0.0 110.396 -178.01 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.664 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.8 tt0 -43.81 165.36 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.505 -0.878 . . . . 0.0 108.848 179.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.479 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -48.23 143.4 4.61 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.353 -179.426 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.794 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.5 OUTLIER -155.91 -168.31 2.73 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.464 -0.773 . . . . 0.0 109.025 179.737 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.7 t -122.17 111.15 16.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.847 -1.158 . . . . 0.0 111.196 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.81 HD23 ' CG ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -114.57 179.73 0.74 Allowed Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.714 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.571 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 36.1 Cg_endo -78.6 36.9 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.68 2.253 . . . . 0.0 112.502 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 55.59 33.03 58.76 Favored Glycine 0 N--CA 1.493 2.483 0 O-C-N 121.102 -0.999 . . . . 0.0 111.299 178.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.598 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 15.4 mmm180 -113.97 78.15 1.12 Allowed 'General case' 0 C--N 1.291 -1.954 0 O-C-N 121.485 -1.009 . . . . 0.0 108.337 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.567 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 59.8 p-90 -148.96 -177.41 5.79 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 120.985 -1.072 . . . . 0.0 111.37 -178.457 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.72 141.61 28.49 Favored Pre-proline 0 N--CA 1.487 1.377 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.47 131.23 13.54 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 C-N-CA 121.936 1.757 . . . . 0.0 111.025 -179.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.559 ' CD ' ' HB2' ' A' ' 58' ' ' GLN . 13.1 ptmt -161.28 -169.8 2.44 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.54 -0.725 . . . . 0.0 109.233 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.486 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 38.4 mtp -151.34 137.98 18.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.36 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.768 HD11 HG21 ' B' ' 50' ' ' ILE . 15.4 pt -95.94 150.0 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 120.987 -1.07 . . . . 0.0 108.491 178.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.07 102.37 0.97 Allowed Glycine 0 N--CA 1.488 2.154 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.534 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -123.08 -134.74 4.43 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.566 -1.302 . . . . 0.0 110.721 -178.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.732 HG23 HD13 ' B' ' 54' ' ' ILE . 58.3 mt -83.02 122.87 38.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 CA-C-O 121.629 0.728 . . . . 0.0 112.548 -177.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 104.64 -53.77 0.66 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.504 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 178.33 -169.24 40.86 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.585 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.2 m-30 -102.37 135.28 44.26 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.021 -1.282 . . . . 0.0 109.312 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.489 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.3 pt -101.52 176.1 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.131 -0.981 . . . . 0.0 109.352 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.527 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -105.35 142.02 35.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.241 -0.912 . . . . 0.0 109.323 -179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.538 HG12 ' HA3' ' A' ' 78' ' ' GLY . 31.1 m -150.93 -179.03 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.001 -1.062 . . . . 0.0 110.652 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.491 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -128.02 91.58 3.3 Favored 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 179.141 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.559 ' HB2' ' CD ' ' A' ' 45' ' ' LYS . 17.1 tt0 -51.29 102.98 0.05 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.443 0.639 . . . . 0.0 111.635 -178.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.81 ' CG ' HD23 ' A' ' 38' ' ' LEU . 24.8 m-85 -90.63 137.3 32.46 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -119.34 121.51 39.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.651 -1.281 . . . . 0.0 110.321 -179.091 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.583 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 5.4 mt-30 83.3 61.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 121.372 0.606 . . . . 0.0 109.882 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.732 HG21 HG21 ' A' ' 75' ' ' VAL . 2.7 mm -111.62 115.79 50.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.35 -0.844 . . . . 0.0 108.782 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.875 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.0 tm? -66.42 87.22 0.12 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.16 -0.963 . . . . 0.0 110.391 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 1.038 HD13 HD11 ' A' ' 66' ' ' ILE . 5.2 tt -88.8 122.94 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.49 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 18.0 tt0 -88.97 96.11 10.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.13 -0.981 . . . . 0.0 108.84 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.038 HD11 HD13 ' A' ' 64' ' ' ILE . 3.2 mt -101.51 122.8 54.1 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.334 -0.854 . . . . 0.0 110.043 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.579 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 60.93 44.66 10.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.636 -0.665 . . . . 0.0 109.773 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 55.7 33.32 59.45 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.579 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 90.7 m-70 -130.85 118.92 21.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.285 -1.127 . . . . 0.0 109.353 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.496 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -56.32 133.62 52.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 108.706 179.626 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -157.42 104.04 2.0 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.255 -0.903 . . . . 0.0 110.199 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.583 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -79.35 154.72 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 120.88 -1.138 . . . . 0.0 108.313 178.78 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.496 ' HA3' HD22 ' A' ' 89' ' ' LEU . . . -177.25 175.43 47.63 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.179 -1.486 . . . . 0.0 110.576 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 59' ' ' TYR . 3.7 m -85.34 115.28 23.0 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.586 -0.949 . . . . 0.0 110.158 -179.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.879 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -103.94 109.49 27.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.121 -0.987 . . . . 0.0 110.288 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.611 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 5.2 mp -82.53 115.81 21.68 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.948 -1.095 . . . . 0.0 108.345 178.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 93.9 t -96.02 121.7 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.754 -1.216 . . . . 0.0 110.213 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.538 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -160.17 -170.84 25.27 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -81.02 42.68 1.39 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.926 2.417 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.664 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.4 t -82.8 141.73 44.61 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.239 -0.913 . . . . 0.0 108.564 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.634 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.9 Cg_endo -79.38 15.31 1.6 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.518 2.145 . . . . 0.0 110.98 -179.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 81' ' ' PRO . 14.1 t -160.43 158.41 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.929 -1.107 . . . . 0.0 110.22 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.57 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -102.06 91.13 4.19 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 176.217 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.622 HG22 ' HB3' ' A' ' 25' ' ' ASP . 41.8 mt -96.63 130.6 45.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.891 -1.131 . . . . 0.0 113.674 -174.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.87 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -89.3 131.9 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.639 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -110.96 -143.48 9.48 Favored Glycine 0 N--CA 1.498 2.797 0 O-C-N 120.688 -1.257 . . . . 0.0 110.847 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.633 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.0 OUTLIER -77.83 -41.61 36.44 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.482 -179.464 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.587 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -54.63 -18.95 5.11 Favored 'General case' 0 N--CA 1.497 1.881 0 C-N-CA 117.438 -1.705 . . . . 0.0 110.246 -178.608 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.713 ' CB ' HG23 ' A' ' 85' ' ' ILE . 1.0 OUTLIER -103.03 -35.97 8.34 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.712 -1.243 . . . . 0.0 110.363 -179.928 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.49 ' HG ' ' O ' ' A' ' 86' ' ' GLY . 66.2 mt -68.86 -19.77 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.876 -1.14 . . . . 0.0 109.599 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.528 HG21 ' HA ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -93.86 -2.9 52.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.734 -1.229 . . . . 0.0 108.809 178.962 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.46 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.0 OUTLIER -99.44 -40.84 7.67 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.261 -0.9 . . . . 0.0 108.949 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.059 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -79.76 -16.1 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 N-CA-C 108.571 -0.899 . . . . 0.0 108.571 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 91.05 30.87 10.43 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.85 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -67.44 138.99 57.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.988 -1.301 . . . . 0.0 109.555 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.456 ' O ' ' O ' ' B' ' 96' ' ' THR . 3.0 p -132.76 128.49 36.94 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.151 -0.968 . . . . 0.0 108.558 179.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.665 HD13 HD23 ' B' ' 5' ' ' LEU . 4.3 mp -90.62 98.43 11.77 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.245 -0.909 . . . . 0.0 109.532 -179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.0 m120 -105.61 125.7 51.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.029 -1.044 . . . . 0.0 109.246 179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.741 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.722 0 CA-C-O 117.959 -1.02 . . . . 0.0 109.295 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.509 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.68 0 N-CA-C 110.825 -0.49 . . . . 0.0 110.825 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.538 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.1 tt0 -85.71 134.27 33.97 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.834 HG12 ' H ' ' B' ' 5' ' ' LEU . 49.4 t -131.5 125.08 55.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.764 -1.21 . . . . 0.0 109.951 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.909 ' O ' HD12 ' B' ' 5' ' ' LEU . 46.7 p -75.89 3.58 9.81 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.48 -0.763 . . . . 0.0 109.656 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.909 HD12 ' O ' ' B' ' 4' ' ' THR . 0.4 OUTLIER 34.35 46.75 0.18 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.801 -0.562 . . . . 0.0 111.476 179.199 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.528 ' HA ' HG21 ' A' ' 91' ' ' THR . 58.8 m95 -57.63 -20.35 32.48 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -147.11 -164.55 2.02 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 1.075 ' HD2' HD13 ' B' ' 23' ' ' LEU . 0.5 OUTLIER -59.22 122.52 64.08 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 120.897 -1.127 . . . . 0.0 109.211 179.735 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.607 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -78.97 66.42 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.376 2.051 . . . . 0.0 109.635 179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.536 HD22 ' CB ' ' B' ' 21' ' ' GLU . 0.9 OUTLIER -81.15 145.65 30.93 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.107 -0.996 . . . . 0.0 109.827 -179.31 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.674 HG21 HG13 ' B' ' 66' ' ' ILE . 2.6 m -136.58 136.53 48.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.53 -0.731 . . . . 0.0 109.434 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 2.9 m -66.09 89.27 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.805 -1.184 . . . . 0.0 107.805 178.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.756 HG12 ' HB2' ' B' ' 22' ' ' ALA . 1.1 pp -80.67 131.52 33.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.514 -0.741 . . . . 0.0 109.596 -179.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.728 ' HE2' HD11 ' B' ' 19' ' ' LEU . 12.0 tttm -98.84 111.59 23.93 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.354 -0.841 . . . . 0.0 108.998 179.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.796 ' CG2' HD21 ' B' ' 38' ' ' LEU . 28.8 mt -116.38 134.65 59.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.221 -0.925 . . . . 0.0 108.9 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.66 -100.49 0.28 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -142.29 35.44 1.74 Allowed Glycine 0 N--CA 1.485 1.906 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HG ' ' B' ' 19' ' ' LEU . 5.8 mt-30 -134.13 179.95 5.94 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.482 -1.011 . . . . 0.0 109.663 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.728 HD11 ' HE2' ' B' ' 14' ' ' LYS . 16.0 mt -147.39 130.26 16.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.531 -0.731 . . . . 0.0 109.139 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.451 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 39.0 mttp -146.12 171.77 14.42 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.166 -0.959 . . . . 0.0 109.199 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.536 ' CB ' HD22 ' B' ' 10' ' ' LEU . 2.9 mm-40 -79.03 148.48 32.48 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.756 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -136.16 108.28 7.22 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.01 -1.056 . . . . 0.0 110.543 -178.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 1.075 HD13 ' HD2' ' B' ' 8' ' ' ARG . 18.8 tp -70.13 102.75 2.14 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.607 HD12 ' HB2' ' B' ' 9' ' ' PRO . 82.5 mt -53.7 96.08 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.055 -1.028 . . . . 0.0 108.867 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 1.003 ' CB ' HG23 ' B' ' 84' ' ' ILE . 35.2 t0 -91.92 90.06 7.28 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.391 -0.818 . . . . 0.0 110.519 -179.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.643 HG22 ' NH2' ' B' ' 87' ' ' ARG . 7.3 m -71.05 -7.49 46.82 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 109.064 178.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.434 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -83.58 -31.3 27.61 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.42 173.15 12.88 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.875 -1.368 . . . . 0.0 109.337 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -101.72 -18.0 16.02 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.073 -1.017 . . . . 0.0 110.764 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.477 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.8 OUTLIER -137.35 -172.54 3.24 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.769 -1.207 . . . . 0.0 110.142 -179.357 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 1.012 HG23 HD12 ' B' ' 85' ' ' ILE . 55.3 m -102.59 82.43 2.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.093 -1.005 . . . . 0.0 109.89 -179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.012 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.71 161.76 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.881 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.012 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.4 OUTLIER -153.25 129.52 10.51 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 118.587 -1.245 . . . . 0.0 111.618 -177.451 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.719 ' HA ' HG22 ' B' ' 80' ' ' THR . 9.5 tt0 -44.22 156.28 0.07 Allowed 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 177.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' B' ' 34' ' ' GLU . 0.5 OUTLIER -40.05 138.12 0.87 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 110.601 -179.074 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.555 ' O ' HG11 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -165.27 148.84 8.32 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.862 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.484 ' O ' ' SD ' ' B' ' 36' ' ' MET . 23.3 t -82.8 125.5 31.37 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.046 -1.034 . . . . 0.0 110.68 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.91 HD12 HG21 ' B' ' 77' ' ' VAL . 2.6 mt -122.93 164.03 29.67 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.271 -0.893 . . . . 0.0 108.653 179.03 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.485 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.7 Cg_endo -73.88 71.78 4.06 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 C-N-CA 122.655 2.237 . . . . 0.0 112.539 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.8 -159.22 0.01 OUTLIER Glycine 0 N--CA 1.497 2.727 0 O-C-N 121.528 -0.732 . . . . 0.0 111.414 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.434 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 2.8 mmt180 61.11 66.54 0.88 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.568 -0.96 . . . . 0.0 109.196 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.591 ' CZ3' ' HD2' ' B' ' 57' ' ' ARG . 65.0 p-90 -149.79 -177.96 6.19 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.575 -0.703 . . . . 0.0 109.731 -179.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' B' ' 57' ' ' ARG . 23.6 mtmt -150.82 160.35 32.5 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 108.974 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' B' ' 43' ' ' LYS . 34.7 Cg_endo -76.33 140.86 22.35 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.384 2.056 . . . . 0.0 110.241 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.621 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -157.81 120.8 3.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.342 -0.849 . . . . 0.0 109.058 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.476 ' HG3' ' CG ' ' B' ' 55' ' ' LYS . 2.5 ttt -101.18 126.72 47.92 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.082 -1.011 . . . . 0.0 109.94 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.696 HD11 HD11 ' B' ' 54' ' ' ILE . 10.0 pt -105.62 150.8 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.046 -1.034 . . . . 0.0 109.327 179.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.608 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -125.47 97.68 0.53 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.8 -130.9 4.09 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.291 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.768 HG21 HD11 ' A' ' 47' ' ' ILE . 66.3 mt -81.77 129.8 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.534 -0.98 . . . . 0.0 112.185 -178.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 100.21 -48.51 1.2 Allowed Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 171.89 -164.63 37.29 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.655 -1.259 . . . . 0.0 109.994 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.608 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 3.1 m-85 -107.03 130.56 54.63 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.423 -1.045 . . . . 0.0 108.921 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.732 HD13 HG23 ' A' ' 50' ' ' ILE . 34.0 pt -112.7 155.18 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 120.977 -1.077 . . . . 0.0 109.885 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.531 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 18.6 mttt -98.95 140.62 32.84 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.184 -0.947 . . . . 0.0 108.68 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.956 HG12 ' HA3' ' B' ' 78' ' ' GLY . 9.9 m -143.7 -176.54 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.9 -1.125 . . . . 0.0 110.149 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.591 ' HD2' ' CZ3' ' B' ' 42' ' ' TRP . 69.0 mtm-85 -132.09 104.1 6.62 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.637 ' HG3' HG22 ' B' ' 74' ' ' THR . 8.5 tt0 -62.0 134.69 56.96 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.654 0.74 . . . . 0.0 110.967 -178.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.54 ' HB3' ' CG1' ' B' ' 62' ' ' ILE . 17.6 m-85 -121.61 93.93 4.16 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.515 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 9.1 m-20 -79.44 130.86 35.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.031 -1.043 . . . . 0.0 110.452 -178.659 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.515 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 6.9 mm100 83.22 62.62 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.329 0.585 . . . . 0.0 109.723 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.57 ' HB ' HG23 ' B' ' 75' ' ' VAL . 40.0 mm -119.86 115.72 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.343 -0.848 . . . . 0.0 109.063 179.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.848 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.8 tm? -66.48 91.86 0.19 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 110.453 -179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.726 HG12 HD12 ' B' ' 66' ' ' ILE . 7.3 tt -98.38 120.68 48.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 178.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.452 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.2 tt0 -90.53 111.88 23.34 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.947 -1.095 . . . . 0.0 109.491 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.726 HD12 HG12 ' B' ' 64' ' ' ILE . 1.0 OUTLIER -100.44 126.47 54.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.741 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.425 ' C ' ' O ' ' B' ' 66' ' ' ILE . 10.2 m 39.43 61.8 1.29 Allowed 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.71 -0.619 . . . . 0.0 110.63 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 56.3 41.05 86.5 Favored Glycine 0 N--CA 1.492 2.377 0 C-N-CA 120.175 -1.012 . . . . 0.0 111.121 178.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.513 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 2.7 m-70 -139.44 135.46 33.61 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.9 -1.353 . . . . 0.0 109.0 178.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.549 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -76.64 132.93 39.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.286 -0.884 . . . . 0.0 109.739 -179.614 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.709 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -154.6 97.17 1.96 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.835 . . . . 0.0 109.822 179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.605 HG12 ' N ' ' B' ' 63' ' ' LEU . 0.2 OUTLIER -83.54 136.85 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 178.638 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.642 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -161.58 -171.96 28.32 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.96 -1.59 . . . . 0.0 110.636 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.637 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.0 m -89.97 106.36 18.42 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.825 -0.809 . . . . 0.0 110.174 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -99.64 116.74 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.484 -0.76 . . . . 0.0 110.03 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.572 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.5 mp -85.33 139.05 31.89 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.91 HG21 HD12 ' B' ' 38' ' ' LEU . 1.6 t -121.32 114.49 43.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.066 -1.021 . . . . 0.0 109.647 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.956 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.06 -162.78 11.64 Favored Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.531 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -80.21 40.61 0.99 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.615 2.21 . . . . 0.0 111.471 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.719 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.5 t -84.88 137.87 37.73 Favored Pre-proline 0 N--CA 1.493 1.678 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.71 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.2 Cg_endo -77.31 14.43 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.565 2.177 . . . . 0.0 111.579 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.71 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.04 151.25 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 120.95 -1.094 . . . . 0.0 110.438 -179.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.567 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 3.6 m-20 -90.62 102.88 15.62 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 176.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 1.003 HG23 ' CB ' ' B' ' 25' ' ' ASP . 2.2 mt -101.97 129.38 53.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 120.902 -1.124 . . . . 0.0 113.083 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 1.012 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -98.63 111.49 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.505 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -97.47 -161.3 31.33 Favored Glycine 0 N--CA 1.495 2.586 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.835 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.643 ' NH2' HG22 ' B' ' 26' ' ' THR . 0.4 OUTLIER -58.4 -34.9 71.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.563 -0.963 . . . . 0.0 110.451 -179.791 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.007 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.6 p-10 -48.05 -27.95 2.56 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.867 -1.145 . . . . 0.0 109.913 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.007 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -109.75 -24.79 10.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.81 -1.181 . . . . 0.0 109.63 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.51 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 90.7 mt -72.43 -4.97 33.39 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.509 HG23 ' O ' ' B' ' 87' ' ' ARG . 74.4 p -100.51 -17.85 16.93 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -85.4 -41.21 15.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.485 -0.76 . . . . 0.0 109.354 179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.741 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.5 pt -87.04 -4.03 9.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 68.29 50.56 38.02 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.136 178.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.677 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -73.05 157.77 36.69 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.071 -1.252 . . . . 0.0 110.198 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.54 HG22 ' CG2' ' A' ' 4' ' ' THR . 50.5 p -149.63 128.39 12.47 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.462 -0.773 . . . . 0.0 109.323 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.54 HD11 HD11 ' A' ' 97' ' ' LEU . 7.5 mp -89.68 104.32 16.89 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.482 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 1.6 m120 -107.64 127.29 53.53 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.05 . . . . 0.0 110.04 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 1.059 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.138 -0.934 . . . . 0.0 109.62 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.623 ' C27' ' HB1' ' A' ' 28' ' ' ALA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.53 ' CD ' ' O ' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.726 0 N-CA-C 110.244 -0.714 . . . . 0.0 110.244 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' B' ' 97' ' ' LEU . 1.7 tm0? -84.67 144.08 28.79 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.765 HG12 ' H ' ' A' ' 5' ' ' LEU . 38.1 t -145.28 123.34 4.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.911 -1.118 . . . . 0.0 109.984 -179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 18.6 p -60.51 -14.76 21.5 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.546 -0.721 . . . . 0.0 110.28 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.765 ' H ' HG12 ' A' ' 3' ' ' VAL . 39.5 mt 73.65 17.02 3.78 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.484 -0.76 . . . . 0.0 110.654 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.698 ' CE3' HG21 ' B' ' 91' ' ' THR . 0.3 OUTLIER -65.45 -12.61 54.1 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.842 -1.161 . . . . 0.0 108.789 179.252 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.521 ' HA ' ' NH2' ' B' ' 87' ' ' ARG . 29.7 mm-40 -146.47 178.86 7.95 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 38.9 mtt180 -72.97 116.08 46.83 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.115 -0.991 . . . . 0.0 109.916 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.745 ' HB2' HD12 ' A' ' 24' ' ' LEU . 32.7 Cg_endo -75.93 77.81 3.32 Favored 'Trans proline' 0 C--N 1.315 -1.227 0 C-N-CA 122.091 1.86 . . . . 0.0 110.107 178.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.568 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.88 167.83 19.44 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.111 -0.993 . . . . 0.0 109.11 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.806 HG23 HG23 ' A' ' 13' ' ' ILE . 27.3 m -150.22 130.0 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.763 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 1.08 HG22 HD22 ' A' ' 19' ' ' LEU . 91.9 m -66.95 92.18 0.23 Allowed 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.871 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.4 pt -86.71 143.05 12.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.418 -0.801 . . . . 0.0 111.216 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.79 ' HD2' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -108.46 97.78 7.4 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.166 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.971 HD12 HG11 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -115.69 140.38 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.182 -0.949 . . . . 0.0 110.223 -178.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 38' ' ' LEU . . . 49.7 29.23 12.27 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 178.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.57 38.26 57.63 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.568 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 7.6 mp0 -136.2 179.43 6.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.477 -1.013 . . . . 0.0 108.284 179.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 1.08 HD22 HG22 ' A' ' 12' ' ' THR . 13.0 mt -144.55 118.98 9.63 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.957 -1.09 . . . . 0.0 109.801 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.571 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -135.44 150.18 49.79 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.605 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 14.9 mm-40 -78.81 112.51 16.02 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 120.819 -1.175 . . . . 0.0 108.133 179.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.884 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -91.85 140.46 29.66 Favored 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.934 0.873 . . . . 0.0 110.788 -178.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.436 ' O ' ' C ' ' A' ' 24' ' ' LEU . 44.6 tp -93.74 97.1 10.21 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.745 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.2 mt -42.43 107.69 0.08 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.158 -0.964 . . . . 0.0 109.153 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.778 ' CB ' HG23 ' A' ' 84' ' ' ILE . 2.7 t70 -113.81 87.82 2.7 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.354 -0.841 . . . . 0.0 110.42 -178.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.842 ' HA ' HD21 ' A' ' 90' ' ' LEU . 10.1 m -70.99 -5.68 32.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.114 -0.991 . . . . 0.0 109.081 178.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.639 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.6 -29.38 32.73 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -77.73 168.59 19.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.214 -1.168 . . . . 0.0 109.691 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -100.19 -19.82 16.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.394 -0.816 . . . . 0.0 109.656 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 39.4 m-20 -133.7 -167.18 1.9 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.147 -0.971 . . . . 0.0 109.74 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.547 HG22 ' O ' ' A' ' 31' ' ' THR . 8.0 m -111.06 89.74 3.13 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.035 -1.04 . . . . 0.0 110.193 -179.233 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.018 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -68.14 172.08 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.132 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.072 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -167.96 113.99 0.69 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.189 -0.944 . . . . 0.0 109.557 -179.511 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.735 ' HA ' HG22 ' A' ' 80' ' ' THR . 9.7 pt-20 -36.24 154.84 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.445 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -44.16 134.86 4.65 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.088 -1.008 . . . . 0.0 109.922 -178.915 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.697 ' HE1' HG22 ' A' ' 15' ' ' ILE . 2.3 ppp? -154.31 -163.72 1.68 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.595 -0.691 . . . . 0.0 109.644 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.513 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 3.1 t -107.81 118.27 36.29 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.921 -1.112 . . . . 0.0 111.149 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.746 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -131.32 -173.57 0.34 Allowed Pre-proline 0 N--CA 1.493 1.692 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 178.512 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.657 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 33.6 Cg_endo -78.97 -163.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.919 1.746 . . . . 0.0 110.861 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -114.18 31.56 6.41 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -118.98 63.82 0.78 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 21.2 p-90 -130.38 -175.39 3.63 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.764 0.792 . . . . 0.0 110.207 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -139.85 156.51 70.71 Favored Pre-proline 0 C--N 1.3 -1.55 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -75.65 141.56 24.96 Favored 'Trans proline' 0 C--N 1.303 -1.849 0 C-N-CA 121.868 1.712 . . . . 0.0 109.68 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 1.3 tttt -149.94 170.14 19.52 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.381 -0.824 . . . . 0.0 109.525 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.445 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -144.27 113.81 7.1 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.655 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.606 ' CD1' HG21 ' B' ' 50' ' ' ILE . 24.9 pt -89.47 141.62 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.079 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.615 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -119.32 115.46 3.05 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.456 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -136.84 -115.05 1.38 Allowed Glycine 0 N--CA 1.485 1.905 0 C-N-CA 119.212 -1.471 . . . . 0.0 111.088 -178.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.835 HD12 H702 ' B' ' 100' ' ' DMP . 17.1 mt -94.07 118.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.733 -0.863 . . . . 0.0 112.585 -177.116 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.89 -11.31 67.99 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 178.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.452 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 137.4 -177.54 19.76 Favored Glycine 0 N--CA 1.493 2.489 0 O-C-N 120.806 -1.408 . . . . 0.0 109.647 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.641 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.5 OUTLIER -102.64 143.92 31.7 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.274 -1.133 . . . . 0.0 109.844 -179.635 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.59 HD11 HG13 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -109.19 -178.21 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.258 -0.901 . . . . 0.0 108.703 178.909 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.58 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 2.4 mttp -109.09 141.7 40.88 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.038 -1.039 . . . . 0.0 109.643 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 54' ' ' ILE . 0.9 OUTLIER -147.61 -171.09 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.05 -1.031 . . . . 0.0 109.521 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.406 ' HG3' ' C ' ' A' ' 56' ' ' VAL . 1.6 mtt180 -133.46 108.12 8.46 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.441 ' HB2' ' HD2' ' A' ' 45' ' ' LYS . 1.3 tt0 -65.28 97.17 0.26 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.322 -0.861 . . . . 0.0 110.428 -179.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.746 ' CD2' HD23 ' A' ' 38' ' ' LEU . 10.3 m-85 -89.93 123.22 33.67 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 178.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -105.58 134.89 47.96 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.736 -1.227 . . . . 0.0 110.665 -178.589 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mp0 73.22 63.22 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 CA-C-O 121.695 0.76 . . . . 0.0 110.195 179.239 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.526 HG13 ' HB3' ' A' ' 59' ' ' TYR . 22.1 mm -117.27 127.27 74.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.586 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -76.37 89.08 3.18 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.032 -1.043 . . . . 0.0 112.276 -177.523 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.747 HD13 HD11 ' A' ' 66' ' ' ILE . 7.2 tt -90.48 112.96 25.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 CA-C-O 121.888 0.852 . . . . 0.0 108.822 177.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.537 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -89.5 113.03 24.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.778 -1.201 . . . . 0.0 108.515 -179.69 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.747 HD11 HD13 ' A' ' 64' ' ' ILE . 2.9 mt -115.17 126.64 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.922 -1.111 . . . . 0.0 110.67 -178.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.2 m 66.75 24.91 9.82 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.638 -0.664 . . . . 0.0 109.895 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.431 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 80.58 7.44 88.55 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 61.0 m-70 -108.86 110.03 21.28 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.208 -1.172 . . . . 0.0 109.226 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' HG3' HD21 ' A' ' 63' ' ' LEU . 1.2 ttpt -52.58 136.29 32.79 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.474 -0.767 . . . . 0.0 109.026 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.94 118.38 4.5 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.618 -0.676 . . . . 0.0 109.36 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.586 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -95.07 158.06 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 120.807 -1.183 . . . . 0.0 108.036 178.709 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.479 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . 177.42 -170.15 42.54 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.734 -1.698 . . . . 0.0 111.47 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 1.5 m -91.18 113.25 25.46 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.918 . . . . 0.0 110.146 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.072 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.5 t -107.93 109.49 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.525 -0.734 . . . . 0.0 111.135 -179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.594 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.9 mp -80.2 125.08 29.4 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.276 -0.89 . . . . 0.0 109.056 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 89.9 t -113.25 131.91 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.999 -1.063 . . . . 0.0 109.853 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -164.47 -167.57 25.21 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.58 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -81.81 40.74 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.592 2.195 . . . . 0.0 110.534 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.735 HG22 ' HA ' ' A' ' 34' ' ' GLU . 14.9 t -81.74 140.72 47.47 Favored Pre-proline 0 N--CA 1.489 1.521 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.463 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.3 Cg_endo -77.72 13.06 1.75 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 C-N-CA 122.227 1.952 . . . . 0.0 111.196 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.647 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.45 163.49 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.74 -1.225 . . . . 0.0 110.731 -179.755 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.642 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 60.0 m-20 -95.8 142.88 27.55 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 176.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 25' ' ' ASP . 12.3 mm -131.95 124.63 53.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.467 -1.396 . . . . 0.0 111.337 -178.098 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.884 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -102.96 94.72 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.656 ' C ' HD13 ' A' ' 90' ' ' LEU . . . -100.75 171.21 22.61 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.382 -177.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.622 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.1 OUTLIER -21.71 -41.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.056 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -179.392 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.978 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.8 p-10 -51.1 -42.89 60.94 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 120.282 -1.511 . . . . 0.0 110.774 -177.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.978 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.8 OUTLIER -97.54 -11.04 24.18 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.146 -0.971 . . . . 0.0 110.414 -179.137 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.842 HD21 ' HA ' ' A' ' 26' ' ' THR . 5.7 mp -69.73 -35.14 74.74 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.084 -1.01 . . . . 0.0 108.788 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 p -70.5 -15.42 62.79 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.455 -0.778 . . . . 0.0 109.252 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.6 mm-40 -89.13 -41.42 12.28 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.019 . . . . 0.0 109.27 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.674 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.9 pt -81.99 -1.89 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 57.19 54.95 33.11 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.876 ' HB3' HD12 ' B' ' 5' ' ' LEU . . . -85.42 127.62 34.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.422 -1.046 . . . . 0.0 110.26 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 69.9 p -122.31 124.9 44.82 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -89.98 100.48 13.29 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.406 -0.809 . . . . 0.0 109.384 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 1.6 m120 -105.96 129.33 54.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.234 -0.916 . . . . 0.0 110.048 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.736 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.265 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.404 -0.652 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.443 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 6.7 tt0 -84.25 129.45 34.88 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 11.4 t -121.76 96.23 4.01 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.762 -1.212 . . . . 0.0 109.499 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.418 HG23 ' H ' ' B' ' 4' ' ' THR . 3.0 p -55.73 135.11 51.73 Favored 'General case' 0 N--CA 1.486 1.362 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.876 HD12 ' HB3' ' A' ' 95' ' ' ALA . 89.5 mt -83.36 4.42 27.46 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.765 -179.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 81.9 m95 -57.05 -20.19 23.21 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -135.4 157.67 46.31 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 8.0 mtt180 -53.25 125.5 42.65 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 120.886 -1.134 . . . . 0.0 109.371 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.799 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.4 Cg_endo -77.65 71.23 6.59 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.281 1.987 . . . . 0.0 109.819 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.553 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -90.63 144.62 25.57 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.26 -179.686 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.659 HG21 HG12 ' B' ' 66' ' ' ILE . 3.1 m -135.14 132.71 53.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.253 -0.904 . . . . 0.0 110.203 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.809 HG22 HD22 ' B' ' 19' ' ' LEU . 91.8 m -65.6 109.56 2.43 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.034 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.1 pt -98.58 144.23 11.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 110.841 -178.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.483 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -112.16 101.9 10.12 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' B' ' 13' ' ' ILE . 11.8 mt -118.58 118.87 59.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.162 -0.961 . . . . 0.0 109.766 -179.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.421 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.83 27.25 73.67 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.2 -2.78 74.84 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.423 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 3.4 mp0 -90.07 -179.34 5.66 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.329 -1.101 . . . . 0.0 108.973 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 1.034 HD23 ' O ' ' B' ' 13' ' ' ILE . 12.4 mt -153.17 124.02 7.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.193 -0.942 . . . . 0.0 110.269 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.443 ' NZ ' HD23 ' B' ' 33' ' ' LEU . 8.4 mtmt -143.89 158.63 43.57 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.553 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.4 OUTLIER -79.29 133.05 36.64 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.978 -1.076 . . . . 0.0 109.54 -179.114 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.824 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.7 156.25 19.29 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.248 -0.908 . . . . 0.0 110.022 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.639 HD21 ' O ' ' A' ' 27' ' ' GLY . 62.4 tp -115.6 95.35 5.1 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.871 HD22 HD21 ' B' ' 90' ' ' LEU . 24.1 mt -42.15 103.44 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.393 -0.817 . . . . 0.0 109.359 -179.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.509 ' HB3' ' CG2' ' B' ' 84' ' ' ILE . 48.8 t0 -114.55 91.02 3.48 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.142 -0.974 . . . . 0.0 110.275 -179.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.563 HG21 HD22 ' A' ' 5' ' ' LEU . 0.9 OUTLIER -68.88 -7.56 35.82 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.066 -1.021 . . . . 0.0 108.73 178.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.429 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -73.8 -41.57 41.54 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.71 166.21 23.69 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.149 -1.206 . . . . 0.0 109.886 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -100.93 -19.91 15.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.145 -0.972 . . . . 0.0 110.786 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.499 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -130.6 -168.17 1.94 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.874 -1.141 . . . . 0.0 109.644 -179.445 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.596 HG22 ' CD1' ' B' ' 33' ' ' LEU . 16.7 m -109.74 95.66 5.75 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.911 -1.118 . . . . 0.0 110.286 -179.066 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.993 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -77.38 162.14 4.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 179.023 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.032 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -160.74 125.78 3.75 Favored 'General case' 0 N--CA 1.485 1.29 0 O-C-N 120.456 -1.402 . . . . 0.0 111.288 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.457 ' O ' ' O ' ' B' ' 33' ' ' LEU . 3.7 tt0 -38.89 159.17 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.724 -0.61 . . . . 0.0 109.677 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.78 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -51.35 150.26 3.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.95 . . . . 0.0 110.285 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.534 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.9 ppp? -168.5 -169.16 1.01 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.293 -0.879 . . . . 0.0 109.11 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.52 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.6 t -121.19 124.42 44.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.929 -1.107 . . . . 0.0 110.372 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.868 HD21 HD12 ' B' ' 62' ' ' ILE . 0.1 OUTLIER -124.64 -172.82 0.26 Allowed Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.347 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.648 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.8 Cg_endo -80.8 59.87 7.63 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.292 1.995 . . . . 0.0 111.005 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 41.95 -157.92 0.06 OUTLIER Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.414 ' HD3' ' HA ' ' B' ' 41' ' ' ARG . 50.7 mmt-85 51.91 96.58 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.544 -0.974 . . . . 0.0 109.077 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.453 ' CE3' ' HG3' ' B' ' 57' ' ' ARG . 16.7 p-90 -155.02 171.93 18.94 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.691 -0.631 . . . . 0.0 109.683 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 7.2 mtpt -129.24 121.4 20.52 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -78.26 141.5 18.31 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.412 2.075 . . . . 0.0 111.423 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.28 -171.93 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.516 ' HG2' ' HG3' ' B' ' 55' ' ' LYS . 17.1 mtp -143.54 133.97 24.74 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.903 -1.123 . . . . 0.0 110.098 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.692 HD12 HG21 ' A' ' 50' ' ' ILE . 19.4 pt -104.94 139.43 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 0.0 108.8 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.9 97.35 0.7 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.294 -1.922 . . . . 0.0 108.294 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.22 -121.37 2.88 Favored Glycine 0 N--CA 1.485 1.914 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.682 -178.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.832 HD12 ' C21' ' B' ' 100' ' ' DMP . 11.2 mt -86.58 124.79 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.854 -0.792 . . . . 0.0 111.982 -177.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 101.49 -53.46 0.83 Allowed Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 176.76 -161.81 29.9 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.0 OUTLIER -111.38 137.33 49.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -1.198 . . . . 0.0 109.359 -179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.591 HD11 HD11 ' B' ' 47' ' ' ILE . 27.6 pt -117.14 159.17 17.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.253 -0.904 . . . . 0.0 109.535 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.527 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.5 OUTLIER -94.69 126.26 39.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 108.8 179.313 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.585 HG12 ' HA3' ' B' ' 78' ' ' GLY . 12.5 m -134.2 153.68 36.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 O-C-N 121.247 -0.908 . . . . 0.0 109.745 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.542 ' N ' ' HD2' ' B' ' 57' ' ' ARG . 2.3 mpt_? -91.63 179.78 5.56 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -138.61 93.06 2.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.131 -0.98 . . . . 0.0 110.523 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.599 ' CG ' HD23 ' B' ' 38' ' ' LEU . 67.2 m-85 -89.29 92.53 9.2 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.503 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 49.0 m-20 -78.62 143.11 36.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.046 -1.034 . . . . 0.0 109.381 -179.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.586 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.1 OUTLIER 74.1 64.18 0.08 Allowed 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.529 -0.732 . . . . 0.0 109.189 -179.571 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.868 HD12 HD21 ' B' ' 38' ' ' LEU . 1.1 mm -121.07 117.15 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.741 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.4 tm? -68.62 85.27 0.3 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.476 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.613 HG22 ' O ' ' B' ' 71' ' ' ALA . 3.4 tt -91.02 117.67 34.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.9 tt0 -89.53 111.47 22.4 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.063 -1.023 . . . . 0.0 109.563 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.789 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -104.35 120.3 54.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.79 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 88.2 m 65.36 20.42 11.81 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.788 -0.57 . . . . 0.0 110.166 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.26 1.61 78.46 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.112 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -97.9 123.0 41.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.214 -1.168 . . . . 0.0 109.123 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.493 ' HG2' HD21 ' B' ' 63' ' ' LEU . 3.9 mtpt -58.71 133.85 56.3 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.613 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -150.96 99.67 2.72 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.014 -1.053 . . . . 0.0 110.26 -179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.711 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.5 OUTLIER -79.55 144.54 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.668 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.74 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.43 -177.8 39.2 Favored Glycine 0 N--CA 1.486 1.991 0 C-N-CA 118.915 -1.612 . . . . 0.0 110.634 -179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.449 HG23 ' OD1' ' B' ' 60' ' ' ASP . 22.0 m -95.83 102.99 14.85 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.723 -0.869 . . . . 0.0 109.432 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.032 ' CG1' HD13 ' B' ' 33' ' ' LEU . 0.9 OUTLIER -92.58 162.11 2.45 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.598 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.704 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.0 mp -129.95 140.35 50.94 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' B' ' 35' ' ' GLU . 9.2 t -120.8 103.19 13.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 O-C-N 121.386 -0.821 . . . . 0.0 110.507 -178.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.585 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -142.54 -166.12 10.87 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.527 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.5 Cg_endo -80.94 41.31 1.12 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.583 2.189 . . . . 0.0 110.956 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -84.45 138.21 38.8 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 178.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.29 14.51 1.56 Allowed 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.193 1.928 . . . . 0.0 111.497 -179.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.541 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.7 OUTLIER -161.13 171.21 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.903 -1.123 . . . . 0.0 110.11 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -105.97 116.07 31.31 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 176.591 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.733 HG12 HG12 ' B' ' 32' ' ' VAL . 5.0 mm -100.45 120.59 50.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.888 0 O-C-N 120.661 -1.274 . . . . 0.0 111.562 -176.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.824 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -95.37 89.83 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 105.987 -1.857 . . . . 0.0 105.987 176.838 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.08 -164.33 27.27 Favored Glycine 0 N--CA 1.493 2.474 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.437 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.521 ' NH2' ' HA ' ' A' ' 7' ' ' GLN . 13.5 mtm180 -60.76 -39.79 90.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.786 -0.832 . . . . 0.0 110.548 -179.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -45.28 -26.49 0.52 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.093 -1.005 . . . . 0.0 110.181 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -108.7 -29.56 8.64 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.026 -1.047 . . . . 0.0 111.041 -178.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.871 HD21 HD22 ' B' ' 24' ' ' LEU . 71.9 mt -65.15 -9.62 24.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.716 -1.24 . . . . 0.0 108.748 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.698 HG21 ' CE3' ' A' ' 6' ' ' TRP . 1.2 p -101.03 -20.71 15.26 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.176 -0.952 . . . . 0.0 109.391 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 36.6 mm-40 -78.06 -40.81 37.46 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.071 -1.018 . . . . 0.0 109.141 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.736 HD12 ' CG ' ' A' ' 99' ' ' PHE . 4.4 pt -86.03 -4.02 9.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 77.28 29.47 56.2 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.558 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -59.97 151.0 27.26 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.042 -1.269 . . . . 0.0 109.037 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.524 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 2.6 p -136.6 173.7 11.42 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.843 HD11 HD11 ' A' ' 97' ' ' LEU . 0.5 OUTLIER -134.31 98.82 4.2 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.735 -1.228 . . . . 0.0 110.088 -179.371 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.7 m120 -99.23 118.62 36.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.964 -1.085 . . . . 0.0 109.37 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.674 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.508 0 CA-C-O 117.94 -1.029 . . . . 0.0 108.935 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.835 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.542 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 N-CA-C 110.231 -0.719 . . . . 0.0 110.231 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.497 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.43 131.07 34.71 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.159 -1.423 . . . . 0.0 107.159 178.204 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.559 HG21 ' HZ ' ' B' ' 99' ' ' PHE . 4.1 t -121.79 94.45 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.991 -1.068 . . . . 0.0 109.768 -178.259 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.528 ' CG2' ' HB ' ' B' ' 96' ' ' THR . 19.3 p -126.01 45.67 2.58 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.335 -0.853 . . . . 0.0 108.93 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.03 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.5 OUTLIER -89.07 36.47 0.82 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.187 -0.946 . . . . 0.0 109.589 -179.721 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 13.4 m0 17.45 51.86 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 CA-C-O 121.631 0.729 . . . . 0.0 111.512 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 1.03 ' HB2' HD12 ' A' ' 5' ' ' LEU . 49.4 mt-30 -156.02 -159.78 0.94 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 10.1 mtm180 -79.66 113.34 36.6 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 120.986 -1.071 . . . . 0.0 109.909 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.77 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.3 Cg_endo -79.79 80.27 3.11 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 C-N-CA 122.355 2.037 . . . . 0.0 110.055 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -100.13 164.78 11.82 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.846 -179.749 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.987 HG21 HG23 ' A' ' 66' ' ' ILE . 2.3 m -148.86 129.47 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 110.256 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.3 m -69.22 94.05 0.66 Allowed 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 178.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.805 HG23 HG23 ' A' ' 11' ' ' VAL . 7.7 pt -82.95 167.42 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 110.949 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.3 tttt -128.65 102.88 6.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.559 -0.713 . . . . 0.0 109.25 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.952 HD11 HD12 ' A' ' 64' ' ' ILE . 11.6 mt -124.47 147.93 28.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 120.987 -1.07 . . . . 0.0 109.592 -179.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.03 32.53 4.83 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.9 43.62 90.97 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.6 tp-100 -138.52 170.79 15.38 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.191 -1.182 . . . . 0.0 109.022 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.484 HD23 ' O ' ' A' ' 13' ' ' ILE . 39.3 mt -135.57 126.41 27.48 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.385 -0.822 . . . . 0.0 109.445 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.41 ' HG3' ' C ' ' A' ' 19' ' ' LEU . 2.3 mtpm? -148.22 158.65 44.21 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.212 -0.93 . . . . 0.0 109.406 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 2.4 mt-10 -79.17 123.81 27.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.585 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -105.08 141.98 35.67 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.333 -0.854 . . . . 0.0 110.225 -178.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.871 HD21 ' O ' ' B' ' 27' ' ' GLY . 19.8 tp -97.67 103.82 15.79 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.747 -0.595 . . . . 0.0 109.918 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.77 HD12 ' HB2' ' A' ' 9' ' ' PRO . 12.1 mt -44.62 113.62 0.58 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 178.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.486 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 25.4 t0 -119.64 89.13 3.07 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.948 -1.095 . . . . 0.0 111.65 -177.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -76.57 -2.95 35.04 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.909 -1.119 . . . . 0.0 108.562 177.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 1.023 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -90.78 -25.12 25.95 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.98 162.13 19.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.953 -1.322 . . . . 0.0 109.027 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -98.1 -13.06 21.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.115 -0.991 . . . . 0.0 110.287 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.513 ' OD1' ' HB ' ' A' ' 74' ' ' THR . 0.2 OUTLIER -142.78 -175.05 4.34 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.93 -1.106 . . . . 0.0 109.732 -179.957 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.57 HG23 HD12 ' A' ' 85' ' ' ILE . 22.6 m -104.63 91.83 4.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.703 -1.248 . . . . 0.0 111.226 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.027 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -71.29 173.34 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.643 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.027 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -167.32 122.78 1.08 Allowed 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.688 -1.257 . . . . 0.0 111.547 -179.417 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.57 ' HA ' HG22 ' A' ' 80' ' ' THR . 12.6 tt0 -39.97 149.21 0.07 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.668 -0.645 . . . . 0.0 109.362 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.426 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -48.68 141.88 6.72 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.191 -0.943 . . . . 0.0 110.295 -179.599 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.514 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -163.64 -172.28 2.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.344 -0.848 . . . . 0.0 109.313 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.2 t -92.7 83.95 4.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.001 -1.062 . . . . 0.0 109.626 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.879 HD11 HD12 ' A' ' 62' ' ' ILE . 61.6 tp -116.2 98.34 51.17 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.25 -0.906 . . . . 0.0 109.182 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -78.37 167.3 23.18 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.656 2.237 . . . . 0.0 110.642 -179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 122.61 171.93 13.9 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 133.41 41.48 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -1.154 . . . . 0.0 108.684 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.615 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 52.5 p-90 -136.67 -177.42 4.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.163 -0.961 . . . . 0.0 110.691 -178.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.401 ' CG ' ' HD2' ' A' ' 44' ' ' PRO . 1.1 tptt -146.28 162.98 32.54 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.401 ' HD2' ' CG ' ' A' ' 43' ' ' LYS . 33.8 Cg_endo -78.0 140.36 17.98 Favored 'Trans proline' 0 C--N 1.301 -1.963 0 C-N-CA 121.756 1.638 . . . . 0.0 109.688 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.591 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -155.4 115.31 3.72 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.105 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.496 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -100.93 122.51 43.61 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.196 -0.94 . . . . 0.0 109.01 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.578 HD12 HG21 ' B' ' 50' ' ' ILE . 22.6 pt -93.24 139.26 18.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.016 -1.052 . . . . 0.0 109.109 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.606 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.64 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.641 -1.783 . . . . 0.0 108.641 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.411 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -125.74 -121.92 2.55 Favored Glycine 0 N--CA 1.483 1.812 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.698 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.82 HD12 ' C71' ' B' ' 100' ' ' DMP . 26.3 mt -86.48 122.23 38.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.875 -0.779 . . . . 0.0 112.571 -177.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.447 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 103.49 -50.98 0.85 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 178.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 176.26 -156.94 22.29 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.606 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 5.2 m-85 -111.9 129.9 56.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -1.034 . . . . 0.0 109.837 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.561 HG13 ' CG1' ' A' ' 47' ' ' ILE . 1.0 OUTLIER -106.97 164.76 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.883 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.1 mtmt -106.82 140.28 39.91 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.865 -1.147 . . . . 0.0 110.497 -179.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.861 HG12 ' HA3' ' A' ' 78' ' ' GLY . 16.1 m -146.63 178.18 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.83 110.63 16.57 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.329 -0.857 . . . . 0.0 108.829 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.414 ' O ' ' CG ' ' A' ' 58' ' ' GLN . 0.0 OUTLIER -64.75 107.03 1.32 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.456 -0.778 . . . . 0.0 110.271 -179.247 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.615 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 8.2 m-85 -100.89 100.45 11.08 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.535 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 85.2 m-20 -83.82 132.62 34.8 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.051 -1.031 . . . . 0.0 110.85 -178.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.2 mt-30 81.17 60.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.82 -0.55 . . . . 0.0 110.767 178.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.879 HD12 HD11 ' A' ' 38' ' ' LEU . 5.1 mm -117.93 118.46 58.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 178.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.156 HD21 ' CG ' ' A' ' 70' ' ' LYS . 1.4 tp -70.35 86.52 0.6 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.035 -1.04 . . . . 0.0 111.145 -178.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.952 HD12 HD11 ' A' ' 15' ' ' ILE . 5.6 tt -86.54 119.75 35.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 177.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.3 OUTLIER -87.79 103.98 16.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.936 -1.102 . . . . 0.0 109.165 -178.589 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.987 HG23 HG21 ' A' ' 11' ' ' VAL . 3.2 mt -109.61 120.93 61.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.479 -0.763 . . . . 0.0 109.717 -179.311 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.601 ' HB3' ' CD2' ' A' ' 69' ' ' HIS . 0.5 OUTLIER 64.42 40.21 6.5 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.531 -0.731 . . . . 0.0 109.476 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.24 30.49 76.11 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.601 ' CD2' ' HB3' ' A' ' 67' ' ' CYS . 87.9 m-70 -122.69 101.38 7.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.178 -1.19 . . . . 0.0 109.592 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 1.156 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -53.04 108.88 0.36 Allowed 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.156 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.74 ' O ' HD12 ' A' ' 63' ' ' LEU . . . -126.56 148.35 49.75 Favored 'General case' 0 C--N 1.287 -2.14 0 C-N-CA 120.304 -0.558 . . . . 0.0 109.603 -179.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 63' ' ' LEU . 1.0 OUTLIER -118.68 147.42 22.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.504 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.817 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -172.45 -168.26 33.6 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 118.789 -1.672 . . . . 0.0 110.987 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.513 ' HB ' ' OD1' ' A' ' 30' ' ' ASP . 27.9 m -96.98 108.0 20.64 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.659 -0.906 . . . . 0.0 109.409 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.801 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.21 111.06 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.469 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.3 mp -81.12 118.38 22.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.057 -1.027 . . . . 0.0 108.306 178.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.426 HG12 ' HA ' ' A' ' 35' ' ' GLU . 8.5 t -104.89 109.99 29.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.124 -0.985 . . . . 0.0 109.68 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.861 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -148.16 -162.16 9.98 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.169 -1.572 . . . . 0.0 109.169 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.538 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -81.66 43.78 1.59 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 C-N-CA 122.637 2.225 . . . . 0.0 110.599 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.57 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.1 t -84.75 136.33 39.31 Favored Pre-proline 0 N--CA 1.491 1.576 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.491 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -79.07 14.54 1.71 Allowed 'Trans proline' 0 C--N 1.307 -1.614 0 C-N-CA 122.389 2.059 . . . . 0.0 110.983 -179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 84' ' ' ILE . 1.2 t -159.9 164.65 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.11 -0.994 . . . . 0.0 109.101 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.531 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -101.36 126.21 48.09 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 104.831 -2.285 . . . . 0.0 104.831 176.649 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 31' ' ' THR . 7.6 mm -113.32 128.94 69.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.333 -1.347 . . . . 0.0 111.794 -176.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.585 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -103.53 90.91 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 177.138 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.75 ' O ' HD22 ' A' ' 90' ' ' LEU . . . -83.97 173.6 50.66 Favored Glycine 0 N--CA 1.498 2.774 0 O-C-N 121.198 -0.939 . . . . 0.0 110.97 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.678 ' HA ' HD23 ' A' ' 90' ' ' LEU . 8.8 mmm180 -39.89 -39.97 0.92 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.806 -0.82 . . . . 0.0 111.335 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.992 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.2 p-10 -44.55 -41.18 6.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.739 -1.226 . . . . 0.0 109.986 -179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.992 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.7 mm? -96.67 -26.62 15.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.237 -0.914 . . . . 0.0 111.745 -179.045 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.75 HD22 ' O ' ' A' ' 86' ' ' GLY . 0.8 OUTLIER -60.28 -36.25 77.41 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.292 -1.505 . . . . 0.0 108.0 179.71 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 81.6 p -70.05 -21.58 63.15 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 108.846 179.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.42 ' HB2' ' O ' ' A' ' 89' ' ' LEU . 22.3 mm-40 -74.78 -40.66 61.04 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.723 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -86.31 -13.08 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.384 -0.822 . . . . 0.0 108.937 179.444 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 83.92 26.78 40.05 Favored Glycine 0 N--CA 1.495 2.633 0 C-N-CA 120.32 -0.943 . . . . 0.0 111.042 178.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.556 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -59.5 143.16 50.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 109.865 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.458 HG22 ' CG2' ' B' ' 4' ' ' THR . 74.2 p -135.34 129.58 33.66 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.401 HD11 HD11 ' B' ' 97' ' ' LEU . 3.7 mp -92.63 99.26 12.0 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.907 -1.12 . . . . 0.0 110.688 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.573 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.4 m120 -108.0 124.48 50.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.413 -0.804 . . . . 0.0 109.046 179.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.73 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 118.037 -0.983 . . . . 0.0 109.163 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.668 0 N-CA-C 110.273 -0.703 . . . . 0.0 110.273 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.573 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.5 tt0 -83.39 144.11 29.85 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.6 t -141.98 105.83 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 C-N-CA 118.364 -1.334 . . . . 0.0 110.87 -177.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.458 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.2 OUTLIER -106.61 -86.51 0.49 Allowed 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 178.137 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.55 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.4 OUTLIER 43.52 20.38 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.576 -0.702 . . . . 0.0 111.308 178.498 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 40.4 m0 16.24 52.16 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.234 0.54 . . . . 0.0 112.16 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.55 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.4 mt-30 -144.03 -128.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.45 130.93 22.14 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.642 -1.286 . . . . 0.0 109.662 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.873 ' HB2' HD12 ' B' ' 24' ' ' LEU . 37.1 Cg_endo -82.52 53.63 4.56 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 C-N-CA 122.456 2.104 . . . . 0.0 109.301 178.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.68 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.7 mt -79.05 143.73 35.33 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.237 -0.914 . . . . 0.0 109.31 -179.175 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 1.062 HG21 HG23 ' B' ' 66' ' ' ILE . 0.8 OUTLIER -142.38 150.89 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -0.823 . . . . 0.0 109.452 -179.713 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 89.8 m -83.92 109.01 17.26 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.751 HD11 HD21 ' B' ' 33' ' ' LEU . 1.1 pt -98.89 139.26 21.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.148 -0.97 . . . . 0.0 111.102 -177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.463 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 0.7 OUTLIER -98.5 98.31 9.52 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.265 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.867 HD11 HD12 ' B' ' 64' ' ' ILE . 4.9 mt -120.3 130.64 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.342 -0.849 . . . . 0.0 109.337 -179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.29 23.54 71.7 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.426 -1.469 . . . . 0.0 109.426 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.4 15.72 80.2 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.463 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -112.25 174.08 6.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.422 -1.046 . . . . 0.0 109.31 179.809 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.484 ' HA ' HD23 ' B' ' 19' ' ' LEU . 27.9 mt -134.8 113.91 12.09 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.248 -0.907 . . . . 0.0 110.018 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 3.3 mttm -134.85 177.48 7.76 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.5 mm-40 -79.58 177.78 8.62 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.859 -1.15 . . . . 0.0 108.883 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.651 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -159.18 101.53 1.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.322 -0.861 . . . . 0.0 109.447 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 1.023 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.3 tp -77.97 98.89 5.84 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.291 -0.88 . . . . 0.0 109.438 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.873 HD12 ' HB2' ' B' ' 9' ' ' PRO . 89.6 mt -45.42 104.74 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.055 -1.028 . . . . 0.0 108.585 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.988 ' HB3' HG23 ' B' ' 84' ' ' ILE . 39.5 t0 -111.69 91.43 3.66 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.356 -0.84 . . . . 0.0 110.646 -178.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.444 HG23 HH11 ' B' ' 87' ' ' ARG . 55.9 m -69.79 -11.57 60.96 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.119 -0.988 . . . . 0.0 108.459 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.871 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -69.24 -39.85 82.03 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.26 150.67 29.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.342 -1.093 . . . . 0.0 109.481 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 59.2 m-20 -91.19 -10.04 43.17 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.23 -0.919 . . . . 0.0 109.805 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.479 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -131.81 -173.13 3.05 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.274 -0.892 . . . . 0.0 109.546 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.664 HG22 ' CD1' ' B' ' 33' ' ' LEU . 29.9 m -113.44 98.51 7.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.01 -1.056 . . . . 0.0 110.229 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.914 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -83.33 166.01 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.157 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.017 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -162.8 126.58 2.94 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.59 -1.319 . . . . 0.0 111.354 -178.438 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.582 ' N ' HG22 ' B' ' 80' ' ' THR . 8.5 tt0 -42.9 154.57 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.602 ' HA ' HG13 ' B' ' 77' ' ' VAL . 1.6 tm-20 -38.8 148.54 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.349 -0.844 . . . . 0.0 110.366 -179.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.577 ' CE ' HG22 ' B' ' 15' ' ' ILE . 24.5 ptm -163.57 -162.31 0.72 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.324 -0.86 . . . . 0.0 109.668 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.5 t -118.68 120.2 36.73 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.083 -1.01 . . . . 0.0 110.794 -179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.761 HD23 ' CD2' ' B' ' 59' ' ' TYR . 0.0 OUTLIER -124.6 173.66 4.53 Favored Pre-proline 0 N--CA 1.491 1.592 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 179.019 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.59 ' HD3' HD12 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.72 47.72 2.61 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 C-N-CA 122.676 2.25 . . . . 0.0 111.634 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.12 -166.88 0.01 OUTLIER Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.408 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.5 mmm180 63.38 70.73 0.52 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.168 -1.195 . . . . 0.0 109.361 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.618 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 10.1 p-90 -140.41 -173.43 3.67 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 121.629 -0.669 . . . . 0.0 109.519 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.94 128.58 16.76 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.216 -0.927 . . . . 0.0 108.516 179.292 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -75.34 139.54 23.55 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 121.879 1.719 . . . . 0.0 110.749 -179.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.17 -162.7 1.57 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.528 -0.732 . . . . 0.0 109.232 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.555 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 0.2 OUTLIER -149.02 130.02 14.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.27 -0.894 . . . . 0.0 109.613 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.793 HD12 HG21 ' A' ' 50' ' ' ILE . 8.3 pt -98.67 143.56 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 120.899 -1.125 . . . . 0.0 108.84 179.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.629 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -118.53 113.3 2.56 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.853 -1.699 . . . . 0.0 108.853 -179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.12 -125.43 2.04 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.452 -1.356 . . . . 0.0 110.707 -179.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.775 HD12 ' C21' ' B' ' 100' ' ' DMP . 21.5 mt -88.7 119.04 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.797 -0.825 . . . . 0.0 112.852 -177.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.446 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 96.6 2.32 60.06 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.203 177.234 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 126.87 -158.75 20.96 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.334 -1.412 . . . . 0.0 110.221 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.66 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.9 OUTLIER -124.6 134.11 53.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.661 -0.905 . . . . 0.0 109.222 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.733 HD11 HD11 ' B' ' 47' ' ' ILE . 13.5 pt -104.26 167.65 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 120.979 -1.076 . . . . 0.0 109.239 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.559 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.91 134.32 48.23 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.191 -0.943 . . . . 0.0 109.159 179.734 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.826 HG12 ' HA3' ' B' ' 78' ' ' GLY . 21.4 m -140.6 -171.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.991 -1.068 . . . . 0.0 110.201 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.457 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.4 mtt-85 -128.87 105.92 8.56 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 33.7 tt0 -69.62 100.34 1.44 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.444 -0.785 . . . . 0.0 110.934 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.761 ' CD2' HD23 ' B' ' 38' ' ' LEU . 17.1 m-85 -89.59 133.42 34.62 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.55 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 67.4 m-20 -108.49 133.14 53.05 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.713 -1.242 . . . . 0.0 109.989 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.558 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.29 63.71 0.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.917 -0.713 . . . . 0.0 109.569 179.581 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.698 ' C ' HD13 ' B' ' 72' ' ' ILE . 26.9 mm -116.52 119.28 61.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.844 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.9 tm? -66.02 84.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 111.28 -178.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.867 HD12 HD11 ' B' ' 15' ' ' ILE . 5.7 tt -90.52 112.19 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.564 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 29.5 tt0 -89.52 115.39 26.9 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.178 -0.951 . . . . 0.0 109.033 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 1.062 HG23 HG21 ' B' ' 11' ' ' VAL . 2.3 mp -112.97 123.43 68.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.032 -1.043 . . . . 0.0 109.719 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.636 ' SG ' HG22 ' B' ' 66' ' ' ILE . 36.8 m 67.17 44.93 1.79 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.487 -0.758 . . . . 0.0 109.444 179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 61.52 21.02 59.75 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.52 ' O ' ' HA ' ' B' ' 65' ' ' GLU . 4.4 m-70 -119.66 130.09 54.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.014 -1.286 . . . . 0.0 109.677 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.581 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -70.56 136.55 49.37 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.559 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -155.9 104.69 2.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.219 -0.925 . . . . 0.0 109.793 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.716 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -80.06 154.54 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.963 -1.085 . . . . 0.0 108.349 178.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.564 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 178.98 -169.74 41.24 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.881 -1.628 . . . . 0.0 111.16 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -95.64 105.9 17.94 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.667 -0.901 . . . . 0.0 110.618 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.017 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.6 158.91 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.726 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.8 mp -126.38 125.42 42.18 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.762 -1.211 . . . . 0.0 107.901 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.602 HG13 ' HA ' ' B' ' 35' ' ' GLU . 94.8 t -106.43 116.39 50.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 O-C-N 120.671 -1.268 . . . . 0.0 109.663 -179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.826 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -156.37 -166.25 15.9 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.559 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -80.09 44.52 1.74 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.511 2.141 . . . . 0.0 110.604 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.66 HG21 HG13 ' B' ' 32' ' ' VAL . 3.2 t -89.74 135.22 30.84 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.645 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -78.17 17.59 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.284 1.99 . . . . 0.0 111.137 -178.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.645 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.5 t -160.32 156.76 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 120.879 -1.138 . . . . 0.0 110.777 -179.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.613 ' OD1' HD23 ' B' ' 33' ' ' LEU . 60.4 m-20 -97.41 86.28 3.84 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 176.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.988 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.6 mt -82.78 124.89 39.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 O-C-N 121.298 -0.876 . . . . 0.0 112.378 -176.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.52 HD13 ' N ' ' B' ' 85' ' ' ILE . 3.7 mm -100.19 109.18 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.572 ' O ' ' N ' ' B' ' 88' ' ' ASN . . . -108.29 164.39 12.76 Favored Glycine 0 N--CA 1.498 2.785 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.881 -178.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.564 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 20.7 mmm180 -19.26 -41.94 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.369 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -178.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.9 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -49.45 -42.12 42.14 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.475 -1.391 . . . . 0.0 110.813 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.9 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.8 OUTLIER -93.75 -27.65 16.37 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.245 -0.91 . . . . 0.0 109.976 -179.653 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.566 ' CD1' ' N ' ' B' ' 90' ' ' LEU . 4.6 mp -58.76 -33.87 70.78 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.097 -1.002 . . . . 0.0 108.831 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 4.3 p -74.12 -21.28 59.95 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.294 -0.879 . . . . 0.0 109.866 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 1.4 mm100 -80.14 -40.47 27.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.163 -0.961 . . . . 0.0 109.053 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.73 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -81.7 -5.39 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.264 -0.897 . . . . 0.0 108.916 179.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.31 60.74 7.79 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.553 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -87.89 160.06 18.12 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.265 -1.138 . . . . 0.0 110.706 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.528 ' HB ' ' CG2' ' A' ' 4' ' ' THR . 4.7 p -141.7 126.96 18.6 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.502 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.5 mp -92.18 97.1 10.7 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.556 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 10.4 m120 -97.41 118.92 34.96 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.378 -0.826 . . . . 0.0 110.453 -178.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.723 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.723 0 CA-C-O 117.923 -1.037 . . . . 0.0 109.334 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.82 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.589 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 4.0 Cg_exo . . . . . 0 N--CA 1.496 1.64 0 N-CA-C 110.763 -0.514 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.534 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 17.6 tt0 -83.77 131.75 34.89 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.494 HG11 ' HB3' ' A' ' 9' ' ' PRO . 20.0 t -124.12 102.06 10.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.575 -1.328 . . . . 0.0 110.484 -177.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.987 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -139.78 48.73 1.8 Allowed 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.55 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -85.59 43.02 1.0 Allowed 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.225 -0.922 . . . . 0.0 110.152 -179.238 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.597 ' CZ3' ' HB ' ' B' ' 91' ' ' THR . 13.4 m95 18.91 48.09 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 CA-C-O 121.46 0.647 . . . . 0.0 111.335 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 37.1 mt-30 -165.23 -168.0 1.3 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.419 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 58.8 mtt180 -75.26 122.49 87.44 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.011 -1.055 . . . . 0.0 108.632 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.818 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.5 Cg_endo -76.53 85.06 1.76 Allowed 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 122.153 1.902 . . . . 0.0 109.991 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.803 HD22 ' HB3' ' A' ' 21' ' ' GLU . 5.5 mt -86.47 142.36 28.44 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.287 -0.883 . . . . 0.0 109.723 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.635 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -146.98 154.4 11.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.218 -0.927 . . . . 0.0 109.243 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.779 HG22 HD22 ' A' ' 19' ' ' LEU . 85.3 m -88.95 112.87 23.85 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.877 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -101.87 153.51 5.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.114 -0.991 . . . . 0.0 110.121 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 2.9 tttt -110.76 109.21 19.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.36 -0.838 . . . . 0.0 109.738 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.937 HD13 HG11 ' A' ' 75' ' ' VAL . 4.5 mt -124.59 135.54 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.03 -1.044 . . . . 0.0 110.343 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 50.04 33.8 22.49 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.454 -1.059 . . . . 0.0 110.454 179.085 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 72.68 35.2 59.11 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 9.0 mm100 -128.19 175.72 8.22 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.318 -1.107 . . . . 0.0 109.057 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.779 HD22 HG22 ' A' ' 12' ' ' THR . 14.2 mt -145.71 123.27 11.76 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -0.946 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.485 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 18.3 mttp -146.61 177.32 9.16 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.803 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -79.19 -179.96 7.03 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.831 -1.168 . . . . 0.0 108.612 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.699 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -165.17 109.2 0.87 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.249 -1.532 . . . . 0.0 110.992 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.636 HD21 ' O ' ' B' ' 27' ' ' GLY . 2.8 tp -78.57 95.79 5.3 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.818 HD12 ' HB2' ' A' ' 9' ' ' PRO . 35.0 mt -48.64 93.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.735 ' HB3' HG23 ' A' ' 84' ' ' ILE . 22.5 t0 -99.57 92.92 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 110.828 -178.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.51 ' OG1' HD21 ' B' ' 97' ' ' LEU . 2.6 m -67.56 -6.84 21.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.095 -1.003 . . . . 0.0 109.467 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.984 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -78.55 -40.83 17.49 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.462 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -72.56 154.15 40.94 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.31 . . . . 0.0 109.256 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 1.8 m-20 -88.2 -13.59 40.73 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.25 -0.906 . . . . 0.0 110.374 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.843 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -137.51 -170.77 2.82 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.984 -1.073 . . . . 0.0 110.482 -179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.712 HG23 HD12 ' A' ' 85' ' ' ILE . 22.8 m -109.05 89.82 3.11 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.034 -1.041 . . . . 0.0 110.677 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.009 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -71.54 167.5 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.009 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.9 130.02 2.23 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.555 -1.34 . . . . 0.0 111.702 -178.212 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.582 ' CG ' ' O ' ' A' ' 80' ' ' THR . 7.2 mt-10 -39.1 157.8 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.618 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -60.12 154.0 20.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.198 -0.938 . . . . 0.0 110.103 179.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.596 ' CE ' HG22 ' A' ' 15' ' ' ILE . 4.1 ptm -176.0 -168.71 0.29 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.478 -0.764 . . . . 0.0 109.186 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 26.8 t -97.82 105.17 17.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.274 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.621 HD12 ' HD2' ' A' ' 39' ' ' PRO . 27.8 tp -131.64 103.4 14.75 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.849 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.6 Cg_endo -78.5 154.27 27.51 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.514 2.143 . . . . 0.0 110.336 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 132.74 -173.16 21.03 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.66 141.28 29.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.33 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.0 p-90 -160.88 175.34 12.65 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.834 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -148.28 154.5 42.26 Favored Pre-proline 0 C--N 1.301 -1.511 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 179.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.53 136.55 13.96 Favored 'Trans proline' 0 C--N 1.304 -1.786 0 C-N-CA 122.233 1.956 . . . . 0.0 110.223 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.569 ' HG3' HG22 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -149.94 -169.26 3.33 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.354 -0.841 . . . . 0.0 109.387 179.669 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.439 ' SD ' ' HG3' ' A' ' 55' ' ' LYS . 9.7 mmm -145.13 118.9 9.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.117 -0.99 . . . . 0.0 109.576 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 9.9 pt -89.75 135.24 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 118.886 -1.126 . . . . 0.0 108.294 178.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.414 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -118.7 105.47 1.19 Allowed Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.417 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -125.64 -123.26 2.67 Favored Glycine 0 N--CA 1.482 1.737 0 C-N-CA 119.552 -1.309 . . . . 0.0 110.632 -179.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.835 HD12 ' C71' ' B' ' 100' ' ' DMP . 13.5 mt -87.22 121.2 37.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.88 -0.776 . . . . 0.0 112.353 -177.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 99.92 -46.16 1.42 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.45 -163.33 33.9 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.626 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -120.93 137.01 54.81 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.121 -1.223 . . . . 0.0 109.628 -179.838 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 79' ' ' PRO . 2.7 pt -111.92 159.18 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.231 -0.918 . . . . 0.0 109.222 179.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -82.19 141.16 33.27 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.225 -0.922 . . . . 0.0 110.255 -179.376 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.569 HG22 ' HG3' ' A' ' 45' ' ' LYS . 2.9 m -148.22 166.32 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -113.71 107.2 15.44 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 6.7 tt0 -65.83 107.63 1.87 Allowed 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.578 -0.701 . . . . 0.0 110.282 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 74' ' ' THR . 8.3 m-85 -97.27 138.68 34.38 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.541 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 21.9 m-20 -119.37 118.02 30.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.877 -1.139 . . . . 0.0 110.267 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.541 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 66.3 mt-30 87.64 55.82 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 CA-C-O 121.362 0.601 . . . . 0.0 110.283 179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.571 HG13 ' HB3' ' A' ' 59' ' ' TYR . 21.8 mm -110.04 124.55 66.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 178.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.902 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.3 tm? -66.56 96.4 0.38 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.221 -0.924 . . . . 0.0 110.661 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.846 HD12 HD11 ' A' ' 15' ' ' ILE . 7.7 tt -105.97 115.91 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.526 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -88.47 140.88 29.02 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 109.231 -179.079 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 1.0 OUTLIER -127.7 130.34 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.3 -0.875 . . . . 0.0 108.993 -179.797 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.428 ' C ' ' O ' ' A' ' 66' ' ' ILE . 58.5 m 40.64 29.66 0.07 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.607 -0.683 . . . . 0.0 109.731 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 83.33 42.62 7.85 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.415 ' O ' ' C ' ' A' ' 70' ' ' LYS . 3.0 m-70 -134.6 100.73 4.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.285 -1.127 . . . . 0.0 109.313 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' A' ' 69' ' ' HIS . 16.9 ttpt -46.47 122.13 3.9 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.573 ' O ' ' CG2' ' A' ' 64' ' ' ILE . . . -148.49 101.21 3.21 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 110.44 -179.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.517 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.7 OUTLIER -81.97 158.72 3.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 107.362 -1.348 . . . . 0.0 107.362 177.932 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.508 ' N ' HG22 ' A' ' 72' ' ' ILE . . . 177.95 -161.46 28.48 Favored Glycine 0 N--CA 1.488 2.133 0 C-N-CA 118.824 -1.655 . . . . 0.0 110.579 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 59' ' ' TYR . 98.9 m -102.0 117.26 34.43 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.122 -1.222 . . . . 0.0 109.787 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.937 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -108.21 117.7 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.341 -0.85 . . . . 0.0 110.397 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.843 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.3 mp -86.75 107.99 18.5 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.405 -0.81 . . . . 0.0 109.213 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 35' ' ' GLU . 1.4 t -91.85 114.17 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.082 -1.011 . . . . 0.0 109.875 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.85 -168.25 15.41 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 54' ' ' ILE . 37.0 Cg_endo -81.55 42.11 1.27 Allowed 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 110.201 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.629 HG21 HG13 ' A' ' 32' ' ' VAL . 5.0 t -82.05 137.91 46.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.577 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.2 Cg_endo -79.45 21.53 0.76 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.483 2.122 . . . . 0.0 111.273 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.591 ' CG1' HG13 ' A' ' 84' ' ' ILE . 1.4 t -161.03 160.65 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 120.871 -1.143 . . . . 0.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.637 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -102.52 94.66 5.78 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 104.855 -2.276 . . . . 0.0 104.855 177.217 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.761 ' C ' HD13 ' A' ' 85' ' ' ILE . 2.8 mt -94.58 128.93 45.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 CA-C-O 122.132 0.968 . . . . 0.0 113.268 -175.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.871 HD13 ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -104.08 107.87 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.353 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -87.71 -168.59 44.67 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.727 -178.142 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.436 ' HD2' ' CG2' ' A' ' 91' ' ' THR . 5.9 mmt180 -60.58 -32.52 71.61 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.696 -0.885 . . . . 0.0 109.953 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.5 p-10 -46.88 -29.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.776 -1.203 . . . . 0.0 109.14 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -106.26 -36.72 6.78 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.505 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 38.0 mt -62.55 -12.78 24.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.889 -1.132 . . . . 0.0 108.694 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.463 ' O ' ' CH2' ' B' ' 6' ' ' TRP . 67.4 p -100.55 -20.36 15.74 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.207 -0.933 . . . . 0.0 108.673 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.6 mm-40 -79.23 -40.86 29.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.321 -0.862 . . . . 0.0 109.089 179.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.029 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -79.98 -15.06 13.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.162 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 100.31 15.66 29.54 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.735 178.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.572 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -56.84 146.4 26.48 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.502 -1.587 . . . . 0.0 109.673 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.664 HG22 ' CG2' ' B' ' 4' ' ' THR . 19.2 p -137.78 129.86 28.91 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' B' ' 97' ' ' LEU . 1.1 mp -87.45 98.81 11.59 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.97 -1.081 . . . . 0.0 109.444 -179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.535 ' C ' ' CD1' ' A' ' 99' ' ' PHE . 1.4 m120 -111.57 136.81 50.26 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.394 -0.816 . . . . 0.0 110.103 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.758 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.273 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.587 0 N-CA-C 109.984 -0.814 . . . . 0.0 109.984 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -83.56 138.87 33.19 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.618 HG11 ' HB3' ' B' ' 9' ' ' PRO . 4.4 t -128.6 111.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 C-N-CA 118.627 -1.229 . . . . 0.0 109.769 -178.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.664 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -142.66 39.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.848 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.554 ' O ' ' N ' ' B' ' 7' ' ' GLN . 4.6 tp -83.93 46.0 1.14 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.107 -0.995 . . . . 0.0 110.266 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' B' ' 5' ' ' LEU . 38.0 m95 17.94 50.06 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 121.489 0.662 . . . . 0.0 112.121 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.554 ' N ' ' O ' ' B' ' 5' ' ' LEU . 15.0 mt-30 -165.62 173.76 10.53 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.14 128.1 56.65 Favored Pre-proline 0 C--N 1.303 -1.435 0 O-C-N 121.089 -1.007 . . . . 0.0 109.043 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.618 ' HB3' HG11 ' B' ' 3' ' ' VAL . 35.0 Cg_endo -79.35 64.64 8.87 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.423 2.082 . . . . 0.0 110.438 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.908 HD22 ' HB2' ' B' ' 21' ' ' GLU . 0.3 OUTLIER -79.43 148.35 31.97 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.161 -0.962 . . . . 0.0 109.222 -179.929 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.78 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -143.72 137.15 24.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.232 -0.917 . . . . 0.0 109.573 -179.302 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 7.1 m -69.13 98.78 1.04 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.005 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -89.79 151.44 3.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.351 -0.843 . . . . 0.0 110.0 -178.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.553 ' HE3' ' CG ' ' B' ' 19' ' ' LEU . 2.1 tttt -117.37 107.1 13.96 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.337 -0.852 . . . . 0.0 108.951 179.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.891 HD13 HG11 ' B' ' 75' ' ' VAL . 4.1 mt -113.5 139.6 38.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.253 -0.905 . . . . 0.0 109.205 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.62 -90.9 0.02 OUTLIER Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.131 -1.587 . . . . 0.0 109.131 179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -151.79 45.72 0.61 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.6 OUTLIER -140.82 169.31 17.87 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.455 -1.026 . . . . 0.0 110.035 -179.332 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.553 ' CG ' ' HE3' ' B' ' 14' ' ' LYS . 27.8 mt -139.07 113.83 9.2 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.483 ' HG3' ' C ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -136.26 163.88 29.39 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.207 -0.933 . . . . 0.0 109.115 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.908 ' HB2' HD22 ' B' ' 10' ' ' LEU . 0.0 OUTLIER -78.13 145.01 35.96 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.277 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.795 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -134.39 116.45 15.2 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.869 -1.145 . . . . 0.0 111.297 -178.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.984 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -71.47 100.13 2.16 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.645 HD22 HD21 ' B' ' 90' ' ' LEU . 18.6 mt -47.18 137.44 7.96 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 179.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.824 ' HB2' HG23 ' B' ' 84' ' ' ILE . 42.4 t0 -142.66 94.24 2.62 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.835 -1.166 . . . . 0.0 111.422 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.526 HG23 ' HD3' ' B' ' 87' ' ' ARG . 6.8 m -74.89 -14.87 60.71 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 178.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.636 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -76.05 -16.18 80.87 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.474 ' HB1' ' C75' ' B' ' 100' ' ' DMP . . . -97.39 160.71 14.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.32 . . . . 0.0 109.053 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -88.23 -21.14 24.67 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.014 . . . . 0.0 110.479 -179.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.637 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 1.6 m-20 -143.05 -173.83 4.02 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.635 -1.291 . . . . 0.0 110.858 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.804 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.2 m -97.54 86.02 3.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.822 -1.173 . . . . 0.0 111.578 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.923 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -67.22 153.61 8.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.423 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.923 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.2 OUTLIER -157.08 124.42 5.26 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.083 -1.011 . . . . 0.0 110.569 -177.722 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.564 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.7 tm-20 -43.07 153.87 0.08 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 109.078 178.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.566 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 2.3 tt0 -45.23 139.49 3.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.309 -0.869 . . . . 0.0 110.902 -179.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.655 ' HE1' HG22 ' B' ' 15' ' ' ILE . 2.3 ppp? -152.04 -164.4 1.96 Allowed 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.495 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -112.73 118.16 34.21 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.88 -1.138 . . . . 0.0 110.539 -179.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.641 ' HG ' ' HD2' ' B' ' 39' ' ' PRO . 0.2 OUTLIER -134.91 -175.08 0.45 Allowed Pre-proline 0 N--CA 1.491 1.595 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.411 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.641 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 34.7 Cg_endo -79.7 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.256 1.971 . . . . 0.0 110.942 -178.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.22 35.93 4.63 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.35 51.75 0.75 Allowed 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.683 -0.892 . . . . 0.0 108.945 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.65 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 39.9 p-90 -137.95 179.83 6.2 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-O 121.776 0.798 . . . . 0.0 110.668 -178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.494 ' HG3' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -140.86 146.13 42.69 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 179.088 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . 0.494 ' HD2' ' HG3' ' B' ' 43' ' ' LYS . 34.9 Cg_endo -78.36 138.67 15.93 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.416 2.077 . . . . 0.0 110.679 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' B' ' 58' ' ' GLN . 1.1 ptpt -160.54 -165.17 1.36 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.45 ' HB3' ' O ' ' B' ' 54' ' ' ILE . 44.4 mtp -151.1 138.48 19.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.172 -0.955 . . . . 0.0 109.997 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.71 ' CD1' HG21 ' A' ' 50' ' ' ILE . 10.3 pt -103.71 148.3 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.114 -0.991 . . . . 0.0 108.83 178.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.626 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -119.57 116.28 3.26 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 108.979 -1.649 . . . . 0.0 108.979 179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.486 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -137.45 -123.23 2.19 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.226 -1.464 . . . . 0.0 111.145 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.889 HD12 ' C21' ' B' ' 100' ' ' DMP . 15.8 mt -84.03 133.48 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.729 -0.866 . . . . 0.0 112.694 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.461 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 85.23 -44.17 3.34 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 178.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 171.24 -171.33 43.9 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.227 -1.463 . . . . 0.0 109.95 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' HA2' ' B' ' 48' ' ' GLY . 7.7 m-30 -96.29 168.82 10.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.432 -1.04 . . . . 0.0 109.748 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.64 HD12 HG13 ' B' ' 56' ' ' VAL . 1.8 pt -142.23 177.23 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.543 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.0 mtpt -114.18 128.65 56.47 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.922 -1.111 . . . . 0.0 109.44 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.654 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.7 m -136.61 -175.04 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.045 -1.034 . . . . 0.0 109.987 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 66.5 mtt180 -130.23 110.97 11.97 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.415 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 2.0 tt0 -69.98 103.49 2.27 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.32 -0.863 . . . . 0.0 110.442 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.65 ' CD1' ' HB3' ' B' ' 42' ' ' TRP . 10.5 m-85 -89.01 141.12 28.75 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 4.0 m-20 -120.12 130.96 54.86 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.681 -1.262 . . . . 0.0 110.953 -178.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.576 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 69.3 62.92 0.29 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-O 121.15 0.5 . . . . 0.0 110.756 179.003 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.784 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -118.48 125.64 74.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.164 -0.96 . . . . 0.0 108.923 178.877 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.787 ' N ' HD13 ' B' ' 72' ' ' ILE . 3.1 tm? -70.63 101.08 1.97 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.496 -0.752 . . . . 0.0 111.658 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.885 HD13 HD11 ' B' ' 66' ' ' ILE . 4.0 tt -101.48 122.27 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.482 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 25.5 tt0 -89.06 100.82 13.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.938 -1.101 . . . . 0.0 109.831 -178.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 1.005 HG13 HG22 ' B' ' 13' ' ' ILE . 1.1 mp -99.53 113.05 33.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.163 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 63.47 25.31 14.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.61 6.75 82.85 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.851 -1.166 . . . . 0.0 110.328 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -103.45 109.49 21.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.156 -1.203 . . . . 0.0 109.252 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.47 133.15 35.56 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.724 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -152.98 98.16 2.28 Favored 'General case' 0 C--N 1.294 -1.831 0 O-C-N 121.257 -0.902 . . . . 0.0 109.88 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.787 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -77.97 145.5 9.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.151 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.5 -175.07 40.96 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.005 -1.569 . . . . 0.0 110.971 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.563 HG23 ' O ' ' B' ' 59' ' ' TYR . 1.5 m -85.75 112.51 21.13 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.668 -0.901 . . . . 0.0 110.461 -179.195 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.891 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -104.8 105.53 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -0.813 . . . . 0.0 110.156 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.6 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 1.1 mp -77.14 129.78 36.45 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.566 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 45.4 t -118.52 122.95 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.126 -0.984 . . . . 0.0 110.247 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.654 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -157.56 -165.41 15.19 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.543 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.9 Cg_endo -81.98 41.87 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.547 2.165 . . . . 0.0 110.312 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.602 HG23 ' O ' ' B' ' 82' ' ' VAL . 8.9 t -79.4 141.71 57.4 Favored Pre-proline 0 N--CA 1.49 1.56 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.317 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.702 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.1 Cg_endo -77.68 14.39 1.46 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 C-N-CA 122.135 1.89 . . . . 0.0 110.874 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.702 HG23 ' O ' ' B' ' 81' ' ' PRO . 3.6 t -161.02 162.52 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.856 -1.152 . . . . 0.0 110.201 -179.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -102.97 99.77 9.68 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 176.665 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.893 ' HB ' HG12 ' B' ' 32' ' ' VAL . 4.7 mt -104.51 129.22 57.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 O-C-N 120.835 -1.166 . . . . 0.0 112.869 -175.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.795 HD11 ' HB1' ' B' ' 22' ' ' ALA . 2.6 mm -88.51 132.39 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 176.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.637 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -107.16 -159.55 21.33 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 118.683 -1.723 . . . . 0.0 110.243 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.526 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -71.08 -30.28 66.36 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.737 -0.86 . . . . 0.0 108.762 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.799 ' ND2' HD23 ' B' ' 89' ' ' LEU . 5.8 p-10 -50.19 -40.07 45.88 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.822 -1.151 . . . . 0.0 108.897 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.799 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -90.25 -32.86 16.38 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 121.42 -0.8 . . . . 0.0 110.027 -179.361 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.645 HD21 HD22 ' B' ' 24' ' ' LEU . 37.0 mt -67.04 -8.03 27.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.99 -1.069 . . . . 0.0 108.655 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.597 ' HB ' ' CZ3' ' A' ' 6' ' ' TRP . 31.5 p -99.43 -18.2 17.59 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.008 -1.058 . . . . 0.0 108.581 179.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.401 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 0.5 OUTLIER -85.01 -40.95 16.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.53 -0.731 . . . . 0.0 109.659 179.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.758 HD12 ' CD2' ' A' ' 99' ' ' PHE . 26.6 pt -83.17 -4.25 8.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.306 -0.871 . . . . 0.0 109.032 179.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.95 60.33 6.17 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.184 -1.566 . . . . 0.0 109.184 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.587 ' CB ' ' CD1' ' A' ' 99' ' ' PHE . . . -93.51 145.18 24.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.282 -1.128 . . . . 0.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.987 HG22 ' CG2' ' A' ' 4' ' ' THR . 10.7 p -137.56 129.49 28.86 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.965 HD11 HD11 ' A' ' 97' ' ' LEU . 5.4 mp -87.14 98.39 11.27 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.534 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.0 m120 -103.6 128.5 50.87 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.868 -1.145 . . . . 0.0 110.123 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 1.029 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.532 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.889 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.588 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 N-CA-C 109.899 -0.846 . . . . 0.0 109.899 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 25.0 tt0 -84.17 120.05 25.73 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 4' ' ' THR . 3.4 t -129.21 94.61 2.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.982 -1.074 . . . . 0.0 109.901 -178.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.766 ' C ' HD12 ' A' ' 5' ' ' LEU . 0.7 OUTLIER -40.3 -68.85 0.15 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 109.404 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.967 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER 128.88 16.25 0.0 OUTLIER 'General case' 0 N--CA 1.511 2.591 0 C-N-CA 123.027 0.531 . . . . 0.0 110.121 179.4 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -48.26 -21.83 0.57 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.916 -1.115 . . . . 0.0 109.245 179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.455 ' O ' ' HD3' ' B' ' 87' ' ' ARG . 29.8 mm100 -127.16 -128.81 0.23 Allowed 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.221 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.466 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.3 OUTLIER -111.04 133.61 21.25 Favored Pre-proline 0 C--N 1.306 -1.304 0 O-C-N 120.661 -1.274 . . . . 0.0 109.064 179.398 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.5 Cg_endo -79.96 51.76 4.03 Favored 'Trans proline' 0 C--N 1.313 -1.299 0 C-N-CA 122.203 1.935 . . . . 0.0 109.322 178.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.596 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -84.63 157.08 21.27 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.241 -0.912 . . . . 0.0 109.776 -179.315 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.728 HG21 HG23 ' A' ' 66' ' ' ILE . 1.2 m -149.15 131.72 6.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.501 -0.75 . . . . 0.0 109.368 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.651 HG21 HD23 ' A' ' 19' ' ' LEU . 25.3 m -65.02 94.8 0.14 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 177.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.771 HG22 HG13 ' A' ' 66' ' ' ILE . 13.6 pt -83.41 151.43 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.352 -0.843 . . . . 0.0 110.367 -178.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.547 ' HG3' HD12 ' A' ' 19' ' ' LEU . 14.0 ttmt -115.41 96.27 5.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 0.0 109.239 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.888 HG23 HG21 ' A' ' 62' ' ' ILE . 11.8 mt -116.76 143.84 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 O-C-N 121.203 -0.936 . . . . 0.0 109.687 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.96 50.91 14.4 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 48.44 46.78 29.18 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -144.48 163.22 34.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -1.207 . . . . 0.0 109.407 179.898 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.651 HD23 HG21 ' A' ' 12' ' ' THR . 0.4 OUTLIER -129.95 132.92 46.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.181 -0.95 . . . . 0.0 109.971 -179.403 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.455 ' NZ ' HD23 ' A' ' 33' ' ' LEU . 4.0 mtmp? -151.13 177.7 9.94 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.596 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -93.86 118.99 32.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.618 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -97.81 143.37 28.5 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.135 -0.978 . . . . 0.0 109.42 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.999 HD11 ' NH2' ' B' ' 87' ' ' ARG . 10.5 tp -107.78 94.15 4.92 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.589 -0.694 . . . . 0.0 109.524 -179.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.572 HD22 HD21 ' A' ' 90' ' ' LEU . 15.5 mt -45.14 111.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.293 -0.879 . . . . 0.0 108.648 179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.59 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 19.4 t0 -126.25 80.02 1.89 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.343 -0.848 . . . . 0.0 110.12 -178.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.509 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.8 m -54.1 -18.95 4.19 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.025 -1.047 . . . . 0.0 108.867 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -56.64 -48.73 75.03 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -75.62 154.88 36.39 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.25 -1.147 . . . . 0.0 109.071 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.99 -7.44 33.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.162 -0.962 . . . . 0.0 110.385 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.667 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.1 OUTLIER -132.59 178.87 6.51 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.981 -1.074 . . . . 0.0 109.539 179.805 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 19.0 m -104.3 89.55 3.28 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.772 -1.205 . . . . 0.0 110.83 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.975 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 171.48 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.946 -1.096 . . . . 0.0 108.307 178.908 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.031 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -170.19 121.38 0.64 Allowed 'General case' 0 C--N 1.305 -1.349 0 O-C-N 120.884 -1.135 . . . . 0.0 110.488 -179.011 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.511 ' HA ' HG22 ' A' ' 80' ' ' THR . 6.4 tt0 -41.4 160.52 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.448 -0.782 . . . . 0.0 109.087 178.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.583 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -48.35 146.86 2.6 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.21 -0.931 . . . . 0.0 110.681 -179.756 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.639 ' SD ' HD13 ' A' ' 38' ' ' LEU . 0.1 OUTLIER -159.31 -161.93 0.99 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.302 -0.874 . . . . 0.0 109.427 179.441 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 t -108.75 101.52 10.64 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.146 -0.971 . . . . 0.0 110.168 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.667 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -121.15 178.75 1.09 Allowed Pre-proline 0 N--CA 1.493 1.683 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.595 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 35.5 Cg_endo -79.54 -158.63 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.698 2.265 . . . . 0.0 110.64 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 29.63 7.75 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.9 mtt-85 -106.29 60.87 0.65 Allowed 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.634 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 59.2 p-90 -139.62 177.89 7.62 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-O 121.772 0.796 . . . . 0.0 110.696 -178.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.487 ' HD3' ' O ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -135.76 140.82 34.77 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.904 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -78.37 129.81 9.67 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 C-N-CA 121.813 1.675 . . . . 0.0 111.215 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HG3' ' O ' ' A' ' 45' ' ' LYS . 2.3 ptpt -161.99 142.57 10.44 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.534 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -107.52 147.84 30.01 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.744 -1.222 . . . . 0.0 109.675 179.688 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 54' ' ' ILE . 6.1 pt -103.65 150.11 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.394 -0.816 . . . . 0.0 108.982 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.24 98.0 0.71 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.084 -1.607 . . . . 0.0 109.084 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -121.15 -121.98 2.86 Favored Glycine 0 N--CA 1.487 2.057 0 C-N-CA 119.479 -1.344 . . . . 0.0 110.478 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.88 HD12 H702 ' B' ' 100' ' ' DMP . 18.2 mt -83.83 128.98 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.584 -0.95 . . . . 0.0 112.463 -177.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.534 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 93.29 -46.56 2.4 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.17 -155.51 25.29 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.099 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.513 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.5 m-85 -105.94 159.3 16.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.621 -0.929 . . . . 0.0 110.24 -179.374 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.911 HD11 HD11 ' A' ' 47' ' ' ILE . 5.8 pt -137.58 159.8 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -102.16 124.66 48.14 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.863 -1.148 . . . . 0.0 109.643 -179.814 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.756 HG12 ' HA3' ' A' ' 78' ' ' GLY . 27.7 m -129.15 -178.33 2.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 O-C-N 121.306 -0.871 . . . . 0.0 109.034 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HB3' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -131.95 105.4 7.4 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.871 . . . . 0.0 109.278 179.834 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.56 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.8 OUTLIER -58.51 95.62 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.484 -0.76 . . . . 0.0 110.105 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.672 ' HB3' HD11 ' A' ' 62' ' ' ILE . 8.9 m-85 -89.98 117.87 29.11 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.565 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -99.58 141.83 31.86 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.561 -1.337 . . . . 0.0 111.035 -178.012 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.593 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 29.9 mt-30 71.16 62.33 0.17 Allowed 'General case' 0 N--CA 1.492 1.671 0 CA-C-O 121.199 0.523 . . . . 0.0 111.578 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.888 HG21 HG23 ' A' ' 15' ' ' ILE . 5.1 mp -120.76 121.31 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.894 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.6 tt -68.84 91.99 0.48 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.947 -1.096 . . . . 0.0 111.074 -178.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 1.003 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -89.09 114.74 27.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 176.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 13.8 tt0 -86.53 101.93 13.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.873 -1.142 . . . . 0.0 108.939 -177.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.003 HD11 HD13 ' A' ' 64' ' ' ILE . 2.1 mt -103.7 126.49 58.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.634 0.731 . . . . 0.0 110.15 -178.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.569 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.1 m 44.2 67.11 0.72 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.654 -0.654 . . . . 0.0 110.261 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 67' ' ' CYS . . . 41.57 35.86 1.46 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.569 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 74.5 m-70 -130.92 101.57 5.68 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.085 -1.244 . . . . 0.0 109.163 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.894 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -50.38 128.29 19.4 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.877 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.661 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.51 102.86 3.36 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.344 -0.848 . . . . 0.0 110.386 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.596 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.2 OUTLIER -79.48 151.45 4.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 178.027 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.721 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -174.44 -178.13 44.1 Favored Glycine 0 N--CA 1.486 2.014 0 C-N-CA 118.444 -1.836 . . . . 0.0 111.482 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.56 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 2.5 m -88.81 103.87 16.39 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.203 -0.587 . . . . 0.0 110.418 -179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.031 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -97.72 108.59 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.45 -0.781 . . . . 0.0 110.582 179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.667 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.4 mp -78.78 117.47 19.93 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.583 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.2 t -103.11 119.71 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 110.382 -178.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.756 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.31 -168.3 16.95 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.018 -1.633 . . . . 0.0 109.018 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 35.9 Cg_endo -79.52 41.94 1.2 Allowed 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.64 2.227 . . . . 0.0 111.088 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.557 HG21 HG13 ' A' ' 32' ' ' VAL . 3.6 t -83.43 139.86 41.6 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.059 -1.026 . . . . 0.0 108.498 179.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.505 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -78.23 13.82 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.322 2.015 . . . . 0.0 111.689 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.9 OUTLIER -160.95 170.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.876 -1.14 . . . . 0.0 109.618 179.512 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.618 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.1 OUTLIER -104.67 127.17 52.35 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 176.63 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.658 HG12 HG12 ' A' ' 32' ' ' VAL . 4.8 mm -112.86 128.33 69.63 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 O-C-N 120.406 -1.434 . . . . 0.0 111.04 -177.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.564 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -104.56 91.51 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -78.64 -167.8 32.8 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 110.637 -177.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.76 -34.25 72.73 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.639 -0.918 . . . . 0.0 110.338 -179.177 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.6 p-10 -48.94 -27.57 3.21 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.892 -1.13 . . . . 0.0 109.405 -179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.5 mm? -108.68 -29.38 8.74 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 121.121 -0.987 . . . . 0.0 110.034 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.603 HD23 HD11 ' A' ' 93' ' ' ILE . 96.7 mt -70.2 -6.27 33.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.08 -1.013 . . . . 0.0 108.463 179.024 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.465 HG23 ' HD3' ' A' ' 87' ' ' ARG . 4.8 p -98.11 -20.26 17.44 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.226 -0.921 . . . . 0.0 108.725 179.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 16.6 mm100 -83.66 -41.7 17.46 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.189 -0.944 . . . . 0.0 108.877 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.7 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.4 pt -80.93 -3.74 6.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.41 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 73.15 29.71 64.11 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.522 -0.847 . . . . 0.0 110.999 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -62.42 136.25 57.82 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.805 -1.409 . . . . 0.0 109.709 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' B' ' 96' ' ' THR . 77.4 p -136.71 129.48 30.63 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.124 -0.985 . . . . 0.0 108.519 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.452 ' O ' ' HB ' ' B' ' 3' ' ' VAL . 5.3 mp -88.13 102.15 14.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.416 -0.802 . . . . 0.0 109.891 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.485 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.4 m120 -110.02 126.74 54.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.971 -1.081 . . . . 0.0 109.175 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.922 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 O-C-N 121.112 -0.993 . . . . 0.0 109.404 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.484 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.654 0 N-CA-C 109.958 -0.824 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.485 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 12.8 tt0 -82.52 139.34 33.93 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 177.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.761 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 7.0 t -132.69 100.01 3.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 117.937 -1.505 . . . . 0.0 110.811 -177.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.535 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -117.01 -70.48 0.79 Allowed 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 178.225 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.745 ' H ' HD22 ' B' ' 5' ' ' LEU . 3.7 mm? 34.86 31.7 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.889 -0.507 . . . . 0.0 110.225 178.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.535 ' N ' ' O ' ' B' ' 4' ' ' THR . 13.0 m0 17.62 49.18 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.553 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.4 mt-30 -163.09 -162.5 0.77 Allowed 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.038 -1.039 . . . . 0.0 110.162 179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.42 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 8.1 mtm105 -86.94 117.97 69.4 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.232 -0.917 . . . . 0.0 110.394 -179.222 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.592 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.3 Cg_endo -81.99 90.24 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.144 1.896 . . . . 0.0 110.742 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 1.004 HD23 ' HB3' ' B' ' 21' ' ' GLU . 3.2 mp -79.49 171.06 15.67 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.821 -1.175 . . . . 0.0 108.565 179.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.595 HG23 HG23 ' B' ' 13' ' ' ILE . 3.1 m -150.68 130.99 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.001 -1.062 . . . . 0.0 110.812 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.685 HG22 HD22 ' B' ' 19' ' ' LEU . 0.2 OUTLIER -70.09 88.11 0.59 Allowed 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 177.592 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.828 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pt -90.09 157.36 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 111.118 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 3.1 tttt -122.78 109.15 13.85 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.745 HG23 HG21 ' B' ' 62' ' ' ILE . 3.0 mt -122.97 119.52 58.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.092 -1.005 . . . . 0.0 109.24 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.36 26.95 74.0 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -5.46 67.99 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.448 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.2 OUTLIER -85.8 169.95 12.88 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.248 -1.148 . . . . 0.0 109.29 179.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.685 HD22 HG22 ' B' ' 12' ' ' THR . 2.4 mt -139.8 128.22 22.79 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.311 -0.868 . . . . 0.0 109.191 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.423 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 3.0 mtpp -151.23 149.94 30.01 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.434 -0.791 . . . . 0.0 109.118 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 1.004 ' HB3' HD23 ' B' ' 10' ' ' LEU . 0.7 OUTLIER -79.64 102.16 8.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.093 -1.005 . . . . 0.0 108.469 179.277 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.876 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -80.04 142.84 34.56 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 122.0 0.905 . . . . 0.0 110.825 -178.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.424 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -92.62 104.26 16.57 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.66 HD22 HD21 ' B' ' 90' ' ' LEU . 4.6 mt -46.29 110.48 0.28 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.878 -1.138 . . . . 0.0 108.593 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.613 ' HB2' HG23 ' B' ' 84' ' ' ILE . 1.0 OUTLIER -118.81 86.71 2.59 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.178 -0.951 . . . . 0.0 110.871 -178.553 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.877 HG23 HD13 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -68.63 -7.88 37.06 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.023 -1.048 . . . . 0.0 108.704 178.488 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.86 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -81.24 -38.84 13.85 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -72.27 147.13 46.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.2 -1.176 . . . . 0.0 109.173 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.492 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 4.9 m-20 -82.83 -16.55 47.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 110.737 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.548 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 7.0 m-20 -138.04 -167.88 2.25 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.935 -1.103 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.589 ' N ' ' OD1' ' B' ' 88' ' ' ASN . 43.0 m -110.57 94.24 4.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.787 -1.196 . . . . 0.0 110.782 -178.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.008 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.76 172.3 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.872 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.008 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -164.4 122.35 1.75 Allowed 'General case' 0 C--N 1.308 -1.225 0 O-C-N 120.775 -1.203 . . . . 0.0 110.822 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.532 ' CG ' ' O ' ' B' ' 80' ' ' THR . 0.3 OUTLIER -35.6 154.13 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.777 -0.577 . . . . 0.0 109.689 179.127 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.519 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.3 mt-10 -47.79 149.06 1.37 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.241 -0.912 . . . . 0.0 110.231 -179.202 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.49 ' CG ' HD23 ' B' ' 38' ' ' LEU . 6.1 ptm -173.45 -163.99 0.21 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.391 -0.818 . . . . 0.0 109.592 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 8.1 t -110.95 103.72 12.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.204 -0.935 . . . . 0.0 110.279 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.575 HD12 ' HD2' ' B' ' 39' ' ' PRO . 3.0 mm? -103.38 173.38 3.48 Favored Pre-proline 0 N--CA 1.492 1.64 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.575 ' HD2' HD12 ' B' ' 38' ' ' LEU . 33.1 Cg_endo -73.9 -162.26 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.996 1.798 . . . . 0.0 110.516 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -100.21 -166.07 28.86 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.908 -1.139 . . . . 0.0 110.304 -179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 58.83 70.12 0.68 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.672 -0.899 . . . . 0.0 109.152 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.619 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 21.4 p-90 -141.44 -169.89 2.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -151.02 134.1 8.77 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.175 -0.953 . . . . 0.0 108.807 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.31 137.35 16.77 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.838 1.692 . . . . 0.0 110.567 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.629 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -160.97 133.79 6.29 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.724 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.517 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 63.1 mtp -91.73 131.93 36.75 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.131 -0.981 . . . . 0.0 109.797 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.708 HD11 HG21 ' A' ' 50' ' ' ILE . 8.8 pt -89.36 143.96 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.04 101.22 0.89 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -120.25 -121.81 2.92 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.744 -179.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.827 HD12 ' C20' ' B' ' 100' ' ' DMP . 20.5 mt -84.87 117.38 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.852 -0.793 . . . . 0.0 112.695 -177.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.459 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 104.16 -53.32 0.71 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 178.314 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -178.4 -157.12 18.43 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.543 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -118.0 135.79 53.94 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.311 -1.111 . . . . 0.0 109.873 -179.751 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.675 HD12 HG13 ' B' ' 56' ' ' VAL . 1.0 OUTLIER -106.48 -177.48 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.246 -0.909 . . . . 0.0 108.926 179.189 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.534 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 36.8 mtmt -111.52 135.82 51.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.057 -1.027 . . . . 0.0 110.019 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.795 HG12 ' HA3' ' B' ' 78' ' ' GLY . 17.5 m -142.77 177.07 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 120.843 -1.161 . . . . 0.0 110.636 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.35 100.72 6.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.492 -0.755 . . . . 0.0 109.241 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -62.87 110.11 1.66 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.265 -0.897 . . . . 0.0 110.909 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.988 ' HB3' HD11 ' B' ' 62' ' ' ILE . 16.0 m-85 -106.92 132.35 52.96 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 177.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 3.7 m-20 -108.6 134.1 51.82 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 120.937 -1.102 . . . . 0.0 110.49 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.589 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 45.0 mt-30 78.14 61.37 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.904 -0.497 . . . . 0.0 111.178 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.988 HD11 ' HB3' ' B' ' 59' ' ' TYR . 3.0 mp -112.83 120.99 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 178.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.84 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -65.07 86.44 0.06 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 110.958 -178.656 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.934 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.6 tt -94.49 110.7 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.3 tt0 -89.04 117.21 27.88 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.051 -1.031 . . . . 0.0 109.464 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.828 HG13 HG22 ' B' ' 13' ' ' ILE . 1.8 mp -116.33 140.95 36.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-O 121.746 0.784 . . . . 0.0 109.845 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.504 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 0.9 OUTLIER 47.42 39.17 8.7 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.681 -0.637 . . . . 0.0 109.778 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 62.2 48.28 83.9 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.504 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 80.7 m-70 -145.38 108.88 4.66 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.247 -1.149 . . . . 0.0 109.384 179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.619 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.3 OUTLIER -48.26 127.38 12.67 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.305 -0.872 . . . . 0.0 108.883 179.709 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.565 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -149.12 104.8 3.45 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.334 -0.854 . . . . 0.0 109.355 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.84 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -83.86 160.31 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 179.107 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.574 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -177.34 -157.24 17.87 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.419 -1.848 . . . . 0.0 111.952 179.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 4.8 m -111.95 109.81 19.79 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.632 -0.922 . . . . 0.0 109.557 -179.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.929 HG23 HD13 ' B' ' 62' ' ' ILE . 1.6 t -105.03 127.75 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.521 -0.737 . . . . 0.0 111.22 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 3.8 mp -96.83 116.22 28.78 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' B' ' 35' ' ' GLU . 13.1 t -96.9 114.96 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.709 -1.244 . . . . 0.0 109.984 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.795 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.72 -174.12 20.78 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.982 -1.647 . . . . 0.0 108.982 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.534 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -79.78 41.83 1.19 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.493 2.129 . . . . 0.0 111.234 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.532 ' O ' ' CG ' ' B' ' 34' ' ' GLU . 9.1 t -80.68 141.01 51.45 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' B' ' 80' ' ' THR . 35.8 Cg_endo -77.76 13.44 1.68 Allowed 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.274 1.983 . . . . 0.0 111.232 -179.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.61 HG13 ' N ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -160.31 173.83 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.921 -1.112 . . . . 0.0 109.677 -179.754 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.61 ' N ' HG13 ' B' ' 82' ' ' VAL . 0.0 OUTLIER -109.68 138.57 45.85 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 176.625 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.613 HG23 ' HB2' ' B' ' 25' ' ' ASP . 4.7 mm -124.6 123.33 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.438 -1.414 . . . . 0.0 111.762 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.876 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -97.26 89.82 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 177.344 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.548 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.04 -157.59 11.58 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.891 -1.147 . . . . 0.0 111.612 -177.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.999 ' NH2' HD11 ' A' ' 23' ' ' LEU . 31.1 mtt180 -68.19 -35.62 78.28 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.915 -0.756 . . . . 0.0 111.407 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.004 ' ND2' HD23 ' B' ' 89' ' ' LEU . 2.6 p-10 -55.57 -24.23 31.46 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.461 -1.399 . . . . 0.0 110.044 -179.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.004 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -106.77 -18.41 13.95 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.999 -1.063 . . . . 0.0 110.26 -178.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.877 HD13 HG23 ' B' ' 26' ' ' THR . 64.5 mt -71.95 -24.45 61.61 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 108.899 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.94 -14.09 56.58 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.092 -1.005 . . . . 0.0 109.839 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.1 -40.85 23.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.99 -1.069 . . . . 0.0 109.164 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.922 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -87.26 -13.07 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.305 -0.872 . . . . 0.0 108.755 179.43 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.69 51.12 9.79 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.67 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -75.86 147.27 39.2 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.026 -1.279 . . . . 0.0 108.851 179.215 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.501 ' O ' ' O ' ' A' ' 96' ' ' THR . 72.6 p -130.76 127.29 38.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 108.908 179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.554 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 5.0 mp -91.58 91.06 7.87 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.516 -0.74 . . . . 0.0 109.182 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.549 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.7 m120 -96.22 125.53 40.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.148 -0.97 . . . . 0.0 109.92 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.7 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.301 -1.526 0 CA-C-O 118.05 -0.976 . . . . 0.0 109.335 179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.88 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.59 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.498 1.768 0 N-CA-C 110.064 -0.783 . . . . 0.0 110.064 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.53 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.0 OUTLIER -84.91 129.11 34.86 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.85 -1.156 . . . . 0.0 108.05 178.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 77.8 t -131.37 124.81 55.67 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.915 -1.115 . . . . 0.0 110.184 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.516 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 7.6 p -64.57 -104.01 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.857 HD11 HG23 ' B' ' 26' ' ' THR . 0.6 OUTLIER 167.04 28.6 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.866 -1.146 . . . . 0.0 110.721 179.407 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 38.1 m95 -65.56 -18.66 65.49 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.809 -1.182 . . . . 0.0 108.507 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.424 ' O ' ' C ' ' A' ' 8' ' ' ARG . 23.2 mt-30 -147.3 159.64 43.43 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.477 ' HD2' HD13 ' A' ' 23' ' ' LEU . 16.0 mtm180 -44.04 141.15 2.52 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.003 . . . . 0.0 109.22 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG3' HG22 ' B' ' 26' ' ' THR . 36.2 Cg_endo -80.61 60.57 7.91 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.478 2.119 . . . . 0.0 109.921 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.676 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -81.66 142.72 32.47 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.243 -0.91 . . . . 0.0 109.97 -179.484 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -140.99 155.62 21.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.46 -0.775 . . . . 0.0 109.283 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.418 HG22 HD22 ' A' ' 19' ' ' LEU . 11.0 m -83.96 101.94 12.08 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 178.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.795 HG22 HG13 ' A' ' 66' ' ' ILE . 14.7 pt -96.31 158.66 3.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.286 -0.884 . . . . 0.0 110.341 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 3.7 tttt -120.71 103.95 9.52 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.433 -0.792 . . . . 0.0 109.88 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.013 HD13 HG11 ' A' ' 75' ' ' VAL . 10.6 mt -119.25 134.35 63.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.079 -1.013 . . . . 0.0 109.588 -179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.96 44.24 98.08 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.08 17.72 24.33 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.63 178.09 4.41 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.299 -1.118 . . . . 0.0 109.444 -179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.536 HD23 ' O ' ' A' ' 13' ' ' ILE . 16.6 mt -138.61 126.34 22.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.447 -0.783 . . . . 0.0 109.826 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.459 ' HD3' ' O ' ' A' ' 19' ' ' LEU . 35.8 mmtt -144.45 -179.31 6.47 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.676 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.9 mt-10 -88.04 164.58 15.69 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.098 -1.001 . . . . 0.0 108.713 179.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.614 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -147.97 116.68 6.69 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.688 -1.258 . . . . 0.0 110.966 -179.215 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.002 HD21 ' O ' ' B' ' 27' ' ' GLY . 16.8 tp -82.05 94.12 7.13 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.602 HD13 ' CE2' ' B' ' 99' ' ' PHE . 63.7 mt -49.69 93.2 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.568 ' CB ' ' HA3' ' B' ' 27' ' ' GLY . 26.8 t0 -107.67 87.21 2.45 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 110.744 -178.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.675 ' HA ' HD12 ' A' ' 90' ' ' LEU . 1.2 m -60.74 -13.81 17.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.051 -1.031 . . . . 0.0 108.638 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.464 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -63.41 -43.69 97.9 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -70.4 171.52 9.89 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.008 -1.289 . . . . 0.0 110.069 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.513 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 0.8 OUTLIER -98.54 -20.51 17.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.34 -0.85 . . . . 0.0 110.603 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.515 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 36.6 m-20 -140.23 -162.9 1.42 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.922 -1.111 . . . . 0.0 109.604 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.759 HG22 ' CD1' ' A' ' 33' ' ' LEU . 23.5 m -107.28 89.99 3.17 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.69 -1.256 . . . . 0.0 110.931 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.966 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.67 164.95 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 178.745 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.966 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -165.58 127.58 2.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.727 -1.233 . . . . 0.0 111.426 -178.742 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.594 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.2 OUTLIER -42.48 153.29 0.08 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 179.03 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.966 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -50.54 146.34 5.63 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.053 -1.029 . . . . 0.0 109.868 -179.821 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.522 ' CE ' HG22 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -156.42 -162.77 1.32 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.485 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.5 t -112.73 101.0 9.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.05 -1.031 . . . . 0.0 110.362 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.625 HD21 HD12 ' A' ' 62' ' ' ILE . 0.1 OUTLIER -108.49 160.03 28.65 Favored Pre-proline 0 N--CA 1.491 1.607 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.573 ' HD3' HD12 ' A' ' 38' ' ' LEU . 34.5 Cg_endo -75.96 69.32 6.29 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.784 2.323 . . . . 0.0 111.867 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . 37.43 -159.62 0.01 OUTLIER Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.51 ' N ' ' HD3' ' A' ' 41' ' ' ARG . 1.3 mpt_? 64.07 68.47 0.56 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.541 -0.976 . . . . 0.0 109.912 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.582 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 64.3 p-90 -152.7 -178.24 6.75 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.653 -0.654 . . . . 0.0 110.001 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.5 mtpt -146.2 137.21 12.62 Favored Pre-proline 0 N--CA 1.49 1.537 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.14 138.35 16.09 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.224 1.95 . . . . 0.0 111.182 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.557 ' HD2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -152.58 -163.19 1.66 Allowed 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.242 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.565 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 1.7 mtt -149.42 126.11 11.06 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.957 -1.089 . . . . 0.0 110.371 -179.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 54' ' ' ILE . 6.8 pt -90.07 146.44 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.512 ' HA2' ' CD1' ' A' ' 53' ' ' PHE . . . -118.45 118.62 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.448 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -146.3 -127.41 1.85 Allowed Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.291 -1.433 . . . . 0.0 111.228 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.821 HD12 ' C70' ' B' ' 100' ' ' DMP . 25.2 mt -81.68 123.85 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.957 -0.731 . . . . 0.0 112.401 -177.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.78 -50.11 1.78 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 178.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.441 ' O ' ' HA3' ' B' ' 51' ' ' GLY . . . 175.14 -168.12 40.51 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 0.4 OUTLIER -107.31 132.53 53.02 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.085 -1.244 . . . . 0.0 109.711 -179.632 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.976 HD11 HD11 ' A' ' 47' ' ' ILE . 10.3 pt -101.74 163.4 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.238 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.565 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 35.6 mtmt -96.59 138.38 34.26 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.112 -0.993 . . . . 0.0 108.867 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.461 HG21 HD23 ' A' ' 76' ' ' LEU . 30.6 m -138.36 177.93 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 120.75 -1.219 . . . . 0.0 110.146 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.512 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -118.17 92.3 3.79 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.431 -0.793 . . . . 0.0 108.919 -179.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.545 ' CG ' ' OD1' ' A' ' 60' ' ' ASP . 16.2 tt0 -53.56 107.69 0.27 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.507 -0.745 . . . . 0.0 110.236 -179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 38' ' ' LEU . 15.1 m-85 -105.02 95.51 5.89 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.545 ' OD1' ' CG ' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -79.01 139.62 38.14 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.867 -1.146 . . . . 0.0 111.061 -178.39 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.564 ' HA ' HG23 ' A' ' 72' ' ' ILE . 47.0 mt-30 68.36 63.57 0.35 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.133 0.492 . . . . 0.0 111.66 178.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.813 ' C ' HD13 ' A' ' 72' ' ' ILE . 0.8 OUTLIER -122.67 124.78 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.795 HD22 HG12 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -66.65 86.21 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.914 -178.342 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.868 HD12 HD11 ' A' ' 15' ' ' ILE . 3.6 tt -87.74 123.83 40.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 176.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 66' ' ' ILE . 8.6 tt0 -88.59 148.37 24.11 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.069 -1.019 . . . . 0.0 109.349 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.795 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -150.19 115.35 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.743 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.501 ' SG ' ' CG ' ' A' ' 1' ' ' PRO . 0.8 OUTLIER 68.23 5.06 4.46 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.581 -0.7 . . . . 0.0 110.127 179.695 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.405 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 108.27 -3.39 33.11 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.954 -1.258 . . . . 0.0 109.954 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.0 m-70 -90.2 131.31 36.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.06 -1.259 . . . . 0.0 109.318 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.505 ' CG ' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -81.75 103.9 11.76 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 121.047 -1.033 . . . . 0.0 108.471 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 63' ' ' LEU . . . -112.79 151.19 30.63 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 120.361 -0.535 . . . . 0.0 109.838 -179.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.813 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -122.42 146.32 27.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 177.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.474 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.75 -162.42 25.56 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 118.429 -1.843 . . . . 0.0 111.063 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.481 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 10.3 m -100.28 104.92 16.42 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.676 -0.896 . . . . 0.0 110.056 -179.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.013 HG11 HD13 ' A' ' 15' ' ' ILE . 1.2 t -95.12 105.36 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.518 -0.739 . . . . 0.0 109.349 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.561 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.9 mp -78.57 118.07 20.34 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.966 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.0 t -106.9 111.09 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.145 -0.972 . . . . 0.0 110.443 -179.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.65 -157.48 7.29 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.55 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.14 38.8 0.78 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.509 2.139 . . . . 0.0 110.34 179.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.594 ' CG2' ' N ' ' A' ' 34' ' ' GLU . 9.9 t -83.58 132.78 48.3 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.683 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.8 Cg_endo -79.9 19.11 1.05 Allowed 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 122.467 2.111 . . . . 0.0 111.558 -178.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.683 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.1 t -161.46 156.77 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.763 -1.21 . . . . 0.0 109.929 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.575 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.4 OUTLIER -95.64 91.0 5.91 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.665 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.68 ' CG1' HG12 ' A' ' 32' ' ' VAL . 3.6 mm -78.54 122.74 34.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 121.418 -0.801 . . . . 0.0 112.085 -176.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.628 HD12 HG23 ' A' ' 31' ' ' THR . 0.9 OUTLIER -101.02 91.78 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 176.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.44 -157.98 13.51 Favored Glycine 0 N--CA 1.493 2.457 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.912 -177.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.513 ' HG3' ' HA ' ' A' ' 29' ' ' ASP . 0.6 OUTLIER -68.87 -37.66 79.19 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 122.023 -0.692 . . . . 0.0 109.828 -178.958 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.033 ' ND2' HD23 ' A' ' 89' ' ' LEU . 13.0 p-10 -45.71 -28.51 1.04 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.933 -1.104 . . . . 0.0 109.52 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.033 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.5 mm? -109.08 -27.03 9.85 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.259 -0.9 . . . . 0.0 110.499 -178.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.679 HD23 HD11 ' A' ' 93' ' ' ILE . 70.0 mt -72.09 -7.88 51.47 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.82 -1.175 . . . . 0.0 109.194 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -98.15 -11.75 22.47 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.004 -1.06 . . . . 0.0 108.242 178.699 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.605 ' OE1' HD13 ' A' ' 89' ' ' LEU . 75.4 mt-30 -90.49 -40.71 11.84 Favored 'General case' 0 N--CA 1.487 1.416 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.75 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -82.91 0.59 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.471 -0.768 . . . . 0.0 108.965 179.164 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.15 32.83 57.91 Favored Glycine 0 N--CA 1.495 2.617 0 C-N-CA 120.575 -0.822 . . . . 0.0 111.147 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.679 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -65.45 140.08 58.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.941 -1.329 . . . . 0.0 110.715 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.453 ' O ' ' O ' ' B' ' 96' ' ' THR . 58.9 p -137.33 126.19 24.11 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' B' ' 97' ' ' LEU . 5.1 mp -88.43 91.94 8.99 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.239 -179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.462 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 4.6 m120 -103.51 121.41 42.81 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.127 -0.983 . . . . 0.0 109.448 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.904 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.683 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.361 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.55 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 2.3 Cg_endo . . . . . 0 N--CA 1.496 1.673 0 N-CA-C 109.875 -0.856 . . . . 0.0 109.875 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.479 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 4.3 tt0 -122.26 142.41 50.49 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 177.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.487 HG21 ' HZ ' ' A' ' 99' ' ' PHE . 38.4 t -142.48 102.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.192 -178.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.599 ' O ' ' C ' ' B' ' 5' ' ' LEU . 63.7 p -89.62 -30.13 18.36 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 178.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.803 HD13 ' HA ' ' B' ' 9' ' ' PRO . 0.5 OUTLIER 13.14 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.832 -179.892 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.423 ' C ' ' O ' ' B' ' 5' ' ' LEU . 2.2 m95 -37.91 -22.23 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.038 -178.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.576 ' N ' ' O ' ' B' ' 5' ' ' LEU . 20.3 mp0 -107.94 -161.85 0.8 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.715 -1.241 . . . . 0.0 107.983 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.511 ' HB3' HD12 ' B' ' 23' ' ' LEU . 19.1 mtt180 -53.84 124.57 44.06 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 120.478 -1.389 . . . . 0.0 109.589 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.803 ' HA ' HD13 ' B' ' 5' ' ' LEU . 37.0 Cg_endo -77.7 71.01 6.7 Favored 'Trans proline' 0 C--N 1.316 -1.159 0 C-N-CA 122.331 2.021 . . . . 0.0 110.401 179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.918 HD22 ' HB3' ' B' ' 21' ' ' GLU . 1.6 mt -78.95 143.1 36.12 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.888 -1.132 . . . . 0.0 110.356 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.816 HG21 HG23 ' B' ' 66' ' ' ILE . 1.3 m -130.76 139.92 50.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.509 -0.744 . . . . 0.0 109.639 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.933 HG22 HD22 ' B' ' 19' ' ' LEU . 2.0 m -67.49 108.01 2.68 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.918 -1.114 . . . . 0.0 108.279 178.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.904 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.2 pp -106.02 140.43 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.081 -1.012 . . . . 0.0 110.865 -178.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.541 ' CG ' ' HG ' ' B' ' 19' ' ' LEU . 0.1 OUTLIER -109.05 106.53 16.5 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.306 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 1.021 HD13 HG11 ' B' ' 75' ' ' VAL . 15.0 mt -124.48 124.99 69.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 O-C-N 121.164 -0.96 . . . . 0.0 109.524 -179.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 67.77 20.01 71.89 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -4.33 86.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -93.47 -178.17 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.115 -1.227 . . . . 0.0 108.908 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.933 HD22 HG22 ' B' ' 12' ' ' THR . 4.3 mt -153.65 125.58 7.81 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.132 -0.98 . . . . 0.0 110.499 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 0.5 OUTLIER -145.94 168.79 20.01 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.012 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.918 ' HB3' HD22 ' B' ' 10' ' ' LEU . 6.5 mt-10 -79.28 157.87 27.66 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.758 -1.214 . . . . 0.0 108.401 179.399 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.626 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -139.34 113.96 9.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.96 -1.087 . . . . 0.0 110.691 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.511 HD12 ' HB3' ' B' ' 8' ' ' ARG . 0.9 OUTLIER -67.75 95.36 0.5 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.031 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.731 HD12 ' HB2' ' B' ' 9' ' ' PRO . 86.2 mt -44.51 102.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.806 ' HB2' HG23 ' B' ' 84' ' ' ILE . 4.8 t70 -101.37 93.53 5.46 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.474 -0.766 . . . . 0.0 110.753 -178.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 5' ' ' LEU . 5.6 m -76.4 3.89 10.16 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.114 -0.991 . . . . 0.0 109.004 178.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 1.002 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -99.67 -24.42 10.03 Favored Glycine 0 N--CA 1.485 1.933 0 C-N-CA 120.056 -1.069 . . . . 0.0 110.743 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.25 168.46 17.61 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.829 -1.395 . . . . 0.0 109.949 -179.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.458 ' OD2' ' HD3' ' A' ' 8' ' ' ARG . 0.9 OUTLIER -101.31 -20.3 15.28 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.366 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.576 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.2 OUTLIER -131.86 -174.83 3.53 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 -179.598 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.687 HG23 HD12 ' B' ' 85' ' ' ILE . 53.2 m -105.33 83.44 1.96 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.676 -1.265 . . . . 0.0 110.315 -178.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.056 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.45 167.16 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 179.035 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.056 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.41 123.86 2.26 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.051 -1.031 . . . . 0.0 110.441 -178.694 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.823 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.0 OUTLIER -39.49 160.0 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.551 -0.718 . . . . 0.0 109.381 179.17 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.462 ' O ' ' OE1' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -39.62 146.71 0.1 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.387 -0.821 . . . . 0.0 110.449 -179.572 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.444 ' HE2' ' HE2' ' B' ' 20' ' ' LYS . 3.0 ppp? -166.4 163.04 17.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.441 -0.787 . . . . 0.0 109.046 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 4.3 t -95.82 105.04 17.0 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.043 -1.036 . . . . 0.0 109.753 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.739 HD21 HD12 ' B' ' 62' ' ' ILE . 9.2 tp -122.43 106.17 35.61 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.372 -0.83 . . . . 0.0 108.932 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.33 140.39 19.43 Favored 'Trans proline' 0 C--N 1.308 -1.553 0 C-N-CA 122.375 2.05 . . . . 0.0 111.125 -179.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 128.23 31.52 0.67 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.474 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 52.88 166.62 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.84 -0.8 . . . . 0.0 110.014 179.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.579 ' CD2' ' HD3' ' B' ' 57' ' ' ARG . 0.2 OUTLIER -160.98 178.49 9.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.138 -0.976 . . . . 0.0 109.769 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -125.88 104.52 26.7 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.76 138.61 41.61 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.025 1.817 . . . . 0.0 112.355 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -150.62 -155.61 0.64 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.55 ' CE ' ' HB3' ' B' ' 53' ' ' PHE . 32.2 mtp -148.13 126.55 12.35 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.026 -1.046 . . . . 0.0 110.312 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 54' ' ' ILE . 7.3 pt -93.24 142.38 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.611 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.93 113.75 2.64 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.121 -1.592 . . . . 0.0 109.121 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.459 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -138.12 -123.94 2.21 Favored Glycine 0 N--CA 1.483 1.811 0 C-N-CA 119.525 -1.322 . . . . 0.0 110.493 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.86 HD12 ' C21' ' B' ' 100' ' ' DMP . 25.6 mt -84.77 119.27 33.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 121.793 -0.827 . . . . 0.0 112.384 -177.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 52' ' ' GLY . . . 103.83 -53.01 0.73 Allowed Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.89 -161.79 27.83 Favored Glycine 0 N--CA 1.49 2.287 0 C-N-CA 119.451 -1.357 . . . . 0.0 110.171 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.611 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -111.84 128.86 56.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.459 -1.024 . . . . 0.0 109.241 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 HD11 ' B' ' 47' ' ' ILE . 16.3 pt -107.38 162.59 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 120.876 -1.14 . . . . 0.0 109.016 179.118 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.6 mptm? -94.53 147.58 23.12 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.153 -0.967 . . . . 0.0 108.88 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 27.5 m -144.94 -170.77 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 120.768 -1.207 . . . . 0.0 110.254 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.579 ' HD3' ' CD2' ' B' ' 42' ' ' TRP . 18.6 mtt85 -131.46 111.24 11.62 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -77.61 101.3 6.49 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 121.566 -0.709 . . . . 0.0 111.07 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.642 ' CG ' HD23 ' B' ' 38' ' ' LEU . 62.7 m-85 -96.18 129.74 43.41 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 14.5 m-20 -109.19 122.45 47.34 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.692 -1.255 . . . . 0.0 110.895 -178.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.546 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 3.0 mt-30 86.1 56.11 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.782 0 CA-C-O 121.31 0.576 . . . . 0.0 110.472 179.069 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.855 HG21 HG23 ' B' ' 15' ' ' ILE . 4.0 mm -111.27 128.07 68.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.879 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.3 tm? -73.84 102.26 4.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.181 -0.95 . . . . 0.0 111.293 -178.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.829 ' CG2' HD11 ' B' ' 89' ' ' LEU . 0.9 OUTLIER -105.59 106.11 19.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 177.579 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.4 OUTLIER -90.0 119.69 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.983 -1.073 . . . . 0.0 109.206 -178.821 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.816 HG23 HG21 ' B' ' 11' ' ' VAL . 1.5 mp -111.54 128.78 67.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.477 -0.765 . . . . 0.0 109.364 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.487 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 15.5 m 65.55 -89.69 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.752 -0.593 . . . . 0.0 109.629 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.88 39.15 0.74 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -139.36 131.91 28.74 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.295 -1.121 . . . . 0.0 109.566 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.68 ' CG ' HD21 ' B' ' 63' ' ' LEU . 15.6 ttmt -70.74 129.11 38.27 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.125 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.625 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -142.25 95.19 2.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.156 -0.965 . . . . 0.0 110.435 -179.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.631 HG12 HD23 ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.99 156.77 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.712 -1.243 . . . . 0.0 108.06 178.297 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.506 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.05 -170.59 43.52 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.674 -1.727 . . . . 0.0 111.213 179.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.478 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 85.9 m -88.68 112.54 23.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.848 -0.795 . . . . 0.0 110.575 -179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.021 HG11 HD13 ' B' ' 15' ' ' ILE . 0.7 OUTLIER -105.18 107.8 23.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.7 -0.625 . . . . 0.0 110.155 179.535 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.576 ' CD1' ' HB3' ' B' ' 30' ' ' ASP . 4.0 mp -82.63 121.82 27.32 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 108.853 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.52 ' O ' ' HG3' ' B' ' 57' ' ' ARG . 69.1 t -109.3 132.04 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.058 -1.026 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -162.8 -159.89 10.76 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.5 Cg_endo -81.43 36.1 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.651 2.234 . . . . 0.0 110.733 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.823 HG22 ' HA ' ' B' ' 34' ' ' GLU . 4.0 t -81.6 136.64 48.37 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.682 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.5 16.36 1.43 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.322 2.015 . . . . 0.0 111.269 -178.581 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.682 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -161.84 148.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 120.88 -1.138 . . . . 0.0 110.108 -179.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.592 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.7 OUTLIER -86.61 102.12 13.87 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 105.922 -1.881 . . . . 0.0 105.922 176.749 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.833 ' HB ' HG12 ' B' ' 32' ' ' VAL . 2.4 mt -101.74 126.66 55.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.856 -1.153 . . . . 0.0 112.137 -175.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.745 HD13 ' N ' ' B' ' 85' ' ' ILE . 1.5 mm -97.08 121.85 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 N-CA-C 107.567 -1.272 . . . . 0.0 107.567 177.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.537 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -102.58 -147.42 19.17 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.592 -1.289 . . . . 0.0 111.551 -178.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.509 ' O ' ' OG1' ' B' ' 91' ' ' THR . 11.6 mtp180 -69.08 -40.86 78.18 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 122.074 -0.662 . . . . 0.0 111.388 -178.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.98 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.2 p-10 -53.78 -30.47 44.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.798 -1.188 . . . . 0.0 111.254 -178.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.98 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.8 mm? -104.44 -28.58 11.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.492 -1.38 . . . . 0.0 110.914 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.662 HD23 ' N ' ' B' ' 90' ' ' LEU . 0.1 OUTLIER -68.2 -9.58 47.99 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.712 -1.242 . . . . 0.0 109.151 179.745 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.22 -20.44 15.92 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.775 -1.203 . . . . 0.0 108.831 179.154 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 46.6 mm-40 -77.89 -41.05 37.93 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.237 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.904 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -81.4 -8.17 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 73.38 35.77 55.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.568 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -61.56 152.18 31.12 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.824 -1.398 . . . . 0.0 109.288 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 4' ' ' THR . 21.5 p -142.27 124.72 15.69 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.151 -0.968 . . . . 0.0 108.889 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.734 HD11 HD11 ' A' ' 97' ' ' LEU . 4.8 mp -86.25 91.08 8.36 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.444 -0.785 . . . . 0.0 109.505 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.545 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -93.92 121.98 35.94 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.049 -1.032 . . . . 0.0 109.227 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.75 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 118.045 -0.979 . . . . 0.0 109.477 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.86 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.465 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 3.8 Cg_exo . . . . . 0 N--CA 1.497 1.686 0 N-CA-C 110.663 -0.553 . . . . 0.0 110.663 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.526 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -84.37 136.73 33.76 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.102 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.622 HG12 ' H ' ' A' ' 5' ' ' LEU . 55.7 t -133.55 115.03 21.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 120.734 -1.229 . . . . 0.0 109.918 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 5' ' ' LEU . 72.6 p -58.8 -12.59 4.53 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.698 -0.626 . . . . 0.0 110.218 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.767 HD21 HD13 ' B' ' 97' ' ' LEU . 0.7 OUTLIER 80.59 -6.6 1.66 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.443 -0.785 . . . . 0.0 110.298 179.398 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.598 ' CZ3' HG21 ' B' ' 91' ' ' THR . 39.8 m95 -53.88 -20.43 5.94 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.949 -1.094 . . . . 0.0 108.848 179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.11 157.54 46.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.422 -0.799 . . . . 0.0 108.914 179.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.433 ' HA ' ' CZ ' ' B' ' 87' ' ' ARG . 4.0 mtm180 -66.92 122.99 84.94 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.155 -0.965 . . . . 0.0 109.595 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.612 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.0 Cg_endo -76.1 80.09 2.76 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 121.927 1.751 . . . . 0.0 109.429 178.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -90.0 149.34 22.59 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.589 -0.695 . . . . 0.0 109.606 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.926 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -150.9 159.33 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.192 -0.942 . . . . 0.0 110.377 -179.063 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.679 HG21 HD23 ' A' ' 19' ' ' LEU . 14.1 m -94.88 104.82 16.71 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 1.154 HD11 HD21 ' A' ' 33' ' ' LEU . 2.2 pt -89.22 141.1 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.177 -0.952 . . . . 0.0 110.389 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.589 ' HG3' HD12 ' A' ' 19' ' ' LEU . 29.5 ttmt -106.34 97.27 7.09 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.868 HG23 ' CG2' ' A' ' 62' ' ' ILE . 16.8 mt -113.53 120.55 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.147 -0.97 . . . . 0.0 110.06 -179.155 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.23 37.65 94.81 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.1 6.4 56.72 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.453 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.3 mm-40 -97.48 163.25 12.94 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.201 -1.176 . . . . 0.0 109.216 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.679 HD23 HG21 ' A' ' 12' ' ' THR . 0.1 OUTLIER -136.89 126.59 25.48 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.293 -0.879 . . . . 0.0 110.798 -179.507 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.8 mttp -150.45 179.95 7.73 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -81.03 -174.67 4.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.876 -1.14 . . . . 0.0 108.891 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -162.25 121.14 2.28 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.031 -1.043 . . . . 0.0 110.001 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.519 ' O ' ' N ' ' A' ' 25' ' ' ASP . 46.5 tp -102.61 95.42 6.21 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.449 -0.782 . . . . 0.0 109.301 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.612 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 17.1 mt -43.33 96.24 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.078 -1.013 . . . . 0.0 109.417 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.759 ' CB ' HG23 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -101.21 81.62 2.24 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.511 -0.743 . . . . 0.0 110.121 -179.493 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.712 HG23 HD13 ' A' ' 90' ' ' LEU . 4.3 m -61.89 -20.64 63.96 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.989 -1.07 . . . . 0.0 108.936 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.805 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -59.32 -45.49 95.35 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -71.96 157.56 37.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.377 -1.072 . . . . 0.0 108.729 179.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -92.01 -10.26 39.91 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.06 -1.025 . . . . 0.0 110.3 -179.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 1.019 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -139.24 -173.46 3.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.956 -1.09 . . . . 0.0 110.053 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.574 HG22 ' CD1' ' A' ' 33' ' ' LEU . 33.4 m -103.23 89.01 3.27 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.265 -0.897 . . . . 0.0 111.281 -178.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.015 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.42 172.15 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.55 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.154 HD21 HD11 ' A' ' 13' ' ' ILE . 0.1 OUTLIER -168.68 132.7 1.51 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.085 -1.009 . . . . 0.0 110.571 -178.966 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.541 ' HA ' HG22 ' A' ' 80' ' ' THR . 20.6 mt-10 -41.46 161.99 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 109.171 -0.678 . . . . 0.0 109.171 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.499 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -61.36 143.7 55.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.036 -1.04 . . . . 0.0 110.043 -179.46 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.544 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -160.1 -179.76 8.04 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.331 -0.855 . . . . 0.0 109.645 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.4 t -92.89 100.0 12.54 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 109.924 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.9 HD12 HG21 ' A' ' 77' ' ' VAL . 12.6 mt -106.45 173.28 3.26 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.658 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.7 Cg_endo -78.18 50.11 3.22 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.327 2.018 . . . . 0.0 112.735 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 34.75 -158.53 0.01 OUTLIER Glycine 0 N--CA 1.498 2.769 0 O-C-N 121.478 -0.763 . . . . 0.0 111.529 178.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.448 ' HG3' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER 53.8 80.33 0.11 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.547 -0.973 . . . . 0.0 109.442 -179.54 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 2.9 p-90 -145.93 -167.85 2.83 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-O 121.506 0.67 . . . . 0.0 109.697 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.44 116.01 11.82 Favored Pre-proline 0 C--N 1.303 -1.433 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 179.169 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -70.59 138.76 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 121.848 1.698 . . . . 0.0 111.731 -178.225 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.468 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -158.61 133.09 8.05 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 54' ' ' ILE . 0.8 OUTLIER -94.03 123.56 37.48 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 -179.729 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.808 HD11 HG21 ' B' ' 50' ' ' ILE . 6.9 pt -92.38 148.23 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.814 -1.179 . . . . 0.0 108.679 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.525 ' HA3' ' CZ ' ' A' ' 53' ' ' PHE . . . -118.39 101.86 0.92 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.764 -1.735 . . . . 0.0 108.764 -179.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.89 -128.28 3.3 Favored Glycine 0 N--CA 1.483 1.793 0 C-N-CA 119.522 -1.323 . . . . 0.0 111.056 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.86 HD12 ' C70' ' B' ' 100' ' ' DMP . 22.4 mt -86.29 114.35 25.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.809 -0.818 . . . . 0.0 112.494 -177.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.507 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.48 -7.14 39.4 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.207 -0.997 . . . . 0.0 110.758 177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.21 -160.98 23.83 Favored Glycine 0 N--CA 1.494 2.516 0 O-C-N 120.894 -1.357 . . . . 0.0 110.405 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.525 ' CZ ' ' HA3' ' A' ' 48' ' ' GLY . 5.1 m-85 -110.73 132.98 53.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.382 -1.07 . . . . 0.0 109.883 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.799 HD12 ' C ' ' A' ' 54' ' ' ILE . 2.6 pp -111.04 162.47 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.065 -1.022 . . . . 0.0 108.603 178.635 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 76.0 mttt -102.36 133.69 46.87 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.034 -1.041 . . . . 0.0 109.673 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.776 HG13 ' CD1' ' A' ' 54' ' ' ILE . 3.1 m -134.77 -173.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.477 ' HB2' ' CE2' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -132.71 100.01 4.8 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.48 -0.762 . . . . 0.0 109.1 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.514 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 31.8 tt0 -57.92 93.79 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.328 -0.858 . . . . 0.0 109.669 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.724 ' C ' HD11 ' A' ' 62' ' ' ILE . 15.6 m-85 -88.36 125.36 34.66 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.466 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 24.6 m-20 -105.29 137.72 42.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.861 -1.15 . . . . 0.0 110.901 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.528 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 1.7 mm-40 72.62 61.43 0.12 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.792 -0.568 . . . . 0.0 110.614 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.868 ' CG2' HG23 ' A' ' 15' ' ' ILE . 4.9 mp -119.64 123.94 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.066 . . . . 0.0 108.92 179.09 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.803 ' O ' HD13 ' A' ' 63' ' ' LEU . 3.3 tm? -69.7 86.56 0.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.316 -0.865 . . . . 0.0 111.831 -178.29 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.576 HG13 ' HB ' ' A' ' 13' ' ' ILE . 3.0 tt -88.32 110.27 20.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 2.0 tt0 -88.77 118.32 28.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.962 -1.086 . . . . 0.0 109.791 -178.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.898 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -108.4 120.2 59.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.326 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 96.2 m 59.72 -99.01 0.09 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -136.72 39.09 1.68 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.0 m170 -128.45 103.33 7.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.423 -1.045 . . . . 0.0 110.164 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.509 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -60.89 117.32 5.29 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 178.721 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.01 127.99 35.33 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.278 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.577 HG12 ' CA ' ' A' ' 63' ' ' LEU . 0.3 OUTLIER -105.06 139.46 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.605 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.589 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -162.73 -170.95 28.31 Favored Glycine 0 N--CA 1.485 1.916 0 C-N-CA 118.93 -1.605 . . . . 0.0 110.295 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.581 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 51.9 m -91.02 109.87 21.12 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.695 -0.885 . . . . 0.0 109.798 -179.694 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.073 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -103.61 112.03 35.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.35 -0.844 . . . . 0.0 110.959 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 1.019 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.0 mp -79.57 122.95 27.13 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.9 HG21 HD12 ' A' ' 38' ' ' LEU . 54.3 t -108.39 121.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.945 -1.097 . . . . 0.0 109.907 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -155.22 -165.17 13.83 Favored Glycine 0 N--CA 1.494 2.555 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.552 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.5 Cg_endo -80.76 42.52 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.564 2.176 . . . . 0.0 110.636 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.571 HG21 HG13 ' A' ' 32' ' ' VAL . 13.1 t -85.9 141.16 35.44 Favored Pre-proline 0 C--N 1.302 -1.473 0 O-C-N 121.156 -0.965 . . . . 0.0 108.814 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.546 ' O ' HG23 ' A' ' 82' ' ' VAL . 35.5 Cg_endo -78.87 15.06 1.55 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.475 2.116 . . . . 0.0 111.546 -179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -160.68 167.37 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.787 -1.196 . . . . 0.0 110.371 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.558 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 69.5 m-80 -100.09 92.54 5.29 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 177.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.759 HG23 ' CB ' ' A' ' 25' ' ' ASP . 11.4 mm -78.91 124.33 37.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 O-C-N 121.153 -0.967 . . . . 0.0 111.846 -176.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.61 ' CD1' ' N ' ' A' ' 85' ' ' ILE . 0.8 OUTLIER -106.22 100.58 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 177.531 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -87.28 -161.61 36.74 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 120.128 -1.034 . . . . 0.0 111.481 -177.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 15.8 mmm180 -62.16 -38.73 90.13 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.843 -0.798 . . . . 0.0 109.841 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.029 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.5 p-10 -43.67 -29.48 0.51 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.231 -0.918 . . . . 0.0 109.387 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.029 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.7 mm? -107.78 -24.62 11.61 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.004 -1.06 . . . . 0.0 109.612 179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.712 HD13 HG23 ' A' ' 26' ' ' THR . 14.7 mt -70.41 -5.81 31.04 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.866 -1.146 . . . . 0.0 108.191 178.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.476 ' HB ' ' CD2' ' B' ' 6' ' ' TRP . 71.3 p -100.63 -17.87 16.83 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 19.1 mm100 -83.64 -39.19 20.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 109.434 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.092 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -84.95 3.52 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.298 -0.876 . . . . 0.0 109.607 179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 73.56 38.22 51.8 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 120.313 -0.946 . . . . 0.0 111.064 178.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -71.16 138.29 49.47 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.079 -1.248 . . . . 0.0 111.072 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.762 HG22 ' CG2' ' B' ' 4' ' ' THR . 48.7 p -133.18 128.76 36.69 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' B' ' 97' ' ' LEU . 1.6 mp -92.84 85.37 5.16 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.18 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.8 m120 -89.68 122.39 32.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.097 -1.002 . . . . 0.0 109.747 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.802 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 117.927 -1.035 . . . . 0.0 108.908 178.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.498 1.761 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.1 tt0 -84.2 131.5 34.75 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.325 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -119.69 118.5 57.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 C-N-CA 118.525 -1.27 . . . . 0.0 110.483 -178.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.762 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.1 OUTLIER -132.31 19.93 4.4 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 178.324 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.572 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -82.17 67.38 8.16 Favored 'General case' 0 N--CA 1.487 1.378 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.531 ' C ' ' O ' ' B' ' 5' ' ' LEU . 41.5 m0 -21.93 84.5 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 CA-C-O 121.578 0.704 . . . . 0.0 111.594 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.572 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.38 -163.04 0.32 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.975 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.42 121.71 71.06 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.115 -0.991 . . . . 0.0 109.27 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.753 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.5 Cg_endo -76.5 74.74 4.63 Favored 'Trans proline' 0 C--N 1.312 -1.352 0 C-N-CA 122.08 1.853 . . . . 0.0 109.068 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.499 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -96.98 147.15 24.28 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.463 -0.773 . . . . 0.0 110.425 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.453 HG21 HG23 ' B' ' 66' ' ' ILE . 0.9 OUTLIER -143.63 132.47 19.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.885 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.951 HG22 HD22 ' B' ' 19' ' ' LEU . 12.0 m -67.54 99.91 0.81 Allowed 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 178.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 3.2 pt -82.73 157.17 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.738 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HB2' ' HB3' ' B' ' 65' ' ' GLU . 0.5 OUTLIER -123.78 98.74 5.95 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.314 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.943 HG23 ' CG2' ' B' ' 62' ' ' ILE . 50.7 mt -113.98 133.37 60.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.332 -0.855 . . . . 0.0 109.605 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.502 ' O ' ' HG2' ' B' ' 18' ' ' GLN . . . 49.98 54.91 16.71 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.65 34.78 21.59 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.51 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.4 mm100 -124.84 167.08 15.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -1.184 . . . . 0.0 109.185 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.951 HD22 HG22 ' B' ' 12' ' ' THR . 12.0 mt -141.82 129.49 21.55 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.159 -0.963 . . . . 0.0 110.757 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.467 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 20.2 mtmt -151.7 169.43 22.2 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.499 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.1 mp0 -78.99 126.67 31.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.943 -1.098 . . . . 0.0 109.029 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.855 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -106.88 120.77 42.94 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.088 -1.008 . . . . 0.0 110.173 -179.712 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.805 HD21 ' O ' ' A' ' 27' ' ' GLY . 20.7 tp -91.82 94.75 9.48 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.437 -0.789 . . . . 0.0 110.093 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.753 HD12 ' HB2' ' B' ' 9' ' ' PRO . 58.0 mt -46.49 101.88 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.033 -1.042 . . . . 0.0 108.676 179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.903 ' HB3' HG23 ' B' ' 84' ' ' ILE . 12.4 t0 -113.34 98.2 6.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.92 . . . . 0.0 110.721 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.738 ' CG2' HD22 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -69.88 -15.32 63.06 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.111 -0.993 . . . . 0.0 108.768 178.699 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.455 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -64.62 -41.03 97.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.478 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -79.73 165.52 22.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.039 -1.271 . . . . 0.0 109.063 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -100.77 -15.42 17.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.132 -0.98 . . . . 0.0 110.573 -179.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.861 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -132.66 -175.33 3.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.712 -1.242 . . . . 0.0 110.316 -179.369 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.62 HG22 ' CD1' ' B' ' 33' ' ' LEU . 72.8 m -103.13 87.92 3.02 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.017 -1.052 . . . . 0.0 110.053 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.43 163.12 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.52 179.611 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.14 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -160.7 138.45 9.53 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.049 -1.032 . . . . 0.0 110.469 -178.539 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.617 ' N ' HG22 ' B' ' 80' ' ' THR . 2.3 mt-10 -47.97 174.97 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.512 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.2 tm-20 -72.5 143.46 48.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.03 -1.044 . . . . 0.0 109.452 179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.413 ' HG3' ' HG ' ' B' ' 38' ' ' LEU . 6.6 ptm -154.93 -167.92 2.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.393 -0.817 . . . . 0.0 109.204 179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -107.22 105.98 16.22 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.092 -1.005 . . . . 0.0 109.653 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.888 HD12 HG21 ' B' ' 77' ' ' VAL . 90.4 mt -117.21 156.44 48.65 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.343 -0.848 . . . . 0.0 109.231 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.486 ' O ' ' O ' ' B' ' 40' ' ' GLY . 35.1 Cg_endo -76.63 74.24 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.885 2.39 . . . . 0.0 112.206 -178.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 34.39 -157.14 0.01 OUTLIER Glycine 0 N--CA 1.497 2.765 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.418 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.3 mtt180 70.02 47.73 0.57 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.263 -1.139 . . . . 0.0 108.459 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.611 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 57.4 p-90 -129.12 -179.03 4.89 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 121.824 0.821 . . . . 0.0 110.297 -178.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -145.26 156.48 54.04 Favored Pre-proline 0 C--N 1.301 -1.516 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 178.667 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -75.75 139.3 22.25 Favored 'Trans proline' 0 C--N 1.302 -1.873 0 C-N-CA 121.803 1.669 . . . . 0.0 110.29 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.705 ' HB3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -144.87 168.82 19.32 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.537 -0.727 . . . . 0.0 109.52 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -150.1 125.08 9.92 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.791 ' CD1' HG21 ' A' ' 50' ' ' ILE . 24.1 pt -120.46 137.82 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 120.74 -1.225 . . . . 0.0 110.385 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.613 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.69 98.51 0.75 Allowed Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.68 -119.02 2.75 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.8 -178.534 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.86 HD12 ' C20' ' B' ' 100' ' ' DMP . 16.4 mt -90.39 119.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.689 -0.889 . . . . 0.0 112.337 -177.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.482 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 103.34 -28.11 17.05 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 120.222 -0.99 . . . . 0.0 110.751 177.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 153.49 -161.9 30.01 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.285 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.613 ' CE2' ' HA3' ' B' ' 48' ' ' GLY . 8.4 m-85 -107.31 125.02 50.63 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -1.036 . . . . 0.0 110.138 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.709 HD13 HG23 ' A' ' 50' ' ' ILE . 11.8 pt -105.96 142.0 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 O-C-N 121.081 -1.012 . . . . 0.0 108.865 178.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.506 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 5.0 mttt -89.06 138.59 31.27 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.031 -1.043 . . . . 0.0 109.294 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.965 HG12 ' HA3' ' B' ' 78' ' ' GLY . 29.4 m -140.44 175.52 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.079 -1.013 . . . . 0.0 110.211 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.592 ' HG2' ' CE3' ' B' ' 42' ' ' TRP . 0.0 OUTLIER -126.29 103.95 7.93 Favored 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.403 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.554 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 8.5 tt0 -58.75 112.73 1.74 Allowed 'General case' 0 C--N 1.295 -1.797 0 O-C-N 121.566 -0.709 . . . . 0.0 111.126 -178.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.611 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 15.2 m-85 -98.4 124.4 43.06 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.502 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.2 m-20 -101.97 130.1 48.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.886 -1.134 . . . . 0.0 111.03 -178.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.611 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 77.98 65.55 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 CA-C-O 121.48 0.657 . . . . 0.0 109.909 179.163 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.943 ' CG2' HG23 ' B' ' 15' ' ' ILE . 10.0 mm -118.54 119.6 61.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.273 -0.892 . . . . 0.0 109.721 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.669 ' C ' HD13 ' B' ' 63' ' ' LEU . 1.4 tm? -63.9 86.93 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.603 -0.686 . . . . 0.0 111.682 -178.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.599 HG23 ' O ' ' B' ' 64' ' ' ILE . 7.9 tt -93.47 113.03 27.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 176.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' B' ' 14' ' ' LYS . 32.9 tt0 -88.32 120.42 29.67 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.054 -1.029 . . . . 0.0 109.484 -178.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -114.29 126.34 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.215 -0.928 . . . . 0.0 109.712 -179.253 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 5.7 m 65.18 4.75 2.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.797 -0.564 . . . . 0.0 110.763 179.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 110.81 -6.75 29.49 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.042 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -92.11 139.29 30.78 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.199 -1.177 . . . . 0.0 108.549 179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.539 ' CG ' HD11 ' B' ' 63' ' ' LEU . 1.7 mttt -84.47 124.75 31.69 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.177 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.533 ' O ' ' HA ' ' B' ' 63' ' ' LEU . . . -134.15 157.89 45.04 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.611 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -131.19 133.91 61.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.593 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.593 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -158.42 -166.48 17.68 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 118.617 -1.754 . . . . 0.0 110.995 -179.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.554 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 51.6 m -92.39 107.1 18.96 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.924 -0.751 . . . . 0.0 109.797 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.14 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -103.77 113.29 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.544 -0.723 . . . . 0.0 109.804 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.861 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.6 mp -78.35 129.25 34.77 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 178.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.888 HG21 HD12 ' B' ' 38' ' ' LEU . 95.7 t -113.78 109.95 30.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 120.895 -1.128 . . . . 0.0 110.039 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.965 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -147.12 -163.59 10.62 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 179.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.506 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -79.87 41.37 1.1 Allowed 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.325 2.016 . . . . 0.0 111.164 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.737 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -88.23 139.74 30.42 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.907 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.652 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.8 Cg_endo -79.81 17.32 1.3 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 C-N-CA 122.488 2.126 . . . . 0.0 112.302 -177.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.737 ' H ' HG23 ' B' ' 80' ' ' THR . 2.1 t -160.69 164.63 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.527 -1.358 . . . . 0.0 110.992 -179.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.567 ' HA ' ' HG ' ' B' ' 33' ' ' LEU . 1.0 OUTLIER -103.61 87.04 2.74 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 177.135 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.903 HG23 ' HB3' ' B' ' 25' ' ' ASP . 1.7 mt -84.42 123.71 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 O-C-N 121.336 -0.852 . . . . 0.0 112.377 -176.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.597 HD11 ' HB1' ' B' ' 22' ' ' ALA . 3.2 mm -91.78 103.25 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 177.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -84.11 -159.16 28.87 Favored Glycine 0 N--CA 1.491 2.353 0 O-C-N 120.71 -1.244 . . . . 0.0 110.671 -178.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.551 ' NH1' HG22 ' B' ' 26' ' ' THR . 11.9 mtt-85 -66.24 -35.58 80.8 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.659 -0.907 . . . . 0.0 109.498 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.994 ' ND2' HD23 ' B' ' 89' ' ' LEU . 7.7 p-10 -48.79 -31.65 7.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.921 . . . . 0.0 109.753 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.994 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -106.16 -17.38 14.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.977 -1.077 . . . . 0.0 110.251 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.523 ' HB2' ' HA ' ' B' ' 87' ' ' ARG . 87.4 mt -77.39 -1.66 31.22 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.143 -0.973 . . . . 0.0 108.529 179.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.598 HG21 ' CZ3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -101.68 -20.58 14.94 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.128 -0.982 . . . . 0.0 108.638 179.038 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.565 HE21 HD13 ' B' ' 89' ' ' LEU . 14.5 mt-30 -75.5 -40.72 56.8 Favored 'General case' 0 N--CA 1.486 1.364 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.802 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -83.39 -9.16 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.411 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.3 36.78 33.61 Favored Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.232 -0.917 . . . . 0.0 111.166 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.643 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -63.7 156.25 27.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.054 -1.263 . . . . 0.0 110.513 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 96' ' ' THR . 66.7 p -147.58 126.61 12.84 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.796 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -95.49 89.28 5.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -0.963 . . . . 0.0 109.717 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.56 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.1 m120 -96.13 118.74 33.31 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.055 -1.028 . . . . 0.0 109.318 179.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 1.092 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 CA-C-O 118.07 -0.967 . . . . 0.0 109.324 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.86 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.458 ' HG2' ' CE1' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 N-CA-C 110.501 -0.615 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.557 ' NE2' HG21 ' A' ' 4' ' ' THR . 9.1 tt0 -85.92 126.8 34.36 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 177.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.705 ' O ' HG12 ' A' ' 3' ' ' VAL . 2.4 t -112.33 91.09 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 120.818 -1.176 . . . . 0.0 109.909 -178.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.73 HG22 HG22 ' B' ' 96' ' ' THR . 64.7 p -117.71 33.04 5.82 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.539 ' O ' ' C ' ' A' ' 6' ' ' TRP . 0.3 OUTLIER -86.79 30.01 0.77 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.882 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 35.8 m0 17.68 52.49 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 -179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -147.73 -163.37 1.75 Allowed 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.741 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -74.68 114.92 39.02 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 120.997 -1.065 . . . . 0.0 109.839 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.609 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.9 Cg_endo -78.06 71.15 6.79 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 121.976 1.784 . . . . 0.0 108.878 177.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 22' ' ' ALA . 0.0 OUTLIER -93.29 157.64 16.14 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.356 -179.167 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.407 ' CG1' ' C ' ' A' ' 10' ' ' LEU . 0.9 OUTLIER -149.96 140.55 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.82 -179.558 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' A' ' 19' ' ' LEU . 9.6 m -73.2 94.15 1.93 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.416 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.869 HD11 HD21 ' A' ' 33' ' ' LEU . 4.7 pt -80.43 163.82 3.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.538 -0.726 . . . . 0.0 110.791 -178.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 21.7 tttm -129.53 103.23 6.76 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.571 -0.706 . . . . 0.0 109.8 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.918 HG23 ' CG2' ' A' ' 62' ' ' ILE . 39.8 mt -119.55 117.05 52.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 O-C-N 120.994 -1.066 . . . . 0.0 109.38 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.27 25.55 75.28 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.96 -1.63 86.06 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.464 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 tp60 -92.11 167.41 12.08 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.99 -1.3 . . . . 0.0 109.396 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' A' ' 12' ' ' THR . 36.4 mt -130.2 134.74 47.49 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.279 -0.888 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.648 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 1.7 tptt -151.32 146.17 25.83 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.348 -0.845 . . . . 0.0 109.627 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.486 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 2.7 mm-40 -78.88 107.94 11.98 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.982 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -98.57 131.82 44.47 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.017 -1.052 . . . . 0.0 111.019 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.604 HD21 ' O ' ' B' ' 27' ' ' GLY . 0.8 OUTLIER -87.33 105.09 17.01 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.901 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.522 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 1.0 OUTLIER -46.99 120.36 3.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.966 -1.084 . . . . 0.0 108.4 179.702 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.851 ' HB2' HG23 ' A' ' 84' ' ' ILE . 56.7 t0 -124.54 83.99 2.22 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.221 -0.925 . . . . 0.0 110.488 -178.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.676 HG23 HD13 ' A' ' 90' ' ' LEU . 3.2 m -65.74 -15.26 62.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.036 -1.04 . . . . 0.0 108.565 178.807 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.524 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -67.13 -45.59 80.22 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.509 ' CB ' ' H25' ' B' ' 100' ' ' DMP . . . -71.81 167.54 19.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -1.184 . . . . 0.0 108.597 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -99.92 -19.8 16.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.828 -1.17 . . . . 0.0 110.785 -178.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 1.031 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.01 179.35 6.37 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.89 -1.131 . . . . 0.0 109.781 -179.687 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.594 HG22 ' CD1' ' A' ' 33' ' ' LEU . 7.4 m -94.66 92.81 7.2 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 120.826 -1.171 . . . . 0.0 110.011 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.872 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -84.49 118.96 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.232 -0.918 . . . . 0.0 109.102 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.869 HD21 HD11 ' A' ' 13' ' ' ILE . 1.2 mp -114.1 144.41 43.19 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.952 -1.093 . . . . 0.0 111.128 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.86 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -47.17 174.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.381 -0.825 . . . . 0.0 108.922 178.569 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.589 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -57.59 146.13 31.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.027 . . . . 0.0 109.642 -179.805 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.502 ' HG3' ' N ' ' A' ' 37' ' ' SER . 2.7 ptm -163.7 -175.49 4.16 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.392 -0.818 . . . . 0.0 109.043 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.502 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.9 t -110.74 120.44 42.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.113 -0.992 . . . . 0.0 109.788 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.783 HD12 HG21 ' A' ' 77' ' ' VAL . 82.0 mt -132.9 159.17 73.7 Favored Pre-proline 0 N--CA 1.49 1.564 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.478 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 34.4 Cg_endo -76.42 133.0 14.08 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.823 2.348 . . . . 0.0 112.436 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . -37.25 129.48 1.23 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.469 -1.053 . . . . 0.0 110.469 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.0 OUTLIER 148.19 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -179.519 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.617 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 50.4 p-90 -138.56 -173.29 3.51 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.741 0.782 . . . . 0.0 110.355 -177.234 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.454 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 0.0 OUTLIER -148.94 163.8 24.0 Favored Pre-proline 0 C--N 1.301 -1.5 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 179.14 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 36.0 Cg_endo -78.37 145.66 21.41 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.966 1.777 . . . . 0.0 109.979 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.756 ' HB2' HG23 ' A' ' 56' ' ' VAL . 0.8 OUTLIER -146.52 142.78 28.4 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.153 -0.967 . . . . 0.0 109.67 -179.52 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.497 ' CE ' ' HE3' ' A' ' 55' ' ' LYS . 0.9 OUTLIER -121.97 107.24 12.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 120.98 -1.075 . . . . 0.0 108.675 179.475 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.672 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.9 pt -101.81 132.39 47.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 C-N-CA 118.793 -1.163 . . . . 0.0 109.588 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.514 ' HA2' ' HA ' ' A' ' 53' ' ' PHE . . . -117.7 105.38 1.25 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.451 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -120.88 -115.89 2.45 Favored Glycine 0 N--CA 1.481 1.695 0 C-N-CA 119.715 -1.231 . . . . 0.0 110.768 -178.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.864 HD12 ' C70' ' B' ' 100' ' ' DMP . 25.6 mt -88.6 116.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.737 0 O-C-N 121.832 -0.805 . . . . 0.0 112.834 -177.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.544 ' HA2' HG22 ' B' ' 54' ' ' ILE . . . 106.7 -42.35 1.94 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.299 -1.121 . . . . 0.0 110.299 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 166.68 -160.98 34.75 Favored Glycine 0 N--CA 1.49 2.259 0 O-C-N 120.833 -1.392 . . . . 0.0 110.172 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.514 ' HA ' ' HA2' ' A' ' 48' ' ' GLY . 6.8 m-85 -102.1 155.79 17.97 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.449 -1.03 . . . . 0.0 110.042 -179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.647 HD11 HD11 ' A' ' 47' ' ' ILE . 2.1 pt -134.42 173.54 14.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.552 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 3.3 mttt -114.15 144.62 42.86 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.315 -0.866 . . . . 0.0 108.742 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.756 HG23 ' HB2' ' A' ' 45' ' ' LYS . 30.6 m -143.39 -177.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 120.97 -1.081 . . . . 0.0 109.624 -179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.525 ' O ' ' N ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -131.52 88.82 2.62 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.547 ' HG3' HG23 ' A' ' 74' ' ' THR . 3.5 tt0 -46.76 91.7 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.497 -0.752 . . . . 0.0 109.804 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.617 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 12.5 m-85 -89.96 95.68 10.33 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.525 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 12.2 m-20 -79.22 133.2 36.69 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.161 -0.962 . . . . 0.0 109.972 -179.004 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.567 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 20.4 mm-40 81.8 61.68 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.495 0.664 . . . . 0.0 110.166 179.171 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.918 ' CG2' HG23 ' A' ' 15' ' ' ILE . 15.4 mm -115.99 120.35 64.59 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.858 ' O ' HD13 ' A' ' 63' ' ' LEU . 1.9 tm? -72.45 81.18 1.06 Allowed 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.171 -0.956 . . . . 0.0 111.094 -178.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.812 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -87.66 117.93 32.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.487 ' HG3' ' N ' ' A' ' 70' ' ' LYS . 1.5 tt0 -93.91 112.38 24.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.07 -1.019 . . . . 0.0 109.763 -178.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.801 HG13 HG22 ' A' ' 13' ' ' ILE . 0.6 OUTLIER -100.34 118.81 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.439 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.3 m 56.42 54.55 7.45 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.735 -0.603 . . . . 0.0 109.807 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 57.69 16.55 23.72 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' C ' ' HG3' ' A' ' 65' ' ' GLU . 25.7 m170 -107.93 91.18 3.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -1.223 . . . . 0.0 109.494 179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.633 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -43.42 137.25 2.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 179.712 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -159.25 124.83 4.27 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.515 -0.74 . . . . 0.0 109.415 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.68 HD13 ' C ' ' A' ' 62' ' ' ILE . 1.0 OUTLIER -95.32 152.45 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.877 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.443 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.41 -171.82 39.73 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 118.832 -1.652 . . . . 0.0 111.089 179.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.547 HG23 ' HG3' ' A' ' 58' ' ' GLN . 96.5 m -98.49 108.85 21.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -1.134 . . . . 0.0 110.619 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.83 HG13 HD13 ' A' ' 33' ' ' LEU . 1.5 t -99.24 109.92 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.675 -0.641 . . . . 0.0 110.349 179.153 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 1.031 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.4 100.95 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.783 HG21 HD12 ' A' ' 38' ' ' LEU . 21.6 t -87.1 121.86 38.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 120.98 -1.075 . . . . 0.0 110.248 -178.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.534 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -156.76 -166.15 15.97 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.552 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 35.7 Cg_endo -80.84 40.67 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 C-N-CA 122.403 2.069 . . . . 0.0 111.103 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.86 HG22 ' HA ' ' A' ' 34' ' ' GLU . 13.4 t -81.36 140.5 48.71 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.713 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.0 Cg_endo -78.73 15.75 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.595 2.197 . . . . 0.0 111.279 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 81' ' ' PRO . 5.2 t -160.53 163.36 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.94 -1.1 . . . . 0.0 110.514 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.648 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -101.01 85.57 2.88 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 105.045 -2.205 . . . . 0.0 105.045 177.109 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.925 HD11 ' C62' ' B' ' 100' ' ' DMP . 4.6 mt -88.88 125.31 41.99 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.139 -0.975 . . . . 0.0 112.69 -175.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.982 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -84.88 149.48 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 176.503 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.496 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -125.61 -170.23 13.01 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 118.672 -1.728 . . . . 0.0 110.462 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.494 ' HD3' ' HB2' ' A' ' 90' ' ' LEU . 6.4 mmt180 -62.98 -26.75 68.99 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.444 -1.033 . . . . 0.0 108.416 179.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.023 ' ND2' HD23 ' A' ' 89' ' ' LEU . 15.7 p-10 -57.65 -28.44 63.74 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.433 -0.792 . . . . 0.0 109.141 179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.023 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -102.36 -24.37 13.87 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.287 -0.883 . . . . 0.0 109.208 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.676 HD13 HG23 ' A' ' 26' ' ' THR . 41.0 mt -71.51 -4.8 28.76 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 178.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.466 ' HB ' ' CE2' ' B' ' 6' ' ' TRP . 21.7 p -101.14 -16.08 17.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.256 -0.902 . . . . 0.0 108.717 178.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.7 mm-40 -86.66 -40.81 14.75 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.31 -0.868 . . . . 0.0 109.433 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.774 HD12 ' CD2' ' B' ' 99' ' ' PHE . 1.6 pt -85.67 0.71 5.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.131 -0.981 . . . . 0.0 108.724 179.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.03 51.49 50.47 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 179.175 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.525 ' HA ' ' O ' ' B' ' 98' ' ' ASN . . . -83.1 155.29 23.92 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.031 -1.276 . . . . 0.0 109.802 179.777 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.74 HG22 ' CG2' ' B' ' 4' ' ' THR . 10.5 p -147.98 130.88 16.16 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' B' ' 97' ' ' LEU . 4.6 mp -91.29 100.86 13.59 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.421 -0.799 . . . . 0.0 109.698 -179.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.546 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 1.6 m120 -102.2 123.37 45.92 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.961 -1.087 . . . . 0.0 109.111 179.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.836 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.09 -0.957 . . . . 0.0 109.241 179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.494 1.509 0 N-CA-C 110.041 -0.792 . . . . 0.0 110.041 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.546 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.7 tt0 -83.55 133.78 34.85 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 178.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 30.7 t -132.69 122.5 47.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 C-N-CA 118.316 -1.354 . . . . 0.0 111.756 -177.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.74 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.4 OUTLIER -132.46 -79.46 0.5 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.612 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 60.1 mt 28.27 38.64 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.095 178.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 25.7 m0 16.51 52.75 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 CA-C-O 121.252 0.549 . . . . 0.0 111.619 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 9.9 mt-30 -142.09 -179.46 6.25 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.234 -0.916 . . . . 0.0 109.868 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -75.62 122.35 86.97 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 1.064 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -77.02 75.73 4.46 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.078 1.852 . . . . 0.0 109.836 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.529 ' CD2' ' CB ' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -91.78 154.91 18.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.904 . . . . 0.0 109.695 -179.543 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.623 HG21 HG12 ' B' ' 66' ' ' ILE . 1.0 OUTLIER -147.91 134.98 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 0.0 109.908 -179.444 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.653 ' CG2' HD23 ' B' ' 19' ' ' LEU . 6.9 m -68.15 105.1 1.97 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.766 -1.208 . . . . 0.0 108.555 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.052 HG22 HG13 ' B' ' 66' ' ' ILE . 1.2 pt -92.86 156.75 3.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 120.944 -1.098 . . . . 0.0 110.261 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.793 ' HG3' HD12 ' B' ' 19' ' ' LEU . 10.5 tttm -121.99 100.06 6.78 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.762 ' CD1' HG11 ' B' ' 75' ' ' VAL . 13.1 mt -116.71 124.24 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.108 -0.995 . . . . 0.0 110.122 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.83 38.86 93.04 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 68.45 21.13 74.21 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.644 -1.383 . . . . 0.0 109.644 179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.526 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -110.13 171.0 7.71 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.201 -1.176 . . . . 0.0 109.136 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.793 HD12 ' HG3' ' B' ' 14' ' ' LYS . 0.1 OUTLIER -148.14 124.36 10.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.298 -0.876 . . . . 0.0 110.565 -179.378 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.516 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mtmp? -151.05 169.23 22.33 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.547 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -81.92 119.02 23.41 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 120.989 -1.069 . . . . 0.0 109.197 -179.931 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.968 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -94.91 130.51 41.49 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.312 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.524 HD21 ' O ' ' A' ' 27' ' ' GLY . 19.0 tp -92.89 92.34 7.85 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 1.064 HD12 ' HB2' ' B' ' 9' ' ' PRO . 92.4 mt -44.11 96.48 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.287 -0.883 . . . . 0.0 108.998 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.784 ' HB3' HG23 ' B' ' 84' ' ' ILE . 3.8 t0 -105.64 86.53 2.42 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.4 -0.813 . . . . 0.0 109.555 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.665 HG23 HD13 ' B' ' 90' ' ' LEU . 0.6 OUTLIER -63.2 -9.44 11.22 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.267 -0.896 . . . . 0.0 109.443 179.457 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.604 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.26 -41.13 47.44 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.543 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -76.36 145.45 39.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.176 -1.191 . . . . 0.0 109.417 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -75.93 -16.22 60.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.322 -0.861 . . . . 0.0 111.614 -178.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.786 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -139.03 -167.47 2.23 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.548 -1.345 . . . . 0.0 110.255 -179.532 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.697 HG23 ' O ' ' B' ' 84' ' ' ILE . 23.5 m -107.88 93.71 4.68 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.247 -0.908 . . . . 0.0 110.695 -178.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.0 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -74.22 167.2 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.133 -0.98 . . . . 0.0 108.599 179.171 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.124 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.56 136.89 4.66 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.826 -1.171 . . . . 0.0 111.188 -178.258 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.592 ' O ' HG13 ' B' ' 77' ' ' VAL . 2.9 tt0 -45.31 157.35 0.09 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.373 -0.83 . . . . 0.0 109.436 178.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.668 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.0 mt-10 -49.52 151.28 1.65 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.227 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 4.9 ptm -173.33 161.86 4.25 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.455 -0.778 . . . . 0.0 109.035 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 23.5 t -82.17 110.38 17.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.152 -0.967 . . . . 0.0 110.046 -179.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.771 ' HB3' ' HD2' ' B' ' 39' ' ' PRO . 48.4 mt -119.36 175.98 1.95 Allowed Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.771 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.4 Cg_endo -71.79 -161.9 0.11 Allowed 'Trans proline' 0 C--N 1.319 -1.006 0 C-N-CA 121.539 1.493 . . . . 0.0 111.945 -178.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.73 35.86 4.74 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -178.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.4 mmt-85 -118.18 62.92 0.76 Allowed 'General case' 0 C--N 1.29 -1.991 0 O-C-N 121.598 -0.942 . . . . 0.0 109.042 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.705 ' CD1' ' CE1' ' B' ' 59' ' ' TYR . 8.3 p-90 -142.97 -172.35 3.65 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -149.26 139.77 13.65 Favored Pre-proline 0 C--N 1.303 -1.414 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.53 130.67 10.01 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.214 1.943 . . . . 0.0 111.103 -178.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.557 ' O ' HG22 ' B' ' 56' ' ' VAL . 3.6 ptmt -162.21 145.61 11.79 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.505 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 42.7 mtp -103.41 137.64 41.24 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.924 -1.11 . . . . 0.0 109.654 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' A' ' 50' ' ' ILE . 3.9 pt -96.45 145.78 8.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.095 -1.003 . . . . 0.0 108.392 179.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.87 101.27 0.86 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -124.53 -127.43 3.16 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.749 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.81 HD12 ' C20' ' B' ' 100' ' ' DMP . 46.4 mt -81.79 132.31 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.835 -0.803 . . . . 0.0 112.207 -177.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.545 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 89.21 -44.71 3.11 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 178.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.24 -162.73 34.8 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -115.72 130.76 56.97 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.435 -1.038 . . . . 0.0 109.22 -179.93 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.544 HG22 ' HA2' ' A' ' 51' ' ' GLY . 23.8 pt -110.51 144.24 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.22 -0.925 . . . . 0.0 109.828 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 10.4 mtmm -72.08 144.06 48.84 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.139 -0.976 . . . . 0.0 109.298 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.557 HG22 ' O ' ' B' ' 45' ' ' LYS . 29.5 m -145.42 -170.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.103 -0.998 . . . . 0.0 109.873 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.583 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 4.4 mtt180 -142.4 102.16 4.03 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.329 -0.857 . . . . 0.0 109.332 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.679 ' HG3' HG22 ' B' ' 74' ' ' THR . 5.5 tt0 -64.77 113.07 3.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.271 -0.893 . . . . 0.0 109.961 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.705 ' CE1' ' CD1' ' B' ' 42' ' ' TRP . 19.1 m-85 -104.38 95.51 5.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.442 -0.786 . . . . 0.0 108.941 179.606 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.1 m-20 -78.71 137.77 37.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.966 -1.084 . . . . 0.0 109.972 -179.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.535 ' HA ' HG23 ' B' ' 72' ' ' ILE . 1.3 mm-40 77.66 64.12 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 CA-C-O 121.456 0.646 . . . . 0.0 109.869 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.797 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.6 OUTLIER -126.48 119.27 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.621 HD11 ' HG3' ' B' ' 70' ' ' LYS . 0.2 OUTLIER -72.53 85.29 1.15 Allowed 'General case' 0 C--N 1.296 -1.724 0 O-C-N 120.933 -1.104 . . . . 0.0 111.805 -177.526 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.645 ' CG2' HD11 ' B' ' 89' ' ' LEU . 4.4 tt -89.49 115.04 28.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 10.1 tt0 -89.57 117.38 28.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.129 -178.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 1.052 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -110.27 120.68 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.244 -0.91 . . . . 0.0 108.88 179.37 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER 57.95 50.71 9.9 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.446 -0.784 . . . . 0.0 109.67 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 59.76 16.77 39.73 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.48 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 69.9 m-70 -106.01 121.15 43.53 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.101 -1.235 . . . . 0.0 109.531 179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.621 ' HG3' HD11 ' B' ' 63' ' ' LEU . 21.4 ttpt -69.45 122.03 18.17 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.41 -0.806 . . . . 0.0 109.585 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.751 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -139.64 106.98 5.52 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 110.356 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.797 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.4 OUTLIER -87.04 139.03 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 177.811 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.18 -159.0 9.69 Favored Glycine 0 N--CA 1.486 2.003 0 C-N-CA 118.545 -1.788 . . . . 0.0 111.285 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.679 HG22 ' HG3' ' B' ' 58' ' ' GLN . 9.3 m -109.17 102.57 11.51 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.64 -0.917 . . . . 0.0 109.67 -179.543 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.124 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -96.91 111.38 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.241 -0.912 . . . . 0.0 111.107 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.786 HD11 ' HB3' ' B' ' 30' ' ' ASP . 1.8 mp -78.39 134.18 37.45 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 177.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.754 HG21 ' CD1' ' B' ' 38' ' ' LEU . 46.5 t -124.43 131.29 72.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 120.869 -1.144 . . . . 0.0 110.145 -179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -163.63 -160.37 11.56 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.535 -1.826 . . . . 0.0 108.535 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.85 40.79 1.02 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.369 2.046 . . . . 0.0 110.401 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' B' ' 32' ' ' VAL . 4.6 t -84.94 138.28 37.37 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.507 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.4 Cg_endo -79.48 23.34 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 122.475 2.117 . . . . 0.0 111.668 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.564 ' CG1' ' N ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -161.67 170.46 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.669 -1.269 . . . . 0.0 110.113 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' B' ' 82' ' ' VAL . 0.1 OUTLIER -110.19 92.73 4.16 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.122 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.784 HG23 ' HB3' ' B' ' 25' ' ' ASP . 20.2 mm -78.77 128.23 38.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.385 -0.822 . . . . 0.0 112.893 -175.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.968 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.4 mp -108.15 89.29 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 176.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -79.53 -162.36 24.26 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.313 -177.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.544 ' NH1' ' O ' ' B' ' 26' ' ' THR . 0.1 OUTLIER -61.89 -40.04 94.04 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.766 -0.844 . . . . 0.0 110.232 -179.219 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.039 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.6 p-10 -43.84 -28.89 0.48 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.141 -0.974 . . . . 0.0 109.465 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.039 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.8 mm? -107.27 -29.61 9.21 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.185 -0.947 . . . . 0.0 110.048 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.717 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 13.6 mt -72.81 -3.66 26.83 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 121.03 -1.044 . . . . 0.0 108.506 179.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.503 ' O ' ' CZ2' ' A' ' 6' ' ' TRP . 15.5 p -101.72 -20.21 15.07 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.167 -0.958 . . . . 0.0 108.857 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.751 HE21 ' HB1' ' B' ' 71' ' ' ALA . 6.7 mt-30 -82.87 -38.05 23.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.321 -0.862 . . . . 0.0 109.236 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.836 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -81.06 3.71 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.877 . . . . 0.0 108.978 179.313 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.509 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 72.5 46.25 33.36 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.311 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.717 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -82.3 136.03 35.1 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.082 -1.246 . . . . 0.0 110.728 -179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.73 HG22 HG22 ' A' ' 4' ' ' THR . 36.3 p -131.78 129.43 40.53 Favored 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.96 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -92.34 93.08 8.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.923 -1.11 . . . . 0.0 109.495 -179.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.3 m120 -100.39 127.27 46.76 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -0.918 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.774 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.213 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.925 ' C62' HD11 ' A' ' 84' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.578 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.4 Cg_endo . . . . . 0 N--CA 1.496 1.662 0 N-CA-C 110.013 -0.803 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 11.9 tt0 -84.15 138.94 32.75 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 177.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 38.8 t -140.04 116.27 8.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 117.857 -1.537 . . . . 0.0 111.921 -177.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.53 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.1 OUTLIER -121.34 -62.75 1.39 Allowed 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 176.874 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.594 ' O ' HD23 ' A' ' 5' ' ' LEU . 0.4 OUTLIER 35.92 26.23 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.903 177.399 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.616 ' HA ' HG21 ' B' ' 91' ' ' THR . 27.8 m95 17.82 48.64 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.298 0.57 . . . . 0.0 112.252 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.582 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -161.91 -157.47 0.48 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.215 179.856 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.478 ' HG2' ' OD1' ' B' ' 29' ' ' ASP . 40.9 mtm180 -78.8 128.82 75.64 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 120.894 -1.129 . . . . 0.0 109.893 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 36.2 Cg_endo -80.64 66.02 8.86 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.36 2.04 . . . . 0.0 108.49 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.614 HD23 ' H ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -90.2 145.18 25.21 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.33 -0.856 . . . . 0.0 110.756 -178.182 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.469 HG23 ' N ' ' A' ' 12' ' ' THR . 0.6 OUTLIER -150.51 164.14 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.277 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.592 HG22 HD22 ' A' ' 19' ' ' LEU . 51.8 m -86.64 133.31 33.71 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 178.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.862 ' O ' HD23 ' A' ' 19' ' ' LEU . 8.3 pt -121.92 156.73 26.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.996 -1.065 . . . . 0.0 110.384 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.552 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 8.0 tttt -117.94 100.55 7.63 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.762 HD11 HD12 ' A' ' 64' ' ' ILE . 18.0 mt -112.24 145.78 17.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.368 -0.832 . . . . 0.0 110.298 -178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 39.82 41.15 1.78 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.84 44.59 94.47 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.552 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -144.13 176.56 9.22 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.121 -1.223 . . . . 0.0 108.756 179.537 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.862 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.0 mt -140.02 123.71 17.32 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 119.305 -0.958 . . . . 0.0 110.535 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -143.27 177.02 8.7 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 179.1 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.542 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 15.3 mp0 -79.86 -178.97 6.7 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.613 -1.304 . . . . 0.0 108.057 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.614 ' H ' HD23 ' A' ' 10' ' ' LEU . . . -160.81 109.53 1.62 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.841 -1.162 . . . . 0.0 110.046 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.611 HD21 ' O ' ' B' ' 27' ' ' GLY . 27.3 tp -89.26 89.36 7.88 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.669 -0.644 . . . . 0.0 109.307 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.555 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 58.2 mt -42.49 97.04 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 56.9 t0 -106.36 87.08 2.47 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.582 -0.699 . . . . 0.0 110.788 -177.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -62.15 -20.15 63.8 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.974 -1.079 . . . . 0.0 108.804 178.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.56 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -58.73 -48.24 86.07 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.55 160.63 31.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.311 -1.111 . . . . 0.0 108.591 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.414 ' OD1' ' HG2' ' B' ' 8' ' ' ARG . 61.9 m-20 -96.65 -11.21 25.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.986 -1.071 . . . . 0.0 110.421 -179.014 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.562 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -138.98 -165.56 1.86 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.957 -1.089 . . . . 0.0 110.624 -179.211 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.539 ' HG1' ' HA ' ' A' ' 75' ' ' VAL . 0.0 OUTLIER -104.0 88.54 3.05 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.069 -1.019 . . . . 0.0 111.658 -178.001 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.775 HG21 HD13 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -72.94 122.99 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.317 -1.49 . . . . 0.0 107.333 177.784 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.787 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.4 OUTLIER -131.27 131.87 44.18 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.539 -1.351 . . . . 0.0 111.345 -177.965 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 33' ' ' LEU . 10.5 pt-20 -41.91 152.98 0.07 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.87 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -50.36 144.44 7.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.213 -0.93 . . . . 0.0 110.239 -179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.452 ' SD ' ' O ' ' A' ' 37' ' ' SER . 0.0 OUTLIER -171.4 179.5 2.91 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.402 -0.811 . . . . 0.0 109.169 179.636 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.452 ' O ' ' SD ' ' A' ' 36' ' ' MET . 8.0 t -84.01 111.08 18.96 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.1 -1.0 . . . . 0.0 109.834 -179.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.845 HD11 HD12 ' A' ' 62' ' ' ILE . 18.6 tp -154.0 90.42 3.29 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 109.702 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -80.21 162.34 22.9 Favored 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.667 2.245 . . . . 0.0 110.408 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . 129.96 42.25 0.22 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.486 ' O ' ' CD1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER 61.1 150.68 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.658 -0.907 . . . . 0.0 109.047 -179.658 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.609 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 26.8 p-90 -154.2 158.38 40.22 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.101 -0.999 . . . . 0.0 109.807 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -120.67 138.38 27.47 Favored Pre-proline 0 C--N 1.299 -1.613 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.16 134.42 17.53 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 121.568 1.512 . . . . 0.0 108.736 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' CG ' ' N ' ' A' ' 46' ' ' MET . 7.1 tttt -148.15 163.49 36.79 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.548 -178.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.498 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 3.9 tpt -134.16 114.13 12.77 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 179.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.775 HD13 HG21 ' A' ' 32' ' ' VAL . 17.5 pt -89.68 143.25 11.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.619 -1.232 . . . . 0.0 109.802 -178.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.653 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.07 98.36 0.76 Allowed Glycine 0 N--CA 1.485 1.911 0 N-CA-C 107.916 -2.074 . . . . 0.0 107.916 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.587 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -122.96 -136.31 4.8 Favored Glycine 0 C--N 1.298 -1.559 0 C-N-CA 119.315 -1.421 . . . . 0.0 111.387 -178.168 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.922 HD12 ' C70' ' B' ' 100' ' ' DMP . 80.6 mt -78.92 132.17 32.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.768 0.794 . . . . 0.0 112.962 -177.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 85.81 -41.58 3.09 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 174.84 -165.11 36.16 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.493 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.653 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 1.1 m-85 -111.04 138.89 46.89 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.647 -0.914 . . . . 0.0 109.244 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.55 HG12 HD11 ' A' ' 47' ' ' ILE . 4.9 pt -119.71 134.13 64.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.853 -1.154 . . . . 0.0 108.854 178.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.496 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 4.2 mttp -74.86 133.38 41.86 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.954 -1.091 . . . . 0.0 110.119 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 1.025 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.2 m -144.57 166.77 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.255 -0.903 . . . . 0.0 109.773 179.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.516 ' HG2' ' CE3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -111.31 172.8 6.67 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.828 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.51 ' CG ' ' CG2' ' A' ' 74' ' ' THR . 37.1 tt0 -135.02 102.82 5.34 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.839 -1.163 . . . . 0.0 110.815 -179.215 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.609 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 87.8 m-85 -91.31 123.0 34.41 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.504 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -96.37 145.82 25.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 110.463 -179.157 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.504 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.8 OUTLIER 75.96 64.51 0.05 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.65 -0.656 . . . . 0.0 110.147 179.425 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.845 HD12 HD11 ' A' ' 38' ' ' LEU . 15.2 mm -124.13 119.91 58.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.331 -0.855 . . . . 0.0 109.473 179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.776 HD21 ' HG3' ' A' ' 70' ' ' LYS . 3.2 tm? -69.85 94.81 0.86 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.665 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.762 HD12 HD11 ' A' ' 15' ' ' ILE . 9.5 tt -96.62 119.2 44.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 178.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.519 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 35.1 tt0 -89.7 103.38 16.03 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.004 -1.06 . . . . 0.0 109.899 -178.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.838 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -96.76 116.18 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.199 -0.938 . . . . 0.0 109.821 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 62.32 17.13 9.11 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.809 -0.557 . . . . 0.0 110.683 178.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.33 6.73 55.16 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.745 -1.217 . . . . 0.0 110.409 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -104.64 133.79 48.89 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.186 -1.184 . . . . 0.0 109.196 179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.776 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -76.09 130.95 39.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.154 -0.966 . . . . 0.0 109.042 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.692 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -150.06 97.96 2.64 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.453 -0.78 . . . . 0.0 110.465 -179.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.568 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.5 OUTLIER -79.03 137.15 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.642 -1.286 . . . . 0.0 107.883 178.791 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.418 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -157.93 -167.88 19.49 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.536 -179.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.517 ' O ' ' OG1' ' A' ' 31' ' ' THR . 26.0 m -97.7 102.08 13.75 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.533 -0.981 . . . . 0.0 109.516 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.787 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.8 OUTLIER -91.47 173.91 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.265 -0.897 . . . . 0.0 109.357 179.727 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -132.54 163.3 29.16 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 179.557 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.87 HG12 ' HA ' ' A' ' 35' ' ' GLU . 2.2 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 120.948 -1.095 . . . . 0.0 110.457 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 1.025 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -139.82 -169.53 11.67 Favored Glycine 0 N--CA 1.485 1.91 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 47.27 2.49 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 C-N-CA 122.551 2.167 . . . . 0.0 110.791 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.684 HG21 HG13 ' A' ' 32' ' ' VAL . 14.8 t -91.02 139.87 25.9 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.147 -0.971 . . . . 0.0 109.133 179.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.34 19.51 0.93 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.696 2.264 . . . . 0.0 112.646 -178.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.574 HG13 ' N ' ' A' ' 83' ' ' ASN . 1.2 t -160.24 171.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.415 -1.428 . . . . 0.0 110.396 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.574 ' N ' HG13 ' A' ' 82' ' ' VAL . 74.0 m-20 -104.9 83.74 2.04 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.673 ' CG1' HG12 ' A' ' 32' ' ' VAL . 7.7 mm -75.74 113.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.461 -0.775 . . . . 0.0 111.712 -176.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.537 ' HB ' ' HA ' ' A' ' 24' ' ' LEU . 1.1 mp -93.92 94.09 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.84 -172.25 41.41 Favored Glycine 0 N--CA 1.494 2.551 0 O-C-N 120.797 -1.19 . . . . 0.0 111.589 -177.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 88' ' ' ASN . 1.2 mtt-85 -56.69 -36.05 69.17 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.957 -0.731 . . . . 0.0 110.38 -179.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.778 ' ND2' HD23 ' A' ' 89' ' ' LEU . 5.8 p-10 -43.39 -40.45 3.7 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.057 -1.027 . . . . 0.0 109.15 -179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.778 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -94.53 -30.04 14.6 Favored 'General case' 0 N--CA 1.485 1.309 0 O-C-N 121.318 -0.864 . . . . 0.0 111.02 -179.299 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.801 ' O ' ' HB3' ' A' ' 95' ' ' ALA . 28.2 mt -65.99 -6.83 13.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.533 -1.354 . . . . 0.0 109.795 -179.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.793 HG21 ' CG ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -101.42 -15.0 17.33 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.978 -1.076 . . . . 0.0 109.101 179.743 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.486 ' OE1' ' O ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -80.0 -41.15 26.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.251 -0.906 . . . . 0.0 109.577 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.819 HD12 ' CG ' ' B' ' 99' ' ' PHE . 4.5 pt -82.71 5.49 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.173 -0.955 . . . . 0.0 108.756 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.52 41.64 35.67 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.876 -1.289 . . . . 0.0 109.876 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' A' ' 90' ' ' LEU . . . -81.81 137.8 35.23 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 120.882 -1.363 . . . . 0.0 110.09 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.821 HG22 ' CG2' ' B' ' 4' ' ' THR . 11.2 p -136.6 130.38 32.23 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' B' ' 97' ' ' LEU . 1.9 mp -88.26 92.16 9.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.747 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.559 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.8 m120 -95.35 123.42 38.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.095 -1.003 . . . . 0.0 109.407 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.872 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 117.93 -1.034 . . . . 0.0 109.529 179.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.604 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.498 1.778 0 N-CA-C 110.326 -0.682 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.499 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -85.01 131.6 34.45 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 178.262 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 16.5 t -127.37 127.76 69.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 120.851 -1.156 . . . . 0.0 110.859 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.821 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -149.44 25.78 0.86 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -82.47 45.07 0.93 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.705 -0.622 . . . . 0.0 110.94 -178.135 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.793 ' CG ' HG21 ' A' ' 91' ' ' THR . 13.8 m95 18.84 51.7 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.271 0 CA-C-O 121.177 0.513 . . . . 0.0 111.214 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.531 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.5 OUTLIER -141.53 -168.5 2.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.982 -1.074 . . . . 0.0 110.336 -179.224 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.414 ' HG2' ' OD1' ' A' ' 29' ' ' ASP . 0.2 OUTLIER -91.76 128.94 44.13 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.399 -0.813 . . . . 0.0 109.148 179.666 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.519 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 36.3 Cg_endo -76.52 72.83 5.41 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.305 2.003 . . . . 0.0 109.879 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.506 HD22 ' HB2' ' B' ' 21' ' ' GLU . 3.2 mt -95.68 134.75 38.23 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.753 -1.217 . . . . 0.0 109.936 -179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.454 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -140.44 154.71 22.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.09 102.78 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 178.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.981 ' CD1' HD12 ' B' ' 15' ' ' ILE . 1.7 pp -87.64 148.68 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.466 -0.772 . . . . 0.0 109.649 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.518 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 16.8 ttmt -117.38 107.88 14.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.246 -0.909 . . . . 0.0 109.399 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.981 HD12 ' CD1' ' B' ' 13' ' ' ILE . 0.9 OUTLIER -117.39 125.26 73.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.151 -0.968 . . . . 0.0 109.647 -179.6 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.36 14.29 68.87 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 6.71 69.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.518 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.2 mt-30 -97.83 167.55 10.86 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.324 -1.103 . . . . 0.0 108.839 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.464 ' HG ' ' HG3' ' B' ' 14' ' ' LYS . 16.2 mt -131.99 129.73 40.52 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.122 -0.986 . . . . 0.0 111.164 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.606 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.3 OUTLIER -149.79 168.61 23.19 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 177.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.546 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 7.2 pt-20 -78.3 -166.09 0.78 Allowed 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.684 ' HB2' HG23 ' B' ' 13' ' ' ILE . . . -168.8 109.84 0.5 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.844 -1.16 . . . . 0.0 109.955 -179.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.558 ' O ' ' N ' ' B' ' 25' ' ' ASP . 14.1 tp -83.76 93.66 8.0 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.458 -0.777 . . . . 0.0 109.181 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.705 HD22 HG21 ' B' ' 85' ' ' ILE . 26.7 mt -44.63 94.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.56 ' HA ' ' CA ' ' A' ' 27' ' ' GLY . 7.5 t0 -99.01 81.78 2.64 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.583 -0.698 . . . . 0.0 109.897 -178.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.557 ' CG2' ' HD3' ' B' ' 87' ' ' ARG . 10.6 m -58.6 -17.27 20.53 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 179.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.611 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.26 -43.98 96.2 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.594 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -72.31 169.33 16.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.133 -1.216 . . . . 0.0 108.852 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.478 ' OD1' ' HG2' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -100.31 -20.37 15.89 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.091 -1.006 . . . . 0.0 110.217 -179.198 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 4.8 m-20 -132.9 -166.88 1.82 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.994 -1.066 . . . . 0.0 110.206 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.782 HG22 ' CD1' ' B' ' 33' ' ' LEU . 9.0 m -107.02 89.3 2.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.816 -1.178 . . . . 0.0 111.397 -177.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.96 HG13 HG21 ' B' ' 80' ' ' THR . 0.6 OUTLIER -68.63 160.45 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.347 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.889 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -157.83 133.92 9.39 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 120.759 -1.213 . . . . 0.0 111.394 -177.741 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.469 ' OE1' ' O ' ' B' ' 80' ' ' THR . 15.1 tp10 -42.34 141.88 0.88 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.732 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -41.07 150.47 0.08 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.462 -0.774 . . . . 0.0 110.252 -179.741 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.49 ' HE1' ' O ' ' B' ' 15' ' ' ILE . 0.1 OUTLIER -170.66 -175.87 1.94 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 11.1 t -109.48 101.76 10.68 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.826 -1.171 . . . . 0.0 110.022 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.905 HD12 HG21 ' B' ' 77' ' ' VAL . 6.2 mt -97.08 170.25 7.55 Favored Pre-proline 0 N--CA 1.489 1.482 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.579 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.0 Cg_endo -76.06 68.31 6.61 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.407 2.071 . . . . 0.0 112.537 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 32.75 -157.27 0.01 OUTLIER Glycine 0 N--CA 1.498 2.771 0 CA-C-O 121.918 0.732 . . . . 0.0 111.594 178.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 54.31 81.91 0.1 Allowed 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.312 -1.11 . . . . 0.0 109.213 -179.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.544 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 58.0 p-90 -155.84 -176.19 5.82 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 121.531 -0.73 . . . . 0.0 109.581 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -141.09 159.52 61.35 Favored Pre-proline 0 N--CA 1.489 1.496 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.93 139.94 12.4 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 C-N-CA 122.249 1.966 . . . . 0.0 110.998 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.644 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -148.38 118.63 7.3 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.401 -0.812 . . . . 0.0 108.977 179.543 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.521 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -96.24 129.57 43.53 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.05 -1.031 . . . . 0.0 109.557 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.602 HD11 HD11 ' B' ' 54' ' ' ILE . 41.0 pt -117.14 132.0 68.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.099 179.01 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.94 100.97 0.84 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 107.976 -2.049 . . . . 0.0 107.976 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.425 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -118.61 -125.87 3.51 Favored Glycine 0 N--CA 1.483 1.804 0 C-N-CA 119.184 -1.484 . . . . 0.0 111.038 -178.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.605 HG13 ' H62' ' B' ' 100' ' ' DMP . 52.9 mt -84.56 121.41 36.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.568 -0.96 . . . . 0.0 112.981 -177.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.506 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 100.74 -36.8 3.92 Favored Glycine 0 N--CA 1.492 2.391 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.172 177.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 169.86 -154.83 24.2 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.553 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.614 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.5 OUTLIER -120.4 140.76 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.53 -0.983 . . . . 0.0 109.718 -179.659 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.89 HD13 HG23 ' A' ' 50' ' ' ILE . 12.5 pt -124.33 132.07 71.88 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.311 -0.868 . . . . 0.0 108.976 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.524 ' O ' ' HD3' ' B' ' 79' ' ' PRO . 15.2 mttt -77.45 140.3 39.82 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.047 -1.033 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.897 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.0 m -138.56 175.07 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 109.956 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.421 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 18.4 mtt-85 -124.86 102.35 7.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.501 -0.749 . . . . 0.0 109.054 179.622 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.559 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.7 OUTLIER -60.28 94.75 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.47 -0.769 . . . . 0.0 110.772 -179.653 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.72 ' HB3' HD11 ' B' ' 62' ' ' ILE . 29.9 m-85 -89.88 114.4 26.17 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.566 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.4 OUTLIER -93.47 143.18 26.53 Favored 'General case' 0 C--N 1.296 -1.748 0 O-C-N 120.912 -1.117 . . . . 0.0 110.337 -178.83 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.566 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.1 OUTLIER 73.18 63.08 0.1 Allowed 'General case' 0 N--CA 1.495 1.82 0 CA-C-O 121.368 0.604 . . . . 0.0 110.54 179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.72 HD11 ' HB3' ' B' ' 59' ' ' TYR . 8.1 mm -120.53 110.76 29.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 178.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.623 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.0 OUTLIER -63.15 87.41 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.033 -1.042 . . . . 0.0 110.768 -178.515 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.893 ' CG2' HD11 ' B' ' 89' ' ' LEU . 8.0 tt -89.85 122.36 41.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 178.181 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.467 ' OE2' ' HA2' ' B' ' 68' ' ' GLY . 1.2 tt0 -90.0 116.96 28.44 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.995 -1.066 . . . . 0.0 109.108 -179.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.665 HD12 HG12 ' B' ' 64' ' ' ILE . 0.4 OUTLIER -111.63 131.65 62.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.277 -0.889 . . . . 0.0 109.351 -179.813 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 33.3 m 45.27 58.95 3.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.642 -0.661 . . . . 0.0 110.856 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.467 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 53.07 31.19 40.07 Favored Glycine 0 N--CA 1.495 2.598 0 C-N-CA 120.163 -1.017 . . . . 0.0 110.865 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 5.1 m-70 -132.62 142.71 49.25 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.928 -1.337 . . . . 0.0 109.453 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.505 ' HG3' HD21 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -75.44 138.15 41.46 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.361 -0.837 . . . . 0.0 109.809 -179.683 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.665 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -159.03 98.71 1.48 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.343 -0.848 . . . . 0.0 109.955 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.623 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.01 159.96 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.678 -1.231 . . . . 0.0 107.678 178.798 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.491 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.18 -171.8 44.64 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.029 -2.034 . . . . 0.0 112.335 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.559 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 5.9 m -95.47 106.64 18.73 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.809 -0.818 . . . . 0.0 110.475 -179.353 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.854 HG13 HD13 ' B' ' 33' ' ' LEU . 1.6 t -98.11 108.81 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.627 -0.67 . . . . 0.0 110.618 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.59 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.8 mp -80.95 125.32 29.99 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.041 -1.037 . . . . 0.0 108.549 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.905 HG21 HD12 ' B' ' 38' ' ' LEU . 1.4 t -104.18 111.3 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.224 -0.922 . . . . 0.0 110.054 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.897 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -145.27 -171.56 15.03 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 179.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.524 ' HD3' ' O ' ' B' ' 55' ' ' LYS . 35.3 Cg_endo -79.91 43.13 1.44 Allowed 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.502 2.134 . . . . 0.0 111.091 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.96 HG21 HG13 ' B' ' 32' ' ' VAL . 2.9 t -89.03 138.29 29.2 Favored Pre-proline 0 N--CA 1.488 1.433 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.725 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.5 Cg_endo -80.42 21.78 0.82 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.508 2.139 . . . . 0.0 111.328 -178.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.725 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.8 t -161.32 161.1 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.623 -1.298 . . . . 0.0 111.029 -178.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.606 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 1.9 m-80 -90.77 88.78 7.21 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.724 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.8 mm -78.85 118.93 27.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.041 -1.037 . . . . 0.0 111.422 -176.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.705 HG21 HD22 ' B' ' 24' ' ' LEU . 1.0 OUTLIER -102.04 99.74 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 106.926 -1.509 . . . . 0.0 106.926 177.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -85.37 -163.08 36.83 Favored Glycine 0 N--CA 1.492 2.389 0 O-C-N 120.871 -1.143 . . . . 0.0 110.704 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.557 ' HD3' ' CG2' ' B' ' 26' ' ' THR . 7.5 mmm180 -63.65 -29.03 70.32 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.653 -0.91 . . . . 0.0 110.113 -179.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.02 ' ND2' HD23 ' B' ' 89' ' ' LEU . 10.8 p-10 -52.53 -40.06 62.07 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.673 -1.267 . . . . 0.0 109.237 179.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.02 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.3 mm? -96.04 -15.86 21.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.295 -0.878 . . . . 0.0 110.904 -179.056 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.845 ' O ' ' HB3' ' B' ' 95' ' ' ALA . 34.4 mt -85.18 -4.18 59.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.866 -1.146 . . . . 0.0 108.827 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.616 HG21 ' HA ' ' A' ' 6' ' ' TRP . 68.9 p -101.83 -13.93 17.48 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.324 -0.86 . . . . 0.0 108.748 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.818 ' OE1' HD13 ' B' ' 89' ' ' LEU . 33.0 mt-30 -87.0 -36.44 18.24 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.41 -0.806 . . . . 0.0 109.281 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.872 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.0 OUTLIER -85.38 4.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.803 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 78.48 31.07 47.12 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.041 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.845 ' HB3' ' O ' ' B' ' 90' ' ' LEU . . . -74.15 132.79 42.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.336 . . . . 0.0 110.353 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 17.1 p -140.81 129.44 22.81 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 178.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.935 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -86.04 94.46 9.24 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.329 -0.857 . . . . 0.0 109.312 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.3 m120 -96.26 122.63 39.33 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.112 -0.992 . . . . 0.0 109.207 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.819 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.421 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.922 ' C70' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.478 ' HG2' ' CE2' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.493 1.476 0 N-CA-C 109.884 -0.852 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.466 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.2 tt0 -84.29 141.04 31.22 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.586 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 10.8 t -135.68 112.66 13.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 120.464 -1.397 . . . . 0.0 110.071 -178.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.807 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.5 OUTLIER -128.3 -78.5 0.57 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.856 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.708 HD12 ' HB2' ' A' ' 7' ' ' GLN . 0.4 OUTLIER 34.94 37.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.802 -0.562 . . . . 0.0 110.268 179.983 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' A' ' 5' ' ' LEU . 43.7 m0 16.1 53.77 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 121.065 0.459 . . . . 0.0 112.204 179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.708 ' HB2' HD12 ' A' ' 5' ' ' LEU . 1.6 mm-40 -156.35 -174.84 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.992 -1.067 . . . . 0.0 109.937 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -68.43 115.33 28.63 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.265 -0.897 . . . . 0.0 109.402 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 24' ' ' LEU . 34.4 Cg_endo -77.15 72.68 5.79 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.12 1.88 . . . . 0.0 110.359 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.797 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -81.76 152.77 26.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.28 -0.887 . . . . 0.0 108.998 179.715 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.771 HG23 HG23 ' A' ' 13' ' ' ILE . 26.9 m -139.07 129.16 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.166 -0.959 . . . . 0.0 110.38 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.503 HG22 HD22 ' A' ' 19' ' ' LEU . 4.4 m -67.74 92.01 0.33 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 178.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.907 HD11 HD21 ' A' ' 33' ' ' LEU . 3.0 pt -88.74 147.21 5.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.462 -0.774 . . . . 0.0 110.886 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 5.9 tttt -109.11 100.37 9.55 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.018 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.709 HD12 ' CD2' ' A' ' 33' ' ' LEU . 3.4 mt -117.17 136.16 55.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.87 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' A' ' 18' ' ' GLN . . . 63.34 25.07 68.1 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.8 17.78 79.92 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 15.3 mp0 -123.75 -174.67 3.03 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -1.158 . . . . 0.0 108.919 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 44.0 mt -137.97 135.48 36.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.137 -0.977 . . . . 0.0 110.06 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.614 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -148.97 148.69 30.07 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.797 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.6 mm-40 -78.61 109.06 12.48 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.947 -1.095 . . . . 0.0 109.295 -179.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.046 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -95.05 116.95 29.35 Favored 'General case' 0 N--CA 1.49 1.534 0 CA-C-O 122.02 0.914 . . . . 0.0 111.265 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.469 ' HA ' ' HG ' ' A' ' 10' ' ' LEU . 8.3 tp -72.46 103.09 3.37 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 178.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 9' ' ' PRO . 20.1 mt -46.65 131.03 11.54 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.105 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.763 ' HB2' HG23 ' A' ' 84' ' ' ILE . 3.6 t70 -139.34 86.57 2.13 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.167 -0.958 . . . . 0.0 111.091 -177.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.967 HG21 HD22 ' A' ' 97' ' ' LEU . 1.5 m -65.64 -11.64 46.42 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.97 -1.081 . . . . 0.0 108.4 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.701 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -72.74 -44.7 37.9 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.061 -1.616 . . . . 0.0 109.061 179.091 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.49 157.79 36.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -1.162 . . . . 0.0 108.936 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -99.18 -9.5 23.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.036 . . . . 0.0 110.226 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.521 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.3 OUTLIER -138.57 177.93 7.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.944 -1.098 . . . . 0.0 110.297 -179.428 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.689 HG22 ' CD1' ' A' ' 33' ' ' LEU . 37.6 m -101.78 102.23 12.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.036 -1.04 . . . . 0.0 109.44 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.778 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -97.11 115.42 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.353 -0.842 . . . . 0.0 109.88 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.054 HD13 ' CG1' ' A' ' 75' ' ' VAL . 6.6 mp -106.52 123.13 47.62 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.309 -0.869 . . . . 0.0 109.767 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.704 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.0 pt-20 -43.09 165.55 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 108.915 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.539 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 2.5 tt0 -42.7 137.48 2.22 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.12 -0.987 . . . . 0.0 110.067 -179.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.489 ' SD ' HD13 ' A' ' 38' ' ' LEU . 2.0 ppp? -153.78 -162.33 1.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.565 -0.709 . . . . 0.0 109.372 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.529 ' HB3' ' NE2' ' A' ' 18' ' ' GLN . 11.7 t -106.2 100.93 10.45 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.202 -0.936 . . . . 0.0 110.275 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.763 HD23 ' CD2' ' A' ' 59' ' ' TYR . 1.4 tp -127.95 149.65 71.4 Favored Pre-proline 0 N--CA 1.491 1.617 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.544 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.5 Cg_endo -73.97 -156.17 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.583 2.189 . . . . 0.0 110.609 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.506 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -93.01 -155.6 32.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.506 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 72.7 43.77 0.42 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.649 -0.912 . . . . 0.0 108.893 -179.557 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.643 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 29.8 p-90 -132.22 178.21 6.98 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.8 0.809 . . . . 0.0 110.328 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.448 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 1.4 mmtp -139.12 150.99 66.76 Favored Pre-proline 0 C--N 1.301 -1.533 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -76.25 138.67 20.37 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 C-N-CA 122.031 1.821 . . . . 0.0 110.233 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.519 ' CG ' ' N ' ' A' ' 46' ' ' MET . 0.0 OUTLIER -147.56 167.36 24.72 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.673 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.519 ' N ' ' CG ' ' A' ' 45' ' ' LYS . 9.1 mtp -143.56 128.28 18.23 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.108 -0.995 . . . . 0.0 108.435 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.835 HD12 HG21 ' B' ' 50' ' ' ILE . 2.1 pt -106.78 141.18 22.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.881 -1.137 . . . . 0.0 109.388 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.64 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.84 96.29 0.65 Allowed Glycine 0 N--CA 1.485 1.943 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -119.23 -128.43 3.76 Favored Glycine 0 N--CA 1.481 1.659 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.854 -178.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.965 HG21 HD12 ' B' ' 47' ' ' ILE . 42.5 mt -81.2 118.22 28.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.775 -0.838 . . . . 0.0 112.511 -177.487 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 106.16 -42.61 1.87 Allowed Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.446 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . 167.43 -157.98 30.63 Favored Glycine 0 N--CA 1.49 2.245 0 O-C-N 120.875 -1.368 . . . . 0.0 110.068 -179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.64 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.1 m-85 -114.62 140.6 48.68 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.436 -1.038 . . . . 0.0 109.784 -179.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.607 HG22 ' HA2' ' B' ' 51' ' ' GLY . 0.9 OUTLIER -116.51 179.53 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.389 0 O-C-N 121.251 -0.906 . . . . 0.0 108.703 179.039 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 10.0 mttm -115.02 141.24 48.26 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.17 -0.957 . . . . 0.0 108.545 179.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 77' ' ' VAL . 4.5 m -144.52 172.1 5.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.941 -1.1 . . . . 0.0 110.641 -178.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.456 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.9 mtt180 -118.96 98.37 6.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.516 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 3.3 tt0 -59.18 91.91 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.125 -0.984 . . . . 0.0 110.155 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.763 ' CD2' HD23 ' A' ' 38' ' ' LEU . 13.6 m-85 -88.5 92.73 9.29 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 178.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.402 ' HB3' ' OE1' ' A' ' 61' ' ' GLN . 7.3 m-20 -78.79 143.37 36.14 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 110.811 -178.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.571 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 3.4 mm100 69.44 67.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-O 121.51 0.672 . . . . 0.0 109.6 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.521 HG13 ' HB3' ' A' ' 59' ' ' TYR . 1.2 mm -126.97 111.48 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.976 HD13 ' N ' ' A' ' 64' ' ' ILE . 3.3 tm? -50.97 143.27 10.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.163 -0.96 . . . . 0.0 109.469 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.976 ' N ' HD13 ' A' ' 63' ' ' LEU . 6.9 tt -150.79 113.89 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.501 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 36.8 tt0 -89.02 102.86 15.51 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.815 -1.178 . . . . 0.0 108.753 -179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.88 HG13 HG22 ' A' ' 13' ' ' ILE . 0.8 OUTLIER -96.89 112.84 29.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-O 121.852 0.834 . . . . 0.0 108.908 -179.652 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 0.1 OUTLIER 71.13 -84.01 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.32 28.2 0.88 Allowed Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -129.68 128.49 42.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -1.112 . . . . 0.0 109.328 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.809 ' HG2' HD21 ' A' ' 63' ' ' LEU . 1.0 OUTLIER -78.79 136.28 37.32 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.754 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.839 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -151.94 131.81 13.31 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.108 -0.995 . . . . 0.0 110.681 -179.045 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.711 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -95.39 148.1 5.39 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 177.848 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -166.39 -171.53 32.63 Favored Glycine 0 N--CA 1.49 2.295 0 C-N-CA 118.401 -1.857 . . . . 0.0 111.48 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.516 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 63.9 m -102.81 105.2 15.56 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.436 -1.038 . . . . 0.0 110.205 -179.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.054 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.36 167.49 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.778 ' HB2' HG23 ' A' ' 32' ' ' VAL . 2.1 mp -139.52 107.44 5.69 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.934 -1.104 . . . . 0.0 108.367 179.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.539 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 31.9 t -88.37 114.04 26.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 -178.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -150.41 -171.34 18.6 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.3 Cg_endo -80.51 40.16 0.94 Allowed 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.588 2.192 . . . . 0.0 111.183 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.704 HG22 ' HA ' ' A' ' 34' ' ' GLU . 5.7 t -82.9 142.3 44.79 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.65 ' O ' HG23 ' A' ' 82' ' ' VAL . 37.4 Cg_endo -79.32 16.3 1.41 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.421 2.08 . . . . 0.0 111.356 -178.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.704 HG12 ' CG1' ' A' ' 84' ' ' ILE . 2.8 t -161.44 160.43 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 120.828 -1.17 . . . . 0.0 110.983 -178.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.665 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 82.5 m-20 -94.35 143.55 26.3 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 103.053 -2.943 . . . . 0.0 103.053 174.408 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.763 HG23 ' HB2' ' A' ' 25' ' ' ASP . 18.4 mt -146.91 135.12 15.3 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 O-C-N 119.295 -2.128 . . . . 0.0 112.562 -176.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 1.046 HD13 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -97.91 107.34 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.05 -167.4 43.47 Favored Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.089 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.581 ' O ' HG23 ' A' ' 91' ' ' THR . 1.9 mmm180 -60.05 -31.71 70.24 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.408 -1.054 . . . . 0.0 109.173 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.051 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.1 p-10 -54.58 -28.47 46.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 110.53 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.051 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.6 mm? -104.57 -29.12 10.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.83 -1.169 . . . . 0.0 110.062 -179.096 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.584 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 14.3 mt -71.36 -5.59 33.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.992 -1.068 . . . . 0.0 108.982 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.581 HG23 ' O ' ' A' ' 87' ' ' ARG . 70.0 p -101.38 -20.91 14.98 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.143 -0.973 . . . . 0.0 109.327 179.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 42.9 mm-40 -81.52 -40.35 23.31 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 109.061 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.965 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.9 OUTLIER -80.13 -2.93 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.202 -0.936 . . . . 0.0 108.655 178.821 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 78.17 30.46 50.62 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.566 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -65.84 136.4 56.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.805 -1.409 . . . . 0.0 109.049 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.493 HG22 HG22 ' B' ' 4' ' ' THR . 81.5 p -131.14 125.4 32.95 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.153 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.967 HD22 HG21 ' A' ' 26' ' ' THR . 1.7 mp -84.5 93.91 8.43 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.525 0.679 . . . . 0.0 110.108 -178.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.496 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.5 m120 -108.37 130.52 55.21 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.737 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 117.949 -1.024 . . . . 0.0 109.09 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.445 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.495 1.565 0 N-CA-C 109.989 -0.812 . . . . 0.0 109.989 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.536 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.9 tt0 -83.96 149.38 26.35 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.059 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.536 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 6.7 t -150.25 117.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 120.665 -1.272 . . . . 0.0 109.582 -179.162 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.592 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.9 OUTLIER -108.62 13.34 25.28 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 178.552 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.521 ' O ' ' CZ ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -26.53 84.32 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.759 0 CA-C-O 121.641 0.734 . . . . 0.0 111.25 -179.037 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.592 ' N ' ' O ' ' B' ' 4' ' ' THR . 16.1 m95 -53.48 -16.67 1.56 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.441 ' O ' ' HG3' ' A' ' 87' ' ' ARG . 30.7 mt-30 -109.42 -106.52 0.35 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.157 -0.964 . . . . 0.0 109.602 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.423 ' HE ' ' CD1' ' B' ' 10' ' ' LEU . 6.1 mtp180 -111.22 120.56 42.76 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 120.945 -1.097 . . . . 0.0 110.705 -179.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.46 ' HA ' ' HG ' ' B' ' 5' ' ' LEU . 37.3 Cg_endo -80.45 62.02 8.4 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 C-N-CA 122.268 1.979 . . . . 0.0 109.692 177.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 1.6 mt -81.66 148.85 28.82 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.076 -1.015 . . . . 0.0 110.327 -179.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 1.059 HG22 ' HB3' ' B' ' 22' ' ' ALA . 5.2 m -141.46 142.69 28.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.448 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.691 HG22 HD22 ' B' ' 19' ' ' LEU . 14.4 m -81.92 96.74 7.77 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.032 HG22 HG13 ' B' ' 66' ' ' ILE . 10.3 pt -84.3 152.41 3.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.227 -0.921 . . . . 0.0 110.41 -178.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.458 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -118.01 101.74 8.49 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.208 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.842 HG23 ' CG2' ' B' ' 62' ' ' ILE . 40.6 mt -105.8 127.14 61.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 121.07 -1.018 . . . . 0.0 109.515 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.8 -86.16 0.36 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 108.606 -1.798 . . . . 0.0 108.606 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -159.76 25.6 0.32 Allowed Glycine 0 N--CA 1.484 1.861 0 N-CA-C 108.039 -2.025 . . . . 0.0 108.039 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -121.0 171.01 8.95 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.739 -0.859 . . . . 0.0 108.749 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.691 HD22 HG22 ' B' ' 12' ' ' THR . 14.4 mt -134.28 130.72 37.49 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.296 -0.877 . . . . 0.0 109.924 -179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -139.99 166.99 23.16 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.375 -1.342 . . . . 0.0 107.375 179.628 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.574 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.6 mt-10 -78.73 -179.94 6.81 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.688 -1.257 . . . . 0.0 107.876 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 1.059 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -158.03 105.26 1.94 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.816 -1.178 . . . . 0.0 110.821 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.701 HD21 ' O ' ' A' ' 27' ' ' GLY . 25.5 tp -77.35 95.52 4.42 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.48 ' HA ' HD22 ' B' ' 24' ' ' LEU . 0.2 OUTLIER -40.44 97.82 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.881 ' HB2' HG23 ' B' ' 84' ' ' ILE . 12.0 t0 -102.57 76.58 1.54 Allowed 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.443 -0.785 . . . . 0.0 110.707 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.946 HG23 HD23 ' B' ' 90' ' ' LEU . 2.7 m -62.91 -11.19 16.81 Favored 'General case' 0 C--N 1.297 -1.679 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.118 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.475 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -79.59 -38.77 19.79 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.04 158.51 36.37 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.093 -1.239 . . . . 0.0 109.065 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -90.68 -11.5 39.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.972 -1.08 . . . . 0.0 110.437 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.538 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.1 OUTLIER -138.88 -164.2 1.61 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.889 -1.132 . . . . 0.0 109.988 -179.646 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.661 HG23 ' O ' ' B' ' 84' ' ' ILE . 16.8 m -115.67 92.76 4.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.927 -1.108 . . . . 0.0 109.718 -179.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.004 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.64 174.19 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.087 -1.008 . . . . 0.0 109.299 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.149 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.0 OUTLIER -171.31 123.25 0.57 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.792 -1.192 . . . . 0.0 110.811 -178.531 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.625 ' HA ' HG22 ' B' ' 80' ' ' THR . 0.6 OUTLIER -42.85 159.75 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.232 -0.917 . . . . 0.0 108.774 178.381 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.886 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -50.61 148.15 4.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.9 -1.125 . . . . 0.0 110.475 -179.284 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.526 ' HG3' ' N ' ' B' ' 37' ' ' SER . 7.4 ptm -155.12 -164.53 1.8 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.526 ' N ' ' HG3' ' B' ' 36' ' ' MET . 3.9 t -105.08 67.27 0.78 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.865 -1.147 . . . . 0.0 110.116 -179.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.657 HD13 ' CG ' ' B' ' 59' ' ' TYR . 11.6 mt -85.1 168.71 19.12 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.033 . . . . 0.0 108.726 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.589 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 30.6 Cg_endo -71.59 -162.52 0.11 Allowed 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.142 1.895 . . . . 0.0 111.374 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.96 29.93 8.85 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 -178.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -107.94 46.12 0.97 Allowed 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.655 ' CD1' ' CZ ' ' B' ' 59' ' ' TYR . 29.9 p-90 -117.73 -179.92 3.88 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.817 0.818 . . . . 0.0 110.356 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -134.27 134.12 22.41 Favored Pre-proline 0 C--N 1.3 -1.556 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -75.76 135.43 17.7 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 121.779 1.653 . . . . 0.0 110.414 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.652 ' HD3' HD23 ' B' ' 76' ' ' LEU . 16.2 ptmt -160.09 -165.91 1.58 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.559 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.562 ' CG ' ' HG3' ' B' ' 55' ' ' LYS . 4.3 mtp -146.56 124.7 12.14 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.364 -0.835 . . . . 0.0 109.451 -179.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.965 HD12 HG21 ' A' ' 50' ' ' ILE . 2.8 pt -89.48 143.23 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.25 113.51 2.64 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.505 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -138.65 -123.99 2.18 Favored Glycine 0 N--CA 1.481 1.7 0 C-N-CA 119.52 -1.324 . . . . 0.0 110.213 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.835 HG21 HD12 ' A' ' 47' ' ' ILE . 28.3 mt -91.22 134.82 28.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.694 -0.886 . . . . 0.0 111.968 -178.001 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.607 ' HA2' HG22 ' A' ' 54' ' ' ILE . . . 87.47 -29.78 5.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 178.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.444 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 156.12 -160.08 29.84 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.555 -1.307 . . . . 0.0 110.011 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.475 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -120.67 133.32 55.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.498 -1.001 . . . . 0.0 109.118 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.682 HD13 HG23 ' A' ' 50' ' ' ILE . 15.6 pt -110.66 141.0 27.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 120.941 -1.099 . . . . 0.0 109.774 -179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.562 ' HG3' ' CG ' ' B' ' 46' ' ' MET . 0.0 OUTLIER -65.21 154.23 38.68 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.027 . . . . 0.0 109.25 179.792 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.516 HG23 ' HG2' ' B' ' 45' ' ' LYS . 19.8 m -151.13 -167.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.973 . . . . 0.0 110.005 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -145.03 96.25 2.82 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.562 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 11.3 tt0 -61.83 107.9 0.92 Allowed 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.341 -0.849 . . . . 0.0 110.533 -179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.657 ' CG ' HD13 ' B' ' 38' ' ' LEU . 29.2 m-85 -102.3 95.18 6.12 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.593 ' OD1' HG23 ' B' ' 74' ' ' THR . 0.5 OUTLIER -79.13 141.61 37.12 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.829 -1.17 . . . . 0.0 109.994 -179.589 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.496 ' HB2' ' O ' ' B' ' 60' ' ' ASP . 0.0 OUTLIER 75.01 59.25 0.06 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.695 -0.628 . . . . 0.0 110.055 179.706 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.842 ' CG2' HG23 ' B' ' 15' ' ' ILE . 5.8 mm -121.35 121.5 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.271 -0.893 . . . . 0.0 108.984 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.92 ' O ' HD13 ' B' ' 63' ' ' LEU . 1.4 tm? -68.54 91.4 0.41 Allowed 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.138 -0.976 . . . . 0.0 110.503 -179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.632 HG22 ' O ' ' B' ' 71' ' ' ALA . 10.8 tt -97.75 120.33 46.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.6 tt0 -88.32 148.56 24.23 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.044 -1.035 . . . . 0.0 108.557 -179.257 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 1.032 HG13 HG22 ' B' ' 13' ' ' ILE . 1.2 mp -147.48 132.98 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.086 -1.009 . . . . 0.0 109.717 -179.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.411 ' C ' ' O ' ' B' ' 66' ' ' ILE . 54.7 m 42.79 37.9 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.533 -0.729 . . . . 0.0 109.723 179.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.77 48.1 51.41 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -145.71 114.42 6.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.204 -1.174 . . . . 0.0 109.445 179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.75 130.85 47.28 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.632 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.8 101.19 2.74 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 110.369 -179.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.584 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -80.08 157.2 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.016 -1.052 . . . . 0.0 108.583 178.767 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.611 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 175.88 -166.33 37.5 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.908 -1.615 . . . . 0.0 111.632 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.593 HG23 ' OD1' ' B' ' 60' ' ' ASP . 16.8 m -98.03 104.86 16.93 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.528 -0.983 . . . . 0.0 110.595 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.149 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.0 OUTLIER -97.16 109.41 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.344 -0.848 . . . . 0.0 110.255 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.652 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.4 mp -80.32 124.27 28.7 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.181 -0.949 . . . . 0.0 108.944 179.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.886 HG12 ' HA ' ' B' ' 35' ' ' GLU . 0.2 OUTLIER -106.86 125.95 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 109.784 -179.893 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -159.42 -167.21 19.76 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 179.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.8 Cg_endo -81.71 54.87 5.28 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.795 2.33 . . . . 0.0 109.916 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.625 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.3 t -97.57 138.43 21.1 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.267 -0.896 . . . . 0.0 108.93 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.445 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.1 Cg_endo -80.06 16.55 1.47 Allowed 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 122.482 2.121 . . . . 0.0 110.71 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.575 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.5 OUTLIER -161.24 172.45 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.016 -1.053 . . . . 0.0 110.206 -179.576 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.619 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 68.6 m-80 -105.03 147.76 27.49 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 104.652 -2.351 . . . . 0.0 104.652 176.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' B' ' 25' ' ' ASP . 24.7 mm -133.64 120.2 36.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.018 0 O-C-N 120.282 -1.511 . . . . 0.0 111.194 -177.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.806 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -102.14 91.9 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 177.997 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.546 ' O ' HD13 ' B' ' 90' ' ' LEU . . . -100.12 170.57 22.72 Favored Glycine 0 N--CA 1.496 2.683 0 C-N-CA 119.748 -1.215 . . . . 0.0 112.344 -177.062 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.789 ' O ' HG23 ' B' ' 91' ' ' THR . 3.7 mmt180 -21.96 -41.37 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.987 ' ND2' HD23 ' B' ' 89' ' ' LEU . 12.0 p-10 -52.43 -43.05 64.63 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.121 -1.612 . . . . 0.0 110.486 -178.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.987 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -91.29 -19.96 22.4 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.189 -0.944 . . . . 0.0 109.685 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.946 HD23 HG23 ' B' ' 26' ' ' THR . 2.2 mp -67.39 -15.22 63.56 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.789 HG23 ' O ' ' B' ' 87' ' ' ARG . 17.2 p -86.9 -18.34 31.07 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.053 -1.029 . . . . 0.0 108.801 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 -87.79 -40.34 14.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.737 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.3 pt -87.28 -2.51 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.362 -0.836 . . . . 0.0 109.143 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.6 35.76 81.65 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 179.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.497 ' HB3' ' HB3' ' B' ' 90' ' ' LEU . . . -63.04 145.06 56.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.949 -1.324 . . . . 0.0 110.936 -179.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.807 HG22 ' CG2' ' A' ' 4' ' ' THR . 20.4 p -150.42 126.98 10.83 Favored 'General case' 0 N--CA 1.494 1.758 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 178.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.681 HD11 HD11 ' A' ' 97' ' ' LEU . 6.9 mp -86.62 103.25 14.93 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.259 -0.901 . . . . 0.0 109.187 -179.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 9.9 m120 -101.4 122.41 43.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.134 -0.979 . . . . 0.0 110.036 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.965 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.433 179.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.829 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.47 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.5 Cg_exo . . . . . 0 N--CA 1.494 1.518 0 N-CA-C 110.551 -0.596 . . . . 0.0 110.551 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.503 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 8.6 tt0 -83.75 126.29 32.76 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 106.102 -1.814 . . . . 0.0 106.102 177.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.4 t -118.14 108.35 24.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.875 -1.14 . . . . 0.0 109.81 -177.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -131.71 41.0 3.33 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.582 -0.699 . . . . 0.0 109.481 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -88.34 43.08 1.1 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.144 -0.973 . . . . 0.0 108.965 179.644 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.527 ' C ' ' O ' ' A' ' 5' ' ' LEU . 16.3 m0 18.13 50.64 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.246 0 CA-C-O 121.237 0.541 . . . . 0.0 111.545 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 5.3 mt-30 -155.45 163.82 39.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.268 -0.895 . . . . 0.0 109.518 179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.493 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -54.19 119.25 18.98 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 109.322 179.894 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.667 ' HB2' HD12 ' A' ' 24' ' ' LEU . 36.8 Cg_endo -78.47 75.07 5.12 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.212 1.941 . . . . 0.0 110.769 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.815 HD23 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -79.52 164.94 23.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.052 -1.03 . . . . 0.0 108.68 179.587 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 11' ' ' VAL . 30.7 m -149.29 127.78 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.052 -1.03 . . . . 0.0 110.296 -178.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.844 HG22 HD22 ' A' ' 19' ' ' LEU . 8.1 m -64.65 91.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 178.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.67 HD12 HG13 ' A' ' 15' ' ' ILE . 1.0 OUTLIER -79.7 149.7 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.505 -178.372 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 18.3 tttt -117.1 91.2 3.51 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.098 HD11 HD12 ' A' ' 64' ' ' ILE . 12.5 mt -114.65 139.93 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 O-C-N 121.208 -0.933 . . . . 0.0 109.959 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 48.41 49.58 25.75 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 52.24 38.37 48.99 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.545 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.7 mm-40 -131.71 168.35 17.92 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.238 -1.154 . . . . 0.0 109.065 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.844 HD22 HG22 ' A' ' 12' ' ' THR . 20.4 mt -137.57 128.94 28.03 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 0.0 109.592 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.433 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 47.0 mtmt -151.1 155.86 39.82 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.395 -0.816 . . . . 0.0 109.368 179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.815 ' HB3' HD23 ' A' ' 10' ' ' LEU . 27.1 mp0 -79.83 106.52 11.92 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.141 -0.975 . . . . 0.0 108.68 179.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.661 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -87.55 132.88 33.89 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.513 -0.742 . . . . 0.0 110.787 -178.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.755 HD21 ' O ' ' B' ' 27' ' ' GLY . 6.0 tp -85.83 98.95 11.04 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.699 HD22 HD21 ' A' ' 90' ' ' LEU . 10.9 mt -45.52 97.34 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.103 -0.998 . . . . 0.0 108.522 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 1.025 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.7 t0 -100.33 90.3 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.471 -0.768 . . . . 0.0 110.503 -178.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -71.1 -16.49 62.57 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.983 -1.073 . . . . 0.0 108.93 178.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.49 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -70.07 -33.84 69.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.445 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -80.31 154.4 27.82 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.213 -1.169 . . . . 0.0 109.342 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -93.8 -12.98 27.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.195 -0.941 . . . . 0.0 109.831 -179.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.559 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -131.64 -175.19 3.63 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.163 -0.961 . . . . 0.0 109.406 179.836 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.689 HG23 HD12 ' A' ' 85' ' ' ILE . 5.9 m -110.72 87.88 2.64 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.789 -1.194 . . . . 0.0 109.808 -179.066 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -73.01 166.33 2.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 179.506 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.022 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -163.57 132.08 3.77 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.79 -1.194 . . . . 0.0 111.343 -177.853 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.548 ' N ' HG22 ' A' ' 80' ' ' THR . 11.3 tt0 -42.21 160.38 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.576 ' HA ' HG13 ' A' ' 77' ' ' VAL . 1.4 mt-10 -61.91 137.19 58.22 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.857 -1.152 . . . . 0.0 109.946 -179.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.95 -164.01 1.89 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.414 -0.804 . . . . 0.0 109.503 179.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 4.1 t -96.73 112.26 24.09 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.123 -0.986 . . . . 0.0 110.39 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.739 HD23 ' CD2' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -133.49 -177.34 0.69 Allowed Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.342 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.601 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -76.4 -179.71 5.56 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.051 1.834 . . . . 0.0 110.656 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.06 29.99 10.35 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -119.76 61.7 0.83 Allowed 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.625 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 11.4 p-90 -121.83 -172.76 2.5 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.537 0.684 . . . . 0.0 109.807 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 1.8 mtpm? -132.85 128.21 20.65 Favored Pre-proline 0 N--CA 1.49 1.568 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -76.36 138.06 19.45 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 121.929 1.753 . . . . 0.0 110.213 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.73 ' HE2' HD23 ' A' ' 76' ' ' LEU . 0.0 OUTLIER -157.16 -179.04 7.82 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.504 -0.878 . . . . 0.0 109.731 179.872 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.509 ' HA ' ' O ' ' A' ' 54' ' ' ILE . 69.4 mtp -136.54 121.23 18.48 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.382 -0.824 . . . . 0.0 108.96 179.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.777 ' CD1' HG21 ' B' ' 50' ' ' ILE . 6.1 pt -88.56 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.565 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.562 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.68 98.0 0.75 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 -179.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.507 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -124.04 -132.29 3.88 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 119.805 -1.188 . . . . 0.0 110.509 -179.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.834 HD11 ' CD1' ' B' ' 84' ' ' ILE . 21.6 mt -84.24 110.5 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.624 -0.927 . . . . 0.0 112.531 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.85 -13.59 17.31 Favored Glycine 0 N--CA 1.495 2.574 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.843 177.734 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 134.27 -154.91 21.61 Favored Glycine 0 N--CA 1.49 2.271 0 C-N-CA 119.204 -1.474 . . . . 0.0 109.951 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.562 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 9.4 m-85 -116.3 127.45 54.71 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.574 -0.956 . . . . 0.0 110.255 -179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.509 ' O ' ' HA ' ' A' ' 46' ' ' MET . 15.8 pt -103.32 179.1 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.572 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -116.07 145.62 42.87 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.861 -1.15 . . . . 0.0 109.302 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.666 HG23 ' HE2' ' A' ' 45' ' ' LYS . 0.7 OUTLIER -146.49 -170.33 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.604 -1.31 . . . . 0.0 110.297 -179.843 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.425 ' HG3' ' O ' ' A' ' 77' ' ' VAL . 2.8 mtm180 -133.8 94.29 3.25 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.539 ' N ' ' HE3' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -53.44 99.56 0.03 OUTLIER 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.38 -0.825 . . . . 0.0 110.217 -179.153 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.739 ' CD2' HD23 ' A' ' 38' ' ' LEU . 22.6 m-85 -98.1 84.88 3.36 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 177.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.837 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.4 OUTLIER -78.16 137.98 38.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 -177.604 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.515 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 51.5 mm-40 80.77 62.28 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.785 HG21 HG23 ' A' ' 15' ' ' ILE . 8.0 mm -124.82 122.85 64.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.893 HD21 ' CG ' ' A' ' 70' ' ' LYS . 17.0 tp -74.4 87.19 2.03 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.109 -1.036 . . . . 0.0 111.755 -177.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 1.098 HD12 HD11 ' A' ' 15' ' ' ILE . 10.9 tt -87.23 120.26 36.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.539 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.7 OUTLIER -89.48 111.68 22.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.143 -0.973 . . . . 0.0 109.474 -178.634 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' CYS . 1.0 OUTLIER -106.7 125.95 62.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.102 -0.999 . . . . 0.0 109.879 -179.522 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.8 m 65.22 11.56 7.33 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.762 -0.586 . . . . 0.0 110.698 178.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.424 ' HA2' ' CD ' ' A' ' 65' ' ' GLU . . . 101.3 1.28 53.98 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.201 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -106.11 119.13 38.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.12 -1.223 . . . . 0.0 108.924 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.893 ' CG ' HD21 ' A' ' 63' ' ' LEU . 2.2 mptp? -63.06 139.75 58.8 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.187 -0.945 . . . . 0.0 109.415 -179.156 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.704 ' C ' HD12 ' A' ' 63' ' ' LEU . . . -151.27 143.12 23.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.454 -0.779 . . . . 0.0 109.307 -179.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.71 HG13 HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -113.19 138.94 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.864 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.412 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -163.05 -159.12 10.2 Favored Glycine 0 N--CA 1.483 1.77 0 C-N-CA 119.208 -1.472 . . . . 0.0 110.213 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.837 HG23 ' OD1' ' A' ' 60' ' ' ASP . 2.2 m -100.1 108.16 20.23 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.769 -0.842 . . . . 0.0 110.05 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.881 HG11 HD13 ' A' ' 15' ' ' ILE . 1.4 t -106.6 107.01 21.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.154 -0.967 . . . . 0.0 109.927 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.73 HD23 ' HE2' ' A' ' 45' ' ' LYS . 3.3 mp -78.58 128.42 33.5 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.576 HG13 ' HA ' ' A' ' 35' ' ' GLU . 54.3 t -114.49 120.53 64.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.698 -179.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.561 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -157.0 -157.72 8.52 Favored Glycine 0 N--CA 1.486 1.988 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.572 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -83.31 36.98 0.63 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.553 2.169 . . . . 0.0 110.758 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.725 HG21 HG13 ' A' ' 32' ' ' VAL . 3.9 t -80.59 134.56 54.1 Favored Pre-proline 0 N--CA 1.489 1.513 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.476 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -77.4 18.59 0.79 Allowed 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.497 2.131 . . . . 0.0 111.825 -178.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.605 ' CG1' HG13 ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.02 160.3 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 109.941 -179.804 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.538 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -99.88 85.99 3.19 Favored 'General case' 0 N--CA 1.495 1.802 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 177.06 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 1.025 HG23 ' CB ' ' A' ' 25' ' ' ASP . 2.3 mt -83.2 122.61 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 CA-C-O 121.805 0.812 . . . . 0.0 112.902 -175.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.689 HD12 HG23 ' A' ' 31' ' ' THR . 0.4 OUTLIER -95.98 102.67 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 177.225 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.531 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -90.87 -162.03 37.87 Favored Glycine 0 N--CA 1.497 2.733 0 C-N-CA 119.82 -1.181 . . . . 0.0 111.478 -178.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.556 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 0.0 OUTLIER -57.4 -40.05 77.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.754 -0.851 . . . . 0.0 110.472 -179.237 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.021 ' ND2' HD23 ' A' ' 89' ' ' LEU . 6.3 p-10 -42.41 -39.28 2.15 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.293 -0.879 . . . . 0.0 110.011 -179.554 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.021 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.9 OUTLIER -100.59 -22.01 15.1 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 121.001 -1.062 . . . . 0.0 110.276 -179.336 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.699 HD21 HD22 ' A' ' 24' ' ' LEU . 81.2 mt -74.67 -1.63 22.65 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.061 -1.024 . . . . 0.0 108.56 179.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.0 p -99.41 -18.65 17.38 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -83.03 -41.63 18.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.391 -0.818 . . . . 0.0 108.982 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.838 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.5 pt -86.87 -10.16 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 178.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.69 45.43 44.61 Favored Glycine 0 N--CA 1.497 2.752 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.275 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.529 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -76.03 131.45 39.52 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.932 -1.334 . . . . 0.0 109.908 179.578 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 77.8 p -129.61 137.82 50.91 Favored 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 179.223 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' B' ' 97' ' ' LEU . 5.9 mp -89.51 120.18 30.6 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.962 -1.086 . . . . 0.0 110.529 -179.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.535 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -119.48 124.77 47.29 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.256 -0.903 . . . . 0.0 108.948 178.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.939 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.531 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.495 1.601 0 N-CA-C 109.964 -0.822 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.489 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.7 tt0 -88.88 150.0 23.08 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.488 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 3.3 t -149.83 126.16 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 120.498 -1.376 . . . . 0.0 110.441 -179.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.542 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.0 OUTLIER -130.98 -60.04 0.97 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 178.733 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.655 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER 34.34 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.944 -0.472 . . . . 0.0 110.852 179.529 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.542 ' N ' ' O ' ' B' ' 4' ' ' THR . 5.5 m95 18.02 42.66 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 112.391 0.515 . . . . 0.0 112.391 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.655 ' N ' ' O ' ' B' ' 5' ' ' LEU . 6.9 mm100 -153.01 -114.81 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.193 -0.942 . . . . 0.0 108.718 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.525 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.1 mtp180 -112.45 141.07 24.52 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 120.23 -1.543 . . . . 0.0 109.195 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' B' ' 23' ' ' LEU . 37.0 Cg_endo -82.15 50.21 3.38 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.316 2.011 . . . . 0.0 109.529 178.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.557 HD23 ' H ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -78.43 137.48 38.0 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.197 -0.939 . . . . 0.0 108.943 -179.597 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -134.15 178.97 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.453 -0.779 . . . . 0.0 109.996 -178.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.768 HG22 HD22 ' B' ' 19' ' ' LEU . 47.8 m -103.86 105.28 15.43 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.814 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.826 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.8 pp -96.17 155.37 3.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.518 -0.738 . . . . 0.0 109.862 -178.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.529 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 8.9 ttmt -122.91 100.14 6.74 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 110.503 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.728 HG13 HD12 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -115.38 142.64 27.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.812 179.591 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 47.98 47.13 26.2 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.945 -1.122 . . . . 0.0 110.351 178.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 55.23 36.42 62.16 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.162 -1.199 . . . . 0.0 110.398 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.523 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.9 OUTLIER -130.7 166.61 20.36 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -1.216 . . . . 0.0 108.425 179.077 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.826 HD23 ' O ' ' B' ' 13' ' ' ILE . 14.8 mt -143.23 125.28 15.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.078 -1.014 . . . . 0.0 111.409 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.503 ' HG3' ' O ' ' B' ' 19' ' ' LEU . 1.0 OUTLIER -145.11 -170.97 3.55 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.875 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.549 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 0.9 OUTLIER -82.45 -176.48 6.25 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.863 -1.148 . . . . 0.0 109.666 -179.846 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.854 ' HB3' HG22 ' B' ' 11' ' ' VAL . . . -163.28 91.49 0.7 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.1 -1.0 . . . . 0.0 110.89 -179.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.543 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 8.8 tp -68.04 93.44 0.43 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.631 -1.293 . . . . 0.0 109.658 179.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.824 HD23 ' HB ' ' B' ' 85' ' ' ILE . 69.8 mt -50.42 94.88 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.856 ' CB ' HG23 ' B' ' 84' ' ' ILE . 29.5 t0 -96.0 84.75 3.89 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.351 -0.843 . . . . 0.0 110.825 -178.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.579 ' HA ' HD12 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -59.51 -16.0 21.69 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.956 -1.09 . . . . 0.0 108.771 178.754 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.755 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -74.19 -38.85 45.98 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 179.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.452 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -70.28 162.76 27.89 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.198 -1.178 . . . . 0.0 109.318 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -101.01 -10.37 20.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.53 ' HA ' ' CG ' ' B' ' 88' ' ' ASN . 0.4 OUTLIER -139.13 -172.57 3.37 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.134 -0.979 . . . . 0.0 110.322 -179.298 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.609 HG22 ' CD1' ' B' ' 33' ' ' LEU . 47.7 m -108.46 89.46 3.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.984 -1.072 . . . . 0.0 111.162 -178.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.897 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -73.34 169.78 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.54 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.125 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -168.81 130.89 1.28 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.777 -1.202 . . . . 0.0 110.683 -179.026 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.566 ' N ' HG23 ' B' ' 80' ' ' THR . 6.0 pt-20 -46.67 170.81 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.276 -0.89 . . . . 0.0 108.693 179.085 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.559 ' HA ' ' CG1' ' B' ' 77' ' ' VAL . 1.6 tt0 -60.42 138.1 58.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.145 -0.972 . . . . 0.0 110.064 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.629 ' HE2' HD21 ' B' ' 38' ' ' LEU . 7.6 ptm -147.05 -163.5 1.78 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.405 -0.809 . . . . 0.0 109.324 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.529 ' N ' ' HG3' ' B' ' 36' ' ' MET . 8.4 t -113.74 98.01 6.77 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -0.881 . . . . 0.0 110.099 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.81 HD12 ' CD2' ' B' ' 59' ' ' TYR . 27.1 mt -106.38 160.39 26.39 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.128 -0.983 . . . . 0.0 109.476 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.475 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 36.6 Cg_endo -77.94 65.28 8.3 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.732 2.288 . . . . 0.0 112.029 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 35.78 -157.37 0.01 OUTLIER Glycine 0 N--CA 1.498 2.813 0 O-C-N 121.442 -0.786 . . . . 0.0 111.239 178.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.494 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 63.25 60.28 1.19 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.513 -0.992 . . . . 0.0 109.237 -179.865 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.7 p-90 -139.08 -175.62 4.22 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' B' ' 43' ' ' LYS . 13.7 mmtm -143.3 136.83 14.18 Favored Pre-proline 0 N--CA 1.488 1.467 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -77.77 125.67 7.59 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.899 1.733 . . . . 0.0 111.403 -179.009 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.82 ' CE ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -162.74 149.93 13.31 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.607 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.463 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 1.8 mtp -110.04 148.0 32.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 0.0 110.414 -178.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.803 ' CD1' HG21 ' A' ' 50' ' ' ILE . 15.5 pt -90.68 155.67 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.513 ' HA3' ' CE2' ' B' ' 53' ' ' PHE . . . -118.87 106.03 1.24 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.512 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -136.12 -128.03 2.7 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.647 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.873 HD12 ' C21' ' B' ' 100' ' ' DMP . 21.5 mt -87.91 127.46 41.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.614 -0.933 . . . . 0.0 112.683 -177.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 96.95 -20.75 49.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.05 -164.59 26.81 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.528 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 3.3 m-85 -105.64 125.74 51.34 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.391 -1.064 . . . . 0.0 109.701 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.7 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -96.38 139.62 18.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.939 -1.1 . . . . 0.0 108.964 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.579 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.1 OUTLIER -78.2 143.04 37.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.806 -1.184 . . . . 0.0 108.995 -179.905 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.658 HG12 ' N ' ' B' ' 78' ' ' GLY . 0.2 OUTLIER -149.3 -173.49 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.87 -1.144 . . . . 0.0 110.074 -179.482 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.435 ' HB2' ' CE2' ' B' ' 59' ' ' TYR . 2.6 mtm-85 -121.28 96.08 4.94 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -60.38 100.18 0.09 Allowed 'General case' 0 C--N 1.299 -1.621 0 O-C-N 121.329 -0.857 . . . . 0.0 109.846 -179.092 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.81 ' CD2' HD12 ' B' ' 38' ' ' LEU . 22.3 m-85 -96.31 94.59 7.55 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.408 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 37.0 m-20 -78.78 140.01 38.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.894 -1.129 . . . . 0.0 110.626 -178.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.681 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.3 OUTLIER 69.17 64.89 0.28 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.714 -0.616 . . . . 0.0 110.309 179.255 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.742 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.7 OUTLIER -123.82 113.12 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.188 -0.945 . . . . 0.0 108.686 179.155 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.672 ' C ' HD13 ' B' ' 63' ' ' LEU . 3.3 tm? -64.68 104.74 0.86 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.239 -0.913 . . . . 0.0 110.869 -178.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.633 HG22 ' O ' ' B' ' 71' ' ' ALA . 1.2 tt -107.76 122.94 62.78 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.3 tt0 -88.09 114.58 24.84 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.04 -1.037 . . . . 0.0 109.078 -179.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.63 HD11 HD13 ' B' ' 64' ' ' ILE . 2.2 mp -111.32 116.79 53.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.321 -0.862 . . . . 0.0 110.052 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.548 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 80.0 m 63.41 8.24 3.4 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.58 -0.7 . . . . 0.0 110.668 179.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 104.53 22.96 8.19 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.045 179.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -125.77 130.92 52.42 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.137 -1.214 . . . . 0.0 109.231 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.534 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -69.45 131.04 44.13 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.53 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.633 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.77 96.87 2.88 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.887 -179.569 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.742 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.18 136.43 24.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 107.985 -1.116 . . . . 0.0 107.985 179.125 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 1.0 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -163.6 -173.45 32.3 Favored Glycine 0 C--N 1.294 -1.792 0 C-N-CA 118.695 -1.716 . . . . 0.0 110.658 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 86.5 m -92.25 106.41 18.42 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.664 -0.903 . . . . 0.0 109.331 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.125 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -95.83 105.05 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.652 -0.655 . . . . 0.0 109.982 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.82 HD23 ' CE ' ' B' ' 45' ' ' LYS . 5.6 mp -78.99 116.82 19.54 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 178.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.559 ' CG1' ' HA ' ' B' ' 35' ' ' GLU . 79.6 t -110.86 118.16 56.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 120.945 -1.097 . . . . 0.0 110.695 -178.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.658 ' N ' HG12 ' B' ' 56' ' ' VAL . . . -157.24 -150.4 5.69 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.579 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -83.07 41.28 1.07 Allowed 'Trans proline' 0 C--N 1.311 -1.416 0 C-N-CA 122.959 2.439 . . . . 0.0 110.258 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.566 HG23 ' N ' ' B' ' 34' ' ' GLU . 3.5 t -90.17 129.75 44.61 Favored Pre-proline 0 N--CA 1.49 1.543 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 179.225 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.552 ' O ' HG22 ' B' ' 82' ' ' VAL . 36.3 Cg_endo -79.02 25.86 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.168 1.912 . . . . 0.0 111.558 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.552 HG22 ' O ' ' B' ' 81' ' ' PRO . 0.2 OUTLIER -161.4 154.01 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.719 -1.238 . . . . 0.0 110.785 -179.976 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.63 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 72.1 m-20 -96.38 83.05 3.48 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 175.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.856 HG23 ' CB ' ' B' ' 25' ' ' ASP . 12.4 mt -78.89 115.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.08 -1.013 . . . . 0.0 112.82 -175.248 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.824 ' HB ' HD23 ' B' ' 24' ' ' LEU . 1.4 mm -95.66 93.05 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' B' ' 25' ' ' ASP . . . -77.87 -169.84 34.43 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.12 -1.038 . . . . 0.0 111.008 -177.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.493 ' HD2' ' HA ' ' A' ' 8' ' ' ARG . 10.1 mtp85 -58.41 -37.56 75.59 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.931 -0.746 . . . . 0.0 110.766 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.01 ' ND2' HD23 ' B' ' 89' ' ' LEU . 14.3 p-10 -46.57 -26.9 0.98 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.554 -1.341 . . . . 0.0 109.451 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.01 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.4 mm? -110.56 -28.87 8.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.212 -0.93 . . . . 0.0 111.132 -178.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.654 HD21 HD22 ' B' ' 24' ' ' LEU . 66.9 mt -65.38 -22.25 66.77 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.745 -1.222 . . . . 0.0 108.29 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.428 ' CG2' ' NH2' ' B' ' 87' ' ' ARG . 82.7 p -83.63 -18.11 39.26 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 108.97 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -79.73 -41.76 26.02 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.881 . . . . 0.0 109.569 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.939 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.6 OUTLIER -82.89 -2.9 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.032 179.431 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 66.54 63.08 4.12 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.623 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -86.29 161.94 18.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.399 -1.059 . . . . 0.0 109.967 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.6 p -141.4 129.92 22.62 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.206 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.901 HD11 HD11 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -99.9 94.4 6.28 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -179.872 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.514 ' N ' ' ND2' ' B' ' 98' ' ' ASN . 0.8 OUTLIER -105.26 130.88 53.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 110.851 -178.49 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.838 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 117.982 -1.009 . . . . 0.0 109.143 179.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.873 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.437 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 3.3 Cg_exo . . . . . 0 N--CA 1.497 1.692 0 N-CA-C 110.76 -0.515 . . . . 0.0 110.76 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.8 tt0 -83.51 142.42 30.92 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.405 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 51.9 t -141.32 128.76 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 C-N-CA 118.012 -1.475 . . . . 0.0 111.047 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.481 ' OG1' ' N ' ' A' ' 5' ' ' LEU . 1.3 p -132.34 -57.26 0.96 Allowed 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.205 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.0 OUTLIER 39.0 28.24 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.548 -0.72 . . . . 0.0 110.414 179.352 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.491 ' C ' ' O ' ' A' ' 5' ' ' LEU . 4.4 m95 18.02 43.91 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.411 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' A' ' 5' ' ' LEU . 15.9 mm100 -158.78 -111.5 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.164 -0.96 . . . . 0.0 108.855 179.385 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 77.1 mtt180 -111.98 134.06 21.49 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 120.621 -1.3 . . . . 0.0 109.352 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.6 Cg_endo -81.18 54.4 5.19 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 C-N-CA 122.357 2.038 . . . . 0.0 110.057 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.743 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -80.72 146.77 30.89 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.946 -1.096 . . . . 0.0 109.69 -179.495 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.643 HG21 HG12 ' A' ' 66' ' ' ILE . 2.4 m -138.03 136.11 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.2 -179.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.663 HG22 HD22 ' A' ' 19' ' ' LEU . 94.9 m -60.35 113.65 2.51 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -106.24 137.02 38.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 O-C-N 121.091 -1.006 . . . . 0.0 110.419 -178.684 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 2.7 ttpt -110.45 105.17 14.05 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.407 -0.808 . . . . 0.0 109.049 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.806 HD11 HD12 ' A' ' 64' ' ' ILE . 40.8 mt -118.42 122.01 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.121 -0.987 . . . . 0.0 109.887 -179.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.02 10.86 59.95 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 178.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.16 -7.02 60.05 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.6 178.36 6.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -1.109 . . . . 0.0 108.987 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 11.3 mt -151.06 129.66 12.24 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.236 -0.915 . . . . 0.0 110.74 -179.663 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 19' ' ' LEU . 0.0 OUTLIER -150.61 157.0 42.46 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.743 ' HB3' HD22 ' A' ' 10' ' ' LEU . 61.6 mt-10 -77.94 131.36 37.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.576 -1.327 . . . . 0.0 108.428 -179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.886 ' HB1' HD13 ' A' ' 85' ' ' ILE . . . -107.7 148.03 29.96 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.086 -1.009 . . . . 0.0 110.235 -178.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.906 HD21 ' O ' ' B' ' 27' ' ' GLY . 30.9 tp -98.9 95.85 7.45 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.163 0.506 . . . . 0.0 110.431 -178.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.536 HD22 ' HB ' ' A' ' 85' ' ' ILE . 0.2 OUTLIER -47.16 115.7 1.17 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 178.916 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.594 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 12.8 t70 -131.8 108.18 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.747 -1.221 . . . . 0.0 111.15 -178.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 1.013 HG23 HD13 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -79.97 -2.59 44.6 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.817 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.48 ' HA3' ' OD2' ' B' ' 25' ' ' ASP . . . -80.74 -21.66 63.32 Favored Glycine 0 N--CA 1.485 1.94 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -97.84 161.83 13.55 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.131 -1.217 . . . . 0.0 109.892 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.54 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 50.4 m-20 -92.85 -20.1 21.03 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.406 -0.809 . . . . 0.0 110.919 -179.083 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.2 OUTLIER -139.17 -169.08 2.58 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.621 -1.3 . . . . 0.0 110.203 -179.438 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 1.006 ' O ' HD12 ' A' ' 76' ' ' LEU . 21.5 m -103.56 107.15 17.88 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.12 -0.988 . . . . 0.0 109.76 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.821 HG12 HG13 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -97.89 126.23 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.972 0 O-C-N 121.076 -1.015 . . . . 0.0 110.003 -179.469 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.046 HD13 ' CG1' ' A' ' 75' ' ' VAL . 3.8 mp -120.88 124.82 45.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.772 -1.205 . . . . 0.0 111.277 -178.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 80' ' ' THR . 3.2 pt-20 -43.77 163.45 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.295 -0.962 . . . . 0.0 108.525 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.418 ' C ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -44.25 137.84 3.32 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.033 -1.042 . . . . 0.0 110.212 -179.409 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.6 ptm -146.71 -163.16 1.69 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.516 ' N ' ' HG3' ' A' ' 36' ' ' MET . 8.4 t -108.22 84.3 1.92 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.975 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.825 HD12 HG21 ' A' ' 77' ' ' VAL . 13.4 mt -108.84 165.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.214 -0.929 . . . . 0.0 108.993 179.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 33.0 Cg_endo -73.45 -167.36 0.36 Allowed 'Trans proline' 0 C--N 1.313 -1.328 0 C-N-CA 122.369 2.046 . . . . 0.0 111.37 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.32 33.03 6.9 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.111 -1.042 . . . . 0.0 110.503 -178.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.63 53.99 0.7 Allowed 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.624 -0.927 . . . . 0.0 108.616 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.628 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 51.2 p-90 -131.6 -168.75 2.07 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.623 0.725 . . . . 0.0 110.616 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 42' ' ' TRP . 15.3 mttt -147.17 131.07 8.41 Favored Pre-proline 0 N--CA 1.49 1.53 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -76.2 141.22 23.08 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.126 1.884 . . . . 0.0 111.042 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.428 ' NZ ' HD23 ' A' ' 76' ' ' LEU . 1.3 ptpp? -152.38 177.06 10.99 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.403 ' N ' ' HG3' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -129.65 124.75 34.42 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.079 -1.013 . . . . 0.0 108.842 179.507 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.798 HD12 HG21 ' B' ' 50' ' ' ILE . 4.9 pt -96.42 149.87 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 118.946 -1.101 . . . . 0.0 109.238 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.646 ' CA ' ' CD2' ' A' ' 53' ' ' PHE . . . -122.48 108.9 1.32 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.79 -124.03 2.41 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 119.388 -1.387 . . . . 0.0 110.453 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.673 HD12 H702 ' B' ' 100' ' ' DMP . 64.7 mt -85.56 128.86 38.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.713 -0.875 . . . . 0.0 112.343 -177.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 93.24 -48.99 2.41 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.87 -157.78 26.22 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.646 ' CD2' ' CA ' ' A' ' 48' ' ' GLY . 3.5 m-85 -111.82 143.54 42.6 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -1.113 . . . . 0.0 109.573 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.609 HD11 HD11 ' A' ' 47' ' ' ILE . 3.8 pt -119.11 150.77 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.184 -0.947 . . . . 0.0 108.975 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.555 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 14.8 mttp -90.16 118.58 29.79 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.11 -0.994 . . . . 0.0 109.925 -179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.868 HG12 ' HA3' ' A' ' 78' ' ' GLY . 14.9 m -125.56 -167.5 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.075 -1.015 . . . . 0.0 109.433 179.226 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.415 ' O ' HD23 ' A' ' 76' ' ' LEU . 75.1 mtt85 -125.76 173.82 8.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.278 -0.889 . . . . 0.0 109.493 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 3.4 tt0 -130.77 123.93 30.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.409 -0.807 . . . . 0.0 109.919 -179.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 41.9 m-85 -121.14 91.36 3.51 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 20.3 m-20 -78.98 133.26 36.86 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.098 -1.001 . . . . 0.0 109.692 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 1.6 mt-30 83.36 57.98 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 CA-C-O 121.482 0.658 . . . . 0.0 109.379 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.715 ' CG2' HG23 ' A' ' 15' ' ' ILE . 3.0 mm -114.3 114.03 45.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.681 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.0 OUTLIER -70.27 87.22 0.6 Allowed 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.271 -178.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.806 HD12 HD11 ' A' ' 15' ' ' ILE . 13.5 tt -88.5 123.68 41.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.495 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -89.46 106.19 18.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.985 -1.072 . . . . 0.0 109.038 -178.995 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.71 HG13 HG22 ' A' ' 13' ' ' ILE . 0.5 OUTLIER -106.13 123.22 60.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.009 -179.621 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 13.6 m 49.11 69.12 0.61 Allowed 'General case' 0 C--N 1.293 -1.854 0 O-C-N 121.486 -0.759 . . . . 0.0 110.452 179.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 42.59 27.3 0.5 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.516 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 1.3 m-70 -122.97 130.74 53.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.897 -1.355 . . . . 0.0 109.065 179.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -75.01 133.21 41.71 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 108.837 179.404 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.47 108.32 2.94 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.876 . . . . 0.0 110.459 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.681 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.8 OUTLIER -85.48 152.45 3.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 177.971 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.42 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.7 -178.32 45.43 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.206 -1.949 . . . . 0.0 111.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.1 m -92.66 106.36 18.35 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.627 -0.925 . . . . 0.0 110.139 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.046 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.3 t -97.01 176.65 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 1.006 HD12 ' O ' ' A' ' 31' ' ' THR . 1.9 mp -139.4 161.48 37.35 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.966 -1.084 . . . . 0.0 108.288 178.127 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.825 HG21 HD12 ' A' ' 38' ' ' LEU . 19.5 t -143.47 105.46 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.91 0 O-C-N 121.379 -0.825 . . . . 0.0 109.734 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.868 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.7 -162.49 10.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.555 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.8 Cg_endo -80.3 40.18 0.94 Allowed 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.473 2.116 . . . . 0.0 110.705 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 34' ' ' GLU . 9.5 t -85.59 132.75 43.61 Favored Pre-proline 0 C--N 1.3 -1.572 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 179.056 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.474 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 33.0 Cg_endo -77.92 17.5 0.99 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.407 2.071 . . . . 0.0 111.356 -179.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.606 HG13 ' O ' ' A' ' 83' ' ' ASN . 1.1 t -162.22 162.22 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.837 -1.165 . . . . 0.0 109.983 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.646 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -96.94 154.38 17.33 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 104.142 -2.54 . . . . 0.0 104.142 175.21 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.821 HG13 HG12 ' A' ' 32' ' ' VAL . 1.1 mm -144.2 134.18 20.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.875 0 O-C-N 120.057 -1.652 . . . . 0.0 109.963 -178.244 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.886 HD13 ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.16 88.97 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 177.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.61 -164.45 22.81 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.905 -1.14 . . . . 0.0 110.278 -177.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.565 ' HD2' ' O ' ' B' ' 7' ' ' GLN . 0.0 OUTLIER -61.82 -35.62 78.78 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.624 -0.927 . . . . 0.0 109.567 -179.134 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.018 ' ND2' HD23 ' A' ' 89' ' ' LEU . 8.1 p-10 -45.15 -25.07 0.31 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.224 -0.923 . . . . 0.0 108.891 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.018 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -112.91 -29.17 7.46 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 121.375 -0.828 . . . . 0.0 110.472 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 1.013 HD13 HG23 ' A' ' 26' ' ' THR . 77.7 mt -68.25 -7.26 29.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.967 -1.083 . . . . 0.0 109.157 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.48 -19.69 15.42 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.162 -0.961 . . . . 0.0 108.607 179.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 82.9 mm-40 -80.65 -41.17 24.27 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.222 -0.924 . . . . 0.0 108.874 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.624 HD12 ' CG ' ' B' ' 99' ' ' PHE . 3.7 pt -83.77 -5.61 9.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 74.01 34.28 55.89 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.577 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -64.25 151.9 42.38 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.057 -1.261 . . . . 0.0 110.624 -179.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 30.9 p -148.32 128.21 13.5 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' B' ' 97' ' ' LEU . 3.0 mp -87.81 95.05 9.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.11 -0.994 . . . . 0.0 109.443 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.591 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 1.0 OUTLIER -114.46 129.97 56.69 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 110.674 -179.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.601 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.172 178.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' ASN . 2.9 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 N-CA-C 109.744 -0.906 . . . . 0.0 109.744 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.591 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 2.2 tt0 -81.92 149.63 28.13 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 178.249 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.517 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 61.2 t -148.46 96.2 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 117.832 -1.547 . . . . 0.0 110.868 -178.301 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.447 ' O ' ' N ' ' B' ' 6' ' ' TRP . 71.3 p -100.75 -55.67 2.52 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.653 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.2 OUTLIER 43.99 18.99 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.757 -0.589 . . . . 0.0 111.524 178.718 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.537 ' C ' ' O ' ' B' ' 5' ' ' LEU . 6.3 m95 18.53 43.15 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.274 0 CA-C-N 118.096 0.407 . . . . 0.0 111.895 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.653 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -170.85 -103.3 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 63.8 mtt180 -113.58 127.87 26.34 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 120.351 -1.468 . . . . 0.0 110.252 -179.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.474 ' O ' ' HG ' ' B' ' 24' ' ' LEU . 36.7 Cg_endo -78.99 71.48 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 121.94 1.76 . . . . 0.0 108.335 177.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.545 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -93.93 152.21 19.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.117 -0.989 . . . . 0.0 110.933 -178.083 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.57 HG21 HG23 ' B' ' 66' ' ' ILE . 2.0 m -151.03 150.39 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.663 -0.648 . . . . 0.0 109.414 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.878 HG22 HD22 ' B' ' 19' ' ' LEU . 99.7 m -78.16 115.45 17.89 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.733 ' O ' HD23 ' B' ' 19' ' ' LEU . 2.5 pp -103.89 151.4 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.024 -1.048 . . . . 0.0 110.507 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.543 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 0.1 OUTLIER -109.47 102.87 11.7 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.198 -0.939 . . . . 0.0 109.694 179.804 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.854 HD13 HG11 ' B' ' 75' ' ' VAL . 3.9 mt -121.37 134.28 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.986 -1.071 . . . . 0.0 110.159 -179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.494 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 58.66 27.24 61.12 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 179.317 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.13 27.3 66.55 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm-40 -124.41 -178.76 4.21 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.464 -1.021 . . . . 0.0 109.121 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 HG22 ' B' ' 12' ' ' THR . 19.8 mt -147.45 125.27 11.92 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 0.0 109.706 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.487 ' HG2' ' O ' ' B' ' 19' ' ' LEU . 6.2 mmtt -144.5 169.28 18.26 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.545 ' HB3' HD22 ' B' ' 10' ' ' LEU . 9.4 mt-10 -79.69 135.43 36.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.015 -1.053 . . . . 0.0 108.442 179.558 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.603 ' HB1' HD11 ' B' ' 85' ' ' ILE . . . -121.9 135.45 54.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.983 -1.073 . . . . 0.0 110.669 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' HG ' ' B' ' 10' ' ' LEU . 15.5 tp -92.04 94.1 9.08 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.48 HD23 ' CG1' ' B' ' 85' ' ' ILE . 14.2 mt -45.83 101.47 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.989 -1.069 . . . . 0.0 108.719 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.724 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.4 t70 -101.59 96.75 7.32 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.754 -0.591 . . . . 0.0 110.419 -178.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.788 ' OG1' HD21 ' A' ' 97' ' ' LEU . 24.6 m -79.68 13.49 2.07 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.234 -0.916 . . . . 0.0 109.486 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.906 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -109.83 -19.33 8.26 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -82.37 170.46 15.29 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.93 -1.336 . . . . 0.0 109.141 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -99.92 -18.08 17.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.196 -0.94 . . . . 0.0 110.088 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.54 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 16.1 m-20 -142.97 -155.16 0.57 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.064 -1.022 . . . . 0.0 109.658 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.57 ' OG1' ' HG ' ' B' ' 89' ' ' LEU . 78.5 m -120.19 97.82 5.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.511 -1.368 . . . . 0.0 111.262 -177.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.044 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -76.83 174.87 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.073 -1.017 . . . . 0.0 108.445 178.969 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.044 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.04 119.46 0.61 Allowed 'General case' 0 N--CA 1.487 1.406 0 O-C-N 120.765 -1.209 . . . . 0.0 110.936 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' B' ' 80' ' ' THR . 41.6 tt0 -36.66 158.77 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 CA-C-O 121.453 0.644 . . . . 0.0 110.009 179.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.506 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -52.42 147.31 8.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.497 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.449 ' SD ' ' HB2' ' B' ' 38' ' ' LEU . 0.0 OUTLIER 179.55 178.35 0.54 Allowed 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 2.6 t -92.49 101.62 14.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.074 -1.017 . . . . 0.0 109.563 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.658 HD13 HG22 ' B' ' 15' ' ' ILE . 58.0 tp -130.69 98.24 20.1 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.866 . . . . 0.0 109.119 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -78.76 -177.77 4.15 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.618 2.212 . . . . 0.0 110.393 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 113.63 31.65 2.29 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.42 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.481 ' O ' ' O ' ' B' ' 40' ' ' GLY . 49.0 mtm180 59.78 141.44 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.901 -0.764 . . . . 0.0 109.401 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 47.9 p-90 -160.3 -172.13 3.46 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.782 -1.199 . . . . 0.0 110.832 -179.286 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.495 ' HD3' ' HD2' ' B' ' 44' ' ' PRO . 1.8 mmtp -148.27 145.16 19.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . 0.495 ' HD2' ' HD3' ' B' ' 43' ' ' LYS . 35.8 Cg_endo -78.16 136.24 14.34 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 122.018 1.812 . . . . 0.0 110.932 -179.595 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.581 ' HD3' HD23 ' B' ' 76' ' ' LEU . 0.3 OUTLIER -160.29 -168.79 2.27 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.456 -0.778 . . . . 0.0 109.592 179.427 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.524 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 60.5 mtp -150.53 138.31 19.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.452 -0.78 . . . . 0.0 109.676 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.669 ' CD1' HG21 ' A' ' 50' ' ' ILE . 4.9 pt -95.93 150.09 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.03 -1.044 . . . . 0.0 108.535 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.82 102.53 0.94 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.41 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -126.81 -135.84 4.25 Favored Glycine 0 N--CA 1.483 1.821 0 C-N-CA 119.324 -1.417 . . . . 0.0 111.015 -178.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.798 HG21 HD12 ' A' ' 47' ' ' ILE . 46.1 mt -79.87 119.63 29.66 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.855 -0.791 . . . . 0.0 112.912 -177.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.518 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 104.97 -54.47 0.61 Allowed Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.076 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.02 -159.62 20.78 Favored Glycine 0 N--CA 1.492 2.378 0 O-C-N 120.947 -1.325 . . . . 0.0 110.201 -179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.607 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-85 -118.9 125.85 50.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.475 -1.015 . . . . 0.0 109.161 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.457 ' CG1' ' CG1' ' B' ' 47' ' ' ILE . 5.2 pt -97.81 173.19 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.255 -0.903 . . . . 0.0 109.438 -179.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mtmt -109.03 125.58 52.23 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.147 -0.971 . . . . 0.0 109.626 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.652 HG12 ' HA3' ' B' ' 78' ' ' GLY . 15.6 m -134.86 168.76 22.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.137 -0.977 . . . . 0.0 110.279 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 18.4 mtt180 -110.33 111.41 22.68 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.588 ' CG ' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -69.04 121.69 17.18 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.409 -0.807 . . . . 0.0 110.471 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.6 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 23.9 m-85 -116.05 93.69 4.35 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 6.4 m-20 -77.6 124.97 28.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.8 -178.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 48.6 mt-30 88.81 60.41 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 CA-C-O 121.32 0.581 . . . . 0.0 110.105 179.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.909 HG21 HG21 ' B' ' 75' ' ' VAL . 19.0 mm -115.57 109.82 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.241 -0.912 . . . . 0.0 109.116 179.498 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.93 HD21 ' HG2' ' B' ' 70' ' ' LYS . 3.0 tm? -65.27 85.56 0.06 Allowed 'General case' 0 N--CA 1.492 1.644 0 CA-C-O 122.033 0.92 . . . . 0.0 110.717 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.652 HG21 ' CD1' ' B' ' 89' ' ' LEU . 0.6 OUTLIER -92.16 119.68 40.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 177.37 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.5 tt0 -87.14 128.84 35.12 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.163 -0.961 . . . . 0.0 108.957 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.57 HG23 HG21 ' B' ' 11' ' ' VAL . 0.9 OUTLIER -114.9 129.76 70.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.014 -179.313 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 86.2 m 54.52 -91.27 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.574 -0.704 . . . . 0.0 109.804 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -147.18 40.82 0.98 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.497 ' CB ' HG22 ' B' ' 93' ' ' ILE . 17.6 m-70 -145.72 149.58 34.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -1.046 . . . . 0.0 109.287 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.93 ' HG2' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -79.04 139.63 38.11 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.077 -1.014 . . . . 0.0 109.467 -179.805 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.522 ' O ' ' CG2' ' B' ' 64' ' ' ILE . . . -147.62 109.55 4.47 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.081 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.577 HG12 ' HA ' ' B' ' 63' ' ' LEU . 0.0 OUTLIER -94.88 145.46 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.215 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.786 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -169.22 -178.09 40.32 Favored Glycine 0 C--N 1.297 -1.636 0 C-N-CA 118.442 -1.837 . . . . 0.0 111.083 179.562 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.588 ' CG2' ' CG ' ' B' ' 58' ' ' GLN . 9.1 m -87.73 100.54 12.91 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 122.139 -0.624 . . . . 0.0 109.951 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.909 HG21 HG21 ' B' ' 62' ' ' ILE . 1.3 t -85.54 121.11 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.053 179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.581 HD23 ' HD3' ' B' ' 45' ' ' LYS . 2.6 mp -96.73 104.25 16.23 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' B' ' 35' ' ' GLU . 21.8 t -93.45 112.03 25.83 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.04 -1.038 . . . . 0.0 109.993 -179.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.652 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -149.67 -160.85 9.45 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.556 -1.817 . . . . 0.0 108.556 179.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.539 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -79.98 38.31 0.73 Allowed 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.388 2.059 . . . . 0.0 110.973 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.678 HG21 HG13 ' B' ' 32' ' ' VAL . 1.8 t -81.98 134.96 48.79 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.584 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.9 Cg_endo -79.04 15.14 1.57 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.583 2.189 . . . . 0.0 111.311 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.584 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.2 t -160.59 161.01 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.999 -1.063 . . . . 0.0 109.804 -179.415 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.559 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.9 OUTLIER -98.24 129.12 44.98 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 104.157 -2.534 . . . . 0.0 104.157 175.51 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.724 HG23 ' HB2' ' B' ' 25' ' ' ASP . 5.0 mm -117.12 129.38 73.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.957 0 O-C-N 120.331 -1.481 . . . . 0.0 111.923 -176.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.62 HG23 HD12 ' B' ' 89' ' ' LEU . 3.4 mm -102.19 105.19 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 176.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -98.8 -163.65 30.14 Favored Glycine 0 N--CA 1.496 2.691 0 C-N-CA 119.826 -1.178 . . . . 0.0 111.823 -177.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.587 ' NH1' ' HG2' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -53.28 -40.91 65.06 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 122.005 -0.703 . . . . 0.0 111.714 -178.193 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.747 ' C ' HD23 ' B' ' 89' ' ' LEU . 53.0 p-10 -48.14 -26.16 1.77 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.548 -1.345 . . . . 0.0 111.007 -177.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.786 HD21 ' HA3' ' B' ' 73' ' ' GLY . 2.3 mt -115.31 -27.77 7.12 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.32 -1.487 . . . . 0.0 111.602 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.772 ' HA ' HD11 ' B' ' 93' ' ' ILE . 3.5 mt -63.38 -11.77 25.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.212 -1.555 . . . . 0.0 108.259 -179.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -101.67 -19.65 15.33 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.196 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 69.9 mm-40 -79.16 -41.23 28.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.726 -0.608 . . . . 0.0 110.581 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.772 HD11 ' HA ' ' B' ' 90' ' ' LEU . 1.0 OUTLIER -80.44 -22.12 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 179.52 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' N ' HD12 ' B' ' 93' ' ' ILE . . . 103.02 35.48 3.68 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.507 ' HA ' ' HD1' ' A' ' 99' ' ' PHE . . . -72.43 135.68 45.83 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.388 -1.066 . . . . 0.0 111.185 -178.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 75.1 p -136.66 128.87 29.78 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.831 HD11 HD11 ' A' ' 97' ' ' LEU . 6.3 mp -83.49 105.32 14.33 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.168 -0.958 . . . . 0.0 108.68 -179.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.487 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 5.9 m120 -103.53 122.62 45.32 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.049 -1.032 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.624 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.135 179.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.787 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.497 1.711 0 N-CA-C 110.178 -0.739 . . . . 0.0 110.178 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.544 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.4 OUTLIER -83.16 148.94 27.17 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 106.471 -1.677 . . . . 0.0 106.471 177.815 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' A' ' 9' ' ' PRO . 2.3 t -140.76 105.98 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 117.295 -1.762 . . . . 0.0 111.902 -178.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.563 ' O ' ' N ' ' A' ' 6' ' ' TRP . 0.2 OUTLIER -122.05 -69.03 0.85 Allowed 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 176.694 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.575 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.8 OUTLIER 31.76 29.94 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.964 177.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.563 ' N ' ' O ' ' A' ' 4' ' ' THR . 17.3 m95 18.88 48.37 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.145 0 CA-C-O 121.331 0.586 . . . . 0.0 111.871 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.575 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -164.25 -175.5 3.99 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.172 -0.955 . . . . 0.0 109.401 179.8 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.486 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 1.6 mtt180 -76.38 119.27 76.61 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.267 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.532 ' HB3' ' CG1' ' A' ' 3' ' ' VAL . 35.3 Cg_endo -79.11 74.52 5.51 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.833 1.689 . . . . 0.0 108.92 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.425 ' HG ' ' HA ' ' A' ' 23' ' ' LEU . 0.4 OUTLIER -80.69 150.65 29.28 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.532 -0.73 . . . . 0.0 110.455 -178.609 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.605 ' O ' ' HB3' ' A' ' 22' ' ' ALA . 2.0 m -150.05 162.04 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.413 -0.804 . . . . 0.0 109.33 179.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.424 HG22 HD22 ' A' ' 19' ' ' LEU . 42.5 m -96.12 114.04 25.7 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.897 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.0 OUTLIER -97.95 171.74 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.899 . . . . 0.0 109.901 -178.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.516 ' HE3' HD11 ' A' ' 19' ' ' LEU . 6.5 tttt -131.78 102.38 5.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 109.406 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.756 HD13 HG11 ' A' ' 75' ' ' VAL . 48.6 mt -118.44 132.09 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 120.984 -1.072 . . . . 0.0 109.902 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.26 40.13 98.16 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.03 18.45 60.12 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.499 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.3 mm-40 -112.89 171.62 7.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.336 -1.097 . . . . 0.0 109.094 179.666 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 13' ' ' ILE . 14.4 mt -142.9 126.92 17.34 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.218 -0.926 . . . . 0.0 110.3 -179.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.482 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 7.2 mttt -143.52 -167.7 2.64 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 178.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 43.5 mt-10 -79.4 -167.82 1.32 Allowed 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.989 -1.07 . . . . 0.0 108.145 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.706 ' CB ' HG23 ' A' ' 13' ' ' ILE . . . -171.3 86.85 0.09 Allowed 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.085 -1.009 . . . . 0.0 109.454 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.578 ' O ' ' N ' ' A' ' 25' ' ' ASP . 36.5 tp -72.47 95.35 1.77 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.346 -0.846 . . . . 0.0 109.032 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.493 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 49.6 mt -48.93 90.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' N ' ' O ' ' A' ' 23' ' ' LEU . 0.6 OUTLIER -99.52 92.98 5.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.49 -0.756 . . . . 0.0 110.825 -177.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 1.022 ' OG1' HD21 ' B' ' 97' ' ' LEU . 1.5 m -73.11 -2.03 19.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.994 -1.082 . . . . 0.0 108.574 178.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.556 ' CA ' ' HA ' ' B' ' 25' ' ' ASP . . . -83.84 -36.36 13.74 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.91 136.74 36.73 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.086 -1.244 . . . . 0.0 109.686 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 87' ' ' ARG . 19.3 m-20 -64.15 -19.2 65.13 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.434 -0.791 . . . . 0.0 111.126 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.744 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.7 OUTLIER -141.79 -179.28 6.1 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.121 -1.432 . . . . 0.0 110.987 -179.324 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.662 HG22 ' CD1' ' A' ' 33' ' ' LEU . 2.3 m -96.18 89.41 5.13 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.471 -0.768 . . . . 0.0 110.612 -178.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.7 OUTLIER -69.38 163.28 3.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.729 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.033 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -158.45 131.72 7.43 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.112 -0.993 . . . . 0.0 110.691 -178.558 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.461 ' N ' ' CG2' ' A' ' 80' ' ' THR . 57.7 tt0 -43.44 164.77 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 178.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.538 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.7 OUTLIER -56.91 134.56 55.6 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.149 -0.97 . . . . 0.0 110.703 -179.285 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' VAL . 2.2 ppp? -162.63 -167.56 1.59 Allowed 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.4 t -106.5 138.33 42.88 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.831 -1.168 . . . . 0.0 110.451 -179.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.837 HD22 HD12 ' A' ' 62' ' ' ILE . 5.4 mt -143.33 171.1 7.4 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.606 ' HD2' ' HB3' ' A' ' 38' ' ' LEU . 29.3 Cg_endo -70.24 -153.65 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 121.853 1.702 . . . . 0.0 110.27 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.52 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -110.6 -167.25 19.27 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 -178.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.52 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.1 OUTLIER 73.07 54.6 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.113 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.662 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 3.9 p-90 -126.01 -176.84 3.75 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.791 0.805 . . . . 0.0 110.543 -178.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.41 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 14.0 mttp -147.54 160.87 37.66 Favored Pre-proline 0 N--CA 1.489 1.517 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 179.115 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 43' ' ' LYS . 32.0 Cg_endo -75.78 147.48 31.15 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.166 1.91 . . . . 0.0 109.373 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.577 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -146.0 165.41 29.09 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.014 -1.054 . . . . 0.0 110.078 -178.932 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.406 ' SD ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -148.38 112.29 5.14 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 179.046 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 54' ' ' ILE . 6.7 pt -106.1 129.45 59.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 C-N-CA 118.48 -1.288 . . . . 0.0 109.467 -179.466 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -116.82 100.71 0.91 Allowed Glycine 0 N--CA 1.482 1.753 0 N-CA-C 107.15 -2.38 . . . . 0.0 107.15 179.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.464 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -119.18 -128.62 3.8 Favored Glycine 0 N--CA 1.479 1.565 0 C-N-CA 119.269 -1.443 . . . . 0.0 111.084 -177.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.806 HG21 HD11 ' B' ' 47' ' ' ILE . 59.1 mt -85.4 119.16 33.51 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 O-C-N 122.074 -0.663 . . . . 0.0 112.429 -177.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.495 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 109.79 -36.42 4.31 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 162.99 -162.09 34.41 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.492 -1.337 . . . . 0.0 110.147 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 2.7 m-85 -115.12 141.99 47.26 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.467 -1.02 . . . . 0.0 109.466 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.894 HD11 HD11 ' A' ' 47' ' ' ILE . 3.0 pt -128.51 178.24 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.509 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -112.66 138.06 50.0 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.05 -1.031 . . . . 0.0 109.405 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.7 HG12 ' HA3' ' A' ' 78' ' ' GLY . 33.5 m -144.09 161.61 15.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.294 -0.879 . . . . 0.0 109.35 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.564 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER -104.49 -176.63 3.14 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.145 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 42' ' ' TRP . 7.1 tt0 -137.6 101.45 4.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.006 . . . . 0.0 109.543 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.815 ' HB3' HD11 ' A' ' 62' ' ' ILE . 40.1 m-85 -103.41 95.73 6.27 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.424 -0.797 . . . . 0.0 109.517 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.5 OUTLIER -78.88 140.85 38.05 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.955 -1.091 . . . . 0.0 108.982 179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.516 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 76.38 64.06 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.819 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.837 HD12 HD22 ' A' ' 38' ' ' LEU . 21.4 mm -121.8 123.34 69.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.859 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.3 tm? -67.56 82.47 0.17 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.355 -0.841 . . . . 0.0 110.935 -178.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 1.028 ' CG2' HD11 ' A' ' 89' ' ' LEU . 2.5 tt -94.34 121.25 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.43 ' HG2' ' C ' ' A' ' 69' ' ' HIS . 1.7 tt0 -89.17 140.57 29.33 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.099 -1.001 . . . . 0.0 108.486 179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.821 HD11 ' CD1' ' A' ' 89' ' ' LEU . 0.4 OUTLIER -126.05 171.97 14.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 107.165 -1.421 . . . . 0.0 107.165 179.672 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.458 ' SG ' ' HB ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -47.96 -38.63 17.21 Favored 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 178.836 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.635 ' O ' ' CG ' ' A' ' 69' ' ' HIS . . . -52.79 -49.59 53.4 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 178.319 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.635 ' CG ' ' O ' ' A' ' 68' ' ' GLY . 5.2 m170 141.66 -173.39 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.076 0 CA-C-O 121.102 0.477 . . . . 0.0 109.838 178.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.533 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -36.56 139.51 0.18 Allowed 'General case' 0 N--CA 1.493 1.693 0 CA-C-O 121.351 0.596 . . . . 0.0 109.773 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -161.8 115.33 1.87 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.304 -0.872 . . . . 0.0 110.02 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.772 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -85.57 150.7 3.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.608 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -175.24 -154.92 11.73 Favored Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.262 -1.446 . . . . 0.0 110.835 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.494 ' HB ' ' OD1' ' A' ' 88' ' ' ASN . 1.4 m -109.7 111.95 23.73 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.246 -1.149 . . . . 0.0 110.087 -179.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.03 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -106.15 108.39 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.262 -0.899 . . . . 0.0 111.243 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.744 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.8 mp -79.12 139.55 38.02 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 177.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.56 ' CG2' HD12 ' A' ' 38' ' ' LEU . 1.3 t -116.2 112.47 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.084 -1.01 . . . . 0.0 110.978 -178.144 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.7 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -149.54 -172.17 18.83 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.2 Cg_endo -81.45 41.62 1.18 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.58 2.187 . . . . 0.0 110.681 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.632 HG21 HG13 ' A' ' 32' ' ' VAL . 3.8 t -79.3 141.56 57.62 Favored Pre-proline 0 N--CA 1.49 1.553 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.21 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.733 ' O ' HG23 ' A' ' 82' ' ' VAL . 38.2 Cg_endo -80.07 20.02 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.583 2.188 . . . . 0.0 110.872 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 81' ' ' PRO . 10.5 t -161.13 166.8 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 120.702 -1.248 . . . . 0.0 110.92 -178.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.545 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 7.8 m-80 -100.44 90.45 4.3 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 105.82 -1.919 . . . . 0.0 105.82 177.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.598 ' O ' ' HA ' ' A' ' 31' ' ' THR . 12.1 mm -79.14 120.04 29.59 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 O-C-N 121.183 -0.948 . . . . 0.0 112.379 -176.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.576 HD13 ' N ' ' A' ' 85' ' ' ILE . 3.3 mm -99.07 106.11 18.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 176.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.507 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -91.47 -152.18 27.94 Favored Glycine 0 N--CA 1.489 2.197 0 O-C-N 120.679 -1.263 . . . . 0.0 111.861 -176.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.774 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -70.7 -41.29 72.15 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 120.111 -0.636 . . . . 0.0 109.852 -179.032 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.57 ' OD1' ' HA ' ' A' ' 30' ' ' ASP . 0.4 OUTLIER -53.33 -16.39 1.33 Allowed 'General case' 0 N--CA 1.498 1.963 0 C-N-CA 117.821 -1.552 . . . . 0.0 110.422 -178.965 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.157 HD13 ' OE1' ' A' ' 92' ' ' GLN . 0.2 OUTLIER -105.76 -20.82 13.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.658 -1.276 . . . . 0.0 109.054 179.825 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.933 HD13 HG23 ' A' ' 26' ' ' THR . 28.7 mt -80.95 1.1 32.55 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 120.654 -1.279 . . . . 0.0 108.535 178.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.774 HG23 ' O ' ' A' ' 87' ' ' ARG . 0.3 OUTLIER -101.08 -10.06 20.83 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.137 -0.977 . . . . 0.0 111.159 -179.958 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 1.157 ' OE1' HD13 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -95.15 -40.81 9.41 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 120.467 -1.396 . . . . 0.0 109.562 -178.552 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.052 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.3 OUTLIER -80.48 3.3 2.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 119.013 -1.075 . . . . 0.0 108.349 178.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 69.87 53.05 16.71 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.575 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -77.27 144.98 37.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.121 -1.223 . . . . 0.0 109.271 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.95 HG22 HG22 ' B' ' 4' ' ' THR . 27.3 p -139.85 123.27 17.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.157 -0.964 . . . . 0.0 109.27 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.738 HD11 HD11 ' B' ' 97' ' ' LEU . 7.4 mp -84.72 100.61 11.61 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 178.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' B' ' 94' ' ' GLY . 18.5 m120 -99.17 120.01 38.8 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 120.447 -1.408 . . . . 0.0 108.934 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.64 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.298 -1.64 0 CA-C-O 118.101 -0.952 . . . . 0.0 109.282 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.7 Cg_exo . . . . . 0 N--CA 1.493 1.488 0 N-CA-C 109.917 -0.839 . . . . 0.0 109.917 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 130.7 35.14 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 56.3 t -123.57 109.04 22.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 118.947 -1.101 . . . . 0.0 109.595 -177.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 96' ' ' THR . 14.7 p -123.97 21.59 8.98 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.411 -0.806 . . . . 0.0 109.967 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.549 ' O ' ' C ' ' B' ' 6' ' ' TRP . 1.6 tp -88.82 27.31 1.34 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.023 -1.048 . . . . 0.0 108.758 178.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.763 ' HB3' HG22 ' A' ' 91' ' ' THR . 0.7 OUTLIER 14.98 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.685 0.755 . . . . 0.0 111.918 179.698 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.54 ' O ' ' HD3' ' B' ' 9' ' ' PRO . 1.0 OUTLIER -129.31 -152.46 0.52 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.448 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 26.5 mtt180 -103.72 101.43 24.37 Favored Pre-proline 0 N--CA 1.488 1.45 0 O-C-N 120.903 -1.123 . . . . 0.0 108.133 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.561 ' HD2' ' CZ ' ' A' ' 87' ' ' ARG . 33.9 Cg_endo -75.13 72.06 4.86 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.413 2.075 . . . . 0.0 110.698 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -89.78 142.88 27.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.017 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.781 HG23 HG23 ' B' ' 13' ' ' ILE . 21.9 m -131.15 126.05 58.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.106 -0.996 . . . . 0.0 110.526 -178.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . . . . . . . . . 1.3 m -67.34 99.88 0.76 Allowed 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 106.041 -1.837 . . . . 0.0 106.041 177.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.857 HG22 HG13 ' B' ' 66' ' ' ILE . 1.1 pp -95.91 140.53 16.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.242 -0.911 . . . . 0.0 111.298 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.519 ' HE3' HD11 ' B' ' 19' ' ' LEU . 0.1 OUTLIER -103.63 106.91 17.56 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 179.734 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.862 HD13 HG11 ' B' ' 75' ' ' VAL . 7.2 mt -119.68 115.65 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.206 -0.934 . . . . 0.0 110.154 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.48 27.78 73.13 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.606 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.77 12.3 81.63 Favored Glycine 0 N--CA 1.492 2.419 0 O-C-N 120.901 -1.353 . . . . 0.0 109.789 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 1.4 mt-30 -107.44 168.57 9.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.208 -1.172 . . . . 0.0 109.134 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.519 HD11 ' HE3' ' B' ' 14' ' ' LYS . 14.7 mt -140.48 122.95 16.06 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 0.0 109.514 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.517 ' CB ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mmtt -143.87 172.95 12.15 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.503 -0.748 . . . . 0.0 109.236 179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' B' ' 83' ' ' ASN . 31.1 mp0 -87.13 132.06 33.97 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.919 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -107.78 147.32 30.99 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.025 -1.047 . . . . 0.0 109.587 -179.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' B' ' 25' ' ' ASP . 18.6 tp -112.84 94.43 4.9 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.569 -0.707 . . . . 0.0 109.462 -179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.517 ' O ' ' HA2' ' A' ' 27' ' ' GLY . 0.0 OUTLIER -41.41 95.81 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.423 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.951 ' HB3' HG23 ' B' ' 84' ' ' ILE . 24.6 t0 -113.57 88.95 2.96 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.198 -0.939 . . . . 0.0 111.538 -178.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.81 HG23 HD22 ' B' ' 90' ' ' LEU . 0.2 OUTLIER -67.69 -19.67 65.2 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 177.265 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.457 ' CA ' ' HA ' ' A' ' 25' ' ' ASP . . . -55.57 -39.51 75.13 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 179.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.404 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -84.46 164.73 18.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.46 -1.023 . . . . 0.0 109.306 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.477 ' OD1' ' HG3' ' A' ' 8' ' ' ARG . 12.4 m-20 -94.96 -19.57 20.11 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.075 -1.016 . . . . 0.0 110.921 -178.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.947 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.9 OUTLIER -137.22 -175.71 4.14 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.747 -1.22 . . . . 0.0 110.198 -179.491 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.741 HG22 ' CD1' ' B' ' 33' ' ' LEU . 52.3 m -100.21 94.7 6.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.03 -1.044 . . . . 0.0 110.856 -178.224 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.037 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -75.05 158.72 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 179.092 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.037 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.5 OUTLIER -155.46 143.07 19.65 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 120.908 -1.12 . . . . 0.0 111.052 -178.092 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.729 ' N ' HG22 ' B' ' 80' ' ' THR . 20.2 tt0 -49.68 156.15 0.72 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' B' ' 78' ' ' GLY . 0.6 OUTLIER -61.69 132.78 54.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.076 -1.015 . . . . 0.0 109.609 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.568 ' HE2' HG22 ' B' ' 15' ' ' ILE . 3.8 ptm -153.33 -164.17 1.85 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.402 ' O ' HD22 ' B' ' 38' ' ' LEU . 28.5 t -102.96 118.12 36.1 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.037 -1.039 . . . . 0.0 110.49 -179.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.552 HD13 ' HD3' ' B' ' 39' ' ' PRO . 3.0 mm? -113.3 169.96 5.84 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.552 ' HD3' HD13 ' B' ' 38' ' ' LEU . 36.2 Cg_endo -79.95 52.02 4.14 Favored 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.696 2.264 . . . . 0.0 111.426 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 49.03 -163.0 0.5 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.2 mmm-85 60.25 84.87 0.12 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -1.14 . . . . 0.0 109.196 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.606 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 60.3 p-90 -159.57 176.54 11.92 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.509 0.671 . . . . 0.0 110.047 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.412 ' CG ' ' HD2' ' B' ' 44' ' ' PRO . 0.0 OUTLIER -139.38 159.68 64.95 Favored Pre-proline 0 N--CA 1.49 1.533 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.374 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' B' ' 43' ' ' LYS . 35.9 Cg_endo -77.95 139.53 17.44 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.21 1.94 . . . . 0.0 110.404 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.793 ' O ' HG22 ' B' ' 56' ' ' VAL . 10.1 tttt -155.53 131.14 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.439 -0.788 . . . . 0.0 109.197 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -110.85 130.68 55.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.099 -1.001 . . . . 0.0 109.289 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.806 HD11 HG21 ' A' ' 50' ' ' ILE . 24.3 pt -113.42 149.86 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.894 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.495 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.15 111.51 2.09 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 179.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.526 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -132.36 -126.08 2.7 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.188 -1.482 . . . . 0.0 111.161 -178.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.598 HG13 ' H62' ' B' ' 100' ' ' DMP . 19.3 mt -91.52 138.44 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 CA-C-O 122.056 0.932 . . . . 0.0 113.179 -177.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.542 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 80.18 -20.19 6.03 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 178.585 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 154.14 -169.44 32.61 Favored Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.649 -1.5 . . . . 0.0 110.321 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.546 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 4.5 m-85 -105.11 153.25 21.76 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.372 -1.075 . . . . 0.0 109.274 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.693 HD13 HG23 ' A' ' 50' ' ' ILE . 7.4 pt -127.11 159.81 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.225 -0.922 . . . . 0.0 109.807 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.529 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.4 OUTLIER -104.29 144.52 31.51 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.769 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.793 HG22 ' O ' ' B' ' 45' ' ' LYS . 23.9 m -142.9 -171.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.78 -1.2 . . . . 0.0 110.598 -178.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 11.4 mtt180 -137.85 88.87 2.36 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -47.41 98.82 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.463 -0.773 . . . . 0.0 110.962 -179.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.975 ' HB3' HD11 ' B' ' 62' ' ' ILE . 18.9 m-85 -91.78 127.54 37.27 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.935 ' OD1' HG23 ' B' ' 74' ' ' THR . 2.4 m-20 -107.69 135.22 49.48 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.785 -1.197 . . . . 0.0 110.632 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.585 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 1.1 mt-30 79.96 60.4 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.823 -0.548 . . . . 0.0 110.889 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 1.058 HD13 HG23 ' B' ' 75' ' ' VAL . 3.5 mp -113.96 119.94 62.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.086 -1.008 . . . . 0.0 109.275 179.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.848 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.9 tm? -68.59 83.51 0.28 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.506 -0.746 . . . . 0.0 110.505 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.761 HD12 HD11 ' B' ' 15' ' ' ILE . 12.5 tt -88.85 124.88 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.489 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 7.4 tt0 -90.28 100.13 13.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.085 -1.01 . . . . 0.0 109.414 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.857 HG13 HG22 ' B' ' 13' ' ' ILE . 0.5 OUTLIER -90.97 119.43 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 O-C-N 121.055 -1.028 . . . . 0.0 109.103 179.949 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.643 ' SG ' HG12 ' B' ' 11' ' ' VAL . 5.3 m 48.5 47.52 20.24 Favored 'General case' 0 C--N 1.291 -1.951 0 O-C-N 121.82 -0.55 . . . . 0.0 110.463 178.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.484 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 68.37 28.13 73.41 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.587 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 8.5 m170 -120.2 97.15 5.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.034 -1.274 . . . . 0.0 109.35 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.57 ' HG3' HD11 ' B' ' 63' ' ' LEU . 0.0 OUTLIER -50.44 126.81 16.07 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.239 -0.913 . . . . 0.0 109.159 179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.764 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -151.26 155.98 39.9 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.665 -0.647 . . . . 0.0 109.459 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.751 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.9 OUTLIER -119.22 153.33 21.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.717 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.419 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -175.61 -177.83 44.96 Favored Glycine 0 N--CA 1.491 2.33 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.453 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.935 HG23 ' OD1' ' B' ' 60' ' ' ASP . 2.7 m -91.18 108.56 19.95 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.706 -0.879 . . . . 0.0 109.877 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.058 HG23 HD13 ' B' ' 62' ' ' ILE . 1.4 t -103.35 112.46 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.401 -0.812 . . . . 0.0 110.328 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.947 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.9 mp -77.73 118.71 20.36 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.012 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' B' ' 56' ' ' VAL . 72.1 t -99.02 117.44 44.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 120.916 -1.115 . . . . 0.0 109.74 -179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.75 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.55 -168.52 18.73 Favored Glycine 0 N--CA 1.487 2.084 0 N-CA-C 108.116 -1.994 . . . . 0.0 108.116 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.529 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.0 Cg_endo -80.83 48.46 2.91 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 C-N-CA 122.263 1.975 . . . . 0.0 110.816 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.842 HG21 HG13 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -91.85 137.45 25.39 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.926 -1.109 . . . . 0.0 108.573 179.481 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.451 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.6 Cg_endo -79.54 19.6 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.557 2.171 . . . . 0.0 112.209 -178.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.76 ' H ' HG23 ' B' ' 80' ' ' THR . 1.1 t -161.23 172.74 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.541 -1.349 . . . . 0.0 110.287 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.585 ' N ' HG13 ' B' ' 82' ' ' VAL . 3.2 m-80 -107.55 79.53 1.3 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.452 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 1.003 HD11 ' C32' ' B' ' 100' ' ' DMP . 1.2 mp -76.8 126.02 37.1 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.374 -0.829 . . . . 0.0 111.48 -176.274 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.919 HD13 ' HB1' ' B' ' 22' ' ' ALA . 1.2 mp -96.14 99.94 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.549 ' C ' HD12 ' B' ' 90' ' ' LEU . . . -95.69 167.68 25.9 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.764 ' O ' HG23 ' B' ' 91' ' ' THR . 22.5 mmm180 -25.77 -39.41 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.265 0 O-C-N 121.818 -0.813 . . . . 0.0 112.826 -178.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.009 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.9 p-10 -49.79 -21.99 1.29 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.577 -1.327 . . . . 0.0 111.264 -178.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.009 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.2 mm? -110.58 -24.06 10.75 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.81 HD22 HG23 ' B' ' 26' ' ' THR . 3.8 mp -68.6 -8.69 44.14 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.764 HG23 ' O ' ' B' ' 87' ' ' ARG . 30.4 p -95.83 -20.22 18.99 Favored 'General case' 0 N--CA 1.485 1.307 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.775 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.504 ' HG3' ' O ' ' B' ' 72' ' ' ILE . 68.5 mm-40 -81.73 -41.46 21.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.137 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.64 HD12 ' CG ' ' A' ' 99' ' ' PHE . 1.9 pt -93.29 -2.82 10.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 98' ' ' ASN . . . 75.48 22.51 75.37 Favored Glycine 0 N--CA 1.494 2.529 0 O-C-N 121.516 -0.74 . . . . 0.0 111.488 178.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.573 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -65.27 123.66 20.15 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.708 -1.466 . . . . 0.0 110.457 -179.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 41.4 p -131.38 132.63 44.56 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 178.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 1.022 HD21 ' OG1' ' A' ' 26' ' ' THR . 4.8 mp -84.87 106.87 16.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.047 -1.033 . . . . 0.0 110.766 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.544 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 2.4 m120 -112.3 121.61 45.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.344 -0.847 . . . . 0.0 108.944 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 1.052 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.686 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.224 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 1.003 ' C32' HD11 ' B' ' 84' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.567 ' O ' ' CD1' ' B' ' 99' ' ' PHE . 3.0 Cg_endo . . . . . 0 N--CA 1.496 1.67 0 N-CA-C 110.398 -0.655 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.413 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.2 tt0 -88.16 139.37 30.57 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 42.8 t -145.54 155.86 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 109.943 -179.293 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.539 HG22 HG22 ' B' ' 96' ' ' THR . 1.1 p -127.66 -168.35 1.88 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.312 -0.868 . . . . 0.0 109.445 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.023 HD22 ' O ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -87.16 -26.89 23.37 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.215 -0.928 . . . . 0.0 109.065 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.589 ' N ' HD13 ' A' ' 5' ' ' LEU . 10.2 m95 -45.48 -22.72 0.16 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.629 -1.295 . . . . 0.0 109.06 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.478 ' N ' ' O ' ' A' ' 5' ' ' LEU . 34.6 mt-30 -146.25 110.32 4.98 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.705 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.462 ' C ' ' O ' ' A' ' 7' ' ' GLN . 14.6 mtm180 -40.95 148.17 0.39 Allowed Pre-proline 0 C--N 1.297 -1.713 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -179.591 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CG ' ' HB2' ' A' ' 24' ' ' LEU . 36.7 Cg_endo -79.71 47.88 2.67 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.579 2.186 . . . . 0.0 109.757 179.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.587 ' HA ' ' O ' ' A' ' 22' ' ' ALA . 0.2 OUTLIER -79.33 143.43 35.17 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.098 -1.001 . . . . 0.0 109.526 -179.222 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 HG23 ' A' ' 66' ' ' ILE . 0.7 OUTLIER -147.24 140.65 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.333 -178.734 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.752 HG22 HD22 ' A' ' 19' ' ' LEU . 78.4 m -74.32 96.78 2.89 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.876 HG22 HG13 ' A' ' 66' ' ' ILE . 4.2 pt -83.81 150.34 4.18 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 121.635 0.731 . . . . 0.0 111.041 -178.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.666 ' HE3' HD11 ' A' ' 19' ' ' LEU . 1.1 tttt -112.14 101.54 9.79 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.028 HD11 HD12 ' A' ' 64' ' ' ILE . 12.2 mt -122.51 138.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.225 -0.922 . . . . 0.0 109.308 -179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' HG2' ' A' ' 18' ' ' GLN . . . 52.11 43.37 56.2 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.14 35.83 66.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 8.0 mm100 -131.32 178.59 6.6 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -1.151 . . . . 0.0 109.186 179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.752 HD22 HG22 ' A' ' 12' ' ' THR . 39.5 mt -146.94 126.45 13.23 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.129 -0.982 . . . . 0.0 110.232 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.601 ' N ' ' HE2' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -146.85 163.34 36.38 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.709 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.557 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 49.3 mm-40 -79.39 137.23 37.21 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.97 -1.081 . . . . 0.0 109.113 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -119.98 156.07 31.59 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.852 -1.155 . . . . 0.0 110.594 -179.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.431 HD21 ' O ' ' B' ' 27' ' ' GLY . 12.3 tp -118.24 99.12 6.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.701 -0.624 . . . . 0.0 109.615 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.527 HD23 ' HB ' ' A' ' 85' ' ' ILE . 18.7 mt -48.34 106.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.878 -1.139 . . . . 0.0 108.932 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' CB ' HG23 ' A' ' 84' ' ' ILE . 54.2 t0 -109.24 98.39 7.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.301 -0.875 . . . . 0.0 109.829 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.724 HG22 HH12 ' A' ' 87' ' ' ARG . 0.2 OUTLIER -71.58 -5.01 30.18 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.303 -0.873 . . . . 0.0 108.748 179.087 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.827 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -83.58 -33.27 22.61 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.569 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -84.36 159.88 20.78 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.073 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.519 ' OD2' ' CZ ' ' B' ' 8' ' ' ARG . 16.8 m-20 -100.77 -13.66 18.36 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.3 -0.875 . . . . 0.0 110.629 -179.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.496 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -127.0 -173.54 2.92 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.982 -1.074 . . . . 0.0 109.545 -179.625 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.582 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 27.9 m -110.47 86.76 2.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.864 -1.147 . . . . 0.0 110.214 -179.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.4 OUTLIER -67.78 173.5 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.1 OUTLIER -169.85 115.2 0.53 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.838 -1.163 . . . . 0.0 110.983 -178.14 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.508 ' C ' ' O ' ' A' ' 33' ' ' LEU . 33.8 tt0 -33.85 150.05 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.879 -0.513 . . . . 0.0 109.649 178.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.649 ' HA ' HG12 ' A' ' 77' ' ' VAL . 1.1 tt0 -37.35 145.08 0.06 Allowed 'General case' 0 N--CA 1.495 1.783 0 CA-C-O 121.56 0.695 . . . . 0.0 110.674 -179.206 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.404 ' SD ' ' CD2' ' A' ' 38' ' ' LEU . 14.3 ptm -156.85 -170.8 3.42 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.0 t -127.77 90.77 3.16 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.827 -1.171 . . . . 0.0 111.364 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.637 ' HB2' ' CE1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -81.49 171.58 11.79 Favored Pre-proline 0 N--CA 1.493 1.716 0 N-CA-C 107.189 -1.411 . . . . 0.0 107.189 177.901 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.537 ' CD ' HD12 ' A' ' 38' ' ' LEU . 36.2 Cg_endo -79.3 43.52 1.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.614 2.21 . . . . 0.0 111.499 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.564 ' O ' ' CB ' ' A' ' 41' ' ' ARG . . . 54.72 111.15 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.034 -1.227 . . . . 0.0 110.034 179.449 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.564 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 157.79 57.74 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.909 . . . . 0.0 108.83 179.792 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.599 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 51.5 p-90 -141.1 179.18 6.89 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-O 121.849 0.833 . . . . 0.0 110.491 -178.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.452 ' HE3' ' HA ' ' A' ' 43' ' ' LYS . 0.0 OUTLIER -130.8 158.04 76.09 Favored Pre-proline 0 C--N 1.302 -1.475 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.783 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -76.32 141.92 23.47 Favored 'Trans proline' 0 C--N 1.303 -1.82 0 C-N-CA 122.144 1.896 . . . . 0.0 110.471 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.497 ' HB3' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -148.39 169.57 19.89 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.428 -0.795 . . . . 0.0 109.352 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.485 ' SD ' ' HB3' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -144.35 111.21 5.75 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.507 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.563 HD11 HD11 ' A' ' 54' ' ' ILE . 6.0 pt -92.33 142.52 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.856 -1.152 . . . . 0.0 109.093 -179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.621 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -122.8 105.08 0.92 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.529 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -124.68 -120.57 2.5 Favored Glycine 0 N--CA 1.483 1.785 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.097 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.865 HG21 HD11 ' B' ' 47' ' ' ILE . 26.3 mt -86.56 121.69 37.89 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.69 -0.888 . . . . 0.0 112.09 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 103.91 -55.71 0.61 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 179.76 -159.3 23.69 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.296 -1.521 . . . . 0.0 109.296 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.621 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.0 m-85 -107.43 131.79 53.9 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.235 -1.156 . . . . 0.0 109.887 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.589 ' CG2' ' N ' ' B' ' 51' ' ' GLY . 7.3 pt -107.98 134.63 49.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.923 -1.111 . . . . 0.0 108.857 178.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.537 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -70.94 148.58 47.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.103 -0.998 . . . . 0.0 110.057 -179.705 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.4 m -150.09 -169.77 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.215 -0.928 . . . . 0.0 109.418 179.725 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.595 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 3.7 mmt85 -133.56 105.11 6.7 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.608 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.503 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 0.0 OUTLIER -62.93 102.06 0.32 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.948 . . . . 0.0 110.448 -179.133 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.637 ' CE1' ' HB2' ' A' ' 38' ' ' LEU . 31.2 m-85 -92.62 90.68 7.22 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 108.858 179.113 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.529 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 3.4 m-20 -79.07 124.72 28.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.008 -1.057 . . . . 0.0 110.47 -179.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 2.7 mm-40 88.33 61.78 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 CA-C-O 121.383 0.611 . . . . 0.0 110.163 179.319 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.975 ' CG2' HG23 ' A' ' 15' ' ' ILE . 14.8 mm -117.82 116.53 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.108 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.953 ' O ' HD13 ' A' ' 63' ' ' LEU . 1.3 tm? -68.66 83.73 0.29 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.372 -0.83 . . . . 0.0 110.092 -179.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 1.028 HD12 HD11 ' A' ' 15' ' ' ILE . 11.8 tt -89.9 112.0 23.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 179.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.517 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 8.6 tp10 -91.63 120.44 32.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.11 -0.994 . . . . 0.0 109.228 -179.255 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.876 HG13 HG22 ' A' ' 13' ' ' ILE . 0.7 OUTLIER -107.01 121.01 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.179 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 60.04 -93.01 0.04 OUTLIER 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.606 -0.684 . . . . 0.0 110.053 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -138.92 27.37 2.68 Favored Glycine 0 N--CA 1.486 1.978 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.42 ' C ' ' OE1' ' A' ' 65' ' ' GLU . 9.6 m-70 -125.53 103.44 7.88 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.188 -1.184 . . . . 0.0 109.385 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.603 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -59.52 133.43 56.09 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.544 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.712 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -145.52 154.9 42.7 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.153 -0.967 . . . . 0.0 110.333 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.556 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -121.25 156.29 24.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 177.491 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.909 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 177.77 -177.77 48.37 Favored Glycine 0 N--CA 1.487 2.039 0 C-N-CA 117.876 -2.107 . . . . 0.0 112.084 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.503 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 91.0 m -90.62 105.12 17.6 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.921 -0.752 . . . . 0.0 109.713 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.902 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -98.63 107.06 19.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.688 -0.632 . . . . 0.0 110.079 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.543 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.8 mp -79.51 120.82 24.42 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.461 -0.774 . . . . 0.0 108.99 179.323 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.649 HG12 ' HA ' ' A' ' 35' ' ' GLU . 21.6 t -107.22 130.67 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.035 -1.041 . . . . 0.0 109.57 179.801 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.646 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -162.21 -159.4 10.23 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.039 -1.624 . . . . 0.0 109.039 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.537 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.72 38.32 0.73 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 122.606 2.204 . . . . 0.0 110.338 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.693 HG21 HG13 ' A' ' 32' ' ' VAL . 2.4 t -83.95 135.08 42.84 Favored Pre-proline 0 N--CA 1.489 1.519 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -78.5 16.82 1.18 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.428 2.085 . . . . 0.0 111.044 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.461 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -160.83 157.73 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.978 -1.076 . . . . 0.0 109.292 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -94.53 126.33 39.74 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 176.041 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.709 ' CG1' HG12 ' A' ' 32' ' ' VAL . 5.0 mm -111.57 122.57 66.19 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 O-C-N 120.486 -1.384 . . . . 0.0 112.384 -176.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.561 HG22 ' O ' ' A' ' 85' ' ' ILE . 0.9 OUTLIER -98.78 85.66 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 176.88 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -78.57 -157.02 9.97 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.34 -0.933 . . . . 0.0 111.461 -177.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.724 HH12 HG22 ' A' ' 26' ' ' THR . 0.0 OUTLIER -64.56 -33.06 75.03 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 122.009 -0.7 . . . . 0.0 111.265 -178.44 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.041 ' ND2' HD23 ' A' ' 89' ' ' LEU . 7.9 p-10 -55.9 -32.15 63.48 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.791 -1.193 . . . . 0.0 110.315 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.041 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.0 mm? -108.05 -19.95 13.33 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.993 -1.067 . . . . 0.0 110.516 -179.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.501 HD23 HD11 ' A' ' 93' ' ' ILE . 12.6 mt -69.9 -36.17 75.19 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 71.2 p -72.55 -20.83 61.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.512 -0.742 . . . . 0.0 109.057 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.449 ' OE1' ' HA ' ' A' ' 92' ' ' GLN . 9.4 mm100 -71.43 -40.18 70.58 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.697 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.4 OUTLIER -85.77 -2.18 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.55 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 65.82 60.36 6.6 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.669 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -81.41 151.72 27.77 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.365 -1.079 . . . . 0.0 110.052 -179.6 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 43.8 p -142.96 125.34 15.6 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' B' ' 97' ' ' LEU . 2.6 mp -91.0 94.27 9.56 Favored 'General case' 0 C--N 1.294 -1.824 0 O-C-N 121.612 -0.68 . . . . 0.0 109.17 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.531 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 2.3 m120 -104.79 129.0 53.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.127 -0.983 . . . . 0.0 110.285 -179.25 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 1.017 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.377 178.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.492 ' HD2' ' OXT' ' A' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 N-CA-C 110.383 -0.66 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.531 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 9.9 tt0 -83.59 129.81 34.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 96.2 t -130.41 107.19 14.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.718 -1.239 . . . . 0.0 110.692 -177.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.547 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.9 p -108.71 -59.56 1.86 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.603 ' O ' ' N ' ' B' ' 7' ' ' GLN . 84.5 mt 35.8 27.9 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.695 -0.628 . . . . 0.0 111.068 179.153 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.547 ' N ' ' O ' ' B' ' 4' ' ' THR . 8.4 m95 17.63 46.48 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.603 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.6 mt-30 -170.65 -166.86 0.53 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.108 -0.995 . . . . 0.0 109.941 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.554 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 2.3 mtm180 -67.78 112.75 11.36 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.474 -0.767 . . . . 0.0 109.545 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.795 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.4 Cg_endo -80.27 86.88 1.59 Allowed 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.204 1.936 . . . . 0.0 110.051 179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.473 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.5 OUTLIER -86.12 136.25 33.29 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.92 . . . . 0.0 109.524 -179.771 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' B' ' 22' ' ' ALA . 3.4 m -125.56 154.17 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.423 -0.798 . . . . 0.0 109.711 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.453 HG21 ' CD2' ' B' ' 19' ' ' LEU . 58.5 m -86.6 111.27 20.47 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 178.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.912 HD11 HD21 ' B' ' 33' ' ' LEU . 1.6 pp -97.76 141.7 15.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.184 -0.948 . . . . 0.0 110.447 -178.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.439 ' HG3' HD12 ' B' ' 19' ' ' LEU . 6.8 ttmm -109.4 96.05 6.03 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.346 -0.846 . . . . 0.0 109.316 179.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 1.095 HG23 ' CG2' ' B' ' 62' ' ' ILE . 7.3 mt -113.02 116.18 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.86 50.69 63.26 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 56.96 17.15 21.27 Favored Glycine 0 N--CA 1.49 2.248 0 O-C-N 121.224 -1.162 . . . . 0.0 110.287 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.506 ' HB2' ' O ' ' B' ' 15' ' ' ILE . 1.7 mt-30 -108.05 134.67 50.61 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.055 -1.262 . . . . 0.0 109.37 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.453 ' CD2' HG21 ' B' ' 12' ' ' THR . 0.3 OUTLIER -113.51 120.06 39.68 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.098 0.951 . . . . 0.0 110.302 -179.726 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.413 ' HB3' HD21 ' B' ' 83' ' ' ASN . 0.7 OUTLIER -141.04 178.55 7.3 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.094 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.552 ' O ' ' CB ' ' B' ' 83' ' ' ASN . 4.1 mt-10 -85.46 178.18 7.52 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 120.802 -1.186 . . . . 0.0 108.812 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.914 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -156.58 111.65 2.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.063 -1.023 . . . . 0.0 110.302 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.827 HD21 ' O ' ' A' ' 27' ' ' GLY . 27.9 tp -82.12 100.28 9.7 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.795 HD12 ' HB2' ' B' ' 9' ' ' PRO . 67.8 mt -43.17 105.96 0.06 Allowed 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.54 ' HB2' HG23 ' B' ' 84' ' ' ILE . 7.7 t0 -114.38 87.47 2.64 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.517 -0.74 . . . . 0.0 110.839 -178.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -71.22 -5.44 32.07 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 120.842 -1.161 . . . . 0.0 108.63 178.427 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.474 ' HA3' ' OD1' ' A' ' 25' ' ' ASP . . . -81.99 -32.76 28.49 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.423 ' CB ' ' C75' ' B' ' 100' ' ' DMP . . . -75.0 162.72 28.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.952 -1.323 . . . . 0.0 109.575 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.421 ' OD1' ' NH2' ' B' ' 87' ' ' ARG . 0.7 OUTLIER -93.4 -20.86 19.92 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.887 -179.421 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.577 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 14.3 m-20 -139.5 -164.81 1.75 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.034 -1.041 . . . . 0.0 109.407 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.643 HG23 ' O ' ' B' ' 84' ' ' ILE . 89.3 m -109.59 95.66 5.76 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.661 -1.274 . . . . 0.0 111.174 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.022 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -72.78 178.01 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 177.879 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.026 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -169.13 118.34 0.68 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.781 -1.199 . . . . 0.0 110.875 -178.885 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.643 ' HA ' HG22 ' B' ' 80' ' ' THR . 2.4 tt0 -35.11 150.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.808 -0.557 . . . . 0.0 109.51 178.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.538 ' N ' ' HG3' ' B' ' 34' ' ' GLU . 0.0 OUTLIER -31.07 141.87 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.75 0.786 . . . . 0.0 111.497 -179.041 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.912 ' SD ' HD22 ' B' ' 38' ' ' LEU . 2.8 ppp? -169.05 175.54 5.73 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 179.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.543 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -122.53 136.28 54.85 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.619 -1.3 . . . . 0.0 111.235 -179.133 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.912 HD22 ' SD ' ' B' ' 36' ' ' MET . 0.2 OUTLIER -120.49 175.83 2.14 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.251 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.85 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.8 Cg_endo -79.47 62.47 8.51 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.632 2.221 . . . . 0.0 111.171 179.397 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.539 ' O ' ' CG ' ' B' ' 41' ' ' ARG . . . 40.29 87.06 0.01 OUTLIER Glycine 0 N--CA 1.495 2.621 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.539 ' CG ' ' O ' ' B' ' 40' ' ' GLY . 4.2 mtt180 -167.67 57.15 0.07 Allowed 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.86 -0.788 . . . . 0.0 109.095 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.629 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 59.3 p-90 -147.96 172.33 14.38 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 122.07 0.938 . . . . 0.0 110.791 -179.307 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mmtm -130.98 144.29 52.94 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.225 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -74.01 133.29 17.96 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 C-N-CA 121.626 1.551 . . . . 0.0 110.486 -179.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.449 ' HG3' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -156.65 -178.83 7.64 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.462 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 62.9 mtp -145.13 131.52 19.66 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.141 -0.975 . . . . 0.0 109.323 179.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.865 HD11 HG21 ' A' ' 50' ' ' ILE . 19.9 pt -96.7 145.91 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.13 -0.982 . . . . 0.0 108.791 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.515 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.6 102.16 0.93 Allowed Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.93 -1.668 . . . . 0.0 108.93 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.411 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -122.34 -122.86 2.84 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.272 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.608 HG13 ' H62' ' B' ' 100' ' ' DMP . 33.3 mt -89.69 121.54 40.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.716 -0.873 . . . . 0.0 112.414 -177.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.589 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 105.43 -52.26 0.72 Allowed Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 178.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.31 -164.64 33.45 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.584 -1.407 . . . . 0.0 109.584 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.515 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 2.9 m-85 -106.35 126.2 51.94 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.436 -1.038 . . . . 0.0 109.171 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.512 HD13 HG23 ' A' ' 50' ' ' ILE . 23.4 pt -97.28 174.99 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 120.917 -1.115 . . . . 0.0 109.149 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.514 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 35.2 mtpt -111.49 127.23 55.63 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.314 -0.866 . . . . 0.0 109.256 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.565 HG12 ' HA3' ' B' ' 78' ' ' GLY . 16.6 m -136.15 -174.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.583 -179.425 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.586 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 0.5 OUTLIER -129.13 104.14 7.38 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.762 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.421 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 1.9 tt0 -62.38 97.4 0.09 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.523 -0.736 . . . . 0.0 110.704 -178.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.639 ' CE2' ' HB2' ' B' ' 38' ' ' LEU . 29.7 m-85 -88.56 127.49 35.55 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.52 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 5.6 m-20 -106.73 133.0 52.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.859 -1.151 . . . . 0.0 110.637 -178.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.544 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 52.2 mm-40 72.32 63.53 0.12 Allowed 'General case' 0 N--CA 1.49 1.539 0 CA-C-O 121.665 0.745 . . . . 0.0 109.469 179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 1.095 ' CG2' HG23 ' B' ' 15' ' ' ILE . 12.6 mm -113.95 122.21 67.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.198 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.788 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.1 OUTLIER -69.97 84.99 0.51 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 111.568 -177.922 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.527 HD11 HD11 ' B' ' 66' ' ' ILE . 1.7 tt -88.62 119.47 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.494 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 13.8 tt0 -100.99 122.86 44.28 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.836 -1.165 . . . . 0.0 109.527 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.555 HG13 HG22 ' B' ' 13' ' ' ILE . 0.7 OUTLIER -109.15 131.45 59.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 121.268 -0.895 . . . . 0.0 109.101 -179.956 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 57.37 -88.69 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.787 -0.57 . . . . 0.0 110.212 179.49 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -149.84 38.62 0.92 Allowed Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -136.36 123.13 21.18 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.304 -1.115 . . . . 0.0 109.175 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.461 ' CG ' HD11 ' B' ' 63' ' ' LEU . 0.4 OUTLIER -66.9 136.33 55.21 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.244 -0.91 . . . . 0.0 108.623 179.551 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.566 ' HB2' HG22 ' B' ' 93' ' ' ILE . . . -152.09 119.96 6.17 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.193 -0.942 . . . . 0.0 110.268 -179.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.788 HD13 ' N ' ' B' ' 63' ' ' LEU . 1.1 mm -89.53 163.31 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 178.016 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.792 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 174.05 173.11 39.89 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 118.931 -1.604 . . . . 0.0 110.777 179.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 59.3 m -83.72 114.8 21.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.469 -1.018 . . . . 0.0 109.892 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.026 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.3 t -106.77 114.91 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.254 -0.903 . . . . 0.0 110.6 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.757 ' HB2' HG23 ' B' ' 32' ' ' VAL . 4.1 mp -86.38 115.03 23.64 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.698 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.518 ' O ' ' CD ' ' B' ' 57' ' ' ARG . 93.0 t -101.14 132.12 47.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.045 -1.034 . . . . 0.0 109.57 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.565 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -169.44 -163.26 23.16 Favored Glycine 0 N--CA 1.488 2.154 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.514 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.1 Cg_endo -79.8 43.55 1.53 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.754 2.303 . . . . 0.0 110.892 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.643 HG22 ' HA ' ' B' ' 34' ' ' GLU . 12.2 t -85.32 137.61 36.82 Favored Pre-proline 0 N--CA 1.488 1.431 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.571 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -78.69 13.62 1.86 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.302 2.001 . . . . 0.0 110.879 -179.315 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.571 HG23 ' O ' ' B' ' 81' ' ' PRO . 1.4 t -161.44 163.34 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.132 -0.98 . . . . 0.0 109.864 -179.235 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 55.0 m-80 -94.34 136.32 34.77 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 104.051 -2.574 . . . . 0.0 104.051 175.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.782 ' CG1' HG12 ' B' ' 32' ' ' VAL . 5.6 mm -121.05 122.42 67.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 O-C-N 119.92 -1.737 . . . . 0.0 111.358 -177.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.914 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 1.0 OUTLIER -98.63 92.07 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 177.638 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -79.18 -155.56 9.39 Favored Glycine 0 N--CA 1.49 2.28 0 C-N-CA 120.005 -1.093 . . . . 0.0 111.096 -178.015 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.938 ' HD2' HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -75.71 -29.66 59.04 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.905 -0.762 . . . . 0.0 110.159 -178.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.885 ' ND2' HD23 ' B' ' 89' ' ' LEU . 19.0 p-10 -51.08 -20.46 1.46 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.888 -1.133 . . . . 0.0 109.831 -179.365 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.885 HD23 ' ND2' ' B' ' 88' ' ' ASN . 4.0 mm? -116.17 -21.25 9.48 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.83 -1.169 . . . . 0.0 110.899 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.455 ' CD2' ' CB ' ' B' ' 95' ' ' ALA . 83.3 mt -66.12 -18.43 65.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.63 -1.294 . . . . 0.0 109.547 -179.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.86 -5.74 25.72 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.927 -1.108 . . . . 0.0 109.212 178.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 5.6 mm-40 -94.15 -41.18 9.64 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 1.017 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.2 pt -88.94 -7.73 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.334 -0.854 . . . . 0.0 108.749 179.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 89.43 28.03 20.87 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.919 178.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.634 ' HB2' HD11 ' B' ' 93' ' ' ILE . . . -71.11 125.72 27.65 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.667 -1.49 . . . . 0.0 109.52 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.539 HG22 HG22 ' A' ' 4' ' ' THR . 66.4 p -127.05 129.91 48.94 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.905 HD11 HD11 ' A' ' 97' ' ' LEU . 4.1 mp -87.35 102.46 14.54 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.249 -0.907 . . . . 0.0 110.256 -178.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.528 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 4.6 m120 -102.21 125.44 48.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.352 -0.843 . . . . 0.0 109.15 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.697 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.086 -0.959 . . . . 0.0 109.296 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.846 H702 HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo . . . . . 0 N--CA 1.497 1.724 0 CA-C-O 121.501 0.542 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.549 ' HA ' ' HA ' ' B' ' 98' ' ' ASN . 1.4 tt0 -83.58 144.51 29.42 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 106.998 -1.482 . . . . 0.0 106.998 178.114 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.527 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 9.5 t -143.84 112.87 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.274 -1.37 . . . . 0.0 110.314 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.719 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -117.92 -67.1 1.02 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 178.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.547 ' O ' ' C ' ' A' ' 6' ' ' TRP . 2.5 pp 27.68 36.58 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.588 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.566 ' N ' ' O ' ' A' ' 4' ' ' THR . 35.7 m95 15.9 53.57 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.245 0 CA-C-O 121.184 0.516 . . . . 0.0 112.268 179.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 2.6 mt-30 -156.88 -166.75 2.17 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.088 -1.007 . . . . 0.0 109.529 179.584 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.479 ' HA ' ' HD3' ' B' ' 87' ' ' ARG . 1.0 OUTLIER -75.04 130.89 79.79 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.363 -0.836 . . . . 0.0 109.131 179.902 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.496 ' O ' ' HG ' ' A' ' 24' ' ' LEU . 36.1 Cg_endo -78.19 79.33 3.31 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.25 1.967 . . . . 0.0 109.342 179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.813 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -96.91 139.52 32.82 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.761 -179.359 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.568 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -135.36 147.47 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.467 -0.771 . . . . 0.0 109.965 -179.223 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.675 HG22 HD22 ' A' ' 19' ' ' LEU . 23.6 m -75.8 105.69 6.98 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.847 HD11 HD21 ' A' ' 33' ' ' LEU . 7.6 pt -99.06 146.4 8.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 121.248 -0.907 . . . . 0.0 110.642 -178.154 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 64' ' ' ILE . 0.3 OUTLIER -111.57 99.51 8.25 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.296 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.875 HD13 HG11 ' A' ' 75' ' ' VAL . 4.2 mt -120.4 132.46 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.21 -0.931 . . . . 0.0 109.651 -179.244 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.77 32.98 83.67 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 66.27 21.81 70.5 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.462 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 1.0 OUTLIER -117.81 174.92 5.91 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.299 -1.118 . . . . 0.0 109.213 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.675 HD22 HG22 ' A' ' 12' ' ' THR . 14.6 mt -140.02 120.2 13.79 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.236 -0.915 . . . . 0.0 110.379 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.7 mmmt -144.1 167.76 21.63 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.813 ' HB3' HD22 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -77.06 165.28 24.82 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 120.808 -1.183 . . . . 0.0 108.391 179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.694 ' HB1' ' CD1' ' A' ' 85' ' ' ILE . . . -142.54 119.82 11.54 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.922 -1.111 . . . . 0.0 109.817 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.608 HD21 ' O ' ' B' ' 27' ' ' GLY . 41.6 tp -88.27 93.33 9.48 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.699 -0.626 . . . . 0.0 109.647 -179.641 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.574 ' HA ' ' HB ' ' A' ' 85' ' ' ILE . 14.7 mt -43.67 97.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.06 -1.025 . . . . 0.0 109.657 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.647 ' CB ' HG23 ' A' ' 84' ' ' ILE . 27.7 t0 -100.56 81.36 2.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.215 -0.928 . . . . 0.0 109.89 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.641 HG23 HD13 ' A' ' 90' ' ' LEU . 1.8 m -60.74 -14.16 19.47 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.17 -0.956 . . . . 0.0 108.88 179.049 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.673 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.27 -33.68 64.53 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.526 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -81.28 169.44 17.29 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.196 -1.179 . . . . 0.0 110.014 -179.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.527 ' HA ' ' HG3' ' A' ' 87' ' ' ARG . 24.1 m-20 -98.38 -17.13 19.0 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.315 -0.866 . . . . 0.0 111.206 -178.808 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.565 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -137.11 -171.13 2.87 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.694 -1.254 . . . . 0.0 110.249 -179.43 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.582 HG23 HD12 ' A' ' 85' ' ' ILE . 18.6 m -104.83 90.6 3.53 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.212 -0.93 . . . . 0.0 110.533 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.01 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.13 174.53 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 178.632 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.088 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -168.8 121.84 0.82 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.83 -1.169 . . . . 0.0 110.859 -179.352 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.578 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 1.1 pt-20 -37.36 156.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.547 -0.721 . . . . 0.0 109.797 178.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.578 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 1.5 tm-20 -45.0 145.75 0.93 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.356 -0.84 . . . . 0.0 110.8 -179.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 13.5 ptm -165.02 -164.97 0.83 Allowed 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -116.81 122.75 45.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.996 -1.065 . . . . 0.0 110.506 -179.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 1.047 HD23 ' CD1' ' A' ' 59' ' ' TYR . 0.3 OUTLIER -128.08 -173.87 0.34 Allowed Pre-proline 0 N--CA 1.496 1.839 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 179.503 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.624 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 34.3 Cg_endo -78.05 -163.3 0.21 Allowed 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 122.171 1.914 . . . . 0.0 111.371 -178.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.72 39.28 2.94 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 -179.072 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.3 mtp85 -128.86 61.52 1.51 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.622 -0.928 . . . . 0.0 108.622 179.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.641 ' CD1' ' CE2' ' A' ' 59' ' ' TYR . 6.3 p-90 -132.9 -177.55 4.55 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.683 0.754 . . . . 0.0 110.47 -178.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.6 mmtt -137.74 138.51 24.22 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.23 138.81 18.27 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.131 1.887 . . . . 0.0 110.85 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.419 ' O ' ' HG2' ' A' ' 46' ' ' MET . 1.6 ptpt -156.56 -169.47 3.02 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.419 ' HG2' ' O ' ' A' ' 45' ' ' LYS . 39.9 mtp -151.3 135.56 16.8 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 109.784 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 54' ' ' ILE . 15.3 pt -100.06 139.29 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.4 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.91 106.07 1.24 Allowed Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -131.78 -123.26 2.45 Favored Glycine 0 N--CA 1.486 2.004 0 C-N-CA 119.74 -1.219 . . . . 0.0 110.308 -179.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.892 HG21 HD11 ' B' ' 47' ' ' ILE . 66.0 mt -88.48 115.29 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.445 -1.032 . . . . 0.0 112.45 -177.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.511 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 115.66 -32.96 5.45 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.361 -1.095 . . . . 0.0 110.361 178.081 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.87 -160.27 28.74 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 4.6 m-85 -110.86 124.55 52.28 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.32 -1.106 . . . . 0.0 109.491 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 1.101 HD11 HD11 ' A' ' 47' ' ' ILE . 2.2 pt -102.26 174.03 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 108.721 179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.544 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.7 OUTLIER -107.38 135.46 48.83 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.163 -0.961 . . . . 0.0 108.935 179.447 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.451 HG12 ' HA3' ' A' ' 78' ' ' GLY . 15.2 m -143.19 152.83 16.73 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 O-C-N 121.228 -0.92 . . . . 0.0 109.865 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 3.6 mtt85 -92.92 167.02 12.11 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -129.2 100.77 5.73 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.01 -1.056 . . . . 0.0 110.004 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 1.047 ' CD1' HD23 ' A' ' 38' ' ' LEU . 81.8 m-85 -100.25 123.36 44.39 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 179.356 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 1.0 OUTLIER -98.73 130.75 45.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.009 . . . . 0.0 109.753 -179.669 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.549 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 0.9 OUTLIER 83.14 59.75 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 CA-C-O 121.389 0.614 . . . . 0.0 109.802 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.755 HG21 HG21 ' A' ' 75' ' ' VAL . 5.3 mm -110.57 117.4 54.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.729 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.1 OUTLIER -69.86 86.82 0.52 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 111.093 -178.459 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.703 HG12 HD12 ' A' ' 66' ' ' ILE . 6.1 tt -88.87 118.21 33.78 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 69' ' ' HIS . 6.0 tt0 -88.22 112.51 22.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.033 -1.042 . . . . 0.0 108.936 -178.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.703 HD12 HG12 ' A' ' 64' ' ' ILE . 0.4 OUTLIER -103.92 118.86 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.348 -0.845 . . . . 0.0 109.052 -179.519 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER 61.67 40.32 13.36 Favored 'General case' 0 C--N 1.293 -1.877 0 O-C-N 121.618 -0.676 . . . . 0.0 109.873 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.07 8.44 61.54 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.484 ' O ' ' HG2' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -101.26 155.99 17.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.176 -1.191 . . . . 0.0 108.989 179.781 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.643 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.1 OUTLIER -89.44 126.63 35.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.017 -1.052 . . . . 0.0 109.754 -179.814 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.59 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -148.89 102.44 3.27 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.313 -0.867 . . . . 0.0 109.441 179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.729 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -81.07 158.89 4.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.028 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.969 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.45 172.81 43.23 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.48 -1.819 . . . . 0.0 111.637 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.477 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 57.2 m -84.86 111.66 19.85 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.665 -0.903 . . . . 0.0 109.938 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.088 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -100.39 144.53 12.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.637 -0.665 . . . . 0.0 109.601 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 4.0 mp -116.07 127.38 54.83 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.578 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 97.3 t -111.03 116.13 51.71 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 120.956 -1.09 . . . . 0.0 110.766 -178.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -151.18 -161.93 10.37 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.544 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -81.16 42.78 1.4 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.443 2.095 . . . . 0.0 110.327 179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.578 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.4 t -88.38 130.51 45.44 Favored Pre-proline 0 C--N 1.303 -1.435 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -78.27 21.05 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 122.417 2.078 . . . . 0.0 111.546 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.516 ' CG1' HD11 ' A' ' 84' ' ' ILE . 1.0 OUTLIER -161.07 159.54 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.881 -1.137 . . . . 0.0 109.81 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.569 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 33.5 m-80 -90.53 136.72 32.88 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 176.112 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.715 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.1 mm -125.75 122.79 62.99 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 O-C-N 119.955 -1.716 . . . . 0.0 111.498 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.694 ' CD1' ' HB1' ' A' ' 22' ' ' ALA . 1.1 mp -105.34 95.59 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 178.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.501 ' O ' ' HG ' ' A' ' 90' ' ' LEU . . . -79.75 -159.24 17.26 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.59 ' O ' HG23 ' A' ' 91' ' ' THR . 0.1 OUTLIER -67.77 -37.04 81.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 -179.383 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.957 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.8 p-10 -45.28 -28.97 0.9 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.89 -1.131 . . . . 0.0 109.743 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.969 HD21 ' HA3' ' A' ' 73' ' ' GLY . 2.6 mm? -106.88 -27.64 10.59 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.92 -1.113 . . . . 0.0 109.428 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.641 HD13 HG23 ' A' ' 26' ' ' THR . 12.7 mt -70.32 -6.15 33.03 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.59 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.8 p -101.87 -20.0 15.06 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.18 -0.95 . . . . 0.0 108.66 178.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 14.0 mm-40 -76.34 -40.22 51.89 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.404 -0.81 . . . . 0.0 109.112 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.974 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -87.44 -1.74 8.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.375 -0.828 . . . . 0.0 109.07 179.324 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.73 29.84 50.53 Favored Glycine 0 N--CA 1.497 2.741 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -57.59 149.13 22.14 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.2 -1.177 . . . . 0.0 111.225 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.8 p -150.44 126.03 10.25 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' B' ' 97' ' ' LEU . 5.2 mp -84.89 109.02 17.82 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.223 -0.923 . . . . 0.0 108.671 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' B' ' 2' ' ' GLN . 7.3 m120 -108.36 121.72 45.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.14 -0.975 . . . . 0.0 110.164 -179.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.641 ' CD1' ' N ' ' A' ' 99' ' ' PHE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.606 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.474 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.504 ' HD2' ' CD2' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 109.97 -0.819 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 98' ' ' ASN . 1.0 OUTLIER -83.34 144.74 29.47 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 105.985 -1.858 . . . . 0.0 105.985 177.354 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.502 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 92.8 t -148.95 114.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 117.56 -1.656 . . . . 0.0 111.413 -177.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.414 ' O ' ' N ' ' B' ' 6' ' ' TRP . 2.6 p -111.64 -70.94 0.78 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.615 ' O ' ' N ' ' B' ' 7' ' ' GLN . 0.1 OUTLIER 45.44 19.41 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.668 -0.645 . . . . 0.0 111.188 178.722 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.585 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 12.1 m95 19.3 44.8 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.332 0 CA-C-O 120.948 0.404 . . . . 0.0 111.48 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.615 ' N ' ' O ' ' B' ' 5' ' ' LEU . 12.9 mm100 -156.56 -156.66 0.64 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.441 -0.787 . . . . 0.0 109.405 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.57 117.22 61.81 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.927 -1.108 . . . . 0.0 109.543 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.491 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.2 Cg_endo -79.19 71.55 6.98 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.142 1.895 . . . . 0.0 109.431 179.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.623 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -91.23 159.83 15.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.864 . . . . 0.0 110.304 -178.986 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.559 ' O ' HG23 ' B' ' 13' ' ' ILE . 0.8 OUTLIER -150.24 135.85 11.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.452 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.871 HG22 HD22 ' B' ' 19' ' ' LEU . 4.9 m -65.77 107.91 1.94 Allowed 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.907 HG22 HG13 ' B' ' 66' ' ' ILE . 1.4 pt -103.88 150.31 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 119.15 -1.02 . . . . 0.0 111.007 -178.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.446 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 6.4 tttt -122.42 106.71 11.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.464 -0.772 . . . . 0.0 108.921 179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 1.0 HD13 HG11 ' B' ' 75' ' ' VAL . 38.0 mt -115.11 143.04 25.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.052 -1.03 . . . . 0.0 109.242 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.81 -89.91 0.09 OUTLIER Glycine 0 N--CA 1.487 2.049 0 N-CA-C 108.87 -1.692 . . . . 0.0 108.87 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -160.32 32.79 0.41 Allowed Glycine 0 N--CA 1.485 1.935 0 N-CA-C 108.406 -1.878 . . . . 0.0 108.406 179.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 -134.97 171.66 14.1 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.671 -0.899 . . . . 0.0 109.34 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.871 HD22 HG22 ' B' ' 12' ' ' THR . 5.6 mt -120.83 137.59 54.48 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.631 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -150.59 144.18 25.11 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.375 -0.828 . . . . 0.0 108.798 -178.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.623 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 5.1 mt-10 -78.24 121.98 25.1 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.256 -0.903 . . . . 0.0 108.648 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.602 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -104.34 131.0 52.16 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 111.731 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.673 HD21 ' O ' ' A' ' 27' ' ' GLY . 33.7 tp -88.11 96.95 10.72 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.491 HD12 ' HB2' ' B' ' 9' ' ' PRO . 18.9 mt -42.3 107.31 0.08 Allowed 'General case' 0 N--CA 1.494 1.765 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.683 ' OD2' ' HB2' ' B' ' 28' ' ' ALA . 41.7 t0 -116.65 92.51 3.89 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.376 -0.827 . . . . 0.0 111.642 -177.645 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.528 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -75.89 -0.78 22.55 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.903 -1.123 . . . . 0.0 108.592 177.729 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.608 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -89.37 -28.66 19.18 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -179.739 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.683 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -78.79 170.67 16.3 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.89 -1.359 . . . . 0.0 109.443 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -100.24 -20.44 15.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.178 -0.951 . . . . 0.0 110.01 -179.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.608 ' HB3' ' CD1' ' B' ' 76' ' ' LEU . 0.9 OUTLIER -142.39 -175.91 4.64 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.075 -1.016 . . . . 0.0 109.764 179.875 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.79 HG23 HD12 ' B' ' 85' ' ' ILE . 4.2 m -100.36 86.19 3.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 110.558 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.042 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -71.75 157.62 6.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.042 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.9 OUTLIER -153.06 128.66 10.05 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.918 -1.114 . . . . 0.0 110.688 -178.12 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.641 ' HA ' HG22 ' B' ' 80' ' ' THR . 1.1 pt-20 -43.37 162.34 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.382 -0.824 . . . . 0.0 109.11 179.396 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.495 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.8 mt-10 -48.92 139.83 9.65 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.225 -0.922 . . . . 0.0 110.126 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.6 OUTLIER -163.0 -171.09 2.54 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.519 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.7 t -111.99 116.15 30.11 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.877 -1.139 . . . . 0.0 110.236 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.706 HD12 HG21 ' B' ' 77' ' ' VAL . 3.4 mt -113.52 167.93 8.61 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.245 -0.909 . . . . 0.0 109.05 179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.574 ' HD2' ' CD2' ' B' ' 38' ' ' LEU . 34.4 Cg_endo -77.37 70.64 6.71 Favored 'Trans proline' 0 C--N 1.312 -1.367 0 C-N-CA 122.783 2.322 . . . . 0.0 112.183 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 35.13 -158.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 O-C-N 121.607 -0.683 . . . . 0.0 111.631 178.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 51.71 90.65 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.633 -0.922 . . . . 0.0 109.476 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.6 ' HB3' ' CD2' ' B' ' 59' ' ' TYR . 44.6 p-90 -161.0 172.91 16.05 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.471 -0.768 . . . . 0.0 109.906 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.466 ' HB2' ' HB3' ' B' ' 58' ' ' GLN . 0.2 OUTLIER -135.46 128.76 18.33 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.903 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.51 141.06 19.62 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.261 1.974 . . . . 0.0 110.966 -179.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -160.11 -167.56 1.97 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.452 -0.78 . . . . 0.0 109.083 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . . . . . . . . . 81.7 mtp -143.28 133.69 24.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.329 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.892 HD11 HG21 ' A' ' 50' ' ' ILE . 35.0 pt -100.8 152.63 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.061 -1.024 . . . . 0.0 108.783 179.146 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.51 102.81 0.98 Allowed Glycine 0 N--CA 1.489 2.167 0 N-CA-C 108.203 -1.959 . . . . 0.0 108.203 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.475 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -127.49 -131.2 3.44 Favored Glycine 0 N--CA 1.482 1.708 0 C-N-CA 119.447 -1.359 . . . . 0.0 111.123 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.939 HD12 ' C20' ' B' ' 100' ' ' DMP . 51.6 mt -88.51 126.0 41.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 122.008 -0.701 . . . . 0.0 112.515 -177.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.464 ' CA ' HG23 ' A' ' 54' ' ' ILE . . . 92.45 5.53 65.11 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 121.06 -166.13 14.07 Favored Glycine 0 N--CA 1.492 2.403 0 O-C-N 120.917 -1.343 . . . . 0.0 110.046 179.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.2 OUTLIER -109.42 135.43 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.377 -1.072 . . . . 0.0 109.57 -179.747 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.539 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.3 pt -104.82 -179.35 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 O-C-N 121.078 -1.014 . . . . 0.0 109.104 179.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.493 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 31.8 mttt -114.84 140.56 48.85 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.161 -0.962 . . . . 0.0 108.955 179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' B' ' 77' ' ' VAL . 33.8 m -149.66 176.55 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.001 -1.062 . . . . 0.0 110.262 -179.577 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.558 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 1.0 OUTLIER -111.3 172.92 6.6 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.981 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.466 ' HB3' ' HB2' ' B' ' 43' ' ' LYS . 45.2 tt0 -128.82 87.92 2.65 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.152 -0.968 . . . . 0.0 110.198 -179.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.653 ' HB3' HD11 ' B' ' 62' ' ' ILE . 72.7 m-85 -89.77 93.98 9.65 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 179.116 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.498 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 3.8 m-20 -80.93 135.37 35.88 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.055 -1.028 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 7.6 mt-30 78.43 62.72 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 CA-C-O 121.672 0.748 . . . . 0.0 109.866 179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.653 HD11 ' HB3' ' B' ' 59' ' ' TYR . 35.1 mm -117.56 123.67 72.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.41 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.854 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.8 tm? -68.42 84.35 0.27 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.378 -0.827 . . . . 0.0 110.672 -178.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.829 HG12 HD12 ' B' ' 66' ' ' ILE . 7.1 tt -87.55 118.39 33.31 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.586 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.3 tt0 -90.95 118.47 30.36 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.141 -0.975 . . . . 0.0 109.68 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.907 HG13 HG22 ' B' ' 13' ' ' ILE . 0.3 OUTLIER -120.14 128.95 75.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.16 -0.962 . . . . 0.0 108.908 179.753 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 85.5 m 57.05 51.41 10.51 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.495 -0.753 . . . . 0.0 109.817 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 54.49 19.45 13.12 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.467 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.8 m-70 -112.23 141.55 45.79 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.152 -1.205 . . . . 0.0 109.425 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -84.33 130.77 34.77 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.234 -0.917 . . . . 0.0 109.17 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.503 ' O ' HD22 ' B' ' 63' ' ' LEU . . . -149.98 141.85 23.78 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.559 -0.713 . . . . 0.0 109.134 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.534 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -115.18 158.88 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.783 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.472 ' N ' HG22 ' B' ' 72' ' ' ILE . . . 176.62 -159.46 26.28 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.687 -1.721 . . . . 0.0 111.454 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 1.1 m -101.33 109.01 20.79 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.473 -1.016 . . . . 0.0 110.136 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.0 HG11 HD13 ' B' ' 15' ' ' ILE . 1.5 t -104.06 108.73 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.397 -0.814 . . . . 0.0 110.225 179.449 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.618 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.1 mp -82.57 137.23 34.62 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.33 -0.856 . . . . 0.0 108.842 179.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.706 HG21 HD12 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -115.15 129.69 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.953 0 O-C-N 121.265 -0.897 . . . . 0.0 109.94 -179.342 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -166.07 -172.21 33.15 Favored Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.493 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.6 Cg_endo -80.56 41.34 1.12 Allowed 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.53 2.153 . . . . 0.0 110.85 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.641 HG22 ' HA ' ' B' ' 34' ' ' GLU . 5.9 t -80.93 143.67 53.92 Favored Pre-proline 0 N--CA 1.49 1.541 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.711 ' O ' HG23 ' B' ' 82' ' ' VAL . 34.7 Cg_endo -77.51 12.47 1.86 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.39 2.06 . . . . 0.0 111.296 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.711 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.3 t -161.61 161.55 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.835 -1.166 . . . . 0.0 110.486 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.631 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -98.36 92.63 5.78 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.774 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.816 HD11 ' C32' ' B' ' 100' ' ' DMP . 2.7 mt -93.39 135.52 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.951 -1.093 . . . . 0.0 113.327 -175.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.79 HD12 HG23 ' B' ' 31' ' ' THR . 0.2 OUTLIER -101.3 108.27 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.984 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.704 ' O ' HD22 ' B' ' 90' ' ' LEU . . . -95.95 173.37 30.48 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.871 -1.291 . . . . 0.0 109.871 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.517 ' NH1' ' O ' ' B' ' 26' ' ' THR . 8.8 mtm-85 -35.91 -35.02 0.06 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.487 -1.008 . . . . 0.0 112.19 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.904 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.7 p-10 -49.14 -43.43 41.69 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.231 -1.543 . . . . 0.0 110.395 -178.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.904 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.6 OUTLIER -93.64 -30.16 15.08 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.096 -1.003 . . . . 0.0 111.168 -178.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.704 HD22 ' O ' ' B' ' 86' ' ' GLY . 0.7 OUTLIER -59.5 -36.33 75.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.532 -1.355 . . . . 0.0 108.719 -179.807 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.407 ' CG2' ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -71.44 -20.7 62.07 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.879 -1.138 . . . . 0.0 109.713 -179.534 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.44 ' NE2' ' O ' ' B' ' 72' ' ' ILE . 11.8 mm-40 -75.11 -38.87 60.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.139 -0.976 . . . . 0.0 109.018 179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.62 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -84.81 -8.5 11.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.181 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 80.51 29.56 43.68 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 178.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.583 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.83 135.38 57.3 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.105 -1.232 . . . . 0.0 109.824 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.719 HG22 HG23 ' A' ' 4' ' ' THR . 73.2 p -131.86 125.64 32.28 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.818 HD11 HD11 ' A' ' 97' ' ' LEU . 1.2 mp -84.86 92.95 8.4 Favored 'General case' 0 C--N 1.293 -1.861 0 O-C-N 121.335 -0.853 . . . . 0.0 109.954 -178.611 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.549 ' HA ' ' HA ' ' A' ' 2' ' ' GLN . 2.6 m120 -105.14 138.8 40.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.577 -0.702 . . . . 0.0 109.962 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.974 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.06 -0.971 . . . . 0.0 109.338 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.939 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.512 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 3.4 Cg_exo . . . . . 0 N--CA 1.496 1.647 0 N-CA-C 110.292 -0.695 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.534 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 1.9 tt0 -85.92 129.07 34.94 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 178.233 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.626 HG12 ' HB3' ' A' ' 9' ' ' PRO . 35.8 t -124.09 111.37 28.47 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 120.74 -1.225 . . . . 0.0 110.595 -178.333 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.506 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -119.28 -72.67 0.68 Allowed 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.228 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' O ' ' N ' ' A' ' 7' ' ' GLN . 1.6 mm? 42.15 29.21 0.13 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.426 -0.797 . . . . 0.0 110.125 179.165 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.539 ' C ' ' O ' ' A' ' 5' ' ' LEU . 20.9 m0 18.61 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.385 0 CA-C-O 121.249 0.547 . . . . 0.0 111.742 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.579 ' N ' ' O ' ' A' ' 5' ' ' LEU . 18.5 mt-30 -165.57 -165.28 0.82 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.372 -0.83 . . . . 0.0 108.805 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . 82.7 mtm180 -64.25 117.08 33.26 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.078 -1.014 . . . . 0.0 109.235 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.626 ' HB3' HG12 ' A' ' 3' ' ' VAL . 34.8 Cg_endo -76.76 75.49 4.45 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 109.974 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.575 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -79.49 160.04 26.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.288 -0.883 . . . . 0.0 109.58 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 24' ' ' LEU . 2.1 m -148.73 139.1 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.282 -0.887 . . . . 0.0 110.386 -179.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.891 HG22 HD22 ' A' ' 19' ' ' LEU . 54.9 m -70.3 98.3 1.37 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.126 -0.983 . . . . 0.0 108.392 178.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.834 ' O ' HD23 ' A' ' 19' ' ' LEU . 19.7 pt -92.12 150.07 3.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.453 -0.78 . . . . 0.0 109.901 -179.264 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 1.014 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -112.07 94.98 5.21 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.478 -0.764 . . . . 0.0 109.003 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.861 HD12 HD22 ' A' ' 33' ' ' LEU . 6.0 mt -114.35 128.17 71.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.357 -0.84 . . . . 0.0 109.561 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.2 30.53 78.04 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.71 9.92 66.44 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 5.7 mm-40 -108.02 175.86 5.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -1.147 . . . . 0.0 108.935 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 1.014 HD21 ' HD3' ' A' ' 14' ' ' LYS . 20.1 mt -142.82 121.63 12.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.105 -0.997 . . . . 0.0 110.347 -179.417 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 3.2 mmtt -140.06 160.58 39.6 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.155 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HB3' HD22 ' A' ' 10' ' ' LEU . 2.6 mp0 -78.86 123.97 27.77 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.937 -1.102 . . . . 0.0 108.461 179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.689 ' HB2' HD13 ' A' ' 13' ' ' ILE . . . -108.16 130.51 55.12 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 110.673 -178.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.763 HD21 ' O ' ' B' ' 27' ' ' GLY . 42.9 tp -80.23 94.97 6.16 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.855 -0.528 . . . . 0.0 109.879 179.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.62 HD12 ' HB2' ' A' ' 9' ' ' PRO . 94.4 mt -46.71 95.04 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.878 ' HB2' HG23 ' A' ' 84' ' ' ILE . 34.6 t0 -99.96 89.12 3.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.317 -0.865 . . . . 0.0 110.837 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.461 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 15.7 m -65.07 -16.63 63.67 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.572 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.05 -34.59 64.78 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -81.66 161.37 23.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.156 -1.203 . . . . 0.0 109.071 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.429 ' HA ' ' HB2' ' A' ' 87' ' ' ARG . 34.6 m-20 -99.37 -12.54 20.19 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.171 -0.956 . . . . 0.0 109.983 -179.589 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' OD1' ' A' ' 88' ' ' ASN . 29.4 m-20 -137.35 173.01 12.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.024 -1.047 . . . . 0.0 110.084 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.856 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -94.07 107.44 19.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.083 -1.011 . . . . 0.0 110.194 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.842 HG23 ' HB2' ' A' ' 76' ' ' LEU . 0.3 OUTLIER -100.26 117.3 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.304 -0.873 . . . . 0.0 109.022 179.441 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.861 HD22 HD12 ' A' ' 15' ' ' ILE . 2.2 mp -107.56 119.28 38.98 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.239 -0.913 . . . . 0.0 110.569 -179.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.711 ' HA ' HG22 ' A' ' 80' ' ' THR . 15.4 pt-20 -42.73 168.41 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.328 -0.857 . . . . 0.0 109.393 178.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.455 ' N ' ' O ' ' A' ' 78' ' ' GLY . 0.9 OUTLIER -43.46 145.99 0.54 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.212 -0.93 . . . . 0.0 111.03 -179.128 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.435 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER 178.68 163.05 0.74 Allowed 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 179.589 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 28.5 t -81.0 103.3 10.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.871 -1.143 . . . . 0.0 110.151 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.732 HD12 ' HD2' ' A' ' 39' ' ' PRO . 5.1 tp -121.8 104.1 39.54 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.857 . . . . 0.0 109.199 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.732 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.3 Cg_endo -77.41 146.89 25.05 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.542 2.161 . . . . 0.0 110.861 -179.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 134.45 172.72 12.9 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -77.45 127.69 32.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -1.233 . . . . 0.0 108.808 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 59' ' ' TYR . 66.6 p-90 -130.26 172.91 11.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.775 -178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.408 ' HG2' ' C ' ' A' ' 42' ' ' TRP . 2.1 mmtm -137.75 147.24 56.19 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.42 131.46 12.71 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 C-N-CA 121.838 1.692 . . . . 0.0 110.289 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.627 ' NZ ' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -162.05 136.85 7.02 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.696 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -112.64 146.32 38.84 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.661 -1.275 . . . . 0.0 109.637 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.755 HD13 HG21 ' A' ' 32' ' ' VAL . 12.6 pt -101.0 140.27 20.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.517 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.66 104.61 1.11 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -126.49 -119.45 2.29 Favored Glycine 0 N--CA 1.485 1.957 0 C-N-CA 119.576 -1.297 . . . . 0.0 110.875 -179.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.838 HG23 HD13 ' B' ' 54' ' ' ILE . 49.9 mt -85.96 119.79 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.817 -0.814 . . . . 0.0 112.66 -177.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.437 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 104.21 -53.38 0.7 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.355 -0.926 . . . . 0.0 110.795 178.038 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.435 ' C ' ' HA3' ' B' ' 51' ' ' GLY . . . -177.63 -157.41 18.45 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.234 -179.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 2.1 m-85 -117.3 126.73 53.2 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.484 -1.009 . . . . 0.0 109.875 -179.672 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.734 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.9 pp -105.08 160.55 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.303 -0.873 . . . . 0.0 109.085 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.561 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.1 OUTLIER -103.02 146.6 28.11 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.046 -1.034 . . . . 0.0 110.115 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.768 HG12 ' HA3' ' A' ' 78' ' ' GLY . 3.1 m -149.39 -177.9 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.18 -0.95 . . . . 0.0 109.328 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.521 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 7.4 mmt85 -123.21 101.75 7.56 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.573 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 3.8 tt0 -73.18 106.17 4.91 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.4 -0.812 . . . . 0.0 111.144 -178.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 42' ' ' TRP . 41.4 m-85 -89.47 130.75 35.76 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.543 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 20.0 m-20 -100.82 121.11 41.14 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.7 -1.25 . . . . 0.0 109.976 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.578 ' HA ' ' CG2' ' A' ' 72' ' ' ILE . 0.8 OUTLIER 85.15 57.07 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.206 0.527 . . . . 0.0 110.048 179.538 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.634 HG21 HG23 ' A' ' 15' ' ' ILE . 16.4 mm -105.54 119.95 55.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -0.923 . . . . 0.0 108.919 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.881 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.4 tm? -68.72 98.59 0.92 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.269 -0.894 . . . . 0.0 110.854 -178.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.739 HG22 ' O ' ' A' ' 71' ' ' ALA . 7.9 tt -102.83 119.36 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.58 116.84 28.03 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.809 -1.182 . . . . 0.0 109.424 -178.915 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.526 HG21 HD13 ' A' ' 93' ' ' ILE . 0.4 OUTLIER -109.25 129.07 64.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.3 -0.875 . . . . 0.0 109.053 -179.836 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.512 ' HB3' ' HG3' ' A' ' 1' ' ' PRO . 1.7 m 38.04 52.15 1.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.459 179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 63.28 48.86 75.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 179.464 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.478 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 92.9 m-70 -145.15 115.19 7.43 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.234 -1.156 . . . . 0.0 109.431 179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.596 ' CG ' HD21 ' A' ' 63' ' ' LEU . 19.6 ttpt -60.97 129.25 40.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.739 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -154.28 99.65 2.23 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.392 -0.818 . . . . 0.0 109.874 -179.093 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.578 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -79.55 160.43 4.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 120.866 -1.146 . . . . 0.0 108.533 178.981 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.641 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 178.99 177.15 47.37 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 118.777 -1.678 . . . . 0.0 111.59 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.573 ' CG2' ' HG3' ' A' ' 58' ' ' GLN . 17.7 m -89.03 111.77 22.57 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.815 -0.815 . . . . 0.0 110.549 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.976 ' C ' HD12 ' A' ' 76' ' ' LEU . 1.4 t -101.05 161.33 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.465 -0.772 . . . . 0.0 109.733 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.976 HD12 ' C ' ' A' ' 75' ' ' VAL . 6.0 mp -130.55 105.0 7.55 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.064 -1.022 . . . . 0.0 108.405 179.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 61.7 t -89.61 117.75 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.792 -1.193 . . . . 0.0 109.973 -179.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.768 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -156.5 -166.97 17.08 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.561 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -82.75 39.02 0.78 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.479 2.119 . . . . 0.0 111.085 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.713 HG23 ' H ' ' A' ' 82' ' ' VAL . 0.8 OUTLIER -85.62 137.57 36.18 Favored Pre-proline 0 N--CA 1.49 1.525 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 178.174 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -77.94 23.04 0.58 Allowed 'Trans proline' 0 C--N 1.303 -1.859 0 C-N-CA 122.187 1.924 . . . . 0.0 111.689 -178.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.713 ' H ' HG23 ' A' ' 80' ' ' THR . 0.5 OUTLIER -162.94 140.93 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 120.621 -1.299 . . . . 0.0 111.899 -178.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.592 ' O ' ' CG1' ' A' ' 84' ' ' ILE . 75.1 m-20 -80.54 154.72 27.33 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 104.037 -2.579 . . . . 0.0 104.037 175.182 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.878 HG23 ' HB2' ' A' ' 25' ' ' ASP . 20.5 mt -155.63 134.04 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 117.065 -1.854 . . . . 0.0 112.443 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.565 ' HB ' HD23 ' A' ' 24' ' ' LEU . 9.5 mm -99.27 104.34 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 178.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -86.13 -161.48 35.41 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.747 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.474 ' O ' ' OG1' ' A' ' 91' ' ' THR . 1.0 OUTLIER -63.73 -35.48 80.72 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.691 -0.888 . . . . 0.0 109.663 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.921 ' ND2' HD23 ' A' ' 89' ' ' LEU . 18.6 p-10 -51.26 -20.88 1.8 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.987 -1.07 . . . . 0.0 110.248 -179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.921 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -113.03 -29.7 7.25 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.727 -1.233 . . . . 0.0 110.265 -179.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.461 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 21.4 mt -66.18 -11.6 50.62 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.994 -1.066 . . . . 0.0 108.957 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -101.38 -10.05 20.59 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.064 -1.023 . . . . 0.0 109.513 179.848 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.5 mm-40 -90.28 -41.19 11.69 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.264 -0.897 . . . . 0.0 109.85 -179.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.708 HD12 ' CD2' ' B' ' 99' ' ' PHE . 2.2 pt -89.72 2.35 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.118 -0.989 . . . . 0.0 109.065 179.371 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 65.84 54.48 24.86 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.314 -1.114 . . . . 0.0 110.314 179.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.562 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -82.75 137.1 34.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.055 -1.262 . . . . 0.0 109.543 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.405 HG22 ' HA ' ' B' ' 4' ' ' THR . 16.4 p -122.78 136.95 55.03 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.223 -0.923 . . . . 0.0 109.117 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' B' ' 97' ' ' LEU . 5.3 mp -97.36 96.67 8.53 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -0.952 . . . . 0.0 109.896 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.7 m120 -101.02 125.17 47.62 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.038 -1.039 . . . . 0.0 109.251 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.691 ' HD2' ' HB2' ' B' ' 95' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.296 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.497 1.678 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.475 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.3 tt0 -130.74 136.69 48.99 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 177.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 8.0 t -132.17 136.24 56.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 120.886 -1.134 . . . . 0.0 109.653 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.673 ' O ' HD23 ' B' ' 5' ' ' LEU . 6.0 p -69.38 -93.14 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.394 -0.816 . . . . 0.0 109.662 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.673 HD23 ' O ' ' B' ' 4' ' ' THR . 0.2 OUTLIER 158.81 -7.44 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.836 -0.54 . . . . 0.0 110.72 179.542 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -50.53 -19.27 0.84 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.667 -1.271 . . . . 0.0 110.535 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.41 -175.92 4.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.806 -1.184 . . . . 0.0 109.9 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.05 130.33 91.49 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.474 ' HB2' HD12 ' B' ' 24' ' ' LEU . 36.9 Cg_endo -79.66 68.16 8.38 Favored 'Trans proline' 0 C--N 1.312 -1.357 0 C-N-CA 122.425 2.083 . . . . 0.0 109.471 179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.79 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -87.21 156.48 19.65 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.167 -0.958 . . . . 0.0 109.977 -179.104 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.897 HG21 HG23 ' B' ' 66' ' ' ILE . 0.7 OUTLIER -147.33 138.37 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.392 -0.817 . . . . 0.0 109.662 -179.627 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.404 HG22 ' HB3' ' B' ' 19' ' ' LEU . 1.5 m -71.53 90.68 1.02 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.89 -1.131 . . . . 0.0 108.287 178.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.929 HG22 HG13 ' B' ' 66' ' ' ILE . 4.4 pt -80.29 150.2 4.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.175 -0.953 . . . . 0.0 109.952 -179.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.514 ' HG3' ' CD2' ' B' ' 19' ' ' LEU . 10.6 tttm -121.75 104.42 9.58 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.366 -0.834 . . . . 0.0 109.403 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.962 HD13 HG11 ' B' ' 75' ' ' VAL . 4.8 mt -117.13 143.21 28.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.24 -90.29 0.05 OUTLIER Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.946 -1.661 . . . . 0.0 108.946 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' B' ' 15' ' ' ILE . . . -158.35 38.67 0.52 Allowed Glycine 0 N--CA 1.486 1.97 0 N-CA-C 108.784 -1.726 . . . . 0.0 108.784 179.286 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -137.46 166.91 22.73 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.447 -1.031 . . . . 0.0 109.67 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.514 ' CD2' ' HG3' ' B' ' 14' ' ' LYS . 17.5 mt -132.23 122.12 24.73 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.431 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -134.89 155.78 50.09 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.035 -1.041 . . . . 0.0 109.9 -178.961 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.79 ' HB3' HD22 ' B' ' 10' ' ' LEU . 5.5 mm-40 -78.98 110.42 14.19 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 178.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -98.63 154.75 17.71 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.29 -0.881 . . . . 0.0 110.341 -178.395 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.572 HD21 ' O ' ' A' ' 27' ' ' GLY . 14.6 tp -101.85 101.18 11.58 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.668 -0.645 . . . . 0.0 109.751 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.681 HD13 ' HE2' ' A' ' 99' ' ' PHE . 19.6 mt -46.23 99.57 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.32 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.671 ' CB ' HG23 ' B' ' 84' ' ' ILE . 44.4 t0 -107.48 96.08 6.15 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.291 -0.88 . . . . 0.0 111.027 -178.225 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.624 ' HA ' HD21 ' B' ' 90' ' ' LEU . 0.7 OUTLIER -78.97 3.22 17.77 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.086 -1.009 . . . . 0.0 109.188 178.599 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.763 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -95.69 -18.62 31.97 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.517 ' HB2' ' OD2' ' B' ' 25' ' ' ASP . . . -85.78 170.83 12.07 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.019 -1.283 . . . . 0.0 109.711 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.453 ' HA ' ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER -100.67 -20.06 15.79 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.186 -0.946 . . . . 0.0 110.797 -178.88 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.51 ' OD1' ' HB ' ' B' ' 74' ' ' THR . 0.2 OUTLIER -137.99 -163.11 1.39 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.803 -1.186 . . . . 0.0 109.851 -179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.534 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 17.8 m -109.88 86.6 2.33 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.972 -1.08 . . . . 0.0 110.538 -178.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.02 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -69.04 175.39 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.825 -1.172 . . . . 0.0 108.157 179.08 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.02 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -170.4 116.94 0.51 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.111 -0.993 . . . . 0.0 109.804 -178.911 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.2 pt-20 -39.58 160.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.465 -0.772 . . . . 0.0 109.515 179.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.3 OUTLIER -38.31 139.81 0.35 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.728 0.775 . . . . 0.0 110.699 -179.411 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -168.53 167.69 11.47 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 179.761 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 28.8 t -100.63 125.78 47.07 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.789 -1.194 . . . . 0.0 111.256 -178.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.603 ' HB2' ' CZ ' ' B' ' 59' ' ' TYR . 3.6 mm? -117.09 171.96 4.38 Favored Pre-proline 0 N--CA 1.493 1.696 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 178.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.544 ' HD2' HD12 ' B' ' 38' ' ' LEU . 36.3 Cg_endo -80.57 59.91 7.64 Favored 'Trans proline' 0 C--N 1.311 -1.398 0 C-N-CA 122.385 2.057 . . . . 0.0 111.38 -179.493 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' B' ' 39' ' ' PRO . . . 40.21 -158.52 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 3.0 mmp_? 58.49 68.22 0.85 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.443 -1.034 . . . . 0.0 109.313 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.62 ' HB3' ' CD1' ' B' ' 59' ' ' TYR . 22.8 p-90 -144.16 -167.44 2.61 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.44 -0.788 . . . . 0.0 109.879 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -146.44 132.08 9.31 Favored Pre-proline 0 N--CA 1.489 1.501 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.57 132.12 11.95 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 121.93 1.753 . . . . 0.0 110.602 -179.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -161.33 -162.24 0.88 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.421 ' HB3' ' HA ' ' B' ' 55' ' ' LYS . 0.0 OUTLIER -152.24 146.33 25.34 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.992 -1.068 . . . . 0.0 109.361 178.743 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.73 HD11 HD11 ' B' ' 54' ' ' ILE . 1.1 pt -96.33 155.83 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.258 -0.901 . . . . 0.0 108.886 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.663 ' CA ' ' CD2' ' B' ' 53' ' ' PHE . . . -119.09 130.7 8.69 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.531 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -158.02 -125.42 0.83 Allowed Glycine 0 N--CA 1.482 1.76 0 C-N-CA 118.949 -1.596 . . . . 0.0 111.338 -179.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.798 HD12 ' C21' ' B' ' 100' ' ' DMP . 19.0 mt -88.96 126.68 41.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.937 -0.743 . . . . 0.0 112.836 -177.271 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.435 ' HA3' ' C ' ' A' ' 52' ' ' GLY . . . 90.48 -28.3 7.73 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 178.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.427 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 157.76 -159.24 29.74 Favored Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.169 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.663 ' CD2' ' CA ' ' B' ' 48' ' ' GLY . 1.5 m-85 -120.49 132.07 55.03 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.654 -0.909 . . . . 0.0 109.627 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.838 HD13 HG23 ' A' ' 50' ' ' ILE . 35.4 pt -103.9 162.84 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.181 -0.95 . . . . 0.0 108.983 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.539 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 13.0 mttt -93.3 154.73 17.83 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.088 -1.007 . . . . 0.0 109.771 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.597 HG12 ' HA3' ' B' ' 78' ' ' GLY . 6.4 m -151.23 -168.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.055 -1.028 . . . . 0.0 110.07 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.577 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 16.7 mmt180 -129.83 89.22 2.78 Favored 'General case' 0 N--CA 1.492 1.637 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -56.48 93.62 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.271 -0.893 . . . . 0.0 110.777 -178.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.873 ' HB3' HD11 ' B' ' 62' ' ' ILE . 27.9 m-85 -88.71 136.04 33.2 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 177.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.493 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -114.58 138.25 50.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.712 -1.242 . . . . 0.0 111.041 -178.302 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.543 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 74.46 60.68 0.07 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.653 -0.654 . . . . 0.0 110.602 178.884 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.933 HG21 HG23 ' B' ' 15' ' ' ILE . 4.2 mp -118.77 118.09 56.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 108.856 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.841 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.8 tm? -68.26 90.13 0.34 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.237 -0.914 . . . . 0.0 110.631 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.701 ' CD1' HD11 ' B' ' 66' ' ' ILE . 2.4 tt -90.07 115.21 29.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.515 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 15.4 tm-20 -89.13 117.53 28.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.932 . . . . 0.0 109.551 -178.586 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.929 HG13 HG22 ' B' ' 13' ' ' ILE . 1.4 mp -115.69 125.02 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.331 -0.856 . . . . 0.0 109.351 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 62.4 m 61.57 -95.06 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.518 -0.739 . . . . 0.0 109.792 179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -145.78 39.78 1.12 Allowed Glycine 0 N--CA 1.484 1.893 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -139.62 133.06 30.15 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.381 -1.07 . . . . 0.0 109.637 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.462 ' CG ' HD21 ' B' ' 63' ' ' LEU . 0.1 OUTLIER -77.04 135.55 38.65 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.022 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.648 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -145.75 97.53 2.98 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.154 -1.018 . . . . 0.0 110.665 -179.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.775 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.6 OUTLIER -78.89 140.17 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 177.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.838 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -167.77 -168.0 29.27 Favored Glycine 0 N--CA 1.485 1.96 0 C-N-CA 118.741 -1.695 . . . . 0.0 110.939 -179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 28.9 m -95.95 109.18 21.59 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.781 -0.835 . . . . 0.0 110.244 -179.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.962 HG11 HD13 ' B' ' 15' ' ' ILE . 1.4 t -96.61 104.97 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.321 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 4.7 mp -79.86 116.74 20.19 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.202 -0.936 . . . . 0.0 108.615 178.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.577 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.3 t -101.39 131.44 49.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.051 -1.031 . . . . 0.0 109.125 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.597 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -162.38 -165.43 19.37 Favored Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.06 -1.543 . . . . 0.0 109.905 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.539 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.93 40.67 1.01 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.753 2.302 . . . . 0.0 110.054 179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' B' ' 34' ' ' GLU . 8.8 t -85.55 138.5 35.89 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.516 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 33.9 Cg_endo -78.38 14.3 1.63 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.51 2.14 . . . . 0.0 111.078 -179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.526 HG12 ' CD1' ' B' ' 84' ' ' ILE . 1.1 t -160.68 167.56 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.102 -0.999 . . . . 0.0 109.382 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.608 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -101.15 144.18 30.34 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 175.816 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.697 ' CG1' HG12 ' B' ' 32' ' ' VAL . 6.8 mm -129.0 123.68 59.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 O-C-N 120.069 -1.644 . . . . 0.0 112.194 -176.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.735 HG22 ' CD1' ' B' ' 90' ' ' LEU . 4.4 mm -102.54 101.48 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 177.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.615 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -107.0 175.25 20.51 Favored Glycine 0 N--CA 1.496 2.695 0 C-N-CA 119.792 -1.194 . . . . 0.0 111.915 -177.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.786 ' N ' HD22 ' B' ' 90' ' ' LEU . 4.0 mtm180 -28.46 -41.44 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.376 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -178.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.991 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.8 p-10 -53.17 -41.38 65.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 120.234 -1.541 . . . . 0.0 110.661 -177.659 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.991 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.6 mm? -98.92 -18.33 17.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.172 -0.955 . . . . 0.0 110.342 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.786 HD22 ' N ' ' B' ' 87' ' ' ARG . 0.4 OUTLIER -69.51 -35.89 75.94 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.143 -0.973 . . . . 0.0 109.391 -179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 49.6 p -70.03 -15.27 62.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.189 -0.944 . . . . 0.0 108.965 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.465 ' OE1' ' O ' ' B' ' 72' ' ' ILE . 26.7 mt-30 -91.63 -40.48 11.28 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.306 -0.871 . . . . 0.0 108.943 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.645 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.9 OUTLIER -81.77 -2.98 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 177.088 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 61.01 43.29 99.63 Favored Glycine 0 N--CA 1.496 2.697 0 O-C-N 121.561 -0.712 . . . . 0.0 111.361 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.691 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -68.38 147.01 52.7 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.874 -1.368 . . . . 0.0 110.289 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.506 HG22 ' CG2' ' A' ' 4' ' ' THR . 14.9 p -144.61 130.78 19.54 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.339 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.491 HD11 HD11 ' A' ' 97' ' ' LEU . 8.0 mp -92.68 102.85 15.27 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.308 -0.87 . . . . 0.0 110.119 -179.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 3.6 m120 -101.65 121.95 42.98 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.088 -1.007 . . . . 0.0 109.688 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.708 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 118.128 -0.939 . . . . 0.0 109.33 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.798 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.468 ' HD2' ' OXT' ' B' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.497 1.687 0 N-CA-C 110.164 -0.745 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.543 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -104.09 126.59 51.33 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.292 -0.88 . . . . 0.0 109.032 179.079 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.436 HG11 ' HB3' ' A' ' 9' ' ' PRO . 13.8 t -121.83 102.46 11.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -179.878 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.554 ' HA ' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -52.27 -84.26 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.324 -0.86 . . . . 0.0 109.953 -178.981 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.846 HD23 HG23 ' B' ' 91' ' ' THR . 31.2 tp 171.84 -25.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.259 -0.9 . . . . 0.0 109.882 -179.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 84.8 m95 -54.77 -19.36 6.2 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.07 -1.019 . . . . 0.0 108.996 -179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -129.51 130.53 45.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.438 -0.789 . . . . 0.0 109.513 179.594 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 6.1 mtt-85 -49.06 146.49 5.7 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.833 ' HB2' HD12 ' A' ' 24' ' ' LEU . 37.0 Cg_endo -79.8 47.75 2.63 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 C-N-CA 122.838 2.359 . . . . 0.0 110.538 179.394 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.553 HD22 ' HB3' ' A' ' 21' ' ' GLU . 1.8 mt -80.03 144.4 33.24 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.1 -1.0 . . . . 0.0 109.276 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG22 ' A' ' 66' ' ' ILE . 1.9 m -148.99 160.15 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.366 -179.379 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.664 HG22 HD22 ' A' ' 19' ' ' LEU . 90.0 m -91.21 107.77 19.43 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.487 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.811 HG12 ' HB2' ' A' ' 22' ' ' ALA . 2.1 pt -99.18 157.97 3.67 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.275 -0.89 . . . . 0.0 110.084 -178.674 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.484 ' HE3' HD11 ' A' ' 19' ' ' LEU . 2.3 ttmt -118.16 100.81 7.76 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.311 -0.868 . . . . 0.0 108.913 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.796 HD13 HG21 ' A' ' 75' ' ' VAL . 1.3 mt -109.8 140.92 26.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 120.858 -1.151 . . . . 0.0 109.4 -179.587 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 62.96 -90.64 0.07 OUTLIER Glycine 0 N--CA 1.488 2.139 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -179.604 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -156.22 35.19 0.6 Allowed Glycine 0 C--N 1.294 -1.787 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 179.404 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.409 ' OE1' ' HB2' ' A' ' 37' ' ' SER . 8.2 mt-30 -138.99 173.78 11.2 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.272 -1.134 . . . . 0.0 109.591 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.766 HD23 ' O ' ' A' ' 13' ' ' ILE . 18.5 mt -133.58 122.04 22.95 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.593 -0.692 . . . . 0.0 109.42 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HE3' ' SD ' ' A' ' 36' ' ' MET . 0.3 OUTLIER -135.72 -179.87 5.92 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.93 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.553 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.5 mt-10 -78.32 176.36 9.39 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 108.191 179.521 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.811 ' HB2' HG12 ' A' ' 13' ' ' ILE . . . -157.71 108.74 2.25 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 120.936 -1.102 . . . . 0.0 109.619 -179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.699 HD21 ' O ' ' B' ' 27' ' ' GLY . 20.8 tp -85.19 93.41 8.65 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.35 -0.844 . . . . 0.0 109.078 179.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.833 HD12 ' HB2' ' A' ' 9' ' ' PRO . 97.8 mt -43.06 97.15 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.686 ' CB ' HG23 ' A' ' 84' ' ' ILE . 3.8 t0 -102.95 77.18 1.54 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.388 -0.82 . . . . 0.0 110.918 -178.245 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.48 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 2.2 m -54.92 -20.19 8.36 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.124 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.731 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -65.24 -44.33 93.93 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.732 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.47 155.72 40.01 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.17 -1.194 . . . . 0.0 108.86 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.68 -17.55 31.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.05 -1.032 . . . . 0.0 110.688 -179.034 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.523 ' OD1' ' CB ' ' A' ' 88' ' ' ASN . 0.2 OUTLIER -138.42 -159.58 0.97 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.779 -1.201 . . . . 0.0 110.108 -179.532 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.83 HG22 ' CD1' ' A' ' 33' ' ' LEU . 35.3 m -114.98 91.41 3.61 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.925 -1.11 . . . . 0.0 110.602 -178.547 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.95 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -74.79 160.12 5.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.675 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.95 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.3 OUTLIER -160.15 123.72 3.57 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.841 -1.162 . . . . 0.0 110.473 -178.595 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.607 ' N ' ' CG2' ' A' ' 80' ' ' THR . 0.6 OUTLIER -41.99 153.46 0.06 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.14 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.542 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.6 OUTLIER -43.11 146.93 0.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.021 -1.049 . . . . 0.0 110.161 -179.55 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.458 ' HE1' ' HB ' ' A' ' 15' ' ' ILE . 21.7 ptm -162.2 -163.64 0.95 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.311 -0.868 . . . . 0.0 109.597 -179.802 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.409 ' HB2' ' OE1' ' A' ' 18' ' ' GLN . 7.4 t -101.31 87.08 3.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.433 -0.792 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.643 HD13 HG22 ' A' ' 15' ' ' ILE . 12.9 tp -127.71 97.34 30.5 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.145 -0.972 . . . . 0.0 110.134 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.04 178.31 7.34 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.497 2.131 . . . . 0.0 109.94 179.366 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.15 -173.86 16.31 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.486 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -78.93 134.86 36.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.326 -1.102 . . . . 0.0 109.239 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.605 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 69.9 p-90 -147.72 159.42 43.82 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -128.26 135.44 27.54 Favored Pre-proline 0 C--N 1.298 -1.652 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.001 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -75.37 135.33 18.28 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 C-N-CA 121.86 1.707 . . . . 0.0 109.968 -179.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.1 ptpt -155.8 -165.66 2.02 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.462 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.481 ' HG3' ' HG2' ' A' ' 55' ' ' LYS . 4.0 mtp -150.4 125.89 10.2 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.293 -0.879 . . . . 0.0 109.641 -179.624 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.732 HD12 HG21 ' B' ' 50' ' ' ILE . 1.1 pt -89.78 147.1 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.014 -1.054 . . . . 0.0 108.422 179.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.433 ' HA2' ' HB3' ' A' ' 53' ' ' PHE . . . -117.97 105.76 1.28 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.503 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -128.39 -132.34 3.54 Favored Glycine 0 N--CA 1.484 1.89 0 C-N-CA 119.459 -1.353 . . . . 0.0 111.043 -178.815 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.812 HD12 ' C71' ' B' ' 100' ' ' DMP . 34.8 mt -83.13 121.06 35.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.838 -0.801 . . . . 0.0 112.537 -177.547 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.457 ' HA3' ' C ' ' B' ' 52' ' ' GLY . . . 97.71 -20.48 50.46 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 178.019 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.87 -161.01 28.88 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 120.808 -1.407 . . . . 0.0 109.993 179.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 0.0 OUTLIER -126.09 132.37 51.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.437 -1.037 . . . . 0.0 109.524 -179.5 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.585 HD11 HD11 ' A' ' 47' ' ' ILE . 14.1 pt -104.38 175.33 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.079 -1.013 . . . . 0.0 109.412 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.481 ' HG2' ' HG3' ' A' ' 46' ' ' MET . 3.6 mtmt -103.77 140.32 37.79 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.095 -1.003 . . . . 0.0 109.258 179.853 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.592 HG21 HD23 ' A' ' 76' ' ' LEU . 27.1 m -144.39 170.08 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.129 -0.982 . . . . 0.0 109.917 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.413 ' O ' ' N ' ' A' ' 59' ' ' TYR . 1.0 OUTLIER -111.21 96.76 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.057 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -55.78 93.74 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.344 -0.848 . . . . 0.0 109.704 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.605 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 5.8 m-85 -89.31 125.98 35.33 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 178.528 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.606 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 65.3 m-20 -106.38 133.8 50.5 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 120.792 -1.192 . . . . 0.0 110.345 -178.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.606 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 1.7 mt-30 74.44 63.32 0.07 Allowed 'General case' 0 N--CA 1.494 1.741 0 CA-C-O 121.855 0.836 . . . . 0.0 109.904 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.584 ' HB ' HG23 ' A' ' 75' ' ' VAL . 16.0 mm -115.14 119.47 61.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 178.616 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.599 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -70.42 90.2 0.71 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.178 -0.951 . . . . 0.0 111.277 -177.919 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.708 ' CG2' HD11 ' A' ' 89' ' ' LEU . 7.3 tt -88.51 113.51 25.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -87.99 111.79 21.88 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.244 -0.91 . . . . 0.0 109.012 -178.282 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.549 HD13 HG22 ' A' ' 13' ' ' ILE . 1.3 mm -97.19 168.1 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 179.45 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.505 ' C ' ' O ' ' A' ' 66' ' ' ILE . 61.3 m -28.68 88.87 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.488 0.661 . . . . 0.0 111.219 -179.074 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.573 ' O ' ' CD2' ' A' ' 69' ' ' HIS . . . 52.31 58.94 9.66 Favored Glycine 0 N--CA 1.494 2.558 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 179.529 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 68' ' ' GLY . 6.8 m-70 -162.27 86.76 0.61 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.372 . . . . 0.0 110.42 179.496 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.566 ' HG3' HD21 ' A' ' 63' ' ' LEU . 4.4 tttm -49.04 118.54 2.69 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.621 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -141.26 108.36 5.47 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 119.416 -0.914 . . . . 0.0 110.456 -178.602 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.599 HD13 ' N ' ' A' ' 63' ' ' LEU . 0.9 OUTLIER -80.74 159.42 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 107.305 -1.369 . . . . 0.0 107.305 178.005 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.894 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 179.42 174.49 45.51 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 118.247 -1.93 . . . . 0.0 111.452 179.577 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 87.6 m -87.14 112.67 22.17 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.606 -0.938 . . . . 0.0 109.956 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.888 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -102.17 118.9 49.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.422 -0.799 . . . . 0.0 110.275 179.679 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.592 HD23 HG21 ' A' ' 56' ' ' VAL . 4.9 mp -87.81 105.75 17.62 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.77 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 35' ' ' GLU . 6.5 t -88.75 113.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.233 -0.917 . . . . 0.0 110.327 -178.67 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -153.85 -168.77 17.96 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 179.451 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -80.35 44.5 1.75 Allowed 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.634 2.223 . . . . 0.0 111.061 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.695 HG21 HG13 ' A' ' 32' ' ' VAL . 9.7 t -82.5 141.25 45.17 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.022 -1.049 . . . . 0.0 108.637 179.241 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.674 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.7 Cg_endo -81.22 17.67 1.43 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.576 2.184 . . . . 0.0 111.163 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.674 HG23 ' O ' ' A' ' 81' ' ' PRO . 2.2 t -161.26 163.28 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.86 -1.15 . . . . 0.0 110.333 -179.23 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 72.5 m-20 -99.18 89.37 4.22 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.686 HG23 ' CB ' ' A' ' 25' ' ' ASP . 8.2 mm -78.27 116.43 21.94 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 O-C-N 121.168 -0.957 . . . . 0.0 111.764 -176.436 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.651 HG12 ' HB1' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -101.63 85.99 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 177.225 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.64 -165.32 28.02 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.288 -0.958 . . . . 0.0 112.346 -176.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.552 ' HD3' ' HD3' ' B' ' 9' ' ' PRO . 27.8 mtm-85 -57.38 -39.91 77.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 122.203 -0.586 . . . . 0.0 111.481 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.929 ' ND2' HD23 ' A' ' 89' ' ' LEU . 16.3 p-10 -45.49 -24.31 0.31 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.537 -1.352 . . . . 0.0 109.63 -179.3 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.929 HD23 ' ND2' ' A' ' 88' ' ' ASN . 3.5 mm? -111.9 -32.48 6.59 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.892 -1.13 . . . . 0.0 110.712 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.48 ' CD1' ' HA ' ' A' ' 26' ' ' THR . 90.1 mt -58.17 -36.58 73.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.824 -1.172 . . . . 0.0 108.841 -179.906 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.4 p -75.69 -20.53 58.34 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.316 -0.865 . . . . 0.0 109.643 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -72.45 -40.31 67.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.863 -1.148 . . . . 0.0 108.472 179.428 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.684 HD12 ' CD2' ' B' ' 99' ' ' PHE . 0.2 OUTLIER -81.65 -1.01 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.581 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 67.47 61.3 5.16 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.506 -1.838 . . . . 0.0 108.506 -179.527 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -89.77 149.27 22.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.442 -1.034 . . . . 0.0 110.003 -179.192 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.731 HG22 HG23 ' B' ' 4' ' ' THR . 49.5 p -137.73 125.43 22.36 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.028 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' B' ' 97' ' ' LEU . 4.8 mp -86.0 104.11 15.31 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.59 -0.694 . . . . 0.0 109.279 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.533 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.2 m120 -104.4 122.32 45.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.083 -1.011 . . . . 0.0 110.03 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.783 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.299 -1.618 0 CA-C-O 117.937 -1.03 . . . . 0.0 109.25 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.478 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.6 Cg_endo . . . . . 0 N--CA 1.496 1.626 0 N-CA-C 109.87 -0.858 . . . . 0.0 109.87 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 1.2 tt0 -84.64 134.0 34.39 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 178.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.62 HG13 HD13 ' B' ' 5' ' ' LEU . 22.2 t -133.73 137.07 53.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 120.762 -1.212 . . . . 0.0 109.9 -179.144 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.731 HG23 HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -129.99 23.84 5.3 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 178.983 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.71 HD23 ' HA ' ' B' ' 9' ' ' PRO . 1.6 mp -39.54 92.24 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.767 0.794 . . . . 0.0 109.801 -179.226 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.558 ' N ' ' O ' ' B' ' 4' ' ' THR . 4.7 m95 -44.42 -21.59 0.05 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.632 -0.667 . . . . 0.0 109.912 -179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.447 ' N ' ' O ' ' B' ' 5' ' ' LEU . 1.7 mt-30 -109.4 -158.85 0.66 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.022 -1.049 . . . . 0.0 108.599 179.122 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -59.01 119.7 40.42 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.037 -1.04 . . . . 0.0 109.469 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.71 ' HA ' HD23 ' B' ' 5' ' ' LEU . 36.6 Cg_endo -78.22 73.14 5.92 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.254 1.969 . . . . 0.0 109.798 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -82.1 163.61 21.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.184 -0.947 . . . . 0.0 109.937 -179.425 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.518 HG23 ' CG2' ' B' ' 13' ' ' ILE . 14.8 m -144.95 142.33 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.429 -0.794 . . . . 0.0 110.143 -179.697 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.744 HG22 HD22 ' B' ' 19' ' ' LEU . 2.7 m -73.97 99.09 3.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.01 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 1.3 pt -92.07 147.46 5.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 110.617 -178.454 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 3.8 tttt -114.08 94.51 4.85 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.829 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.826 HD11 HD12 ' B' ' 64' ' ' ILE . 22.3 mt -115.03 129.94 70.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.132 -0.98 . . . . 0.0 109.609 -179.429 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.05 52.99 49.08 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.442 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.35 23.57 9.01 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.629 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.482 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -119.26 170.67 8.9 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -1.151 . . . . 0.0 109.476 179.955 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.744 HD22 HG22 ' B' ' 12' ' ' THR . 13.8 mt -141.52 122.42 14.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.139 -0.976 . . . . 0.0 110.24 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 mttt -147.22 145.92 29.63 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 179.139 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 11.8 mt-10 -78.37 133.24 37.59 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.863 -1.148 . . . . 0.0 108.504 -179.9 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -112.38 162.8 15.15 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.521 -0.872 . . . . 0.0 109.883 -179.04 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.731 HD21 ' O ' ' A' ' 27' ' ' GLY . 59.4 tp -99.7 101.52 12.72 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.837 -0.539 . . . . 0.0 110.06 -178.856 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' B' ' 9' ' ' PRO . 2.9 mt -44.98 97.37 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.214 -0.929 . . . . 0.0 108.51 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.733 ' CB ' HG23 ' B' ' 84' ' ' ILE . 10.3 t0 -100.87 95.39 6.58 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.089 -1.007 . . . . 0.0 110.863 -178.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.53 HG21 HD13 ' B' ' 97' ' ' LEU . 0.2 OUTLIER -83.0 9.67 9.66 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.257 -0.902 . . . . 0.0 108.861 178.301 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.699 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -108.0 -14.13 17.88 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -95.5 170.03 9.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.111 -1.229 . . . . 0.0 109.089 179.803 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.08 -14.94 17.59 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.038 -1.039 . . . . 0.0 111.825 -178.397 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.535 ' HB3' HD11 ' B' ' 76' ' ' LEU . 14.3 m-20 -141.91 -169.33 2.89 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.507 -1.371 . . . . 0.0 110.639 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.779 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 38.5 m -104.48 84.75 2.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.199 -0.938 . . . . 0.0 110.475 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.659 HG13 HG21 ' B' ' 80' ' ' THR . 1.0 OUTLIER -78.75 112.19 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.244 -0.91 . . . . 0.0 110.387 -179.636 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.886 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.5 OUTLIER -107.76 123.17 48.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.583 -0.698 . . . . 0.0 110.176 179.895 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.736 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.0 pt-20 -43.36 164.34 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.943 -1.098 . . . . 0.0 108.831 178.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.819 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -47.74 145.03 2.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.996 -1.065 . . . . 0.0 110.112 -179.231 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.488 ' CG ' ' HG ' ' B' ' 38' ' ' LEU . 10.5 ptm -155.66 -165.55 2.0 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.36 -0.838 . . . . 0.0 109.135 179.802 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.4 ' N ' ' HG3' ' B' ' 36' ' ' MET . 21.2 t -102.44 87.14 2.95 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.111 -0.993 . . . . 0.0 109.508 179.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 1.06 HD12 HG21 ' B' ' 77' ' ' VAL . 31.3 mt -112.88 163.92 16.75 Favored Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 121.246 -0.909 . . . . 0.0 109.17 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 33.9 Cg_endo -75.8 -166.45 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.354 2.036 . . . . 0.0 110.492 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -94.28 -152.17 29.01 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.626 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 3.0 mmp_? 62.97 58.71 1.45 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.888 -0.772 . . . . 0.0 109.067 -179.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.584 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 30.0 p-90 -134.92 175.61 9.41 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.649 -0.657 . . . . 0.0 109.746 -179.537 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -135.03 123.65 15.97 Favored Pre-proline 0 N--CA 1.49 1.542 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 179.229 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -75.38 137.44 20.9 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.217 1.944 . . . . 0.0 111.543 -178.689 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.24 -167.29 2.72 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.105 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.51 ' HG2' ' CG ' ' B' ' 55' ' ' LYS . 54.6 mtp -145.69 131.36 18.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.94 -1.1 . . . . 0.0 110.159 -179.275 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.579 ' CD1' HG21 ' A' ' 50' ' ' ILE . 5.2 pt -97.75 149.04 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.171 -0.955 . . . . 0.0 108.694 179.08 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.06 116.94 3.49 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.987 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.42 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -139.27 -125.86 2.31 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.449 -1.358 . . . . 0.0 110.536 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.732 HG21 HD12 ' A' ' 47' ' ' ILE . 66.6 mt -87.23 129.27 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.948 . . . . 0.0 112.676 -177.794 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 92.07 -47.37 2.68 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 178.252 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.457 ' C ' ' HA3' ' A' ' 51' ' ' GLY . . . 178.87 -156.26 18.31 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.055 -179.701 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.626 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.5 m-85 -120.97 136.22 55.02 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.681 -0.894 . . . . 0.0 109.414 -179.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.45 HG12 ' CG2' ' A' ' 50' ' ' ILE . 7.1 pt -107.16 173.1 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.125 -0.984 . . . . 0.0 109.102 179.219 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.551 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 9.8 mttm -110.06 145.53 36.92 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.028 -1.045 . . . . 0.0 109.099 179.708 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.589 HG12 ' HA3' ' B' ' 78' ' ' GLY . 30.6 m -141.48 -173.79 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.868 -1.145 . . . . 0.0 110.39 -179.583 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.496 ' O ' ' N ' ' B' ' 59' ' ' TYR . 5.2 mtt85 -129.31 90.09 2.96 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . . . . . . . . . 12.0 tt0 -48.76 92.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.363 -0.836 . . . . 0.0 109.97 -179.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.584 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 10.3 m-85 -92.93 92.14 7.73 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 178.596 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.2 OUTLIER -79.52 140.17 37.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.147 -0.971 . . . . 0.0 110.626 -178.519 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.522 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 0.0 OUTLIER 76.76 60.61 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 CA-C-O 121.514 0.673 . . . . 0.0 110.019 179.539 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.786 ' CG2' HG23 ' B' ' 15' ' ' ILE . 6.1 mm -120.77 115.48 47.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.786 ' N ' HD13 ' B' ' 72' ' ' ILE . 0.5 OUTLIER -66.7 104.0 1.21 Allowed 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.848 -1.157 . . . . 0.0 110.73 -178.664 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.826 HD12 HD11 ' B' ' 15' ' ' ILE . 9.2 tt -106.19 112.65 40.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 177.486 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.492 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 14.0 tt0 -88.89 106.58 18.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.955 -1.091 . . . . 0.0 109.79 -177.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.75 HG13 HG22 ' B' ' 13' ' ' ILE . 1.6 mp -105.01 117.47 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.285 -0.884 . . . . 0.0 109.406 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.495 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 9.7 m 58.54 57.66 3.7 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.453 -0.779 . . . . 0.0 109.916 179.796 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.56 34.48 20.29 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.636 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.495 ' CD2' ' O ' ' B' ' 67' ' ' CYS . 61.8 m-70 -126.51 117.1 22.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.255 -1.144 . . . . 0.0 109.309 179.794 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.678 ' HG3' HD21 ' B' ' 63' ' ' LEU . 23.0 ttpt -65.38 124.82 23.27 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.363 -0.836 . . . . 0.0 109.452 -179.927 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.703 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -146.44 96.02 2.7 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.353 -0.842 . . . . 0.0 109.523 -179.829 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.786 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -79.14 152.46 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.048 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.56 ' HA3' ' CD2' ' B' ' 89' ' ' LEU . . . -173.07 -157.42 14.77 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 118.428 -1.844 . . . . 0.0 111.781 179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.447 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 3.4 m -110.66 104.97 13.71 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.679 -0.895 . . . . 0.0 110.001 -179.089 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.886 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -96.65 110.41 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.635 -0.666 . . . . 0.0 110.215 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.602 HD12 ' H ' ' B' ' 76' ' ' LEU . 3.8 mp -79.56 106.75 11.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.208 -0.932 . . . . 0.0 109.461 179.439 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 1.06 HG21 HD12 ' B' ' 38' ' ' LEU . 2.8 t -88.67 111.43 22.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.95 -1.094 . . . . 0.0 109.779 -179.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.589 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -141.65 -170.5 12.42 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.901 -1.68 . . . . 0.0 108.901 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.551 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -81.09 42.55 1.36 Allowed 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 122.474 2.116 . . . . 0.0 110.648 179.839 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.736 HG22 ' HA ' ' B' ' 34' ' ' GLU . 10.0 t -88.94 139.45 29.07 Favored Pre-proline 0 N--CA 1.49 1.536 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.458 ' HG2' ' H33' ' B' ' 100' ' ' DMP . 35.6 Cg_endo -80.43 18.21 1.25 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.553 2.169 . . . . 0.0 111.19 -179.313 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.669 HG13 ' O ' ' B' ' 83' ' ' ASN . 0.8 OUTLIER -161.59 163.01 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 120.917 -1.114 . . . . 0.0 110.008 -179.348 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.669 ' O ' HG13 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -94.62 160.33 14.68 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 104.482 -2.414 . . . . 0.0 104.482 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.779 ' O ' ' HA ' ' B' ' 31' ' ' THR . 12.6 mm -144.05 95.05 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 O-C-N 120.051 -1.655 . . . . 0.0 111.054 -178.354 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 1.051 HG22 HD11 ' B' ' 90' ' ' LEU . 0.3 OUTLIER -77.71 101.41 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 N-CA-C 107.294 -1.373 . . . . 0.0 107.294 178.196 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.691 ' C ' HD22 ' B' ' 90' ' ' LEU . . . -112.99 -176.07 19.49 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.674 -177.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.73 ' N ' HD22 ' B' ' 90' ' ' LEU . 7.1 mtt85 -29.65 -42.16 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -178.614 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.011 ' ND2' HD23 ' B' ' 89' ' ' LEU . 4.8 p-10 -57.56 -42.64 83.41 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.124 -1.61 . . . . 0.0 110.482 -177.688 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.011 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -95.8 -10.57 28.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.299 -0.876 . . . . 0.0 109.662 -179.589 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 1.051 HD11 HG22 ' B' ' 85' ' ' ILE . 1.2 mp -79.06 -32.0 44.68 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.319 -0.863 . . . . 0.0 109.186 -179.623 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.846 HG23 HD23 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -73.9 -20.22 60.47 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.064 -1.022 . . . . 0.0 109.413 179.611 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.819 ' OE1' HD13 ' B' ' 89' ' ' LEU . 28.0 mt-30 -82.13 -41.24 20.73 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.029 -1.045 . . . . 0.0 109.03 179.562 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.783 HD12 ' CB ' ' A' ' 99' ' ' PHE . 1.1 pt -82.48 -9.11 11.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 178.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.3 57.37 15.48 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.224 -1.15 . . . . 0.0 110.224 178.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.655 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -81.15 142.14 33.55 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.253 -1.145 . . . . 0.0 110.446 -179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.554 HG22 ' HA ' ' A' ' 4' ' ' THR . 24.3 p -129.82 126.2 37.51 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.713 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.704 HD11 HD11 ' A' ' 97' ' ' LEU . 2.7 mp -90.53 90.43 8.0 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 109.537 -179.609 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.543 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 5.1 m120 -95.63 127.63 41.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.294 -0.879 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.684 ' CD2' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.96 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.13 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.812 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.497 1.73 0 N-CA-C 110.65 -0.558 . . . . 0.0 110.65 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 0.1 OUTLIER -84.4 146.0 27.9 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 177.865 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.54 HG11 ' HB3' ' A' ' 9' ' ' PRO . 2.2 t -134.19 124.56 46.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 C-N-CA 118.486 -1.286 . . . . 0.0 110.091 -179.04 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.594 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.3 OUTLIER -130.14 14.02 5.67 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 178.128 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.2 OUTLIER -43.75 93.51 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 CA-C-O 121.9 0.857 . . . . 0.0 109.152 -179.301 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.538 ' N ' ' O ' ' A' ' 4' ' ' THR . 2.5 m95 -45.24 -15.15 0.02 OUTLIER 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.879 -0.513 . . . . 0.0 110.426 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.514 ' N ' ' O ' ' A' ' 5' ' ' LEU . 28.9 mt-30 -106.48 -115.65 0.26 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.62 -1.3 . . . . 0.0 108.951 179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.504 ' NE ' ' OD2' ' B' ' 29' ' ' ASP . 46.3 mtp180 -111.03 136.48 20.8 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 120.406 -1.434 . . . . 0.0 110.235 -179.691 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.54 ' HB3' HG11 ' A' ' 3' ' ' VAL . 38.0 Cg_endo -81.09 63.09 8.7 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.597 2.198 . . . . 0.0 109.785 178.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.484 HD22 ' HB3' ' A' ' 21' ' ' GLU . 2.4 mt -84.79 140.29 31.33 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.623 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.499 HG22 ' HB3' ' A' ' 22' ' ' ALA . 1.1 m -140.32 151.64 21.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.321 -0.862 . . . . 0.0 109.128 179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 23.5 m -86.08 99.92 11.82 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.206 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.854 HG22 HG13 ' A' ' 66' ' ' ILE . 1.9 pt -91.5 161.04 2.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.388 -0.82 . . . . 0.0 110.311 -178.178 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.529 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 1.2 tttt -117.07 97.85 6.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 109.174 179.491 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.912 ' CD1' HG21 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -113.67 126.93 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.096 -1.003 . . . . 0.0 109.463 -179.833 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 66.63 31.02 77.33 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.733 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 70.7 11.36 68.91 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 91.7 mm-40 -108.01 167.53 9.93 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -1.148 . . . . 0.0 108.901 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.508 ' O ' ' HD2' ' A' ' 20' ' ' LYS . 35.1 mt -126.23 123.35 37.97 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.011 -1.056 . . . . 0.0 109.368 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.508 ' HD2' ' O ' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -140.66 173.99 10.95 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.911 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 83' ' ' ASN . 1.6 mt-10 -79.25 177.23 8.99 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.602 ' HA ' ' HB2' ' A' ' 83' ' ' ASN . . . -154.75 112.0 3.37 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 120.849 -1.157 . . . . 0.0 109.798 179.471 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 25' ' ' ASP . 13.4 tp -89.53 95.35 10.23 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.646 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.536 HD13 HD23 ' B' ' 97' ' ' LEU . 30.4 mt -43.85 98.85 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.691 ' CB ' HG23 ' A' ' 84' ' ' ILE . 5.5 t0 -105.1 73.71 1.07 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.375 -0.828 . . . . 0.0 110.999 -177.651 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.0 m -57.15 -18.33 14.74 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 120.861 -1.149 . . . . 0.0 108.052 178.348 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.658 ' O ' HD11 ' B' ' 23' ' ' LEU . . . -64.97 -45.34 92.66 Favored Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.71 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.546 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -75.66 163.48 27.26 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.203 -1.174 . . . . 0.0 109.328 -179.923 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -95.43 -14.89 23.39 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.166 -0.958 . . . . 0.0 110.888 -179.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.547 ' HB3' ' CD1' ' A' ' 76' ' ' LEU . 0.1 OUTLIER -139.01 -165.44 1.84 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.671 -1.268 . . . . 0.0 111.338 -178.972 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.747 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 0.3 OUTLIER -102.47 88.52 3.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.487 -0.758 . . . . 0.0 110.953 -178.426 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.886 HG21 HD13 ' A' ' 47' ' ' ILE . 0.6 OUTLIER -79.38 113.38 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.013 -1.679 . . . . 0.0 107.933 178.566 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.93 HD13 ' CG1' ' A' ' 75' ' ' VAL . 1.1 mp -115.02 132.58 56.55 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 111.33 -177.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -43.39 165.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 178.202 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.4 OUTLIER -57.05 142.72 41.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.029 -1.045 . . . . 0.0 110.238 -179.561 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.646 ' HE2' HG22 ' A' ' 15' ' ' ILE . 4.2 ptm -161.82 -161.16 0.75 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.431 -0.793 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 9.2 t -104.15 114.89 29.45 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.321 -0.862 . . . . 0.0 110.358 -179.427 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.878 HD23 ' CD2' ' A' ' 59' ' ' TYR . 3.1 tp -138.68 145.7 47.33 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 179.514 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.636 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 31.6 Cg_endo -72.28 157.11 54.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.345 2.03 . . . . 0.0 110.507 -179.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.525 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -49.8 -162.09 0.01 OUTLIER Glycine 0 N--CA 1.493 2.473 0 CA-C-O 121.858 0.699 . . . . 0.0 111.881 -178.475 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.525 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.0 OUTLIER 75.59 50.29 0.07 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.904 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.614 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 6.9 p-90 -122.56 177.88 5.23 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-O 122.124 0.964 . . . . 0.0 111.269 -178.297 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.46 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 1.3 mtmm -139.51 118.49 8.96 Favored Pre-proline 0 C--N 1.303 -1.417 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 178.698 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -74.91 138.63 23.51 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.038 1.826 . . . . 0.0 110.91 -178.706 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.74 -173.21 4.0 Favored 'General case' 0 N--CA 1.49 1.528 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.901 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.5 ' CE ' ' HG3' ' A' ' 55' ' ' LYS . 0.0 OUTLIER -138.79 120.62 15.38 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.882 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 54' ' ' ILE . 3.1 pt -91.68 144.11 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.886 -1.134 . . . . 0.0 109.331 -179.877 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.631 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -119.01 135.04 11.15 Favored Glycine 0 N--CA 1.486 2.031 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 179.892 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.475 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -159.64 -129.5 1.06 Allowed Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.395 -179.614 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.711 HG23 HD13 ' B' ' 54' ' ' ILE . 77.6 mt -82.15 109.27 16.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.704 -0.88 . . . . 0.0 112.57 -177.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 111.78 -29.23 8.7 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 178.167 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 151.63 -161.52 29.26 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.424 179.65 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.631 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.5 m-85 -112.02 131.97 55.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.408 -1.054 . . . . 0.0 109.931 -179.464 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 47' ' ' ILE . 16.2 pt -105.12 173.0 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.978 -1.076 . . . . 0.0 108.889 178.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.528 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 6.4 mttt -110.09 128.84 55.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.253 -0.904 . . . . 0.0 109.301 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.894 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.9 m -137.34 -174.61 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.101 -1.0 . . . . 0.0 109.998 -179.835 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 77' ' ' VAL . 0.9 OUTLIER -120.37 173.57 7.06 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 178.98 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.81 ' OE1' HG22 ' A' ' 74' ' ' THR . 0.1 OUTLIER -136.66 89.53 2.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.894 -1.129 . . . . 0.0 110.8 -179.528 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.878 ' CD2' HD23 ' A' ' 38' ' ' LEU . 96.5 m-85 -90.01 122.25 32.83 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 178.354 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -96.94 146.29 25.1 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.882 -1.136 . . . . 0.0 110.531 -178.914 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.601 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.9 OUTLIER 71.28 65.78 0.16 Allowed 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.563 179.409 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.556 ' C ' HG12 ' A' ' 72' ' ' ILE . 13.5 mm -120.14 106.62 19.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.327 -0.858 . . . . 0.0 109.271 179.656 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.87 HD21 ' HG2' ' A' ' 70' ' ' LYS . 1.6 tm? -54.43 87.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.653 -0.654 . . . . 0.0 110.413 -178.759 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.815 HG22 ' O ' ' A' ' 71' ' ' ALA . 2.9 tt -89.68 122.09 40.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.872 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.521 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 7.1 tp10 -89.15 122.05 32.06 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.847 -1.158 . . . . 0.0 109.455 -178.69 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.854 HG13 HG22 ' A' ' 13' ' ' ILE . 0.3 OUTLIER -118.18 132.18 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.275 -0.89 . . . . 0.0 108.787 -179.912 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.448 ' C ' ' O ' ' A' ' 66' ' ' ILE . 21.5 m 38.24 49.96 1.36 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.635 . . . . 0.0 110.637 179.271 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.51 47.96 78.51 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 179.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.46 ' O ' ' HA ' ' A' ' 65' ' ' GLU . 77.6 m-70 -142.67 137.02 29.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.291 -1.123 . . . . 0.0 109.462 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.87 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -85.28 126.19 33.51 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.27 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.815 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -147.5 98.94 3.06 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.351 -0.843 . . . . 0.0 110.094 -178.794 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.601 HG23 ' HA ' ' A' ' 61' ' ' GLN . 0.0 OUTLIER -81.73 142.71 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 120.887 -1.133 . . . . 0.0 107.992 179.068 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' CD2' ' A' ' 89' ' ' LEU . . . -160.85 -159.02 9.64 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.834 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.81 HG22 ' OE1' ' A' ' 58' ' ' GLN . 3.1 m -101.78 105.25 16.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.945 -0.738 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.93 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.2 t -103.24 163.59 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.063 -1.023 . . . . 0.0 109.534 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.553 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 1.2 mp -129.87 158.88 38.28 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 178.68 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.601 HG12 ' HA ' ' A' ' 35' ' ' GLU . 23.8 t -142.68 106.44 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 O-C-N 121.101 -1.0 . . . . 0.0 110.133 -179.462 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.894 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -144.86 -163.61 10.16 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 108.524 -1.831 . . . . 0.0 108.524 179.576 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.528 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.8 41.45 1.12 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 C-N-CA 122.374 2.049 . . . . 0.0 111.393 -179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.572 HG21 HG13 ' A' ' 32' ' ' VAL . 6.0 t -84.52 132.64 46.34 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.054 -1.029 . . . . 0.0 108.536 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.42 17.69 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.834 2.356 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.612 HG13 ' N ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -160.87 173.68 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.836 -1.165 . . . . 0.0 109.843 -179.776 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.612 ' N ' HG13 ' A' ' 82' ' ' VAL . 57.4 m-80 -102.26 139.46 37.85 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.99 -2.596 . . . . 0.0 103.99 176.217 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.747 ' O ' ' HA ' ' A' ' 31' ' ' THR . 11.7 mm -128.66 95.59 2.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 O-C-N 120.283 -1.511 . . . . 0.0 110.533 -176.428 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.64 ' HA ' HG23 ' A' ' 31' ' ' THR . 1.0 OUTLIER -78.94 90.58 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.023 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -79.59 -160.44 19.97 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -178.432 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.612 ' O ' HG23 ' A' ' 91' ' ' THR . 0.0 OUTLIER -64.15 -28.37 69.72 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.547 -0.972 . . . . 0.0 110.663 -179.154 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.819 ' ND2' HD23 ' A' ' 89' ' ' LEU . 1.5 p-10 -53.61 -42.71 67.99 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.94 -1.1 . . . . 0.0 110.725 -178.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.819 HD23 ' ND2' ' A' ' 88' ' ' ASN . 0.4 OUTLIER -95.15 -24.85 16.66 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.893 -1.13 . . . . 0.0 108.874 -179.729 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 91.4 mt -69.07 -4.38 16.92 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.343 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.612 HG23 ' O ' ' A' ' 87' ' ' ARG . 36.2 p -100.82 -13.35 18.44 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.879 -1.138 . . . . 0.0 109.165 179.608 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 85.2 mm-40 -89.45 -40.99 12.33 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 0.0 109.726 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.686 HD12 ' CG ' ' B' ' 99' ' ' PHE . 10.5 pt -85.63 -0.09 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.144 -0.973 . . . . 0.0 108.98 179.525 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.88 43.74 40.38 Favored Glycine 0 N--CA 1.497 2.748 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.061 178.873 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.565 ' CA ' ' HB3' ' B' ' 99' ' ' PHE . . . -72.1 142.98 49.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.92 -1.341 . . . . 0.0 110.144 179.665 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 16.1 p -148.35 127.69 13.05 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.541 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' B' ' 97' ' ' LEU . 7.5 mp -86.55 95.86 9.89 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.269 -0.895 . . . . 0.0 109.453 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.546 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 3.4 m120 -99.02 117.99 34.77 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.042 -1.036 . . . . 0.0 109.679 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.748 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.297 -1.676 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.319 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.503 ' HD3' ' NE2' ' B' ' 69' ' ' HIS . 2.8 Cg_endo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.202 -0.73 . . . . 0.0 110.202 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.546 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 8.1 tt0 -83.64 139.44 32.81 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 178.151 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.589 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 2.5 t -131.23 111.05 18.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 118.456 -1.298 . . . . 0.0 110.911 -178.149 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.523 ' O ' ' N ' ' B' ' 6' ' ' TRP . 1.0 OUTLIER -123.21 -65.55 1.08 Allowed 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.587 ' O ' ' N ' ' B' ' 7' ' ' GLN . 1.2 tp 36.47 26.96 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.572 178.152 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.609 ' CZ3' ' HB ' ' A' ' 91' ' ' THR . 24.1 m95 18.07 47.63 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.302 0 CA-C-O 121.187 0.518 . . . . 0.0 112.172 179.882 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.587 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.0 OUTLIER -170.47 -158.05 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.965 . . . . 0.0 109.443 -179.755 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.643 ' HB3' HD12 ' B' ' 23' ' ' LEU . 11.5 mtm180 -70.07 125.58 92.05 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.092 -1.005 . . . . 0.0 109.056 179.467 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.589 ' HB3' ' CG1' ' B' ' 3' ' ' VAL . 35.5 Cg_endo -79.09 70.69 7.39 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.434 2.09 . . . . 0.0 109.653 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.806 HD23 ' C ' ' B' ' 22' ' ' ALA . 7.0 mt -85.29 137.93 32.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.267 -0.896 . . . . 0.0 110.816 -178.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.521 HG23 ' N ' ' B' ' 12' ' ' THR . 1.7 m -141.11 168.8 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 179.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.521 ' N ' HG23 ' B' ' 11' ' ' VAL . 3.9 m -94.91 120.98 36.03 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.894 HG22 HG13 ' B' ' 66' ' ' ILE . 1.6 pt -115.09 147.45 18.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 121.168 -0.958 . . . . 0.0 110.061 -179.201 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.473 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 4.1 ttmt -106.9 101.18 10.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.403 -0.811 . . . . 0.0 109.709 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.87 HG23 ' CG2' ' B' ' 62' ' ' ILE . 39.2 mt -117.86 140.28 41.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.464 ' HA3' HD12 ' B' ' 38' ' ' LEU . . . 50.47 55.08 18.02 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 45.68 34.68 5.38 Favored Glycine 0 N--CA 1.494 2.508 0 O-C-N 121.306 -1.114 . . . . 0.0 110.428 179.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 2.1 mm100 -132.54 171.71 13.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.059 -1.26 . . . . 0.0 108.807 179.249 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.475 ' HA ' HD23 ' B' ' 19' ' ' LEU . 13.7 mt -135.5 119.11 17.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.121 -0.987 . . . . 0.0 109.964 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.478 ' HB2' ' ND2' ' B' ' 83' ' ' ASN . 0.0 OUTLIER -135.62 178.12 7.29 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.682 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.572 ' HB3' HD22 ' B' ' 10' ' ' LEU . 3.6 mp0 -78.73 -176.06 4.73 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 179.038 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.823 ' HB2' HG12 ' B' ' 13' ' ' ILE . . . -164.82 105.07 0.81 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.786 -1.196 . . . . 0.0 110.627 -179.797 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.658 HD11 ' O ' ' A' ' 27' ' ' GLY . 0.2 OUTLIER -79.9 90.04 5.31 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 108.793 179.227 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' B' ' 9' ' ' PRO . 75.7 mt -43.63 98.54 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.463 -0.939 . . . . 0.0 108.463 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.821 ' HB2' HG23 ' B' ' 84' ' ' ILE . 56.9 t0 -100.28 94.13 6.04 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.51 -0.744 . . . . 0.0 111.131 -178.348 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.676 ' OG1' HD21 ' A' ' 97' ' ' LEU . 16.8 m -67.56 -15.22 63.54 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.968 -1.083 . . . . 0.0 108.339 178.187 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.494 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -71.76 -40.8 57.67 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 -179.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -80.83 149.91 29.36 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.963 -1.316 . . . . 0.0 109.662 -179.649 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.504 ' OD2' ' NE ' ' A' ' 8' ' ' ARG . 1.8 m-20 -92.01 -8.28 46.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.323 -0.861 . . . . 0.0 110.021 -179.471 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.52 ' HA ' ' HB3' ' B' ' 88' ' ' ASN . 0.1 OUTLIER -129.52 178.3 6.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.105 -0.997 . . . . 0.0 109.943 -179.335 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.785 HG22 ' CD1' ' B' ' 33' ' ' LEU . 21.5 m -108.42 83.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.75 -1.219 . . . . 0.0 109.677 -179.515 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.023 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -70.31 157.34 6.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.044 179.667 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.082 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.8 OUTLIER -153.51 133.67 13.36 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.572 -178.007 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.537 ' N ' HG23 ' B' ' 80' ' ' THR . 3.1 tt0 -50.98 153.45 1.82 Allowed 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.868 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' B' ' 34' ' ' GLU . 3.3 tt0 -35.12 142.81 0.05 Allowed 'General case' 0 N--CA 1.495 1.812 0 CA-C-O 121.477 0.656 . . . . 0.0 110.78 -179.634 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.652 ' SD ' HD13 ' B' ' 38' ' ' LEU . 0.2 OUTLIER -155.76 -170.38 3.4 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.403 -0.81 . . . . 0.0 109.099 179.429 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 9.5 t -109.68 66.4 0.63 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.943 -1.098 . . . . 0.0 111.157 -178.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.742 HD23 ' CG ' ' B' ' 59' ' ' TYR . 1.2 tp -87.24 158.31 52.49 Favored Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 177.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.636 ' HD2' ' HG ' ' B' ' 38' ' ' LEU . 32.1 Cg_endo -77.24 -155.37 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.927 1.751 . . . . 0.0 110.228 -179.484 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.514 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -84.47 -148.04 8.98 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 -179.345 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.514 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 1.7 mmp_? 65.41 57.06 0.92 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 122.054 -0.674 . . . . 0.0 109.234 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.668 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 54.8 p-90 -147.15 -176.57 5.27 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.863 0.839 . . . . 0.0 110.466 -179.67 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -148.13 139.32 13.61 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 179.092 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.43 136.61 15.89 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.281 1.987 . . . . 0.0 111.016 -178.889 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -160.76 -163.0 0.99 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.578 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.549 ' CE ' ' HG3' ' B' ' 55' ' ' LYS . 57.7 mtp -151.13 129.24 11.84 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.205 -0.935 . . . . 0.0 109.111 179.642 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.698 HD11 HD11 ' B' ' 54' ' ' ILE . 4.5 pt -91.64 144.41 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 118.356 -1.338 . . . . 0.0 107.999 178.771 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.565 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -117.44 107.43 1.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -178.923 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.52 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -133.23 -126.8 2.72 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.534 -1.317 . . . . 0.0 110.74 -179.138 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.829 HD12 ' C21' ' B' ' 100' ' ' DMP . 56.0 mt -85.87 134.56 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.851 -0.793 . . . . 0.0 113.045 -177.402 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.415 ' N ' HG23 ' A' ' 54' ' ' ILE . . . 88.03 -15.89 53.82 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.019 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 142.22 -160.06 27.16 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.264 179.55 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 2.9 m-85 -114.91 138.48 50.76 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.519 -0.989 . . . . 0.0 109.782 -179.541 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.711 HD13 HG23 ' A' ' 50' ' ' ILE . 23.1 pt -116.19 149.92 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.233 -0.917 . . . . 0.0 109.625 179.981 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.549 ' HG3' ' CE ' ' B' ' 46' ' ' MET . 3.2 mttm -85.26 136.52 33.47 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.339 -0.851 . . . . 0.0 108.936 179.574 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.483 ' O ' ' HG2' ' B' ' 57' ' ' ARG . 4.4 m -142.74 -164.81 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 O-C-N 120.957 -1.09 . . . . 0.0 110.245 -179.836 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 56' ' ' VAL . 4.9 mtt180 -147.46 111.34 5.06 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.736 ' NE2' HG21 ' B' ' 74' ' ' THR . 0.4 OUTLIER -74.69 124.81 27.42 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.059 -1.025 . . . . 0.0 110.413 -179.151 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.742 ' CG ' HD23 ' B' ' 38' ' ' LEU . 17.9 m-85 -112.89 109.39 18.8 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.568 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 2.7 m-20 -88.51 128.14 35.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.079 -1.013 . . . . 0.0 110.505 -179.307 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.581 ' HA ' HG23 ' B' ' 72' ' ' ILE . 8.2 mm-40 89.86 61.95 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.961 0 CA-C-O 121.216 0.531 . . . . 0.0 110.598 179.266 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.87 ' CG2' HG23 ' B' ' 15' ' ' ILE . 24.0 mm -119.04 106.73 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 108.878 178.927 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.805 ' N ' HD13 ' B' ' 72' ' ' ILE . 1.0 OUTLIER -61.29 92.57 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.172 -0.955 . . . . 0.0 110.129 -178.884 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.832 ' CG2' HD11 ' B' ' 89' ' ' LEU . 2.6 tt -97.38 117.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 178.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.53 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 16.4 tt0 -89.16 121.11 31.16 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.84 -1.162 . . . . 0.0 109.486 -179.127 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.894 HG13 HG22 ' B' ' 13' ' ' ILE . 0.6 OUTLIER -108.87 135.7 46.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.132 -0.98 . . . . 0.0 108.789 179.769 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.63 -92.4 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.734 -0.604 . . . . 0.0 109.492 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' B' ' 66' ' ' ILE . . . -141.82 54.59 0.61 Allowed Glycine 0 N--CA 1.485 1.908 0 N-CA-C 109.332 -1.507 . . . . 0.0 109.332 179.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.503 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 38.1 m-70 -154.24 151.82 29.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.278 -1.131 . . . . 0.0 109.986 -179.544 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.75 139.52 30.46 Favored 'General case' 0 N--CA 1.489 1.478 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 179.086 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.685 ' O ' HG22 ' B' ' 64' ' ' ILE . . . -151.52 97.68 2.42 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 110.817 -179.075 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.805 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.8 OUTLIER -79.48 139.65 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 178.19 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -164.1 -159.01 10.51 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 118.659 -1.734 . . . . 0.0 111.421 -179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.736 HG21 ' NE2' ' B' ' 58' ' ' GLN . 18.7 m -106.7 108.74 20.41 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.654 -0.909 . . . . 0.0 110.852 -178.74 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.082 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -104.43 127.82 58.46 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.503 -0.748 . . . . 0.0 111.415 -179.879 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.742 ' HB2' HG23 ' B' ' 32' ' ' VAL . 0.6 OUTLIER -84.84 141.3 30.55 Favored 'General case' 0 N--CA 1.496 1.851 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.728 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.62 115.96 46.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 O-C-N 121.003 -1.061 . . . . 0.0 108.667 178.716 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -162.04 -158.12 9.34 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.453 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -81.71 41.57 1.16 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.746 2.297 . . . . 0.0 110.471 179.868 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.537 HG23 ' N ' ' B' ' 34' ' ' GLU . 9.3 t -89.76 133.23 34.53 Favored Pre-proline 0 C--N 1.301 -1.54 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.347 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.618 ' O ' HG23 ' B' ' 82' ' ' VAL . 37.8 Cg_endo -80.15 22.94 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.479 2.119 . . . . 0.0 111.432 -178.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.618 HG23 ' O ' ' B' ' 81' ' ' PRO . 55.2 t -160.22 153.67 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 120.498 -1.376 . . . . 0.0 111.888 -178.671 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 76.0 m-20 -93.98 77.57 4.13 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 176.041 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.821 HG23 ' HB2' ' B' ' 25' ' ' ASP . 53.6 mt -79.71 119.59 29.4 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.561 0.695 . . . . 0.0 112.601 -175.556 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.521 HD13 ' N ' ' B' ' 85' ' ' ILE . 4.0 mm -95.48 104.57 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.181 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.748 ' C ' HD13 ' B' ' 90' ' ' LEU . . . -99.83 163.16 19.42 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.678 -1.249 . . . . 0.0 110.001 -179.38 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.645 ' N ' HD13 ' B' ' 90' ' ' LEU . 0.0 OUTLIER -25.74 -37.45 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 -178.829 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.931 ' ND2' HD23 ' B' ' 89' ' ' LEU . 8.7 p-10 -46.52 -42.11 15.19 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.021 -1.674 . . . . 0.0 110.113 -178.629 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.931 HD23 ' ND2' ' B' ' 88' ' ' ASN . 0.7 OUTLIER -93.76 -17.58 23.0 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.276 -0.89 . . . . 0.0 110.116 -179.514 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.748 HD13 ' C ' ' B' ' 86' ' ' GLY . 5.9 mp -69.55 -35.36 75.35 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.019 -1.073 . . . . 0.0 109.21 -179.548 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 72.3 p -70.99 -6.94 42.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.007 -1.058 . . . . 0.0 109.794 -179.538 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.703 ' OE1' HD22 ' B' ' 89' ' ' LEU . 8.3 mt-30 -100.01 -40.6 7.56 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.34 -0.85 . . . . 0.0 109.463 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.748 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.8 pt -82.87 3.56 2.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.203 -0.936 . . . . 0.0 108.817 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.7 42.41 97.22 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.534 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -77.38 138.18 39.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.945 -1.327 . . . . 0.0 109.697 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.594 HG22 ' CG2' ' A' ' 4' ' ' THR . 71.1 p -130.61 123.64 29.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.292 -0.88 . . . . 0.0 108.646 179.064 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.939 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -84.84 86.97 7.3 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 -179.658 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 7.4 m120 -97.81 132.19 43.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.456 -0.777 . . . . 0.0 110.492 -178.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.686 ' CG ' HD12 ' A' ' 93' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.287 178.664 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.829 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.581 ' O ' ' CE1' ' B' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.497 1.704 0 N-CA-C 110.316 -0.686 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.442 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 2.1 tt0 -84.05 138.41 33.09 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 178.136 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.421 HG11 ' HB3' ' A' ' 9' ' ' PRO . 4.4 t -132.55 134.45 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 120.722 -1.236 . . . . 0.0 110.441 -178.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.832 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.8 OUTLIER -143.3 -82.66 0.17 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.41 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.559 ' O ' ' C ' ' A' ' 6' ' ' TRP . 9.5 mt 34.41 32.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.895 -0.503 . . . . 0.0 110.719 178.896 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.559 ' C ' ' O ' ' A' ' 5' ' ' LEU . 44.2 m0 17.87 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.35 0 CA-C-O 121.393 0.616 . . . . 0.0 111.18 -179.875 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.553 ' HA ' ' NH1' ' B' ' 87' ' ' ARG . 2.3 mt-30 -144.56 -168.65 2.96 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.486 -0.759 . . . . 0.0 109.489 -179.329 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.0 mtt180 -81.22 122.37 81.3 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.337 -0.852 . . . . 0.0 108.917 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HB2' HD12 ' A' ' 24' ' ' LEU . 35.1 Cg_endo -77.94 69.9 7.26 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.146 1.897 . . . . 0.0 109.88 179.373 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.537 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.71 145.82 29.38 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.264 -0.898 . . . . 0.0 109.482 -179.678 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' HG23 ' A' ' 11' ' ' VAL . 6.1 m -138.89 127.63 29.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.648 -179.68 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.876 HG22 HD23 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -62.83 103.29 0.42 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 178.354 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.765 HD11 HD21 ' A' ' 33' ' ' LEU . 11.5 pt -89.83 139.19 17.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.003 -1.061 . . . . 0.0 110.114 -178.458 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.773 ' HE2' HD11 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -108.54 96.69 6.52 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.171 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.894 ' CD1' HG11 ' A' ' 75' ' ' VAL . 24.4 mt -113.18 119.87 61.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.361 -0.837 . . . . 0.0 109.537 -179.012 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD12 ' A' ' 38' ' ' LEU . . . 69.7 28.97 71.5 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -179.391 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.22 3.86 62.3 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.081 -1.607 . . . . 0.0 109.081 -179.197 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.524 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.8 OUTLIER -89.59 161.92 15.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.307 -1.113 . . . . 0.0 108.891 179.675 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.876 HD23 HG22 ' A' ' 12' ' ' THR . 0.1 OUTLIER -133.31 125.51 29.39 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.302 -0.874 . . . . 0.0 109.98 -179.394 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 2.5 mtmt -151.51 162.88 40.19 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -78.95 136.27 37.2 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 108.249 179.591 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.707 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -114.0 152.86 30.31 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.986 -1.071 . . . . 0.0 109.886 -179.313 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.495 ' O ' ' N ' ' A' ' 25' ' ' ASP . 38.6 tp -109.47 88.77 2.82 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.646 -0.659 . . . . 0.0 109.651 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.644 HD12 ' HB2' ' A' ' 9' ' ' PRO . 13.8 mt -43.1 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 179.526 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.645 ' HB3' HG22 ' A' ' 84' ' ' ILE . 9.9 t0 -109.9 97.58 7.07 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.427 -0.795 . . . . 0.0 110.982 -177.68 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.563 HG23 ' NH2' ' A' ' 87' ' ' ARG . 10.7 m -73.13 -6.54 46.43 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.329 -0.857 . . . . 0.0 109.114 178.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.567 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -79.96 -29.02 48.34 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.493 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -89.66 162.89 15.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.922 -1.34 . . . . 0.0 109.659 -179.688 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 0.7 OUTLIER -100.61 -8.39 23.01 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.231 -0.918 . . . . 0.0 110.729 -178.974 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.525 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -135.54 -177.69 4.78 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.075 -1.016 . . . . 0.0 109.442 -179.712 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.585 HG23 HD12 ' A' ' 85' ' ' ILE . 21.0 m -108.8 88.86 2.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.974 -1.079 . . . . 0.0 110.126 -179.196 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.12 174.02 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.098 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.05 119.46 1.29 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.823 -1.173 . . . . 0.0 111.694 -178.597 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.562 ' HA ' ' CG2' ' A' ' 80' ' ' THR . 2.5 mt-10 -36.02 154.68 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.185 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.556 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.0 OUTLIER -47.6 137.47 9.08 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.922 -1.111 . . . . 0.0 109.739 -179.871 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -161.72 164.94 28.76 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.326 -0.859 . . . . 0.0 109.407 179.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 10.9 t -90.14 104.21 16.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.223 -0.923 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.846 HD13 HG22 ' A' ' 15' ' ' ILE . 48.3 tp -122.08 118.58 29.09 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.236 -0.915 . . . . 0.0 109.304 179.492 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HD2' HD12 ' A' ' 38' ' ' LEU . 35.4 Cg_endo -77.99 120.27 4.97 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.401 2.068 . . . . 0.0 110.641 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.25 -177.75 33.95 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 179.839 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.06 144.73 28.06 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.119 -1.224 . . . . 0.0 108.716 179.521 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.577 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 21.5 p-90 -138.62 156.27 47.59 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.176 -0.953 . . . . 0.0 110.295 -179.613 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.424 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 14.2 mtpt -121.35 136.39 25.8 Favored Pre-proline 0 N--CA 1.488 1.469 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.251 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.69 129.28 9.92 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 122.263 1.975 . . . . 0.0 111.196 -178.853 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.8 ptmm? -164.17 152.4 12.83 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.324 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.545 ' CB ' ' O ' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -118.25 146.77 44.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.527 -1.358 . . . . 0.0 109.856 179.315 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.752 ' CD1' HG21 ' B' ' 50' ' ' ILE . 15.5 pt -102.6 149.56 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.37 -0.831 . . . . 0.0 109.077 179.903 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.604 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.89 111.52 2.12 Favored Glycine 0 N--CA 1.487 2.039 0 N-CA-C 108.331 -1.908 . . . . 0.0 108.331 179.832 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -134.89 -117.23 1.71 Allowed Glycine 0 N--CA 1.484 1.85 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.687 -178.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.824 HD12 ' C71' ' B' ' 100' ' ' DMP . 8.2 mt -91.01 130.17 40.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.78 -0.835 . . . . 0.0 112.542 -177.564 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.632 ' HA2' HG23 ' B' ' 54' ' ' ILE . . . 89.76 -23.27 20.76 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.021 177.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 150.84 -163.19 29.63 Favored Glycine 0 N--CA 1.491 2.347 0 O-C-N 120.744 -1.445 . . . . 0.0 110.375 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.604 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.1 m-85 -109.68 132.13 54.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.514 -0.992 . . . . 0.0 109.245 -179.639 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.784 ' CD1' HG13 ' A' ' 56' ' ' VAL . 1.1 pp -107.07 177.86 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.026 -1.046 . . . . 0.0 109.472 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 11.1 mmtt -112.49 138.99 48.45 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.206 -0.934 . . . . 0.0 109.45 179.231 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.815 HG12 ' HA3' ' A' ' 78' ' ' GLY . 6.6 m -146.66 -174.9 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.908 . . . . 0.0 109.687 -179.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.519 ' HB3' ' HB2' ' A' ' 42' ' ' TRP . 3.8 mtt85 -122.83 178.19 5.14 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.445 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 26.0 tt0 -135.97 101.57 4.77 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.131 -0.98 . . . . 0.0 110.827 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.703 ' CG ' HD23 ' A' ' 38' ' ' LEU . 61.7 m-85 -94.49 106.38 18.36 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 178.613 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 67.8 m-20 -88.28 123.27 32.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.124 -0.985 . . . . 0.0 110.576 -178.745 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.532 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 63.7 mm-40 86.06 59.98 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.635 0.731 . . . . 0.0 110.072 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.81 HG21 HG23 ' A' ' 15' ' ' ILE . 31.4 mm -115.84 121.9 68.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.777 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.009 HD21 ' HG2' ' A' ' 70' ' ' LYS . 0.4 OUTLIER -73.78 88.18 1.76 Allowed 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.725 -1.19 . . . . 0.0 110.966 -178.311 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.694 HD13 HD11 ' A' ' 66' ' ' ILE . 2.5 tt -85.82 117.4 30.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 177.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.478 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 3.6 tt0 -87.08 117.96 26.16 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.054 -1.029 . . . . 0.0 109.111 -178.495 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.694 HD11 HD13 ' A' ' 64' ' ' ILE . 1.0 OUTLIER -110.43 123.9 66.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.792 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.1 m 47.55 36.1 4.96 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.541 -0.724 . . . . 0.0 110.039 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.52 34.24 50.43 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 179.522 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 70' ' ' LYS . 31.9 m-70 -122.1 91.74 3.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.03 -1.277 . . . . 0.0 109.448 179.696 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 1.009 ' HG2' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -44.74 102.82 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.616 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.492 ' N ' HD11 ' A' ' 63' ' ' LEU . . . -127.24 132.88 50.3 Favored 'General case' 0 C--N 1.287 -2.109 0 O-C-N 121.804 -0.56 . . . . 0.0 109.806 -179.151 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.537 HG12 ' HA ' ' A' ' 63' ' ' LEU . 0.7 OUTLIER -108.17 152.21 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.867 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.542 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -176.41 -166.47 33.67 Favored Glycine 0 N--CA 1.487 2.045 0 C-N-CA 118.667 -1.73 . . . . 0.0 111.15 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.505 HG23 ' OD1' ' A' ' 60' ' ' ASP . 20.4 m -98.77 107.01 19.35 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.49 -1.006 . . . . 0.0 109.381 -179.921 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.098 ' CG1' HD13 ' A' ' 33' ' ' LEU . 0.2 OUTLIER -103.52 119.49 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.335 -0.853 . . . . 0.0 110.402 -179.546 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' H ' ' A' ' 76' ' ' LEU . 4.0 mp -88.63 142.87 27.33 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.332 -0.855 . . . . 0.0 108.906 178.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.556 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.9 t -126.8 118.65 51.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.398 -0.814 . . . . 0.0 109.875 179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.815 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.01 13.05 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.817 -1.713 . . . . 0.0 108.817 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 37.0 Cg_endo -82.69 41.75 1.17 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 C-N-CA 122.416 2.077 . . . . 0.0 110.015 179.803 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.562 ' CG2' ' HA ' ' A' ' 34' ' ' GLU . 5.1 t -82.45 140.16 44.83 Favored Pre-proline 0 C--N 1.305 -1.347 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.062 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.477 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 32.2 Cg_endo -76.22 10.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 C-N-CA 122.177 1.918 . . . . 0.0 111.438 -178.873 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.72 HG12 HD11 ' A' ' 84' ' ' ILE . 0.7 OUTLIER -161.19 168.02 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.882 -1.136 . . . . 0.0 109.653 179.828 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.57 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 0.3 OUTLIER -102.72 145.78 29.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 176.707 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.722 ' C ' HD13 ' A' ' 85' ' ' ILE . 3.5 mm -130.24 126.07 60.86 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 120.726 -1.234 . . . . 0.0 111.212 -177.536 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.85 HD13 ' N ' ' A' ' 85' ' ' ILE . 0.6 OUTLIER -101.47 92.18 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 177.446 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -81.34 -163.25 30.56 Favored Glycine 0 N--CA 1.496 2.693 0 O-C-N 121.241 -0.912 . . . . 0.0 111.995 -177.242 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.563 ' NH2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -60.82 -40.0 91.08 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.979 -0.718 . . . . 0.0 110.442 -179.283 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.052 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.0 p-10 -43.61 -31.1 0.69 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.274 -0.891 . . . . 0.0 109.298 -179.66 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.052 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.9 mm? -105.45 -26.02 12.11 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.168 -0.958 . . . . 0.0 109.998 -179.764 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.534 ' HB2' ' HA ' ' A' ' 87' ' ' ARG . 97.3 mt -71.1 -5.42 31.44 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.926 -1.109 . . . . 0.0 108.211 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.434 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.1 OUTLIER -100.42 -15.21 18.02 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.691 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.2 mm-40 -86.12 -40.82 15.3 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.623 -0.673 . . . . 0.0 109.569 179.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.955 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.2 pt -85.06 -5.18 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.175 -0.953 . . . . 0.0 108.982 179.726 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 72.93 49.93 15.16 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 178.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.571 ' HB2' ' HD2' ' B' ' 99' ' ' PHE . . . -83.44 149.5 26.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.008 -1.29 . . . . 0.0 110.557 -179.95 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 25.6 p -140.28 126.1 19.4 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' B' ' 97' ' ' LEU . 3.8 mp -85.98 96.53 9.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.385 -0.822 . . . . 0.0 109.843 -179.225 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.553 ' ND2' ' HG3' ' B' ' 2' ' ' GLN . 2.6 m120 -101.13 126.8 47.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.219 -0.926 . . . . 0.0 109.441 179.694 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.803 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.568 0 CA-C-O 118.039 -0.981 . . . . 0.0 109.446 179.568 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.537 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 2.8 Cg_endo . . . . . 0 N--CA 1.494 1.552 0 N-CA-C 109.873 -0.857 . . . . 0.0 109.873 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.553 ' HG3' ' ND2' ' A' ' 98' ' ' ASN . 3.0 tt0 -83.64 137.64 33.71 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.432 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' B' ' 5' ' ' LEU . 8.4 t -133.68 114.77 20.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 C-N-CA 118.565 -1.254 . . . . 0.0 110.501 -178.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.591 ' O ' ' N ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER -101.01 3.78 41.8 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 177.468 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.52 ' HB2' ' CG1' ' B' ' 3' ' ' VAL . 0.8 OUTLIER -21.66 83.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.654 0.74 . . . . 0.0 111.06 -179.438 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.591 ' N ' ' O ' ' B' ' 4' ' ' THR . 7.8 m95 -46.1 -21.05 0.12 Allowed 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.513 -0.742 . . . . 0.0 109.103 179.618 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.451 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -107.9 -165.51 1.05 Allowed 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 178.644 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.451 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.4 OUTLIER -66.68 125.49 90.72 Favored Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 120.919 -1.113 . . . . 0.0 109.65 -179.615 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.742 ' HB2' HD12 ' B' ' 24' ' ' LEU . 34.7 Cg_endo -77.49 75.72 4.57 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 122.035 1.823 . . . . 0.0 109.899 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.557 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.73 146.05 32.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.16 -0.963 . . . . 0.0 109.483 -179.69 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.551 ' CG1' HD11 ' B' ' 24' ' ' LEU . 5.5 m -131.02 148.71 33.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.303 -0.873 . . . . 0.0 109.82 -179.506 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.711 HG22 HD22 ' B' ' 19' ' ' LEU . 73.7 m -83.22 117.26 22.81 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 178.234 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.75 HG22 HG13 ' B' ' 66' ' ' ILE . 2.0 pp -112.62 131.35 64.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 O-C-N 121.117 -0.99 . . . . 0.0 110.739 -177.893 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.488 ' HG3' ' HG ' ' B' ' 19' ' ' LEU . 4.2 tttm -99.73 110.83 23.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.21 -0.931 . . . . 0.0 108.678 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.779 HD13 HG11 ' B' ' 75' ' ' VAL . 9.3 mt -116.67 141.79 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.043 . . . . 0.0 109.529 -179.326 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.54 -97.69 0.07 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -148.38 39.6 0.97 Allowed Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 179.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.414 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 44.5 mm-40 -140.52 -175.23 4.2 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.528 -0.984 . . . . 0.0 109.617 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.711 HD22 HG22 ' B' ' 12' ' ' THR . 6.8 mt -150.79 129.67 12.48 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.723 0.773 . . . . 0.0 110.621 -178.916 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.513 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 2.3 mptp? -148.03 168.34 22.59 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.321 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.557 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 1.8 mt-10 -79.11 172.84 13.24 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.655 -1.278 . . . . 0.0 109.129 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.568 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -149.51 106.14 3.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.343 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.567 HD21 ' O ' ' A' ' 27' ' ' GLY . 28.0 tp -64.06 99.42 0.26 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.552 -0.717 . . . . 0.0 110.006 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.742 HD12 ' HB2' ' B' ' 9' ' ' PRO . 44.4 mt -52.28 111.35 0.61 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.985 -1.072 . . . . 0.0 108.658 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.836 ' HB3' HG23 ' B' ' 84' ' ' ILE . 49.4 t0 -124.29 90.0 3.18 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.188 -0.945 . . . . 0.0 110.785 -178.554 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.58 ' HA ' HD12 ' B' ' 90' ' ' LEU . 3.0 m -63.96 -14.68 55.74 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.676 -1.265 . . . . 0.0 108.676 178.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.476 ' HA3' ' OD2' ' A' ' 25' ' ' ASP . . . -64.69 -46.93 88.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -71.05 158.97 35.58 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.899 -1.354 . . . . 0.0 108.802 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -92.12 -13.37 30.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.086 -1.009 . . . . 0.0 110.791 -178.621 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.564 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.7 OUTLIER -139.35 -173.87 3.72 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.783 -1.198 . . . . 0.0 110.041 -179.661 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.732 HG22 ' CD1' ' B' ' 33' ' ' LEU . 3.7 m -102.21 88.81 3.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.915 -1.115 . . . . 0.0 110.294 -179.177 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.99 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.4 OUTLIER -69.92 162.44 3.97 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.804 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.0 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.2 OUTLIER -158.78 126.6 5.07 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.938 -1.101 . . . . 0.0 110.719 -178.397 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' B' ' 33' ' ' LEU . 4.3 tt0 -40.68 161.25 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.826 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.543 ' HA ' HG12 ' B' ' 77' ' ' VAL . 1.6 tt0 -50.54 146.14 5.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.195 -0.94 . . . . 0.0 110.133 -179.543 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.526 ' HE1' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -174.98 160.67 2.84 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.385 -0.822 . . . . 0.0 108.805 179.553 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.0 t -79.51 97.63 6.51 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.877 -1.139 . . . . 0.0 109.286 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.576 HD21 ' CG2' ' B' ' 15' ' ' ILE . 0.8 OUTLIER -107.21 107.59 60.67 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 0.0 109.69 -179.66 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 129.04 10.1 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.517 2.145 . . . . 0.0 110.521 179.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 147.13 -165.41 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 -95.55 124.95 39.82 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.278 -1.131 . . . . 0.0 108.831 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.601 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 56.8 p-90 -128.77 172.25 11.45 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.171 -0.956 . . . . 0.0 110.309 -179.197 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 8.1 mptt -140.07 137.75 18.54 Favored Pre-proline 0 C--N 1.3 -1.573 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 178.653 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -76.28 134.96 16.27 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.858 1.705 . . . . 0.0 110.299 -179.257 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.464 ' CG ' HG23 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -153.7 -177.11 6.16 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.656 -0.818 . . . . 0.0 109.823 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.482 ' HG2' ' O ' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -138.28 115.19 10.79 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 109.192 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 54' ' ' ILE . 31.6 pt -94.49 130.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 C-N-CA 118.772 -1.171 . . . . 0.0 108.351 178.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.421 ' HA2' ' HA ' ' B' ' 53' ' ' PHE . . . -117.02 103.73 1.13 Allowed Glycine 0 N--CA 1.486 2.001 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 -179.337 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.419 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -123.04 -118.45 2.44 Favored Glycine 0 N--CA 1.483 1.816 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.367 -178.968 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.804 HD12 ' C21' ' B' ' 100' ' ' DMP . 15.6 mt -91.8 115.56 31.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 O-C-N 121.852 -0.793 . . . . 0.0 112.138 -177.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.605 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 112.34 -40.14 2.63 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 178.399 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 163.88 -162.77 35.39 Favored Glycine 0 N--CA 1.491 2.365 0 O-C-N 120.846 -1.385 . . . . 0.0 110.161 179.896 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.7 OUTLIER -112.55 127.64 56.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.456 -1.026 . . . . 0.0 109.732 -179.872 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.852 HD11 HD11 ' B' ' 47' ' ' ILE . 4.7 pt -109.81 169.18 3.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.195 -0.94 . . . . 0.0 108.657 178.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.535 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 23.1 mttt -109.82 132.44 54.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.03 -1.044 . . . . 0.0 108.9 179.6 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.782 HG12 ' HA3' ' B' ' 78' ' ' GLY . 3.1 m -130.96 -172.45 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.909 -1.119 . . . . 0.0 110.495 -179.281 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.427 ' HG3' ' C ' ' B' ' 56' ' ' VAL . 5.6 mtp180 -134.97 85.23 2.16 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.523 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 0.9 OUTLIER -52.73 100.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.6 -0.688 . . . . 0.0 110.901 -179.077 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.601 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 14.6 m-85 -90.28 123.07 33.75 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.498 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 0.0 OUTLIER -100.68 141.0 34.16 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.792 -1.193 . . . . 0.0 110.121 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.763 ' HA ' HG23 ' B' ' 72' ' ' ILE . 0.0 OUTLIER 72.08 65.61 0.13 Allowed 'General case' 0 N--CA 1.493 1.712 0 CA-C-O 121.441 0.638 . . . . 0.0 109.495 179.783 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.665 ' C ' HD13 ' B' ' 72' ' ' ILE . 27.8 mm -119.26 116.15 49.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.481 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.835 ' O ' HD13 ' B' ' 63' ' ' LEU . 3.1 tm? -68.94 83.22 0.31 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.454 -0.779 . . . . 0.0 110.582 -178.502 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.879 HG12 HD12 ' B' ' 66' ' ' ILE . 7.9 tt -88.16 125.1 41.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.493 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.446 ' OE2' ' HE3' ' B' ' 70' ' ' LYS . 4.0 tt0 -91.71 110.01 21.34 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.935 -1.103 . . . . 0.0 109.768 -178.409 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.879 HD12 HG12 ' B' ' 64' ' ' ILE . 0.3 OUTLIER -109.97 122.59 64.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.237 -0.914 . . . . 0.0 108.827 179.65 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.425 ' O ' ' CD2' ' B' ' 69' ' ' HIS . 33.7 m 52.05 62.66 2.59 Favored 'General case' 0 C--N 1.293 -1.878 0 O-C-N 121.644 -0.66 . . . . 0.0 110.378 179.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 47.81 25.21 3.43 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.16 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 79.2 m-70 -118.29 117.43 29.08 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.089 -1.242 . . . . 0.0 109.101 179.39 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.446 ' HE3' ' OE2' ' B' ' 65' ' ' GLU . 0.0 OUTLIER -67.94 133.16 48.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.137 -0.977 . . . . 0.0 108.968 179.725 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.693 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -149.26 139.19 21.99 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.371 -0.831 . . . . 0.0 110.168 -179.335 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.763 HG23 ' HA ' ' B' ' 61' ' ' GLN . 0.5 OUTLIER -110.31 140.8 27.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 177.679 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.49 -168.93 28.42 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 118.638 -1.744 . . . . 0.0 111.058 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' B' ' 59' ' ' TYR . 26.2 m -99.15 106.42 18.6 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.653 -0.91 . . . . 0.0 110.551 -179.185 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.0 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.7 t -100.68 108.89 24.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.47 -0.769 . . . . 0.0 110.813 179.3 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.662 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 5.2 mp -79.2 134.29 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.562 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.0 OUTLIER -118.39 118.44 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.109 -0.995 . . . . 0.0 109.448 -179.502 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.782 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -155.71 -167.16 16.78 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.535 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.7 Cg_endo -79.54 40.13 0.91 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.689 2.259 . . . . 0.0 111.295 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.837 HG23 ' H ' ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.45 142.97 33.51 Favored Pre-proline 0 C--N 1.302 -1.466 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 178.948 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.637 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.9 Cg_endo -79.86 17.56 1.28 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 C-N-CA 122.516 2.144 . . . . 0.0 112.246 -178.427 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.837 ' H ' HG23 ' B' ' 80' ' ' THR . 1.4 t -162.41 157.25 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 120.425 -1.422 . . . . 0.0 111.368 -179.501 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.581 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 2.1 m-20 -99.34 103.16 14.95 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.447 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.836 HG23 ' HB3' ' B' ' 25' ' ' ASP . 2.3 mt -104.18 131.31 53.27 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 120.723 -1.236 . . . . 0.0 112.607 -176.085 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.577 HD13 ' N ' ' B' ' 85' ' ' ILE . 2.3 mm -95.35 107.72 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 177.887 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -88.99 -154.58 29.09 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 120.787 -1.196 . . . . 0.0 111.142 -178.374 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.553 ' NH1' ' HA ' ' A' ' 7' ' ' GLN . 5.5 mtm180 -64.67 -40.09 94.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.832 -0.805 . . . . 0.0 109.911 -179.333 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.984 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.9 p-10 -45.15 -38.08 4.93 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.175 -0.953 . . . . 0.0 110.395 -179.073 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.984 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.0 mm? -96.75 -27.7 14.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.817 -1.177 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.58 HD12 ' HA ' ' B' ' 26' ' ' THR . 53.9 mt -71.22 -5.79 34.68 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 178.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 17.3 p -100.97 -10.93 20.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.226 -0.921 . . . . 0.0 108.696 178.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.722 ' OE1' HD22 ' B' ' 89' ' ' LEU . 13.9 mt-30 -91.89 -41.06 10.81 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.441 -0.787 . . . . 0.0 109.196 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.803 HD12 ' CD2' ' A' ' 99' ' ' PHE . 2.0 pt -85.74 2.41 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.29 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.28 51.49 52.18 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 178.783 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.7 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -78.73 142.32 37.14 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.154 -1.204 . . . . 0.0 110.184 179.746 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.832 HG22 ' CG2' ' A' ' 4' ' ' THR . 27.6 p -137.96 130.55 29.52 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.487 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.668 HD11 HD11 ' A' ' 97' ' ' LEU . 6.5 mp -91.21 94.08 9.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.339 -0.851 . . . . 0.0 110.035 -179.171 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.537 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 2.0 m120 -97.59 120.38 37.86 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.057 -1.027 . . . . 0.0 109.343 179.379 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.955 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.054 179.666 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.824 ' C71' HD12 ' A' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.428 ' HG3' ' HB3' ' A' ' 67' ' ' CYS . 2.6 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 N-CA-C 109.622 -0.953 . . . . 0.0 109.622 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.543 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 14.4 tt0 -84.3 139.71 32.13 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 178.408 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 1.114 HG13 HD23 ' A' ' 5' ' ' LEU . 87.7 t -143.79 117.46 3.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 118.385 -1.326 . . . . 0.0 110.583 -178.532 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.634 HG23 HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -98.54 -34.25 10.67 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 177.941 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.114 HD23 HG13 ' A' ' 3' ' ' VAL . 1.3 mm? 22.36 74.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.289 179.413 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.634 ' CE3' HG21 ' B' ' 91' ' ' THR . 41.3 m95 -41.56 -20.62 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.751 -0.593 . . . . 0.0 110.329 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' A' ' 5' ' ' LEU . 58.9 mt-30 -108.57 -105.1 0.36 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.607 -1.308 . . . . 0.0 109.282 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 8.9 mtt-85 -110.98 132.57 21.6 Favored Pre-proline 0 N--CA 1.496 1.835 0 O-C-N 120.654 -1.279 . . . . 0.0 110.215 -179.53 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 37.3 Cg_endo -78.92 66.34 8.73 Favored 'Trans proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.336 2.024 . . . . 0.0 109.867 178.25 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.584 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.2 OUTLIER -80.03 152.06 29.62 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.983 -1.073 . . . . 0.0 109.975 -179.32 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.638 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -142.09 170.9 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.382 -0.824 . . . . 0.0 109.404 -179.587 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.665 HG22 HD22 ' A' ' 19' ' ' LEU . 4.3 m -101.04 92.29 4.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 178.238 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.553 ' HA ' ' O ' ' A' ' 65' ' ' GLU . 22.1 pt -86.08 142.1 13.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.263 -0.898 . . . . 0.0 110.17 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 18' ' ' GLN . 6.9 ttmt -114.77 99.31 7.4 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.409 -0.807 . . . . 0.0 109.499 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.759 HG22 ' CG2' ' A' ' 62' ' ' ILE . 0.2 OUTLIER -116.15 158.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.065 -1.022 . . . . 0.0 109.427 179.829 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.477 ' C ' ' O ' ' A' ' 15' ' ' ILE . . . 34.86 50.72 0.8 Allowed Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 50.95 52.49 30.49 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.797 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.543 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 0.4 OUTLIER -152.1 172.49 16.25 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.459 -1.024 . . . . 0.0 108.493 179.574 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.665 HD22 HG22 ' A' ' 12' ' ' THR . 26.6 mt -141.96 132.03 24.66 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.08 -1.013 . . . . 0.0 110.549 -179.303 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 12.5 mmmt -150.68 162.52 40.54 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.714 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.4 mm-40 -79.25 141.54 37.01 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.942 -1.099 . . . . 0.0 108.19 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.664 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -124.05 131.72 53.59 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.992 -1.068 . . . . 0.0 110.21 -178.682 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.516 HD21 ' O ' ' B' ' 27' ' ' GLY . 25.2 tp -91.15 97.94 11.45 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.69 -0.631 . . . . 0.0 109.783 -179.774 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.547 HD13 HD21 ' A' ' 90' ' ' LEU . 0.2 OUTLIER -45.97 115.16 0.91 Allowed 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.397 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' HB3' HG22 ' A' ' 84' ' ' ILE . 14.9 t0 -125.7 84.4 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.331 -0.856 . . . . 0.0 111.021 -177.536 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.679 HG23 ' CD1' ' A' ' 90' ' ' LEU . 0.2 OUTLIER -62.68 -11.91 20.17 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.005 -1.059 . . . . 0.0 109.159 178.742 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -72.0 -41.52 54.52 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -179.28 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.508 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . . . -71.23 168.8 16.51 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.135 -1.214 . . . . 0.0 109.709 -179.4 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -100.74 -20.81 15.41 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.204 -0.935 . . . . 0.0 110.176 -179.444 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.576 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.3 OUTLIER -133.32 -164.99 1.56 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.068 -1.02 . . . . 0.0 109.548 -179.61 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 30.1 m -112.64 90.86 3.46 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.738 -1.226 . . . . 0.0 110.575 -179.034 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.071 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.52 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.053 -1.029 . . . . 0.0 108.826 179.536 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.126 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -165.81 121.41 1.29 Allowed 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.099 -1.001 . . . . 0.0 111.019 -178.849 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.496 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.6 OUTLIER -38.46 152.9 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.432 -0.792 . . . . 0.0 109.663 178.842 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 77' ' ' VAL . 2.6 mt-10 -46.07 141.61 3.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.177 -0.952 . . . . 0.0 110.459 -179.279 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.498 ' CE ' HD13 ' A' ' 15' ' ' ILE . 6.0 ptm -158.21 -177.21 6.39 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.348 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.3 t -101.09 101.7 12.5 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.069 -1.02 . . . . 0.0 109.903 -179.498 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 1.001 HD12 HG21 ' A' ' 77' ' ' VAL . 32.5 mt -106.72 162.43 19.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.062 -1.024 . . . . 0.0 109.971 -179.921 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.9 Cg_endo -78.23 65.85 8.41 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.895 2.397 . . . . 0.0 112.082 -179.219 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 37.36 -160.67 0.01 OUTLIER Glycine 0 N--CA 1.499 2.846 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 178.74 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.49 59.94 0.61 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.354 -1.086 . . . . 0.0 109.486 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.588 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 64.1 p-90 -148.7 168.67 22.27 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.626 0.727 . . . . 0.0 110.115 -179.556 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.1 136.35 28.69 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.04 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.0 139.1 17.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.222 1.948 . . . . 0.0 110.872 -179.272 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HE2' ' HB2' ' A' ' 58' ' ' GLN . 0.7 OUTLIER -153.42 -165.61 2.2 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.264 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.491 ' HG3' ' HG3' ' A' ' 55' ' ' LYS . 5.4 ttt -144.71 126.57 15.34 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.951 -1.093 . . . . 0.0 110.163 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.684 HD12 HG21 ' B' ' 50' ' ' ILE . 24.8 pt -96.1 133.65 36.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.612 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -117.67 101.0 0.89 Allowed Glycine 0 N--CA 1.486 1.999 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.413 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -121.53 -117.46 2.49 Favored Glycine 0 N--CA 1.483 1.806 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.65 -178.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.845 HD12 ' C71' ' B' ' 100' ' ' DMP . 12.8 mt -88.94 122.85 40.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.729 -0.865 . . . . 0.0 112.506 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 100.44 -51.53 1.01 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 178.213 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -179.86 -159.98 24.6 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 119.228 -1.463 . . . . 0.0 110.748 -179.604 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.612 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 3.2 m-85 -113.33 129.38 56.55 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.55 -0.971 . . . . 0.0 109.95 -179.254 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.525 ' CG2' ' HA2' ' B' ' 51' ' ' GLY . 1.9 pt -109.94 152.98 11.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.214 -0.929 . . . . 0.0 108.701 178.895 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.558 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 2.6 mtpt -93.84 123.39 37.15 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.11 -0.994 . . . . 0.0 109.508 -179.577 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.529 HG12 ' HA3' ' A' ' 78' ' ' GLY . 25.9 m -126.59 -170.08 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.22 -0.925 . . . . 0.0 109.939 -179.529 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.55 ' O ' ' HA ' ' A' ' 76' ' ' LEU . 22.5 mtt180 -124.31 174.42 7.73 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.249 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.452 ' HB2' ' HE2' ' A' ' 45' ' ' LYS . 37.2 tt0 -131.17 98.33 4.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.157 -0.964 . . . . 0.0 109.979 -179.342 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.598 ' CG ' HD13 ' A' ' 38' ' ' LEU . 64.9 m-85 -97.69 97.59 9.15 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.24 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.624 ' OD1' HG23 ' A' ' 74' ' ' THR . 1.1 m-20 -82.44 139.48 33.96 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 0.0 110.856 -178.601 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.473 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.1 OUTLIER 75.6 60.32 0.05 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.583 -0.698 . . . . 0.0 109.693 179.607 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.839 HG21 HG21 ' A' ' 75' ' ' VAL . 3.5 mm -116.49 122.82 70.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.489 -0.757 . . . . 0.0 108.979 -179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.93 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.1 tm? -74.7 94.99 2.79 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.206 -0.933 . . . . 0.0 111.159 -178.751 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 66' ' ' ILE . 8.2 tt -97.89 121.97 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 178.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.553 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 50.0 tt0 -89.67 101.54 14.23 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.01 -1.056 . . . . 0.0 108.86 -179.45 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 2.3 mp -102.68 120.5 52.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.993 -179.037 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 92.6 m 63.36 34.96 12.62 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.738 -0.601 . . . . 0.0 110.32 179.013 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.79 12.21 80.86 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -106.24 137.24 44.53 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -1.228 . . . . 0.0 109.255 179.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.449 ' HG3' HD21 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -80.96 123.93 28.72 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 109.094 179.84 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.734 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -142.79 155.53 44.83 Favored 'General case' 0 C--N 1.293 -1.852 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.552 -179.759 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.721 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.9 OUTLIER -125.18 149.81 29.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.005 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.898 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -175.42 176.24 47.31 Favored Glycine 0 N--CA 1.484 1.859 0 C-N-CA 118.484 -1.817 . . . . 0.0 111.158 -179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.624 HG23 ' OD1' ' A' ' 60' ' ' ASP . 6.5 m -86.76 108.74 18.83 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.702 -0.881 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.126 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.1 t -98.32 110.5 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.532 -0.73 . . . . 0.0 109.779 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.576 HD11 ' HB3' ' A' ' 30' ' ' ASP . 3.9 mp -78.9 139.16 38.35 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 120.997 -1.064 . . . . 0.0 108.356 179.133 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 1.001 HG21 HD12 ' A' ' 38' ' ' LEU . 15.9 t -125.04 114.72 41.55 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 O-C-N 121.481 -0.762 . . . . 0.0 110.054 -179.287 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.529 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -154.41 -159.67 9.36 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 108.915 -1.674 . . . . 0.0 108.915 179.664 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.558 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.9 Cg_endo -79.83 41.1 1.05 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.659 2.239 . . . . 0.0 111.072 -179.874 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.68 HG21 HG13 ' A' ' 32' ' ' VAL . 1.8 t -87.97 133.03 38.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.666 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -77.15 16.26 1.03 Allowed 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.687 2.258 . . . . 0.0 111.77 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.55 HG12 ' CD1' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -161.45 164.38 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 120.955 -1.091 . . . . 0.0 109.604 -179.812 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.597 ' OD1' ' N ' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -100.83 132.88 46.02 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 104.801 -2.296 . . . . 0.0 104.801 176.53 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.604 HG22 ' HB3' ' A' ' 25' ' ' ASP . 3.9 mm -119.8 119.98 61.93 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 O-C-N 120.447 -1.408 . . . . 0.0 111.362 -176.867 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.701 HD13 ' N ' ' A' ' 85' ' ' ILE . 2.0 mm -95.01 89.07 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 177.461 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 25' ' ' ASP . . . -78.98 -165.42 29.23 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.962 -1.114 . . . . 0.0 111.46 -177.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.501 ' CZ ' ' HB2' ' A' ' 87' ' ' ARG . 1.3 mtp-105 -59.34 -40.66 87.08 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.853 -0.792 . . . . 0.0 110.638 -178.904 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.986 ' ND2' HD23 ' A' ' 89' ' ' LEU . 12.9 p-10 -45.4 -24.99 0.35 Allowed 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.971 -1.081 . . . . 0.0 109.675 -179.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.986 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.1 mm? -110.64 -26.85 9.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.011 -1.056 . . . . 0.0 109.614 -179.298 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.679 ' CD1' HG23 ' A' ' 26' ' ' THR . 65.8 mt -72.09 -6.91 45.85 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 108.589 179.179 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.481 ' O ' ' CZ2' ' B' ' 6' ' ' TRP . 57.4 p -100.92 -19.17 16.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.041 -1.037 . . . . 0.0 108.252 179.116 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 -84.22 -41.14 17.25 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.8 . . . . 0.0 109.159 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.867 HD12 ' HB3' ' B' ' 99' ' ' PHE . 1.1 pp -80.36 -7.28 10.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 68.98 59.41 5.94 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.606 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.841 ' HB2' HD11 ' A' ' 93' ' ' ILE . . . -86.63 157.97 19.58 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -1.212 . . . . 0.0 110.356 -179.702 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -150.24 126.66 10.78 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.464 -0.772 . . . . 0.0 109.279 179.401 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' B' ' 97' ' ' LEU . 8.6 mp -86.09 111.57 20.46 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.1 m120 -108.73 121.76 45.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.852 -1.155 . . . . 0.0 109.78 179.951 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.692 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.427 179.897 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.418 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.495 1.603 0 N-CA-C 110.066 -0.782 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.466 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 3.9 tt0 -83.4 141.55 31.65 Favored 'General case' 0 N--CA 1.487 1.399 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 178.379 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.466 ' N ' ' HG2' ' B' ' 2' ' ' GLN . 40.6 t -142.66 112.73 2.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 120.565 -1.334 . . . . 0.0 110.694 -178.367 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.517 ' OG1' ' N ' ' B' ' 5' ' ' LEU . 0.2 OUTLIER -124.11 -71.7 0.71 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.713 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.543 ' O ' ' C ' ' B' ' 6' ' ' TRP . 18.5 mt 36.62 31.01 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.737 -0.602 . . . . 0.0 109.866 179.415 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.543 ' C ' ' O ' ' B' ' 5' ' ' LEU . 15.3 m0 17.27 52.75 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.144 0 CA-C-O 121.609 0.719 . . . . 0.0 111.404 -179.427 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.538 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.7 OUTLIER -150.55 -165.84 2.38 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.691 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -84.15 115.9 62.34 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.144 -0.973 . . . . 0.0 109.389 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.744 ' HB2' HD12 ' B' ' 24' ' ' LEU . 35.9 Cg_endo -77.29 73.3 5.58 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.391 2.061 . . . . 0.0 110.507 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 1.024 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.6 OUTLIER -79.6 163.47 24.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.157 -0.964 . . . . 0.0 108.786 179.617 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.663 HG23 HG23 ' B' ' 13' ' ' ILE . 4.6 m -144.53 128.01 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.994 -1.066 . . . . 0.0 110.765 -178.794 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 1.045 HG22 HD22 ' B' ' 19' ' ' LEU . 1.2 m -71.07 87.88 0.77 Allowed 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.529 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.07 HG22 HG13 ' B' ' 66' ' ' ILE . 17.3 pt -85.65 142.57 12.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-O 121.716 0.77 . . . . 0.0 111.58 -177.18 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.511 ' HA ' ' O ' ' B' ' 18' ' ' GLN . 2.8 tttt -103.29 94.21 5.39 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.187 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.616 HG22 ' CE ' ' B' ' 36' ' ' MET . 0.3 OUTLIER -104.28 115.78 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.164 -0.96 . . . . 0.0 110.358 -178.444 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.55 26.37 71.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.28 88.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' B' ' 14' ' ' LYS . 0.0 OUTLIER -96.96 -179.91 4.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -1.19 . . . . 0.0 108.704 179.427 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 1.045 HD22 HG22 ' B' ' 12' ' ' THR . 5.1 mt -148.82 128.25 13.07 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.972 -1.08 . . . . 0.0 110.382 -179.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.498 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 9.9 mttm -151.19 155.58 39.16 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.562 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 1.024 ' HB3' HD23 ' B' ' 10' ' ' LEU . 2.7 mm-40 -78.36 100.72 6.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.15 -0.969 . . . . 0.0 108.519 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 1.085 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -85.26 104.17 14.87 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.261 -0.899 . . . . 0.0 110.698 -178.738 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' B' ' 25' ' ' ASP . 5.4 tp -58.54 103.96 0.19 Allowed 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.445 179.26 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.744 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.3 mt -49.83 96.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.039 -1.038 . . . . 0.0 108.558 179.476 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.92 ' CB ' HG23 ' B' ' 84' ' ' ILE . 15.6 t0 -102.5 91.94 4.45 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.195 -0.94 . . . . 0.0 110.469 -179.075 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.503 HG23 HD13 ' B' ' 90' ' ' LEU . 6.9 m -70.39 -6.37 35.01 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.948 -1.095 . . . . 0.0 108.791 178.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.516 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -77.45 -39.91 24.72 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -76.39 154.88 34.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.019 -1.283 . . . . 0.0 109.305 -179.691 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -88.47 -17.96 29.25 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.16 -0.962 . . . . 0.0 110.753 -178.856 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.536 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -131.78 -170.36 2.38 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.948 -1.095 . . . . 0.0 110.464 -179.178 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.809 HG23 HD12 ' B' ' 85' ' ' ILE . 65.4 m -109.12 103.78 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.991 -1.068 . . . . 0.0 110.29 -178.634 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 0.943 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.3 OUTLIER -87.82 171.63 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.11 -0.994 . . . . 0.0 108.678 179.417 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.02 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.06 125.57 2.29 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.928 -1.107 . . . . 0.0 110.319 -179.048 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.663 ' HA ' HG22 ' B' ' 80' ' ' THR . 14.3 tt0 -37.8 160.59 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.391 0.615 . . . . 0.0 109.936 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.473 ' N ' ' O ' ' B' ' 78' ' ' GLY . 1.4 tt0 -53.6 148.45 9.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 110.46 -179.514 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.616 ' CE ' HG22 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -170.71 -166.55 0.51 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.611 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.46 ' N ' ' SD ' ' B' ' 36' ' ' MET . 5.4 t -115.06 76.73 1.01 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.797 -1.189 . . . . 0.0 110.923 -179.171 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.795 HD12 ' CG2' ' B' ' 77' ' ' VAL . 8.0 mt -80.43 173.31 7.91 Favored Pre-proline 0 N--CA 1.493 1.697 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 178.633 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.618 ' HD2' ' HB3' ' B' ' 38' ' ' LEU . 29.3 Cg_endo -71.01 -155.63 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.323 0 C-N-CA 121.776 1.651 . . . . 0.0 111.092 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . -103.0 -157.6 25.27 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.046 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.44 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 8.1 mmm-85 65.72 57.91 0.82 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.511 -0.993 . . . . 0.0 108.809 -179.639 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.607 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 52.0 p-90 -135.59 -172.6 3.13 Favored 'General case' 0 C--N 1.294 -1.807 0 CA-C-O 121.747 0.784 . . . . 0.0 110.282 -179.015 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 1.5 mptt -148.43 140.85 14.84 Favored Pre-proline 0 N--CA 1.489 1.487 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 179.126 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.48 135.4 14.72 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.74 1.627 . . . . 0.0 109.856 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.5 ' O ' ' HG2' ' B' ' 46' ' ' MET . 0.0 OUTLIER -158.46 -169.68 2.83 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.574 -0.85 . . . . 0.0 109.596 -179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' O ' ' B' ' 45' ' ' LYS . 10.1 mtp -149.26 131.39 15.41 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 109.097 179.849 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 54' ' ' ILE . 9.3 pt -89.04 140.34 15.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.95 -1.094 . . . . 0.0 108.312 179.271 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.18 111.43 2.17 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 -179.702 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.488 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -135.77 -114.29 1.36 Allowed Glycine 0 N--CA 1.481 1.697 0 C-N-CA 119.442 -1.361 . . . . 0.0 111.096 -178.806 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.848 HD12 ' C21' ' B' ' 100' ' ' DMP . 11.3 mt -92.64 124.47 45.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.862 -0.787 . . . . 0.0 112.385 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.525 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 94.85 -48.86 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 178.87 -157.15 20.42 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.66 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.1 OUTLIER -124.21 131.79 53.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.377 -1.072 . . . . 0.0 109.391 179.87 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.739 HD11 HD11 ' B' ' 47' ' ' ILE . 4.0 pt -99.01 -177.85 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.197 -0.939 . . . . 0.0 109.101 179.839 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.54 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -108.7 137.17 47.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.955 -1.09 . . . . 0.0 109.471 179.722 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.463 HG12 ' HA3' ' B' ' 78' ' ' GLY . 4.0 m -143.78 176.71 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 0.0 109.771 179.953 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -127.19 108.64 11.06 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.781 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.468 ' HG3' ' CG2' ' B' ' 74' ' ' THR . 0.6 OUTLIER -66.18 102.43 0.83 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.514 -0.741 . . . . 0.0 110.725 -179.085 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.607 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 9.7 m-85 -97.04 94.13 6.99 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.535 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.1 OUTLIER -79.1 134.31 36.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 0.0 110.093 -178.832 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.536 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 9.1 mm100 82.74 60.71 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.943 -0.473 . . . . 0.0 110.558 179.252 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.509 HG13 ' HB3' ' B' ' 59' ' ' TYR . 11.6 mm -124.05 126.72 72.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.994 -1.066 . . . . 0.0 109.202 178.876 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.81 HD22 HG13 ' B' ' 72' ' ' ILE . 0.2 OUTLIER -71.91 95.91 1.62 Allowed 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 121.72 0.771 . . . . 0.0 111.799 -178.52 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.551 ' HB ' HD11 ' B' ' 15' ' ' ILE . 3.5 tt -96.08 109.81 23.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 175.765 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.493 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 3.8 tm-20 -88.2 118.25 27.67 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.911 -1.118 . . . . 0.0 110.252 -177.571 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 1.07 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -112.74 113.13 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.555 -0.716 . . . . 0.0 109.195 179.929 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 1.2 m 66.06 6.33 4.05 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.653 -0.654 . . . . 0.0 110.314 179.356 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.457 ' N ' ' OE2' ' B' ' 65' ' ' GLU . . . 110.93 -3.1 28.7 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 56.5 m-70 -88.39 115.91 26.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.161 -1.199 . . . . 0.0 108.953 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.556 ' HG3' HD11 ' B' ' 63' ' ' LEU . 1.5 mptp? -69.45 107.24 3.26 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.574 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -121.98 110.06 15.36 Favored 'General case' 0 C--N 1.291 -1.938 0 O-C-N 121.627 -0.671 . . . . 0.0 109.683 -179.354 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.81 HG13 HD22 ' B' ' 63' ' ' LEU . 1.2 mt -94.63 120.64 44.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 120.894 -1.128 . . . . 0.0 108.271 178.782 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.677 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -140.32 -165.89 10.46 Favored Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.554 -179.645 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.468 ' CG2' ' HG3' ' B' ' 58' ' ' GLN . 59.5 m -97.73 106.69 19.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.68 -0.894 . . . . 0.0 109.651 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.02 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.5 t -91.34 172.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.541 -0.724 . . . . 0.0 109.49 179.44 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.667 ' HB2' HG23 ' B' ' 32' ' ' VAL . 3.6 mp -140.36 112.67 7.83 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.795 ' CG2' HD12 ' B' ' 38' ' ' LEU . 1.9 t -97.52 117.49 42.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 O-C-N 120.932 -1.105 . . . . 0.0 110.305 -178.508 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.473 ' O ' ' N ' ' B' ' 35' ' ' GLU . . . -154.19 -171.42 21.13 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.746 -1.742 . . . . 0.0 108.746 179.712 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.54 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 37.0 Cg_endo -80.92 41.56 1.17 Allowed 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 122.336 2.024 . . . . 0.0 110.926 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.663 HG22 ' HA ' ' B' ' 34' ' ' GLU . 6.5 t -82.38 138.7 44.83 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.854 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.411 ' O ' HG23 ' B' ' 82' ' ' VAL . 36.0 Cg_endo -78.23 18.16 0.96 Allowed 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.283 1.989 . . . . 0.0 110.973 -179.579 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.657 ' O ' HG23 ' B' ' 80' ' ' THR . 0.9 OUTLIER -159.71 163.82 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.107 -0.996 . . . . 0.0 109.638 -179.552 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.555 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -109.44 119.86 40.73 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 104.417 -2.438 . . . . 0.0 104.417 176.319 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.92 HG23 ' CB ' ' B' ' 25' ' ' ASP . 6.0 mt -120.4 132.67 69.4 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 120.117 -1.614 . . . . 0.0 113.859 -174.688 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 1.085 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -96.67 102.51 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.002 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.536 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -83.35 -160.26 29.32 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.532 -1.318 . . . . 0.0 110.076 -179.344 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.494 ' HD2' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -69.79 -30.25 67.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.472 -1.016 . . . . 0.0 109.848 -179.797 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.938 ' ND2' HD23 ' B' ' 89' ' ' LEU . 11.8 p-10 -49.38 -24.29 1.87 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.942 -1.099 . . . . 0.0 109.571 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.938 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.7 mm? -111.06 -23.42 10.93 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.998 -1.064 . . . . 0.0 109.76 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.625 HD21 HD22 ' B' ' 24' ' ' LEU . 51.8 mt -69.32 -6.17 27.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.027 -1.045 . . . . 0.0 109.225 179.7 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.634 HG21 ' CE3' ' A' ' 6' ' ' TRP . 0.0 OUTLIER -100.65 -20.53 15.6 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.075 -1.016 . . . . 0.0 108.969 179.401 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.574 HE21 ' HB1' ' B' ' 71' ' ' ALA . 7.9 mt-30 -81.04 -40.42 24.23 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.418 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.692 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -82.79 -5.54 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 177.923 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 77.12 25.95 62.98 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.151 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.596 ' N ' ' HB3' ' A' ' 99' ' ' PHE . . . -62.89 132.64 52.78 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.803 -1.41 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.634 HG22 HG23 ' A' ' 4' ' ' THR . 15.7 p -131.47 128.49 39.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.156 -0.965 . . . . 0.0 108.666 179.315 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.819 HD11 HD11 ' A' ' 97' ' ' LEU . 2.4 mp -85.76 96.83 9.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.409 -0.807 . . . . 0.0 110.358 -178.773 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.563 ' C ' ' CD1' ' B' ' 99' ' ' PHE . 2.6 m120 -111.05 139.75 46.15 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.366 -0.834 . . . . 0.0 109.499 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.867 ' HB3' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.056 -1.028 . . . . 0.0 109.533 179.438 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.848 ' C21' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.504 ' HG2' ' CD2' ' B' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.618 0 N-CA-C 110.232 -0.719 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.503 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 4.3 tt0 -91.48 128.62 37.38 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 178.156 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.413 HG11 ' HB3' ' A' ' 9' ' ' PRO . 53.0 t -125.56 131.88 71.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.028 -178.447 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.621 ' CG2' HG22 ' B' ' 96' ' ' THR . 0.0 OUTLIER -154.41 51.57 0.65 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.352 -0.842 . . . . 0.0 109.143 -179.733 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.549 ' O ' ' N ' ' A' ' 7' ' ' GLN . 0.1 OUTLIER -94.64 42.67 1.09 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.226 -0.921 . . . . 0.0 110.178 -179.401 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.529 ' C ' ' O ' ' A' ' 5' ' ' LEU . 26.9 m95 18.13 49.06 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.415 0 CA-C-O 121.131 0.491 . . . . 0.0 112.176 179.797 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.549 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -166.61 -173.89 2.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.145 -0.972 . . . . 0.0 109.359 179.66 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HD3' ' OD1' ' B' ' 29' ' ' ASP . 5.3 mtm180 -63.88 111.09 4.61 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.324 -0.86 . . . . 0.0 110.049 -179.629 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.534 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 34.1 Cg_endo -77.29 84.31 1.98 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 121.957 1.771 . . . . 0.0 109.117 178.668 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.732 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.3 OUTLIER -89.89 149.11 22.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 110.248 -178.882 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.855 HG21 HG23 ' A' ' 66' ' ' ILE . 0.9 OUTLIER -135.97 137.74 48.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.388 -0.82 . . . . 0.0 109.551 179.741 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.821 HG22 HD22 ' A' ' 19' ' ' LEU . 29.2 m -72.96 98.84 2.57 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 178.635 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.687 HG22 HG13 ' A' ' 66' ' ' ILE . 15.3 pt -88.6 144.02 9.99 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 O-C-N 121.407 -0.808 . . . . 0.0 110.805 -178.363 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.814 ' HD3' HD21 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -107.01 105.23 15.16 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.725 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.688 HD13 HG11 ' A' ' 75' ' ' VAL . 24.8 mt -121.74 124.45 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.049 -1.032 . . . . 0.0 109.872 -179.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.88 18.4 72.46 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.372 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.55 0.61 84.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.471 ' O ' ' HG3' ' A' ' 14' ' ' LYS . 28.7 mm-40 -99.9 -178.62 3.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.175 -1.191 . . . . 0.0 109.058 179.746 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.821 HD22 HG22 ' A' ' 12' ' ' THR . 16.7 mt -141.29 129.6 22.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.181 -0.949 . . . . 0.0 110.002 -179.579 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.456 ' HB2' ' ND2' ' A' ' 83' ' ' ASN . 3.1 mmtp -142.88 -170.49 3.25 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.492 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.732 ' HB3' HD22 ' A' ' 10' ' ' LEU . 1.2 mt-10 -103.26 146.52 28.32 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.161 -0.962 . . . . 0.0 109.025 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.712 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -130.22 136.21 48.97 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.931 -1.106 . . . . 0.0 110.221 -179.566 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.841 HD21 ' O ' ' B' ' 27' ' ' GLY . 53.0 tp -105.17 111.55 24.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.495 -0.753 . . . . 0.0 110.041 -179.329 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.534 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . 0.4 OUTLIER -46.71 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.907 -1.121 . . . . 0.0 109.324 179.618 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.701 ' CB ' HG23 ' A' ' 84' ' ' ILE . 33.4 t0 -98.65 71.43 1.96 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.116 -0.99 . . . . 0.0 109.563 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.564 ' CG2' ' HG3' ' B' ' 9' ' ' PRO . 64.9 m -58.1 -15.88 11.12 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.103 -0.998 . . . . 0.0 108.537 179.066 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.686 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -69.64 -41.14 76.17 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.742 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.502 ' HB2' ' C25' ' B' ' 100' ' ' DMP . . . -76.94 155.97 32.35 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -1.213 . . . . 0.0 109.78 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.524 ' OD2' ' CG ' ' B' ' 8' ' ' ARG . 1.3 m-20 -96.47 -9.97 28.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.769 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 88' ' ' ASN . 0.3 OUTLIER -131.6 -170.11 2.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 109.549 -179.677 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.563 HG23 HD12 ' A' ' 85' ' ' ILE . 11.2 m -113.81 88.37 2.83 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.058 -1.027 . . . . 0.0 109.973 -179.367 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.93 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -69.93 171.19 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 178.725 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.039 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -164.08 123.36 1.97 Allowed 'General case' 0 C--N 1.303 -1.42 0 O-C-N 120.406 -1.434 . . . . 0.0 111.875 -179.261 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.661 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -42.32 145.81 0.37 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 178.517 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.601 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.8 OUTLIER -48.23 138.75 9.29 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.149 -0.969 . . . . 0.0 109.826 -179.683 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.506 ' HE1' ' O ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -147.63 -164.47 2.01 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.424 -0.798 . . . . 0.0 109.209 179.419 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.443 ' N ' ' SD ' ' A' ' 36' ' ' MET . 18.1 t -100.01 87.67 3.55 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.284 -0.885 . . . . 0.0 110.041 -179.639 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 1.054 HD12 HG21 ' A' ' 77' ' ' VAL . 16.2 mt -110.92 159.96 30.62 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.106 -0.996 . . . . 0.0 108.935 179.19 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.471 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 34.8 Cg_endo -77.35 154.23 31.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.598 2.199 . . . . 0.0 110.361 179.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.542 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -59.29 -154.98 0.02 OUTLIER Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.542 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 4.7 mmm180 69.86 49.58 0.51 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.831 -0.805 . . . . 0.0 109.48 -179.595 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.616 ' HB3' ' CE1' ' A' ' 59' ' ' TYR . 45.8 p-90 -135.31 -171.4 2.81 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.0 mtpm? -138.9 134.36 16.97 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.963 -1.085 . . . . 0.0 108.85 179.598 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -77.69 139.26 17.74 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.073 1.849 . . . . 0.0 111.26 -179.181 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.523 ' HE2' ' CD2' ' A' ' 76' ' ' LEU . 11.4 pttt -159.03 153.6 24.35 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.307 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.458 ' HG3' ' O ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -110.85 128.94 55.97 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.778 -1.201 . . . . 0.0 110.4 -179.093 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.843 ' CD1' HG21 ' B' ' 50' ' ' ILE . 10.0 pt -96.81 142.07 14.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 120.95 -1.094 . . . . 0.0 108.152 178.305 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.619 ' HA3' ' CE2' ' A' ' 53' ' ' PHE . . . -118.79 100.56 0.83 Allowed Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.607 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.12 -122.76 2.78 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.71 -1.234 . . . . 0.0 110.099 -179.716 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.819 HD12 ' C71' ' B' ' 100' ' ' DMP . 10.5 mt -87.33 123.21 39.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.629 -0.924 . . . . 0.0 111.854 -178.466 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 105.79 -52.78 0.68 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.146 -1.181 . . . . 0.0 110.146 178.573 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.46 -155.2 21.84 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.751 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.619 ' CE2' ' HA3' ' A' ' 48' ' ' GLY . 6.8 m-85 -114.12 123.22 49.1 Favored 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.412 -1.052 . . . . 0.0 110.014 -179.755 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.71 ' CD1' HG23 ' B' ' 50' ' ' ILE . 32.0 pt -102.79 162.43 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.076 -1.015 . . . . 0.0 108.509 178.597 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.562 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.9 OUTLIER -95.96 144.78 25.97 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.215 -0.928 . . . . 0.0 109.018 -179.932 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.65 HG12 ' HA3' ' A' ' 78' ' ' GLY . 17.0 m -142.91 -173.73 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.889 -1.132 . . . . 0.0 109.711 -179.83 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.571 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 36.2 mtt180 -133.04 93.21 3.14 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 179.541 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -50.03 101.65 0.03 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-O 121.585 0.707 . . . . 0.0 110.036 -179.632 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.616 ' CE1' ' HB3' ' A' ' 42' ' ' TRP . 7.3 m-85 -100.95 88.29 3.5 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.74 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.498 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.2 OUTLIER -78.73 137.68 37.89 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.201 -0.937 . . . . 0.0 110.401 -178.517 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.628 ' HA ' HG23 ' A' ' 72' ' ' ILE . 0.0 OUTLIER 74.01 61.79 0.08 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.755 -0.591 . . . . 0.0 110.531 179.329 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.851 ' C ' HD13 ' A' ' 72' ' ' ILE . 1.2 mt -122.02 124.21 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.516 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.815 ' O ' HD13 ' A' ' 63' ' ' LEU . 3.1 tm? -70.06 92.24 0.73 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.442 -0.787 . . . . 0.0 111.82 -177.559 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.77 HD13 HD11 ' A' ' 66' ' ' ILE . 4.2 tt -96.91 118.53 43.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 177.846 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.556 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 39.1 tt0 -89.61 100.81 13.54 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.983 -1.073 . . . . 0.0 109.766 -178.778 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.855 HG23 HG21 ' A' ' 11' ' ' VAL . 1.3 mp -97.12 121.8 47.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.268 -0.895 . . . . 0.0 108.965 179.769 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.407 ' O ' ' CD2' ' A' ' 69' ' ' HIS . 1.3 m 58.09 57.32 4.09 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.515 -0.741 . . . . 0.0 109.641 179.614 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 49.71 26.33 7.78 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.764 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.461 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 59.8 m-70 -122.24 118.9 29.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.991 -1.3 . . . . 0.0 109.267 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.638 ' HG3' HD21 ' A' ' 63' ' ' LEU . 2.9 mptt -61.38 139.58 58.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.312 -0.867 . . . . 0.0 109.258 -179.886 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.67 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -159.88 102.33 1.48 Allowed 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.173 -0.954 . . . . 0.0 110.473 -179.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.851 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.6 OUTLIER -78.58 147.25 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.525 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.847 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -173.09 -170.89 37.25 Favored Glycine 0 N--CA 1.487 2.099 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.903 -179.882 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.2 m -95.33 106.08 18.09 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.729 -0.865 . . . . 0.0 110.174 -179.488 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.039 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -99.04 106.58 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.701 -0.625 . . . . 0.0 109.708 179.358 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.548 ' HB2' ' HA ' ' A' ' 32' ' ' VAL . 2.8 mp -79.81 113.26 17.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.119 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 1.054 HG21 HD12 ' A' ' 38' ' ' LEU . 7.9 t -97.91 107.98 21.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 O-C-N 120.908 -1.12 . . . . 0.0 110.261 -178.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.65 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -140.24 -166.48 10.68 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.101 -2.0 . . . . 0.0 108.101 179.088 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.562 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 36.6 Cg_endo -79.92 40.42 0.96 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.305 2.003 . . . . 0.0 110.522 179.208 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.661 HG22 ' HA ' ' A' ' 34' ' ' GLU . 11.5 t -81.75 137.25 47.45 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.33 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.566 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.1 Cg_endo -78.91 16.3 1.35 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 C-N-CA 122.483 2.122 . . . . 0.0 111.476 -179.089 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.4 t -161.07 149.65 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 120.809 -1.182 . . . . 0.0 110.251 -179.845 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.617 ' HA ' ' HA ' ' A' ' 33' ' ' LEU . 0.7 OUTLIER -85.85 100.07 11.81 Favored 'General case' 0 N--CA 1.485 1.297 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 176.774 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.701 HG23 ' CB ' ' A' ' 25' ' ' ASP . 18.9 mm -84.52 120.46 35.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.234 -0.916 . . . . 0.0 112.994 -175.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.912 HG22 HD11 ' A' ' 90' ' ' LEU . 0.6 OUTLIER -103.0 99.36 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.836 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.493 ' O ' HD13 ' A' ' 90' ' ' LEU . . . -106.54 175.99 21.31 Favored Glycine 0 N--CA 1.497 2.72 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.243 -177.069 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.753 ' N ' HD22 ' A' ' 90' ' ' LEU . 13.2 mmm180 -25.81 -41.41 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -179.085 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.034 ' ND2' HD23 ' A' ' 89' ' ' LEU . 11.8 p-10 -52.54 -42.54 64.5 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.184 -1.573 . . . . 0.0 110.562 -177.683 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.034 HD23 ' ND2' ' A' ' 88' ' ' ASN . 1.8 mm? -92.98 -23.96 18.53 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.043 -1.035 . . . . 0.0 108.607 179.598 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.912 HD11 HG22 ' A' ' 85' ' ' ILE . 0.4 OUTLIER -67.81 -8.03 32.59 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.309 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -97.82 -20.66 17.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.928 -1.108 . . . . 0.0 108.844 179.824 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 30.6 mm-40 -85.71 -40.21 16.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.216 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.71 HD12 ' CB ' ' B' ' 99' ' ' PHE . 1.1 pt -83.12 2.16 3.49 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.236 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 66.46 31.93 80.25 Favored Glycine 0 N--CA 1.499 2.887 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.186 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.685 ' HB3' ' HB3' ' A' ' 90' ' ' LEU . . . -61.06 143.72 54.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.247 -1.149 . . . . 0.0 111.433 -179.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.707 HG22 ' CG2' ' B' ' 4' ' ' THR . 58.0 p -152.05 141.49 21.6 Favored 'General case' 0 N--CA 1.501 2.107 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.13 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' B' ' 97' ' ' LEU . 0.0 OUTLIER -98.23 118.31 34.58 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.786 -1.196 . . . . 0.0 110.358 -179.916 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 2.5 m120 -118.0 123.75 46.48 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.637 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.97 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 118.043 -0.979 . . . . 0.0 109.481 179.894 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.574 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.4 Cg_exo . . . . . 0 N--CA 1.495 1.576 0 N-CA-C 110.176 -0.74 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.511 ' HG2' ' N ' ' B' ' 3' ' ' VAL . 1.8 tt0 -89.12 146.41 24.83 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.216 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . 0.58 ' CG1' ' HB3' ' B' ' 9' ' ' PRO . 12.2 t -138.93 118.17 13.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 O-C-N 120.525 -1.359 . . . . 0.0 110.673 -178.615 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.707 ' CG2' HG22 ' A' ' 96' ' ' THR . 0.0 OUTLIER -123.94 -71.83 0.7 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.277 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.743 ' N ' HD22 ' B' ' 5' ' ' LEU . 3.1 mm? 36.92 34.47 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.654 -0.654 . . . . 0.0 110.656 179.574 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.532 ' C ' ' O ' ' B' ' 5' ' ' LEU . 17.8 m95 18.61 48.17 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.285 0 CA-C-O 121.233 0.54 . . . . 0.0 112.165 179.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.569 ' N ' ' O ' ' B' ' 5' ' ' LEU . 2.2 mt-30 -163.16 -158.9 0.5 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.53 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 0.0 OUTLIER -71.94 124.19 90.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.348 -0.845 . . . . 0.0 109.431 179.888 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.639 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.7 Cg_endo -76.99 74.15 5.12 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.146 1.897 . . . . 0.0 110.094 179.387 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.818 HD23 ' HB3' ' B' ' 21' ' ' GLU . 0.2 OUTLIER -79.41 164.24 24.15 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.03 -1.044 . . . . 0.0 110.091 -179.498 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.467 HG23 HG23 ' B' ' 13' ' ' ILE . 2.8 m -151.27 152.76 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.475 -0.766 . . . . 0.0 109.927 -179.007 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.947 HG22 HD22 ' B' ' 19' ' ' LEU . 27.9 m -85.89 103.32 14.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.422 -1.423 . . . . 0.0 107.717 177.562 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 1.06 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.7 pt -94.53 148.6 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.065 -1.022 . . . . 0.0 110.479 -178.566 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . . . . . . . . . 9.6 tttt -117.12 105.47 12.3 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.739 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.945 HG22 HD21 ' B' ' 38' ' ' LEU . 16.3 mt -116.75 134.01 61.61 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 120.826 -1.171 . . . . 0.0 109.438 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 64.09 -99.37 0.31 Allowed Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.954 -1.659 . . . . 0.0 108.954 -179.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . 0.403 ' C ' ' HG2' ' B' ' 18' ' ' GLN . . . -145.31 32.05 1.66 Allowed Glycine 0 N--CA 1.484 1.857 0 N-CA-C 108.471 -1.851 . . . . 0.0 108.471 179.237 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.403 ' HG2' ' C ' ' B' ' 17' ' ' GLY . 3.0 mm100 -132.72 178.31 6.96 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.492 -1.005 . . . . 0.0 109.635 -179.539 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 1.06 HD23 ' O ' ' B' ' 13' ' ' ILE . 9.0 mt -143.62 130.8 20.74 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.416 ' HG2' ' C ' ' B' ' 19' ' ' LEU . 3.3 mmmt -143.44 156.14 44.57 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.818 ' HB3' HD23 ' B' ' 10' ' ' LEU . 1.9 mp0 -79.49 122.34 26.33 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.981 -1.074 . . . . 0.0 108.811 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.609 ' HA ' ' HB2' ' B' ' 83' ' ' ASN . . . -104.38 129.93 52.28 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.434 -0.791 . . . . 0.0 110.647 -178.787 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.686 HD21 ' O ' ' A' ' 27' ' ' GLY . 22.9 tp -80.17 97.72 7.02 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.841 HD22 HD21 ' B' ' 90' ' ' LEU . 15.2 mt -44.22 113.01 0.47 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.715 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.609 ' HB3' HG22 ' B' ' 84' ' ' ILE . 57.7 t0 -126.39 88.12 2.78 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.05 -177.789 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.576 HG21 ' CD2' ' B' ' 97' ' ' LEU . 1.8 m -64.06 -12.83 42.43 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.037 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.841 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -73.1 -41.92 45.8 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.171 -1.171 . . . . 0.0 110.171 -179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.12 152.3 46.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.061 -1.258 . . . . 0.0 109.449 -179.684 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.574 ' HA ' ' HD2' ' B' ' 87' ' ' ARG . 30.6 m-20 -85.0 -21.69 29.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 110.378 -178.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.51 ' HA ' ' OD1' ' B' ' 88' ' ' ASN . 0.2 OUTLIER -139.98 -160.38 1.06 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.811 -1.181 . . . . 0.0 109.429 179.965 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.567 ' HA ' ' O ' ' B' ' 84' ' ' ILE . 21.0 m -110.94 94.13 4.84 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.731 -1.23 . . . . 0.0 111.56 -178.242 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.051 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.49 174.73 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.053 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.051 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -169.72 117.35 0.59 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.932 -1.105 . . . . 0.0 110.311 -179.178 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.772 ' HA ' HG22 ' B' ' 80' ' ' THR . 5.5 pt-20 -38.13 158.22 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.544 -0.722 . . . . 0.0 109.586 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.689 ' HA ' HG12 ' B' ' 77' ' ' VAL . 2.6 tt0 -46.34 149.71 0.72 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.212 -0.93 . . . . 0.0 110.668 -179.119 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.456 ' SD ' ' O ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -178.68 167.58 1.74 Allowed 'General case' 0 N--CA 1.494 1.768 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.513 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.456 ' O ' ' SD ' ' B' ' 36' ' ' MET . 48.0 t -87.88 109.24 19.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.967 -1.083 . . . . 0.0 109.765 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.945 HD21 HG22 ' B' ' 15' ' ' ILE . 8.6 mt -114.65 105.12 53.88 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.166 -0.959 . . . . 0.0 109.255 179.649 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -78.47 102.02 1.52 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.542 2.161 . . . . 0.0 111.233 -179.526 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' B' ' 41' ' ' ARG . . . 168.31 31.13 0.02 OUTLIER Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.596 179.288 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.52 ' O ' ' O ' ' B' ' 40' ' ' GLY . 0.0 OUTLIER 55.63 153.52 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.778 -0.837 . . . . 0.0 109.721 179.647 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.621 ' HB3' ' CE1' ' B' ' 59' ' ' TYR . 51.5 p-90 -161.37 176.14 11.48 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 120.803 -1.185 . . . . 0.0 110.123 -179.764 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.421 ' CD ' ' HD2' ' B' ' 44' ' ' PRO . 0.1 OUTLIER -134.08 162.92 54.79 Favored Pre-proline 0 C--N 1.3 -1.565 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.6 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . 0.421 ' HD2' ' CD ' ' B' ' 43' ' ' LYS . 33.4 Cg_endo -76.38 139.95 21.33 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 C-N-CA 121.827 1.685 . . . . 0.0 109.721 179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.715 ' O ' HG23 ' B' ' 56' ' ' VAL . 7.4 tttm -159.58 119.79 3.05 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.414 -0.804 . . . . 0.0 109.105 -179.412 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.5 ' HG2' ' HA ' ' B' ' 55' ' ' LYS . 76.5 mtp -98.9 132.26 44.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.415 -0.803 . . . . 0.0 109.291 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.798 ' CD1' HG21 ' A' ' 50' ' ' ILE . 17.6 pt -94.26 149.05 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.987 -1.071 . . . . 0.0 108.826 179.386 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.534 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -119.36 100.51 0.81 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.829 -1.708 . . . . 0.0 108.829 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.445 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -126.25 -129.34 3.29 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.3 -1.429 . . . . 0.0 110.665 -179.241 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.904 HD12 ' C20' ' B' ' 100' ' ' DMP . 47.4 mt -84.42 118.37 31.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.752 -0.852 . . . . 0.0 112.948 -177.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.654 ' HA2' HG23 ' A' ' 54' ' ' ILE . . . 100.02 -1.77 56.53 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 177.805 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 127.85 -154.63 19.83 Favored Glycine 0 N--CA 1.49 2.274 0 O-C-N 120.969 -1.312 . . . . 0.0 109.999 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.63 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 0.4 OUTLIER -121.18 141.53 50.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.53 -0.982 . . . . 0.0 109.799 -179.628 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.607 HD11 HD11 ' B' ' 47' ' ' ILE . 18.8 pt -107.22 178.67 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.151 -0.968 . . . . 0.0 108.995 179.097 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.583 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.2 OUTLIER -109.5 130.13 55.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.234 -0.916 . . . . 0.0 109.568 -179.881 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.715 HG23 ' O ' ' B' ' 45' ' ' LYS . 2.2 m -144.11 174.06 4.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 O-C-N 121.094 -1.004 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 46.7 mtm180 -116.73 115.47 25.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.386 -0.821 . . . . 0.0 108.813 179.847 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.521 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 5.6 tt0 -69.77 106.8 3.24 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.139 -0.976 . . . . 0.0 110.13 -179.349 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.621 ' CE1' ' HB3' ' B' ' 42' ' ' TRP . 18.0 m-85 -99.65 87.31 3.53 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 178.536 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.589 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -78.71 125.68 29.7 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.875 -1.14 . . . . 0.0 110.177 -178.783 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.589 ' CB ' ' O ' ' B' ' 60' ' ' ASP . 1.5 mt-30 91.16 60.65 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.336 0.588 . . . . 0.0 110.402 179.329 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.695 ' CG2' HG23 ' B' ' 15' ' ' ILE . 33.1 mm -121.87 125.68 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.306 -0.871 . . . . 0.0 108.752 178.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.915 ' O ' HD13 ' B' ' 63' ' ' LEU . 2.1 tm? -73.91 86.38 1.76 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.219 -0.926 . . . . 0.0 112.364 -178.081 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.93 HD12 HD11 ' B' ' 15' ' ' ILE . 16.5 tt -89.8 114.61 27.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.426 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 0.7 OUTLIER -90.14 127.51 36.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.912 -1.118 . . . . 0.0 108.765 -179.836 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.666 HG13 HG22 ' B' ' 13' ' ' ILE . 1.0 OUTLIER -124.3 125.89 71.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.129 -0.982 . . . . 0.0 109.988 -179.248 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.532 ' HB3' ' HG3' ' B' ' 1' ' ' PRO . 54.9 m 55.91 12.78 0.95 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.687 -0.633 . . . . 0.0 111.111 179.169 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . 0.425 ' HA2' ' OE2' ' B' ' 65' ' ' GLU . . . 101.24 21.7 11.4 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.301 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.919 ' HB2' HG22 ' B' ' 93' ' ' ILE . 23.9 m-70 -118.0 114.52 23.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.057 -1.26 . . . . 0.0 109.333 179.544 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.691 ' CG ' HD21 ' B' ' 63' ' ' LEU . 9.6 tttt -64.4 117.4 7.23 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.12 -0.987 . . . . 0.0 109.006 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -138.14 124.04 20.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.302 -0.873 . . . . 0.0 110.358 -178.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.578 HG12 ' CA ' ' B' ' 63' ' ' LEU . 0.7 OUTLIER -103.43 129.89 54.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 177.749 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.428 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -149.29 -159.91 8.86 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.506 -1.331 . . . . 0.0 110.364 -179.439 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.521 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 7.6 m -100.93 110.71 22.78 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.442 -1.034 . . . . 0.0 109.553 -179.916 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 0.975 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -100.1 107.14 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.312 -0.867 . . . . 0.0 110.516 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 32' ' ' VAL . 2.4 mp -79.06 121.44 24.97 Favored 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.855 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.758 HG21 HD12 ' B' ' 38' ' ' LEU . 3.4 t -110.7 114.27 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.106 -0.996 . . . . 0.0 110.557 -178.68 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.692 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -148.63 -165.13 11.93 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 179.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.583 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -81.57 41.38 1.13 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 122.588 2.192 . . . . 0.0 110.486 -179.915 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.772 HG22 ' HA ' ' B' ' 34' ' ' GLU . 13.6 t -81.43 140.82 48.58 Favored Pre-proline 0 N--CA 1.489 1.486 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.596 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.7 Cg_endo -78.81 12.52 2.19 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.426 2.084 . . . . 0.0 110.742 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.596 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -161.22 167.12 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.191 -0.943 . . . . 0.0 109.563 -179.573 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.609 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 0.3 OUTLIER -105.38 144.37 32.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 104.486 -2.413 . . . . 0.0 104.486 175.761 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.609 HG22 ' HB3' ' B' ' 25' ' ' ASP . 5.7 mm -130.25 130.01 65.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 O-C-N 120.284 -1.51 . . . . 0.0 111.735 -177.059 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.497 ' CD1' HG23 ' B' ' 31' ' ' THR . 0.8 OUTLIER -101.15 100.42 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.483 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.9 -155.42 8.81 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.736 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.574 ' HD2' ' HA ' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -79.68 -30.04 41.0 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 179.388 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.982 ' ND2' HD23 ' B' ' 89' ' ' LEU . 18.4 p-10 -47.51 -22.95 0.53 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.302 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.982 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.4 mm? -113.42 -42.89 3.4 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.123 -0.985 . . . . 0.0 111.036 -178.58 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.841 HD21 HD22 ' B' ' 24' ' ' LEU . 93.8 mt -52.63 -35.88 55.47 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.592 -1.318 . . . . 0.0 109.425 -179.547 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.504 HG21 ' HA ' ' A' ' 6' ' ' TRP . 49.4 p -80.42 -21.79 41.86 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.233 -0.917 . . . . 0.0 110.978 -178.738 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.718 HE21 HD13 ' B' ' 89' ' ' LEU . 32.1 mt-30 -75.06 -38.19 61.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.78 -1.2 . . . . 0.0 108.737 179.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.97 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.8 OUTLIER -79.84 2.09 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.392 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 71.37 60.32 4.46 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.818 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 98' ' ' ASN . . . -100.01 163.42 12.44 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.308 -1.113 . . . . 0.0 110.021 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.621 HG22 ' CG2' ' A' ' 4' ' ' THR . 2.2 p -148.92 135.19 19.3 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.494 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 1.016 HD13 HD13 ' A' ' 97' ' ' LEU . 0.0 OUTLIER -90.17 114.83 26.88 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.286 179.952 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.503 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 4.2 m120 -119.24 130.59 55.54 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.869 -0.519 . . . . 0.0 109.863 -179.069 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.71 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.171 -0.919 . . . . 0.0 109.09 178.567 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.904 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo . . . . . 0 N--CA 1.495 1.615 0 N-CA-C 110.179 -0.739 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.551 ' HG3' ' ND2' ' B' ' 98' ' ' ASN . 0.3 OUTLIER -83.81 145.89 28.43 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 177.632 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.462 ' N ' ' HG2' ' A' ' 2' ' ' GLN . 55.1 t -146.72 105.93 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 117.82 -1.552 . . . . 0.0 111.143 -178.436 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.546 ' O ' ' N ' ' A' ' 6' ' ' TRP . 13.5 p -107.16 -57.22 2.1 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 177.811 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.588 ' O ' ' N ' ' A' ' 7' ' ' GLN . 7.8 tp 33.92 29.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.938 -0.476 . . . . 0.0 111.119 178.659 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.546 ' N ' ' O ' ' A' ' 4' ' ' THR . 9.0 m95 18.19 47.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 CA-C-O 121.121 0.486 . . . . 0.0 111.91 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.588 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.3 OUTLIER -167.41 -175.49 2.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.797 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.546 HH21 HD11 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -56.2 125.74 65.57 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.412 -0.805 . . . . 0.0 109.558 179.755 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.528 ' HG2' ' HB2' ' A' ' 24' ' ' LEU . 35.9 Cg_endo -79.05 70.89 7.3 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 C-N-CA 122.179 1.919 . . . . 0.0 109.177 178.843 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.606 ' CD2' ' HB3' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -82.99 156.12 23.6 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.42 -0.8 . . . . 0.0 110.093 -178.908 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.545 HG21 HG23 ' A' ' 66' ' ' ILE . 2.1 m -149.31 130.25 4.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.512 -0.743 . . . . 0.0 109.245 179.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 1.01 HG22 HD22 ' A' ' 19' ' ' LEU . 23.0 m -65.7 96.34 0.27 Allowed 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 178.728 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.831 HD11 HD21 ' A' ' 33' ' ' LEU . 1.9 pt -79.28 140.07 17.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.395 -0.816 . . . . 0.0 109.785 -178.737 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.651 ' HE3' HD11 ' A' ' 19' ' ' LEU . 29.0 tttt -105.64 95.52 5.86 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.242 -0.911 . . . . 0.0 108.981 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.791 HG23 ' CG2' ' A' ' 62' ' ' ILE . 15.1 mt -118.78 147.53 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.153 -0.967 . . . . 0.0 109.924 -179.295 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 44.69 50.62 8.39 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 179.207 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 49.26 43.99 34.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.7 mm-40 -142.66 176.67 8.86 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.366 -1.079 . . . . 0.0 109.152 179.864 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 12' ' ' THR . 16.9 mt -149.64 124.2 9.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.037 -1.039 . . . . 0.0 110.115 -179.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.578 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -138.25 168.78 19.02 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.119 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.606 ' HB3' ' CD2' ' A' ' 10' ' ' LEU . 6.0 mm-40 -80.63 116.03 20.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.096 -1.003 . . . . 0.0 108.671 179.516 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.675 ' HB1' HD11 ' A' ' 85' ' ' ILE . . . -96.75 142.51 28.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.12 -0.988 . . . . 0.0 110.065 -179.214 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.605 HD21 ' O ' ' B' ' 27' ' ' GLY . 26.5 tp -104.41 91.54 3.94 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.647 -0.658 . . . . 0.0 109.281 -179.753 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.827 HD23 ' HB ' ' A' ' 85' ' ' ILE . 15.1 mt -44.12 101.98 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -0.895 . . . . 0.0 108.714 179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.563 ' HB3' ' CG2' ' A' ' 84' ' ' ILE . 42.5 t0 -111.57 91.4 3.64 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.351 -0.843 . . . . 0.0 110.495 -178.699 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HD13 ' A' ' 90' ' ' LEU . 1.1 m -66.6 -10.61 47.46 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.144 -0.973 . . . . 0.0 108.556 178.643 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.472 ' O ' HD21 ' B' ' 23' ' ' LEU . . . -71.44 -44.2 51.7 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.468 ' HB1' ' C27' ' B' ' 100' ' ' DMP . . . -75.85 164.79 25.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.096 -1.237 . . . . 0.0 109.322 -179.844 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 50.8 m-20 -100.55 -15.21 17.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.154 -0.966 . . . . 0.0 111.282 -178.695 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.543 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.4 OUTLIER -130.88 -169.96 2.26 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.813 -1.18 . . . . 0.0 109.571 -179.614 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.597 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 50.2 m -109.51 91.35 3.61 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.767 -1.208 . . . . 0.0 110.438 -179.099 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.034 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -72.11 171.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 120.969 -1.082 . . . . 0.0 108.167 179.099 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.123 HD13 ' CG1' ' A' ' 75' ' ' VAL . 0.1 OUTLIER -169.07 121.98 0.79 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.02 -1.05 . . . . 0.0 109.713 -178.857 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.712 ' HA ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -42.46 166.57 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.146 -0.971 . . . . 0.0 109.535 179.506 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.561 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -51.1 149.71 3.58 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.127 -0.983 . . . . 0.0 110.378 -179.447 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.409 ' HG3' ' N ' ' A' ' 37' ' ' SER . 8.2 ptm -164.95 -161.68 0.57 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.439 -0.788 . . . . 0.0 109.08 179.592 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.409 ' N ' ' HG3' ' A' ' 36' ' ' MET . 3.8 t -122.73 109.94 14.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.093 -1.005 . . . . 0.0 111.158 -178.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.605 ' HB2' ' CZ ' ' A' ' 59' ' ' TYR . 0.1 OUTLIER -111.21 167.02 9.67 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 178.18 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.578 ' HD3' HD12 ' A' ' 38' ' ' LEU . 35.5 Cg_endo -77.08 66.62 7.73 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 122.94 2.427 . . . . 0.0 112.352 -179.149 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.523 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . 26.66 105.74 0.0 OUTLIER Glycine 0 N--CA 1.504 3.215 0 CA-C-O 121.674 0.597 . . . . 0.0 112.315 178.534 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.456 ' CB ' ' O ' ' A' ' 40' ' ' GLY . 1.8 mtp180 167.11 51.19 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.316 -1.108 . . . . 0.0 109.115 178.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.608 ' CD1' ' CZ ' ' A' ' 59' ' ' TYR . 54.5 p-90 -131.49 -179.49 5.4 Favored 'General case' 0 C--N 1.294 -1.828 0 CA-C-O 121.829 0.823 . . . . 0.0 110.302 -179.049 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 57' ' ' ARG . 0.5 OUTLIER -138.41 166.89 22.21 Favored Pre-proline 0 C--N 1.303 -1.455 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.7 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -76.29 140.62 22.22 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.147 1.898 . . . . 0.0 110.796 -179.773 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.91 ' O ' HG22 ' A' ' 56' ' ' VAL . 0.5 OUTLIER -160.17 141.36 12.34 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.48 ' HG2' ' HG2' ' A' ' 55' ' ' LYS . 59.3 mtp -125.97 141.57 51.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.837 -1.164 . . . . 0.0 109.915 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 54' ' ' ILE . 6.9 pt -118.94 141.09 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.268 -0.895 . . . . 0.0 109.171 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.527 ' HA3' ' CE1' ' A' ' 53' ' ' PHE . . . -118.18 103.44 1.04 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -123.78 -127.47 3.22 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.478 -1.344 . . . . 0.0 110.445 -178.961 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.755 HD12 ' C70' ' B' ' 100' ' ' DMP . 67.5 mt -79.67 116.33 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.703 -0.88 . . . . 0.0 112.251 -178.139 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.563 ' N ' ' CG2' ' B' ' 54' ' ' ILE . . . 111.98 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.382 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.74 -161.48 34.34 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.43 -1.367 . . . . 0.0 110.305 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.527 ' CE1' ' HA3' ' A' ' 48' ' ' GLY . 4.3 m-30 -99.95 131.26 46.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.503 -0.998 . . . . 0.0 109.555 -179.498 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.749 HD11 HD11 ' A' ' 47' ' ' ILE . 5.1 pt -110.41 172.45 2.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.156 -0.965 . . . . 0.0 108.841 179.103 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.545 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -110.04 147.36 33.7 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.875 . . . . 0.0 109.024 179.657 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.91 HG22 ' O ' ' A' ' 45' ' ' LYS . 7.3 m -151.03 -171.53 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 120.739 -1.225 . . . . 0.0 110.424 -179.472 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.587 ' HG2' ' CZ3' ' A' ' 42' ' ' TRP . 2.0 mtt180 -140.1 108.85 5.95 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.228 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.475 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 30.6 tt0 -65.85 103.38 0.9 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.308 -0.87 . . . . 0.0 111.104 -178.468 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.608 ' CZ ' ' CD1' ' A' ' 42' ' ' TRP . 11.8 m-85 -91.58 124.67 35.92 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 177.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 0.9 OUTLIER -109.35 124.2 50.58 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.816 -1.177 . . . . 0.0 110.59 -178.852 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.54 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 6.4 mm100 86.29 58.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.848 0 CA-C-O 121.229 0.538 . . . . 0.0 110.648 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.791 ' CG2' HG23 ' A' ' 15' ' ' ILE . 26.2 mm -111.88 119.9 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 178.577 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.896 ' O ' HD13 ' A' ' 63' ' ' LEU . 1.3 tm? -67.48 84.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 111.054 -178.5 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.593 HD13 HD11 ' A' ' 66' ' ' ILE . 3.5 tt -87.86 118.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 178.248 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' CB ' ' A' ' 14' ' ' LYS . 28.0 tt0 -91.42 113.43 25.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.213 -0.929 . . . . 0.0 109.186 -179.189 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.593 HD11 HD13 ' A' ' 64' ' ' ILE . 1.3 mp -106.25 118.29 53.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 -179.667 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 66' ' ' ILE . 77.8 m 65.38 21.36 11.91 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.744 -0.598 . . . . 0.0 110.935 179.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.475 ' HA2' ' OE2' ' A' ' 65' ' ' GLU . . . 90.31 1.59 75.01 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.506 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -97.34 121.18 38.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.075 -1.25 . . . . 0.0 108.827 179.548 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -61.82 127.51 31.78 Favored 'General case' 0 C--N 1.295 -1.775 0 O-C-N 121.363 -0.835 . . . . 0.0 109.416 -179.789 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.482 ' O ' HD22 ' A' ' 63' ' ' LEU . . . -148.19 137.55 22.12 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.541 -0.724 . . . . 0.0 109.454 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.536 ' CG2' ' HA ' ' A' ' 61' ' ' GLN . 0.6 OUTLIER -110.29 160.43 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 177.819 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.875 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . 175.46 177.51 44.58 Favored Glycine 0 N--CA 1.485 1.901 0 C-N-CA 118.222 -1.942 . . . . 0.0 111.527 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.508 ' HA ' ' O ' ' A' ' 59' ' ' TYR . 75.3 m -82.27 114.74 20.96 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 122.057 -0.672 . . . . 0.0 109.902 -179.715 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.123 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -108.56 109.92 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.395 -0.816 . . . . 0.0 109.951 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.543 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.2 mp -79.21 126.06 30.26 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.114 -0.991 . . . . 0.0 108.729 179.307 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.561 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 58.6 t -111.43 116.48 52.64 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 109.94 -179.311 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.474 ' HA3' HG12 ' A' ' 56' ' ' VAL . . . -150.09 -166.25 13.26 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 179.553 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.545 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 37.2 Cg_endo -82.96 40.16 0.92 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 C-N-CA 122.47 2.113 . . . . 0.0 110.014 179.711 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.712 HG22 ' HA ' ' A' ' 34' ' ' GLU . 10.2 t -81.38 137.36 48.64 Favored Pre-proline 0 N--CA 1.488 1.447 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.48 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.9 Cg_endo -77.84 15.8 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 C-N-CA 122.451 2.1 . . . . 0.0 111.829 -178.664 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.631 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.5 OUTLIER -161.41 165.97 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.728 -1.233 . . . . 0.0 111.025 -179.64 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.631 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 55.4 m-20 -99.39 142.61 30.65 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 177.046 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.73 ' CG1' HG12 ' A' ' 32' ' ' VAL . 2.9 mm -133.22 113.59 19.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 O-C-N 120.398 -1.439 . . . . 0.0 111.618 -176.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.827 ' HB ' HD23 ' A' ' 24' ' ' LEU . 0.9 OUTLIER -92.68 92.95 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 177.326 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -84.03 -156.96 24.75 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 120.048 -1.072 . . . . 0.0 111.685 -177.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.512 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 1.8 mtp180 -63.38 -39.13 93.69 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.91 -0.759 . . . . 0.0 110.84 -178.865 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.002 ' ND2' HD23 ' A' ' 89' ' ' LEU . 9.2 p-10 -48.07 -26.57 1.88 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.053 -1.03 . . . . 0.0 110.282 -178.73 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.002 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.8 mm? -112.52 -12.93 13.4 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.762 -1.211 . . . . 0.0 109.85 -179.796 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.593 HD13 HG23 ' A' ' 26' ' ' THR . 50.1 mt -80.67 -5.75 57.43 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 77.3 p -100.67 -16.91 17.24 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.922 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.7 mm-40 -83.37 -40.58 19.22 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.587 -0.696 . . . . 0.0 109.477 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.987 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.8 OUTLIER -87.29 -3.86 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.145 -0.972 . . . . 0.0 109.429 179.607 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 69.09 56.68 8.61 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.43 ' HA ' ' HD1' ' B' ' 99' ' ' PHE . . . -81.93 148.86 28.51 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.031 -1.276 . . . . 0.0 110.23 -179.769 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.869 HG22 HG22 ' B' ' 4' ' ' THR . 55.8 p -142.89 124.08 14.56 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 178.744 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' B' ' 97' ' ' LEU . 4.7 mp -85.07 108.13 17.5 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 4.9 m120 -107.2 122.15 45.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.742 -1.224 . . . . 0.0 109.259 -179.669 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.632 ' CG ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.685 0 CA-C-O 117.922 -1.037 . . . . 0.0 109.747 -179.805 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.603 ' HG2' ' CE2' ' A' ' 99' ' ' PHE . 4.5 Cg_exo . . . . . 0 N--CA 1.495 1.613 0 N-CA-C 110.693 -0.541 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.44 131.92 35.0 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 178.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.16 115.41 44.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 120.812 -1.18 . . . . 0.0 109.853 -177.905 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.998 ' O ' HD22 ' B' ' 5' ' ' LEU . 1.0 OUTLIER -119.01 -102.34 0.42 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.919 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.998 HD22 ' O ' ' B' ' 4' ' ' THR . 0.0 OUTLIER 25.91 36.44 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.32 0 CA-C-O 120.752 0.31 . . . . 0.0 110.974 179.823 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.629 ' N ' ' O ' ' B' ' 4' ' ' THR . 19.3 m0 13.77 85.16 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 CA-C-O 121.174 0.511 . . . . 0.0 111.775 179.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.89 155.18 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.156 -0.965 . . . . 0.0 109.422 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 48.0 mtm180 -50.48 119.61 11.32 Favored Pre-proline 0 N--CA 1.489 1.493 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.576 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.822 ' HB2' HD12 ' B' ' 24' ' ' LEU . 33.6 Cg_endo -75.23 71.81 5.02 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 C-N-CA 122.158 1.905 . . . . 0.0 110.6 179.861 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.518 ' CD2' ' HB3' ' B' ' 21' ' ' GLU . 0.0 OUTLIER -87.87 161.15 17.66 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.267 -0.896 . . . . 0.0 108.953 179.795 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.954 HG23 HG23 ' B' ' 13' ' ' ILE . 18.7 m -150.84 138.11 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.006 -1.059 . . . . 0.0 110.198 -179.355 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.581 ' CG2' ' CD2' ' B' ' 19' ' ' LEU . 24.5 m -72.61 96.66 2.01 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.763 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.961 HG22 HG13 ' B' ' 66' ' ' ILE . 10.7 pt -90.44 142.24 13.22 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 O-C-N 121.293 -0.88 . . . . 0.0 110.967 -177.332 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.557 ' HE3' ' CD1' ' B' ' 19' ' ' LEU . 0.3 OUTLIER -108.04 98.6 8.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.667 -0.646 . . . . 0.0 109.608 -179.639 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 1.016 HG23 HG21 ' B' ' 62' ' ' ILE . 11.4 mt -120.1 135.32 60.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 120.981 -1.075 . . . . 0.0 109.859 -179.742 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.475 ' HA3' HD13 ' B' ' 38' ' ' LEU . . . 43.11 60.01 3.2 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 179.349 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 16' ' ' GLY . . . 43.02 41.83 4.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.698 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.519 ' HB2' ' CE ' ' B' ' 36' ' ' MET . 38.0 mm-40 -138.45 116.24 11.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.366 -1.079 . . . . 0.0 109.464 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' B' ' 12' ' ' THR . 0.2 OUTLIER -90.79 127.71 36.44 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.685 0.755 . . . . 0.0 110.069 179.699 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.597 ' HB3' ' ND2' ' B' ' 83' ' ' ASN . 1.1 mttt -150.74 142.65 23.88 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.63 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.518 ' HB3' ' CD2' ' B' ' 10' ' ' LEU . 0.1 OUTLIER -78.59 111.09 14.3 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.994 -1.066 . . . . 0.0 108.711 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 1.012 ' HB1' HD13 ' B' ' 85' ' ' ILE . . . -93.76 132.82 37.77 Favored 'General case' 0 N--CA 1.488 1.446 0 CA-C-O 121.984 0.897 . . . . 0.0 111.062 -178.45 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.488 HD12 HD12 ' B' ' 10' ' ' LEU . 12.1 tp -83.8 102.46 12.34 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.535 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.822 HD12 ' HB2' ' B' ' 9' ' ' PRO . 13.2 mt -44.95 120.19 2.26 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.141 -0.974 . . . . 0.0 108.392 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.523 ' HB3' HG22 ' B' ' 84' ' ' ILE . 46.5 t0 -128.39 82.4 2.08 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -178.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.906 HG23 HD13 ' B' ' 90' ' ' LEU . 1.4 m -62.9 -15.24 54.39 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.015 -1.053 . . . . 0.0 108.738 179.125 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.605 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -64.93 -37.89 94.83 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.411 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -77.73 163.53 26.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.292 -1.123 . . . . 0.0 109.463 -179.905 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.457 ' OD1' ' NE ' ' A' ' 8' ' ' ARG . 3.9 m-20 -98.23 -10.12 24.52 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.247 -0.908 . . . . 0.0 109.494 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.528 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 19.5 m-20 -140.25 -165.9 2.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.3 -0.875 . . . . 0.0 108.844 -179.883 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.727 HG23 HD12 ' B' ' 85' ' ' ILE . 17.6 m -118.11 93.17 4.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.692 -1.255 . . . . 0.0 111.02 -178.668 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.053 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -72.89 174.03 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.152 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 ' CG1' ' B' ' 75' ' ' VAL . 0.1 OUTLIER -164.46 117.16 1.32 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.82 -1.175 . . . . 0.0 110.846 -179.086 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.601 ' HA ' ' CG2' ' B' ' 80' ' ' THR . 16.3 tt0 -36.15 155.37 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.492 -0.755 . . . . 0.0 109.94 178.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.711 ' HA ' HG12 ' B' ' 77' ' ' VAL . 0.0 OUTLIER -33.35 146.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.766 0.793 . . . . 0.0 111.41 -179.145 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.538 ' N ' HG11 ' B' ' 77' ' ' VAL . 0.2 OUTLIER -177.64 179.61 0.9 Allowed 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.555 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . . . . . . . . . 5.1 t -122.08 122.84 40.19 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.434 -1.416 . . . . 0.0 111.911 -178.299 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.604 HD12 ' CD ' ' B' ' 39' ' ' PRO . 0.5 OUTLIER -102.58 175.58 2.21 Favored Pre-proline 0 N--CA 1.495 1.785 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 177.899 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.604 ' CD ' HD12 ' B' ' 38' ' ' LEU . 35.4 Cg_endo -78.05 68.8 7.72 Favored 'Trans proline' 0 C--N 1.312 -1.383 0 C-N-CA 122.066 1.844 . . . . 0.0 110.953 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' B' ' 39' ' ' PRO . . . 43.8 -172.12 0.01 OUTLIER Glycine 0 N--CA 1.493 2.478 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 179.202 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 56.84 101.67 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.418 -1.048 . . . . 0.0 109.921 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.604 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 3.8 p-90 -160.7 171.55 18.66 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.609 -0.682 . . . . 0.0 109.625 179.682 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . 0.524 ' O ' ' CB ' ' B' ' 58' ' ' GLN . 1.4 mtmt -128.71 115.4 19.34 Favored Pre-proline 0 N--CA 1.489 1.477 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.367 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -75.62 136.03 18.68 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 121.807 1.671 . . . . 0.0 110.828 -179.334 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 1.024 ' NZ ' HD23 ' B' ' 76' ' ' LEU . 0.0 OUTLIER -156.45 178.62 10.11 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.539 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.479 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 27.2 mtp -127.56 136.28 51.47 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.841 -1.162 . . . . 0.0 110.61 -178.754 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 54' ' ' ILE . 5.8 pt -100.68 143.6 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.328 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.62 ' HA3' ' CD2' ' B' ' 53' ' ' PHE . . . -118.36 108.92 1.68 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.549 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.89 -125.01 2.55 Favored Glycine 0 N--CA 1.484 1.839 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.522 -179.242 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.865 HD12 H202 ' B' ' 100' ' ' DMP . 50.6 mt -84.3 121.46 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.825 -0.809 . . . . 0.0 112.578 -177.939 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.456 ' N ' ' CG2' ' A' ' 54' ' ' ILE . . . 98.45 -16.57 59.68 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.019 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 140.58 -155.95 25.03 Favored Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.936 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.62 ' CD2' ' HA3' ' B' ' 48' ' ' GLY . 1.1 m-85 -116.12 134.9 54.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.543 -0.975 . . . . 0.0 109.485 -179.873 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.805 HD11 HD11 ' B' ' 47' ' ' ILE . 6.0 pt -105.53 159.58 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.004 -1.06 . . . . 0.0 109.245 179.436 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.577 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 1.0 OUTLIER -99.61 131.43 45.61 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 179.372 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.946 HG23 ' CE ' ' B' ' 45' ' ' LYS . 0.2 OUTLIER -138.96 -173.14 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.787 -1.195 . . . . 0.0 109.756 -179.838 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' B' ' 77' ' ' VAL . 0.0 OUTLIER -114.74 165.84 12.38 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 178.557 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.569 ' NE2' HG22 ' B' ' 74' ' ' THR . 10.0 tp60 -128.98 91.57 3.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.57 -1.331 . . . . 0.0 110.99 -178.923 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' B' ' 42' ' ' TRP . 94.1 m-85 -93.88 92.16 7.27 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.223 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.537 ' O ' ' CB ' ' B' ' 61' ' ' GLN . 51.5 m-20 -79.08 134.85 36.73 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.323 -0.86 . . . . 0.0 109.916 -178.841 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.56 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 42.9 mt-30 83.54 63.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.589 0.709 . . . . 0.0 109.291 179.55 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 1.016 HG21 HG23 ' B' ' 15' ' ' ILE . 24.9 mm -119.15 120.48 63.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.534 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.951 HD21 ' CG ' ' B' ' 70' ' ' LYS . 16.4 tp -72.86 86.83 1.28 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 118.977 -1.089 . . . . 0.0 110.695 -178.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.731 ' CD1' HD11 ' B' ' 66' ' ' ILE . 1.6 tt -85.23 122.24 38.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.647 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.5 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 6.8 tt0 -89.73 109.61 20.58 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.973 -1.079 . . . . 0.0 109.72 -178.411 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.961 HG13 HG22 ' B' ' 13' ' ' ILE . 0.4 OUTLIER -105.76 122.25 59.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 O-C-N 121.262 -0.899 . . . . 0.0 109.087 179.91 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . 0.475 ' HB2' ' O ' ' B' ' 66' ' ' ILE . 76.2 m 66.71 12.26 8.72 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.997 -0.439 . . . . 0.0 110.294 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 99.37 0.42 56.89 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 6.7 m-70 -98.82 125.03 44.08 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.191 -1.182 . . . . 0.0 108.904 179.717 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 0.951 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.7 mptm? -70.28 135.11 48.64 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.281 -0.887 . . . . 0.0 108.613 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.824 ' HB1' HE21 ' B' ' 92' ' ' GLN . . . -150.27 138.72 20.53 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.383 -0.823 . . . . 0.0 109.077 -179.41 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.56 ' CG2' ' HA ' ' B' ' 61' ' ' GLN . 0.6 OUTLIER -108.13 142.69 20.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 178.212 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . . . . . . . . . . . -163.54 -165.73 21.2 Favored Glycine 0 N--CA 1.483 1.828 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.993 -179.694 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.569 HG22 ' NE2' ' B' ' 58' ' ' GLN . 7.0 m -97.81 110.33 22.92 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.745 -0.856 . . . . 0.0 110.06 -179.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.065 ' CG1' HD13 ' B' ' 33' ' ' LEU . 1.4 t -109.65 147.26 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.09 -1.006 . . . . 0.0 109.697 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 1.024 HD23 ' NZ ' ' B' ' 45' ' ' LYS . 5.6 mp -125.27 142.91 51.22 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.058 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' B' ' 35' ' ' GLU . 15.1 t -124.03 124.23 68.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.102 -0.999 . . . . 0.0 110.1 179.916 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.723 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -160.31 -158.06 9.02 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.577 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 36.9 Cg_endo -80.57 40.56 1.0 Allowed 'Trans proline' 0 C--N 1.31 -1.485 0 C-N-CA 122.806 2.338 . . . . 0.0 110.966 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.601 ' CG2' ' HA ' ' B' ' 34' ' ' GLU . 10.1 t -86.95 133.81 38.43 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 178.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.606 ' O ' HG23 ' B' ' 82' ' ' VAL . 35.5 Cg_endo -77.16 14.16 1.4 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.269 1.979 . . . . 0.0 111.086 -178.939 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.606 HG23 ' O ' ' B' ' 81' ' ' PRO . 2.1 t -160.81 151.24 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 120.94 -1.1 . . . . 0.0 110.397 -179.241 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.597 ' ND2' ' HB3' ' B' ' 20' ' ' LYS . 21.0 m-20 -80.06 130.74 35.48 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 103.723 -2.695 . . . . 0.0 103.723 175.077 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.663 HG13 HG12 ' B' ' 32' ' ' VAL . 0.8 OUTLIER -125.88 116.26 45.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 119.781 -1.824 . . . . 0.0 112.93 -176.437 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 1.012 HD13 ' HB1' ' B' ' 22' ' ' ALA . 0.9 OUTLIER -89.07 147.28 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 176.708 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.528 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -136.31 -161.1 9.0 Favored Glycine 0 N--CA 1.492 2.433 0 C-N-CA 118.771 -1.681 . . . . 0.0 110.055 -179.766 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.444 ' O ' ' OG1' ' B' ' 91' ' ' THR . 0.0 OUTLIER -57.59 -37.62 73.51 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.702 -0.881 . . . . 0.0 109.793 -179.725 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 1.049 ' ND2' HD23 ' B' ' 89' ' ' LEU . 9.8 p-10 -50.67 -29.72 11.84 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.625 -179.29 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 1.049 HD23 ' ND2' ' B' ' 88' ' ' ASN . 1.5 mm? -107.13 -24.02 12.08 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.619 -1.301 . . . . 0.0 110.815 -179.082 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.906 HD13 HG23 ' B' ' 26' ' ' THR . 9.2 mt -71.63 -5.68 35.33 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.883 -1.136 . . . . 0.0 108.888 -179.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.5 -14.42 18.26 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.925 . . . . 0.0 109.023 179.319 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . 0.824 HE21 ' HB1' ' B' ' 71' ' ' ALA . 18.6 mt-30 -85.96 -40.88 15.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -0.867 . . . . 0.0 109.363 -179.816 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.632 HD12 ' CG ' ' A' ' 99' ' ' PHE . 2.2 pt -85.99 4.78 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.144 -0.973 . . . . 0.0 108.542 178.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 63.7 42.97 98.49 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.345 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.509 ' CA ' ' HB3' ' A' ' 99' ' ' PHE . . . -69.53 145.46 52.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.901 -1.352 . . . . 0.0 108.882 179.327 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . . . . . . . . . 45.4 p -136.86 128.36 28.51 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 179.052 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.86 HD11 HD11 ' A' ' 97' ' ' LEU . 0.7 OUTLIER -91.13 96.66 10.71 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 -178.992 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.551 ' ND2' ' HG3' ' A' ' 2' ' ' GLN . 1.3 m120 -109.64 132.92 53.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.47 -0.769 . . . . 0.0 110.045 -179.426 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.987 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 118.054 -0.974 . . . . 0.0 109.062 179.41 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.865 H202 HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.513 ' HD2' ' CD2' ' B' ' 99' ' ' PHE . 2.9 Cg_endo . . . . . 0 N--CA 1.495 1.568 0 N-CA-C 110.168 -0.743 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.508 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 5.8 tt0 -83.2 127.62 33.78 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 178.069 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.48 HG12 HD22 ' A' ' 5' ' ' LEU . 20.7 t -130.91 102.32 6.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.167 -177.663 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 5' ' ' LEU . 5.5 p -48.68 -24.34 1.34 Allowed 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 179.213 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.869 HD12 ' HG3' ' B' ' 87' ' ' ARG . 0.5 OUTLIER 71.34 35.6 1.5 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.547 -0.721 . . . . 0.0 109.817 179.679 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.433 ' C ' ' HG2' ' A' ' 7' ' ' GLN . 2.1 m95 -55.21 -20.37 10.53 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.876 -1.14 . . . . 0.0 108.416 179.611 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HG2' ' C ' ' A' ' 6' ' ' TRP . 4.4 mm100 -138.52 -142.49 0.16 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.022 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.49 ' HG2' ' OD2' ' B' ' 29' ' ' ASP . 0.0 OUTLIER -92.18 141.8 25.5 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 120.778 -1.201 . . . . 0.0 109.339 179.494 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.656 ' HD3' HD11 ' A' ' 5' ' ' LEU . 37.6 Cg_endo -80.16 59.38 7.41 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.502 2.135 . . . . 0.0 110.243 179.532 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 21' ' ' GLU . 6.0 mt -79.47 132.41 36.34 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.969 -1.082 . . . . 0.0 109.053 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 1.01 HG22 ' HB3' ' A' ' 22' ' ' ALA . 0.9 OUTLIER -134.63 150.37 30.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 O-C-N 121.327 -0.858 . . . . 0.0 109.326 -179.323 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 1.099 HG22 HD22 ' A' ' 19' ' ' LEU . 32.8 m -86.0 95.88 9.65 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.801 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.75 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.1 pt -79.01 155.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 O-C-N 121.478 -0.764 . . . . 0.0 110.298 -178.818 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.566 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -120.06 89.96 3.23 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.8 HD13 HG11 ' A' ' 75' ' ' VAL . 24.9 mt -110.8 130.24 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.196 -0.94 . . . . 0.0 109.963 -179.102 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.72 44.85 93.94 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 179.327 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 57.27 23.7 48.79 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 6.7 mm100 -117.4 163.53 16.23 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.153 -1.204 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 1.099 HD22 HG22 ' A' ' 12' ' ' THR . 11.6 mt -132.97 127.68 34.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.992 -1.068 . . . . 0.0 110.853 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' CD ' ' O ' ' A' ' 19' ' ' LEU . 1.2 mmmt -146.59 173.7 12.09 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.091 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.792 ' HB3' HD22 ' A' ' 10' ' ' LEU . 4.0 mm-40 -79.26 179.57 7.32 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.809 -1.182 . . . . 0.0 108.801 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' HG22 ' A' ' 11' ' ' VAL . . . -159.35 114.07 2.41 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.766 -1.209 . . . . 0.0 110.608 -179.753 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.041 HD21 ' O ' ' B' ' 27' ' ' GLY . 29.3 tp -87.8 96.73 10.57 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.684 -0.635 . . . . 0.0 109.357 179.61 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.568 HD23 ' HB ' ' A' ' 85' ' ' ILE . 19.1 mt -43.67 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.698 ' CB ' HG23 ' A' ' 84' ' ' ILE . 8.1 t0 -106.11 86.17 2.32 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.402 -0.811 . . . . 0.0 111.165 -177.891 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.473 ' HA ' ' CD1' ' A' ' 90' ' ' LEU . 62.1 m -68.53 -14.18 62.83 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.919 -1.113 . . . . 0.0 108.596 178.437 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.41 -22.59 67.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.919 -1.273 . . . . 0.0 109.919 -179.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.51 ' CB ' ' C25' ' B' ' 100' ' ' DMP . . . -86.71 164.77 16.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.029 -1.277 . . . . 0.0 109.807 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.481 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 1.3 m-20 -94.19 -21.07 19.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.324 -0.86 . . . . 0.0 110.961 -178.785 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.824 ' HB3' HD11 ' A' ' 76' ' ' LEU . 0.2 OUTLIER -141.55 -166.57 2.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.655 -1.278 . . . . 0.0 110.596 -179.524 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' ILE . 60.5 m -103.25 89.48 3.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.189 -0.944 . . . . 0.0 111.02 -178.336 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.959 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -73.84 175.45 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.722 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.959 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.0 OUTLIER -171.92 121.7 0.48 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.75 -1.219 . . . . 0.0 110.214 -179.475 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.497 ' HA ' HG23 ' A' ' 80' ' ' THR . 0.1 OUTLIER -39.39 155.61 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.063 -1.023 . . . . 0.0 110.218 179.499 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.548 ' HA ' ' CG1' ' A' ' 77' ' ' VAL . 0.7 OUTLIER -46.4 151.04 0.58 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.383 -0.823 . . . . 0.0 110.265 -179.808 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.407 ' SD ' ' C ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -172.63 174.27 3.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.258 -0.901 . . . . 0.0 109.522 179.581 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.407 ' C ' ' SD ' ' A' ' 36' ' ' MET . 34.7 t -89.48 83.65 6.36 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.012 -1.055 . . . . 0.0 109.724 -179.722 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.9 HD21 HD12 ' A' ' 62' ' ' ILE . 6.1 tp -109.78 105.54 57.31 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.239 -0.913 . . . . 0.0 109.715 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 38' ' ' LEU . 36.0 Cg_endo -78.47 146.63 21.94 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.573 2.182 . . . . 0.0 110.369 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.82 -165.83 26.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.842 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 127.94 49.49 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.26 -1.141 . . . . 0.0 108.595 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.593 ' HB3' ' CD1' ' A' ' 59' ' ' TYR . 42.6 p-90 -136.0 -173.99 3.54 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.985 . . . . 0.0 110.293 -179.355 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.25 129.71 7.74 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.173 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -74.96 136.52 20.61 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.907 1.738 . . . . 0.0 111.369 -178.659 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.586 ' HG2' HG23 ' A' ' 56' ' ' VAL . 9.5 ptmm? -153.74 -165.41 2.12 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 178.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.435 ' HG2' ' HB3' ' A' ' 53' ' ' PHE . 3.3 ttt -147.6 125.92 12.31 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.66 -1.275 . . . . 0.0 110.232 -179.395 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 54' ' ' ILE . 5.2 pt -98.27 135.92 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.06 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.473 ' HA3' ' CD2' ' A' ' 53' ' ' PHE . . . -118.35 112.35 2.36 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -179.653 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -129.35 -111.53 1.53 Allowed Glycine 0 N--CA 1.485 1.915 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.041 -179.509 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.784 HG21 ' CD1' ' B' ' 47' ' ' ILE . 27.4 mt -97.84 132.53 42.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 O-C-N 121.296 -1.12 . . . . 0.0 111.477 -178.445 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' B' ' 52' ' ' GLY . . . 96.69 -50.48 1.56 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.074 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 173.49 -158.7 28.22 Favored Glycine 0 N--CA 1.491 2.3 0 O-C-N 121.022 -1.281 . . . . 0.0 110.15 -179.872 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.473 ' CD2' ' HA3' ' A' ' 48' ' ' GLY . 32.8 m-85 -107.72 151.36 25.79 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.611 -0.935 . . . . 0.0 109.954 -179.654 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.814 HD11 HD11 ' A' ' 47' ' ' ILE . 18.0 pt -136.2 140.61 43.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.508 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.538 ' O ' ' CD ' ' A' ' 79' ' ' PRO . 8.8 mttt -80.7 137.12 36.28 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.043 -1.035 . . . . 0.0 109.389 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.586 HG23 ' HG2' ' A' ' 45' ' ' LYS . 27.2 m -128.66 -176.72 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.36 -0.838 . . . . 0.0 109.469 -179.73 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.569 ' HD3' ' CE3' ' A' ' 42' ' ' TRP . 2.6 mmt85 -125.74 85.35 2.39 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.393 -0.817 . . . . 0.0 108.981 179.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.552 ' HG2' ' CG2' ' A' ' 74' ' ' THR . 1.2 tt0 -45.32 89.53 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 121.441 0.639 . . . . 0.0 110.261 -179.633 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.618 ' HB3' HG13 ' A' ' 62' ' ' ILE . 6.3 m-85 -90.58 82.51 5.82 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 61' ' ' GLN . 0.3 OUTLIER -77.57 137.39 38.56 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.235 -178.349 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 77.62 59.99 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.198 0.523 . . . . 0.0 110.399 179.701 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.9 HD12 HD21 ' A' ' 38' ' ' LEU . 0.6 OUTLIER -131.54 126.49 58.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.633 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.056 HD11 ' HG2' ' A' ' 70' ' ' LYS . 5.3 tt -74.68 93.33 2.54 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.187 -0.945 . . . . 0.0 112.839 -176.746 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.687 ' CG2' HD11 ' A' ' 89' ' ' LEU . 1.9 tt -87.33 115.76 28.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 105.966 -1.865 . . . . 0.0 105.966 176.236 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.566 ' HB3' ' HB2' ' A' ' 14' ' ' LYS . 0.5 OUTLIER -87.97 116.97 26.51 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.11 -0.994 . . . . 0.0 109.013 -178.057 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 64' ' ' ILE . 1.5 mp -111.92 125.64 69.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.243 -0.911 . . . . 0.0 109.95 -179.076 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 7.7 m 51.75 -94.84 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.585 -0.697 . . . . 0.0 109.75 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -140.51 49.55 0.79 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.823 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -145.2 109.8 5.0 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.322 -1.105 . . . . 0.0 110.158 -179.767 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 1.056 ' HG2' HD11 ' A' ' 63' ' ' LEU . 0.5 OUTLIER -63.73 120.05 11.11 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.796 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.643 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -132.7 129.01 38.2 Favored 'General case' 0 C--N 1.291 -1.953 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.755 -178.355 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.815 HD13 ' C ' ' A' ' 62' ' ' ILE . 0.5 OUTLIER -105.69 138.93 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 177.269 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.458 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -161.97 -157.23 8.79 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 118.966 -1.588 . . . . 0.0 110.641 -179.472 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.552 ' CG2' ' HG2' ' A' ' 58' ' ' GLN . 9.9 m -107.42 104.47 14.06 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.879 -0.777 . . . . 0.0 108.946 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.935 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -91.28 99.94 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.539 -0.726 . . . . 0.0 109.721 -179.757 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.824 HD11 ' HB3' ' A' ' 30' ' ' ASP . 2.7 mp -78.16 106.34 9.99 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.074 -1.016 . . . . 0.0 108.857 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.548 ' CG1' ' HA ' ' A' ' 35' ' ' GLU . 50.1 t -95.75 123.9 48.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.424 -0.797 . . . . 0.0 110.358 -179.271 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -155.45 -163.92 12.62 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 179.36 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.538 ' CD ' ' O ' ' A' ' 55' ' ' LYS . 34.9 Cg_endo -79.75 39.62 0.85 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.56 2.173 . . . . 0.0 111.193 179.742 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.754 HG21 HG13 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -85.66 135.77 37.79 Favored Pre-proline 0 N--CA 1.491 1.625 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.794 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' HG2' ' H63' ' B' ' 100' ' ' DMP . 34.6 Cg_endo -78.24 18.79 0.88 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.793 2.329 . . . . 0.0 112.21 -178.529 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.589 ' CG1' HD11 ' A' ' 84' ' ' ILE . 0.6 OUTLIER -161.87 163.02 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.575 -1.328 . . . . 0.0 110.476 -179.962 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.587 ' HB2' ' HA ' ' A' ' 22' ' ' ALA . 54.6 m-20 -91.46 140.04 30.14 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 105.175 -2.158 . . . . 0.0 105.175 176.549 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.796 ' C ' HD13 ' A' ' 85' ' ' ILE . 18.3 mm -128.64 122.79 58.06 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 O-C-N 120.346 -1.471 . . . . 0.0 111.539 -177.211 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.796 HD13 ' C ' ' A' ' 84' ' ' ILE . 1.4 mm -102.91 96.71 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.184 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -79.34 -156.41 10.68 Favored Glycine 0 N--CA 1.495 2.62 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.525 -177.416 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.522 ' HA ' ' HB2' ' A' ' 90' ' ' LEU . 7.9 mtt180 -72.81 -35.17 67.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.874 -0.78 . . . . 0.0 109.799 -179.309 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.893 ' ND2' HD23 ' A' ' 89' ' ' LEU . 0.0 OUTLIER -54.19 -18.87 4.27 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.005 -1.06 . . . . 0.0 108.857 -178.977 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.893 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.2 mm? -110.37 -22.22 11.81 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.167 -0.958 . . . . 0.0 109.096 179.524 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.634 HD23 HD11 ' A' ' 93' ' ' ILE . 64.1 mt -74.67 -17.24 60.71 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.299 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.59 HG22 ' CD2' ' B' ' 5' ' ' LEU . 0.8 OUTLIER -89.84 -10.28 45.97 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 179.029 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.643 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 72.6 mt-30 -94.52 -41.74 9.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.402 -0.811 . . . . 0.0 109.302 179.972 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.854 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.7 OUTLIER -84.25 -3.81 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.203 -0.936 . . . . 0.0 108.772 179.116 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 67.67 43.06 86.39 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 178.817 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.527 ' CB ' HD22 ' A' ' 90' ' ' LEU . . . -66.54 153.05 43.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.867 -1.373 . . . . 0.0 110.082 179.865 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.499 HG22 ' HA ' ' B' ' 4' ' ' THR . 17.7 p -145.09 128.31 16.74 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.327 -0.858 . . . . 0.0 109.094 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' B' ' 97' ' ' LEU . 6.7 mp -93.16 96.72 10.21 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.44 -0.787 . . . . 0.0 109.441 -179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.584 ' ND2' ' CG ' ' B' ' 2' ' ' GLN . 3.2 m120 -101.13 121.22 41.43 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.822 -1.173 . . . . 0.0 109.674 179.654 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.77 ' CD2' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.479 179.541 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.576 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.2 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 N-CA-C 110.408 -0.651 . . . . 0.0 110.408 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.584 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 1.9 tt0 -96.37 132.08 42.26 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.456 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 52.7 t -131.82 120.85 45.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.032 -1.042 . . . . 0.0 109.624 -179.049 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.941 ' C ' HD13 ' B' ' 5' ' ' LEU . 0.3 OUTLIER -60.19 -97.26 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.434 -0.791 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.941 HD13 ' C ' ' B' ' 4' ' ' THR . 0.0 OUTLIER -168.88 -17.87 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.963 -1.086 . . . . 0.0 111.325 179.685 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.591 ' H ' HD22 ' B' ' 5' ' ' LEU . 67.0 m95 -66.19 -11.6 50.7 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.546 -1.346 . . . . 0.0 109.792 -179.799 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -117.56 147.12 43.1 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 110.235 -179.601 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.92 131.21 81.83 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.34 -0.85 . . . . 0.0 109.028 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.802 ' HB2' HD12 ' B' ' 24' ' ' LEU . 38.0 Cg_endo -81.08 45.42 1.99 Allowed 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.135 1.89 . . . . 0.0 109.825 178.732 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' B' ' 22' ' ' ALA . 0.1 OUTLIER -81.1 147.45 30.1 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.156 -0.965 . . . . 0.0 109.279 -179.672 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' B' ' 66' ' ' ILE . 0.9 OUTLIER -150.31 135.48 10.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.023 -1.048 . . . . 0.0 110.569 -179.184 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.878 ' CG2' HD22 ' B' ' 19' ' ' LEU . 7.5 m -64.03 113.83 3.75 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.207 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.725 HG21 ' HB2' ' B' ' 22' ' ' ALA . 1.4 pp -100.57 135.67 35.54 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 O-C-N 121.323 -0.861 . . . . 0.0 110.182 -179.034 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.604 ' HD3' HD21 ' B' ' 19' ' ' LEU . 0.8 OUTLIER -108.33 108.54 19.57 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.24 -0.912 . . . . 0.0 108.967 179.5 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.74 HD13 HG11 ' B' ' 75' ' ' VAL . 28.9 mt -110.67 123.52 66.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 121.163 -0.961 . . . . 0.0 108.876 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.6 -90.46 0.38 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.734 -1.746 . . . . 0.0 108.734 -179.402 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -152.34 27.05 0.88 Allowed Glycine 0 N--CA 1.483 1.813 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 179.396 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.478 ' O ' ' HG3' ' B' ' 14' ' ' LYS . 4.6 mt-30 -125.78 176.31 7.02 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.259 -1.142 . . . . 0.0 109.579 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.878 HD22 ' CG2' ' B' ' 12' ' ' THR . 18.9 mt -136.48 128.09 28.8 Favored 'General case' 0 N--CA 1.488 1.46 0 CA-C-O 121.621 0.724 . . . . 0.0 110.312 -179.263 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.45 ' HB3' HD21 ' B' ' 83' ' ' ASN . 7.6 mmtt -138.64 155.93 47.88 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.494 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.556 ' O ' ' ND2' ' B' ' 83' ' ' ASN . 6.9 mm-40 -78.81 145.13 34.47 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.631 -1.293 . . . . 0.0 109.615 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.76 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -120.54 148.84 43.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.941 -1.099 . . . . 0.0 110.762 -179.303 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.422 ' O ' ' C ' ' B' ' 24' ' ' LEU . 30.3 tp -118.42 95.56 4.92 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.802 HD12 ' HB2' ' B' ' 9' ' ' PRO . 21.2 mt -45.48 107.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.994 -1.066 . . . . 0.0 109.395 -179.659 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 0.639 ' HB3' HG23 ' B' ' 84' ' ' ILE . 22.5 t0 -119.77 90.4 3.32 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.791 -179.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.475 HG23 ' CD ' ' B' ' 87' ' ' ARG . 1.2 m -60.36 -14.27 17.75 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.067 -1.021 . . . . 0.0 108.977 179.282 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 1.041 ' O ' HD21 ' A' ' 23' ' ' LEU . . . -61.67 -44.46 97.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.922 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . 0.515 ' HB2' ' C75' ' B' ' 100' ' ' DMP . . . -80.78 148.43 30.06 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -1.17 . . . . 0.0 109.654 -179.913 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.49 ' OD2' ' HG2' ' A' ' 8' ' ' ARG . 37.6 m-20 -89.12 -8.79 53.1 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.281 -0.887 . . . . 0.0 110.04 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.741 ' HB3' HD11 ' B' ' 76' ' ' LEU . 0.2 OUTLIER -133.39 -171.01 2.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.025 -1.047 . . . . 0.0 109.329 -179.923 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.592 HG23 ' O ' ' B' ' 84' ' ' ILE . 43.5 m -111.97 93.25 4.36 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.778 -1.201 . . . . 0.0 110.974 -178.844 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.017 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -70.92 172.83 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.299 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.065 HD13 HG13 ' B' ' 75' ' ' VAL . 0.1 OUTLIER -166.84 124.3 1.29 Allowed 'General case' 0 C--N 1.305 -1.347 0 O-C-N 120.59 -1.319 . . . . 0.0 111.92 -178.838 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' B' ' 33' ' ' LEU . 0.2 OUTLIER -35.87 154.72 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 178.053 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -53.86 130.33 36.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.113 -0.992 . . . . 0.0 110.335 -179.428 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' B' ' 37' ' ' SER . 0.0 OUTLIER -141.33 -178.39 5.59 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.85 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.513 ' N ' ' SD ' ' B' ' 36' ' ' MET . 4.2 t -105.15 103.45 12.99 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.639 -1.288 . . . . 0.0 110.532 -178.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.709 HD12 HG21 ' B' ' 77' ' ' VAL . 51.6 mt -106.88 156.58 37.05 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 108.975 179.253 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' B' ' 40' ' ' GLY . 36.4 Cg_endo -79.35 77.99 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.695 2.263 . . . . 0.0 111.475 -179.097 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' B' ' 41' ' ' ARG . . . 37.37 -158.41 0.01 OUTLIER Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.212 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' B' ' 40' ' ' GLY . 22.5 mmm180 63.65 74.84 0.41 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.597 -0.943 . . . . 0.0 109.169 -179.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.519 ' HB3' ' CE2' ' B' ' 59' ' ' TYR . 67.8 p-90 -159.13 175.9 12.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.746 . . . . 0.0 109.761 -179.294 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.54 138.71 31.81 Favored Pre-proline 0 N--CA 1.492 1.669 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.035 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.28 127.97 9.44 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.021 1.814 . . . . 0.0 111.286 -178.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.798 ' O ' HG22 ' B' ' 56' ' ' VAL . 0.0 OUTLIER -162.9 136.48 5.96 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.852 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.475 ' HG2' ' HG2' ' B' ' 55' ' ' LYS . 32.4 mtp -102.09 137.26 40.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.844 -1.16 . . . . 0.0 109.098 -179.91 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.784 ' CD1' HG21 ' A' ' 50' ' ' ILE . 19.0 pt -89.59 145.46 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.373 179.237 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . 0.491 ' HA2' ' CD1' ' B' ' 53' ' ' PHE . . . -118.23 100.92 0.87 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.748 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . 0.426 ' HA3' H701 ' B' ' 100' ' ' DMP . . . -120.29 -126.85 3.43 Favored Glycine 0 N--CA 1.483 1.775 0 C-N-CA 119.527 -1.32 . . . . 0.0 111.054 -178.611 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.931 HD12 ' C20' ' B' ' 100' ' ' DMP . 38.5 mt -83.28 118.7 31.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.694 0 O-C-N 121.863 -0.787 . . . . 0.0 112.741 -177.292 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . 0.55 ' HA2' ' CG2' ' A' ' 54' ' ' ILE . . . 100.62 -51.91 0.97 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 178.134 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.497 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . -174.6 -171.61 38.95 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.265 -1.445 . . . . 0.0 110.108 -179.523 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.568 ' CD1' ' N ' ' B' ' 53' ' ' PHE . 1.2 m-30 -106.06 128.83 54.13 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.335 -1.097 . . . . 0.0 109.349 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.554 HG12 ' CG2' ' A' ' 50' ' ' ILE . 5.0 pt -100.84 161.39 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.129 -0.982 . . . . 0.0 109.276 179.904 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.519 ' O ' ' CD ' ' B' ' 79' ' ' PRO . 13.6 mttt -89.6 134.46 34.12 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.131 -0.981 . . . . 0.0 109.208 179.929 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.798 HG22 ' O ' ' B' ' 45' ' ' LYS . 17.0 m -142.05 172.99 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.966 -1.084 . . . . 0.0 109.588 179.842 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . . . . . . . . . 6.9 mtm180 -124.75 101.32 7.04 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.547 ' HG2' ' CG2' ' B' ' 74' ' ' THR . 6.7 tt0 -58.4 96.36 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 O-C-N 121.287 -0.883 . . . . 0.0 110.032 -179.624 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.564 ' HB3' HG13 ' B' ' 62' ' ' ILE . 13.3 m-85 -89.57 94.34 9.83 Favored 'General case' 0 N--CA 1.487 1.4 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.006 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.516 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 1.0 OUTLIER -78.87 141.76 37.4 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.108 -0.995 . . . . 0.0 110.307 -178.846 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.65 ' HA ' HG23 ' B' ' 72' ' ' ILE . 15.2 mt-30 69.38 64.02 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.334 0.588 . . . . 0.0 110.765 179.479 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 0.812 ' C ' HD13 ' B' ' 72' ' ' ILE . 0.9 OUTLIER -119.84 125.01 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 108.847 178.727 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 1.148 HD21 ' CG ' ' B' ' 70' ' ' LYS . 2.8 tm? -74.4 86.45 2.01 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.309 -0.87 . . . . 0.0 110.903 -178.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.616 HG23 ' O ' ' B' ' 64' ' ' ILE . 3.4 tt -90.81 116.93 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.007 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.51 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 2.7 tt0 -90.07 116.56 28.19 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.811 -1.181 . . . . 0.0 109.72 -179.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.628 ' CG1' HG21 ' B' ' 11' ' ' VAL . 0.5 OUTLIER -105.11 116.93 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.157 -0.964 . . . . 0.0 109.675 -179.898 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.2 m 51.85 16.55 0.52 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.782 -0.574 . . . . 0.0 111.603 178.454 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . 106.99 18.65 10.3 Favored Glycine 0 N--CA 1.495 2.604 0 C-N-CA 119.277 -1.439 . . . . 0.0 110.679 179.016 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -116.08 98.85 6.86 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.084 -1.245 . . . . 0.0 108.898 179.459 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . 1.148 ' CG ' HD21 ' B' ' 63' ' ' LEU . 2.6 ttpm? -54.36 120.06 6.05 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.901 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.65 130.86 22.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 110.693 -178.827 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.812 HD13 ' C ' ' B' ' 62' ' ' ILE . 0.8 OUTLIER -94.19 147.1 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.581 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.813 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . -171.09 175.83 44.62 Favored Glycine 0 N--CA 1.489 2.209 0 C-N-CA 118.557 -1.782 . . . . 0.0 111.538 -179.601 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.547 ' CG2' ' HG2' ' B' ' 58' ' ' GLN . 8.6 m -87.97 102.41 14.71 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.927 -0.749 . . . . 0.0 110.465 -179.616 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.065 HG13 HD13 ' B' ' 33' ' ' LEU . 1.5 t -94.12 108.64 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.368 -0.832 . . . . 0.0 110.01 179.189 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.741 HD11 ' HB3' ' B' ' 30' ' ' ASP . 3.0 mp -79.83 111.03 15.75 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.84 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . 0.709 HG21 HD12 ' B' ' 38' ' ' LEU . 11.2 t -93.68 116.51 35.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.117 -0.99 . . . . 0.0 110.122 -179.014 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.488 ' HA3' HG12 ' B' ' 56' ' ' VAL . . . -151.53 -172.83 20.76 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 179.477 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.519 ' CD ' ' O ' ' B' ' 55' ' ' LYS . 35.6 Cg_endo -80.42 42.99 1.43 Allowed 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.525 2.15 . . . . 0.0 110.839 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.722 HG21 HG13 ' B' ' 32' ' ' VAL . 0.9 OUTLIER -83.01 143.62 46.16 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.035 -1.041 . . . . 0.0 108.496 179.198 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.54 14.8 1.54 Allowed 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.275 1.983 . . . . 0.0 110.874 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.459 HG13 ' N ' ' B' ' 83' ' ' ASN . 1.2 t -160.91 165.08 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.902 -1.124 . . . . 0.0 109.816 -179.527 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.61 ' HA ' ' HA ' ' B' ' 33' ' ' LEU . 1.1 m-20 -103.2 119.01 38.08 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 104.675 -2.343 . . . . 0.0 104.675 176.272 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 0.639 HG23 ' HB3' ' B' ' 25' ' ' ASP . 14.6 mm -102.17 126.41 56.22 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 O-C-N 120.762 -1.211 . . . . 0.0 111.9 -175.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.76 HG21 ' CD2' ' B' ' 24' ' ' LEU . 1.0 OUTLIER -103.89 88.33 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 177.304 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -78.59 -158.3 11.84 Favored Glycine 0 N--CA 1.49 2.289 0 C-N-CA 120.145 -1.026 . . . . 0.0 111.228 -177.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.869 ' HG3' HD12 ' A' ' 5' ' ' LEU . 7.3 mmm180 -69.01 -37.81 78.9 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.666 -0.902 . . . . 0.0 110.672 -178.748 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.977 ' ND2' HD23 ' B' ' 89' ' ' LEU . 15.7 p-10 -43.45 -25.18 0.13 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.647 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.977 HD23 ' ND2' ' B' ' 88' ' ' ASN . 3.3 mm? -111.5 -29.79 7.63 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.07 -1.019 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.711 HD21 HD22 ' B' ' 24' ' ' LEU . 33.6 mt -67.33 -8.32 31.49 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.243 -0.91 . . . . 0.0 108.965 179.319 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . 0.599 HG23 HH21 ' B' ' 87' ' ' ARG . 0.0 OUTLIER -100.6 -20.28 15.74 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 179.162 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 -81.4 -40.2 23.8 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.35 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.77 HD12 ' CD2' ' A' ' 99' ' ' PHE . 0.7 OUTLIER -81.28 -2.66 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 108.839 178.89 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 81.95 24.23 55.75 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 178.996 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.706 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -60.58 137.62 58.15 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.842 -1.387 . . . . 0.0 109.994 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.483 ' O ' ' O ' ' A' ' 96' ' ' THR . 44.5 p -132.65 122.1 24.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.645 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.774 HD11 HD11 ' A' ' 97' ' ' LEU . 0.3 OUTLIER -89.51 94.37 9.85 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 121.324 0.583 . . . . 0.0 109.503 -178.683 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.508 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.8 OUTLIER -109.43 130.94 55.48 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.279 -0.888 . . . . 0.0 110.53 -179.312 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.854 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.759 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.096 178.464 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.931 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.514 ' HD2' ' O ' ' B' ' 99' ' ' PHE . 2.7 Cg_endo . . . . . 0 N--CA 1.495 1.604 0 N-CA-C 109.767 -0.897 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.544 ' CG ' ' ND2' ' B' ' 98' ' ' ASN . 2.4 tt0 -83.32 134.84 34.9 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 177.686 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.566 HG11 ' HB3' ' A' ' 9' ' ' PRO . 6.6 t -126.84 101.82 8.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.585 -1.246 . . . . 0.0 110.501 -178.092 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.695 HG22 HG22 ' B' ' 96' ' ' THR . 1.7 p -115.18 -81.52 0.61 Allowed 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.342 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.54 ' O ' ' C ' ' A' ' 6' ' ' TRP . 92.0 mt 33.71 32.91 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.923 -0.486 . . . . 0.0 110.441 178.866 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.54 ' C ' ' O ' ' A' ' 5' ' ' LEU . 7.2 m0 18.33 50.74 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.499 0.666 . . . . 0.0 111.651 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.534 ' N ' ' O ' ' A' ' 5' ' ' LEU . 0.6 OUTLIER -143.6 -163.83 1.74 Allowed 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.549 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.436 ' HG2' ' NH1' ' B' ' 87' ' ' ARG . 0.0 OUTLIER -84.86 136.64 38.64 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 108.869 179.703 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.566 ' HB3' HG11 ' A' ' 3' ' ' VAL . 36.4 Cg_endo -78.97 67.63 8.51 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 122.316 2.011 . . . . 0.0 109.776 179.099 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.434 HD22 ' HB3' ' A' ' 21' ' ' GLU . 0.8 OUTLIER -86.91 143.04 27.58 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.19 -0.944 . . . . 0.0 109.592 -179.619 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.606 HG21 HG23 ' A' ' 66' ' ' ILE . 0.8 OUTLIER -139.51 160.66 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.829 . . . . 0.0 109.412 -179.745 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.841 HG22 HD22 ' A' ' 19' ' ' LEU . 34.5 m -95.33 109.96 22.03 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 178.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.882 ' O ' HD23 ' A' ' 19' ' ' LEU . 1.7 pt -97.8 159.1 3.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.299 -0.876 . . . . 0.0 110.401 -178.312 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.52 ' HE3' HD11 ' A' ' 19' ' ' LEU . 0.0 OUTLIER -119.3 99.1 6.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.485 -0.759 . . . . 0.0 109.095 179.53 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.935 HD13 HG11 ' A' ' 75' ' ' VAL . 17.0 mt -114.64 130.55 68.82 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 O-C-N 121.165 -0.959 . . . . 0.0 109.534 -179.653 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.63 50.56 62.35 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.807 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 51.67 26.18 16.16 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.946 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 14' ' ' LYS . 2.5 mt-30 -120.37 173.66 7.0 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -1.158 . . . . 0.0 109.041 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 13' ' ' ILE . 13.2 mt -140.46 126.94 20.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.128 -0.983 . . . . 0.0 110.352 -179.678 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.656 ' HB3' ' ND2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -144.13 175.04 10.36 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 179.516 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.454 ' O ' ' CG ' ' A' ' 83' ' ' ASN . 1.9 mm-40 -79.44 178.15 8.33 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.845 -1.16 . . . . 0.0 108.721 179.67 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.691 ' HB1' HG12 ' A' ' 85' ' ' ILE . . . -158.38 117.97 3.19 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.875 -1.14 . . . . 0.0 110.035 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 25' ' ' ASP . 59.0 tp -90.56 95.47 10.18 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.431 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.643 ' CD1' ' CZ ' ' B' ' 99' ' ' PHE . 10.9 mt -46.16 97.09 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 -179.682 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.566 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 18.9 t0 -103.49 91.67 4.15 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.533 -0.729 . . . . 0.0 110.647 -177.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.877 HG23 HD12 ' A' ' 90' ' ' LEU . 0.1 OUTLIER -67.77 -6.74 22.62 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.886 -1.134 . . . . 0.0 108.977 178.767 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.49 ' HA3' ' CG ' ' B' ' 25' ' ' ASP . . . -80.11 -39.49 16.04 Favored Glycine 0 N--CA 1.49 2.294 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.446 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -69.89 160.71 31.32 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.824 -1.398 . . . . 0.0 109.52 -179.505 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -99.85 -16.46 18.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.21 -0.932 . . . . 0.0 109.062 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' ' HA3' ' A' ' 86' ' ' GLY . 0.4 OUTLIER -132.29 -161.19 1.11 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.44 -0.787 . . . . 0.0 109.152 -180.0 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.748 HG22 ' CD1' ' A' ' 33' ' ' LEU . 21.5 m -121.04 89.8 3.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.559 -1.338 . . . . 0.0 110.675 -178.526 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.03 ' O ' HD12 ' A' ' 33' ' ' LEU . 0.5 OUTLIER -70.07 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 178.953 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 1.03 HD12 ' O ' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -161.17 129.44 4.4 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.965 -1.084 . . . . 0.0 110.679 -178.707 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.466 ' C ' ' O ' ' A' ' 33' ' ' LEU . 7.0 tt0 -40.8 156.85 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.111 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.794 ' HA ' HG12 ' A' ' 77' ' ' VAL . 0.3 OUTLIER -52.89 153.09 3.52 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.06 -1.025 . . . . 0.0 110.364 -179.155 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 4.1 ptm -177.47 -163.76 0.08 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.407 -0.808 . . . . 0.0 109.019 179.71 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -107.52 142.17 37.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.147 -0.971 . . . . 0.0 109.697 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.779 HD21 HG22 ' A' ' 15' ' ' ILE . 9.3 mt -150.33 167.22 13.43 Favored Pre-proline 0 N--CA 1.492 1.63 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.531 ' O ' ' O ' ' A' ' 40' ' ' GLY . 34.2 Cg_endo -76.78 138.43 18.86 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.299 1.999 . . . . 0.0 109.342 179.33 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.59 ' O ' ' HB2' ' A' ' 41' ' ' ARG . . . -48.0 -169.33 0.01 OUTLIER Glycine 0 N--CA 1.492 2.42 0 CA-C-O 121.854 0.696 . . . . 0.0 111.438 -178.669 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.59 ' HB2' ' O ' ' A' ' 40' ' ' GLY . 0.2 OUTLIER 81.91 46.92 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 -178.965 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.679 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 57.8 p-90 -137.24 -172.02 3.1 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.405 0.621 . . . . 0.0 109.798 -179.196 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.19 138.65 11.97 Favored Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 121.41 -0.806 . . . . 0.0 109.204 179.226 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.32 139.48 18.68 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.117 1.878 . . . . 0.0 110.028 179.455 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' HB2' ' A' ' 58' ' ' GLN . 0.2 OUTLIER -160.59 -159.46 0.69 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.432 -0.793 . . . . 0.0 108.951 -179.775 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.509 ' HG2' ' HG3' ' A' ' 55' ' ' LYS . 69.4 mtp -148.93 130.5 14.91 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.119 -0.988 . . . . 0.0 109.41 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.828 HD11 HG21 ' B' ' 50' ' ' ILE . 14.6 pt -88.95 144.68 8.59 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -117.14 97.91 0.76 Allowed Glycine 0 N--CA 1.488 2.126 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.228 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.458 ' HA3' H201 ' B' ' 100' ' ' DMP . . . -121.68 -126.43 3.26 Favored Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.325 -179.151 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.902 HG21 HD12 ' B' ' 47' ' ' ILE . 21.8 mt -87.43 112.17 22.94 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.809 -0.818 . . . . 0.0 112.639 -177.787 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.544 ' N ' HG23 ' B' ' 54' ' ' ILE . . . 116.77 -48.52 0.93 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 110.244 -1.142 . . . . 0.0 110.244 178.054 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 172.76 -154.57 21.22 Favored Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.023 -179.618 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.578 ' N ' ' CD1' ' A' ' 53' ' ' PHE . 1.1 m-85 -114.14 116.4 29.04 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.562 -0.964 . . . . 0.0 110.009 -179.454 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.566 ' CG1' ' CG1' ' A' ' 47' ' ' ILE . 5.0 pt -89.85 175.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.149 -0.969 . . . . 0.0 109.084 179.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.542 ' O ' ' HD2' ' A' ' 79' ' ' PRO . 0.0 OUTLIER -104.13 142.5 34.38 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 108.853 179.423 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.76 HG21 HD23 ' A' ' 76' ' ' LEU . 15.1 m -150.93 175.25 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.943 -1.098 . . . . 0.0 110.293 -179.54 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.53 ' HD3' ' CZ3' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -126.61 98.23 5.32 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.646 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.541 ' HG3' ' CG2' ' A' ' 74' ' ' THR . 0.7 OUTLIER -58.1 102.58 0.11 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.219 -0.925 . . . . 0.0 110.971 -179.016 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.679 ' CE1' ' CD1' ' A' ' 42' ' ' TRP . 23.0 m-85 -98.89 94.35 6.53 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.114 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.579 ' OD1' HG23 ' A' ' 74' ' ' THR . 0.6 OUTLIER -79.02 139.41 38.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.159 -0.963 . . . . 0.0 110.465 -178.538 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER 73.96 62.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.674 -0.641 . . . . 0.0 110.064 179.499 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.603 HG21 HG23 ' A' ' 15' ' ' ILE . 10.5 mm -119.69 114.46 44.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.145 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.905 ' O ' HD13 ' A' ' 63' ' ' LEU . 2.3 tm? -63.61 87.02 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.362 -0.836 . . . . 0.0 110.944 -178.586 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 66' ' ' ILE . 5.6 tt -89.59 115.23 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 178.078 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.458 ' OE2' ' N ' ' A' ' 69' ' ' HIS . 1.1 tm-20 -88.35 123.51 33.0 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.106 -0.996 . . . . 0.0 109.181 -178.773 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.67 HD11 ' CD1' ' A' ' 64' ' ' ILE . 2.3 mt -126.13 122.42 61.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.36 -0.837 . . . . 0.0 110.188 -179.049 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 56.15 46.68 21.02 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.662 -0.649 . . . . 0.0 111.174 179.021 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.77 22.62 68.42 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 120.163 -1.018 . . . . 0.0 110.928 178.406 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.458 ' N ' ' OE2' ' A' ' 65' ' ' GLU . 5.9 m-70 -123.41 130.79 53.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.993 -1.298 . . . . 0.0 109.186 179.24 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.618 ' CG ' HD21 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -72.48 129.18 37.72 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.208 -0.932 . . . . 0.0 108.908 179.713 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.56 ' O ' HG22 ' A' ' 64' ' ' ILE . . . -146.55 109.57 4.68 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.54 -0.725 . . . . 0.0 109.677 -179.324 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.588 HG12 HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -90.43 156.88 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.764 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.788 ' HA3' HD21 ' A' ' 89' ' ' LEU . . . -178.53 -171.31 41.68 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 118.435 -1.84 . . . . 0.0 111.597 179.819 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.579 HG23 ' OD1' ' A' ' 60' ' ' ASP . 7.7 m -96.79 104.92 16.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.737 -0.861 . . . . 0.0 109.542 -179.669 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 1.023 ' CG1' HD13 ' A' ' 33' ' ' LEU . 1.4 t -100.33 113.4 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.294 -0.879 . . . . 0.0 110.567 -179.573 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.76 HD23 HG21 ' A' ' 56' ' ' VAL . 5.3 mp -82.78 125.3 31.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -0.847 . . . . 0.0 108.841 178.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.794 HG12 ' HA ' ' A' ' 35' ' ' GLU . 3.1 t -103.92 110.45 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.0 -1.062 . . . . 0.0 109.423 -179.959 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.524 ' HA3' ' O ' ' A' ' 55' ' ' LYS . . . -145.61 -171.47 15.21 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.949 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.542 ' HD2' ' O ' ' A' ' 55' ' ' LYS . 36.7 Cg_endo -81.47 42.42 1.33 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.454 2.103 . . . . 0.0 110.41 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.601 HG21 HG13 ' A' ' 32' ' ' VAL . 6.5 t -81.47 141.89 49.5 Favored Pre-proline 0 C--N 1.303 -1.425 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.542 ' O ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -79.74 16.95 1.35 Allowed 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.408 2.072 . . . . 0.0 111.339 -179.629 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.542 HG23 ' O ' ' A' ' 81' ' ' PRO . 1.0 OUTLIER -161.05 165.87 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.917 -1.114 . . . . 0.0 109.894 -179.571 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.656 ' ND2' ' HB3' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -103.79 96.72 6.89 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 105.11 -2.181 . . . . 0.0 105.11 176.761 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.613 ' CG1' HG12 ' A' ' 32' ' ' VAL . 6.4 mm -83.15 115.42 25.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 O-C-N 121.082 -1.011 . . . . 0.0 113.1 -175.756 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.837 HD13 ' N ' ' A' ' 85' ' ' ILE . 0.5 OUTLIER -95.0 91.99 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 N-CA-C 105.321 -2.103 . . . . 0.0 105.321 175.612 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.578 ' HA3' ' O ' ' A' ' 30' ' ' ASP . . . -77.32 -157.38 8.6 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.884 -1.15 . . . . 0.0 110.783 -177.047 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 88' ' ' ASN . 0.1 OUTLIER -69.56 -37.14 76.88 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.884 -0.774 . . . . 0.0 110.37 -178.804 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 1.03 ' ND2' HD23 ' A' ' 89' ' ' LEU . 14.7 p-10 -46.58 -28.86 1.57 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.762 -1.211 . . . . 0.0 109.634 -179.757 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 1.03 HD23 ' ND2' ' A' ' 88' ' ' ASN . 2.3 mm? -110.96 -30.96 7.3 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.994 -1.067 . . . . 0.0 111.466 -178.361 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.877 HD12 HG23 ' A' ' 26' ' ' THR . 0.6 OUTLIER -59.57 -31.46 69.46 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.769 -1.207 . . . . 0.0 108.642 -179.869 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.4 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -78.85 -20.7 48.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.898 . . . . 0.0 110.123 -179.89 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 -69.77 -40.66 75.93 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.88 -1.138 . . . . 0.0 108.262 179.319 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.943 HD12 ' CB ' ' B' ' 99' ' ' PHE . 0.6 OUTLIER -83.67 -7.17 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.864 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' B' ' 99' ' ' PHE . . . 71.52 62.92 3.25 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.805 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -83.21 148.88 27.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.315 -1.109 . . . . 0.0 109.674 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.579 HG22 ' CG2' ' B' ' 4' ' ' THR . 5.0 p -137.46 129.74 29.45 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.142 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.679 HD11 HD11 ' B' ' 97' ' ' LEU . 4.9 mp -96.58 88.65 4.73 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.263 -0.898 . . . . 0.0 109.422 -179.745 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' B' ' 95' ' ' ALA . 3.1 m120 -93.6 121.59 35.18 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.116 -0.99 . . . . 0.0 109.126 179.827 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.636 ' CB ' HD12 ' B' ' 93' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 CA-C-O 117.968 -1.015 . . . . 0.0 109.402 -179.876 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 1' ' ' PRO . . . . . 0.605 ' O ' ' CE1' ' A' ' 99' ' ' PHE . 3.0 Cg_exo . . . . . 0 N--CA 1.496 1.619 0 N-CA-C 110.641 -0.561 . . . . 0.0 110.641 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 2' ' ' GLN . . . . . 0.439 ' CG ' ' ND2' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -91.01 136.9 32.77 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 177.85 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 25.2 t -133.93 105.89 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 120.574 -1.329 . . . . 0.0 110.57 -178.558 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.579 ' CG2' HG22 ' A' ' 96' ' ' THR . 15.8 p -122.03 -70.13 0.8 Allowed 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.063 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . 0.538 ' O ' ' C ' ' B' ' 6' ' ' TRP . 0.2 OUTLIER 31.24 37.79 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.81 -0.556 . . . . 0.0 110.743 179.146 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 6' ' ' TRP . . . . . 0.538 ' C ' ' O ' ' B' ' 5' ' ' LEU . 5.5 m95 18.8 50.25 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.186 0 CA-C-O 121.504 0.669 . . . . 0.0 111.924 -179.756 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.537 ' N ' ' O ' ' B' ' 5' ' ' LEU . 0.4 OUTLIER -154.55 165.4 36.6 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.155 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.5 ' HB3' ' CD1' ' B' ' 23' ' ' LEU . 71.2 mtm180 -49.0 133.15 15.0 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 120.905 -1.122 . . . . 0.0 109.012 -179.827 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 9' ' ' PRO . . . . . 0.494 ' HG2' ' HB2' ' B' ' 24' ' ' LEU . 34.6 Cg_endo -80.09 64.83 8.91 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.312 2.008 . . . . 0.0 109.514 179.028 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 10' ' ' LEU . . . . . 0.699 HD22 ' HB3' ' B' ' 21' ' ' GLU . 0.1 OUTLIER -79.89 148.24 31.38 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.33 -0.856 . . . . 0.0 109.521 -179.663 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.756 HG21 HG23 ' B' ' 66' ' ' ILE . 1.4 m -140.29 132.28 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.307 -0.871 . . . . 0.0 109.592 179.872 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 12' ' ' THR . . . . . 0.66 HG22 HD22 ' B' ' 19' ' ' LEU . 11.8 m -64.09 99.77 0.28 Allowed 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.498 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.635 ' O ' HD23 ' B' ' 19' ' ' LEU . 1.0 OUTLIER -90.41 147.89 4.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.255 -0.903 . . . . 0.0 110.615 -178.178 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 14' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' B' ' 64' ' ' ILE . 2.8 tttt -107.93 107.94 18.87 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 1.046 HD13 HG11 ' B' ' 75' ' ' VAL . 14.8 mt -122.88 119.04 56.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.205 -0.934 . . . . 0.0 109.604 -179.273 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . 0.402 ' HA3' ' CD1' ' B' ' 38' ' ' LEU . . . 68.59 20.99 74.4 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.38 -7.74 79.66 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.545 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 18' ' ' GLN . . . . . 0.524 ' NE2' ' O ' ' B' ' 37' ' ' SER . 30.6 mt-30 -87.19 -175.25 5.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.318 -1.107 . . . . 0.0 109.52 -179.961 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 19' ' ' LEU . . . . . 0.66 HD22 HG22 ' B' ' 12' ' ' THR . 40.9 mt -152.19 119.95 6.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 0.0 109.919 -179.861 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.526 ' CD ' ' O ' ' B' ' 19' ' ' LEU . 2.5 mmmt -134.82 161.61 34.73 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.699 ' HB3' HD22 ' B' ' 10' ' ' LEU . 0.1 OUTLIER -79.09 122.82 26.71 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.526 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . 0.759 ' HB1' ' CD1' ' B' ' 85' ' ' ILE . . . -108.63 119.4 39.43 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.921 -1.112 . . . . 0.0 111.145 -178.578 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 23' ' ' LEU . . . . . 0.5 ' CD1' ' HB3' ' B' ' 8' ' ' ARG . 24.9 tp -75.43 99.59 4.21 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.633 179.561 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 24' ' ' LEU . . . . . 0.698 ' CD2' HD21 ' B' ' 90' ' ' LEU . 4.6 mt -48.68 96.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.28 179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 25' ' ' ASP . . . . . 1.05 ' CB ' HG23 ' B' ' 84' ' ' ILE . 8.7 t0 -96.88 95.6 7.97 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 110.068 -179.379 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 26' ' ' THR . . . . . 0.684 HG21 HD13 ' B' ' 97' ' ' LEU . 9.8 m -74.27 -4.29 35.25 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.157 -0.964 . . . . 0.0 108.467 178.455 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 27' ' ' GLY . . . . . 0.478 ' HA3' ' CG ' ' A' ' 25' ' ' ASP . . . -85.81 -26.25 35.54 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 28' ' ' ALA . . . . . . . . . . . . . . . -88.85 162.32 16.22 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.869 -1.371 . . . . 0.0 109.999 -179.304 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 29' ' ' ASP . . . . . 0.501 ' N ' ' OD1' ' B' ' 29' ' ' ASP . 2.2 m-20 -100.62 -13.9 18.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -0.799 . . . . 0.0 110.719 -179.132 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.511 ' O ' ' HA3' ' B' ' 86' ' ' GLY . 0.2 OUTLIER -132.82 -172.22 2.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.912 -1.117 . . . . 0.0 109.506 -179.706 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 31' ' ' THR . . . . . 0.55 HG22 ' CD1' ' B' ' 33' ' ' LEU . 20.6 m -111.04 87.28 2.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.519 -1.363 . . . . 0.0 110.702 -178.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 32' ' ' VAL . . . . . 1.041 ' O ' HD12 ' B' ' 33' ' ' LEU . 0.5 OUTLIER -73.43 170.6 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 178.179 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 1.041 HD12 ' O ' ' B' ' 32' ' ' VAL . 0.1 OUTLIER -163.51 122.12 1.99 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.533 -1.354 . . . . 0.0 110.609 -178.576 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.696 ' HA ' HG22 ' B' ' 80' ' ' THR . 88.5 tt0 -40.26 152.92 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.371 -0.831 . . . . 0.0 109.311 179.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' B' ' 78' ' ' GLY . 2.8 tt0 -46.09 147.77 0.98 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 110.602 -179.313 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 36' ' ' MET . . . . . . . . . . . . . 3.8 ptt? -168.01 156.81 9.26 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 37' ' ' SER . . . . . 0.524 ' O ' ' NE2' ' B' ' 18' ' ' GLN . 4.6 t -79.26 85.63 5.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 109.788 -179.339 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 1.075 HD21 HD12 ' B' ' 62' ' ' ILE . 62.7 tp -103.14 115.13 64.51 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.273 -0.892 . . . . 0.0 109.338 179.716 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 39' ' ' PRO . . . . . 0.737 ' HD2' HD12 ' B' ' 38' ' ' LEU . 34.1 Cg_endo -77.05 125.28 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.44 2.094 . . . . 0.0 110.534 -179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 40' ' ' GLY . . . . . . . . . . . . . . . 145.96 154.49 6.18 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.98 153.02 38.47 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -1.182 . . . . 0.0 109.287 -179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 42' ' ' TRP . . . . . 0.492 ' CE3' ' HB3' ' B' ' 57' ' ' ARG . 58.0 p-90 -156.58 172.45 18.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.141 -0.975 . . . . 0.0 109.394 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 43' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.66 137.39 30.26 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 109.028 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.35 137.74 15.2 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 122.112 1.874 . . . . 0.0 111.093 -179.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 45' ' ' LYS . . . . . 0.563 ' HG2' HG23 ' B' ' 56' ' ' VAL . 3.8 ptmt -159.98 -172.9 3.81 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.161 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 46' ' ' MET . . . . . 0.415 ' HA ' ' O ' ' B' ' 54' ' ' ILE . 28.1 mtp -141.58 137.61 32.05 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.662 -1.274 . . . . 0.0 109.842 -179.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 47' ' ' ILE . . . . . 0.902 HD12 HG21 ' A' ' 50' ' ' ILE . 1.4 pt -96.06 152.74 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.475 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.48 116.33 3.37 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.778 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -149.13 -124.66 1.35 Allowed Glycine 0 N--CA 1.488 2.154 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.25 -179.681 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 50' ' ' ILE . . . . . 0.882 HD12 ' C20' ' B' ' 100' ' ' DMP . 20.4 mt -86.59 123.93 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.527 -0.984 . . . . 0.0 112.375 -178.181 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 51' ' ' GLY . . . . . . . . . . . . . . . 94.78 -7.93 70.72 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 120.27 -0.967 . . . . 0.0 111.148 177.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . 125.91 -159.22 20.32 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 53' ' ' PHE . . . . . 0.538 ' HA ' ' O ' ' B' ' 47' ' ' ILE . 0.0 OUTLIER -112.96 142.03 46.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.314 -1.11 . . . . 0.0 109.843 -179.585 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.831 HD11 HD11 ' B' ' 47' ' ' ILE . 6.5 pt -107.17 -178.3 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.258 -0.901 . . . . 0.0 109.368 179.554 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 55' ' ' LYS . . . . . 0.576 ' O ' ' HD2' ' B' ' 79' ' ' PRO . 0.0 OUTLIER -106.34 148.21 28.3 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.421 -0.799 . . . . 0.0 108.894 179.475 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 56' ' ' VAL . . . . . 0.563 HG23 ' HG2' ' B' ' 45' ' ' LYS . 29.3 m -151.22 -179.1 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.687 -1.258 . . . . 0.0 110.408 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 57' ' ' ARG . . . . . 0.492 ' HB3' ' CE3' ' B' ' 42' ' ' TRP . 2.6 mtt-85 -130.47 86.41 2.38 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 58' ' ' GLN . . . . . 0.5 ' HB2' ' HD2' ' B' ' 45' ' ' LYS . 24.5 tt0 -47.41 105.63 0.07 Allowed 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.588 -0.695 . . . . 0.0 111.301 -178.469 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 59' ' ' TYR . . . . . 0.715 ' CD2' HD23 ' B' ' 38' ' ' LEU . 5.1 m-85 -99.03 90.3 4.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 60' ' ' ASP . . . . . 0.438 ' O ' ' HB2' ' B' ' 61' ' ' GLN . 2.8 m-20 -79.0 136.32 37.17 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.872 -1.143 . . . . 0.0 111.502 -177.753 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 61' ' ' GLN . . . . . 0.534 ' HA ' ' CG2' ' B' ' 72' ' ' ILE . 13.9 mt-30 68.21 62.5 0.38 Allowed 'General case' 0 N--CA 1.487 1.377 0 CA-C-O 121.179 0.514 . . . . 0.0 110.632 178.542 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 62' ' ' ILE . . . . . 1.075 HD12 HD21 ' B' ' 38' ' ' LEU . 0.1 OUTLIER -122.51 122.39 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.205 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 1.01 ' O ' HD13 ' B' ' 63' ' ' LEU . 1.3 tm? -60.51 87.4 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.759 0.79 . . . . 0.0 111.896 -177.741 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 64' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' B' ' 71' ' ' ALA . 2.6 tt -95.81 111.53 26.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 176.561 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 65' ' ' GLU . . . . . 0.562 ' O ' ' HA ' ' B' ' 13' ' ' ILE . 1.4 tt0 -90.25 124.64 35.04 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.76 -1.212 . . . . 0.0 109.152 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 66' ' ' ILE . . . . . 0.756 HG23 HG21 ' B' ' 11' ' ' VAL . 1.0 OUTLIER -106.53 128.23 61.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.156 -0.965 . . . . 0.0 109.269 -179.728 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 67' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 58.86 -90.1 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.683 -0.636 . . . . 0.0 109.682 179.583 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 68' ' ' GLY . . . . . . . . . . . . . . . -146.92 40.95 0.99 Allowed Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 69' ' ' HIS . . . . . 0.509 ' NE2' ' HD3' ' B' ' 1' ' ' PRO . 86.6 m-70 -137.64 114.14 10.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -1.132 . . . . 0.0 109.768 179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.47 120.86 8.39 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.351 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 71' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' B' ' 64' ' ' ILE . . . -132.87 151.63 52.0 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.405 -0.809 . . . . 0.0 109.429 179.897 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 72' ' ' ILE . . . . . 0.857 HD13 ' N ' ' B' ' 63' ' ' LEU . 0.9 OUTLIER -125.22 156.5 34.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 105.716 -1.957 . . . . 0.0 105.716 177.527 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 73' ' ' GLY . . . . . 0.601 ' HA3' HD21 ' B' ' 89' ' ' LEU . . . 177.27 -165.15 34.86 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 117.906 -2.093 . . . . 0.0 111.492 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.501 ' HB ' ' OD2' ' B' ' 30' ' ' ASP . 8.5 m -99.41 103.61 15.41 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.906 -0.761 . . . . 0.0 110.017 -179.476 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 75' ' ' VAL . . . . . 1.046 HG11 HD13 ' B' ' 15' ' ' ILE . 1.3 t -94.73 102.19 13.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.471 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.49 HD12 ' H ' ' B' ' 76' ' ' LEU . 2.8 mp -79.12 112.74 16.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.033 -1.042 . . . . 0.0 108.981 179.956 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 77' ' ' VAL . . . . . . . . . . . . . 52.9 t -97.89 117.72 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.102 -0.999 . . . . 0.0 109.814 -179.521 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' B' ' 55' ' ' LYS . . . -149.89 -164.28 11.67 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 179.739 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 79' ' ' PRO . . . . . 0.576 ' HD2' ' O ' ' B' ' 55' ' ' LYS . 36.4 Cg_endo -82.76 38.04 0.71 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 122.202 1.935 . . . . 0.0 110.404 179.814 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 80' ' ' THR . . . . . 0.696 HG22 ' HA ' ' B' ' 34' ' ' GLU . 3.6 t -79.85 134.32 57.08 Favored Pre-proline 0 C--N 1.305 -1.328 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 178.785 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 81' ' ' PRO . . . . . 0.547 ' O ' HG23 ' B' ' 82' ' ' VAL . 32.1 Cg_endo -77.5 17.04 0.97 Allowed 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.393 2.062 . . . . 0.0 111.701 -178.556 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.651 HG12 ' CD1' ' B' ' 84' ' ' ILE . 0.9 OUTLIER -162.23 151.4 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 120.755 -1.216 . . . . 0.0 109.972 -179.956 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.611 ' HB2' ' HA ' ' B' ' 22' ' ' ALA . 84.8 m-20 -89.57 127.08 35.84 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 105.11 -2.182 . . . . 0.0 105.11 176.23 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 84' ' ' ILE . . . . . 1.05 HG23 ' CB ' ' B' ' 25' ' ' ASP . 3.9 mt -127.89 121.79 57.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 119.903 -1.748 . . . . 0.0 112.655 -176.538 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.759 ' CD1' ' HB1' ' B' ' 22' ' ' ALA . 0.7 OUTLIER -89.43 111.1 22.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.384 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' B' ' 30' ' ' ASP . . . -92.15 -159.15 35.06 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.57 -178.821 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 87' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' B' ' 90' ' ' LEU . 5.0 mtp180 -68.63 -29.47 67.97 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.685 -0.891 . . . . 0.0 109.984 -179.524 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 88' ' ' ASN . . . . . 0.989 ' ND2' HD23 ' B' ' 89' ' ' LEU . 16.1 p-10 -53.62 -26.92 24.11 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.062 -1.024 . . . . 0.0 109.601 -179.588 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.989 HD23 ' ND2' ' B' ' 88' ' ' ASN . 2.9 mm? -108.87 -30.48 8.11 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.066 -1.021 . . . . 0.0 109.847 -179.494 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.698 HD21 ' CD2' ' B' ' 24' ' ' LEU . 85.0 mt -61.29 -30.31 70.4 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.247 -0.908 . . . . 0.0 108.849 179.863 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 91' ' ' THR . . . . . . . . . . . . . 1.1 p -78.47 -22.0 48.21 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.292 -0.88 . . . . 0.0 108.796 179.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 92' ' ' GLN . . . . . . . . . . . . . 39.6 mm-40 -72.16 -40.73 67.79 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.326 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 93' ' ' ILE . . . . . 0.636 HD12 ' CB ' ' A' ' 99' ' ' PHE . 0.5 OUTLIER -87.89 -8.12 10.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.349 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.466 ' O ' ' HA ' ' A' ' 99' ' ' PHE . . . 64.09 61.41 6.11 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 179.255 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 95' ' ' ALA . . . . . 0.549 ' HB2' ' HD2' ' A' ' 99' ' ' PHE . . . -88.53 158.55 18.27 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -1.152 . . . . 0.0 110.341 -179.664 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 96' ' ' THR . . . . . 0.695 HG22 HG22 ' A' ' 4' ' ' THR . 43.7 p -135.29 127.6 30.23 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 97' ' ' LEU . . . . . 0.684 HD13 HG21 ' B' ' 26' ' ' THR . 0.2 OUTLIER -91.4 95.69 10.12 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.302 -0.874 . . . . 0.0 109.902 -178.786 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 98' ' ' ASN . . . . . 0.544 ' ND2' ' CG ' ' A' ' 2' ' ' GLN . 0.9 OUTLIER -106.83 131.36 54.02 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.868 . . . . 0.0 109.941 -179.882 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' B' B ' 99' ' ' PHE . . . . . 0.943 ' CB ' HD12 ' A' ' 93' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.284 179.476 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 100' ' ' DMP . . . . . 0.882 ' C20' HD12 ' B' ' 50' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_